(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 July 2019 (04.07.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/133531 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *C07K 16/00* (2006.01)
A61K 47/64 (2017.01) *C07K 16/18* (2006.01)
A61K 47/68 (2017.01) *C07K 16/28* (2006.01)

(21) International Application Number:
PCT/US20 18/067304

(22) International Filing Date:
2 1 December 2018 (21. 12.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/610,397	26 December 2017 (26. 12.2017)	US
62/653,178	05 April 2018 (05.04.2018)	US
62/694,955	06 July 2018 (06.07.2018)	US
62/712,377	31 July 2018 (3 1.07.2018)	US

(71) Applicant: **KYMERA THERAPEUTICS, INC.** [US/US]; 400 Technology Square, 10th Floor, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **MAINOLFI, Nello;** 24 Hastings Road, Bel¬ mont, Massachusetts 02478 (US). **JI, Nan;** 5 Stony Brook Road, Arlington, Massachusetts 02476 (US). **KLUGE, Arthur F.;** 70 Beharrell Street, Apt. 237, Concord, Mass¬ achusetts 01742 (US). **WEISS, Matthew M.;** 99 Revere Street, Boston, Massachusetts 021 14 (US). **ZHANG, Yi;** 171 School Street, Belmont, Massachusetts 02478 (US).

(74) Agent: **REID, Andrea L.C.** et al.; One International Place, 40th Floor, 100 Oliver Street, Boston, Massachusetts 021 10-2605 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2019/133531 A1

(54) Title: IRAK DEGRADERS AND USES THEREOF

(57) Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.

IRAK DEGRADERS AND USES THEREOF

TECHNICAL FIELD OF THE INVENTION

[0001] The present invention relates to compounds and methods useful for the modulation of one or more interleukin-1 receptor-associated kinases ("IRAK") via ubiquitination and/or degradation by compounds according to the present invention. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.

BACKGROUND OF THE INVENTION

[0002] Ubiquitin-Proteasome Pathway (UPP) is a critical pathway that regulates key regulator proteins and degrades misfolded or abnormal proteins. UPP is central to multiple cellular processes, and if defective or imbalanced, it leads to pathogenesis of a variety of diseases. The covalent attachment of ubiquitin to specific protein substrates is achieved through the action of E3 ubiquitin ligases.

[0003] There are over 600 E3 ubiquitin ligases which facilitate the ubiquitination of different proteins in vivo, which can be divided into four families: HECT-domain E3s, U-box E3s, monomeric RING E3s and multi-subunit E3s. See generally Li et al. (PLOS One, 2008, 3, 1487) titled "Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling."; Bemdsen et al. (Nat. Struct. Mol. Biol., 2014, 21, 301-307) titled "New insights into ubiquitin E3 ligase mechanism"; Deshaies et al. (Ann. Rev. Biochem., 2009, 78, 399-434) titled"RING domain E3 ubiquitin ligases."; Spratt et al. (Biochem. 2014, 458, 421-437) titled "RBR E3 ubiquitin ligases: new structures, new insights, new questions."; and Wang et al. (Nat. Rev. Cancer., 2014, 14, 233-347) titled "Roles of F-box proteins in cancer."

[0004] UPP plays a key role in the degradation of short-lived and regulatory proteins important in a variety of basic cellular processes, including regulation of the cell cycle, modulation of cell surface receptors and ion channels, and antigen presentation. The pathway has been implicated in several forms of malignancy, in the pathogenesis of several genetic diseases (including cystic fibrosis, Angelman's syndrome, and Liddle syndrome), in immune surveillance/viral pathogenesis,

and in the pathology of muscle wasting. Many diseases are associated with an abnormal UPP and negatively affect cell cycle and division, the cellular response to stress and to extracellular modulators, morphogenesis of neuronal networks, modulation of cell surface receptors, ion channels, the secretory pathway, DNA repair and biogenesis of organelles.

[0005] Aberrations in the process have recently been implicated in the pathogenesis of several diseases, both inherited and acquired. These diseases fall into two major groups: (a) those that result from loss of function with the resultant stabilization of certain proteins, and (b) those that result from gain of function, i.e. abnormal or accelerated degradation of the protein target.

[0006] The UPP is used to induce selective protein degradation, including use of fusion proteins to artificially ubiquitinate target proteins and synthetic small-molecule probes to induce proteasome-dependent degradation. Bifunctional compounds composed of a target protein-binding ligand and an E3 ubiquitin ligase ligand, induced proteasome-mediated degradation of selected proteins via their recruitment to E3 ubiquitin ligase and subsequent ubiquitination. These drug-like molecules offer the possibility of temporal control over protein expression. Such compounds are capable of inducing the inactivation of a protein of interest upon addition to cells or administration to an animal or human, and could be useful as biochemical reagents and lead to a new paradigm for the treatment of diseases by removing pathogenic or oncogenic proteins (Crews C, Chemistry & Biology, 2010, l7(6):55 1-555; Schnnekloth JS Jr., Chembiochem, 2005, 6(l):40-46).

[0007] An ongoing need exists in the art for effective treatments for disease, especially hyperplasias and cancers, such as multiple myeloma. However, non-specific effects, and the inability to target and modulate certain classes of proteins altogether, such as transcription factors, remain as obstacles to the development of effective anti-cancer agents. As such, small molecule therapeutic agents that leverage E3 ligase mediated protein degradation to target cancer-associated proteins such as interleukin-l receptor-associated kinases (“IRAK”) hold promise as therapeutic agents. Accordingly, there remains a need to find bifunctional compounds that are IRAK degraders useful as therapeutic agents.


SUMMARY OF THE INVENTION

[0008] The present application relates novel bifunctional compounds, which function to recruit IRAK kinases to E3 Ubiquitin Ligase for degradation, and methods of preparation and uses

thereof. In particular, the present disclosure provides bifunctional compounds, which find utility as modulators of targeted ubiquitination of IRAK kinases, which are then degraded and/or otherwise inhibited by the bifunctional compounds as described herein. An advantage of the compounds provided herein is that a broad range of pharmacological activities is possible, consistent with the degradation/inhibition of IRAK kinases. In addition, the description provides methods of using an effective amount of the compounds as described herein for the treatment or amelioration of a disease condition, such as cancer, e.g., multiple myeloma.

[0009] The present application further relates to targeted degradation of IRAK kinases through the use of bifunctional molecules, including bifunctional molecules that link a cereblon-binding moiety to a ligand that binds IRAK kinasses.

[0010] It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are effective as degraders of IRAK kinases. Such compounds have the general formula **I**:



I

or a pharmaceutically acceptable salt thereof, wherein each variable is as defined and described herein.

[0011] Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful for treating a variety of diseases, disorders or conditions, associated with regulation of signaling pathways implicating IRAK kinases. Such diseases, disorders, or conditions include those described herein.

[0012] Compounds provided by this invention are also useful for the study of IRAK enzymes in biological and pathological phenomena; the study of intracellular signal transduction pathways occurring in bodily tissues; and the comparative evaluation of new IRAK inhibitors or IRAK degraders or other regulators of kinases, signaling pathways, and cytokine levels *in vitro* or *in vivo.*


DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

1. General Description of Certain Embodiments of the Invention:

[0013] Compounds of the present invention, and compositions thereof, are useful as degraders and/or inhibitors of one or more IRAK protein kinases. In some embodiments, a provided

compound degrades and/or inhibits IRAK-l/2/3/4.

[0014] In certain embodiments, the present invention provides a compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

IRAK is an IRAK binding moiety capable of binding to one or more of IRAK-l, -2, -3, or -4;

L is a bivalent moiety that connects IRAK to LBM; and

LBM is a ligase binding moiety.


2. Compounds and Definitions:


[0015] Compounds of the present invention include those described generally herein, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry", 5th Ed., Ed.: Smith, M.B. and March, T, John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.

[0016] The term "aliphatic" or "aliphatic group", as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as "carbocycle," "cycloaliphatic" or "cycloalkyl"), that has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms. In some embodiments, "cycloaliphatic" (or "carbocycle" or "cycloalkyl") refers to a monocyclic C_3-C_6

hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.

[0017] As used herein, the term "bridged bicyclic" refers to any bicyclic ring system, i.e. carbocyclic or heterocyclic, saturated or partially unsaturated, having at least one bridge. As defined by IUPAC, a "bridge" is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a "bridgehead" is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen). In some embodiments, a bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such bridged bicyclic groups are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise specified, a bridged bicyclic group is optionally substituted with one or more substituents as set forth for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bridged bicyclics include:





[0018] The term “lower alkyl” refers to a C_{1-4} straight or branched alkyl group. Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.

[0019] The term “lower haloalkyl” refers to a C_{1-4} straight or branched alkyl group that is substituted with one or more halogen atoms.

[0020] The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2//-pyrrolyl), NH (as in pyrrolidinyl) or NR^+ (as in N-substituted pyrrolidinyl)).


[0021] The term "unsaturated," as used herein, means that a moiety has one or more units of unsaturation.

[0022] As used herein, the term “bivalent C_{1-8} (or C_{1-6}) saturated or unsaturated, straight or branched, hydrocarbon chain”, refers to bivalent alkylene, alkenylene, and alkynylene chains that are straight or branched as defined herein.

[0023] The term “alkylene” refers to a bivalent alkyl group. An “alkylene chain” is a polymethylene group, i.e., $-(CH_2)_{n-}$, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.

[0024] The term “alkenylene” refers to a bivalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.

[0025] As used herein, the term “cyclopropylenyl” refers to a bivalent cyclopropyl group of

the following structure:  .

[0026] The term "halogen" means F, Cl, Br, or I.

[0027] The term "aryl" used alone or as part of a larger moiety as in "aralkyl," "aralkoxy," or "aryloxyalkyl," refers to monocyclic or bicyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term "aryl" may be used interchangeably with the term "aryl ring." In certain embodiments of the present invention, "aryl" refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents. Also included within the scope of the term "aryl," as it is used herein, is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like.

[0028] The terms "heteroaryl" and "heteroar-," used alone or as part of a larger moiety, e.g., "heteroaralkyl," or "heteroaralkoxy," refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 π electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms. The term "heteroatom" refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. The terms "heteroaryl" and "heteroar-", as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring. Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, ***AH***–quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-l,4-oxazin-3(4H)-one. A heteroaryl group may be mono- or bicyclic. The term "heteroaryl" may be used interchangeably with the terms "heteroaryl ring," "heteroaryl group," or "heteroaromatic," any of which terms include rings that are optionally substituted. The term "heteroaralkyl" refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.

[0029] As used herein, the terms “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7-lO-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-*2H*–pyrrolyl), NH (as in pyrrolidinyl), or $^{+}$NR (as in *N*–substituted pyrrolidinyl).

[0030] A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. The terms “heterocycle,” “heterocyclyl,” “heterocyclyl ring,” “heterocyclic group,” “heterocyclic moiety,” and “heterocyclic radical,” are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, *3H*–indolyf chromanyl, phenanthridinyl, or tetrahydroquinolinyl. A heterocyclyl group may be mono- or bicyclic. The term “heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.

[0031] As used herein, the term “partially unsaturated” refers to a ring moiety that includes at least one double or triple bond. The term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.

[0032] As described herein, compounds of the invention may contain “optionally substituted” moieties. In general, the term “substituted,” whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by

this invention are preferably those that result in the formation of stable or chemically feasible compounds. The term "stable," as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.

[0033] Suitable monovalent substituents on a substitutable carbon atom of an "optionally substituted" group are independently halogen; -$(CH_2)_{0-4}R^\circ$; -$(CH_2)_{0-4}OR^\circ$; -$O(CH_2)_{0-4}OR^\circ$; -$(CH_2)_{0-4}CH(OR^\circ)_2$; -$(CH_2)_{0-4}SR^\circ$; -$(CH_2)_{0-4}Ph$, which may be substituted with R°; -$(CH_2)_{0-4}O(CH_2)_{0-1}Ph$ which may be substituted with R°; -CH=CHPh, which may be substituted with R°; -$(CH_2)_{0-4}O(CH_2)_{0-1}$-pyridyl which may be substituted with R°; -NO_2; -CN; -N_3; -$(CH_2)_{0-4}N(R^\circ)_2$; -$(CH_2)_{0-4}N(R^\circ)C(O)R^\circ$; -$N(R^\circ)C(S)R^\circ$; -$(CH_2)_{0-4}N(R^\circ)C(O)NR^\circ_2$; -$N(R^\circ)C(S)NR^\circ_2$; -$(CH_2)_{0-4}N(R^\circ)C(O)OR^\circ$; -$N(R^\circ)N(R^\circ)C(O)R^\circ$; -$N(R^\circ)N(R^\circ)C(O)NR^\circ_2$; -$N(R^\circ)N(R^\circ)C(O)OR^\circ$; -$(CH_2)_{0-4}C(O)R^\circ$; -$C(S)R^\circ$; -$(CH_2)_{0-4}C(O)OR^\circ$; -$(CH_2)_{0-4}C(O)SR^\circ$; -$(CH_2)_{0-4}C(O)OSiR^\circ_3$; -$(CH_2)_{0-4}OC(O)R^\circ$; -$OC(O)(CH_2)_{0-4}SR^\circ$, -$SC(S)SR^\circ$; -$(CH_2)_{0-4}SC(O)R^\circ$; -$(CH_2)_{0-4}C(O)NR^\circ_2$; -$C(S)NR^\circ_2$; -$C(S)SR^\circ$; -$SC(S)SR^\circ$, -$(CH_2)_{0-4}OC(O)NR^\circ_2$; -$C(O)N(OR^\circ)R^\circ$; -$C(O)C(O)R^\circ$; -$C(O)CH_2C(O)R^\circ$; -$C(NOR^\circ)R^\circ$; -$(CH_2)_{0-4}SSR^\circ$; -$(CH_2)_{0-4}S(O)_2R^\circ$; -$(CH_2)_{0-4}S(O)_2OR^\circ$; -$(CH_2)_{0-4}OS(O)_2R^\circ$; -$S(O)_2NR^\circ_2$; -$(CH_2)_{0-4}S(O)R^\circ$; -$N(R^\circ)S(O)_2NR^\circ_2$; -$N(R^\circ)S(O)_2R^\circ$; -$N(OR^\circ)R^\circ$; -$C(NH)NR^\circ_2$; -$P(O)_2R^\circ$; -$P(O)R^\circ_2$; -$OP(O)R^\circ_2$; -$OP(O)(OR^\circ)_2$; SiRN; -(Ci-$_4$ straight or branched alkylene)O-$N(R^\circ)_2$; or -(Ci-$_4$ straight or branched alkylene)C(O)O-$N(R^\circ)_2$, wherein each R° may be substituted as defined below and is independently hydrogen, Ci-$_6$ aliphatic, -CH_2Ph, -$O(CH_2)_{0-1}$Ph, -CH_2-(5-6 membered heteroaryl ring), or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R°, taken together with their intervening atom(s), form a 3-l2-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted as defined below.

[0034] Suitable monovalent substituents on R° (or the ring formed by taking two independent occurrences of R° together with their intervening atoms), are independently halogen, -$(CH_2)_{0-2}R^*$, -(haloR*), -$(CH_2)_{0-2}OH$, -$(CH_2)_{0-2}OR^*$, -$(CH_2)_{0-2}CH(OR^*)_2$; -O(haloR*), -CN, -N_3, -$(CH_2)_{0-}$

$_2$C(0)R·, **-(CH $_2$)$_{O-2}$C(0)OH, -(CH $_2$)$_{O-2}$C(0)OR·, -(CH $_2$)$_{O-2}$SR*, -(CH $_2$)$_{O-2}$SH, -(CH $_2$)$_{O-2}$NH$_2$, -(CH$_2$)$_{O-2}$NHR·, -(CH $_2$)$_{O-2}$NR* $_2$,** -N0 $_2$, -SiR* $_3$, -OSiR's, -C(0)SR* , **-(Ci$_{-4}$** straight or branched alkylene)C(0)0R*, or -SSR* wherein each R* is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently selected from **C$_{1-4}$** aliphatic, **-CH$_2$Ph, -0(CH $_2$)o-iPh,** or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents on a saturated carbon atom of R° include =0 and =S.

[0035] Suitable divalent substituents on a saturated carbon atom of an "optionally substituted" group include the following: =0, =S, =NNR%, =NNHC(0)R *, =NNHC(0)0R *, =NNHS(0) $_2$R*, =NR *, =NOR *, -0(C(R *$_2$))$_{2-3}$0-, or -S(C(R *$_2$))$_{2-3}$S-, wherein each independent occurrence of R* is selected from hydrogen, C1-6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents that are bound to vicinal substitutable carbons of an "optionally substituted" group include: -0(CR *$_2$)$_{2-3}$O-, wherein each independent occurrence of R* is selected from hydrogen, C1-6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0036] Suitable substituents on the aliphatic group of R* include halogen, -R", -(haloR*), **-OH,** -OR*, -0(haloR*), **-CN, -C(0)OH, -C(0)OR*, -NH$_2$, –NHR*, -NR* $_2$,** or **-N0 $_2$,** wherein each R* is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently **C$_{1-4}$** aliphatic, **-CH$_2$Ph, -0(CH $_2$)o-iPh,** or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0037] Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include -R†, -NR†$_2$, -C(0)R †, -C(0)OR †, -C(0)C(0)R †, –C(0)CH $_2$C(0)R †, -S(0) $_2$R†, -S(0) $_2$NR†$_2$, -C(S)NR †$_2$, -C(NH)NR †$_2$, or -N(R †)S(0) $_2$R†; wherein each R† is independently hydrogen, C1-6 aliphatic which may be substituted as defined below, unsubstituted -OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R†, taken together with their

intervening atom(s) form an unsubstituted 3-l2-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0038] Suitable substituents on the aliphatic group of R÷ are independently halogen, -R·, -(haloR*), -OH, -OR*, -0(haloR*), -CN, -C(0)0H, -C(0)0R*, $-NH_2$, -NHR*, $-NR*_2$, or -NO2, wherein each R• is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently $Ci-_4$ aliphatic, $-CH_2Ph$, $-0(CH_2)o-iPh$, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0039] As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphor sulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.

[0040] Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and $N^+(Ci\text{^}alkyl)_4$ salts. Representative alkali or alkaline earth metal salts include

sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.

[0041] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a ^{13}C- or ^{14}C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention

[0042] As used herein, the term "inhibitor" is defined as a compound that binds to and /or inhibits an IRAK kinase with measurable affinity. In certain embodiments, an inhibitor has an IC50 and/or binding constant of less than about 50 μM, less than about 1 μM, less than about 500 nM, less than about 100 nM, less than about 10 nM, or less than about 1 nM.

[0043] As used herein, the term "degrader" is defined as a heterobifunctional compound that binds to and /or inhibits both an IRAK kinase and an E3 ligase with measurable affinity resulting in the ubiqitination and subsequent degradation of the IRAK kinase. In certain embodiments, a degrader has an DC50 of less than about 50 μM, less than about 1 μM, less than about 500 nM, less than about 100 nM, less than about 10 nM, or less than about 1 nM.

[0044] A compound of the present invention may be tethered to a detectable moiety. It will be appreciated that such compounds are useful as imaging agents. One of ordinary skill in the art will recognize that a detectable moiety may be attached to a provided compound *via* a suitable substituent. As used herein, the term "suitable substituent" refers to a moiety that is capable of covalent attachment to a detectable moiety. Such moieties are well known to one of ordinary skill

in the art and include groups containing, e.g., a carboxylate moiety, an amino moiety, a thiol moiety, or a hydroxyl moiety, to name but a few. It will be appreciated that such moieties may be directly attached to a provided compound or *via* a tethering group, such as a bivalent saturated or unsaturated hydrocarbon chain. In some embodiments, such moieties may be attached via click chemistry. In some embodiments, such moieties may be attached via a 1,3-cycloaddition of an azide with an alkyne, optionally in the presence of a copper catalyst. Methods of using click chemistry are known in the art and include those described by Rostovtsev *et al.,* Angew. Chem. Int. Ed. 2002, 41, 2596-99 and Sun *et al.,* Bioconjugate Chem., 2006, 17, 52-57.

[0045] As used herein, the term "detectable moiety" is used interchangeably with the term "label" and relates to any moiety capable of being detected, e.g., primary labels and secondary labels. Primary labels, such as radioisotopes (e.g., tritium, ^{32}P, ^{33}P, ^{35}S, or ^{14}C), mass-tags, and fluorescent labels are signal generating reporter groups which can be detected without further modifications. Detectable moieties also include luminescent and phosphorescent groups.

[0046] The term "secondary label" as used herein refers to moieties such as biotin and various protein antigens that require the presence of a second intermediate for production of a detectable signal. For biotin, the secondary intermediate may include streptavidin-enzyme conjugates. For antigen labels, secondary intermediates may include antibody-enzyme conjugates. Some fluorescent groups act as secondary labels because they transfer energy to another group in the process of nonradiative fluorescent resonance energy transfer (FRET), and the second group produces the detected signal.

[0047] The terms "fluorescent label", "fluorescent dye", and "fluorophore" as used herein refer to moieties that absorb light energy at a defined excitation wavelength and emit light energy at a different wavelength. Examples of fluorescent labels include, but are not limited to: Alexa Fluor dyes (Alexa Fluor 350, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 660 and Alexa Fluor 680), AMCA, AMCA-S, BODIPY dyes (BODIPY FL, BODIPY R6G, BODIPY TMR, BODIPY TR, BODIPY 530/550, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY 630/650, BODIPY 650/665), Carboxyrhodamine 6G, carboxy-X-rhodamine (ROX), Cascade Blue, Cascade Yellow, Coumarin 343, Cyanine dyes (Cy3, Cy5, Cy3.5, Cy5.5), Dansyl, Dapoxyl, Dialkylaminocoumarin, 4',5'-Dichloro-2',7'-dimethoxy-fluorescein, DM-NERF, Eosin, Erythrosin, Fluorescein, FAM, Hydroxycoumarin, IRDyes (IRD40, IRD 700, IRD 800), JOE, Lissamine rhodamine B, Marina


Blue, Methoxycoumarin, Naphthofluorescein, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, PyMPO, Pyrene, Rhodamine B, Rhodamine 6G, Rhodamine Green, Rhodamine Red, Rhodol Green, 2',4',5',7'-Tetra-bromosulfone-fluorescein, Tetramethyl-rhodamine (TMR), Carboxytetramethylrhodamine (TAMRA), Texas Red, Texas Red-X.

[0048] The term "mass-tag" as used herein refers to any moiety that is capable of being uniquely detected by virtue of its mass using mass spectrometry (MS) detection techniques. Examples of mass-tags include electrophore release tags such as N-[3-[4'-[(p-Methoxytetrafluorobenzyl)oxy]phenyl]-3-methylglyceronyl]isonipecotic Acid, 4'-[2,3,5,6-Tetrafluoro-4-(pentafluorophenoxyl)]methyl acetophenone, and their derivatives. The synthesis and utility of these mass-tags is described in United States Patents 4,650,750, 4,709,016, 5,360,8191, 5,516,931, 5,602,273, 5,604,104, 5,610,020, and 5,650,270. Other examples of mass-tags include, but are not limited to, nucleotides, dideoxynucleotides, oligonucleotides of varying length and base composition, oligopeptides, oligosaccharides, and other synthetic polymers of varying length and monomer composition. A large variety of organic molecules, both neutral and charged (biomolecules or synthetic compounds) of an appropriate mass range (100-2000 Daltons) may also be used as mass-tags.

[0049] The terms "measurable affinity" and "measurably inhibit," as used herein, means a measurable change in an IRAK protein kinase activity between a sample comprising a compound of the present invention, or composition thereof, and an IRAK protein kinase, and an equivalent sample comprising an IRAK protein kinase, in the absence of said compound, or composition thereof.

3. Description of Exemplary Embodiments:

[0050] As described above, in certain embodiments, the present invention provides a compound of formula I:



I


or a pharmaceutically acceptable salt thereof, wherein:

IRAK is an IRAK binding moiety capable of binding to one or more of IRAK-l, -2, -3, or -4;

L is a bivalent moiety that connects IRAK to LBM; and

LBM is a ligase binding moiety.

[0051] In some embodiments, the present invention provides a compound of formula **I**:



I

or a pharmaceutically acceptable salt thereof, wherein:


IRAK is an IRAK-4 binding moiety;

L is a bivalent moiety that connects IRAK to LBM; and


LBM is a cereblon ligase binding moiety.

[0052] In some embodiments, LBM is an E3 ligase ligand. Such E3 ligase ligands are well known to one of ordinary skill in the art and include those described in M. Toure, C. M. Crews, *Angew. Chem. Int. Ed.* **2016,** 55, 1966, T. Uehara *et al. Nature Chemical Biology* **2017,** *13,* 675, WO 2017/176708, US 2017/0281784, WO 2017/161119, WO 2017/176957, WO 2017/176958, WO 2015/160845, US 2015/0291562, WO 2016/197032, WO 2016/105518, US 2018/0009779, WO 2017/007612, 2018/0134684, WO 2013/106643, US 2014/0356322, WO 2002/020740, US 2002/0068063, WO 2012/078559, US 2014/0302523, WO 2012/003281, US 2013/0190340, US 2016/0022642, WO 2014/063061, US 2015/0274738, WO 2016/118666, US 2016/0214972, WO 2016/149668, US 2016/0272639, WO 2016/169989, US 2018/0118733, WO 2016/197114, US 2018/0147202, WO 2017/011371, US 2017/0008904, WO 2017/011590, US 2017/0037004, WO 2017/079267, US 2017/0121321, WO 2017/117473, WO 2017/117474, WO 2013/106646, WO 2014/108452, WO 2017/197036, WO 2017/197046, WO 2017/197051, WO 2017/197055, and WO 2017/197056 each of, the entirety of each of which is herein incorporated by reference.


[0053] In certain embodiments, the present invention provides a compound of Formula **I,** wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety










,




,




,



,

,

,

,

,

, or

; thereby forming a compound of formula **I-a-1, I-a-2, I-a-3, I-a-4, I-a-5, I-a-6, I-a-7, I-a-8, I-a-9,** or **I-a-10** respectively:




I-a-1




I-a-2




I-a-3




I-a-4




I-a-5




I-a-6




I-a-7




I-a-8




I-a-9




I-a-10

or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein each of the variables  , X, Xi, X_2, Y, Ri, R_3, Rri, R_4, R_5, t, m and n is as defined and described in WO 2017/007612 and US 2018/0134684, the entirety of each of which is herein incorporated by reference.


[0054] In certain embodiments, the present invention provides a compound of Formula **I,** wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety




,




,




,







,




,




,



,

,

, or

; thereby forming a compound of formula **I-a′-1**, **I-a′-2**, **I-a′-3**, **I-a′-4**, **I-a′-5**, **I-a′-6**, **I-a′-7**, **I-a′-8**, **I-a′-9**, or **I-a′-10** respectively:




I-a′-1




I-a′-2




I-a′-3




I-a′-4




I-a′-5





I-a′-6






I-a'-7 **I-a'-8**













I-a'-9 **I-a'-lO**



or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein each of the variables  , X, Xi, X_2, Y, Ri, R_3, Rri, R_4, R_5, t, m and n is as defined and described in WO 2017/007612 and US 2018/0134684, the entirety of each of which is herein incorporated by reference.


[0055] In certain embodiments, the present invention provides a compound of Formula **I,** wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety

 ,  ,  ,


 ,  ,  ,

 ,  ,



, or 
; thereby forming a compound of formula **I-a″-1**, **I-a″-2**, **I-a″-3**, **I-a″-4**, **I-a″-5**, **I-a″-6**, **I-a″-7**, **I-a″-8**, **I-a″-9**, or **I-a′-10** respectively:




I-a″-1




I-a″-2




I-a″-3




I-a″-4




I-a″-5




I-a″-6




I-a"-7




I-a"-8




I-a"-9





I-a"-10


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein each of the variables 


, X, Xi, X_2, Y, Ri, R_3, R_3', R_4, R_5, t, m and n is as defined and described in WO 2017/007612 and US 2018/0134684, the entirety of each of which is herein incorporated by reference.

[0056] In certain embodiments, the present invention provides a compound of Formula **I,** wherein LBM is a VHL E3 ubiquitin ligase binding moiety 


, 

, 


, 

, or 


; thereby forming a compound of formula **I-b-1, 1-b-2, 1-b-3, 1-b-4,** or **I-b-5** respectively:




I-b-1




I-b-2



I-b-3




I-b-4



I-b-5


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein each of the variables $R^{1'}$, $R^{2'}$, $R^{3'}$, X, and X' is as defined and described in WO 2013/106643 and US 2014/0356322, the entirety of each of which is herein incorporated by reference.

[0057] In certain embodiments, the present invention provides a compound of Formula **I,**




wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety ;

thereby forming a compound of formula **I-c:**



























I-c


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein:

X^1 is a bivalent moiety selected from a covalent bond, $-CH_{2-}$, -C(O)-, -C(S)-, or  ;

R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, $-S(0)_2R$, $-NR_2$, or an optionally substituted Ci_{-4} aliphatic;

each R^2 is independently hydrogen, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

Ring A is a bi- or tricyclic ring selected from  , , ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  .



, or wherein

Ring B is a fused ring selected from 6-membered aryl containing 0-2 nitrogen atoms, 5 to 7-membered partially saturated carbocyclyl, 5 to 7-membered partially saturated heterocyclyl with 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;

R^3 is selected from hydrogen, halogen, -OR, $-N(R)_2$, or -SR;

each R^4 is independently hydrogen, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

R^5 is hydrogen, Ci_{-4} aliphatic, or -CN;


each R^6 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

m is 0, 1, 2, 3 or 4; and

each R is independently hydrogen, or an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:


two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[0058] In certain embodiments, the present invention provides a compound of Formula **I,**




wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety ;

thereby forming a compound of formula **I-c':**



I-c′

or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein:












X^1 is a bivalent moiety selected from a covalent bond, $-CH_2-$, -C(O)-, -C(S)-, or  ;


X^2 is a carbon atom or silicon atom;


X^3 is a bivalent moiety selected from $-CH_2-$ or $-Si(R_2)-$;

R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, $-S(0)_2R$, $-N(R)_2$, $-Si(R)_3$, or an optionally substituted C_{i-4} aliphatic;

each R^2 is independently hydrogen, deuterium, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-Si(R)_3$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, $-N(R)C(0)0R$, $-N(R)C(0)R$, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

Ring A is a bi- or tricyclic ring selected from  , , ,  ,  ,  ,  ,  ,  ,  ,  ,  , 





, or wherein

Ring B is a fused ring selected from 6-membered aryl containing 0-2 nitrogen atoms, 5 to 7-membered partially saturated carbocyclyl, 5 to 7-membered partially saturated heterocyclyl with 1-2 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;

R^3 is selected from hydrogen, halogen, -OR, $-N(R)_2$, or -SR;

each R^4 is independently hydrogen, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

R^5 is hydrogen, Ci_{-4} aliphatic, or -CN;


each R^6 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

m is 0, 1, 2, 3 or 4; and


each R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[0059] In some embodiments, the compound of formala **I-c'** above is provided as a compound of formula **I-c"** or formula **I-c'":**



I-c''




I-c'''


or a pharmaceutically acceptable salt thereof, wherein:

each of IRAK, Ring A, L, R^1, R^2, X^1, X^2, X^3, and m is as defined above.

[0060] In certain embodiments, the present invention provides a compound of Formula **I,** wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety




; thereby forming a compound of formula **I-d:**

























I-d

or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein:

X^1 is a bivalent moiety selected from a covalent bond, $-CH_{2-}$, -C(O)-, -C(S)-, or  ;

R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, $-S(0)_2R$, $-NR_2$, or an optionally substituted C_{i-4} aliphatic;

Ring A is a mono- or bicyclic ring selected from  , ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  .



each R^2 is independently hydrogen, $-R^6$, halogen, -CN, -NO2, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

Ring B is selected from a 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;

each of R^3 and R^4 is independently hydrogen, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;


R^5 is hydrogen, Ci_{-4} aliphatic, or -CN;

each R^6 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

m is 0, 1, or 2;

n is 0, 1, 2, 3, or 4;

p is 0 or 1, wherein when p is 0, the bond connecting Ring A and Ring B is connected to




; and


each R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[0061] In certain embodiments, the present invention provides a compound of Formula **I,** wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety




; thereby forming a compound of formula **I-d':**



I-d'

































or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein:


X^1 is a bivalent moiety selected from a covalent bond, -CFF-, -C(O)-, -C(S)-, or  ;

X^2 is a carbon atom or silicon atom;

X^3 is a bivalent moiety selected from $-CH_{2-}$ or $-Si(R_2)-$;

R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, -S(0) $_2$R, -N(R) $_2$, -Si(R)$_3$, or an optionally substituted Ci-$_4$ aliphatic;

Ring A is a mono- or bicyclic ring selected from  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  , , , , ,



each R^2 is independently hydrogen, deuterium, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-Si(R)3$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

Ring B is selected from a 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;

each of R^3 and R^4 is independently hydrogen, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;


R^5 is hydrogen, Ci_{-4} aliphatic, or -CN;

each R^6 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

m is 0, 1, or 2;

n is 0, 1, 2, 3, or 4;

p is 0 or 1, wherein when p is 0, the bond connecting Ring A and Ring B is connected to




; and

each R is independently hydrogen, or an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring


having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[0062] In some embodiments, the compound of formala **I-d'** above is provided as a compound of formula **I-d"** or formula **I-d'":**



I-d''




I-d'"


or a pharmaceutically acceptable salt thereof, wherein:

each of IRAK, Ring A, Ring B, L, R^1, R^2, R^3, X^1, X^2, X^3, m, and p is as defined above.

[0063] In certain embodiments, the present invention provides a compound of Formula **I,** wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety




; thereby forming a compound of formula **I-e:**

















I-e


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein:










X^1 is a bivalent moiety selected from a covalent bond, $-CH_{2-}$, -C(O)-, -C(S)-, or  ;


R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, $-S(0)_2R$, $-NR_2$, or an optionally substituted C_{i-4} aliphatic;

Ring A is a mono- or bicyclic ring selected from  ,  ,


,

,

,

,

,

,

,

,

,

,

,





,

,

,

,

,

,

,

,

,



each R^2 is independently hydrogen, $-R^6$, halogen, -CN, -NO2, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

Ring B is selected from a 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;

each of R^3 and R^4 is independently hydrogen, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

R^5 is hydrogen, Ci_{-4} aliphatic, or -CN;

each R^6 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

m is 0, 1, or 2;

n is 0, 1, 2, 3, or 4;


p is 0 or 1; and

each R is independently hydrogen, or an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:


two R groups on the same nitrogen are optionally taken together with their intervening

atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[0064] In certain embodiments, the present invention provides a compound of Formula **I,** wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety




; thereby forming a compound of formula **I-e'**:



I-e'













or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein:












X^1 is a bivalent moiety selected from a covalent bond, $-CH_{2-}$, -C(O)-, -C(S)-, or  ;


X^2 is a carbon atom or silicon atom;













X^3 is a bivalent moiety selected from $-CH_{2-}$ or $-Si(R_2)-$;


R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, $-S(0)_2R$, $-N(R)_2$, $-Si(R)_3$, or an optionally substituted C_{i-4} aliphatic;


Ring A is a mono- or bicyclic ring selected from  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  , 



















,

,

,

,

,

,

,

,

,

,

,

,



,


,


,


, or


;

each R^2 is independently hydrogen, deuterium, $-R^6$, halogen, -CN, -NO2, -OR, -SR, $-NR_2$, $-Si(R)_3$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

Ring B is selected from a 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;

each of R^3 and R^4 is independently hydrogen, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

R^5 is hydrogen, Ci_{-4} aliphatic, or -CN;

each R^6 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms

independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

m is 0, 1, or 2;


n is 0, 1, 2, 3, or 4;

p is 0 or 1; and


each R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[0065] In some embodiments, the compound of formala **I-e'** above is provided as a compound of formula **I-e"** or formula **I-e‴**:









I-e″




I-e‴


or a pharmaceutically acceptable salt thereof, wherein:

each of IRAK, Ring A, Ring B, L, R^1, R^2, R^3, X^1, X^2, X^3, p, and m is as defined above.


[0066] In certain embodiments, the present invention provides a compound of Formula **I,** wherein LBM is a VHL E3 ubiquitin ligase binding moiety  ,  ,  ,  ,  , or  ; thereby forming a compound of formula **I-f-1, 1-f-2, I-f-3, 1-f-4, 1-f-5** or **I-f-6** respectively:




I-f-1




I-f-2




I-f-3



I-f-4





I-f-5




I-f-6

or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein each of the variables $R^{1'}$, $R^{2'}$, $R^{3'}$, R_5, R_6, R_7, R_9, Rio, R11, R14, R15, Ri_6, R17, R23, R25, E, G, M, X, X', Y, Zi, Z_2, Z3, Z_4, and o is as defined and described in WO 2016/149668 and US 2016/0272639, the entirety of each of which is herein incorporated by reference.


[0067] As used herein, depiction of brackets around any LBM 

means that the 


moiety is covalently attached to said LBM at any available modifiable carbon, nitrogen, oxygen, or sulfur atom. For purposes of clarity and by way of example, such available modifiable carbon, nitrogen, oxygen, or sulfur atoms in the following LBM compound structure are depicted below, wherein each wavy bond defines the point of attachment to said




[0068] In certain embodiments, the present invention provides a compound of Formula **I,**




wherein LBM is a VHL E3 ubiquitin ligase binding moiety




, or




; thereby forming a compound of formula **I-g-1, 1-g-2,** or **I-g-3** respectively:



I-g-1




I-g-2




I-g-3

or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein each of the variables R^p, R9, Rio, R11, Ri_{4a}, Ri4t>, R_{15}, Ri_6, W^3, W^4, W^5, X^1, X^2, and o is as defined and described in WO 2016/118666 and US 2016/0214972, the entirety of each of which is herein incorporated by reference.


[0069] In certain embodiments, the present invention provides a compound of Formula **I,** wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety




,




,




,




,




, or




; thereby forming a compound of formula **I-h-1, 1-h-2, 1-h-3, 1-h-4, 1-h-5,** or **I-h-6** respectively:




I-h-1




I-h-2




I-h-3



I-h-4



I-h-5



I-h-6

or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein

W is independently selected from the group CH_2, CHR, C=0, $S0_2$, NH, and N-alkyl;

X is independently selected from the group O, S and H_2;

Y is independently selected from the group NH, N-alkyl, N-aryl, N-hetaryl, N-cycloalkyl, N-heterocyclyl, O, and S;

Z is independently selected from the group O, and S or H_2, except that both X and Z cannot be H_2;

G and G' are independently selected from the group H, alkyl, OH, CH_2-heterocyclyl optionally substituted with R', and benzyl optionally substituted with R';

Q1-Q4 represent a carbon C substituted with a group independently selected from R', N or N-oxide;

A is independently selected from the group H, alkyl, cycloalkyl, Cl and F;

R comprises, but is not limited to: —CONR'R", —OR', —NR'R", —SR', —$S0_2$R', —SOiNRR", —CRR" —, —CRTNR'R"—, -aryl, -hetaryl, -alkyl, -cycloalkyl, -heterocyclyl, —P(0)(0R')R", —P(0)R'R", —0P(0)(0R')R", —0P(0)R'R", —Cl, —F, —Br, —I, —CF_3, —CN, —NR'SOiNR'R", —NR'CONR'R", —CONR'COR", —NR'C(=N —CN)NR'R", —C(=N —CN)NR'R", —NR'C(=N —CN)R", —NR'C(=C—N0_2)NRR", —SOiNR'COR", —N0_2, —C0_2R', —C(C=N —OR')R", —CR—CR'R", —CCR', —S(C=0)(C=N— R')R", —SF_5 and —OCF_3;

R' and R" are independently selected from a bond, H, alkyl, cycloalkyl, aryl, hetaryl, heterocyclyl;


n is an integer from 1-4;


〰 represents a bond that may be stereospecific ((R) or (S)) or non-stereospecific; and


R_n comprises 1-4 independent functional groups or atoms;


as defined and described in WO 2016/197114 and US 2018/0147202, the entirety of each of which is herein incorporated by reference.


[0070] In certain embodiments, the present invention provides a compound of Formula **I,** wherein LBM is a MDM2 (i.e. human double minute 2 or HDM2) E3 ligase binding moiety



,



,



,



,



,


,



,


.







,



,




, or




;


thereby forming a compound of formula **I-i-1, 1-i-2, 1-i-3, I-i-4, 1-i-5, 1-i-6, I-i-7, 1-i-8, 1-i-9, I-i-10, 1-i-11, 1-i-12, 1-i-13, 1-i-14, 1-i-15, 1-i-16, 1-i-17,** or **I-i-18** respectively:




I-i-1




I-i-2




I-i-3




I-i-4




I-i-5




I-i-6




I-i-7




I-i-8




I-i-9




I-i-10




I-i-11


IRAK
L
R1'
R3'
N
N
R4'
N
N
O
R6'
R2'


I-i-12


IRAK
L
R10'
N
R11'
O
R7'
R1"
N
R9'
N
R8'


I-i-13


IRAK
L
Z
R12'
NH
O
R7'
R1"
N
R9'
N
R8'


I-i-14




I-i-15



I-i-16










I-i-17




I-i-18


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein each of the variables Ri, R_2, R3, R4, R_5, Rs, R7, Rs, R9, Rio, Rll, R12, R13, R14, R15, Rl6, Rl7, Rl8, Rl9, R_{20}, R_{21}, R_{22}, R_{23}, R_{24}, R_{25}, R_{26}, R_{27}, R_{28}, Rl', R_{2}', R3', R4', R_{5}', R', R7', R8', R9', Rio', Rir, RI_{2}', Ri", A, A', A", X, Y, and Z is as defined and described in WO 2017/011371 and US 2017/0008904, the entirety of each of which is herein incorporated

by reference.


[0071] In certain embodiments, the present invention provides a compound of Formula **I,** wherein LBM is a CRBN or VHL E3 ubiquitin ligase binding moiety selected from the group consisting of  ,  ,  ,  ,  ,  , and  ; thereby forming a compound of formula **I-j-1, 1-j-2, 1-j-3, 1-j-4, 1-j-5, 1-j-6,** or **I-j-7** respectively:




I-j-1




I-j-2




I-j-3




I-j-4



I-j-5



I-j-6



I-j-7

or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein

A^1 is selected from the group consisting of -C(R^{16a})= and -N=;

A^2 is selected from the group consisting of -C(R^{16b})= and -N=;

A^3 is selected from the group consisting of -C(R^{16c})= and -N=;

G is selected from the group consisting of -C(R^{16d})= and -N=;

Z is selected from the group consisting of -CH_2 and -C(=0)-;

R^5 is selected from the group consisting of hydrogen, methyl, and fluoro;





R^{16a} is selected from the group consisting of hydrogen, halo, and C_{i-4} alkyl;







R^{16b} is selected from the group consisting of hydrogen, halo, and C_{i-4} alkyl;


R^{16C} is selected from the group consisting of hydrogen, halo, and C_{i-4} alkyl; and

R^{16d} is selected from the group consisting of hydrogen, halo, and C_{i-4} alkyl;


as defined and described in WO 2017/176958, the entirety of which is herein incorporated by reference.

[0072] In certain embodiments, the present invention provides a compound of Formula **I,** wherein LBM is a CRBN or VHL E3 ubiquitin ligase binding moiety selected from the group consisting of  ,  ,  ,  ,



,

,

,

,

, and

; thereby forming a compound of formula I-j'-l, **I-j′′-1**, **I-j′-2**, **I-j′′-2**, I-j'-3, 1-j"-3, 1-j'-4, 1-j"-4, 1-j'-7 or I-j"-7 respectively:




I-j′-1




I-j′′-1




I-j′-2




I-j″-2




I-j′-3




I-j″-3




I-j′-4



I-j''-4




I-j'-7






I-j''-7


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein each of the variables A^1, A^2, A^3, R^5, G and Z is as defined and described in WO 2017/176958, the entirety of which is herein incorporated by reference.

[0073] In certain embodiments, the present invention provides a compound of Formula **I,**




wherein LBM is an IAP E3 ubiquitin ligase binding moiety





; thereby forming a compound of formula I-k-1, I-k-2, I-k-3, or I-k-4 respectively:




I-k-1



I-k-2




I-k-3




I-k-4


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein each of the variables R^1, R^2, R^3, R^4, R^5, R^6, and R^7, is as defined and described in WO 2017/011590 and US 2017/0037004, the entirety of each of which is herein incorporated by reference.

[0074] In certain embodiments, the present invention provides a compound of Formula **I,**


wherein LBM is an IAP E3 ubiquitin ligase binding moiety 

,




, 


, or




; thereby forming a compound of formula **I-k'-l**, **I-k'-2, I-k'-3,** or **I-k'-4** respectively:




I-k'-1



I-k'-2




I-k'-3



I-k'-4


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein each of the variables R^1, R^3, R^4, R^5, R^6, and R^7, is as defined and described in WO 2017/011590 and US 2017/0037004, the entirety of each of which is herein incorporated by reference.

[0075] In certain embodiments, the present invention provides a compound of formula **I,** wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety




;

Thereby forming a compound of formula **1-1**:



1-1

or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described herein, and wherein:








X^1 is a bivalent moiety selected from a covalent bond, $-CH_{2-}$, -C(O)-, -C(S)-, or  ;


R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, $-S(0)_2R$, $-NR_2$, or an optionally substituted C_{i-4} aliphatic;

each R^2 is independently hydrogen, $-R^6$, halogen, -CN, -NO2, -OR, -SR,

$-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

Ring A is a bi- or tricyclic ring selected from



, or wherein

Ring B is a fused ring selected from 6-membered aryl containing 0-2 nitrogen atoms, 5 to 7-membered partially saturated carbocyclyl, 5 to 7-membered partially saturated heterocyclyl with 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen

or sulfur;


R^3 is selected from hydrogen, halogen, -OR, $-N(R)_2$, or -SR;


each R^4 is independently hydrogen, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

R^5 is hydrogen, Ci_{-4} aliphatic, or -CN;


each R^6 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

L^1 is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-so hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -O-, -NR-, -S-, -OC(O)-, -C(0)0-, -C(O)-, -S(O)-, $-S(0)_2-$, $-NRS(0)_2-$, $-S(0)_2NR-$, -NRC(O)-, -C(O)NR-, -OC(O)NR-, –NRC(O)O-,





, or



, wherein:

each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroaryl enyl having 1-4 heteroatoms independently

selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

m is 0, 1, 2, 3 or 4;


each of n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and

each R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.


[0076] Where a point of attachment of-$(R^2)_n$ is depicted on Ring B, it is intended, and one of ordinary skill in the art would appreciate, that the point of attachment of -$(R^2)_n$ may be on Ring A and may also be at any available carbon or nitrogen atom on Ring A including the ring to which Ring B is fused. Where -R^2 is attached to a nitrogen atom bound to R^4 or R^5, R^4 or R^5 is absent and -R^2 takes the place of the R^4 or R^5 group. Where -R^2 is attached to a carbon atom bound to R^3, R^3 is absent and -R^2 takes the place of the R^3 group.

[0077] In certain embodiments, the present invention provides a compound of formula I, wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety



;


Thereby forming a compound of formula **I-l′**:



I-l′

or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and

described herein, and wherein:




















X^1 is a bivalent moiety selected from a covalent bond, $-CH_{2-}$, -C(O)-, -C(S)-, or  ;


X^2 is a carbon atom or silicon atom;


X^3 is a bivalent moiety selected from $-CH_{2-}$ or $-Si(R_2)-$;


R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, $-S(0)_2R$, $-N(R)_2$, $-Si(R)_3$, or an optionally substituted C_{i-4} aliphatic;

each R^2 is independently hydrogen, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

Ring A is a bi- or tricyclic ring selected from  , , ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  .





, or


wherein


Ring B is a fused ring selected from 6-membered aryl containing 0-2 nitrogen atoms, 5 to 7-membered partially saturated carbocyclyl, 5 to 7-membered partially saturated heterocyclyl with 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;


R^3 is selected from hydrogen, halogen, -OR, -N(R) $_2$, or -SR;


each R^4 is independently hydrogen, - R^6, halogen, -CN, -N0 $_2$, -OR, -SR, -NR_2, -S(0) $_2$R, -S(0) $_2$$NR_2$, -S(0)R, -C(0)R, -C(0)0R, -C(0)NR $_2$, -C(0)N(R)0R, -0C(0)R, -0C(0)NR $_2$, -N(R)C(0)0R, -N(R)C(0)R, -N(R)C(0)NR $_2$, or -N(R)S(0) $_2$R;

R^5 is hydrogen, C_{i-4} aliphatic, or -CN;

each R^6 is independently an optionally substituted group selected from C_{i-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

L^1 is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-so hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -NR-, -S-, -OC(O)-, -C(0)0-, -C(O)-, -S(O)-, -S(0) $_2$-, -NRS(0) $_2$-, -S(0) $_2$NR-, -NRC(O)-, -C(O)NR-, -OC(O)NR-, –NRC(O)O-,


,


, or


, wherein:

each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl,

an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

m is 0, 1, 2, 3 or 4;


each of n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and

each R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:


two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[0078] Where a point of attachment of-$(R^2)_n$ is depicted on Ring B, it is intended, and one of ordinary skill in the art would appreciate, that the point of attachment of -$(R^2)_n$ may be on Ring A and may also be at any available carbon or nitrogen atom on Ring A including the ring to which Ring B is fused. Where -R^2 is attached to a nitrogen atom bound to R^4 or R^5, R^4 or R^5 is absent and -R^2 takes the place of the R^4 or R^5 group. Where -R^2 is attached to a carbon atom bound to R^3, R^3 is absent and -R^2 takes the place of the R^3 group.

[0079] In some embodiments, a compound of formala I-I′ above is provided as a compound of formula 1-1" or formula 1-1'":



1-1′′




I-l′′′

or a pharmaceutically acceptable salt thereof, wherein:


each of IRAK, Ring A, L, L^1, R^1, R^2, X^1, and m is as defined above.

[0080] In certain embodiments, the present invention provides a compound of formula **I,** wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety



;

Thereby forming a compound of formula **I-m:**






I-m

or a pharmaceutically acceptable salt thereof, wherein, L and IRAK are as defined above and described in embodiments herein, and wherein:

X^1 is a bivalent moiety selected from a covalent bond, $-CH_{2-}$, -C(O)-, -C(S)-, or  ;

R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, $-S(0)_2R$, $-NR_2$, or an optionally substituted C_{i-4} aliphatic;

Ring A is a mono- or bicyclic ring selected from  ,  ,



each R^2 is independently hydrogen, $-R^6$, halogen, -CN, $-NO_2$, -OR, -SR,

$-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;


Ring B is selected from a 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;


each of R^3 and R^4 is independently hydrogen, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

R^5 is hydrogen, Ci_{-4} aliphatic, or -CN;

each R^6 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

L^1 is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-so hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -O-, -NR-, -S-, -OC(O)-, -C(O)O-, -C(O)-, -S(O)-, $-S(O)_2-$, $-NRS(O)_2-$, $-S(O)_2NR-$, -NRC(O)-, -C(O)NR-, -OC(O)NR-, –NRC(O)O-,





, or

, wherein:


each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected

from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

m is 0, 1, or 2;

n is 0, 1, 2, 3, or 4;

p is 0 or 1, wherein when p is 0, the bond connecting Ring A and Ring B is connected to




;

each of q is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and

each R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:


two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[0081] In certain embodiments, the present invention provides a compound of formula **I,** wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety




;

Thereby forming a compound of formula I-m':



I-m'























or a pharmaceutically acceptable salt thereof, wherein, L and IRAK are as defined above and described in embodiments herein, and wherein:


X^1 is a bivalent moiety selected from a covalent bond, $-CH_{2-}$, -C(O)-, -C(S)-, or  ;

X^2 is a carbon atom or silicon atom;

X^3 is a bivalent moiety selected from $-CH_{2-}$ or $-Si(R_2)-$;

R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, $-S(0)_2R$, $-N(R)_2$, $-Si(R)_3$, or an optionally substituted C_{i-4} aliphatic;

Ring A is a mono- or bicyclic ring selected from  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  .



each R^2 is independently hydrogen, $-R^6$, halogen, -CN, -NO2, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;



Ring B is selected from a 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;

each of R^3 and R^4 is independently hydrogen, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

R^5 is hydrogen, Ci_{-4} aliphatic, or -CN;

each R^6 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;


L^1 is a covalent bond or a bivalent, saturated or unsaturated, straight or branched C_{1-50} hydrocarbon

chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -NR-, -S-, -OC(O)-, -C(0)0-, -C(O)-, -S(O)-, -S(0)$_2$-, -NRS(0)$_2$-, -S(0)$_2$NR-, -NRC(O)-, -C(O)NR-, -OC(O)NR-, –NRC(O)O-,  ,  , or , wherein:

each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

m is 0, 1, or 2;

n is 0, 1, 2, 3, or 4;

p is 0 or 1, wherein when p is 0, the bond connecting Ring A and Ring B is connected to  ;


each of q is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and

each R is independently hydrogen, or an optionally substituted group selected from C$_{1-6}$ aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring


having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[0082] In some embodiments, a compound of formala **I-m'** above is provided as a compound of formula **I-m"** or formula **I-m'":**



I-m″




I-m‴

or a pharmaceutically acceptable salt thereof, wherein:


each of IRAK, Ring A, Ring B, L, L^1, R^1, R^2, R^3, X^1, p, and m is as defined above.

[0083] In certain embodiments, the present invention provides a compound of formula **I,** wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety




;

Thereby forming a compound of formula **I-n:**





















I-n













or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein:










X^1 is a bivalent moiety selected from a covalent bond, $-CH_{2-}$, -C(O)-, -C(S)-, or  ;


R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, $-S(0)_2R$, $-NR_2$, or an optionally substituted C_{i-4} aliphatic;


Ring A is a mono- or bicyclic ring selected from  ,  ,  ,  ,  ,  ,


(R3)n
B
p
(R2)m
N
R4
N
NR5
,

(R3)n
B
p
(R2)m
N
N
NR5
,

(R3)n
B
p
(R2)m
N
N
R4
N
,

(R3)n
B
p
(R2)m
N
R4
N
N
,

(R3)n
B
p
(R2)m
N
O
,

(R3)n
B
p
(R2)m
N
O
,

(R3)n
B
p
(R2)m
N
O
,

(R3)n
B
p
(R2)m
N
S
,

(R3)n
B
p
(R2)m
N
NR5
,



, or


;


each R^2 is independently hydrogen, $-R^6$, halogen, -CN, -NO2, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;


Ring B is selected from a 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;


each of R^3 and R^4 is independently hydrogen, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

R^5 is hydrogen, Ci_{-4} aliphatic, or -CN;


each R^6 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

L^1 is a covalent bond or a bivalent, saturated or unsaturated, straight or branched C_{1-50} hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -NR-, -S-, -OC(O)-, -C(0)0-, -C(O)-, -S(O)-, $-S(0)_2-$, $-NRS(0)_2-$, $-S(0)_2NR-$, -NRC(O)-, -C(O)NR-, -OC(O)NR-, –NRC(O)O-,


,


,


,

 , or , wherein:

each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

m is 0, 1, or 2;

n is 0, 1, 2, 3, or 4;


p is 0 or 1;

each of q is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and

each R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:


two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[0084] In certain embodiments, the present invention provides a compound of formula **I,** wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety




;

Thereby forming a compound of formula **I-n′**:



I-n′



or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein:


X^1 is a bivalent moiety selected from a covalent bond, $-CH_{2-}$, -C(O)-, -C(S)-, or  ;













X^2 is a carbon atom or silicon atom;










X^3 is a bivalent moiety selected from $-CH_{2-}$ or $-Si(R_2)-$;


R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, $-S(0)_2R$, $-N(R)_2$, $-Si(R)_3$, or an optionally substituted C_{i-4} aliphatic;


Ring A is a mono- or bicyclic ring selected from  ,  ,




















,

,

,

,

,

,

,

,

,



,


,


,


, or


;

each R^2 is independently hydrogen, $-R^6$, halogen, -CN, -NO2, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;






Ring B is selected from a 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;

each of R^3 and R^4 is independently hydrogen, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

R^5 is hydrogen, Ci_{-4} aliphatic, or -CN;

each R^6 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms

independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

L^1 is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-so hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -O-, -NR-, -S-, -OC(O)-, -C(O)O-, -C(O)-, -S(O)-, $-S(O)_2-$, $-NRS(O)_2-$, $-S(O)_2NR-$, -NRC(O)-, -C(O)NR-, -OC(O)NR-, –NRC(O)O-,  ,  ,  ,  , or  , wherein:

each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroaryl enyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

m is 0, 1, or 2;

n is 0, 1, 2, 3, or 4;

p is 0 or 1;


each of q is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and

each R is independently hydrogen, or an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring


having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

[0085] two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[0086] In some embodiments, a compound of formala **I-n'** above is provided as a compound of formula **I-n"** or formula **I-n'":**



I-n''




I-n'''

or a pharmaceutically acceptable salt thereof, wherein:


each of IRAK, Ring A, Ring B, L, L^1, R^1, R^2, R^3, X^1, p, and m is as defined above.

[0087] In certain embodiments, the present invention provides a compound of formula **I,** wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety



;

thereby forming a compound of formula **I-o:**



I-o

or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein:

Ar is aryl, heteroaryl, cycloalkyl, or heterocyclyl;

L^1 is absent or a linker selected from the group consisting of -S0 $_2$, -S0 $_2$R'; S0 $_2$R'R",- SOzNR'R"; -$SO_2NR'R"C(=O)$; -NR'SO_2R"; -R'$SO_2NR'R'"$; -C(=0); -C(=0)R'; -0C(=0)R'; -C(=O)NR'R"; -NR'C(=0)R"; -NR'C(=0)R"C(=0); -OR'; -NR'R'"; -SR'; -N_3-C(=0)0R'; -O(CR'R")rC(=O)R'; -0(CR'R")rNR"C(=0)R; -0(CR'R")rNR"S0 $_2$R'; -0C(=0)NRR"; -NR'C(=O)OR"; and substituted or unsubstituted Ci-C_6 aliphatic alkyl;

wherein R', R", and R'" are individually selected from hydrogen; substituted or unsubstituted alkyl; substituted or unsubstituted alkenyl; substituted or unsubstituted ether; substituted or unsubstituted cycloalkyl; substituted or unsubstituted heterocyclyl; substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkylheteroaryl, or substituted or unsubstituted amine; and r is an integer from 1 to 6;

R^1, R^2, and R^3 are individually selected from the group consisting of hydrogen, halogen, hydroxyl, azide, alkoxyl, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, cyano, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, substituted or unsubstituted amine, substituted or unsubstituted amide, nitro, ester, morpholino, dioxolane, substituted or unsubstituted alkyl, substituted or unsubstituted alkylhalide, substituted or unsubstituted aralkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkyl; substituted or unsubstituted heterocyclyl; substituted or unsubstituted

cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkylheteroaryl, and combinations thereof; or

wherein R^1 and R^2 combine to form a 5-7 membered heterocyclic ring; and wherein when R^1 and R^2 combine to form a 5-7 membered heterocyclic ring, Ar is optionally not fused to the 5-7 membered heterocyclic ring but is a substituent of the 5-7 membered heterocyclic ring;


R^4 and R^5 are individually selected from the group consisting of hydrogen, halogen, hydroxyl, azide, ether, alkoxyl, sulfhydryl, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, substituted or unsubstituted alkyl, substituted or unsubstituted alkylhalide, substituted or unsubstituted aralkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, heterocyclyl, and combinations thereof;

R^8 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkylhalide, substituted or unsubstituted aralkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, and combinations thereof; and


x is 0, 1, or 2;

as described and defined in WO 2017/161119, the entirety of which is herein incorporated by reference.

[0088] In certain embodiments, the present invention provides a compound of formula **I,**



wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety ; thereby forming a compound of formula **I-p:**



I-p


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and further wherein:

A is C, S; substituted of unsubstituted Ci-C_8 alkyl, or combinations thereof;

R^6 and R^7 are individually =0, hydrogen, Ci-Cx alkyl, or R^6 and R^7combine to form =0; and


each of the variables Ar, R^1, R^2, R^3, R^4, R^5, R^8, x, and the bond — is as decribed above and as described and defined in WO 2017/161119, the entirety of each of which is herein incorporated by reference.

[0089] In certain embodiments, the present invention provides a compound of formula **I,**



wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety ;


thereby forming a compound of formula **I-q:**



I-q

or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein each of the variables R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, A, x, and the bond — is as decribed above described and defined in WO 2017/161119, the entirety of each of which is herein incorporated by reference.


[0090] In certain embodiments, the present invention provides a compound of formula **I,**



wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety

;


thereby forming a compound of formula **I-r:**



I-r


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein each of the variables Ar, R^1, R^2, R^3, R^4, R^5, R^8, L, x, y, and the bond — is as decribed above and described and defined in WO 2017/161119, the entirety of each of which is herein incorporated by reference.

[0091] In certain embodiments, the present invention provides a compound of formula **I,**



wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety ;

thereby forming a compound of formula I-s:



I-s


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein:

G comprises C, S, N, substituted of unsubstituted C1-C8 alkyl, or combinations thereof; R^3 is selected from the group consisting of hydrogen, halogen, hydroxyl, azide, alkoxyl,

sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, cyano, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, substituted or unsubstituted amine, substituted or unsubstituted amide, nitro, ester, morpholino, dioxolane, substituted or unsubstituted alkyl, substituted or unsubstituted alkylhalide, substituted or unsubstituted aralkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkyl; substituted or unsubstituted heterocyclyl; substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkylheteroaryl, and combinations thereof; and


each of the variables R^3, R^4, R^5, R^6, R^7, R^8, x, and the bond — is as decribed above and described and defined in WO 2017/161119, the entirety of each of which is herein incorporated by reference.

[0092] In certain embodiments, the present invention provides a compound of formula **I,**



wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety ;


thereby forming a compound of formula **I-t:**



I-t


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein each of the variables R^3, R^4, R^5, R^6, R^7, R^8, x, and the bond — is as decribed above for I-o and described and defined in WO 2017/161119, the entirety of each of which is herein incorporated by reference.

[0093] In certain embodiments, the present invention provides a compound of formula **I,**



wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety ;


thereby forming a compound of formula **I-u:**



I-u


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein each of the variables R^3, R^4, R^5, R^8, L, and the bond — is as decribed above forl-o and described and defined in WO 2017/161119, the entirety of each of which is herein incorporated by reference.

[0094] In certain embodiments, the present invention provides a compound of formula **I,**



wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety ;


thereby forming a compound of formula I-v:



I-v


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein each of the variables R^1, R^3, R^4, R^5, L, y, and the bond --- is as decribed above for I-o and described and defined in WO 2017/161119, the entirety of each of which is herein incorporated by reference.

[0095] In certain embodiments, the present invention provides a compound of formula I, wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety






;


thereby forming a compound of formula I-x:




I-x

or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein each of the variables A, B, C, W, X, Y, and Z is as described and defined in ETS 5,721,246, the entirety of each of which is herein incorporated by reference.


[0096] In certain embodiments, the present invention provides a compound of Formula **I,** wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety  , a DCAF15 E3 ubiquitin ligase binding moiety  , or a VHL E3 ubiquitin ligase binding moiety  ; thereby forming a compound of formula **I-y-l, I-y-2, or I-y-3:**



I-y-1





i-y-2



I-y-3

or a pharmaceutically acceptable salt thereof, wherein IRAK is as defined above and described in embodiments herein, and wherein:

each of X^1, X^2, and X^3 is independently a bivalent moiety selected from a covalent bond, $-CH_{2-}$, –C(O)–, –C(S)–, or  ;

each of X^4 and X^5 is independently a bivalent moiety selected from $-CH_{2-}$, -C(O)-, -C(S)-, or  ;

R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, $-S(0)_2R$, $-NR_2$, or an optionally substituted Ci_{-4} aliphatic;

each of R^2, R^3, and R^4 is independently hydrogen, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

R^5 is hydrogen or Ci_{-6} aliphatic;






each R^6 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

Ring A is a fused ring selected from 6-membered aryl containing 0-2 nitrogen atoms, 5 to 7-membered partially saturated carbocyclyl, 5 to 7-membered partially saturated heterocyclyl

with 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;

Ring B is selected from 6-membered aryl containing 0-2 nitrogen atoms or a 8-10 membered bicyclic heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

Ring C is a selected from 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;

L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-so hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -O-, -NR.-, -S-, -OC(O)-, -C(0)0-, -C(O)-, -S(O)-, -S(0) $_2$-, -NR.S(0) $_2$-, -S(0) $_2$NR-, -NR.C(0)-, -C(O)NR-, -OC(O)NR-, –NRC(O)O-,  ,  ,  ,  , or  , wherein:

each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroaryl enyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

m is 0, 1, 2, 3 or 4;

each of n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;


p is 0, 1, 2, 3 or 4;

q is 0, 1, 2, 3 or 4; and


each R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.


[0097] In certain embodiments, the present invention provides a compound of Formula **I,**




wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety



; thereby forming a compound of formula **I-y'-l** or **I-y"-l:**




I-y′-1






I-y″-1

or a pharmaceutically acceptable salt thereof, wherein IRAK, L, Ring A, X^1, X^2, X^3, R^1, R^2 and m are as described above.


[0098] In certain embodiments, the present invention provides a compound of Formula **I,**

wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety  ,


 , or  , thereby forming a compound of formula **I-z-1, 1-z-2,** or **I-z-3** respectively:



I-z-1



I-z-2



I-z-3

or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described herein, and wherein:

W^1 is CR^6R^7, C=0, C=S, $C=CH_2$, $S0_2$, S(0), P(0)0alkyl, P(0)NHalkyl, $P(0)N(alkyl)_2$, P(0)alkyl, P(0)0H, $P(0)NH_2$;

W^2 is CR^8R^9, C=0, C=S, $C=CH_2$, S02, S(0), P(0)0alkyl, P(0)NHalkyl, $P(0)N(alkyl)_2$, P(0)alkyl, P(0)0H, $P(0)NH_2$;

X is independently selected from NH, NR^3, CH_2, CHR^3, $C(R^3)_2$, O, and S;


n is 0, 1, 2, or 3;


=== is a single or double bond;

wherein when === represents a single bond, n is 0, 1, 2, or 3;

wherein when === represents a double bond, n is 0, 1, or 2;


R^1 is selected from:






and R1*;


or R1 is selected from:





R^2 is alkyl, hydrogen, aliphatic, heteroaliphatic, aryl, heteroaryl or heterocyclic;

or R^1 and R^2 are combined to form a 4, 5, 6, 7, 8, 9, or 10 membered heterocyclo or heteroaryl species, wherein the heterocyclo or heteroaryl species is substituted with R^{12} at any desired position, wherein the heterocyclo or heteroaryl species is optionally further substituted with one or more substituents selected from R^5;

R^{1*} is selected from: 

R^3 is selected at each instance from: alkyl, -C(0)H, -C(0)0H, -C(0)alkyl, -C(0)0alkyl, alkene, and alkyne, aliphatic, heteroaliphatic, aryl, heteroaryl and heteroalkyl;

R^4 is selected at each instance from: alkyl, alkene, alkyne, halogen, hydroxyl, alkoxy, azide, amino, cyano, -NH(aliphatic), -N(aliphatic)2, -NHS0 $_2$(aliphatic), - N(aliphatic)S0 $_2$alkyl, -NHS0 $_2$(aryl, heteroaryl or heterocyclic), -N(alkyl)S0 $_2$(aryl, heteroaryl or heterocyclic) -NHSCkalkenyl, -N(alkyl)S0 $_2$alkenyl, -NHSChalkynyl, -N(alkyl)S0 $_2$alkynyl, and haloalkyl; aliphatic, heteroaliphatic, aryl, heteroaryl, heteroalkyl and carbocyclic;

or two R^4 substituents together with the carbon atom(s) to which they are bound can form a 3, 4, 5 or 6 membered ring; R^5 and R^{14} are selected at each instance from: hydrogen, alkyl, alkene, alkyne, halogen, hydroxyl, alkoxy, azide, amino, cyano, -NH(aliphatic), -N(aliphatic)2, -NHS0 $_2$(aliphatic), -N(aliphatic)S0 $_2$alkyl, -NHSCktaryl, heteroaryl or

heterocyclic), -N(alkyl)S0 $_{2(}$aryl, heteroaryl or heterocyclic) -NHSCkalkenyl, -N(alkyl)S0 $_{2}$alkenyl, -NHS02alkynyl, -N(alkyl)S0 $_{2}$alkynyl, and haloalkyl; aliphatic, heteroaliphatic, aryl, heteroaryl, heteroalkyl and carbocyclic;

or R^5 is independently selected from C(0)R^4, cyano, aryl, aryloxy, heterocyclo, heteroaryl, arylalkyl, alkoxy, hydroxyl, O-arylalkyl, or cycloalkyl;

R^6, R^7, R^8, R^9, R^{10}, and R^{11}, are independently selected from hydrogen, alkyl, aliphatic, heteroaliphatic, hydroxyl, alkoxy, amine, -NH(aliphatic), and -N(aliphatic)2;

or R^6 and R^7 together with the carbon to which they are bound form a 3-, 4-, 5-, or 6- membered spirocarbocycle, or a 4-, 5-, or 6-membered spiroheterocycle comprising 1 or 2 heteroatoms selected from N and O;

or R^8 and R^9 together with the carbon to which they are bound form a 3-, 4-, 5-, or 6- membered spirocarbocycle, or a 4-, 5-, or 6-membered spiroheterocycle comprising 1 or 2 heteroatoms selected from N and O;

or R^{10} and R^{11} together with the carbon to which they are bound form a 3-, 4-, 5-, or 6- membered spirocarbocycle, or a 4-, 5-, or 6-membered spiroheterocycle comprising 1 or 2 heteroatoms selected from N and O;

or R^6 and R^8 form a 1 or 2 carbon bridged ring;

or R^6 and R^{10} form a 1 or 2 carbon bridged ring;

or R^8 and R^{10} form a 1 or 2 carbon bridged ring;

or R^{14} and R^6 form a 3, 4, 5, or 6 carbon fused ring;


or R^{14} and R^{10} form a 3, 4, 5, or 6 carbon fused ring;

or R^{14} and R^8 form a 1 or 2 carbon bridged ring;


or R^{14} and R^4 form a 3, 4, 5, or 6 carbon fused ring wherein R^5 is on the carbon alpha to R^{14} or a 1, 2, 3, or 4 carbon bridged ring wherein R^5 is not on the carbon alpha to R^{14};

R^{12} is L;


R^{17} is selected from:




Y is independently selected from N, CH, or CR^{101}, wherein 0, 1, 2, or 3 instances of Y are selected to be N;

R^{101} is independently selected at each occurrence from hydrogen, alkyl, alkene, alkyne, haloalkyl, alkoxy, hydroxyl, aryl, heteroaryl, heterocycle, arylalkyl, heteroarylalkyl, heterocycloalkyl, aryloxy, heteroaryloxy, CN, -COOalkyl, COOH, NO_2, F, Cl, Br, I, CF_3, NH_2, NHalkyl, $N(alkyl)_2$, aliphatic, and heteroaliphatic as defined in WO 2017/197051, the entirety of which is herein incorporated by reference, and wherein 

is attached to R^1, the ring formed by combining R^1 and R^2, or R^{17} at the site of attachment of


R^{12} as defined in WO 2017/197051 such that  takes the place of the R^{12} substituent.

[0099] In certain embodiments, the present invention provides a compound of Formula **I,**




wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety ;

thereby forming a compound of formula **I-aa:**




I-aa



or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein:




X^1 is a bivalent moiety selected from a covalent bond, $-CH_{2-}$, -C(O)-, -C(S)-, or  ;






R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, $-S(0)_2R$, $-NR_2$, or an optionally substituted Ci_{-4} aliphatic;






each R^2 is independently hydrogen, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)OR, $-C(0)NR_2$, -C(0)N(R)OR, -OC(0)R, $-OC(0)NR_2$, -N(R)C(0)OR, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;



Ring A is a bi- or tricyclic ring selected from  wherein Ring B is other than





imidazo or benzo,  ,  wherein Ring B is other than benzo,






 wherein Ring B is other than benzo,  ,  ,






 ,  ,  ,  ,  ,


 ,  ,  ,  ,  ,

 ,  wherein Ring B is other than benzo,

 ,  ,  ,  ,

 ,  ,  ,  ,  ,

 ,  ,  ,  ,  ,



wherein

Ring B is a fused ring selected from 6-membered aryl containing 0-2 nitrogen atoms, 5 to 7-membered partially saturated carbocyclyl, 5 to 7-membered partially saturated heterocyclyl with 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;

R^3 is selected from hydrogen, halogen, -OR, $-N(R)_2$, or -SR;

each R^4 is independently hydrogen, $-R^6$, halogen, -CN, -NO2, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

R^5 is hydrogen, Ci_{-4} aliphatic, or -CN;


each R^6 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

m is 0, 1, 2, 3 or 4; and

each R is independently hydrogen, or an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:


two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[00100] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety ;


thereby forming a compound of formula **I-aa':**



I-aa′

or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and

described in embodiments herein, and wherein:

















X^1 is a bivalent moiety selected from a covalent bond, $-CH_{2-}$, -C(O)-, –C(S)–, or  ;



X^2 is a carbon atom or silicon atom;

X^3 is a bivalent moiety selected from $-CH_{2-}$ or $-Si(R_2)-$;




















R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, $-S(0)_2R$, $-N(R)_2$, $-Si(R)_3$, or an optionally substituted C_{i-4} aliphatic;











each R^2 is independently hydrogen, deuterium, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-Si(R)_3$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, $-N(R)C(0)0R$, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

Ring A is a bi- or tricyclic ring selected from  wherein Ring B is other than imidazo or benzo,  ,  , wherein Ring B is other than benzo,  wherein Ring B is other than benzo,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  , 





wherein Ring B is other than benzo,





wherein

Ring B is a fused ring selected from 6-membered aryl containing 0-2 nitrogen atoms, 5 to 7-membered partially saturated carbocyclyl, 5 to 7-membered partially saturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;

R^3 is selected from hydrogen, halogen, -OR, $-N(R)_2$, or -SR;

each R^4 is independently hydrogen, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

R^5 is hydrogen, Ci_{-4} aliphatic, or -CN;

each R^6 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;


m is 0, 1, 2, 3 or 4; and

each R is independently hydrogen, or an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring


having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[00101] In some embodiments, the compound of formala **I-aa'** above is provided as a compound of formula **I-aa"** or formula **I-aa'":**



I-aa″




I-aa‴


or a pharmaceutically acceptable salt thereof, wherein:

each of IRAK, Ring A, L, R^1, R^2, X^1, X^2, X^3, and m is as defined above.

[00102] In certain embodiments, the present invention provides a compound of Formula **I,** wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety




; thereby forming a compound of formula **I-bb:**






























I-bb


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and

described in embodiments herein, and wherein:

X^1 is a bivalent moiety selected from a covalent bond, $-CH_{2-}$, -C(0)-, -C(S)-, or  ;

R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, $-S(0)_2R$, $-NR_2$, or an optionally substituted C_{i-4} aliphatic;

Ring A is a mono- or bicyclic ring selected from  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  , , , , , .



each R^2 is independently hydrogen, $-R^6$, halogen, –CN, $-NO_{¾}$ -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

Ring B is selected from a 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;

each of R^3 and R^4 is independently hydrogen, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;


R^5 is hydrogen, Ci_{-4} aliphatic, or -CN;

each R^6 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

m is 0, 1, or 2;

n is 0, 1, 2, 3, or 4;

p is 0 or 1, wherein when p is 0, the bond connecting Ring A and Ring B is connected to




; and

each R is independently hydrogen, or an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring


having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[00103] In certain embodiments, the present invention provides a compound of Formula **I,** wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety




; thereby forming a compound of formula **I-bb':**



I-bb'



or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein:


X^1 is a bivalent moiety selected from a covalent bond, $-CH_{2-}$, -C(O)-, -C(S)-, or  ;

X^2 is a carbon atom or silicon atom;

X^3 is a bivalent moiety selected from $-CH_{2-}$ or $-Si(R_2)-$;

R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, –S(0)R, $-S(0)_2R$, $-N(R)_2$, $-Si(R)_3$, or an optionally substituted Ci_{-4} aliphatic;

Ring A is a mono- or bicyclic ring selected from  ,  ,



each R^2 is independently hydrogen, deuterium, $-R^6$, halogen, -CN, -NO2, -OR, -SR, $-NR_2$, $-Si(R)_3$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

Ring B is selected from a 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered

heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;

each of R^3 and R^4 is independently hydrogen, $-R^6$, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, -S(O)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, or $-N(R)S(O)_2R$;


R^5 is hydrogen, C_{1-4} aliphatic, or -CN;

each R^6 is independently an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

m is 0, 1, or 2;

n is 0, 1, 2, 3, or 4;

p is 0 or 1, wherein when p is 0, the bond connecting Ring A and Ring B is connected to




; and


each R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[00104] In certain embodiments, the present invention provides a compound of Formula **I,** wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety




; thereby forming a compound of formula **I-cc:**

















I-cc













or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein:


X^1 is a bivalent moiety selected from a covalent bond, $-CH_{2-}$, -C(O)-, -C(S)-, or  ;


R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, $-S(0)_2R$, $-NR_2$, or an optionally substituted C_{i-4} aliphatic;


Ring A is a mono- or bicyclic ring selected from  ,  ,

































,



,



,


,


,


,


,


, or


;

each R^2 is independently hydrogen, $-R^6$, halogen, -CN, -NO2, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

Ring B is selected from a 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;

each of R^3 and R^4 is independently hydrogen, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)OR, $-C(0)NR_2$, -C(0)N(R)OR, -OC(0)R, $-OC(0)NR_2$, -N(R)C(0)OR, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

R^5 is hydrogen, Ci_{-4} aliphatic, or -CN;

each R^6 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

m is 0, 1, or 2;


n is 0, 1, 2, 3, or 4;

p is 0 or 1; and


each R is independently hydrogen, or an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[00105] In some embodiments, the compound of formala **I-bb'** above is provided as a compound of formula **I-bb"** or formula **I-bb'":**



I-bb"




I-bb‴


or a pharmaceutically acceptable salt thereof, wherein:

each of IRAK, Ring A, Ring B, L, R^1, R^2, R^3, X^1, X^2, X^3, p, and m is as defined above.

[00106] In certain embodiments, the present invention provides a compound of Formula **I,** wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety




; thereby forming a compound of formula **I-cc':**



I-cc′

or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein:












X^1 is a bivalent moiety selected from a covalent bond, $-CH_{2-}$, -C(O)-, -C(S)-, or  ;













X^2 is a carbon atom or silicon atom;













X^3 is a bivalent moiety selected from $-CH_{2-}$ or $-Si(R_2)-$;

R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR,

–S(0)R, -S(0) $_2$R, -N(R) $_2$, -Si(R)$_3$, or an optionally substituted Ci-$_4$ aliphatic;

Ring A is a mono- or bicyclic ring selected from  ,  ,  ,  ,  ,  ,  ,  ,  ,  , 


,

,

,

,

,

,

,

,

,

,

,


, or ;

each R^2 is independently hydrogen, deuterium, $-R^6$, halogen, -CN, -NO2, -OR, -SR, $-NR_2$, $-Si(R)_3$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

Ring B is selected from a 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;

each of R^3 and R^4 is independently hydrogen, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

R^5 is hydrogen, Ci_{-4} aliphatic, or -CN;

each R^6 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

m is 0, 1, or 2;


n is 0, 1, 2, 3, or 4;

p is 0 or 1; and


each R is independently hydrogen, or an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[00107] In some embodiments, a compound of formala **I-cc'** above is provided as a compound of formula **I-cc"** or formula **I-cc'":**



I-cc″




I-cc‴


or a pharmaceutically acceptable salt thereof, wherein:

each of IRAK, Ring A, Ring B, L, R^1, R^2, R^3, X^1, X^2, X^3, p, n, and m is as defined above.


[00108] In certain embodiments, the present invention provides a compound of Formula **I,**




wherein IRAK is an IRAK-4 inhibitor or



; thereby forming a compound of formula **I-dd-1** or **I-dd-2** respectively:



I-dd-1



I-dd-2

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

A is optionally substituted heteroaryl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted (heterocycloalkyl)alkyl, optionally substituted aralkyl, optionally substituted heteroaralkyl, optionally substituted cycloalkyl-$NR_{x—}$, optionally substituted heterocycloalkyl-$NR_{x—}$, optionally substituted aryl-$NR_{x—}$, optionally substituted heteroaryl-$NR_{X—}$, optionally substituted cycloalkyl-0 —, optionally substituted heterocycloalkyl-0 —, optionally substituted aryl-0 — or optionally substituted heteroaryl-0 —; e.g., wherein each optional substituent independently represents an occurrence of R_z;

B is hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxy, —$NR_aR_{b,}$ optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, optionally substituted (cycloalkyl)alkyl, optionally substituted (heterocycloalkyl)alkyl, optionally substituted aralkyl, optionally substituted heteroaralkyl, optionally substituted cycloalkyl-$NR_{x—}$, optionally substituted heterocycloalkyl-$NR_{x—}$, optionally substituted aryl-$NR_{x—}$, optionally substituted heteroaryl-$NR_{X—}$, optionally substituted cycloalkyl-

O—, optionally substituted heterocycloalkyl-0 —, optionally substituted aryl-0 —, optionally substituted heteroaryl-0 —; e.g., wherein each optional substituent independently represents an occurrence of R_y;

Q is absent or optionally substituted heterocycloalkyl, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted (heterocycloalkyl)alkyl, optionally substituted (heteroaryl)alkyl, optionally substituted aralkyl, optionally substituted (cycloalkyl)alkyl, —NR_3R_4, —O—R_3 or —S—R; e.g., wherein each optional substituent independently represents an occurrence of R_z;

W is N or CH;

Ri is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted (heterocycloalkyl)alkyl, optionally substituted heterocycloalkyl, optionally substituted aralkyl, optionally substituted (heteroaryl)alkyl-, optionally substituted alkoxyalkyl, optionally substituted aminoalkyl, or —$(CH_2)_m$—R_2; e.g., wherein each optional substituent independently represents halo, hydroxy, alkoxy, amino, nitro, cycloalkyl, aryl, heterocycloalkyl or heteroaryl;

R_2 is hydrogen, —NR_aR_b, alkoxy, hydroxy, optionally substituted heteroaryl or optionally substituted heterocycloalkyl; e.g., wherein each optional substituent independently represents an occurrence of R_y;

each R_3 and R_4 is independently selected from optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted aralkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted (heteroaryl)alkyl and optionally substituted (heterocycloalkyl)alkyl; e.g., wherein each optional substituent is independently selected from alkyl, halo, haloalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, amino, nitro, cycloalkyl, (cycloalkyl)alkyl, aryl, aralkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, heteroaryl and (heteroaryl)alkyl;

each R_a and R_b is independently selected from hydrogen, alkyl, aminoalkyl, acyl and heterocyclyl; or R_a and R_b are taken together with the nitrogen to which they are attached to form an optionally substituted ring;

R_x is hydrogen, alkyl, hydroxy, hydroxyalkyl, acyl or cycloalkyl;

each R_y and R_x is independently selected from hydroxy, hydroxyalkyl, halo, alkyl, oxo, haloalkyl, alkoxy, alkenyloxy, amino, nitro, cyano, —SH, —S(alkyl), glycinate, ester, thioester,

cycloalkyl, heterocycloalkyl, aryl, heteroaryl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, aralkyl, and (heteroaryl)alkyl; optionally wherein the hydroxy, hydroxyalkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are further substituted by one or more substituents selected from alkyl, halo, alkenyl, amino, nitro, cycloalkyl and (cycloalkyl)alkyl; or


R_y and R_z taken together with the atoms to which they are attached form an alkyl chain having 1-10 carbon atoms; optionally wherein 1-3 carbon atoms are replaced by O, NH or S;

m is 1, 2, or 3; and


n is 1 or 2;

as defined and described in WO 2017/009798 and US 2018/0201609, the entirety of each of which is herein incorporated by reference.


[00109] In certain embodiments, the present invention provides a compound of Formula **I,**




wherein IRAK is an IRAK4 inhibitor ,




,




or




[1]; thereby forming a compound of formula **I-ee-1, I-ee-2, I-ee-3,** or **I-ee-4** respectively:




I-ee-1



I-ee-2



I-ee-3



I-ee-4

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

Ring A is selected from phenyl and 5- or 6-membered heteroaryl;

Ring B is selected from phenyl and 5- or 6-membered heteroaryl;

n is 0, 1, or 2;

p is 0, 1, or 2;

one of W and X is N, and the other of W and X is C;

Y is N or C—R^2;

R^1 is selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, 3- to 6-membered saturated heterocyclyl, halo, —CN, —$C(R^{1a})$=$NR(OR^{1a})$, —$C(R^{1a})$=$N(R^{1a})$, —$C(O)R^{1a}$, —$C(O)_2R^{1a}$, —$C(O)N(R^{1a})_2$, —NO_2, —$N(R^{1a})_2$, —$N(R^{1a})C(O)R^{1a}$, —$N(R^{1a})C(O)_2R^{1a}$, —$N(R^{1a})C(O)N(R^{1a})_2$, —$N(R^{1a})S(O)_2R^{1a}$, —OR^{1a}, —$OC(O)R^{1a}$, —$OC(O)N(R^{1a})_2$, —SR^{1a}, —$S(0)R^{1a}$, —$S(0)_2R^{1a}$, —$S(0)N(R^{1a})_2$, and —$S(0)_2N(R^{1a})_2$, wherein said Ci-ealkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C3-6cycloalkyl, and 3- to 6-membered saturated heterocyclyl are optionally substituted with one or more R^{10}; or two R^1 substituents, together with their intervening atoms, form a Cs-vcycloalkyl or a saturated 5- to 7-membered heterocyclic ring, wherein said Cs-vcycloalkyl or a saturated 5- to 7-membered heterocyclic ring are optionally substituted with one or more R^{15};

R^{1a} in each occurrence is independently selected from H, Ci_{-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3- to 6-membered monocyclic carbocyclyl, and 3- to 6-membered monocyclic heterocyclyl wherein said Ci_{-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3- to 6-membered monocyclic carbocyclyl, and 3- to 6-membered monocyclic heterocyclyl in each occurrence are optionally and independently substituted with one or more R^{10};

R^{10} in each occurrence is independently selected from Ci_{-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3- to 6-membered carbocyclyl, 3- to 6-membered heterocyclyl, halo, —CN, —$C(R^{10a})$=$NR(OR^{10a})$, —$C(R^{10a})$=$N(R^{10a})$, —$C(O)R^{10a}$, —$C(O)_2R^{10a}$, —$C(O)N(R^{10a})_2$, —$N0_2$, —$N(R^{10a})_2$, —$N(R^{10a})C(O)R^{10a}$, —$N(R^{10a})C(0)_2Rio_a$, —$N(R^{10a})C(O)N(R^{10a})_2$, —$N(R^{10a})S(O)_2R^{10a}$, —$OR^{10a}$, —$OC(O)R^{10a}$, —$OC(O)N(R^{10a})_2$, —$SR^{10a}$, —$S(O)R^{10a}$, —$S(O)_2R^{10a}$, —$S(O)N(R^{10a})_2$, and —$S(O)_2N(R^{10a})_2$;

R^{10a} in each occurrence is independently selected from H and Ci_{-6}alkyl, wherein said Ci_{-6}alkyl is optionally substituted with one or more halo;

R^{15} in each occurrence is independently selected from Ci_{-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3- to 6-membered carbocyclyl, 3- to 6-membered heterocyclyl, halo, —CN, —$C(R^{15a})$=$NR(OR^{15a})$, —$C(R^{15a})$=$N(R^{15a})$, —$C(0)R^{15a}$, —$C(0)_2R^{15a}$, —$C(0)N(R^{15a})_2$, —$N0_2$, —$N(R^{15a})_2$, —$N(R^{15a})C(0)R^{15a}$, —$N(R^{15a})C(0)_2R^{15a}$, —$N(R^{15a})C(0)N(R^{15a})_2$, —

$N(R^{15a})S(0)_2R^{15a}$, —OR^{15a}, —$0C(0)R^{15a}$, —$0C(0)N(R^{15a})_2$, —SR^{15a}, —$S(0)R^{15a}$, —$S(0)_2R^{15a}$, —$S(0)N(R^{15a})_2$, and —$S(0)_2N(R^{15a})_2$;

R^{15a} in each occurrence is independently selected from H and Ci_{-6}alkyl, wherein said Ci_{-6}alkyl is optionally substituted with one or more halo;

R^2 is selected from H, Ci_{-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, halo, —CN, —$C(R^{2a})$═$NR(OR^{2a})$, —$C(R^{2a})$=$N(R^2)$, —$C(0)R^{2a}$, —$C(0)_2R^{2a}$, —$C(0)N(R^{2a})_2$, —$N0_2$, —$N(R^{2a})_2$, —$N(R^{2a})C(0)R^{2a}$, —$N(R^{2a})C(0)_2R^{2a}$, —$N(R^{2a})C(0)N(R^{2a})_2$, —$N(R^{2a})S(0)_2R^{2a}$, —OR^{2a}, —$OC(O)R^{2a}$, —$0C(0)N(R^{2a})_2$, —SR^{2a}, —$S(0)R^{2a}$, —$S(0)_2R^{2a}$, —$S(0)N(R^{2a})_2$, and —$S(0)_2N(R^{2a})_2$, wherein said Ci-ealkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3- to 7-membered carbocyclyl, and 3-7 membered heterocyclyl are optionally substituted with one or more R^{20};

R^{2a} in each occurrence is independently selected from H and Ci_{-6}alkyl, wherein said Ci_{-6}alkyl in each occurrence is optionally and independently substituted with one or more R^{20};

R^{20} in each occurrence is independently selected from Ci_{-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-7}cycloalkyl, 3- to 7-membered saturated heterocyclyl, halo, —CN, —$C(R^{20a})$=$NR(OR^{20a})$, —$C(R^{20a})$=$N(R^{20a})$, —$C(O)R^{20a}$, —$C(O)_2R^{20a}$, —$C(O)N(R^{20a})_2$, —$N0_2$, —$N(R^{20a})_2$, —$N(R^{20a})C(O)R^{20a}$, —$N(R^{20a})C(O)_2R^{20a}$, —$N(R^{20a})C(O)N(R^{20a})_2$, —$N(R^{20a})S(O)_2R^{20a}$, —$OR^{20a}$, —$OC(O)R^{20a}$, —$OC(O)N(R^{20a})_2$, —$SR^{20a}$, —$S(O)R^{20a}$, —$S(O)_2R^{20a}$, —$S(O)N(R^{20a})_2$, and —$S(O)_2N(R^{20a})_2$, wherein said Ci_{-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-7}cycloalkyl, and 3-7 membered saturated heterocyclyl in each occurrence are optionally and independently substituted with one or more R^{25};

R^{20a} in each occurrence is independently selected from H and Ci_{-6}alkyl, wherein said Ci_{-6}alkyl is optionally substituted with R^{25};

R^{25} is selected from halo and —OR^{253};

R^{25a} is selected from H and Ci_{-6}alkyl;

R^3 is selected from Ci_{-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, 3- to 6-membered saturated heterocyclyl, halo, —CN, —$C(R^{3a})$=$NR(OR^{3a})$, —$C(R^{3a})$=$N(R^{3a})$, —$C(0)R^{3a}$, —$C(0)_2R^{3a}$, —$C(0)N(R^{3a})_2$, —$N0_2$, —$N(R^{3a})_2$, —$N(R^{3a})C(0)R^{3a}$, —$N(R^{3a})C(0)_2R^{3a}$, —$N(R^{3a})C(0)N(R^{3a})_2$, —$N(R^{3a})S(0)_2R^{3a}$, —OR^{3a}, —$0C(0)R^{3a}$, —$0C(0)N(R^{3a})_2$, —SR^{3a}, —$S(0)R^{3a}$, —$S(0)_2R^{3a}$, —$S(0)N(R^{3a})_2$, and —$S(0)_2N(R^{3a})_2$, wherein said Ci_{-6}alkyl, C_2.

$_6$alkenyl, C_{2-6}alkynyl, C3-6cycloalkyl, and 3- to 6-membered saturated heterocyclyl are optionally substituted with one or more R^{30};

R^{3a} in each occurrence is independently selected from H, Ci_{-6}alkyl, 3- to 6-membered carbocyclyl, and 3- to 6-membered heterocyclyl, wherein said Ci_{-6}alkyl, 3- to 6-membered carbocyclyl, and 3- to 6-membered heterocyclyl in each occurrence are optionally and independently substituted with one or more R^{30};

R^{30} in each occurrence is independently selected from Ci_{-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3- to 6-membered carbocyclyl, 3- to 6-membered heterocyclyl, halo, —CN, —$C(R^{30a})$═$NR(OR^{30a})$, —$C(R^{30a})$═$N(R^{30a})$, —$C(O)R^{30a}$, —$C(O)_2R^{30a}$, —$C(O)N(R^{30a})_2$, —NO_2, —$N(R^{30a})_2$, —$N(R^{30a})C(O)R^{30a}$, —$N(R^{30a})C(O)_2R^{30a}$, —$N(R^{30a})C(O)N(R^{30a})_2$, —$N(R^{30a})S(O)_2R^{30a}$, —$OR^{30a}$, —$OC(O)R^{30a}$, —$OC(O)N(R^{30a})_2$, —$SR^{30a}$, —$S(O)R^{30a}$ $S(O)_2R^{30a}$, —$S(O)N(R^{30a})_2$, and —$S(O)_2N(R^{30a})_2$, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3-6 membered carboyclyl, 3- to 6-membered heterocyclyl in each occurrence are optionally and independently substituted with one or more R^{35};

R^{30a} in each occurrence is independently selected from H and Ci_{-4}alkyl, wherein Ci_{-4}alkyl is optionally substituted with one or more R^{35};

R^{35} in each occurrence is independently selected from halo and —OR^{35a};


R^{35a} in each occurrence is independently selected from H and Ci_{-6}alkyl;

R^4 is selected from H, halo, Ci_{-6}alkyl, $N(R^{4a})_2$, and —OR^{4a}; and




R^{4a} in each occurrence is independently selected from H and Ci_{-6}alkyl;


as defined and described in WO 2016/011390 and US 2017/0204093, the entirety of each of which is herein incorporated by reference.

[00110] In certain embodiments, the present invention provides a compound of Formula I,




wherein IRAK is an IRAK4 inhibitor ,




or

; thereby forming a compound of formula **I-ff-1, 1-ff-2, 1-ff-3,** or **I-ff-4** respectively:




I-ff-1



I-ff-2



I-ff-3



I-ff-4

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

Ring A is selected from phenyl and 5- or 6-membered heteroaryl;

Ring B is selected from phenyl and 5- or 6-membered heteroaryl;

Ring C is a 3- to 6-membered carbocyclyl,

n is 1, 2 or 3;

p is 0, 1, or 2;

one of W and X is N, and the other of W and X is C;

Y is N or C-R^2;

R^1 is selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, halo, -CN, -$C(R^{la})$=$NR(OR^{la})$, -$C(R^{la})$=$N(R^{la})$, -$C(O)R^{la}$, -$C(O)_2R^{la}$, -$C(O)N(R^{la})_2$, -NO_2, -$N(R^{la})_2$, -$N(R^{la})C(O)R^{la}$, -$N(R^{la})C(O)_2R^{la}$, -$N(R^{la})C(O)N(R^{la})_2$, -$N(R^{la})S(O)_2R^{la}$, -OR^{la}, -$OC(O)R^{la}$, -$OC(O)N(R^{la})_2$, -SR^{la}, -$S(0)R^{la}$, -$S(0)_2R^{la}$, -$S(0)N(R^{la})_2$, and -$S(0)_2N(R^{la})_2$, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, and C_{2-6}alkynyl are optionally substituted with one or more R^{10};

R^{la} in each occurrence is independently selected from H or C_{1-6}alkyl wherein said C_{1-6}alkyl in each occurrence are optionally and independently substituted with one or more R^{10};

R^{10} in each occurrence is independently selected from halo, -CN, -$C(R^{10a})$=$NR(OR)^{10a}$, -$C(R^{10a})$=$N(R^{10a})$, -$C(O)R^{10a}$, -$C(O)_2R^{10a}$, -$C(O)N(R^{10a})_2$, -NO_2, -$N(R^{10a})_2$, -$N(R^{10a})C(O)R^{10a}$, -$N(R^{10a})C(O)_2R^{10a}$, -$N(R^{10a})C(O)N(R^{10a})_2$, -$N(R^{10a})S(O)_2R^{10a}$, -$OR^{10a}$, -$OC(O)R^{10a}$, -$OC(O)N(R^{10a})_2$, -$SR^{10a}$, -$S(O)R^{10a}$, -$S(O)_2R^{10a}$, -$S(O)N(R^{10a})_2$, and -$S(O)_2N(R^{10a})_2$;

R^{10a} in each occurrence is independently selected from H and C_{i-6}alkyl, wherein said C_{i-6}alkyl is optionally substituted with one or more halo;

R is selected from H, C_{i-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3- to 7-membered carbocyclyl, 3-to 7-membered heterocyclyl, halo, -CN, -$C(R^{2a})$=$NR(OR^{2a})$, -$C(R^{2a})$=$N(R^{2a})$, -$C(0)R^{2a}$, -$C(0)_2R^{2a}$, -$C(0)N(R^{2a})_2$, -$N0_2$, -$N(R^{2a})_2$, -$N(R^{2a})C(0)R^{2a}$, -$N(R^{2a})C(0)_2R^{2a}$, -$N(R^{2a})C(0)N(R^{2a})_2$, -$N(R^{2a})S(0)_2R^{2a}$, -OR^{2a}, -$0C(0)R^{2a}$, -$0C(0)N(R^{2a})_2$, -SR^{2a}, -$S(0)R^{2a}$, -$S(0)_2R^{2a}$, -$S(0)N(R^{2a})_2$, and -$S(0)_2N(R^{2a})_2$, wherein said C_{i-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3-to 7-membered carbocyclyl, and 3-7 membered heterocyclyl are optionally substituted with one or more R^{20};

R^{2a} in each occurrence is independently selected from H and C_{i-6}alkyl, wherein said C_{i-6}alkyl in each occurrence is optionally and independently substituted with one or more R 20 ;

R^{20} in each occurrence is independently selected from C_{i-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-7}cycloalkyl, 3-to 7-membered saturated heterocyclyl, halo, -CN, -$C(R^{20a})$=$NR(OR^{20a})$, -$C(R^{20a})$=$N(R^{20a})$, -$C(O)R^{20a}$, -$C(O)_2R^{20a}$, -$C(O)N(R^{20a})_2$, -$N0_{¾}$ -$N(R^{20a})_2$, -$N(R^{20a})C(O)R^{20a}$, -$N(R^{20a})C(O)_2R^{20a}$, -$N(R^{20a})C(O)N(R^{20a})_2$, -$N(R^{20a})S(O)_2R^{20a}$, -$OR^{20a}$, -$OC(O)R^{20a}$, -$OC(O)N(R^{20a})_2$, -$SR^{20a}$, -$S(O)R^{20a}$, -$S(O)_2R^{20a}$, -$S(O)N(R^{20a})_2$, and -$S(O)_2N(R^{20a})_2$, wherein said C_{i-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C3-7cycloalkyl, and 3-7 membered saturated heterocyclyl in each occurrence are optionally and independently substituted with one or more R^{25};

R^{20a} in each occurrence is independently selected from H and C_{i-6}alkyl, wherein said C_{i-6}alkyl is optionally substituted with R^{25};

R^{25} is selected from halo and -OR^{25a};

R^{25a} is selected from H and C_{i-6}alkyl;

R is selected from C_{i-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C3-6cycloalkyl, 3-to 6-membered saturated heterocyclyl, halo, -CN, -$C(R^{3a})$=$NR(OR^{3a})$, -$C(R^{3a})$=$N(R^{3a})$, -$C(0)R^{3a}$, -$C(0)_2R^{3a}$, -$C(0)N(R^{3a})_2$, -$N0_2$, -$N(R^{3a})_2$, -$N(R^{3a})C(0)R^{3a}$, -$N(R^{3a})C(0)_2R^{3a}$, -$N(R^{3a})C(0)N(R^{3a})_2$, -

$N(R^{3a})S(0)_2R^{3a}$, $-OR^{3a}$, $-0C(0)R^{3a}$, $-0C(0)N(R^{3a})_2$, $-SR^{3a}$, $-S(0)R^{3a}$, $-S(0)_2R^{3a}$, $-S(0)N(R^{3a})_2$, and $-S(0)_2N(R^{3a})_2$, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, and 3-to 6-membered saturated heterocyclyl are optionally substituted with one or more R^{30};

R^{3a} in each occurrence is independently selected from H, C_{1-6}alkyl, 3- to 6-membered carbocyclyl, and 3- to 6-membered heterocyclyl, wherein said C_{1-6}alkyl, 3- to 6- membered carbocyclyl, and 3- to 6-membered heterocyclyl in each occurrence are optionally and independently substituted with one or more R^{30};

R^{30} in each occurrence is independently selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3- to 6-membered carbocyclyl, 3-to 6-membered heterocyclyl, halo, -CN, $-C(R^{30a})=NR(OR^{30a})$, $-C(R^{30a})=N(R^{30a})$, $-C(O)R^{30a}$, $-C(O)_2R^{30a}$, $-C(O)N(R^{30a})_2$, $-N0_2$, $-N(R^{30a})_2$, $-N(R^{30a})C(O)R^{30a}$, $-N(R^{30a})C(O)_2R^{30a}$, $-N(R^{30a})C(O)N(R^{30a})_2$, $-N(R^{30a})S(O)_2R^{30a}$, $-OR^{30a}$, $-OC(O)R^{30a}$, $-OC(O)N(R^{30a})_2$, $-SR^{30a}$, $-S(O)R^{30a}$, $-S(O)_2R^{30a}$, $-S(O)N(R^{30a})_2$, and $-S(O)_2N(R^{30a})_2$, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3-6 membered carbocyclyl, 3- to 6-membered heterocyclyl in each occurrence are optionally and independently substituted with one or more R^{35};


R^{30a} in each occurrence is independently selected from H and C_{1-4}alkyl, wherein C_{1-4}alkyl is optionally substituted with one or more R^{35};

R^{35} in each occurrence is independently selected from halo and $-OR^{35a}$; and


R^{35a} in each occurrence is independently selected from H and C_{1-6}alkyl;

as defined and described in WO 2017/127430, the entirety of which is herein incorporated by reference.

[00111] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK4 inhibitor ; thereby forming a compound of formula **I-gg-1:**



I-gg-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

HET is a heteroaryl selected from pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, imidazolo[4,5-b]pyridinyl, and imidazolo[4,5-d]pyrimidinyl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a nitrogen ring atom in said heteroaryl and wherein said heteroaryl is substituted with zero to 2 R_b;

A is pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxadiazolyl or dihydroisoxazolyl, each substituted with R_a;

R_3 is C2-3 alkyl, C2-3 fluoroalkyl, C3-4 hydroxyalkyl, or a cyclic group selected from C3-6 cycloalkyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, and pyrazolyl, wherein said cyclic group is substituted with zero to 2 substituents independently selected from F, —OH, C1-2 alkyl, and — CH2CHF2;

R_a is:

(i) H, F, Ci, —OH, —CN, Ci_{-6} alkyl, Ci_{-6} fluoroalkyl, C1-4 cyanoalkyl, Ci_{-6} hydroxyalkyl, Ci-5 hydroxy-fluoroalkyl, C2-4 alkenyl, Ci_{-6}aminoalkyl, —(CH2)i-3NHR$_y$, —(CH2)i-3NR$_y$R$_y$, —CH_2CH(OH)(phenyl), —CH(CH$_2$OH)(phenyl), —CH_2CH(OH)CH$_2$(phenyl), —CH_2CH(0H)CH$_2$0(methoxyphenyl), —CH_2CH(NH2)CH$_2$(phenyl), —$(CH_2CH_20)_4H$, —$(CH_2)_{I-3}$0(C$_{I.3}$ alkyl), —CH_2CH(0H)CH$_2$0(C$_{1-3}$alkyl), —CH_2C(0)(C$_{1-3}$ alkyl), —CH_2C(0)NR$_y$R$_y$, —(CH2)i-3NR$_y$C(0)(Ci.3 alkyl), —CH_2C(0)0(Ci$_{-3}$ alkyl), —C(0)NH$_2$, —CH_2NR$_y$C(0)NH$_2$, —(CH2)i.2NR$_y$C(0)0(Ci.2 alkyl), —(CR$_y$R$_y$)i$_{-5}$0C(0)CH$_2$NR$_y$R$_y$, —CH_2CH_2S(0)$_2$CH$_3$, —CH_2S(0)$_2$(C$_{I.3}$ alkyl), —CH_2S(0)$_2$(phenyl), or —NH(aminocyclohexyl); or


(ii) —(CH_2)o-3R_z or —(CH_2)o-iC(0)R_z, wherein R_z is C3-6 cycloalkyl, azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl, pyrrolyl, pyrrolidinonyl, morpholinyl, pyrrolidinyl, phenyl, pyrazolyl, imidazolyl, pyridinyl, pyrimidinyl, dioxopyrimidinyl, benzo[d]imidazolyl, benzo[d]thiazolyl, l,3-dioxolanyl, or 8-azabicyclo[3.2.l]octanyl, each substituted with zero to 4 substituents independently from F, —CN, —OH, —NR_yR_y, C1-3 alkyl, C1-3 fluoroalkyl, C1-3 hydroxyalkyl, —CH(phenyl)$_2$, —0(Ci$_{-4}$ alkyl), —C(0)(Ci$_{-4}$ alkyl), —C(0)(Ci$_{-4}$ deuteroalkyl), —C(0)(Ci-$_5$ hydroxyalkyl), — C(0)(C$_{1-3}$ fluoroalkyl), — C(0)(C$_{3-6}$cycloalkyl), — C(0)0(C$_{1-3}$ alkyl), — C(0)NR_yR_y, — C(0)(phenyl), — C(0)(pyridinyl), —C(0)CH_2(C_{3-6} cycloalkyl), — C(0)0(Ci-$_4$ alkyl), — NH(C$_{I-4}$ alkyl), — NH(C$_{I-3}$ fluoroalkyl), —NHC(0)CH_3, — NHC(0)0(C$_{i-3}$ alkyl), —NHC(0)0C(CH_3)3, —S(0)$_2$(Ci-$_3$ alkyl), —0S(0)$_2$(Ci-$_3$ alkyl), methyl oxadiazolyl, and pyrimidinyl;




each R_b is independently selected from H, Cl, —CN, —NH_2, and —C(0)NH_2, wherein said heteroaryl is attached to the pyridinyl group by a nitrogen atom in said heteroaryl; and

each R_y is independently H or Ci$_{-2}$ alkyl;


as defined and described in WO 2016/210034 and US 2018/0186799, the entirety of each of which is herein incorporated by reference.

[00112] In certain embodiments, the present invention provides a compound of Formula **I,**


wherein IRAK is an IRAK4 inhibitor  ,

 ,  , or  ;


thereby forming a compound of formula **I-hh-1, 1-hh-2, 1-hh-3,** or **I-hh-4** respectively:




I-hh-1



I-hh-2



I-hh-3



I-hh-4

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

each Xi, X_2 and X_3 are independently CR^2 or N;

A is O, S, S(O) or $S(0)_2$;

Z_1 is optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted (heterocycloalkyl)alkyl-, optionally substituted aralkyl-, optionally substituted heteroaralkyl-, optionally substituted (cycloalkyl)alkyl-, optionally substituted aryloxy-, optionally substituted heteroaryloxy-, optionally substituted heterocycloalkyloxy-, optionally substituted cycloalkyloxy-, optionally substituted aryl-NR'—, optionally substituted heteroaryl-NR'—, optionally substituted heterocycloalkyl-NR'—, optionally substituted cycloalkyl-NR'—, optionally substituted aryl-S—, optionally substituted heteroaryl-S—, optionally substituted heterocycloalkyl-S—, optionally substituted cycloalkyl-S—, optionally substituted (cycloalkyl)alkyl-NR'—, optionally substituted aralkyl-NR'—, optionally substituted (heterocycloalkyl)alkyl-NR'—, optionally substituted heteroaralkyl-NR'—, optionally substituted (cycloalkyl)alkyl-S—, optionally substituted aralkyl-S—, optionally substituted (heterocycloalkyl)alkyl-S—, optionally substituted heteroaralkyl-S—, optionally substituted (cycloalkyl)alkyl-O—, optionally substituted aralkyl-0—, optionally substituted (heterocycloalkyl)alkyl-O—, optionally substituted heteroaralkyl-O—; e.g., wherein each optional substituent independently represents an occurance of R_x;

Z_2 is absent or optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, optionally substituted aryloxy-, optionally substituted heteroaryloxy-, optionally substituted cycloalkyloxy-, optionally substituted heterocycloalkyloxy-, optionally substituted (cycloalkyl)alkyl-, optionally substituted aralkyl-, optionally substituted (heterocycloalkyl)alkyl-, optionally substituted heteroaralkyl-, optionally substituted (cycloalkyl)alkyl-NR"—, optionally substituted aralkyl-NR"—, optionally substituted (heterocycloalkyl)alkyl-NR"—, optionally substituted heteroaralkyl-NR"—, optionally substituted (cycloalkyl)alkyl-O—, optionally substituted aralkyl-0—, optionally substituted (heterocycloalkyl)alkyl-O—, optionally substituted heteroaralkyl-O—, optionally substituted (cycloalkyl)alkyl-S—, optionally substituted aralkyl-S—, optionally substituted (heterocycloalkyl)alkyl-S— or optionally substituted heteroaralkyl-S—; e.g., wherein each optional substituent independently represents an occurance of R_y;

Z_3 is optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, optionally substituted aryloxy-, optionally substituted heteroaryloxy-, optionally substituted cycloalkyloxy-, optionally substituted heterocycloalkyloxy-, optionally substituted (cycloalkyl)alkyl-, optionally substituted aralkyl-, optionally substituted (heterocycloalkyl)alkyl-, optionally substituted heteroaralkyl-, optionally substituted (cycloalkyl)-NR'''—, optionally substituted aryl-NR'''—, optionally substituted heteroaryl-NR'''—, optionally substituted heterocycloalkyl-NR'''—, optionally substituted aryl-S—, optionally substituted heteroaryl-S—, optionally substituted cycloalkyl-S—, optionally substituted heterocycloalkyl-S—, optionally substituted (cycloalkyl)alkyl-NR'''—, optionally substituted aralkyl-NR'''—, optionally substituted (heterocycloalkyl)alkyl-NR'''—, optionally substituted heteroaralkyl-NR'''—, optionally substituted (cycloalkyl)alkyl-O—, optionally substituted aralkyl-0—, optionally substituted (heterocycloalkyl)alkyl-O—, optionally substituted heteroaralkyl-O—, optionally substituted (cycloalkyl)alkyl-S—, optionally substituted aralkyl-S—, optionally substituted (heterocycloalkyl)alkyl-S— or optionally substituted heteroaralkyl-S—; e.g., wherein each optional substituent independently represents an occurance of R_z;

each R^2 is independently selected from hydrogen, alkyl, haloalkyl, halo, cyano, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl-, optionally substituted cycloalkyloxy-, optionally substituted aryl, optionally substituted aralkyl-, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, optionally substituted (heterocycloalkyl)alkyl-, optionally substituted heteroaralkyl-, —NR_aR_b, —O—R_3 and —S—Ry e.g., wherein each optional substituent independently represents alkyl, alkoxy, halo, haloalkyl, hydroxy, hydroxyalkyl, —SH, —S(alkyl), cyano, amido, amino, carboxylate, glycinate, alaninate, oxo, aryl, cycloalkyl, heterocycloalkyl or heteroaryl;

each R', R" and R''' is independently selected from hydrogen, alkyl, hydroxy, hydroxyalkyl, acyl and cycloalkyl;

each R_x, R_y and R_z is independently selected from alkyl, alkenyl, alkynyl, halo, hydroxy, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, —SH, —S(alkyl), cyano, amido, carboxylic acid, carboxylate, ester, thioester, alkoxycarbonyl, —C(0)NH(alkyl), oxo, cycloalkyl, cycloalkyloxy, (cycloalkyl)alkyl-, aryl, aralkyl-, heterocycloalkyl, heteroaryl,

(heterocycloalkyl)alkyl-, heteroaralkyl-, —NR_aR_b, —O—R_4 or —S—R_4; optionally wherein the cycloalkyl, aryl, heterocycloalkyl, and heteroaryl are further substituted by one or more substituents selected from halo, haloalkyl, amino, hydroxy, alkyl, cyano, nitro, alkenyl, aminoalkyl, hydroxyalkyl and haloalkoxy;


each R_a and R_b is independently selected from hydrogen, alkyl, aminoalkyl, acyl, aminoacyl, halo, haloalkyl, hydroxy, haloalkoxy, hydroxyalkyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, (cycloalkyl)alkyl-, (heterocycloalkyl)alkyl-, aralkyl-, and (heteroaryl)alkyl-; optionally wherein the cycloalkyl, heterocycloalkyl, aryl and heteroaryl are further substituted by one or more substituents selected from alkyl, halo, alkenyl, cyano, hydroxy, hydroxyalkyl, alkoxy, amino and nitro; or

R_a and R_b are taken together along with the atoms which they are attached to form a 3 to 8 membered optionally substituted ring; and


each R_3 and R_4 is independently selected from hydrogen, alkyl, aminoacyl, phosphate, phosphonate, alkylphosphate, alkoxycarbonyl, cycloalkyl, (cycloalkyl)alkyl-, aryl, heteroaryl, heterocycloalkyl, aralkyl-, heteroaralkyl and (heterocycloalkyl)alkyl-;

as defined and described in WO 2017/009806 and US 2018/0208605, the entirety of each of which is herein incorporated by reference.

[00113] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK4 inhibitor ; thereby forming a compound of formula **I-ii-1:**



I-ii-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

X is CR orN;

A is O, S, $S0_2$, SO, —NRC(O), —NRSO2, or N(R); or A is absent;

R^3 is —R, halogen, -haloalkyl, —OR, —SR, —CN, —$N0_2$, —$S0_2R$, —SOR, —C(0)R, —$C0_2R$, —C(0)$N(R)_2$, —NRC(0)R, —NRC(0)$N(R)_2$, —NRSO2R, or —$N(R)_2$; or

when A is —NRC(O), —NRSO2, or N(R); then R and R^3, together with the atoms to which each is attached, may form a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;

X' is CR orN;

Ring Z is a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;

R^1 is —R, halogen, -haloalkyl, —OR, —SR, —CN, —$N0_2$, —$S0_2R$, —SOR, —C(0)R, —$C0_2R$, —C(0)$N(R)_2$, —NRC(0)R, —NRC(0)$N(R)_2$, —NRSO2R, or —$N(R)_2$;

R^a is absent, —R, halogen, -haloalkyl, —OR, —SR, —CN, —$N0_2$, —$S0_2R$, —SOR, —C(0)R, —CO2R, —C(0)$N(R)_2$, —NRC(0)R, —NRC(0)$N(R)_2$, —NRSO2R, or —$N(R)_2$;

Ring Y is an optionally substituted 5-6 membered monocyclic heteroaryl ring having 2-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

R^2 is —R, halogen, -haloalkyl, —OR, —SR, —CN, —$N0_2$, —$S0_2R$, —SOR, —C(0)R, —$C0_2R$, —C(0)$N(R)_2$, —NRC(0)R, —NRC(0)$N(R)_2$, —NRSO2R, or —$N(R)_2$;


R^b is absent, —R, halogen, -haloalkyl, —OR, —SR, —CN, —NO_2, —SO_2R, —SOR, —C(O)R, —CO_2R, —C(O)N(R)$_2$, —NRC(O)R, —NRC(O)N(R)$_2$, —NRSO2R, or —N(R)$_2$;

each R is independently hydrogen, C_{1-6} aliphatic, C3-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted; or


two R groups on the same atom are taken together with the atom to which they are attached to form a C3-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;

as defined and described in WO 2016/081679 and US 2016/0145252, the entirety of each of which is herein incorporated by reference.


[00114] In certain embodiments, the present invention provides a compound of Formula **I,**




wherein IRAK is an IRAK4 inhibitor or



; thereby forming a compound of formula I-jj-1 or I-jj-2 respectively:



I-jj-1



I-jj-2

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

X is NH or O;

b is 0 or 1;

n is 0, 1, 2, 3 or 4;

Ri and R_2 are independently H, (Ci-C_4)alkyl and heterocyclyl, or Riand R_2 can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic (fused, bridged or spirocyclic) heterocycle containing 3-8 carbon atoms optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said alkyl and heterocycle are optionally substituted with one or more substituents selected from R_a;

R_3 is (Ci-C_4)alkyl wherein two adjacent alkyl groups can join together and form a bridged moiety of 3-6 carbon atoms;

R_4 is absent, halo or O_b(Ci-C_4)alkyl;

R_5 is selected from Ci-C_4 alkyl and C_2-C_4 alkenyl which are optionally substituted with one or more substituents selected from R_b;


Rsis absent, halo, or 0(Ci-C_4)alkyl;

R_a is halo, oxo, OH, O_b(Ci-C_4)alkyl, CF_3, $S0_2$(Ci-C_4)alkyl, or heterocyclyl, said heterocyclyl optionally substituted with one or more substituents independently selected from F, and (Ci-C_4)alkyl; and


R_b is independently selected from OH, halo, O_b(Ci-C_4)alkyl, and CN;

as defined and described in WO 2016/053769 and US 2017/0247388, the entirety of each of which is herein incorporated by reference.


[00115] In certain embodiments, the present invention provides a compound of Formula **I,**




wherein IRAK is an IRAK4 inhibitor or



; thereby forming a compound of formula **I-kk-1** or **I-kk-2** respectively:



I-kk-1



I-kk-2

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

B is CH, N or S; D is CH or N; E is CH or N; F is CH or N; G is CH or N; and J is C or N, wherein when B is S then D is CH, E is N, F is CH, G is N and J is C;

X is O, S, CH_2 or N;

m is 0 or 1; n is 0, 1 or 2;

Ring A is pyridinyl, pyrazolyl, thiophenyl, furanyl or phenyl;

Ri is independently selected from (Ci-C_4)alkyl, pyrimidine, piperidine and phenyl, each optionally substituted with (Ci-C_4)alkyl, OH, halo, 0(Ci-C_4)alkyl, methylpiperidine, $S(0)_2R_c$, C(0)N(R_b)$_2$, or C(0)0(Ci-C_4)alkyl;



R_2 is absent or H and R_3 is independently selected from: (Ci-C_4)alkyl, pyranyl, cyclopentyl, cyclohexyl, cycloheptyl, thiopyranyl, pyrazolyl, piperidinyl, morpholinyl, piperazinyl each optionally substituted with one or more substituents independently selected from halo, OH, oxo, N(R_b)$_2$, oxopyrrolidinyl, or morpholinyl, or R_2 and R_3 can be taken together with the nitrogen to which they are attached to form piperazine or morpholine, each optionally substituted with oxo;


R_4 is independently H or methyl;

R_b is independently selected from H and (Ci-C_4)alkyl; and


R_e is methyl;

as defined and described in WO 2016/144844 and ETS 2018/0051027, the entirety of each of which is herein incorporated by reference.

[00116] In certain embodiments, the present invention provides a compound of Formula **I,** wherein IRAK is an IRAK4 inhibitor  or  ; thereby forming a compound of formula **I-kk'-l** or **I-kk'-2** respectively:




I-kk'-1




I-kk'-2

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein each of the variables A, B, D, E, F, G, J, X, Ri, R_2, R_3 and n is as defined and described in WO 2016/144844 and US 2018/0051027, the entirety of each of which is herein incorporated by reference. Such IRAK4 inhibitors are well known to one of ordinary skill in the art and include those described in Smith et al., *Bioorg. Med. Chem.,* 2017, 27(12): 2721-2726 and Lim et ak, *ACS Med. Chem. Lett.,* 2015, 6(6): 683-688.

[00117] In certain embodiments, the present invention provides a compound of Formula **I,**




wherein IRAK is an IRAK4 inhibitor




or

; thereby forming a compound of formula **1-11-1** or **I-ll'-2** respectively:



I-ll-1



i-ir-2

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

Ring A is aryl or heterocyclyl;

n is 0, 1, 2, 3 or 4;

R_1 is independently selected from: (Ci-C_4)alkyl, (C3-C_6)cycloalkyl, heterocyclyl, CF_3, CHF_2, CN, halo, said alkyl, cycloalkyl and heterocyclyl optionally substituted with halo, OH, CH_3, and OCH_3;


R_2 is H and R_3 is independently selected from: (Ci-C_6)alkyl, (C_3-C_8)cycloalkyl, and heterocyclyl each optionally substituted with one or more halo, OH, $N(R_b)_2$, or morpholinyl, or R_2 and R_3 can be taken together with the nitrogen to which they are attached to form a heterocyclyl, said heterocyclyl optionally substituted with one or more substituents selected from R_a;

R_a is independently selected from (Ci-C_4)alkyl, (C_3-C_6)cycloalkyl, CF_3, CHF_2, OH, halo and NH_2, said alkyl optionally substituted with (C_3-C_6)cycloalkyl and CF_3; and


R_b is independently selected from H and (Ci-C_4)alkyl;

as defined and described in WO 2016/144847 and US 2018/0051029, the entirety of each of which is herein incorporated by reference.


[00118] In certain embodiments, the present invention provides a compound of Formula **I,**




wherein IRAK is an IRAK4 inhibitor or



; thereby forming a compound of formula **I-mm-1** or **I-mm'-2** respectively:



I-mm-1



I-mm'-2

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

Ring A is aryl or heterocyclyl;

n is 0, 1, 2, 3 or 4;

R_i is independently selected from: (C_i-C_4)alkyl, (C_3-C_6)cycloalkyl, heterocyclyl, CF_3, CHF_2, CN and halo, said alkyl, cycloalkyl and heterocyclyl optionally substituted with halo, OH, CH_3, and OCH_3;


R_2 is H and R_3 is independently selected from: (C_i-C_6)alkyl, (C_3-C_8)cycloalkyl, and heterocyclyl each optionally substituted with one or more halo, OH, $N(R_b)_2$, or morpholinyl, or R_2 and R_3 can be taken together with the nitrogen to which they are attached to form a heterocyclyl, said heterocyclyl optionally substituted with one or more substituents selected from R_a;

R_a is independently selected from (C_1-C_4)alkyl, (C_3-C_6)cycloalkyl, CF_3, CHF_2, OH, halo and NH_2, said alkyl optionally substituted with (C_3-C_6)cycloalkyl or CF_3; and


R_b is independently selected from H and (C_1-C_4)alkyl;

as defined and described in WO 2016/144846 and US 2018/0051028, the entirety of each of which is herein incorporated by reference.


[00119] In certain embodiments, the present invention provides a compound of Formula **I,**




wherein IRAK is an IRAK4 inhibitor or



; thereby forming a compound of formula **I-nn-1** or **I-nn'-2** respectively:



I-nn-1



I-nn'-2

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

Ring A is aryl or heterocyclyl;

n is 0, 1, 2, 3 or 4;

R_i is independently selected from: (C_1-C_4)alkyl, (C_3-C_6)cycloalkyl, heterocyclyl, CF_3, CHF_2, CN, halo, said alkyl, cycloalkyl and heterocyclyl optionally substituted with halo, OH, CH_3, and OCH_3;


R_2 is H and R_3 is independently selected from: (C_1-C_6)alkyl, (C_3-C_8)cycloalkyl, and heterocyclyl each optionally substituted with one or more halo, OH, $N(R_b)_2$, or morpholinyl, or R_2 and R_3 can be taken together with the nitrogen to which they are attached to form a heterocyclyl, said heterocyclyl optionally substituted with one or more substituents selected from R_a;

R_a is independently selected from (C_1-C_4)alkyl, (C_3-C_6)cycloalkyl, CF_3, CHF_2, OH, halo and NH_2, said alkyl optionally substituted with (C_3-C_6)cycloalkyl and CF_3; and


R_b is independently selected from H and (C_1-C_4)alkyl;

as defined and described in WO 2016/144848 and US 2018/0051030, the entirety of each of which is herein incorporated by reference.


[00120] In certain embodiments, the present invention provides a compound of Formula **I,**




wherein IRAK is an IRAK4 inhibitor or



; thereby forming a compound of formula **I-oo-l** or **I-oo'-2** respectively:



I-oo-1



I-oo'-2

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

Ring A is aryl or heterocyclyl;

n is 0, 1, 2, 3 or 4;

Ri is independently selected from: (Ci-C_4)alkyl, (C3-C_6)cycloalkyl, heterocyclyl, CF_3, CHF_2, CN, halo, said alkyl, cycloalkyl and heterocyclyl optionally substituted with halo, OH, CH_3, and OCH_3;


R_2 is H and R_3 is independently selected from: (Ci-C_6)alkyl, (C_3-C_8)cycloalkyl and heterocyclyl each optionally substituted with one or more halo, OH, $N(R_b)_2$, or morpholinyl, or R_2 and R_3 can be taken together with the nitrogen to which they are attached to form a heterocyclyl, said heterocyclyl optionally substituted with one or more substituents selected from R_a;

R_a is independently selected from (Ci-C_4)alkyl, (C_3-C_6)cycloalkyl, CF_3, CHF_2, OH, halo and NH_2, said alkyl optionally substituted with (C_3-C_6)cycloalkyl and CF_3; and


R_b is independently selected from H and (Ci-C_4)alkyl;

as defined and described in WO 2016/144849 and US 2018/0051035, the entirety of each of which is herein incorporated by reference.

[00121] In certain embodiments, the present invention provides a compound of Formula **I,**




wherein IRAK is an IRAK1 and IRAK4 inhibitor ; thereby forming a compound of formula **I-pp-1:**




I-pp-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

Ring A is a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

Ring B is 

wherein ~~ represents the portion of the ring fused to the pyrimidine ring and # is $-L^2(R^4)p-R^x$; each R^1 and $R^{1'}$ is independently $-R^2$, halogen, -CN, $-NO_2$, -OR, -SR, $-N(R)_2$, $-S(O)_2R$, $-S(O)_2N(R)_2$, -S(O)R, -C(O)R, -C(O)OR, $-C(O)N(R)_2$, -C(O)N(R)OR, -N(R)C(O)OR, $-N(R)C(O)N(R)_2$, Cy, or $-N(R)S(O)_2R$; or R^1 is selected from one of the following formulae:



; or

two R^1 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each Cy is independently an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-10 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or

sulfur; each R is independently hydrogen, or an optionally substituted group selected from Ci-$_6$ aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or:

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, or sulfur;

each R^2 is independently an optionally substituted group selected from Ci-$_6$aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R^4 is independently halogen, -CN, -N0 $_2$, -OR, -SR, -N(R)$_2$, -S(0) $_2$R, -S(0) $_2$N(R)$_2$, -S(0)R, -C(0)R, -C(0)0R, -C(0)N(R) $_2$, - N(R)C(0)R,

-N(R)C(0)N(R) $_2$, -C(0)N(R)0R, -N(R)C(0)0R, -N(R)S(0) $_2$N(R)$_2$, -N(R)S(0) $_2$R, or an optionally substituted group selected from Ci-$_6$ aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

R^x is hydrogen, -R^2, -CN, -N0 $_2$, halogen, -C(0)N(R) $_2$, -C(0)0R, -C(0)R, -N(R)$_2$, -NH[Ar], -OR, or -S(0) $_2$N(R)$_2$;

R^z is hydrogen, -R^2, -CN, -N0 $_2$, halogen, -C(0)N(R) $_2$, -C(0)0R, -C(0)R, -N(R)$_2$, -NH[Ar], -OR, or -S(0) $_2$N(R)$_2$;

[Ar] is phenyl or a 5-6 membered heteroaromatic ring having 1-4 heteroatoms indepently selected from nitrogen, oxygen, and sulfur, wherein [Ar] is substituted by m instances of R^1;

L^1 is a covalent bond or a Ci-$_6$ bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -N(R)-, -N(R)C(0)-, - C(0)N(R)-, -N(R)S(0) $_2$-, -S(0) $_2$N(R)-, -0-, -C(O)-, -OC(O)-, -C(0)0-, -S-, -S(O)- or -S(0) $_2$-;

L^2 is a covalent bond or a Ci-$_6$ bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -N(R)-, -N(R)C(0)-, - C(0)N(R)-, -N(R)S(0) $_2$-, -S(0) $_2$N(R)-, -0-, -C(O)-, -OC(O)-, -C(0)0-, -S-, -S(O)- or -S(0) $_2$-;


m is 0-4;

n is 0-4; and

p is 0-2;


as defined and described in WO 2017/004133, the entirety of each of which is herein incorporated by reference.

[00122] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK1 and IRAK4 inhibitor ;

thereby forming a compound of formula **I-qq-1:**




I-qq-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

Y is N or C-R^x;

Ring A is a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R^1 and R^v is independently $-R^2$, halogen, $-CN$, $-NO_2$, $-OR$, $-SR$, $-N(R)_2$, $-S(O)_2R$, $-S(O)_2N(R)_2$, $-S(O)R$, $-C(O)R$, $-C(O)OR$, $-C(O)N(R)_2$, $-C(O)N(R)OR$, $-N(R)C(O)OR$, $-N(R)C(O)N(R)_2$, Cy, or $-N(R)S(O)_2R$; or R^1 is selected from one of the following formulas:



two R^1 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each Cy is independently an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-10 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, or sulfur;

each R^2 is independently an optionally substituted group selected from C_{1-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each of R^x and R^y is independently hydrogen, $-R^2$, $-CN$, $-NO_2$, halogen, $-C(O)N(R)_2$, $-C(O)OR$, $-C(O)R$, $-N(R)_2$, $-NH[Ar]$, $-OR$, or $-S(O)_2N(R)_2$; or

R^x and R^y are taken together together with their intervening atoms to form a 4-7 membered partially unsaturated carbocyclic ring or a partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

R^z is hydrogen, $-R^2$, $-CN$, $-NO_2$, halogen, $-C(O)N(R)_2$, $-C(O)OR$, $-C(O)R$, $-N(R)_2$, $-NH[Ar]$, $-OR$, or $-S(O)_2N(R)_2$;

[Ar] is phenyl or a 5-6 membered heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said [Ar] is substituted by m instances of R^r;


L^1 is a covalent bond or a C_{i-6} bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -N(R)-, -N(R)C(0)-, - C(0)N(R)-, -N(R)S(0) $_2$-, -S(0) $_2$N(R)-, -0-, -C(O)-, -OC(O)-, -C(0)0-, -S-, -S(O)- or -S(0) $_2$-;

m is 0-4; and


n is 0-4;

as defined and described in WO 2017/004134, the entirety of each of which is herein incorporated by reference.


[00123] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK inhibitor ,




, or




;


thereby forming a compound of formula **I-rr-1, 1-rr-2,** or **I-rr-3:**



I-rr-1



I-rr-2



I-rr-3

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

R is aliphatic, heteroaliphatic, heteroaryl, aryl, halo, amide or CN;

R^1 is H, aliphatic or heteroaliphatic;

or R and R^1, together with the atoms to which they are attached, form a heterocyclyl ring;


R^2 is H, aliphatic, heteroaliphatic, heterocycloaliphatic, aryl, amide, heterocyclyl or araliphatic;

each R^3 independently is H, aliphatic, halogen, heteroaliphatic, —O-aliphatic, heterocyclyl, aryl, araliphatic, —O-heterocyclyl, hydroxyl, nitro, cyano, carboxyl, carboxyl ester, acyl, amide, amino, sulfonyl, sulfonamide, sulfanyl, sulfmyl, haloalkyl, alkylphosphate, or alkylphosphonate;


y is from 1 to 6;

as defined and described in WO 2016/172560 and US 2016/03 11839, the entirety of each of which is herein incorporated by reference.

[00124] In certain embodiments, the present invention provides a compound of Formula **I,**




wherein IRAK is an IRAK4 inhibitor ; thereby forming a compound of formula **I-ss-1:**



I-ss-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:



A is

X is N or C—R^7;

R is hydrogen, R^1, halogen, cyano, nitro, —OR^1, —C(=O)—R^1, —C(=O)O—R^1, —C(=O)NR^{11}—R^1, —$S(=O)_2$—R^1, —NR^{11}C(=O)—R^1, —NR^{11}C(=O)$NR^{11}R^{11}$, —NR^{11}C(=O)O—R^1, —$NR^{11}S(=O)_2R^1$ or —$NR^{11}R^{11}$;

R^1 is Ci-$_6$ alkyl substituted with 0-4 R^{1a}, Ci$_{-6}$ haloalkyl, C2-6 alkenyl substituted with 0-3 R^{1a}, C2-$_6$ alkynyl substituted with 0-3 R^{1a}, C3-10 cycloalkyl substituted with 0-3 R^{1a}, C_6-io aryl substituted with 0-3 R^{1a}, a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{1a}, or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{1a};

R^{1a} is hydrogen, =0, F, Cl, Br, OCF3, CN, N0$_2$, —$(CH_2)_r$$OR^b$, —$(CH_2)_r$$SR^b$, —$(CH_2)_r$C(0)$R^b$, —$(CH_2)_r$C(0)$OR^b$, —$(CH_2)_r$0C(0)$R^b$, —$(CH_2)_r$$NR^{11}R^{11}$, —$(CH_2)_r$C(0)$NR^{11}R^{11}$, —$(CH_2)_r$$NR^b$C(0)$R^c$, —$(CH_2)_r$$NR^b$C(0)$OR^c$, —$NR^b$C(0)$NR^{11}R^{11}$, —S(0)$_p$$NR^{11}R^{11}$, —$NR^b$S(0)$_p$$R^c$, —S(0)$R^c$, —S(0)$_2$$R^c$, Ci$_{-6}$ alkyl substituted with 0-2 R^a, Ci$_{-6}$ haloalkyl, —$(CH_2)_r$-3-l4 membered carbocycle substituted with 0-3 R^a, or —$(CFl_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(0)$_p$ substituted with 0-3 R^a;

R^2 is C_6-io aryl substituted with 0-4 R^{2a}, a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, substituted with 1-4 R^{2a}, or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-4 R^{2a};

R^{2a} at each occurrence is independently selected from hydrogen, =0, halo, OCF3, CN, NO2, —$(CH_2)_r$$OR^b$, —(CFh)$_r$$SR^b$, —$(CH_2)_r$C(0)$R^b$, —$(CH_2)_r$C(0)$OR^b$, —$(CH_2)_r$OC(0)$R^b$, —$(CH_2)_r$$NR^{11}R^{11}$, —$(CH_2)_r$C(0)$NR^{11}R^{11}$, —$(CH_2)_r$$NR^b$C(0)$R^c$, —$(CH_2)_r$$NR^b$C(0)$OR^c$, —$NR^b$C(0)$NR^{11}R^{11}$, —S(0)$_p$$NR^{11}R^{11}$, —$NR^b$S(0)p$R^c$, —S(0)$R^c$, —S(0)$_2$$R^c$, Ci$_{-6}$ alkyl

substituted with 0-2 R^a, C_{1-6} haloalkyl, —$(CH_2)_r$-3-l4 membered carbocycle substituted with 0-1 R^a, or —$(CH_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-2 R^a;

R^3 is C_{1-6} alkyl substituted with 0-3 R^{3a}, C_{1-6} haloalkyl, C_{2-6} alkenyl substituted with 0-3 R^{3a}, C_{2-6} alkynyl substituted with 0-3 R^{3a}, C_{3-10} cycloalkyl substituted with 0-3 R^{3a}, C_{6-10} aryl substituted with 0-3 R^{3a}, a 5-10 membered heterocyclyl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{3a} or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{3a};

R^{3a} is hydrogen, =O, F, Cl, Br, OCF_3, CN, NO_2, —$(CH_2)_rOR^b$, —$(CH_2)_rSR^b$, —$(CH_2)_rC(O)R^b$, —$(CH_2)_rC(O)OR^b$, —$(CH_2)_rOC(O)R^b$, —$(CH_2)_rNR^{11}R^{11}$, —$(CH_2)_rC(O)NR^{11}R^{11}$, —$(CH_2)_rNR^bC(O)R^c$, —$(CH_2)_rNR^bC(O)OR^c$, —$NR^bC(O)NR^{11}R^{11}$, —$S(O)_pNR^{11}R^{11}$, —$NR^bS(O)_pR^c$, —$S(0)R^c$, —$S(0)_2R^c$, C_{1-6} alkyl substituted with 0-2 R^a, C_{1-6}haloalkyl, —$(CH_2)_r$-3-l4 membered carbocycle substituted with 0-1 R^a, or —$(CH_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-1 R^a;

R^4 and R^5 are independently selected from hydrogen, C_{1-4} alkyl substituted with 0-1 R^f, (CH_2)-phenyl substituted with 0-3 R^d, and a —(CH_2)-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$;

R^6 and R^7 are independently at each occurrence is selected from hydrogen, =0, F, Cl, Br, OCF3, CN, NO_2, —$(CH_2)_rOR^b$, —$(CH_2)_rSR^b$, —$(CH_2)_rC(O)R^b$, —$(CH_2)_rC(O)OR^b$, —$(CH_2)_rOC(O)R^b$, —$(CH_2)_rNR^{11}R^{11}$, —$(CH_2)_rC(O)NR^{11}R^{11}$, —$(CH_2)_rNR^bC(O)R^c$, —$(CH_2)_rNR^bC(O)OR^c$, —$NR^bC(O)NR^{11}R^{11}$, —$S(O)_pNR^{11}R^{11}$, —$NR^bS(O)_pR^c$, —$S(O)_2R^c$, —$S(0)_2R^c$, C_{1-6} alkyl substituted with 0-2 R^a, C_{1-6}haloalkyl, —$(CH_2)_r$-3-l4 membered carbocycle substituted with 0-3 R^a, or —$(CH_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-3 R^a, provided R^6 and R^7 are not both hydrogen;

R^{11} at each occurrence is independently hydrogen, R^c, C_{1-4} alkyl substituted with 0-1 R^f, CH_2-phenyl substituted with 0-3 R^d, or —(CH_2)-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-3 R^d; or

R^{11} and along with another R^{11}, R^1, or R^2 on the same nitrogen atom may join to form an optionally substituted heterocycle;

R^a is hydrogen, F, Cl, Br, OCF_3, CF_3, CHF_2, CN, NO_2, $—(CH_2)_rOR^b$, $—(CH_2)_rSR^b$, $—(CH_2)_rC(O)R^b$, $—(CH_2)_rC(O)OR^b$, $—(CH_2)_rOC(O)R^b$, $—(CH_2)_rNR''R''$, $—(CH_2)_rC(O)NR^{11}R^{11}$, $—(CH_2)_rNR^bC(O)R^c$, $—(CH_2)_rNR^bC(O)OR^c$, $—NR^bC(O)NR^{11}R^{11}$, $—(O)_pNR^{11}R^{11}$, $—NR^bS(O)_pR^c$, $—S(O)R^c$, $—S(O)_2R^c$, C_{1-6} alkyl substituted with 0-1 R^f, C_{1-6} haloalkyl, $—(CH_2)_r$-3-14 membered carbocycle, or $—(CH_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$; or two R^a on adjacent or the same carbon atom form a cyclic acetal of the formula $—O—(CH_2)_n—O—$, or $—O—CF_2—O—$, wherein n is selected from 1 or 2;

R^b is hydrogen, R^c, C_{1-6} alkyl substituted with 0-2 R^d, C_{1-6}haloalkyl, C3-6 cycloalkyl substituted with 0-2 R^d, or $(CH_2)_r$-phenyl substituted with 0-3 R^d;

R^c is C_{1-6} alkyl substituted with 0-1 R^f, C_{3-6} cycloalkyl, or $(CH_2)_r$-phenyl substituted with 0-3 R^f;

R^d is hydrogen, F, Cl, Br, OCF_3, CF_3, CN, NO_2, $—OR^e$, $—(CH_2)_rC(O)R^c$, $—NR^eR^e$, $—NR^eC(O)OR^c$, C_{1-6} alkyl, or $(CH_2)_r$-phenyl substituted with 0-3 R^f;

R^e is selected from hydrogen, C_{1-6} alkyl, C3-6 cycloalkyl, and $(CH_2)_r$-phenyl substituted with 0-3 R^f;

R^f is hydrogen, halo, NH_2, OH, or $O(C_{1-6}$alkyl);


p is 0, 1, or 2;

r is 0, 1, 2, 3, or 4; and


m is 0, 1, or 2;

as defined and described in WO 2013/106612 and US 2015/0011532, the entirety of each of which is herein incorporated by reference.

[00125] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK4 inhibitor ; thereby forming a compound of formula **I-tt-1:**



I-tt-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

A is a triazole optionally substituted by 0-2 R;

X is N or C—R^7;

R is hydrogen, R', halogen, cyano, nitro, —OR^1, —C(=0) —R^1, —C(=0)0 —R^1, —$C(=O)NR^{11}$—R^1, —$S(=O)_2$—R^1, —$NR^{11}C(=O)$—R′, —$NR^{11}C(=O)NR^{11}R^1$, —$NR^{11}C(=O)O$—R′, —$NR^{11}S(=O)_2R^1$ or —$NR^{11}R^1$;

R^1 is Ci-$_6$ alkyl substituted with 0-4 R^{1a}, Ci$_{-6}$ haloalkyl, C2-6 alkenyl substituted with 0-3 R^{1a}, C_{2-6} alkynyl substituted with 0-3 R^{1a}, C3-iocycloalkyl substituted with 0-3 R^{1a}, C_6-io aryl substituted with 0-3 R^{1a}, a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{1a}, or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{1a};

R^{1a} is hydrogen, =O, F, Cl, Br, OCF_3, CN, NO_2, —$(CH_2)_rOR^b$, —$(CH_2)_rSR^b$, —$(CH_2)_rC(O)R^b$, —$(CH_2)_rC(O)OR^b$, —$(CH_2)_rOC(O)R^b$, —$(CH_2)_rNR^{11}R^{11}$, —$(CH_2)_rC(O)NR^{11}R^{11}$, —$(CH_2)_rNR^bC(O)R^c$, —$(CH_2)_rNR^bC(O)OR^c$, —$NR^bC(O)NR^{11}R^{11}$, —$S(O)_pNR^{11}R^{11}$, —$NR^bS(0)_pR^c$, —S(C)$R^c$, —$S(0)_2R^c$, Ci$_{-6}$ alkyl substituted with 0-2 R^a, Ci$_{-6}$ haloalkyl, —$(CH_2)_r$-3-l4 membered carbocycle substituted with 0-3 R^a, or —$(CH_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-3 R^a;

R^2 is $C_{6\text{-}io}$ aryl substituted with 0-4 R^{2a}, a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, substituted with 1-4 R^{2a}, or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-4 R^{2a};

R^{2a} at each occurrence is independently selected from hydrogen, =0, halo, OCF_3, CN, NO2, —$(CH_2)_rOR^b$, —$(CH_2)_rSR^b$, —$(CH_2)_rC(O)R^b$, —$(CH_2)_rC(O)OR^b$, —$(CH_2)_rOC(O)R^b$, —$(CH_2)_rNR^{11}R^{11}$, —$(CH_2)_rC(O)NR^{11}R^{11}$, —$(CH_2)_rNR^bC(O)R^c$, —$(CH_2)_rNR^bC(O)OR^c$, —$NR^bC(O)NR^{11}R^{11}$, —$S(O)_pNR^{11}R^{11}$, —$NR^bS(O)_pR^c$, —$S(O)R^c$, —$S(O)_2R^c$, $C_{1\text{-}6}$ alkyl substituted with 0-2 R^a, $Ci_{\text{-}6}$ haloalkyl, —$(CH_2)_r$-3-l4 membered carbocycle substituted with 0-1 R^a, or —$(CH_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, 0, and $S(0)_p$ substituted with 0-2 R^a;

R^3 is $Ci\text{-}_6$ alkyl substituted with 0-3 R^{3a}, $Ci_{\text{-}6}$ haloalkyl, $C_{2\text{-}6}$ alkenyl substituted with 0-3 R^{3a}, $C_{2\text{-}6}$ alkynyl substituted with 0-3 R^{3a}, C3-iocycloalkyl substituted with 0-3 R^{3a}, $C_{6\text{-}io}$ aryl substituted with 0-3 R^{3a}, a 5-10 membered heterocyclyl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 $R^{3'}$ or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{3a};

R^{3a} is hydrogen, =0, F, Cl, Br, OCF3, CN, $N0_2$, —$(CH_2)_rOR^b$, —$(CH_2)_rSR^b$, —$(CH_2)_rC(0)R^b$, —$(CH_2)_rC(0)OR^b$, —$(CH_2)_rOC(0)R^b$, —$(CH_2)_rNR"R"$, —$(CH_2)_rC(0)NR^{11}R^{11}$, —$(CH_2)_rNR^bC(0)R^c$, —$(CH_2)_rNR^bC(0)OR^c$, —$NR^bC(0)NR^{11}R^{11}$, —$S(0)_pNR^{11}R^{11}$, —$NR^bS(0)_pR^c$, —$S(0)R^c$, —$S(0)_2R^c$, $C_{I\text{-}6}$ alkyl substituted with 0-2 R^a, $Ci_{\text{-}6}$ haloalkyl, —$(CH_2)_r$-3-l4 membered carbocycle substituted with 0-1 R^a, or —$(CH_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-1 R^a;

R^4 and R^5 are independently selected from hydrogen, $Ci_{\text{-}4}$ alkyl substituted with 0-1 R^f, (CH_2)-phenyl substituted with 0-3 R^d, and a —(CH_2)-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$;

R^6 and R^7 are independently at each occurrence is selected from hydrogen, =0, F, Cl, Br, OCF3, CN, $N0_2$, —$(CH_2)_rOR^b$, —$(CH_2)_rSR^b$, —$(CH_2)_rC(0)R^b$, —$(CH_2)_rC(0)OR^b$, —$(CH_2)_rOC(0)R^b$, —$(CH_2)_rNR"R"$, —$(CH_2)_rC(0)NR^{11}R^{11}$, —$(CH_2)_rNR^bC(0)R^c$, —$(CH_2)_rNR^bC(0)OR^c$, —$NR^bC(0)NR^{11}R^{11}$, —$S(0)_pNR^{11}R^{11}$, —$NR^bS(0)_pR^c$, —$S(0)R^c$, —$S(0)_2R^c$, $C_{I\text{-}6}$ alkyl substituted with 0-2 R^a, $Ci_{\text{-}6}$ haloalkyl, —$(CH_2)_r$-3-l4 membered carbocycle substituted with 0-3 R^a, or —$(CH_2)_r$-5-7 membered heterocycle or heteroaryl,

each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-3 R^a, provided R^6 and R^7 are not both hydrogen;

R^{11} at each occurrence is independently hydrogen, R^e, C_{1-4} alkyl substituted with 0-1 R^f, CH_2-phenyl substituted with 0-3 R^d, or —(CH_2)-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-3 R^d; or

R^{11} and along with another R^{11}, R^1, or R^2 on the same nitrogen atom may join to form an optionally substituted heterocycle;

R^a is hydrogen, F, Cl, Br, OCF_3, CF_3, CHF_2, CN, NO_2, $—(CH_2)_rOR^b$, $—(CH_2)_rSR^b$, $—(CH_2)_rC(0)R^b$, $—(CH_2)_rC(0)OR^b$, $—(CH_2)_rOC(0)R^b$, $—(CH_2)_rNR^{11}R^{11}$, $—(CH_2)_rC(0)NR^{11}R^{11}$, $—(CH_2)_rNR^bC(0)R^c$, $—(CH_2)_rNR^bC(0)OR^c$, $—NR^bC(0)NR^{11}R^{11}$, $—S(0)_pNR^{11}R^{11}$, $—NR^bS(0)pR^c$, $—S(0)R^c$, $—S(0)_2R^c$, C_{1-6} alkyl substituted with 0-1 R^f, C_{1-6} haloalkyl, $—(CH_2)_r$-3-l4 membered carbocycle, or $—(CH_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$; or two R^a on adjacent or the same carbon atom form a cyclic acetal of the formula $—O—(CH_2)_{n—}O—$, or $—O—CF_{2—}O—$, wherein n is selected from 1 or 2;

R^b is hydrogen, R^e, C_{1-6} alkyl substituted with 0-2 R^d, C_{1-6} haloalkyl, C_{3-6} cycloalkyl substituted with 0-2 R^d, or $(CH_2)_r$-phenyl substituted with 0-3 R^d;

R^c is C_{1-6} alkyl substituted with 0-1 R^f, C_{3-6} cycloalkyl, or $(CH_2)_r$-phenyl substituted with 0-3 R^f;

R^d is hydrogen, F, Cl, Br, OCF3, CF_3, CN, NO_2, $—OR^e$, $—(CH_2)_rC(0)R^c$, $—NR^eR^e$, $—NR^eC(0)OR^c$, C_{1-6} alkyl, or $(CH_2)_r$-phenyl substituted with 0-3 R^f;

R^e is selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, and $(CH_2)_r$-phenyl substituted with 0-3 R^f;

R^f is hydrogen, halo, NH_2, OH, or $0(C_{1-6}$alkyl);


p is 0, 1, or 2;

r is 0, 1, 2, 3, or 4; and


m is 0, 1, or 2;

as defined and described in WO 2013/106614 and US 2015/0045347, the entirety of each of which is herein incorporated by reference.

[00126] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK4 inhibitor ; thereby forming a compound of formula **I-uu-1:**



I-uu-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

X is N or C—R^7;

R is R^1, halogen, cyano, nitro, —O—R^1, —C(=0) —R^1, —C(=0)0 —R^1, —C(=0)NR^{11}—R^1, —S(=0)$_2$— R^1, —NR^{11}C(=0) —R^1, —NR^{11}C(=0)NR^{11}—R^1, —NR^{11}C(=0)0 —R^1, —NR^{11}S(=0)$_2$— R^1, or— NR^{11}—R^1;

R^1 is Ci-$_6$ alkyl substituted with 0-4 R^{1a}, Ci$_{-6}$ haloalkyl, C_{2-6} alkenyl substituted with 0-3 R^{1a}, C_{2-6} alkynyl substituted with 0-3 R^{1a}, C3-iocycloalkyl substituted with 0-3 R^{1a}, C_{6-io} aryl substituted with 0-3 R^{1a}, a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{1a}, a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{1a};

R^{1a} is hydrogen, =O, F, Cl, Br, OCF_3, CN, NO_2, —$(CH_2)_rOR^b$, —$(CH_2)_rSR^b$, —$(CH_2)_rC(O)R^b$, —$(CH_2)_rC(O)OR^b$, —$(CH_2)_rOC(O)R^b$, —$(CH_2)_rNR^{11}R^{11}$, —$(CH_2)_rC(O)NR^{11}R^{11}$, —$(CH_2)_rNR^bC(O)R^c$, —$(CH_2)_rNR^bC(O)OR^c$, —$NR^bC(O)NR^{11}R^{11}$, —$S(O)_pNR^{11}R^{11}$, —

$NR^bS(0)_pR^c$, —S(0)R^c, —S(0)$_2R^c$, C_{1-6} alkyl substituted with 0-2 R^a, Ci_{-6} haloalkyl, —$(CH_2)_r$-3-l4 membered carbocycle substituted with 0-3 R^a, or —$(CH_2)_r$-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-3 R^a;

R^2 is C_{6-io} aryl substituted with 0-4 R^{2a}, a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-4 R^{2a}, a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-4 R^{2a};

R^{2a} at each occurrence is independently selected from hydrogen, =0, halo, OCF_3, CN, $N0_2$, —$(CH_2)_rOR^b$, —$(CH_2)_rSR^b$, —$(CH_2)_rC(O)R^b$, —$(CH_2)_rC(O)OR^b$, —$(CH_2)_rOC(O)R^b$, —$(CH_2)_rNR^{11}R^{11}$, —$(CH_2)_rC(O)NR^{11}R^{11}$, —$(CH_2)_rNR^bC(O)R^c$, —$(CH_2)_rNR^bC(O)OR^c$, —$NR^bC(O)NR^{11}R^{11}$, —$S(O)_pNR^{11}R^{11}$, —$NR^bS(O)_pR^c$, —S(O)$R^c$, —S(O)$_2R^c$, C_{1-6} alkyl substituted with 0-2 R^a, Ci_{-6} haloalkyl, —$(CH_2)_r$-3-l4 membered carbocycle substituted with 0-1 R^a, or —$(CH_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-2 R^a;

R^3 is Ci_{-6} alkyl substituted with 0-3 R^{3a}, Ci_{-6} haloalkyl, C_{2-6} alkenyl substituted with 0-3 R^{3a}, C_{2-6} alkynyl substituted with 0-3 R^{3a}, C3-iocycloalkyl substituted with 0-3 R^{3a}, C_{6-io} aryl substituted with 0-3 R^{3a}, a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{3a}, or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{3a};

R^{3a} is hydrogen, =O, F, Cl, Br, OCF_3, CN, NO_2, —$(CH_2)_rOR^b$, —$(CH_2)_rSR^b$, —$(CH_2)_rC(O)R^b$, —$(CH_2)_rC(O)OR^b$, —$(CH_2)_rOC(O)R^b$, —$(CH_2)_rNR^{11}R^{11}$, —$(CH_2)_rC(O)NR^{11}R^{11}$, —$(CH_2)_rNR^bC(O)R^c$, —$(CH_2)_rNR^bC(O)OR^c$, —$NR^bC(O)NR^{11}R^{11}$, —$S(O)_pNR^{11}R^{11}$, —$NR^bS(O)_pR^c$, —S(O)$R^c$, —S(O)$_2R^c$, C_{1-6} alkyl substituted with 0-2 R^a, Ci_{-6} haloalkyl, —$(CH_2)_r$-3-l4 membered carbocycle substituted with 0-1 R^a, or —$(CH_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-1 R^a;

R^4 and R^5 are independently selected from hydrogen, Ci_{-4} alkyl substituted with 0-1 R^f, (CH_2)-phenyl substituted with 0-3 R^d, and a —(CH_2)-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$;

R^6 and R^7 are independently at each occurrence is selected from hydrogen, =0, F, Cl, Br, OCF3, CN, $N0_2$, —$(CH_2)_rOR^b$, —$(CH_2)_rSR^b$, —$(CH_2)_rC(0)R^b$, —$(CH_2)_rC(0)OR^b$, —

$(CH_2)_rOC(O)R^b$, $—(CH_2)_rNR^{11}R^{11}$, $—(CH_2)_rC(O)NR^{11}R^{11}$, $—(CH_2)_rNR^bC(O)R^c$, $—(CH_2)_rNR^bC(O)OR^c$, $—NR^bC(O)NR^{11}R^{11}$, $—S(O)_pNR^{11}R^{11}$, $—NR^bS(O)_pR^c$, $—S(O)R^c$, $—S(0)_2R^c$, C_{I-6} alkyl substituted with 0-2 R^a, Ci_{-6} haloalkyl, $—(CH_2)_r$-3-l4 membered carbocycle substituted with 0-3 R^a, or $—(Cl¾)_t$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-3 R^a, provided R^6 and R^7 are not both hydrogen;

R^{11} at each occurrence is independently R^z, Ci_{-4} alkyl substituted with 0-1 R^f, CH2-phenyl substituted with 0-3 R^d, or $—(CH_2)$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-3 R^d;

alternatively, R^{11} and along with another R^{11}, R^1, or R^2 on the same nitrogen atom may join to form an optionally substituted azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, or 4-(Ci-6alkyl jpiperazinyf

R^a is R^d, F, Cl, Br, OCF_3, CF_3, CHF_2, CN, NO_2, $—(CH_2)_rOR^b$, $—(CH_2)_rSR^b$, $—(CH_2)_rC(O)R^b$, $—(CH_2)_rC(O)OR^b$, $—(CH_2)_rOC(O)R^b$, $—(CH_2)_rNR^{11}R^{11}$, $—(CH_2)_rC(O)NR^{11}R^{11}$, $—(CH_2)_rNR^bC(O)R^c$, $—(CH_2)_rNR^bC(O)OR^c$, $—NR^bC(O)NR^{11}R^{11}$, $—S(O)_pNR^{11}R^{11}$, $—NR^bS(O)_pR^z$, $—S(0)_2R^c$, $—S(0)_2R^z$, C_{I-6} alkyl substituted with 0-1 R^f, Ci_{-6} haloalkyl, $—(CH_2)_r$-3-l4 membered carbocycle, or $—(CH_2)_r$-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$; alternatively two R^a on adjacent or the same carbon atom form a cyclic acetal of the formula $—O—(CFl_2)_n—O—$, or $—O—CF2—O—$, wherein n is selected from 1 or 2;

R^b is R^z, Ci_{-6} alkyl substituted with 0-2 R^d, Ci_{-6} haloalkyl, C3-6cycloalkyl substituted with 0-2 R^d, or $(CFh)_r$-phenyl substituted with 0-3 R^d;

R^z is Ci_{-6} alkyl substituted with 0-1 R^f, C3-6 cycloalkyl, or $(CH2)_r$-phenyl substituted with 0-3 R^f;

R^d is hydrogen, F, Cl, Br, OCF3, CF_3, CN, $N0_2$, $—OR^z$, $—(CH_2)_rC(0)R^c$, $—NR^zR^z$, $—NR^zC(0)OR^c$, Ci_{-6} alkyl, or $(CFh)_r$-phenyl substituted with 0-3 R^f;

R^z is selected from hydrogen, Ci_{-6} alkyl, C3-6 cycloalkyl, and $(CFh)_r$-phenyl substituted with 0-3 R^f;

R^f is hydrogen, halo, NFh, OH, or $0(Ci_{-6}$alkyl);


p is 0, 1, or 2;

r is 0, 1, 2, 3, or 4; and


m is 0, 1, or 2;

as defined and described in WO 2013/106641 and US 2015/0018344, the entirety of each of which is herein incorporated by reference.


[00127] In certain embodiments, the present invention provides a compound of Formula **I,**




wherein IRAK is an IRAK4 inhibitor or



; thereby forming a compound of formula **I-vv-1** or **I-vv-2:**



I-vv-1



I-vv-2

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

R^1 is:

(a) C_{2-3} hydroxyalkyl substituted with zero to 4 R^{1a} wherein R^{1a} is independently selected from F, Cl, —OH, —CHF_2, —CN, —CF_3, —OCH_3, and cyclopropyl;

(b) C1-3 alkyl substituted with —0(Ci-$_3$ alkyl) and zero to 4 R^{1a} wherein R^{1a} is independently selected from F, Cl, —OH, —CHF_2, —CN, —CF3, and cyclopropyl;

(c) C4-8 alkyl substituted with zero to 7 R^{1a} wherein R^{1a} is independently selected from F, Cl, —OH, —CHF_2, —CF3, —CN— OCH3, cyclopropyl, and —0P(0)(0H)$_2$;

(d) —$(CH_2)_{2-4}$NHC(0)(C$_{1-6}$ alkyl), —$(CH_2)_2$CH(CH_3)NHC(0)(Ci$_{-6}$alkyl), —$(CH_2)_2$CH(CH3)NHC(O)(CH_2)$_{0-I}$NH(C$_{1-6}$ alkyl), or —$(CH_2)_2$CH(CH_3)NHC(0)(CH_2)o-iN(Ci$_{-4}$ alkyl)$_2$;

(e) cyclohexyl substituted with zero to 2 substituents independently selected from —OH, —OCH3, C1-6 alkyl, Ci$_{-6}$hydroxyalkyl, —C(0)NH_2, —C(0)NH(C$_{1-3}$ alkyl), —C(0)NH(Ci-$_6$hydroxyalkyl), —C(0)NH(C$_{3-6}$ cycloalkyl), —C(0)NH(C$_{3-6}$ fluoro cycloalkyl), —NHC(0)(Ci$_{-3}$ alkyl), —NHC(0)0(Ci$_{-3}$ alkyl), —NHS(0)$_2$$CH_3$, —S(0)$_2$$NH_2$, —S(0)$_2$(Ci-$_3$ alkyl), —S(Ci-$_3$ alkyl), thiazolyl, methyl pyrazolyl, and Ci-$_3$ alkyl substituted with —OH and cyclopropyl;

(f) —$(CH_2)_2$(phenyl) wherein said phenyl is substituted with —C(0)NH_2, —C(0)NH(CI-3 alkyl), or —S(0)$_2$NH_2; or

(g) piperidinyl substituted with —C(0)(Ci-$_3$ alkyl);

R^2 is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazolyl, thiazolyl, ortriazolyl, each substituted with zero to 2 substituents independently selected from F, Cl, —OH, —CN, Ci-$_3$ alkyl, —$CH_2C(0)0CH_3$, —0(Ci $_3$alkyl), —NH_2, —NH (C_{1-3} alkyl), —NH(cyclopropyl), —C(0)NH_2, —NHC(0)(C_{1-3} alkyl), —NH(tetrahydropyranyl), hydroxypyrrolidinyl, =0, —O(piperidinyl), and pyridinyl; and


R^3 is:


(a) Ci-$_6$ alkyl substituted with zero to 4 substituents independently selected from F, —OH, —C¾, —CF_3, and C3-6cycloalkyl;

(b) C_{3-6} cycloalkyl substituted with zero to 2 substituents independently selected from F, —OH, C_{1-3} hydroxyalkyl, —C¾, —CF_2H, —NH_2, and —C(0)0CH_2CH_3;

(c) oxetanyl, tetrahydropyranyl, or fluoro tetrahydropyranyl;


(d) phenyl substituted with zero to 2 substituents independently selected from —OH, —CN, —0(Ci- $_3$ alkyl), C_{1-3} hydroxyalkyl, —C(0)NH_2, —S(0)$_2NH_2$, —NHS(0)$_2$(C_{1-3} alkyl), pyrazolyl, imidazolyl, and methyl tetrazolyl; or




(e)  ;

as defined and described in WO 2014/074675 and US 2015/0284382, the entirety of each of which is herein incorporated by reference.

[00128] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK4 inhibitor ; thereby forming a compound of formula **I-xx-1**



I-xx-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

R^1 is an optionally substituted aromatic heterocyclic group or an optionally substituted C_{6-14} aryl group;

R^2 is a hydrogen atom or a substituent;

R^3 and R^4 are independently a hydrogen atom or a substituent, or R^3 and R^4 in combination optionally form an optionally substituted ring;

R^5 and R^6 are independently a hydrogen atom or a substituent, or R^5 and R^6 in combination optionally form an optionally substituted ring;


X is CR^7R^8, NR^9, O or S;

R^7 and R^8 are independently a hydrogen atom or a substituent, or R^7 and R^8 in combination optionally form an optionally substituted ring; and


R^9 is a hydrogen atom or a substituent;

as defined and described in WO 2015/068856 and US 2015/0133451, the entirety of each of which is herein incorporated by reference.

[00129] In certain embodiments, the present invention provides a compound of Formula **I,**




wherein LBM is an E3 ubiquitin ligase (IAP) binding moiety ; thereby forming a compound of formula **I-yy-1**



i-yy-i


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein the variable R is as defined and described in Ohoka, N. et al. (2017). *In Vivo* Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs). *Journal of Biological Chemistry, 292(11),* 4556-4570,, the entirety of each of which is herein incorporated by reference.

[00130] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK4 inhibitor ;

thereby forming a compound of formula I-zz-1



I-zz-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

R^1 denotes absent, A or Q-Het,

Z is 

wherein

X denotes O, S or N,

Y denotes C or N,

T denotes C or N, or

Z denotes a pyridine or a pyridazine group,

R^a is absent, OR^3, CF_3, Hal, or NO_2,

R^b is absent, A, or COHet,

R^2 denotes H, Het, Q-Het, Cyc, A or OA,

each Het is independently a 4-9 membered monocyclic ring or a fused, spiro or bridged bicyclic ring, which is saturated, unsaturated, or aromatic, which contains 1 to 3 heteroatoms independently selected from N, O, and S, and a group CO, SO or SO_2, and wherein 1 or 2 H atoms may be replaced by A, OA, COA, CN, Hal, NO_2, OR^3, SOA and/or SO_2A,

Cyc denotes a 4-8 saturated carbocyclic ring optionally containing a group SO, SO_2, or CO, and optionally substituted once or twice by a group selected from $CO(NR^3)_2$, COHet, OR^3, Het^1, A, $CHzHet^1$, NH_2, NHCOA, OCH_2Cyc', SO_2A and —SA(=NH)(=0),

each Q is independently a linear or branched alkylene, having 1 to 6 carbon atoms wherein 1-5 H atoms may be replaced by a group independently selected from OR^3, Hal, and $N(R^3)_2$, and wherein 1 or 2 CH_2 groups may be replaced by a group independently selected from CO, SO, SO_2 and NR^3, or Q denotes a 4-8-membered bivalent heterocyclic ring, which is saturated, unsaturated or aromatic and which contains 1 to 3 heteroatoms independently selected from N, O and S,

each A is independently a linear or branched alkyl having 1 to 10 carbon atoms wherein 1 to 7 H atoms may be replaced by a group independently selected from —OR^3, Hal, $NHSO_2A$, SO_2A, SOA, and $N(R^3)_2$, and wherein 1, 2 or 3 non-adjacent —CH_2— groups may be replaced by a group independently selected from —CO—, NR^3 and —O—,


each Hal is independently F, Cl, Br or I,

each R^3 is independently H or Ci-C_6-alkyl wherein 1 H atom may be replaced by a group selected from OH, O—Ci-C_6-alkyl, and Hal,


each Het^1 is independently a five- or six membered saturated monocyclic heterocycle which contains 1-3 N- and/or O-atoms, which optionally is monosubstituted by A,

Cyc^1 denotes cycloalkyl with 3-7 atoms; as defined and described in WO 2014/008992 and US 2015/0141396, the entirety of each of which is herein incorporated by reference.

[00131] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK4 inhibitor ; thereby forming a compound of formula **I-aaa-1**



I-aaa-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

Ring A is a monocyclic heteroaryl;

R^1 is one to three optionally substituted with R^{10} monocyclic or bicyclic heteroaryl;

R^2 is, -C(0)NH_2, -C(0)NH-R°, -C(O)NH-R^{00}-OH, -C(O)NH-R^{00}-OR°, -C(0)N(R°)$_2$, -C(0)NH-

cycloalkyl, -C(0)NH-heterocycloalkyl, -C(0)NH-(pyrazolyl optionally substituted with R°> -C(0)-R°, -C(0)-cycloalkyl, -S(0) $_2$NH$_2$, -S(0) $_2$NH-R°, -S(0) $_2$NH-cycloalkyl, -R^{00}-OH' -R^{00}-OR° , -R^{00}-(morpholin-4-yl) phenyl, oxadiazolyl, or tetrazolyl optionally substituted with R^{0,} wherein oxadiazolyl in R^2 is, R°, R^{00}-OH or may be substituted with R°-OR°;

R^3 is, H, R°, halogeno-lower alkyl, cycloalkyl, heterocycloalkyl, phenyl, pyridyl, pyrimidinyl, pyrazinyl, -C(0)N(R°) $_2$, -R^{00}-cycloalkyl, -R^{00}-heterocycloalkyl, -R^{00}-phenyl, -R^{00}-OH or a -R ^{00} -OR^0, wherein the cycloalkyl in R^3, heterocycloalkyl, phenyl and pyridyl, R°, halogen, -C(O)OR^0, -C(0)-R°, -OH, -OR^0, -S(0) $_2$-R°, -O-halogeno-lower alkyl, -OR^{00}-(morpholin-4-yl), -R^{00}-OH, -R^{00}-OR°, morpholin-4-yl or, -R^{00}-(morpholin-4-yl) may be substituted;


R^{10} may be the same or different from each other, R°, halogen, halogeno-lower alkyl, cycloalkyl, -OR^0, optionally substituted amino, -O-halogeno-lower alkyl, -R^{00}-OH, -R^{00}-OR° or, -R^{00}-is optionally amino substituted,

R° is the same or different from each other, lower alkyl,


R^{00} are identical or different from each other, it is a lower alkylene;

as defined and described in WO 2011/043371, the entirety of which is herein incorporated by reference.


[00132] In some embodiments, the compound of formala **I-aaa-1** above is provided as a compound of formula **I-aaa-2, 1-aaa-3,** or **I-aaa-4:**



I-aaa-2



I-aaa-3




I-aaa-4


or a pharmaceutically acceptable salt thereof, wherein:

each of LBM, L, R^1, R^2, R^3, and R^{10} is as defined above.

[00133] In some embodiments, In certain embodiments, the present invention provides a compound of Formula **I,** wherein IRAK is an IRAK4 inhibitor



; thereby forming a compound of formula **I-bbb-1**



I-bbb-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

X is selected from O, S, and NH;

A is selected from aryl or heteroaryl;

R at each occurrence is independently selected from hydrogen, cyano, halo, hydroxy, $-NO_2$, $-NR^3R^4$, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkyi, optionally substituted heterocycloalkyl or optionally substituted heteroaryl; wherein the optional substituent, in each occurrence, is independently selected from halo, alkyl, haloalkyl, cyano, $-NR^5R^6$ or $-COOR^7$;

R^1 at each occurence is independently selected from hydrogen, halogen, alkyl, aryl, heterocycloalkyl, heterocycloalkylalkyi, heteroaryl, Y-arylalkyl or -Y-cycloalkyl; wherein cycloalkyi, aryl, heterocycloalkyl, heterocycloalkylalkyi, heteroaryl and arylalkyl can be optionally substituted with hydroxy, alkyl, haloalkyl, cyano or halo;

Y is selected from direct bond, O, -C(O)- or NR^7;

R^2 at each occurence is independently selected from hydrogen, carboxy, cyano, hydroxy, hydroxyalkyl, alkyl, aryl, heteroaryl, $-SO^2R^5$ or oxo;

R^3 and R^4 are independently selected from hydrogen, hydroxyalkyl, aminoalkyl, optionally substituted alkyl, optionally substituted heterocyclyl, optionally substituted aryl; wherein the optional substituent, in each occurrence, is independently selected from halo, haloalkyl or $-COOR^7$;


R^5 and R^6 are independently selected from hydrogen, alkyl, COR^7 or $-COOR^7$;

R^7 at each occurrence is independently selected from hydrogen or alkyl; and


m, n and p are selected from 1, 2 or 3;

as defined and described in WO 2013/042137, the entirety of which is herein incorporated by reference.

[00134] In certain embodiments, the present invention provides a compound of Formula **I,** wherein IRAK is an IRAK4 inhibitor



; thereby forming a compound of formula **I-ccc-1**



I-ccc-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

Ring Zi is an optionally substituted heteroaryl;

Ring Z_2 is an optionally substituted heterocycloalkyl, optionally substituted heteroaryl or a direct bond;

Ri is alkyl, cyano, —NR_aR_b or optionally substituted groups selected from cycloalkyl, aryl or heterocyclyl; wherein the substituent, at each occurrence, independently is alkyl, alkoxy,

halogen, hydroxyl, hydroxyalkyl, amino, aminoalkyl, nitro, cyano, haloalkyl, haloalkoxy, —OCO—CH_2— O-alkyl, —0P(0)(0-alkyl) $_2$ or —CH_2— 0P(0)(0-alkyl) $_2$;

R_2, at each occurrence, independently is an optionally substituted group selected from alkyl or cycloalkyl; wherein the substituent, at each occurrence, is independently halogen, alkoxy, hydroxyl, hydroxyalkyl, haloalkyl or haloalkoxy;

R_3, at each occurrence, independently is hydrogen, halogen, alkyl, haloalkyl, haloalkoxy, alkoxy, —NR_aR_b, hydroxyl or hydroxyalkyl;


R_a is hydrogen or alkyl;

R_b is hydrogen, alkyl, acyl, hydroxyalkyl, —SCk-alkyl or optionally substituted cycloalkyl;


m and n are independently 1 or 2;

as defined and described in WO 2015/104662 and US 2016/0326151, the entirety of each of which is herein incorporated by reference.

[00135] In certain embodiments, the present invention provides a compound of Formula **I,** wherein IRAK is an IRAK4 inhibitor



; thereby forming a compound of formula **I-ddd-1**



I-ddd-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

Xi and X_3 independently are CH or N; X_2 is CR_2 or N; provided one and not more than one of Xi, X_2 or X_3 is N;

A is O or S;

Y is —CH_2— or O;

Ring Z is aryl or heterocyclyl;

Ri, at each occurrence, is independently halo or optionally substituted heterocyclyl; wherein the substituent is alkyl, alkoxy, aminoalkyl, halo, hydroxyl, hydroxyalkyl or —NR_aR_b;

R_2 is hydrogen, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl or —NR_aR_b; wherein the substituent is alkyl, amino, halo or hydroxyl;

R_3, at each occurrence, is alkyl or hydroxyl;


R_a and R_b are independently hydrogen, alkyl, acyl or heterocyclyl;

m and n are independently 0, 1 or 2;


p is 0 or 1;

as defined and described in WO 2015/104688 and US 2016/0340366, the entirety of each of which is herein incorporated by reference.

[00136] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK4 inhibitor ; thereby forming a compound of formula **I-eee-1**



I-eee-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

Z_i is optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl or is absent;

Z_2 is optionally substituted cycloalkyl, aryl or heterocyclyl;

R_i is hydrogen, optionally substituted alkyl, amino, halogen, cyano, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl;

R_2 at each occurrence is hydrogen, halogen, amino, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl;

R_3 at each occurrence is hydroxy, halogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted cycloalkyl or $—NR_aR_b$;


R_a and R_b, independently for each occurrence, are hydrogen, optionally substituted alkyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl;

m at each occurrence, is 0, 1 or 2; and

n at each occurrence, is 0, 1, or 2;


as defined and described in WO 2015/193846 and US 2017/0152263, the entirety of each of which is herein incorporated by reference.

[00137] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK4 inhibitor ;

thereby forming a compound of formula **I-fff-1**



I-fff-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherei R° represents hydrogen or Ci-C_4-alkyl, where the Ci-C_4-alkyl radical may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy and halogen;

R^1 represents hydrogen, halogen, cyano, C(=0)0H, C(=0)0R [a], C(=0)NH_2, C(=0)N(H)R [a], C(=0)N(R [a])R[b], C(=0)R [d], hydroxy or Ci-C_6-alkyl, where the Ci-C_6-alkyl radical is optionally mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, C(=0)0R [a], S(=0) $_2$— Ci-C_6-alkyl, NH_2, NHR[a], N(R[a])R[b], Ci-C_6-alkoxy which is optionally mono- or polysubstituted by identical or different radicals from the group consisting of halogen, Cri-Cx-cycloalkoxy which is optionally mono- or polysubstituted by identical or different radicals from the group consisting of halogen, heterocycloalkyl which is optionally mono- or polysubstituted by identical or different radicals from the group consisting of R[c],

or represents Ci-C_6-alkoxy, where the Ci-C_6-alkoxy radical may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, C(=0)0R^a, S(=0)$_2$— Ci-Ce-alkyl, NH_2, NHR^a, $N(R^a)R^b$, C_3-Cx-cycloalkyl which is optionally mono- or polysubstituted by identical or different radicals from the group consisting of halogen, Ci-C_6-alkoxy which is optionally mono- or polysubstituted by identical or different radicals from the group consisting of halogen, C_3-Cx-cycloalkoxy which is optionally mono- or polysubstituted by identical or different radicals from the group consisting of halogen, heterocycloalkyl which is optionally mono- or polysubstituted by identical or different radicals from the group consisting of R^c, aryl which is optionally mono- or polysubstituted by identical or different radicals from the group consisting of R^c, or 5- or 6-membered heteroaryl which is optionally mono- or polysubstituted by identical or different radicals from the group consisting of R^c,

or represents C_3-Cx-cycloalkoxy or heterocycloalkoxy which may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano and Ci-C_6-alkyl,

or represents aryloxy or 5- or 6-membered heteroaryloxy in which aryloxy and 5- or 6-membered heteroaryloxy may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, C(=0)0R^a, Ci-Ce-alkyl and Ci-C_6-alkoxy,

or represents C_3-C_8-cycloalkyl or heterocycloalkyl which may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano and Ci-C_6-alkyl,

or represents C2-C_6-alkenyl or C2-C_6-alkynyl,

or represents aryl, 5- to lO-membered heteroaryl, aryl-Ci-C_4-alkyl or 5- or 6-membered heteroaryl-Ci-C_4-alkyl, where aryl and heteroaryl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of halogen, hydroxy, cyano, C(=0)0H, C(=0)0R^a, Ci-C_6-alkyl, C_3-C_8-cycloalkyl and Ci-C_6-alkoxy;

R^a represents Ci-C_6-alkyl, C_3-Cio-cycloalkyl, heterocycloalkyl, aryl or heteroaryl, where alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of halogen,

hydroxy, cyano, Ci-C_3-alkyl, Ci-C_3-alkoxy, heterocycloalkyl, —C(=0)0 —Ci-C_6-alkyl and S(=0) $_{2}$— Ci-Ce-alkyl;

R^b represents Ci-C_6-alkyl or C_3-Cio-cycloalkyl;

or R^a and R^b together with the nitrogen atom form a 5- or 6-membered heterocycle which may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, and Ci-C_6-alkyl;

R^c represents hydroxy, halogen, cyano, Ci-C_3-alkyl or Ci-C_3-alkoxy;

R^d represents hydrogen, Ci-C_6-alkyl or C_3-Cio-cycloalkyl;

R^2 represents hydrogen, Ci-C_6-alkyl or C_3-C_6-cycloalkyl;

R^{13} represents hydrogen or Ci-C_6-alkyl;

W represents 5-membered heteroaryl which contains one to three heteroatoms selected from the group consisting of N, O and S and may optionally be monosubstituted by R^3 and optionally be mono- or polysubstituted by identical or different radicals R^4 or

W represents pyridyl, pyrazinyl, pyridazinyl, l,2,4-triazinyl or l,3,5-triazinyl which may optionally be monosubstituted by R^3 and optionally be mono- or polysubstituted by identical or different radicals R^4;

R^3 represents hydrogen, halogen, cyano, C(=0)R^a, NH_2, NHR^a, $N(R^a)R^b$, N(H)C(=0)R^a or Ci-C_6-alkyl,

where Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)R^a, C(=0)0H, C(=0)0R^a, S(=0) $_{2}$— Ci-Ce-alkyl, NH_2, NHR^a, $N(R^a)R^b$, Ci-C_6-alkoxy, C_3-C_8-cycloalkoxy,

where Ci-C_6-alkoxy and C_3-C_8-cycloalkoxy may optionally be mono- or polysubstituted by identical or different halogen radicals;

or Ci-C_6-alkyl is optionally mono- or polysubstituted by identical or radicals from the group consisting of C_3-C_6-cycloalkyl and heterocycloalkyl,

where C_3-C_6-cycloalkyl and heterocycloalkyl may optionally be mono-, di- or trisubstituted by identical or different radicals from the group consisting of halogen, cyano, Ci-C_3-alkyl and Ci-C_3-alkoxy,

or Ci-C_6-alkyl is optionally mono- or polysubstituted by identical or different radicals from the group consisting of aryl and 5- or 6-membered heteroaryl,

where aryl and 5- or 6-membered heteroaryl may optionally be mono-, di- or trisubstituted by identical or different radicals from the group consisting of halogen, cyano, C1-C3-alkyl and Ci-C3-alkoxy,

or R^3 represents Ci-C_6-alkoxy,

where Ci-C_6-alkoxy may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0R^a, S(=0)$_2$— Ci-C_6-alkyl, N(R^a)R^b, Cx-Cx-cycloalkyl, Ci-C_4-alkoxy, C_3-Cx-cycloalkoxy,

or represents C3-C_6-cycloalkyl, heterocycloalkyl or C_5-C_{11}-spirocycloalkyl, where cycloalkyl, heterocycloalkyl and spirocycloalkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)R^a, C(=0)0H, C(=0)0R^a, Ci-Ce-alkyl and Ci-C_4-alkoxy;

or represents aryl or 5- to lO-membered heteroaryl,

where aryl and heteroaryl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of halogen, hydroxy, cyano, C(=0)0R^a, S(=0)$_2$— Ci-Ce-alkyl, N0$_2$, NH_2, NHR^a, N(R^a)R^b, N(H)C(=0)R^a, Cs-Ce-cycloalkyl, Ci-C3-alkoxy and Ci-C3-alkyl, where

Ci-C3-alkyl may optionally be mono- or polysubstituted by identical or different halogen radicals;

R^4 represents halogen, hydroxy, cyano or Ci-C_6-alkyl, where Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of halogen, Ci-C_6-alkoxy, where Ci-C_6-alkoxy may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of halogen, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C3-Cio-cycloalkyl, 3- to lO-membered heterocycloalkyl and aryl, where aryl may optionally be mono- or polysubstituted by identical or different radicals R;

or R^4 represents aryl or heteroaryl which may optionally be mono- or polysubstituted by identical or different radicals R;

or R^4 represents C(=0)R^a, C(=0)NH_2, C(=0)N(H)R^a, C(=0)N(R^a)R^b, C(=0)0R^a, NH_2, NHR^a, N(R^a)R^b, N(H)C(=0)R^a, N(R^a)C(=0)R^a, N(H)C(=0)NH_2, N(H)C(=0)NHR^a, N(H)C(=0)N(R^a)R^b, N(R^a)C(=0)NH_2, N(R^a)C(=0)NHR^a, N(R^a)C(=0)N (R^a)R^b, N(H)C(=0)0R^a, N(R^a)C(=0)0R^a, N0$_2$, N(H)S(=0)R^a, N(R^a)S(=0)R^a, N(H)S(=0)$_2$R^a, N(R^a)S(=0)$_2$R^a, N=S(=0)(R^a)R^b, 0C(=0)R^a, 0C(=0)NH_2, 0C(=0)NHR^a,


$OC(=O)N(R^a)R^b$, SH, SR^a, $S(=O)R^a$, $S(=O)_2R^a$, $S(=O)_2NH_2$, $S(=O)_2NHR^a$, $S(=O)_2N(R^a)R^b$ or $S(=O)(=N—R^a)R^b$;

R represents halogen, cyano, Ci-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C3-Cio-cycloalkyl, 3- to lO-membered heterocycloalkyl, aryl, heteroaryl, $C(=0)R^a$, $C(=0)NH_2$, $C(=0)N(H)R^a$, $C(=0)N(R^a)R^b$, $C(=0)0R^a$, NH_2, NHR^a, $N(R^a)R^b$, $N(H)C(=0)R^a$, $N(R^a)C(=0)R^a$, $N(H)C(=0)NH_2$, $N(H)C(=0)NHR^a$, $N(H)C(=0)N(R^a)R^b$, $N(R^a)C(=0)NH_2$, $N(R^a)C(=0)NHR^a$, $N(R^a)C(=0)N(R^a)R^b$, $N(H)C(=0)0R^a$, $N(R^a)C(=0)0R^a$, $N0_2$, $N(H)S(=0)R^a$, $N(R^a)S(=0)R^a$, $N(H)S(=0)_2R^a$, $N(R^a)S(=0)_2R^a$, $N=S(=0)(R^a)R^b$, OH, Ci-Ce-alkoxy, $0C(=0)R^a$, $0C(=0)NH_2$, $0C(=0)NHR^a$, $0C(=0)N(R^a)R^b$, SH, SR^a, $S(=0)R^a$, $S(=0)_2R^a$, $S(=0)_2NH_2$, $S(=0)_2NHR^a$, $S(=0)_2N(R^a)R^b$ or $S(=0)(=NR^a)R^b$;

n represents 0 or 1;

Y represents a group selected from:

(II)



where * represents the point of attachment of the group to the remainder of the molecule;

R^5 represents hydrogen, Ci-C_6-alkyl or C3-Cio-cycloalkyl, where

Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, $C(=0)0R^a$, $S(=0)_2$—Ci-C_6-alkyl, $N(R^a)R^b$, Ci-C_4-alkoxy and Cx-Cx-cydoalkyl;

R^6 represents hydrogen or Ci-C_6-alkyl, where

Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C3-Cio-cycloalkyl, $C(=0)R^a$, C(=0)0H, $C(=0)0R^a$, $S(=0)_2$— Ci-Ce-alkyl, $N(R^a)R^b$, Ci-C_4-alkoxy and C_3-C_8-cycloalkoxy, or represents C3-Cio-cycloalkyl, where

C3-Cio-cydoalkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano and Ci-C_6-alkyl, where

Ci-C_6-alkyl may optionally be substituted by hydroxy, or represents heterocycloalkyl, where

heterocycloalkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of halogen, cyano, Ci-C_3-alkyl and Ci-C_3-alkoxy, or represents aryl or 5- or 6-membered heteroaryl, where

aryl and 5- or 6-membered heteroaryl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of halogen, cyano, Ci-C_3-alkyl, Ci-C_3-alkoxy, $S(=0)_2NH_2$, $S(=0)_2NHR^a$ and $S(=0)_2N(R^a)R^b$;

R^{7a} represents hydrogen, halogen, $N(R^a)R^b$, Ci-C_6-alkyl or C_3-Cio-cycloalkyl, where Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, C(=0)0R ^{a}, $S(=0)_2$— Ci-C_6-alkyl, $N(R^a)R^b$, Ci-C_4-alkoxy, C_3-C_8-cycloalkyl and heterocycloalkyl;

R^{7b} represents hydrogen, halogen or Ci-C_6-alkyl, where Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, C(=0)0R ^{a}, $S(=0)_2$— Ci-Ce-alkyl, $N(R^a)R^b$, Ci-C_4-alkoxy, C_3-Cx-cycloalkyl and heterocycloalkyl;

or R^{7a} and R^{7b} together with the carbon atom form C_3-C_6-cycloalkyl which may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano and Ci-C_6-alkyl,

or R^{7a} and R^{7b} together represent an oxo group;

R^{7c} represents hydrogen, halogen, $N(R^a)R^b$, Ci-C_6-alkyl or C_3-Cio-cycloalkyl, where

Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, C(=0)0R ^{a}, $S(=0)_2$— Ci-C_6-alkyl, $N(R^a)R^b$, Ci-C_4-alkoxy, C_3-C_8-cycloalkyl and heterocycloalkyl;

R^{7d} represents hydrogen, halogen or Ci-C_6-alkyl, where

Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, C(=0)0R ^{a}, $S(=0)_2$— Ci-C_6-alkyl, $N(R^a)R^b$, Ci-C_4-alkoxy, C_3-C_8-cycloalkyl and heterocycloalkyl;

or R^{7c} and R^{7d} together with the carbon atom form C_3-C_6-cycloalkyl which may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano and Ci-C_6-alkyl,

or R^{7c} and R^{7d} together represent an oxo group;

R^{8a} represents hydrogen, halogen, $N(R^a)R^b$, Ci-C_6-alkyl or C_3-Cio-cycloalkyl, where

Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, C(=0)0R[a], S(=0)$_2$—Ci-C_6-alkyl, N(R[a])R[b], Ci-C_4-alkoxy, Cx-Cx-cydoalkyl and heterocycloalkyl;

R^{8b} represents hydrogen, halogen or Ci-C_6-alkyl, where

Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, C(=0)0R[a], S(=0)$_2$—Ci-C_6-alkyl, N(R[a])R[b], Ci-C_4-alkoxy, Cx-Cx-cydoalkyl and heterocycloalkyl;

or R^{8a} and R^{8b} together with the carbon atom form C3-C_6-cycloalkyl which may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano and Ci-C_6-alkyl,

R^{8c} represents hydrogen, halogen, N(R[a])R[b], Ci-C_6-alkyl or C3-Cio-cycloalkyl, where

Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, C(=0)0R[a], S(=0)$_2$—Ci-C_6-alkyl, N(R[a])R[b], Ci-C_4-alkoxy, Cx-Cx-cydoalkyl and heterocycloalkyl;

R^{8d} represents hydrogen, halogen or Ci-C_6-alkyl, where

Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, C(=0)0R[a], S(=0)$_2$—Ci-C_6-alkyl, N(R[a])R[b], Ci-C_4-alkoxy, Cx-Cx-cydoalkyl and heterocycloalkyl;

or R^{8c} and R^{8d} together with the carbon atom form C3-C_6-cycloalkyl which may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano and Ci-C_6-alkyl,

or R^{8c} and R^{8d} together represent an oxo group;

o represents 0, 1 or 2,

p represents 0, 1 or 2,

q represents 0, 1 or 2,

r represents 0, 1 or 2,

s represents 0, 1 or 2,

where o, p, q, r and s do not simultaneously represent 0;

Z represents a group selected from C(=0), CR^9R^{10}, NR^{11}, O, S, S(=0) and S(=0)$_2$;

R^9 represents hydrogen or Ci-C_6-alkyl,

R^{10} represents hydrogen, halogen, cyano, C(=0)R^a, C(=0)0H, C(=0)0R^a, C(=0)NH_2, C(=0)N(H)R^a, C(=0)N(R^a)R^b, N(H)C(=0)R^a, N(R^b)C(=0)R^a, S(=0)$_2R^a$, hydroxy, N(R^a)R^b and Ci-C_6-alkyl, where

Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)R^a, C(=0)0H, C(=0)0R^a, S(=0)$_2$— Ci-C_6-alkyl, N(R^a)R^b, Ci-C_4-alkoxy and C_3-Cx-cycloalkoxy, or represents Ci-C_6-alkoxy, where

Ci-C_6-alkoxy may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, C(=0)0R^a, S(=0)$_2$— Ci-C_6-alkyl, N(R^a)R^b, C_3-Cx-cycloalkyl, Ci-C_4-alkoxy, C_3-Cx-cycloalkoxy, heterocycloalkyl, aryl and 5- or 6-membered heteroaryl, where

aryl and 5- or 6-membered heteroaryl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of halogen, cyano, Ci-Cx-alkyl and Ci-Cx-alkoxy, or represents aryloxy or 5- or 6-membered heteroaryloxy in which aryloxy and 5- or 6-membered heteroaryloxy may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, C(=0)0R^a, Ci-Cs-alkyl and Ci-C_3-alkoxy,

or represents C_3-C_8-cycloalkyl, C_3-C_8-cycloalkyl-Ci-C_4-alkyl, heterocycloalkyl or heterocycloalkyl-Ci-C_4-alkyl, which may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)R^a, C(=0)0H, C(=0)0R^a, Ci-C_6-alkyl and Ci-C_6-alkoxy, where

Ci-C_6-alkoxy may optionally be mono- or polysubstituted by identical or different halogen radicals or an oxo group;

or represents C_2-C_6-alkenyl or C_2-C_6-alkynyl,

or represents aryl, 5- to lO-membered heteroaryl, aryl-Ci-C_4-alkyl or 5- or 6-membered heteroaryl-Ci-C_4-alkyl, where

aryl and heteroaryl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of halogen, hydroxy, cyano, C(=0)0H, C(=0)0R^a, NHR^a, N(R^a)R^b, Ci-C_3-alkyl, C_3-C_8-cycloalkyl and Ci-C_3-alkoxy;

or R^9 and R^{10} together with the carbon atom form C_3-C_8-cycloalkyl or a 4- to 6-membered heterocycle, where

the Cs-Cs-cycloalkyl radical or the 4- to 6-membered heterocycle may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, Ci-C_6-alkyl, C(=0)R^a and an oxo group;

R^{11} represents hydrogen, C(=0)R^a, C(=0)0R^a, C(=0)NH_2, C(=0)N(H)R^a, C(=0)N(R^a)R^b, S(=0)$_2R^a$, S(=0)$_2$N(R^a)R^b or Ci-Ce-alkyl, where

Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)R^a, C(=0)0R^a, C(=0)NH_2, C(=0)N(H)R^a, C(=0)N(R^a)R^b, S(=0)$_2$__ Ci-Ce-alkyl, N(R^a)R^b, Cs-Cs-cycloalkyl, Ci-C_4-alkoxy and C_3-C_8-cycloalkoxy, where

C_3-C_8-cycloalkyl, Ci-C_4-alkoxy and C_3-Cs-cycloalkoxy may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy and halogen;

or represents C_3-Cs-cycloalkyl, heterocycloalkyl or heterocycloalkyl-Ci-C_4-alkyl which may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, Ci-C_6-alkyl, Ci-C_6-alkoxy, where alkyl and alkoxy may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of halogen and an oxo group,


or represents C_2-C_6-alkenyl or C_2-C_6-alkynyl,

or represents aryl, 5- to lO-membered heteroaryl, aryl-Ci-C_4-alkyl or 5- or 6-membered heteroaryl-Ci-C_4-alkyl, where


aryl and heteroaryl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of halogen, hydroxy, cyano, C(=0)0H, C(=0)0R^a, Ci-C_3-alkyl, C_3-C_8-cycloalkyl and Ci-C_3-alkoxy;

as defined and described in WO 2015/091426 and US 2016/0311833, the entirety of each of which is herein incorporated by reference.

[00138] In certain embodiments, the present invention provides a compound of Formula **I,** wherein IRAK is an IRAK4 inhibitor



; thereby forming a compound of formula **I-ggg-1**



I-ggg-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

Ring A is phenylene or 5- to 6-membered heteroarylene containing 1-3 heteroatoms chosen from O, S, and N, wherein ring A is optionally substituted with lower alkyl that is further optionally substituted,

Ring B is phenylene, 5- to 6-membered heterocycloalkylene containing 1-3 heteroatoms chosen from O, S, and N, or 5- to 6-membered heteroarylene containing 1-3 heteroatoms chosen from O, S, and N, wherein ring B is optionally substituted with lower alkyl that is further optionally substituted,

R^3 is chosen from hydrogen, lower alkyl optionally substituted with alkoxy, amino, N-(alkyl)amino, N,N-(dialkyl)amino, or phenyl, heterocycloalkyl, and heteroaryl,

wherein phenyl, heterocycloalkyl, and heteroaryl are optionally substituted with one or two groups independently chosen from lower alkyl and wherein alkoxy is optionally substituted with tri(alkyl)silyl,

R^4 is chosen from heteroarylene and arylene, each of which is optionally substituted, or R^4 and R^3 taken together with the nitrogen to which they are bound, form an optionally substituted 3- to 7-membered heterocycloalkyl ring, or R^4 is an alkylene chain having 1-3 carbon atoms that is optionally substituted with one or two groups independently chosen from lower alkyl and cycloalkyl, each of which groups is optionally substituted with hydroxyl or alkoxy, or R^4 is absent,

R^5 is chosen from C(0)NR^{51}, NR^{52}, and O or R^5 is absent, provided that if R^4 is absent, then R^5 is absent,

R^6 is an alkylene or alkenylene chain having one or two double bonds,

wherein the alkylene or alkenylene chain has 2 to 10 carbon atoms,

wherein the alkylene or alkenylene chain is optionally substituted with one or two groups independently chosen from lower alkyl and cycloalkyl, each of which groups is optionally substituted with hydroxyl or alkoxy, and

further wherein one or two of the carbon atoms in the alkylene chain is optionally replaced by an O, S, SO, SO_2, or NR^{61}, and

wherein two of the carbon atoms in the alkylene chain, are optionally connected by a two or three carbon atom alkylene chain to form a 5- to 7-membered ring.

R^7 is chosen from NR^{71} and O or R^7 is absent,

R^{51} is chosen from hydrogen and lower alkyl,

R^{52} is chosen from hydrogen, lower alkyl, and —C(0)0R^{81},


R^{61} is chosen from hydrogen, lower alkyl, and —C(0)0R^{81},

R^{71} is chosen from hydrogen, lower alkyl, and —C(0)0R^{81}, and


R^{81} is lower alkyl;

as defined and described in WO 2014/143672 and US 2016/0002265, the entirety of each of which is herein incorporated by reference.

[00139] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK4 inhibitor ; thereby forming a compound of formula **I-hhh-1**



I-hhh-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein HET is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-lH-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-bjpyridinyl, and purinyl, wherein said heteroaryl is substituted with R_a and R_t;

R_a is H, F, Cl, Br, —CN, —OH, C_{i-4} alkyl, C_{i-4} fluoroalkyl, C_{i-4}hydroxyalkyl, C_{i-4} alkoxy, —NH_2, —NH(CI $_{-4}$ alkyl), —N(CI $_{-4}$ alkyl)$_2$, —NH(CI- $_4$ hydroxyalkyl), —NH(CI- $_4$ fluoroalkyl), —NH(Ci-$_6$ hydroxy-fluoroalkyl), —C(0)NH_2, —CH_2NHC(0)(Ci $_{-6}$ alkyl), —CH_2NHC(0)(Ci $_{-6}$hydroxyalkyl), —CH_2NHC(0)NH(Ci $_{-6}$ alkyl), —CH_2NHC(0)NHCH $_2$(phenyl), —CH_2NHC(0)N(Ci $_{-4}$ alkyl)$_2$, —CH_2NHC(0)0(Ci $_{-4}$ alkyl), —CH_2NHC(0)(C $_{3-6}$ cycloalkyl), —CH_2NHC(0)(tetrahydrofuranyl), —CH_2NHC(0)CH $_2$(C$_{3-6}$ cycloalkyl), —CH_2NHC(0)CH $_2$(tetrahydropyranyl), —CH_2NHC(0)CH $_2$(phenyl), —NHC(0)(Ci- $_4$ alkyl), pyrrolidinyl, hydroxypyrrolidinyl, or pyridazinyl;

R_b is H or —NH_2;

R i is:

(i) Ci-$_6$ alkyl, C i$_{-6}$ fluoroalkyl, C i$_{-6}$ hydroxyalkyl, C i$_{-8}$ hydroxy -fluoroalkyl, —(Ci-$_6$ alkylenyl)0(Ci-$_4$ alkyl), —(Ci$_{-6}$ alkylenyl)0(Ci.$_4$fluoroalkyl), —(Ci-6fluoroalkylenyl)0(Ci-4 alkyl), —(Ci$_{-6}$fluoroalkylenyl)0(Ci$_{-4}$ deuteroalkyl), —(Ci$_{-6}$ fluoroalkylenyl)0(Ci-4fluoroalkyl), —(Ci-4 fluoroalkylenyl)C(C3-6cycloalkyl)$_2$(OH), —(Ci-4alkylenyl)NHC(0)(Ci.4 alkylenyl)0C(0)(Ci-3 alkyl), —(Ci-6alkylenyl)NHS(0)$_2$(Ci.4 alkyl), —(Ci$_{-6}$ alkyl enyl)P(0)(Ci-4 alkoxy)$_2$, —(Ci-6fluoroalkylenyl)NH(Ci-4 alkyl), —(Ci$_{-6}$ alkylenyl)C(0)NH(Ci-4 alkyl), —(Ci-6fluoroalkylenyl)C(0)NH(Ci-4 alkyl), —(Ci$_{-6}$fluoroalkylenyl)C(0)NH(Ci$_{-4}$ hydroxyalkyl), or —(Ci-$_6$fluoroalkylenyl)0P(0)(0H)$_2$;

(ii) —(C i-3 alkyl enyl)R$_x$, —(C1-3 fluoroalkylenyl)R$_x$, —(Ci-$_3$alkylenyl)C(0)R$_x$, —(Ci-$_3$ alkylenyl)C(0)NHR$_x$, —(Ci-$_3$fluoroalkylenyl)C(0)R$_x$, or —CH_2CF=(tetrahydropyranyl), wherein R_x is a cyclic group selected from C3-$_6$ cycloalkyl, tetrazolyl, l,l-dioxidotetrahydrothiophenyl, 1,1-dioxidothiomorpholinyl, oxadiazolyl, piperidinyl, piperazinyl, pyrrolidinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyridinyl, imidazolyl, morpholinyl, phenyl, and triazinyl, wherein each cyclic group is substituted with zero to 3 substituents independently selected from F, —OH, —C¾, —$C(CH_2)_2OH$, —$_0$ CH3, —C(0)CH$_2$CN, —S(0)$_2$CH$_3$, —S(0)$_2$NH$_2$, —NHC(0)CH$_3$, —N(S(0)$_2$CH$_3$)$_2$, —CH_2CH_2(acetamidophenyl), —CH_2CH_2(methoxyphenyl), —CH_2CH_2(sulfamoylphenyl), oxetanyl, benzyl, and morpholinyl;

(iii) C3-6 cycloalkyl or C4-6 cycloalkenyl, each substituted with zero to 3 substituents independently selected from F, —OH, —CN, Ci^alkyl, C1-3 alkoxy, —S(Ci-$_3$ alkyl), —N 0$_2$, —S(0)$_2$(Ci-$_3$ alkyl), C i$_{-4}$hydroxyalkyl, —C(Ci-$_3$ alkyl)(OH)(C$_{3-6}$ cycloalkyl), —CH$_2$C(0)NH(Ci$_{-3}$ alkyl), —NHC(0)(Ci$_{-3}$ alkyl), —NHC(0)(Ci-$_4$hydroxyalkyl), —C(0)NH(C$_{I-3}$ alkyl), —C(0)NH(C$_{I-3}$ deuteroalkyl), —C(0)NH(C$_{3-6}$ cycloalkyl), —NHC(0)0(Ci$_{-3}$ alkyl), —NHS(0)$_2$(Ci-$_3$alkyl), pyridinyl, imidazolyl, pyrazolyl, methylimidazolyl, methylpyrazolyl, and thiazolyl;

(iv) tetrahydropyranyl, piperidinyl, pyrazolyl, phenyl, pyridinyl, or pyrimidinyl, each substituted with zero to 1 substituent selected from —OH, C1-3 alkyl, Ci-

$_3$ fluoroalkyl, Ci-$_4$ hydroxyalkyl, Ci$_{-3}$alkoxy, —C(0)(Ci$_{-4}$ alkyl), —S(0)$_2$(Ci-$_4$ alkyl), —S(0)$_2$NH(Ci$_{-4}$ alkyl), —NH(CI$_{-3}$ alkyl), —N(CI-$_3$ alkyl)$_2$, —0(Ci-$_3$ alkylenyl)N(Ci$_{-3}$ alkyl)$_2$, —CH$_2$(morpholinyl), azetidinyl, oxetanyl, tetrahydropyranyl, morpholinyl, piperazinyl, piperidinyl, methylpiperazinyl, methoxypiperidinyl, pyridinyl, pyrimidinyl, methyl sulfonyl azetidinyl, and —C(0)(m ethyl sulfonyl azetidinyl); or

(v) pyrrolo[2,3-c]pyridinyl, bicyclo[2.2.l]heptan-l-ol, tetrahydrobenzo[d]thiazol-2-amine, or l,3-diazaspiro[4.5]decane-2,4-dione; and

R_2 is:

(i) Ci-7 alkyl or C_{2-6} alkenyl, each substituted with zero to three substituents independently selected from F, —OH, and —CN; —(Ci$_{-4}$ alkylenyl)0(Ci$_{-4}$ alkyl), —(Ci$_{-4}$ alkylenyl)0(Ci$_{-4}$ fluoroalkyl), —(Ci$_{-6}$ alkyl enyl)NH$_2$, —(Ci-$_6$ alkylenyl)S(0)$_2$(Ci$_{-3}$ alkyl), —(Ci-$_6$fluoroalkylenyl)NH(Ci$_{-3}$ alkyl), or —(Ci-$_6$ alkylenyl)NHC(0)(Ci$_{-4}$fluoroalkyl);

(ii) —(Ci$_{-4}$ alkyl enyl)R_y wherein R_y is C_{3-6} cycloalkyl, azetidinyl, oxetanyl, oxazolyl, pyridinyl, tetrahydropyranyl, or morpholinyl, each substituted with zero to 2 substituents independently selected from F, —OH, and Ci$_{-3}$ alkyl;

(iii) C_{3-6} cycloalkyl, azetidinyl, oxetanyl, furanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, or tetrahydropyranyl, each substituted with zero to 3 substituents independently selected from F, —OH, Ci$_{-3}$alkyl, Ci$_{-3}$ hydroxyalkyl, —C(0)(Ci-$_3$ alkyl), —C(0)(Ci$_{-3}$ fluoroalkyl), —C(0)(Ci$_{-3}$ cyanoalkyl), —C(0)0(Ci$_{-3}$ alkyl), —C(0)NH$_2$, —C(0)NH(C$_{I-3}$ alkyl), —C(0)(difluorophenyl), —NH$_2$, —NH(Ci-$_3$ alkyl), —NH(C$_{I-3}$ fluoroalkyl), —NH(oxetanyl), —NHC(0)(C$_{I-3}$ alkyl), —NHC(0)(C$_{I-3}$ fluoroalkyl), —NHC(0)(C$_{3-6}$ cycloalkyl), —NHC(0)(fluorophenyl), —S(0)$_2$(Ci-$_3$ alkyl), imidazolyl, phenyl, pyrimidinyl, fluoropyrimidinyl, chloropyrimidinyl, and methoxypyrimidinyl;


(iv) adamantanyl, hydroxyadamantanyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]triazolyl, benzothiazolyl, bicyclo[l.l.l]pentanyl, or hydroxy-bicyclo[2.2.l]heptanyl; or

(v) phenyl, pyrazolyl, thiazolyl, thiadiazolyl, or indazolyl, each substituted with 0 to 2 substituents independently selected from F, Cl, —OH, —CN, Ci$_{-4}$ alkyl, Ci-


$_4$ hydroxyalkyl, C_{i-4} fluoroalkyl, C_{i-4} cyanoalkyl, C_{i-3} alkoxy, C3-6 cycloalkyl, —(Ci-$_3$ alkylenyl)0(Ci-$_3$alkyl), —(C1-3 alkyl enyl)0(C$_{1-3}$ fluoroalkyl), —C(0)NH$_2$, —C(0)NH(C$_{1-3}$ alkyl), —NHC(0)(Ci$_{-3}$ alkyl), —NHC(0)S(0)$_2$(Ci-$_3$alkyl), —S(0)$_2$NH$_2$, —S(0)$_2$(Ci-$_3$ alkyl), pyrazolyl, methyl pyrazolyl, imidazolyl, triazolyl, methyl tetrazolyl, ethyl tetrazolyl, phenyl, pyrimidinyl, fluoropyrimidinyl, and tetrahydropyranyl ;

as defined and described in WO 2015/103453 and US 2015/0191464, the entirety of each of which is herein incorporated by reference.

[00140] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK4 inhibitor ; thereby forming a compound of formula **I-iii-1**



I-iii-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein ═══ is a single or double bond;

W is selected from CH, CH—CH, O, S, NR^6, and CO;

Y is N or CR^9;

Z is N or C, and Z is N if W is CH and Y is CR^9;

R^4 is selected from hydrogen, halogen, OR^6, CN, NR^7R^8, CH_2OR^6, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted non-aromatic ring, an optionally substituted carbocycle, an optionally substituted Ci-C_6 alkyl, an optionally substituted Ci-C_6 haloalkyl, an optionally substituted Ci-C_6 heteroalkyl, an optionally substituted Ci-C_6 alkenyl, an optionally substituted Ci-C_6 alkynyl, CO2R^6, SO_3R^6, SO2R^6 and S0 $_2$NR^7R^8;

R_5 is selected from hydrogen, halogen, OR^6, an optionally substituted Ci-C_6 alkyl, an optionally substituted Ci-C_6 haloalkyl, an optionally substituted Ci-C_6 heteroalkyl, an optionally substituted Ci-C_6 haloheteroalkyl, an optionally substituted Ci-C_6 alkenyl, and an optionally substituted Ci-C_6 alkynyl;

or R_4 and R_5 are linked to form an optionally substituted non-aromatic ring;

each R_6 is independently selected from an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted non-aromatic ring, each optionally fused with a substituted aryl or a substituted heteroaryl, hydrogen, an optionally substituted Ci-Cioalkyl, an optionally substituted C_1-C_{10} haloalkyl, and an optionally substituted Ci-C_{10} heteroalkyl;

each R^7 and R^8 is independently selected from an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted non-aromatic ring, each optionally fused with a substituted aryl or a substituted heteroaryl, hydrogen, an optionally substituted Ci-C_{10} alkyl, an optionally substituted C_1-C_{10} haloalkyl, an optionally substituted Ci-C_{10} alkenyl, an optionally substituted C_1-C_{10} alkynyl, and an optionally substituted Ci-C_{10} heteroalkyl, or R^7 and R_8 are linked to form an optionally substituted non-aromatic ring;

R^9 is selected from hydrogen, halogen, OR^6, CN, NR^7R^8, CH_2OR^6, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted non-aromatic ring, an optionally substituted Ci-C_6 alkyl, an optionally substituted Ci-C_6 haloalkyl, an optionally substituted Ci-C_6 heteroalkyl, an optionally substituted Ci-C_6 alkenyl, an optionally substituted Ci-C_6 alkynyl, CO_2R^6, SO_3R^6, and S0 2NR^7R^8;


A is an optionally substituted aryl or an optionally substituted heteroaryl group;

each optionally substituted group is either unsubstituted or substituted with one or more groups independently selected from alkyl, heteroalkyl, alkenyl, alkynyl, haloalkyl,

heterohaloalkyl, aryl, arylalkyl, heteroaryl, non-aromatic ring, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, =0, =S, amino, and protected derivatives of amino groups;


as defined and described in WO 2012/068546 and US 2014/0155379, the entirety of each of which is herein incorporated by reference.

[00141] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK4 inhibitor ;

thereby forming a compound of formula I-jjj-1



i-jjj-i

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

Q denotes Ar or Het;

E denotes —$(CH_2)_mCO$—, —$(CH_2)_mS0_2$, —$(CH_2)_q$— , —$(CH_2)_mNHCO$—, or a single bond;

R^1 denotes H, OH, NH—Ci-C_6-alkyl, OCi-C_6-alkyl, Ci-C_6-alkyl, C2-C_6-alkenyl, C2-C_6-alkynyl, Cyc, Hal, Het^1, O-Het^1, CO-Het^1, NH-Het^1, CO—Ar^1, O—Ar^1, Ar^1, NH—Ar^1, —$(CH_2)_qHet^1$, —CONH—$(CH_2)_qHet^1$, —CONH-Het^1, —$(CH_2)_qO$-Het^1, —$(CH_2)_qO$—Ar^1, —$(CH_2)_qAr^1$, —CONH—$(CH_2)_qAr^1$, —CONH—Ar^1, —CONHCs-Ce-cycloalkyl, —$(CH_2)_qHal$, —$(CH_2)_qCyc$, CF_3, —$(CH_2)_sNH$—$(CH_2)_q$-Het^1, —$(CH_2)_sNH$—$(CH_2)_q$— Ar^1, wherein NH—Ci-C_6-alkyl, OCi-C_6-alkyl, Ci-C_6-alkyl, C2-C_6-alkenyl, C2-C_6-alkynyl, C_3-C_6-cycloalkyl may be substituted by 1 to 3 groups independently selected from OCi-C_3-alkyl, OH, $CONH_2$, NH_2;

R^2 denotes H, Ci-C_6-alkyl, C2-C_6-alkenyl, C2-C_6-alkynyl, Hal, CF_3, preferably H;

R^3 denotes Het^1, Ar^1, NR^aR^b, COOH, —$(CH_2)_qHet^1$, —$(CH_2)_qAr^1$, —$(CH_2)_qNR^aR^b$, —$(CH_2)_q$COOH, or Ci-C_6-alkyl wherein 1 to 3 hydrogen atoms may be independently replaced by OH or CF_3;

R^4 denotes H, Ci-C_6-alkyl, C2-C_6-alkenyl, Hal;

R^a denotes H, linear, branched or cyclic Ci-C_6-alkyl;

R^b denotes H, Het^b, Ar^b, —CO-Het^b, —CO—Ar^b, a C_3-C_8-cycloalkyl or a linear or branched alkyl having 1 to 6 carbon atoms, wherein 1 to 3 hydrogen atoms may be replaced by Het^b, Ar^b, NH_2, N(Ci-C_6-alkyl)$_2$, NH(Ci-C_6-alkyl), N(Ci-C_6-alkyl)(C_3-C_8-cydoalkyl), NH(C_3-C_8-cycloalkyl), 0(Ci-C_6-alkyl), CN, OH, CF_3, Hal;

n is 0, 1, 2, 3 or 4;

m is 0, 1, 2, 3 or 4;

q is 1, 2, or 3;

s is 0, 1, 2 or 3;

Hal denotes Cl, Br, I, F, preferably Cl or F;

Ar denotes a divalent monocyclic or fused bicyclic arylen group having 6 to 14 carbon atoms, which may be further substituted with 1 to 4 substitutents selected from Hal, Ci-C_6-alkyl, —$(CH_2)_m$OCi-C_6-alkyl, CN, OH, N0 $_2$, CF_3, —$(CH_2)_m$COOH, —$(CH_2)_m$COOCi-C_6-alkyl;

Het denotes a divalent monocyclic or fused bicyclic unsaturated, saturated or aromatic heterocyclic group having 1 to 5 heteroatom independently selected from N, O, S and/or a group —C=0, which may be further substituted with 1 to 4 substituent selected from Hal, Ci-C_6-alkyl, —$(CH_2)_m$OCi-C_6-alkyl, CN, OH, N0 $_2$, CF_3, —$(CH_2)_m$COOH, —$(CH_2)_m$COOCi-C_6-alkyl;

Ar^1 denotes a monocyclic or bicyclic, aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, —CF_3, —OCF_3, —NO2, —CN, perfluoroalkyl, Hal, —CF_3, —OCF_3, —$N0_2$, —CN, perfluoroalkyl, linear or branched Ci-C_6-alkyl, cycloalkyl, —OH, —OCi-C_6-alkyl, —COCi-Ce-alkyl, —NH_2, —COH, —COOH, —$CONH_2$, a group R^b such as —CH_20(Ci-Ce-alkyl), —$S0_2NR^aR^b$ or $S0_2$(Ci-C_6alkyl);

Het^1 denotes a monocyclic or bicyclic (fused, bridged or spiro) saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 heteroatom independently selected from N, O, S and/or a CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, —CF_3, —OCF_3, —NO?, —CN, perfluoroalkyl, linear or branched Ci-C_6-alkyl, C_3-Cx-cycloalkyl, —OH, —OCi-C_6-alkyl, —NH_2, —N(Ci-C_6-alkyl)$_2$, —COH, —COOH, —$CONH_2$, —COCi-C_6-alkyl, —NHCO(C_3-C_6cycloalkyl), a group R^b—$S0_2NR^aR^b$ or $S0_2$(Ci-C_6alkyl);


Het^b denotes a monocyclic or bicyclic (fused or spiro) saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 heteroatom independently selected from N, O, S and/or a CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, —CF_3, —OCF_3, —$N0_2$, —CN, perfluoroalkyl, —OH, —OCi-Ce-alkyl, —NH_2, —COH, —COOH, —$CONH_2$, or by a linear or branched Ci-C_6-alkyl wherein 1 to 3 hydrogen atoms may be replaced by NH_2, N(Ci-C_6-alkyl)$_2$, NH(Ci-C_6-alkyl), N(Ci-C_6-alkyl)(C_3-C_8-cycloalkyl), NH(C_3-C_8-cycloalkyl), 0(Ci-C_6-alkyl), CN, OH, CF_3, Hal, C_3-C_8-cycloalkyl, or by a 4 to 8-membered heterocyclic ring containing an heteroatom selected from O, S and N;

Ar^b denotes a monocyclic or bicyclic, aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, —CF_3, —OCF_3, —$N0_2$, —CN, perfluoroalkyl, Hal, —CF_3, —OCF_3, —$N0_2$, —CN, perfluoroalkyl, —OH, —OCi-C_6-alkyl, —NH_2, —COH, —COOH, —$CONH_2$, or by a linear or branched Ci-C_6-alkyl wherein 1 to 3 hydrogen atoms may be replaced by NH_2, N(Ci-C_6-alkyl)$_2$, NH(Ci-C_6-alkyl), N(Ci-C_6-alkyl)(C_3-C_8-cycloalkyl), NH(C_3-C_8-cycloalkyl), 0(Ci-C_6-alkyl), CN, OH, CF_3, Hal, C_3-C_8-cycloalkyl, or by a 4 to 8-membered heterocyclic ring containing an heteroatom selected from O, S and N;


Cyc denotes a saturated or unsaturated carbocyclic ring having 3 to 8 carbon atoms, preferrably 5 or 6 carbon atoms, wherein 1 to 5 H atoms are replaced by Hal, —CF_3, —OCF_3, —$N0_2$, —CN, perfluoroalkyl, Hal, —CF3, —OCF3, —$N0_2$, —CN, perfluoroalkyl, linear or branched Ci-C_6-alkyl, cycloalkyl, —OH, —OCi-C_6-alkyl, —COCi-C_6-alkyl, —NH_2, —COH, —COOH, —CONH2, a group R^b such as —CH_20(Ci-C_6-alkyl), —$S0_2NR^aR^b$ or $S0_2$(Ci-C_6alkyl); or

as defined and described in WO 2012/084704 and US 2013/0274241, the entirety of each of which is herein incorporated by reference.

[00142] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK4 inhibitor ; thereby forming a compound of formula **I-kkk-1**



I-kkk-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

R^1 is aryl, heteroaryl, heterocyclyl or (C_{1-6} alkyl)R^6, wherein said aryl, heteroaryl, and heterocyclyl groups are optionally substituted with one or two substituents selected from the group consisting of halo, cyano, R^4, C3-8 cycloalkyl, C_{1-3} aminoalkyl, C1-3hydroxyalkyl, OR^4, NR^4R^5, NR^4COR^6, $NR^4SO_2R^6$, $SO_2NR^4R^5$, $CONR^4R^5$and $CONR^4R^5$;

R^2 is aryl, heteroaryl, C3-8 cycloalkyl, heterocyclyl or (C_{1-6} alkyl)R^6, wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl groups are optionally substituted with one or two substituents selected from the group consisting of halo, cyano, oxo, hydroxyl, imino, hydroxyimino, R^4, OR^4, $O(C_{3-8}$ cycloalkyl), $(C=O)OR^4$, SO_mR^6, SO_mR^4, NR^4R^5, $SO_2NR^4R^5$ and $NR^4SO_2R^6$;

R^3 is halo, cyano, oxo, hydroxyl, imino, hydroxyimino, R^4, OR^4, C3-8cycloalkyl, SO_mR^6, $SO_mR^4NR^4R^5$ or $(C=O)NR^4R^5$, $NR^4(CO)R^6$, $SO_mNR^4R^5$ and $NR^4SO_2R^6$;

R^4 is hydrogen or C_{1-6} alkyl, wherein said alkyl is optionally substituted with one to three halo or hydroxyl;


R^5 is hydrogen or C_{1-6} alkyl, wherein said alkyl is optionally substituted with halo or hydroxyl;

R^6 is aryl, heteroaryl, C_{3-8} cycloalkyl or heterocyclyl;


m is an integer from zero to two;

as defined and described in WO 2012/129258 and US 2014/0194404, the entirety of each of which is herein incorporated by reference.

[00143] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK4 inhibitor ; thereby forming a compound of formula 1-111-1



1-111-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

X is —N= or —CH=;

Y is selected from the group consisting of —NR^2—, —CH_2—, —CHR— and —O—, such that when Y is —CHR—, R and R^3 together with the carbon to which they are attached optionally form a 4- to 6-membered cycloalkyl, cycloalkenyl or heterocyclic ring, wherein the 4- to 6-membered cycloalkyl, cycloalkenyl, or heterocyclic ring is optionally substituted with one to three substituents independently selected from the group consisting of Ci-$_4$ alkyl, C_{3-6} cycloalkyl, phenyl, CF_3, heterocyclyl, halogen, —$COOR^8$, —NHR^8, —SR^8, —OR^8, —SO_2R^8, —COR^8, —$NHCOR^8$, and —$CONHR^8$; or when Y is —NR^2—, R^2 and R^3 together with the nitrogen to which they are attached optionally form a 4- to 6-membered heterocyclic ring, wherein the 4- to 6-membered heterocyclic ring is optionally substituted with one to three substituents independently selected from the group consisting of C_{1-4} alkyl, C_{3-6} cycloalkyl, phenyl, CF_3, heterocyclyl, halogen, —$COOR^8$, —NHR^8, —SR^8, —OR^8, —SO_2R^8, —COR^8, —$NHCOR^8$, and —$CONHR^8$;

R^1 is selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{3-8} cycloalkyl, aryl, heterocyclyl, halogen, —$COOR^7$, —NHR^7, —SR^7, —OR^7, —SO_2R^7, —COR^7, —$NHCOR^7$, and —$CONHR^7$; wherein said alkyl, cycloalkyl, aryl and heterocyclyl are optionally substituted with one to three substituents independently selected from the group consisting of Ci-$_4$ alkyl, C_{3-6} cycloalkyl, CN, phenyl, CF_3, heterocyclyl, halogen, —$COOR^8$, —NHR^8, —

SR^8, —OR^8, — $SO2R^8$, —COR^8, —$NHCOR^8$, and —$CONHR^s$, wherein said —NHR^8 is optionally substituted with —N(Ci-4alkyl)NH2 or —N(C_{3-6} cycloalkyl)NH2;

R^2 is selected from the group consisting of hydrogen, C_{1-10} alkyl, and C_{3-8} cycloalkyl;

R^3 is selected from the group consisting of hydrogen, C_{1-10} alkyl, C3-8cycloalkyl, aryl, heterocyclyl, and —$COOR^7$; wherein said alkyl, cycloalkyl, aryl and heterocyclyl are optionally substituted with one to three substituents independently selected from the group consisting of C_{1-4} alkyl, C3-6 cycloalkyl, phenyl, CF3, heterocyclyl, halogen, —$COOR^8$, —NHR^8, —SR^8, —OR^8, — $SO2R^8$, —COR^8, —$NHCOR^8$, and —$CONHR^8$;


R^6 is selected from the group consisting of C_{1-10} alkyl, C_{3-8} cycloalkyl, aryl, heterocyclyl, —$COOR^7$, — SO_2R^7, and —COR^7; wherein said alkyl, cycloalkyl, aryl and heterocyclyl are optionally substituted with one to three substituents independently selected from the group consisting of C_{1-4} alkyl, C_{3-6} cycloalkyl, phenyl, CF_3, heterocyclyl, halogen, —$COOR^8$, —NHR^8, —SR^8, —OR^8, — SO_2R^8, —COR^8, —$NHCOR^8$, and —$CONHR^8$;

R^7 is selected from the group consisting of hydrogen, C_{1-10} alkyl, C3-8cycloalkyl, aryl, and heteroaryl; wherein said alkyl, cycloalkyl, aryl and heterocyclyl are optionally substituted with one to three substituents independently selected from the group consisting of Ci_{-4} alkyl, C3-6cycloalkyl, phenyl, CF3, heterocyclyl, halogen, —$COOR^8$, —NHR^8, — SR^8, — OR^8, — $SO2R^8$, —COR^8, —$NHCOR^8$, and —$CONHR^8$; and

R^8 is selected from the group consisting of hydrogen, Ci_{-6} alkyl and C3-6 cycloalkyl;


as defined and described in WO 2013/066729 and US 2014/0329799, the entirety of each of which is herein incorporated by reference.

[00144] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK4 inhibitor ; thereby forming a

compound of formula **l-mimii-1**



l-iniiiiii-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

X is independently CH or N;

Y is H or methyl;

a is 0 or 1; b is 0 or 1; m is 0, 1 or 2; n is 0, 1, 2, 3 or 4;

Ring A is (Cx-Cx)cycloalkenyl, aryl or heterocycle optionally substituted with one to three substituents independently selected from Ri;

Ri is selected from: H, oxo, (C=0) $_a$O$_b$(Ci-Cio)alkyl, (C=0) $_a$0 $_b$-aryl, (C=0) $_a$O$_b$(C$_2$-Cio)alkenyl, (C=0) $_a$O$_b$(C$_2$-Cio)alkynyl, C0 $_2$H, halo, OH, O$_b$(Ci-C $_6$)fluoroalkyl, (C=0) $_a$NR$_5$R$_6$, CN, (C=0) $_a$0 $_b$(C$_3$-C$_8$)cycloalkyl, S(0) $_m$NR$_5$R$_6$, SH, S(0) $_m$— (Ci-Cio)alkyl and (C=0) $_a$0 $_b$-heterocyclyl, said alkyl, aryl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are optionally substituted with one or more substituents selected from R$_a$;

R$_2$ and R$_x$ are independently selected from: H, (C=0) $_a$O$_b$Ci-Cio alkyl, (C=0) $_a$0 $_b$aryl, C$_2$-Cio alkenyl, C$_2$-Cio alkynyl, (C=0) $_a$0 $_b$ heterocyclyl, C0 $_2$H, CN, O$_b$Ci-C $_6$fluoroalkyl, 0 $_a$(C=0)bNR $_5$R$_6$, CHO, (N=0)R $_5$R$_6$, S(0) $_m$NR$_5$R$_6$, SH, S(0) $_m$— (Ci-Cio)alkyl, (C=0) $_a$0 $_b$Cx-Cx cycloalkyl, optionally substituted with one or more substituents selected from Ri; or R$_2$ and R$_x$ can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 3-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N,

O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from Ri;

R_4 is independently selected from: (Ci-C_6)alkyl, OH, methoxy, CF_3 and F, said alkyl optionally substituted with OH;


R_5 and R_6 are independently selected from H, (C=0) $_aO_b$(Ci-Cio)alkyl, (C=0) $_aO_b$-aryl, (C=0) $_aO_b$(C_2-Cio)alkenyl, (C=0) $_aO_b$(C_2-Cio)alkynyl, C0 $_2$H, O_b(Ci-C_6)fluoroalkyl, (C=0) $_aN(R_a)_2$, CN, (C=0) $_aO_b$(C_3-C_8)cycloalkyl, S(0) $_mN(R_a)_2$, SH, S(0) $_m$— (Ci-Cio)alkyl and (C=0) $_aO_b$-heterocyclyl, said alkyl, aryl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are optionally substituted with one or more substituents selected from R_a;

R_a is independently selected from R_b, OH, (Ci-C_6)alkoxy, halogen, cyclopropyl, C0 $_2$H, CN, O_a(C=0) $_b$(Ci-C_6)alkyl, oxo, and N(R_b)$_2$; and


R_b is independently selected from H and (Ci-C_6)alkyl;

as defined and described in WO 2014/058685 and US 2015/0299224, the entirety of each of which is herein incorporated by reference.

[00145] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK4 inhibitor ; thereby forming a compound of formula **I-nnn-1**



I-nnn-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

X is CH or N;

a is 0 or 1; b is 0 or 1; m is 0, 1 or 2;

Ring A is (Cx-Cx)cycloalkyl, (Cx-Cx)cycloalkenyl, aryl or heterocycle optionally substituted with one to three substituents independently selected from Ri;

Ri is selected from: H, oxo, (C=0) $_a$O$_b$(Ci-Cio)alkyl, (C=0) $_a$0 $_b$-aryl, (C=0) $_a$O$_b$(C$_2$-Cio)alkenyl, (C=0) $_a$O$_b$(C$_2$-Cio)alkynyl, C0 $_2$H, halo, OH, O$_b$(Ci-C $_6$)fluoroalkyl, (C=0) $_a$NR$_5$R$_6$, CN, (C=0) $_a$0 $_b$(C3-C$_8$)cycloalkyl, S(0) $_m$NR$_5$R6, SH, S(0) $_m$— (Ci-Cio)alkyl and (C=0) $_a$0 $_b$-heterocyclyl, said alkyl, aryl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are optionally substituted with one or more substituents selected from R$_a$;

R$_2$ and R$_x$ are independently selected from: H, (C=0) $_a$O$_b$Ci-Cio alkyl, (C=0) $_a$0 $_b$aryl, C$_2$-Cio alkenyl, C$_2$-Cio alkynyl, (C=0) $_a$0 $_b$ heterocyclyl, C0 $_2$H, CN, O$_b$Ci-C $_6$ fluoroalkyl, 0 $_a$(C=0)bNR $_5$R$_6$, CHO, (N=0)R $_5$R6, S(0) $_m$NR $_5$R6, SH, S(0) $_m$— (Ci-Cio)alkyl, (C=0) $_a$0 $_b$Cx-Cx cycloalkyl, optionally substituted with one or more substituents selected from Ri; or R$_2$ and R$_x$ can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 3-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from Ri;

R$_4$ is selected from: (Ci-C $_6$)alkyl and (C3-C$_6$)cycloalkyl, optionally substituted with R$_a$;


R_5 and R_6 are independently selected from: H, oxo, (C=0) $_aO_b$(Ci-Cio)alkyl, (C=0) $_a0_b$-aryl, (C=0) $_aO_b$(C_2-Cio)alkenyl, (C=0) $_aO_b$(C_2-Cio)alkynyl, C0 $_2$H, O_b(Ci-C_6)fluoroalkyl, (C=0) $_aN(R_a)_2$, CN, (C=0) $_a0_b$(C_3-C_8)cycloalkyl, S(0) $_mN(R_a)_2$, SH, S(0) $_m$— (Ci-Cio)alkyl and (C=0) $_aO_b$-heterocyclyl, said alkyl, aryl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are optionally substituted with one or more substituents selected from R_a;

R_a is independently selected from R_b, OH, (Ci-C_6)alkoxy, halogen, cyclopropyl, C0 $_2$H, CN, O_a(C=0) $_b$(Ci-C_6)alkyl, oxo, and $N(R_b)_2$; and


R_b is independently selected from H and (Ci-C_6)alkyl;

as defined and described in WO 2014/058691 and US 2015/0274708, the entirety of each of which is herein incorporated by reference.

[00146] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK4 inhibitor ; thereby forming a compound of formula **I-nnn'-l**




I-nnn'-l


or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein each of the variables R_3, R_4, X, and Ring A is as

defined and described in WO 2014/058691, the entirety of each of which is herein incorporated by reference.

[00147] In certain embodiments, the present invention provides a compound of Formula **I,**




wherein IRAK is an IRAK4 inhibitor ; thereby forming a compound of formula **I-ooo-l**



I-ooo-l

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

Z denotes a group  ; wherein

X is CH or N;

Y is CH or N;

Ra, Rc, Rl denote each independently H, Hal or Al;


Rb is H or alkyl;

Al is branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, such as 1 to 7, H atoms may be replaced by Hal, ORb, COORb, CN or $N(Rb)_2$ and wherein one or more, preferably 1 to 5 CH_2-groups may be replaced by O, CO, NRb or S, SO, $S0_2$, 1,2-, 1,3- or 1,4-phenylen, —CH=CH— or —C≡C—; and


Hal denotes F, Cl, Br, I;

as defined and described in WO 2014/121931 and US 2015/0376167, the entirety of each of which is herein incorporated by reference.

[00148] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK4 inhibitor ; thereby forming a compound of formula **I-ppp-1**



I-ppp-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

Rl, R3 denote each, independently of one another H, $(CH_2)_pCON(R5)_2$, OA, Hal, COOH, COOA, $(CH_2)_pNHCOA$, $(CH_2)_pHetl$, $(CH_2)_pNR2R5$, or OH;

R2 denotes H or linear or branched alkyl with 1, 2 or 3 C atoms, wherein one or two H atoms of the alkyl group are optionally replaced by OR6, NR5R6, NHCOR5, CONR5R6;

R4 denotes H or A;

R5 denotes H or linear or branched alkyl with 1, 2 or 3 C atoms;

R6 denotes H or linear or branched alkyl with 1, 2 or 3 C atoms;

Z is absent or denotes Ar-diyl or Het-diyl;

L denotes $(CH_2)_n$ wherein one or two CH_2 groups are optionally replaced by O and/or a CH=CH-group, and/or wherein one or two H atoms are optionally replaced by OR2, NR2R5 or Hetl;

Ar-diyl denotes 1,2-, 1,3- or l,4-phenylen optionally substituted with from 1 to 5 groups independently selected from the group consisting of Hal, CN, —CF_3, —OCF_3, OH, O-A, $S0_2$-A, COOH, COOA, —CO-A, O-phenyl, $S0_2$-phenyl, $S0_2$— CF3, Het2 and A;

Het-diyl denotes an unsaturated, saturated or aromatic 5- or 6-membered heterocycle comprising 1 to 2 N, O and/or S atoms, which are optionally unsubstituted or mono-, di- or trisubstituted by Hal, CN, —CF_3, —OCF3, O-A, $S0_2$-A, COOH, COOA, —CO-A, O-phenyl, $S0_2$-phenyl, $S0_2$— CF3, Het2 and/or A;

A denotes an unbranched or branched alkyl comprising 1 to 10 C atoms, in which 1 to 5 H atoms are optionally replaced by F and/or in which one or two non-adjacent CH_2 groups are optionally replaced by O;

Hetl denotes morpholinyl, piperidinyl or pyrrolidinyl;

Het2 denotes morpholinyl, piperidinyl or pyrrolidinyl;


Hal denotes F, Cl, Br, I;

n denotes 1, 2, 3, 4, 5 or 6;


p denotes 0, 1 or 2;

as defined and described in WO 2014/121942 and US 2015/0376206, the entirety of each of which is herein incorporated by reference.

[00149] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK 1 and/or IRAK4 inhibitor ; thereby forming a compound of formula **I-qqq-1**




I-qqq-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein Ring A is a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

n is 0-4;

each R^1 is independently —R, halogen, —CN, —NO_2, —OR, —CH_2OR, —SR, —$N(R)_2$, —SO2R, —$SO_2N(R)_2$, —SOR, —C(0)R, —COiR, —C(0)N(R)$_2$, —C(0)N(R)— OR, —NRC(0)R, —NRC(0)N(R)$_2$, Cy, or —NRSO2R; or R^1 is selected from one of the following formulas:



or two R^1 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each Cy is an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R is independently hydrogen or an optionally substituted group selected from Ci_{-6} aliphatic, aryl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or:

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, or sulfur;

R^z is —R, —CN, —NO_2, halogen, —C(0)N(R)$_2$, —C(0)0R, —C(0)R, —$N(R)_2$, —OR, or —$SO_2N(R)_2$;


Ring B is an unsubstituted 4-8 membered partially unsaturated carbocyclic fused ring; and

L is a C1-6 bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —NR—, —N(R)C(0) —, —C(0)N(R) —, —N(R)SO_2—, —$SO_2N(R)$—, —O—, —C(O)—, —OC(O)—, —C(0)0—, —S—, —SO—or —SO2—;


as defined and described in WO 2012/097013 and US 2012/0283238, the entirety of each of which is herein incorporated by reference.

[00150] In certain embodiments, the present invention provides a compound of Formula **I,**

wherein IRAK is an IRAK1 and/or IRAK4 inhibitor



; thereby forming a compound of formula **I-rrr-1**




I-rrr-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

Ring A is a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

n is 0-4;

each R^1 is independently —R, halogen, —CN, —NO_2, —OR, —CH_2OR, —SR, —$N(R)_2$, —SO_2R, —$SO_2N(R)_2$, —SOR, —C(0)R, —CO_2R, —C(0)$N(R)_2$, —C(0)N(R)—OR, —NRC(0)0R, —NRC(0)$N(R)_2$, Cy, or —NRSO?R; or R^1 is selected from one of the following formulas:



or two R^1 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each Cy is an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R is independently hydrogen, or an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or:

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, or sulfur;

Ring B is a cyclopento or cyclohexo fused ring;

m is 1-2;

p is 0-2;

W is N;

R^z is R, CN, $N0_2$, halogen, —C(0)N(R)$_2$, —C(0)0R, —C(0)R, —N(R)C(0)0R, —NRC(0)N(R)$_2$, —OR, or —$S0_2$N(R)$_2$;

L^1 is a covalent bond or a Ci_{-6} bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —NR—, —N(R)C(0) —, —C(0)N(R) —, —N(R)$S0_{2_}$, —$S0_2$N(R)—, —O—, —C(O)—, —OC(O)—, —C(0)0— , —S—, —SO— or —$S0_{2_}$;

each L^2 is independently a covalent bond or a Ci_{-6} bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —NR—, —N(R)C(0) —, —C(0)N(R)— , —N(R)$S0_{2_}$, —$S0_2$N(R)—, —O—, —C(O)—, —OC(O)—, —C(0)0— , —S—, —SO— or —$S0_{2_}$;


each R^4 is independently halogen, —CN, —NO?, —OR, —SR, —N(R)$_2$, —$S0_2$R, —$S0_2$N(R)$_2$, —SOR, —C(0)R, —$C0_2$R, —C(0)N(R)$_2$, —NRC(0)R, —NRC(0)N(R)$_2$, —

C(0)N(R)0R, —N(R)C(0)0R, —N(R)S(0) $_2$N(R)$_2$, —NRS0 $_2$R, or an optionally substituted group selected from Ci$_{-6}$aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or:

two -L^2(R^4)$_p$_ R^4 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;


as defined and described in WO 2013/106535 and US 2013/0231328, the entirety of each of which is herein incorporated by reference.

[00151] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK1 and/or IRAK4 inhibitor ;

thereby forming a compound of formula I-sss-1




I-sss-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein Ring A is a 3-7 membered saturated or

partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

n is 0-4;

each R^1 is independently —R, halogen, —CN, —NO_2, —OR, —CH_2OR, —SR, —$N(R)_2$, —$S(O)_2R$, —$S(O)_2N(R)_2$, —SOR, —C(O)R, —CO_2R, —$C(O)N(R)_2$, —C(O)N(R)—OR, —N(R)C(O)R, —N(R)C(O)OR, —$N(R)C(O)N(R)_2$, Cy, or —$N(R)S(O)_2R$, or R^1 is selected from one of the following formulas:



or two R^1 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each Cy is an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur;

Ring B is selected from a benzo fused ring and a 5-6 membered heteroaromatic fused ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said Ring B may be optionally substituted by one or more oxo, thiono, or imino groups;

m is 0-4;

p is 0-2;

W is N or —$C(R^3)$—;

R^z is R, CN, NO2, halogen, —C(0)N(R) $_2$, —C(0)0R, —C(0)R, —N(R) $_2$, —N(R)C(0)0R, —N(R)C(0)N(R) $_2$, —OR, or —S(0) $_2$N(R) $_2$;

R^3 is hydrogen, halogen, —CN, Ci $_{-4}$ aliphatic, C $_{1-4}$ haloaliphatic, —OR, —C(0)R, or —C(0)N(R) $_2$;

L^1 is a covalent bond or a Ci $_{-6}$ bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(0) —, —C(0)N(R) —, —N(R)S(0) $_{2-}$, —S(0) $_2$N(R)—, —O—, —C(O)—, —OC(O)—, —C(0)0— , —S—, —S(O)— or —S(0) $_{2-}$;


each L^2 is independently a covalent bond or a Ci $_{-6}$ bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(0) —, —C(0)N(R)— , —N(R)S(0) $_{2-}$, —S(0) $_2$N(R)—, —O—, —C(O)—, —OC(O)—, —C(0)0— , —S—, —S(O)— or —S(0) $_{2-}$; and

each R^4 is independently halogen, —CN, —NO?, —OR, —SR, —N(R) $_2$, —S(0) $_2$R, —S(0) $_2$N(R) $_2$, —S(0)R, —C(0)R, —C0 $_2$R, —C(0)N(R) $_2$, —N(R)C(0)R, —N(R)C(0)N(R) $_2$, —C(0)N(R)0R, —N(R)C(0)0R, —N(R)S(0) $_2$N(R) $_2$, —N(R)S(0) $_2$R, or an optionally substituted group selected from Ci $_{-6}$ aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or

two -L^2(R^4)$_{p-}$ R^4 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;


as defined and described in WO 2014/011902 and US 2014/0018343, the entirety of each of which is herein incorporated by reference.

[00152] In certain embodiments, the present invention provides a compound of Formula I,



wherein IRAK is an IRAK1 and/or IRAK4 inhibitor ... ;

thereby forming a compound of formula **I-ttt-1**




I-ttt-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein Ring A is a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

n is 0-4;

each R^1 is independently —R, halogen, —CN, —NO$_2$, —OR, —CH$_2$OR, —SR, —N(R)$_2$, —S(O)$_2$R, —S(O)$_2$N(R)$_2$, —S(O)R, —C(O)R, —C(O)OR, —C(O)N(R)$_2$, —C(O)N(R)—OR, —N(R)C(O)R, —N(R)C(O)OR, —N(R)C(O)N(R)$_2$, Cy, or —N(R)S(O)$_2$R; or R^1 is selected from one of the following formulas:



two R^1 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each Cy is an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each R is independently hydrogen, or an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur;

Ring B is selected from a 4-8 membered partially unsaturated carbocyclic fused ring and a 4-7 membered partially unsaturated heterocyclic fused ring having 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur; wherein said Ring B may be optionally substituted by one or more oxo, thiono, or imino groups;

m is 0-4;

p is 0-2;

R^z is —R, —CN, —$N0_2$, halogen, —$C(0)N(R)_2$, —C(0)OR, —C(0)R, —$N(R)_2$, —N(R)C(0)OR, —N(R)C(0)$N(R)_2$, —OR, or —$S(0)_2N(R)_2$;

R^3 is hydrogen, halogen, —CN, Ci_{-4} aliphatic, Ci_{-4} haloaliphatic, —OR, —C(0)R, or —$C(0)N(R)_2$;

L^1 is a covalent bond or a Ci_{-6} bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(0)—, —C(0)N(R)—, —N(R)$S(0)_2$—, —$S(0)_2$N(R)—, —O—, —C(O)—, —OC(O)—, —C(0)0— , —S—, —S(O)— or —$S(0)_2$— ;

each L^2 is independently a covalent bond or a Ci_{-6} bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —


N(R)C(0) —, —C(0)N(R)— , —N(R)S(0) $_{2}$— , —S(0) $_{2}$N(R)—, —O—, —C(O)—, —OC(O)—, —C(0)0— , —S—, —S(O)— or —S(0) $_{2}$— ; and

each R^4 is independently halogen, —CN, —NO?, —OR, —SR, —$N(R)_2$, —S(0) $_{2}$R, —S(0) $_{2}$N(R) $_{2}$, —S(0)R, —C(0)R, —C(0)OR, —C(0)N(R) $_{2}$, —N(R)C(0)R, —N(R)C(0)N(R) $_{2}$, —C(0)N(R)OR, —N(R)C(0)OR, —N(R)S(0) $_{2}$N(R) $_{2}$, —N(R)S(0) $_{2}$R, or an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or

two $-L^2(R^4)_p$— R^4 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;


as defined and described in WO 2014/011906 and US 2014/0018357, the entirety of each of which is herein incorporated by reference.

[00153] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK1 and/or IRAK4 inhibitor ;

thereby forming a compound of formula **I-uuu-1**




I-uuu-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

Ring A is a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

n is 0-4;

each R^1 is independently —R, halogen, —CN, —NO$_2$, —OR, —CH_2OR, —SR, —N(R)$_2$, —S(O)$_2$R, —S(O)$_2$N(R)$_2$, —S(O)R, —C(O)R, —C(O)OR, —C(O)N(R)$_2$, —C(O)N(R)—OR, —N(R)C(O)R, —N(R)C(O)OR, —N(R)C(O)N(R)$_2$, Cy, or —N(R)S(O)$_2$R; or R^1 is selected from one of the following formulas:




or two R^1 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each Cy is an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each R is independently hydrogen, or an optionally substituted group selected from C$_{1-6}$ aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur;

each of R^x and R^y is independently —R, halogen, —CN, —NO?, —OR, —SR, —N(R)$_2$, —S(O)$_2$R, —S(O)$_2$N(R)$_2$, —S(O)R, —C(O)R, —C(O)OR, —C(O)N(R)$_2$, —N(R)C(O)R, —N(R)C(O)N(R)$_2$, or —N(R)S(O)$_2$R, or:

R^x and R^y are taken together with their intervening atoms to form Ring B substituted with m occurrences of  ;

Ring B is selected from a benzo fused ring, a 4-8 membered partially unsaturated carbocyclic fused ring, a 4-8 membered partially unsaturated heterocyclic fused ring having one or two heteroatoms independently selected from nitrogen oxygen and sulfur, and a 5-6 membered heteroaromatic fused ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said Ring B may be optionally substituted by one or more oxo, thiono, or imino groups;

m is 0-4;

p is 0-2;

Q is —O— or —N(R)—

W is N or —C(R^3)—;

R^z is —R, —CN, —N0 $_2$, halogen, —C(0)N(R) $_2$, —C(0)0R, —C(0)R, —N(R)$_2$, —N(R)C(0)0R, —N(R)C(0)N(R) $_2$, —OR, or —S(0) $_2$N(R)$_2$;

R^3 is hydrogen, halogen, —CN, Ci-$_4$ aliphatic, Ci-$_4$ haloaliphatic, —OR, —C(0)R, or —C(0)N(R) $_2$;

L^1 is a covalent bond or a Ci$_{-6}$ bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(0) —, —C(0)N(R) —, —N(R)S(0) $_2$— , —S(0) $_2$N(R)—, —O—, —C(O)—, —OC(O)—, —C(0)0— , —S—, —S(O)— or —S(0) $_2$— ;

each L^2 is independently a covalent bond or a Ci$_{-6}$ bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(0) —, —C(0)N(R)— , —N(R)S(0) $_2$— , —S(0) $_2$N(R)—, —O—, —C(O)—, —OC(O)—, —C(0)0— , —S—, —S(O)— or —S(0) $_2$— ; and


each R^4 is independently halogen, —CN, —NO?, —OR, —SR, —N(R)$_2$, —S(0) $_2$R, —S(0) $_2$N(R)$_2$, —S(0)R, —C(0)R, —C(0)0R, —C(0)N(R) $_2$, —N(R)C(0)R, —N(R)C(0)N(R) $_2$, —C(0)N(R)0R, —N(R)C(0)0R, —N(R)S(0) $_2$N(R)$_2$, —N(R)S(0) $_2$R, or an optionally substituted group selected from Ci$_{-6}$ aliphatic, phenyl, 4-7 membered

saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or


two $-L^2(R^4)_p-R^4$ groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

as defined and described in WO 2014/011911 and US 2014/0018361, the entirety of each of which is herein incorporated by reference.

[00154] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK1 and/or IRAK4 inhibitor ; thereby forming a compound of formula **I-vvv-1**



I-vvv-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:


Q is CH, C—CN, orN;

X is $C-L^2(R^4)_p-R^x$ and Y is N; or

X is N and Y is C—Rx;

Ring A is a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R^1 and $R^{1'}$ is independently —R^2, halogen, —CN, —NO?, —OR, —SR, —$N(R)_2$, —$S(0)_2R$, —$S(0)_2N(R)_2$, —S(0)R, —C(0)R, —C(0)0R, —$C(0)N(R)_2$, —C(0)N(R)0R, —N(R)C(0)0R, —$N(R)C(0)N(R)_2$, Cy, or —N(R)S(0)?R; or R^1 is selected from one of the following formulas:



or two R^1 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each Cy is an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-10 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R is independently hydrogen, or an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or:

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, or sulfur;

each R^2 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R^4 is independently halogen, —CN, —$N0_2$, —OR, —SR, —$N(R)_2$, —$S(0)_2R$, —$S(0)_2N(R)_2$, —S(0)R, —C(0)R, —C(0)0R, —$C(0)N(R)_2$, —N(R)C(0)R, —

N(R)C(0)N(R) $_2$, __ C(0)N(R)0R, —N(R)C(0)0R, —N(R)S(0) $_2$N(R)$_2$, —N(R)S(0) $_2$R, or an optionally substituted group selected from Ci$_{-6}$ aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

R^x is hydrogen, —R^2, —CN, —N0 $_2$, halogen, —C(0)N(R) $_2$, —C(0)0R, —C(0)R, —N(R)$_2$, —NH[Ar], —OR, or —S(0) $_2$N(R)$_2$;

R^z is hydrogen, —R^2, —CN, —N0 $_2$, halogen, —C(0)N(R) ¾ __ C(0)0R, —C(0)R, —N(R)$_2$, —NH[Ar], —OR, or —S(0) $_2$N(R)$_2$;

[Ar] is a phenyl or heteroaromatic ring substituted by m instances of $R^{1'}$;

L^1 is a covalent bond or a Ci$_{-6}$ bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(0) —, —C(0)N(R) —, —N(R)S(0) $_2$— , —S(0) $_2$N(R)—, —O—, —C(O)—, —OC(O)—, —C(0)0— , —S—, —S(O)— or —S(0) $_2$— ;

L^2 is a covalent bond or a Ci$_{-6}$ bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(0) —, —C(0)N(R) —, —N(R)S(0) $_2$— , —S(0) $_2$N(R)—, —O—, —C(O)—, —OC(O)—, —C(0)0— , —S—, —S(O)— or —S(0) $_2$— ;


m is 0-4;

n is 0-4; and


p is 0-2;

as defined and described in WO 2015/048281 and US 2015/0094305, the entirety of each of which is herein incorporated by reference.

[00155] In some embodiments, the present invention provides a compound of Formula I,



wherein IRAK is an IRAK4 inhibitor ; thereby forming a compound of formula I-vvv'-l:



I-vvv'-l

or a pharmaceutically acceptable salt thereof, wherein


L and LBM are as defined above and described in embodiments herein;


each A, B, C, D, E, F, G, H, X^1, X^2, and X^3 are independently a carbon atom, a nitrogen atom, an oxygen atom, or a sulfur atom; and

each R^1, R^2, R^3, and R^4 are independently hydrogen or a substituted group selected from C_{1-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:



















R^1 and R^2 and R^3 and R^4 are each optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, independently selected from nitrogen, oxygen, and sulfur.


[00156] Such IRAK4 inhibitors are well known to one of ordinary skill in the art and include those described in Scott et al., *J Med. Chem.,* 2017, 60(24): 10071-10091 and Degorce et al., *Bioorg. Med. Chem.,* 2018, 26(4): 913-924.

[00157] In certain embodiments, the present invention provides a compound of Formula **I,** wherein IRAK is an IRAK4 inhibitor 



















, 

,



,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

;

,

,

thereby forming a compound of formula I-vvv'-2, I-vvv'-3, I-vvv'-4, I-vvv'-5, I-vvv'-6, I-vvv'-7, 1-vvv'-8, I-vvv'-9, I-vvv'-10, I-vvv'-11, 1-vvv'-12, I-vvv'-13, I-vvv'-14, I-vvv'-15, I-vvv'-16, I-vvv'-17, 1-vvv'-18, 1-vvv'-19, 1-vvv'-20, 1-vvv'-21, 1-vvv'-22, 1-vvv'-23, 1-vvv'-24, 1-vvv'-25, 1-vvv'-


26,1-wv'-27, 1-vvv'-28, 1-vvv'-29, I-vvv'-30, 1-vvv'-31, 1-vvv'-32, 1-vvv'-33, 1-vvv'-34, 1-vvv'-**35**,I-vvv'-36, I-vvv'-37, I-vvv'-38, and I-vvv'-39:




I-vvv'-2




I-vvv'-3




I-vvv'-4




I-vvv'-5




I-vvv'-6




I-vvv'-7




I-vvv'-8




I-vvv'-9




I-vvv'-lO




I-vvv'-11




I-vvv'-12




I-vvv'-13




I-vvv'-14




I-vvv'-15




I-vvv'-16




I-vvv'-17




I-vvv'-18




I-vvv'-19




I-vvv'-20




I-vvv'-21




I-vvv'-22




I-vvv'-23




I-vvv'-24




I-vvv'-25




I-vvv'-26




I-vvv'-27




I-vvv'-28




I-vvv'-29




I-vvv'-30




I-vvv'-31




I-vvv'-32




I-vvv'-33




I-vvv'-34




I-vvv'-35




I-vvv'-36



I-vvv'-37



I-vvv'-38



I-vvv'-39

or a pharmaceutically acceptable salt thereof, wherein

L and LBM are as defined above and described in embodiments herein;


each X^1, X^2, and X^3 are independently a carbon atom, a nitrogen atom, an oxygen atom, or a sulfur atom; and

each R^1, R^2, R^3, and R^4 are independently hydrogen or a substituted group selected from C_{1-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2


heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

R^1 and R^2 or R^3 and R^4 are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, independently selected from nitrogen, oxygen, and sulfur.

[00158] In certain embodiments, the present invention provides a compound of Formula **I,**



wherein IRAK is an IRAK1 and/or IRAK4 inhibitor ; thereby forming a compound of formula **I-www-1**



I-www-1


or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

Q is =N— or =CH—;

Ring A is a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R^1 is independently —R^2, halogen, —CN, —NO_2, —OR, —SR, —NR_2, —$S(O)_2R$, —$S(O)_2NR_2$, —S(O)R, —C(O)R, —C(O)OR, —$C(O)NR_2$, —C(O)N(R)OR, —

N(R)C(0)0R, —N(R)C(0)NR $_2$, Cy, or —N(R)S(0)?R; or R^{1}is selected from one of the following formulas:



or two R^{1}groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each Cy is independently an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-10 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R is independently hydrogen, or an optionally substituted group selected from Ci$_{-6}$ aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or:

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, or sulfur;

each R^{2}is independently an optionally substituted group selected from Ci$_{-6}$ aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each of R^{5}and R^{6}is independently hydrogen or -L^2(R^4)$_p$_ R^x; or

R^{5}and R^{6}are taken together with their intervening atoms to form a 4-7 membered partially unsaturated, or aromatic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R^{4}is independently halogen, —CN, —N0 $_2$, —OR, —SR, —NR$_2$, —S(0) $_2$R, —S(0) $_2$NR$_2$, —S(0)R, —C(0)R, —C(0)0R, —C(0)NR $_2$, —N(R)C(0)R, —N(R)C(0)NR $_2$, —C(0)N(R)0R, —N(R)C(0)0R, —N(R)S(0) $_2$NR$_2$, —N(R)S(0) $_2$R, or an optionally

substituted group selected from C_{1-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

R^x is hydrogen, —R^2, —CN, —NO_2, halogen, —$C(O)NR_2$, —C(O)OR, —C(O)R, —NR_2, —NH[Ar], —OR, or —$S(O)_2NR_2$;

R^z is hydrogen, —R^2, —CN, —NO_2, halogen, —$C(O)NR_2$, —C(O)OR, —C(O)R, —NR_2, —NH[Ar], —OR, or —$S(O)_2NR_2$;

[Ar] is an optionally substituted phenyl or an optionally substituted 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

L^1 is a covalent bond or a C_{1-6} bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(O)—, —C(O)N(R)—, —N(R)S(O)$_2$—, —$S(O)_2$N(R)—, —O—, —C(O)—, —OC(O)—, —C(O)O— , —S—, —S(O)— or —$S(O)_2$— ;

L^2 is a covalent bond or a C_{1-6} bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(O)—, —C(O)N(R)—, —N(R)S(O)$_2$—, —$S(O)_2$N(R)—, —O—, —C(O)—, —OC(O)—, —C(O)O— , —S—, —S(O)— or —$S(O)_2$— ;


m is 0-4;

n is 0-4; and


p is 0-2;

as defined and described in WO 2015/164374 and US 2015/0329498, the entirety of each of which is herein incorporated by reference.

[00159] In certain embodiments, the present invention provides a compound of Formula I,



wherein IRAK is an IRAK4 inhibitor ; thereby forming a compound of formula **I-xxx-1**



I-xxx-1

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

X and X' are each independently CR^8, N or $—N^+—CT$; Y is independently N, $—N^+—O^-$ or $CR^{8'}$; provided that at least one of X, X' or Y is neither N nor $—N^+—CT$ and that no more than one of X, X' or Y is $—N^+—CT$;

R^1 is Ci-C_6alkyl; C2-C_6alkenyl; C2-C_6alkynyl; $—(CR^{3a}R^{3b})_m$-(3- to 7-membered cycloalkyl); $—(CR^{3a}R^{3b})_m$-(3- to 7-membered heterocycloalkyl) having one to three heteroatoms; $—(CR^{3a}R^{3b})_m$-(5- to lO-membered heteroaryl), having one to three heteroatoms; or $—(CR^{3a}R^{3b})_m—$ C_6-Ci2aryl; wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl or aryl is optionally substituted with one to five halogen, deuterium, $—OR^5$, $—SR^5$, $—NR^{lla}R^{llb}$, cyano, Ci-C_6alkyl, C3-C_6cycloalkyl or —Ci-C_6alkoxy;

R^2 is —$(CR^{3a}R^{3b})_m$-(3- to lO-membered cycloalkyl); —$(CR^{3a}R^{3b})_m$-(3- to lO-membered heterocycloalkyl) having one to three heteroatoms; —$(CR^{3a}R^{3b})_m$-(5- to 10 membered heteroaryl) having one to three heteroatoms; or —$(CR^{3a}R^{3b})_m$—C_6-Ci2aryl; wherein said cycloalkyl, heterocycloalkyl, heteroaryl or aryl is optionally substituted with one to five R^4; and wherein, if the heteroatom on said heterocycloalkyl and heteroaryl is N, said N is optionally substituted with $R^{4'}$; or R^2 is Ci-C_6alkyl, wherein said alkyl is optionally substituted with NH_2, OH or cyano;

R^{3a} and R^{3b} for each occurrence are independently hydrogen or Ci-C_3alkyl;

R^4 for each occurrence is independently a bond, deuterium halogen, cyano, Ci-C_6alkyl, C_2-Cealkenyl, oxo, —OR^5, —SR^5, —$S(0)R^9$, —$S(0)_2R^9$, —$NR^{lla}R^{llb}$, —$C(0)R^{10}$, —$(CR^{3a}R^{3b})_n$-(3- to 7-membered cycloalkyl), —$(CR^{3a}R^{3b})_n$-(4- to lO-membered heterocycloalkyl), having one to three heteroatoms, —$(CR^{3a}R^{3b})_n$-(5- to 10 membered heteroaryl), having one to three heteroatoms, or —$(CR^{3a}R^{3b})_n$— C_6-Ci_2aryl wherein said alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or aryl is each optionally and independently substituted with one to five deuterium, halogen, OR^5, —SR^5, —$NR^{lla}R^{llb}$, cyano, Ci-C_6alkyl, C3-C_6cycloalkyl or —Ci-C_6alkoxy; or two R^4 taken together with the respective carbons to which each are bonded form a 3- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein said cycloalkyl or heterocycloalkyl is optionally substituted with one to three halogen, deuterium, —OR^5, —SR^5, —$NR^{lla}R^{llb}$, cyano or Ci-C_6alkyl or Ci-C_6alkoxy, wherein the alkyl or alkoxy is optionally substituted with halogen, deuterium, —OR^5, —SR^5, —$NR^{lla}R^{llb}$, or cyano; and wherein, if a heteroatom on said heterocycloalkyl is N, said N is optionally substituted with $R^{4'}$;

$R^{4'}$ is independently Ci-C_6alkyl, C_2-C_6alkenyl, —$C(0)R^{10}$, —$S(0)_2R^9$, —$(CR^{3a}R^{3b})_n$-(3- to 7-membered cycloalkyl), —$(CR^{3a}R^{3b})_n$-(4- to lO-membered heterocycloalkyl) or $C(0)(CH_2)_tCN$; wherein said alkyl, alkenyl, cycloalkyl, or heterocycloalkyl is each optionally and independently substituted with one to five deuterium, halogen, OH, cyano or Ci-C_6alkoxy; or R^4 and $R^{4'}$ taken together with the respective atoms to which each are bonded form a 3- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein said cycloalkyl or heterocycloalkyl is optionally substituted with one to three halogen, deuterium, —OR^5, —SR^5, —$NR^{lla}R^{llb}$, cyano, Ci-C_6alkyl or Ci-C_6alkoxy,

wherein the alkyl or alkoxy is optionally substituted with halogen, deuterium, —OR^5, —SR^5, —$NR^{lla}R^{11b}$, or cyano;

R^5 is independently hydrogen or Ci-C_6alkyl, wherein said alkyl is optionally substituted with halogen, deuterium, Ci-C_6alkoxy, Ci-C_6alkylthiolyl, —$NR^{lla}R^{11b}$, cyano, Ci-C_6alkyl or C3-C_6cycloalkyl; or two R^5 taken together with the oxygen atoms to which they are bonded form a 5- or 6-membered heterocycloalkyl;

R^6 is —C(0)NHR^7, C0 $_2R^7$ or cyano;

R^7 is hydrogen or Ci-C_6alkyl;

each R^8 is independently hydrogen, halogen, cyano, —OR^5, —SR^5, —$NR^{lla}R^{llb}$, C_6alkyl, C_3-C_6cycloalkyl, 3- to lO-membered heterocycloalkyl or 5- to 6-membered heteroaryl or aryl, wherein said alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or aryl is optionally substituted with one to three halogen, —$NR^{lla}R^{llb}$, OR^5, —SR^5, cyano, C_1-C_3 alkyl, —$C(O)R^{10}$ or oxo;

$R^{8'}$ is hydrogen, deuterium, halogen, cyano, —OR^5, —SR^5 or $NR^{lla}R^{11b}$;

R^9 is —$(CR^{3a}R^{3b})_p$— (Ci-Csalkyl), —$(CR^{3a}R^{3b})_p$-(4- to 6-membered cycloalkyl), —$(CR^{3a}R^{3b})_p$-(4- to 6-membered heterocycloalkyl) or —$(CR^{3a}R^{3b})_p$— (C_5-C<;aryl), wherein said alkyl, cycloalkyl, heterocycloalkyl or aryl are each optionally substituted with fluoro or Ci-C_3alkyl;

R^{10} is Ci-C_6alkyl, wherein said alkyl is optionally substituted with deuterium, halogen, OH, Ci-C_6alkoxy or cyano;

R^{lla} and R^{11b} are each independently hydrogen or Ci-C_6alkyl, wherein said alkyl is optionally substituted with deuterium, Ci-C_6alkoxy or cyano; and if C2-C_6alkyl, said alkyl is optionally substituted with deuterium, Ci-C_6alkoxy, cyano, halogen or OH;

m is independently 0, 1, 2 or 3;


n is independently 0, 1, 2 or 3;

p is independently 0 or 1; and


t is 1, 2 or 3;

as defined and described in WO 2015/150995 and US 2015/0284405, the entirety of each of which is herein incorporated by reference.


[00160] In certain embodiments, the present invention provides a compound of Formula **I,**




wherein IRAK is an IRAK4 inhibitor or



; thereby forming a compound of formula **I-yyy-1** or **I-yyy-2**:



i-yyy-i



i-yyy-2

or a pharmaceutically acceptable salt thereof, wherein L and LBM are as defined above and described in embodiments herein, and wherein:

X is N or CH

m is 1 or 2;

Ar is optionally substituted aryl or optionally substituted heteroaryl;

R^1 is hydrogen, C_{i-6}alkyl, C_{i-6}alkoxy, hydroxyl, hydroxy-C_{i-6}alkyl, C_{i-6}alkyl-amino, amino-C_{i-6}alkyl, amino-Ci^alkyl-amino, hydroxy-Ci^alkylamino, C3-6cycloalkylamino, amino-C_{3-6}cycloalkylamino, amino-C3-6heterocycloalkylamino, aminocarbonyl, halo, hydroxy-C_{i-6}alkyl, or hydroxy-C_{i-6}alkoxy; and


R^2 is hydrogen or C_{i-6}alkyl;

as defined and described in WO 2012/007375 and US 2012/0015962, the entirety of each of which is herein incorporated by reference.

[00161] As defined above and described herein, IRAK is an IRAK binding moiety capable of binding to one or more of IRAK-1, -2, -3, or -4.


[00162] In some embodiments, IRAK is an IRAK binding moiety capable of binding to IRAK-1. In some embodiments, IRAK is an IRAK binding moiety capable of binding to IRAK-2. In some embodiments, IRAK is an IRAK binding moiety capable of binding to IRAK-3. In some embodiments, IRAK is an IRAK binding moiety capable of binding to IRAK-4.


[00163] In some embodiments, IRAK is selected from a moiety recited in Aurigene Discovery Tech. Ltd. Presentation: *Novel IRAK-4 Inhibitors exhibit highly potent anti-proliferative activity inDLBCL cell lines with activation MYD88 L264P mutation,* such as, for example: AU-5850, AU-


2807, AU-6686, and AU-5792, wherein 


is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.


[00164] In some embodiments, IRAK is selected from a moiety recited in Scott, J.S. *et al. Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88 Diffuse Large B-cell Lymphoma.* J. Med. Chem. Manuscript, Nov, 29 2017, l0.l02l/acs.jmedchem.7b0l290 such as, for example:



Cmp 1



Cmp 2



Cmp 3



Cmp 4



Cmp 5


Cmp 6



Cmp 7


Cmp 8



Cmp 9




Cmp 10




Cmp 11




Cmp 12




Cmp 13




Cmp 14




Cmp 15




Cmp 16




Cmp 17




Cmp 18a/b




Cmp 19a/b




Cmp 20




Cmp 21




Cmp 22




Cmp 23




Cmp 24




Cmp 25




Cmp 26




Cmp 27




Cmp 28




Cmp 29




Cmp 30




Cmp 31




Cmp 32




Cmp 33




Cmp 34






, and


Cmp 35 Cmp 36

wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.


[00165] In some embodiments, IRAK is selected from a moiety recited in Powers, J.P. *et al.*, *Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4,* Bioorg. Med Chem Lett. (2006) 16(11): 2842-45, such as, for example:




Compound 1




Compound 2




Compound 3




Compound 4




Compound 5




Compound 6




Compound 7




Compound 8




Compound 9




Compound 10




Compound 11





Compound 12



Compound 13










Compound 14

Compound 15

Compound 16









Compound 17

Compound 18


Compound 19




Compound 20




Compound 21




Compound 22




Compound 23




Compound 24




Compound 25




Compound 26




Compound 27




Compound 28




Compound 29




Compound 30




Compound 31




Compound 32




Compound 33




Compound 34




Compound 35




Compound 36




Compound 37




Compound 38




Compound 39




Compound 40




Compound 41




Compound 42




Compound 43




Compound 44



Compound 45




Compound 46




Compound 47


, and




Compound 48

wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.


[00166] In some embodiments, IRAK is selected from a moiety recited in Wang, *et al*., *Crystal Structure of IRAK-4 Kinase in Complex with Inhibitors: Serine/Threonine Kinase with Tyrosine as a Gatekeeper*, Structure, 2006, 14(12): 1835-44, such as, for example:




Compound 1

wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.


[00167] In some embodiments, IRAK is selected from a moiety recited in Wang, Z. *et al*., *Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associated kinase 4*, Bioorg. Med. Chem Lett., 2015, 25(23): 5546-50, such as, for example:




Compound 1




Compound 2




Compound 3




Compound 4




Compound 5




Compound 6







Compound 7




Compound 8




Compound 9




Compound 10



Compound 11




Compound 12




Compound 13


Compound 14




Compound 15




Compound 16



Compound 17




Compound 18




, and


Compound 19

wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.


[00168] In some embodiments, IRAK is selected from a moiety recited in Chaudhary, D. *etal*., *Recent Advances in the Discovery of Small Molecule Inhibitors of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) as a Therapeutic Targetfor Inflammation and Oncology Disorders*, J. Med Chem., 2015, 58(1): 96-110, such as, for example:




1




2




3




4




5




6




7




8







9




10




11




12




13




14




15




16



17




18




19


20 (AS2444697)




21




22




23




24




25




26




27




Prodrug







28




29



30




31




32


33




34




35






36





37



38


39






40


41






42


43




44




45




46




47




48




49




50




51



52




53




54


, and




55


wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.

[00169] In some embodiments, IRAK is selected from a moiety recited in Zhang, D. *et* ***al.,*** *Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma,* Clin. Can. Res., 2017, 23(7): 1748-59, such as, for example:




wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.


[00170] In some embodiments, IRAK is selected from a moiety recited in Cushing, L. *et al.*, *IRAK4 kinase controls Toll-like receptor induced inflammation through the transcription factor IRF5 in primary human monocytes*, J. Bio. Chem., 2017, 292(45): 18689-698, such as, for example:




PF-06426779

wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.

[00171] In some embodiments, IRAK is selected from a moiety recited in Li, N. *etal.*, *Targeting interleukin-1 receptor-associated kinase for human hepatocellular carcinoma*, J. Ex. Clin. Can. Res., 2016, 35(1): 140-50, such as, for example:




1-5409 (Sigma)


wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.

[00172] In some embodiments, IRAK is selected from a moiety recited in Dudhgaonkar, S. *et al., Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing Activity*, J. of Immun., 2017, 198(3): 1308-19, such as, for example:


BMS-986126

wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.


[00173] In some embodiments, IRAK is selected from a moiety recited in Wang, Z. *et al.*, *IRAK-4 Inhibitors for Inflammation*, Cur. Top. Med. Chem., 2009, 9(8): 724-37, such as, for example:




1




2




3




4




5




6




7




8




9




10




11




12




13




14




15




16




17




18




19



20




21




, and

22




wherein is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.


[00174] In some embodiments, IRAK is selected from a moiety recited in Kelly, P.N. *et al.*, *Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy*, J. Exp. Med., 2015, 212(13): 2189-201, such as, for example:



ND-1659




ND-2110




, and


ND-2158

wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.


[00175] In some embodiments, IRAK is selected from a moiety recited in Dunne, A. *et al.*, *IRAKI and IRAK4 Promote Phosphorylation, Ubiquitation, and Degradation of MyD88 Adaptor-like* (*Bruton's tyrosine kinase*), J. Bio. Chem., 2010, 285(24): 18276-82, such as, for example:




IRAK1/4 inhibitor

wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.


[00176] In some embodiments, IRAK is selected from a moiety recited in Kiippers, R., *IRAK inhibition to shut down TLR signaling in autoimmunity andMyD88-dependent lymphomas*, J. Exp. Med, 2015, 212(13): 2184, such as, for example:




and




ND-2110 ND-2158

wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.


[00177] In some embodiments, IRAK is selected from a moiety recited in Chiang, E.Y. *et al, Immune Complex-Mediated Cell Activation from Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients Elaborate Different Requirements for IRAKI/4 Kinase Activity across human Cell Types,* J. Immunol., 2011, 186(2): 1279-88, such as, for example:




IRAK1/4 inhibitor

wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.


[00178] In some embodiments, IRAK is selected from a moiety recited in Lee, K.L. *et al., Discovery of Clinical Candidate 1-{[2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoine-6-carboxamide (PF-06650833'), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 9IRAK4), by Fragment-Based Drug Design,* J. Med. Chem., 2017, 60(13): 5521-42, such as, for example:




Amgen 1




Amgen 2




UCB 3




Pfizer 4




Merck 5




Merck 6




Merck 7




Nimbus 8




10




12




14




16




20




21




22




23




24




26




30




31




32




33




36




37




38




39




40



41




44




45

and




50

,


wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.


[00179] In some embodiments, IRAK is selected from a moiety recited in Kondo, M. *et al.*, *Renoprotective effects of novel interleukin-1 receptor-associated kinase 4 inhibitor AS2444697*


through anti-inflammatory action in 5/6 nephrectomized rats, Naunyn-Schmiedeb erg's Arch Pharmacol., 2014, 387(10): 909-19, such as, for example:




AS2444697

wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.


[00180] In some embodiments, IRAK is selected from a moiety recited in Song, K.W. *et al.*, *The Kinase activities of interleukin-1 receptor associated kinase (IRAK)-1 and 4 are redundant in the control of inflammatory cytokine expression in human cells*, Mol. Immunol., 2009, 46(7): 1458-66, such as, for example: RO0884, R01679, or R06245, wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.

[00181] In some embodiments, IRAK is selected from a moiety recited in Vollmer, S. *etal*., *The mechanism of activation of IRAKI and IRAK4 by interleukin-1 and Toll-like receptor agonists*, Biochem. J., 2017, 474(12): 2027-38, such as, for example: IRAK-IN-1A, JNK-IN-7, and JNK-IN-8, wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.


[00182] In some embodiments, an IRAK ligand is selected from moiety recited in McElroy, W.T., *et al., Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation*, Med. Chem. Lett., 2015, 6(6): 677-82, such as, for example:




1




2




6




7




8




9




10




11




12




13




14




15




16




17




18




19




20




21




22




23




24




25




26




27




28




29



30




31




, and


32




33

wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.


[00183] In some embodiments, an IRAK ligand is selected from moiety recited in Seganish, W.M., *et al., Discovery and Structure Enabled Synthesis of 2,6-diaminopyrimidine-4-one IRAK4 Inhibitors*, Med. Chem. Lett., 2015, 6(8): 942-47, such as, for example:




1




2




3




4




5




6




7




8




9




10




11




12




13




14




15




16




17




18




19




20




21




22




23




24




25




26




27




28



29




30




, and


31

wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.


[00184] In some embodiments, an IRAK ligand is selected from moiety recited in Seganish, W.M., *et al., Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4,* Bioorg. Med. Chem. Lett., 2015, 25(16): 3203-207, such as, for example:




1




2




3




4




5




6




7




8




9




10




11




12




13




14




15




16




17




18




19




20




21




22




23




24




25




26




27




28




29



30




31




32


, and




33

wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.


[00185] In some embodiments, an




[00186] In some embodiments, IRAK is . In some IRAK ligand is selected from moiety recited in McElroy, W.T., *et al., Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine Inhibitors of interleukin-1 receptor-associated kinase 4*, Bioorg. Med. Chem. Lett., 2015, 25(9): 1836-41, such as, for example:




1




2




3




4




5




6




7




8




9




10




11




12




13




14




15




16




17




18




19




20




21




22




23




24




25




26




27




28




29




30




31




32




33




34




35



36




37




, and


38

wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.


[00187] In some embodiments, an IRAK ligand is selected from moiety recited in Turney, L.N., *et al., Identification and optimization of indolo[2,3-c]quinoline inhibitors ofIRAK4* , Bioorg. Med. Chem. Lett., 2014, 24(9): 2066-72, such as, for example:




3




4




5




6




7




8




9




10




11





12




13









14 15 16




17




18




19




22




23




24




25




26






27




29


28




29 (sic)



30 (sic)





31 (sic)




, and


32 (sic)

wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.


[00188] In some embodiments, IRAK is  . In some




embodiments, IRAK is . In some embodiments, IRAK is




. In some embodiments, IRAK is




. In some embodiments, IRAK is




. In some embodiments, IRAK is




. In some embodiments, IRAK is




. In some




embodiments, IRAK is . In some embodiments, IRAK is




.




[00189] In some embodiments, IRAK is . In some embodiments,









IRAK is . In some embodiments, IRAK is









. In some embodiments, IRAK is




. In


some embodiments, IRAK is  . In some embodiments, IRAK is  . In some embodiments, IRAK is  . In some embodiments, IRAK is  . In some embodiments, IRAK is  . In some embodiments, IRAK is  .

[00190] In some embodiments, IRAK is  . In


some embodiments, IRAK is  . In some embodiments, IRAK is  . In some embodiments, IRAK is  . In some embodiments, IRAK is  . In some embodiments, IRAK is  . In some embodiments, IRAK is




. In some embodiments, IRAK is



. In some embodiments, IRAK is




. In some embodiments, IRAK is




.


[00191] In some embodiments, IRAK is




. In some embodiments, IRAK is





. In some embodiments, IRAK is





. In some embodiments, IRAK is



. In some embodiments, IRAK is



. In some embodiments, IRAK is



. In some embodiments, IRAK is


.


[00192] In some embodiments, IRAK is 
. In some embodiments, IRAK is


. In some embodiments, IRAK is



. In some embodiments, IRAK is




. In some embodiments, IRAK is




. In some embodiments, IRAK is




. In some embodiments, IRAK is




. In some embodiments, IRAK is




. In some embodiments, IRAK is




.




[00193] In some embodiments, IRAK is . In some embodiments, IRAK is




. In some embodiments, IRAK is




. In some embodiments, IRAK is




. In some embodiments, IRAK is










. In some embodiments, IRAK is









. In some embodiments, IRAK is










. In some embodiments, IRAK is  . In some embodiments, IRAK is  . In some embodiments, IRAK is  . In some embodiments, IRAK is  .


[00194] In some embodiments, IRAK is  . In some embodiments, IRAK is  . In some embodiments, IRAK is  . In


some embodiments, IRAK is  . In some embodiments, IRAK is  . In some embodiments, IRAK is  . In some embodiments, IRAK is  . In some embodiments, IRAK is  .


[00195] In some embodiments, IRAK is  . In some



embodiments, IRAK is  . In some embodiments, IRAK is  . In some embodiments, IRAK is  . In some embodiments, IRAK is  . In some embodiments, IRAK is  . In some embodiments, IRAK is  . In some embodiments, IRAK is


. In some embodiments, IRAK is


. In some embodiments, IRAK is


. In some embodiments, IRAK is


. In some embodiments, IRAK is








. In some embodiments, IRAK is

.

[00196] In some embodiments, IRAK is selected from those depicted in **Table 1,** below.


















[00197] As defined above and described herein, L is a bivalent moiety that connects IRAK to LBM.

[00198] In some embodiments, L is a bivalent moiety that connects IRAK to LBM.




[00199] In some embodiments, L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-so hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -NR-, -S-, -OC(O)-, -C(0)0-, -C(O)-, -S(O)-, -S(0) $_2$-, -NRS(0) $_2$-, -$S(O)_2NR$-, -NRC(O)-, -C(O)NR-, -OC(O)NR-, –NRC(O)O-,  ,  ,  ,  , or  , wherein: each –Cy– is independently an optionally substituted bivalent ring selected from phenyl enyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroaryl enyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaryl enyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.











[00200] In some embodiments, each -Cy- is independently an optionally substituted bivalent phenylenyl. In some embodiments, each -Cy- is independently an optionally substituted 8-10 membered bicyclic arylenyl. In some embodiments, each -Cy- is independently an optionally substituted 4-7 membered saturated or partially unsaturated carbocyclylenyl. In some embodiments, each -Cy- is independently an optionally substituted 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl. In some embodiments, each -Cy- is independently an optionally substituted 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl. In some embodiments, each -Cy- is independently an optionally substituted 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each -Cy- is











independently an optionally substituted 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each -Cy- is independently an optionally substituted 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each -Cy- is independently an optionally substituted 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each -Cy- is independently an optionally substituted 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.


[00201] In some embodiments, -Cy- is  . In some embodiments, -Cy- is  . In some embodiments, -Cy- is  . In some embodiments, -Cy- is  . In some embodiments, -Cy- is  . In some embodiments, –Cy– is  . In some embodiments, –Cy– is  . In some embodiments, –Cy– is  . In some embodiments, –Cy– is  . In some embodiments, –Cy– is  . In some embodiments, -Cy- is  . In some embodiments, -Cy- is  . In some embodiments, -Cy- is  . In some embodiments, -Cy- is  . In some embodiments, -Cy- is  . In some embodiments, -Cy- is . In some embodiments, -Cy- is . In some embodiments, -Cy- is  . In some embodiments, -Cy- is  . In some embodiments, -Cy- is .


embodiments, -Cy- is  . In some embodiments, -Cy- is  .


In some embodiments, –Cy– is  . In some embodiments, –Cy– is  . In some embodiments, –Cy– is  .


[00202] In some embodiments, L is  . In some embodiments, L is  . In some embodimentsn, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  .


[00203] In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  .


[00204] In some embodiments, L is  . In some embodiments, L is



. In some embodiments, L is


. In some embodiments, L is



. In some embodiments, L is



. In some embodiments, L is



. In some embodiments, L is


.


In some embodiments, L is



. In some embodiments, L is



. In some embodiments, L is



.


[00205] In some embodiments, L is



. In some embodiments, L is



. In some embodiments, L is



. In some embodiments, L is



. In some embodiments, L is



. In some embodiments, L is




. In some embodiments, L is



. In some embodiments, L is



. In some embodiments, L is



. In some embodiments, L is



.


[00206] In some embodiments, L is 
. In some embodiments, L is 
. In some embodiments, L is



. In some embodiments, L is



. In some embodiments, L is



. In some embodiments, L is




. In some embodiments, L is



. In some embodiments, L is



. In some embodiments, L is



. In some embodiments, L is



.






[00207] In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is













. In some embodiments, L is
















. In some embodiments, L is



. In some embodiments, L is


. In some embodiments, L is


 . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  .










[**00208**] In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  .


[00209] In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is














.





[00210] In some embodiments, L is . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  .


[00211] In some embodiments, L is  . In


some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  .


[00212] In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is



. In some embodiments, L is



. In some embodiments, L is



. In some embodiments, L is





. In some embodiments, L is









. In some embodiments, L is







. In some embodiments, L is









. In some embodiments, L is









.


[00213] In some embodiments, L is 
. In some embodiments, L is 
. In some embodiments, L is 
.


embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  .


[00214] In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is




 . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  .










[00215] In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is
















. In some embodiments, L is





. In some embodiments, L is







.






[00216] In some embodiments, Lis 
. In some embodiments, L is 
. In some embodiments, L is 
.


[00217] In some embodiments, L is 
. In some embodiments, L is 
. In some embodiments, L is 
. In some embodiments, L is 
. In some embodiments, L is 
. In some embodiment, L is 
. in some embodiment, L is 
. In some embodiment, L is 
. In some embodiments, L is 
.

In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  .

















[00218] In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In

some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  .





















[00219] In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is






































.














[00220] In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is









. In some embodiments, L is . In some embodiments, L is . In some embodiments, L is . In some embodiments, L is



 . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is . In some embodiments, L is  . In some embodiments, L is . In some embodiments, L is . In some embodiments, L is . In some embodiments, L is . In some embodiments, L is . In some embodiments, L is  . In some


embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is . In some embodiments, L is . In some embodiments, L is . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  .

 . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  .


some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is


. In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  .


[00222] In some embodiments, L is  . In some embodiments, L is  .




. In some embodiments, L is












. In some embodiments, L is










. In some embodiments, L is














.









[00223] In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  .








. In some embodiments, L is 
. In some embodiments, L is 
.



















[00224] In some embodiments, L is 
. In some embodiments, L is 
. In some embodiments, L is 
. In some embodiments, L is 
.





[00225] In some embodiments, L is 
. In some embodiments, L is 
. In some embodiments, L is 
. In some embodiments, L is 
. In some embodiments, L is 
. In some embodiments, L is 
. In some embodiments, L is 
. In some embodiments, L is 
. In some embodiments, L is 
. In some embodiments, L is














. In some embodiments, L is

.




















[00226] In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is 
.







[00227] In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  .











 . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, Lis  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is . In some embodiments, L is . In some embodiments, L is  . In some embodiments, L is




 . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In




[**00228**] In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is


 . In some embodiment, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In


some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  .

[00229] In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is .

some embodiments, L is  . In some embodiments, L is  . In some embodiments, L is  . In

[00232] In some embodiments, LBM is LBM is an E3 ubiquitin ligase (cereblon) binding moiety  , a DCAF15 E3 ubiquitin ligase binding moiety  , or a VHL E3 ubiquitin ligase binding moiety  ,

wherein each of X^1, X^2, and X^3 is independently a bivalent moiety selected from a covalent bond, $-CH_2-$, $-C(O)-$, $-C(S)-$, or  ;

each of X^4 and X^5 is independently a bivalent moiety selected from -CEE-, -C(O)-, -C(S)-, or  ;

R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, -S(0) $_2$R, -NR $_2$, or an optionally substituted Ci $_{-4}$ aliphatic;

each of R^2, R^3, and R^4 is independently hydrogen, - R^6, halogen, -CN, -N0 $_2$, -OR, -SR, $-NR_2$, -S(0) $_2$R, -S(0) $_2$NR $_2$, -S(0)R, -C(0)R, -C(0)0R, -C(0)NR $_2$, -C(0)N(R)0R, -0C(0)R, -0C(0)NR $_2$, -N(R)C(0)0R, -N(R)C(0)R, -N(R)C(0)NR $_2$, or -N(R)S(0) $_2$R;

R^5 is hydrogen or Ci $_{-6}$ aliphatic;

each R^6 is independently an optionally substituted group selected from Ci $_{-6}$ aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

Ring A is a fused ring selected from 6-membered aryl containing 0-2 nitrogen atoms, 5 to 7-membered partially saturated carbocyclyl, 5 to 7-membered partially saturated heterocyclyl with 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;

Ring B is selected from 6-membered aryl containing 0-2 nitrogen atoms or a 8-10 membered bicyclic heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

Ring C is a selected from 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;

m is 0, 1, 2, 3 or 4;


each of n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;





p is 0, 1, 2, 3 or 4;




q is 0, 1, 2, 3 or 4; and


each R is independently hydrogen, or an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.


[00233] In some embodiments, LBM is  . In some embodiments, LBM is


. In some embodiments, LBM is 
. In some embodiments, LBM is 
. In some embodiments, LBM is 
.


[00234] In some embodiments, LBM is 
. In some embodiments, LBM is 
. In some embodiments, LBM is 
.




[00235] In some embodiments, LBM is . In some embodiments, LBM is




. In some embodiments, LBM is




.




[00236] In some embodiments, LBM is . In some embodiments, LBM is




. In some embodiments, LBM is




. In some embodiments, LBM is




. In some embodiments, LBM is









. In some embodiments, LBM is






. In some embodiments, LBM is





.


[00237] In some embodiments, LBM is  . In some embodiments, LBM is  . In some embodiments, LBM is  . In some embodiments, LBM is  . In some embodiments, LBM is  . In some embodiments, LBM is  .

[00238] In some embodiments, LBM is  . In some embodiments, LBM is  . In some embodiments, LBM is




. In some embodiments, LBM is  ,




. In some embodiments, LBM is  .

[00239] In some embodiments, LBM is a E3 Ubiquitin ligase (cereblon) binding moiety recited in Varfolomeev, E. *et al, IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB activation, and TNFa-Dependent Apoptosis,* Cell, 2007, 131(4): 669-81, such as, for example:




, and


MV1




BV6


wherein  is attached to a modifiable carbon, oxygen, nitrogen or sulfur atom.

[00240] In some embodiments, LBM is selected from those depicted in **Table** 1, below.

[00241] As defined above and described herein, each of X^1, X^2, and X^3 is independently a bivalent moiety selected from a covalent bond, -CH_{2-}, -C(O)-, -C(S)-, or  .

[00242] In some embodiments, X^1 is a covalent bond, -CH_{2-}, -C(O)-, -C(S)-, or  .

[00243] In some embodiments, X^1 is selected from those depicted in **Table 1,** below.


[00244] In some embodiments, X^2 is a covalent bond, -CH_{2-}, -C(O)-, -C(S)-, or  .

[00245] In some embodiments, X^2 is selected from those depicted in **Table 1,** below.


[00246] In some embodiments, X^3 is a covalent bond, -CH_{2-}, -C(O)-, -C(S)-, or  .

[00247] In some embodiments, X^3 is selected from those depicted in **Table 1,** below.

[00248] As defined above and described herein, each of X^4 and X^5 is independently a bivalent moiety selected from –CH_2–, –C(O)–, –C(S)–, or  .

[00249] In some embodiments, X^4 is –CH_2–, –C(O)–, –C(S)–, or  .

[00250] In some embodiments, X^4 is selected from those depicted in **Table 1,** below.

[00251] In some embodiments, X^5 is –CH_2–, –C(O)–, –C(S)–, or  .

[00252] In some embodiments, X^5 is selected from those depicted in **Table 1,** below.

[00253] As defined above and described herein, R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, -$S(0)_2$R, -NR_2, or an optionally substituted Ci-$_4$ aliphatic.

[00254] In some embodiments, R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, --$S(0)_2$R, -NR_2, or an optionally substituted Ci-$_4$ aliphatic.

[00255] In some embodiments, R^1 is selected from those depicted in **Table 1,** below.

[00256] As defined above and described herein, each of R^2, R^3, and R^4 is independently

hydrogen, -R6, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(0)2R, -S(0)2NR2, -S(0)R, -C(0)R, -C(0)0R, –C(0)NR2, -C(0)N(R)0R, -0C(0)R, -0C(0)NR2, -N(R)C(0)0R, -N(R)C(0)R, -N(R)C(0)NR2, or -N(R)S(0)2R.

[00257] In some embodiments, R2 is hydrogen, -R6, halogen, -CN, -N02, -OR, -SR, -NR2, -S(0)2R, -S(0)2NR2, -S(0)R, -C(0)R, -C(0)0R, –C(0)NR2, -C(0)N(R)0R, -0C(0)R, -0C(0)NR2, -N(R)C(0)0R, -N(R)C(0)R, -N(R)C(0)NR2, or -N(R)S(0)2R.

[00258] In some embodiments, R2 is selected from those depicted in Table 1, below.

[00259] In some embodiments, R3 is hydrogen, -R6, halogen, -CN, -N02, -OR, -SR, -NR2, -S(0)2R, -S(0)2NR2, -S(0)R, -C(0)R, -C(0)OR, –C(0)NR2, -C(0)N(R)OR, -OC(0)R, -OC(0)NR2, -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0)NR2, or -N(R)S(0)2R.

[00260] In some embodiments, R3 is methyl.

[00261] In some embodiments, R3 is selected from those depicted in Table 1, below.

[00262] In some embodiments, R4 is hydrogen, -R6, halogen, -CN, -N02, -OR, -SR, -NR2, -S(0)2R, -S(0)2NR2, -S(0)R, -C(0)R, -C(0)OR, –C(0)NR2, -C(0)N(R)OR, -OC(0)R, -OC(0)NR2, -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0)NR2, or -N(R)S(0)2R.

[00263] In some embodiments, R4 is methyl.

[00264] In some embodiments, R4 is selected from those depicted in Table 1, below.

[00265] As defined above and described herein, R5 is hydrogen or Ci-6 aliphatic.

[00266] In some embodiments, R5 is /-butyl.

[00267] In some embodiments, R5 is selected from those depicted in Table 1, below.

[00268] As defined above and described herein, each R6 is independently an optionally substituted group selected from Ci-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[00269] In some embodiments, R6 is an optionally substituted Ci-6 aliphatic group. In some embodiments, R6 is an optionally substituted phenyl. In some embodiments, R6 is an optionally

substituted 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R^6 is an optionally substituted 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[00270] In some embodiments, R^6 is selected from those depicted in Table 1, below.

[00271] As defined above and described herein, Ring A is a fused ring selected from 6-membered aryl containing 0-2 nitrogen atoms, 5 to 7-membered partially saturated carbocyclyl, 5 to 7-membered partially saturated heterocyclyl with 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur.


[00272] In some embodiments Ring A is a fused 6-membered aryl containing 0-2 nitrogen atoms. In some embodiments Ring A is a fused 5 to 7-membered partially saturated carbocyclyl. In some embodiments Ring A is a fused 5 to 7-membered partially saturated heterocyclyl with 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur. In some embodiments Ring A is a fused 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[00273] In some embodiments, Ring A is a fused phenyl.

[00274] In some embodiments, Ring A is selected from those depicted in Table 1, below.

[00275] As defined above and described herein, Ring B is selected from 6-membered aryl containing 0-2 nitrogen atoms or a 8-10 membered bicyclic heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[00276] In some embodiments, Ring B is a 6-membered aryl containing 0-2 nitrogen atoms. In some embodiments, Ring B is a 8-10 membered bicyclic heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.


[00277] In some embodiments, Ring B is 

.

[00278] In some embodiments, Ring B is selected from those depicted in Table 1, below.

[00279] As defined above and described herein, Ring C is selected from 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[00280] In some embodiments, Ring C is a 6-membered aryl containing 0-2 nitrogen atoms. In some embodiments, Ring C is a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[00281] In some embodiments, Ring C is  .

[00282] In some embodiments, Ring C is selected from those depicted in **Table 1,** below.

[00283] As defined above and described herein, m is 0, 1, 2, 3 or 4.

[00284] In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4.

[00285] In some embodiments, m is selected from those depicted in **Table 1,** below.

[00286] As defined above and described herein, each of n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[00287] In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6. In some embodiments, n is 7. In some embodiments, n is 8. In some embodiments, n is 9. In some embodiments, n is 10.

[00288] In some embodiments, n is selected from those depicted in **Table 1,** below.

[00289] As defined above and described herein, p is 0, 1, 2, 3 or 4.

[00290] In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 2. In some embodiments, p is 3. In some embodiments, p is 4.

[00291] In some embodiments, p is selected from those depicted in **Table 1,** below.

[00292] As defined above and described herein, q is 0, 1, 2, 3 or 4.

[00293] In some embodiments, q is 0. In some embodiments, q is 1. In some embodiments, q is 2. In some embodiments, q is 3. In some embodiments, q is 4.

[00294] In some embodiments, q is selected from those depicted in **Table 1,** below.


[00295] As defined above and described herein, each **R** is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: two **R** groups on the same nitrogen are optionally

taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[00296] In some embodiments, **R** is hydrogen. In some embodiments, **R** is phenyl. In some embodiments, **R** is a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, **R** is a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, two **R** groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.


[00297] In some embodiments, **R** is selected from those depicted in **Table 1,** below.

[00298] As described above, in certain embodiments, the present invention provides a compound of formula **I-zzz:**



I-zzz

or a pharmaceutically acceptable salt thereof, wherein:

X^1 is a bivalent moiety selected from a covalent bond, $-CH_{2-}$, -C(O)-, -C(S)-, or  ;

X^2 is a carbon atom or silicon atom;

X^3 is a bivalent moiety selected from $-CH_{2-}$ or $-Si(R_2)-$;

R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, $-S(0)_2R$, $-N(R)_2$, $-Si(R)_3$, or an optionally substituted C_{i-4} aliphatic;


each R is independently hydrogen, or an optionally substituted group selected from C_{i-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are taken together with their intervening atoms to form

a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur;

each R^2 is independently hydrogen, $-R^3$, halogen, -CN, -NO2, -OR, -SR, $-N(R)_2$, $-Si(R)_3$, $-S(0)_2R$, $-S(0)_2N(R)_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)N(R)_2$, -C(0)N(R)0R, $-C(R)_2N(R)C(0)R$, $-C(R)_2N(R)C(0)N(R)_2$, -0C(0)R, $-0C(0)N(R)_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)N(R)_2$, or $-N(R)S(0)_2R$;

each R^3 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

Ring A is a tricyclic ring selected from 


, wherein

each of Ring B, Ring C, and Ring D is independently a fused ring selected from 6-membered aryl containing 0-3 nitrogens, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl ring with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; and


m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16;

wherein L and IRAK are as described in embodiments herein.

[00299] In some embodiments, a compound of formala **I-zzz** above is provided as a compound of formula **I-zzz'** or formula **I-zzz":**



I-zzz'




I- zzz"

or a pharmaceutically acceptable salt thereof, wherein:


each of IRAK, Ring A, L, R^1, R^2, X^1, and m is as defined above.

[00300] As described above, in certain embodiments, the present invention provides a compound of formula **I-aaaa:**



I-aaaa

or a pharmaceutically acceptable salt thereof, wherein:

X^1 is a bivalent moiety selected from a covalent bond, $-CH_{2-}$, -C(O)-, -C(S)-, or  ;

R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, $-S(0)_2R$, $-N(R)_2$, $-Si(R)_3$, or an optionally substituted Ci_{-4} aliphatic;


each R is independently hydrogen, or an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur;

each R^2 is independently hydrogen, $-R^3$, halogen, -CN, $-N0_2$, -OR, -SR, $-N(R)_{¾}$ $-Si(R)_3$, $-S(0)_2R$, $-S(0)_2N(R)_{2,}$ -S(0)R, -C(0)R, -C(0)OR, $-C(0)N(R)_2$, -C(0)N(R)OR, $-C(R)_2N(R)C(0)R$, $-C(R)_2N(R)C(0)N(R)_2$, -OC(0)R, $-OC(0)N(R)_2$, -

N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0)N(R)$_2$, or -N(R)S(0)$_2$R;

each R^3 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

Ring A is a tricyclic ring selected from 


, wherein

each of Ring B, Ring C, and Ring D is independently a fused ring selected from 6-membered aryl containing 0-3 nitrogens, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl ring with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; and


m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16;

wherein L and IRAK are as described in embodiments herein.

[00301] In some embodiments, a compound of formala **I-aaaa** above is provided as a compound of formula **I-aaaa'** or formula **I-aaaa":**



I-aaaa′




I- aaaa"

or a pharmaceutically acceptable salt thereof, wherein:


each of IRAK, Ring A, L, R^1, R^2, X^1, and m is as defined above.

[00302] As described above, in certain embodiments, the present invention provides a compound of formula **I-bbbb:**



I-bbbb

or a pharmaceutically acceptable salt thereof, wherein:

X^1 is a bivalent moiety selected from a covalent bond, -CH_{2-}, -C(O)-, –C(S)–, or  ;






R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, -$S(0)_2R$, -$N(R)_2$, -$Si(R)_3$, or an optionally substituted Ci_{-4} aliphatic;

each R is independently hydrogen, or an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur;

each R^2 is independently hydrogen, -R^3, halogen, -$N0_2$, -OR, -SR, -$N(R)_{¾}$ -$Si(R)_3$, -$S(0)_2R$, -$S(0)_2N(R)_{2,}$ -S(0)R, -C(0)R, -C(0)OR, -$C(0)N(R)_2$, -C(0)N(R)OR, -$C(R)_2N(R)C(0)R$, -$C(R)_2N(R)C(0)N(R)_2$, -OC(0)R, -$OC(0)N(R)_2$, -N(R)C(0)OR, -N(R)C(0)R, -$N(R)C(0)N(R)_2$, or -$N(R)S(0)_2R$;

each R^3 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

Ring A is a tricyclic ring selected from  ,  ,  ,  , or  , wherein

each of Ring B and Ring C is independently a fused ring selected from 6-membered aryl containing 0-3 nitrogens, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl ring with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen or sulfur, or 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;


Ring D is a fused ring selected from aryl containing 0-3 nitrogens, saturated or partially unsaturated carbocyclyl, saturated or partially unsaturated heterocyclyl ring with 1-2 heteroatoms independently selected from nitrogen, oxygen, silicon, or sulfur, or heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;

=== is a single or double bond;


m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16;

wherein L and IRAK are as described in embodiments herein.

[00303] In some embodiments, a compound of formala **I-bbbb** above is provided as a compound of formula **I-bbbb'** or formula **I-bbbb":**



I-bbbb′




I- bbbb"

or a pharmaceutically acceptable salt thereof, wherein:


each of IRAK, Ring A, L, R^1, R^2, X^1, and m is as defined above.

[00304] As described above, in certain embodiments, the present invention provides a compound of formula **I-cccc:**



I-cccc

or a pharmaceutically acceptable salt thereof, wherein:

X^1 is a bivalent moiety selected from a covalent bond, $-CH_{2-}$, -C(O)-, -C(S)-, or  ;

R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, $-S(0)_2R$, $-N(R)_2$, $-Si(R)_3$, or an optionally substituted Ci_{-4} aliphatic;










each R is independently hydrogen, or an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur;

each R^2 is independently hydrogen, $-R^3$, halogen, $-N0_2$, -OR, -SR, $-N(R)_2$, $-Si(R)_3$, $-S(0)_2R$, $-S(0)_2N(R)_2$, -S(0)R, -C(0)R, -C(0)OR, $-C(0)N(R)_2$, -C(0)N(R)OR, $-C(R)_2N(R)C(0)R$, $-C(R)_2N(R)C(0)N(R)_2$, -OC(0)R, $-OC(0)N(R)_2$, -N(R)C(0)OR, -N(R)C(0)R, $-N(R)C(0)N(R)_2$, or $-N(R)S(0)_2R$;

each R^3 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms

independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

Ring A is a tricyclic ring selected from  ,  ,  ,  ,  ,  ,  ,  , or  , wherein


each of Ring B and Ring C is independently a fused ring selected from 6-membered aryl containing 0-2 nitrogens, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl ring with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;

=== is a single or double bond;


m is 0, 1, 2, 3, 4, 5, 6, 7, or 8;

wherein L and IRAK are as described in embodiments herein.

[00305] In some embodiments, a compound of formala **I-cccc** above is provided as a compound of formula **I-cccc'** or formula **I-cccc":**




I-cccc′




I- cccc"

or a pharmaceutically acceptable salt thereof, wherein:

each of IRAK, Ring A, L, R^1, R^2, X^1, and m is as defined above.

[00306] As defined above and described herein, X^1 is a bivalent moiety selected from a covalent bond, $–CH_2–$, –C(O)–, –C(S)–, or  .

[00307] In some embodiments, X^1 is a covalent bond. In some embodiments, X^1 is $-CH_2-$. In some embodiments, X^1 is -C(O)-. In some embodiments, X^1 is -C(S)-. In some embodiments, X^1 is  .

[00308] In some embodiments, X^1 is selected from those depicted in Table 1, below.

[00309] As defined above and described herein, X^2 is a carbon atom or silicon atom.

[00310] In some embodiments, X^2 is a carbon atom. In some embodiments, X^2 is a silicon atom.

[00311] In some embodiments, X^2 is selected from those depicted in Table 1, below.

[00312] As defined above and described herein, X^3 is a bivalent moiety selected from $-CH_2–$ or $-Si(R_2)-$.

[00313] In some embodiments, X^3 is $-CH_2-$. In some embodiments, X^2 is $-Si(R_2)-$.

[00314] In some embodiments, X^3 is selected from those depicted in Table 1, below.

[00315]

[00316] As defined above and described herein, R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, $-S(0)_2R$, $-NR_2$, $-Si(R_3)$, or an optionally substituted C_{i-4} aliphatic.

[00317] In some embodiments, R^1 is hydrogen. In some embodiments, R^1 is deuterium. In some embodiments, R^1 is halogen. In some embodiments, R^1 is -CN. In some embodiments, R^1 is -OR. In some embodiments, R^1 is -SR. In some embodiments, R^1 is -S(0)R. In some embodiments, R^1 is $-S(0)_2R$. In some embodiments, R^1 is $-NR_2$. In some embodiments, R^1 is $-Si(R_3)$. In some embodiments, R^1 is an optionally substituted Ci_{-4} aliphatic.

[00318] In some embodiments, R^1 is selected from those depicted in Table 1, below.

[00319] As defined above and described herein, each R is independently hydrogen, or an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[00320] In some embodiments, R is hydrogen. In some embodiments, R is optionally substituted Ci_{-6} aliphatic. In some embodiments, R is optionally substituted phenyl. In some embodiments, R is optionally substituted 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is optionally substituted 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[00321] In some embodiments, R is selected from those depicted in Table 1, below.

[00322] As defined above and described herein, each R^2 is independently hydrogen, $-R^3$, halogen, -CN, $-N0_2$, -OR, -SR, $-N(R)_2$, $-Si(R_3)$, $-S(0)_2R$, $-S(0)_2N(R)_2$, -S(0)R, -C(0)R, -C(0)OR, $-C(0)N(R)_2$, -C(0)N(R)OR, $-C(R)_2N(R)C(0)R$, $-C(R)_2N(R)C(0)N(R)_2$, -OC(0)R, $-OC(0)N(R)_2$, -N(R)C(0)OR, -N(R)C(0)R, $-N(R)C(0)N(R)_2$, or $-N(R)S(0)_2R$.

[00323] In some embodiments, R^2 is hydrogen. In some embodiments, R^2 is $-R^3$. In some embodiments, R^2 is halogen. In some embodiments, R^2 is -CN. In some embodiments, R^2 is $-N0_2$. In some embodiments, R^2 is -OR. In some embodiments, R^2 is -SR. In some embodiments,

R^2 is $-NR_2$. In some embodiments, R^2 is $-Si(R_3)$. In some embodiments, R^2 is $-S(0)_2R$. In some embodiments, R^2 is $-S(0)_2NR_2$. In some embodiments, R^2 is -S(0)R. In some embodiments, R^2 is -C(0)R. In some embodiments, R^2 is -C(0)OR. In some embodiments, R^2 is $-C(0)NR_2$. In some embodiments, R^2 is -C(0)N(R)OR. In some embodiments, R^2 is $-C(R)_2N(R)C(0)R$. In some embodiments, R^2 is $-C(R)_2N(R)C(0)N(R)_2$. In some embodiments, R^2 is $-OC(0)R$. In some embodiments, R^2 is $-OC(0)NR_2$. In some embodiments, R^2 is -N(R)C(0)OR. In some embodiments, R^2 is -N(R)C(0)R. In some embodiments, R^2 is $-N(R)C(0)NR_2$. In some embodiments, R^2 is $-N(R)S(0)_2R$.


[00324] In some embodiments, R^2 is selected from those depicted in **Table 1,** below.

[00325] As defined above and described herein, each **R^3** is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[00326] In some embodiments, R^3 is an optionally substituted Ci_{-6} aliphatic. In some embodiments, R^3 is an optionally substituted phenyl. In some embodiments, R^3 is an optionally substituted 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R^3 is an optionally substituted 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.


[00327] In some embodiments, R^3 is selected from those depicted in **Table 1,** below.

[00328] As defined above and described herein, Ring A is a tricyclic ring selected from



.

[00329] In some embodiments, Ring A is



.


[00330] In some embodiments, Ring A is selected from those depicted in **Table 1,** below.


[00331] As defined above and described herein, each of Ring B, Ring C, and Ring D is independently a fused ring selected from 6-membered aryl containing 0-3 nitrogens, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl ring with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur.


[00332] In some embodiments, each Ring B, Ring C, and Ring D is independently a 6-membered aryl containing 0-2 nitrogen atoms. In some embodiments, each Ring B, Ring C, and Ring D is independently a 5 to 7-membered saturated or partially unsaturated carbocyclyl. In some embodiments, each Ring B, Ring C, and Ring D is independently a 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur. In some embodiments, each Ring B, Ring C, and Ring D is independently a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur.


[00333] In some embodiments, Ring B, Ring C, and Ring D is selected from those depicted in **Table** 1, below.


[00334] As defined above and described herein, Ring A is a tricyclic ring selected from




,






,


,


, or


.




















[00335] In some embodiments, Ring A is . In some embodiments, Ring A is  . In some embodiment, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  .








[00336] In some embodiments, Ring A is selected from those depicted in Table 1, below.


[00337] As defined above and described herein, Ring D is a fused ring selected from aryl containing 0-3 nitrogens, saturated or partially unsaturated carbocyclyl, saturated or partially unsaturated heterocyclyl ring with 1-2 heteroatoms independently selected from nitrogen, oxygen, silicon, or sulfur, or heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur.


[00338] In some embodiments, Ring D is an aryl containing 0-2 nitrogen atoms. In some embodiments, Ring D is a saturated or partially unsaturated carbocyclyl. In some embodiments, each Ring D is a saturated or partially unsaturated heterocyclyl with 1-2 heteroatoms independently selected from nitrogen, oxygen, silicon, or sulfur. In some embodiments, Ring D is a heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur.


[00339] In some embodiments, Ring D is  . In some embodiments, Ring D is  . In some embodiments, Ring D is  . In some embodiments, Ring D is  . In some embodiments, Ring D is  . In some embodiments, Ring D is  . In some embodiments, Ring D is  . In some embodiments, Ring D is  . In some embodiments, Ring D is  . In some embodiments, Ring D is  . In some embodiments, Ring D is  . In some embodiments, Ring D is  . In some embodiments, Ring D is . In some embodiments, Ring D is . In some embodiments, Ring D is . In some embodiments, Ring D is  . In some embodiments, Ring D is



. In some embodiments, Ring D is 
. In some embodiments, Ring D is 
. In some embodiments, Ring D is 
.


[00340] In some embodiments, Ring D is 
. In some embodiments, Ring D is 
. In some embodiments, Ring D is 
. In some embodiments, Ring D is 
. In some embodiments, Ring D is 
. In some embodiments, Ring D is 
. In some embodiments, Ring D is 
. In some embodiments, Ring D is





. In some embodiments, Ring D is 


. In some embodiments, Ring D is 


. In some embodiments, Ring D is 


. In some embodiments, Ring D is 

. In some embodiments, Ring D is 

. In some embodiments, Ring D is 

. In some embodiments, Ring D is 

. In some embodiments, Ring D is 

. In some embodiments, Ring D is 

.










[00341] In some embodiments, Ring D is selected from those depicted in **Table 1,** below.

[00342] As defined above and described herein, m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16.





[00343] In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, m is 5. In some embodiments, m is 6. In some embodiments, m is 7. In some embodiments, m is 8. In some embodiments, m is 9. In some embodiments, m is 10. In some embodiments, m is 11. In some embodiments, m is 12. In some embodiments, m is 13. In some embodiments, m is 14. In some embodiments, m is 15. In some embodiments, m is 16.






[00344] In some embodiments, m is selected from those depicted in **Table 1,** below.

[00345] As defined above and described herein, Ring A is a tricyclic ring selected from

, or .



[00346] In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiment, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is





. In some embodiments, Ring A is 
. In some embodiments, Ring A is 
. In some embodiments, Ring A is 
. In some embodiments, Ring A is 
.








[00347] In some embodiments, Ring A is selected from those depicted in **Table 1,** below.



[00348] As defined above and described herein, each Ring B and Ring C is independently a fused ring selected from 6-membered aryl containing 0-2 nitrogen atoms, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur.




[00349] In some embodiments, each Ring B and Ring C is independently a 6-membered aryl containing 0-2 nitrogen atoms. In some embodiments, each Ring B and Ring C is independently a 5 to 7-membered saturated or partially unsaturated carbocyclyl. In some embodiments, each Ring B and Ring C is independently a 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur. In some embodiments, each Ring B and Ring C is independently a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[00350] In some embodiments, each Ring B and Ring C is independently 
. In some embodiments, each Ring B and Ring C is independently 
. In some

embodiments, each Ring B and Ring C is independently  . In some embodiments, each Ring B and Ring C is independently  . In some embodiments, Ring B and Ring C is independently  .

[00351] In some embodiments, Ring B and Ring C is independently is  . in some embodiments, Ring B and Ring C is independently  . I_n some embodiments, Ring B and Ring C is independently  . In some embodiments, Ring B and Ring C is independently  . In some embodiments, Ring B and Ring C is independently  . In some embodiments, Ring B and Ring C is independently  . In some embodiments, Ring B and Ring C is independently  .

[00352] In some embodiments, Ring B and Ring C is independently  . In some embodiments, Ring B and Ring C is independently  . In some embodiments, B and

Ring C is independently  . in some embodiments, Ring B and Ring C is independently  . In some embodiments, Ring B and Ring C is independently  .

[00353] In some embodiments, Ring B and Ring C is independently selected from those depicted in Table 1, below.


[00354] As defined above and described herein, ═ is a single or double bond


[00355] In some embodiments, ═ is a single bond. In some embodiments, ═ is a double bond.


[00356] As defined above and described herein, m is 0, 1, 2, 3, 4, 5, 6, 7, or 8.


[00357] In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, m is 5. In some embodiments, m is 6. In some embodiments, m is 7. In some embodiments, m is 8.


[00358] In some embodiments, m is selected from those depicted in Table 1, below.


[00359] In some embodiments, In some embodiments, LBM is  .

In some embodiments, LBM is  . In some embodiments, LBM is



. In some embodiments, In some embodiments, LBM is



. In some embodiments, LBM is



. In some embodiments, LBM is



.

[00360] In some embodiments, LBM is



. In some embodiments, LBM is


. In some embodiments, LBM is


. In some embodiments, LBM is



.

[00361] In certain embodiments, the present invention provides a compound of formula **I,**



wherein LBM is a VHL binding moiety ;


thereby forming a compound of formula **I-dddd:**



I-dddd


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein each of the variables R^9, R^{10}, R^{11}, R^{14a}, and R^{15} is as described and defined in WO 2017/030814, WO 2016/118666, and US 2017/0327469, the entirety of each of which is herein incorporated by reference.

[00362] In certain embodiments, the present invention provides a compound of formula **I,**



wherein LBM is a VHL binding moiety ;


thereby forming a compound of formula **I-eeee:**



I-eeee


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein each of the variables X, R^9, R^{10}, R^{11}, R^{14a}, and R^{15} is as described and defined in WO 2017/030814, WO 2016/118666, and US 2017/0327469, the entirety of each of which is herein incorporated by reference.

[00363] In certain embodiments, the present invention provides a compound of formula **I,**



wherein LBM is an IAP binding moiety or derivative thereof;


thereby forming a compound of formula **I-ffff:**



I-ffff


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein each of the variables W, Y, Z, R^1, R^2, R^3, R^4, and R^5 is as described and defined in WO 2014/044622, US 2015/0225449. WO 2015/071393, and US 2016/0272596, the entirety of each of which is herein incorporated by reference.

[00364] In certain embodiments, the present invention provides a compound of formula **I,**



wherein LBM is a MDM2 binding moiety or derivatives thereof;


thereby forming a compound of formula **I-gggg:**



i-gggg


or derivative thereof, or a pharmaceutically acceptable salt thereof, as described and defined in Hines, J. et al., *Cancer Res.* (DOI: 10.1158/0008-5472.CAN-18-2918), the entirety of each of which is herein incorporated by reference.

[00365] In certain embodiments, the present invention provides a compound of formula **I,**



wherein LBM is a DCAF16 binding moiety or derivatives thereof;


thereby forming a compound of formula **I-hhhh:**



I-hhhh


or derivative thereof, or a pharmaceutically acceptable salt thereof, as described and defined in Zhang, X. et al., *bioRxiv* (doi: https://doi.org/l0.H0l/443804), the entirety of each of which is herein incorporated by reference.

[00366] In certain embodiments, the present invention provides a compound of formula **I,**



wherein LBM is a RNF114 binding moiety or derivatives thereof;


thereby forming a compound of formula **I-iiii:**




I-iiii

[00367] or derivative thereof, or a pharmaceutically acceptable salt thereof, as described and defined in Spradin, J.N. et al., *bioRxiv* (doi: https://doi.org/l0.H0l/436998), the entirety of each of which is herein incorporated by reference.

[00368] In certain embodiments, the present invention provides a compound of formula **I,**

wherein IRAK is an IRAK4 binding moiety  or derivative thereof;


thereby forming a compound of formula **I-jjjj :**




i-jjjj

or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein X, Y, Ri, R_2, and R_3 are as defined and described in WO 2018/209012, the entirety of which is herein incorporated by reference.

[00369] In certain embodiments, the present invention provides a compound of formula **I,**

wherein IRAK is an IRAK4 binding moiety  or derivative thereof;


thereby forming a compound of formula **I-kkkk:**



I-kkkk


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein Ri, R_2, R_3, R_4, R_5, R_6, and R_7 are as defined and described in US 2018/0230157, the entirety of which is herein incorporated by reference.

[00370] In certain embodiments, the present invention provides a compound of formula I, wherein IRAK is an IRAK1 and/or IRAK4 binding moiety



or derivative thereof;


thereby forming a compound of formula 1-1111:



1-1111

or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein Ring Al, Ring B, Ring C, L^{1A}, R^1, R^2, R^3, R^4, n, and p are as defined and described in WO 2018/098367, the entirety of which is herein incorporated by reference.


[00371] In certain embodiments, the present invention provides a compound of formula I, wherein IRAK is an IRAK4 binding moiety



or

derivative thereof;


thereby forming a compound of formula **I-mmmm:**



I-mmmm


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein R^1, R^2, R^3, R^4, R^5, and R^6 are as defined and described in WO 2018/052058, the entirety of which is herein incorporated by reference.

[00372] In certain embodiments, the present invention provides a compound of formula **I,** wherein IRAK is an IRAK1 and/or IRAK4 binding moiety



or derivative thereof;

thereby forming a compound of formula **I-nnnn:**




I-nnnn

or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein Ring A, Ring B, R^1, R^2, and R^3 are as defined and


described in US 2017/0369476, the entirety of which is herein incorporated by reference.

[00373] In certain embodiments, the present invention provides a compound of formula **I,**



wherein IRAK is an IRAK4 binding moiety or derivative thereof;


thereby forming a compound of formula **I-oooo:**



I-oooo


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein R^1, R^2, R^3, and R^4 are as defined and described in WO 2017/207385, the entirety of which is herein incorporated by reference.

[00374] In certain embodiments, the present invention provides a compound of formula **I,**



wherein IRAK is an IRAK4 binding moiety or derivative thereof;


thereby forming a compound of formula **I-pppp:**



I-pppp


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein Ring A, X, Y, L^1, Cy^1, Cy^2, R^1 R^8, R^9, k, m, and n are as defined and described in WO 2017/205766, the entirety of which is herein incorporated by reference.

[00375] In certain embodiments, the present invention provides a compound of formula **I,**



wherein IRAK is an IRAK4 binding moiety or derivative thereof;


thereby forming a compound of formula **I-qqqq:**




I-qqqq

or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein Ring A, L^1, Cy^1, Cy^2, R^1 R^8, R^9, m, and n are as defined and described in WO 2017/205762, the entirety of which is herein incorporated by

reference.


[00376] In certain embodiments, the present invention provides a compound of formula **I,** wherein IRAK is an IRAK4 binding moiety  or derivative thereof;

thereby forming a compound of formula **I-rrrr:**




I-rrrr

or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein Ring A, R^1, R^3, R^4, R^5, and R^{16} are as defined and described in WO 2017/108723, the entirety of which is herein incorporated by reference.

[00377] In certain embodiments, the present invention provides a compound of formula **I,** wherein IRAK is an IRAK1 and/or IRAK4 binding moiety  or derivative thereof;


thereby forming a compound of formula I-ssss:



I-sss


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein Ring X, Z, R^1, R^2, R^3, R^4, R^a and p are as defined and described in WO 2017/049068, the entirety of which is herein incorporated by reference.

[00378] In certain embodiments, the present invention provides a compound of formula **I,**



wherein IRAK is an IRAK4 binding moiety or derivative thereof;

thereby forming a compound of formula **I-ssss:**




I-ssss

or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein X, X', Y, Y', Z, R^1, R^2, R^3, R^{4a}, R^{4b}, R^{5a}, R^{5b} and R^6 are as defined and described in WO 2017/033093, the entirety of which is herein incorporated


by reference.

[00379] In certain embodiments, the present invention provides a compound of formula **I,**



wherein IRAK is an IRAK4 binding moiety or derivative thereof;


thereby forming a compound of formula **I-ssss:**



I-ssss


or a pharmaceutically acceptable salt thereof, wherein L and IRAK are as defined above and described in embodiments herein, and wherein X, X', Y, Y', Z, R^1, R^2, R^3, R^{4a}, R^{4b}, R^{5a}, R^{5b} and R^6 are as defined and described in WO 2017/033093, the entirety of which is herein incorporated by reference.

[00380] In certain embodiments, the present invention provides a compound of formula **I,**



wherein LBM is a RNF114 binding moiety or derivatives thereof;

thereby forming a compound of formula **I-iiii:**









I-iiii






[00381] or derivative thereof, or a pharmaceutically acceptable salt thereof, as described and defined in Ward, C.C., et al., *bioRxiv* (doi: https://doi.0rg/l O.l 101/439125), the entirety of each of which is herein incorporated by reference.





[00382] Exemplary compounds of the invention are set forth in **Table 1,** below.






Table 1. Exemplary Compounds






I-#	Structure
I-1	
I-2	






I-3	
I-4	
I-5	
I-6	






I-7	
I-8	
I-9	
I-10	
I-11	





I-12	
I-13	
I-14	
I-15	





I-16	
I-17	
I-18	
I-19	
I-20	







I-21	
I-22	
I-23	
I-24	
I-25	








I-26	
I-27	
I-29	
I-30	
I-31	







I-32	
I-33	
I-34	
I-35	
I-36	







I-37	
I-38	
I-39	
I-40	








I-41	
I-42	
I-43	
I-44	







I-45	
I-46	
I-47	
I-48	
I-49	
I-50	








I-51	
I-52	
I-53	
I-54	
I-55	
I-56	
I-57	





I-58	
I-59	
I-60	
I-61	
I-62	
I-63	








I-64	
I-65	
I-66	
I-67	
I-68	
I-69	







I-70	
I-71	
I-72	
I-73	
I-74	
I-75	
I-76	








I-77	
I-78	
I-79	
I-80	
I-81	
I-82	







I-83	
I-84	
I-85	
I-86	
I-87	
I-88	
I-89	





I-90	
I-91	
I-92	
I-93	







I-94	
I-95	
I-96	
I-97	
I-98	
I-99	
I-100	







I-101	
I-102	
I-103	
I-104	
I-105	
I-106	







I-107	
I-108	
I-109	
I-110	
I-111	
I-112	
I-113	








I-114	
I-115	
I-116	
I-117	
I-118	
I-119	







I-120	
I-121	
I-122	
I-123	






I-124	
I-125	
I-126	
I-127	
I-128	
I-129	





I-130	
I-131	
I-132	
I-133	
I-134	
I-135	






I-136	
I-137	
I-138	
I-139	
I-140	
I-141	








I-142	
I-143	
I-144	
I-145	
I-146	
I-147	
I-148	






I-149	
I-150	
I-151	
I-152	
I-153	
I-154	






I-155	
I-156	
I-157	
I-158	
I-159	






I-160	
I-161	
I-162	
I-163	






I-164	
I-165	
I-166	
I-167	
I-168	







I-169	
I-170	
I-171	
I-172	
I-173	
I-174	
I-175	







I-176	
I-177	
I-178	
I-179	
I-180	







I-181	
I-182	
I-183	
I-184	
I-185	






I-186	
I-187	
I-188	
I-189	
I-190	






I-191	
I-192	
I-193	
I-194	
I-195	







I-196	
I-197	
I-198	
I-199	
I-200	
I-201	







I-202	
I-203	
I-204	
I-205	
I-206	
I-207	







I-208	
I-209	
I-210	
I-211	
I-212	
I-213	







I-214	
I-215	
I-216	
I-217	
I-218	







I-219	
I-220	
I-221	
I-222	
I-223	







I-224	
I-225	
I-226	
I-227	
I-228	
I-229	








I-230	
I-231	
I-232	
I-233	
I-234	
I-235	







I-236	
I-237	
I-238	
I-239	
I-240	
I-241	







I-242	
I-243	
I-244	
I-245	
I-246	
I-247	







I-248	
I-249	
I-250	
I-251	
I-252	
I-253	





I-254	
I-255	
I-256	
I-257	
I-258	
I-259	





I-260	
I-261	
I-262	
I-263	
I-264	
I-265	
I-266	





I-267	
I-268	
I-269	
I-270	
I-271	
I-272	





I-273	
I-274	
I-275	
I-276	
I-277	
I-278	






I-279	
I-280	
I-281	
I-282	
I-283	
I-284	







I-285	
I-286	
I-287	
I-288	







I-289	
I-290	
I-291	
I-292	







I-293	
I-294	
I-295	
I-296	








I-297	
I-298	
I-299	
I-300	







I-301	
I-302	
I-303	
I-304	
I-305	






I-306	
I-307	
I-308	
I-309	
i-310	
I-311	





I-312	
I-313	
I-314	
I-315	
I-316	
I-317	






I-318	
I-319	
I-320	
I-321	
I-322	
I-323	








I-324	
I-325	
I-326	
I-327	
I-328	
I-329	
I-330	







I-331	
I-332	
I-333	
I-334	
I-335	
I-336	








I-337	
I-338	
I-339	
I-340	
I-341	








I-342	
I-343	
I-344	
I-345	







I-346	
I-347	
I-348	
I-349	
I-350	







I-351	
I-352	
I-353	
I-354	
I-355	
I-356	
I-357	







I-358	
I-359	
I-360	
I-361	
I-362	
I-363	







I-364	
I-365	
I-366	
I-367	
I-368	
I-369	
I-370	






I-371	
I-372	
I-373	
I-374	
I-375	
I-376	
I-377	







I-378	
I-379	
I-380	
I-381	
I-382	
I-383	






I-384	
I-385	
I-386	
I-387	
I-388	
I-389	







I-390	
I-391	
I-392	
I-393	
I-394	
I-395	







I-396	
I-397	
I-398	
I-399	
I-400	
I-401	






I-402	
I-403	
I-404	
I-405	
I-406	






I-407	
I-408	
I-409	
I-410	
I-411	
I-412	





I-413	
I-414	
I-415	
I-416	
I-417	




I-418	
I-419	
I-420	
I-421	
I-422	
I-423	





I-424	
I-425	
I-426	
I-427	
I-428	
I-429	





I-432	
I-434	
I-435	
I-436	
I-437	





I-438	
I-439	
I-440	
I-441	
I-442	





I-444	
I-445	
I-446	
I-447	






I-448	
I-449	
I-455	





I-456	
I-457	
I-458	
I-459	





I-460	
I-461	
I-462	
I-463	






I-464	
I-465	
I-466	
I-467	






I-468	
I-469	
I-470	
I-471	




I-472	
I-473	
I-475	
I-476	
I-477	





I-478	
I-479	
I-481	
I-482	





I-483	
I-484	
I-485	
I-487	






I-488	
I-489	
I-490	
I-491	
I-494	






I-495	
I-504	
I-506	
I-508	
I-509	





I-513	
I-514	
I-515	







I-517	
I-522	
I-523	
I-524	






I-525	
I-526	
I-527	
I-528	





I-529	
I-530	
I-531	
I-532	
I-533	






I-534	
I-535	
I-536	
I-537	
I-538	





I-539	
I-540	
I-541	
I-542	






I-543	
I-544	
I-545	
I-548	
I-549	
I-550	






I-551	
I-552	
I-553	
I-554	
I-555	





I-556	
I-557	
I-558	
I-559	






I-560	
I-563	
I-564	
I-567	
I-568	






I-572	
I-573	
I-574	
I-575	





I-576	
I-578	
I-579	
I-580	
I-581	






I-582	
I-583	
I-584	
I-585	
I-587	







I-588	
I-589	
I-590	
I-591	


I-592	
I-593	
I-595	
I-596	
I-597	

I-598	
I-599	
I-614	
I-617	
I-691	

I-692	
I-693	
I-694	
I-684	

I-685	
I-699	
I-700	
I-688	
I-689	

I-690	
I-519	
I-520	
I-521	
I-680	
I-681	

I-682	

[00383] In some embodiments, the present invention provides a compound set forth in **Table 1,** above, or a pharmaceutically acceptable salt thereof.

4. General Methods of Providing the Present Compounds

[00384] The compounds of this invention may be prepared or isolated in general by synthetic and/or semi-synthetic methods known to those skilled in the art for analogous compounds and by methods described in detail in the Examples, herein.

[00385] In the Schemes below, where a particular protecting group, leaving group, or transformation condition is depicted, one of ordinary skill in the art will appreciate that other protecting groups, leaving groups, and transformation conditions are also suitable and are contemplated. Such groups and transformations are described in detail in *March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure*, M. B. Smith and J. March, 5th Edition, John Wiley & Sons, 2001, *Comprehensive Organic Transformations*, R. C. Larock, 2nd Edition, John Wiley & Sons, 1999, and *Protecting Groups in Organic Synthesis*, T. W. Greene and R G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, the entirety of each of which is hereby incorporated herein by reference.


[00386] As used herein, the phrase "oxygen protecting group" includes, for example, carbonyl protecting groups, hydroxyl protecting groups, etc. Hydroxyl protecting groups are well known in the art and include those described in detail in *Protecting Groups in Organic Synthesis*, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, the entirety of which is incorporated herein by reference. Examples of suitable hydroxyl protecting groups include, but

are not limited to, esters, allyl ethers, ethers, silyl ethers, alkyl ethers, arylalkyl ethers, and alkoxyalkyl ethers. Examples of such esters include formates, acetates, carbonates, and sulfonates. Specific examples include formate, benzoyl formate, chloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate, 4,4-(ethylenedithio)pentanoate, pivaloate (trimethylacetyl), crotonate, 4-methoxy-crotonate, benzoate, p-benylbenzoate, 2,4,6-trimethylbenzoate, carbonates such as methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, and p-nitrobenzyl. Examples of such silyl ethers include trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triisopropylsilyl, and other trialkylsilyl ethers. Alkyl ethers include methyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl, t-butyl, allyl, and allyloxycarbonyl ethers or derivatives. Alkoxyalkyl ethers include acetals such as methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl, benzyloxymethyl, beta-(trimethylsilyl)ethoxymethyl, and tetrahydropyranyl ethers. Examples of arylalkyl ethers include benzyl, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, O-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, and 2- and 4-picolyl.

[00387] Amino protecting groups are well known in the art and include those described in detail in *Protecting Groups in Organic Synthesis*, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, the entirety of which is incorporated herein by reference. Suitable amino protecting groups include, but are not limited to, aralkylamines, carbamates, cyclic imides, allyl amines, amides, and the like. Examples of such groups include t-butyloxycarbonyl (BOC), ethyloxycarbonyl, methyloxycarbonyl, trichloroethyloxycarbonyl, allyloxycarbonyl (Alloc), benzyloxocarbonyl (CBZ), allyl, phthalimide, benzyl (Bn), fluorenylmethylcarbonyl (Fmoc), formyl, acetyl, chloroacetyl, dichloroacetyl, trichloroacetyl, phenylacetyl, trifluoroacetyl, benzoyl, and the like.

[00388] In certain embodiments, compounds of the present invention are generally prepared according to Scheme 1 set forth below:


Scheme 1: Synthesis of Compounds of Formula I



[00389] As depicted in Scheme 1, above, amine **A-l** is coupled to acid **A-2** using the coupling agent HATU in the presence of the base DIPEA in DMF to form a compound of formula **I** with a linker comprising an amide bond. The squiggly bond, ~~~, represents the portion of the linker between IRAK and the terminal amino group of **A-l** or the portion of the linker between LBM and the terminal carboxyl group of **A-2,** respectively. Additionally, an amide bond can be formed using coupling reagents known in the art such as, but not limited to DCC, DIC, EDC, HBTU, HCTU, PyAOP, PyBrOP, BOP, BOP-C1, DEPBT, T3P, TATU, TBTU, TNTU, TOTU, TPTU, TSTU, or TDBTU.

[00390] In certain embodiments, compounds of the present invention are generally prepared according to Scheme 2 set forth below:


Scheme 2: Synthesis of Compounds of Formula I



[00391] As depicted in Scheme 2, above, amine **A-l** is coupled to acid **A-2** using the coupling agent PyBOP in the presence of the base DIPEA in DMF to form a compound of formula **I** with a linker comprising an amide bond. The squiggly bond, ~~~, represents the portion of the linker between IRAK and the terminal amino group of **A-l** or the portion of the linker between LBM and the terminal carboxyl group of **A-2,** respectively. Additionally, an amide bond can be formed using coupling reagents known in the art such as, but not limited to DCC, DIC, EDC, HBTU, HCTU, PyAOP, PyBrOP, BOP, BOP-C1, DEPBT, T3P, TATU, TBTU, TNTU, TOTU, TPTU, TSTU, or TDBTU.

[00392] In certain embodiments, compounds of the present invention are generally prepared according to Scheme 3 set forth below:


Scheme 3: Synthesis of Compounds of Formula I



[00393] As depicted in Scheme 3, above, acid **A-3** is coupled to amine **A-4** using the coupling agent HATU in the presence of the base DIPEA in DMF to form a compound of formula **I** with a linker comprising an amide bond. The squiggly bond, ~~~, represents the portion of the linker between IRAK and the terminal carboxyl group of **A-3** or the portion of the linker between LBM and the terminal amino group of **A-4,** respectively. Additionally, an amide bond can be formed using coupling reagents known in the art such as, but not limited to DCC, DIC, EDC, HBTU, HCTU, PyAOP, PyBrOP, BOP, BOP-C1, DEPBT, T3P, TATU, TBTU, TNTU, TOTU, TPTU, TSTU, or TDBTU.

[00394] In certain embodiments, compounds of the present invention are generally prepared according to Scheme 4 set forth below:


Scheme 4: Synthesis of Compounds of Formula I



[00395] As depicted in Scheme 4, above, acid **A-3** is coupled to amine **A-4** using the coupling agent PyBOP in the presence of the base DIPEA in DMF to form a compound of formula **I** with a linker comprising an amide bond. The squiggly bond, ~~~, represents the portion of the linker between IRAK and the terminal carboxyl group of **A-3** or the portion of the linker between LBM and the terminal amino group of **A-4,** respectively. Additionally, an amide bond can be formed using coupling reagents known in the art such as, but not limited to DCC, DIC, EDC, HBTU, HCTU, PyAOP, PyBrOP, BOP, BOP-C1, DEPBT, T3P, TATU, TBTU, TNTU, TOTU, TPTU, TSTU, or TDBTU.

[00396] In certain embodiments, compounds of the present invention are generally prepared according to Scheme 5 set forth below:

Scheme 5: Synthesis of Compounds of Formula I




[00397] As depicted in Scheme 5, above, an S_NAr displacement of fluoride **A-6** by amine **A-5**

is effected in the presence of the base DIPEA in DMF to form a compound of formula **I** with a linker comprising a secondary amine. The squiggly bond, ~~~, represents the portion of the linker between IRAK and the terminal amino group of **A-5.**


[00398] In certain embodiments, compounds of the present invention are generally prepared according to Scheme 6 set forth below:

Scheme 6: Synthesis of Compounds of Formula I



[00399] As depicted in Scheme 6, above, an S_NAr displacement of fluoride **A-7** by amine **A-8** is effected in the presence of the base DIPEA in DMF to form a compound of formula **I** with a linker comprising a secondary amine. The squiggly bond, ^^^^, represents the portion of the linker between LBM and the terminal amino group of **A-8.**

Scheme 7: Synthesis of Compounds of Formula I



[00400] As depicted in Scheme 7, above, reductive amination of the mixture of aldehyde **A-9** and amine **A-10** is effected in the presence of $NaHB(OAc)_3$ and KOAc in DMF/THF to form a compound of formula **I** with a linker comprising a secondary amine. The squiggly bond, ~~~, represents the portion of the linker between LBM and the terminal amino group of **A-8.**

[00401] One of skill in the art will appreciate that various functional groups present in compounds of the invention such as aliphatic groups, alcohols, carboxylic acids, esters, amides, aldehydes, halogens and nitriles can be interconverted by techniques well known in the art including, but not limited to reduction, oxidation, esterification, hydrolysis, partial oxidation, partial reduction, halogenation, dehydration, partial hydration, and hydration. "March's Advanced Organic Chemistry", 5th Ed., Ed.: Smith, M.B. and March, T, John Wiley & Sons, New York: 2001, the entirety of which is incorporated herein by reference. Such interconversions may require one

or more of the aforementioned techniques, and certain methods for synthesizing compounds of the invention are described below in the Exemplification.

5. ***Uses, Formulation and Administration***

Pharmaceutically acceptable compositions

[00402] According to another embodiment, the invention provides a composition comprising a compound of this invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The amount of compound in compositions of this invention is such that is effective to measurably degrade and/or inhibit an IRAK protein kinase, or a mutant thereof, in a biological sample or in a patient. In certain embodiments, the amount of compound in compositions of this invention is such that is effective to measurably degrade and/or inhibit an IRAK protein kinase, or a mutant thereof, in a biological sample or in a patient. In certain embodiments, a composition of this invention is formulated for administration to a patient in need of such composition. In some embodiments, a composition of this invention is formulated for oral administration to a patient.

[00403] The term "patient," as used herein, means an animal, preferably a mammal, and most preferably a human.

[00404] The term "pharmaceutically acceptable carrier, adjuvant, or vehicle" refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

[00405] A "pharmaceutically acceptable derivative" means any non-toxic salt, ester, salt of an ester or other derivative of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily

or degratorily active metabolite or residue thereof.

[00406] As used herein, the term "inhibitorily active metabolite or residue thereof' means that a metabolite or residue thereof is also an inhibitor of an IRAK protein kinase, or a mutant thereof.

[00407] As used herein, the term "degratorily active metabolite or residue thereof means that a metabolite or residue thereof is also a degrader of an IRAK protein kinase, or a mutant thereof.

[00408] Compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously. Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in l,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.

[00409] For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.

[00410] Pharmaceutically acceptable compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include lactose

and com starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

[00411] Alternatively, pharmaceutically acceptable compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

[00412] Pharmaceutically acceptable compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.

[00413] Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.

[00414] For topical applications, provided pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, provided pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

[00415] For ophthalmic use, provided pharmaceutically acceptable compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutically acceptable

compositions may be formulated in an ointment such as petrolatum.

[00416] Pharmaceutically acceptable compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.

[00417] Most preferably, pharmaceutically acceptable compositions of this invention are formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, pharmaceutically acceptable compositions of this invention are administered without food. In other embodiments, pharmaceutically acceptable compositions of this invention are administered with food.

[00418] The amount of compounds of the present invention that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration. Preferably, provided compositions should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the compound can be administered to a patient receiving these compositions.

[00419] It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of a compound of the present invention in the composition will also depend upon the particular compound in the composition.

Uses of Compounds and Pharmaceutically Acceptable Compositions

[00420] Compounds and compositions described herein are generally useful for the degradation and/or inhibition of kinase activity of one or more enzymes.

[00421] Examples of kinases that are degraded and/or inhibited by the compounds and compositions described herein and against which the methods described herein are useful include those of the interleukin- 1 receptor-associated kinase (IRAK) family of kinases, the members of which include IRAK-l, IRAK-2, and IRAK-4, or a mutant thereof. Li et al., "IRAK-4: A novel member of the IRAK family with the properties of an IRAK-kinase," *PNAS* 2002, 99(8), 5567-

5572, Flannery et al., " The interleukin-l receptor-associated kinases: Critical regulators of innate immune signaling" Biochem Pharm 2010, 80(12), 1981-1991 incorporated by reference in its entirety .

[00422] The activity of a compound utilized in this invention as a degrader and/or inhibitor of IRAK-l, IRAK-2, and/or IRAK-4, or a mutant thereof, may be assayed *in vitro*, *in vivo* or in a cell line. *In vitro* assays include assays that determine inhibition of either the phosphorylation activity and/or the subsequent functional consequences, or ATPase activity of activated IRAK-l, IRAK-2, and/or IRAK-4, or a mutant thereof. Alternate *in vitro* assays quantitate the ability of the inhibitor to bind to IRAK-l, IRAK-2 and/or IRAK-4. Inhibitor binding may be measured by radiolabeling the inhibitor prior to binding, isolating the inhibitor/IRAK-l, inhibitor/IRAK-2, or inhibitor/IRAK-4 complex and determining the amount of radiolabel bound. Alternatively, inhibitor binding may be determined by running a competition experiment where new inhibitors are incubated with IRAK-l, IRAK-2, and/or IRAK-4 bound to known radioligands. Representative *in vitro* and *in vivo* assays useful in assaying an IRAK-4 inhibitor include those described and disclosed in, *e.g.*, Kim et al., "A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity," *J Exp. Med.* 2007 204(5), 1025-1036; Lebakken et al., "A Fluorescence Lifetime Based Binding Assay to Characterize Kinase Inhibitors," *J. Biomol. Screen.* 2007, 12(6), 828-841; Maschera et al., "Overexpression of an enzymatically inactive interleukin-1-receptor-associated kinase activates nuclear factor-κB," *Biochem. J.* 1999, 339, 227-231; Song et al., "The kinase activities of interleukin-e receptor associated kinase (IRAK)-l and 4 are redundant in the control of inflammatory cytokine expression in human cells," *Mol. Immunol.* 2009, 46, 1458-1466, each of, the entirety of each of which is herein incorporated by reference. Detailed conditions for assaying a compound utilized in this invention as a degrader and/or inhibitor of IRAK-l, IRAK-2, and/or IRAK-4, or a mutant thereof, are set forth in the Examples below.

[00423] The best characterized member of the IRAK family is the serine/threonine kinase IRAK-4. IRAK-4 is implicated in signaling innate immune responses from Toll-like receptors (TLRs) and Toll/IL-l receptors (TIRs).

[00424] Innate immunity detects pathogens through the recognition of pathogen-associated molecular patterns by TLRs, when then links to the adaptive immune response. TLRs recognize conserved structures of both microbes and endogenous molecules. TLRs which recognize

bacterial and fungal components are located on the cell surface, whereas TLRs which recognize viral or microbial nucleic acids are localized to intracellular membranes such as endosomes and phagosomes. Cell surface TLRs can be targeted by small molecules and antibodies, whereas intracellular TLRs require targeting with oligonucleotides.

[00425] TLRs mediate the innate immune response by upregulating the expression of inflammatory genes in multiple target cells. *See, e.g.,* Sen et al., "Transcriptional signaling by double-stranded RNA: role of TLR3," *Cytokine & Growth Factor Rev.* 2005, 16, 1-14, incorporated by reference in its entirety. While TLR-mediated inflammatory response is critical for innate immunity and host defense against infections, uncontrolled inflammation is detrimental to the host leading to sepsis and chronic inflammatory diseases, such as chronic arthritis, atherosclerosis, multiple sclerosis, cancers, autoimmune disorders such as rheumatoid arthritis, lupus, asthma, psoriasis, and inflammatory bowel diseases.

[00426] Upon binding of a ligand, most TLRs recruit the adaptor molecule MyD88 through the TIR domain, mediating the MyD88-dependent pathway. MyD88 then recruits IRAK-4, which engages with the nuclear factor-κB (NF-κB), mitogen-activated protein (MAP) kinase and interferon-regulatory factor cascades and leads to the induction of pro-inflammatory cytokines. The activation of NF-κB results in the induction of inflammatory cytokines and chemokines, such as TNF-α, IL-l a , IL-6 and IL-8. The kinase activity of IRAK-4 has been shown to play a critical role in the TLR-mediated immune and inflammatory responses. IRAK4 is a key mediator of the innate immune response orchestrated by interleukin-l receptor (IL-1R), interleukin- 18 receptor (IL-18R), IL-33 receptor (IL-33R), and Toll-like receptors (TLRs). Inactivation of IRAK-l and/or IRAK-4 activity has been shown to result in diminished production of cytokines and chemokines in response to stimulation of IL-l and TLR ligands. *See, e.g.*, Picard et al., "Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency," *Medicine (Baltimore),* 2010, 89(6), 043-25; Li, "IRAK4 in TLR/IL-1R signaling: Possible clinical applications," *Eur. J. Immunology* 2008, 38:614-618; Cohen et al., "Targeting protein kinases for the development of anti-inflammatory drugs," *Curr. Opin. Cell Bio.* 2009, 21:317-324; Flannery et al., "The interleukin-l receptor-associated kinases: Critical regulators of innate immune signalling," *Biochem. Pharm.* 2010, 80(12), 1981-1991; Gottipati et al., "IRAK1: A critical signaling mediator of innate immunity," *Cellular Signaling* 2008, 20, 269-276; Kim et al., "A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity," *J. Exp. Med.* 2007 204(5), 1025-1036;

Koziczak-Holbro et al., "IRAK-4 Kinase Activity Is Required for Interleukin-l (IL-l) Receptor- and Toll-like Receptor 7-mediated Signaling and Gene Expression," *./. Biol. Chem.* 2007, 282(18), 13552-13560; Kubo-Murai et al., "IRAK-4-dependent Degradation of IRAK-l is a Negative Feedback Signal for TLR-mediated NF-κB Activation," *./. Biochem.* 2008, 143, 295-302; Maschera et al., "Overexpression of an enzymatically inactive interleukin-l -receptor-associated kinase activates nuclear factor-κB," *Biochem. J*. 1999, 339, 227-231; Lin et al., "Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR /IL-1R signalling," *Nature* 2010, 465(17), 885-891; Suzuki et al., "IRAK-4 as the central TIR signaling mediator in innate immunity," *TRENDS in Immunol.* 2002, 23(10), 503-506; Suzuki et al., "Severe impairment of interleukin-l and Toll-like receptor signalling in mice lacking IRAK-4," *Nature* 2002, 416, 750-754; Swantek et al., "IL-1 Receptor-Associated Kinase Modulates Host Responsiveness to Endotoxin," *J. Immunol.* 2000, 164, 4301-4306; Hennessy, E., et al., "Targeting Toll-like receptors: emerging therapeutics?" *Nature Reviews*, vol. 9, pp: 293-307 (2010); Dinarello, C. "Interleukin-18 and the Pathogenesis of Inflammatory Diseases," *Seminars in Nephrology,* vol. 27, no. 1, pp: 98-114 (2007), each of, the entirety of each of which is herein incorporated by reference. In fact, knockdown mice that express a catalytically inactive mutant IRAK-4 protein are completely resistant to septic shock and show impaired IL-l activity. Moreover, these mice are resistant to joint and bone inflammation/destruction in an arthritis model, suggesting that IRAK-4 may be targeted to treat chronic inflammation. Further, while IRAK-4 appears to be vital for childhood immunity against some pyogenic bacteria, it has been shown to play a redundant role in protective immunity to most infections in adults, as demonstrated by one study in which patients older than 14 lacking IRAK-4 activity exhibited no invasive infections. Cohen et al., "Targeting protein kinases for the development of anti-inflammatory drugs," *Curr. Opin. Cell Bio.* 2009, 21:317-324; Ku et al., "Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity," *J. Exp. Med.* 2007, 204(10), 2407-2422; Picard et al., "Inherited human IRAK-4 deficiency: an update," *Immunol. Res.* 2007, 38, 347-352; Song et al., "The kinase activities of interleukin-e receptor associated kinase (IRAK)-l and 4 are redundant in the control of inflammatory cytokine expression in human cells," *Mol. Immunol.* 2009, 46, 1458-1466; Rokosz, L. et al., "Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges," *Expert Opinions on Therapeutic Targets*, 12(7), pp: 883-903 (2008); Gearing, A. "Targeting toll-like receptors for drug development: a summary

of commercial approaches," *Immunology and Cell Biology*, 85, pp: 490-494 (2007); Dinarello, C. "IL-l: Discoveries, controversies and future directions," *European Journal of Immunology*, 40, pp: 595-653 (2010), each of, the entirety of each of which is herein incorporated by reference. Because TLR activation triggers IRAK-4 kinase activity, IRAK-4 inhibition presents an attractive target for treating the underlying causes of inflammation in countless diseases.

[00427] Representative IRAK-4 inhibitors include those described and disclosed in *e.g.*, Buckley et al., *Bioorg. Med. Chem. Lett.* 2008, 18, 3211-3214; Buckley et al., *Bioorg. Med. Chem. Lett.* 2008, 18, 3291-3295; Buckley et al., *Bioorg. Med. Chem. Lett.* 2008, 18, 3656-3660; Powers et al., "Discovery and initial SAR of inhibitors of interleukin-l receptor-associated kinase-4," *Bioorg. Med. Chem. Lett.* 2006, 16, 2842-2845; Wng et al., "IRAK-4 Inhibitors for Inflammation," *Curr. Topics in Med. Chem.* 2009, 9, 724-737, each of, the entirety of each of which is herein incorporated by reference.

[00428] As used herein, the terms "treatment," "treat," and "treating" refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.

[00429] Provided compounds are degraders and/or inhibitors of one of more of IRAK-1, IRAK-2, and/or IRAK-4 and are therefore useful for treating one or more disorders associated with activity of one or more of IRAK-l, IRAK-2, and/or IRAK-4. Thus, in certain embodiments, the present invention provides a method for treating a IRAK-l -mediated, a IRAK-2-mediated, and/or a IRAK-4-mediated disorder comprising the step of administering to a patient in need thereof a compound of the present invention, or pharmaceutically acceptable composition thereof.

[00430] As used herein, the terms "IRAK-l -mediated", "IRAK-2-mediated", and/or "IRAK-4-mediated" disorders, diseases, and/or conditions as used herein means any disease or other deleterious condition in which one or more of IRAK-l, IRAK-2, and/or IRAK-4, or a mutant thereof, are known to play a role. Accordingly, another embodiment of the present invention relates to treating or lessening the severity of one or more diseases in which one or more of IRAK-

1, IRAK-2, and/or IRAK-4, or a mutant thereof, are known to play a role.

[00431] In some embodiments, the present invention provides a method for treating one or more disorders, diseases, and/or conditions wherein the disorder, disease, or condition is a cancer, a neurodegenative disorder, a viral disease, an autoimmune disease, an inflammatory disorder, a hereditary disorder, a hormone-related disease, a metabolic disorder, conditions associated with organ transplantation, immunodeficiency disorders, a destructive bone disorder, a proliferative disorder, an infectious disease, a condition associated with cell death, thrombin-induced platelet aggregation, liver disease, pathologic immune conditions involving T cell activation, a cardiovascular disorder, or a CNS disorder.

[00432] Diseases and conditions treatable according to the methods of this invention include, but are not limited to, cancer *(see, e.g.,* Ngo, V. et al., "Oncogenically active *MYD88* mutations in human lymphoma," *Nature*, vol. 000, pp: 1-7 (2010); Lust, J. et al., "Induction of a Chronic Disease State in patients With Smoldering of Indolent Multiple Myeloma by Targeting Interleukin lB-Induced Interleukin 6 Production and the Myeloma Proliferative Component," *Mayo Clinic Proceedings*, 84(2), pp: 114-122 (2009)), diabetes, cardiovascular disease, viral disease, autoimmune diseases such as lupus *(see, e.g,* Dinarello, C. " Interleukin-18 and the Pathogenesis of Inflammatory Diseases," *Seminars in Nephrology,* vol. 27, no. 1, pp: 98-114 (2007); Cohen et al., "Targeting protein kinases for the development of anti-inflammatory drugs," *Curr. Opin. Cell Bio.* 2009, 21:317-324) and rheumatoid arthritis *(see, e.g,* Geyer, M. et al., "Actual status of antiinterleukin-1 therapies in rheumatic diseases," *Current Opinion in Rheumatology,* 22, pp: 246-251 (2010)), autoinflammatory syndromes *(see, e.g,* Hoffman, H. et al., "Efficacy and Safety of Rilonacept (Interleukin-1 Trap) in Patients with Cryopyrin-Associated Periodic Syndromes," *Arthritis & Rheumatism,* vol. 58, no. 8, pp: 2443-2452 (2008)), atherosclerosis, psoriasis, allergic disorders, inflammatory bowel disease *(see, e.g,* Cario, E. "Therapeutic Impact of Toll-like Receptors on Inflammatory Bowel Diseases: A Multiple-edged Sword," *Inflamm. Bowel Dis.*, 14, pp: 411-421 (2008)), inflammation *(see, e.g.,* Dinarello, C. "Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process, " *The American Journal of Clinical Nutrition,* 83, pp: 447S-455S (2006)), acute and chronic gout and gouty arthritis *(see, e.g,* Terkeltaub, R. "Update on gout: new therapeutic strategies and options," *Nature,* vol. 6, pp: 30-38 (2010); Weaver, A. "Epidemiology of gout," *Cleveland Clinic Journal of Medicine,* vol. 75, suppl. 5, pp: S9-S12 (2008); Dalbeth, N. et al., "Hyperuricaemia and gout: state of the art and future

perspectives," *Annals of Rheumatic Diseases,* 69, pp: 1738-1743 (2010); Martinon, F. et al., "Gout-associated uric acid crystals activate the NALP3 inflammasome," *Nature*, vol. 440, pp: 237-241 (2006); So, A. et al., "A pilot study of IL-l inhibition by anakinra in acute gout," *Arthritis Research & Therapy*, vol. 9, no. 2, pp: 1-6 (2007); Terkeltaub, R. et al., "The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study*f Annals of Rheumatic Diseases,* 68, pp: 1613-1617 (2009); Torres, R. et al., "Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis," *Annals of Rheumatic Diseases,* 68, pp: 1602-1608 (2009)), neurological disorders, metabolic syndrome *(see, e.g.,* Troseid, M. "The role of interleukin-18 in the metabolic syndrome," *Cardiovascular Diabetology,* 9:11, pp:l-8 (2010)), immunodeficiency disorders such as AIDS and HIV *(see, e.g,* Iannello, A. et al., "Role of Interleukin-18 in the Development and Pathogenesis of AIDS," *AIDS Reviews,* 11, pp: 115-125 (2009)), destructive bone disorders *(see, e.g,* Hennessy, E., et al., "Targeting Toll-like receptors: emerging therapeutics?" *Nature Reviews,* vol. 9, pp: 293-307 (2010)), osteoarthritis, proliferative disorders, Waldenstrom's Macroglobulinemia *(see, e.g,* Treon, et al., "Whole genome sequencing reveals a widely expressed mutation (MYD88 L265P) with oncogenic activity in Waldenstrom's Macroglobulinemia" 53rd ASH Annual Meeting; Xu, et al., "A somatic variant in MYD88 (L256P) revealed by whole genome sequencing differentiates lymphoplasmacytic lymphoma from marginal zone lymphomas" 53rd ASH Annual Meeting; Yang et al., "Disruption of MYD88 pathway signaling leads to loss of constitutive IRAK1, NK-kB and JAK/STAT signaling and induces apoptosis of cells expressing the MYD88 L265P mutation in Waldenstrom's Macroglobulinemia" 53rd ASH Annual Meeting; Iriyama et al., "Clinical significance of genetic mutations of CD79B, CARD11, MYD88, and EZH2 genes in diffuse large B-cell lymphoma patients" 53rd ASH Annual Meeting; infectious diseases, conditions associated with cell death, pathologic immune conditions involving T cell activation, and CNS disorders in a patient. In one embodiment, a human patient is treated with a compound of the current invention and a pharmaceutically acceptable carrier, adjuvant, or vehicle, wherein said compound is present in an amount to measurably degrade and/or inhibit IRAK-l only, IRAK-2-only, IRAK-4-only and/or IRAK1 and IRAK4 kinase activity.

[00433] Compounds of the current invention are useful in the treatment of a proliferative disease selected from a benign or malignant tumor, solid tumor, carcinoma of the brain, kidney, liver,

adrenal gland, bladder, breast, stomach, gastric tumors, ovaries, colon, rectum, prostate, pancreas, lung, vagina, cervix, testis, genitourinary tract, esophagus, larynx, skin, bone or thyroid, sarcoma, glioblastomas, neuroblastomas, multiple myeloma, gastrointestinal cancer, especially colon carcinoma or colorectal adenoma, a tumor of the neck and head, an epidermal hyperproliferation, psoriasis, prostate hyperplasia, a neoplasia, a neoplasia of epithelial character, adenoma, adenocarcinoma, keratoacanthoma, epidermoid carcinoma, large cell carcinoma, non-small-cell lung carcinoma, lymphomas, Hodgkins and Non-Hodgkins, a mammary carcinoma, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, an IL-l driven disorder, an MyD88 driven disorder, Smoldering of indolent multiple myeloma, or hematological malignancies (including leukemia, diffuse large B-cell lymphoma (DLBCL), ABC DLBCL, chronic lymphocytic leukemia (CLL), chronic lymphocytic lymphoma, primary effusion lymphoma, Burkitt lymphoma/leukemia, acute lymphocytic leukemia, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenstrom's macroglobulinemia (WM), splenic marginal zone lymphoma, multiple myeloma, plasmacytoma, intravascular large B-cell lymphoma).

[00434] In some embodiments the proliferative disease which can be treated according to the methods of this invention is an MyD88 driven disorder. In some embodiments, the MyD88 driven disorder which can be treated according to the methods of this invention is selected from ABC DLBCL, Waldenstrom's macroglobulinemia, Hodgkin's lymphoma, primary cutaneous T-cell lymphoma and chronic lymphocytic leukemia.

[00435] In some embodiments the proliferative disease which can be treated according to the methods of this invention is an IL-l driven disorder. In some embodiments the IL-l driven disorder is Smoldering of indolent multiple myeloma.

[00436] Compounds according to the invention are useful in the treatment of inflammatory or obstructive airways diseases, resulting, for example, in reduction of tissue damage, airways inflammation, bronchial hyperreactivity, remodeling or disease progression. Inflammatory or obstructive airways diseases to which the present invention is applicable include asthma of whatever type or genesis including both intrinsic (non-allergic) asthma and extrinsic (allergic) asthma, mild asthma, moderate asthma, severe asthma, bronchitic asthma, exercise-induced asthma, occupational asthma and asthma induced following bacterial infection. Treatment of asthma is also to be understood as embracing treatment of subjects, e.g. of less than 4 or 5 years

of age, exhibiting wheezing symptoms and diagnosed or diagnosable as "wheezy infants", an established patient category of major medical concern and now often identified as incipient or early-phase asthmatics.

[00437] Compounds according to the invention are useful in the treatment of heteroimmune diseases. Examples of such heteroimmune diseases include, but are not limited to, graft versus host disease, transplantation, transfusion, anaphylaxis, allergies (e.g., allergies to plant pollens, latex, drugs, foods, insect poisons, animal hair, animal dander, dust mites, or cockroach calyx), type I hypersensitivity, allergic conjunctivitis, allergic rhinitis, and atopic dermatitis.

[00438] Prophylactic efficacy in the treatment of asthma will be evidenced by reduced frequency or severity of symptomatic attack, e.g. of acute asthmatic or bronchoconstrictor attack, improvement in lung function or improved airways hyperreactivity. It may further be evidenced by reduced requirement for other, symptomatic therapy, such as therapy for or intended to restrict or abort symptomatic attack when it occurs, for example antiinflammatory or bronchodilatory. Prophylactic benefit in asthma may in particular be apparent in subjects prone to "morning dipping". "Morning dipping" is a recognized asthmatic syndrome, common to a substantial percentage of asthmatics and characterised by asthma attack, e.g. between the hours of about 4 to 6 am, i.e. at a time normally substantially distant form any previously administered symptomatic asthma therapy.

[00439] Compounds of the current invention can be used for other inflammatory or obstructive airways diseases and conditions to which the present invention is applicable and include acute lung injury (ALI), adult/acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary, airways or lung disease (COPD, COAD or COLD), including chronic bronchitis or dyspnea associated therewith, emphysema, as well as exacerbation of airways hyperreactivity consequent to other drug therapy, in particular other inhaled drug therapy. The invention is also applicable to the treatment of bronchitis of whatever type or genesis including, but not limited to, acute, arachidic, catarrhal, croupus, chronic or phthinoid bronchitis. Further inflammatory or obstructive airways diseases to which the present invention is applicable include pneumoconiosis (an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts) of whatever type or genesis, including, for example, aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis and byssinosis.

[00440] With regard to their anti-inflammatory activity, in particular in relation to inhibition of eosinophil activation, compounds of the invention are also useful in the treatment of eosinophil related disorders, e.g. eosinophilia, in particular eosinophil related disorders of the airways (e.g. involving morbid eosinophilic infiltration of pulmonary tissues) including hypereosinophilia as it effects the airways and/or lungs as well as, for example, eosinophil- related disorders of the airways consequential or concomitant to Loffler's syndrome, eosinophilic pneumonia, parasitic (in particular metazoan) infestation (including tropical eosinophilia), bronchopulmonary aspergillosis, polyarteritis nodosa (including Churg-Strauss syndrome), eosinophilic granuloma and eosinophil-related disorders affecting the airways occasioned by drug-reaction.

[00441] Compounds of the invention are also useful in the treatment of inflammatory or allergic conditions of the skin, for example psoriasis, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforma, dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid, lupus erythematosus, systemic lupus erythematosus, pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, epidermolysis bullosa acquisita, acne vulgaris, and other inflammatory or allergic conditions of the skin.

[00442] Compounds of the invention may also be used for the treatment of other diseases or conditions, such as diseases or conditions having an inflammatory component, for example, treatment of diseases and conditions of the eye such as ocular allergy, conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis, diseases affecting the nose including allergic rhinitis, and inflammatory disease in which autoimmune reactions are implicated or having an autoimmune component or etiology, including autoimmune hematological disorders (e.g. hemolytic anemia, aplastic anemia, pure red cell anemia and idiopathic thrombocytopenia), systemic lupus erythematosus, rheumatoid arthritis, polychondritis, scleroderma, Wegener granulamatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (e.g. ulcerative colitis and Crohn's disease), irritable bowel syndrome, celiac disease, periodontitis, hyaline membrane disease, kidney disease, glomerular disease, alcoholic liver disease, multiple sclerosis, endocrine opthalmopathy, Grave's disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, multiple sclerosis, primary biliary cirrhosis, uveitis (anterior and posterior), Sjogren’s syndrome, keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis, systemic juvenile idiopathic arthritis, cryopyrin-associated periodic syndrome, nephritis,

vasculitis, diverticulitis, interstitial cystitis, glomerulonephritis (with and without nephrotic syndrome, e.g. including idiopathic nephrotic syndrome or minal change nephropathy), chronic granulomatous disease, endometriosis, leptospiriosis renal disease, glaucoma, retinal disease, ageing, headache, pain, complex regional pain syndrome, cardiac hypertrophy, musclewasting, catabolic disorders, obesity, fetal growth retardation, hyperchlolesterolemia, heart disease, chronic heart failure, mesothelioma, anhidrotic ecodermal dysplasia, Behcet's disease, incontinentia pigmenti, Paget's disease, pancreatitis, hereditary periodic fever syndrome, asthma (allergic and non-allergic, mild, moderate, severe, bronchitic, and exercise-induced), acute lung injury, acute respiratory distress syndrome, eosinophilia, hypersensitivities, anaphylaxis, nasal sinusitis, ocular allergy, silica induced diseases, COPD (reduction of damage, airways inflammation, bronchial hyperreactivity, remodeling or disease progression), pulmonary disease, cystic fibrosis, acid-induced lung injury, pulmonary hypertension, polyneuropathy, cataracts, muscle inflammation in conjunction with systemic sclerosis, inclusion body myositis, myasthenia gravis, thyroiditis, Addison's disease, lichen planus, Type 1 diabetes, or Type 2 diabetes, appendicitis, atopic dermatitis, asthma, allergy, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, chronic graft rejection, colitis, conjunctivitis, Crohn's disease, cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, Henoch-Schonlein purpura, hepatitis, hidradenitis suppurativa, immunoglobulin A nephropathy, interstitial lung disease, laryngitis, mastitis, meningitis, myelitis myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, phlebitis, pneumonitis, pneumonia, polymyositis, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, ulcerative colitis, uveitis, vaginitis, vasculitis, or vulvitis.

[00443] In some embodiments the inflammatory disease which can be treated according to the methods of this invention is an disease of the skin. In some embodiments, the inflammatory disease of the skin is selected from contact dermatitits, atompic dermatitis, alopecia areata, erythema multiforma, dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid, pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, epidermolysis bullosa acquisita, and other inflammatory or allergic conditions of the skin.

[00444] In some embodiments the inflammatory disease which can be treated according to the methods of this invention is selected from acute and chronic gout, chronic gouty arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, Juvenile rheumatoid arthritis, Systemic jubenile idiopathic arthritis (SJIA), Cryopyrin Associated Periodic Syndrome (CAPS), and osteoarthritis.

[00445] In some embodiments the inflammatory disease which can be treated according to the methods of this invention is a TH17 mediated disease. In some embodiments the TH17 mediated disease is selected from Systemic lupus erythematosus, Multiple sclerosis, and inflammatory bowel disease (including Crohn's disease or ulcerative colitis).

[00446] In some embodiments the inflammatory disease which can be treated according to the methods of this invention is selected from Sjogren's syndrome, allergic disorders, osteoarthritis, conditions of the eye such as ocular allergy, conjunctivitis, keratoconjunctivitis sicca and vernal conjunctivitis, and diseases affecting the nose such as allergic rhinitis.

[00447] Cardiovascular diseases which can be treated according to the methods of this invention include, but are not limited to, restenosis, cardiomegaly, atherosclerosis, myocardial infarction, ischemic stroke, congestive heart failure, angina pectoris, reocclusion after angioplasty, restenosis after angioplasty, reocclusion after aortocoronary bypass, restenosis after aortocoronary bypass, stroke, transitory ischemia, a peripheral arterial occlusive disorder, pulmonary embolism, and deep venous thrombosis.

[00448] In some embodiments, the neurodegenerative disease which can be treated according to the methods of this invention include, but are not limited to, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cerebral ischemia, and neurodegenerative disease caused by traumatic injury, glutamate neurotoxicity, hypoxia, epilepsy, treatment of diabetes, metabolic syndrome, obesity, organ transplantation and graft versus host disease.

[00449] The loss of IRAK4 function results in decreased Aβ levels in an *in vivo* murine model of Alzheimer's disease and was associated with diminished microgliosis and astrogliosis in aged mice. Analysis of microglia isolated from the adult mouse brain revealed an altered pattern of gene expression associated with changes in microglial phenotype that were associated with expression of IRF transcription factors that govern microglial phenotype. Further, loss of IRAK4 function also promoted amyloid clearance mechanisms, including elevated expression of insulin-degrading enzyme. Finally, blocking IRAK function restored olfactory behavior (Cameron *et al.* "Loss of

Interleukin Receptor-Associated Kinase 4 Signaling Suppresses Amyloid Pathology and Alters Microglial Phenotype in a Mouse Model of Alzheimer's Disease" Journal of Neuroscience (2012) 32(43), 15112-15123.

[00450] In some embodiments the invention provides a method of treating, preventing or lessening the severity of Alzheimer's disease comprising administering to a patient in need thereof a compound of formula I or a pharmaceutically acceptable salt or composition thereof.

[00451] In some embodiments the invention provides a method of treating a disease or condition commonly occurring in connection with transplantation. In some embodiments, the disease or condition commonly occurring in connection with transplantation is selected from organ transplantation, organ transplant rejection, and graft versus host disease.

[00452] In some embodiments the invention provides a method of treating a metabolic disease. In some embodiments the metabolic disease is selected from Type 1 diabetes, Type 2 diabetes, metabolic syndrome, and obesity.

[00453] In some embodiments the invention provides a method of treating a viral disease. In some embodiments, the viral infection is HIV infection.

[00454] Furthermore, the invention provides the use of a compound according to the definitions herein, or a pharmaceutically acceptable salt, or a hydrate or solvate thereof for the preparation of a medicament for the treatment of a proliferative disease, an inflammatory disease, an obstructive respiratory disease, a cardiovascular disease, a metabolic disease, a neurological disease, a neurodegenerative disease, a viral disease, or a disorder commonly occurring in connection with transplantation.

Combination Therapies

[00455] Depending upon the particular condition, or disease, to be treated, additional therapeutic agents, which are normally administered to treat that condition, may be administered in combination with compounds and compositions of this invention. As used herein, additional therapeutic agents that are normally administered to treat a particular disease, or condition, are known as "appropriate for the disease, or condition, being treated."

[00456] In certain embodiments, a provided combination, or composition thereof, is administered in combination with another therapeutic agent.

[00457] In some embodiments, the present invention provides a method of treating a disclosed disease or condition comprising administering to a patient in need thereof an effective amount of a compound disclosed herein or a pharmaceutically acceptable salt thereof and co-administering simultaneously or sequentially an effective amount of one or more additional therapeutic agents, such as those described herein. In some embodiments, the method includes co-administering one additional therapeutic agent. In some embodiments, the method includes co-administering two additional therapeutic agents. In some embodiments, the combination of the disclosed compound and the additional therapeutic agent or agents acts synergistically.

[00458] Examples of agents the combinations of this invention may also be combined with include, without limitation: treatments for Alzheimer's Disease such as Aricept® and Exelon®; treatments for HIV such as ritonavir; treatments for Parkinson's Disease such as L-DOPA/carbidopa, entacapone, ropinrole, pramipexole, bromocriptine, pergolide, trihexephendyl, and amantadine; agents for treating Multiple Sclerosis (MS) such as beta interferon (e.g., Avonex® and Rebif®), Copaxone®, and mitoxantrone; treatments for asthma such as albuterol and Singulair®; agents for treating schizophrenia such as zyprexa, risperdal, seroquel, and haloperidol; anti-inflammatory agents such as corticosteroids, TNF blockers, IL-l RA, azathioprine, cyclophosphamide, and sulfasalazine; immunomodulatory and immunosuppressive agents such as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, interferons, corticosteroids, cyclophophamide, azathioprine, and sulfasalazine; neurotrophic factors such as acetylcholinesterase inhibitors, MAO inhibitors, interferons, anti-convulsants, ion channel blockers, riluzole, and anti-Parkinsonian agents; agents for treating cardiovascular disease such as beta-blockers, ACE inhibitors, diuretics, nitrates, calcium channel blockers, and statins; agents for treating liver disease such as corticosteroids, cholestyramine, interferons, and anti-viral agents; agents for treating blood disorders such as corticosteroids, anti-leukemic agents, and growth factors; agents that prolong or improve pharmacokinetics such as cytochrome P450 inhibitors (i.e., inhibitors of metabolic breakdown) and CYP3A4 inhibitors (e.g., ketokenozole and ritonavir), and agents for treating immunodeficiency disorders such as gamma globulin.

[00459] In certain embodiments, combination therapies of the present invention, or a pharmaceutically acceptable composition thereof, are administered in combination with a monoclonal antibody or an siRNA therapeutic.

[00460] Those additional agents may be administered separately from a provided combination

therapy, as part of a multiple dosage regimen. Alternatively, those agents may be part of a single dosage form, mixed together with a compound of this invention in a single composition. If administered as part of a multiple dosage regime, the two active agents may be submitted simultaneously, sequentially or within a period of time from one another normally within five hours from one another.

[00461] As used herein, the term "combination," "combined," and related terms refers to the simultaneous or sequential administration of therapeutic agents in accordance with this invention. For example, a combination of the present invention may be administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form.

[00462] The amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.

[00463] One or more other therapeutic agent may be administered separately from a compound or composition of the invention, as part of a multiple dosage regimen. Alternatively, one or more other therapeutic agents agents may be part of a single dosage form, mixed together with a compound of this invention in a single composition. If administered as a multiple dosage regime, one or more other therapeutic agent and a compound or composition of the invention may be administered simultaneously, sequentially or within a period of time from one another, for example within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 18, 20, 21, 22, 23, or 24 hours from one another. In some embodiments, one or more other therapeutic agent and a compound or composition of the invention are administerd as a multiple dosage regimen within greater than 24 hours aparts.

[00464] In one embodiment, the present invention provides a composition comprising a compound of formula **I** and one or more additional therapeutic agents. The therapeutic agent may be administered together with a compound of formula **I,** or may be administered prior to or following administration of a compound of formula **I**. Suitable therapeutic agents are described in further detail below. In certain embodiments, a compound of formula **I** may be administered

up to 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5, hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, or 18 hours before the therapeutic agent. In other embodiments, a compound of formula **I** may be administered up to 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5, hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, or 18 hours following the therapeutic agent.

[00465] In another embodiment, the present invention provides a method of treating an inflammatory disease, disorder or condition by administering to a patient in need thereof a compound of formula **I** and one or more additional therapeutic agents. Such additional therapeutic agents may be small molecules or recombinant biologic agents and include, for example, acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, etodolac (Lodine®) and celecoxib, colchicine (Colcrys®), corticosteroids such as prednisone, prednisolone, methylprednisolone, hydrocortisone, and the like, probenecid, allopurinol, febuxostat (Uloric®), sulfasalazine (Azulfidine®), antimalarials such as hydroxychloroquine (Plaquenil®) and chloroquine (Aralen®), methotrexate (Rheumatrex®), gold salts such as gold thioglucose (Solganal®), gold thiomalate (Myochrysine®) and auranofm (Ridaura®), D-penicillamine (Depen® or Cuprimine®), azathioprine (Imuran®), cyclophosphamide (Cytoxan®), chlorambucil (Leukeran®), cyclosporine (Sandimmune®), leflunomide (Arava®) and “anti-TNF” agents such as etanercept (Enbrel®), infliximab (Remicade®), golimumab (Simponi®), certolizumab pegol (Cimzia®) and adalimumab (Humira®), “anti-rL-l” agents such as anakinra (Kineret®) and rilonacept (Arcalyst®), canakinumab (Haris®), anti-Jak inhibitors such as tofacitinib, antibodies such as rituximab (Rituxan®), “anti-T-cell” agents such as abatacept (Orencia®), “anti-IL-6” agents such as tocilizumab (Actemra®), diclofenac, cortisone, hyaluronic acid (Synvisc® or Hyalgan®), monoclonal antibodies such as tanezumab, anticoagulants such as heparin (Calcinparine® or Liquaemin®) and warfarin (Coumadin®), antidiarrheals such as diphenoxylate (Lomotil®) and loperamide (Imodium®), bile acid binding agents such as cholestyramine, alosetron (Lotronex®), lubiprostone (Amitiza®), laxatives such as Milk of Magnesia, polyethylene glycol (MiraLax®), Dulcolax®, Correctol® and Senokot®, anticholinergics or antispasmodics such as dicyclomine (Bentyl®), Singulair®, beta-2 agonists such as albuterol (Ventolin® HFA, Proventil® HFA), levalbuterol (Xopenex®), metaproterenol (Alupent®), pirbuterol acetate (Maxair®), terbutaline

sulfate (Brethaire®), salmeterol xinafoate (Serevent®) and formoterol (Foradil®), anticholinergic agents such as ipratropium bromide (Atrovent®) and tiotropium (Spiriva®), inhaled corticosteroids such as beclomethasone dipropionate (Beclovent®, Qvar®, and Vanceril®), triamcinolone acetonide (Azmacort®), mometasone (Asthmanex®), budesonide (Pulmocort®), and flunisolide (Aerobid®), Afviar®, Symbicort®, Dulera®, cromolyn sodium (Intal®), methylxanthines such as theophylline (Theo-Dur®, Theolair®, Slo-bid®, Uniphyl®, Theo-24®) and aminophylline, IgE antibodies such as omalizumab (Xolair®), nucleoside reverse transcriptase inhibitors such as zidovudine (Retrovir®), abacavir (Ziagen®), abacavir/lamivudine (Epzicom®), abacavir/lamivudine/zidovudine (Trizivir®), didanosine (Videx®), emtricitabine (Emtriva®), lamivudine (Epivir®), lamivudine/zidovudine (Combivir®), stavudine (Zerit®), and zalcitabine (Hivid®), non-nucleoside reverse transcriptase inhibitors such as delavirdine (Rescriptor®), efavirenz (Sustiva®), nevairapine (Viramune®) and etravirine (Intelence®), nucleotide reverse transcriptase inhibitors such as tenofovir (Viread®), protease inhibitors such as amprenavir (Agenerase®), atazanavir (Reyataz®), darunavir (Prezista®), fosamprenavir (Lexiva®), indinavir (Crixivan®), lopinavir and ritonavir (Kaletra®), nelfmavir (Viracept®), ritonavir (Norvir®), saquinavir (Fortovase® or Invirase®), and tipranavir (Aptivus®), entry inhibitors such as enfuvirtide (Fuzeon®) and maraviroc (Selzentry®), integrase inhibitors such as raltegravir (Isentress®), doxorubicin (Hydrodaunorubicin®), vincristine (Oncovin®), bortezomib (Velcade®), and dexamethasone (Decadron ®) in combination with lenalidomide (Revlimid ®), or any combination(s) thereof.

[00466] In another embodiment, the present invention provides a method of treating gout comprising administering to a patient in need thereof a compound of formula **I** and one or more additional therapeutic agents selected from non-steroidal anti-inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, etodolac (Lodine®) and celecoxib, colchicine (Colcrys®), corticosteroids such as prednisone, prednisolone, methylprednisolone, hydrocortisone, and the like, probenecid, allopurinol and febuxostat (Uloric®).

[00467] In another embodiment, the present invention provides a method of treating rheumatoid arthritis comprising administering to a patient in need thereof a compound of formula **I** and one or more additional therapeutic agents selected from non-steroidal anti-inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, etodolac (Lodine®) and celecoxib, corticosteroids such as prednisone, prednisolone, methylprednisolone, hydrocortisone, and the like, sulfasalazine

(Azulfidine®), antimalarials such as hydroxychloroquine (Plaquenil®) and chloroquine (Aralen®), methotrexate (Rheumatrex®), gold salts such as gold thioglucose (Solganal®), gold thiomalate (Myochrysine®) and auranofm (Ridaura®), D-penicillamine (Depen® or Cuprimine®), azathioprine (Imuran®), cyclophosphamide (Cytoxan®), chlorambucil (Leukeran®), cyclosporine (Sandimmune®), leflunomide (Arava®) and "anti-TNF" agents such as etanercept (Enbrel®), infliximab (Remicade®), golimumab (Simponi®), certolizumab pegol (Cimzia®) and adalimumab (Humira®), "anti-IL-l" agents such as anakinra (Kineret®) and rilonacept (Arcalyst®), antibodies such as rituximab (Rituxan®), "anti-T-cell" agents such as abatacept (Orencia®) and "anti-IL-6" agents such as tocilizumab (Actemra®).

[00468] In some embodiments, the present invention provides a method of treating osteoarthritis comprising administering to a patient in need thereof a compound of formula **I** and one or more additional therapeutic agents selected from acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, etodolac (Lodine®) and celecoxib, diclofenac, cortisone, hyaluronic acid (Synvisc® or Hyalgan®) and monoclonal antibodies such as tanezumab.

[00469] In some embodiments, the present invention provides a method of treating lupus comprising administering to a patient in need thereof a compound of formula **I** and one or more additional therapeutic agents selected from acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, etodolac (Lodine®) and celecoxib, corticosteroids such as prednisone, prednisolone, methylprednisolone, hydrocortisone, and the like, antimalarials such as hydroxychloroquine (Plaquenil®) and chloroquine (Aralen®), cyclophosphamide (Cytoxan®), methotrexate (Rheumatrex®), azathioprine (Imuran®) and anticoagulants such as heparin (Calcinparine® or Liquaemin®) and warfarin (Coumadin®).

[00470] In some embodiments, the present invention provides a method of treating inflammatory bowel disease comprising administering to a patient in need thereof a compound of formula **I** and one or more additional therapeutic agents selected from mesalamine (Asacol®) sulfasalazine (Azulfidine®), antidiarrheals such as diphenoxylate (Lomotil®) and loperamide (Imodium®), bile acid binding agents such as cholestyramine, alosetron (Lotronex®), lubiprostone (Amitiza®), laxatives such as Milk of Magnesia, polyethylene glycol (MiraLax®), Dulcolax®, Correctol® and Senokot® and anticholinergics or antispasmodics such as dicyclomine (Bentyl®), anti-TNF therapies, steroids, and antibiotics such as Flagyl or ciprofloxacin.

[00471] In some embodiments, the present invention provides a method of treating asthma comprising administering to a patient in need thereof a compound of formula **I** and one or more additional therapeutic agents selected from Singulair®, beta-2 agonists such as albuterol (Ventolin® HFA, Proventil® HFA), levalbuterol (Xopenex®), metaproterenol (Alupent®), pirbuterol acetate (Maxair®), terbutaline sulfate (Brethaire®), salmeterol xinafoate (Serevent®) and formoterol (Foradil®), anticholinergic agents such as ipratropium bromide (Atrovent®) and tiotropium (Spiriva®), inhaled corticosteroids such as prednisone, prednisolone, beclomethasone dipropionate (Beclovent®, Qvar®, and Vanceril®), triamcinolone acetonide (Azmacort®), mometasone (Asthmanex®), budesonide (Pulmocort®), flunisolide (Aerobid®), Afviar®, Symbicort®, and Dulera®, cromolyn sodium (Intal®), methylxanthines such as theophylline (Theo-Dur®, Theolair®, Slo-bid®, Uniphyl®, Theo-24®) and aminophylline, and IgE antibodies such as omalizumab (Xolair®).

[00472] In some embodiments, the present invention provides a method of treating COPD comprising administering to a patient in need thereof a compound of formula **I** and one or more additional therapeutic agents selected from beta-2 agonists such as albuterol (Ventolin® HFA, Proventil® HFA), levalbuterol (Xopenex®), metaproterenol (Alupent®), pirbuterol acetate (Maxair®), terbutaline sulfate (Brethaire®), salmeterol xinafoate (Serevent®) and formoterol (Foradil®), anticholinergic agents such as ipratropium bromide (Atrovent®) and tiotropium (Spiriva®), methylxanthines such as theophylline (Theo-Dur®, Theolair®, Slo-bid®, Uniphyl®, Theo-24®) and aminophylline, inhaled corticosteroids such as prednisone, prednisolone, beclomethasone dipropionate (Beclovent®, Qvar®, and Vanceril®), triamcinolone acetonide (Azmacort®), mometasone (Asthmanex®), budesonide (Pulmocort®), flunisolide (Aerobid®), Afviar®, Symbicort®, and Dulera®,

[00473] In some embodiments, the present invention provides a method of treating HIV comprising administering to a patient in need thereof a compound of formula **I** and one or more additional therapeutic agents selected from nucleoside reverse transcriptase inhibitors such as zidovudine (Retrovir®), abacavir (Ziagen®), abacavir/lamivudine (Epzicom®), abacavir/lamivudine/zidovudine (Trizivir®), didanosine (Videx®), emtricitabine (Emtriva®), lamivudine (Epivir®), lamivudine/zidovudine (Combivir®), stavudine (Zerit®), and zalcitabine (Hivid®), non-nucleoside reverse transcriptase inhibitors such as delavirdine (Rescriptor®), efavirenz (Sustiva®), nevairapine (Viramune®) and etravirine (Intelence®), nucleotide reverse

transcriptase inhibitors such as tenofovir (Viread®), protease inhibitors such as amprenavir (Agenerase®), atazanavir (Reyataz®), darunavir (Prezista®), fosamprenavir (Lexiva®), indinavir (Crixivan®), lopinavir and ritonavir (Kaletra®), nelfmavir (Viracept®), ritonavir (Norvir®), saquinavir (Fortovase® or Invirase®), and tipranavir (Aptivus®), entry inhibitors such as enfuvirtide (Fuzeon®) and maraviroc (Selzentry®), integrase inhibitors such as raltegravir (Isentress®), and combinations thereof.

[00474] In another embodiment, the present invention provides a method of treating a hematological malignancy comprising administering to a patient in need thereof a compound of formula **I** and one or more additional therapeutic agents selected from rituximab (Rituxan®), cyclophosphamide (Cytoxan®), doxorubicin (Hydrodaunorubicin®), vincristine (Oncovin®), prednisone, a hedgehog signaling inhibitor, a BTK inhibitor, a JAK/pan-JAK inhibitor, a TYK2 inhibitor, a PI3K inhibitor, a SYK inhibitor, and combinations thereof.

[00475] In another embodiment, the present invention provides a method of treating a solid tumor comprising administering to a patient in need thereof a compound of formula **I** and one or more additional therapeutic agents selected from rituximab (Rituxan®), cyclophosphamide (Cytoxan®), doxorubicin (Hydrodaunorubicin®), vincristine (Oncovin®), prednisone, a hedgehog signaling inhibitor, a BTK inhibitor, a JAK/pan-JAK inhibitor, a TYK2 inhibitor, a PI3K inhibitor, a SYK inhibitor, and combinations thereof.

[00476] In another embodiment, the present invention provides a method of treating a hematological malignancy comprising administering to a patient in need thereof a compound of formula **I** and a Hedgehog (Hh) signaling pathway inhibitor. In some embodiments, the hematological malignancy is DLBCL (Ramirez *et al* "Defining causative factors contributing in the activation of hedgehog signaling in diffuse large B-cell lymphoma" Leuk. Res. (2012), published online July 17, and incorporated herein by reference in its entirety).

[00477] In another embodiment, the present invention provides a method of treating diffuse large B-cell lymphoma (DLBCL) comprising administering to a patient in need thereof a compound of formula **I** and one or more additional therapeutic agents selected from rituximab (Rituxan®), cyclophosphamide (Cytoxan®), doxorubicin (Hydrodaunorubicin®), vincristine (Oncovin®), prednisone, a hedgehog signaling inhibitor, and combinations thereof.

[00478] In another embodiment, the present invention provides a method of treating multiple myeloma comprising administering to a patient in need thereof a compound of formula **I** and one

or more additional therapeutic agents selected from bortezomib (Velcade®), and dexamethasone (Decadron®), a hedgehog signaling inhibitor, a BTK inhibitor, a JAK/pan-JAK inhibitor, a TYK2 inhibitor, a PI3K inhibitor, a SYK inhibitor in combination with lenalidomide (Revlimid®).

[00479] In another embodiment, the present invention provides a method of treating Waldenstrom's macroglobulinemia comprising administering to a patient in need thereof a compound of formula **I** and one or more additional therapeutic agents selected from chlorambucil (Leukeran®), cyclophosphamide (Cytoxan®, Neosar®), fludarabine (Fludara®), cladribine (Leustatin®), rituximab (Rituxan®), a hedgehog signaling inhibitor, a BTK inhibitor, a JAK/pan-JAK inhibitor, a TYK2 inhibitor, a PI3K inhibitor, and a SYK inhibitor.

[00480] In some embodiments, one or more other therapeutic agent is an antagonist of the hedgehog pathway. Approved hedgehog pathway inhibitors which may be used in the present invention include sonidegib (Odomzo®, Sun Pharmaceuticals); and vismodegib (Erivedge®, Genentech), both for treatment of basal cell carcinoma.

[00481] In some embodiments, one or more other therapeutic agent is a Poly ADP ribose polymerase (PARP) inhibitor. In some embodiments, a PARP inhibitor is selected from olaparib (Lynparza®, AstraZeneca); rucaparib (Rubraca®, Clovis Oncology); niraparib (Zejula®, Tesaro); talazoparib (MDV3800/BMN 673/LT00673, Medivation/Pfizer/Biomarin); veliparib (ABT-888, AbbVie); and BGB-290 (BeiGene, Inc.).

[00482] In some embodiments, one or more other therapeutic agent is a histone deacetylase (HDAC) inhibitor. In some embodiments, an HDAC inhibitor is selected from vorinostat (Zolinza®, Merck); romidepsin (Istodax®, Celgene); panobinostat (Farydak®, Novartis); belinostat (Beleodaq®, Spectrum Pharmaceuticals); entinostat (SNDX-275, Syndax Pharmaceuticals) (NCT00866333); and chidamide (Epidaza®, HBI-8000, Chipscreen Biosciences, China).

[00483] In some embodiments, one or more other therapeutic agent is a CDK inhibitor, such as a CDK4/CDK6 inhibitor. In some embodiments, a CDK 4/6 inhibitor is selected from palbociclib (Ibrance®, Pfizer); ribociclib (Kisqali®, Novartis); abemaciclib (Ly28352l9, Eli Lilly); and trilaciclib (G1T28, G1 Therapeutics).

[00484] In some embodiments, one or more other therapeutic agent is a folic acid inhibitor. Approved folic acid inhibitors useful in the present invention include pemetrexed (Alimta®, Eli Lilly).

[00485] In some embodiments, one or more other therapeutic agent is a CC chemokine receptor 4 (CCR4) inhibitor. CCR4 inhibitors being studied that may be useful in the present invention include mogamulizumab (Poteligeo®, Kyowa Hakko Kirin, Japan).

[00486] In some embodiments, one or more other therapeutic agent is an isocitrate dehydrogenase (IDH) inhibitor. IDH inhibitors being studied which may be used in the present invention include AG120 (Celgene; NCT02677922); AG221 (Celgene, NCT02677922; NCT02577406); BAY1436032 (Bayer, NCT02746081); IDH305 (Novartis, NCT02987010).

[00487] In some embodiments, one or more other therapeutic agent is an arginase inhibitor. Arginase inhibitors being studied which may be used in the present invention include AEB1102 (pegylated recombinant arginase, Aeglea Biotherapeutics), which is being studied in Phase 1 clinical trials for acute myeloid leukemia and myelodysplastic syndrome (NCT02732184) and solid tumors (NCT02561234); and CB-1158 (Calithera Biosciences).

[00488] In some embodiments, one or more other therapeutic agent is a glutaminase inhibitor. Glutaminase inhibitors being studied which may be used in the present invention include CB-839 (Calithera Biosciences).

[00489] In some embodiments, one or more other therapeutic agent is an antibody that binds to tumor antigens, that is, proteins expressed on the cell surface of tumor cells. Approved antibodies that bind to tumor antigens which may be used in the present invention include rituximab (Rituxan®, Genentech/Biogenldec); ofatumumab (anti-CD20, Arzerra®, GlaxoSmithKline); obinutuzumab (anti-CD20, Gazyva®, Genentech), ibritumomab (anti-CD20 and Yttrium-90, Zevalin®, Spectrum Pharmaceuticals); daratumumab (anti-CD38, Darzalex®, Janssen Biotech), dinutuximab (anti-glycolipid GD2, Unituxin®, United Therapeutics); trastuzumab (anti-HER2, Herceptin®, Genentech); ado-trastuzumab emtansine (anti-HER2, fused to emtansine, Kadcyla®, Genentech); and pertuzumab (anti-HER2, Peijeta®, Genentech); and brentuximab vedotin (anti-CD30-drug conjugate, Adcetris®, Seattle Genetics).

[00490] In some embodiments, one or more other therapeutic agent is a topoisomerase inhibitor. Approved topoisomerase inhibitors useful in the present invention include irinotecan (Onivyde®, Merrimack Pharmaceuticals); topotecan (Hycamtin®, GlaxoSmithKline). Topoisomerase inhibitors being studied which may be used in the present invention include pixantrone (Pixuvri®, CTI Biopharma).

[00491] In some embodiments, one or more other therapeutic agent is an inhibitor of anti-apoptotic proteins, such as BCL-2. Approved anti-apoptotics which may be used in the present invention include venetoclax (Venclexta®, AbbVie/Genentech); and blinatumomab (Blincyto®, Amgen). Other therapeutic agents targeting apoptotic proteins which have undergone clinical testing and may be used in the present invention include navitoclax (ABT-263, Abbott), a BCL-2 inhibitor (NCT02079740).

[00492] In some embodiments, one or more other therapeutic agent is an androgen receptor inhibitor. Approved androgen receptor inhibitors useful in the present invention include enzalutamide (Xtandi®, Astellas/Medivation); approved inhibitors of androgen synthesis include abiraterone (Zytiga®, Centocor/Ortho); approved antagonist of gonadotropin-releasing hormone (GnRH) receptor (degaralix, Firmagon®, Ferring Pharmaceuticals).

[00493] In some embodiments, one or more other therapeutic agent is a selective estrogen receptor modulator (SERM), which interferes with the synthesis or activity of estrogens. Approved SERMs useful in the present invention include raloxifene (Evista®, Eli Lilly).

[00494] In some embodiments, one or more other therapeutic agent is an inhibitor of bone resorption. An approved therapeutic which inhibits bone resorption is Denosumab (Xgeva®, Amgen), an antibody that binds to RANKL, prevents binding to its receptor RANK, found on the surface of osteoclasts, their precursors, and osteoclast-like giant cells, which mediates bone pathology in solid tumors with osseous metastases. Other approved therapeutics that inhibit bone resorption include bisphosphonates, such as zoledronic acid (Zometa®, Novartis).

[00495] In some embodiments, one or more other therapeutic agent is an inhibitor of interaction between the two primary p53 suppressor proteins, MDMX and MDM2. Inhibitors of p53 suppression proteins being studied which may be used in the present invention include ALRN-6924 (Aileron), a stapled peptide that equipotently binds to and disrupts the interaction of MDMX and MDM2 with p53. ALRN-6924 is currently being evaluated in clinical trials for the treatment of AML, advanced myelodysplastic syndrome (MDS) and peripheral T-cell lymphoma (PTCL) (NCT02909972; NCT02264613).

[00496] In some embodiments, one or more other therapeutic agent is an inhibitor of transforming growth factor-beta (TGF-beta or TGFB). Inhibitors of TGF-beta proteins being studied which may be used in the present invention include NIS793 (Novartis), an anti-TGF-beta antibody being tested in the clinic for treatment of various cancers, including breast, lung,

hepatocellular, colorectal, pancreatic, prostate and renal cancer (NCT 02947165). In some embodiments, the inhibitor of TGF-beta proteins is fresolimumab (GC1008; Sanofi-Genzyme), which is being studied for melanoma (NCT00923 169); renal cell carcinoma (NCT003 56460); and non-small cell lung cancer (NCT02581787). Additionally, in some embodiments, the additional therapeutic agent is a TGF-beta trap, such as described in Connolly et al. (2012) Int'l J. Biological Sciences 8:964-978. One therapeutic compound currently in clinical trials for treatment of solid tumors is M7824 (Merck KgaA - formerly MSB0011459X), which is a bispecific, anti-PD-Ll/TGFB trap compound (NCT02699515); and (NCT025 17398). M7824 is comprised of a fully human IgGl antibody against PD-L1 fused to the extracellular domain of human TGF-beta receptor II, which functions as a TGFB "trap."

[00497] In some embodiments, one or more other therapeutic agent is selected from glembatumumab vedotin-monomethyl auristatin E (MMAE) (Celldex), an anti-glycoprotein NMB (gpNMB) antibody (CR011) linked to the cytotoxic MMAE. gpNMB is a protein overexpressed by multiple tumor types associated with cancer cells' ability to metastasize.

[00498] In some embodiments, one or more other therapeutic agent is an antiproliferative compound. Such antiproliferative compounds include, but are not limited to aromatase inhibitors; antiestrogens; topoisomerase I inhibitors; topoisomerase II inhibitors; microtubule active compounds; alkylating compounds; histone deacetylase inhibitors; compounds which induce cell differentiation processes; cyclooxygenase inhibitors; MMP inhibitors; mTOR inhibitors; antineoplastic antimetabolites; platin compounds; compounds targeting/decreasing a protein or lipid kinase activity and further anti-angiogenic compounds; compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase; gonadorelin agonists; anti-androgens; methionine aminopeptidase inhibitors; matrix metalloproteinase inhibitors; bisphosphonates; biological response modifiers; antiproliferative antibodies; heparanase inhibitors; inhibitors of Ras oncogenic isoforms; telomerase inhibitors; proteasome inhibitors; compounds used in the treatment of hematologic malignancies; compounds which target, decrease or inhibit the activity of Flt-3; Hsp90 inhibitors such as 17-AAG (l7-allylaminogeldanamycin, NSC330507), 17-DMAG (l7-dimethylaminoethylamino-l7-demethoxy-geldanamycin, NSC707545), IPI-504, CNF 1010, CNF2024, CNF1010 from Conforma Therapeutics; temozolomide (Temodal®); kinesin spindle protein inhibitors, such as SB715992 or SB743921 from GlaxoSmithKline, or

pentamidine/chlorpromazine from CombinatoRx; MEK inhibitors such as ARRY142886 from Array BioPharma, AZd$_6$244 from AstraZeneca, PD 18 1461 from Pfizer and leucovorin.

[00499] In some embodiments, the present invention provides a method of treating Alzheimer's disease comprising administering to a patient in need thereof a compound of formula **I** and one or more additional therapeutic agents selected from donepezil (Aricept ®), rivastigmine (Excelon ®), galantamine (Razadyne ®), tacrine (Cognex ®), and memantine (Namenda ®).

[00500] In some embodiments, one or more other therapeutic agent is a taxane compound, which causes disruption of microtubules, which are essential for cell division. In some embodiments, a taxane compound is selected from paclitaxel (Taxol®, Bristol-Myers Squibb), docetaxel (Taxotere®, Sanofi-Aventis; Docefrez®, Sun Pharmaceutical), albumin-bound paclitaxel (Abraxane®; Abraxis/Celgene), cabazitaxel (Jevtana®, Sanofi-Aventis), and SID530 (SK Chemicals, Co.) (NCT00931008).

[00501] In some embodiments, one or more other therapeutic agent is a nucleoside inhibitor, or a therapeutic agent that interferes with normal DNA synthesis, protein synthesis, cell replication, or will otherwise inhibit rapidly proliferating cells.

[00502] In some embodiments, a nucleoside inhibitor is selected from trabectedin (guanidine alkylating agent, Yondelis®, Janssen Oncology), mechlorethamine (alkylating agent, Valchlor®, Aktelion Pharmaceuticals); vincristine (Oncovin®, Eli Lilly; Vincasar®, Teva Pharmaceuticals; Marqibo®, Talon Therapeutics); temozolomide (prodrug to alkylating agent 5-(3-methyltriazen-l-yl)-imidazole-4-carboxamide (MTIC) Temodar®, Merck); cytarabine injection (ara-C, antimetabolic cytidine analog, Pfizer); lomustine (alkylating agent, CeeMJ®, Bristol-Myers Squibb; Gleostine®, NextSource Biotechnology); azacitidine (pyrimidine nucleoside analog of cytidine, Vidaza®, Celgene); omacetaxine mepesuccinate (cephalotaxine ester) (protein synthesis inhibitor, Synribo®; Teva Pharmaceuticals); asparaginase *Erwinia chrysanthemi* (enzyme for depletion of asparagine, Elspar®, Lundbeck; Erwinaze®, EETSA Pharma); eribulin mesylate (microtubule inhibitor, tubulin-based antimitotic, Halaven®, Eisai); cabazitaxel (microtubule inhibitor, tubulin-based antimitotic, Jevtana®, Sanofi-Aventis); capacetrine (thymidylate synthase inhibitor, Xeloda®, Genentech); bendamustine (bifunctional mechlorethamine derivative, believed to form interstrand DNA cross-links, Treanda®, Cephalon/Teva); ixabepilone (semi-synthetic analog of epothilone B, microtubule inhibitor, tubulin-based antimitotic, Ixempra®, Bristol-Myers Squibb); nelarabine (prodrug of deoxyguanosine analog, nucleoside metabolic

inhibitor, Arranon®, Novartis); clorafabine (prodrug of ribonucleotide reductase inhibitor, competitive inhibitor of deoxycytidine, Clolar®, Sanofi-Aventis); and trifluridine and tipiracil (thymidine-based nucleoside analog and thymidine phosphorylase inhibitor, Lonsurf®, Taiho Oncology).

[00503] In some embodiments, one or more other therapeutic agent is a kinase inhibitor or VEGF-R antagonist. Approved VEGF inhibitors and kinase inhibitors useful in the present invention include: bevacizumab (Avastin®, Genentech/Roche) an anti-VEGF monoclonal antibody; ramucirumab (Cyramza®, Eli Lilly), an anti-VEGFR-2 antibody and ziv-aflibercept, also known as VEGF Trap (Zaltrap®; Regeneron/Sanofi). VEGFR inhibitors, such as regorafenib (Stivarga®, Bayer); vandetanib (Caprelsa®, AstraZeneca); axitinib (Inlyta®, Pfizer); and lenvatinib (Lenvima®, Eisai); Raf inhibitors, such as sorafenib (Nexavar®, Bayer AG and Onyx); dabrafenib (Tafmlar®, Novartis); and vemurafenib (Zelboraf®, Genentech/Roche); MEK inhibitors, such as cobimetanib (Cotellic®, Exelexis/Genentech/Roche); trametinib (Mekinist®, Novartis); Bcr-Abl tyrosine kinase inhibitors, such as imatinib (Gleevec®, Novartis); nilotinib (Tasigna®, Novartis); dasatinib (Sprycel®, BristolMyersSquibb); bosutinib (Bosulif®, Pfizer); and ponatinib (Inclusig®, Ariad Pharmaceuticals); Her2 and EGFR inhibitors, such as gefitinib (Iressa®, AstraZeneca); erlotinib (Tarceeva®, Genentech/Roche/Astellas); lapatinib (Tykerb®, Novartis); afatinib (Gilotrif®, Boehringer Ingelheim); osimertinib (targeting activated EGFR, Tagrisso®, AstraZeneca); and brigatinib (Alunbrig®, Ariad Pharmaceuticals); c-Met and VEGFR2 inhibitors, such as cabozanitib (Cometriq®, Exelexis); and multikinase inhibitors, such as sunitinib (Sutent®, Pfizer); pazopanib (Votrient®, Novartis); ALK inhibitors, such as crizotinib (Xalkori®, Pfizer); ceritinib (Zykadia®, Novartis); and alectinib (Alecenza®, Genentech/Roche); Bruton's tyrosine kinase inhibitors, such as ibrutinib (Imbruvica®, Pharmacyclics/Janssen); and Flt3 receptor inhibitors, such as midostaurin (Rydapt®, Novartis).

[00504] Other kinase inhibitors and VEGF-R antagonists that are in development and may be used in the present invention include tivozanib (Aveo Pharmaecuticals); vatalanib (Bayer/Novartis); lucitanib (Clovis Oncology); dovitinib (TKI258, Novartis); Chiauanib (Chipscreen Biosciences); CEP-11981 (Cephalon); linifanib (Abbott Laboratories); neratinib (HKI-272, Puma Biotechnology); radotinib (Supect®, IY5511, Il-Yang Pharmaceuticals, S. Korea); ruxolitinib (Jakafi®, Incyte Corporation); PTC299 (PTC Therapeutics); CP-547,632

(Pfizer); foretinib (Exelexis, GlaxoSmithKline); quizartinib (Daiichi Sankyo) and motesanib (Amgen/Takeda).

[00505] In another embodiment, the present invention provides a method of treating organ transplant rejection or graft vs. host disease comprising administering to a patient in need thereof a compound of formula **I** and one or more additional therapeutic agents selected from a steroid, cyclosporin, FK506, rapamycin, a hedgehog signaling inhibitor, a BTK inhibitor, a JAK/pan-JAK inhibitor, a TYK2 inhibitor, a PI3K inhibitor, and a SYK inhibitor.

[00506] In another embodiment, the present invention provides a method of treating or lessening the severity of a disease comprising administering to a patient in need thereof a compound of formula **I** and a BTK inhibitor, wherein the disease is selected from inflammatory bowel disease, arthritis, systemic lupus erythematosus (SLE), vasculitis, idiopathic thrombocytopenic purpura (ITP), rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, diabetes, myasthenia gravis, Hashimoto's thyroiditis, Ord's thyroiditis, Graves' disease, autoimmune thyroiditis, Sjogren's syndrome, multiple sclerosis, systemic sclerosis, Lyme neuroborreliosis, Guillain-Barre syndrome, acute disseminated encephalomyelitis, Addison's disease, opsoclonus-myoclonus syndrome, ankylosing spondylosis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hepatitis, autoimmune gastritis, pernicious anemia, celiac disease, Goodpasture's syndrome, idiopathic thrombocytopenic purpura, optic neuritis, scleroderma, primary biliary cirrhosis, Reiter's syndrome, Takayasu's arteritis, temporal arteritis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, psoriasis, alopecia universalis, Behcet's disease, chronic fatigue, dysautonomia, membranous glomerulonephropathy, endometriosis, interstitial cystitis, pemphigus vulgaris, bullous pemphigoid, neuromyotonia, scleroderma, vulvodynia, a hyperproliferative disease, rejection of transplanted organs or tissues, Acquired Immunodeficiency Syndrome (AIDS, also known as HIV), type 1 diabetes, graft versus host disease, transplantation, transfusion, anaphylaxis, allergies (e.g., allergies to plant pollens, latex, drugs, foods, insect poisons, animal hair, animal dander, dust mites, or cockroach calyx), type I hypersensitivity, allergic conjunctivitis, allergic rhinitis, and atopic dermatitis, asthma, appendicitis, atopic dermatitis, asthma, allergy, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, chronic graft rejection, colitis, conjunctivitis, Crohn's disease, cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis,

Henoch- Schonlein purpura, hepatitis, hidradenitis suppurativa, immunoglobulin A nephropathy, interstitial lung disease, laryngitis, mastitis, meningitis, myelitis myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, phlebitis, pneumonitis, pneumonia, polymyositis, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, ulcerative colitis, uveitis, vaginitis, vasculitis, or vulvitis, B-cell proliferative disorder, e.g., diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, acute lymphocytic leukemia, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, multiple myeloma (also known as plasma cell myeloma), non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasmacytoma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, Burkitt lymphoma/leukemia, or lymphomatoid granulomatosis, breast cancer, prostate cancer, or cancer of the mast cells (e.g., mastocytoma, mast cell leukemia, mast cell sarcoma, systemic mastocytosis), bone cancer, colorectal cancer, pancreatic cancer, diseases of the bone and joints including, without limitation, rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis and Reiter's disease), Behcet's disease, Sjogren's syndrome, systemic sclerosis, osteoporosis, bone cancer, bone metastasis, a thromboembolic disorder, (e.g., myocardial infarct, angina pectoris, reocclusion after angioplasty, restenosis after angioplasty, reocclusion after aortocoronary bypass, restenosis after aortocoronary bypass, stroke, transitory ischemia, a peripheral arterial occlusive disorder, pulmonary embolism, deep venous thrombosis), inflammatory pelvic disease, urethritis, skin sunburn, sinusitis, pneumonitis, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, hepatitis, gastritis, enteritis, dermatitis, gingivitis, appendicitis, pancreatitis, cholocystitus, agammaglobulinemia, psoriasis, allergy, Crohn's disease, irritable bowel syndrome, ulcerative colitis, Sjogren's disease, tissue graft rejection, hyperacute rejection of transplanted organs, asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD), autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome), autoimmune alopecia, pernicious anemia, glomerulonephritis, dermatomyositis, multiple sclerosis, scleroderma, vasculitis, autoimmune hemolytic and thrombocytopenic states, Goodpasture's syndrome, atherosclerosis, Addison's disease,

Parkinson's disease, Alzheimer's disease, diabetes, septic shock, systemic lupus erythematosus (SLE), rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, osteoarthritis, chronic idiopathic thrombocytopenic purpura, Waldenstrom macroglobulinemia, myasthenia gravis, Hashimoto's thyroiditis, atopic dermatitis, degenerative joint disease, vitiligo, autoimmune hypopituitarism, Guillain-Barre syndrome, Behcet's disease, scleraderma, mycosis fungoides, acute inflammatory responses (such as acute respiratory distress syndrome and ischemia/reperfusion injury), and Graves' disease.

[00507] In another embodiment, the present invention provides a method of treating or lessening the severity of a disease comprising administering to a patient in need thereof a compound of formula **I** and a PI3K inhibitor, wherein the disease is selected from a cancer, a neurodegenative disorder, an angiogenic disorder, a viral disease, an autoimmune disease, an inflammatory disorder, a hormone-related disease, conditions associated with organ transplantation, immunodeficiency disorders, a destructive bone disorder, a proliferative disorder, an infectious disease, a condition associated with cell death, thrombin-induced platelet aggregation, chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), liver disease, pathologic immune conditions involving T cell activation, a cardiovascular disorder, and a CNS disorder.

[00508] In another embodiment, the present invention provides a method of treating or lessening the severity of a disease comprising administering to a patient in need thereof a compound of formula **I** and a PI3K inhibitor, wherein the disease is selected from benign or malignant tumor, carcinoma or solid tumor of the brain, kidney (e.g., renal cell carcinoma (RCC)), liver, adrenal gland, bladder, breast, stomach, gastric tumors, ovaries, colon, rectum, prostate, pancreas, lung, vagina, endometrium, cervix, testis, genitourinary tract, esophagus, larynx, skin, bone or thyroid, sarcoma, glioblastomas, neuroblastomas, multiple myeloma or gastrointestinal cancer, especially colon carcinoma or colorectal adenoma or a tumor of the neck and head, an epidermal hyperproliferation, psoriasis, prostate hyperplasia, a neoplasia, a neoplasia of epithelial character, adenoma, adenocarcinoma, keratoacanthoma, epidermoid carcinoma, large cell carcinoma, non-small-cell lung carcinoma, lymphomas, (including, for example, non-Hodgkin's Lymphoma (NHL) and Hodgkin's lymphoma (also termed Hodgkin's or Hodgkin's disease)), a mammary carcinoma, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, or a leukemia, diseases include Cowden syndrome, Lhermitte-Dudos

disease and Bannayan-Zonana syndrome, or diseases in which the PI3K/PKB pathway is aberrantly activated, asthma of whatever type or genesis including both intrinsic (non-allergic) asthma and extrinsic (allergic) asthma, mild asthma, moderate asthma, severe asthma, bronchitic asthma, exercise-induced asthma, occupational asthma and asthma induced following bacterial infection, acute lung injury (ALI), adult/acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary, airways or lung disease (COPD, COAD or COLD), including chronic bronchitis or dyspnea associated therewith, emphysema, as well as exacerbation of airways hyperreactivity consequent to other drug therapy, in particular other inhaled drug therapy, bronchitis of whatever type or genesis including, but not limited to, acute, arachidic, catarrhal, croupus, chronic or phthinoid bronchitis, pneumoconiosis (an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts) of whatever type or genesis, including, for example, aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis and byssinosis, Loffler's syndrome, eosinophilic, pneumonia, parasitic (in particular metazoan) infestation (including tropical eosinophilia), bronchopulmonary aspergillosis, polyarteritis nodosa (including Churg-Strauss syndrome), eosinophilic granuloma and eosinophil-related disorders affecting the airways occasioned by drug-reaction, psoriasis, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforma, dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid, lupus erythematosus, pemphisus, epidermolysis bullosa acquisita, conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis, diseases affecting the nose including allergic rhinitis, and inflammatory disease in which autoimmune reactions are implicated or having an autoimmune component or etiology, including autoimmune hematological disorders (e.g. hemolytic anemia, aplastic anemia, pure red cell anemia and idiopathic thrombocytopenia), systemic lupus erythematosus, rheumatoid arthritis, polychondritis, sclerodoma, Wegener granulamatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (e.g. ulcerative colitis and Crohn's disease), endocrine opthalmopathy, Grave's disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, multiple sclerosis, primary biliary cirrhosis, uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis and glomerulonephritis (with and without nephrotic syndrome, e.g. including idiopathic nephrotic syndrome or minal change

nephropathy, restenosis, cardiomegaly, atherosclerosis, myocardial infarction, ischemic stroke and congestive heart failure, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and cerebral ischemia, and neurodegenerative disease caused by traumatic injury, glutamate neurotoxicity and hypoxia.

[00509] In some embodiments, one or more other therapeutic agent is a phosphatidylinositol 3 kinase (PI3K) inhibitor. In some embodiments, a PI3K inhibitor is selected from idelalisib (Zydelig®, Gilead), alpelisib (BYL719, Novartis), taselisib (GDC-0032, Genentech/Roche); pictilisib (GDC-0941, Genentech/Roche); copanlisib (BAY806946, Bayer); duvelisib (formerly IPI-145, Infinity Pharmaceuticals); PQR309 (Piqur Therapeutics, Switzerland); and TGR1202 (formerly RP5230, TG Therapeutics).

[00510] The compounds and compositions, according to the method of the present invention, may be administered using any amount and any route of administration effective for treating or lessening the severity of a cancer, an autoimmune disorder, a proliferative disorder, an inflammatory disorder, a neurodegenerative or neurological disorder, schizophrenia, a bone-related disorder, liver disease, or a cardiac disorder. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like. Compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. The expression "dosage unit form" as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts. The term “patient”, as used herein, means an animal, preferably a mammal, and most preferably a human.

[00511] Pharmaceutically acceptable compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracistemally, intravaginally,

intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated. In certain embodiments, the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.

[00512] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

[00513] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in l,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.R and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.

[00514] Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

[00515] In order to prolong the effect of a compound of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of

dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.

[00516] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

[00517] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

[00518] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other

coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.

[00519] The active compounds can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.

[00520] Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

[00521] According to one embodiment, the invention relates to a method of inhibiting protein

kinase activity or degading a protein kinase in a biological sample comprising the step of contacting said biological sample with a compound of this invention, or a composition comprising said compound.

[00522] According to another embodiment, the invention relates to a method of inhibiting or degrading IRAK-l, IRAK-2, and/or IRAK-4, or a mutant thereof, activity in a biological sample comprising the step of contacting said biological sample with a compound of this invention, or a composition comprising said compound.

[00523] The term "biological sample", as used herein, includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.

[00524] Inhibition and/or degradation of a protein kinase, or a protein kinase selected from IRAK-l, IRAK-2, and/or IRAK-4, or a mutant thereof, activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, blood transfusion, organ-transplantation, biological specimen storage, and biological assays.

[00525] Another embodiment of the present invention relates to a method of degrading a protein kinase and/or inhibiting protein kinase activity in a patient comprising the step of administering to said patient a compound of the present invention, or a composition comprising said compound.

[00526] According to another embodiment, the invention relates to a method of degrading and/or inhibiting one or more of IRAK-l, IRAK-2, and/or IRAK-4, or a mutant thereof, activity in a patient comprising the step of administering to said patient a compound of the present invention, or a composition comprising said compound. In other embodiments, the present invention provides a method for treating a disorder mediated by one or more of IRAK-l, IRAK-2, and/or IRAK-4, or a mutant thereof, in a patient in need thereof, comprising the step of administering to said patient a compound according to the present invention or pharmaceutically acceptable composition thereof. Such disorders are described in detail herein.

[00527] Depending upon the particular condition, or disease, to be treated, additional therapeutic agents that are normally administered to treat that condition, may also be present in the compositions of this invention. As used herein, additional therapeutic agents that are normally administered to treat a particular disease, or condition, are known as "appropriate for the disease, or condition, being treated."

[00528] A compound of the current invention may also be used to advantage in combination with other antiproliferative compounds. Such antiproliferative compounds include, but are not limited to aromatase inhibitors; antiestrogens; topoisomerase I inhibitors; topoisomerase II inhibitors; microtubule active compounds; alkylating compounds; histone deacetylase inhibitors; compounds which induce cell differentiation processes; cyclooxygenase inhibitors; MMP inhibitors; mTOR inhibitors; antineoplastic antimetabolites; platin compounds; compounds targeting/decreasing a protein or lipid kinase activity and further anti-angiogenic compounds; compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase; gonadorelin agonists; anti-androgens; methionine aminopeptidase inhibitors; matrix metalloproteinase inhibitors; bisphosphonates; biological response modifiers; antiproliferative antibodies; heparanase inhibitors; inhibitors of Ras oncogenic isoforms; telomerase inhibitors; proteasome inhibitors; compounds used in the treatment of hematologic malignancies; compounds which target, decrease or inhibit the activity of Flt-3; Hsp90 inhibitors such as 17-AAG (17-allylaminogeldanamycin, NSC330507), 17-DMAG (l7-dimethylaminoethylamino-l7-demethoxy-geldanamycin, NSC707545), IPI-504, CNF 1010, CNF2024, CNF 1010 from Conforma Therapeutics; temozolomide (Temodal®); kinesin spindle protein inhibitors, such as SB715992 or SB743921 from GlaxoSmithKline, or pentamidine/chlorpromazine from CombinatoRx; MEK inhibitors such as ARRY142886 from Array BioPharma, AZD6244 from AstraZeneca, PD 18 1461 from Pfizer and leucovorin.

[00529] The term "aromatase inhibitor" as used herein relates to a compound which inhibits estrogen production, for instance, the conversion of the substrates androstenedione and testosterone to estrone and estradiol, respectively. The term includes, but is not limited to steroids, especially atamestane, exemestane and formestane and, in particular, non-steroids, especially aminoglutethimide, roglethimide, pyridoglutethimide, trilostane, testolactone, ketokonazole, vorozole, fadrozole, anastrozole and letrozole. Exemestane is marketed under the trade name Aromasin™. Formestane is marketed under the trade name Lentaron™. Fadrozole is marketed under the trade name Afema™. Anastrozole is marketed under the trade name Arimidex™. Letrozole is marketed under the trade names Femara™ or Femar™. Aminoglutethimide is marketed under the trade name Orimeten™. A combination of the invention comprising a chemotherapeutic agent which is an aromatase inhibitor is particularly useful for the treatment of hormone receptor positive tumors, such as breast tumors.

[00530] In some embodiments, one or more other therapeutic agent is an mTOR inhibitor, which inhibits cell proliferation, angiogenesis and glucose uptake. In some embodiments, an mTOR inhibitor is everolimus (Afmitor®, Novartis); temsirolimus (Torisel®, Pfizer); and sirolimus (Rapamune®, Pfizer).

[00531] In some embodiments, one or more other therapeutic agent is an aromatase inhibitor. In some embodiments, an aromatase inhibitor is selected from exemestane (Aromasin®, Pfizer); anastazole (Arimidex®, AstraZeneca) and letrozole (Femara®, Novartis).

[00532] The term "antiestrogen" as used herein relates to a compound which antagonizes the effect of estrogens at the estrogen receptor level. The term includes, but is not limited to tamoxifen, fulvestrant, raloxifene and raloxifene hydrochloride. Tamoxifen is marketed under the trade name Nolvadex™. Raloxifene hydrochloride is marketed under the trade name Evista™. Fulvestrant can be administered under the trade name Faslodex™. A combination of the invention comprising a chemotherapeutic agent which is an antiestrogen is particularly useful for the treatment of estrogen receptor positive tumors, such as breast tumors.

[00533] The term "anti-androgen" as used herein relates to any substance which is capable of inhibiting the biological effects of androgenic hormones and includes, but is not limited to, bicalutamide (Casodex™). The term "gonadorelin agonist" as used herein includes, but is not limited to abarelix, goserelin and goserelin acetate. Goserelin can be administered under the trade name Zoladex™.

[00534] The term "topoisomerase I inhibitor" as used herein includes, but is not limited to topotecan, gimatecan, irinotecan, camptothecian and its analogues, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148. Irinotecan can be administered, e.g. in the form as it is marketed, e.g. under the trademark Camptosar™. Topotecan is marketed under the trade name Hycamptin™.

[00535] The term "topoisomerase II inhibitor" as used herein includes, but is not limited to the anthracyclines such as doxorubicin (including liposomal formulation, such as Caelyx™), daunorubicin, epirubicin, idarubicin and nemorubicin, the anthraquinones mitoxantrone and losoxantrone, and the podophillotoxines etoposide and teniposide. Etoposide is marketed under the trade name Etopophos™. Teniposide is marketed under the trade name VM 26-Bristol Doxorubicin is marketed under the trade name Acriblastin ™ or Adriamycin™. Epirubicin is marketed under the trade name Farmorubicin™. Idarubicin is marketed under the trade name

Zavedos™. Mitoxantrone is marketed under the trade name Novantron.

[00536] The term "microtubule active agent" relates to microtubule stabilizing, microtubule destabilizing compounds and microtublin polymerization inhibitors including, but not limited to taxanes, such as paclitaxel and docetaxel; vinca alkaloids, such as vinblastine or vinblastine sulfate, vincristine or vincristine sulfate, and vinorelbine; discodermolides; cochicine and epothilones and derivatives thereof. Paclitaxel is marketed under the trade name Taxol™. Docetaxel is marketed under the trade name Taxotere™. Vinblastine sulfate is marketed under the trade name Vinblastin R.P™. Vincristine sulfate is marketed under the trade name Farmistin™.

[00537] The term "alkylating agent" as used herein includes, but is not limited to, cyclophosphamide, ifosfamide, melphalan or nitrosourea (BCNU or Gliadel). Cyclophosphamide is marketed under the trade name Cyclostin™. Ifosfamide is marketed under the trade name Holoxan™.

[00538] The term "histone deacetylase inhibitors" or "HDAC inhibitors" relates to compounds which inhibit the histone deacetylase and which possess antiproliferative activity. This includes, but is not limited to, suberoylanilide hydroxamic acid (SAHA).

[00539] The term "antineoplastic antimetabolite" includes, but is not limited to, 5-fluorouracil or 5-FU, capecitabine, gemcitabine, DNA demethylating compounds, such as 5-azacytidine and decitabine, methotrexate and edatrexate, and folic acid antagonists such as pemetrexed. Capecitabine is marketed under the trade name Xeloda™. Gemcitabine is marketed under the trade name Gemzar™.

[00540] The term "platin compound" as used herein includes, but is not limited to, carboplatin, cis-platin, cisplatinum and oxaliplatin. Carboplatin can be administered, e.g., in the form as it is marketed, e.g. under the trademark Carboplat™. Oxaliplatin can be administered, e.g., in the form as it is marketed, e.g. under the trademark Eloxatin™.

[00541] The term “Bcl-2 inhibitor” as used herein includes, but is not limited to compounds having inhibitory activity against B-cell lymphoma 2 protein (Bcl-2), including but not limited to ABT-199, ABT-731, ABT-737, apogossypol, Ascenta’s pan-Bcl-2 inhibitors, curcumin (and analogs thereof), dual Bcl-2/Bcl-xL inhibitors (Infinity Pharmaceuticals/Novartis Pharmaceuticals), Genasense (G3139), HA14-1 (and analogs thereof; see W02008118802), navitoclax (and analogs thereof, see US7390799), NH-l (Shenayng Pharmaceutical University), obatoclax (and analogs thereof, see W02004106328), S-001 (Gloria Pharmaceuticals), TW series

compounds (Univ. of Michigan), and venetoclax. In some embodiments the Bcl-2 inhibitor is a small molecule therapeutic. In some embodiments the Bcl-2 inhibitor is a peptidomimetic.

[00542] The term "compounds targeting/decreasing a protein or lipid kinase activity; or a protein or lipid phosphatase activity; or further anti-angiogenic compounds" as used herein includes, but is not limited to, protein tyrosine kinase and/or serine and/or threonine kinase inhibitors or lipid kinase inhibitors, such as a) compounds targeting, decreasing or inhibiting the activity of the platelet-derived growth factor-receptors (PDGFR), such as compounds which target, decrease or inhibit the activity of PDGFR, especially compounds which inhibit the PDGF receptor, such as an N-phenyl-2-pyrimidine-amine derivative, such as imatinib, SU101, SU6668 and GFB-111; b) compounds targeting, decreasing or inhibiting the activity of the fibroblast growth factor-receptors (FGFR); c) compounds targeting, decreasing or inhibiting the activity of the insulin-like growth factor receptor I (IGF-IR), such as compounds which target, decrease or inhibit the activity of IGF-IR, especially compounds which inhibit the kinase activity of IGF-I receptor, or antibodies that target the extracellular domain of IGF-I receptor or its growth factors; d) compounds targeting, decreasing or inhibiting the activity of the Trk receptor tyrosine kinase family, or ephrin B4 inhibitors; e) compounds targeting, decreasing or inhibiting the activity of the Axl receptor tyrosine kinase family; f) compounds targeting, decreasing or inhibiting the activity of the Ret receptor tyrosine kinase; g) compounds targeting, decreasing or inhibiting the activity of the Kit/SCFR receptor tyrosine kinase, such as imatinib; h) compounds targeting, decreasing or inhibiting the activity of the C-kit receptor tyrosine kinases, which are part of the PDGFR family, such as compounds which target, decrease or inhibit the activity of the c-Kit receptor tyrosine kinase family, especially compounds which inhibit the c-Kit receptor, such as imatinib; i) compounds targeting, decreasing or inhibiting the activity of members of the c-Abl family, their gene-fusion products (e.g. BCR-Abl kinase) and mutants, such as compounds which target decrease or inhibit the activity of c-Abl family members and their gene fusion products, such as an N-phenyl-2-pyrimidine-amine derivative, such as imatinib or nilotinib (AMN107); PD 180970; AG957; NSC 680410; PD173955 from ParkeDavis; or dasatinib (BMS-354825); j) compounds targeting, decreasing or inhibiting the activity of members of the protein kinase C (PKC) and Raf family of serine/threonine kinases, members of the MEK, SRC, JAK/pan-JAK, FAK, PDK1, PKB/Akt, Ras/MAPK, PI3K, SYK, TYK2, BTK and TEC family, and/or members of the cyclin-dependent kinase family (CDK) including staurosporine derivatives, such as midostaurin;

examples of further compounds include UCN-01, safmgol, BAY 43-9006, Bryostatin 1, Perifosine; llmofosine; RO 318220 and RO 320432; GO 6976; lsis 3521; LY333531/LY379196; isochinoline compounds; FTIs; PD184352 or QAN697 (a P13K inhibitor) or AT7519 (CDK inhibitor); k) compounds targeting, decreasing or inhibiting the activity of protein-tyrosine kinase inhibitors, such as compounds which target, decrease or inhibit the activity of protein-tyrosine kinase inhibitors include imatinib mesylate (Gleevec™) or tyrphostin such as Tyrphostin A23/RG-50810; AG 99; Tyrphostin AG 2 13; Tyrphostin AG 1748; Tyrphostin AG 490; Tyrphostin B44; Tyrphostin B44 (+) enantiomer; Tyrphostin AG 555; AG 494; Tyrphostin AG 556, AG957 and adaphostin (4-{[(2,5- dihydroxyphenyl)methyl]amino}-benzoic acid adamantyl ester; NSC 680410, adaphostin); 1) compounds targeting, decreasing or inhibiting the activity of the epidermal growth factor family of receptor tyrosine kinases (EGFRi ErbB2, ErbB3, ErbB4 as homo- or heterodimers) and their mutants, such as compounds which target, decrease or inhibit the activity of the epidermal growth factor receptor family are especially compounds, proteins or antibodies which inhibit members of the EGF receptor tyrosine kinase family, such as EGF receptor, ErbB2, ErbB3 and ErbB4 or bind to EGF or EGF related ligands, CP 358774, ZD 1839, ZM 105180; trastuzumab (Herceptin™), cetuximab (Erbitux™), Iressa, Tarceva, OSI-774, C1-1033, EKB-569, GW-2016, El.l, E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 or E7.6.3, and 7H-pyrrolo-[2,3-d]pyrimidine derivatives; m) compounds targeting, decreasing or inhibiting the activity of the c-Met receptor, such as compounds which target, decrease or inhibit the activity of c-Met, especially compounds which inhibit the kinase activity of c-Met receptor, or antibodies that target the extracellular domain of c-Met or bind to HGF, n) compounds targeting, decreasing or inhibiting the kinase activity of one or more JAK family members (JAK1/JAK2/JAK3/TYK2 and/or pan-JAK), including but not limited to PRT-062070, SB-1578, baricitinib, pacritinib, momelotinib, VX-509, AZD-1480, TG-101348, tofacitinib, and ruxolitinib; o) compounds targeting, decreasing or inhibiting the kinase activity of PI3 kinase (PI3K) including but not limited to ATU-027, SF-1126, DS-7423, PBI-05204, GSK-2126458, ZSTK-474, buparlisib, pictrelisib, PF-4691502, BYL-719, dactolisib, XL-147, XL-765, and idelalisib; and; and q) compounds targeting, decreasing or inhibiting the signaling effects of hedgehog protein (Hh) or smoothened receptor (SMO) pathways, including but not limited to cyclopamine, vismodegib, itraconazole, erismodegib, and IPI-926 (saridegib).

[00543] Compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase are e.g. inhibitors of phosphatase 1, phosphatase 2A, or CDC25, such as okadaic acid or a derivative thereof.

[00544] In some embodiments, one or more other therapeutic agent is a growth factor antagonist, such as an antagonist of platelet-derived growth factor (PDGF), or epidermal growth factor (EGF) or its receptor (EGFR). Approved PDGF antagonists which may be used in the present invention include olaratumab (Lartruvo®; Eli Lilly). Approved EGFR antagonists which may be used in the present invention include cetuximab (Erbitux®, Eli Lilly); necitumumab (Portrazza®, Eli Lilly), panitumumab (Vectibix®, Amgen); and osimertinib (targeting activated EGFR, Tagrisso®, AstraZeneca).

[00545] The term "PI3K inhibitor" as used herein includes, but is not limited to compounds having inhibitory activity against one or more enzymes in the phosphatidylinositol-3 -kinase family, including, but not limited to PI3K α, PI3K γ, PI3K δ, PI3K β, PI3K-C2a, PI3K-C2p, PI3K-C2y, Vps34, pllO-a, pl 10-β, ρ 110-γ, ρ 110-δ, p85-a, ρ85-β, ρ55-γ, ρ 150, plOl, and ρ87. Examples of PI3K inhibitors useful in this invention include but are not limited to ATE[-027, SF-1126, DS-7423, PBI-05204, GSK-2126458, ZSTK-474, buparlisib, pictrelisib, PF-4691502, BYL-719, dactolisib, XL-147, XL-765, and idelalisib.

[00546] The term "BTK inhibitor" as used herein includes, but is not limited to compounds having inhibitory activity against Bruton's Tyrosine Kinase (BTK), including, but not limited to AVL-292 and ibrutinib.

[00547] The term "SYK inhibitor" as used herein includes, but is not limited to compounds having inhibitory activity against spleen tyrosine kinase (SYK), including but not limited to PRT-062070, R-343, R-333, Excellair, PRT-062607, and fostamatinib

[00548] Further examples of BTK inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this invention can be found in W02008039218 and WO201 1090760, the entirety of which are incorporated herein by reference.

[00549] Further examples of SYK inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this invention can be found in W02003063794, W02005007623, and W02006078846, the entirety of which are incorporated herein by reference.

[00550] Further examples of PI3K inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this invention can be found in W02004019973,

W02004089925, W02007016176, US8138347, W02002088112, W02007084786, W020071 29161, W02006 122806, W02005 113554, and W02007044729 the entirety of which are incorporated herein by reference.

[00551] Further examples of JAK inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this invention can be found in W02009114512, W02008109943, W02007053452, W02000142246, and W02007070514, the entirety of which are incorporated herein by reference.

[00552] Further anti-angiogenic compounds include compounds having another mechanism for their activity, e.g. unrelated to protein or lipid kinase inhibition e.g. thalidomide (Thalomid™) and TNP-470.

[00553] Examples of proteasome inhibitors useful for use in combination with compounds of the invention include, but are not limited to bortezomib, disulfiram, epigallocatechin-3-gallate (EGCG), salinosporamide A, carfilzomib, ONX-0912, CEP-18770, and MLN9708.

[00554] Compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase are e.g. inhibitors of phosphatase 1, phosphatase 2A, or CDC25, such as okadaic acid or a derivative thereof.

[00555] Compounds which induce cell differentiation processes include, but are not limited to, retinoic acid, α- γ- or δ- tocopherol or a- γ- or δ-tocotrienol.

[00556] The term cyclooxygenase inhibitor as used herein includes, but is not limited to, Cox-2 inhibitors, 5-alkyl substituted 2-arylaminophenylacetic acid and derivatives, such as celecoxib (Celebrex™), rofecoxib (Vioxx™), etoricoxib, valdecoxib or a 5-alkyl-2- arylaminophenylacetic acid, such as 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenyl acetic acid, lumiracoxib.

[00557] The term "bisphosphonates" as used herein includes, but is not limited to, etridonic, clodronic, tiludronic, pamidronic, alendronic, ibandronic, risedronic and zoledronic acid. Etridonic acid is marketed under the trade name Didronel™. Clodronic acid is marketed under the trade name Bonefos™. Tiludronic acid is marketed under the trade name Skelid™. Pamidronic acid is marketed under the trade name Aredia™. Alendronic acid is marketed under the trade name Fosamax™. Ibandronic acid is marketed under the trade name Bondranat™. Risedronic acid is marketed under the trade name Actonel™. Zoledronic acid is marketed under the trade name Zometa™. The term "mTOR inhibitors" relates to compounds which inhibit the mammalian target of rapamycin (mTOR) and which possess antiproliferative activity such as sirolimus

(Rapamune®), everolimus (Certican™), CCI-779 and ABT578.

[00558] The term "heparanase inhibitor" as used herein refers to compounds which target, decrease or inhibit heparin sulfate degradation. The term includes, but is not limited to, PI-88. The term "biological response modifier" as used herein refers to a lymphokine or interferons.

[00559] The term "inhibitor of Ras oncogenic isoforms", such as H-Ras, K-Ras, or N-Ras, as used herein refers to compounds which target, decrease or inhibit the oncogenic activity of Ras; for example, a "farnesyl transferase inhibitor" such as L-744832, DK8G557 or R l 15777 (Zamestra™). The term "telomerase inhibitor" as used herein refers to compounds which target, decrease or inhibit the activity of telomerase. Compounds which target, decrease or inhibit the activity of telomerase are especially compounds which inhibit the telomerase receptor, such as telomestatin.

[00560] The term "methionine aminopeptidase inhibitor" as used herein refers to compounds which target, decrease or inhibit the activity of methionine aminopeptidase. Compounds which target, decrease or inhibit the activity of methionine aminopeptidase include, but are not limited to, bengamide or a derivative thereof.

[00561] The term "proteasome inhibitor" as used herein refers to compounds which target, decrease or inhibit the activity of the proteasome. Compounds which target, decrease or inhibit the activity of the proteasome include, but are not limited to, Bortezomib (Velcade™),); carfilzomib (Kyprolis®, Amgen); and ixazomib (Ninlaro®, Takeda), and MLN 341.

[00562] The term "matrix metalloproteinase inhibitor" or ("MMP" inhibitor) as used herein includes, but is not limited to, collagen peptidomimetic and nonpeptidomimetic inhibitors, tetracycline derivatives, e.g. hydroxamate peptidomimetic inhibitor batimastat and its orally bioavailable analogue marimastat (BB-2516), prinomastat (AG3340), metastat (NSC 683551) BMS-279251 , BAY 12-9566, TAA211 , MMI270B or AAJ996.

[00563] The term "compounds used in the treatment of hematologic malignancies" as used herein includes, but is not limited to, FMS-like tyrosine kinase inhibitors, which are compounds targeting, decreasing or inhibiting the activity of FMS-like tyrosine kinase receptors (Flt-3R); interferon, l-P-D-arabinofuransyl cytosine (ara-c) and bisulfan; and ALK inhibitors, which are compounds which target, decrease or inhibit anaplastic lymphoma kinase.

[00564] Compounds which target, decrease or inhibit the activity of FMS-like tyrosine kinase receptors (Flt-3R) are especially compounds, proteins or antibodies which inhibit members of the

Flt-3R receptor kinase family, such as PKC412, midostaurin, a staurosporine derivative, SU11248 and MLN518.

[00565] The term "HSP90 inhibitors" as used herein includes, but is not limited to, compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90; degrading, targeting, decreasing or inhibiting the HSP90 client proteins via the ubiquitin proteosome pathway. Compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90 are especially compounds, proteins or antibodies which inhibit the ATPase activity of HSP90, such as l7-allylamino,l7-demethoxygeldanamycin (17AAG), a geldanamycin derivative; other geldanamycin related compounds; radicicol and HDAC inhibitors.

[00566] The term "antiproliferative antibodies" as used herein includes, but is not limited to, trastuzumab (Herceptin™), Trastuzumab-DMl, erbitux, bevacizumab (Avastin™), rituximab (Rituxan®), PR064553 (anti-CD40) and 2C4 Antibody. By antibodies is meant intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies formed from at least 2 intact antibodies, and antibodies fragments so long as they exhibit the desired biological activity.

[00567] For the treatment of acute myeloid leukemia (AML), compounds of the current invention can be used in combination with standard leukemia therapies, especially in combination with therapies used for the treatment of AML. In particular, compounds of the current invention can be administered in combination with, for example, farnesyl transferase inhibitors and/or other drugs useful for the treatment of AML, such as Daunorubicin, Adriamycin, Ara-C, VP-16, Teniposide, Mitoxantrone, Idarubicin, Carboplatinum and PKC412.

[00568] Other anti-leukemic compounds include, for example, Ara-C, a pyrimidine analog, which is the 2'-alpha-hydroxy ribose (arabinoside) derivative of deoxycytidine. Also included is the purine analog of hypoxanthine, 6-mercaptopurine (6-MP) and fludarabine phosphate. Compounds which target, decrease or inhibit activity of histone deacetylase (HDAC) inhibitors such as sodium butyrate and suberoylanilide hydroxamic acid (SAHA) inhibit the activity of the enzymes known as histone deacetylases. Specific HDAC inhibitors include MS275, SAHA, FK228 (formerly FR901228), Trichostatin A and compounds disclosed in US 6,552,065 including, but not limited to, N-hydroxy-3-[4-[[[2-(2-methyl-lH-indol-3-yl)-ethyl]- amino]methyl]phenyl]-2E-2-propenamide, or a pharmaceutically acceptable salt thereof and N-hydroxy-3-[4-[(2-hydroxyethyl){2-(lH-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2- propenamide, or a pharmaceutically acceptable salt thereof, especially the lactate salt. Somatostatin receptor

antagonists as used herein refer to compounds which target, treat or inhibit the somatostatin receptor such as octreotide, and SOM230. Tumor cell damaging approaches refer to approaches such as ionizing radiation. The term "ionizing radiation" referred to above and hereinafter means ionizing radiation that occurs as either electromagnetic rays (such as X-rays and gamma rays) or particles (such as alpha and beta particles). Ionizing radiation is provided in, but not limited to, radiation therapy and is known in the art. See Hellman, Principles of Radiation Therapy, Cancer, in Principles and Practice of Oncology, Devita et al., Eds., 4th Edition, Vol. 1 , pp. 248-275 (1993).

[00569] Also included are EDG binders and ribonucleotide reductase inhibitors. The term "EDG binders" as used herein refers to a class of immunosuppressants that modulates lymphocyte recirculation, such as FTY720. The term "ribonucleotide reductase inhibitors" refers to pyrimidine or purine nucleoside analogs including, but not limited to, fludarabine and/or cytosine arabinoside (ara-C), 6-thioguanine, 5-fluorouracil, cladribine, 6-mercaptopurine (especially in combination with ara-C against ALL) and/or pentostatin. Ribonucleotide reductase inhibitors are especially hydroxyurea or 2-hydroxy-lH-isoindole-l ,3-dione derivatives.

[00570] Also included are in particular those compounds, proteins or monoclonal antibodies of VEGF such as l-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine or a pharmaceutically acceptable salt thereof, l-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate; Angiostatin™; Endostatin™; anthranilic acid amides; ZD4190; ZD6474; SET5416; SET6668; bevacizumab; or anti-VEGF antibodies or anti-VEGF receptor antibodies, such as rhuMAb and RHUFab, VEGF aptamer such as Macugon; FLT-4 inhibitors, FLT-3 inhibitors, VEGFR-2 IgGI antibody, Angiozyme (RPI 4610) and Bevacizumab (Avastin™).

[00571] Photodynamic therapy as used herein refers to therapy which uses certain chemicals known as photosensitizing compounds to treat or prevent cancers. Examples of photodynamic therapy include treatment with compounds, such as Visudyne™ and porfimer sodium.

[00572] Angiostatic steroids as used herein refers to compounds which block or inhibit angiogenesis, such as, e.g., anecortave, triamcinolone, hydrocortisone, ll-a-epihydrocotisol, cortex olone, l7a-hydroxyprogesterone, corticosterone, desoxycorticosterone, testosterone, estrone and dexamethasone.

[00573] Implants containing corticosteroids refers to compounds, such as fluocinolone and dexamethasone.

[00574] Other chemotherapeutic compounds include, but are not limited to, plant alkaloids,

hormonal compounds and antagonists; biological response modifiers, preferably lymphokines or interferons; antisense oligonucleotides or oligonucleotide derivatives; shRNA or siRNA; or miscellaneous compounds or compounds with other or unknown mechanism of action.

[00575] The compounds of the invention are also useful as co-therapeutic compounds for use in combination with other drug substances such as anti-inflammatory, bronchodilatory or antihistamine drug substances, particularly in the treatment of obstructive or inflammatory airways diseases such as those mentioned hereinbefore, for example as potentiators of therapeutic activity of such drugs or as a means of reducing required dosaging or potential side effects of such drugs. A compound of the invention may be mixed with the other drug substance in a fixed pharmaceutical composition or it may be administered separately, before, simultaneously with or after the other drug substance. Accordingly the invention includes a combination of a compound of the invention as hereinbefore described with an anti-inflammatory, bronchodilatory, antihistamine or anti-tussive drug substance, said compound of the invention and said drug substance being in the same or different pharmaceutical composition.

[00576] Suitable anti-inflammatory drugs include steroids, in particular glucocorticosteroids such as budesonide, beclamethasone dipropionate, fluticasone propionate, ciclesonide or mometasone furoate; non-steroidal glucocorticoid receptor agonists; LTB4 antagonists such LY293111, CGS025019C, CP-195543, SC-53228, BIIL 284, ONO 4057, SB 209247; LTD4 antagonists such as montelukast and zafirlukast; PDE4 inhibitors such cilomilast (Ariflo® GlaxoSmithKline), Roflumilast (Byk Gulden),V-ll294A (Napp), BAY19-8004 (Bayer), SCH-351591 (Schering- Plough), Arofylline (Almirall Prodesfarma), PD 189659 / PD 168787 (Parke-Davis), AWD-12- 281 (Asta Medica), CDC-801 (Celgene), SelCID(TM) CC-10004 (Celgene), VM554/UM565 (Vernalis), T-440 (Tanabe), KW-4490 (Kyowa Hakko Kogyo); A2a agonists; A2b antagonists; and beta-2 adrenoceptor agonists such as albuterol (salbutamol), metaproterenol, terbutaline, salmeterol fenoterol, procaterol, and especially, formoterol and pharmaceutically acceptable salts thereof. Suitable bronchodilatory drugs include anticholinergic or antimuscarinic compounds, in particular ipratropium bromide, oxitropium bromide, tiotropium salts and CHF 4226 (Chiesi), and glycopyrrolate.

[00577] Suitable antihistamine drug substances include cetirizine hydrochloride, acetaminophen, clemastine fumarate, promethazine, loratidine, desloratidine, diphenhydramine and fexofenadine hydrochloride, activastine, astemizole, azelastine, ebastine, epinastine,

mizolastine and tefenadine.

[00578] Other useful combinations of compounds of the invention with anti-inflammatory drugs are those with antagonists of chemokine receptors, e.g. CCR-l , CCR-2, CCR-3, CCR-4, CCR-5, CCR-6, CCR-7, CCR-8, CCR-9 and CCR10, CXCR1 , CXCR2, CXCR3, CXCR4, CXCR5, particularly CCR-5 antagonists such as Schering-Plough antagonists SC-35 1125, SCH-55700 and SCH-D, and Takeda antagonists such as N-[[4-[[[6,7-dihydro-2-(4-methylphenyl)-5H-benzo-cyclohepten-8-yl]carbonyl]amino]phenyl]-methyl]tetrahydro-N,N-dimethyl-2H-pyran-4-aminium chloride (TAK-770).

[00579] The structure of the active compounds identified by code numbers, generic or trade names may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g. Patents International (e.g. IMS World Publications).

[00580] A compound of the current invention may also be used in combination with known therapeutic processes, for example, the administration of hormones or radiation. In certain embodiments, a provided compound is used as a radiosensitizer, especially for the treatment of tumors which exhibit poor sensitivity to radiotherapy.

[00581] A compound of the current invention can be administered alone or in combination with one or more other therapeutic compounds, possible combination therapy taking the form of fixed combinations or the administration of a compound of the invention and one or more other therapeutic compounds being staggered or given independently of one another, or the combined administration of fixed combinations and one or more other therapeutic compounds. A compound of the current invention can besides or in addition be administered especially for tumor therapy in combination with chemotherapy, radiotherapy, immunotherapy, phototherapy, surgical intervention, or a combination of these. Long-term therapy is equally possible as is adjuvant therapy in the context of other treatment strategies, as described above. Other possible treatments are therapy to maintain the patient's status after tumor regression, or even chemopreventive therapy, for example in patients at risk.

[00582] Those additional agents may be administered separately from an inventive compound-containing composition, as part of a multiple dosage regimen. Alternatively, those agents may be part of a single dosage form, mixed together with a compound of this invention in a single composition. If administered as part of a multiple dosage regime, the two active agents may be submitted simultaneously, sequentially or within a period of time from one another normally

within five hours from one another.

[00583] As used herein, the term "combination," "combined," and related terms refers to the simultaneous or sequential administration of therapeutic agents in accordance with this invention. For example, a compound of the present invention may be administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form. Accordingly, the present invention provides a single unit dosage form comprising a compound of the current invention, an additional therapeutic agent, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

[00584] The amount of both an inventive compound and additional therapeutic agent (in those compositions which comprise an additional therapeutic agent as described above) that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Preferably, compositions of this invention should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of an inventive compound can be administered.

[00585] In those compositions which comprise an additional therapeutic agent, that additional therapeutic agent and the compound of this invention may act synergistically. Therefore, the amount of additional therapeutic agent in such compositions will be less than that required in a monotherapy utilizing only that therapeutic agent. In such compositions a dosage of between 0.01 - 1,000 μg/kg body weight/day of the additional therapeutic agent can be administered.

[00586] The amount of one or more other therapeutic agent present in the compositions of this invention may be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably the amount of one or more other therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent. In some embodiments, one or more other therapeutic agent is administered at a dosage of about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% of the amount normally administered for that agent. As used herein, the phrase "normally administered" means the amount an FDA approved therapeutic agent is approvided for dosing per the FDA label insert.

[00587] The compounds of this invention, or pharmaceutical compositions thereof, may also be incorporated into compositions for coating an implantable medical device, such as prostheses,

artificial valves, vascular grafts, stents and catheters. Vascular stents, for example, have been used to overcome restenosis (re-narrowing of the vessel wall after injury). However, patients using stents or other implantable devices risk clot formation or platelet activation. These unwanted effects may be prevented or mitigated by pre-coating the device with a pharmaceutically acceptable composition comprising a kinase inhibitor. Implantable devices coated with a compound of this invention are another embodiment of the present invention.

Exemplary Immuno-Oncology agents

[00588] In some embodiments, one or more other therapeutic agent is an immuno-oncology agent. As used herein, the term "an immuno-oncology agent" refers to an agent which is effective to enhance, stimulate, and/or up-regulate immune responses in a subject. In some embodiments, the administration of an immuno-oncology agent with a compound of the invention has a synergic effect in treating a cancer.

[00589] An immuno-oncology agent can be, for example, a small molecule drug, an antibody, or a biologic or small molecule. Examples of biologic immuno-oncology agents include, but are not limited to, cancer vaccines, antibodies, and cytokines. In some embodiments, an antibody is a monoclonal antibody. In some embodiments, a monoclonal antibody is humanized or human.

[00590] In some embodiments, an immuno-oncology agent is (i) an agonist of a stimulatory (including a co-stimulatory) receptor or (ii) an antagonist of an inhibitory (including a co-inhibitory) signal on T cells, both of which result in amplifying antigen-specific T cell responses.

[00591] Certain of the stimulatory and inhibitory molecules are members of the immunoglobulin super family (IgSF). One important family of membrane-bound ligands that bind to co-stimulatory or co-inhibitory receptors is the B7 family, which includes B7-1, B7-2, B7-H1 (PD-L1), B7-DC (PD-L2), B7-H2 (ICOS-L), B7-H3, B7-H4, B7-H5 (VISTA), and B7-H6. Another family of membrane bound ligands that bind to co-stimulatory or co-inhibitory receptors is the TNF family of molecules that bind to cognate TNF receptor family members, which includes CD40 and CD40L, OX-40, OX-40L, CD70, CD27L, CD30, CD30L, 4-1BBL, CD 137 (4-1BB), TRAIL/Apo2-L, TRAILR1/DR4, TRAILR2/DR5, TRAILR3, TRAILR4, OPG, RANK, RANKL, TWEAKR/Fnl4, TWEAK, BAFFR, EDAR, XEDAR, TACI, APRIL, BCMA, LTpR, LIGHT, DcR3, HVEM, VEGETL1A, TRAMP/DR3, EDAR, EDA1, XEDAR, EDA2, TNFR1,

Lymphotoxin α/TNFp, TNFR2, TNFa, LTpR, Lymphotoxin α1β2, FAS, FASL, RELT, DR6, TROY, NGFR.

[00592] In some embodiments, an immuno-oncology agent is a cytokine that inhibits T cell activation (e.g., IL-6, IL-10, TGF-β, VEGF, and other immunosuppressive cytokines) or a cytokine that stimulates T cell activation, for stimulating an immune response.

[00593] In some embodiments, a combination of a compound of the invention and an immuno-oncology agent can stimulate T cell responses. In some embodiments, an immuno-oncology agent is: (i) an antagonist of a protein that inhibits T cell activation (e.g., immune checkpoint inhibitors) such as CTLA-4, PD-l, PD-L1, PD-L2, LAG-3, TIM-3, Galectin 9, CEACAM-l, BTLA, CD69, Galectin-l, TIGIT, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD1H, LAIR1, TIM-l, and TIM-4; or (ii) an agonist of a protein that stimulates T cell activation such as B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL, ICOS, ICOS-L, 0X40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3 and CD28H.

[00594] In some embodiments, an immuno-oncology agent is an antagonist of inhibitory receptors on NK cells or an agonists of activating receptors on NK cells. In some embodiments, an immuno-oncology agent is an antagonists of KIR, such as lirilumab.

[00595] In some embodiments, an immuno-oncology agent is an agent that inhibits or depletes macrophages or monocytes, including but not limited to CSF-1R antagonists such as CSF-1R antagonist antibodies including RG7155 (W011/70024, WO11/107553, WO11/131407, WO13/87699, WO13/119716, WO13/132044) or FPA-008 (WO11/140249; WO13169264; WO14/036357).

[00596] In some embodiments, an immuno-oncology agent is selected from agonistic agents that ligate positive costimulatory receptors, blocking agents that attenuate signaling through inhibitory receptors, antagonists, and one or more agents that increase systemically the frequency of anti-tumor T cells, agents that overcome distinct immune suppressive pathways within the tumor microenvironment (e.g., block inhibitory receptor engagement (e.g., PD-L1/PD-1 interactions), deplete or inhibit Tregs (e.g., using an anti-CD25 monoclonal antibody (e.g., daclizumab) or by ex vivo anti-CD25 bead depletion), inhibit metabolic enzymes such as IDO, or reverse/prevent T cell energy or exhaustion) and agents that trigger innate immune activation and/or inflammation at tumor sites.

[00597] In some embodiments, an immuno-oncology agent is a CTLA-4 antagonist. In some embodiments, a CTLA-4 antagonist is an antagonistic CTLA-4 antibody. In some embodiments, an antagonistic CTLA-4 antibody is YERVOY (ipilimumab) or tremelimumab.

[00598] In some embodiments, an immuno-oncology agent is a PD-l antagonist. In some embodiments, a PD-l antagonist is administered by infusion. In some embodiments, an immuno-oncology agent is an antibody or an antigen-binding portion thereof that binds specifically to a Programmed Death- 1 (PD-l) receptor and inhibits PD-l activity. In some embodiments, a PD-l antagonist is an antagonistic PD-l antibody. In some embodiments, an antagonistic PD-l antibody is OPDIVO (nivolumab), KEYTRUDA (pembrolizumab), or MEDI-0680 (AMP-5 14; WO2012/145493). In some embodiments, an immuno-oncology agent may be pidilizumab (CT-011). In some embodiments, an immuno-oncology agent is a recombinant protein composed of the extracellular domain of PD-L2 (B7-DC) fused to the Fc portion of IgGl, called AMP -224.

[00599] In some embodiments, an immuno-oncology agent is a PD-L1 antagonist. In some embodiments, a PD-L1 antagonist is an antagonistic PD-L1 antibody. In some embodiments, a PD-L1 antibody is MPDL3280A (RG7446; WO20 10/077634), durvalumab (MEDI4736), BMS-936559 (W02007/005874), and MSB00 1071 8C (WO20 13/79 174).

[00600] In some embodiments, an immuno-oncology agent is a LAG-3 antagonist. In some embodiments, a LAG-3 antagonist is an antagonistic LAG-3 antibody. In some embodiments, a LAG3 antibody is BMS-986016 (W010/19570, WO14/08218), or IMP-73 1 or IMP-321 (WO08/1 32601, WO009/44273).

[00601] In some embodiments, an immuno-oncology agent is a CD137 (4-1BB) agonist. In some embodiments, a CD137 (4-1BB) agonist is an agonistic CD137 antibody. In some embodiments, a CD137 antibody is urelumab or PF-05082566 (W012/32433).

[00602] In some embodiments, an immuno-oncology agent is a GITR agonist. In some embodiments, a GITR agonist is an agonistic GITR antibody. In some embodiments, a GITR antibody is BMS-986153, BMS-986156, TRX-518 (WO006/1 05021, W0009/009116), or MK-4166 (WOl 1/028683).

[00603] In some embodiments, an immuno-oncology agent is an indoleamine (2,3)-dioxygenase (IDO) antagonist. In some embodiments, an IDO antagonist is selected from epacadostat (INCB024360, Incyte); indoximod (NLG-8189, NewLink Genetics Corporation); capmanitib (INC280, Novartis); GDC-0919 (Genentech/Roche); PF-06840003 (Pfizer);

BMS:F00l287 (Bristol-Myers Squibb); Phy906/KDl08 (Phytoceutica); an enzyme that breaks down kynurenine (Kynase, Kyn Therapeutics); and NLG-919 (W009/73620, WO009/1 156652, WOl 1/56652, W012/142237).

[00604] In some embodiments, an immuno-oncology agent is an 0X40 agonist. In some embodiments, an 0X40 agonist is an agonistic 0X40 antibody. In some embodiments, an 0X40 antibody is MEDI-6383 or MED 1-6469.

[00605] In some embodiments, an immuno-oncology agent is an OX40L antagonist. In some embodiments, an OX40L antagonist is an antagonistic 0X40 antibody. In some embodiments, an OX40L antagonist is RG-7888 (WO06/029879).

[00606] In some embodiments, an immuno-oncology agent is a CD40 agonist. In some embodiments, a CD40 agonist is an agonistic CD40 antibody. In some embodiments, an immuno-oncology agent is a CD40 antagonist. In some embodiments, a CD40 antagonist is an antagonistic CD40 antibody. In some embodiments, a CD40 antibody is lucatumumab or dacetuzumab.

[00607] In some embodiments, an immuno-oncology agent is a CD27 agonist. In some embodiments, a CD27 agonist is an agonistic CD27 antibody. In some embodiments, a CD27 antibody is varlilumab.

[00608] In some embodiments, an immuno-oncology agent is MGA271 (to B7H3) (WOl 1/109400).

[00609] In some embodiments, an immuno-oncology agent is abagovomab, adecatumumab, afutuzumab, alemtuzumab, anatumomab mafenatox, apolizumab, atezolimab, avelumab, blinatumomab, BMS-936559, catumaxomab, durvalumab, epacadostat, epratuzumab, indoximod, inotuzumab ozogamicin, intelumumab, ipilimumab, isatuximab, lambrolizumab, MED14736, MPDL3280A, nivolumab, obinutuzumab, ocaratuzumab, ofatumumab, olatatumab, pembrolizumab, pidilizumab, rituximab, ticilimumab, samalizumab, or tremelimumab.

[00610] In some embodiments, an immuno-oncology agent is an immunostimulatory agent. For example, antibodies blocking the PD-l and PD-L1 inhibitory axis can unleash activated tumor-reactive T cells and have been shown in clinical trials to induce durable anti-tumor responses in increasing numbers of tumor histologies, including some tumor types that conventionally have not been considered immunotherapy sensitive. See, e.g., Okazaki, T. *et al.* (2013) Nat. Immunol. 14, 1212-1218; Zou *et al.* (2016) Sci. Transl. Med. 8. The anti-PD-l antibody nivolumab (Opdivo®, Bristol-Myers Squibb, also known as ONO-4538, MDX1106 and BMS-936558), has shown

potential to improve the overall survival in patients with RCC who had experienced disease progression during or after prior anti-angiogenic therapy.

[00611] In some embodiments, the immunomodulatory therapeutic specifically induces apoptosis of tumor cells. Approved immunomodulatory therapeutics which may be used in the present invention include pomalidomide (Pomalyst®, Celgene); lenalidomide (Revlimid®, Celgene); ingenol mebutate (Picato®, LEO Pharma).

[00612] In some embodiments, an immuno-oncology agent is a cancer vaccine. In some embodiments, the cancer vaccine is selected from sipuleucel-T (Provenge®, Dendreon/Valeant Pharmaceuticals), which has been approved for treatment of asymptomatic, or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer; and talimogene laherparepvec (Imlygic®, BioVex/Amgen, previously known as T-VEC), a genetically modified oncolytic viral therapy approved for treatment of unresectable cutaneous, subcutaneous and nodal lesions in melanoma. In some embodiments, an immuno-oncology agent is selected from an oncolytic viral therapy such as pexastimogene devacirepvec (PexaVec/JX-594, SillaJen/formerly Jennerex Biotherapeutics), a thymidine kinase- (TK-) deficient vaccinia virus engineered to express GM-CSF, for hepatocellular carcinoma (NCT02562755) and melanoma (NCT004293 12); pelareorep (Reolysin®, Oncolytics Biotech), a variant of respiratory enteric orphan virus (reovirus) which does not replicate in cells that are not RAS-activated, in numerous cancers, including colorectal cancer (NCT0 1622543); prostate cancer (NCT01619813); head and neck squamous cell cancer (NCT01 166542); pancreatic adenocarcinoma (NCT00998322); and non-small cell lung cancer (NSCLC) (NCT 00861627); enadenotucirev (NG-348, PsiOxus, formerly known as ColoAdl), an adenovirus engineered to express a full length CD80 and an antibody fragment specific for the T-cell receptor CD3 protein, in ovarian cancer (NCT02028117); metastatic or advanced epithelial tumors such as in colorectal cancer, bladder cancer, head and neck squamous cell carcinoma and salivary gland cancer (NCT02636036); ONCOS-102 (Targovax/formerly Oncos), an adenovirus engineered to express GM-CSF, in melanoma (NCT03003676); and peritoneal disease, colorectal cancer or ovarian cancer (NCT0296383 1); GL-ONC1 (GLV-lh68/GLV-lhl53, Genelux GmbH), vaccinia viruses engineered to express beta-galactosidase (beta-gal)/beta-glucoronidase or beta-gal/human sodium iodide symporter (hNIS), respectively, were studied in peritoneal carcinomatosis (NCT01443260); fallopian tube cancer,

ovarian cancer (NCT 02759588); or CG0070 (Cold Genesys), an adenovirus engineered to express GM-CSF, in bladder cancer (NCT02365818).

[00613] In some embodiments, an immuno-oncology agent is selected from JX-929 (SillaJen/formerly Jennerex Biotherapeutics), a TK- and vaccinia growth factor-deficient vaccinia virus engineered to express cytosine deaminase, which is able to convert the prodrug 5-fluorocytosine to the cytotoxic drug 5-fluorouracil; TG01 and TG02 (Targovax/formerly Oncos), peptide-based immunotherapy agents targeted for difficult-to-treat RAS mutations; and TILT-123 (TILT Biotherapeutics), an engineered adenovirus designated: Ad5/3-E2F-delta24-hTNFa-IRES-hIL20; and VSV-GP (ViraTherapeutics) a vesicular stomatitis virus (VSV) engineered to express the glycoprotein (GP) of lymphocytic choriomeningitis virus (LCMV), which can be further engineered to express antigens designed to raise an antigen-specific $CD8^+$ T cell response.

[00614] In some embodiments, an immuno-oncology agent is a T-cell engineered to express a chimeric antigen receptor, or CAR. The T-cells engineered to express such chimeric antigen receptor are referred to as a CAR-T cells.

[00615] CARs have been constructed that consist of binding domains, which may be derived from natural ligands, single chain variable fragments (scFv) derived from monoclonal antibodies specific for cell-surface antigens, fused to endodomains that are the functional end of the T-cell receptor (TCR), such as the CD3-zeta signaling domain from TCRs, which is capable of generating an activation signal in T lymphocytes. Upon antigen binding, such CARs link to endogenous signaling pathways in the effector cell and generate activating signals similar to those initiated by the TCR complex.

[00616] For example, in some embodiments the CAR-T cell is one of those described in U.S. Patent 8,906,682 (June; hereby incorporated by reference in its entirety), which discloses CAR-T cells engineered to comprise an extracellular domain having an antigen binding domain (such as a domain that binds to CD19), fused to an intracellular signaling domain of the T cell antigen receptor complex zeta chain (such as CD3 zeta). When expressed in the T cell, the CAR is able to redirect antigen recognition based on the antigen binding specificity. In the case of CD19, the antigen is expressed on malignant B cells. Over 200 clinical trials are currently in progress employing CAR-T in a wide range of indications. [https://clinicaltrials.gov/ct2/results?term=chimeric+antigen+receptors&pg=l].

[00617] In some embodiments, an immunostimulatory agent is an activator of retinoic acid receptor-related orphan receptor γ (RORyt). RORyt is a transcription factor with key roles in the differentiation and maintenance of Type 17 effector subsets of CD4+ (Thl7) and CD8+ (Tcl7) T cells, as well as the differentiation of IL-17 expressing innate immune cell subpopulations such as NK cells. In some embodiments, an activator of RORyt is LYC-55716 (Lycera), which is currently being evaluated in clinical trials for the treatment of solid tumors (NCT02929862).

[00618] In some embodiments, an immunostimulatory agent is an agonist or activator of a toll-like receptor (TLR). Suitable activators of TLRs include an agonist or activator of TLR9 such as SD-101 (Dynavax). SD-101 is an immunostimulatory CpG which is being studied for B-cell, follicular and other lymphomas (NCT02254772). Agonists or activators of TLR8 which may be used in the present invention include motolimod (VTX-2337, VentiRx Pharmaceuticals) which is being studied for squamous cell cancer of the head and neck (NCT02124850) and ovarian cancer (NCT02431559).

[00619] Other immuno-oncology agents that may be used in the present invention include urelumab (BMS-663513, Bristol-Myers Squibb), an anti-CDl37 monoclonal antibody; varlilumab (CDX-1127, Celldex Therapeutics), an anti-CD27 monoclonal antibody; BMS-986178 (Bristol-Myers Squibb), an anti-OX40 monoclonal antibody; lirilumab (IPH2102/BMS-986015, Innate Pharma, Bristol-Myers Squibb), an anti-KIR monoclonal antibody; monalizumab (IPH2201, Innate Pharma, AstraZeneca) an anti-NKG2A monoclonal antibody; andecaliximab (GS-5745, Gilead Sciences), an anti-MMP9 antibody; MK-4166 (Merck & Co.), an anti-GITR monoclonal antibody.

[00620] In some embodiments, an immunostimulatory agent is selected from elotuzumab, mifamurtide, an agonist or activator of a toll-like receptor, and an activator of RORyt.

[00621] In some embodiments, an immunostimulatory therapeutic is recombinant human interleukin 15 (rhIL-l5). rhIL-l5 has been tested in the clinic as a therapy for melanoma and renal cell carcinoma (NCT01021059 and NCT01369888) and leukemias (NCT02689453). In some embodiments, an immunostimulatory agent is recombinant human interleukin 12 (rhIL-l2). In some embodiments, an IL-15 based immunotherapeutic is heterodimeric IL-15 (hetIL-l5, Novartis/ Admune), a fusion complex composed of a synthetic form of endogenous IL-15 complexed to the soluble IL-15 binding protein IL-15 receptor alpha chain (IL l5:sIL-l5RA), which has been tested in Phase 1 clinical trials for melanoma, renal cell carcinoma, non-small cell

lung cancer and head and neck squamous cell carcinoma (NCT02452268). In some embodiments, a recombinant human interleukin 12 (rhIL-l2) is NM-IL-12 (Neumedicines, Inc.), NCT02544724, or NCT02542124.

[00622] In some embodiments, an immuno-oncology agent is selected from those descripted in Jerry L. Adams ET. AL., "Big opportunities for small molecules in immuno-oncology," Cancer Therapy **2015,** Vol. 14, pages 603-622, the content of which is incorporated herein by refenrece in its entirety. In some embodimetne, an immuno-oncology agent is selected from the examples described in Table 1 of Jerry L. Adams ET. AL. In some embodiments, an immuno-oncology agent is a small molecule targeting an immuno-oncoloby target selected from those listed in Table 2 of Jerry L. Adams ET. AL. In some embodiments, an immuno-oncology agent is a small molecule agent selectd from those listed in Table 2 of Jerry L. Adams ET. AL.

[00623] In some embodiments, an immuno-oncology agent is selected from the small molecule immuno-oncology agents described in Peter L. Toogood, "Small molecule immuno-oncology therapeutic agents," Bioorganic & Medicinal Chemistry Letters **2018,** Vol. 28, pages 319-329, the content of which is incorporated herein by refenrece in its entirety. In some embodiments, an immuno-oncology agent is an agent targeting the pathways as described in Peter L. Toogood.

[00624] In some embodiments, an immuno-oncology agent is selected from those described in Sandra L. Ross et al., "Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing", PLoS ONE 12(8): e0l83390, the conten of which is incorporated herein by reference in its entirety. In some embodiments, an immuno-oncology agent is a bispecific T cell engager (BiTE®) antibody construct. In some embodimens, a bispecific T cell engager (BiTE®) antibody construct is a CD19/CD3 bispecific antibody construct. In some embodimens, a bispecific T cell engager (BiTE®) antibody construct is an EGFR/CD3 bispecific antibody construct. In some embodimens, a bispecific T cell engager (BiTE®) antibody construct activates T cells. In some embodimens, a bispecific T cell engager (BiTE®) antibody construct activates T cells, which release cytokines inducing upregulation of intercellular adhesion molecule 1 (ICAM-l) and FAS on bystander cells. In some embodimens, a bispecific T cell engager (BiTE®) antibody construct activates T cells which result in induced bystander cell lysis. In some embodiments, the bystander cells are in solid tumors. In some embodiments, the bystander cells being lysed are in proximity to the BiTE®-acticvated T cells. In some embodiment, the bystander cells comprises tumor-associated antigen (TAA) negatgive cancer cells. In some embodiment, the

bystander cells comprise EGFR-negative cancer cells. In some embodiments, an immuno-oncology agent is an antibody which blocks the PD-L1/PD1 axis and/or CTLA4. In some embodiments, an immuno-oncology agent is an ex-vivo expanded tumor-infiltrating T cell. In some embodiments, an immuno-oncology agent is a bispecific antibody construct or chimeric antigen receptors (CARs) that directly connect T cells with tumor-associated surface antigens (TAAs).

Exemplary Immune Checkpoint Inhibitors

[00625] In some embodiments, an immuno-oncology agent is an immune checkpoint inhibitor as described herein.

[00626] The term "checkpoint inhibitor" as used herein relates to agents useful in preventing cancer cells from avoiding the immune system of the patient. One of the major mechanisms of anti-tumor immunity subversion is known as "T-cell exhaustion," which results from chronic exposure to antigens that has led to up-regulation of inhibitory receptors. These inhibitory receptors serve as immune checkpoints in order to prevent uncontrolled immune reactions.

[00627] PD-l and co-inhibitory receptors such as cytotoxic T-lymphocyte antigen 4 (CTLA-4, B and T Lymphocyte Attenuator (BTLA; CD272), T cell Immunoglobulin and Mucin domain-3 (Tim-3), Lymphocyte Activation Gene-3 (Lag-3; CD223), and others are often referred to as a checkpoint regulators. They act as molecular "gatekeepers" that allow extracellular information to dictate whether cell cycle progression and other intracellular signaling processes should proceed.

[00628] In some embodiments, an immune checkpoint inhibitor is an antibody to PD-l. PD-l binds to the programmed cell death 1 receptor (PD-l) to prevent the receptor from binding to the inhibitory ligand PDL-l, thus overriding the ability of tumors to suppress the host anti-turnor immune response.

[00629] In one aspect, the checkpoint inhibitor is a biologic therapeutic or a small molecule. In another aspect, the checkpoint inhibitor is a monoclonal antibody, a humanized antibody, a fully human antibody, a fusion protein or a combination thereof. In a further aspect, the checkpoint inhibitor inhibits a checkpoint protein selected from CTLA-4, PDL1, PDL2, PD1, B7-H3, B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK 1, CHK2, A2aR, B-7 family ligands or a combination thereof. In an additional aspect, the checkpoint

inhibitor interacts with a ligand of a checkpoint protein selected from CTLA-4, PDL1, PDL2, PD1, B7-H3, B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK 1, CHK2, A2aR, B-7 family ligands or a combination thereof. In an aspect, the checkpoint inhibitor is an immunostimulatory agent, a T cell growth factor, an interleukin, an antibody, a vaccine or a combination thereof. In a further aspect, the interleukin is IL-7 or IL-15. In a specific aspect, the interleukin is glycosylated IL-7. In an additional aspect, the vaccine is a dendritic cell (DC) vaccine.

[00630] Checkpoint inhibitors include any agent that blocks or inhibits in a statistically significant manner, the inhibitory pathways of the immune system. Such inhibitors may include small molecule inhibitors or may include antibodies, or antigen binding fragments thereof, that bind to and block or inhibit immune checkpoint receptors or antibodies that bind to and block or inhibit immune checkpoint receptor ligands. Illustrative checkpoint molecules that may be targeted for blocking or inhibition include, but are not limited to, CTLA-4, PDL1, PDL2, PD1, B7-H3, B7-H4, BTLA, HVEM, GAL9, LAG3, TIM3, VISTA, KIR, 2B4 (belongs to the CD2 family of molecules and is expressed on all NK, γδ, and memory $CD8^+$ (αβ) T cells), CD 160 (also referred to as BY55), CGEN-15049, CHK 1 and CHK2 kinases, A2aR, and various B-7 family ligands. B7 family ligands include, but are not limited to, B7- 1, B7-2, B7-DC, B7-H1, B7-H2, B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7. Checkpoint inhibitors include antibodies, or antigen binding fragments thereof, other binding proteins, biologic therapeutics, or small molecules, that bind to and block or inhibit the activity of one or more of CTLA-4, PDL1, PDL2, PD1, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD 160 and CGEN-15049. Illustrative immune checkpoint inhibitors include Tremelimumab (CTLA-4 blocking antibody), anti-OX40, PD-L1 monoclonal Antibody (Anti-B7-Hl; MEDI4736), MK-3475 (PD-l blocker), Nivolumab (anti-PDl antibody), CT-011 (anti-PDl antibody), BY55 monoclonal antibody, AMP224 (anti-PDLl antibody), BMS- 936559 (anti-PDLl antibody), MPLDL3280A (anti-PDLl antibody), MSB0010718C (anti-PDLl antibody), and ipilimumab (anti-CTLA-4 checkpoint inhibitor). Checkpoint protein ligands include, but are not limited to PD-L1, PD-L2, B7-H3, B7-H4, CD28, CD86 and TIM-3.

[00631] In certain embodiments, the immune checkpoint inhibitor is selected from a PD-l antagonist, a PD-L1 antagonist, and a CTLA-4 antagonist. In some embodiments, the checkpoint inhibitor is selected from the group consisting of nivolumab (Opdivo®), ipilimumab (Yervoy®),

and pembrolizumab (Keytruda®). In some embodiments, the checkpoint inhibitor is selected from nivolumab (anti-PD-1 antibody, Opdivo®, Bristol-Myers Squibb); pembrolizumab (anti-PD-1 antibody, Keytruda®, Merck); ipilimumab (anti-CTLA-4 antibody, Yervoy®, Bristol-Myers Squibb); durvalumab (anti-PD-Ll antibody, Imfinzi®, AstraZeneca); and atezolizumab (anti-PD-L l antibody, Tecentriq®, Genentech).

[00632] In some embodiments, the checkpoint inhibitor is selected from the group consisting of lambrolizumab (MK-3475), nivolumab (BMS-936558), pidilizumab (CT-011), AMP-224, MDX-1105, MED 14736, MPDL3280A, BMS-936559, ipilimumab, lirlumab, IPH2101, pembrolizumab (Keytruda®), and tremelimumab.

[00633] In some embodiments, an immune checkpoint inhibitor is REGN2810 (Regeneron), an anti-PD-l antibody tested in patients with basal cell carcinoma (NCT03 132636); NSCLC (NCT03088540); cutaneous squamous cell carcinoma (NCT02760498); lymphoma (NCT02651662); and melanoma (NCT03002376); pidilizumab (CureTech), also known as CT-011, an antibody that binds to PD-l, in clinical trials for diffuse large B-cell lymphoma and multiple myeloma; avelumab (Bavencio®, Pfizer/Merck KGaA), also known as MSB0010718C), a fully human IgGl anti-PD-Ll antibody, in clinical trials for non-small cell lung cancer, Merkel cell carcinoma, mesothelioma, solid tumors, renal cancer, ovarian cancer, bladder cancer, head and neck cancer, and gastric cancer; or PDR001 (Novartis), an inhibitory antibody that binds to PD-l, in clinical trials for non-small cell lung cancer, melanoma, triple negative breast cancer and advanced or metastatic solid tumors. Tremelimumab (CP-675,206; Astrazeneca) is a fully human monoclonal antibody against CTLA-4 that has been in studied in clinical trials for a number of indications, including: mesothelioma, colorectal cancer, kidney cancer, breast cancer, lung cancer and non-small cell lung cancer, pancreatic ductal adenocarcinoma, pancreatic cancer, germ cell cancer, squamous cell cancer of the head and neck, hepatocellular carcinoma, prostate cancer, endometrial cancer, metastatic cancer in the liver, liver cancer, large B-cell lymphoma, ovarian cancer, cervical cancer, metastatic anaplastic thyroid cancer, urothelial cancer, fallopian tube cancer, multiple myeloma, bladder cancer, soft tissue sarcoma, and melanoma. AGEN-1884 (Agenus) is an anti-CTLA4 antibody that is being studied in Phase 1 clinical trials for advanced solid tumors (NCT02694822).

[00634] In some embodiments, a checkpoint inhibitor is an inhibitor of T-cell immunoglobulin mucin containing protein-3 (TIM-3). TIM-3 inhibitors that may be used in the present invention

include TSR-022, LY3321367 and MBG453. TSR-022 (Tesaro) is an anti-TIM-3 antibody which is being studied in solid tumors (NCT02817633). LY3321367 (Eli Lilly) is an anti-TIM-3 antibody which is being studied in solid tumors (NCT03099109). MBG453 (Novartis) is an anti-TIM-3 antibody which is being studied in advanced malignancies (NCT02608268).

[00635] In some embodiments, a checkpoint inhibitor is an inhibitor of T cell immunoreceptor with Ig and ITEM domains, or TIGIT, an immune receptor on certain T cells and NK cells. TIGIT inhibitors that may be used in the present invention include BMS-986207 (Bristol-Myers Squibb), an anti-TIGIT monoclonal antibody (NCT02913313); OMP-313M32 (Oncomed); and anti-TIGIT monoclonal antibody (NCT03119428).

[00636] In some embodiments, a checkpoint inhibitor is an inhibitor of Lymphocyte Activation Gene-3 (LAG-3). LAG-3 inhibitors that may be used in the present invention include BMS-986016 and REGN3767 and IMP321. BMS-986016 (Bristol-Myers Squibb), an anti-LAG-3 antibody, is being studied in glioblastoma and gliosarcoma (NCT02658981). REGN3767 (Regeneron), is also an anti-LAG-3 antibody, and is being studied in malignancies (NCT03005782). IMP321 (Immutep S.A.) is an LAG-3-Ig fusion protein, being studied in melanoma (NCT02676869); adenocarcinoma (NCT02614833); and metastatic breast cancer (NCT00349934).

[00637] Checkpoint inhibitors that may be used in the present invention include 0X40 agonists. 0X40 agonists that are being studied in clinical trials include PF-04518600/PF-8600 (Pfizer), an agonistic anti-OX40 antibody, in metastatic kidney cancer (NCT03092856) and advanced cancers and neoplasms (NCT02554812; NCT05082566); GSK3 174998 (Merck), an agonistic anti-OX40 antibody, in Phase 1 cancer trials (NCT02528357); MED 10562 (Medimmune/AstraZeneca), an agonistic anti-OX40 antibody, in advanced solid tumors (NCT023 18394 and NCT02705482); MEDI6469, an agonistic anti-OX40 antibody (Medimmune/AstraZeneca), in patients with colorectal cancer (NCT02559024), breast cancer (NCT0 1862900), head and neck cancer (NCT02274155) and metastatic prostate cancer (NCT01303705); and BMS-986178 (Bristol-Myers Squibb) an agonistic anti-OX40 antibody, in advanced cancers (NCT02737475).

[00638] Checkpoint inhibitors that may be used in the present invention include CD137 (also called 4-1BB) agonists. CD137 agonists that are being studied in clinical trials include utomilumab (PF-05082566, Pfizer) an agonistic anti-CDl37 antibody, in diffuse large B-cell lymphoma (NCT02951156) and in advanced cancers and neoplasms (NCT02554812 and

NCT05082566); urelumab (BMS-663513, Bristol-Myers Squibb), an agonistic anti-CDl37 antibody, in melanoma and skin cancer (NCT02652455) and glioblastoma and gliosarcoma (NCT02658981).

[00639] Checkpoint inhibitors that may be used in the present invention include CD27 agonists. CD27 agonists that are being studied in clinical trials include varlilumab (CDX-1127, Celldex Therapeutics) an agonistic anti-CD27 antibody, in squamous cell head and neck cancer, ovarian carcinoma, colorectal cancer, renal cell cancer, and glioblastoma (NCT02335918); lymphomas (NCT01460134); and glioma and astrocytoma (NCT02924038).

[00640] Checkpoint inhibitors that may be used in the present invention include glucocorticoid-induced tumor necrosis factor receptor (GITR) agonists. GITR agonists that are being studied in clinical trials include TRX518 (Leap Therapeutics), an agonistic anti-GITR antibody, in malignant melanoma and other malignant solid tumors (NCT01239134 and NCT02628574); GWN323 (Novartis), an agonistic anti-GITR antibody, in solid tumors and lymphoma (NCT 02740270); INCAGN01876 (Incyte/Agenus), an agonistic anti-GITR antibody, in advanced cancers (NCT02697591 andNCT03l26H0); MK-4166 (Merck), an agonistic anti-GITR antibody, in solid tumors (NCT02132754) and MEDI1873 (Medimmune/AstraZeneca), an agonistic hexameric GITR-ligand molecule with a human IgGl Fc domain, in advanced solid tumors (NCT02583 165).

[00641] Checkpoint inhibitors that may be used in the present invention include inducible T-cell co-stimulator (ICOS, also known as CD278) agonists. ICOS agonists that are being studied in clinical trials include MED 1-570 (Medimmune), an agonistic anti-ICOS antibody, in lymphomas (NCT02520791); GSK3359609 (Merck), an agonistic anti-ICOS antibody, in Phase 1 (NCT02723955); JTX-2011 (Jounce Therapeutics), an agonistic anti-ICOS antibody, in Phase 1 (NCT02904226).

[00642] Checkpoint inhibitors that may be used in the present invention include killer IgG-like receptor (KIR) inhibitors. KIR inhibitors that are being studied in clinical trials include lirilumab (IPH2102/BMS-986015, Innate Pharma/Bristol-Myers Squibb), an anti-KIR antibody, in leukemias (NCT01687387, NCT02399917, NCT02481297, NCT02599649), multiple myeloma (NCT02252263), and lymphoma (NCT01 592370); IPH2101 (1-7F9, Innate Pharma) in myeloma (NCT01222286 and NCT01217203); and IPH4102 (Innate Pharma), an anti-KIR antibody that binds to three domains of the long cytoplasmic tail (KIR3DL2), in lymphoma (NCT02593045).

[00643] Checkpoint inhibitors that may be used in the present invention include CD47 inhibitors of interaction between CD47 and signal regulatory protein alpha (SIRPa). CD47/SIRPa inhibitors that are being studied in clinical trials include ALX-148 (Alexo Therapeutics), an antagonistic variant of (SIRPa) that binds to CD47 and prevents CD47/SIRPa-mediated signaling, in phase 1 (NCT03013218); TTI-621 (SIRPa-Fc, Trillium Therapeutics), a soluble recombinant fusion protein created by linking the N-terminal CD47-binding domain of SIRPa with the Fc domain of human IgGl, acts by binding human CD47, and preventing it from delivering its "do not eat" signal to macrophages, is in clinical trials in Phase 1 (NCT02890368 andNCT026635l8); CC-90002 (Celgene), an anti-CD47 antibody, in leukemias (NCT02641002); and Hu5F9-G4 (Forty Seven, Inc.), in colorectal neoplasms and solid tumors (NCT02953782), acute myeloid leukemia (NCT02678338) and lymphoma (NCT02953509).

[00644] Checkpoint inhibitors that may be used in the present invention include CD73 inhibitors. CD73 inhibitors that are being studied in clinical trials include MEDI9447 (Medimmune), an anti-CD73 antibody, in solid tumors (NCT02503774); and BMS-986179 (Bristol-Myers Squibb), an anti-CD73 antibody, in solid tumors (NCT02754141).

[00645] Checkpoint inhibitors that may be used in the present invention include agonists of stimulator of interferon genes protein (STING, also known as transmembrane protein 173, or TMEM173). Agonists of STINGthat are being studied in clinical trials include MK-1454 (Merck), an agonistic synthetic cyclic dinucleotide, in lymphoma (NCT03010176); and ADU-S100 (MIW815, Aduro Biotech/Novartis), an agonistic synthetic cyclic dinucleotide, in Phase 1 (NCT02675439 and NCT03 172936).

[00646] Checkpoint inhibitors that may be used in the present invention include CSF1R inhibitors. CSF 1R inhibitors that are being studied in clinical trials include pexidartinib (PLX3397, Plexxikon), a CSF1R small molecule inhibitor, in colorectal cancer, pancreatic cancer, metastatic and advanced cancers (NCT02777710) and melanoma, non-small cell lung cancer, squamous cell head and neck cancer, gastrointestinal stromal tumor (GIST) and ovarian cancer (NCT02452424); and IMC-CS4 (LY3022855, Lilly), an anti-CSF-lR antibody, in pancreatic cancer (NCT03 153410), melanoma (NCT03 101254), and solid tumors (NCT02718911); and BLZ945 (4-[2((lR,2R)-2-hydroxycyclohexylamino)-benzothiazol-6-yloxyl]-pyridine-2-carboxylic acid methylamide, Novartis), an orally available inhibitor of CSF1R, in advanced solid tumors (NCT02829723).

[00647] Checkpoint inhibitors that may be used in the present invention include NKG2A receptor inhibitors. NKG2A receptor inhibitors that are being studied in clinical trials include monalizumab (IPH2201, Innate Pharma), an anti-NKG2A antibody, in head and neck neoplasms (NCT02643550) and chronic lymphocytic leukemia (NCT02557516).

[00648] In some embodiments, the immune checkpoint inhibitor is selected from nivolumab, pembrolizumab, ipilimumab, avelumab, durvalumab, atezolizumab, or pidilizumab.

EXEMPLIFICATION

[00649] **Abbreviations**

Ac: acetyl

AcOH: acetic acid

ACN: acetonitrile

Ad: adamantly

AIBN: 2,2'-azo bisisobutyronitrile

Anhyd: anhydrous

Aq: aqueous

B_2Pin_2: bis (pinacolato)diboron -4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2-dioxaborolane)

BINAP: 2,2'-bis(diphenylphosphino)- 1,1'-binaphthyl

BH_3: Borane

Bn: benzyl

Boc: *tert*-butoxycarbonyl

Boc_20: di-tert-butyl dicarbonate

BPO: benzoyl peroxide

^nBuOH: n-butanol

CDI: carbonyldiimidazole

COD: cyclooctadiene

d: days

DABCO: l,4-diazobicyclo[2.2.2]octane

DAST: diethylaminosulfur trifluoride

dba: dibenzylideneacetone

DBU : 1,8-diazobicyclo[5 .4. 0]undec-7-ene

DCE: l,2-dichloroethane

DCM: dichloromethane

DEA. diethylamine

DHP: dihydropyran

DIBAL-H: diisobutylaluminum hydride

DIPA: diisopropylamine

DIPEA or DIEA: N,N-diisopropylethylamine

DMA: N,N-dimethylacetamide

DME: l,2-dimethoxy ethane

DMAP: 4-dimethylaminopyridine

DMF : N,N-dimethylformamide

DMP: Dess-Martin periodinane

DMSO-dimethyl sulfoxide

DPPA: diphenylphosphoryl azide

dppf : 1,1'-bis(diphenylphosphino)ferrocene

EDC or EDCI: l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride

ee: enantiomeric excess

ESI: electrospray ionization

EA: ethyl acetate

EtOAc: ethyl acetate

EtOH: ethanol

FA: formic acid

h or hrs: hours

HATU: N,N,N',N ',-tetramethyl-0-(7-azabenzotriazol-l-yl)uronium hexafluorophosphate

HC1: hydrochloric acid

HPLC: high performance liquid chromatography

HOAc: acetic acid

IBX: 2-iodoxybenzoic acid

IPA: isopropyl alcohol

KHMDS: potassium hexamethyldisilazide

K_2CO_3: potassium carbonate

LAH: lithium aluminum hydride

LDA: lithium diisopropylamide

m-CPBA: meta-chloroperbenzoic acid

M: molar

MeCN: acetonitrile

MeOH: methanol

Me_2S: dimethyl sulfide

MeONa: sodium methylate

Mel: iodomethane

min: minutes

mL: milliliters

mM: millimolar

mmol: millimoles

MPa: mega pascal

MOMC1: methyl chloromethyl ether

MsCl: methanesulfonyl chloride

MTBE: methyl *tert*-butyl ether

nBuLi: n-butyllithium

NaNCh: sodium nitrite

NaOH: sodium hydroxide

Na_2S0_4: sodium sulfate

NBS: N-bromosuccinimide

NCS: N-chlorosuccinimide

NFSI: N-Fluorobenzenesulfonimide

NMO: N-methylmorpholine N-oxide

NMP: N-methylpyrrolidine

NMR: Nuclear Magnetic Resonance

°C: degrees Celsius

Pd/C: Palladium on Carbon

$Pd(OAc)_2$: Palladium Acetate

PBS: phosphate buffered saline

PE: petroleum ether

POCh: phosphorus oxychloride

PPI13: triphenylphosphine

PyBOP: (Benzotriazol-l-yloxy)tripyrrolidinophosphonium hexafluorophosphate

Rel: relative

R.T. or rt: room temperature

sat: saturated

SEMC1: chloromethyl-2-trimethylsilyl ethyl ether

SFC: supercritical fluid chromatography

SOCb: sulfur dichloride

tBuOK: potassium /c/V-butoxide

TBAB: tetrabutylammonium bromide

TBAI: tetrabutylammonium iodide

TEA: triethylamine

Tf: trifluoromethanesulfonate

TfAA, TFMSAor Tf_20 : trifluoromethanesulfonic anhydride

TFA: trifluoracetic acid

TIPS: triisopropylsilyl

THF : tetrahydrofuran

THP: tetrahydropyran

TLC: thin layer chromatography

TMEDA: tetramethylethylenediamine

pTSA: para-toluenesulfonic acid

wt: weight

Xantphos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene

[00650] General Synthetic Methods

[00651] The following examples are intended to illustrate the invention and are not to be

construed as being limitations thereon. Temperatures are given in degrees centigrade. If not mentioned otherwise, all evaporations are performed under reduced pressure, preferably between about 15 mm Hg and 100 mm Hg (= 20-133 mbar). The structure of final products, intermediates and starting materials is confirmed by standard analytical methods, e.g., microanalysis and spectroscopic characteristics, e.g., MS, IR, NMR. Abbreviations used are those conventional in the art.

[00652] All starting materials, building blocks, reagents, acids, bases, dehydrating agents, solvents, and catalysts utilized to synthesis the compounds of the present invention are either commercially available or can be produced by organic synthesis methods known to one of ordinary skill in the art (Houben-Weyl 4th Ed. 1952, Methods of Organic Synthesis, Thieme, Volume 21). Further, the compounds of the present invention can be produced by organic synthesis methods known to one of ordinary skill in the art as shown in the following examples.

[00653] All reactions are carried out under nitrogen or argon unless otherwise stated.

[00654] Proton NMR ('H NMR) is conducted in deuterated solvent. In certain compounds disclosed herein, one or more ^{1}H shifts overlap with residual proteo solvent signals; these signals have not been reported in the experimental provided hereinafter.

[00655] Table 2: Analytical instruments

LCMS	Shimadzu UFLC MS: LCMS-2020 Agilent Technologies 1200 series MS: Agilent Technologies 6110 Agilent Technologies 1200 series MS: LC/MSD VL
NMR	BRUKER AVANCE III/400; Frequency (MHz) 400.13; Nucleus: 1H; Number of Transients: 8
Prep-HPLC	Gilson GX-281 systems: instruments GX-A, GX-B, GX-C, GX-D, GX-E, GX-F, GX-G and GX-H
GCMS	SHIMADZU GCMS-QP2010 Ultra
Analytical	Agilent Technologies 1290 Infinity

cSFC	
Prep-cSFC	Waters SFC Prep 80

[00656] For acidic LCMS data:

[00657] LCMS was recorded on an Agilent 1200 Series LC/MSD or Shimadzu LCMS2020 equipped with electro-spray ionization and quadruple MS detector [ES+ve to give MH^+] and equipped with Chromolith Flash RP-l8e 25*2.0 mm, eluting with 0.0375 vol% TFA in water (solvent A) and 0.01875 vol% TFA in acetonitrile (solvent B). Other LCMS was recorded on an Agilent 1290 Infinity RRLC attached with Agilent 6120 Mass detector. The column used was BEH C18 50*2.1 mm, 1.7 micron. Column flow was 0.55 ml /min and mobile phase were used (A) 2 mM Ammonium Acetate in 0.1% Formic Acid in Water and (B) 0.1 % Formic Acid in Acetonitrile.

[00658] For basic LCMS data:

[00659] LCMS was recorded on an Agilent 1200 Series LC/MSD or Shimadzu LCMS 2020 equipped with electro-spray ionization and quadruple MS detector [ES+ve to give MEL] and equipped with Xbridge C18, 2.1X50 mm columns packed with 5 mm Cl8-coated silica or Kinetex EVO C18 2.lX30mm columns packed with 5 mm Cl8-coated silica, eluting with 0.05 vol% NFL-FLO in water (solvent A) and acetonitrile (solvent B).

[00660] HPLC Analytical Method:

[00661] HPLC was carried out on X Bridge C18 150*4.6 mm, 5 micron. Column flow was 1.0 ml /min and mobile phase were used (A) 0.1 % Ammonia in water and (B) 0.1 % Ammonia in Acetonitrile.

[00662] Prep HPLC Analytical Method:

[00663] The compound was purified on Shimadzu LC-20AP and UV detector. The column used was X-BRIDGE C18 (250*l9)mm, 5µ. Column flow was 16.0 ml/min. Mobile phase were used (A) 0.1% Formic Acid in Water and (B) Acetonitrile Basic method used (A) 5mM ammonium bicarbonate and 0.1% NH3 in Water and (B) Acetonitrile or (A) 0.1% Ammonium Hydroxide in Water and (B) Acetonitrile. The UV spectra were recorded at 202nm & 254nm.


[00664] NMR Method:

[00665] The 1H NMR spectra were recorded on a Bruker Ultra Shield Advance 400 MHz/5 mm Probe (BBFO). The chemical shifts are reported in part-per-million.

[00666] As depicted in the Examples below, in certain exemplary embodiments, compounds are prepared according to the following general procedures. It will be appreciated that, although the general methods depict the synthesis of certain compounds of the present invention, the following general methods, and other methods known to one of ordinary skill in the art, can be applied to all compounds and subclasses and species of each of these compounds, as described herein.

[00667] **INTERMEDIATES:**


[00668] **l-azido-5-bromopentane [Intermediate A)**



A

[00669] To a stirred solution of sodium azide (2.5 g, 38.5 mmol) in DMF (85 mL) was added l,5-dibromopentane (8.4 g, 36.7 mmol) at room temperature. The resulting reaction mixture was then stirred at 50 °C for 16 h. The reaction mixture was transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 100 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give l-azido-5-bromopentane as colorless oil (5.0 g, 71 %). ^{1}H NMR (400 MHz, DMSO) δ 3.44 (t, J = 6.8 Hz, 2H), 3.32 (t, J = 4 Hz, 2H), 1.95-1.91 (m, 2H), 1.67-1.62 (m, 2H), 1.56-1.46 (m, 2H).

[00670] **fe/7-butyl (5-(2-(2-((5-aminopentyPoxy)ethoxy)ethoxy)pentyPcarbamate (Intermediate B)**



[00671] Step 1 - *tert*-butyl (5-hydroxypentyl)carbamate

[00672] To a stirred solution of 5-aminopentan-1-ol (10.0 g, 96.9 mmol) in DCM (75 mL) was added Boc-anhydride (25.4 g, 116.3 mmol) dropwise at 0 °C. The resulting reaction mixture was allowed to warm to room temperature and stirred at rt for 1 h. The reaction mixture was transferred into ice water and the resulting mixture was extracted using DCM (3 x 100 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give ter/-butyl (5-hydroxypentyl)carbamate as colorless oil (16 g, 81 %). ^{1}H NMR (400 MHz, DMSO) δ 4.56 (bs, 1H), 3.69-3.64 (m, 2H), 3.17-3.12 (m, 2H), 1.64-1.62 (m, 2H), 1.54-1.53 (m, 6H), 1.51-1.49 (m, 1H), 1.46 (s, 9H), 1.43-1.37 (m, 2H).

[00673] Step 2 - 5-((*tert*-butoxycarbonyl)amino)pentyl methanesulfonate

[00674] To a stirred solution of *tert*-butyl (5-hydroxypentyl)carbamate (6.0 g, 29.5 mmol) and triethylamine (13 mL, 88.5 mmol) in DCM (100 mL) was added mesyl chloride (3.7 mL, 44.3 mmol) dropwise at 0 °C. The resulting reaction mixture was allowed to warm to room temperature and stirred at rt for 2 h. The reaction mixture was transferred into water and the resulting mixture was extracted using DCM (3 x 100 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give 5-{{*tert*-butoxycarbonyl)amino)pentyl methanesulfonate as white solid (7.0 g, 84%). LCMS: (ES$^+$) m/z $(M+H)^+$

[00675] Step 3 - *tert*-butyl (5-(2-(2-(benzyloxy)ethoxy)ethoxy)pentyl)carbamate

[00676] To a stirred solution of 2-(2-(benzyloxy)ethoxy)ethan-1-ol (3.3 g, 16.8 mmol, CAS#

2050-25-1) and 5-((/er/-butoxycarbonyl)amino)pentyl methanesulfonate (7.0 g, 25.2 mmol) in toluene (50 mL) and 8 N Aqueous NaOH solution (50 mL) was added TBAB (catalytic amount) at room temperature. The resulting reaction mixture was allowed to stir at 80 °C for 16 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 100 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to afford the crude product. The crude product was purified using silica gel column chromatography (25% EtOAc-Hexanes) to give *tert*-butyl (5-(2-(2-(benzyloxy)ethoxy)ethoxy)pentyl)carbamate as colorless oil (3.5 g, 55%). ^{1}H NMR (400 MHz, DMSO) δ 7.36 (d, *J* = 4.4 Hz, 2H), 7.32-7.28 (m, 2H), 4.59 (s, 1H), 3.71-3.70 (m, 2H), 3.69-3.67 (m, 1H), 3.66-3.65 (m, 1H), 3.13-3.11 (m, 1H), 1.65-1.61 (m, 2H), 1.59-1.54 (m, 6H), 1.50-1.48 (m, 1H).

[00677] Step 4 - *tert*-butyl (5-(2-(2-hydroxyethoxy)ethoxy)pentyl)carbamate

[00678] To a stirred solution of *tert*-butyl (5-(2-(2-(benzyloxy)ethoxy)ethoxy)pentyl)carbamate (3.5 g, 9.2 mmol) in ethanol (30 mL), THF (30 mL), ethyl acetate (30 mL) and acetic acid (2 mL) was added 20% $Pd(OH)_2$ (2.5 g) at room temperature under nitrogen atmosphere. The resulting reaction mixture was allowed to stir under hydrogen gas (20 kg/cm^2 pressure) in an autoclave at 60 °C for 16 h. The reaction mixture was filtered through celite with a vacuum and washed with MeOH (50 mL). The filtrate was evaporated under reduced pressure to give *tert*-butyl (5-(2-(2-hydroxyethoxy)ethoxy)pentyl)carbamate as colorless oil (2.5 g, 93 %). ^{1}H NMR (400 MHz, DMSO) δ 4.68 (bs, 1H), 3.77-3.75 (m, 2H), (s, 1H), 3.71-3.69 (m, 2H), 3.69-3.64 (m, 2H), 3.63-3.59 (m, 2H), 3.51-3.48 (m, 2H), 3.14-3.13 (m, 3H), 1.71-1.61 (m, 2H), 1.59-1.55 (m, 2H), 1.45 (s, 9H), 1.42-1.36 (m, 2H).

[00679] Step 5 - *tert*-butyl (5-(2-(2-(Y5-azidopentyDoxy)ethoxy)ethoxy)pentyDcarbamate


[00680] To a stirred solution of tert-butyl (5-(2-(2-hydroxyethoxy)ethoxy)pentyl)carbamate (1.4 g, 4.8 mmol) and l-azido-5-bromopentane (2.8 g, 14.4 mmol, Intermediate A) in toluene (10 mL) and 8 N aqueous NaOH solution (10 mL) was added TBAB (catalytic amount) at rt. The resulting reaction mixture was then heated to 80 °C and stirred for 16 h. The reaction mixture was transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 100 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give *tert*-butyl (5-(2-(2-((5-azidopentyl)oxy)ethoxy)ethoxy)pentyl)carbamate as colorless oil (0.95 g, 50%). ^{1}H NMR (400

MHz, DMSO) δ 4.56 (bs, 1H), 3.69-3.61 (m, 4H), 3.50-3.46 (m, 3H), 3.33-3.27 (m, 1H), 3.14-3.12 (m, 1H), 1.68-1.61 (m, 4H), 1.53-1.42 (m, 7H).


[00681] Step 6 - *tert*-butyl (5-(2-(2-hydroxyethoxy)ethoxy)pentyl)carbamate

[00682] To a stirred solution of te/7-butyl (5-(2-(2-((5-azidopentyl)oxy)ethoxy)ethoxy)pentyl)carbamate (0.45 g, 1.12 mmol) in methanol (30 mL) was added 20% $Pd(OH)_2$ (0.45 g) at room temperature under nitrogen atmosphere. The resulting reaction mixture was stirred under hydrogen gas (20 kg/cm2 pressure) in an auto clave at rt for 3 h. The reaction mixture was filtered through a pad of celite under vacuum and washed with MeOH (50 mL). The filtrate was evaporated under reduced pressure to give *tert*-butyl (5-(2-(2-((5-aminopentyl)oxy)ethoxy)ethoxy)pentyl)carbamate as colorless oil (0.35 g, 83 %).

[00683] (1R,4R)-4-(6-((1,6-naphthyridin-2-yl)amino)-4-[cyclopropylaminolnicotinamidolcyclohexane-l-carboxylic acid [Intermediate C)



N



C

[00684] Step 1: Methyl (TR.4R)-4-(6-(YL6-naphthyridin-2-v0amino)-4-(cyclopropylaminoinicotinamidoicyclohexane- 1-carboxylate

[00685] To a stirred solution of 6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinic acid (1.85 g, 5.76 mmol, Intermediate N) and methyl (lR,4R)-4-aminocyclohexane-l-carboxylate hydrochloride (1.34 g, 6.91 mmol) in DMF (10 mL) was added DIPEA (5 mL, 28.8 mmol) and PyBOP (4.5 g, 8.64 mmol) at rt. The resulting reaction mixture was stirred at rt for 16 h. The reaction mixture was then transferred into ice water and the resulting precipitate was filtered off, and dried reduced pressure. The crude product was purified using silica


gel column chromatography (7% MeOH-DCM) to give methyl (lr,4r)-4-(6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinamido)cyclohexane-l-carboxylate as light a green solid (1.3 g, 49%). LC-MS (ESI+) m/z 460.54 (M+H)+

[00686] Step 2 - (1R,4R)-4-(6-((1.6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinamido)cyclohexane-l -carboxylic acid

[00687] To a stirred solution of methyl (lR,4R)-4-(6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinamido)cyclohexane-l-carboxylate (1.2 g, 2.6 mmol) in MeOH (20 mL) was added NaOH (2 g, 50 mmol) in 20 mL water dropwise at rt. The resulting reaction mixture was stirred at rt for 3 h. The reaction mixture was then evaporated under vacuum, water (10 mL) was added and pH was adjusted to 6-7 using 10 % citric acid solution. The resulting mixture was stirred for 15 min, the solid precipitate was filtered off and dried under vacuum to give (1R,4R)-4-(6-((l,6-naphthyri din-2-yl)amino)-4-(cyclopropylamino)nicotinamido)cyclohexane-l -carboxylic acid as a brown solid (0.9 g, 77%). LC-MS (ESI+) m/z 446.51 (M+H)+

[00688] **2-((2-(2.,6-dioxopiperidin-3-vP-l.,3-dioxoisoindolin-4-vPoxy)acetic acid**

[Intermediate D)



D

[00689] Step 1 - *tert*-butyl (2.6-dioxopiperidin-3-yl)carbamate

[00690] To a stirred solution of (/er/-butoxycarbonyl)-L-glutamine (6.0 g, 24 mmol) in THF (60 mL) was added CDI (4.2 g, 25.9 mmol) and DMAP (0.012 g, 0.098 mmol) at rt. The resulting reaction mixture heated to 70 °C and stirred for 16 h. The reaction precipitate was filtered and washed with THF (50 mL), and dried under reduced pressure to give *tert*-butyl (2,6-dioxopiperidin-3-yl)carbamate as white solid (1.8 g, 32%). LCMS (EST) *m/z* 227.2 $(M-H)^-$.

[00691] Step 2 - 3-aminopiperidine-2.6-dione (TFA salt)

[00692] *tert*-Butyl (2,6-dioxopiperidin-3-yl)carbamate (1.8 g, 7.9 mmol) was dissolved in TFA (10 mL) and stirred at rt for 1 h. The reaction mixture was then evaporated under reduced pressure to give 3-aminopiperidine-2,6-dione as the TFA salt as a brown solid (1.7 g, 96%). LCMS (ESI^+) *m/z* 129 $(M+H)^+$.

[00693] Step 3 - 2-(2.6-dioxopiperidin-3-vO-4-hvdroxyisoindoline-L3-dione

[00694] To a stirred solution of 4-hydroxyisobenzofuran-l,3-dione (1.2 g, 7.3 mmol) in pyridine (25 mL) was added 3-aminopiperidine-2,6-dione-TFA salt (1.8 g, 7.3 mmol) at room temperature. The resulting reaction mixture was then warmed to 110 °C and stirred for 16 h. The reaction mixture was then evaporated under reduced pressure. The crude product was purified using silica gel column chromatography (4% MeOH-DCM) to give 2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-l,3-dione as yellow solid (1 g, 50%). LC-MS (EST) *m/z* 273.2 $(M-H)^+$.

[00695] Step 4 - *tert*-butyl 2-((2-(2.6-dioxopiperidin-3-vO-L3-dioxoisoindolin-4-vOoxylacetate


[00696] To a stirred solution of 2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-l,3-dione (2.95 g, 10.76 mmol) and K_2CO_3 (2.22 g, 16.14 mmol) in DMF (40 mL) was added *tert*-butyl 2-bromoacetate (1.6 mL, 10. 16 mmol) in DMF (10 mL) dropwise at rt. The resulting reaction mixture was stirred at rt for 2 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 100 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (50% EAc-Hexanes) to give *tert*-butyl 2-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)oxy)acetate as white solid (3 g, 72%). LC-MS (EST) *m/z* 387.2 $(M-H)^+$.

[00697] Step 5 - 2-((2-(2.6-dioxopiperidin-3-yl)-1.3-dioxoisoindolin-4-yl)oxy)acetic acid

[00698] *tert*-Butyl 2-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)oxy)acetate (3.0 g, 7.7 mmol) was dissolved in TFA (30 mL) and stirred at rt for 1 h. The reaction mixture was then

evaporated under reduced pressure and triturated with MTBE to give 2-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)oxy)acetic acid as white solid (2 g, 78%). ^{1}H NMR (400 MHz, DMSO) δ ppm 13.27 (s, 1H), 11.12 (s, 1H), 7.82-7.78 (m, 1H), 7.48 (d, J = 7.6 Hz, 1H), 7.40 (d, J = 8.4 Hz, 1H), 5.13-5.04 (m, 1H), 4.99 (s, 2H), 2.94-2.85 (m, 1H), 2.73-2.57 (m ,2H), 2.07-2.02 (m, 1H). LCMS (ESI$^+$) *m/z* 333 (M+H)$^+$.

[00699] ***tert*-butyl (5-((5-aminopentyloxy)pentyl)carbamate [Intermediate E)**



[00700] Step 1 - *tert*-butyl (5-hydroxypentyl)carbamate

[00701] To a stirred solution of 5-aminopentan-l-ol (10.0 g, 96.9 mmol) in DCM (75 mL) was added Boc-anhydride (25.4 g, 116.3 mmol) dropwise at 0 °C. The resulting reaction mixture was stirred at room temperature for 1 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using DCM (3 x 100 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give ter/-butyl (5-hydroxypentyl)carbamate as colorless oil (16 g, 81 %). ^{1}H NMR (400 MHz, DMSO) δ 4.56 (bs, 1H), 3.69-3.64 (m, 2H), 3.17-3.12 (m, 2H), 1.64-1.62 (m, 2H), 1.54-1.53 (m, 6H), 1.51-1.49 (m, 1H), 1.46 (s, 9H), 1.43-1.37 (m, 2H).

[00702] Step 2 - *tert*-butyl (5-(Y5-azidopentyloxy)pentyl)carbamate


[00703] To a stirred solution of /ɛvt-butyl (5-hydroxypentyl)carbamate (2.5 g, 12.3 mmol) in DMF (20 mL) was added Nal (catalytic amount) and NaH (0.74 g, 18.4 mmol, 60% dispersion in mineral oil) at room temperature. The resulting reaction mixture was stirred at room temperature for 0.5 h. To this reaction mixture l-azido-5-bromopentane (3.55 g, 18.4 mmol, Intermediate A) in DMF (5 mL) was added dropwise at room temperature. The resulting reaction mixture was stirred at room temperature for 16 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 100 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure. The crude product was purified using silica gel column chromatography (6% EAc-Hexanes) to give /ɛvt-butyl (5-((5-azidopentyl)oxy)pentyl)carbamate as colorless oil (0.85 g,

22%). LC-MS (ESI+) *m/z* 315.39 $(M+H)^+$.

[00704] Step 3 - *tert*-butyl (5-(Y5-aminopentvOoxy)pentvOcarbamate

[00705] To a stirred solution of *tert*-butyl (5-((5-azidopentyl)oxy)pentyl)carbamate (0.2 g, 0.6 mmol) in methanol (5 mL) was added 10% Pd/C (0.1 g, 50% wet) at room temperature under nitrogen atmosphere. The resulting reaction mixture was stirred under hydrogen gas (5 kg/cm^2 pressure) in auto clave at rt for 5 h. The reaction mixture was filtered through a pad of celite under vacuum and washed with MeOH (20 mL). The filtrate was evaporated under reduced pressure to give *tert*-butyl (5-((5-aminopentyl)oxy)pentyl)carbamate as colorless oil (0.15 g, 82 %). LC-MS (ESI+) *m/z* 289.43 $(M+H)^+$.

[00706] ***tert*-butyl (5-(2-((5-aminopentvPoxy)ethoxy)pentvPcarbamate [Intermediate F)**



[00707] Step 1 - (Y2-(Y5-bromopentvDoxy)ethoxy)methvPbenzene

[00708] A solution of 2-(benzyloxy) ethan-l-ol (1.67 g, 10.96 mmol), l,5-dibromopentane (10.0 g, 43.0 mmol), and ammonium bromide (0.5 g) in 8N NaOH (20 mL) was stirred at room temperature for 25 h. The reaction mixture was then transferred into ice water mixture, the pH was adjusted to 6-7, and resulting mixture was extracted using n-hexane (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulphate and filtered. The filtrate was evaporated under vacuum to give ((2-((5-bromopentyl)oxy)ethoxy)methyl)benzene as colorless liquid (23 g, 95%). LC-MS (ESL) *m/z* 303 $(M+H)^{+2}$.

[00709] Step 2 - (Y2-(Y5-azidopentvDoxy)ethoxy)methvPbenzene

[00710] A solution of ((2-((5-bromopentyl)oxy)ethoxy) methyl)benzene (23.0 g, 76.6 mmol) and sodium azide (7.47 g, 114.93 mmol) in DMF (125 mL) was heated to 60 °C and stirred for 18 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 200 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (10 % EtOAc-Hexane) to give ((2-((5-azidopentyl)oxy)ethoxy)methyl)benzene as a colorless liquid (10.5 g, 82%). LC-MS (ESI^+) *m/z* 281.2 $(M+l8)^+$.

[00711] Step 3 - *tert*-butyl (5-(2-hvdroxyethoxy)pentvDcarbamate

[00712] A solution of ((2-((5-azidopentyl)oxy)ethoxy) methyl)benzene (10.5 g, 39.9 mmol), 10 % $Pd/(OH)_2$ (50% wet) (5 g) and Boc anhydride (13.04 g, 59.84 mmol) in MeOH (100 mL) and acetic acid (1 mL) was stirred in an autoclave. The reaction mixture was heated to 60 °C under hydrogen gas (30 kg/cm^2 pressure) for 48 h. The reaction mixture was filtered through a pad of celite and washed with methanol (100 mL). The filtrate was evaporated under reduced pressure and the crude product (with tert-butyl (5-(2-(benzyloxy)ethoxy)pentyl)carbamate as a side product) was purified using silica gel column chromatography (20% EtOAc- hexane) to give *tert*-butyl (5-(2-hydroxyethoxy)pentyl)carbamate as colorless oil (1.6 g, 13%).

[00713] Step 4 - *tert*-butyl (5-(2-(Y5-azidopentvDoxy)ethoxy)pentvPcarbamate


[00714] A solution of *tert*-butyl (5-(2-hydroxyethoxy)pentyl)carbamate (1.6 g, 6.5 mmol), TBAB (0.3 g, catalytic amount) and l-azido-5-bromopentane (1.85 g, 9.71 mmol, Intermediate A) were dissolved in a mixture of toluene (30 mL) and 8 N NaOH (20 mL) and heated at 80 °C for 24 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (25 % EtOAc-Hexane) to give *tert*-butyl (5-(2-((5-azidopentyl)oxy)ethoxy)pentyl)carbamate as a colorless oil (0.7 g, 30%). LC-MS (ESI^+) *m/z* 359.3 $(M+H)^+$.

[00715] Step 5 - *tert*-butyl (5-(2-(Y5-aminopentvDoxy)ethoxy)pentvDcarbamate

[00716] A solution of *tert*-butyl (5-(2-((5-azidopentyl) oxy)ethoxy)pentyl)carbamate (0.7 g, 19.9 mmol) and 10 wt % Pd/C (50% wet) (0.05 g) was dissolved in MeOH (10 mL) in an autoclave. The reaction mixture was heated to 50 °C under hydrogen gas (20 kg/cm^2 pressure) for 4 h. Upon

completion, the reaction mixture was filtered through a pad of celite and washed with methanol (20 mL). The filtrate was evaporated under reduced pressure to give as *tc/t*-butyl (5-(2-((5-aminopentyl)oxy)ethoxy)pentyl)carbamate as a colorless oil (0.55 g) which was used directly in the next step without further purification.

[00717] [2S,4RM-[[S)-2-amino-3.,3-dimethylbutanoyD-4-hydroxy-N-[4-[4-methylthiazol-5-vDbenzvPpyrrolidine-2-carboxamide _ hydrochloride_ [Intermediate_ G)



G

[00718] Step 1 - 4-(4-methylthiazol-5-v0benzonitrile

[00719] To a solution of 4-bromobenzonitrile (1.0 g, 5.5 mmol) and palladium acetate (0.061 g, 2.75 mmol) in dimethyl acetamide (5 mL) was added potassium acetate (1.08 g, 11.0 mmol) and 4-methylthiazole (1 mL, 11.0 mmol) at rt. The reaction mixture was then heated and stirred at 130 °C for 18 h. The reaction mixture was transferred into ice water and the resulting mixture was extracted using DCM (3 x 20 mL). The combined organic layers were dried over anhydrous sodium

sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (10% EtOAc-hexane) to give 4-(4-methylthiazol-5-yl)benzonitrile as yellow solid (0.6 g, 55%). LC-MS (ESI^+) *m/z* 200 $(M+H)^+$.

[00720] Step 2 - *tert*-butyl (4-(4-methylthiazol-5-vPbenzvDcarbamate

[00721] To a stirred solution of 4-(4-methylthiazol-5-yl)benzonitrile (0.6 g, 3.0 mmol) in methanol (50 mL) was added $NiCl_2 \cdot 6H_20$ (0.07 g, 0.3 mmol) and hoc anhydride (1 mL, 4.5 mmol) at 0 °C and stirred for 15 minutes. After 15 minutes, NaBEE (0.8 g, 21.0 mmol) was added in portions over 30 minutes at 0 °C and stirred additional for 30 minutes. Then triethylamine (0.8 mL, 6.0 mmol) was added and the mixture was stirred for a further 3 h. The reaction mixture was then evaporated under vacuum and diluted with ethyl acetate (50 mL) and filtered through celite. The filtrate was washed using water (50 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (15% EtOAc-Hexane) to give *tert*-butyl (4-(4-methylthiazol-5-yl)benzyl)carbamate as yellow semisolid (0.5 g, 55%). LC-MS (ESI^+) *m/z* 305.2 $(M+H)^+$.

[00722] Step 3 - (4-(4-methylthiazol-5-vDphenvDmethanamine hydrochloride

[00723] To a stirred solution of *tert*-butyl (4-(4-methylthiazol-5-yl)benzyl)carbamate (0.5 g, 1.6 mmol) in DCM (5 mL) was added 4N HC1 in dioxane (1 mL) and the reaction mixture was stirred at rt for 3 h. The reaction mixture was then evaporated under vacuum and triturated using diethyl ether to give (4-(4-methylthiazol-5-yl)phenyl)methanamine hydrochloride as yellow solid (0.35 g, 89%). LC-MS (ESI^+) *m/z* 205.2 $(M+H)^+$.

[00724] Step 4 - fer/-butyl (2S.4R)-4-hvdroxy-2-((4-(4-methylthiazol-5-vDbenzvDcarbamovDpyrrolidine- 1-carboxylate

[00725] To a solution of (2S,4R)-l-(/er/-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (0.25 g, 1.08 mmol, CAS# 13726-69-7) in DCM (5 mL) was added N-hydroxysuccinimide (0.16 g, 1.40 mmol) and EDC·HC1 (0.25 g, 1.30 mmol) and the reaction was stirred at rt for 3 h. After 3 h, (4-(4-methylthiazol-5-yl)phenyl)methanamine hydrochloride (0.31 g, 1.30 mmol) and DIPEA (0.6 mL, 3.24 mmol) was added and the reaction mixture was stirred at room temperature for 18 h. The reaction mixture was diluted with saturated NaHCCh solution (50 mL) and extracted in DCM (50 mL x 3). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified

using silica gel column chromatography (2% MeOH-DCM) to give *tert*-butyl (2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-l-carboxylate as yellow solid (0.3 g, 66%). LC-MS (ESI$^+$) *m/z* 418.8 (M+H)$^+$.

[00726] Step 5 - (2S.4R)-4-hvdroxy-N-(4-(4-methylthiazol-5-yl ibenzyl)pyrrolidine-2-carboxamide hydrochloride

[00727] To a stirred solution of *tert*-butyl (2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-l-carboxylate (0.3 g, 0.7 mmol) in DCM (10 mL) was added 4N HC1 in dioxane (1 mL) and the reaction mixture was stirred at rt for 3 h. The reaction mixture was then evaporated under vacuum and triturated using diethyl ether to give (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride as yellow solid (0.2 g, 79 %). LC-MS (ESL) *m/z* 318.0 (M+H)$^+$.

[00728] Step 6 - *tc/t*-butyl ((S)-1-(Y2S.4R)-4-hvdroxy-2-(Y4-(4-methylthiazol-5-yl ibenzyl icarbamoyl Lpyrrolidin- 1-yl)-3,3-di methyl - 1-oxobutan-2-yl)carbamate


[00729] To a solution of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (0.2 g, 0.6 mmol), (S)-2-((/er/-butoxycarbonyl)amino)-3,3-dimethylbutanoic acid (0.13 g, 0.57 mmol, CAS# 62965-35-9) and DIPEA (0.4 mL, 2.28 mmol) in DMF (2 mL), was added HATU (0.3 g, 0.63 mmol) and the reaction mixture was stirred at rt for 1 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 20 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (4% MeOH-DCM) to give *tert*-butyl ((S)-l-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-l-yl)-3,3-dimethyl-l-oxobutan-2-yl)carbamate as yellow semisolid (0.15 g, 44%). LC-MS (ESI$^+$) *m/z* 531.81 (M+H)$^+$.

[00730] Step 7 - (2S.4R)- 1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-vnbenzvDpyrrolidine-2-carboxamide hydrochloride

[00731] To a stirred solution of tert-butyl ((S)-l-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-l-yl)-3,3-dimethyl-l-oxobutan-2-yl)carbamate (0.15 g, 0.28 mmol) in DCM (10 mL) was added 4N HC1 in dioxane (1 mL) and the reaction mixture was stirred at rt for 3 h. The reaction mixture was then evaporated under vacuum and solid was triturated using diethyl ether to give (2S,4R)-l-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-

methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride as yellow solid (0.12 g, 91 %). ^{1}H NMR (400 MHz, DMSO) δ 9.10 (s, 1H), 8.78 (t, *J* = 6 Hz, 1H), 8.27-8.07 (m, 3H), 7.50-7.31 (m, 4H), 4.55 (t, *J* = 8.2 Hz, 1H), 4.50-4.30 (m, 2H), 4.29-4.15 (m, 1H), 4.05-3.85 (m, 1H), 3.84-3.70 (m, 1H), 3.65-3.45 (m, 1H), 2.46 (s, 3H), 2.20-2.05 (m, 1H), 1.95-1.80 (m, 1H), 1.32-1.27 (m, 1H), 1.03 (s, 9H). LC-MS (ESI$^+$) *m/z* 431.85 (M+H)$^+$.

[00732] fer/-butyl ((1R,3R)-3-((2-(2-(2-aminoethoxy)ethoxy)ethoxy)methyl)cyclobutyl) carbamate (Intermediate H)



[00733] Step 1 - methyl (1R.3R)-3-((tert-butoxycarbonyl)amino)cyclobutane- 1-carboxylate

[00734] To a stirred solution of methyl (lR,3R)-3-aminocyclobutane-l-carboxylate hydrochloride (1.0 g, 6.1 mmol), TEA (2 mL, 12 mmol) in DCM (5 mL) was added and Boc anhydride (1.7 g, 7.8 mmol) at 0 °C. The reaction mixture was then stirred at rt for 3 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 50 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give methyl (1R,3R)-3-((/c/V-butoxycarbonyl)amino)cyclobutane-l -carboxylate as a white solid (1.2 g, 72%). ^{1}H NMR (400 MHz, DMSO) δ 7.26 (d, *J* = 7.6 Hz, 1H), 4.10 (m, 1H), 3.62(s, 3H), 2.96-2.9l(m, 1H), 2.36-2.31 (m, 2H), 2.19-2.12 (m, 2H), 1.42 (s, 9H).

[00735] Step 2 - /c/-*t*-butyl ((1R.R4-3-(hydroxymethyl)cyclobutyl icarbamate

[00736] To a stirred solution of methyl (lR,3R)-3-((tert-butoxycarbonyl)amino)cyclobutane-l-carboxylate (1.0 g, 4.4 mmol) in THF (20 mL) was added 3M lithium borohydride (9 mL, 9 mmol) at 0 °C. Then the reaction mixture was heated and stirred at 60 °C for 3 h. The reaction mixture was then transferred into dilute NaOH and the resulting mixture was extracted using ethyl acetate (3 x 50 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (3 % MeOH-DCM) to give tert-butyl ((lr3r)-3-(hydroxymethyl)cyclobutyl)carbamate as a white solid (0.8 g, 91%). ^{1}HNMR (400 MHz, DMSO) δ 4.77 (bs, 1H), 4.24 (d, J = 6.8 Hz, 1H), 3.7l(d, J = 6.0 Hz, 3H), 2.39(s, 1H), 2.25-2.21 (m, 2H), 2.05-1.98 (m, 2H), 1.67-1.29 (m, 13H).

[00737] Step_3_-_(OR,_3R)-3-((*tert*-butoxycarbonvl)_amino)cvclobutvPmethyl_methane sulfonate

[00738] To a stirred solution of tert-butyl ((lR,3R)-3-(hydroxymethyl)cyclobutyl)carbamate (0.8 g, 4.0 mmol) in dichloromethane (20 mL) was added triethylamine (1.67 mL, 11.91 mmol) at 0 °C. Mesyl chloride (0.82 mL, 5.96 mmol) was then added and the mixture was allowed to warm to rt and stirred for 2 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 50 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give ((1R, 3R)-3-((tert-butoxycarbonyl) amino)cyclobutyl)methyl methane sulfonate as yellow solid (0.9 g, 81%).

[00739] Step_4_-_tert-butyl_((TR.3RV3-(T2-phenyl-2.5.8. 11-tetraoxadodecvDcvclobutvDcarbamate

[00740] A solution of 2-(2-(2-(benzyloxy)ethoxy) ethoxy)ethan-l-ol (0.43 g, 1.79 mmol, Intermediate T), ((lR,3R)-3-((tert-butoxycarbonyl)amino)cyclobutyl)methyl methanesulfonate (2.9 g, 10.39 mmol) and TBAB (20 mg,) in toluene:8N NaOH (1:1, 16 mL) was stirred at 90 °C for 16 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 25 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (45 % EtOAc-Hexane) to give *tert-butyl* ((lR,3R)-3-(l8-phenyl-2,5,8,ll,l4,l7-hexaoxaoctadecyl)cyclobutyl)carbamate as a light yellow liquid (0.7 g, 76%). LC-MS (ESI$^+$) *m/z* 441.50 $(M+H)^+$.

[00741] **Step_ 5 - fer/-butyl (Yl R.3R)-3-(Y2-(2-(2-hvdiOxyethoxy)ethoxy)ethoxy)methvDcvclobutvDcarbamate**

[00742] To a stirred solution of *tert*-butyl ((lr,3r)-3-(l2-phenyl-2,5,8,ll-tetraoxadodecyl) cyclobutyl)carbamate (0.7 g, 1.65 mmol) in EtOH (20 mL) was added 10 % Pd/C (50% wet) (0.7 g) and the reaction mixture was stirred under hydrogen atmosphere at rt for 6 h. The reaction mixture was then filtered through celite and evaporated under reduced pressure to give *tεv't*-butyl ((lR,3R)-3-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)methyl)cyclobutyl)carbamate as a colorless liquid (0.5 g). LC-MS (ESI^+) *m/z* 351.45 $(M+H)^+$.

[00743] Step_ 6_ -_ 2-(2-(2-(((TR.3R)-3-((tert-butoxycarbonvDamino)cvclobutvDmethoxy)ethoxy)ethoxy)ethyl methanesulfonate

[00744] To a stirred solution of *tεv't*-butyl ((lR,3R)-3-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)methyl)cyclobutyl)carbamate (0.5 g, 1.5 mmol) and triethylamine (0.7 mL, 4.5 mmol) in dichlorom ethane (5 mL) was added mesyl chloride (0.15 mL, 1.8 mmol) at 0 °C. The reaction was allowed to warm to rt and stirred for 3 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using DCM (3 x 25 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give 2-(2-(2-(((lR,3R)-3-((tert-butoxycarbonyl)amino)cyclobutyl)methoxy)ethoxy)ethoxy)ethyl methanesulfonate as a light yellow solid (0.53 g, 85%).


[00745] Step 7 - fer/-butyl *i*(1R,3R)-3-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl) cvclobutyl icarbamate

[00746] To a stirred solution of 2-(2-(2-(((lR,3R)-3-((tert-butoxycarbonyl)amino)cyclobutyl)methoxy)ethoxy)ethoxy)ethyl methanesulfonate (0.53 g, 1.30 mmol) in DMF (4 mL) was added sodium azide (0.13 g, 1.93 mmol) at rt. Then the reaction mixture was heated at 65°C for 5 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 25 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to afford crude product. The crude product was purified using silica gel column chromatography (2 % MeOH-DCM) to give *tεv't*-butyl ((lR,3R)-3-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)cyclobutyl)carbamate as a light yellow liquid (0.45 g, 82%). LC-MS (ESI^+) *m/z* 376 $(M+l8)^+$.

[00747] Step_ 8 - *te/t*-butyl ((lR.3RV3-((2-(2-(2-aminoethoxy)ethoxy)ethoxy)methvOcvclobutvO carbamate

[00748] To a stirred solution of *tcv't*-butyl ((lR,3R)-3-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)cyclobutyl)carbamate (0.45 g, 1.25 mmol) in EtOH (20 mL) was added 10 % Pd/C (50% wet) (0.45 g) and the reaction mixture was stirred under hydrogen atmosphere for 5 h. The reaction mixture was filtered through celite and concentrated under reduced pressure to give *tert*-butyl((lr,3r)-3-((2-(2-(2-aminoethoxy)ethoxy)ethoxy)methyl)cyclobutyl)carbamate as a colorless liquid (0.35 g,). LC-MS (ESI^+) *m/z* 334.45 $(M+l8)^+$.


[00749] **12-[[tert-butoxycarbonvDamino)dodecanoic acid [Intermediate_ I)**



I

[00750] A mixture of l2-aminododecanoic acid (2.0 g, 9.3 mmol, CAS# 693-57-2), Boc anhydride (2.4 mL, 10.2 mmol) and triethylamine (1.4 mL, 10.2 mmol) in methanol (50 mL) was refluxed for 18 h. The reaction mixture then cooled to rt and was concentrated under vacuum and diluted with ethyl acetate (200 mL). The organic layer was washed with 5% citric acid (100 mL x 2), water (100 mL), dried over anhydrous sodium sulphate, and evaporated to give 12-*((tert*-butoxycarbonyl)amino)dodecanoic acid as a white solid (2.5 g, 85%). LC-MS (ESI^+) *m/z* 314.2 $(M-H)^+$.

[00751] l-phenyl-2,5,8,ll-tetraoxatridecan-13-ol [Intermediate J)




J

[00752] To a stirred solution of 2,2'-((oxybis(ethane-2,l-diyl))bis(oxy))bis(ethan-l-ol) (20.0 g, 103 mmol) in THF (150 mL) was added 60% NaH in paraffin (2.06 g, 51.5 mmol) at 10 °C in an ice water bath and the reaction mixture was stirred 0.5 h. To this reaction mixture benzyl bromide (5.9 mL, 51.49 mmol) in THF (50 mL) was added dropwise at 10 °C over 1.5 h. The resulting reaction mixture was allowed to warm to rt and stirred for 16 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column

chromatography (3% MeOH-DCM) to give l-phenyl-2,5,8,ll-tetraoxatridecan-l3-ol as a yellow oil (15 g, 51%). LC-MS (ESI+) m/z 284.35 $(M+H_20)^+$.

[00753] ***tert*-butyl ((lR,4R)-4-[13-amino-2,5,8,ll-tetraoxatridecvBcvclohexyBcarbamate [Intermediate K)**



[00754] Step 1 - methyl (l R,4R)-4-((*tert*-butoxycarbonyl)amino)cvclohexane- 1-carboxyl ate

[00755] To a stirred solution of methyl (lR,4R)-4-aminocyclohexane-l-carboxylate hydrochloride (6.5 g, 31.0 mmol) and triethylamine (6.8 mL, 92.94 mmol) in DCM (100 mL) was added Boc-anhydride (8.1 g, 37.18 mmol) dropwise at 0 °C. The resulting reaction mixture was warmed to rt and stirred for 1.5 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using DCM (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give methyl (lR,4R)-4-((/er/-butoxycarbonyl)amino)cyclohexane-l-carboxylate as a white solid (6.6 g, 83 %). LC-MS (ESI^+) *m/z* 258.2 $(M+H)^+$.

[00756] Step 2 - *tert*-butyl ((lR.4R)-4-(hvdroxymethyl icyclohexyl icarbamate

[00757] To a stirred solution of methyl (lR,4R)-4-((/er/-butoxycarbonyl)amino)cyclohexane-l-carboxylate (5.5 g, 21.4 mmol) in THF (20 mL) was added 3 M L1BH4 in THF (16 mL, 43 mmol) dropwise at 0 °C. The resulting reaction mixture then heated to 75 °C and stirred for 1 h. The

reaction mixture was then transferred into 5% citric acid solution. The pH of the reaction mixture was adjusted to pH 8 to 9 with 8 N NaOH solution. The resulting mixture was then extracted using ethyl acetate (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (25% EAc-Hexanes) to give *tert*-butyl ((lr,4r)-4-(hydroxymethyl)cyclohexyl)carbamate as white solid (1.5 g, 31%). LC-MS (ESI^+) *m/z* 230.2 $(M+H)^+$.

[00758] Step 3 - ((1R,4R)-4-((*tert*-butoxycarbonyl)amino)cvclohexyl)methyl methanesulfonate

[00759] To a solution of *te/'t*-butyl ((lR,4R)-4-(hydroxymethyl)cyclohexyl)carbamate (1.8 g, 7.8mmol) in DCM (50 mL) was added triethylamine (2.36 g, 23.4 mmol) and MsCl(0.9 mL, 11.7 mmol) at 0 °C and the reaction was stirred for 90 minutes. The reaction mixture was then diluted with water (50 mL) and product was extracted in DCM (50 mL x3). The organic layer was dried over anhydrous sodium sulphate, filtered and evaporated in vacuum to give ((1R,4R)-4-((toV-butoxycarbonyl)amino)cyclohexyl)methyl methanesulfonate as a light brown solid (1.8 g, 75%); LC-MS (ESI^+) *m/z* 308.2 $(M+H)^+$.

[00760] Step_ __4_ __-_ __tov-butyl_ __((TR.4RV4-(T5-phenyl-2.5.8.ll.l4-pentaoxapentadecvDcvclohexyDcarbamate

[00761] To a solution of l-phenyl-2,5,8,ll-tetraoxatridecan-l3-ol (1.4 g, 4.9 mmol, Intermediate J) in toluene (20 mL) and 8NNaOH (20 mL) was added a catalytic amount of TBAB and the reaction was stirred for 15 minutes at rt. After 15 minutes, ((1R,4R)-4-((toV-butoxycarbonyl)amino)cyclohexyl)methyl methanesulfonate (1.8 g, 5.9 mmol) was added and the reaction mixture was refluxed for 16 h. The reaction mixture was then diluted with water (200 mL) and extracted in ethyl acetate (250 mL x3). The organic layer was dried over anhydrous sodium sulphate, filtered and evaporated in vacuo. The crude product was purified by silica gel column chromatography (45-50% EtOAC -Hexane) to give toV-butyl ((lR,4R)-4-(l5-phenyl-2,5,8,ll,l4-pentaoxapentadecyl)cyclohexyl)carbamate as a yellow semisolid (0.8 g, 33%); LC-MS (ESI^+) *m/z* 496.5 $(M+H)^+$.

[00762] Step_ __5_ __-_ __**toV-butyl**_ __((*I*R,4R)-4-(13-hydroxy-2. 5.8.11-tetraoxatridecvDcvclohexyDcarbamate

[00763] To a stirred solution of toV-butyl ((lR,4R)-4-(l5-phenyl-2,5,8,ll,l4-pentaoxapentadecyl)cyclohexyl)carbamate (0.8 g, 1.6 mmol) in ethanol (50 mL) was added 10%

Pd/C (50% wet) (0.8 g) and acetic acid (0.2 mL) at room temperature with hydrogen gas bubbling through the solution for 2h. The reaction mixture was then filtered through a pad of celite and the filtrate was evaporated to give *tert*-butyl ((lR,4R)-4-(l3-hydroxy-2,5,8,ll-tetraoxatridecyl)cyclohexyl)carbamate as a brown oil (0.7 g, 64%); LC-MS (ESI^+) *m/z* 406.4 $(M+H)^+$.

[00764] Step 6 1-((1R.4R)-4-((fe/7-butoxycarbonyl iaminoicvclohexyl)-2.5.8. 11-tetraoxatridecan- 13-yl methanesulfonate

[00765] To a stirred solution of *tert*-butyl ((lR,4R)-4-(l3-hydroxy-2,5,8,ll-tetraoxatridecyl)cyclohexyl)carbamate (0.37 g, 0.91 mmol) in DCM (10 mL) was added triethylamine (0.3 mL, 2.7 mmol) at 0 °C followed by mesyl chloride (0.11 g, 1.37 mmol) then the reaction was stirred for 2h. The reaction was then quenched with water (50 mL) and product was extracted using DCM (50 mL x3). The organic layer was dried over anhydrous sodium sulphate and evaporated in vacuo to give l-((lR,4R)-4-((tert-butoxycarbonyl)amino)cyclohexyl)-2,5,8,ll-tetraoxatridecan-l3-yl methanesulfonate as a yellow oil (0.37 g; 82%).

[00766] Step 7 - *tert*-butyl (cis-lr.4r)-4-(l3-azido-2.5.8J 1-tetraoxatridecyl icyclohexyl icarbamate


[00767] To a stirred solution of l-((lR,4R)-4-((/er/-butoxycarbonyl)amino)cyclohexyl)-2,5,8, 11-tetraoxatridecan- 13-yl methanesulfonate (0.36 g, 0.74 mmol) in DMF (5 mL) was added NaN_3 (0.072 g, 1.11 mmol) and the reaction mixture was heated at 70 °C for 2h. The reaction mixture was then cooled to rt and diluted with water (250 mL) and extracted in ethyl acetate (100 mL x3). The organic layer was dried over anhydrous sodium sulphate and evaporated in vacuo to give and the crude product was purified by silica gel column chromatography (40% EtOAc-Hexane) to give *tert*-butyl ((lr,4r)-4-(l3-azido-2,5,8,ll-tetraoxatridecyl)cyclohexyl)carbamate as a yellow semisolid (0.29 g; 90%); LC-MS (ESI^+) *m/z* 448.8 $(M+l8)^+$.

[00768] Step 8 - fer/-butyl (Ylr.4r)-4-(T3-amino-2.5.8.ll-tetraoxatridecvDcvclohexyDcarbamate

[00769] To a stirred solution of *tert*-butyl ((lR,4R)-4-(l3-azido-2,5,8,ll-tetraoxatridecyl)-cyclohexyl)carbamate (0.29 g, 0.67 mmols) in ethanol (20 mL) was added 10% $Pd(OH)_2/C$ (50% wet) (0.29 g) at rt and the reaction mixture was stirred in autoclave under hydrogen gas (20 kg/cm^2 pressure) for 5h. The reaction mixture was filtered through a pad of celite and the filtrate was evaporated in vacuo to give tert-butyl ((lR,4R)-4-(l3-amino-2,5,8,ll-tetraoxatridecyl)cyclohexyl)carbamate as a yellow semisolid (0.17, 62%); LC-MS (ESI^+) *m/z*

405.4 $(M+H)^+$.

[00770] **6-(5-cvano-lH-Dvrazolo[3,4-blDvridin-l-vl)-4-(cvcloDroDvlamino)nicotinic acid (Intermediate L)**



L

[00771] Step 1 - methyl 6-chloro-4-(cvclopropylamino)nicotinate

[00772] A solution of methyl 4,6-dichloronicotinate (10.0 g, 48.5 mmol), DIPEA (6.26 g , 48.5 mmol, 8.23 mL) and cyclopropylamine (3.04 g, 53.4 mmol) in DMA (80 mL) was stirred at 90 °C for 3 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 25 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (10 % EtOAc-Hexane) to give methyl 6-chloro-4-(cyclopropylamino)nicotinate as a white solid (8.5 g, 77 %). ^{1}H NMR (400 MHz, DMSO-d6) δ 8.538 (s, 1H), 8.079 (s, 1H), 7.040 (s, 1H), 3.826 (s, 3H), 2.634-2.594 (m, 1H), 0.892-0.846 (m, 2H), 0.595- 0.557 (m, 2H).

[00773] Step 2 - 6-chloro-4-(cvclopropylamino)nicotinic acid

[00774] A stirred solution of methyl 6-chloro-4-(cyclopropylamino)nicotinate (6.8 g, 30.0 mmol) in ethanol (70 mL) was cooled to 0-l0°C. Then a solution of lithium hydroxide (3.6 g, 85.7 mmol in water (10 mL) was added. The reaction mixture was allowed to warm to rt and was stirred for 3h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (2 x 100 mL). The aqueous layer was acidified by addition of saturated citric acid solution until the pH = 3-4. The mixture was then extracted with ethyl acetate (3 x 250 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The

filtrate was evaporated under reduced pressure and the crude product was triturated using hexane to give 6-chloro-4-(cyclopropylamino)nicotinic acid as an off-white solid (5g, 78%). ^{1}H NMR (400 MHz, DMSO-d6) δ 13.415 (bs, 1H), 8.525 (s,lH) 8.318 (s, 1H), 7.007 (s, 1H), 2.616-2.592 (m, 1H), 0.891-0.845 (m, 2H), 0.620- 0.564 (m, 2H).

[00775] Step 3 - *tert*-butyl 6-chloro-4-(cyclopropylamino)nicotinate

[00776] A stirred solution 6-chloro-4-(cyclopropylamino)nicotinic acid (2.5 g, 11.74 mmol) and DMF-DTA (10.2 g, 50.3 mmol) in toluene (50 mL) was heated at 110 °C for 16 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 250 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (6% EtOAc-Hexane) to give *tert*-butyl 6-chloro-4-(cyclopropylamino)nicotinate as a white solid (2.23 g, 70%). LC-MS (ESI$^+$) *m/z* 269.3 (M+H)$^+$.

[00777] Step 4 - fer/-butyl 6-(5-cvano- lH-pyrazolor3.4-b1pyridin- 1-yl)-4-(cvclopropylamino) nicotinate


[00778] Linder an atmosphere of argon, lH-pyrazolo[3,4-b]pyridine-5-carbonitrile (1.0 g, 6.94 mmol), *tert*-butyl 6-chloro-4-(cyclopropylamino)nicotinate (2.05 g, 7.63 mmol), potassium carbonate (2.9 g, 20.83 mmol), Xantphos (L6lg, 2.77mmol) and $Pd(dba)_2$ (L6g, 2.77mmol) in l,4-dioxane (50 mL) was heated at 120 °C for 20 h. The reaction mixture was filtered through celite and washed with ethyl acetate (3 x 300 mL). The combined organic layer was washed with water (400mL), dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (1% MeOH-DCM) to give *tert*-butyl 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(cyclopropylamino) nicotinate as a brown solid (0.6 g, 21%). LC-MS (ESI$^+$) *m/z* 377.3 (M+H)$^+$

[00779] Step 5 - 6-(5-cvano- lH-pyrazolor3.4-b1pyridin- 1-yl)-4-(cvclopropylamino)nicotinic acid (as the TFA salt)

[00780] A solution of *tert*-butyl 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(cyclopropylamino)nicotinate (0.4 g, 1.06 mmol) and TFA (4 mL) in DCM (10 mL) was stirred at rt for 6 h. The organic solvent was evaporated and the residue was triturated with MTBE (20 mL) to give 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(cyclopropylamino)nicotinic acid as the TFA salt as a white solid (0.3 g, 88%). ^{1}H NMR (400 MHz, DMSO-d6) δ 13.38 (bs, 1H), 9.10 (d, *J* = 2 Hz, 1H), 9.04 (d, *J* = 2 Hz, 1H), 8.76 (s, 1H), 8.70 (s, 1H), 8.43 (s, 1H), 7.83 (s, 1H), 2.66-

2.60 (m, 1H), 0.93-0.89 (m, 2H), 0.65- 0.62 (m, 2H).

[00781] l,6-naphthyridin-2-amine [Intermediate M)



M


[00782] Step 1 - tert-butyl (l .6-naphthyridin-2-yl icarbamate

[00783] To a stirred solution of l,6-naphthyridine-2-carboxylic acid (20.0 g, 114 mmol) in *I*-BuOH (200 mL) was added Et_3N (16 mL, 114 mmol) and diphenyl phosphoryl azide (37.0 g, 137 mmol) respectively at rt. The resulting mixture then heated to 80 °C and stirred for 24 h. The reaction mixture was evaporated carefully under vacuum, diluted with ice water and resulting solid was collected by filtration. The solid was treated with hot ethanol and again filtered and dried under vacuum to give *tert*-butyl (l,6-naphthyridin-2-yl)carbamate as a light brown solid (13.1 g, 46 %). ¾ NMR (400 MHz, DMSO-de) δ 10.49 (s, 1H), 9.20 (s, 1H), 8.61 (d, *J* = 6 Hz, 1H), 8.47 *(d, J* = 9.2 Hz, 1H), 8.18 *(d, J* = 8.8 Hz, 1H), 7.62 (s, 1H), 1.50 (s, 9H). LC-MS (ESI^+) *m/z* 246.2 $(M+H)^+$

[00784] Step 2 - E6-naphthyridin-2-amine

[00785] To a stirred solution of *tert*-butyl (l,6-naphthyridin-2-yl)carbamate (4.37 g, 17.8 mmol) in MeOH: DCM (40 mL, 3:1 ratio) was added 4N HC1 in dioxane (15 mL) at 0 °C. The resulting reaction mixture was allowed to warm to rt and stirred for 18 h. The reaction mixture was then evaporated under vacuum and diluted with 30 mL of water. Saturated NaHCCh solution (15 mL) was added and the resulting mixture was extracted using EtOAc (2 x 50 mL). The combined organic layers were dried under vacuum to give l,6-naphthyridin-2-amine as a white solid (2.45 g, 94 %). ^1H NMR (400 MHz, DMSO-de) δ 9.03 (s, 1H), 8.43 (d, *j* = 6 Hz, 1H), 8.14 (d, *j* = 8.8 Hz, 1H), 7.72 (bs, 2H), 7.45 (d, *J* = 6 Hz, 1H), 6.96 (d, *J* = 8.8 Hz, 1H); LCMS (ESI^+) *m/z* 146.4 $(M+H)^+$.

[00786] [6-[[l,6-naphthyridin-2-vBaminoV4-[cvclopropylamino)nicotinic acid [Intermediate N)



[00787] Step 1 - methyl 6-chloro-4-(cyclopropylamino)nicotinate

[00788] To a stirred solution of methyl 4,6-dichloronicotinate (10.0 g, 48.5 mmol) in DMA (80 mL) was added DIPEA (6.6 mL, 48.5 mmol) and cyclopropylamine (3.7 mL, 53.0 mmol) at rt. The resulting mixture then heated at 90 °C for 3 h. After 3 h, the reaction mixture was cooled to rt and diluted with ice water. The resulting mixture was stirred for 20 min and the solid precipitate was collected by filtration and dried under vacuum. The crude product was purified by silica gel column chromatography (10% EtOAc-hexanes) to give methyl 6-chloro-4-(cyclopropylamino)nicotinate as a white solid (9.5 g, 87 %). ^{1}H NMR (400 MHz, CDCb) δ 8.67 (s, 1H), 8.20 (bs, 1H), 6.98 (s, 1H), 3.89 (s, 3H), 2.51 (m, 1H), 0.91 (q, *J* = 6.8 Hz, 2H), 0.61-0.65 (m, 2H); LC-MS (ESI$^+$) *m/z* 227.2 (M+H)$^+$.


[00789] Step 2 - methyl 6-((1,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinate

[00790] To a stirred solution of methyl 6-chloro-4-(cyclopropylamino)nicotinate (2.5 g, 11.8 mmol) and l,6-naphthyridin-2-amine (1.6 g, 11.76 mmol, Intermediate M) in DMA (50 mL) was added Xantphos (2.5 g, 4.4 mmol) and CS2CO3 (5.76 g, 17.60 mmol) and resulting reaction mixture was degassed using argon for 30 min. Then of $Pd_2(dba)_3$ (2.0 g, 2.2 mmol) was added. The resulting mixture was heated at 120 °C for 18 h. The reaction mixture was cooled to rt and ice water was added. The resulting solid precipitate was collected by filtration and dried under vacuum. The crude product was purified by silica gel column chromatography (5% MeOH-DCM) to give methyl 6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinate as a yellow solid (2.2 g, 59%). ^{1}H NMR (400 MHz, DMSO-de) δ 10.5 (s, 1H), 9.08 (s, 1H), 8.66 (s, 1H), 8.58-8.60 (m, 2H), 8.31 (d, *j* = 8.8 Hz, 1H), 8.03 (s, 1H), 7.61 (d, *j* = 6 Hz, 1H), 7.51 (d, *j* = 8.8 Hz, 1H), 3.80 (s, 3H), 2.67-2.70 (m, 1H), 0.99-1.02 (m, 2H), 0.65-0.67 (m, 2H). LC-MS (ESI$^+$) *m/z* 336.6 (M+H)$^+$.


[00791] Step 3 - 6-((1,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinic acid

[00792] To a stirred solution of methyl 6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinate (1.6 g, 1.8 mmol) in methanol:water (30 mL, 1:1 ratio) was added NaOH (0.36 g, 5 mmol) at rt. The resulting reaction mixture was then heated at 70 °C for 16 h. Upon completion, the reaction mixture was *in vacuo* and the resulting solid was triturated using ethyl acetate and collected by filtration. The solid was taken in water and the pH was adjusted to 6-7 using dilute HC1 and the resulting solid was collected by filtration and dried under vacuum to give 6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinic acid as a dark yellow solid (0.45 g, 78 %). LC-MS (ESI$^+$) *m/z* 322.6 $(M+H)^+$

[00793] **(1R,3R)-3-(6-((1,6-naphthyridin-2-yl)amino)-4-[cyclopropylaminolnicotinamidolcyclobutane-l-carboxylic acid [Intermediate O)**



N



O

[00794] Step 1 - methyl (1R,3R)-3-(6-((1,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino) nicotinamido)cyclobutane-l-carboxylate

[00795] To a stirred solution of methyl (lR,3R)-3-aminocyclobutane-l-carboxylate-HCl (0.2 g, 1.6 mmol) and 6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinic acid (0.5 g, 1.6 mmol, Intermediate N) in DMF (4 mL) was added DIPEA (0.9 mL, 4.7 mmol) and PyBOP (1.2 g, 2.3 mmol) at rt. The resulting reaction mixture was stirred at rt for 2 h. The reaction mixture was then transferred into ice water and the resulting mixture was filtered, dried and dried under reduced pressure. The crude product was triturated with MTBE and dried in vacuo to give methyl (lr,3r)-3-(6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinamido)cyclo butane-l-


carboxylate as a yellow solid. (0.55 g, 81%). LC-MS (ESI^+) *m/z* 433.2 $(M+H)^+$.

[00796] Step 2 - (1R,3R)-3-((6-((1,6-naphthyridin-2-yl)amino)-4-(cyclopropylaminoinicotinamido)

[00797] cyclobutane-1-carboxylic acid

[00798] To a stirred solution of methyl (1R,3R)-3-(6-((1,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinamido)cyclobutane-1-carboxylate (0.55 g, 1.27 mmol) in THF:MeOH (15 mL, 1:1) was dropwise added NaOH (0.16 g, 3.82 mmol) in 5 mL water at rt. The resulting reaction mixture was stirred at rt for 3 h. The reaction mixture was then evaporated under vacuum, and water (10 mL) was added and the pH was adjusted to 6-7 using 10 % citric acid solution. The resulting mixture was then stirred for 15 min, and the solid precipitate was filtered off and dried under vacuo to give (1R,3R)-3-(6-((1,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)-nicotinamido)cyclobutane-1-carboxylic acid as a yellow solid. (0.4 g, 75%). ^1H NMR (400 MHz, DMSO) δ 11.18 (s, 1H), 10.36 (s, 1H), 9.05 (*d*, *J* = 7.2 Hz, 1H), 8.59-8.45 (m, 4H), 8.28-8.23(m, 1H), 7.58-7.03 (m, 4H), 4.52-4.46 (m, 1H), 2.91 (t, *J* = 8.8 Hz, 1H), 2.58-2.27 (m, 4H), 0.90 (m, 2H), 0.52 (m, 2H).

[00799] Ethyl 2-(4-aminopiperidin-1-yl)acetate hydrochloride [Intermediate P)



P

[00800] Step 1 - methyl 2-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)acetate


[00801] A solution of tert-butyl piperidin-4-ylcarbamate (0.5 g, 2.5 mmol), ethyl bromo acetate (0.45 g, 2.75 mmol) and DIPEA (0.65 mL, 3.76 mmol) in DCM (5 mL) was stirred at rt for 3 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using DCM (3 x 20 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give methyl 2-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)acetate as a colorless oil (0.55 g, 81 %). LC-MS (ESI^+) *m/z* 287.2 $(M+H)^+$.

[00802] Step 2 - ethyl 2-(4-aminopiperidin-1-yl)acetate hydrochloride

[00803] To a solution of ethyl 2-(4-((ter/-butoxycarbonyl)amino)piperidin-1-yl)acetate (0.55 g, 1.92 mmol) in DCM (10 mL) was added 4N HC1 in dioxane (3 mL) at 0 °C and then the reaction was allowed to warm to rt and stirred for 4 h. The reaction mixture was then evaporated under

vacuum and the solid was triturated using MTBE (5 mL) to give ethyl 2-(4-aminopiperidin-l-yl)acetate hydrochloride as white solid (0.3 g, 86 %). LC-MS (ESI+) *m/z* 187.2 (M+H)+.

[00804] **Methyl 2-13-aminoazetidin-l-vBacetate 2,2,2-trifluoroacetate [Intermediate Q1**



Q


[00805] Step 1 - methyl 2-(3-(Ytert-butoxycarbonvDamino)azetidin-l-vDacetate

[00806] To a mixture of tert-butyl azetidin-3-ylcarbamate (0.5 g, 0.58 mmol) and K2CO3 (0.6 g, 0.87 mmol) in ACN (5 mL) at 0 °C was added a solution of methyl 2-bromoacetate (0.444 g, 0.58 mmol) in ACN (5 mL) at same temperature and the reaction mixture was stirred for 25 minutes. The reaction mixture was then diluted with water (100 mL) and product was extracted in ethyl acetate (50 mL x3). The organic layer was dried over anhydrous sodium sulphate, filtered and evaporated in vacuo. The crude product was purified by silica gel column chromatography (3% MeOH-DCM) to give methyl 2-(3-((tert-butoxycarbonyl)amino)azetidin-l-yl)acetate as a yellow semi-solid (0.15 g, 21%); LC-MS (ESI+) *m/z* 245.2 (M+H)+.

[00807] Step 2 - methyl 2-(3-aminoazetidin-l-vDacetate 2.2.2-trifluoroacetate

[00808] To a stirred solution of methyl 2-(3-((tert-butoxycarbonyl)amino)azetidin-l-yl)acetate (0.15 g, 0.61 mmol) in DCM (10 mL) was added TFA (3 mL) at 0 °C and the reaction was stirred for 3h. The reaction mixture was then evaporated in vacuo and triturated with diethyl ether to give methyl 2-(3-aminoazetidin-l-yl)acetate 2,2,2-trifluoroacetate as a brown semisolid (0.1 g, 63%); LC-MS (ESI+) *m/z* 145.16 (M+H)+.

[00809] **2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (Intermediate R)**



R

[00810] Step 1 - 5-amino-2-(4-fluoro-L3-dioxoisoindolin-2-vD-5-oxopentanoic acid


[00811] To a stirred solution of 4-fluoroisobenzofuran-l,3-dione (25 g, 150 mmol, CAS# 652-39-1) in DMF (100 mL) was added L-glutamine (22 g, 150 mmol) at rt. The resulting reaction

mixture was heated to at 90 °C and stirred for 2 h. The reaction mixture was then evaporated under reduced pressure, transferred into 4 N aqueous HC1 solution and the resulting mixture was stirred for 36 h at rt. The solid precipitate was then filtered off, washed with cold water and dried under reduced pressure to give 5-amino-2-(4-fluoro-l,3-dioxoisoindolin-2-yl)-5-oxopentanoic acid as a white solid (28 g, 63%). LC-MS (ESI$^+$) *m/z* 295 $(M+H)^+$.

[00812] Step 2 - 2-(2.6-dioxopiperidin-3-vP-4-fluoroisoindoline-L3-dione

[00813] To a stirred solution of 5-amino-2-(4-fluoro-l,3-dioxoisoindolin-2-yl)-5-oxopentanoic acid (28 g, 95 mmol) in acetonitrile (200 mL) was added CDI (19 g, 110 mmol) and DMAP (0.14 g, 1.1 mmol) at rt. The resulting reaction mixture then heated to 90 °C and stirred for 5 h. The reaction mixture was then evaporated under reduced pressure. The crude product was purified using silica gel column chromatography (2% MeOH-DCM) to give 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-l,3-dione as a yellow solid (12 g, 46%). ^{1}H NMR (400 MHz, DMSO) δ ppm 11.16 (s, 1H), 7.98-7.93 (m, 1H), 7.80-7.76 (m, 2H), 5.19-5.14 (m, 1H), 2.94-2.85 (m, 1H), 2.63-2.54 (m, 2H), 2.09-2.04 (m, 1H).


[00814] **fert-butyl [3-[3-aminopropoxy)propyDcarbamate [Intermediate S)**



S

[00815] A solution of 3,3'-oxybis(propan-l-amine) (1.0 g, 7.6 mmol, CAS# 2157-24-6), and Boc anhydride (0.83 g, 3.78 mmol) in DCM (8 mL) was stirred at rt for 16 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using DCM (3 x 50 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure. The crude product was purified using silica gel column chromatography (5% MeOH-DCM) to give ter/-butyl (3-(3-aminopropoxy)propyl)carbamate as a white solid (0.36 g, 21%). 'H NMR (400 MHz, DMSO) δ 10.34 (s, 1H), 9.05 (s, 1H), (d, *J* = 5.2 Hz, 3H), 8.42 (s, 1H), 8.28 (d, *J* = 9.2 Hz, 1H), 8.14 (d, *J* = 7.6 Hz, 1H), 7.70-7.67 (m, 1H), 6.76 (bs, 1H), 3.70 (t, *J* = 2.8 Hz, 1H), 3.00-3.05 (m, 2H), 2.89-2.86 (m, 2H), 2.06 (s, 1H), 1.88 (d, *J* = 12.4 Hz, 2H), 1.77 (d, *J* = 11.6 Hz, 2H), 1.48-1.21 (m, 17H). LC-MS (ESI$^+$) *m/z* 233.35 $(M+H)^+$


[00816] **2-[2-[2-[benzyloxy)ethoxy)ethoxy)ethan-l-ol [Intermediate T]**



T

[00817] To a stirred solution of 2,2'-(ethane-l,2-diylbis(oxy))bis(ethan-l-ol) (30 g, 200 mmol) in THF (125 mL) was added 60% NaH in paraffin (4 g, 100 mmol) at 10 °C. The resulting reaction mixture stirred at the same temperature for 0.5 h. To this reaction mixture was then added benzyl bromide (17 g, 100 mmol) in THF (125) dropwise at 10 °C over 1.5 h. The resulting reaction mixture then stirred at rt for 16 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using DCM (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (4% MeOH-DCM) to give 2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethan-l-ol as a yellow oil (20 g, 42%). LC-MS (ESI^+) *m/z* 241.35 $(M+H)^+$

[00818] fe/7-butyl_ ((lR,3R)-3-((2-(2-(2-aminoethoxylethoxylethoxylmethvPcvclopentvPcarbamate (Intermediate_ L[)



U

[00819] Step 1 - methyl (lS,3S)-3-((/d/7-butoxycarbonyl)amino)cvclopentane-1-carboxylate

[00820] To a stirred solution of methyl (lS,3S)-3-aminocyclopentane-l-carboxylate hydrochloride (4.5 *g*, 25 mmol) and TEA (10.5 mL, 75 mmol) in DCM (100 mL) was dropwise added Boc-anhydride (6.6 g, 30 mmol) at 0 °C. The resulting reaction mixture was then allowed to warm to rt and then stirred for 1.5 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using DCM (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (40% EAc-Hexanes) to give methyl (lS,3S)-3-((ter/-butoxycarbonyl)amino)cyclopentane-l-carboxylate as a white solid (5.1 g, 84 %). LC-MS (ESI$^+$) *m/z* 261.3 (M+l8) $^+$.

[00821] Step 2 - *tert*-butyl ((1S,3S)-3-(hvdroxymethyl)cvclopentyl)carbamate

[00822] To a stirred solution of methyl (lS,3S)-3-((/er/-butoxycarbonyl)amino)cyclopentane-l-carboxylate (2.5 g, 10.2 mmol) in THF (50 mL) was added 4 M $LiBH_4$ in THF (5.13 mL, 20.4

mmol) dropwise at 0 °C. The resulting reaction mixture then heated to 75 °C and stirred for 1 h. The reaction mixture was then transferred into 5% citric acid solution. The pH of the solution was then adjusted to pH = 8 to 9 with 8 N NaOH solution. The resulting mixture was extracted using ethyl acetate (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and crude product was purified using silica gel column chromatography (3% MeOH-DCM) to give *tert*-butyl ((lS,3S)-3-(hydroxymethyl)cyclopentyl)carbamate as a white solid (1.9 g, 86%). LC-MS (ESI^+) *m/z* 233.15 $(M+l8)^+$.

[00823] Step 3 - ((1S,3S)-3-((*tert*-butoxycarbonyl)amino)cyclopentyl)methyl methanesulfonate

[00824] To a stirred solution of *tert*-butyl ((lS,3S)-3-(hydroxymethyl)cyclopentyl)carbamate (1.6 g, 7.4 mmol) and TEA (3.1 mL, 22.3 mmol) in DCM (25 mL) was added Mesyl chloride (0.91 mL, 11.14 mmol) dropwise at 0 °C. The resulting reaction mixture was allowed warm to room temperature and then stirred for 1 h. The reaction mixture was then transferred into water and the resulting mixture was extracted using DCM (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give ((lS,3S)-3-((/er/-butoxycarbonyl)amino)cyclopentyl)methyl methanesulfonate as a white solid (1.9 g, 87%). LC-MS (ESI^+) *m/z* 238.3 $(M-56)^+$.

[00825] Step 4 - *tert*-butyl ((TR.3RV3-(T2-phenyl-2.5.8. 11-tetraoxadodecvDcvclopentvDcarbamate

[00826] To a stirred solution of 2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethan-l-ol (1.3 g, 5.4 mmol, Intermediate T) and ((lS,3S)-3-((ter/-butoxycarbonyl)amino)cyclopentyl)methyl methanesulfonate (1.9 g, 6.5 mmol) in toluene (20 mL) and 8 N Aqueous NaOH solution (20 mL) was added TBAB (catalytic amount) at rt. The resulting reaction mixture was then heated to 90 °C and stirred for 16 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (2% MeOH-DCM) to give *tert*-butyl ((lR,3R)-3-(l2-phenyl-2,5,8,ll-tetraoxadodecyl)cyclopentyl)carbamate as a yellow oil (0.8 g, 41%). LC-MS (ESI^+) *m/z* 338.4 $(M-l00)^+$.

[00827] Step 5 : fer/-butyl ((TR,3R)-3-((2-(2-(2-

hvdiOxyethoxy)ethoxy)ethoxy)methvDcvclopentvDcarbamate

[00828] To a stirred solution of *tert*-butyl ((lR,3R)-3-(l2-phenyl-2,5,8,ll-tetraoxadodecyl)cyclopentyl)carbamate (0.8 g, 1.8 mmol) in ethanol (25 mL) and acetic acid (0.3 mL) was added 10% Pd/C (0.8 g, 50% wet) at rt under nitrogen atmosphere. The resulting reaction mixture was stirred under hydrogen gas (2 kg/cm^2 pressure) in an autoclave at rt for 1.5 h. The reaction mixture was then filtered through a pad of celite under vacuum and washed with MeOH (50 mL). The filtrate was evaporated under reduced pressure to give *tert*-butyl ((lR,3R)-3-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)methyl)cyclopentyl)carbamate as a yellow oil (0.6 g, 94 %). LC-MS (ESI+) *m/z* 248.5 (M-l00) +.

[00829] Step 6 - 2-(2-(2-(((lR.3RV3-((fert-butoxycarbonvDamino)cvclopentvDmethoxy)ethoxy)

[00830] ethoxylethyl methanesulfonate

[00831] To a stirred solution of *tert*-butyl ((lR,3R)-3-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)methyl)cyclopentyl)carbamate (0.6 g, 1.7 mmol) and TEA (0.75 mL, 5.18 mmol) in DCM (10 mL) was added Mesyl chloride (0.21 mL, 2.59 mmol) dropwise at 0 °C. The resulting reaction mixture then warmed to rt and stirred for 1 h. The reaction mixture was then transferred into water and the resulting mixture was extracted using DCM (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give 2-(2-(2-(((lR,3R)-3-((/er/-butoxycarbonyl)amino)cyclopentyl)methoxy)ethoxy)ethoxy)ethyl methanesulfonate as a brown oil (0.72 g, 98%). LC-MS (ESI+) *m/z* 370.3 (M-56)+.

[00832] Step 7 - *tert*-butyl ((TR.3R)-3-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methvDcvclopentvD

[00833] carbamate


[00834] To a stirred solution of 2-(2-(2-(((lR,3R)-3-((/er/-butoxycarbonyl)amino)cyclopentyl)methoxy)ethoxy)ethoxy)ethyl methanesulfonate (0.78 g, 1.83 mmol) in DMF (10 mL) was added NaN_3 (0.18 g, 2.74 mmol) at rt. The resulting reaction mixture was then heated to 65 °C and stirred for 2 h. The reaction mixture was then transferred into water and the resulting mixture was extracted using ethyl acetate (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (3%

MeOH-DCM) to give *tert*-butyl ((lR,3R)-3-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)cyclopentyl)carbamate as a colorless oil (0.65 g, 95%). LC-MS (ESI$^+$) *m/z* 390.4 (M+l8)$^+$.

[00835] Step 8 - *tert*-butyl ((lR.3RV3-((2-(2-(2-aminoethoxy)ethoxy)ethoxy)methvOcvclopentvOcarbamate

[00836] To a stirred solution of /ɛv*t*-butyl ((lR,3R)-3-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)cyclopentyl)carbamate (0.75 g, 2.01 mmol) in ethanol (20 mL) was added 10% Pd/C (0.75 g, 50% wet) at rt under nitrogen atmosphere. The resulting reaction mixture then stirred under hydrogen gas (15 kg/cm^2 pressure) in autoclave at rt for 6 h. The reaction mixture was then filtered through a pad of celite under vacuum and washed with MeOH (50 mL). The filtrate was evaporated under reduced pressure to give /ɛv*t*-butyl ((lR,3R)-3-((2-(2-(2-aminoethoxy)ethoxy)ethoxy)methyl)cyclopentyl)carbamate as a yellow oil (0.48 g, 69 %). LC-MS (ESI$^+$) *m/z* 347.5 (M+H)$^+$.

[00837] ***te*/T-butyl (14-amino-3.,6.,9.,12-tetraoxatetradecyP(methyPcarbamate (Intermediate V)**



V

[00838] Step 1 - 14-hydroxy-3,6,9,12-tetraoxatetradecyl 4-methylbenzenesulfonate

[00839] To a solution of 3,6,9, l2-tetraoxatetradecane-l,l4-diol (10 g, 41.96 mmol, CAS# 4792-15-8), silver oxide (14.6 g, 62.94 mmol) and Nal (7 g, 46.56 mmol) in DCM (250 mL) was added tosyl chloride (8.5 g, 41.96 mmol) at 0 °C. The reaction mixture was then allowed to warm to rt and stirred for 1 h. The reaction mixture was then filtered through celite and the filtrate was washed with 10% NaHCCh solution (125 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was then evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (3% MeOH-DCM) to give l4-hydroxy-3,6,9,l2-tetraoxatetradecyl 4-methylbenzenesulfonate as a yellow oil (13 g, 79%). LC-MS (ESI^+) *m/z* 394.3 $(M+H)^+$.

[00840] Step 2 - 5,8,1 L 14-tetraoxa-2-azahexadecan- 16-ol

[00841] To a stirred solution of l4-hydroxy-3,6,9,l2-tetraoxatetradecyl 4-methylbenzenesulfonate (3.0 g, 7.7 mmol) in THF (10 mL) was added 2M methyl amine solution in THF (16 mL, 30.6 mmol) dropwise at rt. The resulting reaction mixture then heated to 65 °C and stirred for 16 h. The reaction mixture was filtered and the filter cake was washed with THF (20 mL). The filtrate was then evaporated under reduced pressure to give 5,8,ll,l4-tetraoxa-2-azahexadecan-l6-ol as a yellow oil (1.8 g, 94 %). MASS (ESI^+) *m/z* 252 $(M+H)^+$.

[00842] Step 3 - *tert*-butyl (l 4-hydroxy-3.6.9. 12-tetraoxatetradecyl)(methyl icarbamate

[00843] To a stirred solution of 5,8,ll,l4-tetraoxa-2-azahexadecan-l6-ol (1.8 g, 7.2 mmol) in DCM (50 mL) was added Boc-anhydride (9.36 g, 42.96 mmol) dropwise at 0 °C. The resulting reaction mixture then warmed to rt and stirred for 2 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using DCM (3 x 50 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (2% MeOH-DCM) to give *tert*-butyl (l4-hydroxy-3,6,9,l2-tetraoxatetradecyl)(methyl)carbamate as a light yellow oil (1.5 g, 59%). LC-MS (ESI^+) *m/z* 351.44 $(M+H)^+$.

[00844] Step 4 - 2.2.5-trimethyl-4-oxo-3.8.lLl4.l7-pentaoxa-5-azanonadecan-l9-yl methanesulfonate

[00845] To a stirred solution of *tert*-butyl (l4-hydroxy-3,6,9,l2-tetraoxatetradecyl)(methyl)carbamate (1.5 g, 4.3 mmol) and TEA (1.8 mL, 12.8 mmol) in DCM (30 mL) was added mesyl chloride (0.5 mL, 6.4 mmol) dropwise at 0 °C. The resulting reaction mixture then warmed to rt and stirred for 1 h. The reaction mixture was then transferred into water

and the resulting mixture was extracted using DCM (3 x 50 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give 2,2,5-trimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azanonadecan-19-yl methanesulfonate as a yellow oil (1.5 g, 82%).


[00846] Step 5 - *tert*-butyl (14-azido-3,6,9,12-tetraoxatetradecyl)(methyl)carbamate

[00847] To a stirred solution of 2,2,5-trimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azanonadecan-19-yl methanesulfonate (1.5 g, 3.5 mmol) in DMF (15 mL) was added sodium azide (0.34 g, 5.23 mmol) at rt. The resulting reaction mixture was then heated to 65 °C and stirred for 2 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 50 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (40% EAc-Hexanes) to give *tert*-butyl (14-azido-3,6,9,12-tetraoxatetradecyl)(methyl)carbamate as a light yellow oil (1.2 g, 92%). LC-MS (ESI^+) *m/z 2112* $(M+H)^+$.

[00848] Step 6 - *tert*-butyl (14-amino-3,6,9,12-tetraoxatetradecyl)(methyl)carbamate

[00849] To a stirred solution of *tert*-butyl (14-azido-3,6,9,12-tetraoxatetradecyl)(methyl)carbamate (1.2 g, 3.2 mmol) in MeOH (30 mL) was added 10% Pd/C (1.2 g, 50% wet) at rt under nitrogen atmosphere. The resulting reaction mixture was then stirred under hydrogen gas (15 kg/cm^2 pressure) in autoclave at rt for 2 h. The reaction mixture was then filtered through a pad of celite under vacuum and washed with MeOH (30 mL). The filtrate was then evaporated under reduced pressure to give *tert*-butyl (14-amino-3,6,9,12-tetraoxatetradecyl)(methyl)carbamate as a colorless oil (1 g, 91 %). LC-MS (ESI^+) *m/z* 351.7 $(M+H)^+$.

[00850] fert-butyl ((1R,4R)-4-((2-(2-(2-aminoethoxytethoxytethoxytmethvPcvclohexvPcarbamate [Intermediate W)



[00851] Step 1 - *tert*-butyl ((1R,4R)-4-(12-phenyl-2,5,8,11-tetraoxadodecyncyclohexyncarbamate

[00852] To a stirred solution of ((lR,4R)-4-((tert-butoxycarbonyl)amino)cyclohexyl)methyl methanesulfonate (1.1 g, 4.6 mmol, synthesized via Steps 1-3 of Intermediate K) and 2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethan-l-ol (1.7 g, 5.5 mmol, Intermediate T) in toluene (20 mL) and 8 N Aqueous NaOH solution (20 mL) was added TBAB (catalytic amount) at rt. The resulting reaction mixture was then heated to 90 °C and stirred for 16 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (2% MeOH-DCM) to give /ɛv·*t*-butyl ((lr,4r)-4-(l2-phenyl-2,5,8,ll-tetraoxadodecyl)cyclohexyl)carbamate as a yellow oil (0.7 g, 28%). LC-MS (ESI^+) *m/z* 452.5 $(M+H)^+$.

[00853] Step 2 - *tert*-butyl *((\RAR)-4-((2-(2-(2-*hvdroxyethoxy)ethoxy)ethoxy)methvDcvclohexyDcarbamate

[00854] To a stirred solution of /ɛv·*t*-butyl ((lR,4R)-4-(l2-phenyl-2,5,8,ll-tetraoxadodecyl)cyclohexyl)carbamate (0.85 g, 1.88 mmol) in ethanol (25 mL) and acetic acid (0.3 mL) was added 10% Pd/C (0.85 g, wet) at rt under nitrogen atmosphere. The resulting reaction mixture was then stirred under hydrogen gas (2 kg/cm^2 pressure) in autoclave at rt for 1.5 h. The reaction mixture was filtered through a pad of celite under vacuum and washed with MeOH (50 mL). The filtrate was evaporated under reduced pressure to give /ɛv·*t*-butyl ((lR,4R)-4-((2-(2-(2-

hydroxyethoxy)ethoxy)ethoxy)methyl)cyclohexyl)carbamate as a yellow oil (0.65 g, 95 %). LC-MS (ESI$^+$) *m/z* 362.4 (M+H)$^+$.

[00855] Step 3 - 2-(2-(2-(((1r,4r)-4-((*tert*-butoxycarbonyl)amino)cyclohexyl)methoxy)ethoxy)ethoxy)ethyl methanesulfonate

[00856] To a stirred solution of *tert*-butyl ((lR,4R)-4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)methyl)cyclohexyl)carbamate (0.65 g, 1.8 mmol) and TEA (0.8 mL, 5.4 mmol) in DCM (10 mL) was added mesyl chloride (0.21 mL, 2.7 mmol) dropwise at 0 °C. The resulting reaction mixture was allowed to warm to rt for 1 h. The reaction mixture was then transferred into water and the resulting mixture was extracted using DCM (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give 2-(2-(2-(((lR,4R)-4-((/er/-butoxycarbonyl)amino)cyclohexyl)methoxy)ethoxy)ethoxy)ethyl methanesulfonate as a brown oil (0.75 g, 95%). LC-MS (ESI$^+$) *m/z* 440.5 (M+H)$^+$.

[00857] Step 4 - *tert*-butyl ((\RAR)A-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methvDcvclohexyDcarbamate


[00858] To a stirred solution of 2-(2-(2-(((lR,4R)-4-((/er/-butoxycarbonyl)amino)cyclohexyl)methoxy)ethoxy)ethoxy)ethyl methanesulfonate (0.75 g, 1.71 mmol) in DMF (10 mL) was added sodium azide (0.17 g, 2.55 mmol) at rt. The resulting reaction mixture was then heated to 65 °C and stirred for 2 h. The reaction mixture was then transferred into water and the resulting mixture was extracted using ethyl acetate (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was then evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (35% EtOAc-Hexanes) to give *tert*-butyl ((lR,4R)-4-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)cyclohexyl)carbamate as a colorless oil (0.55 g, 83%). LC-MS (ESI$^+$) *m/z* 387.4 (M+H)$^+$.

[00859] Step 5 - fer/-butyl ((1R,4R)A-((2-(2-(2-aminoethoxy)ethoxy)ethoxy)methvDcvclohexyDcarbamate

[00860] To a stirred solution of *tert*-butyl ((lR,4R)-4-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)cyclohexyl)carbamate (0.55 g, 1.42 mmol) in ethanol (15 mL) was added 10% Pd/C (0.55 g, wet) at rt under nitrogen atmosphere. The resulting reaction mixture was then stirred under hydrogen gas (15 kg/cm^2 pressure) in autoclave at rt for 5 h. The reaction

mixture was filtered through a pad of celite under vacuum and washed with MeOH (50 mL). The filtrate was evaporated under reduced pressure to give *tert*-butyl ((lR,4R)-4-((2-(2-(2-aminoethoxy)ethoxy)ethoxy)methyl)cyclohexyl)carbamate as a yellow oil (0.45 g, 88 %). LC-MS (ESI^+) *m/z* 361.45 $(M+H)^+$.

[00861] l-phenyl-2,5,8,ll,14-pentaoxahexadecan-16-yl 4-methylbenzenesulfonate (Intermediate X)



X


[00862] Step 1 - l-phenyl-2.5.8.lLl4-pentaoxahexadecan-l6-ol

[00863] To a stirred solution of 3,6,9, l2-tetraoxatetradecane-l,l4-diol (10 g, 42 mmol, CAS# 4792-15-8) in THF (50 mL) was added 60% NaH in paraffin (0.84 g, 2 1 mmol) at 10 °C. The resulting reaction mixture was stirred at the same temperature for 0.5 h. To this reaction mixture benzyl bromide (3.6 g, 2 1 mmol) in THF (50) was added dropwise at 10 °C over 1.5 h. The resulting reaction mixture was allowed warm to rt and stirred for 16 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (3% MeOH-DCM) to give l-phenyl-2,5,8,ll,l4-pentaoxahexadecan-l6-ol as a yellow oil (6 g, 43%). LC-MS (ESI^+) *m/z* 347.4 $(M+H_20)^+$.

[00864] Step 2 - 1-phenyl-2,5.8.11.14-pentaoxahexadecan- 16-yl 4-methylbenzenesulfonate

[00865] To a stirred solution of methyl l-phenyl-2,5,8,ll,l4-pentaoxahexadecan-l6-ol (6.0 g, 18.2 mmol) and TEA (8 mL, 55 mmol) in DCM (150 mL) was added tosyl chloride (5.2 g, 27.3 mmol) at rt. The resulting reaction mixture then stirred at rt for 16 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using DCM (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (2% MeOH-DCM) to give l-phenyl-2,5,8,ll,l4-pentaoxahexadecan-l6-yl 4-methylbenzenesulfonate as a yellow oil (7 g, 79%). LC-MS (ESI^+) *m/z* 484.2 $(M+H)^+$.

[00866] ***tert*-butyl [[lR.4RV4-[16-amino-2.5.8.11.14-pentaoxahexadecvncvclohexyncarbamate [Intermediate Y)**



[00867] Step 1 - *tert*-butyl ((1R,4R)-4-(18-phenyl-2,5,8,11,14,17-hexaoxaoctadecvPcvclohexyDcarbamate

[00868] To a stirred solution of tert-butyl ((lR,4R)-4-(hydroxymethyl)cyclohexyl)carbamate (1.5 g, 0.7 mmol, synthesized via Steps 1-2 of Intermediate K) and 1-phenyl-2, 5,8, 11, 14-pentaoxahexadecan-l6-yl 4-methylbenzenesulfonate (4.74 g, 0.98 mmol, Intermediate X) in THF (30 mL) was added KOH (3.67 g, 65.4 mmol) at rt. The resulting reaction mixture then heated to 60 °C and stirred for 16 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (2% MeOH-DCM) to give /<//7-butyl ((lR,4R)-4-(l8-phenyl-2,5,8,ll,l4,l7-hexaoxaoctadecyl)cyclohexyl)carbamate as a yellow oil (0.92 g, 26%). LC-MS (ESI$^+$) *m/z* 557.4 (M+l8) $^+$.

[00869] Step 2 - *tert*-butyl ((TR.4RV4-(T6-hvdroxy-2.5.8.lLl4-pentaoxahexadecvPcvclohexyDcarbamate

[00870] To a stirred solution of *tei*7-butyl ((lR,4R)-4-(l8-phenyl-2,5,8,ll,l4,l7-hexaoxaoctadecyl)cyclohexyl)carbamate (0.91 g, 1.68 mmol) in ethanol (15 mL) was added 10% Pd/C (0.9 g, 50% wet) at rt under nitrogen atmosphere. The resulting reaction mixture was stirred

under hydrogen gas (2 kg/cm^2 pressure) in an autoclave at rt for 6 h. The reaction mixture was filtered through a pad of celite under vacuum and washed with MeOH (50 mL). The filtrate was evaporated under reduced pressure to give *tert*-butyl ((lR,4R)-4-(l6-hydroxy-2,5,8,ll,l4-pentaoxahexadecyl)cyclohexyl)carbamate as a yellow oil (0.75 g, 99 %). LC-MS (ESI$^+$) *m/z* 450.2 (M+H)$^+$.

[00871] Step 3 - 1-((\R.4R)-4-((*tert*-butoxycarbonyl)amino)cyclohexyl)-2,5,8,11,14-pentaoxahexadecan-l6-yl methanesulfonate

[00872] To a stirred solution of ter/-butyl ((lR,4R)-4-(l6-hydroxy-2,5,8,ll,l4-pentaoxahexadecyl)cyclohexyl)carbamate (0.8 g, 1.8 mmol) and TEA (0.75 mL, 5.33 mmol) in DCM (10 mL) was added mesyl chloride (0.2 mL, 2.66 mmol) dropwise at 0 °C. The resulting reaction mixture was allowed to warm to rt and stirred for 1 h. The reaction mixture was then transferred into water and the resulting mixture was extracted using DCM (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give l-((lR,4R)-4-((/er/-butoxycarbonyl)amino)cyclohexyl)-2,5,8,ll,l4-pentaoxahexadecan-l6-yl methanesulfonate as a brown oil (0.9 g, 96%). LC-MS (ESI$^+$) *m/z* 545.6 (M+l8)$^+$.

[00873] Step 4 - *tert*-butyl ((TR.4RV4-(T6-azido-2.5.8.lU4-pentaoxahexadecvPcvclohexyDcarbamate


[00874] To a stirred solution of l-((lR,4R)-4-((/er/-butoxycarbonyl)amino)cyclohexyl)-2,5,8, 11, l4-pentaoxahexadecan-l6-yl methanesulfonate (0.9 g, 1.7 mmol) in DMF (10 mL) was added sodium azide (0.17 g, 2.55 mmol) at rt. The resulting reaction mixture was then heated to 65 °C and stirred for 2 h. The reaction mixture was then transferred into water and the resulting mixture was extracted using ethyl acetate (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (45% EAc-Hexanes) to give *tert*-butyl ((lR,4R)-4-(l6-azido-2,5,8,ll,l4-pentaoxahexadecyl)cyclohexyl)carbamate as a colorless oil (0.72 g, 90%).

[00875] Step 5 - *tert*-butyl ((TR.4RV4-(T6-amino-2.5.8.lU4-pentaoxahexadecvPcvclohexyDcarbamate

[00876] To a stirred solution of *tert*-butyl ((lR,4R)-4-(l6-azido-2,5,8,ll,l4-pentaoxahexadecyl)cyclohexyl)carbamate (0.7 g, 1.47 mmol) in ethanol (20 mL) was added 10%

Pd/C (0.7 g, 50% wet) at rt under nitrogen atmosphere. The resulting reaction mixture was then stirred under hydrogen gas (15 kg/cm^2 pressure) in an autoclave at rt for 4 h. The reaction mixture was then filtered through a pad of celite under vacuum and washed with MeOH (50 mL). The filtrate was evaporated under reduced pressure to give *tert*-butyl ((1R,4R)-4-(16-amino-2,5,8,11,14-pentaoxahexadecyl)cyclohexyl)carbamate as a yellow oil (0.52 g, 78 %). LC-MS (ESI$^+$) *m/z* 449.5 (M+H)$^+$.

[00877] **4-((14-amino-3,6,9,12-tetraoxatetradecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride (Intermediate Z)**



R

Z


[00878] Step 1 - *tert*-butyl (14-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxatetradecyl)carbamate

[00879] To a stirred solution of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (0.95 g, 3.44 mmol, Intermediate R) and DABCO (0.5 g, 4.5 mmol) in DMF (25 mL) was added *tert*-butyl (14-amino-3,6,9,12-tetraoxatetradecyl)carbamate (1.5 g, 4.5 mmol, CAS # 811442-84-9) at rt. The resulting reaction mixture then heated at 80 °C for 3 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 50 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (2% MeOH-DCM) to give *tert*-butyl (14-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxatetradecyl)carbamate as a yellow oil (0.35 g, 17%). LCMS (ESI$^+$) *m/z* 593.6 (M+H)$^+$.

[00880] Step 2 - 4-((14-amino-3,6,9,12-tetraoxatetradecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride

[00881] To a stirred solution of *tert*-butyl (14-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxatetradecyl)carbamate (0.35 g, 0.59 mmol) in 1,4 dioxane (10 mL) was added 4 M HCl in dioxane (10 mL) at 0 °C. The resulting reaction mixture was allowed to warm to rt and stirred for 16 h. The reaction mixture was then evaporated under vacuum and triturated using MTBE to give 4-((14-amino-3,6,9,12-tetraoxatetradecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride as a yellow solid (0.28 g, 90%). LCMS (ESI^+) *m/z* 493.45 $(M+H)^+$.

[00882] ***tert*-butyl 6-bromohexanoate [Intermediate AA)**



AA


[00883] Step 1 - 6-bromohexanoyl chloride

[00884] To a stirred solution of 6-bromohexanoic acid (5.0 g, 25.6 mmol) and **DMF** (catalytic amount) in **DCM** (50 mL) was added oxalyl chloride (2.5 mL, 28.16 mmol) dropwise at 0 **°C.** The resulting reaction mixture was then warmed to rt and stirred for 16 h. The reaction mixture was then evaporated under reduced pressure to give 6-bromohexanoyl chloride as a brown oil (5 g, 91 %).

[00885] Step 2 - *tert*-butyl 6-bromohexanoate

[00886] To a stirred solution of 6-bromohexanoyl chloride (5.5 g, 25.8 mmol) and pyridine (2.55 mL, 30.9 mmol) in DCM (50 mL) was added /er/-butanol (3.71 mLg, 38.62 mmol) dropwise at rt. The resulting reaction mixture stirred at rt for 16 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using DCM (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (6% EAc-Hexanes) to give *tert*-butyl 6-bromohexanoate as a colorless oil (4.5 g, 70%). ^{1}HNMR (400 MHz, DMSO) δ 3.43 (*t*, J = 8 Hz, 2H), 2.25 (*t*, J = 7.2 Hz, 2H), 1.93-1.86 (m, 2H), 1.67-1.60 (m, 2H), 1.52-1.50 (m, 2H), 1.46 (s, 9H).

[00887] ***tert*-butyl 6-[[7-aminoheptyDoxy)hexanoate [Intermediate AB)**



AB

[00888] Step 1: 7-azidoheptan-l-ol

[00889] To a stirred solution of 7-bromoheptan-l-ol (0.5 g, 2.6 mmol) and TBAB (0.083 g, 0.25 mmol) in toluene (10 mL) was added sodium azide (0.35 g, 5.12 mmol) at rt. The resulting reaction mixture was then heated to 90 °C and stirred for 16 h. The reaction mixture was then filtered through celite, washed with DCM (25 mL), and filtrate was evaporated under reduced pressure. The crude product was purified using silica gel column chromatography (10% EAc-Hexanes) to give 7-azidoheptan-l-ol as a colorless oil (0.35 g, 87%). LC-MS (ESI+) m/z 157.2 $(M+H)^+$.

[00890] Step 2 - *tert*-butyl 6-(Y7-azidoheptvDoxy)hexanoate


[00891] To a stirred solution of 7-azidoheptan-l-ol (1.1 g, 7.2 mmol) in DMF (30 mL) was added Nal (0.18 g, 1.19 mmol) and 60% NaH (0.36 g, 8.9 mmol) at rt. The resulting reaction mixture was stirred at rt for 0.5 h then *tert*-butyl 6-bromohexanoate (1.5 g, 5.97 mmol) in DMF (5 mL) was added dropwise at rt. The resulting reaction mixture then heated to 50 °C and stirred for 16 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (3% EAc-Hexanes) to give *te/'t*-butyl 6-((7-azidoheptyl)oxy)hexanoate as a colorless oil (0.3 g, 10 %). 'H NMR (400 MHz, DMSO) δ 3.43-3.39 (m, 4H), 3.27 (*t*, *J* = 7.2 Hz, 2H), 2.23 (t, *J* = 7.6 Hz, 2H), 1.66-1.48 (m, 8H), 1.46 (m, 9H), 1.44-1.41 (m, 8H).

[00892] Step 3 - *tert*-butyl 6-(Y7-aminoheptvDoxy)hexanoate

[00893] To a stirred solution of *tei*7-butyl 6-((7-azidoheptyl)oxy)hexanoate (0.3 g, 0.92 mmol) in methanol (30 mL) was added 20% $Pd(OH)_2$ (0.3 g) at rt under nitrogen atmosphere. The resulting reaction mixture then stirred under hydrogen gas (20 kg/cm^2 pressure) in an autoclave at rt for 4 h. The reaction mixture was then filtered through a pad of celite under vacuum and washed with MeOH (50 mL). The filtrate was then evaporated under reduced pressure to give *te/'t*-butyl 6-

((7-aminoheptyl)oxy)hexanoate as a colorless oil (0.25 g, 90 %). ^{1}H NMR (400 MHz, DMSO) δ 3.42-3.38 (m, 4H), 2.69 (t, *J* = 7.2 Hz, 2H), 2.23 (t, *J* = 7.6 Hz, 2H), 1.65-1.56 (m, 8H), 1.46 (m, 10H), 1.42-1.33 (m, 8H).

[00894] **fc/T-biityl(2-(2-(2-(methylamino)ethoxy)ethoxy)ethyl)carbamate [Intermediate AO**



AC

[00895] Step 1 - *tert*-butyl (2-(2-(2-hvdroxyethoxy)ethoxy)ethvOcarbamate

[00896] A solution of 2-(2-(2-aminoethoxy)ethoxy)ethan-l-ol (1.5 g, 10.1 mmol), triethylamine (3.3 mL, 15.1 mmol), and Boc-anhydride (3.3 g, 15.1 mmol) in DCM (10 mL) was stirred at rt for 2 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using DCM (3 x 25 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (3 % MeOH-DCM) to give *tert*-butyl (2-(2-(2-hydroxyethoxy)ethoxy)ethyl)carbamate as a colorless oil (1.8 g, 72%). LC-MS (ESI$^+$) *m/z* 267.35 $(M+H)^+$.

[00897] Step 2 - 2.2-dimethyl-4-oxo-3.8. 11-trioxa-5-azatridecan- 13-yl methanesulfonate


[00898] To a stirred solution of /er/-butyl(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)carbamate (1.8 g, 7.2 mmol) and triethylamine (3.0 g, 4.15 mL, 21.7 mmol) in DCM (12 mL) was added of mesyl chloride (0.85 g, 10.8 mmol) and the reaction mixture was stirred at rt for 2 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using DCM (3 x 25 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give 2,2-dimethyl-4-oxo-3,8,ll-trioxa-5-azatri decan- 13-yl methanesulfonate as a yellow semisolid (2.2 g, 93%).

[00899] Step 3 - *tert*-butyl (2-(2-(2-(methylamino)ethoxy)ethoxy)ethvncarbamate

[00900] A stirred solution of /er/-butyl(2-(2-(2-(methylamino)ethoxy)ethoxy)ethyl)carbamate (2.0 g, 6.1 mmol), 2M Methyl amine in THF (36.66 mL, 73.32 mmol) and DIPEA (3 mL, 3 eq) in DMF (20 mL) was heated at 90 °C for 10 h. The reaction mixture was then transferred into ice

water and the resulting mixture was extracted using ethyl acetate (3 x 25 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give *tert*-butyl (2-(2-(2-(methylamino)ethoxy)ethoxy)ethyl)carbamate (1.2 g, 68%).


[00901] **2-azidoethan-l-ol [Intermediate AD]**



AD

[00902] To a stirred solution of 2-bromoethan-l-ol (10 g, 80 mmol) in water (100 mL) was added sodium azide (10.4 g, 160.1 mmol) and the reaction mixture was heated at 80 °C for 16 h. The reaction mixture was then extracted using diethyl ether (250 mL><3), dried over anhydrous sodium sulphate and evaporated in vacuum to give 2-azidoethan-l-ol as a light yellow oil (6.5 g, 93%); ^{1}H NMR (400 MHz, DMSO) δ 5.00 (t, *J* = 5.2 Hz, 1H), 3.7-3. 5 (m, 2H), 3.3-3.2 (m, 2H).


[00903] **2-azidoethyl 4-methylbenzenesulfonate [Intermediate AE)**



AD AE

[00904] To a stirred mixture of 2-azidoethan-l-ol (0. 1 g, 1.2 mmol, Intermediate AD) in DCM (5 mL) was added TEA (0.5 mL, 3.5 mmol) and TsCl (0.286 g, 1.5 mmol) at 0 °C and the reaction mixture was stirred for 3h. The reaction mixture was then diluted with water (100 mL) and extracted using DCM (50 mL x3). The combined organic layer was dried over anhydrous sodium sulphate, filtered and evaporated in vacuo and the crude product was purified by silica gel column chromatography (10-15% EtOAc-Hexane) to give 2-azidoethyl 4-methylbenzenesulfonate as a colorless semisolid (0.15 g, 54%). ^{1}H NMR (400 MHz, DMSO) δ 7.83 (d, *J* = 8.4 Hz, 2H), 7.52 (d, *J* = 8.0 Hz, 2H), 4.17 (t, *J* = 4.8 Hz, 2H), 3.56 (t, *J* = 4.8 Hz, 2H), 2.52 (d, *J* = 1.6 Hz, 2H).

[00905] ***tert*-butyl [2-[[6-[[2-aminoethoxy)methyl)pyridin-3-yl)methoxy)ethyl) carbamate [Intermediate AF)**



[00906] Step 1 - methyl 6-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)nicotinate

[00907] To a stirred solution of methyl 6-(hydroxymethyl)nicotinate (0.5 g, 3.0 mmol) in DCM (50 mL), was added p-TsOH (0.63 g, 3.3 mmol) at 0 °C followed by 3,4-dihydro-2i7-pyran (0.9 mL, 9.0 mmol) at same temperature. The mixture was allowed to warm to rt then stirred for 16 h. The reaction mixture was diluted with water (50 mL) and product was extracted using DCM (50 mL x3). The combined organic layer was dried over anhydrous sodium sulphate and vacuum evaporated and the crude product was purified by silica gel column chromatography (0-1% MeOH-DCM to give methyl 6-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)nicotinate as a yellow semi solid (0.7 g, 90%); LC-MS (ESI$^+$) *m/z* 252.3 $(M+H)^+$.

[00908] Step 2 - (6-(((tetrahydro-2H-pyran-2-yl)oxy)methyDpyridin-3-yDmethanol

[00909] To a stirred solution of methyl 6-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)nicotinate (0.7 g, 2.79 mmol) in THF (25 mL) was added 1M lithium aluminum hydride in THF (7 mL, 7 mmol) dropwise at -70 °C and the mixture was stirred for 30 minutes at the same temperature. The reaction mixture was then quenched with water (100 mL), filtered through celite and the filtrate was extracted in ethyl acetate (100 mL x3). The combined organic layer was dried over anhydrous

sodium sulphate, filtered and evaporated in vacuo and the crude product was purified by silica gel column chromatography (70-80% EtOAc-Hexane) to give (6-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)pyridin-3-yl)methanol as a yellow semisolid (0.3 g, 48%); LC-MS (ESI^+) *m/z* 224.25 $(M+H)^+$.

[00910] Step 3 - 5-(bromomethyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)pyridine

[00911] To a stirred solution of (6-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)pyridin-3-yl)methanol (0.3 g, 1.34 mmol) in DCM (10 mL) was added carbon tetrabromide (0.668 g, 2.02 mmol) and triphenylphosphine (0.334 g, 1.47 mmol) at 0 °C and the reaction mixture was stirred for 4 h. The reaction mixture was then diluted with water (50 mL) and product was extracted using DCM (50 mL x3). The combined organic layer was dried over anhydrous sodium sulphate, filtered and evaporated in vacuo. The crude product was purified by silica gel column chromatography (50% EtOAc-Hexane) to give 5-(bromomethyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)pyridine as a yellow oil (0.05 g, 13%); LC-MS (ESI^+) *m/z* 288.2 $(M+H)^+$.

[00912] Step 4 - 5-((2-azidoethoxy)methyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)pyridine

[00913] To a stirred solution of 2-azidoethan-1-ol (0.8 g, 9.1 mmol, Intermediate AD) in DMF (10 mL) was added 60% NaH in oil (0.363 g, 9.09 mmol) at 0 °C followed by addition of a solution of 5-(bromomethyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)pyridine (1.3 g, 4.54 mmol) in DMF (5 mL) and the reaction was stirred for 15 min. The reaction mixture was then quenched with water (50 mL) and product was extracted in ethyl acetate (250 mL). The organic layer was washed with water (250 mL ×3) and dried over anhydrous sodium sulphate, filtered and evaporated in vacuo. The crude product was purified by silica gel column chromatography (50% EtOAc-Hexane) to give 5-((2-azidoethoxy)methyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)pyridine as a yellow oil (1.1 g, 83%); LC-MS (ESI^+) *m/z* 293.3 $(M+H)^+$.

[00914] Step 5 - (5-((2-azidoethoxy)methyl)pyridin-2-yl)methanol

[00915] To a stirred solution of 5-((2-azidoethoxy)methyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)pyridine (1.1 g, 3.8 mmol) in methanol (25 mL) was added p-TsOH (0.648 g, 3.76 mmol) at 0 °C and the reaction mixture was allowed to warm to rt and stirred for 16 h. The reaction mixture was then concentrated, diluted with water (250 mL) and extracted in ethyl acetate (200 mL x3). The combined organic layer was dried over anhydrous sodium sulphate, filtered and evaporated in vacuo. The crude product was purified by silica gel column chromatography u(l0%

MeOH-DCM) to give (5-((2-azidoethoxy)methyl)pyridin-2-yl)methanol as a yellow semisolid (0.55 g, 70%); LC-MS (ESI^+) *m/z* 209.2 $(M+H)^+$.

[00916] Step 6 - tert-butyl (2-((6-(hvdiOxymethvDpyridin-3-vDmethoxy)ethvDcarbamate

[00917] To a stirred solution of (5-((2-azidoethoxy)methyl)pyridin-2-yl)methanol (0.55 g, 2.64 mmol) in ethanol (50 mL) was added Boc anhydride (0.91 mL, 3.96 mmol) and 20% $Pd(OH)_2/C$ (50% wet) (0.55 g) in autoclave at rt under hydrogen gas (20 kg/cm^2 pressure) and the reaction was stirred for 6 h. The reaction mixture was then filtered through celite and the filtrate was concentrated in vacuo. The crude product was purified by silica gel column chromatography (70-80% EtOAc-Hexane) to give tert-butyl (2-((6-(hy droxymethyl)pyri din-3-yl)methoxy)ethyl)carbamate as a yellow semisolid (0.4 g, 54%); LC-MS (ESI^+) *m/z* 283.3 $(M+H)^+$.

[00918] Step 7 - tert-butyl (2-(Y6-(Y2-azidoethoxy)methv0pyridin-3-yl)methoxy)ethyl icarbamate


[00919] To a stirred solution of tert-butyl (2-((6-(hy droxymethyl)pyri din-3-yl)methoxy)ethyl)carbamate (0. 15 g, 0.53 mmol), 8N NaOH in water (2 mL) and TBAB in toluene (2 mL) was added 2-azidoethyl 4-methylbenzenesulfonate (3 mL, 18 mmols, Intermediate AE) and the mixture was refluxed for 48 h. The reaction mixture was then diluted with water (100 mL) and extracted using ethyl acetate (50 mL x3). The combined organic layer was dried over anhydrous sodium sulphate, filtered and evaporated in vacuo. The crude product was purified by silica gel column chromatography (2% MeOH-DCM) to give tert-butyl (2-((6-((2-azidoethoxy)methyl)pyridin-3-yl)methoxy)ethyl)carbamate as a colorless oil (0.065 g, 35%); LC-MS (ESL) *m/z* 352.3 $(M+H)^+$.

[00920] Step 8 - *tert*-butyl (2-((6-((2-aminoethoxy)methvl)pyr din-3-yl)methoxy)ethvl) carbamate

[00921] To a stirred solution of *tert*-butyl (2-((6-((2-azidoethoxy)methyl)pyri din-3-yl)methoxy)ethyl)carbamate (0.145 g) in ethanol (10 mL) was added 20% $Pd(OH)_2/C$ (50% wet) (0.14 g) in an autoclave at rt and the reaction mixture was stirred under hydrogen gas (20 kg/cm^2 pressure) for 4 h. The reaction mixture was then filtered through celite and the filtrate was concentrated and evaporated in vacuo to give *tert*-butyl (2-((6-((2-aminoethoxy)methyl)pyri din-3-yl)methoxy)ethyl)carbamate as a yellow semisolid (0.1 g, 74%); LC-MS (ESI^+) *m/z* 326.5 $(M+H)^+$.

[00922] **[lR,4R]-4-[6-[5-cvano-lH-pyrazolo[3,4-b]pyridin-l-vB-4-**

(cvclopropylaminofnicotinamidofcvclohexane-l-carboxylic acid (Intermediate AG)



[00923] Step 1 - methyl (1R.4R)-4-(6-(5-cvano- lH-pyrazoloUA-blpyridin-l -yl)-4-(cvclopropylaminofnicotinamidofcvclohexane- 1-carboxylate


[00924] A stirred solution of 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(cyclopropylamino)nicotinic acid (0.3 g, 0.94 mmol, Intermediate L), methyl (lR,4R)-4-aminocyclohexane-l-carboxylate hydrochloride (0.18 g, 0.94 mmol), HATU (0.54 g, 1.41 mmol) and DIPEA (0.54 mL, 1.41 mmol) in DMF (5 mL) was stirred at rt for 4 h. The reaction mixture was transferred then into ice water and the resulting precipitate was filtered off and dried under vacuum to give methyl (lR,4R)-4-(6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(cyclopropylamino)nicotinamido)cyclohexane-l-carboxylate as an off white solid (0.38 g, 88%). LC-MS (ESI^+) *m/z* 460.2 $(M+H)^+$.

[00925] Step 2 - (TR.4R)-4-(6-(5-cvano-lH-pyrazolor3.4-b1pyridin-l-vO-4-(cvclopropylamino)nicotinamido)cvclohexane-l -carboxylic acid

[00926] To a stirred solution of methyl (lr,4r)-4-(6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(cyclopropylamino)nicotinamido)cyclohexane-l-carboxylate (0.38 g, 0.82 mmol) in THF: water (1:1, 10 mL) was added lithium hydroxide monohydrate (0. 11 g, 2.48 mmol) at rt and the reaction mixture was stirred for 2 h. The reaction mixture was then transferred into ice water and the pH was adjusted to 5-6 using 10% citric acid solution. The resulting precipitate was filtered off and dried under vacuum to give (lR,4R)-4-(6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(cyclopropylamino)nicotinamido)cyclohexane-l -carboxylic acid as an off-white solid (0.25 g,

76%). LC-MS (ESL) *m/z* 446.4 $(M+H)^+$.

[00927] **3-1DIBENZYLAMINOV2-FLUORO-PROPAN-1-OL [INTERMEDIATE AH]**



AH

[00928] Step 1 - Methyl 2-(dibenzylamino)-3-hvdroxy-propanoate

[00929] To a mixture of methyl 2-amino-3-hydroxy-propanoate (15.0 g, 96.4 mmol, HC1 salt) and benzyl bromide (36.3 g, 212 mmol, 25.2 mL) in acetonitrile (200 mL) was added potassium carbonate (66.6 g, 482 mmol). The mixture was stirred at rt for 12 h. On completion, the reaction mixture was filtered and washed with acetonitrile. The combined organic layers were concentrated *in vacuo.* The residue was purified by column chromatography to give the title compound (16. 1 g, 56% yield) as a white solid. ^{1}H NMR (400MHz, DMSO^) δ 7.39 - 7.28 (m, 8H), 7.27 - 7.20 (m, 2H), 4.80 (dd, *J* = 4.8, 6.0 Hz, 1H), 3.84 - 3.80 (m, 2H), 3.69 (s, 3H), 3.56 (d, *J* = 14.4Hζ, 2H), 3.40 - 3.30 (m, 2H); LC-MS (ESI^+) m/z 300.1 $(M+H)^+$.


[00930] Step 2 - Methyl 3-(dibenzylamino)-2-fluoro-propanoate

[00931] To a solution of methyl 2-(dibenzylamino)-3-hydroxy-propanoate (5.00 g, 16.7 mmol) in THF (20.0 mL) was added a solution of DAST (3.23 g, 20.0 mmol, 2.65 mL) in 10 mL THF. The reaction mixture was stirred at rt for 1 h. On completion, the reaction mixture was quenched by the addition of ice-water (50 mL) followed by ethyl acetate (200 mL). The mixture was rapidly stirred and solid $NaHC0_3$ was added until effervescence ceased .The layers were then separated and the aqueous layer was extracted with ethyl acetate (2 X 50 mL). The combined organic phase was washed with water (50 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (3.63 g, 72% yield) as a yellow oil. ^{1}H NMR (400MHz, CDCb) δ 7.42 - 7.25 (m, 10H), 5.19 - 5.01 (m, 1H), 3.88 (d, *J* = 13.6 Hz, 2H), 3.77 - 3.71 (s, 3H), 3.57 *(d, J* = 13.6 Hz, 2H), 3.16 - 2.96 (m, 2H); LC-MS (ESL) m/z 302. l$(M+H)^+$.

[00932] Step 3 - 3-(Dibenzylamino)-2-fluoro-propan-l-ol

[00933] To a solution of lithium borohydride (50.6 mg, 2.3 mmol) in THF (5 mL) was added a solution of methyl 3- (dibenzylamino)-2-fluoro-propanoate (500 mg, 1.66 mmol) in THF (10 mL) at -15 °C under nitrogen. The reaction was allowed to warm to rt and was stirred for 4 h. On completion, the reaction mixture was quenched with saturated ammonium chloride solution (10 mL) dropwise, and then extracted with ethyl acetate. The combined organic phase was dried over Na_2S04, filtered and concentrated *in vacuo* to give the title compound (2.70 g, 96% yield) as a white oil. ^{1}H1NMR (400MHz, CDCh) δ 7.44 - 7.28 (m, 10H), 4.76 - 4.58 (m, 1H), 3.82 - 3.67 (m, 4FI), 3.66 - 3.60 (m, 2H), 3.11 - 3.08 (m, 1H), 2.90 - 2.84 (m, 2H); LC-MS (ESI$^+$) m/z 274.1 (M +H)$^+$.

[00934] **Tert-butyl (2-(2-(2-(3-amiiio-2-fliioroDroDoxy)ethoxy)ethoxy)ethyl)carbamate [Intermediate AI)**



[00935] Step 1 - 2.2-Dimethyl-4-oxo-3.8.11-trioxa-5-azatridecan-13-yl methanesulfonate

[00936] To a solution of tert-butyl /V-[2-[2-(2-hydroxyethoxy)ethoxy]ethyl]carbamate (4.00 g, 16.0 mmol, CAS# 139115-92-7) in dichloromethane (5 mL) was added triethylamine (3.25 g, 32.0 mmol) and MsCl (2.21 g, 19.2 mmol) at 0 °C. The reaction mixture was then allowed to warm to rt and stirred for 1 . On completion, the reaction mixture was quenched with water (10 mL) and extracted with dichloromethane (3 X 100 mL). The combined organic layer was washed with brine (2 X 50 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (5.23 g, 99% yield) as a colorless oil. ¾ NMR (400MHz, CDCh) δ 4.94 (s, 1H), 4.44 - 4.37 (m, 2H), 3.83 - 3.75 (m, 2H), 3.69 - 3.65 (m, 2H), 3.64 - 3.59 (m, 2H), 3.54 (t, J = 5.2 Hz, 2H), 3.36 - 3.29 (m, 2H), 3.08 (s, 3H), 1.45 (s, 9H).

[00937] Step 2 - Tert-butyl (2-benzyl -4-fluoro- 1-phenyl -6.9. 12-trioxa-2-azatetradecan- 14-yl)


[00938] To a solution of 3-(dibenzylamino)-2-fluoro-propan-l-ol (3.64 g, 13.3 mmol,

Intermediate AH) in DMF (5 mL) was added sodium hydride (1.60 g, 39.5 mmol, 60% oil dispersion) at 0 °C under nitrogen atmosphere. The reaction mixture was stirred at 0 °C for 1 h. Then, 2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethyl methane sulfonate (5.23 g, 15.9 mmol) was added. The resulting reaction mixture was stirred at rt for 3 h. On completion, the reaction mixture was quenched with saturated NH_4Cl (20 mL) and extracted with ethyl acetate (3 X 100 mL). The combined organic layer was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo.* The residue was purified by reverse phase flash column (0. 1% $NH_3 \bullet H_2O$) to give the title compound (2.95 g, 44% yield) as a colorless oil. ^1H NMR (400MHz, CDCb) δ 7.40 - 7.28 (m, 10H), 5.02 (s, 1H), 4.89 - 4.70 (m, 1H), 3.72 - 3.61 (m, 12H), 3.60 - 3.56 (m, 2H), 3.54 (t, *J* = 5.2 Hz, 2H), 3.31 - 3.18 (m, 2H), 2.82 - 2.69 (m, 2H), 1.46 (s, 9H); LC-MS $(ESI)^+$ *m/z* 505.2. $(M+H)^+$.

[00939] Step 3 - Tert-butyl (2-(2-(2-(3-amino-2-fluoropropoxy)ethoxy)ethoxy)ethv0carbamate

[00940] To a solution of tert-butyl /V-[2-[2-[2-[3-(dibenzylamino)-2-fluoro-propoxy]ethoxy]ethoxy]ethyl] carbamate (2.90 g, 5.75 mmol) in THF (5 mL) was added $Pd(OH)_2/C$ (1.00 g, 10 wt %) and Pd/C (1.00 g, 10 wt %) under nitrogen atmosphere. The suspension was degassed and purged with hydrogen gas 3 times. The mixture was then stirred under hydrogen gas (50 psi pressure) at rt for 24 h. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (1.70 g, 91% yield) as a white gum. LC-MS $(ESI)^+$ *m/z* 325.1. $(M+H)^+$.

[00941] Benzyl N-[2-[2-|2-|2-[2-hvdroxyethoxy)ethoxy]ethoxy]ethoxy]ethyl] carbamate [Intermediate AJ)



AJ

[00942] Step 1 - 2-r2-r2-r2-(2-Hvdroxyethoxy)ethoxy1ethoxy1ethoxy1ethyl 4-

methylbenzenesulfonate

[00943] To a solution of 2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethanol (3.50 g, 14.7 mmol, CAS# 4792-15-8) in tetrahydrofuran (30 mL) was added a solution of sodium hydroxide (763 mg, 19.1 mmol) in water (30 mL) at 0 °C. Then a solution of TsCl (2.80 g, 14.7 mmol) in tetrahydrofuran (90 mL) was added slowly dropwise at 0 °C. The reaction mixture was then allowed to warm to rt and stirred for 12 h. On completion, the reaction mixture was diluted with water (100 mL) and extracted with dichlorom ethane (3 X 100 mL). The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (5.20 g, 87% yield) as a yellowish oil. LC-MS (ESI^+) *m/z* 393.0 $(M+H)^+$.

[00944] Step 2 - 2-r2-r2-r2-(2-Azidoethoxy)ethoxy1ethoxy1ethoxy1ethanol

[00945] To a mixture of 2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (4.50 g, 11.5 mmol) in DMF (30 mL) was added sodium azide (1.86 g, 28.6 mmol). Then the reaction mixture was stirred at 80 °C for 12 h. On completion, the reaction mixture was diluted with water (30 mL) and extracted with a mixture of dichlorom ethane and methanol (10:1, 3 X 30 mL). The organic layer was concentrated *in vacuo* to give the title compound (3.00 g, 99% yield) as a yellowish oil. LC-MS (ESI^+) *m/z* 264.1 $(M+H)^+$.

[00946] Step 3 - 2-r2-r2-r2-(2-Aminoethoxy)ethoxy1ethoxy1ethoxy1ethanol


[00947] To a mixture of 2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]ethanol (3.00 g, 11.4 mmol) in ethanol (30 mL) was added Pd/C (1.00 g, 11.4 mmol, 5 wt %). Then the reaction mixture was stirred at rt for 48 hours under hydrogen gas (15 psi pressure). On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (2.70 g, 100% yield) as a yellowish oil. LC-MS (ESI^+) *m/z* 238.1 $(M+H)^+$.

[00948] Step 4 - Benzyl N-[2-[2-[2-[2-(2-hvdroxyethoxy)ethoxy1 ethoxy] ethoxy] ethyl]carbamate

[00949] To a mixture of 2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethanol (1.20 g, 5.06 mmol) in acetonitrile (10 mL) and water (10 mL) was added sodium bicarbonate (1.27 g, 15.1 mmol) and CbzCl (1.04 g, 6.07 mmol). Then the reaction mixture was stirred at 25 °C for 12 h. On completion, the reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 X 100 mL). Then the organic layer was dried over Na_2S0_4 and concentrated *in vacuo.* The residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 1:1) to give the title compound (1.50 g, 70% yield) as white solid. LC-MS (ESI^+) *m/z* 372.1

$(M+H)^+$.

[00950] **Tert-butyl N-[2-[2-[2-[2-[2-(3-amino-2-fluoro-propoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate [Intermediate AK)**



[00951] Step 1 - Tert-butyl N-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethyl]carbamate

[00952] To a solution of benzyl N-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethyl]carbamate (3.40 g, 9.15 mmol, Intermediate AJ) in ethyl acetate (35.0 mL) was added $Pd(OH)_2/C$ (1.00 g, 10 wt %) and $(Boc)_20$ (3.00 g, 13.7 mmol, 3.15 mL). The reaction mixture was stirred under hydrogen gas (15 psi pressure) at rt for 16 h. On completion, the mixture was filtered through a pad of celite and washed with ethyl acetate (2 X 5 mL). Then the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (DCM: MeOH = 20: 1) to give the title compound (2.45 g, 79% yield) as a colorless oil. ^1H NMR (400MHz, CDCh) δ 5.34 (s, 1H), 3.76 - 3.70 (m, 2H), 3.70 - 3.58 (m, 14H), 3.57 - 3.50 (m, 2H), 3.39 - 3.20 (m, 2H), 1.43 (s, 9H).

[00953] Step 2 - 2-[2-[2-[2-[2-(Tert-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethoxy]ethyl methanesulfonate

[00954] To a solution of tert-butyl N-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethyl]carbamate (2.45 g, 7.26 mmol) and triethylamine

(1.47 g, 14.5 mmol) in DCM (15.0 mL) was added mesyl chloride (998 mg, 8.71 mmol) at 0 °C. Then the reaction mixture was allowed to warm to rt and stirred for 1 hr. On completion, the mixture was diluted with water (30 mL), extracted with DCM (3 X 50 mL). The organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (2.88 g, 95% yield) as a yellow oil. ^{1}H NMR (400MHz, CDCh) δ 4.94 (s, 1H), 4.34 - 4.28 (m, 2H), 3.72 - 3.67 (m, 2H), 3.61 - 3.54 (m, 12H), 3.47 (t, *J* = 5.2 Hz, 2H), 3.28 - 3.20 (m, 2H), 3.01 (s, 3H), 1.38 (s, 9H).


[00955] Step 3 - Tert-butyl N-r2-r2-r2-r2-r2-r3-(dibenzylamino)-2-fluoro-propoxylethoxylethoxylethoxyl ethoxylethyllcarbamate

[00956] To a solution of 3-(dibenzylamino)-2-fluoro-propan-l-ol (0.50 g, 1.83 mmol, Intermediate AH) in DMF (5.00 mL) was added sodium hydride (219 mg, 5.49 mmol, 60% purity) at 0 °C. The mixture was stirred at 0 °C for 1 h, then 2-[2-[2-[2-[2-(tertbutoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethoxy] ethylmethanesulfonate (912 mg, 2.20 mmol) was added to the reaction and the reaction mixture was allowed to warm to rt and stirred for 16 hrs. On completion, the mixture was quenched with water (50 mL) and extracted with ethyl acetate (3 X 50 mL). The organic layers were dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The mixture was purified by reverse phase chromatography (0.1% NH_3•H_20) to give the title compound (0.26 g, 22% yield) as a colorless oil. LC-MS (ESI$^+$) *m/z* 593.4 $(M+H)^+$.

[00957] Step 4 - Tert-butyl N-r2-r2-r2-r2-r2-(3-amino-2-fluoro-propoxy)ethoxy1ethoxy1ethoxy1ethoxy1ethvn carbamate

[00958] To a solution of tert-butyl N-[2-[2-[2-[2-[2-[3-(dibenzylamino)-2-fluoro-propoxy] ethoxy] ethoxy] ethoxy]ethoxy]ethyl]carbamate (1.66 g, 2.80 mmol) in methanol (8.00 mL) was added $Pd(OH)_2$/C (0.50 g, 10 wt %) and Pd/C (0.50 g, 10 wt %) under nitrogen atmosphere. The suspension was degassed and purged with hydrogen gas 3 times. The mixture was stirred under hydrogen (50 psi pressure) at rt for 16 h. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (0.80 g, 69% yield) as a yellow oil. ^{1}H NMR (400MHz, CDCh) δ 5.06 (s, 1H), 4.63 - 4.43 (m, 1H), 3.66 - 3.54 (m, 18H), 3.47 (t, *J* = 5.2 Hz, 2H), 3.28 - 3.19 (m, 2H), 2.93 - 2.83 (m, 2H), 1.37 (s, 9H).

[00959] **4-(DibenzylaminoV3-fluoro-butan-2-ol [Intermediate AL)**



AL

[00960] Step 1 - 3-(Dibenzylamino)-2-fluoro-propanoic acid

[00961] To a mixture of methyl 3-(dibenzylamino)-2-fluoro-propanoate (15.0 g, 49.7 mmol, synthesized via Steps 1-2 of Intermediate AH) in THF (150 mL) and water (50 mL) was added LiOH•H2O (4.18 g, 99.5 mmol). The reaction mixture was stirred at rt for 12 h. On completion, the reaction mixture was acidified with HC1 (2 M) until the pH = 5 ~ 6 and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase chromatography (0.1% FA condition) to give the title compound (13.4 g, 92% yield) as a light yellow gum. LC-MS (ESI^+) *m/z* 288.0 $(M+H)^+$.

[00962] Step 2 - 3-(Dibenzylamino)-2-fluoro-N-methoxy-N-methyl-propanamide

[00963] To a mixture of /V-methoxymethanamine (9.10 g, 93.2 mmol, HC1 salt) in DMF (150 mL) was added DIPEA (36.1 g, 279 mmol), then 3-(dibenzylamino)-2-fluoro-propanoic acid (13.4 g, 46.6 mmol) and HATU (35.4 g, 93.2 mmol). The reaction mixture was stirred at rt for 2.5 hrs. On completion, the reaction mixture was concentrated *in vacuo.* The residue was diluted with water (100 mL) and extracted with ethyl acetate (3 X 100 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (15.0 g, 94% yield) as a light yellow oil. LC-MS (ESL) *m/z* 331.1 $(M+H)^+$.

[00964] Step 3 - 4-(Dibenzylamino)-3-fluoro-butan-2-one


[00965] To a mixture of 3-(dibenzylamino)-2-fluoro-/V-methoxy-/V-methyl-propanamide (7.00 g, 21.1 mmol) in THF (80 mL) was added methyl magnesium bromide (3 M, 21.1 mL, 63.3mmol) at 0 °C. The reaction mixture was then warmed to rt and stirred for 2 h. On completion, the reaction mixture was quenched with slow addition of saturated ammonium chloride solution (30 mL) under stirring. The reaction mixture was then poured into 3 mL of water and extracted with ethyl acetate


(3 X 80 mL). The combined organic layer was dried over Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (4.40 g, 72% yield) as a light yellow solid. ^{1}H NMR (400MHz, CDCL) δ 7.29 - 7.15 (m, 10H), 4.93 - 4.77 (m, 1H), 3.72 (d, *J* = 13.6 Hz, 2H), 3.49 (d, *J* = 13.6 Hz, 2H), 2.95 - 2.84 (m, 2H), 2.02 (d, *J* = 4.0 Hz, 3H); LC-MS (ESI$^+$) *m/z* 286.1 $(M+H)^+$.

[00966] Step 4 - 4-(Dibenzylamino)-3-fluoro-butan-2-ol

[00967] To a mixture of 4-(dibenzylamino)-3-fluoro-butan-2-one (4.40 g, 15.4 mmol) in THF (40 mL) and methanol (20 mL) was added sodium borohydride (1.17 g, 30.8 mmol) at 0 °C. The reaction mixture was then allowed to warm to rt and stirred for 1 hour. On completion, the reaction mixture was quenched with slow addition of sat. NH_4Cl solution (4 mL) under stirring. The reaction mixture was concentrated *in vacuo*. The residue was then poured into (5 mL) of water and extracted with ethyl acetate (3 X 10 mL). The combined organic layer was dried over Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (4.30 g, 93% yield) as a colorless oil. LC-MS (ESI$^+$) *m/z* 288.1 $(M+H)^+$.

[00968] Tert-butyl N-[2-[2-[2-(3-amino-2-fluoro-l-methyl-nropoxyiethoxyl ethoxy] ethyl] carbamate [Intermediate AM)





AM

[00969] Step 1 - 2-[2-[2-(Tert-butoxycarbonylamino)ethoxy1ethoxy1ethyl methanesulfonate

[00970] To a mixture of *tert*-butyl /V-[2-[2-(2-hydroxyethoxy)ethoxy]ethyl]carbamate (2.00 g, 8.02 mmol, CAS# 139115-92-7) and triethylamine (2.44 g, 24.0 mmol) in DCM (20 mL) was added mesyl chloride (1.10 g, 9.63 mmol) at 0 °C. The reaction mixture was then allowed to warm to rt and stirred for 2 h. On completion, the reaction mixture was poured into water (15 mL) and extracted with DCM (3 X 20 mL). The combined organic layer was dried over Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (2.60 g, 98% yield) as a light yellow oil. ^{1}H

NMR (400MHz, CDCb) δ 4.87 (s, 1H), 4.35 - 4.29 (m, 2H), 3.73 - 3.66 (s, 2H), 3.63 - 3.52 (m, 4H), 3.50 - 3.43 (m, 2H), 3.30 - 3.20 (s, 2H), 3.01 (s, 3H), 1.38 (s, 9H).


[00971] Step 2 - Tert-butyl N-r2-r2-r2-r3-(dibenzylamino)-2-fluoro-l-methyl-propoxylethoxylethoxylethyll carbamate

[00972] To a mixture of 4-(dibenzylamino)-3-fluoro-butan-2-ol (1.60 g, 5.57 mmol, Intermediate AL) in DMF (20 mL) was added sodium hydride (668 mg, 16.7 mmol, 60% oil dispersion) at 0 °C and the reaction was stirred for 0.5 h. Then 2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethyl methanesulfonate (2.60 g, 7.94 mmol) was added. The reaction mixture was allowed to warm to rt and stirred C for 2 h. On completion, the reaction mixture was quenched with slow addition of water (3 mL) under stirring. The reaction mixture was then poured into water (20 mL) and extracted with ethyl acetate (4 X 20 mL). The combined organic layer was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% $NH_3•H_2O$ condition) to give the title compound (1.25 g, 41% yield) as a light yellow oil. LC-MS (ESI^+) *m/z* 519.3 $(M+H)^+$.

[00973] Step 3 - Tert-butyl N-[2-[2-[2-(3-amino-2-fluoro-l-methyl-propoxyiethoxyl ethoxy]ethyl]carbamate

[00974] To a mixture of *tert*-butyl /V-[2-[2-[2-[3-(dibenzylamino)-2-fluoro- 1-methyl-propoxy] ethoxy] ethoxy] ethyl]carbamate (1.30 g, 2.51 mmol) in MeOH (10 mL) was added $Pd(OH)_2$/C (470 mg, 10 wt %) and Pd/C (470 mg, 10 wt %) under hydrogen atmosphere (15 psi pressure). The reaction mixture was stirred at rt for 14 h. On completion, the reaction mixture was filtered through a pad of celite and the filtrate was concentrated *in vacuo* to give the title compound (820 mg, 96% yield) as a colorless oil. LC-MS (ESI^+) *m/z* 339.3 $(M+H)^+$.

[00975] **2-[3-(dibenzylamino)-2-fluoro-l.,l-dimethyl-propoxylethanol [Intermediate AN]**



AN

[00976] Step 1 - 4-(Dibenzylamino)-3-fluoro-2-methyl-butan-2-ol

[00977] To a mixture of methyl 3-(dibenzylamino)-2-fluoro-propanoate (15.0 g, 49.7 mmol, , synthesized via Steps 1-2 of Intermediate AH) in THF (250 mL) was added MeMgBr (3 M, 41.4 mL) dropwise at 0 °C under nitrogen atmosphere. The reaction mixture was stirred at rt for 1 h. On completion, the reaction mixture was quenched with saturated aqueous ammonium chloride (10 mL) at 0 °C and extracted with ethyl acetate (2 X 50 mL). The organic layers were collected, dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (15.0 g, 89% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 302.1 $(M+H)^+$.


[00978] Step 2 - Ethyl 2-r3-(dibenzylamino)-2-fluoro-Ll-dimethyl-propoxy1acetate

[00979] To a solution of 4-(dibenzylamino)-3-fluoro-2-methyl-butan-2-ol (30.0 g, 99.5 mmol) in DCM (200 mL) was added $Rh(OAc)_2$ (440 mg, 1.99 mmol) then ethyl 2-diazoacetate (34.0 g, 298 mmol) in DCM (100 mL) was added. The reaction mixture was stirred at rt for 12 h. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by silica gel chromatography to give the title compound (11.7 g, 28% yield) as a colorless oil. LC-MS (ESI^+) *m/z* 388.1 $(M+H)^+$

[00980] Step 3 - 2-r3-(Dibenzylamino)-2-fluoro-Ll-dimethyl-propoxy1ethanol

[00981] To a solution of ethyl 2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]acetate (8.00 g, 20.6 mmol) in THF (220 mL) was added lithium aluminum hydride(L20 g, 30.9 mmol, 98% purity) at 0 °C, then reaction mixture was allowed to warm to rt and stirred for 3 h. On completion, the reaction mixture was quenched with water (2 mL) and NaOH solution (15%, 6 mL) at 0 °C and the reaction mixture was filtered. The filtrate was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography to give the title compound (5.90 g, 81% yield) as a colorless oil. ^1H NMR (400MHz, CDCh) δ 7.44 - 7.22 (m, 10H), 4.64 - 4.46 (dd, *J* = 7.6, 48.8 Hz, 1H), 3.82 (d, *J* = 13.6 Hz, 2H), 3.58 (d, *J* = 13.6 Hz, 2H), 3.53 - 3.48 (m, 2H), 3.44 - 3.31 (m, 2H), 2.99 - 2.82 (m, 1H), 2.75 - 2.61 (m, 1H), 1.72 (s, 1H), 1.13 (s, 3H), 1.09 (s, 3H).

[00982] **2-[2-[2-|2-(tert-biitoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethyl methanesulfonate [Intermediate AO)**



AO

[00983] Step 1 - 2-r2-r2-(2-Hvdroxyethoxy)ethoxy1ethoxy1ethyl 4-methylbenzenesulfonate

[00984] To a solution of 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethanol (20.0 g, 103 mmol, CAS# 112-60-7) and potassium iodide (1.71 g, 10.3 mmol) in DCM (2 L) was added 4-methylbenzenesulfonyl chloride (19.6 g, 103 mmol) and silver oxide (28.6 g, 124 mmol). The reaction mixture was stirred at rt for 17 h. On completion, the reaction mixture was filtered and concentrated *in vacuo*. The residue was purified by silica gel chromatography to give the title compound (25.1 g, 70% yield) as a yellow oil. ^{1}H NMR (400MHz, CDCh) δ 7.83 - 7.78 (m, 2H), 7.37 - 7.33 (m, 2H), 4.19 - 4.14 (m, 2H), 3.74 - 3.60 (m, 14H), 2.45 (s, 3H); LC-MS (ESI$^+$) *m/z* 349.0 (M+H)$^+$.

[00985] Step 2 - 2-r2-r2-(2-Azidoethoxy)ethoxy1ethoxy1ethanol

[00986] To a solution of 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (13.5 g, 38.8 mmol) in DMF (100 mL) was added sodium azide (5.04 g, 77.5 mmol) slowly. The reaction mixture was stirred at 80 °C for 18 h. On completion, the reaction mixture was concentrated *in vacuo*. The residue was diluted with ethyl acetate (200 ml), filtered and the filtrate was concentrated *in vacuo* to a half volume(50 mL). The crude product ethyl acetate solution was used in next step directly.

[00987] Step 3 - Tert-butyl N-r2-r2-r2-(2-hvdroxyethoxy)ethoxy1ethoxy1ethyl1carbamate


[00988] To a solution of 2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethanol (15.0 g, 68.4 mmol) and $(Boc)_20$ (74.7 g, 342 mmol) in ethyl acetate (300 mL) was added Pd/C (5 g, 10 wt %) under nitrogen atmosphere. The suspension was degassed and purged with hydrogen gas three times. The reaction mixture was stirred under hydrogen gas (15 Psi pressure) at rt for 18 h. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo*. The residue was purified by

silica gel chromatography (SiO_2, DCM/MeOH = 10/1) to give the title compound (5.1 g, 25% yield) as a light yellow oil. ^1H NMR (400MHz, $CDCl_3$) δ 5.67 (s, 1H), 3.78 - 3.72 (m, 4H), 3.69 - 3.63 (m, 8H), 3.55 (t, *J* = 4.8 Hz, 2H), 3.34 (d, *J* = 4.8 Hz, 2H), 3.07 (s, 1H), 1.46 (s, 9H).

[00989] Step 4 - 2-[2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethyl methanesulfonate

[00990] To a solution of tert-butyl N-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]carbamate (3.0 g, 10.2 mmol) and triethylamine (2.07 g, 2.77 mL, 20.5 mmol) in DCM (30 mL) was added mesyl chloride (1.41 g, 12.3 mmol) at 0 °C. The reaction mixture was stirred at rt for 17 h. On completion, the mixture was quenched with water (30 mL) and extracted with DCM (2 X 30 mL). The organic layer was washed with sat.$NaHCO_3$ (40 mL), then washed with brine (40 mL), dried over Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (3.6 g, 95% yield) as a light yellow oil. ^1H NMR (400MHz, $CDCl_3$) δ 5.05 (s, 1H), 4.43 - 4.39 (m, 2H), 3.82 - 3.78 (m, 2H), 3.71-3.69 (m, 2H), 3.69 - 3.67 (m, 2H), 3.67 - 3.62 (m, 4H), 3.56 (t, *J* = 4.8 Hz, 2H), 3.34 (q, *J* = 4.8 Hz, 2H), 3.10 (s, 3H), 1.46 (s, 9H).

[00991] Tert-butyl N-[2-[2-[2-[2-[2-(3-amino-2-fluoro-Ll-dimethyl-propoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate [Intermediate AP)



[00992] Step 1 - Tert-butyl N-[2-[2-[2-[2-[2-[3-(dibenzylamino)-2-fluoro-Ll-dimethyl-propoxy] ethoxy] ethoxy] ethoxy]ethoxy]ethyl]carbamate


[00993] To a mixture of 2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]ethanol (1.50 g, 4.34 mmol, Intermediate AN) in DMF (10 mL) was added sodium hydride (521 mg, 13.0 mmol, 60% oil dispersion) at 0 °C for 0.5 h. Then the 2-[2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethyl methanesulfonate (2.42 g, 6.51 mmol, Intermediate AO) was added. The reaction mixture was allowed to warm to rt and stirred for 6 hours. On completion, the reaction mixture was quenched with slow addition of water (10 mL)

under stirring. The mixture was extracted with DCM (3 X 20 mL). The combined organic layer was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase chromatography (0.1% $NH_3 \cdot H_20$ condition) to give the title compound (1.10 g, 39% yield) as a light yellow oil. LC-MS (ESI^+) *m/z* 621.5 $(M+H)^+$.

[00994] Step 2 - Tert-butyl N-r242424242-(3-amino-2-fluoro-Ll-dimethyl-propoxy)ethoxy1ethoxy1ethoxy1 ethoxylethyllcarbamate

[00995] To a mixture of tert-butyl N-[2-[2-[2-[2-[2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy] ethoxy] ethoxy]ethoxy]ethoxy]ethyl]carbamate (1.10 g, 1.77 mmol) in methanol (10 mL) was added $Pd(OH)_2/C$ (600 mg, 10 wt %), Pd/C (600 mg, 10 wt %) and $N¾ \cdot H_20$ (455 mg, 12.9 mmol, 500 uL) under hydrogen atmosphere (15 psi pressure). The reaction mixture was stirred at rt for 15 h. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (750 mg, 96% yield) as a light yellow oil. LC-MS (ESI^+) *m/z* 441.3 $(M+H)^+$.


[00996] **2-[2-[2-Bromoethoxy)ethyl]isoindoline-l,3-dione [Intermediate AO)**



AQ

[00997] A solution of (l,3-dioxoisoindolin-2-yl)potassium (10.0 g, 53.9 mmol) and 1-bromo-2-(2- bromoethoxy)ethane (37.5 g, 161 mmol) in acetone (250 mL) was stirred at 60 °C for 12 h. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (12.0 g, 74% yield) as a white solid. ^1H NMR (400MHz, $CDCl_3$) δ 7.91 - 7.84 (m, 2H), 7.77 - 7.72 (m, 2H), 3.96 - 3.90 (m, 2H), 3.84 - 3.77 (m, 4H), 3.42 (t, ./ = 6.0 Hz, 2H).

[00998] **Tert-butylN-[2-[2-[2-(3-amino-2-fluoro-l,l-dimethyl-propoxytethoxyl ethoxy] ethyl] carbamate (Intermediate AR)**



[00999] Step 1 - 2-r2-r2-r2-r3-(Dibenzylamino)-2-fluoro- L l-dimethyl - propoxylethoxylethoxylethylliso indoline- 1,3-dione

[001000] To a solution of 2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]ethanol (2.00 g, 5.79 mmol, Intermediate AN) in DMF (35 mL) was added sodium hydride (694 mg, 17.3 mmol, 60% oil dispersion) at 0 °C. The reaction mixture was stirred at 0 °C for 0.5 h, and then 2-[2-(2-bromoethoxy)ethyl]isoindoline-l,3-dione (2.76 g, 9.26 mmol, Intermediate AQ) was added and the reaction mixture was stirred allowed to warm to rt and stirred for 17 h. On completion, the reaction mixture was quenched with water (1 mL) at 0°C, and then concentrated *in vacuo* to give the product (5.00 g) as yellow oil. LC-MS $(ESI)^+$ *m/z* 563.2. $(M+H)^+$.

[001001] Step 2 - 3-r2-r2-(2-Aminoethoxy)ethoxy1ethoxy1-NN-dibenzyl-2-fluoro-3-methyl-butan- 1-amine

[001002] To a solution of 2-[2-[2-[2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]ethoxy]ethoxy]ethyl] isoindoline-l,3-dione (5.00 g, 8.89 mmol) in EtOH (40 mL) was added hydrazine (2.27 g, 44.4 mmol, 98% purity) and the reaction mixture was stirred at 80 °C for 38 h. On completion, the reaction mixture was filtered and the filtrate concentrated *in vacuo* to give the title compound (2.50 g) as a yellow oil. LC-MS $(ESI)^+$ *m/z* 433.1. $(M+H)^+$.

[001003] Step 3 - Tert-butyl N-r2-r2-r2-r3-(dibenzylamino)-2-fluoro-Ll-dimethyl-propoxy] ethoxy] ethoxy] ethyl] carbamate


[001004] To a solution of 3-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]-N,N-dibenzyl-2-fluoro-3-methyl-butan-l- amine (2.50 g, 5.78 mmol, crude) in DCM (30 mL) was added $(Boc)_20$ (2.52 g,

11.56 mmol) and the reaction mixture was stirred at rt for 3 h. On completion, the mixture was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase chromatography (0.1% $NH_3•H_2O$) to give the title compound (950 mg, 30% yield) as a colorless oil. ^1H NMR (400MHz, CDCh) δ 7.42 (d, *J* = 7.2 Hz 4H), 7.31 (t, *J* = 7.2 Hz, 4H), 7.26 - 7.19 (m, 2H), 5.01 (s, 1H), 4.64 (dd, *J* = 8.0, 49.2 Hz, 1H), 3.75 (d, *J* = 13.6 Hz, 2H), 3.60 (d, *J* = 13.6 Hz, 2H), 3.57 - 3.38 (m, 10H), 3.31 (d, *J* = 3.6 Hz, 2H), 2.98 - 2.80 (m, 1H), 2.79 - 2.65 (m, 1H), 1.45 (s, 9H), 1.10 (d, *J* = 8.8 Hz, 6H); LC-MS $(ESI)^+$ *m/z* 533.4. $(M+H)^+$.

[001005] Step 4 - Tert-butylN-r2-r2-r2-(3-amino-2-fluoro-l. 1-dimethyl - propoxy)ethoxy1ethoxy1ethyl1 carbamate

[001006] To a solution of tert-butyl N-[2-[2-[2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy] ethoxy] ethoxy] ethyl]carbamate (950 mg, 1.78 mmol) in MeOH (20 mL) was added $Pd(OH)_2/C$ (500 mg, 10 wt %), Pd/C (500 mg, 10 wt %) and $NH_3•H_20$ (1.92 g, 20.7 mmol, 38 wt %) under nitrogen atmosphere. The suspension was degassed under vacuum and purged with hydrogen gas three times. The reaction mixture was stirred under hydrogen atmosphere (15 psi pressure) at rt for 55 h. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (550 mg, 88% yield) as a colorless oil. ^1H NMR (400MHz, CDCh) δ = 5.51 (s, 1H), 4.32 - 4.15 (m, 1H), 3.67 - 3.57 (m, 8H), 3.54 (t, *J* = 5.2 Hz, 2H), 3.36 - 3.28 (m, 2H), 3.07 - 2.96 (m, 1H), 2.95 - 2.85 (m, 1H), 1.45 (s, 9H), 1.23 (dd, *J* = 1.6, 10 Hz, 6H); LC-MS $(ESI)^+$ *m/z* 353.2. $(M+H)^+$.

[001007] Tert-butyl N-r2-r2-r2-r2-r2-(3-amino-2-fluoro-l-methyl-propoxylethoxy] ethoxy] ethoxy] ethoxy] ethyl] carbamate (Intermediate AS)



[001008] Step 1 -Tert-butyl N-r2-r2-r2-r2-r2-r3-(dibenzylamino)-2-fluoro-l-methyl-propoxy] ethoxy] ethoxy] ethoxylethoxylethyllcarbamate


[001009] To a solution of 4-(dibenzylamino)-3-fluoro-butan-2-ol (968 mg, 3.37 mmol, Intermediate AL) in DMF (20 mL) was added NaH (404 mg, 10. 1 mmol, 60% dispersion in mineral

oil) and the reaction mixture was stirred at rt for 30 min. Then 2-[2-[2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethoxy]ethyl methanesulfonate (2.10 g, 5.05 mmol, synthesized via Steps 1-2 of Intermediate AK) was added into the mixture and the reaction was stirred at rt for 12 h. On completion, the reaction mixture was quenched by addition H_20 (20 mL) and extracted with ethyl acetate (2 X 30 mL). The combined organic layers were dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (0.1% $NH_3•H_20$ condition) to give the title compound (640 mg, 25% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 607.3 $(M+H)^+$.

[001010] Step 2 -Tert-butyl N-[2-[2-[2-[2-[2-(3-amino-2-fluoro- 1-methyl-propoxylethoxylethoxylethoxyl ethoxylethyllcarbamate

[001011] To a mixture of tert-butyl /V-[2-[2-[2-[2-[2-[3-(dibenzylamino)-2-fluoro-l-methyl-propoxy] ethoxy] ethoxy]ethoxy]ethoxy]ethyl]carbamate (840 mg, 1.38 mmol) in MeOH (20 mL) and $NH_3•H_20$ (1 mL) was added $Pd(OH)_2/C$ (300 mg, 10 wt %) and Pd/C (300 mg, 10 wt %). The reaction mixture was stirred under hydrogen atmosphere (50 psi pressure) at rt for 12 h. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo* to give the title compound (540 mg, 91% yield) as a colorless oil. LC-MS (ESI^+) *m/z* 427.2 $(M+H)^+$.

[001012] Tert-butyl N-[3-[3-13-amino-2-fluoro-l,l-dimethyl-propoxylpropoxy] propyl]carbamate (Intermediate AT)



AT

[001013] Step 1 -2-r3-(dibenzylamino)-2-f1uoro- 1、1-dimethyl-propoxylacetic acid

[001014] To a solution of ethyl 2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]acetate (5.00 g, 12.9 mmol, synthesized via Steps 1-2 of Intermediate AN) in THF (50.0 mL) and H_20 (30.0 mL) was added LiOH (1.24 g, 51.6 mmol) and the reaction mixture was stirred at rt for 6 h. On completion, the mixture was concentrated and acidified with 5 N HC1 (1 mL) until pH = 5 and was then concentrated *in vacuo* again. The residue was purified by reverse phase chromatography (0.1% FA) to give the title compound (3.50 g, 64% yield) as a light yellow oil. ^{1}H NMR (400MHz, CDCb) δ 7.50 - 7.31 (m, 1OH), 4.64 - 4.44 (m, 1H), 4.06 - 3.96 (m, 6H), 3.07 - 2.77 (m, 2H), 1.10 (s, 3H), 1.07 (s, 3H)

[001015] Step 2 - 2-r3-(dibenzylamino)-2-fluoro-Ll-dimethyl-propoxy1acetyl chloride

[001016] To a solution of 2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]acetic acid (2.00 g, 5.56 mmol) in DCM (40.0 mL) was added DMF (4.07 mg, 55.6 umol, 4.28 uL) and $(COCl)_2$ (2.12 g, 16.6 mmol, 1.46 mL) at 0 °C, then reaction mixture was allowed to warm to rt and stirred for 3 h. On completion, the mixture was concentrated *in vacuo* to give the title

compound (2.00 g, 98% yield) as a light yellow oil. LC-MS (ESI^+) m/z 388.2 $(M+H)^+$ (+OEt from quench with ethanol).

[001017] Step 3 - l-diazo-3-r3-(dibenzylamino)-2-fluoro-Ll-dimethyl-propoxy1propan-2-one

[001018] To a solution of 2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]acetyl chloride (3.40 g, 9.00 mmol) in THF (20.0 mL) and ACN (20.0 mL) was dropwise added TMSCHN2 (2 M, 9.00 mL) at 0 °C. Then the reaction mixture was allowed to warm to rt and stirred for 19 h. On completion, the mixture was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (PE: EA= 5: 1) to give the title compound (2.30 g, 65% yield) as a yellow solid. ¾ NMR (400MHz, CDCb) δ 7.46 - 7.21 (m, 10H), 5.08 (s, 1H), 4.61 - 4.45 (m, 1H), 3.92 - 3.80 (m, 4H), 3.60 - 3.50 (m, 2H), 3.00 - 2.62 (m, 2H), 1.13 (s, 3H), 1.10 (s, 3H)

[001019] Step 4 - Methyl 3-r3-(dibenzylamino)-2-fluoro-Ll-dimethyl-propoxy1propanoate

[001020] To a solution of l-diazo-3 -[3 -(dibenzylamino)-2-fluoro- 1,1 -dimethyl - propoxy]propan-2-one (2.00 g, 5.22 mmol) in MeOH (30 mL) was added Ag_20 (120 mg, 521 umol) and the reaction mixture was stirred at 50 °C for 16 h. On completion, the mixture was filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE: EA = 5: 1) to give the title compound (1.10 g, 48% yield) as a colorless oil. ^1H NMR (400MHz, CDCb) δ 7.43 - 7.20 (m, 10H), 4.61 - 4.42 (m, 1H), 3.81 - 3.73 (m, 2H), 3.66 (s, 3H), 3.63 - 3.49 (m, 4H), 2.94 - 2.63 (m, 2H), 2.40 - 2.36 (m, 2H), 1.11 (s, 3H), 1.08 (s, 3H)

[001021] Step 5 - 3-r3-(dibenzylamino)-2-fluoro- 1,1 -dimethyl -propoxylpropan-l-ol

[001022] To a solution of methyl 3-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]propanoate (900 mg, 2.32 mmol) in THF (15.0 mL) was added $LiAlH_4$ (116 mg, 3.02 mmol, 98% purity) at 0 °C under nitrogen atmosphere. The reaction mixture was allowed to warm to rt and stirred for 1 hr. On completion, the mixture was quenched with water (1 mL) and 15 % NaOH (1.5 mL) at 0 °C. The mixture was then filtered, dried over Na_2S0_4, filtered again and concentrated *in vacuo* to give the title compound (800 mg, 90% yield) as a colorless oil. 'H NMR (400MHz, CDCb) δ 7.42 - 7.21 (m, 10H), 4.64 - 4.45 (m, 1H), 3.82 - 3.77 (m, 2H), 3.66 - 3.56 (m, 4H), 3.55 - 3.41 (m, 2H), 2.96 - 2.63 (m, 2H), 2.28 (s, 1H), 1.68 - 1.62 (m, 2H), 1.11 (s, 3H), 1.09 (s, 3H).

[001023] Step 6 - 3-[3-[3-(dibenzylamino)-2-fluoro- 1,1-dimethyl-propoxyl]propoxyl]propanenitrile

[001024] To a mixture of 3-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]propan-l-ol (560 mg, 1.56 mmol) and prop-2-enenitrile (1.60 g, 30.1 mmol, 2.00 mL) was added NaOMe (841 ug, 15.5 umol), and the reaction mixture was stirred at rt for 50 h. On completion, the mixture was concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE: EA = 5: 1) to give the title compound (550 mg, 83% yield) as a colorless oil. ^{1}H NMR (400MHz, CDCh) δ 7.43 - 7.20 (m, 10H), 4.64 - 4.43 (m, 1H), 3.80 - 3.77 (m, 2H), 3.66 - 3.52 (m, 4H), 3.44 - 3.28 (m, 4H), 3.00 - 2.62 (m, 2H), 2.56 - 2.53 (m, 2H), 1.70 - 1.60 (m, 2H), 1.11 (s, 3H), 1.07 (s, 3H).

[001025] Step 7 - 3-r3-(3-aminopropoxy)propoxy1-N.N-dibenzyl-2-f1uoro-3-methyl-butan-1-

[001026] A solution of BH3-Me_2S (10 M, 145 uL) in THF (20.0 mL) was added to a solution of 3-[3-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]propoxy]propanenitrile (300 mg, 727 umol) in THF (5.00 mL) at 0 °C and stirred for 30 min. Then the reaction mixture was heated to 70 °C and stirred for 16 h. On completion, the mixture was quenched with MeOH (3 mL) and concentrated *in vacuo* to give the title compound (300 mg, 65% yield) as yellow oil. LC-MS (ESI^+) m/z 417.4 $(M+H)^+$.

[001027] Step 8 - Tert-butyl N-r3-r3-r3-(dibenzylamino)-2-fluoro-Ll-dimethyl-propoxyl]propoxyl]propyll carbamate


[001028] To a solution of 3-[3-(3-aminopropoxy)propoxy]-N,N-dibenzyl-2-fluoro-3-methyl-butan-l-amine (300 mg, 720 umol) in DCM (5.00 mL) was added $(Boc)_20$ (314 mg, 1.44 mmol, 330 uL) and the reaction mixture was stirred at rt for 2 h. On completion, the mixture was concentrated *in vacuo.* The mixture was purified by reverse phase chromatography (0.1% $NH_3 \cdot H_20$) to give the title compound (180 mg, 45% yield) as a yellow solid. LCMS $(M+l)^+$: 517.3.

[001029] Step 9 - Tert-butyl N-r3-r3-(3-amino-2-fluoro-L 1-dimethyl-propoxyipropoxyl]propyllcarbamate

[001030] To a solution of tert-butyl N-[3-[3-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]propoxy] propyl]carbamate (180 mg, 348 umol) and $NH_3 \bullet H_20$ (151 mg, 1.30 mmol, 166 uL, 30 wt %) in MeOH (5.00 mL) was added Pd/C (90.0 mg, 348 umol, 10 wt %) and $Pd(OH)_2/C$

(90.0 mg, 348 umol, 10 wt %) under nitrogen. The suspension was degassed under vacuum and purged with hydrogen gas several times. The reaction mixture was stirred under hydrogen atmosphere (50 psi pressure) at rt for 16 h. On completion, the mixture was filtered and the filtrate concentrated *in vacuo* to give the title compound (70.0 mg, 59 % yield) as a yellow oil. LC-MS (ESI^+) m/z 337.2 $(M+H)^+$

[001031] **Tert-butyl N-[2-[2-[3-amino-2-fluoro-l,l-dimethyl-propoxylethoxy] ethyl] carbamate [Intermediate AUl**



[001032] STEP **1** - ETHYL 2-[2-[3-(DIBENZYL AMIN OV2-FLUORO- **1, 1**-DIMETHYL-PROPOXY1ETHOXY1ACETATE

[001033] To a solution of 2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]ethanol (4.00 g, 11.6 mmol, Intermediate AN) and $Rh(OAc)_2$ (128 mg, 579 umol) in DCM (80 mL) was added a solution of ethyl 2-diazoacetate (3.96 g, 34.7 mmol) in DCM (40 mL) dropwise at rt. The reaction mixture was stirred at rt for 20 h. On completion, the reaction mixture was diluted with H_20 (60 mL) and extracted with DCM (2 X 50 mL). The organic layer was dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (4.63 g, 93% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 432.2 $(M+H)^+$.

[001034] Step 2 - 2-r2-r3-(Dibenzylamino)-2-fluoro-Ll-dimethyl-propoxy1ethoxy1ethanol

[001035] To a mixture of L1AIH4 (611 mg, 16.1 mmol) in THF (20 mL) was added a solution of ethyl 2-[2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]ethoxy]acetate (4.63 g, 10.7 mmol) in THF (40 mL) dropwise at 0 °C. The reaction mixture was stirred at 0 °C for 2 h. On completion, the reaction mixture was quenched with H_20 (0.55 mL) at 0°C. Then 15% NaOH solution (1.5 mL) was added to the reaction mixture. The mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (3.53 g, 84% yield) as a yellow oil.

[001036] Step_3_-_2-r2-r3-(Dibenzylamino)-2-fluoro-Ll-dimethyl-propoxy1ethoxy1ethyl methanesulfonate

[001037] To a solution of 2-[2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy] ethoxy] ethanol (3.53 g, 9.06 mmol) and TEA (2.29 g, 22.7 mmol) in DCM (35 mL) was added MsCl (1.56 g, 13.6 mmol) dropwise at 0 °C. The reaction mixture was stirred at rt for 1 hour. On completion, the mixture was quenched with H_20 (30 mL) and extracted with DCM (2 X 30 mL). The organic layer was washed with brine (50 mL), dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (4.50 g, 100% yield) as a yellow oil. ^{1}H NMR (400MHz, CDCb) δ 7.44 - 7.24 (m, 10H), 4.63 - 4.46 (m, 1H), 4.35 - 4.30 (m, 2H), 3.81 - 3.75 (m, 2H), 3.68 - 3.64 (m, 2H), 3.63 - 3.59 (m, 2H), 3.54 - 3.39 (m, 4H), 3.04 (s, 3H), 2.96 - 2.67 (m, 2H), 1.11 (s, 6H).

[001038] Step_4_-_2-[2-[2-[3-(Dibenzylamino)-2-fluoro-1,1-dimethyl-propoxy1ethoxy1ethvnisoindoline-L3-dione

[001039] To a solution of 2-[2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy] ethoxy] ethyl methane sulfonate (4.50 g, 9.62 mmol) in DMF (45 mL) was added (1,3-dioxoisoindolin-2-yl)potassium (2.67 g, 14.4 mmol). The reaction mixture was stirred at 80 °C for 3 h. On completion, the mixture was diluted with H2O (30 mL) and extracted with EtOAc (3 X 40 mL). The organic layer was washed with brine (50 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (5.90 g, 96% yield) as a yellowish oil. LC-MS (ESI^+) *m/z* 519.3 $(M+H)^+$.

[001040] Step 5 - 3-[2-(2-Aminoethoxy)ethoxy1-N.N-dibenzyl-2-fluoro-3-methyl-butan-1-amine

[001041] To a solution of 2-[2-[2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]ethoxy]ethyl]isoindoline-l,3-dione (4.99 g, 9.62 mmol) in EtOH (60 mL) was added $NH_2NH_2•H_20$ (2.41 g, 48.1 mmol). The reaction mixture was stirred at 80 °C for 15 hours. On

completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to remove solvent. The residue was diluted with DCM (30 mL), filtered and the filtrate was concentrated *in vacuo* to give the title compound (3.74 g, 100% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 389.2 $(M+H)^+$.


[001042] Step 6 - Tert-butyl N-r2-r2-r3-(dibenzylamino)-2-f1uoro- l,1-dimethyl-propoxyl ethoxy] ethyl] carbamate

[001043] To a solution of 3-[2-(2-aminoethoxy)ethoxy]-N,N-dibenzyl-2-fluoro-3-methyl-butan-l-amine (3.74 g, 9.63 mmol) in DCM (40 mL) was added $(Boc)_20$ (4.20 g, 19.3 mmol). The reaction mixture was stirred at rt for 3 hours. On completion, the reaction mixture was concentrated *in vacuo* to remove solvent. The residue was purified by reverse phase chromatography (0.1% $NH_3•H_20$) to give the title compound (3.10 g, 66% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 489.1 $(M+H)^+$.

[001044] Step 7 - Tert-butyl N-r2-r2-(3-amino-2-fluoro-l.l-dimethyl-propoxyiethoxylethyllcarbamate

[001045] To a solution of tert-butyl N-[2-[2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]ethoxy]ethyl] carbamate (3.10 g, 6.34 mmol) in MeOH (30 mL) was added Pd/C (1.5 g, 10 wt %), $Pd(OH)_2/C$ (1.5 g, 10 wt %) and $NH_3·H_20$ (910 mg, 6.49 mmol, 25 wt %). The reaction mixture was stirred at rt for 17 h under hydrogen atmosphere (15 psi pressure). On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (1.82 g, 93% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 309.1 $(M+H)^+$.

[001046] Tert-butyl N-[2-[2-!3-amino-2-fluoro-propoxy)ethoxy| ethyl] carbamate (Intermediate AV)



[001047] Step 1 - 2-r2-r2-r3-(Dibenzylamino)-2-fluoro-propoxy1ethoxy1ethyl1isoindoline-L3-dione

[001048] To a solution of 3-(dibenzylamino)-2-fluoro-propan-l-ol (1.00 g, 3.66 mmol, Intermediate AH) in DMF (15.0 mL) was added NaH (439 mg, 10.9 mmol, 60% dispersion in mineral oil) under 0 °C and the mixture was stirred at 0 °C for 30 minutes. Then 2-[2-(2-bromoethoxy)ethyl]isoindoline-l,3-dione (1.64 g, 5.49 mmol, Intermediate AQ) was added and the mixture was allowed to warm to rt and stirred 4 h. On completion, the mixture was quenched with H_20 (1 mL) and concentrated *in vacuo* to give the title compound (1.79 g, 80% yield) as yellow solid. LC-MS (ESI^+) *m/z* 491.3 $(M+H)^+$.

[001049] Step 2 - 3-r2-(2-Aminoethoxy)ethoxy1-N.N-dibenzyl-2-fluoro-propan- 1-amine

[001050] To a solution of 2-[2-[2-[3-(dibenzylamino)-2-fluoro-propoxy]ethoxy]ethyl]isoindoline-l,3-dione (2.68 g, 5.46 mmol) in EtOH (30.0 mL) was added $N_2H_4H_2O$ (5.58 g, 109 mmol, 5.42 mL, 98% purity). The reaction mixture was stirred at 80 °C for 40 hours. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo.* The solid was diluted with DCM(50 mL) and stirred for 15 minutes, filtered, and the organic layer was concentrated *in vacuo* to give the title compound (1.97 g, 80% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 361.2 $(M+H)^+$.


[001051] Step 3 - Tert-butyl N-r24243Adibenzylamino)-2-fluoro-propoxylethoxylethyllcarbamate

[001052] To a solution of 3-[2-(2-aminoethoxy)ethoxy]-N,N-dibenzyl-2-fluoro-propan-l-amine (1.97 g, 5.47 mmol) in DCM (20.0 mL) was added $(Boc)_20$ (2.39 g, 10.9 mmol, 2.51 mL) and the reaction mixture was stirred at rt for 16 hours. On completion, the mixture was concentrated *in vacuo.* The mixture was purified by reverse phase chromatography (0.1% $NH_3•H_2O$) to give the title compound (930 mg, 36% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 461.2 $(M+H)^+$.


[001053] Step 4 - Tert-butyl N-r2-r2-(3-amino-2-fluoro-propoxy)ethoxy1ethyl1carbamate


[001054] To a solution of tert-butyl N-[2-[2-[3-(dibenzylamino)-2-fluoro-propoxy]ethoxy]ethyl]carbamate (930 mg, 2.02 mmol) in MeOH (10.0 mL) and NH3.H2O (200 uL) was added Pd/C (500 mg, 10 wt %) and Pd(OH)2/C (500 mg, 10 wt %) under nitrogen atmosphere. The suspension was degassed *in vacuo* and purged with hydrogen gas several times. The mixture was stirred under hydrogen atmosphere (50 psi pressure) at rt for 16 hours. On completion, the mixture was filtered and concentrated *in vacuo* to give the title compound (560 mg, 98% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 281.1 $(M+H)^+$.

[001055] Tert-butyl N-[2-[3-amino-2-fluoro-l,l-dimethyl-propoxylethyl1carbamate (Intermediate AW)



AN





AW

[001056] Step 1 - 2-r3-(Dibenzylamino)-2-fluoro-L l-dimethyl-propoxylethyl methanesulfonate

[001057] To a mixture of 2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]ethanol

(1.50 g, 4.34 mmol, Intermediate AN) and Et_3N (1.32 g, 13.0 mmol, 1.81 mL) in DCM (10 mL) was added MsCl (746 mg, 6.51 mmol). The mixture was stirred at rt for 2 hours. On completion, the mixture was quenched with water (15 mL) and extracted with DCM (2 X 20 mL). The organic layer was washed with brine (10 mL), dried over anhydrous Na_2S0_4, then filtered and concentrated *in vacuo* to give the title compound (1.90 g, 98% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 424.2 $(M+H)^+$.

[001058] Step 2 - 2-[2-[3-(Dibenzylamino)-2-fluoro- 1,1-dimethyl-propoxy1ethvnisoindoline-L3-

[001059] To a solution of 2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]ethyl methanesulfonate (1.70 g, 4.01 mmol) in DMF (20 mL) was added (l,3-dioxoisoindolin-2-yl) potassium (817 mg, 4.42 mmol). The mixture was heated at 60 °C for 16 hours. On completion, the mixture was diluted with water (10 mL) and extracted with EtOAc (2 X 50 mL). The organic layer was washed with brine (20 mL), dried over anhydrous Na_2S0_4, then filtered and concentrated *in vacuo* to give the title compound (1.90 g, 99% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 475.2 $(M+H)^+$.

[001060] Step 3 - 3-(2-Aminoethoxy)-N.N-dibenzyl-2-fluoro-3-methyl-butan- 1-amine

[001061] To a solution of 2-[2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]ethyl]isoindoline-l,3-dione (1.90 g, 4.00 mmol) in EtOH (20 mL) was added $NH_2NH_2 \cdot H_20$ (2.05 g, 40.0 mmol, 1.99 mL, 98% purity). The reaction mixture was stirred at 80 °C for 16 hours. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (2.50 g, crude) as a white solid. LC-MS (ESI^+) *m/z* 345.2 $(M+H)^+$.


[001062] Step 4 - Tert-butyl N-r2-r3-(dibenzylamino)-2-fluoro-Ll-dimethyl-propoxy1ethyl1

[001063] To a solution of 3-(2-aminoethoxy)-N,N-dibenzyl-2-fluoro-3 -methyl-butan-l-amine (1.00 g, 2.90 mmol) inMeOH (10 mL) was added $(Boc)_20$ (1.27 g, 5.81 mmol). The mixture was stirred at rt for 2 hours. On completion, the mixture was concentrated *in vacuo.* The residue was purified by silica gel chromatography to give the title compound (1.29 g, 90% yield). ^1H NMR (400MHz, CDCh) δ 7.44 - 7.22 (m, 10H), 4.66 - 4.41 (m, 2H), 3.82 (d, 7 = 13.6 Hz, 2H), 3.60 (d, *J* = 13.6 Hz, 2H), 3.41 - 3.24 (m, 2H), 3.18 - 3.00 (m, 2H), 2.99 - 2.81 (m, 1H), 2.77 - 2.61 (m, 1H), 1.47 (s, 9H), 1.13 - 1.06 (m, 6H); LC-MS (ESI^+) *m/z* 445.3 $(M+H)^+$.

[001064] Step 5 - Tert-butyl N-r2-(3-amino-2-fluoro-Ll-dimethyl-propoxy)ethyl1carbamate

[001065] To a solution of *tert*-butyl N-[2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]ethyl]carbamate (1.3 g, 2.9 mmol) in MeOH (15 mL) was added Pd/C (0.5 g, 10 wt %), Pd(OH)2/C (0.5 g, 10 wt %) and $NH_3 \bullet H_2O$ (100 uL, 30 wt %, catalytic amount). The mixture was degassed and purged with hydrogen gas three times. The mixture was stirred at rt for 24 hours under hydrogen gas (50 psi pressure). On completion, the mixture was filtered and concentrated *in vacuo* to give the title compound (700 mg, 90% yield) as a colorless oil. ^{1}H NMR (400MHz, CDCb) δ 4.93 (s, 1H), 3.57 - 3.43 (m, 2H), 3.38 - 3.19 (m, 2H), 3.13 - 2.91 (m, 2H), 2.38 - 2.30 (m, 2H), 1.46 (s, 9H), 1.22 (dd, J = 1.2, 10.6 Hz, 6H); LC-MS (ESI^+) *m/z* 265.1 $(M+H)^+$.

[001066] **Tert-butyl _N-[2-[3-amino-2-fluoro-propoxylethyl1carbamate _[Intermediate AX)**



[001067] Step 1 - Ethyl 2-r3-(dibenzylamino)-2-fluoro-propoxy1acetate

[001068] To a solution of 3-(dibenzylamino)-2-fluoro-propan-l-ol (5.00 g, 18.2 mmol, Intermediate AH) in DCM (100 mL) was added $[Rh(OAc)_2]_2$ (80.8 mg, 365 umol) in DCM (50.0 mL) then and ethyl 2-diazoacetate (6.26 g, 54.8 mmol, 5.74 mL) was added dropwise. The reaction mixture was stirred at rt for 60 h. On completion, the mixture was concentrated *in vacuo.* The mixture was purified by reverse phase column (0.1% $NH_3 \bullet H_2O$) to give the title compound (7.23

g, 78% yield) as a yellow oil. ^{1}H NMR (400MHz, CDCh) δ 7.42 - 7.25 (m, 10H), 4.92 - 4.71 (m, 1H), 4.28 - 4.18 (m, 2H), 4.13 - 4.08 (m, 2H), 3.79 - 3.53 (m, 6H), 2.82 - 2.71 (m, 2H), 1.30 (t, *J* = 7.2 Hz, 3H).

[001069] Step 2 - 2-r3-(Dibenzylamino)-2-fluoro-propoxy1 ethanol

[001070] To a solution of $LiAlH_4$ (1.15 g, 30.1 mmol) in THF (70.0 mL) was added a solution of ethyl 2-[3-(dibenzylamino)-2-fluoro-propoxy] acetate (7.23 g, 20.1 mmol) dissolved in THF (30.0 mL) dropwise at 0 °C. The reaction mixture was stirred at 0 °C for 2 h. On completion, the mixture was quenched with water (3 mL), then 15% NaOH (3 mL) was added until no precipitate formed. The reaction mixture was then filtered and the filtrate was concentrated *in vacuo* to give the title compound (5.88 g, 92% yield) as a yellow solid. ¾NMR (400MHz, CDCh) δ 7.39 - 7.26 (m, 10H), 4.86 - 4.64 (m, 1H), 3.71 - 3.61 (m, 8H), 3.58 - 3.51 (m, 3H), 2.80 - 2.70 (m, 2H).

[001071] Step 3 - 2-r3-(Dibenzylamino)-2-fluoro-propoxy1 ethyl methanesulfonate

[001072] To a solution of 2-[3-(dibenzylamino)-2-fluoro-propoxy]ethanol (2.00 g, 6.30 mmol) and TEA (1.28 g, 12.6 mmol, 1.75 mL) in DCM (20.0 mL) was added MsCl (866 mg, 7.56 mmol, 585 uL) at 0 °C. The reaction mixture was then allowed to warm to rt and stirred for 1 hr. On completion, the mixture was diluted with DCM (30 mL), then washed with H_20 (3 X 30 mL). The organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (2.27 g, 90% yield) as a yellow solid. ^{1}H NMR (400MHz, CDCh) δ 7.41 - 7.25 (m, 10H), 4.83 - 4.63 (m, 1H), 4.33 - 4.28 (m, 2H), 3.69 - 3.66 (m, 6H), 3.64 - 3.55 (m, 2H), 2.99 (s, 3H), 2.81 - 2.69 (m, 2H)

[001073] Step 4 - 2-r2-r3-(Dibenzylamino)-2-fluoro-propoxy1ethyl1isoindoline-L3-dione

[001074] To a solution of 2-[3-(dibenzylamino)-2-fluoro-propoxy]ethyl methanesulfonate (2.27 g, 5.74 mmol) in DMF (20.0 mL) was added (l,3-dioxoisoindolin-2-yl)potassium (1.59 g, 8.61 mmol) and the reaction mixture was stirred at 80 °C for 3 h. On completion, the mixture was diluted with water (50 mL) then extracted with EtOAc (3 X 30 mL). The organic layers were dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (2.56 g, 80% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 447.2 $(M+H)^+$.

[001075] Step 5 - 3-(2-Aminoethoxy)-N.N-dibenzyl-2-f1uoro-propan- l-amine

[001076] To a solution of 2-[2-[3-(dibenzylamino)-2-fluoro-propoxy]ethyl]isoindoline-l,3-dione (2.56 g, 5.73 mmol) in EtOH (25.0 mL) was added $N_2H_4 \cdot H_20$ (1.46 g, 28.6 mmol, 1.42 mL, 98% purity) and the reaction mixture was stirred at 80 °C for 16 h. On completion, the mixture

was filtered, and the filtrate was concentrated *in vacuo*. The resulting residue was diluted with DCM (50 mL), stirred for 15 min, filtered, and the filtrate was concentrated *in vacuo* to give the title compound (1.50 g, 82% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 317.1 $(M+H)^+$.


[001077] Step 6 - Tert-butyl N-r2-r3-(dibenzylamino)-2-fluoro-propoxy1ethyl1carbamate

[001078] To a solution of 3-(2-aminoethoxy)-/V,/V-dibenzyl-2-fluoro-propan-l-amine (1.50 g, 4.74 mmol) in DCM (15.0 mL) was added $(Boc)_20$ (1.55 g, 7.11 mmol, 1.63 mL) and the reaction mixture was stirred at rt for 16 h. On completion, the mixture was concentrated *in vacuo*. The mixture was purified by reverse phase chromatography (0.1% $NH_3•H_20$) to give the title compound (1.37 g, 67% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 417.2 $(M+H)^+$.

[001079] Step 7 - Tert-butyl N-r2-(3-amino-2-fluoro-propoxy)ethyl1carbamate

[001080] To a solution of tert-butyl /V-[2-[3-(dibenzylamino)-2-fluoro-propoxy]ethyl]carbamate (1.30 g, 3.12 mmol) in a solvent mixed solution ofMeOH (15.0 mL) and $NH_3•H_20$ (300 uL) was added Pd/C (600 mg, 10 wt %) and $Pd(OH)_2/C$ (600 mg, 10 wt %) under nitrogen atmosphere. The suspension was degassed under vacuum and purged with hydrogen gas several times. The mixture was stirred under hydrogen atmosphere (50 psi pressure) at rt for 16 h. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (730 mg, 99% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 237.0 $(M+H)^+$.

[001081] Tert-butyl N-[2-!3-amino-2-fluoro-l-methyl-propoxy)ethyl1carbamate (Intermediate AY)



[001082] Step 1 - Ethyl 2-r3-(dibenzylamino)-2-fluoro-l-methyl-propoxy1acetate

[001083] To a mixture of 4-(dibenzylamino)-3-fluoro-butan-2-ol (1.00 g, 3.48 mmol. Intermediate AL) and $[Rh(OAc)_2]_2$ (15.3 mg, 69.6 umol) in DCM (20 mL) was added a solution of ethyl 2-diazoacetate (1.19 g, 10.4 mmol) in DCM (10 mL) dropwise. The reaction mixture was stirred at rt for 20 h. On completion, the reaction mixture was poured into 30 mL of water and extracted with DCM (3 X 30 mL). The combined organic layer was dried over Na-SO·, filtered and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase chromatography (0. 1% $NH_3 \cdot H_20$) to give the title compound (890 mg, 67% yield) as a light yellow oil. ^{1}H NMR (400MHz, CDCh) δ 7.45 - 7.22 (m, 10H), 4.83 - 4.50 (m, 1H), 4.25 - 4.00 (m, 4H), 3.81 - 3.57 (m, 5H), 2.99 - 2.75 (m, 2H), 1.31 - 1.26 (m, 3H), 1.12 - 1.02 (m, 3H); LC-MS (ESI^+) *m/z* 374.1 $(M+H)^+$.

[001084] Step 2 - 2-r3-(Dibenzylamino)-2-fluoro-l-methyl-propoxy1ethanol

[001085] To a mixture of ethyl 2-[3-(dibenzylamino)-2-fluoro-l-methyl-propoxy]acetate (890 mg, 2.38 mmol) in THF (3 mL) was added $LiAlH_4$ (138 mg, 3.57 mmol, 98% purity) at 0 °C. The reaction mixture was then allowed to warm to rt and stirred 30 min. On completion, the

reaction mixture was quenched with water (0.5 mL) and NaOH solution (15 %, 0.5 mL) at 0 °C. Then the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (730 mg, 95% yield) as a light yellow oil. LC-MS (ESI^+) *m/z* 332.1 $(M+H)^+$.

[001086] Step 3 - 2-r3-(Dibenzylamino)-2-fluoro-l-methyl-propoxy1ethyl methanesulfonate

[001087] To a mixture of 2-[3-(dibenzylamino)-2-fluoro-l-methyl-propoxy]ethanol (730 mg, 2.20 mmol) and TEA (668 mg, 6.61 mmol) in DCM (10 mL) was added MsCl (378 mg, 3.30 mmol) at 0 °C. The reaction mixture was allowed to warm to rt and stirred for 2 h. On completion, the reaction mixture was diluted with water (20 mL) and extracted with DCM (3 X 50 mL). The combined organic layer was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (900 mg, 100% yield) as a light yellow oil. LC-MS (ESI^+) *m/z* 410.1 $(M+H)^+$.

[001088] Step 4 - 2-r2-r3-(Dibenzylamino)-2-fluoro-l-methyl-propoxy1ethyl1isoindoline-L3-dione

[001089] To a mixture of 2-[3-(dibenzylamino)-2-fluoro-l-methyl-propoxy]ethyl methanesulfonate (900 mg, 2.20 mmol) in DMF (10 mL) was added (l,3-dioxoisoindolin-2-yl)potassium (610 mg, 3.30 mmol). The reaction mixture was stirred at 100 °C for 3 h. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (1.00 g, 95% yield) as a light yellow solid. LC-MS (ESI^+) *m/z* 461.2 $(M+H)^+$.

[001090] Step 5 - 3-(2-Aminoethoxy)-N.N-dibenzyl-2-f1uoro-butan- l-amine

[001091] To a mixture of 2-[2-[3-(dibenzylamino)-2-fluoro-l-methyl-propoxy]ethyl]isoindoline-l,3-dione (1.00 g, 2.17 mmol) in EtOH (15 mL) was added $NH_2NH_2 \cdot H_20$ (869 mg, 17.3 mmol). The reaction mixture was stirred at 80 °C for 20 h. On completion, the reaction mixture was filtered and concentrated *in vacuo.* The residue was poured into 30 mL of DCM, filtered and concentrated *in vacuo* to give the title compound (800 mg, 73% purity, 75% yield) as a light yellow solid. LC-MS (ESI^+) *m/z* 333.1 $(M+H)^+$.

[001092] Step 6 - Tert-butyl N-r243Tdibenzylamino)-2-fluoro-l-methyl-propoxylethyllcarbamate


[001093] To a mixture of 3-(2-aminoethoxy)-/V,/V-dibenzyl-2-fluoro-butan-l-amine (800 mg, 2.42 mmol) in DCM (10 mL) was added $(Boc)_20$ (1.06 g, 4.84 mmol). The reaction mixture was stirred at rt for 2 h. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by reverse phase chromatography (0.1% $NH_3 \cdot H_20$) to give the title compound (520

mg, 48% yield) as a light yellow oil. ^{1}H NMR (400MHz, CDCb) δ 7.42 - 7.23 (m, 10H), 4.87 - 4.41 (m, 2H), 3.81 - 3.68 (m, 2H), 3.68 - 3.59 (m, 2H), 3.59 - 3.44 (m, 2H), 3.39 - 3.24 (m, 1H), 3.19 (d, *J* = 5.2 Hz, 2H), 2.91 - 2.65 (m, 2H), 1.48 - 1.45 (m, 9H), 1.07 - 0.98 (m, 3H); LC-MS (ESI$^+$) *m/z* 431.2 $(M+H)^+$.

[001094] Step 7 - Tert-butyl N-r2-(3-amino-2-fluoro-l-methyl-propoxy)ethyl1carbamate

[001095] To a mixture of *tert*-butyl A-[2-[3-(dibenzylamino)-2-fluoro- l-methyl-propoxy]ethyl]carbamate (520 mg, 1.21 mmol), Pd/C (300 mg, 10 wt %) and $Pd(OH)_2$/C (300 mg, 10 wt %) in MeOH (10 mL) was added NHb •H_20 (169 mg, 1.21 mmol 25% wt %) under hydrogen atmosphere (15 psi pressure). The reaction mixture was stirred at rt for 16 h. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (280 mg, 100% yield) as a light yellow oil. ^{1}H NMR (400MHz, CDCb) δ 5.09 - 4.78 (m, 1H), 4.41 - 4.07 (m, 1H), 3.63 - 3.49 (m, 2H), 3.47 - 3.38 (m, 1H), 3.26 - 3.16 (m, 2H), 2.96 - 2.77 (m, 2H), 1.70 - 1.60 (m, 2H), 1.38 (s, 9H), 1.14 - 1.10 (m, 3H).

[001096] **Tert-butyl N-[2-[2-(3-amino-2-fluoro-l-methyl-propoxylethoxy] ethyl] carbamate (Intermediate *AZ)***



[001097] Step 1 - Ethyl 2-r2-r3-(dibenzylamino)-2-fluoro-l-methyl-propoxy1ethoxy1acetate

[001098] To a solution of 2-[3-(dibenzylamino)-2-fluoro-l-methyl-propoxy]ethanol (3.30 g, 9.96 mmol, synthesized via Steps 1-2 of Intermediate AY) in DCM (50 mL) was added $Rh(OAc)_2$ (44 mg, 199 umol), then a solution of ethyl 2-diazoacetate (3.41 g, 29.9 mmol, 3.13 mL) in DCM (50 mL) was added dropwise. The mixture was stirred at rt for 20 h. On completion, the mixture was concentrated *in vacuo* and the residue was purified by silica gel chromatography to give the title compound (2.70 g, 58% yield) as a colorless oil. LC-MS (ESI^+) *m/z* 418.1 $(M+H)^+$.

[001099] Step 2 - 2-r2-r3-(Dibenzylamino)-2-fluoro-l-methyl-propoxy1ethoxy1ethanol

[001100] To a solution of ethyl 2-[2-[3-(dibenzylamino)-2-fluoro-l-methyl-propoxy] ethoxy] acetate (1.00 g, 2.40 mmol) in THF (30 mL) was added LiAlLL (136 mg, 3.59 mmol). The mixture was stirred at 0 °C for 1 hr. On completion, the mixture was quenched by adding water (1 mL), 15% NaOH (3 mL) then more water (1 mL). A large quantity of white precipitate was formed, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (880 mg, 93% yield) as a colorless oil. LC-MS (ESI^+) *m/z* 376.2 $(M+H)^+$.

[001101] Step 3 - 2-r2-r3-(Dibenzylamino)-2-fluoro-l-methyl-propoxy1ethoxy1ethyl methanesulfonate

[001102] To a solution of 2-[2-[3-(dibenzylamino)-2-fluoro-l-methyl-propoxy] ethoxy] ethanol (2.40 g, 6.39 mmol) in DCM (25 mL) was added Et_3N (1.94 g, 19.2 mmol, 2.67 mL) and MsCl (1.10 g, 9.59 mmol, 742 uL). The mixture was stirred at 0 °C for 1 hr. On completion, the reaction was quenched with water (20 mL) and extracted with DCM (2 X 30 mL). The combined organic layer was washed with brine, dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (2.90 g, 98% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 454.1 $(M+H)^+$.

[001103] Step 4 - 2-r2-r2-r3-(Dibenzylamino)-2-fluoro- 1-methyl-propoxy1ethoxy1ethyl1isoindoline-L3-dione

[001104] To a solution of 2-[2-[3-(dibenzylamino)-2-fluoro-l-methyl-propoxy]ethoxy]ethyl methanesulfonate (2.90 g, 6.39 mmol) in DMF (30 mL) was added (l,3-dioxoisoindolin-2-yl)potassium (1.30 g, 7.03 mmol). The mixture was stirred at 60 °C for 10 h. On completion, the mixture was diluted with water (50 mL) and extracted with EtOAc (2 X 100 mL). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na_2S0_4, then filtered and

concentrated *in vacuo* to give the title compound (3.8 g) as a light yellow oil. LC-MS (ESI^+) *m/z* 505.2 $(M+H)^+$.

[001105] Step 5 - 3-r2-(2-Aminoethoxy)ethoxy1-N.N-dibenzyl-2-fluoro-butan-1-amine

[001106] To a solution of 2-[2-[2-[3-(dibenzylamino)-2-fluoro-l-methyl-propoxy]ethoxy]ethyl]isoindoline-l,3-dione (3.80 g, 7.53 mmol) in EtOH (50 mL) was added $NH_2NH_2 \cdot H_20$ (3.85 g, 75.3 mmol, 3.73 mL, 98% purity). The mixture was stirred at 90 °C for 3 h. On completion, the mixture was concentrated *in vacuo* to give the title compound (3.00 g, 100%) as a white solid. LC-MS (ESI^+) *m/z* 375.1 $(M+H)^+$.


[001107] Step 6 - Tert-butyl N-r2-r2-r3-(dibenzylamino)-2-fluoro-l-rnethyl-propoxylethoxylethyllcarbamate

[001108] To a solution of 3-[2-(2-aminoethoxy)ethoxy]-N,N-dibenzyl-2-fluoro-butan-l-amine (3.00 g, 8.01 mmol) in MeOH (30 mL) was added $(Boc)_20$ (3.50 g, 16.02 mmol, 3.68 mL). The mixture was stirred at rt for 16 h. On completion, the mixture was concentrated *in vacuo* and the residue was purified by silica gel chromatography to give the title compound (4.00 g, 100%) as a white solid. LC-MS (ESI^+) *m/z* 475.2 $(M+H)^+$.

[001109] Step 7 - Tert-butyl N-[2-[2-(3-amino-2-fluoro-1-methyl-propoxylethoxylethyllcarbamate

[001110] To a solution of tert-butyl A-[2-[2-[3-(dibenzylamino)-2-fluoro-l-methyl-propoxy] ethoxy] ethyl]carbamate (2.00 g, 4.21 mmol) in MeOH (20 mL) was added Pd/C (400 mg, 10 wt %), $Pd(OH)_2/C$ (400 mg, 10 wt %), $NH_3 \bullet H_20$ (404 mg, 3.46 mmol, 30 wt %). The suspension was degassed and purged with hydrogen gas three times. The mixture was stirred under hydrogen atmosphere (15 psi pressure) at rt for 36 h. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo*. The residue was purified by silica gel chromatography to give the title compound (400 mg, 32% yield) as a colorless oil. ¾**NMR** (400MHz, CDCh) δ 5.36 - 5.13 (m, 1H), 4.54 - 4.29 (m, 1H), 3.79 - 3.46 (m, 7H), 3.33 (s, 2H), 3.08 - 2.73 (m, 2H), 1.71 (s, 2H), 1.57 - 1.38 (m, 9H), 1.36 - 1.14 (m, 3H).

[001111] Tert-butyl N-[2-[2-[2-r2-(3-amino-2-fluoro-propoxylethoxy] ethoxy] ethoxy] ethyl] carbamate (Intermediate BA)



[001112] Step 1 - Tert-butyl N-r2-r2-r2-r2-r3-(dibenzylamino)-2-fluoro-propoxylethoxylethoxylethoxylethyll- carbamate


[001113] To a solution of 3-(dibenzylamino)-2-fluoro-propan-l-ol (550 mg, 2.01 mmol, Intermediate AH) in /V,/V-dimethylformamide(16 mL) was added sodium hydroxide (241 mg, 6.04 mmol, 60% dispersion in mineral oil). The mixture was stirred at 0 °C for 30 minutes then 2-[2-[2-[2-(tert-butoxycarbonylamino) ethoxy]ethoxy]-ethoxy]ethyl methanesulfonate (747 mg, 2.01 mmol, Intermediate AO) was added. Then, the reaction mixture was allowed to warm to rt and stirred for 4.5 hours under nitrogen atmosphere. On completion, the reaction mixture was quenched by addition of ice water (30 mL) and extracted with ethyl acetate (3 X 20 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to get a residue. The residue was purified by reversed phase chromatography (0.1% $NH_3 \bullet H_20$) to give the title compound (600 mg, 54% yield) as a colorless gum. ^{1}H NMR (400MHz, CDCh) δ 7.40 - 7.23 (m, 10H), 5.08 (m, 1H), 4.89 - 4.70 (m, 1H), 3.69 - 3.60 (m, 17H), 3.57 - 3.52 (m, 3H), 3.36 - 3.29 (m, 2H), 2.77 (d, *J* = 5.4 Hz, 1H), 2.72 (d, *J* = 5.4 Hz, 1H), 1.46 (s, 9H).

[001114] Step 2 - Tert-butyl N-r2424242A3-amino-2-fluoro-propoxylethoxy] ethoxy]ethoxy]ethyl]carbamate

[001115] To a solution of tert-butyl /V-[2-[2-[2-[2-[3-(dibenzylamino)-2-fluoro-propoxy]ethoxy]ethoxy]ethoxy]- ethyl]carbamate (600 mg, 1.09 mmol) in methanol (20 mL) was added Pd/C (300 mg, 10 wt %) and $Pd(OH)_2$/C (300 mg, 10 wt %) under nitrogen gas atmosphere. The suspension was degassed under vacuum and purged with hydrogen gas several times. The mixture was stirred under hydrogen gas (15 psi pressure) at rt for 18 h. On completion, the reaction mixture was filtered through a pad of celite and the filter cake was washed with methanol (3 X 10 mL). The filtrate was concentrated *in vacuo* to give the title compound (310 mg, 76% yield) as a colorless oil. LC-MS (ESI^+) *m/z* 369.2 $(M+H)^+$.

[001116] **Tert-butyl N-[2-[2-[2-[2-(3-amino-2-fluoro-l-methyl-**

propoxyethoxyl ethoxyl ethoxyl ethyll carbamate (Intermediate BB)




[001117] Step 1 - Tert-butyl N-r2-r2-r2-r2-r3-(dibenzylamino)-2-fluoro-l-methyl-propoxyl ethoxyl ethoxyl ethoxyl ethyl]carb am ate

[001118] To a solution of 4-(dibenzylamino)-3-fluoro-butan-2-ol (476 mg, 1.66 mmol, Intermediate AL) in DMF (8 mL) was added NaH (199 mg, 4.97 mmol) at 0 °C for 0.5 h. Then 2-[2-[2-[2-(tert -butoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethyl methanesulfonate (800 mg, 2.15 mmol, Intermediate AO) was added into the above mixture. The reaction mixture allowed to warm to rt and stirred for 17 hrs. On completion, the reaction mixture was quenched with H_20 (20 mL) and extracted with EA (3 X 20 mL). The organic layer was dried with Na_2S0_4, filtered and the filtrate was concentrated *in vacuo.* The residue was purified by reverse phase chromatography (0.1% NHvH?0) to give the title compound (362 mg, 29% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 563.1 $(M+H)^+$.

[001119] Step 2 - Tert-butyl N-r2-r2-r2-r2-(3-amino-2-fluoro-l-methyl-propoxy)ethoxy1ethoxy1ethoxy1ethvn carbamate

[001120] To a solution of tert-butyl N-[2-[2-[2-[2-[3-(dibenzylamino)-2-fluoro-l-methyl-propoxy] ethoxy] ethoxy]ethoxy]ethyl]carbamate (430 mg, 764 umol) in MeOH (10 mL) was added Pd/C (200 mg, wt %), $Pd(OH)_2/C$ (200 mg, wt %) and $NH_3•H_20$ (182 mg, 30 wt %, 1.30 mmol). The suspension was degassed and purged with hydrogen gas three times. The reaction mixture was stirred at rt for 17 h under hydrogen atmosphere (50 psi pressure). On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (250 mg, 86% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 383.1 $(M+H)^+$.

[001121] **Tert-butyl N-[2-[2-[2-[2-[3-amino-2-fluoro-l,l-dimethyl-propoxylethoxyl ethoxyl ethoxyl ethyll carbamate (Intermediate BC)**




[001122] Step 1 - Tert-butyl N-r2-r2-r2-r2-r3-(dibenzylamino)-2-f1uoro- l,1-dimethyl-propoxyl ethoxy] ethoxy] ethoxylethyllcarbamate

[001123] To a solution of 2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]ethanol (800 mg, 2.32 mmol, Intermediate AN) in DMF (12 mL) was added NaH (277 mg, 6.95 mmol, 60% oil dispersion) at 0°C and the mixture was stirred at 0 °C for 0.5 h. Then 2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethyl methanesulfonate (834 mg, 2.55 mmol, synthesized via Step 1 of Intermediate AM) was added and the mixture was allowed to warm to rt and stirred for 5 hrs. On completion, the reaction mixture was quenched with water (20 mL) and extracted with EtOAc (3 X 30 mL). The combined organic layer was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase chromatography (0.1% $NH_3•H_20$) to give the title compound (700 mg, 49% yield) as a colorless oil. LC-MS (ESI^+) *m/z* 577.2 $(M+H)^+$.

[001124] Step 2 - Tert-butyl N-r2-r2-r2-r2-(3-amino-2-fluoro-Ll-dimethyl-propoxylethoxylethoxylethoxyl ethyllcarbamate

[001125] To a solution of *tert*-butyl /V-[2-[2-[2-[2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy] ethoxy] ethoxy]ethoxy]ethyl]carbamate (450 mg, 780 umol) in MeOH (10 mL) was added $Pd(OH)_2/C$ (150 mg, 10 wt %), Pd/C (150 mg, 10 wt %) and $NH_3·H_20$ (455 mg, 4.93 mmol, 38 wt %) under nitrogen atmosphere. The suspension was degassed under vacuum and purged with hydrogen gas three times. The mixture was stirred under hydrogen atmosphere (15 psi pressure) at rt for 62 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (200 mg, 64% yield) as colorless oil. ^1H NMR (400MHz, CDCh) δ 5.24 (s, 1H), 4.33 - 4.10 (m, 1H), 3.70 - 3.58 (m, 12H), 3.54 (t, J = 4.8 Hz, 2H), 3.38 - 3.25 (m, 2H), 3.05 - 2.88 (m, 2H), 1.60 (br. s, 2H), 1.45 (s, 9H), 1.23 (d, 7 = 1.6 Hz, 3H), 1.20 (d, 7 = 1.2 Hz, 3H).

[001126] **Tert-butyl N-|2-(2-aminoethoxy)ethyl|-N-|2-|2-|3-(benzyloxycarbonylamino)-2-fluoro-l.,l -dimethyl-propoxy] ethoxy]ethyl]carbamate (Intermediate BD)**



[001127] Step 1 - Tert-butyl N-r2-r2-r3-(benzyloxycarbonylamino)-2-f1uoro- l,1-dimethyl-propoxyl ethoxylethyllcarbamate

[001128] To a solution of tert-butyl N-[2-[2-(3-amino-2-fluoro-l,l-dimethyl-propoxy)ethoxy]ethyl]carbamate (1.1 g, 3.57 mmol, Intermediate AU) in a mixed solvent ofACN (10 mL) and H_20 (10 mL) was added $NaHC0_3$ (898 mg, 10.7 mmol, 416 uL) and CbzCl (730 mg, 4.28 mmol, 608 uL).The mixture was stirred at rt for 5 h. On completion, the mixture was extracted with DCM (2X20mL) and the organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE: EA=3 :1) to give the title compound (1.50 g, 95% yield) as a colorless oil. LC-MS (ESI^+) m/z 465.2$(M + Na)^+$.

[001129] Step 2 - Benzyl N-r3-r2-(2-aminoethoxy)ethoxy1-2-fluoro-3-methyl-butyllcarbamate

[001130] To a solution of tert-butyl N-[2-[2-[3-(benzyloxycarbonylamino)-2-fluoro-l,l-dimethyl-propoxy] ethoxy]ethyl]carbamate (1.5 g, 3.4 mmol) in DCM (15 mL) was added

HCl/dioxane (4 M, 3.00 mL). The mixture was stirred at rt for 1 h. On completion; the reaction mixture was concentrated *in vacuo* to give the title compound (1.3 g, 93% yield, HC1 salt) as a colorless oil. LC-MS (ESI$^+$) *m/z* 343. l(M +H)$^+$.

[001131] Step 3 - Benzyl N-[3-[2-[2-[2-(T,3-άioχois θiηάoïiη-2-vDethoxylethylaminolethoxylethoxyl-2- fluoro-3-methyl-butyllcarbamate

[001132] To a solution of benzyl N-[3-[2-(2-aminoethoxy)ethoxy]-2-fluoro-3-methyl-butyl]carbamate (1.3 g, 3.80 mmol) in ACN (10 mL) was added K_2CO_3 (1.05 g, 7.59 mmol) and 2-[2-(2-bromoethoxy)ethyl]isoindoline l,3-dione (1.08 g, 3.61 mmol, Intermediate AQ) .The mixture was stirred at 60 °C for 16 h. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (2.1 g, crude, 65% yield) as yellow oil. LC-MS (ESL) *m/z* 560.3 (M +H)$^+$.


[001133] Step 4 - Tert-butyl N-r2-r2-r3-(benzyloxycarbonylamino)-2-fluoro-Ll-dimethyl-propoxy] ethoxy] ethyl1-N-r2-r2-(L3-dioxoisoindolin-2-v0ethoxy1ethyl1carbamate

[001134] To a solution of benzyl N-[3-[2-[2-[2-[2-(l,3-dioxoisoindolin-2-yl)ethoxy]ethylamino]ethoxy] ethoxy]-2-fluoro-3-methylbutyl]carbamate (2.1 g, 3.8 mmol) in ACN (20 mL) was added $(Boc)_20$ (1.23 g, 5.63 mmol, 1.29 mL) and TEA (379 mg, 3.75 mmol, 522 uL). The mixture was stirred at rt for 3 h. On completion, the reaction mixture was filtered, and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE: EA=3:l) to give the title compound (700 mg, 27% yield) as a colorless oil. LC-MS (ESL) *m/z* 682.3 (M +Na)$^+$.

[001135] Step 5 - Tert-butyl N-r2-(2-aminoethoxy)ethyl1-N-r2-r2-r3-(benzyloxycarbonylamino)-2-fluoro-Ll -dimethyl -propoxylethoxylethyllcarbamate

[001136] To a solution of tert-butyl N-[2-[2-[3-(benzyloxycarbonylamino)-2-fluoro-l,l-dimethyl-propoxy] ethoxy]ethyl]-N-[2-[2-(l,3-dioxoisoindolin-2-yl)ethoxy]ethyl]carbamate (500 mg, 757 umol) in EtOH (30 mL) was added N2H4.H2O (193 mg, 3.79 mmol, 187 uL, 98% purity) and the reaction mixture was stirred at 80 °C for 16 h. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (S1O2, DCM: MeOH =10/1). to give the title compound (340 mg, 84% yield) as a yellow oil. LC-MS (ESL) *m/z* 530.3 (M +H)$^+$.

[001137] **Tert-butyl N-r2-r2-r2-(4-amino-3-fluoro-butoxylethoxy] ethoxy]ethyl]carbamate (Intermediate BE)**



BE

[001138] Step 1 - Ethyl 4-(dibenzylamino)-3-oxo-butanoate

[001139] To a mixture of N-benzyl-l-phenyl-methanamine (49.5 g, 251 mmol, 48.1 mL) ethyl 4-bromo-3-oxo- butanoate(25 g, 119 mmol) in THF (200 mL) was added a solution of ethyl 4-bromo-3-oxo-butanoate (25 g, 119 mmol) in THF (50 mL) dropwise. The reaction mixture was stirred at rt for 1.5 h. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase chromatography (ACN/H2O) to give the title compound (27 g, 69 % yield) as a black brown oil. LC-MS (ESI^+) *m/z* 326. l$(M+H)^+$.

[001140] Step 2 - Ethyl 4-(dibenzylamino)-3-hvdroxy-butanoate

[001141] To a mixture of ethyl 4-(dibenzylamino)-3-oxo-butanoate (4 g, 12.2 mmol) in EtOH (50 mL) was added $NaBH_4$ (930 mg, 24.5 mmol) dropwise at 0 °C. The reaction mixture was then allowed to warm to rt and stirred for 2 h. On completion, the reaction mixture was quenched by saturated NH_4Cl solution (5 mL) under stirring, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was poured into H_20 (15 mL) and extracted with EtOAc (3 X 30mL). The combined organic layer was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (3.4 g, 85% yield) as a yellow oil. LC-MS (ESI^+) m/z 328.1 $(M+H)^+$.

[001142] Step 3 - Ethyl 3-rtert-butyl(dimethvnsilyl1oxy-4-(dibenzylamino)butanoate

[001143] To a solution of ethyl 4-(dibenzylamino)-3-hydroxy-butanoate (3.0 g, 9.2 mmol) in

DCM (30 mL) was added imidazole (2.5 g, 36.7 mmol) and TBDMSC1 (4.14 g, 27.4 mmol, 3.37 mL) dropwise at 0 °C. The mixture was then stirred at rt for 12 h. On completion, the reaction mixture was filtered, and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 5/1,) to give the title compound (3.6 g, 88% yield) as a colorless oil^HNiVlR (400MHz, CDCh) δ 7.30 - 7.20 (m, 10H), 4.23 - 4.13 (m, 1H), 4.11 - 3.99 (m, 2H), 3.65 - 3.60 (m, 2H), 3.51 - 3.47 (m, 2H), 2.78 - 2.76 (m, 1H), 2.47 - 2.43 (m, 2H), 2.22 - 2.18 (m, 1H), 1.21 (t, *J* = 7.2 Hz, 3H), 0.80 (s, 9H), 0.00 (s, 6H).

[001144] Step 4 - 3-rTert-butyl(dimethvnsilyl1oxy-4-(dibenzylamino)butan-l-ol

[001145] To a solution of ethyl 3-[tert-butyl(dimethyl)silyl]oxy-4-(dibenzylamino)butanoate (3.6 g, 8.2 mmol) in THF (40 mL) was added $LiBH_4$ (532 mg, 24.4 mmol) in portions at 0 °C. Then the reaction mixture was stirred at rt for 12 h. On completion, the reaction mixture was quenched by sat. NH_4Cl (20 mL), and then diluted with H_20 (20 mL) and extracted with EtOAc (2 X 50 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (PE/EA = 5/1) to give the title compound (1.8 g, 51% yield) as a yellow oil. ^1H NMR (400MHz, CDCh) δ 7.37 - 7.26 (m, 10H), 3.97 - 3.89 (m, 1H), 3.80 - 3.67 (m, 3H), 3.61 - 3.48 (m, 4H), 2.70 - 2.65 (m, 1H), 2.50 - 2.46 (m, 1H), 1.94 - 1.86 (m, 1H), 1.79 - 1.72 (m, 1H), 0.88 (s, 9H), 0.05 (d, *j* = 5.2 Hz, 6H).

[001146] Step 5 - Tert-butyl N-r2-r2-r2-r4-(dibenzylamino)-3-hvdroxy-butoxyl ethoxy] ethoxy] ethyl]carbamate

[001147] To a solution of 3-[tert-butyl(dimethyl)silyl]oxy-4-(dibenzylamino)butan-l-ol (1.8 g, 4.50 mmol) in DMF (30 mL) was added NaH (540 mg, 13.5 mmol) and the mixture was stirred at rt for 30 mins. Then 2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethyl methanesulfonate (2.21 g, 6.76 mmol, synthesized via Step 1 of Intermediate AM) was added. The reaction mixture was stirred at rt for 3 h. On completion, the reaction mixture was quenched with H_20 (20 mL), and then extracted with EtOAc (2 X 50 mL). The combined organic phase was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase chromatography (0.1% $NH_3 \cdot H_20$ condition) to give the title compound (250 mg, 11% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 517.2 $(M+H)^+$.

[001148] Step 6 - Tert-butyl N-r2-r2-r2-r4-(dibenzylamino)-3-fluoro-


butoxyl ethoxy] ethoxy] ethyl] carbamate

[001149] To a solution of tert-butyl N-[2-[2-[2-[4-(dibenzylamino)-3-hydroxy-butoxy] ethoxy] ethoxy] ethyl] carbamate (230 mg, 445 umol) in THF (8 mL) was added DAST (86.1 mg, 534 umol, 70.5 uL) dropwise and the mixture was stirred at rt for 1 hr. On completion, the mixture was diluted with H_20 (10 mL) and extracted with ethyl acetate (2 X 20 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (200 mg, 71% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 519.3 $(M+H)^+$.

[001150] Step 7 - Tert-butyl N-r2-r2-r2-(4-amino-3-fluoro-butoxyiethoxyl ethoxy] ethyl] carbamate

[001151] A mixture of tert-butyl N-[2-[2-[2-[4-(dibenzylamino)-3-fluoro-butoxy] ethoxy] ethoxy] ethyl] carbamate (0.28 g, 539.85 umol) in MeOH (10 mL) and $NH_3 \cdot H_20$ (0.5 mL) was added $Pd(OH)_2/C$ (100 mg, 539 umol, 10 wt %) and Pd/C (100 mg, 539 umol, 10 wt %). The reaction mixture was stirred at rt for 24 h under hydrogen atmosphere (50 psi pressure). On completion, the mixture was filtered and concentrated *in vacuo* to give the title compound (140 mg, 68% yield) as a colorless oil. LC-MS (ESI^+) m/z 339.0 $(M+H)^+$.

[001152] **Tert-butyl N-|2-(2-aininoethoxy)ethyl|-N-|2-|3-(dibenzylainino)-2-fluoro-Ll-dimethyl- propoxyl ethyl] carbamate (Intermediate BF)**



[001153] Step 1 - 2-[2-[2-[2-[3-(Dibenzylamino)-2-fluoro- 1, 1-dimethyl-propoxyl ethylamino] ethoxy] ethylli so- indoline- 1, 3-dione

[001154] To a solution of 2-[2-(2-bromoethoxy)ethyl]isoindoline-l,3-dione (1.95 g, 6.53 mmol, Intermediate AQ) in acetonitrile (150 mL) was added potassium carbonate (3.01 g, 21.7 mmol) and 3-(2-aminoethoxy)-A',A'-dibenzyl- 2-fluoro-3 -methyl-butan-l -amine (2.50 g, 7.26

mmol, synthesized via Steps 1-3 of Intermediate AW). The mixture was stirred at 80 °C for 14 h. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (4.00 g, 51% purity, 50% yield) as a light yellow gum. LC-MS (ESI^+) *m/z* 562.3 $(M+H)^+$.


[001155] Step 2 - Tert-butyl N-r2-r3-(dibenzylamino)-2-fluoro- l,1-dimethyl-propoxy1ethyl1-N-r2-r2-(l,3-di- oxoisoindolin-2-vDethoxylethvncarbamate

[001156] To a solution of 2-[2-[2-[2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]ethylamino]ethoxy]- ethyl]isoindoline-l,3-dione (4.00 g, 51% purity, 3.63 mmol) in acetonitrile (100 mL) was added Boc_20 (2.38 g, 10.9 mmol, 2.50 mL).The mixture was stirred at 60 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to get a residue. The residue was purified by column chromatography (petroleum ether: ethyl acetate = 8:1 to 5:1) to give the title compound (2.20 g, 91% yield) as a colorless gum. ^1H NMR (400MHz, CDCh) δ 7.88 - 7.82 (m, 2H), 7.74 - 7.68 (m, 2H), 7.40 - 7.38 (m, 4H), 7.32 - 7.29 (m, 4H), 7.26 - 7.19 (m, 2H), 4.57 - 4.40 (m, 1H), 3.92 - 3.87 (m, 2H), 3.78 - 3.59 (m, 6H), 3.54 - 3.15 (m, 8H), 2.93 - 2.78 (m, 1H), 2.76 - 2.63 (m, 1H), 1.43 (s, 9H), 1.06 (s, 3H), 1.04 (s, 3H).

[001157] Step 3 - Tert-butyl N-r2-(2-aminoethoxy)ethyl1-N-r2-r3-(dibenzylamino)-2-fluoro-1. 1-dimethyl- propoxylethyllcarbamate

[001158] To a solution of tert-butyl /V-[2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]ethyl]-/V-[2-[2- (l,3-dioxoisoindolin-2-yl)ethoxy]ethyl]carbamate (1.00 g, 1.51 mmol) in ethanol (50 mL) was added hydrazine hydrate (1.51 g, 30.2 mmol, 1.47 mL). The mixture was stirred at 80 °C for 12 h. On completion, the reaction mixture was concentrated *in vacuo* to get a residue. Then the residue was diluted with (petroleum ether: ethyl acetate = 5:1, 25 mL). The insoluble substance was filtered and the filtrate was dried over anhydrous magnesium sulfate, filtered and concentrated *in vacuo* to give the title compound (780 mg, 97% yield) as a colorless gum. ^1H NMR (400MHz, CDCh) δ 7.34 - 7.28 (m, 4H), 7.26 - 7.20 (m, 4H), 7.18 - 7.11 (m, 2H), 4.50 - 4.34 (m, 1H), 3.68 (d, *J* = 13.6 Hz, 2H), 3.53 *(d, J* = 13.6 Hz, 2H), 3.44 - 3.11 (m, 10H), 2.86 - 2.52 (m, 4H), 1.52 (br. s, 2H), 1.37 (s, 9H), 0.99 (s, 3H), 0.98 (s, 3H).

[001159] **Tert-butyl N-[5-(3-amino-2-fluoro-propoxy)pentyl]carbamate [Intermediate BG1**



[001160] Step 1 - 2-(5-BromopentvOisoindoline-L3-dione

[001161] To a solution of l,5-dibromopentane (55.9 g, 243 mmol, 32.9 mL) in acetone (250 mL) was added (l,3-dioxoisoindolin-2-yl)potassium (15.0 g, 81.0 mmol) in portions over 30 minutes. The mixture was then stirred at rt for 30 minutes, and then heated to 60 °C and stirred for 15 hrs. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE: EA= 15:1 to 10:1) to give the title compound (20.0 g, 82% yield) as a white solid. LC-MS (ESI^+) *m/z* 296.0 $(M+H)^+$.

[001162] Step 2 - 2-r5-r3-(Dibenzylamino)-2-fluoro-propoxy1pentyl1isoindoline-E3-dione

[001163] To a solution of 3-(dibenzylamino)-2-fluoro-propan-l-ol (2.00 g, 7.32 mmol, Intermediate AH) in DMF (80 mL) was added NaH (878 mg, 22.0 mmol, 60% oil dispersion) and the mixture was stirred at rt for 0.5 h. Then 2-(5-bromopentyl)isoindoline-l,3-dione (5.20 g, 17.6 mmol) was added and the reaction mixture was stirred at 70 °C for a further 34.5 h. On completion, the reaction mixture was quenched by adding H_20 (50 mL), and then extracted with ethyl acetate (3 X 20 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase chromatography to give the title compound (560 mg, 16% yield) as colorless oil. LC-MS (ESI^+) *m/z* 489.3 $(M+H)^+$.

[001164] Step 3 - 5-r3-(Dibenzylamino)-2-fluoro-propoxy1 pentan-l -amine

[001165] To a solution of 2-[5-[3-(dibenzylamino)-2-fluoro-propoxy]pentyl]isoindoline-l,3-dione (560 mg, 1.14 mmol) in EtOH (10 mL) was added $NH_2NH_2·H_20$ (676 mg, 13.5 mmol). The

reaction mixture was stirred at 80 °C for 24 h. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (380 mg, 31% purity, 49% yield) as a light yellow solid. LC-MS (ESI^+) *m/z* 359.1 $(M+H)^+$.


[001166] Step 4 - Tert-butyl N-r5-r3-(dibenzylamino)-2-fluoro-propoxy1pentyl1carbamate

[001167] To a solution of 5-[3-(dibenzylamino)-2-fluoro-propoxy] pentan-l -amine (380 mg, 1.06 mmol) in DCM (10 mL) was added $(Boc)_20$ (462 mg, 2.12 mmol) and the reaction mixture was stirred at rt for 3 h. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography ($Si0_2$, petroleum ether: ethyl acetate = 12: 1) to give the title compound (390 mg, 77% yield) as a colorless oil. LC-MS (ESI^+) *m/z* 459.3 $(M+H)^+$.

[001168] Step 5 - Tert-butyl N-r5-(3-amino-2-fluoro-propoxy)pentyl1carbamate

[001169] To a solution of *tεv't*-butyl N-[5-[3-(dibenzylamino)-2-fluoro-propoxy]pentyl]carbamate (390 mg, 816 umol) in MeOH (10 mL) was added $Pd(OH)_2$/C (190 mg, 10 wt %), Pd/C (190 mg, 10 wt %) and $NH_3 \cdot H_20$ (91.0 mg, 779 umol, 30 wt %) under nitrogen atmosphere. The suspension was degassed and purged with hydrogen gas several times. The mixture was stirred at rt for 12 h under hydrogen atmosphere (15 psi pressure). On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (206 mg, 61% purity, 55% yield) as a light yellow oil. LC-MS (ESI^+) *m/z* 279.1 $(M+H)^+$.

[001170] Tert-butyl (2-(3-amino-2-fluoropropoxy)ethylK2-(2-(l.,3-dioxoisoindolin-2-yllethoxylethyll carbamate [Intermediate BHD



BH

[001171] Step 1 - 2-(3-(Dibenzylamino)-2-fluoropropoxy)ethylmethanesulfonate

[001172] To a solution of 2-[3-(dibenzylamino)-2-fluoro-propoxy]ethanol (2.00 g, 6.30 mmol, synthesized via Steps 1-2 of Intermediate AX) and TEA (1.28 g, 12.6 mmol, 1.75 mL) in DCM (20 mL) was added MsCl (866 mg, 7.56 mmol, 585 uL) at 0 °C. Then the mixture was allowed to warm to rt and stirred for 3 h. On completion, the reaction mixture was diluted with H_20 (50 mL) and extracted with DCM (3 X 50 mL). The combined organic layers were washed with saturated NH_4Cl solution (3 X 50 mL), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (2.65 g, 90% purity, 96% yield) as a colorless oil. ^1H NMR (400MHz, CDCh) δ 7.45 - 7.25(m, 10H), 4.85 - 4.65 (m, 1H), 4.38 - 4.27 (m, 2H), 3.70 - 3.59 (m, 8H), 2.99 (s, 3H), 2.80 - 2.70 (m, 2H).

[001173] Step 2 - 2-(2-(3-(Dibenzylamino)-2-fluoropropoxy)ethv0isoindoline-L3-dione

[001174] A mixture of 2-(3-(dibenzylamino)-2-fluoropropoxy)ethylmethanesulfonate (2.65 g, 6.03 mmol, 90% purity) and potassium l,3-dioxoisoindolin-2-ide (2.23 g, 12.1 mmol) in DMF (45 mL) was stirred at 85 °C for 12 h. On completion, the reaction mixture was diluted with H_20

(50 mL) and extracted with EA (200 mL). The combined organic layer was washed with brine (3 X 150 mL), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (3.00 g, 90% yield) as a yellow oil. LC-MS (ESI)$^+$ *m/z* 447.3. (M+H)$^+$.

[001175] Step 3 - 3-(2-Aminoethoxy)-N.N-dibenzyl-2-f1uoropropan- l-amine

[001176] To a solution of 2-[2-[3-(dibenzylamino)-2-fluoro-propoxy]ethyl]isoindoline-l,3-dione (3.00 g, 1.34 mmol) in EtOH (150 mL) was added N_2H_4•H_2O (5 mL, 98% purity) at rt. The mixture was stirred at 85 °C for 12 h. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was triturated with DCM (100 mL) and white precipitate was filtered off. The filtrate was concentrated *in vacuo* to give the title compound (1.93 g, 85% purity, 86% yield) as a colorless oil. LC-MS (ESI)$^+$ *m/z* 317.3. (M+H)$^+$.

[001177] Step 4 - 2-(2-Benzyl-4-fluoro-l -phenyl-6,l2-dioxa-2.9-diazatetradecan-l4-vDisoindoline-L3-dione

[001178] To a mixture of 3-(2-aminoethoxy)-/V,/V-dibenzyl-2-fluoro-propan-l-amine(l.93 g, 5.19 mmol, 85% purity), K2CO3 (2.17 g, 15.6 mmol) and KI (86.2 mg, 519 umol) in MeCN (50 mL) was added dropwise a solution of 2-[2-(2-bromoethoxy)ethyl]isoindoline-l,3-dione (1.39 g, 4.67 mmol, 0.9 eq, Intermediate AQ) in MeCN (10 mL) at rt. The reaction mixture then heated to 80 °C and stirred for 12 h. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (3.33 g, 45% purity, 54% yield) as a colorless oil. LC-MS (ESI)$^+$ *m/z* 534.3. (M+H)$^+$.

[001179] Step 5 - Tert-butyl(2-(3-(dibenzylamino)-2-fluoropropoxy)ethvD(2-(2-(T.3-dioxoisoindolin-2-vD ethoxyjethyl icarbamate


[001180] A mixture of 2-[2-[2-[2-[3-(dibenzylamino)-2-fluoro-propoxy]ethylamino]ethoxy]ethyl]isoindoline -l,3-dione (3.22 g, 45% purity, 2.72 mmol) and B0C2O (1.19 g, 1.25 mL) in MeOH (30 mL) was stirred at 60 °C for 6 h. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (S1O2, Petroleum ether: Ethyl acetate = 1:0 to 5:1) to give the title compound (1.40 g, 79% purity, 65% yield) as a colorless oil. LC-MS (ESI)$^+$ *m/z* 634.4. (M+H)$^+$.


[001181] Step 6 - Tert-butyl (2-(3-amino-2-fluoropropoxy)ethvD(2-(2-(T.3-dioxoisoindolin-2-yl)ethoxy)ethvl) carbamate

[001182] A mixture of *tert*-butyl /V-[2-[3-(dibenzylamino)-2-fluoro-propoxy]ethyl]-/V-[2-[2-(l,3-dioxoisoindo lin-2-yl)ethoxy]ethyl]carbamate (400 mg, 79% purity), Pd/C (200 mg, 10 wt %)

and $Pd(OH)_2/C$ (200 mg, 10 wt %) in MeOH (15 mL) was purged with hydrogen gas several times. The reaction mixture was stirred under hydrogen atmosphere (50 psi pressure) at 45 °C for 6 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (273 mg, 71.6% purity) as a colorless oil. LC-MS $(ESI)^+$ *m/z* 454.3. $(M+H)^+$.

[001183] **Ethyl 2-[2-[2-[2-methylsulfonyloxyethoxylethoxy] ethoxy] acetate [Intermediate BI)**





BI

[001184] Step 1 -Ethyl 2-r2-r2-(2-hvdroxyethoxy)ethoxy1ethoxy1acetate


[001185] A solution of 2-[2-(2-hydroxyethoxy)ethoxy] ethanol (10.0 g, 66.6 mmol) and $BF_3.Et_20$ (205 mg, 665 umol) in DCM (150 mL) was cooled to 0°C. Then ethyl 2-diazoacetate (7.60 g, 66.9 mmol) was added to the mixture dropwise. After that, the mixture was stirred at rt for 12 h. On completion, the reaction mixture was quenched with saturated NH_4Cl (5 mL), then diluted with water (100 mL) and extracted with DCM (3 X 50 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE:EA= 1:3) to give the title compound (5.00 g, 31% yield) as a colorless oil. ¾NMR (400MHz, CDCb) δ 4.17 (q, *J* = 7.2 Hz, 2H), 4.11 (s, 2H), 3.72 - 3.60 (m, 10H), 3.59 - 3.54 (m, 2H), 2.82 (s, 2H), 1.24 (t, *J* = 7.2 Hz, 3H).

[001186] Step 2 - Ethyl 2-r2-r2-(2-methylsulfonyloxyethoxy)ethoxy1ethoxy1acetate


[001187] A solution of ethyl 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]acetate (900 mg, 3.81 mmol) and TEA (1.16 g, 11.4 mmol) in DCM (10 mL) was cooled to 0°C. Then, MsCl (523 mg, 4.57 mmol) in DCM (2 mL) was added to the reaction mixture dropwise. The mixture was stirred at rt for 1 hour. On completion, the reaction mixture was quenched with water (8 mL) and then extracted with dichloromethane (3 X 5 mL). The combined organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (1.10 g, 91% yield) as a colorless oil. ^1H NMR (400MHz, CDCb) δ 4.40 - 4.36 (m, 2H), 4.21 (q, *J* = 7.2 Hz, 2H), 4.13 (s,


2H), 3.79 - 3.74 (m, 2H), 3.74 - 3.65 (m, 8H), 3.08 (s, 3H), 1.28 (t, *J* = 7.2 Hz, 3H).

[001188] **Ethyl 2-r2-r2-r2-r2-13-amino-2-fluoro-Ll-dimethyl-propoxylethoxy] ethoxy] ethoxy] ethoxy] acetate [Intermediate BJ)**



BI





BJ

[001189] Step 1 = 2-r2-r2-r2-r2-r3-(Dibenzylamino)-2-fluoro-Ll-dimethyl-propoxylethoxylethoxylethoxyl ethoxylacetic acid

[001190] To a mixture of 2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]ethanol (3.66 g, 10.6 mmol, Intermediate AN) in DMF (40 mL) was added NaH (1.27 g, 31.8 mmol, 60% dispersion in mineral oil) at 0 °C and stirred for 0.5 hour. Then ethyl 2-[2-[2-(2-methylsulfonyloxyethoxy)ethoxy]ethoxy]acetate (4.00 g, 12.7 mmol, Intermediate BI) was added and the reaction was allowed to warm to rt and stirred for 16 hours. On completion, the reaction mixture was quenched with water (1 mL) and concentrated *in vacuo* to give the title compound (5.00 g, 88% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 536.1 $(M+H)^+$.

[001191] Step 2 - Ethyl 2-r2-r2-r2-r2-r3-(dibenzylamino)-2-fluoro-Ll-dimethyl-propoxylethoxylethoxylethoxyl ethoxy]acetate


[001192] To a mixture of 2-[2-[2-[2-[2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]ethoxy]ethoxy] ethoxy]ethoxy]acetic acid (5.00 g, 9.33 mmol) in EtOH (50 mL) was added $SOCl_2$ (3.33 g, 28.0 mmol). The reaction mixture was stirred at 80 °C for 4 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was diluted with water (10 mL) and basified with $NaHC0_3$ until the pH = 7-8, then the mixture was extracted with EA (3 X 20mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo*

to give a residue. The residue was purified by reverse phase chromatography (0.1 % $NH_3•H_20$) to give the title compound (1.80 g, 34% yield) as a light yellow oil. LC-MS (ESI^+) *m/z* 564.4 $(M+H)^+$.

[001193] Step 3 - Ethyl 2-[2-[2-[2-[2-(3-amino-2-fluoro- 1.1-dimethyl-propoxylethoxylethoxylethoxylethoxyl acetate

[001194] To a mixture of ethyl 2-[2-[2-[2-[2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy] ethoxy] ethoxy] ethoxy] ethoxy] acetate (900 mg, 1.60 mmol) and $Pd(OH)_2/C$ (600 mg, 10% purity) in EtOH (10 mL) was added TFA (161 mg, 1.60 mmol) under hydrogen atmosphere (15 psi pressure). The reaction mixture was stirred at rt for 16 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (610 mg, 90% yield) as a light yellow oil. ^1H NMR (400MHz, CDCb) δ 4.54 - 4.37 (m, 1H), 4.24 (q, *J* = 7.6 Hz, 2H), 4.15 (s, 2H), 3.80 - 3.50 (m, 18H), 3.31 - 3.01 (t, 7 = 7.6 Hz, 3H), 1.31 - 1.23 (m, 6H).

[001195] **Ethyl 2-|2-|2-|2-[2-methylsulfonyloxyethoxy)ethoxylethoxylethoxylacetate [Intermediate BK)**



BK


[001196] Step 1 - Ethyl 2-r2-r2-r2-(2-hvdroxyethoxy)ethoxy1ethoxy1ethoxy1acetate


[001197] Asolution of 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethanol (10.0 g, 51.5 mmol, CAS# 112-60-7) and $BF_3.Et_20$ (159 mg, 515 umol) in DCM (150 mL) was cooled to 0°C. Then ethyl 2-diazoacetate (5.87 g, 51.5 mmol) was added to the solution dropwise. After that, the mixture was stirred at rt for 12 h. On completion, the reaction mixture was quenched with saturated NH_4CI aqueous solution (5 mL), diluted with water (100 mL), then extracted with dichlorom ethane (3 X 50 mL). The combined organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE:EA = 1:3) to give the title compound (2.90 g, 20% yield) as a colorless oil. ^1H NMR (400 MHz, CDCb) δ 4.19 (q, *J* = 7.2 Hz, 2H), 4.12 (s, 2H), 3.73 - 3.63 (m, 14H), 3.61 - 3.56 (m, 2H), 1.26 (t, *J* = 7.2 Hz, 3H)


[001198] Step 2 - Ethyl 2-[2-[2-[2-(2-methylsulfonyloxyethoxy)ethoxy]ethoxy]ethoxy]acetate

[001199] A solution of ethyl 2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]acetate (800 mg, 2.85 mmol) and TEA (577 mg, 5.70 mmol) in DCM (30 mL) was cooled to 0 °C . Then, a solution of MsCl (392 mg, 3.42 mmol) in DCM (4 mL) was added to the mixture dropwise. The mixture was then allowed to warm to rt and stirred for 1 hour. On completion, the reaction mixture was quenched with water (25 mL), and extracted with dichloromethane (3 X 10 mL). The combined organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (1.90 g, 90% yield) as a yellowish oil.

[001200] **Methyl 2-[2-[2-[2-[2-(3-amino-2-fluoro-l-methyl-propoxylethoxy] ethoxy] ethoxy] ethoxy] acetate [Intermediate BL)**







BL

[001201] Step 1 - 2-[2-[2-[2-[2-[3-(Dibenzylamino)-2-fluoro- 1-methyl-propoxylethoxylethoxylethoxylethoxyl acetic acid

[001202] To a solution of 4-(dibenzylamino)-3-fluoro-butan-2-ol (600 mg, 2.09 mmol, Intermediate AL) in DMF (10 mL) was added NaH (209 mg, 5.22 mmol) at 0 °C. After 0.5 h, ethyl 2-[2-[2-[2-(2- methylsulfonyloxyethoxy)ethoxy]ethoxy]ethoxy]acetate (898 mg, 2.51 mmol, Intermediate BK) was added to the reaction mixture. The reaction mixture was then allowed to warm to rt and stirred for 17 h. On completion, the mixture was acidified with 1N HC1 solution until the pH = 4-5, then concentrated *in vacuo.* The residue was purified by reverse phase chromatography (0.1% TFA) to give the title compound (640 mg, 53% yield) as a yellow oil. LC-

MS (ESI+) *m/z* 522.1 (M+H)+.


[001203] Step 2 - Methyl 2-r2-r2-r2-r3-(dibenzylamino)-2-fluoro-l-methyl-propoxylethoxylethoxylethoxyl ethoxy] acetate

[001204] To a solution of 2-[2-[2-[2-[2-[3-(dibenzylamino)-2-fluoro-l-methyl-propoxy]ethoxy]ethoxy]ethoxy] ethoxy]acetic acid (640 mg, 1.11 mmol) in MeOH (10 mL) was added $SOCl_2$ (396 mg, 3.33 mmol). The reaction mixture then heated to 65 °C and stirred for 15 h. On completion, the mixture was concentrated *in vacuo* to remove the solvent MeOH then diluted with H_20 (20 mL). The mixture was then basified with 1N NaOH solution until the pH = 8-9, and extracted with DCM (3 X 20 mL). The combined organic layer was washed with brine (30 mL), dried over Na_2S0_4, and concentrated *in vacuo.* The residue was purified by reverse phase chromatography (0.1% FA) to give the title compound (280 mg, 47% yield) as a yellow oil. LC-MS (ESL) *m/z* 536.3 (M+H)+.

[001205] Step 3 - Methyl 2-r2-r2-r2-r2-(3-amino-2-fluoro- 1-methyl-propoxylethoxylethoxylethoxylethoxyl acetate

[001206] To a solution of methyl 2-[2-[2-[2-[2-[3-(dibenzylamino)-2-fluoro-l-methyl-propoxy] ethoxy] ethoxy] ethoxy] ethoxy] acetate (280 mg, 522 umol) in EtOH (4 mL) was added Pd(OH)2/C (0.3 g, 10 wt %), Pd/C (0.3 g, 10 wt %) and TFA (59.6 mg, 523 umol, 0.59 mmol). The suspension was degassed and purged with hydrogen gas three times. The reaction mixture was stirred under hydrogen atmosphere (15 psi pressure) at rt for 17 h. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (200 mg, 100% yield). ^{1}H NMR (400MHz, CDCb) δ 4.68 - 4.29 (m, 1H), 4.17 - 4.11 (m, 1H), 3.75 - 3.53 (m, 21H), 3.27 - 3.14 (m, 2H), 1.21 - 1.18 (m, 3H).

[001207] Methyl 2-[2-[2-[3-[[6-(5-cvanopyrazolo[3.,4-blpyridin-l-vD-4-lcvclopropylaminolpyridine-3- carbonyllaminol-2-fluoro-l-methyl-propoxy]ethoxy]ethoxy]acetate [Intermediate BM)



[001208] Step 1 - Ethyl 2-r2-(2-hvdroxyethoxy)ethoxy1acetate

[001209] To a mixture of 2-(2-hydroxyethoxy)ethanol (5.00 g, 47.1 mmol, 4.46 mL) and $Rh_2(OAc)_4$ (278 mg, 628 umol) in DCM (50 mL) was added a solution of ethyl 2-diazoacetate (3.58 g, 31.4 mmol, 3.29 mL) in DCM (35 mL) dropwise. Then, the reaction mixture was stirred at rt for 16 h. On completion, the reaction mixture was quenched by adding H_20 (10 mL), and then extracted with DCM (2 X 15 mL). The combined organic layers were dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel column chromatography (Petroleum ether: Ethyl acetate = 10:1 to 0:1) to give the title compound (1.68 g, 28% yield) as a black-brown oil. ^1H NMR (400MHz, $CDCl_3$-*d*) δ 4.22 (q, *J* = 7.2 Hz, 2H), 4.14 (s, 2H), 3.77 - 3.68 (m, 6H), 3.64 - 3.59 (m, 2H), 2.60 (s, 1H), 1.29 (t, *j* = 7.2 Hz, 3H).

[001210] Step 2 - Ethyl 2-r2-(2-methylsulfonyloxyethoxy)ethoxy1acetate

[001211] To a solution of ethyl 2-[2-(2-hydroxyethoxy)ethoxy] acetate (800 mg, 4.16 mmol) in DCM (8 mL) was added TEA (1.26 g, 12.5 mmol, 1.74 mL) and MsCl (715 mg, 6.24 mmol, 483 uL) at 0 °C. The reaction mixture was then allowed to warm to rt and stirred for 30 minutes. On completion, the reaction mixture was quenched by adding H_20 (10 mL) and then citric acid (5 mL). The mixture was then extracted with DCM (2 X 10 mL). The combined organic layers were

washed with $NaHCO_3$ solution (20 mL), dried over anhydrous Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (1.00 g, 88% yield) as a black-brown oil. ^1H NMR (400MHz, CDCh) δ 4.44 - 4.37 (m, 2H), 4.24 (q, *J* = 7.2 Hz, 2H), 4.17 - 4.12 (m, 2H), 3.84 - 3.78 (m, 2H), 3.77 - 3.69 (m, 4H), 3.10 (s, 3H), 1.31 (t, *J* = 7.2 Hz, 3H).

[001212] Step 3 - 2-r2-r2-r3-(Dibenzylamino)-2-fluoro- 1-methyl - propoxylethoxylethoxylacetic acid

[001213] To a solution of 4-(dibenzylamino)-3-fluoro-butan-2-ol (818 mg, 2.85 mmol, Intermediate AL) in DMF (10 mL) was addedNaH (341 mg, 8.54 mmol, 60% dispersion in mineral oil) at 0 °C and the reaction was stirred for 0.5 hour. Then, ethyl 2-[2-(2-methylsulfonyloxyethoxy)ethoxy]acetate (1.00 g, 3.70 mmol) was added, and the reaction mixture was allowed to warm to rt and stirred for a further 16.5 h. On completion, the reaction mixture was adjusted to pH < 7 with 10% hydrochloride acid, and then concentrated *in vacuo* to give the title compound (3.00 g, 31% purity, 76% yield,) as a black-brown gum. LC-MS (ESI^+) *m/z* 434.1 $(M+H)^+$.

[001214] Step 4 - Methyl 2-r2-r2-r3-(dibenzylamino)-2-fluoro-l-methyl- propoxy] ethoxy] ethoxy] acetate

[001215] To a solution of 2-[2-[2-[3-(dibenzylamino)-2-fluoro-l-methyl-propoxy]ethoxy]ethoxy]acetic acid (3.00 g, 6.92 mmol) in MeOH (30 mL) was added SOCh (2.47 g, 20.8 mmol, 1.51 mL) . The reaction mixture then heated to 65 °C and stirred for 15 h. On completion, the reaction mixture was concentrated *in vacuo.* The residue was then adjusted to pH > 8 with saturated $NaHCO_3$ solution, and then extracted with ethyl acetate (2 X 20 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 30:1 to 10:1) first, and then purified by reverse phase column chromatography (0.1% FA) to give the title compound (250 mg, 95% purity, 8% yield) as a brown oil. ^1H NMR (400MHz, CDCh) δ 7.30 - 7.15 (m, 10H), 4.65 - 4.36 (m, 1H), 4.07 (d, *j* = 3.2 Hz, 2H), 3.69 - 3.43 (m, 15H), 3.43 - 3.35 (m, 1H), 2.77 - 2.62 (m, 2H), 0.99 - 0.92 (m, 3H).

[001216] Step 5 - Methyl 2-r2-r2-(3-amino-2-fluoro-l-methyl- propoxyiethoxyl ethoxy] acetate


[001217] To a solution of methyl 2-[2-[2-[3-(dibenzylamino)-2-fluoro-l-methyl-propoxy]ethoxy]ethoxy]acetate (250 mg, 559 umol) in MeOH (5 mL) was added Pd/C (120 mg,

10 wt %) , $Pd(OH)_2/C$ (120 mg, 10 wt %) and HC1 (1 M, 2.5 mL). The reaction mixture was stirred at rt for 15 h under hydrogen atmosphere (15 psi pressure). On completion, the reaction mixture was filtered and the filtrate concentrated *in vacuo* to give the title compound (200 mg, 92% purity, 100% yield) as a light yellow oil. LC-MS (ESI^+) *m/z* 254.1 $(M+H)^+$.

[001218] Step 6 - Methyl 2-r2-r2-r3-IT6-(5-cvanopyrazolor3.4-b1pyridin-l-vO-4-(cvclopropylamino)pyridine-3- carbonyllaminol-2-fluoro-l-methyl-propoxyl ethoxy] ethoxy] acetate

[001219] To a solution of 2-[2-[2-(3-amino-2-fluoro-l -methyl-propoxy)ethoxy]ethoxy]acetic acid (140 mg, 553 umol) in MeOH (3 mL) was added $SOCl_2$ (197 mg, 1.66 mmol, 120 uL). The reaction mixture was then heated to 65 °C and stirred for 3 h. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (120 mg, 85% purity, 69% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 268.1 $(M+H)^+$.


[001220] **Tert-butyl N-|2-|2-|2-[2-azidoethoxy)ethoxy]ethoxy]ethyl]carbamate [Intermediate BN)**



AO BN

[001221] To a solution of 2-[2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethyl methanesulfonate (3.6 g, 9.7 mmol, Intermediate AO) in DMF (20 mL) was added NaN_3 (1.26 g, 19.4 mmol). The reaction mixture was then heated to 80 °C and stirred for 18 h. On completion, the solvent DMF was removed *in vacuo.* The residue was diluted with EtOAc (50 mL), filtered and the filtrate was removed under nitrogen gas sweep to give the title compound (3.2 g, 90% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 219.1 $(M+H-l00)^+$

[001222] **2-[2-[2-[2-[2-[2-[Tert-butoxycarbonylaminoiethoxyl ethoxy] ethoxy] ethoxy] ethoxy] ethyl methanesulfonate [Intermediate BO)**



BO

[001223] Step 1 - 2-r2-r2-r2-r2-(2-Hvdroxyethoxy)ethoxy1ethoxy1ethoxy1ethoxy1ethyl4-methylbenzene sulfonate

[001224] To a solution of 2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethanol (10.0 g, 35.4 mmol, CAS# 2615-15-8) in DCM (1.00 L) was added Ag_20 (9.85 g, 42.5 mmol), KI (587 mg, 3.54 mmol) and 4-methylbenzenesulfonylchloride (6.75 g, 35.4 mmol). The reaction mixture was stirred under nitrogen atmosphere at rt for 24 h. On completion, the mixture was filtered through a pad of celite and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by silica column chromatography (DCM : MeOH = 100 : 1) to give the title compound (15.0 g, 97% yield) as a yellowish oil. ^{1}H NMR (400MHz, CDCh) δ 7.73 (d, *J* = 8.4 Hz, 2H), 7.27 (d, *J* = 8.4 Hz, 2H), 4.12 - 4.06 (m, 2H), 3.68 - 3.50 (m, 22H), 2.38 (s, 3H).

[001225] Step 2 - 2-r2-r2-r2-r2-(2-Azidoethoxy)ethoxy1ethoxy1ethoxy1ethoxy1ethanol

[001226] To a solution of 2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzene sulfonate (15.0 g, 34.3 mmol) in DMF (75.0 mL) was added NaN_3 (4.50 g, 69.2 mmol) and the mixture was heated to 80 °C and stirred for 12 h. On completion, the DMF solvent was removed under nitrogen gas sweep. Then the reaction mixture was diluted with water (100 mL) and extracted with DCM: MeOH (10 : 1) (2 X 200 mL). The organic layer was purged under nitrogen to give the title compound (10.0 g, 94% yield) as a colorless oil.

[001227] Step 3 - 2-r2-r2-r2-r2-(2-Aminoethoxy)ethoxy1ethoxy1ethoxy1ethoxy1ethanol

[001228] To a solution of 2-[2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethanol (10.0 g, 32.5 mmol) in EtOH (80.0 mL) was

added Pd/C (4.00 g, 10 wt %). The reaction mixture was stirred under hydrogen atmosphere (15 psi pressure) at rt for 12 h. On completion, the mixture was filtered and concentrated *in vacuo* to give the title compound (8.50 g, 92% yield) as a light yellow oil. LC-MS $(ESI)^+$ *m/z* 282. 1. $(M+H)^+$.

[001229] Step 4 - Benzyl N-[2-[2-[2-[2-[2-(2-hydroxyethoxyiethoxyl ethoxy] ethoxy] ethoxy] ethyl]carbamate

[001230] To a solution of 2-[2-[2-[2-[2-(2-aminoethoxy)ethoxy] ethoxy] ethoxy] ethoxy] ethanol (4.00 g, 14.2 mmol) in ACN (40.0 mL) and H_20 (40.0 mL) was added $NaHC0_3$ (3.58 g, 42.6 mmol) and CbzCl (2.91 g, 17.0 mmol), and the mixture was stirred at rt for 12 h. On completion, the mixture was extracted with DCM (2 X 100 mL). The organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by silica gel column chromatography (DCM: MeOH = 10: 1) to give the title compound (4.00 g, 67% yield) as a colorless oil. ^1H NMR (400MHz, CDCh) δ 7.38 - 7.33 (m, 5H), 5.56 (s, 1H), 5.11 (s, 2H), 3.73 - 3.42 (m, 23H).

[001231] Step 5 - Tert-butyl N-[2-[2-[2-[2-[2-(2-hydroxyethoxyiethoxyl ethoxy] ethoxy] ethoxy] ethyl]carbamate


[001232] To a solution of benzyl N-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy] ethoxy] ethoxy] ethoxy] ethyl] carbamate (3.00 g, 7.22 mmol) in EtOAc (60.0 mL) was added $Pd(OH)_2/C$ (100 mg, 2.41 mmol, 10 wt%) and $(Boc)_20$ (1.89 g, 8.66 mmol), and the mixture was stirred at rt for 12 h. On completion, the mixture was filtered and concentrated *in vacuo.* The residue was purified by silica column chromatography (DCM: MeOH = 10: 1) to give the title compound (2.00 g, 72% yield) as a colorless oil. ^1H NMR (400MHz, CDCh) δ 5.19 (s, 1H), 3.84 - 3.82 (m, 2H), 3.80 - 3.34 (m, 20H), 3.33 (s, 2H), 1.46 (s, 9H).

[001233] Step 6 - 2-I2-I2-I2-I2-I2-(Tert-butoxycarbonylaminoiethoxyl ethoxy] ethoxy] ethoxy] ethoxy] ethyl methanesulfonate


[001234] To a solution of tert-butyl N-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy] ethoxy] ethoxy] ethoxy] ethyl] carbamate (1.70 g, 4.46 mmol) in DCM (5.00 mL) was added MsCl (765 mg, 6.68 mmol) and TEA (1.35 g, 13.3 mmol), and the mixture was stirred at 0 °C for 1 h. On completion, the mixture was quenched with water (20 mL) and extracted with DCM (3 X 30 mL). The combined organic layer was washed with brine (3 X 30 mL). The organic layer was dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title


compound (1.8 g, 87% yield) as a yellow oil. ^{1}H NMR (400MHz, CDCb) δ 5.07 (s, 1H), 4.44 - 4.38 (m, 2H), 3.81 - 3.76 (m, 2H), 3.71 - 3.62 (m, 16H), 3.56 (t, *J* = 5.2 Hz, 2H), 3.39 - 3.29 (m, 2H), 3.11 (s, 3H), 1.46 (s, 9H).

[001235] **Tert-butyl N-[2-[2-[2-[2-[2-[2-13 -amino-2-fluoro-propoxylethoxy] ethoxy] ethoxy] ethoxy] ethoxylethyl] carbamate [Inter mediate BP)**



BO





BP


[001236] Step 1 - Tert-butyl N-r2-r2-r2-r2-r2-r2-r3-(dibenzylamino)-2-fluoro-propoxyl ethoxy] ethoxy] ethoxy] ethoxy] ethoxy] ethyl] carb amate

[001237] To a solution of 3-(dibenzylamino)-2-fluoro-propan-l-ol (0.50 g, 1.83 mmol, Intermediate AH) in DMF (10.0 mL) was added NaH (219 mg, 5.49 mmol, 60% dispersion in mineral oil), and the mixture was stirred at 0 °C for 1 h. Then 2-[2-[2-[2-[2-[2-(tertbutoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylmethane sulfonate (1.01 g, 2.20 mmol, Intermediate BO) was added to the reaction mixture and the mixture was allowed to warm to rt and stirred for 16 h. On completion, the mixture was quenched with water (50 mL) and extracted with EA (3 X 50 mL). The organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The mixture was purified by reverse phase flash column chromatography ($NH_3·H_2O$, ACN 50% ~ 60%) to give the title compound (300 mg, 21% yield) as a colorless oil. LC-MS $(ESI)^+$ *m/z* 637.4. $(M+H)^+$.

[001238] Step 2 - Tert-butyl N-[2-[2-[2-[2-[2-[2-(3 -amino-2-fluoro-propoxylethoxylethoxylethoxylethoxyl ethoxylethyl] carbamate

[001239] To a solution of tert-butyl N-[2-[2-[2-[2-[2-[2-[3-(dibenzylamino)-2-fluoropropoxy] ethoxy] ethoxy] ethoxy]ethoxy]ethoxy]ethyl]carbamate (0.40 g, 628 umol) in MeOH (5.00 mL) and NH3.H2O (0.2 mL) was added $Pd(OH)_2/C$ (0.10 g, 10 wt %) and Pd/C (0.10 g, 10 wt %) under nitrogen atmosphere. The suspension was degassed and purged with hydrogen gas three times. The mixture was stirred under hydrogen atmosphere (50 psi pressure) at rt for 12 h. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (210 mg, 73% yield) as a colorless oil. LC-MS $(ESI)^+$ *m/z* 457.1. $(M+H)^+$.


[001240] **Tert-butyl N-[2-[2-[2-[2-[2-12-azidoethoxylethoxy] ethoxy] ethoxy] ethoxy] ethyl] carbamate [Intermediate BQ)**



BO BQ

[001241] To a solution of 2-[2-[2-[2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy] ethylmethane sulfonate (4.45 g, 9.68 mmol, Intermediate BO) in DMF (50 mL) was added NaN_3 (1.26 g, 19.37 mmol). The reaction mixture then heated to 80 °C and stirred for 16 hours. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (3.90 g, 99% yield) as a yellow oil. LC-MS (ESL) *m/z* 424.1 $(M+l8)^+$.

[001242] **Tert - butyl N-[2-[2-[2-[2-[2-[4-[2-(3-amino-2-fluoro-propoxy)ethyllpiperazin-1-yl]ethoxy] ethoxylethoxylethoxylethyllcarbamate (Intermediate BR)**



[001243] Step 1 - Tert-butyl 4-(2-methylsulfonyloxyethvQpiperazine-l-carboxylate

[001244] To a solution of tert-butyl 4-(2-hydroxyethyl)piperazine-l-carboxylate (500 mg, 2.17 mmol, CAS# 77279-24-4) in DCM (10 mL) at 0° C was added TEA (329 mg, 3.26 mmol, 451 uL). After 5 minutes, MsCl (298 mg, 2.60 mmol, 201 uL) was added, and the reaction mixture was allowed to warm to rt and was stirred under nitrogen atmosphere for 3 hours. On completion, the reaction mixture was diluted with H_20 (20 mL) and extracted with DCM (2 X 50 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (620 mg, 93% yield) as a yellowish oil.

[001245] Step 2 - Tert-butyl 4-r2-r3-(dibenzylamino)-2-fluoro-propoxy1ethyl1piperazine-l-carboxylate

[001246] To a mixture of tert-butyl 4-(2-methylsulfonyloxyethyl)piperazine-l-carboxylate (620 mg, 2.01 mmol) in DMF (3.00 mL) was added NaH (110 mg, 2.74 mmol, 60% dispersion in mineral oil) at rt under nitrogen atmosphere. The mixture was stirred at rt for 30 minutes, then 3-(dibenzylamino)-2-fluoro-propan-l-ol (500 mg, 1.83 mmol, Intermediate AH) was added to the mixture at rt and the reaction mixture was stirred for 48 hours. On completion, the reaction mixture

was quenched with sat. NH_4Cl solution (20 mL), then diluted with H_20 (20 mL) and extracted with EA (2 X 50 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by reversed phase flash chromatography ($NH_3•H_2O$) to give the title compound (160 mg, 18% yield) as a yellow oil. LC-MS (ESI^+) m/z 486.3 $(M+H)^+$.

[001247] Step 3 - N.N-dibenzyl-2-fluoro-3-(2-piperazin-l-ylethoxy)propan-l -amine

[001248] To a mixture of tert-butyl 4-[2-[3-(dibenzylamino)-2-fluoro-propoxy]ethyl]piperazine-l-carboxylate (160 mg, 329 umol) in DCM (5.00 mL) and MeOH (1.00 mL) was added HC1 in dioxane (329 umol, 2.00 mL). The mixture was stirred at rt for 1 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (200 mg) as a yellow oil. LC-MS (ESI^+) m/z 386.2 $(M+H)^+$.


[001249] Step 4 - Tert - butyl N-r2-r2-r2-r2-r2-r4-r2-r3-(dibenzylamino)-2-fluoro-propoxylethyllpiperazin-l-vn ethoxylethoxylethoxylethoxylethyllcarbamate

[001250] To a mixture of N,N-dibenzyl-2-fluoro-3-(2-piperazin-l-ylethoxy)propan-l -amine (200 mg, 518 umol) and 2-[2-[2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethoxy]ethyl methanesulfonate (259 mg, 623 umol, synthesized via Steps 1-2 of Intermediate AK) inDMF (1.00 mL) and MeCN (3.00 mL) was added K_2CO_3 (215 mg, 1.56 mmol). The mixture was then heated to 80 °C and stirred for 12 hours. On completion, the mixture was diluted with H_2O (20 mL) and extracted with ethyl acetate (2 X 40 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by prep-TLC (PE:EA = 1:1) to give the title compound (220 mg, 60% yield) as a yellow oil. LC-MS (ESI^+) m/z 705.3 $(M+H)^+$.

[001251] Step 5 - Tert - butyl N-r2-r2-r2-r2-r2-r4-r2-(3-amino-2-fluoro-propoxyiethyllpiperazin- 1-yllethoxyl ethoxylethoxylethoxylethyllcarbamate

[001252] To a solution of tert-butyl N-[2-[2-[2-[2-[2-[4-[2-[3-(dibenzylamino)-2-fluoro-propoxy]ethyl] piperazin-l-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate (220 mg, 312 umol) in MeOH (7.00 mL) was added $Pd(OH)_2$ (100 mg, 71.2 umol, 10 wt %) and Pd/C (100 mg, 312 umol, 10 wt %). The suspension was degassed under vacuum and purged with hydrogen gas several times. The mixture was then stirred at rt for 192 hours under hydrogen atmosphere (50 psi pressure). On completion, the mixture was filtered and concentrated *in vacuo* to give the title compound (100 mg, 61% yield) as a white oil.

[001253] **Tert-butyl 115-amino-14-fluoro-13,13-dimethyl-10-oxo-3,6,12-trioxa-9-azapentadecyl) carbamate [Intermediate BS1**



BS

[001254] Step 1 - N-(2-(2-(2-aminoethoxy)ethoxy)ethvD-2-(Y4-(dibenzylarnino)-3-fluoiO-2-methylbutan- 2-v0oxy)acetamide

[001255] A solution of ethyl 2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy]acetate (337 mg, 870 umol, synthesized via Steps 1-2 of Intermediate AN) and 2-[2-(2-aminoethoxy)ethoxy]ethanamine (644 mg, 4.35 mmol, CAS# 929-59-9) in methanol (2 mL). The reaction mixture was heated to 80 °C for 12 hrs. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (850 mg, 40% yield) as a colorless oil. LC-MS (ESI^+) *m/z* 490.3 $(M+H)^+$.

[001256] Step 2 - Tert-butyl (2-benzyl-4-fluoro-5.5-dimethyl-8-oxo-l-phenyl-6.l2.l5-trioxa-2.9- diazaheptadecan-l7-vDcarbamate


[001257] To a solution of A-[2-[2-(2-aminoethoxy)ethoxy] ethyl]-2-[3-(dibenzyl amino)-2-fluoro-l,l- dimethyl- propoxy]acetamide (920 mg, 1.60 mmol) in DCM (5 mL) was added $(BOC)_20$ (5.23 g, 24.0 mmol). The reaction mixture was stirred at rt for 14 h. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by reversed phase chromatography ($NH_3•H_2O$, 0.1%) to give the title compound (440 mg, 44% yield) as a colorless oil. ¾NMR (400MHz, CDCh) δ = 7.42 - 7.37 (m, 4H), 7.35 - 7.33 (m, 4H), 7.28 - 7.23 (m, 2H), 6.80 (s, 1H), 5.01 (s, 1H), 4.66 - 4.45 (m, 1H), 3.93 - 3.83 (m, 2H), 3.81 - 3.70 (m, 2H), 3.63 - 3.60

(d, *J* = 14.0 Hz, 2H), 3.60 - 3.44 (m, 10H), 3.32 - 3.31 (m, 2H), 2.91 - 2.67 (m, 2H), 1.46 (s, 9H), 1.10 (s, 6H). LC-MS (ESI$^+$) *m/z* 590.4 (M+H)$^+$.

[001258] Step 3 - Tert-butyl (T5-amino-l4-fluoro-l3.l3-dimethyl-l0-oxo-3.6.l2-trioxa-9-azapentadecyl) carbamate

[001259] To a solution of tert-butyl /V-[2-[2-[2-[[2-[3-(dibenzylamino)-2-fluoro-l,l-dimethyl-propoxy] acetyl] amino]ethoxy]ethoxy]ethyl]carbamate (440 mg, 746 umol) in MeOH (5 mL) was added $Pd(OH)_2/C$ (200 mg, 10 wt %) and Pd/C (200 mg, 10 wt %) under nitrogen atmosphere. The suspension was degassed and purged with hydrogen gas three times. The mixture was stirred under hydrogen atmosphere (55 psi pressure) at rt for 15 h. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (270 mg, 88% yield) as a yellow solid. LC-MS (ESI$^+$) *m/z* 410.2 (M+H)$^+$.

[001260] **Tert-butyl N-[2-[2-[2-(3-amino-2-fluoro-propoxy)-l-methyl-ethoxy] ethoxy] ethyl] carbamate [Intermediate HT)**



BT

[001261] Step 1 - 2-r2-r2-(2-Benzyloxy-l-methyl-ethoxy)ethoxy1ethyl1isoindoline-E3-dione

[001262] To a solution of 1-benzyloxypropan-2-ol (2.5 g, 15.0 mmol, synthesized via Step 1 of Intermediate BU) in DMF (40 mL) was added NaH (1.80 g, 45.12 mmol, 60% dispersion in mineral oil) and the mixture was stirred at rt for 30 min. Then 2-[2-(2-Bromoethoxy)ethyl]isoindoline-l,3-dione (4.48 g, 15.0 mmol, Intermediate AQ) was added to the mixture and the mixture was stirred at rt for an additional 12 h. On completion, the reaction mixture was quenched with H_20 (10 mL) and then concentrated *in vacuo* to give the title compound (5 g) as yellow solid. LC-MS (ESI^+) m/z 384. l$(M + H)^+$.

[001263] Step 2 - 2-r2-(2-Benzyloxy-l-methyl-ethoxy)ethoxy1ethanamine

[001264] To a solution of 2-[2-[2-(2-benzyloxy-l-methyl-ethoxy)ethoxy]ethyl]isoindoline-l,3-dione (10 g, 26.0 mmol) in EtOH (100 mL) was added $N_2H_4 \cdot H_20$ (6.66 g, 130 mmol, 6.47 mL, 98% solution), and the mixture was heated to 80 °C and stirred for 12 h. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (6 g) as a yellow oil. LC-MS (ESI^+) m/z 254. l$(M + H)^+$.

[001265] Step 3 - Tert-butyl N-r2-r2-(2-benzyloxy-l-methyl-ethoxy)ethoxy1ethyl1carbamate

[001266] To a solution of 2-[2-(2-benzyloxy-l-methyl-ethoxy)ethoxy]ethanamine (6 g, 23.6 mmol) in DCM (40 mL) was added Boc_20 (10.3 g, 47.3 mmol, 10.8 mL) and the mixture was stirred at rt for 2 h. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase chromatography ($NH_3 \cdot H_20$) to give the title compound (3 g, 32% yield over steps 1-3) as a white solid. LC-MS (ESI^+) m/z 376.2$(M + Na)^+$.

[001267] Step 4 - Tert-butyl N-r2-r2-(2-hvdroxy-l-methyl-ethoxy)ethoxy1ethyl1carbamate

[001268] To a solution of tert-butyl N-[2-[2-(2-benzyloxy-l-methyl-ethoxy)ethoxy]ethyl]carbamate (3 g, 8.49 mmol) in MeOH (30 mL) was added Pd/C (1.5 g, 10 wt %). The mixture was then heated to 40 °C and stirred under hydrogen atmosphere (50 psi pressure) for 18 h. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (2 g, 45% yield) as a colorless oil. ^1H NMR (400MHz, CDCh) δ 5.14 (s, 1H), 3.84 - 3.76 (m, 1H), 3.68 - 3.55 (m, 7H), 3.54 - 3.45 (m, 1H), 3.34 (, J = 4.8 Hz, 2H), 1.46 (s, 9H), 1.15 (d, J = 6.4 Hz, 3H).

[001269] Step_ 5_ _ 2-r2-r2-(Tert-butoxycarbonylamino)ethoxy1ethoxy1propyl methanesulfonate

[001270] **To a** solution of tert-butyl N-[2-[2-(2-hydroxy-l-methyl-

ethoxy)ethoxy]ethyl]carbamate (0.44 g, 1.67 mmol) in DCM (5 mL) was added TEA (507 mg, 5.01 mmol, 697 uL) and MsCl (287 mg, 2.51 mmol, 193 uL) dropwise at 0°C. The mixture was allowed to warm to rt and stirred for 3 h. On completion, the reaction mixture was diluted with water (10 mL) and extracted with DCM (2 χ 20 mL). The organic phase was dried over Na_2S0_4, filtered and the filtrate was concentrated *in vacuo* to give the title compound (0.56 g, 90% yield) as a yellow oil.


[001271] Step 6 - Tert-butyl N-r2424243Adibenzylamino)-2-fluoro-propoxy]-l-methyl-ethoxyl ethoxy] ethyl] carbamate

[001272] To a solution of 3-(dibenzylamino)-2-fluoro-propan-l-ol (298 mg, 1.09 mmol, Intermediate AH) inDMF (8 mL) was added NaH (131 mg, 3.28 mmol, 60% dispersion in mineral oil) and the mixture was stirred at rt for 30 min. Then 2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]propyl methanesulfonate (0.56 g, 1.64 mmol) was added to the mixture and the mixture was stirred at rt for an additional 12 h. On completion, the reaction mixture was quenched with water (0.5 mL) and then concentrated *in vacuo* to give a residue. The residue was purified by reversed phase chromatography (0.1% $NH_3•H_2O$) to give the title compound (130 mg, 22% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 5l9.4$(M + Na)^+$.

[001273] Step 7 - Tert-butyl N-r24242A3-amino42-fluoro-propoxy)-l-methyl-ethoxy]ethoxy]ethyl] carbamate

[001274] To a solution of tert-butyl N-[2-[2-[2-[3-(dibenzylamino)-2-fluoro-propoxy]-l-methyl-ethoxy]ethoxy] ethyl]carbamate (0.3 g, 578 umol) in MeOH (10 mL) and $NH_3•H_20$ (1 mL) was added $Pd(OH)_2$/C (0.2 g, 10 wt %) and Pd/C (0.2 g, 10 wt %), and the mixture was stirred at rt for 12 h under hydrogen atmosphere (15 psi pressure). On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (140 mg, 71% yield) as a colorless oil. LC-MS (ESI^+) *m/z* 339.2 $(M + H)^+$.

[001275] 2-[2-[2-[2-[3-Amino-2-fluoro-propoxylethoxy1ethoxy1propyl1isoindoline-l,3-dione [Intermediate BU)



[001276] Step 1 - 1-Benzyl oxypropan-2-ol

[001277] To a solution of L1AIH4 (7.56 g, 199 mmol) in anhydrous tetrahydrofuran (100 mL) was added a solution of 2-(benzyloxymethyl)oxirane (21.8 g, 132 mmol, 20.1 mL) in anhydrous tetrahydrofuran (300 mL) dropwise at 0 °C under nitrogen atmosphere. The mixture was then stirred for 1 hour. On completion, the reaction mixture was quenched with water (15 mL), then 15% sodium hydroxide solution (15 mL) was added, and the mixture was stirred for a further 15 minutes until no precipitate formed. Next, the inorganic salt precipitate was filtered off and the filter cake was washed with ethyl acetate (2 X 100 mL). The combine organic phase was dried over anhydrous magnesium sulfate, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (petroleum ether: ethyl acetate = 2:1) to give the title compound (21.3 g, 96% yield) as a colorless oil. ^{1}H NMR (400MHz, CDCb) δ 7.40 - 7.29 (m, 5H), 4.57 (s, 2H), 4.08 - 3.94 (m, 1H), 3.49 (dd, *J* = 3.2, 9.2 Hz, 1H), 3.30 (dd, *J* = 8.4, 9.2 Hz, 1H), 2.40 (d, *J* = 2.4 Hz, 1H), 1.16 (d, *J* = 6.4 Hz, 3H).

[001278] Step 2 - 2-r2-(2-Bromoethoxy)ethoxy1propoxym ethylbenzene

[001279] A mixture of 1-benzyl oxypropan-2-ol (4.00 g, 24.0 mmol), l-bromo-2-(2-bromoethoxy)ethane (27.9 g, 120 mmol, 15.0 mL), tetrabutylammonium bromide (7.76 g, 24.0 mmol), potassium iodide (3.99 g, 24.0 mmol) and sodium hydride (2.89 g, 72.2 mmol, 60% dispersion in mineral oil) in A',A-dimethylformamide (40 mL) was degassed and purged with nitrogen gas three times. Then the mixture was stirred at rt for 20 hours under nitrogen atmosphere. On completion, the reaction mixture was poured into ice water (100 mL) and extracted with ethyl acetate (3 X 100 mL). The combined organic phase was dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to get a residue. The residue was purified by column chromatography (petroleum ether: ethyl acetate = 6:1) to give the title compound (4.20 g, 55% yield) as a colorless oil. ¾NMR (400MHz, CDCh) δ 7.40 - 7.25 (m, 5H), 4.58 (s, 2H), 3.83 (t, *J* = 6.4 Hz, 2H), 3.75 - 3.66 (m, 5H), 3.56 - 3.42 (m, 4H), 1.20 (d, *J* = 6.4 Hz, 3H).

[001280] Step 3 - N.N-dibenzyl-3-r2-r2-(2-benzyloxy-l -methyl -ethoxy iethoxylethox y]-2-fluoro-propan-l- amine

[001281] To a solution of 3-(dibenzylamino)-2-fluoro-propan-l-ol (2.00 g, 7.32 mmol, Intermediate AH) in *N*,A'-dimethy1formamide (40 mL) was added sodium hydride (878 mg, 21.9 mmol, 60% dispersion in mineral oil) at 0 °C and the reaction was stirred for 30 minutes. Then 2-[2-(2-bromoethoxy)ethoxy]propoxy -methylbenzene (2.50 g, 7.88 mmol) was added and the reaction mixture was then allowed to warm to rt and stirred for a further 15.5 hours. On completion, the reaction mixture was quenched with ice water (120 mL) and extracted with ethyl acetate (3 X 50 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to get a residue. The residue was purified by column chromatography (petroleum ether: ethyl acetate = 4:1) to give the title compound (2.60 g, 69% yield) as a colorless oil. ^{1}H NMR (400MHz, CDCh) δ 7.40 - 7.34 (m, 15H), 4.91 - 4.71 (m, 1H), 4.59 (d, *J* = 2.4 Hz, 2H), 3.74 - 3.60 (m, 16H), 3.48 - 3.42 (m, 1H), 2.81 - 2.72 (m, 2H), 1.21 (d, *J* = 6.4 Hz, 3H).

[001282] Step 4 - 2-r2-r2-(3-Amino-2-fluoro-propoxy)ethoxy1ethoxy1propan-l-ol

[001283] To a solution of A',A'-dibenzyl-3-[2-[2-(2-benzyloxy- l-methyl - ethoxy)ethoxy]ethoxy]-2-fluoro-propan- l-amine (2.30 g, 4.51 mmol) in methanol (30 mL) was added Pd/C (1.00 g, 10 wt %) and Pd(OH)$_2$/C (1.00 g, 10 wt %) under nitrogen gas atmosphere. The suspension was degassed under vacuum and purged with hydrogen gas several times. The mixture was stirred under hydrogen gas (50 psi pressure) at rt for 18 h. On completion, the reaction

mixture was filtered through a pad of celite and the pad and the filter cake was washed with methanol (3 X 10 mL). The filtration was concentrated *in vacuo* to give the crude product (930 mg, 86% yield) as a colorless oil. LC-MS (ESI)$^+$ *m/z* 240.0. (M+H)$^+$.

[001284] Step 5 - Tert-butyl N-r2-fluoro-3-r2-r2-(2-hvdroxy-l-methyl-ethoxyiethoxylethoxylpropyHcarbamate

[001285] To a solution of 2-[2-[2-(3-amino-2-fluoro-propoxy)ethoxy]ethoxy]propan-l-ol (850 mg, 3.55 mmol) in dichloromethane (30 mL) was added Boc_20 (852 mg, 3.91 mmol, 897 uL) dropwise. The mixture was stirred at rt for 2 hours. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 0:1) to give the title compound (930 mg, 77% yield) as a colorless gum. ^{1}H NMR (400MHz, CDCh) δ 5.28 (m, 1H), 4.83 - 4.60 (m, 1H), 3.87 - 3.79 (m, 1H), 3.73 - 3.58 (m, 11H), 3.50 - 3.36 (m, 3H), 3.13 (br s, 1H), 1.45 (s, 9H), 1.13 (d, 7 = 6.4 Hz, 3H).

[001286] Step 6 - 2-[2-[2-[3-(Tert-butoxycarbonylamino)-2-fluoro-propoxylethoxylethoxylpropyl methane- sulfonate

[001287] To a solution of tert-butyl A-[2-fluoro-3-[2-[2-(2-hydroxy- l-methyl-ethoxy)ethoxy]ethoxy]propyl]- carbamate (880 mg, 2.59 mmol) in dichloromethane (30 mL) was added triethylamine (787 mg, 7.78 mmol, 1.08 mL) and the reaction mixture was cooled to 0 °C. Then methyl sulfonyl chloride (445 mg, 3.89 mmol, 301 uL) was added dropwise at 0 °C. Then, the mixture was allowed to warm to rt and stirred for 30 minutes. On completion, the reaction mixture was quenched with ice water (30 mL), The organic phase was separated, washed with citric acid (30 mL), then dried over anhydrous magnesium, filtered and concentrated *in vacuo* to give the title compound (1.00 g, 92% yield) as a colorless gum. ^{1}H NMR (400MHz, CDCh) δ 4.97 (m, 1H), 4.80 - 4.60 (m, 1H), 4.24 - 4.12 (m, 2H), 3.82 - 3.61 (m, 11H), 3.47 - 3.28 (m, 2H), 3.08 (s, 3H), 1.45 (s, 9H), 1.22 (d, J = 6.4 Hz, 3H).

[001288] Step 7 - Tert-butyl N-r3-r2-r2-r2-(T.3-dioxoisoindolin-2-vD-l-methyl-ethoxy] ethoxy] ethoxy] -2- fluoro-propyllcarbamate


[001289] To a solution of 2-[2-[2-[3-(tert-butoxycarbonylamino)-2-fluoro-propoxy]ethoxy]ethoxy]propyl methanesulfonate (1.00 g, 2.40 mmol) in A(A'-dimethylformamide (20 mL) was added (l,3-dioxoiso- indolin-2-yl)potassium (532 mg, 2.87 mmol). The mixture then heated to 80 °C and stirred for 16 h. On completion, the reaction mixture was concentrated *in*

vacuo to get a residue. The residue was diluted in ice water (20 mL) and extracted with ethyl acetate (3 X 15 mL). The organic phase was collected, dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 3:1) to give the title compound (730 mg, 65% yield) as a colorless gum. ¾NMR (400MHz, CDCh) δ 7.78 (m, 2H), 7.65 (m, 2H), 4.91 (m, 1H), 4.70 - 4.49 (m, 1H), 3.81 - 3.70 (m, 2H), 3.66 - 3.42 (m, 12H), 3.30 - 3.18 (m, 1H), 1.37 (s, 9H), 1.14 (d, J = 6.4 Hz, 3H).

[001290] Step 8 - 2-r2-r2-r2-(3-Amino-2-fluoro-propoxy)ethoxy1ethoxy1propyl1isoindoline-L3-dione

[001291] To a solution of tert-butyl N-[3-[2-[2-[2-(l,3-dioxoisoindolin-2-yl)-l-methyl-ethoxy]ethoxy]ethoxy]- 2-fluoro-propyl]carbamate (350 mg, 747 umol) in dichloromethane (14 mL) was added a solution of hydrochloric acid in dioxane (4 M, 14 mL). The mixture was stirred at rt for 30 minutes. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (300 mg, 99% yield, hydrochloride salt) as a colorless gum. LC-MS $(ESI)^+$ *m/z* 369.1. $(M+H)^+$.

[001292] **Tert-butyl N-[3-[3-(3-amino-2-f uoro-propoxy)propoxy]propyl]carbamate (Intermediate BV)**



BV

[001293] Step 1 - 3-(3-Hvdroxypropoxy)propanenitrile

[001294] To a mixture of propane- 1,3-diol (28.7 g, 377 mmol, 27.3 mL) and prop-2-enenitrile (20.0 g, 377 mmol, 25.0 mL) was added NaOMe (204 mg, 3.77 mmol). The mixture was stirred at

rt for 20 h. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by silica column chromatography to give the title compound (20.3 g, 41% yield) as a colorless oil. ^{1}H NMR (400MHz, CDCh) δ 3.70 (t, *J* = 6.0 Hz, 2H), 3.65 - 3.57 (m, 4H), 2.55 (t, *J* = 6.4 Hz, 2H), 1.99 (s, 1H), 1.79 (m, 2H).

[001295] Step 2 - Tert-butyl N-r3-(3-hvdroxypropoxy)propyl1carbamate

[001296] To a solution of 3-(3-hydroxypropoxy)propanenitrile (5.00 g, 38.7 mmol) in MeOH (50 mL) was added Raney-Ni (1.00 g) and $(Boc)_20$ (12.7 g, 13.3 mL) under nitrogen atmosphere. The suspension was degassed and purged with hydrogen gas three times. The mixture was stirred under hydrogen atmosphere (50 psi pressure) at rt for 72 h. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by silica column chromatography to give the title compound (6.5 g, 72% yield) as a colorless oil. ^{1}H NMR (400MHz, CDCh) δ 4.86 (s, 1H), 3.79 (t, *J* = 5.6 Hz, 2H), 3.60 (t, *J* = 6.0 Hz, 2H), 3.50 (t, *J* = 6.0 Hz, 2H), 3.30 - 3.18 (m, 2H), 2.63 (s, 1H), 1.87 - 1.70 (m, 4H), 1.45 (s, 9H).

[001297] Step 3 - 3-r3-(Tert-butoxycarbonylamino)propoxy1propyl methanesulfonate

[001298] To a solution of *tc/t*-butyl A-[3-(3-hydroxypropoxy)propyl]carbamate (1.20 g, 5.14 mmol) in DCM (10 mL) was added Et_3N (1.56 g, 2.15 mL, 15.4 mmol) and MsCl (884 mg, 7.72 mmol). The mixture was stirred at rt for 2 h. On completion, the reaction was quenched with water (10 mL) and extracted with DCM (2 X 30 mL). The organic layer was washed with brine (20 mL), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (1.60 g, 99% yield) as a yellow oil. ¾NMR (400MHz, CDCh) δ 4.88 - 4.78 (s, 1H), 4.36 (t, *J* = 6.0 Hz, 2H), 3.52 (m, 4H), 3.27 - 3.19 (m, 2H), 3.03 (s, 3H), 2.01 (t, *j* = 6.0 Hz, 2H), 1.76 (t, *j* = 6.0 Hz, 2H), 1.45 (s, 9H).

[001299] Step 4 - Tert-butyl N-r3-r3-(3-amino-2-fluoro-propoxy)propoxy1propyl1carbamate


[001300] To a solution of 3-(dibenzylamino)-2-fluoro-propan-l-ol (1.00 g, 3.66 mmol, Intermediate AH) in DMF (20 mL) was added NaH (439 mg, 11.0 mmol, 60% dispersion in mineral oil) and the reaction mixture was stirred for 30 minutes at rt. Then, 3-[3-{*tert*-butoxycarbonylamino) propoxy]propyl methanesulfonate (1.48 g, 4.76 mmol) was added and the mixture was stirred at rt for an additional 12 h. On completion, the mixture was quenched with saturated M L Cl solution and extracted with EA (3 X 50 mL). The organic layer was dried over Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by reversed phase chromatography (0.1% NH3Ή 20 in water) to give the title compound (800 mg, 45% yield). LC-

MS (ESI+) *m/z* 489.4 $(M+H)^+$.

[001301] Step 5 - Tert-butyl N-r3-r3-(3-amino-2-fluoro-propoxy)propoxy1propyl1carbamate

[001302] To a solution of *tert*-butyl *N*-[3-[3-[3-(dibenzylamino)-2-fluoro-propoxy]propoxy]propyl]carbamate (600 mg, 1.23 mmol) in MeOH (10 mL) was added Pd/C (200 mg, 10 wt %) and $Pd(OH)_2/C$ (200 mg, 10 wt %) under nitrogen atmosphere. The suspension was degassed and purged with hydrogen gas three times. The mixture was stirred under hydrogen atmosphere (50 psi pressure) at rt for 18 h. On completion, the mixture was filtered and concentrated *in vacuo* to give the title compound (370 mg, 98% yield) as a white gum. LC-MS (ESI+) *m/z* 309.0 $(M+H)^+$.

[001303] **Methyl 2-[2-[2-[2-[2-r2-(3-amino-2-fluoro-propoxylethoxy] ethoxy] ethoxy] ethoxy] ethoxy] acetate (Intermediate BW)**



BW

[001304] Step 1 - Ethyl 2-[2-[2-[2-[2-(2-hydroxyethoxyiethoxyl ethoxy]ethoxy]ethoxy]acetate

[001305] To a mixture 2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethanol (14.0 g, 58.7 mmol, CAS# 4792-15-8) and BF_3•Et_20 (833 mg, 5.88 mmol) in DCM (200 mL) was added dropwise ethyl 2-diazoacetate (6.70 g, 58.7 mmol) in DCM (100 mL) at rt under nitrogen atmosphere. The reaction mixture was stirred at rt for 12 hours. On completion, the reaction mixture was concentrated *in vacuo*. The residue was purified by flash chromatography (DCM/MeOH = 100/1) to give the title compound (5.00 g, 26% yield) as a colorless oil. ^{1}H NMR (400MHz, CDCh) δ 4.20 (q, *J* = 7.2 Hz, 2H), 4.14 (s, 2H), 3.75 - 3.62 (m, 18H), 3.62 - 3.58 (m, 2H), 2.69 (s, 1H), 1.27 (t, *j* = 7.2 Hz, 3H).

[001306] Step_ _____2_ _____-_ _____Ethyl_ _____2-[2-[2-[2-[2-(2-methylsulfonyloxyethoxyiethoxyl ethoxy]ethoxy]ethoxy]acetate

[001307] To a mixture of ethyl 2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]acetate (5.00 g, 15.4 mmol) in DCM (50 mL) was added TEA (4.68 g, 46.2 mmol) and the reaction was cooled to 0 °C. Then MsCl (2.12 g, 18.4 mmol) was added dropwise at 0 °C and the reaction mixture was allowed to warm to rt and stirred for 3 hours. On completion, the reaction mixture was diluted with water (30 mL) and extracted with DCM (3 X 50 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (6.60 g, 95% yield) as a light yellow oil. 'H NMR (400MHz, CDCh) δ 4.39 - 4.35 (m, 2H), 4.20 (q, *J* = 7.2 Hz, 2H), 4.14 (s, 2H), 3.79 - 3.60 (m, 18H), 3.08 (s, 3H), 1.27 (t, 7 = 7.2 Hz, 3H).

[001308] Step_ ___3_ ___-_ ___2-r2-r2-r2-r2-r2-r3-(Dibenzylamino)-2-fluoro-propoxylethoxylethoxylethoxylethoxylethoxyl acetic acid

[001309] To a mixture of 3-(dibenzylamino)-2-fluoro-propan-l-ol (67.9 mg, 248 umol, Intermediate AH) in DMF (4 mL) was added NaH (14.9 mg, 372 umol, 60% dispersion in mineral oil) at 0 °C. Then, the reaction mixture was allowed to warm to rt and stirred for 0.5 hour. Then ethyl 2-[2-[2-[2-[2-(2-methylsulfonyloxyethoxy)ethoxy]ethoxy]ethoxy] ethoxy]acetate (100 mg, 248 umol) was added and the reaction mixture was stirred at rt for an additional 12 hours. On completion, the reaction mixture was concentrated *in vacuo*. The residue was diluted with water (10 mL) and extracted with EA (2 X 20 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by prep-TLC (DCM/MeOH= 10/1) to give the title compound (64.0 mg, 46% yield) as a colorless oil. LC-MS $(ESI)^+$ *m/z* 552.2. $(M+H)^+$.


[001310] Step 4 . Methyl 2-r2-r2-r2-r2-r2-r3-(dibenzylamino)-2-fluoro-propoxylethoxylethoxylethoxylethoxyl ethoxy] acetate

[001311] To a mixture of 2-[2-[2-[2-[2-[2-[3-(dibenzylamino)-2-fluoro-propoxy]ethoxy]ethoxy]ethoxy]ethoxy] ethoxy]acetic acid (2. 10 g, 3.81 mmol) in MeOH (20 mL) was added $SOCl_2$ (3.28 g, 27.5 mmol). The reaction mixture was stirred at rt for 38 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give a residue. The residue was diluted with water (10 mL) and extracted with DCM (4 X 30 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel column chromatography to give the title compound (550 mg, 25% yield) as a light yellow oil. ^1H NMR (400MHz, CDCb) δ 7.30 - 7.21 (m, 8H), 7.18 - 7.13 (m, 2H), 4.10 (s, 2H), 3.69 - 3.60 (m, 8H), 3.60 - 3.51 (m, 22H), 2.68 (d, *J* = 5.6 Hz, 1H), 2.63 (d, *J* = 5.2 Hz, 1H).

[001312] Step 5 : Methyl 2-r2-r2-r2-r2-r2-(3-amino-2-fluoro-propoxylethoxylethoxylethoxylethoxyl ethoxy] acetate

[001313] To a mixture of methyl 2-[2-[2-[2-[2-[2-[3-(dibenzylamino)-2-fluoro-propoxy]ethoxy]ethoxy]ethoxy] ethoxy]ethoxy]acetate (10.0 mg, 17.6 umol) in EtOH (1 mL) was added TFA (15.4 mg, 10.0 uL, 135 umol) and $Pd(OH)_2/C$ (20.0 mg, 10 wt %) under hydrogen atmosphere (15 psi pressure). The reaction mixture was stirred at rt for 12 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo.* The residue was diluted with water (8 mL) and extracted with EA (3 X 15 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (6.00 mg, 88% yield) as a light yellow oil. LC-MS $(ESI)^+$ *m/z* 386.2. $(M+H)^+$.

[001314] Methyl 2-[2-[2-[3-amino-2-fluoropropoxy)ethoxy)ethoxy)acetate [Intermediate BX)



BX

[001315] Step **1** - 2-r2-r2-r3-(Oibenzylamino)-2-fluoro-propoxy1ethoxy1ethoxy1acetic acid

[001316] To a solution of 3-(dibenzylamino)-2-fluoro-propan-l-ol (1.5 g, 5.49 mmol, Intermediate AH) in DMF (20 mL) was added NaH (658 mg, 60% dispersion in mineral oil) at rt. After stirred for 30 minutes, ethyl 2-[2-(2-methylsulfonyloxyethoxy)ethoxy]acetate (1.93 g, 7.13 mmol, synthesized via Steps 1-2 of Intermediate BM) was added and the mixture was stirred at rt for 12 h. On completion, the mixture was poured into water (60 mL) and extracted with EA (3 X 50 mL). The organic layer was washed with brine (20 mL), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (2.00 g, 40% yield). LC-MS (ESI^+) *m/z* 420. 1 $(M+H)^+$.

[001317] Step 2 - Methyl 2-r2-r2-r3-(dibenzylamino)-2-fluoro-propoxy] ethoxy] ethoxy] acetate


[001318] A mixture of 2-[2-[2-[3-(dibenzylamino)-2-fluoro-propoxy]ethoxy]ethoxy]acetic acid (2.00 g, 4.77 mmol), SOCL (24.6 g, 15 mL) and MeOH (20 mL) was stirred at 70 °C for 1 hour under nitrogen atmosphere. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by silica gel chromatography (DCM: MeOH = 100 : 1 to 20 : 1) to give the title compound (900 mg, 39% yield) as a red oil. LC-MS (ESI^+) *m/z* 434.1 $(M+H)^+$.

[001319] Step 3 - Methyl 2-(2-(2-(3-amino-2-fluoropropoxy)ethoxy)ethoxy)acetate

[001320] To a solution of methyl 2-[2-[2-[3-(dibenzylamino)-2-fluoro-propoxy]ethoxy]ethoxy]acetate (1.00 g, 2.3 1 mmol) in MeOH (20 mL) was added $Pd(OH)_2$/C (100 mg, 10 wt %), Pd/C (100 mg, 10 wt %) and acetic acid (0.1 mL) under nitrogen atmosphere. The suspension was degassed and purged with hydrogen gas three times. The mixture was stirred under hydrogen atmosphere (50 psi pressure) at rt for 24 hrs. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was dissolved in DCM (10 mL) and HC1 (4M in EA, 5 mL) was added. The mixture was triturated with MTBE (100 mL) and the white

solid was collected to give the title compound (400 mg, 60% yield). LC-MS (ESI+) *m/z* 254.0 $(M+H)^+$.

[001321] **6-[l,3-Benzothiazol-6-ylaminol-4-[cvclopropylaminolpyridine-3-carboxylic acid [Intermediate BY)**



BY

[001322] Step 1 - Ethyl 6-chloro-4-(cvclopropylamino)pyridine-3-carboxylate

[001323] To a mixture of ethyl 4,6-dichloropyridine-3-carboxylate (30.0 g, 136 mmol) in DMA (300 mL) was added DIPEA (17.6 g, 136 mmol) and cyclopropanamine (8.56 g, 149 mmol). The reaction mixture was heated to 90 °C and stirred for 3 h. On completion, the reaction mixture was quenched with crushed ice. The resulting slurry was stirred and filtered. The filter cake was purified by flash chromatography (PE/EA= 3/l)to give the title compound (28.4 g, 86% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-r¾) δ 8.53 (s, 1H), 8.08 (s, 1H), 7.02 (s, 1H), 4.30 (q, *J* = 7.2 Hz, 2H), 2.63 - 2.57 (m, 1H), 1.30 (t, *j* = 7.2 Hz, 3H), 0.87 - 0.84 (m, 2H), 0.58 - 0.56 (m, 2H).

[001324] Step 2 - Ethyl 6-(T.3-benzothiazol-6-ylaminoV4-(cvclopropylamino)pyridine-3-carboxylate


[001325] To a solution of ethyl 6-chloro-4-(cyclopropylamino)pyridine-3-carboxylate (5.00 g, 20.7 mmol) in a mixed solvent of dioxane (30.0 mL) and H_20 (5.00 mL) was added 1,3-benzothiazol-6-amine (3.12 g, 20.7 mmol), Xantphos (4.81 g, 8.31 mmol) and Na_2C0_3 (8.81 g, 83.1 mmol), followed by $Pd_2(dba)_3$ (7.61 g, 8.31 mmol) to the reaction mixture under nitrogen. The reaction mixture was then heated at 115 °C for 12 h. On completion, the reaction mixture was diluted with water (100 mL) and extracted with DCM (2 X 100 mL). The organic layer was dried

with Na_2S0_4, filtered and concentrated *in vacuo*. The residue was purified by silica gel chromatography (DCM: MeOH = 100: 1) to give the title compound (0.60 g, 6% yield) as a white solid. ^1H NMR (400MHz, CDCh) δ 8.91 (s, 1H), 8.68 (s, 1H), 8.13 (d, *J* = 2.0 Hz, 1H), 8.09 (d, *J* = 8.8 Hz, 2H), 7.43 (dd, 7 = 2.0, 8.8 Hz, 1H), 6.89 - 6.84 (m, 1H), 6.46 (s, 1H), 4.30 (q, *J* = 7.2 Hz, 2H), 2.45 - 2.36 (m, 1H), 1.38 (t, *J* = 7.2 Hz, 3H), 0.80 - 0.74 (m, 2H), 0.62 - 0.57 (m, 2H).

[001326] Step 3 - 6-(L3-Benzothiazol-6-ylamino)-4-(cvclopropylamino)pyridine-3-carboxylic acid

[001327] To a solution of ethyl 6-(l,3-benzothiazol-6-ylamino)-4-(cyclopropylamino)pyridine-3-carboxylate (0.43 g, 1.21 mmol) in a mixed solvent of H_20 (1.00 mL) and THF (3.00 mL) was added $LiOH•H_20$ (152 mg, 3.64 mmol). The reaction mixture was stirred at 40 °C for 24 h. On completion, the reaction was acidified with 2 N HC1 until pH = 4. The reaction mixture was then concentrated *in vacuo* and lyophilized to give the title compound (500 mg, 79% yield, HC1 salt) as a white solid. LC-MS (ESI^+) *m/z* 327.0 $(M+H)^+$.

[001328] **6-[[5-Cyano-3-fluoro-2-pyridyDamino1-4-[cyclopropylamino)pyridine-3-carboxylic acid [Intermediate BZ)**



BZ

[001329] Step 1 - 6-Amino-5-fluoro-pyridine-3-carbonitrile

[001330] To a solution of 5-bromo-3-fluoro-pyridin-2-amine (5.00 g, 26.1 mmol), potassium ferrocyanide (3.86 g, 10.4 mmol) and $Pd(PPh_{3)4}$ (1.51 g, 1.31 mmol) in a mixed solvent of t-BuOH (40.0 mL) and H_20 (40.0 mL) was added DBU (996 mg, 6.54 mmol, 986 uL) under nitrogen. The reaction mixture was heated to 85 °C and stirred for 16 h. On completion, the mixture was diluted with water (20.0 mL) and extracted with EA (3 X 20 mL). The combined organic layer was dried

over anhydrous Na_2S0_4, filtered and concentrated *in vacuo*. The residue was purified by silica gel chromatography (PE: EA= 5:1) to give the title compound (2.50 g, 69% yield) as a yellow solid. ¾NMR (400MHz, DMSO-^e) δ 8.23 (s, 1H), 7.85 (dd, *J* = 1.6, 11.6 Hz, 1H), 7.38 (s, 2H).


[001331] Step_ _2_ _-_ _Ethyl_ _6-i(5-cvano-3-fluoro-2-pyridvnaminol -4-(cvclopropylamino)pyridine-3-carboxylate

[001332] To a solution of 6-amino-5-fluoro-pyridine-3-carbonitrile (2.50 g, 18.2 mmol), ethyl 6-chloro-4-(cyclopropylamino)pyridine-3-carboxylate (4.39 g, 18.2 mmol, synthesized via Step 1 of Intermediate BY) and Na_2C0_3 (7.73 g, 72.9 mmol) in a mixed solvent of dioxane (40.0 mL) and H_20 (8.00 mL) was added Xantphos (527 mg, 911 umol) and $Pd_2(dba)_3$ (834 mg, 911 umol) under nitrogen. The reaction mixture was then heated to H5°C and stirred for 16 h. On completion, the mixture was diluted with a mixed solvent of DCM and MeOH (80.0 mL, 10:1), and stirred for 1 h, then filtered. The solid was washed with water (50 mL) and triturated with a mixed solvent of DCM and MeOH (30 mL, 10: 1) to give the title compound (2.20 g, 35% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-^e) δ 9.83 (s, 1H), 8.62 (d, *J* = 2.0 Hz, 1H), 8.56 (s, 1H), 8.21 (dd, *J* = 1.6, 11.2 Hz, 1H), 8.05 - 7.98 (m, 2H), 4.27 (q, *J* = 7.2 Hz, 2H), 2.55 - 2.54 (m, 1H), 1.31 (t, *J* = 7.2 Hz, 3H), 0.95 - 0.86 (m, 2H), 0.60 - 0.55 (m, 2H).

[001333] Step 3 - 6-r(5-Cvano-3-fluoro-2-pyridvDamino1-4-(cvclopropylamino)pyridine-3-carboxylic acid

[001334] To a solution of ethyl 6-[(5-cyano-3-fluoro-2-pyridyl)amino]-4-(cyclopropylamino)pyridine-3- carboxylate (500 mg, 1.46 mmol) in a mixed solvent of THF (3.00 mL), MeOH (1.00 mL) and H_20 (1.00 mL) was added $LiOH•H_20$ (307 mg, 7.32 mmol). The reaction mixture was stirred at 45 °C for 2 hrs. On completion, the mixture was acidified with 1N HC1 until the pH=3. The mixture was lyophilized to give the title compound (800 mg, 80% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 314.0 $(M+H)^+$.

[001335] 2-[2-[2,6-Dioxo-3-piperidvB-l,3-dioxo-isoindolin-4-yl1oxyacetic _ acid [Intermediate_CA)



CA

[001336] Step 1 - 2-(2,6-Dioxo-3-piperidyl)-4-hydroxy-isoindoline-1,3-dione

[001337] To a solution of 4-hydroxyisobenzofuran-1,3-dione (20.0 g, 122 mmol) in pyridine (100 mL) was added 3-aminopiperidine-2,6- dione (20.0 g, 122 mmol, HC1 salt). The reaction mixture was stirred at 110 °C for 16 h. On completion, the mixture was concentrated *in vacuo.* The residue was diluted with water (500 mL) and stirred for 16 h. The mixture was then filtered and the filter cake was dried *in vacuo* to give the title compound (24.8 g, 74% yield) as a white solid. LC-MS (ESI^+) *m/z* 297.0 $(M+Na)^+$.

[001338] Step 2 - Tert-butyl 2-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]oxyacetate


[001339] To a mixture of 2-(2,6-dioxo-3-piperidyl)-4-hydroxy-isoindoline-1,3-dione (20 g, 72.9 mmol) and tert-butyl 2-chloroacetate (16.5 g, 109 mmol) in DMF (50 mL) was added Ag_20 (16.9 g, 72.9 mmol), K_2CO_3 (25.2 g, 182 mmol) and KI (1.21 g, 7.29 mmol). The reaction mixture was stirred at rt for 12 h. On completion, the reaction mixture was filtered and the filtrate was diluted with H_20 (40 mL) and extracted with DCM (2 X 200 mL). The combined organic layer was dried over Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by silica gel chromatography to give the title compound (2.40 g, 8.5% yield) as a white solid. ^1H NMR (400MHz, DMSO-i¾) δ 11.13 (s, 1H), 7.84 - 7.78 (m, 1H), 7.49 (d, *J* = 7.2 Hz, 1H), 7.38 (d, *J* = 8.8 Hz, 1H), 5.12 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.98 (s, 2H), 2.60 - 2.54 (m, 1H), 2.52 - 2.50 (m, 2H), 2.10 - 2.01 (m, 1H), 1.43 (s, 9H).

[001340] Step 3 - 2-[2-(2,6-Dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]oxyacetic acid

[001341] To a mixture of tert-butyl 2-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]oxyacetate (2.40 g, 6.18 mmol) in DCM (10 mL) was added TFA (61.5 g, 539 mmol). Then the

reaction mixture was stirred at rt for 12 h. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (3.10 g, 90% yield, TFA salt) as a white solid. ^{1}H NMR (400MHz, DMSO-£¾) δ 11.13 (S, 1H), 7.80 (dd, *J* = 7.2, 8.4 Hz, 1H), 7.48 (d, *J* = 7.2 Hz, 1H), 7.40 (d, 7 = 8.4 Hz, 1H), 5.11 (dd, *J* = 5.2, 12.8 Hz, 1H), 5.00 (s, 2H), 2.95 - 2.84 (m, 1H), 2.64 - 2.53 (m, 2H), 2.11 - 1.98 (m, 1H); LC-MS (ESI$^+$) *m/z* 332.9 (M+H)$^+$.

[001342] **[3S,4S.,5S)-4-Ethyl-3-fluoro-5-[hvdroxymethv0pyrrolidin-2-one [Intermediate_ CB1**



[001343] Step 1 - (S)-3,3-Dimethyltetrahvdropyrrolo[l,2-c1oxazol-5(3H)-one

[001344] To a mixture of (5S)-5-(hydroxymethyl)pyrrolidin-2-one (200 g, 1.74 mol) and 2,2-dimethoxypropane (517 g, 4.97 mol) in toluene (2.4 L) was added TsOHH$_2$0 (13.2 g, 69.5 mmol). The reaction mixture was then stirred at 120 °C for 16 h. On completion, the reaction mixture was concentrated *in vacuo* and diluted with EA (5L). The mixture was washed with 1N NaOH solution (2L) and extracted with EA (8 x 1L). The organic layer was dried over Na$_2$S0$_4$, filtered and concentrated *in vacuo*. The residue was triturated with PE (200 mL) to give the title compound (200 g, 74% yield) as a black brown crystal. ^{1}H NMR (400MHz, CDCh) δ 4.29 - 4.19 (m, 1H), 4.05 (dd, *J* = 5.6, 8.4 Hz, 1H), 3.42 (t, *J* = 8.4 Hz, 1H), 2.81 - 2.71 (m, 1H), 2.58 - 2.44 (m, 1H), 2.21 - 2.08 (m, 1H), 1.82 - 1.66 (m, 1H), 1.68 (s, 3H), 1.47 (s, 3H).

[001345] Step 2 - (S)-3.3-Dimethyl-5-((trimethylsilyl)oxy)-l,3,7,7a-tetrahydropyrr lo[1.2-cloxazole

[001346] To a solution of **DIPA** (119 g, 1.18 mol) in THF (1.3 mL) was added n-BuLi (2.5 M, 433 mL) at -25 °C. The reaction mixture was stirred for 30 min. Then, the reaction mixture was cooled to -70 °C. **A** solution of (S)-3,3-dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3//)-one (140 g, 902 mmol) in THF (500 mL) was added dropwise. The reaction mixture was stirred at -60 °C for 5 min. Then, TMSC1 (127 g, 1.17 mmol) was added dropwise at -60 °C. The reaction mixture was allowed to warm to -10 °C and stirred for 25 min. On completion, the reaction mixture was concentrated *in vacuo.* The residue was triturated with hexane (1 L), filtered and the filtrate was concentrated *in vacuo* to give the title compound (140 g, 68% yield) as a colorless oil. The product was unstable and was used for the next step directly without purification.

[001347] Step 3 (7aS)-3.3-dimethyl-L7a-dihvdropyrrolon .2-c1oxazol-5-one

[001348] To a mixture of (S)-3,3-dimethyl-5-((trimethylsilyl)oxy)-l,3,7,7a-tetrahydropyrrolo[l,2-c]oxazole (140 g, 616 mmol) and allyl methyl carbonate (107 g, 923 mmol) in THF (1.4 L) was added $Pd(OAc)_2$ (41.5 g, 185 mmol). The reaction mixture was stirred at 65 °C for 8 h under nitrogen. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by silica gel chromatography (PE: EA = 5:1) to give the title compound (30 g, 32% yield) as a colorless oil. ^{1}H NMR (400MHz, CDCh) δ 7.00 (d, *J* = 5.6 Hz, 1H), 6.04 (d, *J* = 5.6 Hz, 1H), 4.67 - 4.49 (m, 1H), 4.09 - 4.04 (m, 1H), 3.27 (t, *J* = 8.8 Hz, 1H), 1.61 (s, 3H), 1.50 (s, 3H).

[001349] Step 4 - (7R.7aS)-7-Ethyl-3.3-dimethyltetrahvdropyrrolor **i**.2-c1oxazol-5(3H)-one

[001350] To a mixture of bromocopper-methylsulfanylmethane (14.1 g, 68.6 mmol) in THF (200 mL) was added EtMgBr (3 M, 45.7 mL) at -10 °C dropwise. Then, the reaction mixture was cooled to -70 °C and TMSC1 (7.45 g, 68.6 mmol) was added dropwise over 15 min. The reaction mixture was then stirred at -70 °C for an additional 15 min. Then a solution of (7aS)-3,3-dimethyl-l,7a-dihydropyrrolo[l,2-c]oxazol-5-one (6.00 g, 27.4 mmol) in THF (20 mL) was added dropwise over 10 min. Then the reaction mixture was stirred at 0 °C for 20 min. On completion, the reaction mixture was poured into cool saturated NH_4Cl solution (100 mL) and extracted with EA (3 X 500 mL). The combined layer was dried over Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by silica gel chromatography (PE: EA = 3:1) to give the title compound (3 g, 60% yield). ^{1}HNMR (400MHz, CDCh) δ 4.34 (td, *J* = 6.4, 9.6 Hz, 1H), 3.90 (dd, *J* = 6.4, 8.4 Hz, 1H), 3.72 (dd, *J* = 8.4, 9.6 Hz, 1H), 2.91 (dd, 7 = 8.0, 16.8 Hz, lH), 2.3l (dd, 7 = L6, 16.8 Hz, 1H), 2.28 - 2.18 (m, 1H), 1.64 (s, 3H), 1.55 - 1.49 (m, 1H), 1.48 (s, 3H), 1.37 - 1.27 (m, 1H), 0.91 (t, 7 = 7.2

Hz, 3H).

[001351] Step 5 - (6S.7S.7aS)-7-Ethyl-6-f1uoro-3.3-dimethyltetrahvdropyrrolor i2 - c]oxazol-5(3H)- one

[001352] A solution of (7R,7aS)-7-ethyl-3,3-dimethyl-l,6,7,7a-tetrahydropyrrolo[l,2-c]oxazol-5-one (2.5 g, 13.6 mmol) in THF (10 mL) was treated at -78 °C with LiHMDS (1 M, 15.0 mL) and the mixture was kept for 0.5 h at -78 °C. A solution of NFSI (5.60 g, 17.8 mmol) in THF (10 mL) was added slowly. The mixture was kept at approximately -78° C for 0.5 h. On completion, the precipitated solid was filtered and washed with THF (20 mL). The filtrate was concentrated *in vacuo* to an oily residue. The oily residue was purified by silica gel chromatography (PE: EA = 10:1). Then, the residue was repurified by reversed phase chromatography (0.1% FA) to give the title compound (575 mg, 21% yield) as a colorless oil. ^{1}H NMR (400MHz, CD_3CN) δ 4.89 - 4.73 (m, 1H), 4.42 (td, *J* = 6.4, 10.4 Hz, 1H), 3.95 (dd, *J* = 5.6, 8.4 Hz, 1H), 3.59 (dd, *J* = 8.4, 10.4 Hz, 1H), 2.49 - 2.33 (m, 1H), 1.59 (s, 3H), 1.58 - 1.51 (m, 1H), 1.45 (s, 3H), 1.44 - 1.37 (m, 1H), 1.00 (t, *J* = 7.2 Hz, 3H).


[001353] Step 6 - (6S.7S.7aS)-7-Eethyl-6-f1uoro-3.3-dimethyltetrahvdropyrrolor i2 - c]oxazol-5(3H)-

[001354] To a solution of diisopropylamine (322 mg, 3.18 mmol) in toluene (5 mL) was added n-BuLi (2.5 M, 1.26 mL) dropwise at -30 °C. The mixture was maintained at -30 °C. for an additional 30 min, then a solution of (6R,7S,7aS)-7-ethyl-6-fluoro-3,3-dimethyl-l,6,7,7a-tetrahydropyrrolo[l,2-c]oxazol-5-one (575 mg, 2.86 mmol) in toluene (2 mL) was added dropwise at -78 °C over 2 h. After the addition was completed, the mixture was kept at -78° C for 30 min more before a solution of BHT (1.30 g, 5.91 mmol) in toluene (2 mL) was added dropwise over 0.5 h, keeping the internal temperature below - 65° C. After the addition was completed, the mixture was kept at -78° C for 30 min. The mixture was then warmed to rt and stirred for 2 hrs. On completion, the reaction was quenched with water (5 mL) and extracted with ethyl acetate (3 X 50 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo.* The residue was purified by silica gel chromatography (PE: EA = 10:1) to give the title compound (244 mg, 40% yield) as a white solid. ^{1}H NMR (400MHz, CDCh) δ 5.36 - 5.15 (m, 1H), 4.12 - 4.01 (m, 2H), 3.79 - 3.68 (m, 1H), 2.78 - 2.64 (m, 1H), 1.80 - 1.70 (m, 1H), 1.69 (s, 3H), 1.50 (s, 3H), 1.42 - 1.32 (m, 1H), 0.98 (t, *J* = 7.2 Hz, 3H). LC-MS (ESI$^+$) *m/z* 202.1 $(M+H)^+$.

[001355] Step 7 - (3S.4S.5S)-4-Ethyl-3-f1uoro-5-(hvdroxymethyl)pyrrolidin-2-one

[001356] (6S,7S,7aS)-7-ethyl-6-fluoro-3,3-dimethyl-l,6,7,7a-tetrahydropyrrolo[l,2-c]oxazol-5-one (330 mg, 1.64 mmol) in acetonitrile (1.5 mL) and H_20 (0.15 mL) was treated with TFA (37.4 mg, 328 umol). The mixture was warmed to ~65 °C over 1 h, and held at that temperature for 3 hrs. On completion, the mixture was concentrated *in vacuo.* The residue was reversed phase chromatography to give the title compound (230 mg, 91% yield). ^{1}H NMR (400MHz, CDCh) δ 7.59 (s., 1H), 4.80 (dd, 1H), 3.69-3.83 (m, 2H), 3.52-3.64 (m, 1H), 3.48 (br. s, 1H), 2.27-2.52 (m, 1H), 1.57-1.73 (m, 1H), 1.49 (dt, 1H), 1.04 (t, 3H). LC-MS (ESI$^+$) *m/z* 162.1 $(M+H)^+$

[001357] **7-Methoxy-l-oxo-l,2-dihydroisoquinoline-6-carbonitrile [Intermediate CC1**



cc

[001358] Step 1 - Methyl 4-iodo-3-methoxybenzoate

[001359] To a solution of 3-hydroxy-4 -iodo-benzoic acid (25.0 g, 94.7 mmol) in acetone (350 mL) was added K2CO3 (52.4 g, 379 mmol) and CH3I (53.8 g, 379 mmol). The reaction mixture was stirred at 50 °C for 16 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was dissolved with ethyl acetate (l50mL) and washed with water (150 mL).The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (24.5 g, 89% yield) as a yellow oil. ^{1}H NMR (400MHz, CDCb) δ 7.86 (d, *J* = 8.0 Hz, 1H), 7.46 (d, *J* = 1.6 Hz, 1H), 7.38 (dd, *J* = 1.6, 8.0 Hz, 1H), 3.95 (s, 3H), 3.93 (s, 3H).

[001360] Step 2 - 4-Iodo-3-methoxybenzoic acid

[001361] To a solution of methyl 4-iodo-3-m ethoxy-benzoate (3.00 g, 10.3 mmol) in a mixture of methanol (20 mL) and water (5 mL) was added LiOHH $_2$0 (1.29 g, 30.8 mmol). The reaction mixture was stirred at rt for 2 h. On completion, the reaction mixture was concentrated *in vacuo* to remove the methanol. The aqueous phase was acidified with 2N HC1 solution until the pH = 2, and filtered. The filter cake was dried *in vacuo* to give the title compound (2.70 g, 95% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-de) δ 13.21 (s, 1H), 7.91 (d, *J* = 8.0 Hz, 1H), 7.42 (d, *J* = 1.6 Hz, 1H), 7.30 (dd, *J* = 1.6, 8.0 Hz, 1H), 3.89 (s, 3H).

[001362] Step 3 - N-(2,2-dimethoxyethvl)-4-iodo-3-methoxybenzamide

[001363] To a mixture of 4-iodo-3-m ethoxy-benzoic acid (2.3 g, 8.3 mmol), HATU (3.77 g, 9.93 mmol) and DIPEA (3.21 g, 24.8 mmol) in DMF (40 mL) was added 2,2-dimethoxyethanamine (1.04 g, 9.93 mmol). The reaction mixture was stirred at rt for 1 h. On completion, the reaction mixture was concentrated *in vacuo.* The residue was diluted with water (40mL), acidified with citric acid, and extracted with EA (3 X 100 mL). The organic phase was dried over anhydrous Na$_2$S0 $_4$, filtered and concentrated *in vacuo.* The crude product was purified by silica gel chromatography (PE/EA=l/2) to give the title compound (2.80 g, 93% yield) as a white solid. ¾NMR (400MHz, CDCh) δ 7.83 (d, *J* = 8.0 Hz, 1H), 7.34 (d, *J* = 2.0 Hz, 1H), 6.99 (dd, *J* = 2.0, 8.0 Hz, 1H), 6.33 (s, 1H), 4.49 (t, *j* = 5.6 Hz, 1H), 3.95 (s, 3H), 3.61 (t, *j* = 5.6 Hz, 2H), 3.45 (s, 6H).

[001364] Step 4 - 6-Iodo-7-methoxyisoquinolin-l(2H)-one


[001365] A mixture of /V-(2,2-dimethoxyethyl)-4-iodo-3-methoxy-benzamide (3.30 g, 9.04 mmol) in concentrated **H$_2$S0 $_4$** (15 mL) was stirred at 60 °**C** for 0.5 h. On completion, the reaction mixture was pour into ice water (200 mL) and extracted with **DCM** (3 X 200 mL). The combined organic layer was dried *in vacuo* to give the title compound (2.50 g, 92% yield) as a white solid. ^{1}H NMR (400MHz, **DMSO-de)** δ 11.29 (s, 1H), 8.22 (s, 1H), 7.54 (s, 1H), 7.07 (d, *J* = 7.2 Hz, 1H), 6.48 (d, *j* = 7.2 Hz, 1H), 3.92 (s, 3H).

[001366] Step 5 - 7-Methoxy-l-oxo-L2-dihvdroisoquinoline-6-carbonitrile

[001367] A mixture of 6-iodo-7-methoxy-2H-isoquinolin-l-one (2.4 g, 7.97 mmol) and CuCN (2.14 g, 23.9 mmol) in DMF (50 mL) was stirred at 125 °C for 1 h under nitrogen. On completion, the reaction mixture was concentrated *in vacuo.* The residue was dissolved in DCM: MeOH = 10:1 (100 mL), filtered and concentrated *in vacuo* to give the title compound (1.40 g, 88% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-de) δ 11.52 (s, 1H), 8.24 (s, 1H), 7.78

(s, 1H), 7.17 (dd, *J* = 5.6, 7.2 Hz, 1H), 6.57 (d, *J* = 7.2 Hz, 1H), 4.02 (s, 3H).

[001368] **1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carbonitrile [Intermediate CD)**



CC CD


[001369] Step 1 - l-Chloro-7-methoxyisoquinoline-6-carbonitrile

[001370] To a mixture of 7-methoxy-l-oxo-2H-isoquinoline-6-carbonitrile (1.25 g, 6.24 mmol, Intermediate CC) in dioxane (50 mL) was added POCh (3.83 g, 25.0 mmol). The reaction mixture was stirred at 110 °C for 2 h. On completion, the reaction mixture was concentrated to remove the solvent. The residue was dissolved in DCM (20 mL) and washed with $NaHC0_3$ solution until the pH= 8. The reaction mixture was then extracted with DCM (3 X 100 mL). The combined layer was dried over Na_2S0_4, filtered, and the filtrate was concentrated *in vacuo.* The residue was purified by silica gel chromatography (PE: DCM = 1:5) to give the title compound (1.00 g, 60% yield) as an off-white solid. LC-MS (ESI^+) *m/z* 219.0 $(M+H)^+$.

[001371] Step 2 - l-(((2S.3S.4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carbonitrile

[001372] A mixture of l-chloro-7-methoxy-isoquinoline-6-carbonitrile (50.0 mg, 229 umol) and (3S,4S,5S)-4-ethyl-3-fluoro-5-(hydroxymethyl)pyrrolidin-2-one (36.9 mg, 229 umol, Intermediate CB) were stirred in DMF (1 mL) and cooled to approximately -10° C. A solution of KHMDS (1 M, 503.11 uL) in THF was then added into the reaction mixture over -15 minutes, maintaining the internal reaction temperature at approximately -10° C. After, the reaction was stirred at -10° C for approximately an additional 30 minutes. On completion, the reaction mixture was quenched with saturated NaH_2P0_4 (20 mL) and extracted with ethyl acetate (3 X 100 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo.* The residue was purified by prep-TLC (EA) to give the title compound (50.0 mg, 49% yield) as a white solid. LC-MS (ESI^+) *m/z* 344.0 $(M+H)^+$

[001373] **l-[[[2S,3S,4S]-3-ethyl-4-fluoro-5-oxo-pyrrolidin-2-yllmethoxyl-7-methoxy-isoquinoline-6-carboxylic acid [Intermediate CE)**



[001374] Step 1 - 7-Methoxy-l-oxo-2H-isoquinoline-6-carboxylic acid

[001375] To a solution of 7-methoxy-l-oxo-2i7-isoquinoline-6-carbonitrile (1.50 g, 7.49 mmol, Intermediate CC) in ethanol (30 mL) was added aqueous sodium hydroxide (10 M, 15.0 mL). The mixture was stirred at 80 °C for 15 h. On completion, the reaction mixture was concentrated *in vacuo* to remove the ethanol. The residue was acidified with saturated citric acid aqueous until the pH < 6. A fine light yellow precipitate formed and the precipitate was filtered and dried *in vacuo* to give the title product (1.20 g, 73% yield) as a light yellow solid. 'H NMR (400MHz, DMSO-de) δ 13.16 (br s, 1H), 11.35 (br s, 1H), 7.91 (s, 1H), 7.70 (s, 1H), 7.10 (dd, *J* = 5.6, 6.8 Hz, 1H), 6.59 (d, *J* = 7.2 Hz, 1H), 3.91 (s, 3H).

[001376] Step 2 - Methyl 7-methoxy-l-oxo-2H-isoquinoline-6-carboxylate

[001377] To a solution of 7-methoxy-l-oxo-2iT-isoquinoline-6-carboxylic acid (1.10 g, 5.02 mmol) in methanol (50 mL) was added sulfonyl chloride (3.58 g, 30.1 mmol, 2.18 mL). The mixture was stirred at 70 °C for 15 h. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was dissolved in ice water (30 mL) and basified with saturated sodium bicarbonate aqueous until the pH > 7 and a fine light yellow precipitate was formed. The precipitate was filtered and dried *in vacuo* to give the title compound (1.10 g, 93% yield) as a light yellow solid. ¾ NMR (400MHz, CDCh) δ 10.79 (br s, 1H), 7.89 (s, 1H), 7.83 (s, 1H), 7.03 (d, *J* = 6.8 Hz, 1H), 6.49 (d, *j* = 7.2 Hz, 1H), 3.96 (s, 3H), 3.89 (s, 3H).

[001378] Step 3 - Methyl l-chloro-7-methoxy-isoquinoline-6-carboxylate

[001379] Methyl 7-methoxy-l-oxo-2i7-isoquinoline-6-carboxylate (1.00 g, 4.29 mmol) was dissolved in $POCl_3$ (30 mL) and the mixture was stirred at l05°C for 14 h. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was dissolved in ice water (50 mL) and basified with saturated sodium bicarbonate aqueous until the pH > 7, and a fine light yellow precipitate was formed. The precipitate was filtered and dried *in vacuo* to give the title compound (1.00 g, 92% yield) as a light yellow solid. ^{1}H NMR (400MHz, CDCh) δ 8.25 (d, *J* = 5.6 Hz, 1H), 8.23 (s, 1H), 7.65 (s, 1H), 7.60 (d, *j* = 5.6 Hz, 1H), 4.09 (s, 3H), 4.00 (s, 3H).

[001380] Step 4 - l-Chloro-7-methoxy-isoquinoline-6-carboxylic acid


[001381] To a solution of methyl l-chloro-7-methoxy-isoquinoline-6-carboxylate (1.00 g, 3.97 mmol) in a mixed solution of tetrahydrofuran (20 mL) and water (10 mL) was added lithium hydroxide (380 mg, 15.8 mmol). The mixture was stirred at rt or 14 h. On completion, the reaction mixture was concentrated *in vacuo* to remove the tetrahydrofuran. The resulting residue was acidified with 1 N hydrochloride acid until the pH = 6 and a white precipitate was formed. The precipitate was filtered and the filter cake was dried *in vacuo* to give the title compound (900 mg, 95% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-de) δ 8.22 (d, *j* = 5.6 Hz, 1H), 8.18 (s, 1H), 7.89 (d, *j* = 5.6 Hz, 1H), 7.53 (s, 1H), 3.98 (s, 3H).

[001382] Step 5 - 1-[[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxo-pyrrolidin-2-yl]methoxy]-7-methoxy-isoquinoline-6- carboxylic acid

[001383] A mixture of l-chloro-7-methoxy-isoquinoline-6-carboxylic acid (200 mg, 841 umol), **(3k,4k,5k)-4-ethyl-3-fluoro-5-(hydroxymethyl)pyrrolidin-2-one** p|35 mg, 841 umol, Intermediate CB) in A,/V- dimethylformamide (8 mL) was cooled to -l0°C, and KHMDS (1 M, 3.53 mL) was added dropwise under nitrogen gas atmosphere to keep the temperature at -10 °C over 0.25 h. The mixture was stirred at 0 °C for 15 h. On completion, the reaction mixture was quenched with ice water (30 mL) and acidified with 1 N hydrochloride acid until the pH = 5, and then extracted with dichloromethane (3 X 15 mL). The combine organic phase was dried over anhydrous magnesium sulfate, filtered and concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 l50*25*l0um; mobile phase: [water (0.05% HCl)-ACN]) to give the title compound (95.0 mg, 28% yield, hydrochloride salt) as a yellow solid. ^{1}H NMR (400MHz, DMSO-de) δ 8.91 (s, 1H), 8.13 (s, 1H), 7.92 (d, *j* = 5.6 Hz, 1H), 7.74 (s, 1H), 7.43 (d, *j* = 5.6 Hz, 1H), 4.99 - 4.82 (m, 1H), 4.55 (dd, *j* = 3.2, 11.2 Hz, 1H),

4.26 (dd, J = 6.4, 11.2 Hz, 1H), 4.10 - 4.09 (m, 1H), 3.94 (s, 3H), 2.69 - 2.55 (m, 1H), 1.66 - 1.56 (m, 2H), 1.02 (t, J = 7.2 Hz, 3H).

[001384] **2,2'-[Pentane-l ,5-diylbis(oxy))diethanamine [Intermediate CF)**



[001385] Step 1 - Diethyl 2.2'-(pentane-L5-diylbis(oxy))diacetate

[001386] To a solution of pentane-l,5-diol (20 g, 192 mmol, 20.2 mL) and $Rh(OAc)_2$ (1.70 g, 7.68 mmol) in DCM (50 mL) was added a solution of ethyl 2-diazoacetate (21.9 g, 192 mmol) in DCM (200 mL), and the reaction mixture was stirred at rt for 12 h. On completion, the reaction mixture was diluted with water (100 mL) and extracted with DCM (2 X 200 mL). The combined organic phase was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE/EA=5/l) to give the title compound (10 g, 19% yield) as a yellow oil. ^{1}H NMR (400MHz, CDCh) δ 4.24 - 4.20 (m, 4H), 4.05 (s, 4H), 3.55 - 3.51 (m, 4H), 1.67 - 1.64 (m, 4H), 1.48 - 1.46 (m, 2H), 1.30 - 1.26 (m, 6H).

[001387] Step 2 - 2.2'-(Pentane-L5-diylbis(oxy))di ethanol

[001388] To a solution of LAH (3.43 g, 90.5 mmol) in THF (100 mL) was added slowly dropwise a solution of ethyl 2-[5-(2-ethoxy-2-oxo-ethoxy)pentoxy]acetate (10.0 g, 36.2 mmol) in THF (100 mL) at 0 °C. The reaction mixture was then allowed to warm to rt and stirred for 1 h under nitrogen. On completion, the reaction mixture was quenched with water (6 mL) and 15% sodium hydroxide solution (10 mL). Then, the mixture was filtered. The filtrate was concentrated *in vacuo* to give the title compound (5.7 g, 83% yield) as a colorless oil. ^{1}H NMR (400MHz, CDCh) δ 3.69 - 3.62 (m, 4H), 3.49 - 3.45 (m, 4H), 3.42 (t, J = 6.0 Hz, 4H), 2.33 (t, J = 6.0 Hz, 2H), 1.60 - 1.52 (m, 4H), 1.44 - 1.35 (m, 2H).

[001389] Step 3 -(Pentane-L5-diylbis(oxy))bis(ethane-2. 1-diyl) dimethanesulfonate

[001390] To a solution of 2-[5-(2-hydroxyethoxy)pentoxy]ethanol (5.7 g, 29.7 mmol) in DCM (60 mL) was added TEA (9.00 g, 89.0 mmol) and MsCl (8.49 g, 74.1 mmol). The reaction mixture was stirred at rt for 1 hr. On completion, the reaction mixture was quenched with water (10 mL). Then, the mixture was washed with 1N citric aqueous (20 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (10 g, 97% yield) as a colorless oil. ^{1}H NMR (400MHz, CDCh) 5 4.45 - 4.33 (m, 4H), 3.76 - 3.68 (m, 4H), 3.51 (t, *J* = 6.4 Hz, 4H), 3.08 (s, 6H), 1.67 - 1.60 (m, 4H), 1.48 - 1.41 (m, 2H).


[001391] Step 4 - 2,2'-((Pentane-L5-diylbis(oxy))bis(ethane-2,1-diyl))bis(isoindoline-L3-dione)

[001392] A solution of 2-[5-(2-methylsulfonyloxyethoxy)pentoxy]ethyl methanesulfonate (10 g, 28.7 mmol) and (l,3-dioxoisoindolin-2-yl)potassium (11.7 g, 63.1 mmol) in DMF (100 mL) was heated to 100 °C for 12 h. On completion, the reaction mixture was concentrated *in vacuo.* The residue was dissolved ethyl acetate (300 mL) and filtered. The filtrate was concentrated *in vacuo.* The residue was purified by silica gel chromatography (PE: EA = 5:1) to give the title compound (11 g, 77% yield). ^{1}H NMR (400MHz, CDCh) 5 7.92 - 7.82 (m, 4H), 7.77 - 7.72 (m, 4H), 3.88 (t, *J* = 6.0 Hz, 4H), 3.64 (t, *J* = 6.0 Hz, 4H), 3.39 (t, *J* = 6.4 Hz, 4H), 1.54 - 1.44 (m, 4H), 1.30 - 1.23 (m, 2H).

[001393] Step 5 - 2.2'-(Pentane-L5-diylbis(oxy))diethanamine

[001394] To a solution of 2-[2-[5-[2-(l,3-dioxoisoindolin-2-yl)ethoxy]pentoxy]ethyl]isoindoline-l,3-dione (1.10 g, 2.44 mmol) in ethanol (20 mL) was added NH2NH2·H2O (624 mg, 12.2 mmol). The reaction mixture was stirred at 80 °C for 2 h. On completion, the reaction mixture was cooled to rt and filtered. The filtrate was concentrated *in vacuo.* Then, the residue was diluted with DCM (20 mL) and filtered again. The filtrate was concentrated *in vacuo* to give the title compound (460 mg, 99% yield) as a colorless oil. ^{1}H NMR (400MHz, CDCh) δ 3.51 - 3.43 (m, 8H), 2.87 (t, *J* = 5.2 Hz, 4H), 1.68 - 1.57 (m, 4H), 1.50 - 1.39 (m, 2H).

[001395] **Tert-butyl N-(ll-aminoundecvPcarbamate (Intermediate CG)**




CG

[001396] To a mixture of undecane- 1,11-diamine (512 mg, 2.75 mmol) in CHCb (25 mL)

was added a solution of tert-butoxyearbonyl tert-butyl carbonate (120 mg, 549 umol) in $CHCl_3$ (5 mL) dropwise. The reaction mixture was stirred at rt for 20 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by column chromatography to give the title compound (120 mg, 76% yield) as a light yellow oil. ^1H NMR (400MHz, $CDCl_3$) δ 4.54 (s, 1H), 3.12 (d, *J* = 6.0 Hz, 2H), 2.70 (t, *J* = 7.0 Hz, 2H), 1.70 - 1.55 (m, 4H), 1.46 (s, 9H), 1.32 - 1.25 (m, 14H).

[001397] **Ethyl 2-[2-[2-[2-[2-tert-butoxycarbonylaminolethoxyl ethoxy] ethoxy] ethoxy] acetate (Intermediate CH)**



CH

[001398] Step 1 - Ethyl 14-hvdroxy-3,6,9,12-tetraoxatetradecan-1-oate

[001399] To a solution of 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethanol (10.0 g, 51.5 mmol, CAS# 112-60-7) in DCM (150 mL) was added BF_3•Et_20 (159 mg, 515 umol) at 0 °C. Then, ethyl 2-diazoacetate (5.87 g, 51.5 mmol) was added to the reaction mixture dropwise. After that, the mixture was allowed to warm to rt and stirred for 12 hours. On completion, the reaction mixture was quenched by ammonium chloride (5 mL), then diluted with water (100 mL), and extracted with DCM (3 X 50 mL). The combined organic layers were dried over sodium sulfate and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography to give the title compound (2.60 g, 18% yield) as a colorless oil. ^1H NMR (400MHz, CDCh) δ 4.16 (q, *J* = 7.2 Hz, 2H), 4.10 (s, 2H), 3.71 - 3.59 (m, 14H), 3.58 - 3.54 (m, 2H), 1.24 (t, *J* = 7.2 Hz, 3H).

[001400] Step 2 - Ethyl 2-[2-[2-[2-(2-methyl sulfonyloxyethoxyiethoxyl ethoxy] ethoxy] acetate

[001401] To a solution of ethyl 2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]acetate (6.86 g, 24.5 mmol) in DCM (50 mL) was added TEA (4.95 g, 48.9 mmol). The reaction mixture

was cooled to 0 °C. Then MsCl (3.36 g, 29.4 mmol) was added into the solution slowly. The reaction mixture was stirred at rt for 0.5 hour. On completion, the reaction mixture was quenched with H_20 (20 mL) and saturated citric acid solution (20 mL) was added until the pH = 5 - 6, then they organic layer was separated. The organic layer was washed with brine (4 X 50 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (8.00 g, 91% yield) as a brown oil. ^1H NMR (400MHz, CDCh) δ 4.43 - 4.37 (m, 2H), 4.23 (q, *J* = 7.2 Hz, 2H), 4.16 (s, 2H), 3.82 - 3.62 (m, 14H), 3.10 (s, 3H), 1.30 (t, *J* = 7.2 Hz, 3H).

[001402] Step 3 - Ethyl 2-r2-r2-r2-(2-azidoethoxy)ethoxy1ethoxy1ethoxy1acetate

[001403] To a solution of ethyl 2-[2-[2-[2-(2-methylsulfonyloxyethoxy)ethoxy]ethoxy]ethoxy]acetate (8.00 g, 22.3 mmol) in DMF (30 mL) was added NaN_3 (2.90 g, 44.6 mmol). The reaction mixture was stirred at 80 °C for 15 h. On completion, the solvent DMF was removed *in vacuo*. Then the residue was diluted with EA (150 mL) and filtered. The filtrate was used for the next step directly without further purification or concentration. LC-MS (ESI^+) *m/z* 278.1 $(M+H-28)^+$.

[001404] Step 4 - Ethyl 2-[2-[2-[2-(tert-butoxycarbonylaminoiethoxyl ethoxy] ethoxy] ethoxy] acetate


[001405] To a solution of ethyl 2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]acetate (6.81 g, 22.3 mmol) in EA(l50 mL) was added Pd/C (700 mg, 10 wt %) and $(Boc)_20$ (24.3 g, 112 mmol). The mixture was degassed and purged with hydrogen gas three times. Then the reaction mixture was stirred at rt for 15 hours. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (DCM/MeOH = 10/1) to give the title compound (5.15 g, 61% yield) as a colorless oil. ¾ NMR (400MHz, CDCh) δ 5.05 (s, 1H), 4.27 (q, *J* = 7.2 Hz, 2H), 4.17 (s, 2H), 3.79 - 3.60 (m, 12H), 3.56 (t, *J* = 5.2 Hz, 2H), 3.37 - 3.27 (m, 2H), 1.45 (s, 9H), 1.31 (t, *J* = 7.2 Hz, 3H).

[001406] Step 5 - Ethyl 2-[2-[2-[2-(tert-butoxycarbonylaminoiethoxyl ethoxy] ethoxy] ethoxy] acetate

[001407] To a solution of ethyl 2-[2-[2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethoxy]acetate (0.40 g, 1.05 mmol) in THF (10 mL) and H_20 (4 mL) was added LiOH (50.5 mg, 2.11 mmol). The reaction mixture was stirred at rt for 16 hours. On completion, the mixture was concentrated *in vacuo* to give a residue, then diluted

with H_20 . The aqueous phase was acidified with cone. HC1 until the pH = 6 and concentrated *in vacuo* to give the title compound (350 mg, 996 umol) as a yellow solid. ¾NMR (400MHz, CDCh) δ 4.18 (m, 2H), 3.80 - 3.63 (m, 14H), 3.46 - 3.17 (m, 2H), 1.46 - 1.41 (s, 9H).

[001408] **(2S,4R)-1-[(2S)-2-amino-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yP-phenyl]methyllpyrrolidine-2-carboxamide _ [Intermediate_ Cl)**



[001409] Step 1 - 4-(4-Methylthiazol-5-vDbenzonitrile

[001410] To a mixture of 4-bromobenzonitrile (32.0 g, 176 mmol), 4-methylthiazole (34.86 g, 352 mmol) and KOAc (34.5 g, 352 mmol) in DMA (100 mL) was added $Pd(OAc)_2$ (820 mg, 3.65 mmol). The mixture was stirred at 150 °C under nitrogen atmosphere for 2 hours. On completion, the mixture was diluted with water (200 mL) and extracted with ethyl acetate (3 X 200 mL). The combined organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the crude product. The crude product was triturated with PE (100 mL) and filtered to give the title compound (28.8 g, 82% yield) as a yellow solid. ^1H NMR (400MHz, MeOD-rL) δ 8.98 (s, 1H), 7.85 - 7.81 (m, 2H), 7.71 - 7.66 (m, 2H), 2.53 (s, 3H); LC-MS (ESI^+) *m/z* 201.0 $(M+H)^+$.

[001411] Step 2 - r4-(4-Methylthiazol-5-vDphenyl1methanamine

[001412] To a solution of 4-(4-methylthiazol-5-yl)benzonitrile (14.7 g, 73.4 mmol) in MeOH

(460 mL) was added dichlorocobalt (14.3 g, 110 mmol) and the mixture was cooled to 0 °C. Then, $NaBH_4$ (13.9 g, 367 mmol) was added in portions over 0.5 hour. Finally, the mixture was allowed to warm to rt and stirred for 12 hours. On completion, the reaction mixture was quenched with NH3·H2O (20 mL, 30 wt %), then diluted with water (100 mL) and extracted with DCM (3 X 80 mL). The combined organic layer was dried over anhydrous Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase flash column (0.1% NH3.H2O in water) to give the title compound (3.50 g, 23.3% yield) as a yellowish oil. LC-MS (ESI^+) *m/z* 205.1 $(M+H)^+$.

[001413] Step 3 - Tert-butyl (2S,4R)-4-hydroxy-2-[[4-(4-methylthiazol-5-yl)phenyl]methylcarbamoyl]

[001414] -pyrrolidine- 1-carboxylate

[001415] A solution of (2S,4R)-l-tert-butoxycarbonyl-4-hydroxy-pyrrolidine-2-carboxylic acid (3.36 g, 14.5 mmol, CAS# 13726-69-7) in DMF (50 mL) was cooled to 0 °C. Then, DIPEA (5.13 g, 39.7 mmol), [4-(4-methylthiazol-5-yl) phenyl] methanamine (2.70 g, 13.2 mmol) and HATU (6.03 g, 15.9 mmol) were added. Finally, the mixture was allowed to warm to rt and stirred for 12 hours. On completion, the reaction mixture was concentrated under reduced pressure to remove the DMF. The residue was diluted with water (50 mL) and extracted with DCM (3 X 60 mL). The combined organic layer was dried over anhydrous Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase flash (0. 1% NFL·FLO in water) column to give the title compound (1.70 g, 30% yield) as a yellowish solid. ^1H NMR (400MHz, MeOD-i¾) δ 8.91 (s, 1H), 7.48 - 7.40 (m, 4H), 4.74 - 4.25 (m, 4H), 3.66 - 3.56 (m, 1H), 3.54 - 3.43 (m, 1H), 2.48 (s, 3H), 2.31 - 2.20 (m, 1H), 2.08 - 1.98 (m, 1H), 1.54 - 1.25 (m, 9H); LC-MS (ESI^+) *m/z* 418.0 $(M+H)^+$.

[001416] Step 4 - (2S.4R)-4-hvdroxy-N-[[4-(4-methylthiazol-5-vnphenyllmethvnpyrrolidine-2-carboxamide

[001417] To a solution of tert-butyl (2S,4R)-4-hydroxy-2-[[4-(4-methylthiazol-5-yl)phenyl]methylcarbamoyl] -pyrrolidine- 1-carboxylate (1.70 g, 4.07 mmol) in DCM (10 mL) was added HC1 in dioxane (4 M, 10 mL) and the mixture was stirred at rt for 6 hours. On completion, the mixture was concentrated under reduced pressure to give the product (1.60 g, HC1 salt, 96% yield) as a yellowish solid. LC-MS (ESI^+) *m/z* 318.0 $(M+H)^+$.

[001418] Step 5 - Tert-butyl N-[(1S)-1-[(2S.4R)-4-hydroxy-2-[[4-(4-methylthiazol-5-


vl)phenyl] methylcarbamoyl] pyrrolidine-1 -carbonyll-2.2-dimethyl-propyllcarbamate

[001419] A solution of (2S,4R)-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2- carboxamide (1.60 g, 4.52 mmol, HC1 salt) in DMF (25.00 mL) was cooled to 0 °C. Then, DIPEA (1.75 g, 13.6 mmol), (2S)-2-(tert-butoxycarbonylamino)-3,3-dimethyl-butanoic acid (1.31 g, 5.65 mmol) and HATU (2.06 g, 5.43 mmol) were added. Finally, the mixture was allowed to warm to rt and stirred for 12 hours. On completion, the reaction mixture was concentrated under reduced pressure to remove the DMF. The residue was diluted with water (40 mL) and extracted with DCM (3 X 40 mL). The combined organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase flash column (0.1% $NH_3{\cdot}HL O$ in water) to give the title compound (1.70 g, 70% yield) as a light yellow solid. ^1H NMR (400MHz, $CDCl_3$-*di)* δ 8.71 (s, 1H), 7.43 (s, 1H), 7.39 - 7.30 (m, 4H), 5.20 (d, *J* = 8.0 Hz, 1H), 4.78 (t, *J* = 1.6 Hz, 1H), 4.59 (m, 1H), 4.33 (m, 1H), 4.18 - 4.09 (m, 2H), 3.58 (m, 1H), 2.60 (m, 1H), 2.52 (s, 3H), 2.14 (m, 1H), 1.41 (s, 9H), 0.92 (s, 9H); LC-MS (ESI$^+$) *m/z* 531.1 $(M+H)^+$.

[001420] Step _6 _- _(2S.4R)-l-r(2S)-2-amino-3.3-dimethyl-butanoyl1-4-hvdroxy-N-rr4-(4-methylthiazol-5-yl)-phenyl1methvnpyrrolidine-2-carboxamide

[001421] To a solution of tert-butyl N-[(l S)-l-[(2S,4R)-4-hydroxy-2-[[4-(4-methylthiazol-5-yl)phenyl]-methyl carbamoyl]pyrrolidine-l-carbonyl]-2,2-dimethyl-propyl]carbamate (1.60 g, 3.01 mmol) in DCM (20 mL) was added HC1 in dioxane (4 M, 20 mL). Then, the mixture was stirred at rt for 6 hours. On completion, the mixture was concentrated under reduced pressure to give the title compound as a light yellow solid (1.90 g, HC1 salt, 95% yield). ^1H NMR (400MHz, MeOD-iL) δ 9.98 (s, 1H), 7.58 - 7.52 (m, 4H), 4.72 - 4.65 (m, 1H), 4.60 - 4.50 (m, 2H), 4.46 - 4.38 (m, 1H), 4.07 (s, 1H), 3.86 -3.83 (m, 1H), 3.75 - 3.68 (m, 1H), 3.60 (s, 1H), 2.61 (s, 3H), 2.33 - 2.28 (m, 1H), 2.11 - 2.05 (m, 1H), 1.14 (s, 9H); LC-MS (ESI$^+$) *m/z* 431.1 $(M+H)^+$.

[001422] **4-Nitro-lH-pyrazole-5-carboxamide _ _[Intermediate_ _CJ)**




CJ

[001423] A solution of ethyl 4-nitro-lH-pyrazole-5-carboxylate (6.00 g, 32.4 mmol, CAS# 55864-87-4) in $NH_3{\cdot}H_20$ (60 mL) was stirred at 100 °C for 16 hours. On completion, the reaction

mixture was concentrated *in vacuo* to give the title compound (5.10 g, 98% yield) as a light yellow solid. ^{1}H NMR (400MHz, DMSO-d$_6$) δ 8.71 (s, 1H), 8.09 (s, 1H), 7.85 (s, 1H).


[001424] **[EVN.JN-dimethvl-2-nitro-ethenamine [Intermediate CK)**



CK

[001425] Amixture of l,l-dimethoxy-N,N-dimethyl-methanamine (20.0 g, 167 mmol, 22.30 mL) in $MeNO_2$ (12.8 mL) was stirred at 80 °C for 30 minutes. On completion, the mixture was concentrated *in vacuo.* The residue was purified by column chromatography to give the title compound (14.0 g, 72% yield) as a red brown solid. ^{1}H NMR (400MHz, DMSO-d$_6$) δ 8.13 (d, *J* = 10.8 Hz 1H), 6.62 (d, *J* = 10.8 Hz, 1H), 3.21 (s, 3H), 2.88 (s, 3H).

[001426] **Methyl 4-[4-amino-3-carbamoyl-pyrazol-l-v0benzoate [Intermediate CL)**



CL

[001427] Step 1 - Ethyl (2E)-2-r(4-bromophenv0hydrazono1-2-chloro-acetate

[001428] To a mixture of 4-bromoaniline (50.0 g, 291 mmol) in a mixed solvent of HCI (12 N, 72.6 mL) and H_20 (150 mL) was added a solution of $NaN0_2$ (22.1 g, 319 mmol) in H_20 (50 mL) dropwise at -5°C. The mixture was stirred at 0°C for 0.5 hour. Then ethyl 2-chloro-3-oxo-butanoate (50.2 g, 305 mmol, 42.2 mL) and NaOAc (71.53 g, 872 mmol) were added to the solution at 0°C and the mixture was stirred for 30 minutes. The reaction mixture was then allowed

to warm to it and stirred for an additional for 2 hours. On completion, the reaction mixture was filtered and the filter cake was dried *in vacuo.* The residue was triturated with MeOH (500 mL) to give the title compound (50.0 g, 56% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-d_6) δ 8.32 (s, 1H), 7.45 - 7.20 (m, 2H), 7.14 - 7.11 (m, 2H), 4.40 (q, *J* = 7.2 Hz, 2H), 1.41 (t, *J* = 7.2 Hz, 3H).

[001429] Step 2 - Ethyl l-(4-bromophenv0-4-nitro-pyrazole-3-carboxylate

[001430] Ethyl (2Z)-2-[(4-bromophenyl)hydrazono]-2-chloro-acetate (1.00 g, 3.27 mmol), (E)-N,N-dimethyl -2-nitro-ethenamine (380 mg, 3.27 mmol, Intermediate CK) and Et_3N (331 mg, 3.27 mmol) were taken up into a microwave tube in CHCh (3 mL). The sealed tube was heated at 140 °C for 1 hour under microwave. On completion, the mixture was concentrated *in vacuo.* The residue was purified by reverse phase flash (0.1% FA in water) to give the title compound (350 mg, 28% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-de) δ 9.76 (s, 1H), 7.97 - 7.90 (m, 2H), 7.85 - 7.78 (m, 2H), 4.43 (q, *J* = 7.2 Hz, 2H), 1.34 (t, *J* = 7.2 Hz, 3H).

[001431] Step 3 - l-(4-BromophenvD-4-nitro-pyrazole-3 -carboxamide

[001432] To a solution of ethyl l-(4-bromophenyl)-4-nitro-pyrazole-3-carboxylate (0.50 g, 1.47 mmol) in THF (10 mL) was added $NH_3 \cdot H_20$ (15.1 g, 129 mmol, 16.6 mL, 30 wt %). The mixture was stirred at 110 °C for 3 hours in a seal tube. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (500 mg, 98% yield) as pale solid. LC-MS (ESI^+) *m/z* 310.9 $(M+H)^+$.

[001433] Step 4 - 4-Amino-l-(4-bromophenvDpyrazole-3 -carboxamide


[001434] To a solution of l-(4-bromophenyl)-4-nitro-pyrazole-3 -carboxamide (500 mg, 1.61 mmol) in MeOH (10 mL) and H_20 (4 mL) was added Fe (898 mg, 16.0 mmol) and NH_4Cl (860 mg, 16.0 mmol). The mixture was stirred at 75 °C for 5 hours. On completion, the mixture was filtered and the filtrate was concentrated in *vacuo.* The residue was dissolved in EA (30 mL) and washed with water (10 mL). The organic layer was separated and concentrated *in vacuo.* The residue was purified by silica gel chromatography to give the title compound (230 mg, 49% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 304.9 $(M+Na+2)^+$.

[001435] Step 5 - Methyl 4-(4-amino-3-carbamoyl-pyrazol-l-vDbenzoate

[001436] A mixture of 4-amino- l-(4-bromophenyl)pyrazole-3 -carboxamide (0.23 g, 818 umol), dppf (18.2 mg, 32.0 umol), $Pd(OAc)_2$ (7.35 mg, 32.0 umol) in DMF (5 mL) and MeOH (5

mL) was degassed and purged with nitrogen gas three times. Then the mixture was stirred at 80 °C for 16 h under CO atmosphere (50 psi pressure). On completion, the mixture was filtered and the filtrate was concentrated to remove MeOH. Then the residue was diluted with EA (200 mL) and washed with water (2 X 50 mL). The organic layer was dried over anhydrous Na_2SO_4, filtered and concentrated *in vacuo*. The residue was purified by silica gel chromatography to give the title compound (140 mg, 61% yield) as a light yellow solid. ^1H NMR (400MHz, DMSO-d_6) δ 8.12 - 7.96 (m, 4H), 7.89 (s, 1H), 7.62 (s, 1H), 7.33 (s, 1H), 4.95 (s, 2H), 3.87 (s, 3H); LC-MS (ESI^+) *m/z* 261.0 $(M+H)^+$.

[001437] **2-[2-[tert-butoxycarbonyl[2,2,2-trifluoroethvnaminol-4-pyridyl]oxazole-4-carboxylic acid [Intermediate CM]**



[001438] Step 1 - Tert-butyl N-(4-biOmo-2-pyridvDcarbamate

[001439] A solution of 4-bromopyridin-2-amine (5.00 g, 28.9 mmol) in dry THF (100 mL) was treated with LiHMDS (1 M, 57.8 mL) at -5 °C and the solution was stirred at -5 °C for 10 minutes. Then $(Boc)_20$ (6.31 g, 28.9 mmol) was added and the mixture was allowed to warm to rt and stirred for 1 h. On completion, the reaction mixture was quenched with saturated ammonium chloride solution (20 mL) and extracted with EtOAc (3 X 100 mL). The combined organic layers were washed with brine (20 mL), dried with Na_2SO_4, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to give the title compound (6.50 g, 82% yield) as a white solid. ^1H NMR (400MHz, CDCb) δ = 8.92 (s, 1H), 8.27 (d, *J* = 0.8 Hz, 1H), 8.13 (d, *J* = 5.2 Hz, 1H), 7.12 (dd, *J* = 1.6, 5.2 Hz, 1H), 1.55 (s, 9H).

[001440] Step 2 - Tert-butyl N-(4-bromo-2-pyridyl)-N-(2,2,2-trifluoroethyl)carbamate

[001441] To a mixture of tert-butyl /V-(4-bromo-2-pyridyl)carbamate (6.10 g, 22.3 mmol), cesium carbonate (11.0 g, 33.7 mmol) and DMF (60 mL) was added 2,2,2-trifluoroethyl trifluoromethanesulfonate (5.18 g, 22.3 mmol). The reaction mixture was stirred at rt for 15 h. On completion, the reaction mixture was quenched with saturated aqueous ammonium chloride solution (50 mL) and extracted with ethyl acetate (3 X 100 mL). The organic layer was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to give the title compound (5.70 g, 72% yield) as a colorless oil. ^{1}H NMR (400MHz, CDCh) δ = 8.18 (d, *J* = 5.2 Hz, 1H), 8.01 - 7.94 (m, 1H), 7.24 (dd, *J* = 1.6, 5.2 Hz, 1H), 4.81 (q, *J* = 8.8 Hz, 2H), 1.55 (s, 9H).

[001442] Step 3 - Tert-butyl N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl]-N-(2,2,2-trifluoro ethyl)carbamate

[001443] To a solution of tert-butyl A'-(4-bromo-2-pyridyl)-A-(2,2,2-trifluoroethyl)carbamate (3.00 g, 8.45 mmol) in dioxane (60 mL) was added 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan -2-yl)-l,3,2- dioxaborolane (10.7 g, 42.2 mmol), KOAc (1.66 g, 16.9 mmol) and Pd(dppf)Cl2*CH2Cl2 (345 mg, 423 umol) under nitrogen atmosphere. The reaction mixture was then heated to 65 °C and stirred for 2 h. On completion, the reaction mixture was diluted with ethyl acetate (100 mL) and filtered. The filtrate was concentrated *in vacuo*. The residue was purified by silica gel column chromatography to give the title compound (3.00 g, 96% yield) as a white solid. ^{1}H NMR (400MHz, CDCh) δ = 8.38 (dd, *J* = 0.8, 4.8 Hz, 1H), 7.91 (s, 1H), 7.42 (d, *j* = 4.8 Hz, 1H), 4.76 (q, *j* = 8.8 Hz, 2H), 1.52 (s, 9H), 1.35 (s, 12H).

[001444] Step 4 - Ethyl 2-r2-rtert-butoxycarbonyl(2.2.2-trif1uoroethyl)amino1-4-pyridylloxazole-4-carboxylate


[001445] To a solution of tert-butyl /V-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2-pyridyl]-/V-(2,2,2- trifluoroethyl)carbamate (4.00 g, 9.94 mmol), ethyl 2-bromooxazole-4-carboxylate (2.19 g, 9.94 mmol) in dioxane (40 mL) and ¾ 0 (8 mL) was added CS2CO3 (6.48 g, 19.9 mmol) and Pd(dppf)Ch·CH2CI2 (406 mg, 497 umol) and the mixture was stirred at 80 °C for 16 h. On completion, the reaction mixture was diluted with ethyl acetate (200 mL) and filtered. The filtrate was concentrated *in vacuo*. The residue was purified by silica gel column chromatography to give the title compound (2.10 g, 51% yield) as a yellow solid. ^{1}H NMR (400MHz, CDCh) δ = 8.50 (d, *j* = 5.2 Hz, 1H), 8.38 (s, 1H), 8.34 (s, 1H), 7.79 *(d, J* = 5.2 Hz, 1H),

4.85 (q, *J* = 8.8 Hz, 2H), 4.45 (q, *J* = 7.2 Hz, 2H), 1.56 (s, 9H), 1.43 (t, *J* = 7.2 Hz, 3H); LC-MS (ESI^+) *m/z* 416.1 $(M+H)^+$.

[001446] Step 5 - 2-r2-rTert-butoxycarbonyl(2.2.2-trifluoroethvDamino1-4-pyridyl1oxazole-4-carboxylic acid

[001447] To a solution of ethyl 2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4- carboxylate (100 mg, 241 umol) in THF (1 mL) and H_20 (200 uL) was added LiOH (11.5 mg, 482 umol). The mixture was stirred at rt for 0.5 h. On completion, the reaction mixture was acidified with 1N HC1 (3 mL) to pH = 5, then extracted with ethyl acetate (5 X 20 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (90.0 mg, 97% yield) as a white solid. ^1H NMR (400MHz, CDCh) δ = 8.53 (dd, *J* = 0.8, 5.2 Hz, 1H), 8.46 (s, 1H), 8.40 (s, 1H), 7.79 (dd, *j* = 1.2, 5.2 Hz, 1H), 7.81 - 7.77 (m, 1H), 4.86 (q, *j* = 8.8 Hz, 2H), 1.57 (s, 9H); LC-MS (ESI^+) *m/z* 388.1 $(M+H)^+$

[001448] **4-[4-[[2-[2-[Tert-butoxycarbonyl[2,2,2-trifluoroethvnamino1-4-pyridyl1oxazole-4-carbonyl1 amino1-3-carbamoyl-pyrazol-l-yl1benzoic acid [Intermediate CN)**



[001449] Step 1 - Methyl 4-[4-[[2-[2-[tert-butoxycarbonyl(2.2.2-trifluoroethvl)amino1-4-pyridvHoxazole-4- carbonyl1amino1-3-carbamoyl-pyrazol-l-yl1benzoate


[001450] To a mixture of methyl 4-(4-amino-3 -carbamoyl-pyrazol-l-yl)benzoate (120 mg,

461 umol, Intermediate CL) and 2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (179 mg, 461 , Intermediate CM) in DMF (5 mL) was added DIPEA (179 mg, 1.38 mmol) and HATU (210 mg, 553 umol) and the mixture was stirred at rt for 2 h. On completion, the mixture was diluted with water (20 mL), extracted with EA (2 X 50 mL), and the organic layer was concentrated *in vacuo.* The residue was purified by silica gel chromatography to give the title compound (223 mg, 72% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-de) δ 11.07 (s, 1H), 9.11 (s, 1H), 9.06 (s, 1H), 8.74 - 8.61 (m, 1H), 8.26 (s, 1H), 8.16 - 8.05 (m, 5H), 7.86 - 7.75 (m, 2H), 4.91 (m, 2H), 3.89 (s, 3H), 1.54 (s, 9H); LC-MS (ESI$^+$) *m/z* 630.2 (M+H)$^+$.

[001451] Step 2 - 4-[4-[[2-[2-[Tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl1oxazole-4-carbonyl1 amino1-3-carbamoyl-pyrazol-l-yl1benzoic acid

[001452] To a solution of methyl 4-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl] oxazole-4-carbonyl]amino]-3-carbamoyl-pyrazol-l-yl]benzoate (210 mg, 333 umol) in THF (5 mL) and H_20 (5 mL) was added LiOH (40.0 mg, 1.67 mmol). The mixture was stirred at rt for 16 h. On completion, the mixture was adjusted to pH = 6 with 1N HC1, then extracted with EA (2 X 100 mL). The organic layer was concentrated *in vacuo* to give the title compound (150 mg, 68% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-d_6) δ 11.08 (s, 1H), 9.12 (s, 1H), 8.99 (s, 1H), 8.67 (d, *J* = 5.2 Hz, 1H), 8.26 (s, 1H), 8.13 - 7.97 (m, 5H), 7.79 - 7.76 (m, 2H), 7.76 (s, 1H), 4.91 (m, 2H), 1.54 (s, 9H); LC-MS (ESI$^+$) *m/z* 616.2 (M+H)$^+$.

[001453] **5-bromo-2-12,6-dioxopiperidin-3-vnisoindoline-l,3-dione [Intermediate CO):**




CO

[001454] To a solution of 4-bromophthalic anhydride (15.0 g, 66.lmmol, CAS# 86-90-8) in acetic acid (225mL) was added 2,6-dioxopiperi din-3-amine hydrochloride (10.87 g, 66.1 mmol, CAS# 24666-56-6) and sodium acetate (5.42g, 66.07mmol) at rt. The reaction mixture was heated to 80 °C and stirred for 16 h. The resulting reaction mixture was cooled to rt and concentrated on a rotary evaporator. The obtained residue was suspended in water (255mL) and the resulting

mixture was cooled to 0°C. The resulting slurry was stirred at 0 °C for 1 h. The resulting precipitate was filtered, washed with water (60mL) and dried under vacuum to give the title compound (20.44 g, 92%) as a purple solid. LC-MS (ESI^+) *m/z* 336.9 $(M+H)^+$.

[001455] **5-(3-(2-aminoethoxy]propyB-2-(2,6-dioxopiperidin-3-vBisoindoline-l,3-dione (Intermediate CP)**



[001456] Step 1 - Tert-butyl N-(2-prop-2-vnoxyethvncarbamate

[001457] To a solution of tert-butyl N-(2-hydroxyethyl)carbamate (1 g, 6.20 mmol) and 3-bromoprop-l-yne (775 mg, 6.51 mmol) in THF (30 mL) was added TBAI (137 mg, 372 umol) and KI (154 mg, 931 umol). Then KOH (409 mg, 6.20 mmol) was added into the above mixture and the reaction mixture was stirred at rt for 20 h. On completion, the mixture was concentrated *in vacuo* to remove the solvent. The residue was diluted with water (40 mL) and extracted with EA (3 X 30 mL). The organic phase was dried over Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by silica gel chromatography ($Si0_2$) to give the title compound (0.84 g, 68% yield) as a colorless oil. ^1H NMR (400MHz, CDCh) δ 4.84 (s, 1H), 4.09 (d, *J* = 2.4 Hz, 2H), 3.52

(t, J = 5.2 Hz, 2H), 3.28 - 3.26 (m, 2H), 2.38 (t, J = 2.4 Hz, 1H), 1.38 (s, 9H).

[001458] Step 2 - Tert-butyl (2-((3-(2-(2.6-dioxopiperidin-3-yl)-1.3-dioxoisoindolin-5-yl)prop-2-vn-l-yl)oxy)ethvl)carbamate

[001459] 5-bromo-2-(2,6-dioxopiperidin-3-yl)isoindoline-l,3-dione (0.4 g, 1.19 mmol, Intermediate CO), CuI (22.6 mg, 119 umol) and $Pd(PPh3)_2Cl2$ (83.3 mg, 119 umol) were put into a microwave tube. Then tert-butyl N-(2-prop-2-ynoxyethyl)carbamate (473 mg, 2.37 mmol), TEA (2.16 g, 2.98 mL, 21.4 mmol) and DMF (3 mL) were added into the tube. The mixture was degassed with nitrogen for 5 minutes. The sealed tube was then heated at 80 °C for 30 minutes under microwave. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was purified by silica gel chromatography ($Si0_2$) to give the title compound (510 mg, 94% yield) as a yellow oil. ^1H NMR (400MHz, CDCh) δ 8.16 (s, 1H), 7.92 (s, 1H), 7.87 - 7.78 (m, 2H), 5.03 - 4.96 (m, 1H), 4.94 (s, 1H), 4.43 (s, 2H), 3.67 (t, J = 5.2 Hz, 2H), 3.39 (*d, J* = 5.2 Hz, 2H), 2.96 - 2.90 (m, 1H), 2.88 - 2.80 (m, 1H), 2.79 - 2.71 (m, 1H), 2.21 - 2.13 (m, 1H), 1.45 (s, 9H).

[001460] Step 3 - Tert-butyl (2-(3-(2-(2.6-dioxopiperidin-3-yl)-1.3-dioxoisoindolin-5-yl)propoxy)ethyl icarbamate


[001461] To a solution of tert-butyl N-[2-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]prop-2-ynoxy] ethyl]carbamate (490 mg, 1.08 mmol) in THF (5 mL) was added Pd/C (0.2 g, 329 umol, 10 wt %) and $Pd(OH)_2/C$ (0.2 g, 329 umol, 10 wt %). The reaction mixture was stirred at rt for 18 h under hydrogen atmosphere (15 Psi pressure). On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (370 mg, 75% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 360.0 $(M+H-l00)^+$.

[001462] Step 4 - 5-(3-(2-aminoethoxy)propyl)-2-(2,6-dioxopiperidin-3-vl)isoindoline-L3-dione

[001463] To a solution of tert-butyl N-[2-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]propoxy]ethyl] carbamate (120 mg, 26 umol) in DCM (1 mL) was added HCl/dioxane (4 M, 1 mL). The reaction mixture was stirred at rt for 0.5 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (90 mg, 96% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 360.0 $(M+H)^+$.

[001464] **5-(3-(2-(2-aminoethoxy)ethoxy)propyD-2-(2.,6-dioxopiperidin-3-**

vl)isoindoline-l ,3-dione (Intermediate CO)



CQ

[001465] Step **1** - Tert-butyl N-r2-(2-prop-2-vnoxyethoxy)ethyl1carbamate

[001466] To a solution of /d/*t*-butyl /V-[2-(2-hydroxyethoxy)ethyl]carbamate (5.00 g, 24.4 mmol, CAS# 139115-91-6) and 3-bromoprop-l-yne (2.90 g, 24.4 mmol, 2.10 mL) in THF (40 mL) was added TBAI (540 mg, 1.46 mmol), KI (606 mg, 3.65 mmol) and KOH (1.61 g, 24.4 mmol, 85% wt *%).* The reaction mixture was stirred at rt for 16 h. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo* to give a residue. The residue was diluted with H_20 (20 mL) and extracted with EA (2 X 50 mL). The organic phase was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography ($Si0_2$, Petroleum ether: Ethyl acetate = 5:1) to give the title compound (4.00 g, 67% yield) as a yellow oil. ^1H NMR (400MHz, CDCh) δ 5.02 (s, 1H), 4.17 (d, J = 2.4 Hz, 2H), 3.68 - 3.63 (m, 2H), 3.62 - 3.58 (m, 2H), 3.51 (t, j = 5.2 Hz, 2H), 3.28 (q, J = 5.2 Hz, 2H), 2.43 (t, J = 2.4 Hz, 1H), 1.43 (s, 9H).

[001467] Step 2 -Tert-butyl (2-(2-((3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)prop-2-yn-1-yl)oxy)ethoxy)ethyl)carbamate

[001468] To a solution of 5-bromo-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (300 mg, 890 umol, Intermediate CO) and *tert*-butyl /V-[2-(2-prop-2-ynoxyethoxy)ethyl]carbamate (433 mg, 1.78 mmol) in DMF (8 mL) was added Pd(PPh3)2Cb (62.5 mg, 88.9 umol), TEA (1.62 g, 16.0 mmol, 2.23 mL) and Cul (16.9 mg, 88.9 umol). The reaction mixture was heated at 80 °C for 30 minutes under microwave. On completion, the mixture was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether: Ethyl acetate = 5:1 to 1:0) to give the title compound (440 mg, 89% yield) as a yellow solid. LC-MS (ESI^+) m/z 400.1 $(M+H-100)^+$.


[001469] Step 3 - Tert-butyl (2-(2-(3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)propoxy)ethoxy)ethyl)carbamate

[001470] To a solution of *tert*-butyl /V-[2-[2-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]prop-2-ynoxy] ethoxy]ethyl]carbamate (580 mg, 1.16 mmol) in THF (10 mL) was added Pd/C (300 mg, 10 wt %) and $Pd(OH)_2/C$ (300 mg, 10 wt %). The reaction mixture was stirred at rt under hydrogen atmosphere (15 psi pressure) for 12 h. On completion, the residue was filtered and the filter was concentrated *in vacuo* to give the title compound (500 mg, 85% yield) as a yellow oil. LC-MS (ESI^+) m/z 526.1 $(M+Na)^+$.

[001471] Step 4- 5-(3-(2-(2-aminoethoxy)ethoxy)propyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione

[001472] To a solution of *tert*-butyl /V-[2-[2-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]propoxy] ethoxy]ethyl]carbamate (200 mg, 397umol) in DCM (2 mL) was added HC1 in dioxane (4 M, 2.00 mL), and the reaction mixture was stirred at rt for 20 minutes. On completion, the mixture was concentrated *in vacuo* to give the title compound (160 mg, 99% yield) as a yellow solid. LC-MS (ESI^+) m/z 404.0 $(M+H)^+$.

[001473] **2-[2-[2-[[4-MethoxyphenylOmethyl-methyl-amino] ethoxy] ethoxy] ethanamine [Intermediate (CR)**



CR


[001474] Step 1 - Tert-butyl N-r2-r2-r2-r(4-methoxyphenv0methyl-methyl-aminolethoxylethoxylethyll carbamate

[001475] To a mixture of 2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethyl methanesulfonate (1.30 g, 3.97 mmol, synthesized via Step 1 of Intermediate AM) and l-(4-methoxyphenyl)-N-methyl-methanamine (600 mg, 3.97 mmol) in DMF (15 mL) was added K2CO3 (1.10 g, 7.94 mmol). The reaction mixture was stirred at rt for 16 hours. On completion, the mixture was diluted with water (10 mL) and extracted with DCM (3 X 20 mL). The organic layers were dried over anhydrous Na_2S0_4, filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase chromatography (0.1% $NH_3•H_2O$) to give the title compound (670 mg, 44% yield) as a light yellow oil. LC-MS (ESI^+) m/z 383.2 $(M+H)^+$.

[001476] Step 2 - 2-[2-[2-[(4-Methoxyphenvl)methyl-methyl-amino] ethoxy] ethoxy] ethanamine

[001477] To a mixture of tert-butyl N-[2-[2-[2-[(4-methoxyphenyl)methyl-methyl-amino]ethoxy]ethoxy]ethyl] carbamate (470 mg, 1.23 mmol) in DCM (4 mL) was added HC1 in dioxane (4 M, 1.5 mL). The reaction mixture was stirred at rt for 2 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (350 mg, 95% yield) as a light yellow oil. LC-MS (ESI^+) m/z 283.1 $(M+H)^+$.

[001478] 5-[l-amino-3,6,9,12-tetraoxapentadec-14-yn-15-vn-2-[2,6-dioxopiperidin-3-vPisoindoline-l.,3-dione hydrochloride [Intermediate CS)



[001479] Step 1 - tert-butyl (1 5-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-3,6,9,12-tetraoxapentadec-14-yn-1-yncarbamate


[001480] In a flame dried reaction assembly equipped with nitrogen bubbler was prepared a solution of 5-bromo-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (1.0 g, 3.0 mmol, Intermediate CO) and *tert*-butyl (3,6,9, 12-tetraoxapentadec-14-yn-1-yl)carbamate (1.18 g, 3.56 mmol, Intermediate EW) in DMF (20mL) at rt. Cuprous iodide (0.11g, 0.59 mmol) and TEA (5.0 mL, 36.0 mmol) were sequentially added to the reaction mixture at rt. The resulting reaction mixture was degassed with argon for 10-15 min. Then $Pd(PPh_3)_2Cl_2$ (0.02 g, 0.029 mmol) was added to the reaction mixture and argon purging was continued for 5-10 min. The reaction mixture was then heated at 70 °C and stirred for 0.5 h under argon atmosphere. The resulting reaction mixture was then cooled to rt and concentrated on a rotary evaporator. The obtained crude product was purified by gradient column chromatography using neutral alumina as stationary phase and DCM/IPAas a mobile phase. The title compound (1.1g, 63%) was isolated as a light yellow viscous oil which solidified upon standing overnight at 0-5 °C temperature. LC-MS (ESI^+) m/z 488.0 $(M-100+H)^+$.

[001481] Step 2 - 5-(1-amino-3, 6,9,12-tetraoxapentadec-14-yn-15-v0-2-(2,6-

dioxopiperidin-3-vOisoindoline-L3-dione hydrochloride

[001482] To a solution of tert-butyl (l5-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-3,6,9,l2-tetraoxapentadec-l4-yn-l-yl)carbamate (2.1 g, 35.8 mmol) in l,4-dioxane (5 mL) was added 4N HC1 in Dioxane (20 mL) at rt. The reaction mixture was stirred at rt for 5h. The resulting reaction mixture was concentrated under vacuum to get a brown color viscous liquid which was further triturated with diethyl ether (20 mL) followed by n-pentanes (30 mL) to give the title compound (1.9 g, 99%) as a yellowish hydroscopic solid. LC-MS (ESI^+) m/z 488.0 $(M+H)^+$.

[001483] 5-[l-amino-3,6,9,12-tetraoxapentadecan-15-vn-2-[2,6-dioxopiperidin-3-vPisoindoline-l.,3-dione hydrochloride [Intermediate CT)



CT


[001484] Step-l tert-butyl (l 5-(2-(2.6-dioxopiperidin-3-yl)- 1.3-dioxoisoindolin-5-yl)-3,6,9,l2-tetraoxapentadecvDcarbamate

[001485] To a solution of tert-butyl (l5-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-3,6,9,l2-tetraoxapentadec-l4-yn-l-yl)carbamate (3.0 g, 51.0 mmol, synthesized via Step 1 of Intermediate CS) in ethanol (100 mL) was added Pd/C (1.5 g, 10 wt %) under nitrogen atmosphere. Hydrogen gas was purged into the reaction mixture and the reaction was stirred for 6 h at rt. The resulting reaction mixture was filtered through a pad of celite and washed with ethanol (30 mL). The resulting filtrate was concentrated under vacuum to give the title compound (3.0 g, 96%) as a green viscous oil. LC-MS (ESI^+) m/z 492.0 $(M-l00+H)^+$.

[001486] Step-2 5-(l-amino-3.6.9.l2-tetraoxapentadecan-l5-vO-2-(2.6-dioxopiperidin-3-vDisoindoline-L3-dione hydrochloride

[001487] To a solution of tert-butyl (l5-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-3,6,9,l2-tetraoxapentadecyl)carbamate (3.0 g, 50.7 mmol) in l,4-dioxane (20 mL) was added 4N HC1 in dioxane (25 mL) at it. The reaction mixture was stirred at rt for 5h. The resulting reaction mixture was concentrated under vacuum to get a brown color viscous liquid which was further triturated with diethyl ether (30 mL) followed by n-pentanes (30 mL) to give the title compound (2.5 g, 93%) as a brown liquid. LC-MS (ESI^+) m/z 492.4 $(M+H)^+$.

[001488] **4-[4-[[6-[2-[Tert-butoxycarbonyl[2,2,2-trifluoroethvnamino] -4-pyridyl1pyridine-2-carbonyl1 aminol-3-carbamoyl-pyrazol-l-yl] benzoic acid [Intermediate CU)**



[001489] Step 1 - Ethyl 6-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino1-4-pyridyllpyridine-2- carboxylate

[001490] To a mixture of ethyl 6-bromopyridine-2-carboxylate (1.50 g, 6.52 mmol) and tert-

butyl A-[4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-2-pyridyl]-A-(2,2,2-trifluoroethyl)carbamate (5.46 g, 6.52 mmol, synthesized via Steps 1-3 of Intermediate CM) in a mixed solvent of dioxane (40 mL) and H_20 (8 mL) was added CS2CO3 (6.37 g, 19.5 mmol) and Pd(dppf)Cl_2 (238 mg, 326 umol). The reaction mixture was stirred at 80 °C for 16 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo.* The residue was purified by column chromatography to give the title compound (1.90 g, 68% yield) as a light yellow oil. LC-MS (ESI+) *m/z* 448.0 $(M+Na)^+$.

[001491] Step 2 - 6-r2-rTert-butoxycarbonyl(2.2.2-trifluoroethyl)amino1-4-pyridyl1pyridine-2-carboxylic acid

[001492] To a mixture of methyl 6-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]pyridine-2- carboxylate (800 mg, 1.94 mmol) in a mixed solvent of THF (6 mL), H_20 (1 mL) and MeOH (1 mL) was added LiOH (93. 1 mg, 3.89 mmol). The reaction mixture was stirred at rt for 0.5 hour. On completion, the reaction mixture was acidified with HC1 (1 N) until the pH = 5-6 and concentrated *in vacuo* to give the title compound (700 mg, 95% yield) as a white solid. LC-MS (ESL) *m/z* 420.1 $(M+Na)^+$.

[001493] Step 3 - Methyl 4-[4-[[6-[2-[tert-butoxycarbonyl(2,2,2-trif uoroethyl)amino1-4-pyridyllpyridine-2- carbonyllaminol-3-carbamoyl-pyrazol-l-yllbenzoate


[001494] To a mixture of methyl 4-(4-amino-3 -carbarn oyl-pyrazol-l-yl)benzoate (550 mg, 2.11 mmol, Intermediate CL) and DIPEA (975 mg, 7.55 mmol in DMF (8 mL) was added 6-[2-[tert-butoxy carbonyl (2,2,2-trifluoroethyl)amino]-4-pyridyl]pyridine-2-carboxylic acid (600 mg, 1.51 mmol) and HATU (688 mg, 1.81 mmol). The reaction mixture was stirred at rt for 0.5 hour. On completion, the reaction mixture was diluted with water (10 mL) and extracted with EA (4 X lOmL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (0.1% FA) to give the title compound (140 mg, 14% yield) as a white solid. LC-MS (ESI+) *m/z* 640.2 $(M+H)^+$.

[001495] Step 4 - 4-[4-[[6-[2-[Tert-butoxycarbonyl(2.2.2-trif uoroethyl)amino1-4-pyridyl1pyridine-2-carbonyl1 aminol-3-carbamoyl-pyrazol-l-yllbenzoic acid

[001496] To a mixture of methyl 4-[4-[[6-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl] pyridine-2-carbonyl]amino]-3-carbamoyl-pyrazol-l-yl]benzoate (80.0 mg, 125 umol) in a mixed solvent of THF (4 mL), MeOH (1 mL) and H2O (1 mL) was added LiOH (14.9 mg, 625 umol). The reaction mixture was stirred at rt for 4 hours. On completion, the

reaction mixture was acidified with HC1 (1 N) until the pH =5-6 and concentrated *in vacuo* to give the title compound (120 mg, 100% yield) as a brown solid. LC-MS (ESI^+) *m/z* 626.2 $(M+H)^+$.

[001497] **N-[l-[4-[bromomethvnphenyl]-3-carbamoyl-pyrazol-4-yl]-2-[2-[2,2,2-trifluoroethylamino) -4-pyridyl]oxazole-4-carboxamide [Intermediate CV)**



[001498] Step 1 - Tert-butyl N-[4-[4-[[3-carbamoyl-1-[4-(hydroxymethyl)phenyl]pyrazol-4-yl]carbamoyl] oxazol-2-yl]-2-pyridyl]-N-(2.2.2-trifluoroethyl)carbamate


[001499] To a solution of 4-[4-[[2-[2-[/er/-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4- carbonyl]amino]-3-carbamoyl-pyrazol-l-yl]benzoic acid (1.00 g, 1.62 mmol, Intermediate CN) in THF (30 mL) was added TEA (329 mg, 3.25 mmol) and isopropyl carbonochloridate (398 mg, 3.25 mmol). The mixture was stirred at -10 °C for 2 hours, then the mixture was filtered and washed with THF (30 mL). To the filtrate was then added $NaBH_4$ (246 mg, 6.50 mmol) and H_20 (5 mL) at 0 °C and the mixture was stirred at 0 °C for 1 hour. On completion, the mixture was extracted with DCM (200 mL). The organic layer was concentrated *in vacuo* and the residue was triturated in DCM to give the title compound (420 mg, 43% yield) as a white solid. LC-MS (ESI^+) *m/z* 602.2 $(M+H)^+$.

[001500] Step 2 - N-[1-[4-(bromomethyl)phenyl]-3-carbamoyl-pyrazol-4-yl]-2-[2-(2,2,2-trifluoroethylamino) -4-pyridyl]oxazole-4-carboxamide

[001501] To a mixture of *tert*-butyl N-[4-[4-[[3-carbamoyl-l-[4-(hydroxymethyl)phenyl]pyrazol-4-yl] carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (0.25 g, 416 umol) in DCM (5 mL) was added PBr_3 (169 mg, 623 umol).

Then the reaction mixture was stirred at rt for 3 hours. On completion, the reaction mixture was quenched with water (20 mL), washed with saturated $NaHCO_3$ (30 mL), and extracted with DCM (3 X 30 mL). The organic layer was dried with Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (0.10 g, 34% yield) as a pale solid. LC-MS (ESI^+) *m/z* 565.9 $(M+H)^+$.

[001502] **4-[4-[[2-[2-[Tert-butoxycarbonyl[2.,2.,2-trifluoroethv0aminol-4-pyridyl]oxazole-4 -carbonyl] amino]-3-carbamoyl-pyrazol-l-yl]cvclohexanecarboxylic acid [Intermediate_ CW)**



[001503] Step 1 - Methyl 4-methylsulfonyloxycyclohexanecarboxylate

[001504] To a solution of methyl 4-hydroxycyclohexanecarboxylate (5.00 g, 31.6 mmol) and TEA (6.40 g, 63.2 mmol, 8.80 mL) in DCM (50 mL) was added MsCl (4.34 g, 37.9 mmol, 2.94 mL) dropwise at 0 °C. Then the reaction mixture was allowed to warm to rt and stirred for 3 hours. On completion, the mixture was diluted with H_2O (20 mL), then extracted with DCM (2 X 40 mL). The combined organic phase was dried over by Na_2SO_4 and concentrated *in vacuo* to give the title compound (7.00 g, 93% yield) as a white solid.

[001505] Step 2 - Methyl 4-(3-carbamoyl-4-nitro-pyrazol-l-vDcvclohexanecarboxylate

[001506] To a solution of 4-nitro-lH-pyrazole-3-carboxamide (4.62 g, 29.6 mmol,

Intermediate CJ) and methyl 4-methylsulfonyloxycyclohexanecarboxylate (7.00 g, 29.6 mmol) in DMF (100 mL) was added CS_2CO_3 (19.3 g, 59.2 mmol). The reaction mixture was stirred at 130 °C for 12 hours. On completion, the mixture was filtered, and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase chromatography (0.1% $NH_3.H_2O$) to give the title compound (2.20 g, 25% yield) as a yellow oil. LC-MS (ESI^+) m/z 297.2 $(M+H)^+$.

[001507] Step 3 - Methyl 4-(4-amino-3 -carbamoyl-pyrazol-l-vDcvclohexanecarboxylate

[001508] To a solution of methyl 4-(3 -carbamoyl-4-nitro-pyrazol-l-yl)cyclohexanecarboxylate (0.60 g, 2.03 mmol) in MeOH (10 mL) was added Pd/C (400 mg, 10 wt %). The reaction mixture was stirred under hydrogen atmosphere (15 psi pressure) at rt for 16 hours. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (490 mg, 90% yield) as a purple oil. LC-MS (ESI^+) m/z 267.1 $(M+H)^+$.

[001509] Step 4 - methyl 4-r4-rr2-r2-rtert-butoxycarbonyl(2.2.2-trifluoroethv0amino1-4-pyridylloxazole-4- carbonyllaminol-3-carbamoyl-pyrazol-l-yllcvclohexanecarboxylate


[001510] To a solution of methyl 4-(4-amino-3 -carbamoyl-pyrazol-l-yl)cyclohexanecarboxylate (150 mg, 563 umol) and 2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (218 mg, 563 umol, Intermediate CM) in DMF (5 mL) was added DIPEA (363 mg, 2.82 mmol, 490 uL). The mixture was stirred at rt for 12 minutes, then HATU (257 mg, 675 umol) was added and the reaction mixture was stirred at rt for 12 hours. On completion, the mixture was diluted with H_2O (10 mL) and then extracted with EtOAc (2 X 20 mL). The organic phase was dried over Na_2S0_4, filtrated and concentrated *in vacuo* to give the title compound (400 mg, 83% purity, 92% yield) as a white solid. LC-MS (ESI^+) m/z 636.2$(M+H)^+$.

[001511] Step 5 - 4-⌈4-⌈⌈2-⌈2-⌈Tert-butoxycarbonyl(2.2.2-trif]uoroethvl)amino1-4-pyridylloxazole-4 -carbonyl] aminol-3-carbamoyl-pyrazol-l-yllcvclohexanecarboxylic acid

[001512] To a solution of methyl 4-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl] oxazole-4 -carbonyl]amino]-3-carbamoyl-pyrazol-l-yl]cyclohexanecarboxylate (400 mg, 629 umol) in THF (10 mL) and H_20 (2 mL) was added LiOH (22.6 mg, 944 umol). The reaction mixture was stirred at rt for 12 hours. On completion, the mixture was concentrated *in vacuo* to remove THF, then diluted with H_20 (20 mL). The mixture was adjusted to pH = 5 with 1N HC1, then extracted with EA (2 X 40 mL). The combined organic phase was dried with Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (330

mg, 84%) as a yellow solid. LC-MS (ESI^+) m/z 644.2 $(M+Na)^+$.

[001513] **N-[3-carbamoyl-l-[4-piperidvnpyrazol-4-yll-2-[2-[2,2,2-trifluoroethylaminol-4-pyridyl] oxazole-4-carboxamide [Intermediate CX)**



CX

[001514] Step 1 - Tert-butyl 4-methylsulfonyloxypiperidine-l-carboxylate

[001515] To a mixture of tert-butyl 4-hydroxypiperidine-l-carboxylate (5.00 g, 24.8 mmol) and TEA (5.03 g, 49.6 mmol) in DCM (50 mL) was added MsCl (4.27 g, 37.2 mmol). The reaction mixture was stirred at rt for 0.5 hour. On completion, the reaction mixture was diluted with water (10 mL) and acidified with citric acid solution until the pH = 5-6. Then the mixture was extracted with DCM (3 X 15 mL). The combined organic layers were diluted with water (10 mL) and basified with $NaHC0_3$ solution until the pH = 7-8. Then the mixture was extracted with DCM (3 X 15 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (7.00 g, 90% yield) as a white solid. ^1H NMR (400MHz, CDCh) δ 4.84 m 4.78 (m, 1H), 3.68 - 3.59 (m, 2H), 3.26 - 3.20 (m, 2H), 2.97 (s, 3H), 1.94 - 1.84 (m, 2H), 1.80 - 1.69 (m, 2H), 1.39 (s, 9H).

[001516] Step 2 - Tert-butyl 4-(3-carbamoyl-4-nitro-pyrazol-l-vDpiperidine-l-carboxylate

[001517] To a mixture of 4-nitro-lH-pyrazole-3-carboxamide (3.91 g, 25.0 mmol, Intermediate CJ) and tert-butyl 4-methylsulfonyloxypiperidine-l-carboxylate (7.00 g, 25.0 mmol) in DMF (70 mL) was added CS_2CO_3 (16.3 g, 50.1 mmol). The reaction mixture was stirred at 130 °C for 16 hours. On completion, the reaction mixture was concentrated *in vacuo*. The residue was purified by prep-HPLC (0.1 % $NH_3 \cdot H_2O$) to give the title compound (1.80 g, 21% yield) as a brown solid. ^1H NMR (400MHz, DMSO-r¾) δ = 8.95 (s, 1H), 8.00 (s, 1H), 7.76 (s, 1H), 4.49 - 4.43 (m, 1H), 4.06 (d, *J* = 11.6 Hz, 2H), 3.01 -2.70 (m, 2H), 2.04 *(d, J* = 9.6 Hz, 2H), 1.87 - 1.70 (m, 2H), 1.42 (s, 9H).

[001518] Step 3 - Tert-butyl 4-(4-amino-3-carbamoyl-pyrazol-l-vDpiperidine-l-carboxylate

[001519] To a mixture of tert-butyl 4-(3-carbamoyl-4-nitro-pyrazol-l-yl)piperidine-1-carboxylate (1.80 g, 5.30 mmol) in MeOH (30 mL) was added Pd/C (1.00 g, 10 wt %) under hydrogen atmosphere (15 psi pressure). The reaction mixture was stirred at rt for 16 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (610 mg, 100% yield) as a light yellow solid. ¾NMR (400MHz, DMSO-de) δ 7.17 (s, 1H), 7.08 (s, 1H), 6.98 (s, 1H), 4.70 - 4.53 (m, 2H), 4.25 - 4.17 (m, 1H), 4.03 (d, *J* = 11.2 Hz, 2H), 2.99 - 2.80 (m, 2H), 1.94 *(d, J* = 10.0 Hz, 2H), 1.80 - 1.70 (m, 2H), 1.42 (s, 9H).

[001520] Step 4 - Tert-butyl4-[4-[[2-[2-[tert-butoxycarbonyl(2.2.2-trifluoroethyl)amino1-4-pyridylloxazole-4- carbonyllaminol-3-carbamoyl-pyrazol-l-yllpiperidine-l-carboxylate


[001521] To a mixture of tert-butyl 4-(4-amino-3-carbamoyl-pyrazol-l-yl)piperidine-1-carboxylate (159 mg, 516 umol) and DIPEA (200 mg, 1.55 mmol) in DMF (5 mL) was added 2-[2-[tert-butoxycarbonyl (2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (200 mg, 516 umol, Intermediate CM) and HATU (235 mg, 619 umol). The reaction mixture was stirred at rt for 0.5 hour. On completion, the reaction mixture was diluted with water (10 mL) and extracted with EA (3 X lOmL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (400 mg, 80% purity, 91% yield) as a light yellow solid. LC-MS (ESI^+) *m/z* 679.3 $(M+H)^+$.

[001522] Step 5 - N-[3-carbamoyl-1-(4-piperidyl)pyrazol-4-yl1-2-r2-(2.2.2-trifluoroethylamino)-4-pyridyl1 oxazole-4-carboxamide

[001523] To a mixture of tert-butyl 4-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl] oxazole-4-carbonyl]amino]-3-carbamoyl-pyrazol-l-

yl]piperidine-l-carboxylate (400 mg, 589 umol) in DCM (4 mL) was added HC1 in dioxane (4 M, 2 mL). The reaction mixture was stirred at rt for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (280 mg, HC1 salt) as a light yellow solid. LC-MS (ESL) *m/z* 479.2 $(M+H)^+$.

[001524] **Tert-butyl 2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)acetate [Intermediate CY)**



[001525] Step 1 - 2-(2-(2-Hydroxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate

[001526] To a solution of 2-[2-(2-hydroxyethoxy)ethoxy] ethanol (50.0 g, 333 mmol, 44.6 mL) in DCM (1 L) was added Ag_20 (84.9 g, 366 mmol) and KI (5.53 g, 33.3 mmol) and TsCl (63.5 g, 333 mmol). The reaction mixture was stirred at rt for 18 hours. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was purified by silica gel chromatography to give the title compound (76.0 g, 74% yield) as a colorless oil. ^{1}H NMR (400MHz, CDCh) δ 7.81 (d, *J* = 8.0 Hz, 2H), 7.35 (d, *J* = 8.0 Hz, 2H), 4.20 - 4.15 (m, 2H), 3.74 - 3.69 (m, 4H), 3.64 - 3.56 (m, 6H), 2.45 (s, 3H); LC-MS (ESI^+) *m/z* 305.0 $(M+H)^+$.

[001527] Step 2 - 2-(2-(2-(2-Hvdroxyethoxy)ethoxy)ethyl)isoindoline-1J-dione

[001528] To a solution of 2-[2-(2-hydroxyethoxy)ethoxy]ethyl 4-methylbenzenesulfonate (20.0 g, 65.7 mmol) in DMF (200 mL) was added (l,3-dioxoisoindolin-2-yl)potassium (12.8 g, 69.0 mmol). The resulting reaction mixture was stirred at 80 °C for 12 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by silica gel chromatography to give the title compound (14.6 g, 80% yield) as a colorless oil. ^{1}H NMR (400MHz, CDCh) δ

7.89 - 7.83 (m, 2H), 7.75 - 7.69 (m, 2H), 3.95 - 3.90 (m, 2H), 3.79 - 3.74 (m, 2H), 3.69 - 3.64 (m, 4H), 3.63 - 3.59 (m, 2H), 3.56 - 3.52 (m, 2H).


[001529] Step 3 - Tert-butyl 2-(2-(2-(2-(L3-dioxoisoindolin-2-vDethoxy)ethoxy)ethoxy)acetate


[001530] To a solution of 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethyl]isoindoline-l,3-dione (10.0 g, 35.8 mmol) and Rh(OAc)2 (396 mg, 1.79 mmol) in DCM (50 mL) was added a solution of tert-butyl 2-diazoacetate (7.63 g, 53.7 mmol) in DCM (200 mL) dropwise. The reaction mixture was stirred at rt for 18 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by silica gel chromatography to give the title compound (11.0 g, 78% yield) as a colorless oil. ^{1}El NMR (400MHz, CDCh) δ 7.88 - 7.82 (m, 2H), 7.75 - 7.69 (m, 2H), 3.99 (s, 2H), 3.94 - 3.88 (m, 2H), 3.77 - 3.72 (m, 2H), 3.68 - 3.58 (m, 8H), 1.47 (s, 9H).

[001531] Step 4 - Tert-butyl 2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)acetate

[001532] To a solution of tert-butyl 2-[2-[2-[2-(l,3-dioxoisoindolin-2-yl)ethoxy] ethoxy] ethoxy] acetate (11.0 g, 28.0 mmol) in ethanol (200 mL) was added NH2NH2·H2O (7.00 g, 140 mmol). The reaction mixture was stirred at 80 °C for 2 hours. On completion, the reaction mixture was filtered. The filtrate was concentrated *in vacuo.* The residue was diluted with DCM (200 mL) and filtered. The filtrate was concentrated *in vacuo* to give the title compound (6.40g, 87% yield) as a colorless oil. ^{1}H NMR (400MHz, CDCh) δ 4.02 (s, 2H), 3.72 - 3.63 (m, 10H), 3.53 - 3.50 (m, 2H), 1.47 (s, 9H); LC-MS (ESI^{+}) *m/z* 264.0 (M+H)$^{+}$.

[001533] **Ethyl 2-[2-12-aminoethoxylethoxyl acetate [Intermediate CZ)**





CZ

[001534] Step **1** - Ethyl 2-r2-r2-(tert-butoxycarbonylamino)ethoxy1ethoxy1acetate


[001535] To a mixture of tert-butyl N-[2-(2-hydroxyethoxy)ethyl]carbamate (10.0 g, 48.7 mmol, CAS# 139115-91-6) and Rh(OAc)2 (215 mg, 974 umol) in DCM (150 mL) was added a solution of ethyl 2-diazoacetate (16.6 g, 146 mmol) in DCM (100 mL) dropwise. The reaction

mixture was stirred at rt for 20 hours. On completion, the reaction mixture was diluted with water (50 mL) and extracted with DCM (2 X 100 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (12.0 g, 84% yield) as a colorless oil. ^1H NMR (400MHz, CDCh) δ 4.23 - 4.16 (m, 4H), 4.11 (s, 1H), 4.05 - 3.97 (m, 2H), 3.67 - 3.58 (m, 3H), 3.51 - 3.41 (m, 2H), 1.47 - 1.37 (m, 9H), 1.28 - 1.26 (m, 3H).

[001536] Step 2 - Ethyl 2-r2-(2-aminoethoxy)ethoxy1acetate

[001537] To a mixture of ethyl 2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]acetate (3.00 g, 10.3 mmol) in DCM (20 mL) was added HC1 in dioxane (4 M, 10 mL). The reaction mixture was stirred at rt for 2 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (2.00 g, 100% yield) as a red brown oil. ^1H NMR (400MHz, CDCh) δ 4.27 - 4.14 (m, 3H), 4.12 (s, 1H), 4.07 - 3.93 (m, 2H), 3.75 - 3.69 (m, 3H), 3.67 (s, 2H), 3.45 - 3.36 (m, 1H), 1.29 (t, J = 7.6 Hz, 3H).

[001538] **Tert-butyl 2-[2-[2-|2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]acetate [Intermediate DA]**



DA

[001539] Step 1 - 2-r2-r2-r2-(2-Hvdroxyethoxy)ethoxy1ethoxy1ethyl1isoindoline- 1J-dione

[001540] To a solution of 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate (20.0 g, 57.4 mmol, synthesized via Step 1 of Intermediate AO) in DMF (200 mL) was added (l,3-dioxoisoindolin-2-yl)potassium (12.7 g, 68.8 mmol) and the mixture was

stirred at 80 °C for 2 h. On completion, the mixture was concentrated *in vacuo.* The residue was then diluted with EA (200 mL) and stirred for 30 min, filtered, and the organic layer was concentrated *in vacuo.* The mixture was purified by silica gel chromatography (petroleum ether: ethyl acetate = 1: 2) to give the title compound (9.00 g, 48% yield) as a yellow solid. ^{1}H NMR (400MHz, CDCh) δ 7.90 - 7.84 (m, 2H), 7.78 - 7.70 (m, 2H), 3.97 - 3.89 (m, 2H), 3.81 - 3.74 (m, 2H), 3.73 - 3.69 (m, 2H), 3.69 - 3.65 (m, 2H), 3.65 - 3.61 (m, 6H), 3.61 - 3.57 (m, 2H).


[001541] Step 2 - Tert-butyl 2-[2-[2-[2-[2-(E3-άioχoisθíηάo1ίη-2-yl)ethoxy]ethoxy] ethoxy] ethoxy] acetate

[001542] To a solution of 2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]isoindoline-l,3-dione (1.00 g, 3.09 mmol) and $Rh(OAc)_2$ (27.3 mg, 123 umol) in DCM (10.0 mL) was added a solution of tert-butyl 2-diazoacetate (1.32 g, 9.28 mmol) in DCM (20 mL) dropwise at rt for 1 hr. The reaction mixture was stirred at rt for 20 h. On completion, the mixture was extracted with H_20 (3 X 30 mL), the organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The mixture was purified by silica gel chromatography (petroleum ether: ethyl acetate = 3: 1) to give the title compound (1.00 g, 73% yield) as a yellow oil. ^{1}H NMR (400MHz, CDC13) δ 7.81 - 7.76 (m, 2H), 7.68 - 7.63 (m, 2H), 3.95 (s, 2H), 3.87 - 3.82 (m, 2H), 3.70 - 3.66 (m, 2H), 3.66 - 3.61 (m, 2H), 3.61 - 3.57 (m, 4H), 3.56 - 3.52 (m, 6H), 1.42 (s, 9H).

[001543] Step 3 - Tert-butyl 2-r2-r2-r2-(2-aminoethoxy)ethoxy1ethoxy1ethoxy1acetate

[001544] To a solution of tert-butyl 2-[2-[2-[2-[2-(l,3-dioxoisoindolin-2-yl)ethoxy] ethoxy] ethoxy] ethoxy] acetate (1.00 g, 2.29 mmol) in EtOH (15.0 mL) was added $NH_2NH_2Ή_20$ (233 mg, 4.57 mmol, 226 uL, 98% purity), and the mixture was stirred at 80 °C for 12 h. On completion, the mixture was concentrated *in vacuo.* The residue was diluted with DCM(30 mL), filtered and the organic layer was concentrated *in vacuo* to give the title compound (700 mg, 99% yield) as a yellow oil. ^{1}H NMR (400MHz, CDC13) δ 4.04 (s, 2H), 3.75 - 3.64 (m, 12H), 3.57 - 3.51 (m, 2H), 2.94 - 2.84 (m, 2H), 2.08 - 1.95 (m, 2H), 1.52 - 1.45 (m, 9H).

[001545] N-[l-[azetidin-3-vD-3-carbamoyl-pyrazol-4-yl]-2- [2-12,2,2-trifluoroethylaminol-4-pyridyl] oxazole-4-carboxamide [Intermediate DB)



[001546] Step 1 - Tert-butyl 3-methylsulfonyloxyazetidine-l-carboxylate

[001547] To a solution of tert-butyl 3-hydroxyazetidine-l-carboxylate (10.0 g, 57.7 mmol) and TEA (17.5 g, 24.1 mL, 173 mmol) in DCM (80.0 mL) was added MsCl (9.92 g, 86.6 mmol) at 0 °C. The mixture was then allowed to warm to rt and stirred for 30 min. On completion, the mixture was washed with H_20 (3 X 50 mL). The organic layer was washed with brine (3 X 30 mL), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (14.2 g, 97% yield) as a yellow oil. ^1H NMR (400MHz, CDCb) δ 5.25 - 5.17 (m, 1H), 4.33 - 4.25 (m, 2H), 4.15 - 4.09 (m, 2H), 3.08 (s, 3H), 1.46 (s, 9H).

[001548] Step 2 - Tert-butyl 3-(3-carbamoyl-4-nitro-pyrazol-l-vnazetidine-l-carboxylate

[001549] To a solution of tert-butyl 3-methylsulfonyloxyazetidine-l-carboxylate (8.85 g, 35.2 mmol) and 4-nitro-lH-pyrazole-3 -carboxamide (5.00 g, 32.0 mmol, Intermediate CJ) in DMF (110 mL) was added CS2CO3 (20.8 g, 64.0 mmol), and the mixture was stirred at l30°C for 16 h. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo.* The mixture was purified by reverse phase chromatography (0. 1% FA) to give the title compound (3.50 g, 35% yield) as a yellow solid. ^{1}HNMR (400MHz, CDCb) δ 9.04 (s, 1H), 8.06 (s, 1H), 7.83 (s, 1H), 5.36

- 5.22 (m, 1H), 4.38 - 4.27 (m, 2H), 4.22 - 4.08 (m, 2H), 1.41 (s, 9H).

[001550] Step 3 - Tert-butyl 3-(4-amino-3-carbamoyl-pyrazol-l-vDazetidine-l-carboxylate

[001551] To a solution of tert-butyl 3-(3-carbamoyl-4-nitro-pyrazol-l-yl)azetidine-l-carboxylate (500 mg, 1.61 mmol) in MeOH (5.00 mL) was added Pd/C (50.0 mg, 10 wt %) under nitrogen. The suspension was degassed under vacuum and purged with hydrogen gas several times. The mixture was stirred under hydrogen atmosphere (15 psi pressure) at rt for 14 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (335 mg, 74% yield) as a purple oil. LC-MS (ESI^+) *m/z* 304.0 $(M+Na)^+$

[001552] Step 4 - Tert-butyl 3-[4-[[2-[2-[tert-butoxycarbonyl(2.2.2-trifluoroethyl)amino1-4-pyridyll oxazole-4-carbonyl1amino1-3-carbamoylpyrazol-l-yl1azetidine-l-carboxylate

[001553] To a solution of tert-butyl 3-(4-amino-3-carbamoyl-pyrazol-l-yl)azetidine-1-carboxylate (145 mg, 516 umol), 2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (200 mg, 516 umol, Intermediate CM) in DMF (3.00 mL) was added HATU (235 mg, 619 umol) and DIPEA (333 mg, 2.58 mmol, 449 uL), and the mixture was stirred at rt for 30 min. On completion, the mixture was diluted with EI_2O (20 mL) and stirred for 20 min. The mixture was filtered and the solid was dried *in vacuo* to give the title compound (250 mg, 74% yield) as a white solid. ^1H NMR (400MHz, DMS04) δ 11.01 (s, 1H), 9.07 (s, 1H), 8.66 (d, *J* = 5.2 Hz, 1H), 8.49 (s, 1H), 8.25 (s, 1H), 7.83 (s, 1H), 7.77 (d, *J* = 5.2 Hz, 1H), 7.59 (s, 1H), 5.42 - 5.32 (m, 1H), 4.96 - 4.87 (m, 2H), 4.36 - 4.28 (m, 2H), 4.27 - 4.17 (m, 2H), 1.53 (s, 9H), 1.43 (s, 9H)

[001554] Step 5 - N-[1-iazetidin-3-yl)-3-carbamoyl-pyrazol-4-yl 1-2-[2-(2,2.2-trifluoroethylamino)-4-pyridyl1 oxazole-4-carboxamide

[001555] To a solution of tert-butyl 3-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl] oxazole-4-carbonyl]amino]-3-carbamoyl-pyrazol-l-yl]azetidine-l-carboxylate (220 mg, 338 umol) in DCM (5.00 mL) was added TFA (7.70 g, 67.5 mmol), and the mixture was stirred at rt for 30 min. On completion, the mixture was concentrated *in vacuo* to give the title compound (190 mg, 99% yield, TFA salt) as a white solid. LC-MS (ESI^+) *m/z* 451.2 $(M+H)^+$.


[001556] **2-[2-[2-[2-Aminoethoxylethoxy] ethoxy]ethanol [Intermediate PC)**



DC

[001557] To a solution of tert-butyl N-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]carbamate (2.00 g, 6.82 mmol, synthesized via Steps 1-3 of Intermediate AO) in DCM (30 mL) was added HC1 in dioxane (4 M, 10.2 mL), and the mixture was stirred rt for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (1.30 g, 82% yield, HC1 salt) as a brown oil. ^{1}H NMR (400MHz, DMSO-d_6) δ 8.03 (s, 2H), 3.57 - 3.50 (m, 13H), 3.43 - 3.41 (m, 2H), 2.97 - 2.90 (m, 2H).

[001558] **3-[4-[[2-[2-[tert-butoxycarbonyl[2,2,2-trifluoroethvnamino]-4-pyridyl1oxazole-4-carbonyl1 amino1-3-carbamoyl-pyrazol-l-yl1benzoic acid [Intermediate DPI**



[001559] Step 1 - Ethyl (2Z)-2-[(3-bromophenyl)hydrazono]-2-chloro-acetate

[001560] To a mixture of 3-bromoaniline (30.0 g, 174 mmol) in a mixed solvent of HC1 (12 M, 43.6 mL) and H_20 (30.0 mL) was added a solution of $NaN0_2$ (13.2 g, 191 mmol) in H_20 (10 mL) at -5 °C dropwise. Then the mixture was stirred at 0 °C for 0.5 hr. Ethyl 2-chloro-3-oxo-butanoate (30.1 g, 183 mmol) and NaOAc (42.9 g, 523mmol) were added to the solution and the mixture was stirred for 30 min. The reaction mixture was then allowed to warm to rt and stirred for an additional for 2 h. On completion, the mixture was filtered and the filter cake was dried *in vacuo* to give the title compound (46.6 g, 87% yield) as a yellow solid. ^1H NMR (400MHz, DMSO-*ck)* δ 10.68 (s, 1H), 7.53 (t, *J* = 2.0 Hz, 1H), 7.38 - 7.33 (m, 1H), 7.29 (t, *J* = 8.0 Hz, 1H), 7.19 - 7.14 (m, 1H), 4.30 (q, *J* = 7.2 Hz, 2H), 1.30 (t, *J* = 7.2 Hz, 3H).

[001561] Step 2 - Ethyl l-(3-bromophenvD-4-nitro-pyrazole-3-carboxylate

[001562] Ethyl (2Z)-2-[(3-bromophenyl)hydrazono]-2-chloro-acetate (2.50 g, 8.18 mmol), (E)-N,N- dimethyl-2-nitro-ethenamine (950 mg, 8.18 mmol) and TEA (827 mg, 8.18 mmol) were taken up into a microwave tube in CHCh (20 mL).The sealed tube was heated at 140 °C for 30 min under microwave. On completion, the mixture was concentrated *in vacuo.* The mixture was purified by silica column chromatography (PE: EA=l0: 1) to give the title compound (0.42 g, 15% yield) as a yellow solid. 1H NMR (400MHz, CDCh) δ 8.63 (s, 1H), 7.98 (t, *J* = 2.0 Hz, 1H), 7.71 - 7.66 (m, 1H), 7.64 - 7.61 (m, 1H), 7.46 - 7.40 (m, 1H), 4.54 (q, *J* = 7.2 Hz, 2H), 1.46 (t, *J* = 7.2 Hz, 3H).

[001563] Step 3 - l-(3-bromophenvO-4-nitro-pyrazole-3-carboxamide

[001564] To a solution of ethyl l-(3-bromophenyl)-4-nitro-pyrazole-3-carboxylate (3.00 g, 8.82 mmol) in THF (20.0 mL) was added N¾ ·H_20 (13.4 g, 115 mmol, 14.7 mL, 30 wt %), and the mixture was stirred at 110 °C for 16 h. On completion, the mixture was concentrated *in vacuo* to give the title compound (2.70 g, 90% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 312.9 $(M+H)^+$.

[001565] Step 4 - 4-amino-l-(3-bromophenvQpyrazole-3-carboxamide

[001566] To a solution of 1-(3-bromophenyl)-4-nitro-pyrazole-3 -carboxamide (2.70 g, 8.68 mmol) in MeOH (50.0 mL) and H_20 (25.0 mL) was added Fe (4.85 g, 86.7 mmol) and NH_4Cl (4.64 g, 86.7 mmol). The mixture was stirred at 80 °C for 3 h. On completion, the mixture was filtered and the filtrated was concentrated *in vacuo* to remove MeOH. The residue was extracted with EA (2 X 200 ml). The combined organic layer was then washed with water (200ml) and concentrated *in vacuo* to give the title compound (1.90 g, 77% yield) as a yellow solid. LC-MS

(ESI+) *m/z* 281.0 and 283.0 $(M+H)^+$.

[001567] Step 5 - Methyl 3-(4-amino-3-carbamoyl-pyrazol-l-vDbenzoate

[001568] To a solution of 4-amino- 1-(3-bromophenyl)pyrazole-3 -carboxamide (1.90 g, 6.76 mmol) in DMF (20 mL) and MeOH (20 mL) was added TEA (683 mg, 6.76 mmol) and $Pd(dppf)Cl_2$ (494 mg, 675 umol). The mixture was stirred at 80 °C for 16 h under CO atmosphere (50 psi pressure). On completion, the mixture was concentrated *in vacuo.* The mixture was purified by silica gel column chromatography (PE: EA=l : 1) to give the title compound (1.10 g, 62% yield) as a yellow solid. ^1H NMR (400MHz, DMSO-d) δ 8.38 (t, *J* = 2.0 Hz, 1H), 8.12 - 8.06 (m, 1H), 7.89 (s, 1H), 7.88 - 7.84 (m, 1H), 7.67 - 7.58 (m, 2H), 7.28 (s, 1H), 4.91 (s, 2H), 3.90 (s, 3H).

[001569] Step 6 - Methyl 3-[4-[[2-[2-[tert-butoxycarbonyl(2.2.2-trifluoroethyl)amino1-4-pyridylloxazole-4- carbonyllaminol-3-carbamoyl-pyrazol-l-yllbenzoate


[001570] To a solution of methyl 3-(4-amino-3 -carbamoyl-pyrazol-l-yl)benzoate (300 mg, 1.15 mmol), 2-[2-[tertbutoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (446 mg, 1.15 mmol, Intermediate CM) in DMF (5.00 mL) was added HATU (525 mg, 1.38 mmol) and DIPEA (446 mg, 3.46 mmol), and the mixture was stirred at 25 °C for 30 min. On completion, the mixture was diluted with H_20 (40 mL) and stirred for 30 min. The mixture was then filtered and the solid was dried *in vacuo* to give the title compound (660 mg, 90% yield) as off-white solid. ^1H NMR (400MHz, DMSO-d_6) δ 11.10 (s, 1H), 9.11 (s, 1H), 9.04 (s, 1H), 8.67 (d, *J* = 5.2 Hz, 1H), 8.50 (s, 1H), 8.31 - 8.25 (m, 2H), 8.18 (s, 1H), 7.97 (d, *J* = 7.6 Hz, 1H), 7.81 - 7.75 (m, 2H), 7.75 - 7.69 (m, 1H), 4.95 - 4.87 (m, 2H), 3.93 (s, 3H), 1.54 (s, 9H).

[001571] Step 7 - 3-[4-[[2-[2-[tert-butoxycarbonyl(2.2.2-trifluoroethyl)amino1-4-pyridyl1oxazole-4-carbonyl1 aminol-3-carbamoyl-pyrazol-l-yllbenzoic acid

[001572] To methyl 3-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl] oxazole-4-carbonyl]amino]-3-carbamoyl-pyrazol-l-yl]benzoate (660 mg, 1.05 mmol) in a solution of THF (10.0 mL), H_2O (1.00 mL) and MeOH (1.00 mL) was added LiOH (125 mg, 5.24 mmol), and the mixture was stirred at rt for 7 h. On completion, the mixture was diluted with H_20 (50 mL) and then acidified with 1N HC1 solution until the pH = 5. The mixture was then extracted with EA (3 X 40 mL). The combined organic layers were dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (620 mg, 96% yield) as an off-white solid. ^1H NMR (400MHz, DMSO-d_6) δ 13.33 (s, 1H), 11.10 (s, 1H), 9.11 (s, 1H), 9.02 (s, 1H), 8.66 (d, *J* = 5.2 Hz, 1H), 8.49 (s, 1H), 8.27 - 8.21 (m, 2H), 8.17 (s, 1H), 7.95 (d, *J* = 7.6 Hz, 1H), 7.80 -

7.74 (m, 2H), 7.71 - 7.65 (m, 1H), 4.95 - 4.85 (m, 2H), 1.53 (s, 9H).

[001573] **4-(4-(2-(2-((Tert-butoxycarbonyP(2,2,2-trifluoroethyPamino)pyridin-4-yPoxazole-4- carboxamido)-3-(trifluoromethyP-lH-pyrazol-l-yPbenzoic acid [Intermediate DE)**



[001574] Step 1 - 4-Nitro-3-(trifluoiOmethyD-lH-pyrazole

[001575] To a solution of 3-(trifluoromethyl)-lH-pyrazole (5.0 g, 36.7 mmol) in concentrated sulfuric acid (75 mL) was carefully added dropwise at 0 °C 65% HNO3 (8.91 g, 91.86 mmol, 6.36 mL). After stirring for 10 min the reaction mixture was heated to 115 °C, and stirring was continued at 115 °C for 4 h. On completion, the reaction mixture was cooled to rt. Then, the reaction mixture was poured onto the 200 mL ice, and extracted with ethyl acetate (3 X 150 mL). The combined organic layers were washed with brine (2 X 100 mL), dried over with anhydrous sodium sulfate, filtered and concentrated *in vacuo*. The residue was purified by silica gel chromatography (PE: EA = 10:1) to give the title compound (5.9 g, 89% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-d_6) δ 14.72 (s, 1H), 9.15 (s, 1H).

[001576] Step 2 - Methyl 4-(4-nitro-3-(trifluoromethyD-lE[-pyrazol-l-yDbenzoate

[001577] **A** mixture of 4-nitro-3-(trifluoromethyl)-lH-pyrazole (5.70 g, 31.5 mmol), (4-methoxycarbonylphenyl) boronic acid (7.00 g, 38.9 mmol), pyridine (9.96 g, 125.9 mmol) and $CU(OAC)_2$ (8.58 g, 47.2 mmol) in DCM (150 mL) was stirred at rt for 5 h. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by silica gel chromatography **(PE: EA=** 10: 1) to give the title compound (4.5 g, 45% yield) as a white solid. 'H NMR (400MHz, CDCh) δ 8.74 (d, J = 0.6 Hz, 1H), 8.22 - 8.12 (m, 2H), 7.82 - 7.74 (m, 2H), 3.90 (s, 3H).

[001578] Step 3 - Methyl 4-(4-amino-3-(trifluoromethv0-lH-pyrazol-l-v0benzoate

[001579] To a solution of methyl 4-[4-nitro-3-(trifluoromethyl)pyrazol-l-yl]benzoate (500 mg, 1.59 mmol) in a mixed solvent of DCM (20 mL) and MeOH (20 mL) was added Pd/C (100 mg, 10 wt %) under nitrogen. The suspension was degassed under vacuum and purged with hydrogen gas several times. The mixture was stirred under hydrogen atmosphere (15 psi pressure) at rt for 14 hours. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (450 mg, 97% yield) as a white solid. LC-MS (ESI^+) *m/z* 286.0 $(M+H)^+$.

[001580] Step 4 - Methyl 4-(4-(2-(2-((tert-butoxycarbonyl)(2.2.2-trifluoroethvDamino)pyridin-4-vDoxazole-4- carboxamido)-3-(trifluorom ethyl)- !H-pyrazol-l-vQbenzoate


[001581] To a solution of methyl 4-[4-amino-3-(trifluorom ethyl)pyrazol-l-yl]benzoate (150 mg, 526 umol) and 2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (204 mg, 526 umol, Intermediate CM) in DMF (5 mL) was added HATU (240 mg, 631 umol) and DIPEA (136 mg, 1.05 mmol, 183 uL). The mixture was stirred at rt for 1 hr. On completion, the reaction mixture was quenched with water 50 mL. A white precipitate formed which was filtered. The filter cake was dried over *in vacuo* to give the title compound (300 mg, 88% yield) as a white solid. ^1H NMR (400MHz, CDCh) δ 9.07 (s, 1H), 8.98 (s, 1H), 8.55 (d, *J* = 4.8 Hz, 1H), 8.45 (s, 1H), 8.37 (s, 1H), 8.19 (d, *J* = 8.0 Hz, 2H), 7.87 (d, *J* = 8.0 Hz, 2H), 7.73 (d, *J* = 4.0 Hz, 1H), 4.98 - 4.81 (m, 2H), 3.97 (s, 3H).

[001582] Step 5 - 4-(4-(2-(2-((Tert-butoxycarbonyl)(2.2.2-trif1uoroethyl)amino)pyridin-4-vDoxazole-4- carboxamido)-3-(trif1uoromethyl)- 1H-pyrazol- 1-yl ibenzoic acid

[001583] To a solution of methyl 4-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole -4-carbonyl]amino]-3-(trifluoromethyl)pyrazol-l-

yljbenzoate (300 mg, 458 umol) in THF (6 mL) and H_20 (2 mL) was added LiOHH $_20$ (38.5 mg, 917 umol). The mixture was stirred at rt for 12 h. On completion, the reaction mixture was concentrated *in vacuo* to remove THF. The residue was acidified with 1N HC1 until the pH = 4, then filtered. The filter cake was collected to give the title compound (460 mg, 99% yield) as a white solid. LC-MS (ESI^+) *m/z* 641.0 $(M+H)^+$.

[001584] **4-[4-[[2-[2-|Tert-butoxycarbonyl(cvclopropylmethyl)amino]-4-pyridyl]oxazole-4-carbonyl] amino]-3-carbamoyl-pyrazol-l-yl]benzoic acid intermediate D F)**



[001585] Step **1** - Tert-butyl N-(4-bromo-2-pyridv0-N-(cvclopropylmethv0carbamate

[001586] To a solution of tert-butyl /V-(4-bromo-2-pyridyl(carbamate (5.0 g, 18.3 mmol, synthesized via Step 1 of Intermediate CM) in DMF (50 mL) was added NaH (1.10 g, 27.5 mmol) at 0 °C for 30 minutes. Then bromomethylcyclopropane (2.97 g, 22.0 mmol) was added into the mixture. The reaction mixture was stirred at rt for 17 h. On completion, the mixture was quenched with water (40 mL) and extracted with EA (2 X 50 mL). The organic phase was washed with brine (60 mL), dried over Na_2S0_4, and concentrated *in vacuo.* The residue was purified by silica gel

chromatography to give the title compound (2.7 g, 45% yield) as a white solid. ^{1}H NMR (400MHz, CDCh) δ 8.18 (d, *J* = 5.2 Hz, 1H), 7.98 (d, *J* = 1.6 Hz, 1H), 7.17 (dd, *J* = 1.6, 5.2 Hz, 1H), 3.88 (d, *J* = 7.2 Hz, 2H), 1.55 (s, 9H), 1.22 - 1.15 (m, 1H), 0.47 - 0.40 (m, 2H), 0.28 - 0.23 (m, 2H).

[001587] Step 2 - Ethyl 2-r2-rtert-butoxycarbonyl(cvclopropylmethvDamino1-4-pyridylloxazole-4-carboxylate

[001588] To a solution of ethyl oxazole-4-carboxylate (1.16 g, 8.25 mmol) and tert-butyl N-(4-bromo-2-pyridyl)-N-(cyclopropylmethyl)carbamate (2.7 g, 8.25 mmol) in DMF (30 mL) was added tris-o-tolylphosphane (502 mg, 1.65 mmol), $Pd(OAc)_2$ (185 mg, 825 umol) and CS2CO3 (5.38 g, 16.5 mmol). The reaction mixture was stirred at 80 °C under nitrogen for 17 h. On completion, the mixture was diluted with water (50 mL) and extracted with EA (3 X 50 mL). The organic layer was washed with water (100 ml), dried over Na_2S0_4, and concentrated *in vacuo.* The residue was purified by silica gel chromatography to give the title compound (1.8 g, 56% yield) as a white oil. ^{1}H NMR (400MHz, CDCh) δ 8.50 (dd, *J* = 1.6, 5.2 Hz, 1H), 8.38 (s, 1H), 8.35 (s, 1H), 7.71 (dd, *j* = 1.6, 5.2 Hz, 1H), 4.46 (q, *j* = 7.2 Hz, 2H), 3.93 (d, *j* = 7.2 Hz, 2H), 1.57 (s, 9H), 1.44 (t, *J* = 7.2 Hz, 3H), 1.24 - 1.16 (m, 1H), 0.46 - 0.40 (m, 2H), 0.28 - 0.24 (m, 2H).

[001589] Step 3 - 2-r2-Tert-butoxycarbonyl(cvclopropylmethvDamino1-4-pyridvnoxazole-4-carboxylic acid

[001590] To a solution of ethyl 2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4- carboxylate (0.5 g, 1.29 mmol) in a mixed solvent of THF (5 mL) and H_20 (1 mL) was added LiOH (92.7 mg, 3.87 mmol). The reaction mixture was stirred at rt for 2 h. On completion, the mixture was acidified with 1N HC1 solution until the pH = 3-5, then extracted with EA (2 X 30 mL). The combined organic phase was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (460 mg, 99% yield) as a white solid. LC-MS (ESI^+) *m/z* 304.0 $(M-56)^+$.

[001591] Step 4 - Methyl 4-[4-[[2-[2-[tert-butoxycarbonyl(cvclopropylmethvl)amino]-4-pyridylloxazole-4- carbonyllaminol-3-carbamoyl-pyrazol-l-yllbenzoate


[001592] To a solution of 2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (360 mg, 1.00 mmol) and methyl 4-(4-amino-3 -carbarnoyl-pyrazol-l-yl)benzoate (443 mg, 1.70 mmol， Intermediate CL) in DMF (5 mL) was added DIPEA (647 mg, 5.01 mmol) and HATU (457 mg, 1.20 mmol). The reaction mixture was stirred at rt for

0.5 hr. On completion, the mixture was diluted with water (40 mL) and extracted with EA (2 X 30 mL). The combined organic layer was washed with brine (40 mL) and concentrated *in vacuo.* The residue was purified by silica gel chromatography to give the title compound (190 mg, 32% yield) as a white solid. LC-MS (ESI^+) *m/z* 602.3 $(M+H)^+$.

[001593] Step 5 - 4-r4-IT2-r2-rTert-butoxycarbonyl(cvclopiOPylrnethvDarnino1-4-pyridyl1oxazole-4-carbonyl1 aminol-3-carbamoyl-pyrazol-l-yllbenzoic acid

[001594] To a solution of methyl 4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole -4-carbonyl]amino]-3-carbamoyl-pyrazol-l-yl]benzoate (190 mg, 316 umol) in a mixed solvent of THF (3 mL), MeOH (2 mL) and H_20 (1 mL) was added LiOH (37.8 mg, 1.58 mmol). The reaction mixture was stirred at rt for 17 h. On completion, the mixture was acidified with 1N HC1 solution until the pH = 5-7, concentrated *in vacuo* to give the title compound (180 mg, 97% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 588.3 $(M+H)^+$.


[001595] **4-[(1,3-Dioxoisoindolin-2-vl)methyl]benzenesulfonyl chloride [Intermediate IK,)**



DG

[001596] A mixture of 2-benzylisoindoline-l,3-dione (5.00 g, 21.0 mmol) and sulfurochloridic acid (17. 1 g, 147 mmol, 9.82 mL) was stirred at 60 °C for 1.5 h until the evolution of hydrochloric gas ceased. On completion, the mixture was poured in a mixture of water and ice (100 mL), and a fine white precipitate was formed. The precipitate was filtered and washed with cold water. The precipitate was purified by column chromatography (dichloromethane: petroleum ether = 1:1) to give the title compound (5.20 g, 73% yield) as a white solid. ^1H NMR (400MHz, DMSO-di) δ 7.91 - 7.85 (m, 4H), 7.57 -7.55 (m, 2H), 7.30 - 7.25 (m, 2H), 4.77 (s, 2H).

[001597] **4-[AminomethvD-N-[3-cvano-4-methyl-lH-indol-7-vDbenzenesulfonamide [Intermediate I)H)**



[001598] Step 1 - 7-Bromo-4-methyl-lH-indole

[001599] To a solution of l-bromo-4-methyl-2-nitro-benzene (40.0 g, 185 mmol, 25.3 mL) in tetrahydrofuran (400 mL) was added bromo(vinyl)magnesium (1 M, 611 mL) at -60 °C under nitrogen gas atmosphere. The reaction mixture was then stirred at -30 °C for 1 hour. On completion, the reaction mixture was quenched with saturated ammonium chloride solution (150 mL), followed with water (100 mL). The mixture was concentrated *in vacuo* to remove the tetrahydrofuran. The residue was extracted with ethyl acetate (2 X 500 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo*. The residue was then purified by column chromatography (petroleum ether: ethyl acetate = 100:1) to give the title compound (18.0 g, 42% yield) as a yellow oil. ^{1}H NMR (400MHz, DMSO-d_6) δ 11.27 (br s, 1H), 7.37 (t, J = 2.8 Hz, 1H), 7.18 (d, J = 7.6 Hz, 1H), 6.75 (dd, J = 0.8, 7.6 Hz, 1H), 6.57 (dd, J = 1.6, 3.2 Hz, 1H), 2.44 (s, 3H).

[001600] Step 2 - 4-Methyl- lH-indole-7-carboxylic acid

[001601] To a mixture of potassium hydride (4.47 g, 34.27 mmol, 30 wt %) suspended in

anhydrous tetrahydrofuran (80 mL) was added 7-bromo-4-methyl- 1//-indole (6.00 g, 28.56 mmol) dissolved in tetrahydrofuran (30 mL) at 0 °C. After 15 minutes, the mixture was cooled to -70 °C and t-BuLi (1.3 M, 54.9 mL) was added dropwise, keeping the temperature below -65 °C. After further 15 minutes, carbon dioxide gas (15 psi pressure) was bubbled into the reaction and the reaction was slowly warmed to rt over 30 minutes. On completion, the reaction mixture was quenched with ice water (120 mL), and washed with ethyl acetate (3 X 60 mL). The aqueous phase was collected and acidified with 1 N hydrochloride acid solution until the pH < 7. Then, the mixture was extracted with ethyl acetate (3 X 60 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give the crude product as a brown solid. The crude product was triturated with petroleum ether: dichloromethane (10:1, 100 mL) to give the product (3.50 g, 69% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-rA) δ 12.82 (br s, 1H), 11.02 (br s, 1H), 7.67 (d, *J* = 7.6 Hz, 1H), 7.35 (t, *J* = 2.8 Hz, 1H), 6.92 (d, *J* = 7.6 Hz, 1H), 6.56 (dd, *J* = 2.0, 3.2 Hz, 1H), 2.54 (s, 3H).

[001602] Step 3 - Tert-butyl N-(4-methyl-lH-indol-7-v0carbamate

[001603] To a solution of 4-methyl-l//-indole-7-carboxylic acid (2.20 g, 12.5 mmol) in t-BuOH (36 mL) was added triethylamine (3.81 g, 37.6 mmol, 5.24 mL) and DPPA (4.49 g, 16.3 mmol, 3.54 mL). The mixture was stirred at 80 °C for 3 h. On completion, the reaction mixture was poured into ice water (150 mL) and extracted with ethyl acetate (3 X 80 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to get a residue. The residue was purified by column chromatography (petroleum ether: ethyl acetate = 10: 1 to 5:1) to give the title compound (2.00 g, 64% yield) as a white solid. ^{1}H NMR (400MHz, CDCh) δ 9.80 (br s, 1H), 7.14 (t, *J* = 2.8 Hz, 1H), 6.70 (d, *J* = 7.6 Hz, 1H), 6.60 (br s, 1H), 6.52 (br s, 1H), 6.45 (dd, *J* = 2.0, 2.8 Hz, 1H), 2.44 (s, 3H), 1.48 (s, 9H).

[001604] Step 4 - Tert-butyl N-(3-formyl-4-methyl-lH-indol-7-vDcarbamate

[001605] Phosphorus oxychloride (2.61 g, 17.0 mmol, 1.58 mL) was added to anhydrous A',A-dimethyl- formamide (20 mL) at 0 °C under nitrogen atmosphere and the reaction mixture was stirred for 30 minutes. Tert-butyl A-(4-methyl-l 7/-indol-7-yl (carbamate (2.80 g, 11.3 mmol) dissolved in *N*,A-dimethylformamide (8 mL) was then added dropwise and the reaction mixture was allowed to warm to rt and then stirred for 1.5 hrs. Next, to the reaction mixture was added 30% sodium hydroxide (100 mL) and the mixture was heated to reflux for 30 minutes. On completion, the mixture was extracted with ethyl acetate (3 X 150 mL). The organic phase was

collected, dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (Petroleum ether: Ethyl acetate = 3:1 to 0:1) to give the title compound (2.70 g, 86% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-di) δ 11.93 (br s, 1H), 9.99 (s, 1H), 9.04 (br s, 1H), 8.27 (s, 1H), 7.43 (br d, *J* = 6.0 Hz, 1H), 6.96 (d, *J* = 8.0 Hz, 1H), 2.76 (s, 3H), 1.55 (s, 9H).

[001606] Step 5 - Tert-butyl N-r3-(hydroxyiminomethyn-4-methyl-lH-indol-7-yl1carbamate

[001607] To a solution of tert-butyl A-(3-formyl-4-methyl-1H-indol-7-yl(carbamate (2.70 g, 9.84 mmol) in ethanol (80 mL) was added NH_2OH•HCl (1.03 g, 14.7 mmol) and anhydrous potassium acetate (2.90 g, 29.5 mmol). The mixture was stirred at 80 °C for 30 minutes. On completion, the reaction mixture was concentrated *in vacuo* to get a residue. The residue was diluted with water (60 mL) and extracted with ethyl acetate (3 X 60 mL). The organic phase was collected, dried over anhydrous magnesium sulfate, filtered and concentrated *in vacuo* to give the title compound (2.80 g, 98% yield) as a white solid. LC-MS (ESI^+) *m/z* 290.2 $(M+H)^+$.

[001608] Step 6 - Tert-butyl N-(3-cvano-4-methyl-lH-indol-7-v0carbamate

[001609] To a solution of tert-butyl A-[3-(hydroxyiminomethyl)-4-methyl-1*H*-indol-7-yl]carbamate (2.60 g, 8.99 mmol) in anhydrous tetrahydrofuran (70 mL) was added di(imidazol-l-yl)methanthione (3.20 g, 17.9 mmol) and the mixture was stirred at rt for 2 h. The reaction mixture was then concentrated *in vacuo* to get a residue. The residue was diluted with ice water (60 mL) and extracted with ethyl acetate (3 X 40 mL). The combined organic phase was collected, dried over anhydrous magnesium sulfate, filtered and concentrated *in vacuo* to get a residue. The residue was purified by column chromatography (Petroleum ether: Ethyl acetate = 5:1 to 2:1) to give the title compound (2.40 g, 98% yield) as a gray solid. ^{1}H NMR (400MHz, CDCh) δ 10.98 (br s, 1H), 7.74 (d, *J* = 3.2 Hz, 1H), 6.89 (d, *J* = 7.6 Hz, 1H), 6.81 (br s, 1H), 6.66 (br d, *J* = 6.8 Hz, 1H), 2.75 (s, 3H), 1.57 (s, 9H).

[001610] Step 7 - 7-Amino-4-methyl-lH-indole-3-carbonitrile

[001611] To a solution of tert-butyl N-(3-cyano-4-methyl-lH-indol-7-yl)carbamate (2.30 g, 8.48 mmol) in anhydrous dichloromethane (23 mL) was added trifluoroacetic acid (17.7 g, 155 mmol, 11.50 mL).The mixture was stirred at rt for 30 minutes. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was diluted with saturated sodium bicarbonate solution (50 mL) and extracted with ethyl acetate (3 X 30 mL). The combined organic phase was collected, dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to

give the crude product. The crude product was triturated with petroleum ether: dichloromethane (30:1, 50 mL) to give the title compound (1.40 g, 96% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-di) δ 11.73 (br s, 1H), 8.12 (d, *J* = 3.2 Hz, 1H), 6.67 (d, *J* = 7.6 Hz, 1H), 6.37 (d, *J* = 7.6 Hz, 1H), 5.09 (br s, 2H), 2.50 (br s, 3H).


[001612] Step 8 - N-(3-cvano-4-methyl-lH-indol-7-vO-4-r(L3-dioxoisoindolin-2-vDmethvnbenzenesulfon- amide

[001613] To a solution of 4-[(l,3-dioxoisoindolin-2-yl)methyl]benzenesulfonyl chloride (1.51 g, 4.50 mmol, Intermediate DG) in dichloromethane (30 mL) was added pyridine (646 mg, 8.18 mmol, 660 uL) and DMAP (49.9 mg, 408 umol) and 7-amino-4-methyl-liT-indole-3-carbonitrile (700 mg, 4.09 mmol). The mixture was stirred at rt for 3 h. On completion, the reaction mixture was concentrated *in vacuo* to get a residue. The residue was triturated with (dichloromethane: methanol = 10:1, 50 mL) to give the title compound (1.00 g, 51% yield) as a white solid. ¾ NMR (400MHz, DMSO-^e) δ 11.92 (d, *J* = 2.4 Hz, 1H), 9.97 (s, 1H), 8.15 (d, *J* = 3.2 Hz, 1H), 7.93 - 7.84 (m, 4H), 7.67 (d, *J* = 8.4 Hz, 2H), 7.46 (d, *J* = 8.4 Hz, 2H), 6.76 *(d, J* = 8.4 Hz, 1H), 6.59 (d, *J* = 8.0 Hz, 1H), 4.83 (s, 2H), 2.55 (s, 3H).

[001614] Step 9 - 4-(Aminomethyl)-N-(3-cvano-4-methyl-lH-indol-7-vObenzenesulfonamide

[001615] To a solution of /V-(3-cyano-4-methyl-lH-indol-7-yl)-4-[(l,3-dioxoisoindolin-2-yl)methyl]-benzene sulfonamide (1.00 g, 2.13 mmol) in ethanol (30 mL) was added hydrazine hydrate (2.13 g, 2.07 mL). The mixture was stirred at 80 °C for 2 h. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (1.05 g, 92% yield) as a white solid. LC-MS (ESI$^+$) *m/z* 341.1 $(M+H)^+$.

[001616] 2-[2-[2-[2-[2-[2-(Tert-butoxycarbonylaminolethoxyl ethoxy]ethoxy]ethoxy]ethoxy]acetic acid [Intermediate Dll



DI


[001617] Step_ 1 - Ethyl ***2-\2-\2-\2-\2-***(tert-butoxycarbonylamino)ethoxy1 ethoxy] ethoxy] ethoxy] ethoxy] acetate

[001618] To a mixture of tert-butyl *N-\2-\2-\2-\2-(2*-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethyl]carbamate (2.00 g, 5.93 mmol, synthesized via Step 1 of Intermediate AK) and $Rh_2(OAc)_4$ (52.4 mg, 119 umol) in dichloromethane (10 mL) was added a solution of ethyl 2-diazoacetate (1.01 g, 8.89 mmol, 931 uL) dissolved in dichloromethane (10 mL) dropwise at rt. Then the reaction mixture was stirred at rt for 17 h. On completion, the reaction mixture was quenched by adding water (15 mL) and was then extracted with dichloromethane (2 X 10 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel column chromatography (Petroleum ether: Ethyl acetate = 5:1 to 1:1) to give the title compound (370 mg, 15% yield) as a colorless oil. ¾NMR (400MHz, CDCh) δ 5.12 (s, 1H), 4.23 (q, *J* = 7.2 Hz, 2H), 4.16 (s, 2H), 3.76 - 3.64 (m, 16H), 3.56 (t, *J* = 5.2 Hz, 2H), 3.33 (d, *J* = 4.8 Hz, 2H), 1.46 (s, 9H), 1.30 (t, *J* = 7.2 Hz, 3H).

[001619] Step_ 2_ -_ 2-[2-[2-[2-[2-[2-(Tert-butoxycarb onylaminoiethoxyl ethoxy] ethoxy] ethoxy] ethoxy] acetic acid

[001620] To a mixed solution of ethyl 2-[2-[2-[2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]- ethoxy] ethoxy] acetate (370 mg, 877 umol) in tetrahydrofuran (4 mL), methanol (1 mL) and H_20 (1 mL) was added lithium hydroxide (41.8 mg, 1.75 mmol). The reaction mixture was stirred at rt for 0.5 hr. On completion, the reaction mixture was adjusted pH < 7 with 1 N hydrochloride acid solution, and then concentrated *in vacuo* to give the title compound (520 mg, 70% purity, 87% yield) as a light yellow oil. ^{1}H NMR (400MHz, CDCh) δ 5.33 (s, 1H), 4.67 (s, 1H), 3.88 (s, 2H), 3.61 - 3.55 (m, 16H), 3.47 (t, *J* = 5.2 Hz, 2H), 3.23 (d, *j* = 5.2 Hz, 2H), 1.37 (s, 9H).

[001621] 4-[2-Aminoethylaminol-2-[2,6-dioxo-3-piperidvnisoindoline-l,3-dione [Intermediate_ DJ)




[001622] Step 1 - Tert-butyl N-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethyl]carbamate

[001623] A mixture of 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-1,3-dione (2.07 g, 7.49 mmol, Intermediate R), *tert*-butyl N-(2-aminoethyl)carbamate (1.00 g, 6.24 mmol) and DIPEA (1.61 g, 12.5 mmol, 2.17 mL) in dioxane (10 mL) was stirred at 115 °C for 12 hours. On completion, the mixture was concentrated *in vacuo*. The residue was purified by column chromatography to give the title compound (0.90 g, 28% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-t_f) δ 11.09 (s, 1H), 7.58 (t, *J* = 7.6 Hz, 1H), 7.15 (d, *J* = 8.8 Hz, 1H), 7.08 - 6.96 (m, 2H), 6.71 (t, *J* = 5.6 Hz, 1H), 5.05 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.41 - 3.35 (m, 2H), 3.13 (m, 2H), 2.97 - 2.82 (m, 1H), 2.65 - 2.53(m, 2H), 2.07 - 1.96 (m, 1H), 1.37 (s, 9H).

[001624] Step 2 - 4-(2-Aminoethylamino)-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione

[001625] To a solution of *tert*-butyl N-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethyl] carbamate (0.30 g, 720 umol) in DCM (10 mL) was added HCl in dioxane (4 N, 3 mL). The reaction mixture was stirred at rt for 0.5 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (0.25 g, 98% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-d6) δ 11.12 (s, 1H), 7.63 (t, *J* = 7.8 Hz, 1H), 7.20 (d, *J* = 8.4 Hz, 1H), 7.10 (d, *J* = 6.8 Hz, 1H), 6.84 (t, *J* = 6.4 Hz, 1H), 5.05 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.62 - 3.57 (m, 2H), 3.01 - 2.89 (m, 2H), 2.90 - 2.89 (m, 1H), 2.62 - 2.55 (m, 2H), 2.05 - 2.03 (m, 1H).

[001626] **2-Chloro-N-cyclopropyl-5-ethynyl-pyridin-4-amine [Intermediate DL)**



DL

[001627] Step 1 - 5-Bromo-2-chloro-N-cyclopropyl-pyridin-4-amine

[001628] To a solution of 5-bromo-2,4-dichloro-pyridine (5 g, 22.0 mmol) and cyclopropanamine (1.32 g, 23.1 mmol) in DMF (50 mL) was added DIPEA (8.54 g, 66.1 mmol). The reaction mixture was stirred at 100 °C for 17 h. On completion, the mixture was diluted with H_2O (40 mL) and extracted with EA (2 X 40 mL). The organic layer was washed with brine (50 mL), dried with anhydrous Na_2SO_4, filtered and concentrated *in vacuo*. The residue was purified by silica gel chromatography to give the title compound (2.10 g, 39% yield) as a white solid. ^1H NMR (400MHz, CDCh) δ 8.14 (s, 1H), 6.90 (s, 1H), 5.22 (s, 1H), 2.56 - 2.49 (m, 1H), 0.96 - 0.90 (m, 2H), 0.69 - 0.64 (m, 2H); LC-MS (ESI$^+$) *m/z* 248.9 and 246.9 $(M+H)^+$.

[001629] Step 2 - 2-Chloro-N-cyclopropyl-5-(2-trimethylsilylethvnvDpyridin-4-amine


[001630] 5-Bromo-2-chloro-N-cyclopropyl-pyridin-4-amine (1.0 g, 4.0 mmol), Cul (46.2 mg, 242 umol) and Pd(PPh $_3$)2Cl2 (170 mg, 242 umol) was taken up into a microwave tube. Then ethynyl(trimethyl)silane (794 mg, 8.08 mmol), TEA (7.36 g, 72.7 mmol) and DMF (5 mL) were added into the above tube. The mixture was degassed with nitrogen gas for 5 minutes. The sealed tube was then heated to 120 °C for 1 h under microwave. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (900 mg, 45% yield) as a brown solid. LC-MS (ESI$^+$) *m/z* 265.0 $(M+H)^+$.

[001631] Step 3 - 2-Chloro-N-cyclopropyl-5-ethvnyl-pyridin-4-amine

[001632] To a solution of 2-chloro-N-cyclopropyl-5-(2-trimethylsilylethynyl)pyridin-4-amine (1.0 g, 3.8 mmol) in a mixed solvent of MeOH (10 mL) and DCM (10 mL) was added K_2CO_3 (2.09 g, 15.1 mmol). The reaction mixture was stirred at rt for 15 h. On completion, the mixture was filtered and concentrated *in vacuo*. The residue was purified by silica gel chromatography to give the title compound (268 mg, 35% yield) as a yellow solid.. 'H NMR

(300MHz, CDCh) δ 8.13 (s, 1H), 6.88 (s, 1H), 5.42 (s, 1H), 3.50 (s, 1H), 2.57 - 2.46 (m, 1H), 0.96 - 0.84 (m, 2H), 0.70 - 0.58 (m, 2H); LC-MS (ESI$^+$) *m/z* 193.0 $(M+H)^+$.

[001633] **2-[2-[2-|2-(Tert-butoxycarbonylamino)ethoxyl ethoxyl ethoxyl acetic_ acid [Intermediate DM]**



DM

[001634] Step 1 - Ethyl 2-r2-r2-r2-(tert-butoxycarbonylamino)ethoxy1ethoxy1ethoxy1


[001635] To a mixture of *tei*7-butyl /V-[2-[2-(2-hydroxyethoxy)ethoxy]ethyl]carhamate (3.00 g, 12.0 mmol, CAS# 139115-92-7) and $Rh(QAc)_2$ (106 mg, 481 umol) in DCM (70 mL) was added a solution of ethyl 2-diazoacetate (4.12 g, 36.1 mmol) in DCM (40 mL) dropwise. The reaction mixture was stirred at rt for ¦16 h. On completion, the reaction mixture was diluted with water (100 mL) and extracted with DCM (3 X 100 mL). The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo.* The residue was purified by column chromatography to give the title compound (600 mg, 14% yield) as a colorless oil. ^{1}H NMR (400MHz, $CDCl_3$) δ 5.15 - 5.13 (m, ¦1H), 4.23 (q, *J* = 7.2 Hz, 2H), 4.16 (s, 2H), 3.77 - 3.69 (m, 4H), 3.68 - 3.61 (m, 4H), 3.55 (t, *J* = 5.2 Hz, 2H), 3.32 (d, *J* = 4.8 Hz, 2H), 1.45 (s, 9H), 1.29 (t, *J* = 7.2 Hz, 3H).

[001636] Step 2 - 2-r2-r2-r2-(Tert-butoxycarbonylamino)ethoxy1ethoxy1ethoxy1acetic acid

[001637] To a solution of ethyl 2-[2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]acetate (300 mg, 894 umol) in a mixed solvent of MeOH (5 mL) and H_20 (5 mL) was added $LiOH•H_20$ (75.0 mg, 1.79 mmol). The reaction mixture was stirred at rt for 1 hour. On completion, the reaction mixture was concentrated *in vacuo.* The residue was acidified with IN HC1 solution until the pH=7. The mixture was lyophilized to give the title compound (300 mg, 100% yield) as a white solid.

[001638] **2-[2,6-Dioxo-3-piperidvD-4-[prop-2-vnylamino)isoindoline-l.,3-dione**

[Intermediate DN)




R DN

[001639] To a solution of prop-2-yn-l -amine (332 mg, 6.03 mmol, 386 uL) and DIPEA (3.90 g, 30.1 mmol, 5.25 mL) in dioxane (20.0 mL) was added 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (2.00 g, 7.24 mmol, Intermediate R), and the mixture was stirred at H5°C for 16 h. On completion, the mixture was concentrated *in vacuo.* The mixture was purified by reverse phase chromatography (0.1% FA) to give the title compound (550 mg, 29% yield) as a yellow solid. ^{1}H NMR (400MHz, CDC13) δ 8.00 (s, 1H), 7.65 - 7.57 (m, 1H), 7.23 (d, *J* = 7.2 Hz, 1H), 7.06 (d, *J* = 8.4 Hz, 1H), 6.50 - 6.48 (m, 1H), 4.99 - 4.91 (m, 1H), 4.14 - 4.10 (m, 2H), 2.91 - 2.77 (m, 2H), 2.31 - 2.28 (m, 1H), 2.20 - 2.11 (m, 1H), 2.07 (s, 1H).

[001640] 4-[But-3-vnylamino)-2-[2,6-dioxo-3-piperidvnisoindoline-l,3-dione

[Intermediate DO)




R DO

[001641] To a mixture of 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (2.04 g, 7.39 mmol. Intermediate R) and but-3-yn-l -amine (650 mg, 6.16 mmol, hydrochloride) in dioxane (20 mL) was added DIPEA (7.96 g, 61.5 mmol). The reaction mixture was stirred at 115 °C for 16 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (0.1 % FA) to give the title compound (800 mg, 39% yield) as a green solid. LC-MS (ESI^{+}) *m/z* 326.0 (M+H)$^{+}$.

[001642] 4-[3-Azidopropylamino)-2-[2.,6-dioxo-3-piperidv0isoindoline-l.,3-dione


[Intermediate DP)



R DP

[001643] To a solution of 3-azidopropan-l-amine (198 mg, 1.45 mmol, HC1, CAS# 88192-19-2) and 2-(2,6-dioxo-3 -piped dyl)-4- fluoro-isoindoline-l,3-dione (0.40 g, 1.45 mmol, Intermediate R) in DMF (10 mL) was added DIPEA (936 mg, 7.24 mmol, 1.26 mL). The reaction mixture was stirred at 115 °C for 12 hours. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase chromatography ($NH_3 \cdot H_2O$) to give the title compound (200 mg, 38.4% yield) as a yellow solid. LC-MS (ESI^+) m/z 357.0 $(M+H)^+$.

[001644] **Tert-butyl 4-(4-hvdroxycvclohexyDpiperazine-l-carboxylate [Intermediate DQ)**



DQ

[001645] Step 1 - Tert-butyl N.N-bis(2-chloroethyl icarbamate


[001646] To a mixture of 2-chl oro-A-(2-chloroethyl)ethanamine (20.0 g, 112 mmol, HC1 salt) in a mixed solution of DCM (150 mL) and NaOH (13.5 g, 3 M, 110 mL) was added a solution of $(BOC)_20$ (24.5 g, 112 mmol) in DCM (80 mL) dropwise. The reaction mixture was stirred at rt for 18 h. On completion, the mixture was separated and the organic layer was washed with brine (300 mL), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by silica gel chromatography to give the title compound (24.5 g, 90% yield) as a colorless oil. ^1H NMR (400MHz, CDCb) δ 3.71 - 3.58 (m, 8H), 1.49 (s, 9H).


[001647] Step 2 - Tert-butyl 4-(4-hvdroxycvclohexyDpiperazine-l-carboxylate

[001648] To a solution of /c/7-butyl A',A-bis(2-chloroethyl (carbarnate (10.0 g, 41.3 mmol) and 4- aminocyclohexanol (5.04 g, 43.8 mmol) in dioxane (200 mL) was added K_2CO_3 (17.1 g,

124 mmol) and KI (20.6 g, 124 mmol). The reaction mixture was stirred at 115 °C for 17 h. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was purified by silica gel chromatography to give the title compound (3.50 g, 30% yield) as a red solid. ^{1}H NMR (400MHz, MeOH-i¾) δ 3.54 - 3.47 (m, 1H), 3.47 - 3.39 (m, 4H), 2.60 - 2.51 (m, 4H), 2.37 - 2.27 (m, 1H), 2.03 - 1.97 (m, 2H), 1.96 - 1.90 (m, 2H), 1.47 (s, 9H), 1.38 - 1.27 (m, 4H).

[001649] [2S)-2-Hydroxy-3-|[8R)-1-[4-piperazin-l-ylcvclohexoxy)-7,8-dihydro-6H-cyclopenta[4,5]_ thieno[l,2-c]pyrimidin-8-yl]propenamide _ [Intermediate_ DR)


NCCH2COOEt
Et2NH, S, EtOH
HCONH2
POCl3
DIBALH
THF
SFC separation
TBSCl, imidazole
DMF
DQ
NaH, THF
TBAF
THF
DMP
DCM
TMSCN, TEA
DCM
TBAF
THF
HCl in dioxane
DCM
R = H, TMS



[001650] Step 1 - Ethyl 2-amino-4-(2-ethoxy-2-oxo-ethyl)-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxylate

[001651] To a solution of ethyl 2-(2-oxocyclopentyl)acetate (30.0 g, 169 mmol) in EtOH (300 mL) was added ethyl 2-cyanoacetate (17.2 g, 152 mmol), Et_2NH (15.2 g, 208 mmol,) and sulphur (6.62 g, 206 mmol) at rt and the mixture was stirred for 90 h. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was diluted with EA (300 mL) and washed with brine (3 X 40 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (SiO_2, PE: EA = 10:1) to give the title compound (25.0 g, 47% yield) as a yellow oil. ^1H NMR (400MHz, $CDCl_3$) δ 5.95 (s, 2H), 4.27 (q, *J* = 7.2 Hz, 2H), 4.15 (q, *J* = 7.2 Hz, 2H), 3.64 - 3.55 (m, 1H), 2.87 - 2.11 (m, 6H), 1.35 (t, *J* = 7.2 Hz, 3H), 1.25 (t, *J* = 7.2 Hz, 3H); LC-MS (ESI^+) *m/z* 298.0 $(M+H)^+$.

[001652] Step 2 - Ethyl 2-(4-hydroxy-7,8-dihydro-6H-cyclopenta[3,4]thieno[2,3-d]pyrimidin-8-yl)acetate

[001653] A mixture of ethyl 2-amino-4-(2-ethoxy-2-oxo-ethyl)-5,6-dihydro-4H-

cyclopenta[£]thiophene-3- carboxylate (28.0 g, 94.1 mmol) and formamide (158 g, 3.51 mol) was stirred at 180 °C for 8 h. On completion, the reaction mixture was cooled to room temperature and then quenched with water/ice (200 mL). The mixture was extracted with ethyl acetate (3 X 100 mL) and the combined organic layer was dried over anhydrous Na_2S04, filtered and concentrated *in vacuo* to give the title compound (15.0 g, 57% yield) as a yellow brown solid. 'H NMR (400MHz, DMSO-7,) δ 12.49 (s, 1H), 8.03 (s, 1H), 4.05 (q, *J* = 7.2 Hz, 2H), 3.66 - 3.52 (m, 1H), 3.28 (dd, 7 = 3.6, 16 Hz, 1H), 3.08 - 2.81 (m, 2H), 2.74 - 2.59 (m, 1H), 2.40 - 2.30 (m, 1H), 2.18 - 1.99 (m, 1H), 1.15 (t, 7 = 7.2 Hz, 3H); LC-MS (ESI^+) *m/z* 279.0 $(M+H)^+$.

[001654] Step 3 - Ethyl 2-(l-chloro-7.8-dihvdro-6H-cvclopentar3.41thienorl.3-d1pyrimidin-8-vDacetate

[001655] A mixture of ethyl 2-(l-hydroxy-7,8-dihydro-6H-cyclopenta[3,4]thieno[l,3-c]pyrimidin-8-yl)acetate (14.0 g, 50.3 mmol) in POCb (165 g, 1.08 mol) was stirred at 85 °C for 16 h. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography ($Si0_2$, PE: EA= 5:1) to give the title compound (12.0 g, 80% yield) as a light yellow oil. ^1H NMR (400MHz, CDCb) δ 8.71 - 8.63 (m, 1H), 4.07 (q, *J* = 7.2 Hz, 2H), 3.93 - 3.83 (m, 1H), 3.16 - 3.04 (m, 1H), 3.00 - 2.90 (m, 1H), 2.85 (dd, *J* = 2.8, 12.8 Hz, 1H), 2.73 - 2.67 (m, 1H), 2.42 (dd, 7 = 10.4, 15.2 Hz, 1H), 2.34 - 2.28 (m, 1H), 1.15 (t, 7 = 7.2 Hz, 3H); LC-MS (ESI^+) *m/z* 297.0 $(M+H)^+$.

[001656] Step_4_- 2-(T-Chloro-7.8-dihvdro-6H-cvclopentar3.41thienorL3-d1pyrimidin-8-vDethanol

[001657] To a solution of ethyl 2-(l-chloro-7,8-dihydro-6iT-cyclopenta[3,4]thieno[l,3-7]pyrimidin-8-yl)acetate (18.0 g, 60.6 mmol) in THF (200 mL) was added DIBAL-H (1 M, 196 mL) at -50 °C dropwise. Then the mixture was stirred at -30 °C for 1 hour. On completion, the mixture was added to water (10 mL) and NaOH solution (15%, 20 mL) at 0 °C. The mixture was then filtered and dried over Na_2S0_4, then filtered again and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography ($Si0_2$, PE: EA = 5:1) to give the title compound (12.0 g, 68% yield) as a light yellow solid. ¾NMR (400MHz, CDCb) δ 8.76 (s, 1H), 3.85 - 3.71 (m, 2H), 3.62 (t, 7 = 8.8 Hζ, IH), 3.21 - 3.07 (m, 1H), 3.06 - 2.93 (m, 1H), 2.70 - 2.60 (m, 1H), 2.44 - 2.33 (m, 1H), 2.20 - 2.08 (m, 1H), 1.78 - 1.68 (m, 1H); LC-MS (ESI^+) *m/z* 254.9 $(M+H)^+$.

[001658] Step 5 - 2-[(8R)-l-chloro-7,8-dihydro-6H-cyclopenta[3,4]thieno[1,3-d]pyrimidin-

8-yll ethanol

[001659] The racemic 2-(l-chloro-7,8-dihydro-6H-cyclopenta[3,4]thieno[l,3-<i]pyrimidin-8-yl)ethanol (23.0 g, 90.2 mmol) was separated by SFC (column: AD(250mm*30mm,l0um);mobile phase: [0.1% NH_3H_2O MEOH]) to give to give two isomers. The first fraction was the desired product: 2-[(8A')-l-chloro-7,8- dihydro-6//-cyclopenta[3,4]thieno[l,3-d]pyrimidin-8-yl]ethanol (10.9 g, 47% yield, tR = 2.562) which was isolated as a yellow solid. The second fraction is 2-[(8,S)-l-chloro-7,8-dihydro-6H-cyclopenta[3,4]thieno[l,3-d]pyrimidin-8-yl] ethanol (11.5 g, 49% yield, tR = 3.522) was also isolated as a yellow solid. ^{1}H NMR (400MHz, CDCh) δ 8.72 (s, 1H), 3.87 - 3.72 (m, 2H), 3.70 - 3.59 (m, 1H), 3.21 - 3.09 (m, 1H), 3.06 - 2.95 (m, 1H), 2.71 - 2.61 (m, 1H), 2.41 - 2.35 (m, 1H), 2.19 - 2.09 (m, 1H), 1.78 - 1.69 (m, 1H) ; LC-MS (ESI^+) *m/z* 255.0 $(M+H)^+$.

[001660] Step 6 - Tert-butyl-[2-[(8R)-l-chloro7.8-dihvdro-6H-cvclopentar3.41thienon .3-dlpyrimidin-8- vl] ethoxyl-dimethyl-silane

[001661] To a solution of 2-[(8i?)-l-chloro-7,8-dihydro-6H-cyclopenta[3,4]thieno[l,3-<i]pyrimidin-8-yl] ethanol (5.9 g, 23.1 mmol) in DMF (60 mL) was added imidazole (2.21 g, 32.4 mmol) and TBSC1 (4.19 g, 27.7 mmol). The reaction mixture was stirred at rt for 13 h under nitrogen atmosphere. On completion, the reaction mixture was diluted with water (30 mL) and extracted with EA (3 X 30 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE: EA = 5:1) to give the title compound (7.80 g, 87% yield) as a light yellow oil. ^{1}H NMR (400MHz, CDCh) δ 8.74 (s, 1H), 3.82 - 3.70 (m, 2H), 3.68 - 3.58 (m, 1H), 3.20 - 3.09 (m, 1H), 3.05 - 2.95 (m, 1H), 2.68 - 2.58 (m, 1H), 2.48 - 2.37 (m, 1H), 2.17 - 2.05 (m, 1H), 1.70 - 1.63 (m, 1H), 0.89 (s, 9H), 0.06 (d, *J* = 0.8 Hz, 6H); LC-MS (ESI^+) *m/z* 369.0 $(M+H)^+$.

[001662] Step 7 - Tert-butyl 4-[4-[[(8R)-8-[2-[tert-butyl(dimethyl)silyl]oxvethyl 1-7.8-dihydro-6H-cvclopenta _ r4.51thienorE2-c1pyrimidin-l-yl1oxy1cvclohexyl1piperazine-l-carboxylate

[001663] To a solution of *tert*-butyl 4-(4-hydroxycyclohexyl)piperazine-l-carboxylate (4.32 g, 15.1 mmol, Intermediate DQ) in THF (80 mL) was added NaH (1.73 g, 43.3 mmol, 60% dispersion in mineral oil) at 0 °C. The reaction mixture was stirred at 0 °C for 1 hour, then a solution of *ter*7-butyl-[2-[(8*R*)-l-chloro-7,8-dihydro-6//-cyclopenta [3,4]thieno[l,3-d]pyrimidin-8-yl]ethoxy]-dimethyl-silane (4.00 g, 10.8 mmol) in THF (40 mL) was added at 0 °C dropwise.

The reaction mixture was then heated to 60 °C and stirred for 14 h. On completion, the reaction mixture was quenched with water (50 mL) and the mixture was extracted with EA (3 X 80 mL). The combined organic layer was dried over Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE: EA = 3:1) to give the title compound (4.00 g, 42% yield) as a light yellow solid. ¾ NMR (400MHz, CDCh) δ 8.49 (s, 1H), 5.27 - 5.14 (m, 1H), 3.77 - 3.63 (m, 2H), 3.50 -3.40 (m, 5H), 3.14 - 3.01 (m, 1H), 2.99 - 2.87 (m, 1H), 2.68 - 2.57 (m, 1H), 2.56 - 2.47 (m, 4H), 2.43 -2.37 (m, 1H), 2.36 - 2.19 (m, 4H), 1.97 (d, *J* = 10.4 Hz, 2H), 1.64 - 1.51 (m, 5H), 1.47 (s, 9H), 0.90 (s, 9H), 0.05 (s, 6H); LC-MS (ESI^+) *m/z* 617.2 $(M+H)^+$.

[001664] Step 8 - Tert-butyl 4-[4-[(8R)-8-(2-hydroxyethyl)-7,8-dihydro-6H-cyclopenta[4,5]thieno[2,3-c]pyridin-1-yl]oxycyclohexyl]piperazine-1-carboxylate

[001665] To a solution of *tert*-butyl 4-[4-[[(8i?)-8-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-7,8-dihydro-6H-cyclopenta[4,5]thieno[l,2-c]pyrimidin-l-yl]oxy]cyclohexyl]piperazine-l-carboxylate (12.0 g, 19.4 mmol) in THF (120 mL) was added TBAF (1 M, 29.1 mL), and the mixture was stirred at rt for 14 h. On completion, the reaction mixture was quenched by addition of water (100 mL), and then extracted with EA (3 X 200 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE: EA = 1:1) to give the title compound (9.7 g, 93% yield) as a light yellow oil. ^1H NMR (400MHz, CDCh) δ 8.50 (s, 1H), 5.29 - 5.16 (m, 1H), 3.79 - 3.67 (m, 2H), 3.52 - 3.40(m, 5H), 3.14 - 3.02 (m, 1H), 2.96 - 2.90 (m, 1H), 2.71 - 2.62 (m, 1H), 2.58 - 2.48 (m, 4H), 2.47 - 2.39 (m, 1H), 2.38 - 2.25 (m, 3H), 2.21 - 2.12 (m, 1H), 2.03 - 1.92 (m, 2H), 1.81 - 1.70 (m, 2H), 1.65 - 1.49 (m, 4H), 1.47 (s, 9H). LC-MS (ESI^+) *m/z* 503.2 $(M+H)^+$.

[001666] Step 9 - Tert-butyl 4-[4-[[(8R)-8-(2-oxoethyl)-7,8-dihydro-6H-cyclopenta[4,5]thieno[2,3-c]pyridin-1-yl]oxycyclohexyl]piperazine-1-carboxylate

[001667] To a solution of *tert*-butyl 4-[4-[[(8i?)-8-(2-hydroxyethyl)-7,8-dihydro-6H-cyclopenta[4,5]thieno[l,2-c]pyrimidin-l-yl]oxy]cyclohexyl]piperazine-l-carboxylate (9.70 g, 19.3 mmol) in DCM (160 mL) was added DMP (16.3 g, 38.5 mmol) at 0 °C. Then the mixture was allowed to warm to rt and stirred for 16 h. On completion, the reaction mixture was quenched by saturated $NaHCO_3$ (200 mL) and then extracted with DCM (3 X 200 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE: EA = 1:1) to give the title compound (9.00 g, 72%

yield) as a yellow oil. ^{1}H NMR (400MHz, CDCh) δ 9.84 (s, 1H), 8.52 (s, 1H), 5.28 - 5.17 (m, 1H), 3.48 (t, *J* = 5.2 Hz, 1H), 3.58 - 3.48 (m, 4H), 3.16 - 2.98 (m, 3H), 2.88 - 2.76 (m, 1H), 2.74 - 2.52 (m, 6H), 2.38 - 2.27 (m, 2H), 2.18 - 2.11 (m, 1H), 2.05 - 1.98 (m, 2H), 1.60 - 1.50 (m, 4H), 1.47 (s, 9H); LC-MS (ESI$^+$) *m/z* 501.2 (M+H)$^+$.

[001668] Step 10 - Tert-butyl 4-r4-ri('8R)-8-('2-cvano-2-trimethylsilyl oxv-ethyl)-7.8-dihydro-6H-cvclopentar 4,5] thienoT l.2-clpyrimidin-l -yl1oxy1cvclohexyl1piperazine-l - carboxylate and tert-butyl 4-[4-[[(8R) -8-(2-cvano-2-hydroxv-ethyl)-7.8-dihydro-6H-cvclopentar4.51thienor i.2-clpyrimidin-l -ylloxylcvclohexyllpiperazine-l -carboxyl ate

[001669] To a solution of *tert*-butyl 4-[4-[[(8i?)-8-(2-oxoethyl)-7,8-dihydro-6iT-cyclopenta[4,5]thieno[l,2-c] pyrimidin-l-yl]oxy]cyclohexyl]piperazine-l-carboxylate (6.00 g, 11.98 mmol) and TEA (1.21 g, 11.9 mmol) in DCM (80 mL) was added TMSCN (3.57 g, 35.9 mmol), and the mixture was stirred at rt for 4 h. On completion, the reaction mixture was diluted with water (60 mL) and extracted with DCM (3 X 80 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated under reduced pressure to give tert-butyl 4-[4-[[(8R)-8-(2-cyano-2-trimethylsilyloxy-ethyl)-7,8-dihydro-6H-cyclopenta[4,5] thieno[l,2-c]pyrimidin-l-yl]°xy]cyclohexyl]piperazine-l-carboxylate (5.5 g) and tert-butyl 4-[4-[[(8R) -8-(2-cyano-2-hydroxy-ethyl)-7,8-dihydro-6H-cyclopenta[4,5]thieno[l,2-c]pyrimidin-l-yl]°xy]cyclohexyl]piperazine-l-carboxylate (0.5 g) as a yellow oil, which were brought on to the next step as a mixture. LC-MS (ESI$^+$) m/z 600.3 (M+H)$^+$.

[001670] Step 11 - Tert-butyl 4-[4-[[(8R)-8-(2-cvano-2-hydroxv-ethyl)-7.8-dihydro-6H-cvclopentar 4.51thieno [1.2-clpyrimidin- 1-yll oxylcvclohexyllpiperazine- 1-carboxylate

[001671] To a solution of *tc/t*-butyl 4-[4-[[(8i?)-8-(2-cyano-2-trimethylsilyloxy-ethyl)-7,8-dihydro-6H- cyclopenta[4,5]thieno[l,2-c]pyrimidin-l-yl]oxy]cyclohexyl]piperazine-l-carboxylate (5.50 g, 9.17 mmol) and *tert*-butyl 4-[4-[[(8i?)-8-(2-cyano-2-hydroxy-ethyl)-7,8-dihydro-6H-cyclopenta[4,5]thieno [l,2-c]pyrimidin-l-yl]oxy]cyclohexyl]piperazine-l-carboxylate (500 mg, 947 umol) in THF (80 mL) was added TBAF (1 M, 13.75 mL), and the mixture was stirred at rt for 3 h. On completion, the reaction mixture was quenched with water (80 mL), and then extracted with EA (3 X 100 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE: EA= 1:1) to give the title compound (4.20 g, 69% yield) as a light yellow oil. ^{1}H NMR (400MHz, CDCh) δ 8.51 (d, *J* = 1.6 Hz, 1H), 5.32 - 5.18 (m, 1H), 4.58 - 4.50 (m,

1H), 3.69 - 3.37 (m, 5H), 3.17 - 2.92 (m, 2H), 2.80 - 2.66 (m, 1H), 2.65 - 2.46 (m, 6H), 2.43 - 2.23 (m, 3H), 2.04 - 1.85 (m, 3H), 1.76 - 1.49 (m, 4H), 1.46 (s, 9H). LC-MS (ESI^+) *m/z* 528.1 $(M+H)^+$.

[001672] Step 12 - 2-Hydroxy-3-[(8R)-8-(4-piperazin-1-ylcyclohexoxy)-7,8-dihydro-6H-cyclopenta[4,5]thieno[1,2-c]pyrimidin-8-yl]propanamide

[001673] To a solution of tert-butyl 4-[4-[[(8R)-8-(2-cyano-2-hydroxy-ethyl)-7,8-dihydro-6H-cyclopenta[4,5]thieno[1,2-c]pyrimidin-1-yl]oxy]cyclohexyl]piperazine-1-carboxylate (4.20 g, 7.96 mmol) in DCM (80 mL) was added HCl in dioxane (4 M, 33.6 mL), and the mixture was stirred at rt for 3 h. On completion, the reaction mixture was quenched with saturated sodium bicarbonate (30 mL). The mixture was concentrated *in vacuo* to give the title compound (4.00 g, 100% yield) as a light yellow solid. LC-MS (ESI^+) *m/z* 446.2 $(M+H)^+$.

[001674] Step 13 - Tert-butyl 4-[4-[[(8R)-8-(3-amino-2-hydroxy-3-oxo-propyl)-7,8-dihydro-6H-cyclopenta[4,5]thieno[1,2-c]pyrimidin-1-yl]oxy]cyclohexyl]piperazine-1-carboxylate

[001675] To a solution of 2-hydroxy-3-[(8R)-8-(4-piperazin-1-ylcyclohexoxy)-7,8-dihydro-6H-cyclopenta[4,5]thieno[1,2-c]pyrimidin-8-yl]propanamide (2.50 g, 5.61 mmol) in a mixed solvent of DCM (25 mL) and MeOH (25 mL) was added TEA (1.70 g, 16.8 mmol) and Boc_2O (2.45 g, 11.2 mmol), and the mixture was stirred at rt for 16 h. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase chromatography (0.1% $NH_3 \cdot H_2O$) to give the title compound (1.50 g, 47% yield) as a colorless oil. ^1H NMR (400MHz, $CDCl_3$) δ 8.49 (d, *J* = 5.2 Hz, 1H), 6.70 - 6.50 (m, 1H), 6.01 - 5.87 (m, 1H), 5.29 - 5.13 (m, 1H), 4.20 - 4.13 (m, 1H), 3.72 - 3.53 (m, 1H), 3.42 (t, *J* = 4.4 Hz, 4H), 3.15 - 3.04 (m, 1H), 3.01 - 2.88 (m, 1H), 2.78 - 2.60 (m, 1H), 2.58 - 2.49 (m, 4H), 2.49 - 2.12 (m, 6H), 1.99 - 1.83 (m, 3H), 1.63 - 1.43 (m, 13H). LC-MS (ESI^+) *m/z* 546.2 $(M+H)^+$.

[001676] Step 14 - Tert-butyl 4-[4-[[(8R)-8-[(2S)-3-amino-2-hydroxy-3-oxo-propyl]-7,8-dihydro-6H-cyclopenta[4,5]thieno[1,2-c]pyrimidin-1-yl]oxy]cyclohexyl]piperazine-1-carboxylate

[001677] The racemic tert-butyl 4-[4-[[(8R)-8-(3-amino-2-hydroxy-3-oxo-propyl)-7,8-dihydro-6H-cyclopenta[4,5]thieno[1,2-c]pyrimidin-1-yl]oxy]cyclohexyl]piperazine-1-carboxylate (1.50 g, 2.66 mmol) was separated by SFC (column: AD(250mm*30mm,10um);mobile phase: [0.1%NH_3H_2O ETOH]) to give the two isomers. The first fraction is *tert*-butyl 4-[4-[[(8R)-8-[(2S)-3-amino-2-hydroxy-3-oxo-propyl]-7,8-dihydro-6H-cyclopenta[4,5]thieno[1,2-c]pyrimidin-1-yl]oxy]cyclohexyl]piperazine-1-carboxylate (700 mg,


46% yield, tR = 1.034) which was isolated as a light yellow solid. ^{1}H NMR (400MHz, CDCh) δ 8.46 (s, 1H), 6.66 (d, *J* = 2.8 Hz, 1H), 5.99 (d, *J* = 2.8 Hz, 1H), 5.25 - 5.11 (m, 1H), 4.21 - 4.10 (m, 1H), 3.67 - 3.56 (m, 1H), 3.47 - 3.29 (m, 4H), 3.13 - 3.01 (m, 1H), 2.98 - 2.86 (m, 1H), 2.70 - 2.57 (m, 1H), 2.54 - 2.43 (m, 4H), 2.40 - 2.04 (m, 6H), 1.97 - 1.79 (m, 3H), 1.75 - 1.26 (m, 13H); LC-MS (ESI$^+$) *m/z* 546.2 (M+H)$^+$.

[001678] The second fraction was the desired 4-[4-[[(8f?)-8-[(2ri)-3-amino-2-hydroxy-3-oxo-propyl]-7,8-dihydro-6H-cyclopenta[4,5]thieno[l,2-c]pyrimidin-l-yl]°xy]cyclohexyl]piperazine-l-carboxylate (560 mg, 37% yield, tR = 1.238) was also isolated as a light yellow solid. ^{1}H NMR (400MHz, CDCh) δ 8.50 (s, 1H), 6.60 (d, *j* = 2.8 Hz, 1H), 5.72 (d, *J* = 2.8 Hz, 1H), 5.30 - 5.23 (m, 1H), 4.18 - 4.10 (m,, 1H), 3.63 - 3.51 (m, 1H), 3.48 - 3.36 (m, 4H), 3.18 - 3.05 (m, 1H), 3.00 - 2.88 (m, 1H), 2.81 - 2.66 (m, 1H), 2.55 - 2.59 (m, 4H), 2.45 - 2.23 (m, 6H), 2.05 - 1.81 (m, 3H), 1.66 - 1.44 (m, 13H) ; LC-MS (ESI$^+$) *m/z* 546.3 (M+H)$^+$.

[001679] Step 15 - (2S)-2-Hvdroxy-3-rt8R)-l -(4-piperazin-l -ylcvclohexoxy)-7.8-dihydro-6H-cvclopentar4.51 thienorE2-c1pyrimidin-8-yl1propanamide

[001680] To a solution of tert-butyl 4-[4-[[(8A>)-8-[(2,V)-3-amino-2-hydroxy-3-oxopropyl]-7,8-dihydro-6H-cyclopenta[4,5]thieno[l,2-c]pyrimidin-l-yl]oxy]cyclohexyl]piperazine-l-carboxylate (80.0 mg, 143 umol) in DCM (2 mL) was added HC1 in dioxane (4 M, 1.37 mL), and the mixture was stirred at rt for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (80 mg, 100% yield, HC1 salt) as a white solid; LC-MS (ESI$^+$) *m/z* 446.1 (M+H)$^+$.

[001681] Tert-butyl 2-12-aminoethoxylacetate (Intermediate DS)



DS

[001682] Step **1** - Tert-butyl 2-[2-(1,3-dioxoisoindolin-2-vl)ethoxy]acetate


[001683] To a solution of 2-(2-hydroxyethyl)isoindoline-l,3-dione (1.00 g, 5.23 mmol, CAS# 3891-07-4) and Rh(OAc)$_2$ (46.2 mg, 209 umol) in DCM (20 mL) was added tert-butyl 2-diazoacetate (1.64 g, 11.5 mmol) in DCM (20 mL) dropwise at rt over 1 hour. The reaction mixture was then stirred at rt for 20 hours. On completion, the mixture was concentrated *in vacuo*. The residue was purified by silica gel chromatography to give the title compound (0.76 g, 48% yield) as a yellow oil. ^{1}H NMR (400MHz, CDCh) δ 7.90 - 7.84 (m, 2H), 7.77 - 7.70 (m, 2H), 3.99 (s,

2H), 3.97 - 3.93 (m, 2H), 3.85 - 3.80 (m, 2H), 1.45 (s, 9H); LC-MS (ESI^+) *m/z* 328.0 $(M+Na)^+$.

[001684] Step 2 - Tert-butyl 2-(2-aminoethoxy)acetate

[001685] To a solution of tert-butyl 2-[2-(l,3-dioxoisoindolin-2-yl)ethoxy]acetate (0.76 g, 2.49 mmol) in EtOH (20 mL) was added $NH_2NH_2 \cdot H_20$ (623 mg, 12.5 mmol). The reaction mixture was stirred at 80 °C for 2 hours. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was diluted with DCM (20 mL), filtered and the filtrate was concentrated *in vacuo* to give the title compound (340 mg, 78% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 176.0 $(M+H)^+$.

[001686] **2-[2-[2-[2-|2-[2-ethoxy-2-oxo-ethoxy)ethoxy| ethoxy]ethoxy]ethoxy]acetic acid [Intermediate DT)**



[001687] Step 1 - Ethyl 2-[2-[2-r2-r2-(2-tert-butoxy-2-oxo-ethoxy)ethoxy1ethoxy]ethoxy]ethoxy]acetate


[001688] To a solution of ethyl 2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]acetate (1.00 g, 3.57 mmol, synthesized via Step 1 of Intermediate BK) and $Rh(OAc)_2$ (39.5 mg, 178 umol) in DCM (20 mL) was added a solution of tert-butyl 2-diazoacetate (1.01 g, 7.14 mmol) in DCM (30 mL) dropwise at it over 30 minutes. The reaction mixture was then stirred at rt for an additional 17 hours. On completion, the mixture was washed with water (3 X 30 mL). The organic phase was separated and was dried over Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by silica gel chromatography to give the title compound (0.64 g, 45% yield) as a yellow oil. ^{1}HNMR (400MHz, CDCh) δ 4.23 (q, *J* = 7.2 Hz, 2H), 4.17 (s, 2H), 4.04 (s, 2H), 3.78 - 3.66 (m, 16H), 1.49 (s, 9H), 1.30 (t, *j* = 7.2 Hz, 3H).

[001689] Step 2 - 2-I2-I2-I2-I2-(2-6&oχv-2-oχo-ethoxylethoxylethoxylethoxylethoxylacetic acid

[001690] To a solution of ethyl 2-[2-[2-[2-[2-(2-tert-butoxy-2-oxo-ethoxy)ethoxy] ethoxy]ethoxy]ethoxy]acetate (200 mg, 507 umol) in DCM (1.5 mL) was added

TFA (1.5 mL). The reaction mixture was stirred at rt for 30 minutes. On completion, the mixture was concentrated *in vacuo* to give the title compound (170 mg, 99% yield) as a yellow oil.


[001691] **(4-Hvdroxycvclohexyl) 4-methylbenzenesulfonate [Intermediate DU]**



DU

[001692] To a solution of pyridine (12.3 g, 155 mmol) in $CHCl_3$ (150 mL) was added cyclohexane-l,4-diol (15.0 g, 129 mmol) at rt. Then the mixture was then cooled to 0 °C and 4-methylbenzenesulfonyl chloride (24.6 g, 129 mmol) was added into the mixture. The reaction mixture was then allowed to warm to rt and stirred for 18 hrs. On completion, the reaction mixture was acidified with 1N HC1 solution until the pH = 5-6, and extracted with EA (3 X 30 mL). The organic layer was washed with brine (50 mL), dried over Na_2S0_4, and concentrated *in vacuo.* The residue was purified by silica gel chromatography to give the title compound (16.0 g, 46% yield) as a white solid. ¾NMR (400MHz, CDCh) δ 7.85 - 7.76 (m, 2H), 7.36 (d, *J* = 8.0 Hz, 2H), 4.66 - 4.49 (m, 1H), 3.80 - 3.70 (m, 1H), 2.47 (s, 3H), 1.97 - 1.91 (m, 2H), 1.72 - 1.65 (m, 2H), 1.64 - 1.50 (m, 4H).

[001693] **Tert-butyl 4-((4-(4.,4.,5.,5-tetramethyl-l.,3.,2-dioxaborolan-2-y0pheny0sulfony0 piperazine-1-_ carboxylate**



DV

[001694] Step **1** - Tert-butyl 4-(Y4-bromophenvOsulfonvOpiperazine-l-carboxylate


[001695] To a solution of tert-butyl piperazine- l-carboxylate (20.1 g, 108 mmol) in THF (250 mL) was added TEA (19.8 g, 196 mmol) at 0 °C. The mixture was stirred at 0 °C for 10 minutes, then 4-bromobenzene sulfonylchloride (25.0 g, 97.8 mmol) was added to the reaction mixture. The reaction mixture was then allowed to warm to rt and stirred for 50 minutes. On completion, the reaction mixture was filtered and concentrated *in vacuo.* The residue was washed with water (100 mL) and 10 % HC1 (50 mL), and then extracted with DCM (2 X 50 mL). The

organic layer was washed with $NaHCO_3$ (50 mL) until the pH = 8. The combined organic layers were dried over Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (petroleum ether/ethyl acetate = 0:1) to give the title compound (33 g, 83% yield)) as a white solid. ¾NMR (400MHz, CDCh) δ 7.72 - 7.70 (m, 2H), 7.64 - 7.62 (m, 2H), 3.54 (t, *J* = 4.8 Hz, 4H), 3.00 (t, *J* = 4.8 Hz, 4H), 1.43 (s, 9H).

[001696] Step 2 - Tert-butyl 4-((4-(4.4.5.5-tetramethyl-L3.2-dioxaborolan-2-vDphenvDsulfonyl) piperazine- 1- carboxylate

[001697] To a solution of tert-butyl 4-(4-bromophenyl)sulfonylpiperazine-l -carboxylate (10.0 g, 24.7 mmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (18.8 g, 74.0 mmol) in dioxane (100 mL) was added $Pd(dppf)Cl_2$ (1.81 g, 2.47 mmol) and KOAc (4.84 g, 49.4 mmol). The reaction mixture was stirred at 80 °C for 3 hours. On completion, the mixture was filtered, and the filter was concentrated *in vacuo* to give a residue. The residue was purified by flash silica gel chromatography (Ethyl acetate: Petroleum ether = 1/1) to give the title compound (8.00 g, 63% yield) as a gray solid. ¾NMR (400MHz, CDCh) δ 7.98 (d, *j* = 8.0 Hz, 2H), 7.74 (d, *J* = 8.0 Hz, 2H), 3.52 (t, *J* = 4.8 Hz, 4H), 2.98 (t, *J* = 4.8 Hz, 4H), 1.42 (s, 9H), 1.37 (s, 12H), LC-MS (ESI$^+$) *m/z* 397.0 $(M+H-56)^+$.


[001698] **Ethyl 2-|2-|2-|2-[2-aminoethoxy)ethoxy]ethoxy]ethoxy]acetate [Intermediate DW1**



DW

[001699] To a solution of ethyl 2-[2-[2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethoxy]acetate (0.80 g, 2.11 mmol, synthesized via Steps 1-4 of Intermediate CH) in DCM (10 mL) was added HC1 in dioxane (4 M, 2.67 mL). The reaction mixture was stirred at rt for 15 minutes. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (0.55 g, 83% yield, HC1) as a yellow oil.

[001700] **Tert-butyl 2-[8-aminooctoxy)acetate [Intermediate l)X)**



DX

[001701] Step 1 - 8-Hydroxyoctyl 4-methylbenzenesulfonate

[001702] To a mixture of octane-1,8-diol (23.5 g, 160 mmol, CAS# 629-41-4) and pyridine (10.1 g, 128 mmol) in DCM (360 mL) was added a solution of TsCl (24.5 g, 128 mmol) in DCM (240 mL) dropwise. The mixture was then stirred at rt for 16 hours. On completion, the mixture was washed with 1N HC1 (2 X 50 mL). The organic layer was dried with Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (petroleum ether : ethyl acetate = 3 : 1) to give the title compound (10.0 g, 20% yield) as a colorless oil. ^{1}H NMR (400MHz, CDCh) δ 7.80 (d, *J* = 8.0 Hz, 2H), 7.35 *(d, J* = 8.0 Hz, 2H), 4.02 (t, *j* = 6.4 Hz, 2H), 3.63 (t, *j* = 6.4 Hz, 2H), 2.45 (s, 3H), 1.69 - 1.60 (m, 2H), 1.56 - 1.53 (m, 2H), 1.36 - 1.23 (m, 8H); LC-MS (ESI$^+$) *m/z* 323.0 $(M+Na)^+$.

[001703] Step 2 - 2-(8-HvdroxyoctvDisoindoline-L3-dione

[001704] To a solution of 8-hydroxy octyl 4-methylbenzenesulfonate (5.00 g, 16.6 mmol) in DMF (80 mL) was added (l,3-dioxoisoindolin-2-yl)potassium (4.01 g, 21.6 mmol). The mixture was stirred at 100 °C for 16 hours. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was diluted with DCM (50 mL), filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE/EA=3/l) to give the title compound (4.50 g, 98% yield) as a white solid. ^{1}H NMR (400MHz, CDCh) δ 7.86 - 7.79 (m, 2H), 7.74 - 7.66 (m, 2H), 3.69 - 3.59 (m, 4H), 1.76 - 1.46 (m, 6H), 1.32

- 1.29 (m, 6H).


[001705] Step 3 - Tert-butyl 2-[8-(1.3-dioxoisoindolin-2-yl)octoxy1acetate

[001706] To a solution of 2-(8-hydroxyoctyl)isoindoline-l,3-dione (3.00 g, 10.9 mmol) and $Rh(OAc)_2$ (120 mg, 544 umol) in DCM (20 mL) was added a solution of tert-butyl 2-diazoacetate (2.32 g, 16.3 mmol) in DCM (80 mL) dropwise. The reaction mixture was stirred at rt for 48 hours. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE/EA= 2/1) to give the title compound (1.40 g, 26% yield) as a light yellow oil. LC-MS (ESI^+) *m/z* 412.2 $(M+Na)^+$.

[001707] Step 4 - Tert-butyl 2-(8-aminooctoxy)acetate

[001708] To a solution of tert-butyl 2-[8-(l,3-dioxoisoindolin-2-yl)octoxy]acetate (1.4 g, 2.91 mmol) in EtOH (25 mL) was added $N_2H_{4*}H_20$ (1.49 g, 29. 1 mmol). Then the reaction mixture was stirred at 80 °C for 16 hours. On completion, the reaction mixture was filtered. The filtrate was concentrated *in vacuo* to give the title compound (750 mg, 99% yield) as a light yellow oil. LC-MS (ESI^+) *m/z* 260.2 $(M+H)^+$.

[001709] **Methyl 5-(4-amino-3-carbamoyl-pyrazol-l-vDpyridine-2-carboxylate Intermediate DY1**



DY

[001710] Step 1 - Ethyl l-(6-bromo-3-pyridvO-4-nitro-pyrazole-3-carboxylate

[001711] To a solution of ethyl 4-nitro-lH-pyrazole-3-carboxylate (5.8 g, 31.3 mmol, CAS# 55864-87-4), pyridine (9.91 g, 125 mmol) and $Cu(OAc)_2$ (8.54 g, 46.9 mmol) in DCM (120 mL) was added (6-bromo-3-pyridyl)boronic acid (7.59 g, 37.5 mmol, CAS# 223463-14-7). The mixture was stirred at rt for 16 hours under an oxygen atmosphere (15 psi pressure). On completion, the reaction mixture was quenched by adding saturated $NH_3 \cdot H_20$ solution (40 mL). The organic layer was separated and dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE/EA=3/l) to give the title compound (2.30 g, 21% yield) as a white solid. ^1H NMR (400MHz, DMSO-7,) δ 9.83 (s, 1H), 9.00 (d, J = 2.8 Hz, 1H), 8.31 (dd, 7 = 3.2, 8.8 Hz, 1H), 7.91 (d, 7 = 8.8 Hz, 1H), 4.42 (q, J = 7.2 Hz, 2H), 1.33 (t, 7 = 7.2 Hz, 3H).

[001712] Step 2 - l-(6-Bromo-3-pyridvD-4-nitro-pyrazole-3-carboxamide

[001713] To a solution of ethyl l-(6-bromo-3-pyridyl)-4-nitro-pyrazole-3-carboxylate (2.30 g, 6.74 mmol) in THF (15 mL) was added $NH_3 \cdot H_20$ (1.03 mmol, 25 mL, 30% solution) in a sealed tube, and the mixture was stirred at 80 °C for 16 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (1.80 g, 72% yield) as a yellow solid. ^1H NMR (400MHz, DMSO-de) δ 9.74 (s, 1H), 9.03 (d, J = 3.2 Hz, 1H), 8.32 (dd, 7 = 2.8, 8.8 Hz, 1H), 8.23 (s, 1H), 7.96 (s, 1H), 7.91 (d, J = 8.8 Hz, 1H); LC-MS (ESI^+) *m/z* 311.9 $(M+H)^+$.

[001714] Step 3 - 4-Amino-l-(6-bromo-3-pyridvDpyrazole-3 -carboxamide


[001715] To a solution of l-(6-bromo-3-pyridyl)-4-nitro-pyrazole-3 -carboxamide (1.80 g, 4.90 mmol) in a mixed solvent of MeOH (45 mL) and H_20 (10 mL) was added Fe (2.74 g, 49.0 mmol) and NH_4Cl (2.62 g, 49.0 mmol). The mixture was stirred at 70 °C for 36 hours. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was triturated with water (20 mL), filtered and the filter cake was dried *in vacuo* to give the title compound (0.90 g, 65% yield) as a brown solid. LC-MS (ESI^+) *m/z* 282.0 $(M+H)^+$.


[001716] Step 4 - Methyl 5-(4-amino-3-carbamoyl-pyrazol-l-vDpyridine-2-carboxylate

[001717] To a solution of 4-amino- l-(6-bromo-3-pyridyl)pyrazole-3 -carboxamide (450 mg, 1.60 mmol) in a mixed solvent of DMF (15 mL) and MeOH (15 mL) was added $Pd(dppf)Cl_2$ (46.6 mg, 63.8 umol) and TEA (161 mg, 1.60 mmol). The suspension was degassed under vacuum and purged with CO three times. The mixture was stirred at 80 °C for 16 hours under CO (50 psi

pressure). On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by silica gel column chromatography (Petroleum ether/Ethyl acetate=l/l) to give the title compound (400 mg, 94% yield) as a brown solid. LC-MS (ESI^+) *m/z* 262.0 $(M+H)^+$.

[001718] **5-[4-[[2-[2-[Tert-butoxycarbonyl[2,2,2-trifluoroethvnamino]-4-pyridyl]oxazole-4-carbonyl] amino]-3-carbamoylpyrazol-l-yl]pyridine-2-carboxylic acid [Intermediate DZ)**





DZ


[001719] Step 1 - Methyl 5-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridylloxazole-4- carbonyl1amino1-3-carbamoyl-pyrazol-l-yl1pyridine-2-carboxylate

[001720] To a solution of 2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (494 mg, 1.28 mmol, Intermediate CM) in DMF (6 mL) was added E1ATE[(630 mg, 1.66 mmol) and DIPEA (494.54 mg, 3.83 mmol). The mixture was stirred at rt for 12 minutes, then methyl 5-(4-amino-3-carbamoyl-pyrazol-l-yl)pyridine-2-carboxylate (340 mg, 1.28 mmol, Intermediate DY) was added, and the mixture was stirred at rt for 2 hours. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography to give the title compound (500 mg, 49% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 631.2 $(M+H)^+$.

[001721] Step 2 - 5-[4-[[2-[2-[Tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl1oxazole-4-carbonyl1 amino1-3-carbamoylpyrazol-l-yl1pyridine-2-carboxylic acid

[001722] To a mixture of methyl 5-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl] oxazole-4-carbonyl]amino]-3-carbamoyl-pyrazol-l-yl]pyridine-2-carboxylate (500 mg, 792 umol) in a mixed solvent of THF (5 mL), MeOH (1 mL) and H_20 (1 mL) was added LiOH (94.9 mg, 3.96 mmol). The reaction mixture was stirred at rt for 2 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (500 mg, 90% yield) as a brown solid. LC-MS (ESI^+) *m/z* 617.2 $(M+H)^+$.

[001723] **Tert-butyl N-[[lS,2RV2-[[2-bromopyrazolo[l,5-a]pyrimidin-5-yl)amino]cyclohexyl] carbamate (Intermediate EA)**



EA

[001724] Step 1 - (2-BromopyrazolorL5-a1pyrimidin-5-vOoxysodium

[001725] To a solution of Na (7.10 g, 309 mmol) in EtOH (125 mL) was added 3-bromo-lH-pyrazol-5-amine (5.00 g, 30.9 mmol, CAS# 1203705-55-8) and l,3-dimethylpyrimidine-2,4-dione (4.33 g, 30.9 mmol, CAS# 874-14-6). The reaction mixture was stirred at 80 °C for 3 hours. On completion, the mixture was cooled to 0-5°C, then filtered. The filter cake was washed with cold EtOH, and dried *in vacuo* to give the title compound (2.80 g, 38% yield) as a yellow solid. ^1H NMR (400MHz, D_20) δ 8.02 (d, *J* = 7.6 Hz, 1H), 5.98 (d, *J* = 7.6 Hz, 1H), 5.85 (s, 1H).

[001726] Step 2 - 2-Bromo-5-chloro-pyrazolorE5-a1pyrimidine


[001727] A mixture of (2-bromopyrazolo[l,5-a]pyrimidin-5-yl)oxysodium (1.00 g, 4.24 mmol) in POCb (10 mL) was stirred at 110 °C for 3 hours. On completion, the mixture was concentrated *in vacuo.* The residue was diluted with EA (20 mL), washed with $NaHC0_3$ (10 ml), and concentrated *in vacuo.* The residue was purified by silica gel chromatography to give the title compound (0.67 g, 68% yield) as a white solid. ^1H NMR (400MHz, CDCh) δ 8.51 (d, *J* = 7.2 Hz, 1H), 6.84 (d, *j* = 7.2 Hz, 1H), 6.69 (s, 1H).

[001728] Step **3** - Tert-butyl N-[(1S.2R)-2-r(2-bromopyrazolor i.5-a1pyrimidin-5-vDaminolcvclohexyll carbamate

[001729] 2-bromo-5-chloro-pyrazolo[l,5-a]pyrimidine (620 mg, 2.67 mmol), tert-butyl N-[(lS,2R)-2-amino cyclohexyl]carbamate (686 mg, 3.20 mmol, CAS#l 84954-75-4) and DIPEA

(379 mg, 2.93 mmol) were taken up into a microwave tube in NMP (6 mL). The sealed tube was heated at 130 °C for 3 hours under microwave. On completion, the mixture was concentrated *in vacuo* to remove the solvent. Then the residue was purified by silica gel chromatography to give the title compound (1.00 g, 91% yield) as a white solid. ^{1}H NMR (400MHz, CDCh) δ 8.08 (d, *J* = 7.6 Hz, 1H), 6.10 (s, 1H), 5.98 (d, *j* = 7.6 Hz, 1H), 5.76 (s, 1H), 4.94 (br s, 1H), 4.20 - 4.11 (m, 1H), 4.01 - 3.92 (m, 1H), 2.00 - 1.83 (m, 1H), 1.75 - 1.49 (m, 6H), 1.45 (s, 9H), 1.39 - 1.22 (m, 1H).

[001730] **Methyl 4-[3-[difluoromethvn-4-[4,4,5,5-tetramethyl-l,3.,2-dioxaborolan-2-yl)pyrazol-1- yllbenzoate [Intermediate EB)**



EB

[001731] Step 1 - Methyl 4-(3-foimyl-lH-pyrazol-l-vObenzoate

[001732] To a solution of lH-pyrazole-3-carbaldehyde (10.0 g, 104 mmol, CAS# 3920-20-1) and (4-methoxy carbonyl-phenyl) boronic acid (22.5 g, 125 mmol, CAS# 99768-12-4) in DCM (50 mL) was added $Cu(OAc)_2$ (22.7 g, 125 mmol) and pyridine (32.9 g, 416 mmol). The reaction mixture was stirred at rt for 18 hours under oxygen gas (balloon). On completion, the mixture was concentrated *in vacuo*. The residue was purified by silica gel chromatography to give the title compound (12.0 g, 50% yield) as a white solid. ^{1}H NMR (400MHZ, CDCh) δ 10.10 (s, 1H), 8.24 - 8.14 (m, 2H), 8.06 (d, *J* = 2.4 Hz, 1H), 7.90 - 7.82 (m, 2H), 7.02 (d, *J* = 2.4 Hz, 1H), 3.95 (s, 3H).

[001733] Step 2 - Methyl 4-(4-bromo-3-formyl-lH-pyrazol-l-vDbenzoate

[001734] To a solution of methyl 4-(3-formylpyrazol-l-yl)benzoate (4.00 g, 17.4 mmol) in DMF (40 mL) was added NBS (6.18 g, 34.8 mmol). The reaction mixture was stirred at rt for 1

hour. Then, the reaction mixture was heated to 50°C and stirred for 12 hours. On completion, the mixture was concentrated *in vacuo*. The residue was purified by prep-HPLC (0.1% FA) to give the title compound (4.50 g, 82% yield) as a white solid. ^{1}H NMR (400MHz, CDCh) δ 10.02 (s, 1H), 8.12 (d, *J* = 8.4 Hz, 2H) 8.04 (s, 1H), 7.75 (d, *J* = 8.4 Hz, 2H), 3.89 (s, 3H); LC-MS (ESI$^+$) *m/z* 308.9, 310.9 (M+l) $^+$.


[001735] Step 3 - Methyl 4-(4-bromo-3-(difluorom ethyl)- lH-pyrazol-l-vObenzoate

[001736] To a solution of methyl 4-(4-bromo-3-formyl-pyrazol-l-yl)benzoate (1.70 g, 5.50 mmol) in DCM (100 mL) was added DAST (7.98 g, 49.5 mmol) at 0 °C. The reaction mixture was then allowed to warm to rt and stirred for 5 hours. On completion, the mixture was quenched with methanol (30 mL) at 0 °C then mixture was concentrated *in vacuo*. The residue was purified by prep-HPLC (0.1% HC1) to give the title compound (1.44 g, 78% yield) as a white solid. ¾NMR (400MHz, CDCh) δ 8.17 (d, *J* = 8.8 Hz, 2H), 8.07 (s, 1H), 7.76 (d, *J* = 8.8 Hz, 2H), 6.80 (t, *j* = 53.2 Hz, 1H), 3.96 (s, 3H); LC-MS (ESI$^+$) *m/z* 330.9 (M+H)$^+$.

[001737] Step 4 - Methyl 4-r3-(difluoromethyl)-4-(4A5.5-tetramethyl-l .3.2-dioxaborolan-2-vDpyrazol-l- yllbenzoate

[001738] Methyl 4-[4-bromo-3-(difluoromethyl)pyrazol-l-yl]benzoate (500 mg, 1.51 mmol), TEA (382 mg, 3.78 mmol), acetonitrile-dichloropalladium (58.8 mg, 227 umol), dicyclohexyl-[2-(2,6-dimethoxy phenyl)phenyl]phosphane (93.0 mg, 227 umol) and HBPin (1.93 g, 15.1 mmol) were taken up into a microwave tube in toluene (10 mL). The sealed tube was heated at 90°C for 60 minutes under microwave. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo*. The residue was purified by silica gel chromatography to give the title compound (440 mg, 54% yield) as a yellow solid. LC-MS (ESI$^+$) *m/z* 379.2 (M+H)$^+$.

[001739] 4-r4-r5-rraR.2SV2-ltert-butoxycarbonylamino)cvclohexyllaminolpyrazolo[l.,5-alpyrimidin _ _ -2-yll-3-(difluoromethyllpyrazol-l-yllbenzoic acid [Intermediate EC)



[001740] Step_ 1 - Methyl 4-r4-r5-rraR.2sv2-(tert-butoxycarbonylamino)cvclohexyl1amino1pyrazolor i.5- a1pyrimidin-2-yl1-3-(difluoromethvOpyrazol- 1-yllbenzoate


[001741] To a solution of methyl 4-[3-(difluoromethyl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrazol -l-yl]benzoate (379 mg, 702 umol, Intermediate EB) and tert-butyl N-[(lS,2R)-2-[(2-bromopyrazolo[l,5-a]pyrimidin-5 -yl)amino]cyclohexyl]carbamate (160 mg, 390 umol, Intermediate EA) in a mixed solvent of **H_20** (0.6 mL) and dioxane (3 mL) was added **K2CO3** (162 mg, 1.17 mmol) and **XPHOS-PD-G2** (30.7 mg, 39.0 umol). The reaction mixture was stirred at 90 °C for 17 hours. On completion, the mixture was concentrated *in vacuo* to remove the solvent dioxane. The residue was purified by reverse phase chromatography (0.1% **HC1)** to give the title compound (80.0 mg, 35% yield) as a yellow solid. **LC-MS** (ESI^+) *m/z* 582.1 **$(M+H)^+$.**

[001742] Step_ 2_ -_ 4-[4-[5-II(TR.2S)-2-(tert-butoxycarbonylamino)cvclohexyl1amino1pyrazolorE5-a1pyrimidin _ -2-yl1-3-(difluoromethvDpyrazol-l-vnbenzoic acid

[001743] To a solution of methyl 4-[4-[5-[[(lR,2S)-2-(tert-butoxycarbonylamino)cyclohexyl]amino]pyrazolo [l,5-a]pyrimidin-2-yl]-3-(difluoromethyl)pyrazol-l-yl]benzoate (80.0 mg, 138 umol) in a mixed solvent of THF (2 mL) and H2O (0.4 mL) was added LiOH (16.5 mg, 688 umol). The reaction mixture was stirred at rt for 17

hours. On completion, the mixture was acidified with 1N HC1 solution until the pH = 6-7, then concentrated *in vacuo* to give the title compound (75.0 mg, 96% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 568.3 $(M+H)^+$.

[001744] **2-[4-Pyridyl)oxazole-4-carboxylic acid [Intermediate ED)**



ED


[001745] Step 1 - Ethyl 2-(4-pyridyl)oxazole-4-carboxylate


[001746] To a solution of 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (1.50 g, 7.31 mmol) and ethyl 2-bromooxazole-4-carboxylate (1.61 g, 7.31 mmol, CAS# 460081-20-3) in a mixed solvent of dioxane (20 mL) and H_20 (4 mL) was added CS2CO3 (7.15 g, 21.9 mmol) and $Pd(dppf)Cl_2$ (267 mg, 365 umol) under nitrogen atmosphere. The reaction mixture was stirred at 80 °C for 16 hours. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (Petroleum ether/Ethyl acetate = 1/1, PE/EA=l/l) to give the title compound (200 mg, 12% yield) as a yellow solid. ^1H NMR (400MHz, CDCb) δ 8.82 - 8.77 (m, 2H), 8.37 (s, 1H), 8.01 - 7.97 (m, 2H), 4.47 (q, *J* = 7.2 Hz, 2H), 1.44 (t, *J* = 7.2 Hz, 3H).

[001747] Step 2 - 2-(4-Pyridyl)oxazole-4-carboxylic acid

[001748] To a solution of ethyl 2-(4-pyridyl)oxazole-4-carboxylate (0.2 g, 916 umol) in THF (5 mL), MeOH (1 mL) and H_20 (1 mL) was added LiOH (26.34 mg, 1.10 mmol). The reaction mixture was stirred at rt for 12 hours. On completion, the mixture was concentrated *in vacuo* to give a residue. The residue was then diluted with H_20 and the aqueous phase was acidified with cone. HC1 until the pH = 6. The mixture was concentrated *in vacuo* to give the title compound (220 mg) as a yellow solid.

[001749] **4-[3-Carbamoyl-4-[[2-[4-pyridyl)oxazole-4-carbonyl1amino]pyrazol-l-yl]benzoic acid [Intermediate EE)**





EE

[001750] Step 1 - Methyl 4-r3-carbamoyl-4-IT2-(4-pyridvDoxazole-4-carbonyllaminolpyrazol- 1-yllbenzoate


[001751] To a solution of 2-(4-pyridyl)oxazole-4-carboxylic acid (200 mg, 1.05 mmol, Intermediate ED) and methyl 4-(4-amino-3- carbamoyl-pyrazol-l-yl)benzoate (328 mg, 1.26 mmol, Intermediate CL) in DMF (5 mL) was added DIPEA (679 mg, 5.26 mmol, 915 uL). The mixture was stirred at rt for 12 minutes, and then E1ATU (479 mg, 1.26 mmol) was added. The reaction mixture was stirred at rt for 12 hours. On completion, the mixture was diluted with E[2O (10 mL) and extracted with EA (2 X 20 mL). The combined organic layers were concentrated *in vacuo* to give the title compound (60.0 mg, 13% yield) as a brown solid. LC-MS (ESI^+) m/z 433.2 $(M+H)^+$.

[001752] Step 2 - 4-[3-Carbamoyl-4-[[2-(4-pyridvl)oxazole-4-carbonvl]amino]pyrazol-1-yllbenzoic acid

[001753] To a solution of methyl 4-[3-carbamoyl-4-[[2-(4-pyridyl)oxazole-4-carbonyl]amino]pyrazol-l-yl]benzoate (60.0 mg, 138 umol) in THF (8 mL) and H_2O (2 mL) was added LiOH (4.99 mg, 208 umol). The reaction mixture was stirred at rt for 12 hours. On completion, the mixture was concentrated *in vacuo* to give a residue. The residue was then diluted with LEO and the aqueous phase was acidified with cone. HC1 until the pH = 6. The reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase chromatography (0. 1% HC1) to give the title compound (25.0 mg, 43% yield) as a white solid. LC-

MS (ESI+) m/z 4l9.l(M+H) +.


[001754] Tert-butyl N-[3-(3-aminopropoxy]propyllcarbamate [Intermediate EF]



EF

[001755] To a mixture of 3-(3-aminopropoxy)propan-l-amine (499 mg, 3.78 mmol, CAS# 2157-24-6) in CHCb (25 mL) was added a solution of tert-butoxy carbonyl tert-butyl carbonate (165 mg, 756 umol) in CHCb (5 mL) dropwise. Then the reaction mixture was stirred at rt for 16 hours. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (DCM:MeOH = 10:1) to give the title compound (140 mg, 79% yield) as a light yellow oil. ^{1}H NMR (400MHz, CDCb) δ 4.87 (s, 1H), 3.42 (q, *J* = 6.4 Hz, 4H), 3.15 (q, *J* = 5.6 Hz, 2H), 2.76 (t, *J* = 6.4 Hz, 2H), 1.70 - 1.63 (m, 4H), 1.37 (s, 9H).

[001756] 4-(4-(2-(2-(YTert-butoxycarbonvP(cvclopropylmethvPamino]pyridin-4-vPoxazole-4- carboxamidol-3-ltrifluoromethvP-lH-pyrazol-l-vPbenzoic acid [Intermediate EG]



EG

[001757] Step_ _____1_ _____-_ _____Methyl_ _____4-(4-(2-(2-((tert-butoxycarbonv0(cvclopropylmethv0amino)pyridin-4-v0oxazole-4-_ _____carboxamido)-3-(trifluoromethyl)- !H-pyrazol- 1-vPbenzoate


[001758] To a solution of methyl 4-[4-amino-3-(trifluorom ethyl)pyrazol-l-yl]benzoate (300 mg, 1.05 mmol, synthesized via Steps 1-3 of Intermediate DE) and 2-[2-[tert-

butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4- carboxylic acid (378 mg, 1.05 mmol, synthesized via Steps 1-4 of Intermediate DF) in DMF (5 mL) was added DIPEA (408 mg, 3.16 mmol). Then, HATU (478 mg, 1.26 mmol) was added and the reaction mixture was stirred at rt for 0.5 hour. On completion, the reaction mixture was quenched with water (20 mL) and filtered. The filtered cake was collected and dried *in vacuo* to give the title compound (659 mg, 100% yield) as a white solid. ^{1}H NMR (400MHz, CDCb) δ 9.09 (s, 1H), 8.99 (s, 1H), 8.55 (d, *J* = 5.2 Hz, 1H), 8.44 (s, 1H), 8.38 (s, 1H), 8.21 (d, *J* = 8.8 Hz, 2H), 7.89 (d, *J* = 8.8 Hz, 2H), 7.65 (dd, *J* = 1.2, 5.2 Hz, 1H), 4.01 - 3.95 (m, 5H), 1.60 (s, 9H), 1.30 - 1.20 (m, 1H), 0.50 - 0.43 (m, 2H), 0.30 (m, 2H); LC-MS (ESI$^+$) *m/z* 627.1 $(M+H)^+$.

[001759] Step 2 - 4-(4-(2-(2-((Tert-butoxycarbonyl)(cvclopropylmethvDamino)pyridin-4-vDoxazole-4- carboxamido)-3-(trif1uoromethyl)- 1H-pyrazol- 1-yl ibenzoic acid

[001760] To a solution of methyl 4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]- oxazole-4-carbonyl]amino]-3-(trifluoromethyl)pyrazol-l-yl]benzoate (659 mg, 1.05 mmol) in a mixed of solvent THF (30 mL), H_20 (10 mL) and methanol (10 mL) was added LiOH (126 mg, 5.26 mmol). The reaction mixture was stirred at rt for 12 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was diluted with water (20 mL) and acidified with 1N HC1 until the pH = 4, then the mixture was filtered. The filtered cake was collected and dried *in vacuo* to give the title compound (700 mg, 91% yield) as a white solid. LC-MS (ESI$^+$) *m/z* 613.0 $(M+H)^+$.

[001761] **[3-[4-Amino-3-(trifluoromethyl)pyrazol-l-yllphenyllmethanol [Intermediate EH)**



EH

[001762] Step **1** - r3-r4-Nitro-3-(trifluoromethvDpyrazol-l-yl1phenyl1methanol


[001763] To a solution of 4-nitro-3-(trifluoromethyl)-lH-pyrazole (10.0 g, 55.2 mmol, synthesized via Step 1 of Intermediate DE) and [3-(hydroxymethyl) phenyl]boronic acid (12.9 g, 85.3 mmol) in DCM (200 mL) was added $Cu(OAc)_2$ (15.0 g, 82.8 mmol) and pyridine (17.4 g,

220 mmol). The mixture was stirred at rt for 16 hours under oxygen (15 psi pressure). On completion, the mixture was concentrated *in vacuo.* The mixture was purified by silica gel column (PE: EA=l : 1) to give the title compound (8.00 g, 50% yield) as a white solid. 'H NMR (400MHz, DMSO-de) δ 9.90 (s, 1H), 7.93 (s, 1H), 7.85 (d, *J* = 8.0 Hz, 1H), 7.58 (t, *J* = 7.6 Hz, 1H), 7.48 (d, *J* = 7.6 Hz, 1H), 5.45 (t, *J* = 6.0 Hz, 1H), 4.62 (d, *J* = 6.0 Hz, 2H).

[001764] Step 2 - r3-r4-Amino-3-(trifluoromethvnpyrazol-l-yl1phenyl1methanol

[001765] To a solution of [3-[4-nitro-3-(trifluoromethyl)pyrazol-l-yl]phenyl]methanol (1.00 g, 3.48 mmol) in MeOH (20.0 mL) was added Pd/C (200 mg, 10 wt %) under hydrogen (15 psi pressure). The mixture was stirred at rt for 3 hours. On completion, the mixture was filtered and concentrated *in vacuo.* The mixture was purified by silica gel column (PE: EA = 1: 1) to give the title compound (700 mg, 78% yield) as a yellow oil. ^{1}H NMR (400MHz, CDCh) δ 7.60 (s, 1H), 7.47 (s, 1H), 7.45 (s, 1H), 7.36 (t, *J* = 8.0 Hz, 1H), 7.24 (d, *J* = 7.2 Hz, 1H), 4.70 (d, *J* = 3.2 Hz, 2H), 3.28 (s, 2H), 1.76 (s, 1H).

[001766] **Tert-butyl N-(cvclopropylmethvl)-N-[4-[4-[[l-[3-(hvdr()xymethvl)phenyl1-3-(trifluoromethvP pyrazol-4-yl] carbamoyl] oxazol-2-yl1-2-pyridyl1 carbamate [Intermediate Ell**




EH EI

[001767] To a solution of [3-[4-amino-3-(trifluoromethyl)pyrazol-l-yl]phenyl]methanol (400 mg, 1.56 mmol, Intermediate EH) and 2-[2-[tertbutoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (558 mg, 1.56 mmol, Intermediate OM) in DMF (5.00 mL) was added HATH (709 mg, 1.87 mmol) and DIPEA (602 mg, 4.67 mmol). The mixture was stirred at rt for 30 minutes. On completion, the mixture was quenched with H_20 (1 mL) and concentrated *in vacuo.* The mixture was purified by reverse phase prep-HPLC (0.1% FA) to give the title compound (320 mg, 34% yield) as a white solid. ¾ NMR (400MHz, CDCh) δ 9.08 (s, 1H), 8.92 (s, 1H), 8.55 (d, *J* = 5.2 Hz, 1H), 8.44 (s, 1H), 8.38 (s, 1H), 7.83 (s, 1H), 7.70 (d, *J* = 8.0 Hz, 1H), 7.66 (dd, *J* = 1.2, 5.2 Hz, 1H), 7.52 (t, *J* = 7.6 Hz, 1H), 7.41 (d, *J* = 7.6 Hz, 1H), 4.83 (d, *J* = 5.2 Hz, 2H), 3.97 (d, *J* = 7.2 Hz, 2H), 1.90 - 1.82 (m, 1H), 1.59 (s, 9H), 1.28 - 1.25 (m, 1H), 0.49 -

0.43 (m, 2H), 0.33 - 0.29 (m, 2H).

[001768] **4-[2-[2-[2-(AminomethvPmorpholin-4-yllethoxylethylaminol-2-(2.,6-dioxo-3-piperidyl] isoindoline-l,3-dione [Intermediate EJ1**



EJ

[001769] Step 1 - Tert-butyl N-Π4-⌈2-⌈2-[⌈2-(2,6-dioxo-3-piperidvP-l¸3-dioxo-isoindolin-4-yl]amino]ethoxy] ethvHmorpholin-2-yllmethvHcarbamate


[001770] To a solution of 2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethyl methanesulfonate (195 mg, 443 umol, synthesized via Steps 1-2 of Example 184) and tert-butyl N-(morpholin-2-ylmethyl)carbamate (287.92 mg, 1.33 mmol, CAS# 173341-02-1) in CH_3CN (30 mL) was added $NaHC0_3$ (111 mg, 1.33 mmol, 51.7 uL). The mixture was stirred at 80 °C for 6 hours. On completion the mixture was concentrated and extracted with EA (3 X 30 mL). The combined organic layers were washed with brine (50 mL, dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The mixture was purified by column chromatography (TLC; PE: EA 1:1) to give the title compound (100 mg, 35% yield) as a yellow oil. LC-MS (ESI^+) m/z 560.2 $(M+H)^+$.

[001771] Step 2 - 4-⌈2-⌈2-⌈2-(Αηίηοηιethyl)morpholin-4-yl]ethoxy1ethylamino1-2-(2.6-dioxo-3-piperidvD isoindoline-E3-dione

[001772] To a solution of tert-butyl N-[[4-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino] ethoxy]ethyl]morpholin-2-yl]methyl]carbamate (50.0 mg, 89.3 umol) in DCM (2 mL) was added HC1 in dioxane (4 M, 1 mL). The mixture was stirred at rt for 0.5 hr. On

completion, the mixture was concentrated *in vacuo* to give the title compound (44.3 mg, HC1 salt, 90% yield) as a yellow oil. LC-MS (ESI^+) m/z 460.2 $(M+H)^+$.


[001773] **Tert-butyl N-[5-oxopentyDcarbamate [Intermediate EK)**



EK

[001774] To a solution of oxalyl dichloride (3 12 mg, 2.46 mmol, 215 uL) in dichloromethane (5 mL) at -78°C was added dimethyl sulfoxide (384 mg, 4.92 mmol, 384 uL) dissolved in dichloromethane (0.5 mL) dropwise, while keeping the temperature below -65°C. Five minutes later, *t*c/*t*-butyl N-(5-hydroxypentyl)carbamate (500 mg, 2.46 mmol, 500 uL, CAS#: 75178-90-4) dissolved in dichloromethane (0.5 mL) was added slowly to the solution and the mixture was stirred at -78°C for 15 min. Finally, triethylamine (1.24 g, 12.3 mmol, 1.71 mL) was added dropwise and stirred the reaction was stirred for 15 min. The mixture was allowed to warm to rt and stirred for 1 hour. The reaction mixture was quenched with water (10 mL), and extracted with dichloromethane (3 X 5 mL). The combined organic layers were washed with brine (2 X 10 mL), dried over sodium sulfate, filtered and concentrated *in vacuo* to give title compound (450 mg, crude) as a brown oil. ^1H NMR (400MHz, DMSO-de) δ 6.76 - 6.60 (m, 1H), 4.96 - 4.74 (m, 1H), 3.13 - 3.02 (m, 1H), 2.00 - 1.93 (m, 2H), 1.76 - 1.68 (m, 2H), 1.43 (s, 9H), 1.20 (t, J = 7.2 Hz, 1H).

[001775] **4-[2-[5-Aminopentylamino)ethylamino1-2-[2,6-dioxo-3-piperidvDisoindoline-1,3-dione [Intermediate EL)**



[001776] Step 1 - Tert-butyl N-[5-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethylamino] pentyl]carbamate


[001777] To a solution of 4-(2-aminoethylamino)-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione (100 mg, 283 umol, HC1, Intermediate DJ) and *tert*-butyl N-(5-oxopentyl)carbamate (68.5 mg, 340 umol, Intermediate EK) in THF (20 mL) was added KOAc (55.6 mg, 567 umol). The mixture was stirred at rt for 30 minutes, then $NaBH(OAc)_3$ (150 mg, 709 umol) was added in portions. The mixture was stirred at rt for 11.5 hours. The reaction mixture was quenched with water (1 mL) and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (Petroleum ether/Ethyl acetate = 5/1 to dichloromethane: methanol = 10/1) to give title compound (60.0 mg, 39% yield) as a yellow oil. ^1H NMR (400MHz, DMSO-d_6) δ 11.11 (s, 1H), 9.07 (s, 2H), 7.65 - 7.60 (m, 1H), 7.31 (d, *J* = 8.8 Hz, 1H), 7.10 (*d*, *J* = 6.8 Hz, 1H), 6.87 (t, *J* = 6.8 Hz, 1H), 5.08 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.77 - 3.67 (m, 2H), 3.14 - 3.04 (m, 2H), 2.97 - 2.85 (m, 3H), 2.81 - 2.72 (m, 2H), 2.64 - 2.56 (m, 2H), 2.10 - 1.98 (m, 1H), 1.68 - 1.61 (m, 2H), 1.59 - 1.53 (m, 2H), 1.45 - 1.34 (m, 2H).

[001778] Step 2 - 4-[2-(5-Aminopentylamino)ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione

[001779] Tert-butyl N-[5-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethyl amino]pentyl] carbamate (60.0 mg, 119 umol, HC1) was dissolved in 4 M HC1 in dioxane (5 mL). The mixture was stirred at rt for 1 hour. The reaction mixture was then

concentrated *in vacuo* to give title compound (60.0 mg, 95% yield) as a brown oil. ^{1}H NMR (400MHz, DMSO-de) δ 11.10 (s, 1H), 9.10 (s, 2H), 7.62 (t, *J* = 7.6 Hz, 1H), 7.31 (d, *J* = 8.4 Hz, 1H), 7.10 (d, *J* = 7.2 Hz, 1H), 6.86 (s, 1H), 5.07 (dd, *J* = 5.2, 12.4 Hz, 1H), 3.98 - 3.86 (m, 1H), 3.51 - 3.41 (m, 4H), 3.36 - 3.29 (m, 1H), 3.11 - 3.03 (m, 2H), 2.96 - 2.86 (m, 3H), 2.76 - 2.73 (m, 2H), 2.69 - 2.59 (m, 2H), 2.07 - 1.99 (m, 1H), 1.70 - 1.53 (m, 4H), 1.43 - 1.33 (m, 2H).


[001780] **[2R)-2-hvdroxy-3-[[8R)-l-[4-piperazin-l-ylcvclohexoxy)-7.,8-dihvdro-6H-cvclopenta[4.,5l thieno[l,2-c]pyrimidin-8-yl]propanamide [Intermediate** EM]



EM

[001781] To a mixture of tert-butyl 4-[4-[[(8R)-8-[(2R)-3-amino-2-hydroxy-3-oxo-propyl]-7,8-dihydro-6H- cyclopenta[4,5]thieno[l,2-c]pyrimidin-l-yl]oxy]cyclohexyl]piperazine-l-carboxylate (0.09 g, 164 umol, synthesized via Steps 1-14 of Intermediate DR) in DCM (2 mL) was added HC1 in dioxane (4.0 M, 6.43 mL). Then the reaction mixture was stirred at rt for 20 minutes. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (79.5 mg, 100% yield) as white solid. LC-MS (ESI$^+$) m/z 446.1 $(M+H)^+$.

[001782] **2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-oic acid [Intermediate** EN**)**



EN

[001783] Step 1 - *tert*-butyl (2-(2-(2-(2-hvdroxyethoxy)ethoxy)ethoxy)ethvDcarbamate


[001784] To a stirred solution of 2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethan-l-ol (1.0 g, 5.2 mmol, CAS# 86770-74-3) and KOH (0.32 g, 5.6 mmol) in 1,4 dioxane (4 mL) and water (8

mL) was added Boc-anhydride (1.24 g, 5.6 mmol) dropwise at 10 °C. The resulting reaction mixture was allowed to warm to rt and stirred for 16 h. The reaction mixture was transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 100 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to afford crude product. The crude product was purified using silica gel column chromatography (8% MeOH-DCM) to give *t*d/*t*-butyl (2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)carbamate as a colorless oil (1.2 g, 79%). LC-MS (ESI$^+$) *m/z* 293.13 (M+H)$^+$.


[001785] Step 2 - 2.2-dimethyl-4-oxo-3.8.lLl4.l7-pentaoxa-5-azanonadecan-l9-oic acid

[001786] To a stirred solution of *tert*-butyl (2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)carbamate (0.38 g, 1.29 mmol) and 2-bromoacetic acid (0.54 g, 3.8 mmol) in toluene : THF (1:1, 4 mL) was added NaOH (0.31 g, 7.7 mmol) at 45 °C. The resulting reaction mixture stirred at 45 °C for 16 h. The reaction mixture was then evaporated, water (10 mL) was added and aqueous layer was acidified with 1 N HC1 solution. The resulting mixture was extracted using DCM (3 x 50 mL) and the combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give 2,2-dimethyl-4-oxo-3,8,ll,l4,l7-pentaoxa-5-azanonadecan-l9-oic acid as a colorless oil (0.24 g, 53%). LC-MS (ESI$^+$) *m/z* 351.4 (M+H)$^+$.

[001787] 6-[[l,6-naphthyridin-2-vBamino]-4-[cvclopropylaminol-N-[piperidin-4-vBnicotinamide hydrochloride [Intermediate EOl



N



EO


[001788] Step 1 – *tert*-butyl 4-(6-((1,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinamido)piperidine-1-carboxylate

[001789] A solution of 6-((1,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinic acid (0.5 g, 1.56 mmol, Intermediate N), *tert*-butyl 4-aminopiperidine-1-carboxylate (0.32 g, 1.56 mmol, CAS# 87120-72-7), PyBOP (1.22 g, 2.34 mmol) and DIPEA (0.4 mL, 2.34 mmol) in DMF (3 mL) was stirred at rt for 2 h. On completion, the reaction mixture was transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 30 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to afford crude product. The crude product was purified using silica gel column chromatography (5% MeOH-DCM) to give *tert*-butyl 4-(6-((1,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinamido)piperidine-1-carboxylate as a yellow solid (0.6 g, 76%). LC-MS (ESI^+) *m/z* 504.50 $(M+H)^+$.

[001790] Step 2 - 6-((1,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)-N-(piperidin-4-yl)nicotinamide hydrochloride

[001791] To the solution *tert*-butyl 4-(6-((1,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinamido)piperidine-1-carboxylate (0.6 g, 1.19 mmol) in DCM (10 mL) was added 4N HCl in dioxane (3 mL) at 0 °C. Then the reaction mixture was allowed to warm to rt and stirred for 3 h. The reaction mixture was evaporated under reduced pressure to afford the crude product. The crude product was triturated using MTBE to give 6-((1,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)-N-(piperidin-4-yl)nicotinamide hydrochloride as a white solid (0.45 g, 85%). LC-MS (ESI^+) *m/z* 404.40 $(M+H)^+$.

[001792] ***tert*-butyl [2-[2-[2-aminoethoxy)ethoxy)ethyl]methyl]carbamate [Intermediate EP)**



EP

[001793] Step 1 - 2-(2-(2-hydroxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate

[001794] To a stirred solution of 2,2'-(ethane-l,2-diylbis(oxy))bis(ethan-l-ol) (15.0 g, 0.10 mmol, CAS# 112-27-6), silver oxide (34.65 g, 34.65 mmol), and sodium iodide (16.5 g, 1.1 mmol) in DCM (200 mL) was added tosyl chloride (19.06 g, 0.10 mmol) portion-wise at 0 °C, and the reaction mixture was stirred for 3 h. On completion, the reaction mixture was filtered through a pad of celite and the filtrate was extracted using DCM (3 x 20 mL). The combined organic layer was washed with water, dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to get the crude product. The crude product was purified using silica gel column chromatography (3 % MeOH: DCM) to give 2-(2-(2-hydroxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate as a yellow liquid (18 g, 59%). LC-MS (ESI^+) *m/z* 305.34 $(M+H)^+$.

[001795] Step 2 - 2-(2-(2-(methylamino)ethoxy)ethoxy)ethan-l-ol

[001796] To a stirred solution of 2-(2-(2-hydroxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (5.0 g, 16.4 mmol) in THF (15 mL) was added 2M Methylamine in THF (34 mL, 66 mmol) at rt, then the reaction mixture was heated to 90 °C and stirred for 8 h. The reaction mixture was then filtered and filtrate was evaporated under reduce pressure to give 2-(2-(2-(methylamino)ethoxy)ethoxy)ethan-l-ol as a yellow oil (2.5 g, 93% yield). LC-MS (ESI^+) *m/z* 164.21 $(M+H)^+$.

[001797] Step 3 - *tert*-butyl (2-(2-(2-hydroxyethoxy)ethoxy)ethyl)(methyl)carbamate

[001798] To a stirred solution of 2-(2-(2-(methylamino)ethoxy)ethoxy)ethan-l-ol (2.5 g, 15.3 mmol) in DCM (40 mL) was added boc anhydride (20 g, 92 mmol) and TEA (4.0 mL, 30.6

mmol) at 0 °C and the reaction mixture was stirred for 2h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted with DCM (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to afford crude product. The crude product was purified using silica gel column chromatography (40 % EtOAc-Hexane) to give *tert*-butyl (2-(2-(2-hydroxyethoxy)ethoxy)ethyl)(methyl)carbamate as a yellow semisolid (2.2 g, 54%). LC-MS (ESI^+) *m/z* 264.32 $(M+H)^+$.

[001799] Step 4 - 2,2,5-trimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl methanesulfonate

[001800] To a stirred solution of fe/7-butyl(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)(methyl)carbamate (2.2 g, 8.4 mmol) and triethylamine (3.5 g, 25.08 mmol) in DCM (15 mL) was added mesyl chloride (1.2 mL, 12.54 mmol) at 0 °C, then the reaction mixture was stirred for 2 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted with DCM (3 x 25 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give 2,2,5-trimethyl-4-oxo-3,8,ll-trioxa-5-azatridecan-l3-yl methanesulfonate as a yellow semisolid (2.8 g, 78%).

[001801] Step 5 - *tert*-butyl (2-(2-(2-azidoethoxy)ethoxy)ethvO(methvQcarbamate


[001802] To a stirred solution of 2,2,5-trimethyl-4-oxo-3,8,ll-trioxa-5-azatridecan-l3-yl methanesulfonate (2.8 g, 8.2 mmol) in DMF (10 mL) was added sodium azide (0.8 g, 12.3 mmol) at rt. Then the reaction mixture was heated to 60 °C and stirred for 3 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted with ethyl acetate (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to afford crude product. The crude product was purified using silica gel column chromatography (30 % EtOAc-Hexane) to give *tert*-butyl (2-(2-(2-azidoethoxy)ethoxy)ethyl)(methyl)carbamate as a yellow semisolid (1.6 g, 98%). LC-MS (ESI^+) *m/z* 355.33 $(M+FA\ adduct)^+$.

[001803] Step 6 - *tert*-butyl (2-(2-(2-aminoethoxy)ethoxy)ethv0(methv0carbamate

[001804] To a stirred solution of /er/-butyl(2-(2-(2-azidoethoxy) ethoxy)ethyl)(methyl)carbamate (1.6 g, 5.6 mmol) in EtOH (15 mL) in an autoclave was added

10 % Pd/C (50% wet) (1.6 g) under hydrogen gas (5 kg/cm^2 pressure) at rt for 3 h. The reaction mixture was filtered through celite and concentrated under reduced pressure to give ter/-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)(methyl)carbamate a as colorless oil (1 g, 68 % yield). LC-MS (ESI$^+$) *m/z* 263.32 $(M+H)^+$


[001805] **2-(2-(benzyloxy)ethoxy)ethyl methanesulfonate (Intermediate EQ)**



EQ

[001806] To a stirred solution of 2-(2-(benzyloxy)ethoxy)ethan-l-ol (0.5 g, 2.5 mmol, CAS# 2050-25-1) and TEA(l.l mL, 7.6 mmol) in DCM (10 mL) was added mesyl chloride (0.3 mL, 3.8 mmol) dropwise at 0 °C. The resulting reaction mixture stirred at 0 °C for 2 h. The reaction mixture was transferred into ice water and the resulting mixture was extracted with DCM (3 x 50 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give 2-(2-(benzyloxy)ethoxy)ethyl methanesulfonate as a colorless oil (0.45 g, 64%).

[001807] ***te*/T-butyl [2-[2-aminoethoxylethylK2,2-dimethyl-4-oxo-3,8,ll-trioxa-5-azatridecan-13-yl)carbamate [Intermediate ER)**



[001808] Step 1 - fer/-butyl (l -phenyl-2.5.11.14-tetraoxa-8-azahexadecan- 16-yl icarbamate

[001809] To a stirred solution of ter/-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate

(3.0 g, 12.1 mmol. CAS # 153086-78-3, Supplier: Chem-Impex) and 2-(2-(benzyloxy)ethoxy)ethyl methanesulfonate (5.0 g, 18.2 mmol, Intermediate EQ) in DMF (45 mL) was added K2CO3 (5 g, 36.2 mmol) at rt. The resulting reaction mixture heated to 80 °C and stirred for 5 h. The reaction mixture was transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to afford crude product. The crude product was purified using silica gel column chromatography (5% MeOH-DCM) to give *tert*-butyl (l-phenyl-2,5,ll,l4-tetraoxa-8-azahexadecan-l6-yl)carbamate as a yellow oil (2.4 g, 47%). LCMS (ESI$^+$) *m/z* 426.55 (M+H)$^+$.

[001810] Step 2 - *tert*-butyl (2-(2-(benzyloxy)ethoxy)ethyl)(2.2-dimethyl-4-oxo-3.8J 1-trioxa-5-azatridecan- 13-vDcarbamate

[001811] To a stirred solution of *tert*-butyl (l-phenyl-2,5,ll,l4-tetraoxa-8-azahexadecan-l6-yl)carbamate (2.4 g, 5.6 mmol) and TEA (1.6 mL, 11.2 mmol) in THF (40 mL) was added Boc anhydride (1.47 g, 6.7 mmol) dropwise at 0°C. The resulting reaction mixture stirred at rt for 1 h. The reaction mixture was transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 50 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give *tert*-butyl (2-(2-(benzyloxy)ethoxy)ethyl)(2,2-dimethyl-4-oxo-3,8,ll-trioxa-5-azatridecan-l3-yl)carbamate as a colorless oil (2.9 g, 98%). LCMS (ESI$^+$) *m/z* 526.67 (M+H)$^+$.

[001812] Step 3 - *tert*-butyl (2.2-dimethyl-4-oxo-3.8. 11-trioxa-5-azatridecan- 13-yl)(2-(2-hydroxyethoxyiethyl icarbamate

[001813] To a stirred solution of *tert*-butyl (2-(2-(benzyloxy)ethoxy)ethyl)(2,2-dimethyl-4-oxo-3,8,ll-trioxa-5-azatridecan-l3-yl)carbamate (3.2 g, 6.1 mmol) in ethanol (60 mL) and acetic acid (0. 1 mL) in autoclave was added 10% Pd/C (50% wet) (3.2 g) at rt under nitrogen atmosphere. The resulting reaction mixture stirred under hydrogen gas (2 kg/cm^2 pressure) in autoclave at rt for 4 h. The reaction mixture was filtered through a pad of celite and washed with MeOH (50 mL). The filtrate was evaporated under reduced pressure to give *tert*-butyl (2,2-dimethyl-4-oxo-3,8,ll-trioxa-5-azatridecan-l3-yl)(2-(2-hydroxyethoxy)ethyl)carbamate as a yellow oil (2.4 g, 81 %). LC-MS (ESL) *m/z* 436.55 (M+H)$^+$.

[001814] Step 4 - 14-(*tert*-butoxycarbonyl)-2,2-dimethyl-4-oxo-3,8,11,17-tetraoxa-5,14-diazanonadecan-19-yl methanesulfonate

[001815] To a stirred solution of *tert*-butyl (2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)(2-(2-hydroxyethoxy)ethyl)carbamate (2.2 g, 5.0 mmol) and TEA (2.1 mL, 15.1 mmol) in dichloromethane (50 mL) was added mesyl chloride (0.6 mL, 7.7 mmol) dropwise at 0 °C. The resulting reaction mixture allowed to warm to rt and stirred for 4 h. The reaction mixture was transferred into ice water and the resulting mixture was extracted with DCM (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give 14-(/tv7-butoxycarbonyl)-2, 2-dimethyl-4-oxo-3,8,11,17-tetraoxa-5,14-diazanonadecan-19-yl methanesulfonate as a brown oil (2.5 g, 96%). LCMS (ESI$^+$) *m/z* 514.63 $(M+H)^+$.

[001816] Step 5 - *tert*-butyl (2-(2-azidoethoxy)ethyl)(2.2-dimethyl-4-oxo-3.8J 1-trioxa-5-azatridecan- 13-vDcarbamate


[001817] To a stirred solution of 14-(/er/-butoxycarbonyl)-2,2-dimethyl-4-oxo-3,8,11,17-tetraoxa-5,14-diazanonadecan-19-yl methanesulfonate (2.5 g, 4.8 mmol) in DMF (25 mL) was added sodium azide (0.48 g, 7.2 mmol) at rt. The resulting reaction mixture was heated to 65 °C and stirred for 4 h. The reaction mixture was transferred into ice water and the resulting mixture was extracted with ethyl acetate (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to afford crude product. The crude product was purified using silica gel column chromatography (1% MeOH-DCM) to give *tert*-butyl (2-(2-azidoethoxy)ethyl)(2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)carbamate as a yellow liquid (2 g, 89%). LCMS (ESI$^+$) *m/z* 461.56 $(M+H)^+$.

[001818] Step 6 - *tert*-butyl (2-(2-aminoethoxy)ethyl)(2.2-dimethyl-4-oxo-3.8. 11-trioxa-5-azatridecan- 13-vDcarbamate

[001819] To a stirred solution of *tert*-butyl (2-(2-azidoethoxy)ethyl)(2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)carbamate (1.8 g, 3.9 mmol) in ethanol (100 mL) was added 10% Pd/C (50% wet) (1.8 g) at rt under nitrogen atmosphere. The resulting reaction mixture was stirred under hydrogen gas (2 kg/cm^2 pressure) in an autoclave at rt for 4 h. The reaction mixture was filtered through a pad of celite and washed with MeOH (50 mL). The filtrate was evaporated

under reduced pressure to give ter/-butyl (2-(2-aminoethoxy)ethyl)(2, 2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-l3-yl)carbamate as a colorless oil (1.4 g, 82 %). LC-MS (ESI+) *m/z* 435.56 $(M+H)^+$.

[001820] ***Tert*-butyl_ (qR.3RV3-q6-amino-2.5.8.1L14-pentaoxahexadecvDcvclobutyllcarbamate [Intermediate ES]**



ES

[001821] Step 1 - fer/-butyl ((1R,3R)-3-(18-phenyl-2,5,8,11,14,17-hexaoxaoctadecyl) cvclobutvO carbamate

[001822] To a stirred solution of ((lR,3R)-3-((/er/-butoxycarbonyl)amino)cyclobutyl)methyl methanesulfonate (2.9 g, 10.4 mmol, synthesized via Steps 1-3 of Intermediate H) and l-phenyl-2,5,8,ll,l4-pentaoxahexadecan-l6-ol (6.8 g, 20.78 mmol, synthesized via Step 1 of Intermediate X) in toluene (30 mL) and 8 N NaOH solution (30 mL) was added TBAB (500 mg, 2.1 mmol) at rt. The resulting reaction mixture then heated to 90 °C and stirred for 16 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted with ethyl acetate (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to afford crude product. The crude product was purified using silica gel column chromatography (1% MeOH-DCM) to give *tert*-butyl ((lR,3R)-3-(l8-phenyl-2,5,8,ll,l4,l7-hexaoxaoctadecyl)cyclobutyl)carbamate as a colorless oil (2.4 g, 46%). LCMS (ESI+) *m/z* 511.66 $(M+H_20)^+$.

[001823] Step 2 - *tert*-butyl ((1R,3R)-3-(16-hydroxy-2,5,8,11J4-pentaoxahexadecyl) cvclobutyl icarbamate

[001824] To a stirred solution of *tert*-butyl ((lr,3r)-3-(l8-phenyl-2,5,8,ll,l4,l7-hexaoxaoctadecyl) cyclobutyl) carbamate (3.15 g, 6.16 mmol) in ethanol (40 mL) and acetic acid (0.3 mL) was added 10% Pd/C (50% wet) (3.15 g) at rt under nitrogen atmosphere. The resulting reaction mixture was stirred under hydrogen gas (2 kg/cm^2 pressure) in autoclave at rt for 4 h. The reaction mixture was filtered through a pad of celite and washed with MeOH (50 mL). The filtrate was evaporated under reduced pressure to give *tert*-butyl ((lR,3R)-3-(l6-hydroxy-2,5,8,ll,l4-pentaoxahexadecyl)cyclobutyl)carbamate as a brown oil (2.1 g, 81 %). LC-MS (ESI$^+$) *m/z* 421.53 $(M+H)^+$.

[001825] Step 3 - 1-((1R,3R)-3-((*tert*-butoxycarbonyl)amino)cvclobutyl)-2.5.8. 11.14-pentaoxahexadecan-l6-yl methanesulfonate

[001826] To a stirred solution of *tert*-butyl ((lR,3R)-3-(l6-hydroxy-2,5,8,ll,l4-pentaoxahexadecyl) cyclobutyl) carbamate (2.1 g, 5.0 mmol) and TEA (2.1 mL, 15.0 mmol) in dichloromethane (50 mL) was added mesyl chloride (0.58 mL, 7.5 mmol) dropwise at 0°C. The resulting reaction mixture stirred at rt for 3 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted with DCM (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to give l-((lR,3R)-3-((/er/-butoxycarbonyl)amino)cyclobutyl)-2,5,8, 11,14-pentaoxahexadecan-l6-yl methanesulfonate as a brown oil (2.3 g, 92%). LCMS (ESI$^+$) *m/z* 499.62 $(M+H)^+$.

[001827] Step 4 - *tert*-butyl ((TR.3RV3-(T6-azido-2.5.8.lLl4-pentaoxahexadecvPcvclobutvDcarbamate


[001828] To a stirred solution of 1-((1R,3R)-3-((/tvV-butoxycarbonyl)amino)cyclobutyl)-2,5,8, 11, l4-pentaoxahexadecan-l6-yl methanesulfonate (2.0 g, 4.0 mmol) in DMF (20 mL) was added sodium azide (390 mg, 6.0 mmol) at rt. The resulting reaction mixture then heated to 65 °C and stirred for 2 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted with ethyl acetate (3 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to afford

crude product which was purified by silica gel column chromatography (2% MeOH-DCM) to give *te/t*-butyl ((lR,3R)-3-(l6-azido-2,5,8,ll,l4-pentaoxahexadecyl) cyclobutyl) carbamate as a colorless liquid (1.75 g, 98%). LCMS (ESI+) *m/z* 446.55 $(M+H)^+$.

[001829] Step 5 - *tert*-butyl ((TR.3RV3-(T6-amino-2.5.8.lU4-pentaoxahexadecvncvclobutvncarbamate


[001830] To a stirred solution of *tert*-butyl ((lR,3R)-3-(l6-azido-2,5,8,ll,l4-pentaoxahexadecyl) cyclobutyl) carbamate (1.8 g, 4.0 mmol) in ethanol (40 mL) was added 10% Pd/C (50% wet) (1.8 g) at rt under nitrogen atmosphere. The resulting reaction mixture was then stirred under hydrogen gas (2 kg/cm^2 pressure) in autoclave at rt for 2 h. The reaction mixture was filtered through a pad of celite and washed with MeOH (50 mL). The filtrate was evaporated under reduced pressure to give *tcrt*-butyl ((lr,3r)-3-(l6-amino-2,5,8,ll,l4-pentaoxahexadecyl) cyclobutyl)carbamate as a brown oil (1.41 g, 83 %). LC-MS (ESI+) *m/z* 420.55 $(M+H)^+$

[001831] 4-(3-carbamoyl-4-(2-(2-((2,2,2-trif uoroethvl)amino)pvridin-4-vl)oxazole-4-carboxamido]-l *I*/-pyrazol-l-vPbenzoic acid [Intermediate ET)



[001832] Prepared a 5:4:1 mixture of DCM:TFA:H_20 by combining DCM (5.6 mL), trifluoroacetic acid (4.5 mL), and water (1.1 mL). To this solution was added Intermediate CN (870 mg, 1.69 mmol) and the reaction mixture was stirred for 2.5 h at rt. On completion, the solvent was removed and the residue was placed under high vacuum to yield 1.07 g (quantitative yield) of the title compound as a brown solid. LC-MS (ESI+) m/z 516.1 $(M+H)^+$.

[001833] 2-(4-iodobutvDisoindoline-l.,3-dione [Intermediate EU)



EU

[001834] Step 1 - 2-(4-hvdroxybutvOisoindoline-L3-dione

[001835] To a suspension of 4-aminobutan-l-ol (5.05 g, 48.95 mmol) in toluene (200 mL) was added phthalic anhydride (7.25 g, 48.95 mmol). The reaction mixture was stirred under a Dean-Stark apparatus at 110 °C for 16 h at . The reaction mixture was then cooled to rt and washed with a 1N aqueous solution of HC1. The organics were washed with brine, dried over magnesium sulfate, filtered and concentrated *in vacuo.* The residue was purified by flash column chromatography (gradient of 25-75% Ethyl Acetate in Hexanes) to yield the title compound (8.62 g, 76%) as a colorless oil.

[001836] Step 2 - 4-(T.3-dioxoisoindolin-2-v0butyl methanesulfonate


[001837] 2-(4-hydroxybutyl)isoindoline-l,3-dione (7.6 g, 32.6 mmol) was dissolved in dichloromethane (200 mL) and cooled to 0 °C. Triethylamine (5.9 mL, 42.4 mmol) and methane sulfonyl chloride (2.77 mL, 35.83 mmol) were added and the reaction was stirred for 1.5 hours. The reaction mixture was then quenched with a saturated aqueous solution of NaHCCh, and the layers were partitioned. The organic layer was washed with a saturated aqueous solution of NaHCCh (3 times), dried over magnesium sulfate, filtered and concentrated *in vacuo* to give the title compound (9.9 g, 97%) as an off-white powder.

[001838] Step 3 - 2-(4-iodobutv0isoindoline-L3-dione

[001839] 4-(l,3-dioxoisoindolin-2-yl)butyl methanesulfonate (9.90 g, 31.82 mmol) was dissolved in acetone (200 mL). Then sodium iodide (14.4 g, 95.5 mmol) was added and the reaction mixture was heated to 58 °C for 2 hours. The reaction mixture was then concentrated *in vacuo*, then the residue was diluted with water and the aqueous layer was extracted with Ethyl Acetate (3 times). The combined organic layer was washed with water, dried over magnesium sulfate, filtered

and concentrated *in vacuo.* The title compound was isolated as a yellow powder (10.22 g, 93%). LC-MS (ESI$^+$) m/z 344.0 $(M+H)^+$.

[001840] **5-[2-[4-[[tetrahydro-2H-pyran-2-yl)oxy)butoxy)ethoxy)pentan-1-amine [Intermediate EV)**



[001841] Step 1 - 2-(4-((tetrahydro-2H-pyran-2-yl)oxy)butoxy)ethan-1-ol

[001842] To a suspension of NaH (2.9 g, 73.42 mmol, 60% dispersion in mineral oil) in dry DMF (150 mL) was added ethylene glycol (17.2 mL, 306 mmol) dropwise. The reaction mixture was stirred for 30 minutes at rt before the addition of potassium iodide (10.15 g, 61.19 mmol) and 2-(4-bromobutoxy)tetrahydro-2H-pyran (15.37 g, 61.19 mmol, CAS# 31608-22-7). The reaction was stirred at rt for 16 h. The reaction mixture was then quenched with a saturated aqueous solution of NH4CI. The aqueous layer was extracted with Ethyl Acetate (3 times). The combined organic layer was dried over magnesium sulfate, filtered and concentrated *in vacuo.* The residue was purified by silica gel column chromatography (gradient of 20-100% Ethyl Acetate in Hexanes). The title compound was isolated as a yellow powder (4.33 g, 30% yield).

[001843] Step 2 - 2-(5-(2-(4-((tetrahydro-2H-pyran-2-yl)oxy)butoxy)ethoxy)pentyl)isoindoline-E3-dione


[001844] 2-(4-((tetrahydro-2H-pyran-2-yl)oxy)butoxy)ethan-l-ol (2.2 g, 9.5 mmol) was dissolved in dry DMF (40 mL). Then NaH (0.41 g, 10.4 mmol, 60% dispersion in mineral oil) was carefully added. After stirring for 30 minutes at rt, 2-(4-iodobutyl)isoindoline-l,3-dione (3.9 g, 11.3 mmol, Intermediate EU) was added and the reaction mixture was stirred at rt for 16 h. The reaction mixture was then was quenched with water and the aqueous layer was extracted with Ethyl Acetate (3 times). The combined organic layer was washed with water, dried over magnesium sulfate, filtered and concentrated. The resulting residue was purified by silica gel

chromatography (gradient of 0-100% Ethyl Acetate in Hexanes) to give the title compound (956 mg, 22% yield) as a colorless oil. LC-MS (ESI^+) m/z 449.2 $(M+H)^+$.

[001845] Step 3 - 5-(2-(4-((tetrahydro-2H-pyran-2-yl)oxy)butoxy)ethoxy)pentan-1-amine

[001846] 2-(5-(2-(4-((tetrahydro-2H-pyran-2-yl)oxy)butoxy)ethoxy)pentyl)isoindoline-1,3-dione (200 mg, 0.44 mmol) was dissolved in methanol (3 mL) and hydrazine hydrate (64 μL, 1.32 mmol) was added. The reaction mixture was heated to 70 °C and stirred for 3 hours. The reaction mixture was then cooled to rt and concentrated *in vacuo.* The residue was triturated in diethyl ether, and the white precipitate was filtered off. The filtrate was then concentrated in vacuo to give the title compound as a colorless oil (120 mg, 87% yield).


[001847] ***Tert-butyl*** **13,6,9,12-tetraoxapentadec-14-yn-1-ylcarbamate [Intermediate EW1**



EW

[001848] To a solution of tert-butyl (2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)carbamate (10.0 g, 34.1 mmol, Step 1 of Intermediate EN) in anhydrous THF (250mL) was added sodium hydride (1.63 g, 40.94 mmol, 60% dispersion in mineral oil) in one portion under nitrogen atmosphere. The reaction mixture was stirred at rt for 0.5 h and thereafter it was cooled to 0 °C. An 80% solution of 3-bromoprop-1-yne in toluene (5.7 mL, 51.2 mmol) was added dropwise to the reaction mixture at 0°C over a period of 10 min. The resulting reaction mixture was stirred at 0°C for 1 h and thereafter it was allowed to warm to rt. The resulting reaction mixture was stirred overnight at rt. Then the reaction mixture was quenched with a small aliquot of methanol (1.6 mL) and concentrated on a rotary evaporator. The obtained crude material was suspended in DCM (100 mL) and was washed with water (2 x 30 mL) and brine (50 mL). The resulting organic layer was dried over anhydrous sodium sulphate, filtered and concentrated on a rotary evaporator. The obtained crude product was purified by silica gel chromatography (gradient Ethyl acetate/Hexanes) to give the title compound (6.25 g, 55%) as a light yellow viscous liquid.

[001849] **3-Benzyloxy-5-methoxy-aniline [Intermediate EX)**



EX

[001850] Step 1 - 3-Methoxy-5 -nitro-phenol

[001851] A mixture of KOH (11.6 g, 206 mmol) and l-bromo-3 -methoxy-5 -nitro-benzene (12.0 g, 51.7 mmol) in a mixed solvent of dioxane (80 mL) and H2O (80 mL) was degassed for 5 minutes. Then $Pd_2(dba)_3$ (473 mg, 517 umol) and tBuXphos (439 mg, 1.03 mmol) were added to the reaction mixture. The resulting reaction mixture was degassed for a further 0.5 hour, and then the reaction mixture was heated at 100° C for 12 hours under a nitrogen atmosphere. On completion, the mixture was cooled, then acidified with 5 M HC1 until the pH = 1.0 and extracted with EtOAc (2 X 200 mL). The combined organic layer was washed with saturated brine (200 mL), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by silica gel chromatography (PE: EA = 3:1) to give the title compound (8.60 g, 98% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-r¾) δ 10.46 (s, 1H), 7.18 (d, *J* = 2.4 Hz, 2H), 6.75 (t, *J* = 2.4 Hz, 1H), 3.81 (s, 3H).

[001852] Step 2 - l-Benzyloxy-3-methoxy-5-nitro-benzene


[001853] To a mixture of 3-methoxy-5 -nitro-phenol (4.00 g, 23.6 mmol) in acetone (150 mL) was added K2CO3 (8.17 g, 59.1 mmol) and BnBr (6.07 g, 35.4 mmol, 4.21 mL). Then the reaction mixture was stirred at 50 °C for 12 hours. On completion, the reaction mixture was filtered, and the filtrate was concentrated *in vacuo* to remove acetone. The residue was washed with water (100 mL) and extracted with EA (2 X 200 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE:EA = 8:1) to give the title compound (6.00 g, 97% yield) as a yellow solid. ^{1}H NMR (400MHz, CDCb) δ 7.52 - 7.34 (m, 7H), 6.84 (t, *J* = 2.4 Hz, 1H), 5.13 (s, 2H), 3.87 (s, 3H).

[001854] Step 3 - 3-Benzyloxy-5-methoxy-aniline


[001855] To a solution of l-benzyloxy-3-methoxy-5-nitro-benzene (2.00 g, 7.71 mmol) in MeOH (45 mL) and H_20 (10 mL) was added Fe (4.31 g, 77.1 mmol) followed by NH_4Cl (4.12 g, 77.1 mmol). Then, the reaction mixture was stirred at 75 °C for 14 hours. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to remove MeOH. The

residue was washed with water (100 mL) and extracted with EA (2 X 200 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (1.14 g, 64% yield) as black brown oil. ^1H NMR (400MHz, CDCh) δ 7.47 - 7.28 (m, 5H), 6.04 (t, J = 2.0 Hz, 1H), 5.98 (t, J = 2.0 Hz, 1H), 5.92 (t, j = 2.0. Hz, 1H), 5.03 (s, 2H), 3.76 (s, 3H); LC-MS (ESI^+) *m/z* 230.1 $(M+H)^+$.

[001856] **2-[2-[2-|2-(Benzyloxycarbonylamino)ethoxy]ethoxy]ethoxy]ethyl methanesulfonate [Intermediate EY)**



DC



EY


[001857] Step 1 - Benzyl N-r2-r2-r2-(2-hvdroxyethoxy)ethoxy1ethoxy1ethyl1carbamate

[001858] To a solution of 2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethanol (6.00 g, 31.0 mmol, Intermediate DC) in ACN (50 mL) and H_20 (50 mL) was added CbzCl (6.36 g, 37.2 mmol) and $NaHCO_3$ (7.83 g, 93.1 mmol). The reaction mixture was stirred at rt for 12 hours. On completion, the reaction mixture was diluted with water (30 mL) and extracted with EA (3 X 30 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (9.20 g, 90% yield) as a colorless oil. LC-MS (ESI^+) *m/z* 350.0 $(M+Na)^+$.

[001859] Step 2 - 2-[2-[2-[2-(Benzyloxycarbonylaminoiethoxyl ethoxy]ethoxy]ethyl methanesulfonate

[001860] To a mixture of benzyl N-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]carbamate (1.00 g, 3.05 mmol) in dichloromethane (10 mL) was added TEA (617 mg, 0.85 mL, 6.10 mmol) and MsCl (524 mg, 0.354 mL, 4.57 mmol) dropwise at 0 °C under nitrogen atmosphere. The reaction mixture then allowed to warm to rt and stirred for 1 hour. On completion, the reaction mixture was poured into 5 mL of water and acidified with citric acid until the pH = 5-6. The mixture was extracted with dichloromethane (2 X 10 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (1.10 g, 88% yield) as a light yellow oil. LC-MS (ESI^+) *m/z* 406.0 $(M+H)^+$.

[001861] **7-((3-Hvdroxy-5-methoxyphenvPamino]-5-(methylthio]imidazo[l.,2-c]pyrimidine-8-carbox amide [Intermediate EZ)**



[001862] Step 1 - 4-(3-Benzyloxy-5-methoxy-anilino)-6-chloro-2-methylsulfanyl-pyrimidine-5-carbonitrile

[001863] To a mixture of 3-benzyloxy-5-methoxy-aniline (6.90 g, 30.1 mmol, Intermediate EX) and 4,6-dichloro-2- methylsulfanyl-pyrimidine-5-carbonitrile (6.62 g, 30.1 mmol, CAS# 33097-13-1) in THF (20 mL) was added DIPEA (5.83 g, 45.1 mmol, 7.88 mL) dropwise at 0 °C. The reaction mixture was then allowed to warm to rt and stirred for 12 hours. On completion, the reaction mixture was concentrated *in vacuo* to remove THF. The residue was washed with water (100 mL) and extracted with EA (2 X 200 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (9.00 g, 72% yield) as a light yellow solid. ¾NMR (400MHz, DMSO^) δ 7.51 - 7.29 (m, 5H), 6.93 (t, *J* = 2.0 Hz, 1H), 6.85 (t, *J* = 2.0 Hz, 1H), 6.45 (t, *J* = 2.4 Hz, 1H), 5.08 (s, 2H), 3.73 (s, 3H), 2.46 (s, 3H); LC-MS (ESI^+) *m/z* 412.9 $(M+H)^+$.

[001864] Step 2 - 4-Amino-6-(3-benzyloxy-5-methoxy-anilino)-2-methylsulfanyl-pyrimidine-5-carbonitrile

[001865] To a solution 4-(3-benzyloxy-5-methoxy-anilino)-6-chloro-2-methylsulfanylpyrimidine-5-carbonitrile (10.2 g, 24.7 mmol) in THF (50 mL) was added $NH_3·H_20$ (30 mL). The reaction mixture was stirred at 70 °C for 12 hours. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was triturated with DCM

(100 mL) and filtered. The filter cake was collected to afford a white solid. Then, the white solid was triturated with acetone (50 mL) to give the title compound (7.79 g, 80% yield) as an off-white solid. LC-MS (ESI^+) *m/z* 394.0 $(M+H)^+$.

[001866] Step 3 - 4-Amino-6-(3-benzyloxy-5-methoxy-anilino)-2-methylsulfanyl-pyrimidine-5-carboxamide

[001867] To a mixture 4-amino-6-(3-benzyloxy-5-methoxy-anilino)-2-methylsulfanylpyrimidine-5-carbonitrile (7.79 g, 19.8 mmol) in DMSO (80 mL) and EtOH (80 mL) was added NaOH (5 M, 19.8 mL) and H2O2 (11.2 g, 99.0 mmol, 9.51 mL, 30% solution) dropwise. The reaction mixture was stirred at rt of 2.5 hours. On completion, the reaction mixture was quenched by slow addition of saturated $Na_2S_20_3$ solution (50 mL) under stirring. The reaction mixture was concentrated *in vacuo* to remove the EtOH. The residue was poured into 100 mL of water and acidified with 1M HC1 until the pH = 7. The mixture was extracted with EA (2 X 200 mL). The combined organic layer was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (10.0 g, 91% yield) as a white solid. ^1H NMR (400MHz, DMSO-rL) δ 9.89 (s, 1H), 7.56 (s, 2H), 7.47 - 7.31 (m, 5H), 6.91 (t, J = 2.0 Hz, 1H), 6.88 (t, j = 2.0 Hz, 1H), 6.85 (s, 2H), 6.25 (t, j = 2.0 Hz, 1H), 5.07 (s, 2H), 3.72 (s, 3H), 2.46 (s, 3H); LC-MS (ESI^+) *m/z* 412.0 $(M+H)^+$.

[001868] Step 4 - 7-(3-Benzyloxy-5-methoxy-anilino)-5-methylsulfanyl-imidazorL2-clpyrimidine-8-carbox amide


[001869] To a mixture of 4-amino-6-(3 -benzyl oxy-5-m ethoxy-anilino)-2-methylsulfanylpyrimidine-5-carbox amide (8.00 g, 19.4 mmol) in DMF (50 mL) was added a solution of 2-chloroacetaldehyde (11.4 g, 58.3 mmol, 9.39 mL, 40% solution in water). The reaction mixture was stirred at 60 °C for 8 hours. On completion, the reaction mixture was concentrated *in vacuo* to remove the DMF. The residue was purified by silica gel chromatography (DCM: MeOH = 80: 1) to give the title compound (2.30 g, 27% yield) as a yellow solid. ^1H NMR (400MHz, CDCb) δ 12.04 (s, 1H), 10.04 (s, 1H), 7.48 - 7.33 (m, 7H), 6.94 - 6.92 (m, 1H), 6.88 - 6.85 (m, 1H), 6.34 (t, j = 2.0 Hz, 1H), 5.74 (s, 1H), 5.07 (s, 2H), 3.81 (s, 3H), 2.80 (s, 3H); LC-MS (ESI^+) *m/z* 436.0 $(M+H)^+$.

[001870] Step 5 - 7-(Y3-Hvdroxy-5-methoxyphenvDamino)-5-(′methylthio)imidazorL2-clpyrimidine-8-carbox amide

[001871] To a solution of 7-(3-benzyloxy-5-methoxy-anilino)-5-methylsulfanyl-

imidazo[l,2-c]pyrimidine-8- carboxamide (2.30 g, 5.28 mmol) in DCM (150 mL) was added a solution of BCl_3 in DCM (1 M, 42.2 mL) under nitrogen atmosphere. The reaction mixture was stirred at rt for 12 h. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by silica gel chromatography (dichloromethane: methanol = 20:1) to give the title compound (1.42 g, 70% yield) as a yellow solid. ¾ NMR (400MHz, DMSO-d«) δ 11.98 (s, 1H), 7.76 (d, 7 = 1.6 Hz, 1H), 7.55 (d, 7 = 1.6 Hz, 1H), 6.67 (d, *J* = 2.0 Hz, 1H), 6.64 (d, *J* = 2.0 Hz, 1H), 6.10 (d, *J* = 2.0 Hz, 1H), 3.71 (s, 3H), 2.80 (s, 3H).

[001872] **7-[4-Hvdroxy-3,5-dimethoxy-anilino]-5-methylsulfanyl-imidazo[l,2-c|pyrimidine-8 -carboxamide [Intermediate** FA]



[001873] STEP 1 - 2.6-DIMETHOXY-4-NITRO-PHENOL

[001874] To a solution of 2,6-dimethoxyphenol (5.00 g, 32.4 mmol) in THF (50 mL) was added dropwise tert-butyl nitrite (10.0 g, 97.3 mmol). Then, the reaction mixture was stirred at rt for 0.5 hr. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by column chromatography to give the title compound (3.73 g, 58% yield) as a yellow solid. ^{1}H NMR (400MHz, CDCb) δ 7.57 (s, 2H), 6.06 (s, 1H), 3.91 (s, 6H).

[001875] Step 2 - 2-Benzyloxy-1,3-dimethoxy-5-nitrobenzene

[001876] To a solution of 2,6-dimethoxy-4-nitro-phenol (8.00 g, 40.2 mmol) in acetone (100 mL) was added K_2CO_3 (11.1 g, 80.3 mmol) and KI (667 mg, 4.02 mmol) at rt. The suspension was stirred at rt for 1 hr. Then, bromomethylbenzene (10.3 g, 60.3 mmol) was added to the mixture dropwise. The reaction mixture was then heated to 60 °C and stirred for 12 hours. On completion, the reaction mixture was concentrated *in vacuo* to remove the acetone. The residue was diluted with water (100 mL) and extracted with EA (3 X 150 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (8.62 g, 74% yield) as a white solid. ^1H NMR (400MHz, CDCb) δ 7.51 (s, 2H), 7.45 (d, J = 6.8 Hz, 2H), 7.39 - 7.27 (m, 3H), 5.14 (s, 2H), 3.91 (s, 6H).

[001877] Step 3 - 4-Benzyloxy-3.5-dimethoxy-aniline

[001878] To a solution of 2-benzyloxy-l,3-dimethoxy-5-nitro-benzene (8.62 g, 29.8 mmol) in a mixed solvent of H_2O (50 mL) and EtOH (170 mL) was added Fe (16.6 g, 298 mmol) followed by NH4CI (15.9 g, 298 mmol). Then, the reaction mixture was stirred at 75 °C under nitrogen for 1.5 hrs. On completion, the mixture was diluted with MeOH (150 mL), filtered through a pad of Celite and washed with MeOH (80 mL). The filtrate was concentrated, and the residue was washed with H2O (100 mL) and extracted with EA (2 X 150 mL). The organic layer was dried over anhydrous Na_2SO_4 and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (7.27 g, 94% yield) as a black brown oil. LC-MS (ESI$^+$) *m/z* 260.0 $(M+H)^+$.

[001879] Step 4 - 4-(4-Benzyloxy-3.5-dimethoxy-anilino)-6-chloro-2-methylsulfanyl-Pyrimidine-5-carbonitrile

[001880] To a solution of 4,6-dichloro-2-methylsulfanyl-pyrimidine-5-carbonitrile (6.17 g, 28.0 mmol) and 4-benzyloxy-3,5-dimethoxy-aniline (7.27 g, 28.0 mmol) in THF (150 mL) was added DIPEA (5.44 g, 42.1 mmol) dropwise. The reaction mixture was stirred at rt for 15 hours. On completion, the reaction mixture was diluted with water (150 mL) and filtered. Then, the filter cake was dried *in vacuo* to give the title compound (9.49 g, 76% yield) as a yellow solid. LC-MS (ESI$^+$) *m/z* 464.9 $(M+Na)^+$.

[001881] Step 5 - 4-Amino-6-(4-benzyloxy-3.5-dimethoxy-anilino)-2-methylsulfanyl-

pyrimidine-5-carbonitrile

[001882] To a mixture of 4-(4-benzyloxy-3,5-dimethoxy-anilino)-6-chloro-2-methylsulfanyl-pyrimidine-5 -carbonitrile (4.49 g, 10.1 mmol) in THF (50 mL) was added $NH_3 \bullet H_2O$ (7.11 g, 203 mmol). Then, the reaction mixture heated to 70 °C and stirred for 17 hours at autoclave. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was triturated with DCM to give the title compound (3.74 g, 87% yield) as a yellow solid. ¾NMR (400MHz, CDCh) δ 7.54 - 7.48 (m, 2H), 7.41 - 7.30 (m, 3H), 6.88 (s, 1H), 6.84 (s, 2H), 5.35 (s, 2H), 5.02 (s, 2H), 3.85 (s, 6H), 2.50 (s, 3H); LC-MS (ESI^+) *m/z* 424.0 $(M+H)^+$.

[001883] Step 6 - 4-Amino-6-(4-benzyloxy-3.5-dimethoxy-anilino)-2-methylsulfanyl-pyrimidine-5- carboxamide

[001884] To a solution of 4-amino-6-(4-benzyloxy-3,5-dimethoxy-anilino)-2-methylsulfanyl-pyrimidine-5- carbonitrile (5.60 g, 13.2 mmol) in DMSO (30 mL) and EtOH (30 mL) at 0 °C was added H2O2 (7.50 g, 66.1 mmol, 30% solution) and NaOH (5 M, 13.2 mL, 20% solution). The reaction mixture was stirred at rt for 3 hours. On completion, the reaction mixture was quenched with sat.Na_2S0_3. Then the mixture was filtered through a pad of celite. After that, the filter cake was washed with H2O (3 X 50 mL) and dried to give the title compound (5.70 g, 98% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-r¾) δ 9.82 (s, 1H), 7.54 (s, 2H), 7.46 (d, *J* = 6.8 Hz, 2H), 7.41 - 7.28 (m, 3H), 6.95 (s, 2H), 6.83 (s, 2H), 4.85 (s, 2H), 3.76 (s, 6H), 2.45 (s, 3H); LC-MS (ESI^+) *m/z* 442.1 $(M+H)^+$.

[001885] Step 7 - 7-(4-Benzyloxy-3.5-dimethoxy-anilino)-5-methylsulfanyl-imidazor 1.2-clpyrimidine-8- carboxamide


[001886] A mixture of 4-amino-6-(4-benzyloxy-3,5-dimethoxy-anilino)-2-methylsulfanyl-pyrimidine-5- carboxamide (5.00 g, 11.3 mmol) and 2-chloroacetaldehyde (3.33 g, 17.0 mmol) in DMF (20 mL) was heated at 60 °C for 6 hours under nitrogen atmosphere. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (5.07 g, 96% yield) as a yellow solid. ^{1}H NMR (400MHz, CDCh) δ 11.88 (s, 1H), 10.00 (s, 1H), 7.42 (d, *J* = 7.2 Hz, 2H), 7.32 - 7.22 (m, 5H), 6.70 (s, 2H), 5.64 (m, 1H), 4.94 (s, 2H), 3.75 (s, 6H), 2.64 (s, 3H); LC-MS (ESI^+) *m/z* 466.0 $(M+H)^+$.

[001887] Step 8 - 7-(4-Hydroxy-3.5-dimethoxy-anilino)-5-methylsulfanyl-imidazor 1.2-

clpyrimidine-8 -carboxamide

[001888] To 7-(4-benzyloxy-3,5-dimethoxy-anilino)-5-methylsulfanyl-imidazo[l,2-c]pyrimidine-8- carboxamide (1.55 g, 3.33 mmol) was added HBr (22.4 g, 15 mL, 110 mmol, 40 % solution). The reaction mixture was stirred at 50 °C for 3 hours under nitrogen atmosphere. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was triturated with dichloromethane: methanol = 10:1 to give the title compound (1.20 g, 96% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 376.0 $(M+H)^+$.

[001889] **5,7-Dichloropyrido[4,3-d1pyrimidin-4[3H]-one [Intermediate FBI**



FB

[001890] Step **1** - Tert-butyl N-tert-butoxycarbonyl-N-(2.6-dichloro-4-pyridyl icarbamate

[001891] A solution of 2,6-dichloropyridin-4-amine (28.0 g, 172 mmol, CAS# 2587-02-2) in THF (400 mL) under nitrogen was cooled to 0 °C with an ice-water bath. To this mixture was added a solution of NaHMDS (1 M, 412 mL) in THF. After the reaction mixture was stirred at 0 °C for 0.5 h, a solution of $(Boc)_20$ (82.5 g, 378 mmol, 86.8 mL) in THF (1.2 L) was added and the ice-water bath was then removed. The reaction mixture was then stirred at rt for 16 hrs. On completion, the reaction mixture was quenched with saturated NH_4Cl (1000 mL) and extracted with ethyl acetate (3 X 500 mL). The combined organic layer was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (42.0 g, 96% yield) as a white solid. ^1H NMR (400MHz, CDCh) δ 8.98 (s, 1H), 8.34 (s, 1H), 1.63 (s, 9H), 1.53 (s, 9H).

[001892] Step 2 - Tert-butyl 4-(tert-butoxycarbonyl amino)-2.6-dichloro-pyridine-3-carboxylate

[001893] To a solution of LDA (2 M, 169 mL) was added a solution of tert-butyl A-tert-butoxycarbonyl-A-(2,6-di chi oro-4-pyridyl (carbamate (35.0 g, 96.4 mmol) in THF (600 mL) under

nitrogen at -78 °C. The reaction mixture was stirred at -78 °C for 0.5 hr. On completion, the reaction mixture was quenched with saturated NH4C1, and extracted with ethyl acetate (3 X 100 mL). The combined organic layer was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo.* The residue was purified by silica gel chromatography (PE: EA = 200:1) to give the title compound (35.0 g, 100% yield) as a white solid. ^{1}H NMR (400MHz, CDCh) δ 8.99 (s, 1H), 8.35 (s, 1H), 1.64 (s, 9H), 1.54 (s, 9H).

[001894] Step 3 - 4-Amino-2.6-dichloro-pyridine-3 -carboxylic acid

[001895] To a solution of tert-butyl 4-(tert-butoxycarbonylamino)-2,6-dichloro-pyridine-3-carboxylate (35 g, 96.4 mmol) in DCM (100 mL) was added TFA (139 g, 1.22 mol, 90 mL). The reaction mixture was stirred at 65 °C for 12 h. On completion, the reaction was mixture was concentrated *in vacuo* to give the title compound (31.0 g, 82% yield, TFA salt) as yellow solid. LCMS (ESI$^+$) *m/z* 206.9 (M+H)$^+$.

[001896] Step 4 - 4-amino-2.6-dichloro- pyridine-3 -carbonyl chloride

[001897] A solution of 4-amino-2,6-dichloro-pyridine-3-carboxylic acid (26.0 g, 81.0 mmol, TFA) and $SOCI_2$ (164 g, 1.38 mol, 100 mL) was heated at 80 °C for 15 min. On completion, the reaction mixture was concentrated *in vacuo* and the title compound was used directly in the next step. LCMS (M+l) $^+$: 221.0

[001898] Step 5 - 4-Amino-2.6-dichloro-pyridine-3 -carboxamide


[001899] To a solution of NH_3/THF (7 M, 50.1 mL) was added a solution of 4-amino-2,6-dichloro- pyridine-3 -carbonyl chloride (5.30 g, 15.6 mmol, TFA salt) in THF (100 mL) at 0 °C. The reaction mixture was then allowed to warm to rt and stirred for 12 h. On completion, the reaction mixture was concentrated *in vacuo.* The crude product was purified by silica gel chromatography (DCM: MeOH = 50:1 to 10:1) to give the title compound (2.00 g, 58% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-^e) δ = 7.99 (s, 1H), 7.72 (s, 1H), 6.61 (s, 1H), 6.59 (s, 2H); LC-MS (ESI$^+$) *m/z* 205.9 (M+H)$^+$.

[001900] Step 6 - 5.7-Dichloropyrido[4.3-d1pyrimidin-4(3H)-one

[001901] A mixture of 4-amino-2,6-dichloro-pyridine-3-carboxamide (3.00 g, 14.6 mmol) and triethyl orthoformate (53.4 g, 360 mmol, 60 mL) was heated to 150 °C for 3 hrs. On completion, the reaction mixture was concentrated *in vacuo* and the residue was triturated with PE/EA = 1:1 (5 mL) to give the title compound (2.0 g, 64% yield) as a yellow solid. ^{1}H NMR

(400MHz, DMSO-#«) δ 12.83 (s, 1H), 8.33 (s, 1H), 7.72 (s, 1H).


[001902] **2-[2-[2-[2-(Benzyloxycarbonylamino)ethoxy]ethoxy]ethoxy]ethyl methane sulfonate [Intermediate** FC]



AJ FC

[001903] To a solution of benzyl N-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethyl]carbamate (500 mg, 1.35 mmol, Intermediate AJ) in dichloromethane (6 mL) was added triethylamine (273 mg, 2.70 mmol, 374 uL) and MsCl (185 mg, 1.62 mmol, 125 uL) at 0 °C. The reaction mixture was stirred at rt for 1 hour. On completion, the reaction mixture was diluted with water (100 mL), and extracted with ethyl acetate (3 X 100 mL). Then the combined organic layer was dried over Na_2S0_4 and concentrated *in vacuo* to give the title compound (600 mg, 98% yield) as a yellowish oil.

[001904] **3-Oxo-l-phenyl-2,7,10-trioxa-4-azadodecan-12-yl methanesulfonate [Intermediate ID)**



FD

[001905] Step 1 - Benzyl N-r2-r2-(2-hvdroxyethoxy)ethoxy1ethyl1carbamate


[001906] To a solution of 2-[2-(2-aminoethoxy)ethoxy]ethanol (3.50 g, 23.5 mmol, CAS# 6338-55-2) in CH3CN (30 mL) and H_20 (30 mL) was added CbzCl (4.80 g, 28.1 mmol) and NaHCCh (5.91 g, 70.4 mmol). The reaction mixture was stirred at rt for 12 hours. On completion, the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3 X 20 mL). The combined organic layer was washed with brine, dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (petroleum ethenethyl acetate = 5:1 to 1:1) to give the title compound (5.00 g, 75% yield) as a colorless oil. ^1H NMR (400MHz, CDCb) δ 7.38 - 7.29 (m, 5H), 5.47 (s, 1H), 5.11 (s, 2H), 3.71 (s, 2H), 3.65 - 3.56 (m, 8H), 3.43 - 3.37 (m, 2H).

[001907] Step 2 - 3-Oxo- 1-phenyl-2. 7. 10-trioxa-4-azadodecan- 12-yl methanesulfonate

[001908] To a solution of benzyl /V-[2-[2-(2-hydroxyethoxy)ethoxy]ethyl]carbamate (2.00 g,

7.06 mmol) in DCM (30 mL) was added TEA (2.14 g, 21.2 mmol, 2.94 mL) and MsCl (1.05 g, 9.18 mmol, 710 uL) at 0 °C. The reaction mixture was then allowed to warm to rt and stirred for 0.5 hr. On completion, the reaction mixture was quenched with saturated citric acid (5 mL), and extracted with dichloromethane (3 X 50 mL). The combined organic layer was washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (2.4 g, 94% yield) as a colorless oil. ¾ NMR (400MHz, CDCb) δ 7.39 - 7.31 (m, 5H), 5.24 (s, 1H), 5.11 (s, 2H), 4.38 - 4.34 (m, 1H), 4.38 - 4.34 (m, 1H), 3.76 (dd, *J* = 3.6, 5.2 Hz, 2H), 3.67 - 3.64 (m, 2H), 3.64 - 3.60 (m, 2H), 3.59 - 3.54 (m, 2H), 3.40 (q, *J* = 5.2 Hz, 2H), 3.02 (s, 3H).

[001909] **N-[2-[[2,5-dichloropyrimidin-4-vnamino1-5-methoxy-phenyllmethanesulfonamide [Intermediate FE)**



[001910] Step 1 - 1-Benzyl oxy-2-methoxy-4-methyl -benzene

[001911] To a mixture of 2-methoxy-4-methyl -phenol (25.0 g, 180 mmol) in acetone (460 mL) was added K2CO3 (62.5 g, 452 mmol) and BnBr (46.4 g, 271 mmol) under nitrogen atmosphere. The reaction mixture was stirred at 50 °C for 12 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to remove the acetone. The residue was diluted with water (100 mL) and extracted with EA (2 X 200 mL). The combined organic layers was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (40.0 g, 96% yield) as white solid. ^{1}H NMR (400MHz, CDCb) δ 7.49 - 7.43 (m, 2H), 7.42 - 7.27 (m, 3H), 6.83 - 6.73 (m, 2H), 6.69 - 6.63 (m, 1H), 5.15 (s, 2H), 3.90 (s, 3H), 2.32 (s, 3H).

[001912] Step 2 - 1-Benzyl oxy-2-methoxy-4-methyl-5-nitro-benzene

[001913] A stirred mixture of l-benzyloxy-2-methoxy-4-methyl-benzene (17.5 g, 76.6 mmol) in HOAc (60 mL) was cooled to 4-6°C and a mixture of concentrated HNO3 (49.0 g, 778 mmol) in HOAc (17 mL) was added dropwise. The reaction mixture was stirred at 4-6 °C for 3 hours. On completion, the reaction mixture was poured into 100 mL of an ice-H_20 mixture. The mixture was filtered and the solid precipitate was washed with water. The solid was dried *in vacuo* to give the title compound (20.0 g, 95% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-rL) δ 7.73 (s, 1H), 7.49 - 7.33 (m, 5H), 7.09 (s, 1H), 5.17 (s, 2H), 3.90 (s, 3H), 2.54 (s, 3H).

[001914] Step 3 - 5-Benzyloxy-4-methoxy-2 -methyl-aniline

[001915] To a mixture of l-benzyloxy-2-methoxy-4-methyl-5-nitro-benzene (10.0 g, 36.5 mmol) in MeOH (100 mL) and H_20 (60 mL) was added Fe (26.5 g, 475 mmol) and NH_4Cl (25.4 g, 475 mmol). The reaction mixture was stirred at 65 °C for 12 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to remove the MeOH. The residue was diluted with water (50 mL), and neutralized with sat. NaHC0 $_3$ (20 mL) until the pH = 8-9. The residue was diluted with water (30 mL) and extracted with EA (2 X 100 mL). The combined organic layer was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (1.60 g, 17% yield) as a white solid. LC-MS (ESI$^+$) *m/z* 244. 1 (M+H)$^+$.

[001916] Step 4 - Nl-(2,5-dichloropyrimidin-4-yl)-4-methoxy-benzene-L2-diamine


[001917] Amixture of 4-methoxybenzene-l, 2-diamine (25.0 g, 180 mmol) and DIPEA (28.0 g, 217 mmol) in IPA (150 mL) was stirred at 0°C. 2,4,5-trichloropyrimidine (33.1 g, 180 mmol) was then added dropwise and the mixture was allowed to warm to rt and stirred for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to remove the IPA. The residue was diluted with water (50 mL) and extracted with EA (2 X 100 mL). The combined organic layer was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (44.0 g, 85% yield) as a pale solid. LC-MS (ESI$^+$) *m/z* 284.9 (M+H)$^+$.

[001918] Step 5 - N-[2-[(2,5-dichloropyrimidin-4-yDaminol -5-methoxy-phenyllmethanesulfonamide

[001919] To a mixture of Nl-(2,5-dichloropyrimidin-4-yl)-4-methoxy-benzene-l, 2-diamine (8.00 g, 28.0 mmol) in pyridine (20 mL) was added MsCl (3.54 g, 30.8 mmol) at 0 °C. Then the reaction mixture was then allowed to warm to rt and stirred for 4 hours. On completion, the reaction

mixture was concentrated *in vacuo.* The residue was purified by column chromatography to give the title compound (7.00 g, 68% yield) as a pale solid. LC-MS (ESI^+) *m/z* 362.9 $(M+H)^+$.


[001920] **2-Methoxy-4-methyl-5-nitro-phenol [Intermediate FF)**



FF

[001921] To a mixture of l-benzyloxy-2-methoxy-4-methyl-5-nitro-benzene (5.00 g, 18.3 mmol, synthesized via Steps 1-2 of Intermediate FE) in DCM (60 mL) was added BCl_3·DCM (1.0 M, 91 mL). Then the reaction mixture was stirred at rt for 8 hours. On completion, the reaction mixture was concentrated *in vacuo.* The reaction mixture was washed with sat.$NaHCO_3$ (150 mL) and extracted with DCM (3 X 100 mL). The organic layer was dried with Na_2SO_4, filtrated and concentrated *in vacuo.* The residue was purified by column chromatography to give the title compound (2.80 g, 83% yield) as yellowish solid. LC-MS (ESI^+) m/z 184.1 $(M+H)^+$.

[001922] **2,3-Dimethoxy-5-nitrophenol [Intermediate FG)**



FG

[001923] Step 1 - 2.3-Dimethoxyphenyl benzenesulfonate

[001924] To a solution of 2,3-dimethoxyphenol (10.0 g, 64.8 mmol, 8.47 mL) in dichloromethane (200 mL) was added triethylamine (13.1 g, 129 mmol, 17.9 mL) at 0 °C. Then benzenesulfonyl chloride (13.7 g, 77.8 mmol, 9.96 mL) was added dropwise over 1 hour at 0 °C. The mixture was then allowed to warm to rt and stirred for 15 hours. On completion, the reaction mixture was diluted with water (700 mL), and then extracted with dichloromethane (4 X 250 mL). The combined organic layers were washed with brine (2 X 250 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (petroleum ethenethyl acetate = 10:1) to give the title compound (17.0 g, 89% yield) as a light yellow oil. ^1H NMR (400MHz, CDCh) δ 7.85 (t, *J* = 7.2 Hz, 2H), 7.57 (d, *J* = 7.6 Hz, 1H), 7.45 (t, *J* = 8.0 Hz, 2H), 6.89 - 6.87 (m, 1H), 6.78 - 6.75 (m, 2H), 3.75 (s, 3H), 3.61 (s,

3H).


[001925] Step 2 - 2.3-Dimethoxy-5-nitrophenyl benzenesulfonate

[001926] To a solution of (2,3-dimethoxyphenyl) benzenesulfonate (17.0 g, 57.7 mmol) in acetic acid (340 mL) was added nitrosoaphyllinic acid (17.0 g, 57.7 mmol, 61.2 mL) dropwise over 1 hour at 0°C. The mixture was then allowed to warm to rt and was stirred for 15 hours. On completion, the reaction mixture was diluted with water 50 mL and extracted with ethyl acetate (3 X 300 mL). The combined organic layers were washed with brine (2 X 300 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give a residue. The residue purified by column chromatography (petroleum ethenethyl acetate = 50:1 to 20:1) to give the title compound (17.0 g, 86% yield) as a white solid. ¾NMR (400MHz, CDCL) δ 7.96 (t, *J* = 5.2 Hz, 1H), 7.74 (d, *J* = 4.8 Hz, 1H), 7.63 - 7.61 (m, 5H), 3.96 (s, 3H), 3.88 (s, 3H).

[001927] Step 3 - 2.3-Dimethoxy-5-nitrophenol

[001928] To a solution of (2,3-dimethoxy-5-nitro-phenyl) benzenesulfonate (2.80 g, 8.25 mmol) in methanol (28.2 mL) was added 20% potassium hydroxide solution (16.89 mL). The mixture was stirred at 50 °C for 4 hours. On completion, the reaction mixture was concentrated *in vacuo* to remove methanol. The residue was diluted with water (50 mL), and acidified with HC1 until the pH = 5-6. The mixture was then filtered, and the solid precipitate was collected and dried *in vacuo* to give the title compound (1.40 g, 85% yield) as a white solid. ^{1}H NMR (400MHz, CDCh) δ 7.45 (d, *j* = 2.8 Hz, 1H), 7.34 (d, *j* = 2.8 Hz, 1H), 5.94 (s, 1H), 3.95 (s, 3H), 3.83 (s, 3H).

[001929] (±)-Tert-butyl 2-ethyl-4-[5-(2-methylsulfonylpyrimidin-4-vD-2-pyridyl1piperazine-l- carboxylate [Intermediate FH)



FH

[001930] Step 1 - (±)-Tert-butyl 4-(5-acetyl-2-pyridv0-2-ethyl-piperazine-l-carboxylate

[001931] To a solution of l-(6-chloro-3-pyridyl)ethanone (4.00 g, 24.9 mmol; CAS# 36357-38-7) in ACN (8 mL) was added DIPEA (9.67 g, 74.8 mmol) and (±)-tert-butyl 2-ethylpiperazine-l-carboxylate (6.41 g, 29.9 mmol; CAS# 393781-71-0). The reaction mixture was stirred at 85 °C for 12 hours. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (petroleum ether: ethyl acetate = 30:1 to 5:1) to give the title compound (8.30 g, 100% yield) as a yellow oil. ^{1}H NMR (400 MHz, CDCh) δ 8.75 (d, *J* = 2.0 Hz, 1H), 8.03 (dd, *J* = 2.4, 9.2 Hz, 1H), 6.58 (d, *J* = 8.8 Hz, 1H), 4.34 (d, *J* = 13.2 Hz, 1H), 4.27 (d, *J* = 10.4 Hz, 1H), 4.13 (q, *J* = 7.2 Hz, 1H), 4.02 (s, 1H), 3.27 (dd, 7 = 4.0, 13.2 Hz, 1H), 3.20 - 3.04 (m, 2H), 2.51 (s, 3H), 1.63 - 1.50 (m, 2H), 1.49 (s, 9H), 0.90 (t, *J* = 7.2 Hz, 3H).

[001932] Step 2 - (±)-Ethyl l-(4-bromo-3.5-dimethyl-phenyl)-5-phenyl-pyrazole-4-carboxylate

[001933] A mixture of (±)-tert-butyl 4-(5-acetyl-2-pyridyl)-2-ethyl-piperazine-l-carboxylate (8.30 g, 24.9 mmol) and l,l-dimethoxy-N,N-dimethyl-methanamine (29.7 g, 249 mmol) was heated to 110 °C for 14 hours. LCMS showed that the starting material remained, thus the reaction was then heated to 120 °C for another 22 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the residue. The residue was purified by column chromatography (petroleum ethenethyl acetate = 5:1 to ethyl acetate) to give the title compound (7.70 g, 80% yield)

as a yellow oil. ¾ NMR (400 MHz, CDCh) δ 8.73 (d, *J* = 2.4 Hz, 1H), 8.07 (dd, *J* = 2.4, 8.8 Hz, 1H), 7.79 *(d, J* = 12.4 Hz, 1H), 6.59 (d, *J* = 8.8 Hz, 1H), 5.66 *(d, J* = 12.4 Hz, 1H), 4.31 - 4.21 (m, 2H), 4.12 (q, *j* = 7.2 Hz, 1H), 3.99 (d, *J* = 10.4 Hz, 1H), 3.49 (s, 1H), 3.24 - 2.97 (m, 8H), 1.67 - 1.52 (m, 2H), 1.49 (s, 9H), 0.90 (t, *J* = 7.2 Hz, 3H).

[001934] Step 3 - (±)-Tert-butyl 2-ethyl-4-r5-(2-sulfanylpyrimidin-4-yl)-2-pyridvHpiperazine-l-carboxylate

[001935] To a solution of (±)-tert-butyl 4-[5-[(Z)-3-(dimethylamino)prop-2-enoyl]-2-pyridyl]-2-ethyl -piperazine -l-carboxylate (7.70 g, 19.8 mmol) in ethanol (80 mL) was added thiourea (3.02 g, 39.6 mmol) and NaOMe (2.68 g, 49.6 mmol). The reaction mixture was stirred at 78 °C for 12 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (7.90 g, 99% yield) as a white solid. LC-MS (ESI^+) *m/z* 401.9 $(M+H)^+$.

[001936] Step 4 - (±)-Tert-butyl 2-ethyl -4-r5-(2-methylsulfanylpyrimidin-4-yl)-2-pyridvHpiperazine-l- carboxylate


[001937] To a solution of (±)-tert-butyl 2-ethyl-4-[5-(2-sulfanylpyrimidin-4-yl)-2-pyridyl]piperazine-l- carboxylate (7.90 g, 19.7 mmol) and iodomethane (11.2 g, 78.7 mmol) in THF (80 mL) was added NaOH (1 M, 29.5 mL). The reaction mixture was stirred at rt for 5 hours. On completion, the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3 X 20 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (petroleum ether: ethyl acetate = 5:1 to dichloromethane:methanol = 100:1) to give the title compound (7.70 g, 94% yield) as a yellow solid. ^{1}HNMR(400MHz, CDCh) δ 8.90 (d, *j* = 2.0 Hz, 1H), 8.45 (d, *j* = 5.2 Hz, 1H), 8.22 (dd, *j* = 2.4, 8.8 Hz, 1H), 7.24 (d, *j* = 5.2 Hz, 1H), 6.66 (d, *J* = 8.8 Hz, 1H), 4.31 *(d, J* = 13.2 Hz, 1H), 4.25 *(d, J* = 11.6 Hz, 1H), 4.18 - 4.08 (m, 1H), 4.03 (s, 1H), 3.25 (dd, 7 = 4.0, 13.2 Hz, 1H), 3.21 - 3.02 (m, 2H), 2.63 (s, 3H), 1.70 - 1.64 (m, 1H), 1.55 (dd, *j* = 7.2, 14.4 Hz, 1H), 1.50 (s, 9H), 0.91 (t, *j* = 7.2 Hz, 3H).

[001938] Step 5 - (±)-Tert-butyl 2-ethyl -4-r5-(2-methylsulfonylpyrimidin-4-yl)-2-pyridyllpiperazine-l- carboxylate

[001939] To a solution of (±)-tert-butyl 2-ethyl-4-[5-(2-methylsulfanylpyrimidin-4-yl)-2-pyridyl]piperazine -l-carboxylate (3.85 g, 9.26 mmol) in acetone (15.0 mL) was added H_20_2 (5.90 g, 52.0 mmol) and disodium dioxide (dioxo) tungsten-dihydrate (306 mg, 926 umol). The reaction

mixture was stirred at 40 °C for 12 hours. On completion, the reaction mixture was quenched with saturated Na_2S0_4 (20 mL) and extracted with dichloromethane (3 X 100 mL). The combined organic layer was washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo.* The residue was purified by silica gel chromatography (dichloromethane:methanol = 100:1) to give the title compound (4.00 g, 97% yield) as a white solid. ^{1}H NMR (400MHz, CDCh) δ 8.93 (d, *J* = 2.0 Hz, 1H), 8.78 (d, *J* = 5.6 Hz, 1H), 8.31 (dd, *J* = 2.4, 9.2 Hz, 1H), 7.74 (d, *J* = 5.6 Hz, 1H), 6.69 (d, *J* = 8.8 Hz, 1H), 4.37 *(d, J* = 13.4 Hz, 1H), 4.29 *(d, J* = 8.8 Hz, 1H), 4.19 - 3.99 (m, 2H), 3.41 (s, 3H), 3.30 (dd, *J* = 3.6, 13.2 Hz, 1H), 3.21 - 3.08 (m, 2H), 1.69 - 1.61 (m, 1H), 1.53 (d, *J* = 7.2 Hz, 1H), 1.50 (s, 9H), 0.92 (t, *J* = 7.2 Hz, 3H).

[001940] 4-|3-|(Tert-biitoxycarbonylamino)methyl]-4-||2-|2-|tert-butoxycarbonyl(2.,2.,2-trifluoroethy0 _amino]-4-pyridyl]oxazole-4-carbonyl]amino]pyrazol-l-yl] benzoic acid [Intermediate FI]



[001941] Step 1 - r4-Amino-l-(4-bromophenvQpyrazol-3-vnmethanol

[001942] To a solution of ethyl l-(4-bromophenyl)-4-nitro-pyrazole-3-carboxylate (3.70 g, 10.8 mmol, synthesized via Steps 1-2 of Intermediate CL) in THF (30.0 mL) was added $LiBH_4$ (1.18 g, 54.3 mmol). The reaction mixture was stirred at 50 °C for 3 hrs under N_2. On completion, the reaction mixture was quenched with water (100 mL), concentrated *in vacuo* to removed the THF, and filtered. The filtered cake was collected and dried under vaccuum to give the title compound (1.80 g, 61% yield) as yellow solid. ¾NMR (400MHz, DMSO-^e) δ 7.72 (s, 1H), 7.69 - 7.62 (m, 4H), 5.07-5.03 (m, 1H), 4.51 (d, J = 5.6 Hz, 2H), 4.16 (s, 2H).

[001943] Step 2 - Methyl 4-r4-amino-3-(hvdroxymethvDpyrazol-l-vnbenzoate

[001944] To a solution of [4-amino-l-(4-bromophenyl)pyrazol-3-yl]methanol (1.60 g, 5.97 mmol) in a mixed solvent of DMF (30.0 mL) and MeOH (30.0 mL) was added Pd(dppf)Cl2.CH2Cl2

(487 mg, 596 umol) and TEA (1.81 g, 17.9 mmol, 2.49 mL) under N_2. The suspension was degassed *in vacuo* and purged with CO several times. The mixture was stirred under CO (50 psi) at 80°C for 36 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the residue. The residue was purified by prep-HPLC (0.1%, HC1) to give the title compound (800 mg, 54% yield) as white solid. ^{1}H NMR (400MHz, DMSO-^e) δ 8.62 (s, 1H), 8.08 (d, *J* = 8.8 Hz, 2H), 8.03 - 7.93 (m, 2H), 4.63 (s, 2H), 3.87 (s, 3H).

[001945] Step 3 - Methyl 4-r4-IT2-r2-rtert-butoxycarbonyl('2.2.2-trifluoroethyl)amino1-4-pyridylloxazole-4- carbonyl1amino1-3-(hvdroxymethvnpyrazol-l-yl1benzoate

[001946] To a solution of methyl 4-[4-amino-3-(hydroxymethyl)pyrazol-l-yl]benzoate (400 mg, 1.62 mmol) and 2-[2-[tertbutoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (626 mg, 1.62 mmol, Intermediate CM) inDMF (3.00 mL) was added DIPEA (418 mg, 3.24 mmol). The reaction mixture was stirred at 25 °C for 0.5 hr. Then, HATU (676 mg, 1.78 mmol) was added. The resulting reaction mixture was stirred at 25 °C for 0.5 hr. On completion, the reaction mixture was quenched with water (15 mL), and a white solid precipitation formed, which was filtered. The filter cake was dried *in vacuo* to give the title compound (920 mg, 92% yield) as white solid. ^{1}HNMR (400MHz, DMSO-^e) δ 9.08 (s, 1H), 8.90 (s, 1H), 8.66 (d, *J* = 5.2 Hz, 1H), 8.10 - 8.04 (m, 2H), 8.02 - 7.96 (m, 2H), 7.73 - 7.70 (m, 2H), 7.83 - 7.75 (m, 1H), 4.91 - 4.87 (m, 2H), 4.80 (d, *J* = 5.2 Hz, 2H), 3.87 (s, 3H), 1.53 (s, 9H).

[001947] Step 4 - Methyl 4-r3-(azidomethv0-4-rr2-r2-rtert-butoxycarbonyl(2.2.2-trifluoroethvDaminol-4- pyridvHoxazole-4-carbonyllaminolpyrazol-l-yllbenzoate

[001948] To a solution of methyl 4-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl] oxazole-4-carbonyl]amino]-3-(hydroxymethyl)pyrazol-l-yl]benzoate (500 mg, 810 umol) in THF (15.0 mL) was added DPPA (334 mg, 1.22 mmol) and DBU (308 mg, 2.03 mmol) at 0 °C. The mixture was stirred at 25 °C for 3 hr. On completion, the mixture was diluted with H_20 (50 mL), then extracted with DCM (3 X 30 mL). The organic layers were dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (520 mg, 70% yield) as yellow solid. LC-MS (ESI^+) *m/z* 642.3 $(M+H)^+$.

[001949] Step 5 - Methyl 4-[3-[(tert-butoxycarbonylamino)methyl]-4-[[2-[2-[tert-butoxycarbonyl(2.2.2- trifluoroethvnamino1-4-pyridyl1oxazole-4-carbonyl1amino1pyrazol-l-yllbenzoate


[001950] To a solution of methyl 4-[3-(azidomethyl)-4-[[2-[2-[tert-butoxycarbonyl(2,2,2-

trifluoroethyl)amino] -4-pyridyl]oxazole-4-carbonyl]amino]pyrazol-l-yl]benzoate (520 mg, 810 umol) and $(Boc)_20$ (265 mg, 1.22 mmol) in MeOH (10.0 mL) was added Pd/C (100 mg, 8l0umol). The mixture was stirred at 25 °C for 3 hrs under H_2 (15 psi). On completion, the mixture was filtered and concentrated *in vacuo.* The mixture was purified by reverse phase (0.1% FA) to give the title compound (500 mg, 86% yield) as white solid. ^{1}H NMR (400MHz, DMSO-d_6) δ 10.64 (s, 1H), 9.05 (s, 1H), 8.95 (s, 1H), 8.64 (d, *J* = 5.2 Hz, 1H), 8.35 (s, 1H), 8.09 (s, 1H), 8.07 (s, 1H), 8.00 (s, 1H), 7.98 (s, 1H), 7.86 (d, *J* = 5.2 Hz, 1H), 7.79 (s, 1H), 4.91 (d, *J* = 8.8 Hz, 2H), 4.29 (d, *j* = 6.8 Hz, 2H), 3.88 (s, 3H), 1.52 (s, 9H), 1.36 (s, 9H).

[001951] Step_ 6_ :_ 4-r3-r(Tert-butoxycarbonylamino)methyl1-4-IT2-r2-rtert-butoxycarbonyl(2.2.2-trif1uoroethyl) amino1-4-pyridyl1oxazole-4-carbonyl1amino1pyrazol-l-yllbenzoic acid (8) - Notebook Page: EW7002-283

[001952] To a solution of methyl 4-[3-[(tert-butoxycarbonylamino)methyl]-4-[[2-[2-[tert-butoxycarbonyl (2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carbonyl]amino]pyrazol-l-yl]benzoate (160 mg, 223 umol) in a mixed solvent of THF (20.0 mL), H_20 (5.00 mL) and MeOH (5.00 mL) was added LiOH (26.7 mg, 1.12 mmol). The mixture was stirred at 25 °C for 16 hrs. On completion, the mixture was acidified with 1N HC1 solution until the pH = 5. The mixture was diluted with H_20 (50 mL), and extracted with EA (3 X 30 mL). The organic layers were dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (70.0 mg, 44% yield) as white solid. LC-MS (ESI$^+$) *m/z* 702.4 $(M+H)^+$.

[001953] **2-[2-[2-[2-14-Iodophenoxylethoxyl ethoxy]ethoxy]ethanamine [Intermediate FJ)**



[001954] Step_ 1_ -_ Tert-butyl_ N-[2-[2-[2-[2-(4-iodophenoxyiethoxyl ethoxy]ethoxy]ethyl]carbamate


[001955] To a solution of 4-iodophenol (1 g, 4.55 mmol) and 2-[2-[2-[2-(tert-

butoxycarbonylamino)ethoxy] ethoxy] ethoxy] ethyl methanesulfonate (1.69 g, 4.55 mmol, Intermediate AO) in DMF (15 mL) was added K_2CO_3 (1.57 g, 11.3 mmol), and the reaction mixture was stirred at 100 °C for 12 hr. On completion, the mixture was diluted with H_20 (30 mL), then extracted with EA(2 X 40 mL), and the organic phase was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (1.00 g, 44% yield) as yellow oil. LC-MS (ESI^+) m/z 496.2 $(M+H)^+$.

[001956] Step 2 - 2-r2-r2-r2-(4-Iodophenoxy)ethoxy1ethoxy1ethoxy1ethanamine

[001957] To a solution of tert-butyl N-[2-[2-[2-[2-(4-iodophenoxy)ethoxy]ethoxy]ethoxy]ethyl]carbamate (0.9 g, 1.82 mmol) in DCM (2 mL) was added HCl/dixoane (4 M, 2.00 mL), and the reaction mixture was stirred at 20 °C for 20 mins. On completion, the residue was concentrated *in vacuo* to give the title compound (800 mg, 99% yield) as yellow oil. LC-MS (ESI^+) m/z 396.1 $(M + 1)^+$.

[001958] **2-[2-[2-[[2-(2,6-Dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yllaminolethoxylethoxyl acetaldehyde [Intermediate Fk)**



FK

[001959] Step_ _____1_ _____-_ _____2-(2.6-Dioxo-3-piperidylV4-r2-r2-(2-hvdroxyethoxy)ethoxy1ethylamino]isoindoline-L3- dione


[001960] To a solution of 2-[2-(2-aminoethoxy)ethoxy]ethanol (1.80 g, 12.0 mmol, CAS# 6338-55-2) and 2-(2,6-dioxo-3-piperidyl)-4-fluoroisoindoline-l,3-dione (4.00 g, 14.4 mmol, Intermediate R) in dioxane (35.0 mL) was added DIPEA (9.36 g, 72.3 mmol). The reaction mixture was stirred at 115 °C for 20 hrs. On completion, the mixture was concentrated *in vacuo* to remove

the solvent. The residue was purified by silica gel chromatography (PE: EA = 1:1) to give the title compound (2.90 g, 59% yield) as yellow solid. ^{1}H NMR (400MHz, CDCh) δ 8.28 (s, 1H), 7.50 (dd, *J* = 7.2, 8.4 Hz, 1H), 7.11 (d, *J* = 7.2 Hz, 1H), 6.91 (d, *J* = 8.4 Hz, 1H), 6.57 (t, *J* = 5.2 Hz, 1H), 4.96 - 4.85 (m, 1H), 3.77 - 3.67 (m, 8H), 3.64 - 3.59 (m, 2H), 3.48 (q, *J* = 5.2 Hz, 2H), 2.92 - 2.70 (m, 3H), 2.62 (s, 1H), 2.17 - 2.08 (m, 1H).

[001961] Step 2 - 2-[2-[2-[2-(2,6-Dioxo-3-piperidyl)-E3-dioxo-isoindolin-4-yllaminolethoxylethoxyl acetaldehyde (11) - Notebook Page: EW7002-288

[001962] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-[2-[2-(2-hydroxyethoxy)ethoxy]ethylamino]isoindoline- l,3-dione (200 mg, 493 umol) in DCM (10.0 mL) was added DMP (209 mg, 493 umol). The mixture was stirred at 25 °C for 16 hrs. On completion, the mixture was diluted with DCM (30 mL), and extracted with saturated $Na_2S_20_3$ (2 X 30 mL) and saturated $NaHC0_3$ (2 X 30 mL). The organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (140 mg, 70% yield) as yellow solid. ^{1}H NMR (400MHz, CDCh) δ 9.74 (s, 1H), 8.15 (s, 1H), 7.52 (t, *J* = 7.6 Hz, 1H), 7.14 (d, *J* = 7.2 Hz, 1H), 6.97 - 6.90 (m, 1H), 6.57 - 6.49 (m, 1H), 4.97 - 4.89 (m, 1H), 3.83 - 3.65 (m, 10H), 2.17 - 2.11 (m, 1H), 1.91 - 1.87 (m, 1H), 1.87 - 1.83 (m, 1H), 1.31 - 1.03 (m, 1H).


[001963] Tert-butyl 5-14,4,5,5-tetramethyl-l,3.,2-dioxaborolan-2-vnisoindoline-2-carboxylate [Intermediate FL)



FL

[001964] To a solution of tert-butyl 5-bromoisoindoline-2-carboxylate (1.20 g, 4.02 mmol, CAS# 201940-08-1), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (1.12 g, 4.43 mmol) in DMSO (20.0 mL) was added KOAc (1.18 g, 12.0 mmol) and $Pd(PPh_3)_4$ (139 mg, 120 umol). The mixture was stirred at 80 °C for 16 hours under N_2. On completion, the mixture was diluted with H_20 (50 mL), and extracted with EA (3 X 30 mL). The organic layers were washed with brine (3 X 30 mL), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The mixture was purified by prep-HPLC (reserve phase (0.1% FA)) to give the title compound (500 mg, 36% yield) as yellow solid. ^{1}H NMR (400MHz, CDCh) δ 7.75 (s, 1H), 7.32 - 7.29 (m, 1H), 7.25 (d, *J* = 7.6 Hz, 1H), 4.74 - 4.66 (m, 4H), 1.54 (s, 9H), 1.37 (s, 12H).

[001965] **Tert-butyl 5-[4-amino-3-(trifluoromethvDpyrazol-l-yllisoindoline-2-carboxylate (Intermediate FM)**



FL

FM

[001966] Step 1 - (2-Tert-butoxycarbonylisoindolin-5-vOboronic acid

[001967] To a solution of tert-butyl 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)isoindoline-2-carboxylate (500 mg, 1.45 mmol, Intermediate FL) in a mixed solvent of THF (20.0 mL) and FLO (4.00 mL) was added $NaI0_4$ (929 mg, 4.34 mmol). The mixture was stirred at 25°C for 0.5 hr. HC1 (3 M, 965 uL) was added to the mixture; and the mixture was stirred at 25°C for 1.5 hrs. On completion, the mixture was diluted with FLO (30 mL), and extracted with EA (3 X 30 mL). The organic layers were washed with brine (3 X 20 mL), the organic layers were dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The mixture was purified by prep-HPLC (reverse phase (0. 1% FA)) to give the title compound (260 mg, 68% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-d) δ 8.05 (s, 2H), 7.72 (s, 1H), 7.70 (s, 1H), 7.29 (t, *J* = 6.4 Hz, 1H), 4.64 - 4.53 (m, 4H), 1.46 (s, 9H).

[001968] Step 2 - Tert-butyl 5-r4-nitro-3-(trifluoromethvDpyrazol-l-yl1isoindoline-2-carboxylate


[001969] To a solution of 4-nitro-3-(trifluoromethyl)-lH-pyrazole (378 mg, 2.09 mmol, synthesized via Step 1 of Intermediate DE), (2-tert-butoxycarbonyl isoindolin-5-yl)boronic acid (660 mg, 2.51 mmol) in DCM (20.0 mL) was added $Cu(OAc)_2$ (569 mg, 3.14 mmol) and pyridine (661 mg, 8.36 mmol). The mixture was stirred at 25°C for 12 hrs under 0_2 (15 psi). On completion, the mixture was concentrated *in vacuo* then washed with $NH_3 \cdot H_20$ (5 mL), filtered and the solid was dried *in vacuo.* The mixture was triturated again with MeOH (5 mL), then filtered and the solid was dried *in vacuo* to give the title compound (400 mg, 48% yield) as white solid. ^{1}H NMR (400MHz, DMS04) δ 9.86 (d, *J* = 6.8 Hz, 1H), 7.93 (d, *J* = 12.8 Hz, 1H), 7.90 - 7.85 (m, 1H),

7.59 - 7.52 (m, 1H), 4.71 - 4.60 (m, 4H), 1.47 (s, 9H).

[001970] Step 3 - Tert-butyl 5-r4-amino-3-(trifluoromethvOpyrazol-l-vnisoindoline-2-carboxylate (7) - Notebook Page: EW7002-281

[001971] To a solution of tert-butyl 5-[4-nitro-3-(trifluoromethyl)pyrazol-l-yl]isoindoline-2-carboxylate (260 mg, 652 umol) in a mixed solvent of DCM (10.0 mL) and MeOH (10.0 mL) was added Pd/C (50.0 mg). Then the reaction mixture was stirred at 25°C for 16 hrs under El_2 (15 psi). On completion, the mixture was filtered and concentrated *in vacuo* to give the title compound (240 mg, 80% yield) as white solid. LC-MS (ESI^+) *m/z* 369.2 $(M+H)^+$.

[001972] **4-(4-Aminobutylamino]-2-(2,6-dioxo-3-piperidvPisoindoline-l,3-dione [Intermediate FN]**



[001973] Step 1 - Tert-butyl N-[4-II2-(2,6-dioxo-3-piperidvl)-l,3-dioxo-isoindolin-4-yllaminolbutyll carbamate


[001974] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (1.50 g, 5.43 mmol, Intermediate R) and tert-butyl N-(4-aminobutyl)carbamate (1.02 g, 5.43 mmol, CAS# 33545-98-1) in dioxane (15 mL) was added DIPEA (2.81 g, 23 mmol). The reaction mixture was stirred at 115 °C for 24 hours. On completion, the mixture was concentrated *in vacuo* to remove the solvent. The residue was purified by silica gel chromatography to give the title compound (0.96 g, 40% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 445.2 $(M+H)^+$.

[001975] Step 2 - 4-(4-Aminobutylamino)-2-(2,6-dioxo-3-piperidvl)isoindoline-E3-dione

[001976] To a solution of tert-butyl N-[4-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]butyl] carbamate (0.96 g, 2.16 mmol) in DCM (5 mL) was added HCl/dioxane (4 M, 10

mL). The reaction mixture was stirred at 25 °C for 3 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (0.82 g, 100% yield, HC1) as a yellow solid. The crude product was used for the next step directly without further purification. LC-MS (ESI^+) *m/z* 345.1 $(M+H)^+$.


[001977] Tert-butyl N-(3-oxopropy0carbamate [Intermediate FO]



FO

[001978] To a solution of DMSO (2.23 g, 28.53 mmol, 2.23 mL, 2.5 *eq)* in DCM (15 mL) was added a solution of $(COCl)_2$ (2.90 g, 22.8 mmol) in DCM (10 mL) dropwise at -70°C. The mixture was stirred at -70°C for 10 minutes. Then a solution of tert-butyl N-(3-hydroxypropyl)carbamate (2.00 g, 11.4 mmol, CAS# 58885-58-8) in DCM (15 mL) was added into the above mixture slowly. After stirred at -70°C for 50 minutes, TEA (6.93 g, 68.5 mmol) was added and the reaction mixture was stirred at -70°C for 0.5 hour. On completion, the mixture was quenched with water (30 mL) and separated. The aqueous phase was extracted with DCM (2 X 30 mL). Then the organic phase was combined and washed with brine (100 mL), dried over Na_2S0_4 and concentrated *in vacuo* to give the title compound (1.70 g, 86% yield) as yellow oil. The residue was used for the next step directly without further purification. ^1H NMR (400MHz, CDCh) δ 9.80 (s, 1H), 5.01 - 4.87 (m, 1H), 3.41 (q, *J* = 6.0 Hz, 2H), 2.70 (t, *J* = 6.0 Hz, 2H), 1.42 (s, 9H).

[001979] 4-[4-(3-Aminopropylamino)butylaminol-2-(2.,6-dioxo-3-piperidv0isoindoline-1,3-dione [Intermediate FP)



[001980] Step 1 - Tert-butyl N-[3-[4-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]butylamino] propyl]carbamate


[001981] To a solution of tert-butyl N-(3-oxopropyl)carbamate (0.10 g, 577 umol, Intermediate FO) and 4-(4-aminobutyl amino) -2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione (264 mg, 693 umol, HC1, Intermediate FN) in THF (20 mL) was added KOAc (113 mg, 1.15 mmol). One hour later, $NaBH(OAc)_3$ (245 mg, 1.15 mmol) was added into the above mixture. The reaction mixture was stirred at 25°C for 72 hours. On completion, the mixture was concentrated *in vacuo.* The residue was purified by reverse phase (0.1% HC1 condition) to give the title compound (60.0 mg, 21% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 502.1 $(M+H)^+$.

[001982] Step 2: 4-[4-(3-Aminopropylamino)butylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione

[001983] To a solution of tert-butyl N-[3-[4-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino] butylamino]propyl]carbamate (60.0 mg, 120 umol) in DCM (2 mL) was added HCl/dioxane (4 mL). The reaction mixture was stirred at 25 °C for 0.5 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (50.0 mg, 95% yield, HC1) as a yellow solid. The residue was used for the next step directly without further purification. LC-MS (ESI^+) *m/z* 402.1 $(M+H)^+$.

[001984] **Tert-butyl N-[3-[4-(aminomethyl)imidazol-1-yl]propyl]carbamate**

(Intermediate FQ)



[001985] Step 1 - Methyl lH-imidazole-4-carboxylate

[001986] To a mixture of lH-imidazole-4-carboxylic acid (5.00 g, 44.6 mmol, CAS# 1072-84-0) in MeOH (50 mL) was added SOCI2 (10.6 g, 89.2 mmol, 6.47 mL). The reaction mixture was stirred at 70 °C for 16 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (5.60 g, 99% yield) as white solid. The residue was used to the next step directly without further purification. ^{1}H NMR (400MHz, DMSO-r#) δ 9.29 - 9.25 (m, 1H), 8.37 (s, 1H), 3.87 (s, 3H).

[001987] Step 2 - Methyl l-r3-(tert-butoxycarbonylamino)propyl1imidazole-4-carboxylate

[001988] To a mixture of methyl lH-imidazole-4-carboxylate (3.10 g, 24.5 mmol) in ACN (50 mL) was added K2CO3 (11.2 g, 81.1 mmol) and tert-butyl N-(3-bromopropyl)carbamate (11.7 g, 49.1 mmol, CAS# 83948-53-2). The reaction mixture was stirred at 25 °C for 16 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by column chromatography (S1O2, PE: EA=5:l) to give the title compound (4.00 g, 57% yield) as colourless oil. ^{1}H NMR (400MHz, DMSO^) δ 8.02 (s, 1H), 7.83 (s, 1H), 7.00 (s, 1H), 4.10 - 4.08 (m, 2H), 3.80 (s, 3H), 2.99 - 2.88 (m, 2H), 1.90 - 1.88 (m, 2H), 1.45 (s, 9H).

[001989] Step 3 - Tert-butyl N-r3-r4-(hvdroxymethvnimidazol-l-yl1propyl1carbamate

[001990] To a mixture of methyl l-[3-(tert-butoxycarbonylamino)propyl]imidazole-4-carboxylate (3.00 g, 10.5 mmol) in THF (50 mL) was added L1AIH4 (602 mg, 15.8 mmol) at 0 °C. The reaction mixture was stirred at 20 °C for 2 hours. On completion, the reaction mixture was quenched with water (3 mL) and NaOH solution (15 %, 5 mL) at 0 °C, then Na_2S0_4 (20 g) was

added. Then the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (2.50 g, 92% yield) as colourless oil. The residue was used to the next step directly without further purification. LC-MS (ESI^+) *m/z* 256.2 $(M+H)^+$.


[001991] Step 4 - Tert-butyl N-r3-r4-(azidomethvDimidazol-l-yl1propyl1carbamate (6) - Notebook Page: EW5435-653

[001992] To a mixture of tert-butyl N-[3-[4-(hydroxymethyl)imidazol-l-yl]propyl] carbamate (1.00 g, 3.92 mmol) and DPPA (1.62 g, 5.88 mmol, 1.27 mL) in THF (20 mL) was added DBET (1.49 g, 9.79 mmol, 1.48 mL) at 0 °C. The reaction mixture was stirred at 25 °C for 12 hours. On completion, the reaction mixture was concentrated *in vacuo*. The residue was diluted with water (10 mL) and extracted with EA (3 X 10 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (1.10 g, 100% yield) as light yellow oil. The residue was used to the next step directly without further purification. LC-MS (ESL) *m/z* 281.3 $(M+H)^+$.

[001993] Step 5 - Tert-butyl N-r3-r4-(aminomethvnimidazol-l-yl1propyl1carbamate

[001994] To a mixture of tert-butyl N-[3-[4-(azidomethyl)imidazol-l-yl]propyl]carbamate (1.10 g, 3.92 mmol) in MeOH (50 mL) was added Pd/C (500 mg, 10 wt %). The reaction mixture was stirred at 25 °C for 3 hours under H_2 (15 Psi) atmosphere. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (950 mg, 95% yield) as light yellow oil. The residue was used in the next step directly without further purification. LC-MS (ESI^+) *m/z* 255.3 $(M+H)^+$.

[001995] 4-12-12-[2-lAminomethvB-l-piperidyl] ethoxy] ethylamino]-2-[2,6-dioxo-3-piperidylliso indoline-l,3-dione [Intermediate FR)



FR


[001996] Step 1- Tert-butyl N-[[1-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethoxy] ethyl]-2-piperidyl]methyl]carbamate

[001997] To a solution of 2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethyl methanesulfonate (500 mg, 1.14 mmol, synthesized via Steps 1-2 of Example 184) in CEECN (20 mL) was added tert-butyl N-(2-piperidylmethyl) carbamate (488 mg, 2.28 mmol, CAS# 141774-61-0), NaHCOs (287 mg, 3.41 mmol) and KI (18.9 mg, 114 umol). The mixture was stirred at 80 °C for 16 hours. On completion, the mixture was concentrated *in vacuo.* The residue was purified by reversed phase flash to give the title compound (450 mg, 71% yield) as yellow solid. LC-MS (ESI^+) *m/z* 558.4 $(M+H)^+$.

[001998] Step 2 - 4-[2-[2-[2-(Aminomethyl)-1-piperidyllethoxylethyl amino]-2-(2.6-dioxo-3-piperidyl)isoindoline-E3-dione

[001999] To a solution of tert-butyl N-[[1-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino] ethoxy]ethyl]-2-piperidyl]methyl]carbamate (450 mg, 807 umol) in DCM (5 mL) was added HCI/dioxane (4 M, 4 mL). The mixture was stirred at 20 °C for 2 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (360 mg, 91% yield) as yellow solid. LC-MS (ESI^+) *m/z* 458.3 $(M+H)^+$.

[002000] 4-[2-[2-[2-Aminoethoxy]ethylamino1ethylamino]-2-[2,6-dioxo-3-piperidyl]isoindoline-1.,3 -dione [Intermediate FS1



FS

[002001] Step 1 - Tert-butyl N-r2-(2-oxoethoxy)ethyl1carbamate

[002002] To a solution of DMSO (1.90 g, 24.4 mmol) in DCM (10 mL) was added a solution of $(COCl)_2$ (2.47 g, 19.5 mmol) in DCM (10 mL) dropwise at -70 °C. The mixture was stirred at this temperature for 10 minutes. Then a solution of tert-butyl N-[2-(2-hydroxyethoxy)ethyl]carbamate (2 g, 9.74 mmol, CAS# 139115-91-6) in DCM (15 mL) was added into the above mixture slowly. After stirring at -70°C for 50 minutes, TEA (7.89 g, 78.0 mmol) was added and the reaction mixture was stirred at -70°C for 0.5 hour. On completion, the mixture was quenched with water (30 mL) and separated. The aqueous phase was extracted with DCM (2 X 30 mL). Then the organic phase was combined and washed with brine (100 mL), dried over Na_2S0_4 and concentrated *in vacuo* to give the title compound (1.30 g, crude) as yellow oil.


[002003] Step 2 - Tert-butyl N-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-L3-dioxo-isoindolin-4-yllaminolethyl aminolethoxylethyllcarbamate

[002004] To a solution of 4-(2-aminoethylamino)-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (202 mg, 572 umol, HC1, Intermediate DJ) and tert-butyl N-[2-(2-oxoethoxy)ethyl]carbamate (90.0 mg, 443 umol) in THF (20 mL) was added KOAc (102 mg, 1.04 mmol). One hour later, $NaBH(OAc)_3$ (220 mg, 1.04 mmol) was added into the above mixture. The reaction mixture was stirred at 25 °C for 17 hours. On completion, the reaction mixture was concentrated *in vacuo*. The residue was purified by reverse phase (0.1% HC1 condition) to give the title compound (80.0 mg, 31% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 504.1 $(M+H)^+$.

[002005] Step 3 - 4-r2-r2-(2-Aminoethoxy)ethylamino1ethyl amino1-2-(2,6-dioxo-3-piperidvOisoindoline-L3 -dione

[002006] To a solution of tert-butyl N-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino] ethylamino]ethoxy]ethyl]carbamate (75.0 mg, 149 umol) in DCM (2 mL) was added HCl/dioxane (2 mL). The reaction mixture was stirred at 25 °C for 0.5 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (65.0 mg, 99% yield, HC1) as a yellow solid. LC-MS (ESI^+) *m/z* 404.1 $(M+H)^+$.

[002007] **4-Bromo-2-[2,6-dioxo-3-piperidvnisoindoline-l,3-dione [Intermediate FT)**



FT


[002008] Step 1 - 4-Bromoisobenzofuran-L3-dione

[002009] A solution of 3-bromophthalic acid (5.00 g, 20.4 mmol, CAS# 116-69-8) in $(Ac)_20$ (20.4 mmol, 20 mL) was stirred at 120 °C for 12 hours. The reaction mixture was then stirred at 25 °C for 16 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (4.60 g, 99% yield) as yellow solid. LC-MS (ESI^+) m/z 227.1 $(M+H)^+$.

[002010] Step 2 - 4-Bromo-2-(2.6-dioxo-3-piperidvDisoindoline-L3-dione

[002011] To a solution of 4-bromoisobenzofuran-l,3-dione (4.60 g, 20.2 mmol) and 3-aminopiperidine-2,6- dione (3.67 g, 22.2 mmol, HC1, CAS# 24666-56-6) in HOAc (40 mL) was added KOAc (6.16 g, 62.8 mmol), the reaction mixture was stirred at 90 °C for 16 hr. On completion, the mixture was cooled to 25 °C and diluted with ice water (800 mL), and then stirred at 0 °C for 0.5 hr. The reaction mixture was filtered and the filter cake was dried *in vacuo* to give the title compound (6.8 g, 99% yield) as gray solid. ^1H NMR (400MHz, DMSO-di) δ 11.17 (s, 1H), 8.19 - 7.65 (m, 3H), 5.41 - 4.91 (m, 1H), 3.35 (s, 1H), 3.05 - 2.85 (m, 1H), 2.72 - 2.54 (m, , 2H), 2.09 (s, 1H).

[002012] **4-[3-Aminopropy0-2-[2.,6-dioxo-3-piperidv0isoindoline-l.,3-dione [Intermediate FU)**



[002013] Step 1 - Tert-butyl N-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl1prop-2-vnyl1carbamate

[002014] To a solution of 4-bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (1.00 g, 2.97 mmol, Intermediate FT) and tert-butyl N-prop-2-ynylcarbamate (598 mg, 3.86 mmol, CAS# 92136-39-5) in DMF (6 mL) was added TEA (5.40 g, 53.3 mmol, 7.43 mL), Cul (56.4 mg, 296 umol) and Pd(PPh $_3$)2Cl2 (208 mg, 296 umol). The reaction mixture was heated at 80 °C for 30 minutes under microwave. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by column chromatography to give the title compound (1.20 g, 98% yield) as yellow solid. LC-MS (ESI$^+$) *m/z* 434.0 (M+Na) $^+$.


[002015] Step 2 - Tert-butyl N-[3-[2-(2,6-dioxo-3-piperidyl)-E3-dioxo-isoindolin-4-yl]propyl] carbamate


[002016] To a mixture of tert-butyl N-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]prop-2-ynyl] carbamate (520 mg, 1.26 mmol) in THF (20 mL) was added Pd(OH)2/C (150 g, 10 wt %) and Pd/C (130 mg, 10 wt%). The reaction mixture was stirred at 25 °C for 12 hours under Hh (15 Psi) atmosphere. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (0.52 g, 99% yield) as light yellow solid. LC-MS (ESI$^+$) *m/z* 438.3 (M+Na) $^+$.

[002017] Step 3 - 4-(3-Aminopropyl)-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione

[002018] To a mixture of tert-butyl N-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yljpropyl] carbamate (520 mg, 1.25 mmol) in DCM (3 mL) was added HCl/dioxane (4 M, 3 mL). The reaction mixture was stirred at 25 °C for 2 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (520 mg, 99% yield, HC1) as light yellow solid. LC-MS (ESI^+) *m/z* 316.1 $(M+H)^+$.

[002019] **4-[3-[5-Aminopentylamino]propyl1-2-[2,6-dioxo-3-piperidvnisoindoline-l,3-dione [Intermediate FV)**





FV


[002020] Step 1 - Tert-butyl N-[5-[3-[2-(2,6-dioxo-3-piperidvl)-E3-dioxo-isoindolin-4-yllpropylaminolpentyll carbamate

[002021] To a mixture of 4-(3-aminopropyl)-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (445 mg, 1.27 mmol, HC1, Intermediate FU) in THF (5 mL) was added TEA (85.4 mg, 844 umol, 117 uL) and tert-butyl N-(5-oxopentyl)carbamate (170 mg, 844 umol, Intermediate EK) and HOAc (76.0 mg, 1.27 mmol, 72.4 uL), then $NaBH(OAc)_3$ (358 mg, 1.69 mmol) was added. The reaction mixture was stirred at 25 °C for 5 hours under N_2 atmosphere. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (0.1 % FA condition) to give the title compound (200 mg, 47% yield) as light yellow oil. LC-MS (ESI^+) *m/z* 501.4 $(M+H)^+$.

[002022] Step 2 - 4-r3-(5-Aminopentylamino)propyl1-2-(2.6-dioxo-3-piperidvnisoindoline-E3-dione

[002023] To a mixture of tert-butyl N-[5-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]propylamino] pentyl]carbamate (170 mg, 339 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 8 mL). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated in *vacuo* to give the title compound (170 mg, 99% yield) as light yellow solid. LC-MS (ESI^+) *m/z* 401.2 $(M+H)^+$.

[002024] **Methyl 4-[4-amino-3-(difluoromethvBpyrazol-l-yllbenzoate [Intermediate FW)**



[002025] Step 1 - Methyl 4-r4-(benzhvdrylideneamino)-3-(difluoiOtnethvDpyrazol-l-yllbenzoate


[002026] Amixture of methyl 4-[4-bromo-3-(difluoromethyl)pyrazol-l-yl]benzoate (0.15 g, 453 umol, synthesized via Steps 1-2 of Intermediate EB), diphenylmethanimine (205 mg, 1.13 mmol), $Pd(OAc)_2$ (20.8 mg, 92.4 umol), Xantphos (26.2 mg, 45.3 umol) and CS2CO3 (448 mg, 1.38 mmol) in dioxane (3 mL) was degassed and purged with N_2 3 times, and then the mixture was stirred at 120 °C for 3 hrs under N_2 atmosphere. On completion, the mixture was concentrated, then H_20 (30 mL) was added and the mixture was extracted with EtOAc (3 X 30 mL). The organic phase was dried with Na_2S0_4, filtrated and concentrated *in vacuo.* The residue was purified by flash silica gel chromatography to give the title compound (0.24 g, 50% yield) as a yellow solid. ^1H NMR (400MHz, CDCb) δ 8.02 - 7.95 (m, 2H), 7.80 - 7.73 (m, 2H), 7.51 - 7.45 (m, 3H), 7.43 - 7.31 (m, 5H), 7.22 - 7.19 (m, 2H), 7.12 - 6.82 (m, 1H), 6.37 (s, 1H), 3.85 (s, 3H); LC-MS (ESI^+) m/z 432.1 $(M+H)^+$.

[002027] Step 2 - Methyl 4-r4-amino-3-(difluoromethvDpyrazol-l-vnbenzoate


[002028] To a solution of methyl 4-[4-(benzhydrylideneamino)-3-(difluoromethyl)pyrazol-l-yl]benzoate (215 mg, 498 umol) in THF (2 mL) and MeOH (20 mL) was added HCl/MeOH (4 M, 124 uL). The mixture was stirred at 25 °C for 30 min. On completion, the mixture was concentrated to give the title compound (0.20 g, 90% yield) as a yellow solid. LC-MS (ESI^+) m/z

268.1 $(M+H)^+$.

[002029] **4-[4-[[2-[2-(CyclopropylmethylaminoV4-pyridylloxazole-4-carbonyllaminol-3-(difluoro methyQpyrazol-l-yllbenzoic acid [Intermediate FX)**



FW



FX

[002030] Step 1 - Methyl 4-[4-[[2-[2-[tert-butoxycarbonyl(cvclopropylmethvl)amino]-4-pyridylloxazole-4- carbonyl1amino1-3-(difluoromethvnpyrazol-l-yl1benzoate


[002031] A mixture of methyl 4-[4-amino-3-(difluoromethyl)pyrazol-l-yl]benzoate (340 mg, 1.27 mmol, Intermediate FW), 2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (412 mg, 1.15 mmol, from Steps 1-4 of Intermediate DF), HATU (484 mg, 1.27 mmol), DIPEA (411 mg, 3.18 mmol, 554 uL) in DMF (10 mL) was degassed and purged with N_2 3 times. Then the mixture was stirred at 25 °C for 6 hrs. On completion, the mixture was diluted with 50 mL H_20 and then filtered. The filter cake was dried *in vacuo* to give the title compound (260 mg, 27% yield) as a yellow solid. LC-MS (ESI^+) m/z 609.2 $(M+H)^+$.

[002032] Step 2 - 4-[4-[[2-[2-(Cvclopropylmethylamino)-4-pyridyl1oxazole-4-carbonyl1amino1-3-(difluoro methyOpyrazol-l-yllbenzoic acid

[002033] To a solution of methyl 4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl] oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]benzoate (200 mg, 329 umol) in THF (5 mL) and H_20 (5 mL) and MeOH (1 mL) was added LiOH (39.4 mg, 1.64 mmol). The mixture was stirred at 25 °C for 6 hrs. On completion, the mixture was concentrated, the residue was diluted with H_20 (50 mL) and added

1M HC1 to pH = 5-6, extracted with EA (3 X 30 mL). The combined organic layers were washed with brine (50 mL), dried over Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (0.13 g, 95% yield) as a yellow solid. LC-MS (ESI^+) m/z 595.4 $(M+H)^+$.

[002034] **Tert-butyl N-methyl-N- [2-(2-prop-2-ynoxyethoxy)ethyl]carbamate (Intermediate FY)**



FY

[002035] Step 1 - Ethyl 2-r2-rtert-butoxycarbonyl(´methv0amino1ethoxy1acetate

[002036] To a solution of tert-butyl N-(2-hydroxyethyl)-N-methyl-carbamate (10 g, 57.0 mmol) and $Rh(OAc)_2$ (630 mg, 2.85 mmol) in DCM (100 mL) was added a solution of ethyl 2-diazoacetate (13.0 g, 114 mmol, CAS# 623-73-4) in DCM (200 mL) dropwise, and the mixture was stirred at 25 °C for 16 hours. On completion, the reaction mixture was washed with water (50 mL X 4), dried over Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (14.5 g, 97% yield) as light yellow liquid. ^1H NMR (400MHz, CDCh) δ 4.21 (q, J = 7.2 Hz, 2H), 4.09 - 4.04 (m, 2H), 3.71 - 3.59 (m, 2H), 3.46 - 3.38 (m, 2H), 2.92 (s, 3H), 1.44 (s, 9H), 1.27 (t, J = 7.2 Hz, 3H).

[002037] Step 2 - Tert-butyl N-r2-(2-hydroxyethoxy)ethyl1-N-methyl-carbamate


[002038] To a solution of ethyl 2-[2-[tert-butoxycarbonyl(methyl)amino]ethoxy]acetate (12.4 g, 47.4 mmol) in THF (200 mL) was added $LiAlH_4$ (2.76 g, 71.1 mmol, 98% purity) at 0 °C under N_2 atmosphere. The reaction mixture was stirred at 20 °C for 1 hour. On completion, the mixture was quenched with water (4 mL) and NaOH aqueous solution (15%, 4 mL) at 0 °C, filtered and dried over Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (9.40 g, 90% yield) as colorless liquid. ^1H NMR (400MHz, CDCh) δ 3.72 - 3.67 (m, 2H), 3.66 - 3.54 (m, 4H), 3.50 - 3.42 (m, 2H), 2.91 (s, 3H), 1.46 (s, 9H).

[002039] Step 3 - Tert-butyl N-methyl-N-r2-(2-prop-2-vnoxyethoxy)ethyl1carbamate

[002040] To a solution of tert-butyl N-[2-(2-hydroxyethoxy)ethyl]-N-methyl-carbamate (8.70 g, 39.6 mmol) and 3-bromoprop-l-yne (5.19 g, 43.6 mmol) in THF (100 mL) was added

TBAI (879 mg, 2.38 mmol), KI (987 mg, 5.95 mmol) and KOH (2.62 g, 39.6 mmol, 85%). The mixture was stirred at 20 °C for 16 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE: EA=3:l) to give the title compound (4.20 g, 41% yield) as colorless oil. ¾ NMR (400MHz, CDCh) δ 4.21 (d, *J* = 2.4 Hz, 2H), 3.72 - 3.67 (m, 2H), 3.67 - 3.62 (m, 2H), 3.61 - 3.55 (m, 2H), 3.45 - 3.35 (m, 2H), 2.92 (s, 3H), 2.43 (t, *J* = 2.4 Hz, 1H), 1.46 (s, 9H).

[002041] **2-(2,6-Dioxo-3-piperidyl)-4-[3-[2-[2-(methylamino)ethoxylethoxylpropyllisoindoline-l.,3- dione [Intermediate FZ)**



[002042] Step 1 - Tert-butyl N-[2-[2-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yllprop-2-vnoxyl ethoxylethyll-N-methyl-carbamate

[002043] 4-Bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (0.60 g, 1.78 mmol, Intermediate FT), CuI (33.9 mg, 178 umol) and Pd(PPh $_3$)2Cl2 (125 mg, 178 umol) was taken up into a microwave tube. Then tert-butyl N-methyl-N-[2-(2-prop-2-ynoxyethoxy)ethyl]carbamate (458 mg, 1.78 mmol, Intermediate FY), TEA (3.24 g, 32.0 mmol) and DMF (5 mL) were added into the above tube. The mixture was degassed with N2 for 5 minutes. The sealed tube was heated at 80 °C for 30 minutes under microwave. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was purified by silica gel chromatography to give the title compound (460 mg, 43% yield, 85% purity) as yellow oil. LC-MS (ESI$^+$) *m/z* 536.3 (M+Na)$^+$.

[002044] Step 2 - Tert-butyl N-[2-[2-[3-[2-(2,6-dioxo-3-piperidyl)-E3-dioxo-isoindolin-4-


yllpropoxylethoxy] ethyll-N-methyl-carbamate

[002045] To a solution of tert-butyl N-[2-[2-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]prop-2- ynoxy]ethoxy]ethyl]-N-methyl-carbamate (460 mg, 761 umol) in THF (5 mL) was added Pd/C (0.2 g, 10% wt) and $Pd(OH)_2/C$ (0.2 g, 10% wt). The reaction mixture was stirred at 25 °C for 18 hrs under H_2 (15 Psi). On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (450 mg, 100% yield) as yellow oil. LC-MS (ESI^+) *m/z* 540.1 $(M+Na)^+$.

[002046] Step_ 3_ -_ 2-(2.6-Dioxo-3-piperidylV4-r3-r2-r2-(methylamino)ethoxy1ethoxy1propyl1isoindoline-L3- dione

[002047] To a solution of tert-butyl N-[2-[2-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]propoxy] ethoxy]ethyl]-N-methyl-carbamate (450 mg, 869 umol) in DCM (3 mL) was added HCl/dioxane (4 M, 4 mL). The reaction mixture was stirred at 25 °C for 0.5 hr. On completion, the residue was concentrated *in vacuo* to give the title compound (330 mg, 84% yield, HC1) as yellow oil. LC-MS (ESI^+) *m/z* 418.1 $(M+H)^+$.


[002048] **5-Bromo-2-[2,6-dioxo-3-piperidvnisoindoline-l,3-dione [Intermediate GA)**



GA

[002049] To a solution of 3-aminopiperidine-2,6-dione (7.98 g, 48.4 mmol, HC1 salt, CAS# 24666-56-6), KOAc (13.4 g, 136 mmol) in HOAc (200 mL) was added 5-bromoisobenzofuran-l,3-dione (10.0 g, 44.0 mmol, CAS# 282-73-5). The mixture was then heated to 90 °C and stirred for 12 hours. On completion, the mixture was cooled down to 25°C and diluted with water (800 mL), and then filtered to give a filter cake. The filter cake was stirred in DCM (20 mL) for 1 hour and filtered to give a filter cake. The filter cake was dried *in vacuo* to give the title compound (9.00 g, 60% yield) as a blue solid. ¾NMR (400MHz, DMSO-7,) δ 11.15 (s, 1H), 8.15 (d, 7 = 1.2 Hz, 1H), 8.10 (dd, *J* = 1.6, 8.0 Hz, 1H), 7.87 (d, 7 = 8.0 Hz, 1H), 5.17 (dd, *J* = 5.6, 12.8 Hz, 1H), 2.95 - 2.83 (m, 1H), 2.65 - 2.52 (m, 2H), 2.11 - 2.00 (m, 1H).

[002050] **4-Amino-l-[4-(hydroxymethv0phenyllpyrazole-3-carboxamide [Intermediate OB)**



[002051] Step 1 - Methyl l-r4-(hvdroxymethvnphenyl1-4-nitro-pyrazole-3-carboxylate

[002052] To a mixture of methyl 4-nitro-lH-pyrazole-3-carboxylate (8.00 g, 38.5 mmol, HC1 salt, Intermediate HL), [4-(hydroxymethyl)phenyl]boronic acid (7.03 g, 46.2 mmol, CAS# 59016-93-2) and pyridine (18.2 g, 231 mmol) in DCM (130 mL) was added $Cu(OAc)_2$ (8.40 g, 46.2 mmol). The mixture was stirred at 25 °C under 0_2 (15 psi) for 16 hours. On completion, the mixture was concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE: EA = 1:1) to give the title compound (4.00 g, 36% yield) as white solid. ^{1}H NMR (400MHz, DMSO-de) δ 9.68 (s, 1H), 7.89 (d, *J* = 8.8 Hz, 2H), 7.51 (d, *J* = 8.8 Hz, 2H), 5.37 (t, *J* = 5.6 Hz, 1H), 4.57 (d, *J* = 5.6 Hz, 2H), 3.94 (s, 3H); LC-MS (ESI$^+$) *m/z* 300.0 $(M+Na)^+$.


[002053] Step 2 - l-r4-(HvdroxymethvDphenvn-4-nitro-pyrazole-3 -carboxamide

[002054] To a solution of methyl l-[4-(hydroxymethyl)phenyl]-4-nitro-pyrazole-3-carboxylate (2.30 g, 7.72 mmol) in THF (15 mL) was added N¾*H $_2$0 (22.7 g, 194 mmol, 30% w/w) in a sealed tube. The mixture was stirred at 80 °C for 16 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (2.20 g, 97% yield) as yellow solid. ^{1}H NMR (400MHz, DMSO-de) δ 9.60 (s, 1H), 8.19 (s, 1H), 7.90 (d, *j* = 8.4 Hz, 3H), 7.50 (d, *j* = 8.4 Hz, 2H), 5.37 (s, 1H), 4.56 (d, *J* = 2.4 Hz, 2H).

[002055] Step 3 - 4-Amino-l-r4-(hvdroxymethvnphenyl1pyrazole-3 -carboxamide

[002056] To a solution of l-[4-(hydroxymethyl)phenyl]-4-nitro-pyrazole-3-carboxamide (1.60 g, 6.10 mmol) in MeOH (120 mL) was added Pd/C (0.8 g, 10% w/w) under N_2. The suspension was degassed *in vacuo* and purged with H_2 three times. The mixture was stirred under H_2 (15 psi) at 20 °C for 40 minutes. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (1.40 g, 91% yield) as yellow solid; LC-MS (ESI$^+$) *m/z* 233.1 $(M+H)^+$.

[002057] **Tert-butyl N-[4-[4-[[3-carbamoyl-l-(4-formylphenvDpyrazol-4-yl]carbamoyl]oxazol-2-yl]-2- pyridyl]-N-(cyclopropylmethyl)carbamate (Intermediate GO**



GC

[002058] Step 1 - Tert-butyl N-[4-[4-[[3-carbamoyl-l-[4-(hvdroxymethvl)phenyl1pyrazol-4-yllcarbamovH oxazol-2-yl1-2-pyridyl1-N-(cvclopropylmethvncarbamate


[002059] To a solution of 2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (1.24 g, 3.44 mmol, from Steps 1-4 of Intermediate DF) in DMF (25 mL) was added DIPEA (1.67 g, 12.9 mmol), HATU (1.96 g, 5.17 mmol) and 4-amino-l-[4-(hydroxymethyl)phenyl]pyrazole-3-carboxamide (1.00 g, 4.31 mmol, Intermediate GB). The mixture was stirred at 20 °C for 2 hours. On completion, the reaction mixture was diluted with water (80 mL), filtered to give a filter cake which was dried *in vacuo* to give the title compound (1.50 g, 60% yield) as brown solid. LC-MS (ESI^+) *m/z* 574.1 $(M+H)^+$.

[002060] Step 2 - Tert-butyl N-[4-[4-[[3-carbamoyl-l-(4-formylphenvDpyrazol-4-yl1carbamovnoxazol-2-vn-2- pyridyl1-N-(cvclopropylmethvDcarbamate

[002061] To a solution of tert-butyl N-[4-[4-[[3-carbamoyl-l-[4-(hydroxymethyl)phenyl]pyrazol-4-yl] carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(cyclopropylmethyl)carbamate (1.5 g, 2.62 mmol) in a THF (300 mL) was added DMP (1.22 g, 2.88 mmol), and the mixture was stirred at 20 °C for 16 hours. On completion, the reaction mixture was quenched with saturated Na_2S20_3 (20 mL) and saturated $NaHC0_3$ (20 mL) at 25°C. This reaction mixture was then stirred for 30 minutes, then extracted with CH2CI2 (80 mL X 3). The combined organic layers were filtered and concentrated *in vacuo* to give the title compound (1 g,

67% yield) as gray solid. ^{1}H NMR (400MHz, DMSO-^e) δ 11.04 (s, 1H), 10.04 (s, 1H), 9.09 (s, 2H), 8.60 (d, *J* = 5.2 Hz, 1H), 8.25 - 8.23 (m, 3H), 8.17 (s, 1H), 8.07 (d, *J* = 8.4 Hz, 2H), 7.81 (br s, 1H), 7.67 *(d, J* = 4.8 Hz, 1H), 3.86 (br d, *J* =7.2 Hz, 2H), 1.52 (s, 9H), 1.20 - 1.16 (m, 1H), 0.46 - 0.35 (m, 2H), 0.25 -0.22 (m, 2H); LC-MS (ESI$^+$) *m/z* 572.1 (M+H)$^+$.

[002062] **2-(2,6-Dioxo-3-piperidyl)-5-[3-[2-[2-(methylamino)ethoxy]ethoxy]propyl]isoindoline-1,3- dione [Intermediate GD)**



[002063] Step 1 - Tert-butyl N-[2-[2-[3-[2-(2,6-dioxo-3-piperidyl)-E3-dioxo-isoindolin-5-yllprop-2-vnoxyl ethoxylethyll-N-methyl-carbamate

[002064] To a solution of 5-bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione (3.73 g, 11.0 mmol, Intermediate GA) and tert-butyl N-methyl-N-[2-(2 -prop-2 - ynoxyethoxy)ethyl]carbamate (3.70 g, 14.3 mmol, Intermediate FY) in DMF (30 mL) was added $Pd(PPh3)_2Cl2$ (776 mg, 1.11 mmol), TEA (20.1 g, 199 mmol) and CuI (210 mg, 1.11 mmol). The mixture was heated at 80 °C for 30 minutes under microwave. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE: EA =1:1) to give the title compound (5.50 g, 96% yield) as brown oil. ^{1}H NMR (400MHz, CDCh) δ 8.09 (s, 1H), 7.91 (s, 1H), 7.87 - 7.78 (m, 2H), 4.99 (dd, *j* = 5.6, 12.4 Hz, 1H), 4.48 (s, 2H), 3.80 - 3.73 (m, 2H), 3.71 - 3.66 (m, 2H), 3.65 - 3.58 (m, 2H), 3.45 - 3.35 (m, 2H), 2.98 - 2.94 (m, 1H), 2.93 (s, 3H), 2.88 - 2.70 (m, 2H), 2.21 - 2.13 (m, 1H), 1.46 (s, 9H).

[002065] Step 2 - Tert-butyl N-[2-[2-[3-[2-(2,6-dioxo-3-piperidyl)-E3-dioxo-isoindolin-5-


yllpropoxylethoxyl ethyll-N-methyl-carbamate (19) - Notebook Page: EW5417-733

[002066] To a solution of tert-butyl N-[2-[2-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl]prop-2- ynoxy]ethoxy]ethyl]-N-methyl-carbamate (1.00 g, 1.95 mmol) in THF (20 mL) was added Pd/C (0.30 g, 10% w/w) and $Pd(OH)_2/C$ (0.30 g, 10% w/w) under N_2 atmosphere. The suspension was degassed under vacuum and purged with H_2 three times. The mixture was stirred under H_2 (15 Psi) at 20°C for 1 hour. On completion, the reaction mixture was filtered and the filterate was concentrated *in vacuo* to give the title compound (0.95 g, 95% yield) as brown oil. ^1H NMR (400MHz, CDCh) δ 8.08 (s, 1H), 7.79 (d, *J* = 8.0 Hz, 1H), 7.72 (s, 1H), 7.59 (dd, *J* = 1.2, 7.6 Hz, 1H), 5.02 (dd, *J* = 5.2, 13.6 Hz, lH),3.67 - 3.55 (m, 6H), 3.48 (t, *j* = 6.0 Hz, 2H), 3.44 - 3.36 (m, 2H), 2.92 (s, 3H), 2.91 - 2.89 (m, 1H), 2.88 - 2.85 (m, 2H), 2.84 - 2.68 (m, 2H), 2.19 - 2.11 (m, 1H), 2.00 - 1.91 (m, 2H), 1.46 (s, 9H); LC-MS (ESI^+) *m/z* 540.3 $(M+Na)^+$.

[002067] Step_ _____3_ _____-_ _____2-(2.6-Dioxo-3-piperidylV5-r3-r2-r2-(methylaminoiethoxylethoxylpropyllisoindoline- 1.3- dione

[002068] To a solution of tert-butyl N-[2-[2-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl]propoxy] ethoxy]ethyl]-N-methyl-carbamate (0.95 g, 1.84 mmol) inDCM (20 mL) was added HCl/dioxane (4 M, 12 mL). The mixture was stirred at 20 °C for 1 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (0.83 g, 99% yield, HC1 salt) as light yellow solid. LC-MS (ESI^+) *m/z* 418.3 $(M+H)^+$.

[002069] N-[3-carbamoyl-l-(4-formylphenv0pyrazol-4-yll-2-(4-pyridv0oxazole-4-carboxamide [Intermediate GE)



EE

GE

[002070] Step 1 - Isopropoxycarbonyl 4-r3-carbamoyl-4-IT2-(4-pyridvDoxazole-4-carbonyllaminolpyrazol-l- vl] benzoate

[002071] To a mixture of 4-[3-carbamoyl-4-[[2-(4-pyridyl)oxazole-4-carbonyl]amino]pyrazol-l-yl]benzoic acid (500 mg, 1.20 mmol, Intermediate EE) in THF (20 mL) was added TEA (483 mg, 4.78 mmol, 665 uL) and isopropyl carbonochloridate (366 mg, 2.99 mmol, 414 uL). The reaction mixture was stirred at -l0°C for 2 hours. On completion, the reaction mixture was filtered. The filtrate was used to the next step directly without further purification to give the title compound (600 mg, 99% yield) as light yellow oil. LC-MS (ESI^+) *m/z* 505.0 $(M+H)^+$.


[002072] Step 2 - N-r3-carbamoyl-l-r4-(hvdroxymethvnphenyl1pyrazol-4-yl1-2-(4-pyridvDoxazole-4- carboxamide

[002073] To a mixture of isopropoxycarbonyl 4-[3-carbamoyl-4-[[2-(4-pyridyl)oxazole-4-carbonyl]amino] pyrazol-l-yl]benzoate (600 mg, 1.19 mmol) in H_20 (5 mL) and THF (50 mL) was added $LiBH_4$ (155 mg, 7.14 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 2 hours. On completion, the reaction mixture was quenched with water (30 mL) under stirring. Then the mixture was extracted with EA (3 X 50 mL). The combined organic layer was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was triturated with DCM/PE (5 mL/30 mL) and filtered to give the title compound (250 mg, 51% yield) as light yellow solid. LC-MS (ESI^+) *m/z* 405.2 $(M+H)^+$.

[002074] Step 3 - N-[3-carbamoyl- l-(4-formylphenv0pyrazol-4-vn-2-(4-pyridv0oxazole-4-carboxamide

[002075] To a mixture of N-[3-carbamoyl-l-[4-(hydroxymethyl)phenyl]pyrazol-4-yl]-2-(4-pyridyl)oxazole -4-carboxamide (250 mg, 618 umol) in DCM (10 mL) and THF (10 mL) was added DMP (524 mg, 1.24 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 2 hours. On completion, the reaction mixture was diluted with $Na_2S_2O_3$ (10 mL), $NaHCO_3$ (10 mL) and stirred for 30 min. Then the mixture was extracted with DCM (3 X lOmL) and the combined organic layers was dried over Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (230 mg, 92% yield) as light yellow solid. LC-MS (ESI^+) *m/z* 403.2 $(M+H)^+$.

[002076] **Tert-butyl N-(cvcloDroDylmethvn-N-|4-|4-||3-(difliioromethyl)-l-(4-formylphenvPpyrazol-4 -yl] carbamoyl] oxazol-2-yl1-2-pyridyl1 carbamate [Intermediate GF)**



[002077] Step 1 - Isopropoxycarbonyl 4-[4-[[2-[2-[tert-butoxycarbonyl(cvclopropylmethvDamino1-4-pyridvn oxazole-4-carbonyl1amino1-3-(difluoromethvOpyrazol- 1-yllbenzoate

[002078] To a solution of 4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4- carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]benzoic acid (250 mg, 420 umol, Intermediate FX) in THF (10 mL) was added TEA (170 mg, 1.68 mmol) and isopropyl carbonochloridate (128 mg, 1.05 mmol). The mixture was stirred at -l0°C for 1 hour. On completion, the mixture was filtered and the filtrate was concentrated in *vacuo* to give the title compound (280 mg, 90% yield) as yellow solid. LC-MS (ESI^+) *m/z* 681.3 $(M+H)^+$.

[002079] Step 2 - Tert-butyl N-(cvclopropylmethvO-N-r4-r4-rr3-(difluoromethvQ-l-r4-


(hydroxymethvOphenyll pyrazol-4-yl1carbamoyl1oxazol-2- vH-2-pyridyl1carbamate

[002080] To a solution of isopropoxycarbonyl 4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4- pyridyl]oxazole-4-carbonyl] amino]-3-(difluoromethyl)pyrazol-l-yl]benzoate (280 mg, 411 umol) in THF (30.0 mL) and H_20 (4.00 mL) was added $NaBH_4$ (62.2 mg, 1.65 mmol). The mixture was stirred at 0°C for 1 hour. On completion, the mixture was diluted with H_20 (50 mL) and extracted with EtOAc (3 X 30 mL). The organic layers were dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The mixture was triturated with DCM: PE= 1:5 (30 mL), and filtered. The filter cake was dried *in vacuo* to give the title compound (200 mg, 83% yield) as white solid. LC-MS (ESI^+) *m/z* 581.3 $(M+H)^+$.

[002081] Step 3 - Tert-butyl N-(cvclopropylmethvO-N-r4-r4-rr3-(difluoromethvO-l-(4-formylphenvDpyrazol-4 -yl1carbamoyl1oxazol-2-yl1-2-pyridyl1carbamate

[002082] To a solution of tert-butyl N-(cyclopropylmethyl)-N-[4-[4-[[3-(difluoromethyl)-l-[4-(hydroxymethyl) phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (140 mg, 241 umol) in DCM (10.0 mL) was added DMP (204 mg, 482 umol). The mixture was stirred at 15 °C for 2 hours. On completion, the mixture was diluted with DCM (30 mL), and washed with saturated $Na_2S_20_3$ (2 X 30 mL) and saturated $NaHC0_3$ (2 X 30 mL). The organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (80.0 mg, 57% yield) as white solid. LC-MS (ESI^+) *m/z* 579.1 $(M+H)^+$.

[002083] **Tert-butyl N-(5-prop-2-vnoxypentvBcarbamate [Intermediate GG]**



GG

[002084] Step 1 - Tert-butyl N-(5-hvdroxypentv0carbamate


[002085] To a solution of 5-aminopentan-l-ol (21.3 g, 206 mmol) in MeOH (200 mL) was added I_2 (2.63 g, 10.3 mmol) and tert-butoxy carbonyl tert-butyl carbonate (54.2 g, 248 mmol). The mixture was stirred at 25 °C for 12 hours. On completion, the mixture was concentrated to give a residue. The residue was purified by silica gel chromatograph to give the title compound (40.0 g, 95% yield) as yellow oil. ¾NMR (400MHz, CDCh) δ 4.60 (s, 1H), 3.69 - 3.59 (m, 2H), 3.12 (d, *J* = 5.6 Hz, 2H), 1.9 - 1.7 (m, 1H), 1.61 - 1.36 (m, 15H).

[002086] Step 2 - Tert-butyl N-(5-prop-2-vnoxypentvDcarbamate

[002087] To a solution of tert-butyl N-(5-hydroxypentyl)carbamate (5.00 g, 24.6 mmol) and 3-bromoprop-l-yne (3.07 g, 25.8 mmol) in THF (100 mL) was added TBAI (545 mg, 1.48 mmol)

and KI (612 mg, 3.69 mmol). Then KOH (1.38 g, 24.6 mmol) was added into the above mixture. The reaction mixture was stirred at 25 °C for 12 hours. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatograph (PE:EA= 5/1) to give the title compound (3.00 g, 50% yield) as a light yellow oil. ^{1}H NMR (400MHz, DMSO-d) δ 4.12 (d, *J* = 2.4 Hz, 2H), 3.50 (t, *J* = 6.4 Hz, 2H), 3.11 (q, *J* = 6.4 Hz, 2H), 2.41 (t, *J* = 2.4 Hz, 1H), 1.65 - 1.55 (m, 2H), 1.53 - 1.33 (m, 13H).

[002088] **4-[3-(5-Aminopentoxy)propyl1-2-(2.,6-dioxo-3-piperidv0isoindoline-l.,3-dione [Intermediate GH)**



[002089] Step 1 - Tert-butyl N-[5-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl1prop-2-ynoxy1pentyl1 carbamate

[002090] 4-bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (500 mg, 1.48 mmol, Intermediate FT) ,CuI (28.2 mg, 148 umol) and Pd(PPh3)$_2$Cl2 (104 mg, 148 umol) was taking up into a microwave tube. Then DMF (10 mL), TEA (2.70 g, 26.7 mmol) and tert-butyl N-(5-prop-2-ynoxypentyl)carbamate (715 mg, 2.97 mmol, Intermediate GG) were added to the tube. The sealed tube was heated to 80 °C and stirred for 0.5 hours. On completion, the reaction mixture was diluted with water (100 mL) and extracted with EA (5 X 10 mL). The organic phase was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica

gel chromatograph (EA/PE=l/l) to give the title compound (1.10 g, 74 % yield) as a white solid. LC-MS (ESI^+) *m/z* 498.1 $(M+H)^+$.


[002091] Step_2_-_Tert-butyl_N-[5-[3-[2-(2,6-dioxo-3-piperidyl)-L3-dioxo-isoindolin-4-yllpropoxylpentyll carbamate

[002092] To a solution of tert-butyl N-[5-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]prop-2- ynoxy]pentyl]carbamate (0.50 g, 1.00 mmol) in THF (5 mL) was added Pd/C (50.0 mg, 10 wt%) and $Pd(OH)_2$ (50 mg, 10 wt%). The mixture was purged with H_2 gas several times. The mixture was stirred under H_2 (15 psi) at 25°C for 12 minutes. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatograph to give the title compound (380 mg, 75% yield) as a yellow gum; LC-MS (ESI^+) *m/z* 502.1 $(M+H)^+$.

[002093] Step 3 - 4-r3-(5-Aminopentoxy)propyl1-2-(2.6-dioxo-3-piperidvnisoindoline-L3-dione

[002094] To a solution of tert-butyl N-[5-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]propoxy] pentyljcarbamate (380 mg, 757 umol) in DCM (4 mL) was added HCl/dioxane (4 M, 4 mL). The mixture was stirred at 20 °C for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the product (330 mg, 65% yield) as light yellow solid; LC-MS (ESI^+) *m/z* 402.3 $(M+H)^+$.

[002095] **Tert-butyl methyl(5-(prop-2-yn-1-yloxy)pentyl)carbamate (Intermediate GI)**



GI

[002096] Step 1 - N-(5-hvdroxypentv0formamide

[002097] A solution of 5-aminopentan-l-ol (CAS# 2508-29-4) (7 g, 67.9 mmol) in ethyl formate (20.1 g, 271 mmol) was heated to 90 °C for 6 hrs. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (8.9 g, 97% yield) as colorless oil. The residue was used for the next step without purification. LC-MS (ESI^+) *m/z* 132. 1 $(M+H)^+$.

[002098] Step 2 - 5-(Methylamino)pentan-l-ol

[002099] To a solution of L1AIH4 (3.09 g, 81.4 mmol) in THF (100 mL) was added *N-(*5-hydroxypentyl)formamide (8.9 g, 67.8 mmol) slowly at 0 °C. Then, the reaction mixture was heated to 80 °C for 2 hrs. On completion, the reaction mixture was quenched with a solution of 15% NaOH (20 mL). Thereafter, 50 g anhydrous sodium sulfate was added, and the mixture was filtered. The filtrate was concentrated in *vacuo* to give the title compound (7.95 g, 100% yield, crude) as colorless oil.


[002100] Step 3 - Tert-butyl (S-hvdroxypentvOrinethvOcarbamate

[002101] To a solution of 5-(methylamino)pentan-l-ol (7.95 g, 67.8 mmol) in methanol (100 mL) was added tert-butoxycarbonyl tert-butyl carbonate (14.8 g, 67.8 mmol, 15.6 mL). The reaction mixture was stirred at 25 °C for 12 hrs. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by silica gel chromatography (PE: EA = 2:1) to give the title compound (9.6 g, 65% yield) as a colorless oil. ^{1}H NMR (400MHz, CDCb) δ 3.66 (t, *J* = 6.4 Hz, 2H), 3.25 - 3.21 (m, 2H), 2.85 (s, 3H), 1.65 - 1.59 (m, 2H), 1.58 - 1.51 (m, 2H), 1.47 (s, 9H), 1.42 - 1.33 (m, 2H).

[002102] Step 4 - Tert-butyl methyl(5-(prop-2-vn-l-yloxy)pentvl)carbamate

[002103] To a solution of tert-butyl N-(5-hydroxypentyl)-N-methyl-carbamate (1.00 g, 4.60 mmol) and 3-bromoprop-l-yne (575 mg, 4.83 mmol) in THF (10 mL) was added KOH (334 mg, 5.06 mmol, 85% purity), KI (153 mg, 920 umol) and TBAI (340 mg, 920 umol). The reaction mixture was stirred at 20 °C for 12 hrs. On completion, the reaction mixture was extracted with ethyl acetate (3 X 50 mL). The combined organic layers was washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo.* The residue was purified by silica gel chromatography (PE: EA = 50:1) to give the title compound (530 mg, 45 % yield) as a colorless oil. ^{1}H NMR (400MHz, CDCb) δ 4.15 (d, *J* = 2.4 Hz, 2H), 3.53 (t, *J* = 6.4 Hz, 2H), 3.24 - 3.22 (m, 2H), 2.85 (s, 3H), 2.43 (t, *J* = 2.4 Hz, 1H), 1.68 - 1.63 (m, 2H), 1.57 - 1.53 (m, 2H), 1.47 (s, 9H), 1.41 - 1.34 (m, 2H).

[002104] 2-(2,6-Dioxopiperidin-3-yl)-4-(3-((5-(methylamino)pentyl)oxy)propyl)isoindoline-l ,3-dione [Intermediate GJ1



[002105] Step 1 - Tert-butyl (5-((3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)prop-2-yn-1-yl)oxy)pentyl(methyl)carbamate

[002106] 4-Bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione (200 mg, 593 umol, Intermediate FT), tert-butyl /V-methyl-/V-(5-prop-2-ynoxypentyl)carbamate (152 mg, 593 umol, Intermediate GI), $Pd(PPh_3)_2Cl_2$ (41.6 mg, 59.3 umol), CuI (11.3 mg, 59.3 umol) and TEA (1.08 g, 10.7 mmol, 1.49 mL) were taken up into a microwave tube in DMF (3 mL) under N_2. The reaction mixture was de-gassed with N_2 and then the seal tube was heated to 80 °C for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by silica gel chromatography (PE: EA = 2:1) to give the title compound (260 mg, 66% yield) as a yellow oil. ^1H NMR (400MHz, $CDCl_3$) δ 8.47 (s, 1H), 7.76 (d, *J* = 7.2 Hz, 1H), 7.71 - 7.67 (m, 1H), 7.65 - 7.60 (m, 1H), 4.95 - 4.91 (m, 1H), 4.38 (s, 2H), 3.60 (t, *J* = 6.8 Hz, 2H), 3.14 (t, *J* = 6.8 Hz, 2H), 2.83 - 2.66 (m, 7H), 1.66 - 1.56 (m, 2H), 1.49 - 1.43 (m, 2H), 1.38 (s, 9H), 1.36 - 1.30 (m, 2H); LC-MS (ESI$^+$) *m/z* 512.1 $(M+H)^+$.


[002107] Step 2 - Tert-butyl (5-(3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)propoxy)pentyl)(methyl) carbamate

[002108] To a solution of tert-butyl A-[5-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]prop-2- ynoxy]pentyl]-N-methyl-carbamate (260 mg, 391 umol) in THF (20 mL) was added Pd(OH)2/C (26 mg, 10% *wt)* and Pd/C (26 mg, 10% *wt)* under N_2. The suspension was degassed under vacuum and purged with ¾ several times. The mixture was stirred under ¾ (15 Psi) at 25 °C for 12 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (260 mg, 99% yield) as a white solid. LC-MS (ESI$^+$) *m/z* 538.1 $(M+Na)^+$.

[002109] Step 3 - 2-(2,6-Dioxopiperidin-3-yl)-4-(3-((5-(methylamino)pentyl)oxy)propyl)isoindoline-1,3-dione

[002110] To a solution of tert-butyl A-[5-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl] propoxy]pentyl]-N-methyl-carbamate (260 mg, 388 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 5 mL) under N_2. The mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (175 mg, 99% yield) as a white solid which was used for the next step without purification. LC-MS (ESI^+) *m/z* 416.1 $(M+H)^+$.


[002111] **Tert-butyl N-methyl-N-(2-prop-2-ynoxyethyl)carbamate [Intermediate GK)**




GK

[002112] To a solution of tert-butyl N-(2-hydroxyethyl)-N-methyl-carbamate (4 g, 22.8 mmol, CAS# 57561-39-4) and 3-bromoprop-l-yne (2.72 g, 22.8 mmol, 1.97 mL) in THF (40 mL) was added TBAI (505 mg, 1.37 mmol), KI (568 mg, 3.42 mmol), and KOH (1.28 g, 22.8 mmol), and the reaction mixture was stirred at 25 °C for 16 hr. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by flash silica gel chromatography (PE/EA=5/l, Rf =0.6) to give the title compound (2.9 g, 59% yield) as yellow oil. ^1H NMR (400MHz, CDCh) δ 4.15 (d, J = 2.4 Hz, 2H), 3.64 (s, 2H), 3.41 (s, 2H), 2.92 (s, 3H), 2.53 - 2.35 (m, 1H), 1.46 (s, 9H)

[002113] **2-(2,6-Dioxo-3-piperidyl)-4-[3-[2-(methylamino)ethoxy]propyl]isoindoline-1,3-dione (Intermediate GL)**



GK



GL

[002114] Step 1 - Tert-butyl N-[2-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]prop-2-ynoxyl ethyl] -N-methyl-carbamate

[002115] To a solution of tert-butyl N-methyl-N-(2-prop-2-ynoxyethyl)carbamate (379 mg, 1.78 mmol, Intermediate GK) and 4-bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione (300 mg, 889 umol, Intermediate FT) in DMF (4 mL) was added TEA (1.62 g, 16.0 mmol, 2.23 mL), CuI (16.9 mg, 88.9 umol) and $Pd(PPh_3)_2Cl_2$ (62.4 mg, 88.9 umol), the reaction mixture was heated at 80 °C for 30 min under microwave. On completion, the mixture was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=5/1 to 1/0, Rf = 0.29) to give the title compound (430 mg, 100% yield) as yellow oil. LC-MS (ESI^+) m/z 370.2 $(M+H-100)^+$.


[002116] Step 2 - Tert-butyl N-[2-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yllpropoxylethyll-N- methyl-carbamate

[002117] To a solution of tert-butyl N-[2-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]prop-2-ynoxy] ethyl]-N-methyl-carbamate (430 mg, 915 umol) in THF (10 mL) was added Pd(OH)2/C (250 mg, 10 wt%) and Pd/C (250 mg, 10 wt%), and the reaction mixture was stirred at 25 °C under ¾ (15 psi) for 16 hr. On completion, the residue was filtered and the filtrate was concentrated *in vacuo* to give the title compound (350 mg, 80% yield) as brown solid. LC-MS (ESI^+) m/z 496.2 $(M + Na)^+$.

[002118] Step 3 - 2-(2.6-Dioxo-3-piperidyD-4-r3-r2-**(methylaminoiethoxylpropyllisoindoline-l ,3-dione**

[002119] To a solution of tert-butyl N-[2-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo -isoindolin-4-yl]propoxy]ethyl] -N-methyl-carbamate (350 mg, 739 umol) in DCM (4 mL) was added HCl/dioxane (4 M, 4 mL), and the reaction mixture was stirred at 25 °C for 20 mins. On completion, the mixture was concentrated *in vacuo* to give the title compound (300 mg, 99% yield) as yellow oil. LC-MS (ESI^+) m/z 374.2 $(M+H)^+$.

[002120] **Tert-butyl N-hex-5-ynyl-N-methyl-carbamate [Intermediate GM)**



GM

[002121] Step 1 - Hex-5-ynyl methanesulfonate

[002122] To a solution of hex-5-yn-l-ol (2.00 g, 20.4 mmol, CAS# 928-90-5) and TEA (5. 16 g, 51.0 mmol) in DCM (20 mL) was added MsCl (2.80 g, 24.5 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 3 hrs. On completion, the mixture was quenched with water (20 mL), and extracted with DCM (2 X 20 mL). The organic layer was washed with brine (50 mL), dried with Na_2S0_4, filtered and the filtrate was concentrated *in vacuo* to give the title compound (3.20 g, 89% yield) as yellow oil. ^1H NMR (400MHz, CDCh) δ 4.27 (t, *J* = 6.4 Hz, 2H), 3.02 (s, 3H), 2.30 - 2.24 (m, 2H), 1.98 (t, *j* = 2.8 Hz, 1H), 1.93 - 1.84 (m, 2H), 1.70 - 1.64 (m, 2H).

[002123] Step 2 - N-methylhex-5-yn-l -amine


[002124] A solution of hex-5-ynyl methanesulfonate (0.60 g, 3.40 mmol) and KI (28.3 mg, 170 umol) in a solution of methanamine (2 M, 8.51 mL) was stirred at 55 °C for 15 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (0.25 g, 66% yield) as yellow oil. ^{1}HNMR (400MHz, CDCh) δ 2.63 (t, *J* = 7.2 Hz, 2H), 2.45 (s, 3H), 2.23 - 2.19 (m, 2H), 1.94 (t, *J* = 2.4 Hz, 1H), 1.68 - 1.56 (m, 4H).

[002125] Step 3 - Tert-butyl N-hex-5-ynyl-N-methyl-carbamate

[002126] To a solution of N-methylhex-5-yn-l-amine (500 mg, 4.50 mmol) in MeOH (10 mL) was added $(Boc)_20$ (1.18 g, 5.40 mmol). The reaction mixture was stirred at 25 °C for 17 hrs. On completion, the mixture was concentrated *in vacuo.* The residue was purified by silica gel

chromatography to give the title compound (670 mg, 70% yield) as colorless oil. ^{1}H NMR (400MHz, CDCh) δ 3.22 - 3.11 (m, 2H), 2.77 (s, 3H), 2.20 - 2.12 (m, 2H), 1.88 (t, *J* = 2.4 Hz, 1H), 1.60 - 1.53 (m, 2H), 1.46 - 1.41 (m, 2H), 1.39 (s, 9H).

[002127] **2-[2,6-Dioxo-3-piperidvD-4-[6-[methylamino)hexyllisoindoline-l.,3-dione [Intermediate GN)**



[002128] Step 1 - Tert-butyl N-r6-r2-(2.6-dioxo-3-piperidv0-E3-dioxo-isoindolin-4-vnhex-5-vnyll-N-methyl- carbamate

[002129] 4-Bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (0.60 g, 1.78 mmol, Intermediate FT), Cul (33.9 mg, 178 umol) and Pd(PPh $_3$)2Cl2 (125 mg, 178 umol) was taken up into a microwave tube. Then tert-butyl N-hex-5-ynyl-N-methyl-carbamate (602 mg, 2.85 mmol, Intermediate GM), TEA (3.24 g, 32.0 mmol) and DMF (5 mL) were added into the above tube. The mixture was degassed with N 2 gas for 5 minutes. The sealed tube was heated at 80°C for 30 minutes under microwave. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was purified by reverse phase (0.1% HC1 condition) to give the title compound (720 mg, 78% yield) as a yellow gum. LC-MS (ESI$^+$) *m/z* 490. 1 (M+Na)$^+$.


[002130] Step 2 - Tert-butyl N-r6-r2-(2.6-dioxo-3-piperidvO-L3-dioxo-isoindolin-4-yl]hexyl 1-N-methyl- carbamate

[002131] To a solution of tert-butyl N-[6-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]hex-5-ynyl]-N- methyl-carbamate (720 mg, 1.39 mmol) in THF (8 mL) was added Pd/C (0.2 g, 10 wt%) and $Pd(OH)_2/C$ (0.2 g, 10 wt%). The reaction mixture was stirred at 25 °C for 18 hrs under H_2 (15 Psi). On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (620 mg, 95% yield) as a light yellow solid. LC-MS (ESI^+) *m/z* 494.1 $(M+Na)^+$.

[002132] Step 3 - 2-(2.6-Dioxo-3-piperidvO-4-r6-(methylamino)hexynisoindoline-L3-dione

[002133] To a solution of tert-butyl N-[6-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]hexyl]-N-methyl- carbamate (620 mg, 1.31 mmol) in DCM (4 mL) was added HCl/dioxane (6 mL). The reaction mixture was stirred at 25 °C for 0.5 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (530 mg, 94% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 372.2 $(M+H)^+$.

[002134] **4-[3-AminopropyD-2-[2.,6-dioxopiperidin-3-vDisoindoline-l.,3-dione [Intermediate GO]**



[002135] Step 1 - Tert-butyl (3-(2-(2.6-dioxopiperidin-3-yl)-1.3-dioxoisoindolin-4-yl)prop-2-yn-l-vDcarbamate

[002136] 4-Bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (200 mg, 593 umol, Intermediate FT), tert-butyl *A*-prop-2-ynyl carbamate (CAS#: 92136-39-5) (92.0 mg, 593 umol),

$Pd(PPh_3)2Cl_2$ (41.6 mg, 59.3 umol) and TEA (1.08 g, 10.7 mmol, 1.49 mL) , Cul (11.3 mg, 59.3 umol) were taken up into a microwave tube in DMF (3 mL) under N_2. The reaction mixture was de-gassed with N_2 and then the seal tube was heated to 80 °C for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by silica gel chromatography (PE: EA= 2:1) to give the title compound (200 mg, 73% yield) as a white solid. ^1H NMR (400MHz, CDCh) δ 8.07 (s, 1H), 7.85 (dd, *J* = 1.2, 7.2 Hz, 1H), 7.78 - 7.69 (m, 2H), 5.01 (dd, *J* = 5.2, 12.4 Hz, 1H), 4.94 (s, 1H), 4.28 (d, *J* = 5.2 Hz, 2H), 2.94 - 2.74 (m, 3H), 2.21 - 2.14 (m, 1H), 1.50 (s, 9H); LC-MS (ESI^+) *m/z* 434.0 $(M+Na)^+$.


[002137] Step 2 - Tert-butyl (3-(2-(2.6-dioxopiperidin-3-yl)-1.3-dioxoisoindolin-4-yl)propyl)carbamate

[002138] To a solution of tert-butyl /V-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]prop-2-ynyl] carbamate (200 mg, 433 umol) in THF (20 mL) was added Pd/C (20 mg, 10% *wi)* and $Pd(OH)_2/C$ (20 mg, 10% *wt)* under N_2. The suspension was degassed under vacuum and purged with H_2 gas several times. The mixture was stirred under H_2 (15 Psi) at 25 °C for 12 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (200 mg, 95% yield) as a white solid. LC-MS (ESI^+) *m/z* 438.0 $(M+Na)^+$.

[002139] Step 3 - 4-(3-Aminopropyl)-2-(2.6-dioxopiperidin-3-yl)isoindoline-1.3-dione

[002140] To a solution of tert-butyl /V-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]propyl] carbamate (200 mg, 404 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 5 mL). The mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (142 mg, 100% yield) as a white solid.

[002141] Tert-butyl (4-(4-((3-carbamoyl-l-(4-(methyl(5-oxopentvPcarbamovPphenvP-lH-pyrazol- 4-vPcarbamovPoxazol-2-vPpyridin-2-vP(cvclopropylmethvPcarbamate (Intermediate GP)



GP

[002142] Step 1 - Tert-butyl *(4-(4-((3*-carbamoyl- 1-*(4-((5-* hydroxypentyl)methyl)carbamoyl)phenyl)-1H- pyrazol-4-yl)carbamoyl)oxazol-2-yl)pyridin-2-yl)(cyclopropyl methyl)carbamate


[002143] To a solution of 5-(methylamino)pentan-l-ol (141 mg, 918 umol, HC1, synthesized via Steps 1-2 of Intermediate GI) and 4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carbonyl]amino]-3-carbamoyl-pyrazol-l-yl]benzoic acid (539 mg, 918 umol, Intermediate DF) in DMF (25 mL) was added DIPEA (593 mg, 4.59 mmol, 799 uL). The reaction mixture was stirred at 0.5 hour. Then HATU (384 mg, 1.01 mmol) was added to the reaction mixture. The resulting reaction mixture was stirred

at 25°C for 0.5 hr. On completion, the reaction mixture was concentrated *in vacuo* to give the residue. The residue was purified by prep-HPLC (acidified condition: 0.1%, HC1) to give the title compound (300 mg, 48% yield) as a white solid. ^NMR (400MHz, CDCh) δ 10.97 (s, 1H), 8.91 (s, 1H), 8.58 - 8.49 (m, 1H), 8.42 (s, 1H), 8.36 (s, 1H), 7.84 (d, *J* = 8.8 Hz, 2H), 7.79 (dd, *J* = 1.2, 5.2 Hz, 1H), 7.62 - 7.54 (m, 2H), 6.91 (s, 1H), 5.58 (s, 1H), 3.95 *(d, J* = 7.2 Hz, 2H), 3.73 - 3.71 (m, 1H), 3.63 - 3.61 (m, 2H), 3.33 - 3.31 (m, 1H), 1.75 - 1.59 (m, 2H), 1.59 (s, 9H), 1.54 - 1.50 (m, 2H), 1.31 - 1.18 (m, 3H), 0.50 - 0.40 (m, 2H), 0.34 - 0.25 (m, 2H).

[002144] Step 2 - Tert-butyl (4-(4-((3-carbamoyl-l-(4-(methyl(5-oxopentvDcarbamovDphenvD-lH-pyrazol- 4-v0carbamov0oxazol-2-v0pyri din-2-vOicvclopropylmethvOcarbamate (9) - Notebook Page: EW53 56-822

[002145] To a solution of tert-butyl /V-[4-[4-[[3-carbamoyl-l-[4-[5-hydroxypentyl(methyl)carbamoyl]phenyl] pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-/V-(cyclopropylmethyl)carbamate (300 mg, 437 umol) in DCM (10 mL) was added DMP (371 mg, 874 umol, 270 uL). The reaction mixture was stirred at 25 °C for 5 hrs. On completion, the reaction mixture was quenched with saturated NaS_20_3 (30 mL), and extracted with DCM (3 X 100 mL). The combined organic layer was washed with saturated $NaHC0_3$ (50 mL), then washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (299 mg, 100% yield) as a white solid. LC-MS (ESI^+) *m/z* 685.1 $(M+H)^+$.

[002146] **Tert-butyl N-tert-butoxycarbonyl-N-non-8-ynyl-carbamate [Intermediate GO)**



GQ

[002147] Step 1 - Non-8-ynyl methanesulfonate


[002148] To a mixture of non-8-yn-l-ol (5.00 g, 35.6 mmol, CAS# 10160-28-8) and TEA (10.8 g, 106 mmol, 14.8 mL) in DCM (100 mL) was added MsCl (6.13 g, 53.4 mmol, 4.14 mL). The reaction mixture was stirred at 25 °C for 2 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was diluted with water (10 mL) and extracted with DCM (3 X 10 mL). The combined organic layers was dried over Na_2S0_4, filtered and concentrated *in vacuo*

to give the title compound (7.70 g, 98% yield) as light yellow oil. ^{1}H NMR (400MHz, CDCh) δ 4.23 (t, 7 = 6.4 Hz, 2H), 3.01 (s, 3H), 2.22 - 2.18 (m, 2H), 1.95 (t, 7 = 2.4 Hz, 1H), 1.80 - 1.73 (m, 2H), 1.58 - 1.50 (m, 2H), 1.47 - 1.36 (m, 6H).

[002149] Step 2 - Tert-butyl N-tert-butoxycarbonyl-N-non-8-vnyl-carbamate

[002150] To a mixture of non-8-ynyl methanesulfonate (1.00 g, 4.58 mmol) and tert-butyl N-tert- butoxycarbonylcarbamate (1.49 g, 6.87 mmol, CAS# 51779-32-9) in ACN (10 mL) was added CS2CO3 (4.48 g, 13.7 mmol). The reaction mixture was stirred at 80 °C for 2 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo.* The residue was purified by column chromatography to give the title compound (650 mg, 41% yield) as colorless oil. ^{1}H NMR (400MHz, CDCh) δ 3.59 - 3.53 (m, 2H), 2.22 - 2.12 (m, 2H), 1.94 (t, *J* = 2.4 Hz, 1H), 1.62 - 1.53 (m, 4H), 1.52 (s, 18H), 1.45 - 1.29 (m, 6H).


[002151] **Tert-butyl N-methyl-N-non-8-vnyl-carbamate [Intermediate GR)**



GR

[002152] To a solution of tert-butyl N-methylcarbamate (300 mg, 2.29 mmol, CAS# 16066-84-5) in DMF (10 mL) was added NaH (183 mg, 4.58 mmol, 60% purity) at 0 °C.The mixture was stirred at 25 °C for 2 hours. Then non-8-ynyl methanesulfonate (0.5 g, 2.29 mmol, synthesized via Step 1 of Intermediate GQ) in dry DMF (2 mL) was added at 0°C, and then the mixture was stirred at 25 °C for 5 hours. On completion, the mixture was quenched by addtion H_20 (30 mL), then extracted with EA(3 X 50 mL), and the organic phase was concentrated *in vacuo* to give a residue. The residue was purified by flash silica gel chromatography to give the title compound (410 mg, 70% yield) as colorless oiI.^{1}H NMR (400MHz, DMSO-^e) δ 3.14 (t, *J* = 7.6 Hz, 2H), 2.75 (s, 3H), 2.74 - 2.72 (m, 1H), 2.17 - 2.11 (m, 2H), 1.48 - 1.42 (m, 4H), 1.39 (s, 9H), 1.35 - 1.18 (m, 6H).

[002153] **2-[2,6-Dioxo-3-piperidyO-4-[9-[methylamino)nonyl1isoindoline-l.,3-dione [Intermediate GS1**



[002154] Step 1 - Tert-butyl N-[9-[2-(2,6-dioxo-3-piperidyl)-E3-dioxo-isoindolin-4-yl]non-8-vnyll-N-methyl- carbamate

[002155] 4-Bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (300 mg, 889 umol, Intermediate FT), Cul (16.9 mg, 88.9 umol) and Pd(PPh $_3$)2Cl2 (62.4 mg, 88.9 umol) were taken up into a microwave tube. Then tert-butyl N-methyl-N-non-8-ynyl-carbamate (405 mg, 1.60 mmol, Intermediate GR), TEA (1.62 g, 16.0 mmol, 2.23 mL) and DMF (3 mL) were added into the above tube. The mixture was degassed with N2 for 5 minutes. The sealed tube was heated at 80°C for 30 minutes under microwave. On completion, the mixture was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (380 mg, 77% yield) as a white solid. LC-MS (ESI^+) m/z 532.4 $(M+Na)^+$.

[002156] Step 2 - Tert-butyl N-[9-[2-(2,6-dioxo-3-piperidyl)-E3-dioxo-isoindolin-4-yllnonyll-N-methyl- carbamate

[002157] To a solution of tert-butyl N-[9-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]non-8-ynyl]-N- methyl-carbamate (380 mg, 745 umol) in THF (10 mL) was added Pd(OH)2/C (100 mg, 10 wt%) and Pd/C (100 mg, 10 wt%). The reaction mixture was stirred under Hh (15 psi) at 25 °C for 12 hours. On completion, the residue was filtered and the filtrate was concentrated *in*


vacuo to give the title compound (380 mg, 99% yield) as yellow oil. LC-MS (ESI^+) m/z 536.2 $(M + Na)^+$.

[002158] Step 3- 2-(2.6-Dioxo-3-piperidvO-4-r9-(methylamino)nonvnisoindoline-L3-dione

[002159] To a solution of tert-butyl N-[9-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl] nonyl]-N-methyl -carbamate (380 mg, 739 umol) in DCM (3 mL) was added HCl/dioxane (4 M, 4 mL), and the reaction mixture was stirred at 25 °C for 20 min. On completion, the mixture was concentrated *in vacuo* to give the title compound (330 mg, 99% yield, HC1) as yellow solid. LC-MS (ESI^+) m/z 414.3 $(M+H)^+$.

[002160] **4-[9-Aminononv0-2-[2.,6-dioxo-3-piperidv0isoindoline-l.,3-dione**

[Intermediate G′O



[002161] Step _1_ - Tert-butyl N-tert-butoxycarbonyl-N-r9-r2-(2.6-dioxo-3-piperidyl)-L3-dioxo-isoindolin-4- vl] non-8-ynyl]carbamate

[002162] To a mixture of 4-bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (300 mg, 889 umol, Intermediate FT) and tert-butyl N-tert-butoxycarbonyl-N-non-8-ynyl-carbamate (453 mg, 1.33 mmol, Intermediate GQ) in DMF (5 mL) was added $Pd(PPh_3)2Cl2$ (62.4 mg, 88.9 umol), Cul (16.9 mg, 88.9 umol) and TEA(L62 g, 16.0 mmol, 2.23 mL). The reaction mixture was heated at 80 °C for 30 mins under microwave. On completion, the reaction mixture was concentrated *in*

vacuo. The residue was purified by prep-HPLC (0.1 % FA condition) compound (340 mg, 64% yield) as brown oil. LC-MS (ESI^+) *m/z* 618.4 $(M+Na)^+$.


[002163] Step 2 - Tert-butyl N-tert-butoxycarbonyl-N-[9-[2-(2,6-dioxo-3-piperidyl)-1.3-dioxo-isoindolin-4- yl] nonyl]carbamate

[002164] To a mixture of tert-butyl N-tert-butoxycarbonyl-N-[9-[2-(2,6-dioxo-3-piperidyl)-1.3-dioxo- isoindolin-4-yl]non-8-ynyl]carbamate (440 mg, 738 umol) in THF (5 mL) was added Pd/C (150 mg, 10 wt%) and $Pd(OH)_2/C$ (150 mg, 10 wt%). The reaction mixture was stirred at 25 °C for 1 hour under H_2 (15 Psi) atmosphere. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (442 mg, 99% yield) as white solid. LC-MS (ESI^+) *m/z* 622.5 $(M+Na)^+$.

[002165] Step 3 - 4-(9-Aminononyl)-2-(2,6-dioxo-3-piperidyl)isoindoline-E3-dione

[002166] To a mixture of tert-butyl N-tert-butoxycarbonyl-N-[9-[2-(2,6-dioxo-3-piperidyl)-1.3-dioxo-isoindolin -4-yl]nonyl]carbamate (442 mg, 737 umol) in DCM (3 mL) was added HCl/dioxane (4 M, 5 mL). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (320 mg, 99% yield, HC1) as colourless oil. LC-MS (ESI^+) *m/z* 400.3 $(M+H)^+$.

[002167] 3-[4-[3-[2-aminoethoxy]propyl1-l-oxo-isoindolin-2-yl]piperidine-2,6-dione [Intermediate_GUI



[002168] Step 1-tert-butyl (2-((3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)oxy)ethyl)carbamate

[002169] To a stirred solution of 3-(4-bromo-l-oxoisoindolin-2-yl)piperidine-2,6-dione (0.5 g, 1.551 mmol, Intermediate IR) in DMF (6.0 ml) was added tert-butyl (2-(prop-2-yn-l-yloxy)ethyl)carbamate (0.46 g, 2.32 mmol, Intermediate IU) at rt. The reaction mixture was purged with N_2 gas for 20 min. To this stirred reaction mixture were added CuI (0.014 g, 0.077 mmol), TEA (6.0 ml, 36.09 mmol), $PdCl_2(PPh_3)_2$(0.054 g, 0.0776 mmol) and the mixture was further purged with N_2 gas for 20 min. The reaction mixture was heated at 80 °C for 3 h. The reaction mixture was then poured into water (100 ml) and the product was extracted with ethyl acetate (3 x 100 ml). The combined organic layer dried over anhydrous NaiSCb, filtered and concentrated under vacuum to afford tert-butyl (2-((3-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)prop-2-yn-l-yl)oxy)ethyl)carbamate (0.28 g, 0.64 mmol). LCMS m/z: ES+ 386.17 $(M-55)^+$.

[002170] Step 2 - tert-butyl (2-(3-(2-(2.6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)propoxy)ethyl)carbamate


[002171] To a solution of tert-butyl (2-((3-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)prop-2-yn-l-yl)oxy)ethyl)carbamate (1.5 g, 3.40 mmol) in methanol (50 ml) was added 10 wt%

Pd/C (0.2 g) at it. Hydrogen gas was purged in to the reaction mixture at rt for 4 h. The resulting reaction mixture was filtered over a bed of celite and washed with methanol (50 ml). The obtained filtrate was concentrated under vacuum. The crude material was purified by silica gel flash chromatography (eluting at 4% MeOH in MDC) to afford tert-butyl (2-(3-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)propoxy)ethyl)carbamate (0.6 g, 1.34 mmol). LCMS m/z: ES+ 346.2 (M-99)+. ^{1}H NMR (400 MHz, DMSO-d6) δ 11.01 (s, 1H), 7.58 (dd, J = 5.0, 3.6 Hz, 1H), 7.49 - 7.45 (m, 2H), 6.80 (t, J = 5.7 Hz, 1H), 5.15 (dd, J = 13.2, 5.1 Hz, 1H), 4.47 (d, J = 17.2 Hz, 1H), 4.31 (d, J = 17.1 Hz, 1H), 3.38 (dd, J = 12.9, 6.4 Hz, 7H), 3.08 (q, J = 6.0 Hz, 2H), 2.94 (ddd, J = 17.3, 13.7, 5.4 Hz, 1H), 2.69 (dd, J = 8.9, 6.5 Hz, 2H), 2.66 - 2.56 (m, 1H), 2.42 (td, J = 13.2, 4.5 Hz, 1H), 2.02 (dtd, J = 12.6, 5.3, 2.3 Hz, 1H), 1.83 (p, J = 6.8 Hz, 2H), 1.37 (s, 9H).

[002172] Step 3 - 3-(4-(3-(2-aminoethoxy)propyl)-1-oxoisoindolin-2-yl)piperidine-2.6-dione

[002173] To a solution of tert-butyl N-[2-[3-[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-4-yl]propoxy] ethyl]carbamate (200 mg, 448 umol) in DCM (2.00 mL) was added HCl/dioxane (4 M, 2.00 mL). The mixture was stirred at 20 °C for 0.5 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (170 mg, 80% yield, HC1) as yellow solid. LC-MS (ESI^{+}) *m/z* 346.3 (M+H)$^{+}$.

[002174] **3-[3-[2-[2-(2-aminoethoxy)ethoxylethyll-2-oxo-benzimidazol-l-yllpiperidine-2,6- dione [Intermediate GV1**



GV

[002175] Step 1: tert-butyl (2-(2-(2-(Y2-nitrophenvOamino)ethoxy)ethoxy)ethvOcarbamate

[002176] To a solution of tert-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (15.0 g, 0.060 mol, CAS# 153086-78-3) in DMF (30 mL) was added l-fluoro-2-nitrobenzene (10.2 g, 0.072 mmol), and K2CO3 (25.1 g, 0.182 mmol) at r.t.. The reaction was heated at 60 °C for 3 h. The mixture was quenched with water and extracted with EtOAc (100 ml x 2). The combined organic layer was washed with brine, dried and concentrated *in vacuo*. The residue was purified via column chromatography (petroleum ether / EtOAc = 5% - 80%) to give the desired compound (12.8 g, 57% yield) as a yellow oil.LC-MS (ESI^+): m/z 370.2 $(M+H)^+$.

[002177] Step 2: tert-butyl (2-(2-(2-(Y2-aminophenvPamino)ethoxy)ethoxy)ethvDcarbamate

[002178] To a solution of tert-butyl (2-(2-(2-((2-nitrophenyl)amino)ethoxy)ethoxy)ethyl)carbamate (12.8 g, 34.7 mmol) in MeOH (200 mL) was added Pd/C (720 mg) at r.t.. The reaction mixture was degassed and purged with hydrogen three times. The reaction was stirred at r.t. for 12 hs under hydrogen. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the desired compound (11.2 g, 95% yield) as a yellow oil. LC-MS (ESI^+): m/z 340.2 $(M+H)^+$.

[002179] Step 3: tert-butyl (2-(2-(2-(2-oxo-2.3-dihydro-l H-benzordlimidazol- 1-

vDethoxy)ethoxy)ethvDcarbamate

[002180] To a solution of tert-butyl (2-(2-(2-((2-aminophenyl)amino)ethoxy)ethoxy)ethyl)carbamate (11.2 g, 33.04 mmol) in THF (100 mL) was added CDI (6.5 g, 40.37 mmol) at r.t.. The reaction was stirred at r.t. overnight. The mixture was quenched with water and extracted with EtOAc (100 ml x 2). The combined organic layer was washed with brine, dried and concentrated *in vacuo.* The residue was purified via column chromatography (petroleum ether / EtOAc =5% - 80%) to give the desired compound (3.7 g, 31% yield) as a yellow oil. ^{1}HNMR (400 MHz, DMSO-i&) δ ppm: 10.84 (s, 1H), 7.20 - 7.13 (m, 1H), 7.03 - 6.94 (m, 3H), 6.75 (t, J = 5.5 Hz, 1H), 3.94 (t, J = 5.7 Hz, 2H), 3.66 (t, J = 5.7 Hz, 2H), 3.51 (d, J = 5.3 Hz, 2H), 3.44 (d, J = 5.2 Hz, 2H), 3.32 (t, J = 6.1 Hz, 2H), 3.02 (q, J = 5.9 Hz, 2H), 1.37 (s, 9H).


[002181] Step 4: tert-butyl (2-(2-(2-(3-(1-(4-methoxybenzyl)-2.6-dioxopiperidin-3-yl)-2-oxo-2.3-dihydro-l H-benzordlimidazol- 1-yl)ethoxy)ethoxy)ethyl icarbamate

[002182] To a stirred solution of tert-butyl (2-(2-(2-(2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l-yl)ethoxy)ethoxy)ethyl)carbamate (1.5 g, 4.12 mmol) in THF (300 ml) was added t-BuOK (370 mg, 3.3 mol) at room temperature portion-wise. After addition, the mixture was stirred at room temperature for 2 h. Then the 3-bromo-l-(4-methoxybenzyl)piperidine-2,6-dione (1.9 g, 6.16 mmol) in THF (20 ml) was added dropwise. The mixture was stirred at room temperature for 2 h. Then a second batch of t-BuOK (370 mg, 3.3 mmol) was added portion-wise, and the mixture was stirred for an additional 30 min. Then the mixture was poured into water, and extracted with EtOAc(3 x 200 ml). The combined organic layers were concentrated under reduced pressure, and the residue was purified by column on silica gel eluting with EtOAc : DCM =2:1 to get the title compound (600 mg, 24% yield) as a white solid. ^{1}H NMR (400 MHz, CDCh) δ ppm: 7.36 (m, J = 8.50 Hz, 2 H), 7.17 (d, J = 7.75 Hz, 1 H), 7.08 (t, J = 7.75 Hz, 1 H), 6.94 (t, J = 7.75 Hz, 1 H), 6.83 (m, J = 8.38 Hz, 2 H), 6.50 (d, J = 7.88 Hz, 1 H), 5.23 (dd, J = 13.13, 5.38 Hz, 1 H), 4.96 (d, J = 2.00 Hz, 2 H), 4.09 (t, J = 5.63 Hz, 2 H), 3.74 - 3.86 (m, 5 H), 3.57 - 3.62 (m, 2 H), 3.51 - 3.56 (m, 2 H), 3.41 - 3.49 (m, 2 H), 3.21 - 3.29 (m, 2 H), 2.95 - 3.07 (m, 1 H), 2.77 - 2.89 (m, 1 H), 2.54 - 2.68 (m, 1 H), 2.13 - 2.22 (m, 1 H), 1.46 (s, 9 H). LC-MS (ESI$^+$): m/z 597.0 $(M+H)^+$.

[002183] Step 5: 3-(3-(2-(2-(2-aminoethoxy)ethoxy)ethvD-2-oxo-2.3 -dihydro- 1H-benzord1imidazol-l-vDpiperidine-2.6-dione

[002184] To a solution of tert-butyl (2-(2-(2-(3-(l-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yl)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l-yl)ethoxy)ethoxy)ethyl)carbamate (640 mg, 1.074 mmol) in toluene (5 mL) was added MsOH (2.1 g, 21 mmol). The reaction was heated at 110 °C for 3 h. The reaction mixture was cooled to room temperature, then concentrated under reduced pressure. The residue was poured into ice water, then basified with sat. NaHCCh to pH = 7-8. Then the mixture was purified by prep HPLC eluting with ACN / $H_2$0 (0. 1% HCOOH) = 0% - 10% to give the desired formic acid salt compound as a colorless oil (62 mg, 15% yield). ¾NMR (400 MHz, DMS04) δ ppm: 7.33 (d, J = 7.38 Hz, 1 H), 7.01 - 7.24 (m, 3 H), 5.45 (dd, J = 12.57, 5.07 Hz, 1 H), 4.27-4.54 (m, 2 H), 4.04 - 4.13 (m, 2 H), 3.68 - 3.86 (m, 2 H), 3.61 (br. s., 2 H) 3.34 - 3.58 (m, 4 H), 2.89 - 3.03 (m, 1 H), 2.63 - 2.84 (m, 2 H), 1.98 - 2.18 (m, 1 H) LC-MS (ESI$^+$): m/z 377.0 $(M+H)^+$.

[0021851 4-[3-i2-Aminoethoxv)DroDvll-2-i2,6-dioxo-3-Dineridvl)isoindoline-l,3-dione [Intermediate GW]



[002186] Step _1_ - _Tert-butyl _N-r2-r3-r2-(2.6-dioxo-3-piperidv0-E3-dioxo-isoindolin-4-yllprop-2-vnoxyl ethyl] carbamate

[002187] To a solution of 4-bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (1.95 g, 5.79 mmol, Intermediate FT) and tert-butyl N-(2 -prop-2 -ynoxyethyl)carbamate (1.50 g, 7.53 mmol, synthesized via Step 1 on Intermediate CP) in DMF (10 mL) was added Pd(PPh $_3$)2Cl2 (406 mg, 579 umol), TEA (10.5 g, 104 mmol) and Cul (110 mg, 579 umol). The mixture was heated at 80 °C for 30 minutes under microwave. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE: EA = 1:1) to

give the title compound (1.80 g, 68% yield) as light yellow oil; LC-MS (ESI^+) *m/z* 478.0 $(M+Na)^+$.


[002188] Step_2_-_Tert-butyl_N-[2-[3-[2-(2,6-dioxo-3-piperidyl)-L3-dioxo-isoindolin-4-yllpropoxylethyll carbamate

[002189] To a solution of tert-butyl N-[2-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]prop-2-ynoxy] ethyl]carbamate (1.00 g, 2.20 mmol) in THF (30 mL) was added Pd/C (0.2 g, 10% w/w) and $Pd(OH)_2/C$ (0.2 g, 10% w/w) under N_2. The suspension was degassed under vacuum and purged with H_2 gas three times. The mixture was stirred under H_2 (15 Psi) at 20 °C for 1 hour. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give title compound (600 mg, 60 % yield) as white solid; LC-MS (ESI^+) *m/z* 482.2 $(M+Na)^+$.

[002190] Step 3 - 4-r3-(2-Aminoethoxy)propyl1-2-(2.6-dioxo-3-piperidyl)isoindoline-l.3-dione (7) - Notebook Page: EW5417-748

[002191] To a solution of tert-butyl N-[2-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]propoxy] ethyl]carbamate (200 mg, 435 umol) in DCM (2 mL) was added HCl/dioxane (4 M, 0.8 mL). The mixture was stirred at 20 °C for 2 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (156 mg, 90% yield, HC1 salt) as white solid; LC-MS (ESI^+) *m/z* 360.1 $(M+H)^+$.

[002192] 4-[3-[2-(2-aminoethoxy)ethoxylpropyll-2-(2.,6-dioxo-3-piperidvDisoindoline-1,3-dione [Intermediate_GX1



[002193] Step 1 - Tert-butyl N-[2-[2-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yllprop-2-vnoxyl ethoxylethyllcarbamate

[002194] To a solution of 4-bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (1 g, 2.97 mmol, Intermediate FT) and tert-butyl N-[2-(2-prop-2-ynoxyethoxy)ethyl]carbamate (1.44 g, 5.93 mmol, synthesized via Step 1 of Intermediate CQ) in DMF (8 mL) was added $Pd(PPh_3)_2Cl_2$ (208 mg, 296 umol), TEA (5.4 g, 53.3 mmol, 7.43 mL) and Cul (56.4 mg, 296 umol). The reaction mixture was heated at 80 °C for 30 min under microwave. On completion, the mixture was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (Si02, Petroleum ether/Ethyl acetate=5/l to 1/0, Rf = 0.73) to give the title compound (1.20 g, 72% yield) as yellow solid. LC-MS (ESI^+) m/z 500.1 $(M+H)^+$.

[002195] Step 2 - Tert-butyl N-[2-[2-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yllpropoxylethoxyl ethyllcarbamate


[002196] To a solution of tert-butyl N-[2-[2-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]prop-2- ynoxy]ethoxy]ethyl]carbamate (600 mg, 1.20 mmol) in THF (10 mL) was added Pd/C (300 mg, 1.20 mmol, 10 wt%) and $Pd(OH)_2/C$ (300 mg, 1.20 mmol, 10 wt%). The reaction mixture was stirred at 25°C under H_2 (15 psi) for 12 hours. On completion, the residue

was filtered and the filtrate was concentrated *in vacuo* to give the title compound (600 mg, 99% yield) as yellow oil. LC-MS (ESI^+) m/z 526.4 $(M + Na)^+$.

[002197] Step 3 - 4-r3-r2-(2-aminoethoxy)ethoxy1propyl1-2-(2.6-dioxo-3-piperidvDisoindoline-E3-dione

[002198] To a solution of tert-butyl N-[2-[2-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]propoxy] ethoxy]ethyl]carbamate (600 mg, 1.19 mmol) in DCM (2 mL) was added HCl/dioxane (4 M, 2.00 mL), and the reaction mixture was stirred at 25 °C for 20 minutes. On completion, the mixture was concentrated *in vacuo* to give the title compound (500 mg, 95% yield) as yellow solid. LC-MS (ESI^+) m/z 404.3 $(M+H)^+$.


[002199] **tert-butyl N-[4-[4-[[3-carbamoyl-l-(4- formylphenvPpyrazol-4-yl1carbamoyl1oxazol-2-yl1-2-pyridyl1-N-(2.,2.,2-trifluoroethyPcarbamate (Intermediate GY)**



GY

[002200] Tert-butyl N-[4-[4-[[3-carbamoyl-l-(4- formylphenyl)pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate was synthesized as described below in Step 1 of Example 171.

[002201] **Tert-butyl N-|2-|2-|2-(2-prop-2-vnoxyethoxy)ethoxylethoxylethyl Icarbamate (Intermediate GZ)**




GZ


[002202] To a solution of tert-butyl N-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]carbamate (2.00 g, 6.82 mmol, synthesized via Steps 1-3 of Intermediate AO) and 3-bromoprop-l-yne (973 mg, 8.18 mmol, 705 uL) in THF (30 mL) was added TBAI (151 mg, 409 umol), KI (169 mg, 1.02 mmol), KOH (382 mg, 6.82 mmol). The reaction mixture was stirred at 25 °C for 16 hours. On completion, the mixture was filtered, and the filterate was concentrated *in vacuo* to give a residue. The residue was purified by flash silica gel chromatography to give the title compound (0.85 g, 37% yield) as yellow oil. ^1H NMR


(400MHz, CDCh) δ 5.06 (s, 1H), 4.21 (d, *J* = 2.4 Hz, 2H), 3.72 - 3.61 (m, 14H), 3.54 (t, *J* = 5.2 Hz, 2H), 2.46 - 2.43 (m, 1H), 1.45 (s, 9H).


[002203] **4-13-12-[2-|2-(2-Aminoethoxy)ethoxy| ethoxy] ethoxy] propyl |-2-(2,6-dioxo-3-piperidyl) isoindoline-l,3-dione [Intermediate HA)**



GZ







HA

[002204] Step 1 - Tert-butyl N-[2-[2-[2-[2-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]prop-2-ynoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate

[002205] To a mixture of tert-butyl N-[2-[2-[2-(2-prop-2-ynoxyethoxy)ethoxy]ethoxy]ethyl]carbamate (690 mg, 2.08 mmol, Intermediate GZ) and 4-bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (540 mg, 1.60 mmol, Intermediate FT) in DMF (6 mL) was added $Pd(PPh3)_2Cl2$ (112 mg, 160 umol), CuI (30.5 mg, 160 umol) and TEA

(2.92 g, 28.8 mmol, 4.01 mL). The reaction mixture was heated at 80 °C for 30 minutes under microwave. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (0.1 % FA condition) to give the title compound (580 mg, 61% yield) as light yellow oil. LC-MS (ESI^+) *m/z* 610.4 $(M+Na)^+$.


[002206] Step 2 - Tert-butyl N-[2-[2-[2-[2-[3-[2-(2.6-άϊοχο-3-ρϊρεριάνl)-1.3-άϊοχο-isoindolin-4-yllpropoxyl ethoxy] ethoxy] ethoxy] ethyl] carb amate

[002207] To a mixture of tert-butyl N-[2-[2-[2-[2-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl] prop-2-ynoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate (380 mg, 646 umol) in THF (10 mL) was added $Pd(OH)_2/C$ (150 mg, 10 wt%) and Pd/C (150 mg, 10 wt%). The reaction mixture was stirred at 25 °C for 0.5 hour under H_2 (15 Psi) atmosphere. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (382 mg, 99% yield) as light yellow oil. LC-MS (ESI^+) *m/z* 592.3 $(M+H)^+$.

[002208] Step 3 - 4-r3-r2-r2-r2-(2-Aminoethoxy)ethoxy1ethoxy1ethoxy1propyl1-2-(2.6-dioxo-3-piperidvD isoindoline-L3-dione

[002209] To a mixture of tert-butyl N-[2-[2-[2-[2-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl] propoxy] ethoxy] ethoxy] ethoxy] ethyl] carb amate (382 mg, 645 umol) in DCM (3 mL) was added HCl/dioxane (4 M, 5 mL). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (340 mg, 99% yield, HC1) as light yellow oil. LC-MS (ESI^+) *m/z* 492.3 $(M+H)^+$.

[002210] 3-[4-[3-[2-(2-aminoethoxy)ethoxylpropyll-l-oxo-isoindolin-2-yllpiperidine-2,6-dione [Intermediate HB)



[002211] Step 1 - (2-(2-((3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)oxy)ethoxy)ethyl)carbamate

[002212] To a stirred solution of 3-(4-bromo-l-oxoisoindolin-2-yl)piperidine-2,6-dione (0.3 g, 0.93 mmol, Intermediate IR) in DMF (6.0 ml) was added tert-butyl (2-(2-(prop-2-yn-l-yloxy)ethoxy)ethyl)carbamate (0.34 g, 1.39 mmol, Intermediate IT) at rt. The reaction mixture was purged with N_2 gas for 20 min. To this stirred reaction mixture were added Cul (0.008 g, 0.0465 mmol), TEA (3.2 ml, 22.35 mmol), $PdCl_2(PPh_3)_2$(0.032 g, 0.0465 mmol) and the reaction was further purged with N_2 gas for 20 min. Then the reaction mixture was heated at 80 °C for 3 h. On completion, the reaction mixture was poured into water (100 ml) and product was extracted with ethyl acetate (3 x 100 ml). The combined organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated under vacuum. The crude material was purified by silica gel flash chromatography (eluting at 3% MeOH in MDC) to afford tert-butyl (2-(2-((3-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)prop-2-yn-l-yl)oxy)ethoxy)ethyl)carbamate (0.2 g, 0.4l2mmol). LCMS m/z: (ES+) 508.2 $(M+23)^+$.


[002213] Step 2 - tert-butyl (2-(2-(3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)propoxy)ethoxy)ethyl) carbamate

[002214] To a solution of tert-butyl (2-(2-((3-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)prop-2-yn-l-yl)oxy)ethoxy)ethyl)carbamate (1.4 g, 2.88 mmol) in methanol (50 ml) was added 10 wt% Pd/C (0.2 g) at rt. Hydrogen gas was purged in to the reaction mixture at rt for 4 h. The resulting reaction mixture was filtered over a bed of celite and washed with methanol (50ml). The obtained filtrate was concentrated under vacuum. The obtained crude material was purified by silica gel chromatography (eluting at 4% MeOH in MDC) to afford tert-butyl (2-(2-(3-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)propoxy)ethoxy)ethyl) carbamate (0.8 g, 1.63 mmol). LCMS m/z: ES+ 390.3 $(M-99)^+$. ^1H NMR (400 MHz, DMSO-d6) δ 11.02 (s, 1H), 7.58 (dd, J = 5.3, 3.3 Hz, 1H), 7.51 - 7.42 (m, 2H), 5.15 (dd, J = 13.3, 5.0 Hz, 1H), 4.47 (d, J = 17.2 Hz, 1H), 4.30 (d, J = 17.1 Hz, 1H), 3.49 (td, J = 5.2, 2.9 Hz, 3H), 3.38 (dd, J = 7.0, 4.4 Hz, 6H), 3.06 (q, J = 6.1 Hz, 2H), 3.00 - 2.86 (m, 1H), 2.70 (d, J = 7.8 Hz, 2H), 2.61 (d, J = 17.6 Hz, 2H), 2.42 (d, J = 4.5 Hz, 1H), 2.01 (dd, J = 9.4, 3.7 Hz, 1H), 1.84 (t, J = 7.5 Hz, 2H), 1.36 (d, J = 4.6 Hz, 9H).

[002215] Step 3 - 3-(4-(3-(2-(2-aminoethoxy)ethoxy)propyP-l-oxoisoindolin-2-vDpiperidine-2.6-dione

[002216] To a solution of tert-butyl N-[2-[2-[3-[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-4-yl]propoxy]ethoxy] ethyl]carbamate (200 mg, 408 umol) in DCM (3 mL) was added HCl/dioxane (4 M, 4 mL). The mixture was stirred at 20 °C for 2 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (155 mg, 89% yield) as yellow solid. LC-MS (ESI^+) m/z 390.1 $(M+H)^+$.

[002217] 3-[4-[3-[2-[2-(2-Aminoethoxy)ethoxylethoxylpropyll-l-oxo-isoindolin-2-yl]piperidine-2.,6- dione [Intermediate HC)



[002218] Step_1_- tert-butyl_(2-(2-(2-((3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)oxy)ethoxy)ethoxy)ethyl)carbamate

[002219] To a stirred solution of 3-(4-bromo-l-oxoisoindolin-2-yl)piperidine-2,6-dione (0.5 g, 1.55 mmol, Intermediate IR) in DMF (6.0 ml) was added tert-butyl (2-(2-(2-(prop-2-yn-l-yloxy)ethoxy)ethoxy)ethyl)carbamate(0.6 g, 2.32 mmol, Intermediate IS) at rt. The reaction mixture was purged with N_2 gas for 20 min. To the stirred reaction mixture were added Cul (0.014 g, 0.0776 mmol), TEA (5.5 ml, 37.26 mmol), PdCl2(PPh_3)2 (0.054 g, 0.0776 mmol) and further

purged with N_2 gas for 20 min. The reaction mixture was heated at 80 °C for 3 h. On completion, the reaction mixture was poured into water (200 ml) and product was extracted with ethyl acetate (3 x 200 ml). The combined organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated under vacuum. The crude material was purified by silica gel flash chromatography (eluting at 4% MeOH in MDC) to afford tert-butyl (2-(2-(2-((3-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)prop-2-yn-l-yl)oxy)ethoxy)ethoxy)ethyl)carbamate (0.5 g, 1.0 mmol). LCMs m/z: (ES+) 528.4 (M-l) $^+$.


[002220] Step 2 - tert-butyl (2-(2-(3-(2-(2.6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)propoxy)ethoxy)ethyl) carbamate

[002221] To a solution of tert-butyl (2-(2-(2-((3-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)prop-2-yn-l-yl)oxy)ethoxy)ethoxy)ethyl)carbamate(l.5 g, 2.83 mmol) in methanol (50 ml) was added 10 wt% Pd/C (0. 15g) at rt. Hydrogen gas was purged into the reaction mixture at rt for 4 h. The resulting reaction mixture was filtered over a bed of celite and washed with methanol (50 ml). The obtained filtrate was concentrated under vacuum. The crude material was purified by combi flash chromatography (eluting at 4% MeOH in MDC) to afford tert-butyl (2-(2-(3-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)propoxy)ethoxy)ethyl) carbamate (0.3 g, 0.56 mmol). LCMS m/z: (ES+) 390.3 (M-99)$^+$. ¾ NMR (400 MHz, DMSO-d6) δ 11.03 (s, 1H), 7.58 (dd, J = 5.6, 3.0 Hz, 1H), 7.49 - 7.44 (m, 2H), 6.78 (t, J = 5.8 Hz, 1H), 5.15 (dd, J = 13.3, 5.1 Hz, 1H), 4.47 (d, J = 17.1 Hz, 1H), 4.30 (d, J = 17.2 Hz, 1H), 3.50 (tq, J = 8.2, 2.8 Hz, 8H), 3.05 (q, J = 6.0 Hz, 3H), 2.94 (ddd, J = 17.2, 13.6, 5.4 Hz, 1H), 2.74 - 2.63 (m, 3H), 2.59 (s, 3H), 2.41 (td, J = 13.2, 4.5 Hz, 1H), 2.05 - 1.92 (m, 1H), 1.91 - 1.77 (m, 2H), 1.37 (d, J = 4.5 Hz, 9H).

[002222] Step 3 - 3-r4-r3-r2-r2-(2-Aminoethoxy)ethoxy1ethoxy1propyl1-l-oxo-isoindolin-2-yl1piperidine-2.6- dione

[002223] To a solution of tert-butyl N-[2-[2-[2-[3-[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-4-yl] propoxy]ethoxy]ethoxy]ethyl]carbamate (200 mg, 374 umol) in DCM (2.00 mL) was added HCl/dioxane (4 M, 4.00 mL). The mixture was stirred at 15 °C for 0.5 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (170 mg, 80% yield) as yellow solid. LC-MS (ESI^+) *m/z* 434.3 $(M+H)^+$.

[002224] **1-[2-[2-[2-(2-Aminoethoxy)ethoxy]ethoxy]ethyl]-4-nitro-pyrazole-3-carboxamide (Intermediate HD)**




[002225] Step 1 - Tert-butyl N-r2-r2-r2-r2-(3-carbamoyl-4-nitro-pyrazol-l-yl)ethoxy]ethoxy] ethoxy] ethyl] carbamate

[002226] To a solution of 2-[2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethyl methanesulfonate (6.50 g, 17.5 mmol, Intermediate AO), 4-nitro-lH-pyrazole-3-carboxamide (2.48 g, 15.9 mmol, Intermediate CJ) in DMF (80.0 mL) was added CS2CO3 (10.3 g, 31.8 mmol). The mixture was stirred at 130 °C for 16 hours. On completion, the mixture was filtered and the organic layer was concentrated *in vacuo*. The mixture was purified by reverse phase (0.1% FA) to give the title compound (2.00 g, 29% yield) as yellow solid. LC-MS (ESI^+) *m/z* 454.3 $(M+Na)^+$.

[002227] Step 2 - l-r2-r2-r2-(2-Aminoethoxy)ethoxy1ethoxy1ethyl]-4-nitro-pyrazole-3-carboxamide

[002228] To a solution of tert-butylN-[2-[2-[2-[2-(3-carbamoyl-4-nitro-pyrazol-l-yl)ethoxy] ethoxy] ethoxy] ethyl]carbamate (1.00 g, 2.32 mmol) in DCM (3.00 mL) was added HCl/dioxane (4 M, 5.00 mL). The mixture was stirred at 15 °C for 0.5 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (500 mg, 80% yield, HC1) as yellow oil. ¾NMR (400MHz, MeOD-i¾) δ 8.64 (s, 1H), 4.41 - 4.38 (m, 2H), 3.90 - 3.87 (m, 2H), 3.68 - 3.65 (m, 4H), 3.62 - 3.60 (m, 6H), 3.13 - 3.09 (m, 2H).

[002229] 4-Amino-l-[2-[2-[2-[2-[[2-[2,6-dioxo-3-piperidvn-l,3-dioxo-isoindolin-4-yl]amino]ethoxy]_ethoxy]ethoxy]ethyl]pyrazole-3-carboxamide [Intermediate HE)




[002230] Step 1 - 1-[2-[2-[2-[2-[2-(2,6-Dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yllaminolethoxylethoxyl ethoxy1ethyl1-4-nitro-pyrazole-3-carboxamide

[002231] To a solution of l-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethyl]-4-nitro-pyrazole-3-carboxamide (300 mg, 815 umol, HC1, Intermediate HD), 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (247 mg, 897 umol, Intermediate R) in dioxane (5.00 mL) was added DIPEA (1.05 g, 8.16 mmol), and the mixture was stirred at 115 °C for 16 hours. On completion, the mixture was concentrated *in vacuo.* The mixture was purified by silica gel column (DCM: MeOH = 30: 1) to give the title compound (100 mg, 20% yield) as yellow oil. LC-MS (ESI^+) *m/z* 588.3 $(M+H)^+$.

[002232] Step 2 - 4-Amino-1-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-E3-dioxo-isoindolin-4-yl]amino] ethoxy] ethoxy] ethoxy] ethyl]pyrazol e-3 -carb oxami de

[002233] To a solution of l-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]ethoxy] ethoxy]ethoxy]ethyl]-4-nitropyrazole-3-carboxamide (70.0 mg, 119 umol) in THF (5.00 mL) was added Pd/C (25.0 mg), and the mixture was stirred at 15 °C for 15 min under H_2 (15 psi). On completion, the mixture was filtered. The filtrate was concentrated *in vacuo* to give the title compound (60.0 mg, 90% yield) as yellow solid. LC-MS (ESI^+) *m/z* 558.2 $(M+H)^+$.

[002234] **4-Amino-l-(2-hvdroxyethvDpyrazole-3-carboxamide [Intermediate HF)**



[002235] Step 1 - Ethyl 2-(3-carbamoyl-4-nitro-pyrazol-1-yl)acetate

[002236] To a solution of 4-nitro-lH-pyrazole-3-carboxamide (1.5 g, 9.61 mmol, Intermediate CJ) and ethyl 2-bromoacetate (1.68 g, 10.0 mmol) in DMF (20 mL) was added CS_2CO_3 (3.13 g, 9.61 mmol), the mixture was stirred at 20 °C for 16 hours. On completion, the mixture was filtered to give the filtrate and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography to give the title compound (1.60 g, 68% yield) as white solid. ^{1}HNMR (400MHz, DMSO-^e) δ 8.87 (s, 1H), 8.05 (s, 1H), 7.78 (s, 1H), 5.19 (s, 2H), 4.20 (q, J = 7.2 Hz, 2H), 1.23 (t, J = 7.2 Hz, 3H).

[002237] Step 2 - Ethyl 2-(4-amino-3-carbamoyl-pyrazol-l-vDacetate


[002238] To a solution of ethyl 2-(3-carbamoyl-4-nitro-pyrazol-l-yl)acetate (1 g, 4.13 mmol) in MeOH (40 mL) was added Pd/C (0.3 g, 10% w/w) under N_2. The suspension was degassed under vacuum and purged with H_2 three times. The mixture was stirred under H_2 (15 Psi) at 20 °C for 12 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (780 mg, 89% yield) as white solid. ¾ NMR (400MHz, DMSO-d_6) δ 7.13 (s, 2H), 7.00 (s, 1H), 4.93 (s, 2H), 4.68 (s, 2H), 4.14 (q, J = 7.2 Hz, 2H), 1.20 (t, J = 7.2 Hz, 3H).

[002239] Step 3 - 4-Amino-l-(2-hvdroxyethv0pyrazole-3-carboxamide

[002240] To a solution of ethyl 2-(4-amino-3-carbamoyl-pyrazol-l-yl)acetate (770 mg, 3.59 mmol) in a mixed solvent of THF (120 mL) and MeOH (15 mL) was added L1BH4 (156 mg, 7.18 mmol) at 0 °C, and the mixture was stirred at 0 °C for 1 hour. On completion, the reaction mixture was quenched with water (0.5 mL), and then concentrated *in vacuo* to give a residue. The residue was diluted with water 20 mL, and then extracted with DCM (100 mL X 3). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (600

mg, 98% yield) as white solid. ^{1}H NMR (400MHz, DMSO-^e) δ 7.10 (s, 2H), 6.93 (s, 1H), 4.97 (t, *J* = 5.6 Hz, 1H), 4.61 (s, 2H), 4.01 (t, *J* = 5.6 Hz, 2H), 3.69 (q, *J* = 5.6 Hz, 2H).

[002241] **Tert-butyl N-[4-[4-[[3-carbamoyl-l-(2-oxoethv0pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2- pyridyl]-N-(cyclopropylmethyl)carbamate (Intermediate HG)**



[002242] Step 1 - Tert-butyl N-[4-[4-[[3-carbamoyl-1-(2-hvdroxyethyl)pyrazol-4-yl1carbamoyl1oxazol-2-vH-2- pyridyl1-N-(cvclopropylmethyl)carbamate


[002243] To a solution of 4-amino- 1-(2-hydroxy ethyl)pyrazole-3 -carboxamide (500 mg, 2.94 mmol, Intermediate HF) in DMF (15 mL) was added 2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4- carboxylic acid (844 mg, 2.35 mmol, synthesized via Steps 1-4 of Intermediate DF), DIPEA(l.l4 g, 8.81 mmol) and HATU (1.23 g, 3.23 mmol). The mixture was stirred at 25 °C for 0.5 hour. On completion, the reaction mixture was diluted with water 80 mL, filtered to give the filter cake which was dried *in vacuo* to give the title compound (1.00 g, 67% yield) as light yellow solid; LC-MS (ESI$^+$) *m/z* 512.4 (M+H)$^+$.

[002244] Step 2 - Tert-butyl N-[4-[4-[[3-carbamoyl-1-(2-oxoethvl)pyrazol-4-yl1carbamovnoxazol-2-vn-2- pyridyl1-N-(cvclopropylmethvDcarbamate

[002245] To a solution of tert-butyl N-[4-[4-[[3-carbamoyl-l-(2-hydroxyethyl)pyrazol-4-yl]carbamoyl]oxazol -2-yl]-2-pyridyl]-N-(cyclopropylmethyl)carbamate (300 mg, 486 umol) in THF (50 mL) was added DMP (412 mg, 973 umol), and the mixture was stirred at 10 °C for 16 hours. On completion, the reaction mixture was filtered to give the filtrate, which was then concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (FA condition) to give the title compound (90.0 mg, 33% yield) as light yellow solid; LC-MS (ESI$^+$) *m/z* 528.3

$(M+H+H_20)^+$.

[002246] **1-[2-[2-[2-[3-(2-Aminoethoxy)propoxy1 ethoxy] ethoxy] ethyl]-4-nitro-pyrazole-3- carboxamide [Intermediate HH)**



HH

[002247] Step_ 1 -_ 2-I2-I2-I2-I2-(TerT-butoxycarbonylamino)ethoxy1ethoxy1ethoxy1ethoxy1ethyl methane sulfonate

[002248] To a solution of tert-butyl N-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethyl]carbamate (4.00 g, 11.9 mmol, CAS# 1404111-67-6) and TEA (3.00 g, 29.6 mmol) in DCM (40 mL) was added MsCl (1.77 g, 15.4 mmol) at 0 °C. The reaction mixture was stirred at 25 °C for 2 hours. On completion, the mixture was quenched with water (20 mL), and extracted with DCM. The organic layer was washed with water (50 mL) and brine (50 mL), dried with Na_2S0_4, and filtered. The filtrate was concentrated *in vacuo* to give the title compound (4.65 g, 94% yield) as a yellow solid. ^1H NMR (400MHz, CDCb) δ 5.05 (s, 1H), 4.41 - 4.31 (m, 2H), 3.79 - 3.74 (m, 2H), 3.69 - 3.58 (m, 12H), 3.56 - 3.51 (m, 2H), 3.34 - 3.27 (m, 2H), 3.08 (s, 3H), 1.44 (s, 9H).

[002249] Step 2 - Tert-butyl N-r2-r2-r2-r2-r2-(3-carbamoyl-4-nitro-pyrazol-l-vl)ethoxy]ethoxy] ethoxy] ethoxy] ethyl] carbamate


[002250] To a solution of 2-[2-[2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethoxy]ethyl methanesulfonate (4.59 g, 11.1 mmol) and 4-nitro-lH-pyrazole-3 -carboxamide (1.50 g, 9.61 mmol, Intermediate CJ) in DMF (25 mL) was added CS2CO3 (7.20 g, 22.1 mmol). The reaction mixture was stirred at 125 °C for 15 hours.

On completion, the mixture was filtered and the filtrate was concentrated *in vacuo,* and the residue was purified by reverse phase (0.1% HC1 condition) to give the title compound (1.45 g, 31% yield) as yellow oil. LC-MS (ESI$^+$) *m/z* 498.3 $(M+Na)^+$.

[002251] Step 3 - l-r2-r2-r2-r3-(2-Aminoethoxy)propoxy1ethoxy1ethoxy1ethyl1-4-nitro-pyrazole-3- carboxamide

[002252] To a solution of tert-butyl N-[2-[2-[2-[2-[2-(3-carbamoyl-4-nitro-pyrazol-l-yl)ethoxy] ethoxy] ethoxy] ethoxy]ethyl]carbamate (1.45 g, 2.99 mmol) in DCM (6 mL) was added HCl/dioxane (10 mL). The reaction mixture was stirred at 25 °C for 20 minutes. On completion, the mixture was concentrated *in vacuo* to give the title compound (1.19 g, 94% yield) as yellow oil. ¾NMR (400MHz, DMSO-^e) δ 8.83 (s, 1H), 8.02 (s, 1H), 7.77 (s, 1H), 4.40 - 4.30 (m, 2H), 3.81 (t, *J* = 5.2 Hz, 2H), 3.60 (t, *j* = 5.2 Hz, 2H), 3.56 - 3.53 (m, 8H), 3.49 - 3.46 (m, 4H), 2.98 - 2.91 (m, 2H); LC-MS (ESI$^+$) *m/z* 376.2 $(M+H)^+$.

[002253] **4-Amino-1- [2- [2-[2- 12- 12- 112-(2,6-dio\o-3-piper idyl)- L3-dio\o-isoindolin-4-vHaniinol ethoxylethoxylethoxylethoxylethyllpyrazole-3-carboxamide [Intermediate HI]**



[002254] Step 1 - 1-[2-[2-[2-[2-[2-[[2-(2,6-Dioχo-3-ρiperiάvl)-1,3-άioχo-isθiήάo1ίη-4-yllaminolethoxylethoxyl ethoxy1ethoxy1ethyl1-4-nitro-pyrazole-3-carboxamide


[002255] To a solution of l-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethyl]-4-

nitro-pyrazole-3- carboxamide (0.50 g, 1.21 mmol, HC1, Intermediate HH) and 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (352 mg, 1.27 mmol, Intermediate R) in dioxane (8 mL) was added DIPEA (785 mg, 6.07 mmol). The reaction mixture was stirred at 115 °C for 12 hours. On completion, the mixture was concentrated *in vacuo*. The residue was purified by silica gel chromatography to give the title compound (280 mg, 37% yield) as yellow oil. LC-MS (ESI^+) *m/z* 632.3 $(M+H)^+$.

[002256] Step 2 - 4-Aminο-1-[2-[2-[2-[2-[2-[[2-(2.6-dioxo-3-piperidyl)-1.3-dioxo-isoindolin-4-yl]amino] ethoxylethoxylethoxylethoxylethvHpyrazole-3-carboxamide

[002257] To a solution of l-[2-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]ethoxy] ethoxy]ethoxy]ethoxy]ethyl]-4-nitro-pyrazole-3-carboxamide (140 mg, 222 umol) in THF (5 mL) was added Pd/C (0.3 g, 20% wt). The reaction mixture was stirred at 25 °C for 0.4 hour under H_2 (15 Psi). On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (100 mg, 75% yield) as yellow oil. LC-MS (ESI^+) *m/z* 602.1 $(M+H)^+$.

[002258] **2-[2-[Tert-butoxycarbonylaminoV4-pyridyl1oxazole-4-carboxylic acid (Intermediate HJ)**



HJ

[002259] Step 1 - Ethyl 2-r2-(teit-butoxycarbonylamino)-4-pyridyl1oxazole-4-carboxylate


[002260] Amixture of tert-butyl N-(4-bromo-2-pyridyl)carbamate (1.00 g, 3.66 mmol, CAS# 207799-10-8), ethyl oxazole-4-carboxylate (517 mg, 3.66 mmol, CAS# 170487-38-4), tris-o-tolylphosphane (223 mg, 732 umol), $Pd(OAc)_2$ (82.2 mg, 366 umol) and CS2CO3 (2.39 g, 7.32 mmol) in DMF (10 mL) was degassed and purged with N_2 3 times, and then the mixture was stirred at 70 °C for 17 hrs under N_2 atmosphere. On completion, the mixture was diluted with water (300 mL), and extracted with EA (3 X 200 mL). The organic layer was washed with water (400 mL), dried over Na_2SO_4, filtrated and concentrated *in vacuo* to give the title compound (1.22 g, 50% yield) as a yellow solid. LC-MS (ESI^+) m/z 278.2 $(M+H-56)^+$.

[002261] Step 2 - 2-r2-(Tert-butoxycarbonylamino)-4-pyridyl1oxazole-4-carboxylic acid

[002262] To a solution of methyl 2-[2-(tert-butoxycarbonylamino)-4-pyridyl]oxazole-4-

carboxylate (1.17 g, 3.66 mmol) in MeOH (5 mL) and H_20 (5 mL) was added LiOHH $_20$ (439 mg, 18.3 mmol). The mixture was stirred at 15 °C for 6 hours. On completion, the mixture was concentrated, then 1M HC1 was added to the residue until the pH = 5-6, and then filtered. The filter cake was dried *in vacuo* to give the title compound (400 mg, 28% yield) as a yellow solid. 'H NMR (400MHz, DMSO-de) δ 13.37 (br s, 1H), 10.31 - 10.12 (m, 1H), 9.13 - 8.95 (m, 1H), 8.52 (s, 1H), 8.50 (d, *J* = 5.4 Hz, 1H), 7.63 - 7.58 (m, 1H), 1.69 - 1.53 (m, 9H); LC-MS (ESI^+) m/z 250.2 $(M+H-56)^+$.

[002263] **4-[2-[2-[(2S)-2-(aminomethyl)morpholin-4-yl]ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyP isoindoline-l,3-dione [Intermediate HK)**



HK

[002264] Step 1 - Tert-butyl N-[[(2S)-4-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4- yl]amino] ethoxy1ethyl1morpholin-2-yl1methyl1carbamate


[002265] To a solution of 2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethyl methanesulfonate (460 mg, 1.05 mmol, synthesized via Steps 1-2 of Example 184) and tert-butyl N-[[(2R)-morpholin-2-yl]methyl]carbamate (453 mg, 2.09 mmol, CAS# 186202-57-3) in ACN (15 mL) was added KI (17.4 mg, 105 umol) and NaHCCb (264 mg, 3.14 mmol). The reaction mixture was stirred at 80 °C for 17 hrs. On completion, the mixture was concentrated *in vacuo*. The residue was purified by silica gel chromatography to give the title compound (530 mg, 91% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 560.2 $(M+H)^+$.

[002266] Step 2 - 4-[2-[2-[(2S)-2-(aminomethyl)morpholin-4-yl]ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyD isoindoline-E3-dione

[002267] To a solution of tert-butyl N-[[(2S)-4-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-

isoindolin-4-yl] amino]ethoxy]ethyl]morpholin-2-yl]methyl]carbamate (630 mg, 1.13 mmol) in DCM (6 mL) was added HCl/dioxane (10 mL). The reaction mixture was stirred at 15 °C for 1 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (550 mg, 99% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 460.4 $(M+H)^+$.

[002268] **Methyl 4-nitro-lH-pyrazole-3-carboxylate [Intermediate HIT**




HL


[002269]


[002270] To a solution of 4-nitro-lH-pyrazole-3-carboxylic acid (50.0 g, 318 mmol, CAS#5334-40-7) in MeOH (250 mL) was added $SOCl_2$ (56.8 g, 477 mmol). The mixture was stirred at 70 °C for 5 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (54.0 g, 99% yield) as white solid. ^1H NMR (400MHz, DMSO-de) δ 14.40 (s, 1H), 9.98 (s, 1H), 3.89 (s, 3H).


[002271] **Tert-butyl (cyclopropylmethyl)(4-(4-((l-(4-formylphenyl)-3-(trif uoromethyl)-lH-pyrazol- 4-y0carbamoy0oxazol-2-y0pyridin-2-y0carbamate [Intermediate H1M)**



EG







HM

[002272] Step 1 - 4-(4-(2-(2-(YTert-butoxycarbonvO(cvclopropylmethvOamino)pyridin-4-vOoxazole-4-carboxamido)- 3-(trifluorom ethyl)- !H-pyrazol- 1-vnbenzoic(isopropylcarbonic)anhvdride

[002273] To a solution of 4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4- carbonyl]amino]-3-(trifluoromethyl)pyrazol-l-yl]benzoic acid (700 mg, 960 umol, Intermediate EG) in THF (10 mL) was added TEA (194 mg, 1.92 mmol). Then, the reaction mixture was cooled to -10 °C. After, isopropyl carbonochloridate (235 mg, 1.92 mmol) was added and the reaction mixture was stirred at -10 °C for 2 hours. On completion, the reaction mixture was filtered. The filtrate was concentrated *in vacuo* to give the title compound (720 mg, 91% yield) as white solid. LC-MS (ESI^+) *m/z* 699.0 $(M+H)^+$.

[002274] Step 2 - Tert-butyl (cyclopropylmethvD(4-(4-(n-(4-(hvdroxymethyl)phenyl)-3-


(trifluoromethyO-lH- pyrazol-4-vDcarbamovDoxazol-2-vDpyridin-2-vDcarbamate

[002275] To a solution of isopropoxycarbonyl 4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4- pyridyl]oxazole-4-carbonyl]amino]-3-(trifluoromethyl)pyrazol-l-yl]benzoate (720 mg, 876 umol) in THF (20 mL) was added $NaBH_4$ (66.3 mg, 1.75 mmol) and water (63.1 mg, 3.50 mmol). The residue was mixture was stirred at 0 °C for 1 hour. On completion, the reaction mixture was quenched with water (5 mL) and the mixture was extracted with DCM (3 X 50 mL). The combined organic layer was washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (520 mg, 99 % yield) as a white solid. ¾ NMR (400MHz, CDCh) δ 9.06 (s, 1H), 8.88 (s, 1H), 8.54 (d, *J* = 5.2 Hz, 1H), 8.42 (s, 1H), 8.36 (s, 1H), 7.76 (d, *J* = 8.4 Hz, 2H), 7.64 (d, *J* = 4.8 Hz, 1H), 7.51 (d, *J* = 8.4 Hz, 2H), 4.78 (s, 2H), 3.96 (d, *J* = 7.2 Hz, 2H), 1.59 (s, 9H), 0.93 - 0.81 (m, 1H), 0.47 - 0.42 (m, 2H), 0.30 - 0.26 (m, 2H); LC-MS (ESI^+) *m/z* 599.2 $(M+H)^+$.

[002276] Step 3 - Tert-butyl (cvclopropylmethylX4-(4-((l-(4-formylphenvD-3-(trifluoromethvP-lH-pyrazol- 4-v0carbamov0oxazol-2-v0pyridin-2-v0carbamate

[002277] To a solution of tert-butyl /V-(cyclopropylmethyl)-/V-[4-[4-[[l-[4-(hydroxymethyl)phenyl]-3- (trifluoromethyl)pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (320 mg, 535 umol) in DCM (10 mL) was added DMP (454 mg, 1.07 mmol). The reaction mixture was stirred at 25 °C for 5 hours. On completion, the reaction mixture was quenched with saturated $Na_2S_20_3$ (20 mL), and extracted with DCM (3 X 30 mL). The combined organic layers was washed with saturated $NaHC0_3$ (2 X 20 mL), then washed with brine (30 mL), dried over with anhydrous sodium sulfate, filtered and concentrated *in vacuo.* The residue was purified by prep-HPLC (0.1% HC1) to give the title compound (123 mg, 39% yield) as a white solid. ^1H NMR (400MHz, CDCh) δ 10.08 (s, 1H), 9.08 (s, 1H), 9.01 (d, *J* = 5.2 Hz, 1H), 8.98 (s, 1H), 8.57 (s, 1H), 8.06 (d, *j* = 8.4 Hz, 2H), 7.95 (d, *j* = 8.8 Hz, 2H), 7.45 (s, 1H), 7.39 (s, 1H), 3.35 (s, 2H), 1.67 (s, 9H), 1.15 - 1.05 (m, 1H), 0.78 - 0.76 (m, 2H), 0.45 - 0.44 (m, 2H).

[002278] 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-vDpiperidine-2.,6-dione (3-(5-bromo-3-methyl-2-oxo-2.,3-dihvdro-lH-l.,3-benzodiazol-l-vnpiperidine-2.,6-dione)



[002279] Step 1 - [1-(4-Methoxyphenyl)methyl]-2,6-dioxo-3-piperidyl] trifluoromethanesulfonate

[002280] To a solution of 3-hydroxy-1-[(4-methoxyphenyl) methyl] piperidine-2,6-dione (43.0 g, 173 mmol, Intermediate IQ) and pyridine (27.3 g, 345 mmol) in DCM (500 mL) was added trifluoromethylsulfonyl trifluoromethanesulfonate (73.0 g, 258.74 mmol) dropwise at 0 °C. The mixture was stirred at 0-10 °C for 1.5 hours under N_2. On completion, the mixture was concentrated *in vacuo.* The residue was purified by column chromatography on silica gel to give the title compound (45.0 g, 68% yield) as light yellow gum. ^{1}H NMR (400MHz, CDCh) δ 7.36 (d, *J* = 8.4 Hz, 2H), 6.85 - 6.82 (m, 2H), 5.32 - 5.28 (m, 1H), 4.91 (s, 2H), 3.79 (s, 3H), 3.02 - 2.97 (m, 1H), 2.79 - 2.74 (m, 1H), 2.41 - 2.35 (m, 2H).

[002281] Step 2 - 3-(5-Bromo-3-methyl-2-oxo-benzimidazol-1-yl)-1-[(4-methoxyphenyl)methyl]piperidine-2,6-dione


[002282] To a solution of 5-bromo-3-methyl-1H-benzimidazol-2-one (4.90 g, 21.6 mmol, Intermediate IP) in THF (300 mL) was added t-BuOK (3.63 g, 32.3 mmol) at 0 °C. The mixture was stirred at 0-10°C for 1 hour under N_2. Then a solution of [1-[(4-methoxyphenyl) methyl]-2,6-dioxo-3-piperidyl] trifluoromethanesulfonate (9.87 g, 25.9 mmol) in THF (100 mL) was added to the reaction mixture at 0-10°C during 30 minutes. The mixture was stirred at 0-10°C for 30 minutes under N_2. An additional solution of [1-[(4-methoxyphenyl) methyl]-2,6-dioxo-3-piperidyl] trifluoromethanesulfonate (2.47 g, 6.47 mmol) in THF (20 mL) was added to the reaction mixture

at 0-l0°C dropwise. The mixture was then stirred at 0-l0°C for another 30 minutes under N_2. On completion, the reaction was quenched water (400 mL) and extracted with EA (3 X 200 mL). The combined organic layer was concentrated *in vacuo*. The residue was triturated with EA (80 mL) and filtered. The filter cake was collected and dried *in vacuo* to give the title compound (6.70 g, 67% yield) as light yellow solid. The filtrate was also concentrated *in vacuo* and the residue was purified by column chromatography to give another batch title compound (1.80 g, 18% yield) as light yellow solid. ¾NMR (400MHz, DMSO-7,) δ 7.47 (d, 7 = 1.6 Hz, 1H), 7.21 - 7.16 (m, 3H), 7.01 (d, *J* = 8.0 Hz, 1H), 6.85 (d, *J* = 8.8 Hz, 2H), 5.55 - 5.51 (m, 1H), 4.84 - 4.73 (m, 2H), 3.72 (s, 3H), 3.33 (s, 3H), 3.04 - 3.00 (m, 1H), 2.83 - 2.67 (m, 2H), 2.07 - 2.05 (m, 1H).

[002283] Step 3 - 3-(5-Bromo-3-methyl-2-oxo-benzimidazol-l-vDpiperidine-2.6-dione

[002284] To a mixture of 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)-l-[(4-methoxyphenyl)methyl] piperidine-2, 6-dione (8.50 g, 18.6 mmol) in toluene (50 mL) was added methanesulfonic acid (33.8 g, 351 mmol, 25 mL) at room temperature (15 °C). The mixture was stirred at 120 °C for 2 hours. On completion, the reaction mixture was cooled to room temperature and concentrated *in vacuo*. The residue was poured into ice/water (200 mL), and extracted with EA(3 X 100 mL). The combined organic layer was washed with brine (50 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo*. The residue was triturated with EA (80 mL) and filtered. The filtrate cake was collected and dried in vacuo to give the title compound (4.20 g, 67% yield) as off-white solid. ¾NMR (400MHz, DMSO-7,) δ 11.12 (s, 1H), 7.47 (d, *J* = 2.0 Hz, 1H), 7.22 (d, *J* = 8.4 Hz, 1H), 7.10 (d, *J* = 8.4 Hz, 1H), 5.40 - 5.35 (m, 1H), 2.34 (s, 3H), 2.92 - 2.88 (m, 1H), 2.71 - 2.60 (m, 2H), 2.03 - 1.99 (m, 1H).

[002285] 3-[5-[3-[2-(2-Aminoethoxy)ethoxy]propyl]-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2.,6 -dione [Intermediate HO)



HN HO

[002286] Step 1 - Tert-butyl N-[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl1prop-2- ynoxylethoxylethyllcarbamate

[002287] To a solution of 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (350 mg, 1.04 mmol, Intermediate HN) and tert-butyl N-[2-(2-prop-2-ynoxyethoxy)ethyl]carbamate (629 mg, 2.59 mmol, synthesized via Step 1 of Intermediate CQ) in DMF (10 mL) was added TEA (2.62 g, 25.8 mmol, 3.60 mL), Cul (98.5 mg, 517 umol) and $Pd(PPh_3)_2Cl_2$ (363 mg, 517 umol). The reaction mixture was stirred at 80 °C for 1.5 hours under N_2. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo* to give a residue. The residue was dissolved in DCM (20 mL) and thiourea (resin) (300 mg) was added. The mixture was stirred at 20 °C for 12 hours. Then the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0. 1% FA condition) to give the title compound (208 mg, 40% yield) as yellow solid. LC-MS (ESI^+) m/z 523.3 $(M + Na)^+$. ^1H NMR (400MHz, DMSO-i&) δ 11.13 (s, 1H), 7.34 (d, J = 0.8 Hz, 1H), 7.22 - 7.12 (m, 2H), 6.83 - 6.70 (m, 1H), 5.40 (dd, J = 5.6, 12.8 Hz, 1H), 4.40 (s, 2H), 3.67 - 3.61 (m, 2H), 3.60 - 3.54 (m, 2H), 3.40 (t, J = 6.0 Hz, 2H), 3.35 (s, 3H), 3.08 (q, J = 6.0 Hz, 2H), 2.96 - 2.84 (m, 1H), 2.73 - 2.60 (m, 2H), 2.09 - 2.00 (m, 1H), 1.38 (s, 9H).

[002288] Step 2 - Tert-butyl N-[2-[2-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-


benzimidazol-5-yllpropoxyl ethoxylethyllcarbamate

[002289] To a solution of tert-butyl N-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] prop-2-ynoxy]ethoxy]ethyl]carbamate (100 mg, 199 umol) in THF (10 mL) was added $Pd(OH)_2/C$ (50 mg, 10 wt%) and Pd/C (50 mg, 10 wt%), and the reaction mixture was stirred under H_2 (15 psi) for 1 hr. On completion, the residue was filtered and the filtrate was concentrated *in vacuo* to give the title compound (100 mg, 99.2% yield) as yellow oil. LC-MS (ESI^+) m/z 527.4 $(M + Na)^+$.

[002290] Step 3- 3-r5-r3-r2-(2-Aminoethoxy)ethoxy1propyl1-3-methyl-2-oxo-benzimidazol-l-yllpiperidine-2.6 -dione

[002291] To a solution of tert-butyl N-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] propoxy]ethoxy]ethyl]carbamate (100 mg, 198.19 umol) in DCM (2 mL) was added HCl/dioxane (4 M, 2 mL), and the reaction mixture was stirred at 20 °C for 1 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (85.0 mg, 97% yield) as yellow oil. LC-MS (ESI^+) m/z 405.2$(M+H)^+$. ^1H NMR (400MHz, DMSO-de) δ 7.09 - 6.96 (m, 2H), 6.88 (d, J = 7.6 Hz, 1H), 5.34 (dd, J = 5.2, 12.8 Hz, 1H), 3.57 - 3.49 (m, 6H), 3.41 (t, J = 6.4 Hz, 2H), 3.33 (s, 3H), 2.98 - 2.83 (m, 2H), 2.76 - 2.68 (m, 1H), 2.64 - 2.68 (m, 2H), 2.63 - 2.54 (m, 1H), 2.46 - 2.44 (m, 1H), 2.04 - 1.97 (m, 1H), 1.87 - 1.78 (m, 2H).

[002292] **3-[4-bromo-3-methyl-2-oxo-2,3-dihvdro-lH-benzo[d]imidazol-l-vPpiperidine-2.,6-dione [Intermediate HP]**



[002293] Step 1 - 2-Bromo-N-methyl-6-nitro-aniline

[002294] To a solution of l-bromo-2-fluoro-3-nitro-benzene (40.0 g, 181 mmol, CAS# 58534-94-4) in THF (40 mL) was added $MeNH_2$ (2 M, 400 mL). The reaction mixture was stirred

at 60 °C for 12 hours. On completion, the reaction mixture was poured into sat.$NaHC0_3$ (30 mL) and extracted with EA (3 X 200 mL). The combined organic layers were washed with brine (2 X 200 mL), dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (40.0 g, 95% yield) as red oil. LC-MS (ESI^+) *m/z* 230.9 $(M+H)^+$.

[002295] Step 2 - 3-**B**romo-N2-m ethyl-benzene- L2-diamine

[002296] To a mixture of 2-bromo-N-methyl-6-nitro-aniline (23.0 g, 99.5 mmol) in EA (300 mL) and H_20 (10 mL) was added AcOH (100 mL). The mixture was warmed to 50 °C. Then Fe (22.2 g, 398 mmol) was added to the reaction mixture and the mixture was heated to 80 °C about 4 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo.* The residue was diluted with water (100 mL) and extracted with EA (3 X 200 mL). The combined organic layers was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (20.0 g, 99% yield) as red oil. ^{1}HNMR (400MHz, DMSO-^e) δ 6.73 - 6.70 (m, 1H), 6.68 - 6.60 (m, 2H), 5.02 (s, 2H), 3.67 (s, 1H), 2.58 (s, 3H).

[002297] Step 3 - 4-Bromo-3-methyl-lH-benzimidazol-2-one

[002298] To a mixture of 3-bromo-N2-m ethyl-benzene- 1,2-diamine (20.0 g, 99.4 mmol) in ACN (300 mL) was added CDI (32.2 g, 198 mmol). The reaction mixture was stirred at 85 °C for 12 hours under N_2 atmosphere. On completion, the reaction mixture was concentrated *in vacuo.* The reaction mixture was diluted with water (200 mL), where a solid precipitate was formed, which was filtered off. The solid was washed with water (1 L) and dried *in vacuo* to give the title compound (20.0 g, 88% yield) as white solid. ^{1}H NMR (400MHz, DMSO-^e) δ 11.17 (s, 1H), 7.14 (dd, *J* = 1.2, 8.0 Hz, 1H), 7.00 - 6.95 (m, 1H), 6.93 - 6.87 (m, 1H), 3.55 (s, 3H).

[002299] Step 4 - 3-(4-Bromo-3 -methyl-2-oxo-benzimidazol- 1-v]) - 1-[(4-**methoxyphenyl]methyllpi peri dine- 2.6-dione**


[002300] To a solution of 4-bromo-3-methyl-lH-benzimidazol-2-one (12.0 g, 52.8 mmol) in THF (300 mL) was added t-BuOK (7.12 g, 63.4 mmol). The reaction mixture was stirred at 0 °C for 0.5 hr. Subsequently, [l-[(4-methoxyphenyl)methyl]-2,6-dioxo-3-piperidyl] trifluoromethanesulfonate (20.1 g, 52.8 mmol, Intermediate IQ) in a solution of THF (100 mL) was added dropwise. The resulting reaction mixture was stirred at 20 °C for 0.5 hr under N_2. On completion, the reaction mixture was quenched with saturated NH_4Cl (100 mL), and extracted with ethyl acetate (200 mL). The combined organic layers were washed with brine (2 X 100 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated *in vacuo.* The crude

product was purified by reversed-phase HPLC (0.1% FA condition) to give the title compound (13.3 g, 55% yield) as a yellow solid. ^{1}H NMR (400MHz, CDCh) δ 7.38 (d, *J* = 8.8 Hz, 2H), 7.22 *(d, J* = 8.0 Hz, 1H), 6.84 (d, *J* = 8.8 Hz, 2H), 6.80 (t, *j* = 8.0 Hz, 1H), 6.48 - 6.40 (d, *J* = 8.0 Hz, 1H), 5.22 (dd, *J* = 5.2, 12.8 Hz, 1H), 5.04 - 4.93 (m, 2H), 3.81 (s, 3H), 3.80 (s, 3H), 3.12 - 2.98 (m, 1H), 2.93 - 2.77 (m, 1H), 2.62 (dq, *J* = 4.4, 13.2 Hz, 1H), 2.20 - 2.17 (m, 1H).

[002301] Step 5 - 3-(4-bromo-3-methyl-2-oxo-2.3-dihvdro-lH-benzord1imidazol-l-yl)piperidine-2.6-dione

[002302] A mixture of 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)-l-[(4-methoxyphenyl)methyl]piperidine -2,6-dione (13.3 g, 29.0 mmol) in a mixed solvent of Tol. (80 mL) and methane sulfonic acid (40 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 120 °C for 2 hrs under N_2 atmosphere. On completion, the reaction mixture was concentrated *in vacuo* to remove toluene. The residue was added 200 mL of ice water, and then white solid precipitate formed. The mixture was filtered and the filtered cake was collected and dried over *in vacuo* to give the title compound (7.30 g, 74% yield) as white solid. ^{1}H NMR (400MHz, DMSO-^e) δ 11.13 (s, 1H), 7.25 (d, *j* = 8.0 Hz, 1H), 7.17 (d, *j* = 8.0 Hz, 1H), 7.05 - 6.93 (m, 1H), 5.41 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.64 (s, 3H), 2.96 - 2.83 (m, 1H), 2.78 - 2.59 (m, 2H), 2.08 - 2.00 (m, 1H).

[002303] 3-[4-[3-[2-(2-Aminoethoxy)ethoxylpropyll-3-methyl-2-oxo-benzimidazol-l-yl]piperidine -2,6-dione [Intermediate HQ)



[002304] Step 1 - Tert-butyl N-[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl1prop-2- ynoxylethoxylethyllcarbamate

[002305] To a mixture of 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (100 mg, 295 umol, Intermediate HP) and tert-butyl N-[2-(2-prop-2-ynoxyethoxy)ethyl]carbamate (93.5 mg, 384 umol, synthesized via Step 1 of Intermediate CQ) in DMF (5 mL) was added Cul (5.63 mg, 29.5 umol), Pd(PPh $_3$)2Cl2 (20.7 mg, 29.5 umol) and TEA (538 mg, 5.32 mmol, 740 uL). The reaction mixture was heated at 80 °C for 30 minutes under microwave. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (column: Kromasil l50*25mm*l0um; mobile phase: [water (0.225%FA)-ACN]) to give the title compound (55.0 mg, 34% yield, FA) as brown solid. ^{1}H NMR (400MHz, DMSO-di) δ 11.12 (s, 1H), 7.18 (d, *J* = 7.6 Hz, 1H), 7.13 (d, *J* = 7.6 Hz, 1H), 7.08 - 7.00 (m, 1H), 6.76 (s, 1H), 5.41 (dd, *J* = 4.4, 12.4 Hz, 1H), 4.47 (s, 2H), 3.69 - 3.65 (m, 2H), 3.65 (s, 3H), 3.57 *(d, J* = 4.4 Hz, 2H), 3.40 (t, *J* = 6.0 Hz, 2H), 3.08 (d, *J* = 5.6 Hz, 2H), 2.96 - 2.84 (m, 1H), 2.77 - 2.63 (m, 2H), 2.09 - 1.97 (m, 1H), 1.37 (s, 9H). LC-MS (ESI$^+$) *m/z* 501.4 (M+H)$^+$.

[002306] Step 2 - Tert-butyl N-[2-[2-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-


benzimidazol-4-yllpropoxyl ethoxylethyllcarbamate

[002307] To a mixture of tert-butyl N-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] prop-2-ynoxy]ethoxy]ethyl]carbamate (50.0 mg, 99.8 umol) in THF (4 mL) was added Pd/C (15 mg, 10 wt%) and $Pd(OH)_2/C$ (15 mg, 10 wt%). The reaction mixture was stirred at 25 °C for 1 hour under H_2 (15 Psi) atmosphere. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (50.0 mg, 99% yield) as brown oil. LC-MS (ESI^+) *m/z* 505.4 $(M+H)^+$.

[002308] Step 3 - 3-r4-r3-r2-(2-Aminoethoxy)ethoxy1propyl1-3-methyl-2-oxo-benzimidazol-l-yllpiperidine -2.6-dione

[002309] To a mixture of tert-butyl N-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propoxy]ethoxy]ethyl]carbamate (50.0 mg, 99.0 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 5 mL). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (43.0 mg, 98% yield, HC1) as colourless oil. LC-MS (ESI^+) *m/z* 405.3 $(M+H)^+$.

[002310] **4-[2-[2-[(2R]-2-(aminomethvPmorpholin-4-yllethoxylethylaminol-2-(2.,6-dioxo-3-piperidvD isoindoline-l,3-dione [Intermediate HR]**



HR

[002311] Step 1 - Tert-butyl N-[[(2R)-4-[2-[2-[[2-(2,6-dioxo-3-piperidyl)- 1J-dioxo-isoindolin-4- vl]amino] ethoxy1ethyl1morpholin-2-yl1methyl1carbamate


[002312] To a solution of 2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-

yl]amino]ethoxy]ethyl methanesulfonate (500 mg, 1.14 mmol, synthesized via Steps 1-2 of Example 184), tert-butyl N-[[(2S)-morpholin-2-yl]methyl] carbamate (492 mg, 2.28 mmol, CAS# 875551-59-0) in ACN (20.0 mL) was added KI (18.8 mg, 113 umol) and NaHCOs (286 mg, 3.41 mmol). The mixture was stirred at 80 °C for 16 hrs. On completion, the mixture was concentrated *in vacuo*. The mixture was purified by silica gel column (DCM: MeOH = 50: 1) to give the title compound (400 mg, 62% yield) as yellow solid. ^{1}H NMR (400MHz, CDCb) δ 8.38 - 8.13 (m, 1H), 7.46 - 7.40 (m, 1H), 7.04 (d, *J* = 7.2 Hz, 1H), 6.83 (d, *J* = 8.8 Hz, 1H), 6.43 (s, 1H), 4.94 - 4.81 (m, 2H), 3.80 - 3.72 (m, 1H), 3.67 - 3.54 (m, 6H), 3.41 - 3.34 (m, 2H), 3.34 - 3.18 (m, 1H), 3.07 - 2.94 (m, 1H), 2.84 - 2.75 (m, 2H), 2.73 - 2.66 (m, 2H), 2.61 - 2.49 (m, 2H), 2.21 - 2.09 (m, 1H), 2.08 - 2.01 (m, 1H), 1.95 - 1.85 (m, 1H), 1.69 - 1.55 (m, 1H), 1.36 (s, 9H).

[002313] Step 2 - 4-[2-[2-[(2R)-2-(aminomethyl)morpholin-4-yl1ethoxy1ethylamino1-2-(2,6-dioxo-3-piperidyl) isoindoline-L3-dione

[002314] To a solution of tert-butyl N-[[(2R)-4-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl] amino]ethoxy]ethyl]morpholin-2-yl]methyl]carbamate (380 mg, 679 umol) in DCM (3.00 mL) was added HCl/dioxane (4 M, 5.00 mL). The mixture was stirred at 15 °C for 1 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (330 mg, 95% yield) as yellow solid. LC-MS (ESI$^+$) *m/z* 460.1 (M+H)$^+$.

[002315] **3-[DifluoromethvB-4-nitro-lH-pyrazole [Intermediate HS]**



[002316] Step 1 - l-Benzyl-lH-pyrazole-3-carbaldehyde

[002317] To a solution of lH-pyrazole-3-carbaldehyde (5.00 g, 52.0 mmol, CAS#: 3920-50-1) and BnBr (9.34 g, 54.6 mmol) in DMF (50 mL) was added CS2CO3 (42.4 g, 130 mmol). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was diluted with water, extracted with ethyl acetate (3 X 100 mL). The combined organic layers was washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo*. The crude product was purified by silica gel chromatography (Petroleum ether: Ethyl acetate = 20:1)

to give the title compound (8.00g, 83% yield) as a colorless oil. ^{1}H NMR (400MHz, CDCh) δ 10.02 (s, 1H), 7.44 (d, *J* = 2.4 Hz, 1H), 7.43 - 7.33 (m, 3H), 7.29 - 7.24 (m, 2H), 6.85 (d, *J* = 2.4 Hz, 1H), 5.42 (s, 2H).

[002318] Step 2 - l-Benzyl-3-(difluoromethvD-lH-pyrazole

[002319] To a solution of 1-benzylpyrazole-3-carbaldehyde (5.00 g, 26.9 mmol) in DCM (30 mL) was added DAST (17.3 g, 107 mmol) at 0 °C. The reaction mixture was stirred at 25 °C for 5 hours. On completion, the reaction mixture was quenched with methanol (30 mL) at 0 °C. After, the mixture was concentrated *in vacuo.* The crude product was purified by silica gel chromatography (petroleum ether: ethyl acetate = 20:1) to give the title compound (3.30 g, 59% yield) as a white solid. ^{1}H NMR (400MHz, CDCh) δ 7.43 - 7.36 (m, 3H), 7.27 - 7.21 (m, 2H), 6.91 - 6.57 (m, 1H), 6.55 - 6.51 (m, 1H), 5.35 (s, 2H); LC-MS (ESI$^+$) *m/z* 209.1 (M+H)$^+$.


[002320] Step 3 - 3-(DifluoromethvD-lH-pyrazole

[002321] To a solution of 1-benzyl-3-(difluoromethyl)pyrazole (1.00 g, 4.80 mmol) in methanol (20 mL) was added $Pd(OH)_2/C$ (0.1 g, 10% purity) under N_2 atmosphere. The suspension was degassed and purged with H_2 for 3 times. The mixture was stirred at 40 °C for 12 hrs under H_2 (50 Psi). On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (470 mg, 83% yield) as colorless oil. ^{1}H NMR (400MHz, DMSO-i¾) δ 13.16 (s, 1H), 7.85 (s, 1H), 7.14 - 6.82 (m, 1H), 6.52 (s, 1H).

[002322] Step 4 - 3-(DifluoromethvO-4-nitro-lH-pyrazole

[002323] To a solution of 3-(difluoromethyl)-lH-pyrazole (470 mg, 3.98 mmol) in H_2S0_4 (5 mL) was carefully added a 65% solution of HNO3 (965 mg, 9.95 mmol) dropwise at 0 °C. After stirring for 10 minutes, the reaction mixture was heated to 115 °C, and stirred for 12 hrs. On completion, the reaction mixture was cooled to 25 °C. Then, the reaction mixture was poured onto the (100 mL) ice, extracted with ethyl acetate (3 X 50 mL). The combined organic layers was washed with brine (2 X 50 mL), dried over with anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (530 mg, 82% yield). 'H NMR (400MHz, DMSO-di) δ 14.41 (s, 1H), 9.04 (s, 1H), 7.50 - 7.17 (m, 1H), 7.50 - 7.17 (m, 1H).

[002324] **14-[3-[Difluoromethvn-4-nitro-lH-pyrazol-l-vn-3,6,9,12-tetraoxatetradecan-1-amine [Intermediate HT)**



[002325] Step 1 - Tert-butyl N-r2-r2-r2-r2-r2-r3-(difluoiOmethvD-4-nitro-pyrazol-l-yl]ethoxy] ethoxy] ethoxy] ethoxy] ethyl] carbamate


[002326] To a solution of 3-(difluoromethyl)-4-nitro-lH-pyrazole (200 mg, 1.23 mmol, Intermediate HS) and 2-[2-[2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethoxy]ethyl methanesulfonate (560 mg, 1.35 mmol, synthesized via Step 1 of Intermediate HH) in DMF (5 mL) was added CS2CO3 (799 mg, 2.45 mmol). The reaction mixture was stirred at 130 °C for 12 hrs. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was purified by prep-HPLC (condition: 0.1% HC1) to give the title compound (220 mg, 36% yield) as a yellow oil. ^{1}H NMR (400MHz, DMSO-^e) δ 8.99 (s, 1H), 7.51 - 7.16 (m, 1H), 6.76 (s, 1H), 4.41 (t, *J* = 5.2 Hz, 2H), 3.83 (t, *J* = 5.2 Hz, 2H), 3.61 - 3.44 (m, 13H), 3.61 - 3.44 (m, 1H), 3.05 (q, *J* = 5.6 Hz, 2H), 1.37 (s, 8H); LC-MS (ESI$^+$) *m/z* 505.4 (M+Na)$^+$.

[002327] Step 2 - 14-(3-(DifluoromethvD-4-nitro- 1H-pyrazol- 1-yl)-3.6.9J2-tetraoxatetradecan- 1-amine

[002328] To a solution of tert-butyl N-[2-[2-[2-[2-[2-[3-(difluoromethyl)-4-nitro-pyrazol-l-yl]ethoxy] ethoxy] ethoxy]ethoxy]ethyl]carbamate (220 mg, 456 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 114 uL). The reaction mixture was stirred at 20 °C for 15 min. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (191 mg, 100% yield) as yellow oil. LC-MS (ESI$^+$) *m/z* 383.0 (M+H)$^+$.

[002329] **4-((14-(4-Amino-3-(difluoromethvO-lH-pyrazol-l-vO-3.,6.,9.,12-**

tetraoxatetradecyl]amino]-2- (2,6-dioxopiperidin-3-yl]isoindoline-l ,3-dione [Intermediate HU)




[002330] Step 1 - 4-(Yl4-(3-(DifluoromethvO-4-nitro-lH-pyrazol-l-vO-3. 6.9.12-tetraoxatetradecvPamino)-2- (2.6-dioxopiperidin-3-yl)isoindoline-l ,3-dione

[002331] To a solution of 2-[2-[2-[2-[2-[3-(difluoromethyl)-4-nitro-pyrazol-l-yl] ethoxy] ethoxy] ethoxy] ethoxy] ethanamine (191 mg, 456 umol, Intermediate HT) and 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (139 mg, 502 umol, Intermediate R) in dioxane (10 mL) was added DIPEA (295 mg, 2.28 mmol). The reaction mixture was stirred at 115 °C for 12 hours. On completion, the mixture was concentrated *in vacuo.* The crude product was purified by prep-HPLC (condition: 0.1% HC1) to give the title compound (170 mg, 58% yield) as a yellow oil. ^{1}H NMR (400MHz, DMSO-^e) δ 11.10 (s, 1H), 8.98 (s, 1H), 7.58 (t, J = 7.6 Hz, 1H), 7.45 - 7.18 (m, 1H), 7.14 (d, *J* = 8.4 Hz, 1H), 7.04 (d, *J* = 6.8 Hz, 1H), 6.60 (s, 1H), 5.06 (dd, *J* = 4.8, 13.2 Hz, 1H), 4.43 - 4.37 (m, 2H), 3.82 (t, *J* = 4.8 Hz, 2H), 3.64 - 3.59 (m, 1H), 3.61 (d, *J* = 4.8 Hz, 1H), 3.56 - 3.46 (m, 14H), 2.97 - 2.80 (m, 1H), 2.65 - 2.55 (m, 2H), 2.09 - 1.98 (m, 1H); LC-MS (ESI^{+}) *m/z* 639. 1 (M+H) $^{+}$.

[002332] Step 2 - 4-((l4-(4-Amino-3-(difluoromethvD-lH-pyrazol-l-vD-3. 6.9.12-tetraoxatetradecv0amino)-2- (2.6-dioxopiperidin-3-yl)isoindoline-l ,3-dione

[002333] To a solution of 4-[2-[2-[2-[2-[2-[3-(difluoromethyl)-4-nitro-pyrazol-l-yl]ethoxy]ethoxy]ethoxy] ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (170 mg, 266 umol) in methanol (20 mL) was added Pd/C (0.05 g, 10% wt) under N_2 atmosphere. The suspension was degassed and purged with H_2 for 3 times. The mixture was stirred at 20 °C for 0.5 hr under H_2 (15 Psi). On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (130 mg, 80% yield) as yellow oil. LC-MS (ESI^+) *m/z* 609.1 $(M+H)^+$.


[002334] **4-Fluoro-2-(2-oxo-3-piperidvQisoindoline-l.,3-dione [Intermediate HV**




HV

[002335] To a solution of 4-fluoroisobenzofuran-l,3-dione (661 mg, 3.98 mmol, CAS#652-39-1) ,KOAc (1.21 g, 12.3 mmol) in HOAc (30 mL) was added 3-aminopiperidin-2-one (0.50 g, 4.38 mmol CAS# 1892-22-4). Then the mixture was stirred at 90 °C for 16 hours. On completion, the mixture was concentrated *in vacuo* to give a residue, which was then diluted with water 60 mL, and filtered to give the filter cake (0.60 g, 57% yield) as yellow solid. ^1H NMR (400MHz, DMSO-*ck)* δ 7.97 - 7.86 (m, 2H), 7.79 - 7.66 (m, 2H), 4.60 (dd, *J* = 6.4, 12.0 Hz, 1H), 3.26 - 3.14 (m, 2H), 2.27 - 2.13 (m, 1H), 2.06 - 1.96 (m, 1H), 1.95 - 1.86 (m, 2H).

[002336] **4-(2-AminoethylaminoV2-(2-oxo-3-piperidv0isoindoline-l.,3-dione [Intermediate I1NV)**



HV



HW


[002337] Step 1 - Tert-butyl N-[2-[[1,3-dioxo-2-(2-oxo-3-piperidyl)isoindolin-4-yl]amino]ethyl]carbamate

[002338] To a solution of tert-butyl N-(2-aminoethyl)carbamate (366 mg, 2.29 mmol) in dioxane (20 mL) was added 4-fluoro-2-(2-oxo-3-piperidyl)isoindoline-1,3-dione (0.6 g, 2.29 mmol, Intermediate HV) and DIPEA (1.48 g, 11.4 mmol), and the mixture was stirred at 115 °C for 16 hours. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (360 mg, 39.06% yield) as light yellow oil. ^{1}H NMR (400MHz, DMSO-d) δ 7.81 (s, 1H), 7.55 (t, *J* = 8.0 Hz, 1H), 7.11 (d, *J* = 8.4 Hz, 1H), 7.07 - 6.95 (m, 2H), 6.68 (t, *J* = 5.6 Hz, 1H), 4.50 (dd, *J* = 6.0, 12.6 Hz, 1H), 3.44 - 3.34 (m, 2H), 3.24 - 3.16 (m, 2H), 3.14 - 3.09 (m, 2H), 2.25 - 2.14 (m, 2H), 1.98 - 1.81 (m, 3H), 1.37 (s, 9H).

[002339] Step 2 - 4-(2-Aminoethylamino)-2-(2-oxo-3-piperidyl)isoindoline-1,3-dione

[002340] To a solution of tert-butyl N-[2-[[1,3-dioxo-2-(2-oxo-3-piperidyl)isoindolin-4-yl]amino]ethyl] carbamate (350 mg, 869 umol) in DCM (4 mL) was added HCl/dioxane (4 M, 3 mL). The mixture was stirred at 5 °C for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (280 mg, 91% yield) as yellow solid; LC-MS (ESI$^+$) *m/z* 303.2 $(M+H)^+$.


[002341] **2-(2,6-dioxo-3-piperidyl)-5-fluoro-isoindoline-1,3-dione [Intermediate HX)**



HX

[002342] To a mixture of 3-aminopiperidine-2,6-dione (10.8 g, 65.8 mmol, HC1) and KOAc (18.2 g, 185 mmol) in HOAc (160 mL) was added 5-fluoroisobenzofuran-l,3-dione (9.95 g, 59.9 mmol, CAS# 319-03-9). Then the mixture was stirred at 90 °C for 16 hours. On completion, the reaction mixture was cooled to 25 °C and diluted with water (600 mL), and then stirred at 0 °C for 0.5 hour then filtered. The filter cake was dried *in vacuo* to give the title compound (14.0 g, 84% yield) as black brown solid. ¾NMR (400MHz, DMSO-^e) δ 11.15 (s, 1H), 8.01 (dd, *J* = 4.4, 8.0 Hz, 1H), 7.84 (dd, *J* = 2.4, 7.6 Hz, 1H), 7.76 - 7.67 (m, 1H), 5.17 (dd, *J* = 5.6, 12.8 Hz, 1H), 2.97 - 2.83 (m, 1H), 2.65 - 2.51 (m, 2H), 2.13 - 2.03 (m, 1H).


[002343] **Tert-butyl N-|2-|2-(2-oxoethoxy)ethoxy|ethyl]carbamate [Intermediate HY)**



HY

[002344] To a solution of DMSO (1.57 g, 20.0 mmol) in DCM (20 mL) was added a solution of $(COCl)_2$ (2.04 g, 16.0 mmol) in DCM (15 mL) dropwise at -70 °C. The mixture was stirred at this temperature for 10 minutes. Then a solution of tert-butyl N-[2-[2-(2-hydroxyethoxy)ethoxy]ethyl]carbamate (2 g, 8.02 mmol, CAS# 139115-92-7) in DCM (15 mL) was added into the above mixture slowly. After stirred at -70 °C for 50 minutes, TEA (6.49 g, 64.2 mmol) was added and the reaction mixture was stirred at -70 °C for 0.5 hr. On completion, the mixture was quenched with water (30 mL) and separated. The aqueous phase was extracted with DCM (2 X 30 mL). Then the organic phase was combined and washed with brine (2 X 50 mL), dried over Na_2S0_4, and concentrated *in vacuo* to give the title compound (1.36 g, 69% yield) as yellow oil. ^{1}H NMR (400MHz, DMSO-^e) δ 9.57 (s, 1H), 6.80 - 6.74 (m, 1H), 4.18 (s, 2H), 3.63 - 3.53 (m, 4H), 3.39 - 3.34 (m, 2H), 3.08 - 3.04 (m, 2H), 1.37 (s, 9H).

[002345] **5-[[1-[2-[2-(2-Aminoethoxy)ethoxy| ethyll-4-piperidyl] amino]-2-[2,6-dioxo-3-piperidvP isoindoline-l,3-dione [Intermediate HZ)**



[002346] Step 1 - Tert-butyl 4-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-5-yl]aminopiperidine-1- carboxylate

[002347] To a solution of 2-(2,6-dioxo-3-piperidyl)-5-fluoro-isoindoline-1,3-dione (600 mg, 2.17 mmol, Intermediate HX) and tert-butyl 4-aminopiperidine-1 -carboxylate (522 mg, 2.61 mmol, CAS# 502482-34-0) in DMSO (7 mL) was added DIPEA (1.40 g, 10.8 mmol, 1.89 mL). The reaction mixture was stirred at 130 °C for 1.5 hours. On completion, the mixture was diluted with LEO (10 mL), then filtered and the filtrate was concentrated *in vacuo* to give the title compound (250 mg, 25% yield) as a yellow solid. LC-MS (ESI^+) m/z 479.2 $(M+Na)^+$.

[002348] Step 2 - 2-(2,6-Dioxo-3-piperidyl)-5-(4-piperidylamino)isoindoline-1,3-dione

[002349] To a solution of tert-butyl 4-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-5-yl]amino]piperidine-1- carboxylate (350 mg, 766 umol) in DCM (4 mL) was added HCl/dixoane (4 M, 4 mL). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (300 m g, 99% yield) as a yellow solid. LC-MS (ESI^+) m/z 357.3 $(M+H)^+$.


[002350] Step 3 - Tert-butyl N-[2-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]propoxy]ethyl] carbamate

[002351] To a solution of 2-(2,6-dioxo-3-piperidyl)-5-(4-piperidylamino)isoindoline-l,3-dione (200 mg, 509 umol, HC1) in THF (20 mL) was added TEA (103 mg, 1.02 mmol, 141 uL), the mixture was stirred at 20 °C for 10 mins, then tert-butyl N-[2-[2-(2-oxoethoxy)ethoxy]ethyl]carbamate (163 mg, 661 umol, Intermediate HY), HOAc (91.7 mg, 1.53 mmol, 87.3 uL) and $NaBH(OAc)_3$ (215 mg, 1.02 mmol) was added to the mixture, and the reaction mixture was stirred at 20 °C for 16 hr. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (110 mg, 37% yield) as a yellow solid. LC-MS (ESI^+) m/z 588.1 $(M+H)^+$.

[002352] Step_4_-_5-[[1-r2-r2-(2-Aminoethoxy)ethoxy1ethyl1-4-piperidyl1amino1-2-(2.6-dioxo-3-piperidvD isoindoline-E3-dione

[002353] To a solution of tert-butyl N-[2-[2-[2-[4-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl]amino] -l-piperidyl]ethoxy]ethoxy]ethyl]carbamate (110 mg, l87umol) in DCM (4 mL) was added HCl/dioxane (4 M, 4 mL). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (95.0 mg, 97% yield) as a yellow solid. LC-MS (ESI^+) m/z 488.3 $(M+H)^+$.

[002354] 4-[4-[2-[2-[2-Aminoethoxy]ethoxy1ethyl]piperazin-l-yl1-2-[2,6-dioxo-3-piperidvBisoindoline_-1,3-dione [Intermediate IA)



[002355] Step 1 - Tert-butyl 4-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yllpiperazine- 1-carboxyl ate

[002356] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (500 mg, 1.81 mmol, Intermediate R), and tert-butyl piperazine- l-carboxylate (404 mg, 2.17 mmol, CAS# 143238-38-4) in dioxane (5.00 mL) was added DIPEA (1.17 g, 9.05 mmol). The mixture was stirred at 115 °C for 16 hrs. On completion, the mixture was concentrated *in vacuo*. The mixture was purified by reverse phase chromatography (0.1 % HC1) to give the title compound (270 mg, 33% yield) as yellow solid. LC-MS (ESI^+) *m/z* 465.2 $(M+Na)^+$.

[002357] Step 2 - 2-(2,6-Dioxo-3-piperidyl)-4-piperazin-l-yl-isoindoline-E3-dione

[002358] To a solution of tert-butyl 4-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]piperazine-l -carboxylate (270 mg, 610 umol) in DCM (2.00 mL) was added HCl/dioxane (4.00 M, 3.00 mL). The mixture was stirred at 15 °C for 0.5 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (230 mg, 95% yield, HC1) as a yellow solid. 'H NMR (400MHz, DMSO-^e) δ 11. 12 (s, 1H), 9.22 (s, 1H), 7.80 - 7.74 (m, 1H), 7.49 - 7.39 (m, 2H), 5.16 - 5.08 (m, 1H), 3.53 - 3.48 (m, 4H), 3.33 - 3.19 (m, 4H), 2.95 - 2.83 (m, 1H), 2.70 - 2.61 (m,

1H), 2.59 - 2.53 (m, 1H), 2.10 - 1.97 (m, 1H).


[002359] Step 3 - Tert-butyl N-[2-[2-[2-[4-[2-(2,6-dioxo-3-piperidyl)-L3-dioxo-isoindolin-4-yl1piperazin-l-vn ethoxy] ethoxy] ethyl] carbamate

[002360] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-piperazin-l-yl-isoindoline-l,3-dione (100 mg, 263 umol, HC1), 2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethyl methanesulfonate (86.4 mg, 263 umol, synthesized via Step 1 of Intermediate AM) in ACN (5.00 mL) was added KI (4.38 mg, 26.4 umol) and NaHCCb (66.5 mg, 791 umol). The mixture was stirred at 80 °C for 16 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (100 mg, 60% yield) as yellow solid., LC-MS (ESI^+) *m/z* 574.4 $(M+H)^+$.

[002361] Step 4 - 4-r4-r2-r2-(2-Aminoethoxy)ethoxy1ethyl1piperazin-l-yl1-2-(2.6-dioxo-3-piperidvDisoindoline -L3-dione

[002362] To a solution of tert-butyl N-[2-[2-[2-[4-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl] piperazin-l-yl]ethoxy]ethoxy]ethyl]carbamate (70.0 mg, 122 umol) in DCM (2.00 mL) was added HCl/dioxane (4.00 M, 4.00 mL). The mixture was stirred at 15 °C for 0.5 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (60.0 mg, 80% yield, HC1) as yellow solid. LC-MS (ESI^+) *m/z* 474.3 $(M+H)^+$.

[002363] 5-[4-[2-[2-[2-Aminoethoxy]ethoxy1ethyl]piperazin-l-yl1-2-[2,6-dioxo-3-piperidvPisoindoline -1,3-dione [Intermediate IB]



[002364] Step 1 - Tert-butyl 4-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-5-yl]piperazine-1-carboxylate

[002365] 5-Bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione (0.5 g, 1.48 mmol, Intermediate GA), tert-butyl piperazine-1-carboxylate (552 mg, 2.97 mmol), CS2CO3 (966 mg, 2.97 mmol) and [2-(2-aminophenyl)phenyl]-chloro-palladium;dicyclohexyl-[2-(2,6-diisopropoxyphenyl)phenyl]-phosphane (115 mg, 148 umol, CAS# 1375325-68-0) in dioxane (10 mL) was degassed and then heated to 80 °C for 15 hours under N_2. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo*. The residue was purified by silica gel chromatography to give the title compound (100 mg, 14% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 465.1 $(M+Na)^+$.

[002366] Step 2 - 2-(2,6-Dioxo-3-piperidyl)-5-piperazin-1-yl-isoindoline-1,3-dione

[002367] To a solution of tert-butyl 4-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-5-yl]piperazine-1-carboxylate (70 mg, 142 umol) in DCM (1 mL) was added HCl/dioxane (2 mL). The reaction mixture was stirred at 20 °C for 1 hr. On completion, the mixture was concentrated

in vacuo to give the title compound (53.0 mg, 98% yield, HC1) as a yellow solid. LC-MS (ESI^+) *m/z* 343.1 $(M+H)^+$.


[002368] Step 3 - Tert-butyl N-[2-[2-[2-[4-[2-(2,6-dioxo-3-piperidyl)-L3-dioxo-isoindolin-5-yl1piperazin-l-vn ethoxylethoxylethyllcarbamate

[002369] To a solution of 2-(2,6-dioxo-3-piperidyl)-5-piperazin-l-yl-isoindoline-l,3-dione (53 mg, 140 umol, HC1) and tert-butyl N-[2-[2-(2-oxoethoxy)ethoxy]ethyl]carbamate (45 mg, 182 umol, Intermediate HY) in THF (10 mL) was added KOAc (27.5 mg, 280 umol). One hour later, $NaBH(OAc)_3$ (59.3 mg, 280 umol) was added and the reaction mixture was stirred at 20 °C for 14 hrs. On completion, the mixture was concentrated *in vacuo.* The residue was purified by silica gel chromatography (S1O2) to give the title compound (70 mg, 87% yield) as yellow oil. LC-MS (ESI^+) *m/z* 574.3 $(M+H)^+$.

[002370] Step 4 - 5-r4-r2-r2-(2-Aminoethoxy)ethoxy1ethyl1piperazin-l-yl1-2-(2.6-dioxo-3-piperidvDisoindoline -E3-dione

[002371] To a solution of tert-butyl N-[2-[2-[2-[4-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl] piperazin-l-yl]ethoxy]ethoxy]ethyl]carbamate (90.0 mg, 157 umol) in DCM (2 mL) was added HCl/dioxane (4 mL). The reaction mixture was stirred at 20 °C for 3 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (80 mg, 100% yield, HC1) as a yellow solid. LC-MS (ESI^+) *m/z* 474.2 $(M+H)^+$.

[002372] 5-[[1-[2-[2-(2-Aminoethoxy)ethoxyl ethyl]azetidin-3-yl] amino]-2-[2,6-dioxo-3-piperidvB isoindoline-l,3-dione [Intermediate IQ



IC

[002373] Step 1 - Tert-butyl 3-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-5-yl]amino]azetidine-1-carboxylate

[002374] A mixture of 5-bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione (500 mg, 1.48 mmol, Intermediate GA), tert-butyl 3-aminoazetidine-1-carboxylate (383 mg, 2.22 mmol, CAS# 193269-78-2), Brettphos-G3 (134 mg, 148 umol), and CS2CO3 (1.45 g, 4.45 mmol) in dioxane (50 mL) was degassed and purged with N_2 3 times. Then the mixture was stirred at 90 °C for 2 hours under N_2 atmosphere. On completion, the mixture was concentrated *in vacuo*. The residue was purified by pre-HPLC to give the title compound (90.0 mg, 13% yield) as yellow solid. LC-MS (ESI^+) *m/z* 451.1 $(M+Na)^+$.

[002375] Step 2 - 5-(Azetidin-3-ylamino)-2-(2.6-dioxo-3-piperidyl)isoindoline-1,3-dione

[002376] To a solution of tert-butyl 3-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-5-yl]amino]azetidine-1-carboxylate (100 mg, 233 umol) in THF (5 mL) was added HCl/dioxane (4 M, 5 mL). The mixture was stirred at 20 °C for 2 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (85.0 mg, 99% yield) as yellow solid. LC-MS (ESI^+) *m/z* 329.0 $(M+H)^+$.


[002377] Step 3 - Tert-butyl N-[2-[2-[2-[3-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-5-yl]amino] azetidin- 1-yl]ethoxy] ethoxy] ethyl] carbamate

[002378] To a mixture of 5-(azetidin-3-ylamino)-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (85.0 mg, 233 umol), tert-butyl N-[2-[2-(2-oxoethoxy)ethoxy]ethyl]carbamate (57.6 mg, 233 umol, Intermediate HY) in THF (10 mL) and DMF (10 mL) was added TEA (23.5 mg, 233 umol, 32.4 uL). The reaction mixture was stirred for 0.5 hour. Then HOAc (13.9 mg, 233 umol) and $NaBH(OAc)_3$ (98.7 mg, 466 umol) was added to the reaction mixture, and the mixture was stirred at 20 °C for 48 hours under N_2 atmosphere. On completion, the mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC to give the title compound (60.0 mg, 40% yield) as yellow oil. LC-MS (ESI^+) *m/z* 560.4 $(M+H)^+$.

[002379] Step 4 - 5-ri l-r2-r2-(2-Aminoethoxy)ethoxy1ethyl1azetidin-3-yl1amino1-2-(2.6-dioxo-3-piperidvD isoindoline-E3-dione

[002380] To a solution of tert-butyl N-[2-[2-[2-[3-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl]amino] azetidin-l-yl]ethoxy]ethoxy]ethyl]carbamate (60.0 mg, 107 umol) in THF (5 mL) was added HCl/dioxane (4 M, 4 mL). The mixture was stirred at 25 °C for 2 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (50.0 mg, 95% yield) as yellow solid. LC-MS (ESI^+) *m/z* 460.3 $(M+H)^+$.


[002381] **Tert-butyl N-|2-|2-(2-azidoethoxy)ethoxy Iethyl Icarbamate [Intermediate ID]**



[002382] **1D**

[002383] To a solution of 2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethyl methanesulfonate (2.30 g, 7.03 mmol, synthesized via Step 1 of Intermediate AM) in DMF (20 mL) was added NaN_3 (913 mg, 14.1 mmol). The reaction mixture was stirred at 80 °C for 12 hrs. On completion, the mixture was diluted with water (50 mL), and extracted with DCM (2 X 30 mL). The organic layer was washed with brine (50 mL), dried under N_2 to give the title compound (1.60 g, 83% yield) as yellow oil. LC-MS (ESI^+) *m/z* 297.1 $(M+Na)^+$.

[002384] **4-[[1-[2-[2-(2-Aminoethoxy)ethoxy| ethylltriazol-4-yl] methylaminol-2-12,6-dioxo-3- piperidyBisoindoline-l,3-dione (Intermediate IE)**




[002385] Step 1 - Tert-butyl N-[2-[2-[2-[4-[[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]methyl] triazol-1-yl]ethoxy]ethoxy]ethyl]carbamate

[002386] To a solution of tert-butyl N-[2-[2-(2-azidoethoxy)ethoxy]ethyl]carbamate (348 mg, 1.27 mmol, Intermediate ID), $CuSO_4$ (507 ug, 3.18 umol) and sodium;(2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5- oxo-2H-furan- 3-olate (1.26 mg, 6.36 umol) in a mixed solvent of H_2O (2 mL) and t-BuOH (2 mL) was added 2-(2,6-dioxo-3-piperidyl)-4-(prop-2-ynylamino)isoindoline-1,3-dione (200 mg, 636 umol, Intermediate DN). The reaction mixture was stirred at 60 °C for 2 hours. On completion, the reaction mixture was diluted with water (10 mL) and extracted with EA (20 mL X 3). The combined organic layers dried over Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE/EA=1/1) to give the title compound (0.30 g, 78% yield) as yellow solid. ^1H NMR (400MHz, DMSO-d_6) δ 11.11 (s, 1H), 7.99 (s, 1H), 7.57 (t, J = 7.8 Hz, 1H), 7.18 (d, J = 8.8 Hz, 1H), 7.12 - 7.02 (m, 2H), 6.76 (t, J = 5.2 Hz, 1H), 5.06 (dd, J = 5.2, 12.8 Hz, 1H), 4.60 (d, J = 6.0 Hz, 2H), 4.48 (t, J = 5.2 Hz, 2H), 3.78 (t, J = 5.2 Hz, 2H), 3.52 - 3.38 (m, 4H), 3.33 - 3.28 (m, 2H), 3.03 (q, J=5.6 Hz, 2H), 2.95 - 2.82 (m, 1H), 2.63 - 2.52 (m, 2H), 2.08 - 1.99 (m, 1H), 1.36 (s, 9H); LC-MS (ESI+) *m/z* 586.4 $(M+H)^+$.

[002387] Step 2 - 4-[[1-[2-[2-(2-Aminoethoxy)ethoxy]ethyl]triazol-4-yl]methylamino]-2-(2,6-dioxo-3- piperidyl)isoindoline-1,3-dione

[002388] To a solution of tert-butyl N-[2-[2-[2-[4-[[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino] methyl]triazol-l-yl]ethoxy]ethoxy]ethyl]carbamate (0.30 g, 502 umol) in DCM (6 mL) was added HCl/dioxane (4 M, 2.94 mL). The mixture was stirred at 5 °C for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (0.22 g, 84% yield) as yellow solid. LC-MS (ESI^+) *m/z* 486.3 $(M+H)^+$.


[002389] **2-[2,6-Dioxo-3-piperidvD-5-[prop-2-vnylamino)isoindoline-l.,3-dione [Intermediate IF)**



HX IF

[002390] To a solution of 2-(2,6-dioxo-3-piperidyl)-5-fluoro-isoindoline-l,3-dione (700 mg, 2.53 mmol, Intermediate HX) and prop-2-yn-l -amine (209 mg, 3.80 mmol) in DMSO (10 mL) was added DIPEA (983 mg, 7.60 mmol). The reaction mixture was stirred at 130 °C for 1.5 hours. On completion, the mixture was diluted with water (40 mL), and extracted with DCM (2 X 30 mL). The organic layers were washed with brine (40 mL), and concentrated *in vacuo.* The residue was purified by silica gel chromatography to give the title compound (0.25 g, 27% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 312.2 $(M+H)^+$.

[002391] **5-[[1-[2-[2-[2-Aminoethoxy)ethoxy1 ethyl1triazol-4-yl1 methylamino]-2-[2,6-dioxo-3-piperidvP isoindoline-l,3-dione [Intermediate IG)**



[002392] Step 1 - Tert-butyl N-[2-[2-[2-[4-[[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-5-yl]amino]methyl] triazol-1-yl]ethoxy]ethoxy]ethyl]carbamate


[002393] To a solution of 2-(2,6-dioxo-3-piperidyl)-5-(prop-2-ynylamino)isoindoline-1,3-dione (200 mg, 546 umol, Intermediate IF) and tert-butyl N-[2-[2-(2-azidoethoxy)ethoxy] ethyl]carbamate (300 mg, 1.09 mmol, Intermediate ID) in a mixed solvent of H_2O (3 mL) and t-BuOH (3 mL) was added $CuSO_4$ (872 ug, 5.46 umol) and sodium;(2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2H-furan-3-olate (2.16 mg, 10.9 umol). The reaction mixture was stirred at 60 °C for 2 hrs. On completion, the mixture was diluted with water (30 mL), and extracted with DCM (30 mL). The organic layers were concentrated *in vacuo*. The residue was purified by silica gel chromatography to give the title compound (240 mg, 75% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 586.1 $(M+H)^+$.

[002394] Step 2 - 5-[[1-[2-[2-(2-Aminoethoxy)ethoxy]ethyl]triazol-4-yl]methylamino]-2-(2,6-dioxo-3-piperidyl) isoindoline-1,3-dione

[002395] To a solution of tert-butyl N-[2-[2-[2-[4-[[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-5-yl]amino] methyl]triazol-1-yl]ethoxy]ethoxy]ethyl]carbamate (240 mg, 410 umol) in DCM (2 mL) was added HCl/dioxane (4 mL). The reaction mixture was stirred at 20 °C for 12 hrs. On completion, the mixture was concentrated in *vacuo* to give the title compound (210 mg, 98% yield, HC1) as a yellow solid. LC-MS (ESI^+) *m/z* 486.1 $(M+H)^+$.

[002396] **4-[2-[3-[2-[2-(2-Aminoethoxy)ethoxy]ethyltriazol-4-yl]ethylamino]-2-[2,6-**

dioxo-3-piperidvP isoindoline-l,3-dione (Intermediate IH



[002397] Step 1 - 4-(But-3-vn-l-ylamino)-2-(2,6-dioxopiperidin-3-vPisoindoline-l,3-dione

[002398] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (400 mg, 1.45 mmol, Intermediate R) and but-3-yn-l -amine (120 mg, 1.74 mmol) in dioxane (10 mL) was added DIPEA (561 mg, 4.34 mmol). The reaction mixture was stirred at 115 °C for 12 hrs. On completion, the reaction mixture was concentrated *in vacuo*. The crude product was purified by reversed phase (0. 1% HC1 condition) to give the title compound (230 mg, 49% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-de) δ 11.1 1 (s, 1H), 7.63 - 7.56 (m, 1H), 7.17 (d, *J* = 8.8 Hz, 1H), 7.06 (d, *J* = 7.2 Hz, 1H), 6.72 (t, *J* = 6.0 Hz, 1H), 5.07 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.70 (t, *J* = 7.0 Hz, 1H), 3.48 (q, *J* = 6.8 Hz, 2H), 2.96 - 2.83 (m, 3H), 2.57 - 2.53 (m, 2H), 2.09 - 1.99 (m, 1H); LC-MS (ESI$^+$) *m/z* 326.1 $(M+H)^+$.

[002399] Step 2 - Tert-butyl (2-(2-(2-(5-(2-((2-(2.6-dioxopiperidin-3-yl)-1**3**-dioxoisoindolin-4-vDamino)ethvD- 1H-l .2.3-triazol-l -yl)ethoxy)ethoxy)ethyl icarbamate


[002400] To a solution of 4-(but-3-ynylamino)-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (280 mg, 861 umol) and tert-butyl N-[2-[2-(2-azidoethoxy)ethoxy]ethyl]carbamate (472 mg, 1.72 mmol, Intermediate ID) in THF (5 mL) was added chlororuthenium(l+); 1,2,3,4,5-pentamethylcyclopenta-l,3- diene;triphenylphosphane (13.7 mg, 17.2 umol, CAS: 92361-49-4).

The reaction mixture was stirred at 65 °C for 12 hrs under N_2. On completion, the reaction mixture was filtered and concentrated *in vacuo*. The crude product was purified by silica gel chromatography (EA: ACN = 1:1) to give the title compound (300 mg, 57% yield) as a yellow solid. ^{1}H NMR (400MHz, CDCh) δ 8.40 (s, 1H), 7.57 - 7.52 (m, 1H), 7.57 - 7.52 (m, 1H), 7.28 (s, 1H), 7.16 (d, *J* = 7.2 Hz, 1H), 6.93 (d, *J* = 8.8 Hz, 1H), 6.40 (t, *J* = 5.6 Hz, 1H), 4.92 *(d, J* = 5.6 Hz, 1H), 4.49 (t, *J* = 5.6 Hz, 2H), 3.93 (t, *J* = 5.6 Hz, 2H), 3.65 (q, *J* = 7.2 Hz, 2H), 3.55 - 3.51 (m, 4H), 3.44 (t, *J* = 5.2 Hz, 2H), 3.27 (d, *J* = 4.8 Hz, 2H), 3.11 (t, *J* = *12* Hz, 2H), 2.93 - 2.74 (m, 3H), 2.22 - 2.11 (m, 1H), 1.45 (s, 9H); LC-MS (ESI$^+$) *m/z* 600.1 (M+H)$^+$.

[002401] Step 3 - 4-r2-r3-r2-r2-(2-Aminoethoxy)ethoxy1ethyl1triazol-4-yl1ethylamino1-2-(2.6-dioxo-3-piperidyl) isoindoline-E3-dione

[002402] To a solution of tert-butyl N-[2-[2-[2-[5-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl] amino]ethyl]triazol-l-yl]ethoxy]ethoxy]ethyl]carbamate (300 mg, 500 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 7.50 mL). The reaction mixture was stirred at 20 °C for 0.5 hr. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (268 mg, 100% yield, HC1 salt) as yellow solid. LC-MS (ESI$^+$) *m/z* 500.1 (M+H)$^+$.

[002403] **4-[[1-[2-[2-(2-Aminoethoxy)ethoxyl ethylltriazol-4-yl] methoxy1-2-[2,6-dioxo-3-piperidvD isoindoline-l,3-dione [Intermediate II)**



[002404] Step 1 - 2-(2.6-Dioxo-3-piperidvD-4-prop-2-vnoxy-isoindoline-l.3-dione

[002405] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-hydroxy-isoindoline-l,3-dione (3.00

g, 10.9 mmol, synthesized via Step 1 of Intermediate CA) in DMF (30 mL) was added K_2CO_3 (1.66 g, 12.0 mmol). Then 3-bromoprop-l-yne (1.43 g, 12.0 mmol) was added and the mixture was stirred at 20 °C for 12 hrs. On completion, the mixture was diluted with water (200 mL), stirred and filtered. The filter cake was purified by reverse phase (0.1% HC1 condition) to give the title compound (0.90 g, 26% yield) as a light yellow solid. LC-MS (ESI^+) *m/z* 313.1 $(M+H)^+$.


[002406] Step 2 - Tert-butyl N-[2-[2-[2-[4-[[2-(2,6-dioxo-3-piperidyl)-L3-dioxo-isoindolin-4-yl]oxymethyl] triazol-1-yl]ethoxy] ethoxy] ethyl]carbamate

[002407] To a solution of tert-butyl N-[2-[2-(2-azidoethoxy)ethoxy]ethyl]carbamate (527 mg, 1.92 mmol, Intermediate ID), $CuS0_4$ (1.53 mg, 9.61 umol) and sodium;(2R)-2-[(lS)-l,2-dihydroxyethyl]-4-hydroxy-5-oxo-2H- furan-3-olate (3.81 mg, 19.2 umol) in a mixed solvent of H2O (3 mL) and t-BuOH (3 mL) was added 2-(2,6-dioxo-3-piperidyl)-4-prop-2-ynoxy-isoindoline-l,3-dione (300 mg, 961 umol). The reaction mixture was stirred at 60 °C for 2 hrs. On completion, the mixture was diluted with H2O (20 mL), and extracted with EA (2 X 30 mL). The organic layer was washed with brine (50 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by silica gel chromatography to give the title compound (460 mg, 82% yield) as a white solid. LC-MS (ESI^+) *m/z* 587.3 $(M+H)^+$.

[002408] Step 3 - 4-ri l-r2-r2-(2-Aminoethoxy)ethoxy1ethyl1triazol-4-yl1methoxy1-2-(2.6-dioxo-3-piperidyl) isoindoline-L3-dione

[002409] To a solution of tert-butyl N-[2-[2-[2-[4-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl] oxymethyl]triazol-l-yl]ethoxy]ethoxy]ethyl]carbamate (105 mg, 179 umol) in DCM (2 mL) was added HCl/dioxane (3 mL). The reaction mixture was stirred at 20 °C for 1 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (93.0 mg, 99% yield, HC1) as a white solid. LC-MS (ESI^+) *m/z* 487.2 $(M+H)^+$.

[002410] 4-12-13-[2-[2-(2-Aminoethoxy)ethoxy]ethyl1triazol-4-yl1 ethoxy1-2-[2,6-dioxo-3-piperidyP isoindoline-l,3-dione [Intermediate IJ)



[002411] Step 1 - 4-But-3-vnoxy-2-(2,6-dioxo-3-piperidyl)isoindoline- l,3-dione

[002412] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-hydroxy-isoindoline-l,3-dione (1 g, 3.65 mmol, synthesized via Step 1 of Intermediate CA) and but-3-yn-l-ol (307 mg, 4.38 mmol, CAS# 927-74-2) in THF (10 mL) was added PPh_3 (1.43 g, 5.47 mmol). Then a solution of DIAD (1.47 g, 7.29 mmol, 1.42 mL, 2.0 *eq*) in THF (10 mL) was added into the above mixture dropwise at 0 °C. The reaction mixture was stirred at 20 °C for 12 hrs. On completion, the mixture was concentrated *in vacuo*. The residue was purified by reverse phase (0.1% HC1 condition) to give the title compound (0.7 g, 59% yield) as an off-white solid. 'H NMR (300MHz, DMSO-c#) δ 11.12 (s, 1H), 7.86 - 7.76 (m, 1H), 7.54 (d, *J* = 8.4 Hz, 1H), 7.47 (d, *J* = 7.2 Hz, 1H), 5.08 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.31 (t, *J* = 6.8 Hz, 2H), 2.92 (t, *j* = 2.8 Hz, 1H), 2.90 - 2.80 (m, 1H), 2.75 - 2.66 (m, 2H), 2.64 - 2.52 (m, 2H), 2.09 - 1.97 (m, 1H).

[002413] Step 2 - Tert-butyl N-[2-[2-[2-[5-[2-(2.6-άioχo-3-ρίρeΓidάvl)-1.3-άioχo-isoindolin-4-vnoxyethvn triazol-l-yl1ethoxy1ethoxy1ethyl1carbamate


[002414] To a solution of 4-but-3-ynoxy-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (0.25 g, 766 umol) and tert-butyl N-[2-[2-(2-azidoethoxy)ethoxy]ethyl]carbamate (420 mg, 1.53 mmol, Intermediate ID) in THF (8 mL) was added chlororuthenium(l+);l,2,3,4,5-pentamethylcyclopenta-l,3- diene;triphenylphosphane (30.5 mg, 38.3 umol, CAS# 92361-49-4). The reaction mixture was stirred at 65 °C for 15 hrs. On completion, the mixture was concentrated

in vacuo. The residue was purified by silica gel chromatography (SiO_2) to give the title compound (330 mg, 68% yield) as a white solid. LC-MS (ESI^+) *m/z* 601.2 $(M+H)^+$.

[002415] Step 3 - 4-[2-[3-[2-[2-(2-Aminoethoxy)ethoxy1ethyl1triazol-4-yl1ethoxy1-2-(2,6-dioxo-3-piperidyD isoindoline-L3-dione

[002416] To a solution of tert-butyl N-[2-[2-[2-[5-[2-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl] oxyethyl]triazol-l-yl]ethoxy]ethoxy]ethyl]carbamate (330 mg, 522 umol) in DCM (2 mL) was added HCl/dioxane (4 mL). The reaction mixture was stirred at 20 °C for 12 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (280 mg, 100% yield, HC1) as an off-white solid. LC-MS (ESI^+) *m/z* 501.1 $(M+H)^+$.

[002417] **2-12-11tbenzyloxylcarbonvDaminolethoxylethyl _ methanesulfonate tlntermediate IK)**



IK


[002418] Step 1 - Benzyl N-r2-(2-hydroxyethoxy)ethyl1 carbamate

[002419] To a solution of 2-(2-aminoethoxy)ethanol (5.00 g, 47.5 mmol, 4.76 mL, CAS# 929-06-6) and NaHCOs (11.9 g, l42mmol, 5.55 mL) in MeCN (50 mL) and H_20 (50 mL) was added CbzCl (9.74 g, 57.07 mmol, 8.11 mL) dropwise at 0 °C. The reaction mixture was stirred at 20 °C for 12 hours. On completion, the mixture was filtered, the filtrate was extracted with EA (2 X 100 mL), and the organic phase was concentrated *in vacuo* to give a residue. The residue was purified by flash silica gel chromatography to give the title compound (10.0 g, 87.9% yield) as yellow oil. ^1H NMR (400MHz, CDCh) δ 7.38 - 7.29 (m, 5H), 5.55 (s, 1H), 5.10 (s, 2H), 3.73 - 3.69 (m, 2H), 3.57 - 3.51 (m, 4H), 3.40 (q, *J* = 5.2 Hz, 2H), 2.84 (s, 1H).


[002420] Step 2 - 2-f2-fffbenzyloxy)carbonv0amino)ethoxy)ethyl methanesulfonate (3) - Notebook Page: EW5765-602, EW5765-605

[002421] To a solution of benzyl N-[2-(2-hydroxyethoxy)ethyl]carbamate (1 g, 4.18 mmol) and TEA (1.27 g, 12.5 mmol, 1.75 mL) in DCM (10 mL) was added MsCl (574 mg, 5.02 mmol, 388 uL) at 0 °C. The reaction mixture was stirred at 20 °C for 1 hour. On completion, the mixture was quenched with the addition of H_20 (30 mL), then exacted with DCM (2 X 50 mL). The organic phase was concentrated *in vacuo* to give a title compound (1.30 g, 98% yield) as yellow oil. LC-MS (ESI^+) m/z 318.2 $(M+H)^+$.

[002422] **Benzyl N-[2-(2-piperazin-l-ylethoxy)ethyl]carbamate [Intermediate IL)**



IK



IL


[002423] Step 1 - tert-butyl 4-(2-(2-(((benzyloxy)carbonvnamino)ethoxy)ethvnpiperazine-l-carboxylate

[002424] To a solution of 2-[2-(benzyloxycarbonylamino)ethoxy]ethyl methanesulfonate (6.6 g, 20.8 mmol) and tert-butyl piperazine- l-carboxylate;hydrochloride (4.49 g, 17.3 mmol, HC1, CAS# 57260-71-6) in MeCN (100 mL) was added KI (287 mg, 1.73 mmol) andNaHCOs (4.37 g, 51.9 mmol, 2.02 mL). The reaction mixture was stirred at 80 °C for 16 hours. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (5.00 g, 71% yield) as yellow oil. ¾NMR (400MHz, CDCh) δ 7.39 - 7.28 (m, 5H), 5.58 (s, 1H), 5.30 (s, 1H), 5.10 (s, 2H), 3.58 (t, *J* = 5.6 Hz, 2H), 3.56 - 3.50 (m, 2H), 3.47 - 3.33 (m, 6H), 2.55 (t, *J* = 5.6 Hz, 2H), 2.42 (m, *J* = 4.8 Hz, 4H), 1.46 (s, 9H).


[002425] Step 2 - Benzyl N-r2-(2-piperazin-l-ylethoxy)ethyl1carbamate

[002426] To a solution of tert-butyl 4-[2-[2-(benzyloxycarbonylamino)ethoxy]ethyl]piperazine-l-carboxylate (5.00 g, 12.2 mmol) in DCM (10 mL) was added HCl/dioxane (4 M, 25 mL). The reaction mixture was stirred at 25 °C for 3 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (3.80 g, 90% yield) as a yellow solid. LC-MS (ESI^+) m/z 308.3 $(M+H)^+$.

[002427] Tert-butyl N-[2-[2-[4-[2-(2-aminoethoxy)ethyl]piperazin-l-yllethoxylethyllcarbamate (Intermediate IM)



IL



IM


[002428] Step 1 - Tert-butyl N-[2-[2-[4-[2-[2-(benzyloxycarbonylamino)ethoxylethyllpiperazin-l-yllethoxyl ethyllcarbamate

[002429] To a solution of benzyl N-[2-(2-piperazin-l-ylethoxy)ethyl]carbamate (2.00 g, 6.51 mmol, Intermediate IL) in THF (50 mL) was added TEA (1.32 g, 13.0 mmol, 1.81 mL). The mixture was stirred at 25 °C for 30 min, then tert-butyl N-[2-(2-oxoethoxy)ethyl]carbamate (1.85 g, 9.11 mmol, synthesized via Step 1 of Intermediate FS), HOAc (1.17 g, 19.5 mmol, 1.12 mL) and $NaBH(OAc)_3$ (2.76 g, 13.0 mmol) was added in the mixture. The reaction mixture was stirred at 25 °C for 24 hours. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (2.00 g, 62% yield) as yellow oil. LC-MS (ESI^+) m/z 495.4 $(M+l)^+$.

[002430] Step 2 - Tert-butyl N-r2-r2-r4-r2-(2-aminoethoxy)ethyl1piperazin-l-yllethoxylethyllcarbamate

[002431] To a solution of tert-butyl N-[2-[2-[4-[2-[2-(benzyloxycarbonylamino)ethoxy]ethyl]piperazin-l-yl] ethoxy]ethyl]carbamate (1.00 g, 2.02 mmol) in THF (5 mL) was added Pd/C (500 mg, 202 umol, 10 wt %). The reaction mixture was stirred at 20 °C under H_2 (15 psi) for 24 hours. On completion, the residue was filtered and the filtrate was concentrated *in vacuo* to give the title compound (600 mg, 82% yield) as colorless oil. LC-MS (ESI^+) m/z 361.3 $(M + H)^+$.

[002432] **4-12-12-14-|2-(2-Aminoethoxy)ethyl| piperazin-l-yl] ethoxy] ethylamino 1-2-12,6-dioxo-3- piperidvBisoindoline-l,3-dione [Intermediate IN**



[002433] Step 1 - Tert-butyl N-[2-[2-[4-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino] ethoxylethyllpiperazin-l-yllethoxylethyllcarbamate


[002434] To a solution of tert-butyl N-[2-[2-[4-[2-(2-aminoethoxy)ethyl]piperazin-l-yl]ethoxy]ethyl]carbamate (300 mg, 832 umol, Intermediate IM) and 2-(2,6-dioxo-3 -piped dyl)-4-fluoro-isoindoline-l,3-dione (229 mg, 832 umol, Intermediate R) in DMSO (10 mL) was added DIPEA (537 mg, 4.16 mmol, 724 uL). The reaction mixture was stirred at 90 °C for 2 hours. On completion, the mixture was diluted with H_20 (30 mL), then extracted with DCM (2 X 60 mL). The combined organic phase was washed with brine, and then concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (200 mg, 39% yield) as a yellow solid. LC-MS (ESI+) m/z 617.4 $(M+H)^+$.

[002435] Step 2 - 4-r2-r2-r4-r2-(2-Aminoethoxy)ethyl1piperazin-l-yl1ethoxy1ethylamino1-2-(2.6-dioxo-3- piperidvDisoindoline-L3-dione

[002436] To a solution of tert-butyl N-[2-[2-[4-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl] amino]ethoxy]ethyl]piperazin-l-yl]ethoxy]ethyl]carbamate (200 mg, 324 umol) in DCM (4 mL) was added HCl/dioxane (4 M, 4 mL), and the reaction mixture was stirred at 25 °C for 1 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (150 mg, 83% yield) as a yellow solid. LC-MS (ESI^+) m/z 517.3 $(M+H)^+$.

[002437] **4- [2-[2- [6- [2-[2-Aminoethoxy)ethyl]-2,6-diazaspiro [3.31 heptan-2-**

yl]ethoxy]ethylamino] -2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione (Intermediate IO)



[002438] Step 1 - Tert-butyl 6-[2-[2-[[2-(2,6-dioxo-3-piperidyl) -E3-dioxo-isoindolin-4-yl]amino] ethoxy] ethyl1-2.6-diazaspiror3.31heptane-2-carboxylate

[002439] To a solution of tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate (0.40 g, 1.70 mmol, HC1, CAS# 1041026-70-3) and 2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethyl methanesulfonate (899 mg, 2.04 mmol, synthesized via Steps 1-2 of Example 184) in CEECN (80 mL) was added NaHCO3 (429 mg, 5.11 mmol). The mixture was stirred at 80 °C for 6 hr. On completion, the mixture was concentrated. The residue was purified by flash silica gel chromatography (DCM: MeOH = 10:1) to give the title compound (0.80 g, 69% yield, 80% purity) as a yellow solid. LC-MS (ESI^+) *m/z* 542.4 $(M+H)^+$.

[002440] Step 2 - 4-[2-[2-(2,6-Diazaspiro[3.3]heptan-2-vl)ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidvD isoindoline-E3-dione

[002441] To a solution of tert-butyl 6-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino] ethoxy]ethyl]-2,6-diazaspiro[3.3]heptane-2-carboxylate (0.80 g, 1.48 mmol) in DCM (50 mL) was added TFA (6. 16 g, 54.0 mmol). The mixture was stirred at 15 °C for

5 min. On completion, the mixture was concentrated. The crude product was purified by reversed-phase chromatography (0.1% FA condition) to give the title compound (0.34 g, 47% yield, FA salt) as a yellow solid. LC-MS (ESI^+) *m/z* 442.3 $(M+H)^+$.


[002442] Step 3 - Tert-butyl N-[2-[2-[6-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethyl]-2,6-diazaspiro[3.3]heptan-2-yl]ethoxy]ethyl]carbamate

[002443] To a solution of 4-[2-[2-(2,6-diazaspiro[3.3]heptan-2-yl)ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl) isoindoline-1,3-dione (0.29 g, 595 umol, FA) and tert-butyl N-[2-(2-oxoethoxy)ethyl]carbamate (363 mg, 1.78 mmol, synthesized via Step 1 of Intermediate FS) in DCM (1 mL) and THF (1 mL) was added Et_3N (181 mg, 1.78 mmol) and AcOH (71.5 mg, 1.19 mmol) and then added $NaBH(OAc)_3$ (252 mg, 1.19 mmol). The mixture was stirred at 15 °C for 6 hrs. On completion, the mixture was concentrated. The crude product was purified by reversed-phase chromatography (0.1% FA condition) to give the title compound (0.32 g, 68% yield, 80% purity) as a yellow solid. LC-MS (ESI^+) *m/z* 629.4 $(M+H)^+$.

[002444] Step 4 - 4-[2-[2-[6-[2-(2-Aminoethoxy)ethyl]-2,6-diazaspiro[3.3]heptan-2-yl]ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione

[002445] To a solution of tert-butyl N-[2-[2-[6-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethyl]-2,6-diazaspiro[3.3]heptan-2-yl]ethoxy]ethyl]carbamate (0.22 g, 350 umol) in DCM (2 mL) was added TFA (39.9 mg, 350 umol). The mixture was stirred at 15 °C for 0.5 hr. On completion, the mixture was concentrated to give the title compound (0.10 g, 31% yield, 70% purity, TFA) as yellow oil. LC-MS (ESI^+) *m/z* 529.4 $(M+H)^+$.

[002446] **5-Bromo-3-methyl-1H-benzimidazol-2-one [Intermediate IP)**



[002447] Step 1 - 5-Bromo-N-methyl-2-nitro-aniline

[002448] 4-bromo-2-fluoro-1-nitro-benzene (230 g, 1.05 mol, CAS#321-23-3) was added to a solution of mehylamine in tetrahydrofuran (2 M, 1.51 L). The mixture was stirred at 15 °C for 10 minutes. On completion, the mixture was diluted with H_20 (250 mL) and extracted with EtOAc (3 X 300 mL). The combined organic layers were washed with brine (300 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (200 g, 83% yield) as a yellow solid.

^{1}H NMR (400MHz, DMSO-r¾) δ 8.22 (s, 1H), 7.98 *(d, J* = 9.2 Hz, 1H), 7.16 (d, *J* = 1.6 Hz, 1H), 6.82 (dd, *J* = 8.4, 1.6 Hz, 1H), 2.95 (d, *J* = 4.8 Hz, 3H).


[002449] Step 2 - 4-Bromo-N2-m ethyl-benzene- 1,2-diamine

[002450] To a mixture of 5-bromo-N-methyl-2-nitro-aniline (200 g, 865 mmol) in EtOAc (1 L) and H_20 (500 mL) was added AcOH (1.00 L). The mixture was warmed to 50 °C, and then Fe (174 g, 3.11 mol) was added to the reaction mixture. After that, the reaction mixture was stirred at 80 °C for 6 hours. On completion, the mixture was filtered through celite. The filtrate was *concentrated in vacuo* and the residue was diluted with H_20 (250 mL) and extracted with EtOAc (3 X 300 mL). The combined organic layers were washed with aq.NaHC0 $_3$ and brine (300 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by flash silica gel chromatography to give the title compound (130 g, 75% yield) as black oil. ^{1}H NMR (400MHz, DMSO-di) δ 6.55 - 6.52 (m, 1H), 6.48 - 6.45 (m, 1H), 6.43 - 6.42 (m, 1H), 4.89 - 4.88 (m, 1H), 4.61 (s, 2H), 2.70 (d, *J* = 4.0 Hz, 3H).

[002451] Step 3 - 5-Bromo-3-methyl-lH-benzimidazol-2-one

[002452] To a solution of 4-bromo-N2-methyl -benzene- 1,2-diamine (110 g, 547 mmol) in CH3CN (1.3 L) was added CDI (177 g, 1.09 mol). The mixture was stirred at 80 °C for 6 hours under N_2. On completion, the mixture was concentrated *in vacuo.* The mixture was diluted with H_20 (1.0 L) and filtered. The filter cake was washed with water (3 X 200 mL) and dried *in vacuo* to give the title compound (106 g, 85% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-d«) δ 11.00 (s, 1H), 7.33 (s, 1H), 7.13 (d, *J* = 8.0 Hz, 1H), 6.92 (d, *J* = 8.0 Hz, 1H), 3.27 (s, 3H).

[002453] [l-[(4-MethoxyphenvD _ methyl1-2,6-dioxo-3-piperidyl] trifluoromethanesulfonate [Intermediate IQ)



IQ

[002454] Step **1** - 5-Oxotetrahydrofuran-2-carboxylic acid

[002455] To a solution of 2-aminopentanedioic acid (210 g, 1.43 mol, CAS# 617-65-2) in H_20 (800 mL) and HC1 (12 M, 210 mL) was added a solution of $NaN0_2$ (147 g, 2.13 mol) in H_20 (400 mL) at - 5 °C. The mixture was stirred at 15 °C for 12 hrs. On completion, the mixture was concentrated and then dissolved in EA (500 mL) and filtered and washed with EA (3 X 100 mL). The filtrate and washed solution were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (200 g, crude) as yellow oil. ^1H NMR (400MHz, CDCh) δ 6.43 (s, 1H), 5.02 - 4.95 (m, 1H), 2.67 - 2.38 (m, 4H)

[002456] Step 2 - N-r(4-methoxyphenvDmethyl1-5-oxo-tetrahvdrofuran-2-carboxamide

[002457] To 5-oxotetrahydrofuran-2-carboxylic acid (120 g, 922 mmol) was added $SOCl_2$ (246 g, 2.07 mol) at 0 °C slowly. The mixture was stirred at 85 °C for 3 hrs, and then the mixture was stirred at 15 °C for 6 hrs. The mixture was concentrated *in vacuo.* The residue was dissolved in dry DCM (1 L) at 0 °C under N_2. After that a solution of Et_3N (187 g, 1.84 mol) and 4-methoxybenzylamine (101 g, 738 mmol) in DCM (400 mL) was added, then the mixture was stirred at 15 °C for 3 hrs. On completion, water (600 mL) was added and the mixture was extracted with DCM (3 X 300mL). The combined organic phase was washed with 0.5 M HC1 (500 mL), brine (500 mL), dried over with anhydrous sodium sulfate and filtered. The filtrate was concentrated *in vacuo* and the residue was purified by flash silica gel chromatography (PE: EA = 1:1) to give the title compound (138 g, 60% yield) as a yellow solid. ^1H NMR (400MHz, CDCh) δ 7.22 - 7.20 (d, *J* = 8.0, 1H), 6.89 - 6.87 (d, *J* = 8.0, 1H), 4.90 - 4.86 (m, 1H), 4.47 - 4.4.36 (m, 2H) 3.81 (s, 3H), 2.67 - 2.64 (m, 1H), 2.59 - 2.54 (m, 2H), 2.40 - 2.38 (m, 1H); LC-MS (ESI^+) *m/z* 272.0 $(M+Na)^+$.

[002458] Step 3 - 3-Hydroxy- **1**-r(4-methoxyphenyl)methyl1piperidine-2.6-dione


[002459] A solution of N-[(4-methoxyphenyl)methyl]-5-oxo-tetrahydrofuran-2-carboxamide (138 g, 553 mmol) in anhydrous THF (1500 mL) was cooled to -78 °C. Then, t-BuOK (62.7 g, 559 mmol) in a solution of anhydrous THF (1000 mL) was added dropwise slowly at -78 °C under nitrogen atmosphere. The resulting reaction mixture was stirred at -40 °C for 1 hr. On completion, the reaction mixture was quenched with saturated NH_4Cl solution (100 mL). The mixture was extracted with ethyl acetate (3 X 1500 mL). The combined organic layer was washed with brine (300 mL), dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated *in vacuo.* The residue was purified by silica gel chromatography (PE: EA = 1:1) to give the title compound (128 g, 92% yield) as a white solid. ^1H NMR (400MHz, CDCh) δ 7.39 -

7.32 (m, 2H), 6.89 - 6.81 (m, 2H), 4.91 (s, 2H), 4.17 - 4.11 (m, 1H), 3.80 (s, 3H), 3.54 (s, 1H), 2.98 - 2.87 (m, 1H), 2.73 - 2.60 (m, 1H), 2.26 - 2.20 (m, 1H), 1.80 (dq, *J* = 4.8, 13.1 Hz, 1H).

[002460] Step 4 - rl-IY4-MethoxyphenvD methyl 1-2.6-dioxo-3 -piperidyl] trifluoromethanesulfonate

[002461] To a solution of 3-hydroxy- l-[(4-methoxyphenyl) methyl] piperidine-2, 6-dione (43.0 g, 173 mmol) and pyridine (27.3 g, 345 mmol) in DCM (500 mL) was added trifluoromethylsulfonyl trifluoromethanesulfonate (73.0 g, 258 mmol) dropwise at 0 °C. The mixture was stirred at -l0°C for 1.5 hours under N_2. On completion, the mixture was concentrated *in vacuo.* The residue was purified by column chromatography on silica gel (PE: EA = 20:1/8:1) to give the title compound (45.0 g, 68% yield) as light yellow gum. ¾NMR (400MHz, CDCh) δ 7.36 (d, *J* = 8.4 Hz, 2H), 6.85 - 6.82 (m, 2H), 5.32 - 5.28 (m, 1H), 4.91 (s, 2H), 3.79 (s, 3H), 3.02 - 2.97 (m, 1H), 2.79 - 2.74 (m, 1H), 2.41 - 2.35 (m, 2H).

[002462] **3-(4-bromo-l-oxoisoindolin-2-vPpiperidine-2.,6-dione [Intermediate IR)**



IR

[002463] Step 1: 3-bromo-2-(bromom ethyl) benzoate


[002464] To a solution of methyl 3-bromo-2-methylbenzoate (10.0 g, 43.64 mmol, CAS *#:* 99548-54-6) in benzene (60 ml) were added N-bromosuccinimide (6. 1 g, 52.37 mmol) and benzoyl peroxide (1.05 g, 4.36 mmol) at rt. The reaction mixture was stirred at 80 °C for 12 h. The resulting reaction mixture was poured into EtOAc (260 mL) and the organic layer was washed with water (200 ml), separated, dried over anhydrous Na_2S0_4 and concentrated under reduced pressure to give the residue. The crude was purified by flash chromatography (eluting at 0-2% ethyl acetate in hexane) to afford 3-bromo-2-(bromomethyl) benzoate (12.0 g, 39.33 mmol). ^{1}H NMR (400 MHz, DMSO-d6) δ 7.92 (dd, J = 8.0, 1.3 Hz, 1H), 7.85 (dd, J = 7.8, 1.3 Hz, 1H), 7.41 (t, J = 7.9 Hz, 1H), 5.02 (s, 2H), 3.87 (s, 3H).

[002465] Step 2: 3-(4-bromo-l-oxoisoindolin-2-vQpiperidine-2.6-dione

[002466] To a solution of 3-bromo-2-(bromomethyl) benzoate (12.0 g, 39.33 mmol) in ACN (100 ml) were added 3-aminopiperidine-2, 6-dione hydrochloride (7.76 g, 47.20 mmol, CAS *#:*

24666-56-6), TEA (11.95 g, 117.9 mmol) at rt. The reaction mixture was heated 80 °C for 12 h then cooled to rt. EtOAc (250 ml) was added and the organic layer was washed with water (500 ml), separated, dried over anhydrous Na_2S0_4 and concentrated under vacuum. The obtained crude material was purified by flash chromatography (eluting at 4-6% Methanol in DCM) to give 3-(4-bromo-l-oxoisoindolin-2-yl)piperidine-2,6-dione (5.60 g, 17.33 mmol). LCMS m/z: (ES+) 323.0 (M+l) $^+$. ¾NMR (400 MHz, DMSO-d6) δ 11.04 (s, 1H), 7.88 (dd, J = 7.9, 0.9 Hz, 1H), 7.78 (dd, J = 7.5, 0.9 Hz, 1H), 7.52 (t, J = 7.7 Hz, 1H), 5.16 (dd, J = 13.3, 5.1 Hz, 1H), 4.43 (d, J = 17.6 Hz, 1H), 4.27 (d, J = 17.7 Hz, 1H), 2.92 (ddd, J = 17.2, 13.7, 5.4 Hz, 1H), 2.61 (dd, J = 17.5, 4.3 Hz, 1H), 2.02 (dtd, J = 12.8, 5.4, 2.3 Hz, 1H).


[002467] tert-butyl (2-(2-(2-(prop-2-yn-l-yloxy)ethoxy)ethoxy)ethyQcarbamate (Intermediate IS)



IS

[002468] To a stirred solution of tert-butyl (2-(2-(2-hydroxyethoxy)ethoxy)ethyl)carbamate (1.0 g, 4.01 mmol, synthesized via Step 1 on Intermediate AC) in THF (50 ml) was added NaH (0.2 g, 4.81 mmol) at 0-5 °C. 3-bromoprop-l-yne (0.9 ml, 6.02 mmol, CAS #: 106-96-7) was added dropwise at 0-5 °C. The reaction mixture was stirred at rt for 5 h. The resulting reaction mixture was poured into ice cold water (200 ml) and extracted with ethyl acetate (3 x 200 ml). The combined organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated under vacuum to afford tert-butyl (2-(2-(2-(prop-2-yn-l-yloxy)ethoxy)ethoxy)ethyl)carbamate (1.1 g, 3.83mmol). LCMS m/z (ES+): 188.2 $(M-99)^+$.

[002469] tert-butyl (2-(2-(prop-2-yn-l-yloxy)ethoxy)ethyQcarbamate [Intermediate IT)




IT

[002470] To a stirred solution of tert-butyl (2-(2-hydroxyethoxy)ethyl)carbamate (2.0 g, 9.74 mmol, CAS #: 139115-91-6) in THF (50 ml) was added NaH (0.47 g, 11.70 mmol) at 0-5 °C. 3-bromoprop-l-yne (2.1 ml, 14.62 mmol) was added dropwise at 0-5 °C. The reaction mixture was stirred at rt for 5 h. The resulting reaction mixture was poured into ice cold water (200 ml) and extracted with ethyl acetate (3 x 200 ml). The combined organic layer was dried over anhydrous

Na_2S0_4, filtered and concentrated under vacuum to afford tert-butyl (2-(2-(prop-2-yn-l-yloxy)ethoxy)ethyl)carbamate (2.1 g, 8.97 mmol). LCMS m/z: (ES+) 144.1 $(M-99)^+$.


[002471] **tert-butyl (2-(prop-2-yn-1-yloxy)ethyl)carbamate (Intermediate IU)**



IU

[002472] To a stirred solution of tert-butyl (2-hydroxyethyl)carbamate (3.70 g, 22.96 mmol, CAS #: 26690-80-) in THF (150 ml) was added NaH (1.1 g, 27.55 mmol) at 0-5°C. Then 3-bromoprop-l-yne (3.3 ml, 34.44 mmol) was added dropwise at 0-5°C. The reaction mixture was stirred at rt for 3 h. The resulting reaction mixture was poured into ice cold water (200 ml) and extracted with ethyl acetate (3 x 100 ml). The combined organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated under vacuum to afford crude material. The isolated crude material was further purified by column chromatography (eluting at 15% ethyl acetate in hexane) to afford tert-butyl (2-(prop-2-yn-l-yloxy)ethyl)carbamate (4.12 g, 20.69 mmol). ^{1}H NMR (400 MHz, DMSO-d6) δ 6.83 (t, J = 5.8 Hz, 1H), 4.12 (d, J = 2.4 Hz, 2H), 3.42 (s, 2H), 3.08 (q, J = 6.0 Hz, 2H), 1.38 (s, 9H).

[002473] **2-(l-Methylpyrazol-4-vDoxazole-4-carboxylic acid (Intermediate IV)**



IV

[002474] Step **1** - Ethyl 2-(T-methylpyrazol-4-vDoxazole-4-carboxylate


[002475] To a solution of ethyl 2-chlorooxazole-4-carboxylate (1.87 g, 10.7 mmol, CAS# 4600081-18-9) and l-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrazole (2.22 g, 10.7 mmol, CAS# 761446-44-0) in a mixed solvent of H_20 (6 mL) and dioxane (30 mL) was added K_2C0_3 (2.94 g, 21.3 mmol) and $Pd(dppf)Cl_2•CH_2Cl_2$ (870 mg, 1.07 mmol). The reaction mixture was stirred at 80 °C for 4 hours under nitrogen. On completion, the reaction mixture was diluted with EA (100 mL) and filtered. The organic layers were dried with anhydrous Na_2S0_4, and concentrated *in vacuo.* The residue was purified by silica column chromatography ($Si0_2$) to give

the title compound (1.50 g, 64% yield) as a white solid. LC-MS (ESI^+) m/z 222.1 $(M+H)^+$.

[002476] Step 2 - 2-n-Methylpyrazol-4-vDoxazole-4-carboxylic acid

[002477] To a solution of ethyl 2-(l-methylpyrazol-4-yl)oxazole-4-carboxylate (1.20 g, 5.42 mmol) in THF (30 mL) was added a solution of $LiOH»H_20$ (683 mg, 16.3 mmol) in H_20 (6 mL). The reaction mixture was stirred at 25 °C for 12 hours. On completion, the reaction mixture was diluted with water (50 mL), acidified with HC1 (1N, 10 mL), and filtered. The filter cake was washed with water (2 X 10 mL) and dried *in vacuo* to give the title compound (1.10 g, 80% purity) as a white solid.

[002478] **N-[3-(difluoromethvD-l-(4-formylphenvDpyrazol-4-yll-2-(l-methylpyrazol-4-vPoxazole-4- carboxamide [Intermediate IW)**



[002479] Step 1 - Methyl 4-[3-(difluoromethyl)-4-[[2-(1-methylpyrazol-4-yl)oxazole-4-carbonyllaminolpyrazol -l-yllbenzoate

[002480] To a solution of 2-(l-methylpyrazol-4-yl)oxazole-4-carboxylic acid (860 mg, 4.45 mmol, Intermediate IV) and methyl 4-[4-amino-3-(difluoromethyl)pyrazol-l-yl]benzoate (833 mg, 3.12 mmol, Intermediate FW) in DMF (30 mL) was added DIPEA (2.30 g, 17.8 mmol) and HATU (1.86 g, 4.90 mmol). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was poured into water (50 mL), and filtered to give the filter cake. The cake was washed with water (2 X 20 mL) and dried *in vacuo* to give the title compound (1.40 g, 68% yield) as a white solid. LC-MS (ESI^+) m/z 443.2 $(M+H)^+$.

[002481] Step 2 - 4-[3-(Difluoromethvl)-4-[[2-(T-methylpyrazol-4-vl)oxazole-4-carbonyllaminolpyrazol-l- vl] benzoic acid

[002482] To a solution of methyl 4-[3-(difluoromethyl)-4-[[2-(l-methylpyrazol-4-yl)oxazole-4- carbonyl]amino] pyrazol-l-yl]benzoate (800 mg, 1.81 mmol) in THF (10 mL) was added a solution of LiOF[•F[$_2$O (228 mg, 5.43 mmol) in FLO (2 mL). The reaction mixture was stirred at 40 °C for 12 hours. On completion, the reaction mixture was quenched with HC1 (1N, 3 mL) and concentrated *in vacuo* to give the title compound (900 mg, 59% purity) as a white solid. LC-MS (ESI^+) m/z 429.0 $(M+H)^+$.

[002483] Step 3 - N-r3-(difluoromethvn-l-r4-(hvdroxymethvnphenyl1pyrazol-4-yl1-2-(l-methylpyrazol-4- vOoxazole-4-carboxamide


[002484] To a solution of 4-[3-(difluoromethyl)-4-[[2-(l-methylpyrazol-4-yl)oxazole-4-carbonyl]amino] pyrazol-l-yl]benzoic acid (775 mg, 1.81 mmol) and TEA (732 mg, 7.24 mmol) in THF (30 mL) was added isopropyl carbonochloridate (443 mg, 3.62 mmol) at -10 °C. The reaction mixture was stirred at -10 °C for 2 hours. After that, H_20 (3 mL) was added. The reaction mixture was warmed to 0 °C. Then $LiBH_4$ (158 mg, 7.24 mmol) was added slowly. The reaction mixture was stirred at 0 °C for 2 hours. On completion, the reaction mixture was diluted with THF (50 mL) and filtered. The filtrate was concentrated *in vacuo* and the residue was purified by silica column chromatography ($Si0_2$) to give the title compound (200 mg, 27% yield) as a white solid. LC-MS (ESI^+) m/z 415.2 $(M+H)^+$.

[002485] Step 4 - N-r3-(difluoromethvD-l-(4-forrnylphenvDpyrazol-4-yl1-2-(T-methylpyrazol-4-vDoxazole-4- carboxamide

[002486] To a solution ofN-[3-(difluoromethyl)-l-[4-(hydroxymethyl)phenyl]pyrazol-4-yl]-2-(l-methylpyrazol -4-yl)oxazole-4-carboxamide (180 mg, 434 umol) in THF (20 mL) was added DMP (184 mg, 434 umol). The reaction mixture was stirred at 25 °C for 12 hours. On completion,

the reaction mixture was quenched with water (5 mL) and concentrated *in vacuo*. The residue was dissolved in EA(200 mL), washed with water (50 mL), sat.NaHCCh (50 mL), and brine (50 mL). The organic layer was dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (200 mg, 71% yield) as a white solid. LC-MS (ESI^+) m/z 413.1 $(M+H)^+$.

[002487] **5-[2-[2-(2-Aminoethoxy)ethoxy|ethylamino]-2-(2.,6-dioxo-3-piperidvPisoindoline-l.,3-dione [Intermediate IX)**




[002488] Step 1 - Tert-butyl N-[2-[2-[2-[[2-(2,6-dioxo-3-piperi dvl)-L3-dioxo-isoindolin-5-yl]amino]ethoxy] ethoxylethyllcarbamate

[002489] To a mixture of 2-(2,6-dioxo-3-piperidyl)-5-fluoro-isoindoline-l,3-dione (100 mg, 362 umol, Intermediate HX) and tert-butyl N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]carbamate (107 mg, 434 umol, CAS# 153086-78-3) in DMSO (5 mL) was added DIPEA (233 mg, 1.81 mmol, 315 uL). The reaction mixture was stirred at 130 °C for 1 hour. On completion, the reaction mixture was diluted with water (20 mL) and extracted with EA (3 X 30 mL). The combined organic layers was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (0.1 % FA condition) to give the title compound (90.0 mg, 49% yield) as light yellow solid. LC-MS (ESI^+) *m/z* 505.1 $(M+H)^+$.

[002490] Step 2 - 5-r2-r2-(2-Aminoethoxy)ethoxy1ethylamino1-2-(2.6-dioxo-3-piperidv0isoindoline-L3-dione

[002491] To a mixture of tert-butyl N-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl]amino] ethoxy]ethoxy]ethyl]carbamate (90.0 mg, 178 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 5 mL). The reaction mixture was stirred at 20 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (72.0 mg, 91% yield, HC1) as light yellow solid. LC-MS (ESI^+) *m/z* 405.3 $(M+H)^+$.


[002492] **Tert-butyl N-methyl-N-prop-2-vnyl-carbamate [Intermediate IY)**



IY

[002493] To a solution of tert-butyl N-methylcarbamate (10.4 g, 79.2 mmol) in THF (120 mL) was added NaH (4.12 g, 103 mmol, 60% purity) under 0 °C. The mixture was stirred at 0 °C for 0.5 hour, then 3-bromoprop-l-yne (13.2 g, 111 mmol) was added dropwise. The mixture was stirred at rt for 16 hours. On completion, the reaction mixture was quenched with water (10 mL) at 0°C, and then concentrated *in vacuo* to give a residue. The residue was diluted with water (80 mL) and extracted with DCM (4 X 60mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (4.50 g, 33% yield) as light yellow oil. 'H NMR (400MHz, DMSO-d) δ 4.05 (s, 2H), 2.92 (s, 3H), 2.22 (t, J = 2.4 Hz, 1H), 1.47 (s, 9H).

[002494] **2-(2,6-Dioxo-3-piperidyl)-4-[3-(methylamino)propyl]isoindoline-1,3-dione [Intermediate IZ)**



IY IZ

[002495] Step 1 - Tert-butyl N-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]prop-2-ynyl]-N-methyl- carbamate

[002496] To a solution of 4-bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (1.87 g, 5.54 mmol, Intermediate FT) and tert-butyl N-methyl-N-prop-2-ynyl-carbamate (1.5 g, 8.86 mmol, Intermediate IY) in DMF (5 mL) was added $Pd(PPh_3)_2Cl_2$ (388 mg, 554 umol), TEA (10.0 g, 99.7 mmol) and CuI (105 mg, 554 umol). The mixture was heated at 80 °C for 30 minutes under

microwave. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE: EA = 1:1) to give the title compound (1.90 g, 71% yield) as light yellow solid. ^{1}H NMR (400MHz, DMSO-d_6) δ 11.13 (s, 1H), 7.93 - 7.89 (m, 1H), 7.89 - 7.84 (m, 2H), 5.15 (dd, J = 5.4, 12.8 Hz, 1H), 4.37 (s, 2H), 3.32 (s, 3H), 3.01 - 2.90 (m, 3H), 2.90 - 2.82 (m, 1H), 2.64 - 2.51 (m, 2H), 2.11 - 2.00 (m, 1H), 1.47 - 1.36 (m, 9H) ; LC-MS (ESI$^+$) *m/z* 448.2 (M+Na)$^+$.


[002497] Step 2 - Tert-butyl N-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yllpropyll-N-methyl- carbamate

[002498] To a solution of tert-butyl N-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]prop-2-ynyl]-N- methyl-carbamate (0.50 g, 1.05 mmol) in THF (20 mL) was added Pd/C (0.2 g, 1.05 mmol, 10 wt%) and $Pd(OH)_2/C$ (0.2 g, 1.05 mmol, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 three times. The mixture was stirred under H_2 (15 Psi) at 20 °C for 2 hours. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (0.4 g, 89% yield) as black brown solid. LC-MS (ESI$^+$) *m/z* 452.3 (M+Na)$^+$.

[002499] Step 3 - 2-(2,6-Dioxo-3-piperidyl)-4-[3-(methylamino)propynisoindoline-L3-dione

[002500] To a solution of tert-butyl N-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]propyl]-N- methyl-carbamate (0.40 g, 828 umol) in DCM (4 mL) was added HCl/dioxane (4 M, 4 mL). The mixture was stirred at 5 °C for 20 minutes. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (0.28 g, 92% yield) as black brown solid. LC-MS (ESI$^+$) *m/z* 330.2 (M+H)$^+$.

[002501] N-[3-carbamoyl-l-(4-formylphenvPpyrazol-4-yll-2-(4-pyridvPoxazole-4-carboxamide [Intermediate JA)



EE

JA

[002502] Step 1 - Isopropoxycarbonyl 4-r3-carbamoyl-4-IT2-(4-pyridvDoxazole-4-carbonyllaminolpyrazol-l- vl] benzoate

[002503] To a mixture of 4-[3-carbamoyl-4-[[2-(4-pyridyl)oxazole-4-carbonyl]amino]pyrazol-l-yl]benzoic acid (500 mg, 1.20 mmol, Intermediate EE) in THF (20 mL) was added TEA (483 mg, 4.78 mmol, 665 uL) and isopropyl carbonochloridate (366 mg, 2.99 mmol, 414 uL). The reaction mixture was stirred at -l0°C for 2 hours. On completion, the reaction mixture was filtered. The filtrate was concentrated to give the title compound (600 mg, 99% yield) as light yellow oil. LC-MS (ESI^+) *m/z* 505.0 $(M+H)^+$.


[002504] Step 2 - N-r3-carbamoyl-l-r4-(hvdroxymethvnphenyl1pyrazol-4-yl1-2-(4-pyridvDoxazole-4- carboxamide

[002505] To a mixture of isopropoxycarbonyl 4-[3-carbamoyl-4-[[2-(4-pyridyl)oxazole-4-carbonyl]amino] pyrazol-l-yl]benzoate (600 mg, 1.19 mmol) in H_20 (5 mL) and THF (50 mL) was added $LiBH_4$ (155 mg, 7.14 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 2 hours. On completion, the reaction mixture was quenched with water (30 mL) under stirring. Then the mixture was extracted with EA (3 X 50 mL). The combined organic layers was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was triturated with DCM/PE (5 mL/30 mL) and filtered to give the title compound (250 mg, 51% yield) as light yellow solid. LC-MS (ESI^+) *m/z* 405.2 $(M+H)^+$.

[002506] Step 3 - N-[3-carbamoyl- l-(4-formylphenvOpyrazol-4-vn-2-(4-pyridvOoxazole-4-carboxamide

[002507] To a mixture of N-[3-carbamoyl-l-[4-(hydroxymethyl)phenyl]pyrazol-4-yl]-2-(4-pyridyl)oxazole -4-carboxamide (250 mg, 618 umol)in DCM (10 mL) and THF (10 mL) was added DMP (524 mg, 1.24 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 2 hours. On completion, the reaction mixture was diluted with $Na_2S_20_3$ (10 mL), $NaHC0_3$ (10 mL) and stirred for 30 min. Then the mixture was extracted with DCM (3 X lOmL) and the combined organic layers was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (230 mg, 92% yield) as light yellow solid. LC-MS (ESI^+) *m/z* 403.2 $(M+H)^+$.


[002508] **i4-i4-Aimno-3-tdifluoromethvDpyrazol-l-yllphenyllmethanol (Intermediate JB)**



FW JB

[002509] To a solution of methyl 4-[4-amino-3-(difluoromethyl)pyrazol-l-yl]benzoate (1.30 g, 4.86 mmol, Intermediate FW) in a mixed solvent of THF (40 mL) was added $LiAlH_4$ (369 mg, 9.73 mmol) at 0 °C. The mixture was stirred at 0 °C for 1 hour. The mixture was quenched with water (0.8 mL) and NaOH aqueus solution (15 %, 0.8 mL) at 0 °C, then filtered and dried over Na_2S0_4, filtered again and concentrated *in vacuo* to give the title compound (1.10 g, 94% yield) as light yellow solid. ^1H NMR (400MHz, DMS0-d_6) δ 7.78 (s, 1H), 7.67 (d, J = 8.8 Hz, 2H), 7.40 (d, J = 8.8 Hz, 2H), 7.05 (t, j = 13.6 Hz, 1H), 5.25 (t, j = 5.6 Hz, 1H), 4.51 (d, J = 5.6 Hz, 2H), 4.39 (s, 2H).

[002510] **Tert-butyl N-[4-[4-[[3-(difluoromethyP-l-(4-formylphenyPpyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl1-N-[2,2,2-trifluoroethvPcarbamate [Intermediate JO**



[002511] Step 1 - Tert-butyl N-[4-[4-[[3-(difhioromethvl)-l-[4-(hydroxym ethyl)phenyl]pyrazol -4-yl]carb amoyl] oxazol-2-yl1-2-pyridyl1-N-(2.2.2-trifluoroethvDcarbamate


[002512] To a solution of 2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (1.42 g, 3.68 mmol, Intermediate CM) and HATU (1.92 g, 5.06 mmol) in DMF (20 mL) was added DIPEA (1.78 g, 13.7 mmol) and [4-[4-amino-3-(difluoromethyl)pyrazol-l-yl]phenyl]methanol (1.1 g, 4.60 mmol, Intermediate JB). The mixture was stirred at 25 °C for 2 hours. On completion, the reaction mixture was diluted with 80 mL water, filtered to give the filter cake and was dried *in vacuo* to give the product (1.90 g, 67% yield) as gray solid. ^{1}H NMR (400MHz, DMSO-^e) δ 10.06 (s, 1H), 9.07 (s, 1H), 8.80 (s, 1H), 8.65 (d, *J* = 5.2 Hz, 1H), 8.31 (s, 1H), 7.87 - 7.77 (m, 3H), 7.48 (d, *J* = 8.4 Hz, 2H), 7.28 (d, *J* = 14.4 Hz, 1H), 5.30 (t, *J* = 5.6 Hz, 1H), 4.90 (q, *J* = 9.2 Hz, 2H), 4.56 (d, *J* = 5.6 Hz, 2H), 1.52 (s, 9H).

[002513] Step 2 - Tert-butyl N-r4-r4-rr3-(difluoromethvD-l-(4-formylphenvDpyrazol-4-yllcarbamovnoxazol-2- yl1-2-pyridyl1-N-(2.2.2-trif1uoroethyl icarbamate

[002514] To a solution of tert-butyl N-[4-[4-[[3-(difluoromethyl)-l-[4-(hydroxymethyl)phenyl]pyrazol-4-yl] carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (1.90 g, 3.12 mmol) in a THF (60 mL) was added DMP (1.59 g, 3.75

mmol). The mixture was stirred at 20 °C for 12 hours. On completion, the reaction mixture was quenched by saturated $Na_2S_2O_3$ (20 mL) and saturated $NaHCO_3$ (20 mL) at 25 °C. The mixture was stirred for 30 minutes, then extracted with CH_2Cl_2 (3 X 100 mL). The combined organic layers dried over Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (1.30 g, 68% yield) as gray solid. ^{1}H NMR (400MHz, DMSO-^e) δ 10.17 (s, 1H), 10.05 (s, 1H), 9.09 (s, 1H), 8.99 (s, 1H), 8.65 (d, *J* = 5.2 Hz, 1H), 8.31 (s, 1H), 8.12 (d, *J* = 8.4 Hz, 2H), 8.04 (d, *J* = 8.4 Hz, 2H), 7.80 (dd, *J* = 0.8, 5.2 Hz, 1H), 7.33 (t, *j* = 14.0 Hz, 1H), 4.90 (q, *j* = 8.8 Hz, 2H), 1.52 (s, 9H); LC-MS (ESI$^+$) *m/z* 607.1 $(M+H)^+$.

[002515] **N-[3-(difluoromethvP-l-(4-formylphenvPpyrazol-4-yll-2-(4-pyridvPoxazole-4-carboxamide [Intermediate JD)**



[002516] Step 1 - N-r3-(difluoromethvn-l-r4-(hvdroxymethvnphenyl1pyrazol-4-yl1-2-(4-pyridvDoxazole-4- carboxamide


[002517] To a solution of 2-(4-pyridyl)oxazole-4-carboxylic acid (1.27 g, 6.69 mmol, Intermediate ED) and HATU (3.18 g, 8.36 mmol) in DMF (60 mL) was added DIPEA (3.24 g, 25.0 mmol) and [4-[4-amino-3-(difluoromethyl) pyrazol-l-yl]phenyl]methanol (2 g, 8.36 mmol, Intermediate JB). The mixture was stirred at 25 °C for 2 hours. On completion, the reaction mixture was diluted with water (80 mL), filtered to give the filter cake and dried *in vacuo* to give the title compound (3.00 g, 87% yield) as gray solid. ^{1}HNMR (400MHz, DMSO-^e) δ 10.05 (s, 1H), 9.04 (s, 1H), 8.83 (d, *j* = 6.0 Hz, 2H), 8.78 (s, 1H), 7.97 (d, *j* = 6.0 Hz, 2H), 7.82 (d, *j* = 8.8 Hz, 2H),

7.48 (d, J = 8.8 Hz, 2H), 7.29 (t, J = 54 Hz, 1H), 5.30 (t, J = 5.2 Hz, 1H), 4.56 (d, J = 4.8 Hz, 2H).

[002518] Step 2 - N-r3-(difluoromethyl)-l-(4-formylphenvDpyrazol-4-yl1-2-(4-pyridvDoxazole-4-carboxamide

[002519] To a solution ofN-[3-(difluoromethyl)-l-[4-(hydroxymethyl)phenyl]pyrazol-4-yl]-2-(4-pyridyl) oxazole-4-carboxamide (2.50 g, 6.08 mmol) in THF (160 mL) was added DMP (3.09 g, 7.29 mmol). The mixture was stirred at 20 °C for 12 hours. On completion, the reaction mixture was quenched with saturated $Na_2S_2O_3$ (20 mL) and saturated $NaHCO_3$ (20 mL) at 25°C, and then stirred for 30 minutes. The mixture was then extracted with CH_2Cl_2 (3 X 100 mL). The combined organic layers dried over Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (1.80 g, 73% yield) as gray solid. LC-MS (ESI^+) *m/z* 410.2 $(M+H)^+$.

[002520] **4-[4-[[2-[2-[Tert-butoxycarbonyl[2,2,2-trifluoroethvnamino]-4-pyridyl] oxazole-4-carbonyll _ aminol-3-tdifluoromethyDpyrazol-l-yllbenzoic _ acid [Intermediate JE)**



[002521] Step 1 - Methyl 4-[4-IT2-[2-[tert-buto xycarbonyl(2,2,2-trifluoiOethvl)aminol-4-pyridylloxazole-4- carbonyl1amino1-3-(difluoromethvnpyrazol-l-yl1benzoate


[002522] To a solution of methyl 4-[4-amino-3-(difluoromethyl)pyrazol-l-yl]benzoate (340 mg, 1.27 mmol, Intermediate FW) and 2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4- carboxylic acid (493 mg, 1.27 mmol, Intermediate CM) in DMF (8 mL) was added DIPEA (658 mg, 5.09 mmol) and HATU (581 mg, 1.53 mmol). The reaction mixture was stirred at 20 °C for 1 hour. On completion, the mixture was quenched with water (80 mL), stirred

and filtered. The filter cake was dried *in vacuo* to give the title compound (0.7 g, 86% yield) as an off-white solid. LC-MS (ESI$^+$) *m/z* 637.3 (M+H)$^+$.

[002523] Step 2 - 4-[4-[[2-[2-[Tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-1-yl]benzoic acid

[002524] To a solution of methyl 4-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl] oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-1-yl]benzoate (0.70 g, 1.10 mmol) in a mixed solvent of THF (10 mL) and H_2O (2 mL) was added LiOH (132 mg, 5.50 mmol). The reaction mixture was stirred at 20 °C for 2 days. On completion, the mixture was acidified with 0.5 N HCl solution until the pH = 3-4, then stirred and filtered. The filter cake was dried *in vacuo* to give the title compound (0.68 g, 99% yield) as a white solid. LC-MS (ESI$^+$) *m/z* 623.2 (M+H)$^+$.

[002525] **3-(7-bromo-2-oxo-1,3-benzoxazol-3-yl)piperidine-2,6-dione [Intermediate JF**



JF

[002526] Step 1 - 3-(3-bromo-2-hydroxyphenylamino)-1-(4-methoxybenzyl)piperidine-2,6-dione

[002527] To a solution of 3-bromo-1-(4-methoxybenzyl)piperidine-2,6-dione (145 mg, 0.77 mmol, Intermediate LJ) in EtOH (10 mL) was added 2-amino-6-bromophenol (200 mg, 0.64 mmol) and at r.t.. The reaction mixture was heated and stirred under microwave irradiation at 140 °C for 25 mins. The reaction mixture was concentrated under reduced pressure. The residue was purified via reverse phase column chromatography (ACN/H2O with 0.1%TFA) to give title compound (80 mg, 30% yield) as a colorless oil. ¾ NMR (400 MHz, DMSO-rie) δ 8.94 (s, 1H), 7.18 (d, J = 8.6 Hz,

2H), 6.85 (d, *J* = 8.7 Hz, 2H), 6.75 (dd, *J* = 6.9, 2.6 Hz, 1H), 6.67 - 6.59 (m, 2H), 5.48 (d, *J* = 7.1 Hz, 1H), 4.76 (q, *J* = 14.3 Hz, 2H), 4.58 - 4.40 (m, 1H), 3.71 (s, 3H), 3.05 - 2.89 (m, 1H), 2.83 - 2.61 (m, 1H), 2.25 - 2.10 (m, 1H), 2.02-1.97 (m, 1H). LC-MS (ESI^+): m/z 421.1 $(M+H)^+$.


[002528] Step 2 - 3-(7-bromo-2-oxobenzo[d]oxazol-3(2H)-yl)-1-(4-methoxybenzyl)piperidine-2.6-dione

[002529] To a solution of 3-(3-bromo-2-hydroxyphenylamino)-l-(4-methoxybenzyl)piperidine-2,6-dione (80 mg, 0.l9mmol) in THF (5 mL) was added a solution of CDI (46mg, 0.284 mmol) in THF (5 mL) at r.t. under N_2. The reaction mixture was stirred at 35 °C for 12 h. The reaction mixture was then concentrated under reduced pressure and the residue was purified via column chromatography (Petroleum ether/EtOAc= 2 / 1) to give title compound (70 mg, 74% yield) as a white solid. 'HNMR (400 MHz, DMSO-rie) δ 7.39 (dd, *J* = 8.0, 1.1 Hz, 1H), 7.23 - 7.16 (m, 4H), 6.86 (d, *J* = 8.7 Hz, 2H), 5.56 (dd, *J* = 13.3, 5.3 Hz, 1H), 4.89 - 4.70 (m, 2H), 3.72 (s, 3H), 3.04-3.01 (m, 1H), 2.87-2.83 (m, 1H), 2.71 - 2.65 (m, 1H), 2.27 - 2.18 (m, 1H). LC-MS (ESI^+): m/z 445.1 $(M+H)^+$.


[002530] Step 3 - 3-(7-bromo-2-oxobenzord1oxazol-3(2H)-yl)piperidine-2.6-dione


[002531] To a solution of 3-(7-bromo-2-oxobenzo[d]oxazol-3(2H)-yl)-l-(4-methoxybenzyl)piperidine-2,6-dione (80 mg, 0.180 mmol) in C¾CN (2 mL) was added a solution of CAN (690 mg, 1.26 mmol) in 0.5 mL of water dropwise at r.t.. The reaction mixture was stirred at r.t. for 2 hours. The reaction mixture was then extracted with EtOAc (l5mL x 2), the organic layer washed with brine, dried over anhydrous Na_2S0_4 and concentrated under reduced pressure. The residue was purified via Pre-TLC (Petroleum ether/EtOAc= 1 / 1) to give the title compound (9.7mg, 17% yield) as a pale yellow solid. TlNMR^OO MHz, DMSO-rie) δ 11.26 (s, 1H), 7.39 (dd, *J* = 8.2, 0.8 Hz, 1H), 7.33 - 7.27 (m, 1H), 7.19 (t, *J* = 8.1 Hz, 1H), 5.42-5.38 (m, 1H), 2.97 - 2.79 (m, 1H), 2.75 - 2.60 (m, 2H), 2.27 - 2.12 (m, 1H). LC-MS (ESI^+): m/z 325.1 $(M+H)^+$.

[002532] 3-[7-[3-[2-[2-Aminoethoxy]ethoxy1propyl1-2-oxo-l,3-benzoxazol-3-yl]piperidine-2.,6-dione [Intermediate JG)



JF





JG

[002533] Step 1 - Tert-butyl N-[2-[2-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-1,3-benzoxazol-7-yl]prop-2-ynoxy]ethoxy]ethyl]carbamate

[002534] To a solution of 3-(7-bromo-2-oxo-1,3-benzoxazol-3-yl)piperidine-2,6-dione (220 mg, 676 umol, Intermediate JF) and tert-butyl N-[2-(2-prop-2-ynoxyethoxy)ethyl]carbamate (411 mg, 1.69 mmol, synthesized via Step 1 of Intermediate CQ) in DMF (10 mL) was added TEA (1.23 g, 12.1 mmol, 1.70 mL), CuI (64.4 mg, 338 umol) and $Pd(PPh_3)_2Cl_2$ (237 mg, 338 umol). The reaction mixture was stirred at 80 °C for 1.5 hours under N_2. On completion, the mixture was filtered; and the filtrate was concentrated *in vacuo* to give a residue. The residue was dissolved in DCM (20 mL) and thiourea (resin) (300 mg) was added. The mixture was stirred at 20 °C for 2 hours. Then the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (250 mg, 76% yield) as a yellow solid. LC-MS (ESI^+) m/z 510.2 $(M + Na)^+$.


[002535] Step 2 - Tert-butyl N-[2-[2-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-1,3-benzoxazol-7-yl]propoxy]ethoxy]ethyl]carbamate

[002536] To a solution of tert-butyl N-[2-[2-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-l,3-benzoxazol-7-yl]prop-2- ynoxy]ethoxy]ethyl]carbamate (250 mg, 5l2umol) in THF (10 mL) was added $Pt0_2$ (58.2 mg, 256 umol). The reaction mixture was stirred at 20 °C under H_2 (15 psi) for 1 hour. On completion, the residue was filtered and the filtrate was concentrated *in vacuo* to give the title compound (250 mg, 99%) as yellow oil. LC-MS (ESI^+) m/z 514.2 $(M + Na)^+$.

[002537] Step _3_-_3-r7-r3-r2-(2-Aminoethoxy)ethoxy1propyl1-2-oxo- 1J-benzoxazol-3-yl1piperidine-2.6-dione

[002538] To a solution of tert-butyl N-[2-[2-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-l,3-benzoxazol-7-yl]propoxy] ethoxy]ethyl]carbamate (250 mg, 508 umol) in DCM (4 mL) was added HCl/dioxane (4 M, 4 mL). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (190 mg, 87% yield) as yellow oil. LC-MS (ESL) m/z 392.3$(M+H)^+$.

[002539] **2-(2,6-Dioxo-3-piperidyl)-5-[3-(methylamino)propyl]isoindoline-l ,3-dione (Intermediate JH)**



[002540] Step 1 - Tert-butyl N-r3-r2-(2.6-dioxo-3-piperidyl)- 1.3-dioxo-isoindolin-5-yl1prop-2-vnyll-N-methyl- carbamate

[002541] To a mixture of tert-butyl N-methyl-N-prop-2-ynyl-carbamate (1.00 g, 5.93 mmol, Intermediate IY) and 5-bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (1.00 g, 2.97 mmol, Intermediate GA) in DMF (4 mL) was added CuI (56.4 mg, 296 umol), TEA (5.40 g, 53.3 mmol, 7.43 mL) and $Pd(PPh_3)_2Cl_2$ (208 mg, 296 umol). The reaction mixture was heated at 80 °C for 0.5 hour under microwave. On completion, the reaction mixture was diluted with water (30 mL) and extracted with EA (3 X 50 mL). The combined organic layer was dried over Na_2S0_4, filtered and

concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (1.20 g, 95% yield) as yellow solid. ^{1}H NMR (400MHz, DMSO-i¾) δ 11.14 (s, 1H), 7.96 - 7.88 (m, 3H), 5.16 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.33 (s, 2H), 3.33 (s, 3H), 2.89 - 2.83 (m, 1H), 2.64 - 2.51 (m, 2H), 2.10 - 2.02 (m, 1H), 1.42 (s, 9H).

[002542] Step 2 - Tert-butyl N-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-5-yl]propyl]-N-methyl-carbamate


[002543] To a mixture of tert-butyl N-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-5-yl]prop-2-ynyl]-N-methyl-carbamate (2.40 g, 5.64 mmol) in MeOH (50 mL) was added Pd/C (500 mg, 10 wt %) and $Pd(OH)_2/C$ (500 mg, 10 wt%). The reaction mixture was stirred at 20°C for 1 hour under H_2 (15 Psi) atmosphere. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (2.40 g, 99% yield) as light yellow solid. LC-MS (ESI^+) *m/z* 452.3 $(M+Na)^+$.

[002544] Step 3 - 2-(2,6-Dioxo-3-piperidyl)-5-[3-(methylamino)propyl]isoindoline-1,3-dione

[002545] To a mixture of tert-butyl N-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-5-yl]propyl]-N-methyl-carbamate (2.40 g, 5.59 mmol) in DCM (10 mL) was added HCl/dioxane (4 M, 19.2 mL). The reaction mixture was stirred at 20 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (2.00 g, 97% yield) as light yellow solid. LC-MS (ESI^+) *m/z* 330.2 $(M+H)^+$.

[002546] **5-(3-Aminopropyl)-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione**

[Intermediate J1]



[002547] Step 1 - Tert-butyl N-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-5-yl]prop-2-ynyl]carbamate

[002548] To a solution of 5-bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (1 g, 2.97 mmol Intermediate GA) and tert-butyl N-prop-2-ynylcarbamate (920 mg, 5.93 mmol) in DMF (4 mL) was added $Pd(PPh_3)2Cl2$ (208 mg, 296 umol) TEA (5.40 g, 53 mmol, 7.43 mL) and Cul (57 mg, 296 umol). The mixture was stirred at 80 °C for 0.5 hr under microwave. On completion, the mixture was concentrated *in vacuo*, the residue was purified by silica gel chromatography to give the title compound (1.3 g, 95% yield) as yellow solid. ¾NMR (400MHz, DMSO-d«) δ 11.15 (s, 1H), 8.01 - 7.81 (m, 3H), 5.17 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.10 - 4.03 (m, 2H), 3.33 (s, 1H), 2.94 - 2.84 (m, 1H), 2.73- 2.53 (m, 2H), 2.13 - 2.02 (m, 1H), 1.47 - 1.36 (m, 9H); LC-MS (ESI^+) *m/z* 434.0 $(M+Na)^+$.


[002549] Step 2 - Tert-butyl N-r3-r2-(2.6-dioxo-3-piperidvO-L3-dioxo-isoindolin-5-yl]propyl] carbamate

[002550] A mixture of tert-butyl N-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl]prop-2- ynyl]carbamate (2.5 g, 6.08 mmol), Pd/C (400 mg), Pd(OH)2/C (400 mg) in THF (40 mL) was degassed and purged with H_2 gas 3 times. The mixture was then stirred at 20 °C for 16 hrs under H_2 atmosphere at 15 psi. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (2.4 g, 95% yield) as brown solid. 'H NMR (400MHz, DMSO-i/e) δ 11.12 (s, 1H), 7.84 (d, *j* = 7.6 Hz, 1H), 7.80 (s, 1H), 7.72 (dd, 7 = 1.2, 7.6 Hz, 1H), 6.94 - 6.85 (m, 1H), 5.14 (dd, *J* = 5.2, 12.8 Hz, 1H), 2.99 - 2.84 (m, 3H), 2.82 - 2.72 (m, 2H), 2.65 - 2.54 (m, 2H), 2.11 - 2.01 (m, 1H), 1.80 - 1.68 (m, 2H), 1.38 (s, 9H) LC-MS (ESI^+) *m/z* 438.1 $(M+Na)^+$.

[002551] Step 3 - 5-(3-AminopropyO-2-(2.6-dioxo-3-piperidvOisoindoline-L3-dione

[002552] To a solution of tert-butyl N-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl]propyl] carbamate (2.4 g, 5.78 mmol) in DCM (25 mL) was added HCl/dioxane (4 M, 10 mL). The mixture was stirred at 20 °C for 2 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (1.2 g, 65% yield) as light yellow solid. ^1H NMR (400MHz, DMSO-d_6) δ 11.14 (s, 1H), 8.01 (s, 3H), 7.88 (d, *J* = 7.6 Hz, 1H), 7.84 (s, 1H), 7.76 (d, *J* = 8.0 Hz, 1H), 5.15 (dd, *J* = 5.2, 12.8 Hz, 1H), 2.95 - 2.84 (m, 3H), 2.83 - 2.72 (m, 2H), 2.69 - 2.52 (m, 2H), 2.11 - 2.01 (m, 1H), 1.97 - l.89(m, 2H); LC-MS (ESI^+) *m/z* 316.2 $(M+H)^+$.

[002553] **5-[Aminomethv0-2-[2.,6-dioxo-3-piperidv0isoindoline-l.,3-dione [Intermediate JJ)**



[002554] Step 1 - 2-(2,6-Dioxo-3-piperidyl)-1,3-dioxo-isoindoline-5-carbonitrile

[002555] To a solution of 5-bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione (450 mg, 1.33 mmol, Intermediate GA), $Zn(CN)_2$ (94.0 mg, 800 umol) in DMF (15.0 mL) was added $Pd(PPh_3)_4$ (154 mg, 133 umol). The mixture was stirred at 100 °C for 3 hours under N_2. On completion, the mixture was diluted with H_20 (50 mL), filtered and the solid was dried *in vacuo*. The solid was triturated with PE: EA = 5: 1 (30 mL), filtered and the solid was dried *in vacuo* to give the title compound (200 mg, 52% yield) as purple solid. ^1H NMR (400MHz, DMSO-d6) δ 11.16 (s, 1H), 8.49 (s, 1H), 8.38 (dd, *J* = 1.2, 7.6 Hz, 1H), 8.12 (d, *J* = 7.6 Hz, 1H), 5.26 - 5.17 (m, 1H), 2.97 - 2.89 (m, 1H), 2.65 - 2.58 (m, 1H), 2.57 - 2.52 (m, 1H), 2.12 - 2.05 (m, 1H).


[002556] Step 2 - Tert-butyl N-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-5-yl]methyl]carbamate

[002557] To a solution of 2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindoline-5-carbonitrile (200 mg, 706 umol) in THF (10.0 mL) and DMF (10.0 mL) was added $(Boc)_20$ (169 mg, 776 umol) and Raney-Ni (50.0 mg, 583 umol). The mixture was stirred at 30 °C for 3 hours under H_2 (50 psi). On completion, the mixture was filtered and concentrated *in vacuo*. The mixture was purified by silica gel column (PE: EA=1: 1) to give the title compound (250 mg, 91% yield) as white solid. ^1H NMR (400MHz, DMSO-d6) δ 11.10 (s, 1H), 7.88 (d, *J* = 7.6 Hz, 1H), 7.76 (s, 1H), 7.72 (d, *J* = 7.6 Hz, 1H), 7.63 - 7.55 (m, 1H), 5.18 - 5.04 (m, 1H), 4.33 - 4.24 (m, 2H), 2.95 - 2.88 (m, 1H), 2.84 - 2.83 (m, 1H), 2.64 - 2.57 (m, 1H), 2.57 - 2.52 (m, 1H), 2.11 - 2.01 (m, 1H), 1.39 (s, 9H).

[002558] Step 3 - 5-(Aminomethyl)-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione

[002559] To a solution of tert-butyl N-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl]methyl]carbamate (250 mg, 645 umol) in DCM (3.00 mL) was added HCl/dioxane (4.00 M, 4.00 mL), and the mixture was stirred at 15 °C for 0.5 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (200 mg, 90% yield, HC1) as white solid. LC-MS (ESI$^+$) *m/z* 288.1 $(M+H)^+$.

[002560] **2-[2,6-Dioxo-3-piperidyn-5-[3-[2-[methylamino]ethoxy1propyl1isoindoline-1,3-dione [Intermediate JK)**



JK

[002561] Step 1 - Tert-butyl N-[2-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-5-yllprop-2-vnoxyl ethyl] -N-methyl-carbamate

[002562] To a solution of tert-butyl N-methyl-N-(2-prop-2-ynoxyethyl)carbamate (2.53 g, 11.8 mmol, Intermediate GK) and 5-bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (2.00 g, 5.93 mmol, Intermediate GA) in DMF (4.00 mL) was added TEA (10.8 g, 106 mmol), CuI (112 mg, 593 umol) and $Pd(PPh3)_2Cl2$ (416 mg, 593 umol), and the reaction mixture was heated at 80 °C for 30 min under microwave. On completion, the mixture was concentrated *in vacuo.* The mixture was purified by silica gel column (PE: EA =l: 1) to give the title compound (2.7 g, 96% yield) as yellow solid. 1H NMR (400MHz, CDCh) δ 8.00 (s, 1H), 7.93 (s, 1H), 7.89 - 7.79 (m, 2H), 5.02 - 4.96 (m, 1H), 4.44 (s, 2H), 3.73 (s, 2H), 3.48 (s, 2H), 2.97 (s, 3H), 2.96 - 2.91 (m, 1H),

2.89 - 2.82 (m, 1H), 2.82 - 2.73 (m, 1H), 2.22 - 2.15 (m, 1H), 1.48 (s, 9H).


[002563] Step 2 - Tert-butyl N-[2-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-5-yl]propoxy]ethyl]-N-methyl-carbamate

[002564] To a solution of tert-butyl N-[2-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-5-yl]prop-2-ynoxy] ethyl]-N-methylcarbamate(2.70 g, 5.75 mmol) in THF (30.0 mL) was added Pd/C (400 mg) and $Pd(OH)_2/C$ (400 mg), and the mixture was stirred at 15 °C for 16 hr under H_2 (15 psi). On completion, the mixture was concentrated *in vacuo* to give the title compound (2.70 g, 95% yield) as black solid. LC-MS (ESI^+) *m/z* 496.1 $(M+Na)^+$.

[002565] Step 3 - 2-(2,6-Dioxo-3-piperidyl)-5-[3-[2-(methylaminoethoxy]propyl]isoindoline-1,3-dione

[002566] To a solution of tert-butyl N-[2-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-5-yl]propoxy] ethyl]-N-methyl-carbamate (2.70 g, 5.70 mmol) in DCM (20.0 mL) was added HCl/dioxane (4.00 M, 20.0 mL). The mixture was stirred at 15 °C for 0.5 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (2.37 g, 90% yield, HC1) as yellow solid., ¾ NMR (400MHz, DMSO-i¾) δ 11.14 (s, 1H), 9.02 (s, 1H), 7.87 - 7.74 (m, 3H), 5.19 - 5.10 (m, 1H), 3.67 - 3.63 (m, 2H), 3.57 (s, 3H), 3.46 - 3.42 (m, 2H), 3.12 - 3.03 (m, 2H), 2.91 - 2.86 (m, 2H), 2.64 - 2.58 (m, 1H), 2.57 - 2.55 (m, 1H), 2.55 - 2.54 (m, 1H), 2.10 - 2.01 (m, 1H), 1.94 - 1.83 (m, 2H).

[002567] **4-[3-(Difluoromethv0-4-[[2-(4-pyridv0oxazole-4-carbonyl1amino1pyrazol-1-yl]benzoic acid [Intermediate JL)**




[002568] Step 1 - DifluoiOmethvD-4-IT2-(4-pyridvDoxazole-4-carbonvnamino1pyrazol-l-yllbenzoate

[002569] A mixture of methyl 4-[4-amino-3-(difluoromethyl)pyrazol-l-yl]benzoate (900 mg, 3.37 mmol, Intermediate FW), 2-(4-pyridyl)oxazole-4-carboxylic acid (640 mg, 3.37 mmol, Intermediate ED), DIPEA (1.31 g, 10 mmol, 1.76 mL), and HATU (1.54 g, 4.04 mmol) in DMF (20 mL) was degassed and purged with N_2 gas 3 times, and then the mixture was stirred at 20 °C for 1 hr under N_2 atmosphere. On completion, the mixture was concentrated *in vacuo*. The residue was purified by prep-HPLC (basic condition) to give the title compound (l.45g, 67% yield) as white solid. LC-MS (ESI^+) *m/z* 440.2 $(M+l)^+$.

[002570] Step 2 - 4-[3-(Difluoromethvl)-4-[[2-(4-pyridvl)oxazole-4-carbonyllaminolpyrazol-l-yllbenzoic acid

[002571] To a solution of methyl 4-[3-(difluoromethyl)-4-[[2-(4-pyridyl)oxazole-4-carbonyl]amino]pyrazol-l-yl] benzoate (1.60 g, 3.64 mmol) in a mixed of THF (160 mL), MeOH (20 mL) and H_20 (30 mL) was added LiOH (436 mg, 18.2 mmol). The mixture was stirred at 20 °C for 16 hrs. On completion, the mixture was adjusted to pH = 6 with 1N HC1, and then filtered and the filter cake was dried *in vacuo* to give the title compound (1.5 g, 96% yield) as white solid. LC-MS (ESL) *m/z* 426.1 $(M+l)^+$.

[002572] **N-[3-(difluoromethvP-l-[4-[methyl(2-oxoethvPcarbamoyllphenyllpyrazol-4-yl]-2-(4-pyridvP oxazole-4-carboxamide [Intermediate JM)**




[002573] Step 1 - N-r3-(difluorornethvD-l-r4-r2-hvdroxyethyl(methvncarbamoyl1phenyl1pyrazol-4-yl1-2- (4-pyridvOoxazole-4-carboxamide


[002574] A mixture of 4-[3-(difluoromethyl)-4-[[2-(4-pyridyl)oxazole-4-carbonyl]amino]pyrazol-l-yl]benzoic acid (500 mg, 1.18 mmol, Intermediate JL), 2-(methylamino)ethanol (88.3 mg, 1.18 mmol, CAS# 109-83-1), DIPEA (456 mg, 3.53 mmol, 614 uL), and HATU (537 mg, 1.41 mmol) in DMF (20 mL) was degassed and purged with N_2 gas 3 times, and then the mixture was stirred at 25 °C for 3 hrs under N_2 atmosphere. On completion, the mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (acid condition) to give the title compound (500 mg, 85% yield) as light yellow solid. ^{1}H NMR (400MHz, DMSO-***di)*** δ 10.16 (s, 1H), 9.07 (s, 1H), 8.91 - 8.74 (m, 3H), 8.03 - 7.84 (m, 4H), 7.59 (d, ***J*** = 8.4 Hz, 2H), 7.48 - 7.10 (m, 1H), 4.83 (s, 1H), 3.64 -3.38 (m, 4H), 3.00 (s, 3H); LC-MS (ESI$^+$) *m/z* 483.2 (M+l) $^+$.

[002575] Step 2 - N-[3-(difh1oromethvl)-l-[4-[methvl(2-oxoethvDcarbamovnphenvnpyrazol-4-vn-2-(4-pyridvD oxazole-4-carboxamide

[002576] To a solution of N-[3-(difhioromethyl)-l-[4-[2-hydroxyethyl(methyl)carbamoyl]phenyl]pyrazol-4-yl]- 2-(4-pyridyl)oxazole-4-carboxamide (500 mg, 1.04 mmol) in THF (10 mL) was added Dess-Martin (528 mg, 1.24 mmol). The mixture was stirred at 25 °C for 3 hrs. On completion, the mixture was quenched with saturated $Na_2S_2O_3$(l0 mL), then extracted with DCM (2x150 mL). The organic layer was concentrated *in vacuo* to give the title compound (490 mg, 98% yield) as yellow solid. LC-MS (ESI$^+$) *m/z* 481.2 (M+l) $^+$.

[002577] **2-(2,6-Dioxo-3-piperidvO-5-[2-(2-hvdroxyethoxy)ethyl1isoindoline-l.,3-dione [Intermediate JN)**





JN


[002578] Step 1 - 2-(2,6-Dioxo-3-piperidyl)-5-[(E)-2-(2-hydroxyethoxy)vinyl]isoindoline-1,3-dione

[002579] To a solution of 5-bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione (2.00 g, 5.93 mmol Intermediate GA), 2-vinyloxyethanol (1.05 g, 11.8 mmol) in dioxane (15.0 mL) was added P(t-Bu)$_3$ (2.40 g, 1.19 mmol, 10 wt%), $Pd_2(dba)_3$ (543 mg, 593 umol) and N-cyclohexyl-N-methyl-cyclohexanamine (1.51 g, 7.71 mmol), and the mixture was stirred at 25 °C for 16 hrs. On completion, the mixture was concentrated *in vacuo*. The mixture was purified by silica gel column (EA) to give the title compound (2.00 g, 97% yield) as yellow solid. ¾NMR (400MHz, DMSO-d_6) δ 11.13 (s, 1H), 7.91 (s, 1H), 7.79 - 7.76 (m, 1H), 7.72 (s, 1H), 7.71 - 7.67 (m, 1H), 6.08 (d, J = 12.8 Hz, 1H), 5.17 - 5.10 (m, 1H), 4.91 - 4.86 (m, 1H), 3.96 (t, J = 4.8 Hz, 2H), 3.70 - 3.63 (m, 2H), 2.95 - 2.84 (m, 1H), 2.65 - 2.57 (m, 1H), 2.57 - 2.53 (m, 1H), 2.11 - 2.01 (m, 1H).

[002580] Step 2 - 2-(2,6-Dioxo-3-piperidyl)-5-[2-(2-hydroxyethoxy)ethyl]isoindoline-1,3-dione

[002581] To a solution of 2-(2,6-dioxo-3-piperidyl)-5-[(E)-2-(2-hydroxyethoxy)vinyl]isoindoline-1,3-dione (1.00 g, 2.90 mmol) in THF (40.0 mL) was added Pd/C (300 mg, 10 wt%) and Pd(OH)$_2$/C (300 mg, 10 wt%). The mixture was stirred at 15 °C for 12 hours under H_2 (15 psi). On completion, the mixture was filtered and concentrated *in vacuo* to give the title compound (1.00 g, 95% yield) as yellow solid. LC-MS (ESI$^+$) *m/z* 347.2 $(M+H)^+$.


[002582] **2-[2-[2-(2,6-Dioxo-3-piperidyl)-1,3-dioxo-isoindolin-5-yl]ethoxy]ethyl methanesulfonate [Intermediate JO]**



JN JO

[002583] To a solution of 2-(2,6-dioxo-3-piperidyl)-5-[2-(2-hydroxyethoxy)ethyl]isoindoline-l,3-dione (300 mg, 866 umol, Intermediate JN) in DCM (30.0 mL) was added MsCl (148 mg, 1.30 mmol) and TEA (262 mg, 2.60 mmol), and the mixture was stirred at 15 °C for 0.5 hr. On completion, the mixture was diluted with DCM (20 mL), and extracted with H_20 (3 X 20 mL). The organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (350 mg, 95% yield) as yellow oil. LC-MS (ESI^+) *m/z* 425.2 $(M+H)^+$.

[002584] **4-[3-(difluoromethv0-4-nitro-pyrazol-l-yllpiperidine [Intermediate JP)**



[002585] Step 1 -Tert-butyl 4-r3-(difluoromethv0-4-nitro-pyrazol-l-vnpiperidine-l-carboxylate


[002586] To a solution of tert-butyl 4-methylsulfonyloxypiperidine-l-carboxylate (3.43 g, 12.26 mmol, synthesized via Step 1 of Intermediate CX) and 3-(difluoromethyl)-4-nitro-lH-pyrazole (2 g, 12.26 mmol, Intermediate HS) in DMF (20 mL) was added Cs_2C0_3 (7.99 g, 24.5 mmol). The reaction mixture was stirred at 115 °C for 12 hours. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo.* The residue was purified by silica column chromatography (PE/EA, 5/1 to 1/1) to give the title compound (2.00 g, 44.1% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 291.0 $(M+H-56)^+$.

[002587] Step 2 - 4-r3-(difluoromethv0-4-nitro-pyrazol-l-vnpiperidine

[002588] To a solution of tert-butyl 4-[3-(difluoromethyl)-4-nitro-pyrazol-l-yl]piperidine-l-carboxylate (1 g, 2.89 mmol) in DCM (10 mL) was added HC1 (4 M, 20 mL). The reaction mixture was concentrated *in vacuo* to give the title compound (830 mg, HC1, 85% purity) as a white solid.

LC-MS (ESL) *m/z* 247.0(M+H)$^+$.

[002589] **5-[2-[2-[4-[4-Amino-3-(difluoromethvPpyrazol-l-yll-l-piperidyllethoxylethyll-2-12.,6 -dioxo-3-piperidvDisoindoline-l.,3-dione [Intermediate JO)**



[002590] Step_ _1_ _-_ 5-[2-[2-[4-[3-(DifluoromethvO-4-nitro-pyrazol- 1-yll-1-piperidyl1ethoxy1ethyl1-2-(2.6-dioxo -3-piperidvOisoindoline-L3-dione


[002591] To a solution of 2-[2-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl]ethoxy]ethyl methanesulfonate (225 mg, 530 umol, Intermediate JO), 4-[3-(difluoromethyl)-4-nitro-pyrazol-l-yl]piperidine (100 mg, 353 umol, HC1, Intermediate JP) in ACN (2.00 mL) was added KI (5.87 mg, 35.3 umol) and NaHC0 $_3$ (89.1 mg, 1.06 mmol). The mixture was stirred at 80 °C for 16 hrs. On completion, the mixture was concentrated *in vacuo*. The mixture was purified by silica gel column (DCM: MeOH=50: 1) to give the title compound (100 mg, 49% yield) as white solid. LC-MS (ESI$^+$) *m/z* 575.1 (M+H)$^+$.

[002592] Step_ 2_ -_ 5-[2-[2-[4-[4-Amino-3 -(difluoromethvDpyrazol- 1-yl]-1-piper dyl1ethoxy1ethyl1-2-(2,6 -dioxo-3-piperidvOisoindoline-L3-dione

[002593] To a solution of 5-[2-[2-[4-[3-(difluoromethyl)-4-nitro-pyrazol-l-yl]-l-piperidyl]ethoxy]ethyl]-2-(2,6- dioxo-3-piperidyl)isoindoline-l,3-dione (90.0 mg, 156 umol) in THF (5.00 mL) was added Pt0 $_2$ (3.56 mg, 15.6 umol), the mixture was stirred at 15 °C for 16 hrs under H_2 (15 psi). On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (85.0 mg, 90% yield) as yellow solid. LC-MS (ESI$^+$) *m/z* 545.3

$(M+H)^+$.

[002594] **5-[3-(2-Aminoethoxy)propyl1-2-(2.,6-dioxo-3-piperidv0isoindoline-l.,3-dione [Intermediate JR)**



[002595] Step _1_ - _Tert-butyl _N-[2-[3-[2-(2,6-dioxo-3-piperidvl)-E3-dioxo-isoindolin-5-vl]ρϊΟρ-2-ynoxyl ethyl] carbamate

[002596] To a solution of tert-butyl N-(2-prop-2-ynoxyethyl)carbamate (2.36 g, 11.8 mmol synthesized via Step 1 on Intermediate CP), 5-bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (2.00 g, 5.93 mmol, Intermediate GA) in DMF (4.00 mL) was added CuI (112 mg, 593 umol), $Pd(PPh_3)2Cl2$ (416 mg, 593 umol), and TEA (10.8 g, 106 mmol). The mixture was stirred at 80 °C for 0.5 hr. On completion, the mixture was concentrated *in vacuo*. The mixture was purified by silica gel column (PE: EA =1: 1) to give the title compound (2.60 g, 96% yield) as yellow solid. ^1H NMR (400MHz, DMSO-d_6) δ 11.2 (s, 1H), 8.01 (s, 1H), 8.00 (s, 2H), 6.97 - 6.87 (m, 1H), 5.28 - 5.17 (m, 1H), 4.52 (s, 2H), 3.66 - 3.55 (m, 2H), 3.25 - 3.17 (m, 2H), 2.95 - 2.89 (m, 1H), 2.71 - 2.63 (m, 1H), 2.62 - 2.58 (m, 1H), 2.17 - 2.09 (m, 1H), 1.43 (s, 9H).

[002597] Step _2_ - _Tert-butyl _N-[2-[3-[2-(2,6-dioxo-3-piperidvl)-E3-dioxo-isoindolin-5-yllpropoxylethyll carbamate


[002598] To a solution of tert-butyl N-[2-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl]prop-2-ynoxy] ethyl]carbamate (2.60 g, 5.71 mmol) in THF (30.0 mL) was added Pd/C (500 mg, 10 wt%), and $Pd(OH)_2/C$ (500 mg, 10 wt%). The mixture was stirred at 15 °C for 16 hours

under ¾ (15 psi). On completion, the mixture was filtered and concentrated *in vacuo* to give the title compound (2.40 g, 91% yield) as yellow solid. LC-MS (ESI^+) *m/z* 482.3 $(M+Na)^+$.

[002599] Step 3 - 5-[3-(2-Aminoethoxy)propyl]-2-(2,6-dioxo-3-piperidyl)isoindoline-L3-dione

[002600] To a solution of tert-butyl N-[2-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl]propoxy]ethyl] carbamate (2.40 g, 5.22 mmol) in DCM (15.0 mL) was added HCl/dioxane (4.00 M, 15.0 mL). The mixture was stirred at 15 °C for 0.5 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (2.00 g, 90% yield, HC1) as yellow solid. 'H NMR (400MHz, DMSO-^e) δ 11.18 (s, 1H), 8.14 (s, 2H), 7.91 (d, *J* = 7.6 Hz, 1H), 7.87 (s, 1H), 7.81 (d, *J* = 7.6 Hz, 1H), 5.25 - 5.15 (m, 1H), 3.66 - 3.63 (m, 2H), 3.52 - 3.47 (m, 2H), 3.07 - 2.98 (m, 2H), 2.97 - 2.94 (m, 1H), 2.93 - 2.88 (m, 2H), 2.70 - 2.64 (m, 1H), 2.62 - 2.58 (m, 1H), 2.15 - 2.08 (m, 1H), 1.99 - 1.90 (m, 2H).


[002601] **Methyl 4-(3-bromo-4-nitro-pyrazol-l-yQbenzoate [Intermediate JS**



JS

[002602] To a solution of 3-bromo-4-nitro-lH-pyrazole (4.8 g, 25.0 mmol, CAS# 784193-37-9) and (4-methoxycarbonylphenyl) boronic acid (6.75 g, 37.5 mmol, CAS# 99768-12-4) in DCM (100 mL) was added $Cu(OAc)_2$ (4.54 g, 25.0 mmol), and pyridine (7.91 g, 100 mmol) under 0_2 (15 Psi). The reaction mixture was stirred at 20 °C for 12 hours under O2 (15 Psi) atmosphere. On completion, the mixture was washed with $NH_3•H_2O$ (50 mL), filtered and extracted with ethyl acetate (3 X 100 mL). The combined organic layers were washed with 2 N aq.HCl (60 mL) and brine (2 X 100 mL), dried over anhydrous sulfate sodium, filtered and concentrated *in vacuo*. The crude product was triturated with PE: EA= 10:1 (100 mL) to give the title compound (5.00 g, 61% yield) as a white solid. ^1H NMR (400MHz, DMSO-^e) δ 9.82 (s, 1H), 8.11 - 8.06 (m, 4H), 3.88 (s, 3H).

[002603] **Methyl 4-[4-amino-3-[3-(2-hydroxyethy0-2-oxo-imidazolidin-l-yllpyrazol-l-yll benzoate [Intermediate JT)**




[002604] Step 1 - Methyl 4-r3-r3-(2-hvdroxyethvn-2-oxo-imidazolidin-l-yl1-4-nitro-pyrazol-l-yllbenzoate

[002605] A mixture of methyl 4-(3-bromo-4-nitro-pyrazol-l-yl)benzoate (500 mg, 1.53 mmol, 1 eq, Intermediate JS), l-(2-hydroxyethyl)imidazolidin-2-one (239 mg, 1.84 mmol, CAS# 3699-54-5), bis (tetrabutylammonium iodide) copper[I] (132 mg, 306 umol), K2CO3 (423 mg, 3.07 mmol) and Nl, N2-dimethyl ethane- 1,2-diamine (27.0 mg, 306 umol) in dioxane (25 mL) was degassed and purged with N_2 3 times. Then the mixture was stirred at 110 °C for 16 hours under N_2 atmosphere. The mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was purified by Pre-HPLC(acid condition) give the title compound (110 mg, 17% yield) as yellow solid; LC-MS (ESI^+) *m/z* 376.0 $(M+H)^+$.

[002606] Step 2 - Methyl 4-r4-amino-3-r3-(2-hvdroxyethvD-2-oxo-imidazolidin-l-yllpyrazol- 1-yllbenzoate

[002607] To a solution of methyl 4-[3-[3-(2-hydroxyethyl)-2-oxo-imidazolidin-l-yl]-4-nitro-pyrazol-l- yl]benzoate (110 mg, 293 umol) in THF (10 mL) was added Pd/C (20 mg, 10 wt%). The mixture was stirred at 20 °C for 3 hours under H_2 (15 Psi). On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (100 mg, 98% yield) as yellow solid; LC-MS (ESI^+) *m/z* 346.2 $(M+H)^+$.

[002608] **3,3-Dimethylpyrrolidin-2-one [Intermediate JU)**



[002609] Step 1 - Tert-butyl 2-oxopyrrolidine-l-carboxylate

[002610] To a solution of pyrrolidin-2-one (20 g, 235 mmol) in ACN (450 mL) was added $(BOC)_20$ (61.5 g, 282 mmol) and DMAP (2.87 g, 23.50 mmol) at 0 °C. The mixture was stirred at 10 °C for 16 hours. On completion, the mixture was concentrated *in vacuo.* The residue was purified by column chromatography ($Si0_2$, PE/EA=3/l) to give the title compound (38 g, 87% yield) as light yellow solid. ^1H NMR (400MHz, CDCh) δ 3.74 (t, *J* = 7.2 Hz, 2H), 2.50 (t, *J* = 8.2 Hz, 2H), 2.06 - 1.93 (m, 2H), 1.52 (s, 9H).


[002611] Step 2 - Tert-butyl 3.3-dimethyl-2-oxo-pyrrolidine- 1-carboxyl ate

[002612] To a mixture of tert-butyl 2-oxopyrrolidine-l-carboxylate (4.5 g, 24.3 mmol) in THF (50 mL) was added LiHMDS (1.0 M, 25.5 mL) at -70 °C. Then the reaction mixture was stirred at -30°C for 0.5 hour. Mel (8.62 g, 60.7 mmol) was added to the mixture. The reaction mixture was stirred at 25 °C for 1 hour. On completion, the mixture was concentrated *in vacuo.* The residue was quenched with water (30 mL) and extracted with EtOAc (3 X 30 mL). The organic layer was dried with Na_2S0_4, filtrated and concentrated *in vacuo.* The residue was purified by column chromatography ($Si0_2$, PE:EA = 5:1) to give the title product (2.80 g, 54% yield) as colorless solid. ^1H NMR (400MHz, CDCh) δ 3.67 (t, *J* = 7.2 Hz, 2H), 1.85 (t, *J* = 7.2 Hz, 2H), 1.55 (s, 9H), 1.20 (s, 6H).

[002613] Step 3 - 3.3-Dim ethyl pyrrol idin-2-one

[002614] To a mixture of tert-butyl 3,3-dimethyl -2-oxo-pyrrolidine-l-carboxylate (2.0 g, 9.38 mmol,) in DCM (3 mL) was added HCl/dioxane (4 M, 2.00 mL). Then the reaction mixture was stirred at 25 °C for 12 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (1.00 g, 94% yield) as yellowish solid. ^1H NMR (400MHz, DMSO-d_6) δ 3.06 (t, *J* = 6.8 Hz, 2H), 1.76 (t, *J* = 6.8 Hz, 2H), 0.93 (s, 6H).

[002615] Methyl 4-[4-amino-3-(3,3-dimethyl-2-oxo-pyrrolidin-l -yl)pyrazol-l - yl]benzoate [Intermediate JV)




[002616] Step 1 - Methyl 4-[3-(3,3-dimethyl-2-oxo-pyrrolidin-1-yl)-4-nitro-pyrazol-1-yllbenzoate

[002617] A mixture of methyl 4-(3-bromo-4-nitro-pyrazol-l-yl)benzoate (500 mg, 1.53 mmol, Intermediate JS), 3,3-dimethylpyrrolidin-2-one (208 mg, 1.84 mmol, Intermediate JU), bis(tetrabutylammonium iodide) copper[I] (132 mg, 306 umol), K_2CO_3 (423 mg, 3.07 mmol) and N,N'-dimethyl ethane- 1,2-diamine (27.0 mg, 306 umol) in dioxane (20 mL) was degassed and purged with N_2 gas 3 times, and then the mixture was stirred at 110 °C for 16 hours under N_2 atmosphere. On completion, the reaction mixture was filtered and the filtrate was *concentrated in vacuo.* The residue was purified by Pre-HPLC (acid condition) to give the title compound (200 mg, 18% yield) as yellow solid, LC-MS (ESI^+) *m/z* 359.2 $(M+H)^+$.


[002618] Step 2 - Methyl 4-r4-amino-3-(3.3-dimethyl-2-oxo-pyrrolidin-l -yl jpyrazol- 1-yllbenzoate

[002619] To a solution of methyl 4-[3-(3,3-dimethyl-2-oxo-pyrrolidin-l-yl)-4-nitro-pyrazol-l-yl]benzoate (50 mg, 139 umol) in MeOH (5 mL) was added Pd/C (30 mg, 10 wt%) under N_2. The suspension was degassed under vacuum and purged with H_2 gas three times. The mixture was stirred at 20 °C for 3 hours under H_2 (15 Psi). On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (45 mg, 97% yield) as light yellow solid; LC-MS (ESI^+) *m/z* 329.2 $(M+H)^+$.

[002620] **2-[2,6-Dioxo-3-piperidvO-4-[4-piperidylamino)isoindoline-l.,3-dione [Intermediate JW1**



R



JW


[002621] Step 1 - Tert-butyl 4-IT2-(2.6-dioxo-3-piperidvP-l.3-dioxo-isoindolin-4-yllaminolpiperidine-l- carboxylate

[002622] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (2.5 g, 9.05 mmol, Intermediate R) and tert-butyl 4-aminopiperidine-l -carboxylate (1.81 g, 9.05 mmol, CAS# 502482-34-0) in dioxane (25 mL) was added DIPEA (4.68 g, 36.2 mmol). The reaction mixture was stirred at 115 °C for 15 hrs. On completion, the mixture was concentrated *in vacuo.* The residue was purified by silica gel chromatography to give the title compound (2.16 g, 52% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 479.1 $(M+Na)^+$.

[002623] Step 2 - 2-(2.6-Dioxo-3-piperidvl)-4-(4-piperidylamino)isoindoline-E3-dione

[002624] To a solution of tert-butyl 4-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]piperidine-l- carboxylate (2.16 g, 4.73 mmol) in DCM (5 mL) was added HCl/dioxane (10 mL). The reaction mixture was stirred at 20 °C for 2 hrs. On completion, the mixture was concentrated *in vacuo.* The residue was triturated with DCM (50 mL), stirred and filtered. The filter cake was dried *in vacuo* to give the title compound (1.20 g, 65% yield, HC1) as a yellow green solid. LC-MS (ESI^+) *m/z* 357.1 $(M+H)^+$.

[002625] **Tert-butyl N-[2-|2-|2-(2-oxoethoxy)ethoxy]ethoxy]ethyl]carbamate (Intermediate JX)**




JX

[002626] To a solution of DMSO (1.33 g, 17.0 mmol) in DCM (10 mL) was added a solution

of $(COCl)_2$ (1.73 g, 13.6 mmol) in DCM (15 mL) dropwise at -70 °C. The mixture was stirred at this temperature for 10 minutes. Then a solution of tert-butyl N-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]carbamate (2.00 g, 6.82 mmol, synthesized via Steps 1-3 of Intermediate AO) in DCM (15 mL) was added into the above mixture slowly. After stirred at -70 °C for 50 minutes, TEA (5.52 g, 54.5 mmol) was added and the reaction mixture was stirred at -70 °C for 0.5 hr. On completion, the mixture was quenched with water (30 mL), and then separated. The aqueous phase was extracted with DCM (2 X 30 mL). Then the organic phase was combined and washed with brine (2 X 30 mL), dried over Na_2SO_4, filtered and the filtrate was concentrated *in vacuo* to give the title compound (1.50 g, 76% yield) as yellow oil, which was used directly in the next step without further purification.

[002627] **4-II1-I2-I2-[2-(2-Aminoethoxy)ethoxyl ethoxy]ethyll-4-piperidyl] aminol-2-(2,6-dioxo-3- piperidvQisoindoline-l.,3-dione [Intermediate JY)**




[002628] Step 1 - Tert-butyl N-[2-[2-[2-[2-[4-[[2-(2,6-ώ οχο-3-ρϊperidvl)-1,3-ώ οχο-isoindolin-4-vnaminol-l- piperidyllethoxylethoxylethoxylethyllcarbamate

[002629] To a mixture of tert-butyl N-[2-[2-[2-(2-oxoethoxy)ethoxy]ethoxy]ethyl]carbamate (386 mg, 1.32 mmol, Intermediate JX) and 2-(2,6-dioxo-3-piperidyl)-4-(4-piperidylamino)isoindoline-l,3-dione (400 mg, 1.02 mmol, HC1, Intermediate JW) in THF (20 mL) was added KOAc (200 mg, 2.04 mmol). One hour later, $NaBH(OAc)_3$ (432 mg, 2.04 mmol) was added and the reaction mixture was stirred at 20 °C for 16 hrs. On completion, the mixture was concentrated *in vacuo.* The residue was purified by reverse phase (0.1% HC1 condition) to give the title compound (550 mg, 86% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 632.4 $(M+H)^+$

[002630] Step 2 - 4-[[1-[2-[2-[2-(2-Aminoethoxy)ethoxy1ethoxy1ethyl1-4-piperidyl1amino1-2-(2.6-dioxo-3- piperidv0isoindoline-L3-dione

[002631] To a solution of tert-butyl N-[2-[2-[2-[2-[4-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl] amino]-l-piperidyl]ethoxy]ethoxy]ethoxy]ethyl]carbamate (550 mg, 871 umol) in DCM (5 mL) was added HCl/dioxane (10 mL). The reaction mixture was stirred at 20 °C for 10 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (460 mg, 93% yield, HC1) as a yellow solid. LC-MS (ESI^+) *m/z* 532.2 $(M+H)^+$.

[002632] **5-[[l-[2-[2-Aminoethoxy]ethyl1-4-piperidyl]amino1-2-[2,6-dioxo-3-piperidvBisoindoline-l.,3-dione [Intermediate** *JZ)*



JZ

[002633] Step 1 - Tert-butyl N-r2-r2-r4-rr2-(2.6-dioxo-3-piperidyl)-l.3-dioxo-isoindolin-5-yllaminol-l- piperidyllethoxylethvHcarbamate


[002634] To a solution of 2-(2,6-dioxo-3-piperidyl)-5-(4-piperidylamino)isoindoline-l,3-dione (400 mg, 1.02 mmol, HC1, synthesized via Steps 1-2 of Intermediate HZ), tert-butyl N-[2-

(2-oxoethoxy)ethyl] carbamate (310 mg, 1.53 mmol, synthesized via Step 1 of Intermediate FS) in a mixed solvent of THF (10.0 mL) and DCM (10.0 mL) was added KOAc (199 mg, 2.04 mmol), the mixture was stirred at 15 °C for 0.5 hr, then $NaBH(OAc)_3$ (431 mg, 2.04 mmol) was added, and the mixture was stirred at 15 °C for 16 hrs. On completion, the mixture was quenched with FLO (2.00 mL) and concentrated *in vacuo.* The crude product was purified by reverse phase: (0.1% HC1 condition) to give the title compound (380 mg, 68% yield) as yellow solid. LC-MS (ESI^+) *m/z* 544.4 $(M+H)^+$.

[002635] Step 2 - 5-[[1-[2-(2-Aminoethoxy)ethyl1-4-piperidyl1amino1-2-(2,6-dioxo-3-piperidvDisoindoline -L3-dione

[002636] To a solution of tert-butyl N-[2-[2-[4-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl] amino]- l-piperidyl]ethoxy]ethyl]carbamate (380 mg, 699 umol) in DCM (3.00 mL) was added HCl/dioxane (4.00 M, 5.00 mL), the mixture was stirred at 15 °C for 0.5 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (300 mg, 90% yield, HC1) as yellow solid. LC-MS (ESI^+) *m/z* 444. 1 $(M+H)^+$.

[002637] **5-II1-I2-I2-[2-(2-Aminoethoxy)ethoxyl ethoxy]ethyll-4-piperidyl] aminol-2-(2,6-dioxo-3- piperidvBisoindoline-l,3-dione [Intermediate KA)**



KA

[002638] Step 1 - Tert-butyl N-[2-[2-[2-[2-[4-[[2-(2.6-άϊοχο-3-ρϊperiάνl)-1,3-άϊοχο-isoindolin-5-vnaminol-l- piperidyllethoxylethoxylethoxylethyllcarbamate


[002639] To a solution of 2-(2,6-dioxo-3-piperidyl)-5-(4-piperidylamino)isoindoline-l,3-

dione (400 mg, 1.02 mmol, HC1, synthesized via Steps 1-2 of Intermediate HZ) in THF (20 mL) was added TEA (206 mg, 2.04 mmol, 283 uL). The mixture was stirred at 20 °C for 30 minutes, then tert-butyl N-[2-[2-[2-(2-oxoethoxy)ethoxy]ethoxy] ethyl]carbamate (385 mg, 1.32 mmol, Intermediate JX), HOAc (183 mg, 3.05 mmol, 174 uL) and $NaBH(OAc)_3$ (431 mg, 2.04 mmol) was added to the mixture. The reaction mixture was stirred at 20 °C for 16 hours. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (400 mg, 62% yield) as a yellow solid. LC-MS (ESI^+) m/z 632.4 $(M+H)^+$.

[002640] Step 2 - 5-[[1-[2-[2-[2-(2-Aminoethoxy)ethoxy1ethoxy1ethyl1-4-piperidyl1amino1-2-(2.6-dioxo-3- piperidv0isoindoline-L3-dione

[002641] To a solution of tert-butyl N-[2-[2-[2-[2-[4-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl] amino]-l-piperidyl]ethoxy]ethoxy]ethoxy]ethyl]carbamate (400 mg, 633 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 6.20 mL). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (350 mg, 97% yield) as a yellow solid. LC-MS (ESI^+) m/z 532.4 $(M+H)^+$.

[002642] **4-14-12-[2-|2-(2-Aminoethoxy)ethoxy| ethoxy] ethyl] piperazin-l-yl 1-2-12,6-dioxo-3-piperidvB isoindoline-l,3-dione [Intermediate KB]**



[002643] Step 1 - Tert-butyl N-[2-[2-[2-[4-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl1piperazin-l -yllethoxylethoxylethoxylethyllcarbamate


[002644] To a mixture of 2-(2,6-dioxo-3-piperidyl)-4-piperazin-l-yl-isoindoline-l,3-dione (250 mg, 659 umol, HC1, synthesized via Steps 1-2 Intermediate IA) and TEA (66.7 mg, 659

umol, 91.8 uL) in THF (10 mL) and DMF (5 mL) was added tert-butyl N-[2-[2-[2-(2-oxoethoxy)ethoxy]ethoxy]ethyl]carbamate (249 mg, 857 umol, Intermediate JX), HOAc (39.6 mg, 659 umol, 37.7 uL) and $NaBH(OAc)_3$ (279 mg, 1.32 mmol). The reaction mixture was stirred at 20 °C for 20 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (FA condition) to give the title compound (200 mg, 49% yield) as yellow solid. LC-MS (ESI^+) *m/z* 618.4 $(M+H)^+$.

[002645] Step_2_-_4-r4-r2-r2-r2-(2-Aminoethoxy)ethoxy1ethoxy1ethyl1piperazin-l-yl1-2-(2,6-dioxo-3-piperidvl) isoindoline-F3-dione

[002646] To a mixture of tert-butyl N-[2-[2-[2-[2-[4-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl] piperazin-l-yl]ethoxy]ethoxy]ethoxy]ethyl]carbamate (200 mg, 323 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 10 mL). The reaction mixture was stirred at 20 °C for 3 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (179 mg, 99% yield, HC1) light yellow gum. LC-MS (ESI^+) *m/z* 518.3 $(M+H)^+$.

[002647] **3-[5-Bromo-l-oxo-isoindolin-2-vBpiperidine-2,6-dione [Intermediate KC1**



KC

[002648] Step **1** - Methyl 4-bromo-2-(bromomethvnbenzoate


[002649] To a solution of methyl 4-bromo-2-methyl-benzoate (5.00 g, 21.8 mmol, CAS# 99548-55-7) in CCl_4 (50.0 mL), NBS (4.66 g, 26.1 mmol) and AIBN (358 mg, 2.18 mmol) were added. The reaction mixture was stirred at 80 °C for 24 hrs. On completion, the reaction was filtered and concentrated *in vacuo.* The residue was purified by silica gel chromatography (PE: EA = 20: 1) to give the title compound (5.1 g, 76% yield) as colorless liquid. ^1H NMR (400MHz, DMSO-de) δ 7.86 (d, J = 8.4 Hz, 1H), 7.59 (s, 1H), 7.54 - 7.52 (m, 1H), 4.92 (s, 2H), 3.96 (s, 3H).

[002650] Step 2 - 3-(5-bromo-l-oxo-isoindolin-2-vDpiperidine-2.6-dione

[002651] To a solution of 3-aminopiperidine-2,6-dione (2.00 g, 12.1 mmol, HC1) and methyl 4-bromo-2-(bromomethyl)benzoate (5.10 g, 16.5 mmol) in DMF (50.0 mL) was added TEA (4.92 g, 48.6 mmol). The reaction mixture was stirred at 75 °C for 12 hrs. On completion, the reaction mixture was diluted with water (200 mL) and filtered. The filtered cake was collected. The reaction mixture was concentrated *in vacuo.* The residue was triturated with EA: H_20 = 1: 1 (50 mL) to

give the title compound (1.70 g, 39% yield) as blue solid. ^{1}H NMR (400MHz, DMSO-d $_6$) δ 10.99 (s, 1H), 7.90 (s, 1H), 7.74 - 7.66 (m, 2H), 5.14 - 5.09 (m, 1H), 4.50 - 4.33 (m, 2H), 2.95 - 2.86 (m, 1H), 2.70 - 2.61 (m, 1H), 2.42 - 2.36 (m, 1H), 2.04 - 2.01 (m, 1H).

[002652] **3-[l-Oxo-5-piperazin-l-yl-isoindolin-2-vnpiperidine-2,6-dione [Intermediate KD)**




[002653] Step 1 - Tert-butyl 4-r2-(2.6-dioxo-3-piperidvO-l-oxo-isoindolin-5-vnpiperazine-l-carboxylate

[002654] To a solution of 3-(5-bromo-l-oxo-isoindolin-2-yl)piperidine-2,6-dione (500 mg, 1.55 mmol, Intermediate KC), and tert-butyl piperazine- l-carboxylate (413 mg, 1.86 mmol, HC1) in dioxane (40.0 mL) was added CS2CO3 (1.01 g, 3.09 mmol), RuPhos (144 mg, 309 umol), [2-(2-aminophenyl)phenyl]-chloro-palladium;dicyclohexyl-[2-(2,6-diisopropoxyphenyl)phenyl]phosphane (240 mg, 309 umol) and 4A molecular sieves (30.0 mg), and the mixture was stirred at 100 °C for 16 hr under N_2. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo*. The mixture was purified by reverse phase: (0. 1% HC1) to give the title compound (350 mg, 95% yield) as yellow oil, LC-MS (ESI$^+$) m/z 429.3 (M+H)$^+$.

[002655] Step 2 - 3-(T-Oxo-5-piperazin-l-yl-isoindolin-2-vDpiperidine-2.6-dione

[002656] To a solution of tert-butyl 4-[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]piperazine- l-carboxylate (160 mg, 373 umol) in DCM (2.00 mL) was added HCl/dioxane (4.00 M, 4.00 mL), the mixture was stirred at 15 °C for 0.5 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (130 mg, 90% yield, HC1) as yellow solid. LC-MS (ESL) m/z 329.2 (M+H)$^+$.

[002657] **3-[5-[4-[2-[2-(2-Aminoethoxy)ethoxy|ethyl1piperazin-l-yl1-l-oxo-isoindolin-2-yl]piperidine -2,6-dione [Intermediate KE)**




[002658] Step 1 - Tert-butyl N-[2-[2-[2-[4-[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yllpiperazin- 1-yl] ethoxylethoxylethyllcarbamate

[002659] To a solution of 3-(l-oxo-5-piperazin-l-yl-isoindolin-2-yl)piperidine-2,6-dione (130 mg, 356 umol, HC1, Intermediate KE), tert-butyl N-[2-[2-(2-oxoethoxy)ethoxy]ethyl]carbamate (105 mg, 427 umol, Intermediate HY) in THF (10.0 mL) was added KOAc (69.9 mg, 712 umol). The mixture was stirred at 15 °C for 0.5 hr, then $NaBH(OAc)_3$ (151 mg, 712 umol) was added, and the mixture was stirred at 15 °C for 16 hrs. On completion, the mixture was diluted with H_20 (1.00 mL) and concentrated *in vacuo*. The crude product was purified by reverse phase: (0.1% HC1) to give the title compound (130 mg, 65% yield) as yellow solid. LC-MS (ESI^+) m/z 560.4 $(M+H)^+$

[002660] Step 2 - 3-r5-r4-r2-r2-(2-Aminoethoxy)ethoxy1ethyl1piperazin-l-yl1-l-oxo-isoindolin-2-vnpiperidine -2.6-dione

[002661] To a solution of tert-butyl N-[2-[2-[2-[4-[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]piperazin-l-yl]ethoxy]ethoxy]ethyl]carbamate (130 mg, 232 umol) in DCM (3.00 mL) was added HCl/dioxane (4.00 M, 4.00 mL), and the mixture was stirred at 15 °C for 0.5 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (110 mg, 90% yield, HC1) as yellow solid. LC-MS (ESI^+) m/z 460.4 $(M+H)^+$.

[002662] **5-[4-[2-[2-Aminoethoxy]ethyl]piperazin-l-yl1-2-[2,6-dioxo-3-piperidvBisoindoline-l.,3-dione [Intermediate KF)**



KF

[002663] Step 1 - Tert-butyl N-[2-[2-[4-[2-(2,6-dioxo-3-piperidyl)-L3-dioxo-isoindolin-5-yllpiperazin- 1-yl] ethoxylethyllcarbamate


[002664] To a solution of 2-(2,6-dioxo-3-piperidyl)-5-piperazin-l-yl-isoindoline-l,3-dione (500 mg, 1.32 mmol, HC1, synthesized via Steps 1-2 of Intermediate IB) in a mixed solvent of DCM (20 mL) and DMF (6 mL) was added TEA (200 mg, 1.98 mmol), HOAc (158 mg, 2.64 mmol) and tert-butyl N-[2-(2-oxoethoxy)ethyl]carbamate (804 mg, 3.96 mmol, synthesized via Step 1 of Intermediate FS) at 5 ° C. The mixture was stirred at 5 ° C for 30 minutes, and then $NaBH(OAc)_3$ (559 mg, 2.64 mmol) was added at 0 ° C, the mixture was stirred at 10 ° C for 72 hours. On completion, the reaction mixture was quenched by water (0.1 mL), and then concentrated *in vacuo.* The residue was purified by prep-HPLC (FA condition) to give the title compound (0.40 g, 53% yield) as yellow solid. LC-MS (ESI^+) *m/z* 530.2$(M+H)^+$.

[002665] Step 2 - 5-r4-r2-(2-Aminoethoxy)ethyl1piperazin-l-yl1-2-(2.6-dioxo-3-piperidvDisoindoline-E3-dione

[002666] To a solution of tert-butyl N-[2-[2-[4-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl]piperazin-l- yl]ethoxy]ethyl]carbamate (0.37 g, 649 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 3 mL). The mixture was stirred at rt for 1.5 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (0.28 g, 91% yield, HC1) as yellow solid. LC-MS (ESI^+) *m/z* 430.1 $(M+H)^+$.

[002667] **2-[2-[Cvclopropylmethylamino)-4-pyridyl1-N-[3-[difluoromethvB-l-[4-**

[[[(2S,4RV4-hydroxy pyrrolidine-2-carbonyllaminolmethyllphenyllpyrazol-4-ylloxazole-4-carboxamide (Intermediate KG)



KG

[002668] Step 1 - Tert-butyl N-r4-r4-nT-r4-(azidomethvQphenvn-3-(difluoromethvOpyrazol-4- vl ıcarbamoyl] oxazol-2-yl1-2-pyridvH-N-(cvclopropylmethvncarbamate

[002669] To a mixture of tert-butyl N-(cyclopropylmethyl)-N-[4-[4-[[3-(difluoromethyl)-l-[4- (hydroxymethyl)phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (1 g, 1.72

mmol, synthesized via Step 1-2 of Intermediate GF) in THF (20 mL) was added DPPA (2.37 g, 8.61 mmol) at 0 °C, then DBU (1.31 g, 8.61 mmol) was added. The mixture was stirred at 20 °C for 16 hrs. On completion, the mixture was quenched with water (10 mL), then extracted with EA (2 X 50 mL). The organic layer was concentrated *in vacuo* to give a residue, which was purified by silica gel chromatography to give the title compound (700 mg, 67% yield) as white solid. LC-MS (ESI+) *m/z* 606.3 (M+l) +.

[002670] Step 2 - Tert-butyl N-[4-[4-[[1-[4-(aminomethvl)phenyl]-3-(difluoromethvDpyrazol-4- vl]_ carbamoyl1oxazol-2-vH-2-pyridyl1-N-(cvclopropylmethvDcarbamate

[002671] To a solution of tert-butyl N-[4-[4-[[l-[4-(azidomethyl)phenyl]-3-(difluoromethyl)pyrazol-4-yl] carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(cyclopropylmethyl)carbamate (700 mg, 1.16 mmol) in THF (100 mL) was added Pd/C (50 mg, 10 wt%). The suspension was degassed and purged with H_2 for 3 times. The mixture was stirred under H_2 (15 Psi) at rt for 16 hrs. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (500 mg, 74% yield) as white solid. LC-MS (ESI+) *m/z* 580.3 (M+l) +.

[002672] **Step 3 - Tert-butyl (28.4 IQ-2-rr4-]4-rr2-]2-]rert-butoxycarbonyl(cvclopropylmethvDamino1-4-pyridyl1 _ oxazole-4-carbonyl1amino1-3-(difluoromethvnpyrazol-l-vnphenyl1methylcarbamovn-4-hvdroxy-pyrrolidine-l-carboxylate**


[002673] A mixture of (2S,4R)-l-tert-butoxycarbonyl-4-hydroxy-pyrrolidine-2-carboxylic acid (199 mg, 862 umol, CAS# 13726-69-7), tert-butyl N-[4-[4-[[l-[4-(aminomethyl)phenyl]-3-(difluoromethyl) pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(cyclopropylmethyl)carbamate (500 mg, 862 umol), HATU (393 mg, 1.04 mmol), and DIPEA (334 mg, 2.59 mmol) in DMF (3 mL) was degassed and purged with N_2 gas 3 times, and then the mixture was stirred at rt for 2 hrs under N_2 atmosphere. On completion, the reaction mixture was quenched with water 20 mL, and then extracted with EA (2 X 100 mL). The combined organic layer was washed with brine (20 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC to give the title compound (460 mg, 67% yield) as white solid. LC-MS (ESI+) *m/z* 793.2 (M+l) +.

[002674] Step 4 - 2-r2-(CvclopropylmethylaminoV4-pyridyl1-N-r3-(difluoromethvD-l-r4-rrr(2S.4R)-4-hydroxy _ pyrrolidine-2-carbonyl1amino1methyl1phenyl1pyrazol-4-yl1oxazole-4-


carboxamide


[002675] To a solution of tert-butyl (2S,4R)-2-[[4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]phenyl]methylcarbamoyl]-4-hydroxy-pyrrolidine-l-carboxylate (200 mg, 252 umol) in DCM (10 mL) was added HCl/dioxane (4 M, 3 mL). The mixture was stirred at rt for 16 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (150 mg, 94% yield) as white solid. LC-MS (ESI^+) *m/z* 593.4 $(M+l)^+$.

[002676] **N-[l-[4-[[[[2S,4R)-l-[[2SV2-amino-3,3-dimethyl-butanoyl1-4-hvdroxy-pyrrolidine-2-carbonyl] amino] methyl] phenyl] -3-(difluoromethv0pyrazol-4-yll -2-12-(cyclopropylmethylaminoV4-pyridylloxazole-4-carboxamide [Intermediate Kill**



KG





KH


[002677] Step **1** - Tert-butyl N-[(1S)-l-[(2S,4R)-2-[[4-[4-[[2-[2-(cyclopropylmethylamino)-4-pyridyl1oxazole-4-carbonvnamino1-3-(difluoromethv0pyrazol-l-yIphenyImethylcarbamoyl 1-4-hvdroxy-pyrroli dine-1-carbonyl 1-2,2-dim ethyl -propyl 1

[002678] A mixture of 2-[2-(cyclopropylmethylamino)-4-pyridyl]-N-[3-(difluoromethyl)-l-[4- [[[(2S,4R)-4-hydroxypyrrolidine-2-carbonyl]amino]methyl]phenyl]pyrazol-4-yl]oxazole-4-carboxamide (70 mg, 111 umol, HC1, Intermediate KG), (2S)-2-(tert-butoxycarbonylamino)-3,3-dimethyl-butanoic acid (26 mg, 111 umol, CAS# 62965-35-9), HATU (51 mg, 133 umol), and DIPEA (43. mg, 334 umol) in DMF (5 mL) was degassed and purged with N_2 gas 3 times, and then the mixture was stirred at rt for 2 hrs under N_2 atmosphere. On completion, the mixture was concentrated *in vacuo*, the residue was purified by prep-HPLC to give the title compound (65 mg, 65% yield) as white solid. LC-MS (ESI^+) *m/z* 806.5 $(M+l)^+$.

[002679] Step 2 - N-[1-[4-[r (2S,4R)- l~[(2S)-2-ami no-3. 3-dim ethyl -butanovn-4-hvdroxy-pyrrolidine-2- _ carbonyl1amino1methyl1phenyl1-3-(difluoromethvnpyrazol-4-yl1-2-r2-(cvclopropylmethylamino)-4-pyridyl1oxazole-4-carboxamide

[002680] To a solution of tert-butyl N-[(lS)-l-[(2S,4R)-2-[[4-[4-[[2-[2-(cyclopropylmethylamino) -4-pyridyl]oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]phenyl]methylcarbamoyl]-4-hydroxy-pyrrolidine-l-carbonyl]-2,2-dimethyl-propyl]carbamate (100 mg, 124 umol) in DCM (6 mL) was added HCl/dioxane (4 M, 2 mL). The mixture was stirred at rt for 2 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (95 mg, 100% yield) as white solid. LC-MS (ESI^+) *m/z* 706.2 $(M+l)^+$

[002681] Ol -Benzyl _ 02-[[3R,5S]-5-[[4-[4-[[2-[2-[cvclopropylmethylamino]-4-pyridyl]oxazole-4- _ carbonyllaminol-3-tdifluoromethvBpyrazol-l-yl1phenyl1methylcarbamoyl1pyrrolidin-3-yl][2SVpyrrolidine-l.,2-dicarboxylate [Intermediate _KD



[002682] Step 1 - Ol-benzyl 02-r(3R.5S)-l-tert-butoxycarbonyl-5-rr4-r4-IT2-r2-rtert-butoxycarbonyl (cvclopropylmethvnamino1-4-pyridyl1oxazole-4-carbonyl1amino1-3-(difluoromethvnpyrazol-l-yllphenyllmethylcarbamoyllpyrrolidin-3-yll (2S)-pyrrolidine-12-dicarboxylate


[002683] To a solution of (2S)-l-benzyloxycarbonylpyrrolidine-2-carboxylic acid (72.3 mg, 290 umol) in DCM (10 mL) was added EDCI (83.4 mg, 435 umol) and DMAP (3.54 mg, 29.0 umol) at 0 °C, then tert-butyl(2S,4R)-2-[[4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]phenyl]methylcarbamoyl]-4-hydroxy-pyrrolidine-l-carboxylate (230 mg, 290 umol, synthesized via Steps 1-3 of Intermediate KG) was added to the mixture, and the reaction mixture was stirred at rt for 12 hr. On completion, the mixture was diluted with H_20 (5 mL), then concentrated *in vacuo* to give a residue. The residue was purified by reverse phase

(0.1% FA condition) to give the title compound (280 mg, 94% yield) as a white solid. LC-MS (ESI^+) m/z 1024.6 $(M+H)^+$.


[002684] Step 2- Ol-benzyl 02-[(3R,5S)-5-[[4-[4-[[2-[2-(cvclopropylmethylamino)-4-pyridylloxazole-4- carbonyl] amino] -3-(difluorom ethyl jpyrazol- 1-ylIphenyl Imethyl carbamoyl 1pyrrolidin-3-yl](2S)-pyrroli dine- 1,2-dicarboxyl ate


[002685] To a solution of Ol-benzyl 02-[(3R, 5S)-l-tert-butoxycarbonyl-5-[[4-[4-[[2-[2-[tert-butoxy carbonyl (cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol- 1-yl]phenyl]methylcarbamoyl]pyrrolidin-3 -yl] (2S)-pyrrolidine- 1,2-dicarboxylate (260 mg, 253 umol) in DCM (2 mL) was added TFA(l.54 g, 13.5 mmol, 1 mL), and the reaction mixture was stirred at rt for 12 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (200 mg, 96% yield) as a white solid. LC-MS (ESI^+) m/z 824.4$(M+H)^+$.

[002686] 02- [(3R,5S)-1-b2SE2-amino-3.3-dimethyl-butanoyll-5- [[4-[4-[[2-[2-(cvclopropylmethylaminoV4-pyridylloxazole-4-carbonyllaminol-3-(difluoromethvPpyrazol-l-yllphenyllmethylcarbamoyllpyrrolidin-3-yll Ol-benzyl (2S)-pyrrolidine-l.,2-dicarboxylate [Intermediate KJ)



KI





KJ

[002687] Step 1- (SVl-Benzyl 2-(Y3R.5S)-l-((S)-2-((tert-butoxycarbonyl)amino)-3.3-dimethylbutanovn-5- (Y4-(4-(2-(2-(YcvclopropvlmethvOamino)pvridin-4-vOoxazole-4-carboxamido)-3-(difluoromethvO-lH-pyrazol-l-vObenzvOcarbamovQpynOlidin-3-vO pyrrolidine- E2-dicarboxylate


[002688] To a solution of 0 1-benzyl 02-[(3R,5S)-5-[[4-[4-[[2-[2-(cyclopropylmethylamino)-4-pyridyl]oxazole -4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]phenyl]methylcarbamoyl]pyrrolidin-3-yl](2S)- pyrrolidine-l,2-dicarboxylate (140 mg, 169 umol, Intermediate KI) and (2S)-2-(tert- butoxycarbonylamino)-3, 3-dimethyl-butanoic acid (39.3 mg, 169 umol, CAS# 62965-35-9) in DMF (10 mL) was added DIPEA (21.9 mg, 169 umol, 29.6 uL) and HATU (77.5 mg, 203 umol), and the mixture was stirred at rt for 12 hr. On completion, the mixture was quenched by addition of H_20 (5mL), and then concentrated *in vacuo* to give a

residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (160 mg, 91% yield) as a white solid. LC-MS (ESI^+) m/z 1037.3 $(M+H)^+$.

[002689] Step 2 - 02-[(3R,5S)-1-[(2S)-2-amino-3,3-dimethyl-butanoyl]-5-[[4-[4-[[2-[2-(cyclopropylmethylamino)-4-pyridyl]oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-1-yl]phenyl]methylcarbamoyl]pyrrolidin-3-yl] Ol-benzyl (2S)-pyrrolidine-1,2-dicarboxylate

[002690] To a solution of Ol-benzyl 02-[(3R,5S)-l-[(2S)-2-(tert-butoxycarbonylamino)-3,3-dimethyl-butanoyl] -5-[[4-[4-[[2-[2-(cyclopropylmethylamino)-4-pyridyl]oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]phenyl]methylcarbamoyl]pyrrolidin-3-yl] (2S)-pyrrolidine-l, 2-dicarboxylate (150 mg, 144 umol) in DCM (4 mL) was added TFA (3.08 g, 27.0 mmol, 2.0 mL), and the reaction mixture was stirred at rt for 3 hr. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (130 mg, 96% yield) as a yellow solid. LC-MS (ESI^+) m/z 937.5 $(M+H)^+$.

[002691] **4-[[1-[2-[2-(2-Aminoethoxy]ethoxyl ethyll-4-piperidyl] amino]-2-[2,6-dioxo-3-piperidvPisoindoline-l.,3-dione [Intermediate KK)**




[002692] Step 1 - Tert-butylN-[2-[2-[2-[4-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]-1-piperidyll ethoxy]ethoxy]ethyl]carbamate

[002693] To a mixture of 2-(2,6-dioxo-3-piperidyl)-4-(4-piperidylamino)isoindoline-l,3-dione (200 mg, 509 umol, HC1, Intermediate JW) in DCM (10 mL) was added KOAc (99.9 mg, 1.02 mmol) and stirred at 1 hr. Tert-butyl N-[2-[2-(3-oxopropoxy)ethoxy]ethyl]carbamate (133 mg, 509 umol, Intermediate HY) and $NaBH(OAc)_3$ (216 mg, 1.02 mmol) was added into the mixture. The reaction mixture was stirred at rt for 11 hrs. On completion, the mixture was concentrated *in vacuo.* The residue was purified by reverse phase (0.1% FA) to give the title compound (165 mg, 55% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 588.2 $(M+H)^+$.

[002694] Step 2 - 4-[[1-r2-r2-(2-Aminoethoxy)ethoxy1ethyl1-4-piperidyl1amino1-2-(2.6-dioxo-3-piperidvOisoindoline-L3-dione

[002695] To a mixture of tert-butyl N-[2-[2-[2-[4-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]-l- piperidyl]ethoxy]ethoxy]ethyl]carbamate (165 mg, 281 umol) in DCM (2 mL) was added HCl/dioxane (4 M, 0.7 mL). The reaction mixture was stirred at rt for 0.5 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (136 mg, 92% yield, HC1) as brown oil. LC-MS (ESI^+) *m/z* 488.2 $(M+H)^+$.

[002696] **4-[4-[2-[2-[2-Aminoethoxy)ethoxy1ethyl]piperazin-l-yl1-2-[2,6-dioxo-3-piperidvBisoindoline-l.,3-dione [Intermediate KL)**



[002697] Step 1 - Tert-butyl N-[2-[2-[2-[4-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-vHpiperazin-l-yll ethoxy] ethoxy] ethyl] carbamate


[002698] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-piperazin-l-yl-isoindoline-l,3-dione

(250 mg, 660 umol, HC1, synthesized via Steps 1-2 Intermediate IA) and tert-butyl N-[2-[2-(2-oxoethoxy)ethoxy]ethyl]carbamate (212 mg, 858 umol, Intermediate HY) in a mixed solvent of THF (15 mL) and DCM (5 mL) was added KOAc (130 mg, 1.32 mmol). Then one hour later, $NaBH(OAc)_3$ (280 mg, 1.32 mmol) was added and the reaction mixture was stirred at rt for 17 hrs. On completion, the mixture was concentrated *in vacuo.* The residue was purified by reverse phase (0.1% HC1 condition) to give the title compound (110 mg, 29% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 574.2 $(M+H)^+$.


[002699] Step 2 - 4-r4-r2-r2-(2-Aminoethoxy)ethoxy1ethyl1piperazin-l-yl1-2-(2.6-dioxo-3-piperidv0isoindoline-L3-dione

[002700] To a solution of tert-butyl N-[2-[2-[2-[4-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl] piperazin-l-yl]ethoxy]ethoxy]ethyl]carbamate (110 mg, 192 umol) in DCM (4 mL) was added HCl/dioxane (4 mL). The reaction mixture was stirred at rt for 1 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (90 mg, 92% yield, HC1) as a yellow solid. LC-MS (ESI^+) *m/z* 474.2 $(M+H)^+$.

[002701] Tert-butyl_ N-⌈4-⌈4-⌈⌈3-carbamoyl-l-⌈4-⌈methyl(2-oxoethvBcarbamoyl] phenyl] pyrazol-4-yl]_ carbamoyl1oxazol-2-yl]-2-pyridyl1-N-(cyclopropylmethyBcarbamate_(Intermediate_KM)



DF



KM


[002702] Step 1 - Tert-butyl N-r4-r4-IT3-carbamoyl-l-r4-r2-hvdiOxyethvKmethvDcarbamoyllphenyllpyrazoM -yl1carbamoyl1oxazol-2-yl1-2-pyridvH-N-(cvclopropylmethvOcarbamate

[002703] To a solution of 4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4- carbonyl]amino]-3-carbamoyl-pyrazol-l-yl]benzoic acid (300 mg, 510 umol, Intermediate DF) and 2-(methylamino) ethanol (38.3 mg, 510 umol, 41.0 Ul, CAS# 109-83-1) in DMF (2 mL) was added HATU (232 mg, 612 umol) and DIPEA (329 mg, 2.55 mmol, 444 uL), and the reaction mixture was stirred at rt for 12 hrs. On completion, the mixture was filtered, and the filter cake was dried *in vacuo* to give the title compound (210 mg, 64% yield) as a yellow solid. LC-MS (ESI^+) m/z 645.4 $(M+H)^+$.

[002704] Step 2 - Tert-butyl N-[4-[4-[[3-carbamoyl-l-[4-[methyl(2-oxoethvncarbamoyl1phenyl1pyrazol-4-yl1 carbamovnoxazol-2-vn-2-pyridyl1-N-(cvclopropylmethvDcarbamate

[002705] To a solution of tert-butyl N-[4-[4-[[3-carbamoyl-l-[4-[2-hydroxyethyl(methyl)carbamoyl]phenyl] pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(cyclopropylmethyl)carbamate (160 mg, 248 umol) in THF (5 mL) was added DMP (126 mg, 297 umol, 92.2 uL). The reaction mixture was stirred at rt for 2 hours. On completion, the mixture was diluted with H_20 (20 mL), then extracted with DCM (2 X 30 mL). The combined organic layer was then washed with $Na_2S_20_3$ (30 mL), $NaHC0_3$ (30 mL), and concentrated *in vacuo* to give the title compound (150 mg, 94% yield) as a yellow solid. LC-MS (ESI^+) m/z 643.4 $(M+H)^+$.

[002706] **Tert-butyl _N-|2-|3-(2-aininoethoxy)nronoxylethyl|carbainate _[Intermediate KN)**



KN

[002707] Step 1 - Ethyl 2-r3-(2-ethoxy-2-oxo-ethoxy)propoxy1acetate

[002708] To a solution of propane-l,3-diol (15.0 g, 197 mmol, CAS# 126-30-7) and $Rh(OAc)_2$ (435 mg, 1.97 mmol) in DCM (200 mL) was added a solution of ethyl 2-diazoacetate (67.4 g, 591 mmol) in DCM (100 mL) dropwise. The mixture was stirred at 10 °C for 16 hours. On completion, the mixture was diluted with H_20 (150 mL) and extracted with DCM (3 X 150 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography ($Si0_2$) to give the title compound (30.0 g, 61% yield) as colorless liquid. ^1H NMR (400MHz, CDCh) δ 4.21 (q, J = 7.2

Hz, 4H), 4.07 (s, 4H), 3.65 (t, *J* = 6.4 Hz, 4H), 1.99 - 1.89 (m, 2H), 1.28 (t, *J* = 7.2 Hz, 6H).

[002709] Step 2 - 2-[3-(2-Hydroxy ethoxylpropoxy] ethanol

[002710] To a solution of ethyl 2-[3-(2-ethoxy-2-oxo-ethoxy)propoxy]acetate (20.0 g, 80.5 mmol) in THF (300 mL) was added $LiAlH_4$ (6.24 g, 161 mmol, 98% purity) at 0 °C. The mixture was then stirred at 10 °C for 1 hour. On completion, the mixture was quenched with water (10 mL) and NaOH aqueus solution (15 %, 10 mL) at 0 °C, and the reaction was filtered. The filtrate was dried over Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (12 g, 90% yield) as colourless oil. ^1H NMR (400MHz, DMSO-d_6) δ 4.53 (t, *J* = 5.2 Hz, 2H), 3.50 - 3.45 (m, 4H), 3.43 (t, *J* = 6.4 Hz, 4H), 3.37 (t, *J* = 5.2 Hz 4H), 1.75 - 1.68 (m, 2H)

[002711] Step 3 - 2-r3-(2-Methylsulfonyloxyethoxy)propoxy1ethyl methanesulfonate

[002712] To a solution of 2-[3-(2-hydroxy ethoxy)propoxy] ethanol (12.0 g, 73.0 mmol) and TEA (44.3 g, 438 mmol) in DCM (160 mL) was added MsCl (25.1 g, 219 mmol) dropwise at 0 °C, then the mixture was stirred at 10 °C for 1 hour. On completion, the reaction mixture was quenched by water (50 mL) at 0 °C, and then extracted with DCM (3 X 150 mL). The combined organic layers were washed with saturated citric acid (2 X 30 mL), dried over Na_2SO_4, filtered and concentrated *in vacuo* to give title compound (23 g, 98% yield) as light yellow oil. ^1H NMR (400MHz, CDCb) δ 3.67 (t, *J* = 4.4 Hz, 4H),, 3.71 (t, *J* = 4.4 Hz, 4H), 3.58 (t, *J* = 6.0 Hz, 4H), 3.06 (s, 6H), 1.93 - 1.79 (m, 2H).

[002713] Step 4 - 2-r2-r3-r2-(L3-Dioxoisoindolin-2-vnethoxy1propoxy1ethyl1isoindoline-L3-dione

[002714] To a solution of 2-[3-(2-methylsulfonyloxyethoxy)propoxy]ethyl methanesulfonate (16.0 g, 49.9 mmol) in DMF (280 mL) was added (l,3-dioxoisoindolin-2-yl)potassium (27.7 g, 149 mmol). The mixture was stirred at 85 °C for 16 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give a residue. The residue was triturated with EA (30 mL) and filtered to give a filter cake. The filter cake was triturated with water (150 mL) and filtered again to give the filter cake as the title compound (19 g, 90% yield) as white solid. ^1H NMR (400MHz, DMSO-i/e) δ 7.87 - 7.78 (m, 8H), 3.67 (t, *J* = 6.0 Hz, 4H), 3.47 (t, *J* = 6.0 Hz, 4H), 3.32 (t, *J* = 6.0 Hz, 4H), 1.59 - 1.52 (m, 2H).

[002715] Step 5 - 2-r3-(2-Aminoethoxy)propoxy1ethanamine


[002716] To a solution of 2-[2-[3-[2-(l,3-dioxoisoindolin-2-yl)ethoxy]propoxy]ethyl]isoindoline-l,3-dione (18.0 g, 42.6 mmol) in EtOH (250 mL) was added

$NH_2NH_2 \cdot H_2O$ (21.7 g, 426 mmol, 98% purity). The mixture was stirred at 80 °C for 16 hours. On completion, the reaction mixture was filtered to give the filtrate which was concentrated *in vacuo* to give the title compound (7.2 g, 100% yield) as colorless oil. ^{1}H NMR (400MHz, DMSO-r#,) δ 3.42 (t, *J* = 6.4 Hz, 4H), 3.31 (t, *J* = 5.6 Hz, 4H), 2.63 (t, *J=5.6* Hz, 4H), 2.46 - 2.09 (m, 4H), 1.75 - 1.68 (m, 2H).


[002717] Step 6 - Tert-butyl N-r2-r3-(2-aminoethoxy)propoxy1ethyl1carbamate

[002718] To a solution of 2-[3-(2-aminoethoxy)propoxy]ethanamine (7.20 g, 44.3 mmol) in CHCh (250 mL) was added a solution of $(Boc)_20$ (3.23 g, 14.7 mmol) in CHCh (80 mL) dropwise. The mixture was stirred at rt for 16 hours. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (S1O2) to give the title compound (2.50 g, 64% yield) as colorless oil. ^{1}H NMR (400MHz, CDCh) δ 4.98 (s, 1H), 3.54 (t, *J* = 6.0 Hz, 4H), 3.51 - 3.42 (m, 4H), 3.34 - 3.25 (m, 2H), 2.86 (t, *j* = 5.2 Hz, 2H), 1.88 - 1.82 (m, 2H), 1.45 (s, 9H).

[002719] **Benzyl N-[4-[4-amino-3-carbamoyl-pyrazol-l-vDphenyllcarbamate [Intermediate KOI**



HL



KO

[002720] Step 1 - Methyl l-r4-(benzyloxycarbonylamino)phenyl1-4-nitro-pyrazole-3-carboxylate

[002721] To a solution of methyl 4-nitro-lH-pyrazole-3-carboxylate (841 mg, 4.92 mmol, CAS# 1345513-95-2, Intermediate HL), [4-(benzyloxycarbonylamino)phenyl]boronic acid (2.00 g, 7.38 mmol, CAS# 192804-36-7) in DCM (70.0 mL) was added pyridine (1.56 g, 19.6 mmol) and $CU(OAC)_2$ (1.34 g, 7.38 mmol), and the mixture was stirred at rt for 16 hrs under O2 (15 psi).

On completion, the mixture was concentrated *in vacuo.* The mixture was purified by silica gel column (PE: EA= 1: 1) to give the title compound (400 mg, 20% yield) as white solid. ^{1}H NMR (400MHz, CDCh) δ 8.14 (s, 1H), 7.50 - 7.45 (m, 2H), 7.40 - 7.36 (m, 2H), 7.35 - 7.30 (m, 5H), 6.79 (s, 1H), 5.16 (s, 2H), 3.87 (s, 3H).


[002722] Step 2 -Benzyl N-r4-(3-carbamoyl-4-nitro-pyrazol-l-vDphenyricarbamate

[002723] To a solution of methyl l-[4-(benzyloxycarbonylamino)phenyl]-4-nitro-pyrazole-3-carboxylate (200 mg, 504 umol) in THF (10.0 mL) was added $NH_3 \cdot H_20$ (4.55 g, 38.9 mmol, 30 wt%), and the mixture was stirred at 110 °C for 16 hrs. On completion, the mixture was concentrated *in vacuo.* The mixture was purified by reverse phase: (0.1% FA) to give the title compound (70.0 mg, 36% yield) as yellow solid. ¾ NMR (400MHz, DMSO-i¾) δ 10.07 (s, 1H), 9.54 (s, 1H), 8.53 (s, 1H), 7.88 (d, *J* = 8.8 Hz, 2H), 7.64 (d, *J* = 8.8 Hz, 2H), 7.48 - 7.36 (m, 5H), 5.19 (s, 2H).

[002724] Step 3 - Benzyl N-r4-(4-amino-3-carbamoyl-pyrazol-l-vDphenvncarbamate

[002725] To a solution of benzyl N-[4-(3-carbamoyl-4-nitro-pyrazol-l-yl)phenyl]carbamate (70.0 mg, 183 umol) in MeOH (10.0 mL) and H_20 (5.00 mL) was added NH_4Cl (98.1 mg, 1.84 mmol) and Zn (60.0 mg, 917 umol), and the mixture was stirred at rt for 1 hr. On completion, the mixture was concentrated *in vacuo.* The mixture was diluted with H_20 (10.0 mL) then extracted with EA (3 X 10 mL). The organic layers were dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (60.0 mg, 93% yield) as yellow solid, LC-MS (ESI$^+$) *m/z* 352.1 $(M+H)^+$

[002726] Tert-butyl N-[4-[4-[[l-(4-aminophenyD-3-carbamoyl-pyrazol-4-yl] carbamoyl] oxazol-2-yl] -2-pyridyll-N-(cyclopropylmethyncarbamate [Intermediate KP)




[002727] Step 1 - Tert-butyl N-R-R-ril-R-fbenzyloxycarbonylamino) phenyll-3-carbamoyl-pyrazol- 4-yl1carbamoyl1oxazol-2-yl1-2-pyridyl1-N-(cvclopropylmethvncarbamate

[002728] To a solution of benzyl N-[4-(4-amino-3-carbamoyl-pyrazol-l-yl)phenyl]carbamate (60.0 mg, 170 umol, Intermediate KO), and 2-[2-[tertbutoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (92.0 mg, 256 umol, synthesized via Steps 1-4 of Intermediate DF) in DMF (3.00 mL) was added DIPEA (66.2 mg, 512 umol) and HATU (97.4 mg, 256 umol), and the mixture was stirred at rt for 0.5 hr. On completion, the mixture was diluted with H_20 (15 mL) and extracted with EA (3 X 15 mL). The organic layers were dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The mixture was purified by reverse phase: (0.1% FA) to give the title compound (70.0 mg, 59% yield) as yellow solid. LC-MS (ESI^+) *m/z* 693.2 $(M+H)^+$.

[002729] Step 2 - Tert-butyl N-r4-r4-ril-(4-aminophenv0-3-carbamoyl-pyrazol-4-yl1carbamoyl1oxazol-2-vH -2-pyridyl1-N-(cvclopropylmethvDcarbamate

[002730] To a solution of tert-butyl N-[4-[4-[[l-[4-(benzyloxycarbonylamino)phenyl]-3-carbamoyl- pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(cyclopropylmethyl)carbamate (70.0 mg, 101 umol) in THF (10.0 mL) was added Pd/C (30.0 mg), the mixture was stirred at rt for 1 hr under H_2 (15 Psi). On completion, the mixture was filtered and concentrated *in vacuo* to give the title compound (55.0 mg, 90% yield) as yellow solid. LC-MS (ESI^+) *m/z* 559.4 $(M+H)^+$.


[002731] **Methyl 4-amino-l-methyl-pyrazole-3-carboxylate [Intermediate KO)**



KQ

[002732] To a solution of methyl l-methyl-4-nitro-pyrazole-3-carboxylate (2 g, 10.8 mmol, CAS# 400877-57-8) in MeOH (20 mL) was added Pd/C (200 mg, 10% *wt)* under N_2 atmosphere. The suspension was degassed and purged with H_2 gas 3 times. The mixture was stirred under H_2 (15 Psi) at rt for 12 hr. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (1.68 g, 100% yield) as a white solid. ^{1}H NMR (400MHz, CDCh) δ 6.95 (s, 1H), 3.92 (s, 3H), 3.86 (s, 3H).

[002733] **4-[[2-[2-[Tert-butoxycarbonvU2,2,2-trifluoroethvnamino1-4-pyridyl1oxazole-4- carbonyl] aminol-l-methyl-pyrazole-3-carboxylic acid [Intermediate KR)**



[002734] Step 1 - Methyl 4-[[2-[2-[tert-butoxycarbonyl(2.2.2-trifluoroethyl)amino1-4-pyridylloxazole-4- carbonyllaminol-l-methyl-pyrazole-3-carboxylate


[002735] To a solution of methyl 4-amino- l-methyl-pyrazole-3-carboxylate (1.68 g, 10.8 mmol, Intermediate KQ) and 2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (4.19 g, 10.8 mmol, Intermediate CM) in DMF (20 mL) was

added DIPEA (2.80 g, 21.7 mmol), The reaction mixture was stirred at rt for 0.5 hr. After, HATU (4.94 g, 13.0 mmol) was added and the resulting reaction mixture was stirred at rt for 0.5 hr. On completion, the reaction mixture was quenched with water (200 mL). White precipitate formed after the reaction was added to water, which was filtered and the filtered cake was dried *in vacuo* to give the title compound (5.1 g, 90% yield) as a white solid; ^{1}H NMR (400MHz, DMSO-d_6) δ 10.30 (s, 1H), 9.09 (s, 1H), 8.65 (s, 1H), 8.43 (s, 1H), 8.31 (s, 1H), 7.76 (s, 1H), 4.93 - 4.86 (m, 2H), 3.95 (s, 3H), 3.93 (s, 3H), 1.53 (s, 9H). LC-MS (ESI$^+$) *m/z* 547.1 (M+Na)$^+$.

[002736] Step 2 - 4-[[2-[2-[Tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino1-4-pyridylloxazole-4- carbonyl] aminol-l-methyl-pyrazole-3-carboxylic acid

[002737] To a solution of methyl 4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4- carbonyl]amino]-l-methyl-pyrazole-3-carboxylate (500 mg, 953 umol) in a mixed solvent of THF (10 mL) and H_2O (2 mL) was added LiOH.H_2O (120 mg, 2.86 mmol). The reaction mixture was stirred at rt for 12 hrs. On completion, the reaction mixture was concentrated *in vacuo.* The residue was diluted with water (50 mL) and acidified with HC1 (2 N) to pH = 5, then filtered. The filtered cake was collected, ground up, and dried for 2 hours at 105-110 °C in the drying oven. This was then ground again to a fine powder to give the title compound (480 mg, 99% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-^e) δ 10.65 (s, 1H), 9.07 (s, 1H), 8.64 (d, *J* = 4.8 Hz, 1H), 8.38 (s, 1H), 8.24 (s, 1H), 7.77 (dd, *j* = 1.2, 5.2 Hz, 1H), 4.89 (q, *J* = 8.8 Hz, 2H), 3.95 (s, 3H), 1.52 (s, 9H).

[002738] **4-[3-(3-Aminopropoxy)propylaminol-2-(2.,6-dioxo-3-piperidvPisoindoline-1,3-dione [Intermediate KS)**



KS


[002739] Step_1_- Tert-butyl N-[3-[3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yllaminolpropoxyl propyllcarbamate

[002740] To a mixture of tert-butyl N-[3-(3-aminopropoxy)propyl]carbamate (1.20 g, 5.17 mmol, Intermediate EF) and 2-(2,6- dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (1.43 g, 5.17 mmol, Intermediate R) in dioxane (50 mL) was added DIPEA (6.68 g, 51.6 mmol, 9.00 mL). The reaction mixture was stirred at 115 °C for 12 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by column chromatography (Si02, PE: EA=l:l PE: EA=l:l, Pl: Rf=0.08) to give the title compound (1.00 g, 39% yield) as yellow solid. LC-MS (ESI^+) *m/z* 511.3 $(M+Na)^+$.

[002741] Step_2_-_4-[3-(3-Aminopropoxy)propyl amino]-2-(2.6-dioxo-3-piperidvDisoindoline-U-dione

[002742] To a mixture of tert-butyl N-[3-[3-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino] propoxy]propyl]carbamate (1.20 g, 2.46 mmol) in DCM (10 mL) was added HCl/dioxane (4 M, 20 mL). The reaction micture was stirred at rt for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (1.00 g, 95% yield, HC1) as yellow solid. LC-MS (ESI^+) *m/z* 389.1 $(M+H)^+$.

[002743] **Tert-butyl N-[4-[4-[[l-(4-formylphenv0-3-(methylcarbamov0pyrazol-4-yl1 carbamoyl]oxazol-2-yl1-2-pyridyl]-N-(2.,2.,2-trifluoroethv0carbamate (Intermediate KT)**



KT

[002744] Step 1 - l-r4-(Hvdroxymethv0phenvn-N-methyl-4-nitro-pyrazole-3-carboxamide

[002745] To a solution of methyl l-[4-(hydroxymethyl)phenyl]-4-nitro-pyrazole-3-carboxylate (200 mg, 721 umol, synthesized via Step 1 of Intermediate GB) in THF (5.00 mL) was added $MeNH_2$ (2.00 M, 5.00 mL), and the mixture was stirred at 70 °C for 16 hrs in a sealed tube. On completion, the mixture was concentrated *in vacuo.* The mixture was diluted with H_20 (30 mL), then extracted with EA (3 X 30 mL). The organic layers were dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (195 mg, 97% yield) as yellow solid. 1H NMR (400MHz, DMSO-di) δ 9.68 (s, 1H), 8.81 - 8.68 (m, 1H), 7.97 (d, *J* = 8.8 Hz, 2H), 7.57 (d, *J* = 8.8 Hz, 2H), 5.39 (t, *J* = 5.6 Hz, 1H), 4.63 (d, *J* = 5.6 Hz, 2H), 2.87 (d, *J* = 4.8 Hz, 3H)

[002746] Step 2 - 4-Amino-l-r4-(hvdroxymethvDphenyl1-N-methyl-pyrazole-3-carboxamide

[002747] To a solution of l-[4-(hydroxymethyl)phenyl]-N-methyl-4-nitro-pyrazole-3-carboxamide (195 mg, 705 umol) in MeOH (100 mL) was added Pd/C (10 wt%, 100 mg), and the mixture was purged with H_2 several times and stirred at 15 °C for 0.5 hr under H_2 (15 psi). On completion, the mixture was filtered and concentrated *in vacuo* to give the title compound (160

mg, 90% yield) as yellow solid. LC-MS (ESI^+) *m/z* 247.1 $(M+H)^+$.


[002748] Step 3 - Tert-butyl N-r4-r4-rrl-r4-(hvdroxymethyl)phenyl1-3-(methylcarbamoyl)pyrazol-4-yl] carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethvDcarbamate

[002749] To a solution of 4-amino-l-[4-(hydroxymethyl)phenyl]-N-methyl-pyrazole-3-carboxamide (160 mg, 649 umol), 2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (251 mg, 649 umol, Intermediate CM) in DMF (3.00 mL) was added DIPEA (251 mg, 1.95 mmol) and HATU (296 mg, 779 umol), and the mixture was stirred at rt for 0.5 hr. On completion, the mixture was diluted with H_20 (1.00 mL) and concentrated *in vacuo.* The mixture was purified by reverse phase chromatography (0.1% $NH_3•H_2O$) to give the title compound (200 mg, 50% yield) as yellow solid. ^1H NMR (400MHz, DMSO-i¾) δ 11.08 (s, 1H), 9.10 (s, 1H), 8.93 (s, 1H), 8.67 (d, *J* = 5.2 Hz, 1H), 8.62 - 8.56 (m, 1H), 8.29 (s, 1H), 7.93 (d, *J* = 8.8 Hz, 2H), 7.82 - 7.77 (m, 1H), 7.50 (d, *J* = 8.8 Hz, 2H), 5.30 (t, *J* = 5.6 Hz, 1H), 4.96 - 4.86 (m, 2H), 4.57 (d, *J* = 5.6 Hz, 2H), 2.87 (d, *J* = 4.8 Hz, 3H), 1.56 (s, 9H).

[002750] Step 4 - Tert-butyl N-[4-[4-[[1-(4-formylphenyl)-S-(methylcarbamoyl)pyrazol-4-yl] carbamoyl]oxazol-2-yl1-2-pyridyl1-N-(2,2,2-trifluoroethyl)carbamate

[002751] To a solution of tert-butyl N-[4-[4-[[l-[4-(hydroxymethyl)phenyl]-3-(methylcarbamoyl)pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (110 mg, 178 umol) in THF (20.0 mL) was added DMP (90.9 mg, 214 umol), and the mixture was stirred at rt for 1 hr. On completion, the mixture was quenched with saturated $Na_2S_20_3$ (30 mL) and washed with saturated $NaHC0_3$ (2 X 30 mL). The organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (105 mg, 90% yield) as yellow solid. LC-MS (ESI^+) *m/z* 614.3 $(M+H)^+$.

[002752] **l-[4-[4-Amino-3-(difluoromethvPpyrazol-l-yllphenyllethenone [Intermediate KU)**



KU


[002753] Step 1- l-r4-r3-(difluoromethvn-4-nitro-pyrazol-l-yl1phenyl1ethanone

[002754] To a mixture of 3-(difluoromethyl)-4-nitro- lH-pyrazole (1.42 g, 8.69 mmol, Intermediate HS), 1- (4-fluorophenyl) ethanone (1.0 g, 7.24 mmol) in DMF (10 mL) was added K2CO3 (1.50 g, 10.8 mmol). The reaction mixture was stirred at 120 °C for 12 hours. On completion, the mixture was concentrated *in vacuo.* The residue was purified by column chromatography (S1O2) to give the title compound (435 mg, 21% yield) as brown oil. ^{1}HNMR (400MHz, DMSO-£¾) δ 9.93 (s, 1H), 8.17 - 8.13 (m, 4H), 7.59 - 7.32 (m, 1H), 2.64 (s, 3H).

[002755] Step 2- l-r4-r4-Amino-3-(difluoromethvDpyrazol-l-yl1phenyl1ethanone

[002756] To a mixture of l-[4-[3-(difluoromethyl)-4-nitro-pyrazol-l-yl]phenyl]ethanone (360 mg, 1.28 mmol) in MeOH (20 mL) and H2O (10 mL) was added Zn (837 mg, 12.8 mmol) and AcOH (769 mg, 12.8 mmol). The reaction mixture was stirred at rt for 1 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (186 mg, 58% yield) as a yellow solid. LC-MS (ESI^{+}) *m/z* 252.2 (M+H) $^{+}$.


[002757] Tert-butyl N-[4-[4-[[l-(4-acetylphenyO-3-(difluoromethyQpyrazol-4-yl]carbamoyl]oxazol-2-yll-2-pyridyll-N-(cyclopropylmethyQcarbamate [Intermediate KV)



KU KV

[002758] To a mixture of l-[4-[4-amino-3-(difluoromethyl)pyrazol-l-yl]phenyl]ethanone (90 mg, 358 umol, Intermediate KU), 2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (154 mg, 429 umol, synthesized via Steps 1-4 of Intermediate DF) in DMF (10 mL) was added DIPEA (139 mg, 1.07 mmol) and HATU (163 mg, 430 umol). The mixture and stirred at rt for 2 hours. On completion, the mixture was concentrated *in vacuo.* The residue was purified by reversed-phase HPLC (0.1% FA condition) to give the title compound (165 mg, 75% yield) as a white solid. LC-MS (ESI^{+}) *m/z* 593.2 (M+H) $^{+}$.

[002759] Methyl 4-(4-amino-3-(3-((tetrahydro-2H-pyran-2-y0oxy)propyQ-lH-pyrazol-1-vDbenzoate [Intermediate KW)



[002760] Step 1 - Methyl 4-(3-(3-hvdroxyprop-l-vn-l-vO-4-nitro-lH-pyrazol-l-vObenzoate

[002761] Methyl 4-(3-bromo-4-nitro-pyrazol-l-yl)benzoate (1 g, 3.07 mmol, Intermediate JS), prop-2-yn-l-ol (500 mg, 8.92 mmol), $Pd(PPh_3)2Cl_2$ (215 mg, 307 umol), TEA (3.10 g, 30.7 mmol), and CuI (58.4 mg, 307 umol) were taken up into a microwave tube in DMF (10 mL)under N_2. The reaction mixture was de-gassed with N_2 and then the sealed tube was heated to 80 °C for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo.* The crude product was purified by silica gel chromatography (PE: EA = 2:1) to give the title compound (920 mg, 100% yield) as a yellow solid. ^1H NMR (400MHz, DMSO-^e) 59.87 (s, 1H), 8.18 (s, 4H), 5.62 (t, *J* = 6.0 Hz, 1H), 5.49 - 5.43 (m, 1H), 4.47 (d, *J* = 6.0 Hz, 2H), 3.94 (s, 3H).

[002762] Step 2 - Methyl 4-(4-nitro-3-(3-((tetrahvdro-2H-pyran-2-vDoxy)prop-l-vn-l-vD-lH-pyrazol-l-vD benzoate


[002763] To a solution of methyl 4-[3-(3-hydroxyprop-l-ynyl)-4-nitro-pyrazol-l-yl]benzoate (600 mg, 1.99 mmol) and DHP (251 mg, 2.99 mmol) in a mixed solvent of DCM (100 mL) and THF (20 mL) was added PPTS (50.1 mg, 199 umol). The reaction mixture was stirred at rt for 12 hours under N_2. On completion, the reaction mixture was concentrated *in vacuo.* The crude product purified by column chromatography ($Si0_2$, Petroleum ether/Ethyl acetate = 5/1) to give the title compound (700 mg, 91% yield) as a white solid. ^1H NMR (400MHz, DMSO-r/p 5 9.83 (s, 1H), 8.13 (s, 4H), 4.94 - 4.86 (m, 1H), 4.66 - 4.50 (m, 2H), 3.90 (s, 3H), 3.79 (ddd, *j* = 3.2, 8.4, 11.2 Hz, 1H), 3.57 - 3.47 (m, 1H), 1.75 - 1.65 (m, 2H), 1.59 - 1.49 (m, 4H). LC-MS (ESI^+) *m/z* 408.1 $(M+Na)^+$.

[002764] Step_3_- Methyl_4-(4-amino-3-(3-((tetrahvdro-2H-pyran-2-vl)oxv)propyl)-lH-pyrazol-l-vDbenzoate

[002765] To a solution of methyl 4-[4-nitro-3-(3-tetrahydropyran-2-yloxyprop-l-ynyl)pyrazol-l-yl]benzoate (930 mg, 2.41 mmol) in MeOH (10 mL) was added Pd/C (50 mg, 10

wt%) and $Pd(OH)_2/C$ (50 mg, 10 wt%) under N_2 atmosphere. The suspension was degassed and purged with H_2 gas 3 times. The mixture was stirred under H_2 (15 Psi) at rt for 24 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (760 mg, 88% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 360.2 $(M+H)^+$.

[002766] **4-(4-(2-(2-((Tert-butoxycarbonvP(2,2,2-trifluoroethvPamino)pyridin-4-vPoxazole-4-carboxamido)-3-[3-Ptetrahvdro-2H-pyran-2-vPoxy)propyP-lH-pyrazol-l-vPbenzoic acid [Intermediate KX)**



[002767] Step 1 - Tert-butyl 4-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yllaminolpiperidine-l- carboxylate


[002768] To a solution of 2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole carboxylic acid (711 mg, 1.84 mmol, Intermediate CM) and methyl 4-[4-amino-3-(3-tetrahydropyran-2 -yloxypropyl)pyrazol-l-yl] benzoate (660 mg, 1.84 mmol, Intermediate KW) in DMF (5 mL) was added DIPEA (475 mg, 3.67 mmol), and the reaction mixture was stirred at rt for 0.5 hour. Then, HATU (838 mg, 2.20 mmol) was added and the resulting reaction mixture

was stirred at rt for an additional 0.5 hour. On completion, the reaction mixture was quenched with water (50 mL) and filtered. The filtered cake was collected and dried over high vacuum to give (800 mg, 60% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 729.1 $(M+H)^+$.


[002769] Step 2 - 4-(4-(2-(2-((Tert-butoxycarbonyl)(2.2.2-trif1uoroethyl)amino)pyridin-4-vDoxazole-4-carboxamido)-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)-1H-pyrazol-1-vQbenzoic acid


[002770] To a solution of methyl 4-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl] oxazole-4-carbonyl]amino]-3-(3-tetrahydropyran-2-yloxypropyl)pyrazol-l-yl]benzoate (800 mg, 1.10 mmol) in a mixed solvent of THF (9 mL) and H_20 (3 mL) was added LiOH.LhO (138 mg, 3.29 mmol). The reaction mixture was stirred at rt for 12 hours. On completion, the reaction mixture was concentrated *in vacuo* to removed THF then diluted with water (10 mL) and acidified with 2 N aq.HCl to pH = 5, then extracted with ethyl acetate (3 X 50 mL). The combined organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (740 mg, 94% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 715.1 $(M+H)^+$.

[002771] Tert-butyl (4-(4-((l-(4-formylphenyl)-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)-1H-pyrazol-4-vDcarbamovDoxazol-2-vDpyridin-2-vD(2.,2.,2-trifluoroethvDcarbamate [Intermediate KY)



KX





KY

[002772] Step 1 - 4-(4-(2-(2-((Tert-butoxycarbonyl)(2,2,2-trifluoroethyl)amino)pyridin-4-yl)oxazole-4-carboxamido)-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)-1H-pyrazol-1-yl)benzoic (isopropyl carbonic) anhydride

[002773] To a solution of 4-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole- 4-carbonyl]amino]-3-(3-tetrahydropyran-2-yloxypropyl)pyrazol-l-yl]benzoic acid (740 mg, 1.04 mmol, Intermediate KX) in THF (20 mL) was added TEA (419 mg, 4.14 mmol). Then, the reaction mixture was cooled to -10 °C and isopropyl carbonochloridate (254 mg, 2.07 mmol) was added. The resulting reaction mixture was stirred at -10 °C for 2 hours. On completion, the reaction mixture was filtered. The filtrate was concentrated *in vacuo* to give the title compound (800 mg, 96% yield) as a white solid. LC-MS (ESI^+) *m/z* 801.1 $(M+H)^+$.


[002774] Step 2 - Tert-butyl (4-(4-((1-(4-(hydroxymethyl)phenyl)-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)-1H-pyrazol-4-yl)carbamoyl)oxazol-2-yl)pyridin-2-yl)(2,2,2-trifluoroethyl)carbamate

[002775] To a solution ofisopropoxycarbonyl 4-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4- pyridyl]oxazole-4-carbonyl]amino]-3-(3-tetrahydropyran-2-yloxypropyl)pyrazol-l-yl]benzoate (800 mg, 999 umol) in THF (50 mL) was added H_20 (180 mg, 9.99 mmol) and $LiBH_4$ (109 mg, 5.00 mmol). The reaction mixture was stirred at 0 °C for 10 minutes. On completion, the mixture was quenched with water (5 mL) and was extracted with DCM (3 x 50 mL). The combined organic layer was washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (700 mg, 100% yield) as a white solid. LC-MS (ESI^+) *m/z* 701.1 $(M+H)^+$.

[002776] Step 3 - Tert-butyl (4-(4-(n-(4-formylphenvD-3-(3-(Ytetrahvdro-2H-pyran-2-yl)oxv)propyl)-1H- pyrazol-4-yl icarbamoyl)oxazol-2-yl)pyridin-2-yl)(2.2.2-trifluoroethvDcarbamate

[002777] To a solution of tert-butyl N-[4-[4-[[l-[4-(hydroxymethyl)phenyl]-3-(3-tetrahydropyran-2-yloxypropyl) pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (700 mg, 999 umol) in DCM (20 mL) was added DMP (847 mg, 2.00 mmol). The reaction mixture was stirred at rt for 2 hours. On completion, the reaction mixture was quenched with water (1 mL) and was concentrated *in vacuo.* The crude product was purified by prep-HPLC (condition: 0.1% FA) to give the title compound (270 mg, 30% yield) as colorless solid. LC-MS (ESI^+) *m/z* 699.1 $(M+H)^+$.

[002778] [4-[l-(Tert-butoxycarbonylamino)cvclopropyl]phenyl1boronic acid [Intermediate KZ)



KZ

[002779] Step 1 - Tert-butyl N-[1-r4-(4A5.5-tetramethyl- l,3,2-dioxaborolan-2-vDphenyllevelopropvl] carbamate


[002780] A mixture of tert-butyl N-[l-(4-bromophenyl)cyclopropyl]carbamate (3 g, 9.61 mmol, CAS# 360773-84-8), Pin_2B_2 (4.88 g, 19.2 mmol), KOAc (2.83 g, 28.8 mmol) and

cyclopentyl(diphenyl) phosphane;dichloromethane;dichloropalladium;iron (392 mg, 480 umol) in DMSO (30 mL) was degassed and then heated to 70 °C for 12 hours under N_2. On completion, the mixture was quenched with water (200 mL) and filtered. The filter cake was purified by silica gel chromatography (S1O2) to give the title compound (3.0 g, 87% yield) as a white solid. LC-MS (ESI+) m/z 398.2 $(M+K)^+$.


[002781] Step 2 - r4-rl-(Tert-butoxycarbonylamino)cvclopropyl1phenyl1boronic acid

[002782] To a solution of tert-butyl N-[l-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl]cyclopropyl] carbamate (1.2 g, 3.34 mmol) in a mixed solvent of THF (30 mL) and H_20 (6 mL) was added $NaI0_4$ (2. 14 g, 10.0 mmol). The reaction mixture was stirred at rt for 0.5 hour. Then, HC1 (3 M, 2.23 mL) was added and the mixture was stirred at rt for 4 hrs. On completion, the mixture was diluted with water, then extracted with EA (30 mL x 2). The organic layer was washed with water and concentrated *in vacuo*. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (0.76 g, 82% yield) as a white solid. LC-MS (ESI^+) m/z 278.1 $(M+H)^+$.

[002783] **Tert-butyl N-[1-[4-[4-amino-3-(difluoromethyl)pyrazol-1-yllphenyllcvclopropyll carbamate [Intermediate LA]**



KZ



LA

[002784] Step 1 - Tert-butyl N-rl-r443AdifhioromethvO-4-nitro-pyrazol-l-yl]phenyl]cvcl opropyl]carb amate


[002785] To a solution of [4-[l-(tert-butoxycarbonylamino)cyclopropyl]phenyl]boronic acid (0.76 g, 2.74 mmol, Intermediate KZ) and 3-(difluoromethyl)-4-nitro-lH-pyrazole (447 mg, 2.74

mmol, Intermediate HS) in DCM (10 mL) was added $Cu(OAc)_2$ (747 mg, 4.11 mmol) and pyridine (4.34 g, 54.9 mmol). The reaction mixture was stirred at rt for 10 hours under oxygen (15 Psi) atmosphere. On completion, the mixture was concentrated *in vacuo.* The residue was purified by silica gel chromatography (SiO_2), then the residue was repurified by reverse phase (0.1% FA condition) to give the title compound (550 mg, 51% yield) as a white solid. ^1H NMR (400MHz, DMSO-di) δ 9.71 (s, 1H), 7.86 (d, *J* = 8.4 Hz, 2H), 7.78 (s, 1H), 7.56 - 7.27 (m, 3H), 1.43 - 1.25 (m, 9H), 1.22 - 1.17 (m, 4H); LC-MS (ESI^+) *m/z* 339.0 $(M-56+H)^+$.

[002786] Step 2 - Tert-butyl N-rl-r4-r4-amino-3-(difluoromethv0pyrazol-l-yl]phenyl]cvclopropyl]carbamate

[002787] To a solution of tert-butyl N-[l-[4-[3-(difluoromethyl)-4-nitro-pyrazol-l-yl]phenyl] cyclopropyl] carbamate (0.55 g, 1.39 mmol) in THF (10 mL) was added Pd/C (0.2 g, 10 wt%). The reaction mixture was stirred at rt for 4 hours under H_2 (15 Psi) atmosphere. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (0.42 g, 83% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 365.1 $(M+H)^+$.

[002788] N-[l-[4-n-aminocvclopropyDphenyll-3-(difluor()iiiethvDpyrazol-4-yll-2-[2-(cvclopropylmethylaminoV4-pyridylloxazole-4-carboxamide [Intermediate LB)



[002789] Step 1 - Tert-butyl N-[4-[4-[[1-[4-[1-(tert-butoxycarbonylamino)cvclopropyl1phenyl1-3- (difluoromethvnpyrazol-4-yl1carbamoyl1oxazol-2-yl1-2-pyridyl1-N-(cvclopropylmethvncarbamate


[002790] To a solution of tert-butyl N-[l-[4-[4-amino-3-(difluoromethyl)pyrazol-l-

yl]phenyl] cyclopropyl] carbamate (220 mg, 604 umol, Intermediate LA) and 2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl] oxazole-4-carboxylic acid (217 mg, 604 umol, synthesized via Steps 1-4 of Intermediate DF) in DMF (5 mL) was added DIPEA (234 mg, 1.81 mmol) and HATU (276 mg, 725 umol). The reaction mixture was stirred at rt for 0.5 hour. On completion, the mixture was quenched with water (50 mL), filtered and the filter cake was dried *in vacuo* to give the title compound (0.27 g, 63% yield) as a brown solid. LC-MS (ESI^+) *m/z* 706.4 $(M+H)^+$.

[002791] Step 2 - N-rl-r4-(l-aminocvclopropy0phenvn-3-(difluoromethvQpyrazol-4-vn-2-[2- (cvclopropylmethylamino)-4-pyridyl1oxazole-4-carboxamide

[002792] To a solution of tert-butyl N-[4-[4-[[l-[4-[l-(tert-butoxycarbonylamino)cyclopropyl]phenyl]-3- (difluoromethyl)pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(cyclopropylmethyl)carbamate (250 mg, 354 umol) in DCM (1 mL) was added 4.0 M HCl/dioxane (1 mL). The reaction mixture was stirred at rt for 10 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (0.19 g, 99% yield, HC1) as a light yellow solid. LC-MS (ESI^+) *m/z* 506.2 $(M+H)^+$.


[002793] **2-[2-Prop-2-ynoxyethoxy)ethanol [Intermediate LC)**



LC

[002794] To a mixture of t-BuOK (4.76 g, 42.5 mmol) in THF (120 mL) was added 2-(2-hydroxyethoxy)ethanol (8.92 g, 84.0 mmol, CAS# 111-46-4) at 0 °C. The reaction mixture was stirred at rt for 30 minutes and then 3-bromoprop-l-yne (5 g, 42.0 mmol) in THF (25 mL) was added dropwise. The reaction mixture was stirred at rt for 12 hours. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was purified by silica gel chromatography (S1O2) to give the title compound (3 g, 50% yield) as yellow oil. ^{1}H NMR (400MHz, CDCL) δ 4.20 (d, *J* = 2.4 Hz, 2H), 3.76 - 3.65 (m, 6H), 3.63 - 3.56 (m, 2H), 2.44 (t, *J* = 2.4 Hz, 1H), 2.41 (s, 1H).


[002795] **2,2-Dimethyl-4-oxo-3,8,H.,14-tetraoxa-5-azahexadecan-16-yl 4-methylbenzenesulfonate [Intermediate LD)**



LD

[002796] To a stirred solution of tert-butyl (2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)carbamate (8 g, 27.30 mmol, synthesized via Step 1 of Intermediate EN) in DCM (100 mL) was added TEA (5.52 g, 54.60 mmol) at rt. To the above reaction mixture was added dropwise TsCl (10.41 g, 54.60 mmol) in DCM (5 mL) at 0 °C. After the addition, the reaction mixture was stirred at rt overnight. The mixture was concentrated *in vacuo* and the residue was purified via column chromatography (Petroleum ether/EtOAc = 5%-80%) to give the title compound (10.9 g, 73 %) as a yellow oil. LC-MS (ESI^+): m/z 448.3 $(M+H)^+$.

[002797] **2-12-13-[l-(2,6-Dioxo-3-piperidvO-3-methyl-2-oxo-benzimidazol-4-yllpropoxy] ethoxy] acetaldehyde [Intermediate LE)**



[002798] Step 1 - 3-r4-r3-r2-(2-hvdroxyethoxy)ethoxy1prop-l-vnyl1-3-methyl-2-oxo-benzimidazol-l- yl1piperidine-2.6-dione

[002799] 2-(2-prop-2-ynoxyethoxy)ethanol (384 mg, 2.66 mmol, Intermediate LC), CuI (84.5 mg, 444 umol) and $Pd(PPh_3)2Cl2$ (311 mg, 444 umol) was taken up into a tube. Then 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl) piperidine-2, 6-dione (300 mg, 887 umol, Intermediate HP), TEA (1.62 g, 16 mmol) and DMF (5 mL) were added into the above tube. The mixture was degassed with N2 and the sealed tube was heated at 80 °C for 2 hours. On completion, the mixture was concentrated *in vacuo*. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (0.12 g, 34% yield) as a brown solid. LC-MS (ESI^+) *m/z* 402.1 $(M+H)^+$.


[002800] Step 2 -3-r4-r3-r2-(2-hvdroxyethoxy)ethoxy1propyl1-3-methyl-2-oxo-benzimidazol-l-yllpiperidine- 2.6-dione

[002801] To a solution of 3-[4-[3-[2-(2-hydroxyethoxy)ethoxy]prop-l-ynyl]-3-methyl-2-oxo-benzimidazol-l -yl]piperidine-2,6-dione (50 mg, 125 umol) in THF (4 mL) was added Pd/C (0. 1 g, 10 wt%) and $Pd(OH)_2/C$ (0. 1 g, 10 wt%). The reaction mixture was stirred at rt for 10 hours under H_2 (15 Psi) atmosphere. On completion, the mixture was filtered and filtrate was concentrated *in vacuo* to give the title compound (50 mg, 99% yield) as yellow oil. LC-MS (ESI^+) *m/z* 406.1 $(M+H)^+$.

[002802] Step 3 - 2-[2-[3-[1-(2,6-Dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yllpropoxylethoxyl acetaldehyde

[002803] To a solution of 3-[4-[3-[2-(2-hydroxyethoxy)ethoxy]propyl]-3-methyl-2-oxo-benzimidazol-l-yl] piperidine-2, 6-dione (50 mg, 123 umol) in THF (3 mL) was added DMP (78.5 mg, 185 umol). The reaction mixture was stirred at rt for 2 hours. On completion, the mixture was quenched with sat. $Na_2S_20_3$ (20 mL) and sat. $NaHC0_3$ (20 mL) and stirred for 0.5 hour. The reaction mixture was then extracted with DCM (2 X 30 mL). The organic layer was washed with brine (40 mL), dried over Na_2S0_4, filtered and the filtrate was concentrated *in vacuo* to give the title compound (30 mg, 60% yield) as yellow oil. LC-MS (ESI^+) *m/z* 404.2 $(M+H)^+$.

[002804] 3-[4-[3-(3-aminopropoxy)propyl1-3-methyl-2-oxo-benzimidazol-l-yl] piperidine-2.,6- dione [Intermediate LF)



[002805] Step 1 - Tert-butyl N-[3-([3-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-4-yl]prop-2-yn-1-yl]oxy)propyl]carbamate

[002806] To a stirred solution of 3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-1*H*-1,3-benzodiazol-1-yl)piperidine-2,6-dione (221 mg, 0.65 mmol,), *tert*-butyl N-[3-(prop-2-yn-1-yloxy)propyl] carbamate (209 mg, 0.98 mmol, Intermediate OH) and TEA(1 mL) in DMA (3 mL) were added CuI (12.4 mg, 0.07 mmol) and $Pd(PPh_3)_2Cl_2$ (45.9 mg, 0.07 mmol) at room temperature under nitrogen atmosphere. The resulting mixture was stirred for 2 h at 90 °C. The mixture was cooled down to room temperature and concentrated under reduced pressure to remove TEA. The residue was purified by reverse phase flash chromatography with the following conditions: Column: WelFlash ™ C18-1, 20-40 pm, 80 g; Eluent A: Water (plus 10 mmol/L FA); Eluent B: ACN; Gradient: 35% - 55% B in 15 min; Flow rate: 50 mL/min; Detector: 220/254 nm; desired fractions were collected at 50% B and concentrated under reduced pressure to afford tert-butyl N-[3-([3-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-4-yl]prop-2-yn-1-yl]oxy)propyl]carbamate (90 mg, 29%) as a light pink solid. ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.12 (s, 1H), 7.20 (d, J = 7.9 Hz, 1H), 7.01 (t, J = 7.9 Hz, 1H), 6.78 (d, J = 7.9 Hz, 1H), 5.22 (dd, J = 12.5, 5.3 Hz, 1H), 4.80 (s, 1H), 4.42 (s, 2H), 3.80 (s, 3H), 3.68 (t, J = 6.0 Hz, 2H), 3.30-3.24 (m, 2H), 3.02-2.95 (m, 1H), 2.91-2.69 (m, 2H), 2.28-2.26 (m, 1H), 1.85 (q, J = 6.2 Hz,

2H), 1.46 (s, 9H); LC/MS (ESI, *m/z):* [(M - 1)]⁻ = 469.5.


[002807] Step 2 - Tert-butyl N-(3-[3-П-(2.6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2.3-dihvdro-lH-E3-benzodiazol-4-vnpropoxy1propyncarbamate

[002808] To a stirred solution of *tert*-butyl A-[3-([3-[l-(2, 6-dioxopi peri din-3 -yl)-3 -methyl - 2-oxo-2,3-dihydro-li7-l,3-benzodiazol-4-yl]prop-2-yn-l-yl]oxy)propyl]carbamate (0.5 g, 1.06 mmol) in THF (10 mL) was added palladium on charcoal (100 mg, 10% w/w) at room temperature under nitrogen atmosphere. The resulting mixture was purged with H_2 gas 3 times and stirred for 16 h at room temperature under hydrogen atmosphere. The reaction mixture was filtered through a Celite pad. The filtrate was concentrated under reduced pressure to afford fe/7-butyl A-(3-[3-[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-liT-l,3-benzodiazol-4-yl]propoxy]propyl)carbamate (430 mg, 85%) as a light green oil. 'H NMR (400 MHz, CDCh) δ 8.07 (s, 1H), 7.01 (t, *J* = 7.8 Hz, 1H), 6.92 (d, *J* = 7.8 Hz, 1H), 6.69 (d, I = 7.7 Hz, 1H), 5.22 (dd, *J* = 12.3, 5.5 Hz, 1H), 4.88 (s, 1H), 3.77 (s, 1H), 3.71 (s, 3H), 3.50 (m, 3H), 3.26 *(d, J* = 6.3 Hz, 2H), 3.08-3.00 (m, 2H), 3.00-2.91 (m, 1H), 2.91-2.71 (m, 2H), 2.32-2.19 (m, 1H), 2.00-1.74 (m, 4H), 1.46 (s, 9H); LC/MS (ESI, *m/z):* [(M - 1)]⁻ = 473.3.

[002809] Step 3 - 3-r4-r3-(3-Aminopropoxy)propyl1-3-methyl-2-oxo-2.3-dihvdro-l//-l.3-benzodiazol-1 -yl]piperi dine-2.6-di one hydrochloride

[002810] To a stirred solution of *tert*-butyl /V-(3-[3-[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di hydro- 1*H*-1,3-benzodi azol-4-yl]propoxy] propyl)carbam ate (430 mg, 0.91 mmol) in I,4-dioxane (5 mL) was added a solution of HC1 in l,4-dioxane (4 M, 5 mL) dropwise at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3 h at room temperature. The resulting mixture was concentrated under reduced pressure and the residue was dissolved in 1,4-dioxane (15 mL) and re-concentrated under reduced pressure to afford 3-[4-[3-(3-ami nopropoxy)propyl]-3 -methyl -2-$_{OXO}$-2, 3-dihydro- 1*H*-1, 3-benzodi azol - 1-yl]piperidine-2,6-dione hydrochloride (310 mg, 91%) as a brown yellow solid. ^{1}H NMR (400 MHz, DMSO-i/e) *δ* II.10 (s, 1H), 7.94 (s, 3H), 7.02-6.92 (m, 2H), 6.88 (dd, *j* = 6.4, 2.5 Hz, 1H), 5.39 (dd, *j* = 12.6, 5.4 Hz, 1H), 3.60-3.54 (s, 3H), 3.51-3.43 (m, 4H), 3.02-2.82 (m, 5H), 2.79-2.58 (m, 2H), 2.09-1.93 (m, 1H), 1.90-1.80 (m, 4H); LC/MS (ESI, *m/z):* [(M + l)]⁺ = 375.3.

[002811] 3-|5-|3-(3-aininopropoxy)propyl| -3-methyl-2-oxo-benzimidazol-l-yl] piperidine-2.,6- dione [Intermediate LG)



[002812] Step 1 - Tert-butyl N-[3-(3-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1*H*-1,3-benzodiazol-5-yl]prop-2-yn-1-yloxy)propyl]carbamate

[002813] To a stirred mixture of 3-(5-bromo-3-methyl-2-oxo-2,3-dihydro-1*H*-1,3-benzodiazol-1-yl)piperidine-2,6-dione (2 g, 6 mmol, Intermediate HN), $Pd(PPh_3)_4$ (683.4 mg, 0.59 mmol) and CuI (225.3 mg, 1.18 mmol) in DMSO (10 mL) and TEA (5 mL) was added *tert*-butyl N-[3-(prop-2-yn-1-yloxy)propyl]carbamate (3.8 g, 18 mmol, Intermediate OH) at room temperature under nitrogen atmosphere. The resulting mixture was purged with nitrogen three times and stirred for 16 h at 90 °C under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure to remove TEA. The resulting mixture was diluted with a solution of AcOH (3 mL) in ice water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layers was washed with brine (30 mL) and dried over anhydrous Na_2SO_4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography with the following conditions: Column: WelFlash ™ C18-1, 20-40 pm, 330 g; Eluent A: Water (plus 10 mmol/L FA); Eluent B: ACN; Gradient: 50% - 60% B in 20 min; Flow rate: 80 mL/min; Detector: 220/254 nm; desired fractions were collected at 57% B and

concentrated under reduced pressure to afford te/7-butyl A'-[3-([3-[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2, 3-dihydro- li7-l,3-benzodiazol-5-yl]prop-2-yn-l-yl]oxy)propyl]carbamate (1.5 g, 54%) as a light yellow solid: ^{1}H NMR (400 MHz, DMSO-7,) ◅ 11.12 (s, 1H), 7.34 (s, 1H), 7.23-7.11 (m, 2H), 6.80 (s, 1H), 5.40 (dd, 7 = 12.7, 5.4 Hz, 1H), 4.35 (s, 2H), 3.51 (t, 7 = 6.4 Hz, 2H), 3.35 (s, 3H), 3.00 (q, *J* = 6.7 Hz, 2H), 2.95-2.83 (m, 1H), 2.79-2.58 (m, 2H), 2.03 (dd, *J* = 9.3, 4.3 Hz, 1H), 1.66 (p, *J* = 6.6 Hz, 2H), 1.37 (s, 9H); LC/MS (ESI, *m/z):* [(M + l)]$^+$ = 469.20.

[002814] Step _2 _- _Tert-butyl _A'-(3-[3-П-(2.6-dioxopiperidin-3-yl)-3-methyl -2-oxo-2. 3-dihydro- 1*H*-1.3-benzodiazol-5-yl1propoxy1propyl icarbamate


[002815] To a stirred solution of te/7-butyl A'-[3-([3-[l -(2, 6-di oxopiperi din-3 -yl)-3 -methyl -2-oxo-2,3-dihydro- 1*H*-\ ,3-benzodiazol-5-yl]prop-2-yn- 1-yl]oxy)propyl]carbamate (800 mg, 1.70 mmol) in THF (20 mL) was added palladium on charcoal (200 mg, 10% w/w) at rt under nitrogen atmosphere. The resulting mixture was purged with H_2 gas 3 times and stirred for 4 h at room temperature under hydrogen atmosphere. The reaction mixture was filtered through a Celite pad. The filtrate was concentrated under reduced pressure to afford te/7-butyl *N*-{3-[3-[l-(2,6-dioxopiperi din-3-yl)-3 -methyl -2-oxo-2, 3-dihydro-l//-l ,3-benzodiazol-5-yl]propoxy]propyl)carbamate (730 mg, 90%) as a white solid. 'H NMR (400 MHz, DMS0-7/) δ 11.08 (s, 1H), 7.06-6.97 (m, 2H), 6.87 (d, *J* = 7.8 Hz, 1H), 6.77 (s, 1H), 5.34 (dd, *J* = 12.7, 5.3 Hz, 1H), 3.61 (s, 1H), 3.40-3.31 (m, 6H), 2.99 (q, 7 = 6.6 Hz, 2H), 2.90 (t, *J* = 15.0 Hz, 1H), 2.73-2.58 (m, 4H), 2.01 (d, *J* = 12.7 Hz, 1H), 1.83-1.73 (m, 2H), 1.66-1.58 (m, 2H), 1.38 (s, 9H); LC/MS (ESI, *m/z):* [(M - 1)]$^-$ = 473.3.

[002816] Step 3 - 3-[5-[3-(3-Aminopropoxy)propyl1-3-methyl-2-oxo-2,3-dihvdro-1*H*-E3-benzodiazol-1 -yl]piperi dine-2.6-di one hydrochloride

[002817] To a stirred solution of tert-butyl 7V-(3-[3-[1-(2, 6-di oxopiperi din-3 -yl)-3-methyl-2-oxo-2, 3-dihydro- l/7-l,3-benzodiazol-5-yl]propoxy]propyl)carbamate (730 mg, 1.54 mmol) in l,4-dioxane (10 mL) was added a solution of HC1 in dioxane (4 M, 10 mL) dropwise at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 16 h at rt under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The residue was dissolved in 1,4-dioxane (20 mL) and re-concentrated under reduced pressure to afford 3-[5-[3-(3-ami nopropoxy)propyl]-3 -methyl -2-OXO-2,3-dihydro-1 *H*-\ ,3-benzodiazol- 1-yl]piperidine-2,6-dione hydrochloride (600 mg, 99%) as a light brown solid. ^{1}H NMR (400 MHz, DMSO-7g) δ 11.09 (s, 1H), 7.74 (br s, 3H), 7.11-6.95 (m, 2H), 6.87 (d, *J* = 8.0 Hz, 1H), 5.35 (dd, 7 = 12.8, 5.4 Hz,

1H), 3.58 (s, 3H), 3.44 (t, J = 6.1 Hz, 2H), 3.39 (t, J = 6.5 Hz, 2H), 2.94-2.80 (m, 3H), 2.77-2.56 (m, 4H), 2.10-1.95 (m, 1H), 1.90-1.76 (m, 4H); LC/MS (ESI, *m/z)*: $[(M + l)]^+$ = 375.10.

[002818] **3-[4-[3-[3-[3-Aminopropoxy]propoxy]propyn-3-methyl-2-oxo-2,3-dihvdro-lH-benzo[d]imidazol-l-vPpiperidine-2.,6-dione [Intermediate LH)**



[002819] Step 1 - fer/-butyl A'-[3-[3-(T3-П-(2.6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2. 3-dihydro-1*H*-1.3-benzodiazol-4-yl1prop-2-yn-l -yl1oxy)propoxy1propyl1 carbamate

[002820] To a solution of 3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-l//- 1,3-benzodiazol- 1-yl)piperidine-2,6-dione (2 g, 5.91 mmol, Intermediate HP) in DMA (30 mL) were added /d/7-butyl A-[3-[3-(prop-2-yn- 1-yloxy)propoxy]propyl]carbamate (3 g, 11.06 mmol, Intermediate OJ), TEA (15 mL), Cul (113 mg, 0.59 mmol) and $Pd(PPh_3)_4$ (0.68 g, 0.59 mmol) at rt under nitrogen atmosphere. The resulting mixture was stirred for 5 h at 90 °C under nitrogen atmosphere. The resulting mixture was cooled down to rt and concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography with the following conditions: Column: WelFlash ™ C18-1, 20-40 pm, 330 g; Eluent A : Water (plus 10 mmol/LHCOOH); EluentB: ACN; Gradient:

35% - 60% B in 15 min; Flow rate: 80 mL/min; Detector: 220/254 nm; desired fractions were collected at 55% B and concentrated under reduced pressure to afford *tert*-butyl A-[3-[3-([3-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lA/-l,3-benzodiazol-4-yl]prop-2-yn-l-yl]oxy)propoxy]propyl]carbamate (1.4 g, 45%) as a light brown solid. 'H NMR (400 MHz, DMSO-d_6) δ 11.12 (br s, 1H), 7.19-7.12 (m, 2H), 7.08-6.95 (m, 1H), 6.75 (br s, 1H), 5.41 (dd, *J* = 12.7, 5.4 Hz, 1H), 4.43 (s, 2H), 3.64 (s, 3H), 3.63-3.55 (m, 4H), 3.42 (t, *J* = 6.4 Hz, 2H), 3.35 (d, *J* = 12.6 Hz, 2H), 3.00-2.83 (m, 3H), 2.71 (m, 2H), 2.10-1.97 (m, 2H), 1.78 (p, *J* = 6.4 Hz, 2H), 1.59 (p, *J* = 6.6 Hz, 2H), 1.37 (s, 9H); LC/MS (ESI, *m/z):* [(M + l)] $^+$ = 529.35.

[002821] Step 2 - *tert*-butyl A'-[3-(3-[3-П-(2.6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2. 3-dihydro- 1*H*-1.3-benzodiazol-4-yl1propoxy1propoxy)propyl1carbamate


[002822] To a stirred solution of *te/'t*-butyl /V-[3-[3-([3-[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro- 1*H*-1,3-benzodiazol-4-yl]prop-2-yn- 1-yl]oxy)propoxy]propyl]carbamate (900 mg, 1.71 mmol) in THF (20 mL) was added palladium on charcoal (300 mg, 10% w/w) at rt under nitrogen atmosphere. The resulting mixture was purged with hydrogen for 3 times and was stirred for 4 h at rt under hydrogen atmosphere. The reaction mixture was filtered through a Celite pad. The filtrate was concentrated under reduced pressure to afford *tert*-butyl A-[3-(3-[3-[l -(2,6-dioxopi peri din-3-yl)-3 -methyl -2-ox o-2,3-di hydro- 1*H*-1,3-benzodiazol-4-yl]propoxy]propoxy)propyl]carbamate (800 mg, 88%) as a light brown solid. 'H NMR (400 MHz, DMSO-^e) ‹5 11.10 (br s, 1H), 7.02-6.98 (m, 2H), 6.90-6.83 (m, 1H), 6.76 (t, *J* = 5.7 Hz, 1H), 5.37 (dd, 7 = 12.6, 5.4 Hz, 1H), 3.56 (s, 3H), 3.52-3.33 (m, 6H), 3.01-2.83 (m, 5H), 2.72-2.58 (m, 2H), 2.00 (ddd, *J* = 11.1, 5.9, 3.6 Hz, 1H), 1.89-1.68 (m, 6H), 1.60 (p, *J* = 6.6 Hz, 2H), 1.37 (s, 9H); LC/MS (ESI, *m/z):* [(M + l)] $^+$ = 533.40.

[002823] Step 3 - 3-(4-r3-r3-(3-Aminopropoxy)propoxy1propyl1-3-methyl-2-oxo-2.3-dihydro- 1*H*-1J-benzodiazol- l-yl)pi peri dine-2.6-di one hydrochloride


[002824] To a stirred solution of *te/'t*-butyl /V-[3-(3-[3-[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2, 3-dihydro- lA7-l,3-benzodiazol-4-yl]propoxy]propoxy)propyl]carbamate (800 mg, 1.50 mmol) in l,4-dioxane (10 mL) was added a solution of hydrochloride in dioxane (4 M, 10 mL) dropwise at 0 °C. The resulting mixture was stirred for 2 h at rt. The resulting mixture was concentrated under reduced pressure to afford 3-(4-[3-[3-(3-aminopropoxy)propoxy]propyl]-3-methyl-2-oxo-2,3-dihydro-lH-l,3-benzodiazol-l-yl)piperidine-2,6-dione hydrochloride (640 mg, 91%) as a white solid. ^{1}H NMR (400 MHz, DMSO-7 $_5$) δ 11.11 (br s, 1H), 7.83 (br s, 3H), 7.05-


6.93 (m, 2H), 6.88 (td, *J* = 6.8, 5.9, 3.1 Hz, 1H), 5.38 (dd, *J* = 12.5, 5.4 Hz, 1H), 3.57 (s, 3H), 3.45-3.31 (m, 8H), 3.04-2.77 (m, 5H), 2.77-2.57 (m, 2H), 1.99 (dd, *J* = 9.8, 4.9 Hz, 1H), 1.90-1.70 (m, 6H); LC/MS (ESI, *m/z):* $[(M + l)]^+$ = 433.30.


[002825] **3-15-13-|3-[3-Aininopropoxy)propoxy Ipropyl|-3-inethyl-2-oxo-2,3-dihvdro-17/-l.,3-benzodiazol-l-yPpiperidine-2.,6-dione [Intermediate LI)**



OJ







LI

[002826] Step 1 - *tert*-Butyl A'-[3-[3-(T3-[1-(2.6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2. 3-dihydro- 1*H*-1.3-benzodiazol-5-yl1prop-2-yn- 1-yl1oxy)propoxy1propyl1 carbarn ate

[002827] To a stirred solution of 3-(5-bromo-3-methyl-2-oxo-2, 3-dihydro- 1*H*-1,3-benzodiazol-l-yl)piperidine-2,6-dione (2.0 g, 5.91 mmol, Intermediate HN) in DMSO (20 mL) were added *tert*-butyl 7V-[3-[3-(prop-2-yn-l-yloxy)propoxy]propyl]carbamate (5.8 g, 21.4 mmol, Intermediate OJ), TEA (10 mL), Cul (0.2 g, 1 mmol) and Pd(PPh $_{3)4}$ (0.7 g, 0.59 mmol) at rt under

nitrogen atmosphere. The resulting mixture was stirred for 3 h at 90 °C. The resulting mixture was cooled to rt and concentrated under reduced pressure. The resulting mixture was diluted with 1% aqueous solution of AcOH (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layers was washed with brine (100 mL) and dried over anhydrous Na_2SO_4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography with the following conditions: Column: WelFlash ™ C18-1, 20-40 pm, 330 g; Eluent A: Water (plus 10 mmol/L AcOH); Eluent B: ACN; Gradient: 45% - 55% B in 10 min; Flow rate: 80 mL/min; Detector: 220/254 nm; desired fractions were collected at 51% B and concentrated under reduced pressure to afford *tert*-butyl A-[3-[3-([3-[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-liT-l,3-benzodiazol-5-yl]prop-2-yn-l-yl]oxy)propoxy]propyl]carbamate (1.5 g, 48%) as a yellow solid. ^{1}H NMR (400 MHz, CDCh) δ 8.21 (br s, 1H), 7.22 (dd, *J* = 8.2, 1.5 Hz, 1H), 7.14 (d, *J* = 1.4 Hz, 1H), 6.77 (d, *J* = 8.1 Hz, 1H), 5.22 (dd, *J* = 12.7, 5.3 Hz, 1H), 4.89 (br s, 1H), 4.39 (s, 2H), 3.69 (t, *j* = 6.3 Hz, 2H), 3.55 (t, *j* = 6.3 Hz, 2H), 3.51 (t, *J* = 5.9 Hz, 2H), 3.44 (s, 3H), 3.23 (q, *j* = 6.1 Hz, 2H), 3.03-2.64 (m, 3H), 2.34-2.24 (m, 1H), 1.92 (p, *j* = 6.3 Hz, 2H), 1.76 (p, *j* = 6.3 Hz, 2H), 1.46 (s, 9H); LC/MS (ESI, *m/z):* $[(M + l)]^+$ = 529.25.

[002828] Step 2 - fer/-Butyl /V-[3-(3-[3-[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1*H*-1,3-benzodiazol-5-yl]propoxy]propoxy)propyl]carbamate


[002829] To a solution of *tert*-butyl A-[3-[3-([3-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-li7-l,3-benzodiazol-5-yl]prop-2-yn-l-yl]oxy)propoxy]propyl]carbamate (200 mg, 0.38 mmol) in THF (10 mL) was added palladium on charcoal (402 mg, 10% w/w) under nitrogen atmosphere. The mixture was purged with hydrogenated for three times and was stirred at rt for 6 h under hydrogen atmosphere. The resulting mixture was filtered through a Celite pad and the filtrate was concentrated under reduced pressure to afford *tert*-butyl /V-[3-(3-[3-[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1*H*-1,3-benzodiazol-5-yl]propoxy]propoxy)propyl]carbamate (150 mg, 74%) as a white solid. ^{1}H NMR (400 MHz, DMSO-i/e) δ 11.09 (br s, 1H), 7.93 (br s, 1H), 7.06-6.98 (m, 2H), 6.87 (d, *j* = 8.0 Hz, 1H), 5.36 (dt, *J* = 12.6, 6.0 Hz, 1H), 3.57 (s, 5H), 3.47-3.34 (m, 8H), 3.04-2.84 (m, 2H), 2.82-2.66 (m, 1H), 2.66-2.58 (m, 3H), 2.04-1.96 (m, 1H), 1.86-1.68 (m, 4H), 1.65-1.53 (m, 1H), 1.37 (s, 9H); LC/MS (ESI, *m/z):* $[(M + l)]^+$ = 533.25.

[002830] Step 3- 3-(5-[3-[3-(3-Aminopropoxy)propoxy]propyl-1-3-methyl-2-oxo-2.3-

dihydro- 177-1 .3-benzodiazol-l -yl)pi peri dine-2. 6-dione hydrochloride

[002831] To a solution of *tert*-butyl /V-[3-(3-[3-[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro- 1/7-1, 3-benzodiazol-5-yl]propoxy]propoxy)propyl]carbamate (300 mg, 0.56 mmol) in dioxane (10 mL) was added a solution of hydrochloride in l,4-dioxane (4 M, 10 mL). The resulting solution was stirred for 4 h at rt under nitrogen atmosphere. The resulting mixture was concentrated under vacuum to afford 3-(5-[3-[3-(3-aminopropoxy)propoxy]propyl]-3-methyl-2-oxo-2, 3-dihydro- 1/7-1, 3-benzodiazol-l-yl)piperi dine-2, 6-dione hydrochloride (200 mg, 76%) as a yellow solid. ^{1}H NMR (400 MHz, DMSO-7 $_6$) δ 11.09 (br s, 1H), 7.93 (br s, 3H), 7.06-6.'99 (m, 2H), 6.87 (d, J = 8.0 Hz, 1H), 5.36 (dd, J = 12.7, 5.5 Hz, 1H), 3.58 (s, 3H), 3.48-3.34 (m, 8H), 3.02-2.54 (m, 7H), 2.00 (dd, 7 = 11.4, 6.2 Hz, 1H), 1.87-1.68 (m, 6H); LC/MS (ESI, *m/z):* [(M + l)] $^+$ = 433.15.

[002832] **3-Bromo-l-[4-methoxybenzvBpiperidine-2,6-dione [Intermediate LJ)**



LJ


[002833] Step 1 - 3-bromopi peri dine-2. 6-dione

[002834] To a stirred solution of piperidine-2, 6-dione (30 g, 0.266 mol) in CH Cl$_3$ (60 mL) was added B r$_2$ (13.5 mL, 0.265 mol) in a sealed glass tube, then the reaction mixture was heated to 113 °C for 1.5 h. The mixture was cooled to r.t. and transferred to a round bottom flask and concentrated. To the residue was added 100 mL ice water, and the solution was basified to pH = ~ 8 with saturated NaHCCh aqueous, then extracted with DCM (100 mL x 5). The organic layer was dried with N a$_2$S0 $_4$, filtered, and concentrated to give crude product, which was dissolved in a solution of DCM: EtOAc = 1:1 (~90 mL), then heated to 80 °C. After the solid was completely dissolved, the heating was stopped and the solution was cooled to r.t. for overnight. The solution was filtered, the solid was collected, and dried under vacuum to give desired compound (15.7 g) as a white solid. The filtrate was also concentrated to dry to give crude product, which was purified by column chromatography on silica gel eluting with DCM : Petroleum ether : EtOAc = 5:5:1 to DCM : Petroleum ether : EtOAc = 5:5:2 to obtain desired the second batch pure product (12 g) as a white solid (total yield: 54.5 %). ^{1}H NMR (400 MHz, DM S0 -d_6) δ 11.06 (s, 1H), 5.00 - 4.78 (m, 1H), 2.69 - 2.54 (m, 2H), 2.45 (dd, J = 10.0, 5.1 Hz, 1H), 2.17-2.12 (m, 1H).

[002835] Step 2 - 3-bromo-l -(4-methoxybenzyl)piperidine-2.6-dione

[002836] To a solution of 3-bromopiperidine-2,6-dione (30 g, 156.3 mmol), (4-methoxyphenyl)methanol (23.3 g, 168 mmol) and PPh_3 (40.5 g, 154.5 mmol) in dry THF (450 mL) was added dropwise DEAD (26.9 g, 154.5 mmol) at 0 °C under N_2 for 30 min. The mixture was stirred for another 1.5 hour at 0 °C under N_2. The mixture was quenched with H_20 (300 mL) at 0 °C, and extracted with EA (400 mLx3). The organic layer was concentrated to give a residue, which was purified by column chromatography on silica gel eluting with PE:EA = 5:1 to PE:EA = 4:1 to give crude product. The crude product was further purified by column chromatrography on silica gel eluting with DCM to give 3-bromo-l -(4-methoxybenzyl) piperidine-2, 6-dione (26.8 g, 55 % yield) as a pale yellow solid. ^{1}H NMR (400 MHz, CDCb) δ 7.32-7.29 (d, *J* = 8.8 Hz, 2H), 6.83-6.81 (d, *J* = 8.8 Hz, 2H), 4.96-4.83 (dd, 7 = 13.6 Hz, *J* = 38 Hz, 2H), 4.72-4.70 (m, 1H), 3.78 (s, 3H), 3.06-2.99 (m, 1H), 2.76-2.72 (m, 1H), 2.36-2.32 (m, 1H), 2.25-2.21 (m, 1H).

[002837] **5-Chloro-l-methyl-N-(4-morpholinocvclohexy0pyrazolo[4.,3-dlpyrimidin-7-amine [Intermediate LK)**



[002838] Step 1 - Methyl 2-methyl-4-nitro-pyrazole-3-carboxylate

[002839] To a mixture of methyl 4-nitro-lH-pyrazole-5-carboxylate (30.0 g, 175 mmol, Intermediate HL) and K2CO3 (48.4 g, 350 mmol) in acetone (600 mL) was added Mel (49.7 g, 350 mmol, 21.8 mL). The reaction mixture was stirred at 70 °C for 2 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo.* The residue was purified by column

chromatography to give the title compound (10.0 g, 30% yield) as light yellow solid. ^{1}H NMR (400MHz, CDCh) δ 7.99 (s, 1H), 4.01 (s, 3H), 4.01 (s, 3H).

[002840] Step 2 - 2-Methyl-4-nitro-pyrazole-3 -carboxamide

[002841] To a mixture of methyl 2-methyl-4-nitro-pyrazole-3-carboxylate (10.0 g, 54.0 mmol) in THF (20 mL) was added N¾ ·$H_2$0 (27.3 g, 740 mmol, 30 mL, 95%). The reaction mixture was stirred at 100 °C for 16 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (8.80 g, 95% yield) as white solid. ^{1}H NMR (400MHz, DMSO-d_6) δ 8.46 (s, 1H), 8.29 (s, 1H), 8.26 (s, 1H), 3.86 (s, 3H).

[002842] Step 3 - 4-Amino-2-methyl-pyrazole-3 -carboxamide

[002843] To a mixture of 2-methyl-4-nitro-pyrazole-3-carboxamide (8.80 g, 51.7 mmol) in MeOH (100 mL) was added Pd/C (6.00 g, 10 wt%). The reaction mixture was stirred at rt for 12 hours under H_2 (15 psi) atmosphere. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (7.10 g, 97% yield) as red solid. ^{1}H NMR (400MHz, DMSO-il_6) δ 7.37 (s, 2H), 7.02 (s, 1H), 4.41 (s, 2H), 3.89 (s, 3H).

[002844] Step 4 - l-Methylpyrazolor4.3-d1pyrimidine-5.7-diol

[002845] To a mixture of 4-amino-2-methyl-pyrazole-3-carboxamide (11.3 g, 80.6 mmol) in DMF (120 mL) was added CDI (26.1 g, 161 mmol). The reaction mixture was stirred at 90 °C for 24 hours. On completion, the reaction mixture was diluted with water (400 mL) then the solid was formed, and filtered to afford solid. The solid was washed with water (1 L) to give the title compound (13.0 g, 97% yield) as off-white solid. ^{1}H NMR (400MHz, DMSO-di) δ 11.08 (s, 1H), 10.92 (s, 1H), 7.33 (s, 1H), 4.04 (s, 3H).

[002846] Step 5 - 5.7-Dichloro- l-methyl-pyrazoloRJ-dlpyrimidine


[002847] To a mixture of l-methylpyrazolo[4,3-d]pyrimidine-5,7-diol (5.00 g, 30.1 mmol) in POCI3 (50.0 g, 326 mmol, 30.3 mL) was added N,N-diethylaniline (4.46 g, 29.8 mmol, 4.78 mL). The reaction mixture was stirred at 110 °C for 4 hours. On completion, the reaction mixture was concentrated *in vacuo*. The residue was purified by column chromatography to give the title compound (3.70 g, 60% yield) as white solid. ^{1}H NMR (400MHz, DMSO-i/e) δ 8.48 (s, 1H), 4.33 (s, 3H).

[002848] Step 6 - 5-Chloro-l -methyl-N-(4-morpholinocvclohexyl ipyrazolo[4,3-dlpyrimidin-7-amine

[002849] To a solution of 5,7-dichloro-l-methyl-pyrazoio[4,3-d]pyrimidine (1.00 g, 4.93

mmol) and 4-morpholinocyclohexanamine (1.27 g, 4.93 mmol, 2HC1, CAS# 558442-97-0) in ACN (30 mL) was added Na_2C0_3 (2.09 g, 19.70 mmol). The reaction mixture was stirred at 80 °C for 12 hours. The reaction mixture was concentrated *in vacuo*, diluted with DCM (30 mL), and filtered. The filtrate was concentrated *in vacuo*. The crude product was triturated with ACN/DCM/PE = 1:0.2:10 (30 mL) to give the title compound (1.30 g, 75% yield) as a yellow solid. ^{1}HNMR (400MHz, CDCL) δ 7.85 (s, 1H), 5.18 (d, *J* = 6.8 Hz, 1H), 4.30 (s, 3H), 4.28 - 4.17 (m, 1H), 3.86 (s, 4H), 2.74 (s, 4H), 2.56 - 2.50 (m, 1H), 2.36 (d, *J* = 11.6 Hz, 2H), 2.13 (d, *J* = 11.6 Hz, 2H), 1.69 - 1.53 (m, 2H), 1.47 - 1.32 (m, 2H).

[002850] **Tert-butyl N-[2-[2-[2-[2-[2-(4-aminopyrazol-1-yl)ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate [Intermediate LL)**



LL

[002851] Step 1 - Tert-butyl N-r2-r2-r2-r2-r2-(4-nitropyrazol-l-vnethoxylethoxylethoxylethoxylethyll carbamate


[002852] To a solution of 2-[2-[2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethoxy]ethyl methanesulfonate (1.76 g, 4.24 mmol, synthesized via Step 1 of Intermediate HH) and 4-nitro-lH-pyrazole (0.40 g, 3.54 mmol, CAS# 2075-46-9) in DMF (15 mL) was added CS2CO3 (2.31 g, 7.07 mmol). The reaction mixture was stirred at 130 °C for 3 hours. On completion, the mixture was diluted with H_20 (50 mL), then extracted with EA (2 X 100 mL). The combined organic phase was concentrated *in vacuo*. The residue was purified by reverse phase (0. 1% FA condition) to give the title compound (1.20 g, 78% yield) as yellow oil. LC-MS (ESI$^+$) *m/z* 455.2 (M+Na)$^+$.

[002853] Step 2 - Tert-butyl N-r2-r2-r2-r2-r2-(4-aminopyrazol-l-yl)ethoxy]ethoxy] ethoxy] ethoxy] ethyl] carbamate

[002854] To a mixture of tert-butyl N-[2-[2-[2-[2-[2-(4-nitropyrazol-l-yl)ethoxy] ethoxy] ethoxy] ethoxy] ethyl]carbamate (1.20 g, 2.77 mmol) in MeOH (20 mL) was added Pd/C (800 mg, 10 wt%). The reaction mixture was stirred at rt for 12 hours under ¾ (15

Psi) atmosphere. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (1.00 g, 89% yield) as red oil. ^{1}H NMR (400MHz, CDCh) δ 7.16 (d, *J* = 5.2 Hz, 2H), 5.23 (s, 1H), 4.17 (t, *J* = 5.2 Hz, 2H), 3.78 (t, *J* = 5.2 Hz, 2H), 3.65 - 3.51 (m, 14H), 3.30 (d, *j* = 4.8 Hz, 2H), 2.67 (s, 2H), 1.43 (s, 9H).

[002855] **l-[2-[2-[2-(4-Aminopyrazol-l-vBethoxylethoxylethoxylpentan-2-one [Intermediate LM)**



[002856] Step 1 - Ethyl 2-r2-r2-r2-(4-nitropyrazol-l-vDethoxy1ethoxy1ethoxy1acetate


[002857] To a mixture of ethyl 2-[2-[2-(2-methylsulfonyloxyethoxy)ethoxy]ethoxy]acetate (0.5 g, 1.59 mmol, Intermediate BI) and 4-nitro-lH-pyrazole (270 mg, 2.38 mmol) in DMF (10 mL) was added CS2CO3 (1.04 g, 3.18 mmol). The reaction mixture was stirred at rt for 24 hours under N_2 atmosphere. On completion, the reaction mixture was diluted with H_20 (20 mL) and extracted with EtO Ac (3 X 20 mL). The combined organic layers were washed with brine (50 ml), dried over Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by flash silica gel chromatography to give the title compound (0.5 g, 1.43 mmol, 90% yield, 95% purity) as a yellow solid. ^{1}H NMR (400MHz, DMSO-de) δ = 8.84 (s, 1H), 8.27 (s, 1H), 4.35 (t, *J* = 5.2 Hz, 2H), 4.19 - 4.04 (m, 4H), 3.82 (t, *J* = 5.2 Hz, 2H), 3.62 - 3.46 (m, 8H), 1.19 (t, *J* = 7.2 Hz, 3H) LC-MS (ESI+) m/z 332.2 $(M+H)^+$.

[002858] Step 2 - l-r2-r2-r2-(4-Aminopyrazol-l-v0ethoxy1ethoxy1ethoxy1pentan-2-one

[002859] To a solution of ethyl 2-[2-[2-[2-(4-nitropyrazol-l-yl)ethoxy] ethoxy] ethoxy] acetate (0.5 g, 1.51 mmol) in EtOH (10 mL) was added Pd/C (0.05 g, 50 wt%) under N_2. The suspension was degassed under vacuum and purged with ¾ several times. The mixture was stirred under H2 (15 psi) at rt for 2 hours. On completion, the mixture was filtered with celite. The filtrate was concentrated in vacuo to give the title compound (0.34 g, 75% yield) as black red oil. ^{1}H NMR (400MHz, DMSO-de) δ 7.14 - 7.01 (m, 1H), 6.96 - 6.83 (m, 1H), 4.17 - 4.09 (m, 4H), 4.08 - 4.03 (m, 2H), 3.72 - 3.66 (m, 2H), 3.63 - 3.57 (m, 2H), 3.55 - 3.51 (m, 2H),

3.49 (s, 4H), 1.25 - 1.17 (m, 3H).

[002860] **3-[4-[4-(4-aminobutoxy)butyll-3-methyl-2-oxo-benzimidazol-l-yllpiperidine-2,6-dione [Intermediate LN]**



[002861] Step _1_ - _7O·t-butyl_ A'-[4-(⌈4-⌈1-(2.6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2.3-dihydro- 1*H*-1.3-benzodiazol-4-yl1but-3-yn- 1-ylloxyibutyllcarbamate

[002862] To a stirred mixture of 3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-li7-l,3-benzodiazol-l-yl)piperidine-2,6-dione (1.5 g, 4.4 mmol, Intermediate HP), $Pd(PPh_3)_2Cl_2$ (311.3 mg, 0.44 mmol) and Cul (84.5 mg, 0.44 mmol) in DMA (22 mL) and TEA (7 mL) was added *tert*-butyl /V-[4-(but-3-yn-l-yloxy)butyl]carbamate (5.4 g, 22.2 mmol, Intermediate OI) at rt under nitrogen atmosphere. The resulting mixture was purged with nitrogen three times and stirred for 16 h at 85 °C under nitrogen atmosphere. The resulting mixture was cooled and concentrated under reduced pressure to remove TEA. The resulting mixture was diluted with a solution of AcOH (3 mL) in ice water (50 mL). The resulting mixture was extracted with EtOAc (2 x 50 mL). The combined organic layers was washed with brine (30 mL) and dried over anhydrous Na_2SO_4. After

filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography with the following conditions: Column: WelFlash ™ C18-1, 20-40 pm, 120 g; Eluent A: Water (plus 10 mmol/L FA); Eluent B: ACN; Gradient: 50% - 60% B in 20 min; Flow rate: 60 mL/min; Detector: 220/254 nm; desired fractions were collected at 57% B and concentrated under reduced pressure to afford *tert*-butyl /V-[4-([4-[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2, 3-dihydro- 177-1,3-benzodiazol-4-yl]but-3-yn-l-yl]oxy)butyl]carbamate (1.4 g, 63%) as a light yellow solid. ^{1}H NMR (400 MHz, DMSO-d_6) ≤ 11.11 (s, 1H), 7.12 (d, J = 7.7 Hz, 1H), 7.05 (d, J = 7.7 Hz, 1H), 7.00 (d, J = 7.8 Hz, 1H), 6.79 (t, J = 5.7 Hz, 1H), 5.39 (dd, J = 12.6, 5.4 Hz, 1H), 3.65 (s, 3H), 3.63-3.54 (m, 2H), 3.43 (t, J = 6.3 Hz, 2H), 2.98-2.83 (m, 3H), 2.79-2.58 (m, 4H), 2.03 (dt, J = 10.8, 5.1 Hz, 1H), 1.56-1.39 (m, 4H), 1.37 (s, 9H); LC/MS (ESI, *m/z):* [(M - l)]$^-$ = 497.15.

[002863] Step 2 - Tert-butyl A'-(4-[4-П-(2.6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2.3-dihydro- 177-1.3-benzodiazol-4-yllbutoxylbutyl)carbamate


[002864] To a stirred solution of *tert*-butyl A'-[4-([4-[1-(2, 6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2, 3-dihydro- 1*H*-\,3-benzodiazol-4-yl]but-3-yn-1-yl]oxy)butyl]carbamate (800 mg, 1.60 mmol) in THF (20 mL) was added palladium on charcoal (80 mg, 10% w/w) at room temperature. The resulting mixture was stirred for 3 h at rt under hydrogen atmosphere. After filtration, the filter cake was washed with EtOAc (2 x 10 mL). The filtrate was concentrated under reduced pressure to afford *te/'t*-butyl A'-(4-[4-[1-(2, 6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2, 3-dihydro- 1*H*-1,3-benzodiazol-4-yl]butoxy]butyl)carbamate (500 mg, 62%) as a white solid: ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.09 (s, 1H), 6.96 (d, j = 5.0 Hz, 2H), 6.87 (q, J = 4.6 Hz, 1H), 6.77 (t, j = 6.2 Hz, 1H), 5.37 (dd, J = 12.5, 5.4 Hz, 1H), 3.56 (s, 3H), 3.40 (t, j = 5.8 Hz, 2H), 3.37-3.29 (m, 2H), 3.00-2.82 (m, 5H), 2.78-2.57 (m, 2H), 2.06-1.95 (m, 1H), 1.71-1.55 (m, 4H), 1.53-1.37 (m, 4H), 1.37 (s, 9H); LC/MS (ESI, *m/z):* [(M + l)]$^+$ = 503.20.

[002865] Step 3 - 3-r4-r4-(4-Aminobutoxy)butyl1-3-methyl-2-oxo-2.3-dihvdro- 177-1.3-benzodiazol-1-yllpiperidine-2.6-dione hydrochloride


[002866] To a stirred solution of *tert*-butyl 7V-(4-[4-[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2, 3-dihydro- 177-1,3-benzodiazol-4-yl]butoxy]butyl)carbamate (500 mg, 0.99 mmol) in dioxane (4 mL) was added a solution of hydrochloride in l,4-dioxane (4 M, 4 mL) dropwise at rt under nitrogen atmosphere. The resulting solution was stirred for 2 h at rt under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure to afford 3-[4-[4-(4-


aminobutoxy)butyl]-3-methyl-2-oxo-2,3-dihydro- 1*H*-\ ,3-benzodiazol- 1-yl]pi peri dine-2,6-di one hydrochloride (420 mg, 96%) as a white solid. ^{1}H NMR (400 MHz, DMSO-i¾) δ 11.08 (s, 1H), 7.88 (br s, 3H), 7.02-6.92 (m, 2H), 6.87 (dd, *J* = 6.2, 2.6 Hz, 1H), 5.38 (dd, *J* = 12.6, 5.4 Hz, 1H), 3.57 (s, 3H), 3.47-3.28 (m, 4H), 2.99-2.84 (m, 3H), 2.79-2.58 (m, 4H), 2.00 (dt, *J* = 11.1, 5.2 Hz, 1H), 1.69-1.50 (m, 8H); LC/MS (ESI, *m/z):* [(M + l)] $^+$ = 403.25.

[002867] **(2S,4R)-1-[(2S)-2-[[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]acetyl]amino]-3,3-dimethyl- butanoyll-4-hvdroxy-N-[[4-(4-methylthiazol-5-vDphenyllmethyllpyrrolidine-2-carboxamide [Intermediate LO)**



CI





LO

[002868] Step 1 - Tert-butyl N-[2-[2-[2-[2-[[(1S)-1-I(2S.4R)-4-hvdroxy-2-IΓ4-(4-methylthiazol-5-vPphenyll methylcarbamoyllpyrrolidine- 1-carbonyl] -2.2-dimethyl-propyl] amino] -2-oxo-ethoxyl ethoxy] ethoxy] ethyl]carbamate


[002869] To a solution of (2S,4R)-l-[(2S)-2-amino-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol- 5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (250 mg, 535 umol, HC1,

Intermediate Cl) and 2-[2- [2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]acetic acid (164 mg, 535 umol, CAS# 462100-06-7) in DMF (5 mL) was added DIPEA (207 mg, 1.61 mmol) and HATU (244 mg, 642 umol). The mixture was stirred at rt for 1 hour. On completion, the reaction mixture was quenched with water 20 mL, and then extracted with EA (3 X 30 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (FA condition) to give the title compound (300 mg, 77% yield) as brown solid. LC-MS (ESI^+) *m/z* 720.4 $(M+H)^+$.


[002870] Step 2 - (2S.4R)-l-I(2S)-2-II2-[2-[2-(2-aminoethoxy)ethoxy1 ethoxy] acetyl] amino] -3,3-dimethyl- butanovn-4-hvdroxy-N-IT4-(4-methylthiazol-5-vnphenyl1methvnpyrrolidine-2-carboxamide


[002871] To a solution of tert-butyl N-[2-[2-[2-[2-[[(lS)-l-[(2S,4R)-4-hydroxy-2-[[4-(4-methylthiazol-5-yl) phenyljmethylcarbamoyljpyrrolidine-l -carbonyl]-2, 2-dimethyl - propyl]amino]-2-oxo-ethoxy]ethoxy]ethoxy]ethyl]carbamate (240 mg, 333 umol) in DCM (12 mL) was added HCl/dioxane (4 M, 2.5 mL). The mixture was stirred at rt for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (0.21 g, 96% yield, HC1) as light yellow solid. LC-MS (ESI^+) *m/z* 620.2 $(M+H)^+$.

[002872] (2S,4R)-1-[(2S)-2-[2-[2-[2-(2-aminoethoxy)ethoxyl ethoxy] ethylaminol-3,3-dimethyl- butanoyll-4-hydroxy-N-[[4-(4-methylthiazol-5-y0phenyllmethyllpyrr()lidine-2-carboxamide [Intermediate LP)



Cl





LP

[002873] Step 1 - Tert-butyl N-[2-[2-[2-[[(1S)-1-[(2S,4R)-4-hydroxy-2-[[4-(4-methylthiazol-5-yl)phenyl]methylcarbamoyl]pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]amino]ethoxy]ethoxy]ethoxy]ethyl]carbamate


[002874] To a mixture of tert-butyl N-[2-[2-[2-(2-oxoethoxy)ethoxy]ethoxy]ethyl]carbamate (500 mg, 1.72 mmol, Intermediate JX), (2S,4R)-1-[(2S)-2-amino-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methyl thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (801 mg, 1.72 mmol, HC1, Intermediate Cl), and TEA (174 mg, 1.72 mmol) in THF (20 mL) was added AcOH (103 mg, 1.72 mmol) and $NaBH(OAc)_3$ (727 mg, 3.43 mmol). Then the mixture was stirred at rt for 72 hrs under N_2 atmosphere. On completion, the mixture was concentrated *in vacuo* to give a residue. The residue was purified by Pre-HPLC (acid condition) to give the title compound (480 mg, 38% yield) as colorless solid. LC-MS (ESI^+) *m/z* 706.5 $(M+H)^+$.

[002875] Step 2 - (2S,4R)-1-[(2S)-2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethylamino]-

3.3-dimethyl- butanoyl1-4-hvdroxy-N-rr4-(4-methylthiazol-5-vnphenyl1methyl1pyrrolidine-2-carboxamide

[002876] To a solution of tert-butyl N-[2-[2-[2-[2-[[(lS)-l-[(2S,4R)-4-hydroxy-2-[[4-(4-methylthiazol-5-yl) phenyl]methylcarbamoyl]pyrrolidine-l -carbonyl]-2, 2-dimethyl -propyl]amino]ethoxy]ethoxy]ethoxy]ethyl]carbamate (380 mg, 538 umol) in THF (10 mL) was added HCl/dioxane (4 M, 12 mL). The mixture was stirred at rt for 6 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (325 mg, 94% yield) as white solid. LC-MS (ESI^+) *m/z* 606.4 $(M+H)^+$.

[002877] **Tert-butyl N-[3-[3-(3-aminopropoxy)propoxy]propyl]carbamate (Intermediate LQ)**



LQ

[002878] Step 1 - 3-r3-(2-Cvanoethoxy)propoxy1propanenitrile

[002879] NaOMe (71.00 mg, 1.31 mmol) was dissolved in a solution of propane-l, 3-diol (10 g, 131 mmol, CAS# 126-30-7). Then prop-2-enenitrile (27.9 g, 525 mmol, CAS# 107-13-1) was added into the mixture. The reaction mixture was stirred at rt for 48 hrs. On completion, the mixture was concentrated *in vacuo.* The residue was purified by column chromatography to give the title compound (21.6 g, 90% yield) as a brown solid. ^{1}HNMR (400MHz, DMSO-r#) δ 3.57 (t, J = 6.4 Hz, 4H), 3.50 (t, J = 6.4 Hz, 4H), 2.74 (t, J = 6.4 Hz, 4H), 1.79 - 1.73 (m, 2H).

[002880] Step 2 - 3-r3-(3-Aminopropoxy)propoxy1propan-l-amine


[002881] To a mixture of 3-[3-(2-cyanoethoxy)propoxy]propanenitrile (10 g, 54.9 mmol) in MeOH (10 mL) was added Raney-Ni (9.40 g, 109 mmol), and the reaction mixture was stirred at 25 °C for 12 hrs under H_2 (50 psi). On completion, the mixture was concentrated *in vacuo.* The residue was purified by column chromatography to give the title compound (8.40 g, 80% yield) as brown oil. ¾NMR (400MHz, CDCh) δ 3.74 - 3.30 (m, 9H), 2.79 - 2.38 (m, 4H), 1.85 - 1.56 (m, 4H), 1.91 - 1.48 (m, 1H).

[002882] Step 3 - Tert-butyl N-r3-r3-(3-aminopropoxy)propoxy1propyl1carbamate

[002883] To a solution of 3-[3-(3-aminopropoxy)propoxy]propan-l-amine (4.00 g, 21.0

mmol) in DCM (40 mL) was dropwise added $(Boc)_20$ (5.51 g, 25.2 mmol). The reaction mixture was stirred at rt for 12 hrs. On completion, the mixture was concentrated *in vacuo.* The residue was purified by column chromatography to give the title compound (2.20 g, 36% yield) brown oil. ^{1}H NMR (400MHz, CDCh) δ 3.66 - 3.60 (m, 3H), 3.66 - 3.60 (m, 3H), 3.49 - 3.45 (m, 4H), 2.61 - 2.53 (m, 4H), 1.88 - 1.68 (m, 6H), 1.41 (s, 9H).

[002884] **4-[3-[3-[3-Aminopropoxy)propoxy1propylamino1-2-[2,6-dioxo-3-piperidvBisoindoline-1.,3- dione [Intermediate LR)**




[002885] Step 1 - Tert-butyl N-[3-[3-[3-Π2-(2,6-dioxo-3-piperidvl)-l,3-dioxo-isoindolin-4-vnaminolpropoxylpropoxylpropyncarbamate

[002886] To a mixture of 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (476 mg, 1.72 mmol, Intermediate R), tert-butyl N-[3-[3-(3-aminopropoxy)propoxy]propyl]carbamate (500 mg, 1.72 mmol, Intermediate LQ) in dioxane (10 mL) was added DIPEA (2.23 g, 17.2 mmol). The reaction mixture was stirred at 115 °C for 12 hrs. On completion, the mixture was concentrated *in vacuo.* The residue was purified by reverse phase (0.1% FA) to give the title compound (820 mg, 87% yield) as brown oil. LC-MS (ESI^+) *m/z* 547.4 $(M+H)^+$.

[002887] Step 2 - 4-r3-r3-(3-Aminopropoxy)propoxy1propyl amino1-2-(2.6-dioxo-3-piperidvOisoindoline-L3- dione

[002888] To a mixture of tert-butyl N-[3-[3-[3-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino] propoxy]propoxy]propyl]carbamate (820 mg, 1.50 mmol) in DCM (5 mL) was added HCl/dioxane (4 M, 750 uL) and the reaction was stirred at rt for 1 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (695 mg, 96% yield, HC1) as yellow oil LC-MS (ESI^+) *m/z* 447. 1 $(M+H)^+$.

[002889] **Tert-butyl _N-[4-[4-[(3-formyl-l-methyl-pyrazol-4-v0carbamoylloxazol-2-yll-2-pyridyl1-N- (2,2.,2-trifluoroethvOcarbamate [Intermediate LSI**



[002890] Step 1 - Isopropoxycarbonyl 4-IT2-r2-rteit-butoxycarbonyl('2.2.2-trifluoroethvnaminol-4-pyridyll oxazole-4-carbonyll amino]- 1-methyl -pyrazole-3-carboxylate

[002891] To a solution of 4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4 -carbonyl]amino]-l-methyl-pyrazole-3-carboxylic acid (3 g, 5.88 mmol, Intermediate KR) in THF (50 mL) was added TEA (595 mg, 5.88 mmol). Then, the reaction mixture was cooled to -10 °C. To the mixture was added isopropyl carbonochloridate (1.44 g, 11.8 mmol). The resulting reaction mixture was stirred at -10 °C for 2 hours. On completion, the reaction mixture was filtered. The filtrate was concentrated *in vacuo* to give the title compound (3.5 lg, 82% yield) as a white solid. LC-MS (ESI^+) *m/z* 597.1 $(M+H)^+$.

[002892] Step 2 - Tert-butyl N-r4-r4-rr3-(hvdroxymethvD-l-methyl-pyrazol-4-yl1carbamovnoxazol-2-vn-2- pyridyl1-N-(2.2.2-trif1uoroethyl icarbamate


[002893] To a solution of isopropoxycarbonyl 4-[[2-[2-[tert-butoxycarbonyl(2,2,2-

trifluoroethyl)amino]- 4-pyridyl]oxazole-4-carbonyl]amino]-l-methyl-pyrazole-3-carboxylate (3.51 g, 4.83 mmol) in THF (60 mL) was added $LiBH_4$ (315 mg, 14.5 mmol) and H_20 (1.37 g, 76.0 mmol). The reaction mixture was stirred at 0 °C for 1 hr. On completion, the reaction mixture was quenched with water (5 mL) and the mixture was extracted with DCM (3 x 50 mL). The combined organic layer was washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (2.92 g, 73% yield) as a white solid. LC-MS (ESI^+) *m/z* 497.1 $(M+H)^+$.

[002894] Step 3 - Tert-butyl N-r4-r4-r(3-formyl-l-methyl-pyrazol-4-v0carbamovnoxazol-2-yl1-2-pyridyl1-N- (2.2.2-trifluoroethyl icarbamate

[002895] To a solution of tert-butyl N-[4-[4-[[3-(hydroxymethyl)-l-methyl-pyrazol-4-yl]carbamoyl]oxazol- 2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (2.42 g, 4.19 mmol) in DCM (30 mL) was added DMP (3.56 g, 8.38 mmol). The reaction mixture was stirred at rt for 5 hrs. On completion, the reaction mixture was quenched with saturated $Na_2S_20_3$ (20 mL), and extracted with DCM (3 X 30 mL). The combined organic layer was washed with saturated $NaHC0_3$ (2 X 20 mL) and brine (30 mL), dried over with anhydrous sodium sulfate, filtered and concentrated *in vacuo.* The residue was triturated with methanol (10 mL) to give the title compound (1.60 g, 77% yield) as a white solid. ^1H NMR(400MHz, DMSO-i¾) δ 10.32 (s, 1H), 10.00 (s, 1H), 9.1 1 (s, 1H), 8.67 (d, *J* = 5.2 Hz, 1H), 8.44 (s, 1H), 8.29 (s, 1H), 7.79 (dd, *J* = 1.2, 5.2 Hz, 1H), 4.91 (q, *J* = 8.8 Hz, 2H), 4.02 (s, 3H), 1.54 (s, 9H). LC-MS (ESI^+) *m/z* 495.1 $(M+H)^+$.

[002896] **2-(2-Chloro-3-pyridvBoxazole-4-carboxylic acid [Intermediate LT)**



LT

[002897] Step 1 - Methyl 2-(2-chloro-3-pyridvDoxazole-4-carboxylate


[002898] To a solution of methyl 2-amino-3-hydroxy-propanoate; hydrochloride (1.10 g, 7.06 mmol, CAS# 2104-89-4) in DMA (20 mL) was added $NaHC0_3$ (1.19 g, 14.1 mmol). The mixture was stirred at rt for 2 hours. Then, to the mixture was added 2-chloropyridine-3-carbaldehyde (1 g, 7.06 mmol, CAS# 36404-88-3) in one portion. The mixture was stirred for 12 hours. Then, to the mixture was added bromo(trichloro)methane (4.20 g, 21.2 mmol) and DBU

(3.23 g, 21.2 mmol) at 0 °C. Then, the mixture was stirred at rt for an additional 12 hours. On completion, the mixture was quenched with water (20 mL) and extracted with EA (2 X 100 mL). The organic layer was washed with brine (30 mL) and concentrated *in vacuo.* The residue was purified by silica gel chromatography (SiO_2) to give the title compound (1.2 g, 71% yield) as a white solid. LC-MS (ESI+) m/z 238.9 $(M+H)^+$.

[002899] Step 2 - 2-(2-Chloro-3-pyridvDoxazole-4-carboxylic acid

[002900] To a solution of methyl 2-(2-chloro-3-pyridyl) oxazole-4-carboxylate (1.2 g, 5.03 mmol) in a mixed solvent of H_2O (4 mL) and THF (20 mL) was added LiOHH $_2$0 (602 mg, 25.1 mmol). The mixture was stirred at rt for 5 hours. On completion, the mixture was adjusted to pH = 7 with 1N aq.HCl, and filtered. The filter cake was dried *in vacuo* to give the title compound (0.7 g, 62% yield) as a white solid. LC-MS (ESI+) m/z 225.0 $(M+H)^+$.

[002901] **3-(DifluoromethvP-l-methyl-pyrazol-4-amine [Intermediate LU)**



HS LU


[002902] Step 1 - 3-DifluoromethvD-l-methyl-4-nitiO-pyrazole

[002903] A mixture of 3-(difluoromethyl)-4-nitro-lH-pyrazole (1 g, 6.13 mmol, Intermediate HS), K2CO3 (1.69 g, 12.3 mmol), and Mel (1.74 g, 12.3 mmol) in acetone (20 mL) was degassed and purged with N_2 gas 3 times. Then the mixture was stirred at 70 °C for 2 hours under N_2 atmosphere. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was purified by silica gel chromatography (SiO_2) to give the title compound (0.5 g, 46% yield) as yellow oil.

[002904] Step 2 - 3-(Difluorom ethyl)- l-m ethyl -pyrazol-4-amine

[002905] To a solution of 3-(difluoromethyl)-l -methyl -4-nitro-pyrazole (200 mg, 1.13 mmol) in MeOH (10 mL) was added Pd/C (200 mg, 10 wt%). The mixture was stirred at rt for 3 hours under H_2 atmosphere (15 Psi). On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (0.2 g, crude) as red oil. ^{1}H NMR (400MHz, CDCb) δ 6.89 (s, 1H), 6.76 - 6.45 (m, 1H), 3.72 (s, 3H), 2.86 (s, 2H).


[002906] **2-(2-Chloro-3-pyridyl)-N-|3-(difluoromethyl)-l -methyl-pyrazol-4-yl|oxazole-4-carboxamide [Intermediate LV)**



LU LV

[002907] A mixture of 3-(difluoromethyl)-l-methyl-pyrazol-4-amine (350 mg, 2.38 mmol, Intermediate LU), 2-(2-chloro-3 -pyridyl)oxazole-4-carboxylic acid (534 mg, 2.38 mmol, Intermediate LT), DIPEA (922 mg, 7.14 mmol), and HATU (1.09 g, 2.85 mmol) in DMF (3 mL) was degassed and purged with N_2 gas 3 times, and then the mixture was stirred at rt for 3 hours under N_2 atmosphere. On completion, the mixture was quenched with water (20 ml) and extracted with EA (2 X 20 mL). The organic layer was washed with brine (20 mL), then concentrated *in vacuo* to give the title compound (0.6 g, 96% yield) as a white solid. LC-MS (ESI+) m/z 354.1 $(M+H)^+$.

[002908] **2-12-12-[2-|2-(2-Aminoethoxy)ethoxy]ethoxy1ethylamino1-3-pyridyl1-N- [3-(difluoromethvP -l-methyl-pyrazol-4-yl1oxazole-4-carboxamide [Intermediate LW)**



LV LW


[002909] Step 1 - Tert-butyl N-[2-[2-[2-[2-[[3-[4-[[3-(difluoromethyl)-1-methyl-pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]amino]ethoxy]ethoxy]ethoxy]ethyl]carbamate

[002910] To a solution of 2-(2-chloro-3-pyridyl)-N-[3-(difluoromethyl)-1-methyl-pyrazol-4-yl]oxazole-4- carboxamide (200 mg, 565 umol, Intermediate LV) in NMP (2 mL) was added tert-butyl N-[2-[2-[2-(2-aminoethoxy) ethoxy]ethoxy]ethyl]carbamate (827 mg, 2.83 mmol, CAS# 101 187-40-0). The mixture was stirred at 150 °C for 1 hour under microwave. On completion, the mixture was concentrated *in vacuo*. The residue was purified by prep-HPLC (acid condition) to give the title compound (0.2 g, 55% yield) as a white solid. LC-MS (ESI^+) m/z 610.4 $(M+H)^+$.

[002911] Step 2 - 2-[2-[2-[2-(2-Aminoethoxy)ethoxy]ethoxy]ethylamino]-3-pyridyl]-N-[3-(difluoromethyl)-1-methyl-pyrazol-4-yl]oxazole-4-carboxamide


[002912] To a solution of tert-butyl N-[2-[2-[2-[2-[[3-[4-[[3-(difhioromethyl)-1-methyl-pyrazol-4-yl] carbamoyl] oxazol-2-yl]-2-pyridyl] amino]ethoxy]ethoxy]ethoxy]ethyl]carbamate (200 mg, 328 umol) in THF (5 mL) was added HCl/dioxane (4 M, 4 mL). The mixture was stirred at rt for 16 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (180 mg, 93% yield, HC1) as a yellow solid. LC-MS (ESI^+) m/z 510.3 $(M+H)^+$.

[002913] **7-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]-2-[(2S)-2-[(2-methoxyacetyl)amino]-3,3-dimethyl-butanoyl]-N-[(1R)-tetralin-1-yl]-3,4-dihydro-1H-isoquinoline-3-carboxamide (Intermediate LX)**



[002914] 7-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]-2-[(2S)-2-[(2-methoxyacetyl)amino]-3,3-dimethyl-butanoyl]-N-[(lR)-tetralin-l-yl]-3,4-dihydro-lH-isoquinoline-3-carboxamide was synthesized as described for Intermediate LY, using 2,2-dimethyl-4-oxo-3,8,ll,l4,l7-pentaoxa-5-azanonadecan-l9-yl4-methylbenzenesulfonate, Intermediate ON, as the tosylate in Step 1 to couple with alcohol Intermediate MH. ^{1}H NMR (400 MHz, DMS04) δ 8.21-8.15 (m, 1H), 7.45-7.30 (m, 1H), 7.14-6.77 (m, 7H), 5.11-4.40 (m, 5H), 4.07-4.02 (m, 2H), 3.90-3.72 (m, 4H), 3.60-3.41 (m, 12H), 3.36-3.20 (m, 7H), 3.05-2.93 (m, 2H), 2.76-2.61 (m, 4H), 1.87-1.52 (m, 4H), 1.03-0.93 (m, 9H). LC-MS (ESI^+): m/z 727.2 $(M+H)^+$

[002915] **7-12-12-|2-(2-aminoethoxy)ethoxy lethoxy Iethoxy |-2-|(2S)-2-|(2-methoxyacetyl) _ amino1-3,3-dimethyl-butanoyl1-N-[[lR]-tetralin-l-yl]-3,4-dihydro-lH-isoquinoline-3-carboxamide [Intermediate _LY)**



[002916] Step 1 - tert-butyl (2-(2-(2-(((S)-2-((S)-2-(2-methoxyacetamido)-3,3-dimethylbutanovD - -3- (((R)- 1.2.3.4-tetrahydronaphthalen- 1-vDcarbamovD- 1.2.3.4-tetrahvdroisoquinolin-7-vPoxy)ethoxy)ethoxy)ethoxy)ethvPcarbamate


[002917] To a mixture of (S)-7-hydroxy-2-((S)-2-(2-methoxyacetamido) -3,3-dimethylbutanoyl) -N- ((R)- 1,2,3,4-tetrahydronaphthalen- 1-yl)- 1,2,3,4-tetrahydroisoquinoline-3 -carboxamide (l.75g, 3.45 mmol, Intermediate MH) and 2,2-dimethyl-4-oxo-3,8,ll,l4-tetraoxa-5-azahexadecan-l6-yl 4-methyl benzenesulfonate (1.7 g, 3.8 mmol, Intermediate LD) in DMF (25 mL) was added K2CO3 (714 mg, 5.2 mmol), and the mixture was stirred at 110 °C for overnight. The solution was then poured into water(l50 mL) and the mixture was extracted with EtOAc (20 mL x 2). The combined organic layer was washed with brine (50 mL x 3), dried over Na_2S0_4, filtered, concentrated *in vacuo* and purified via column chromatography (Petroleum ether / EtOAc= 1/ 1) to give the title compound (1.38 g, 51.1 % yield) as a colorless oil. LC-MS (ESI^+): m/z 683.2 $(M-99)^+$.

[002918] Step 2 - (S)-7-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethoxy)-2- ((S)-2-(2-

methoxyacetamido) -3.3-dimethylbutanoyl)-N-((R)-1,2,3.4-tetrahydronaphthalen- 1-yl)- 1.2.3.4-tetrahydroisoquinoline-3-carboxamide

[002919] To a mixture of tert-butyl (2-(2-(2-(2-(((S)-2-((S)-2- (2-methoxyacetamido) -3,3-dimethyl butanoyl) -3- (((R)-l, 2,3,4-tetrahydronaphthalen -l-yl)carbamoyl)- 1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)ethoxy)ethoxy)ethoxy)ethyl)carbamate (1.38 g, 1.76 mmol) in THF (15 mL) was added 4 M HCl/dioxane(l0 mL), and the mixture was stirred at rt for overnight. Then the solution was poured into aq.NaHCO, (100 mL), and the mixture was extracted with EtOAc (20 mL x 2). The combined organic layer was washed with brine (50 mL x 3), dried over Na_2S0_4, filtered, concentracted *in vacuo* and purified via column chromatography (DCM / MeOH= 10 / 1) to give the title compound (600 mg, 50 % yield) as a white solid. ^{1}H NMR (400 MHz, DMSO-d) δ (s, 1H), 8.23-8.17 (m, 1H), 7.46-7.30 (m, 1H), 7.14-6.77 (m, 7H), 5.12-4.41 (m, 5H), 4.07-4.03 (m, 2H), 3.90-3.73 (m, 4H), 3.60-3.47 (m, 10H), 3.32-3.29 (m, 3H), 3.06-2.93 (m, 2H), 2.81-2.64 (m, 4H), 1.87-1.52 (m, 4H), 1.03-0.94 (m, 9H). LC-MS (ESI^+): m/z 683.2 $(M+H)^+$.

[002920] 3-|4-|3-|3-(3-aininopropoxy)-2,2-diinethyl-propoxy|propyl|-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione [Intermediate LZ)



[002921] Step 1 - Tert-butyl *N*-[3-[3-([3-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro- 1*H*-1.3-benzodiazol-4-yl1prop-2-yn-l -yl1oxy)-2.2-dimethylpropoxy1propyl1carbamate

[002922] To a stirred solution of 3-(4-bromo-3 -methyl -2-oxo-2, 3-dihydro- 1*H*-1,3-benzodiazol-l-yl)piperidine-2,6-dione (2.45 g, 7.25 mmol, Intermediate HP) and ter/-butyl /V-[3-


[2,2-dimethyl-3-(prop-2-yn-l-yloxy)propoxy]propyl]carbamate (1.5 g, 4.85 mmol, Intermediate OG) in DMA (25 mL) were added Cul (138.0 mg, 0.72 mmol), TEA (10 mL) andPd(PPh $_{3}$)$_{4}$ (837.2 mg, 0.72 mmol) at rt under nitrogen atmosphere. The resulting mixture was stirred for 5 h at 90 °C under nitrogen atmosphere. The resulting mixture was cooled and concentrated under reduced pressure to remove TEA. The residue was purified by reverse phase flash chromatography with the following conditions: Column: WelFlash ™ C18-1, 20-40 pm, 300 g; Eluent A : Water (plus 10 mmol/L FA); Eluent B : ACN; Gradient: 48% - 68% B in 25 min; Flow rate: 80 mL/min; Detector: 220/254 nm; desired fractions were collected at 60% B and concentrated under reduced pressure to afford *tert*-butyl /V-[3-[3-([3-[l-(2, 6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2, 3-dihydro- 1/7-1,3-benzodiazol-4-yl]prop-2-yn-l-yl]oxy)-2,2-dimethylpropoxy]propyl]carbamate (1.4 g, 33%) as a light brown solid: ¾NMR (400 MHz, DMSO-^) δ 11.12 (s, 1H), 7.20-7.16 (m, 1H), 7.12 (dd, *J* = 8.0, 1.1 Hz, 1H), 7.03 (t, *j* = 7.9 Hz, 1H), 6.71 (s, 1H), 5.41 (dd, 7 = 12.6, 5.4 Hz, 1H), 4.44 (s, 2H), 3.65 (s, 3H), 3.36 (t, *J* = 6.2 Hz, 2H), 3.32-3.30 (m, 2H), 3.13 (s, 2H), 2.97 (q, *J* = 6.6 Hz, 2H), 2.94-2.84 (m, 1H), 2.79-2.58 (m, 2H), 2.09-1.99 (m, 1H), 1.59 (p, *J* = 6.5 Hz, 2H), 1.36 (s, 9H), 0.88 (s, 6H); LC/MS (ESI, *m/z):* [(M - 100 + l)]$^{+}$ = 457.4.

[002923] Step 2 - 3-(4-r3-r3-(3-Aminopropoxy)-2.2-dimethylpropoxy1propyl1-3-methyl-2-ox0-2.3-dihydro-1*H*-7-1J-benzodiazol-1-yl)piperidine-2.6-dione hydrochloride


[002924] To a solution of *tert*-butyl A-[3-[3-([3-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro- 1/7-1,3-benzodiazol-4-yl]prop-2-yn-l-yl]oxy)-2, 2-dimethylpropoxy]propyl]carbamate (800 mg, 1.44 mmol) in THF (15 mL) was added palladium on charcoal (152.9 mg, 10% w/w) in a pressure tank. The mixture was purged with hydrogen gas 3 times at rt and the mixture was hydrogenated at rt under 1 psi for 16 h. After filtration, the filter cake was concentrated under reduced pressure. The residue was dissolved in dioxane (8 mL). To it was added a solution of HC1 in 1,4-dioxane (4 M, 8 mL) dropwise at rt under nitrogen atmosphere. The resulting solution was stirred for 2 hours at rt under nitrogen atmosphere. The resulting solution was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography with the following conditions: Column: WelFlash ™ C18-1, 20-40 pm, 80 g; Eluent A : Water (plus 10 mmol/L FA); Eluent B : ACN; Gradient: 45% - 70% B in 25 min; Flow rate: 50 mL/min; Detector: 220/254 nm; desired fractions were collected at 63% B and concentrated under reduced pressure to afford 3-(4-[3-[3-(3-aminopropoxy)-2,2-dimethylpropoxy]propyl]-3-methyl-2-oxo-2,3-dihydro-l/7-l,3-benzodiazol-l-yl)piperidine-2,6-


dione hydrochloride (72.8 mg, 10%) as a light yellow solid: ^{1}H NMR (400 MHz, CDCh) δ 8.51 (br s, 1H), 7.48 (br s, 3H), 6.99 (t, *J* = 7.8 Hz, 1H), 6.90 (d, *J* = 7.8 Hz, 1H), 6.74 (d, *J* = 7.8 Hz, 1H), 5.22 (dd, *J* = 12.4, 5.5 Hz, 1H), 3.69 (s, 3H), 3.51-3.38 (m, 4H), 3.20-3.08 (m, 4H), 3.06-2.93 (m, 4H), 2.89-2.66 (m, 3H), 2.22-2.13 (m, 1H), 1.99-1.83 (m, 4H), 0.87 (s, 6H); LC/MS (ESI, *m/z):* [(M + l)] $^+$ = 461.35.

[002925] **3-|5-|3-|3-(3-ainiiiopropoxy)-2,2-diinethyl-propoxy|propyl|-3-inethyl-2-oxo -benzimidazol-l-yllpiperidine-2,6-dione [Intermediate** MA**)**



OG





MA

[002926] Step 1 - Tert-butyl A'-[3-[3-(T3-Π-(2.6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2. 3-dihydro- 1*H*-1.3-benzodiazol-5-yl1prop-2-yn-l -yl1oxy)-2.2-dimethylpropoxy1propyl1carbamate

[002927] To a stirred solution of 3-(5-bromo-3-methyl-2-oxo-2, 3-dihydro- 1/7-1,3-benzodiazol-l-yl)piperidine-2,6-dione (1.68 g, 4.97 mmol, Intermediate HN) and *t*c/*t*-butyl 7V-[3-[2,2-dimethyl-3-(prop-2-yn-l-yloxy)propoxy]propyl]carbamate (996.6 mg, 3.33 mmol, Intermediate OG) in DMA (15 mL) were added Cul (94.6 mg, 0.50 mmol), TEA (10 mL) and Pd(PPh $_{3)4}$ (574.1 mg, 0.50 mmol) at room temperature under nitrogen atmosphere. The mixture was purged with nitrogen gas 3 times, and the resulting mixture was stirred for 5 h at 90 °C under nitrogen atmosphere. After cooling to rt, the mixture was purified by reverse phase flash


chromatography with the following conditions: Column: WelFlash ™ C18-I, 20-40 pm, 300 g; Eluent A : Water (plus 10 mmol/L FA); Eluent B : ACN; Gradient: 48% - 68% B in 20 min; Flow rate: 80 mL/min; Detector: 220/254 nm; desired fractions were collected at 60% B and concentrated under reduced pressure to afford *tc/t*-butyl /V-[3-[3-([3-[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-l 77- 1,3-benzodiazol-5-yl]prop-2-yn-l -yl]oxy)-2,2-dimethylpropoxy]propyl]carbamate (600 mg, 22%) as a light brown solid. 'H NMR (400 MHz, DMSO-di) δ 11.12 (br s, 1H), 7.32 (d, *J* = 1.4 Hz, 1H), 7.22-7.07 (m, 2H), 6.84-6.64 (m, 1H), 5.40 (dd, *J* = 12.8, 5.4 Hz, 1H), 4.37 (s, 2H), 3.40-3.32 (m, 5H), 3.29 (s, 2H), 3.13 (s, 2H), 2.98 (*q, j* = 6.6 Hz, 2H), 2.95-2.83 (m, 1H), 2.76-2.59 (m, 2H), 2.04 (ddd, *J* = 10.8, 6.0, 3.9 Hz, 1H), 1.61 (t, *J* = 6.7 Hz, 2H), 1.37 (s, 9H), 0.88 (s, 6H); LC/MS (ESI, *m/z):* [(M + l)] $^+$ = 557.25.

[002928] Step 2 - 3-(5-[3-[3-(3-Aminopropoxy)-2,2-dimethylpropoxy]propyl]-3-methyl-2-oxo-2,3-dihydro-177-1J-benzodiazol- l-yl)piperidine-2,6-dione hydrochloride

[002929] To a solution of *tert*-butyl A'-[3-[3-([3-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2, 3-dihydro- 1/7-1, 3-benzodiazol-5-yl]prop-2-yn-l-yl]oxy)-2, 2-dimethylpropoxy]propyl]carbamate (600 mg, 1.08 mmol) in THF (10 mL) was added palladium on charcoal (114.7 mg, 10% w/w) in a pressure tank. The mixture was purged with hydrogen gas 3 times and was hydrogenated at rt under 1 psi of hydrogen for 16 h. After filtration, the filtrate was concentrated under reduced pressure. The residue was dissolved in dioxane (5 mL). To it was added a solution of HC1 in l,4-dioxane (4 M, 5 mL) dropwise at rt under nitrogen atmosphere. The resulting solution was stirred for 2 hours at rt under nitrogen atmosphere, then was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography with the following conditions: Column: WelFlash ™ C18-I, 20-40 pm, 80 g; Eluent A : Water (plus 10 mmol/L FA); Eluent B : ACN; Gradient: 45% - 70% B in 25 min; Flow rate: 50 mL/min; Detector: 220/254 nm; desired fractions were collected at 63% B and concentrated under reduced pressure to afford 3-(5-[3-[3-(3 -aminopropoxy)-2,2-dimethylpropoxy]propyl] -3-methyl -2-oxo-2,3 -dihydro- 1/7-1, 3-benzodiazol-l-yl)piperidine-2,6-dione hydrochloride (58.1 mg, 10%) as a light yellow solid. ^{1}H NMR (400 MHz, CDCh) δ 8.47 (s, 1H), 8.21 (br, 3H), 6.96-6.76 (m, 3H), 5.28 (dd, *J* = 12.7, 5.4 Hz, 1H), 3.47 - 3.39 (m, 5H), 3.39-3.32 (m, 2H), 3.19-3.08 (m, 4H), 2.96 (t, *J* = 6.9 Hz, 2H), 2.88-2.79 (m, 2H), 2.72 (q, *J* = 11.8, 9.5 Hz, 3H), 2.22-2.12 (m, 1H), 1.87 (q, 7 = 6.4, 5.6 Hz, 4H), 0.87 (s, 3H), 0.86 (s, 3H); LC/MS (ESI, *m/z):* [(M + l)] $^+$ = 461.40.

[002930] **N-[3-carbamoyl-l-(4-formylphenvBpyrazol-4-ylloxazole-4-carboxamide**

[Intermediate MB)




[002931] Step 1 - N-r3-carbamoyl-l-r4-(hvdroxymethvnphenyl1pyrazol-4-yl1oxazole-4-carboxamide

[002932] To a solution of 4-amino-l-[4-(hydroxymethyl)phenyl]pyrazole-3-carboxamide (200 mg, 861 umol, Intermediate GB) and oxazole-4-carboxylic acid (97.3 mg, 861 umol, CAS# 23012-13-7) in DMF (3 mL) was added DIPEA (333 mg, 2.58 mmol) and HATU (392 mg, 1.03 mmol). The mixture was stirred at rt for 0.5 hour. On completion, the mixture was diluted with H_20 (15 mL), the mixture was filtered and the solid was dried *in vacuo* to give the title compound (270 mg, 75% yield) as white solid. LC-MS (ESI+) m/z 350.2 $(M+Na)^+$.

[002933] Step 2 - N-r3-carbamoyl-l-(4-formylphenvDpyrazol-4-yl1oxazole-4-carboxamide

[002934] To a soluton of N-[3-carbamoyl-l-[4-(hydroxymethyl)phenyl]pyrazol-4-yl]oxazole-4-carboxamide (270 mg, 824 umol) in DCM (30 mL) was added DMP (419 mg, 989 umol). The mixture was stirred at rt for 2 hours. On completion, the mixture was quenched with saturated aq. $Na_2S_20_3$ (30 mL) and washed with saturated aq. $NaHC0_3$ (2 X 30 mL). The organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (100 mg, 40% yield) as yellow solid. LC-MS (ESI^+) *m/z* 326.1 $(M+H)^+$.


[002935] l-Methyl-4- [[2-[2-[2,2.,2-trifluoroethylamino)-4-pyridyl1oxazole-4-carbonyllaminolpyrazole -3-carboxylic acid [Intermediate MCI



KR MC

[002936] To a solution of 4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4- carbonyl]amino]-l-methyl-pyrazole-3-carboxylic acid (35 mg, 68.6 umol, Intermediate KR) in DCM (2 mL) was added 4.0 M HCl/dioxane (2 mL). The reaction mixture was stirred at rt for 2 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (30 mg, 98% yield, HC1) as a yellow solid. LC-MS (ESI^+) *m/z* 411.5 $(M+H)^+$.

[002937] (2S,4R)-1-[(2S)-2-[[2-[2-[2-[2-[2-[2-(2-aminoethoxytethoxy] ethoxy] ethoxy] ethoxy] ethoxy] acetyl] amino1-3,3-dimethyl-butanoyl] -4-hydroxy-N-[[4-(4-methylthiazol-5-y0phenyl1methyl]pyrrolidine-2-carboxamide [Intermediate Ml))



[002938] Step 1 - tert-butyl ((S)-22-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-


yl)benzyl (carbamoyl)pyrrolidine- 1-carbonyl)-23,23-dimethyl-20-oxo-3,6,9, 12, 15, 18-hexaoxa-2 1-azatetracosvOcarbamate

[002939] To a solution of (2S,4R)-l-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (1.0 g, 2.15 mmol, Intermediate G) in DMF (100 mL) was added 2,2-dimethyl-4-oxo-3,8,ll,l4,l7,20,23-heptaoxa-5-azapentacosan-25-oic acid (1.083 g, 2.47 mmol, Intermediate OF), HATU (939.1 mg, 2.47 mmol), and DIPEA (693.4 mg, 5.4 mmol) at rt. The reaction mixture was stirred rt for 1 h. The reaction mixture was diluted with water, then extracted with EA (100 mL x 2). The combined organic layer was washed with brine (50 mLx 3), dried over anhydrous Na_2S0_4, filtered, and concentrated *in vacuo.* The residue was purified by column chromatography (DCM/MeOH = 0%-l0%) to give the desired compound (1.4 g, 76.5 %) as a colorless oil. LC-MS (ESI^+): m/z 852.6 $(M+H)^+$.

[002940] Step 2 - (2S,4R)-1-((S)-23-amino-2-(tert-butyl)-4-oxo-6,9,12,15,18,21-hexaoxa-3-azatricosan-l-ovD-4-hvdroxy-N-(4-(4-methylthiazol-5-vDbenzvDpynOlidine-2-carboxamide


[002941] A solution of tert-butyl ((S)-22-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-l-carbonyl)-23,23-dimethyl-20-oxo-3,6,9,l2,l5,l8-hexaoxa-2l-azatetracosyl)carbamate (1.4 g, 1.65 mmol) in dioxane (4 N HC1 in dioxane, 20 mL) was stirred rt for 2 h. The reaction mixture was concentrated *in vacuo* and the residue was purified via reverse phase column chromatography (LEO (0. 1 % formic acid) /CH_3CN = 0% - 100%) to give the desired FA salt compound (545.1 g, 43.99 %) as a colorless oil. ^1H NMR (400 MHz, DMSO-d_6) δ 8.88 (s, 1H), 7.49 - 7.38 (m, 4H), 4.70 (s, 1H), 4.59 - 4.48 (m, 3H), 4.36 (dd, J = 15.2, 3.4 Hz, 1H), 4.09 (s, 2H), 3.83 (dt, J = 11.0, 7.4 Hz, 2H), 3.74 (dd, J = 6.4, 3.8 Hz, 2H), 3.72 - 3.60 (m, 20H), 3.13 (dd, J = 6.4, 3.9 Hz, 2H), 2.47 (s, 3H), 2.30 - 2.20 (m, 1H), 2.09 (ddd, J = 13.3, 9.2, 4.4 Hz, 1H), 1.05 (s, 9H). LC-MS (ESI^+): m/z 752.4 $(M+H)^+$.

[002942] (2S,4R)-1-[(2S)-2-[[2-[2-[2-[2-(2-aminoethoxy)ethoxyl ethoxy] ethoxy] acetyl] amino] -3,3-dimethyl-butanoyl1-4-hydroxy-N-[[4-(4-methylthiazol-5-yQphenyl] methyl] pyrrolidine-2-carboxamide [Intermediate ME)



[002943] (2S,4R)-l-[(2S)-2-[[2-[2-[2-[2-(2-aminoethoxy)ethoxy] ethoxy]ethoxy]acetyl]amino] -3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide was synthesized as described for Intermediate MD, using 2,2-dimethyl-4-oxo-3,8,ll,l4,l7-pentaoxa-5-azanonadecan-l9-oic acid (Intermediate EN) as the acid which coupled with Intermediate G in the first step. ^{1}H NMR (400 MHz, DMSO-r/f,) δ 8.99 (s, 1H), 8.61-8.58 (t, J = 6.0 Hz, 1H), 7.79 (s, 3H), 7.51-7.38 (m, 5H), 4.58-4.55 (d, J = 9.6 Hz, 1H), 4.45-4.23 (m, 4H), 3.98 (s, 2H), 3.69-3.51 (m, 16H), 2.99-2.95 (m, 2H), 2.44 (s, 3H), 2.09-2.04 (m, 1H), 1.93-1.87 (m, 1H), 0.95 (s, 9H). LC-MS (ESI^{+}): m/z 664.2 $(M+H)^{+}$.

[002944] **l-Methyl-4-(oxazole-4-carbonylamino)pyrazole-3-carboxylic acid [Intermediate MF)**




[002945] Step 1 - Methyl l-methyl-4-(oxazole-4-carbonylamino)pyrazole-3-carboxylate

[002946] To a solution of methyl 4-amino- l-methyl-pyrazole-3-carboxylate (100 mg, 645 umol, Intermediate KQ) and oxazole-4-carboxylic acid (72.9 mg, 645 umol, CAS# 23012-13-7) in DMF (2 mL) was added DIPEA (333 mg, 2.58 mmol) and HATU (294 mg, 773 umol). The reaction mixture was stirred at rt for 0.5 hour. On completion, the mixture was quenched with water (30 mL), filtered and the filter cake was dried *in vacuo* to give the title compound (100 mg, 62% yield) as a white solid. LC-MS (ESI^+) *m/z* 251.2 $(M+H)^+$.

[002947] Step 2 - l-Methyl-4-(oxazole-4-carbonylamino)pyrazole-3 -carboxylic acid

[002948] To a solution of methyl l-methyl-4-(oxazole-4-carbonylamino) pyrazole-3-carboxylate (100 mg, 400 umol) in a mixed solvent of THF (2 mL), MeOH (1 mL) and LEO (0.4 mL) was added LiOH (47.9 mg, 2.00 mmol). The reaction mixture was stirred at rt for 12 hours. On completion, the mixture was acidified with 1N aq.HCl to pH = 4-6, then stirred and filtered. The filter cake was dried *in vacuo* to give the title compound (50 mg, 53% yield) as a white solid. LC-MS (ESI^+) *m/z* 237.1 $(M+H)^+$.

[002949] **3-[4-(3-AminopropyO-3-methyl-2-oxo-benzimidazol-l-yllpiperidine-2.,6-dione [Intermediate MG)**



[002950] Step 1 - Tert-butyl N-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl -2-oxo-benzi midazol-**4**-yl]prop-**2**-ynyl] carbamate

[002951] To a mixture of 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (150 mg, 444 umol, Intermediate HP), tert-butyl N-prop-2-ynyl carbamate (172 mg, 1.11 mmol) in DMF (2.5 mL) was added TEA (808 mg, 7.98 mmol), CuI (25.3 mg, 133 umol), $Pd(PPh_3)2Cl2$ (93.4 mg, 133 umol) under N_2. The reaction mixture was stirred at 80 °C for 12 hrs. On completion, the reaction mixture was poured into water (10 mL). The aqueous phase was then

extracted with ethyl acetate (2 X 20 mL). The combined organic phase was washed with brine (2 X 25 mL), dried with anhydrous Na_2SO_4, filtered and concentrated *in vacuo.* The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=3:1) to give the title compound (96 mg, 52% yield) as brown oil. LC-MS (ESI^+) *m/z* 357.2 $(M-55)^+$.


[002952] Step 2- Tert-butyl N-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yllpropyn carbamate

[002953] To a solution of tert-butyl N-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] prop-2-ynyl]carbamate (112 mg, 272 umol) in THF (5 mL) was added Pd/C (543 umol, 20 wt%) and $Pd(OH)_2/C$ (543 umol, 20 wt%) under N_2. The suspension was degassed under vacuum and purged with H_2 gas 3 times. The mixture was stirred (15 Psi) at rt for 12 hours under H_2. On completion, the mixture was filtered and concentrated *in vacuo* to give the title compound (112 mg, 91% yield) as a white solid. LC-MS (ESI^+) *m/z* 439.3 $(M + Na)^+$.

[002954] Step 3- 3-r4-(3-AminopropyD-3-methyl-2-oxo-benzimidazol-l-vnpiperidine-2.6-dione

[002955] To a solution of tert-butyl N-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]propyl] carbamate (112 mg, 269 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 134 uL). The mixture was stirred at rt for 1 hr. On completion, the mixture was concentrated *in vacuo* to get the title compound (92 mg, 97% yield, HC1) as a white solid. LC-MS (ESI^+) *m/z* 217.2 $(M+Na)^+$.

[002956] (S)-7-hvdroxy-2-((S)-2-(2-methoxyacetamido)-3,3-dimethylbiitanoyl)-N-((R)-1.2.3,4-tetrahvdronaphthalen-l-v0-l,2,3,4-tetrahydroisoquinoline-3-carboxamide [Intermediate MH)



[002957] Step 1 - (S)-7-hydroxy-6,8-diiodo-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride

[002958] To concentrate HCl (780 mL) was added (S)-2-amino-3-(4-hydroxy-3,5-diiodophenyl)propanoic acid (65 g, 150 mmol, CAS# 18835-59-1), CH_2O (37 % in H_2O) and DME (65 mL). The mixture was heated to 72 °C slowly, and then stirred vemight. To the mixture was added another 20 mL of CH_2O (37 % in H_2O), and the reaction was stirred for another 4 h at 72 °C. The mixture was cooled to 0 °C and filtered. The filter cake was washed with DME (50 mL) give (S)-7-hydroxy-6,8-diiodo-l,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride HCl salt (32 g, 72 % yield) as a yellow solid. ^1H NMR (400 MHz, DMSO-^e) δ 9.89 (s, 1H), 9.69 (s, 1H), 7.73 (s, 1H), 4.34-4.30 (dd, J = 4.8 Hz, J = 11.2 Hz, 1H), 4.14-4.00 (dd, J = 16.4 Hz, J = 40 Hz, 2H), 3.24-3.18 (m, 1H), 3.09-3.02 (m, 1H). LC-MS (ESI^+): m/z 482.5 $(M+H)^+$.

[002959] Step 2 - (S)-2-(tert-butoxycarbonyl)-7-hydroxy-6,8-diiodo-1,2,3,4-

tetrahydroisoquinoline-3-carboxylic acid

[002960] A mixture of (S)-7-hydroxy-6,8-diiodo-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride (20 g, 41.6 mmol), $(Boc)_2O$ (13.6 g, 62.4 mmol), TEA (16.8 g, 166 mmol), H_2O (40 mL) and DMF (300 mL) was stirred overnight at rt. To the mixture was added H_2O (200 mL), and the solution was washed with EA (200 mL). The aqueous layer adjusted with 1 N HCl to pH < 7, then extracted with EA (300 mL). The organic layer was washed with brine (100 mL), dried over Na_2SO_4, filtered, concentrated, and purified by column to give (S)-2-(tert-butoxycarbonyl)-7-hydroxy-6,8-diiodo-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (15.5 g, 68 % yield) as a yellow solid. ^1H NMR (400 MHz, DMSO) δ 12.77 (s, 1H), 9.46 (s, 1H), 7.64 (s, 1H), 4.83-4.67 (m, 1H), 4.49-4.39 (m, 1H), 4.21-4.17 (d, J = 16.8 Hz, 1H), 3.05-3.04 (d, J = 4 Hz, 2H), 1.47-1.40 (d, J = 24.4 Hz, 9H).

[002961] Step 3: (S)-2-(tert-butoxycarbonyl)-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid

[002962] A mixture of (S)-2-(tert-butoxycarbonyl)-7-hydroxy-6,8-diiodo-1, 2,3,4-tetrahydroisoquinoline-3-carboxylic acid (7 g, 12.8 mmol), Pd/C (10 wt%, 1.4 g), TEA (2.9 g, 28.3 mmol) and MeOH (100 mL) was stirred for overnight at rt under N_2. The mixture was filtered to remove Pd/C, concentrated to dry, then H_2O (100 mL) was added and the mixture was washed with EA (100 mL). The aqueous layer was adjusted with 1N HCl to pH < 7, then extracted with EA (300 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated to give (S)-2-(tert-butoxycarbonyl)-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (3 g, 80 % yield) as a yellow solid. ^1H NMR (400 MHz, DMSO-d_6) δ 12.58 (s, 1H), 9.26 (s, 1H), 6.97 (t, J = 8.4 Hz, 1H), 6.58-6.52 (m, 2H), 4.83-4.25 (m, 3H), 3.01-2.96 (m, 2H), 1.45-1.39 (d, J = 26.4 Hz, 9H). LC-MS (ESI^+): m/z 294.4 $(M+H)^+$.

[002963] Step 4 - (S)-tert-butyl 7-hydroxy-3-((R)-1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[002964] To a mixture of (S)-2-(tert-butoxycarbonyl)-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (32 g, 109 mmol) and (R)-1,2,3,4-tetrahydronaphthalen-1-amine (19.3 g, 131 mmol, CAS# 23357-46-2) in DMF (150 mL) was added HATU (54 g, 142 mmol) and DIPEA (42 g, 328 mmol), and the mixture was stirred at rt for 15 min. The solution was then poured into water (500 mL) and extracted with EtOAc (200 mL x 2). The combined organic layer was washed with brine (500 mL x 3), dried over Na_2SO_4, filtered,

concentrated *in vacuo* and purified via column chromatography (Petroleum ether / EtOAc= 4 / 1) to give the title compound (40.2 g, 86.9 % yield) as a white solid. LC-MS (ESI^+): m/z 423.1 $(M+H)^+$

[002965] Step 5 - (S)-7-hydroxy-N-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide hydrochloride

[002966] To a mixture of (S)-tert-butyl7-hydroxy-3-(((R)-l,2,3,4-tetrahydronaphthalen-l-yl) carbamoyl) -3,4-dihydroisoquinoline-2(lH)-carboxylate (44 g, 104 mmol) in THF (300 mL) was added 4N HC1 in dioxane(300 mL), and the mixture was stirred at rt overnight. The solution was concentrated under reduced pressure to give the crude product, which was recrystallized by EAto give the title compound (33.3 g, 82.0 % yield) as a white solid. LC-MS (ESI^+): m/z 323. 1 $(M+H)^+$.

[002967] Step 6 - tert-butyl ((S)-1-((S)-7-hydroxy-3-(((R)-1,2,3,4-tetrahydronaphthalen-l-yl) carbamoyl) -3.4-dihydroisoquinolin-2(l H)-yl)-3.3-dimethyl-l -oxobutan-2-yl icarbamate

[002968] To a mixture of (S)-7-hydroxy-N-((R)-l,2,3,4-tetrahydronaphthalen-l-yl) -1,2,3,4-tetrahydroisoquinoline-3-carboxamidehydrochloride(33.3 g, 92.8 mmol) and (S)-2-((tert- butoxy carbonyl)amino)-3,3-dimethylbutanoic acid (22.5, 97.4 mmol, CAS# 62963-35-9) in DMF (400 mL) was added E1ATU (42.3 g, 111.3 mmol) and DIPEA (48 g, 371 mmol), and the mixture was stirred at rt for 1.5 h. The solution was then poured into water (2500 mL) and the mixture was extracted with EtOAc (200 mL x 2). The combined organic layer was washed with brine (500 mL x 3), dried over Na_2S0_4, filtered, concentrated *in vacuo* and purified via column chromatography (Petroleum ether /EtOAc= 2 / 1) to give the title compound (21.5 g, 43.9 % yield) as a white solid. LC-MS (ESI^+): m/z 536.2 $(M+H)^+$.


[002969] Step 7 - (S)-2-((S)-2-amino-3,3-dimethylbutanoyl)-7-hydroxy-N-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide hydrochloride

[002970] To a mixture of tert-butyl ((S)-l-((S)-7-hydroxy-3-(((R)-l,2,3,4-tetrahydronaphthalen-l-yl) carbamoyl)-3,4-dihydroisoquinolin-2(lH)-yl)-3,3-dimethyl-l-oxobutan-2-yl)carbamate (21.5 g, 40 mmol) in THF (200 mL) was added 4N HC1 in dioxane(200 mL), and the mixture was stirred at rt overnight. The solution was then poured into aq.NaHCO, (1000 mL), and the mixture was extracted with EtOAc (200 mL x 2). The combined organic layer was washed with brine (500 mL x 3), dried over Na_2S0_4, filtered, and concentrated *in vacuo* to give the title compound as the HC1 salt (17 g, 97 % yield) as a white solid. LC-MS (ESI^+): m/z 436.1 $(M+H)^+$.

[002971] Step 8 - (S)-7-hydroxy-2-((S)-2-(2-methoxyacetamido)-3,3-dimethylbutanoyl)-N-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide

[002972] To a mixture of (S)-2-((S)-2-amino-3,3-dimethylbutanoyl) -7-hydroxy-N- ((R)-1,2,3,4- tetrahy dronaphthalen-l-yl)-l,2,3,4-tetrahydroisoquinoline-3-carboxamide hydrochloride (14.4 g, 33 mmol) and 2-methoxyacetic acid (2.97 g, 131 mmol) in DMF (120 mL) was added HATU (15 g, 39.6 mmol) and DIPEA (6.4 g, 49.5 mmol), and the mixture was stirred at rt for 1 h. The solution was then poured into water (1500 mL), and the mixture was extracted with EtOAc (200 mL x 2). The combined organic layer was washed with brine (500 mL x 3), dried over Na_2SO_4, filtered, concentrated *in vacuo* and purified via column chromatography (Petroleum ether / EtOAc= 1 / 1) to give the title compound (14 g, 83.8 % yield) as a white solid. LC-MS (ESI^+): m/z 508.2 $(M+H)^+$.

[002973] **l-methyl-4-[[2-(4-pyridvDoxazole-4-carbonyllaminolpyrazole-3-carboxylic acid [Intermediate** MI]



[002974] Step 1 - Methyl l-methyl-4-[[2-(4-pyridvl)oxazole-4-carbonvl]amino]pyrazole-3-carboxylate


[002975] A mixture of methyl 4-amino- l-methyl-pyrazole-3-carboxylate (500 mg, 3.22 mmol, Intermediate KQ), 2-(4-pyridyl)oxazole-4-carboxylic acid (612 mg, 3.22 mmol, Intermediate ED), ELATU (1.47 g, 3.87 mmol), and DIPEA (1.25 g, 9.67 mmol) in DMF (10 mL) was degassed and purged with N_2 gas 3 times, and then the mixture was stirred at rt for 2 hours under N_2 atmosphere. On completion, the mixture was quenched with water (50 mL), filtered and the filter cake was dried *in vacuo* to give the title compound (900 mg, 85% yield) as white solid. LC-MS (ESI^+) *m/z* 328.2 $(M+H)^+$.

[002976] Step 2 - l-methyl-4-[[2-(4-pyridvl)oxazole-4-carbonvl]amino]pyrazole-3-carboxylic acid

[002977] To a solution of methyl l-methyl-4-[[2-(4-pyridyl) oxazole-4-carbonyl] amino]

pyrazole-3-carboxylate (900 mg, 2.75 mmol) in H_20 (4 mL) and THF (20 mL) was added LiOH (32 mg, 13.7 mmol). The mixture was stirred at rt for 4 hours. On completion, the mixture was adjusted to pH = 6 with 1N aq.HCl, filtered and the filter cake was dried *in vacuo* to give the title compound (600 mg, 69% yield) as white solid. LC-MS (ESI^+) *m/z* 314.1 $(M+H)^+$.

[002978] **[4-[(4-Tert-butoxycarbonylmorpholin-2-vDmethoxymethyl]phenyl]boronic acid [Intermediate MJ)**



MJ

[002979] Step 1 - Tert-butyl 2-r(4-bromophenv0methoxymethyl1morpholine-4-carboxylate

[002980] To a mixture of l-bromo-4-(bromom ethyl)benzene (10.3 g, 41.4 mmol, CAS# 3433-80-5), tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate (4.50 g, 20.7 mmol, CAS# 135065-69-9), TBAI (0.80 g, 2.07 mmol) in DMF (80 mL) was added NaH (1.70 g, 41.4 mmol, 60% oil dispersion) at 0 °C. The mixture was then stirred at rt for 12 hrs. On completion, the mixture was concentrated *in vacuo.* The mixture was poured into a solution of saturated sodium bicarbonate (60 mL) and extracted with ethyl acetate (2 X 80 mL). The combined organic phase was washed with brine (2 X 80 mL), dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo* at 45°C. The residue was purified by silica gel chromatography (petroleum ether : ethyl acetate = 20 : 1) to give the title compound (4.80 g, 61% yield) as a brown oil. ^1H NMR (400 MHz, CDCb) δ 7.47 (d, *J* = 8.4 Hz, 2H), 7.23 - 7.18 (m, 1H), 7.21 (d, *J* = 8.4 Hz, 1H), 4.51 (s, 2H), 3.90 (d, *j* = 10.4 Hz, 3H), 3.64 - 3.43 (m, 4H), 2.94 (s, 1H), 2.74 (s, 1H), 1.47 (s, 9H).

[002981] Step 2 - Tert-butyl 2-ΓΓ4-(4A 5.5-tetramethvl-L3.2-dioxaborolan-2-yl)phenyl]methoxymethyl] morpholine-4-carboxylate


[002982] To a mixture of tert-butyl 2-[(4-bromophenyl)methoxymethyl]morpholine-4-carboxylate (460 mg, 11.9 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (363 mg, 14.3 mmol) in dioxane (50 mL) was added $Pd(dppf)Cl_2$

(972mg, 1.19 mmol) and KOAc (234 mg, 23.8 mmol). The reaction mixture was stirred at 100 °C for 12 hrs. On completion, the mixture was concentrated *in vacuo*. The residue was purified by column chromatography to give the title compound (480 mg, 93% yield) as brown oil. ^{1}H NMR (400 MHz, CDCh) δ 7.72 (d, *J* = 7.8 Hz, 2H), 7.26 (d, *J* = 7.8 Hz, 2H), 4.51 (s, 2H), 3.83 (d, *J* = 8.8 Hz, 3H), 3.52 - 3.36 (m, 4H), 2.86 (s, 1H), 2.66 (t, *J* = 12.0 Hz, 1H), 1.39 (s, 9H), 1.27 (s, 12H).

[002983] Step 3 - r4-r(4-Tert-butoxycarbonylmorpholin-2-vnmethoxymethyllphenyllboronic acid

[002984] To a mixture of tert-butyl 2-[[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl]methoxymethyl] morpholine-4-carboxylate (4.80 g, 11.1 mmol) in THF (40 mL) and H_20 (8 mL) was added $NaI0_4$ (7.10 g, 33.3 mmol). After that, to the reaction mixture was added 4M HC1 (7.4 mL) and the mixture was stirred at rt for 12 hrs. On completion, the mixture was concentrated *in vacuo*. The residue was purified by column chromatography to give the title compound (1.50 g, 38% yield) as brown oil. ^{1}H NMR (400MHz, DMSO-r¾) δ 8.02 (s, 2H), 7.77 (d, *J* = 8.0 Hz, 2H), 7.28 (d, *J* = 7.9 Hz, 2H), 4.50 (s, 2H), 3.90 - 3.74 (m, 2H), 3.73 - 3.64 (m, 1H), 3.53 - 3.37 (m, 7H), 1.41 (s, 9H).

[002985] **Tert-butyl 2-[[4-(4-amino-3-carbamoyl-pyrazol-l-yl)phenyl]methoxymethyl]morpholine-4-carboxylate [Intermediate MK)**



[002986] Step 1 - Tert-butyl 2-[[4-(3-methoxycarbonyl-4-nitro-pyrazol-l-ynphenyllmethoxymethyll morpholine-4-carboxylate

[002987] To a mixture of methyl 4-nitro-lH-pyrazole-3-carboxylate (0.80 g, 4.70 mmol,

CAS# 170487-38-4), [4-[(4-tert-butoxycarbonylmorpholin-2-yl)methoxymethyl]phenyl]boronic acid (1.50 g, 4.27 mmol, Intermediate MJ) in DCM (20 mL) was added pyridine (1.35 g, 17.1 mmol) and $Cu(OAc)_2$ (1.16 g, 6.41 mmol) under oxygen, and the mixture was stirred at rt for 12 hrs. On completion, the mixture was concentrated *in vacuo.* The residue was purified by column chromatography to give the title compound (1.10 g, 54% yield) as brown oil. ¾ NMR (400MHz, DMSO-di) δ 9.74 (s, 1H), 7.93 (s, 1H), 7.52 (s, 1H), 7.10 (s, 1H), 6.73 (d, *J* = 8.4 Hz, 1H), 4.60 - 4.57 (m, 1H), 4.58 (s, 1H), 4.35 (s, 1H), 4.03 (q, *J* = 7.2 Hz, 1H), 3.95 (s, 3H), 3.82 (d, *J* = 8.8 Hz, 2H), 3.70 (d, *J* = 12.4 Hz, 1H), 3.48 - 3.36 (m, 4H), 1.41 (s, 9H).


[002988] Step 2 - Tert-butyl 2-[[4-(3-carbamoyl-4-nitro-pyrazol-1-yl)phenyl]methoxymethyl]morpholine-4-carboxylate

[002989] To a sealed tube was added a solution of tert-butyl 2-[[4-(3-methoxycarbonyl-4-nitro-pyrazol-l-yl) phenyl] methoxymethyl]morpholine-4-carboxylate (1.10 g, 2.31 mmol), $NH_3.H_2O$ (971 mg, 6.93 mmol, 25% solution) in THF (10 mL). The mixture was stirred at 80 °C for 12 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (840 mg, 79% yield) as brown oil. LC-MS (ESI^+) *m/z* 484.1 $(M+Na)^+$.

[002990] Step 3 - Tert-butyl 2-[[4-(4-amino-3-carbamoyl-pyrazol-1-yl)phenyl]methoxymethyl]morpholine-4-carboxylate

[002991] To a mixture of tert-butyl 2-[[4-(3-carbamoyl-4-nitro-pyrazol-l-yl)phenyl]Methoxymethyl] morpholine-4-carboxylate (300 mg, 650 umol) in MeOH (3 mL) was added Pd/C (150 mg, 1.30 mmol) under H_2 (15 Psi), and the mixture was stirred at rt for 0.2 hr. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (275 mg, 98% yield) as brown oil. LC-MS (ESI^+) *m/z* 454.1 $(M+Na)^+$.

[002992] [4-[[l-Tert-butoxycarbonyl-2-piperidyl]methoxymethyl]phenyl]boronic acid [Intermediate ML]



[002993] Step 1 - Tert-butyl 2-r(4-biOmophenvDmethoxymethyl1morpholine-4-carboxylate

[002994] To a mixture of l-bromo-4-(bromom ethyl)benzene (1.15 g, 4.60 mmol, CAS# 3433-80-5), tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate (0.50 g, 2.30 mmol, CAS# 157634-00-9) and TBAI (85.0 mg, 0.23 mmol) in DMF (10 mL) was added NaH (184 mg, 4.60 mmol, 60% oil dispersion) at 0 °C. The mixture was stirred at rt for 12 hrs. On completion, the reaction mixture was concentrated *in vacuo.* The mixture was poured into a solution of saturated sodium bicarbonate (20 mL) and extracted with ethyl acetate (2 X 20 mL). The combined organic phase was washed with brine (2 X 30 mL), dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo* at 45 °C. The residue was purified by silica gel chromatography to give the title compound (554 mg, 62% yield) as brown oil. ^1H NMR (400MHz, CDCh) δ 7.39 (d, *J* = 8.4 Hz, 2H), 7.13 (d, *J* = 8.4 Hz, 2H), 4.43 (s, 2H), 3.96 - 3.63 (m, 3H), 3.41 (dd, *J* = 4.8, 8.0 Hz, 4H), 2.94 - 2.59 (m, 2H), 1.39 (s, 9H).

[002995] Step 2 - Tert-butyl2-ri4-(4 A 5,5-tetramethyl- lA2-dioxaborolan-2-yPphenyllmethoxymethynpiperi dine- l-carboxylate


[002996] To a mixture of tert-butyl 2-[(4-bromophenyl)methoxymethyl]piperidine-l-carboxylate (5.00 g, 13.0 mmol), 4,4,5,5-tetramethyl-2-(4, 4,5,5-tetramethyl-l, 3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (3.30 g, 13.0 mmol) in dioxane (50 mL) was added dioxane (50 mL) and KOAc (2.55 g, 26.0 mmol) and Pd(dppf)Cl2.CH2Cl2 (1.06 g, 1.30 mmol). The reaction mixture was stirred at 100 °C for 12 hrs. On completion, the mixture was concentrated *in vacuo.* The residue was purified by column chromatography to give the title compound (3.20 g, 57% yield) as brown oil. ¾NMR (400MHz, CDCh) δ 7.88 - 7.77 (m, 2H), 7.41 - 7.33 (m, 2H), 4.65 - 4.53 (m, 3H), 3.99 (d, *J* = 10.8 Hz, 1H), 3.61 - 3.52 (m, 1H), 3.63 - 3.47 (m, 1H), 2.85 - 2.65 (m, 1H), 1.90 - 1.72 (m, 1H), 1.88 - 1.71 (m, 1H), 1.66 - 1.53 (m, 3H), 1.47 (s, 9H), 1.37 (s, 12H).


[002997] Step 3 - r4-r(l-Tert-butoxycarbonyl-2-piperidvnmethoxymethyl1phenyl1boronic acid

[002998] To a mixture of tert-butyl 2-[[4-(4, 4,5,5-tetramethyl-l, 3,2-dioxaborolan-2-yl)phenyl]methoxymethyl] piperidine- l-carboxylate (3.20 g, 7.42 mmol) in THF (60 mL) and H_20 (12 mL) was added $NaI0_4$ (4.76 g, 22.2 mmol, 1.2 mL). Then HC1 (3 M, 4.95 mL) was added to the mixture. The reaction mixture was stirred at rt for 12 hrs. On completion, the mixture was diluted with H2O (30 mL), and extracted with EA (3 X 30 mL). The organic layers were washed with brine (3 X 20mL), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The

residue was purified by column chromatography to give the title compound (1.50 g, 58% yield) as brown oil. ^{1}H NMR (400MHz, DMSO-^e) δ 8.02 (s, 2H), 7.76 (d, *J* = 8.0 Hz, 2H), 7.27 (d, *J* = 8.0 Hz, 2H), 4.58 - 4.44 (m, 2H), 4.30 (s, 1H), 3.82 *(d, J* = 12.4 Hz, 1H), 3.58 - 3.47 (m, 2H), 3.35 (s, 3H), 2.79 - 2.63 (m, 1H), 1.70 (d, *J* = 7.2 Hz, 1H), 1.59 - 1.41 (m, 4H), 1.37 (s, 9H), 1.32 - 1.21 (m, 1H).

[002999] **Tert-butyl 2-[[4-(4-amino-3-carbamoyl-pyrazol-l-yl)phenyl]methoxymethyl]piperidine- 1-carboxylate [Intermediate** MM)





[003000] Step 1 - Tert-butyl 2-[[4-(3-methoxycarbonyl-4-nitro-pyrazol-l-yl)phenyl]methoxymethyl]piperidine- l-carboxylate

[003001] To a mixture of [4-[(l-tert-butoxycarbonyl-2-piperidyl)methoxymethyl]phenyl]boronic acid (1.50 g, 4.30 mmol, Intermediate ML), and methyl 4-nitro-lH-pyrazole-3-carboxylate (0.70 g, 4.08 mmol, CAS# 170487-38-4) in DCM (20 mL) was added pyridine (1.36 g, 17.2 mmol) and $Cu(OAc)_2$ (1.17 g, 6.44 mmol) under oxygen. The reaction mixture was stirred at rt for 12 hrs. On completion, the mixture was concentrated *in vacuo*. The residue was purified by column chromatography to give the title compound (1.50 g, 73% yield)) as a brown oil. ¾NMR (400MHz, DMSO-^e) δ 9.75 (s, 1H), 7.94 (d, *J* = 8.8 Hz, 2H), 7.55 - 7.50 (m, 2H), 4.64 - 4.51 (m, 2H), 4.41 - 4.29 (m, 2H), 3.95 (s, 3H), 3.63 - 3.50 (m, 2H), 3.45 *(d, J* = 7.6 Hz, 1H), 1.61 - 1.42 (m, 6H), 1.38 (s, 9H).

[003002] Step 2 - Tert-butyl 2-[[4-(3-carbamoyl-4-nitro-pyrazol- 1-yl)phenyl]methoxymethyl]piperidine-l- carboxylate


[003003] To a sealed tube was added a mixture of tert-butyl 2-[[4-(3-methoxycarbonyl-4-nitro-pyrazol-l-yl) phenyl]methoxymethyl]piperidine- l-carboxylate (1.50 g, 3.16 mmol) in

MeOH (10 mL). Then NH3.H2O (1.33 g, 9.48 mmol, 1.46 mL) was added and the mixture was stirred at 80 °C for 12 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (850 mg, 58% yield) as brown oil. LC-MS (ESI^+) *m/z* 482.2 $(M+Na)^+$.

[003004] Step 3 - Tert-butyl 2-[[4-(4-amino-3-carbamoyl-pyrazol-1-yl)phenyl]methoxymethyl]piperidine-1-carboxylate

[003005] To a mixture of tert-butyl 2-[[4-(3-carbamoyl-4-nitro-pyrazol-1-yl)phenyl]methoxymethyl]piperidine-1-carboxylate (300 mg, 653 umol) in MeOH (3 mL) was added Pd/C (120 mg, 652.89 umol) under H_2 (15 Psi). The mixture was stirred at rt for 0.3 hour. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (265 mg, 94% yield) as brown oil. LC-MS (ESI^+) *m/z* 452.1 $(M+Na)^+$.


[003006] **4-[3-[2-[2-(2-Aminoethoxy)ethoxy]ethoxy]prop-1-ynyl]-2-[2,6-dioxo-3-piperidyl]isoindoline-1,3-dione (Intermediate MN)**



MN

[003007] To a mixture of tert-butyl N-[2-[2-[2-[2-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]prop-2-ynoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate (300 mg, 510 umol, synthesized via Step 1 of Intermediate HA) in DCM (3 mL) was added HCl/dioxane (4 M, 0.3 mL). The reaction mixture was stirred at rt for 0.5 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (245 mg, 91% yield) as a brown solid. LC-MS (ESI^+) *m/z* 488.3 $(M+H)^+$.

[003008] **2-(2-Methyl-4-pyridyl)oxazole-4-carboxylic acid (Intermediate MO)**



MO


[003009] Step 1 - Ethyl 2-(2-methylpyridin-4-vDoxazole-4-carboxylate

[003010] To a solution of 4-bromo-2-methyl-pyridine (1.50 g, 8.72 mmol, from CAS# 22282-99-1) and ethyl oxazole-4-carboxylate (1.23 g, 8.72 mmol, from CAS# 170487-38-4) in DMF (40 mL) was added tris-o-tolylphosphane (531 mg, 1.74 mmol), $Pd(OAc)_2$ (196 mg, 872 umol) and CS_2CO_3 (5.68 g, 17.4 mmol). The reaction mixture was stirred at 70 °C for 12 hours under nitrogen. On completion, the reaction mixture was filtered and concentrated. The residue was purified by silica gel column chromatography to give the title compound (1.10 g, 44% yield) as a yellow solid. ^1H NMR (400MHz, CDCb) δ 8.65 (d, *J* = 5.2 Hz, 1H), 8.31 - 8.36 (m, 1H), 7.86 (s, 1H), 7.75 (d, *J* = 5.2 Hz, 1H), 4.44 (q, *J* = 7.2 Hz, 2H), 2.64 (s, 3H), 1.41 (t, *J* = 7.2 Hz, 3H); LC-MS (ESI^+) m/z 233.1 $(M+H)^+$.

[003011] Step 2 - 2-(2-Methyl-4-pyridv0oxazole-4-carboxylic acid

[003012] To a solution of ethyl 2-(2-methyl-4-pyridyl)oxazole-4-carboxylate (1.10 g, 4.74 mmol) in THF (20 mL) was added $LiOH»H_20$ (795 mg, 19.0 mmol) in H_20 (4 mL). The reaction mixture was stirred at rt for 12 hours. On completion, the reaction mixture was filtered and the filter cake was dissolved in water (20 mL). The solution was acidified to pH = 4 and filtered. The filter cake was washed with water (2 X 5 mL) and dried *in vacuo*. The residue was purified by prep-HPLC to give the title compound (600 mg, 52% yield) as a white solid.

[003013] **4-[3-Carbamoyl-4-[[2-(2-methyl-4-pyridvDoxazole-4-carbonyllaminolpyrazol-l-yllbenzoic acid [Intermediate MP)**




[003014] Step 1 - Methyl4-r3-carbamovl-4-IT2-(2-tnethvl-4-pvridvDoxazole-4-carbonyllaminolpyrazol-l- vl] benzoate

[003015] To a solution of 2-(2-methyl-4-pyridyl)oxazole-4-carboxylic acid (200 mg, 831.11 umol, HC1, Intermediate MO) and methyl 4-(4-amino-3 -carbarn oyl-pyrazol-l-yl)benzoate (173 mg, 665 umol, Intermediate CL) in DMF (20 mL) was added DIPEA (322 mg, 2.49 mmol) and HATU (379 mg, 997 umol). The reaction mixture was stirred at rt for 0.5 hour. On completion, the reaction mixture was quenched with water (5 mL) and filtered. The filter cake was washed with water (3 X 3 mL) and dried *in vacuo* to give the title compound (200 mg, 53% yield) as a white solid. LC-MS (ESI^+) m/z 447.3 $(M+H)^+$.

[003016] Step 2 - 4-[3-Carbamoyl-4-[[2-(2-methyl-4-pyridyl)oxazole-4-carbonyllaminolpyrazol-l-yllbenzoic acid

[003017] To a solution of methyl 4-[3-carbamoyl-4-[[2-(2-methyl-4-pyridyl)oxazole-4-carbonyl]amino]pyrazol- l-yl]benzoate (150 mg, 336 umol) in THF (20 mL) and MeOH (4 mL) was added LiOHH $_2$0 (42.3 mg, 1.01 mmol) in $H_2$0 (4 mL). The reaction mixture was stirred at rt for 12 hours. On completion, the reaction mixture was poured into HC1 (1N, 2mL) and concentrated *in vacuo* to give the title compound (200 mg, 100% yield) as a white solid. LC-MS (ESI+) m/z 433.2 $(M+H)^+$.

[003018] **2-(2-Cvclopropyl-4-pyridvDoxazole-4-carboxylic acid [Intermediate MQ)**



MQ


[003019] Step 1 - Ethyl 2-(2-cvclopropyl-4-pyridv0oxazole-4-carboxylate

[003020] To a solution of 4-bromo-2-cyclopropyl-pyridine (512 mg, 2.59 mmol, CAS# 1086381-28-3) and ethyl oxazole-4-carboxylate (365 mg, 2.59 mmol, CAS# 170487-38-4) in DMF (5 mL) was added tris-o-tolylphosphane (157 mg, 517 umol), $Pd(OAc)_2$ (58.0 mg, 259 umol) and CS2CO3 (1.68 g, 5.17 mmol). The reaction mixture was stirred at 70 °C for 12 hours under nitrogen. On completion, the reaction mixture was diluted with EA (100 mL), poured into sat.MLCl (50 mL) and extracted with EA(3 X 50 mL). The combined organic layers were washed with brine (50 mL), dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo*. The residue was purified by silica column chromatography (PE/EA, 10/1 to 5/1) to give the title compound (380 mg, 55% yield) as a white solid. ^{1}HNMR (400MHz, DMSO-i¾) δ 8.57 (d, *J* = 4.8 Hz, 1H), 8.33 (s, 1H), 7.82 (s, 1H), 7.67 (dd, *J* = 1.6, 5.2 Hz, 1H), 4.44 (q, *J* = 7.2 Hz, 2H), 2.16 - 2.07 (m, 1H), 1.42 (t, *J* = 7.2 Hz, 3H), 1.12 - 1.02 (m, 4H). LC-MS (ESI$^+$) m/z 259.1 (M+H)$^+$.

[003021] Step 2 - 2-(2-Cvclopropyl-4-pyridvDoxazole-4-carboxylic acid

[003022] To a solution of ethyl 2-(2-cyclopropyl-4-pyridyl)oxazole-4-carboxylate (370 mg, 1.43 mmol) in THF (20 mL) was added a solution of $LiOH•H_20$ (150 mg, 3.57 mmol) in H_20 (4 mL). The reaction mixture was stirred at rt for 12 hours. On completion, the reaction mixture was quenched with 4 mL of HC1 (1N) and concentrated *in vacuo* to give the title compound (450 mg, 100% yield) as a white solid. LC-MS (ESI$^+$) m/z 231.1 (M+H)$^+$.

[003023] **2-12-12-Aminoethoxylethoxylethanol [Intermediate MR]**




MR

[003024] To a solution of tert-butyl N-[2-[2-(2-hydroxyethoxy)ethoxy]ethyl]carbamate (1.60 g, 6.42 mmol, from CAS# 139115-92-7) in DCM (10 mL) was added HCl/dioxane (4 M, 1.60 mL). The reaction mixture was stirred at rt for 1 hour. On completion, the reaction mixture was

concentrated *in vacuo* to give the title compound (1.19 g, 100% yield) as colorless oil.

[003025] **4-[2-[2-(2-Azidoethoxy)ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione [Intermediate MS)**



[003026] Step 1 - 2-(2.6-Dioxopiperidin-3-yl)-4-((2-(2-(2-hydroxyethoxy)ethoxy)ethylamino)isoindoline-1.3-dione

[003027] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-1,3-dione (1.50 g, 5.43 mmol, Intermediate R) and 2-[2-(2-aminoethoxy)ethoxy]ethanol (1.01 g, 5.43 mmol, HC1, Intermediate MR) in DMF (5 mL) was added DIPEA (2.81 g, 21.7 mmol). The reaction mixture was stirred at 115 °C for 12 hours. On completion, the reaction mixture was poured into sat.$NaHCO_3$ (30 mL) and extracted with EA (3 X 100 mL). The combined organic layers were washed with brine (100 mL), dried with anhydrous Na_2SO_4, filtered and concentrated *in vacuo.* The residue was purified by silica column chromatography (PE/EA, 1/1 to 0/1) to give the title compound (600 mg, 27% yield) as a yellow solid. LC-MS (ESI^+) m/z 406.2 $(M+H)^+$.


[003028] Step 2 - 2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl methanesulfonate

[003029] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-[2-[2-(2-hydroxyethoxy)ethoxy]ethylamino]isoindoline -1,3-dione (100 mg, 247 umol) in DCM (5 mL) was added TEA (49.9 mg, 493 umol) and MsCl (37.0 mg, 323 umol) at 0 °C. The reaction mixture was then stirred at rt for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo* to give title compound (130 mg, 100% yield) as a yellow solid. LC-MS (ESI^+) m/z 484.2 $(M+H)^+$.

[003030] Step 3 - 4-r2-r2-(2-Azidoethoxy)ethoxy1ethylamino1-2-(2.6-dioxo-3-piperidvOisoindoline-L3-dione

[003031] To a solution of 2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy] ethyl methanesulfonate (60.0 mg, 124 umol) in DMF (3 mL) was added NaN_3 (16.1 mg, 248 umol). The reaction mixture was stirred at 65 °C for 2 hours. On completion, the reaction mixture was poured into sat. $NaHC0_3$ (30 mL) and extracted with DCM (2 X 50 mL). The combined organic layers were washed with brine (50 mL), dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (60.0 mg, 100% yield) as a yellow solid. LC-MS (ESI^+) m/z 453.2 $(M+Na)^+$.

[003032] **4-Amino-l-prop-2-vnyl-pyrazole-3-carboxamide [Intermediate MT)**



CJ MT


[003033] Step 1 - 4-Nitro-l-(prop-2-vn-l-vD-lH-pyrazole-3-carboxamide

[003034] To a solution of 4-nitro-lH-pyrazole-3-carboxamide (2.00 g, 12.8 mmol, Intermediate CJ) and 3-bromoprop-l-yne (3.05 g, 25.6 mmol, 2.21 mL) in DMF (30 mL) was added K_2C0_3 (3.54 g, 25.6 mmol). The reaction mixture was stirred at 60 °C for 1 hour. On completion, the reaction mixture was diluted with EA (50 mL) and filtered, then the filtrate was concentrated *in vacuo.* The residue was purified by silica column chromatography (PE/EA, 1/1 to 0/1) to give the title compound (1.30 g, 52% yield) as an off-white solid. ^1H NMR (300 MHz, DMSO-di) δ 8.90 (s, 1H), 8.07 (s, 1H), 7.82 (s, 1H), 5.14 (d, J = 2.4 Hz, 2H), 3.67 (t, J = 2.4 Hz, 1H), 2.73 (s, 1H).

[003035] Step 2 - 4-Amino-l-prop-2-vnyl-pyrazole-3 -carboxamide

[003036] To a solution of 4-nitro-l -prop-2 -ynyl-pyrazole-3 -carboxamide (1.20 g, 6.18 mmol) in MeOH (30 mL) was added a solution of NH_4Cl (1.65 g, 30.9 mmol) in H_20 (10 mL) and Fe (1.73 g, 30.9 mmol). The reaction mixture was stirred at 80 °C for 12 hours under nitrogen. On completion, the reaction mixture was diluted with DCM (400 mL), stirred at rt for 10 min, then washed with brine (2 X 50 mL). The organic layer was dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (800 mg, 79% yield) as a light yellow solid.


[003037] **2-(2-Prop-2-ynoxyethoxy)ethanamine (Intermediate MU)**



MU

[003038] To a mixture of tert-butyl N-[2-(2-prop-2-ynoxyethoxy)ethyl]carbamate (2.50 g, 10.3 mmol, synthesized via Step 1 of Intermediate CQ) in DCM (20 mL) was added HCl/dioxane (4 M, 5.14 mL) and the reaction was stirred at rt for 0.5 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (1.80 g, 97% yield, HC1) as a brown solid. 'H NMR (400MHz, DMSO^) δ 8.27 (s, 2H), 4.14 (d, *J* = 2.4 Hz, 2H), 3.62 (t, *J* = 5.6 Hz, 2H), 3.59 - 3.54 (m, 4H), 3.45 (t, *J* = 2.4 Hz, 1H), 2.91 (s, 2H).


[003039] **2-[2,6-Dioxo-3-piperidvO-4-[2-[2-prop-2-vnoxyethoxy)ethylamino]isoindoline-l.,3-dione [Intermediate MV)**



MV

[003040] To a mixture of 2-(2-prop-2-ynoxyethoxy)ethanamine (1.80 g, 10.0 mmol, HC1, Intermediate MU) in dioxane (30 mL) was added DIPEA (3.88 g, 30.0 mmol, 5.24 mL), and 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3- dione (2.77 g, 10.0 mmol, Intermediate R) into the mixture. The reaction mixture was stirred at H5°C for 12 hrs. On completion, the mixture was concentrated *in vacuo.* The residue was purified by column chromatography to give the title compound (1.10 g, 27% yield) as a brown solid. ¾ NMR (400MHz, CDCh) δ 8.61 (s, 1H), 7.49 (t, 7 = 7.6 Hz, 1H), 7.10 (d, *J* = 7.2 Hz, 1H), 6.93 (d, 7 = 8.8 Hz, 1H), 6.49 (t, *J* = 5.6 Hz, 1H), 4.98 - 4.89 (m, 1H), 4.21 (d, *J* = 2.4 Hz, 2H), 3.75 - 3.70 (m, 6H), 3.49 (q, *J* = 5.6 Hz, 2H), 2.90 - 2.73 (m, 3H), 2.46 (t, *J* = 2.4 Hz, 1H), 2.18 - 2.06 (m, 1H).

[003041] **4-[Azetidin-3-ylamino]-2-[2,6-dioxo-3-piperidvnisoindoline-l,3-dione [Intermediate MW]**



R MW


[003042] Step 1 - Tert-butyl 3-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]azetidine-1-carboxylate

[003043] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-1,3-dione (500 mg, 1.81 mmol, Intermediate R) and tert-butyl 3-aminoazetidine-1-carboxylate (374 mg, 2.17 mmol, CAS# 193269-78-2) in DMSO (20 mL) was added DIPEA (702 mg, 5.43 mmol). The reaction mixture was stirred at 90 °C for 15 hrs. On completion, the reaction mixture was filtered and acidified to pH = 5. The crude product was purified by reversed phase (0.1% HC1 condition) to give the title compound (350 mg, 44% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-di) δ 11.12 (s, 1H), 7.61 (t, *J* = 8.0 Hz, 1H), 7.13 (d, *J* = 7.2 Hz, 1H), 6.96 (d, *J* = 8.4 Hz, 1H), 6.89 (d, *J* = 6.4 Hz, 1H), 5.08 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.49 - 4.41 (m, 1H), 4.19 - 4.23 (m, 2H), 3.80 - 3.84 (m, 2H), 2.95 - 2.84 (m, 1H), 2.95 - 2.84 (m, 1H), 2.65 - 2.60 (m, 1H), 2.54 - 2.52 (m, 1H), 2.09 - 1.99 (m, 1H), 1.39 (s, 9H).

[003044] Step 2 - 4-(Azetidin-3-ylamino)-2-(2.6-dioxo-3-piperidyl)isoindoline-1,3-dione

[003045] To a solution of tert-butyl 3-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]azetidine-1-carboxylate (430 mg, 1.00 mmol) in DCM (5 mL) was added HCl/dioxane (4 M, 5.12 mL). The reaction mixture was stirred at rt for 1 hr. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (430 mg, 100% yield, HC1) as a yellow solid. LC-MS (ESI$^+$) *m/z* 329.0 $(M+H)^+$.

[003046] **4-[[1-[2-[2-(2-aminoethoxy)ethoxyl ethyl]azetidin-3-yl] amino]-2-[2,6-dioxo-3-piperidyl isoindoline-1,3-dione [Intermediate** MX)




[003047] Step 1 - Tert-butyl N-[2-[2-[2-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino] azetidin- 1-yl]ethoxy] ethoxy] ethyl] carbamate

[003048] To a solution of 4-(azetidin-3-ylamino)-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (250 mg, 685 umol, Intermediate MW) and tert-butyl N-[2-[2-(2-oxoethoxy)ethoxy]ethyl]carbamate (220 mg, 891 umol, Intermediate HY) in DCM (10 mL) and THF (20 mL) was added KOAc (135 mg, 1.37 mmol) and $NaBH(OAc)_3$ (218 mg, 1.03 mmol). The reaction mixture was stirred at rt for 2 hrs. On completion, the reaction mixture was quenched with water (2 mL), and concentrated *in vacuo.* The crude product was purified by reversed phase (acidified condition: 0.1% FA) to give the title compound (270 mg, 66% yield) as yellow oil. ^1H NMR (400MHz, DMSO-de) δ 11.09 (s, 1H), 7.72 - 7.54 (m, 1H), 7.09 (d, *J* = 8.8 Hz, 1H), 7.01 (d, *J* = 8.8 Hz, 1H), 6.76 - 6.74 (m, 1H), 6.61 *(d, J* = 6.8 Hz, 1H), 5.07 (dd, *j=5.2,* 12.8 Hz, 1H), 4.34 - 4.19 (m, 1H), 3.70 (t, *J* = 6.8 Hz, 2H), 3.50 - 3.36 (m, 10H), 3.06 (q, *J* = 6.0 Hz, 2H), 3.00 - 2.96 (m, 2H), 2.92 - 2.84 (m, 1H), 2.65 - 2.61 (m, 2H), 2.09 - 2.01 (m, 1H), 1.37 (s, 9H); LC-MS (ESI^+) *m/z* 560.1 $(M+H)^+$.

[003049] Step_2_-_4-[[1-r2-r2-(2-aminoethoxy)ethoxy1ethyl1azetidin-3-yl1amino1-2-(2.6-dioxo-3-piperidvD isoindoline-L3-dione

[003050] To a solution of tert-butyl N-[2-[2-[2-[3-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino] azetidin-l-yl]ethoxy]ethoxy]ethyl]carbamate (270 mg, 483 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 121 uL). The reaction mixture was stirred at 20 °C for 1 hr. On completion, the reaction mixture was concentrated in *vacuo* to give the title compound (239 mg, 100% yield, HC1 salt) as a yellow solid. LC-MS (ESI$^+$) *m/z* 460.3 (M+H)$^+$.

[003051] **5-12-13-[2-[2-(2-Aminoethoxy)ethoxy1 ethylltriazol-4-yl] ethylaminol-2-12,6-dioxo-3-piperidvD isoindoline-l,3-dione [Intermediate MY]**



[003052] Step 1 - 5-(But-3-vnylamino)-2-(2.6-dioxo-3-piperidyl)isoindoline- 1J-dione

[003053] To a mixture of 2-(2,6-dioxo-3-piperidyl)-5-fluoro-isoindoline-l,3-dione (650 mg, 2.35 mmol, Intermediate HX), but-3-yn-l -amine (373 mg, HC1, CAS# 14044-63-4) in DMSO (10 mL) was added DIPEA (3.04 g, 23.5 mmol) and stirred at 130 °C for lhr. On completion, the mixture was poured into water (20 mL). The aqueous phase was extracted with ethyl acetate (2 X 20 mL). The combined organic phase was washed with brine (2 X 30 mL), dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by column chromatography ($Si0_2$, Petroleum ether/Ethyl acetate=l:l) to give the title compound (386 mg, 50% yield) as a brown solid; LC-MS (ESI$^+$) *m/z* 326.0 (M+H)$^+$.


[003054] Step 2 - Tert-butylN-[2-[2-[2-[5-[2-[[2-(2,6-dioxo-3-piperidvl)-L3-dioxo-isoindolin-5- vl]amino] ethyl1triazol-l-yl1ethoxy1ethoxy1ethyl1carbamate

[003055] To a mixture of 5-(but-3-ynylamino)-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (200 mg, 0.615 mmol), tert-butyl N-[2-[2-(2-azidoethoxy)ethoxy]ethyl]carbamate (506 mg, 1.84 mmol, Intermediate ID) in THF (5 mL) was added chlororuthenium(l+); 1,2,3,4,5-pentamethylcyclopenta-l, 3-diene; triphenylphosphane (24.4 mg, 0.030 mmol). The mixture was stirred at 65 °C for 12 hrs. On completion, the mixture was concentrated *in vacuo*. The residue was purified by column chromatography (S1O2, Petroleum ether/Ethyl acetate=l:l) to give the title compound (210 mg, 54% yield) as a brown oil; LC-MS (ESI^+) *m/z* 600.2 $(M+H)^+$.

[003056] Step 3 - 5-r2-r3-r2-r2-(2-Aminoethoxy)ethoxy1ethyl1triazol-4-yl1ethylamino1-2-(2,6-dioxo-3-piperidvl) isoindoline-E3-dione

[003057] To a mixture of tert-butyl N-[2-[2-[2-[5-[2-[[2-(2, 6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl] amino]ethyl]triazol-l-yl]ethoxy]ethoxy]ethyl]carbamate (210 mg, 350 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 87.5 uL) and stirred at 15 °C for 0.5 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (185 mg, 98% yield, HC1) brown oil. LC-MS (ESI^+) *m/z* 500.2 $(M+H)^+$.


[003058] **2-(2,6-Dioxo-3-piperidvl)-5-hvdroxy-isoindoline-l,3-dione [Intermediate MZ)**



MZ

[003059] To a solution of 5-hydroxyisobenzofuran-l,3-dione (1.00 g, 6.09 mmol, CAS# 27550-59-0) and 3-aminopiperidine-2,6-dione (1.05 g, 6.40 mmol, HC1) in HOAc (20 mL) was added KOAc (1.79 g, 18.3 mmol). The mixture was stirred at 90 °C for 6 hrs. On completion, the mixture was poured into ice water(l00 mL), and solid was obtained and then filtered. The residue was washed with H_20 (3 X 50 mL), dried *in vacuo* to give the title compound (1.40 g, 83% yield) as a light white solid. ^1H NMR (400MHz, DMSO-^e) δ 11.29 - 10.90 (m, 2H), 7.75 (d, *J* = 8.2 Hz, 1H), 7.39 - 6.87 (m, 2H), 5.09 (dd, 7=5.4, 12.8 Hz, 1H), 3.34 (s, 1H), 2.96 - 2.82 (m, 1H) , 2.69 - 2.58 (m, 1H), 2.08 - 1.99 (m, 1H).


[003060] **2-(2,6-Dioxo-3-piperidvl)-5-prop-2-vnoxy-isoindoline-l,3-dione (Intermediatea_NA)**



MZ NA

[003061] To a solution of 2-(2,6-dioxo-3-piperidyl)-5-hydroxy-isoindoline-l,3-dione (1.40 g, 5.11 mmol, Intermediate MZ) in DMF (20 mL) was added K2CO3 (847 mg, 6.13 mmol) and 3-bromoprop-l-yne (668 mg, 5.62 mmol, 484 uL). The mixture was stirred at 15 °C for 6 hrs. On completion, the residue was diluted with H_20 (50 mL) and extracted with EA (3 X 50 mL). The combined organic layers were washed with brine (100 mL), dried over Na_2S0_4, filtered and concentrated to give a residue. The residue was purified by reversed phase (FA condition) to give the title compound (0.700 g, 43% yield) as a light yellow solid. ¾**NMR** (400MHz, DMSO-rL) δ 11.11 (s, 1H), 7.89 (d, *J* = 8.4 Hz, 1H), 7.53 (d, *J* = 2.4 Hz, 1H), 7.41 (dd, *J* = 2.4, 8.4 Hz, 1H), 5.14 (dd, *J* = 5.4, 12.8 Hz, 1H), 5.07 (d, 7 = 2.0 Hz, 2H), 3.70 (t, 7 = 2.4 Hz, 1H), 3.41 - 3.35 (m, 1H), 2.97 - 2.83 (m, 1H), 2.65 - 2.52 (m, 2H), 2.11 - 2.01 (m, 1H); LC-MS (ESI^+) *m/z* 313.2 $(M+H)^+$.

[003062] **5-[[1-[2-[2-(2-Aminoethoxy]ethoxyl ethylltriazol-4-yl] methoxy] _-2-[2,6-dioxo-3-piperidvD isoindoline-l,3-dione [Intermediate NB)**



NA

NB

[003063] Step **1** - Tert-butyl N-[2-[2-[2-[4-[[2-(2.6-άïοχο-3-ρϊρeΙϊάνl) -L3-dioxo-isoindolin-


5-yl]oxymethyl] triazol-1-yl]ethoxy]ethoxyl ethyl]carbamate

[003064] To a solution of 2-(2,6-dioxo-3-piperidyl)-5-prop-2-ynoxy-isoindoline-l,3-dione (0.6 g, 1.92 mmol, Intermediate NA), $CuS0_4$ (3.07 mg, 19.2 umol) and sodium;(2R)-2-[(lS)-l,2-dihydroxyethyl] -4-hydroxy-5-oxo -2H-furan-3-olate (7.61 mg, 38.4 umol) in H_20 (3 mL) and t-BuOH (3 mL) was added tert-butyl N-[2-[2-(2-azidoethoxy)ethoxy]ethyl]carbamate (527.06 mg, 1.92 mmol, Intermediate ID). The mixture was stirred at 60 °C for 2 hrs. On completion, the mixture was diluted with H_20 (20 ml), extracted with EA (2 X 30ml), washed with brine (50ml), dried over Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by reversed phase (FA condition) to give the title compound (0.800 g, 71% yield) as a yellow solid. ^1H NMR (400MHz, DMSO-di) δ 11.10 (s, 1H), 8.25 (s, 1H), 7.85 (d, *J* = 8.2 Hz, 1H), 7.61 (s, 1H), 7.45 (d, *J* = 8.2 Hz, 1H), 6.72 (s, 2H), 5.38 (s, 2H), 5.17 - 5.09 (m, 1H), 4.55 (s, 2H), 4.10 - 3.97 (m, 4H), 3.83 (s, 2H), 3.65 - 3.51 (m, 13H), 3.07 (d, *J* = 6.0 Hz, 4H), 2.88 (d, *J* = 13.6 Hz, 1H), 2.70 - 2.57 (m, 4H), 1.38 (s, 9H).

[003065] Step 2 - 5-[[1-[2-[2-(2-Aminoethoxy)ethoxy1ethyl1triazol-4-yl1methoxy1 -2-(2.6-dioxo-3-piperidvD isoindoline-L3-dione

[003066] To a solution of tert-butyl N-[2-[2-[2-[4-[[2-(2,6-dioxo-3-piperidyl) -l,3-dioxo-isoindolin-5-yl] oxymethyl]triazol-l-yl]ethoxy]ethoxy]ethyl]carbamate (0.800 g, 1.36 mmol) in DCM (10 mL) was added HCl/dioxane (4 M, 1 mL).The mixture was stirred at rt for 30 minutes. On completion, the mixture was concentrated, to give the title compound (500 mg 70% yield, HC1) as a yellow solid. LC-MS (ESI^+) *m/z* 487.3 $(M+H)^+$.

[003067] **5-But-3-vnoxy-2-[2,6-dioxo-3-piperidvBisoindoline-l,3-dione [Intermediate NO**




MZ NC

[003068] To a mixture of 2-(2,6-dioxo-3-piperidyl)-5-hydroxy-isoindoline-l,3-dione (1.00 g, 3.65 mmol, Intermediate MZ) and but-3-yn-l-ol (307 mg, 4.38 mmol, CAS# 927-74-2) in THF (10 mL) was added PPh_3 (1.43 g, 5.47 mmol). Then DIAD (1.47 g, 7.29 mmol) was added into the mixture at 0 °C and the mixture was stirred at rt for 12 hrs. On completion, the mixture was concentrated *in vacuo.* The residue was purified by column chromatography ($Si0_2$) to give the title

compound (568 mg, 48% yield) as a brown solid. LC-MS (ESI^+) *m/z* 327.0 $(M+H)^+$.

[003069] **5-[2-[3-[2-|2-(2-aminoethoxy)ethoxy]ethyll triazol-4-yll ethoxyl-2-(2,6-dioxo-3-piperidvP isoindoline-l,3-dione [Intermediate ND)**



[003070] Step 1 - Tert-butylN-[2-[2-[2-[5-[2-[2-(2,6-dioxo-3-piperidvl)-1,3-dioxo-isoindolin-5-vnoxyethvn triazol-l-yl1ethoxy1ethoxy1ethyl1carbamate


[003071] To a mixture of 5-but-3-ynoxy-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (115 mg, 352 umol, Intermediate NC), tert-butyl N-[2-[2-(2-azidoethoxy)ethoxy]ethyl]carbamate (290 mg, 1.06 mmol, Intermediate ID) in THF (3 mL) was added chlororuthenium(l+); 1,2,3,4,5-pentamethylcyclopenta-l,3-diene;triphenylphosphane (14.0 mg, 17.6 umol). The mixture was stirred at 65 °C for 12 hrs. On completion, the mixture was concentrated *in vacuo*. The residue was purified by column chromatography (S1O2) to give the title compound (156 mg, 73% yield) as brown oil. LC-MS (ESI^+) *m/z* 60l.l$(M+H)^+$.

[003072] Step 2 -5-r2-r3-r2-r2-(2-aminoethoxy)ethoxy1ethyl1triazol-4-yl1ethoxy1-2-(2.6-dioxo-3-piperidvD isoindoline-E3-dione

[003073] To a mixture of tert-butyl N-[2-[2-[2-[5-[2-[2-(2,6-dioxo-3-piperidyl)-l, 3-dioxo-isoindolin-5-yl] oxyethyl]triazol-l-yl]ethoxy]ethoxy]ethyl]carbamate (156 mg, 259 umol) in DCM (2 mL) was added HCl/dioxane (4 M, 129 uL). The reaction mixture was stirred at rt for 0.5 hr. On completion, the mixture was concentrated *in vacuo*. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (135 mg, 96% yield, HC1) as brown oil. LC-

MS (ESI+) *m/z* 501.1 $(M+H)^+$.

[003074] **5-12-12-14-|2-(2-Aminoethoxy)ethyl]piperazin-l-yll ethoxyl ethylamino 1-2-12,6-dioxo-3- piperidvQisoindoline-l.,3-dione [Intermediate NE)**



NE

[003075] Step 1 - Tert-butyl N-[2-[2-[4-[2-[2-[[2-(2,6-άioχo-3-ριρeτidvl)-1,3-άioχo-isoindolin-5-vl]amino] ethoxylethyllpiperazin-l-yllethoxylethyllcarbamate


[003076] To a solution of 2-(2,6-dioxo-3-piperidyl)-5-fluoro-isoindoline-l,3-dione (250 mg, 905 umol, Intermediate HX) and tert-butyl N-[2-[2-[4-[2-(2-aminoethoxy)ethyl]piperazin-l-yl]ethoxy]ethyl]carbamate (343 mg, 950 umol, Intermediate IM) in DMSO (8 mL) was added DIPEA (351 mg, 2.72 mmol). The reaction mixture was stirred at 130 °C for 13 hours. On completion, the reaction mixture was quenched with water (2 mL), concentrated *in vacuo.* The crude product was purified by reversed phase (acidified condition: 0.1% FA) to give the title compound (324 mg, 55% yield) as a yellow oil. LC-MS (ESI+) *m/z* 517.2 $(M+H-l00)^+$.

[003077] Step 2 - 5-r2-r2-r4-r2-(2-Aminoethoxy)ethyl1piperazin-l-yl1ethoxy1ethylamino1-2-(2.6-dioxo-3- piperidvDisoindoline-E3-dione

[003078] To a solution of tert-butyl N-[2-[2-[4-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl] amino]ethoxy]ethyl]piperazin-l-yl]ethoxy]ethyl]carbamate (350 mg, 534 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 133 uL). The reaction mixture was stirred at rt for 1 hr. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound

(290 mg, 98% yield) as a yellow solid. LC-MS (ESI$^+$) *m/z* 517.2 (M+H)$^+$.

[003079] **2-[2-[[2-(2,6-Dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl]amino]ethoxy]ethyl methanesulfonate [Intermediate NF)**



[003080] Step 1 - 2-(2,6-Dioxopiperidin-3-yl)-5-((2-(2-hydroxyethoxyiethyl)amino)isoindoline- 1J-dione


[003081] To a solution of 2-(2,6-dioxo-3-piperidyl)-5-fluoro-isoindoline-l,3-dione (500 mg, 1.81 mmol, Intermediate HX) and 2-(2-aminoethoxy)ethanol (210 mg, 2.00 mmol) in DMSO (10.0 mL) was added DIPEA (702 mg, 5.43 mmol). The reaction mixture was stirred at 130 °C for 15 hrs. On completion, the mixture was added E$_2$O (10.0 mL) and extracted with DCM (3 X 100 mL). The combined organic layers were washed with brine (50 mL), dried over Na$_2$S0$_4$, filtered and concentrated to give the title compound (250 mg, 38% yield) as a yellow solid. ^{1}HNMR (400MHz, CDCh) δ 8.14 (s, 1H), 7.62 (d, *J* = 8.4 Hz, 1H), 7.01 (d, *J* = 2.0 Hz, 1H), 6.79 (dd, *J* = 2.0, 8.4 Hz, 1H), 5.05 (s, 1H), 4.95 (dd, 7 = 5.2, 12.8 Hz, 1H), 3.81 (d, *J* = 4.2 Hz, 2H), 3.78 (t, *J* = 5.2 Hz, 2H), 3.68 - 3.63 (m, 2H), 3.45 (t, *J* = 5.2 Hz, 2H), 2.95 - 2.70 (m, 3H), 2.19 - 2.11 (m, 1H). LC-MS (ESL) *m/z* 362.1 (M+H)$^+$.

[003082] Step 2 - 2-[2-[[2-(2,6-Dioxo-3-piperidyl)-L3-dioxo-isoindolin-5-yllaminolethoxylethyl methanesulfonate

[003083] To a solution of 2-(2,6-dioxo-3-piperidyl)-5-[2-(2-hydroxyethoxy)ethylamino]isoindoline-l,3-dione (300 mg, 830 umol) in DCM (20.0 mL) was added TEA (168 mg, 1.66 mmol) and MsCl (105 mg, 913 umol). The reaction mixture was stirred at rt for 2 hrs. On completion, the reaction mixture was diluted with water (50 mL) and extracted with DCM (2 X 100 mL). The organic layer was washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (360 mg, 98% yield) as a yellow solid. ^{1}H NMR (400MHz, CDCh) δ 7.99 (s, 1H), 7.64 (d, *J* = 8.4 Hz, 1H), 7.02 (d, *J*

= 2.0 Hz, 1H), 6.83 (dd, *J* = 2.0, 8.4 Hz, 1H), 5.03 - 4.89 (m, 1H), 4.52 - 4.39 (m, 2H), 3.85 - 3.76 (m, 4H), 3.44 (t, *J* = 5.2 Hz, 2H), 3.10 (s, 3H), 2.96 - 2.72 (m, 3H), 2.24 - 2.10 (m, 1H).

[003084] **5-[2-[2-[6-[2-[2-Aminoethoxy)ethyll-2,6-diazaspiro[3.31heptan-2-yl]ethoxylethylaminol-2-(2,6-dioxo-3-piperidvPisoindoline-l,3-dione [Intermediate NG)**



[003085] Step_1_- Tert-butyl_6-[2-[2-[[2-(2,6-dioxo-3-piperidvl)-l,3-dioxo-isoindolin-5-yl]amino]ethoxy]ethyl]- 2.6-diazaspiror3.3]heptane-2-carboxylate

[003086] To a solution of 2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl]amino]ethoxy]ethyl methanesulfonate (260 mg, 592 umol, Intermediate NF) and tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate (139 mg, 592 umol, HC1, CAS# 1041026-70-3) in ACN (15.0 mL) was added NaHCCb (149 mg, 1.77 mmol) and TBAI (21.9 mg, 59.2 umol). The reaction mixture was stirred at 80 °C for 16 hrs. On completion, the mixture was concentrated *in vacuo*. The crude product was purified by silica gel chromatography (DCM: MeOH = 20: 1) to give the title compound (159 mg, 45% yield) as a yellow solid., ¾NMR (400MHz, DMSO-i¾) δ 11.07 (s, 1H), 7.57 (d, *J* = 8.4 Hz, 1H), 7.16 (s, 1H), 7.01 (s, 1H), 6.90 (d, 7 = 8.4 Hz, 1H), 5.04 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.86 (s, 4H), 3.54 (t, *J* = 5.2 Hz, 2H), 3.44 - 3.35 (m, 10H), 2.96 - 2.80 (m, 1H), 2.63 - 2.59 (m, 2H), 2.00 (d, *J* = 10.8 Hz, 1H), 1.36 (s, 9H). LC-MS (ESI$^+$) *m/z* 542.3 (M+H)$^+$.

[003087] Step 2 - 5-r2-r2-(2.6-Diazaspiror3.31heptan-2-vOethoxy1ethylamino1-2-(2.6-dioxo-3-piperidvD isoindoline-L3-dione

[003088] To a solution of tert-butyl 6-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl]amino] ethoxy]ethyl]-2,6-diazaspiro[3.3]heptane-2-carboxylate (177 mg, 327 umol) in DCM (5.00 mL) was added TFA (2.48 g, 21.7 mmol). The reaction mixture was stirred at rt for 1 hr. On completion, the mixture was concentrated *in vacuo*. Then, the residue was diluted with anhydrous toluene (30.0 mL). Then the mixture was concentrated *in vacuo* to give the title compound (181 mg, 100% yield, TFA) as a yellow solid. LC-MS (ESI^+) *m/z* 442.3 $(M+H)^+$.


[003089] Step 3 - Tert-butyl N-[2-[2-[6-[2-[2-[[2-(2.6-άϊoχo-3-ρϊperiάvl)-1.3-άϊoχo-isoindolin-5- vl]amino] ethoxy1ethyl1-2.6-diazaspiror3.31heptan-2-yl1ethoxy1ethyl1carbamate

[003090] To a solution of 5-[2-[2-(2,6-diazaspiro[3.3]heptan-2-yl)ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl) isoindoline-l,3-dione (181 mg, 327 umol, TFA) and tert-butyl N-[2-(2-oxoethoxy)ethyl]carbamate (230 mg, 1.13 mmol, synthesized via Step 1 of Intermediate FS) in a mixed solvent of THF (15.0 mL) and DMF (5.00 mL) was added TEA (66.1 mg, 654 umol) and HOAc (78.5 mg, 1.31 mmol). The reaction mixture was stirred at rt for 12 hrs. After, $NaBH(OAc)_3$ (83.1 mg, 392 umol) was added and the resulting reaction mixture was stirred at rt for 24 hrs. On completion, the mixture was quenched with water (1.00 mL). The mixture was concentrated *in vacuo*. The crude product was purified by reversed phase (condition: 0.1% FA) to give the title compound (77 mg, 34% yield) as yellow solid. LC-MS (ESI^+) *m/z* 629.4 $(M+H)^+$.

[003091] Step 4 - 5-r2-r2-r6-r2-(2-Aminoethoxy)ethyl1-2.6-diazaspiror3.31heptan-2-yl1ethoxy1ethylamino1-2- (2.6-dioxo-3-piperidyl)isoindoline-L3-dione

[003092] To a solution of tert-butyl N-[2-[2-[6-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl] amino]ethoxy]ethyl]-2,6-diazaspiro[3.3]heptan-2-yl]ethoxy]ethyl]carbamate (100 mg, 151 umol) in DCM (5.00 mL) was added TFA (86.2 mg, 756 umol). The reaction mixture was stirred at rt for 1 hr. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (97 mg, 100% yield, TFA) as a yellow solid. LC-MS (ESI^+) *m/z* 529.4 $(M+H)^+$.

[003093] 4-[AminomethvB-2-[2,6-dioxo-3-piperidvBisoindoline-l,3-dione [Intermediate_Ml)



FT NH


[003094] Step 1 - Tert-butyl N-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]methyl]carbamate

[003095] To a solution of 4-bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione (700 mg, 2.08 mmol, Intermediate FT) and potassium N-Boc-amino methyltrifluoroborate (738 mg, 3.11 mmol, CAS# 1314538-55-0) in dioxane (10 mL) and H_2O (2 mL) was added K2CO3 (861 mg, 6.23 mmol) and Pd(dppf)Cl2.CH2Cb (170 mg, 208 umol). The reaction mixture was stirred at 85 °C for 6 hours under nitrogen. On completion, the reaction mixture was poured into brine (30 mL) and extracted with EA (3 X 80 mL). The combined organic layers were washed with brine (80 mL), dried with anhydrous Na_2SO_4, filtered, concentrated *in vacuo*. The residue was purified by silica column chromatography (PE/EA, 3/1 to 1/1) to give the title compound (270 mg, 34% yield) as a yellow solid. ^1H NMR (400 MHz, DMSO^) δ 11.11 (s, 1H), 7.88 - 7.77 (m, 2H), 7.74 - 7.64 (m, 1H), 5.20 - 5.09 (m, 1H), 4.69 - 4.54 (m, 2H), 3.02 - 2.79 (m, 1H), 2.69 - 2.56 (m, 2H), 2.17 - 2.01 (m, 1H), 1.41 (s, 9H).

[003096] Step 2 - 4-(Aminomethyl)-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione

[003097] To a solution of tert-butyl N-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]methyl]carbamate (80.0 mg, 207 umol) in DCM (10 mL) was added HCl/dioxane (4 M, 12.3 mL). The reaction mixture was stirred at rt for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (60.0 mg, 90% yield) as yellow oil.

[003098] **5-[2-[2,6-Dioxo-3-piperidyl]-1,3-dioxo-isoindolin-4-yl]pentyl methanesulfonate [Intermediate NI)**



FT NI

[003099] Step 1 - 2-(2,6-Dioxo-3-piperidyl)-4-(5-hydroxypent-1-ynyl)isoindoline-1,3-dione

[003100] To a solution of 4-bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (1.00 g, 2.97 mmol, Intermediate FT) and pent-4-yn-l-ol (499 mg, 5.93 mmol, CAS# 5390-04-5) in DMF (10 mL) was added $Pd(PPh_3)2Cl2$ (208 mg, 296 umol), TEA (5.40 g, 53.3 mmol, 7.43 mL), and Cul (56.4 mg, 296 umol) under N2. The reaction mixture was stirred at 80 °C for 30 min under microwave. On completion, the reaction mixture was diluted with EA (20 mL), filtered and concentrated *in vacuo*. The residue was purified by column chromatography (S1O2, Petroleum ether/Ethyl acetate = 5:1 to 1:1) to give the title compound (800 mg, 76% yield) as a light yellow solid. LC-MS (ESI^+) m/z 341.1 $(M + H)^+$.

[003101] Step 2 - 2-(2.6-Dioxo-3-piperidyl)-4-(5-hvdroxypentyl)isoindoline-1J-dione


[003102] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-(5-hydroxypent-l-ynyl)isoindoline-l,3-dione (800 mg, 2.35 mmol) in THF (25 mL) was added Pd/C (100 mg, 2.35 mmol, 10 wt%) and Pd(OH)2/C (100 mg, 71.2 umol, 10 wt%). The reaction mixture was stirred at rt for 12 hours under Hh (15 psi). On completion, the residue was filtered and the filtrate was concentrated *in vacuo* to give the title compound (810 mg, 95% yield) as a black brown solid. LC-MS (ESI^+) m/z 345.3 $(M + H)^+$.

[003103] Step 3 - 5-[2-(2,6-Dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]pentyl methanesulfonate

[003104] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-(5-hydroxypentyl)isoindoline-l,3-dione (300 mg, 871 umol) and TEA (264 mg, 2.61 mmol, 363 uL) in DCM (5 mL) was added

MsCl (119 mg, 1.05 mmol, 80.9 uL). The reaction mixture was stirred at rt for 0.5 hour. The mixture was quenched by addition of H_20 (50 mL), then extracted with DCM (2 X 100 mL). The organic phase was concentrated *in vacuo* to give the title compound (370 mg, 90% yield) as a yellow solid. LC-MS (ESI^+) m/z 423.2 $(M+H)^+$.

[003105] **2-[2-[2-(2,6-Dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]ethoxy]ethyl methanesulfonate [Intermediate NJ)**



[003106] Step 1 - 2-(2.6-Dioxo-3-piperidyl)-4-r(Z)-2-(2-hvdroxyethoxy)vinyl1isoindoline-L3-dione

[003107] To a solution of 4-bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (1.5 g, 4.45 mmol, Intermediate FT) and 2-vinyloxyethanol (784 mg, 8.90 mmol, CAS# 764-48-7) in dioxane (100 mL) was added $P(t\text{-}Bu)_3$ (1.80 g, 889 umol, 2.09 mL, 10% purity), DIPEA (690 mg, 5.34 mmol, 930 uL) and $Pd_2(dba)_3$ (407 mg, 444 umol). The reaction mixture was stirred at rt for 12 hours under N_2. On completion, the reaction mixture was poured into sat.NLLCl (30 mL) and extracted with EA (3 X 100 mL). The combined organic layers were washed with brine (50 mL), dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by column chromatography ($Si0_2$, Petroleum ether/Ethyl acetate = 2:1 to 0:1) to give the title compound (600 mg, 33% yield) as a light yellow solid. LC-MS (ESI^+) m/z 345.1 $(M + H)^+$.

[003108] Step 2 - 2-(2.6-Dioxo-3-piperidyl)-4-r2-(2-hvdroxyethoxy)ethyl1isoindoline-l .3-dione


[003109] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-[(Z)-2-(2-hydroxyethoxy)vinyl]isoindoline-l,3-dione (500 mg, 1.45 mmol) in THF (20 mL) was added Pd/C


(50 mg, 1.45 mmol, 10 wt%). The reaction mixture was stirred at rt for 24 hours under H_2 (15 Psi). Then $Pd(OH)_2/C$ (50 mg, 35.6 umol, 10 wt%) was added. The reaction mixture was stirred at rt for 12 hours under H_2 (15 Psi). On completion, the residue was filtered and the filtrate was concentrated *in vacuo* to give the title compound (600 mg, 85% purity) as a light yellow solid. LC-MS (ESI^+) m/z 347.2 $(M+H)^+$.

[003110] Step 3 - 2-r2-r2-(2.6-Dioxo-3-piperidvn-l.3-dioxo-isoindolin-4-yl1ethoxy1ethyl methanesulfonate

[003111] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-[2-(2-hydroxyethoxy)ethyl]isoindoline-l,3-dione (250 mg, 721.85 umol) in DCM (10 mL) was added TEA (219 mg, 2.17 mmol, 301 uL) and MsCl (124 mg, 1.08 mmol, 83.8 uL) at 0 °C. The reaction mixture was stirred at rt for 30 min. The mixture was quenched by addition H_20 (50 mL), then extracted with DCM (2 X 100 mL). The organic phase was concentrated *in vacuo* to give the title compound (310 mg, 63% purity) as a yellow solid. LC-MS (ESI^+) m/z 425.0 $(M+H)^+$.

[003112] 4-[2-[2-[4-[4-Amino-3-(difluoromethvPpyrazol-l-yll-l-piperidyllethoxylethyll-2-(2.,6-dioxo- 3-piperidvDisoindoline-l.,3-dione [Intermediate NK)





[003113] Step 1 - 4-[2-[2-[4-[3-(Difluoromethyl)-4-nitro-pyrazol-1-yl]-1-piperidyl1ethoxy1ethyl1-2-(2.6-dioxo-3 -piperidvOisoindoline-L3-dione


[003114] To a solution of 2-[2-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-

yl]ethoxy]ethyl methanesulfonate (300 mg, 706 umol, Intermediate NJ) and 4-[3-(difluoromethyl)-4-nitro-pyrazol-l-yl]piperidine (199 mg, 706 umol, HC1, Intermediate JP) in CLLCN (20 mL) was added NaHCCb (178 mg, 2.12 mmol) and KI (11.7 mg, 70.6 umol). The reaction mixture was stirred at 80 °C for 12 hours. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo* to give the title compound (410 mg, 85% purity) as a yellow solid. LC-MS (ESI^+) m/z 575.2 $(M+H)^+$.

[003115] Step 2 - 4-[2-[2-[4-[4-Amino-3-(difluoromethvDpyrazol-1-yl]-1-piperidyl1ethoxy1ethyl1-2-(2.6-dioxo-3-piperidvOisoindoline-L3-dione

[003116] To a solution of 4-[2-[2-[4-[3-(difluoromethyl)-4-nitro-pyrazol-l-yl]-l-piperidyl]ethoxy]ethyl]-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (260 mg, 452 umol) in THF (10 mL) was added $Pt0_2$ (41.1 mg, 181 umol), the reaction mixture was stirred at rt under H_2 (15 psi) for 16 hrs. On completion, the mixture was filtered, the filtrate was concentrated was concentrated *in vacuo* to give the title compound (40 mg, 16% yield) as a white solid. LC-MS (ESL) m/z 545.3 $(M+H)^+$.

[003117] **4-[5-[4-[4-Amino-3-[difluoromethvnpyrazol-l-yl1-l-piperidyl]pentyl1-2-[2,6-dioxo-3-piperidvQisoindoline-l.,3-dione [Intermediate NL)**



[003118] Step 1 - 4-r5-r4-r3-(DifluoromethvD-4-nitro-pyrazol-l-yl1-l-piperidyl1pentyl1-2-(2,6-dioxo-3-piperidvl) isoindoline-L3-dione


[003119] To a solution of 5-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]pentyl

methanesulfonate (260 mg, 615 umol, Intermediate NI) and 4-[3-(difluoromethyl)-4-nitro-pyrazol-l-yl]piperidine (133 mg, 473 umol, HC1, Intermediate JP) in ACN (15 mL) was added NaHC0 $_3$ (119 mg, 1.42 mmol, 55.2 uL) and KI (7.86 mg, 47.3 umol), the reaction micture was stirred at 80 °C for 16 hr. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo.* The residue was purified by column chromatography (S1O2, DCM/MeOH= 100/1 to 50/1) to give the title compound (140 mg, 51% yield) as a white solid. LC-MS (ESI$^+$) m/z 573.3 (M+H)$^+$.

[003120] Step 2 - 4-r5-r4-r4-Amino-3-(difluoromethv0pyrazol-l-yl1-l-piperidyl1pentyl1-2-(2.6-dioxo-3- piperidvnisoindoline-L3-dione

[003121] To a solution of 4-[5-[4-[3-(difluoromethyl)-4-nitro-pyrazol-l-yl]-l-piperidyl]pentyl]-2-(2,6-dioxo-3- piperidyl)isoindoline-l,3-dione (190 mg, 331 umol) in THF (5 mL) was added Pt0 $_2$ (37.6 mg, 165 umol), and the reaction mixture was stirred at rt under ¾ (15 psi) for 3 hrs. On completion, the mixture was filtered, the filtrate was concentrated *in vacuo* to give the title compound (180 mg, 99% yield) as a white solid. LC-MS (ESI$^+$) m/z 543.4 (M+H)$^+$.

[003122] **3-[2-[2,6-Dioxo-3-piperidvB-l,3-dioxo-isoindolin-4-yl]propyl methanesulfonate [Intermediate** NM**)**



[003123] Step 1- 2-(2,6-Dioxo-3-piperidvl)-4-(3-hvdroxyprop-l-vnvl)isoindoline-L3-dione

[003124] 4-Bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (1.00 g, 2.97 mmol, Intermediate FT), prop-2-yn-l-ol (332 mg, 5.93 mmol, CAS# 107-19-7), Pd(PPh $_3$)2Cl2 (208 mg, 296 umol), Cul (113 mg, 593 umol), and TEA (5.40 g, 53.4mmol) were taken up into a microwave tube in DMF (20 mL). The sealed tube was heated at 80 °C for 0.5 hr under microwave. On completion, the mixture was poured into water (100 mL). The aqueous phase was extracted with

ethyl acetate (2 X 50 mL). The combined organic phase was washed with brine (2 X 40 mL), dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by column chromatography ($Si0_2$, Petroleum ether/Ethyl acetate=0:l) to give the title compound (185 mg, 9% yield) as white solid. LC-MS (ESI^+) *m/z* 335.0 $(M+Na)^+$.


[003125] Step 2- 2-(2,6-Dioxo-3-piperidyl)-4-(3-hydroxypropyl)isoindoline-E3-dione

[003126] To a mixture of 2-(2, 6-dioxo-3-piperidyl)-4-(3-hydroxyprop-l-ynyl)isoindoline-l,3-dione (320 mg, 1.02 mmol) in THF (10 mL) was added Pd/C (2.05 mmol, 10 wt%), and $Pd(OH)_2$ (288 mg, 2.05 mmol) under H_2 (15 Psi), and the reaction mixture was stirred at rt for 5 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (296 mg, 91% yield) as brown oil. LC-MS (ESI^+) *m/z* 339.0 $(M+Na)^+$.

[003127] Step_ %_ 3-r2-(2.6-Dioxo-3-piperidyn-L3-dioxo-isoindolin-4-yl1propyl methanesulfonate

[003128] To a mixture of 2-(2,6-dioxo-3-piperidyl)-4-(3-hydroxypropyl)isoindoline-l,3-dione (296 mg, 935 umol) in DCM (10 mL) was added DIPEA (362 mg, 2.81 mmol) and the mixture was cooled to 0 °C. MsCl (161 mg, 1.40 mmol) was added into the mixture. The reaction mixture was stirred at rt for 1 hr. On completion, the mixture was poured into water (15 mL). The aqueous phase was extracted with ethyl acetate (2 X 20 mL).The combined organic phase was washed with brine (2 X 20 mL), then dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give title compound (348 mg, 94% yield) as brown oil. LC-MS (ESI^+) *m/z* 395.0 $(M+H)^+$.

[003129] **4-[3-[4-[3-[Difluoromethyn-4-nitro-pyrazol-l-yl1-l-piperidyl]propyl1-2-[2,6-dioxo-3- piperidyQisoindoline-l.,3-dione [Intermediate** NN1



[003130] Step _1- 4-r3-r4-r3-(DifluoromethvD-4-nitiO-pyrazol-l-yl1-l-piperidyl1piOPyl1-2-(2,6-dioxo-3-piperidvl)isoindoline-E3-dione


[003131] To a mixture of 3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]propyl methanesulfonate (348 mg, 882 umol, Intermediate NM), 4-[3-(difluoromethyl)-4-nitro-pyrazol-l-yl]piperidine (274.36 mg, 970umol, HC1, Intermediate JP) in $CE[_3CN$ (10 mL) was added NaHCCh (296 mg, 3.53 mmol) and the mixture was stirred at 80 °C for 12 hrs. On completion, the mixture was concentrated *in vacuo.* The crude product was purified by column chromatography (Si02, Petroleum ether/Ethyl acetate=0: 1) to give title compound (190 mg, 30% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 545.3 $(M+H)^+$.

[003132] Step 2 - 4-r3-r4-r3-(DifhioromethvD-4-nitro-pyrazol-l-yl1-l-piperidyl1propyl1-2-(2.6-dioxo-3- piperidvnisoindoline-E3-dione

[003133] To a mixture of 4-[3-[4-[3-(difluoromethyl)-4-nitro-pyrazol-l-yl]-l-piperidyl]propyl]-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (20.0 mg, 36.7 umol) in THF (2 mL) was added $Pt0_2$ (1.67 mg, 7.35 umol) under Eh (15 Psi) and the reaction mixture was stirred at rt for 12 hrs. On completion, the mixture was concentrated *in vacuo* to give title compound (15 mg, 80% yield) as brown oil. LC-MS (ESI^+) *m/z* 515.2 $(M+H)^+$.

[003134] **5-[2-[2,6-Dioxo-3-piperidvn-l,3-dioxo-isoindolin-5-yl]pentyl**

methanesulfonate (Intermediate NO)



[003135] Step 1 - 2-(2,6-Dioxo-3-piperidyl)-5-(5-hydroxypent-1-ynyl)isoindoline-1,3-dione

[003136] A mixture of 5-bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione (1.00 g, 2.97 mmol, Intermediate GA), pent-4-yn-1-ol (499 mg, 5.93 mmol), $Pd(PPh_3)_2Cl_2$ (208 mg, 296 umol), CuI (56.0 mg, 296 umol) and TEA (5.40 g, 53.3 mmol, 7.43 mL) in DMF (4 mL) was degassed and purged with N_2 gas 3 times. The mixture was stirred at 80 °C for 0.5 hr under microwave. On completion, the mixture was extracted with EA(2 X 100 mL). The organic layer was washed with brine (100 mL), dried over anhydrous Na_2SO_4, then filtered and concentrated *in vacuo*. The residue was purified by silica gel chromatography to give the title compound (900 mg, 89% yield) as light yellow solid. ^1H NMR (400MHz, DMSO-^e) δ 11.14 (s, 1H), 7.94 - 7.78 (m, 3H), 5.17 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.57 (t, *J* = 5.2 Hz, 1H), 3.55 (q, *j* = 6.0 Hz, 2H), 2.97 - 2.84 (m, 1H), 2.67 - 2.55 (m, 4H), 2.15 - 2.02 (m, 1H), 1.77 - 1.70 (m, 2H).

[003137] Step 2 - 2-(2.6-Dioxo-3-piperidyD-5-(5-hydroxypentyl)isoindoline-1.3-dione


[003138] To a solution of 2-(2,6-dioxo-3-piperidyl)-5-(5-hydroxypent-1-ynyl)isoindoline-1,3-dione (900 mg, 2.64 mmol) in THF (20 mL) was added Pd/C (100 mg, 10 wt%) and $Pd(OH)_2/C$ (100 mg, 10 wt%) under H_2 atmosphere (15 psi). The mixture was stirred at rt for 2 hrs. On

completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (800 mg, 87% yield) as light yellow solid. ^{1}H NMR (400MHz, DMSO-i¾) δ 11.12 (s, 1H), 7.89 - 7.65 (m, 3H), 5.14 (dd, 7 = 5.2, 12.8 Hz, 1H), 4.38 - 4.33 (m, 1H), 3.43 - 3.34 (m, 2H), 2.89 (s, 1H), 2.78 (t, *J* = 7.6 Hz, 2H), 2.65 - 2.52 (m, 2H), 2.12 - 2.00 (m, 1H), 1.80 - 1.72 (m, 1H), 1.68 - 1.60 (m, 2H), 1.48 - 1.41 (m, 2H), 1.35 - 1.24 (m, 2H).

[003139] Step 3 - 5-r2-(2.6-Dioxo-3-piperidvO-l.3-dioxo-isoindolin-5-yl1pentyl methanesulfonate

[003140] To a solution of 2-(2,6-dioxo-3-piperidyl)-5-(5-hydroxypentyl)isoindoline-l,3-dione (200 mg, 580 umol) in DCM (20 mL) was added TEA (176 mg, 1.74 mmol) and MsCl (133 mg, 1.16 mmol, 89.9 uL). The mixture was stirred at rt for 3 hrs. On completion, the mixture was washed with citric acid (10 mL), and brine (20 mL). The organic layer was dried over anhydrous Na_2S0_4, filtered and the filtrate was concentrated *in vauco* to give the title compound (240 mg, 97% yield) as yellow oil. LC-MS (ESI$^+$) *m/z* 423.3 (M+l)$^+$.

[003141] **5-[3-[4-[4-Amino-3-[difluoromethvnpyrazol-l-yl1-l-piperidyl]propyl1-2-[2,6-dioxo-3- piperidvQisoindoline-l.,3-dione [Intermediate NP1**



[003142] Step 1 - 5-r5-r4-r3-(DifluoiOmethvD-4-nitiO-pyrazol-l-yl1-l-piperidyl1pentyl1-2-(2.6-dioxo-3 -piperidvD isoindoline-l.3-dione


[003143] To a mixture of 5-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl]pentyl methanesulfonate (179 mg, 424 umol, Intermediate NO) and 4-[3-(difluoromethyl)-4-nitro-

pyrazol-l-yl]piperidine (100 mg, 354 umol, HC1, , Intermediate JP) in ACN (8 mL) was added NaHCCb (89.2 mg, 1.06 mmol) and KI (5.87 mg, 35.4 umol). The mixture was stirred at 80 °C for 16 hrs. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo*, the residue was purified by Pre-HPLC (acid condition) to give the title compound (140 mg, 69% yield) as white solid. ^{1}H NMR (400MHz, DMSO-^e) δ 11.11 (s, 1H), 9.08 (s, 1H), 7.85 (d, *J* = 7.6 Hz, 1H), 7.79 (s, 1H), 7.73 (d, *J* = 7.2 Hz, 1H), 7.46 - 7.17 (m, 1H), 5.14 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.38 - 4.27 (m, 1H), 3.03 - 2.95 (m, 2H), 2.94 - 2.85 (m, 1H), 2.83 - 2.77 (m, 2H), 2.71 - 2.53 (m, 2H), 2.38 - 2.31 (m, 2H), 2.16 - 1.95 (m, 7H), 1.73 - 1.62 (m, 2H), 1.55 - 1.44 (m, 2H), 1.37 - 1.28 (m, 2H).

[003144] Step 2 - 5-r3-r4-r4-Amino-3-(difluoromethvDpyrazol-l-yl1-l-piperidyl1propyl1-2-(2.6-dioxo-3- piperidvDisoindoline-U-dione

[003145] To a solution of 5-[5-[4-[3-(difluoromethyl)-4-nitro-pyrazol-l-yl]-l-piperidyl]pentyl]-2-(2,6-dioxo -3-piperidyl)isoindoline-l,3-dione (140 mg, 244 umol) in THF (20 mL) was added Pt0 $_2$ (11.1 mg, 48.9umol). The mixture was stirred at rt for 16 hrs under H_2 (l5psi). On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (130 mg, 98% yield) as white solid. ^{1}H NMR (400MHz, DMSO-i¾) δ 11.11 (s, 1H), 7.85 - 7.83 (m, 2H), 7.78 (s, 1H), 7.74 - 7.7l(m, 2H), 7.17 (s, 1H), 7.03 - 6.61 (m, 3H), 5.14 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.99 - 3.94 (m, 1H), 2.96 - 2.88 (m, 3H), 2.84 - 2.76 (m, 2H), 2.67 - 2.58 (m, 2H), 2.30 - 2.24 (m, 2H), 1.98 - 1.74 (m, 7H), 1.72 - 1.60 (m, 2H), 1.53 - 1.41 (m, 2H), 1.33 - 1.22 (m,2H).

[003146] **3-[2-[2,6-Dioxo-3-piperidvn-l,3-dioxo-isoindolin-5-yl]propyl methanesulfonate [Intermediate NQ]**



GA

NQ

[003147] Step 1 - 2-(2,6-Dioxo-3-piperidyl)-5-(3-hydroxyprop- 1-ynyl)isoindoline- 1J-dione

[003148] Amixture of 5-bromo-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (1.00 g, 2.97 mmol, Intermediate GA), prop-2-yn-l-ol (333 mg, 5.93 mmol, CAS# 107-19-7), $Pd(PPh3)_2Cl2$ (208 mg, 297 umol), Cul (56.5 mg, 297 umol) and TEA (5.40 g, 53.4 mmol, 7.43 mL) in DMF (4 mL) was degassed and purged with N_2 gas 3 times, and then the mixture was stirred at 80 °C for 0.5 hr under microwave. On completion, the mixture was extracted with EA (2 X 100 mL), the organic layer was washed with brine (100 mL), dried over anhydrous Na_2S0_4, then filtered and concentrated in *vacuo.* The residue was purified by silica gel chromatography to give the title compound (800 mg, 86% yield) as light white solid. ^1H NMR (400MHz, DMSO-di) δ 11.15 (s, 1H), 7.96 - 7.90 (m, 3H), 5.48 (t, *J* = 6.0 Hz, 1H), 5.l7(dd, *J* = 5.2, 12.8 Hz, 1H), 4.38 (d, *J* = 6.0 Hz, 2H), 2.96 - 2.84 (m, 1H), 2.70 - 2.54 (m, 2H), 2.13 - 2.03 (m, 1H).


[003149] Step 2 - 2-(2,6-Dioxo-3-piperidyl)-5-(3-hydroxypropyl)isoindoline-1,3-dione

[003150] To a solution of 2-(2,6-dioxo-3-piperidyl)-5-(3-hydroxyprop-l-ynyl)isoindoline-l,3-dione (800 mg, 2.56 mmol) in THF (20 mL) was added Pd/C (200 mg, 10 wt%) and $Pd(OH)_2/C$ (200 mg, 10 wt%). The mixture was stirred at rt for 3 hrs under H_2 (15 psi) atmosphere. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (800 mg, 98% yield) as light brown solid. ^1H NMR (400MHz, DMSO-i/e) δ 11.12 (s, 1H), 7.86 - 7.69 (m, 3H), 5.14 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.54 (t, *J* = 5.2 Hz, 1H), 3.45 - 3.38 (m, 2H), 2.96 - 2.90 (m, 1H), 2.87 - 2.79 (m, 2H), 2.69 - 2.53 (m, 2H), 2.11 - 2.01 (m, 1H), 1.83 - 1.72 (m, 2H).

[003151] Step 3 - 3-[2-(2,6-Dioxo-3-piperidyl)-L3-dioxo-isoindolin-5-yl]propyl methanesulfonate

[003152] To a solution of 2-(2,6-dioxo-3-piperidyl)-5-(3-hydroxypropyl)isoindoline-l,3-dione (300 mg, 948 umol) in DCM (10 mL) was added MsCl (217 mg, 1.90 mmol) and TEA (288 mg, 2.85 mmol). The mixture was stirred at rt for 3 hrs. On completion, the mixture was washed with citric acid (10 mL), and brine (20 mL). The organic layer was dried over anhydrous Na_2S0_4, filtered and the filtrate was concentrated *in vauco* to give the title compound (350 mg, 93% yield) as yellow solid. LC-MS (ESI^+) *m/z* 412.2 $(M+l8)^+$.

[003153] 5-[3-[4-[4-Amino-3-[difluoromethvnpyrazol-l-yl1-l-piperidyl]propyl1-2-[2,6-dioxo -3-piperidvQisoindoline-l.,3-dione [Intermediate NR)



[003154] Step 1 - 5-r3-r4-r4-Amino-3-(difluoiOmethvDpyrazol-l-yl1-l-piperidyl1piOPyl1-2-(2.6-dioxo-3- piperidvDisoindoline-l.3-dione


[003155] To a mixture of 3-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5-yl]propyl methanesulfonate (167 mg, 424 umol, Intermediate NQ) and 4-[3-(difluoromethyl)-4-nitro-pyrazol-l-yl]piperidine (100 mg, 354 umol, HC1, Intermediate JP) in ACN (10 mL) was added NaHC03 (89.0 mg, 1.06 mmol) and KI (5.87 mg, 35.4 umol). The mixture was stirred at 80 °C for 16 hrs. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo*, the residue was purified by Pre-HPLC (acid condition) to give the title compound (100 mg, 52% yield) as white solid. ^{1}H NMR (400MHz, DMSO-r¾) δ 11.11 (s, 1H), 9.09 (s, 1H), 7.87 - 7.80 (m, 1H), 7.78 - 7.71 (m, 1H), 7.46 - 7.17 (m, 1H), 5.14 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.38 - 4.28 (m, 1H), 3.00 - 2.93 (m, 2H), 2.91 - 2.79 (m, 3H), 2.65 - 2.53 (m, 2H), 2.39 - 2.29 (m, 2H), 2.12 - 2.00 (m, 7H), 1.88 - 1.76 (m, 2H).

[003156] Step 2 - 5-r3-r4-r4-Amino-3-(difluoromethvDpyrazol-l-yl1-l-piperidyl1propyl1-2-(2.6-dioxo -3-piperidyl)isoindoline-l.3-dione

[003157] To a solution of 5-[3-[4-[3-(difluoromethyl)-4-nitro-pyrazol-l-yl]-l-piperidyl]propyl]-2-(2,6-dioxo -3-piperidyl)isoindoline-l,3-dione (100 mg, 184 umol) in THF (15 mL) was added Pt0 $_2$ (41.7 mg, 184 umol). The mixture was stirred at rt for 16 hrs under H_2 (15 psi) atmosphere. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo*

to give the title compound (80 mg, 85% yield) as white solid. LC-MS (ESI^+) *m/z* 515.3 $(M+l)^+$.

[003158] **3-[l-Oxo-4-[4-piperidylamino]isoindolin-2-yl]piperidine-2,6-dione [Intermediate NS]**



NS

[003159] Step 1 - Tert-butyl 4-rr2-(2.6-dioxo-3-piperidvl)- 1-oxo-isoindolin-4-yl1amino1piperidine-l- carboxylate


[003160] To a solution of 3-(4-amino-l-oxo-isoindolin-2-yl)piperidine-2,6-dione (400 mg, 1.54 mmol, CAS# 191732-72-6) and tert-butyl 4-ox opiperi dine- 1-carboxylate (615 mg, 3.09 mmol) in a mixed solvent of DCE (10 mL) and HOAc (1.05 g, 17.5 mmol) was added molecular sieves (200 mg, 386 umol, 4 A). The reaction mixture was stirred at 30 °C for 4 hrs. Then, $NaBH(OAc)_3$ (327 mg, 1.54 mmol) was added . The resulting reaction mixture was stirred at 30 °C for 12 hrs. On completion, the reaction mixture was concentrated *in vacuo* to give the crude product which was purified by reversed-phase chromatography (0.1% FA condition) to give the title compound (168 mg, 22% yield) as a white solid. ^1H NMR (400MHz, DMSO-i¾) δ 11.00 (s, 1H), 7.29 (t, *J* = 7.6 Hz, 1H), 6.95 *(d, J* = 7.6 Hz, 1H), 6.86 (d, *J* = 8.4 Hz, 1H), 5.35 *(d, J* = 8.4 Hz, 1H), 5.12 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.31 - 4.10 (m, 2H), 3.92 *(d, J* = 12.6 Hz, 2H), 3.02 - 2.85 (m, 3H), 2.71 - 2.59 (m, 1H), 2.38 - 2.23 (m, 1H), 2.09 - 2.00 (m, 1H), 1.92 - 1.90 (m, 2H), 1.41 (s, 9H), 1.33 - 1.29 (m, 2H) LC-MS (ESI^+) *m/z* 387.1 $(M-56)^+$.

[003161] Step 2 - 3-rl-Oxo-4-(4-piperidylamino)isoindolin-2-yl1piperidine-2.6-dione

[003162] To a solution of tert-butyl 4-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-4-yl]amino]piperidine-l- carboxylate (210 mg, 475 umol) in dichloromethane (10 mL) was added HCl/dioxane (4 M, 5 mL). The reaction mixture was stirred at 20 °C for 1 hr. On completion, the reaction mixture was concentrated in vacuo to give the title compound (180 mg, 100% yield, HC1

salt) as a white solid which was used for the next step without purification. LC-MS (ESI+) *m/z* 343.1 (M+H)+.

[003163] **3-[4-[[l-[2-[2-(2-Aminoethoxy)ethoxylethyll-4-piperidyllaminol-l-oxo-isoindolin-2- yl]piperidine-2,6-dione [Intermediate NT]**



[003164] Step 1 - Tert-butyl N-[2-[2-[2-[4-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-4-ynaminol-l-piperidyll ethoxy] ethoxy] ethyl] carbamate


[003165] To a solution of 3-[l-oxo-4-(4-piperidylamino)isoindolin-2-yl]piperidine-2,6-dione (180 mg, 475 umol, HC1, Intermediate NS) and tert-butyl N-[2-[2-(2-oxoethoxy)ethoxy]ethyl]carbamate (176.0 mg, 712 umol, Intermediate HY) in THF (20 mL) was added KOAc (93.2 mg, 949 umol) and NaBH(OAc) $_3$ (111 mg, 522 umol). The reaction mixture was stirred at rt for 36 hrs. On completion, the reaction mixture was quenched with water (1 mL) and the mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (condition: 0.1% FA) to give the title compound (130 mg, 45% yield) as a colorless oil. LC-MS (ESI+) *m/z* 574.2 (M+H)+. 1H NMR (400MHz, DMSO-^e) δ 11.03 (s, 1H), 7.30 - 7.25 (m, 1H), 6.93 (d, *J=1* .6 Hz, 1H), 6.82 - 6.75 (m, 2H), 5.33 (d, *j* = 7.6 Hz, 1H), 5.13 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.26 - 4.11 (m, 2H), 4.26 - 4.10 (m, 1H), 3.06 *(d, J* = 6.0 Hz, 2H), 2.99 - 2.89 (m, 3H), 2.68 - 2.59 (m,

1H), 2.30 - 2.26 (m, 1H), 2.20 - 2.14 (m, 2H), 2.06 - 2.00 (m, 1H), 1.92 - 1.88 (m, 2H), 1.48 - 1.42 (m, 2H), 1.37 (s, 9H).

[003166] Step 2 - 3-[4-[[1-[2-[2-(2-Aminoethoxy)ethoxy]ethyl]-4-piperidyl]amino]-1-oxo-isoindolin-2- yl1piperidine-2.6-dione

[003167] To a solution of tert-butyl N-[2-[2-[2-[4-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-4-yl]amino]-l- piperidyl]ethoxy]ethoxy]ethyl]carbamate (130 mg, 227 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 5 mL). The reaction mixture was stirred at rt for 1 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (116 mg, 99% yield, HC1 salt) as a white solid. LC-MS (ESI$^+$) *m/z* 474.2 (M+H)$^+$.

[003168] **4-[[l-[2-[2-Aminoethoxy]ethyl1-4-piperidyl]amino1-2-[2,6-dioxo-3-piperidvPisoindoline-1.,3 -dione [Intermediate NU1**



[003169] Step **1** - Tert-butyl N-[2-[2-[4-[[2-(2,6-dioxo-3-piperidvl)-1,3-dioxo-isoindolin-4-yllaminol-l- piperidvHethoxylethyllcarbamate


[003170] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-(4-piperidylamino)isoindoline-l,3-dione (300 mg, 764 umol, HC1, Intermediate JW) and tert-butyl N-[2-(2-oxoethoxy)ethyl]carbamate (233 mg, 1.15 mmol, synthesized via Step 1 of Intermediate FS) in THF (10 mL) was added KOAc (150 mg, 1.53 mmol). One hour later, $NaBH(OAc)_3$ (324 mg, 1.53 mmol) was added. The reaction mixture was stirred at rt for 16 hrs. On completion, the mixture was concentrated *in vacuo*. The residue was purified reverse phase (0.1% HC1 condition) to give the title compound (300 mg, 72% yield) as a white solid. LC-MS (ESI$^+$) *m/z* 544.4 (M+H)$^+$.

[003171] Step 2 - 4-[[1-[2-(2-Aminoethoxy)ethyl1-4-piperidyl1amino1-2-(2,6-dioxo-3-

piperidvDisoindoline-l.3 -dione

[003172] To a solution of tert-butyl N-[2-[2-[4-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino] -l-piperidyl]ethoxy]ethyl]carbamate (300 mg, 552 umol) in DCM (5 mL) was added HCl/dioxane (10 mL). The reaction mixture was stirred at rt for 10 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (240 mg, 91% yield, HC1) as a yellow solid. LC-MS (ESI^+) *m/z* 444.1 $(M+H)^+$.

[003173] **3-(5-Amino-l-oxo-isoindolin-2-vPpiperidine-2.,6-dione [Intermediate** NV1



NV

[003174] Step **1** - Methyl 2-(bromomethvD-4-nitro-benzoate

[003175] To a solution of methyl 2-methyl -4-nitro-benzoate (3.00 g, 15.4 mmol) in CCl_4 (60.0 mL) was added NBS (3.28 g, 18.4 mmol) and BOP (68.0 mg, 154 umol). The reaction mixture was stirred at 85 °C for 12 hrs. On completion, the mixture was washed with saturated $NaHC0_3$ (20.0 mL) and brine (50.0 mL), dried over anhydrous $MgS0_4$, filtered and concentrated *in vacuo.* The residue was purified by silica gel column chromatography (PE: AcOEt = 3: 1) to give the title compound (4.2lg, 100% yield) as a colorless oil. ^1H NMR (400MHz, CDCh) δ 8.30 (d, *J* = 2.0 Hz, 1H), 8.20 (dd, *J* = 2.0, 6.4 Hz, 1H), 8.10 (d, *J* = 6.4 Hz, 1H), 4.96 (s, 2H), 4.00 (s, 3H).

[003176] Step 2 - 3-(5-Nitro-l-oxo-isoindolin-2-vDpiperidine-2.6-dione


[003177] To a solution of 3-aminopiperidine-2,6-dione (2.00 g, 12.2 mmol, HC1) and methyl 2-(bromomethyl)-4-nitro-benzoate (4.21 g, 15.4 mmol) in DMF (10.0 mL) was added TEA (3.07 g, 30.4 mmol). The reaction mixture was stirred at 75 °C for 12 hrs. On completion, the reaction mixture was diluted with water (200 mL), filtered. The filtered cake was collected. The reaction mixture was concentrated *in vacuo.* The residue was triturated EA: H_20 = 1: 1 (50 mL) to give the title compound (1.7 g, 48% yield) as a blue solid. ^1H NMR (400MHz, DMSO-i¾) δ 11.04 (s, 1H),

8.53 (d, *J* = 1.2 Hz, 1H), 8.36 (dd, 7 = 2.0, 8.4 Hz, 1H), 7.98 (d, 7 = 8.4 Hz, 1H), 5.17 (dd, 7 = 5.2, 13.2 Hz, 1H), 4.69 - 4.45 (m, 1H), 3.01 - 2.86 (m, 1H), 2.68 - 2.59 (m, 1H), 2.48 - 2.35 (m, 1H), 2.13 - 2.02 (m, 1H).

[003178] Step 3 - 3-(5-Amino-l-oxo-isoindolin-2-vDpiperidine-2.6-dione

[003179] To a solution of 3-(5-nitro-l-oxo-isoindolin-2-yl)piperidine-2,6-dione (500 mg, 1.73 mmol) in a mixed of solvent DMF (5.00 mL) and THF (10.0 mL) was added Pd/C (50.0 mg, 1.73 mmol, 10% wt) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at rt for 12 hours. On completion, the reaction mixture was filtered and the filter cake was collected and dried *in vacuo* to give the title compound (530 mg, 82% yield) as a brown solid. LC-MS (ESI^+) *m/z* 260.2 $(M+H)^+$.

[003180] **3-[l-Oxo-5-[4-piperidylamino]isoindolin-2-yl]piperidine-2,6-dione [Intermediate NW1**



[003181] Step 1 - Tert-butyl 4-[[2-(2.6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-vHaminolpiperidine-l- carboxylate


[003182] To a solution of 3-(5-amino-l-oxo-isoindolin-2-yl)piperidine-2,6-dione (448 mg, 1.73 mmol, Intermediate NV) and tert-butyl 4-oxopiperidine-l -carboxylate (689 mg, 3.46 mmol) in a mixed solvent of DCE (10 mL) and HOAc (1.18 g, 19.6 mmol) was added molecular sieves (200 mg, 386 umol, 4Å). The reaction mixture was stirred at 30 °C for 4 hrs. Then, $NaBH(OAc)_3$ (366 mg, 1.73 mmol) was added. The resulting reaction mixture was stirred at 30 °C for 12 hrs. On completion, the reaction mixture was concentrated *in vacuo* to give the crude product, which was purified by reversed-phase chromatography (0.1% FA condition) to give the title compound (120 mg, 15% yield) as a white solid. ¾NMR (400MHz, DMSO-7 ₅) δ 10.93 (s, 1H), 7.39 (d, *J* = 8.8 Hz, 1H), 7.26 - 7.17 (m, 1H), 6.69 (s, 1H), 6.28 (d, 7 = 8.8 Hz, 1H), 5.02 (dd, *J* = 5.2, 13.2 Hz,

1H), 4.34 - 4.10 (m, 2H), 3.89 *(d, J* = 12.4 Hz, 2H), 3.06 - 2.82 (m, 3H), 2.71 - 2.55 (m, 1H), 2.41 - 2.29 (m, 1H), 1.95 - 1.93 (m, 1H), 1.92 - 1.89 (m, 2H), 1.41 (s, 9H), 1.27 - 1.24 (m, 2H); LC-MS (ESI^+) *m/z* 443.1 $(M+H)^+$.

[003183] Step 2 - 3-rl-Oxo-5-(4-piperidylamino)isoindolin-2-yl1piperidine-2.6-dione

[003184] To a solution of tert-butyl 4-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]amino]piperidine-l- carboxylate (120 mg, 257.6 umol) in DCM (5.00 mL) was added HCl/dioxane (4.00 M, 2.83 mL). The reaction mixture was stirred at rt for 1 hr. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (97.6 mg, 100% yield, HC1) as a white solid. LC-MS (ESI^+) *m/z* 343.1 $(M+H)^+$.

[003185] **3-[5-[[l-[2-[2-(2-Aminoethoxy)ethoxylethyll-4-piperidyllaminol-l-oxo-isoindolin-2-yl] piperidine-2,6-dione [Intermediate** NX]



[003186] Step **1** - Tert-butyl N-[2-[2-[2-[4-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-ynaminol-l-piperidyll ethoxy] ethoxy] ethyl] carbamate


[003187] To a solution of 3-[l-oxo-5-(4-piperidylamino)isoindolin-2-yl]piperidine-2,6-dione (97.0 mg, 256 umol, HC1, Intermediate NW) and 2-(2,6-dioxo-3-piperidyl)-5-piperazin-l-yl-isoindoline-l,3-dione (82.3 mg, 333 umol, synthesized via Steps 1-2 of Intermediate IB) in a mixed of solvent DMF (3.00 mL) and DCM (20.0 mL) was added KOAc (50.3 mg, 512 umol) and $NaBH(OAc)_3$ (81.4 mg, 384 umol). The reaction mixture was stirred at rt for 12 hrs. On completion, the reaction mixture was quenched with water (1.00 mL) and the mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (condition: 0.1% FA) to give the

title compound (60 mg, 33% yield) as a colorless oil. LC-MS (ESI^+) *m/z* 574.2 $(M+H)^+$.

[003188] Step 2 - 3-[5-[[1-[2-[2-(2-Aminoethoxy)ethoxy1ethyl1-4-piperidyl1amino1-l-oxo-isoindolin-2- vl] piperidine-2.6-dione

[003189] To a solution of tert-butyl N-[2-[2-[2-[4-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]amino]-l- piperidyl]ethoxy]ethoxy]ethyl]carbamate (60 mg, 105 umol) in DCM (10.0 mL) was added HCl/dioxane (4.00 M, 5.00 mL). The reaction mixture was stirred at rt for 1 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (53 mg, 99% yield, HC1) as a white solid. LC-MS (ESI^+) *m/z* 474.2 $(M+H)^+$.


[003190] **Tert-butyl N-[2-[2-[4-[2-t2,6-dioxo-3-piperidylM,3-dioxo-isoindolin-4-yllpiperazin -l-yl1ethoxy1ethyl1carbamate (Intermediate NY]**



NY

[003191] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-piperazin-l-yl-isoindoline-l,3-dione (0.5 g, 1.46 mmol, HC1, synthesized via Steps 1-2 Intermediate IA) and tert-butyl N-[2-(2-oxoethoxy)ethyl]carbamate (445 mg, 2.19 mmol, synthesized via Step 1 of Intermediate FS) in THF (10 mL) was added Et_3N (296 mg, 2.92 mmol, 407 uL) and AcOH (263 mg, 4.38 mmol, 251 uL) and then was added $NaBH(OAc)_3$ (619 mg, 2.92 mmol). The mixture was stirred at rt for 6 hr. On completion, the mixture was concentrated *in vacuo.* The crude product was purified by reversed-phase chromatography (0.1% HC1 condition) to give the title compound (0.3 g, crude) as a yellow solid. LC-MS (ESI^+) *m/z* 530.4 $(M+H)^+$.

[003192] **5-14-12-[2-|2-(2-Aminoethoxy)ethoxy| ethoxy] ethyl] piperazin-l-yl 1-2-12,6-dioxo-3- piperidyBisoindoline-l,3-dione [Intermediate NZ)**



NZ

[003193] Step 1 - Tert-butyl N-[2-[2-[2-[2-[4-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-5-yl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]ethyl]carbamate


[003194] A mixture of 2-(2,6-dioxo-3-piperidyl)-5-piperazin-1-yl-isoindoline-1,3-dione (390 mg, 1.03 mmol, HC1, synthesized via Steps 1-2 of Intermediate IB), tert-butyl N-[2-[2-[2-(2-oxoethoxy)ethoxy]ethoxy]ethyl]carbamate (250 mg, 858 umol, Intermediate JX), TEA (86.8 mg, 858 umol) in THF (10 mL) was added HOAc (51.5 mg, 858 umol, 49.0 uL) and $NaBH(OAc)_3$ (363 mg, 1.72 mmol), the mixture was stirred at rt for 72 hrs under N_2 atmosphere. On completion, the mixture was concentrated *in vacuo*. The residue was purified by Pre-HPLC (0.1% FA condition) to give the title compound (220 mg, 41% yield) as yellow solid. LC-MS (ESI^+) *m/z* 618.4 $(M+H)^+$.

[003195] Step 2 - 5-[4-[2-[2-[2-(2-Aminoethoxy)ethoxy]ethoxy]ethyl]piperazin-1-yl]-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione

[003196] To a solution of tert-butyl N-[2-[2-[2-[2-[4-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-5-yl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]ethyl]carbamate (220 mg, 356 umol) in THF (10 mL) was added HCl/dioxane (4 M, 5 mL). The mixture was stirred at rt for 3 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (190 mg, 96% yield) as yellow solid. LC-MS (ESI^+) *m/z* 518.3 $(M+H)^+$.

[003197] **5-[4-[2-[2-[2-Aminoethoxy]ethoxy]ethyl]piperazin-1-yl]-2-[2,6-dioxo-3-**

piperidvBisoindoline-l,3-dione [Intermediate OA)



OA

[003198] Step 1 - Tert-butyl N-[2-[2-[2-[4-[2-(2,6-dioxo-3-piperidvl)-L3-dioxo-isoindolin-5-yl1piperazin-l-vn ethoxy] ethoxy] ethyl] carbamate


[003199] To a solution of 2-(2,6-dioxo-3-piperidyl)-5-piperazin-l-yl-isoindoline-l,3-dione (250 mg, 730 umol, HC1, synthesized via Steps 1-2 of Intermediate IB) and tert-butyl (2-(2-(2-oxoethoxy)ethoxy)ethyl)carbamate (271 mg, 1.10 mmol, Intermediate HY) in THF (20.0 mL) was added KOAc (143 mg, 1.46 mmol) and $NaBH(OAc)_3$ (170 mg, 803 umol). The reaction mixture was stirred at rt for 3 hrs. On completion, the reaction mixture was quenched with water (1.00 mL). The mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (condition: 0.1% FA) to give the title compound (275 mg, 62% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 574.2 $(M+H)^+$.

[003200] Step 2 - 5-r4-r2-r2-(2-Aminoethoxy)ethoxy1ethyl1piperazin-l-yl1-2-(2.6-dioxo-3-piperidvDisoindoline -L3-dione

[003201] To a solution of tert-butyl N-[2-[2-[2-[4-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-5- yl]piperazin-l-yl]ethoxy]ethoxy]ethyl]carbamate (275 mg, 455 umol) in DCM (10.0 mL) was added HCl/dioxane (4.00 M, 7.60 mL). The reaction mixture was stirred at rt for 1 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (232 mg, 99% yield, HC1) as a yellow solid. LC-MS (ESI^+) *m/z* 474.3 $(M+H)^+$.

[003202] [[3R,5S]-5-[[4-[4-[[2-[2-[Cvclopropylmethylamino]-4-pyridyl]oxazole-4-carbonyllaminol- _3-[difluoromethvBpyrazol-l-yl1phenyl1methylcarbamoyl]pyrrolidin-3-yl1

acetate (Intermediate OB)



OB

[003203] Step 1 - Tert-butyl (2S,4R)-4-acetoxy-2-[[4-[4-[[2-[2-[tert-butoxycarbonvKcvclopropylmethvDaminol -4-pyridyl1oxazole-4-carbonyl1amino1-3-(difluoromethvDpyrazol- 1-yllphenyllmethylcarbamoyllpyrrolidine- 1-carboxylate


[003204] To a solution of tert-butyl (2S,4R)-2-[[4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]- 4-pyridyl]oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]phenyl]methylcarbamoyl]-4-hydroxy-pyrrolidine-l-carboxylate (180 mg, 227 umol, synthesized via Steps 1-3 of Intermediate KG) in pyridine (5.00 mL) was added acetyl acetate (545 mg, 5.34 mmol). The reaction mixture was stirred at rt for 12 hrs. On completion, the reaction mixture was concentrated *in vacuo.* The crude product was purified by prep-HPLC (0.1%, HC1) to give the title compound (180 mg, 95% yield) as colorless oil. LC-MS (ESI^+) *m/z* 835.1 $(M+H)^+$.

[003205] Step 2 - [(3R,5S)-5-[[4-[4-[[2-[2-(Cyclopropylmethylamino)-4-pyridyl1oxazole-4-

carbonyllaminol- _ 3-(difluoiOmethvDpyrazol-l-yl1phenyl1methylcarbamoyl1pyrrolidin-3-yl1 acetate

[003206] To a solution of tert-butyl (2S,4R)-4-acetoxy-2-[[4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl) amino]-4-pyridyl]oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]phenyl]methylcarbamoyl]pyrrolidine-l-carboxylate (110 mg, 132 umol) in DCM (3.00 mL) was added HCl/dioxane (4.00 M, 7.33 mL). The reaction mixture was stirred at rt for 1 hr. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (88.4 mg, 100% yield) as a white solid. LC-MS (ESI^+) *m/z* 635.2 $(M+H)^+$.

[003207] **rt3R.5SVl-rt2SV2-Amino-3.3-dimethyl-butanoyll-5-rr4-r4-rr2-r2-(cvclopropyl methylamino) _ -4-pyridyl1oxazole-4-carbonyl1amino1-3-(difluoromethyOpyrazol-l-yllphenyllmethylcarbamoyllpyrrolidin-3-yll _ acetate [Intermediate OO**



[003208] Step 1- [(3R,5S)- 1-r(2S)-2-(Tert-butoxycarbonylamino)-3.3-dimethyl -butanoyll-


5-[[4-[[4-[[2-[[2-(cyclopropylmethylamino)-4-pyridyl]oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]phenyl]methylcarbamoyl]pyrrolidin-3-yl acetate

[003209] To a solution of [(3R,5S)-5-[[4-[4-[[2-[2-(cyclopropylmethylamino)-4-pyridyl]oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]phenyl]methylcarbamoyl]pyrrolidin-3-yl] acetate (88.4 mg, 132 umol, Intermediate OB) and (2S)-2-(tert-butoxycarbonylamino)-3, 3-dimethyl-butanoic acid (36.6 mg, 158 umol, CAS# 62965-35-9) in DMF (3.00 mL) was added DIPEA (85.1 mg, 659 umol), The reaction mixture was stirred at rt for 0.5 hr. After, HATU (60.10 mg, 158.07 umol) was added. The resulting reaction mixture was stirred at rt for 0.5 hr. On completion, the reaction mixture was quenched with water (15.0 mL), and extracted with ethyl acetate (3 X 30 mL). The combined organic layer was washed with brine (20 mL), dried over anhydrous sulfate sodium, filtered and concentrated *in vacuo* to give the title compound (110 mg, 99% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-di) δ 9.07 (s, 1H), 8.74 (s, 1H), 8.30 (s, 1H), 8.17 (d, *J* = 5.2 Hz, 1H), 7.58 (d, *J* = 8.4 Hz, 2H), 7.33 (d, *J* = 8.4 Hz, 2H), 7.24 (s, 1H), 7.13 *(d, J* = 5.2 Hz, 1H), 7.05 - 6.73 (m, 2H), 5.28 (s, 1H), 5.06 (d, *J* = 10.0 Hz, 1H), 4.68 (t, *j* = 7.6 Hz, 1H), 4.51 (dd, *j* = 6.4, 16 Hz, 1H), 4.28 (dd, *j* = 5.2, 14.9 Hz, 1H), 4.11 *(d, J* = 10.0 Hz, 1H), 4.00 - 3.98 (m, 1H), 3.68 - 3.61 (m, 1H), 3.17 (dd, *J* = 5.2, 6.8 Hz, 2H), 2.76 - 2.68 (m, 1H), 1.98 (s, 3H), 1.34 (s, 9H), 1.08 (s, 1H), 0.83 (s, 9H), 0.57 - 0.50 (m, 2H), 0.28 - 0.22 (m, 2H). LC-MS (ESI$^+$) *m/z* 848.3 (M+H)$^+$.

[003210] Step 2 - [(3R,5S)-l-[(2S)-2-Amino-3.3-dimethyl-butanoyl1-5-[[4-[4-[[2-[2-(cvclopropylmethylamino) -4-pyridyl1oxazole-4-carbonyl1amino1-3-(difluoromethyl)pyrazol-l-yl1phenyl1methylcarbamoyl1pyrrolidin-3-yl1 acetate

[003211] To a solution of [(3R,5S)-l-[(2S)-2-(tert-butoxycarbonylamino)-3,3-dimethyl-butanoyl]-5-[[4-[4-[[2-[2-(cyclopropylmethylamino)-4-pyridyl]oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]phenyl]methylcarbamoyl]pyrrolidin-3-yl] acetate (110 mg, 130 umol) in DCM (5.00 mL) was added HCl/dioxane (4.00 M, 5.45 mL). The reaction mixture was stirred at rt for 1 hr. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (100 mg, 98% yield) as a white solid. LC-MS (ESI$^+$) *m/z* 748.2 (M+H)$^+$.

[003212] 3-[5-[4-(4-aminobutoxy)butyll-3-methyl-2-oxo-benzimidazol-l-yllpiperidine-2,6- dione [Intermediate OD1



[003213] Step 1- *Tert*-butyl *N*-[4-([4-[1-(2.6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2.3-dihydro-1*H*-1.3-benzodiazol-5-yl1but-3-yn-1-ylloxyibutyllcarbamate

[003214] To a solution of 3-(5-bromo-3-methyl-2-oxo-2,3-dihydro-l//-1,3-benzodiazol-1-yl)piperidine-2,6-dione (2 g, 6 mmol, Intermediate HN) in DMSO (20 mL) were added *tert*-butyl *N*-[4-(but-3-yn-1-yloxy)butyl]curbamate (4.3 g, 18 mmol, Intermediate OI), $Pd(PPh_3)_4$ (683.4 mg, 0.59 mmol), Cul (225.3 mg, 1.18 mmol) and TEA (10 mL) at rt under nitrogen atmosphere. The resulting mixture was stirred for 16 h at 85 °C under nitrogen atmosphere. The reaction mixture was cooled to rt and concentrated under reduced pressure to remove the TEA. The resulting mixture was diluted with ice/water (50 ml, plus 3 ml AcOH) and extracted with EtOAc (2 x 50 mL). The combined organic layer was washed with brine (30 mL) and dried over anhydrous Na_2SO_4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography with the following conditions: Column: WelFlash ™ C18-1, 20-40 pm, 330 g; Eluent A: Water (plus 10 mmol/LFA); Eluent B: ACN; Gradient: 5% B - 5% B in 10 min; 50% B - 60% B in 25 min; Flow rate: 80 mL/min; Detector: 220/254 nm; desired fractions were collected at 57% B and concentrated under reduced pressure to afford *tert*-butyl A-[4-([4-[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-liT-l,3-benzodiazol-5-

yl]but-3-yn-l-yl]oxy)butyl]carbamate (1.5 g, 51%) as ayellow solid. ¾NMR (400 MHz, DMSO-*de)* δ 11.12 (s, 1H), 7.24 (s, 1H), 7.10 (s, 2H), 6.79 (s, 1H), 5.41-5.34 (m, 1H), 3.55 (t, *J* = 6.8 Hz, 2H), 3.44 (t, *J* = 6.3 Hz, 2H), 3.32 (s, 3H), 2.96-2.88 (m, 3H), 2.71-2.65 (m, 4H), 2.11-2.00 (m, 1H), 1.49 (s, 2H), 1.48-1.40 (m, 2H), 1.37 (s, 9H); LC/MS (ESI, *m/z):* [M - 1]⁻ = 497.2.

[003215] Step 2 - ///V-butyl A'-(4-[4-П-(2.6-dioxopiperidin-3-yl)-3-methyl -2-oxo-2. 3-dihydro- 1/7-1 .3-benzodiazol-5-yl1butoxy1butyl icarbamate


[003216] To a solution of *tert*-butyl /V-[4-([4-[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro- 1/7-1,3-benzodiazol-5-yl]but-3-yn-l-yl]oxy)butyl]carbamate (1.5 g, 3.01 mmol) in THF (50 mL) was added palladium on charcoal (0.15 g, 10% w/w) under nitrogen atmosphere. The mixture was hydrogenated at rt for 4 h using a hydrogen balloon. The resulting mixture was filtered through a celite pad and concentrated under reduced pressure to afford *tert*-butyl *N*-{4-[4-[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-l/7-l,3-benzodiazol-5-yl]butoxy]butyl)carbamate (1.2 g, 79%) as a white solid. ^{1}H NMR (400 MHz, CDCh) *S* 8.12 (br s, 1H), 6.94-6.89 (m, 1H), 6.87 (d, *J* = 1.5 Hz, 1H), 6.73 (d, *J* = 8.0 Hz, 1H), 5.23 (dd, *J* = 12.5, 5.4 Hz, 1H), 4.73-4.60 (m, 1H), 3.49-3.36 (m, 7H), 3.15 (d, *J* = 6.1 Hz, 2H), 2.97 (d, *J* = 16.7 Hz, 1H), 2.87 (dd, *J* = 13.3, 5.0 Hz, 1H), 2.70 (t, *j* = 7.6 Hz, 2H), 2.32-2.19 (m, 1H), 1.76-1.50 (m, 9H), 1.46 (s, 9H); LC/MS (ESI, *m/z):* [M + l]$^+$ = 503.4.

[003217] Step 3 - 3-r5-r4-('4-Aminobutoxy)butyl1-3-methyl-2-oxo-2.3-dihydro- 1*H*- 1**3**-benzodiazol- 1-yl]piperi dine-2.6-di one hydrochloride

[003218] A solution of *tert*-butyl A-(4-[4-[l-(2, 6-dioxopi peri din-3 -yl)-3 -methyl -2-oxo-2, 3-dihydro- 1/7-1,3-benzodiazol-5-yl]butoxy]butyl)carbamate (150 mg, 0.29 mmol) in dioxane (2 mL) was treated with a solution of HC1 (gas) in l,4-dioxane (4 M, 2 mL) for 16 h at rt under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure to afford 3-[5-[4-(4-aminobutoxy)butyl]-3-methyl-2-oxo-2,3-dihydro-l/7-l,3-benzodiazol-l-yl]piperidine-2,6-dione hydrochloride (100 mg, 77%) as a light yellow solid. ¾ NMR (400 MHz, DMSO-r/,) *δ* 11.08 (s, 1H), 7.86 (br s, 3H), 7.05-6.98 (m, 2H), 6.87 (d, *j* = 8.0 Hz, 1H), 5.35 (dd, *J* = 12.7, 5.3 Hz, 1H), 3.74-3.63 (m, 1H), 3.57 (s, 1H), 3.49 (dd, *J* = 11.6, 4.4 Hz, 1H), 3.42-3.33 (m, 4H), 2.97-2.85 (m, 1H), 2.82-2.59 (m, 6H), 2.06-1.96 (m, 1H), 1.67-1.48 (m, 8H); LC/MS (ESI, *m/z):* [(M + l)] $^+$ = 403.2.


[003219] **(S)-7-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)-2- ((S)-2-(2-methoxyacetamido) -3,3-dimethylbutanoyO-N-((R)-l.,2.,3.,4-tetrahydr(maphthalen-l-yO-**

l,2,3.,4-tetrahvdroisoquinoline-3-carboxamide [Intermediate OE)



[003220] (S)-7-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethoxy)-2-((S)-2-(2-methoxyacetamido) -3,3-dimethylbutanoyl)-N-((R)- 1,2,3,4-tetrahydronaphthalen- 1-yl)- 1,2,3,4-tetrahydroisoquinoline-3-carboxamide was synthesized as described for Intermediate LY, using 2,2-dimethyl-4-oxo-3,8,ll,l4,l7,20-hexaoxa-5-azadocosan-22-yl 4-methylbenzenesulfonate, Intermediate 00, as the tosylate in Step 1 to couple with alcohol Intermediate MH. 'H NMR (400 MHz, DMSO-i/e) δ 8.37 (br. s., 1 H), 8.17 - 8.23 (m, 1 H), 7.30-7.46 (m, 1 H), 6.77 - 7.14 (m, 7 H), 4.63-5.11 (m, 5H), 4.03 - 4.10 (m, 2 H), 3.70 - 3.92 (m, 4 H), 3.40 - 3.63 (m, 18 H), 3.28 - 3.35 (m, 3 H), 2.91 - 3.08 (m, 2 H), 2.78 - 2.88 (m, 2 H), 2.61 - 2.76 (m, 2 H), 1.52-1.88 (m, 4 H), 0.84-1.04 (m, 9 H). LC-MS (ESI^+): m/z 771.2 $(M+H)^+$.

[003221] 2,2-dimethyl-4-oxo-3,8,ll,14,17,20,23-heptaoxa-5-azapentacosan-25-oic acid [Intermediate OF]



OF

[003222] Step 1 - 2-(17-hydroxy-3,6,9,12,15-pentaoxaheptadecyl)isoindoline-1,3-dione

[003223] To a stirred solution of 3,6,9,12,15-pentaoxaheptadecane-1,17-diol (10 g, 35.4 mmol, CAS# 2615-15-8) in THF (200 ml) was added phtalimide (6.253 g, 42.51 mmol), and PPh_3 (12.06 g, 46.02 mmol) at room temperature. The reaction mixture was degassed and purged with nitrogen several times. The reaction mixture was cooled to 0 °C then DEAD (8.02 g, 46.02 mmol) was added dropwise to the reaction mixture at 0 °C. After the addition, the mixture was stirred at room temperature for 12 h. The mixture was concentrated *in vacuo* and the residue was purified via column chromatography (DCM / MeOH = 0% - 10%) to give the desired compound (6.4 g, 44.0 %) as a colorless oil. ^{1}HNMR (400 MHz, DMSO-d) δ 7.93 - 7.81 (m, 4H), 4.57 (t, J = 5.5 Hz, 1H), 3.75 (t, J = 5.8 Hz, 2H), 3.63 (t, J = 5.8 Hz, 2H), 3.54 - 3.48 (m, 7H), 3.46 (ddd, J = 7.0, 4.7, 1.9 Hz, 7H), 3.43 - 3.38 (m, 6H).

[003224] Step 2 - tert-butyl 20-(1,3-dioxoisoindolin-2-yl)-3,6,9,12,15,18-hexaoxaicosan-1-oate

[003225] To a solution of 2-(17-hydroxy-3,6,9,12,15-pentaoxaheptadecyl)isoindoline-1,3-dione (7.0 g, 17.03 mmol) in THF (200 mL) was added 60% NaH (885.6 mg, 22.14 mmol) at 0 °C. After stirring for 0.5 h at 0 °C, tert-butyl 2-bromoacetate (4.65 g, 23.84 mmol) was added

dropwise to the reaction mixture at 0 °C. The reaction mixture was stirred at 0 °C for 2hrs, then warmed to rt with stirring on for another 2 hrs. The reaction mixture was quenched with water at 0 °C, and extracted with EtOAc (100 mL x 2). The combined organic layer was washed with brine (50 mL x 3), dried over anhydrous Na_2S0_4, filtered, and concentrated *in vacuo.* The residue was purified by column chromatography (DCM/MeOH = 0%-l0%) to give the desired compound (4.5 g, 50.3 %) as a pale yellow solid. LC-MS (ESI^+): m/z 526.3 $(M+H)^+$.


[003226] Step 3 - 20-(T,3-dioxoisoindolin-2-vl)-3,6,9,12,15,l8-hexaoxaicosan-l-oic acid

[003227] To a solution of tert-butyl 20-(l,3-dioxoisoindolin-2-yl)-3,6,9,l2,l5,l8-hexaoxaicosan-l-oate (4.5 g, 8.571 mmol) in DCM (100 mL) was added TFA (50 mL) at rt. The reaction mixture was stirred at rt for 2 hs, then concentrated *in vacuo* to give the desired compound (3.5 g, 87.1 %) as a yellow solid. LC-MS (ESI^+): m/z 470.2 $(M+H)^+$.

[003228] Step 4: 2.2-dimethyl-4-oxo-3.8.ll.l4.l7.20.23-heptaoxa-5-azapentacosan-25-oic acid

[003229] To a solution of 20-(l,3-dioxoisoindolin-2-yl)-3,6,9,l2,l5,l8-hexaoxaicosan-l-oic acid (3.5 g, 7.463 mmol) in EtOH (50 mL) was added hydrazinium (716.8 mg, 22.4 mmol, 99 %) at r.t.. The reaction mixture was heated to reflux for 3 hs. A white solid formed, then the reaction mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was dissolved in CH_3CN (100 mL). $(Boc)_20$ (9.8 g, 44.8 mmol) was added to the reaction mixture at rt and the mixture was stirred at room temperature for 2 hr. The reaction mixture was then concentrated *in vacuo* to give a residue which was purified by column chromatography (DCM/MeOH = 0%-l0%) to give the desired compound (1.4 g, 42.7 %) as a colorless oil. LC-MS (ESI^+): m/z 440.5 $(M+H)^+$.

[003230] **Tert-butyl N-[3-[2,2-dimethyl-3-fprop-2-yn-l-yloxylpropoxy] propyl]carbamate [Intermediate OG)**



[003231] Step **1** - 2-[3-(3-Hydroxy-2. 2-dim ethyl propoxyipropyl 1-2.3-dihvdro- 1*H*-isoindole-L3-dione

[003232] To a solution of 2,2-dimethylpropane-l,3-diol (38.8 g, 373 mmol, CAS# 126-30-7) in DMF (400 mL) was added sodium hydride (60% dispersion in mineral oil, 15.0 g, 375 mmol) at 0 °C. The mixture was stirred for 15 min at the same temperature. Then a solution of 2-(3-bromopropyl)-2,3-dihydro-li#-isoindole-l,3-dione (50 g, 187 mmol, CAS# 5460-29-7) in DMF (50 mL) was added dropwise and the mixture was allowed to warm to room temperature and stirred for 16 hours. The reaction was quenched by the addition of a solution of HOAc (60 g) in water (1 L) at rt. The resulting mixture was extracted with EtOAc (3 x 500 mL). The combined organic layer was washed with brine (500 mL) and dried over anhydrous Na_2S0_4, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 50% ethyl acetate in petroleum ether to afford 2-[3-(3-hydroxy-2, 2-dimethyl propoxy)propyl]-2, 3-dihydro- 1//-isoindole-1 ,3-dione (7.4 g, 11%) as a light yellow solid. ^1H NMR (400 MHz, CDCh) δ 7.81 (dd, *J* = 5.5, 3.1 Hz, 2H), 7.69 (dd, *J* = 5.5, 3.1 Hz, 2H), 3.77 (t, *J* = 6.6 Hz, 2H), 3.44-3.37 (m, 4H), 3.20 (s, 2H), 1.92 (p, *J* = 6.2 Hz, 2H), 0.86 (s, 6H); LC/MS (ESI, *m/z):* [(M + l8)] $^+$ = 292.30.

[003233] Step 2 - Tert-butyl A-[3-(3-hydroxy-2,2-dimethylpropoxy)propyllcarbamate


[003234] To a stirred solution of2-[3-(3-hydroxy-2,2-dimethylpropoxy)propyl]-2,3-dihydro-l#7-isoindole-l,3-dione (6.1 g, 20.9 mmol) in EtOH (400 mL) was added hydrazine hydrate (2.1 g, 41.9 mmol, 98%) at rt under nitrogen atmosphere. The resulting solution was stirred for 2 h at 70 °C. The mixture was cooled down to room temperature. To the above mixture was added di-*tert*-butyl dicarbonate (27.4 g, 125.6 mmol) at rt and the resulting mixture was stirred for additional 16 hours at rt. After filtration, the filter cake was washed with EtOH (50 mL) and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 25% ethyl acetate in petroleum ether, to afford *tert*-butyl A-[3-(3-hydroxy-2,2-dimethylpropoxy)propyl]carbamate (5.6 g, 82%) as a light yellow oil. ^{1}HNMR (400 MHz, CDCh) δ 5.00 (br s, 1H), 3.45 (td, *J* = 5.8, 1.3 Hz, 2H), 3.40 (t, *J* = 2.0 Hz, 2H), 3.25-3.14 (m, 4H), 1.71 (p, *j* = 6.6, 6.1 Hz, 2H), 1.41 (s, 9H), 0.87 (s, 6H); LC/MS (ESI, *m/z):* [(M - 100 + l)] $^+$ = 162.35.

[003235] Step 3 - Tert-butyl A-[3-[2,2-dimethyl-3-(prop-2-yn-l-yloxyipropoxylpropyllcarbamate

[003236] To a solution of *tert*-butyl A-[3-(3-hydroxy-2, 2-dimethylpropoxy)propyl]carbamate (5.6 g, 21.4 mmol) in DMF (60 mL) was added sodium


hydride (60% dispersion in mineral oil, 1.7 g, 42.5 mmol) at 0 °C. The mixture was stirred for 15 min at the same temperature. Then a solution of 3-bromoprop-l-yne (2.5 g, 21.43 mmol) in DMF (20 mL) was added dropwise and the mixture was allowed to warm to rt and stirred for 16 hours. The reaction was quenched by the addition of saturated aqueous NH_4Cl (300 mL) at room temperature. The resulting mixture was diluted with water (200 mL) and extracted with EtOAc (3 x 200 mL). The combined organic layers was washed with brine (500 mL) and dried over anhydrous Na_2S0_4, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 10% ethyl acetate in petroleum ether, to afford *tert*-butyl /V-[3-[2,2-dimethyl-3-(prop-2-yn-l-yloxy)propoxy]propyl]carbamate (2.9 g, 45%) as a light yellow oil: ¾NMR (400 MHz, DMSO-^e) *S* 6.71 (t, *J* = 5.7 Hz, 1H), 4.10 (d, *J* = 2.4 Hz, 2H), 3.41-3.31 (m, 3H), 3.20 (s, 2H), 3.10 (s, 2H), 2.98 (q, *J* = 6.6 Hz, 2H), 1.61 (p, *j* = 6.6 Hz, 2H), 1.38 (s, 9H), 0.84 (s, 6H); LC/MS (ESI, *m/z):* $[(M + l)]^+$ = 300.20.

[003237] ***Tert-butyl*/V-[3-(prop-2-vn-l-yloxy)propyl]carbamate [Intermediate OH)**



[003238] A solution of /ert-butyl *A*-(3-hydroxypropyl)carbamate (1 g, 6 mmol, CAS# 58885-58-8) in THF (40 mL) was treated with NaH (60% dispersion in mineral oil, 0.3 g, 14 mmol) for 30 min at 0 °C under nitrogen atmosphere. Next, a solution of 3-bromoprop-l-yne (0.7 g, 6.28 mmol) in THF (5 mL) was added dropwise at 0 °C. The resulting mixture was stirred for 16 h at rt. The reaction was quenched with saturated aqueous NH4HCO3 (100 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layer was washed with brine (50 mL) and dried over anhydrous Na_2S0_4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 5%-20% ethyl acetate in petroleum ether, to afford /ert-butyl /V-[3-(prop-2-yn-l-yloxy)propyl]carbamate (0.6 g, 49%) as a yellow oil: ^1H NMR (400 MHz, DMSO-^e) *S* 6.77 (t, *j* = 5.7 Hz, 1H), 4.10 (t, *j* = 2.0 Hz, 2H), 3.44-3.39 (m, 3H), 2.99-2.91 (m, 2H), 1.64-1.59 (m, 2H), 1.38 (s, 9H); LC/MS (ESI, *m/z):* $[(M - l)]^-$ = 212.2.

[003239] **Tert-butyl/V-[4-(but-3-yn-l-yloxy)butyl]carbamate [Intermediate OI)**



OI

[003240] Step 1 - 4-(4-Bromobutoxy)but-l-yne

[003241] To a stirred solution of l,4-dibromobutane (201 g, 933 mmol) in acetone (1 L) were added CS2CO3 (223 g, 685 mmol) and but-3-yn-l-ol (43.6 g, 622.05 mmol) at rt. The resulting mixture was stirred for 16 h at rt under nitrogen atmosphere. After filtration, the filter cake was washed with acetone (2 x 50 mL). The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 1% ethyl acetate in petroleum ether to afford 4-(4-bromobutoxy)but-l-yne (29 g, 23%) as a light yellow oil. 'H NMR (400 MHz, CDCh) δ 3.54 (t, *J* = 6.9 Hz, 2H), 3.49 (t, *j* = 6.2 Hz, 2H), 3.44 (t, *J* = 6.6 Hz, 2H), 2.45 (td, *J* = 7.0, 2.6 Hz, 2H), 2.02-1.88 (m, 3H), 1.80-1.65 (m, 2H).

[003242] Step 2 - 4-(4-Azidobutoxy)but-l-yne

[003243] A mixture of 4-(4-bromobutoxy)but-l-yne (29 g, 141 mmol) and NaN3 (14 g, 212 mmol) in DMSO (300 mL) was stirred for 4 h at rt under nitrogen atmosphere. The resulting mixture was diluted with ice water (1 L) and extracted with petroleum ether/EtOAc (5/1, v/v, 2 x 500 mL). The combined organic layers was washed with brine (500 mL) and dried over anhydrous Na_2S0_4. After filtration, the filtrate was concentrated under reduced pressure to afford 4-(4-azidobutoxy)but-l-yne (22.2 g, 94%) as a light yellow oil: 'H NMR (400 MHz, CDCb) δ 3.53 (td, *J* = 6.9, 1.6 Hz, 2H), 3.47 (td, 7 = 6.0, 1.7 Hz, 2H), 3.29 (t, *J* = 6.2 Hz, 2H), 2.44 (tt, *J* = 7.0, 2.2 Hz, 2H), 1.97 (t, *J* = 2.7 Hz, 1H), 1.73-1.57 (m, 4H); LC/MS (ESI, *m/z):* $[(2M + l)]^+$ = 335.25.

[003244] Step 3 - 4-(But-3-vn-l-yloxy)butan-l-amine


[003245] A solution of 4-(4-azidobutoxy)but-l-yne (22.2 g, 132.8 mmol) and PtuP (52.2 g, 199.2 mmol) in THF (400 mL) and H_20 (80 mL) was stirred for 4 h at 50 °C under nitrogen atmosphere. The resulting mixture was cooled and concentrated under reduced pressure to remove THF. The residue was acidified to pH = 1 with 4 M aqueous HC1. The resulting mixture was extracted with EtOAc (2 x 500 mL). The water layer was neutralized to pH = 7 with 2 M aqueous NaOH, and extracted with DCM (2 x 500 mL). The combined organic layers was washed with

brine (500 mL) and dried over anhydrous Na_2SO_4. After filtration, the filtrate was concentrated under reduced pressure to afford crude product (18 g). LC/MS (ESI, *m/z)*: $[(M + l)]^+ = 142.1$.

[003246] Step 4 - 7gr/-butyl A-r4-(but-3-vn-l-yloxy)butyl1carbamate

[003247] To a stirred solution of 4-(but-3-yn-l-yloxy)butan-l -amine (18 g, 127.5 mmol) in DCM (500 mL) and H_20 (500 mL) were added NaHCCL (21.4 g, 254.9 mmol) and Boc_20 (33.4 g, 152.9 mmol) at rt. The resulting mixture was stirred for 16 h at rt under nitrogen atmosphere. The resulting mixture was extracted with CH_2Cl_2 (2 x 500 mL). The combined organic layers was washed with brine (500 mL) and dried over anhydrous Na_2SO_4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 20% ethyl acetate in petroleum ether to afford *tert*-butyl /V-[4-(but-3-yn-l-yloxy)butyl]carbamate (30 g, 98%) as a light yellow oil. ^{1}H NMR (400 MHz, CDCh) δ 4.67 (s, 1H), 3.54 (td, *J* = 6.9, 3.6 Hz, 2H), 3.51-3.42 (m, 2H), 3.13 (q, *J* = 5.6, 4.7 Hz, 2H), 2.45 (dh, *j* = 7.2, 4.0, 3.5 Hz, 2H), 1.98 (q, *j* = 2.8 Hz, 1H), 1.58 (td, *j* = 8.7, 7.7, 4.4 Hz, 4H), 1.42 (s, 9H); LC/MS (ESI, *m/z):* $[(M + l)]^+ = 242.3$.

[003248] ***te/t*-butyl /V-|3-|3-(prop-2-yn-l-yloxyipropoxyIpropyl lcarbamate [Intermediate OJ)**



OJ

[003249] Step 1 - ferf-butyl iV-r3-(methanesulfonyloxy)propyl1 carbamate

[003250] To a stirred solution of *tert*-butyl A-(3-hydroxypropyl)carbamate (92.6 g, 528.4 mmol, CAS# 58885-58-8) in DCM (800 mL) were added TEA (80.2 g, 792.7 mmol) and a solution of MsCl (60.5 g, 528.5 mmol) in DCM (200 mL) dropwise at 0 °C over 30 min under nitrogen atmosphere. The resulting mixture was stirred for 30 min at rt under nitrogen atmosphere. The resulting mixture was diluted with water (2 L) and extracted with CH_2Cl_2 (3 x 800 mL). The combined organic layers was washed with brine (1 L) and dried over anhydrous Na_2SO_4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 40% ethyl acetate in petroleum ether to afford *tert*-butyl /V-[3-(methanesulfonyloxy)propyl]carbamate (112 g, 84%) as a light brown solid. ^{1}H NMR (400

MHz, CDCh) δ 4.91 (br s, 1H), 4.24 (td, J = 6.9, 6.4, 2.9 Hz, 2H), 3.21 (d, J = 7.9 Hz, 2H), 3.06-2.92 (m, 3H), 1.89 (pd, J = 6.3, 2.6 Hz, 2H), 1.39 (d, J = 3.0 Hz, 9H).

[003251] Step 2 - *tert*-butyl *N*-r3-(3-hvdroxypropoxy)propyl1carbamate


[003252] To a solution of propane-l,3-diol (50 g, 657 mmol) in DMF (500 mL) was added sodium hydride (4.79 g, 200 mmol, 60% dispersed in mineral oil) at 0 °C. The mixture was stirred for 15 min at rt. To the above mixture was added a solution of *tert*-butyl A-[3-(methanesulfonyloxy)propyl]carbamate (25.3 g, 100 mmol) in DMF (150 mL) dropwise rt and the mixture was stirred for 16 hours at rt. The reaction was quenched with sat. NH_4Cl (200 mL) at 0 °C. The resulting mixture was concentrated under reduced pressure. The residue was diluted with brine (1.5 L) and extracted with EtOAc (3 x 500 mL). The combined organic layers was washed with brine (500 mL) and dried over anhydrous Na_2S0_4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 30% ethyl acetate in petroleum ether to afford *tert*-butyl A-[3-(3-hydroxypropoxy)propyl]carbamate (13.7 g, 59%) as a light yellow oil. ^{1}H NMR (400 MHz, CDCh) δ 4.11 (s, 1H), 3.57 (td, J = 6.3, 1.9 Hz, 2H), 3.50-3.42 (m, 4H), 3.19 (q, J = 6.5 Hz, 2H), 1.88-1.78 (m, 2H), 1.71 (p, J = 6.5 Hz, 2H), 1.41 (s, 9H); LC/MS (ESI, *m/z):* $[(M + l)]^+$ = 234.15.

[003253] Step 3 - *tert*-butyl Λ'-[3-[3-(ρΓορ-2-νη-1-yloxyipropoxylpropyllcarbamate

[003254] To a solution of *tert*-butyl /V-[3-(3-hydroxypropoxy)propyl]carbamate (12.5 g, 53.6 mmol) in THF (300 mL) was added sodium hydride (2.6 g, 108.3 mmol, 60% dispersion in mineral oil) at 0 °C. The mixture was stirred for 15 min. To the mixture was added a solution of 3-bromoprop-l-yne (6.4 g, 53.8 mmol) in THF (50 mL) dropwise and the mixture was warmed to rt and stirred for 16 hours. The reaction was quenched with sat. NH_4Cl (200 mL) at 0 °C, diluted with brine (500 mL) and extracted with EtOAc (3 x 300 mL). The combined organic layers was washed with brine (500 mL) and dried over anhydrous Na_2S0_4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 25% ethyl acetate in petroleum ether to afford *tert*-butyl A-[3-[3-(prop-2-yn-l-yloxy)propoxy]propyl]carbamate (9.2 g, 60%) as a light yellow solid. ^{1}H NMR (400 MHz, CDCh) δ 4.90 (br s, 1H), 4.11 (d, J = 2.4 Hz, 2H), 3.57 (t, j = 6.3 Hz, 2H), 3.50-3.40 (m, 4H), 3.18 (t, J = 7.2 Hz, 2H), 2.42 (t, J = 2.4 Hz, 1H), 1.83 (p, J = 6.2 Hz, 2H), 1.71 (p, J = 6.2 Hz, 2H), 1.41 (s, 9H).


[003255] **4-[2-[2-[2-aminoethoxy]ethoxy1ethylamino1-2-[2,6-dioxo-3-**

piperidynisoindoline-l,3-dione [Intermediate OK)




[003256] 4-[2-[2-(2-aminoethoxy)ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione was synthesized as described in Steps 1-2 of Example 127.

[003257] **2-[2-[2-[2-[[2-(2,6- dioxo-3-piperidvP-l.,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethoxy]acetic acid [Intermediate OL)**



[003258] 2-[2-[2-[2-[[2-(2,6- dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethoxy]acetic acid was synthesized via Steps 1-2 of Example 152.


[003259] **2-[2-[tert-butoxycarbonvUcvclopropylmethvPaminol-4-pyridylloxazole-4-carboxylic acid [Intermediate OM)**



OM

[003260] 2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid was synthesized via Steps 1-4 of Intermediate DF.

[003261] **2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-yl 4-methylbenzenesulfonate [Intermediate ON]**



ON

[003262] Step 1 - 3,6,9,l2-tetraoxatetradecane-E !4-diyl bis(4-methylbenzenesulfonate)

[003263] To a mixture of 3,6,9,l2-tetraoxatetradecane-l,l4-diol (10 g, 42 mmol, CAS# 75506-78-4) and TsCl (17.56 g,92.4 mmol) in DCM(200 ml) was added TEA (17 g, 168 mmol) dropwise at rt and the mixture was stirred at rt overnight. Then the reaction mixture was concentrated *in vacuo*, the residue was dissolved in EtOAc (100 ml) and washed with water (100 ml x 2), brine (100 ml), dried with Na_2S0_4, and filtered. The organic phase was evaporated and

the residue was purified by silica gel chromatography (PE: EA = 1:1) to give the title compound (19.17 g, 83.35 yield) as a yellow solid LC-MS (ESI^+): m/z 547.1 $(M+H)^+$.


[003264] Step 2 - 3.6.9. 12-tetraoxatetradecane- 1. 14-di yl bis(4-methylbenzenesulfonate)

[003265] To a solution of 3,6,9, 12-tetraoxatetradecane- 1,1 4-di yl bis(4-methylbenzenesulfonate) (19.17 g, 35.1 mmol) in DMF (100 ml) was added NaN_3(2.5l g, 38.62 mmol). The mixture was stirred rt for 2 days. The mixture was poured into water (300 ml) and extracted with EtOAc (3 x 300 ml). The combined organic layers were washed with water (300 ml x 3) and brine (300 ml), dried with Na_2S0_4, and filtered. The organic phase was evaporated and the residue was purified by silica gel chromatography (PE: EA) to give the title compound as a colorless oil (6.5 g, 44% yield). LC-MS (ESI^+): m/z 418.2 $(M+H)^+$.

[003266] Step 3 - 2.2-dimethyl-4-oxo-3.8.lEl4.l7-pentaoxa-5-azanonadecan-l9-yl 4-methylbenzenesulfonate

[003267] Amixture of l4-azido-3,6,9,l2-tetraoxatetradecyl 4-methylbenzenesulfonate (10 g, 20.4 mmol), Pd/C (20 %, 1 g), $(Boc)_20$ (6.7 g, 30.6 mmol) and MeOH (200 mL) was stirred for overnight at rt under H_2. The mixture was filtered and concentrated *in vacuo*. To the mixture was added H_20 (200 mL) then it was extracted with EA (300 mL). The organic layer was concentrated and purified by column chromatography (PE/EA = 2/1 to 1/1 to EA) to give 2,2-dimethyl-4-oxo-3.8.11.14.17-pentaoxa-5-azanonadecan-l9-yl 4-methylbenzenesulfonate (8.2 g, 69 % yield) as a yellow oil. ^1H NMR (400 MHz, CDCh) δ 7.81-7.79 (d, J = 8 Hz, 2H), 7.35-7.33 (d, J = 8 Hz, 2H), 4.17-4.13 (t, J = 4.8 Hz, 2H), 3.70-3.47 (m, 16H), 3.31-3.29 (t, J = 5.2 Hz, 2H), 2.45 (s, 3H), 1.44 (s, 9H). LC-MS (ESI^+): m/z 492.7 $(M+H)^+$.

[003268] 2,2-dimethyl-4-oxo-3,8,H.,14,17,20-hexaoxa-5-azadocosan-22-yl 4-methylbenzenesulfonate [Intermediate OO)



0 0

[003269] Step 1- tert-butyl tert-butyl (17-hydroxy-3 ,6,9,12,15-


pentaoxaheptadecvDcarbamate

[003270] To a stirred solution of l7-amino-3,6,9,l2,l5-pentaoxaheptadecan-l-ol (4.0 g, 14.22 mmol, CAS# 39160-70-8) in THF (50 mL) was added $(Boc)_20$ (3.72 g, 17.06 mmol) and NaHCCh (saturated solution, 2 mL) at rt. The reaction mixture was stirred at rt for 3 h. The mixture was concentrated *in vacuo* and the residue was purified by column to give the desired compound (4.96 g, yield, 73%) as a yellow oil. LC-MS (ESI^+): m/z 382.43 $(M+H)^+$.

[003271] Step_2_-_2.2-dimethyl-4-oxo-3.8.lLl4.l7.20-hexaoxa-5-azadocosan-22-yl_4-methylbenzenesulfonate

[003272] To a stirred solution of tert-butyl (l7-hydroxy-3,6,9,l2,l5-pentaoxaheptadecyl)carbamate (2.0 g, 5.25 mmol) in DCM (10 mL) was added TEA (1.06 g, 10.5 mmol) at rt. To the above reaction mixture was added dropwise TsCl (2.0 g, 10.5 mmol) in DCM (5 mL) at 0 °C. After the addition, the reaction was stirred at rt overnight. The mixture was concentrated *in vacuo* and the residue was purified via column chromatography (Petroleum ether/EtOAc = 5% - 80%) to give the desired compound (1.85 g, 66 %) as a yellow oil. LC-MS (ESI^+): m/z 536.50 $(M+H)^+$.

[003273] N-[4-piperazin-l-ylcvclohexyB-5-tetrahvdropyran-4-yl-pyrrolo[2,l-f][l,2,4]triazin-4-amine [Intermediate_OP]



[003274] Step 1 - Tert-butyl 4-(trans-4-(((benzyloxy)carbonvnamino)cvclohexynpiperazine-l-carboxylate (3)

[003275] The reaction was performed in parallel for two batches: to a solution of tert-butyl piperazine- l-carboxylate (24.0 g, 129 mmol) in DCM (400 mL) was added benzyl N-(4-oxocyclohexyl)carbamate (31.9 g, 129 mmol, CAS#l680l-63-l), HOAc (3.15 g, 52.5 mmo) and $NaBH(OAc)_3$ (81.9 g, 387 mmol) successively at 0-10 °C, and the mixture was stirred at 15 °C for 16 hours under N_2. On completion, the mixture of two bathces was combined, basified to pH = 8 with sat.aq.$NaHC0_3$, and partitioned. The aqueous phase was extracted with DCM (2 X 200 mL). The combined organic layer was washed with brine (300 mL), dried over Na_2S0_4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC (column: Phenomenex Gemini C18 250*50mm*l0 um;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 50%-75%,26MIN,40%min) to give two fractions. The first fraction is the title compound (20.0 g, 18%

yield) as white solid. ^{1}H NMR (400MHz, CDCh) δ ppm 7.46-7.29 (m, 5H), 5.09 (s, 2H), 4.57 (s, 1H), 3.43 (m, 5H), 2.50 (m, 4H), 2.28 (m, 1H), 2.10 (d, *J* = 12.0 Hz, 2H), 1.90 (d, *J* = 11.6 Hz, 2H), 1.46 (s, 9H), 1.40-1.27 (m, 2 H), 1.22-1.08 (m, 2H). The second fraction is undesired cis-isomer (12.7 g, 11% yield).

[003276] Step 2 - Tert-butyl 4-(trans-4-aminocvclohexynpiperazine-l-carboxylate (4)

[003277] A mixture of tert-butyl 4-[4-(benzyloxycarbonylamino)cyclohexyl]piperazine-l-carboxylate (8.00 g, 16.4 mmol) and Pd/C (800 mg, 10% purity) in MeOH (80 mL) was stirred at 25°C for 2 hours under H_2 (15 Psi). On completion, the mixture was filtered, and the cake was washed with MeOH (50 mL). The filtrate and washings were combined and concentrated in vacuum to give the title compound (5.3 g, crude) as white solid. ^{1}H NMR (400 MHz, CDCb) δ ppm 3.49-3.21 (m, 4H), 2.64-2.58 (m, 1H), 2.54 (m, 4H), 2.31-2.20 (m, 1H), 1.88 (t, *j* = 15.2 Hz, 4H), 1.45 (s, 9H), 1.34-1.22 (m, 2H), 1.17-1.05 (m, 2H).

[003278] Step 3 - Tert-butyl 4-r4-rt5-bromopyrrolor2J -f][l.2.41triazin-4-vDaminolcvclohexyllpiperazine-l- carboxylate (6)

[003279] 5-bromo-4-chloro-pyrrolo[2,l-f][l,2,4]triazine (250 mg, 1.08 mmol, CAS#l403767-33-8), DIPEA (555 mg, 4.30 mmol) and tert-butyl 4-(4-aminocyclohexyl)piperazine-l -carboxylate (350 mg, 1.23 mmol) were suspended in IPA (5 mL) under nitrogen and sealed into a microwave tube. The resulting suspension was heated to 150 °C for 3 hours under microwave irradiation. On completed, the mixture was concentrated in *vacuo*. The crude product was triturated with methanol (5 mL) to give the title compound (300 mg, 58% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-i¾) δ 7.92 (s, 1H), 7.72 (d, *j* = 2.8 Hz, 1H), 6.80 (d, *J* = 2.8 Hz, 1H), 6.61 (d, *J* = 6.8 Hz, 1H), 4.08 - 4.00 (m, 1H), 3.32 - 3.20 (m, 4H), 2.93 - 2.91 (m, 1H), 2.45 - 2.41 (m, 2H), 2.11 - 2.07 (m, 2H), 1.84 - 1.80 (m, 1H), 1.57 - 1.16 (m, 16H); LC-MS (ESI$^+$) *m/z* 481.2 & 479.2 (M+H)$^+$.

[003280] Step 4 - Tert-butyl 4-r4-rr5-(3.6-dihvdro-2H-pyran-4-yl)ρ\rτo|o[2.1-flfl .2.41triazin-4-yl1amino1 cvclohexyllpiperazine-l -carboxylate (8)

[003281] A mixture of tert-butyl 4-[4-[(5-bromopyrrolo[2,l-f][l,2,4]triazin-4-yl)amino]cyclohexyl]piperazine- l-carboxylate (300 mg, 625 umol), 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-l,3,2- dioxaborolane (394 mg, 1.88 mmol, CAS#287944-l6-5), Brettphos-Pd-G3 (56.7 mg, 62.5 umol) and K2CO3 (173 mg, 1.25 mmol) in a mixed solvent of THF (20 mL) and $H_2$0 (4 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at

55 °C for 12 hrs under N_2 atmosphere. On completion, the reaction mixture was concentrated in *vacuo*. The residue was washed with water (60 mL), extracted with ethyl acetate (3 X 50 mL). The organic layer was dried with Na_2SO_4, filtrated and concentrated in *vacuo*. The crude product was purified by reversed-phase HPLC (0.1% FA condition) to give the title compound (220 mg, 73% yield) as yellow oil. ¾NMR (400MHz, DMSO-^e) δ 7.89 (s, 1H), 7.62 (d, *J* = 2.8 Hz, 1H), 6.66 *(d, J* = 2.8 Hz, 1H), 6.20 (d, *J* = 8.0 Hz, 1H), 5.82 (s, 1H), 4.22 - 4.19 (m, 2H), 3.98 - 3.94 (m, 1H), 3.84 (t, *J* = 5.2 Hz, 2H), 3.28 - 3.26 (m, 4H), 2.46 - 2.44 (m, 4H), 2.36 (t, *J* = 10.8 Hz, 1H), 2.10 - 2.07 (m, 2H), 1.83 - 1.80 (m, 2H), 1.39 (s, 9H), 1.37 - 1.23 (m, 4H); LC-MS (ESI+) *m/z* 483.4 $(M+H)^+$.

[003282] Step 5 - Tert-butyl 4-r4-r(5-tetrahvdropyran-4-yl pyrrolo[2.1-i'][1.2.41triazin-4-vOaminolcvclohexyll piperazine- l-carboxylate *(9)*

[003283] To a solution of tert-butyl 4-[4-[[5-(3,6-dihydro-2H-pyran-4-yl)pyrrolo[2,l-f][l,2,4]triazin-4-yl] amino]cyclohexyl]piperazine-l-carboxylate (220 mg, 455 umol) in methanol (30 mL) was added Pd/C (100 mg, 10%, *wt)* under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 16 hours. On completion, the reaction mixture was filtered. The filtrate was concentrated in *vacuo* to give the title compound (190 mg, 86% yield) as a white solid. ^1H NMR (400MHz, DMSO-d_6) δ 7.78 (s, 1H), 7.54 (d, *J* = 2.8 Hz, 1H), 6.53 (d, *J* = 2.8Hz, 1H), 6.21 (d, *J* = 8.0 Hz, 1H), 4.17 - 3.97 (m, 1H), 3.92 - 3.88 (m, 2H), 3.57 - 3.51 (m, 2H), 3.44 - 3.38 (m, 1H), 3.29 - 3.27 (m, 4H), 2.45 - 2.43 (m, 4H), 2.35 - 2.29 (m, 1H), 2.01 - 1.98 (m, 2H), 1.84 - 1.81 (m, 2H), 1.79 - 1.72 (m, 2H), 1.66 - 1.63 (m, 2H), 1.57 - 1.47 (m, 2H), 1.39 (s, 9H), 1.37 - 1.28 (m, 2H); LC-MS (ESI+) *m/z* 485.4 $(M+H)^+$.


[003284] Step 6 - N-(4-piperazin- l-ylcyclohexyl)-5-tetrahvdropyran-4-yl-pyrrolor2. 1-f][1.2.41triazin-4-amine (Intermediate OP)

[003285] To a solution of tert-butyl 4-[4-[(5-tetrahydropyran-4-ylpyrrolo[2,l-f][l,2,4]triazin-4-yl)amino] cyclohexyl]piperazine- l-carboxylate (180 mg, 345 umol) in DCM (3 mL) was added HCl/dioxane (4 M, 50 mL). The reaction mixture was stirred at 20 °C for 20 minutes. On completion, the mixture was filtered and concentrated in *vacuo* to give the title compound (145 mg, 99% yield) as a white solid. LC-MS (ESI+) *m/z* 385.3 $(M+H)^+$.

[003286] Step 7 - 1-r4-r4-r(5-Tetrahvdropyran-4-ylpyrrolor2J -i'][1.2.41triazin-4-vDaminolcvclohexyll piperazin-l-yllethanone (10)

[003287] To a solution of N-(4-piperazin-l-ylcyclohexyl)-5-tetrahydropyran-4-yl-pyrrolo[2,l-f][l,2,4]triazin- 4-amine (153 mg, 363 umol, HC1 salt) and AcOH (24.0 mg, 399 umol) in DMF (3 mL) was added HATU (165 mg, 436 umol). Then, DIPEA (187 mg, 1.45 mmol) was added. The reaction mixture was stirred at 20 °C for 0.5 hr. On completion, the reaction mixture was concentrated in *vacuo.* The crude product was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]; B%: 3%-33%, 10 min) to give the title compound (94.0 mg, 61% yield) as white solid. ^{1}H NMR (400MHz, DMSO-^) δ 7.79 (s, 1H), 7.54 (d, *J* = 2.8 Hz, 1H), 6.54 (d, *J* = 2.8 Hz, 1H), 6.20 (d, *J* = 8.0 Hz, 1H), 4.14 - 4.01 (m, 1H), 3.91 (dd, *J* = 3.2, 10.8 Hz, 2H), 3.55 (t, *J* = 10.8 Hz, 2H), 3.44 - 3.40 (m, 6H), 2.58 - 2.54 (m, 2H), 2.43 - 2.39 (m, 1H), 2.04 - 2.00 (m, 2H), 1.98 (s, 3H), 1.87 - 1.85 (m, 2H), 1.78 - 1.72 (m, 2H), 1.71 - 1.59 (m, 2H), 1.58 - 1.47 (m, 2H), 1.44 - 1.31 (m, 2H); LC-MS (ESI^{+}) *m/z* 427.3 (M+H)$^{+}$.

[003288] **Nl-methyl-N4-[5-tetrahvdropyran-4-yl-7H-pyrrolo[2,3-d1pyrimidin-4-vBcvclohexane-1.,4- diamine [Intermediate_OO)**



[003289] **Step 1 - Tert-butyl N-[4-(dibenzylamino)cvclohexyllcarbamate** *(2)*

[003290] To a solution of tert-butyl N-(4-aminocyclohexyl)carbamate (3.00 g, 14.0 mmol, CAS#l 77906-48-8) in ACN (50 mL) was added K2CO3 (5.80 g, 42.0 mmol) and BnBr (7.18 g, 42.0 mmol). The mixture was stirred at 60°C for 16 hours. On completion, the reaction mixture was filtered and concentrated in vacuo to give a residue. The residue was purified by column chromatography to give the title compound (4.60 g, 83% yield) as white solid. ^{1}H NMR (400MHz, DMSO-d_6) δ 7.38 - 7.26 (m, 8H), 7.24 - 7.14 (m, 2H), 6.58 (d, J = 8.0 Hz, 1H), 3.56 (s, 4H), 3.16 (d, J = 8.4 Hz, 1H), 2.32 (t, J = 12.0 Hz, 1H), 1.78 *(d, J* = 10.4 Hz, 4H), 1.49 - 1.38 (m, 2H), 1.35 (s, 9H), 1.08 - 0.91 (m, 2H); LC-MS (ESI$^+$) *m/z* 395.3 (M+H)$^+$.

[003291] **Step 2 - Tert-butyl N-[4-(dibenzylamino)cvclohexyll-N-methyl-carbamate** 131

[003292] To a solution of tert-butyl N-[4-(dibenzylamino)cyclohexyl]carbamate (4.00 g, 10.1 mmol) in DMF (80 mL) was added NaH (810 mg, 20.2 mmol, 60% purity) at 0°C. The

mixture was stirred at 0°C for 0.5 hour, and then Mel (2.88 g, 20.2 mmol) was added. The mixture was stirred at 20°C for 16 hours. On completion, the reaction mixture was quenched by water (60 mL) at 0°C, and then extracted with EA (3 X 100 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated in *vacuo* to give a residue. The residue was triturated with DMF (8 mL) to give the title compound (3.70 g, 89% yield) as white solid. ^1H NMR (400MHz, CDCh) δ 7.38 (d, *J* = 7.2 Hz, 4H), 7.30 (t, *J* = 7.2 Hz, 4H), 7.25 - 7.18 (m, 2H), 3.63 (s, 4H), 2.66 (s, 3H), 2.52 - 2.39 (m, 1H), 1.96 *(d, J* = 11.6 Hz, 2H), 1.72 *(d, J* = 11.2 Hz, 2H), 1.58 - 1.30 (m, 14H); LC-MS (ESI+) *m/z* 409.2 $(M+H)^+$.

[003293] **Step 3 - Tert-butyl N-(4-aminocvclohexy0-N-methyl-carbamate *(4)***

[003294] To a solution of tert-butyl N-[4-(dibenzylamino)cyclohexyl]-N-methyl-carbamate (2.60 g, 6.36 mmol) in a mixed solvent of MeOH (10 mL) and EA (50 mL) was added $Pd(OH)_2/C$ (200 mg, 10% purity), Pd/C (200 mg, 10% purity) and NH3·H20 (182 mg, 0.2 mL, 38% purity) under N_2 atmosphere. The suspension was degassed under vacuum and purged with H_2 three times. The mixture was stirred at 20°C for 16 hours under H_2 (15 psi). On completion, the reaction mixture was filtered and concentrated in vacuo to give the title compound (1.40 g, 96% yield) as colorless oil. ^1H NMR (400MHz, CDCh) δ 2.70 (s, 3H), 2.64 - 2.57 (m, 1H), 1.91 (d, *J* = 12.0 Hz, 2H), 1.67 (d, *J* = 12.0 Hz, 2H), 1.58 - 1.48 (m, 2H), 1.45 (s, 9H), 1.32 - 1.17 (m, 3H).

[003295] **Stei_ 4_ -_ Tert-butyl_ N-[4-[[5-broïuo-7-(2-trimethylsilylethoxymethvDpyrrolo[2.,3-d1pyrimidin-4-yl1 aminolcvclohexyll-N-methyl-carbamate (6)**

[003296] To a solution of tert-butyl N-(4-aminocyclohexyl)-N-methyl-carbamate (1.25 g, 5.47 mmol) and 2-[(5-bromo-4-chloro-pyrrolo[2,3-d]pyrimidin-7-yl)methoxy]ethyl-trimethyl-silane (2.18 g, 6.02 mmol, from **1-442)** in ACN (50 mL) was added Na_2C0_3 (1.16 g, 10.9 mmol). The mixture was stirred at 85°C for 16 hours. On completion, the reaction mixture was filtered and concentrated in *vacuo* to give a residue. The residue was purified by silica gel chromatography to give the title compound (2.40 g, 79% yield) as light yellow oil. ^1H NMR (400MHz, DMSO-d_6) δ 8.21 (s, 1H), 7.55 (s, 1H), 6.06 (d, *j* = 8.0 Hz, 1H), 5.46 (s, 2H), 4.06 (s, 1H), 3.49 (t, *j* = 8.0 Hz, 2H), 3.32 - 3.29 (m, 1H), 2.69 (s, 3H), 2.08 (d, *J* = 10.0 Hz, 2H), 1.73 - 1.54 (m, 4H), 1.54 - 1.44 (m, 2H), 1.40 (s, 9H), 0.81 (t, *J* = 8.0 Hz, 2H), -0.09 (s, 9H); LC-MS (ESI+) *m/z* 554.2 $(M+H)^+$.

[003297] Step 5 - Tert-butyl N-[4-[[5-(3.6-dihvdro-2H-pyran-4-vl)-7-(2-trimethylsilylethoxymethvDpyrrolo [2,3-dl pyrimidin-4-yl] amino] cyclohexyll-N-methyl-carbamate (8)

[003298] To a mixture of tert-butyl N-[4-[[5-bromo-7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-d]pyrimidin- 4-yl]amino]cyclohexyl]-N-methyl-carbamate (1.20 g, 2.16 mmol) and 2-(3,6-dihydro-2H-pyran-4-yl)- 4,4,5,5-tetramethyl-l,3,2-dioxaborolane (1.36 g, 6.49 mmol, CAS#287944-l6-5) in a mixed solvent of THF (20 mL) and H_20 (4 mL) was added BrettPhos-Pd-G_3 (196 mg, 216 umol) and K2CO3 (598 mg, 4.33 mmol). The mixture was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 55 °C for 16 hours under N_2 atmosphere. On completion, the reaction mixture was filtered and concentrated in vacuo to give a residue. The residue was washed with water (30 mL) and extracted with EA (6 X 30 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated in vacuo to give a residue. The residue was purified by silica gel chromatography to give the title compound (0.92 g, 76% yield) as light yellow solid. ¾NMR (400MHz, DMSO-d_6) δ 8.20 (s, 1H), 7.36 (s, 1H), 5.81 (s, 1H), 5.62 (d, J = 8.0 Hz, 1H), 5.47 (s, 2H), 4.24 (d, J = 2.4 Hz, 2H), 4.07 - 3.94 (m, 1H), 3.84 (t, J = 5.6 Hz, 2H), 3.49 (t, J = 8.0 Hz, 2H), 2.69 (s, 3H), 2.44 (s, 2H), 2.09 (d, J = 10.4 Hz, 2H), 1.73 - 1.55 (m, 4H), 1.45 - 1.35 (m, 11H), 0.81 (t, J = 8.0 Hz, 2H), -0.08 (s, 9H); LC-MS (ESI^+) *m/z* 558.4 $(M+H)^+$.

[003299] Step 6 - Tert-butyl N-methyl-N-|4-||5-tetrahvdropyran-4-yl-7-(2-trimethylsilylethoxymethyllpyrrolo [2,3-dlpyrimidin-4-yllaminolcyclohexyllcarbamate (9)

[003300] To a solution of tert-butyl N-[4-[[5-(3,6-dihydro-2H-pyran-4-yl)-7-(2-trimethylsilylethoxymethyl) pyrrolo[2,3-d]pyrimidin-4-yl]amino]cyclohexyl]-N-methyl-carbamate (200 mg, 358 umol) in MeOH (10 mL) was added Pd/C (60.0 mg, 10% purity) under N_2. The suspension was degassed in vacuo and purged with H_2 three times. The mixture was stirred under H_2 (15 psi) at 25°C for 16 hours. On completion, the reaction mixture was filtered and concentrated in vacuo to give the title compound (195 mg, 88% yield) as light yellow solid. LC-MS (ESI^+) *m/z* 560.3 $(M+H)^+$.

[003301] Step 7- [4-[[4-(Methylamino)cyclohexyllaminol-5-tetrahydropyran-4-yl-pyrrolo [2,3-d] pyrimidin-7- yllmethanol (101


[003302] To a solution of tert-butyl N-methyl-N-[4-[[5-tetrahydropyran-4-yl-7-(2-trimethylsilylethoxymethyl) pyrrolo[2,3-d]pyrimidin-4-yl]amino]cyclohexyl]carbamate (190 mg,

339 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 2 mL). The reaction mixture was stirred at 45°C for 16 hours. On completion, the reaction mixture was concentrated in vacuo to give the title compound (120 mg, 63% yield) as light yellow solid. LC-MS (ESI^+) *m/z* 360.1 $(M+H)^+$.

[003303] **Step 8 - Nl-methyl-N4-[5-tetrahvdropyran-4-yl-7H-pyrrolo[2,3-d]pyrimidin-4-vDcvclohexane-l.,4- diamine [Intermediate OO)**

[003304] To a solution of [4-[[4-(methylamino)cyclohexyl]amino]-5-tetrahydropyran-4-yl-pyrrolo[2,3-d] pyrimidin-7-yl]methanol (120 mg, 303 umol) in a mixed solvent of THF (6 mL) and H_2O (1.5 mL) was added LiOLI•LI_2O (50.8 mg, 1.21 mmol). The mixture was stirred at 25°C for 16 hours. On completion, the reaction mixture was acidified with 1N HC1 solution till pH = 7, and then concentrated in vacuo give a residue. The residue was purified by prep-HPLC (column: Phenomenex Gemini l50*25mm*l0 um; mobile phase: [water (0.04%NH_3H_2O+l0mM NH4HCO3) to give the title compound (12.1 mg, 12% yield) as white solid. ^1H NMR (400MHz, **DMS0 -d_6)** δ 11.31 (s, 1H), 8.07 (s, 1H), 6.83 (s, 1H), 5.53 (d, *J* = 8.0 Hz, 1H), 4.13 - 3.99 (m, 1H), 3.90 (dd, 7 = 3.2, 11.2 Hz, 2H), 3.54 (t, *J* = 11.6 Hz, 2H), 3.28 - 3.19 (m, 2H), 2.32 - 2.21 (m, 4H), 2.01 - 1.80 (m, 6H), 1.60 - 1.49 (m, 2H), 1.47 - 1.32 (m, 2H), 1.20 - 1.01 (m, 2H); LC-MS (ESI^+) *m/z* 330.3 $(M+H)^+$.

[003305] **3-tl-t2,6-Dioxopiperidin-3-vn-3-methyl-2-oxo-2,3-dihvdro-lH-benzofdlimidazol-4-vI) propanal [Intermediate OR)**



[003306] Step 1 - (E)-3-(4-(3-hydroxyprop-l -en- 1-yl)-3-methyl-2-oxo-2.3-dihydro 1H-benzordlimidazol-l-yl) piped dine-2.6-di one

[003307] A mixture of 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (1.00 g, 2.96 mmol, Intermediate HP), prop-2-en-l-ol (0.500 g, 8.61 mmol), DIPEA (764. mg, 5.91 mmol), $Pd_2(dba)_3$ (271 mg, 296 umol) and P(t-Bu)$_3$ (1.20 g, 591 umol, 10% purity in hexane solution) in dioxane (50 mL) was de-gassed and then heated to 30 °C for 24 hours under N_2. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by reverse phase chromatography (0.1% FA condition) to give the title compound (860 mg, 88% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 316.1 $(M + H)^+$.


[003308] Step 2 3-(4-(3-Hvdroxypropyl)-3-methyl-2-oxo-2.3-di hydro- 1H-benzordlimidazol-l-vDpiperidine- 2.6-dione

[003309] To a solution of 3-[4-[(E)-3-hydroxyprop-l-enyl]-3-methyl-2-oxo-benzimidazol-l-yl]piperidine- 2,6-dione (860 mg, 2.73 mmol) in THF (10 mL) was added Pd/C (100 mg, 163 umol) (10%, *wt)* under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 20 °C for 48 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo.* The residue was purified by reversed-phase chromatography (0. 1% FA condition) to give the title compound (450 mg, 44% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 318. 1 $(M + H)^+$.

[003310] Step 3 - 3-(T-(2.6-Dioxopiper din-3-vl)-3-methyl-2-oxo-2.3-dihydro-lH-benzordlimidazol-4- vl) propanal

[003311] To a solution of 3-[4-(3-hydroxypropyl)-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione (250 mg, 788 umol) in DCM (10 mL) was added DMP (400 mg, 945 umol). The reaction mixture was stirred at 25 °C for 12 hours. On completion, the reaction mixture was quenched with saturated sodium thiosulfate (50 mL) and saturated aq.$NaHC0_3$, then extracted with DCM (3 X 150 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated *in vacuo* to give the title compound (240 mg, 96% yield) as a white solid. ¾ NMR (400MHz, CDCh) δ 9.80 (s, 1H), 8.33 - 8.04 (m, 1H), 6.96 - 6.91 (m, 1H), 6.82 (d, *J* = 8.0 Hz, 1H), 6.62 (d, *J* = 8.0 Hz, 1H), 5.13 (dd, *J* = 5.6, 12.4 Hz, 1H), 3.61 (s, 3H), 3.21 (t, *j* = 7.6 Hz, 2H), 2.81 (t, *J* = 7.6 Hz, 2H).


[003312] **3-(4-(3-(((6-(Aminomethyl)hexahydrofuro[3,2-b]furan-3-yl)methyl)amino)propyl)-3-_ methyl_ -2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l-yl]piperidine-2.,6-dione [Intermediate OS)**



OR OS

[003313] To a solution of 3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]propanal (120 mg, 380 umol, Intermediate OR) and [6-(aminomethyl)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]methanamine (328 mg, 1.90 mmol, Intermediate OT) in DMF (5 mL) was added 4A MS (100 mg) and HOAc (45.7 mg, 761 umol). The reaction mixture was stirred at 80 °C for 1 hour. Then, NaB¾CN (47.8 mg, 761 umol) was added. The resulting reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (column: Shim-pack C18 150*25*l0um; mobile phase: [water (0.225%FA)-ACN]; B%: l%-25%, lOmin) to give the title compound (50.0 mg, 23% yield) as a white solid. LC-MS (ESI^+) *m/z* 472.3 $(M + H)^+$.

[003314] **[6-(AminomethvD-2.,3.,3a,5,6,6a-hexahvdrofuro[3,2-blfuran-3-yllmethanamine [Intermediate OT)**



OT

[003315] Step 1 - r(3R.3aS.6R.6aS)-6-(Trif1uoromethylsulfonyloxy)-2.3.3a.5.6.6a-hexahydrofuror3.2-b1 furan-3-yll trifluoromethanesulfonate

[003316] To a solution of (3R,3aR,6R,6aR)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3,6-diol (25.0 g, 171 mmol, CAS# 641-74-7) and pyridine (32.4 g, 410 mmol) in DCM (250 mL) at 0

°C was added Tf_20 (115 g, 410 mmol, 67.74 mL) dropwise. Then the mixture was stirred at rt for 3 hours. On completion, the reaction mixture was acidified with 1N aq.HCl until the pH= 3. The mixture was washed with H_20 (3 X 50 mL). The organic layer was basified with saturated $NaHC0_3$ solution until the pH= 8. The organic layer was then washed with brine (2 X 30 mL) and dried over Na_2S0_4, then filtered. The filtrate was concentrated *in vacuo* to give the title compound (70.0 g, 99% yield) as yellow solid. ^1H NMR (400MHz, CDCh) δ 5.28 - 5.19 (m, 2H), 4.82 - 4.75 (m, 2H), 4.22 - 4.12 (m, 4H).


[003317] Step 2 - 2.3.3 A.5.6.6a-Hexahvdrofuror3.2-b1furan-3.6-dicarbonitrile

[003318] To a mixture of l8-crown-6 (58.9 g, 223 mmol) and KCN (48.4 g, 743 mmol) in THF (400 mL) was added a solution of [(3R,3aS,6R,6aS)-6-(trifluoromethylsulfonyloxy)-2,3,3a,5,6,6a -hexahydrofuro[3,2-b]furan-3-yl]trifluoromethanesulfonate (61.0 g, 148 mmol) in THF (400 mL). Then the reaction mixture was stirred at 0 °C for 3 hours. On completion, the reaction was warmed to room temperature, then the mixture was poured into cold water (200 mL) and extracted with chloroform (5 X 100 mL). The combined organic layers were dried over Mg_2S0_4, then filtered. The filtrate was decolorized with activated carbon. After filtration through celite, the filtrate was concentrated *in vacuo.* The residue was purified by Prep-TLC ($Si0_2$, PE: EA = 1: 1) to give the title compound (5.00 g, 20% yield) as yellowish solid. ^1H NMR (400MHz, CDCh) δ 5.03 (s, 2H), 4.14 - 4.07 (m, 4H), 3.22 - 3.19 (m, 2H).

[003319] Step 3 - [6-(Aminomethyl)-2.3.3a.5.6.6a-hexahydrofurc>r3.2-b1furan-3-yllmethanamine

[003320] To a solution of 2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3,6-dicarbonitrile (2.50 g, 15.2 mmol) in THF (25.0 mL) was added BH_3-Me_2S (10.0 M, 25.0 mL) dropwise. The mixture was stirred at 20 °C for 16 hours under N_2. On completion, the reaction mixture was quenched with MeOH (50 mL). The mixture was concentrated *in vacuo* to give the title compound (2.62 g, 100% yield) as white solid. ^1H NMR (400MHz, D_20) δ 4.30 - 3.86 (m, 1H), 3.71 - 3.47 (m, 4H), 3.12 - 2.91 (m, 3H), 2.68 - 2.50 (m, 2H), 1.68 - 1.40 (m, 2H).

[003321] **3-[l-[2,6-Dioxo-3-piperidvB-3-methyl-2-oxo-benzimidazol-5-yl]propanal [Intermediate_OIJ)**



HN

ou

[003322] Step 1 - 3-r5-(3-Hvdroxyprop-l-envO-3-methyl-2-oxo-benzimidazol-l-yl1piperidine-2.6-dione

[003323] To a solution of 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (1.00 g, 2.96 mmol, Intermediate HN) and prop-2-en-l-ol (350 mg, 6.03 mmol) in dioxane (10.0 mL) was added $P(t\text{-}Bu)_3$ (1.20 g, 591 umol, 10 wt %), $Pd_2(dba)_3$ (270 mg, 295 umol) and DIPEA (496 mg, 3.84 mmol). The mixture was stirred at 20 °C for 16 hours under N_2. On completion, the mixture was concentrated *in vacuo.* The residue was purified by reverse phase chromatography (0.1% FA) to give the title compound (750 mg, 80% yield) as yellow solid. ^1H NMR (400MHz, DMSO-^e) δ 12.74 (s, 1H), 11.08 (s, 1H), 9.80 - 9.62 (m, 1H), 7.11 - 7.07 (m, 1H), 7.01 (d, *J* = 8.0 Hz, 1H), 6.95 - 6.93 (m, 1H), 6.96 - 6.83 (m, 1H), 5.41 - 5.25 (m, 1H), 3.31 (s, 3H), 2.94 - 2.89 (m, 2H), 2.81 - 2.76 (m, 1H), 2.75 - 2.65 (m, 1H), 2.65 - 2.54 (m, 1H), 2.04 - 1.94 (m, 1H).

[003324] Step 2 - 3-r5-(3-HvdroxypropyD-3-methyl-2-oxo-benzimidazol-l-yl1piperidine-2.6-dione


[003325] To a solution of 3-[5-[(E)-3-hydroxyprop-l-enyl]-3-methyl-2-oxo-benzimidazol-l-yl] piperidine-2, 6-dione (750 mg, 2.38 mmol) in THF (30.0 mL) was added $Pt0_2$ (54.0 mg, 237 umol). The mixture was stirred at 20 °C for 16 hours under H_2 (15 psi). On completion, the mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was purified by reverse phase chromatography (0.1% FA) to give the title compound (220 mg, 29% yield) as white solid. ^1H NMR (400MHz, DMSO-^e) δ 11.08 (s, 1H), 7.06 - 6.96 (m, 2H), 6.90 - 6.82 (m, 1H), 5.38 - 5.27

(m, 1H), 3.45 - 3.42 (m, 2H), 3.33 (s, 3H), 2.98 - 2.78 (m, 2H), 2.76 - 2.68 (m, 1H), 2.64 - 2.60 (m, 1H), 2.59 - 2.52 (m, 1H), 2.05 - 1.93 (m, 1H), 1.83 - 1.66 (m, 2H).

[003326] Step 3 - 3-[l-(2,6-Dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]propanal

[003327] To a solution of 3-[5-(3-hydroxypropyl)-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione (220 mg, 693 umol) in DCM (10.0 mL) was added DMP (352 mg, 831 umol). The mixture was stirred at 25 °C for 1 hour. On completion, the mixture was quenched with saturated $Na_2S_2O_3$ (30 mL) and washed with saturated $NaHCO_3$ (2 X 30 mL). The organic layer was dried over anhydrous Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (200 mg, 91% yield) as yellow solid. LC-MS (ESI^+) *m/z* 316.1(M+H)$^+$.


[003328] **3-[5-[3-[[3-(AminomethvB-2.,3.,3a,5,6,6a-hexahvdrofuro[3,2-blfuran-6-yl] methylamino]_ _____propyl1-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione [Intermediate OV)**




OU OV

[003329] To a solution of 3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yljpropanal (190 mg, 602 umol, Intermediate OU), [6-(aminomethyl)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl]methanamine (518 mg, 3.01 mmol, Intermediate OT) in DMF (6.00 mL) was added HOAc (72.3 mg, 1.21 mmol) and 4Å molecular sieves (10.0 mg). The mixture was stirred at 80 °C for 1 hour. The mixture was cooled to 25 °C, then NaB¾CN (75.7 mg, 1.21 mmol) was added, and the mixture was stirred at 25 °C for 16 hours. On completion, the mixture was quenched with H_2O (1 mL), filtered and the filtrate was concentrated *in vacuo*. The residue was purified by prep-HPLC (column: Shim-pack C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]; B%: l%-30%, 10 min) to give the title compound (120 mg, 42% yield) as yellow solid. ^1H NMR (400MHz, DMSO-^e) δ 8.19 (s, 1H), 8.04 (s, 1H), 7.07 - 6.98 (m, 2H), 6.87 (d, *J* = 7.2 Hz, 1H), 5.42 - 5.28 (m, 1H), 4.42 - 4.35 (m, 2H), 4.31 - 4.22 (m, 2H), 3.85 - 3.78 (m, 2H), 3.33 (s, 3H), 3.12 - 3.06 (m, 2H), 3.02 - 2.94 (m, 2H), 2.79 - 2.73 (m, 1H), 2.66 - 2.64 (m, 1H), 2.47 - 2.46 (m, 1H), 2.32 - 2.24 (m, 6H), 2.07 - 1.94 (m, 1H), 1.79 - 1.70 (m, 2H).

[003330] **4-Amino-l-[4-(hydroxymethyBphenyl]pyrazole-3-carbonitrile _[Intermediate OW1 (IRW-598)**





OW


[003331] Step 1- l-r4-(Hvdroxymethv0phenvn-4-nitro-pyrazole-3-carbonitrile

[003332] To a mixture of 4-nitro-lH-pyrazole-3-carbonitrile (3.00 g, 21.7 mmol, CAS# 61241-07-4) and [4-(hydroxylmethyl)phenyl] boronic acid (2.20 g, 14.4 mmol, CAS# 59012-93-2) in mixed solvents of pyridine (25 mL) and DCM (75 mL) was added $Cu(OAc)_2$ (3.94 g, 21.7 mmol) under O2 (15 psi), then the mixture was stirred at 20 °C for 12 hours. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (S1O2) to give the title compound (3.00 g, 78% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-#«) δ 9.90 (s, 1H), 7.95 (d, *J* = 8.8 Hz, 2H), 7.56 (d, *J* = 8.4 Hz, 2H), 4.62 (s, 2H), 4.39 (s, 1H).

[003333] Step 2- 4-Amino-l-r4-(hvdroxymethvnphenyl1pyrazole-3-carbonitrile

[003334] To a mixture of l-[4-(hydroxymethyl)phenyl]-4-nitro-pyrazole-3-carbonitrile (3.00 g, 12.3 mmol) in a mixed solvents of EtOH (120 mL) and H2O (30 mL) was added NH_4Cl (6.57 g, 123 mmol). The mixture was heated to 65 °C. Then Fe (6.86 g, 123 mmol) was added in portions. The reaction mixture was stirred at 65 °C for 1 hour. On completion, the reaction mixture was cooled to 25 °C, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (S1O2) to give the title compound (1.20 g, 42% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO^) δ 7.84 (s, 1H), 7.70 (d, *j* = 8.8 Hz, 2H), 7.41 (d, *J* = 8.8 Hz, 2H), 5.25 (t, *J* = 5.6 Hz, 1H), 5.00 (s, 2H), 4.50 (d, *J* = 5.6 Hz, 2H).

[003335] Tert-butyl N-[4-[4-[[3-cyano-l-(4-formylphenyDpyrazol-4-yl]carbamoyl]oxazol-2-yl]-2- pyridyll-N-(cyclopropylmethyDcarbamate [Intermediate OX]



[003336] Step 1- Tert-butyl N-[4-[4-[[3-cvano-1-[4-(hvdroxymethvl)phenyl1pyrazol-4-yllcarbamovnoxazol-2- yl1-2-pyridyl1-N-(cvclopropylmethvncarbamate

[003337] To a mixture of 4-amino- l-[4-(hydroxym ethyl)phenyl]pyrazole-3-carbonitrile (300 mg, 1.40 mmol, Intermediate OW) and 2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (503 mg, 1.40 mmol, Intermediate OM) in DMF (10 mL) was added DIPEA (543 mg, 4.20 mmol) and HATU (639 mg, 1.68 mmol). The reaction mixture was stirred at 20 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (453 mg, 52% yield) as a yellow solid. ¾NMR (400MHz, DMSO-r¾) δ 10.73 (s, 1H), 9.08 (s, 1H), 8.85 (s, 1H), 8.61 (d, *J* = 5.2 Hz, 1H), 8.36 (s, 1H), 7.86 (d, *J* = 8.8 Hz, 2H), 7.72 (d, 7 = 1.2, 4.0 Hz, 1H), 7.51 (d, *J* = 8.4 Hz, 2H), 5.34 (t, *J* = 5.6 Hz, 1H), 4.58 (d, *J* = 5.6 Hz, 2H), 3.88 (d, *J* = 6.8 Hz, 2H), 1.52 (s, 9H), 1.20 - 1.15 (m, 1H), 0.46 - 0.37 (m, 2H), 0.30 - 0.20 (m, 2H).

[003338] Step 2- Tert-butyl N-[4-[4-[[3-cvano-1-(4-formylphenvl)pyrazol-4-yl1carbamoyl1oxazol-2-vH-2- pyridyl1-N-(cvclopiOPylmethvDcarbamate

[003339] To a mixture of tert-butyl N-[4-[4-[[3-cyano-l-[4-(hydroxymethyl)phenyl]pyrazol-4-yl]carbamoyl] oxazol-2-yl]-2-pyridyl]-N-(cyclopropylmethyl)carbamate (350 mg, 630 umol) in DCM (15 mL) was added DMP (294 mg, 693 umol). The reaction was stirred at 20 °C for 1 hour. On completion, a solution of sodium thiosulfate aqueous solution (20 mL) and saturated sodium bicarbonate (20 mL) was added into the mixture and stirred for 10 minutes. Then the mixture was

extracted with DCM (2 X 20 mL). The combined organic layer was washed with brine (2 X 30 mL), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give title compound (320 mg, 91% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-^e) δ 10.85 (s, 1H), 10.07 (s, 1H), 9.14 - 9.02 (m, 2H), 8.61 (d, *J* = 5.2 Hz, 1H), 8.36 (s, 1H), 8.23 - 8.15 (m, 2H), 8.14 - 8.08 (m, 2H), 7.72 *(d, J* = 5.2 Hz, 1H), 3.88 *(d, J* = 7.2 Hz, 2H), 1.52 (s, 9H), 1.26 - 1.11 (m, 1H), 0.49 - 0.37 (m, 2H), 0.30 - 0.21 (m, 2H).


[003340] **6-Bromo-3H-l,3-benzoxazol-2-one [Intermediate OY)**




OY

[003341] To a solution of 2-amino-5-bromo-phenol (4.50 g, 23.9 mmol, CAS# 38191-34-3) in THF (120 mL) was added CDI (4.66 g, 28.7 mmol). The reaction mixture was stirred at 70 °C for 2 hours. On completion, the reaction mixture was added to water (240 mL) and the mixture was adjusted pH = 6 ~ 7 with 2.0 M aq.HCl, then ethyl acetate (150 mL) was added. The organic layer was separated and washed with a saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The residue was recrystallized in toluene (60 mL) to give the title compound (3.75 g, 90% yield) as an off-white solid. ^{1}H NMR (400MHz, DMSO-d_6) δ 7.58 *(d, J* = 1.6 Hz, 1H), 7.32 (dd, *j* = 1.8, 8.4 Hz, 1H), 7.06 (s, 1H), 7.04 - 7.01 (m, 1H). LC-MS (ESI$^+$) *m/z* 216.0 & 214.0 $(M + Na)^+$.

[003342] **3-(6-Bromo-2-oxo-l.,3-benzoxazol-3-vPpiperidine-2,6-dione [Intermediate OZ)**



OY



OZ

[003343] Step_ ___1_ ___-_____3-(6-Bromo-2-oxo-L3-benzoxazol-3-vO-l-IY4-methoxyphenyl)methyl1piperidine-2.6-dione


[003344] To a solution of 6-bromo-3H-l,3-benzoxazol-2-one (2.00 g, 9.35 mmol, Intermediate OY) in THF (50 mL) was added t-BuOK (1.26 g, 11.2 mmol). The reaction mixture was stirred at 0 °C for 0.5 hour. Subsequently, [l-[(4-methoxyphenyl)methyl]-2,6-dioxo-3-piperidyl] trifluoromethanesulfonate (4.81 g, 12.6 mmol, Intermediate IQ) in a solution of THF (30 mL) was added dropwise. The resulting reaction mixture was stirred at 20 °C for 0.5 hour under N_2. On completion, the reaction mixture was quenched with saturated NH_4Cl (100 mL), and extracted with ethyl acetate (100 mL). The combined organic layer was washed with brine (2 X 100 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated *in vacuo.* The residue was purified by silica gel chromatography (PE: EA: DCM = 5:1:2) to give the title compound (3.75 g, 90% yield) as a yellow solid. ¾NMR (400MHz, CDCh) δ 7.22 - 7.20 (d, *J* = 8.0 Hz, 1H), 6.89 - 6.87 (d, *j* = 8.0 Hz, 1H), 4.90 - 4.86 (m, 1H), 4.47 - 4.36 (m, 2H) 3.81 (s, 3H), 2.67 - 2.64 (m, 1H), 2.59 - 2.54 (m, 2H), 2.40 - 2.38 (m, 1H). LC-MS (ESI^+) *m/z* 466.9 & 468.9 $(M + Na)^+$.

[003345] Step 2 - 3-(6-Bromo-2-oxo-L3-benzoxazol-3-vDpiperidine-2.6-dione


[003346] To a mixture of 3-(6-bromo-2-oxo-l,3-benzoxazol-3-yl)-l-[(4-methoxyphenyl)methyl]piperidine- 2,6-dione (2.00 g, 4.49 mmol) in ACN (60 mL) was added


CAN (7.39 g, 13.4 mmol) in solution of H_20 (20 mL), and the reaction mixture was degassed and purged with N_2 for 3 times. Then the mixture was stirred at 20 °C for 3 hours under N_2 atmosphere. On completion, the reaction mixture was filtered. The filtered cake was collected and dried *in vacuo* to give the title compound (900 mg, 61% yield) as a white solid. ^{1}HNMR(400MHz, DMSO-*di)* δ 11.24 (s, 1H), 7.74 (d, *J* = 1.6 Hz, 1H), 7.48 - 7.41 (m, 1H), 7.27 (d, *J* = 8.4 Hz, 1H), 5.39 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.00 - 2.80 (m, 1H), 2.76 - 2.60 (m, 2H), 2.18 - 2.15 (m Hz, 1H). LC-MS (ESI$^+$) *m/z* 325.0 &327.0 $(M+H)^+$.

[003347] **2-_ 3-[6-[3-[2-[2-Aminoethoxy)ethoxy]propyl]-2-oxo-l,3-benzoxazol-3-yl] piperidine-2.,6- dione [Intermediate PA)**



OZ





PA

[003348] Step 1 - Tert-butyl N-r2-r2-r3-r3-(2.6-dioxo-3-piperidvO-2-oxo-l.3-benzoxazol-6-yllpropoxylethoxyl ethyllcarbamate

[003349] 3-(6-bromo-2-oxo-l,3-benzoxazol-3-yl)piperidine-2,6-dione (400 mg, 1.23 mmol, Intermediate OZ), tert-butylN-[2- (2-prop-2-ynoxyethoxy)ethyl]carbamate (898 mg, 3.69 mmol, synthesized via Step 1 of Intermediate CQ), $Pd(PPh_3)_2Cl_2$ (86.3 mg, 123 umol), Cul (23.4 mg, 123

umol), 4A MS (400 mg, 307 umol) and CS2CO3 (2.00 g, 6.15 mmol) in DMF (6 mL) was stirred at 80 °C for 2 hours under N_2. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo*. The residue was purified by column chromatography (ACN) to give an impure product. The impure product was re-purified by reverse phase (0.1% FA condition) to give the title compound (340 mg, 54% yield) as yellow oil. ¾NMR (400MHz, DMSO-d«) δ 11.23 (s, 1H), 7.53 (s, 1H), 7.37 - 7.33 (m, 1H), 7.31 - 7.27 (m, 1H), 6.82 - 6.75 (m, 1H), 5.40 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.39 (s, 2H), 3.65 - 3.60 (m, 2H), 3.57 - 3.53 (m, 2H), 3.41 - 3.38 (m, 2H), 3.07 - 3.02 (m, 2H), 2.93 - 2.81 (m, 1H), 2.72 - 2.61 (m, 2H), 2.18 - 2.16 (m, 1H), 1.37 (s, 9H), 1.37 - 1.36 (m, 1H). LC-MS (ESI+) *m/z* 510.2 (M + Na)+.


[003350] Step 2 - Tert-butyl N-[2-[2-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-L3-benzoxazol-6-yllpropoxylethoxyl ethyllcarbamate

[003351] To a solution of tert-butyl N-[2-[2-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-l,3-benzoxazol-6-yl]prop- 2-ynoxy]ethoxy]ethyl]carbamate (420 mg, 861 umol) in THF (30 mL) was added Pd/C (0.1 g, 10% *wi)* and $Pd(OH)_2/C$ (0.1 g, 10% *wi)* under N_2. The suspension was degassed under vacuum and purged with H_2 gas several times. The mixture was stirred under H_2 (15 psi) at 20 °C for 12 hours. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (440 mg, 93% yield) as yellow oil. 'H NMR (400MHz, DMSO-t/$_f$) δ 11.25 (s, 1H), 7.32 (s, 1H), 7.22 (d, *J* = 8.0 Hz, 1H), 7.11 (d, *J* = 8.0 Hz, 1H), 6.79 (s, 1H), 5.40 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.57 - 3.53 (m, 4H), 3.46 - 3.43 (m, 4H), 3.13 (d, *J* = 6.0 Hz, 2H), 3.00 - 2.89 (m, 1H), 3.00 - 2.89 (m, 1H), 2.80 - 2.67 (m, 4H), 2.25 - 2.20 (m, 1H), 1.88 - 1.83 (m, 2H), 1.43 - 1.42 (m, 9H). LC-MS (ESI+) *m/z* 514.2 (M+ Na)+.

[003352] Step 3 - 2- 3-r6-r3-r2-(2-Aminoethoxy)ethoxy1propyl1-2-oxo-L3-benzoxazol-3-yllpiperidine-2.6- dione

[003353] To a solution of tert-butyl N-[2-[2-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-l,3-benzoxazol-6-yl]propoxy] ethoxy]ethyl]carbamate (150 mg, 305 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 7.50 mL). The reaction mixture was stirred at 20 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (130 mg, 99% yield, HC1 salt) as a white solid. LC-MS (ESI+) *m/z* 392.2 (M+H)+.


[003354] 2-|2-(CvcloDronylmethylamino)-4-nvndyl|-N-|3-(difluoromethvn-l-(4-formylphenyllpyrazol_-4-yl1oxazole-4-carboxamide_[Intermediate_PB)



GF PB

[003355] To a solution of tert-butyl N-(cyclopropylmethyl)-N-[4-[4-[[3-(difluoromethyl) -1-(4-formylphenyl) pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (100 mg, 172 umol, Intermediate GF) in DCM (3.00 mL) was added HCl/dioxane (4.00 M, 3.00 mL), and the mixture was stirred at 25 °C for 0.5 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (80.0 mg, 96% yield) as yellow solid. LC-MS (ESI^+) *m/z* 479.2 $(M+H)^+$.

[003356] **Tert-butyl N-(4-hydroxy-4-methyl-hept-6-enyl)carbamate [Intermediate PC)**



PC

[003357] Step 1 - Tert-butyl N-(4-oxopentyl)carbamate


[003358] To a solution of tert-butyl 2-oxopyrrolidine-l-carboxylate (5.00 g, 26.9 mmol) in THF (50.0 mL) was added MeMgBr (3.00 M, 10.8 mL) dropwise at -78 °C under N_2, and the mixture was stirred at -78 °C for 3 hrs. On completion, the mixture was poured into cool water (50 mL) and then extracted with MTBE (2 X 50 mL). The organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated *in vacuo.* The mixture was purified by silica gel column (PE: EA= 5: 1) to give the title compound (4.45 g, 81% yield) as yellow solid. ^1H NMR (400MHz, CDCh) δ 4.67 (s, 1H), 3.19 - 3.02 (m, 2H), 2.51 - 2.47 (m, 2H), 2.14 (s, 3H), 1.80 - 1.70 (m, 2H), 1.42 (s, 9H).

[003359] Step 2 - Tert-butyl N-(4-hydroxy-4-methyl-hept-6-enyl)carbamate

[003360] To a solution of tert-butyl N-(4-oxopentyl)carbamate (2.00 g, 9.94 mmol) in THF (20.0 mL) was added allyl(bromo)magnesium (1.00 M, 12.9 mL) dropwise at -78 °C, and the mixture was stirred at 0 °C for 3 hrs under N_2. On completion, the mixture was quenched with saturated NH_4Cl (30 mL), then extracted with MTBE (3 X 30 mL). The organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated *in vacuo.* The mixture was purified by silica gel column (PE: EA= 5: 1) to give the title compound (770 mg, 31% yield) as yellow oil. ^1H NMR

(400MHz, DMSO-i¾) δ 6.74 (s, 1H), 5.91 - 5.74 (m, 1H), 5.03 (s, 1H), 4.99 (d, *J* = 3.6 Hz, 1H), 4.15 (s, 1H), 2.91 - 2.83 (m, 2H), 2.15 - 2.05 (m, 2H), 1.46 - 1.39 (m, 2H), 1.38 (s, 9H), 1.31 - 1.24 (m, 2H), 1.00 (s, 3H).

[003361] **3-[5-(7-Amino-4-hydroxy-4-methyl-heptvO-3-methyl-2-oxo-benzimidazol-l-yl]piperidine -2,6-dione [Intermediate PD]**



[003362] Step 1 - Tert-butyl N-[(E)-7-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol -5-yl1-4-hvdroxy-4-methyl-hept-6-enyl1carbamate

[003363] To a solution of 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (200 mg, 591 umol, Intermediate HN), tert-butyl N-(4-hydroxy-4-methyl-hept-6-enyl) carbamate (287 mg, 1.18 mmol, Intermediate PC) in dioxane (12.0 mL) was added tris-o-tolylphosphane (36.0 mg, 118 umol), $Pd(OAc)_2$ (13.2 mg, 59.1 umol) and DIPEA (1.53 g, 11.8 mmol) under N_2. The mixture was stirred at 120 °C for 16 hrs. On completion, the mixture was concentrated *in vacuo.* The mixture was purified by reverse phase chromatography (0.1% FA) to give the title compound (180 mg, 60% yield) as yellow solid. ^1H NMR (400MHz, DMSO-d«) δ

11.10 (s, 1H), 7.27 (s, 1H), 7.04 (s, 2H), 6.76 (s, 1H), 6.45 - 6.34 (m, 1H), 6.33 - 6.21 (m, 1H), 5.40 - 5.30 (m, 1H), 4.26 (s, 1H), 2.92 - 2.89 (m, 1H), 2.89 - 2.84 (m, 2H), 2.71 - 2.67 (m, 1H), 2.64 - 2.56 (m, 1H), 2.30 - 2.20 (m, 2H), 2.08 (s, 3H), 2.05 - 1.96 (m, 1H), 1.52 - 1.41 (m, 2H), 1.36 (s, 9H), 1.35 - 1.31 (m, 2H), 1.07 (s, 3H).


[003364] Step 2 - Tert-butyl N-[7-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]-4-hydroxy-4-methyl-heptyllcarbamate

[003365] To a solution of tert-butyl N-[(E)-7-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] -4-hydroxy-4-methyl-hept-6-enyl]carbamate (160 mg, 319 umol) in THF (8.00 mL) was added $Pd(OH)_2/C$ (50.0 mg, 10% *wt)* and Pd/C (50 mg, 10% *wi),* and the mixture was stirred at 25 °C for 3 hrs under H_2 gas (15 psi). On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (160 mg, 99% yield) as white solid. ^1H NMR (400MHz, DMSO^) δ 11.13 (s, 1H), 7.08 (s, 1H), 7.05 (d, *J* = 8.0 Hz, 1H), 6.92 (s, 2H), 6.79 (s, 1H), 5.44 - 5.34 (m, 1H), 4.03 (s, 1H), 3.38 (s, 3H), 3.01 - 2.95 (m, 1H), 2.94 - 2.87 (m, 2H), 2.80 - 2.69 (m, 2H), 2.68 - 2.64 (m, 1H), 2.64 - 2.60 (m, 1H), 2.11 - 2.01 (m, 1H), 1.69 - 1.59 (m, 2H), 1.48 - 1.43 (m, 2H), 1.42 (s, 9H), 1.40 - 1.36 (m, 2H), 1.40 - 1.35 (m, 2H), 1.05 (s, 3H).

[003366] Step 3 - 3-r5-(7-Amino-4-hvdroxy-4-methyl-heptvD-3-methyl-2-oxo-benzimidazol-l-yllpiperidine -2.6-dione

[003367] To a solution of tert-butyl N-[7-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]-4- hydroxy-4-methylheptyl]carbamate (150 mg, 298 umol) in DCM (10.0 mL) was added HCl/dioxane (4.00 M, 1.00 mL) at 0 °C, and the mixture was stirred at 0 °C for 3 hrs. On completion, the mixture was concentrated *in vacuo.* The mixture was purified by reverse phase chromatography (0.1% FA) to give the title compound (50.0 mg, 41% yield) as yellow solid. 'H NMR (400MHz, DMSO-i¾) δ 8.43 (s, 1H), 7.05 - 6.98 (m, 2H), 6.87 (d, *J* = 7.6 Hz, 1H), 5.40 - 5.28 (m, 1H), 3.33 (s, 3H), 2.96 - 2.87 (m, 1H), 2.74 - 2.68 (m, 2H), 2.69 - 2.63 (m, 2H), 2.62 - 2.56 (m, 2H), 2.06 - 1.98 (m, 1H), 1.67 - 1.46 (m, 4H), 1.40 - 1.28 (m, 4H), 1.02 (s, 3H).


[003368] Benzyl _((S)-l-(((S)-1-((S)-7-hydroxy-3-(((R)-l,2,3,4-tetrahydronaphthalen-l-yl)carbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-3,3-dimethyl-l-oxobutan-2-yl)amino)-l-oxopropan-2-ylRmethvBcarbamate [Intermediate_PE)



PE

[003369] To a solution of (S)-2-((S)-2-amino-3,3-dimethylbutanoyl)-7-hydroxy-N-((R)-l,2,3,4-tetrahydronaphthalen-l-yl)-l,2,3,4-tetrahydroisoquinoline-3-carboxamide (13.45 g, 30.92 mmol, synthesized via Steps 1-7 of Intermediate MH), (S)-2-(((benzyloxy)carbonyl)(methyl)amino)propanoic acid (7.70 g, 32.47 mmol, CAS# 21691-41-8) in DMF (150 mL) was added HOBT (4.59 g, 34.01 mmoL), EDCI (6.53 g, 34.01 mmoL), and DIPEA (9.97 g, 77.30 mmoL) at rt. The reaction mixture was stirred at r.t. for 4 h. The mixture was then concentrated under reduce pressure. Then the mixture was poured into H_2O (200 mL), extracted with EA (3 x 100 mL), and the combined organic layers were dried over anhydrous Na_2SO_4. The solid was filtered and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel chromatography eluted with DCM/MEOH=lO:l to give the title compound (13.7 g, 63% yield) as a white solid. LC/MS (ESI, *m/z*): $[M+1]^+ = 655.4$.

[003370] Benzyl N-[(lS)-2-[[(lS)-l-[(3S)-7-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]-3-[[(1R)-tetralin-l-yl]carbamoyl]-3,4-dihydro-lH-isoquinoline-2-carbonyl]-2.,2-dimethyl-propyl]amino]-l-methyl-2-oxo-ethyl]-N-methyl-carbamate [Intermediate PF)



PF

[003371] Step 1 - benzyl ((S)-1-(((S)-1-((S)-7-((2,2-dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azahexadecan-16-yl)oxy)-3-(((R)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-1-oxopropan-2-yl)(methyl)carbamate


[003372] To a solution of benzyl ((S)-1-(((S)-1-((S)-7-hydroxy-3-(((R)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-1-oxopropan-2-yl)(methyl)carbamate (1.50 g, 2.29 mmol, Intermediate PE) in CEECN (20 mL) was added 2,2-dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azahexadecan-16-yl 4-methylbenzenesulfonate (1.23 g, 2.75 mmoL, Intermediate LD), and K2CO3 (475 mg, 3.44 mmoL). The mixture was stirred at 82 °C overnight. The reaction mixture was then concentrated under reduced pressure and purified by silica gel chromatography eluted with DCM/EA=1:1 to give the title compound (1.64 g, 77% yield) as a yellow oil. LC/MS (ESI, *m/z)*. [M +1] $^{+}$ = 931.4.

[003373] Step 2 - benzyl ((S)-1-(((S)-1-((S)-7-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethoxy)-3-(((R)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)-3,4-

dihydroisoquinolin-2n H)-yl)-3,3-dimethyl- 1-oxobutan-2-yl)amino)-l -oxopropan-2-vOimethvOcarbamate

[003374] A solution of benzyl ((S)-l-(((S)-l-((S)-7-((2,2-dimethyl-4-oxo-3,8,ll,l4-tetraoxa-5-azahexadecan- 16-yl)oxy)-3 -(((R)- 1,2,3 ,4-tetrahydronaphthalen- 1-yl)carbamoyl)-3 ,4-dihydroisoquinolin-2(lH)-yl)-3,3-dimethyl-l-oxobutan-2-yl)amino)-l-oxopropan-2-yl)(methyl)carbamate (1.37 g, 1.47 mmoL) in TFA/DCM=lO mL/5 mL was stirred at rt for 1 h. The mixture was then concentrated under reduced pressure to give the title compound (900 mg, 74% yield) as a white solid. LC/MS (ESI, *m/z):* [M +l] $^{+}$ = 830.7. ^{1}H NMR (400 MHz, DMSO-d) δ 8.23 (dd, *J* = 49.6, 8.8 Hz, 1H), 7.81 - 7.56 (m, 4H), 7.35 (s, 5H), 7.16 - 6.71 (m, 7H), 5.29 - 4.58 (m, 8H), 4.06 (d, *J* = 3.2 Hz, 2H), 3.76 - 3.73 (m, 2H), 3.64 - 3.52 (m, 10H), 3.05 - 2.91 (m, 3H), 2.87 - 2.80 (m, 2H), 2.78 - 2.61 (m, 3H), 1.91 - 1.50 (m, 4H), 1.20 (d, J = 7.2 Hz, 2H), 1.12 (d, J = 7.2 Hz, 1H), 0.99 (s, 6H), 0.92 (s, 3H).

[003375] Tert-butyl N-[[4-[4-[[2-[2-[tert-butoxycarbonvUcvclopropylmethvPaminol-4-pyridyl]oxazole -4-carbonyl]amino]-3-(difluoromethyPpyrazol-l-yl]phenyl]methyl]-N-(5-oxopentvPcarbamate [Intermediate PG)



GF

PG

[003376] Step 1 - Tert-butyl N-(cvclopropylmethvO-N-r4-r4-rr3-(difluoromethvO-l-r4-r(5-hydroxypentyl amino)methyl1phenyl1pyrazol-4-yl1carbamoyl1oxazol-2-yl1-2-pyridyl1

[003377] A solution of tert-butyl N-(cyclopropylmethyl)-N-[4-[4-[[3-(difluoromethyl)-l-(4-formylphenyl) pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (700 mg, 1.21 mmol, Intermediate GF) and 5-aminopentan-l-ol (187 mg, 1.81 mmol, CAS# 2508-29-4) in DMF (4 mL) and dioxane (20 mL) was stirred at 100 °C for 30 min. Then the reaction mixture was cooled to 25 °C, and AcOH (217 mg, 3.63 mmol, 207 uL) and $NaBH(OAc)_3$ (769 mg, 3.63 mmol) were added . The reaction mixture was stirred at 25 °C for 1 hour. Then another batch $NaBH(OAc)_3$ (256 mg, 1.21 mmol) was added to the reaction mixture. The reaction mixture was stirred at 25 °C for another 2 hours. On completion, the reaction was quenched with sat.$NaHC0_3$ (50 mL) and

extracted with EA (2 X 300 mL). The organic layers were washed with brine (2 X 70 mL), dried with anhydrous Na_2SO_4 and filtered. The filtrate was concentrated *in vacuo* to give the title compound (500 mg, 62% yield) as a white solid. ¾ NMR (400MHz, DMSO-i¾) δ 10.09 (s, 1H), 9.06 (s, 1H), 8.82 (s, 1H), 8.60 (d, *J* = 4.8 Hz, 1H), 8.32 (s, 1H), 8.28 (s, 1H), 7.85 (d, *J* = 8.8 Hz, 2H), 7.55 (d, *J* = 8.8 Hz, 2H), 7.44 - 7.15 (m, 1H), 3.91 - 3.78 (m, 4H), 3.38 (t, *J* = 6.4 Hz, 2H), 2.63 *(t, J* = 6.4 Hz, 2H), 1.54 - 1.28 (m, 13H), 1.25 - 1.13 (m, 1H), 0.48 - 0.39 (m, 2H), 0.27 - 0.20 (m, 2H).

[003378] Step 2 - Tert-butyl N-[[4-[4-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-1-yl]phenyl]methyl]-N-(5-hydroxypentyl)carbamate


[003379] To a solution of tert-butyl N-(cyclopropylmethyl)-N-[4-[4-[[3-(difluoromethyl)-1-[4-[(5-hydroxypentylamino)methyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (450 mg, 675 umol) in DCM (5 mL) was added $(Boc)_2O$ (147 mg, 675 umol) and TEA (136 mg, 1.35 mmol). The reaction mixture was stirred at 25 °C for 0.5 hour. On completion, the reaction mixture was poured into sat.$NaHCO_3$ (60 mL) and extracted with EA (2 X 150 mL). The combined organic layers were washed with brine (70 mL), dried with anhydrous Na_2SO_4, filtered and concentrated *in vacuo*. The residue was purified by silica column chromatography (PE/EA, 4/1 to 1/1) to give the title compound (370 mg, 483 umol, 71% yield) as a white solid. ^1H NMR (400MHz, DMSO-i¾) δ 10.06 (s, 1H), 9.05 (s, 1H), 8.80 (s, 1H), 8.60 (d, *J* = 5.2 Hz, 1H), 8.32 (s, 1H), 7.84 *(d, J* = 8.4 Hz, 2H), 7.70 (dd, *J* = 1.2, 5.2 Hz, 1H), 7.45 - 7.11 (m, 2H), 4.42 (s, 2H), 3.87 (d, *j* = 6.8 Hz, 2H), 3.33 (s, 9H), 2.59 - 2.52 (m, 3H), 1.52 (s, 9H), 1.48 - 1.40 (m, 8H), 1.27 - 1.23 (m, 1H), 0.49 - 0.32 (m, 2H), 0.32 - 0.16 (m, 2H).

[003380] Step 3 - Tert-butyl N-[[4-[4-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-1-yl]phenyl]methyl]-N-(5-oxopentyl)carbamate


[003381] To a solution of tert-butyl N-[[4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl] oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-1-yl]phenyl]methyl]-N-(5-hydroxypentyl)carbamate (370 mg, 483 umol) in DCM (20 mL) was added DMP (225 mg, 531 umol). The reaction mixture was stirred at 25 °C for 2 hours. On completion, the reaction mixture was quenched sat.$Na_2S_2O_3$ (lOmL) and extracted with EA (2 X 100). The combined organic layers were washed with brine (70 mL), dried with

anhydrous Na_2SO_4 and filtered. The filtrate was concentrated *in vacuo* to give the title compound (350 mg, 458 umol, 94% yield) as a light yellow solid. ^1H NMR (400MHz, DMSO-d«) δ 10.06 (s, 1H), 9.08 - 8.99 (m, 1H), 8.83 - 8.74 (m, 1H), 8.65 - 8.52 (m, 1H), 8.36 - 8.27 (m, 1H), 8.02 - 7.93 (m, 1H), 7.87 - 7.77 (m, 2H), 7.73 - 7.69 (m, 1H), 7.50 - 7.44 (m, 1H), 7.42 - 7.37 (m, 1H), 7.30 - 7.20 (m, 1H), 4.42 (s, 2H), 3.91 - 3.82 (m, 2H), 3.33 (s, 9H), 2.56 - 2.52 (m, 2H), 2.47 - 2.34 (m, 1H), 1.55 - 1.41 (m, 15H), 0.92 - 0.70 (m, 1H), 0.45 - 0.36 (m, 2H), 0.30 - 0.18 (m, 2H).

[003382] **3-[5-(AminomethvO-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2.,6-dione [Intermediate PH)**



HN



PH


[003383] Step 1 - 1-(2,6-Dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazole-5-carbonitrile


[003384] To a mixture of 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (3.00 g, 8.87 mmol, Intermediate HN) in DMF (30 mL) was added $Zn(CN)_2$ (1.04 g, 8.87 mmol) and $Pd(PPh_3)_4$ (1.03 g, 887 umol). The reaction mixture was stirred at 100 °C for 3 hours under N_2. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was diluted with water (50 mL) and extracted with EA (3 X 100 mL). The combined organic layers were dried over Na_2SO_4, filtered and the filtrate concentrated *in vacuo.* The residue was purified by prep-HPLC (0.1 % FA condition) to give the title compound (1.50 g, 59% yield) as a white solid. ¾ NMR (400 MHz, DMSO-r¾) δ 11.31 - 11.00 (m, 1H), 11.15 (s, 1H), 7.75 (d, *J* = 1.2 Hz, 1H), 7.57 - 7.52 (m, 1H), 7.34 (d, *J* = 8.4 Hz, 1H), 5.49 - 5.42 (m, 1H), 3.38 (s, 3H), 2.95 - 2.83 (m, 1H), 2.79 - 2.59 (m, 2H), 2.10 - 2.01 (m, 1H).


[003385] Step 2 - 3-r5-(Aminomethyl)-3-methyl-2-oxo-benzimidazol-1-yllpiperidine-2.6-dione


[003386] To a solution of l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazole-5-carbonitrile (1.40 g, 4.92 mmol) in THF (150 mL) was added Raney-Ni (421 mg, 4.92 mmol) and HCl/dioxane (4 M, 4.92 mL). The reaction mixture was stirred at 25 °C for 36 hours under H_2 (50 Psi). On completion, the reaction mixture was filtered. The filter cake was washed with DMF (3 X 10 mL). The combined organic layers were concentrated *in vacuo* to give the title compound (1.40 g, 98% yield) as a green solid. LC-MS (ESI^+) m/z 289.0 $(M+H)^+$.

[003387] 2-[2-rTert-butoxycarbonyl- [[4-[4-[[2-[2-rtert-butoxycarbonvUcvclopropylmethvOaminol -4-_ _pyridyl1oxazole-4-carbonyl]amino1-3-(difluoromethyQpyrazol-l-yll phenyl] methyl] amino] ethoxy] ethyl_ methanesulfonate [Intermediate PI)









[003388] Step 1 - Tert-butyl N-(cvclopropylmethvD-N-r4-r4-rr3-(difluoiOmethvD-l-r4-IT2-(2-hydroxyethoxy) _ ethylamino1methyl1phenyl1pyrazol-4-yl1carbamoyl1oxazol-2-yl1-2-pyridyllcarbamate

[003389] To a solution of tert-butyl N-(cyclopropylmethyl)-N-[4-[4-[[3-(difluoromethyl)-l-(4-formylphenyl) pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (600 mg, 1.04 mmol, Intermediate GF) in a mixed solvent of DMF (10 mL) and THF (100 mL) was added 2-(2-aminoethoxy)ethanol (141 mg, 1.35 mmol, CAS# 929-06-6) and HOAc (124 mg, 2.07 mmol). The reaction mixture was stirred at 25 °C for 0.5 hr. Then, $NaBH(OAc)_3$ (659 mg, 3.11 mmol) was added. The resulting reaction mixture was stirred at 25 °C for 16 hours. On completion, the reaction mixture was quenched with water (1 mL) and concentrated *in vacuo*. The residue was purified by reversed-phase flash chromatography (FA, 0.1 %) to give the title compound (400 mg, 57% yield) as a yellow solid. ^1H NMR (400MHz, DMSO-7 $_5$) δ 10.06 (s, 1H), 9.05 (s, 1H), 8.82 (s, 1H), 8.60 (d, J = 5.2 Hz, 1H), 8.32 (s, 1H), 7.86 (d, J = 8.8 Hz, 2H), 7.70 (dd, J = 1.6, 5.2 Hz, 1H), 7.55 (d, J = 8.8 Hz, 2H), 7.43 - 7.15 (m, 1H), 5.75 (s, 1H), 3.92 (s, 2H), 3.87 (d, J = 6.8 Hz, 2H), 3.56 (t, J = 5.6 Hz, 2H), 3.53 - 3.50 (m, 2H), 3.45 - 3.42 (m, 2H), 2.81 (t, 7 = 5.6 Hz, 2H), 1.52 (s, 9H), 1.24 - 1.12 (t, J = 7.8 Hz, 1H), 0.45 - 0.38 (m, 2H), 0.27 - 0.22 (m, 2H).


[003390] Step 2 - Tert-butyl N-rr4-I4-rr2-I2-Tert-butoxycarbonyl(cvclopropylmethvDamino1-4-pyridyl1oxazole _ -4-carbonyl1amino1-3-(difluoromethvDpyrazol-l-yl1phenyl1methyl1-N-r2-(2-hvdroxyethoxy)ethyl1carbamate

[003391] To a solution of tert-butyl N-(cyclopropylmethyl)-N-[4-[4-[[3-(difluoromethyl)-l-[4-[[2-(2- hydroxyethoxy)ethylamino]methyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (400 mg, 599 umol) in DCM (20 mL) was added TEA (181 mg, 1.80 mmol) and Boc_20 (156 mg, 718 umol). The reaction mixture was stirred at 25 °C for 0.5 hour. On completion, the reaction mixture was poured into sat. $NaHC0_3$ (30 mL) and extracted with EA (3 X 100 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na_2S0_4, and filtered. The filtrate was concentrated *in vacuo* to give the title compound (450 mg, 100% yield) as a white solid. LC-MS (ESI^+) m/z 768.1 $(M+H)^+$.


[003392] Step 3 - 2-r2-rTert-butoxycarbonyl-rr4-r4-rr2-r2-rtert-butoxycarbonyl(cvclopropylmethyl)amino1-4- _ pyridyl]oxazole-4-carbonyl]amino]-3-(difluoromethvDpyrazol- 1-yllphenyllmethyllaminolethoxylethyl methanesulfonate


[003393] To a solution of tert-butyl N-[[4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl] oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol- 1-yl]phenyl]methyl]-N-[2-(2-hydroxyethoxy)ethyl]carbamate (400 mg, 520 umol) in DCM (20 mL) was added TEA (158 mg, 1.56 mmol). The reaction mixture was cooled to 0 °C. Then, MsCl (119 mg, 1.04 mmol) was dropwise into the mixture slowly. The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was poured into sat.$NaHC0_3$ (30 mL) and extracted with EA (3 X 50 mL). The combined organic layers were washed with brine (50 mL), dried with anhydrous Na_2S0_4 and filtered. The filtrate was concentrated *in vacuo* to give the title compound (400 mg, 100% yield) as a yellow solid. LC-MS (ESI^+) m/z 846.2 $(M+H)^+$.

[003394] Benzyl N-[(1*S*)-2-[[(1*S*)-1-[(3*S*)-7-[2-[2-[2-[2-(2-aminoethoxy]ethoxy] ethoxy]ethoxy] ethoxy]-3-[[(1*R*)-tetralin-1-yl]carbamoyl]-3,4-dihydro-1H-isoquinoline-2-carbonyl]-2.,2-dimethyl-propyl]amino]-1-methyl-2-oxo-ethyl]-N-methyl-carbamate [Intermediate PJ)



PE





PJ


[003395] Step 1 - benzyl ((S)-1-(((S)-1-((S)-7-((2,2-dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azanonadecan-19-yl)oxy)-3-(((R)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-1-oxopropan-2-yl)(methyl)carbamate

[003396] To a solution of benzyl ((S)-1-(((S)-1-((S)-7-hydroxy-3-(((R)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-1-oxopropan-2-yl)(methyl)carbamate (1.0 g, 1.53 mmol, Intermediate PE) in CEECN (50 mL) was added 2,2-dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azanonadecan-19-yl 4-methylbenzenesulfonate (901 mg, 1.84 mmol, Intermediate ON) and K_2CO_3 (317 mg, 2.3 mmol) at rt. The reaction mixture was then stirred at 80 °C for 12 h. The reaction mixture was cooled to rt and filtered. The filtrate was concentrated under reduced pressure. The residue was purified via column chromatography (EtOAc / petroleum ether) to give the title compound (1.08 g, 73% yield) as a pale yellow oil. LC/MS (ESI, *m/z)*: [M+1] $^+$ = 974.68.

[003397] Step 2 - benzyl ((S)-1-(((S)-1-((S)-7-(T14-amino-3.6.9J 2-tetraoxatetradecyl)oxy)-3-(((R)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)-3.4-dihydroisoquinolin-2n H)-yl)-3.3-dimethyl-l-oxobutan-2-vnamino)-l-oxopropan-2-vn(methvncarbamate 2.2.2-trifluoroacetate

[003398] To a solution of benzyl ((S)-1-(((S)-1-((S)-7-((2,2-dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azanonadecan-19-yl)oxy)-3-(((R)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-1-oxopropan-2-yl)(methyl)carbamate (1.4 g, 1.43 mmol) in DCM (20 mL) was added TFA (20 mL) and the reaction mixture was stirred at rt for 3 h. The reaction mixture was concentrated under reduced pressure and the residue was purified via reverse phase column chromatography (ACN / H_20) to give the title compound (1.341 g, 94.8 % yield) as as a white solid. ^{1}H NMR (400 MHz, DMSO-d_6) δ: 8.30 - 8.15 (m, 1H), 7.77 - 7.56 (m, 4H), 7.40 - 7.35 (m, 5H), 7.18 - 6.70 (m, 7H), 5.28 - 4.23 (m, 9H), 4.13 - 4.00 (m, 2H), 3.74 (t, J = 4.5 Hz, 2H), 3.69 - 3.23 (m, 14H), 3.02 - 2.64 (m, 8H), 1.95 - 1.45 (m, 4H), 1.21 - 1.11 (m, 13H), 0.99 - 0.91 (m, 9H). LC/MS (ESI, *m/z):* [M+1] $^+$ = 874.55.


[003399] 3-(Tert-butoxycarbonylamino)nronyl (4-nitrophenyl) carbonate [Intermediate PK)



PK

[003400] To a solution of tert-butyl N-(3-hydroxypropyl)carbamate (0.600 g, 3.42 mmol, CAS# 58885-58-8) and (4-nitrophenyl) carbonochloridate (759 mg, 3.77 mmol, CAS# 7693-46-1) in DCM (25 mL) was added TEA (866 mg, 8.56 mmol) at 0 °C. The reaction mixture was stirred at this temperature for 1 hr. On completion, the mixture was quenched with water (10 mL), then concentrated *in vacuo.* The residue was purified by silica gel chromatography (SiO_2) to give the title compound (520 mg, 45% yield) as colorless oil. ¾ NMR (300MHz, CDCh) δ 8.34 - 8.25 (m, 2H), 7.44 - 7.35 (m, 2H), 4.77 (s, 1H), 4.36 (t, *J* = 6.4 Hz, 2H), 3.29 (q, *J* = 6.4 Hz, 2H), 2.03 - 1.90 (m, 2H), 1.45 (s, 9H).

[003401] **3-Aminopropyl N-[[l-(2.,6-dioxo-3-piperidv0-3-methyl-2-oxo-benzimidazol-5-yl]methyl] carbamate (Intermediate PL)**



[003402] Step 1 - 3-(Tert-butoxycarbonylamino)propyl N-ri l-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo- benzimidazol-5-yllmethyllcarbamate


[003403] To a solution of 3-[5-(aminomethyl)-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione (120 mg, 416 umol, Intermediate PH) and 3-(tert-

butoxycarbonylamino)propyl (4-nitrophenyl) carbonate (170 mg, 500 umol, Intermediate PK) in DMF (2 mL) was added TEA (84.2 mg, 832 umol). The reaction mixture was stirred at 25 °C for 3 hrs. On completion, the mixture was concentrated in *vacuo.* The residue was purified by reverse phase (0.1% FA condition) to give the title compound (110 mg, 54% yield) as a white solid. ^{1}H NMR (400 MHz, DMSO-^e) δ 11.05 (s, 1H), 7.64 (s, 1H), 7.10 - 7.01 (m, 2H), 6.98 - 6.91 (m, 1H), 6.86 - 6.78 (m, 1H), 5.43 - 5.29 (m, 1H), 4.19 (d, *J* = 6.0 Hz, 2H), 3.95 (t, *J* = 6.4 Hz, 2H), 3.30 (s, 3H), 3.02 - 2.94 (m, 2H), 2.94 - 2.84 (m, 1H), 2.69 - 2.56 (m, 2H), 2.09 - 1.94 (m, 1H), 1.73 - 1.58 (m, 2H), 1.37 (s, 9H); LC-MS (ESI$^+$) *m/z* 512.3 (M+Na)$^+$.

[003404] Step 2 - 3-Aminopropyl N-ri l-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yllmethvn carbamate

[003405] To a solution of 3-(tert-butoxycarbonylamino)propyl N-[[l-(2,6-dioxo-3-piperidyl)-3 -methyl -2-oxo- benzimidazol-5-yl]methyl]carbamate (140 mg, 286 umol) in DCM (5 mL) was added TFA (5 mL). The reaction mixture was stirred at 25 °C for 1 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (140 mg, 97% yield, TFA) as a white solid. LC-MS (ESI$^+$) m/z 390.2 (M+H)$^+$

[003406] **Tert-butyl 4-(3-methyl-2-oxo-lH-benzimidazol-5-vBpiperazine-l-carboxylate [Intermediate PM)**




IP PM

[003407] To a solution of 5-bromo-3-methyl-lH-benzimidazol-2-one (4.00 g, 17.6 mmol, Intermediate IP), tert-butyl piperazine- l-carboxylate (4.92 g, 26.4 mmol, CAS# 1433238-38-4) and t-BuOK (4.35 g, 38.8 mmol), was added RuPhos (822 mg, 1.76 mmol) and [2-(2-aminophenyl)phenyl] -chloro-palladium;dicyclohexyl-[2-(2,6-diisopropoxyphenyl) phenyl] phosphane (1.37 g, 1.76 mmol) in dioxane (100 mL), and the mixture was stirred at 90 °C for 1 hr at N_2. On completion, the residue was diluted with H_20 (50 mL) and extracted with EtOAc (3 X 100 mL). The combined organic layers were washed with brine (150 mL), dried over Na_2S0_4, filtered and concentrated under reduced pressure to give a residue. The residue was triturated with PE: EA (10:1, 50 mL), filtered and filtered caked was dried under reduced pressure to give the title

compound (3.80 g, 65% yield) as a yellow solid. ¾NMR (400 MHz, DMSO-d«) δ 10.54 (s, 1 H), 6.83 (d, *J* = 8.4 Hz, 1 H), 6.78 (d, *J* = 2.20 Hz, 1 H), 6.60 (dd, *J* = 8.4, Hz, 1 H), 3.43 - 3.50 (m, 4 H), 3.24 (s, 3 H), 2.98 - 3.03 (m, 4 H), 1.42 (s, 9 H), LC-MS (ESI+) m/z 333.1 $(M+H)^+$.

[003408] **3-(3-Methyl-2-oxo-5-piperazin-l-yl-benzimidazol-l-vDpiperidine-2.,6-dione [Intermediate PN)**




[003409] Step 1 - Tert-butyl 4-[1-[1-[(4-methoxyphenyl)methyl]-2,6-dioxo-3-piperidyl]-3-methyl-2-oxo- benzimidazol-5-yllpiperazine-l-carboxylate

[003410] To a solution of tert-butyl 4-(3-methyl-2-oxo-lH-benzimidazol-5-yl)piperazine-l-carboxylate (3.80 g, 11.4 mmol, Intermediate PM) in THF (100 mL) was added t-BuOK (2.57 g, 22.9 mmol); then [l-[(4-methoxyphenyl)methyl]-2,6-dioxo-3-piperidyl] trifluoromethanesulfonate (8.72 g, 22.86 mmol, Intermediate IQ) in THF (20 mL) was added at 0 °C.The mixture was stirred at 0 °C for 2 hrs. On completion, the residue was diluted with H_20 (50 mL) and extracted with EtOAc (3 X 50mL). The combined organic layers were washed with brine (100 mL), dried over Na_2S0_4, filtered and concentrated under reduced pressure to give a residue. The residue was triturated with PE: EA (10:1, 50 mL), filtered and the filtered cake was dried *in vacuo* to give the title compound (3.00 g, 37% yield, 80% purity) as a blue solid. LC-MS (ESI+) m/z 564.3 $(M+H)^+$.

[003411] Step 2 - 3-(3-Methyl-2-oxo-5-piperazin-l-yl-benzimidazol-l-vDpiperidine-2.6-dione

[003412] To a solution of tert-butyl 4-[l-[l-[(4-methoxyphenyl)methyl]-2,6-dioxo-3-piperidyl] -3-methyl-2-oxo-benzimidazol-5-yl]piperazine-l-carboxylate (2.50 g, 4.44 mmol) in DCM (40 mL) was added TFA (38.5 g, 338 mmol, 25.0 mL), and the mixture was stirred at 15 °C for 1 hr. Then methanesulfonic acid (33.8 g, 351 mmol, 25 mL) was added and the mixture was stirred at 15 °C for 25 hrs. On completion, the mixture was concentrated *in vacuo*. The residue was purified by reversed-phase HPLC (0.1% FA condition) to give the title compound (700 mg, 40% yield) as a blue solid. ^{1}H NMR (400 MHz, DMSO-^e) δ 10.89 - 11.20 (m, 1 H), 6.98 (d, *J* = 8.4 Hz, 1 H), 6.89 *(d, J* = 1.6 Hz, 1 H), 6.67 (dd, *J* = 8.4, 1.6 Hz, 1 H), 5.31 (dd, *J* = 12.8, 5.6 Hz, 1 H), 3.21 (d, 7 = 3.6 Hz, 4 H), 3.15 (s, 4 H), 2.85 - 2.95 (m, 1 H), 2.63 - 2.75 (m, 2 H), 1.96 - 2.04 (m, 1 H), LC-MS (ESI+) m/z 344.1 $(M+H)^{+}$.


[003413] **Tert-butyl N-methyl-N-(3-prop-2-vnoxypropyl)carbamate [Intermediate PO)**



PO

[003414] To a solution of 3-bromoprop-l-yne (1.32 g, 11.1 mmol, CAS# 106-96-7) and tert-butyl N-(3-hydroxypropyl)-N-methyl-carbamate (2.00 g, 10.6 mmol, CAS# 98642-44-5) in THF (20 mL) was added TBAI (234 mg, 634 umol) and Kl (263 mg, 1.59 mmol). Then KOH (698 mg, 10.6 mmol, 85% purity) was added into the above mixture. The reaction mixture was stirred at 25 °C for 12 hrs. On completion, the mixture was concentrated *in vacuo* to remove the solvent, the residue was diluted with water (30 mL), then extracted with EA (3 X 40 mL). The organic phase was dried over Na_2S0_4, filtered and the filtrate was concentrated *in vacuo*. The residue was purified by silica gel chromatography ($Si0_2$) to give the title compound (1.15 g, 48% yield) as colorless oil. ^{1}H NMR (400MHz, CDCh) δ 4.15 - 4.11 (m, 2H), 3.57 - 3.49 (m, 2H), 3.29 (t, *J* = 6.8 Hz, 2H), 2.86 (s, 3H), 2.42 (t, *J* = 2.4 Hz, 1H), 1.85 - 1.76 (m, 2H), 1.46 (s, 9H).

[003415] **3-[3-Methyl -4- [3-[3-(methylamino)propoxy|propyl-2-oxo-benzimidazol-l-yl] piperidine- 2,6-dione [Intermediate PP1**



[003416] Step 1 - Tert-butyl N-[3-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl1prop-2- ynoxyIpropyll-N-methyl-carbamate

[003417] 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (300 mg, 887 umol, Intermediate HP), tert-butyl N-m ethyl -N-(3-prop-2-ynoxypropyl)carbamate (504 mg, 2.22 mmol, Intermediate PO), Pd(PPh $_3$)2Cl2 (125 mg, 177 umol), CS2CO3 (1.45 g, 4.44 mmol), Cul (33.8 mg, 177 umol) and 4A molecular sieves (150 mg) in DMF (8 mL) was heated at 80 °C for 2 hrs under N2. On completion, the mixture was concentrated *in vacuo.* The residue was purified by reverse phase (0.1% FA condition) to give the title compound (200 mg, 40% yield) as a yellow solid. LC-MS (ESI$^+$) *m/z* 507.3 (M+Na)$^+$.

[003418] Step 2 - Tert-butyl N-[3-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazoM-yllpropoxyl propyl-N-methyl-carbamate


[003419] To a solution of tert-butyl N-[3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] prop-2-ynoxy]propyl]-N-methyl-carbamate (200 mg, 351 umol) in THF (6 mL) was added Pd/C (0.100 g, 10% *wi)* and Pd(OH)2/C (0.100 g, 10% *wi).* The reaction mixture was stirred at 25 °C for 10 hrs under ¾ (15 Psi) atmosphere. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (200 mg, 93% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-i¾) δ 11.10 (s, 1H), 7.00 - 6.92 (m, 2H), 6.90 - 6.84

(m, 1H), 5.44 - 5.24 (m, 1H), 3.56 (s, 3H), 3.44 - 3.40 (m, 4H), 3.22 (t, *j* = 7.2 Hz, 2H), 2.99 - 2.92 (m, 2H), 2.76 (s, 3H), 2.74 - 2.69 (m, 1H), 2.65 - 2.58 (m, 2H), 2.04 - 1.96 (m, 1H), 1.87 - 1.79 (m, 2H), 1.74 - 1.65 (m, 2H), 1.38 (s, 9H); LC-MS (ESI^+) m/z 511.3 $(M+Na)^+$.

[003420] Step 3 - 3-[3-Methyl -4- r3-r3-(methylamino)propoxy1propyl-2-oxo-benzimidazol-l-yllpiperidine- 2.6-dione

[003421] To a solution of tert-butyl N-[3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propoxy]propyl]-N-methyl-carbamate (200 mg, 327 umol) in DCM (4 mL) was added HCl/dioxane (4 M, 3.20 mL). The reaction mixture was stirred at 25 °C for 2 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (160 mg, 100% yield, HC1) as a white solid. ^1H NMR (400MHz, DMSO-r¾) δ 11.08 (s, 1H), 7.02 - 6.92 (m, 2H), 6.90 - 6.83 (m, 1H), 5.44-5.24 (dd, *J* = 5.6, 12.4 Hz, 1H), 3.57 (s, 3H), 3.49 - 3.43 (m, 4H), 3.00 - 2.91 (m, 4H), 2.74 - 2.53 (m, 6H), 2.04 - 1.94 (m, 1H), 1.90 - 1.81 (m, 4H); LC-MS (ESI^+) *m/z* 389.2 $(M+H)^+$.


[003422] **Tert-butyl N-(3-prop-2-viioxypropyl)carbainate [Intermediate PX)**



PX

[003423] To a mixture of tert-butyl N-(3-hydroxypropyl)carbamate (10.0 g, 57.1 mmol, CAS# 58885-58-8), 3-bromoprop-l-yne (8.15 g, 68.5 mmol, CAS# 106-96-7) in THF (150 mL) was added TBAI (1.26 g, 3.42 mmol) KOH (3.20 g, 57.07 mmol) and KI (1.42 g, 8.56 mmol). The mixture was stirred at 20 °C for 12 hours. On completion, the reaction mixture was concentrated *in vacuo* to give residue. The residue was purified by column chromatography to give the title compound (6.80 g, 55% yield) as yellow solid. ¾NMR (400MHz, CDCh) δ 4.76 (s, 1H), 4.10 - 4.05 (m, 2H), 3.51 (t, *J* = 6.0 Hz, 2H), 3.16 (q, *J* = 6.0 Hz, 2H), 2.37 (t, *J* = 2.4 Hz, 1H), 1.74 - 1.65 (m, 2H), 1.37 (s, 9H).

[003424] **3-[7-[3-[3-Aminopropoxy)propyl1-2-oxo-l,3-benzoxazol-3-yl]piperidine-2,6-dione [Intermediate PY)**



[003425] Step 1 - Tert-butyl N-[3-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-1,3-benzoxazol-7-yl1prop-2-vnoxy1propyl1 carbamate

[003426] To a mixture of 3-(7-bromo-2-oxo-l,3-benzoxazol-3-yl)piperidine-2,6-dione (3.00 g, 9.23 mmol, Intermediate JF) and tert-butyl N-(3-prop-2-ynoxypropyl)carbamate (4.92 g, 23.0 mmol, Intermediate PX) in DMF (30 mL) was added CS_2CO_3 (15.0 g, 46.1 mmol), Cul (175 mg, 922 umol) and $Pd(PPh3)_2Cl2$ (647 mg, 922 umol). The reaction mixture was stirred at 80 °C for 2 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo*. The residue was diluted with water (50 mL) and extracted with EA (3 X 100 mL). The combined organic layers was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1 % FA condition) to give the title compound (2.70 g, 63 % yield) as light yellow solid. ^1H NMR (400MHz, DMSO-r¾) δ 11.23 (s, 1H), 7.32 (dd, *J* = 2.0, 7.2 Hz, 1H), 7.27 - 7.19 (m, 2H), 6.81 - 6.77 (m, 1H), 5.39 (dd, *J* = 5.6, 13.2 Hz, 1H), 4.43 (s, 2H), 3.53 (t, *j* = 6.4 Hz, 2H), 3.02 - 2.97 (m, 2H), 2.92 - 2.81 (m, 1H), 2.73 - 2.58 (m, 2H), 2.22 - 2.13 (m, 1H), 1.70 - 1.64 (m, 2H), 1.36 (s, 9H); LC-MS (ESI^+) *m/z* 480.2 $(M+Na)^+$.


[003427] Step 2 - Tert-butyl N-r3-r3-r3-(2.6-dioxo-3-piperidyl)-2-oxo-1,3-benzoxazol-7-yllpropoxylpropyll carbamate

[003428] To a mixture was tert-butyl N-[3-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-l,3-benzoxazol-7-yl]prop-2- ynoxy]propyl]carbamate (2.30 g, 5.03 mmol) in THF (200 mL) was added Pd/C (0.6 g, 10% *wt)* and $Pd(OH)_2$/C (0.6 g, 10% *wt).* The reaction mixture was stirred at 25 °C for 12 hours under H_2 (15 Psi) atmosphere. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (2.30 g, 99% yield) as off-white solid. LC-MS (ESI^+) *m/z* 484.2 $(M+Na)^+$.

[003429] Step 3 - 3-[7-[3-(3-Aminopropoxy)propyl1-2-oxo- l.3-benzoxazol-3-yl1piperidine-2.6-dione

[003430] To a mixture of tert-butyl N-[3-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-l,3-benzoxazol-7-yl]propoxy] propyl]carbamate (2.30 g, 4.98 mmol) in DCM (10 mL) was added HCl/dioxane (4 M, 10 mL). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (1.80 g, 90% yield, HC1 salt) as off-white solid. ^1H NMR (400MHz, DMSO-r¾) δ 11.20 (s, 1H), 7.86 (s, 2H), 7.17 - 7.09 (m, 2H), 7.04 - 7.00 (m, 1H), 5.37 (dd, J = 5.2, 13.2 Hz, 1H), 3.47 - 3.43 (m, 2H), 3.43 - 3.41 (m, 2H), 2.90 - 2.84 (m, 2H), 2.83 - 2.79 (m, 1H), 2.78 - 2.72 (m, 2H), 2.70 - 2.61 (m, 2H), 2.20 - 2.10 (m, 1H), 1.91 - 1.84 (m, 2H), 1.83 - 1.78 (m, 2H).

[003431] 3-[6-[3-[3-Aminopropoxy]propyl1-2-oxo-l,3-benzoxazol-3-yl]piperidine-2,6-dione [Intermediate_PZ)



[003432] Step 1 - Tert-butyl N-[3-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-1,3-benzoxazol-6-yllprop-2-vnoxylpropyn carbamate

[003433] To a mixture of 3-(6-bromo-2-oxo-l,3-benzoxazol-3-yl)piperidine-2,6-dione (1.20 g, 3.69 mmol, Intermediate OZ) and tert-butyl N-(3-prop-2-ynoxypropyl)carbamate (1.57 g, 7.38 mmol, Intermediate PX) in DMF (30 mL) was added CuI (210 mg, 1.11 mmol), Pd(PPh $_3$)2Cl2 (777 mg, 1.11 mmol), CS2CO3 (6.01 g, 18.5 mmol) and 3A molecular sieves (100 mg, 3.69 mmol) under N2. The reaction mixture was stirred at 80 °C for 2 hours. On completion, the reaction mixture was cooled to 25 °C. Then the mixture was filtered and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (868 mg, 42% yield) as brown solid. ^{1}H NMR (400MHz, CDCb) δ 8.49 (s, 1H), 7.74 - 7.65 (m, 1H), 7.61 - 7.54 (m, 1H), 7.36 (d, *J* = 1.0 Hz, 1H), 7.30 - 7.27 (m, 1H), 6.79 (d, *J* = 8.4 Hz, 1H), 5.07 *(d, J* = 5.6, 13.2 Hz, 1H), 4.37 (s, 2H), 3.66 (t, *J* = 6.0 Hz, 2H), 3.27 (d, *J* = 6.0 Hz, 2H), 3.05 - 2.95 (m,

1H), 2.92 - 2.80 (m, 1H), 2.79 - 2.65 (m, 1H), 2.40 - 2.26 (m, 1H), 1.85 - 1.80 (m, 2H), 1.45 (s, 9H).


[003434] Step 2 - Tert-butyl N-[3-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-1,3-benzoxazol-6-yl]propoxy]propyl]carbamate

[003435] To a mixture of tert-butyl N-[3-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-l,3-benzoxazol-6-yl]prop-2-ynoxy]propyl]carbamate (868 mg, 1.90 mmol) in THF (30 mL) was added Pd/C (200 mg, 10 wt%) and $Pd(OH)_2/C$ (200 mg, 10 wt%). The suspension was degassed under vacuum and purged with H_2 gas 3 times. The mixture was stirred under H_2 (15 psi) at 20 °C for 12 hours. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (835 mg, 95% yield) as brown solid. ^1H NMR (400 MHz, DMSO-d_6) δ 11.22 (s, 1H), 7.66 - 7.59 (m, 1H), 7.27 (s, 1H), 7.16 (s, 1H), 7.05 (s, 1H), 5.37 - 5.32 (m, 1H), 2.98 (d, ***J*** = 6.4 Hz, 2H), 2.71 - 2.64 (m, 5H), 2.34 ***(d, J*** = l.6Hz, 3H), 2.16 - 2.15 (m, 2H), 1.88 - 1.72 (m, 2H), 1.66 - 1.54 (m, 2H), 1.37 (s, 9H).

[003436] Step 3 - 3-[6-[3-(3-Aminopropoxy)propyl]-2-oxo-1,3-benzoxazol-3-yl]piperidine-2,6-dione

[003437] To a mixture of tert-butyl N-[3-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-l,3-benzoxazol-6-yl]propoxy] propyl]carbamate (680 mg, 1.47 mmol) in DCM (20 mL) was added HCl/dioxane (4 M, 0.7 mL). The reaction mixture was stirred at 20 °C for 2 hours. On completion, the reaction mixture was concentrated *in vacuo* to give title compound (580 mg, 98% yield) as a white solid. LC-MS (ESI^+) *m/z* 362.1 $(M+H)^+$.

[003438] 3-[7-[3-[3-[Methylamino)propoxy]propyl]-2-oxo-l,3-benzoxazol-3-yl]piperidine-2.,6-dione [Intermediate QA)



[003439] Step 1 - Tert-butyl N-[3-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-1,3-benzoxazol-7-yllprop-2-vnoxylpropyn -N-methyl-carbamate

[003440] To a solution of tert-butyl N-methyl-N-(3-prop-2-ynoxypropyl)carbamate (1.05 g, 4.61 mmol, Intermediate PO) and 3-(7-bromo-2-oxo-l,3-benzoxazol-3-yl)piperidine-2,6-dione (500 mg, 1.54 mmol, Intermediate JF) in DMF (10 mL) was added $Pd(PPh_3)2Cl2$ (215 mg, 307 umol), Cul (58.5 mg, 307 umol) and $CS2CO3$ (2.51 g, 7.69 mmol). The reaction mixture was stirred at 80 °C for 2 hr under N2. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (440 mg, 60% yield) as a yellow solid. ^{1}H NMR (400MHz, DMS0-d_6) δ 11.21 (s, 1H), 7.35 - 7.28 (m, 1H), 7.28 - 7.19 (m, 2H), 5.39 (dd, J = 5.2, 12.8 Hz, 1H), 4.45 (s, 2H), 3.53 (t, j = 6.4 Hz, 2H), 3.23 (t, J = 6.8 Hz, 2H), 2.94 - 2.82 (m, 1H), 2.77 (s, 3H), 2.71 - 2.60 (m, 2H), 2.22 - 2.13 (m, 1H), 1.81 - 1.68 (m, 2H), 1.37 (s, 9H); LC-MS (ESI^+) m/z 372.1 (M +H-l00) $^+$.

[003441] Step 2 - Tert-butyl N-r3-r3-r3-(2.6-dioxo-3-piperidyl)-2-oxo-1,3-benzoxazol-7-yllpropoxylpropyll-N- methyl-carbamate


[003442] To a solution of tert-butyl N-[3-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-l,3-benzoxazol-7-yl]prop-2- ynoxy] propyl]-N-methyl-carbamate (440 mg, 933 umol) in THF (10

mL) was added $Pd(OH)_2/C$ (150 mg, 10 wt%) and Pd/C (150 mg, 10 wt%). The reaction mixture was stirred at 25 °C under H_2 (15 psi) for 12 hours. On completion, the residue was filtered and the filtrate was concentrated *in vacuo* to give the title compound (400 mg, 90% yield) as a white solid. ^1H NMR (400MHz, DMSO-d_6) δ ¾NMR (400MHz, DMSO^) δ 11.21 (s, 1H), 7.18 - 7.06 (m, 2H), 7.01 (d, J = 7.2 Hz, 1H), 5.35 (dd, J = 5.2, 12.8 Hz, 1H), 3.42 - 3.38 (m, 2H), 3.35 - 3.30 (m, 2H), 3.21 (t, j = 7.2 Hz, 2H), 2.93 - 2.83 (m, 1H), 2.78 - 2.71 (m, 5H), 2.70 - 2.61 (m, 2H), 2.19 - 2.10 (m, 1H), 1.91 - 1.79 (m, 2H), 1.74 - 1.63 (m, 2H), 1.37 (s, 9H); LC-MS (ESI^+) m/z 489.2 $(M+Na)^+$.

[003443] Step 3 - 3-r7-r3-r3-(Methylamino)propoxy1propyl1-2-oxo-L3-benzoxazol-3-yl1piperidine-2.6-dione

[003444] To a solution of tert-butyl N-[3-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-l,3-benzoxazol-7-yl]propoxy]propyl] -N-methyl-carbamate (400 mg, 841 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 5 mL).The reaction mixture was stirred at 20 °C for 1 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (340 mg, 98% yield, HC1) as a white solid. LC-MS (ESI^+) m/z 376.2$(M+H)^+$.

[003445] **2-Tert-butvl N-[2-[2-[2-(2-oxo-3H-benzimidazol-l-yl)ethoxy]ethoxy]ethyl]carbamate (Intermediate QB)**



QB

[003446] Step 1 - Tert-butyl N-r2-r2-r2-(2-nitroanilino)ethoxy1ethoxy1ethyl1carbamate

[003447] To a mixture of l-fluoro-2-nitro-benzene (2.84 g, 20.1 mmol, 2.12 mL, CAS# 127723-77-7) and tert-butyl N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]carbamate (5.00 g, 20.1 mmol, CAS# 153086-78-3) in DMF (50 mL) was added K2CO3 (8.35 g, 60.4 mmol). The reaction mixture was stirred at 80 °C for 2 hours. On completion, the reaction mixture was diluted with water (50 mL) and extracted with EA (2 X 100 mL). The combined organic layers was dried over Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (7.40 g, 99% yield) as red oil. 'H

NMR (400 MHz, CDCh) δ 8.25 (s, 1H), 8.20 - 8.14 (m, 1H), 7.48 - 7.40 (m, 1H), 6.86 (d, *J* = 8.4 Hz, 1H), 6.71 - 6.61 (m, 1H), 5.07 (s, 1H), 3.80 (t, *J* = 5.2 Hz, 2H), 3.71 - 3.62 (m, 4H), 3.59 - 3.49 (m, 4H), 3.88 - 3.27 (m, 2H), 1.43 (s, 9H).


[003448] Step 2 - Tert-butyl N-r2-r2-r2-(2-aminoanilino)ethoxy1ethoxy1ethyl1carbamate

[003449] To a mixture of tert-butyl N-[2-[2-[2-(2-nitroanilino)ethoxy]ethoxy]ethyl]carbamate (7.00 g, 18.9 mmol) in THF (100 mL) was added Pd/C (3.00 g, 10 wt%). The reaction mixture was stirred at 25 °C for 12 hours under H_2 (15 Psi) atmosphere. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (6.40 g, 99% yield) as red oil. ^{1}H NMR (400 MHz, CDCh) δ 6.84 - 6.78 (m, 1H), 6.74 - 6.64 (m, 3H), 5.32 (s, 1H), 3.76 (t, *j* = 5.2 Hz, 2H), 3.67 - 3.60 (m, 4H), 3.54 (t, *j* = 5.2 Hz, 2H), 3.35 - 3.27 (m, 4H), 1.45 (s, 9H).


[003450] Step 3 - 2-Tert-butyl N-r2-r2-r2-(2-oxo-3H-benzimidazol-l-vDethoxylethoxylethvncarbamate

[003451] To a mixture of tert-butyl N-[2-[2-[2-(2-aminoanilino)ethoxy]ethoxy]ethyl]carbamate (6.70 g, 19.7 mmol) in THF (100 mL) was added CDI (11.8 g, 73.0 mmol) and DIPEA (9.44 g, 73.0 mmol, 12.7 mL). The mixture was stirred at 25 °C for 3 hours. On completion, the reaction mixture was diluted with water (50 mL) and extracted with EA (2 X 100 mL). The combined organic layers was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (7.20 g, 99% yield) as red oil. ¾NMR (400 MHz, DMSO-di) δ 10.86 (s, 1H), 7.02 - 6.94 (m, 4H), 6.74 (s, 1H), 3.93 (t, *J* = 5.6 Hz, 2H), 3.65 (t, *J* = 5.6 Hz, 2H), 3.52 - 3.41 (m, 4H), 3.32 (t, *j* = 6.0 Hz, 2H), 3.10 - 2.94 (m, 2H), 1.36 (s, 9H).

[003452] 3-[3-[2-[2-(2-Aminoethoxy)ethoxylethyll-2-oxo-benzimidazol-l-yllpiperidine-2,6-dione [Intermediate QC)



QB



QC


[003453] Step 1 - Tert-butyl N-[2-[2-[2-[3-[1-RA-methoxyphenyl)methyl1-2.6-dioxo-3-piperidyll-2-oxo- benzimidazol-l-yl1ethoxy1ethoxy1ethyl1carbamate

[003454] To a mixture of tert-butyl N-[2-[2-[2-(2-oxo-3H-benzimidazol-l-yl)ethoxy]ethoxy]ethyl]carbamate (3.00 g, 8.21 mmol, Intermediate QB) in THF (50 mL) was added t-BuOK (1.38 g, 12.3 mmol), the mixture was stirred at 0 °C for 0.5 hour. Then [l-[(4-methoxyphenyl)methyl]-2,6-dioxo-3-piperidyl]trifluoromethane sulfonate (4.70 g, 12.3 mmol, Intermediate IQ) in THF (20 mL) was added to the mixture. The reaction mixture was stirred at 0 °C for 2 hours under N_2 atmosphere. On completion, the reaction mixture was diluted with water (30 mL) and extracted with EA (2 X 200 mL). The combined organic layers was dried over Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (0.1% FA condition) to give the title compound (4.00 g, 81% yield) as brown oil. ^{1}H NMR (400 MHz, DMSO-£¾) δ 7.26 (d, *J* = 7.6 Hz, 1H), 7.21 (d, *J* = 8.8 Hz, 2H), 7.09 - 7.04 (m, 1H), 7.02 - 6.95 (m, 2H), 6.85 (d, *J* = 8.8 Hz, 2H), 6.70 (s, 1H), 5.57 - 5.48 (m, 1H), 4.87 - 4.73 (m, 2H), 4.02 - 3.98 (m, 2H), 3.72 (s, 3H), 3.68 (d, *J* = 5.2 Hz, 2H), 3.54 - 3.49 (m, 2H), 3.46 - 3.41 (m, 2H), 3.33 (s, 2H), 3.12 - 3.05 (m, 1H), 3.04 - 2.97 (m, 2H), 2.86 - 2.69 (m, 2H), 2.10 - 2.01 (m, 1H), 1.36 (s, 9H).

[003455] Step 2 - 3-r3-r2-r2-(2-Aminoethoxy)ethoxy1ethyl1-2-oxo-benzimidazol-l-yl1piperidine-2.6-dione

[003456] To a mixture of tert-butyl N-[2-[2-[2-[3-[l-[(4-methoxyphenyl)methyl]-2,6-dioxo-3-piperidyl]-2-oxo- enzimidazol-l-yl]ethoxy]ethoxy]ethyl]carbamate (1.00 1.68 mmol) in DCM (10 mL) was added TFA (7.70 g, 67.5 mmol, 5.00 mL). The mixture was stirred at 25 °C for 0.5 hour. Then CF3SO3H (4.25 g, 28.3 mmol, 2.50 mL) was added to the mixture. The mixture was stirred at 25 °C for 30 hours. On completion, the reaction mixture was diluted with water (20 mL) and basified with saturated aqueous K2CO3 till pH = 8-9, then the solution was extracted with DCM (3 X 50 mL). The aqueous phase was concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (0.1% HC1 condition) to give the title compound (330 mg, 52% yield) as brown oil. ¾ NMR (400 MHz, DMSO^) δ 11.10 (s, 1H), 7.74 (s, 2H), 7.25 (d, *J* = 7.2 Hz, 1H), 7.15 - 7.09 (m, 1H), 7.09 - 7.00 (m, 2H), 5.41 - 5.33 (m, 1H), 4.01 (t, *j* = 5.4 Hz, 2H), 3.70 (t, *j* = 5.4 Hz, 2H), 3.58 - 3.55 (m, 2H), 3.53 - 3.50 (m, 4H), 2.94 - 2.85 (m, 3H), 2.78 - 2.63 (m, 2H), 2.06 - 1.97 (m, 1H).

[003457] Benzyl_ ((S)-l-(((S)-1-cyclohexyl-2-((S)-2-(4-(3-hydroxybenzoyl)thiazol-2-vBpyrrolidin-l-vB-2-oxoethvBaminoM-oxopropan-2-vB[methvBcarbamate [Intermediate OP)



[003458] Step 1 - (S)-tert-butyl 2-carbamothioylpyrrolidine-l-carboxylate

[003459] To a stirred solution Boc-D-prolinamide (50.0 g, 234.0 mmol) in CH2CI2 (25 mL) at rt was added Lawesson's reagent (62.2 g, 140.0 mmol). The mixture was stirred overnight, then washed with NaHCCb (sat., 500 mL). The organic layer was washed with brine, and dried over anhydrous Na_2S0_4. The oily residue was purified by column chromatography on silica gel, eluted with a 0-10 percent MeOH in CH2CI2 gradient, to afford the title compound (42 g, 78% yield) as

a white solid. ^{1}H NMR (400 MHz, DMSO-d_6) δ 9.51 (s, 1H), 9.08 (m, 1H), 4.41 (dd, J = 8.4, 3.3 Hz, 1H), 3.47 - 3.46 (m, 1H), 3.27 (s, 1H), 2.27 - 2.09 (m, 1H), 1.92 - 1.65 (m, 3H), 1.37 (m, 9H).

[003460] Step 2 - ethyl (S)-2-n-(tert-butoxycarbonvnpyrrolidin-2-vnthiazole-4-carboxylate

[003461] Ethyl bromopyruvate (4.15 g, 21.3 mmol) was added dropwise via syringe to a mixture of (S)-tert-butyl 2-carbamothioylpyrrolidine-l-carboxylate (3.5 g, 15.2 mmol) and potassium bicarbonate (50.5 g, 504 mmol) in 35 mL of dimethoxyethane at 23c°C. The resulting mixture was stirred vigorously for 25 minutes, and then the mixture was cooled to 0 °C. A mixture of trifluoroacetic anhydride (TFAA) (3.19 g, 15.2 mmol, 1 equiv.) and 2,4,6-collidine (2.94 g, 24.3 mmol, 1.6 equiv.) was then added dropwise via canula to the yellow mixture prepared above at 0 °C. Following this addition, an additional three portions of neat TFAA (3.19 g, 15.2 mmol, 1 equiv.) and 2,4,6-collidine (2.94 g, 24.3 mmol, 1.6 equiv.) were prepared and added in sequence dropwise via canula to the yellow reaction mixture at 0° C. The resulting yellow mixture was stirred vigorously at 0 °C. for 3 h. Then water (1,000 mL) was added and the solution was extracted with dichloromethane (2 x 50 mL). The organic phases were combined, washed with 0.5 N aqueous HC1 (100 mL), washed with brine (100 mL), and dried over anhydrous sodium sulfate. The solution was filtered and concentrated to afford a light yellow solid. This solid was purified by flash column chromatography on silica gel (1:9 to 2:3 ethyl acetate: hexanes) providing a light yellow solid. This solid was triturated with ether (20 mL) to afford the title compound as a white solid (2.2 g, 44% yield). ^{1}H NMR (400 MHz, DMS0 -d_6) *S* 8.41 (d, J = 9.8 Hz, 1H), 5.08 (d, J = 7.3 Hz, 1H), 4.33 - 4.25 (m, 2 H), 3.53 - 3.34 (m, 2H), 2.38 - 2.27 (m, 1H), 2.04-1.99 (m, 1H), 1.93 - 1.79 (m, 2H), 1.43 (s, 6H), 1.30 (t, J = 7.1 Hz, 3H), 1.24 (s, 3H). LC/MS (ESI, *m/z):* [M +l] $^+$ = 327.3.

[003462] Step 3 - (S)-2-n-(tert-butoxycarbonvnpyrrolidin-2-vnthiazole-4-carboxylic acid

[003463] A solution of (S)-ethyl 2-(l-(tert-butoxycarbonyl)pyrrolidin-2-yl)thiazole-4-carboxylate (14.5 g, 44.5 mmol, 1 equiv.) in tetrahydrofuran (60 mL) was added to a solution of sodium hydroxide (5.33 g, 134.5 mmol, 3 equiv.) in water (40 mL) at 23 °C. The resulting mixture was stirred vigorously at 23 °C. for 3 h. Then the mixture was concentrated to 20 mL. The concentrated mixture was cooled to 0 °C and the pH was adjusted to 3 by the addition of concentrated HC1 solution dropwise. A lot of white solid was formed and the solid was collected by filtration to provide the title compound as a white solid (10.4 g, 74% yield). LC/MS (ESI, *m/z):* [M +l] $^+$ = 299.4.

[003464] Step 4 - tert-butyl (Sy2-(4-(methoxy(methvDcarbamovDthiazol-2-vDpynOlidine-1-carboxylate

[003465] (S)-2-(l-(tert-butoxycarbonyl)pyrrolidin-2-yl)thiazole-4-carboxylic acid (22.6 g, 75.8 mmol), O,N-dimethylhydroxylamine hydrochloride (11.9 g, 122.7 mmol), diisopropyl ethyl amine (45.0 mL, 243 mmol) and HATU (46.2 g, 122.0 mmol) in DMF (200 mL) were stirred at rt for 12 hours. The reaction mixture was quenched with water, and the layers were separated. The aqueous layer was extracted with EtOAc (100 mL><3), and the combined organic layers were dried, filtered and concentrated. The crude product was purified via column chromatography on silica gel, eluting with hexanes/ethyl acetate (1:1) to give the title compound as an oil (23.0 g, 89% yield). LC/MS (ESI, *m/z):* [M +l] $^{+}$ = 342.2. ^{1}H NMR (400 MHz, DMSO-d_6) S 8.11 (s, 1H), 5.08 (m, 1H), 3.72 (s, 3H), 3.52 - 3.35 (m, 2H), 3.29 (s, 3H), 2.32 (m, 1H), 2.06 (m, 1H), 1.96 - 1.77 (m, 2H), 1.50-1.20 (d, 9H).

[003466] Step_5_- (SVtert-butyl_2-(4-(3-(Ytert-butyldimethylsilv0oxy)benzov0thiazol-2-vDpyrrolidine- 1-carboxylate

[003467] To a solution of tert-butyl(3-iodophenoxy)dimethylsilane (6.9 g, 20.6 mmol) in THF (50 mL) was added isopropylmagnesium chloride solution (9.27 mL, 2.0 M in THF) dropwise at -10 °C under N_2. The reaction mixture was stirred at 0 °C for 30 min. Then this resulting mixture, which formed (3-((tert-butyldimethylsilyl)oxy)phenyl)magnesium iodide, was added dropwise via syringe to a solution of the weinreb amide tert-butyl (S)-2-(4-(methoxy(methyl)carbamoyl)thiazol-2-yl)py^{rr}°lidine-l -carboxylate (3.9 g, 11.4 mmol) in THF (10 mL) at 0 °C. The mixture was stirred at 0 ° C for 30 min then warmed up to rt and stirred for 4 h. The mixture was then cooled to -5 °C and quenched with saturated ammonium chloride solution (20 mL). The mixture was partitioned between water (30 mL) and ethyl acetate (100 mL). The organic phase was separated and the aqueous phase was further extracted with ethyl acetate (3x 100 mL). The organic phases were combined, washed with brine (50 mL) and dried over anhydrous sodium sulfate. The dried solution was filtered and concentrated to give a light yellow oil. This oil was purified by flash column chromatography on silica gel (1:30 to 1:10 ethyl acetate: hexanes) providing the title compound as a colorless oil (5.13 g, 92.1%). ^{1}H NMR (400 MHz, CDCh) S 8.10 (s, 1H), 7.76 (d, J = 7.7 Hz, 1H), 7.71 - 7.66 (m, 1H), 7.34 (t, j = 7.9 Hz, 1H), 7.07 (d, J = 7.0 Hz, 1H), 5.30-5.19 (m, 1H), 3.66 - 3.41 (m, 2H), 2.42 - 2.19 (m, 2H), 2.01 - 1.90 (m, 2H), 1.50 (s, 3H), 1.35 (s, 6H), 1.02 - 0.98 (m, 9H), 0.28 - 0.14 (m, 6H); LC/MS (ESI, *m/z):* [M +l] $^{+}$ = 489.5.

[003468] Step 6 - (S)-(3-(Ytert-butyldimethylsilvOoxy)phenvO(2-(pynOlidin-2-vOthiazol-4-vDmethanone

[003469] To a solution of (S)-tert-butyl 2-(4-(3-((tert-butyldimethylsilyl)oxy)benzoyl)thiazol-2-yl)pyrrolidine-l-carboxylate (12.0 g, 20.5 mmol) in l,4-dioxane (60 mL) was added HCl-dioxane (40 mL) (4 M in dioxane) dropwise. The reaction mixture was stirred at rt for 3 h. The reaction mixture concentrated *in vacuo* and used directly without further purification to afford (S)-(3-hydroxyphenyl)(2-(pyrrolidin-2-yl)thiazol-4-yl)methanone HC1 salt (8.0 g). To a solution of (S)-(3-hydroxyphenyl)(2-(pyrrolidin-2-yl)thiazol-4-yl)methanone HC1 salt (8.00 g, 25.7 mmol) in DCM (80 mL) was added imidazole (5.2 g, 57.2 mmol) slowly at 0° C. Then TBSC1 (3.89 g, 34.3 mmol, in 20 mLDCM) was added slowly at 0 °C. The resulting mixture was stirred at rt for 130 min. The reaction mixture was quenched with water, extracted with ethyl acetate (3x 100 mL), washed with brine (50 mL) and dried over anhydrous sodium sulfate. The solution was filtered, concentrated, and purified by flash column chromatography on silica gel (1:100 to 1:40 methanol / DCM) to give the title compound as a yellow oil (8.0 g, 84% yield). ^{1}HNMR (400 MHz, DMS0-d_6) *S* 8.38 (s, 1H), 7.71 - 7.64 (m, 2H), 7.43 (t, *J* = 8.0 Hz, 1H), 7.14 (ddd, *J* = 8.0, 2.4, 1.1 Hz, 1H), 4.51 (dd, *J* = 8.3, 4.9 Hz, 1H), 3.56 (s, 1H), 3.00 - 2.89 (m, 2H), 2.27 - 2.10 (m, 1H), 1.75-1.70 (m, 1H), 1.77 - 1.65 (m, 2H), 0.97 (s, 9H), 0.22 (s, 6H).

[003470] Step_ 7_ -_ benzyl_ ((S)-1-(((SV2-((SV2-(4-(3 -((tert-butyldimethylsilyl)oxy)benzoyl)thiazol-2-yl)pyrrolidin-l-yl)-l-cvclohexyl-2-oxoethyl)amino)-l-oxopropan-2-vD(methyl)carbamate


[003471] In a 250-mL round-bottom flask, was placed (S)-(3-((tert-butyldimethylsilyl)oxy)phenyl)(2-(pyrrolidin-2-yl)thiazol-4-yl)methanone (7.5 g, 19.3 mmol), (S)-2-((S)-2-(((benzyloxy)carbonyl)(methyl)amino)propanamido)-2-cyclohexylacetic acid (9.5 g, 25.1 mmol, Intermediate UU), and 4-methylmorpholine (3.90 g, 38.60 mmol) in EtOAc (100 mL) at 0 °C. DMT-MM (6.94 g, 25.1 mmol) was then added and the resulting solution was stirred for 3 h at 0 °C. Then H_20 (40 mL) was added, and the resulting solution was extracted with EtOAC (3 x 50 mL). The combined organic layers were washed with 50 mL of brine, dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column eluting with ethyl acetate/petroleum ether (1 :2) to give the title compound as a yellow solid. (7.3 g, 60% yield). ^{1}H NMR (400 MHz, DMS0-d_6) *S* 8.49 (s, 1H), 7.95 (d, *J* = 39.4 Hz, 1H), 7.74 -

7.63 (m, 2H), 7.43 (t, *J* = 7.9 Hz, 1H), 7.35 - 7.31 (m, 5 H), 7.16 (dd, *J* = 8.0, 2.5 Hz, 1H), 5.37 (dd, *J* = 7.6, 2.2 Hz, 1H), 5.08 - 5.01 (m, 1H), 4.66 (d, *J* = 6.6 Hz, 1H), 4.37 (t, *j* = 7.5 Hz, 1H), 3.83-3.75 (m, 2H), 2.83 (s, 3H), 2.33-2.14 (m, 2 H), 2.07 - 1.98 (m, 2H), 1.67-1.48 (m, 6H), 1.25 (s, 3H), 1.07 - 0.89 (m, 14H), 0.22 (s, 6H). LC/MS (ESI, *m/z):* [M +l] $^{+}$ = 747.6.

[003472] Step 8 - benzyl ((S)-l-(((S)-l-cvclohexyl-2-((S)-2-(4-(3-hvdroxybenzovnthiazol-2-vOpynOlidin-l-vO-2-oxoethvOamino)-l-oxopropan-2-vO(´methvOcarbamate

[003473] To a stirred solution of benzyl ((S)-l-(((S)-2-((S)-2-(4-(3-((tert-butyldimethylsilyl)oxy)benzoyl)thiazol-2-yl)pyrrolidin-l-yl)-l-cyclohexyl-2-oxoethyl)amino)-l-oxopropan-2-yl)(methyl)carbamate (5.0 g, 6.68 mmol) in THF (20 mL) was added TBAF (8.0 mL, 8.0 mmol) a rt. The reaction mixture was stirred at rt for 4 h. Then H_20 (20 mL) was added and the mixture was extracted with EtOAc (50 mL x 2). The combined organic layer was washed with brine, dried and concentrated *in vacuo.* The mixture was purified via column chromatography (DCM / EtOAc = 5% - 80%) to give the title compound (3.2 g, 76% yield) as a yellow solid. ^{1}H NMR (400 MHz, MeOD-7 $_4$) *S* 8.26 (s, 1H), 7.59 - 7.53 (m, 1H), 7.51 (dd, *J* = 2.3, 1.7 Hz, 1H), 7.37 - 7.28 (m, 6H), 7.05 (ddd, 7 = 8.1, 2.6, 0.9 Hz, 1H), 5.50 - 5.39 (m, 1H), 5.13 (s, 2H), 4.69 (s, 1H), 4.54 - 4.38 (m, 1H), 4.02 - 3.93 (m, 1H), 3.90 - 3.86 (m, 1H), 2.94 (s, 3H), 2.23 - 2.10 (m, 4H), 1.72 - 1.56 (m, 6H), 1.37 (d, *J* = 5.2Hz, 3H), 1.16 - 0.88 (m, 5H); LC-MS (ESI^{+}): m/z 633.5(M+H) $^{+}$.

[003474] Benzyl _N-[(1S)-2-[[(1S)-2-[(2S)-2-[4-[3-[2-[2-[2-[2-[2-(2-aminoethoxy)ethoxyl ethoxy] ethoxy] ethoxy|ethoxy|benzoyl1thiazol-2-yl1pyrrolidin-l-yl1-l-cyclohexyl-2-oxo-ethyllaminol-l-methyl-2-oxo-ethyll-N-methyl-carbamate _[Intermediate_QE)




[003475] Step_1_- benzyl ((S)-l-(((S)-l-cvclohexyl-2-((S)-2-(4-(3-((2.2-dimethyl-4-oxo-3,8.11.14,17.20-hexaoxa-5-azadocosan-22-yl)oxy)benzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethvl)amino)-l-oxopropan-2-ylYmethvl)carbamate

[003476] To a solution of benzyl ((S)-l-(((S)-l-cyclohexyl-2-((S)-2-(4-(3-hydroxybenzoyl)thiazol-2-yl)pyrrolidin-l-yl)-2-oxoethyl)amino)-l-oxopropan-2-yl)(methyl)carbamate (1.3 g, 2.06 mmol, Intermediate QD) in CH_3CN (100 mL) was added 2,2-dimethyl-4-oxo-3,8,ll,l4,l7,20-hexaoxa-5-azadocosan-22-yl 4-methylbenzenesulfonate (1.32 g, 2.47 mmol, Intermediate OO) and K_2CO_3 (340.9 mg, 2.47 mmol) at rt. Then the reaction mixture was stirred at 80 °C for 12 h. The reaction mixture solvent was removed under reduced pressure. The residue was purified via column chromatography (EtOAc / Petroleum ether) to give the title compound (1.71 g, 84 % yield) as a pale yellow oil. LC/MS (ESI, *m/z*): $[M+1]^+$ = 997.56.

[003477] Step 2 - benzyl ((S)-1-(((S)-2-((S)-2-(4-(3-((17-amino-3,6,9,12,15-pentaoxaheptadecyl)oxy)benzoyl)thiazol-2-yl)pyrrolidin-1-yl)-1-cyclohexyl-2-oxoethyl)amino)-1-oxopropan-2-yl)(methyl)carbamate 2,2,2-trifluoroacetate

[003478] To a solution of benzyl ((S)-1-(((S)-1-cyclohexyl-2-((S)-2-(4-(3-((2,2-dimethyl-4-oxo-3,8,11,14,17,20-hexaoxa-5-azadocosan-22-yl)oxy)benzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)amino)-1-oxopropan-2-yl)(methyl)carbamate (1.6 g, 1.61 mmol) in DCM (30 mL) was added TFA (30 mL) and the reaction mixture was stirred at rt for 3 h. Then the reaction mixture solvent was removed under reduced pressure and the residue was purified via reverse phase column chromatography (ACN / H_2O) to give the title compound (1.4 g, 86% yield) as a pale yellow oil. ^1H NMR (400 MHz, MeOD) δ: 8.32 (s, 1H), 7.86 - 7.67 (m, 2H), 7.45 (t, J = 7.9 Hz, 1H), 7.41 - 7.13 (m, 6H), 5.62 - 5.47 (m, 1H), 5.13 (s, 2H), 4.73 - 4.68 (m, 1H), 4.59 - 4.34 (m, 1H), 4.24 - 4.22 (m, 2H), 4.07 - 3.79 (m, 4H), 3.79 - 3.52 (m, 18H), 3.19 - 3.05 (m, 2H), 2.94 - 2.77 (m, 3H), 2.62 - 1.91 (m, 4H), 1.88 - 1.49 (m, 6H), 1.37 - 1.35 (m, 3H), 1.23 - 0.82 (m, 5H). LC/MS (ESI, *m/z):* $[M+1]^+$ = 896.57.

[003479] Benzyl N-[(1S)-2-[[(1S)-2-[(2S)-2-[4-[3-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]benzoyl]thiazol-2-yl]pyrrolidin-1-yl]-1-cyclohexyl-2-oxo-ethyl]amino]-1-methyl-2-oxo-ethyl]-N-methyl-carbamate [Intermediate OF)



[003480] Step_1_- benzyl ((S)-l-(((S)-l-cvclohexyl-2-((S)-2-(4-(3-((2.2-dimethyl-4-oxo-3,8,1 E 14-tetraoxa-5-azahexadecan- 16-yl)oxy)benzoyl)thiazol-2-yl)pyrrolidin- l-yl)-2-oxoethvl)amino)-l-oxopropan-2-ylYmethvl)carbamate


[003481] To a solution of benzyl ((S)-l-(((S)-l-cyclohexyl-2-((S)-2-(4-(3-hydroxybenzoyl)thiazol-2-yl)pyrrolidin-l-yl)-2-oxoethyl)amino)-l-oxopropan-2-yl)(methyl)carbamate (1.50 g, 2.38 mmol, Intermediate QD) in CH3CN (100 mL) was added 2,2-dimethyl-4-oxo-3,8,ll,l4-tetraoxa-5-azahexadecan-l6-yl 4-methylbenzenesulfonate (1.30 g, 3.09 mmol, Intermediate LD) and K2CO3 (346.4 mg, 2.51 mmol) at rt. The reaction mixture was stirred at 80 °C for 12 hours. The reaction mixture was then concentrated under reduced pressure. The residue was purified via column chromatography on silica gel (EtOAc / petroleum ether=l/l-EA) to give the title compound (1.80 g, 80% yield) as a white solid. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.49 (s, 1H), 7.97 (d, J = 40.8 Hz, 1H), 7.69 - 7.64 (m, 2H), 7.46 (t, j = 7.9 Hz, 1H), 7.39 - 7.29 (m, 5H), 7.26 (dd, J = 8.2, 1.9 Hz, 1H), 6.73 (t, j = 5.1 Hz, 1H), 5.40 - 5.37 (m, 1H), 5.09 - 5.06 (m, 2H), 4.70 - 4.65 (m, 1H), 4.38 (t, j = 7.5 Hz, 1H), 4.23 - 4.12 (m, 2H), 3.85 - 3.73 (m, 4H), 3.62 - 3.59 (m, 2H), 3.55 -3.47 (m, 6H), 3.36 (t, J = 6.2 Hz, 2H), 3.05 (q, J = 5.9 Hz, 2H), 2.84 (s,

3H), 2.28 - 2.14 (m, 2H), 2.08 -2.01 (m, 2H), 1.66 - 1.44 (m, 6H), 1.36 (s, 9H), 1.26 (br s, 3H), 1.09 - 0.86 (m, 5H). LC/MS (ESI, *m/z):* [M +l] $^{+}$ = 908.6.

[003482] Step 2 - benzyl ((S)-1-(((SV2-((SV2-(4-(3-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethoxy)benzovPthiazol-2-vDpyrrolidin- 1-vl)- 1-cvclohexyl-2-oxoethvPamino)-l-oxopropan-2-vP(methvPcarbamate

[003483] To a solution of benzyl ((S)-l-(((S)-l-cyclohexyl-2-((S)-2-(4-(3-((2,2-dimethyl-4-oxo-3,8, 11, l4-tetraoxa-5-azahexadecan-l6-yl)oxy)benzoyl)thiazol-2-yl)pyrrolidin-l-yl)-2-oxoethyl)amino)-l-oxopropan-2-yl)(methyl)carbamate (1.8 g, 1.47 mmol) in DCM (30 mL) was added TFA (30 mL) and the reaction mixture was stirred at rt for 3 h. The reaction mixture was concentrated under reduced pressure to give the title compound (1.8 g, 100% yield, TFA salt) as a light yellow oil. ^{1}H NMR (400 MHz, CD_3OD) δ 8.32 (s, 1H), 7.80 (br s, 1H), 7.76 - 7.70 (m, 2H), 7.44 (t, *J* = 7.9 Hz, 1H), 7.38 - 7.30 (m, 5H), 7.26 - 7.20 (m, 1H), 5.47-5.46 (m, 1H), 5.13 (s, 2H), 4.73-4.65 (m, 1H), 4.53 - 4.40 (m, 1H), 4.22 (dd, *J* = 5.3, 3.8 Hz, 2H), 4.00 - 3.94 (m, 1H), 3.89 - 3.86 (m, 3H), 3.76 - 3.72 (m, 2 H), 3.70 - 3.66 (m, 8H), 3.12 - 3.08 (m, 2H), 2.94 (s, 3H), 2.40 - 2.19 (m, 3 H), 2.17 - 2.09 (m, 1 H), 1.72 - 1.57 (m, 6H), 1.36 (d, *J* = 7.2 Hz, 3H), 1.19 - 0.94 (m, 5H). LC/MS (ESI, *m/z):* [M +l] $^{+}$ = 808.6.

[003484] Benzyl N-[(l SV2-[[(1S)-2-[(2S)-2-[4-[3-[2-[2-[2-[2-t2-aminoethoxy)ethoxyl ethoxy] ethoxy] ethoxy|benzoyl1thiazol-2-yl1pyrrolidin-l-yl1-l-cyclohexyl-2-oxo- ethyllaminol-l-methyl-2-oxo-ethyll-N-methyl-carbamate [Intermediate OG)




[003485] Step 1 - benzyl ((S)-l-(((S)-l-cvclohexyl-2-((S)-2-(4-(3-((2.2-dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azanonadecan- 19-yl)oxy)benzovl)thiazol-2-vl)pyrrolidin-1-vD-2-oxoethvl)amino)-l-oxopropan-2-ylYmethvl)carbamate

[003486] To a solution of benzyl ((S)-l-(((S)-l-cyclohexyl-2-((S)-2-(4-(3-hydroxybenzoyl)thiazol-2-yl)pyrrolidin-l-yl)-2-oxoethyl)amino)-l-oxopropan-2-yl)(methyl)carbamate (1.32 g, 2.09 mmol, Intermediate QD) in CH_3CN (100 mL) was added 2,2-dimethyl-4-oxo-3,8,ll,l4,l7-pentaoxa-5-azanonadecan-l9-yl 4-methylbenzenesulfonate (1.23 g, 2.51 mmol, Intermediate ON) and K_2CO_3 (346.4 mg, 2.51 mmol) at rt. Then the reaction mixture was stirred at 80 °C for 12 h. The reaction mixture was then concentrated under reduced pressure. The residue was purified via column chromatography on silica gel (EtOAc / petroleum ether) to give the title compound (1.68 g, 85% yield) as a pale yellow oil. LC/MS (ESI, *m/z)*: $[M+l]^+$ = 953.7.

[003487] Step 2 - benzyl ((S)-1-(((S)-2-((S)-2-(4-(3-((T4-amino-3.6.9.12-tetraoxatetradecvPoxy)benzovDthiazol-2-vDpynOlidin- 1-vl)- 1-cvclohexyl-2-oxoethvPamino)- 1-oxopropan-2-vP(methvPcarbamate 2.2.2-trifluoroacetate

[003488] To a solution of benzyl ((S)-l-(((S)-l-cyclohexyl-2-((S)-2-(4-(3-((2,2-dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azanonadecan- 19-yl)oxy)benzoyl)thiazol-2-yl)pyrrolidin- 1-yl)-2-oxoethyl)amino)-l-oxopropan-2-yl)(methyl)carbamate (1.4 g, 1.47 mmol) in DCM (30 mL) was added TFA (30 mL) and the reaction mixture was stirred at rt for 3 h. Then the reaction mixture was concentrated under reduced pressure and the residue was purified via reverse phase column chromatography (ACN / H_20) to give the title compound (1.2 g, 84% yield) as a colorless oil. ^1H NMR (400 MHz, CD_3OD) *S*: 8.33 (s, 1H), 7.90 - 7.68 (m, 3H), 7.50 - 7.40 (m, 1H), 7.40 - 7.19 (m, 5H), 5.67 - 5.30 (m, 1H), 5.13 (s, 2H), 4.73-4.67 (m, 1H), 4.50 - 4.40 (m, 1H), 4.29 - 4.12 (m, 2H), 4.05 - 3.79 (m, 4H), 3.78 - 3.52 (m, 14H), 3.10 - 3.07 (m, 2H), 2.94 (s, 3H), 2.57 - 1.95 (m, 4H), 1.85 - 1.46 (m, 6H), 1.40 - 1.29 (m, 3H), 1.27 - 0.86 (m, 5H). LC/MS (ESI, *m/z*): $[M+l]^+$ = 852.7.

[003489] Benzyl N-raSV2-rraSV2-ri2SV2-r4-r3-r2-r2-[2-aminoethoxylethoxyl ethoxy]benzoyll_ thiazol-2-yllpyrrolidin-l-yll-l-cvclohexyl-2-oxo-ethyllamino]-l-methyl-2-oxo-ethyll-N-methyl-carbamate [Intermediate OH)




[003490] Step 1 - benzyl ((S)-1-(((S)-1-cyclohexyl-2-((S)-2-(4-(3-((2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)oxy)benzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)amino)-1-oxopropan-2-yl)(methyl)carbamate

[003491] To a solution of benzyl ((S)-1-(((S)-1-cyclohexyl-2-((S)-2-(4-(3-hydroxybenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)amino)-1-oxopropan-2-yl)(methyl)carbamate (1.30 g, 2.05 mmol, Intermediate QD) in CH_3CN (25 mL) was added 2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl 4-methylbenzenesulfonate (1.20 g, 2.46 mmol, Intermediate UV) and K_2CO_3 (368 mg, 2.67 mmol) at rt. The reaction mixture was stirred at 80 °C for 12 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified via column chromatography on silica gel (EtOAc / Petroleum ether=1/1-EA) to give the title compound (1.30 g, 68 % yield) as a white solid. ¾ NMR (400 MHz, CD_3OD) δ 8.32 (s, 1H), 7.73 - 7.71 (m, 2H), 7.43 (t, *J* = 8.0 Hz, 1H), 7.39 - 7.29 (m, 5H), 7.26 - 7.20 (m, 1H), 5.47 - 5.46 (m, 1H), 5.13 (s, 2H), 4.69 (br s, 1H), 4.52 - 4.41 (m, 1H), 4.22 - 4.18 (m, 2H), 4.00 - 3.93 (m, 1H), 3.89 - 3.87 (m, 3H), 3.73 - 68 (m, 2H), 3.66 - 3.61 (m, 2H), 3.52 - 3.49 (m, 2H), 3.23 - 3.19 (m, 2H), 2.94 (s, 3H), 2.36 - 2.20 (m, 3H), 2.18 - 2.06 (m, 1H), 1.76 - 1.50 (m, 6H), 1.41 (s, 9H), 1.36 (d, *J* = 7.2 Hz, 3H), 1.17 - 0.96 (m, 5H). LC/MS (ESI, *m/z):* $[M+1]^+$ = 864.6.

[003492] Step 2 - benzyl ((S)-1-(((S)-2-((S)-2-(4-(3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)benzoyl)thiazol-2-yl)pyrrolidin-1-yl)-1-cyclohexyl-2-oxoethyl)amino)-1-oxopropan-2-yl)(methyl)carbamate

[003493] To a solution of benzyl ((S)-1-(((S)-1-cyclohexyl-2-((S)-2-(4-(3-((2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)oxy)benzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)amino)-1-oxopropan-2-yl)(methyl)carbamate (1.2 g, 1.39 mmol) in DCM (5mL) was added TFA (5 mL) and the reaction mixture was stirred at rt for 3 h. The reaction mixture was concentrated under reduced pressure to give the title compound (1.2 g, 100 % yield, TFA salt) as a light yellow oil. ¾ NMR (400 MHz, CD_3OD) *δ* 8.33 (s, 1H), 7.79 - 7.71 (m, 2H), 7.45 (t, *j* = 8.0 Hz, 1H), 7.38 - 7.28 (m, 5H), 7.25 - 7.22 (m, 1H), 5.47 - 5.46 (m, 1H), 5.13 (s, 2H), 4.73 - 4.64 (m, 1H), 4.52 - 4.40 (m, 1H), 4.24 - 4.21 (m, 2H), 4.01 - 3.94 (m, 1H), 3.90 - 3.88 (m, 3H), 3.77 - 3.74 (m, 2H), 3.72 - 3.69 (m, 4H), 3.11(t, *J* = 4.8 Hz, 2H), 2.94 (s, 3H), 2.39 - 2.11 (m, 4H), 1.75 - 1.54 (m, 6H), 1.36 (t, *J* = 8.0 Hz, 3H), 1.16 - 0.99 (m, 5H). LC/MS (ESI, *m/z):* $[M+1]^+$ = 764.6.

[003494] **[3-Methyl-5-[3-[3-[methylamino)propoxy1propyl1-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione [Intermediate QI)**



[003495] Step 1 - Tert-butyl N-[3-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl1prop-2- ynoxyIpropyll-N-methyl-carbamate

[003496] To a solution of tert-butyl N-methyl-N-(3-prop-2-ynoxypropyl)carbamate (604 mg, 2.66 mmol, Intermediate PO) and 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (450 mg, 1.33 mmol, Intermediate HN) in DMF (10 mL) was added Pd(PPh $_3$)2Cl2 (186 mg, 266 umol), Cul (50.6 mg, 266 umol) and CS2CO3 (2.17 g, 6.65 mmol). The reaction mixture was stirred at 80 °C for 2 hr under N2. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (550 mg, 85% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO -d_6) δ 11.13 (s, 1H), 7.65 - 7.52 (m, 3H), 5.39 (dd, J = 5.6, 12.8 Hz, 1H), 4.45 - 4.18 (m,

2H), 3.62 - 3.44 (m, 2H), 3.22 (t, *J* = 7.2 Hz, 2H), 2.92 - 2.83 (m, 1H), 2.80 - 2.59 (m, 7H), 2.08 - 2.00 (m, 1H), 1.77 - 1.70 (m, 2H), 1.38 (s, 9H); LC-MS (ESI^+) m/z 507.1 $(M+Na)^+$.


[003497] Step 2 - Tert-butyl N-r3-r3-rl-(2.6-dioxo-3-piperidvD-3-methyl-2-oxo-benzimidazol-5-yl1propoxy1 propyll-N-methyl-carbamate

[003498] To a solution of tert-butyl N-[3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]prop -2-ynoxy]propyl]-N-methyl-carbamate (530 mg, 1.09 mmol) in THF (10 mL) was added $Pd(OH)_2/C$ (200 mg, 10 wt%) and Pd/C (200 mg, 10 wt%). The reaction mixture was stirred at 25 °C under H_2 (15 Psi) for 12 hrs. On completion, the residue was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 l50*25*l0um; mobilephase: [water (0.225%FA)-ACN]; B%: 38%-65%, 9 min) to give the title compound (300 mg, 56% yield) as yellow oil. ^1H NMR (400MHz, DMSO-d) δ 11.08 (s, 1H), 7.05 - 6.98 (m, 2H), 6.87 (d, *J* = 8.0 Hz, 1H), 5.33 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.36 - 3.33 (m, 4H), 3.32 (s, 3H), 3.22 (t, *J* = 7.2 Hz, 2H), 2.95 - 2.85 (m, 1H), 2.77 (s, 3H), 2.73 - 2.60 (m, 4H), 2.03 - 1.98 (m, 1H), 1.86 - 1.78 (m, 2H), 1.73 - 1.69 (m, 2H), 1.38 (s, 9H); LC-MS (ESI^+) m/z 389.2 $(M + H-l00)^+$.

[003499] Step 3 - 3-r3-Methyl-5-r3-r3-(methylamino)propoxy1propyl1-2-oxo-benzimidazol-l-yllpiperidine -2.6-dione

[003500] To a solution of tert-butyl N-[3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] propoxy] propyl]-N-methyl -carbamate (50.0 mg, 102 umol) in DCM (3 mL) was added HCl/dioxane (4 M, 2 mL). The reaction mixture was stirred at 25 °C for 2 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (40.0 mg, 92% yield, HC1) as a white solid. ^1H NMR (400MHz, DMSO-7,) δ 11.09 (s, 1H), 7.06 - 6.97 (m, 2H),6.90 - 6.84 (m, 1H), 5.34 (dd, 7 = 5.2, 12.8 Hz, 1H), 3.56 (s, 2H), 3.43 (t, *J* = 6.0 Hz, 2H), 3.32 (s, 3H), 2.96 - 2.86 (m, 3H), 2.72 - 2.58 (m, 4H), 2.56 - 2.52 (m, 3H), 2.02 - 1.97 (m, 1H), 1.90 - 1.78 (m, 4H); LC-MS (ESI^+) m/z 389.2$(M+H)^+$.

[003501] **Tert-butyl (2-methyl-4-(prop-2-yn-l-yloxy)butan-2-yl)carbamate [Intermediate OJ)**



QJ


[003502] Step 1 - Tert-butyl (4-hydroxy-2-methylbutan-2-vDcarbamate

[003503] To a solution of 3-amino-3 -methylbutan-l-ol (4.0 g, 38.8 mmol, CAS# 42514-50-1) and TEA(3.92 g, 38.8 mmol, 5.4 mL) in THF (50 mL) added dropwise $(Boc)_20$ (9.3lg, 9.8 mL, 42.6 mmol) at 20 °C and the mixture was stirred at 20 °C for 16 hours. Once completion, the reaction mixture was quenched by water (15 mL), and then extracted with EA (3 X 30 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography ($Si0_2$, PE/EA = 10:1) to give the title compound (1.50 g, 19% yield) as a light yellow oil. ^1H NMR (400 MHz, CDCh) δ 4.90 (s, 1H), 3.76 (q, 2H), 2.04 (s, 1H), 1.88 (t, J = 6.4 Hz, 2H), 1.43 (s, 9H), 1.32 (s, 6H).

[003504] Step 2 - Tert-butyl (2-methyl-4-(prop-2-vn-l-yloxy)butan-2-vDcarbamate

[003505] To a solution of tert-butyl (4-hydroxy-2-methylbutan-2-yl)carbamate (1.40 g, 6.89 mmol) and 3-bromoprop-l-yne (1.23 g, 10.3 mmol) in THF (20 mL) was added KI (171 mg, 1.03 mmol), TBAI (152 mg, 0.41 mmol) and KOH (463 mg, 8.26 mmol) at 30 °C. Then the mixture was stirred at 30 °C for 16 hours. On completion, the reaction mixture was filtered and the filtrate was concentrated in vacuo to give the residue. The residue was purified by column chromatography ($Si0_2$, PE/EA = 30:1) to give the title compound (1.40 g, 84% yield) as a light yellow liquid. ^1H NMR (400 MHz, CDCh) δ 4.84 (s, 1H), 4.12 (d, J = 2.4 Hz, 2H), 3.62 (t, J = 6.4 Hz, 2H), 2.42 (t, j = 2.4 Hz, 1H), 1.91 (t, j = 6.4 Hz, 2H), 1.42 (s, 9H), 1.31 (s, 6H).

[003506] **3-[7-[3-[3-Amino-3-methyl-butoxy)propyl1-2-oxo-l,3-benzoxazol-3-yl]piperidine-2.,6-dione [Intermediate_OK)**



[003507] Step 1 - Tert-butyl N-[3-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-1,3-benzoxazol-7-yllprop-2-ynoxyl-L 1- dimethyl-propyllcarbamate

[003508] To a solution of 3-(7-bromo-2-oxo-l,3-benzoxazol-3-yl)piperidine-2,6-dione (320 mg, 0.98 mmol, Intermediate JF) and tert-butyl (2-methyl-4-(prop-2-yn-l-yloxy)butan-2-yl)carbamate (593 mg, 2.46 mmol, Intermediate QJ) in DMF (20 mL) was added CS2CO3 (1.28 g, 3.94 mmol), Cul (37.49 mg, 0.2 mmol), Pd(PPh 3)2Cl2 (138 mg, 0.2 mmol) and 4Å molecular sieves (80 mg) at 25 °C under N2. Then the reaction mixture was heated to 80 °C and stirred for 2 hours. On completion, the reaction mixture was quenched by addition of water (10 m)L, and then extracted with EA (30 mL, 3 X 10 mL). The combined organic layers and dried over Na_2SO_4, filtered and concentrated in vacuo to give a residue. The residue was purified by column chromatography (S1O2, Petroleum ether/Ethyl acetate= 2/1 to 1/1) to give the title compound (330 mg, 69% yield) as a white solid. ¾ NMR (400 MHz, CDCb) δ 8.18 (s, 1H), 7.25 - 7.19 (m, 1H), 7.13 (t, *J* = 8.0 Hz, 1H), 6.82 - 6.75 (m, 1H), 5.08 - 5.01 (m, 1H), 4.91 (s, 1H), 4.41 (s, 2H), 3.73 (t, *j* = 6.4 Hz, 2H), 3.04 - 2.95 (m, 1H), 2.91 - 2.66 (m, 2H), 2.40 - 2.27 (m, 1H), 1.97 (t, *J* = 6.2 Hz, 2H), 1.41 (s, 9H), 1.35 (s, 6H); LC-MS (ESI$^+$) *m/z* 386.0 (M+H-l00) $^+$.


[003509] Step 2 - Tert-butyl N-[3-[3-[3-(2,6-dioxo-3-piperidvl)-2-oxo-1,3-benzoxazol-7-yllpropoxyl- 1.1- dimethyl-propyllcarbamate

[003510] To a mixture of tert-butyl N-[3-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-l,3-benzoxazol-7-yl]prop-2 -ynoxy]- 1, 1-dimethyl -propyl]curbamate (130 mg, 0.27 mmol) in THF (15 mL) was added Pd/C (10 wt%) and $Pd(OH)_2/C$ (10 wt%) under N_2. The suspension was degassed under vacuum and purged with H_2 gas several times. The mixture was stirred at 25 °C for 16 hours under H_2 (15 psi). On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (127 mg, 85% yield) as a white solid. LC-MS (ESI+) m/z 390.2 (M+H-100)+.

[003511] Step _3_ - _3-r7-r3-('3-Amino-3-methyl-butoxy)propyl1-2-oxo- 1J-benzoxazol-3-yl1piperidine-2.6-dione

[003512] To a mixture of tert-butyl N-[3-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-l,3-benzoxazol-7-yl]propoxy] -l,l-dimethyl-propyl]carbamate (127 mg, 0.26 mmol) in DCM (5 mL) was added TFA (591 mg, 0.52 mmol, 0.38 mL) at 25 °C. The mixture was stirred at 25 °C for 60 min. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (126 mg, 96% yield, TFA) as light yellow oil. ¾NMR (400 MHz, CDCh) δ 9.05 (s, 1H), 7.13 (t, J = 16 Hz, 1H), 7.03 - 6.98 (m, 1H), 6.78 (d, J = 8.0 Hz, 1H), 5.14 - 5.09 (m, 1H), 3.67 (t, J = 5.6 Hz, 2H), 3.56 (t, j = 5.6 Hz, 2H), 2.99 - 2.71 (m, 6H), 2.37 - 2.33 (m, 1H), 2.04 - 1.96 (m, 2H), 1.84 (t, J = 5.6 Hz, 2H), 1.40 (s, 6H); LC-MS (ESI+) m/z 390.1 $(M+H)^+$.


[003513] **2-[2-[2-(Tert-butoxvcarbonvlamino)ethoxvlethoxvlethyl (4-nitrophenvO carbonate [Intermediate QL)**



QL

[003514] To a solution of (4-nitrophenyl) carbonochloridate (711 mg, 3.53 mmol, CAS# 7693-46-1) and tert-butyl N-[2-[2-(2-hydroxyethoxy)ethoxy]ethyl]carbamate (800 mg, 3.21 mmol, CAS# 139135-92-7) in DCM (20 mL) was added TEA (812 mg, 8.02 mmol) at 0 °C. The reaction mixture was stirred at this temperature for 1 hr. On completion, the mixture was quenched with water (10 mL), and concentrated *in vacuo* to give the title compound (1.2 g, 90% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 437.2 $(M+Na)^+$.

[003515] **3-[5-(AminomethvO-l-oxo-isoindolin-2-yl]piperidine-2.,6-dione (Intermediate *m* .**



KC

QM

[003516] Step 1 - 2-(2,6-Dioxo-3-piperidyl)-1-oxo-isoindoline-5-carbonitrile

[003517] To a solution of 3-(5-bromo-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione (1.70 g, 5.26 mmol, Intermediate KC) and $Zn(CN)_2$ (370 mg, 3.16 mmol) in DMF (30.0 mL) was added $Pd(PPh_3)_4$ (607 mg, 526 umol). The mixture was stirred at 100 °C for 3 hour under N_2. On completion, the mixture was diluted with H_20 (50 mL), then mixture was filtered and the solid was dried *in vacuo*. The solid was triturated with PE: EA=5: 1 (50 mL), filtered and the solid was dried *in vacuo* to give the title compound (1.10 g, 77% yield) as purple solid. ^{1}H NMR (400MHz, DMSO-di) δ 11.02 (s, 1H), 8.16 (s, 1H), 8.01 - 7.90 (m, 2H), 5.20 - 5.09 (m, 1H), 4.59 - 4.37 (m, 2H), 2.99 - 2.87 (m, 1H), 2.70 - 2.57 (m, 1H), 2.46 - 2.37 (m, 1H), 2.11 - 1.98 (m, 1H).


[003518] Step 2 - Tert-butyl N-[[2-(2.6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yllmethvncarbamate


[003519] To a solution of 2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindoline-5-carbonitrile (1.50 g, 5.57 mmol) in THF (15.0 mL) and DMF (15.0 mL) was added $(Boc)_20$ (1.34 g, 6.13 mmol) and Raney-Ni (750 mg, 8.75 mmol). The mixture was stirred at 30 °C for 40 hour under H_2 (50 psi). On completion, the mixture was concentrated *in vacuo*. The mixture was purified by silica gel column (PE: EA = 1: 2) to give the title compound (900 mg, 43% yield) as white solid. ^{1}H NMR (400MHz, DMSO-t/$_f$) δ 10.99 (s, 1H), 7.68 (d, *J* = 7.6 Hz, 1H), 7.52 (t, *J* = 6.0 Hz, 1H), 7.45 (s, 1H), 7.38 (d, *J* = 7.6 Hz, 1H), 5.17 - 5.03 (m, 1H), 4.48 - 4.27 (m, 2H), 4.24 (d, *J* = 6.0 Hz, 2H), 2.98 - 2.85 (m, 1H), 2.65 - 2.55 (m, 1H), 2.44 - 2.31 (m, 1H), 2.06 - 1.96 (m, 1H), 1.40 (s, 9H).

[003520] Step 3 - 3-r5-(AminomethvD-1-oxo-isoindolin-2-vnpiperidine-2.6-dione

[003521] To a solution of tert-butyl N-[[2-(2, 6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl] methyljcarbamate (200 mg, 535 umol) in DCM (5.00 mL) was added HCl/dioxane (4.00 M, 5.00 mL). The mixture was stirred at rt for 0.5 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (160 mg, 90% yield, HC1) as white solid. LC-MS (ESI^+) *m/z* 274.1 $(M+H)^+$.

[003522] **2-[2-12-Aminoethoxylethoxy] ethyl_ _N-[[2-(2.,6-dioxo-3-piperidvD-l-oxo-isoindolin-5- yl] methyl] carbamate [Intermediate ON]**





[003523] Step 1 - 2-[2-[2-(Tert-butoxycarbonylamino)ethoxy]ethoxy]ethylN-[[2-(2,6-dioxo-3-piperidvO-l- oxo-isoindolin-5-yllmethyllcarbamate


[003524] To a solution of 3-[5-(aminomethyl)-l-oxo-isoindolin-2-yl]piperidine-2,6-dione (100 mg, 323 umol, HC1, Intermediate QM) and 2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethyl (4-nitrophenyl) carbonate (268 mg, 646 umol, Intermediate QL) in DMF (3 mL) was added TEA (163 mg, 1.61 mmol) under N_2 atmosphere. The reaction mixture was stirred at 25 °C for 1 h. On completion, the mixture was concentrated *in vacuo*. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (110 mg, 62% yield) as a white solid. ^1H NMR (400MHz, DMSO-^e) δ 11.00 (s, 1H), 7.93 - 7.86 (m, 1H), 7.70 - 7.65 (m, 1H), 7.47 (s, 1H), 7.42 - 7.36 (m, 1H), 6.82 - 6.72 (m, 1H), 5.14 - 5.06

(m, 1H), 4.47 - 4.40 (m, 1H), 4.34 - 4.25 (m, 3H), 4.12 - 4.03 (m, 2H), 3.60 - 3.55 (m, 2H), 3.50 - 3.47 (m, 4H), 3.38 - 3.36 (m, 2H), 3.05 (q, J = 5.6 Hz, 2H), 2.97 - 2.85 (m, 1H), 2.59 - 2.53 (m, 2H), 2.04 - 1.93 (m, 1H), 1.36 (s, 9H); LC-MS (ESI^+) *m/z* 549.3 $(M+H)^+$.

[003525] Step 2 - 2-r2-(2-Aminoethoxy)ethoxy1ethyl N-I[2-(2,6-dioxo-3-piperidvl)-1-oxo-isoindolin-5- yllmethyllcarbamate

[003526] To a solution of 2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethyl N-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl]methyl]carbamate (150 mg, 273 umol) in DCM (3 mL) was added HCl/dioxane (4 M, 5 mL). The reaction mixture was stirred at 25 °C for 2 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (130 mg, 98% yield, HC1) as a white solid. LC-MS (ESI^+) *m/z* 449.2 $(M+H)^+$.


[003527] **2-(Tert-butoxycarbonylamino)ethyl (4-nitrophenyQ carbonate [Intermediate OO)**



QO

[003528] To a solution of tert-butyl N-(2-hydroxyethyl)carbamate (500 mg, 3.10 mmol), (4-nitrophenyl)carbonochloridate (687 mg, 3.41 mmol) in DCM (20.0 mL) was added TEA (784 mg, 7.75 mmol) at 0 °C. The mixture was stirred at 0 °C for 1 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (1.00 g, 90% yield) as yellow solid. LC-MS (ESI^+) *m/z* 349.1 $(M+Na)^+$.

[003529] **2-Aminoethyl N-[[2-(2.,6-dioxo-3-piperidy0-l-oxo-isoindolin-5-yl]methyl]carbamate [Intermediate OP)**



[003530] Step 1 - 2-(Tert-butoxycarbonylamino)ethyl N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl] methyllcarbamate


[003531] To a solution of 3-[5-(aminomethyl)-l-oxo-isoindolin-2-yl]piperidine-2,6-dione (200 mg, 645umol, HC1, Intermediate QM) and 2-(tertbutoxycarbonylamino)ethyl (4-nitrophenyl) carbonate (421 mg, 1.29 mmol, Intermediate QO) in DMF (10.0 mL) was added TEA (326 mg, 3.23 mmol). The reaction mixture was stirred at 20 °C for 2 hrs. On completion, the mixture was concentrated *in vacuo*. The mixture was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA) - ACN]; B%: 26%-56%, 10 min) to give the title compound (160 mg, 53% yield) as white solid. ^{1}HNMR (400MHz, DMSO-i¾) δ 11.00 (s, 1H), 7.82 (t, *J* = 6.0 Hz, 1H), 7.68 (d, *J* = 8.0 Hz, 1H), 7.49 (s, 1H), 7.41 (d, *J* = 8.0 Hz, 1H), 6.94 - 6.87 (m, 1H), 5.16 - 5.07 (m, 1H), 4.49 - 4.31 (m, 2H), 4.30 (d, *J* = 6.4 Hz, 2H), 3.99 - 3.90 (m, 2H), 3.18 - 3.09 (m, 2H), 2.97 - 2.89 (m, 1H), 2.64 - 2.58 (m, 1H), 2.44 - 2.35 (m, 1H), 2.05 - 1.95 (m, 1H), 1.38 (s, 9H).

[003532] Step 2 - 2-Aminoethyl N-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yllmethyncarbamate

[003533] To a solution of 2-(tert-butoxycarbonylamino) ethyl N-[[2-(2,6-dioxo-3- piperidyl)-l-oxo- isoindolin-5-yl]methyl]carbamate (140 mg, 304 umol) in DCM (2.00 mL) was added HCl/dioxane (4.00 M, 14.0 mL). The mixture was stirred at 25 °C for 0.5 hr. On completion, the

mixture was concentrated *in vacuo* to give the title compound (120 mg, 99% yield) as yellow solid. LC-MS (ESI$^+$) *m/z* 361.2 $(M+H)^+$.

[003534] **3-[7-[3-[2-Aminoethoxy)propyl1-2-oxo-l,3-benzoxazol-3-yl]piperidine-2,6-dione [Intermediate OR)**



QR

[003535] Step 1 - Tert-butyl N-[2-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-1,3-benzoxazol-7-yl1 prop-2-ynoxyl ethyllcarbamate

[003536] To a solution of tert-butyl N-(2-prop-2-ynoxyethyl)carbamate (689 mg, 3.46 mmol, synthesized via Step 1 on Intermediate CP) and 3-(7-bromo-2-oxo-l,3-benzoxazol-3-yl)piperidine-2,6-dione (450 mg, 1.38 mmol, Intermediate JF) in DMF (10 mL) was added $Pd(PPh_3)_2Cl_2$ (194 mg, 276 umol), Cul (52.7 mg, 277 umol) and CS2CO3 (2.25 g, 6.92 mmol). The reaction was stirred at 80 °C for 3 hrs under N_2. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (510 mg, 83% yield) as a brown solid. ^1H

NMR (400 MHz, DMSO-^e) δ 11.23 (s, 1H), 7.31 (dd, *J* = 7.2 Hz, 1H), 7.26 - 7.19 (m, 2H), 6.92 - 6.77 (m, 1H), 5.46 - 5.32 (m, 1H), 4.45 (s, 2H), 3.52 (t, *J* = 6.0 Hz, 3H), 3.12 (q, *J* = 5.6 Hz, 2H), 2.93 - 2.82 (m, 1H), 2.66 - 2.57 (m, 1H), 2.22 - 2.13 (m, 1H), 1.36 (s, 9H); LC-MS (ESI^+) m/z 344.1 $(M + H - 100)^+$.


[003537] Step_2_-_Tert-butyl N-[2-[3-[3-(2.6-dioxo-3-piperidyl)-2-oxo-1,3-benzoxazol-7-yllpropoxylethyll carbamate

[003538] To a solution of tert-butyl N-[2-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-l,3-benzoxazol-7-yl]prop-2- ynoxy]ethyl]carbamate (340 mg, 766 umol) in THF (20 mL) was added $Pd(OH)_2/C$ (150 mg, 10 wt%) and Pd/C (150 mg, 50 wt%). The reaction mixture was stirred at 25 °C for 2 hrs under H_2 (15psi). On completion, the reaction mixture was filtered through celite and concentrated *in vacuo* to give the title compound (350 mg, 90% yield) as gray solid. LC-MS (ESI^+) m/z 348.1 $(M + H-l00)^+$.

[003539] Step 3 - 3-r7-r3-(2-Aminoethoxy)propyl1-2-oxo-l.3-benzoxazol-3-yl1piperidine-2.6-dione

[003540] To a solution of tert-butyl N-[2-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-l,3-benzoxazol-7-yl]propoxy] ethyl]carbamate (70.0 mg, 156 umol) in DCM (2 mL) was added HCl/dioxane (4 M, 1 mL). The reaction mixture was stirred at 25 °C for 2 hrs. On completion, the reaction mixture was filtered and the filter cake was concentrated *in vacuo* to give the title compound (60.0 mg, 99 % yield, HC1) as a white solid. LC-MS (ESI^+) m/z 348.l$(M+H)^+$.

[003541] 4-[[2-[2-[Tert-butoxycarbonyl[2,2,2-trifluoroethvnamino1-4-pyridyl1oxazole-4-carbonyl]_amino1-l-(4-formylphenvQpyrazole-3-carboxylic _acid [Intermediate_OU)



[003542] Step 1 - Methyl 4-amino-l-r4-(hvdroxymethvnphenyl1pyrazole-3-carboxylate

[003543] To a solution of methyl l-[4-(hydroxymethyl)phenyl]-4-nitro-pyrazole-3-carboxylate (15.0 g, 54.1 mmol, synthesized via Step 1 of Intermediate GB) in MeOH (200 mL) was added Pd/C (5.00 g, 10 wt%). The reaction mixture was stirred at 25 °C for 2 hours under H_2 (15 Psi). On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (13.0 g, 97% yield) as a light yellow solid. ^{1}H NMR (400MHz, DMSO-di) δ 7.82 (s, 1H), 7.74 (d, *J* = 8.4 Hz, 2H), 7.42 (d, *J* = 8.4 Hz, 2H), 5.27 (t, *J* = 5.6 Hz, 1H), 4.89 (s, 2H), 4.53 (d, 7=5 .6 Hz, 2H), 3.83 (s, 3H).

[003544] Step 2 - Methyl 4-[[2-[2-[tert-butoxycarbonyl(2.2.2-trifluoroethyl)amino1-4-pyridylloxazole-4- carbonyl1amino1-l-r4-(hvdroxymethvnphenyl1pyrazole-3-carboxylate

[003545] To a solution of methyl 4-amino- l-[4-(hydroxym ethyl)phenyl]pyrazole-3-carboxylate (4.10 g, 16.5 mmol) and 2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (5.14 g, 13.2 mmol, Intermediate CM) in DMF (100 mL) was added DIPEA (4.29 g, 33.1 mmol) and HATU (6.31 g, 16.5 mmol). The reaction mixture was

stirred at 25 °C for 0.5 hour. On completion, the reaction was quenched with water (500 mL) and the reaction mixture was filtered. The filter cake was washed with water (2 X 100 mL), MeOH (2 X 10 mL) and then dried *in vacuo* to give the title compound (10.0 g, 100% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 639.0 $(M+Na)^+$.


[003546] Step 3 - Methyl 4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carbonyl]amino]-1-(4-formylphenyl)pyrazole-3-carboxylate

[003547] To a solution of methyl 4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carbonyl]amino]-1-[4-(hydroxymethyl)phenyl]pyrazole-3-carboxylate (7.00 g, 11.3 mmol) in THF (250 mL) was added DMP (5.78 g, 13.6 mmol). The reaction mixture was stirred at 0 °C for 1 hour. On completion, the reaction mixture was diluted with DCM (300 mL) and filtered. The filtrate was concentrated *in vacuo* to give the title compound (7.00 g, 100% yield) as a yellow solid. ^1H NMR (400MHz, DMSO-d_6) δ 10.39 (s, 1H), 10.05 (s, 1H), 9.15 (d, *J* = 3.6 Hz, 1H), 8.66 (d, *J* = 5.2 Hz, 1H), 8.33 (s, 1H), 8.19 (d, *J* = 8.8 Hz, 1H), 8.11 - 8.03 (m, 2H), 8.03 - 7.95 (m, 1H), 7.78 -7.75 (m, 1H), 4.91 (q, *J* = 8.8 Hz, 2H), 1.54 (s, 9H), 1.35 (s, 3H); LC-MS (ESI^+) m/z 637.0 $(M+Na)^+$.

[003548] Step 4 - 4-[[2-[2-[Tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carbonyl] amino]-1-(4-formylphenyl)pyrazole-3-carboxylic acid

[003549] To a solution of methyl 4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carbonyl]amino]-1-(4-formylphenyl)pyrazole-3-carboxylate (4.00 g, 6.51 mmol) in THF (10 mL) and H_2O (2 mL) was added LiOH (467 mg, 19.5 mmol). The reaction mixture was stirred at 25 °C for 3 hours. On completion, the reaction mixture was acidified with HCl (0.5 N) to pH=6 and filtered to give the title compound (3.00 g, 76% yield) as a white solid. LC-MS (ESI^+) m/z 601.0 $(M+H)^+$.


[003550] Tert-butyl N-[4-[4-[[1-(4-formylphenyl)-3-(4-methylpiperazine-1-carbonyl)pyrazol-4-yl] carbamoyl] oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate [Intermediate QV]



QU QV

[003551] To a solution of 4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4- carbonyl]amino]-l-(4-formylphenyl)pyrazole-3-carboxylic acid (1.50 g, 2.50 mmol, Intermediate QU) and l-methylpiperazine (200 mg, 2.00 mmol, CAS# 109-01-3) in DMF (50 mL) was added DIPEA (968 mg, 7.49 mmol) and HATU (949 mg, 2.50 mmol). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was quenched with water (100 mL), filtered and washed with water (2 X 30 mL) to give the filter cake. The filter cake was then purified by reverse phase (0.1% FA) to give the title compound (1.00 g, 58% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-i¾) δ 11.17 - 11.06 (m, 1H), 10.05 (s, 1H), 9.15 (s, 1H), 9.1 1 (s, lH),8.66 (d, *J* = 5.2 Hz, 1H), 8.16 (s, 3H), 8.12 - 8.05 (m, 2H), 7.78 - 7.74 (m, 1H), 4.91 (q, *J* = 8.8 Hz, 2H), 4.39 - 4.32 (m, 2H), 3.85 - 3.70 (m, 2H), 2.48 - 2.40 (m, 4H), 2.24 (s, 3H), 1.54 (s, 9H); LC-MS (ESI^{+}) m/z 683.1 $(M+H)^{+}$.

[003552] 4-[4-[[2-[2-[Tert-butoxycarbonyl[2,2,2-trifluoroethvnamino1-4-Pyridyl1oxazole-4-carbonyl1 aminol-3-(4-methylpiperazine-l-carbonvQpyrazol-l-yllbenzoic acid [Intermediate OW)




QV QW

[003553] To a solution of tert-butyl N-[4-[4-[[l-(4-formylphenyl)-3-(4-methylpiperazine-l-carbonyl)pyrazol-4- yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (100 mg, 146 umol, Intermediate QV) and NaH_2P0_4 (87.8 mg, 732 umol) in ACN (1 mL) was added H_20_2 (33.2 mg, 292 umol, 30% sol) at 0 °C. Then sodium chlorite (92.7 mg, 1.03 mmol) in


H_20 (1 mL) was added dropwise at 0 °C. The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was acidified by HC1 (0.5 N) to pH = 6 and filtered. The filter cake was collected and dried *in vacuo* to give the title compound (100 mg, 97% yield) as a white solid. LC-MS (ESI^+) *m/z* 699.1 $(M+H)^+$.

[003554] Tert-butyl N-[4-[4-[[3-[2-(dimethylamino)ethylcarbamoyll-l-(4-formylphenvPpyrazol-4-yll carbamoyl1oxazol-2-yl]-2-pyridyl1-N-[2,2,2-trifluoroethyncarbamate [Intermediate OX)



[003555] To a solution of 4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4- carbonyl]amino]-l-(4-formylphenyl)pyrazole-3-carboxylic acid (800 mg, 1.33 mmol, Intermediate QU) and N',N'- dimethyl ethane- 1,2-diamine (117 mg, 1.33 mmol, 145 uL, CAS# 108-00-9) in DMF (10 mL) was added HATU (607 mg, 1.60 mmol) and DIPEA (860 mg, 6.66 mmol, 1.16 mL). The reaction mixture was stirred at 25 °C for 2 hrs. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (230 mg, 25% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 10.99 (s, 1H), 10.05 (s, 1H), 9.12 (s, 1H), 8.70 (t, 7 = 5.2, 1H), 8.66 (d, J = 5.2 Hz, 1H), 8.29 (s, 1H), 8.26 - 8.08 (m, 5H), 7.80 - 7.74 (m, 1H), 4.90 (q, J = 8.8 Hz, 2H), 3.54 - 3.48 (m, 2H), 2.71 - 2.63 (m, 2H), 2.36 (s, 6H), 1.54 (s, 9H); LC-MS (ESI^+) m/z 671.3 $(M+H)^+$.


[003556] 4-[4-[[2-[2-[Tert-butoxycarbonvU2,2,2-trifluoroethvnamino]-4-pyridyl] oxazole-4-carbonyll aminol-3-[2-(dimethylamino)ethylcarbamoyllpyrazol-l-yl] benzoic acid [Intermediate QY)




QX QY

[003557] To a solution of tert-butyl N-[4-[4-[[3-[2-(dimethylamino)ethylcarbamoyl]-l-(4-formylphenyl) pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (150 mg, 223 umol, Intermediate QX) in CH3CN (10 mL) was added a solution of NaH_2P04 (134 mg, 1.12 mmol and $NaClO_2$ (141 mg, 1.57 mmol) in H_20 (10 mL) at 0 °C, then H2O2 (126 mg, 1.12 mmol, 107 uL, 30% sol) was added to the mixture. The reaction mixture was stirred at 25 °C for 3 hrs . On completion, the mixture was diluted with 0.5N HC1 (10 mL) and extracted with EA (2 X 40 mL). The organic phase was concentrated *in vacuo* to give the title compound (120 mg, 78% yield) as a white solid. LC-MS (ESI^+) m/z 687.2$(M+H)^+$.

[003558] 12-rraSM-r(2S.4RE4-hvdroxy-2-rr4-(4-methylthiazol-5-vPphenyllmethylcarbamoyll pyrrolidine-l-carbonyl1-2,2-dimethyl-propyl]amino1-12-oxo-dodecanoic acid [Intermediate QZ)



G



QZ

[003559] Step 1 - methyl 12-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-12-oxododecanoate


[003560] To a solution of 12-methoxy-12-oxododecanoic acid (0.623 g, 2.55 mmol, CAS# 3909-40-0) in DMF (20 mL) was added HATU (0.989 g, 2.55 mmol) and DIPEA (0.599 g, 4.64 mmol). The mixture was stirred for 10 min at rt. Then to the mixture was added a solution of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide HC1 salt (1 g, 2.32 mmol, Intermediate G) in DMF (10 mL) and the mixture was stirred for 3 h at rt. On completion, H_20 (50 mL) was added to the mixture, then extracted with EA (100 mL). The organic layer was washed with brine, dried over Na_2S0_4, filtered, concentrated and purified by column (PE/EA= 1/1 to EA) to give the title compound (700 mg, 50 % yield) as a white solid. ^{1}H NMR (400 MHz, CDCh) δ 8.80 (s, 1 H), 7.39-7.31 (m, 5H), 6.10 (d, *J* = 8.8 Hz, 1H), 4.73 (t, 7 = 8.0 Hz, 1H), 4.61-4.48 (m, 3H), 4.34 (dd, *J* = 1.6 Hz, *J* = 14.8 Hz, 1H), 4.15-4.10 (m, 1H), 3.66 (s, 3H), 3.60 (dd, *J* = 3.6 Hz, 7 = 11.6 Hz, 1H), 2.56-2.53 (m,

4H), 2.29 (t, *J* = 7.6 Hz, 2H), 2.21-2.10 (m, 3H), 1.62-1.57 (m, 4H), 1.28-1.26 (m, 11H), 0.93 (s, 9H). LC/MS (ESI, *m/z):* [M +l] $^{+}$ = 657.6.

[003561] Step 2 - 12-t((S)-1-(Y2S.4R)-4-hvdroxy-2-(Y4-(4-methylthiazol-5-yl)benzyl icarbamoyl ipyrrolidin- 1-yl)-3,3-dimethyl- 1-oxobutan-2-yl)amino)- 12-oxododecanoic acid

[003562] To a solution of methyl l2-(((S)-l-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-l-yl)-3,3-dimethyl-l-oxobutan-2-yl)amino)-l2-oxododecanoate (2.4 g, 3.65 mmol) in MeOH (30 mL), $H_2$0 (30 mL) and THF (30 mL) was added NaOH (877 mg, 21.9 mmol). The mixture was stirred for 3 h at rt. To the mixture was added then added 0.06 N HC1 until the pH = 6.5, then the mixture was extracted with EA (100 mL). The organic layer was washed with brine (50 mL), dried over Na_2S0_4, filtered, concentrated to the title compound (2.3 g, 100% yield) as a white solid. ^{1}HNMR (400 MHz, CDCh) δ 8.89 (s, 1H), 7.39 (s, 4H), 7.20 (t, *J* = 7.2 Hz, 1H), 7.12 (d, *j* = 9.2 Hz, 1H), 4.74-4.64 (m, 3H), 4.58 (s, 1H), 4.33 (dd, *J* = 4.8 Hz, *J* = 14.8 Hz, 1H), 4.21 (d, *J* = 11.2 Hz, 1H), 3.69 (dd, *J* = 4.0 Hz, *J* = 12 Hz, 1H), 2.58 (s, 3H), 2.51-2.45 (m, 1H), 2.35 (t, *J* = 6.0 Hz, 2H), 2.26-2.19 (m, 3H), 1.69-1.56 (m, 4H), 1.34-1.28 (m, 12H), 0.95 (s, 9H). LC/MS (ESI, *m/z):* [M +l] $^{+}$ = 643.3.

[003563] 2-[2-[2-[2-[2-[2-[[(1S)-1-[i2S,4R)-4-hvdroxy-2-[[4-(4-methylthiazol-5-yl)phenyl] methylcarbamoyl]pyrrolidine-1-carbonyl1-2,2-dimethyl-propyl]amino1-2-oxo-ethoxyl ethoxy] ethoxy] ethoxy] ethoxy] acetic acid [Intermediate RA)




[003564] Step 1 - (S)-19-(Y2S.4R)-4-hvdroxy-2-(Y4-(4-methylthiazol-5-vObenzvOcarbamovOpynOlidine-l-carbonvO-20.20-dimethyl-l7-oxo-3.6.9.12.15-pentaoxa-18-azahenicosanoic acid

[003565] To a mixture of 3,6,9, 12, 15-pentaoxaheptadecanedioic acid (1.04 g, 3.36 mmol, Intermediate UF), DIPEA(289 mg, 2.24 mmol) in DMF(15 mL) was added HATU (511 mg, 1.344 mmmol). Then the (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (500 mg, 1.12 mmol, Intermediate G) in DMF (5 mL) was added dropwise to the solution. After the addition, the mixture was stirred at rt for 30 min. Then the mixture was poured into water, acidified to pH < 6 by addition of 1M HC1, then extracted with EtOAc (3 x 30 mL). The combined organic layers was washed with brine (50 mL x 2), dried over anhydrous Na_2SO_4, filtered and concentrated *in vacuo*. The residue was purified by prep HPLC to give the title compound (311 mg, 38% yield) as a white solid. ^1H NMR (400 MHz, METHANOL-^) *S* 9.05 (s, 1H), 7.53 - 7.44 (m, 4H), 4.74 - 4.70 (m, 1H), 4.61 - 4.51 (m, 3H), 4.38 (d, .7=15.51 Hz, 1H), 4.13 (s, 2H), 4.08 (d, 7=3.13 Hz, 2H), 3.90 -

3.81 (m, 2H), 3.73 - 3.63 (m, 16H), 2.52 (s, 3H), 2.27 - 2.08 (m, 2H), 1.07 (s, 9H); LC/MS (ESI, *m/z):* [M +l] $^{+}$ = 723.2.

[003566] **2-[2-[2-[2-[[(1S)-1-b2S.4RE4-hvdroxy-2- rr4-(4-methylthiazol-5-vnphenyll methylcarbamoyllpyrrolidine-l-carbonyl]-2,2-dimethyl-propyllaminol-2-oxo-ethoxylethoxylethoxyl acetic acid Intermediate RB)**




G RB

[003567] Step 1 - (S)-l3-((2S.4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl (carbamoyl ipyrrolidine- l-carbonyl)-14. 14-di methyl - 11-oxo-3.6.9-trioxa- 12-azapentadecanoic acid

[003568] To a mixture of 2,2'-((oxybis(ethane-2,l-diyl))bis(oxy))diacetic acid (1.36 g, 4.3 mmol, CAS# 13887-98-4), DIPEA (415 mg, 3.23 mmol) in DMF(5 mL) was added HATU (488 mg, 1.29 mmmol). Then (2S,4R)-l-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (500 mg, 1.12 mmol, Intermediate G) in DMF(5 mL) was added dropwise into the mixture. After the addition, the mixture was stirred at rt for 30 min. Then the mixture was poured into water, acidified to pH < 6 by the addition of 1M HC1, then extracted with EtOAc (3 x 30 mL). The combined organic layers was washed with brine (50 mL x 2), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by prep HPLC to give the title compound (125 mg, 18%) as a white solid. ¾NMR (400 MHz, METHANOL-^) *S* 9.10 (br. s., 1H), 7.45 - 7.25 (m, 4H), 4.60 (s, 1H), 4.50 - 4.40 (m, 3H), 4.26 (d, .7=15.51 Hz, 1H), 4.03 - 3.94 (m, 4H), 3.79 - 3.68 (m, 2H), 3.63 - 3.58 (m, 8H), 2.41 (s, 3H), 2.16 - 1.93 (m, 2H), 0.94 (s, 9H); LC/MS (ESI, *m/z):* [M +l] $^{+}$ = 635.1.

[003569] **5-(4-Tert-butoxycarbonylpiperazin-l-vDpyrazolo[l.,5-alpyrimidine-3-carboxylic acid [Intermediate RC)**



RC

[003570] Step 1 - Ethyl 5-(4-tert-butoxycarbonylpiperazin- 1-yl ipyrazolof 1.5-alpyrimidine-3-carboxylate


[003571] To a mixture of ethyl 5-chloropyrazolo[l,5-a]pyrimidine-3-carboxylate (0.50 g, 2.22 mmol, CAS# 1224944-77-7) and tert-butyl piperazine-l-carboxylate (619 mg, 3.32 mmol) in MeCN (6 mL) was added DIPEA (857 mg, 6.63 mmol, 1.16 mL), and the resulting mixture was stirred at 60 °C for 2 hours. On completion, the mixture was concentrated *in vacuo.* The residue was diluted with water (30 mL) and acidified with HC1 (1 N) until the pH = 5, then the mixture was extracted with EA (3 X 50 mL). The combined organic layers was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the compound (0.81 g, 97% yield) as white solid; ^1H NMR (400MHz, CDCh) δ 8.32 - 8.31 (m, 1H), 8.29 (s, 1H), 6.43 - 6.41 (m, 1H), 4.38 - 4.32 (m, 2H), 3.90 - 3.80 (m, 4H), 3.59 - 3.56 (m, 4H), 1.49 (s, 9H), 1.41 - 1.37 (m, 3H).

[003572] Step 2 - 5-(4-Tert-butoxycarbonylpiperazin-l-vOpyrazolorL5-a1pyrimidine-3-carboxylic acid

[003573] To a solution of ethyl 5-(4-tert-butoxycarbonylpiperazin-l-yl)pyrazolo[l,5-a] pyrimidine-3 -carboxylate (0.80 g, 2.13 mmol) in THF (16.0 mL) was added a solution of $LiOH•H_20$ (223 mg, 5.33 mmol) in H_20 (4.00 mL). The reaction mixture was stirred at 20 °C for 16 hours, then an additional solution of $LiOH•H_20$ (1.00 g, 23.8 mmol) in H_20 (4.00 mL) was added, and the reaction mixture was stirred at 20 °C for 8 hours. The mixture was then heated to 45 °C and stirred for 16 hours. On completion, the mixture was concentrated *in vacuo.* The residue was extracted with EA (20 mL) to remove organic impurities. Then the water phase was acidified with 1 N HC1 (aq.) until pH = 4, and extracted with EA/MeOH (10/1, 2 X 20 mL). The combined

organic layer was dried overNa $_2$S0 $_4$, filtered and concentrated *in vacuo* to give the title compound (0.72 g, 97% yield) as yellowish solid. ^{1}H NMR (400MHz, CDCh) δ 8.74 - 8.72 (m, 1H), 8.17 (s, 1H), 6.84 - 6.82 (m, 1H), 3.75 - 3.74 (m, 4H), 3.46 - 3.43 (m, 4H), 1.42 (s, 9H).

[003574] **N-[3-(difluoromethvD-l-methyl-pyrazol-4-yl]-5-piperazin-l-yl-pyrazolo[l.,5-a]pyrimidine-3- carboxamide [Intermediate RD)**



RC RD

[003575] Step_ %_ Tert-butyl_ 4-[3-[[3-(dif uoromethvl)-l-methyl-pyrazol-4-yllcarbamoyllpyrazolor i,5-a] pyrimidin-5 - yllpiperazine-l-carboxylate


[003576] To a mixture of 3-(difluoromethyl)-l -methyl -pyrazol-4-amine (847 mg, 5.76 mmol, Intermediate LU), 5-(4-tert-butoxycarbonylpiperazin-l-yl)pyrazolo[l,5-a]pyrimidine-3-carboxylic acid (2.00 g, 5.76 mmol, Intermediate RC) in DMF (20 mL) was added DIPEA (2.23 g, 17.3 mmol) and HATU (2.63 g, 6.91 mmol). The reaction mixture was stirred at 20 °C for 1 hour. On completion, the reaction mixture was poured into water (60 mL). The aqueous phase was extracted with ethyl acetate (2 X 30 mL). The combined organic phase was washed with brine (2 X 30 mL), dried with anhydrous Na$_2$S0 $_4$, filtered and concentrated *in vacuo.* The residue was purified by column chromatography (Si0 $_2$, Ethyl acetate) to give the title compound (734 mg, 26% yield) as reddish brown solid. ^{1}H NMR (400MHz, CDCh) δ 9.42 (s, 1H), 8.37 (s, 1H), 8.32 - 8.25 (m, 2H), 6.70 (t, *J* = 54.0 Hz, 1H), 6.35 (d, *J* = 8.0 Hz, 1H), 3.83 (s, 3H), 3.75 (s, 4H), 3.59 - 3.49 (m, 4H), 1.44 (s, 9H).

[003577] Step_ 2-____N-r3-(difluoromethvD-l-methyl-pyrazol-4-vn-5-piperazin-l-yl-pyrazolorL5-a1pyrimidine-3- carboxamide


[003578] To a mixture of tert-butyl 4-[3-[[3-(difluoromethyl)-l-methyl-pyrazol-4-yl]carbamoyl]pyrazolo[l,5-a] pyrimidin-5-yl]piperazine-l-carboxylate (684 mg, 1.44 mmol) in DCM (2 mL) was added HCl/dioxane (4 M, 717 uL). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (575 mg, 91% yield, HC1) as a white solid. ^{1}H NMR (400MHz, DMSO-de) δ 9.65 (s, 2H), 9.33 (s,

1H), 8.90 (d, *J* = 8.0 Hz, 1H), 8.35 (d, *J* = 12.4 Hz, 1H), 7.13 (t, *J* = 53.6 Hz, 1H), 6.96 (d, *J* = 7.6 Hz, 1H), 4.08 (s, 4H), 3.89 (s, 3H), 3.23 (s, 4H). LC-MS (ESI^+) *m/z* 377.2$(M + H)^+$.

[003579] **3-[5-[4-[2-(2-Aminoethoxy)ethyllpiperazin-l-yll-3-methyl-2-oxo-benzimidazol-l-yl] piperidine-2,6-dione [Intermediate RG]**



PN



RG


[003580] Step 1 - Tert-butyl N-[2-[2-[4-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl1piperazin -l-zyllethoxylethyllcarbamate

[003581] To a mixture of 3-(3-methyl-2-oxo-5-piperazin-l-yl-benzimidazol-l-yl)piperidine-2,6-dione (20.0 mg, 582 umol, Intermediate PN) in THF (4 mL) and DMF (4 mL) was added TEA (589 mg, 5.82 mmol, 811 uL). The reaction mixture was stirred at 25°C for 0.5 hour. Then tert-butyl N-[2-(2-oxoethoxy) ethyl]carbarnate (500 mg, 2.46 mmol, synthesized via Step 1 of Intermediate FS) and HOAc (385 mg, 6.41 mmol, 366 uL) were added to the above solution. The reaction mixture was stirred at 25°C for 0.5 hour. Then $NaBH(OAc)_3$ (247 mg, 1.16 mmol) was added to the reaction mixture. Then the mixture was stirred at 25 °C for 6 hrs under N_2 atmosphere. On completion, the mixture was concentrated *in vacuo* give a residue. The residue was purified by reversed-phase HPLC (0.1% FA condition) to give the title compound (60.0 mg, 19% yield) as a yellow solid. LC-MS (ESI^+) m/z 531.3 $(M+H)^+$.

[003582] Step 2 - 3-r5-r4-r2-(2-Aminoethoxy)ethyl1piperazin-l-yl1-3-methyl-2-oxo-benzimidazol-l-yll piperidine-2.6-dione

[003583] To a solution of tert-butyl N-[2-[2-[4-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] piperazin-l-yl]ethoxy]ethyl]carbamate (60.0 mg, 113 umol) in DCM (10 mL) was added TFA (4.62 g, 40.5 mmol, 3.00 mL). The mixture was stirred at 15 °C for 0.5 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (50.0 mg, 95% yield) as yellow oil. LC-MS (ESI^+) m/z 431.2 $(M+H)^+$.

[003584] **3-[5-[3-(2-Aminoethoxy)propyll-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2.,6-dione [Intermediate RH)**



RH

[003585] Step 1 - Tert-butyl N-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl1prop-2- ynoxylethyllcarbamate

[003586] To a solution of 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (600 mg, 1.77 mmol, Intermediate HN) and tert-butyl N-(2-prop-2-ynoxyethyl)carbamate (883 mg, 4.44 mmol, synthesized via Step 1 on Intermediate CP) in DMF (10 mL) was added CS2CO3 (2.31 g, 7.10 mmol), Cul (67.5 mg, 354 umol), 4Å molecular sieve (20 mg) and $Pd(PPh_3)_2Cl_2$ (249 mg, 354. umol). The mixture was heated at 80 °C for 2 hours. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was diluted

with water (30 mL), and then extracted with EA (3 X 40 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (FA condition) to give the title compound (650 mg, 80% yield) as light yellow solid. ^1H NMR (400MHz, DMSO-d_6) δ 11.12 (s, 1H), 7.32 (s, 1H), 7.19 - 7.10 (m, 2H), 6.90 - 6.78 (m, 1H), 5.39 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.37 (s, 2H), 4.11 (d, *J* = 2.4 Hz, 1H), 3.50 (t, *J* = 6.0 Hz, 2H), 3.34 (s, 3H), 3.18 - 3.09 (m, 2H), 2.95 - 2.82 (m, 1H), 2.73 - 2.55 (m, 2H), 2.09 - 1.99 (m, 1H), 1.37 (s, 9H); LC-MS (ESI$^+$) *m/z* 357.2 (M+H-l00) $^+$.


[003587] Step 2 - Tert-butyl N-r2-r3-rl-(2.6-dioxo-3-piperidvD-3-methyl-2-oxo-benzimidazol-5-yllpropoxyl ethyllcarbamate

[003588] To a solution of tert-butyl N-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] prop-2-ynoxy]ethyl]carbamate (600 mg, 1.31 mmol) in THF (20 mL) was added $Pd(OH)_2$/C (150 mg, 10 wt%) and Pd/C (150 mg, 10 wt%) under N_2. The suspension was degassed under vacuum and purged with H_2 gas three times. The mixture was stirred at 25°C for 16 hours under H_2 (15 PSI). On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (500 mg, 82% yield) as white solid. ^1H NMR (400MHz, DMSO-d) δ 11.07 (s, 1H), 7.08 - 6.92 (m, 2H), 6.86 (dd, 7 = 1.2, 8.4 Hz, 1H), 6.77 (t, *J* = 5.2 Hz, 1H), 5.33 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.39 - 3.33 (m, 4H), 3.32 (s, 3H), 3.15 - 3.03 (m, 2H), 2.97 - 2.81 (m, 1H), 2.73 - 2.58 (m, 4H), 2.03 - 1.95 (m, 1H), 1.86 - 1.74 (m, 2H), 1.37 (s, 9H); LC-MS (ESI$^+$) *m/z* 483.1 (M+Na)$^+$.

[003589] Step 3 - 3-r5-r3-(2-Aminoethoxy)propyl1-3-methyl-2-oxo-benzimidazol-l-yl1piperidine-2.6-dione

[003590] To a solution of tert-butyl N-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] propoxy]ethyl]carbamate (150 mg, 325 umol) in DCM (3 mL) was added TFA (1.54 g, 13.5 mmol). The mixture was stirred at 30 °C for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (150 mg, 97% yield, TFA) as light yellow solid. LC-MS (ESI$^+$) *m/z* 361.1 (M+H)$^+$.

[003591] 4-3-[4-[3-(2-Aminoethoxy)propyll-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2.,6-dione [Intermediate RI)



RI

[003592] Step 1 - Tert-butyl N-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl1prop-2- ynoxylethyllcarbamate

[003593] To a mixture of tert-butyl N-(2-prop-2-ynoxyethyl)carbamate (4.42 g, 22.1 mmol, synthesized via Step 1 on Intermediate CP) and 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (3.00 g, 8.87 mmol, Intermediate HP) in DMF (50 mL) was added CS2CO3 (14.4 g, 44.3 mmol), Cul (168 mg, 887 umol) and Pd(PPh3)$_2$Cl2 (622 mg, 887 umol). The reaction mixture was stirred at 80 °C for 2 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo.* The residue was diluted with water (50 mL) and extracted with EA (3 X 100 mL). The combined organic layers was dried over Na$_2$S0$_4$, filtered and concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (0.1 % FA condition) to give the title compound (2.70 g, 66% yield) as brown solid. ^{1}H NMR (400 MHz, DMSO-r¾) δ 11.13 (s, 1H), 7.23 - 7.09 (m, 2H), 7.08 - 6.99 (m, 1H), 6.92 - 6.82 (m, 1H), 5.45 - 5.36 (m, 1H), 4.44 (s, 2H), 3.64 (s, 3H), 3.52 (t, *J* = 6.0 Hz, 2H), 3.16 - 3.08 (m, 2H), 2.96 - 2.83 (m, 1H), 2.78 - 2.60 (m, 2H), 2.07 - 1.95 (m, 1H), 1.36 (s, 9H).

[003594] Step 2 - Tert-butyl N-[2-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yllpropoxyl ethyllcarbamate


[003595] To a mixture of tert-butyl N-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]prop -2-ynoxy]ethyl]carbamate (200 mg, 438 umol) in THF (5 mL) was added Pd/C (100 mg, 10 wt%) and Pd(OH)2/C (100 mg, 10 wt%). The reaction mixture was stirred at 25

°C for 12 hours under H_2 (15 PSI) atmosphere. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (200 mg, 99% yield) as light yellow oil. ^{1}H NMR (400 MHz, DMSO-^e) δ 11.08 (s, 1H), 7.00 - 6.92 (m, 2H), 6.91 - 6.84 (m, 1H), 6.79 (s, 1H), 5.39 - 5.32 (m, 1H), 3.56 (s, 3H), 3.44 (t, *J* = 6.0 Hz, 2H), 3.40 - 3.38 (m, 2H), 3.09 (d, *J* = 5.6 Hz, 2H), 2.98 - 2.93 (m, 2H), 2.90 - 2.83 (m, 1H), 2.71 - 2.60 (m, 2H), 2.03 - 1.94 (m, 1H), 1.88 - 1.76 (m, 2H), 1.37 (s, 9H).

[003596] Step 3 - 4-3-r4-r3-(2-Aminoethoxy)propyl1-3-methyl-2-oxo-benzimidazol-l-yl1piperidine-2.6-dione

[003597] To a mixture of tert-butyl N-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propoxy]ethyl]carbamate (200 mg, 434 umol) in DCM (3 mL) was added HCl/dioxane (4 M, 5 mL). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (172 mg, 99% yield) as light yellow solid. LC-MS (ESI^+) *m/z* 361.1 $(M+H)^+$.

[003598] 3-[5-[3-[(2RV2-(aminomethvDmorpholin-4-yllpropyll-3-methyl-2-oxo-benzimidazol-l-yl] piperidine-2,6-dione [Intermediate RJ)



[003599] Step 1 - Tert-butyl N-[[(2R)-4-prop-2-vnylmorpholin-2-yl1methyl1carbamate

[003600] To a solution of tert-butyl N-[[(2S)-morpholin-2-yl]methyl]carbamate (1.00 g, 4.62 mmol, CAS# 875551-59-0) and 3-bromoprop-l-yne (550 mg, 4.62 mmol) in THF (20 mL) was added K_2CO_3 (1.28 g, 9.25 mmol). The reaction mixture was stirred at 25 °C for 12 hours. On completion, the mixture was diluted with water (30 mL) and extracted with EA (3 X 80 mL). The combined organic layers was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography ($S1O_2$, Petroleum ether/Ethyl acetate = 10/1 to 2/1) to give the title compound (800 mg, 68% yield) as yellow oil. ^1H NMR (400 MHz, CDCb) δ 4.93 (s, 1H), 3.93 - 3.87 (m, 1H), 3.68 (dt, *J* = 2.4, 11.2 Hz, 1H), 3.64 - 3.57 (m, 1H), 3.31 *(d, J* = 2.4 Hz, 2H), 3.15 - 3.05 (m, 1H), 2.78 - 2.72 (m, 1H), 2.70 - 2.65 (1H), 2.39 (dt, 7 = 3.6, 11.2 Hz, 1H), 2.27 (t, *J* = 2.4 Hz, 1H), 2.13 (t, *J* = 10.8 Hz, 1H), 1.87 (s, 1H), 1.45 (s, 9H).

[003601] Step _2_-_Tert-butyl _N-[[(2R)-4-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yllprop- _2-vnyl1morpholin-2-yl1methyl1carbamate

[003602] To a solution of tert-butyl N-[[(2R)-4-prop-2-ynylmorpholin-2-yl]methyl]carbamate (846 mg, 3.33 mmol) and 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (450 mg, 1.33 mmol, Intermediate HN) in DMF (15 mL) was added CS_2CO_3 (2.17 g, 6.65 mmol), CuI (25.3 mg, 133 umol) and $Pd(PPh3)_2Cl2$ (93.4 mg, 133 umol). The reaction mixture was stirred at 80 °C for 2 hr under N_2. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (550 mg, 80% yield) as a yellow solid. ¾ NMR (400 MHz, DMSO-^e) δ 11.1 1 (s, 1H), 7.28 (s, 1H), 7.16 - 7.10 (m, 2H), 6.86 - 6.83 (m, 1H), 5.38 (dd, *J* = 5.2, 12.4 Hz, 1H), 3.79 (t, *J* = 13.2 Hz, 2H), 3.52 (s, 2H), 3.34 (s, 3H), 3.01 - 2.92 (m, 3H), 2.80 - 2.70 (m, 2H), 2.69 - 2.65 (m, 2H), 2.35 - 2.27 (m, 1H), 2.25 - 2.15 (m, 1H), 2.06 - 1.95 (m, 2H), 1.37 (s, 9H); LC-MS (ESI^+) m/z 512.2 $(M + H)^+$.


[003603] Step _3_-_Tert-butyl _N-rr(2R)-4-r3-rl-(2.6-dioxo-3-piperidvD-3-methyl-2-oxo-benzimidazol-5-yl1propyl1 morpholin-2-yllmethyllcarbamate

[003604] To a solution of tert-butyl N-[[(2R)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] prop-2-ynyl]morpholin-2-yl]methyl]carbamate (300 mg, 586 umol) in THF (10 mL) was added Pd/C (100 mg, 10 wt%) and Pd(OH)2/C (100 mg, 10 wt%). The reaction mixture was stirred at 25 °C under H_2 (15 psi) for 12 hours. On completion, the residue was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*l0um; mobile phase: [water (0.225%FA)-ACN]; B%: l%-3 1%, lOmin) to give the title compound (120 mg, 39% yield) as a white solid. ^1H NMR (400MHz, DMS0 -d_6) δ 11.08 (s, 1H), 7.04 (s, 1H), 7.00 (d, 7 = 8.0 Hz, 1H), 6.87 (d, *J* = 8.0 Hz, 1H), 6.82 (t, *J* = 5.6 Hz, 1H), 5.33 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.43 - 3.40 (m, 3H), 3.32 (s, 3H), 3.03 - 2.87 (m, 3H), 2.73 - 2.58 (m, 6H), 2.36 - 2.25 (m, 2H), 2.03 - 1.95 (m, 2H), 1.79 - 1.66 (m, 3H), 1.36 (s, 9H); LC-MS (ESI^+) m/z 516.3 $(M+H)^+$.

[003605] Step 4 - 3-[5-[3-[(2R)-2-(aminomethyl)morpholin-4-yl1propyl1-3-methyl-2-oxo-benzimidazol-l-yl] piperidine-2.6-dione

[003606] To a solution of tert-butyl N-[[(2R)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] propyl]morpholin-2-yl]methyl]carbamate (120 mg, 232 umol) in DCM (3 mL) was added HCl/dioxane (4 M, 1 mL). The reaction mixture was stirred at 25 °C for 2 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (100 mg, 95% yield) as a white solid. LC-MS (ESI^+) m/z 4l6.2$(M+H)^+$.

[003607] **3-[5-[3-[(2S)-2-(aminomethyl)morpholin-4-yl]propyll-3-methyl-2-oxo-benzimidazol-l-yl] piperidine-2,6-dione [Intermediate RK)**



[003608] Step 1 -Tert-butyl N-[[(2S)-4-prop-2-vnylmorpholin-2-yl1methyl1carbamate

[003609] To a mixture of tert-butyl N-[[(2R)-morpholin-2-yl]methyl]carbamate (3 g, 13.8 mmol, CAS# 186202 -57-3) and 3- bromoprop-l-yne (1.98 g, 16.6 mmol) in THF (60 mL) was added K_2CO_3 (3.83 g, 27.7 mmol). The reaction mixture was stirred at 25 °C for 16 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography ($S1O_2$, petroleum ether/ethyl acetate=4/l) to give the title compound (2.4 g, 68% yield) as light yellow solid. ^{1}H NMR (400MHz, CDCb) δ 4.90 (s, 1H), 3.96 - 3.83 (m, 1H), 3.74 - 3.50 (m, 2H), 3.33 -3.25 (m, 3H), 3.13 - 3.08 (m, 1H), 2.78 - 2.62 (m, 2H), 2.41 - 2.33 (m, 1H), 2.26 (t, J = 2.4 Hz, 1H), 2.13 (t, J = 10.4 Hz, 1H), 1.44 (s, 9H).

[003610] Step _2 _- _Tert-butyl _N-[[(2S)-4-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yllprop _-2-vnyl1morpholin-2-yl1methyl1carbamate

[003611] To a solution of 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (265 mg, 784 umol, Intermediate HN) and tert-butyl N-[[(2S)-4-prop-2-ynylmorpholin-2-yl]methyl]carbamate (299 mg, 1.18 mmol) in DMF (15 mL) was added Cul (29.9 mg, 157 umol), $Pd(PPh_3)_2Cl_2$ (110 mg, 157 umol), CS2CO3 (1.02 g, 3.13 mmol) and 4Å molecular sieves (20 mg) at 25 °C. The reaction mixture was stirred at 80 °C for 3 hours. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was diluted with water (30 mL), and then extracted with EA (3 x 50 mL). The combined organic layers were washed with brine (50 mL), then dried over Na_2SO_4, filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (270 mg, 67% yield) as a white solid. 1H NMR (400 MHz, CDCb) δ 8.18 (s, 1H), 7.17 (d, *J* = 1.2 Hz, 1H), 7.10 (s, 1H), 6.73 (d, 7 = 8.4 Hz, 1H), 5.20 - 5.16 (m, 1H), 4.93-4.89 (m, 1H), 3.95 - 3.89 (m, 1H), 3.72 - 3.71 (m„ 1H), 3.54 - 3.49 (m, 2H), 3.43 (s, 3H), 3.15 - 3.07 (m, 1H), 2.99 - 2.99 (m, 1H), 2.99 - 2.92 (m, 1H), 2.89 - 2.61 (m, 6H), 2.48 - 2.40 (m, 1H), 2.28 - 2.22 (m, 1H), 2.17 (t, 7 = 3.6 Hz, 1H), 1.43 (s, 9H); LC-MS (ESI+) m/z 512.3 $(M+H)^+$.


[003612] Step _3_ - _Tert-butyl _N-[[(2S)-4-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5- vl] propyl1morpholin-2-yl1methyl1carbamate

[003613] To a solution of tert-butyl N-[[(2S)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5- yl]prop-2-ynyl]morpholin-2-yl]methyl]carbamate (270 mg, 528 umol) in THF (15 mL) was added Pd/C (120 mg, 528umol, 10 wt%) and Pd(OH)2/C (110 mg, 528 umol, 10 wt%) at 25 °C. The reaction mixture was stirred at 25 °C for 2 hours under ¾ (15 PSI). On completion, the reaction mixture was filtered with celite and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (230 mg, 85% yield) as a brown solid. LC-MS (ESI^+) m/z 516.1 $(M+H)^+$.

[003614] Step 4 - 3-[5-[3-[(2S)-2-(aminomethvl)morpholin-4-yl]propyl]-3-methyl-2-oxo-benzimidazol-l-yl] piperidine-2.6-dione

[003615] To a solution of tert-butyl N-[[(2S)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] propyl]morpholin-2-yl]methyl]carbamate (130 mg, 252 umol) in DCM (2 mL) was added TFA (1.67 g, 14.6 mmol). The reaction mixture was stirred at 25 °C for 2 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (100 mg, 95% yield, TFA) as a brown oil. LC-MS (ESI^+) m/z 4l6.3$(M+H)^+$.

[003616] **2-[(2S)-4-prop-2-vnylmorpholin-2-yl]acetonitrile [Intermediate RL)**



[003617] Step 1 - Tert-butyl (2R)-2-(methylsulfonyloxymethyl)morpholine-4-carboxylate

[003618] To a solution of tert-butyl (2R)-2-(hydroxymethyl)morpholine-4-carboxylate (10.0 g, 46.0 mmol, CAS# 135065-71-3) and TEA (9.32 g, 92.0 mmol) in DCM (100 mL) was added MsCl (6.36 g, 55.5 mmol) at 0 °C. The reaction mixture was stirred at 25 °C for 2 hours. On completion, the reaction mixture was poured into sat.$NaHCO_3$ (50 mL) and extracted with EA (3 X 300 mL). The combined organic layers were washed with brine (300 mL), dried with anhydrous Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (13.5 g, 99% yield) as colorless oil, ^1H NMR (400MHz, CDCh) δ 4.23 (d, *J* = 4.8 Hz, 2H), 4.06 - 3.77 (m, 3H), 3.74 - 3.64 (m, 1H), 3.59 - 3.49 (m, 1H), 3.06 (s, 3H), 3.01 - 2.88 (m, 1H), 2.81 - 2.67 (m, 1H), 1.49 - 1.42 (m, 9H).

[003619] Step 2 - Tert-butyl (2SV2-(cvanomethvDmorpholine-4-carboxylate

[003620] To a solution of tert-butyl (2R)-2-(methylsulfonyloxymethyl)morpholine-4-carboxylate (13.0 g, 44.0 mmol) and KI (10.9 g, 66.0 mmol) in DMSO (200 mL) was added KCN (3.15 g, 48.4 mmol, 2.07 mL). The reaction mixture was stirred at 80 °C for 3 hours. The reaction mixture was then stirred at 100 °C for 4 hours. On completion, the reaction mixture was poured into sat.$NaHCO_3$ (100 mL) and extracted with EA (3 X 500 mL). The combined organic layers were washed with brine (50 mL), dried with anhydrous Na_2SO_4, filtered and concentrated *in vacuo.* The residue was purified by silica column chromatography (PE/EA= 10/1 to 6/1) to give the title compound (8.00 g, 80% yield) as a white solid. ^1H NMR (400MHz, CDCh) δ 4.10 - 3.78 (m, 3H), 3.72 - 3.62 (m, 1H), 3.60 - 3.50 (m, 1H), 2.97 (t, *J* = 11.2 Hz, 1H), 2.84 - 2.65 (s, 1H), 2.62 - 2.50 (m, 2H), 1.47 (s, 9H).

[003621] Step 3 - 2-[(2S)-Morpholin-2-yl1acetonitrile


[003622] To a solution of tert-butyl (2S)-2-(cyanomethyl)morpholine-4-carboxylate (4.50 g, 19.8 mmol) in DCM (10 mL) was added TFA (138 g, 1.22 mol). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title

compound (4.70 g, 98% yield) as colorless oil. ¾ NMR (400MHz, DMSO-d«) δ 9.29 - 8.83 (m, 2H), 4.05 - 3.88 (m, 2H), 3.77 - 3.63 (m, 1H), 3.31 - 3.15 (m, 2H), 3.03 - 2.76 (m, 3H), 2.41 - 2.18 (m, 1H).

[003623] Step 4 - 2-[(2S)-4-prop-2-vnylmorpholin-2-yl1acetonitr le

[003624] To a solution of 2-[(2S)-morpholin-2-yl]acetonitrile (4.70 g, 19.5 mmol, TFA) and 3-bromoprop-l-yne (3.49 g, 29.3 mmol) in THF (100 mL) was added KI (324 mg, 1.96 mmol) and K2CO3 (8. 11 g, 58.7 mmol). The reaction mixture was stirred at 25 °C for 48 hours. On completion, the reaction mixture was diluted with EA(500 mL) and filtered to give the filtrate. The filtrate was concentrated *in vacuo* to give a residue. The residue was purified by silica column chromatography (PE/EA= 10/1 to 6/l) to give the title compound (1.50 g, 46% yield) as a light yellow oil. ¾NMR (400MHz, CDCb) δ 3.97 - 3.90 (m, 1H), 3.87 - 3.78 (m, 1H), 3.70 (dt, 7 = 2.4, 11.2 Hz, 1H), 3.33 (d, J = 2.0 Hz, 2H), 2.85 - 2.80 (m, 1H), 2.67 - 2.60 (m, 1H), 2.56 (d, J = 6.0 Hz, 2H), 2.44 (dt, J = 3.2, 11.2 Hz, 1H), 2.29 (t, J = 2.4 Hz, 1H), 2.35 (t, 7 = 10.0 Hz, 1H).

[003625] **3-[5-[3-[(2S)-2-(2-aminoethyl)morpholin-4-yl]propyl]-3-methyl-2-oxo-benzimidazol-1- yl]piperidine-2,6-dione [Intermediate RM)**



[003626] Step 1 - 2-[(2S)-4-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]prop-2-ynyl] morpholin-2- yl]acetonitrile

[003627] To a solution of 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (1.00 g, 2.96 mmol, Intermediate HN) and 2-[(2S)-4-prop-2-ynylmorpholin-2-yl]acetonitrile (971 mg, 5.91 mmol, Intermediate RL) in DMSO (50 mL) was added $Pd(PPh_3)2Cl2$ (415 mg, 591 umol), DIPEA (1.91 g, 14.7 mmol) and Cul (112 mg, 591 umol). The reaction mixture was stirred at 85 °C for 2 hours. On completion, the reaction mixture was filtered. The filtrate was diluted with EA (30 mL), poured into water (300 mL) and extracted with EA (2 X 200 mL). The organic layer was washed with water (2 X 200 mL), brine (200 mL), dried with anhydrous Na_2S0_4 and filtered. The filtrate was concentrated *in vacuo.* The residue was purified by reversed-phase chromatography (FA, 0.1%) to give the title compound (1.00 g, 80% yield) as a yellow solid. LC-MS (ESI^+) m/z 422.2 $(M+H)^+$.


[003628] Step 2 - 3-[5-[3-[(2S)-2-(2-aminoethyl)morpholin-4-yl]prop-1-ynyl]-3-methyl-2-oxo-benzimidazol-l- yl1piperidine-2.6-dione

[003629] To a solution of 2-[(2S)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]prop-2- ynyl]morpholin-2-yl]acetonitrile (600 mg, 1.42 mmol) and AcOH (170 mg, 2.85 mmol) in THF (40 mL) was added Raney-Ni (50.0 mg, 583 umol). The reaction mixture was stirred at 25 °C for 4 hours under Lb (50 Psi). On completion, the reaction mixture was filtered. The filter cake was triturated with water (3 X 30 mL) and filtered to give the filtrate. The filtrate was concentrated *in vacuo* to give the title compound (600 mg, 100% yield, HOAc) as light yellow oil. LC-MS (ESI^+) m/z 426.1 $(M+H)^+$.

[003630] Step 3 - 3-[5-[3-[(2S)-2-(2-aminoethyl)morpholin-4-yl]propyl]-3-methyl-2-oxo-benzimidazol-l- yl1piperidine-2.6-dione

[003631] To a solution of 3-[5-[3-[(2S)-2-(2-aminoethyl)morpholin-4-yl]prop-l-ynyl]-3-methyl-2-oxo- benzimidazol-l-yl]piperidine-2,6-dione (550 mg, 1.13 mmol, HOAc) in THF (30 mL) was added $Pt0_2$ (51.4 mg, 226 umol). The reaction was stirred at 25 °C for 4 hours under ¾ (15 Psi). On completion, the reaction mixture was filtered to give the filtrate and concentrated *in vacuo* to give the title compound (400 mg, 100% yield, HOAc) as yellow oil. LC-MS (ESI^+) m/z 430.2 $(M+H)^+$.

[003632] **2-[(2R)-4-Prop-2-vnylmorpholin-2-yll acetonitrile [Intermediate RN)**



RN

[003633] Step 1 - Tert-butyl (2S)-2-(methylsulfonyloxymethyl)morpholine-4-carboxylate

[003634] To a mixture of tert-butyl (2S)-2-(hydroxymethyl)morpholine-4-carboxylate (5.00 g, 23.0 mmol, CAS# 135065-76-8) in DCM (50 mL) was added TEA (3.03 g, 29.9 mmol) and MsCl (6.06 g, 52.9 mmol) at 0°C. Then the reaction mixture was stirred at 25°C for 2 hours. On completion, the reaction mixture was poured into the ice-water (50 mL), and extracted with DCM (2 X 30 mL).The combined organic phase was washed with brine (2 X 50 mL), dried over anhydrous Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (6.50 g, 95% yield) as a white oil. ^1H NMR (400 MHz, CDCh) δ 4.23 (d, *J* = 4.8 Hz, 2H), 3.92 - 3.85 (m, 3H), 3.69- 3.65 (m, 1H), 3.57 - 3.51 (m, 1H), 3.06 (s, 3H), 3.01 - 2.95 (m, 1H), 2.82 - 2.76 (m, 1H), 1.46 (s, 9H).

[003635] Step 2 - Tert-butyl (2R)-2-(cyanomethyl)morpholine-4-carboxylate

[003636] To a mixture of tert-butyl (2S)-2-(methylsulfonyloxymethyl)morpholine-4-carboxylate (6.50 g, 22.0 mmol) in DMSO (80mL) was added KCN (1.50 g, 23.1 mmol) and KI (5.48 g, 33.0 mmol) at 25 °C. The reaction mixture was then stirred at 100 °C for 4 hours. On completion, the reaction mixture was poured into the ice-water (50 mL), and extracted with DCM (2 X 30 mL). The combined organic phase was washed with brine (2 X 50 mL), dried over anhydrous Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate=3:1) to give the title compound (2.30 g, 46% yield) as a white solid. ^1H NMR (400 MHz, CDCh) δ 4.04-3.83 (m, 3H), 3.62-3.59 (m, 1H), 3.51-3.48 (m, 1H), 2.93 - 2.90 (m, 1H), 2.68 (m, 1H), 2.50 - 2.43 (m, 2H), 1.40 (s, 9H).

[003637] Step 3 - 2-[(2R)-Morpholin-2-yl]acetonitrile


[003638] To a solution of tert-butyl (2R)-2-(cyanomethyl) morpholine-4-carboxylate (1.00 g, 4.42 mmol) in DCM (6 mL) was added TFA (3 mL) at 25 °C. The mixture was stirred at 25 °C for 1 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (1.06 g, 95% yield, TFA) as light yellow gum. ^1H NMR (400 MHz, DMSO-^e) δ 9.11 (s, 2H), 4.04 -

4.01 (m, 1H), 4.00 - 3.9l(m, 1H), 3.79 - 3.67 (m, 1H), 3.34 - 3.16 (m, 2H), 3.07 - 2.89 (m, 2H), 2.87 - 2.73 (m, 2H).

[003639] Step 4 - 2-r(2R)-4-Prop-2-vnylmorpholin-2-yl1acetonitrile

[003640] To a mixture of 2-[(2R)-morpholin-2-yl]acetonitrile (1.06 g, 4.41 mmol, TFA) and K2CO3 (1.83 g, 13.2 mmol) in DMF (15 mL) was added 3-bromoprop-l-yne (577 mg, 4.85 mmol) at 25 °C. The mixture was stirred at 25 °C for 16 hours. On completion, the mixture was filtered and the cake was washed with EA (20 mL). The filtrate and washing were combined and concentrated *in vacuo*. The residue was purified by column chromatography (S1O2, PE: EA= 20: 1-5:1) to give the title compound (650 mg, 89% yield) as light yellow oil. ^{1}H NMR (400 MHz, CDCb) δ 3.93 (m, 1H), 3.88 - 3.81 (m, 1H), 3.72 (m, 1H), 3.36 - 3.30 (m, 2H), 2.88 (s, 1H), 2.68 (m, 1H), 2.57 (d, J = 6.0 Hz, 2H), 2.46 (m, 1H), 2.32 - 2.21 (m, 2H).

[003641] **3-[5-[3-[(2R)-2-(2-AminoethvPmorpholin-4-yl]propyl]-3-methyl-2-oxo-benzimidazol-l-yl] piperidine-2,6-dione [Intermediate RO)**



RO

[003642] Step 1- 2-[(2R)-4-[3-[1-(2,6-Dioxo-3-piperidvl)-3-methyl-2-oxo-benzimidazol-5-vHprop-2-vnyll _morpholin-2- vl]acetonitrile

[003643] A mixture of 2-[(2R)-4-prop-2-ynylmorpholin-2-yl]acetonitrile (588 mg, 3.58 mmol, Intermediate RN), 3-(5-bromo-3- methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (480 mg, 1.42 mmol, Intermediate HN), Cul (58 mg, 304 umol), $Pd(PPh3)_2Cl2$ (201 mg, 286 umol), 4A MS (300 mg) and CS2CO3 (2.3 1 g, 7.10 mmol) in DMF (15 mL) was stirred at 80°C for 2 hours under N_2. On completion, the mixture was filtered and the filter cake was washed with EA (10 mL). The filtrate and washing were combined and concentrated *in vacuo.* The residue was purified by reversed phase (FA condition) and prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.l%TFA)- ACN]; B%: 2%-30%, lOmin) to give the title compound (280 mg, 47% yield) as yellow solid. ^{1}H NMR (400 MHz, DMS0 -d_6) δ 11.13 (s, 1H), 7.35 (d, *J* = 1.2 Hz, 1H), 7.27 - 7.20 (m, 1H), 7.20 - 7.13 (m, 1H), 5.42 - 5.38 (m, 1 H), 4.17 (s, 2H), 4.08 (d, *J* = 12.4 Hz, 1H), 3.91 m, 1H), 3.77 - 3.67 (m, 1H), 3.35 (s, 3H), 3.34 - 3.3 1 (m, 1H), 3.02 - 2.81 (m, 5H), 2.77 - 2.58 (m, 3H), 2.06 - 1.97 (m, 1H).


[003644] Step 2 - 3-r5-r3-r(2R)-2-(2-Aminoethyl)morpholin-4-yl1prop-l-enyl1-3-methyl-2-oxo-benzimidazol - 1-yl1piperidine-2.6-dione

[003645] A mixture of 2-[(2R)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]prop -2-ynyl]morpholin-2-yl]acetonitrile (270 mg, 640 umol) , Raney-Ni (100 mg) and HOAc (210 mg, 3.50 mmol) in THF (6 mL) was stirred at 25 °C for 16 hours under ¾ (45 Psi). On completion, the mixture was filtered and the cake was washed with THF (10 mL). The combined organic layer was concentrated *in vacuo* to give the title compound (320 mg, 100% yield, HOAc) as light yellow gum. LC-MS (ESI^+) *m/z* 428.3 $(M+H)^+$.

[003646] Step 3 - 3-r5-r3-r(2R)-2-(2-Aminoethyl)morpholin-4-yl1propyl1-3-methyl-2-oxo-benzimidazol-l-yll piperidine-2.6-dione

[003647] A mixture of 3-[5-[3-[(2R)-2-(2-aminoethyl) morpholin-4-yl] prop-l-enyl]-3-methyl-2-oxo -benzimidazol -l-yl] piperidine-2, 6-dione (320 mg, 640 umol) and $Pt0_2$ (50.0 mg, 220 umol) in THF (10 mL) was stirred at 25 °C for 3 hours under ¾ (15 Psi). On completion, the mixture was filtered and the filter cake was washed with THF (10 mL). The filtrate and washing were combined and concentrated *in vacuo* to give the title compound (280 mg, 98% yield, HOAc) as light yellow gum. LC-MS (ESI^+) *m/z* 430.3 $(M+H)^+$.


[003648] 4-[3-[DifluoromethvB-4-[[2-[2-[2,2,2-trifluoroethylamino)-4-pyridyl1oxazole-4-carbonyl]_aminolpyrazol-l-yllbenzoic _acid [Intermediate_RP)



JE RP

[003649] To a solution of 4-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4- carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]benzoic acid (70.0 mg, 112 umol, Intermediate JE) in DCM (4 mL) was added TFA (4 mL). The reaction mixture was stirred at 25 °C for 2 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (71.5 mg, 100% yield, TFA) as a white solid. LC-MS (ESI^+) *m/z* 523.2 $(M+H)^+$.

[003650] **l-(4-methoxyphenvO-N-methyl-N-[[(2SV4-prop-2-vnylmorpholin-2-yl]methyl]methanamine [Intermediate RQ)**



RQ

[003651] Step 1- Tert-butyl (2R)-2-formylmorpholine-4-carboxylate

[003652] To a solution of tert-butyl (2f?)-2-(hydroxymethyl)morpholine-4-carboxylate (2.00 g, 9.21 mmol, CAS# 135065-71-3) in DCM (40 mL) was added DMP (4.69 g, 11.0 mmol) at 0 °C. The reaction mixture was stirred at 25 °C for 2 hours. On completion, the mixture was quenched with aq. $Na_2S_20_3$ (50 mL) and aq. $NaHC0_3$ (50 mL). The mixture was stirred for 15 minutes and extracted with EA (2 X 50 mL). The organic layer was washed with brine (50 mL), dried with Na_2S0_4, and concentrated *in vacuo* to give the title compound (1.50 g, 76% yield) as colorless oil. ^1H NMR (400 MHz, CDCh) δ 9.65 (s, 1H), 4.08 - 4.00 (m, 1H), 3.95 - 3.85 (m, 2H), 3.83 - 3.75 (m, 1H), 3.68 - 3.53 (m, 2H), 3.12 - 3.03 (m, 1H), 1.47 (s, 9H).

[003653] Step 2 - Tert-butyl (2S)-2-[[(4-methoxyphenyl)methyl-methyl-aminolmethyllmorpholine-4- carboxylate

[003654] To a solution of tert-butyl (2f?)-2-formylmorpholine-4-carboxylate (1.5 g, 6.97 mmol) and l-(4-methoxyphenyl)-N-methyl-methanamine (1.05 g, 6.97 mmol) in DCM (30 mL) was added HOAc (418 mg, 6.97 mmol) and the reaction was stirred at 25 °C. Thirty minutes later, $NaBH(OAc)_3$ (1.77 g, 8.36 mmol) was added and the reaction mixture was stirred at 25 °C for 10 hours. On completion, the mixture was concentrated *in vacuo.* The residue was purified by reversed phase (0.1% FA) to give the title compound (1.4 g, 57% yield) as a yellow solid. ^1H NMR (300 MHz, CDCh) δ 7.22 (d, *J* = 8.4 Hz, 2H), 6.85 (d, *J* = 8.4 Hz, 2H), 4.07 - 3.94 (m, 1H), 3.93 - 3.83 (m, 2H), 3.90 (s, 3H), 3.58 - 3.43 (m, 4H), 3.01 - 2.80 (m, 1H), 2.62 - 2.46 (m, 2H), 2.41 - 2.31 (m, 1H), 2.26 (s, 3H), 1.48 (s, 9H); LC-MS (ESI^+) *m/z* 351.1 $(M+H)^+$.


[003655] Step 3 - l-(4-MethoxyphenylVN-methyl-N-rr(2RVmorpholin-2-yllmethvnmethanamine hydrochloride

[003656] To a solution of tert-butyl (2*S*')-2-[[(4-ηιethoxyphenyl)m ethyl-methyl-amino]methyl]morpholine-4- carboxylate (1.40 g, 3.99 mmol) in HCl/dioxane (10 mL) was added DCM (10 mL). The reaction mixture was stirred at 25 °C for 2 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (1.15 g, 100% yield, HC1) as a yellow solid. LC-MS (ESL) *m/z* 251.1 $(M+H)^+$.

[003657] Step 4 - l-(4-methoxyphenvO-N-methyl-N-nY2SV4-prop-2-vnylmorpholin-2-vHmethyllmethanamine

[003658] To a solution of l-(4-methoxyphenyl)-N-methyl-N-[[(2i?)-morpholin-2-yl]methyl]methanamine (1.15 g, 4.01 mmol, HC1) and 3-bromoprop-l-yne (525 mg, 4.41 mmol) in DMF (20 mL) was added K_2CO_3 (1.66 g, 12.0 mmol). The reaction mixture was stirred at 25 °C for 12 hours. On completion, the mixture was diluted with water (100 mL), and extracted with EA (2 X 50 mL). The organic layer was washed with brine (100 mL), then concentrated *in vacuo.* The residue was purified by reversed phase chromatography (0.1% FA condition) to give the title compound (700 mg, 61% yield) as colourless oil. LC-MS (ESI^+) *m/z* 289.2 $(M+H)^+$.

[003659] 3-[3-Methyl-5-[3-[(2S)-2-(methylaminomethvBmorpholin-4-yllpropyll-2-oxo-benzimidazol- l-yl]piperidine-2,6-dione [Intermediate RR)



[003660] Step 1 - 3-[5-[3-[(2S)-2-[[(4-methoxyphenyl)methyl-methyl-aminolmethvnmorpholin-4-vnprop-l- ynyl 1-3 -methyl -2-oxo-benzi midazol-1 -yllpiperidine-2.6-dione

[003661] 1-(4-methoxyphenyl)-N-methyl-N-[[(2A)-4-prop-2-ynylmorpholin-2-yl]methyl]methanamine (1.01 g, 3.51 mmol, Intermediate RQ), 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (660 mg, 1.95 mmol, Intermediate HN), Pd(PPh $_3$)2Cl2 (274 mg, 390 umol), Cul (74.3 mg, 390 umol), 4A molecular sieves (200 mg) and CS2CO3 (2.54 g, 7.81 mmol) in DMF (12 mL) was degassed with N2 and then heated at 80 °C for 2 hours under N2. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* and purified by prep-HPLC (column: Phenomenex luna C18 250*50mm*l0 um; mobile phase: [water (0.225%FA)-ACN]; B%: 5%-35%, 28 mins) to give the title compound (850 mg, 80% yield) as a yellow solid. ^{1}H NMR (400 MHz, DMSO-i&) δ 11.13 (s, 1H), 7.33 - 7.23 (m, 3H), 7.17 - 7.12 (m, 2H), 6.89 - 6.84 (m, 2H), 5.44 - 5.35 (m, 1H), 3.87 - 3.79 (m, 1H), 3.78 - 3.72 (m, 1H), 3.71 - 3.69 (m, 3H), 3.68 - 3.56 (m, 4H), 3.53 (s, 2H), 3.34 (s, 3H), 2.93 - 2.80 (m, 1H), 2.74 - 2.60 (m, 2H),

2.30 (s, 3H), 2.28 - 2.24 (m, 1H), 2.21 - 2.18 (m, 1H), 2.18 - 2.15 (m, 1H), 2.05 - 2.00 (m, 2H), 1.98 - 1.96 (m, 1H); LC-MS (ESI^+) *m/z* 546.3 $(M+H)^+$.


[003662] Step 2 - Tert-butyl N-[(2R)-4-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5- yl]propyl] morpholin-2-yl1methyl1-N-methyl-carbamate

[003663] To a mixture of 3-[5-[3-[(2Y)-2-[[(4-methoxyphenyl)methyl-methyl-amino]methyl]morpholin-4-yl] prop-l-ynyl]-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione (200 mg, 367 umol) and $(Boc)_20$ (96.0 mg, 440 umol) in a mixed solvent of IPA (5 mL) and EA (10 mL) was added $Pd(OH)_2/C$ (0. 1 g, 20 wt%) and Pd/C (0. 1 g, 10 wt%). The reaction mixture was stirred at 25 °C for 12 hours under H_2 (50 Psi) atmosphere. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo*. The residue was purified by reversed phase (0.1% FA) to give the title compound (85.0 mg, 44% yield) as a white solid. LC-MS (ESI^+) *m/z* 530.3 $(M+H)^+$.

[003664] Step 3 - 3-[3-Methyl-5-[3-[(2S)-2-(methylaminomethyl)morpholin-4-yl1propyl1-2-oxo-benzimidazol- 1-yl1piperidine-2.6-dione

[003665] To a solution of tert-butyl N-[[(2f?)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5- yl]propyl]morpholin-2-yl]methyl]-N-methyl-carbamate (85.0 mg, 160 umol) in DCM (3 mL) was added TFA (3 mL). The reaction mixture was stirred at 25 °C for 2 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (87.0 mg, 100% yield, TFA) as a yellow solid. LC-MS (ESI^+) *m/z* 430.3 $(M+H)^+$.


[003666] **Tert-butyl N-(4-but-3-ynoxybutyl)-N-methyl-carbamate [Intermediate RS)**



SY RS

[003667] To a solution of tert-butyl N-(4-but-3-ynoxybutyl)carbamate (5.00 g, 20.7 mmol, Intermediate SY) in THF (100 mL) was added NaH (1.24 g, 31.0 mmol, 60% oil dispersion) at 0 °C. The mixture was stirred 20 °C for 1 hour. Then MeI (4.41 g, 31.0 mmol) was added. The mixture was stirred at 20 °C for 15 hrs. On completion, the mixture was quenched by water (10 mL) and extracted with EA (2 X 250 mL). The combined organic layers were concentrated *in vacuo* to give the title compound (5.00 g, 94% yield) as yellow oil. ^1H NMR (400MHz, CDCh) δ 3.57 (t, *J* = 7.2 Hz, 2H), 3.50 (t, *J* = 6.0 Hz, 2H), 3.24 (s, 2H), 2.85 (s, 3H), 2.48 (dt, *J* = 2.8, 6.8 Hz, 2H), 2.03 - 1.96 (m, 1H), 1.62 - 1.56 (m, 4H), 1.47 (s, 9H).

[003668] **3-[3-Methyl-5-[4-[4-(methylamino)butoxylbutyl1-2-oxo-benzimidazol-l-yl]piperidine- 2,6-dione [Intermediate RT)**



[003669] Step 1 - Tert-butyl N-[4-[4-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yll but-3-ynoxyl butyll-N-methyl-carbamate

[003670] A mixture of tert-butyl N-(4-but-3-ynoxybutyl)-N-methyl-carbamate (3.06 g, 12.0 mmol, Intermediate RS), 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (1.50 g, 4.44 mmol, Intermediate HN), Pd(PPh $_3$)2Cl2 (934 mg, 1.33 mmol), CuI (253 mg, 1.33 mmol) and TEA (8.08 g, 79.8 mmol) in DMF (30 mL) was degassed and purged with N2 for 3 times. Then the mixture was stirred at 85 °C for 4 hrs under N2 atmosphere. On completion, the mixture was diluted with water (100 mL) and extracted with EA (2 X 200 mL). The organic layer was concentrated *in vacuo.* The residue was purified by reversed phase (0.1% FA) to give the title compound (1.1 g, 46% yield) as yellow solid. ^{1}HNMR (400MHz, DMSO-d_6) δ 11.12 (s, 1H), 7.24 (s, 1H), 7.14 - 7.05 (m, 2H), 5.38 (dd, J = 5.2, 12.8 Hz, 1H), 3.56 (t, j = 6.8 Hz, 2H), 3.46 (t, J = 6.0 Hz, 2H), 3.33 (s, 3H), 3.17 (t, J = 6.4 Hz, 2H), 2.93 - 2.90 (m, 1H), 2.74 (s, 3H), 2.69 - 2.63

(m, 2H), 2.53 - 2.51 (m, 2H), 2.08 - 2.00 (m, 1H), 1.56 - 1.45 (m, 4H), 1.37 (s, 9H); LC-MS (ESI^+) *m/z* 535.3 $(M+Na)^+$.


[003671] Step 2 - Tert-butyl N-[4-[4-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-vnbutoxyl butyll-N-methyl-carbamate

[003672] To a solution of tert-butyl N-[4-[4-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] but-3-ynoxy]butyl]-N-methyl-carbamate (1.10 g, 2.15 mmol) in THF (30 mL) was added Pd/C (0.10 g, 10 wt%) and $Pd(OH)_2/C$ (0.10 g, 10 wt%). The mixture was stirred at 30 °C for 16 hrs under H_2 (15 psi). On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (1.10 g, 100% yield) as yellow solid. ^1H NMR (400MHz, DMSO-i/e) δ 11.09 (s, 1H), 7.06 - 6.94 (m, 2H), 6.90 - 6.83 (m, 1H), 5.34 (dd, J = 5.2, 12.8 Hz, 1H), 3.40 - 3.34 (m, 4H), 3.32 (s, 3H), 3.15 (t, J = 6.8 Hz, 2H), 2.92 - 2.88 (m, 1H), 2.74 (s, 3H), 2.64 - 2.58 (m, 4H), 2.07 - 1.95 (m, 1H), 1.67 - 1.58 (m, 2H), 1.57 - 1.43 (m, 6H), 1.37 (s, 9H); LC-MS (ESI^+) *m/z* 539.2 $(M+Na)^+$.

[003673] Step 3 - 3-r3-Methyl-5-r4-r4-(methylamino)butoxy1butyl1-2-oxo-benzimidazol-l-yllpiperidine- 2.6-dione

[003674] To a solution of tert-butyl N-[4-[4-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] butoxy]butyl]-N-methyl-carbamate (1.10 g, 2.13 mmol) in DCM (20 mL) was added HCl/dioxane (4 M, 5 mL). The mixture was stirred at 25 °C for 3 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (1.10 g, 100% yield) as yellow solid. LC-MS (ESL) *m/z* 417.2 $(M+H)^+$.

[003675] **4-(4-(2-(2-(YCvclopropylmethvPamino]pyridin-4-vPoxazole-4-carboxamido]-3- (difluoromethvP-lH-pyrazol-l-vPbenzoic acid [Intermediate RU)**




FX RU

[003676] To a solution of 4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole- 4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]benzoic acid (44.6 mg, 75.1 umol, Intermediate FX) in DCM (1 mL) was added TFA (770 mg, 6.75 mmol) under N_2

atmosphere. The mixture was stirred at 25 °C for 1 hr. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (41.0 mg, 100% yield, TFA) as colorless oil. LC-MS (ESI+) *m/z* 495.2 (M+H) +.

[003677] **(S)-tert-butyl methyl((4-(prop-2-yn-l-v0morpholin-2-v0methv0carbamate (Intermediate RV)**



RV

[003678] Step 1 - (S)-morpholin-2-ylmethanol

[003679] To a solution of tert-butyl (2S)-2-(hydroxymethyl)morpholine-4-carboxylate (25.0 g, 115 mmol, CAS# 135065-76-8) in DCM (40 mL) was added HCl/dioxane (4 M, 57.5 mL), the reaction mixture was stirred at 25 °C for 2 hrs. On completed, the reaction mixture was concentrated *in vacuo* to give the title compound (17.0 g, 96% yield, HC1) as yellow oil. ^{1}H NMR (400MHz, CDCh) δ 4.47 (s, 1H), 3.92 - 3.89 (m, 1H), 3.75 - 3.72 (m, 2H), 3.40 - 3.37 (m, 2H), 3.13 (t, *J* = 2.4, 2H), 2.92 - 2.6(m, 2H).

[003680] Step 2 - (S)-(4-(prop-2-yn-l-vDmorpholin-2-vDmethanol

[003681] To a solution of [(2S)-morpholin-2-yl]methanol (12.0 g, 78.1 mmol, HC1) and 3-bromoprop-l-yne (9.29 g, 78.1 mmol) in DMF (200 mL) was added K2CO3 (32.4 g, 234 mmol). The reaction mixture was stirred at 25 °C for 12 hrs. On completion, the reaction mixture was diluted with water (300 mL) and extracted with EA (3 X 80 mL). The combined organic layers was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate=l0/l to 2/1) to give the title compound (10.5 g, 86% yield) as a yellow solid. ^{1}H NMR (400MHz, CDCb) δ 3.98 - 3.91 (m, 1H), 3.76 - 3.63 (m, 3H), 3.62 - 3.56 (m, 1H), 3.31 (d, *J* = 2.4 Hz, 2H), 2.76 - 2.66 (m, 2H), 2.41 (dt, *J* = 3.6, 11.2 Hz, 1H), 2.28 (t, *J* = 2.4 Hz, 1H), 2.22 (t, *J* = 10.4 Hz, 1H), 1.97 - 1.66 (m, 1H).


[003682] Step 3 - (S)-(4-(prop-2-vn-l-vDmorpholin-2-vDmethyl methanesulfonate

[003683] To a solution of [(2S)-4-prop-2-ynylmorpholin-2-yl]methanol (2 g, 12.8 mmol) in DCM (30 mL) was added TEA (2.61 g, 25.7 mmol) and MsCl (1.62 g, 14.1 mmol). The mixture was stirred at 25 °C for 2 hrs. On completion, the reaction mixture was quenched with water (2 mL), and then extracted with DCM (3 X 100 mL). The combined organic layers were washed with brine (2 X 30 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (3.00 g, 99% yield) as a yellow oil. ^{1}H NMR (400MHz, CDCh) δ 4.28 - 4.20 (m, 2H), 3.99 - 3.91 (m, 1H), 3.91 - 3.81 (m, 1H), 3.71 (dt, *J* = 2.4, 11.2 Hz, 1H), 3.33 (d, *J* = 2.4 Hz, 2H), 3.09 (s, 3H), 2.82 - 2.75 (m, 1H), 2.69 (dd, 7 = 1.2, 11.2 Hz, 1H), 2.51 - 2.36 (m, 1H), 2.33 - 2.19 (m, 2H).

[003684] Step 4 - (S)-tert-butyl methyl (Y4-(prop-2-vn-l-vDmorpholin-2-vDmethvDcarbamate

[003685] To a solution of tert-butyl N-methylcarbamate (1.69 g, 12.8 mmol) and Nal (192 mg, 1.29 mmol) in DMF (30 mL) was added NaH (771 mg, 19.2 mmol, 60% oil dispersion). The reaction mixture was stirred at 25 °C for 0.5 hr. After, [(2S)-4-prop-2-ynylmorpholin-2-yl]methyl methanesulfonate (3.00 g, 12.8 mmol) was added into the mixture. The resulting reaction mixture was stirred 90 °C for 12 hrs. On completion, the reaction mixture was quenched with water (0.1 mL) and concentrated *in vacuo*. The residue was purified by column chromatography (S1O2, PE: EA = 5:1) to give the title compound (250 mg, 7% yield) as a yellow oil. ^{1}H NMR (400MHz, CDCh) δ 3.95 - 3.86 (m, 1H), 3.77 - 3.61 (m, 2H), 3.47 - 3.38 (m, 1H), 3.32 - 3.30 (m, 2H), 3.17 (dd, 7 = 2.4, 10.8 Hz, 1H), 2.93 (s, 3H), 2.79 - 2.65 (m, 2H), 2.39 (dt, 7 = 2.4, 11.2 Hz, 1H), 2.28 - 2.26 (m, 1H), 2.11 (t, 7 = 10.8 Hz, 1H), 1.46 (s, 9H).

[003686] 3-(3-Methyl-5-(3-((RV2-(Ymethylamino)methvDmorpholino)propyD-2-oxo-2,3-dihydro-lH- benzo[dlimidazol-l-vQpiperidine-2.,6-dione [Intermediate RW)



[003687] Step 1 - Tert-butyl (((2S)-4-(3-(1-(2.6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2.3-dihydro-lH-benzordl imidazol-S-vOprop^-vn-l-vOmorpholin^-vOmethvOfmethvOcarbamate

[003688] To a mixture of 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (180 mg, 532 umol, Intermediate HN), tert-butyl N-methyl-N-[[(2S)-4-prop-2-ynylmorpholin-2-yl]methyl]carbamate (214 mg, 798 umol, Intermediate RV), $Pd(PPh3)_2Cl2$ (37.3 mg, 53.2 umol), Cul (10.1 mg, 53.2 umol), 4A molecular sieves (200 mg) and CS2CO3 (693 mg, 2.13 mmol) in DMF (10 mL) was de-gassed with N2 and then heated to 80°C for 2 hours under N_2. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by reversed-phase HPLC (0.1% FA, condition) to give the title compound (150 mg, 42% yield) as yellow oil. LC-MS (ESI^+) *m/z* 526. 1 $(M+ H)^+$.


[003689] Step 2 - Tert-butyl t((2S)-4-(3-(1-(2.6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2.3-dihvdro-HT-benzordl imidazol-5-vl)propvl)morpholin-2-vl)methvl)fmethvl)carbamate

[003690] To a solution of tert-butyl N-[[(2S)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol- 5-yl]prop-2-ynyl]morpholin-2-yl]methyl]-N-methyl-carbamate (150 mg, 228 umol) in THF (20 mL) was added $Pt0_2$ (13.8 mg, 6.10 umol) under N2 atmosphere. The suspension was degassed and purged with ¾ seven times. The mixture was stirred under ¾ (15 Psi) at 25 °C for 2 hrs. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (40.0 mg, 31% yield) as colorless oil. LC-MS (ESI^+) *m/z* 530.3 $(M+H)^+$.


[003691] Step 3 - 3-(3-Methyl-5-(3-((R)-2-((methylamino)methvl)morpholino)propyl)-2-oxo-2.3-dihydro-lH- benzord1imidazol-l-vPpiperidine-2.6-dione


[003692] To a solution of tert-butyl N-[[(2S)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] propyl]morpholin-2-yl]methyl]-N-methyl-carbamate (40.0 mg, 75.5 umol) in DCM (3 mL) was added TFA (308 mg, 2.70 mmol) under N_2 atmosphere. The mixture was stirred at 25 °C for 15 minutes. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (41.0 mg, 100% yield, TFA) as colorless. LC-MS (ESI^+) *m/z* 430.2 $(M+H)^+$.

[003693] **2-[2-[2-[2-[3-[l-(2.,6-dioxo-3-piperidy0-3-methyl-2-oxo-benzimidazol-4-yl]propoxy] ethoxy]ethoxy]ethoxy]acetic acid [Intermediate RX)**



HP





RX

[003694] Step 1 - Tert-butyl 2-[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl1prop-2- ynoxy]ethoxy]ethoxy]ethoxy]acetate

[003695] To a mixture of 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (600 mg, 1.77 mmol, Intermediate HP), tert-butyl 2-[2-[2-(2-prop-2-ynoxyethoxy)ethoxy] ethoxy]acetate (1.07 g, 3.55 mmol, synthesized via Steps 1-2 of Example

441, 1-447) in DMF (10 mL) was added CuI (67.6 mg, 355 umol), CS2CO3 (2.89 g, 8.87 mmol) and Pd(PPh3)$_2$Cl2 (249.08 mg, 355 umol) under N_2. The reaction mixture was stirred at 80 °C for 3 hours. On completion, the mixture was poured into water (30 mL). The aqueous phase was extracted with ethyl acetate (2 X 30 mL). The combined organic phase was washed with brine (2 X 30 mL), dried with anhydrous Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by reversed-phase (0.1% FA condition) to give the title compound (598 mg, 60% yield) as brown oil. ^{1}H NMR (400MHz, CDCb) δ 8.29 (s, 1H), 7.16 (d, *J* = 7.6 Hz, 1H), 6.97 (t, *j* = 8.0 Hz, 1H), 6.75 *(d, J* = 8.0 Hz, 1H), 5.23 - 5.15 (m, 1H), 4.46 (s, 2H), 4.01 (s, 2H), 3.76 (s, 3H), 3.76 - 3.66 (m, 12H), 2.99 - 2.68 (m, 3H), 2.29 - 2.16 (m, 1H), 1.46 (s, 9H).

[003696] Step 2 - Tert-butyl 2-r2-r2-r2-r3-rl-(2.6-dioxo-3-piperidvD-3-methyl-2-oxo-benzimidazol-4-yll propoxyl ethoxy] ethoxy] ethoxy] acetate

[003697] To a solution of tert-butyl 2-[2-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] prop-2-ynoxy] ethoxy] ethoxy] ethoxy] acetate (578 mg, 1.03 mmol) in THF (5 mL) was added Pd/C (100 mg, 20 wt%) and Pd(OH)2/C (100 mg, 20 wt%) under N_2. The suspension was degassed under vacuum and purged with ¾ gas three times. The mixture was stirred at 20 °C for 12 hours under ¾ (15 psi). On completion, the mixture was filtrated and the filtrate was concentrated *in vacuo* to give a title compound (540 mg, 92% yield) as brown oil. LC-MS (ESI$^+$) *m/z* 586.3 (M+Na)$^+$.

[003698] Step 3 - 2-[2-[2-[2-[3-[l-(2,6-Dioxo-3-piperidvl)-3-methyl-2-oxo-benzimidazol-4-yllpropoxylethoxyl ethoxy] ethoxy] acetic acid


[003699] To a mixture of tert-butyl 2-[2-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4- yl] prop oxy] ethoxy] ethoxy] ethoxy] acetate (520 mg, 922 umol) in DCM (2 mL) was added TFA (210 mg, 1.85 mmol). The reaction mixture was stirred at 20 °C for 1 hour. On completion, the mixture was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (436 mg, 93% yield) as brown oil. LC-MS (ESI$^+$) *m/z* 508.3 (M+H)$^+$.

[003700] Step 2 - Tert-butyl 4-(trans-4-aminocvclohexy0piperazine-l-carboxylate


[003701] A mixture of tert-butyl 4-[4-(benzyloxycarbonylamino)cyclohexyl]piperazine-l-carboxylate (8.00 g, 16.4 mmol) and Pd/C (800 mg, 10 wt%) in MeOH (80 mL) was stirred at 25 °C for 2 hours under ¾ (15 Psi). On completion, the mixture was filtered, and the cake was washed with MeOH (50 mL). The filtrate and washings were combined and concentrated *in vacuo* to give

the title compound (5.30 g, 100% crude yield) as white solid. ^{1}H NMR (400 MHz, CDCh) δ 3.49 - 3.21 (m, 4H), 2.64 - 2.58 (m, 1H), 2.54 (m, 4H), 2.31 - 2.20 (m, 1H), 1.88 (t, *J* = 15.2 Hz, 4H), 1.45 (s, 9H), 1.34 - 1.22 (m, 2H), 1.17 - 1.05 (m, 2H).

[003702] **2-[4-[4-[l-(2, 6-Dioxo-3-piperidvD-3-methyl-2-oxo-benzimidazol-5-yllbutoxylbutylaminol acetic acid [Intermediate SB)**



OD



SB

[003703] Step 1 - Tert-butyl 2-[4-[4-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-vnbutoxyl butylaminolzacetate


[003704] A mixture of 3-[5-[4-(4-aminobutoxy)butyl]-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione (200 mg, 455 umol, HC1, Intermediate OD), tert-butyl 2-bromoacetate (80.0 mg, 410 umol, CAS# 5292-43-3) and TEA (100 mg, 988 umol) in DMF (2 mL) was stirred at 25 °C for 16 hours. On completion, the mixture was purified by reverse phase flash chromatography (FA condition) to give the title compound (100 mg, 31% yield) as light yellow gum. ^{1}H NMR (400 MHz, DMSO-i&) δ 11.09 (s, 1H), 7.02 - 6.98 (m, 2H), 6.86 (d, *j* = 8.0 Hz, 1H), 5.37 - 5.28 (m, 1H), 3.62 - 3.57 (m, 2H), 3.34 (s, 3H), 3.32 (m, 4H), 2.91 - 2.83 (m, 1H), 2.65 - 2.56 (m, 6H), 2.04 - 1.95 (m, 1H), 1.77 - 1.73 (m, 1H), 1.63 - 1.47 (m, 8H), 1.41 (s, 9H).

[003705] Step 2 - 2-[4-[4-[1-(2, 6-Dioxo-3-piperidvD-3-methyl-2-oxo-benzimidazol-5-yllbutoxylbutylaminol acetic acid

[003706] To a solution of tert-butyl 2-[4-[4-[l-(2, 6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] butoxy]butylamino]acetate (125 mg, 176 umol) in DCM (2 mL) was added TFA (1 mL) at 25 °C. The mixture was stirred at 25 °C for 6 hours. On completion, the mixture

was concentrated *in vacuo* to give the title compound (120 mg, crude, TFA) as yellow gum. LC-MS (ESI+) *m/z* 461.2 $(M+H)^+$.

[003707] **Tert-butyl N-(3-biit-3-ynoxypropyl)carbamate [Intermediate SD)**



SD

[003708] Step 1 - 3-But-3-ynoxypropanenitrile

[003709] To a solution of prop-2-enenitrile (2.00 g, 37.6 mmol) and but-3-yn-l-ol (7.93 g, 113 mmol) in THF (40.0 mL) was added NaOMe (203 mg, 3.77 mmol). The mixture was stirred at 25 °C for 16 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (4.60 g, 99% yield) as yellow oil. ^1H NMR (400MHz, CDCh) δ 3.71 (t, *J* = 6.4 Hz, 2H), 3.63 (t, *J* = 6.8 Hz, 2H), 2.62 (t, *J* = 6.4 Hz, 2H), 2.52 - 2.45 (m, 2H), 2.00 (t, *J* = 2.4 Hz, 1H).

[003710] Step 2 - 3-But-3-ynoxypropan-l -amine


[003711] To a mixture of diethylsilane (3.58 g, 40.6 mmol) and tris(perfluorophenyl)borane (83.1 mg, 162 umol) in DCM (30.0 mL) was added 3-but-3-ynoxypropanenitrile (2.00 g, 16.2 mmol). The mixture was stirred at 25 °C for 16 hours. Then HCl/dioxane (4.00 M, 20.0 mL) was added, and the mixture was stirred for 1 hour. On completion, the mixture was concentrated *in vacuo.* The residue was dissolved in water (10.0 mL), and then extracted with EA (10.0 mL). The aqueous layer was concentrated *in vacuo* to give the title compound (2.30 g, 86% yield, HC1) as colorless oil. ^1H NMR (400MHz, CDCh) δ 8.06 (s, 2H), 3.80 - 3.76 (m, 2H), 3.63 - 3.59 (m, 2H), 3.24 (s, 2H), 2.64 - 2.57 (m, 2H), 2.21 - 2.15 (m, 1H), 2.08 - 2.04 (m, 2H).

[003712] Step 3 - Tert-butyl N-(3-but-3-ynoxypropyDcarbamate

[003713] To a solution of 3-but-3-ynoxypropan-l -amine (300 mg, 1.83 mmol, HC1) in MeOH (10.0 mL) was added $(Boc)_20$ (1.00 g, 4.58 mmol) and TEA (371 mg, 3.67 mmol). The mixture was stirred at 25 °C for 16 hours. On completion, the mixture was concentrated *in vacuo.* The residue was purified by silica gel chromatography (PE: EA= 5: 1) to give the title compound (200 mg, 48% yield) as colorless oil. ^1H NMR (400MHz, DMSO-^e) δ 4.85 (s, 1H), 3.51 - 3.44

(m, 4H), 3.21 - 3.10 (m, 2H), 2.43 - 2.38 (m, 2H), 1.95 - 1.90 (m, 1H), 1.75 - 1.63 (m, 2H), 1.37 (s, 9H).

[003714] **3-[(5*S*)-5-[3- bromophenvD-2-oxo-oxazolidin-3-yllpiperidine-2.,6-dione [Intermediate SE)**



[003715] Step **1** - (S)-2-bromo-l-(3-bromophenvOethanol

[003716] To a stirred solution of (S)- 1-methyl-3, 3-diphenylhexahy dropyrrolof 1,2-c][l,3,2]oxazaborole (1 g, 3.61 mmol, CAS# 112022-81-8) in THF (50 mL) was added BH_3·DMS (10 M, 2.5 mL, 25.3 mmol) at 0 °C. The mixture was stirred for 0.5 h at 0 °C. To the reaction mixture was added a solution of 2-bromo-l-(3-bromophenyl)ethanone (10 g, 36.1 mmol) in THF (30 mL) dropwise at 0 °C. The mixture was stirred for 12 h at rt. To the mixture was added MeOH dropwise, where the mixture released bubbles of gas. Addition of MeOH was halted after bubbling stopped. Then the mixture was concentrated and purified by column (PE/EA = 50/1 to 20/1 to 10/1 to 5/1) to give the title compound (10 g, 100 % yield) as a white solid. ^{1}H NMR (400 MHz, CDCb) δ 7.56 (t, *J* = 1.8 Hz, 1 H), 7.47-7.45 (m, 1 H), 7.32-7.30 (m, 1 H), 7.26-7.22 (m, 1 H), 4.90 *(d, J* = 8.7 Hz, 1 H), 3.63 (dd, *J* = 10.5, 3.4 Hz, 1 H), 3.51 (dd, *J* = 10.5, 8.8 Hz, 1 H), 2.68 (d, *J* = 1.6 Hz, 1 H).

[003717] Step 2 - (S)-2-amino-l-(3-bromophenvPethanol

[003718] To a solution of (S)-2-bromo-l-(3-bromophenyl)ethanol (11 g, 90.3 mmol) in MeOH (80 mL) was added NH_3·H_2O (25%, 200 mL) at 0 °C under N_2. The reaction mixture was stirred for 12 h under N_2 at room temperature. The mixture was concentrated. The solid was washed with EA to give the title compound (6.2 g, 74% yield) as a white solid. ^{1}H NMR (400

MHz, DMSO-d) δ 7.70 (br s, 2 H), 7.60 (t, *J* = 1.9 Hz, 1 H), 7.54-7.51 (m, 1 H), 7.42-7.34 (m, 2 H), 6.17 (d, *J* = 3.8 Hz, 1 H), 4.81-4.79 (m, 1 H), 3.09 (dd, *J* = 12.8, 3.2 Hz, 1 H), 2.87 (dd, *J* = 12.8, 9.6 Hz, 1 H).

[003719] Step 3 - (S)-5-(3-bromophenvOoxazolidin-2-one

[003720] A mixture of (S)-2-amino-l-(3-bromophenyl)ethanol (1 g, 4.63 mmol), **CDI** (1.1 g, 6.94 mmol) and THF (30 mL) was heated to 80 °C and stirred for overnight at 80 °C under N_2. To the mixture was added H_20 (20 mL), then the mixture was extracted with EA(50 mL). The organic layer was concentracted and purified by column chromatography on silica gel (PE/EA = 2/1 to 1/1) to give the title compound (300 mg, 27% yield) as a yellow solid. ^{1}H NMR (400 MHz, **CDCh)** δ 7.55-7.54 (m, 1 H), 7.51 (dt, *J* = 6.9, 2.0 Hz, 1 H), 7.32-7.29 (m, 2 H), 5.60 (t, *j* = 8.0 Hz, 1 H), 5.09 (br s, 1 H), 4.00 (dt, *J* = 0.6, 8.7 Hz, 1 H), 3.53-3.49 (m, 1 H).

[003721] Step 4 - (R)-3-((S)-5-(3-bromophenvl)-2-oxooxazolidin-3-vl)-l-(4-methoxybenzyl)pi peri dine-2.6-di one


[003722] To a solution of (S)-5-(3-bromophenyl)oxazolidin-2-one (8. 1 g, 33.5 mmol) in THF (100 mL) was added /-BuOK (5.6 g, 50.3 mmol) at 0 °C under N_2. The mixture was stirred for 1 h at 0 °C. Then to the mixture was added l-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yl trifluoromethanesulfonate (14 g, 36.8 mmol) at 0 °C under N_2. The mixture was stirred for 2 h at 0 °C~l0 °C. To the mixture was added EA (100 mL), then the solution was washed with H_20 (100 mL), brine (50 mL), dried over Na_2S0_4, filtered, concentrated and purified by column chromatography on silica gel (PE/EA = 2/1) to give a mixture of desired product and starting material. Then the mixture was re-purified by flash column chromatography (210 nm, 30 % MeCN in H_20) to give product (R)-3-((S)-5-(3-bromophenyl)-2-oxooxazolidin-3-yl)-l-(4-methoxybenzyl)piperidine-2,6-dione (4.0 g, 25% yield) as a white solid. ^{1}H NMR (400 MHz, CDCh) δ 7.60-7.57 (m, 2 H), 7.39-7.36 (m, 2 H), 7.32-7.28 (m, 2 H), 6.81-6.77 (m, 2 H), 5.48 (t, *j* = 8.4 Hz, 1 H), 4.87 (s, 2 H), 4.69 (dd, 7 = 13.5, 5.2 Hz, 1 H), 3.79 (t, *J* = 8.4 Hz, 1 H), 3.76 (s, 3 H), 3.42 (t, *J* = 8.0 Hz, 1 H), 2.95 (ddd, *J* = 17.8, 4.5, 2.4 Hz, 1 H), 2.77 (ddd, *J* = 17.8, 13.5, 5.5 Hz, 1 H), 2.24-2.07 (m, 2 H).

[003723] Step 5 - (R)-3-((S)-5-(3-bromophenvl)-2-oxooxazolidin-3-vl)piperi dine-2,6-dione

[003724] To a solution of (R)-3-((S)-5-(3-bromophenyl)-2-oxooxazolidin-3-yl)-l-(4-methoxybenzyl)piperidine-2,6-dione (4.0 g, 8.47 mmol) in MeCN (90 mL) was added dropwise a solution of CAN (18.6 g, 33.9 mmol) in H_20 (20 mL) at 0 °C. The mixture was stirred for 3 h at 0

°C~l0 °C. To the mixture was added H2O (50 mL), then the solution was extracted with EA (100 mL). The organic layer was washed with brine (30 mL), dried over Na_2S0_4, filtered, concentrated to give a yellow solid. The solid was washed with EA (30 mL) to give the title compound (1.2 g, 40% yield) as a white solid. The filtrate was concentrated and purified by flash (210 nm, 30 % MeCN in H20) to give another portion of the title compound (0.2 g, 7% yield) as a white solid, the total yield is 47%. ^{1}H NMR (400 MHz, DMS04) δ 11.00 (s, 1H), 7.72 (t, *J* = 1.6 Hz, 1H), 7.63-7.60 (m, 1 H), 7.50-7.49 (m, 1H), 7.42 (t, *J* = 8 Hz, 1H), 5.63 (dd, *J* = 7.6, 8.8 Hz, 1H), 4.71 (dd, J = 5.2, 13.2 Hz, 1H), 3.94 (t, J = 8.8 Hz, 1H), 3.29-3.25 (m, 1H), 2.92-2.82 (m, 1H), 2.59-2.57 (m, 1H), 2.25-2.14 (m, 1H), 2.03-2.01 (m, lH).LC/MS (ESI, *m/z):* [M+l] $^+$ = 355.0.

[003725] **3-[(5S)-5-[3-[4-(3-aminopropoxy)but-1-ynyl]phenyl]-2-oxo-oxazolidin-3-yl]piperidine-2,6- dione (Intermediate SF)**



[003726] Step 1 - Tert-butyl N-[3-[4-[3-[(5S)-3-(2,6-dioxo-3-piperidyl)-2-oxo-oxazolidin-5-yl]phenyl]but-3- ynoxy]propyl]carbamate


[003727] To a solution of tert-butyl N-(3-but-3-ynoxypropyl)carbamate (146 mg, 645 umol, Intermediate SD) and 3-[(5ri)-5-(3- bromophenyl)-2-oxo-oxazolidin-3-yl]piperidine-2,6-dione (190 mg, 537 umol, Intermediate SE) in DMF (8.00 mL) was added $Pd(PPh3)_2Cl2$ (37.7 mg, 53.8 umol), CuI (10.2 mg, 53.8 umol), CS2CO3 (701 mg, 2.15 mmol) and 4Å molecular sieves (30 mg) under N_2, and the mixture was stirred at 80 °C for 3 hrs. On completion, the mixture was filtered

and the filtrate was concentrated *in vacuo*. The mixture was purified by prep-HPLC (reverse phase: 0.1% FA) to give the title compound (140 mg, 52% yield) as yellow solid. ^{1}H NMR (400MHz, DMSO-di) δ 11.0 (s, 1H), 7.51 - 7.39 (m, 4H), 6.79 (s, 1H), 5.73 - 5.58 (m, 1H), 4.76 - 4.63 (m, 1H), 3.97 - 3.84 (m, 1H), 3.59 - 3.51 (m, 2H), 3.46 - 3.43 (m, 2H), 3.30 - 3.22 (m, 1H), 3.03 - 2.95 (m, 2H), 2.92 - 2.76 (m, 1H), 2.70 - 2.67 (m, 2H), 2.61 - 2.54 (m, 1H), 2.28 - 2.14 (m, 1H), 2.05 - 1.93 (m, 1H), 1.68 - 1.57 (m, 2H), 1.38 (s, 9H).

[003728] Step 2 - 3-[(5S)-5-[3-[4-(3-aminopropoxy)but-1-ynyl]phenyl]-2-oxo-oxazolidin-3-yl]piperidine-2,6- dione

[003729] To a solution of tert-butyl N-[3-[4-[3-[(5,S)-3-(2,6-dioxo-3-piperidyl)-2-oxo-oxazolidin-5-yl]phenyl] but-3-ynoxy]propyl]carbamate (110 mg, 220 umol) in DCM (4.00 mL) was added TFA (6.16 g, 54.0 mmol). The reaction mixture was stirred at 25 °C for 1 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (110 mg, 97% yield, TFA) as yellow solid. LC-MS (ESI$^+$) *m/z* 400.2(M+H)$^+$.


[003730] **But-3-ynyl methanesulfonate [Intermediate SG)**



SG

[003731] To a solution of but-3-yn-l-ol (10.0 g, 142 mmol, CAS# 927-74-2) and TEA (43.3 g, 428 mmol) in DCM (250 mL) was added MsCl (21.2 g, 185 mmol) dropwise at 0 °C. The mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was quenched by water (150 mL) at 0 °C. The organic layers were washed with water (150 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (20.0 g, 95% yield) as light yellow oil. ¾NMR (400MHz, CDCh) 4.31 (t, J = 6.4 Hz, 2H), 3.06 (s, 3H), 2.68 -2.64 (M, 2H), 2.07 (t, J = 2.8 Hz, 1H).

[003732] **Tert-butyl N-[(1-but-3-ynyl-4-piperidyl)methyl]-N-methyl-carbamate (Intermediate SH)**




SH

[003733] To a solution of tert-butyl N-methyl-N-(4-piperidylmethyl)carbamate (3.00 g, 13.1 mmol, CAS# 138200- 04-5) in a mixed solvent of $CHCl_3$ (25 mL) and ACN (25 mL) was added K_2CO_3 (3.63 g, 26.2 mmol) and but-3-ynyl methanesulfonate (2.53 g, 17.0 mmol, Intermediate

SG). The mixture was stirred at 70 °C for 16 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (S1O2, PE/EA=6/l) to give the title compound (2.30 g, 62% yield) as light yellow oil. ^{1}H NMR (400MHz, CDCb) δ 3.09 (d, *J* = 6.8 Hz, 2H), 2.97 - 2.97 (m, 2H), 2.84 (s, 3H), 2.59 (t, 7 = 8.0 Hz, 2H), 2.45 - 2.32 (m, 2H), 2.04 - 1.93 (m, 3H), 1.65 - 1.55 (m, 3H), 1.45 (s, 9H), 1.30 - 1.20 (m, 2H).

[003734] **3-[3-Methyl-5-[4-[4-(methylaminomethvD-l -piperidyl] but-1-vnyl]-2-oxo-benzimidazol-l-yll piperidine-2,6-dione [Intermediate SI)**



[003735] Step 1 - Tert-butyl N-[[1-[4-[1-(2.6-dioxo-3 -piperidyl)-3-methyl -2-oxo-- benzimidazol-5-yl1but-3-vnyl1 -4-piperidvHmethyll-N-methyl-carbamate


[003736] To a solution of 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (500 mg, 1.48 mmol, Intermediate HN) and tert-butyl N-[(l-but-3-ynyl-4-piperidyl)methyl]-N-methyl-carbamate (1.04 g, 3.70 mmol, Intermediate SH) in DMF (15 mL) was added CS2CO3 (1.93 g, 5.91 mmol), CuI (56.3 mg, 295 umol), 4Å molecular sieves (500 mg) and $Pd(PPh3)_2Cl2$ (207 mg, 295 umol). The mixture was stirred at 80 °C for 2 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo*; the residue was diluted with water (30 mL), and then extracted with EA (3 X 40 mL). The combined organic layers were dried over Na_2S0_4, filtered

and concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (FA condition) to give the title compound (80.0 mg, 10% yield) as white solid. ^{1}H NMR (400MHz, DMSO-d_6) δ 8.16 (s, 1H), 7.14 (dd, J = 1.6, 8.4 Hz, 1H), 7.07 (s, 1H), 6.72 (d, J = 8.0 Hz, 1H), 5.19 (dd, J = 5.6, 12.8 Hz, 1H), 3.42 (s, 3H), 3.12 (d, J = 6.8 Hz, 2H), 3.07 - 2.92 (m, 3H), 2.89 - 2.81 (m, 4H), 2.80 - 2.58 (m, 5H), 2.29 - 2.21 (m, 1H), 2.19 - 2.00 (m, 2H), 1.46 (s, 9H), 1.39 - 1.24 (m, 2H); LC-MS (ESI$^+$) *m/z* 538.3 (M+H)$^+$.

[003737] Step 2 - 3-r3-Methyl-5-r4-r4-(methylaminomethvn-l-piperidyl1but-l-vnyl1-2-oxo-benzimidazol-l-yl] piperidine-2.6-dione

[003738] To a solution of tert-butyl N-[[l-[4-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]but-3- ynyl]-4-piperidyl]methyl]-N-methyl-carbamate (60.0 mg, 111 umol) in DCM (3 mL) was added TFA (924 mg, 8.10 mmol). The mixture was stirred at 30 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (60.0 mg, 97% yield, TFA) as light yellow oil. LC-MS (ESI$^+$) *m/z* 438.3 (M+H)$^+$.

[003739] **Tert-butyl N-|3-(2-piperazin-l-ylethoxy)cyclobutyl]carbamate [Intermediate SJ)**



SJ

[003740] Step 1 - Ethyl 2-r3-(tert-butoxycarbonylamino)cvclobutoxy1acetate

[003741] To a solution of tert-butyl N-(3-hydroxycyclobutyl)carbamate (8.00 g, 43.0 mmol, CAS# 389890-42-0) in DCM (80 mL) was added diacetoxy rhodium (0.38 g , 0.85 mmol), the mixture was stirred at 25 °C for 0.5 hour. Then a solution of ethyl 2-diazoacetate (5.90 g, 51.0 mmol, CAS# 623-73-4) in DCM (20 mL) was added to the reaction mixture and stirred at 25 °C

for 12 hours. On completion, the reaction mixture was diluted with saturated sodium bicarbonate solution (100 mL) and extracted with DCM (2 X 150 mL). The combined organic layers were washed with brine (2 X 200 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (9.00 g, 77% yield) as yellow oil. ^1H NMR (400MHz, CDCh) δ 4.23 - 4.19 (m, 4H), 3.97 (s, 2H), 2.45 - 2.41 (m, 2H), 2.17 - 2.14 (m, 2H), 1.43 (m, 9H), 1.30-1.28 (m, 3H).

[003742] Step 2 - Tert-butyl N-r3-(2-hvdroxyethoxy)cvclobutyl1carbamate

[003743] To a solution of ethyl 2-[3-(tert-butoxycarbonylamino)cyclobutoxy]acetate (9.00 g, 33.0 mmol) in THF (100 mL) was added LiBLL (1.20 g, 53.0 mmol) at 0 °C. The reaction mixture was stirred at 25 °C for 2 hours. On completion, the reaction mixture was quenched by H_20 (60 mL) at 25 °C, and then extracted with ethyl acetate (2 X 100 mL). The combined organic layers were washed with (2 X 200 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (7.0 g, 92% yield) as colorless oil.

[003744] Step 3 - 2-r3-(Tert-butoxycarbonylamino)cvclobutoxy1ethyl methanesulfonate

[003745] To a solution of tert-butyl N-[3-(2-hydroxyethoxy)cyclobutyl]carbamate (2.00 g, 8.70 mmol) in DCM (20 mL) was added Et_3N (1.80 g, 17.0 mmol) and MsCl (1.50 g, 13.0 mmol) at 0 °C. Then the reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was diluted with H_20 (50 mL) and extracted with DCM (2 X 50 mL). The combined organic layers were washed with brine (2 X 100 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (2.00 g, 75% yield) as colorless oil.


[003746] Step 4 - Benzyl 4-r2-r3-(tert-butoxycarbonylamino)cvclobutoxy1ethyl1piperazine-l-carboxylate

[003747] To a solution of 2-[3-(tert-butoxycarbonylamino)cyclobutoxy]ethyl methanesulfonate (2.00 g, 6.50 mmol) and benzylpiperazine-l-carboxylate (2.90 g, 13.0 mmol, CAS# 31166-44-6) in ACN (40 mL) was added Et_3N (2.00 g, 19.0 mmol) and KI (1.30 g, 7.80 mmol). Then the reaction mixture was stirred at 70 °C for 12 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give a residue. The crude product was purified by reverse phase HPLC (0.1% FA condition) to give the title compound (2.00 g, 77% yield) as colorless oil. ^{1}HNMR (400MHz, DMSO-^e) δ 7.39 - 7.33 (m, 5H), 7.18 (d, J = 6.0 Hz, 1H), 5.11 (s, 2H), 4.06 - 4.00 (m, 3H), 3.57 (d, J = 4.0 Hz, 2H), 3.31 (s, 3H), 3.11 (d, 7 = 9.2 Hz, 2H), 2.52 (s, 4H), 2.22 - 2.18 (m, 2H), 2.12 - 2.08 (m, 2H), 1.37 (s, 9H); LC-MS (ESI^+) *m/z* 434.3 $(M+H)^+$.


[003748] Step 5 - Tert-butyl N-r3-(2-piperazin-l-ylethoxy)cvclobutyl1carbamate

[003749] To a solution of benzyl 4-[2-[3-(tert-butoxycarbonylamino)cyclobutoxy]ethyl]piperazine-l- carboxylate (1.50 g, 3.50 mmol) in MeOH (20 mL) was added Pd/C (0.200 g, 3.50 mmol, 10 wt%). Then the reaction mixture was degassed and purged with H_2 gas 3 times and stirred at 25 °C for 12 hours under H_2 (15 psi) atmosphere. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (1.0 g, 97% yield) as colorless oil.

[003750] **l-(2.,6-Dioxo-3-piperidvP-3-methyl-2-oxo-benzimidazole-5-carbaldehvde [Intermediate SK)**



HN



SK

[003751] Step 1 - 3-(3-Methyl-2-oxo-5-vinyl-benzimidazol- 1-yl)piperidine-2.6-dione


[003752] A mixture of 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (3.00 g, 8.87 mmol, Intermediate HN), potassium hydride, trifluoro (vinyl)boron (3.57 g, 26.6 mmol), Cs_2C0_3 (2 M solution, 8.87 mL), Pd(dppf)Cl_2·CH_2Cl_2 (724 mg, 887 umol) and in dioxane (30 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 80 °C for 3 hours under N_2 atmosphere. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (TFA condition) to give the title compound (1.60 g, 58% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 286.0 $(M+H)^+$.

[003753] Step 2 - 1-(2.6-Dioxo-3-piperidyl)-3-methyl-2-oxo-benzi midazole-5-carbaldehyde

[003754] To a solution of 3-(3-methyl-2-oxo-5-vinyl-benzimidazol-l-yl)piperidine-2,6-dione (0.30 g, 1.05 mmol) in a mixed solvent of dioxane (20 mL) and H_20 (2 mL) was added $NaI0_4$ (449 mg, 2.10 mmol), $Os0_4$ (267 mg, 1.00 mmol) and NMO (61.0 mg, 525 umol). The mixture was stirred at 25 °C for 0.5 hr. On completion, the residue was diluted with water (10 mL)

and extracted with ethyl acetate (2 X 20 mL). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (TFA condition) to give the title compound (0.1 g, 32% yield) as a gray solid. LC-MS (ESI+) m/z 288.0 $(M+H)^+$.

[003755] **3-[5-[[4-[2-(3-Aminocyclobutoxy)ethyllpiperazin-l-yllmethyll-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione [Intermediate SL)**



[003756] Step 1 - Tert-butylN-[3-[2-[4-[[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-vnmethvnpiperazin-l-vnethoxylcvclobutyllcarbamate


[003757] To a solution of l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazole-5-carbaldehyde (0.20 g, 696 umol, Intermediate SK) and tert-butyl-N-[3-(2-piperazin-l-ylethoxy)cyclobutyl]carbamate (0.420 g, 1.40 mmol, Intermediate SJ) in THF (4 mL) was added HOAc (84.0 mg, 1.40 mmol) and stirred at 40 °C for 1 hour. Then $NaBH(OAc)_3$ (0.440 g, 2.10 mmol) was added to the reaction mixture and stirred at 40 °C for 12 hrs. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (column: Luna Cl8 150*25 5u; mobile phase: [water (0.075%TFA)-ACN]; B%: l5%-45%, 9 min) to give the title compound (0.21 g, 46% yield) as a colorless oil. LC-MS (ESI+) m/z 571.2 $(M+H)^+$.

[003758] Step 2 - 3-[5-[[4-[2-(3-Aminocyclobutoxy)ethyl1piperazin-l-yl1methyl1-3-methyl-2-oxo-Benzimidazol-l-yl1piperidine-2.6-dione

[003759] To a solution of tert-butylN-[3-[2-[4-[[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] methyl]piperazin-l-yl]ethoxy]cyclobutyl]carbamate (0.35 g, 0.61 mmol) in DCM (6 mL) was added HCl/dioxane (4 M, 3.1 mL). Then the reaction mixture was stirred at 25

°C for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (0.1 g, 34% yield, HC1) as colorless oil. LC-MS (ESI+) m/z 471.2 $(M+H)^+$.

[003760] **3-[(5S)-5-[3-[3-[(2S)-2-(aminomethvPmorpholin-4-yl]prop-l-vnyl]phenyl]-2-oxo-oxazolidin -3-yl]piperidine-2,6-dione [Intermediate SM)**



SM

[003761] Step 1 - Tert-butvl N-[[(2S)-4-[3-[3-[(5S)-3-(2,6-dioxo-3-piperidvl)-2-oxo-oxazolidin-5-yllphenyll prop-2-vnyl1morpholin-2-yl1methyl1carbamate


[003762] To a mixture of tert-butyl N-[[(2ri)-4-prop-2-ynylmorpholin-2-yl]methyl]carbamate (540 mg, 2.12 mmol, synthesized via Step 1 of Intermediate RK) and 3-[(5ri)-5-(3-bromophenyl)-2-oxo-oxazolidin-3-yl]piperidine-2,6-dione (300 mg, 849 umol, Intermediate SE) in DMF (5 mL) was added $Pd(PPh_3)2Cl2$ (59.6 mg, 84.9 umol), CuI (16. 1 mg, 84.9 umol) and CS_2CO_3 (1.38 g, 4.25 mmol). The reaction mixture was stirred at 80 °C for 2 hours under N2 atmosphere. On completion, the reaction mixture was filtered and concentrated *in vacuo.* The residue was diluted with water (30 mL) and extracted with EA (3 X 30 mL). The combined organic layers was dried over Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0. 1 % FA condition) to give the title compound (450 mg, 95% yield) as light yellow solid. LC-MS (ESI^+) *m/z* 527.3 $(M+H)^+$.

[003763] Step 2 - 3-[(5S)-5-[3-[3-[(2S)-2-(aminomethyl)morpholin-4-yl]prop-1-vnyl1phenyl1-2-oxo-oxazolidin -3-yl1piperidine-2.6-dione

[003764] To a mixture of tert-butyl N-[[(2ri)-4-[3-[3-[(5ri)-3-(2,6-dioxo-3-piperidyl)-2-oxo-oxazolidin-5-yl] phenyl]prop-2-ynyl]morpholin-2-yl]methyl]carbamate (180 mg, 341 umol) in DCM (3 mL) was added TFA (4.62 g, 40.5 mmol, 3 mL). The reaction mixture was stirred at 25

°C for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (184 mg, 99% yield, TFA) as red oil. LC-MS (ESI^+) *m/z* 427.1 $(M+H)^+$.

[003765] **3-[(5*S*)-5-(4-br()mophenvl)-2-oxo-oxazolidin-3-yl]piperidine-2,6-dione [Intermediate SN)**



[003766] Step 1 - (S)-2-bromo-l-(4-bromophenv0ethanol

[003767] To a stirred solution of (S)-l -methyl-3, 3-diphenylhexahy dropyrrolo[1,2-c][l,3,2]oxazaborole (0.5 g, 1.81 mmol) in THF (25 mL) was added BH3·DMS (10 M, 1.3 mL, 12.7 mmol) at 0 °C. The mixture was stirred for 0.5 h at 0 °C. To the reaction mixture was then added a solution of 2-bromo-l-(4-bromophenyl)ethanone (5 g, 18.1 mmol) in THF (15 mL) dropwise at 0 °C. The mixture was stirred for 12 h at rt. To the mixture was then added MeOH dropwise where gas evolved. MeOH was added until no more bubbling occurred. The mixture was concentrated and purified by column chromatography on silica gel (PE/EA= 50/1 to 20/1 to 10/1 to 5/1) to give the title compound (5 g, 100 % yield) as a white solid. ^1H NMR (400 MHz, DMSO-i/e) *S* 7.55-7.52 (m, 2 H), 7.38-7.34 (m, 2 H), 5.89 (d, *J* = 4.9 Hz, 1 H), 4.82-4.78 (m, 1 H), 3.66 (dd, *J* = 10.2, 4.6 Hz, 1 H), 3.57 (dd, *J* = 10.2, 6.8 Hz, 1 H).

[003768] Step 2 - (S)-2-amino-l-(4-bromophenv0ethanol

[003769] To a solution of (S)-2-bromo-l-(4-bromophenyl)ethanol (15 g, 123 mmol) in MeOH (100 mL) was added $NH_3·H_2O$ (25 %, 250 mL) at 0 °C under N_2. The reaction mixture was stirred at rt for 12 h under N_2. Then the mixture was concentrated. The solid was washed with EA to give the title compound (8.4 g, 74 % yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ

7.54 (d, *J* = 8.4 Hz, 2 H), 7.32 (d, *J* = 8.4 Hz, 2 H), 5.51 (br s, 3 H), 4.64 (dd, *J* = 8.4, 3.6 Hz, 1 H), 2.83 (dd, *J* = 12.8, 3.4 Hz, 1 H), 2.69 (dd, *J* = 12.6, 6.8 Hz, 1 H).

[003770] Step 3 - (S)-5-(4-bromophenyl)oxazolidin-2-one

[003771] A mixture of (S)-2-amino-l-(4-bromophenyl)ethanol (22 g, 102 mmol), CDI (24.2 g, 153 mmol) and THF (500 mL) was heated to 80 °C and stirred for overnight at 80 °C under N_2. To the mixture was then added H_20 (200 mL), and the mixture was extracted with EA (300 mL). The organic layer was concentracted and purified by column (PE/EA= 2/1 to 1/1) to give the title compound (8.0 g, 33% yield) as a yellow solid.

[003772] Step 4 - (R)-3-((S)-5-(4-bromophenvD-2-oxooxazolidin-3-yl)-l-(4-methoxybenzyl)pi peri dine-2.6-di one

[003773] To a solution of (S)-5-(3-bromophenyl)oxazolidin-2-one (8.0 g, 30.2 mmol) in THF (100 mL) was added /-BuOK (5.5 g, 49.8 mmol) at 0 °C under N_2. The mixture was stirred for 1 h at 0 °C. Then to the mixture was added l-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yl trifluoromethanesulfonate (13.9 g, 36.8 mmol) at 0 °C under N_2. The mixture was stirred at 0 °C~l0 °C for 2 h. To the mixture was then added EA (100 mL), the solution was then washed with H_20 (100 mL), brine (50 mL), dried over Na_2S0_4, filtered, concentrated and purified by column chromatography on silica gel (PE/EA = 2/1) to give a mixture of desired product (R)-3-((S)-5-(4-bromophenyl)-2-oxooxazolidin-3-yl)-l -(4-methoxybenzyl)piperidine-2,6-dione and starting material.. Then the mixture was re-purified by flash column chromatography (210 nm, 30 % MeCN in H_20) to give the title compound (4.5 g, 28% yield) as a white solid. ^1H NMR (400 MHz, CDCh) *S* 7.57-7.52 (m, 2 H), 7.34-7.29 (m, 2 H), 7.26-7.24 (m, 2 H), 6.86-6.80 (m, 2 H), 5.89 (dd, *J* = 8.7, 7.1 Hz, 1 H), 4.89 (s, 2 H), 4.58 (dd, *J* = 12.8, 6.0 Hz, 1 H), 3.94 (t, *J* = 8.4 Hz, 1 H), 3.78 (s, 3 H), 3.80 (dd, *J* = 17.9, 7.1 Hz, 1 H), 2.97-2.90 (m, 1 H), 2.79-2.70 (m, 1 H), 2.20-2.04 (m, 2 H).

[003774] Step 5 - (R)-3-((S)-5-(4-bromophenyl)-2-oxooxazolidin-3-yl)piperidine-2.6-dione


[003775] To a solution of (R)-3-((S)-5-(4-bromophenyl)-2-oxooxazolidin-3-yl)-l-(4-methoxybenzyl)piperidine-2,6-dione (50 mg, 0.106 mmol) in MeCN (5 mL) was added dropwise a solution of CAN (232 mg, 0.424 mmol) in H_20 (1 mL) at 0 °C. The mixture was stirred for 3 h at 0 °C~l0 °C. To the mixture was then added H_20 (100 mL), and the solution was extracted with EA (200 mL). The organic layer was washed with brine (50 mL), dried over Na_2S0_4, filtered, concentrated and purified by column (PE/EA = 1/1) to give the title compound (5 mg, 14 % yield)

as a white solid. ^{1}H NMR (400 MHz, CDCh) δ 8.20 (s, 1 H), 7.56 (d, *J* = 8.0 Hz, 2 H), 7.35 (d, *J* = 8.0 Hz, 2 H), 5.49 (t, *J* = 8.2 Hz, 1 H), 4.74 (dd, *J* = 13.0, 5.2 Hz, 1 H), 3.84 (t, *J* = 8.4 Hz, 1 H), 3.48 (t, *J* = 7.8 Hz, 1 H), 2.91-2.87 (m, 1 H), 2.82-2.73 (m, 1 H), 2.22-2.11 (m, 2 H). LC/MS (ESI, *m/z):* [M+l] $^+$ = 355.0.

[003776] Step 6 - (S)-3-(YS)-5-(4-biOmophenvP-2-oxooxazolidin-3-vDpiperidine-2.6-dione

[003777] To a solution of (S)-3-((S)-5-(4-bromophenyl)-2-oxooxazolidin-3-yl)-l-(4-methoxybenzyl)piperidine-2,6-dione (80 mg, 0.169 mmol) in MeCN (10 mL) was added dropwise a solution of CAN (372 mg, 0.678 mmol) in H_20 (2 mL) at 0 °C. The mixture was stirred for 3 h at 0 °C~l0 °C. To the mixture was added H_20 (100 mL), then the mixture was extracted with EA (200 mL). The organic layer was washed with brine (50 mL), dried over Na_2S0_4, filtered, concentrated and purified by column (PE/EA= 1/1) to give the title compund (1.5 mg, 3% yield) as a white solid. ^{1}H NMR (400 MHz, CDCh) *S* 7.86 (s, 1 H), 7.56 (d, *J* = 8.2 Hz, 2 H), 7.26-7.22 (m, 2 H), 5.60 (t, *J* = 7.8 Hz, 1 H), 4.64 (dd, *J* = 12.0, 5.2 Hz, 1 H), 4.00 (t, *J* = 8.2 Hz, 1 H), 3.41 (t, *J* = 7.4 Hz, 1 H), 2.91-2.86 (m, 1 H), 2.78-2.73 (m, 1 H), 2.24-2.20 (m, 2 H). LC/MS (ESI, *m/z):* [M+l] $^+$ = 355.0.

[003778] **3-[(5S)-5-[4-[3-[(2S)-2-(aminomethvl)morpholin-4-yl]prop-l-vnyl]phenyl]-2-oxo- oxazolidin-3-yl]piperidine-2,6-dione [Intermediate SO)**




[003779] Step 1 - Tert-butyl N-[[(2S)-4-[3-[4-[(5S)-3-(2,6-dioxo-3-piperidyl)-2-oxo-oxazolidin-5-vnphenyll prop-2-vnyl1morpholin-2-yl1methyl1carbamate

[003780] To a solution of tert-butyl N-[[(2A)-4-prop-2-ynylmorpholin-2-yl]methyl]carbamate (648 mg, 2.55 mmol, synthesized via Step 1 of Intermediate RK) and 3-[(5*S*)-5-(4-bromophenyl)-2-oxo-oxazolidin-3-yl]piperidine-2,6-dione (300 mg, 849 umol, Intermediate SN) in **DMF** (15 mL) was added $Pd(PPh_3)2Cl2$ (119 mg, 169 umol), Cul (32.3 mg, 169 umol) and **CS2CO3** (1.38 g, 4.25 mmol). The reaction mixture was stirred at 80 °C for 2 hours under N2. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (440 mg, 80% yield) as a yellow solid. ¾NMR (400 MHz, **DMSO-^e)** 511.00 (d, *J* = 6.0 Hz, 1H), 7.53 - 7.40 (m, 4H), 6.88 - 6.84 (m, 1H), 5.73 - 5.61 (m, 1H), 4.75 - 4.63 (m, 1H), 3.94 (t, *J* = 8.8 Hz, 1H), 3.89 (t, *J* = 8.8 Hz, 1H), 3.80 (t, *J* = 7.2 Hz, 2H), 3.50 - 3.40 (m, 4H), 3.30 - 3.21 (m, 2H), 2.60 - 2.52 (m, 2H), 2.37 - 2.15 (m, 3H), 2.02 - 1.92 (m, 2H), 1.36 (s, 9H); **LC-MS** (ESI^+) m/z 527.3 $(M+H)^+$.

[003781] Step 2 - 3-r(5S)-5-r4-r3-r(2S)-2-(aminomethyl)morpholin-4-yl1prop-l-vnyllphenyll-2-oxo- oxazolidin-3-yl1piperidine-2.6-dione

[003782] To a solution of tert-butyl N-[[(25)-4-[3-[4-[(5S)-3-(2,6-dioxo-3-piperidyl)-2-oxo-oxazolidin-5-yl] phenyl] prop-2-ynyl]morpholin-2-yl]methyl]carbamate (150 mg, 284 umol) in DCM (3 mL) was added TFA (1.54 g, 13.5 mmol, 1 mL). The reaction mixture was stirred at 25 °C for 2 hours. On completion, the residue concentrated *in vacuo* to give the title compound (150 mg, 97% yield) as yellow oil. LC-MS (ESI^+) m/z 427.2 $(M+H)^+$.

[003783] **3-[3-Methyl-4-[3-[2-[2-(methylamino]ethoxyl ethoxy] propyl] -2-oxo-benzimidazol-l-yl] piperidine-2,6-dione [Intermediate SP)**



[003784] Step 1 - Tert-butyl N-[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl1prop-2-vnoxy1ethoxy1ethyl1-N-methyl-carbamate

[003785] To a mixture of tert-butyl N-methyl-N-[2-(2-prop-2-ynoxyethoxy)ethyl]carbamate (1.37 g, 5.32 mmol, Intermediate FY), 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (600 mg, 1.77 mmol, Intermediate HP) in DMF (30 mL) was added CS2CO3 (2.89 g, 8.87 mmol), Pd(PPh3)$_2$Cl2 (249 mg, 354 umol) and Cul (67.5 mg, 354 umol) under N_2. The reaction mixture was stirred at 80 °C for 2 hours. On completion, the mixture was filtered, the filtrate was poured into water (100 mL), and the aqueous phase was extracted with ethyl acetate (2 X 40 mL). The combined organic phase was washed with brine (2 X 40 mL), dried with anhydrous Na_2SO_4, filtered and concentrated *in vacuo* to get residue. The residue was purified by reverse phase (0.1% FA condition) to get title compound (480 mg, 52% yield) as a brown solid. ^1H NMR (400 MHz, CDCb) δ 8.29 (s, 1H), 7.22 - 7.16 (m, 1H), 7.03 - 7.00 (m, 1H), 6.78 (d, J = 8.0 Hz, 1H), 5.28 - 5.17 (m, 1H), 4.49 (s, 2H), 4.20 - 4.08 (m, 1H), 3.81 - 3.78 (m, 3H), 3.71 - 3.67 (m, 2H), 3.62 (s, 3H), 3.61 - 3.55 (m, 4H), 2.93 (s, 3H), 2.92 (s, 2H), 2.30 - 2.20 (m, 1H), 2.03 (s, 1H), 1.47 (s, 9H).


[003786] Step 2 - Tert-butyl N-[2-[2-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-vnpropoxylethoxylethvn-N-methyl -carbamate

[003787] To a mixture of tert-butyl N-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]prop-2-ynoxy]ethoxy]ethyl]-N-methyl-carbamate (480 mg, 933 umol) in THF (20 mL) was added Pd/C (100 mg, 1.87 mmol, 10 wt%) and $Pd(OH)_2/C$ (100 mg, 1.87 mmol, 10 wt%) under N_2. The suspension was degassed *in vacuo* and purged with H_2 gas three times. The mixture was stirred at 20 °C for 12 hours under H_2 (15 psi). On completion, the mixture was filtered and concentrated *in vacuo* to give the title compound (360 mg, 74% yield) as brown oil. LC-MS (ESI^+) *m/z* 541.2 $(M+Na)^+$.

[003788] Step 3 - 3-r3-Methyl-4-r3-r2-r2-(methylamino)ethoxy1ethoxy1propyl1-2-oxo-benzimidazol-l-yl] piperidine-2.6-dione

[003789] To a mixture of tert-butyl N-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propoxy]ethoxy]ethyl]-N-methyl-carbamate (350 mg, 675 umol) in DCM (2 mL) was added TFA (154 mg, 1.35 mmol). The reaction mixture was stirred at 25 °C for 0.1 hour. On completion, the mixture was concentrated *in vacuo* to get title compound (365 mg, 100% yield) as brown oil. LC-MS (ESI^+) *m/z* 419.1 $(M+H)^+$.

[003790] **3-[4-[3-[(2R)-2-(aminomethyl)morpholin-4-yl]propyl]-3-methyl-2-oxo-benzimidazol-1- yl]piperidine-2,6-dione [Intermediate SO)**



SQ

[003791] Step 1 - Tert-butyl N-п(211)-4-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yllprop -2-vnyl1morpholin-2-yl1methyl1carbamate

[003792] To a solution of tert-butyl N-[[(2R)-4-prop-2-ynylmorpholin-2-yl]methyl]carbamate (940 mg, 3.70 mmol, synthesized via Step 1 of Intermediate RJ) and 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (500 mg, 1.48 mmol, Intermediate HP) in DMF (15 mL) was added CS2CO3 (2.41 g, 7.39 mmol), Cul (28.1 mg, 147 umol) and $Pd(PPh3)_2Cl2$ (103 mg, 147 umol). The reaction mixture was stirred at 80 °C for 2 hr under N_2. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (500 mg, 66% yield) as a yellow solid. LC-MS (ESI^+) m/z 512.3 $(M+H)^+$.


[003793] Step 2 - Tert-butyl N-[[(2R)-4-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]propyl] morpholin-2-yllmethyllcarbamate

[003794] To a solution of tert-butyl N-[[(2R)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol- 4-yl]prop-2-ynyl]morpholin-2-yl]methyl]carbamate (500 mg, 977 umol) in THF (20 mL) was added Pd/C (100 mg, 10 wt%) and Pd(OH)2/C (100 mg, 10 wt%). The reaction mixture was stirred at 25 °C under ¾ (15 psi) for 12 hrs. On completion, the residue was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (370 mg, 73% yield) as a white solid. ^1H NMR (400MHz, DMS04) δ 11.09 (s, 1H), 7.04 - 6.91 (m, 2H), 6.91 - 6.79 (m, 2H), 5.36 (dd, *J* = 5.2, 12.4 Hz, 1H), 3.76 (d, *J* = 10.4 Hz, 1H), 3.56 (s, 3H), 3.46 (t, *J* = 10.8 Hz, 1H), 3.40 - 3.35 (m, 1H), 3.02 - 2.79 (m, 6H), 2.75 - 2.61 (m, 3H), 2.45 - 2.31 (m, 2H), 2.06 - 1.94 (m, 2H), 1.82 - 1.63 (m, 3H), 1.37 (s, 9H); LC-MS (ESI^+) m/z 516.3 $(M+H)^+$.

[003795] Step 3 - 3-[4-[3-[(2R)-2-(aminomethvl)morpholin-4-yl1propvl1-3-methyl-2-oxo-benzimidazol-l- yl1piperidine-2.6-dione

[003796] To a solution of tert-butyl N-[[(2i?)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propyl]morpholin-2-yl]methyl]carbamate (370 mg, 717 umol) in DCM (3 mL) was added HCl/dioxane (4 M, 3.08 mL). The reaction mixture was stirred at 25 °C for 2 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (320 mg, 98% yield, HC1) as a white solid. LC-MS (ESI^+) m/z 416.3 $(M+H)^+$.

[003797] **3-[4-[3-[(2S)-2-(aminomethvl)morpholin-4-yl]propyl]-3-methyl-2-oxo-benzimidazol-1- yl]piperidine-2,6-dione [Intermediate SR]**



SR

[003798] Step 1 - Tert-butyl N-[[(2S)-4-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yll prop-2-vnyl1morpholin-2-yl1methyl1carbamate

[003799] To a solution of 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (500 mg, 1.48 mmol, Intermediate HP) and tert-butyl N-[[(2X)-4-prop-2-ynylmorpholin-2-yl]methyl]carbamate (564 mg, 2.22 mmol, synthesized via Step 1 of Intermediate RK) in DMF (20 mL) was added CS2CO3 (1.93 g, 5.91 mmol), Cul (56.3 mg, 295 umol), 4Å molecular sieves (20 mg) and Pd(PPh3)$_2$Cl2 (207 mg, 295 umol), and the mixture was heated at 80 °C for 2 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo*. The residue was diluted with water (40 mL), and then extracted with EA (50 mL X 3). The combined organic layers were dried over Na$_2$S0$_4$, filtered and concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (FA condition) to give the title compound (430 mg, 56% yield) as light yellow solid. ^{1}H NMR (400MHz, CDCb) δ 8.35 (s, 1H), 7.18 (dd, *J* = 0.8, 8.0 Hζ,, 1H), 7.98 (t, *J* = 8.0 Hz, 1H), 6.77 (dd, *J* = 0.8, 8.0 Hz, 1H), 5.22 (dd, 7 = 5.2, 12.8 Hz, 1H), 4.90 (s, 1H), 3.94 (dd, 7 = 0.8, 11.6 Hz, 1H), 3.77 (s, 3H), 3.74 - 3.70 (m, 1H), 3.68 - 3.62 (m, 1H), 3.58 (d, *J* = 2.0 Hz, 2H), 3.40 - 3.31 (m, 1H), 3.18 - 3.08 (m, 1H), 3.01 - 2.91 (m, 1H), 2.90 - 2.73 (m, 4H), 2.50 - 2.44 (m, 1H), 2.31 - 2.17 (m, 2H), 1.44 (s, 9H). LC-MS (ESI$^+$) *m/z* 512.3 (M+H)$^+$.


[003800] Step 2 - Tert-butyl N-[[(2S)-4-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-vnpropyn morpholin-2-yllmethyllcarbamate

[003801] To a solution of tert-butyl N-[[(2ri)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4- yl]prop-2-ynyl]morpholin-2-yl]methyl]carbamate (360 mg, 703 umol) in THF (5 mL) was added $Pd(OH)_2/C$ (40.0 mg, 10 wt%) and Pd/C (40.0 mg, 10 wt%) under N_2. The suspension was degassed under vacuum and purged with H_2 three times. The mixture was stirred under H_2 (15 psi) at 25 °C for 4 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (FA condition) to give the title compound (280 mg, 77% yield) as light yellow solid. ¾NMR (400MHz, CDCh) δ 8.32 (s, 1H), 7.89 (t, J = 8.4 Hz, 1H), 7.18 (d, J = 0.8, 8.0 Hζ,, 1H), 6.67 (d, J = 7.6 Hz, 1H), 5.22 (dd, J = 5.2, 12.4 Hz, lH)„ 4.90 (s, 1H), 3.87 (d, 7 = 10.8 Hz, 1H), 3.72 - 3.52 (m, 5H), 3.40 - 3.25 (m, 1H), 3.17 - 3.03 (m, 1H), 3.01 - 2.91 (m, 3H), 2.87 - 2.66 (m, 4H), 2.41 (t, J = 6.8 Hz, 2H), 2.26 - 2.08 (m, 2H), 1.94 - 1.83 (m, 3H), 1.45 (s, 9H); LC-MS (ESI^+) *m/z* 516.2 $(M+H)^+$.

[003802] Step 3 - 3-[4-[3-[(2S)-2-(aminomethvl)morpholin-4-yl1propyl1-3-methyl-2-oxo-benzimidazol-l- yl1piperidine-2.6-dione

[003803] To a solution of tert-butyl N-[[(25)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propyl]morpholin-2-yl]methyl]carbamate (200 mg, 387 umol) in DCM (3 mL) was added TFA (924 mg, 8.10 mmol). The mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (200 mg, 98% yield, TFA) as light yellow oil. LC-MS (ESI^+) *m/z* 416.3 $(M+H)^+$.

[003804] 3-[7-[3-[(2S)-2-(aminomethvDmorpholin-4-yl1propyl]-2-oxo-l.,3-benzoxazol-3-yl] piperidine -2,6-dione [Intermediate SS)



SS

[003805] Step 1 - Tert-butyl (((2S)-4-(3-(3-(2,6-dioxopiperidin-3-yl)-2-oxo-2,3-dihydrobenzordloxazol-7- yl) prop-2-yn-l-ynmorpholin-2-ynmethyncarbamate

[003806] To a solution of 3-(7-bromo-2-oxo-l,3-benzoxazol-3-yl)piperidine-2,6-dione 2 (600 mg, 1.85 mmol, Intermediate JF) and tert-butyl N-[[(2,V)-4-prop-2-ynylmorpholin-2-yl]methyl]carbamate (704 mg, 2.77 mmol, synthesized via Step 1 of Intermediate RK) in DMF (15 mL) was added CS_2CO_3 (2.41 g, 7.38 mmol), Cul (70.3 mg, 369 umol), 4A molecular sieves (30.0 mg) and $Pd(PPh3)_2Cl2$ (259 mg, 369 umol) at 25 °C under N_2. Then the mixture was heated at 80 °C for 2 hours. On completion, the residue was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography ($S1O_2$, petroleum ether/ethyl acetate = 1:2 to 1:3) to give the title compound (684 mg, 74% yield) as a yellow solid. ^1H NMR (400 MHz, CDCb) δ 8.18 (s, 1H), 7.43 (s, 1H), 7.23 - 7.20 (m, 1H), 7.14 - 7.10 (t, *J* = 8.0 Hz, 1H), 6.80 - 6.77 (m, 1H), 5.07 - 5.02 (m, 1H), 4.91 - 4.90 (m, 1H), 3.96 - 3.92 (m, 1H), 3.74 - 3.60 (m, 4H), 3.16 - 3.09 (m, 1H), 3.02 - 2.97 (m, 1H), 2.89 - 2.68 (m, 4H), 2.54 - 2.47 (m, 1H), 2.37 - 2.21 (m, 2H), 1.44 (s, 9H); LC-MS (ESI+) m/z 499.1 $(M+H)^+$.


[003807] Step 2 - Tert-butyl N-[[(2S)-4-[3-[3-(2.6-dioxo-3 -piperidyl)-2-oxo- 1,3-benzoxazol-7-y1]ρΓορνΠιηοΓpholin- 2-yHmethyllcarbamate

[003808] To a mixture of tert-butyl N-[[(2A)-4-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-l,3-benzoxazol-7-yl]prop- 2-ynyl]morpholin-2-yl]methyl]carbamate (250 mg, 501 umol) in THF (5 mL) was added Pd/C (75.0 mg, 10 wt%) and $Pd(OH)_2$ (75.0 mg, 10 wt%) under N_2. The suspension was degassed *in vacuo* and purged with H_2 three times. The mixture was stirred under H_2 (15 psi) at 25 °C for 16 hours. On completion, the reaction mixture was filtered to remove Pd/C and $Pd(OH)_2$/C, and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA) to give the title compound (120 mg, 55% yield) as a white solid. ^1H NMR (400 MHz, CDCh) δ 8.38 (s, 1H), 7.10 (t, *J* = 8.0 Hz, 1H), 7.00 (d, *J* = 7.8 Hz, 1H), 6.70 (d, *J* = 7.8 Hz, 1H), 5.08 - 5.04 (m, 1H), 4.89 (s, 1H), 3.92 - 3.76 (m, 3H), 3.34 - 3.29 (m, 1H), 3.18 - 3.09 (m, 1H), 3.01 - 2.69 (m, 8H), 2.57 (d, J = 5.4 Hz, 2H), 2.36 - 2.30 (m, 2H), 2.04 - 1.99 (m, 2H), 1.45 (s, 9H); LC-MS (ESI+) m/z 503.1 $(M+H)^+$.

[003809] Step 3 - 3-r7-r3-r(2S)-2-(aminomethyl)morpholin-4-yl1propyl1-2-oxo-l.3-benzoxazol-3-yllpiperidine -2.6-dione

[003810] To a mixture of tert-butyl N-[[(25)-4-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-l, 3-ben zoxazol-7-yl]propyl] orpholin-2-yl]methyl]carbamate (140 mg, 278 umol) in DCM (2 mL) was added TFA (317 mg, 2.79 mmol) in one portion at 25 °C. The mixture was stirred at 25 °C for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (139 mg, 96% yield, TFA) as light yellow oil. ^1H NMR (400 MHz, DMSO-d) δ 11.22 (s, 1H), 8.06 (s, 2H), 7.23 - 7.12 (m, 2H), 7.10 - 7.00 (m, 1H), 5.40 - 5.35 (m, 1H), 5.41 - 5.34 (m, 1H), 4.11 (d, *J* = 10.4 Hz, 1H), 4.01 - 3.89 (m, 1H), 3.74 (t, *J* = 12.0 Hz, 1H), 3.64 - 3.43 (m, 2H), 3.32 - 3.11 (m, 2H), 3.11 - 2.98 (m, 2H), 2.97 - 2.59 (m, 7H), 2.18 - 2.11 (m, 1H), 2.09 - 2.00 (m, 2H); LC-MS (ESI+) m/z 403.2 $(M+H)^+$.

[003811] 3-[7-[3-[(2R)-2-(aminomethvDmorpholin-4-yl1propyl1-2-oxo-l.,3-benzoxazol-3-yl]piperidine -2,6-dione [Intermediate ST]



ST

[003812] Step 1 - Tert-butyl N-[[(2R)-4-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-1,3-benzoxazol-7-yl]prop-2-ynyl] morpholin-2-yllmethyllcarbamate

[003813] To a solution of tert-butyl N-[[(2f?)-4-prop-2-ynylmorpholin-2-yl]methyl]carbamate (488 mg, 1.92 mmol, synthesized via Step 1 of Intermediate RJ) and 3-(7-bromo-2-oxo-l,3-benzoxazol-3-yl)piperidine-2,6-dione (250 mg, 768 umol, Intermediate JF) in DMF (15 mL) was added $Pd(PPh_3)_2Cl_2$ (53.9 mg, 76.9 umol), Cul (14.6 mg, 76.9 umol) and CS2CO3 (1.25 g, 3.84 mmol). The reaction mixture was stirred at 80 °C for 2 hrs under N_2. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (350 mg, 91% yield) as a yellow solid. LC-MS (ESI^+) m/z 499.2 $(M+H)^+$.

[003814] Step 2 - Tert-butyl N-rr(2R)-4-r3-r3-(2.6-dioxo-3-piperidyl)-2-oxo-l.3-benzoxazol-7-yl1propyl1 morpholin-2-yl1methyl1carbamate


[003815] To a solution of tert-butyl N-[[(2i?)-4-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-l,3-benzoxazol-7-yl] prop- 2-ynyl]morpholin-2-yl]methyl]carbamate (350 mg, 702 umol) in THF (20 mL) was added Pd/C (100 mg, 10 wt%) and Pd(OH)2/C (100 mg, 10 wt%). The reaction mixture was stirred at 25 °C under F_2 (15 psi) for 12 hrs. On completion, the residue was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (290 mg, 82% yield) as a white solid. ^1H NMR

(400MHz, DMSO-d) δ 11.21 (s, 1H), 7.17 - 7.07 (m, 2H), 7.02 (d, *J* = 6.8 Hz, 1H), 6.82 (t, *J* = 5.6 Hz, 1H), 5.38 - 5.32 (m, 1H), 3.77 (d, 7 = 10.2 Hz, 1H), 3.47 (d, 7 = 11.2 Hz, 1H), 3.43 - 3.39 (m, 1H), 2.99 - 2.87 (m, 3H), 2.79 - 2.65 (m, 6H), 2.44 - 2.31 (m, 2H), 2.21 - 2.07 (m, 2H), 1.87 - 1.69 (m, 3H), 1.36 (s, 9H); LC-MS (ESI^+) m/z 503.3 $(M+H)^+$.

[003816] Step 3 - 3-[7-[3-[(2R)-2-(aminomethyl)morpholin-4-yl]propyl]-2-oxo-l,3-benzoxazol-3-vnpiperidine -2.6-dione

[003817] To a solution of tert-butyl N-[[(2i?)-4-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-l,3-benzoxazol-7-yl]propyl] morpholin-2-yl]methyl]carbamate (290 mg, 577 umol) in DCM (3 mL) was added HCl/dioxane (4 M, 2.48 mL). The reaction mixture was stirred at 25 °C for 2 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (250 mg, 98% yield, HC1) as a white solid. LC-MS (ESI^+) m/z 403.2$(M+H)^+$.

[003818] **3-(6-(Y2-(2-(2-Aminoethoxy)ethoxy)ethvDamino)-9H-pyrido[2.,3-blindol-9-vDpiperidine- 2,6-dione [Intermediate** SU1



[003819] Step 1 - tert-butyl (2-(2-(2-oxoethoxy)ethoxy)ethvDcarbamate

[003820] To a solution of tert-butyl (2-(2-(2-hydroxyethoxy)ethoxy)ethyl)carbamate (2 g, 8.03 mmol, synthesized via Step 1 on Intermediate AC) in DCM (20 mL) was added Dess-Martin

periodinane (5.1 g, 12.04 mmol) and AcOH (1 mL) portion wise. After addition, the mixture was stirred at rt overnight. The mixture was then concentrated *in vacuo*. The residue was purified by flash chromatography to give the title compound (300 mg, 15%) as an oil. LC/MS (ESI, *m/z):* [M +l] $^{+}$ = 248.2.


[003821] Step 2 - tert-butyl t2-(2-(2-((9-(2.6-dioxopiperidin-3-yl)-9H-pyridor2.3-b1indol-6-vDamino)ethoxy)ethoxy)ethvDcarbamate

[003822] To a mixture of 3-(6-amino-9H-pyrido[2,3-b]indol-9-yl)piperidine-2,6-dione (200 mg, 0.68 mmol, Intermediate UG), tert-butyl (2-(2-(2-oxoethoxy)ethoxy)ethyl)carbamate (176.3 mg, 0.714 mmol) in THF(5 mL) was added AcOH (5 drops). The mixture was stirred at rt for 2 h. Then sodium cyanoborohydride (85.4 mg, 1.36 mmol) was added, and the mixture was heated to 40 °C and stirred overnight. Then the mixture was poured into water, and extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo*. The residue was purified by prep HPLC to give the title compound (70 mg, 20% yield) as a white solid. ¾NMR (400 MHz, DMSO-d_6) δ 11.09 (br. s., 1H), 8.52 - 8.26 (m, 2H), 7.36 - 7.32 (m, 2H), 7.15 (dd, J=7.63, 4.88 Hz, 1H), 6.93 - 6.90 (m, 1H), 6.78 - 6.76 (m, 1H), 5.91 (br. s., 1H), 5.30 (br. s., 1H), 3.64 (t, *J*=5.82 Hz, 2H), 3.51 - 3.59 (m, 4H), 3.40 (t, *J*=5.13 Hz, 2H), 3.30 - 3.28 (m, 2H), 3.09 - 2.98 (m, 4H), 2.69 - 2.66 (m, 1H), 2.00 - 2.12 (m, 1H), 1.37 (s, 9H); LC/MS (ESI, *m/z):* [M +l] $^{+}$ = 526.55.

[003823] Step 3 - 3-(6-((2-(2-(2-Aminoethoxy)ethoxy)ethyl)amino)-9H-pyridor2.3-b1indol-9-vDpiperidine- 2.6-dione

[003824] To a solution of tert-butyl N-[2-[2-[2-[[9-(2,6-dioxo-3-piperidyl)pyrido[2,3-b]indol-6-yl]amino] ethoxy] ethoxy] ethyl] carbarnate (20.0 mg, 38.0 umol) in DCM (3 mL) was added HCl/dioxane (4 M, 2 mL). The reaction mixture was stirred at 25 °C for 0.5 hr. On completion, the reaction mixture was concentrated in vacuo to give the title compound (17.5 mg, 100% yield, HC1) as a white solid. LC-MS (ESI+) m/z 426.2 (M+H)+.

[003825] 3-[4-[3-[2-(2-aminoethoxy)ethoxylpropyll-3-methyl-2-oxo-benzimidazol-l-yl]-l-methyl-piperidine-2.,6-dione [Intermediate SV)



SV

[003826] Step 1 - 3-(4-Bromo-3-methyl-2-oxo-benzimidazol-1-yl)-1-methyl-piperidine-2.6-dione

[003827] To a solution of 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (4.00 g, 11.8 mmol, Intermediate HP) and 4Å molecular sieves (300 mg) in DMF (40 mL) was added MeI (1.68 g, 11.8 mmol) and K2C03 (1.63 g, 11.8 mmol). The reaction mixture was stirred at 25 °C for 12 hrs. On completion, the mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by silica gel chromatography to give the title compound (3.70 g, 89% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 7.24 (d, J = 8.0 Hz, 1H), 7.17 (d, J = 7.8 Hz, 1H), 7.00 - 6.94 (m, 1H), 5.46 (dd, J = 5.2, 12.8 Hz, 1H), 3.63 (s, 3H), 3.03 (s, 3H), 3.00 - 2.90 (m, 1H), 2.83 - 2.66 (m, 2H), 2.08 - 1.97 (m, 1H).

[003828] Step 2 - Tert-butyl N-[2-[2-[3-[3-methyl-1-(1-methyl-2. 6-dioxo-3-piperidyl)-2-oxo-benzimidazol-4-yl1prop-2-vnoxy1ethoxy1ethyl1carbamate

[003829] A mixture of 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)-l-methyl-piperidine-2,6-dione (800 mg, 2.27 mmol), tert-butyl N-[2-(2-prop-2-

ynoxyethoxy)ethyl]carbamate (1.38 g, 5.68 mmol, synthesized via Step 1 of Intermediate CQ), $Pd(PPh_3)_2Cl_2$ (319 mg, 454 umol), Cul (86.5 mg, 454 umol), CS_2CO_3 (3.70 g, 11.4 mmol), and 4A molecular sieve (800 mg) in DMF (40 mL) was de-gassed and then heated at 80 °C for 2 hrs under N_2. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was purified by reverse phase (0.1% FA condition) to give the title compound (650 mg, 45% yield) as a yellow solid. ^1H NMR (400 MHz, DMSO-^e) δ 7.18 (d, *J* = 7.6 Hz, 1H), 7.13 (d, *J* = 7.2 Hz, 1H), 7.05 - 6.98 (m, 1H), 6.82 - 6.75 (m, 1H), 5.51 - 5.43 (m, 1H), 4.46 (s, 2H), 3.67 - 3.64 (m, 2H), 3.64 (s, 3H), 3.57 - 3.54 (m, 2H), 3.47 - 3.42 (m, 2H), 3.10 - 3.06 (m, 2H), 3.03 (s, 3H), 2.99 - 2.90 (m, 1H), 2.79 - 2.63 (m, 2H), 2.06 - 1.92 (m, 1H), 1.36 (s, 9H); LC-MS (ESI^+) *m/z* 537.3 $(M+Na)^+$.


[003830] Step 3 - Tert-butyl N-[2-[2-[3-[3-methyl-1-(1-methyl-2.6-dioxo-3-piperidyl)-2-oxo-benzimidazol-4- yllpropoxylethoxylethyllcarbamate

[003831] To a solution of tert-butyl N-[2-[2-[3-[3-methyl-l-(l-methyl-2,6-dioxo-3-piperidyl)-2-oxo- benzimidazol-4-yl]prop-2-ynoxy]ethoxy]ethyl]carbamate (1.30 g, 2.02 mmol) in THF (20 mL) was added Pd/C (300 mg, 10% wt) and Pd(OH)2/C (300 mg, 10% wt). The reaction mixture was stirred at 25 °C for 10 hrs under ¾ (15 psi) atmosphere. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (1.30 g, 99% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 541.3 $(M+Na)^+$.

[003832] Step 4 - 3-r4-r3-r2-(2-Aminoethoxy)ethoxy1propyl1-3-methyl-2-oxo-benzimidazol-l-yll-l -methyl- piperidine-2.6-dione

[003833] To a solution of tert-butyl N-[2-[2-[3-[3-methyl-l-(l-methyl-2,6-dioxo-3-piperidyl)-2-oxo- benzimidazol-4-yl]propoxy]ethoxy]ethyl]carbamate (1.20 g, 1.85 mmol) in DCM (10 mL) was added HCl/dioxane (10 mL). The reaction mixture was stirred at 25 °C for 2 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (1.10 g, 98% yield, HC1 salt) as a yellow solid. LC-MS (ESI^+) *m/z* 419.2 $(M+H)^+$

[003834] Tertbutyl N-methyl-N-|3-(2-ninerazin- l-ylethoxy)cvclobutyl Icarbamate [Intermediate SW)



SW

[003835] Step 1 - Ethyl 2-r3-rtert-butoxycarbonyl(´methvOamino1cvclobutoxy1acetate

[003836] To a solution of ethyl 2-[3-(tert-butoxycarbonylamino)cyclobutoxy]acetate (5.00 g, 18 mmol, synthesized via Step 1 of Intermediate SJ) in DMF (50 mL) at 0 °C was added NaH (1.50 g, 36 mmol, 60% oil dispersion) and stirred at 0 °C for 0.5 hour. Then a solution of C¾I (3.10 g, 22 mmol) in DMF (5 mL) was added to the reaction mixture and stirred at 0 °C for 1 hour. On completion, the reaction mixture was quenched by H_20 (20 mL) at 0 °C, and then extracted with ethyl acetate (2 X 20 mL). The combined organic layers were washed with brine (2 X 25 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (5.00 g, 95% yield) as yellow oil. ^1H NMR (400MHz, DMSO^) δ 4.66 - 4.59 (m, 1H), 4.29 - 4.00 (m, 5H), 2.73 (s, 3H), 2.33 - 2.28 (m, 2H), 2.15 - 2.07 (m, 2H), 1.38 (s, 9H), 1.22 - 1.16 (m, 3H).

[003837] Step 2 - Tert-butyl N-r3-(2-hvdroxyethoxy)cvclobutyl1-N-methyl-carbamate

[003838] To a solution of ethyl 2-[3-[tert-butoxycarbonyl(methyl)amino]cyclobutoxy]acetate (2.50 g, 8.7 mmol) in THF (30 mL) was added $LiBH_4$ (0.57 g, 26mmol) at 0 °C, then the reaction mixture was stirred at 25 °C for 2 hour. On completion, the reaction mixture was quenched by water (20 mL) at 25 °C, and then extracted with ethyl acetate (2 X 30 mL). The combined organic layers were washed with brine (2 X 40 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (2.00 g, 93% yield) as colorless oil.

[003839] Step 3 - 2-r3-rTert-butoxycarbonyl(methvDamino1cvclobutoxy1ethyl

methanesulfonate

[003840] To a solution of tert-butyl N-[3-(2-hydroxyethoxy)cyclobutyl]-N-methyl-carbamate (2.00 g, 8.20 mmol) and Et_3N (1.7 g, 16 mmol) inDCM (20 mL) was added MsCl (1.40 g, 12 mmol), then the reaction mixture was stirred at 0 °C for 1 hour. On completion, the reaction mixture was quenched by water (25 mL) at 25 °C, and extracted with DCM (2 X 30 mL). The combined organic layers were washed with brine (2 X 40 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (2.50 g, 94% yield) as colorless oil.


[003841] Step 4 - Benzyl 4-[2-[3-[tert-butoxycarbonvKmethvDaminolcvclobutoxylethyllpiperazine- 1- carboxylate

[003842] To a solution of 2-[3-[tert-butoxycarbonyl(methyl)amino]cyclobutoxy]ethyl methanesulfonate (2.50 g, 7.70 mmol) and benzyl piperazine- 1-carboxylate (3.40 g, 15.0 mmol) in ACN (30 mL) was added Et_3N (2.4 g) and KI (1.50 g, 9.3 mmol), then the reaction mixture was stirred at 70 °C for 12 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo.* The crude product was purified by reverse phase HPLC (0.1% FA condition) to give the title compound (0.60 g, 16% yield) as a white solid. LC-MS (ESI^+) *m/z* 448.1 $(M+H)^+$.

[003843] Step 5 - Tertbutyl N-methyl-N-r3-(2-piperazin-l-ylethoxy)cvclobutyl1carbamate

[003844] To a solution of benzyl 4-[2-[3-[tert-butoxycarbonyl(methyl)amino]cyclobutoxy]ethyl]piperazine-l- carboxylate (0.60 g, 1.3 mmol) in MeOH (5 mL) was added Pd/C (60 mg, 10% wt), then the mixture was degassed and purged with Ih gas three times. The mixture was stirred at 25 °C for 2 hours under Ih atmosphere. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (0.40 g, 95% yield) as colorless oil.

[003845] 3-[3-Methyl-5-[[4-[2-[3-(methylamino)cyclobutoxy| ethyl]piperazin- 1-yl]methyl]-2-oxo- benzimidazol-l-yl]piperidine-2,6-dione [Intermediate SX)




[003846] Step 1 - Tert-butyl N-[3-[2-[4-[[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl methyllpiperazin-l-yllethoxyIcvclobutyll-N-methyl-carbamate

[003847] To a solution of l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazole-5-carbaldehyde (0.15 g, 0.52 mmol, Intermediate SK) and tertbutyl N-methyl-N-[3-(2-piperazin-l-ylethoxy)cyclobutyl] carbamate (0.16 g, 0.52 mmol, Intermediate SW) in a mixed solvent of THF (2 mL) and DMF (2 mL) was added $Ti(i\text{-}PrO)_4$ (0.22 g, 0.78 mmol) and stirred at 50 °C for 4 hour, then $NaBH(OAc)_3$ (0.22 g, 1.0 mmol) was added at 25 °C. The reaction mixture was stirred at 25 °C for 12 hours. On completion, the mixture was concentrated *in vacuo.* The crude product was purified by reverse phase HPLC (0.1% TFA condition) to give the title compound (40.0 mg, 8.7% yield) as colorless oil. LC-MS (ESI^+) *m/z* 585.4 $(M+H)^+$.

[003848] Step 2 - 3-[3-Methyl-5-[[4-[2-[3-(methylamino)cvclobutoxy1ethyl1piperazin-1-yllmethvH-2-oxo- benzimidazol-l-yl1piperidine-2.6-dione

[003849] To a solution of tert-butyl N-[3-[2-[4-[[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] methyl]piperazin-l-yl]ethoxy]cyclobutyl]-N-methyl-carbamate (30.0 mg, 51.3 umol) in TFA (1.5 mL) was added DCM (2 mL). The reaction mixture was stirred at 25 °C for 2 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (30.7 mg, 100% yield) as yellow oil. LC-MS (ESI^+) *m/z* 485.3 $(M+H)^+$.

[003850] **Tert-butyl N-(4-but-3-ynoxybutvBcarbamate [Intermediate SY)**



SY

[003851] Step 1 - l-bromo-4-but-3-vnoxy-butane

[003852] A mixture of but-3-yn-l-ol (40 g, 571 mmol, 43.2 mL, CAS# 927-74-2), 1,4-dibromobutane (185 g, 856 mmol, 103 mL, CAS# 110-52-1), CS2CO3 (204 g, 627 mmol) in acetone (500 mL) was degassed and purged with N_2 for 3 times. Then the mixture was stirred at 70 °C for 72 hrs under N_2 atmosphere. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was purified by silica gel chromatography to give the title compound (40.0 g, 34% yield) as colorless oil. ^{1}H NMR (400MHz, CDCb) δ 3.57 (t, *J* = 6.8 Hz, 2H), 3.52 (t, *J* = 6.2 Hz, 2H), 3.49 - 3.45 (m, 3H), 2.48 (dt, *j* = 2.8, 6.8 Hz, 2H), 2.08 - 2.04 (m, 1H), 2.03 - 1.96 (m, 2H), 1.80 - 1.71 (m, 2H).

[003853] Step 2 - 2-(4-But-3-vnoxybutvDisoindoline-L3-dione

[003854] To a solution of l-bromo-4-but-3-ynoxy-butane (27.0 g, 131 mmol) in DMF (300 mL) was added (l,3-dioxoisoindolin-2-yl)potassium (29.3 g, 158 mmol). The mixture was stirred at 60 °C for 6 hrs. On completion, 1500 mL H_20 was added to the mixture, and the mixture was extracted with EA (2 X 800 mL). The organic layer was washed with brine (300 mL), and then concentrated *in vacuo* to give the title compound (30.0 g, 84% yield) as white solid. 'H NMR (400MHz, CDCb) δ 7.87 - 7.83 (m, 2H), 7.75 - 7.70 (m, 2H), 3.73 (t, *J* = 7.2 Hz, 2H), 3.53 (td, *J* = 6.8, 19.2 Hz, 4H), 2.45 (dt, *J* = 2.8, 7.2 Hz, 2H), 1.98 (t, *J* = 2.8 Hz, 1H), 1.83 - 1.71 (m, 2H), 1.69 - 1.59 (m, 2H).

[003855] Step 3 - 4-But-3-ynoxybutan-l -amine


[003856] To a solution of 2-(4-but-3-ynoxybutyl)isoindoline-l,3-dione (50.0 g, 184 mmol)

in EtOH (1000 mL) was added $NH_2NH_2•H_2O$ (92.3 g, 1.84 mol, 89.6 mL). The mixture was stirred at 80 °C for 4 hrs. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (21.0 g, 31% yield) as colorless oil. ¾NMR (400MHz, CDCh) δ 3.49 (t, *J* = 7.2 Hz, 2H), 3.43 - 3.38 (m, 2H), 2.65 (t, *J* = 7.2 Hz, 2H), 2.39 (dt, *J* = 2.8, 6.8 Hz, 2H), 1.91 (t, *J* = 2.8 Hz, 1H), 1.89 (s, 2H), 1.60 - 1.52 (m, 2H), 1.49 - 1.40 (m, 2H).


[003857] Step 4 - Tert-butyl N-(4-but-3-ynoxybutvDcarbamate


[003858] To a solution of 4-but-3-ynoxybutan-l -amine (30.0 g, 212 mmol) in MeOH (300 mL) was added $(Boc)_20$ (69.6 g, 318 mmol, 73.2 mL). The mixture was stirred at 25 °C for 4 hrs. On completion, the mixture was concentrated *in vacuo.* The residue was purified by silica gel chromatography to give the title compound (50.0 g, 97% yield) as colorless oil. ^1H NMR (400MHz, CDCh) δ 4.68 (s, 1H), 3.57 (t, *J* = 6.8 Hz, 2H), 3.49 (t, *J* = 6.0 Hz, 2H), 3.20 - 3.11 (m, 2H), 2.48 (dt, *J* = 2.8, 6.8 Hz, 2H), 1.99 (t, *J* = 2.8 Hz, 1H), 1.68 - 1.59 (m, 4H), 1.46 (s, 9H).

[003859] **3-[3-methyl-5-[3-[(2R)-2-(methylaminomethyl)morpholin-4-yl]propyl]-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione [Intermediate** SZ)



TO





SZ

[003860] Step 1 - 3-[5-[3-[(2R)-2-[[(4-methoxyphenyl)methyl-methyl-

amino1methyl1morpholin-4-yl1prop-l- _ynyl1-3-methyl -2-oxo-benzi midazol-1 -yllpiperidine-2.6-dione

[003861] To a solution of l-(4-methoxyphenyl)-N-methyl-N-[[(2R)-4-prop-2-ynylmorpholin-2-yl]methyl] methanamine (900 mg, 3.12 mmol, Intermediate TO) and 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6 -dione (703 mg, 2.08 mmol, Intermediate HN) in DMF (20 mL) was added 4A molecular sieves (300 mg), $Pd(PPh_3)2Cl2$ (146 mg, 208 umol), CS2CO3 (2.71 g, 8.32 mmol) and Cul (39.6 mg, 208 umol). The reaction mixture was stirred at 80 °C for 2 hr under N2. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (1.10 g, 96% yield) as a yellow solid. LC-MS (ESI^+) m/z 546.4 $(M+H)^+$.


[003862] Step _2 _- _Tert-butyl _N-[[(2S)-4-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-S-yllpropyll morphohn-2-yl1methyl1-N-methyl-carbamate

[003863] To a solution of 3-[5-[3-[(2R)-2-[[(4-methoxyphenyl)methyl-methyl-amino]methyl]morpholin-4-yl] prop-l-ynyl]-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione (500 mg, 916 umol) in IPA (15 mL) and EA (30 mL) was added Pd(OH)2/C (200 mg, 10 wt%), Pd/C (200 mg, 10 wt%) and $(Boc)_20$ (300 mg, 1.37 mmol, 315 uL). The reaction mixture was stirred at 25 °C for 48 hr under Hh (50 psi). On completion, the residue was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (300 mg, 62% yield) as a yellow solid. ^1H NMR (400MHz, DMSO-i/e) δ 11.08 (s, 1H), 7.08 - 6.93 (m, 2H), 6.86 (d, J = 8.0 Hz, 1H), 5.75 (s, 1H), 5.33 (dd, J = 5.2, 12.8 Hz, 1H), 3.63 - 3.56 (m, 4H), 3.52 - 3.46 (m, 2H), 3.31 (s, 3H), 3.26 - 3.12 (m, 3H), 2.93 - 2.85 (m, 1H), 2.72 - 2.58 (m, 6H), 2.07 - 1.96 (m, 2H), 1.81 - 1.69 (m, 3H), 1.37 (s, 9H); LC-MS (ESI^+) m/z 530.3 $(M + H)^+$.

[003864] Step 3 - 3-[3-Methyl-5-[3-[(2R)-2-(methylaminomethyl)morpholin-4-yl1propyl1-2-oxo-benzimidazol - 1-yl1piperidine-2.6-dione

[003865] To a solution of tert-butyl N-[[(2S)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] propyl]morpholin-2-yl]methyl]-N-methyl -carbamate (300 mg, 566 umol) in DCM (8 mL) was added HCl/dioxane (4 M, 4 mL). The reaction mixture was stirred at 25 °C for 2 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (260 mg, 98% yield, HC1) as a white solid. LC-MS (ESI^+) m/z 430.2 $(M+H)^+$.

[003866] **tert-butyl_ 4-[3-[[3-(difluoromethvO-l-(4-formylphenvOpyrazol-4-yllcarbamoyllpyrazolo[l.,5-alpyrimidin-5-yllpiperazine-l-carboxylate [Intermediate TA)**



[003867] Step_ __1_ __-_ __Tert-butyl_ __4-r3-rr3-(difluoromethvO-l-(4-methoxycarbonylphenvnpyrazol-4-yllcarbamoyll ___pyrazoloTl_.5-a1pyrimidin-5-yl1piperazine-_1-

carboxylate

[003868] To a solution of methyl 4-[4-amino-3-(difluoromethyl)pyrazol-l-yl]benzoate (650 mg, 2.43 mmol, Intermediate FW), 5-(4-tertbutoxycarbonylpiperazin-l-yl)pyrazolo[l,5-a]pyrimidine-3-carboxylic acid (650 mg, 1.87 mmol, Intermediate RC) in ACN (15.0 mL) was added DIPEA (725 mg, 5.61 mmol), HATU (1.42 g, 3.74 mmol). The mixture was stirred at 60 °C for 16 hrs. On completion, the mixture was concentrated *in vacuo*. The mixture was purified by reverse phase: (0.1% FA) to give the title compound (700 mg, 62% yield) as yellow solid. ^{1}H NMR (400MHz, CDCh) δ 9.60 (s, 1H), 9.05 (s, 1H), 8.48 (s, 1H), 8.38 (d, *J* = 8.0 Hz, 1H), 8.17 (d, *J* = 8.8 Hz, 2H), 7.83 (d, *J* = 8.8 Hz, 2H), 7.09 - 6.76 (m, 1H), 6.46 (d, *J* = 8.0 Hz, 1H), 3.96 (s, 3H), 3.86 (s, 4H), 3.65 (s, 4H), 1.54 (s, 9H).

[003869] Step 2 - 4-[4-[[5-(4-Tert-butoxycarbonylpiperazin-l-yl)pyrazolo[1,5-a]pyrimidine-3-carbonyllaminol -3-(difluoromethvDpyrazol-l-vnbenzoic acid

[003870] To a solution of tert-butyl 4-[3-[[3-(difluoromethyl)-l-(4-methoxycarbonylphenyl)pyrazol-4-yl] carbamoyl]pyrazolo[l,5-a]pyrimidin-5-yl]piperazine-l-carboxylate (1.00 g, 1.68 mmol) in THF (40.0 mL) and H_20 (8 mL) was added LiOH (200 mg, 8.38 mmol). The mixture was stirred at 20 °C for 16 hrs. On completion, the mixture was concentrated *in vacuo*. The mixture was diluted with H_20 (30 mL), then the mixture was acidified with 1N HC1 solution until the pH = 5. The mixture was filtered and the filter cake was dried *in vauco* to give the title compound (900 mg, 92% yield) as yellow solid. ^{1}H NMR (400MHz, DMSO-d_6) δ 12.01 (s, 1H), 9.48 (s, 1H), 9.08 (s, 1H), 8.82 (d, *J* = 8.0 Hz, 1H), 8.32 (s, 1H), 8.07 (d, *J* = 8.8 Hz, 2H), 7.97 (d, *J* = 8.8 Hz, 2H), 7.52 - 7.16 (m, 1H), 6.89 (d, *J* = 8.0 Hz, 1H), 3.82 (s, 4H), 3.50 (s, 4H), 1.44 (s, 9H).

[003871] Step 3 - Tert-butyl 4-r3-rr3-(difhioromethvO-l-(4-isopropoxycarbonyloxycarbonylphenvD pyrazol-4-yl1carbamoyl1pyrazolorL5-a1pyrimidin-5-yllpiperazine- 1-carboxylate

[003872] To a solution of 4-[4-[[5-(4-tert-butoxycarbonylpiperazin-l-yl)pyrazolo[l,5-a]pyrimidine-3-carbonyl] amino]-3-(difluoromethyl)pyrazol-l-yl]benzoic acid (900 mg, 1.54 mmol), TEA (625 mg, 6.18 mmol) in THF (30.0 mL) was added isopropyl carbonochloridate (473 mg, 3.86 mmol) at -10 °C. The mixture was stirred at -10 °C for 1 hrs. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (1.00 g, 90% yield) as yellow solid. LC-MS (ESI$^+$) *m/z* 669.2 $(M+H)^+$.

[003873] Step 4 - Tert-butyl 4434r3Tdifhioromethv0-l-r4-(hvdroxymethvnphenyl1pyrazol-4-yl1carbamoyl1 pyrazolopl .5-a1pyrimidin-5-yl1piperazine- 1-carboxyl ate


[003874] To a solution of tert-butyl 4-[3-[[3-(difluoromethyl)-l-(4-isopropoxycarbonyloxycarbonylphenyl) pyrazol-4-yl]carbamoyl]pyrazolo[l,5-a]pyrimidin-5-yl]piperazine-l-carboxylate (1.00 g, 1.50 mmol) in THF (50.0 mL) and H_20 (10.0 mL) was added $LiBH_4$ (195 mg, 8.97 mmol) at 0 °C. The mixture was stirred at 0 °C for 1 hr. On completion, the mixture was quenched with H_20 (10 mL), then extracted with DCM (2 X 30 mL). The organic layers were dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The mixture was triturated with DCM (5 mL) to give the title compound (700 mg, 82% yield) as yellow solid. ^1H NMR (400MHz, DMSO-^e) δ 9.49 (s, 1H), 8.98 (s, 1H), 8.85 (d, *J* = 8.0 Hz, 1H), 8.33 (s, 1H), 7.80 (d, *J* = 8.4 Hz, 2H), 7.48 (d, *J* = 8.4 Hz, 2H), 7.34 - 6.96 (m, 1H), 6.91 (d, *J* = 8.0 Hz, 1H), 5.35 - 5.24 (m, 1H), 4.56 (d, *j* = 4.4 Hz, 2H), 3.84 (s, 4H), 3.50 (s, 4H), 1.45 (s, 9H).

[003875] Step 5 - Tert-butyl 4-r3-rr3-(difluoromethvD-l-(4-formylphenvDpyrazol-4-yllcarbamoyllpyrazolo [1,5-a1pyr midin-5-yl1piperazine-l-carboxylate

[003876] To a solution of tert-butyl 4-[3-[[3-(difluoromethyl)-l-[4-(hydroxymethyl)phenyl]pyrazol-4-yl] carbamoyl]pyrazolo[l,5-a]pyrimidin-5-yl]piperazine-l-carboxylate (700 mg, 1.23 mmol) in THF (30.0 mL) was added DMP (626 mg, 1.48 mmol). The mixture was stirred at 20 °C for 1 hr. On completion, the mixture was quenched with saturated $Na_2S_20_3$ (30 mL) and washed with saturated $NaHC0_3$ (2 X 30 mL). The organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (680 mg, 90% yield) as yellow solid. ¾ NMR (400MHz, DMSO-^e) δ 10.04 (s, 1H), 9.52 (s, 1H), 9.17 (s, 1H), 8.86 (d, *j* = 8.0 Hz, 1H), 8.35 (s, 1H), 8.15 - 8.10 (m, 2H), 8.09 - 8.03 (m, 2H), 7.54 - 7.23 (m, 1H), 6.96 - 6.86 (m, 1H), 3.85 (s, 4H), 3.51 (s, 4H), 1.45 (s, 9H).

[003877] **2-|(E)-2-[l-[2,6-Dioxo-3-piperidvB-3-methyl-2-oxo-benzimidazol-5-**

yl]vinyloxy]ethyl methanesulfonate (Intermediate TB)



[003878] Step _1_ - 3-r5-r(E)-2-(2-Hvdroxyethoxy)vinyl1-3-methyl-2-oxo-benzimidazol-l-yl1piperidine-2.6-dione


[003879] To a solution of 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (1.00 g, 2.96 mmol, Intermediate HN), 2-vinyloxyethanol (782 mg, 8.88 mmol, CAS# 764-48-7) in dioxane (25 mL) was added $P(t\text{-}Bu)_3$ toluene solution (2.08 mL, 591 umol, 10 wt%), $Pd_2(dba)3$ (542 mg, 591 umol) and DIPEA (497 mg, 3.84 mmol) under N_2. The mixture was stirred at 25 °C for 16 hours. On completion, the mixture was concentrated *in vacuo*. The residue was purified by silica gel column to give the title compound (500 mg, 49% yield) as yellow solid. ^1H NMR (400MHz, DMSO-^e) δ 11.08 (s, 1H), 7.25 - 7.19 (m, 1H), 7.19 - 7.09 (m, 1H), 6.99 (d, *J* = 8.4 Hz, 1H), 6.95 - 6.90 (m, 1H), 6.35 (d, *J* = 7.2 Hz, 1H), 5.88 *(d, J* = 12.8 Hz, 1H), 5.38 - 5.29 (m, 1H), 5.25 (d, *J* = 7.2 Hz, 1H), 3.99 - 3.83 (m, 1H), 3.85 (t, *J* = 5.2 Hz, 1H), 3.69 - 3.61 (m, 2H), 3.39 (s, 3H), 2.97 - 2.82 (m, 1H), 2.66 - 2.58 (m, 1H), 2.53 *(d, J* = 1.6 Hz, 1H), 2.06 - 1.99 (m, 1H).

[003880] Step _2_-_2-rfE)-2-rl-(2.6-Dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yllvinyloxylethyl methanesulfonate

[003881] To a solution of 3-[5-[(E)-2-(2-hydroxyethoxy)vinyl]-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione (750 mg, 2.l7mmol) in DCM (100 mL) was added TEA (659 mg, 6.52 mmol) and MsCl (373 mg, 3.26 mmol) at 0 °C. The reaction mixture was stirred at

25 °C for 2 hours. On completion, the reaction mixture was poured into water (30 mL) and extracted with DCM (2 X 100 mL). The combined organic layers were washed with brine (80 mL) and sat. aq. $NaHCO_3$ (2 X 70 mL), dried with anhydrous Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (800 mg, 70% yield, 75% purity) as a brown solid. LC-MS (ESI^+) m/z 423.9 $(M+H)^+$.

[003882] **3-[5-[2-[2-[(2S)-2-(Aminomethyl)morpholin-4-yl]ethoxy]ethyl]-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione [Intermediate TO**



[003883] Step_1_-_Tert-butylN-rr(2S)-4-r2-r(E)-2-r i-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5- vl] vinyl oxy1ethyl1morpholin-2-yl1methyl1carbamate

[003884] To a solution of 2-[(E)-2-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]vinyloxy]ethyl methanesulfonate (350 mg, 827 umol, Intermediate TB), tert-butyl N-[[(2R)-morpholin-2-yl]methyl]carbamate (268 mg, 1.24 mmol, CAS# 186202-57-3) in DMF (5 mL) was added DIPEA (320 mg, 2.48 mmol) at 20 °C. The mixture was stirred at 110 °C for 1 hour. On completion, the mixture was concentrated *in vacuo*. The mixture was purified by prep-HPLC (reverse phase: 0.1% FA) to give the title compound (270 mg, 60% yield) as a yellow solid. ^1H NMR (400MHz, CDCh) δ 8.28 (s, 1H), 6.97 - 6.82 (m, 2H), 6.82 - 6.69 (m, 1H), 6.12 (d,

J = 7.2 Hz, 1H), 5.95 (d, 7=12.8 Hz, 1H), 5.43 (d, *J* = 7.1 Hz, 1H), 5.26 - 5.18 (m, 1H), 4.89 (s, 1H), 4.39 - 4.18 (m, 2H), 4.06 (d, *J* = 7.2 Hz, 2H), 3.98 - 3.87 (m, 1H), 3.68 - 3.54 (m, 2H), 3.46 - 3.43 (m, 3H), 3.41 - 3.36 (m, 2H), 3.33 - 3.24 (m, 2H), 2.99 - 2.91 (m, 2H), 2.87 - 2.81 (m, 1H), 2.79 - 2.75 (m, 1H), 2.74 - 2.68 (m, 1H), 2.31 - 2.21 (m, 1H), 1.47 (s, 9H).


[003885] Step 2 - Tert-butyl N-[[(2S)-4-[2-[2-П-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5- νl] ethoxy1ethyl1morpholin-2-yl1methyl1carbamate

[003886] To a solution of tert-butyl N-[[(2S)-4-[2-[(E)-2-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo -benzimidazol-5-yl]vinyloxy]ethyl]morpholin-2-yl]methyl]carbamate (270 mg, 496 umol) in THF (20 mL) was added Pd/C (50.0 mg, 10 wt%) and $Pd(OH)_2/C$ (50.0 mg, 10 wt%) at 25 °C. The mixture was stirred at 25 °C for 2 hours under H_2 (15 psi). On competion, the mixture was filtered. The filtrate was concentrated *in vacuo.* The mixture was purified by prep-HPLC (reverse phase: 0.l%FA) to give the title compound (150 mg, 30% yield) as a yellow solid. ^1H NMR (400MHz, DMSO-de) δ 11.10 (s, 1H), 7.09 (s, 1H), 7.04 - 6.94 (m, 2H), 6.65 (s, 1H), 5.37 - 5.33 (m, 1H), 3.68 (s, 3H), 3.65 - 3.59 (m, 4H), 3.34 (s, 3H), 3.04 - 2.93 (m, 4H), 2.91 - 2.79 (m, 4H), 2.75 - 2.70 (m, 1H), 2.66 - 2.61 (m, 1H), 2.55 - 2.53 (m, 1H), 2.04 - 1.96 (m, 1H), 1.78 - 1.75 (m, 2H), 1.36 (s, 9H).

[003887] Step 3 - 3-[5-[2-[2-[(2S)-2-(Aminomethvl)morpholin-4-yl1ethoxy1ethyl1-3-methyl-2-oxo -benzimidazol-1 -yl]piperi dine-2.6-di one

[003888] To a solution of tert-butyl N-[[(2S)-4-[2-[2-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol -5-yl]ethoxy]ethyl]morpholin-2-yl]methyl]carbamate (100 mg, 184 umol) in DCM (2 mL) was added TFA (1 mL) at 15 °C. The mixture was stirred at 15 °C for 2 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (80.0 mg, 98% yield, TFA salt) as a white solid. LC-MS (ESI^+) m/z 446.3 $(M+H)^+$.

[003889] 3-[6-[3-[2-[2-[Methylamino)ethoxy1ethoxy1propyl1-2-oxo-l,3-benzoxazol-3-yl]piperidine- 2,6-dione [Intermediate TF)



[003890] Step 1 - Tert-butyl N-[2-[2-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-1,3-benzoxazol-6-yl]prop-2-ynoxy] ethoxylethyll-N-methyl-carbamate

[003891] A mixture of tert-butyl N-methyl-N-[2-(2-prop-2-ynoxyethoxy)ethyl]carbamate (427 mg, 1.66 mmol, Intermediate FY), 3-(6-bromo-2-oxo-l,3-benzoxazol-3-yl)piperidine-2,6-dione (300 mg, 923 umol, Intermediate OZ), 4Å molecular sieves (40 mg), $Pd(PPh_3)_2Cl_2$ (129 mg, 185 umol), Cul (35.2 mg, 184 umol) and Cs_2CO_3 (1.50 g, 4.61 mmol) in DMF (10 mL) was de-gassed and then heated at 80 °C for 2 hrs. On completion, the reaction mixture was concentrated *in vacuo*. The crude product was purified by reversed-phase HPLC (0.1% FA condition) to give the title compound (280 mg, 61% yield) as yellow oil. LC-MS (ESI^+) *m/z* 524.3 $(M+Na)^+$.

[003892] Step 2 - Tert-butyl N-[2-[2-[3-[3(2,6-dioxo-3-piperidyl)-2-oxo-1,3-benzoxazol-6-yllpropoxylethoxyl thyll-N-methyl-carbamate


[003893] To a solution of tert-butyl-[2-[2-[3-[3-(2,6-dioxo-3-piperidyl)-2-xo-l,3-benzoxazol-6-l]prop-2- noxy]ethoxyethyl]-N-methyl-carbamate (280 mg, 558 umol) in THF (20 mL) was added Pd/C (50 mg, 10% *wi)* and Pd(OH)2/C (50 mg, 10% *wf)* under N_2 atmosphere. The

suspension was degassed under vacuum and purged with H_2 several times. The reaction mixture was stirred at 25 °C for 4 hrs under H_2 (15 psi). On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (150 mg, 53% yield) as yellow oil. ^1H NMR (400 MHz, DMSO-^e) δ 11.19 (s, 1H), 7.25 - 7.23 (m, 1H), 7.15 - 7.11 (m, 1H), 7.03 (d, *J* = 7.6 Hz, 1H), 5.34 (dd, *J* = 5.2, 12 Hz, 1H), 3.5 - 3.48 (m, 4H), 3.42 - 3.39 (m, 2H), 3.37 - 3.35 (m, 3H), 3.31 - 3.27 (m, 4H), 2.81 - 2.80 (m, 2H), 2.69 - 2.61 (m, 1H), 2.63 - 2.61 (m, 2H), 2.13 - 2.10 (m, 1H), 1.80 - 1.75 (m, 2H), 1.37 (s, 9H); LC-MS (ESI+) m/z 528.3 $(M+Na)^+$.

[003894] Step 3 - 3-r6-r3-r2-r2-(Methylamino)ethoxy1ethoxy1propyl1-2-oxo-l.3-benzoxazol-3-vnpiperidine- 2.6-dione

[003895] To a solution of tert-butyl N-[2-[2-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-l,3-benzoxazol-6-yl]propoxy] ethoxy]ethyl]-N-methyl-carbamate (140 mg, 277 umol) in DCM (3 mL) was added TFA (2 mL). The mixture was stirred at 25 °C for 2 hrs under N_2 atmosphere. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (11.9 mg, 39% yield) as white solid. LC-MS (ESI+) m/z 406.2 $(M+H)^+$.

[003896] 3-[6-[3-[3-(Methylamino)propoxyl propyll pyrido [2,3-bl indol-9-yll piperidine-2,6-dione [Intermediate TH)



[003897] Step 1 - tert-butyl (3-((3-(9-(2,6-dioxopiperidin-3-yl)-9H-pyrido[2,3-b]indol-6-yl)prop-2-yn-1-yl)oxy)propyl)(methyl)carbamate

[003898] A mixture of 3-(6-bromo-9H-pyrido[2,3-b]indol-9-yl)piperidine-2,6-dione (100 mg, 0.279 mmol, Intermediate UH), tert-butyl methyl(3-(prop-2-yn-1-yloxy)propyl)carbamate (190 mg, 0.838 mmol, Intermediate UI), $Pd(PPh_3)_2Cl_2$ (30 mg, 0.0419 mmol), CuI (4 mg, 0.0223 mmol), Cs_2CO_3 (455 mg, 1.40 mmol), 4Å MS (200 mg) and DMF (5 mL) was heated to 80 °C under microwave for 1.5 h under N_2. The mixture was then poured into 1N HCl (20 mL), then extracted with EA (3 x 20 mL). The organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered, concentrated and purified by column chromatography on silica gel (PE/EA = 10/1 to 5/1 to 2/1) to give the title compound (50 mg, 35% yield) as a white solid. ^1H NMR (400 MHz, $CDCl_3$) δ 8.57 (d, J = 7.2 Hz, 1H), 8.46 (dd, J = 1.2 Hz, J = 5.6 Hz, 1H), 8.25 (d, J = 1.2 Hz, 1H), 8.13 (s, 1H), 7.65 (dd, J = 1.6 Hz, J = 4.0 Hz, 1H), 7.25-7.19 (m, 2 H), 5.90 (dd, J = 2.8 Hz, J = 6.0 Hz, 1H), 4.41 (s, 2H), 3.63 (t, J = 6.4 Hz, 2H), 3.34 (t, J = 7.2 Hz, 2H), 3.02-2.91 (m, 3H), 2.89 (s, 3H), 2.50-2.47 (m, 1H), 1.88 (t, J = 6.8 Hz, 2H), 1.46 (s, 9H). LC/MS (ESI, *m/z):* $[M+1]^+$ = 505.2.

[003899] Step 2 - tert-butyl (3-((3-(9-(2,6-dioxopiperidin-3-yl)-9H-pyrido[2,3-b]indol-6-yl)propoxy)propyl)(methyl)carbamate


[003900] A mixture of tert-butyl (3-((3-(9-(2,6-dioxopiperidin-3-yl)-9H-pyrido[2,3-b]indol-6-yl)prop-2-yn-1-yl)oxy)propyl)(methyl)carbamate (320 mg, 0.634 mmol), Pd/C (320 mg) and EA (10 mL) was stirred for overnight at rt under H_2. The mixture was filtered, concentrated and purified by column (PE/EA = 1/1) to give the title product (170 mg, 53 % yield) as a white solid. ^1H NMR (400 MHz, $CDCl_3$) δ 8.41 (dd, J = 1.6 Hz, J = 4.8 Hz, 1H), 8.32 (d, J = 7.6 Hz, 1H), 8.15 (s, 1H), 7.91 (d, J = 0.8 Hz, 1H), 7.33 (dd, J = 1.2 Hz, J = 8.0 Hz, 1H), 7.22-7.16 (m, 2H), 5.94 (br s, 1H), 3.45 (dd, J = 6.4 Hz, J = 11.6 Hz, 4H), 3.13 (t, J = 5.8 Hz, 2H), 3.07-2.95 (m, 3H), 2.88-2.84 (m, 5H), 2.33-2.29 (m, 1H), 2.01-1.93 (m, 2H), 1.85-1.78 (m, 2H), 1.46 (s, 9H). LC/MS (ESI, *m/z):* $[M-BOC+H]^+$ = 409.2 and [M-56+H] = 453.2.

[003901] Step 3 - 3-[6-[3-[3-(Methylamino)propoxy]propyl]pyrido[2,3-b]indol-9-yl]piperidine-2,6-dione

[003902] To a solution of tert-butyl N-[3-[3-[9-(2,6-dioxo-3-piperidyl)pyrido[2,3-b]indol-6-yl]propoxy]propyl]- N-methyl-carbamate (85.0 mg, 167 umol) in DCM (6 mL) was added TFA (381 mg, 3.34 mmol). The mixture was stirred at 25 °C for 2 hrs. On completion, the reaction

mixture was concentrated *in vacuo* to give the title compound (87 mg, 95% yield, TFA salt) as light yellow oil. LC-MS (ESI^+) *m/z* 409.3 $(M+H)^+$.


[003903] **2-(2-Pron-2-vnoxyethoxy)ethyl 4-methylbenzenesulfonate [Intermediate TI)**



LC TI

[003904] To a solution of 2-(2-prop-2-ynoxyethoxy)ethanol (2.00 g, 13.8 mmol, Intermediate LC), TEA (4.21 g, 41.6 mmol) and DMAP (170 mg, 1.39 mmol) in DCM (60 mL) was added 4-methylbenzenesulfonyl chloride (5.29 g, 27.7 mmol) at 0 °C. The mixture was then stirred at 25 °C for 16 hours. On completion, the mixture was washed with 2.0 M aq.HCl (20 mL) and brine (20 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel to give the title compound (3.40 g, 82% yield) as light yellow oil. ^{1}HNMR (400 MHz, CDCh) δ 7.81 (d, *J* = 8.4 Hz, 2H), 7.35 (m, *j* = 8.0 Hz, 2H), 4.23 - 4.14 (m, 4H), 3.73 - 3.68 (m, 2H), 3.67 - 3.59 (m, 4H), 2.46 (s, 3H), 2.44 (t, *J* = 2.4 Hz, 1H).

[003905] **N-[6-n-hvdroxy-l-methyl-ethvD-2H-indazol-5-yll-6-(trifluoromethvPpyridiiie-2- carboxamide [Intermediate TJ)**



TJ

[003906] Step 1 - Methyl 5-nitro-lH-indazole-6-carboxylate

[003907] To a solution of methyl lH-indazole-6-carboxylate (10.0 g, 56.7 mmol) in H2SO4 (100 mL) was added a solution of HNO3 (12.1 g, 125 mmol, 65% purity) in H2SO4 (20 mL) at -l0-0°C during 30 minutes. The mixture was stirred at -l0-0°C for 1 hour. On completion, the mixture was poured into ice/water (1.0 L) slowly. The mixture was filtered and the filter cake was washed with water (2 X 200 mL). Then the cake was collected and dried *in vacuo* to give the title

compound (11.9 g, 94% yield) as yellow solid. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.69 (s, 1H), 8.44 (s, 1H), 7.97 (s, 1H), 3.86 (s, 3H).

[003908] Step 2 - Methyl 5-amino-lH-indazole-6-carboxylate

[003909] To a solution of methyl 5-nitro-lH-indazole-6-carboxylate (10.9 g, 49.2 mmol) in MeOH (100 mL) and THF (60 mL) was added a solution of NH_4Cl (26.3 g, 492 mmol) in H_20 (100 mL) at 25 °C. Then Fe (13.7 g, 245 mmol) was added to the mixture in portions at 70 °C, and the mixture was stirred at 70 °C for 1 hour. On completion, the mixture was filtered and the filter cake was washed with EA (200 mL). The filtrate was concentrated *in vacuo.* The residue was washed with water (100 mL), and extracted with EA (3 X 100 mL). The combined organic layer was washed with brine (100 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo* to the title compound (7.30 g, 77% yield) as yellow solid. ^{1}H NMR (400 MHz, DMSO-^e) δ 12.82 (s, 1H), 7.99 (s, 1H), 7.85 (s, 1H), 6.99 (s, 1H), 6.00 (s, 2H), 3.85 (s, 3H).

[003910] Step 3 - Methyl 5-[[6-(trifluoromethyl)pyridine-2-carbonyl]amino]-1H-indazole-6-carboxylate


[003911] To a solution of methyl 5-amino-lH-indazole-6-carboxylate (7.20 g, 37.6 mmol), 6-(trifluoromethyl)pyridine-2-carboxylic acid (6.48 g, 33.9 mmol, CAS# 131747-42-7) and DIPEA (7.35 g, 56.8 mmol) in THF (70 mL) was added T_3P (47.9 g, 44.8 mL, 50 wt%) slowly at 0 °C. Then the mixture was stirred at 0-5°C for 2 hours. On completion, the reaction was quenched with cold water (0.1 mL). The mixture was diluted with water (280 mL), and stirred at 25 °C for 0.5 hour. The mixture was filtered and the filter cake was washed with water (30 mL). The filter cake was collected and dried *in vacuo* to give the title compound (12.3 g, 99% yield) as yellow solid. ^{1}H NMR (400 MHz, DMSO-i&) δ 12.58 (s, 1H), 9.15 (s, 1H), 8.47 (d, J = 7.6 Hz, 1H), 8.39 (t, j = 7.6 Hz, 1H), 8.30 (s, 1H), 8.25 (s, 1H), 8.20 (d, j = 8.0 Hz, 1H), 3.97 (s, 3H).

[003912] Step 4 - N-[6-(1-hydroxy-1-methyl-ethyD-2H-indazol-5-yn-6-(trifluoromethvnpyridine-2- carboxamide

[003913] To a solution of methyl 5-[[6-(trifluoromethyl)pyridine-2-carbonyl]amino]-lH-indazole-6-carboxylate (4.00 g, 10.9 mmol) in THF (40 mL) was added MeMgBr-Et_20 solution (3.0 M, 29.3 mL) slowly at 0°C. The mixture was stirred at 0 - 25 °C for 16 hours. On completion, the reaction was quenched with sat.MLCl (40 mL) slowly at 0 - 10 °C. The mixture was extracted with EA (3 X 40 mL). The combined organic layer was concentrated *in vacuo.* The residue was purified by reverse phase chromatography (FA condition) to give the title compound (1.50 g, 37%


yield) as light yellow solid. ^{1}H NMR (400 MHz, CDCh) δ 12.23 (s, 1H), 8.96 (s, 1H), 8.52 (d, *J* = 7.6 Hz, 1H), 8.12 (t, *j* = 7.6 Hz, 1H), 8.07 (s, 1H), 7.85 (d, *j* = 7.6 Hz, 1H), 7.50 (s, 1H), 1.80 (s, 6H).

[003914] **N-[6-(l-hydroxy-l-methyl-ethy0-2-[2-(2-prop-2-ynoxyethoxy)ethyllindazol-5-yll-6-(trifluoromethy0pyridine-2-carboxamide [Intermediate TK)**



[003915] To a solution of N-[6-(l-hydroxy-l-methyl-ethyl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine -2-carboxamide (300 mg, 823 umol, Intermediate TJ) and DIPEA (532 mg, 4.12 mmol) in toluene (10 mL) was added a solution of 2-(2-prop-2-ynoxyethoxy)ethyl 4-methylbenzenesulfonate (983 mg, 3.29 mmol, Intermediate TI) in toluene (5 mL) at 110 °C during 1 hour. Then, the mixture was stirred at 110 °C for 35 hours. On completion, after cooled to 25°C, the mixture was concentrated *in vacuo.* The residue was purified by column chromatography on silica gel to give the title compound (130 mg, 32% yield) as light yellow oil. ^{1}H NMR (400 MHz, CDCh) δ 12.26 (s, 1H), 8.83 (s, 1H), 8.47 (d, *j* = 8.0 Hz, 1H), 8.08 (t, *j* = 8.0 Hz, 1H), 8.00 (s, 1H), 7.82 (m, *J* = 7.6 Hz, 1H), 7.67 (s, 1H), 4.57 (t, *J* = 5.2 Hz, 2H), 4.16 (d, *J* = 2.4 Hz, 2H), 3.97 (t, *J* = 5.2 Hz, 2H), 3.66 - 3.58 (m, 4H), 2.47 (t, *J* = 2.4 Hz, 1H), 1.79 (s, 6H).

[003916] **3-[6-[3-[2-(2-Aminoethoxy)ethoxyl propyl]pyrido[2,3-b]indol-9-yll piperidine-2,6-dione [Intermediate TL)**



[003917] Step 1 - tert-butyl (2-(2-((3-(9-(2,6-dioxopiperidin-3-yl)-9H-pyrido[2,3-b]indol-6-yl)prop-2-yn-1-yl)oxy)ethoxy)ethyl)carbamate

[003918] A mixture of 3-(6-bromo-9H-pyrido[2,3-b]indol-9-yl)piperidine-2,6-dione (600 mg, 1.68 mmol, Intermediate UH), tert-butyl (2-(2-(prop-2-yn-1-yloxy)ethoxy)ethyl)carbamate (1.2 g, 5.03 mmol, Intermediate IT), $Pd(PPh_3)_2Cl_2$ (179 mg, 0.252 mmol), CuI (26 mg, 0.134 mmol), Cs_2CO_3 (5.5 g, 16.8 mmol), 4Å MS (1 g) and DMF (10 mL) was heated to 80 °C under microwave for 1.5 h under N_2. The mixture was then poured into 1N HCl (400 mL), and extracted with EA (100 mL). The organic layer was washed with brine (30 mL), dried over Na_2SO_4, filtered, concentrated and purified by column (PE/EA = 10/1 to 5/1 to 2/1) to give the title compound (250 mg, 29 % yield) as a white solid. ^1H NMR (400 MHz, $CDCl_3$) δ 8.45 (dd, J = 1.2 Hz, J = 4.8 Hz, 1H), 8.34 (dd, J = 1.2 Hz, J = 7.6 Hz, 1H), 8.21 (d, J = 0.8 Hz, 1H), 8.15 (s, 1H), 7.59 (dd, J = 1.2 Hz, J = 8.4 Hz, 1H), 7.27-7.22 (m, 2H), 5.95 (br s, 1H), 5.01 (br s, 1H), 4.47 (s, 2H), 3.81-3.79 (m, 2H), 3.71-3.69 (m, 2H), 3.58 (t, J = 5.2 Hz, 2H), 3.33-3.34 (m, 2H), 3.09-2.96 (m, 2H), 2.35-2.31 (m, 1H), 2.02-1.99 (m, 1H), 1.44 (s, 9H). LC/MS (ESI, *m/z):* $[M-Boc+1]^+$ = 421.3.

[003919] Step 2 - tert-butyl (2-(2-(3-(9-(2,6-dioxopiperidin-3-yl)-9H-pyrido[2,3-b]indol-6-


vDpropoxy)ethoxy)ethvDcarbamate

[003920] A mixture of tert-butyl (2-(2-((3-(9-(2,6-dioxopiperidin-3-yl)-9H-pyrido[2,3-b]indol-6-yl)prop-2-yn-l-yl)oxy)ethoxy)ethyl)carbamate (250 mg, 0.481 mmol), Pd/C (100 mg) and EA (15 mL) was stirred for overnight at rt under H_2. The mixture was filtered, concentrated and purified by column (PE/EA = 1/1) to give the title compound (150 mg, 60% yield) as a white solid. ^{1}H NMR (400 MHz, CDCh) δ 8.41 (dd, *J* = 1.2 Hz, *J* = 4.8 Hz, 1H), 8.31 (dd, *J* = 1.6 Hz, *J* = 7.6 Hz, 1H), 8.22 (s, 1H), 7.92 (d, *J* = 0.8 Hz, 1H), 7.33 (dd, 7 = 1.6 Hz, 7 = 8.4 Hz, 1H), 7.21-7.16 (m, 2H), 5.92-5.88 (m, 1H), 5.04 (br s, 1H), 3.64-3.50 (m, 8H), 3.33 (d, *J* = 4.8 Hz, 2H), 3.08-2.85 (m, 5H), 2.32-2.28 (m, 1H), 2.04-1.97 (m, 2H), 1.43 (s, 9H); LC/MS (ESI, *m/z):* [M - Boc +l] $^+$ = 425.2.

[003921] Step 3 - 3-r6-r3-r2-(2-Aminoethoxy)ethoxy1propyl1pyridor2.3-b1indol-9-yl1piperidine-2.6-dione

[003922] To a solution of tert-butyl N-[2-[2-[3-[9-(2,6-dioxo-3-piperidyl)pyrido[2,3-b]indol-6-yl]propoxy] ethoxy]ethyl]carbamate (54.0 mg, 102 umol) in DCM (3 mL) was added TFA (352 mg, 3.09 mmol). The mixture was stirred at 25 °C for 1 hr. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (55.0 mg, 95% yield, TFA salt) as light yellow oil. LC-MS (ESI$^+$) *m/z* 425.3 $(M+H)^+$.

[003923] **Step 1 - Tert-butyl 4-prop-2-vnoxypiperidine-l-carboxylate [Intermediate TM)**




TM

[003924] To a solution of tert-butyl 4-hydroxypiperidine-l-carboxylate (2.00 g, 9.94 mmol, CAS# 109384-19-2) in anhydrous THF (10 mL) was cooled to 0 °C, and subsequently NaH (477 mg, 11.9 mmol, 60% oil dispersion) was added. The reaction mixture was stirred at 0 °C for 0.5 hr. Then, 3-bromoprop-l-yne (1.18 g, 9.94 mmol, 856 uL) was added. The resulting reaction mixture was stirred at 25 °C for 12 hrs. On completed, the reaction mixture was quenched with water (1 mL), then diluted with ethyl acetate (100 mL). The organic layers were washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated *in vacuo.* The residue was purified by column chromatography to give the title compound (2.38 g, 100%

yield) as yellow oil. ^{1}H NMR (400MHz, CDCb) δ 4.22 (d, *J* = 2.4 Hz, 2H), 3.84 - 3.75 (m, 2H), 3.73 - 3.70 (m, 1H), 3.15 - 3.09 (m, 2H), 2.43 (t, *J* = 2.4 Hz, 1H), 1.93 - 1.82 (m, 2H), 1.61 - 1.50 (m, 2H), 1.47 (s, 9H).

[003925] **3-[3-Methyl-2-oxo-4-[3-(4-piperidyloxy)propyl1benzimidazol-l-yl1piperidine-2,6-dione [Intermediate TN)**



[003926] Step **1** - Tert-butyl **4-**[**3-**[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-**4-**νιιρΓθρ-**2-**νηοχν] piperidine-l-carboxylate

[003927] A suspension of 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (300 mg, 887 umol, Intermediate HP), tert-butyl 4-prop-2-ynoxypiperidine-l-carboxylate (318 mg, 1.33 mmol, Intermediate TM), Pd(PPh3)$_2$Cl2 (124 mg, 177 umol), Cul (33.8 mg, 177 umol), 4Å molecular sieves (400 mg) and CS2CO3 (1.16 g, 3.55 mmol) in DMF (5 mL) was de-gassed under vacuum and purged with N2 several times and then heated to 80 °C for 2 hours under N_2. On completion, the reaction mixture was concentrated *in vacuo* to remove DMF. The residue was diluted with EA (50 mL) and water (20 mL). After, the organic layer was separated and washed with brine (5 mL X 2), dried over anhydrous Na_2S0_4, filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase to give the title compound (222

mg, 48% yield) as a yellow solid. ^{1}H NMR (400MHz, CDCb) δ 8.09 (s, 1H), 7.10 (d, *J* = 8.0 Hz, 1H), 6.92 (t, *j* = 8.0 Hz, 1H), 6.69 (d, *j* = 8.0 Hz, 1H), 5.13 (dd, *j* = 5.2, 12.8 Hz, 1H), 4.39 (s, 2H), 3.76 - 3.66 (m, 6H), 3.09 - 3.03(m, 2H), 2.94 - 2.84 (m, 1H), 2.82 - 2.71 (m, 1H), 2.71 - 2.59 (m, 1H), 2.22 - 2.11 (m, 1H), 1.83 - 1.78 (m, 2H), 1.57 - 1.49 (m, 2H), 1.39 (s, 9H), LC-MS (ESI$^+$) *m/z* 441.2 (M+H-56) $^+$.


[003928] Step 2 - Tert-butyl4-r3-n -(2.6-dioxo-3-piperidyl)-3-methyl -2-oxo-benzi midazol-4-yllpropoxyl piperidine- 1-carboxylate

[003929] To a solution of tert-butyl 4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]prop- 2-ynoxy]piperi dine- 1-carboxylate (370 mg, 745 umol) in THF (10 mL) was added Pd/C (0.1 g, 10% *wf)* and $Pd(OH)_2$/C (0.1 g, 10% *wf).* The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 12 hours. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (330 mg, 88% yield) as a white solid. ^{1}H NMR (400MHz, CDCb) δ 8.03 (s, 1H), 6.91 (d, *j* = 8.0 Hz, 1H), 6.83 (d, *J* = 8.0 Hz, 1H), 6.59 (t, *J* = 8.0 Hz, 1H), 5.20 - 5.09 (m, 1H), 3.70 - 3.64 (m, 2H), 3.62 (s, 3H), 3.44 (t, *J* = 5.6 Hz, 2H), 3.41 - 3.34 (m, 1H), 3.06 - 3.04(m, 2H), 2.98 - 2.93 (m, 2H), 2.91 - 2.80 (m, 1H), 2.79 - 2.63 (m, 2H), 2.19 - 2.10 (m, 1H), 1.89 - 1.81 (m, 2H), 1.80 - 1.73 (m, 2H), 1.47 - 1.39 (m, 2H), 1.39 (s, 9H); LC-MS (ESI$^+$) *m/z* 523.1 (M+Na) $^+$.

[003930] Step 3 - 3-r3-Methyl-2-oxo-4-r3-(4-piperidyloxy)propyl1benzimidazol-l-yl1piperidine-2.6-dione

[003931] To a solution of tert-butyl 4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]propoxy] piperidine- 1-carboxylate (100 mg, 199 umol) in DCM (4 mL) was added HCl/dioxane (4 M, 2 mL). The reaction mixture was stirred at 25 °C for 0.5 hr. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (87.0 mg, 100% yield, HC1 salt) as a white solid. LC-MS (ESI$^+$) *m/z* 401.1 (M+H) $^+$.

[003932] l-(4-Methoxyphenyl)-N-methyl-N-[[(2R)-4-prop-2-ynylmorpholin-2-yl]methyl] methanamine [Intermediate TO]




[003933] Step 1 - (2S)-4-prop-2-vnylmorpholine-2-carbaldehvde

[003934] To a solution of [(2S)-4-prop-2-ynylmorpholin-2-yl]methanol (5.00 g, 32.2 mmol, synthesized via Steps 1-2 of Intermediate RV) in DCM (250 mL) was added DMP (17.0 g, 40.0 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 2 hrs. On completion, the reaction mixture was quenched with saturated NaS_20_3 (30 mL), then extracted with DCM (3 X 100 mL). The combined organic layers was washed with saturated $NaHC0_3$ (50 mL), then washed with brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated *in vacuo* to give the title compound (2.80 g, 56% yield) as yellow oil.

[003935] Step_2_-_l-(4-MethoxyphenvO-N-m ethyl-N-[[(2R)-4-prop-2-vnylmorpholin-2-yl]methyl] methanamine

[003936] To a solution of (2S)-4-prop-2-ynylmorpholine-2-carbaldehyde (2.80 g, 18.2 mmol) and l-(4-methoxyphenyl)-N-methylmethanamine(2.76 g, 18.2 mmol, CAS# 702-24-9) in DCM (50 mL) was added $NaBH(OAc)_3$ (4.65 g, 21.9 mmol), 4Å molecular sieves (lg) and HOAc (1.10 g, 18.2 mmol, 1.05 mL). The reaction mixture was stirred at 25 °C for 12 hrs. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% $NH_3 \cdot H_20$ condition) to give the title compound (1.50 g, 25% yield) as yellow oil. ^{1}H NMR (400 MHz, CDCh) δ 7.25 - 7.18 (m, 2H), 6.90 - 6.82 (m, 2H), 3.96 - 3.88 (m, 1H), 3.81 (s, 3H), 3.78 - 3.73 (m, 1H), 3.73 - 3.65 (m, 1H), 3.56 - 3.44 (m, 2H), 3.31 (t, *J* = 2.4 Hz, 2H), 2.86 - 2.80 (m, 1H), 2.73 - 2.67 (m, 1H), 2.55 - 2.48 (m, 1H), 2.41 - 2.33 (m, 2H), 2.27 (t, *J* = 2.4 Hz, 1H), 2.25 (s, 3H), 2.09 - 2.03 (m, 1H); LC-MS (ESI^+) m/z 289.2 $(M+H)^+$.

[003937] 3-[(5SV5-[4-[4-(3-aminopropoxy)but-l-vnyllphenyll-2-oxo-oxazolidin-3-yl]piperidine-2.,6 -dione [Intermediate_TP)



[003938] Step 1 - Tert-butyl N-[3-[4-[4-[(5S)-3-(2,6-dioxo-3-piperidyl)-2-oxo-oxazolidin-5-yl]phenyl]but-3- ynoxy]propyl]carbamate


[003939] To a solution of tert-butyl N-(3-but-3-ynoxypropyl)carbamate (250 mg, 1.10 mmol, Intermediate SD) and 3-[(5S)-5-(4-bromophenyl)-2-oxo-oxazolidin-3-yl]piperidine-2,6-dione (323 mg, 916 umol, Intermediate SN) in DMF (15 mL) was added $Pd(PPh3)_2Cl2$ (64.3 mg, 91.6 umol), CuI (17.4 mg, 91.6 umol) and Cs_2C0_3 (1.19 g, 3.67 mmol). The reaction mixture was stirred at 80 °C for 2 hrs under N_2. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (250 mg, 54% yield) as a yellow solid. ^{1}H NMR (400 MHz, DMSO -d_6) δ ^{1}H NMR (400 MHz, DMSO-d) δ 11.00 (m, 1H), 7.50 - 7.35 (m, 4H), 6.79 (t, J = 5.2 Hz, 1H), 5.72 - 5.59 (m, 1H), 4.78 - 4.61 (m, 1H), 3.97 - 3.83 (m, 1H), 3.59 - 3.51 (m, 2H), 3.44 (t, J = 6.0 Hz, 2H), 3.25 (t, J = 8.4 Hz, 1H), 2.99 (q, J = 6.8 Hz, 2H), 2.92 - 2.77 (m, 1H), 2.70 - 2.64 (m, 2H), 2.59 - 2.54 (m, 1H), 2.29 - 2.14 (m, 1H), 2.05 - 1.91 (m, 1H), 1.67 - l.58(m, 2H), 1.37 (s, 9H); LC-MS (ESI$^+$) m/z 522.3 (M +Na)$^+$.

[003940] Step 2 - 3-[(5S)-5-[4-[4-(3-aminopropoxy)but-l-vnyl1phenyl1-2-oxo-oxazolidin-3-yllpiperidine-2.6 -dione

[003941] To a solution of tert-butyl N-[3-[4-[4-[(5S)-3-(2,6-dioxo-3-piperidyl)-2-oxo-oxazolidin-5-yl]phenyl] but-3-ynoxy]propyl]carbamate (100 mg, 200 umol) in DCM (3 mL) was added TFA (1.54 g, 13.5 mmol, 1.00 mL). The reaction mixture was stirred at 25 °C for 2 hr. On

completion, the residue concentrated *in vacuo* to give the title compound (100 mg, 97% yield) as yellow oil. LC-MS (ESI^+) m/z 400.2 $(M + H)^+$.

[003942] **3-[3-Methyl-4-[3-[(2S)-2-(methylaminomethvDmorpholin-4-yl]propyl]-2-oxo-benzimidazol- l-yl]piperidine-2,6-dione [Intermediate TT)**



[003943] Step 1 - 3-[4-[3-[(2S)-2-[[(4-Methoxyphenyl)methyl-methyl-aminolmethyllmorpholin-4-yllprop-l- ynyl1-3-methyl-2-oxo-benzimidazol-1-yllpiperidine-2.6-dione

[003944] To a mixture of 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (300 mg, 887 umol, Intermediate HP) and l-(4-methoxyphenyl)-N-methyl-N-[[(2S)-4-prop-2-ynylmorpholin-2-yl] methyl]methanamine (383 mg, 1.33 mmol, Intermediate RQ) in DMF (20 mL) was added CS_2CO_3 (1.45 g, 4.44 mmol), CuI (50.7 mg, 266 umol), $Pd(PPh_3)_2Cl_2$ (187 mg, 266 umol) and 4Å molecular sieves (20 mg). The reaction mixture was stirred at 80 °C for 2 hours under N_2. On completion, the reaction mixture was filtered. The filtrate was washed with water (100 mL) and extracted with ethyl acetate (2 X 40 mL). The combined organic phase was washed with brine (2 X 40 mL), dried with anhydrous Na_2SO_4, filtered and concentrated *in vacuo* to give residue. The residue was purified by reverse phase HPLC (0.1% FA condition) to give the title compound (285 mg, 58% yield) as brown solid. ¾ NMR (400 MHz, DMSO-d«) δ 11.13 (s, 1H),

8.15 (s, 2H), 7.21 - 7.15 (m, 3H), 7.13 - 7.09 (m, 1H), 6.83 - 6.79 (m, 2H), 5.41 *(d, J* = 5.6, 12.8 Hz, 1H), 3.83 - 3.77 (m, 2H), 3.69 (s, 4H), 3.64 (s, 4H), 3.56 - 3.51 (m, 5H), 2.39 *(d, J* = 6.0 Hz, 2H), 2.35 - 2.26 (m, 2H), 2.15 (s, 3H), 2.10 - 2.05 (m, 1H), 2.03 - 1.96 (m, 2H).


[003945] Step _2 _- _Tert-butyl _N-п(2R.)-4-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4- νl]ρϊΟρνl] morpholin-2-yl1methyl1-N-methyl-carbamate

[003946] To a mixture of 3-[4-[3-[(2S)-2-[[(4-methoxyphenyl)methyl-methyl-amino]methyl]morpholin-4-yl] prop-l-ynyl]-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione (285 mg, 522 umol) in EA (20 mL) and IPA (10 mL) was added Pd/C (50.0 mg, 10 wt%), $Pd(OH)_2/C$ (50.0 mg, 10 wt%) and $(Boc)_20$ (171 mg, 783 umol). The suspension was degassed under vacuum and purged with H_2 three times. The mixture was then stirred at 25 °C for 16 hours under H_2 (50 psi) atmosphere. On completion, the reaction mixture was filtrated and filtrate was concentrated *in vacuo* to give residue. The residue was purified by reverse phase HPLC (0.1% FA condition) to give title compound (130 mg, 45% yield) as a brown solid. LC-MS (ESI^+) *m/z* 530.4$(M+H)^+$.

[003947] Step 3 - 3-r3-Methyl-4-r3-r(2S)-2-(methylaminomethyl)morpholin-4-yl1propyl1-2-oxo-benzimidazol- 1-yl1piperidine-2.6-dione

[003948] To a mixture of tert-butyl N-[[(2R)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propyl]morpholin-2-yl]methyl]-N-methyl -carbamate (130 mg, 245 umol) in DCM (2 mL) was added TFA (83.9 mg, 736 umol). The reaction mixture was stirred at 25 °C for 2 hours. On completion, the reaction mixture was concentrated *in vacuo* to give title compound (133 mg, 100% yield, TFA salt) as brown oil. LC-MS (ESI^+) *m/z* 430.4 $(M+H)^+$.

[003949] 3-[3-Methyl-4-[3-[(2RV2-(methylaminomethvBmorpholin-4-yllpropyll-2-oxo-benzimidazol -l-yl]piperidine-2,6-dione [Intermediate TIP)



[003950] Step 1 -3-[4-[3-[(2R)-2-[[(4-methoxyphenyl)methyl-methyl-aminolmethyllmorpholin-4-yllprop-l-ynyl1-3-methyl-2-oxo-benzimidazol-1-yllpiperidine-2.6-dione

[003951] To a solution of l-(4-methoxyphenyl)-N-methyl-N-[[(2R)-4-prop-2-ynylmorpholin-2-yl]methyl] methanamine (450 mg, 1.56 mmol, Intermediate TO) and 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl) piperidine - 2,6-dione (352mg, 1.04 mmol, Intermediate HP) in DMF (10 mL) was added CS2CO3 (1.36 g, 4.16 mmol), CuI (39.6 mg, 208 umol), 4A molecular sieves (50 mg) and $Pd(PPh_3)_2Cl_2$ (146.03 mg, 208.1 umol) at 25 °C. The reaction mixture was stirred at 80 °C for 2 hrs. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was diluted with water 30 mL, and then extracted with EA (3 X 50 mL). The combined organic layers were washed with brine and dried over Na_2SO_4, filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (355 mg, 63% yield) as a yellow solid. ^1H NMR (400 MHz, DMSO-^e) δ 11.12 (s, 1H), 8.15 (s, 1H), 7.20 - 7.14 (m, 4H), 7.13 - 7.08 (m, 1H), 7.02 (t, *J* = 8.0 Hz, 1H), 6.80 (d, *J* = 8.8 Hz, 3H), 5.40 (dd, *j* = 5.2 Hz, 1H), 3.79 (d, *j* = 10.0 Hz, 2H), 3.68 (s, 4H), 3.63 (s, 3H), 3.60 (d, *j* = 7.2 Hz, 2H), 2.91 *(d, J* = 11.6 Hz, 2H), 2.74 - 2.64 (m, 4H), 2.37 (d, *J* = 6.0 Hz, 2H), 2.30 - 2.25 (m, 1H), 2.14

(s, 3H), 2.03 - 1.97 (m , 1H); LC-MS (ESI+) m/z 546.3 $(M+H)^+$.


[003952] Step 2 - Tert-butyl N-[[(2S)-4-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]propyl] morpholin-2-yllmethyll-N-methyl-carbamate

[003953] To a solution of 3-[4-[3-[(2R)-2-[[(4-methoxyphenyl)methyl-methyl-amino]methyl]morpholin-4-yl] prop-l-ynyl]-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione (355 mg, 651 umol) in EA (20 mL) and IPA (10 mL) was added Pd/C (180 mg, 20 wt%), $Pd(OH)_2/C$ (dry) (180 mg, 10 wt%) and $(Boc)_20$ (213 mg, 976 umol, 224 uL) at 25 °C. The reaction mixture was stirred at 25 °C for 2 hrs under H_2 (50 Psi) atmosphere. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA) to give the title compound (225 mg, 65% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_f) δ 11.08 (s, 1H), 7.00 - 6.91 (m, 2H), 6.89 - 6.84 (m, 1H), 5.36 (dd, J = 5.2 Hz, 1H), 3.78 (d, J = 11.2 Hz, 1H), 3.55 (s, 3H), 3.47 (s, 1H), 3.22 (d, J = 4.8 Hz, 1H), 3.17 (d, J = 6.8 Hz, 1H), 2.96 - 2.87 (m, 3H), 2.80 (d, J = 8.8 Hz, 3H), 2.73 - 2.58 (m, 4H), 2.42 - 2.31 (m, 3H), 2.06 - 1.94 (m, 2H), 1.79 - 1.68 (m, 3H), 1.37 (s, 9H); LC-MS (ESI+) m/z 530.3 $(M+H)^+$.

[003954] Step 3 - 3-[3-Methyl-4-[3-[(2R)-2-(methylaminomethyl)morpholin-4-yl1propyl1-2-oxo-benzimidazol - 1-yl1piperidine-2.6-dione

[003955] To a solution of tert-butyl N-[[(2S)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propyl]morpholin-2-yl]methyl]-N-methyl-carbamate (120 mg, 227 umol) in DCM (2 mL) was added HCl/dioxane (4 M, 1 mL) at 25 °C. The reaction mixture was stirred at 25 °C for 2 hrs. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (95.0 mg, 98% yield) as a white solid. LC-MS (ESI^+) m/z 430.3 $(M+H)^+$.

[003956] Benzyl N-methyl-N-[2-[(2RV4-prop-2-ynylmorpholin-2-yl1 ethyl] carbamate [Intermediate TV)



TV

[003957] Step 1 - Tert-butyl (2R)-2-(2-aminoethyl)morpholine-4-carboxylate

[003958] A mixture of tert-butyl (2R)-2-(cyanomethyl)morpholine-4-carboxylate (3.86 g, 17.0 mmol, synthesized via Steps 1-2 of Intermediate RN) and Raney-Ni (3.00 g, 35.0 mmol) in MeOH (120 mL) and NH_3H_2O (12 mL) was stirred at 25 °C for 4 hours under H_2 (45 Psi). On completion, the mixture was filtered, and the filter cake was washed with MeOH (50 mL). The filtrate and washing were combined and concentrated *in vacuo* to give the title compound (3.90 g, 99% yield) as light yellow gum. ^1H NMR (400 MHz, CDCh) δ 3.87 - 3.84 (m, 3H), 3.53 - 3.44 (m, 2H), 2.87 - 2.81 (m, 3H), 2.65 (m, 1H), 1.65 - 1.56 (m, 4H), 1.47 (s, 9H).

[003959] Step 2 - Tert-butyl (2R)-2-[2-(benzyloxycarbonylamino)ethyl]morpholine-4-carboxylate

[003960] To a solution of tert-butyl (2R)-2-(2-aminoethyl) morpholine-4-carboxylate (3.90 g, 16.9 mmol) and TEA (3.55 g, 35.0 mmol) in DCM (50 mL) was added CbzCl (3.03 g, 17.7 mmol) at 0 °C. The mixture was stirred at 0 - 10 °C for 1 hour. On completion, the mixture was washed with water (20 mL) and concentrated *in vacuo.* The residue was dissolved in EA (50 mL), washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (6.00 g, 97% yield) as light yellow oil. ^1H NMR (400 MHz, CDCh) δ 7.41 - 7.33 (m, 5H), 5.18- 5.16 (m, 1H), 5.10 (s, 2H), 4.12 - 3.83 (m, 3H), 3.48 - 3.40 (m, 4H), 2.90 (m, 1H), 2.62 - 2.61 (m, 1H), 1.44 (s, 9H).

[003961] Step 3 - Tert-butyl (2R)-2-[2-(benzyloxycarbonyl(methyl)amino)ethyl]morpholine-4-carboxylate

[003962] To a solution of tert-butyl (2R)-2-[2-(benzyloxycarbonylamino)ethyl]morpholine-

4-carboxylate (6.00 g, 16.4 mmol) in THF (60 mL) was added NaH (1.32 g, 33.0 mmol, 60% oil disperion) at 0 °C. The mixture was stirred at 0 °C for 30 minutes. Then MeI (7.01 g, 49.3 mmol) was added to the reaction mixture at 0 °C. The mixture was stirred at 0 - 25 °C for another 3 hours. On completion, the reaction was quenched with sat. aq. NH_4Cl (10 mL). The mixture was diluted with water (50 mL), then extracted with EA(3 X 50 mL). The combined organic layer was washed with brine (10 mL), dried over Na_2SO_4, filtered and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel to give the title compound (5.20 g, 83% yield) as light yellow oil. ¾ NMR (400 MHz, CDCb) δ 7.37 - 7.31 (m, 5H), 5.13 (s, 2H), 3.86 - 3.82 (m, 3H), 3.43 - 3.40 (m, 4H), 2.99 - 2.83 (m, 4H), 2.69 - 2.52 (m, 1H), 1.74 - 1.62 (m, 2H), 1.47 (s, 9H).


[003963] Step 4 - Benzyl N-methyl-N-[2-[(2R)-morpholin-2-yl1ethyl1carbamate

[003964] To a solution of tert-butyl (2R)-2-[2-[benzyloxycarbonyl(methyl)amino]ethyl]morpholine-4- carboxylate (5.20 g, 13.7 mmol) in DCM (30 mL) was added TFA (10 mL) at 25 °C. The mixture was stirred at 25 °C for 2 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (5.30 g, 98% yield, TFA salt) as light yellow gum.

[003965] Step 5 - Benzyl N-methyl-N-[2-[(2R)-4-prop-2-vnylmorpholin-2-yllethyllcarbamate

[003966] To a mixture of benzyl N-methyl-N-[2-[(2R)-morpholin-2-yl]ethyl]carbamate (5.30 g, 13.5 mmol, TFA salt) and K2CO3 (7.59 g, 54.9 mmol) in THF (60 mL) was added 3-bromoprop-l-yne (1.63 g, 13.7 mmol) at 25 °C. The mixture was stirred at 25 °C for 16 hours. On completion, the mixture was filtered, and the filter cake was washed with EA (20 mL). The filtrate and washing were combined and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel to give the title compound (2.90 g, 67 % yield) as light yellow oil. ^1H NMR (400 MHz, CDCb) δ 7.37 - 7.31 (m, 5H), 5.13 (d, *J* = 3.2 Hz, 2H), 3.87 (t, *J* = 13.2 Hz, 1H), 3.70 - 3.46 (m, 2H), 3.40 (t, *J* = 7.6 Hz, 2H), 3.28 (d, *J* = 10.8 Hz, 2H), 2.94 (s, 3H), 2.79 - 2.63 (m, 2H), 2.44 - 2.33 (m, 1H), 2.27 (t, *J* = 2.4 Hz, 1H), 2.16 - 2.06 (m, 1H), 1.76 - 1.63 (m, 2H).

[003967] **3-|3-Methyl-5-|3-[(2R)-2-|2-(methylamino)ethyl]morpholin-4-yl]propyl]-2-oxo- benzimidazol-l-yl]piperidine-2,6-dione [Intermediate TW)**



[003968] Step 1 - Benzyl N-[2-[(2R)-4-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]prop-2-ynyl]morpholin-2-yl]ethyl-N-methyl-carbamate

[003969] A mixture of benzyl N-methyl-N-[2-[(2R)-4-prop-2-ynylmorpholin-2-yl]ethyl]carbamate (1.93 g, 6.11 mmol, Intermediate TV), 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (1.38 g, 4.08 mmol, Intermediate HN), Cul (165 mg, 866 umol), Pd(PPh $_3$)2Cl2 (580 mg, 826 umol), CS2CO3 (6.65 g, 20.4 mmol) and 4Å molecular sieves (1.00 g) in DMF (30 mL) was stirred at 80 °C for 2 hours under N_2. On completion, the reaction mixture was cooled to 25 °C. The mixture was filtered and the filter cake was washed with EA (20 mL). The filtrate and washing were combined and concentrated *in vacuo.* The residue was purified by reversed phase flash (FA condition) to give the title compound (1.50 g, 64% yield) as light yellow solid. ^{1}H NMR (400 MHz, DMSO-r¾) δ 11.13 (s, 1H), 7.36 - 7.29 (m, 6H), 7.17 - 7.09 (m, 2H), 5.41 - 5.36 (m, 1H), 5.05 (s, 2H), 3.85 - 3.76 (m, 1H), 3.49 (s, 3H), 3.42 - 3.38 (m, 3H), 3.26 (m, 1H), 2.86 - 2.82 (m, 4H), 2.76 - 2.68 (m, 2H), 2.65 - 2.62 (m, 1H), 2.52 - 2.52 (m, 3H), 2.31 - 2.25 (m, 1H), 2.06 - 1.98 (m, 2H), 1.61 - 1.57 (m, 2H).

[003970] Step 2 - Benzyl N-r2-r(2R)-4-r3-rl-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl1propyl1 morpholin-2-yllethyll-N-methyl-carbamate


[003971] A mixture of benzyl N-[2-[(2R)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-

benzimidazol -5-yl]prop-2-ynyl]morpholin-2-yl]ethyl]-N-methyl-carbamate (1.50 g, 2.61 mmol), Pd/C (400 mg, 10 wt%), and $Pd(OH)_2/C$ (400 mg, 10 wt%) in THF (60 mL) was stirred at 25 °C for 2 hours under H_2 (15 psi). On completion, the mixture was filtered, and the filter cake was washed with EA (10 mL). The filtrate and washing were combined and concentrated *in vacuo*. The residue was purified by reversed phase flash chromatography (FA condition) to give the title compound (960 mg, 58% yield) as light yellow solid. ^1H NMR (400 MHz, CDCh) δ 8.21 (s, 1H), 7.37 - 7.31 (m, 5H), 6.92 - 6.84 (m, 2H), 6.72 (d, *J* = 8.0 Hz, 1H), 5.26 - 5.18 (m, 1H), 5.13 (s, 2H), 3.92 - 3.81 (m, 1H), 3.75 - 3.58 (m, 2H), 3.42 (s, 3H), 3.41 - 3.35 (m, 2H), 2.93 (s, 3H), 2.80 - 2.68 (m, 7H), 2.56 - 2.46 (m, 2H), 2.29 - 2.19 (m, 2H), 2.08 - 1.96 (m, 1H), 1.95 - 1.85 (m, 2H), 1.71 - 1.58 (m, 2H).

[003972] Step 3 - 3-[3-Methyl-5-[3-[(2R)-2-[2-(methylamino)ethyl1morpholin-4-yl1propyl1-2-oxo- benzimidazol- l-yl1piperidine-2.6-di one

[003973] To a solution of benzyl N-[2-[(2R)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] propyl]morpholin-2-yl]ethyl]-N-methyl-carbamate (950 mg, 1.52 mmol) in DCM (10 mL) was added a solution of hydrogen bromide (2.30 mL, 13.9 mmol, 33% solution) in HOAc at 20 °C. The mixture was stirred at 20 °C for 3 hours. On completion, the mixture was concentrated *in vacuo* at 20°C. The residue was diluted with water and lyophilized to give the title compound (790 mg, 98% yield, HBr salt) as light yellow solid. LC-MS (ESI^+) m/z 444.3 $(M+H)^+$.

[003974] Benzyl N-methyl-N-|2-[(2S)-4-prop-2-ynylmorpholin-2-yl]ethyl]carbamate [Intermediate TX)



[003975] Step 1 - Tert-butyl (2S)-2-(2-aminoethyl)morpholine-4-carboxylate

[003976] To a solution of tert-butyl (2S)-2-(cyanomethyl)morpholine-4-carboxylate (4.00 g, 17.6 mmol, synthesized via Steps 1-2 of Intermediate RL) in MeOH (20 mL) was added NH3.H2O (2.08 g, 19.5 mmol, 2.29 mL, 33% solution) and Raney-Ni (1.51 g, 17.6 mmol). The reaction mixture was stirred at 25 °C for 12 hours under H_2 (50 psi). On completion, the reaction mixture was filtered and the filter cake was washed with MeOH. Then the filtrate was concentrated *in vacuo* to give the title compound (4.00 g, 98% yield) as colorless oil. ¾NMR (400MHz, DMSO-***di)*** δ 3.84 - 3.60 (m, 4H), 3.43 - 3.33 (m, 4H), 2.90 - 2.77 (m, 1H), 2.59 (s, 2H), 1.51 - 1.25 (m, 11H).

[003977] Step 2 - Tert-butyl (2S)-2-[2-(benzyloxycarbonylamino)ethyl1morpholine-4-carboxylate

[003978] To a solution of tert-butyl (2S)-2-(2-aminoethyl)morpholine-4-carboxylate (3.50 g, 15.2 mmol) and TEA (3.08 g, 30.3 mmol, 4.23 mL) in DCM (40 mL) was added CbzCl (2.85 g, 16.7 mmol, 2.38 mL). The mixture was stirred at 25 °C for 3 hrs. On completion, the mixture was diluted with H_20 (20 mL) and extracted with DCM (2 X 40 mL). The organic phase was dried over Na_2S0_4, and then concentrated *in vacuo* to give the title compound (5.50 g, 99% yield) as yellow oil. ¾NMR (400 MHz, CDCb) δ 7.40 - 7.32 (m, 5H), 5.25 - 5.06 (m, 2H), 4.01 - 3.69 (m, 3H), 3.57 - 3.34 (m, 3H), 3.34 - 3.22 (m, 1H), 2.98 - 2.82 (m, 1H), 2.61 (s, 1H), 2.10 - 1.78 (m, 1H), 1.76 - 1.55 (m, 2H), 1.47 (s, 9H).

[003979] Step 3 - Tert-butyl (2S)-2-[2-[benzyloxycarbonyl(methyl)amino1ethyl1morpholine-4-carboxylate

[003980] To a solution of tert-butyl (2S)-2-[2-(benzyloxycarbonylamino)ethyl]morpholine-4-carboxylate (2.00 g, 5.49 mmol) in THF (40 mL) was added NaH (439 mg, 10.9 mmol, 60% oil dispersion) at 0 °C. The reaction mixture was stirred at 25 °C for 30 minutes, and then Mel (1.95 g, 13.7 mmol, 854 uL) was added to the mixture. The mixture was stirred at 25 °C for 3 hrs. On completion, the reaction mixture was quenched with H2O (20 mL) and extracted with EA (2 X 40 mL). The organic phase was dried over Na_2S0_4, filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (1.30 g, 62% yield) as yellow oil. ^{1}H NMR (400 MHz, CDCb) δ 7.40 - 7.28 (m, 5H), 5.14 (s, 2H), 4.02 - 3.72 (m, 3H), 3.56 - 3.27 (m, 4H), 3.00 - 2.81 (m, 4H), 2.71 - 2.50 (m, 1H), 1.79 - 1.63 (m, 2H), 1.47 (s, 9H).


[003981] Step 4 - Benzyl N-methyl-N-[2-[(2S)-morpholin-2-yl1ethyl1carbamate

[003982] To a solution of tert-butyl (2S)-2-[2-[benzyloxycarbonyl(methyl)amino]ethyl]morpholine-4- carboxylate (1.20 g, 3.17 mmol) in DCM (10 mL) was added TFA (4.62 g, 40.5 mmol, 3.00 mL). The reaction mixture was stirred at 25 °C for 2 hrs. On completion, the residue was filtered and the filtrate was concentrated *in vacuo* to give the title compound (1.20 g, 96% yield, TFA) as yellow oil. LC-MS (ESI^+) m/z 279.l(M+H) $^+$.

[003983] Step 5 - Benzyl N-methyl-N-[2-[(2S)-4-prop-2-vnylmorpholin-2-yllethyllcarbamate

[003984] To a solution of benzyl N-methyl-N-[2-[(2S)-morpholin-2-yl]ethyl]carbamate (1.30 g, 3.31 mmol, TFA) and 3-bromoprop-l-yne (394 mg, 3.31 mmol, 285 uL) in THF (20 mL) was added K2CO3 (1.37 g, 9.94 mmol). The reaction mixture was stirred at 25 °C for 16 hrs. On completion, the reaction mixture was diluted with water (30 mL) and extracted with EA (3 X 80 mL). The combined organic layers was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (900 mg, 85% yield) as a yellow solid. ¾NMR (400 MHz, CDCb) 57.42 - 7.28 (m, 5H), 5.13 (s, 2H), 3.87 (t, *J* = 12.4 Hz, 1H), 3.70 - 3.47 (m, 2H), 3.40 (t, *J* = 7.2 Hz, 2H), 3.28 (d, *J* = 9.6 Hz, 2H), 2.94 (s, 3H), 2.79 - 2.62 (m, 2H), 2.39 (t, *J* = 10.8 Hz, 1H), 2.30 - 2.23 (s, 1H), 2.16 - 2.06 (m, 1H), 1.75 - 1.63 (m, 2H).

[003985] 3-[3-Methyl-5-[3-[(2S)-2-[2-(methylamino)ethyllmorpholin-4-yllpropyll-2-oxo-benzimidazol_-l-yl]piperidine-2,6-dione_[Intermediate_TY)



[003986] Step 1 - Benzyl N-[2-[(2S)-4-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl1prop-2- ynyllmorpholin-2-yllethyll-N-methyl-carbamate

[003987] To a solution of benzyl N-methyl-N-[2-[(2S)-4-prop-2-ynylmorpholin-2-yl]ethyl]carbamate (350 mg, 1.11 mmol, Intermediate TX) and 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (249 mg, 737 umol, Intermediate HN) in DMSO (10 mL) was added DIPEA (476 mg, 3.69 mmol, 642 uL), Cul (14.0 mg, 73.7 umol) and $Pd(PPh3)_2Cl2$ (51.7 mg, 73.7 umol). The reaction mixture was stirred at 80 °C for 2 hrs under N_2. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (120 mg, 28% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-d_6) δ 11.14 (s, 1H), 7.38 - 7.28 (m, 6H), 7.24 - 7.09 (m, 2H), 5.40 (dd, *J* = 5.2, 12.8 Hz, 1H), 5.06 (s, 2H), 3.72 - 3.39 (m, 6H), 3.35 (s, 6H), 2.92 - 2.80 (m, 5H), 2.77 - 2.71 (m, 1H), 2.66 - 2.59 (m, 2H), 2.07 - 2.00 (m, 1H), 1.74 - 1.55 (m, 2H); LC-MS (ESI$^+$) m/z 574.3 $(M+H)^+$.

[003988] Step 2 - Benzyl N-[2-[(2S)-4-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-S-yllpropyll morphohn-2-vHethyll-N-methyl-carbamate


[003989] To a solution of benzyl N-[2-[(2S)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] prop-2-ynyl]morpholin-2-yl]ethyl]-N-methyl-carbamate (100 mg, 174

umol) in THF (20 mL) was added $Pd(OH)_2/C$ (2 mg, 10 wt%) and Pd/C (2 mg, 10 wt%). The reaction mixture was stirred at 25 °C for 12 hrs under H_2 (15 psi). On completion, the residue was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (80.0 mg, 79% yield) as a yellow solid. LC-MS (ESI^+) m/z 578.3 $(M+H)^+$.

[003990] Step 3 - 3-[3-Methyl-5-[3-[(2S)-2-[2-(methylamino)ethyl1morpholin-4-yl1propyl1-2-oxo-benzimidazol -l-yl1piperidine-2.6-dione

[003991] To a solution of benzyl N-[2-[(2S)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] propyl]morpholin-2-yl]ethyl]-N-methyl-carbamate (80.0 mg, 138 umol) in DCM (2 mL) was added HBr/CLLCOOH (8.66 umol, 1 mL, 35% solution). The reaction mixture was stirred at 20 °C for 4 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (70.0 mg, 96% yield, HBr) as a white solid. LC-MS (ESI^+) m/z 444.3$(M+H)^+$.

[003992] l-[4-[l-Amino-2.,2.,2-trifluoro-ethv0phenyl1-4-nitro-pyrazole-3-carboxamid [Intermediate TZ)



TZ

[003993] Step 1 - Methyl l-(4-formylphenvO-4-nitro-pyrazole-3-carboxylate

[003994] To a solution of methyl l-[4-(hydroxymethyl)phenyl]-4-nitro-pyrazole-3-carboxylate (5.00 g, 18.0 mmol, synthesized via Step 1 of Intermediate GB) in DCM (100 mL) was added DMP (9.18 g, 21.6 mmol). The reaction mixture was stirred at 20 °C for 12 hrs. On completion, the mixture was quenched with sat. $Na_2S_20_3$ (100 mL) and sat. $NaHC0_3$ (100 mL), stirred and extracted with DCM (2 X 100 mL). The organic layer was washed with brine (200 mL), dried with Na_2S0_4, filtered and the filtrate was concentrated *in vacuo.* The residue was triturated with PE/DCM =2:1 (50 mL), filtered and the filter cake was dried *in vacuo* to give the title compound (4.30 g, 87% yield) as a yellow solid. ^{1}H NMR (400MHZ, DMSO-d«) δ 10.08 (s, 1H), 9.90 (s, 1H), 8.25 - 8.19 (m, 2H), 8.17 - 8.09 (m, 2H), 3.96 (s, 3H).

[003995] Step 2 - Methyl 4-nitro- l-[4-(2,2,2-trifluoro-l-hydroxy-ethyl)phenyl1pyrazole-3-carboxylate

[003996] To a solution of methyl l-(4-formylphenyl)-4-nitro-pyrazole-3-carboxylate (4.30 g, 15.6 mmol) in THF (80 mL) was added TMSCF3 (4.44 g, 31.3 mmol) and CS2CO3 (10.2 g, 31.3 mmol). The reaction mixture was stirred at 20 °C for 2 hrs. Then HCl/dioxane (30 mL) was added and the mixture was stirred at 20 °C for 10 hrs. On completion, the mixture was quenched with water, extracted with EA (2 X 70 mL). The organic layer was washed with water, then concentrated *in vacuo.* The residue was purified by silica gel chromatography (S1O2) to give the title compound (1.20 g, 22% yield) as yellow oil. ^{1}H NMR (400MHz, DMSO-^e) δ 9.75 (s, 1H), 8.03 - 7.97 (m, 2H), 7.70 (d, *J* = 8.8 Hz, 2H), 7.02 (d, *J* = 5.6 Hz, 1H), 5.37 - 5.27 (m, 1H), 3.95 (s, 3H).

[003997] Step 3 - 4-Nitro-l-r4-(2.2.2-trifluoro-l-hvdroxy-ethyl)phenyl1pyrazole-3-carboxamide

[003998] To a solution of methyl 4-nitro-l-[4-(2,2,2-trifluoro-l-hydroxy-ethyl)phenyl]pyrazole-3-carboxylate (1.20 g, 3.48 mmol) in THF (20 mL) was add $NH_3 \cdot H_2O$ (9.75 g, 69.5 mmol, 25% solution). The reaction mixture was stirred at 75 °C for 10 hrs. On completion, the mixture was diluted with water (40 mL), then extracted with EA (2 X 40 mL). The organic layer was concentrated *in vacuo.* The residue was purified by silica gel chromatography (S1O2) to give the title compound (720 mg, 63% yield) as an off-white solid. 'H NMR (400MHz, DMSO-d_6) 9.65 (s, 1H), 8.19 (s, 1H), 8.06 - 7.96 (m, 2H), 7.91 (s, 1H), 7.73 - 7.65 (m, 2H), 7.00 (d, *j* = 5.6 Hz, 1H), 5.34 - 5.26 (m, 1H).

[003999] Step 4 - [1-r4-(3-Carbamoyl-4-nitro-pyrazol-l -yl)phenyl1-2.2.2-trifluoro-ethyl1 methanesulfonate

[004000] To a solution of 4-nitro- 1-[4-(2, 2,2-trifluoro-l -hydroxy-ethyl)phenyl]pyrazole-3-carboxamide (720 mg, 2.18 mmol) and TEA (662 mg, 6.54 mmol) in a mixed solvent of DCM (10 mL) and THF (10 mL) was added MsCl (500 mg, 4.36 mmol) at 0 °C. Then the reaction mixture was stirred at 20 °C for 3 hrs. On completion, the mixture was quenched with water (50 mL), then extracted with DCM (2 X 50 mL). The organic layer was washed with brine (50 mL), dried with Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by silica gel chromatography (S1O2) to give the title compound (850 mg, 95% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-di) δ 9.69 (s, 1H), 8.22 (s, 1H), 8.13 - 8.08 (m, 2H), 7.94 (s, 1H), 7.83 - 7.74 (m, 2H), 6.70 - 6.60 (m, 1H), 3.33 (s, 3H).


[004001] Step 5 - 1-[4-(1-Azido-2.2.2-trifluoro-ethyl)phenyl1-4-nitro-pyrazole-3-carboxamide

[004002] To a solution of [l-[4-(3-carbamoyl-4-nitro-pyrazol-l-yl)phenyl]-2,2,2-trifluoro-ethyl] methanesulfonate (500 mg, 1.22 mmol) and TBAI (45.2 mg, 122 umol) in DMF (10 mL) was added NaN_3 (159 mg, 2.45 mmol). The reaction mixture was stirred at 25 °C for 1 hr and then heated at 80 °C for 12 hrs. On completion, the mixture was diluted with water (30 mL), then extracted with DCM (2 X 30 mL). The organic layer was concentrated *in vacuo.* The residue was purified by reverse phase (0.1% FA condition) to give the title compound (130 mg, 30% yield) as a white solid. LC-MS (ESI^+) *m/z* 356.1 $(M+H)^+$.

[004003] Step 6 - 1-[4-(1-Amino-2.2.2-trifluoro-ethyl)phenyl1-4-nitro-pyrazole-3-carboxamide

[004004] To a solution of l-[4-(l-azido-2,2,2-trifluoro-ethyl)phenyl]-4-nitro-pyrazole-3-carboxamide (130 mg, 366 umol) in a mixed solvent of FLO (0.2 mL) and THF (10 mL) was added PPh_3 (192 mg, 732 umol). The mixture was stirred at 20 °C for 2 hrs, then the mixture was heated at 80 °C for 10 hrs. On completion, the mixture was concentrated *in vacuo.* The residue was purified by silica gel chromatography (S1O2) to give the title compound (90.0 mg, 72% yield) as a white solid. ^1H NMR (400MHz, DMSO-^e) δ 9.64 (s, 1H), 8.19 (s, 1H), 8.01 - 7.94 (m, 2H), 7.91 (s, 1H), 7.74 - 7.68 (m, 2H), 4.62 (s, 1H), 2.65 - 2.54 (m, 2H); LC-MS (ESI+) m/z 330.1 $(M+H)^+$.

[004005] 3-|5-|3-|2-(2-Hvdroxyethoxy)ethoxy|propyl|-3-inethyl-2-oxo-benziinidazol-l-yl]piperidine- 2,6-dione [Intermediate UA)



[004006] Step 1 - 3-r5-r3-r2-(2-Hvdroxyethoxy)ethoxy1prop-l-vnyl1-3-methyl-2-oxo-benzimidazol-l-yll piperidine-2.6-dione


[004007] To a solution of 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (500 mg, 1.48 mmol, Intermediate HN) and 2-(2-prop-2-ynoxyethoxy)ethanol (639 mg, 4.44 mmol, Intermediate LC) in DMSO (15 mL) was added CuI (56.3 mg, 295 umol), $Pd(PPh_3)_2Cl_2$ (103 mg, 147 umol), DIPEA (955 mg, 7.39 mmol), 4Amoleculare sieves (0.5 g) and$P(t\text{-}Bu)_3$ (2.30 g, 1.48 mmol, 13 wt%). The reaction mixture was heated at 80 °C for 2 hours. On completion, the reaction mixture was quenched by water (30 mL), and then extracted with EA (3 X 40 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (FA condition) to give the title compound (590 mg, 99% yield) as light yellow solid. ^{1}HNMR (400MHz, DMSO-^e) δ 11.11 (s, 1H), 7.33 (d, *J* = 0.8 Hz, 1H), 7.20 - 7.09 (m, 2H), 5.40 (dd, *J* = 5.2, 12.4 Hz, 1H), 4.43 - 4.37 (m, 2H), 3.67 - 3.62 (m, 2H), 3.61 - 3.56 (m, 2H), 3.52 - 3.49 (m, 2H), 3.46 - 3.42 (m, 3H), 3.34 (s, 3H), 2.96 - 2.81 (m, 1H), 2.76 - 2.59 (m, 2H), 2.07 - 1.94 (m, 1H); LC-MS (ESI^+) *m/z* 402.1 $(M+H)^+$.

[004008] Step 2 - 3-r5-r3-r2-(2-Hvdroxyethoxy)ethoxy1propyl1-3-methyl-2-oxo-benzimidazol-l-yllpiperidine- 2.6-dione

[004009] To a solution of 3-[5-[3-[2-(2-hydroxyethoxy)ethoxy]prop-l-ynyl]-3-methyl-2-oxo-benzimidazol-l- yl]piperidine-2,6-dione (650 mg, 1.62 mmol) in THF (20 mL) was added Pd/C (100 mg, 10 wt%) and $Pd(OH)_2/C$ (100 mg, 10 wt%) under N_2. The suspension was degassed

under vacuum and purged with Eh three times. The mixture was stirred under Eh (15 psi) at 25 °C for 16 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (570 mg, 86% yield) as light yellow solid. ^{1}H NMR (400MHz, DMSO-d_6) δ 11.08 (s, 1H), 7.04 (s, 1H), 7.00 (d, J = 8.0 Hz, 1H), 6.92 - 6.82 (m, 1H), 5.33 (dd, J = 5.2, 12.8 Hz, 1H), 4.58 (t, J = 5.2 Hz, 1H), 3.54 - 3.37 (m, 10H), 2.97 - 2.82 (m, 1H), 2.76 - 2.57 (m, 4H), 2.01 (s, 1H), 1.87 - 1.72 (m, 2H); LC-MS (ESI$^+$) *m/z* 406.2 (M+H)$^+$.


[004010] **2-12-13-[l-(2.,6-dioxo-3-piperidvP-3-methyl-2-oxo-benzimidazol-5-yllpropoxy] ethoxy] ethyl methanesulfonate [Intermediate UB)**



UA UB

[004011] To a solution of 3-[5-[3-[2-(2-hydroxyethoxy)ethoxy]propyl]-3-methyl-2-oxo-benzimidazol-l-yl] piperidine-2, 6-dione (100 mg, 246 umol) and TEA (74.8 mg, 739 umol) in DCM (4 mL) was added MsCl (42.3 mg, 369 umol) at 0 °C, the mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was quenched by water (15 mL), and then extracted with DCM (3 X 15 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (110 mg, 92% yield) as light yellow oil. LC-MS (ESI$^+$) *m/z* 484.1 (M+H)$^+$.

[004012] **2-12-13-[l-(2.,6-Dioxo-3-piperidvP-3-methyl-2-oxo-benzimidazol-5-yllpropoxy] ethoxy] acetaldehyde [Intermediate UC1**





UB UC


[004013] To a solution of 3-[5-[3-[2-(2-hydroxyethoxy)ethoxy]propyl]-3-methyl-2-oxo-benzimidazol-l-yl] piperidine-2, 6-dione (270 mg, 666 umol, Intermediate ETA) in THF (10 mL) was added DMP (339 mg, 799 umol). The mixture was stirred at 25 °C for 4 hrs. On completion,

the reaction mixture was quenched by saturated $Na_2S_2O_3$ (6 mL) and saturated NaHCCh (6 mL) at 25°C, stirred for 30 minutes. Then the mixture was extracted with DCM (3 X 30 mL). The combined organic layers dried over Na_2SO_4, filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (0.1% FA condition) to give the title compound (150 mg, 56% yield) as a light yellow solid. ^1H NMR (400MHz, DMSO-d«) δ 11.08 (s, 1H), 9.62 (s, 1H), 7.10 - 6.92 (m, 2H), 6.85 - 6.72 (s, 1H), 5.41 - 5.38 (m, 1H), 4.18 (s, 1H), 3.72 - 3.65 (m, 1H), 3.60 - 3.35 (m, 6H), 3.34 - 3.25 (m, 3H), 2.99 - 2.81 (m, 1H), 2.75 - 2.55 (m, 4H), 2.05 - 1.91 (m, 1H), 1.88 - 1.70 (m, 2H); LC-MS (ESI^+) *m/z* 404.2 $(M+H)^+$.

[004014] **4-Amino-1- [4- 11-12-12-13- [l-(2.,6-dioxo-3-piperidvP-3-methyl-2-oxo-benzimidazol-5-yl] propoxy]ethoxy]ethylamino]-2,2,2-trifluoro-ethyl]phenyl]pyrazole-3-carboxamide [Intermediate UP]**







[004015] Step 1 - l-[4-[l-[2-[2-[3-[l-(2,6-Dioxo-3-piperidvl)-3-methyl-2-oxo-benzimidazol-5-vnpropoxyl ethoxy1ethylamino1-2.2.2-trifluoro-ethyl1phenyl1-4-nitro-pyrazole-


3-carboxamide

[004016] To a solution of 2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]propoxy] ethoxy]acetaldehyde (98.0 mg, 243 umol, Intermediate UC) and l-[4-(l -amino-2,2,2-trifluoro-ethyl)phenyl]-4-nitro- pyrazole-3 -carboxamide (80.0 mg, 243 umol, Intermediate TZ) in THF (3 mL) was added HOAc (14.6 mg, 243 umol). The mixture pH was adjusted to 5-6 and $NaBH(OAc)_3$ (103 mg, 486 umol) was added into the mixture. The reaction mixture was stirred at 25 °C for 12 hrs. On completion, the mixture was concentrated *in vacuo*. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (25.0 mg, 14% yield) as a white solid. ^1H NMR (400MHz, DMSO-^e) δ 11.08 (s, 1H), 9.63 (s, 1H), 8.18 (s, 1H), 7.99 (d, *J* = 8.8 Hz, 2H), 7.92 (s, 1H), 7.68 (d, *J* = 8.8 Hz, 2H), 7.02 - 6.96 (m, 2H), 6.84 (d, *J* = 8.0 Hz, 1H), 6.54 (s, 1H), 5.32 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.70 - 4.55 (m, 1H), 3.50 - 3.44 (m, 6H), 3.37 (t, *J* = 6.4 Hz, 2H), 3.30 (s, 3H), 2.93 - 2.82 (m, 2H), 2.72 - 2.66 (m, 1H), 2.66 - 2.62 (m, 4H), 2.03 - 1.95 (m, 1H), 1.84 - 1.74 (m, 2H); LC-MS (ESI^+) *m/z* 717.0 $(M+H)^+$.

[004017] Step _9_-_4-Amino-l-r4-rl-r2-r2-r3-rl-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yll_ __propoxylethoxyl ethyl amino]-2.2.2-trifluoro-ethyl1phenyl1pyrazole-3-carboxamide

[004018] To a solution of l-[4-[l-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] propoxy]ethoxy]ethylamino]-2,2,2-trifluoro-ethyl]phenyl]-4-nitro-pyrazole-3-carboxamide (22.0 mg, 29.2 umol) in THF (4 mL) was added $Pt0_2$ (6.62 mg, 29.2 umol). The reaction mixture was stirred at 25 °C for 4 hrs under H_2 (15 psi) atmosphere. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (20.0 mg, 100% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 687.3 $(M+H)^+$

[004019] 4-[2-[2-[2-[2-[2-12-Aminoethoxylethoxy] ethoxy] __ethoxy] ethoxy] ethylamino] -2-(2,6-dioxo-3 -piperidvBisoindoline-l,3-dione [Intermediate UE)



R

UE


[004020] Step 1 - Tert-butyl N-[2-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate

[004021] A solution of 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-1,3-dione (550 mg, 1.99 mmol, Intermediate R), tert-butyl N-[2-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate (500 mg, 1.31 mmol, CAS# 189209-27-6) and DIPEA (1.36 g, 10.5 mmol) in DMSO (20 mL) was stirred at 120-130 °C for 16 hours. On completion, the reaction mixture was cooled to rt and diluted with water (150 mL), then extracted with EA (3 X 80 mL). The combined organic layer was washed with brine (50 mL), dried over Na_2SO_4, filtered and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel to give crude product (800 mg). The crude product was purified by reversed phase chromatography (phase A: 0.1% FA water, B: CLLCN, 53% CLLCN) to the title compound (490 mg, 58% yield) as yellow gum. ^1H NMR (400MHz, CDCh) δ 8.29 (s, 1H), 7.50 (dd, J = 7.2 Hz, J = 8.4 Hz, 1H), 7.12 (d, J = 7.2 Hz, 1H), 6.93 (d, J = 8.4 Hz, 1H), 6.51 (m, 1H), 5.09 (m, 1H), 4.94-4.90 (m, 1H), 3.74-3.63 (m, 18H), 3.55-3.54 (m, 4H), 3.32-3.31 (m, 2H), 2.83-2.77 (m, 3H), 2.15 (m, 1H), 1.45 (s, 9H). LC-MS (ESI^+) *m/z* 659.3 (M+Na), 537.3 (M-Boc+l) $^+$.

[004022] Step_ __2_ __-_ __4-[2-[2-[2-[2-/2- Aminoethoxy)ethoxy1 ethoxy] ethoxy1ethoxy1ethylamino1-2-(2.6-dioxo-3 -piperidvQisoindoline-L3-dione

[004023] To a solution of tert-butyl N-[2-[2-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4 -yl] amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate (490 mg, 770 umol) in DCM (10 mL) was added 4.0 M HCl/dioxane (5 mL) at it, and the mixture was stirred at rt for 2 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (530 mg, quant. crude yield, HC1) as yellow gum. LC-MS (ESI$^+$) *m/z* 537.3 $(M+H)^+$.

[004024] **3,6,9,12,15-pentaoxaheptadecanedioic acid [Intermediate UF)**



UF


[004025] Step 1 - di-tert-butyl 3.6.9. 12. 15-pentaoxaheptadecanedioate

[004026] To a solution of NaH (60% dispersion in mineral oil, 4.54 g, 113.4 mmol) in THF (200 mL) was added 2,2'-((oxybis(ethane-2,l-diyl))bis(oxy))di ethanol (10 g, 51.5 mmol, CAS# 112-60-7) portion wise at 0 °C. After addition, the mixture was stirred at 0 °C for lh, then tert-butyl 2-bromoacetate (22 g, 113.4 mmol) was added. After addition, the mixture was warmed to rt and stirred overnight. The mixture was quenched by addition of water, then extract with EtOAc (3 x 50 mL). The combined organic layers was washed with brine (100 mLx 2), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by flash chromatography eluting with PE/EA=4/l to give the title compound (5.5 g, 25.2%) as an colorless oil. LC/MS (ESI, *m/z):* $[M+l]^+$ = 423.1.

[004027] Step 2 - 3,6,9,12,l5-pentaoxaheptadecanedioic acid

[004028] To a solution of di-tert-butyl 3,6,9, 12,1 5-pentaoxaheptadecanedioate (5.5 g, 13 mmol) in DCM(2 mL) was added 4M HC1 in dioxane (18 mL). The mixture was stirred at rt overnight. The mixture was concentrated *in vacuo* to give the the title compound (3.5 g, 87% yield). LC/MS (ESI, *m/z):* $[M+l]^+$ = 311.0.

[004029] **3-(6-Amino-9H-pyrido[2.,3-blindol-9-vDpiperidine-2,6-dione [Intermediate UG)**



UG

[004030] **Step 1 - 6-nitro-9H-pyrido [2,3-bl indole**

[004031] To a mixture 68%-70% nitric acid in H_20 (20 mL) and fuming nitric acid (20 mL) was added 9H-pyrido[2,3-b]indole (2.5 g, 14.88 mmol) in portions at room temperature and the temperature was maintained under 30 °C. The mixture was stirred at 25 °C for 1 h. Then the mixture was set aside overnight at 0 °C. A lot of solid was formed. The resulting solid was filtered off and stirred with dilute ammonium hydroxide solution (50 mL) (33% in H20). It was then filtered off and washed with water to leave the crude compound. The crude compound was triturated with EA and filtrated to give 6-nitro-9H-pyrido[2,3-b]indole as a grey solid. (2.6 g, yield:82%). LC/MS (ESI, *m/z*): $[M+l]^+$ = 214.2

[004032] **Step C: l-(4-methoxybenzvP-3-(6-nitro-9H-pyrido[2.,3-blindol-9-vDpiperidine-2.,6-dione**

[004033] To a solution of 6-nitro-9H-pyrido[2,3-b]indole (2.6 g, 12.2 mmol) in THF (50 mL) was added t-BuOK (2.05 g, 18.3 mmol) at 0 °C. The mixture was stirred at 0-10 °C for 1 hour under N_2. Then a solution of [l-[(4-methoxyphenyl) methyl]-2, 6-dioxo-3-piperidyl] trifluoromethanesulfonate (6.98 g, 18.3 mmol) in THF (50 mL) was added to the reaction mixture at 0-10 °C during 30 minutes. The mixture was stirred at 0-10 °C for 30 minutes under N_2. The reaction was quenched water (40 mL) and extracted with EA (3 X 50 mL). The combined organic layers were concentrated under reduced pressure. The residue was triturated with EA and filtrated to give l-(4-methoxybenzyl)-3-(6-nitro-9H-pyrido[2,3-b]indol-9-yl)piperidine-2,6-dione as a grey solid (4.95 g, yield 91%). LC/MS (ESI, *m/z):* $[M+l]^+$ = 445.1


[004034] **Step D: 3-(6-nitro-9H-pyrido[2.,3-b]indol-9-vPpiperidine-2,6-dione**


[004035] To a solution of l-(4-methoxybenzyl)-3-(6-nitro-9H-pyrido[2,3-b]indol-9-yl)piperidine-2,6-dione (400 mg, 0.90 mmol) in ACN (10 mL) was added CAN (2.46 g, 0.45 mmol) in water (3 mL) at 0 °C. After the addition, the mixture was warmed up to room temperature and stirred overnight. The reaction mixture was poured into water (50 mL), extract with EtOAc (3 x 50 mL), the combined organic layers were concentrated under reduced pressure. The residue was triturated with DMF/EA and filtrated to give 3-(6-nitro-9H-pyrido[2,3-b]indol-9-yl)piperidine-2,6-dione as a grey solid (130 mg, yield:44.4%). LC/MS (ESI, *m/z):* [M +l] $^{+}$ = 325.1

[004036] **Step E: 3-(6-amino-9H-pyrido [2,3-b] indol-9-ynpiperidine-2,6-dione**

[004037] To a solution of 3-(6-nitro-9H-pyrido[2,3-b]indol-9-yl)piperidine-2,6-dione (130 mg, 0.401 mmol) in THF (5 mL) and EA (5 mL) was added Palladium on activated carbon 10% Pd (50 mg). The mixture was stirred at room temperature under H2 balloon overnight. The reaction mixture was filtered, the filtrate was concentrated under reduce pressure, the residue was triturated with DMF/EA and filtrated to give 3-(6-amino-9H-pyrido[2,3-b]indol-9-yl)piperidine-2,6-dione as a grey solid (55 mg, yield:46.4%). ^{1}H NMR (400 MHz, DMSO-^e) ‹511.08 (s, 1H), 8.26 - 8.39 (m, 2H), 7.24 - 7.36 (m, 2H), 7.14 (dd, *J* = 7.63, 4.88 Hz, 1H), 6.85 (dd, J=8.63, 2.13 Hz, 1H), 5.90 (br. s., 1H), 4.87 (s, 2H), 2.93 - 3.08 (m, 2H), 2.68 (d, J=l2.26 Hz, 1H), 2.01 - 2.11 (m, 1H). LC/MS (ESI, *m/z):* [M +l] $^{+}$ = 295.1.

[004038] **3-(6-bromo-9H-pyrido [2,3-bl indol-9-ynpiperidine-2,6-dione [Intermediate IJII)**





UH

[004039] Step 1 - 6-bromo-9H-pyridor2.3-b1indole

[004040] To a stirred solution of 9H-pyrido[2,3-b]indole (3 g, 17.9 mmol, CAS# 26148-68-5) in DCM (50 mL) was added Br_2 (3.4 g, 21.4 mmol) dropwise at 0 °C. The reaction mixture was stirred at 0 °C for 4 h. To the mixture was added aq. NaHCCh (100 mL), then the solution was extracted with EA (200 mL). The organic layer was washed with brine (50 mL), dried over Na_2S0_4, filtered, concentrated to give the title compound (2.7 g, 61% yield) as yellow solid. ¾ NMR (400 MHz, DMSO-7,) *S* 12.02 (s, 1 H), 8.60 (dd, 7 = 1.2 Hz, 7 = 7.6 Hz, 1H), 8.48-8.44 (m, 2H), 7.60-7.58 (m, 1H), 7.48 (d, 7 = 8.4 Hz, 1H), 7.26 (dd, 7 = 4.8 Hz, 7 = 7.6 Hz, 1H). LC/MS (ESI, *m/z):* $[M+l]^+$ = 247.8

[004041] Step 2 - 3-(6-bromo-9H-pyridor2.3 -blindol-9- vl)- 1-*(4-* methoxybenzvDpiperidine-2.6-dione


[004042] To a stirred solution of 6-bromo-9H-pyrido[2,3-b]indole (200 mg, 0.810 mmol) and l8-crown-6 (43 mg, 0.162 mmol) in THF (10 mL) was added NaHMDS (0.6 mL, 2 M in THF) dropwise at -30 °C under N_2. The mixture was stirred for 1 h at -30 °C under N_2. Then to the mixture was added a solution of l-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yl trifluoromethanesulfonate (463 mg, 1.21 mmol) in THF (5 mL) dropwise at - 30 °C under N_2. The mixture was stirred for 2 h at -30 °C. The mixture was added to aq. NH_4Cl (20 mL), then extracted with EA (50 mL). The organic layer was washed with brine (30 mL), dried over Na_2S0_4, filtered, concentrated and purified by column (PE/EA/DCM = 10/1/1 to 3/1/1) to give the title compound (220 mg, 57% yield) as a yellow oil. ¾NMR (400 MHz, CDCh) *S* 8.41 (dd, 7 = 1.6 Hz, 7 = 5.2 Hz, 1H), 8.29 (dd, 7 = 1.2 Hz, 7 = 7.6 Hz, 1H), 8.20 (d, 7 = 1.6 Hz, 1H), 7.45 (dd, 7 = 2.0 Hz, 7 = 8.8 Hz, 1H), 7.40 (d, 7 = 8.8 Hz, 2H), 7.24-7.21 (m, 1H), 6.84 (d, 7 = 8.8 Hz, 3H), 5.90-5.87 (m, 1H), 5.01 (dd, 7 = 13.6 Hz, 7 = 20.4 Hz, 2H), 3.79 (s, 3H), 3.09-2.88 (m, 3H), 3.27-2.24 (m, 1H). LC/MS (ESI, *m/z):* $[M+l]^+$ = 479.1.

[004043] Step 3 - 3-(6-bromo-9H-pyridor2.3-b1indol-9-vDpiperidine-2.6-dione

[004044] A mixture of 3-(6-bromo-9H-pyrido[2,3-b]indol-9-yl)-l-(4-methoxybenzyl)piperidine-2,6-dione (1.3 g, 2.72 mmol), MsOH (10 mL) and toluene (20 mL) was heated to 110 °C and stirred for 3 h under N_2. The solvent was concentrated to remove toluene. Then to the mixture was added EtOAc (50 mL), and the solution was washed with brine (50 mL) to remove MsOH. The organic layer was dried over Na_2S0_4. The solid was filter and the filtrate was concentrated. The resulting residue was purified by column chromatography on silica gel

(PE/EA = 1/1) to give the title compound (500 mg, 51% yield) as a white solid. ^{1}H NMR (400 MHz, DMSO-i¾) δ 11.17 (s, 1H), 8.64 (dd, *J* = 1.6 Hz, *J* = 7.6 Hz, 1H), 8.52 (d, *J* = 2.0 Hz, 1H), 8.47 (dd, *J* = 1.6 Hz, *J* = 4.8 Hz, 1H), 7.68-7.64 (m, 2H), 7.32 (dd, *J* = 4.8 Hz, *J* = 7.6 Hz, 1H), 6.06 (br s, 1H), 3.16-2.96 (m, 2H), 2.73-2.67 (m, 1H), 2.16-2.13 (m, 1H). LC/MS (ESI, *m/z):* [M +l] $^+$ = 358.0.


[004045] **tert-butyl methyl(3-(prop-2-yn-1-yloxy)propyl)carbamate [Intermediate UP**




Ul

[004046] To a solution of tert-butyl (3-hydroxypropyl)(methyl)carbamate (2 g, 10.6 mmol, CAS# 98642-44-5) in DCM (30 mL) was added aq. NaOH (40 %, 20 mL), 3-bromoprop-l-yne (1.9 g, 15.9 mmol) and TBAHS (180 mg, 0.530 mmol) at rt. The mixture was stirred at rt for 3 h. To the mixture was added H_20 (100 mL), then the mixture was extracted with DCM (3 x 30 mL). The organic layers were washed with brine (50 mL), dried over Na_2S0_4, filtered, concentrated and purified by column (PE/EA = 20/1 to 10/1 to 4/1) to give the title compound (1.4 g, 58% yield) as a yellow oil. ¾NMR (400 MHz, CDCh) δ 4.14 (d,J= 2.4 Hz, 2H), 3.53 (t, *J* = 6.4 Hz, 2H), 3.29 (t, *J* = 6.8 Hz, 2H), 2.86 (s, 3H), 2.42 (t, *j* = 2.4 Hz, 1H), 1.83-1.80 (m, 2H), 1.46 (s, 9H). LC/MS (ESI, *m/z):* [M +l] $^+$ = 227.9.

[004047] **2-12-12-[2-(4-Nitropyrazol-l-vBethoxyl ethoxy] ethoxy] ethanamine [Intermediate UJ)**





UJ

[004048] Step 1 - Tert-butyl N-r2-r2-r2-r2-(4-nitropyrazol-l-vnethoxy] ethoxy] ethoxy] ethyl] carbamate


[004049] To a solution of 2-[2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethyl

methanesulfonate (3 g, 8.08 mmol, Intermediate AO) and 4-nitro-lH-pyrazole (608 mg, 5.38 mmol) in DMF (40 mL) was added CS_2CO_3 (3.51 g, 10.7 mmol). The reaction mixture was stirred at 130 °C for 2 hours. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo.* The residue was purified by reverse phase (0.1% FA condition) to give the title compound (1.20 g, 57% yield) as yellow oil. LC-MS (ESI^+) *m/z* 411.2 $(M+Na)^+$.


[004050] Step 2 - 2-r2-r2-r2-(4-Nitropyrazol-l-vOethoxy1ethoxy1ethoxy1ethanamine

[004051] To a solution of tert-butyl N-[2-[2-[2-[2-(4-nitropyrazol-l-yl)ethoxy]ethoxy]ethoxy]ethyl]carbamate (750 mg, 1.93 mmol) in DCM (6 mL) was added HCl/dioxane (4 M, 4.50 mL). The reaction mixture was stirred at 20 °C for 1.5 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (620 mg, 99% yield, HC1 salt) as a yellow solid. LC-MS (ESI^+) *m/z* 289.2 $(M+H)^+$.

[004052] **4-[2-[2-[2-[2-(4-Aminopyrazol-l-vPethoxylethoxylethoxylethylaminol-2-(2.,6-dioxo-3- piperidvDisoindoline-l.,3-dione [Intermediate UK]**



UJ



UK

[004053] Step 1 - 2-(2,6-Dioxo-3-piperidvl)-4-[2-[2-[2-[2-(4-nitropyrazol-1-


vDethoxylethoxylethoxyl ethyl aminolisoindoline- 1J-dione

[004054] To a solution of 2-[2-[2-[2-(4-nitropyrazol-l-yl)ethoxy]ethoxy]ethoxy]ethanamine (670 mg, 2.06 mmol, HC1 salt, Intermediate UJ) and 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (570 mg, 2.06 mmol, Intermediate R) in dioxane (20 mL) was added DIPEA (1.33 g, 10.3 mmol). The reaction mixture was stirred at 120 °C for 12 hours. On completion, the reaction mixture was concentrated *in vacuo*. The residue was purified by reversed phase (0.1%, FA condition) to give the title compound (400 mg, 36% yield) as yellow oil. ^{1}H NMR (400MHz, DMSO-di) δ 11.11 (s, 1H), 8.82 (s, 1H), 8.26 (s, 1H), 7.62 - 7.52 (m, 1H), 7.14 (d, *J* = 8.8 Hz, 1H), 7.04 (d, *J* = 7.2 Hz, 1H), 6.59 (t, *J* = 6.0 Hz, 1H), 5.06 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.33 (t, *J* = 5.2 Hz, 2H), 3.79 (t, *J* = 5.2 Hz, 2H), 3.62 - 3.59 (m, 2H), 3.56 - 3.46 (m, 10H), 3.56 - 3.44 (m, 1H), 2.94 - 2.83 (m, 1H), 2.63 - 2.56 (m, 1H), 2.57 - 2.54 (m, 1H), 2.07 - 1.99 (m, 1H). LC-MS (ESI^+) *m/z* 545.2 $(M+H)^+$.

[004055] Step 2 - 4-r2-r2-r2-r2-(4-Aminopyrazol-l-yl)ethoxy1ethoxy1ethoxy1ethylamino1-2-(2.6-dioxo-3- piperidvDisoindoline-U-dione

[004056] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-[2-[2-[2-[2-(4-nitropyrazol-l-yl)ethoxy] ethoxy] ethoxy] ethylamino]isoindoline-l,3-dione (400 mg, 735 umol) in THF (40 mL) was added $Pt0_2 \cdot H_20$ (50 mg, 220 umol) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 20 °C for 12 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (370 mg, 98% yield) as yellow oil. ^{1}H NMR (400MHz, DMSO-d«) δ 11.10 (s, 1H), 7.63 - 7.53 (m, 1H), 7.15 (d, *J* = 8.8 Hz, 1H), 7.07 - 7.01 (m, 2H), 6.89 (s, 1H), 6.60 (t, *J* = 5.8 Hz, 1H), 5.06 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.03 (t, *j* = 5.6 Hz, 2H), 3.66 (t, *j* = 5.6 Hz, 2H), 3.57 - 3.54 (m, 2H), 3.54 - 3.45 (m, 10H), 2.96 - 2.82 (m, 1H), 2.63 - 2.60 (m, 1H), 2.59 - 2.57 (m, 1H), 2.05 - 1.98 (m, 1H).

[004057] 2-[2-[2-|2-(2-Tert-biitoxy-2-oxo-ethoxy)ethoxy]ethoxy] ethoxy] acetic_ acid [Intermediate_UM)



UM


[004058] **Step 1** -Ethyl 2-r2-r2-r2-(2-tert-butoxy-2-oxo-ethoxy)ethoxy1 ethoxy] ethoxy] acetate

[004059] To a solution of ethyl 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]acetate (150 mg, 635 umol, synthesized via Step 1 of Intermediate BI) and diacetoxyrhodium (6.00 mg, 13.6 umol) in anhydrous DCM (4 mL) was added a solution of tert-butyl 2-diazoacetate (271 mg, 1.91 mmol, CAS# 35059-50-8) in DCM (4 mL) dropwise at 0-l0°C. The mixture was stirred at 25 °C for 16 hours under N_2. On completion, the reaction was quenched with HOAc (0. 1 mL). The mixture was stirred at 25°C for 15 minutes. The mixture was then concentrated *in vacuo.* The residue was purified over column chromatography on silica gel (PE: EA= 5:1-3:1) to give the title compound (130 mg, 58% yield) as light green oil. ^{1}H NMR (400MHz, CDCh) δ 4.22 (q, *J* = 7.2 Hz, 2H), 4.16 (s, 2H), 4.03 (s, 2H), 3.74 - 3.68 (m, 12H), 1.48 (s, 9H), 1.29 (t, *j* = 7.2 Hz, 3H).

[004060] Step 2 - 2-r2-r2-r2-(2-Tert-butoxy-2-oxo-ethoxy)ethoxy1ethoxy1ethoxy1acetic acid

[004061] To a solution of ethyl 2-[2-[2-[2-(2-tert-butoxy-2-oxo-ethoxy)ethoxy] ethoxy] ethoxy] acetate (130 mg, 371 umol) in THF (3 mL) was added a solution of lithium hydroxide hydrate (17.0 mg, 405 umol) in H_20 (1 mL) at 25 °C. The mixture was stirred at 25 °C for 16 hours. On completion, the mixture was diluted with water (20 mL), acidified to pH = 5 with 1.0 M aq. HC1, then extracted with EA (3 X 10 mL). The combined organic layer was washed with brine (10 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (110 mg, 92% yield) as light green oil. ¾NMR (400MHz, CDCh) δ 4.17 (s, 2H), 4.03 (s, 2H), 3.77 - 3.70 (m, 12H), 1.48 (s, 9H).

[004062] **2-r2-r2-r2-r2-rraSVl-r[2S.4R]-4-Hvdroxy-2-rr4-14-methylthiazol-5-vnphenyll methylcarbamoyl1pyrrolidine-l-carbonyl1-2,2-dimethyl-propyl]amino1-2-oxo-ethoxyl ethoxy] ethoxy] ethoxy] acetic acid [Intermediate** UN]



UM

UN


[004063] Step 1 - Tert-butyl 2-[2-[2-[2-[2-[(2S,4R)-4-hydroxy-2-[[4-(4-methylthiazol-5-yl)phenyl]methyl carbamoyl]pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]amino]-2-oxo-ethoxy]ethoxy]ethoxy]ethoxy]acetate


[004064] A mixture of (2S,4R)-1-[(2S)-2-amino-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (180 mg, HCl, Intermediate Cl), 2-[2-[2-[2-(2-tert-butoxy-2-oxo-ethoxy)ethoxy]ethoxy]ethoxy]acetic acid (100 mg, 310 umol, Intermediate UM), HATU (155 mg, 408 umol) and DIPEA (121 mg, 936 umol) in DMF (5 mL) was stirred at 25 °C for 2 hours. On completion, the reaction mixture was diluted with water (50 mL), then extracted with EA (3 X 30 mL). The combined organic layer was washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated *in vacuo*. The residue was purified over column chromatography on silica gel (DCM: MeOH = 50:1-20:1) to give the title compound (130 mg, 48% yield, 84% purity) as light yellow gum. LC-MS (ESI^+) *m/z* 735.3 $(M+H)^+$, 757.3 $(M+Na)^+$.

[004065] Step 2 - 2-[2-[2-[2-[2-[[(1S)-1-[(2S,4R)-4-Hydroxy-2-[[4-(4-methylthiazol-5-yl)phenyl]methyl carbamoyl]pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]amino]-2-oxo-ethoxy]ethoxy]ethoxy]ethoxy]acetic acid

[004066] To a solution of tert-butyl 2-[2-[2-[2-[2-[[(lS)-l-[(2S,4R)-4-hydroxy-2-[[4-(4-methylthiazol-5-yl) phenyljmethylcarbamoyljpyrrolidine-l -carbonyl]-2, 2-dimethyl - propyl]amino]-2-oxo-ethoxy]ethoxy] ethoxy] ethoxy] acetate (110 mg, 125 umol) in DCM (4 mL) was added TFA (2 mL) at 25 °C. The mixture was stirred at 25 °C for 3 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (140 mg, quant. crude yield, TFA) as light yellow gum. LC-MS (ESI^+) *m/z* 679.4 $(M+H)^+$.

[004067] **2-[2-[2-(2-Tert-butoxy-2-oxo-ethoxy)ethoxy]ethoxy]acetic acid [Intermediate UQI**





UQ

[004068] Step 1 - Ethyl 2-r2-r2-(2-tert-butoxy-2-oxo-ethoxy)ethoxy1ethoxy1acetate


[004069] To a stirring mixture of ethyl 2-[2-(2-hydroxyethoxy)ethoxy] acetate (0.80 g, 4.16 mmol, synthesized via Step 1 of Intermediate BM) and diacetoxyrhodium (33.6 mg, 76.0 umol) in DCM (10 mL) was added a solution of tert-butyl 2-diazoacetate (1.78 g, 12.49 mmol, CAS# 35059-50-8) in DCM (10 mL) drop-wise under ice-cooling bath (0 °C). After the addition, the resulting mixture was stirred at 20 °C for 16 hours. Diacetoxyrhodium (33.6 mg, 76.02 umol) and tert-butyl 2-diazoacetate (1.78 g, 12.49 mmol) were supplied subsequently, and the resulting mixture was stirred at 20 °C for another 4 hours. On completion, the mixture was quenched with AcOH (1.2 mL) and concentration *in vacuo.* The residue was purified by column chromatography ($Si0_2$, Petroleum ether/Ethyl acetate = 5/1 to 3/1) to give the title compound (1.11 g, 87% yield) as blue oil. ^{1}HNMR (400MHz, CDCh) δ 4.28 (q, *J* = 7.2 Hz, 2H), 4.02 (s, 2H), 4.15 (s, 2H), 3.73 - 3.70 (m, 8H), 1.48 (m, 9H), 1.28 (t, *J* = 7.2 Hz, 3H).

[004070] Step 2 - 2-r2-r2-(2-Tert-butoxy-2-oxo-ethoxy)ethoxy1ethoxy1acetic acid

[004071] To a solution of ethyl 2-[2-[2-(2-tert-butoxy-2-oxo-ethoxy)ethoxy] ethoxy] acetate (1 g, 3.26 mmol) in THF (40 mL) was added a solution of $Li0H.H_20$ (170 mg, 4.05 mmol) in H_20 (20 mL). The mixture was stirred at 20 °C for 16 hours. On completion, the mixture was diluted with H_20 (30 mL), adjusted to pH = 4-5 with 1M aq. HC1, extracted with EA (2 X 50 mL). The

organic phases were combined and dried over Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (800 mg, 88% yield) as yellowish oil.

[004072] **2-[2-[2-[[(1S)-1-b2S.4R)-4-Hvdroxy-2- rr4-(4-methylthiazol-5-vPphenyllmethylcarbamoyl] pyrrolidine-l-carbonyl]-2,2-dimethyl-propyl]amino]-2-oxo-ethoxy] ethoxy] ethoxy] acetic acid [Intermediate UR)**



[004073] Step 1 - Tert-butyl 2-[2-[2-[2-[[(1S)-1-[(2S,4R)-4-hydroxy-2-[[4-(4-methylthiazol-5-yl) phenyl] methylcarbamoyl]pyrrolidine- 1-carbonyl 1-2.2-dimethyl -propyl laminol-2-oxo-ethoxy] ethoxy] ethoxy] acetate

[004074] To a mixture of 2-[2-[2-(2-tert-butoxy-2-oxo-ethoxy)ethoxy]ethoxy]acetic acid (200 mg, 718 umol, Intermediate UQ) and HATU (327 mg, 862 umol) in DMF (20 mL) was added

DIPEA (278 mg, 2.16 umol, 375 uL) and (2S,4R)-l-[(2S)-2-amino-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl] methyl]pyrrolidine-2-carboxamide (335 mg, 718 umol, HC1, Intermediate Cl) subsequently, then the resulting mixture was stirred at 20 °C for 16 hours. On completion, the mixture was diluted with H_20 (20 mL), then extracted with EA (2 X 50 mL), the organic phase was concentrated *in vacuo.* The residue was purified by column chromatography ($Si0_2$, PE/EA=l/l, EA/MeOH=40/l to 10/1) to give the title compound (400 mg, 70% yield) as yellowish solid. LC-MS (ESI^+) m/z 69l.3$(M+H)^+$.


[004075] Step 2 - (S)-Methyl 13- ((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl) pyrrolidine- 1-carbonyl)- 14, 14-dimethyl- 11-oxo-3, 6,9-trioxa-l2-azapentadecan- 1-oate

[004076] To a solution of tert-butyl 2-[2-[2-[2-[[(lS)-l-[(2S,4R)-4-hydroxy-2-[[4-(4-methylthiazol-5-yl)phenyl] methyl carbamoyl]pyrrolidine-l -carbonyl]-2, 2-dimethyl - propyl]amino]-2-oxo-ethoxy]ethoxy]ethoxy]acetate (100 mg, 144 umol) in MeOH (5 mL) was added HCl/dioxane (4 M, 2 mL). The mixture was stirred at 20 °C for 16 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (150 mg, quant. crude yield) as colorless oil. LC-MS (ESI^+) m/z 649.3 $(M+H)^+$.

[004077] Step 3 - 2-[2-[2-[2-[[(1S)-1-[(2S,4R)-4-Hydroxy-2-[[4-(4-methylthiazol-5-yl)phenyl]methylcarbamoyl] pyrrolidine- 1-carbonyl]-2,2-dimethyl-propyl]amino]-2-oxo-ethoxy] ethoxy] ethoxy] acetic acid

[004078] To a solution of (S)-methyl 13- ((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl) pyrrolidine- 1-carbonyl)- 14, 14-dimethyl- 11-oxo-3, 6,9-trioxa-l2-azapentadecan-l-oate (150 mg) in THF (10 mL) was added a solution of $LiOH.H_2O$ (200 mg, 4.77 mmol) in H_20 (5 mL). The mixture was stirred at 20 °C for 20 mins. On completion, the mixture was concentrated *in vacuo* to remove THF, then diluted with H_20 (20 mL) and the pH was adjusted to 5 with 1.0 M aq. HC1, extracted with EA (2 X 40 mL). The organic phases were concentrated *in vacuo* to give the title compound (80 mg, 96%) as yellowish oil. LC-MS (ESI+) m/z 635.4 $(M+H)^+$.

[004079] **Tert-butyl N-[2-[2-[2-(4-aminopyrazol-l-yl)ethoxy]ethoxy]ethyl]carbamate (Intermediate US)**



US


[004080] Step 1 -Tert-butyl N-r2-r2-r2-(4-nitropyrazol-l-vnethoxy1ethoxy1ethyl1carbamate

[004081] To a solution of 2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethyl methanesulfonate (2.08 g, 6.37 mmol, synthesized via Step 1 of Intermediate AM) and 4-nitro-lH-pyrazole (0.600 g, 5.31 mmol, CAS# 2075-46-9) in DMF (40 mL) was added CS2CO3 (3.46 g, 10.6 mmol). The mixture was stirred at 130 °C for 2 hours. On completion, after cooling to 25 °C , the mixture was filtered, and the filtrate was concentrated *in vacuo.* The residue was purified by reverse phase (0. 1% FA condition) to give the title compound (1.50 g, 82% yield) as yellow oil. ^{1}H NMR (400MHz, CDCb) δ 8.29 (s, 1H), 8.00 (s, 1H), 4.90 (s, 1H), 4.28 (t, *J* = 4.8 Hz, 2H), 3.84 - 3.77 (m, 2H), 3.56 - 3.50 (m, 4H), 3.46 (t, *J* = 5.2 Hz, 2H), 3.30 - 3.21 (m, 2H), 1.37 (s, 9H). LC-MS (ESI$^+$) *m/z* 367.2(M+Na) $^+$.

[004082] Step_ __2_ __-_ __Tert-butyl_ __N-r2-r2-r2-(4-aminopyrazol-l-vDethoxylethoxylethvncarbamate

[004083] To a solution of tert-butyl N-[2-[2-[2-(4-nitropyrazol-l-yl)ethoxy]ethoxy]ethyl]carbamate (500 mg, 1.45 mmol) in MeOH (10 mL) was added Pd/C (220 mg, 10 wt%). The mixture was stirred at 20 °C for 12 hours under H_2 (15 psi) atmosphere. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (400 mg, 87.6% yield) as red oil. LC-MS (ESI$^+$) *m/z* 3l5.2(M+H) $^+$.

[004084] N5-[l-[2-[2-(2-aminoethoxy)ethoxy]ethyl]pyrazol-4-yl]-l-methyl-N7-(4-morpholinocyclohexyDpyrazolo[4,3-dlpyrimidine-5,7-diamine [Intermediate UT)



[004085] Step 1 - Tert-butyl N-[2-[2-[2-[4-[[1-methyl-7-[(4-morpholinocyclohexyl)amino]pyrazolo[4,3-d]pyrimidin-5-yl]amino]pyrazol-1-yl]ethoxy]ethoxy]ethyl]carbamate


[004086] Tert-butyl N-[2-[2-[2-(4-aminopyrazol-1-yl)ethoxy]ethoxy]ethyl]carbamate (300 mg, 954 umol, Intermediate US), 5-chloro-1-methyl-N-(4-morpholinocyclohexyl)pyrazolo[4,3-d]pyrimidin-7-amine (223 mg, 636 umol, Intermediate LK) and TsOH (21.9 mg, 127 umol) were taken up into a microwave tube in NMP (10 mL). The sealed tube was heated at 150 °C for 2 hours under microwave. On completion, after cooled to 25 °C , the reaction mixture was diluted with water (50 mL) and extracted with DCM (2 X 80 mL). The combined organic layer was concentrated *in vacuo*. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (100 mg, 25% yield) as a white solid. LC-MS (ESI^+) *m/z* 629.2 $(M+H)^+$.

[004087] Step 2 - N5-[1-[2-[2-(2-aminoethoxy)ethoxy]ethyl]pyrazol-4-yl]-1-methyl-N7-(4-morpholinocyclohexyl)pyrazolo[4,3-d]pyrimidine-5,7-diamine

[004088] To a solution of tert-butyl N-[2-[2-[2-[4-[[1-methyl-7-[(4-morpholinocyclohexyl)amino]pyrazolo[4,3-d]pyrimidin-5-yl]amino]pyrazol-1-yl]ethoxy]ethoxy]ethyl]carbamate (80.0 mg, 127 umol) in DCM (2 mL) was added HCl/dioxane (4 M, 1 mL). The reaction mixture was stirred at 25 °C for 14 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (70 mg, 97.3%, HC1) as a white

solid. LC-MS (ESI+) *m/z* 529.5 $(M+H)^+$.

[004089] **(S)-2-((S)-2-(((benzyloxy)carbonyl)(methyl)amino)propanamido)-2-cyclohexylacetic acid (Intermediate UU)**



uu

[004090] Step 1 - methyl (SV2-((SV2-(((benzyloxy)carbonyl)(methyl)amino)propanamido)-2-cyclohexylacetate


[004091] To a solution ofN-((benzyloxy)carbonyl)-N-methyl-L-alanine (13.04 g, 55 mmol) and methyl (S)-2-amino-2-cyclohexylacetate hydrochloride (10.4 g, 50 mmol) in DMF (100 mL) was added HATU (24.72 g, 65 mmol) and DIPEA (19.35 g, 150 mmol). The reaction mixure was stirred at room temperature for 8 h. Water (300 mL) was then added, and the mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (60 mL), dried over anhydrous Na_2SO_4. The solid was filtered and the filtrate was concentrated under reduced pressure, the resulting residue was purified by column chromatography on silica gel to give the title compound as an oil (18 g, 96% yield). ^1H NMR (400 MHz, CDC13) δ 7.37 - 7.27 (m, 5H), 5.19 (s, 2H), 4.81 (br s, 1 H), 4.49 (dd, *J* = 10.8, 5.3 Hz, 1H), 3.72 (s, 3H), 2.88 (s, 3H), 1.76-1.50 (m, 6 H), 1.36 (d, 7 = 7.1 Hz, 3 H), 1.27 - 1.13 (m, 2H), 1.08 - 0.90 (m, 3H).

[004092] Step 2 - (S)-2-((S)-2-(((benzyloxy)carbonyl)(methyl)amino)propanamido)-2-cyclohexylacetic acid

[004093] To a solution of methyl (S)-2-((S)-2-(((benzyloxy)carbonyl)(methyl)amino)propanamido)-2-cyclohexylacetate (18.0 g, 46.15 mmol) in THF (60 mL) and H20 (12 mL) was added LiOH (1.44 g, 60 mmol) at 0 °C. The reaction mixure was stirred at 0 °C for 1 h then at rt for 4 h. THF was removed under reduced pressure, then the mixture was adjusted with critic acid to pH = 2~3, and the mixture was extracted with

EtOAc (3 x 200 mL). The combined organic layers were washed with brine (60 mL), dried over anhydrous Na_2SO_4. The solid was filtered and the filtrate was concentrated under reduced pressure to give the title compound (14 g, 81% yield). ^1H NMR (400 MHz, DMSO-d_6) δ 12.55 (s, 1H), 7.39 - 7.28 (m, 5H), 5.07 (d, *J* = 9.3 Hz, 2H), 4.69 (br s, 1H), 4.10-4.07 (m, 1 H), 2.85 (s, 3H), 1.65-1.56 (m, 6 H), 1.35 - 1.28 (m, 3H), 1.19 - 1.08 (m, 5H).


[004094] 2,2-dimethyl-4-oxo-3,8,ll-trioxa-5-azatridecan-13-yl 4-methylbenzenesulfonate [Intermediate UV)




UV


[004095] To a solution of tert-butyl (2-(2-(2-hydroxyethoxy)ethoxy)ethyl)carbamate (1lg, 44.12 mmol, CAS# 139115-92-7) in DCM (100 mL) was added Et_3N (8.91 g, 88.24 mmol), then TosCl (16.82 g, 88.24 mmol) was added portions at room temperature. The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, the resulting residue was purified by column chromatography on silica gel to give the product 2,2-dimethyl-4-oxo-3,8,ll-trioxa-5-azatridecan-l3-yl 4-methylbenzenesulfonate as an oil (17 g, yield 96%). ^1H NMR (400 MHz, CDCh) δ 7.81 - 7.79 (m, 2H), 7.34 (d, *J* = 8.0 Hz, 2H), 4.90 (br s, 1 H), 4.19-4.16 (m, 2 H), 3.72 - 3.68 (m, 2 H), 3.61 - 3.57 (m, 2 H), 3.56 - 3.53 (m, 2 H), 3.50 (t, 7 = 5.2 Hz, 2 H), 3.29 (t, J = 5.1 Hz, 2 H), 2.45 (s, 3 H), 1.42 (s, 9 H).


[004096] 3-14-13-[2-|2-|2-(2-Aminoethoxy)ethoxy]ethoxy]ethoxy]propyll-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione [Intermediate UX)



GZ







UX

[004097] Step 1 - Tert-butyl N-[2-[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]prop-2-ynoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate

[004098] To a mixture of tert-butyl N-[2-[2-[2-(2-prop-2-ynoxyethoxy)ethoxy]ethoxy]ethyl]carbamate (0.500 g, 1.51 mmol, Intermediate GZ), 3-(4-bromo-3-methyl-2-oxo-benzimidazol-1-yl)piperidine-2,6-dione (170 mg, 502 umol, Intermediate HP), CuI (47.8 mg, 251 umol) and $Pd(PPh_3)_2Cl_2$ (176 mg, 251 umol) in DMF (10 mL) was added TEA (916 mg, 9.05 mmol, 1.26 mL) in a glove box. Then the resulting mixture was stirred at 80 °C for 2 hours. On completion, the mixture was diluted with water (90 mL), then extracted with EA (2 X 100 mL). The combined organic layers was dried over Na_2SO_4, filtered and concentrated *in vacuo*. The residue was purified by column chromatography to give the title compound (131 mg, 30% yield) as brown liquid. LC-MS (ESI^+) *m/z* 611.1 $(M+Na)^+$.


[004099] Step 2 - Tert-butyl N-[2-[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]propoxy]ethoxy]ethoxy]ethyl]carbamate

[004100] To a mixture tert-butyl N-[2-[2-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] prop-2-ynoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate (110 mg) in THF (15 mL) was added Pd/C (0.04 g, 10 wt%) and $Pd(OH)_2/C$ (0.04 g, 284 umol). The reaction mixture was stirred at 20 °C for 40 hours under H_2 (15 psi). On completion, the reaction mixture was filtered through celite and concentrated *in vacuo*. The residue was purified by column chromatography ($Si0_2$, EA) to give the title compound (100 mg, 59% yield) as brown liquid. LC-MS (ESI^+) *m/z* 615.1 $(M+Na)^+$.

[004101] Step 3 - 3-r4-r3-r2-r2-r2-(2-Aminoethoxy)ethoxy1ethoxy1ethoxy1propyl1-3-methyl-2-oxo- benzimidazol-l-yl1piperidine-2.6-dione

[004102] To a solution of tert-butyl N-[2-[2-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol -4-yl]propoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate (0.10 g, 168 umol) in DCM (10 mL) was added HCl/dioxane (4 M, 2 mL). The reaction mixture was stirred at 20 °C for 16 hours. On completion, the mixture was concentrated *in vacuo*. The residue was purified by reverse flash (0.1 % FA condition) to give the title compound (25.0 mg, 30% yield) as gray solid. LC-MS (ESI^+) *m/z* 493.3 $(M+H)^+$.


[004103] **2-|2-|2-(2-Pron-2-vnoxyethoxy)ethoxylethoxy|ethanol [Intermediate UY)**



UY

[004104] To a mixture of 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethanol (20.0 g, 102 mmol, 17.7 mL, CAS# 25322-68-3) and 3-bromoprop-l-yne (14.7 g, 123 mmol) in THF (200 mL) was added TBAI (2.28 g, 6.18 mmol), KI (2.56 g, 15.45 mmol) and KOH (5.78 g, 102 mmol). The mixture was stirred at 25 °C for 12 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo*. The residue was purified by column chromatography (PE: EA= 5/1 to 0/1) to give the title compound (16.0 g, 67% yield) as a light yellow oil. ^1H NMR (400MHz, CDCh) δ 4.18 (d, J = 2.4 Hz, 2H), 3.70 (d, J = 4.8 Hz, 2H), 3.67 (d, J = 3.2 Hz, 2H), 3.69 - 3.61 (m, 10H), 3.60 - 3.57 (m, 2H), 2.73 (s, 1H), 2.42 (t, J = 2.4 Hz, 1H).

[004105] **2-[2-[2-[2-[(4-MethoxyphenvDmethyl-methyl-aminol ethoxy] ethoxy] ethoxy] ethanamine [Intermediate UZ)**




[004106] Step 1 - Tert-butyl N-r2-r2-r2-r2-r(4-methoxyphenvDmethyl-methyl-aminol ethoxy] ethoxy] ethoxy] ethyllcarbamate

[004107] To a solution of 2-[2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethyl methanesulfonate (1.65 g, 4.44 mmol, Intermediate AO), l-(4-methoxyphenyl)-N-m ethyl-methanamine (671 mg, 4.44 mmol) in DMF (20.0 mL) was added K2CO3 (1.23 g, 8.88 mmol). The mixture was stirred at 20 °C for 15 hours. On completion, the mixture was diluted with H_20 (60 mL), then extracted with EA (3 X 30 mL). The organic layers were washed with brine (3 X 30 mL) and dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo*. The mixture was purified by reverse phase: (0.1% FA) to give the title compound (700 mg, 36% yield) as yellow oil. 1H NMR (400MHz, CDCL) δ 8.52 (s, 1H), 7.33 (d, *J* = 8.4 Hz, 2H), 6.90 (d, *J* = 8.8 Hz, 2H), 3.87 (s, 2H), 3.83 (s, 3H), 3.81 - 3.75 (m, 2H), 3.68 - 3.61 (m, 8H), 3.56 - 3.48 (m, 2H), 3.38 - 3.25 (m, 2H), 2.96 - 2.84 (m, 2H), 2.48 (s, 3H), 1.46 (s, 9H).

[004108] Step 2 - 2-[2-[2-[2-[(4-Methoxyphenvl)methyl-methyl-amino] ethoxy] ethoxy] ethoxy] ethanamine

[004109] To a solution of tert-butyl N-[2-[2-[2-[2-[(4-methoxyphenyl) methyl-methyl-amino] ethoxy] ethoxy] ethoxy]ethyl]carbamate (700 mg, 1.64 mmol) in DCM (10.0 mL) was added HCl/dioxane (4.00 M, 10.0 mL). The mixture was stirred at 15 °C for 0.5 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (590 mg, 90% yield, HC1 salt) as yellow oil. LC-MS (ESI^+) *m/z* 327.3 $(M+H)^+$.

[004110] 2-(2,6-Dioxo-3-piperidyl)-4-[2-[2-[2-[2-(methylaminolethoxyl ethoxy] ethoxy] ethylamino] isoindoline-l,3-dione [Intermediate VA**)**




[004111] Step 1 - 2-(2.6-Dioxo-3-piperidyl)-4-r2-r2-r2-r2-r(4-methoxyphenyl)methyl-methylaminolethoxyl ethoxylethoxylethylaminolisoindoline- 1,3-dione

[004112] To a solution of 2-[2-[2-[2-[(4-methoxyphenyl)methyl-methyl-amino] ethoxy] ethoxy] ethoxy] ethanamine (590 mg, 1.63 mmol, HC1, Intermediate UZ), 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (494 mg, 1.79 mmol, Intermediate R) in dioxane (10.0 mL) was added DIPEA (2. 10 g, 16.2 mmol). The mixture was stirred at 115 °C for 16 hours. On completion, the mixture was concentrated *in vacuo.* The mixture was purified by reverse phase: (0. 1% FA) to give the title compound (500 mg, 52% yield) as yellow solid. LC-MS (ESI^+) *m/z* 583.3 $(M+H)^+$.

[004113] Step 2 - 2-(2.6-Dioxo-3-piperidylV4-r2-r2-r2-r2-(methylamino)ethoxylethoxylethoxylethylaminol isoindoline-E3-dione

[004114] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-[2-[2-[2-[2-[(4-methoxyphenyl)methyl-methylamino] ethoxy]ethoxy]ethoxy]ethylamino]isoindoline-l,3-dione (400 mg, 686 umol) in MeOH (10.0 mL) was added Pd/C (200 mg) and $Pd(OH)_2$/C (200 mg) and HC1 (1.00 M, 686 uL). The mixture was stirred at 15 °C for 1 hour under H_2 (15 psi). On completion, the mixture was filtered and the filtrate was concentrated *in vacuo.* The mixture was purified by reverse phase (0.1% HC1) to give the title compound (160 mg, 50% yield) as yellow solid. LC-MS (ESI^+) *m/z* 463.3 $(M+H)^+$.

[004115] 3-14-13-12-[2-[2-(2-Hydroxyethoxy)ethoxylethoxylethoxylpropyll-3-methyl-2-oxo- benzimidazol-l-yl]piperidine-2,6-dione [Intermediate VB)



[004116] Step 1 - 3-r4-r3-r2-r2-r2-(2-Hvdroxyethoxy)ethoxy1ethoxy1ethoxy1prop-l-vnyl1-3-methyl -2-oxo- benzimidazol-l-yl1piperidine-2.6-dione


[004117] To a mixture of 2-[2-[2-(2-prop-2-ynoxyethoxy)ethoxy]ethoxy]ethanol (1.03 g, 4.44 mmol, Intermediate UY) and 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (0.50 g, 1.48 mmol, Intermediate HP) in DMSO (20 mL) was added Cul (56.3 mg, 295umol), P(t-Bu) $_3$ (2.30 g, 1.48 mmol, 2.67 mL, 13% solution of toluene), DIPEA (955 mg, 7.39 mmol) and Pd(PPh $_3$)$_2$Cl$_2$ (103 mg, 147 umol). The reaction mixture was stirred at 80 °C for 3 hours. On completion, the reaction mixture was diluted with water (60 mL) and extracted with EA (4 X 60 mL). The combined organic layers was dried over Na$_2$S0 $_4$, filtered and concentrated *in vacuo* to give a residue. The crude product was purified by prep-HPLC (0.1 % FA condition) to give the title compound (0.50 g, 69% yield) as brown oil. ^{1}H NMR (400MHz, DMSO-i¾) δ 11.11 (s, 1H), 7.17 (d, *J* = 8.0 Hz, 1H), 7.15 - 7.11 (m, 1H), 7.06 - 7.00 (m, 1H), 5.40 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.55 (t, 7 = 5.2 Hz, 1H), 4.46 (s, 2H), 3.70 - 3.61 (m, 5H), 3.60 - 3.57 (m, 2H), 3.53 - 3.51 (m, 6H), 3.49 - 3.47 (m, 4H), 3.41 - 3.39 (m, 2H), 2.95 - 2.84 (m, 1H), 2.77 - 2.58 (m, 2H), 2.07 - 1.99 (m,

1H).

[004118] Step _2_-_3-r4-r3-r2-r2-r2-(2-Hvdroxyethoxy)ethoxy1ethoxy1ethoxy1propyl1-3-methyl-2-oxo- benzimidazol-l-yl1piperidine-2.6-dione

[004119] To a mixture of 3-[4-[3-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]prop-l-ynyl]-3-methyl-2- oxo-benzimidazol-l-yl]piperidine-2,6-dione (200 mg, 408 umol) in THF (10 mL) was added Pd/C (100 mg, 10% *wi)* and $Pd(OH)_2/C$ (100 mg, 10% *wf).* The reaction mixture was stirred at 25 °C for 12 hours under H_2 (15 psi) atmosphere. On completion, the reaction mixture was filtrated and concentrated *in vacuo* to give the title compound (180 mg, 89% yield) as white solid. ^1H NMR (400MHz, DMSO^) δ 11.09 (s, 1H), 6.96 (d, *J* = 4.4 Hz, 2H), 6.90 - 6.86 (m, 1H), 5.36 (dd, *J* = 5.2, 12.4 Hz, 1H), 4.57 (t, *j* = 5.2 Hz, 1H), 4.03 (q, *J* = 7.2 Hz, 1H), 3.56 (s, 3H), 3.52 *(d, J* = 5.6 Hz, 10H), 3.48 - 3.45 (m, 4H), 3.40 *(d, J* = 5.2 Hz, 2H), 2.98 - 2.93 (m, 2H), 2.89 - 2.84 (m, 1H), 2.72 - 2.63 (m, 2H), 2.61 - 2.58 (m, 2H), 2.02 - 1.96 (m, 2H), 1.85 - 1.81 (m, 1H); LC-MS (ESI^+) *m/z* 494.3 $(M+H)^+$.

[004120] **2-[[2-[[2-[BenzyloxycarbonvUmethvPamino1acetyll-methyl-amino1acetyl1-methyl-amino] acetic acid [Intermediate** VC]



VC

[004121] Step 1 -Methyl 2-rr2-rbenzyloxycarbonyl(methyl)amino1acetyl1-methyl-amino] acetate

[004122] To a solution of 2-[benzyloxycarbonyl(methyl)amino]acetic acid (4.30 g, 19.2 mmol, CAS# 39608-31-6) and methyl 2-(methylamino)acetate (2.69 g, 19.2 mmol, HC1, CAS # 5473-12-1) in DMF (25 mL) was added DIPEA (4.98 g, 38.5 mmol) and HATU (8.79 g, 23.1 mmol). The reaction mixture was stirred at 25 °C for 1 hours. On completion, the reaction mixture was quenched with water (100 mL) and extracted with EA (3 X 200 mL). The combined organic layers were washed with brine (2 x 200 mL), dried with anhydrous Na_2S0_4, filtered and

concentrated *in vacuo*. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (5.00 g, 84% yield) as colorless oil. LC-MS (ESI+) *m/z* 309.1 $(M+H)^+$.

[004123] Step_2_-_2-rr2-rBenzyloxycarbonyl(´methv0amino1acetvn-methyl-amino1acetic acid

[004124] To a solution of methyl 2-[[2-[benzyloxycarbonyl(methyl)amino]acetyl]-methyl-amino] acetate (2.00 g, 6.49 mmol) in THF (20 mL) and H_20 (4 mL) was added LiOH (310 mg, 12.9 mmol). The reaction mixture was stirred at 25 °C for 12 hours. On completion, the reaction mixture was acidified to pH = 5 with 1.0 M aq. HC1 and concentrated *in vacuo*. The residue was purified by flash (0.1 %, HC1) to give the title compound (1.80 g, 91% yield) as colorless oil. LC-MS (ESI+) *m/z* 295.1 $(M+H)^+$.

[004125] Step_3_-_Methyl_2-rr2-rr2-rbenzyloxycarbonyl(methvnamino1acetyl1-methyl-aminolacetyll-methyl- aminolacetate


[004126] To a solution of methyl 2-(methylamino)acetate (1.02 g, 7.34 mmol, HC1, CAS # 5473-12-1) and 2-[[2-[benzyloxycarbonyl(methyl)amino]acetyl]-methyl-amino]acetic acid (1.80 g, 6.12 mmol) in DMF (20 mL) was added DIPEA (2.37 g, 18.3 mmol) and HATU (2.56 g, 6.73 mmol). The reaction mixture was stirred at 25 °C for 30 minutes. On completion, the reaction mixture was quenched with water (30 mL) and extracted with EA (3 X 100 mL). The combined organic layers were washed with brine (50 mL), dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo*. The residue was purified by silica column chromatography (PE/EA, 5/1 to 1/1) to give the title compound compound (1.30 g, 56% yield) as colorless oil. ¾NMR (400MHz, METHANOL-i/4) δ 7.40 - 7.26 (m, 5H), 5.1 1 (d, *J* = 17.1 Hz, 2H), 4.44 - 4.00 (m, 6H), 3.81 - 3.68 (m, 3H), 3.1 1 - 2.91 (m, 9H).

[004127] Step_4_-_2-rr2-rr2-rBenzyloxycarbonyl(methvnamino1acetyl1-methyl-aminolacetyll-methyl-aminol acetic acid

[004128] To a solution of methyl 2-[[2-[[2-[benzyloxycarbonyl(methyl)amino]acetyl]-methyl-amino] acetyl]-methyl-amino]acetate (1.00 g, 2.64 mmol) in THF (20 mL) and H_20 (4 mL) was added LiOH (126 mg, 5.27 mmol). The reaction mixture was stirred at 25 °C for 2 hours. On completion, the reaction mixture was concentrated *in vacuo*, diluted with water (30 mL) and acidified to pH = 5 with 1.0 M aq.HCl. The reaction mixture was concentrated *in vacuo*. The residue was purified by flash (0.1 %, HC1) to give the title compound (600 mg, 62% yield) as a white solid. ^{1}H NMR (400MHz, DMS0-d_6) δ 7.41 - 7.23 (m, 5H), 5.13 - 5.01 (m, 2H), 4.35 - 3.88

(m, 5H), 4.35 - 3.87 (m, 1H), 3.04 - 2.74 (m, 9H).

[004129] **3-[3-Methyl-4-[3-(methylamino)propyll-2-oxo-benzimidazol-l-yllpiperidine-2,6-dione [Intermediate VD)**



[004130] Step 1 - Tert-butyl N-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]prop-2-ynyl]-N-methyl-carbamate

[004131] To a solution of tert-butyl N-methyl-N-prop-2-ynyl-carbamate (450 mg, 2.66 mmol, Intermediate IY) and 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (300 mg, 887 umol, Intermediate HP) in DMF (15 mL) was added CS2CO3 (1.45 g, 4.44 mmol), CuI (33.7 mg, 177 umol) and Pd(PPh3)$_2$Cl2 (124 mg, 177 umol). The reaction mixture was stirred at 80 °C for 2 hours under N_2. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo*. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (200 mg, 58% yield) as yellow solid. LC-MS (ESI^+) m/z 449.2 $(M+Na)^+$.

[004132] Step 2 - Tert-butyl N-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]prop-2-ynyl]-N-methyl-carbamate


[004133] To a solution of tert-butyl N-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]prop-2- ynyl]-N-methyl-carbamate (220 mg, 515 umol) in THF (20 mL) was added Pd/C (250 mg, 10 wt%) and Pd(OH)2/C (250 mg, 10 wt%). The mixture was stirred at 25 °C under ¾ (15 psi) for 2 hours. On completion, the residue was filtered and the filtrate was concentrated *in vacuo* to give the title compound (210 mg, 94% yield) as a white solid. ^{1}H NMR

(400MHz, DMSO-r/e) δ 11.08 (s, 1H), 7.00 - 6.93 (m, 2H), 6.91 - 6.86 (m, 1H), 5.36 (dd, *J* = 5.2, 12.4 Hz, 1H), 3.55 (s, 3H), 3.28 - 3.21 (m, 2H), 2.91 - 2.83 (m, 3H), 2.80 (s, 3H), 2.75 - 2.61 (m, 2H), 2.01 - 1.96 (m, 1H), 1.86 - 1.72 (m, 2H), 1.36 (s, 9H). LC-MS (ESI$^+$) m/z 453. l(M + Na)$^+$.

[004134] Step 3 - 3-r3-Methyl-4-r3-(methylamino)propyl1-2-oxo-benzimidazol-l-yl1piperidine-2.6-dione

[004135] To a solution of tert-butyl N-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]propyl] -N-methyl -carbamate (210 mg, 487 umo)in DCM (3 mL) was added HCl/dioxane (4 M, 3 mL). The mixture was stirred at 25 °C for 2 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (178 mg, 99% yield, HC1) as a white solid. LC-MS (ESL) m/z 331.1 (M+H)$^+$.

[004136] **N-[2-[[2-[3-[l-(2.,6-dioxo-3-piperidvD-3-methyl-2-oxo-benzimidazol-4-yl]propyl-methyl- amino1-2-oxo-ethyl1-methyl-amino1-2-oxo-ethyl1-N-methyl-2-(methylaminolacetamide [Intermediate VE)**



[004137] Step 1 - Benzyl N-[2-[[2-[[2-[3-[1-(2,6-dioxo-3-piperidvl)-3-methyl-2-oxo-benzimidazoM-yllpropyl- methyl-amino1-2-oxo-ethyl1-methyl-amino1-2-oxo-ethyl1-methyl-aminol-2-oxo-ethyll-N-methyl-carbamate


[004138] To a solution of 3-[3-methyl-4-[3-(methylamino)propyl]-2-oxo-benzimidazol-l-yl]piperidine -2,6-dione (100 mg, 272 umol, HC1, Intermediate VD) and 2-[[2-[[2-[benzyloxycarbonyl(methyl)amino]acetyl] -methyl-amino]acetyl]- methyl-amino]acetic acid

(99.6 mg, 272 umol, Intermediate VC) in DMF (5 mL) was HATU (124 mg, 327 umol) and DIPEA (176 mg, 1.36 mmol, 237 uL). The mixture was stirred at 25 °C for 1.5 hours. On completion, the reaction mixture was diluted with H_2O (5 mL) and then concentrated *in vacuo*. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (140 mg, 75% yield) as a white solid. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.08 (s, 1H), 7.41 - 7.19 (m, 5H), 7.03 - 6.81 (m, 3H), 5.36 (dd, *J* = 5.2, 12.4 Hz, 1H), 5.10 - 4.94 (m, 2H), 4.35 - 4.13 (m, 4H), 4.08 - 3.85 (m, 2H), 3.61 - 3.51 (m, 3H), 3.46 - 3.26 (m, 5H), 2.98 - 2.76 (m, 14H), 2.72 - 2.59 (m, 2H), 2.04 - 1.71 (m, 3H). LC-MS (ESI$^+$) m/z 678.3(M+H)$^+$.

[004139] Step 2 - N-[2-[[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yllpropyl-methyl- amino1-2-oxo-ethyl1-methyl-amino1-2-oxo-ethyl1-N-methyl-2-(methylamino)acetamide

[004140] To a solution of benzyl N-[2-[[2-[[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propyl-methyl-amino]-2-oxo-ethyl]-methyl-amino]-2-oxo-ethyl]-methyl-amino]-2-oxo-ethyl]-N-methyl-carbamate (200 mg, 295 umol) in THF (10 mL) was added Pd/C (100 mg, 915 umol, 10 wt%) and Pd(OH)$_2$/C (100 mg, 915 umol, 10 wt%). The mixture was stirred at 25 °C under H_2 (15 psi) for 12 hours. On completion, the residue was filtered and the filtrate was concentrated *in vacuo* to give the title compound (140 mg, 87% yield) as a white solid. LC-MS (ESI$^+$) m/z 544.3(M+H)$^+$.

[004141] **2-[[2-[[2-[Tert-butoxycarbonvUmethvDaminolacetyll-methyl-aminolacetyll-methyl- amino] acetic acid [Intermediate VF)**



[004142] Step 1 - Methyl 2-rr2-rTert-butoxycarbonyl(´methvDamino1acetyl1-methyl-amino] acetate

[004143] To a solution of 2-[tert-butoxycarbonyl(methyl)amino]acetic acid (5.00 g, 26.4

mmol, CAS# 13734-36-6) in THF (25 mL) was added CDI (4.28 g, 26.4 mmol) under ice-cooling bath. The resulting mixture was stirred for 1 hour; then methyl 2-(methylamino)acetate (3.69 g, 26.4 mmol, HC1) was added followed by addition of a solution of TEA (2.94 g, 29.0 mmol, 4.05 mL) in THF (20 mL). The resulting mixture was stirred at 20 °C for 20 hours. On completion, the mixture was concentrated *in vacuo.* The residue was diluted with EA (100 mL), washed with 10% aq. $NaHC0_3$ and 1 M aq. HC1 subsequently; dried with Na_2S0_4 filtered and concentrated *in vacuo* to give the title compound (3.73g, 51% yield) as yellow oil. ¾NMR (400MHz, DMSO-d_6) δ 4.35 - 4.23 (m, 4H), 3.55 - 3.45 (m, 3H), 3.05 (s, 3H), 2.89 - 2.93 (m, 3H), 1.47 - 1.25 (m, 9H).

[004144] Step 2 - Methyl 2-rmethyl-r2-(methylamino)acetyl1amino1acetate

[004145] To a solution of methyl 2-[[2-[tert-butoxycarbonyl(methyl)amino]acetyl]-methyl-amino] acetate (3.73 g, 13.60 mmol) in DCM (10 mL) was added TFA(7.70 g, 67.53 mmol, 5 mL) under 0 °C. The resulting mixture was stirred at 20 °C for 16 hours. On completion, the mixture was concentrated *in vacuo* to give to give the title compound (3.85 g, 98% yield, TFA salt) as yellow oil.

[004146] Step 3 -Methyl 2-rr2-rr2-rtert-butoxycarbonyl(´methvDamino1acetyl1-methyl-aminolacetyll -methyl- aminolacetate


[004147] To a solution of 2-[tert-butoxycarbonyl(methyl)amino]acetic acid (1.31 g, 6.94 mmol, CAS #13734-36-6) and TEA (3.51 g, 34.7 mmol, 4.83 mL) in THF (50 mL) was isobutyl carbonochloridate (2.37 g, 17.3 mmol, 2.28 mL, CAS# 543-27-1) at 0 °C. The mixture was stirred at 25 °C for 0.5 hour, then methyl 2-[methyl-[2- (methylamino)acetyl]amino]acetate (2.00 g, 6.94 mmol, TFA) was added, and the mixture was stirred at 25 °C for 3 hours. On completion, the reaction mixture was diluted with H_20 (50 mL), and extracted with EA (2 X 100 mL), then concentrated *in vacuo.* The residue was purified by prep-HPLC (column: Kromasil l50*25mm*l0um; mobile phase: [water(0.225%FA)-ACN];B%: l7%-47%,l0min) to give the title compound (400 mg, 16% yield) as yellow oil. ^1H NMR (400MHz, CD_3CI) δ 4.15 - 4.12 (m, 3H), 3.78 (s, 1H), 3.82 - 3.77 (m, 1H), 3.75 - 3.73 (m, 2H), 3.09 - 3.05 (m, 5H), 2.99 - 2.95 (m, 2H), 2.92 (s, 3H), 2.95 - 2.88 (m, 3H), 1.46 (s, 9H).

[004148] Step 4 - 2-rr2-rr2-rTert-butoxycarbonyl(´methvDamino1acetyl1-methyl-aminolacetyll-methyl- amino] acetic acid

[004149] To a solution of methyl 2-[[2-[[2-[tert-butoxycarbonyl(methyl)amino] acetyl]-methyl-amino] acetyl]-methyl -amino] acetate (200 mg, 579 umol) in THF (4 mL) and H_20 (2 mL)

was added LiOH (27.7 mg, 1.16 mmol). The reaction mixture was stirred at 25 °C for 12 hr. On completion, the mixture was concentrated *in vacuo.* The residue was diluted with H_20 (4 mL), and then adjusted to pH = 5 with 1.0 M aq.HCl to give the title compound (190 mg, 99% yield) as yellow oil. LC-MS (ESI^+) m/z 232.1 $(M+H)^+$.

[004150] **3-[3-Methyl-5-[3-(methylamino)propyl1-2-oxo-benzimidazol-l-yl1piperidine-2,6-dione [Intermediate VG)**



[004151] Step 1 - Tert-butyl N-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]prop-2-ynyl]-N-methyl-carbamate

[004152] To a solution of 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (400 mg, 1.18 mmol, Intermediate HN), tert-butyl N-methyl-N-prop-2-ynyl-carbamate (400 mg, 2.37 mmol, Intermediate IY) and $Pd(PPh_3)2Cl2$ (83.0 mg, 118 umol) in DMF (4 mL) was added PPh_3 (62.0 mg, 236 umol), TEA (2.15 g, 21.2 mmol) and CuI (22.5 mg, 118 umol). The reaction mixture was stirred at 80 °C for 3 hours under N_2. On completion, the reaction mixture was quenched with aq. NH_4Cl (30 mL) and extracted with EA (3 X 50 mL). The combined organic layers were washed with brine (50 mL), dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by flash (0.1%, FA) to give the title compound (200 mg, 37% yield) as a yellow solid. LC-MS (ESI^+) m/z 427.1 $(M+H)^+$.

[004153] Step 2 - Tert-butyl N-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]prop-2-ynyl]-N - methyl -carbamate


[004154] To a solution of tert-butyl N-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]prop-2- ynyl]-N-methyl-carbamate (200 mg, 468 umol) in THF (20 mL) was

added $Pd(OH)_2$ (25.0 mg, 178 umol) and Pd/C (25.0 mg, 10 wt%). The reaction mixture was stirred at 25 °C for 12 hours under H_2 (15 psi). On completion, the reaction mixture was diluted with EA (20 mL), filtered through a short of silica column and washed with EA (2 X 50 mL). The organic layers were concentrated *in vacuo.* The residue was purified by flash chromatography (0.1%, FA) to give the title compound (200 mg, 99% yield) as a white solid. LC-MS (ESI^+) m/z 331.0 $(M-100+H)^+$.

[004155] Step 3 - 3-r3-Methyl-5-r3-(methylamino)propyl1-2-oxo-benzimidazol-l-yl1piperidine-2.6-dione

[004156] To a solution of tert-butyl N-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]propyl]- N-methyl-carbamate (200 mg, 464 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 5 mL). The reaction mixture was stirred at 25 °C for 20 min. On completion, the reaction mixture was concentrate *in vacuo* to give the title compound (150 mg, 97% yield) as a white solid. LC-MS (ESI^+) m/z 331.1 $(M+H)^+$.

[004157] N-[2-[[2-[3-[l-(2.,6-dioxo-3-piperidyD-3-methyl-2-oxo-benzimidazol-5-yl]propyl-methyl- aminol-2-oxo-ethyll-methyl-aminol-2-oxo-ethyll-N-methyl-2-(methylamino)acetamide [Intermediate VH)



[004158] Step 1 - Tert-butyl N-[2-[[2-[[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]propyl-methyl-amino]-2-oxo-ethyl]-methyl-amino]-2-oxo-ethyl]-methyl-aminol-2-oxo-ethyll-N-methyl-carbamate


[004159] To a solution of 3-[3-methyl-5-[3-(methylamino)propyl]-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione (100 mg, 272 umol, HC1, Intermediate VG) and 2-[[2-[[2-[tert-butoxycarbonyl(methyl)amino]acetyl]-methyl- amino]acetyl]-methyl-amino]acetic acid (108 mg, 327 umol, Intermediate VF) in DMF (5 mL) was added DIPEA (105 mg, 817 umol) and HATU (124 mg, 327 umol). The reaction mixture was stirred at 25 °C for 30 mines. On completion, the reaction mixture was quenched with water (5 mL), concentrated *in vacuo*. The residue was purified by flash chromatography (0.1%, FA) to give the title compound (50.0 mg, 28% yield) as a white solid. LC-MS (ESI^+) m/z 644.2 $(M+H)^+$.

[004160] Step 2 - N-[2-[[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yllpropyl-methyl- amino]-2-oxo-ethyl]-methyl-amino]-2-oxo-ethyl]-N-methyl-2-(methylamino)acetamide


[004161] To a solution of tert-butyl N-[2-[[2-[[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-

oxo-benzimidazol-5- yl]propyl-methyl-amino]-2-oxo-ethyl]-m ethyl-amino]-2-oxo-ethyl]-methyl-amino]-2-oxo-ethyl]-N-methyl-carbamate (50.0 mg, 77.6 umol) in DCM (4 mL) was added HCl/dioxane (4 M, 10 mL). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (40.0 mg, 88% yield, HC1) as a white solid. LC-MS (ESI$^+$) m/z 544.2 (M+H)$^+$.

[004162] **N-[3-carbamoyl-l-(4-formylphenvPpyrazol-4-yll-4-cvano-pyridine-2-carboxamide [Intermediate VI)**



GB



VI

[004163] Step 1 - N-r3-carbamoyl-l-r4-(hvdroxymethvnphenyl1pyrazol-4-yl1-4-cvano-pyridine-2 -carboxamide


[004164] To a solution of 4-amino-l-[4-(hydroxymethyl)phenyl]pyrazole-3-carboxamide (200 mg, 861 umol, Intermediate GB) and 4-cyanopyridine-2-carboxylic acid (102 mg, 688 umol, CAS# 640296-19-1) in DMF (5 mL) was added DIPEA (222 mg, 1.72 mmol) and HATU (327 mg, 861 umol). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was poured into water (10 mL), the solid was filtered and washed with water (2 X 5 mL). Then the solid was dried *in vacuo* to give the title compound (200 mg, 42% yield) as a white solid. LC-MS (ESI$^+$) *m/z* 385.0 (M+Na)$^+$.

[004165] Step 2 - N-r3-carbamoyl-l-(4-formylphenv0pyrazol-4-vn-4-cvano-pyridine-2-carboxamide

[004166] To a solution of N-[3-carbamoyl-l-[4-(hydroxymethyl)phenyl]pyrazol-4-yl]-4-cyano-pyridine-2- carboxamide (130 mg, 358 umol) in THF (10 mL) was added DMP (152 mg,

358 umol) at 0 °C. Then the reaction mixture was stirred at 25 °C for 2 hours. On completion, the reaction mixture was filtered. The filtrate was concentrated *in vacuo* to give the title compound (100 mg, 277 umol, 77% yield) as a white solid. LC-MS (ESI^+) *m/z* 383.0 $(M+Na)^+$.


[004167] 2-[2-[2-[2-[3-[l-(2.,6-Dioxo-3-piperidvP-3-methyl-2-oxo-benzimidazol-4-yllpropoxy] ethoxy] ethoxy] ethoxy] ethyl methanesulfonate (Intermediate VJ)




VB VJ


[004168] To a solution of 3-[4-[3-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]propyl]-3-methyl-2 -oxo-benzimidazol-l-yl]piperidine-2,6-dione (150 mg, 304 umol, Intermediate VB) in DCM (10 mL) was added TEA (92 mg, 911 umol) and MsCl (104 mg, 911 umol). The mixture was stirred at 25 °C for 4 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (170 mg, 98% yield) as yellow oil. LC-MS (ESI^+) *m/z* 572.3 $(M+l)^+$.

[004169] 3-[4-[3-[2-[2-[2-(4-Aιηiηo-1-piperidyllethoxy] ethoxy] ethoxy] ethoxy] propyl]-3-methyl-2 -oxo-benzimidazol-1-yl]piperidine-2.,6-dione [Intermediate VK)



VJ





VK

[004170] Step 1 - Tert-butyl N-[1-[2-[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]propoxy]ethoxy]ethoxy]ethyl]-4-piperidyl]carbamate


[004171] To a solution of 2-[2-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propoxy] ethoxy]ethoxy]ethoxy]ethylmethanesulfonate (250 mg, 437 umol, Intermediate VJ) in ACN (10 mL) was added KI (7.26 mg, 43 umol), NaHCCb (110 mg, 1.31 mmol) and tert-butyl N-(4-piperidyl)carbamate (175 mg, 875 umol, CAS# 73874-95-0). The mixture was stirred at 80 °C for 16 hours. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was purified by reversed phase flash chromatography to give the title compound (200 mg, 66% yield) as light yellow oil. LC-MS (ESI^+) *m/z* 676.4 $(M+l)^+$.

[004172] Step 2 - 3-[4-[3-[2-[2-[2-(4-Amino-1-piperidyl]ethoxy]ethoxy]ethoxy]propyn-3-methyl-2-oxo-benzimidazol-l-yllpiperidine-2.6-dione

[004173] To a solution of tert-butyl N-[l-[2-[2-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo- benzimidazol-4-yl]propoxy]ethoxy]ethoxy]ethoxy]ethyl]-4-piperidyl]carbamate (200 mg,

295 umol) in DCM (10 mL) was added HCl/dioxane (4 M, 5 mL). The mixture was stirred at 25 °C for 3 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (180 mg, 99% yield) as yellow solid. LC-MS (ESI^+) *m/z* 576.4 $(M+l)^+$.

[004174] **[4-[4,5,6,7-Tetrahvdropyrazolo[4,3-b]pyridin-2-vnphenyl]methanol [Intermediate VL)**



VL

[004175] Step 1 - Tert-butyl 2.5.6.7-tetrahvdropyrazolor4.3-b1pyridine-4-carboxyl ate

[004176] To a mixture of 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-b]pyridine (500 mg, 3.13 mmol, HC1, CAS# 1187830-47-2) and $(Boc)_20$ (752 mg, 3.45 mmol) in MeOH (15 mL) was added aq.K_2C0_3 (3 M, 2.09 mL). The reaction mixture was stirred at 20 °C for 15 hours. On completion, the mixture was concentrated *in vacuo.* The residue was purified by silica gel chromatography ($Si0_2$) to give the title compound (500 mg, 71% yield) as a white solid. ^1H NMR (400MHz, DMSO-di) δ 12.05 (s, 1H), 7.55 (s, 1H), 3.66 - 3.55 (m, 2H), 2.65 (t, *J* = 6.4 Hz, 2H), 1.94 - 1.82 (m, 2H), 1.51 (s, 9H).

[004177] Step 2 - Tert-butyl 2-r4-(hvdroxymethyl)phenyl1-6.7-dihydro-5 H-pyrazolo[4.3-blpyridine-4- carboxylate


[004178] To a solution of [4-(hydroxym ethyl)phenyl]boronic acid (112 mg, 739 umol, CAS# 59016-93-2) and tert-butyl 2,5,6,7-tetrahydropyrazolo[4,3-b]pyridine-4-carboxylate (110 mg, 493 umol) in DCM (5 mL) was added $Cu(OAc)_2$ (179 mg, 985 umol) and pyridine (2 mL). The reaction mixture was stirred at 25 °C for 12 hours under oxygen (15 psi) atmosphere. On completion, the mixture was quenched with ammonia water (20 mL), stirred and separated. The organic layer was acidified to pH = 5 with 1N aq.HCl (20 mL), separated and washed with brine (20 mL), then concentrated *in vacuo.* The mixture was purified by silica gel chromatography ($Si0_2$) to give the title compound (80.0 mg, 49% yield) as colorless oil. ^1H NMR (400MHz, DMSO-di) δ 8.16 (s,

1H), 7.64 (d, *J* = 8.4 Hz, 2H), 7.39 (d, *J* = 8.8 Hz, 2H), 4.93 (t, *J* = 5.6 Hz, 1H), 4.53 (d, *J* = 5.6 Hz, 2H), 3.72 - 3.62 (m, 2H), 2.78 - 2.71 (m, 2H), 2.00 - 1.91 (m, 2H), 1.54 (s, 9H); LC-MS (ESI^+) *m/z* 330.2 $(M+H)^+$.

[004179] Step 3 - r4-(4.5.6.7-Tetrahvdropyrazolor4.3-b1pyridin-2-yl iphenyllmethanol

[004180] To a solution of tert-butyl 2-[4-(hydroxymethyl)phenyl]-6,7-dihydro-5H-pyrazolo[4,3-b]pyridine-4- carboxylate (60.0 mg, 182 umol) in DCM (4 mL) was added HCl/dioxane (4 mL). The reaction mixture was stirred at 25 °C for 12 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (45 mg, 93% yield, HC1) as a yellow solid. LC-MS (ESI^+) *m/z* 230.1 $(M+H)^+$.

[004181] Tert-butyl N-[4-[4-[2-(4-formylphenvO-6.,7-dihvdro-5H-pyrazolo[4.,3-blpyridine-4-carbonyl] oxazol-2-yl|-2-pyridyl]-N-(2,2,2-trif uoroethyl)carbamate (Intermediate VM)




[004182] Step 1 - Tert-butyl N-[4-[4-[2-[4-(hvάrθχvmethyl)phenyl1-6.7-dihydro-5H-pyrazolor4.3-b1pyridine-4- carbon yl1oxazol-2-yl1-2-pyridyl1-N-(2. 2.2-trifluoroethyl icarbamate

[004183] To a solution of [4-(4,5,6,7-tetrahydropyrazolo[4,3-b]pyridin-2-yl)phenyl]methanol (45.0 mg, 169 umol, HC1, Intermediate VL) and 2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (52.5 mg, 135 umol, Intermediate CM) in DMF (4 mL) was added HATU (64.4 mg, 169 umol) and DIPEA (109 mg, 847 umol). The reaction mixture was stirred at 25 °C for 0.5 hour. On completion, the mixture was quenched with water (50 mL), stirred and filtered. The filter cake was dried *in vacuo* to give the title compound (70 mg, 69% yield) as a brown solid. LC-MS (ESI^+) *m/z* 599.3 $(M+H)^+$

[004184] Step 2 - Tert-butyl N-[4-[4-[2-(4-formylphenyl)-6,7-dihydro-5H-pyrazolo[4,3-b]pyridine-4-carbonyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate

[004185] To a solution of tert-butyl N-[4-[4-[2-[4-(hydroxymethyl)phenyl]-6,7-dihydro-5H-pyrazolo[4,3-b] pyridine-4-carbonyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (70.0 mg, 117 umol) in DCM (4 mL) was added DMP (74.4 mg, 175 umol). The reaction mixture was stirred at 25 °C for 2 hours. On completion, the mixture was quenched with sat.$NaHCO_3$ (20 mL) and sat. $Na_2S_2O_3$ (20 mL) and extracted with DCM (2 X 30 mL). The organic layer was washed with brine (40 mL), dried over Na_2SO_4, filtered and the filtrate was concentrated *in vacuo* to give the title compound (65 mg, 93% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 597.3 $(M+H)^+$.


[004186] (4-Nitrophenyl) N-[2-[2-[2-(tert-butoxycarbonylaminolethoxy] ethoxy]ethyl]carbamate [Intermediate VN)




VN


[004187] To a solution of tert-butyl N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]carbamate (500 mg, 2.01 mmol, CAS# 153086-78-3), (4-nitrophenyl)carbonochloridate (446 mg, 2.21 mmol) in DCM (20.0 mL) was added TEA (509 mg, 5.03 mmol). The mixture was stirred at 0 °C for 1 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (800 mg, 90% yield) as yellow solid. LC-MS (ESI^+) *m/z* 314.1 $(M+H-100)^+$.

[004188] l-[2-[2-(2-Aminoethoxy)ethoxylethyll-3-[[2-(2.,6-dioxo-3-piperidyD-l-oxo-isoindolin-5- yl]methyl]urea [Intermediate VO]



QM





VO


[004189] Step 1 - Tert-butyl N-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5-yl]methylcarbamoylamino]ethoxy]ethoxy]ethyl]carbamate

[004190] To a solution of 3-[5-(aminomethyl)-l-oxo-isoindolin-2-yl]piperidine-2,6-dione (130 mg, 419 umol, HC1, Intermediate QM), (4-nitrophenyl) N-[2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethyl]carbamate (347 mg, 839 umol, Intermediate VN) in DMF (15.0 mL) was added TEA (212 mg, 2.10 mmol). The mixture was stirred at 20 °C for 1 hour. On completion, the mixture was concentrated *in vacuo.* The mixture was purified by reverse phase chromatography (0.1% FA) to give the title compound (170 mg, 73% yield) as white solid. ^{1}H NMR (400MHz, DMSO-^e) δ 10.99 (s, 1H), 7.67 (d, *J* = 7.6 Hz, 1H), 7.45 (s, 1H), 7.38 (d, *J* = 7.6 Hz, 1H), 6.78 (s, 1H), 6.56 (t, *J* = 6.0 Hz, 1H), 6.04 (t, *J* = 5.6 Hz, 1H), 5.16 - 5.05 (m, 1H), 4.47 - 4.24 (m, 4H), 3.53 - 3.36 (m, 8H), 3.24 - 3.13 (m, 2H), 3.10 - 3.02 (m, 2H), 2.99 - 2.85 (m, 1H), 2.65 - 2.55 (m, 1H), 2.46 - 2.36 (m, 1H), 2.05 - 1.94 (m, 1H), 1.37 (s, 9H).

[004191] Step 2 - 1-[2-[2-(2-Aminoethoxy)ethoxy]ethyl]-3-[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-5- yllmethyllurea

[004192] To a solution of tert-butyl N-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l-oxo-isoindolin-5-yl] methylcarbamoylamino]ethoxy]ethoxy]ethyl]carbamate (170 mg, 310 umol) in DCM (10.0 mL) was added HCl/dioxane (4.00 M, 8.00 mL). The mixture was stirred at 15 °C for 0.5 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (150 mg, 90% yield, HC1) as white solid. LC-MS (ESI^+) *m/z* 448.1 $(M+H)^+$.

[004193] **Methyl 5-[4-amino-3-(difluoromethvDpyrazol-l-yllpyridine-2-carboxylate [Intermediate VP)**



HS VP

[004194] Step 1 - Methyl 5-r3-(difluoromethvn-4-nitro-pyrazol-l-yl1pyridine-2-carboxylate


[004195] To a solution of 3-(difluoromethyl)-4-nitro-lH-pyrazole (200 mg, 1.23 mmol, Intermediate HS), (6-methoxycarbonyl-3-pyridyl)boronic acid (266 mg, 1.47 mmol, CAS# 1072945-86-8) in DCM (20 mL) was added $Cu(OAc)_2$ (334 mg, 1.84 mmol) and pyridine (388 mg, 4.91 mmol). The mixture was stirred at 15 °C for 6 hrs under 0_2 (15 psi). On completion, the mixture washed with $NH_3 \cdot H_20$ (100 mL) and then the layers were washed with brine (50 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo.* The residue was triturated with PE: EA = 1:1 (50 mL) and filtered. The filtered cake was dried *in vacuo* to give the title compound (100 mg, 27 % yield) as a yellow solid. ^1H NMR (400 MHz, CDCh) δ 9.23 - 9.08 (m, 1H), 8.85 (s, 1H), 8.35 (s, 2H), 7.26 - 7.06 (t, *J* = 5.2 Hz, 1H), 4.08 (s, 3H).

[004196] Step 2 - Methyl 5-r4-amino-3-(difluoromethvDpyrazol-l-vnpyridine-2-carboxylate

[004197] To a solution of methyl 5-[3-(difluoromethyl)-4-nitro-pyrazol-l-yl]pyridine-2-carboxylate (100 mg, 335 umol) in DCM (10 mL) was added Pd/C (50.0 mg, 50 wt%). The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred

under H_2 (15 psi) at 15 °C for 2 hours. On completion, the mixture was filtered through celite. The filtrate was concentrated *in vacuo* to give the title compound (89.0 mg, 332 umol, 99% yield) as a yellow solid. ^{1}H NMR (400 MHz, DMSO-d_6) δ 9.13 (d, J=2.0 Hz, 1H), 8.32-8.29 (m, 1H), 8.16 (d, J=8.4 Hz, 1H), 7.29 - 6.97 (t, J=5.2 Hz, 1H), 8.00 (s, 1H), 3.91 (s, 3H), 4.62 (s, 2H).

[004198] **5-[4-[[2-[2-[Tert-butoxycarbonvUcvclopropylmethv0amino]-4-pyridyl]oxazole-4-carbonyl]aminol-3-(difluoromethv0pyrazol-l-yll pyridine-2-carboxylic acid [Intermediate VO)**



[004199] Step 1 - Methyl 5-[4-[[2-[2-[tert-butoxycarbonyl(cvclopropylmethvl)amino]-4-pyridylloxazole-4 -carbonyl1amino1-3-(difluoromethvnpyrazol-l-yl1pyridine-2-carboxylate


[004200] To a solution of methyl 5-[4-amino-3-(difluoromethyl)pyrazol-l-yl]pyridine-2-carboxylate (0.300 g, 1.12 mmol, Intermediate VP) and 2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (402 mg, 1.12 mmol, Intermediate OM) in DMF (2 mL) was added HATU (510 mg, 1.34 mmol) and DIPEA (361 mg, 2.80 mmol). The mixture was stirred at 15 °C for 2 hrs. On completion, to the mixture was added into H_20 and a precipitate formed. The mixture was filtered and the filter cake was dried *in vacuo* to give the title compound (50.0 mg, 820 umol, 73% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 610.3 $(M+H)^+$.

[004201] Step 2 - 5-[4-[[2-[2-[Tert-butoxycarbonyl(cvclopropylmethvl)amino]-4-pyridyl1oxazole-4-carbonyl1 amino1-3-(difluoromethvDpyrazol-l-vnpyridine-2-carboxylic acid

[004202] To a solution of methyl 5-[4-[[2-[2-[tert-

butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl] oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]pyridine-2-carboxylate (500 mg, 820 umol) in THF (50 mL), H_20 (50 mL) and MeOH (10 mL) was added LiOH·HLO (172 mg, 4.10 mmol). The mixture was stirred at 15 °C for 6 hrs. On completion, the mixture was adjusted to pH=6-7 with 1.0 M aq.HCl and a precipitate formed. The mixture was filtered and the filter cake was dried *in vacuo* to give the title compound (500 mg, 90% yield, 90% purity) as a yellow solid. ^{1}H NMR (400 MHz, DMSO-i¾) δ 10.16 (s, 1H) 9.28 (d, *J* = 2.4 Hz, 1H) 9.07 (s, 2H) 8.60 (d, *J* = 5.2 Hz, 1H) 8.44 - 8.52 (m, 1H) 8.32 (s, 1H) 8.18 - 8.25 (m, 1H) 7.64 - 7.78 (m, 1H) 7.19 - 7.52 (m, 1H) 1.52 (s, 9H) 1.09 - 1.28 (m, 1H) 0.35 - 0.50 (m, 2H) 0.24 (q, *J* = 4.8 Hz, 2H); LC-MS (ESI+) m/z 596.2 $(M+H)^+$.

[004203] **3-[5-[3-[2-(2-Aminoethoxy)ethoxy]propyl]-3-methyl-2-oxo-benzimidazol-l-yl]piperidine- 2,6-dione [Intermediate VR)**



[004204] Step 1 - Tert-butyl N-[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl1prop-2 -ynoxylethoxylethyllcarbamate

[004205] To a solution of 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (250 mg, 739 umol, Intermediate HN) and tert-butyl N-[2-(2-prop-2-ynoxyethoxy)ethyl]carbamate (540 mg, 2.22 mmol, synthesized via Step 1 of Intermediate CQ) in DMSO (10 mL) was added CuI (28.2 mg, 148 umol), DIPEA (478 mg, 3.70 mmol) and $Pd(PPh_3)2Cl2$ (104 mg, 148 umol). The mixture was stirred at 80 °C for 2 hrs in a glove box. On completion, the reaction mixture was purified by reverse phase chromatography (0.1% FA condition) to give the title compound (140 mg, 35 % yield) as a yellow solid. ^1H NMR (400 MHz, DMSO-*d6*) δ 11.12 (s, 1H), 7.33 (s, 1H), 7.22 - 7.09 (m, 2H), 6.86 - 6.71 (m, 1H), 5.42-5.37 (m, 1H), 4.40 (s, 2H), 3.67 - 3.61 (m, 2H), 3.59 - 3.53 (m, 2H), 3.08 (m, 2H), 2.95 - 2.86 (m, 1H), 2.08 - 2.00 (m, 1H), 1.37 (s, 9H). LC-MS (ESI^+) *m/z* 506.3 $(M+4)^+$.


[004206] Step 2 - Tert-butyl N-[2-[2-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] propoxy] ethoxy] ethyl] carbamate

[004207] To a solution of tert-butyl N-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] prop-2-ynoxy]ethoxy]ethyl]carbamate (120 mg, 240 umol) in THF (20 mL) was added Pd/C (50 mg, 50 wt%) and $Pd(OH)_2/C$ (50 mg, 10 wt%) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 15 °C for 2 hours. On completion, the mixture was filtered through celite. The filtrate was concentrated *in vacuo* to give the title compound (100 mg, 80% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 505.3 $(M+H)^+$.

[004208] Step 3 - 3-r5-r3-r2-(2-Aminoethoxy)ethoxy1propyl1-3-methyl-2-oxo-benzimidazol-l-yllpiperidine- 2.6-dione

[004209] To a solution of tert-butyl N-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] propoxy]ethoxy]ethyl]carbamate (100 mg, 198 umol) in DCM (10 mL) was added HCl/dioxane (4 M, 5 mL). The mixture was stirred at 15 °C for 0.5 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (80.0 mg, 95% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 405.2 $(M+H)^+$.


[004210] Tert-butyl N-[2-[2-(2-prop-2-ynoxyethoxy)ethoxy]ethyl]carbamate [Intermediate VS)




VS


[004211] A mixture of tert-butyl N-[2-[2-(2-hydroxyethoxy)ethoxy]ethyl]carbamate (3.00 g, 12.0 mmol), 3-bromoprop-l-yne (1.72 g, 14.4 mmol, 1.24 mL), TBAI (356 mg, 962 umol), KI (299 mg, 1.81 mmol) and KOH (675 mg, 12.0 mmol) in THF (30 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 25 °C for 16 hrs under N_2 atmosphere. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo*. The residue was purified by silica gel chromatography to give the title compound (2.50 g, 72% yield) as light yellow oil. ^{1}H NMR (400MHz, CDCh) δ 5.05 (s, 1H), 4.22 (d, *J* = 2.4 Hz, 2H), 3.76 - 3.60 (m, 8H), 3.55 (t, *J* = 5.2 Hz, 2H), 3.35 - 3.27 (m, 2H), 2.44 (t, *J* = 2.4 Hz, 1H), 1.47 (s, 9H).


[004212] **3-15-13-[2-|2-(2-Aminoethoxy)ethoxy|ethoxy1propyl1-3-methyl-2-oxo-benzimidazol-l-yl] piperidine-2,6-dione [Intermediate VT)**



VS







VT

[004213] Step _1_ - _Tert-butyl _N-r2-r2-r2-r3-rl-(2.6-dioxo-3-piperidvD-3-methyl-2-oxo-benzimidazol-5-yllprop- _2-vnoxylethoxylethoxylethyllcarbamate

[004214] A mixture of tert-butyl N-[2-[2-(2-prop-2-ynoxyethoxy)ethoxy]ethyl]carbamate (849 mg, 2.96 mmol, Intermediate VS), 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (500 mg, 1.48 mmol, Intermediate HN), $Pd(PPh3)_2Cl2$ (311 mg, 443 umol), Cul (84 mg, 443 umol) and TEA (2.69 g, 26.6 mmol, 3.70 mL) in DMF (15 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 80 °C for 3 hrs under N_2 atmosphere. On completion, the mixture was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase chromatography (0.1% FA) to give the title compound (400 mg, 49% yield) as light yellow solid. ^1H NMR (400MHz, DMSO-^) δ 11.12 (s, 1H), 7.33 (s, 1H), 7.21 - 7.12 (m, 2H), 6.77 - 6.71 (m, 1H), 5.39 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.40 (s, 2H), 3.68 - 3.62 (m, 2H), 3.61 - 3.56 (m, 2H), 3.55 - 3.47 (m, 6H), 3.35 (s, 3H), 3.07 (q, *J* = 6.0 Hz, 2H), 2.96 - 2.80 (m, 1H), 2.72 - 2.58 (m, 2H), 2.08 - 1.99 (m, 1H), 1.37 (s, 9H).


[004215] Step_2_-_Tert-butyl_N-[2-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]propoxy]ethoxy]ethoxy]ethyl]carbamate

[004216] To a solution of tert-butyl N-[2-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo- benzimidazol-5-yl]prop-2-ynoxy]ethoxy]ethoxy]ethyl]carbamate (400 mg, 734 umol) in THF (100 mL) was added Pd/C (300 mg, 10 wt%) and $Pd(OH)_2$/C (300 mg, 10 wt%). The mixture was stirred at 20 °C for 4 hrs under H_2 (15 psi) atmosphere. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (270 mg, 67% yield) as light yellow solid. ^1H NMR (400MHz, DMSO-r¾) δ 11.07 (s, 1H), 7.08 - 6.96 (m, 2H), 6.87 (d, *J* = 7.2 Hz, 1H), 6.73 (s, 1H), 5.34 (dd, *J* = 5.2, 12.4 Hz, 1H), 3.69 - 3.35 (m, 15H), 3.09 - 3.01 (m, 2H), 2.97 - 2.81 (m, 1H), 2.77 - 2.57 (m, 4H), 2.08 - 1.94 (m, 1H), 1.89 - 1.71 (m, 2H), 1.37 (s, 9H).

[004217] Step_3_-_3-r5-r3-r2-r2-(2-Aminoethoxy)ethoxy1ethoxy1propyl1-3-methyl-2-oxo-benzimidazol-l-yll piperidine-2.6-dione

[004218] To a solution of tert-butyl N-[2-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol -5-yl]propoxy]ethoxy]ethoxy]ethyl]carbamate (270 mg, 492 umol) in DCM (10 mL) was added HCl/dioxane (4 M, 5 mL). The mixture was stirred at 25 °C for 3 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (220 mg, 92% yield) as light yellow solid. ¾NMR (400MHz, DMSO-de) δ 11.08 (s, 1H), 7.86 (s, 3H), 7.07 - 6.97 (m, 2H), 6.91 - 6.84 (m, 1H), 5.40 - 5.29 (m, 1H), 3.61 (t, *J* = 5.2 Hz, 2H), 3.59 - 3.56 (m, 4H), 3.55 - 3.53 (m, 2H), 3.52 - 3.48 (m, 2H), 3.43 - 3.40 (m, 2H), 3.33 (s, 3H), 3.02 - 2.84 (m, 3H), 2.76 - 2.58 (m, 4H), 2.05 - 1.97 (m, 1H), 1.87 - 1.73 (m, 2H).

[004219] **3-14-13-[2-|2-(2-Aminoethoxy)ethoxy]ethoxylpropyll-3-methyl-2-oxo-benzimidazol-l-yll piperidine-2,6-dione [Intermediate VU)**



[004220] Step 1 - Tert-butyl N-[2-[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]prop-2-ynoxy]ethoxy]ethoxy]ethyl]carbamate

[004221] A mixture of tert-butyl N-[2-[2-(2-prop-2-ynoxyethoxy)ethoxy]ethyl]carbamate (1.27 g, 4.44 mmol, Intermediate VS), 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (500 mg, 1.48 mmol, Intermediate HP), CuI (85 mg, 446 umol), $Pd(PPh3)_2Cl2$ (311 mg, 443 umol) and CS2CO3 (2.41 g, 7.39 mmol) in DMF (12 mL) was stirred at 80 °C for 2 hours under N2 atmosphere. On completion, after cooled to 25 °C, the mixture was filtered through a pad of celite and the cake was washed with EA (50 mL). The filtrate and washing were combined, diluted with water (100 mL), and extracted with EA (3 X 40 mL). The combined organic layer was washed with brine (10 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo*. The residue was

purified by reversed phase chromatography (0.1% FA condition) to give the title compound (420 mg, 52% yield) as light yellow gum. ^{1}H NMR (400 MHz, DMSO-^e) δ 11.11 (s, 1H), 7.17 (d, *J* = 8.0 Hz, 1H), 7.10 - 7.15 (m, 1H), 7.00 - 7.06 (m, 1H), 5.39 (dd, *J* = 12.4, 5.6 Hz, 1H), 4.46 (s, 2H), 3.61 - 3.69 (m, 5H), 3.55 - 3.60 (m, 2H), 3.46 - 3.55 (m, 6H), 3.05 (q, *J* = 6.0 Hz, 2H), 2.83 - 2.93 (m, 1H), 2.58 - 2.76 (m, 3H), 2.04 - 2.02 (m, 1H), 1.36 (s, 9 H).


[004222] Step 2 - Tert-butyl N-[2-[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propoxy]ethoxy]ethoxy]ethyl]carbamate

[004223] To a solution of tert-butyl N-[2-[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] prop-2-ynoxy]ethoxy]ethoxy]ethyl]carbamate (500 mg, 918 umol) in THF (10 mL) was added Pd/C (200 mg, 918 umol, 10 wt%) and $Pd(OH)_2$ (200 mg, 1.42 mmol). The mixture was stirred at 25 °C for 16 hours under H_2 (15 psi). On completion, the mixture was filtered through a pad of celite, and the cake was washing with EA (20 mL). The filtrate and washing were combined and concentrated *in vacuo* to give the title compound (500 mg, 90% yield) as light yellow gum. LC-MS (ESI^+) *m/z* 549.2 $(M+H)^+$.

[004224] Step 3 - 3-r4-r3-r2-r2-(2-Aminoethoxy)ethoxy1ethoxy1propyl1-3-methyl-2-oxo-benzimidazol-l-yll piperidine-2.6-dione

[004225] To a mixture of tert-butyl N-[2-[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propoxy]ethoxy]ethoxy]ethyl]carbamate (100 mg, 182 umol) in DCM (2 mL) was added HCl/dioxane (4 M, 4.00 mL). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (100 mg, 98% yield, HC1) as light yellow solid. LC-MS (ESI^+) *m/z* 449.3 $(M+H)^+$.

[004226] **Tert-butyl 2-(2-allyloxyethoxy)acetate [Intermediate W)**




VV

[004227] To a mixture of 2-allyloxyethanol (3.00 g, 29.3 mmol) and diacetoxyrhodium (520 mg, 1.18 mmol) in DCM (30 mL) was added a solution of tert-butyl 2-diazoacetate (12.5 g, 88.1 mmol, CAS# 35059-50-8) in DCM (30 mL) at 25 °C dropwise during 2 hours. The mixture was stirred at 25 °C for 16 hours under N_2. On completion, to the mixture was added HOAc (5.0 mL). Then, the mixture was stirred at 25 °C for 0.5 hour. The mixture was concentrated *in vacuo*. The

residue was purified by column chromatography over silica gel to give the title compound (6.80 g, 100% yield) as light yellow oil. ^{1}H NMR (400 MHz, CDCh) δ 6.00 - 5.85 (m, 1H), 5.29 (dd, *J* = 17.2, 2.0 Hz, 1H), 5.19 (dd, *J* = 10.4, 1.6 Hz, 1H), 4.07 - 4.02 (m, 4H), 3.77 - 3.71 (m, 2H), 3.67 - 3.59 (m, 2H), 1.49 (s, 9H).

[004228] **2-[2-[3-[l-(2, 6-Dioxo-3-piperidvD-3-methyl-2-oxo-benzimidazol-5-yllpropoxy] ethoxy] acetic acid [Intermediate VW)**



[004229] Step 1 - Tert-butyl 2-[2-[(E)-3-Π-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yllallyloxyl ethoxy] acetate

[004230] A mixture of tert-butyl 2-(2-allyloxyethoxy)acetate (1.50 g, 4.62 mmols, Intermediate VV), 3-(5-bromo-3-methyl-2-oxo- benzimidazol-l-yl)piperidine-2,6-dione (600 mg, 1.77 mmol, Intermediate HN), $Pd_2(dba)_3$ (168 mg, 183 umol), t-Bu_3P (720 mg, 355 umol, 10 wt%) and DIPEA (468 mg, 3.62 mmol) in dioxane (30 mL) was stirred at 25 °C for 16 hours under N_2. On completion, the mixture was filtered. The filtrate was concentrated *in vacuo.* The residue was

purified by reversed phase (0. 1% FA condition) to give the title compound (500 mg, 59% yield) as light yellow oil. LC-MS (ESI^+) *m/z* 496.1 $(M+Na)^+$.


[004231] Step 2 -Tert-butyl 2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-vnpropoxyl ethoxy] acetate


[004232] A mixture of tert-butyl 2-[2-[(E)-3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol -5-yl]allyloxy]ethoxy]acetate (500 mg), Pd/C (200 mg, 10 wt%) and $Pd(OH)_2$ (200 mg, 1.42 mmol) in THF (10 mL) was stirred at 25 °C for 16 hours under Eh (15 psi). On completion, the mixture was filtered, and the cake was washed with EA (20 mL). The filtrate and washings were combined and concentrated *in vacuo.* The residue was purified by reversed phase (0.1% FA condition) to give the title compound (400 mg) as light yellow oil. ^1H NMR (400 MHz, CDCh) δ 8.14 (s, 1H), 6.93 - 6.87 (m, 2H), 6.72 (d, *J* = 8.0 Hz, 1H), 5.25 - 5.20 (m, 1H), 4.05 (s, 2H), 3.75 - 3.72 (m, 2H), 3.66 - 3.62 (m, 2H), 3.49 (t, *J* = 6.4 Hz, 2H), 3.45 (s, 3H), 2.96 - 2.83 (m, 2H), 2.76 - 2.71 (m, 2H), 2.29 - 2.19 (m, 2H), 1.95 - 1.90 (m, 2H) 1.49 (s, 9H).

[004233] Step 3 - 2-[2-[3-[1-(2, 6-Dioxo-3-piperidvD-3-methyl-2-oxo-benzimidazol-5-yllpropoxylethoxyl acetic acid

[004234] To a solution of tert-butyl 2-[2-[3-[l-(2, 6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] propoxy] ethoxy] acetate (400 mg, 815 umol) in DCM (4 mL) was added TFA (4 mL) at 25 °C. The mixture was stirred at 25 °C for 16 hours. On completion, the mixture was concentrated *in vacuo.* The residue was purified by reverse phase flash (0.1% TFA condition) to give the title compound (180 mg, 42% yield) as light yellow gum. ^1H NMR (400 MHz, CDCh) δ 8.35 (s, 1H), 6.94-6.87 (m, 2H), 6.74 (d, *J* = 8.0 Hz, 1H), 5.26 - 5.22 (m, 1H), 4.18 (s, 2H), 3.81 - 3.74 (m, 2H), 3.64 - 3.62 (m, 2H), 3.55 (t, *J* = 6.4 Hz, 2H), 3.44 (s, 3H), 2.92 - 2.72 (m, 6H), 2.29 - 2.19 (m, 1H), 2.00 - 1.90 (m, 2H).

[004235] **Methyl 4-[4-amino-3-(difluoromethvDpyrazol- l-yll-2-fluoro-benzoate [Intermediate VX)**





[004236] Step 1 - Methyl 4-r3-(difluoromethvn-4-nitro-pyrazol-l-yl1-2-fluoro-benzoate


[004237] To a solution of 3-(difluoromethyl)-4-nitro-lH-pyrazole (1.00 g, 6.13 mmol, Intermediate HS) and (3-fluoro-4-methoxycarbonyl-phenyl)boronic acid (1.58 g, 7.97 mmol, CAS# 3505083-04-5) in DCM (20 mL) was added $Cu(OAc)_2$ (2.23 g, 12.3 mmol) and pyridine (10 mL). The reaction mixture was stirred at 25 °C for 12 hrs under oxygen (15 psi) atmosphere. On completion, the mixture was quenched with ammonia water (30 mL), then the mixture was stirred and separated. The organic layer was acidified with 1N HC1 (20 mL) to pH < 5, separated and washed with brine (20 mL), concentrated *in vacuo.* The residue was purified by silica gel chromatography ($Si0_2$), and then triturated with PE/EA= 10/1 (50 mL), filtered and the filter cake was concentrated *in vacuo* to give the title compound (360 mg, 19% yield) as a white solid. ^1H NMR (400MHz, DMSO^) δ 9.92 (s, 1H), 8.16 - 8.04 (m, 2H), 8.02 - 7.94 (m, 1H), 7.61 - 7.30 (m, 1H), 3.89 (s, 3H).

[004238] Step 2 - Methyl 4-r4-amino-3-(difluoromethv0pyrazol-l-vn-2-fluoro-benzoate

[004239] To a solution of methyl 4-[3-(difluoromethyl)-4-nitro-pyrazol-l-yl]-2-fluoro-benzoate (350 mg, 1.11 mmol) in THF (10 mL) was added Pd/C (0.1 g, 10% *wf).* The reaction mixture was stirred at 25 °C for 10 hrs under H_2 (15 psi) atmosphere. On completion, the mixture was concentrated *in vacuo* to give the title compound (310 mg, 98% yield) as a white solid. LC-MS (ESI^+) *m/z* 286.1 $(M+H)^+$.

[004240] **4-[4-[[2-[2-[Tert-butoxycarbonvUcvclopropylmethv0amino1-4-**

Pyridylloxazole-4-carbonyll _amino]-3-(dif uoromethyl)pyrazol-1-yl]-2-f uoro-benzoic acid (Intermediate VY)



[004241] Step 1 - Methyl 4-r4-IT2-r2-rtert-butoxycarbonyl(cvclopiOpylmethvDamino1-4-pyridylloxazole-4- carbonyl1amino1-3-(difluoromethvnpyrazol-l-yl1-2-fluoro-benzoate


[004242] To a solution of methyl 4-[4-amino-3-(difluoromethyl)pyrazol-l-yl]-2-fluoro-benzoate (310 mg, 1.09 mmol, Intermediate VX) and 2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (391 mg, 1.09 mmol, Intermediate OM) in DMF (6.00 mL) was added HATU (496 mg, 1.30 mmol) and DIPEA (421 mg, 3.26 mmol). The reaction mixture was stirred at 20 °C for 0.5 hr. On completion, the mixture was quenched with water (50 mL), and filtered. The filter cake was dried *in vacuo* to give the title compound (600 mg, 88% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-i¾) δ 10.15 (s, 1H), 9.06 (s, 1H), 9.01 (s, 1H), 8.60 (d, *J* = 5.2 Hz, 1H), 8.32 (s, 1H), 8.06 (t, *J* = 8.4 Hz, 1H), 8.00 - 7.94 (m, 1H), 7.94 - 7.88 (m, 1H), 7.75 - 7.66 (m, 1H), 7.46 - 7.16 (m, 1H), 3.88 (s, 3H), 3.86 (s, 2H), 1.52 (s, 9H), 1.22 - 1.12 (m, 1H), 0.45 - 0.37 (m, 2H), 0.28 - 0.21 (m, 2H); LC-MS (ESI^{+}) *m/z* 627.0 $(M+H)^{+}$.

[004243] Step 2 - 4-[4-[[2-[2-[Tert-butoxycarbonyl(cvclopropylmethvl)amino]-4-Pyridyl1oxazole-4-carbonyl1 amino1-3-(difluoromethvnpyrazol-l-yl1-2-fluoro-benzoic acid


[004244] To a mixture of methyl 4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole -4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]-2-fluoro-benzoate (600 mg, 958 umol) in a mixed solvent of THF


(10 mL) and H_20 (2 mL) was added $LiOH•H_20$ (160 mg, 3.83 mmol). The reaction mixture was stirred at 25 °C for 10 hrs. On completion, the mixture was concentrated *in vacuo* to remove the THF. The residue was diluted with water (30 mL), acidified with 1N HC1 to pH = 3-5, filtered and the filter cake was dried *in vacuo* to give the title compound (570 mg, 97% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-^e) δ 10.15 (s, 1H), 9.15 - 8.95 (m, 2H), 8.60 (d, *J* = 5.2 Hz, 1H), 8.32 (s, 1H), 8.03 (t, 7 = 8.0 Hz, 1H), 7.94 - 7.83 (m, 2H), 7.71 (d, 7 = 4.8 Hz, 1H), 7.47 - 7.15 (m, 1H), 3.87 (d, *J* = 6.8 Hz, 2H), 1.52 (s, 9H), 0.80 - 0.69 (m, 1H), 0.49 - 0.36 (m, 2H), 0.29 - 0.15 (m, 2H); LC-MS (ESI$^+$) *m/z* 613.2 (M+H)$^+$.

[004245] Tert-butyl _N-(cvclopropylinethvn-N-|4-|4-||3-(difluoromethvn-l-(3-fluoro-4-formyl-phenyl) _ pyrazol-4-yl] carbamoyl] oxazol-2-yl1-2-pyridyl1 carbamate _ [Intermediate VZ)



VY





VZ

[004246] Step_ ___1 ___-_ ___Isopropoxycarbonyl _ ___4-⌈4-[⌈2-⌈2-⌈tert-butoxycarbonyl(cvclopropylmethvnamino1-4-pyridyl1 _____oxazole-4-carbonyl1amino1-3-

(difluoromethvOpyrazol-l-vn-2-fluoro-benzoate

[004247] To a solution of 4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4- carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]-2-fluoro-benzoic acid (1.00 g, 1.63 mmol, Intermediate VY) and TEA (413 mg, 4.08 mmol) in THF (30 mL) was added isopropyl carbonochloridate (400 mg, 3.27 mmol) dropwise. The reaction mixture was stirred at 0 °C for 2 hrs. On completion, the mixture was filtered and the filtrate was used for the next step directly without further purification. LC-MS (ESI^+) *m/z* 699.0 $(M+H)^+$.

[004248] Step_2_-_Tert-butyl_N-(cvclopropylmethvO-N-r4-r4-rr3-(difluoromethvO-l-r3-fluoro-4-(hvdroxymethvn phenyl1pyrazol-4-yl1carbamoyl1oxazol-2-yl1-2-pyridyl1carbamate


[004249] To a solution of isopropoxycarbonyl 4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4- pyridyl]oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]-2-fluoro-benzoate (1.14 g, 1.63 mmol) in a mixed solvent of THF (60 mL) and H_20 (1 mL) was added $LiBH_4$ (178 mg, 8.16 mmol). The reaction mixture was stirred at 0 °C for 2 hrs. On completion, the mixture was quenched with water (50 mL), then extracted with EA (2 X 50 mL). The organic layers were washed with brine (50 mL), dried over Na_2S0_4, and concentrated *in vacuo*. The residue was triturated with DCM/PE = 1/10 (50 mL), filtered and the filter cake was dried *in vacuo* to give the title compound (0.91 g, 93% yield) as a white solid. ^1H NMR (300MHz, DMSO-i¾) δ 10.09 (s, 1H), 9.05 (s, 1H), 8.87 (s, 1H), 8.60 (d, *J* = 5.1 Hz, 1H), 8.32 (s, 1H), 7.80 - 7.68 (m, 3H), 7.61 (t, *J* = 8.4 Hz, 1H), 7.30 (t, *J* = 54.3, Hz, 1H), 5.37 (t, *J* = 5.7 Hz, 1H), 4.58 *(d, J* = 5.7 Hz, 2H), 3.86 *(d, J* = 7.2 Hz, 2H), 1.51 (s, 9H), 1.20 - 1.10 (m, 1H), 0.44 - 0.37 (m, 2H), 0.27 - 0.20 (m, 2H); LC-MS (ESI^+) *m/z* 599.2 $(M+H)^+$.

[004250] Step_3_-_Tert-butyl_N-(cvclopropylmethvl)-N-[4-[4-[[3-(dif uoromethyl)-l-(3-fluoro-4-formyl-phenvD pyrazol-4-yl1carbamoyl1oxazol-2-yl1-2-pyridyl1carbamate

[004251] To a solution of tert-butyl N-(cyclopropylmethyl)-N-[4-[4-[[3-(difluoromethyl)-l-[3-fluoro-4- (hydroxymethyl)phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (0.91 g, 1.52 mmol) in DCM (20 mL) was added DMP (774 mg, 1.82 mmol). The reaction mixture was stirred at 25 °C for 10 hrs. On completion, the mixture was quenched with $Na_2S_20_3$ (30 mL) and $NaHC0_3$ (30 mL), stirred for 10 minutes, then extracted with DCM (2 X 30 mL). The organic layers were washed with brine (50 mL), dried with Na_2S0_4, filtered and the filtrate was concentrated *in vacuo*. The residue was triturated with PE/DCM (10/1, 50 mL), filtered and the filter cake was dried *in vacuo* to give the title compound (840 mg, 93% yield) as a yellow solid.

^{1}H NMR (400MHz, DMSO^) δ 10.43 (s, 1H), 10.20 (s, 1H), 9.07 (s, 1H), 9.05 (s, 1H), 8.59 (d, *J* = 5.2 Hz, 1H), 8.31 (s, 1H), 8.06 - 7.91 (m, 3H), 7.70 (dd, *J* = 1.2, 5.2 Hz, 1H), 7.35 (t, *J* = 107.6 Hz, 1H), 3.86 (d, *J* = 6.8 Hz, 2H), 1.52 (s, 9H), 1.21 - 1.14 (m, 1H), 0.44 - 0.38 (m, 2H), 0.28 - 0.20 (m, 2H); LC-MS (ESI$^+$) *m/z* 597.2 (M+H)$^+$.


[004252] **2- Methyl 4-amino-l-methyl-pyrazole-3-carboxylate [Intermediate WA)**




WA

[004253] To a mixture of methyl 2-methyl-4-nitro-pyrazole-3-carboxylate (0.5 g, 2.70 mmol, synthesized via Step 1 of Intermediate LK) in MeOH (20 mL) was added Pd/C (300 mg, 10% *wt).* The reaction mixture was stirred at 25 °C for 12 hours under H_2 (15 psi) atmosphere. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (400 mg, 95% yield) as white solid. ^{1}H NMR (400MHz, DMSO-^) δ 7.12 (s, 1H), 4.67 (s, 2H), 3.74 (s, 3H), 3.72 (s, 3H).

[004254] **l-4-[[5-(4-Tert-butoxycarbonylpiperazin-l-yDpyrazolo[l.,5-alpyrimidine-3-carbonyl] aminol-l-methyl-pyrazole-3-carboxylic acid [Intermediate WB)**





WB


[004255] Step 1 - Tert-butyl 4-r3-r(3-methoxycarbonyl-l-methyl-pyrazol-4-yl)carbamoyl1pyrazolon ,5-a] pyrimidin-5-yllpiperazine-l-carboxylate

[004256] To a mixture of methyl 4-amino- l-methyl-pyrazole-3-carboxylate (232 mg, 1.50 mmol, Intermediate WA) and 5-(4-tert-butoxycarbonylpiperazin-l-yl)pyrazolo[l,5-a]pyrimidine-3-carboxylic acid (400 mg, 1.15 mmol, Intermediate RC) in ACN (10 mL) was added DIPEA (446 mg, 3.45 mmol, 601 uL) and HATU (875 mg, 2.30 mmol,). The reaction mixture was stirred at 60 °C for 12 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (0.1 % FA condition) to give the title compound (250 mg, 44% yield) as white solid. ^{1}HNMR (400MHz, DMSO-r¾) δ 10.17 (s, 1H), 8.80 (d, *J* = 8.0 Hz, 1H), 8.44 (s, 1H), 8.29 (s, 1H), 6.88 (d, *J* = 8.0 Hz, 1H), 4.02 - 3.92 (m, 7H), 3.86 (s, 3H), 3.61 - 3.49 (m, 4H), 1.42 (s, 9H).

[004257] Step 2 - l-4-rr5-(4-Tert-butoxycarbonylpiperazin-l-vDpyrazolorl.5-a1pyrimidine-3-carbonyll aminol-l-methyl-pyrazole-3-carboxylic acid

[004258] To a mixture of tert-butyl 4-[3-[(3-methoxycarbonyl-l-methyl-pyrazol-4-yl)carbamoyl]pyrazolo [l,5-a]pyrimidin-5-yl]piperazine-l-carboxylate (200 mg, 412 umol) in a solution of THF (10 mL), MeOH (2 mL) and $H_2$0 (2 mL) was added LiOH (98.8 mg, 4.13 mmol). The reaction mixture was stirred at 25 °C for 12 hours. On compound, the reaction mixture was acidified with HC1 (1 N) until pH = 5-6, then the mixture was concentrated *in vacuo* to give the title compound (194 mg, 99% yield) as white solid. ^{1}H NMR (400MHz, DMSO-d_6) δ 10.53 (s, 1H), 8.76 (d, *J* = 7.2 Hz, 1H), 8.28 *(d, J* = 17.6 Hz, 2H), 6.85 (d, *J* = 7.6 Hz, 1H), 4.12 - 3.87 (m, 4H), 3.86 (s, 3H), 3.55 - 3.49 (m, 4H), 1.43 (s, 9H).

[004259] Methyl 5-(4-amino-l-methyl-pyrazol-3-yQ pyridine-3-carboxylate [Intermediate WO



WC

[004260] Step 1 - 3-Bromo-4-nitro-lH-pyrazole

[004261] To a solution of 3-bromo-lH-pyrazole (10 g, 68.0 mmol) in H2SO4 (50 mL) was added HNO3 (10.7 g, 170 mmol) at 0-10 °C. Then, the mixture was stirred at 80 °C for 2 hours. On completion, the mixture was cooled to 25 °C. Then, the mixture was poured into ice/water (300 mL), then extracted with EA (3 X 150 mL). The combined organic layer was washed with sat. aq. $NaHC0_3$ (100 mL) and brine (100 mL), dried over Na_2S0_4, and filtered. The filtrate was concentrated *in vacuo* to give the title compound (11.2 g, 85% yield) as yellow solid. 'H NMR (400MHz, DMSO-i¾) δ 8.94 (s, 1 H).

[004262] Step 2 - 3-Bromo-l-methyl-4-nitro-pyrazole

[004263] To a mixture of 3-bromo-4-nitro-lH-pyrazole (6.20 g, 32.3 mmol) and K2CO3 (5.36 g, 38.7 mmol) in DMF (40 mL) was added Mel (5.50 g, 38.7 mmol) at 0 °C. Then, the mixture was stirred at 25 °C for 2 hours. On completion, the mixture was diluted with water (200 mL), then extracted with EA (3 X 80 mL). The combined organic layer was washed with brine (50 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by column chromatography over silica gel (PE: EA= 20:1-3:1) to give the title compound (3.90 g, 58% yield) as light yellow solid. ¾NMR (400MHz, CDCb) δ 8.16 (s, 1H), 3.97 (s, 3H).

[004264] Step 3 - Methyl 5-(T-methyl-4-nitro-pyrazol-3-vD pyridine-3 -carboxylate


[004265] A mixture of 3-bromo-l-methyl-4-nitro-pyrazole (3.80 g, 18.4 mmol), (5-methoxycarbonyl-3 -pyridyl)boronic acid (4.67 g, 25.8 mmol, CAS# 871329-53-2), Pd(dppf)Cl2.CH2Cl2 (800 mg, 979 umol) and $NaHC0_3$ (3.10 g, 36.8 mmol) in dioxane (50 mL) and H2O (10 mL) was stirred at 80 °C under N2 for 2 hours. On completion, the mixture was cooled

to 25 °C. The mixture was diluted with water (100 mL), then extracted with EA (3 X 80 mL). The combined organic layer was washed with brine (50 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by column chromatography on silica gel (PE: EA = 5:l-DCM: EA = 2:1) to give the title compound (2.95 g, 61% yield) as light yellow solid. ^1H NMR (400MHz, CDCh) δ 9.29 (s, 1H), 9.12 (s, 1H), 8.68 (s, 1H), 8.31 (s, 1H), 4.05 (s, 3H), 4.00 (s, 3H).

[004266] Step 4 - Methyl 5-(4-amino-l-methyl-pyrazol-3-vD pyridine-3 -carboxylate

[004267] A mixture of methyl 5-(l-methyl-4-nitro-pyrazol-3-yl)pyridine-3-carboxylate (2.90 g, 11.0 mmol) and Pd/C (500 mg, 11.0 mmol, 10% w7) in DCM (80 mL) and MeOH (40 mL) was stirred at 25 °C for 6 hours under H_2 (15 psi). On completion, the mixture was filtered, and the cake was washed with MeOH (50 mL). The filtrate and washing were combined and concentrated *in vacuo.* The residue was purified by reversed phase flash (NH_3.H_20 condition) to give crude product (1.8 g). The crude product was purified by prep-HPLC (column: Xbridge BEH C18, 250*50mm, lOum; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: l%-26%, 32MIN; 45% min) to give the title compound (470 mg, 18% yield) as light yellow solid. ^1H NMR (400 MHz, CDCh) δ 9.23 (d, *J* = 1.6 Hz, 1H), 9.13 (d, *J* = 1.6 Hz, 1H), 8.70 (t, *J* = 1.6 Hz, 1H), 7.10 (s, 1H), 3.97 (s, 3H), 3.88 (s, 3H).

[004268] 5-[4-[[2-[2-[Tert-butoxycarbonvU2,2,2-trifluoroethvBamino]-4-pyridyl1oxazole-4-carbonyl1 amino1-l-methyl-pyrazol-3-yl]pyridine-3-carboxylic acid [Intermediate WD)



[004269] Step 1 - 5-[4-[[2-[2-[Tert-butoxycarbonyl(2.2.2-trifluoroethyl)amino1-4-pyridylloxazole-4-carbonyl1amino1-l-methyl-pyrazol-3-yl1pyridine-3-carboxylate


[004270] A mixture of methyl 5-(4-amino-l-methyl-pyrazol-3-yl)pyridine-3-carboxylate (90.0 mg, 387 umol, Intermediate WC), 2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (153 mg, 395 umol, Intermediate CM), HATU (192 mg, 504 umol) and DIPEA (101 mg, 781 umol) in DMF (3 mL) was stirred at 25 °C for 1 hour. On completion, the mixture was combined with another identical batch. The combined mixture quenched with water (1 mL) and purified by reverse phase flash (FA condition) to give the title compound (200 mg, 86% yield) as light yellow solid. ^{1}H NMR (400 MHz, CDCh) δ 9.24 (s, 1H), 9.18 (d, *J* = 1.6 Hz, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.51 (d, *J* = 4.8 Hz, 1H), 8.42 (s, 1H), 8.36 (s, 1H), 8.19 (s, 1H), 7.73 (d, *j* = 5.2 Hz, 1H), 4.88 (q, *j* = 8.8 Hz, 2H), 4.02 (s, 3 H), 3.97 (s, 3 H), 1.55 (s, 9 H).

[004271] Step 2 - 5-[4-[[2-[2-[Tert-butoxycarbonyl(2,2,2-trifluoroethyl)aminol-4-pyridyl1oxazole-4-carbonyl1 amino1-l-methyl-pyrazol-3-yl1pyridine-3-carboxylic acid


[004272] To a solution of methyl 5-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4 -pyridyl]oxazole-4-carbonyl]amino]-l-methyl-pyrazol-3-yl]pyridine-3-carboxylate (200 mg, 332 umol) in THF (6 mL) was added a solution of LiOHH$_2$0 (21 mg, 500 umol) in H$_2$0 (2 mL) at 25 °C. Then, the mixture was stirred at 25 °C for 16 hours. On completion, the reaction mixture was quenched with TFA (60 mg). The mixture was concentrated *in vacuo*. The residue was purified by reversed phase flash (TFA condition) to give the title compound (190


mg, 81% yield) as light yellow solid. ¾ NMR (400 MHz, DMSO-^e) δ 13.47 (s, 1H), 10.1 1 (s, 1H), 9.08 (d, *J* = 2.0 Hz, 1H), 8.98 (s, 2H), 8.64 (d, *j* = 5.2 Hz, 1H), 8.54 (s, 1H), 8.30 (s, 1H), 8.03 (s, 1H), 7.80 (d, *j* = 5.2 Hz, 1H), 4.89 (q, *j* = 9.2 Hz, 2H), 3.95 (s, 3H), 1.50 (s, 9H).

[004273] **Benzyl N-[(1S)-2-[[(1S)-1-[(3S)-7-[2-[2-[2-[2-[2-(2-aminoethoxylethoxy] ethoxy] ethoxy] ethoxy] ethoxy]-3-[[(lRVtetralin-l-yll carbamoyl]-3,4-dihydro-lH-isoquinoline-2-carbonyl1-2-2-dimethyl-propyl1amino1-l-methyl-2-oxo-ethyl]-N-methyl-carbamate [Intermediate WE)**



PE





WE

[004274] Step 1 - benzyl ((S)-1-(((S)-1-((S V7-(Y2.2-dimethyl-4-oxo-3 .8. 11. 14. 17,20-hexaoxa-5-azadocosan-22-yl)oxy)-3-((YR)-l .2.3.4-tetrahydronaphthalen- l-yl icarbamoyl)-3,4-dihydroisoquinolin-2n H)-yl)-3,3-dimethyl- 1-oxobutan-2-yl)amino)-l -oxopropan-2-vOimethvOcarbamate


[004275] To a solution of benzyl ((S)-l-(((S)-l-((S)-7-hydroxy-3-(((R)-l,2,3,4-tetrahydronaphthalen-l-yl)carbamoyl)-3,4-dihydroisoquinolin-2(lH)-yl)-3,3-dimethyl-l-

oxobutan-2-yl)amino)-l-oxopropan-2-yl)(methyl)carbamate (1.6 g, 2.45 mmol, Intermediate PE) in CEECN (75 mL) was added 2,2-dimethyl-4-oxo-3,8,ll,l4,l7,20-hexaoxa-5-azadocosan-22-yl 4-methylbenzenesulfonate (1.57 g, 2.94 mmol, Intermediate 00) and K2CO3 (507.2 mg, 3.68 mmol) at rt. Then the reaction mixture was stirred at 80 °C for 12 h. The solid was then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified via column chromatography (DCM / MeOH) to give the title compound(l.58 g, 61% yield) as a colorless oil. LC-MS (ESI+): m/z 510.01 (M+H)+.

[004276] Step 2 - benzyl ((SVl-(((SVl-((SV7-(q7-amino-3.6.9.l2.l5-pentaoxaheptadecyl)oxy)-3-(Y(R)-1,2.3.4-tetrahydronaphthalen-1-yl icarbamoyl)-3.4-dihydroisoquinolin-2n H)-yl)-3.3-dimethyl- 1-oxobutan-2-yl)amino)-l -oxopropan-2-yOrinethyOcarbamate 2.2.2-trifluoroacetate

[004277] To a solution of benzyl ((S)-l-(((S)-l-((S)-7-((2,2-dimethyl-4-oxo-3,8,ll,l4,l7,20-hexaoxa-5-azadocosan-22-yl)oxy)-3-(((R)-l,2,3,4-tetrahydronaphthalen-l-yl)carbamoyl)-3,4-dihydroisoquinolin-2(lH)-yl)-3,3-dimethyl-l-oxobutan-2-yl)amino)-l-oxopropan-2-yl)(methyl)carbamate (1.3 g, 1.28 mmol) in DCM (20 mL) was added TFA (20 mL) at rt. The reaction mixture was stirred at rt for 3 h. The reaction mixture was then concentration under reduced pressure and the residue was purified via reverse phase column chromatography (ACN / H2O) to give the title compound (1.05 g, 89% yield) as a white solid. ^{1}H NMR (400 MHz, DMSO-d_6) S 8.22 (dd, J = 49.8, 8.6 Hz, 1H), 8.00 - 7.48 (m, 4H), 7.35 (s, 5H), 7.23 - 6.61 (m, 7H), 5.31 - 4.23 (m, 9H), 4.11 - 4.03 (m, 2H), 3.75 - 3.73 (m, 2H), 3.62 - 3.27 (m, 18H), 2.99 - 2.94 (m, 3H), 2.92 - 2.80 (m, 2H), 2.79 - 2.62 (m, 3H), 1.96 - 1.47 (m, 4H), 1.21 - 1.11 (m, 3H), 0.99 (s, 6H), 0.92 (s, 3H). LC/MS (ESI, m/z): [M +l]+ = 918.7.

[004278] **2-[2-(Tert-butoxycarbonylamino)ethoxy]acetic acid [Intermediate WF)**



WF

[004279] Step 1 - Ethyl 2-r2-(tert-butoxycarbonylamino)ethoxy1acetate


[004280] To a mixture of tert-butyl N-(2-hydroxyethyl)carbamate (10.0 g, 62.0 mmol, 9.62 mL, CAS# 26690-80-2) and Rh(OAc)2 (274 mg, 1.24 mmol) in DCM (200 mL) was added a solution of ethyl 2-diazoacetate (10.6 g, 93.0 mmol, 9.74 mL, CAS# 623-73-4) in DCM (250 mL)

dropwise slowly. The reaction mixture was stirred at 25 °C for 12 hours. On completion, the reaction mixture was diluted with water (200 mL) and extracted with DCM (2 X 200 mL). The combined organic layers was dried over anhydrous Na_2SO_4, filtered and concentrated *in vacuo.* The residue was purified by column chromatography to give the title compound (12.0 g, 78% yield) as light yellow oil. ^1H NMR (400MHz, CDCh) δ 5.25 (s, 1H), 4.19 (q, *J* = 7.2 Hz, 2H), 4.05 (s, 2H), 3.58 (t, *J* = 5.2 Hz, 2H), 3.31 (q, *J* = 5.2 Hz, 2H), 1.42 (s, 9H), 1.26 (t, *J* = 7.1 Hz, 3H).

[004281] Step 2 - 2-r2-(Tert-butoxycarbonylamino)ethoxy1acetic acid

[004282] To a mixture of ethyl 2-[2-(tert-butoxycarbonylamino)ethoxy]acetate (1.00 g, 4.04 mmol) in a mixed solvent of THF (10 mL) and H_20 (5 mL) was added LiOH (193 mg, 8.09 mmol). The reaction mixture was stirred at 25 °C for 2 hours. On completion, the reaction mixture was acidified with HC1 (1 N) until the pH = 5 - 6, then the mixture was concentrated *in vacuo* to removed THF, and the residue was extracted with EA (5 x 10 mL). The combined organic layer was dried over anhydrous Na_2SO_4, filtered and the filtrate was concentrated *in vacuo* to give the title compound (886 mg, 99% yield) as light yellow gum. 'H NMR (400MHz, DMSO-rL) δ 7.37 (s, 1H), 3.57 (s, 2H), 3.43 - 3.40 (m, 2H), 3.06 (q, *J* = 5.2 Hz, 2H), 1.37 (s, 9H).

[004283] 3-[5-[aminomethvD-3-methyl-2-oxo-benzimidazol-l-yl] piperidine-2,6-dione [Intermediate WG)



WG

[004284] Step 1 - 5-bromo-N-methyl-2-nitroaniline

[004285] To a solution of 4-bromo-2-fluoro-l -nitrobenzene (23 g, 105 mmol) in EtOH (50 mL) was added $MeNH_2$ (250 ml, 33% in EtOH). After the addition, the mixture was stirred at rt overnight. The reaction mixture was concentrated under reduce pressure. The residue was dissolved in EtOAc (300 mL), washed with water (200 mL x 2) and brine (200 mL), dried over anhydrous Na_2S0_4, filtered and concentrated to afford the title compound (23 g, 95% yield) as a yellow solid. ^1H NMR (400 MHz, CDCh) δ 8.03 (d, J = 9.2 Hz, 2H), 7.0l(s, 1H), 6.76 (d, J = 9.2 Hz, 1H), 3.02 (s,3H). LC/MS (ESI, *m/z):* $[M+l]^+$ = 231.1

[004286] Step 2 - 5-bromo-Nl-methylbenzene-E2-diamine

[004287] To a solution of 5-bromo-N-methyl-2-nitroaniline (23.0 g, 0.10 mol) in AcOH (230 mL)/ EtOAc (230 mL)/(50 mL) was added Fe (20 g, 0.36 mol) at 50 °C. After the addition, the reaction mixture was heated to 80 °C and stirred for 1 h. Then the mixture was cooled to rt and filtered. The filtrate was concentrated under reduce pressure. The residue was diluted with EtOAc (300 mL) and H_20 (300 mL). The organic layer was washed with H_20 (500 mL x 2) and brine (200 mL), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The residue was

purified with column (EA: PE = 1:2) to afford the title compound (14 g, 70% yield) as a yellow solid. LC/MS (ESI, *m/z):* [M+l] $^{+}$ = 201.1.

[004288] Step 3 - 6-bromo-l-methyl-E3-dihvdro-2H-benzord1imidazol-2-one

[004289] To a solution of 5-bromo-Nl-methylbenzene-l, 2-diamine (14 g, 69.3 mmol) in THF (200 mL) was added CDI (13.4 g, 83.2 mmol). The reaction mixture was heated for reflux 2 h under N_2 atmosphere. The reaction mixture was cooled to rt and concentrated under reduce pressure. The residue was purified with column (EA : PE = 1 : 2) to afford the title compound (10 g, 63% yield) as a white solid. ^{1}H NMR (400 MHz, DMSO-^e) ć51 1.0 (s, 1H), 7.33 (s, 1H), 7.13 (t, *J* = 8.0 Hz 1H), 6.92 (d, *J* = 8.0 Hz, 1H), 3.26 (s, 3H). LC/MS (ESI, *m/z):* [M+l] $^{+}$ = 227.1.

[004290] Step 4 - 3-(ˈ5-bromo-3-methyl-2-oxo-2.3-dihvdro- 1H-benzordlimidazol- 1-yl)- 1-*(4-*methoxybenzyl)pi peri dine-2.6-di one

[004291] To a solution of 6-bromo-l-methyl-l,3-dihydro-2H-benzo[d]imidazol-2-one (5.0 g, 22.1 mmol) in THF (50 mL) was added /-BuOK (2.48 g, 22.lmmol) at 0 °C. The reaction mixture was stirred at 0 °C for 30 min, then 3-bromo-l-(4-methoxybenzyl)piperidine-2,6-dione (6.9 g, 22. 1 mmol) was added. After addition, the reaction mixture was stirred at r.t overnight. The reaction mixture was diluted with sat.aq. Ammonia chloride, extracted with EA (80 mL x 2). The combined organic lays were washed with H_20 (80 mL x 2) and brine (80 mL), dried over anhydrous Na_2S0_4, filtered and concentrated under reduced pressure. The residue was purified with column (EtOAc : DCM = 1 : 1) to afford 3-(5-bromo-3-methyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l-yl)-l-(4-methoxybenzyl)piperidine-2,6-dione (3.7 g, 36.6% yield) as a yellow solid. ^{1}H NMR (400 MHz, DMSO-d) *S* 7.47 (d, *J* = 1.9 Hz, 1H), 7.23 - 7.13 (m, 3H), 7.00 (d, *J* = 8.4 Hz, 1H), 6.88 - 6.81 (m, 2H), 5.53 (dd, *J* = 13.0, 5.4 Hz, 1H), 4.78 (q, *J* = 14.3 Hz, 2H), 3.72 (s, 3H), 3.33 (s, 3H), 3.12 - 2.95 (m, 1H), 2.86 - 2.63 (m, 2H), 2.12 - 2.01 (m, 1H). LC/MS (ESI, *m/z):* [M+l] $^{+}$ = 458.1.

[004292] Step 5 - 3-(5-bromo-3-methyl-2-oxo-2.3-dihvdro-lH-benzord1imidazol-l-vDpiperidine-2.6-dione

[004293] To a solution of 3-(5-bromo-3-methyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l-yl)-l-(4-methoxybenzyl)piperidine-2,6-dione (7.6 g, 16.6 mmol) in toluene (50 mL) was added methanesulfonic acid (20 mL). The reaction solution was heated to H0°C and stirred for 3 h. The reaction mixture was cooled to rt and concentrated to remove toluene. The residue was diluted with CH_3CN and purified via reverse phase column chromatography (CH_3CN/H_20 = 5%-80%) to

give the title compound (3.4 g, 61% yield) as a white solid. ^{1}H NMR (400 MHz, DMSO) δ 11.11 (s, 1H), 7.47 (d, *J* = 1.9 Hz, 1H), 7.21 (dd, *J* = 8.4, 1.9 Hz, 1H), 7.10 (d, *J* = 8.4 Hz, 1H), 5.38 (dd, *J* = 12.8, 5.4 Hz, 1H), 3.34 (s, 3H), 2.93 - 2.83 (m, 1H), 2.74 - 2.60 (m, 2H), 2.03 - 1.97 (m, 1H). LC/MS (ESI, *m/z):* [M +l] $^+$ = 338.1.


[004294] Step 6 - 1-(2.6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2.3-dihvdro-l H-benzordlimidazole-5-carbonitrile

[004295] A mixture of 3-(5-bromo-3-methyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l-yl)piperidine-2,6-dione (5 g, 14. 8 mmol), zinc cyanide (6.9 g, 59.2 mmol), tris(dibenzylideneacetone)dipalladium (1.4 g, 1.5 mmol) and 1,1'-Ferrocenebis(diphenylphosphine) (1.6 g, 3.0 mmol) in DMF (100 mL) was heated to 120 °C and stirred for 19 h under nitrogen atmosphere in sealed tube. The reaction mixture was cooled to rt, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EA/DCM = 2/1) to give the title compound (3 g, 71%) as a white solid. ^{1}H NMR (400 MHz, DMSO-i/e) ≤ 11.16 (s, 1 H), 7.75 (d, *J* = 1.5 Hz, 1 H), 7.55 (dd, *J* = 8.2, 1.5 Hz, 1 H), 7.34 (d, *J* = 8.2 Hz, 1 H), 5.46 (dd, J = 12.8, 5.4 Hz, 1 H), 3.38 (s, 3 H), 2.83 - 2.94 (m, 1 H), 2.59 - 2.78 (m, 2 H), 2.01 - 2.09 (m, 1 H). LC/MS (ESI, *m/z):* [M+l] $^+$ = 284.9.

[004296] Step 7 - 3-(5-(aminomethvP-3-methyl-2-oxo-2.3-dihydro-lH-benzord1imidazol-l-vDpiperidine-2.6-dione acetate

[004297] To a solution of l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazole-5-carbonitrile (2.3 g, 8.1 mmol) in AcOH (20 mL) was added PtO_2 (98.8 mg, 0.41 mmol) and 10 wt% palladium on activated carbon (850 mg, 0.81 mmol). The mixture was hydrogenated for 1 h at 85 psi at rt. The reaction mixture was filtered, the filtrate was concentrated under reduced pressure and dried to give the title compound (2.8 g, quant. yield) as a salt with AcOH. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.24 (s, 1 H), 7.01 - 7.10 (m, 2 H), 5.36 (dd, *J* =12.76, 5.38 Hz, 1 H), 3.84 (s, 2 H), 3.33 (s, 3 H), 2.83 - 2.96 (m, 1 H), 2.57 - 2.78 (m, 2 H), 1.97 - 2.05 (m, 1 H), 1.85 (br. s., 6 H). LC/MS (ESI, *m/z):* [M- NH_2]$^+$ = 272.17.

[004298] 2-(2-Aminoethoxy)-N-[[l-(2.,6-dioxo-3-piperidyO-3-methyl-2-oxo-benzimidazol-5-yl]_methyl]acetamide [Intermediate WH)



[004299] Step 1 - Tert-butyl N-[2-[2-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] methylamino]-2-oxo-ethoxy]ethyl]carbamate


[004300] To a mixture of 2-[2-(tert-butoxycarbonylamino)ethoxy]acetic acid (405 mg, 1.85 mmol, Intermediate WF) and DIPEA (994 mg, 7.70 mmol, 1.34 mL) in DMF (5 mL) was added HATU (702 mg, 1.85 mmol). The reaction mixture was stirred at 0 °C Then, 3-[5-(aminomethyl)-3-methyl-2-oxo-benzimidazol-1-yl] piperidine-2, 6-dione (0.50 g, 1.54 mmol, HC1, Intermediate WG) was added. The reaction mixture was stirred at 25 °C for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (0.1 % FA condition) to give the title compound (500 mg, 66% yield) as white solid. LC-MS (ESI^+) *m/z* 390.2 $(M+H-100)^+$.

[004301] Step 2 - 2-(2-Aminoethoxy)-N-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] methylacetamide

[004302] To a mixture of tert-butyl N-[2-[2-[[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] methylamino]-2-oxo-ethoxy]ethyl]carbamate (400 mg, 817 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 20 mL). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (0.1 % FA condition) to give the title compound (240 mg, 75% yield) as white solid. ^1H NMR (400MHz, DMSO-d6) δ 11.08 (s, 1H), 8.53 (t, *J* = 6.0 Hz, 1H), 8.03 (s, 2H), 7.12 (s, 1H),

7.08 - 6.95 (m, 2H), 5.36 (dd, *j* = 5.2, 12.8 Hz, 1H), 4.36 (d, *j* = 6.0 Hz, 2H), 3.98 (s, 2H), 3.65 (t, *J* = 5.2 Hz, 2H), 3.37 (s, 3H), 3.02 *(d, J* = 4.4 Hz, 2H), 2.97 - 2.85 (m, 1H), 2.77 - 2.59 (m, 2H), 2.07 - 1.92 (m, 1H); LC-MS (ESI$^+$) *m/z* 390.2 (M+H)$^+$.

[004303] **3-[4-[4-(4-Aminobutoxy)butyll-3-methyl-2-oxo-benzimidazol-l-yllpiperidine-2,6-dione [Intermediate WI)**



[004304] Step 1 - Tert-butyl N-[4-[4-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl1but-3-ynoxy1 butyllcarbamate

[004305] A mixture of 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (500 mg, 1.48 mmol, Intermediate HP), tert-butyl N-(4-but-3-ynoxybutyl)carbamate (1.07 g, 4.44 mmol, Intermediate SY), Cul (84 mg, 443 umol), Pd(PPh $_3$)2Cl2 (311 mg, 443 umol) and TEA (2.69 g, 26.6 mmol) in DMF (10 mL) was degassed and purged with N2three times, and then the mixture was stirred at 85 °C for 4 hrs under N2 atmosphere. On completion, the mixture was dilute with H2O (20 mL), then extracted with EA (2 X 60 mL). The organic layer was washed with brine (30 mL), dried over anhydrous Na$_2$S0 $_4$, and then concentrated *in vacuo.* The residue was purified by reversed phase flash to give the title compound (460 mg, 58% yield) as light yellow solid. ^{1}H NMR (400MHz, DMSO-de) δ 11.12 (s, 1H), 7.12 (d, *J* = 7.6 Hz, 1H), 7.09 - 7.04 (m, 1H), 7.02 -

6.97 (m, 1H), 6.79 (s, 1H), 5.39 (dd, J = 5.2, 12.8 Hz, 1H), 3.65 (s, 3H), 3.58 (t, J = 6.4 Hz, 2H), 3.43 (t, J = 6.0 Hz, 2H), 2.96 - 2.86 (m, 3H), 2.77 - 2.58 (m, 4H), 2.06 - 1.99 (m, 1H), 1.51 - 1.40 (m, 4H), 1.37 (s, 9H); LC-MS (ESI^+) *m/z* 499.3 $(M+l)^+$.


[004306] Step 2 - Tert-butyl N-[4-[4-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-vnbutoxylbutyll carbamate

[004307] To a solution of tert-butyl N-[4-[4-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]but- 3-ynoxy]butyl]carbamate (460 mg, 922 umol) in THF (50 mL) was added Pd/C (100 mg, 10 wt%) and $Pd(OH)_2/C$ (100 mg, 10 wt%). The mixture was stirred at 25 °C for 4 hrs under H_2 (15 psi). On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (463 mg, 99% yield) as white solid. ^1H NMR (400MHz, DMSO-***di)*** δ 11.09 (s, 1H), 6.99 - 6.95 (m, 2H), 6.89 - 6.87 (m, 1H), 6.80 - 6.75 (m, 1H), 5.37 (dd, J = 5.2, 12.4 Hz, 1H), 3.55 (s, 3H), 3.40 (t, j = 5.6 Hz, 2H), 3.36 - 3.33 (m, 2H), 2.96 - 2.85 (m, 5H), 2.77 - 2.58 (m, 2H), 2.05 - 1.96 (m, 1H), 1.69 - 1.57 (m, 4H), 1.52 - 1.40 (m, 4H), 1.37 (s, 9H).

[004308] Step 3 - 3-r4-r4-(4-Aminobutoxy)butyl1-3-methyl-2-oxo-benzimidazol-l-yl1piperidine-2.6-dione

[004309] To a solution of tert-butyl N-[4-[4-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] butoxy]butyl]carbamate (460 mg, 915 umol) in DCM (20 mL) was added HCl/dioxane (4 M, 10 mL). The mixture was stirred at 25 °C for 3 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (360 mg, 90% yield) as light yellow solid. ^1H NMR (400MHz, DMSO-de) δ 11.01 (s, 1H), 7.68 (s, 2H), 6.94 - 6.85 (m, 2H), 6.81 - 6.79 (m, 1H), 5.30 (dd, J = 5.2, 12.8 Hz, 1H), 3.49 (s, 3H), 3.37 - 3.35 (m, 2H), 3.31 - 3.28 (m, 2H), 2.89 - 2.77 (m, 3H), 2.76 - 2.55 (m, 4H), 1.97 - 1.88 (m, 1H), 1.61 - 1.45 (m, 8H); LC-MS (ESI^+) *m/z* 403.1 $(M+l)^+$.

[004310] Tert-butyl N-[4-[4-[[3-(5-formyl-3-pyridyQ-l-methyl-pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2.,2.,2-trifluoroethy0carbamate (Intermediate WJ)



[004311] Step 1 - Isopropoxycarbonyl 5-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoiOethvDaminol-4-pyridvH oxazole-4-carbonyl1amino1-l-methyl-pyrazol-3-yl1pyridine-3-carboxylate

[004312] To a solution of 5-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl] oxazole-4-carbonyl]amino]-l-methyl-pyrazol-3-yl]pyridine-3-carboxylic acid (640 mg, 1.09 mmol, Intermediate WD) and TEA(560 mg, 5.53 mmol) in THF (20 mL) was added isopropyl carbonochloridate (340 mg, 2.77 mmol) at 0 °C. Then, the mixture was stirred at 0-10 °C for 2 hours. On completion, the mixture was filtered and the filter cake was washed with THF (10 mL). The filtrate and washing were combined and used directly in the next step. LC-MS (ESI^+) *m/z* 674.3 $(M+H)^+$.

[004313] Step 2 - Tert-butyl N-[4-[4-[[3-[5-(hvdroxymethvl)-3-pyr dyl1-l-methyl-pyrazol-4-yllcarbamovn oxazol-2-yl1-2-pyridyl1-N-(2.2.2-trif1uoroethyl icarbamate


[004314] To a solution of isopropoxycarbonyl 5-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl) amino]-4-pyridyl]oxazole-4-carbonyl]amino]-l-methyl-pyrazol-3-yl]pyridine-3-carboxylate in THF (30 mL) was added $LiBH_4$ (147 mg, 6.75 mmol) at 0 °C. Then, the mixture was stirred at 0-10 °C for 1 hour. On completion, the mixture was added water (100 mL). The mixture was extracted with EA (3 X 60 mL). The combined organic layer was concentrated *in vacuo*. The residue was purified by reversed phase flash (0.1% FA condition) to give the title compound (380 mg, 60% yield via two steps) as light yellow solid. ^1H NMR (400 MHz, CDCh) δ 8.94 - 8.92 (m, 2H), 8.59 (m, 1H), 8.51 (d, *J* = 5.2 Hz, 1H), 8.41 - 8.39 (m, 2H), 8.24 (s, 1H), 8.14

(s, 1H), 7.68 - 7.66 (m, 1H), 4.89 (q, *J* = 8.8 Hz, 2H), 4.81 (s, 2H), 4.01 (s, 3H), 1.59 (s, 9H).

[004315] Step 3 - Tert-butyl N-[4-[4-[[3-(5-formyl-3-pyridyl)-1-methyl-pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate

[004316] To a solution of tert-butyl N-[4-[4-[[3-[5-(hydroxymethyl)-3-pyridyl]-1-methyl-pyrazol-4-yl] carbamoyl] oxazol-2-yl]-2-pyridyl]-N-(2, 2, 2-trifluoroethyl) carbamate (360 mg, 573 umol) in DCM (20 mL) was added Dess-Martin (360 mg, 848 umol) at 0 °C. Then, the mixture was stirred at 3 hours at 0-10 °C. On completion, the mixture was diluted with DCM (20 mL), washed with sat. aq. $Na_2S_2O_3$ (10 mL). The organic layer was washed with sat.$NaHCO_3$ (10 mL) and brine (10 mL), dried over Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (320 mg, 97% yield) as light yellow solid. ^1H NMR (400 MHz, CDCh) δ 10.21(s, 1H), 9.26 (d, *j* = 2.0 Hz, 1H), 9.08 (d, *J* = 2.0 Hz, 1H), 8.82 (s, 1H), 8.54 - 8.52 (m, 2H), 8.41 (s, 1H), 8.38 (s, 1H), 8.18 (s, 1H), 7.73 (d, 7 = 1.6 Hz, 1H), 4.87 (q, 7 = 8.8 Hz, 2H), 4.01 (s, 3H), 1.56 (s, 9H).


[004317] **2-[2-lMethylaminolethoxy] ethanol [Intermediate WK)**



WK

[004318] To a solution of tert-butyl N-[2-(2-hydroxyethoxy)ethyl]-N-methyl-carbamate (3.00 g, 13.7 mmol, synthesized via Steps 1-2 of Intermediate FY) in DCM (20 mL) was added HCl/dioxane (4 M, 20 mL). The reaction mixture was stirred at 25 °C for 1 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (2.10 g, 99% yield, HC1 salt) as a white solid. ^1H NMR (400 MHz, DMSO-^e) δ 3.67 (t, *J* = 5.2 Hz, 2H), 3.57 - 3.51 (m, 2H), 3.50 - 3.46 (m, 2H), 3.13 - 3.02 (m, 2H), 2.55 (t, *J* = 5.2 Hz, 3H).

[004319] **Tert-butyl 4-(2-prop-2-ynoxyethoxy)piperidine-1-carboxylate [Intermediate WM1**



WM

[004320] Step 1 - Tert-butyl 4-(2-ethoxy-2-oxo-ethoxy)piperidine-l-carboxylate

[004321] To a mixture of tert-butyl 4-hydroxypiperidine-l-carboxylate (5.00 g, 24.8 mmol, CAS# 109384-19-2) and diacetoxyrhodium (274 mg, 1.24 mmol) in DCM (80 mL) was added a solution of ethyl 2-diazoacetate (8.50 g, 74.5 mmol) in DCM (60 mL) at 0 - 10 °C during 2 hours. The mixture was stirred at 25 °C for 40 hours. On completion, the mixture was concentrated *in vacuo.* The residue was purified by column chromatography to give the title compound (7.00 g, 98% yield) as light yellow oil. ^{1}H NMR (400 MHz, CDCh) δ 4.28 - 4.20 (m, 2H), 4.12 (s, 2H), 3.81 - 3.75 (m, 2H), 3.57 (m, 1H) 3.12 - 3.05 (m, 2H), 1.87 - 1.86 (m, 2H), 1.59 - 1.52 (m, 2H), 1.46 (s, 9H), 1.33 - 1.28 (s, 3H).

[004322] Step 2 - Tert-butyl 4-(2-hydroxyethoxy)piperidine-l-carboxylate


[004323] To a suspension of LAH (1.59 g, 41.8 mmol) in THF (40 mL) was added a solution of tert-butyl 4-(2-ethoxy-2-oxo-ethoxy)piperidine-l-carboxylate (6.00 g, 16.5 mmol) in THF (20 mL) slowly at 0-10 °C. The mixture was stirred at 0-10 °C for 3 hours. On completion, the reaction was quenched with water (1.60 mL) slowly at 0-l0°C. Then 10% aq.NaOH (1.60 mL) and water (4.80 mL) were added to the mixture. The mixture was filtered and the filter cake was washed with EA(50 mL). The filtrate and washing were combined and concentrated *in vacuo.* The residue was purified by column chromatography on silica gel to give the title compound (4.00 g, 67% yield) as light yellow oil. ^{1}H NMR (400 MHz, CDCh) δ 3.76 - 3.75 (m, 2H), 3.74 - 3.73 (m, 2H), 3.60 - 3.58 (m, 2H), 3.50 (m, 1H), 3.13 - 3.07 (m, 2H), 1.85 - 1.84 (m, 2H), 1.57 - 1.52 (m, 2H), 1.47 (s, 9H).

[004324] Step 3 - Tert-butyl 4-(2-prop-2-vnoxyethoxy)piperidine-l-carboxylate

[004325] To a solution of tert-butyl 4-(2-hydroxyethoxy)piperidine-l-carboxylate (3.80 g, 15.4 mmol) in THF (40 mL) was added NaH (1.86 g, 46.5 mmol, 60% oil dispersion) at 0 °C. The mixture was stirred at 25 °C for 0.5 hour. Then 3-bromoprop-l-yne (2.76 g, 23.2 mmol) was added

to the mixture at 25 °C. The mixture was stirred at 25 °C for 16 hours. On completion, the reaction was quenched with sat.aq.NH4O (20 mL). The mixture was diluted with water (100 mL), then extracted with EA (3 X 80 mL). The combined organic layer was washed with brine (30 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo*. The residue was purified by column chromatography to give the title compound (3.70 g, 84% yield) as light yellow oil. ^1H NMR (400 MHz, CDCb) δ 4.22 (d, *J* = 2.4 Hz, 2H), 3.86 - 3.75 (m, 2H), 3.73 - 3.62 (m, 4H), 3.53 - 3.45 (m, 1H), 3.10 - 3.00 (m, 2H), 2.44 (t, *J* = 2.4 Hz, 1H), 1.90 - 1.80 (m, 2H), 1.56 - 1.48 (m, 2H), 1.46 (s, 9H).

[004326] **3-[3-Methyl-2-oxo-5-[3-[2-(4-piperidyloxy)ethoxy]propyl]benzimidazol-1-yl]piperidine-2.,6-dione [Intermediate WN)**



[004327] Step 1 - Tert-butyl 4-[2-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl1prop-2-ynoxylethoxylpiperidine-l-carboxylate

[004328] A mixture of tert-butyl 4-(2-prop-2-ynoxyethoxy)piperidine-l-carboxylate (800 mg, 2.82 mmol, Intermediate WM), 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (400 mg, 1.18 mmol, Intermediate HN), CuI (45.0 mg, 236 umol), $Pd(PPh_3)_2Cl_2$ (166 mg, 236 umol), CS2CO3 (1.93 g, 5.91 mmol) and 4Å M S (400 mg) in DMF (15 mL) was stirred at

80 °C for 2 hours. On completion, the reaction mixture was cooled to 20 °C. The mixture was diluted with EA (50 mL), filtered and the cake was washed with EA (30 mL). The filtrate and washing were combined and concentrated *in vacuo*. The residue was purified by reversed phase flash (FA condition) to give the title compound (420 mg, 65% yield) as light yellow solid. ^{1}H NMR (400 MHz, DMSO-di) δ 11.13 (m, 1H), 7.33 (s, 1H), 7.19 - 7.08 (m, 2H), 5.41 - 5.37 (m, 1H), 4.40 (s, 2H), 4.18 - 4.11 (m, 1H), 3.63 - 3.59 (m, 4H), 3.56 - 3.51 (m, 2H), 3.50 - 3.41 (m, 2H), 3.36 (s, 3H), 2.93 - 2.83 (m, 1H), 2.76 - 2.61 (m, 2H), 2.07 - 1.99 (m, 1H), 1.80 - 1.75 (m, 2H) 1.38 (s, 9H), 1.35 - 1.30 (m, 2H).


[004329] Step 2 - Tert-butyl 4-[2-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-vnpropoxyl ethoxylpiperidine-l-carboxylate

[004330] A mixture of tert-butyl 4-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] prop-2-ynoxy]ethoxy]piperidine-l-carboxylate (400 mg, 739 umol), $Pd(OH)_2/C$ (100 mg, 739 umol, 10 wt%) and Pd/C (100 mg, 739 umol, 10 wt%) in THF (20 mL) was stirred at 25 °C for 20 hours under H_2 (15 psi). On completion, the mixture was filtered, and the cake was washed with EA (10 mL). The filtrate and washing were combined and concentrated *in vacuo* to give the title compound (400 mg, 99 % yield) as light yellow gum. ^{1}H NMR (400 MHz, CDCh) δ 8.11 (s, 1H), 6.94 - 6.89 (m, 1H), 6.88 (s, 1H), 6.72 (d, J = 8.0 Hz, 1H), 5.25 - 5.18 (m, 1H), 3.75 - 3.70 (m, 1H), 3.60 - 3.56 (m, 2H), 3.52 - 3.46 (m, 4H), 3.43 (s, 3H), 3.11 - 3.02 (m, 3H), 2.90 - 2.83 (m, 1H), 2.77 - 2.70 (m, 3H), 2.27 - 2.21 (m, 1H), 1.93 - 1.91 (m, 2H), 1.88 - 1.81 (m, 3H), 1.64 - 1.60 (m, 1H), 1.55 - 1.51 (m, 2H), 1.46 (s, 9H).

[004331] Step 3 - 3-r3-Methyl-2-oxo-5-r3-r2-(4-piperidyloxy)ethoxy1propyl1benzimidazol-l-yllpiperidine-2.6 -dione

[004332] To a solution of tert-butyl 4-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] propoxy]ethoxy]piperidine-l-carboxylate (100 mg, 183 umol) in DCM (3.0 mL) was added TFA (1.0 mL) at 20 °C. The reaction mixture was stirred at 20 °C for 1 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (81.0 mg, 99% yield) as light yellow gum. LC-MS (ESI^+) m/z 445.3 $(M+H)^+$.

[004333] Tert-butyl N-methyl-N-[[(2R)-4-prop-2-ynylmorpholin-2-yl]methyl]carbamate (Intermediate WP)



WP

[004334] Step 1 - Benzyl (2R)-2-(hydroxymethyl)morpholine-4-carboxylate

[004335] To a solution of [(2R)-morpholin-2-yl]methanol (2.50 g, 16.2 mmol, HC1, CAS# 156925-22-3), NaHC0 $_3$ (4.10 g, 48.8 mmol) in a mixed solvent of ACN (80.0 mL) and $H_2$0 (80.0 mL) was added CbzCl (4.16 g, 24.4 mmol, 3.47 mL) at 0 °C dropwise. The mixture was then stirred at 25 °C for 16 hrs. On completion, the mixture was concentrated *in vacuo* to remove ACN. Then the mixture was extracted with EA (2 X 20 mL), and the combined organic layers were concentrated *in vacuo*. The residue was purified by silica gel column (PE: EA=l: 1) to give the title compound (3.7 g, 90% yield) as colorless oil. ^{1}H NMR (400MHz, CDCh) δ 7.42 - 7.33 (m, 5H), 5.17 (d, *J* = 2.0 Hz, 2H), 4.08 - 3.88 (m, 3H), 3.77 - 3.65 (m, 1H), 3.63 - 3.46 (m, 3H), 3.13 - 2.73 (m, 2H), 2.07 - 1.96 (m, 1H).

[004336] Step 2 - Benzyl (2R)-2-(methylsulfonyloxymethyl)morpholine-4-carboxylate

[004337] To a solution of benzyl (2R)-2-(hydroxymethyl)morpholine-4-carboxylate (3.70 g, 14.7 mmol), and TEA (4.47 g, 44. 1 mmol) in DCM (40.0 mL) was added MsCl (2.53 g, 22.0 mmol) at 0°C, then the mixture was stirred at 25 °C for 1 hr. On completion, the mixture was diluted with DCM (20 mL) and washed with $H_2$0 (3 X 30 mL). The organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (4.85 g, 100% yield) as yellow oil. ¾NMR (400MHz, CDCh) δ 7.43 - 7.33 (m, 5H), 5.20 - 5.15 (m, 2H), 4.26 (d, *J* = 4.8 Hz, 2H), 4.10 - 3.83 (m, 3H), 3.80 - 3.65 (m, 1H), 3.63 - 3.48 (m, 1H), 3.08 (s, 3H), 3.07 - 2.75 (m, 2H).

[004338] Step 3 - Benzyl (2S)-2-(methylaminomethyl)morpholine-4-carboxylate

[004339] To a solution of benzyl (2R)-2-(methylsulfonyloxymethyl)morpholine-4-

carboxylate (4.3 g, 13.0 mmol) in EtOH (10.0 mL) was added $MeNH_2$ (40.5 g, 391 mmol, 30% solution in ethanol), and the mixture was stirred at 80 °C for 16 hrs in a 100 mL of autoclave. On completion, the mixture was concentrated *in vacuo* to give the title compound (3.45 g, 100% yield) as yellow oil. LC-MS (ESI^+) *m/z* 265.1 $(M+H)^+$.

[004340] Step 4 - Benzyl (2S)-2-[[tert-butoxycarbonyl(methyl)amino]methyl]morpholine-4-carboxylate

[004341] To a solution of benzyl (2S)-2-(methylaminomethyl)morpholine-4-carboxylate (3.45 g, 13.0 mmol) in MeOH (50.0 mL) was added TEA (1.58 g, 15.6 mmol, 2.18 mL). Then $(BOC)_20$ (4.27 g, 19.5 mmol, 4.50 mL) was added into the above mixture dropwise. The mixture was stirred at 25 °C for 2 hrs. On completion, the mixture was concentrated *in vacuo.* The residue was purified by silica gel column (PE: EA = 5: 1) to give the title compound (4.10 g, 86% yield) as yellow oil. ^1H NMR (400MHz, CDCh) δ 7.43 - 7.30 (m, 5H), 5.24 - 5.09 (m, 2H), 4.11 - 3.83 (m, 3H), 3.68 - 3.34 (m, 3H), 3.30 - 3.14 (m, 1H), 3.09 - 2.97 (m, 1H), 2.94 (s, 3H), 2.80 - 2.62 (m, 1H), 1.47 (s, 9H).

[004342] Step 5 - Tert-butyl N-methyl-N-rr(2R)-morpholin-2-yl1methyl1carbamate


[004343] To a solution of benzyl (2S)-2-[[tert-butoxycarbonyl(methyl)amino]methyl]morpholine-4-carboxylate (4.10 g, 11.2 mmol) in MeOH (40.0 mL) was added Pd/C (1.00 g, 10% *wi),* and the mixture was stirred at 25 °C for 16 hrs under H_2 (15 psi). On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (2.54 g, 98% yield) as colorless oil. ^1H NMR (400MHz, DMSO-i/e) δ 3.75 - 3.65 (m, 1H), 3.50 - 3.42 (m, 1H), 3.41 - 3.37 (m, 1H), 3.24 - 3.13 (m, 1H), 3.10 - 3.03 (m, 1H), 2.85 - 2.75 (m, 3H), 2.70 - 2.53 (m, 4H), 2.37 - 2.23 (m, 1H), 1.39 (s, 9H).

[004344] Step 6 - Tert-butyl N-methyl-N-[[(2R)-4-prop-2-vnylmorpholin-2-yllmethyllcarbamate

[004345] To a solution of tert-butyl N-methyl-N-[[(2R)-morpholin-2-yl]methyl]carbamate (1.00 g, 4.34 mmol), 3-bromoprop-l-yne (516 mg, 4.34 mmol, CAS# 106-96-7) in DMF (10.0 mL) was added K_2C0_3 (3.00 g, 21.7 mmol). The mixture was stirred at 25 °C for 2 hrs. On completion, the mixture was diluted with H_20 (20 mL), then extracted with EA (2 X 20 mL). The combined organic layers were washed with brine (2 X 20 mL), dried over anhydrous Na_2S0_4, filtered and the filtrate was concentrated *in vacuo.* The residue was purified by silica gel column (PE: EA = 5: 1) to give the title compound (960 mg, 82% yield) as yellow oil. ^1H NMR (400MHz,

DMSO-di) δ 3.85 - 3.76 (m, 1H), 3.63 - 3.52 (m, 1H), 3.50 - 3.40 (m, 1H), 3.30 - 3.24 (m, 2H), 3.20 - 3.14 (m, 2H), 2.84 - 2.78 (m, 3H), 2.68 - 2.55 (m, 2H), 2.54 - 2.52 (m, 1H), 2.30 - 2.16 (m, 1H), 2.03 - 1.90 (m, 1H), 1.39 (s, 9H).

[004346] **3-[3-Methyl-5-[3-[(2S)-2-(methylaminomethvDmorpholin-4-yllprop-l-vnyll-2-oxo -benzimidazol-l-yl]piperidine-2,6-dione [Intermediate WO)**



WQ

[004347] Step 1 - Tert-butyl N-[[(2R)-4-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yll prop-2-vnyl1morpholin-2-yl1methyl1-Nmethyl-carbamate


[004348] To a solution of tert-butyl N-methyl-N-[[(2R)-4-prop-2-ynylmorpholin-2-yl]methyl]carbamate (571 mg, 2.13 mmol, Intermediate WP), 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (400 mg, 1.18 mmol, Intermediate HN) in DMF (15.0 mL) was added Pd(PPh $_3$)2Cl2 (83.0 mg, 118 umol), 4A molecular sieves (50.0 mg), CS2CO3 (1.93 g, 5.91 mmol) and CuI (22.5 mg, 118 umol). The mixture was stirred at 80 °C for 2 hrs under N2. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo*. The residue was purified by reverse phase (0.1% FA) to give the title compound (400 mg, 64% yield) as yellow solid. ^{1}H NMR (400MHz, CDCb) δ 8.28 (s, 1H), 7.17 (d, *J* = 8.0 Hz, 1H), 7.10 (s, 1H), 6.74 (d, *J* = 8.0 Hz, 1H), 5.25 - 5.14 (m, 1H), 3.99 - 3.90 (m, 1H), 3.82 - 3.65 (m, 2H), 3.57 - 3.47 (m, 2H), 3.43 (s, 3H), 3.25 - 3.14 (m, 1H), 3.00 - 2.94 (m, 1H), 2.94 (s, 3H), 2.89 - 2.82 (m, 2H), 2.82 - 2.74 (m, 2H), 2.74 - 2.63 (m, 1H), 2.50 - 2.38 (m, 1H), 2.30 - 2.21 (m, 1H), 2.20 - 2.13 (m, 1H), 1.45

(s, 9H).

[004349] Step 2 - 3-[3-Methyl-5-[3-[(2S)-2-(methylaminomethyl)morpholin-4-yl]prop-1-ynyl]-2-oxo -benzimidazol-l-yl1piperidine-2.6-dione

[004350] To a solution of tert-butyl N-[[(2R)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] prop-2-ynyl]morpholin-2-yl]methyl]-N-methyl-carbamate (150 mg, 285 umol) in DCM (5.00 mL) was added TFA (7.70 g, 67.5 mmol, 5.00 mL). The mixture was stirred at 20 °C for 1 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (150 mg, 97% yield, TFA salt) as yellow solid. ^{1}H NMR (400MHz, DMSO-^e) δ 11.15 (s, 1H), 8.83 (s, 1H), 7.37 (d, *J* = 1.2 Hz, 1H), 7.27 - 7.22 (m, 1H), 7.22 - 7.17 (m, 1H), 5.47 - 5.37 (m, 1H), 4.39 - 4.21 (m, 3H), 4.18 - 4.14 (m, 1H), 4.09 - 4.03 (m, 1H), 3.84 - 3.73 (m, 1H), 3.58 - 3.44 (m, 2H), 3.36 (s, 3H), 3.27 - 3.17 (m, 1H), 3.12 - 3.02 (m, 2H), 2.95 - 2.84 (m, 2H), 2.68 - 2.62 (m, 1H), 2.60 - 2.57 (m, 3H), 2.09 - 2.00 (m, 1H).

[004351] **3-[3-methyl-4-[4-[4-(methylamino)butoxylbutyll-2-oxo-benzimidazol-l-yl]piperidine-2.,6- dione [Intermediate WR)**



[004352] Step 1 Tert-butyl N-[4-[4-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-vnbut-3-ynoxy1 butyll-N-methyl-carbamate

[004353] To a solution of tert-butyl N-(4-but-3-ynoxybutyl)-N-methyl-carbamate (500 mg, 1.96 mmol, Intermediate RS) and 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-

dione (221 mg, 653 umol, Intermediate HP) in DMF (10 mL) was added CuI (24.8 mg, 131 umol), CS2CO3 (213 mg, 653 umol), $Pd(PPh_3)2Cl2$ (91.6 mg, 131 umol) and 4A molecular sieves (200 mg, 653 umol) at 25 °C. The reaction mixture was stirred at 80 °C for 2 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo*. The residue was diluted with water (30 mL), and then extracted with EA (3 X 50 mL). The combined organic layers were washed with brine (30 mL), dried over Na_2S0_4, filtered and the filtrate was concentrated *in vacuo*. The residue was purified by reverse phase (FA condition) to give the title compound (320 mg, 95% yield) as a purple solid. LC-MS (ESI^+) m/z 413.2 $(M+H-l00)^+$.


[004354] Step 2 - Tert-butyl N-[4-[4-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-vnbutoxyl butyll-N-methyl-carbamate

[004355] To a solution of tert-butyl N-[4-[4-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] but-3-ynoxy]butyl]-N-methyl-carbamate (300 mg, 585 umol) in THF (20 mL) was added Pd(OH)2/C (500 mg, 585 umol, 20 wt%) and Pd/C (500 mg, 585 umol, 10 wt%) at 25 °C. The reaction mixture was stirred at 25 °C for 2 hours under ¾ (15 psi). On completion, the reaction mixture was filtered through celite and the filtrate was concentrated *in vacuo* to give the title compound (280 mg, 92% yield) as colorless oil. LC-MS (ESI^+) m/z 417.3$(M+H-100)^+$.

[004356] Step 3 - 3-r3-methyl-4-r4-r4-(methylamino)butoxy1butyl1-2-oxo-benzimidazol-l-yl1piperidine-2.6-dione

[004357] To a solution of tert-butyl N-[4-[4-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] butoxy]butyl]-N-methyl-carbamate (140 mg, 271 umol) in DCM (10 mL) was added TFA (5 mL) at 25 °C. The reaction mixture was stirred at 25 °C for 2 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (110 mg, 97% yield) as colorless oil. LC-MS (ESI^+) m/z 417.2 $(M+H)^+$.

[004358] **Tert-butyl (3RV3-prop-2-vnoxypyrrolidine-l-carboxylate [Intermediate WU)**




WU

[004359] To a mixture of tert-butyl (3R)-3-hydroxypyrrolidine-l-carboxylate (5.00 g, 26.7 mmol, CAS# 109431-87-0) and TBAI (493 mg, 1.34 mmol) in THF (50 mL) was added sodium hydride (1.28 g, 32.0 mmol, 60% oil dispersion) in portions at 0 °C. After 0.5 hour, 3-bromoprop-

l-yne (6.35 g, 53.4 mmol) was added to the mixture. The reaction mixture was stirred at 0 - 25 °C for 12.5 hours. On completion, the reaction was quenched with water (1.0 mL). The mixture was filtrated and the filtrate was concentrated *in vacuo*. The residue was purified by silica gel chromatography on silica gel to give the title compound (6.00 g, 99% yield) as yellow oil. ^{1}H NMR (400 MHz, CDCh) δ 4.28 (s, 1H), 4.24 - 4.06 (m, 2H), 3.55 - 3.32 (m, 4H), 2.44 (t, *J* = 2.4 Hz, 1H), 2.13 - 1.88 (m, 2H), 1.46 (s, 9H).

[004360] **3-[3-Methyl-2-oxo-4-[3-[(3R)-pyrrolidin-3-yl]oxypropyl]benzimidazol-1-yl]piperidine-2,6-dione [Intermediate WV)**



[004361] Step 1 - Tert-butyl (3R)-3-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl1prop-2-ynoxylpyrrolidine-l-carboxylate

[004362] A mixture of tert-butyl (3R)-3-prop-2-ynoxypyrrolidine-l-carboxylate (666 mg, 2.96 mmol, Intermediaet WU), 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (400 mg, 1.18 mmol, Intermediate HP), Pd(PPh$_3$)2Cl2 (166 mg, 236 umol), Cul (45.0 mg, 236 umol), 4Å M S (100 mg, 1.18 mmol) and CS2CO3 (1.93 g, 5.91 mmol) in DMF (8 mL) was stirred at 80 °C for 2 hours under N2. On completion, the reaction mixture was filtered and the

filtrate was concentrated *in vacuo*. The residue was purified by reverse phase (FA condition) to give the title compound (330 mg, 57% yield) as brown solid. ^{1}H NMR (400 MHz, DMSO-d«) δ 11.13 (s, 1H), 7.18 (d, *J* = 7.6 Hz, 1H), 7.13 (d, *J* = 7.6 Hz, 1H), 7.06 - 7.00 (m, 1H), 5.42 - 5.38 (m, 1H), 4.48 (s, 2H), 4.34 - 4.24 (m, 1H), 3.63 (s, 3H), 3.37 - 3.35 (m, 1H), 3.27 - 3.17 (m, 2H), 2.95 - 2.82 (m, 1H), 2.77 - 2.63 (m, 2H), 2.07 - 1.89 (m, 4H), 1.38 (d, *J* = 9.6 Hz, 9H).


[004363] Step 2 - Tert-butyl (3R)-3-[3-Π-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4- νl] propoxyl pyrrolidine- l-carboxylate

[004364] To a solution of tert-butyl (3R)-3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] prop-2-ynoxy]pyrrolidine- l-carboxylate (300 mg, 621 umol) in THF (10 mL) was added Pd/C (150 mg, 10 wt%) and $Pd(OH)_2$/C (150 mg, 20 wt%) at 20 °C. The reaction mixture was stirred at 20 °C for 12 hours under H_2 (15 psi). On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (300 mg, 99% yield) as brown solid. ¾NMR (400 MHz, DMSO-^) δ 11.09 (s, 1H), 6.99 - 6.92 (m, 2H), 6.90 - 6.82 (m, 1H), 5.42 - 5.38 (m, 1H), 4.06 -3.96 (m, 1H), 3.55 (s, 3H), 3.50 - 3.39 (m, 2H), 3.32 - 3.30 (m, 1H), 3.30 - 3.26 (m, 2H), 3.26 - 3.20 (m, 1H), 2.98 - 2.91 (m, 2H), 2.90-2.82 (m, 1H), 2.75 - 2.57 (m, 2H), 2.03 - 1.95 (m, 1H), 1.94 - 1.86 (m, 2H), 1.85 - 1.74 (m, 2H), 1.40 (s, 9H).

[004365] Step 3 - 3-[3-Methyl-2-oxo-4-[3-[(3R)-pyrrolidin-3-yl1oxypropyl1benzimidazol-l-yllpiperidine-2.6- dione

[004366] To a solution of tert-butyl (3R)-3-[3-[l-(2, 6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propoxy] pyrrolidine- l-carboxylate (300 mg, 616 umol) in dichloromethane (3 mL) was added TFA (3 mL) at 15 °C. The reaction mixture was stirred at 15 °C for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (330 mg, 100% yield, TFA salt) as yellow semisolid. LC-MS (ESI^+) *m/z* 387.2 $(M+H)^+$.

[004367] **l-(2.,6-dioxo-3-piperidvP-3-methyl-2-oxo-benzimidazole-4-carbaldehvde [Intermediate WW)**




1 WW

[004368] To a solution of 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-

dione (500 mg, 1.48 mmol, Intermediate HP) in DMF (20 mL) was added TEA (448 mg, 4.44 mmol), $Pd(dppf)Cl_2$ (162 mg, 221 umol) and Et_3SiH (515 mg, 4.44 mmol). The reaction mixture was stirred at 80 °C for 16 hours under CO (50 Psi). On completion, the reaction mixture was concentrated *in vacuo* and purified by reverse phase (0.1% FA) to give the title compound (400 mg, 47% yield) as a white solid. LC-MS (ESI^+) m/z 288.0 $(M+H)^+$.

[004369] **3-[3-Methyl-4-[[4-lmethylaminol- 1-piperidyl]methyl]-2-oxo-benzimidazol- 1-yl]piperidine-2.,6-dione [Intermediate WX)**



[004370] Step 1 - Tert-butyl N-[1-[[-(2.6-dioxo-3-piperidvl)-3-methyl-2-oxo-benzimidazol-4-yl1methyl1-4- piperidyll-N-methyl -carbamate


[004371] To a solution of l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazole-4-carbaldehyde (160 mg, 556 umol, Intermediate WW) and tert-butyl N-methyl-N-(4-piperidyl)carbamate (119 mg, 556 umol) in a mixed solvents of THF (3 mL) and DMF (1.5 mL) was added AcOH until the pH = 5 - 7. After the reaction mixture was stirred at 20 °C for 3 hours. $NaBH(OAc)_3$ (l77mg, 835 umol) was added to the reaction mixture. The mixture was stirred at 20 °C for 12 hours. On completion, the reaction mixture was quenched by water (3 drops) and filtered. The filtrate was concentrated *in vacuo.* The residue was purified by reverse phase (FA condition) to give the title compound (220 mg, 46% yield) as white solid. LC-MS (ESI^+) *m/z* 486.2 $(M+H)^+$.

[004372] Step 2 - 3-r3-Methyl-4-rr4-(methylamino)-l-piperidyl1methyl1-2-oxo-benzimidazol-l-vnpiperidine-2.6-dione

[004373] To a solution of tert-butyl N-[l-[[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-

benzimidazol-4- yl]methyl]-4-piperidyl]-N-methyl-carbamate (200 mg, 235 umol) in DCM (3 mL) was added TFA(3 mL). The reaction mixture was stirred at 15 °C for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (220 mg, 100% yield, TFA salt) as yellow oil. LC-MS (ESI^+) *m/z* 386.2 $(M+H)^+$.

[004374] **3-[3-Methyl-4-[4-[4-(methylaminomethvQ-l -piperidyl] but-l-ynyl] -2-oxo-benzimidazol-l-yl] piperidine-2,6-dione [Intermediate WZ)**



WZ

[004375] Step 1 - 3-[4-(4-Hvdroxybut-l -ynyl)-3-methyl -2-oxo-benzimidazol-l-yl1piperidine-2.6-dione

[004376] To a solution of 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (1.00 g, 2.96 mmol, Intermediate HP) andbut-3-yn-l-ol (518 mg, 7.39 mmol, 559 uL, CAS# 927-74-2) in DMSO (15 mL) was added $Pd(PPh_3)_2Cl2$ (207 mg, 295 umol), Cul (56.3 mg, 295 umol) and DIPEA (1.91 g, 14.7 mmol, 2.58 mL). The reaction mixture was stirred at 80 °C for 2 hrs under N_2. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (600 mg, 62% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 11.13 (s, 1H), 7.15 - 6.97 (m, 3H), 5.39 (dd, J = 4.8, 12.4 Hz, 1H), 4.94 (s, 1H), 3.65 (s, 3H), 3.34 (s, 2H), 2.95

- 2.84 (m, 1H), 2.69 - 2.59 (m, 4H), 2.06 - 2.00 (m, 1H); LC-MS (ESI^+) m/z 328.1 $(M+H)^+$.

[004377] Step 2 - 4-[1-(2.6-Dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl1but-3-ynyl methane sulfonate

[004378] To a solution of 3-[4-(4-hydroxybut-l-ynyl)-3 -methyl-2-oxo-benzimidazol- 1-yl]piperidine-2,6-dione (600 mg, 1.83 mmol) and TEA (556 mg, 5.50 mmol, 765 uL) in DCM (20 mL) was added MsCl (3 14 mg, 2.75 mmol, 212 uL) dropwise at 0 °C. The reaction mixture was stirred at 25 °C for 2 hrs. On completion, the reaction mixture was quenched with H_20 (30 mL), then extracted with DCM (2 X 50 mL). The organic phase was dried with Na_2S0_4, filtrated and concentrated *in vacuo* to give the title compound (500 mg, 67% yield) as a yellow solid. LC-MS (ESL) m/z 406.2 $(M+H)^+$.

[004379] Step 3 - Tert-butyl N-ri l-[4-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-vnbut-3-ynvn- 4-piperidyllmethyll-N-methyl-carbamate


[004380] To a solution of 4-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]but-3-ynyl methanesulfonate (400 mg, 986umol) and tert-butyl N-methyl-N-(4-piperidylmethyl)carbamate (270 mg, 1.18 mmol, CAS# 138022-04-5) in MeCN (10 mL) and $CHCl_3$ (10 mL) was added K2CO3 (409 mg, 2.96 mmol). The reaction mixture was stirred at 65 °C for 16 hrs. On completion, the reaction mixture was diluted with water (30 mL) and extracted with EA (3 X 50 mL). The combined organic layers was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (140 mg, 26% yield) as a yellow solid. ^1H NMR (400MHz, DMSO-i¾) δ 11.1 1 (s, 1H), 7.1 1 (d, J = 7.2 Hz, 1H), 7.07 - 7.02 (m, 1H), 7.01 - 6.96 (m, 1H), 5.38 (dd, J = 5.2, 12.8 Hz, 1H), 3.67 (s, 3H), 3.05 (d, J = 6.4 Hz, 2H), 2.96 - 2.87 (m, 3H), 2.69 - 2.58 (m, 9H), 2.05 - 1.94 (m, 3H), 1.58 - 1.51 (m, 3H), 1.38 (s, 9H), 1.18 - 1.08 (m, 2H);LC-MS (ESL) m/z 538.4 $(M+H)^+$.

[004381] Step 4 - 3-r3-Methyl-4-r4-r4-(methylaminomethvn-l-piperidyl1but-l-vnyl1-2-oxo-benzimidazol-l-yl] piperidine-2.6-dione

[004382] To a solution of tert-butyl N-[[l-[4-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] but-3-ynyl]-4-piperidyl]methyl]-N-methyl-carbamate (140 mg, 260 umol) in DCM (3 mL) was added $ZnBr_2$ (293 mg, 1.30 mmol, 65.1 uL). The reaction mixture was stirred at 20 °C for 48 hrs. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (100

mg, 87% yield) as a white solid. LC-MS (ESI^+) m/z 438.2 $(M+H)^+$.

[004383] **Tert-butyl (2,2-difluoro-3-(prop-2-yn-1-yloxy)propyl(methyl)carbamate [Intermediate XA)**



XA

[004384] Step 1 - Tert-butyl (2,2-difluoro-3-hydroxypropyl)carbamate

[004385] To a solution of 3-amino-2, 2-difluoro-propan-1-ol (2.00 g, 18.0 mmol, CAS# 155310-11-5) in a mixed solvents of THF (75 mL) and H_20 (75 mL) was added Boc_20 (3.93 g, 18.0 mmol) slowly at 0 °C. The reaction mixture was stirred at 25 °C for 16 hours. On completion, the reaction mixture was diluted with 1.0 M aq.HCl (100 mL) and extracted with EA (2 X 150 mL). The combined organic phase was washed with brine (50 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (3.76 g, 98% yield) as white solid. ^1H NMR (400 MHz, CDCh) δ 5.04 (s, 1H), 4.10 - 3.87 (m, 1H), 3.76 - 3.63 (m, 2H), 3.60 - 3.54 (m, 2H), 1.48 (s, 9H).

[004386] Step 2 - Tert-butyl (2,2-difluoro-3-(prop-2-yn-1-yloxy)propyl)carbamate


[004387] To a solution of tert-butyl N-(2,2-difluoro-3-hydroxy-propyl)carbamate (5.00 g, 23.7 mmol) in THF (100 mL) was added KOH (1.33 g, 23.7 mmol), KI (393 mg, 2.37 mmol), TBAI (1.31 g, 3.55 mmol) and 3-bromoprop-1-yne (4.22 g, 28.41 mmol) at 25 °C. The reaction mixture was stirred at 25 °C for 16 hours. On completion, the reaction mixture was diluted with sat. aq. NH_4Cl (100 mL) and extracted with EA (2 X 150 mL). The combined organic phase was concentrated *in vacuo.* The residue was purified by silica gel chromatography (PE: EA = 40: 1) to give title compound (3.27 g, 55% yield) as colorless oil. ^1H NMR (400 MHz, CDCh) δ 4.95 - 4.73 (m, 1H), 4.30 - 4.24 (m, 2H), 3.84 - 3.74 (m, 2H), 3.72 - 3.58 (m, 2H), 2.56 - 2.46 (m, 1H), 1.47 (s, 9H).

[004388] Step 3 - Tert-butyl (2,2-difluoro-3-(prop-2-yn-1-yloxy)propyl)(methyl)carbamate

[004389] To solution of tert-butyl N-(2,2-difluoro-3-prop-2-ynoxy-propyl)carbamate (3.00 g, 12.1 mmol) in THF (50 mL) was added NaH (578 mg, 14.4 mmol, 60% dispersion in mineral

oil) at 0 °C. The mixture was stirred at 0 °C for 0.5 hour, then Mel (3.42 g, 24. 1 mmol) was added. The reaction mixture stirred at 0 - 25 °C for 2 hours. On completion, the reaction was queched with water (100 mL). The mixture was extracted with EA (2 X 100 mL). The combined organic phase was concentrated *in vacuo* to give the title compound (3.00 g, 95% yield) as yellow oil. 'H NMR (400 MHz, CDCh) δ 4.25 - 4.18 (m, 2H), 3.72 - 3.58 (m, 4H), 2.89 (s, 3H), 2.42 (s, 1H), 1.40 (s, 9H).

[004390] **3-[4-[3-[2,2-Difluoro-3-[methylamino)propoxy)propyn-3-methyl-2-oxo-2,3-dihydro-lH -benzo[dlimidazol-l-vQpiperidine-2.,6-dione [Intermediate XB)**



[004391] Step 1 - Tert-butyl *(3-((3-(\ -(2.6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2.3-dihydro-lH-benzordl imidazol-4-yl)prop-2-yn-l -yl)oxy)-2.2-dif1uoropropyl)(methyl)carbamate*

[004392] To a solution of tert-butyl N-(2,2-difluoro-3-prop-2-ynoxy-propyl)carbamate (442 mg, 1.77 mmol, Intermediate XA) and 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (300 mg, 887 umol, Intermediate HP) in DMF (6 mL) was added $Pd(PPh_3)2Cl2$ (125 mg, 177 umol), Cul (33.8 mg, 177 umol), CS_2CO_3 (1.45 g, 4.44 mmol) and 4Å molecular sieves (100 mg) at 20 °C. The mixture was stirred at 80 °C for 2 hours under N2. On completion, the reaction mixture was cooled to 20 °C. The mixture was diluted with EA (50 mL) and filtered. The filtrate was washed with brine (50 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by reverse phase (FA condition) to give the title compound (160 mg, 35% yield) as

brown solid. ^{1}H NMR (400 MHz, DMSO-de) δ 11.11 (s, 1H), 7.24 - 7.17 (m, 1H), 7.17 - 7.11 (m, 1H), 7.08 - 7.01 (m, 1H), 5.46 - 5.35 (m, 1H), 4.58 (s, 2H), 3.89 - 3.78 (m, 2H), 3.78 - 3.68 (m, 2H), 3.67 - 3.59 (m, 3H), 1.38 (s, 9H). LC-MS (ESI$^+$) *m/z* 543.l(M+Na) $^+$.


[004393] Step 2 - Tert-butyl (3-(3-(1-(2.6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2.3-dihydro-lH-benzordl imidazol-4-yl)propoxy)-2.2-difluoropropyl)(methyl icarbamate

[004394] To a solution of tert-butyl N-[3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] prop-2-ynoxy]-2,2-difluoro-propyl]-N-methyl-carbamate (200 mg, 384 umol) in THF (10 mL) was added Pd/C (50.0 mg, 10 wt%) and $Pd(OH)_2$/C (50.0 mg, 10 wt%) at 25 °C. The mixture was stirred at 25 °C for 18 hours under H_2 (15 psi). On completion, the reaction mixture was diluted with THF (40 mL), filtrated and concentrated *in vacuo* to give the title compound (195 mg, 97% yield) as yellow solid. ¾ NMR (400 MHz, DMSO-i/e) δ 11.08 (s, 1H), 7.01 - 6.94 (m, 2H), 6.91 - 6.84 (m, 1H), 5.40 - 5.33 (m, 1H), 3.64 - 3.58 (m, 6H), 3.58 - 3.56 (m, 3H), 3.02 - 2.93 (m, 2H), 2.87 (s, 3H), 1.91 - 1.82 (m, 2H), 1.79 - 1.74 (m, 4H), 1.40 (s, 9H); LC-MS (ESL) *m/z* 547.3(M+Na) $^+$.

[004395] Step 3 - 3-(4-(3-(2.2-Difluoro-3-(methylamino)propoxy)propyl)-3-methyl-2-oxo-2,3-dihydro- 1H -benzor dlimidazol- 1-yQpiperidine-2.6-dione

[004396] To the solution of tert-butyl N-[3-[3-[l-(2, 6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propoxy]-2, 2-difluoro-propyl]-N-methyl-carbamate (180 mg, 343 umol) in DCM (3 mL) was added HCl/dioxane (3 mL) at 25 °C. The reaction mixture was stirred at 25 °C for 2 hours. On completion, the mixture was concentrated *in vacuo* to give the title compound (155 mg, 98% yield, HC1 salt). LC-MS (ESI$^+$) *m/z* 425.1(M+H)$^+$.

[004397] **3-[6-[3-[3-[Methylamino)propoxy1propyl1-2-oxo-l,3-benzoxazol-3-yl]piperidine-2.,6-dione [Intermediate XC1**



[004398] Step 1 - Tert-butyl N-[3-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-1,3-benzoxazol-6-yl]prop-2-ynoxy]propyl]-N-methyl-carbamate

[004399] To a mixture of 3-(6-bromo-2-oxo-1,3-benzoxazol-3-yl)piperidine-2,6-dione (450 mg, 1.38 mmol, Intermediate OZ), tert-butyl N-methyl-N-(3-prop-2-ynoxypropyl)carbamate (566 mg, 2.49 mmol, Intermediate PO) in DMF (10 mL) was added Cs_2CO_3 (2.25 g, 6.92 mmol), CuI (79.08 mg, 415.24 umol), $Pd(PPh_3)_2Cl_2$ (97.1 mg, 138 umol) and molecular sieves 4Å (50 mg). The reaction mixture was stirred at 80 °C for 2 hours under N_2. On completion, the reaction was filtered. And the filtrate was poured into water (100 mL), then the aqueous phase was extracted with ethyl acetate (2 X 40 mL). The combined organic phase was washed with brine (2 X 40 mL), dried with anhydrous Na_2SO_4, filtered and concentrated *in vacuo* to give the residue. The residue was purified by reversed-phase HPLC (0.1% FA condition) to give the title compound (350 mg, 49% yield) as a brown solid. ^1H NMR (300 MHz, $CDCl_3$) δ 8.24 - 8.11 (m, 1H), 7.35 (s, 2H), 6.78 (d, J = 8.4 Hz, 1H), 5.06 (d, J = 5.2, 12.8 Hz, 1H), 4.37 (s, 2H), 3.60 (d, J = 6.4 Hz, 2H), 3.34 (d, J = 6.8 Hz, 2H), 2.89 (s, 3H), 1.94 - 1.78 (m, 3H), 1.75 - 1.61 (m, 3H), 1.47 (s, 9H).

[004400] Step 2 - Tert-butyl N-[3-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-1,3-benzoxazol-6-yl]propoxy]propyl]-N- methyl-carbamate


[004401] To a mixture of tert-butyl N-[3-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-1,3-benzoxazol-6-yl]prop-2-ynoxy] propyl]-N-methyl -carbamate (350 mg, 742 umol) in THF (10 mL) was added Pd/C (50 mg, 10 wt%) and Pd(OH)2/C (50 mg, 10 wt%) under N_2. The suspension was

degassed under vacuum and purged with H_2 three times. The mixture was stirred at 25 °C for 12 hours under H_2 (15 psi). On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (330 mg, 93% yield) as brown oil. ^{1}H NMR (400 MHz, CDCh) δ 8.19 (s, 1H), 7.12 (s, 1H), 7.00 (d, *J* = 8.0 Hz, 1H), 6.73 (d, *J* = 8.0 Hz, 1H), 5.06 (d, *J* = 5.6, 13.2 Hz, 1H), 3.41 (q, *J* = 6.4 Hz, 4H), 3.30 (s, 2H), 3.03 - 2.94 (m, 1H), 2.89 - 2.84 (m, 3H), 2.78 - 2.68 (m, 3H), 2.37 - 2.26 (m, 1H), 1.94 - 1.72 (m, 4H), 1.63 (d, *J* = 6.8 Hz, 2H), 1.46 (s, 8H).

[004402] Step 3 - 3-r6-r3-r3-(Methylamino)propoxy1propyl1-2-oxo- 1,3-benzoxazol-3-yl1piperidine-2.6-dione

[004403] To a mixture of tert-butyl N-[3-[3-[3-(2,6-dioxo-3-piperidyl)-2-oxo-l,3-benzoxazol-6-yl]propoxy] propyl]-N-methyl-carbamate (320 mg, 673 umol) in DCM (10 mL) was added TFA (153 mg, 1.35 mmol). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (320 mg, 97% yield, TFA salt) as a white solid. LC-MS (ESI$^+$) *m/z* 376.2 (M+H)$^+$.


[004404] 3-[3-Methyl-4-[3-[3-[methylamino)propoxy1prop-l-vnyl]-2-oxo-benzimidazol-l-yl] piperidine -2,6-dione [Intermediate XD)



XD

[004405] To a mixture of tert-butyl N-[3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]prop- 2-ynoxy]propyl]-N-methyl-carbamate (180 mg, 371 umol, synthesized via Step 1 of Intermediate PP) in DCM (5 mL) was added TFA (7.70 g, 67.5 mmol, 5.00 mL). The reaction mixture was stirred at 25 °C for 2 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (180 mg, 97% yield, TFA salt) as a yellow solid. ^{1}H NMR (400 MHz, DMSO-r¾) δ 11.13 (s, 1H), 8.35 (s, 2H), 7.19 (d, *J* = 7.6 Hz, 1H), 7.14 - 7.1 1 (m, 1H), 7.06 - 7.01 (m, 1H), 5.40 (dd, *J* = 12.8 Hz, 1H), 4.45 (s, 3H), 3.65 (s, 3H), 3.60 (s, 2H), 2.97 (m, 2H), 2.91 - 2.83 (m, 1H), 2.73 - 2.60 (m, 2H), 2.52 - 2.50 (m, 2H), 2.06 - 1.99 (m, 1H), 1.90 - 1.83 (m, 2H).

[004406] 2-(Methylamino)ethylN-[[l-(2.,6-dioxo-3-piperidvO-3-methyl-2-oxo-benzimidazol-5-yl]_methyl]carbamate [Intermediate XE)



[004407] Step 1 - 2-rTert-butoxycarbonvK methvOaminolethyl (4-nitrophenvO carbonate

[004408] To a mixture of tert-butyl N-(2-hydroxyethyl)-N-methyl-carbamate (1.00 g, 5.71 mmol, CAS # 57561-39-4) and (4-nitrophenyl) carbonochloridate (1.15 g, 5.71 mmol, CAS #7693-46-1) in DCM (20 mL) was added TEA (1.44 g, 14.27 mmol) at 0 °C for 1 hour. On completion, the reaction was poured into the ice-water (50 mL) and extracted with DCM (2 X 30 mL). The combined organic phase was washed with brine (2 X 50 mL), dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (1.80 g, 92% yield) as a white solid. ^{1}H NMR (300 MHz, CDCh) δ 8.30 (d, *J* = 9.2 Hz, 2H), 7.41 (d, *J* = 9.2 Hz, 2H), 4.41 (t, *J* = 5.6 Hz, 2H), 3.61 (s, 2H), 2.98 (s, 3H), 1.48 (s, 9H).

[004409] Step 2 - Tert-butylN-r2-rrl-(2.6-dioxo-3-piperidvD-3-methyl-2-oxo-benzimidazol-5-yllmethylcar bamoyloxyIethyll-N-methyl-carbamate


[004410] To a mixture of 2-[tert-butoxycarbonyl(methyl)amino]ethyl (4-nitrophenyl) carbonate (172 mg, 507 umol), 3-[5-(aminomethyl)-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione (102 mg, 253 umol, TFA salt, Intermediate PH) in DMF (10 mL) was added TEA (128 mg, 1.27 mmol). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the residue. The residue was purified by reversed-phase HPLC (0.1% FA condition) to give the title compound (105 mg, 84%

yield) as brown solid. ^{1}H NMR (400 MHz, DMSO-^e) δ 11.08 (s, 1H), 7.69 (s, 1H), 7.09 - 7.02 (m, 2H), 6.95 (d, *J* = 8.4 Hz, 1H), 5.39 - 5.32 (m, 1H), 4.21 *(d, J* = 6.0 Hz, 2H), 4.10 - 4.03 (m, 2H), 3.36 (t, *J* = 5.6 Hz, 2H), 2.97 - 2.85 (m, 1H), 2.80 (s, 2H), 2.74 (d, *J* = 4.4, 8.8 Hz, 1H), 2.67 - 2.59 (m, 1H), 2.10 - 1.59 (m, 3H), 1.37 (s, 9H).

[004411] Step 3 - 2-fMethylamino)ethylN-rrl-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yll methyl] carbamate

[004412] To a mixture of tert-butyl N-[2-[[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] methylcarbamoyloxy] ethyl] -N-methyl-carbamate (105 mg, 214 umol) in DCM (10 mL) was added TFA (24.4 mg, 214 umol). The reaction mixture was stirred at 25 °C for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (107 mg, 99% yield, TFA salt) as brown oil. LC-MS (ESI$^+$) *m/z* 390.1 (M+H)$^+$.

[004413] **3-(5-bromo-9H-pyrido [2,3-bl indol-9-yl)piperidine-2.,6-dione [Intermediate XF1**



XF

[004414] Step 1 - N-(3-bromophenvO-3-nitro-pyridin-2-amine

[004415] To a solution of 2-chloro-3-nitro-pyridine (5.00 g, 315 mmol, CAS# 34515-82-7) and 3-bromoaniline (5.97 g, 34.7 mmol, CAS# 591-19-5) in dioxane (40 mL) was added DIPEA (12.2 g, 94.6 mmol). The reaction mixture was stirred at 115 °C for 2 days. Then the mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography to give the title compound (8.00 g, 86% yield) as a red solid. LC/MS (ESI, *m/z*): [M +l] $^{+}$ = 295.1.

[004416] Step 2 - /V2-(3-bromophenvDpyridine-2.3-diamine

[004417] To a solution of A-(3-bromophenyl)-3-nitro-pyridin-2-amine (5.00 g, 17.0 mmol) and NH_4CI (9.09 g, 170 mmol) in a mixed solvent of H_20 (80 mL) and EtOH (80 mL) was added Fe (9.49 g, 170 mmol). The reaction mixture was stirred at 80 °C for 1 h. The mixture was then diluted with water (80 mL) and extracted with EA (2 x 80 mL). The organic layers were washed with brine (2 x 30 mL), dried with Na_2S0_4, filtered and the filtrate was concentrated under reduced

pressure to give the title compound (4.00 g, 89% yield) as a brown solid. LC/MS (ESI, *m/z):* [M +l] $^{+}$ = 265.1.

[004418] Step 3 - 3-(3-BromophenvOtriazolor4.5-/>1Pyridine

[004419] To a solution of /V2-(3-bromophenyl)pyridine-2, 3-diamine (4.00 g, 15.1 mmol) in a mixed solvent of HOAc (25 mL) and DCM (25 mL) was added a solution of $NaN0_2$ (1.36 g, 19.7 mmol) in H_20 (15 mL) dropwise at 0 °C. The reaction mixture was stirred at 25 °C for 30 minutes. On completion, the mixture was diluted with water (50 mL), and extracted with DCM (2 X 50 mL). The organic layers were washed with brine (2 X 50 mL), dried with Na_2S0_4, filtered and the filtrate was concentrated under reduced pressure to give the title compound (4.10 g, 98% yield) as a brown solid. LC/MS (ESI, *m/z):* [M +l] $^{+}$ = 276.1.

[004420] Step 4 - 5-Bromo-9H-pyridor2.3-/>1indole

[004421] Amixture of 3-(3-bromophenyl)triazolo[4,5-Z>]pyridine (3.60 g, 13.1 mmol) in PPA (20 mL) was heated at 170 °C for 3 h. On completion, the mixture was poured into the ice water (200 mL), stirred for 1 h, then filtered. The filter cake was dried under reduced pressure. The filter cake contained two isomers 5-bromo-9H-pyrido[2,3-b]indole and its isomer 7-bromo-9H-pyrido[2,3-b]indole, which were brought on to the next step directly.

[004422] Step 5 - *te/'t*-butyl 5-bromo-9i7-pyridor2.3-/>1indole-9-carboxylate

[004423] To a mixture of 5-bromo-9//-pyrido[2,3-b]indole and 7-bromo-9H-pyrido[2,3-b]indole (10.0 g, 40.0 mmol) in THF/H_20 (100 mL /100 mL) was added Boc_20 (17.4 g, 80.0 mmol) and NaOH (4.8 g, 120.0 mmol), and the mixture was stirred at rt for 3 h. On completion, the mixture was poured into the water (200 mL), and extracted with EA(2 X 100 mL). The organic layers were washed with brine (2 X 100 mL), dried over Na_2S0_4, filtered and the filtrate was concentrated to give crude product which was purification by column chromatography to give *tert*-butyl 5-bromo-9//-pyrido[2,3-/ ,]indole-9-carboxylate (4.10 g, 7% yield for two steps) as brown product. LC/MS (ESI, *m/z):* [M +l] $^{+}$ = 348.2.

[004424] Step 6 - 5-Bromo-9iT-pyridor2.3-/>1indole

[004425] Amixture of *tcv't*-butyl 5-bromo-9i7-pyrido[2,3-Z>]indole-9-carboxylate (9.0 g, 25.9 mmol) in DCM (20 mL) was added TFA (15 mL), and the mixture was stirred at rt for 16 h. On completion, the mixture was concentrated to give the title product (6.0 g, 94% yield) as brown solid.

[004426] Step 7 - 3-(5-Bromopyridor2.3-b1indol-9-vD-l-r(4-


methoxyphenyl)methyl1piperidine-2.6-dione

[004427] To a mixture of 5-bromo-9i7-pyrido[2,3-/>]indole (250 mg, 1.01 mmol) and 18-crown-6 (53 mg, 0.2 mmol) in THF (5 mL) was added NaHMDS (0.75 mL, 1.5 mmol) (2 M in THF) at -30 °C. After stirring for 1 h at -30 °C, a solution of [l-[(4-methoxyphenyl)methyl]-2,6-dioxo-3-piperidyl] trifluoromethanesulfonate (579 mg, 1.5 mmol) in THF (2 mL) was added into the above mixture dropwise at -30 °C. The reaction mixture was stirred at -30 °C for 2 h. On completion, the mixture was quenched with NH_4Cl aqueous, then extracted with EAThe combined EA layers were concentrated and purified by reverse phase (0.1% FA) to give the title compound (286 mg, 60% yield) as a brown solid. ^1H NMR (400 MHz, DMSO-r¾) δ 8.91 (dd, *J* = 1.2, 7.6 Hz, 1H), 8.59 - 8.46 (m, 1H), 7.57 - 7.50 (m, 1H), 7.49 - 7.42 (m, 1H), 7.41 - 7.35 (m, 1H), 7.33 - 7.23 (m, 2H), 7.22 - 7.05 (m, 1H), 6.94 - 6.86 (m, 2H), 6.32 - 5.97 (m, 1H), 4.92 - 4.75 (m, 2H), 3.75 (s, 3H), 3.24 - 3.06 (m, 2H), 2.97 - 2.84 (m, 1H), 2.27 - 2.15 (m, 1H).

[004428] Step 8 - 3-(5-Bromopyridor2.3-Z>1indol-9-vDpiperidine-2.6-dione

[004429] To a solution of 3-(5-bromopyrido[2,3-/>]indol-9-yl)-l-[(4-methoxyphenyl)methyl]piperidine-2,6-dione (6.0 g, 12.5 mmol) in toluene (50 mL) was added MsOH (10 mL). The reaction mixture was stirred at 110 °C for 4 h. On completion, the mixture was quenched with water (20 mL), then extracted with EA (2 X 20 mL). The organic layers were concentrated under reduced pressure. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]; B%: 38%-68%, 10 min) to give the title compound (2.8 g, 62% yield) as a white solid. ^1H NMR (400 MHz, DMSO-di) δ 11.19 (s, 1H), 8.91 (dd, *J* = 7.8, 1.5 Hz, 1H), 8.53 (dd, *J* = 4.7, 1.3 Hz, 1H), 7.72 (br s, 1H), 7.54 - 7.53 (m, 1H), 7.49 - 7.45 (m, 1H), 7.38 (dd, 7 = 7.9, 4.8 Hz, 1H), 6.19 - 6.00 (m, 1H), 3.16 - 2.98 (m, 2H), 2.74 - 2.67 (m, 1H), 2.17 - 2.14 (m, 1H); LC/MS (ESI, *m/z):* [M +l] $^+$ = 358.0/360.0.

[004430] 3-[5-[3-[2-(2-Aminoethoxy)ethoxy]propyl]pyrido[2,3-bl indol-9-yll piperidine-2,6-dione [Intermediate XG)



XG

[004431] Step 1 - tert-butyl (2-(2-((3-(9-(2,6-dioxopiperidin-3-yl)-9H-pyrido[2,3-b]indol-5-yl)prop-2-yn-1-yl)oxy)ethoxy)ethyl)carbamate

[004432] A mixture of 3-(5-bromo-9i7-pyrido[2,3-b]indol-9-yl)piperidine-2,6-dione (270 mg, 0.75 mmol), *tert*-butyl (2-(2-(prop-2-yn-l-yloxy)ethoxy)ethyl)carbamate (270 mg, 2.25 mmol, Intermediate IT) CS2CO3 (270 mg, 2.25 mmol), PdCh(PPh3)2 (105 mg, 0.15 mmol) and Cul (14 mg, 0.075 mmol) in DMF (10 mL) was stirred at 80 °C for 1 h under N2 with microwave . The mixture was cooled to rt, poured into water (100 mL), extracted with EtOAc (3 x 100 mL). The combined organic layers were concentrated under reduced pressure, the residue was purified by column chromatography on silica gel (petroleum ether: ethyl acetate = 2:1) to give the title product (180 mg, 41% yield) as a white solid. LC/MS (ESI, *m/z):* [M +l] $^{+}$ = 360.28. ^{1}H NMR (400 MHz, DMSO-i¾) δ 11.18 (s, 1H), 8.81 (dd, 7 = 7.8, 1.6 Hz, 1H), 8.50 (dd, *J* = 4.8, 1.7 Hz, 1H), 7.73-7.68 (m, 1 H), 7.54 (t, *j* = 7.9 Hz, 1H), 7.45 - 7.28 (m, 2H), 6.80-6.76 (m, 1 H), 6.08 (s, 1H), 4.65 (s, 2H), 3.81 - 3.70 (m, 2H), 3.62 (dd, 7 = 5.7, 3.6 Hz, 2H), 3.43 (t, *J* = 6.1 Hz, 2H), 3.17 - 2.96 (m, 3H), 2.76 - 2.64 (m, 1H), 2.50 -2.45 (m, 1 H), 2.17-2.13 (m, 1 H), 1.35 (s, 9H).

[004433] Step 2 - tert-butyl (2-(2-(3-(9-(2.6-dioxopiperidin-3-yl)-9H-pyridor2J-b1indol-5-vDpropoxy)ethoxy)ethvDcarbamate


[004434] To a mixture of tert-butyl (2-(2-((3-(9-(2,6-dioxopiperidin-3-yl)-9H-pyrido[2,3-b]indol-5-yl)prop-2-yn-l-yl)oxy)ethoxy)ethyl)carbamate (180 mg, 0.34 mmol), Pd/C (100 mg) in EA (10 mL) was stirred at rt under ¾ for 16 h. The mixture was filtered and the solid was washed

with EA, the filtrate was concentrated under reduced pressure. Then the residue was purified by column chromatography on silica gel (petroleum ether: ethyl acetate = 2:1) to give the title compound (100 mg, 56% yield) as a white solid. LC/MS (ESI, *m/z):* [M +l] $^{+}$ =525.1. ^{1}H NMR (400 MHz, DMS0 -d_6) *S* 11.15 (s, 1H), 8.54 (dd, *J* = 7.9, 1.5 Hz, 1H), 8.42 (dd, *J* = 4.9, 1.5 Hz, 1H), 7.52 - 7.40 (m, 2 H), 7.28 (dd, *J* = 7.8, 4.9 Hz, 1H), 7.11 (d, *J* = 7.4 Hz, 1H), 6.77-6.74 (m, 1 H), 6.10-6.00 (m, 1 H), 3.61 - 3.50 (m, 6H), 3.43 (t, *J* = 6.1 Hz, 2H), 3.23-3.20 (m, 2 H), 3.12 - 2.96 (m, 4H), 2.72 - 2.65 (m, 1H), 2.12-2.06 (m, 1 H), 1.99-1.89 (m, 2 H), 1.34 (s, 9H).

[004435] Step 3 - 3-r5-r3-r2-(2-Aminoethoxy)ethoxy1propyl1pyridor2.3-b1indol-9-yl1piperidine-2.6-dione

[004436] To a solution of tert-butyl N-[2-[2-[3-[9-(2,6-dioxo-3-piperidyl)pyrido[2,3-b]indol-5-yl]propoxy] ethoxy]ethyl]carbamate (100 mg, 190 umol) in DCM (2 mL) was added TFA (1.54 g, 13.5 mmol, 1 mL). The reaction mixture was stirred at 25 °C for 2 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (100 mg, 97% yield, TFA) as a white solid. LC-MS (ESI^{+}) m/z 425.2(M+H) $^{+}$.


[004437] **Tert-butyl N-methyl-N-(l-prop-2-vnyl-4-piperidv0carbamate [Intermediate XH)**



XH

[004438] To a solution of tert-butyl N-methyl-N-(4-piperidyl)carbamate (1.50 g, 7.00 mmol, CAS# 108612-54-0) and 3-bromoprop-l-yne (915 mg, 7.70 mmol, 663 uL, CAS# 106-96-70) in THF (30 mL) was added K_2CO_3 (2.90 g, 21.0 mmol). The reaction mixture was stirred at 25 °C for 16 hrs. On completion, the mixture was diluted with water (30 mL) and extracted with EA (3 X 80 mL). The combined organic layers was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (1.50 mg, 85% yield) as yellow solid. ^{1}H NMR (400 MHz, CDCb) δ 4.16 - 3.61 (m, 1H), 3.29 (d, *J* = 2.0 Hz, 2H), 3.01 - 2.90 (m, 2H), 2.73 (s, 3H), 2.35 - 2.21 (m, 3H), 1.81 - 1.72 (m, 2H), 1.69 - 1.63 (m, 2H), 1.46 (s, 9H).

[004439] **3-[3-Methyl-4-[3-[4-tmethylamino)-l-piperidyl]propyl1-2-oxo-benzimidazol-1-yl] piperidine- 2,6-dione [Intermediate XI)**



[004440] Step 1 - Tert-butyl N-[1-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]prop-2-ynyl] -4-piperidyll-N-methyl-carbamate

[004441] To a solution of tert-butyl N-methyl-N-(l-prop-2-ynyl-4-piperidyl)carbamate (559 mg, 2.22 mmol, Intermediate XH) and 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (500 mg, 1.48 mmol, Intermediate HP) in DMF (5 mL) was added Pd(PPh $_3$)2Cl2 (103 mg, 147 umol), Cul (28. 1 mg, 147 umol) and CS2CO3 (955 mg, 2.93 mmol, 2.58 mL). The reaction mixture was stirred at 80 °C for 2 hr under N2. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (700 mg, 93% yield) as a gray solid. ¾NMR (400 MHz, DMSO-i¾) δ 11.13 (s, 1H), 7.20 - 6.93 (m, 3H), 5.40 (dd, J = 5.2, 12.8 Hz, 1H), 3.66 (s, 3H), 3.58 (s, 2H), 2.98 - 2.84 (m, 3H), 2.68 (s, 3H), 2.66 - 2.59 (m, 2H), 2.25 (t, J = 10.8 Hz, 2H), 2.07 - 1.99 (m, 1H), 1.75 - 1.50 (m, 5H), 1.40 (s, 9H); LC-MS (ESI$^+$) m/z 510.3 (M+H)$^+$.

[004442] Step 2 - Tert-butyl N-[1-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazolM-yl]propyl]-4- piperidyll-N-methyl -carbamate


[004443] To a solution of tert-butyl N-[l-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] prop-2- ynyl]-4-piperidyl]-N-methyl-carbamate (650 mg, 1.28 mmol) in THF (20 mL) was added Pd/C (150 mg, 1.28 mmol, 10 wt%) and Pd(OH)2/C (150 mg, 10 wt%). The

reaction mixture was stirred at 25 °C under H_2 (15 psi) for 2 hrs. On completion, the residue was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0. 1% FA condition) to give the title compound (480 mg, 73% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-i&) δ 11.08 (s, 1H), 6.96 (d, *J* = 4.8 Hz, 2H), 6.93 - 6.86 (m, 1H), 5.36 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.93 - 3.65 (m, 1H), 3.56 (s, 3H), 3.08 - 2.97 (m, 2H), 2.96 - 2.81 (m, 3H), 2.76 - 2.67 (m, 1H), 2.66 (s, 3H), 2.64 - 2.58 (m, 1H), 2.49 - 2.39 (m, 2H), 2.14 - 2.05 (m, 2H), 2.03 - 1.94 (m, 1H), 1.83 - 1.62 (m, 4H), 1.56 - 1.48 (m, 2H), 1.39 (s, 9H); LC-MS (ESI^+) m/z 514.3 $(M+H)^+$.

[004444] Step 3 - 3-r3-Methyl-4-r3-r4-(methylamino)-l-piperidyl1propyl1-2-oxo-benzimidazol-l-yllpiperidine- 2.6-dione

[004445] To a solution of tert-butyl N-[l-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propyl]-4-piperidyl]-N-methyl-carbamate (100 mg, 194 umol) in DCM (2 mL) was added HCl/dioxane (4 M, 1 mL). The reaction mixture was stirred at 20 °C for 2 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (85.0 mg, 97% yield, HC1) as a white solid. LC-MS (ESI^+) m/z 4l4.3$(M+H)^+$.

[004446] Tert-butyl N-methyl-N-[2-(4-piperidylmethoxy) ethyl] carbamate [Intermediate XJ)



XJ

[004447] Step **1** - Benzyl 4-(Y2-ethoxy-2-oxoethoxy)methvQpiperidine-l-carboxylate

[004448] A solution of benzyl 4-(hydroxymethyl) piperidine- l-carboxylate (15.0 g, 60.2 mmol, CAS# 122860 -33-7) in DCM (15 mL) was added diacetoxyrhodium (1.33 g, 3.01 mmol,

CAS# 623-73-4). The mixture was stirred at 25 °C for 0.5 hour. Then ethyl 2-diazoacetate (13.7 g, 120 mmol) in DCM (15 mL) was added dropwise slowly to the solution. The mixture was stirred at 25 °C for 12 hours. On completion, the reaction mixture was quenched by water (10 mL), and extracted with DCM (3 X 20 mL). The combined organic layers dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (16.8 g, 83% yield) as yellow oil. LC-MS (ESI^+) m/z 336.2 $(M+H)^+$.

[004449] Step 2 - Benzyl 4-(Y2-hvdroxyethoxy)methvDpiperidine-l-carboxylate

[004450] To a solution of benzyl 4-[(2-ethoxy-2-oxo-ethoxy)methyl]piperidine-l-carboxylate (16.8 g, 50.1 mmol) in THF (180 mL) was added LiBLL (2.18 g, 100 mmol) at 0 °C. The mixture was stirred at 25 °C for 12 hours. On completion, the reaction mixture was quenched with H_2O (200 mL) and then extracted with ethyl acetate (2 X 300 mL). Then the organic layers were washed with brine (2 X 150 mL). The combined organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (13.2 g, 90% yield) as colorless oil. LC-MS (ESI^+) m/z 294.2 $(M+H)^+$.

[004451] Step 3 - Benzyl 4-(Y2-azidoethoxy)methvDpiperidine-l-carboxylate

[004452] To a solution of benzyl 4-(2-hydroxyethoxymethyl)piperidine-l-carboxylate (4.00 g, 13.6 mmol) in toluene (40 mL) was added DPPA (4.50 g, 16.4 mmol) and DBU (2.49 g, 16.4 mmol). The mixture was stirred at 100 °C for 12 hours. On completion, the reaction mixture was diluted with H_20 (50 mL) and extracted with ethyl acetate (3 X 50 mL). The combined organic layers were dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (4.34 g, 98% yield) as yellow oil.

[004453] Step 4 - Benzyl 4-(2-aminoethoxymethvDpiperidine-l-carboxylate

[004454] To a solution of benzyl 4-(2-azidoethoxymethyl)piperidine-l-carboxylate (4.34 g, 13.6 mmol) in a mixed solvent of THF (45 mL) and H_20 (5 mL) was added PPh_3 (3.58 g, 13.6 mmol). The mixture was stirred at 66 °C for 12 hours. On completion, the reaction mixture was diluted with H_20 (50 mL) and extracted with ethyl acetate (3 X 50 mL). The organic layers were dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (3.99 g, 99% yield) as yellow oil. LC-MS (ESI+) m/z 293.2 $(M+H)^+$.

[004455] Step 5 - Benzyl 4-r2-(tert-butoxycarbonylamino)ethoxymethyl1piperidine-l-carboxylate

[004456] To a solution of benzyl 4-(2-aminoethoxymethyl)piperidine-l-carboxylate (3.99 g, 13.7 mmol) in THF (40 mL) was added Boc_20 (4.47 g, 20.5 mmol) and TEA (4.14 g, 40.9 mmol). The mixture was stirred at 25 °C for 12 hours. On completion, the reaction mixture was diluted with H_20 (100 mL) and extracted with (2 X 100 mL). The organic layers were dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (4.70 g, 80% yield) as yellow oil. LC-MS (ESI^+) m/z 415.3 $(M+Na)^+$.


[004457] Step 6 - Benzyl 4-r2-rtert-butoxycarbonvKmethvDaminolethoxymethvnpiperidine-l- carboxylate

[004458] To a solution of benzyl 4-[2-(tert-butoxycarbonylamino)ethoxymethyl]piperidine-l-carboxylate (4.60 g, 11.7 mmol) in DMF (50 mL) was added NaH (938 mg, 23.4 mmol, 60% dispersion in oil) at 0 °C. Then CLLI (3.33 g, 23.4 mmol) was added dropwise to the solution. The mixture was stirred at 0-25 °C for 2 hours. On completion, the reaction mixture was quenched with saturated NH_4Cl (20 mL). Then H_20 (50 mL) and ethyl acetate (lOOmL) was added. The aqueous layer was extracted with ethyl acetate (2 X 100 mL). The combined organic layers were washed with brine (50 mL). The organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (3.80 g, 79% yield) as yellow oil.

[004459] Step 7 - Tert-butyl N-methyl-N-r2-(4-piperidylmethoxy) ethyllcarbamate

[004460] To a solution of benzyl 4-[2-[tert-butoxycarbonyl(methyl)amino]ethoxymethyl]piperidine-l- carboxylate (3.80 g, 9.35 mmol) in MeOH (80 mL) was added Pd/C (400 mg, 377 umol, 10 wt%) . The mixture was stirred at 25 °C for 12 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (3.30 g, 98% yield) as yellowish oil. LC-MS (ESI^+) m/z 273.2 $(M+H)^+$.

[004461] 3-[3-methyl-5-[4-[[2-[methylamino)ethoxy)methvBpiperidin-l-vB-2-oxo-2.,3-dihvdro -lH-benzo[d]imidazol-l-vBpiperidine-2,6-dione methanesulfonate [Intermediate XK)



[004462] Step 1 - Tert-butyl N-methyl-N-[2-[[1-[3-(methylamino)-4-nitro-phenyl1-4-piperidyll methoxyl ethyllcarbamate

[004463] To a solution of tert-butyl N-methyl-N-[2-(4-piperidylmethoxy)ethyl]carbamate (3.30 g, 12.1 mmol, Intermediate XJ) in DMF (30 mL) was added 5-fluoro-N-methyl-2-nitro-aniline (2.06 g, 12.1 mmol) and K2CO3 (5.02 g, 36.4 mmol). Then the mixture was stirred at 80 °C for 12 hours. On completion, the reaction mixture was diluted with H_20 (50 mL) and extracted with ethyl acetate (3 X 100 mL). The organic layers were washed with brine (3 X 50 mL). Then the organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (4.40 g, 85% yield) as orange oil. LC-MS (ESI+) m/z 423.5 $(M+H)^+$.

[004464] Step 2 - Tert-butyl (2-((l-(4-amino-3-(methylamino)phenvnpiperidin-4-yl)methoxy)ethvl) (methvDcarbamate

[004465] To a solution of tert-butyl N-methyl-N-[2-[[l-[3-(methylamino)-4-nitro-phenyl]-4-piperidyl] methoxy]ethyl]carbamate (3.6 g, 8.52 mmol) in MeOH (100 mL) was

added Pd/C (0.7 g, 10 wt%) under N_2. The suspension was degassed *in vacuo* and purged with H_2 three times. The mixture was stirred under H_2 (15 Psi) at 25 °C for 4 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (3.2 g, 97% yield) as brown oil. ^{1}H NMR (400 MHz, CDCh) δ 6.63 (d, *J* = 8.2 Hz, 1H), 6.34 (d, *J* = 2.4 Hz, 1H), 6.28 (dd, *J* = 2.6, 8.2 Hz, 1H), 3.52 (d, *J* = 12.0 Hz, 4H), 3.45 - 3.31 (m, 4H), 2.93 (s, 3H), 2.86 (s, 3H), 2.62 (dt, *j* = 2.0, 11.6 Hz, 2H), 1.83 (d, *j* = 12.6 Hz, 2H), 1.73 - 1.60 (m, 1H), 1.49 - 1.40 (m, 11H); LC-MS (ESI+) m/z 393.2 $(M+H)^+$.

[004466] Step 3 - Tert-butyl (2-((T-(4-amino-3-(methylamino)phenvDpiperidin-4-yl)methoxy)ethvO (methvDcarbamate

[004467] To a mixture of tert-butyl N-[2-[[l-[4-amino-3-(methylamino)phenyl]-4-piperidyl]methoxy] ethyl]-N-methyl-carbamate (1.5 g, 3.82 mmol) in MeCN (30 mL) was added CDI (1.24 g, 7.64 mmol) under N_2. The mixture was stirred for at 85 °C 16 hours. On completion, the reaction mixture was concentrated *in vacuo* to remove THF. The residue was diluted with water (20 mL) and extracted with EA (3 X 20 mL). The combined organic layers was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (FA condition) to give the title compound (1.10 g, 69% yield) as a purple solid. ^{1}H NMR (400 MHz, CDCh) δ 9.06 (s, 1H), 6.95 (d, *j* = 8.4 Hz, 1H), 6.74 - 6.69 (m, 1H), 6.62 (d, *J* = 2.2 Hz, 1H), 3.60 - 3.52 (m, 4H), 3.39 (s, 3H), 3.37 - 3.31 (m, 2H), 2.93 (s, 3H), 2.73 - 2.65 (m, 2H), 1.86 (d, J = 11.8 Hz, 2H), 1.77 - 1.67 (m, 2H), 1.47 - 1.33 (m, 13H; LC-MS (ESI^+) m/z 419.2 $(M+H)^+$.

[004468] Step 4 - Tert-butyl (2-((l-(4-amino-3-(methylamino)phenvnpiperidin-4-yl)methoxy)ethvl) (methvDcarbamate


[004469] To a mixture of tert-butyl N-methyl-N-[2-[[l-(3-methyl-2-oxo-lH-benzimidazol-5-yl)-4- piperidyl]methoxy]ethyl]carbamate (1.10 g, 2.63 mmol) in THF (20 mL) was added /-BuOK (442 mg, 3.94 mmol) at 0 °C under N_2. Then a solution of [l-[(4-methoxyphenyl)methyl]-2,6 -dioxo-3-piperidyl] trifluoromethanesulfonate (1.50 g, 3.94 mmol, Intermediate IQ) in THF (20 mL) was added dropwise at 0 °C. The mixture was warmed slowly to 25 °C and stirred at 25 °C for 24 hours. On completion, the reaction mixture was quenched by addition water (10 mL) at 25 °C, and then extracted with EA (3 X 20 mL). The combined organic layers, dried over Na_2S0_4, filtered and concentrated *in vacuo*

to give a residue. The residue was purified by column chromatography to give the title compound (800 mg, 24% yield) as brown oil. LC-MS (ESI$^+$) m/z 650.2 $(M+H)^+$.

[004470] Step 5 - 3-(3-methyl-5-(4-((2-(methylamino)ethoxy)methvnpiperidin-l-vO-2-oxo-2.3-dihydro -1H-benzordlimidazol- 1-yl)piperidine-2.6-dione methanesulfonate

[004471] To a mixture of tert-butyl N-[2-[[l-[l-[l-[(4-methoxyphenyl)methyl]-2,6-dioxo-3-piperidyl] -3-methyl-2-oxo-benzimidazol-5-yl]-4-piperidyl]methoxy]ethyl]-N-methyl-carbamate (500 mg, 769 umol) in toluene (10 mL) was added CH_3SO_3H (2.22 g, 23.1 mmol) at 25 °C. The mixture was stirred at 120 °C for 3 hours. On completion, the reaction mixture was quenched by addition water (2 mL) at 25°C, and then neutralized by adding NEt3 to pH = 5. Then the mixture was filtered and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (FA condition) to give the title compound (100 mg, 25% yield, CH3SO3H) as yellow oil. LC-MS (ESI+) m/z 430.1 $(M+H)^+$.


[004472] **Tert-butyl 4-(2-prop-2-ynoxyethyl]piperazine-l-carboxylate [Intermediate XL]**



XL

[004473] A mixture of tert-butyl 4-(2-hydroxyethyl)piperazine-l-carboxylate (5.00 g, 21.7 mmol, CAS# 77279-24-4), 3-bromoprop-l-yne (2.58 g, 21.7 mmol, CAS# 106-96-7) in THF (35 mL) was added TBAI (802 mg, 2.17 mmol), KI (541 mg, 3.26 mmol) and KOH (1.22 g, 21.7 mmol). The mixture was stirred at 25 °C for 12 hrs under N_2 atmosphere. On completion, the reaction mixture was diluted with water (2 X 100 mL) and extracted with ethyl acetate (3 X 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography ($Si0_2$, PE: EA = 10:1 to 3:1) to give the title compound (1.30 g, 18% yield) as yellow oil. ^{1}H NMR (400 MHz, DMSO-r¾) δ 4.12 (d, *J* = 2.4 Hz, 2H), 3.54 (t, *J* = 5.6 Hz, 2H), 3.41 (s, 1H), 3.30 - 3.26 (m, 4H), 2.49 - 2.47 (m, 2H), 2.36 - 2.33 (m, 4H), 1.39 (s, 9H).

[004474] **3-[3-Methyl-2-oxo-4-[3-(2-piperazin-l-ylethoxy]propyl]benzimidazol-l-yl]piperidine-2.,6-dione [Intermediate XM)**



[004475] Step 1 - Tert-butyl 4-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl1prop-2- ynoxylethyllpiperazine-l-carboxylate

[004476] A mixture of tert-butyl 4-(2-prop-2-ynoxyethyl)piperazine-l-carboxylate (476 mg, 1.77 mmol, Intermediate XL), 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (300 mg, 887 umol, Intermediate HP), CS2CO3 (1.45 g, 4.44mmol), 4Å molecular sieves (50 mg), $Pd(PPh3)_2Cl2$ (124 mg, 177 umol) and Cul (33.8 mg, 177 umol) in DMF (8 mL) under N2 atmosphere. The mixture was de-gassed and then heated at 80 °C for 2 hrs. On completion, the reaction mixture was concentrated *in vacuo*. The crude product was purified by reversed-phase HPLC (0.1% FA condition) to give the title compound (400 mg, 77% yield) as brown oil. ^{1}H NMR (400 MHz, DMSO-di) δ 11.12 (s, 1H), 7.19 (d, *J* = 7.2 Hz, 1H), 7.13 (d, *J* = 7.6 Hz, 1H), 7.06 - 6.94 (m, 1H), 5.41 (dd, *j* = 4.8, 12.4 Hz, 1H), 4.47 (s, 2H), 3.74 (s, 2H), 3.64 (s, 3H), 3.56 - 3.52 (m, 4H), 2.94 - 2.89 (m, 1H), 2.85 - 2.71 (m, 4H), 2.63 - 2.58 (m, 4H), 2.09 - 1.97 (m, 1H), 1.39 (s, 9H); LC-MS (ESI+) m/z 526.3 $(M+H)^+$.


[004477] Step 2 - Tert-butyl 4-[2-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl1propoxy1 ethyllpiperazine- 1-carboxylate

[004478] To a solution of tert-butyl 4-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3- methyl-2-oxo-benzimidazol-4-yl]prop -2-ynoxy]ethyl]piperazine-l-carboxylate (400 mg, 679 umol) in THF (20 mL) was added Pd/C (50.0 mg, 10 wt%) and $Pd(OH)_2$ (50.0 mg) under N_2 atmosphere. The mixture was stirred at 25 °C for 12 hrs under H_2 (15 Psi). On completion, the reaction mixture was concentrated *in vacuo.* The product was filtered under reduced pressure to give the title compound (395 mg, 99% yield) as brown solid. ^1H NMR (400 MHz, DMSO-7 $_5$) δ 11.08 (s, 1H), 6.97 (d, *J* = 5.2 Hz, 2H), 6.90 - 6.85 (m, 1H), 5.37 (dd, *J* = 5.2, 12.4 Hz, 1H), 4.26 (t, *J* = 7.2 Hz, 1H), 4.15 (t, *J* = 6.5 Hz, 1H), 3.69 - 3.62 (m, 2H), 3.56 (s, 3H), 3.50 - 3.45 (m, 4H), 2.98 - 2.95 (m, 2H), 2.75 - 2.71 (m, 2H), 2.69 - 2.66 (m, 2H), 2.65 - 2.59 (m, 4H), 2.19 - 2.13 (m, 1H), 1.88 - 1.82 (m, 2H), 1.77 - 1.71 (m, 1H), 1.40 (s, 9H). LC-MS (ESI+) m/z 530.3 $(M+H)^+$.

[004479] Step 3 - 3-r3-Methyl-2-oxo-4-r3-(2-piperazin-l-ylethoxy)propyl1benzimidazol-l-yl1piperidine-2.6-dione

[004480] To a solution of tert-butyl 4-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4- yl]propoxy]ethyl]piperazine-l-carboxylate (100 mg, 189 umol) in DCM (4 mL) was added HCl/dioxane (2 mL). The mixture was stirred at 25 °C for 2 hrs. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (87 mg, 58% yield, HC1) as brown solid. LC-MS (ESI+) m/z 430.3 $(M+H)^+$.

[004481] **Tert-butyl _N-isopropyl-N-(3-prop-2-vnoxypropyQcarbamate _[Intermediate XN)**



XN

[004482] Step 1 - 3-(Tsopropylamino)propan-l-ol

[004483] A solution of 3-bromopropan-l-ol (5.00 g, 36.0 mmol) in propan-2-amine (6.19 g, 105 mmol) was stirred at 50 °C for 12 hours. On completion, the mixture was concentrated to give the title compound (7.00 g, 90% yield, 50% purity) as colorless oil. ^1H NMR (400 MHz, CDCh) δ 3.84 (t, *J* = 5.6 Hz, 2H), 3.40 - 3.33 (m, 1H), 3.12 (t, 7 = 6.4 Hz, 2H), 2.1 1 - 1.99 (m, 2H), 1.39

(d, J = 6.6 Hz, 6H).


[004484] Step 2 - Tert-butyl N-(3-hydroxypropyl)-N-isopropyl-carbamate

[004485] To a solution of 3-(isopropylamino)propan-l-ol (7.00 g, 30.0 mmol, 50% purity) in DCM (10 mL) was added $(Boc)_20$ (13.0 g, 59.7 mmol, 13.7 mL) and Et_3N (8.00 g, 79.0 mmol) at 15 °C. The mixture was stirred at 15 °C for 6 hours. On completion, the mixture was concentrated *in vacuo*. The residue was purified by flash silica gel chromatography to give the title compound (3.60 g, 50% yield) as yellow oil. ^1H NMR (400 MHz, CDCh) δ 3.58 (m, 2H), 3.35 (m, 2H), 1.67 (m, 2H), 1.48 (s, 9H), 1.16 (d, J = 6.8 Hz, 6H), 0.91 - 0.86 (m, 1H).

[004486] Step 3 - Tert-butyl N-isopropyl-N-(3-prop-2-ynoxypropyl)carbamate

[004487] To a solution of tert-butyl N-(3-hydroxypropyl)-N-isopropyl-carbamate (3.40 g, 15.7 mmol) and TBAI (57.8 mg, 156 umol) in THF (100 mL) was added NaH (750 mg, 18.7 mmol, 60% dispersion in oil) at 0 °C. The mixture was stirred at 0 °C for 0.5 hour. 3-bromoprop-l-yne (2.79 g, 23.5 mmol) was added at 0 °C. The mixture was stirred at 0 - 15 °C for 6 hours. On completion, the reaction mixture was quenched with sat. aq. NH_4Cl (30 mL) at 0 °C. The mixture was extracted with EA (3 X 100 mL). The combined organic layers were washed with brine (100 ml), dried over Na_2S0_4, filtered and concentrated *in vacuo*. The residue was purified by flash silica gel chromatography to give the title compound (3.50 g, 80% yield) as yellow oil. ^1H NMR (400 MHz, CDCh) δ 4.13 (d, J = 2.4 Hz, 2H), 3.53 (t, J = 6.4 Hz, 2H), 3.14 (m, 2H), 2.41 (t, J = 2.4 Hz, 1H), 1.86 - 1.77 (m, 2H), 1.46 (s, 9H), 1.12 (d, J = 6.8 Hz, 6H), 0.90 - 0.80 (m, 1H).

[004488] 3-[4-[3-[3-(Isopropylamino)propoxy]propyl]-3-methyl-2-oxo-benzimidazol-1-yl]piperidine-2,6-dione (Intermediate XO)



[004489] Step 1 - Tert-butyl N-[3-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl1prop-2 -ynoxylpropyll-N-isopropyl-carbamate

[004490] To a solution of tert-butyl N-isopropyl-N-(3-prop-2-ynoxypropyl)carbamate (755 mg, 2.96 mmol, Intermediate XN) and 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (400 mg, 1.18 mmol, Intermediate HP) in DMF (10 mL) was added $Pd(dppf)Cl_2$ (173 mg, 237 umol) and CS2CO3 (1.54 g, 4.73 mmol) and Cul (45.1 mg, 237 umol) at 20 °C. The mixture was stirred at 80 °C for 2 hours under N_2. On completion, the mixture was filtered through celite and the filtrate was concentrated *in vacuo.* The residue was purified by reversed-phase HPLC (FA condition) to give the title compound (350 mg, 55% yield) as yellow solid. ^1H NMR (400 MHz, DMSO-d_6) δ 11.14 (s, 1H), 7.18 (d, *J* = 7.6 Hz, 1H), 7.14 - 7.10 (m, 1H), 7.08 - 6.99 (m, 1H), 5.43 - 5.38 (m, 1H), 4.44 (s, 2H), 3.09 (m, 2H), 2.95 - 2.84 (m, 1H), 2.09 - 1.97 (m, 1H), 1.82 - 1.69 (m, 2H), 1.38 (s, 9H), 1.08 (d, *J* = 6.0 Hz, 6H).

[004491] Step 2 - Tert-butyl N-[3-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yllpropoxyl propyll-N-isopropyl-carbamate


[004492] To a solution of tert-butyl N-[3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] prop-2-ynoxy]propyl]-N-isopropyl-carbamate (350 mg, 683 umol) in THF (20

mL) was added $Pd(OH)_2/C$ (350 mg, 683 umol, 10 wt%) and Pd/C (350 mg, 682 umol, 10 wt%). The mixture was stirred at 15 °C for 2 hours. On completion, the mixture was filtered with celite and the filtrate was concentrated *in vacuo* to give the title compound (350 mg, 99% yield) as yellow oil. LC-MS (ESI^+) *m/z* 539.4 $(M+23)^+$

[004493] Step 3 - 3-r4-r3-r3-(Isopropylamino)propoxy1propyl1-3-methyl-2-oxo-benzimidazol-l-yllpiperidine -2.6-dione

[004494] To a solution of tert-butyl N-[3-[3-[l-(2, 6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propoxy]propyl]-N-isopropyl -carbamate (320 mg, 619 umol) in DCM (4 mL) was added TFA(l0.7 mL) at 15 °C. The mixture was stirred at 15 °C for 0.5 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (320 mg, 97% yield, TFA salt) as yellow oil. LC-MS (ESI^+) *m/z* 417.3 $(M+H)^+$.

[004495] **Tert-butyl N-cvclopropyl-N-(3-prop-2-vnoxypropyl)carbamate [Intermediate XP)**



XP

[004496] Step 1 - 3-(Cvclopropylamino)propan-l-ol

[004497] A mixture of 3-bromopropan-l-ol (5.00 g, 35.9 mmol, 3.25 mL, CAS# 627-18-9) in cyclopropanamine (10.2 g, 179 mmol, 12.4 mL, CAS# 765-30-0) was stirred at 50 °C for 12 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (4.00 g, 96% yield) as light yellow oil. ^1H NMR (400 MHz, DMSO-i¾) δ 3.45 (t, J = 6.0 Hz, 2H), 3.01 (t, J = 7.6 Hz, 2H), 2.75 - 2.68 (m, 1H), 1.81 - 1.73 (m, 2H), 0.88 - 0.82 (m, 2H), 0.74 - 0.70 (m, 2H).

[004498] Step 2 - Tert-butyl N-cvclopropyl-N-(3-hvdroxypropyDcarbamate


[004499] To a mixture of 3-(cyclopropylamino)propan-l-ol (4.00 g, 34.7 mmol) in DCM (60 mL) was added TEA (10.5 g, 104 mmol, 14.5 mL) and Boc_20 (15.1 g, 69.4 mmol, 15.9 mL). The

reaction mixture was stirred at 25 °C for 12 hours. On completion, the reaction mixture was diluted with water (30 mL) and extracted with EA (3X 50 mL). The combined organic layers was dried over Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (3.70 g, 49% yield) as light yellow oil. ^1H NMR (400 MHz, CDCh) δ 3.54 (d, *J* = 5.0 Hz, 2H), 3.36 (t, *J* = 6.0 Hz, 2H), 2.49 - 2.41 (m, 1H), 1.74 - 1.65 (m, 2H), 1.45 (s, 9H), 0.75 - 0.68 (m, 2H), 0.62 - 0.55 (m, 2H).

[004500] Step 3 - Tert-butyl N-cvclopropyl-N-(3-prop-2-vnoxypropyOcarbamate

[004501] To a mixture of tert-butyl N-cyclopropyl-N-(3-hydroxypropyl)carbamate (3.20 g, 14.8 mmol) in THF (30 mL) was added NaH (1.19 g, 29.7 mmol, 60% dispersion in oil) at 0 °C for 0.5 hour. Then 3-bromoprop-l-yne (3.54 g, 29.7 mmol, 2.56 mL) was added to the mixture. The reaction mixture was stirred at 25 °C for 12 hours. On completion, the reaction mixture was quenched with sat. NH_4Cl solution (10 mL) under stirring. The mixture was diluted with water (30 mL) and extracted with EA (3 X 50 mL). The combined organic layers was dried over Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (3.70 g, 98% yield) as light yellow oil. ^1H NMR (400 MHz, CDCh) δ 4.13 (d, *J* = 2.4 Hz, 2H), 3.53 (t, *J* = 6.4 Hz, 2H), 3.32 - 3.25 (m, 2H), 2.54 - 2.46 (m, lH), 2.4l (t, 7 = 2.4 Hz, 1H), 1.89 - 1.81 (m, 2H), 1.45 (s, 9H), 0.75 - 0.70 (m, 2H), 0.61 - 0.57 (m, 2H).

[004502] **3-[4-[3-[3-(Cyclopropylamino)propoxy|propyl1-3-methyl-2-oxo-benzimidazol-l-yl] piperidine -2,6-dione [Intermediate** XQ1



[004503] Step 1 - Tert-butyl N-cyclopropyl-N-[3-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4- yl1prop-2-vnoxy1propyl1carbamate

[004504] To a mixture of tert-butyl N-cyclopropyl-N-(3-prop-2-ynoxypropyl)carbamate (599 mg, 2.37 mmol, Intermediate XP) and 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (400 mg, 1.18 mmol, Intermediate HP) in DMF (5 mL) was added Cul (22.5 mg, 118 umol), CS2CO3 (1.93 g, 5.91 mmol), Pd(PPh3)$_2$Cl2 (83.0 mg, 118 umol) and 4A molecular sieves (10 mg). The reaction mixture was stirred at 80 °C for 2 hours under N2 atmosphere. On completion, the reaction mixture was filtered and concentrated *in vacuo.* The residue was purified by reverse phase (0.1 % FA condition) to give the title compound (240 mg, 39% yield) as brown solid. ^{1}H NMR (400 MHz, DMSO-r¾) δ 11.14 (s, 1H), 7.18 (d, *J* = 7.6 Hz, 1H), 7.13 - 7.09 (m, 1H), 7.05 - 7.00 (m, 1H), 5.43 - 5.37 (m, 1H), 4.43 (s, 2H), 3.64 (s, 3H), 3.53 (t, *J* = 6.3 Hz, 2H), 3.44 - 3.37 (m, 2H), 3.21 (t, *J* = 7.2 Hz, 2H), 2.94 - 2.83 (m, 1H), 2.75 - 2.55 (m, 3H), 2.07 - 1.98 (m, 1H), 1.80 - 1.70 (m, 2H), 1.39 (s, 2H), 1.37 (s, 9H), 0.70 - 0.63 (m, 2H), 0.57 - 0.49 (m, 2H).

[004505] Step 2 - Tert-butyl N-cvc1oρΓθρv1-N-[3-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4- yllpropoxylpropyllcarbamate


[004506] To a mixture of tert-butyl N-cyclopropyl-N-[3-[3-[l-(2,6-dioxo-3-piperidyl)-3-

methyl-2-oxo- benzimidazol-4-yl]prop-2-ynoxy]propyl]carbamate (180 mg, 352 umol) in THF (20 mL) was added $Pd(OH)_2/C$ (30.0 mg, 10 wt%) and Pd/C (30.0 mg, 10 wt%). The reaction mixture was stirred at 25 °C for 2.5 hours under H_2 (15 Psi) atmosphere. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (181 mg, 99% yield) as light yellow solid. The residue was used to the next step directly without further purification. ¾NMR (400 MHz, DMSO^) δ 11.09 (s, 1H), 6.96 (d, *J* = 4.4 Hz, 2H), 6.89 - 6.84 (m, 1H), 5.39 - 5.33 (m, 1H), 3.56 (s, 3H), 3.41 (d, *J* = 6.0 Hz, 2H), 3.38 (t, *J* = 6.0 Hz, 2H), 3.21 (t, *j* = 7.2 Hz, 2H), 2.99 - 2.93 (m, 2H), 2.91 - 2.84 (m, 1H), 2.72 - 2.62 (m, 3H), 2.02 - 1.99 (m, 1H), 1.85 - 1.79 (m, 2H), 1.77 - 1.70 (m, 2H), 1.38 (s, 9H), 0.70 - 0.64 (m, 2H), 0.56 - 0.50 (m, 2H).

[004507] Step 3 - 3-r4-r3-r3-(Cvclopropylamino)propoxy1propyl1-3-methyl-2-oxo-benzimidazol-l-yllpiperidine -2.6-dione

[004508] To a mixture of tert-butyl N-cyclopropyl-N-[3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo- benzimidazol-4-yl]propoxy]propyl]carbamate (190 mg, 369 umol) in DCM (1 mL) was added TFA(4.62 g, 40.5 mmol, 3.00 mL). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (195 mg, 99% yield, TFA salt) as red oil. LC-MS (ESI^+) *m/z* 415.3 $(M+H)^+$.

[004509] **Tert-butyl 4-(4-piperidylmethvDpiperidine-l-carboxylate [Intermediate XS)**



[004510] Step 1 - Tert-butyl 4-(4-pyridylmethv0piperidine-l-carboxylate


[004511] To a solution of tert-butyl 4-methylenepiperidine-l-carboxylate (6.00 g, 30.4 mmol, CAS# 159635-49-1) was added 9-BBN THF solution (0.5 M, 60.5 mL) at 25 °C. The reaction mixture was stirred at 80 °C for 1 hour under N_2. After cooling to 25 °C, 4-bromopyridine (4.33 g, 27.4 mmol, CAS# 1120-87-2), K_2C0_3 (5.04 g, 36.5 mmol), $Pd(dppf)Cl_2{\cdot}CH_2Cl_2$ (683 mg, 836 umol), DMF (50 mL) and H_20 (5 mL) were added to the reaction mixture was added. The reaction mixture was stirred at 60 °C for 3 hours. After cooling to 25 °C, another charge of $Pd(dppf)Cl_2{\cdot}CH_2Cl_2$ (683 mg, 836 umol) was added to the reaction mixture. The mixture was stirred at 60 °C for 24 hours. On completion, the mixture was cooled to 25 °C and poured into

water (60 mL). The pH was adjusted to 11 with 10% aq. NaOH. The mixture was extracted with ethyl acetate (2 X 100 mL). The combined organic layers were dried over $NaSO_4$, filtered and concentrated *in vacuo*. The residue was purified by column chromatography to give the title compound (5.80 g, 76% yield) as yellow oil. ^1H NMR (400 MHz, CDCh) δ 8.53 - 8.47 (m, 2H), 7.08 (d, *J* = 6.0 Hz, 2H), 2.64 (t, *J* = 12.0 Hz, 2H), 2.54 (d, *J* = 7.6 Hz, 2H), 1.77 - 1.64 (m, 2H), 1.63 - 1.56 (m, 2H), 1.54 - 1.47 (m, 1H), 1.45 (s, 9H), 1.21 - 1.09 (m, 2H).

[004512] Step 2 Tert-butyl 4-(4-piperidylmethv0piperidine-l-carboxylate

[004513] To a solution of tert-butyl 4-(4-pyridylmethyl)piperidine-l-carboxylate (5.80 g, 20.9 mmol) inEtOH (100 mL) and HOAc (1.26 g, 20.9 mmol) was added PtO_2 (1.02 g, 4.48 mmol) at 20 °C. The reaction mixture was stirred at 20 °C for 54 hours under H_2 (50 Psi). On completion, the reaction mixture was filtered with celite and the filtrate was concentrated *in vacuo* to give the title compound (4.68 g, 79% yield) as black oil. ^1H NMR (400 MHz, CDCh) δ 4.26 - 4.00 (m, 4H), 3.l6 (d, *J* = 9.6 Hz, 2H), 2.70 - 2.60 (m, 3H), 1.69 (d, *J* = 12.8 Hz, 2H), 1.65 - 1.56 (m, 2H), 1.54 - 1.46 (m, 2H), 1.44 (s, 9H), 1.29 - 1.20 (m, 2H), 1.20 - 1.13 (m, 2H), 1.11 - 0.97(m, 2H); LC-MS (ESI^+) m/z 283.0 $(M + H)^+$.

[004514] **3-[3-methyl-2-oxo-4-[[4-(4-piperidylmethvD-l-piperidyl1methyl1benzimidazol-l- yl]piperidine-2,6-dione [Intermediate XT]**



[004515] Step 1-Tert-butyl 4-ri l-[[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl1methvn-4- piperidyllmethyllpiperidine-l-carboxylate


[004516] To a solution of tert-butyl 4-(4-piperidylmethyl)piperidine-l-carboxylate (128 mg,

452 umol, Intermediate XS) in THF (10 mL) and DMF (5 mL) was added TEA (45.8 mg, 452 umol). The mixture was stirred at 25 °C for 10 minutes. HOAc (27.2 mg, 452 umol) and l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo -benzimidazole-4-carbaldehyde (195 mg, 679 umol , Intermediate WW) were added to the above mixture. The reaction mixture was stirred at 25 °C for 20 minutes. Then $NaBH(OAc)_3$ (192 mg, 905 umol) was added. The reaction mixture was stirred at 25 °C for 16 hours. On completion, the reaction was quenched with H_20 (1 mL). The mixture was concentrated *in vacuo.* The residue was purified by reverse phase (FA condition) to give the title compound (250 mg, 99% yield) as a yellow solid. ¾NMR (400 MHz, DMSO-d«) δ 11.09 (s, 1H), 7.19 (d, *J* = 6.4 Hz, 1H), 6.95 (t, *j* = 7.6 Hz, 1H), 6.86 (d, *J* = 7.2 Hz, 1H), 5.36 *(d, J* = 5.6 Hz, 1H), 3.97 - 3.81 (m, 2H), 3.66 (s, 3H), 3.60 (s, 2H), 2.96 - 2.83 (m, 2H), 2.83 - 2.69 (m, 4H), 2.66 - 2.58 (m, 3H), 2.06 - 1.89 (m, 4H), 1.58 *(d, J* = 12.4 Hz, 4H), 1.37 (s, 9H), 1.14 - 0.98 (m, 4H), 0.96 - 0.81 (m, 2H); LC-MS (ESI^+) m/z 554.4$(M+H)^+$.

[004517] Step_ __2_ __-_ __3-r3-methyl-2-oxo-4-IT4-(4-piperidylmethvO-l-piperidvHmethvHbenzimidazol-l- yl1piperidine-2.6-dione

[004518] To a solution of tert-butyl 4-[[l-[[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]methyl] -4-piperidyl]methyl]piperidine-l-carboxylate (100 mg, 181 umol) in DCM (2 mL) was added 4 M HCl/dioxane (1 mL) at 25 °C. The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by reverse phase (FA condition) to give the title compound (65.0 mg, 79 % yield) as a white solid. LC-MS (ESI^+) m/z 454.5 $(M+H)^+$.

[004519] **3-(7-bromo-9H-pyrido [2,3-blindol-9-vBpiperidine-2,6-dione [Intermediate XU)**



XU

[004520] Step 1 - 3-bromo-N-(3-nitrophenvOpyridin-2-amine

[004521] To a mixture of 3-bromopyridin-2-amine (5 g, 28.9 mmol), l-iodo-3 -nitrobenzene (7.2 g, 28.9 mmol), Xanphos (1.07 g, 2.89 mmol), and Cs_2C0_3(l8.9 g, 57.8 mmol) in DMF (50 mL) was added $Pd(OAc)_2$ (323.7 mg, 1.44 mmol). The mixture was degrassed with N_2 and stirred at 130 °C overnight. The reaction mixture was cooled to rt, poured into water, and extracted with EtOAc (3 x 200 mL). The combined organic layers was washed with water (200 mL x 2) and brine (200 mL x 2), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by flash chromatography eluting with EA/PE=20% to give the title compound (5.6 g, 66% yield) as a light yellow solid. LC/MS (ESI, *m/z)*: $[M+l]^+$ = 294.0, 296.0.

[004522] Step 2 - 7-nitro-9H-pyridor2.3-b1indole

[004523] To a mixture of 3-bromo-N-(3-nitrophenyl)pyridin-2-amine (4 g, 6.78 mmol), DCPHB (474 mg, 1.356 mmol), and DBE[(4.12 g, 27.12 mmol) in DMA (12 mL) was added $Pd(OAc)_2$ (152 mg, 0.678 mmol). The mixture was degrassed with N_2 and stirred at 170 °C for 1 h. The reaction mixture was cooled to rt, poured into water, and extracted with EtOAc (3 x 50 mL).

The combined organic layers was washed with water(l00 mL x 2) and brine (100 mL x 2), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by flash chromatography eluting with EA/PE=l:l to give the title compound (1 g, 34% yield) as a light yellow solid. ^1H NMR (400 MHz, DMSO-d_6) *S* 12.40 (s, 1H), 8.73 - 8.70 (m, 1H), 8.60 - 8.58 (m, 1H), 8.44 (d, *J*=8.63 Hz, 1H), 8.33 (d, *J*=2.00 Hz, 1H), 8.13 - 8.10 (m, 1H), 7.35 (dd, J=7.75, 4.75 Hz, 1H); LC/MS (ESI, *m/z):* $[M+l]^+$ = 214.1.

[004524] Step 3 - 1-(4-methoxybenzyl)-3-(7-nitro-9H-pyridor2.3-b1indol-9-yl jpiperidine-2.6-dione

[004525] To a solution of 7-nitro-9H-pyrido[2,3-b]indole (910 mg, 4.27 mmol) in THF (lOmL) and DMF (2 mL) was added t-BuOK (718 mg, 6.41 mmol) portion wise at 0 °C under N_2 atmosphere. After addition, the mixture was stirred at 0 °C-5 °C for 1 h. Then l-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yl trifluoromethanesulfonate (2.44 g, 6.41 mmol) in THF(l0 mL) was added dropwise at 0 °C-5 °C over 20 min. After addition, the reaction mixture was stirred at 0 °C-5 °C for an additional 1 h. The reaction mixture was quenched by the addition of water, then extracted with EtOAc (3 x 20 mL). The combined organic layers was washed with brine (10 mL x 2), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The residue was triturated with EtOAc and dried to give (1.3 g, 69% yield) as a light yellow solid. LC/MS (ESI, *m/z):* $[M+l]^+$ = 445.2.

[004526] Step 4 - 3-(7-nitro-9H-pyridor2.3-b1indol-9-vDpiperidine-2.6-dione

[004527] To a solution of l-(4-methoxybenzyl)-3-(7-nitro-9H-pyrido[2,3-b]indol-9-yl)piperidine-2,6-dione (1.7 g, 3.83 mmol) in CH_3CN(20 mL) was added CAN (10.5 g, 19.15 mmol) in water (5 mL) at 0 °C dropwise. After addition, the mixture was stirred at rt overnight. The mixture was poured into water (50 mL), then extracted with EtOAc (3 x 50 mL). The combined organic layers was washed with brine (2 x 20 mL), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The residue was triturated with EtOAc and dried to give the title compound (850 mg, 69% yield) as a light yellow solid. LC/MS (ESI, *m/z):* $[M+l]^+$ = 325.2.

[004528] Step 5 - 3-(7-amino-9H-pyridor2.3-b1indol-9-vDpiperidine-2.6-dione


[004529] To a solution of 3-(7-nitro-9H-pyrido[2,3-b]indol-9-yl)piperidine-2,6-dione (850 mg, 2.62 mmol) in EtOAc(l5 mL) was added 10% palladium on activated carbon (170 mg). The mixture was hydrogened at rt overnight. The reaction mixture was filtered, the filtrate was concentrated *in vacuo* to give the title compound (764 mg, 99% yield) as a white solid. LC/MS

(ESI, *m/z)·*. [M +l] $^{+}$ = 295.2.

[004530] Step 6 - 3-(7-bromo-9H-pyridor2.3-b1indol-9-vOpiperidine-2.6-dione

[004531] To a solution of 3-(7-amino-9H-pyrido[2,3-b]indol-9-yl)piperidine-2,6-dione (66lm g, 2.26 mmol) in 40% HBr solution (10 mL) was added $NaNO_2$ (156 mg, 2.26 mmol) portion wise at 0 °C. After addition, the mixture was stirred at 0 °C for 30 min. Then the diazonium solution was added dropwise to CuBr (972 mg, 6.78 mmol) in 40% HBr solution (10 mL). The mixture was stirred at rt for 2 h. Then the mixture was poured into water (50 mL), basified to pH > 8 with saturated NaHCCh solution, then extracted with EtOAc (3 x 50 mL). The combined organic layers was washed with brine (2 x 30 mL), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by prep-HPLC to give the title compound (382 mg, 47% yield) as a yellow solid. LC/MS (ESI, *m/z)·*. [M +l] $^{+}$ = 358.1, 360.1.

[004532] **3-[7-[3-[2-(2-Aminoethoxy)ethoxy]propyl]pyrido[2,3-bl indol-9-yl]piperidine-2,6-dione [Intermediate XV)**



[004533] Step 1 - tert-butyl (2-(2-((3-(9-(2.6-dioxopiperidin-3-yl)-9H-pyridor2.3-b1indol-7-vl)prop-2-vn-l-yl)oxy)ethoxy)ethvl)carbamate

[004534] To a mixture of 3-(7-bromo-9H-pyrido[2,3-b]indol-9-yl)piperidine-2,6-dione (461 mg, 1.29 mmol, Intermediate XU), tert-butyl (2-(2-(prop-2-yn-l-yloxy)ethoxy)ethyl)carbamate (941 mg, 3.87 mmol, Intermediate IT), and Cs_2C0_3(2.l g, 6.45 mmol) in DMF was added Cul (49 mg, 0.258 mmol) and PdCh(PPh $_3)_2$(l8l mg, 0.258 mmol). The mixture was degrassed with N_2 and stirred at 80 °C for 1 h under microwave condition. The reaction mixture was cooled to rt,

poured into water, then extracted with EtOAc (3 x 20 mL). The combined organic layers was washed with water (20 mL x 2) and brine (2 x 30 mL), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by flash chromatography eluting with EA/DCM=l:l to the title compound (410 mg, 68% yield) as yellow solid. LC/MS (ESI, *m/z):* [M -55+H]$^+$ = 466.1.


[004535] Step 2 - tert-butyl (2-(2-(3-(9-(2.6-dioxopiperidin-3-yl)-9H-pyridor2J-b1indol-7-vOpropoxy)ethoxy)ethvOcarbamate

[004536] To a solution of tert-butyl (2-(2-((3-(9-(2,6-dioxopiperidin-3-yl)-9H-pyrido[2,3-b]indol-7-yl)prop-2-yn-l-yl)oxy)ethoxy)ethyl)carbamate (400 mg, 0.77 mmol) in EtOAc(5 mL) was added 10% palladium on activated carbon (81 mg). The mixture was hydrogened at rt overnight. The reaction mixture was filtered, the filtrate was concentrated *in vacuo.* The residue was purified by P-TLC eluting with EA/DCM=l:2 firstly, then the crude compound was purified by prep HPLC to give the title compound (132 mg, 66% yield) as a white solid. ^{1}H NMR (400 MHz, DMSO-i/e) ≤ 11.13 (s, 1H), 8.49 (dd, J=7.63, 1.50 Hz, 1H), 8.38 - 8.35 (m, 1H), 8.11 (d, *J*=7.88 Hz, 1H), 7.47 (br. s., 1H), 7.24 (dd, J=7.63, 4.88 Hz, 1H), 7.12 - 7.18 (m, 1H), 6.77 - 6.74 (m, 1H), 6.01 (br. s., 1H), 3.47 - 3.55 (m, 4H), 3.45 - 3.37 (m, 4H), 3.15 - 3.02 (m, 4H), 2.80 (t, *J*=7.69 Hz, 2H), 2.73 - 2.68 (m, 1H), 2.13 - 2.07 (m, 1H), 1.94 - 1.88 (m, 2H), l.36(s, 9H); LC/MS (ESI, *m/z):* [M +l] $^+$ = 525.3.

[004537] Step 3 - 3-r7-r3-r2-(2-Aminoethoxy)ethoxy1propyl1pyridor2.3-b1indol-9-yl1piperidine-2.6-dione

[004538] To a solution of tert-butyl N-[2-[2-[3-[9-(2,6-dioxo-3-piperidyl)pyrido[2,3-b]indol-7-yl]propoxy] ethoxy]ethyl]carbamate (95.0 mg, 181 umol) in DCM (3 mL) was added TFA (722 mg, 6.34 mmol). The reaction mixture was stirred at 25 °C for 1 hr. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (95 mg, 95% yield, TFA) as light yellow oil. LC-MS (ESI$^+$) m/z 425.2 (M+H)$^+$.


[004539] 2-[2-(Cvclopropylmethylamino)-4-Pyridyl1oxazole-4-carboxylic acid [Intermediate XW)



OM XW

[004540] To a mixture of 2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (400 mg, 1.11 mmol, Intermediate OM) in DCM (10 mL) was added TFA (127 mg, 1.11 mmol). The reaction mixture was stirred at 25 °C for 2 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (397 mg, 95% yield, TFA salt) as brown oil. LC-MS (ESI$^+$) *m/z* 260.l(M+H) $^+$.

[004541] **3-(4-Bromo-9H-pyrido [2,3-bl indol-9-yl]piperidine-2.,6-dione [Intermediate XY]**



XY

[004542] Step 1 - 9H-ρνriάo[2,3-biindole 1-oxide

[004543] To a stirred solution of 9H-pyrido[2,3-b]indole (10 g, 59.5 mmol) in AcOH (100 mL) was added 30% H2O2 (50 mL) dropwise. After the addition, the reaction mixture was heated to 110 °C and stirred for 6 h. Then the reaction mixture was cooled to rt and concentrated *in vacuo.* To the residue was added sat. aq. K2CO3 to basify to $pH = 8$. The mixture was stirred at rt overnight and filtered. The solid was washed with water and dried to afford the title compound (7.3 g, 67% yield) as a yellow solid. ¾NMR (400 MHz, DMSO-d_6) δ 12.58 (s, 1H), 8.36 - 8.34 (m, 1H), 8.25 - 8.14 (m, 2H), 7.58 - 7.50 (m, 2H), 7.35 - 7.18 (m, 2H). LC/MS (ESI, *m/z):* [M+l] $^+$ = 185.1

[004544] Step 2 - 4-bromo-9H-pyridor2.3-b1indole

[004545] To a solution of 9H-pyrido[2,3-b]indole l-oxide (9.3 g, 50.5 mmol) in DMF (100 mL) was added phosphorusoxybromide (29.0 g, 101.1 mmol) at rt. The reaction mixture was stirred at rt overnight and filtered. The solid was washed with water and dried to afford the title compound (9.0 g, 73% yield) as a yellow solid. ¾ NMR (400 MHz, CDCb) δ 9.28 (s, 1H), 8.61

(d, J = 8.0 Hz, 1H), 8.25 (d, *J* = 5.4 Hz, 1H), 7.59 - 7.52 (m, 2H), 7.43 - 7.33 (m, 2H). LC/MS (ESI, *m/z):* $[M+l]^+$ = 247.3, 249.3.


[004546] Step 3 - 3-(4-bromo-9H-pyridor2.3-b1indol-9-yl)- 1-(4-methoxybenzyl jpiperidine-2.6-dione

[004547] To a solution of 4-bromo-9H-pyrido[2,3-b]indole (8.8 g, 35.6 mmol) and l8-crown-6 (1.9 g, 7.13 mmol) in THF (100 mL) was added NaHMDS (26.7 mL, 53.4 mmol, 2N in THF) dropwise at -30 °C under N_2 atmosphere. After addition, the reaction mixture was stirred at -30 °C for 1 h. Then l-(4-methoxybenzyl)-2,6-di oxopiperi din-3-yl trifluoromethanesulfonate (20.4 g in 30 mL THF, 53.4 mmol) was added to solution dropwise. After addition, the reaction mixture was stirred at -30 °C for 2 h and quenched by sat. aq. NH_4Cl (100 mL), then extracted with EA (150 mLx 2). The combined organic layers were washed with brine (100 mLx 2), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by column to give the title compound (10.0 g, 59% yield) as a white solid. LC/MS (ESI, *m/z)·.* $[M+l]^+$ = 478.3.

[004548] Step 4 - 3-(4-bromo-9H-pyridor2.3-b1indol-9-vDpiperidine-2.6-dione

[004549] To a solution of 3-(4-bromo-9H-pyrido[2,3-b]indol-9-yl)-l-(4-methoxybenzyl)piperidine-2,6-dione (10 g, 20.9 mmol) in toluene (50 mL) was added methanesulfonic acid (20 mL). The reaction solution was heated to H0°C and stirred for 2 h. The reaction mixture was cooled to rt and concentrated to remove toluene. The residue was diluted with CH_3CN and purified via reverse phase column chromatography (CH_3CN/H_20 = 5%-80%) to give the title compound (3.7 g, 50% yield) as a white solid. ^1H NMR (400 MHz, DMSO-r/f,) δ 11.19 (s, 1H), 8.57 (d, *J* = 7.9 Hz, 1H), 8.30 *(d, J* = 5.3 Hz, 1H), 7.73 - 7.69 (m, 1H), 7.63 (t, *j* = 7.9 Hz, 1H), 7.56 (d, *J* = 5.3 Hz, 1H), 7.41 (t, *j* = 7.9 Hz, 1H), 6.10 (s, 1H), 3.14 - 2.98 (m, 2H), 2.73 - 2.68 (m, 1H), 2.18 - 2.12 (m, 1H). LC/MS (ESI, *m/z):* $[M+l]^+$ = 358.0.

[004550] **3-[4-[3-[2-(2-Aminoethoxy)ethoxyl propyl]pyrido [2,3-bl indol-9-yl] piperidine-2.6-dione [Intermediate XZ)**



[004551] Step 1 - tert-butyl (2-(2-(Y3-(9-(2.6-dioxopiperi din-3-vl)-9H-ρvrido[2.3-blindol-4-vl)prop-2-vn-l-yl)oxy)ethoxy)ethvl)carbamate

[004552] To a mixture of 3-(4-bromo-9H-pyrido[2,3-b]indol-9-yl)piperidine-2,6-dione (0.3 g, 0.84 mmol, Intermediate XY), tert-butyl (2-(2-(prop-2-yn-l-yloxy)ethoxy)ethyl)carbamate (0.31 g, 1.26 mmol, Intermediate IT), Cs_2C0_3(2.7 g, 8.38 mmol) in DMF(l0 mL) was added Cul (16 mg, 0.084 mmol) and $PdCl_2$(PPh3)2 (0.12 g, 0.17 mmol). The mixture was degrassed with N_2 and stirred at 80 °C for 1 h under microwave condition. The reaction mixture was cooled to rt, poured into water, then extracted with EtOAc (3 x 20 mL). The combined organic layers was washed with water (20 mL x 2) and brine, dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo*. The residue was purified by flash chromatography eluting with EA/DCM=l:l to give the title compound (0.16 g, 37% yield) as yellow solid. LC/MS (ESI, *m/z)*: $[M-55+H]^+$ = 466.1.

[004553] Step 2 - tert-butyl (2-(2-(3-(9-(2.6-dioxopiperidin-3-yl)-9H-pyridor2.3-b1indol-4-vDpropoxy)ethoxy)ethvDcarbamate


[004554] To a solution of tert-butyl (2-(2-((3-(9-(2,6-dioxopiperidin-3-yl)-9H-pyrido[2,3-b]indol-4-yl)prop-2-yn-l-yl)oxy)ethoxy)ethyl)carbamate (0.16 g, 0.31 mmol) in EtOAc(5 mL) was added 10% palladium on activated carbon (32 mg). The mixture was hydrogened at rt overnight. Then the reaction mixture was filtered and the filtrate was concentrated *in vacuo*. The residue was purified by P-TLC eluting with EA/DCM=l:2 firstly, then the crude compound was

purified by prep HPLC to give the title compound (60 mg, 38% yield) as a white solid. ^{1}H NMR (400 MHz, CDCh) *S* 8.32 *(d, J* = 5.1 Hz, 1H), 8.20 *(d, J* = 7.9 Hz, 1H), 8.12 (s, 1H), 7.53 - 7.46 (m, 1H), 7.34 - 7.28 (m, 2H), 7.06 - 7.04(m, 1H), 5.96 (s, 1H), 5.00 (s, 1H), 3.66 - 3.56 (m, 8H), 3.41 - 3.24 (m, 4H), 3.09 - 2.99 (m, 3H), 2.33 - 2.29 (m, 1H), 2.18 - 2.11 (m, 2H), 1.43 (s, 9H). LC/MS (ESI, *m/z):* [M +l] $^+$ = 525.4.

[004555] Step 3 - 3-r4-r3-r2-(2-Aminoethoxy)ethoxy1propyl1pyridor2.3-b1indol-9-yl1piperidine-2.6-dione

[004556] To a solution of tert-butyl N-[2-[2-[3-[9-(2,6-dioxo-3-piperidyl)pyrido[2,3-b]indol-4-yl]propoxy] ethoxy]ethyl]carbamate (66.0 mg, 125 umol) in DCM (2 mL) was added TFA (573 mg, 5.03 mmol). The mixture was stirred at 25 °C for 2 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (67.0 mg, 95% yield, TFA) as light yellow oil. LC-MS (ESI$^+$) *m/z* 425.0 (M+H)$^+$.


[004557] **Tert-butyl 3-(prop-2-ynoxymethyDazetidine-l-carboxylate [Intermediate YA)**



YA

[004558] To a solution of tert-butyl 3-(hydroxymethyl)azetidine-l-carboxylate (2.00 g, 10.7 mmol, CAS# 142253-56-3) in DMF (20 mL) was added NaH (641 mg, 16.0 mmol, 60% oil dispersion) at 0 °C. Thirty minutes later, 3-bromoprop-l-yne (1.40 g, 11.8 mmol, 1.01 mL, CAS# 106-96-7) was added and the reaction mixture was stirred at 25 °C for 12 hrs. On completion, the mixture was quenched with water (50 mL), then extracted with EA (2 X 30 mL). The combined organic layer was washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo.* The residue was purified by silica gel chromatography (S1O2, PE: EA = 15: 1) to give the title compound (0.60 g, 25% yield) as yellow oil. ^{1}H NMR (400 MHz, CDCh) δ 4.17 (d, *J* = 2.4 Hz, 2H), 4.00 (t, *J* = 8.4 Hz, 2H), 3.71 - 3.64 (m, 4H), 2.87 - 2.69 (m, 1H), 2.45 (t, *J* = 2.4 Hz, 1H), 1.44 (s, 9H).

[004559] **3-[4-[3-(Azetidin-3-ylmethoxy)propyll-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2.,6-dione [Intermediate YB)**



[004560] Step 1 - Tert-butyl 3-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]prop-2-ynoxymethyl]azetidine-1-carboxylate

[004561] To a solution of tert-butyl 3-(prop-2-ynoxymethyl)azetidine-1-carboxylate (480 mg, 2.13 mmol, Intermediate YA) and 3-(4-bromo-3-methyl-2-oxo-benzimidazol-1-yl)piperidine-2,6-dione (400 mg, 1.18 mmol, Intermediate HP) in DMF (8 mL) was added $Pd(PPh_3)_2Cl_2$ (166 mg, 236 umol), Cs_2CO_3 (1.93 g, 5.91 mmol), and CuI (45.1 mg, 236 umol) under N_2 atmosphere. The mixture was de-gassed and then heated at 80 °C for 2 hrs under N_2 atmosphere. On completion, the mixture was concentrated *in vacuo*. The residue was washed with ethyl acetate (60 mL), the filtrate was concentrated *in vacuo*. The residue was purified by reversed-phase HPLC (0.1% FA condition) to give the title compound (450 mg, 63% yield) as brown solid. ^1H NMR (400 MHz, DMSO-d) δ 11.12 (m, 1H), 7.20 - 7.10 (m, 2H), 7.06 - 6.99 (m, 1H), 5.39 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.47 (s, 2H), 3.64 (s, 3H), 3.60 - 3.56 (m, 4H), 2.80 - 2.70 (m, 4H), 2.61 - 2.59 (m, 2H), 2.06 - 1.98 (m, 1H), 1.35 (s, 9H); LC-MS (ESI+) m/z 505.2 $(M+Na)^+$.

[004562] Step 2 - Tert-butyl 3-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yllpropoxymethyll azetidine- 1-carboxylate


[004563] To a solution of tert-butyl 3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]prop-2- ynoxymethyl]azetidine-l-carboxylate (400 mg, 829 umol) in THF (8

mL) was added Pd/C (80.0 mg, 10% *wt)* and $Pd(OH)_2/C$ (80.0 mg, 10% *wt)* under N_2 atmosphere. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred at 25 °C for 12 hrs. On completion, the mixture was filtered and then the filtrate was concentrated *in vacuo* to give the title compound (400 mg, 79% yield) as brown solid. ^1H NMR (400 MHz, DMSO-i/e) δ 11.09 (s, 1H), 6.99 - 6.95 (m, 2H), 6.87 - 6.85 (m, 1H), 5.37 (dd, *J* = 5.2, 12.4 Hz, 1H), 3.56 (s, 3H), 3.52 - 3.46 (m, 4H), 3.33 (s, 3H), 3.00 - 2.92 (m, 2H), 2.91 - 2.84 (m, 1H), 2.78 - 2.55 (m, 4H), 2.04 - 1.96 (m, 1H), 1.89 - 1.77 (m, 2H), 1.38 - 1.36 (m, 9H). LC-MS (ESI+) m/z 509.3 $(M+Na)^+$.

[004564] Step 3 - 3-r4-r3-(Azetidin-3-ylmethoxy)propyl1-3-methyl-2-oxo-benzimidazol-l-yl1piperidine-2.6-dione

[004565] To a solution of tert-butyl 3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propoxymethyl]azetidine-l-carboxylate (313 mg, 514 umol) in DCM (3 mL) was added TFA (3 mL). The mixture was stirred at 25 °C for 2 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (230 mg, 89% yield, TFA salt) as yellow solid. LC-MS (ESI+) m/z 387.2 $(M+H)^+$.

[004566] **Tert-butyl N-but-3-ynyl-N-methyl-carbamate [Intermediate YC1**



YC


[004567] Step 1 - Tert-butyl N-but-3-ynylcarbamate

[004568] To a solution of but-3-yn-l -amine (4.30 g, 40.7 mmol, HC1) and TEA (4. 12 g, 40.7 mmol) in DCM (150 mL) was added $(Boc)_20$ (9.16 g, 41.9 mmol) dropwise at 0 °C. The reaction mixture was stirred at 0 °C for 30 minutes. Then TEA (4.12 g, 40.7 mmol) added dropwise at 0 °C. The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was diluted with DCM (400 mL) and washed with water (2 X 100 mL) and HC1 (0.5 N, 3 X 300 mL). The organic layers were dried with anhydrous Na_2S0_4 and filtered. The filtrate was concentrated *in vacuo.* The residue was purified by silica column chromatography to give the title compound (4.00 g, 58% yield) as colorless oil. ^1H NMR (300MHz, CDCh) δ 4.93 (s, 1H), 3.25 (q, *j* = 6.0 Hz, 2H), 2.35 (dt, *j* = 2.7, 6.0 Hz, 2H), 1.98 (t, *j* = 2.7 Hz, 1H), 1.41 (s, 9H).

[004569] Step 2 - Tert-butyl N-but-3-ynyl-N-methyl-carbamate

[004570] To a solution of tert-butyl N-but-3-ynylcarbamate (1.00 g, 5.91 mmol) in THF (20 mL) was added NaH (354 mg, 8.86 mmol, 60% oil dispersion) at 0 °C. The reaction mixture was stirred at 0 °C for 0.5 hour, then MeI (1.26 g, 8.86 mmol) was added. The reaction mixture was stirred at 25 °C for 12 hours. On completion, the reaction mixture was quenched with sat. NH_4Cl (30 mL) and extracted with EA (2 X 100 mL). The combined organic layers were washed with brine (50 mL), dried with anhydrous Na_2SO_4 and filtered. The filtrate was concentrated *in vacuo.* The residue was purified by column chromatography to give the title compound (1.00 g, 92% yield) as colorless oil. ^1H NMR (300MHz, CDCb) δ 3.43 - 3.28 (m, 2H), 2.87 (s, 3H), 2.44 - 2.33 (m, 2H), 1.95 (t, J = 2.4 Hz, 1H), 1.44 (s, 9H).

[004571] **3-[3-Methyl-4-[4-(methylamino]butyll-2-oxo-benzimidazol-l-yllpiperidine-2,6-dione [Intermediate YD]**



[004572] Step 1 - Tert-butyl N-[4-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-vnbut-3-vnyl1-N- methyl-carbamate

[004573] To a solution of 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (500 mg, 1.48 mmol, Intermediate HP) and 4Å molecular sieves (50 mg) in DMF (5 mL) was added $Pd(PPh3)_2Cl_2$ (103 mg, 147 umol), CuI (56.3 mg, 295 umol) and Cs_2CO_3 (1.93 g, 5.91 mmol). The reaction mixture was degassed with N_2 for three times. Then tert-butyl N-but-3-ynyl-N-methyl-carbamate (487 mg, 2.66 mmol, Intermediate YC) was added. The reaction mixture was stirred at 85 °C for 2 hours. On completion, the reaction mixture was filtered. The organic layer

was diluted with EA (300 mL), washed with sat.MLCl (2 X 100 mL) and brine (100 mL), dried with anhydrous Na_2S0_4 and filtered. The filtrate was concentrated *in vacuo.* The residue was purified by reverse phase flash (0.1%, FA) to give the title compound (400 mg, 61% yield) as a light yellow solid, LC-MS (ESI^+) m/z 463.1 $(M+Na)^+$.


[004574] Step 2 - Tert-butyl N-[4-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl1butyl1-N- methyl-carbamate

[004575] To a solution of tert-butyl N-[4-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]but-3- ynyl]-N-methyl-carbamate (400 mg, 908 umol) in THF (25 mL) was added Pd/C (200 mg, 10 wt%) and $Pd(OH)_2/C$ (1.28 g, 10 wt%). The reaction mixture was stirred at 25 °C under H_2 (15 psi) for 12 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (400 mg, 99% yield) as a white solid, ^1H NMR (400MHz, DMSO-$t/_f$) δ 11.08 (s, 1H), 6.99 - 6.93 (m, 2H), 6.89 - 6.84 (m, 1H), 5.40 - 5.32 (m, 1H), 3.55 (s, 3H), 3.24 - 3.14 (m, 2H), 2.99 - 2.82 (m, 3H), 2.75 (s, 3H), 2.72 - 2.59 (m, 2H), 2.04 - 1.94 (m, 1H), 1.63 - 1.48 (m, 4H), 1.36 (s, 9H).

[004576] Step 3 - 3-r3-Methyl-4-r4-(methylamino)butyl1-2-oxo-benzimidazol-l-yl1piperidine-2.6-dione

[004577] To a solution of tert-butyl N-[4-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]butyl]- N-methyl-carbamate (390 mg, 877 umol) in DCM (15 mL) was added HCl/dioxane (4 M, 15 mL). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (300 mg, 89% yield, HC1) as a white solid. LC-MS (ESI^+) m/z 345.2 $(M+H)^+$.

[004578] **2-[2-[Tert-butoxycarbonvUmethvPaminol-4-pyridylloxazole-4-carboxylic acid [Intermediate** YE)



YE

[004579] Step 1 - 4-Bromo-N-methyl-pyridin-2-amine

[004580] To a solution of 4-bromo-2-fluoro-pyridine (5.00 g, 28.4 mmol, CAS# 128071-98-7) in THF (50.0 mL) was added a solution of $MeNH_2$ in EtOH (2.00 M, 42.6 mL). The mixture was stirred at 120 °C for 2 hrs under seal tube. The mixture was concentrated *in vacuo.* The mixture was purified by silica gel column (PE: EA = 80: 1) to give the title compound (4.50 g, 84% yield) as white solid. ^1H NMR (400 MHz, DMSO-d_6) δ 7.87 - 7.84 (m, 1H), 6.75 - 6.74 (m, 1H), 6.66 - 6.65 (m, 1H), 6.64 (s, 1H), 2.75 (s, 3H).

[004581] Step 2 - Tert-butyl N-(4-bromo-2-pyridvD-N-methyl-carbamate

[004582] To a solution of 4-bromo-N-methyl-pyridin-2-amine (4.00 g, 21.4 mmol) in THF (30.0 mL) was added LiHMDS (1.00 M, 47.1 mL) dropwise at - 5 °C. Then a solution of $(Boc)_20$ (4.67 g, 21.4 mmol, 4.91 mL) in THF (10.0 mL) was added into the above mixture slowly. The reaction mixture was stirred at - 5 °C for 10 minutes, then heated to 20 °C and stirred for 1 hr. The reaction mixture was quenched with sat. NH_4Cl (100 ml), extracted with EA (2 X 50 mL), then concentrated *in vacuo* to give a residue. The residue was purified by silica gel column chromatography (PE: EA = 100: 1-8: 1) to give the title compound (5.00 g, 81% yield) as a yellow liquid. ^1H NMR (400 MHz, DMS04) δ 8.16 (d, J = 5.6 Hz, 1H), 8.02 - 8.01 (m, 1H), 7.13 (dd, J = 5.2 Hz, J = 5.6 Hz, 1H), 3.39 (s, 3H), 1.53 (s, 9H).


[004583] Step_3_-_Ethyl_2-r2-rtert-butoxycarbonyl(methvDamino1-4-pyridyl1oxazole-4-carboxylate

[004584] A mixture of tert-butyl N-(4-bromo-2-pyridyl)-N-methyl-carbamate (4.00 g, 13.9 mmol), ethyl oxazole-4-carboxylate (1.97 g, 13.9 mmo, CAS# 170487-38-4), $Pd(OAc)_2$ (313 mg, 1.39 mmol), tris-o-tolylphosphane (848 mg, 2.79 mmol) and K_2C0_3 (5.78 g, 41.8 mmol) in DMF (60.0 mL) was degassed and purged with N_2 three times, and then the mixture was stirred at 70 °C for 16 hrs under N_2 atmosphere. On completion, the reaction mixture was diluted by addition H_20 (30 mL) and extracted with EA (3 X 50 mL). The combined organic layers were washed with saturated NaCl (2 X 100 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The crude product was purified by reverse phase (0.1% FA condition) to give the title compound (2.20 g, 45% yield) as a white solid. ^1H NMR (400MHz, CDCh) δ 8.49 (d, J = 6.8 Hz, 1H), 8.42 (s, 1H), 8.33 (s, 1H), 7.71 - 7.69 (m, 1H), 4.47 - 4.41 (m, 2H), 3.45 (s, 3H), 1.56 (s, 9H), 1.42 (t, J = 13.2 Hz, 3H).

[004585] Step 4 - 2-r2-rTert-butoxycarbonyl(´methv0amino1-4-pyridvnoxazole-4-carboxylic acid

[004586] To a solution of ethyl 2-[2-[tert-butoxycarbonyl(methyl)amino]-4-pyridyl]oxazole-4-carboxylate (200 mg, 575 umol) in THF (10.0 mL) and H_20 (2.00 mL) was added LiOH (68.9 mg, 2.88 mmol). The mixture was stirred at 20 °C for 15 hrs. On completion, the reaction mixture was quenched with water (1 mL), and the mixture was acidified with 1N HC1 solution until the pH = 5. The aqueous phase was extracted with EA (3 X 10 mL). The combined organic layer was washed with brine (2 X 10 mL), dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (160 mg, 87 % yield) as an off-white solid. ^{1}H NMR (400MHz, DMSO-d_6) δ 8.96 (s, 1H), 8.57 (d, *J* = 5.2 Hz, 1H), 8.35 (s, 1H), 7.65 (dd, *Ji* = 4.8 Hz, *J* = 5.2 Hz, 1H), 3.37 (s, 3H), 1.52 (s, 9H).


[004587] **Tert-butyl 3-prop-2-vnoxypyrrolidine-l-carboxylate [Intermediate YG)**



YG

[004588] To a solution of tert-butyl (3S)-3-hydroxypyrrolidine-l-carboxylate (5.00 g, 26.7 mmol, CAS# 101469-92-5) in THF (150 mL) was added NaH (1.60 g, 40.0 mmol, 60% oil dispersion) at 0 °C. The reaction mixture was stirred at 0 °C for 30 minutes. Then TBAI (986 mg, 2.67 mmol) and 3-bromoprop-l-yne (4.37 g, 29.3 mmol, CAS# 106-96-7) was added. The reaction mixture was stirred at 25 °C for 12 hours. On completion, the reaction mixture was diluted with EA(300 mL) and quenched with sat. NH_4Cl (100 mL). The organic layer was washed with water (2 X 30 mL) and brine (50 mL). The organic layer was dried with anhydrous Na_2S0_4 and filtered. The filtrate was concentrated *in vacuo.* The residue was purified by silica column chromatography to give the title compound (5.90 g, 98% yield) as light yellow oil, ^{1}H NMR (300MHz, CDC13) δ 4.29 - 4.21 (m, 1H), 4.17 - 4.10 (m, 2H), 3.51 - 3.32 (m, 4H), 2.50 - 2.34 (s, 1H), 2.02 - 1.90 (m, 2H), 1.43 (s, 9H).

[004589] **3-[3-Methyl-2-oxo-4-[3-[(3SVpyrrolidin-3-yll oxypropyl] benzinidazol-1-yl] piperidine-2,6-dione [Intermediate YH)**



[004590] Step 1 - Tert-butyl (3S)-3-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl1prop-2- ynoxylpyrrolidine-l -carboxylate

[004591] To a solution of 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (600 mg, 1.77 mmol, Intermediate HP) in DMF (10 mL) was added Pd(PPh $_3$)2Cl2 (124 mg, 177 umol), Cul (33.7 mg, 177 umol) and CS2CO3 (2.31 g, 7.08 mmol). The reaction mixture was degassed with N2 three times. Then tert-butyl 3-prop-2-ynoxypyrrolidine-l -carboxylate (598mg, 2.66 mmol, Intermediate YG) was added. The reaction mixture was stirred at 80 °C for 8 hours. On completion, the reaction mixture was filtered. The filtrate was concentrated *in vacuo*. The residue was purified by reversed-phase flash (FA, 0.1%) to give the title compound (450 mg, 52% yield) as a yellow solid, ^{1}H NMR (400MHz, DMSO-^e) δ 11.13 (s, 1H), 7.19 - 7.10 (m, 2H), 7.04 (d, *J* = 8.0 Hz, 1H), 5.44 - 5.34 (m, 1H), 4.48 (s, 2H), 4.32 - 4.25 (m, 1H), 3.63 (s, 3H), 3.29 - 3.07 (m, 4H), 2.94 - 2.82 (m, 1H), 2.77 - 2.62 (m, 2H), 2.56 - 2.52 (m, 1H), 2.04 - 1.92 (m, 3H), 1.38 (d, *J* = 9.2 Hz, 9H).


[004592] Step 2 - Tert-butyl (3S)-3-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-vnpropoxyl pyrrolidine-l-carboxylate

[004593] To a solution of tert-butyl (3S)-3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] prop-2-ynoxy]pyrrolidine-l-carboxylate (400 mg, 828 umol) in THF (25 mL) was added Pd/C (200 mg, 10 wt%) and $Pd(OH)_2/C$ (200 mg, 10 wt%). The reaction mixture was stirred at 25 °C for 12 hours under H_2 (15 psi). On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (400 mg, 99% yield) as a yellow solid. ^1H NMR (400MHz, DMSO^) δ 11.08 (s, 1H), 6.98 - 6.94 (m, 2H), 6.88 - 6.84 (m, 1H), 5.39 - 5.31 (m, 1H), 4.05 - 4.00 (m, 1H), 3.55 (s, 3H), 3.47 - 3.39 (m, 2H), 3.30 - 3.22 (m, 4H), 2.96 - 2.84 (m, 3H), 2.76 - 2.60 (m, 2H), 2.55 - 2.52 (m, 2H), 2.02 - 1.96 (m, 1H), 1.93 - 1.87 (m, 2H), 1.84 - 1.78 (m, 2H), 1.40 (s, 10H).


[004594] Step 3 - 3-[3-Methyl-2-oxo-4-[3-[(3S)-pyrrolidin-3-yl1oxypropyl1benzimidazol-1-yllpiperidine- 2.6-dione

[004595] To a solution of tert-butyl (3S)-3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propoxy]pyrrolidine-l-carboxylate (395 mg, 811 umol) in DCM (15 mL) was added HCl/dioxane (4 M, 15 mL). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (300 mg, 87% yield, HC1) as a white solid. LC-MS (ESI^+) *m/z* 387.2 $(M+H)^+$.

[004596] [3-Methyl-4-[[4-(methylaminomethvD-l-piperidyllmethyll-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione [Intermediate YD



WW



YI

[004597] Step 1 - Tert-butyl N-[[1-[[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl1methvn-4- piperidyllmethyll-N-methyl-carbamate


[004598] To a solution of l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazole-4-carbaldehyde (150 mg, 522 umol, Intermediate WW) and tert-butyl N-methyl-N-(4-piperidylmethyl)carbamate (119 mg, 522 umol, CAS# 138022-04-5) in THF (2 mL) and DMF (0.5 mL) was added HOAc (31.4 mg, 522 umol) at 25°C. The mixture was stirred for 0.5 hour, then $NaBH(OAc)_3$ (221 mg, 1.04 mmol) was added. The mixture was stirred at 25 °C for 2 hours. On completion, the mixture was quenched by water (0.2 mL), and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (180 mg, 69% yield) as a white solid. ^1H NMR (400 MHz, CDCh) δ 8.48 (s, 1H), 8.24 (s, 1H), 7.08 - 6.97 (m, 2H), 6.85 - 6.72 (m, 1H), 5.28 - 5.22 (m, 1H), 3.78 (d, J = 5.0 Hz, 5H), 3.68 - 3.51 (m, 2H), 3.10 (s, 2H), 3.04 - 2.94 (m, 2H), 2.94 - 2.90 (m, 1H), 2.86 (s, 4H), 2.81 - 2.72 (m, 1H), 2.27 - 2.20 (m, 1H), 1.71 - 1.62 (m, 2H), 1.46 (s, 9H), 1.39 - 1.21 (m, 2H); LC-MS (ESI^+) m/z 500.4 $(M+H)^+$.

[004599] Step 2 - r3-Methyl-4-rr4-(methylaminomethvn-l-piperidyl1methyl1-2-oxo-benzimidazol-l-yllpiperidine 2.6-dione

[004600] To a mixture of tert-butyl N-[[l-[[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] methyl]-4-piperidyl]methyl]-N-methyl-carbamate (106 mg, 212 umol) in DCM (2 mL) was added TFA (483 mg, 4.24 mmol) at 25 °C. The mixture was stirred at 25 °C for 2 hours. On completion, the reaction mixture was concentrated *in vacuo* give the title compound (108 mg, 99% yield, TFA). LC-MS (ESI+) m/z 399.9 $(M+H)^+$.

[004601] **3-[3-Methyl-4-[[(2SV2-(methylaminomethvBmorpholin-4-yllmethyll-2-oxo-benzimidazo**

[004602] **l-l-yl]piperidine-2,6-dione [Intermediate YJ)**



[004603] Step 1 - Tert-butyl-N-[[(2R)-4-[[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]methyl]morpholin-2-yl] methyl]-N-methyl-carbamate


[004604] To a solution of tert-butyl N-methyl-N-[[(2R)-morpholin-2-yl]methyl]carbamate (158 mg, 689 umol, synthesized via Steps 1-5 of Intermediate WP), l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazole-4-carbaldehyde (180 mg, 626 umol, Intermediate WW) in DMF (3.00 mL) and THF (10.0 mL) was added HOAc (75.2 mg, 1.25 mmol). The mixture was stirred at 20 °C for 0.5 hr, then $NaBH(OAc)_3$ (265 mg, 1.25 mmol) was added, and the mixture was stirred at 20 °C for 14 hrs. On completion, the reaction mixture was quenched with H_20 (3 mL) at 20 °C, and extracted with EA 60 mL (3 X 20 mL). The combined organic layers were washed with brine (2 X 10 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by reversed-phase HPLC (0.1% FA condition) to give the title compound (215 mg, 68% yield) as a white solid. ^1H NMR (400MHz, CDCh) δ 8.07 (s, 1H), 6.88 - 6.86 (m, 1H), 6.82 - 6.80 (m, 1H), 6.69 (d, J = 7.6 Hz, 1H), 5.19 - 5.07 (m, 1H), 3.79 - 3.72 (m, 1H), 3.72 - 3.71 (m, 3H), 3.57 (s, 2H), 3.53 - 3.47 (m, 2H), 3.39 - 3.36 (m, 2H), 2.87 (s, 2H), 2.83 (s, 3H), 2.73 - 2.72 (m, 1H), 2.63 - 2.54 (m, 2H), 2.19 - 2.12 (m, 2H), 1.87 - 1.80 (m, 1H), 1.36 (s, 9H).

[004605] Step 2 - 3-[3-Methyl-4-[[(2S)-2-(methylaminomethyl)morpholin-4-yl]methyl]-2-oxo-benzimidazol- 1-yl1piperidine-2.6-dione

[004606] To a solution of tert-butyl N-[[(2R)-4-[[l-(2, 6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] methyl] morpholin-2-yl] methyl]-N-methyl-carbamate (100 mg, 199 umol) in DCM (3.00 mL) was added HCl/dioxane (4.00 M, 5.00 mL). The mixture was stirred at 20 °C for 1 hr. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound

(87.0 mg, quant. crude yield, HC1) as yellow solid. LC-MS (ESI+) *m/z* 401.2 (M+H)+.

[004607] **3-[3-Methyl-4-[[(2R)-2-(methylaminomethyl)morpholin-4-yl]methyl]-2-oxo-benzimidazol-1- yllpiperidine-2,6-dione [Intermediate YK)**




[004608] Step 1 - N-[[(2S)-4-[[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxodpenzimidazol-4-yllmethyllmorpholin- 2-vHmethyll-N-methyl-carbamate


[004609] To a solution of l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazole-4-carbaldehyde (249 mg, 868 umol, Intermediate WW) and tert-butyl N-methyl-N-[[(2S)-morpholin-2-yl]methyl] carbamate (200 mg, 868 umol, Intermediate YM) in THF (15 mL) was added TEA (87.8 mg, 868 umol). The reaction mixture was stirred at 25 °C for 15 minutes. Then AcOH (156 mg, 2.61 mmol) and $NaBH(OAc)_3$ (552 mg, 2.61 mmol) was added. The reaction mixture was stirred at 25 °C for 12 hours. On completion, the reaction was quenched with water (3 mL) and the reaction mixture was concentrated *in vacuo.* The residue was purified by reverse phase (0.1% FA) to give the title compound (250 mg, 57% yield) as a white solid. LC-MS (ESI+) m/z 502.1 (M+H)+.

[004610] Step 2 - 3-[3-Methyl-4-[[(2R)-2-(methylaminomethyl)morpholin-4-yl1methyl1-2-oxo-benzimidazol-l- yl1piperidine-2.6-dione

[004611] To a solution of tert-butyl N-[[(2S)-4-[[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] methyl]morpholin-2-yl]methyl]-N-methyl-carbamate (100 mg, 199 umol) in DCM (1 mL) was added HCl/dioxane (4 M, 20.0 mL). The reaction mixture was stirred at 25 °C for 30 minutes. On completely, the reaction mixture was concentrated *in vacuo* to give the title compound (80.0 mg, 91% yield, HC1) as a white solid. LC-MS (ESI+) m/z 402.1 (M+H)+.

[004612] **3-[3-Methyl-2-oxo-4-[2-(4-piperidvPethvnyllbenzimidazol-l-yllpiperidine-2,6-dione [Intermediate YL)**





YL

[004613] Step 1 - Tert-butyl 4-[2-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yllethvnvn piperidine -1-carboxylate


[004614] To a solution of 3-(4-bromo-3-methyl-2-oxobenzimidazol-l-yl)piperidine-2,6-dione (400 mg, 1.18 mmol, Intermediate HP), and tert-butyl 4-ethynylpiperidine-l-carboxylate (446 mg, 2.13 mmol, CAS# 287192-97-6) in DMF (5.00 mL) was added Cs_2C0_3 (1.93 g, 5.91 mmol), 4A molecular sieves (100 mg), $Pd(PPh3)_2Cl_2$ (83.0 mg, 118 umol) and Cul (22.5 mg, 118 umol). The mixture was stirred at 80 °C for 2 hrs under N_2. On completion, the reaction mixture was filtered and the filter cake was washed with ACN (10 mL). The filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (330 mg, 707 umol, 60% yield) as yellow solid. ^{1}H NMR (400MHz, DMSO- d_5) δ 11.11 (s, 1H), 7.13 - 7.11 (m, 1H), 7.07 - 7.05 (m, 1H), 7.01 - 6.97 (m, 1H), 5.40 - 5.36 (m, 1H), 3.72 - 3.66 (m, 2H), 3.63 (s, 3H), 3.12 - 3.07 (m, 2H), 2.93 - 2.87 (m, 2H), 2.75 - 2.68 (m, 1H), 2.65 - 2.60 (m, 1H), 2.04 - 1.99 (m, 1H), 1.88 - 1.85 (m, 2H), 1.8 - 1.50 (m, 2H), 1.40 (s, 9H).

[004615] Step 2 - 3-r3-Methyl-2-oxo-4-r2-(4-piperidvPethvnvnbenzimidazol-l-yl1piperidine-2.6-dione

[004616] To a solution of tert-butyl 4-[2-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]ethynyl] piperidine- l-carboxylate (300 mg, 643 umol) in DCM (3.00 mL) was added $ZnBr_2$ (2.17 g, 9.65 mmol). The mixture was stirred at 20 °C for 20 hrs. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (235 mg, 99% yield) as

yellow gum. LC-MS (ESI+) *m/z* 367.2 (M+H)+.

[004617] **Tert-butyl N-methyl-N-[[(2S)-mornholin-2-yl Imethyl Icarbamate [Intermediate YM)**



YM

[004618] Step 1 - Benzyl (2S)-2-(hvdiOxymethvl)morpholine-4-carboxylate

[004619] To a solution of [(2S)-morpholin-2-yl]methanol (5 g, 32.5 mmol, HC1; CAS# 132073-83-7) and NaHCCb (6.84 g, 81.4 mmol) in a mixed solvent of ACN (10 mL) and H_20 (10 mL) was added CbzCl (8.33 g, 48.8 mmol). The reaction mixture was stirred at 25 °C for 12 hrs. On completion, the mixture was concentrated *in vacuo* to remove ACN. The residue was extracted with EA (2 X 20 mL), then the combined organic layers were concentrated *in vacuo.* The residue was purified by silica gel column (PE: EA=l: 1) to give the title compound (7.1 g, 87% yield) as colorless oil. ^{1}H NMR (400MHz, CDCh) δ 7.42 - 7.33 (m, 5H), 5.17 (d, *J* = 2.0 Hz, 2H), 4.08 - 3.88 (m, 3H), 3.77 - 3.65 (m, 1H), 3.63 - 3.46 (m, 3H), 3.13 - 2.73 (m, 2H), 2.07 - 1.96 (m, 1H). LC-MS (ESI+) *m/z* 274.1 (M+Na)+.

[004620] Step 2 - Benzyl (2S)-2-(methylsulfonyloxymethvnmorpholine-4-carboxylate

[004621] To a solution of benzyl (2S)-2-(hydroxymethyl)morpholine-4-carboxylate (7.1 g, 28.2 mmol) and triethylamine (5.72 g, 56.5 mmol) in dichloromethane (70 mL) was added methanesulfonyl chloride (4.86 g, 42.3 mmol) at 0 °C. The reaction mixture was stirred at 25 °C for 1 hr. On completion, the mixture was diluted with dichloromethane (20 mL) and washed with water (3 X 30 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (9.31 g, 100% yield) as yellow oil. 'H NMR (400MHz, CDCh) δ 7.43 - 7.33 (m, 5H), 5.20 - 5.15 (m, 2H), 4.26 (d, *J* = 4.8 Hz, 2H), 4.10 - 3.83 (m, 3H), 3.80 - 3.65 (m, 1H), 3.63 - 3.48 (m, 1H), 3.08 (s, 3H), 3.07 - 2.75 (m, 2H).

[004622] Step 3 - Benzyl (2R)-2-(methylaminomethvl)morpholine-4-carboxylate

[004623] A solution of benzyl (2S)-2-(methylsulfonyloxymethyl)morpholine-4-carboxylate (9.3 1 g, 28.2 mmol) in EtOH (10 mL) saturated with methanamine (58.5 g, 565 mmol) was stirred

under 50 Psi at 80 °C for 12 hrs in a 100 mL of autoclave. On completion, the mixture was concentrated *in vacuo* to give the title compound (7.47 g, 100% yield) as yellow oil, which was used for the next step without purification.


[004624] Step 4 - Benzyl (2R)-2-r tert-butoxycarbonyl(methvl)amino]methvl]morpholine-4-carboxylate

[004625] To a solition of benzyl (2R)-2-(methylaminomethyl)morpholine-4-carboxylate (7.47 g, 28.2 mmol) in MeOH (100 mL) was added $(Boc)_20$ (9.25 g, 42.4 mmol, 9.74 mL) and TEA (4.29 g, 42.4 mmol). The reaction mixture was stirred at 25 °C for 12 hrs. On completion, the mixture was concentrated in *vacuo.* The residue was purified by silica gel column (PE: EA = 5: 1) to give the title compound (9.10 g, 88% yield) as yellow oil, ^{1}H NMR (400MHz, CDCh) δ 7.43 - 7.30 (m, 5H), 5.24 - 5.09 (m, 2H), 4.11 - 3.83 (m, 3H), 3.68 - 3.34 (m, 3H), 3.30 - 3.14 (m, 1H), 3.09 - 2.97 (m, 1H), 2.94 (s, 3H), 2.80 - 2.62 (m, 1H), 1.47 (s, 9H).

[004626] Step 5 - Tert-butyl N-methyl-N-rr(2S)-morpholin-2-yl1methyl1carbamate

[004627] To a solution of benzyl (2R)-2-[[tert-butoxycarbonyl(methyl)amino]methyl]morpholine-4-carboxylate (9.1 g, 24.9 mmol) in THF (100 mL) was added Pd/C (1.00 g, 10% *wt)* under N_2 atmosphere. The suspension was degassed and purged with H_2 three times. The mixture was stirred under H_2 (15 Psi) at 25 °C for 12 hrs. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (5.7 g, 99% yield) as colorless oil. ^{1}H NMR (400MHz, CDCh) δ 3.91 - 3.83 (m, 1H), 3.68 - 3.55 (m, 2H), 3.48 - 3.33 (m, 1H), 3.12 (dd, *J* = 6.2, 14.4 Hz, 1H), 2.94 (s, 3H), 2.92 - 2.88 (m, 1H), 2.86 (dd, *J* = 3.2, 10.8 Hz, 1H), 2.84 - 2.78 (m, 1H), 2.57 (dd, *J* = 10.3, 12.0 Hz, 1H), 1.47 (s, 9H).

[004628] **3-[4-[AminomethvB-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione [Intermediate YN)**



[004629] Step 1 - l-(2.6-Dioxo-3 -piped dyl)-3 -methyl -2-oxo-benzimidazole-4-carbonitrile

[004630] To a solution of 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (500 mg, 1.48 mmol, Intermediate HP) in DMF (10 mL) was added $Zn(CN)_2$ (190 mg, 1.62 mmol) and $Pd(PPh_3)_4$ (180 mg, 155 umol) at 25°C. The mixture was stirred at 100 °C for 3 hours under N_2. On completion, the mixture was cooled to 25 °C. The mixture was filtered, and the cake was washed with EA (30 mL). The filtrate and washing were combined and concentrated *in vacuo.* The residue was purified by reversed phase flash (FA condition) to give the title compound (100 mg, 24% yield) as light yellow solid. ^1H NMR (400 MHz, DMSO-^e) δ 11.17 (s, 1H), 7.48 (d, *J* = 7.6 Hz, 2H), 7.19 (t, *J* = 8.0 Hz, 1H), 5.47 - 5.44 (m 1H), 3.61 (s, 3H), 2.72 - 2.69 (m, 1H), 2.66 - 2.62 (m, 2H), 2.07 - 2.03 (m, 1H); LC-MS (ESI^+) *m/z* 285.1 $(M+H)^+$.


[004631] Step 2 - Tert-butyl N-[[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxodpenzimidazol-4-yl]methyl] carbamate


[004632] To a solution of l-(2, 6-dioxo-3 -piped dyl)-3-methyl-2-oxo-benzimidazole-4-carbonitrile (100 mg, 351 umol) and Boc_20 (85.0 mg, 389 umol) in THF (2 mL) and DMF (2 mL) was added Raney-Ni (100 mg) at 20 °C. The mixture was stirred at 30 °C for 16 hours under H_2 (50 Psi). On completion, the mixture was filtered, and the filter cake was washed with THF (20 mL). The filtrate and washing were combined and concentrated *in vacuo* to give the title compound (120 mg, 87% yield) as light yellow gum. LC-MS (ESI^+) *m/z* 411.2 $(M+Na)^+$.

[004633] Step 3 - 3-r4-(Aminomethyl)-3-methyl-2-oxo-benzimidazol-1 -yllpiperidine-2.6-dione

[004634] To a solution of tert-butyl N-[[l-(2, 6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] methyl]carbamate (120 mg, 308 umol) in DCM (2 mL) was added TFA (1 mL) at 20 °C. The mixture was stirred at 20 °C for 1 hour. On completion, the mixture was concentrated *in vacuo* to give the title compound (120 mg, 96% yield, TFA) as light yellow solid. LC-MS (ESI^+) m/z 311.2 $(M+Na)^+$.

[004635] **Tert-butyl N-methyl-N-(3-prop-2-vnoxycvclobutyl)carbamate [Intermediate YO)**





YO

[004636] Step 1 - 3-(Methylamino)cvclobutanol

[004637] To a stirred solution of LAH (2.43 g, 64.1 mmol) in THF (100 mL) was added a solution of tert-butyl N-(3-hydroxycyclobutyl)carbamate (10.0 g, 53.4 mmol, CAS# 389890-42-0) in THF (100 mL) at 0 °C. Then the reaction mixture was stirred at 60 °C for 24 hrs. On completion, the reaction mixture was concentrated *in vacuo.* On completion, the mixture was cooled to 0 °C, quenched with H_20 (2.4 mL) and added l5%NaOH (2.4 mL). After stirred for 15 minutes, H_20 (2.4 mL X 3) was added into the above mixture. Then the mixture was warmed to rt and added anhydrous Na_2S0_4. The mixture was stirred for 10 minutes, filtered and the filtrate was concentrated *in vacuo* to give the title compound (4.90 g, 91% yield) as colorless oil. ^1H NMR (400 MHz, DMSO-di) δ 5.01 (s, 1H), 4.23 - 4.20 (m, 1H), 3.13 - 3.00 (m, 1H), 2.13 (s, 3H), 1.93 - 1.84 (m, 4H), 1.70 - 1.47 (m, 1H).

[004638] Step 2 - Tert-butyl N-(3-hvdroxycvclobutvD-N-methyl-carbamate


[004639] To a solution of 3-(methylamino)cyclobutanol (4.90 g, 48.4 mmol) in methyl alcohol (50 mL) was added $(Boc)_20$ (11.6 g, 53.3 mmol, 12.2 mL) for 3 hr at 25 °C. Then another batch of $(BOC)_20$ (10.6 g, 48.4 mmol) was added. The mixture was stirred at 25 °C for another 19 hrs. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by column chromatography ($Si0_2$, Petroleum ether/Ethyl acetate= 1:1) to give the title compound

(2.85 g, 30% yield) as yellow oil. ^{1}H NMR (DMSO-^) δ 4.94 (s, 1H), 4.25 - 4.21 (m, 1H), 4.10 - 4.19 (m, 1H), 2.72 (s, 3H), 2.23 - 2.35 (m, 2H), 1.91 - 2.03 (m, 2H), 1.38 (s, 9H).

[004640] Step 3 - Tert-butyl N-methyl-N-(3-prop-2-vnoxycvclobutvOcarbamate

[004641] To a solution of tert-butyl N-(3-hydroxycyclobutyl)-N-methyl-carbamate (450 mg, 2.24 mmol) in THF (15 mL) was added NaH (107 mg, 2.68 mmol, 60% dispersion in oil), TBAI (82.6 mg, 223 umol) at 0 °C, and the mixture was stirred for 30 minutes. Then 3-bromoprop-l-yne (3.35 mmol, 289 uL) was added to the mixture at 0 °C. The reaction mixture was stirred at 10 °C for 18 hrs. On completion, the reaction mixture was quenched 30 mL sat.aq NH_4Cl at l0°C and diluted with 30 mL water. Then the reaction mixture was then extracted with EA (3 X 50 mL). The combined organic layers were washed with 50 mL brine, dried over Na_2S0_4, filtered and the filtrate was concentrated *in vacuo* to give the title compound (500 mg, 93% yield) as yellow oil. 'H NMR (400 MHz, CDCh) δ 4.68 (s, 1H), 4.27 - 4.19 (m, 1H), 4.08 (d, J = 2.4 Hz, 2H), 2.83 (s, 3H), 2.41 (t, J = 2.4 Hz, 1H), 2.38 - 2.26 (m, 4H), 1.46 (s, 9H).

[004642] **3-[3-methyl-4-[3-[3-(methylamino]cvclobutoxylpropyll-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione [Intermediate YP)**



[004643] Step 1 - Tert-butyl N-[3-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl1prop-2-ynoxy] cvclobutyll-N-methyl-carbamate

[004644] To a solution of tert-butyl N-methyl-N-(3-prop-2-ynoxycyclobutyl)carbamate (500

mg, 2.09 mmol, Intermediate YO) and 3-(4-bromo-3 -methyl -2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (353 mg, 1.04 mmol, Intermediate HP) in DMF (15 mL) was added Cul (39.8 mg, 209 umol), CS2CO3 (1.70 g, 5.22 mmol), $Pd(PPh_3)Cl_2$ (153 mg, 209 umol) and 4A molecular sieves (600 mg) at 25 °C. The reaction mixture was stirred at 80 °C for 2 hrs. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was diluted with 30 mL water, and then extracted with EA (3 X 30 mL). The combined organic layers were washed with brine (30 mL), and then dried over Na_2S0_4, filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (380 mg, 73% yield) as a white solid. ^1H NMR (400 MHz, DMSO-di) δ 11.11 (s, 1H), 7.17 (d, *J* = 7.6 Hz, 1H), 7.12 (d, *J* = 7.6 Hz, 1H), 7.06 - 7.00 (m, 1H), 5.39 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.39 (s, 2H), 4.22 (t, *j* = 6.8 Hz, 1H), 3.63 (s, 3H), 3.29 (s, 1H), 2.95 - 2.83 (m, 1H), 2.75 (s, 3H), 2.65 - 2.64 (m, 1H), 2.70 - 2.64 (m, 1H), 2.36 - 2.30 (m, 2H), 2.26 - 2.16 (m, 2H), 2.09 - 1.98 (m, 1H), 1.38 (s, 9H); LC-MS (ESI^+) m/z 397.0 $(M+H-l00)^+$.

[004645] Step 2 - Tert-butyl N-[3-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yllpropoxyl cvclobutyll-N-methyl-carbamate


[004646] To a solution of tert-butyl N-[3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]prop-2-ynoxy]cyclobutyl]-N-methyl-carbamate (340 mg, 685 umol) in THF (15 mL) was added $Pd(OH)_2/C$ (400 mg, 685 umol, 10 wt%) and Pd/C (400 mg, 685 umol, 20 wt%) at 25 °C. The reaction mixture was stirred at 25 °C for 2 hrs under H_2 (15 psi). On completion, the reaction mixture was filtered with celite and the filtrate was concentrated *in vacuo* to give the title compound (330 mg, 96% yield) as black oil. LC-MS (ESI^+) m/z 50l.2$(M+H)^+$.

[004647] Step 3 - 3-r3-methyl-4-r3-r3-(methylamino)cvclobutoxy1propyl1-2-oxo-benzimidazol-l-vnpiperidine-2.6-dione

[004648] To a solution of tert-butyl N-[3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propoxy]cyclobutyl]-N-methyl-carbamate (300 mg, 599 umol) in DCM (8 mL) was added HCl/dioxane (4 M, 5 mL) at 25 °C. The reaction mixture was stirred at 25 °C for 1 hr. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (220 mg, 91% yield) as a white solid. ^1H NMR (400 MHz, DMSO^) δ 11.08 (s, 1H), 9.06 (s, 1H), 6.98 - 6.96 (m, 1H), 6.90 - 6.87(m, 1H), 5.37 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.23 - 4.14 (m, 1H), 3.57 (s, 3H), 3.35 (s, 3H), 3.00 - 2.92 (m, 3H), 2.91 - 2.84 (m, 1H), 2.75 - 2.70 (m, 1H), 2.60 (s, 2H), 2.45 (t, *j* = 5.6 Hz, 4H),

2.27 - 2.17 (m, 2H), 2.03 - 1.95 (m, 1H), 1.88 - 1.77 (m, 2H); LC-MS (ESI^+) m/z 401.3 $(M+H)^+$.

[004649] **3-[3-Methyl-4-[3-[(2S)-2-(methylaminomethvDmorpholin-4-yllpropyll-2-oxo-benzimidazol-l-yllpiperidine-2,6-dione [Intermediate YQ)**



[004650] Step 1 - Tert-butyl N-[[(2R)-4-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yllprop -2-vnyl1morpholin-2-yl1methyl1-N-methyl-carbamate

[004651] To a solution of tert-butyl N-methyl-N-[[(2R)-4-prop-2-ynylmorpholin-2-yl]methyl]carbamate (400 mg, 1.49 mmol, Intermediate WP) and 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine -2,6-dione (336 mg, 994 umol, Intermediate HP) in DMF (15 mL) was added CS_2CO_3 (1.62 g, 4.97 mmol), 4A molecular sieves (500 mg, 994 umol), Cul (37.8 mg, 199 umol) and $Pd(PPh3)_2Cl2$ (l39mg, 199 umol) at 25 °C. The reaction mixture was stirred at 80 °C for 2 hrs. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was diluted with water 30 mL, and then extracted with EA (3 X 20 mL). The combined organic layers were washed with brine (20 mL), and then dried over Na_2S0_4, filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (340 mg, 65% yield) as a white solid. ^1H NMR (400 MHz, DMSO-i¾ δ 11.10 (s, 1H), 7.18 - 7.13 (m, 1H), 7.12 - 7.06 (m,

1H), 7.04 - 6.99 (m, 1H), 5.39 (dd, *J* = 5.2, 12.4 Hz, 1H), 3.83 (d, *J* = 9.6 Hz, 1H), 3.64 (s, 3H), 3.62 - 3.46 (m, 4H), 3.34 (s, 3H), 3.15 (s, 1H), 2.86 - 2.78 (m, 4H), 2.75 - 2.66 (m, 3H), 2.11 - 1.98 (m, 2H), 1.35 (s, 9H); LC-MS (ESI^+) m/z 526.3 $(M+H)^+$.


[004652] Step 2 - Tert-butyl N-[[(2R)-4-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4- νl]ρϊΟρνl] morpholin-2-yl1methyl1-N-methyl-carbamate

[004653] To a solution of tert-butyl N-[[(2R)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] prop-2-ynyl]morpholin-2-yl]methyl]-N-methyl-carbamate (300 mg, 571 umol) in THF (20 mL) and Pd/C (200 mg, 20 wt%) was added $Pd(OH)_2$/C (200 mg, 10 wt%) at 25 °C. The reaction mixture was stirred at 25 °C for 2 hrs under H_2 (15 psi). On completion, the reaction mixture was filtered with celite and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (130 mg, 43% yield) as a white solid. ¾NMR (400 MHz, DMSO-i¾) δ 11.10 (s, 1H), 6.99 - 6.91 (m, 2H), 6.89 - 6.83 (m, 1H), 5.36 (dd, *J* = 5.2, 12.4 Hz, 1H), 3.77 (d, *J* = 11.2 Hz, 1H), 3.55 (s, 3H), 3.46 (t, *J* = 10.4 Hz, 2H), 3.22 (d, J = 5.2 Hz, 1H), 3.18 - 3.15 (m, 1H), 2.94 - 2.88 (m, 2H), 2.84 - 2.76 (m, 3H), 2.72 - 2.62 (m, 4H), 2.52 (s, 3H), 2.39 - 2.34 (m, 1H), 2.05 - 1.95 (m, 2H), 1.77 - 1.71 (m, 2H), 1.37 (s, 9H); LC-MS (ESI^+) m/z 530.4 $(M+H)^+$.

[004654] Step 3 - 3-[3-Methyl-4-[3-[(2S)-2-(methylaminomethvl)morpholin-4-yl1propyl1-2-oxo-benzimidazol- 1-yl1piperidine-2.6-dione

[004655] To a solution of tert-butyl N-[[(2R)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propyl]morpholin-2-yl]methyl]-N-methyl -carbamate (110 mg, 208 umol) in DCM (6 mL) was added HCl/dioxane (4 M, 3 mL) at 25 °C. The reaction mixture was stirred at 25 °C for 1 hr. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (80.0 mg, 89% yield) as a white solid. LC-MS (ESI^+) m/z 430.2$(M+H)^+$.

[004656] 3-[3-Methyl-4-[3-[(2S)-2-[2-(methylamino)ethyllmorpholin-4-yllpropyll-2-oxo-benzimidazol -l-yl]piperidine-2,6-dione [Intermediate YR)



[004657] Step 1 - Benzyl N-[2-[(2S)-4-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]prop-2-ynyl]morpholin-2-yl]ethyl]-N-methyl-carbamate


[004658] To a solution of benzyl N-methyl-N-[2-[(2S)-4-prop-2-ynylmorpholin-2-yl]ethyl]carbamate (426 mg, 1.35 mmol, Intermediate TX) and 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (350 mg, 1.04 mmol, Intermediate HP) in DMF (15 mL) was added CS2CO3 (1.69 g, 5.18 mmol), CuI (39.4 mg, 207 umol), 4A molecular sieves (500 mg, 147.86 umol) and Pd(dppf)Cl_2 (151 mg, 207 umol) at 25 °C. The reaction mixture was stirred at 80 °C for 2 hrs. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the residue. The residue was diluted with water 30 mL, and then extracted with EA (3 X 20 mL). The combined organic layers were washed with brine (20 mL), and then dried over Na_2SO_4, filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (400 mg, 67% yield) as a white solid. ^{1}H NMR (400 MHz, DMSO-^e) δ 11.11 (s, 1H), 7.34 (d, *J* = 2.0 Hz, 5H), 7.18 - 7.08(m, 2H), 7.05 - 6.98 (m, 1H), 5.39 (dd, *J* = 5.2, 12.8 Hz, 1H), 5.05 (s, 2H), 3.84 - 3.74 (m, 1H), 3.63 (s, 3H), 3.56 (s, 3H), 3.46 - 3.41 (m, 2H), 2.94 - 2.87 (m, 1H), 2.88 - 2.80(m, 4H), 2.77 - 2.70 (m, 2H), 2.67 - 2.58 (m, 2H), 2.31 - 2.25 (m, 1H), 2.08 - 1.98 (m, 2H), 1.65 - 1.55 (m, 2H); LC-MS (ESI$^+$) m/z 574.1 $(M+H)^+$.

[004659] Step 2 - 3-[3-Methyl-4-[3-[(2S)-2-[2-(methylamino)ethyl]morpholin-4-yl]propyl]-2-oxo-benzimidazol -l-yl]piperidine-2.6-dione

[004660] To a solution of benzyl N-[2-[(2S)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-

oxo-benzimidazol-4-yl] prop-2-ynyl]morpholin-2-yl]ethyl]-N-methyl-carbamate (370 mg, 645 umol) in THF (15 mL) was added Pd/C (300 mg, 20 wt%) and $Pd(OH)_2/C$ (300 mg, 10 wt%) at 25 °C. The mixture was stirred at 25 °C for 2.5 hrs under H_2 (15 psi). On completion, the reaction mixture was filtered with celite and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (140 mg, 48% yield) as a brown solid. LC-MS (ESI^+) m/z 444.3 $(M+H)^+$.


[004661] Tert-butyl 4-(prop-2-vnoxymethvDpiperidine-l-carboxylate [Intermediate YS1



YS

[004662] To a mixture of tert-butyl 4-(hydroxymethyl)piperidine-l-carboxylate (5.00 g, 23.2 mmol, CAS# 123855-51-6) was added NaH (1.11 g, 27.8 mmol, 60% oil dispersion) at 0 °C for 0.5 hour. Then 3-bromoprop-l-yne (4.14 g, 27.8 mmol, 3.00 mL, CAS# 106-96-7) and TBAI (857 mg, 2.32 mmol) was added to the mixture. The reaction mixture was stirred at 25 °C for 12 hours. On completion, the reaction mixture was quenched by addition sat. H_20 (10 mL), and extracted with EA (50 mL X 2). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (5.00 g, 84% yield) as yellow oil. 'H NMR (400 MHz, CDCh) δ 4.12 (d, J = 2.4 Hz, 2H), 3.36 (d, J = 6.2 Hz, 2H), 2.69 (t, J = 12.2 Hz, 2H), 2.41 (t, 7 = 2.4 Hz, 1H), 1.81 - 1.74 (m, 1H), 1.73 - 1.67 (m, 2H), 1.45 (s, 9H), 1.15 - 1.10 (m, 2H).

[004663] 3-[3-Methyl-2-oxo-5-[3-(4-piperidylmethoxy)propyll benzimidazol-1-yl]piperidine-2.,6-dione [Intermediate YT)



[004664] Step 1 - Tert-butyl 4-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]prop-2-ynoxymethyl]piperidine-1-carboxylate

[004665] To a mixture of tert-butyl 4-(prop-2-ynoxymethyl)piperidine-1-carboxylate (749 mg, 2.96 mmol, Intermediate YS) and 3-(5-bromo-3-methyl-2-oxo-benzimidazol-1-yl)piperidine-2,6-dione (400 mg, 1.18 mmol, Intermediate HN) in DMF (1 mL) was added $Pd(PPh_3)_2Cl_2$ (83.0 mg, 118 umol), CuI (22.5 mg, 118 umol), Cs_2CO_3 (1.93 g, 5.91 mmol) and 4Å molecular sieves (10.0 mg, 147 umol). The reaction mixture was stirred at 80 °C for 2 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo*. The residue was purified by reverse phase (0.1 % FA condition) to give the title compound (320 mg, 52% yield) as a yellowish solid. ^1H NMR (400 MHz, DMSO^) δ 11.19 - 11.03 (m, 1H), 7.66 - 7.52 (m, 1H), 7.32 (d, *J* = 0.8 Hz, 1H), 7.16 - 7.13 (m, 1H), 5.39 (dd, *J* = 12.8 Hz, 1H), 4.36 (s, 2H), 3.40 (t, *j* = 2.4 Hz, 1H), 3.37 (*d*, *J* = 6.2 Hz, 2H), 3.34 (s, 3H), 3.30 - 3.27 (m, 2H), 2.97 - 2.82 (m, 1H), 2.76 - 2.64 (m, 4H), 2.11 - 1.96 (m, 1H), 1.64 (s, 2H), 1.38 (s, 9H), 1.07 - 1.01 (m, 2H).

[004666] Step 2 - Tert-butyl 4-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-vnpropoxymethvn piperidine- l-carboxylate


[004667] To a mixture of tert-butyl 4-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-

benzimidazol-5-yl]prop-2- ynoxymethyl]piperidine-l-carboxylate (320 mg, 626umol) in THF (5 mL) was added Pd/C (100 mg, 626 umol, 10% *wt)* and $Pd(OH)_2/C$ (100 mg, 626 umol, 10% *wt).* The mixture was stirred at 25 °C for 12 hours under H_2 (15 psi). On completion, the mixture was filtered and concentrated *in vacuo* to give the title compound (320 mg, 99 yield) as a white solid. ^1H NMR (400 MHz, DMSO-i¾) δ 11.07 (s, 1H), 7.69 - 7.50 (m, 1H), 7.03 - 7.00 (m, 1H), 6.87 - 6.84 (m, 1H), 5.33 (dd, *J* = 12.8 Hz, 1H), 3.92 (d, *J* = 12.0 Hz, 2H), 3.38 - 3.34 (m, 3H), 3.31 - 3.27 (m, 2H), 3.20 (t, *J* = 6.6 Hz, 4H), 1.86 - 1.76 (m, 2H), 1.73 - 1.67 (m, 1H), 1.64 - 1.60 (m, 2H), 1.55 - 1.44 (m, 2H), 1.38 (s, 9H), 1.35 (s, 2H).

[004668] Step_3_-_3-r3-Methyl-2-oxo-5-r3-(4-piperidylmethoxy)propyl1benzimidazol-l-yl1piperidine-2.6-dione

[004669] To a mixture of tert-butyl 4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] propoxymethyl]piperidine-l-carboxylate (310 mg, 602 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 4.00 mL). The reaction mixture was stirred at 25 °C for 2 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (220 mg, 88% yield) as a white solid. ^1H NMR (400 MHz, DMSO-i¾) δ 11.07 (s, 1H), 7.07 - 6.97 (m, 2H), 6.89 - 6.82 (m, 1H), 5.34 (dd, *J* = 12.8 Hz, 1H), 3.57 (s, 4H), 3.40 - 3.37 (m, 2H), 3.22 - 3.21 (m, 2H), 2.96 - 2.70 (m, 6H), 2.67 - 2.64 (m, 2H), 1.85 - 1.81 (m, 2H), 1.52 - 1.47 (m, 1H), 1.41 - 1.33 (m, 4H), 0.90 - 0.81 (m, 1H), 0.86 (t, *J* = 7.2 Hz, 1H).

[004670] **3-[3-Methyl-2-oxo-4- [3-(4-piperidylmethoxy)propyll benzimidazol-1-yl]piperidine-2.,6-dione [Intermediate YU)**



[004671] Step 1 - Tert-butyl 4-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl1prop-2-ynoxymethyllpiperidine-1-carboxylate

[004672] To a mixture of tert-butyl 4-(prop-2-ynoxymethyl)piperidine-l-carboxylate (749 mg, 2.96 mmol, Intermediate YS) and 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (400 mg, 1.18 mmol, Intermediate HP) in DMF (5 mL) was added CuI (22.5 mg, 118 umol), CS_2CO_3 (1.93 g, 5.91 mmol), $Pd(PPh3)_2Cl2$ (83.0 mg, 118 umol) and 4A molecular sieves (20.0 mg). The reaction mixture was stirred at 80 °C for 4 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo*. The residue was purified by reverse phase (0.1 % FA condition) to give the title compound (300 mg, 49% yield) as brown solid. ^{1}HNMR (400 MHz, DMSO-di) δ 11.11 (s, 1H), 7.20 - 7.09 (m, 2H), 7.06 - 7.00 (m, 1H), 5.43 - 5.36 (m, 1H), 4.43 (s, 2H), 4.10 (d, J = 2.4 Hz, 1H), 3.93 (d, J = 10.8 Hz, 2H), 3.64 (s, 3H), 3.40 - 3.38 (m, 2H), 3.28 (d, J = 6.4 Hz, 1H), 2.95 - 2.83 (m, 1H), 2.70 - 2.65 (m, 2H), 2.06 - 1.99 (m, 1H), 1.81 - 1.70 (m, 1H), 1.67 - 1.60 (m, 2H), 1.38 (s, 9H), 1.08 - 1.01 (m, 2H).

[004673] Step 2 - Tert-butyl 4-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-vnpropoxymethvn piperidine-l-carboxylate


[004674] To a mixture of tert-butyl 4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]prop-2-ynoxymethyl]piperi dine-l-carboxylate (300 mg, 587 umol) in THF (30 mL) was added Pd/C (100 mg, 10 wt%) and Pd(OH)2/C (100 mg, 10 wt%). The reaction mixture

was stirred at 25 °C for 12 hours under H_2 (15 psi) atmosphere. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (302 mg, 99% yield) as light yellow solid. ^{1}H NMR (400 MHz, DMSO^) δ 11.08 (s, 1H), 6.96 (d, *J* = 4.4 Hz, 2H), 6.88 - 6.83 (m, 1H), 5.41 - 5.30 (m, 1H), 3.96 - 3.91 (m, 2H), 3.55 (s, 3H), 3.42 (t, *J* = 5.6 Hz, 2H), 3.28 - 3.18 (m, 4H), 2.99 - 2.92 (m, 2H), 2.90 - 2.83 (m, 1H), 2.71 - 2.66 (m, 2H), 2.05 - 1.94 (m, 1H), 1.86 - 1.78 (m, 2H), 1.66 - 1.62 (m, 2H), 1.51 - 1.46 (m, 1H), 1.39 (s, 9H), 1.06 - 0.99 (m, 2H).

[004675] Step_3_-_3-r3-Methyl-2-oxo-4-r3-(4-piperidylmethoxy)propyl1benzimidazol-l-yl1piperidine-2.6-dione

[004676] To a mixture of tert-butyl 4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propoxymethyl]piperidine-l-carboxylate (290 mg, 563 umol) in DCM (2 mL) was added HCl/dioxane (4 M, 29.00 mL). The reaction mixture was stirred at 25 °C for 2 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (254 mg, 99% yield, HC1 salt) as white solid. LC-MS (ESI$^+$) *m/z* 415.3 $(M+H)^+$.


[004677] **Tert-butyl 3-prop-2-vnoxyazetidine-l-carboxylate [Intermediate YV)**



YV

[004678] To a mixture of tert-butyl 3-hydroxyazetidine-l-carboxylate (5.00 g, 28.8 mmol, CAS# 141699-55-0) in THF (5 mL) was added NaH (1.39 g, 34.6 mmol, 60% oil dispersion) at 0 °C for 0.5 hour. Then 3-bromoprop-l- yne (5.15 g, 34.6 mmol, 3.73 mL) and TBAI (1.07 g, 2.89 mmol) were added to the mixture. The reaction mixture was stirred at 25 °C for 2 hours. On completion, the reaction mixture was quenched with sat. NH_4Cl (50 mL), diluted with water (100 mL) and extracted with EA (2 X 100 mL). The combined organic layers was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (5.70, 93 % yield) as a yellow solid. ^{1}H NMR (400 MHz, CDCh) δ 4.45 - 4.37 (m, 1H), 4.13 (d, *J* = 2.4 Hz, 2H), 4.12 - 4.07 (m, 2H), 3.89 (dd, J = 9.6 Hz, 2H), 2.45 - 2.43 (m, 1H), 1.43 (s, 9H).

[004679] **3-[5-[3-(Azetidin-3-yloxy)propyll-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2.,6-dione [Intermediate YW)**



[004680] Step 1 - Tert-butyl 3-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]prop-2-ynoxy]azetidine-1-carboxylate

[004681] To a mixture of ert-butyl 3-prop-2-ynoxyazetidine-l -carboxylate (499 mg, 2.37 mmol, Intermediate YV) and 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (400 mg, 1.18 mmol, Intermediate HN) in DMF (20 mL) was added Cs_2C0_3 (1.93 g, 5.91 mmol), Cul (22.5 mg, 118 umol), $Pd(PPh_3)_2Cl_2$ (83.0 mg, 118 umol) and 4Å molecular sieves (100 mg). The reaction mixture was stirred at 80 °C for 2 hours. On completion, the mixture was filtered and concentrated *in vacuo.* The residue was purified by reverse phase (0.1% FA condition) to give the title compound (300 mg, 54% yield) as colorless oil. ^{1}H NMR (400 MHz, DMSO-i/e) δ 11.11 (s, 1H), 7.66 - 7.59 (m, 1H), 7.58 - 7.49 (m, 1H), 7.18 - 7.13 (m, 1H), 4.49 - 4.43 (m, 1H), 4.10 - 3.97 (m, 4H), 3.77 - 3.76 (m, 1H), 3.77 - 3.72 (m, 1H), 3.46 (t, *J* = 2.4 Hz, 1H), 3.34 (s, 3H), 2.97 - 2.83 (m, 1H), 2.77 - 2.58 (m, 2H), 2.09 - 1.94 (m, 1H), 1.37 (s, 9H).

[004682] Step 2 - Tert-butyl 3-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]prop-2-ynoxy]azetidine-1-carboxylate


[004683] To a solution of tert-butyl 3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]prop-2- ynoxy]azetidine-l -carboxylate (300 mg, 640 umol) in THF (5 mL) was added Pd/C (100 mg, 71.2 mmol, 10% *w/t)* and $Pd(OH)_2$/C (100 mg, 71.2 mmol, 10% *w/t*) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture

was stirred at 25 °C for 17 hours under ¾ (15 psi). On completion, the mixture was filtered and concentrated *in vacuo* to give the title compound (240 mg, 79% yield) as a white solid. ¹H NMR (400 MHz, DMSO-i¾) δ 11.07 (s, 1H), 7.07 - 6.98 (m, 2H), 6.87 (td, *J* = 8.0 Hz, 1H), 5.33 (dd, *J* = 12.8 Hz, 1H), 4.24 - 4.17 (m, 2H), 4.06 - 4.01 (m, 2H), 3.63 (s, 1H), 3.32 (s, 3H), 3.27 - 3.24 (m, 2H), 2.68 - 2.64 (m, 2H), 1.99 (s, 2H), 1.86 - 1.79 (m, 2H), 1.50 (t, *J* = 7.2 Hz, 2H), 1.37 (s, 9H).

[004684] Step 3 - 3-r5-r3-(Azetidin-3-yloxy)propyl1-3-methyl-2-oxo-benzimidazol-l-yl1piperidine-2.6-dione

[004685] To a mixture of tert-butyl 3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]propoxy] azetidine-l-carboxylate (220 mg, 465 umol) in DCM (5 mL) was added TFA (33.8 g, 297 mmol, 22.0 mL). The reaction mixture was stirred at 25 °C for 2 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (150 mg, 86% yield) as a yellow solid. LC-MS (ESI⁺) *m/z* 373.2 (M+H)⁺.

[004686] **4-n-[2,6-Dioxopiperidin-3-vn-3-methyl-2-oxo-2,3-dihvdro-lH-benzo[d1imidazol-5-vPbut- 3-yn-l-yl methanesulfonate [Intermediate YX)**



[004687] Step 1 - 3-(5-(4-Hvdroxybut-l-vn-l-yl)-3-methyl-2-oxo-2.3-dihvdro-lH-benzordlimidazol-l-yl) piped dine-2.6-dione


[004688] To a solution of 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (500 mg, 1.48 mmol, Intermediate HN) and but-3-yn-l-ol (207 mg, 2.96 mmol, CAS# 927-74-2) in DMF (8 mL) was added Pd(PPh $_3$)2Cl2 (207 mg, 295 umol), CS2CO3 (1.93 g, 5.91 mmol), CuI (56.3 mg, 295 umol) and 4Å molecular sieves at 25 °C under N2. The mixture was then heated

to 80 °C and stirred for 2 hours. On completion, the reaction mixture was quenched by addition water (10 mL) at 25 °C, and then diluted with CH2CI2 (20 mL) and extracted with CH2CI2 (3 X 20 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (FA condition) to give the title compound (355 mg, 73% yield) as a yellow solid. ^{1}H NMR (400 MHz, DMSO-^e) δ 11.10 (s, 1H), 7.24 (s, 1H), 7.09 (s, 2H), 5.41 - 5.33 (m, 1H), 4.88 (s, 1H), 3.58 (t, *J* = 7.0 Hz, 2H), 3.33 (s, 3H), 2.91 - 2.84 (m, 1H), 2.73 - 2.64 (m, 2H), 2.55 (t, *J* = 7.0 Hz, 2H), 2.05 - 1.99 (m, 1H); LC-MS (ESI$^+$) m/z 328.1 (M+H)$^+$.

[004689] Step 2 - 4-(T-(2,6-Dioxopiperidin-3-vl)-3-methyl-2-oxo-2,3-dihydro-lH-benzord1imidazol-5-vQbut- 3-yn-l-yl methanesulfonate

[004690] To a mixture of 3-[5-(4-hydroxybut-l-ynyl)-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione (350 mg, 1.07 mmol) in DCM (10 mL) was added TEA (324 mg, 3.21 mmol) and MsCl (159 mg, 1.39 mmol) at 0 °C. The mixture was stirred at 0 °C for 0.5 hour. On completion, the reaction mixture was quenched by addition water (20 mL) at 25 °C, and then extracted with DCM (3 X 30 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (400 mg, 92% yield) as yellowish oil. 'H NMR (400 MHz, CDCb) δ 8.16 (s, 1H), 7.09 - 7.06 (m, 1H), 7.00 (s, 1H), 6.67 (d, *j* = 8.2 Hz, 1H), 5.14 - 5.09 (m, 1H), 4.33 (t, *J* = 6.8 Hz, 2H), 3.35 (s, 3H), 3.00 (s, 3H), 2.82 (t, *j* = 6.8 Hz, 2H); LC-MS (ESI$^+$) m/z 406.3 (M+H)$^+$.

[004691] 3-[5-[4-[4-(AminomethyD-l-piperidyllbut-l-ynyll-3-methyl-2-oxo-benzimidazol-l-yl] piperidine-2,6-dione [Intermediate YY)



[004692] Step 1 - Tert-butyl N-[[1-[4-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-vl]but-3-ynyl] -4-piperidyl1methvHcarbamate


[004693] To a solution of 4-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]but-3-ynyl methanesulfonate (350 mg, 863 umol, Intermediate YX) and tert-butyl N-(4-piperidylmethyl)carbamate (222 mg, 1.04 mmol, CAS# 135632-53-0) in a mixed solvent of CHCh (5 mL) and ACN (5 mL) was added K_2CO_3 (239 mg, 1.73 mmol). The reaction mixture was stirred at 65 °C for 12 hrs. On completion, the mixture was diluted with water (50 mL), then extracted with EA (2 X 50 mL). The organic layer was washed with brine (50 mL), dried with Na_2S0_4, filtrated and concentrated *in vacuo.* The residue was purified by prep-HPLC (column: Phenomenex Synergi Max-RP l50*50mm*l0 um; mobile phase: [water (0.225%FA)-ACN]; B%: l0%-40%, 10 min) to give the title compound (165 mg, 37% yield) as a yellow solid. ^{1}H NMR (400 MHz, DMSO-di) δ 11.11 (s, 1H), 7.23 (s, 1H), 7.11 - 7.06 (m, 2H), 6.83 (t, *J* = 5.6 Hz, 1H), 5.37 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.32 (s, 3H), 2.95 - 2.84 (m, 3H), 2.79 (t, *J* = 6.4 Hz, 2H), 2.74 - 2.54 (m, 6H), 2.06 - 1.96 (m, 3H), 1.64 - 1.54 (m, 2H), 1.36 (s, 9H), 1.35 - 1.31 (m, 1H), 1.17 - 1.04 (m, 2H).

[004694] Step 2 - 3-r5-r4-r4-(Aminomethvn-l-piperidyl1but-l-vnyl1-3-methyl-2-oxo-benzimidazol-l-yl] piperidine-2.6-dione

[004695] To a solution of tert-butyl N-[[l-[4-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] but-3-ynyl]-4-piperidyl]methyl]carbamate (90.0 mg, 172 umol) in DCM (5

mL) was added $ZnBr_2$ (387 mg, 1.72 mmol). The reaction mixture was stirred at 20 °C for 10 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (70.0 mg, 96% yield) as a white solid. LC-MS (ESI^+) *m/z* 424.3 $(M+H)^+$.

[004696] **2-[2-[2-[Methylamino)ethoxy]ethyl]isoindoline-l,3-dione [Intermediate YZ)**



YZ

[004697] Step 1 - N-r2-(2-hvdroxyethoxy)ethyl1formamide

[004698] A solution of 2-(2-aminoethoxy)ethanol (5.00 g, 47.5 mmol, CAS# 929-06-6) in ethyl formate (18.4 g, 248 mmol, CAS# 109-94-4) was stirred at 90 °C for 6 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (6.30 g, 99% yield) as yellow oil. LC-MS (ESI^+) *m/z* 134.1 $(M+H)^+$.

[004699] Step 2 - 2-r2-(Methylamino)ethoxy1ethanol

[004700] To a solution of LiAlEE (2.16 g, 56.7 mmol) in THF (30.0 mL) was added a solution of N-[2-(2-hydroxyethoxy)ethyl]formamide (6.30 g, 47.3 mmol) in THF (30.0 mL) dropwise at 0 °C. The mixture was stirred at 80 °C for 2 hrs. On completion, the reaction mixture was quenched with a solution of 15% NaOH (20 mL). Thereafter, 50 g anhydrous sodium sulfate was added, and the mixture was filtered. The filtrate was concentrated *in vacuo* to give the title compound (5.64 g, 100% yield) as yellow oil.

[004701] Step 3 - Tert-butyl N-r2-(2-hvdroxyethoxy)ethyl1-N-methyl-carbamate

[004702] To a solution of 2-[2-(methylamino)ethoxy]ethanol (5.60 g, 46.9 mmol) in MeOH (70.0 mL) was added $(Boc)_20$ (15.3 g, 70.4 mmol), the mixture was stirred at 25 °C for 12 hrs. On completion, the mixture was concentrated *in vacuo*. The residue was purified by silica gel column

(PE: EA=2: 1) to give the title compound (8.00 g, 77% yield) as colorless oil. ^{1}H NMR (400MHz, CDCh) δ 3.80 - 3.68 (m, 2H), 3.67 - 3.52 (m, 4H), 3.48 - 3.33 (m, 2H), 2.92 (s, 3H), 1.47 (s, 9H).

[004703] Step 4 - 2-r2-rTert-butoxycarbonyl(´methv0amino1ethoxy1ethyl methanesulfonate

[004704] To a solution of tert-butyl N-[2-(2-hydroxyethoxy)ethyl]-N-methyl-carbamate (1.00 g, 4.56 mmol), TEA(l.38 g, 13.6 mmol) in DCM (10.0 mL) was added MsCl (783 mg, 6.84 mmol) at 0 °C. The mixture was stirred at 20 °C for 1 hr. On completion, the mixture was diluted with DCM (20 mL), washed with H_20 (3 X 20 mL). The organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (1.28 g, 94% yield) as yellow oil. ^{1}H NMR (400MHz, CDCh) δ 4.33 - 4.26 (m, 2H), 3.68 - 3.62 (m, 2H), 3.59 - 3.48 (m, 2H), 3.39 - 3.28 (m, 2H), 2.98 (s, 3H), 2.84 (s, 3H), 1.39 (s, 9H).


[004705] Step _5_ -Tert-butyl _N-r2-r2-(E3-dioxoisoindolin-2-vDethoxy1ethvn-N-methyl-carbamate


[004706] To a solution of 2-[2-[tert-butoxycarbonyl(methyl)amino]ethoxy]ethyl methanesulfonate (1.08 g, 3.63 mmol) in DMF (10.0 mL) was added (l,3-dioxoisoindolin-2-yl)potassium (1.01 g, 5.45 mmol). The mixture was stirred at 80 °C for 3 hrs. On completion, the mixture was diluted with H_20 (40 mL), then extracted with EA (3 X 30 mL). The organic layers were washed with brine (2 X 30 mL) and dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by silica gel column (PE: EA= 5: 1) to give the title compound (1.2 g, 94% yield) as white solid. ^{1}H NMR (400MHz, DMSO-^e) δ 7.89 - 7.83 (m, 4H), 3.81 - 3.71 (m, 2H), 3.68 - 3.56 (m, 2H), 3.54 - 3.42 (m, 2H), 3.28 - 3.20 (m, 2H), 2.69 (s, 3H), 1.32 (s, 9H).

[004707] Step 6 - 2-r2-r2-(Methylamino)ethoxy1ethyl1isoindoline-L3-dione

[004708] To a solution of tert-butyl N-[2-[2-(l,3-dioxoisoindolin-2-yl)ethoxy]ethyl]-N-methyl-carbamate (200 mg, 574 umol) in DCM (3.00 mL) was added HCl/dioxane (4.00 M, 4.00 mL). The mixture was stirred at 20 °C for 0.5 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (160 mg, 97% yield, HC1) as white solid. ^{1}H NMR (400MHz, DMSO-di) δ 8.84 (s, 1H), 7.92 - 7.84 (m, 4H), 3.84 - 3.76 (m, 2H), 3.73 - 3.65 (m, 4H), 3.10 - 2.92 (m, 2H), 2.49 (s, 3H).

[004709] Tert-butyl N-[[(2SV4-(2-aminoethv0morpholin-2-yl]methyl1-N-methyl-carbamate (Intermediate ZA)





ZA

[004710] Step 1 - Tert-butyl N-[(2S)-4-[2-(1,3-dioxoisoindolin-2-yl)ethyl]morpholin-2-yl]methyl-N-methyl-carbamate


[004711] To a solution of tert-butyl N-methyl-N-[[(2S)-morpholin-2-yl]methyl]carbamate (1.00 g, 4.34 mmol, Intermediate YM) in ACN (30 mL) was added K2CO3 (535 mg, 13.0 mmol) and 2-(2-bromoethyl)isoindoline-1,3-dione (1.21 g, 4.77 mmol, CAS# 574-98-1) andKI (72.1 mg, 434 umol). The reaction mixture was stirred at 80 °C for 12 hrs. On completion, the mixture was diluted with H_20 (20 mL), then extracted with EA (2 X 20 mL). The combined organic layers were washed with brine (2 X 20 mL), dried over anhydrous Na_2S0_4, filtered and the filtrate was concentrated *in vacuo*. The residue was purified by silica gel column (PE: EA = 1:1) to give the title compound (1.75 g, 100% yield) as yellow oil. ^{1}H NMR (400 MHz, CDCb) δ 7.89 - 7.81 (m, 2H), 7.77 - 7.67 (m, 2H), 3.96 - 3.75 (m, 3H), 3.65 - 3.48 (m, 2H), 3.42 - 3.29 (m, 1H), 3.14 (dd, *J* = 6.4, 14.4 Hz, 1H), 2.89 (s, 3H), 2.86 - 2.73 (m, 2H), 2.70 - 2.51 (m, 2H), 2.17 (t, *J* = 10.4 Hz, 1H), 1.93 - 1.90 (m, 1H), 1.45 (s, 9H).

[004712] Step 2 - Tert-butyl N-[[(2S)-4-(2-aminoethyl)morpholin-2-yl]methyl]-N-methyl-carbamate

[004713] To a solution of tert-butyl N-[[(2S)-4-[2-(1,3-dioxoisoindolin-2-yl)ethyl]morpholin-2-yl]methyl]-N- methyl-carbamate (1.00 g, 2.48 mmol) in EtOH (10 mL) was added $NH_2NH_2H_2O$ (633 mg, 12.4 mmol). The reaction mixture was stirred at 80 °C for 2 hrs. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (650 mg, 96% yield) as yellow solid. ^{1}H NMR (400MHz, CDCL) δ 3.94 - 3.81 (m, 1H), 3.76 - 3.60 (m, 2H), 3.53 - 3.30 (m, 1H), 3.24 - 3.09 (m, 1H), 2.92 (s, 3H), 2.82 - 2.78 (m, 2H), 2.75 - 2.71 (m, 1H), 2.68 - 2.65 (m, 1H), 2.43 (t, *J* = 6.0 Hz, 2H), 2.51 - 2.35 (m, 1H), 2.17 -

2.15 (, 1H), 1.88 (t, *J* = 10.4 Hz, 1H), 1.46 (s, 9H).

[004714] **Benzyl_ N-[[l-[2,6-dioxo-3-piperidvB-3-methyl-2-oxo-benzimidazol-5-ylImethyl I-N-I2-K2R)_ -2-(methylaminomethyl)morpholin-4-yl]ethyl]carbamate tlntermediate ZB)**



[004715] Step 1 - Tert-butyl N-[[(2S)-4-[2-[[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yll methylaminolethyllmorpholin-2-yllmethyll-N-methyl-carbamate

[004716] To a solution of l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazole-5-carbaldehyde (400 mg, 1.04 mmol, Intermediate SK) and tert-butyl N-[[(2S)-4-(2-aminoethyl)morpholin-2-yl]methyl]-N- methyl-carbamate (428 mg, 1.57 mmol, Intermediate ZA) in a mixed solvent of THF (5 mL) and DMF (2 mL) was added HOAc (62 mg, 1.04 mmol). The reaction mixture was stirred at 25 °C for 0.5 hr. Then, $NaBH(OAc)_3$ (266 mg, 1.25 mmol) was added. The reaction mixture was stirred at 25 °C for 12 hrs. On completion, the mixture was quenched with water (0.5 mL) and concentrated *in vacuo*. The crude product was purified by reverse phase HPLC (0.1% FA condition) to give the title compound (410 mg, 61% yield) as white solid. ^1H NMR (400MHz, DMSO-^e) δ ll.l0(s, 1H), 7.24 (s, 1H), 7.16 - 7.02 (m, 2H), 5.37 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.53 - 4.50 (m, 1H), 3.91 (s, 2H), 3.80 - 3.75 (m, 2H), 3.35 (s, 3H), 3.23 -

3.17 (m, 2H), 2.92 - 2.87 (m, 1H), 2.80 - 2.73 (m, 4H), 2.69 - 2.58 (m, 7H), 2.06 - 1.98 (m, 2H), 1.82 - 1.74 (m, 1H), 1.36 (s, 9H).


[004717] Step 2 - Tert-butyl N-rr(2S)-4-r2-rbenzyloxycarbonyl-rrl-(2.6-dioxo-3-piperidvO-3-methyl-2-oxo-_ benzimidazol-5-yl1methyl1amino1ethyl1morpholin-2-yl1methyl1-N-methyl-carbamate

[004718] To a solution of tert-butyl N-[[(2S)-4-[2-[[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol- 5-yl]methylamino]ethyl]morpholin-2-yl]methyl]-N-methyl-carbamate (100 mg, 184 umol) in THF (5 mL) was added TEA (55.7 mg, 550 umol). Then, CbzCl (47.0 mg, 275 umol) was added. The reaction mixture was stirred at 25 °C for 1 hr. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (50.0 mg, 38% yield) as white solid. ^{1}H NMR (400MHz, DMSO-^e) δ 11.09 (s, 1H), 7.49 - 7.26 (m, 5H), 7.11 - 6.90 (m, 3H), 5.36 (dd, *J* = 5.2, 12.8 Hz, 1H), 5.13 (s, 2H), 4.52 (s, 2H), 3.75 - 3.67 (m, 1H), 3.57 - 3.44 (m, 5H), 3.22 - 3.11 (m, 4H), 2.96 - 2.90 (m, 1H), 2.79 (s, 2H), 2.73 - 2.66 (m, 2H), 2.62 - 2.55 (m, 3H), 2.43 - 2.37 (m, 2H), 2.06 - 1.96 (m, 2H), 1.80 - 1.68 (m, 1H), 1.37 (s, 9H); LC-MS (ESI$^+$) *m/z* 679.2 $(M+H)^+$.

[004719] Step 3 - Benzyl N-[[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl1methvl]-N-[2-[(2R) -2-(methylaminomethvnmorpholin-4-yl1ethyl1carbamate

[004720] To a solution of tert-butyl N-[[(2S)-4-[2-[benzyloxycarbonyl-[[l-(2,6-dioxo-3-piperidyl)-3 -methyl -2- oxo-benzimidazol-5-yl]methyl]amino]ethyl]morpholin-2-yl]methyl]-N-methyl-carbamate (50.0 mg, 73.6 umol) in DCM (2 mL) was added HCl/dioxane (4 M, 1 mL). The reaction mixture was stirred at 20 °C for 1 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (45.0 mg, 99% yield) as white solid. LC-MS (ESI$^+$) *m/z* 579.2 $(M+H)^+$.

[004721] **3-[3-Methyl-2-oxo-5-[2-(4-piperidvDethvnyl1benzimidazol-l-yl]piperidine-2,6-dione [Intermediate ZD]**



YD

[004722] Step 1 - Tert-butyl 4-[2-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yllethynyl piperidine-1-carboxylate


[004723] To a solution of tert-butyl 4-ethynylpiperidine-1-carboxylate (743 mg, 3.55 mmol CAS# 287192-97-6) and 3-(5-bromo-3-methyl-2-oxo-benzimidazol-1-yl)piperidine-2,6-dione (600 mg, 1.77 mmol, Intermediate HN) in DMF (20 mL) was added $Pd(PPh_3)_2Cl_2$ (249 mg, 355 umol), CuI (67.6 mg, 355 umol), 4Å molecular sieves (80 mg) and Cs_2CO_3 (2.89 g, 8.87 mmol). The mixture was de-gassed and then heated at 80 °C for 2 hrs. On completion, the reaction mixture was concentrated *in vacuo*. The crude product was purified by reversed-phase HPLC (0.1% FA condition) to give the title compound (500 mg, 58% yield) as brown solid. ^1H NMR (400 MHz, DMSO-d6) δ 11.11 (s, 1H), 7.25 (s, 1H), 7.09 (s, , 2H), 5.37 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.70 - 3.59 (m, 2H), 3.33 - 3.33 (m, 3H), 3.19 - 3.08 (m, 2H), 2.95 - 2.80 (m, 2H), 2.75 - 2.62 (m, 2H), 2.07 - 1.98 (m, 1H), 2.00 - 1.81 (m, 2H), 1.56 - 1.45 (m, 2H), 1.40 (s, 9H); LC-MS (ESI$^+$) *m/z* 489.3 $(M+Na)^+$.

[004724] Step 2 - 3-[3-Methyl-2-oxo-5-[2-(4-piperidyl)ethynyl]benzimidazol-1-yl]piperidine-2,6-dione

[004725] To a solution of tert-butyl 4-[2-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]ethynyl] piperidine-1-carboxylate (60.0 mg, 129 umol) in DCM (5 mL) was added ZnBr2 (347 mg, 1.54 mmol, 77.2 uL). The mixture was stirred at 25 °C for 24 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (40.0 mg, 68%

yield) as yellow solid. LC-MS (ESI+) m/z 367.1 $(M+H)^+$.

[004726] **Tert-butyl (3RV3-piperazin-l-ylpyrrolidine-l-carboxylate [Intermediate** ZE]



ZE

[004727] Step 1 - Tert-butyl (3S)-3-methylsulfonyloxypyrrolidine-l-carboxylate

[004728] To a solution of tert-butyl (3S)-3-hydroxypyrrolidine-l-carboxylate (5.00 g, 26.7 mmol, CAS# 101469 -92-5) inDCM (80 mL) was added TEA (8.11 g, 80.1 mmol) and MsCl (3.98 g, 34.7 mmol) at 0 °C. The mixture was then stirred at 25 °C for 0.5 hr. On completion, the reaction mixture was washed with water (3 X 60 mL). The organic layer was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (7.00 g, 95% yield) as light yellow oil. ^1H NMR (400 MHz, CDCh) δ 5.30 - 5.23 (m, 1H), 3.70 - 3.42 (m, 4H), 3.05 (s, 3H), 2.38 - 2.08 (m, 2H), 1.47 (s, 9H).

[004729] Step 2 - Benzyl 4-r(3R)-l-tert-butoxycarbonylpyrrolidin-3-yl1piperazine-l-carboxylate


[004730] To a solution of tert-butyl (3S)-3-methylsulfonyloxypyrrolidine-l-carboxylate (3 g, 11.3 mmol) and benzyl piperazine-l-carboxylate (4.98 g, 22.61 mmol, CAS# 31166-44-6) in ACN (30 mL) was added TEA (3.43 g, 33.9 mmol) and KI (2.82 g, 16.9 mmol). The mixture was stirred as 80 °C for 40 hrs. On completion, the mixture was concentrated *in vacuo* to give a residue. The reaction mixture was diluted with water (30 mL) and extracted with EA (3 X 30 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography ($Si0_2$, PE/EA =3/1) to give the title compound (1.35 g, 30% yield) as light yellow oil. ^1H NMR (400 MHz, CDCh) δ 7.43 - 7.28 (m, 5H), 5.14 (s, 2H), 3.75 - 3.38 (m, 6H), 3.34 - 3.20 (m, 1H), 3.09 - 3.05(m, 1H), 2.86 - 2.70 (m, 1H), 2.61 - 2.31 (m, 4H), 2.12 - 2.05 (m, 1H), 1.85 - 1.75 (m, 1H), 1.46 (s, 9H).

[004731] Step 3 - Tert-butyl (3R)-3-piperazin-l-ylpyrrolidine-l-carboxylate

[004732] To a solution of benzyl 4-[(3R)-l-tert-butoxycarbonylpyrrolidin-3-yl]piperazine-l-carboxylate (1.20 g, 3.08 mmol) in MeOH (20 mL) was added Pd/C (400 mg, 10 wt%) under N_2.

The suspension was degassed under vacuum and purged with H_2 three times. The mixture was stirred at 25 °C for 16 hours under H_2 (15 psi). On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (780 mg, 96% yield) as colorless oil. ^{1}H NMR (400 MHz, CDCh) δ 3.76 - 3.48 (m, 2H), 3.30 - 3.19 (m, 1H), 3.08 (t, J = 9.2 Hz, 1H), 2.90 (t, J = 4.4 Hz, 3H), 2.83 - 2.69 (m, 1H), 2.62 - 2.34 (m, 4H), 2.13 - 2.02 (m, 1H), 1.73 - 1.67 (m, 1H), 1.45 (s, 9H).

[004733] **3-[3-Methyl-2-oxo-5-[[4-[(3RVpyrrolidin-3-yll piperazin-1-yllmethyllbenzimidazol-l- yl]piperidine-2,6-dione [Intermediate ZF)**



[004734] Step 1 - Tert-butyl (3R)-3-[4-[[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yllmethyll piperazin- 1-yllpyrrolidine- 1-carboxylate

[004735] To a mixture of tert-butyl (3R)-3-piperazin- l-ylpyrrolidine-l -carboxylate (200 mg, 783 umol, Intermediate ZE) in a mixed solvent of THF (4 mL) and DMF (0.2 mL) was added 1-(2,6-dioxo-3-piperidyl)-3 -methyl-2- oxo-benzimidazole-5-carbaldehyde (225 mg, 783 umol, Intermediate SK) and HOAc (9.41 mg, 156 umol). The mixture was stirred at 25 °C for 30 minutes. After that, NaBH(OAc) $_3$ (331 mg, 1.57 mmol) was added. The mixture was stirred 25 °C for 72 hours. On completion, the reaction mixture was quenched by water (10 mL), and then extracted with EA (3 X 15 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (column:

Phenomenex Synergi Max-RP 150*50 mm*l0 um; mobile phase: [water (0.225% FA)-ACN]) to give the title compound (290 mg, 70% yield) as white solid. ^{1}H NMR (400 MHz, DMSO-r#,) δ 11.08 (s, 1H), 7.11 - 6.91 (m, 3H), 5.35 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.48 (s, 2H), 3.45 (s, 1H), 3.42 - 3.34 (m, 1H), 3.33 (s, 3H), 3.21 - 3.10 (m, 1H), 2.98 - 2.84 (m, 2H), 2.75 - 2.59 (m, 3H), 2.45 - 2.3 (m, 8H), 2.06 - 1.93 (m, 2H), 1.71 - 1.51 (m, 1H), 1.38 (s, 9H); LC-MS (ESI^{+}) *m/z* 527.2 (M+H)$^{+}$.

[004736] Step 2 - 3-[3-Methyl-2-oxo-5-[[4-[(3R)-pyrrolidin-3-yl1piperazin-l-yllmethvnbenzimidazol-l- yl]piperi dine-2.6-di one

[004737] To a solution of tert-butyl (3R)-3-[4-[[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] methyl]piperazin-l-yl]pyrrolidine-l-carboxylate (120 mg, 227 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 2.28 mL). The mixture was stirred at 25 °C for 1 hr. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (105 mg, 99% yield, HC1) as white solid. LC-MS (ESI^{+}) *m/z* 427.5 (M+H)$^{+}$.


[004738] **Tert - butyl methyl(3-oxopropyPcarbamate (Intermediate ZG)**



ZG

[004739] To a solution of tert-butyl N-(3-hydroxypropyl)-N-methyl-carbamate (1.00 g, 5.28 mmol, CAS# 98642-44-5) in DCM (20 mL) was added DMP (3.36 g, 7.93 mmol) at 20 °C. Then the reaction mixture was stirred at 20 °C for 2 hours. On completion, the reaction mixture was diluted with petroleum ether (10 mL) and stirred for 10 minutes, filtered and concentrated *in vacuo.* The residue was purified by flash silica gel chromatography to give the title compound (750 mg, 50% yield) as colorless oil. ^{1}HNMR (400 MHz, CDCh) δ 9.78 (s, 1H), 3.53 - 3.47 (m, 2H), 2.85 (s, 3H), 2.66 - 2.62 (m, 2H), l.43(s, 9H).

[004740] **3-f3-Methyl-2-oxo-4-fpiperidin-4-vn-2,3-dihvdro-lH-benzo[d]imidazol-l-vPpiperidine-2.,6-dione hydrochloride (Intermediate ZH)**



[004741] Step 1 - Tert - butyl4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2.3-dihydro-lH-benzordlimidazol -4- yl)-5,6-dihvdropyridine-1(2H)-carboxylate

[004742] A mixture of 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (1.00 g, 2.96 mmol, Intermediate HP), tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-l-carboxylate (1.19 g, 3.84 mmol, CAS# 286961-14-6), XPhos-Pd-G3 (376 mg, 0.444 mmol), K3PO4 (1.88 g, 8.87 mmol) in dioxane (20 mL) and water (2 mL) was degassed and purged with N_2 three times. The mixture was stirred at 60 °C for 3 hours under N_2 atmosphere. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was purified by reverse phase (0.1% FA condition) to give the title compound (1.00 g, 75% yield) as white solid. ^{1}H NMR (400 MHz, DMSO^) δ 11.09 (s, 1H), 7.10 - 6.95 (m, 2H), 6.82 (d, *J* = 7.2 Hz, 1H), 5.40 - 5.35 (m, 1H), 3.99 (s, 3H), 3.67 - 3.50 (m, 3H), 2.95 - 2.83 (m ,IH), 2.80 - 2.55 (m, 3H), 2.43 - 2.30 (m ,3H), 2.05 - 1.95 (m, 1H), 1.44 (s, 9H); LC-MS (ESI$^+$) m/z 441.0 $(M+H)^+$.


[004743] Step 2 - Tert - butyl 4-(1-(2.6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2.3-dihydro-lH-benzordlimidazol- 4-vDpiperidine-l-carboxylate

[004744] To a solution of tert - butyl 4-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]-3,6- dihydro-2H-pyridine-l-carboxylate (900 mg, 2.04 mmol) in THF (270 mL)was added Pd/C (180 mg, 10 wt%) under N_2 atmosphere. The suspension was degassed and purged with H_2 three times. The mixture was stirred at 30 °C for 48 hours under H_2 (50 Psi.). On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (900 mg, 92% yield) as white solid. LC-MS (ESI$^+$) m/z 387.2 $(M+H-56)^+$.

[004745] Step 3 - 3-(3-Methyl-2-oxo-4-(piperidin-4-yl)-2.3-dihydro- lH-benzordlimidazol-1-yl)piperidine-2.6-dione hydrochloride

[004746] To a solution of tert-butyl 4-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]piperidine-l-carboxylate (1.00 g, 2.26 mmol) in DCM (10 mL) was added HCl/dioxane (4mol/L, 5 mL). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (900 mg, 88% yield) as white solid. LC-MS (ESI^+) m/z 343.2 $(M+H)^+$.

[004747] **3-(3-Methyl-4-n-(3-(methylamino)propyDpiperidin-4-vD-2-oxo-2.,3-dihvdr()-lH-benzo[dlimidazol-l-vDpiperidine-2.,6-dione hydrochloride [Intermediate ZD**




[004748] Step 1- Tert - butyl (3-(4-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2.3-dihvdro-lH-benzordlimidazoM-vOpiperidin-l-vOpropyOrinethvQcarbamate

[004749] To a solution of 3-[3-methyl-2-oxo-4-(4-piperidyl)benzimidazol-l-yl]piperidine-2,6-dione (350 mg, 0.924 mmol, Intermediate ZH) in THF (5 mL) and DMF (1 mL) was added Et_3N (140 mg, 1.39 mmol). Then the reaction mixture was stirred at 20 °C for 0.5 hour. Then HOAc (83.2 mg, 1.39 mmol) and tert-butyl N-methyl-N-(3-oxopropyl)carbamate (580 mg, 2.04 mmol, Intermediate ZG) were added to the above mixture. The reaction mixture was stirred at 20°C for 0.5 hour. $NaBH(OAc)_3$ (392 mg, 1.85 mmol) was added to the reaction mixture and stirred at 20 °C for 16 hours. On completion, the reaction mixture was quenched with water (0.5 mL) and concentrated *in vacuo.* The residue was purified by reverse phase (0.1 % FA condition) to give the title compound (450 mg, 83% yield) as off-white solid. LC-MS (ESI^+) m/z 514.4 $(M+H)^+$.

[004750] Step 2 - 3-(3-Methyl-4-(1-(3-(methylamino)propyl)piperidin-4-yl)-2-oxo-2.3-dihydro-1H-benzordlimidazol-1-yl)piperidine-2.6-dione hydrochloride

[004751] To a solution of tert-butyl N-[3-[4-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]-l- piperidyl]propyl]-N-methyl-carbamate (450 mg, 0.876 mmol) in DCM (5 mL) was added HC1/EA (4 mol/L, 2 mL), the the reaction mixture was stirred at 20 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (390 mg, 99% yield) as a white solid. LC-MS (ESI^+) m/z 414.3 $(M+H)^+$.

[004752] **3-(3-Methyl-4-(3-((R)-2-(2-(methylamino)ethyl)morpholino)propyl)-2-oxo-2,3-dihydro-lH-benzo[d1imidazol-l-yl)piperidine-2,6-dione hydrobromide [Intermediate ZIP**



[004753] Step 1 - Benzyl (2-((2R)-4-(3-(1-(2.6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2.3-dihydro-lH-benzor d1imidazol-4-vnprop-2-yn- 1-yl)morpholin-2-vl)ethyl)(methvl)carbamate

[004754] A mixture of benzyl N-methyl-N-[2-[(2R)-4-prop-2-ynylmorpholin-2-

yl]ethyl]carbamate (700 mg, 2.07 mmol, Intermediate TV), 3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l-yl)piperidine-2,6-dione (982 mg, 3.11 mmol, Intermediate HP), $Pd(PPh_3)_2Cl_2$ (145 mg, 0.207 mmol), Cul (39.4 mg, 0.207 mmol) and CS_2CO_3 (1.35 g, 4.14 mmol) in DMF (10 mL) was degassed and purged with N_2 three times. Then the mixture was stirred at 80 °C for 2 hours under N_2 atmosphere. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was purified by reverse phase (0.1% of FA condition) to give the title compound (1.10 g, 73%yield) as a yellow solid. ^1H NMR (400 MHz, CDCb) δ11.11 (s, 1H), 7.40 - 7.30 (s, 5H), 7.13 (dd, 7 = 16.0 Hz, *J* = 7.6 Hz, 2H), 7.06 - 6.95 (m, 1H), 5.47 - 5.32 (m, 1H), 5.05 (s, 2H), 3.90 - 3.75 (m, 1H), 3.63 (s, 3H), 3.56 (s, 3H), 3.27 - 3.15 (m, 2H), 2.90 - 2.80 (m, 5H), 2.75 - 2.55 (m, 4H), 2.35 - 2.25 (m, 1H), 2.10 - 1.95 (m, 2H), 1.76 - 1.72 (m, 1H), 1.65-1.55 (m, 2H); LC-MS (ESI^+) m/z 574.1 $(M+H)^+$.


[004755] Step 2 - Benzyl (2-((2R)-4-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-benzordl imidazol-4-yl)propyl)morpholin-2-yl)ethyl)fmethyl)carbamate

[004756] To a solution of benzyl N-[2-[(2R)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]prop-2-ynyl]morpholin-2-yl]ethyl]-N-methyl-carbamate (1.00 g, 1.74 mmol) in THF (200 mL) was added Pd/C (200 mg, 5 wt%) and Pd(OH)2/C (200 mg, 10 wt%) under N_2 atmosphere. The suspension was degassed and purged with ¾ three times. The mixture was stirred at 20 °C for 48 hours under ¾ (15 psi). On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (1.00 g, 99% yield) as yellow-white solid. LC-MS (ESI^+) m/z 578.2 $(M+H)^+$.

[004757] Step 3 - 3-(3-Methyl-4-(3-((R)-2-(2-(methylamino)ethvnmorpholino)propyn-2-oxo-2.3-dihvdro-lH-benzord1imidazol-l-vDpiperidine-2.6-dione hydrobromide

[004758] To a solution of benzyl N-[2-[(2R)-4-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propyl]morpholin-2-yl]ethyl]-N-methyl-carbamate (1.00 g, 1.73 mmol) in DCM (10 mL) was added HBr/HOAc (4 mL, 40% solution). The mixture was stirred at 20 °C for 3 hours. On completion, the reaction mixture was concentrated *in vacuo.* Then the residue was purified by reverse phase (0.1% of FA condition) to give the title compound (700 mg, 64% yield) as off-white solid. LC-MS (ESI^+) m/z 444.4 $(M+H)^+$.

[004759] 3-[3-Methyl-2-oxo-5-[3-(4-piperidyloxy)propyllbenzimidazol-l-yllpiperidine-2,6-dione [Intermediate ZM)



[004760] Step 1 - Tert-butyl 4-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]prop-2-ynoxy] piperidine-1-carboxylate

[004761] To a mixture of 3-(5-bromo-3-methyl-2-oxo-benzimidazol-1-yl)piperidine-2,6-dione (350 mg, 1.04 mmol, Intermediate HN) and tert-butyl 4-prop-2-ynoxypiperidine-1-carboxylate (371 mg, 1.55 mmol, Intermediate TM) in DMF (20 mL) was added $Pd(PPh_3)_2Cl_2$ (72.6 mg, 103 umol), CuI (39.4 mg, 207 umol), CS2CO3 (1.35 g, 4.14 mmol) and 4A molecular sieves (200 mg, 1.04 mmol) in one portion at 25 °C under N_2. The reaction mixture was stirred at 80 °C for 2 hours. On completion, the reaction mixture was quenched by addition water (0.5 mL) at 25 °C, and then extracted with EA (3 X 20 mL). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (FA condition) to give the title compound (300 mg, 58% yield) as a yellow solid. ^1H NMR (400 MHz, CDCb) δ 8.14 (s, 1H), 7.23 - 7.17 (m, 1H), 7.12 (d, J = 1.2 Hz, 1H), 6.75 *(d, J* = 8.1 Hz, 1H), 5.24 - 5.17 (m, 1H), 4.43 (s, 2H), 3.85 - 3.72 (m, 3H), 3.43 (s, 3H), 3.18 - 3.09 (m, 2H), 3.01 - 2.92 (m, 1H), 2.90 - 2.67 (m, 2H), 2.30 - 2.20 (m, 1H), 1.94 - 1.86 (m, 2H), 1.64 - 1.57 (m, 2H), 1.47 (s, 9H); LC-MS (ESI^+) m/z 519.3 $(M+Na)^+$.

[004762] Step 2 - Tert-butyl 4-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-vnpropoxylpiperidine-1-carboxylate


[004763] To a solution of tert-butyl 4-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]prop-2-ynoxy] piperidine-1-carboxylate (300 mg, 604 umol) in THF (4 mL)

was added Pd/C (50 mg, 10 wt%) and $Pd(OH)_2/C$ (50 mg, 10 wt%) under N_2. The suspension was degassed under vacuum and purged with H_2 three times. The mixture was stirred at 25 °C for 2 hours under H_2 (15 psi). On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (FA condition) to give the title compound (300 mg, 84% yield) as a yellow solid. ^1H NMR (400 MHz, CDCh) δ 8.24 (s, 1H), 6.95 - 6.85 (m, 2H), 6.73 (d, *J* = 8.2 Hz, 1H), 5.26 - 5.18 (m, 1H), 3.81 - 3.73 (m, 2H), 3.49 - 3.42 (m, 6H), 3.15 - 3.05 (m, 2H), 2.99 - 2.82 (m, 2H), 2.75 (t, *J* = 7.6 Hz, 3H), 2.28 - 2.19 (m, 1H), 1.95 - 1.77 (m, 4H), 1.53 (d, *J* = 8.8 Hz, 2H), 1.47 (s, 9H); LC-MS (ESI^+) m/z 401.0 $(M+H-100)^+$.

[004764] Step 3 - 3-r3-Methyl-2-oxo-5-r3-(4-piperidyloxy)propyl1benzimidazol-l-yl1piperidine-2.6-dione

[004765] To a mixture of tert-butyl 4-[3-[l-(2, 6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]propoxy] piperidine- l-carboxylate (270 mg, 539 umol) in DCM (4 mL) was added TFA (1.84 g, 16.2 mmol) at 25 °C. The mixture was stirred at 25 °C for 2 hours. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (TFA condition) to give the title compound (162 mg, 58% yield, TFA salt) as a yellow solid. LC-MS (ESI+) m/z 401.0 $(M+H)^+$.

[004766] 3-[4-[3-(Azetidin-3-yloxy)propyll-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2.,6-dione [Intermediate ZN)



[004767] Step 1 - Tert-butyl 3-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-

4-yl1prop-2-ynoxy1 azetidine- 1-carboxylate

[004768] To a mixture of tert-butyl 3-prop-2-ynoxyazetidine-l -carboxylate (499 mg, 2.37 mmol, Intermediate YV) and 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (400 mg, 1.18 mmol, Intermediate HP) in DMF (3 mL) was added Cul (22.5 mg, 118 umol), CS_2CO_3 (1.93 g, 5.91 mmol), $Pd(PPh3)_2Cl2$ (83.0 mg, 118 umol) and 4Å molecular sieves (100 mg). The reaction mixture was stirred at 80 °C for 4 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo*. The residue was purified by reverse phase (0.1 % FA condition) to give the title compound (400 mg, 72% yield) as brown solid. ^1H NMR (400 MHz, DMSO-di) δ 11.11 (s, 1H), 7.21 - 7.16 (m, 1H), 7.14 - 7.11 (m, 1H), 7.06 - 7.01 (m, 1H), 5.42 - 5.37 (m, 1H), 4.49 - 4.45 (m, 3H), 4.09 - 4.04 (m, 2H), 3.77 - 3.72 (m, 2H), 3.63 (s, 3H), 2.92 - 2.84 (m, 1H), 2.73 - 2.62 (m, 2H), 2.07 - 2.00 (m, 1H), 1.37 (s, 9H).


[004769] Step 2 - Tert-butyl 3-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl -2-oxo-benzi midazol-4-ν1]ρΓορoχν] azetidine- 1-carboxylate

[004770] To a mixture of tert-butyl 3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] prop-2-ynoxy]azetidine-l -carboxylate (400 mg, 853 umol) in THF (10 mL) was added Pd/C (150 mg, 10 wt%) and Pd(OH)2/C (150 mg, 10 wt%). The reaction mixture was stirred at 25 °C for 12 hours under ¾ (15 Psi). On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (300 mg, 74% yield) as light yellow solid. LC-MS (ESI^+) *m/z* 417.2 $(M+H-56)^+$.

[004771] Step 3 - 3-r4-r3-(Azetidin-3-yloxy)propyl1-3-methyl-2-oxo-benzimidazol-l-yl1piperidine-2.6-dione

[004772] To a mixture of tert-butyl 3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]propoxy] azetidine-l-carboxylate (290 mg, 613.71 umol) in DCM (3 mL) was added TFA (44.6 g, 391 mmol, 29.0 mL). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (298 mg, 99% yield, TFA salt) as red oil. LC-MS (ESI^+) *m/z* 373.2 $(M+H)^+$.

[004773] 3-[4-[3-[4-Piperidyloxy)propyl]pyrido [2,3-bl indol-9-yl] piperidine-2,6-dione [Intermediate ZO)



[004774] Step 1 - Tert-butyl 4-r3-r9-(˙2.6-dioxo-3-piperidyl ¨)pyridor2.3-b1indol-4-yl1prop-2-vnoxylpiperidine -l-carboxylate

[004775] To a solution 3-(4-bromopyrido[2,3-b]indol-9-yl)piperidine-2,6-dione (400 mg, 1.12 mmol, Intermediate XY) and tert-butyl 4-prop-2-ynoxypiperi dine- l-carboxylate (534 mg, 2.23 mmol, Intermediate TM) in DMF (8 mL) was added $Pd(PPh_3)_2Cl_2$ (157 mg, 223 umol), CuI (42.5 mg, 223 umol), CS2CO3 (1.82 g, 5.58 mmol) and 4Å molecular sieves (40 mg). The mixture was de-gassed and then heated at 80 °C for 2 hrs. On completion, the reaction mixture was concentrated *in vacuo.* The crude product was purified by reverse phase HPLC (0.1% FA condition) to give the title compound (200 mg, 34% yield) as brown solid. ^1H NMR (400 MHz, DMSO-di) δ 11.15 (s, 1H), 8.49 (d, 7 = 7.6 Hz, 1H), 8.42 (d, *J* = 5.2 Hz, 1H), 7.72 - 7.64 (m, 1H), 7.62 - 7.56 (m, 1H), 7.36 - 7.33 (m, 1H), 7.32 - 7.29 (m, 1H), 6.06 (s, 1H), 4.71 (s, 2H), 3.88 - 3.84 (m, 1H), 3.70 - 3.65 (m, 2H), 3.10 - 3.05 (m, 2H), 3.05 - 2.95 (m, 1H), 2.77 - 2.68 (m, 1H), 2.61 (s, 1H), 2.20 - 2.11 (m, 1H), 1.96 - 1.88 (m, 2H), 1.52 - 1.44 (m, 2H), 1.39 (s, 9H); LC-MS (ESI^+) *m/z* 539.3 $(M+Na)^+$.

[004776] Step 2 - Tert-butyl 4-[3-[9-(2,6-dioxo-3-piperidyl)pyrido[2,3-b]indol-4-yllpropoxylpiperidine-l - carboxylate


[004777] To a solution of tert-butyl 4-[3-[9-(2,6-dioxo-3-piperidyl)pyrido[2,3-b]indol-4-yl]prop-2-ynoxy] piperidine- l-carboxylate (200 mg, 387 umol in THF (5 mL) was added $Pd(OH)_2$ (40.0 mg, l0 wt%), Pd/C (40.0 mg, 10 wt%) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred at 25 °C for 15 hours under H_2 (15 psi). On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (120 mg, 59% yield) as white solid. ^1H NMR (400 MHz, DMSO-di) δ 11.13 (s, 1H), 8.31 (d, *J* = 5.2 Hz, 1H), 8.24 (d, 7 = 7.6 Hz, 1H), 7.67 - 7.58 (m, 1H), 7.55 - 7.47 (m, 1H), 7.28 (t, *J* = 7.6 Hz, 1H), 7.10 (d, 7 = 5.2 Hz, 1H), 6.18 - 5.92 (m, 1H), 3.67 - 3.47 (m, 6H), 3.29 (s, 1H), 3.28 - 3.21 (m, 2H), 3.17 - 2.93 (m, 4H), 2.15 - 2.07 (m, 1H), 2.03 - 1.93 (m, 2H), 1.86 - 1.76 (m, 2H), 1.39 (s, 9H), 1.35 (s, 1H); LC-MS (ESI^+) m/z 521.3 $(M+Na)^+$.

[004778] St

ep 3 - 3-r4-r3-(4-Piperidyloxy)propyl1pyridor2.3-b1indol-9-yl1piperidine-2.6-dione

[004779] To a mixture of tert-butyl 4-[3-[9-(2, 6-dioxo-3-piperidyl)pyrido[2,3-b]indol-4-yl] propoxy]piperidine -l-carboxylate (100 mg, 192 umol) in DCM (2 mL) was added HCl/dioxane (2 mL). The reaction mixture was stirred at 25 °C for 2 hrs. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (80.0 mg, 91% yield) as brown solid. LC-MS (ESI+) m/z 421.3 $(M+H)^+$.

[004780] 3-[3-Methyl-4-[3-[2-(methylamino)ethoxylpropyll-2-oxo-benzimidazol-l-yl]piperidine-2.,6-dione [Intermediate ZP)



[004781] Step 1 - Tert-butyl N-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl1prop-2- ynoxylethyll-N-methyl-carbamate

[004782] 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (400 mg, 1.18 mmol, Intermediate HP), tert-butyl N-methyl-N-(2-prop-2-ynoxyethyl)carbamate (440 mg, 2.06 mmol, Intermediate GK), Pd(PPh $_3$)2Cl2 (166 mg, 237 umol), Cul (45.1 mg, 237 umol), 4A molecular sieves (400 mg) and CS2CO3 (1.54 g, 4.73 mmol) in DMF (5 mL) was de-gassed and then heated at 80 °C for 2 hours under N2. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was purified by reversed-phase (0.1% FA condition) to give the title compound (310 mg, 39% yield) as a yellow solid. LC-MS (ESI$^+$) *m/z* 415.1 (M+H-56) $^+$.

[004783] Step 2 - Tert-butyl N-[2-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yllpropoxyl ethyll-N-methyl-carbamate


[004784] To a solution of tert-butyl N-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]prop- 2-ynoxy]ethyl]-Nmethyl-carbamate (390 mg, 829 umol) in THF (10 mL) was added Pd/C (0.1 g, 10% wt) and Pd(OH)2/C (0.1 g, 20% wt). The suspension was degassed under vacuum and purged with ¾ several times. The reaction mixture was stirred at 25 °C for 12 hours under ¾ (15 psi). On completion, the mixture was filtered and the filtrate was concentrated

in vacuo to give the title compound (390 mg, 99% yield) as a yellow solid. ^{1}H NMR (400 MHz, DMSO-di) δ 8.25 (s, 1H), 7.12 - 6.96 (m, 1H), 6.95 - 6.86 (m, 1H), 6.72 - 6.60 (m, 1H), 5.30 - 5.15 (m, 1H), 3.48 (s, 3H), 3.65 - 3.58 (m, 2H), 3.52 - 3.45 (m, 2H), 3.45 - 3.35 (m, 2H), 3.08 - 2.95 (m, 3H), 2.92 (s, 3H), 2.85 - 2.60 (m, 2H), 2.25 - 2.15 (m, 1H), 1.96 - 1.85 (m, 2H), 1.50 (s, 1H); LC-MS (ESI$^+$) *m/z* 375.1 (M+H-l00) $^+$.

[004785] Step 3 - 3 -r3-Methyl-4-r3-r2-(methylamino)ethoxy1propyl1-2-oxo-benzimidazol-l-vHpiperidine-2.6- dione

[004786] To a solution of tert-butyl N-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propoxy]ethyl]-N-m ethyl-carbamate (100 mg, 2 11 umol) in DCM (2 mL) was added HCl/dioxane (2 mL). The reaction mixture was stirred at 20 °C for 2 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (85.0 mg, 98% yield, HC1 salt) as a yellow solid. LC-MS (ESI$^+$) *m/z* 375.1 (M+H)$^+$.


[004787] **3-[3-Methyl-5-[3-[3-(methylamino)propoxy|prop-l-ynyll-2-oxo-benzimidazol-l-yl] piperidine-2,6-dione [Intermediate ZQ)**



ZQ

[004788] To a solution of tert-butyl N-[3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol -5-yl]prop-2-ynoxy]propyl]-N-methyl-carbamate (200 mg, 412 umol, synthesized via Step 1 of Intermediate QI) in DCM (3.00 mL) was added $ZnBr_2$ (1.39 g, 6.19 mmol). The mixture was stirred at 20 °C for 20 hrs. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (158 mg, 99% yield) as yellow solid. LC-MS (ESI$^+$) *m/z* 385.2 (M+H)$^+$.

[004789] **3-[3-Methyl-5-[[4-(methylaminomethyB-l-piperidyll methyl]-2-oxo-benzimidazol-l-yl] piperidine-2,6-dione [Intermediate ZR)**



ZR

[004790] Step 1 - Tert-butyl N-[[1-[[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl1methvn-4- piperidyllmethyll-N-methylcarbamate


[004791] To a solution of tert-butyl N-methyl-N-(4-piperidylmethyl)carbamate (119 mg, 522 umol, CAS# 138022-04-5) and l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazole-5-carbaldehyde (150 mg, 522 umol, Intermediate SK) in a mixed solvents of DMF (1.2 mL) and THF (2.4 mL) was added HOAc until the pH = 5~ 6. After the reaction mixture was stirred at 10 °C for 1 hr, then $NaBH(OAc)_3$ (221 mg, 1.04 mmol) was added. Then the reaction mixture was stirred at 10 °C for 48 hrs. On completion, the reaction mixture was quenched by H_20 (0.5 mL), filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0. 1% FA condition) to give the title compound (230 mg, 88% yield) as a white solid. ¾NMR (400 MHz, CDCh) δ 8.53 (s, 1H), 7.21 (d, *J* = 16.0 Hz, 1H), 7.01 *(J* = 8.0 Hz, 1H), 6.76 (d, *j* = 8.0 Hz, 1H), 5.24 (dd, *j* = 5.2, 12.8 Hz, 1H), 4.06 - 3.80 (m, 2H), 3.43 (s, 3H), 3.24 (d, *j* = 8.0 Hz, 2H), 3.13 (s, 2H), 2.98 - 2.87 (m, 1H), 2.87 (s, 3H), 2.79 *(d, J* = 4.8 Hz, 1H), 2.77 - 2.63 (m, 1H), 2.57 - 2.39 (m, 1H), 2.37 - 2.16 (m, 2H), 1.91 - 1.78 (m, 1H), 1.78 - 1.60 (m, 2H), 1.60 - 1.48 (m, 1H), 1.44 (s, 9H); LC-MS (ESI^+) m/z 500.4 $(M+H)^+$.

[004792] Step 2 - 3-r3-Methyl-5-rr4-(methylaminomethvn-l-piperidyl1methyl1-2-oxo-benzimidazol-l-yl] piperidine-2.6-dione

[004793] To a solution of tert-butyl N-[[l-[[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] methyl]-4-piperidyl]methyl]-N-methyl-carbamate (230 mg, 460 umol) in DCM (3 mL) was added HCl/dioxane (4 M, 3 mL). The reaction mixture was stirred at 20 °C for

2 hrs. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (200 mg, 99% yield, HC1) as a white solid. LC-MS (ESI^+) m/z 400.3 $(M+H)^+$.

[004794] **3-[3-Methyl-5-[3-[2-(methylamino)ethoxylpropyll-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione [Intermediate ZS)**



ZS

[004795] Step 1 - Tert-butyl N-[2-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yllprop- 2-ynoxylethyll-N-methyl-carbamate

[004796] To a solution tert-butyl N-methyl-N-(2 -prop-2 -ynoxyethyl)carbamate (946 mg, 4.44 mmol, Intermediate GK) and 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (600 mg, 1.77 mmol, Intermediate HN) in DMF (10 mL) was added $Pd(PPh3)_2Cl2$ (249 mg, 355 umol), Cul (67.6 mg, 355 umol), 4Å molecular sieves (80.0 mg, 305 umol) and CS_2CO_3 (2.89 g, 8.87 mmol). The reaction mixture was stirred at 80 °C for 4 hrs. On completion, the reaction mixture was concentrated *in vacuo.* The crude product was purified by reverse phase HPLC (0. 1% FA condition) to give the title compound (540 mg, 52% yield) as yellow solid. ^1H NMR (400 MHz, DMSO-di) δ 11.10 (s, 1H), 7.31 (s, 1H), 7.18 - 7.12 (m, 2H), 5.38 (dd, *J* = 5.6, 12.4 Hz, 1H), 4.39 (s, 2H), 3.62 (t, *j* = 5.6 Hz, 2H), 3.38 - 3.36 (m, 2H), 3.34 (s, 3H), 2.82 (s, 3H), 2.77 - 2.70 (m, 1H), 2.65 - 2.58 (m, 2H), 2.08 - 2.00 (m, 1H), 1.39 (s, 9H); LC-MS (ESI^+) m/z 493.3 $(M+Na)^+$.


[004797] Step 2 - Tert-butyl N-[2-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-vnpropoxyl ethyll-N-methyl-carbamate

[004798] To a solution of tert-butyl N-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] prop-2-ynoxy]ethyl]-N-methyl-carbamate (530 mg, 1.13 mmol) in THF (5 mL) was added Pd/C (40.0 mg, 10 wt%), $Pd(OH)_2$ (40.0 mg, 10 wt%) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred at 25 °C for 15 hours under H_2 (15 psi). On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (450 mg, 84% yield) as yellow oil. ^1H NMR (400 MHz, DMSO^) δ 11.07 (s, 1H), 7.04 - 6.97 (m, 2H), 6.85 *(d, J* = 8.0 Hz, 1H), 5.33 (dd, *J* = 4.8, 12.4 Hz, 1H), 3.48 - 3.43 (m, 2H), 3.38 - 3.30 (m, 3H), 2.82 (s, 3H), 2.72 - 2.61 (m, 4H), 2.33 (s, 1H), 2.07 (s, 4H), 2.04 - 1.96 (m, 1H), 1.86 - 1.74 (m, 2H), 1.38 (s, 9H); LC-MS (ESI+) m/z 497.3 $(M+Na)^+$.

[004799] Step 3 - 3-r3-Methyl-5-r3-r2-(methylamino)ethoxy1propyl1-2-oxo-benzimidazol-l-yl1piperidine-2.6-dione

[004800] To a solution of tert-butyl N-[2-[3-[l-(2, 6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] propoxy]ethyl]-N-methyl-carbamate (430 mg, 906 umol) in DCM (2 mL) was added HCl/dioxane (2 mL). The mixture was stirred at 25 °C for 2 hrs. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (330 mg, 78% yield) as white solid. LC-MS (ESI+) m/z 375.2 $(M+H)^+$.

[004801] Tert-butyl N-methyl-N-(3-vinyloxynronyl)carbainate [Intermediate ZT)




ZT


[004802] To a mixture of tert-butyl N-(3-hydroxypropyl)-N-methyl-carbamate (5.00 g, 26.4 mmol, CAS# 98642-44-5) and vinyl acetate (3.41 g, 39.6 mmol, CAS# 108-05-4) in toluene (20 mL) was added chloroiridium (lZ,5Z)-cycloocta-l, 5-diene (177 mg, 264 umol, CAS# 12112-67-3) and Na_2C0_3 (1.68 g, 15.8 mmol) at 25 °C under N_2 in glove box. The mixture was stirred at 100 °C for 2 hours. On completion, the reaction mixture was quenched with water (20 mL), filtered and the filtrate was extracted with EA (2 X 25 mL). The combined organic layers were washed

with brine (10 mL), dried over Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate= 30/1) to afford the title compound (2.40 g, 42% yield) as a yellow oil. ¾NMR (400 MHz, CDCh) δ 6.51 - 6.42 (m, 1H), 4.21 - 4.13 (m, 1H), 4.02 - 3.96 (m, 1H), 3.69 (t, *J* = 6.2 Hz, 2H), 3.32 (s, 2H), 2.86 (s, 3H), 1.94 - 1.80 (m, 2H), 1.46 (s, 9H).

[004803] **3-[3-Methyl-5-[2-[3-(methylamino)propoxy1ethyl1-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione [Intermediate ZIP)**



HN



zu

[004804] Step 1 - Tert-butyl N-[3-[2-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yllethoxyl propyll-N-methyl-carbamate

[004805] To a solution of tert-butyl N-methyl-N-(3-vinyloxypropyl)carbamate (900 mg, 4.18 mmol, Intermediate ZT) in THF (10 mL) was added 9-BBN (0.5 M, 8.36 mL). The mixture was stirred at 25 °C for 2 hours. Then a solution of 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (471 mg, 1.39 mmol, Intermediate HN), K_3PO_4 (739 mg, 3.48 mmol) and ditert-butyl(cyclopentyl)phosphane; dichloro palladium; iron (90.8 mg, 139 umol) in DMF (15 mL) and H_20 (3 mL) was added to the above mixture. The reaction mixture was stirred at 75 °C for 20 minutes under N_2. On completion, the reaction mixture was diluted with EA (100 mL), poured into water (50 mL) and extracted with EA (2 X 50 mL). The combined organic layers were dried with Na_2SO_4, filtrated and concentrated *in vacuo.* The residue was purified by reverse phase (0.1% FA) to give the title compound (300 mg, 45% yield) as a light yellow solid. LC-MS (ESI^+) m/z 375.3 $(M+H-l00)^+$.


[004806] Step 2 - 3-r3-Methyl-5-r2-r3-(methylamino)propoxy1ethyl1-2-oxo-benzimidazol-

1-yl1piperidine-2.6-dione

[004807] To a solution of tert-butyl N-[3-[2-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] ethoxy]propyl]-N-methyl -carbamate (200 mg, 421 umol) in DCM (2 mL) was added TFA (30.8 g, 270 mmol, 20 mL). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (200 mg, 91% yield, 94% purity, TFA) as yellow oil. LC-MS (ESI^+) m/z 375.3 $(M+H)^+$.

[004808] **METHODS:**

[004809] **Example 1 [Method 1): 6-[[l,6-naphthyridin-2-vDamino)-4-(cvclopropylamino)-N-((1R,4R)-4-((1-((2-(2,6-dioxopiperidin-3-vl)-l,3-dioxoisoindolin-4-yl)oxy)-2-oxo-9,12,15-trioxa-3-azaicosan-20-vl)carbamovl)cvclohexyl)nicotinamide, 1-1**



B C D

[004810] Step 1 - *tert*-butyl (1-((1R,4R)-4-(6-((1,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)-nicotinamido)-cyclohexy0-l-oxo-8.ll.l4-trioxa-2-azanonadecan-l9-vOcarbamate

[004811] To a stirred suspension of (lR,4R)-4-(6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinamido)cyclohexane-l -carboxylic acid (0.2 g, 0.5 mmol, Intermediate C) and *tert*-butyl (5-(2-(2-((5-aminopentyl)oxy)ethoxy)ethoxy)pentyl)carbamate (0.25 g, 0.67 mmol, Intermediate B) in DMF (2 mL) was added DIPEA (0.4 mL, 2.2 mmol) and PyBOP (0.35 g, 0.67 mmol) at rt. The resulting reaction mixture was stirred at rt for 1 h. The reaction mixture was transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The

filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (10% MeOH-DCM) to give *tert*-butyl (l-((lr,4r)-4-(6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinamido)cyclohexyl)- 1-oxo-8, 11,1 4-trioxa-2-azanonadecan-l9-yl)carbamate as a brown solid (0.18 g, 50%). LC-MS (ESI$^+$) *m/z* 804.1 (M-H)-

[004812] Step 2 - 6-((l.6-naDhthyridin-2-vnamino)-N-((lR.4RV4-((5-(2-(2-((5-aminopentvDoxy)ethoxy)-ethoxy)-pentvDcarbamovDcvclohexyD-4-(cvclopropylamino)nicotinamide hydrochloride

[004813] To a stirred solution of te/V-butyl (l-((lr,4r)-4-(6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinamido)cyclohexyl)- 1-oxo-8, 11,1 4-trioxa-2-azanonadecan- 19-yl)-carbamate (0.18 g, 0.22 mmol) in 1,4 dioxane (3 mL) was added 4N HC1 in dioxane (1 mL) at 0 °C. The resulting reaction mixture was warmed to rt and stirred for 2 h. The reaction mixture was evaporated under vacuum and triturated using diethyl ether to give 6-((l,6-naphthyridin-2-yl)amino)-N-((lr,4r)-4-((5-(2-(2-((5-aminopentyl)oxy)ethoxy)ethoxy)pentyl)carbamoyl)-cyclohexyl)-4-(cyclopropylamino)nicotinamide hydrochloride as yellow solid (0.16 g, 96%). LCMS (ESI$^+$) *m/z* 706.6 (M+H)$^+$.

[004814] Step 3 - 6-((E6-naphthyridin-2-vl)amino)-4-(cvclopropylamino)-N-((1R,4R)-4-((l-((2-(2.6-dioxopiperidin-3-vD-l.3-dioxoisoindolin-4-yl)oxy)-2-oxo-9.l2.l5-trioxa-3-azaicosan-20-vncarbamoyl)cvclohexyl)nicotinamide

[004815] To a solution of 2-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)oxy)acetic acid (0.085 g, 0.24 mmol, Intermediate D) in DMF (5 mL) was added E1ATE[(0.14 g, 0.36 mmol) at 0 °C and the reaction mixture was stirred for 30 minutes. To this reaction mixture, 6-((l,6-naphthyridin-2-yl)amino)-N-((lr,4r)-4-((5-(2-(2-((5-aminopentyl)oxy)ethoxy)ethoxy)pentyl)-carbamoyl)-cyclohexyl)-4-(cyclopropylamino)nicotinamide hydrochloride (0.18 g, 0.24 mmol) and DIPEA (0.15 mL, 0.72 mmol) was added at 0 °C. The resulting reaction mixture was warmed to rt and stirred for 1 h. The reaction mixture was transferred into ice water, and the resulting precipitate was filtered off and washed with water and dried under reduced pressure. The crude product was purified using preparative HPLC (0.1% formic acid in water/ ACN) to give 6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)-N-((lr,4r)-4-((l-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)oxy)-2-oxo-9,l2,l5-trioxa-3-azaicosan-20-yl)carbamoyl)cyclohexyl)-nicotinamide 1-1 as off

white solid (0.04 g, 16 %). ¾ NMR (400 MHz, DMSO) δ 11.11 (s, 1H), 10.34 (s, 1H), 9.02 (s, 1H), 8.55-8.53 (m, 3H), 8.40 (s, 1H), 8.24 (d, J = 9.2 Hz, 1H), 8.13-8.11 (m, 1H), 7.96-7.93 (m, 1H), 7.79 (t, J = 7.6 Hz, 1H), 7.78-7.69 (m, 1H), 7.54 (d, J = 5.6 Hz, 1H), 7.49-7.46 (m, 2H), 7.36 (d, *J* = 8.4 Hz, 1H), 5.12-5.09 (m, 1H), 4.75 (s, 2H), 3.72 (bs, 1H), 3.48-3.47 (m, 7H), 3.14-3.09 (m, 2H), 2.99-2.98 (m, 2H), 2.96-2.94 (m, 1H), 2.59-2.52 (m, 2H), 2.03-2.0 (m, 2H), 1.85-1.83 (m, 2H), 1.73-1.71 (m, 2H), 1.45-1.42 (m, 6H), 1.40-1.38 (m, 2H), 1.36-1.34 (m , 2H), 1.31-1.28 (m, 1H), 1.25-1.24 (m, 4H), 0.92-0.91 (m, 2H), 0.56 (s, 2H). LC-MS (ESI$^+$) *m/z* 1020.2 (M+H)$^+$.

[004816] **Table 2: Compounds synthesized via Method 1, with the coupling of various amines with acid Intermediate C in Step 1, followed by coupling with acid Intermediate D in Step 3.**


Ex-#	I-#	Intermediate Amine	LCMS (ES+) m/z (M+H)+	HNMR (400MHz, DMSO-d6) δ
2	**I-2**	E	932.2	11.15 (s, 1H), 10.37 (s, 1H), 9.05 (s, 1H), 8.42 (s, 1H), 8.33-8.26 (m, 2H), 8.15 (d, J = 7.6 Hz, 1H), 7.98 (s, 1H), 7.81 (t, J = 8 Hz, 2H), 7.57-7.49 (m, 3H), 7.38 (d, J = 8.4 Hz, 1H), 5.15-5.10 (m, 2H), 4.77 (s, 1H), 3.16-2.87 (m, 6H), 2.05-2.02 (m, 4H), 1.87-1.72 (m, 5H), 1.46-1.23 (m, 18H), 0.94-0.85 (m, 4H), 0.58 (s, 2H)
3	**I-3**	*tert*-butyl (5-aminopentyl)carbamate (CAS# 51644-96-3)	845.8	11.14 (s, 1H), 10.37 (s, 1H), 9.04 (s, 1H), 8.65-8.45 (m, 3H), 8.40 (s, 1H), 8.23 (d, *J* = 9.2 Hz, 1H), 8.18-8.05 (m, 2H), 7.98-7.88 (m, 1H), 7.81 (t, *J* = 8.0 Hz, 1H), 7.75-7.65 (m, 1H), 7.63-7.53 (m, 1H), 7.52-7.42 (m, 2H), 7.38 (d, *J* = 8.4 Hz, 1H), 5.05-5.15 (m, 1H), 4.76 (s, 2H), 3.75-3.61 (m, 1H), 3.18-3.08 (m, 2H), 3.15-2.95 (m, 2H), 2.94-2.81 (m, 1H), 2.61-2.51 (m, 3H), 2.11-1.97 (m, 2H), 1.90-1.80 (m, 2H), 1.79-1.70 (m, 2H), 1.50-1.20 (m, 10H), 0.92 (d, *J* = 5.2 Hz, 2H), 0.57 (s, 2H)
4[a]	**I-4**	*tert*-butyl (5-aminopentyl)carbamate (CAS# 51644-96-3)	845.0	11.18 (s, 1H), 10.38 (s, 1H), 9.05 (s, 1H), 8.57-8.56 (m, 3H), 8.42(s, 1H), 8.28 (d, J = 9.2 Hz, 1H), 8.15 (s, 1H), 8.14 (d, J = 2.8 Hz, 1H), 7.96 (t, J = 5.2 Hz, 1H), 7.83 (t, J = 7.2 Hz, 1H), 7.72 (t, J = 5.2 Hz, 1H), 7.57 (d, J = 6 Hz, 1H), 7.51 (d, J = 7.6 Hz, 2H), 7.41 (d, J = 8.8 Hz, 1H), 5.16-5.12 (m, 1H), 4.77 (s, 2H), 3.67 (bs, 2H), 3.41-3.12 (m, 2H), 3.02-2.94 (m, 2H), 2.90-2.86 (m, 2H), 2.60-2.51 (m, 3H), 2.08-2.03 (m, 2H), 1.87 (d, J = 10 Hz, 2H), 1.76 (d, J = 10.4 Hz, 2H), 1.46-1.23 (m, 11H), 0.95-0.93 (m, 2H), 0.59 (s, 2H)

5	**I-5**	F	976.1	11.11 (s, 1H), 10.34 (s, 1H), 9.03 (s, 1H), 8.55-8.53 (m, 3H), 8.40 (s, 1H), 8.25 (d, *J* = 9.2 Hz, 1H), 8.15 (s, 1H), 8.13 (d, *J* = 7.6 Hz, 1H), 7.94 (t, *J* = 5.6 Hz, 1H), 7.79 (t, *J* = 7.6 Hz, 1H), 7.69 (t, *J* = 5.2 Hz, 1H), 7.55 (d, *J* = 5.6 Hz, 1H), 7.49-7.46 (m, 2H), 7.37 (d, *J* = 8.8 Hz, 1H), 3.70-3.60 (m, 1H), 3.43 (s, 3H), 3.12 (d, *J* = 6.0 Hz, 2H), 2.99 (d, *J* = 6.0 Hz, 2H), 2.90-2.80 (m, 1 H), 2.59-2.55 (m, 2H), 2.10-1.95 (m, 2H), 1.90-1.95 (m, 4H), 1.50-1.20 (m, 16H), 0.92 (d, *J* = 5.2 Hz, 2H), 0.56 (s, 2H)
6[b]	**I-6**	tert-butyl (2-(2-aminoethoxy) ethyl)carbamate (CAS# 127828-22-2)	847.8	11.1 (s, 1H), 9.51 (s, 1H), 8.94 (s, 1H), 8.81 (d, *J* = 6.0 Hz, 1H), 8.8-8.7 (m, 1H), 8.65 (d, *J* = 8.8 Hz, 1H), 8.50 (s, 1H), 8.32-8.22 (m, 1H), 8.05 (d, *J* = 5.4 Hz, 1H), 7.83-7.78 (m, 2H), 7.61 (d, *J* = 8.8 Hz, 1H), 7.49 (d, *J* = 7.6 Hz, 1H), 7.39 (d, *J* = 8.8 Hz, 2H), 5.12 (dd, *J* = 12.8 Hz & 5.4 Hz, 1H), 4.79 (s, 2H), 3.7-3.6 (m, 2H), 3.46-3.43 (m, 2H), 3.41-3.37 (m, 2H), 3.33-3.30 (m, 2H), 3.22-3.15 (m, 2H), 3.22-3.15 (m, 2H), 3.95-3.80 (m, 1H), 3.70-3.55 (m, 1H), 2.15-2.01 (m, 2H), 1.90-1.81 (m, 2H), 1.80-1.70 (m, 2H), 1.49-1.22 (m, 4H), 0.93 (d, *J* = 5.6 Hz, 2H), 0.67 (s, 2H)
7[a]	**I-7**	*tert*-butyl (3-aminopropyl) carbamate (CAS# 75178-96-0)	816.9	11.18 (s, 1H), 9.50 (s, 1H), 8.57-8.56 (m, 3H), 8.42 (s, 1H), 8.27(d, J = 8.8 Hz, 1H), 8.15-8.13 (m, 2H), 8.00 (t, J = 6 Hz, 1H), 7.82 (t, J = 8 Hz, 1H), 7.75 (t, J = 1.3 Hz, 1H), 7.57 (d, J = 5.6 Hz, 1H), 7.51 (d, J = 7.6 Hz, 1H), 7.41 (d, J = 8.8 Hz, 1H), 5.15-5.10 (m, 1H), 4.79 (s, 2H), 3.68 (bs, 1H), 3.15 (d, J = 1.3 Hz, 2H), 3.05 (d, J = 6 Hz, 2H), 2.94-2.87 (m, 3H), 2.05-2.02 (m, 2H), 1.87-1.85 (m, 2H), 1.77-1.74 (m, 2H), 1.57 (t, J = 6.4 Hz, 2H), 1.47-1.30 (m, 5H), 0.94 (d, J = 5.2 Hz, 2H), 1.94 (s, 2H)
8[b]	**I-8**	*tert*-butyl (2-aminoethyl)carbamate (CAS# 57260-73-8)	$(M-H)^-$ 801.8	11.14 (s, 1H), 10.36 (s, 1H), 9.05 (s, 1H), 8.65-8.55 (m, 3H), 8.42 (s, 1H), 8.27 (d, *J* = 9.2 Hz, 1H), 8.18-8.08 (m, 2H), 8.1-8.0 (m, 1H), 7.89-7.79 (m, 2H), 7.57 (d, *J* = 5.6 Hz, 1H), 7.55-7.45 (m, 1H), 7.40 (d, *J* = 8.4 Hz, 1H), 5.15-5.10 (m, 1H), 4.78 (s, 2H), 3.19-3.11 (m, 3H), 3.0-2.75 (m, 3H), 2.65-2.55 (m, 1H), 2.11-2.95 (m, 3H), 2.90-2.80 (m, 2H), 2.79-2.70 (m, 2H), 1.50-1.20 (m, 5H), 0.94 (d, *J* = 5.6 Hz, 2H), 0.58 (s, 2H)
9[b]	**I-9**	*tert*-butyl (4-aminobutyl)carbamate (CAS#	831.7	11.12 (s, 1H), 10.34 (s, 1H), 9.03 (s, 1H), 8.86-8.53 (m, 2H), 8.40 (s, 1H), 8.25 (d, *J* = 9.2 Hz, 1H), 8.15-8.05 (m, 2H), 7.97 (t, *J* = 5.6 Hz, 1H), 7.81 (t, *J* = 7.8 Hz, 1H), 7.72 (t, *J* = 5.6 Hz, 2H), 7.54 (d, *J*

		68076-36-8)		= 6.0 Hz, 1H), 7.49 (d, *J* = 7.6 Hz, 1H), 7.37 (d, *J* = 9.6 Hz, 1H), 5.11 (dd, *J* = 12.8 Hz & 5.2 Hz, 1H), 4.76 (s, 2H), 3.75-3.6 (m, 1H), 3.2-3.11 (m, 2H), 3.1-2.99 (m, 2H), 2.98-2.80 (m, 1H), 2.65-3.5 (m, 3H), 2.10-2.0 (m, 2H), 1.9-1.7 (m, 4H), 1.5-1.2 (m, 8H), 0.92 (d, *J* = 4.8 Hz, 2H), 0.57 (s, 2H)

*The intermediate formed in Step 1-2 could be triturated with diethyl ether, MBTE, or n-pentanes. Step 1 was run for 1-2 h. [a]Step 2 started at 0 °C then run at rt for 6 h; Step 3 was run for 4 h at rt. [b]Once water was added to quench the reaction in Step 1, the product precipitated out of solution and was collected, dried and used directly in the next step. For Step 3, PyBOP was used as the coupling reagent instead of HATH and the reaction was run at rt for 1 hr.

[004817] Example 10 [Method 21: 6-[[l,6-naphthyridin-2-yl]amino]-4-(cyclopropylamino)-N-((l S,4r)-4-((7-(((S)-l-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)-pyrrolidin-l-yl)-3,3-dimethyl-l-oxobutan-2-yl)amino)-7-oxoheptyl)carbamoyl)cyclohexyl)-nicotinamide, 1-10



[004818] Step 1 - *tert*-butyl (7-(((S)-l-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)-pyrrolidin-l-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-7-oxoheptyl)carbamate

[004819] To a solution of 7-((/er/-butoxycarbonyl)amino)heptanoic acid (0.3 g, 1.2 mmol, CAS# 60142-89-4), (2S,4R)-l-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)-benzyl)pyrrolidine-2-carboxamide hydrochloride (0.74 g, 1.59 mmol, Intermediate G) and DIPEA (1.1 mL, 6.1 mmol) in DMF (2 mL) was added PyBOP (0.95 g, 1.5 mmol) at rt and the mixture was stirred for 2 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 20 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel column chromatography (4% MeOH-DCM) to give *te/t*-butyl (7-(((S)-l-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)-pyrrolidin-l-yl)-3,3-dimethyl-l-oxobutan-2-yl)amino)-7-oxoheptyl)carbamate as brownish yellow semisolid (0.8 g, 99%). LC-MS (ESI^+) *m/z* 658.7 $(M+H)^+$.

[004820] Step 2 - (2S.4R)- 1-((S)-2-(7 -aminoheptanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-vDbenzvDpynOlidine-2-carboxamide hydrochloride

[004821] To a stirred solution of *tcrt*-butyl (7-(((S)-l-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-l-yl)-3,3-dimethyl-l-oxobutan-2-yl)amino)-7-oxoheptyl)carbamate (0.8 g, 1.2 mmol) in DCM (10 mL) was added 4N HC1 in dioxane (2 mL) at 0 °C. The resulting reaction mixture was warmed to rt and stirred for 2 h. The reaction mixture was then evaporated under vacuum and triturated using diethyl ether to give (2S,4R)-l-((S)-2-(7-aminoheptanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)-pyrrolidine-2-carboxamide hydrochloride as yellow solid (0.5 g, 70%). LCMS (ESI^+) *m/z* 558.61 $(M+H)^+$.

[004822] Step 3 - 6-((1,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)-N-((1S,4r)-4-((7-(YtS)-l -(Y2S.4R)-4-hvdroxy-2-(Y4-(4-methylthiazol-5-yl ibenzyl icarbamoyl jpyrrolidin- 1-yl)-3.3-dimethyl-l-oxobutan-2-vDamino)-7-oxoheptvDcarbamovDcvclohexyDnicotinamide

[004823] To a stirred suspension of (lR,4R)-4-(6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinamido)cyclohexane-l -carboxylic acid (0.2 g, 0.5 mmol, Intermediate C) and (2S,4R)-l-((S)-2-(7-aminoheptanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (0.34 g, 0.58 mmol) in DMF (5 mL) was added DIPEA (0.5 mL, 2.3 mmol) and PyBOP (0.35 g, 0.68 mmol) and the reaction mixture was stirred at rt for 1 h. The reaction mixture was then transferred into ice water and the

resulting mixture was extracted using ethyl acetate (3 x 20 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using preparative HPLC (0.1% formic acid in water/ACN) to give 6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)-N-((lS,4r)-4-((7-(((S)-l-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-l-yl)-3,3-dimethyl-l-oxobutan-2-yl)amino)-7-oxoheptyl)carbamoyl)cyclohexyl)nicotinamide **1-10** as light yellow solid (0.21 g, 37 %). ^{1}H NMR (400 MHz, DMSO) δ 10.36 (s, 1H), 9.05 (s, 1H), 8.99 (s, 1H), 8.63-8.51 (m, 3H), 8.42 (s, 1H), 8.27 (d, *J* = 9.2 Hz, 1H), 8.15 (d, *J* = 7.6 Hz, 1H), 7.88 (d, *J* = 9.2 Hz, 1H), 7.71-7.63 (m, 1H), 7.57 (d, *J* = 5.6 Hz, 1H), 7.51 (d, *J* = 8.8 Hz, 1H), 7.48-7.31 (m, 3H), 4.55 *(d, J* = 9.2 Hz, 1H), 4.49-4.41 (m, 1H), 4.40-4.31 (m, 2H), 4.30-4.15 (m, 1H), 3.75-3.61 (m, 2H), 3.05-2.95 (m, 2H), 2.65-2.55 (m, 1H), 2.45 (s, 3H), 2.41-1.71 (m, 8H), 1.51-1.21 (m, 10H), 0.94 (s, 9H), 0.55 (s, 2H). LC-MS (ESI$^+$) *m/z* 987.25 $(M+H)^+$.

[004824] **Table 3: Compounds synthesized via Method 2, with the coupling of various amines with acids in Step 1, followed by coupling with acids in Step 3.**

Ex-#	I-#	Step 1 Intermediate Amine	Step 1 Intermediate Acid	Step 3 Acid	LCMS (ES+) m/z $(M+H)^+$	HNMR (400MHz, DMSO-d6) δ
11	**I-11**	*tert*-butyl (2-(2-(2-(2-aminoethoxy)-ethoxy)-ethoxy)ethyl)carbamate (CAS# 153086-78-3)	D	C	936.0	11.13 (s, 1H), 10.35 (s, 1H), 9.05 (s, 1H), 8.56 (t, *J* = 4 Hz, 3H), 8.42 (s, 1H), 8.28 (d, *J* = 8.8 Hz, 1H), 8.17 (s, 1H), 8.14 (d, *J* = 7.6 Hz, 1H), 8.03 (t, *J* = 5.6 Hz, 1H), 7.83-7.79 (m, 2H), 7.57 (d, *J* = 6 Hz, 1H), 7.52 (m, 2H), 7.41 (d, *J* = 8.4 Hz, 1H) 5.14-5.10 (m, 1H), 4.79 (s, 2H), 3.70 (bs, 1H), 3.52-3.17 (m, 20H), 2.93-2.87 (m, 1H), 2.67-2.50 (m, 4H), 2.08-2.03 (m, 2H), 1.87 (d, *J* = 10 Hz, 2H), 1.76 (d, *J* = 12.4 Hz, 2H), 1.46-1.30 (m, 4H), 0.96-0.93 (m, 2H), 0.58 (s, 2H)


12	**I-12**	G	I	C	1056.8	10.37 (s, 1H), 9.05 (s, 1H), 8.99 (s, 1H), 8.61-8.55 (m, 4H), 8.42 (s, 1H), 8.27 (d, *J* = 8.8 Hz, 1H), 8.2-8.13 (m, 2H), 7.88 (d, *J* = 9.6 Hz, 1H), 7.75-7.65 (m, 2H), 7.57 (d, *J* = 5.6 Hz, 1H), 7.50 (d, *J* = 9.2 Hz, 1H), 7.43-7.35 (m, 3H), 5.14 (bs, 1H), 4.60-4.50 (m, 1H), 4.49-4.31 (m, 3H), 4.25-4.15 (m, 2H), 3.80-3.60 (m, 5H), 3.10-2.95 (m, 6H), 2.45 (s, 3H), 2.39-2.01 (m, 5H), 1.95-1.81 (m, 3H), 1.80-1.65 (m, 5H), 1.55-1.15 (m, 24H), 0.94 (s, 10H), 0.58 (s, 2H)
13[c]	**I-13**	G	EN	C	1090.7 $(M-H)^+$	10.35 (s, 1H), 9.05 (s, 1H), 8.99 (s, 1H), 8.62-8.56 (m, 4H), 8.42 (s, 1H), 8.26 (d, J = 8.8 Hz, 1H), 8.15-8.13 (m, 2H), 7.81 (bs, 1H), 7.57-7.55 (m, 1H), 7.51-7.49 (m, 1H), 7.45-7.43 (m, 5H), 5.16 (bs, 1H), 4.58-4.56 (m, 1H), 4.46-4.35 (m, 4H), 4.27-4.24 (m, 1H), 3.97 (s, 2H), 3.68-3.66 (m, 2H), 3.66-3.61 (m, 4H), 3.58-3.54 (m, 4H), 3.53-3.48 (m, 4H), 3.37-3.34 (m, 3H), 3.18-3.17 (m, 2H), 2.67-2.60 (m, 1H), 2.44 (s, 3H), 2.08-2.06 (m, 2H), 1.87-1.85 (m, 3H), 1.76-1.73 (m, 2H), 1.46-1.28 (m, 4H), 0.95 (s, 9H), 0.58 (s, 2H)
14[b]	**I-14**	AB	C	G	1087.3	10.37 (s, 1H), 9.051-8.991 (m, 2H), 8.57 (s, 4H), 8.42 (s, 1H), 8.27 (bs, 1H), 8.15 (bs, 1H), 7.90 (bs, 1H), 7.72 (bs, 1H), 7.56-7.41 (m, 5H), 5.16 (bs, 1H), 4.55-4.23 (m, 4H), 3.65 (bs, 3H), 3.0 (bs, 2H), 2.44-2.33 (m, 4H), 2.12-2.04 (m, 3H), 1.92-1.87 (m, 3H), 1.83-1.74 (m, 2H), 1.46-1.25 (m, 19H), 0.93 (s, 10H), 0.58 (s, 2H)
15[c]	**I-15**	G	5-((tert-butoxycarbonyl)amino)pentanoic acid	C	959.3	9.03 (s, 1H), 8.96 (s, 1H), 8.58-8.53 (m, 4H), 8.40 (s, 1H), 8.25 (d, J = 4.8 h, 1H), 8.13-8.11 (m, 1H), 7.87 (d, J = 9.2 h, 1H), 7.71 (t, J = 5.2 Hz, 1H), 7.55 (d, J =

			(CAS# 27219-07-4)			5.6 Hz, 1H), 7.49 (d, J = 9.2 Hz, 1H), 7.41-7.35 (m, 4H), 5.13 (s, 1H), 4.53 (d, J = 9.2 Hz, 1H), 4.44 (m, 3H), 4.22-4.17 (m, 1H), 3.00 (d, J = 6 Hz, 2H), 2.65-2.58 (m, 1H), 2.48 (s, 3H), 2.31-2.21 (m, 1H), 2.14-2.01 (m, 3H), 1.91-1.71 (m, 5H), 1.46-1.26 (m, 8H), 0.92 (s, 11H), 0.56 (s, 2H)
16[a]	**I-16**	*tert*-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (CAS# 153086-78-3)	D	O	863.7	12.80 (bs, 1H), 11.12 (s, 1H), 10.35 (s, 1H), 9.03 (s, 1H), 8.54-8.50 (m, 3H), 8.44 (s, 1H), 8.26 (d, *J* = 8.8 Hz, 1H), 8.11 (s, 1H), 8.01 (t, *J* = 5.2 Hz, 1H), 7.82-7.77 (m, 2H), 7.55-7.47 (m, 3H), 7.38 (d, *J* = 8.4 Hz, 1H), 5.12-5.08 (m, 1H), 4.78 (s, 2H), 4.53-4.47 (m, 1H), 3.50 (s, 3H), 3.46-3.32 (m, 4H), 3.32-3.29 (m, merged with water peak of DMSO, 3H), 3.22-3.17 (m, 2H), 2.91-2.85 (m, 2H), 2.65-2.48 (m, 3H), 2.35-2.30 (m, 2H), 2.26-2.19 (m, 2H), 2.03-2.01 (m, 1H), 0.91 (s, 2H), 0.54 (s, 2H)
17[d]	**I-17**	*tert*-butyl (2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl) carbamate (CAS# 101187-40-0)	D	AG	934.0	11.03 (s, 1H), 9.07-9.04 (m, 2H), 8.67 (s, 1H), 8.60 (s, 1H), 8.55 (s, 1H), 8.40 (d, *J* = 7.6 Hz, 1H), 8.05-8.02 (m, 1H), 7.84-7.80 (m, 2H), 7.68 (s, 1H), 7.51 (d, *J* = 7.2 Hz, 1H), 7.41 (d, *J* = 8.4 Hz, 1H), 5.15-5.11 (m, 1H), 4.80 (s, 2H), 3.73-3.71 (m, 1H), 3.53-3.48 (m, 11H), 3.46-3.39 (m, 3H), 3.38-3.35 (m, 1H), 3.20-3.18 (m, 2H), 2.95-2.86 (m, 1H), 2.68-2.63 (m, 2H), 2.63-2.59 (m, 2H), 2.11-2.04 (m, 2H), 1.92-1.89 (m, 2H), 1.78-1.76 (m, 2H), 1.48-1.24 (m, 4H), 0.86 (d, *J* = 5.2 Hz, 2H), 0.58 (s, 2H)

18	**I-18**	K	D	L	922.4	11.15 (s, 1H), 9.06 (dd, *J* = 1.6 and 12.8 Hz, 2H), 8.67 (s, 1H), 8.61 (s, 1H), 8.57 (s, 1H), 8.42 (d, *J* = 7.2 Hz, 1H), 8.08-8.01 (m, 1H), 7.87-7.77 (m, 1H), 7.68 (s, 1H), 7.51 (d, *J* = 7.2 Hz, 1H), 7.41 (d, *J* = 8.8 Hz, 1H), 5.16-5.11 (m, 1H), 4.81 (s, 2H), 3.80-3.55 (m, 1H), 3.55-3.45 (m, 11H), 3.35-3.25 (m, 3H), 3.22 (d, *J* = 6.4 Hz, 2H), 3.0-2.80 (m, 1H), 2.70-2.55 (m, 3H), 2.5-2.4 (m, 2H), 2.10-2.0 (m, 1H), 1.95-1.7 (m, 4H), 1.60-1.45 (m, 1H), 1.4-1.3 (m, 2H), 1.1-0.9 (m, 2H), 0.86 (d, *J* = 5.2 Hz, 2H), 0.57 (s, 2H)

[d]HATU used instead of PyBOP as the coupling reagent in Step 1 and the reaction was run for 2 h at rt in DCM. In Step 2, the reaction was run for 3 h and the product was triturated with MBTE. Step 3 was run for 3 h. [b]TFA was used instead of HC1 for the deprotection in Step 2 and was added at 0 °C, then the reaction was stirred at rt for 16 h. The product triturated using n-pentanes. In Step 3, HATU was used instead of PyBOP as the coupling reagent and the final product was purified using preparative HPLC (0.1% ammonia in water/ACN). [c]HATU was used as the coupling agent in Step 1 instead of PyBOP. In Step 2, the intermediate was triturated using MTBE. [d]The final product was purified by silica gel column chromatography (7% MeOH-DCM).

[004825] Example 19 [Method 3): 6-[[l,6-naphthyridin-2-vBamino)-4-(cvclopropylamino)-N-n-(2-(Y2-(2-(2-(Y2-(2.,6-dioxopiperidin-3-vB-l.,3-dioxoisoindolin-4-vBamino)ethoxy)ethoxy)ethvBamino)-2-oxoethvBpiperidin-4-vBnicotinamide, 1-19



[004826] Step 1 Ethyl 2-(4-(6-((1,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinamido)piperidin-1-yl)acetate

[004827] A solution of 6-((1,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinic acid (0.19 g, 0.58 mmol, Intermediate N), ethyl 2-(4-aminopiperidin-1-yl)acetate hydrochloride (0.13 g, 0.58 mmol, Intermediate P), PyBOP (0.45 g, 0.87 mmol) and DIPEA (0.23 mL, 1.73 mmol) in DMF (3 mL) was stirred at rt for 3 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 25 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to and the crude product was purified using silica gel column chromatography (50 % EtOAc-Hexane) to give ethyl 2-(4-(6-((1,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinamido)piperidin-1-yl)acetate as a light yellow solid (0.15 g, 39%). ^{1}H NMR (400 MHz, DMSO) δ 10.74 (bs, 1H), 9.11 (s, 1H), 8.61-8.32 (m, 5H), 7.75-7.60 (m, 1H), 7.53 (d, *J* = 8.8 Hz, 1H), 4.22-4.18 (m, 2H), 4.10-3.80 (m, 3H), 3.00-2.93 (m, 2H), 2.67-250 (m, 2H), 2.08-1.65 (m, 4H), 1.26-1.15 (m, 4H), 0.95 (d, *J* = 4.8Hz, 2H), 0.86-0.81 (m, 1H), 0.59 (s, 2H).


[004828] Step 2 - 2-(4-(6-(YE6-naphthyridin-2-v0amino)-4-(cyclopropylamino)nicotinamidoVpiperidin-l-vDacetic acid

[004829] A solution of ethyl 2-(4-(6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino) nicotinamido)piperidin-l-yl)acetate (0.15 g, 0.31 mmol) and LiOHH $_2$0 (0.04 g, 0.93 mmol) in THF :MeOH (5 mL, 1:1) was stirred at rt for 5 h. The reaction mixture was then adjusted to pH of 4-5 using citric acid solution. The solid precipitate was collected using filtration and the solid was dried under vacuum to give 2-(4-(6-((l,6-naphthyri din-2 -yl)amino)-4-(cyclopropylamino)nicotinamido)piperidin-l-yl)acetic acid as a light yellow solid (0.065 g, 53%). LC-MS (ESI$^+$) *m/z* 462.04 (M+H)$^+$.

[004830] Step 3 - 6-((1.6-naphthyridin-2-yl)amino)-4-(cvclopropylamino)-N-(l -(2-((2-(2-(2-((2-(2.6-dioxopiperidin-3-yl)- 1.3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)amino)-2-oxoethvnpiperidin-4-vnnicotinamide

[004831] A solution of 4-((2-(2-(2-aminoethoxy)ethoxy)ethyl) amino)-2-(2,6-dioxopiperidin-3-yl) isoindoline-l,3-dione (0.06 g, 0.14 mmol, synthesized via Method 4, Step 1-2 of Example 23), 2-(4-(6-((l,6-naphthyri din-2 -yl)amino)-4-(cyclopropylamino)nicotinamido)piperidin-l-yl)acetic acid (0.06 g, 0.14 mmol), PyBOP (0.11 g, 0.20 mmol) and DIPEA (0.05 mL, 0.4 mmol) in DMF (3 mL) was stirred at rt for 2 h. The reaction mixture was then transferred into ice water and resulting solid was filtered and purified by preparative HPLC (0.1% formic acid in water/ ACN) purification to give 6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)-N-(l-(2-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)amino)-2-oxoethyl)piperidin-4-yl)nicotinamide **1-19** as a light yellow solid (0.022 g, 19%). ^{1}H NMR (400 MHz, DMSO) δ 11.10 (s, 1H), 9.67 (bs, 1H), 9.18 (s, 1H), 8.63-8.37 (m, 4H), 7.73 (bs, 1H), 7.59-7.49 (m, 2H), 7.14 (d, *J* = 8.4 Hz, 1H), 7.04 (d, *J* = 7.2 Hz, 1H), 6.59 (s, 1H), 5.06-5.02 (m, 1H), 3.86-3.71 (m, 1H), 3.60-3.54 (m, 6H), 3.46-3.33 (m, 6H), 3.11-3.08 (m, 1H), 2.90-2.83 (m, 1H), 2.59-2.52 (m, 2H), 2.16-1.98 (m, 5H), 1.89-1.82 (m, 3H), 0.94 (d, *J* = 5.6 Hζ,, 2H), 0.58 (s, 2H); LC-MS (ESI$^+$) *m/z* (M+H)$^+$ = 848.93


[004832] **Example 20: 6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)-N-(l-(2-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)amino)-2-oxoethyl)azetidin-3-yl)nicotinamide, 1-20**



1-20

[004833] 6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)-N-(l-(2-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)amino)-2-oxoethyl)azeti din-3-yl)nicotinamide was synthesized via Method 3 starting with Intermediate Q as the amine and Intermediate N as the acid in Step 1. Step 1 was started at 0 °C then allowed to warm to rt and stirred for 16 h. After the water quench, the product was extracted using 5% methanol in DCM and the product was purified by silica gel column chromatography (8-9% MeOH-DCM). Step 2 was run at 0 °C for 2 h. Upon completion, the reaction mixture was acidified with Dowex 50 Resin and the reaction mixture was filtered through celite and used directly in the subsequent step. In Step 3, the amine 4-((2-(2-(2-aminoethoxy)ethoxy)ethyl) amino)-2-(2,6-dioxopiperi din-3-yl) isoindoline-l,3-dione (synthesized via Method 4, Step 1-2 of Example 23) was coupled under the conditions described at 0 °C and stirred for 45 min. Purification by HPLC (5mM ammonium bicarbonate with 0.1% ammonia in water/ ACN) gave the title product **1-20.** '**H** NMR (400 MHz, DMSO - *ck)* δ 11.11 (s, 1H), 10.38 (s, 1H), 9.06 (s, 1H), 8.66 (d, *J* = 6.8 Hz, 1H), 8.65-8.50 (m, 3H), 8.48 (s, 1H), 8.28 (d, *J* = 1.6 Hz, 1H), 7.70-7.55 (m, 3H), 7.51 (d, *J* = 8.8 Hz, 1H), 7.14 (d, *J* = 8.4 Hz, 1H), 7.03 *(d, J* = 7.2 Hz, 1H), 6.69-6.59 (m, 1H), 5.06 (dd, *J* = 12.8 Hz & 5.2 Hz, 1H), 4.55-4.45 (m, 1H), 3.70-3.60 (m, 3H), 3.59-3.40 (m, 8H), 3.30-3.20 (m, 2H), 3.15-2.95 (m, 4H), 2.94-2.80 (m, 2H), 2.65-2.55 (m, 1H), 2.10-1.95 (m, 2H), 1.80-1.70 (m, 1H), 0.94 (d, *J* = 4.8 Hz, 2H), 0.58 (s, 2H), LC-MS (ESI$^+$) *m/z* 820.21 (M+H$^+$).

[004834] Example 21: 6-(5-cvano-lH-pyrazolo[3.,4-blpyridin-l-vD-4-(cvclopropylamino)-N-((1r,3r)-3-((14-((2-(2,6-dioxopiperidin-3-vP-l ,3-dioxoisoindolin-4-vDaminoy3.,6.,9.,12-tetraoxatetradecvDcarbamovDcvclobutvDnicotinamide, 1-21




1-21

[004835] 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(cyclopropylamino)-N-((lr,3r)-3-((l4-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)amino)-3,6,9,l2-tetraoxatetradecyl)carbamoyl)cyclobutyl)nicotinamide was synthesized via Method 3 starting with methyl trans-3-aminocyclobutane-l-carboxylate hydrochloride (CAS# 74316-29-3) as the amine

and Intermediate L as the acid in the first step. In Step 1, HATU was used at the coupling reagent instead of PyBOP and the reaction mixture was stirred with acid Intermediate L for 30 min at 0 °C then the amine and base were added and the reaction was stirred at rt for 1 h. After the aqueous work up, the solid precipitate was collected and used directly in the subsequent reaction. Step 2 was run in a 1:1 mixture of THF:water as the solvent. In Step 3 the starting material amine used was Intermediate Z and the final product was purified using silica gel column chromatography (4% MeOH-DCM) to give the title compound **1-21**. ^{1}H NMR (400 MHz, DMSO) δ 11.12 (s, 1H), 9.07 (d, *J* = 2 Hz, 1H), 9.04 (d, *J* = 2 Hz, 1H), 8.80 (d, *J* = 7.2 Hz, 1H), 8.65 (d, *J* = 11 Hz, 2H), 8.56 (s, 1H), 7.87-7.84 (m, 1H), 7.68 (s 1H), 7.58 (t, J = 7.2 Hz, 1H), 7.14 (d, *J* = 8.8 Hz, 1H), 7.03 (d, *J* = 6.8 Hz, 1H), 6.61 (t, J = 5.6 Hz, 1H), 5.08-5.03 (m, 1H), 4.56-4.54 (m, 1H), 3.63-3.60 (m, 2H), 3.56-3.55 (m, 13H), 3.47-3.42 (m, 2H), 3.24-3.20 (m, 2H), 2.93-2.85 (m, 2H), 2.60-2.56 (m, 3H), 2.40-2.35 (m, 2H), 2.33-2.30 (m, 2H), 2.26-2.01 (m, 1H), 0.87-0.83 (m, 2H), 0.58-0.56 (m, 2H). LC-MS (ESI$^+$) *m/z* 892.8 (M+H)$^+$.

[004836] Example 22: 6-(5-cvano-lH-pyrazolo[3,4-blpyridin-l-vO-4-(cvclopropylamino)-N-((1r,4r)-4-((14-((2-(2,6-dioxopiperidin-3-vl)-l,3-dioxoisoindolin-4-yl)amino)i-3,6,9,12-itetraoxatetradecyl)carbamoyl)cyclohexyl)nicotinamide, 1-22





[004837] 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(cyclopropylamino)-N-((lr,4r)-4-((l4-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)amino)-3,6,9,l2-tetraoxatetradecyl)carbamoyl)cyclohexyl)nicotinamide **1-22** was synthesized via Step 3 of Method 3 starting with acid Intermediate AG and amine Intermediate Z.


[004838] ^{1H} NMR (400 MHz, DMSO) δ 11.12 (s, 1H), 9.07 (s, 1H), 9.05 (s, 1H), 8.67 (s, 1H), 8.67 (s, 1H), 8.56 (s, 1H), 8.42 (d, *j* = 8 Hz, 1H), 7.81 (d, *j* = 5.2 Hz, 1H), 7.68 (s, 1H), 7.59 (t, *J* = 8 Hz, 1H), 7.17 (d, *J* = 8.4 Hz, 1H), 7.05 (d, *j* = 7.2 Hz, 1H), 6.62 (s, 1H), 5.09-5.04 (m, 1H), 3.73-3.34 (m, 19H), 3.35-3.25 (m, 2H), 3.03-3.02 (m, 2H), 2.94-2.86 (m, 2H), 2.68-2.51 (m, 3H), 2.11-2.02 (m, 3H), 1.98-1.89 (m, 2H), 1.79-1.74 (m, 4H), 1.46-1.33 (m, 4H), 0.87 (d, *J* = 5.2

Hz, 2H), 0.57 (s, 1H). LC-MS (ESI$^+$) *m/z* 921.5 $(M+H)^+$.

[004839] **Example 23 [Method 41: 6-[[l,6-naphthyridin-2-vBamino]-4-(cvclopropylamino]-N-(YlR.,4R]-4-((2-(2-(2-(Y2-(2.,6-dioxopiperidin-3-vB-l.,3-dioxoisoindolin-4-vBamino]ethoxy]ethoxy]-ethvBcarbamovBcvclohexyBnicotinamide, 1-23**







[004840] Step 1 - *tdrt*-butvl (2-(2-(2-((2-(2.6-dioxopiperidin-3-yl)- 1.3-dioxoisoindolin-4-vOamino)ethoxy)ethoxy)ethvOcarbamate

[004841] To a stirred solution of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-l,3-dione (2.6 g, 9.4 mmol, Intermediate R) and DABCO (1.4 g, 12.2 mmol) in DMF (15 mL) was added *te/t*-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (2.8 g, 11.3 mmol, CAS# 153086-78-3) at rt. The resulting reaction mixture heated to 80 °C and stirred for 2 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 50 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using silica gel

column chromatography (2% MeOH-DCM) to give /c/7-butyl (2-(2-(2-((2-(2, 6-dioxopiperi din-3-yl)-l,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)carbamate as a yellow oil (0.6 g, 13%). LCMS (ESI^+) *m/z* 505.5 $(M+H)^+$.

[004842] Step 2 - 4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-v0isoindoline-L3-dione hydrochloride


[004843] To a stirred solution of /c/7-butyl (2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)carbamate (0.6 g, 1.2 mmol) in 1,4 dioxane (15 mL) was added 4 M HC1 in dioxane (10 mL) at 0 °C. The resulting reaction mixture was allowed to warm to rt and stirred for 16 h. The reaction mixture was then evaporated under vacuum and the residue was triturated using MTBE to give 4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-l,3-dione hydrochloride as yellow solid (0.48 g, 91%). LCMS (ESI^+) *m/z* 405.4 $(M+H)^+$.

[004844] Step 3 - 6-((E6-naphthyridin-2-vl)amino)-4-(cvclopropylamino)-N-((1R,4R)-4-((2-(2-(2-((2-(2,6-dioxopiperidin-3-vl)-E3-dioxoisoindolin-4-vDamino)ethoxy)ethoxy)ethvDcarbamovP-cvclohexyDnicotinamide

[004845] To a stirred suspension of (lR,4R)-4-(6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinamido)cyclohexane-l -carboxylic acid (0.4 g, 0.9 mmol, Intermediate C) and 4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-l,3-dione hydrochloride (0.48 g, 1.07 mmol) in DMF (15 mL) was added DIPEA (0.8 mL, 4.5 mmol) and PyBOP (0.7 g, 1.3 mmol) at rt. The resulting reaction mixture was stirred at rt for 1 h. The reaction mixture was then transferred into ice water and the resulting solid was filtered off and dried reduced pressure. The crude product was purified using silica gel column chromatography (6% MeOH-DCM) to give 6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)-N-((lR,4R)-4-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)-carbamoyl)cyclohexyl)nicotinamide **1-23** as a yellow oil (0.41 g, 55%). ^1H NMR (400 MHz, DMSO) δ ppm 11.09 (s, 1H), 10.34 (s, 1H), 9.03 (s, 1H), 8.55-8.54 (m, 3H), 8.39 (s, 1H), 8.24 (d, J = 8.8 Hz, 1H), 8.12 (d, J = 7.6 Hz, 1H), 7.73-7.77 (m, 1H), 7.57-7.53 (m, 2H), 7.49-7.47 (m, 1H), 7.13 (d, J = 8.8 Hz, 1H), 7.02 (d, J = 7.2 Hz, 1H), 6.60 (m, 1H), 5.03-4.96 (m, 1H), 3.61-3.59 (m, 3H), 3.55-3.54 (m, 2H), 3.51-3.50 (m, 2H), 3.47-3.44 (m, 2H), 3.39-3.36 (m, 2H), 3.16-3.14 (m, 2H), 2.90-2.82 (m, 1H), 2.58-2.55 (m, 1H), 2.03 (m, 2H), 1.84-1.82 (m, 2H), 1.73-1.71 (m ,2H), 1.42-1.38 (m, 2H), 1.35-1.33 (m, 4H), 0.92-0.9l(m, 2H), 0.56 (s, 2H). LC-MS (ESI^+) *m/z*


833.8 $(M+H)^+$.

[004846] Example 24: 6-((1,6-naphthyridin-2-yl)aminoV4-(cvclopr()PylaminoVN-((1R,4R)-4-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-vPaminolethoxylethoxylethvPcarbamovPcvclohexyPnicotinamide, 1-24



[004847] 6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)-N-((lr,4r)-4-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl) carbamoyl)cyclohexyl)nicotinamide **1-24** was synthesized via Method 4 with Intermediate R as the fluorine and *tv't*-butyl (l4-amino-3,6,9,l2-tetraoxatetradecyl)carbamate (CAS# 811442-84-9) as the amine in Step 1. Intermediate C was used as the acid in Step 3. ^{1}H NMR (400 MHz, DMSO) δ ppm 11.09 (s, 1H), 10.34 (s, 1H), 9.03 (s, 1H), 8.55-8.54 (m, 3H), 8.40 (s, 1H), 8.24 (d, *J* = 8.8 Hz, 1H), 8.11 (d, *J* = 7.6 Hz, 1H), 7.81-7.73 (m, 1H), 7.58-7.47 (m, 3H), 7.13 (d, *J* = 8.8 Hz, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.60-6.58 (m, 1H), 4.96 (m, 1H), 3.68-3.61 (m, 3H), 3.60-3.59 (m, 3H), 3.54-3.52 (m, 7H), 3.37-3.34 (m, 2H), 3.17-3.15 (m, 2H), 3.17-3.15 (m, 2H), 2.91-2.82 (m, 1H), 2.65-2.58 (m, 1H), 2.06-1.99 (m, 2H), 1.85-1.82 (m, 2H), 1.74-1.70 (m ,3H), 1.45-1.21 (m, 4H), 0.92-0.84 (m, 2H), 0.56 (s, 2H). LC-MS (ESI^+) *m/z* 922.2 $(M+H)^+$


[004848] Example 25: 6-Rl,6-naphthyridin-2-vnamino)-4-fcvclopropylamino)-N-((1r,4r)-4-((2-(2-((2-(2,6-dioxopiperidin-3-vP-l,3-dioxoisoindolin-4-vPaminolethoxylethvPcarbamovPcvclohexyPnicotinamide, 1-25



[004849] 6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)-N-((lr,4r)-4-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-

yl)amino)ethoxy)ethyl)carbamoyl)cyclohexyl)nicotinamide **1-25** was synthesized via Method 4 using Intermediate R as the fluorine and *tert*-butyl (2-(2-aminoethoxy)ethyl)carbamate (CAS# 127828-22-2) as the amine in Step 1. The product of Step 2 was triturated with diethyl ether instead of MBTE. Intermediate C was used as the acid in Step 3 and the final product was purified by HPLC (0.1% formic acid in water/ACN). ^{1}H NMR (400 MHz, DMSO - d_6) δ 11.1 (s, 1H), 10.34 (s, 1H), 9.03 (s, 1H), 8.56-8.54 (m, 3H), 8.40 (s, 1H), 8.25 (d, *J* = 9.2 Hz, 1H), 8.15-8.05 (m, 2H), 7.81-7.75 (m, 1H), 7.60-7.5 (m, 2H), 7.50 (*d, J* = 8.8 Hz, 1H), 7.14 (d, *J* = 8.4 Hz, 1H), 7.04 (d, *J* = 7.2 Hz, 1H), 6.59 (d, *j* = 6.0 Hz, 1H), 5.04(dd, *J* = 13.0 Hz & 5.4 Hz, 1H), 3.7-3.55 (m, 3H), 3.50-3.40 (m, 4H), 3.25-3.15 (m, 2H), 2.90-2.80 (m, 1H), 2.55-2.65 (m, 2H), 2.10-1.95 (m, 2H), 1.85-1.65 (m, 4H), 1.45-1.21 (m, 4H), 0.92 (d, *J* = 5.2 Hz, 2H), 0.57 (s, 2H); LC-MS (ESI$^+$) *m/z* 789.7 (M+H)$^+$.


[004850] Example 26: 6-ffl,6-naphthyridin-2-vnamino)-4-fcvclopropylamino)-N-((1r,3r)-3-((2-(2-(2-((2-(2,6-dioxopiperidin-3-vP-l,3-dioxoisoindolin-4-vPamino)ethoxy)ethoxy)ethvP carbamoyl) cyclobutyPnicotinamide, 1-26



[004851] 6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)-N-((lr,3r)-3-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl) carbamoyl) cyclobutyl)nicotinamide **1-26** was synthesized via Method 4 using Intermediate R as the fluorine and *tert*-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (CAS# 153086-78-3) as the amine in Step 1. Intermediate O was used as the acid in Step 3. In Step 3, HATH was used as the coupling reagent instead of PyBOP and the reaction was run at rt for 4 h. ^{1}H NMR (400 MHz, DMSO) δ 11.09 (s, 1H), 10.36 (s, 1H), 9.03 (s, 1H), 8.55-8.50 (m, 3H), 8.44 (s, 1H), 8.26 (d, *J* = 8.8 Hz, 1H), 7.79 (t, *j* = 5.6 Hz, 1H), 7.58-7.54 (m, 2H), 7.49 (*d, J* = 9.2 Hz, 1H), 7.14 (*d, J* = 8.4 Hz, 1H), 7.00 (d, *J* = 7.2 Hz, 1H), 6.60 (s, 1H), 5.06-5.02 (m, 1H), 4.51-4.49 (m, 1H), 3.62-3.32 (m, 10H), 3.20-3.14 (m, 3H), 2.87-2.83 (m, 2H), 2.58-2.48 (m, 1H), 2.33-2.21 (m, 4H), 2.02-1.97 (m, 2H), 1.21 (m, 1H), 0.92 (*d, J* = 5.2 Hz, 2H), 0.55 (s, 2H). LC-MS (ESI$^+$) *m/z* 805.68 (M+H)$^+$


[004852] Example 27: 6-[5-cvano-lH-pyrazolo[3,4-blpyridin-l-vP-4-

(cvclopropylamino)-N-(YlR.,3R)-3-((2-(2-(2-(Y2-(2.,6-dioxopiperidin-3-vP-l.,3-dioxoisoindolin-4-yPamin(pethoxy)ethoxy)ethyP carbamoyPcyclobutyPnicotinamide, 1-27



[004853] 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(cyclopropylamino)-N-((lr,3r)-3-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl) carbamoyl)cyclobutyl)nicotinamide **1-27** was synthesized via Method 4 using Intermediate R as the fluorine and *tert*-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (CAS# 153086-78-3) as the amine in Step 1. (lR,3R)-3-(6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(cyclopropylamino)nicotinamido)cyclobutane-l -carboxylic acid (synthesized via Steps 1-2 of Method 3 for Example 21) was used as the acid in Step 3 which was run at rt for 2 h. The final compound was purified by prep HPLC (0.1% formic acid in water/ACN). ^{1}H NMR (400 MHz, DMSO) δ 11.13 (s, 1H), 9.07 (d, *J* = 2 Hz, 1H), 9.04 (d, *J* = *2* Hz, 1H), 8.81 (d, *J* = 7.2 Hz, 1H), 8.67 (s, 1H), 8.64 (s, 1H), 8.56 (s, 1H), 7.84 (t, *J* = 6 Hz, 1H), 7.68 (s, 1H), 7.59 (t, *J* = 7.2 Hz, 1H), 7.16 (d, *J* = 8.4 Hz, 1H), 7.05 (d, *J* = 7.2 Hz, 1H), 6.62 (t, *J* = 5.6 Hz, 1H), 5.09-5.04 (m, 1H), 4.56-4.52 (m, 1H), 3.64-3.50 (m, 6H), 3.48-3.35 (m, 5H), 3.24-3.20 (m, 2H), 2.92-2.84 (m, 2H), 2.61-2.51 (m, 2H), 2.39-2.23 (m, 4H), 2.04-2.02 (m, 1H). LC-MS (ESI^+) *m/z* 804.5.


[004854] Example 29: 6-(5-cyano-lH-pyrazolo[3.,4-blpyridin-l-yP-4-(cvclopropylamin(p-N-((1r,4r)-4-((2-(2-(2-((2-(2,6-dioxopiperidin-3-vP-l ,3-dioxoisoindolin-4-vPamino)ethoxy)ethoxy) ethyPcarbamoyPcyclohexyPnicotinamide, 1-29



[004855] 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(cyclopropylamino)-N-((lr,4r)-4-

((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy) ethyl)carbamoyl)cyclohexyl)nicotinamide **1-29** was synthesized via Method 4 using Intermediate R as the fluorine and *tert*-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (CAS# 153086-78-3) as the amine in Step 1. Intermediate AG was used as the acid in Step 3 which was run at rt for 2 h. The final product was purified using preparative HPLC (0.1% formic acid in water/ACN). Characterization of the final product: ^{1}H NMR (400 MHz, DMSO) δ 11.13 (s, 1H), 9.08 (dd, J_1 = 2 Hz, J_2 = 13 Hz, 1H), 8.67 (s, 2H), 8.60 (d, J = 18.4 Hz, 1H), 8.42 (d, J = 7.6 Hz, 1H), 7.82-7.76 (m, 1H), 7.69 (s, 1H), 7.60 (t, j = 7.6 Hz, 1H), 7.18 (d, j = 8.4 Hz, 1H), 7.07 (d, j = 6.8 Hz, 1H), 6.63 (t, J = 5.6 Hz, 1H), 5.10-5.05 (m, 1H), 3.71-3.36 (m, 9H) 3.22-3.19 (m, 2H), 3.04-3.00 (m, 1H), 2.94-2.85 (m, 1H), 2.62-2.51 (m, 2H), 2.11-1.91 (m, 2H), 1.88-1.78 (m, 2H), 1.76-1.73 (m, 2H), 1.48-1.24 (m, 3H), 1.39-1.32 (m, 2H), 0.87-0.58 (m, 2H). LC-MS (ESI$^+$) *m/z* 832.78 (M+H)$^+$.

[004856] Example 30 [Method 5): 6-((1,6-naphthyridin-2-vl)amino)-4-(cvclopropylamino)-N-((1R,4R)-4-((3-(3-((2-(2,6-dioxopiperidin-3-vP-l,3-dioxoisoindolin-4-vnaminolpropoxyfpropyncarbamovn cvclohexyPnicotinamide, 1-30



[004857] Step 1 - fer/-butyl (3-(3-((2-(2,6-dioxopiperidin-3-vl)-E3-dioxoisoindolin-4-vOamino)propoxy)propyOcarbamate

[004858] A solution of *tert*-butyl (3-(3-aminopropoxy)propyl)carbamate (0.36 g, 1.55 mmol, Intermediate S), 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-l,3-dione (0.47 g, 1.70 mmol, Intermediate R) and DIPEA (0.4 mL, 2.3 mmol) in DMF (3 mL) was stirred at 80 °C for 1 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 20 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure. The crude product was purified using silica gel column chromatography (3% MeOH-DCM) to give tert-butyl (3-(3-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)amino)propoxy)propyl)carbamate as a yellow semi-solid (0.1 g, 13%). LC-MS (ESI$^+$) *m/z* 489.5 (M+H)$^+$.

[004859] Step 2 - 4-((3-(3-aminopropoxy)propyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride

[004860] To a solution of *tert*-butyl (3-(3-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)amino)propoxy)propyl)carbamate (0.1 g, 0.2 mmol) in DCM (5 mL) was added 4N HCl in dioxane (2 mL) at 0 °C. The reaction mixture was then allowed to come to rt and was stirred for 3 h. The reaction mixture was then evaporated under vacuum to afford the crude product which was triturated using MTBE (5 mL) to give 4-((3-(3-aminopropoxy)propyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-l,3-dione hydrochloride as a yellow solid (0.06 g, 69%). LC-MS (ESI$^+$) *m/z* 389.4 (M+H)$^+$.

[004861] Step 3 - 6-((1,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)-N-((1R,4R)-4-((3-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propoxy)propyl)carbamoyl)cyclohexyl)nicotinamide

[004862] A solution of 4-((3-(3-aminopropoxy)propyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-l,3-dione hydrochloride (0.06 g, 0.14 mmol), (lR,4R)-4-(6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotineamido)cyclohexane-l-carboxylic acid (0.063 g, 0.14 mmol, Intermediate C), PyBOP (0.11 g, 0.21 mmol) and DIPEA (0.1 mL, 0.42 mmol) in DMF (3 mL) was stirred at rt for 2 h. The reaction mixture was then poured in ice water mixture (50 mL) and the solid precipitated was filtered. The crude solid was then purified by prep HPLC (0.1% formic acid in water/ACN) to give 6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)-N-((lR,4R)-4-((3-(3-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)amino)propoxy) propyl)carbamoyl) cyclohexyl)nicotinamide **1-30** as a yellow solid (0.018 g, 16%). ^{1}**H** NMR (400 MHz, DMSO) δ 11.11 (s, 1H), 10.36 (s, 1H), 9.05 (s, 1H), 8.57 (d, *J* = 5.2 Hz, 2H), 8.42 (s, 1H),

8.28 (d, J = 8.8 Hz, 1H), 8.15 (d, J = 4.4 Hz, 1H), 7.73-7.71 (m, 1H), 7.59-7.49 (m, 3H), 7.12 (d, J = 8.8 Hz, 2H), 7.04 (d, j = 7.2 Hz, 1H), 6.75-6.65 (m, 1H), 5.14-5.10 (m, 1H), 3.60-3.70 (m, 2H), 3.45 (t, j = 5.6 Hz, 2H), 3.39-3.34 (m, 3 H), 3.11-3.09 (m, 2H), 3.00-2.80 (m, 2H), 2.67-2.50 (m, 4H), 2.33 (s, 1H), 2.10-2.00 (m, 2H), 2.05- 1.63 (m, 7H), 1.45-1.25 (m, 4H), 0.95 (d, J = 4.8 Hz, 2H), 0.58 (s, 2H). LC-MS (ESI$^+$) *m/z* 817.8 (M+H)$^+$.

[004863] **Table 4: Compounds synthesized via Method 5 with the addition of various amines to fluoride Intermediate R in Step 1, followed coupling with various acids in Step 3**

Ex-#	I-#	Step 1 Intermediate Amine	Step 3 Acid	LCMS (ES+) m/z (M+H)$^+$	HNMR (400MHz, DMSO-d6) δ
31	**I-31**	H	N	792.4	11.13 (s, 1H), 10.38 (s, 1H), 9.06 (s, 1H), 8.58 -8.55 (m, 4H), 8.48 (s, 1H), 8.29 (d, J = 9.2 Hz, 1H), 7.61-7.50 (m, 3H), 7.33-7.32 (m, 1H), 7.17 (d, J = 8.8 Hz, 1H), 7.06 (d, J = 7.2 Hz, 1H), 6.64 (t, J = 5.6 Hz, 1H), 5.10-5.05 (m, 1H), 4.51-4.41 (m, 2H), 3.66-3.41 (m, 13H), 2.68-2.57 (m, 2H), 2.37-2.34 (m, 1H), 2.20-2.13 (m, 2H), 2.06-2.20 (m, 3H), 1.24 (m, 1H), 0.95 (d, J = 4.8 Hz, 2H), 0.58 (s, 2H)
32	**I-32**	W	L	819.8	11.11 (s, 1H), 9.08 (d, J = 2 Hz, 1H), 9.04 (d, J = 2 Hz, 1H), 8.68 (s, 1H), 8.63 (s, 1H), 8.59 (s, 1H), 8.43 (d, J = 7.6 Hz, 1H), 7.74 (s, 1 Hz, 1H), 7.61-7.57 (m, 1H), 7.16 (d, J = 8.8 Hz, 1H), 7.05 (d, J = 7.2 Hz, 1H), 6.62 (s, 1H), 5.07-5.04 (m, 1H), 3.71-3.68 (m, 1H), 3.65-3.58 (m, 2H), 3.57-2.53 (m, 11H), 3.21-3.19 (m, 2H), 2.89-2.84 (m, 1H), 2.60-2.57 (m, 2H), 2.05-2.01 (m, 1H), 1.87-1.85 (m, 2H), 1.78-1.75 (m, 2H), 1.47-1.45 (m, 1H), 1.34-1.27 (m, 2H), 1.03-0.97 (m, 2H), 0.87-0.84 (m, 2H), 0.57 (s, 2H)


33	**I-33**	Y	L	907.8	11.11 (s, 1H), 9.08 (s, 1H), 9.04 (s, 1H), 9.89-9.59 (m, 3H), 8.46 (d, *J* = 5.6 Hz, 1H), 7.76 (s, 1H), 7.58 (t, *J* = 7.6 Hz, 1H), 7.15-7.03 (m, 2H), 6.61 (s, 1H), 5.06 (d, *J* = 7.6 Hz, 1H), 3.70-3.56 (m, 9H), 3.50-3.20 (m, 12H), 2.92-2.85 (m, 1H), 2.08-2.02 (m, 2H), 1.88-1.76 (m, 4H), 1.48-1.23 (m, 5H), 1.09-0.98 (m, 2H), 0.88-0.86 (m, 2H), 0.58 (s, 3H)
34	**I-34**	H	N	791.7	11.13 (s, 1H), 9.07 (dd, J_1 = 2 Hz, J_2 = 2 Hz, 2H), 8.81 (d, *J* = 6.8 Hz, 2H), 8.66 (s, 1H), 8.64 (s, 1H), 8.57 (s, 1H), 7.68 (s, 1H), 8.14 (t, *J* = 7.2 Hz, 1H), 7.16 (d, *J* = 8.4 Hz, 1H), 7.05 (d, *J* = 7.2 Hz, 1H), 6.25 (t, *J* = 6 Hz, 1H), 5.08-5.04 (m, 1H), 4.48-4.42 (m, 1H) 3.68-3.45 (m, 12H), 2.93-2.84 (m, 1H), 2.60-2.50 (m, 4H), 2.39-2.33 (m, 1H), 2.21-2.01 (m, 3H), 0.87-0.82 (m, 2H), 0.57-0.53 (m, 2H)
35	**I-35**	U	L	805.7	11.13 (s, 1H), 9.07 (d, *J* = 12 Hz, 1H), 8.68 (s, 1H), 8.63 (s, 1H), 8.54 (s, 1H), 8.50 (d, *J* = 8 Hz, 1H), 7.68 (s, 1H), 7.59 (t, *J*= 8Hz, 1H), 7.15 (d, *J* = 12 Hz, 1H), 7.05 (d, *J* = 4 Hz, 1H), 6.63 (s, 1H), 5.07 (d, *J* = 8 Hz, 1H), 4.25 (d, *J* = 4 Hz, 1H), 3.65-3.49 (m, 13H), 3.29-3.28 (m, 2H), 2.94-2.87 (m, 1H), 2.62-2.56 (m, 3H), 2.34 (d, *J* = 8 Hz, 1H), 2.06-1.95 (m, 2H), 1.83 (s, 1H), 1.70-1.58 (m, 3H), 1.25 (s, 1H), 0.87-0.84 (m, 2H), 0.58 (s, 2H)

36[a]	**I-36**	ES	L	878.9	11.03 (s, 1H), 9.07 (d, *J* = 4 Hz, 1H), 9.04 (d, *J* = 4 Hz, 1H), 8.83 (d, *J* = 8 Hz, 1H), 8.67 (d, *J* = 8 Hz, 2H), 8.59 (s, 1H), 7.69 (s, 1H), 7.59 (t, *J* = 8 Hz, 1H), 7.15 (d, *J* = 8 Hz, 1H), 7.04 (d, *J* = 4 Hz, 1H), 6.63-6.61 (m, 1H), 5.09-5.05 (m, 1H), 4.50-4.44 (m, 1H), 3.64-3.62 (m, 2H), 3.57-3.48 (m, 18H), 2.94-2.85 (m, 1H), 2.62-2.52(m, 3H), 2.42-2.35 (m, 1H), 2.24-22.19 (m, 2H), 2.11-2.03 (m, 3H), 0.89-0.84 (m, 2H), 0.57 (s, 2H)
37	**I-37**	EP	(1R,3R)-3-(6-(5-cyano-1H-pyrazolo[3,4-b]pyridin-1-yl)-4-(cyclopropyl-amino)-nicotinamido)-cyclobutane-1-carboxylic acid (synthesized via Steps 1-2 of Method 3 for Example 21)	818.7	11.13 (s, 1H), 9.09-9.05 (m, 2H), 8.84 (t, *J* = 7.2 Hz, 1H), 868 (d, *J* = 7.6 Hz, 2H), 8.56 (s, 1H), 7.69 (d, *J* = 2.4 Hz, 1H), 7.59-7.57 (m, 1H), 7.15 (t, *J* = 9.2 Hz, 1H), 7.04 (t, *J* = 7.2 Hz, 1H), 6.65-6.60 (m, 1H), 2.10-5.04 (m, 1H), 4.42-4.35 (m, 1H), 3.66-3.28 (m, 11H), 2.93-2.85 (m, 4H), 2.69-2.35 (m, 5H), 2.33-2.26 (m, 2H), 2.06-2.02 (m, 1H), 0.88-0.84 (m, 2H), 0.59 (d, *J* = 6.8 Hz, 2H)
38	**I-38**	V	AG	934.9	11.11 (s, 1H), 9.08-9.03 (m, 2H), 8.67 (s, 1H), 8.60 (s, 1H), 8.53 (s, 1H), 8.45-8.40 (m, 1H), 7.68 (s, 1H), 7.61-7.54 (m, 1H), 7.17-7.11 (m, 1H), 7.06-7.02 (m, 1H), 6.58-6.55 (m, 1H), 5.05-5.02 (m, 1H), 3.72-3.65 (m, 1H), 3.63-3.61 (m, 2H), 3.60-3.54 (m, 9H), 4.46-3.43 (m, 6H), 3.06 (s, 2H), 2.93-2.86 (m, 2H), 2.68-2.57 (m, 4H), 2.51-2.34 (m, 3H), 2.05-2.03 (m, 1H), 2.02-1.92 (m, 2H), 1.76-1.74 (m, 2H), 1.48-1.42 (m ,4H), 0.97-0.85 (m, 2H), 0.57 (m, 2H)

39	**I-39**	V	(1R,3R)-3-(6-(5-cyano-1H-pyrazolo[3,4-b]pyridin-1-yl)-4-(cyclopropyl-amino)-nicotinamido)-cyclobutane-1-carboxylic acid (synthesized via Step 1-2 of Method 3 for Example 21)	906.8	11.12 (s, 1H), 9.07-9.04 (m, 2H), 8.87-8.84 (m, 1H), 8.68-8.67 (m, 2H), 8.57 (s, 1H), 7.70 (s, 1H), 7.58-7.56 (m, 1H), 7.16-7.12 (m, 1 Hz, 1H), 7.05-7.02 (m, 1H), 6.61-6.59 (m, 1H), 5.08-5.04 (m, 1H), 4.42-4.40 (m, 1H), 3.64-3.62 (m, 2H), 3.61-3.54 (m, 11H), 3.53-3.50 (m, 3H), 2.91 (s, 2H), 2.86 (s, 1H), 2.68-2.57 (m, 4H), 2.51-2.46 (m, 3H), 2.34-2.29 (m, 3H), 2.05-0.02 (m, 1H), 0.87-0.85 (m, 2H), 0.57 (s, 2H)

*Step 1 was ran at 80-90 °C for 1-1.5 h. The intermediate of Step 2 could also be triturated with similar solvents to MBTE, such as diethyl ether. The final product of Step 3 was often purified by silica gel column chromatography (10% MeOH-DCM) first, then preparative HPLC (0.1% formic acid in water/ACN). [a]Step 2 was run for 16 h at rt and the intermediate was not triturated.

[004864] Example 40 [Method 6): 6-((l.,6-naphthyridin-2-vDaminoV4-(cvclopropylamino)-N-(YlR.,4R)-4-((2-(2-(2-(Y2-(2.,6-dioxopiperidin-3-vP-l.,3-dioxoisoindolin-4-vnamino)ethoxy)ethoxy)ethylKmethvn carbamovncvclohexynnicotinamide, 1-40



[004865] Step 1 - /d/V-butyl (2-(2-(2-(YlR.4R)-4-(6-(Yl.6-naphthyridin-2-vOamino)-4-(cvclopropylamino)nicotinamido)-N-methylcvclohexane-l-carboxamido)ethoxy)ethoxy) ethvOcarbamate

[004866] A solution of (lR,4R)-4-(6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino) nicotinamido)cyclohexane-l -carboxylic acid (0.7 g, 1.57 mmol, Intermediate C), /er/-butyl(2-(2-(2-(methylamino)ethoxy)ethoxy)ethyl)carbamate (0.42 g, 1.57 mmol, Intermediate AC), PyBOP (1.23 g, 2.40 mmol) and DIPEA (0.7 mL, 2.5 mmol) in DMF (10 mL) was stirred at rt for 2 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 30 mL). The combined organic layer was dried over anhydrous sodium sulfate

and filtered. The filtrate was evaporated under reduced pressure and the crude product which was purified using silica gel column chromatography (5% MeOH-DCM) to give *tert*-butyl (2-(2-(2-((lR,4R)-4-(6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)nicotinamido)-N-methylcyclohexane-l-carboxamido)ethoxy)ethoxy) ethyl)carbamate as a yellow solid (0.3 g, 24%)

[004867] LC-MS (ESI^+) *m/z* 494.5 $(M+H)^+$.

[004868] Step 2 - 6-((1.6-naphthyridin-2-yl)amino)-N-(Tl R.4R)-4-((2-(2-(2-aminoethoxy) ethoxyfethvOfmethvOcarbamovOcvclohexyl M-fcvclopropylaminofnicotinamide hydrochloride


[004869] To the solution of *tert*-butyl (2-(2-(2-((lR,4R)-4-(6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropyl amino)nicotinamido)-N-methylcyclohexane-l-carboxamido)ethoxy)ethoxy)ethyl)-carbamate (0.3 g, 0.43 mmol) in DCM (3 mL) was added 4N HC1 in dioxane (2 mL) at 0 °C. The reaction mixture was allowed to warm to rt and stirred for 3 h. The reaction mixture was then evaporated under vacuum to afford the crude product which was triturated using MTBE (5 mL) to give 6-((l,6-naphthyridin-2-yl)amino)-N-((lR,4R)-4-((2-(2-(2-aminoethoxy) ethoxy)ethyl)-(methyl)carbamoyl)cyclohexyl)-4-(cyclopropylamino)nicotinamide hydrochloride as a light yellow solid (0.25 g, 97%). LC-MS (ESI^+) *m/z* 591.4 $(M+H)^+$.

[004870] Step 3 - 6-(YL6-naphthyridin-2-v0amino)-4-(cvclopropylamino)-N-((TR.4R)-4-((2-(2-(2-((2-(2.6-dioxopiper i din-3-vl)-1.3-dioxoisoindolin-4-vDaminofethoxyfethoxyfethvDfmethvD carbamovDcvclohexyDnicotinamide

[004871] A solution of 6-((l,6-naphthyridin-2-yl)amino)-N-((lR,4R)-4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)(methyl)carbamoyl)cyclohexyl)-4-(cyclopropylamino) nicotinamidehydrochloride (0.25 g, 0.42 mmol), 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-l,3-dione (0.13 g, 0.46 mmol, Intermediate R) and DIPEA (0.22 mL, 1.26 mmol) in DMF (2 mL) was heated at 90 °C for 1 h. The reaction mixture was then transferred into ice water and the resulting mixture was extracted using ethyl acetate (3 x 20 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified using preparative HPLC (0.1% formic acid in water/ ACN) to give 6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)-N-((lR,4R)-4-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)(methyl) carbamoyl)cyclohexyl)nicotinamide **1-40** as yellow solid (0.01 g, 5%). ^1H NMR (400 MHz, DMSO) δ 11.11 (s, 1H), 10.35 (s, 1H), 9.05 (s, 1H), 8.57-8.56 (m, 3H), 8.42 (d, *J* = 5.2 Hz, 1H), 8.28 (d, *J* = 9.2 Hz, 1H), 7.16 (s, 1H), 8.14-8.11 (m, 1H), 7.61-


7.50 (m, 3H), 7.16-7.13 (m, 1H), 7.06-7.03 (m, 1H), 6.62 (t, *J* = 5.6 Hz, 1H), 5.03 (t, *J* = 8.4 Hz, 1H), 3.64-3.34 (m, 11H), 3.03 (s, 2H), 2.85 (s, 2H), 2.67-2.50 (m, 3H), 2.04 (bs, 1H), 1.90-1.80 (m, 2H), 1.46-1.38 (m, 4H), 0.95 (t, *J* = 5.2 Hz, 1H), 0.57 (s, 1H). LC-MS (ESI$^+$) *m/z* 848 (M+H)$^+$.

[004872] **Example 41: 6-((1,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)-N-((1r,4r)-4-((2-((5-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)methyl)pyridin-2-yl)methoxy)ethyl)carbamoyl)cyclohexyl)nicotinamide, I-41**




[004873] 6-((1,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)-N-((1r,4r)-4-((2-((5-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)methyl)pyridin-2-yl)methoxy)ethyl)carbamoyl)cyclohexyl)nicotinamide **1-41** was synthesized via Method 6 using Intermediate AF as the amine and Intermediate C as the acid in Step 1. In Step 3, Intermediate R was used as the fluorine and the reaction was run for 2 h at 90 °C. The final product was purified first by silica gel column chromatography (15% MeOH-DCM) followed by preparative HPLC (0.1% formic acid in water/ACN). Characterization of the final product: ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.13 (s, 1H), 10.37 (s, 1H) 9.06 (s, 1H), 8.60-8.55 (m, 3H), 8.49 (s, 1H), 8.43 (s, 1H), 8.28 (d, *J* = 9.2 Hz, 1H), 8.15 (d, *J* = 8.0 Hz, 1H), 7.91 (t, *J* = 5.2 Hz, 1H), 7.76 (d, *J* = 6.4 Hz, 1H), 7.61-7.55 (m, 2H), 7.52 (d, *J* = 9.2 Hz, 1H), 7.43 (d, *J* = 7.6 Hz, 1H), 7.17 (d, *J* = 8.4 Hz, 1H), 7.05 *(d, J* = 7.2 Hz, 1H), 6.70-6.60 (m, 1H), 5.11-5.06 (m, 1H), 4.65-4.50 (m, 4H), 3.75-3.65 (m, 3H), 3.60-3.50 (m, 4H), 3.33-3.25 (m, 2H), 3.30-2.80 (m, 2H), 2.70-2.60 (m, 2H), 2.22-2.00 (m, 2H), 1.95-1.85 (m, 2H), 1.80-1.60 (m, 2H), 1.50-1.25 (m, 4H), 0.95 *(d, J* = 5.2 Hz, 2H), 0.59 (s, 2H), LC-MS (ESI$^+$) *m/z* 909.8 (M+H)$^+$.

[004874] **Example 42: 6-(5-cyano-1H-pyrazolo[3,4-b]pyridin-1-yl)-4-(cyclopropylamino)-N-((1r,4r)-4-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl (methyl)carbamoyl)cyclohexyl)nicotinamide, 1-42**



[004875] 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(cyclopropylamino)-N-((lr,4r)-4-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)(methyl)carbamoyl)cyclohexyl)nicotinamide **1-42** was synthesized via Method 6 using Intermediate AC as the amine and Intermediate AG as the acid in Step 1. In Step 3, Intermediate R was used as the fluorine. Characterization of the final product: ^{1}H NMR (400 MHz, DMSO) δ 11.13 (s, 1H), 9.07 (s, 1H), 9.04 (d, *J* = 2 Hz, 1H), 8.67 (s, 1H), 8.60 (t, *J* = 4.4 Hz, 1H), 8.53 (s, 1H), 8.45-8.39 (m, 1H), 7.68 (s, 1H), 7.62-7.57 (m, 1H), 7.18-7.14 (m, 1H), 7.07-7.03 (m, 1H), 6.63 (bs, 1H), 5.10-5.05 (m, 1H), 3.70 (bs, 1H), 3.63-3.39 (m, 11H), 3.04 (s, 2H), 2.93-2.85 (m, 1H), 2.80 (s, 2H), 2.68-2.51 (m, 4H), 2.09-2.04 (m, 1H), 1.92-1.85 (m, 2H), 1.74-1.72 (m, 2H), 1.47-1.40 (m, 4H), 0.87(d, *J* = 5.2 Hz, 1H), 0.58 (s, 2H). LC-MS (ESI$^+$) *m/z* 846.2


[004876] **Example 43: 6-Rl,6-naphthyridin-2-vnamino)-4-fcvclopropylamino)-N-fl-f2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-vP-l,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)acetyl) piperidin-4-vnnicotinamide, 1-43**



[004877] 6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)-N-(l-(2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)acetyl)piperidin-4-yl)nicotinamide **1-43** was synthesized via Method 6 using Intermediate EO as the amine and 2,2-dimethyl-4-oxo-3,8,ll,l4-tetraoxa-5-azahexadecan-l6-oic acid (CAS # 462100-06-7) as the acid in Step 1. In Step 3, Intermediate R was used as the fluorine. Characterization of the final product: ^{1}H NMR (400 MHz, DMSO) δ 11.11 (s, 1H), 10.36 (s, 1H), 9.05 (s, 1H), 8.57-8.54 (m, 3H), 8.43 (s, 1H), 8.28 (d, *J* = 9.2 Hz, 1H), 8.22-8.16 (m, 1H), 7.59-7.49 (m, 3H), 7.14 (d, *J* = 8.4 Hz, 1H), 7.04 (d, *J* = 6.8 Hz, 1H), 6.61 (t, *J* = 5.6 Hz, 1H), 5.08-5.03 (m, 1H), 4.30-4.27


(m, 1H), 4.19-4.08 (m, 2H), 3.99-3.97 (m, 1H), 3.83-3.80 (m, 1H), 3.83-3.61 (m, 2H), 3.57-3.33 (m, 8H), 3.10-3.00 (m, 1H), 2.88-2.85 (m, 1H), 2.70-2.50 (m, 5H), 2.04-2.01 (m, 1H), 1.90-1.75 (m, 2H), 1.55-1.30 (m, 2H), 0.95 (d, J = 5.2 Hz, 1H), 0.58 (s, 1H). LC-MS (ESI^+) *m/z* 849.4 $(M+H)^+$.

[004878] Example 44: 6-(5-cvano-lH-pyrazolo[3.,4-blpyridin-l-vP-4-(cyclopropylamino)-N-((1r,4r)-4-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yP-l,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl) (methvPcarbamovPcvclohexyPnicotinamide, 1-44




[004879] 6-((l,6-naphthyridin-2-yl)amino)-4-(cyclopropylamino)-N-((lr,3r)-3-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)(methyl) carbamoyl)cyclobutyl)nicotinamide **1-44** was synthesized via Method 6 using Intermediate AC as the amine and Intermediate O as the acid in Step 1. In Step 3, Intermediate R was used as the fluorine. Characterization of the final product: ^1H NMR (400 MHz, DMSO) δ 11.10 (s, 1H), 10.36 (d, J = 4 Hz, 1H), 9.05 (s, 1H), 8.57-8.56 (m, 3H), 8.47 (s, 1H), 8.28 (d, j = 9.2 Hz, 1H), 7.60-7.50 (m, 3H), 7.16 (t, j = 8.4 Hz, 1H), 7.05-7.02 (m, 1H), 6.63-6.60 (m, 1H), 5.08-5.03(m, 1H), 4.38-4.30 (m, 1H), 3.64-3.44 (m, 12H), 2.91 (s, 3H), 2.67-2.54 (m, 3H), 251-2.50 (m, 3H), 2.42-2.24 (m, 3H), 2.04-2.01 (m, 1H), 0.94 (t, J = 6.4 Hz, 1H), 0.57 (t, j = *6.4* Hz, 1H). LC-MS (ESI^+) *m/z* 818.92 $(M+H)^+$.

[004880] Example 45: 6-(5-cvano-lH-pyrazolo[3.,4-blpyridin-l-vP-4-(cyclopropylamin(p-N-((lR,4R)-4-((14-((2-(2,6-dioxopiperidin-3-vP-l,3-dioxoisoindolin-4-vPamino)-3,9,12-trioxa-6-azatetradecvPcarbamovPcvclohexyPnicotinamide, 1-45



[004881] 6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(cyclopropylamino)-N-((lR,4R)-4-((l4-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)amino)-3,9,l2-trioxa-6-azatetradecyl)carbamoyl)cyclohexyl)nicotinamide **1-45** was prepared via Method 6 using Intermediate ER as the amine and Intermediate AG as the acid in Step 1. In Step 2, the BOC intermediate was deprotected using TFA at rt in DCM for 2 h. In Step 3, Intermediate R was used as the fluorine and the reaction was run at 80 °C for 2 h. Characterization of the final product: 'H NMR (400 MHz, DMSO-i&) δ 11.05 (s, 1H), 9.08-9.04 (m, 2H), 8.67 (s, 1H), 8.61 (s, 1H), 8.56 (s, 1H), 8.42 (d, *J* = 7.2 Hz, 1H), 7.86-7.83 (m, 1H), 7.69 (s, 1H), 7.61-7.57 (m, 1H), 7.17-7.15 (m, 1H), 7.06-7.04 (m, 1H), 6.64-6.61 (m, 1H), 5.09-5.05 (m, 1H), 3.74-3.72 (m, 2H), 3.65-3.63 (m, 5H), 3.60-3.59 (m, 6H), 3.41-3.38 (m, 4H), 3.23-3.20 (m, 2H), 2.94-2.90 (m, 1H), 2.76-2.74 (m, 4H), 2.69-2.62 (m, 2H), 2.15-2.09 (m, 2H), 2.03-1.93 (m, 2H), 1.90-1.79 (m, 2H), 1.50-1.31 (m, 5H), 0.89-0.86 (m, 2H), 0.58 (s, 2H), LC-MS (ESI$^+$) *m/z* 919.09 (M+H)$^+$.

[004882] Example 46 [Method 7): 6-f5-Cvanopyrazolo[3,4-b1pyridin-l-vB-4-(cyclopropylamino)-N-[3-[2-[2-[2-[[2-(2.,6-dioxo-3 -piperidvB-l,3-dioxo-isoindolin-4-yl] amino] ethoxy] ethoxy] ethoxy] -2-fluoro-propyl] pyridine-3-carboxamide, 1-46



[004883] Step 1 - Tert-butyl N-[2-[2-[2-[3-[6-(5-cyanopyrazolo[3,4-b]pyridin-1-yl)-4-(cyclopropylamino) pyridine-3-carbonyl]amino]-2-fluoro-propoxy]ethoxy]ethoxy]ethyl]carbamate

[004884] To a solution of tert-butyl N-[2-[2-[2-(3-amino-2-fluoro-propoxy)ethoxy]ethoxy]ethyl]carbamate (200 mg, 617 umol, Intermediate AI), 6-(5-cyanopyrazolo[3,4-b]pyridin-1-yl)-4-(cyclopropylamino) pyridine-3-carboxylic acid (268 mg, 617 umol, Intermediate L, as the TFA salt) and DIPEA (398 mg, 3.08 mmol) in DMF (3 mL) was added HATU (281 mg, 740 umol). The mixture was stirred at rt for 1 h. On completion, the reaction mixture was diluted with H_20 (30 mL), extracted with EA (3 X 20 mL), dried with Na_2S0_4, filtered

and concentrated *in vacuo*. The residue was purified by prep-HPLC (0.1% $NH_3 \cdot H_2O$) to give the title compound (82.0 mg, 21% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 627.4 $(M+H)^+$.

[004885] Step 2 - N-r3-r2-r2-(2-aminoethoxy)ethoxy1ethoxy1-2-fluoro-propyl1-6-(5-cvanopyrazolor3.4-b1 pyridin-l-vD-4-(cvclopropylamino)pyridine-3 -carboxamide

[004886] To a solution of tert-butyl N-[2-[2-[2-[3-[[6-(5-cyanopyrazolo[3,4-b]pyridin-l-yl)-4-(cyclopropylamino)pyridine-3-carbonyl]amino]-2-fluoro-propoxy]ethoxy]ethoxy]ethyl]carbamate (90.0 mg, 144 umol) in DCM (2 mL) was added HC1 in dioxane (4 M, 2 mL). The mixture was stirred at rt for 15 minutes. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (75.0 mg, 93% yield) as a yellow oil. LC-MS (ESL) *m/z* 527.4 $(M+H)^+$.

[004887] Step 3 - 6-(5-Cvanopyrazolor3.4-b1pyridin-l-vD-4-(cvclopropylamino)-N-r3-r2-[2-[2-[[2-(2,6-dioxo-3 -piperidvn-L3-dioxo-isoindolin-4-yl1amino1ethoxy1ethoxy1ethoxy1-2-fluoro-propynpyridine-3-carboxamide

[004888] To a solution of N-[3-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]-2-fluoro-propyl]-6-(5-cyanopyrazolo[3,4 -b]pyridin-l-yl)-4-(cyclopropylamino)pyridine-3-carboxamide (75.0 mg, 133 umol, HC1 salt) in dioxane (4 mL) was added DIPEA (172 mg, 1.33 mmol) and 2-(2,6-dioxo-3-piperidyl)-4-fluoro- isoindoline-l,3-dione (36.8 mg, 133 umol, Intermediate R). The mixture was heated to 115 °C and stirred for 60 h. On completion, the mixture was concentrated *in vacuo*. The residue was further purification by pre-HPLC (column: Boston Green ODS 150*30 5u; mobile phase: [water (0.225%FA)-ACN]; B%: 32%-62%, lOmin) to give the title compound **1-46** (42.0 mg, 38% yield) as yellow solid. ^1H NMR (400MHz, DMSO-^e) δ 11.16 - 11.08 (m, 1H), 9.09 - 9.06 (m, 1H), 9.05 - 9.02 (m, 1H), 8.85 (t, *J* = 5.2 Hz, 1H), 8.68 (s, 1H), 8.64 (s, 1H), 8.59 - 8.54 (m, 1H), 7.71 (s, 1H), 7.59 - 7.53 (m, 1H), 7.15 (d, *J* = 8.8 Hz, 1H), 7.04 (d, *J* = 6.8 Hz, 1H), 6.63 - 6.59 (m, 1H), 5.09 - 5.02 (m, 1H), 4.87 - 4.70 (m, 1H), 3.71 - 3.65 (m, 1H), 3.64 - 3.61 (m, 2H), 3.60 - 3.52 (m, 10H), 3.50 - 3.46 (m, 2H), 2.91 - 2.83 (m, 1H), 2.63 - 2.56 (m, 2H), 2.56 - 2.54 (m, 2H), 2.07 - 1.99 (m, 1H), 0.90 - 0.83 (m, 2H), 0.57 - 0.55 (m, 2H); LC-MS (ESI^+) *m/z* 783.2 $(M+H)^+$.

[004889] **Table 5: Compounds synthesized via Method 7, with the coupling of amines and acids in Step 1, followed by the addition to fluoride Intermediate R in Step 3**

Ex-#	I-#	Intermediate Amine	Intermediate Acid	LCMS (ES+) m/z	HNMR (400MHz, DMSO-d6) δ

				$(M+H)^+$	
47[c]	**I-47**	BR	N	984.6	11.11 (s, 1H), 10.37 (s, 1H), 9.05 (s, 1H), 8.58 - 8.55 (m, 4H), 8.46 (s, 1H), 8.28 (s, 1H), 7.61 - 7.55 (m, 2H), 7.51 (d, *J* = 8.8 Hz, 1H), 7.14 (d, *J* = 8.4 Hz, 1H), 7.04 (d, *J* = 6.8 Hz, 1H), 6.60 (t, *J* = 5.6 Hz, 1H), 5.05 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.83 - 4.69 (m, 1H), 3.50 - 3.42 (m, 22H), 2.96 - 2.78 (m, 2H), 2.61 (s, 2H), 2.55 (d, *J* = 9.2 Hz, 2H), 2.46 (s, 2H), 2.44 - 2.41 (m, 4H), 2.39 - 2.35 (m, 4H), 2.05 - 1.90 (m, 2H), 1.18 - 1.06 (m, 1H), 0.96 - 0.92 (m, 2H), 0.60 - 0.57 (m, 2H)
48	**I-48**	AK	N	872.5	11.10 (s, 1H), 10.36 (s, 1H), 9.05 (s, 1H), 8.59 - 8.55 (m, 3H), 8.46 (s, 1H), 8.26 (d, *J* = 9.2 Hz, 1H), 8.16 (s, 1H), 7.59 - 7.53 (m, 2H), 7.50 (d, *J* = 8.8 Hz, 1H), 7.12 (d, *J* = 8.8 Hz, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.59 (t, *J* = 5.6 Hz, 1H), 5.11 - 5.01 (m, 1H), 4.85 - 4.66 (m, 1H), 3.72 - 3.65 (m, 1H), 3.65 - 3.51 (m, 14H), 3.49 - 3.40 (m, 8H), 2.93-2.80 (m, 1H), 2.65 - 2.55 (m, 2H), 2.55 - 2.51 (m, 2H), 2.07 - 1.96 (m, 1H), 0.97 - 0.91 (m, 2H), 0.61 - 0.55 (m, 2H)
49[c,d]	**I-49**	AI	N	784.1	11.11 (s, 1H), 10.38 (s, 1H), 9.05 (s, 1H), 8.60 - 8.53 (m, 4H), 8.46 (s, 1H), 8.27 (d, *J* = 8.8 Hz, 1H), 7.60 - 7.53 (m, 2H), 7.49 (d, *J* = 8.8 Hz, 1H), 7.12 (d, *J* = 8.4 Hz, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.60 (t, *J* = 5.6 Hz, 1H), 5.05 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.83 - 4.67 (m, 1H), 3.72 - 3.58 (m, 8H), 3.49 - 3.42 (m, 6H), 3.01 - 2.75 (m, 2H), 2.59 - 2.54 (m, 4H), 2.07 - 1.97 (m, 1H), 0.97 - 0.91 (m, 2H), 0.59 - 0.56 (m, 2H)
50[d]	**I-50**	BA	N	828.2	11.11 (s, 1H), 10.37 (s, 1H), 9.05 (s, 1H), 8.60 - 8.52 (m, 4H), 8.45 (s, 1H), 8.27 (d, *J* = 8.8 Hz, 1H), 7.60 - 7.53 (m, 2H), 7.49 (d, *J* = 8.8 Hz, 1H), 7.12 (d, *J* = 8.8 Hz, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.59 (s, 1H),

					5.05 (dd, *J* = 5.2, 12.6 Hz, 1H), 4.84 - 4.66 (m, 1H), 3.70 - 3.53 (m, 18H), 3.05 - 2.71 (m, 2H), 2.64 - 2.57 (m, 2H), 2.57 - 2.53 (m, 2H), 2.07 - 1.97 (m, 1H), 0.97 - 0.90(m, 2H), 0.62 - 0.54 (m, 2H)
51	**I-51**	BP	N	916.5	11.1 (s, 1H), 10.3 (s, 1H), 9.05 (s, 1H), 8.59 - 8.54 (m, 4H), 8.47 (s, 1H), 8.27 (d, *J* = 8.8 Hz, 1H), 7.59 - 7.55 (m, 2H), 7.51 (d, *J* = 8.8 Hz, 1H), 7.13 (d, *J* = 7.2 Hz, 1H), 7.03 (d, *J* = 6.8 Hz, 1H), 6.60 (t, *J* = 5.6 Hz, 1H), 5.06 (dd, *J* = 5.2, 8.8 Hz, 1H), 4.84 - 4.69 (m, 1H), 3.70 - 3.69 (m, 1H), 3.68 - 3.53 (m, 26H), 2.94 - 2.83 (m, 1H), 2.61 (s, 2H), 2.58 - 2.53 (m, 2H), 2.06 - 1.99 (m, 1H), 0.95 - 0.94 (m, 2H), 0.61 - 0.58 (m, 2H)
52	**I-52**	AK	BY	877.3	11.1 (s, 1H), 9.38 (s, 1H), 9.15 (s, 1H), 8.67 (d, *J* = 2.0 Hz, 1H), 8.46 (t, *J* = 5.6 Hz, 1H), 8.30 (s, 1H), 7.95 (d, *J* = 8.8 Hz, 1H), 7.66 - 7.51 (m, 2H), 7.13 (d, *J* = 8.8 Hz, 1H), 7.04 (d, *J* = 6.8 Hz, 1H), 6.60 (t, *J* = 5.6 Hz, 1H), 6.41 (s, 1H), 5.06 (dd, *J* = 5.6, 6.4 Hz, 1H), 4.84 - 4.65 (m, 1H), 3.55 - 3.44 (m, 22H), 2.94 - 2.82 (m, 1H), 2.60 - 2.56 (m, 1H), 2.55 - 2.52 (m, 2H), 2.47 - 2.42 (m, 2H), 2.06 - 1.98 (m, 1H), 0.83 - 0.74 (m, 2H), 0.53 - 0.48 (m, 2H)
53	**I-53**	tert-butyl *N*-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]-ethoxy]ethoxy]-ethyl]carbamate (CAS# 01187-40-0)	CN	1012.0[a]	11.10 (s, 1H), 11.01 (s, 1H), 9.03 (d, *J* = 4.8 Hz, 2H), 8.65 (t, *J* = 5.2 Hz, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.18 - 8.00 (m, 5H), 7.78 (s, 1H), 7.70 (t, *J* = 6.8 Hz, 1H), 7.61 - 7.53 (m, 1H), 7.27 (s, 1H), 7.18 (d, *J* = 6.0 Hz, 1H), 7.12 (d, *J* = 8.4 Hz, 1H), 7.03 (d, *J* = 7.2 Hz, 1H), 6.58 (t, *J* = 6.0 Hz, 1H), 5.05 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.31 - 4.19 (m, 2H), 3.69 - 3.46 (m, 20H), 2.95 - 2.82 (m, 1H), 2.63 - 2.57 (m, 2H), 2.10 - 1.97 (m, 1H)
54[b]	**I-54**	AI	BY	789.1	11.12 (s, 1H), 9.39 (s, 1H), 9.16 (s, 1H), 8.68 (s, 1H), 8.46 (t, *J* = 5.6 Hz,

					1H), 8.40 (s, 1H), 8.18 (s, 1H), 7.95 (d, *J* = 8.8 Hz, 1H), 7.64 - 7.53 (m, 2H), 7.13 (d, *J* = 8.8 Hz, 1H), 7.04 (d, *J* = 7.2 Hz, 1H), 6.65 - 6.56 (m, 1H), 6.41 (s, 1H), 5.06 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.84 - 4.62 (m, 1H), 3.69 - 3.55 (m, 16H), 2.95 - 2.82 (m, 1H), 2.59 - 2.44 (m, 3H), 2.07 - 1.98 (m, 1H), 0.79 - 0.77 (m, 2H), 0.51 - 0.49(m, 2H)
55	**I-55**	BS	N	869.3	11.10 (s, 1H), 10.36 (s, 1H), 9.05 (s, 1H), 8.64 (t, *J* = 5.2 Hz, 1H), 8.59 - 8.55 (m, 3H), 8.47 (s, 1H), 8.27 (d, *J* = 8.8 Hz, 1H), 7.59 - 7.53 (m, 2H), 7.50 (d, *J* = 8.4 Hz, 2H), 7.09 (d, *J* = 8.4 Hz, 1H), 7.01 (d, *J* = 7.2 Hz, 1H), 6.59 (t, *J* = 5 .6 Hz, 1H), 5.05 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.61 - 4.45 (m, 1H), 3.90 (s, 2H), 3.84 - 3.77 (m, 1H), 3.74 - 3.59 (m, 10H), 3.30 - 3.26 (m, 2H), 2.94 - 2.83 (m, 1H), 2.65 - 2.56(m, 2H), 2.50 - 2.41 (m, 2H), 2.06 - 1.97 (m, 1H), 1.22 (d, *J* = 5.2 Hz, 6H), 0.98 - 0.90 (m, 2H), 0.61 - 0.54 (m, 2H)
56	**I-56**	AR	N	812.5	11.11 (s, 1H), 10.36 (s, 1H), 9.05 (s, 1H), 8.62 - 8.51 (m, 4H), 8.27 (d, *J* = 8.8 Hz, 1H), 8.15 (s, 1H), 7.59 - 7.52 (m, 2H), 7.49 (d, *J* = 7.2 Hz, 1H), 7.12 (d, *J* = 8.8 Hz, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.60 (t, *J* = 5.6 Hz, 1H), 5.05 (dd, *J* = 5.2, 12.4 Hz, 1H), 4.56 - 4.39 (dd, *J* = 8.8, 49.6 Hz, 1H), 3.64 - 3.51 (m, 14H), 2.93 - 2.81 (m, 1H), 2.64 - 2.52 (m, 3H), 2.06 - 1.97 (m, 1H), 1.18 (s, 6H), 0.93 (d, *J* = 4.8 Hz, 2H), 0.58 (s, 2H)
57	**I-57**	AK	L	871.4	11.1 (s, 1H), 9.06 (d, *J* = 2.0 Hz, 1H), 9.02 (d, *J* = 2.0 Hz, 1H), 8.86 (t, *J* = 5.6 Hz, 1H), 8.66 (s, 1H), 8.63 (s, 1H), 8.56 (s, 1H), 7.72 (s, 1H), 7.57 (t, *J* = 7.6 Hz, 1H), 7.13 (d, *J* = 8.4 Hz, 1H), 7.03 (d, *J* = 7.2 Hz, 1H), 6.59(t, *J* = 5.6 Hz, 1H), 5.05 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.89 - 4.69 (m, 1H), 3.72 - 3.66 (m, 1H),

					3.59 - 3.47 (m, 22H), 2.89 - 2.85 (m, 1H), 2.65 - 2.59 (m, 2H), 2.58 - 2.48 (m, 2H), 2.07 - 1.98 (m, 1H), 0.89 - 0.83 (m, 2H), 0.60 - 0.56 (m, 2H)
58	**I-58**	AI	BZ	776.4	11.1 (s, 1H), 9.77 (s, 1H), 8.66 - 8.56 (m, 2H), 8.50 (s, 1H), 8.43 (s, 1H), 8.18 (d, *J* = 11.2 Hz, 1H), 7.92 (s, 1H), 7.57 (t, *J* = 7.6 Hz, 1H), 7.14 (d, *J* = 8.8 Hz, 1H), 7.03 (d, *J* = 7.2 Hz, 1H), 6.61 (t, *J* = 5.6 Hz, 1H), 5.10 - 5.01 (m, 1H), 4.83 - 4.63 (m, 1H), 3.66 -3.62 (m, 1H), 3.56 -3.49 (m, 14H), 2.87 (d, *J* = 14.8 Hz, 1H), 2.71 - 2.61 (m, 2H), 2.58 - 2.56 (m, 2H), 2.06-1.97 (m, 1H), 0.86 -0.85 (m, 2H), 0.53 - 0.47 (m, 2H)
59	**I-59**	AR	L	811.4	11.11 (s, 1H), 9.09 - 9.06 (m, 1H), 9.03 (d, *J* = 1.6 Hz, 1H), 8.87 - 8.82 (m, 1H), 8.67 (s, 1H), 8.63 (s, 1H), 8.61 (s, 1H), 7.71 (s, 1H), 7.56 (t, *J* = 8.0 Hz, 1H), 7.13 (d, *J* = 8.8 Hz, 1H), 7.02 (d, *J* = 6.8 Hz, 1H), 6.63 - 6.58 (m, 1H), 5.05 (dd, *J* = 5.6, 12.4 Hz, 1H), 4.60 - 4.41 (m, 1H), 3.79 - 3.70 (m, 1H), 3.66 - 3.62 (m, 2H), 3.60 - 3.51 (m, 10H), 2.91 - 2.82 (m, 1H), 2.63 - 2.55 (m, 2H), 2.55 - 2.53 (m, 2H), 2.07 - 1.98 (m, 1H), 1.20 (s, 6H), 0.89 - 0.82 (m, 2H), 0.60 - 0.53 (m, 2H)
60	**I-60**	AP	L	899.7	11.10 (br s, 1H), 9.07 (d, *J* = 2.0 Hz, 1H), 9.03 (d, *J* = 2.0 Hz, 1H), 8.86 (t, *J* = 5.6 Hz, 1H), 8.67 (s, 1H), 8.64 (s, 1H), 8.62 (s, 1H), 7.72 (s, 1H), 7.60 - 7.54 (m, 1H), 7.13 (d, *J* = 8.8 Hz, 1H), 7.03 (d, *J* = 7.2 Hz, 1H), 6.60 (t, *J* = 5.6 Hz, 1H), 5.06 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.60 - 4.43 (m, 1H), 3.79 - 3.64 (m, 1H), 3.63 - 3.59 (m, 2H), 3.56 - 3.43 (m, 19H), 2.95 - 2.83 (m, 1H), 2.63 - 2.54 (m, 3H), 2.07 - 1.98 (m, 1H), 1.21 (s, 6H), 0.89 - 0.83 (m, 2H), 0.60 - 0.55 (m, 2H)
61	**I-61**	AV	N	740.3	11.11 (s, 1H), 10.38 (s, 1H), 9.06 (s, 1H), 8.60 - 8.56 (m, 3H), 8.54 (s,

					1H), 8.28 (d, *J* = 9.2 Hz, 1H), 8.21 (s, 1H), 7.61 - 7.55 (m, 2H), 7.50 (d, *J* = 9.2 Hz, 1H), 7.15 (d, *J* = 8.8 Hz, 1H), 7.03 (d, *J* = 7.2 Hz, 1H), 6.63 (t, *J* = 6.0 Hz, 1H), 5.06 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.86 - 4.66 (m, 1H), 3.74 - 3.69 (m, 1H), 3.67 - 3.60 (m, 8H), 3.51 - 3.49 (m, 2H), 2.92 - 2.82 (m, 1H), 2.65 - 2.54 (m, 2H), 2.58 - 2.53 (m, 2H), 2.07 - 1.95 (m, 1H), 0.98 - 0.91 (m, 2H), 0.62 - 0.55 (m, 2H)
62	**I-62**	AM	N	798.4	11.10 (s, 1H), 10.36 (s, 1H), 9.05 (s, 1H), 8.59 - 8.50 (m, 4H), 8.27 (d, *J* = 8.8 Hz, 1H), 8.18 (s, 1H), 7.59 - 7.54 (m, 2H), 7.51 (d, *J* = 8.8 Hz, 1H), 7.12 (d, *J* = 8.8 Hz, 1H), 7.02 (d, *J* = 6.6 Hz, 1H), 6.60 (t, *J* = 5.6 Hz, 1H), 5.05 (dd, *J* = 5.6, 12.6 Hz, 1H), 4.65 - 4.47 (m, 1H), 3.67 -3.65 (m, 1H), 3.64 - 3.54 (m, 14H), 2.93 - 2.86 (m, 1H), 2.65 - 2.54 (m, 2H), 2.56 - 2.54 (m, 1H), 2.06 - 1.97 (m, 1H), 1.14 (t, *J* = 5.6 Hz, 3H), 0.97 - 0.91 (m, 2H), 0.60 - 0.58 (m, 2H)
63	**I-63**	AM	L	797.4	11.10 (s, 1H), 9.07 (d, *J* = 1.6 Hz, 1H), 9.02 (d, *J* = 2.0 Hz, 1H), 8.86 - 8.78 (m, 1H), 8.66 (s, 1H), 8.63 (d, *J* = 1.6 Hz, 1H), 8.57 (d, *J* = 6.4 Hz, 1H), 7.71 (d, *J* = 2.8 Hz, 1H), 7.56 (t, *J* = 7.6 Hz, 1H), 7.12 (d, *J* = 8.4 Hz, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.59 (t, *J* = 5.6 Hz, 1H), 5.05 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.70 - 4.48 (m, 1H), 3.73 - 3.66 (m, 1H), 3.63 (t, *J* = 5.2 Hz, 4H), 3.59 - 3.50 (m, 8H), 3.48 - 3.45 (m, 2H), 2.94 - 2.82 (m, 1H), 2.62 - 2.55 (m, 2H), 2.55 - 2.53 (m, 1H), 2.07 - 1.98 (m, 1H), 1.15 - 1.12 (m, 3H), 0.90 - 0.82 (m, 2H), 0.59 - 0.53 (m, 2H)
64	**I-64**	AP	N	900.6	(CD_3CN) δ 10.01 (br s, 1H), 9.04 (s, 1H), 8.58 (d, *J* = 5.6 Hz, 1H), 8.51 (s, 1H), 8.49 (s, 1H), 8.29 (s, 1H), 8.19 (d, *J* = 8.8 Hz, 1H), 8.11 (s, 1H), 7.65 (d, *J* = 5.6 Hz, 1H), 7.52

					(t, *J* = 8.0 Hz, 1H), 7.37 (d, *J* = 8.8 Hz, 1H), 7.34 (s, 1H), 7.03 (s, 1H), 7.01 (d, *J* = 2.4 Hz, 1H), 6.46 (t, *J* = 5.6 Hz, 1H), 4.98 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.56 - 4.39 (m, 1H), 3.90 - 3.74 (m, 1H), 3.66 (t, *J* = 5.2 Hz, 2H), 3.63 - 3.47 (m, 17H), 3.43 (q, *J* = 5.2 Hz, 2H), 2.84 - 2.61 (m, 4H), 2.17 - 2.10 (m, 1H), 1.26 (s, 6H), 1.02 - 0.95 (m, 2H), 0.68 - 0.61 (m, 2H)
65	**I-65**	AR	BY	817.3	11.08 (s, 1H), 9.36 (s, 1H), 9.14 (s, 1H), 8.64 (s, 1H), 8.43 (t, *J* = 5.6 Hz, 1H), 8.33 (s, 1H), 8.13 (s, 1H), 7.95 (d, *J* = 8.8 Hz, 1H), 7.63 - 7.52 (m, 2H), 7.13 (d, *J* = 8.4 Hz, 1H), 7.03 (d, *J* = 6.8 Hz, 1H), 6.59 (t, *J* = 5.6 Hz, 1H), 6.40 (s, 1H), 5.04 (dd, *J* = 5.2, 12.4 Hz, 1H), 4.55 - 4.36 (m, 1H), 3.64 - 3.44 (m, 14H), 2.93 - 2.82 (m, 1H), 2.63 - 2.54 (m, 2H), 2.45 - 2.39 (m, 1H), 2.06 - 1.97 (m, 1H), 1.17 (s, 6H), 0.80 - 0.74 (m, 2H), 0.51 - 0.46 (m, 2H)
66	**I-66**	AS	L	885.5	11.10 (s, 1H), 9.06 (d, *J* = 1.6 Hz, 1H), 9.02 (d, *J* = 2.0 Hz, 1H), 8.87 - 8.80 (m, 1H), 8.66 (s, 1H), 8.63 (s, 1H), 8.58 (d, *J* = 7.6 Hz, 1H), 7.71 (d, *J* = 1.6 Hz, 1H), 7.56 (t, *J* = 8.0 Hz, 1H), 7.12 (d, *J* = 8.8 Hz, 1H), 7.03 (d, *J* = 7.2 Hz, 1H), 6.59 (t, *J* = 5.2 Hz, 1H), 5.05 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.73 - 4.49 (m, 1H), 3.74 - 3.64 (m, 2H), 3.61 (t, *J* = 5.2 Hz, 2H), 3.58 - 3.47 (m, 17H), 3.45 (d, *J* = 5.4 Hz, 2H), 2.97 - 2.81 (m, 1H), 2.63 - 2.56 (m, 2H), 2.55 - 2.53 (m, 1H), 2.06 - 1.96 (m, 1H), 1.19 - 1.13 (m, 3H), 0.90 - 0.83 (m, 2H), 0.57 - 0.55 (m, 2H)
67	**I-67**	AR	BZ	804.4	11.10 (s, 1H), 8.61 - 8.55 (m, 2H), 8.52 (s, 1H), 8.16 (dd, *J* = 1.6, 11.2 Hz, 1H), 7.91 (s, 1H), 7.57 - 7.53 (m, 1H), 7.13 (d, *J* = 8.8 Hz, 1H), 7.02 (d, *J* = 6.8 Hz, 1H), 6.59 (t, *J* = 5.6 Hz, 1H), 5.05 (dd, *J* = 5.2, 12.8

					Hz, 1H), 4.56 - 4.37 (m, 1H), 3.67 - 3.49 (m, 14H), 2.94 - 2.82 (m, 1H), 2.63 - 2.52 (m, 2H), 2.46 - 2.42 (m, 1H), 2.07 - 1.96 (m, 1H), 1.17 (s, 6H), 0.88 - 0.80 (m, 2H), 0.53 - 0.46 (m, 2H)
68	**I-68**	AP	BY	905.4	11.10 (s, 1H), 9.37 (s, 1H), 9.15 (s, 1H), 8.66 (d, *J* = 2.0 Hz, 1H), 8.45 (t, *J* = 5.6 Hz, 1H), 8.40 (s, 1H), 8.35 (s, 1H), 7.95 (d, *J* = 8.8 Hz, 1H), 7.65 - 7.52 (m, 2H), 7.13 (d, *J* = 8.8 Hz, 1H), 7.04 (d, *J* = 6.8 Hz, 1H), 6.60 (t, *J* = 5.6 Hz, 1H), 6.41 (s, 1H), 5.06 (dd, *J* = 5.2, 12.9 Hz, 1H), 4.63 - 4.34 (m, 1H), 3.68 (d, *J* = 14.4 Hz, 1H), 3.63 - 3.59 (m, 2H), 3.57 - 3.44 (m, 19H), 2.95 - 2.80 (m, 1H), 2.64 - 2.53 (m, 2H), 2.44 – 2.43 (m, 1H), 2.07 - 1.98 (m, 1H), 1.19 (s, 6H), 0.83 - 0.70 (m, 2H), 0.56 - 0.41 (m, 2H)
69	**I-69**	AP	BZ	892.4	11.11 (s, 1H), 9.73 (s, 1H), 8.66 - 8.51 (m, 3H), 8.44 (s, 1H), 8.17 (dd, *J* = 1.6, 11.0 Hz, 1H), 7.92 (s, 1H), 7.58 (dd, *J* = 7.2, 8.4 Hz, 1H), 7.13 (d, *J* = 8.4 Hz, 1H), 7.04 (d, *J* = 7.2 Hz, 1H), 6.60 (t, *J* = 5.6 Hz, 1H), 5.08 - 5.03 (m, 1H), 4.62 - 4.40 (m, 1H), 3.69 - 3.53 (m, 7H), 3.51 - 3.33 (m, 15H), 3.00 - 2.83 (m, 1H), 2.63 - 2.54 (m, 2H), 2.47 (s, 1H), 2.07 - 1.95 (m, 1H), 1.19 (s, 6H), 0.93 - 0.77 (m, 2H), 0.58 - 0.42 (m, 2H)
70	**I-70**	BT	N	798.3	11.10 (s, 1H), 10.37 (s, 1H), 9.06 (s, 1H), 8.61 - 8.53 (m, 4H), 8.30 - 8.25 (m, 2H), 7.61 - 7.53 (m, 2H), 7.51 (d, *J* = 8.8 Hz, 1H), 7.13 (d, *J* = 8.4 Hz, 1H), 7.03 (d, *J* = 6.4 Hz, 1H), 6.61 (t, *J* = 5.6 Hz, 1H), 5.05 (dd, *J* = 5.6, 13.2 Hz, 1H), 4.85 - 4.66 (m, 1H), 3.60 - 3.45 (m, 15H), 2.93 - 2.87 (m, 1H), 2.63 - 2.56 (m, 2H), 2.56 - 2.53 (m, 1H), 2.06 - 1.98 (m, 1H), 1.05 (d, *J* = 6.4 Hz, 3H), 0.98 - 0.91 (m, 2H), 0.62 - 0.54 (m, 2H)
71	**I-71**	BB	L	841.4	11.10 (s, 1H), 9.07 (d, *J* = 2.0 Hz,

					1H), 9.03 (d, *J* = 2.0 Hz, 1H), 8.86 - 8.79 (m, 1H), 8.67 (s, 1H), 8.63 (s, 1H), 8.60 - 8.55 (m, 1H), 7.71 (d, *J* = 2.0 Hz, 1H), 7.56 (t, *J* = 7.6 Hz, 1H), 7.12 (d, *J* = 8.8 Hz, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.59 (t, *J* = 5.6 Hz, 1H), 5.06 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.69 - 4.48 (m, 1H), 3.71 - 3.63 (m, 2H), 3.62 - 3.60 (m, 2H), 3.60 - 3.50 (m, 13H), 3.48 - 3.44 (m, 2H), 2.94 - 2.83 (m, 1H), 2.62 - 2.55 (m, 2H), 2.55 - 2.53 (m, 1H), 2.07 - 1.97 (m, 1H), 1.19 - 1.13 (m, 3H), 0.89 - 0.83 (m, 2H), 0.60 - 0.53 (m, 2H)
72	**I-72**	BA	L	827.4	11.09 (m, 1H), 9.07 (d, *J* = 2.0 Hz, 1H), 9.03 (d, *J* = 2.0 Hz, 1H), 8.85 (t, *J* = 5.6 Hz, 1H), 8.67 (s, 1H), 8.64 (s, 1H), 8.56 (s, 1H), 7.72 (s, 1H), 7.57 (dd, *J* = 7.2, 8.4 Hz, 1H), 7.13 (d, *J* = 8.4 Hz, 1H), 7.03 (d, *J* = 7.2 Hz, 1H), 6.60 (t, *J* = 5.6 Hz, 1H), 5.06 (dd, *J* = 5.6, 13.2 Hz, 1H), 4.88 - 4.70 (m, 1H), 3.75 - 3.44 (m, 20H), 2.94 - 2.83 (m, 1H), 2.63 - 2.53 (m, 3H), 2.07 - 1.99 (m, 1H), 0.90 - 0.83 (m, 2H), 0.60 - 0.54 (m, 2H)
73	**I-73**	BC	L	855.3	11.07 (s, 1H), 9.06 (d, *J* = 1.6 Hz, 1H), 9.02 (d, *J* = 2.0 Hz, 1H), 8.84 (t, *J* = 5.2 Hz, 1H), 8.66 (s, 1H), 8.63 (s, 1H), 8.60 (s, 1H), 7.71 (s, 1H), 7.55 (t, *J* = 8.0 Hz, 1H), 7.12 (d, *J* = 8.4 Hz, 1H), 7.01 (d, *J* = 6.8 Hz, 1H), 6.59 (t, *J* = 5.6 Hz, 1H), 5.04 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.60 - 4.40 (m, 1H), 3.79 - 3.57 (m, 4H), 3.55 - 3.43 (m, 14H), 2.94 - 2.81 (m, 1H), 2.62 - 2.52 (m, 3H), 2.06 - 1.97 (m, 1H), 1.20 (s, 6H), 0.89 - 0.81 (m, 2H), 0.60 - 0.52 (m, 2H)
74	**I-74**	AW	N	724.1	11.10 (s, 1H), 10.37 (s, 1H), 9.06 (s, 1H), 8.65 - 8.54 (m, 4H), 8.28 (d, *J* = 8.8 Hz, 1H), 8.22 (s, 1H), 7.65 - 7.55 (m, 2H), 7.50 (d, *J* = 8.8 Hz, 1H), 7.18 (d, *J* = 8.8 Hz, 1H), 7.05 (d, *J* = 7.2 Hz, 1H), 6.62 (t, *J* = 5.2 Hz, 1H), 5.07 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.65

					- 4.37 (m, 1H), 3.84 - 3.60 (m, 3H), 3.49 - 3.32 (m, 3H), 2.96 - 2.80 (m, 1H), 2.72 - 2.55 (m, 3H), 2.09 - 1.92 (m, 1H), 1.23 (s, 6H), 1.01 - 0.89 (m, 2H), 0.60 - 0.57 (m, 2H)
75	**I-75**	AW	L	723.1	11.10 (s, 1H), 9.06 (dd, *J* = 2.0, 15.6 Hz, 2H), 8.92 - 8.84 (m, 1H), 8.71 - 8.58 (m, 3H), 7.72 (s, 1H), 7.66 - 7.55 (m, 1H), 7.18 (d, *J* = 8.8 Hz, 1H), 7.05 (d, *J* = 6.8 Hz, 1H), 6.62 (t, *J* = 5.6 Hz, 1H), 5.07 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.65 - 4.44 (m, 1H), 3.83 - 3.63 (m, 3H), 3.53 - 3.40 (m, 3H), 2.93 - 2.80 (m, 1H), 2.58 (m, 3H), 2.09 - 1.96 (m, 1H), 1.25 (d, *J* = 2.8 Hz, 6H), 0.89 - 0.84 (m, 2H), 0.59 - 0.55 (m, 2H)
76	**I-76**	AV	L	739.4	11.10 (s, 1H), 9.07 (d, *J* = 2.0 Hz, 1H), 9.04 (d, *J* = 2.0 Hz, 1H), 8.84 (s, 1H), 8.67 (s, 1H), 8.63 (s, 1H), 8.55 (s, 1H), 7.71 (s, 1H), 7.59 - 7.54 (m, 1H), 7.15 (d, *J* = 8.4 Hz, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.65 - 6.60 (m, 1H), 5.05 (m, 1H), 4.87 - 4.71 (m, 1H), 3.75 - 3.60 (m, 9H), 3.55 (m, 1H), 3.49 (m, 2H), 2.94 - 2.80 (m, 1H), 2.59 (s, 3H), 2.03 (m, 1H), 0.89 - 0.84 (m, 2H), 0.57 (m, 2H)
77	**I-77**	AY	N	710.3	11.10 (s, 1H), 10.36 (s, 1H), 9.06 (s, 1H), 8.61 - 8.56 (m, 3H), 8.54 (d, *J* = 5.6 Hz, 1H), 8.27 (d, *J* = 9.2 Hz, 1H), 8.22 (s, 1H), 7.63 - 7.55 (m, 2H), 7.51 (d, *J* = 8.8 Hz, 1H), 7.17 (d, *J* = 8.4 Hz, 1H), 7.05 (d, *J* = 7.2 Hz, 1H), 6.63 (s, 1H), 5.06 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.68 - 4.49 (m, 1H), 3.69 - 3.64 (m, 7H), 2.91 - 2.83 (m, 1H), 2.63 - 2.58 (m, 2H), 2.54 - 2.53 (m, 1H), 2.06 - 1.92 (m, 1H), 1.19 (d, *J* = 5.2 Hz, 3H), 0.98 - 0.92 (m, 2H), 0.58 (s, 2H)
78[c]	**I-78**	tert-butyl *N*-[2-[2-[2-[2-(2-aminoethoxy)-ethoxy]-	CE	837.3	(CD_3CN) δ 9.08 (br s, 1H), 8.43 (s, 1H), 8.17 (br s, 1H), 7.89 (d, *J* = 5.6 Hz, 1H), 7.74 (s, 1H), 7.54 - 7.48 (m, 1H), 7.34 (d, *J* = 5.6 Hz, 1H), 7.09 (br s, 1H), 7.03 - 6.97 (m, 2H),

		ethoxy]ethoxy]-ethyl]carbamate (CAS# 01187-40-0)			6.45 (t, *J* = 5.6 Hz, 1H), 4.98 - 4.81 (m, 2H), 4.68 - 4.64 (m, 1H), 4.36 (dd, *J* = 6.4, 11.2 Hz, 1H), 4.19 - 4.13 (m, 1H), 4.06 (s, 3H), 3.66 - 3.52 (m, 18H), 3.42 (q, *J* = 5.6 Hz, 2H), 2.79 - 2.59 (m, 4H), 2.13 - 2.08 (m, 1H), 1.80 - 1.62 (m, 2H), 1.10 (t, *J* = 7.2 Hz, 3H)
79	**I-79**	AU	L	767.4	11.09 (s, 1H), 9.07 (s, 1H), 9.03 (s, 1H), 8.85 - 8.79 (m, 1H), 8.67 (s, 1H), 8.62 (s, 1H), 8.60 (s, 1H), 7.71 (s, 1H), 7.56 (t, *J* = 7.2 Hz, 1H), 7.15 (d, *J* = 8.8 Hz, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.65 - 6.60 (m, 1H), 5.07 - 5.01 (m, 1H), 4.57 - 4.55 (m, 1H), 3.76 - 3.69 (m, 1H), 3.68 - 3.63 (m, 2H), 3.57 - 3.48 (m, 6H), 2.89 - 2.81 (m, 1H), 2.63 - 2.55 (m, 4H), 2.05 - 1.96 (m, 1H), 1.20 (s, 6H), 0.88 - 0.83 (m, 2H), 0.60 - 0.53 (m, 2H)
80	**I-80**	AU	N	768.4	11.10 (s, 1H), 10.36 (s, 1H), 9.06 (s, 1H), 8.59 - 8.51 (m, 4H), 8.28 (d, *J* = 8.8 Hz, 1H), 8.22 (s, 1H), 7.60 - 7.54 (m, 2H), 7.50 (d, *J* = 8.8 Hz, 1H), 7.15 (d, *J* = 8.4 Hz, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.63 (t, *J* = 5.6 Hz, 1H), 5.04 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.57 - 4.38 (m, 1H), 3.75 - 3.70 (m, 1H), 3.68 - 3.56 (m, 8H), 2.90 - 2.82 (m, 1H), 2.64 - 2.58 (m, 2H), 2.57 - 2.55 (m, 1H), 2.54 - 2.53 (m, 1H), 2.05 - 1.96 (m, 1H), 1.19 (s, 6H), 0.97 - 0.92 (m, 2H), 0.61 - 0.55 (m, 2H)
81	**I-81**	AX	N	696.3	11.1 (s, 1H), 10.4 (s, 1H), 9.06 (s, 1H), 8.60 - 8.56 (m, 3H), 8.54 (s, 1H), 8.28 (d, *J* = 9.2 Hz, 1H), 8.21 (s, 1H), 7.63 - 7.56 (m, 2H), 7.50 (d, *J* = 8.8 Hz, 1H), 7.18 (d, *J* = 8.8 Hz, 1H), 7.05 (d, *J* = 6.8 Hz, 1H), 6.69 - 6.61 (m, 1H), 5.08 - 5.03 (m, 1H), 4.89 - 4.68 (m, 1H), 3.77 - 3.56 (m, 8H), 2.92 - 2.86 (m, 1H), 2.64 - 2.59 (m, 2H), 2.57 - 2.55 (m, 1H), 2.05 - 1.96 (m, 1H), 0.97 - 0.92 (m, 2H), 0.61 - 0.57 (m, 2H)
82	**I-82**	AX	L	695.3	11.1 (s, 1H), 9.09 (d, *J* = 2.0 Hz,

					1H), 9.05 (d, *J* = 2.0 Hz, 1H), 8.90 (t, *J* = 5.2 Hz, 1H), 8.70 (s, 1H), 8.65 (s, 1H), 8.63 (s, 1H), 7.80 (s, 1H), 7.60 (dd, *J* = 7.2, 8.4 Hz, 1H), 7.18 (d, *J* = 8.4 Hz, 1H), 7.05 (d, *J* = 7.0 Hz, 1H), 6.69 - 6.61 (m, 1H), 5.06 (dd, *J* = 5.5, 12.9 Hz, 1H), 4.91 - 4.72 (m, 1H), 3.75 - 3.65 (m, 4H), 3.54 - 3.51 (m, 4H), 2.93 - 2.82 (m, 1H), 2.71 - 2.56 (m, 3H), 2.07 - 1.99 (m, 1H), 0.90 - 0.84 (m, 2H), 0.62 - 0.57 (m, 2H)
83	**I-83**	AY	L	709.3	11.09 (s, 1H), 9.07 (d, *J* = 1.6 Hz, 1H), 9.04 (d, *J* = 1.6 Hz, 1H), 8.86 (s, 1H), 8.67 (s, 1H), 8.64 (s, 1H), 8.56 (d, *J* = 8.4 Hz, 1H), 7.71 (s, 1H), 7.60 (t, *J* = 8.0 Hz, 1H), 7.18 (d, *J* = 8.8 Hz, 1H), 7.05 (d, *J* = 6.8 Hz, 1H), 6.64 (s, 1H), 5.06 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.75 - 4.51 (m, 1H), 3.83 - 3.43 (m, 7H), 2.94 - 2.81 (m, 1H), 2.62 - 2.56 (m, 2H), 2.55 - 2.54 (m, 1H), 2.02 (d, *J* = 9.6 Hz, 1H), 1.24 - 1.17 (m, 3H), 0.89 - 0.84 (m, 2H), 0.60 - 0.55 (m, 2H)
84	**I-84**	AZ	N	754.4	11.11 (s, 1H), 10.37 (s, 1H), 9.06 (s, 1H), 8.63 - 8.40 (m, 3H), 8.33 - 8.18 (m, 2H), 7.60 - 7.48 (m, 3H), 7.15 (d, *J* = 8.4 Hz, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.63 (t, *J* = 5.6 Hz, 1H), 5.05 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.66 - 4.45 (m, 2H), 3.74 - 3.41 (m, 11H), 2.93 - 2.82 (m, 1H), 2.69 - 2.58 (m, 3H), , 2.06 - 1.97 (m, 1H), 1.23 - 1.12 (m, 3H), 1.01 - 0.89 (m, 2H), 0.58 (m, 2H)
85	**I-85**	AZ	L	753.4	11.09 (s, 1H), 9.07 (d, *J* = 2.0 Hz, 2H), 9.03 (s,1H), 8.86 - 8.76 (m, 1H), 8.70 - 8.61 (m, 2H), 8.60 - 8.52 (m, 1H), 7.74 - 7.67 (m, 1H), 7.56 (m, 1H), 7.14 (d, *J* = 8.8 Hz, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.62 (t, *J* = 5.6 Hz, 1H), 5.05 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.72 - 4.48 (m, 1H), 3.76 - 3.45 (m, 11H), 2.97 - 2.80 (m, 1H), 2.64 - 2.54 (m, 3H), 2.09 - 1.96 (m,


					1H), 1.24 - 1.12 (m, 3H), 0.90 - 0.82 (m, 2H), 0.57 (m, 2H)
86	**I-86**	AT	L	795.1	11.1 (s, 1H), 9.07 (d, *J* = 2.0 Hz, 1H), 9.02 (d, *J* = 2.0 Hz, 1H), 8.85 (t, *J* = 5.6 Hz, 1H), 8.66 (s, 1H), 8.63 (s, 1H), 8.60 (s, 1H), 7.71 (s, 1H), 7.57 (t, *J* = 8.0 Hz, 1H), 7.08 (d, *J* = 8.8 Hz, 1H), 7.01 (d, *J* = 7.2 Hz, 1H), 6.71 - 6.61 (m, 1H), 5.07 - 5.00 (m, 1H), 4.57 - 4.41 (m, 1H), 3.80 - 3.46 (m, 10H), 2.95 - 2.80 (m, 1H), 2.63 - 2.55 (m, 3H), 2.06 - 1.97 (m, 1H), 1.87 - 1.78 (m, 2H), 1.77 - 1.68 (m, 2H), 1.18 (s, 6H), 0.89 - 0.83 (m, 2H), 0.61 - 0.53 (m, 2H)
87	**I-87**	tert-butyl N-[2-[2-(2-aminoethoxy)-ethoxy]ethyl]-carbamate (CAS# 153086-78-3)	CE	749.1	11.10 (s, 1H), 8.88 (s, 1H), 8.43 (t, *J* = 5.6 Hz, 1H), 8.15 (s, 1H), 7.90 (d, *J* = 5.6 Hz, 1H), 7.72 (s, 1H), 7.58 - 7.51 (m, 1H), 7.42 (d, *J* = 5.6 Hz, 1H), 7.10 (d, *J* = 8.4 Hz, 1H), 6.99 (d, *J* = 7.2 Hz, 1H), 6.59 (t, *J* = 5.6 Hz, 1H), 5.05 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.99 - 4.82 (m, 1H), 4.54 (dd, *J* = 3.6, 11.2 Hz, 1H), 4.25 (dd, *J* = 6.4, 11.2 Hz, 1H), 4.13 - 4.04 (m, 1H), 3.96 (s, 3H), 3.68 - 3.56 (m, 8H), 3.50 - 3.43 (m, 4H), 2.94 - 2.81 (m, 1H), 2.62 - 2.53 (m, 3H), 2.07 - 1.97 (m, 1H), 1.65 - 1.56 (m, 2H), 1.02 (t, *J* = 7.2 Hz, 3H)
88	**I-88**	BE	L	797.3	11.05 (s, 1H), 9.07 (d, *J* = 2.0 Hz, 1H), 9.03 (d, *J* = 2.0 Hz, 1H), 8.87 (t, *J* = 5.6 Hz, 1H), 8.66 (d, *J* = 6.0 Hz, 2H), 8.58 (s, 1H), 7.72 (s, 1H), 7.60 - 7.51 (m, 1H), 7.12 (d, *J* = 8.8 Hz, 1H), 7.02 (d, *J* = 6.8 Hz, 1H), 6.59 (t, *J* = 6.0Hz, 1H), 5.05 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.88 - 4.67 (m, 1H), 3.65 - 3.60 (m, 2H), 3.58 - 3.46 (m, 14H), 2.94 - 2.83 (m, 1H), 2.63 - 2.54 (m, 3H), 2.08 - 1.98 (m, 1H), 1.96 - 1.75 (m, 2H), 0.90 - 0.80 (m, 2H), 0.61 - 0.51 (m, 2H)

Variations of temperature and time for Method 7 were as follows: Step 1 was run a from 0.5-3 hrs; Step 2 was run from 15-60 minutes; Step 3 was run at 110-115 °C for 14-136 hrs, with most

complete within 40-60 h. rinass is $(M+Na)^+$. [b]Step 1 was ran at rt for 12 h. [c]Step 3 was run at 90 °C for 12 h. [d]The product of Step 1 was purified by silica gel chromatography (DCM: MeOH = 25:1) instead of prep-HPLC.

[004890] **Further Examples using synthetic methods similar to Method 7:**

[004891] **Example 89: 1-[[(2S,3S,4S)-1-[2-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]-3-ethyl-4-fluoro-5-oxo-Pyrrolidin-2-yl]methoxy]-7-methoxy-isoquinoline-6-carboxamide, 1-89**



[004892] Step 1 - Tert-butyl (14-(((2S,3S,4S)-2-(((6-cvano-7-methoxyisoquinolin-1-yl)oxy)methyl)-3-ethyl-4- fluoro-5-oxopyrrolidin-1-yl)-3,6,9,12-tetraoxatetradecyl)carbamate

[004893] To a solution of l-[[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxo-pyrrolidin-2-yl]methoxy]-7-methoxy- isoquinoline-6-carbonitrile (50 mg, 145.6 umol, Intermediate CD) in DMF (3 mL) was added NaH (11.7 mg, 291 umol, 60% dispersion in mineral oil) at 0 °C. The reaction mixture was stirred at 0 °C for 1 hr. Then, 2-[2-[2-[2-[2-(tert-butoxycarbonyl-amino)ethoxy]ethoxy]ethoxy]ethoxy]ethyl methanesulfonate (90.8 mg, 218 umol, synthesized via Steps 1-2 of Intermediate AK) was added. The resulting reaction mixture was allowed to warm to rt and stirred for 12 h. On completion, the reaction mixture was quenched with water (2 mL) and extracted with ethyl acetate (3 X 200 mL). The combined organic layers were washed with

saturated brine solution (50 mL), dried over with anhydrous sodium sulfate, and filtered. The filtrate was concentrated *in vacuo*. The residue was purified by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: l5%-75%) to give the title compound (25 mg, 25% yield) as a colorless oil. ^{1}H NMR (400MHz, CDCh) δ 8.03 (s, 1H), 7.93 (d, *J* = 5.6 Hz, 1H), 7.75 (s, 1H), 7.20 (d, *J* = 5.6 Hz, 1H), 5.10 - 4.92 (m, 2H), 4.85 (dd, 7 = 3.2, 12.4 Hz, 1H), 4.45 (dd, 7 = 2.4, 12.4 Hz, 1H), 4.32 - 4.25 (m, 1H), 4.03 (s, 3H), 3.68 - 3.50 (m, 18H), 3.32 - 3.31 (m, 2H), 2.65 - 2.42 (m, 1H), 1.88 - 1.76 (m, 1H), 1.69 - 1.63 (m, 1H), 1.44 (s, 9H), 1.11 (t, J = 7.2 Hz, 3H). LC-MS (ESI$^+$) *m/z* 663.2 (M+H)$^+$.

[004894] Step 2 - Tert-butyl (T4-((2S,3S,4S)-2-((Y6-carbamoyl-7-methoxyisoquinolin-l-yl)oxy)methvl)-3- ethyl-4-fluoro-5-oxopynOlidin-l-vD-3.6.9.l2-tetraoxatetradecvDcarbamate

[004895] To a solution of tert-butyl N-[2-[2-[2-[2-[2-[(2S, 3S,4S)-2-[(6-cyano-7-m ethoxy- 1-isoquinolyl) oxymethyl]-3-ethyl-4-fluoro-5-oxo-pyrrolidin-lyl]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate (20 mg, 30.2 umol) in DMSO (1 mL) was added K_2CO_3 (4.17 mg, 30.2 umol) at rt. Then, H_2O_2 (6.84 mg, 60.4 umol, 30% solution) was added slowly. The reaction mixture was stirred at rt for 3 h. On completion, the reaction mixture was diluted with water (3 mL) and extracted with ethyl acetate (3 X 20 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (18 mg, 88% yield) as a colorless oil. LC-MS (ESI$^+$) *m/z* 703.2 (M+H)$^+$.

[004896] Step 3 - l-(((2S,3S,4S)-l-(T4-amino-3,6,9,l2-tetraoxatetradecvl)-3-ethyl-4-f uoro-5- oxopyrrolidin- 2-v0methoxy)-7-methoxyisoquinoline-6-carboxamide


[004897] To a solution of tert-butyl N-[2-[2-[2-[2-[2-[(2S,3S,4S)-2-[(6-carbamoyl-7-methoxy-l- isoquinolyl) oxymethyl]-3-ethyl-4-fluoro-5-oxo-pyrrolidin-l-yl]ethoxy]ethoxy]ethoxy]ethoxy]-ethyl]carbamate(l8.0 mg, 26.44 umol) in DCM (2 mL) was added HC1 in dioxane (4 M, 1 mL). The reaction mixture was stirred at rt for 30 min. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (16.3 mg, 99% yield, hydrochloride salt). LC-MS (ESI$^+$) *m/z* 603.2 (M+H)$^+$.

[004898] Step _4 _- _l-[[(2S.3S.4S)-l-[2-[2-[2-[2-[2-[[2-(2.6-dioxo-3-piperi dvl)-l.3-dioxo-isoindolin-4-yllaminol ethoxy1ethoxy1ethoxy1ethoxy1ethyl1-3-ethyl-4-fluoro-5-oxo-pyrrolidin-2-yl1methoxy1-7-methoxy-isoquinoline-6-carboxamide

[004899] To a solution of l-[[(2S,3S,4S)-l-[2-[2-[2-[2-(2-


aminoethoxy)ethoxy]ethoxy]ethoxy]ethyl]-3-ethyl- 4-fluoro-5-oxo-pyrrolidin-2-yl]methoxy]-7-methoxy-isoquinoline-6-carboxamide (16.3 mg, 26.5 umol, HC1 salt) and 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (9.50 mg, 34.4 umol, Intermediate R) in dioxane (5 mL) was added DIPEA (34.2 mg, 46 uL, 264 umol). The reaction mixture was stirred at 120 °C for 76 hrs. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 l50*25*l0um; mobile phase: [water(0.225%FA)-ACN];B%: 35%-65%) to give the title compound **1-89** (10.0 mg, 42% yield,) as a yellow solid. ^{1}H NMR (400MHz, CD_3CN) δ 9.09 (s, 1H), 8.45 (s, 1H), 7.91 (d, *J* = 6.0 Hz, 1H), 7.73 (s, 1H), 7.64 (s, 1H), 7.57 - 7.50 (m, 1H), 7.36 (d, *j* = 6.0 Hz, 1H), 7.04 (s, 1H), 7.02 (d, *j* = 1.6 Hz, 1H), 6.48 (t, *j* = 5.2 Hz, 1H), 6.39 (s, 1H), 5.08 - 4.95 (m, 1H), 4.92 (dd, *j* = 6.0, 8.4 Hz, 1H), 4.81 (dd, *j* = 3.6, 12.4 Hz, 1H), 4.46 (dd, *J* = 3.2, 12.4 Hz, 1H), 4.30 -3.80(m, 1H), 4.02 (s, 3H), 3.82 - 3.80 (m, 1H), 3.71 - 3.42 (m, 18H), 3.41 - 3.33 (m, 1H), 2.84 - 2.48 (m, 4H), 2.14 - 2.09 (m, 1H), 1.81 - 1.63 (m, 2H), 1.08 (t, *j* = 7.2 Hz, 3H). LC-MS (ESI^+) *m/z* 837.1 $(M+H)^+$.

[004900] Example 90: (2S)-3-[(8R)-1-[4-[4-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethyl]piperazin-l-yl]cyclohexoxy]-7,8-dihydro-6H-cyclopenta[4.,5]thieno[l.,2-c]pyrimidin-8-yl]-2-hydroxy-propanamide, 1-90




[004901] To a solution of (2A)-2-hydroxy-3-[(8A?)-1-(4-piperazin-1-ylcyclohexoxy)-7,8-dihydro-677- cyclopenta[4,5]thieno[l,2-c]pyrimidin-8-yl]propanamide (80.0 mg, 160 umol, HC1 salt, Intermediate DR) in DMF (2 mL) was added K2CO3 (89.0 mg, 643 umol) and 2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy] ethyl methanesulfonate (79.0 mg, 241 umol, synthesized via Step 1 of Intermediate AI), and the mixture was stirred at 60 °C for 20 h. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase chromatography (0.1% NH3·H20) to give tert-butyl N-[2-[2-[2-[4-[4-[[(8R)-8-[(2S)-3-amino-2-hydroxy-3-oxo-propyl]-7, 8-dihydro -6H-cyclopenta[4,5]thieno[l,2-c]pyrimidin-l-yl]°xy]cyclohexyl]piperazin-l-yl]ethoxy]ethoxy]ethyl]carbamate **1-90** (60.0 mg, 53% yield) as a light yellow solid (LC-MS (ESI+) *m/z* 677.5 (M+H)+). Steps 2 & 3 followed Method 7, where Step 2 was run at rt for 1 h and Step 3 used fluoride Intermediate R for the coupling at 115 °C for 20 h. Characterization of the final product: 'H NMR (400MHz, DMSO-r/;) δ 11.13 (s, 1H), 8.52 (m, 1H), 7.59 (dd, *J* = 7.6, 8.4 Hz, 1H), 7.23 - 7.09 (m, 3H), 7.05 (d, *J* = 7.2 Hz, 1H), 6.60 (t, *j* = 5.6 Hz, 1H), 5.17 - 5.09 (m, 1H), 5.05 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.91 (t, *J* = 6.8 Hz, 1H), 3.64 -3.61 (m, 3H), 3.59 - 3.53 (m, 7H), 3.18 - 3.14 (s, 2H), 3.11 - 2.80 (m, 4H), 2.64 - 2.54 (m, 3H), 2.43 - 2.25 (m, 10H), 2.20 - 1.97 (m, 4H), 1.84 - 1.81 (m, 2H), 1.70 - 1.43 (m, 4H), 1.41 - 1.27 (m, 2H). LC-MS (ESI+) *m/z* 833.4 (M+H)+.

[004902] **Example 91: (2R)-3-[(8R)-1-[4-[4-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethyl]piperazin-1-yl]cyclohexoxy]-7,8-dihydro-6H-cyclopenta[4,5]thieno[l,2-c]pyrimidin-8-yl]-2-hydroxy-propanamide, 1-91**



[004903] To a mixture of (2R)-2-hydroxy-3-[(8R)-l-(4-piperazin-l-ylcyclohexoxy)-7,8-dihydro-6H-cyclopenta [4,5]thieno[l,2-c]pyrimidin-8-yl]propanamide (60.0 mg, 124 umol, Intermediate EM) in DMF (2 mL) was added K2CO3 (68.8 mg, 497 umol) and 2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethyl methanesulfonate (81.5 mg, 248 umol, synthesized via Step 1 of Intermediate AI). Then the reaction mixture was stirred at 60°C for 12 hours. On completion, the reaction mixture was concentrated *in vacuo.* The crude product was purified by revered phase (FA) to give *tert*-butyl N-[2-[2-[2-[4-[4-[[(8R)-8-[(2R)-3-amino-2-hydroxy-3-oxo-propyl]-7,8-dihydro-6H-cyclopenta[4,5]thieno[l,2-c]pyrimidin-l-yl]oxy]cyclohexyl]piperazin-l-yl]ethoxy]ethoxy]ethyl]carbamate **1-91** (75.0 mg, 63% yield) as yellowish oil. LC-MS (ESI^+) m/z 677.2 $(M+H)^+$. Steps 2 & 3 followed Method 7, where Step 2 was run at rt for 30 min and Step 3 used fluoride Intermediate R for the coupling at 115 °C for 12 h. Characterization of the final product: ^1H NMR (400MHz, DMSO-de) δ 11.13 (s, 1H), 8.60 - 8.48 (m, 1H), 7.66 - 7.50 (m, 1H), 7.21 - 7.14 (m, 2H), 7.12 (s, 1H), 7.06 (d, *J* = 7.2 Hz, 1H), 6.61 (t, *J* = 5.6 Hz, 1H), 5.19 - 5.11 (m, 1H), 5.06 (dd, *J* = 5.6, 13.2 Hz, 1H), 3.86 - 3.84 (m, 1H), 3.72 - 3.57 (m, 10H), 2.98 - 2.85 (m, 2H), 2.66 - 2.55 (m, 2H), 2.48 - 2.40 (m, 8H), 2.37 - 2.23 (m, 4H), 2.18 - 1.99 (m, 4H), 1.85 (d, *J* = 11.6 Hz, 2H), 1.74 - 1.46 (m, 4H), 1.44 - 1.26 (m, 2H); LC-MS (ESI^+) m/z 833.1 $(M+H)^+$.

[004904] Example 92: N-[3-carbamoyl-1-[4-[2-[2-[2-[[2-[2,6-dioxo-3-piperidyl]-1,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethoxymethyl]phenyl]pyrazol-4-yl]-2-[2-[2,2,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide. 1-92




[004905] To a solution of *tert*-butyl N-[2-[2-(2-hydroxyethoxy)ethoxy]ethyl]carbamate (88.0 mg, 354 umol, CAS# 139115-92-7) in THF (10 mL) was added Na metal (20 mg, 886 umol). After stirring for 30 minutes at rt, N-[1-[4-(bromomethyl)phenyl]-3-carbamoyl-pyrazol-4-yl]-2-[2-

(2,2,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide (200 mg, 354 umol, Intermediate CV) was added. The mixture was stirred at rt for 30 hours. On completion, the mixture was concentrated *in vacuo.* The residue was purified by reverse phase chromatography to give tert-butyl N-[2-[2-[2-[[4-[3-carbamoyl-4-[[2-[2-(2,2,2-trifluoroethylamino)-4-pyridyl] oxazole-4-carbonyl]amino]-pyrazol-l-yl]phenyl]methoxy]ethoxy]ethoxy]ethyl]carbamate (30.0 mg, 12% yield) as white solid. LC-MS (ESI^+) *m/z* 733.3 $(M+H)^+$.

[004906] Steps 2 & 3 followed Method 7 as described above where the deprotection was run at rt for 2 h. Intermediate R was used as the fluorine coupling partner in the last step, where the reaction was run at 115 °C for 72 hours. The final product was purified by pre-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]; B%: 40%-70%, 22 min) to give the title compound **1-92** (5.03 mg, 14% yield) as yellow solid. ^1H NMR (400MHz, DMSO-de) δ = 11.10 (s, 1H), 11.01 (s, 1H), 9.03 (s, 1H), 8.93 (s, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.06 (s, 1H), 7.99 - 7.88 (d, *J* = 8.0 Hz, 2H)„ 7.81 - 7.66 (m, 2H), 7.57 (t, *J* = 7.6 Hz, 1H), 7.50 - 7.46 (m, 2H), 7.27 (s, 1H), 7.20 - 7.12 (m, 2H), 7.03 (d, *J* = 7.2 Hz, 1H), 6.61 (m, 1H), 5.05 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.54 (s, 2H), 4.35 - 4.16 (m, 2H), 3.69 - 3.46 (m, 12H), 2.95 - 2.81 (m, 1H), 2.60 - 2.57 (m, 2H), 2.06 - 1.97 (m, 1H); LC-MS (ESI^+) *m/z* 889.8 $(M+H)^+$.


[004907] Example 93: _4-(Cyclopropylamino)-N-[3-[2-[2-[2-[[2-(2.,6-dioxo-3-piperidyB-l,3-dioxo-isoindolin-4 _ -yl1amino1-l-methyl-ethoxy1ethoxy1ethoxy1-2-fluoro-propyl]-6-[l,6-naphthyridin-2-ylamino)pyridine-3-carboxamide, _ 1-93



[004908] 4-(cyclopropylamino)-/V-[3-[2-[2-[2-(l, 3-dioxoisoindolin-2-yl)-l -methyl -ethoxy]-ethoxy]ethoxy]-2-fluoro-propyl]-6-(l,6-naphthyridin-2-ylamino)pyridine-3-carboxamide was synthesized via Step 1 of Method 7, coupling amine BU with acid Intermediate N. This compound was then deprotected in Step 2 using hydrazine hydrate dissolved in EtOH and stirring at 80 °C for 14 hours. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by reversed phase chromatography (0.1% $NH_3•H_2O$) to give the title compound **1-93** (120 mg, 65% yield) as a brown solid. (LC-MS $(ESI)^+$ *m/z* 542.3. $(M+H)^+$). Step 3 followed Method 7, where fluoride Intermediate R was utilized. Final product characterization: ^1H NMR (400MHz, DMSO-^e) δ 11.10 (br s, 1H), 10.37 (s, 1H), 9.06 (s, 1H), 8.60 - 8.51 (m, 4H), 8.31 - 8.24 (m, 2H), 7.60 - 7.54 (m, 2H), 7.51 (d, *J* = 8.8 Hz, 1H), 7.14 *(d, J* = 8.8 Hz, 1H), 7.03 (d, *J* = 7.2 Hz, 1H), 6.60 (t, *J* = 5.6 Hz, 1H), 5.06 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.83 - 4.65 (m, 1H),

3.72 - 3.20 (m, 15H), 2.95 - 2.84 (m, 1H), 2.65 - 2.54 (m, 3H), 2.08 - 1.99 (m, 1H), 1.15 (d, *J* = 6.4 Hz, 3H), 0.98 - 0.91 (m, 2H), 0.62 - 0.56 (m, 2H); LC-MS (ESI)$^+$ *m/z* 798.3. (M+H)$^+$.


[004909] Example 94: 6-(5-Cvano-lH-pyrazolo[3.,4-blpyridin-l-vP-4-(cvclopropylamino)-N-(3-(2-((2-(2-((2-(2,6-dioxopiperidin-3-vP-l.,3-dioxoisoindolin-4-vPaminolethoxylethvPaminolethoxyl^-fluoropropyPnicotinamide., 1-94



[004910] Tert-butyl (2-(3-(6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(cyclopropylamino)nicotin amido)-2-fluoropropoxy)ethyl)(2-(2-(l,3-dioxoisoindolin-2-yl)ethoxy)ethyl)carbamate was synthesized using Step 1 of Method 7 by coupling amine Intermediate BH with acid Intermediate L. For Step 2, the amine was deprotected $N_2H_4 \cdot H_20$ (54.8 mg, 1.07 mmol) in EtOH (4 mL). The mixture was stirred at 80 °C for 2 hrs. On completion, the reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-TLC ($Si0_2$, DCM: MeOH = 4/1) to give tert-butyl (2-(2-aminoethoxy)ethyl)(2-(3-(6-(5-cyano-lH-pyrazolo[3,4-b]pyridin-l-yl)-4-(cyclopropylamino)nicotinamido)-2-fluoropropoxy)ethyl)carbamate (45.0 mg, 92.2% yield) as colorless oil (LC-MS (ESI)$^+$ m/z 626.2. (M+H)$^+$). Step 3 coupled Intermediate R as the fluoride

under the conditions described for Method 7. The final compound was deprotected by dissolving *tert*-butyl (2-(3-(6-(5-cyano-li7-pyrazolo[3,4-b]pyridin-l-yl)-4-(cyclopropylamino)nicotin amido)-2-fluoropropoxy)ethyl)(2-(2-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)carbamate (39 mg, 44.2 mg) in DCM (2 mL) and adding HC1 in dioxane (4 M, 0.5 mL). The reaction mixture was stirred at 25 °C for 0.5 hr. On completion, the reaction mixture was diluted with MeCN (2 mL) and basified with $NaHC0_3$ solid until the pH = 7. After filtration, the mixture was purified directly by prep-HPLC (column: Phenomenex Synergi C18 150*25* 10 um; mobile phase: [water (0.225% FA)-ACN]) to give the title compound **1-94** (2.06 mg, 3.7% yield, FA salt) as a yellow solid. ^{1}H NMR (400MHz, DMSO) δ 11.1 (s, 1H), 9.05 (d, *J* = 2.0 Hz, 1H), 9.01 (d, *J* = 2.0 Hz, 1H), 8.83 (t, *J* = 5.6 Hz, 1H), 8.65 (s, 1H), 8.61 (s, 1H), 8.53 (s, 1H), 8.34 (s, 1H), 7.70 (s, 1H), 7.55 (s, *J* = 7.2 Hz, 1H), 7.ll(d, *J* = 8.8 Hz, 1H), 7.0l(d, *J* = 7.2 Hz, 1H), 6.6l(d, *J* = 6.0 Hz, 1H), 5.09 - 5.00 (m, 1H), 4.88 - 4.70 (m, 1H), 3.70 - 3.50 (m, 5H), 2.95 - 2.84 (m, 2H), 2.80 - 2.63 (m, 9H), 2.37 - 2.30 (m, 4H), 2.05 - 1.98 (m, 1H), 0.85 (dd, *J* = 6.8, 11.6 Hz, 2H), 0.55 (dd, *J* = 6.8, 11.6 Hz, 2H); LC-MS (ESI)$^+$ *m/z* 804.2. (M+Na)$^+$.

[004911] Example 95 (Method 81: 6-(5-Cvanopyrazolo[3.,4-b]pyridin-l-vP-4-(cvclopropylamino]-N-[3-[2-[2-[[2-[2-(2.,6-dioxo-3 _ -piperidylM,3-dioxo-isoindolin-4-yl]oxyacetyl]amino]ethoxy]ethoxy]-2-fluoro-propyl]pyridine-3-carboxamide, _ 1-95



[004912] Step 1 - Tert-butyl N-r2-r2-r3-IT6-(5-cvanopyrazolor3.4-b1pyridin-l-vO-4-(cvclopropylamino)pyridine -3-carbonyl1amino1-2-fluoropropoxy1ethoxy1ethyl1carbamate

[004913] To a solution of tert-butyl N-[2-[2-(3-amino-2-fluoro-propoxy)ethoxy]ethyl]carbamate (100 mg, 356 umol, Intermediate AV) and 6-(5-cyanopyrazolo[3,4-b]pyridin-l-yl)-4-(cyclopropylamino)pyridine-3-carboxylic acid (171 mg, 535 umol, Intermediate L) in DMF (3.00 mL) was added HATU (162 mg, 428 umol) and DIPEA (138 mg, 1.07 mmol, 186 uL). The mixture was stirred at rt for 1 hour. On completion, the mixture was diluted with water (30 mL) and extracted with EA (3 X 30 mL). The organic layers were dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by reverse phase (0.1% $NH_3•H_2O$) to give the title compound (80.0 mg, 38% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 583.3 $(M+H)^+$.

[004914] Step 2 - N-r3-r2-(2-aminoethoxy)ethoxy1-2-fluoro-propyl1-6-(5-cvanopyrazolor3.4-b1pyridin- l-yl) -4-(cvclopropylamino)pyridine-3 -carboxamide

[004915] To a solution of tert-butyl N-[2-[2-[3-[[6-(5-cyanopyrazolo[3,4-b]pyridin-l-yl)-4-(cyclopropylamino) pyridine-3-carbonyl]amino]-2-fluoro-propoxy]ethoxy]ethyl]carbamate (80.0 mg, 137 umol) in DCM (4.00 mL) was added HC1 in dioxane (4 M, 2.00 mL) and the mixture was stirred at rt for 30 minutes. On completion, the mixture was concentrated *in vacuo* to give the title compound (70.0 mg, 98% yield) as white solid. LC-MS (ESI^+) *m/z* 483.2 $(M+H)^+$.

[004916] Step 3 - 6-(5-Cvanopyrazolor3.4-b1pyridin-l-vO-4-(cvclopropylamino)-N-r3-r2-[2-[[2-[2-(2.6- άïοχo-3 -piperidvn-L3-dioxo-isoindolin-4-yl1oxyacetyl1amino1ethoxy1ethoxy1-2-fluoro-propynpyridine-3-carboxamide

[004917] To a solution of N-[3-[2-(2-aminoethoxy)ethoxy]-2-fluoro-propyl]-6-(5-cyanopyrazolo[3,4-b]pyridin- l-yl)-4-(cyclopropylamino)pyridine-3-carboxamide (50.0 mg, 96.3 umol, HC1) and 2-[2-(2,6-dioxo-3- piperidyl)-l,3-dioxo-isoindolin-4-yl]oxyacetic acid (32.0 mg, 96.3 umol, Intermediate CA) in DMF (2.00 mL) was added HATU (43.9 mg, 115 umol) and DIPEA (62.2 mg, 481 umol, 83.9 uL). The mixture was stirred at rt for 1 hour. On completion, the mixture was diluted with H_20 (30 mL) and extracted with EA (3 X 15 mL). The organic layers were dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The mixture was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]; B%: 20%-50%, 10 min) to give the title compound **1-95** (35.36 mg, 43% yield, FA) as a white solid. ^1H NMR (400MHz, DMSO-^e) δ 11.1 (s, 1H), 9.06 (d, *J* = 1.6 Hz, 1H), 9.02 (d, *J* =

1.6 Hz, 1H), 8.91 - 8.81 (m, 1H), 8.66 (s, 1H), 8.62 (s, 1H), 8.54 (s, 1H), 8.07 - 7.98 (m, 1H), 7.82 - 7.76 (m, 1H), 7.71 (s, 1H), 7.48 (d, *J* = 7.2 Hz, 1H), 7.39 (d, *J* = 8.8 Hz, 1H), 5.13 - 5.09 (m, 1H), 4.79 (s, 2H), 4.88 - 4.7l(m, 1H), 3.61 - 3.46 (m, 12H), 2.95 - 2.83 (m, 1H), 2.63 - 2.54 (m, 3H), 2.09 - 2.02 (m, 1H), 0.89 - 0.83 (m, 2H), 0.60 - 0.53 (m, 2H); LC-MS (ESI$^+$) *m/z* 797.4 $(M+H)^+$.

[004918] **Table 6: Compounds synthesized via Method 8 with the coupling of various amines and acids in Step 1, followed by coupling with acid Intermediate CA in Step 3.**

Ex-#	I-#	Intermediate Amine	Intermediate Acid	LCMS (ES+) m/z $(M+H)^+$	HNMR (400MHz, DMSO-d6) δ
96	**I-96**	AI	N	842.4	12.08 (s, 1H), 11.14 (s, 1H), 9.61 (s, 1H), 9.13 (s, 1H), 8.95 (s, 1H), 8.86 (d, *J* = 6.8 Hz, 1H), 8.70 (d, *J* = 8.8 Hz, 1H), 8.50 (s, 1H), 8.34 (d, *J* = 6.4 Hz, 1H), 8.02 (t, *J* = 5.6 Hz, 1H), 7.83 - 7.79 (m, 1H), 7.55 (d, *J* = 8.8 Hz, 1H), 7.49 (d, *J* = 7.2 Hz, 1H), 7.39 (d, *J* = 8.4 Hz, 1H), 7.14 (s, 1H), 5.12 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.88 - 4.73 (m, 3H), 3.75 - 3.60 (m, 6H), 3.53 - 3.44 (m, 6H), 3.34 - 3.30 (m, 2H), 2.97 - 2.84 (m, 2H), 2.71 (s, 1H), 2.60 - 2.57 (m, 1H), 2.56 - 2.52 (m, 2H), 2.10 - 1.98 (m, 1H), 0.99 - 0.91 (m, 2H), 0.73 - 0.69
97	**I-97**	AK	N	930.5	11.14 (s, 1H), 10.38 (s, 1H), 9.05 (s, 1H), 8.60 - 8.55 (m, 3H), 8.47 (s, 1H), 8.27 (d, *J* = 9.0 Hz, 1H), 8.19 (s, 1H), 8.02 (t, *J* = 5.6 Hz, 1H), 7.80 (dd, *J* = 7.6, 8.4 Hz, 1H), 7.57 (d, *J* = 5.6 Hz, 1H), 7.54 - 7.44 (m, 2H), 7.39 (d, *J* = 8.4 Hz, 1H), 5.12 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.87 - 4.65 (m, 3H), 3.73 - 3.51 (m, 12H), 3.50 - 3.40 (m, 10H), 3.37 - 3.21 (m, 2H), 2.99 - 2.84 (m, 1H), 2.65 - 2.56 (m, 2H), 2.55 (d, *J* = 4.4 Hz, 1H), 2.10 - 2.02 (m, 1H), 1.04 - 0.89 (m, 2H), 0.69 - 0.52 (m, 2H)

98	**I-98**	BA	N	886.1	13.12 (s, 1H), 11.14 (s, 1H), 9.64 (s, 1H), 9.32 (s, 1H), 8.93 (s, 1H), 8.86 (d, *J* = 6.4 Hz, 1H), 8.73 (d, *J* = 8.8 Hz, 1H), 8.63 (s, 1H), 8.50 (d, *J* = 5.6 Hz, 1H), 8.12 - 8.03 (m, 1H), 7.85 - 7.73 (m, 2H), 7.48 (d, *J* = 7.2 Hz, 1H), 7.43 (s, 1H), 7.39 (d, *J* = 8.2 Hz, 1H), 5.12 (dd, *J* = 5.2, 12.6 Hz, 1H), 4.90 - 4.73 (m, 3H), 3.74 - 3.56 (m, 12H), 3.48 - 3.44 (m, 4H), 3.38 - 3.08 (m, 2H), 3.04 - 2.80 (m, 2H), 2.68 - 2.62 (m, 2H), 2.55 - 2.52 (m, 2H), 2.07 - 1.99 (m, 1H), 0.98 - 0.90 (m, 2H), 0.74 - 0.66 (m, 2H)
99	**I-99**	AV	N	798.3	11.15 (s, 1H), 10.38 (s, 1H), 9.06 (s, 1H), 8.61 - 8.55 (m, 3H), 8.53 (s, 1H), 8.28 (d, *J* = 9.2 Hz, 1H), 8.22 (s, 1H), 8.04 (t, *J* = 5.6 Hz, 1H), 7.86 - 7.72 (m, 1H), 7.57 (d, *J* = 5.6 Hz, 1H), 7.52 - 7.44 (m, 2H), 7.39 (d, *J* = 8.4 Hz, 1H), 5.12 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.83 - 4.66 (m, 3H), 3.71 - 3.68 (m, 1H), 3.66 - 3.56 (m, 10H), 2.94 - 2.88 (m, 1H), 2.65 - 2.58 (m, 2H), 2.57- 2.53 (m, 2H), 2.08 - 2.00 (m, 1H), 0.95 (d, *J* = 5.2 Hz, 2H), 0.63 - 0.55 (s, 2H)
100	**I-100**	BV	N	826.5	11.13 (s, 1H), 10.37 (s, 1H), 9.06 (s, 1H), 8.60 - 8.55 (m, 3H), 8.46 (s, 1H), 8.28 (d, *J* = 9.2 Hz, 1H), 8.21 (s, 1H), 7.95 (t, *J* = 5.6 Hz, 1H), 7.85 - 7.78 (m, 1H), 7.57 (d, *J* = 6.0 Hz, 1H), 7.53 - 7.47 (m, 2H), 7.39 (d, *J* = 8.4 Hz, 1H), 5.14 - 5.10 (m, 1H), 4.84 - 4.68 (m, 3H), 3.67 - 3.57 (m, 2H), 3.55 - 3.41 (m, 8H), 3.25 - 3.18 (m, 2H), 2.88 (m, 1H), 2.70 - 2.61 (m, 2H), 2.37 - 2.30 (m, 1H), 2.09 - 2.00 (m, 1H), 1.79 - 1.63 (m, 4H), 0.98 - 0.92 (m, 2H), 0.63 - 0.55 (m, 2H)


101	**I-101**	AU	L	825.4	11.18 (s, 1H), 9.08 (d, *J* = 2.0 Hz, 1H), 9.04 (d, *J* = 2.0 Hz, 1H), 8.85 - 8.80 (m, 1H), 8.67 (s, 1H), 8.61 (s, 1H), 8.60 - 8.59 (m, 1H), 8.01 (t, *J* = 5.6 Hz, 1H), 7.80 - 7.75 (m, 1H), 7.71 (s, 1H), 7.46 (d, *J* = 7.2 Hz, 1H), 7.39 (d, *J* = 8.8 Hz, 1H), 5.12 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.79 (s, 2H), 4.59 - 4.42 (m, 1H), 3.80 - 3.62 (m, 2H), 3.58 - 3.46 (m, 6H), 3.46 - 3.43 (m, 1H), 2.95 - 2.83 (m, 1H), 2.65 - 2.60 (m, 1H), 2.60 - 2.56 (m, 2H), 2.55 - 2.54 (m, 1H), 2.07 - 2.02 (m, 1H), 1.21 (s, 6H), 0.89 - 0.83 (m, 2H), 0.60 - 0.55 (m, 2H)
102	**I-102**	BG	L	795.4	11.13 (s, 1H), 9.07 (d, *J* = 1.6 Hz, 1H), 9.03 (d, *J* = 2.0 Hz, 1H), 8.88 - 8.82 (m, 1H), 8.67 (s, 1H), 8.63 (s, 1H), 8.56 (s, 1H), 7.96 (s, 1H), 7.81 (t, *J* = 7.6 Hz, 1H), 7.72 (s, 1H), 7.49 (d, *J* = 7.6 Hz, 1H), 7.39 (d, *J* = 8.4 Hz, 1H), 5.12 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.89 - 4.69 (m, 3H), 3.69 - 3.41 (m, 4H), 3.20 - 3.12 (m, 2H), 2.96 - 2.84 (m, 1H), 2.68 - 2.66 (m, 1H), 2.64 - 2.56 (m, 3H), 2.34 - 2.30 (m, 1H), 2.04 - 2.00 (m, 1H), 1.57 - 1.43 (m, 4H), 1.33 - 1.30 (m, 2H), 0.87 - 0.80 (m, 2H), 0.58 - 0.56 (m, 2H)
103	**I-103**	tert-butyl *N*-[2-[2-[2-[2-(2-aminoethoxy)-ethoxy]-ethoxy]ethoxy]-ethyl]carbamate (CAS# 01187-40-0)	CE	895.4	11.12 (br s, 1H), 8.88 (s, 1H), 8.46 (t, *J* = 5.6 Hz, 1H), 8.16 (s, 1H), 8.01 (t, *J* = 5.2 Hz, 1H), 7.91 (d, *J* = 5.6 Hz, 1H), 7.84 - 7.78 (m, 1H), 7.75 (s, 1H), 7.49 (d, *J* = 7.2 Hz, 1H), 7.44 (d, *J* = 5.6 Hz, 1H), 7.39 (d, *J* = 8.4 Hz, 1H), 5.12 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.99 - 4.82 (m, 1H), 4.79 (s, 2H), 4.54 (dd, *J* = 3.2, 11.2 Hz, 1H), 4.26 (dd, *J* = 6.4, 11.2 Hz, 1H), 4.10 - 4.08 (m, 1H), 3.97 (s, 3H), 3.60 - 3.43 (m, 18H), 3.32 - 3.27 (m, 2H), 2.96 - 2.84 (m, 1H), 2.70 - 2.57 (m, 3H), 2.09 - 2.00 (m, 1H), 1.66 - 1.55 (m, 2H), 1.02 (t, *J* = 7.2 Hz, 3H)

104	**I-104**	CG	CN	998.1	11.11 (s, 1H), 11.02 (s, 1H), 9.04 (d, *J* = 4.0 Hz, 2H), 8.55 (s, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.13 (s, 1H), 8.10 (d, *J* = 8.4 Hz, 2H), 8.04 - 7.89 (m, 3H), 7.86 - 7.75 (m, 2H), 7.69 (t, *J* = 6.0 Hz, 1H), 7.50 (d, *J* = 7.2 Hz, 1H), 7.40 (d, *J* = 8.4 Hz, 1H), 7.28 (s, 1H), 7.19 (d, *J* = 5.2 Hz, 1H), 5.12 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.83 - 4.73 (m, 2H), 4.32 - 4.19 (m, 2H), 3.29 - 3.26 (m, 2H), 3.14 (d, *J* = 6.0 Hz, 2H), 2.89 (d, *J* = 9.2 Hz, 1H), 2.64 - 2.56 (m, 2H), 2.11 - 1.98 (m, 1H), 1.61 - 1.37 (m, 4H), 1.31 - 1.21 (m, 14H)

Variations in reaction time for Method 8 were as follows: Step 1 was run anywhere from 0.5-16 h, Step 2 anywhere from 0.5-3 h, Step 3 anywhere from 0.5-12 h.

[004919] **Further Examples using synthetic methods similar to Method 8:**

[004920] **Example 105: N-[3-carbamoyl-1-[4-[2-[2-[2-[2-[[2-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl] oxyacetyl] amino] ethoxy] ethoxy] ethoxy] ethoxymethyl] phenyl] pyrazol-4-yl]-2- [2-12,2,2-trifluoroethylamino)-4-pyridyl1oxazole-4-carboxamide, 1-105**




[004921] To a mixture of *tert*-butyl N-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]carbamate (3 1.0 mg, 106 umol, synthesized via Steps 1-3 of Intermediate AO) in THF (15 mL) was added Na metal (6.00 mg, 267 umol) and N-[l-[4-(bromomethyl)phenyl]-3- carbamoyl-pyrazol-4-yl]-2-[2-(2,2,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide (60.0 mg, 106 umol, Intermediate CV). The mixture was stirred at rt for 18 hours. On completion, the mixture was concentrated *in vacuo.* The residue was purified by reverse phase chromatography (0.1% FA in water) to give the tert-butyl N-[2-[2-[2-[2-[[4-[3-carbamoyl-4-[[2-[2-(2,2,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carbonyl]amino]-pyrazol-l-

yl]phenyl]methoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate compound (15.0 mg, 18% yield) as a white solid. LC-MS (ESI$^+$) *m/z* 799.4 (M+Na)T

[004922] Steps 2 & 3 followed Method 8 as described above where the deprotection was run at rt for 30 min. Intermediate CA was used as the acid coupling partner in the last step, where the reaction was run at rt for 18 h. The final product was purified by Pre-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]; B%: 30%-60%, 10 min) to give the title compound **1-105** (1.20 mg, 6% yield) as white solid. ^{1}HNMR (400MHz, DMSO-d_6) δ 11.08 (s, 1H), 10.99 (s, 1H), 9.01 (s, 1H), 8.93 (s, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.11 - 7.86 (m, 4H), 7.83 - 7.76 (m, 1H), 7.74 - 7.64 (m, 2H), 7.50 - 7.47 (m, 3H), 7.42 - 7.34 (m, 2H), 7.27 (s, 1H), 7.18 (d, *J* = 5.2 Hz, 1H), 5.11 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.78 (s, 2H), 4.55 (s, 2H), 4.31 - 4.19 (m, 2H), 3.61 - 3.38 (m, 16H), 2.95 - 2.88 (m, 1H), 2.61 - 2.58 (m, 2H), 2.06 - 2.03 (m, 1H); LC-MS (ESI$^+$) *m/z* 1013.3 (M+Na)T

[004923] **Example 106 [Method 91: N-[3-carbamoyl-1-[4-[5-[[2-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]oxyacetyl] aminolpentylcarbamoyllphenyllpyrazol-4-yl]-2-[2-[2.,2.,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide, 1-106**



[004924] Step 1 - Tert-butyl N-[5-[[2-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]oxyacetyl]amino] pentyl] carbamate

[004925] To a mixture of tert-butyl N-(5-aminopentyl)carbamate (1.50 g, 7.41 mmol, CAS # 51644-96-3) and DIPEA (3.83 g, 29.6 mmol) in DMF (15 mL) was added 2-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]oxyacetic acid (2.46 g, 7.41 mmol, Intermediate CA) and HATU (3.38 g, 8.90 mmol). The reaction mixture was stirred at rt for 1 hour. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (0.1 % $NH_3 \cdot H_2O$) to give the title compound (2.10 g, 54% yield) as a white solid. LC-MS (ESI^+) *m/z* 417.0 $(M+H-l00)^+$.

[004926] Step 2 - N-(5-aminopentyl)-2-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-ylloxy-acetamide

[004927] To a mixture of tert-butyl N-[5-[[2-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]oxyacetyl] amino]pentyl]carbamate (500 mg, 967 umol) in DCM (4 mL) was added HC1 in dioxane (4 M, 2 mL). The reaction mixture was stirred at rt for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (0.1 % $NH_3 \cdot H_2O$) to give the title compound (400 mg, 99% yield) as white solid. LC-MS (ESI^+) *m/z* 417.1 $(M+H)^+$.

[004928] Step 3 - Tert-butyl N-r4-r4-rr3-carbamoyl-l-r4-r5-rr2-r2-(2.6-dioxo-3-piperidvD-L3-dioxo-isoindolin- _ _ 4-yl1oxyacetyl1amino1pentylcarbamoyl1phenyl1pyrazol-4-yl1carbamoyl1oxazol-2-yl1-2-pyridyl1-N-(2.2.2-trif1uoroethyl icarbamate

[004929] To a mixture of N-(5-aminopentyl)-2-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]oxy- acetamide (250 mg, 552 umol, HC1) and DIPEA (356 mg, 2.76 mmol) in DMF (4 mL) was added 4-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carbonyl]amino]-3-carbamoyl-pyrazol-l-yl]benzoic acid (339 mg, 552 umol, Intermediate CN) and HATU (251 mg, 662 umol). The reaction mixture was stirred at rt for 0.5 hour. On completion, the reaction mixture was diluted with water (5 mL) and filtered and concentrated *in vacuo* to give the title compound (400 mg, 80% yield) as light yellow solid. LC-MS (ESI^+) *m/z* 1014.3 $(M+H)^+$.

[004930] Step 4 - N-[3-carbamoyl-l-[4-[5-[[2-[2-(2,6-dioxo-3-piperidvl)-1,3-dioxo-isoindolin-4-vl]oxyacetyl] aminolpentyl carbamoyl]phenyl]pyrazol-4-yll -2-[2-(2,2,2-trifluoroethylamino)-4-pyridyl1oxazole-4-carboxamide

[004931] To a mixture of tert-butyl N-[4-[4-[[3-carbamoyl-l-[4-[5-[[2-[2-(2,6-dioxo-3-

piperidyl)-l,3-dioxo- isoindolin-4-yl]oxyacetyl]amino]pentylcarbamoyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (400 mg, 394 umol) in DCM (3 mL) was added HC1 in dioxane (4 M, 2 mL). The reaction mixture was stirred at rt for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo*. The residue was purified by prep-HPLC (column: Phenomenex lunaCl8 250*50 mm* 10 um; mobile phase: [water (0.225% FA)-ACN]) to give the title compound **1-106** (79.4 mg, 20% yield) as white solid. ^{1}**H** NMR (400MHz, DMSO-d_6) δ 11.13 (s, 1H), 11.03 (s, 1H), 9.04 (s, 2H), 8.56 (t, *J* = 5.6 Hz, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.15 (s, 1H), 8.12 - 8.08 (m, 2H), 8.04 - 7.94 (m, 3H), 7.85 - 7.76 (m, 2H), 7.71 (t, *j* = 6.4 Hz, 1H), 7.49 (d, *j* = 7.2 Hz, 1H), 7.40 (d, *j* = 8.4 Hz, 1H), 7.28 (s, 1H), 7.21 - 7.16 (m, 1H), 5.14 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.81 (s, 2H), 4.29 - 4.21 (m, 2H), 3.30 - 3.27 (m, 2H), 3.18 *(d, J* = 6.0 Hz, 2H), 2.96 - 2.86 (m, 1H), 2.66- 2.61 (m, 1H), 2.60 - 2.56 (m, 1H), 2.10 - 2.01 (m, 1H), 1.60 - 1.46 (m, 4H), 1.40 - 1.29 (m, 2H); LC-MS (ESI^+) *m/z* 914.3 $(M+H)^+$.

[004932] **Table 7: Compounds synthesized via Method 9 with the coupling of various amines and acids in Step 1, followed by coupling with acid Intermediate CN in Step 3**

Ex-#	I-#	Step 1 Intermediate Amine	Step 1 Intermediate Acid	LCMS (ES+) m/z $(M+H)^+$	HNMR (400MHz, DMSO-d6) δ
107	**I-107**	CI	CH	1161.2	11.01 (s, 1H), 9.07 - 8.99 (m, 2H), 8.96 (s, 1H), 8.74 - 8.56 (m, 2H), 8.26 (d, *J* = 5.6 Hz, 1H), 8.15 (s, 1H), 8.12 - 8.06 (m, 2H), 8.05 - 7.99 (m, 2H), 7.78 (s, 1H), 7.72 -7.64 (m, 1H), 7.47 - 7.35 (m, 5H), 7.26 (s, 1H), 7.19 (d, *J* = 5.4 Hz, 1H), 5.21 (s, 1H), 4.56 (d, *J* = 9.6 Hz, 1H), 4.48 - 4.33 (m, 3H), 4.31 - 4.17 (m, 3H), 4.00 - 3.90 (m, 2H), 3.71 - 3.53 (m, 18H), 2.43 (s, 3H), 2.11 - 2.02 (m, 1H), 1.96 - 1.86 (m, 1H), 0.96 - 0.89 (m, 9H)

108	**I-108**	tert-butyl N-[2-[2-[2-(2-aminoethoxy)-ethoxy]ethoxy]-ethyl]carbamate (CAS# 101187-40-0)	CA	1026.3[a]	11.12 (br s, 1H), 11.01 (s, 1H), 9.04 (d, *J* = 4.0 Hz, 2H), 8.65 (t, *J* = 5.2 Hz, 1H), 8.27 (d, *J* = 5.2 Hz, 1H), 8.19 - 8.07 (m, 3H), 8.06 - 7.97 (m, 3H), 7.85 - 7.75 (m, 2H), 7.70 (t, *J* = 6.4 Hz, 1H), 7.49 (d, *J* = 7.2 Hz, 1H), 7.39 (d, *J* = 8.4 Hz, 1H), 7.28 (s, 1H), 7.19 (d, *J* = 5.2 Hz, 1H), 5.19 - 5.05 (m, 1H), 4.78 (s, 2H), 4.35 - 4.17 (m, 2H), 3.59 - 3.49 (m, 12H), 3.48 - 3.45 (m, 4H), 2.97 - 2.83 (m, 1H), 2.66 - 2.61 (m, 1H), 2.60 - 2.56 (m, 1H), 2.07 - 2.00 (m, 1H)
109	**I-109**	tert-butyl N-(8-aminooctyl)-carbamate (CAS# 88829-82-7)	CA	956.4	11.12 (s, 1H), 11.01 (s, 1H), 9.03 (d, *J* = 4.8 Hz, 2H), 8.55 (t, *J* = 5.6 Hz, 1H), 8.26 (d, *J* = 5.6 Hz, 1H), 8.14 (s, 1H), 8.12 - 8.07 (m, 2H), 8.05 - 7.98 (m, 2H), 7.93 (t, *J* = 5.6 Hz, 1H), 7.85 - 7.79 (m, 1H), 7.77 (s, 1H), 7.69 (t, *J* = 6.4 Hz, 1H), 7.50 (d, *J* = 7.2 Hz, 1H), 7.40 (d, *J* = 8.4 Hz, 1H), 7.27 (s, 1H), 7.19 (d, *J* = 5.2 Hz, 1H), 5.14 - 5.08 (m, 1H), 4.77 (s, 2H), 4.30 - 4.20 (m, 2H), 3.29 - 3.22 (m, 2H), 3.18 - 3.11 (m, 2H), 2.96 - 2.85 (m, 1H), 2.64 - 2.56 (m, 2H), 2.08 - 2.01 (m, 1H), 1.60 - 1.38 (m, 4H), 1.29 (s, 8H)
110	**I-110**	tert-butyl *N*-[2-(2-aminoethoxy)-ethyl]carbamate (CAS# 127828-22-2)	CA	915.9	11.12 (s, 1H), 11.03 (s, 1H), 9.05 (s, 1H), 9.03 (s, 1H), 8.60 (t, *J* = 5.2 Hz, 1H), 8.27 (d, *J* = 5.2 Hz, 1H), 8.14 (s, 1H), 8.09 - 8.05 (m, 2H), 8.05 - 7.98 (m, 3H), 7.83 - 7.76 (m, 2H), 7.71 (t, *J* = 6.4 Hz, 1H), 7.47 (d, *J* = 7.2 Hz, 1H), 7.39 (d, *J* = 8.8 Hz, 1H), 7.28 (s, 1H), 7.19 (dd, *J* = 1.6, 5.2 Hz, 1H), 5.15 - 5.12 (m, 1H), 4.79 (s, 2H), 4.31 - 4.20 (m, 2H), 3.61 - 3.56 (m, 2H), 3.55 - 3.51 (m, 2H), 3.50 - 3.44 (m, 2H), 3.40 - 3.37 (m, 2H), 2.95 - 2.84 (m, 1H), 2.64 - 2.55 (m, 2H), 2.10 - 2.01 (m, 1H)


111	**I-111**	tert-butyl *N*-(4-aminobutyl)-carbamate (CAS# 68076-36-8)	CA	900.3	11.12 (s, 1H), 11.02 (s, 1H), 9.04 (d, *J* = 4.0 Hz, 2H), 8.59 (t, *J* = 5.6 Hz, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.15 - 8.08 (m, 3H), 8.02 (m, 3H), 7.85 - 7.80 (m, 1H), 7.78 (s, 1H), 7.70 (t, *J* = 6.8 Hz, 1H), 7.49 (d, *J* = 7.2 Hz, 1H), 7.40 (d, *J* = 8.4 Hz, 1H), 7.28 (s, 1H), 7.21 - 7.17 (m, 1H), 5.12 (dd, *J* = 5.6, 13.2 Hz, 1H), 4.79 (s, 2H), 4.31 - 4.20 (m, 2H), 3.30 - 3.26 (m, 2H), 3.24 - 3.18 (m, 2H), 2.95 - 2.84 (m, 1H), 2.64 - 2.54 (m, 2H), 2.07 – 2.00 (m, 1H), 1.53 (m, 4H)
112	**I-112**	tert-butyl *N*-(3-aminopropyl)-carbamate (CAS# 75178-96-0)	CA	886.5	11.12 (s, 1H), 11.02 (s, 1H), 9.04 (d, *J* = 2 Hz, 2H), 8.59 (t, *J* = 6 Hz, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.17 - 8.07 (m, 3H), 8.07 - 7.98 (m, 3H), 7.83 (dd, *J* = 7.2, 8.4 Hz, 1H), 7.78 (s, 1H), 7.70 (t, *J* = 6.4 Hz, 1H), 7.50 (d, *J* = 7.2 Hz, 1H), 7.42 (d, *J* = 8.4 Hz, 1H), 7.28 (s, 1H), 7.19 (dd, *J* = 1.6, 5.2 Hz, 1H), 5.13 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.80 (s, 2H), 4.31 - 4.19 (m, 2H), 3.27 (m, 2H), 3.25 (m, 2H), 2.98 - 2.84 (m, 1H), 2.65 - 2.54 (m, 2H), 2.09 - 2.00 (m, 1H), 1.78 - 1.68 (m, 2H)
113	**I-113**	DH	CH	1071.3	11.03 (s, 1H), 9.05 (d, *J* = 3.2 Hz, 2H), 8.65 (t, *J* = 5.2 Hz, 1H), 8.31 (t, *J* = 6.4 Hz, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.15 (s, 1H), 8.13 - 8.08 (m, 3H), 8.06 - 8.00 (m, 2H), 7.78 (br s, 1H), 7.71 (t, *J* = 6.8 Hz, 1H), 7.66 (d, *J* = 8.0 Hz, 2H), 7.34 (d, *J* = 8.0 Hz, 2H), 7.28 (s, 1H), 7.19 (dd, *J* = 1.2, 5.2 Hz, 1H), 6.72 (d, *J* = 7.6 Hz, 1H), 6.62 (d, *J* = 7.6 Hz, 1H), 4.34 (d, *J* = 6.0 Hz, 2H), 4.30 - 4.20 (m, 2H), 3.95 (s, 2H), 3.62 - 3.40 (m, 16H), 2.56 - 2.54 (m, 3H)

114	**I-114**	DH	DI	1115.8	11.03 (s, 1H), 9.05 (d, *J* = 3.2 Hz, 2H), 8.65 (br t, *J* = 5.2 Hz, 1H), 8.31 (br t, *J* = 6.4 Hz, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.14 (br s, 1H), 8.13 - 8.08 (m, 3H), 8.06 - 8.01 (m, 2H), 7.78 (br s, 1H), 7.71 (br t, *J* = 6.3 Hz, 1H), 7.66 (d, *J* = 8.4 Hz, 2H), 7.35 (d, *J* = 8.4 Hz, 2H), 7.28 (s, 1H), 7.21 - 7.16 (m, 1H), 6.72 (d, *J* = 7.6 Hz, 1H), 6.61 (d, *J* = 7.6 Hz, 1H), 4.34 (br d, *J* = 6.0 Hz, 2H), 4.30 - 4.20 (m, 2H), 3.95 (s, 2H), 3.62 - 3.41 (m, 20H), 2.54 - 2.53 (s, 3H)
115	**I-115**	CI	DM	1117.4	11.02 (s, 1H), 9.04 (d, *J* = 4.0 Hz, 2H), 8.97 (s, 1H), 8.64 (t, *J* = 5.2 Hz, 1H), 8.59 (t, *J* = 6.0 Hz, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.13 (s, 1H), 8.11 - 8.08 (m, 2H), 8.05 - 8.01 (m, 2H), 7.77 (s, 1H), 7.70 (t, *J* = 6.4 Hz, 1H), 7.47 - 7.36 (m, 5H), 7.28 (s, 1H), 7.18 (dd, *J* = 1.2, 5.2 Hz, 1H), 5.16 (s, 1H), 4.57 (d, *J* = 9.6 Hz, 1H), 4.49 - 4.34 (m, 3H), 4.31 - 4.23 (m, 3H), 3.97 (s, 2H), 3.71 - 3.65 (m, 1H), 3.61 - 3.54 (m, 10H), 3.47 - 3.42 (m, 2H), 2.53 (d, *J* = 2.0 Hz, 1H), 2.44 (s, 3H), 2.11 - 2.02 (m, 1H), 1.94 - 1.87 (m, 1H), 0.96 - 0.91 (m, 9H)

Variations in reaction time for Method 9 were as follows: Step 1 was run anywhere from 0.5-12 h, Step 3 anywhere from 0.5-12 h, and Step 4 anywhere from 0.5-12 hr. [a]mass measured as $(M+Na)^+$.

[004933] **Further Examples using synthetic methods similar to Method 9:**


[004934] **Example 116: N-(3-carbamoyl-1-(4-((2-((5-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)ethoxy)pentyl)oxy)ethyl)carbamoyl)phenyl)-1H-pyrazol-4-yl)-2-(2-(2,2,2-trifluoroethyl)amino)pyridin-4-yl)oxazole-4-carboxamide, I-116**



[004935] N-(3-carbamoyl-l-(4-((2-((5-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)oxy) acetamido)ethoxy)pentyl)oxy)ethyl)carbamoyl)phenyl)-lH-pyrazol-4-yl)-2-(2-((2,2,2-trifluoroethyl)amino)pyridin-4-yl)oxazole-4-carboxamide **1-116** was synthesized via Method 9, by coupling amine Intermediate CF with acid Intermediate CN in Step 1. Step 2 was not performed as the amine did not have a BOC group for deprotection. In Step 3, Intermediate CA was employed as the acid for the coupling. Characterization of the final product: ^{1}H NMR (400MHz, DMSO-d6) δ 11.12 (s, 1H), 11.00 (s, 1H), 9.02 (d, *J* = 8.4 Hz, 2H), 8.64 (t, *J* = 5.2 Hz,

1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.14 (s, 1H), 8.11 - 8.06 (m, 2H), 8.05 - 8.00 (m, 2H), 7.97 (t, *J* = 6.4 Hz, 1H), 7.82 - 7.75 (m, 2H), 7.69 (t, *J* = 6.4 Hz, 1H), 7.48 (d, *J* = 7.2 Hz, 1H), 7.38 (d, J = 8.4 Hz, 1H), 7.26 (s, 1H), 7.20 - 7.16 (m, 1H), 5.10 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.78 (s, 2H), 4.30 - 4.18 (m, 2H), 3.40 - 3.28 (m, 12H), 2.94 - 2.84 (m, 1H), 2.65 - 2.60 (m, 1H), 2.52 - 2.44 (m, 1H), 2.08 - 2.02 (m, 1H), 1.53 - 1.44 (m, 4H), 1.35 - 1.27 (m, 2H). LC-MS (ESI$^+$) *m/z* 1002.4 (M+H)$^+$.

[004936] Example 117: N-(3-carbamoyl-1-(4-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yP-1-oxoisoindolin-4-vPamino) ethoxy)ethoxy)ethvPcarbamovPphenvP-lH-pyrazol-4-vP-2-(2-P2,2.,2-trifluoroethvPamino)pyridin-4-vPoxazole-4-carboxamide, 1-117




[004937] Tert-butyl (2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)amino)ethoxy)ethoxy) ethyl)carbamate was synthesized in Step 1 as follows: To a mixture of 3-(4-amino-l-oxo-isoindolin-2-yl)piperidine-2,6-dione (0.10 g, 385 umol, CAS# 191732-72-6) in DMA (2 mL) was added 2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethyl methanesulfonate (151 mg, 462 umol, synthesized via Step 1 of Intermediate AI), Nal (17.3 mg, 115 umol) and DIPEA (149 mg, 1.16 mmol, 201 uL). Then the reaction mixture was stirred at 80

°C for 2 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-TLC (PE:EA = 0:1) to give the title compound **1-117** (0.18 g, 50% purity, 47% yield) as a yellowish solid (LC-MS (ESI^+) m/z 513.1 $(M+Na)^+$).

[004938] Steps 2-4 followed Method 9, where Intermediate CN was used as the acid in Step 3 which was coupled with the amine at rt for 12 hours. Characterization of the final product: ^1H NMR (400MHz, DMSO-de) δ 11.13 - 10.90 (m, 2H), 9.04 (s, 2H), 8.65 (t, *J* = 5.2 Hz, 1H), 8.26 (d, 7 = 5.2 Hz, 1H), 8.16 - 8.07 (m, 3H), 8.05 - 7.99 (m, 2H), 7.78 (s, 1H), 7.70 (t, *J* = 6.4 Hz, 1H), 7.32 - 7.24 (m, 2H), 7.19 (dd, 7 = 1.2, 5.2 Hz, 1H), 6.94 (d, *J* = 7.2 Hz, 1H), 6.79 (d, *J* = 8.0 Hz, 1H), 5.58 (s, 1H), 5.11 (dd, 7 = 5.2, 13.2 Hz, 1H), 4.29 - 4.11 (m, 4H), 3.77 - 3.52 (m, 8H), 3.49 - 3.41 (m, 4H), 2.97 - 2.87 (m, 1H), 2.64 - 2.59 (m, 2H), 2.05 - 2.03 (m, 1H). LC-MS (ESI^+) m/z 888.1 $(M+H)^+$.

[004939] Example 118 [Method 101: [2-[2-[[(1S)-1-[(4R)-4-1ινάrφχν-2-[[4-(4-methylthiazol-5-vPphenyl1methylcarbamoyl1pyrrolidine-l-carbonyl1-2.,2-diiiiethyl-propyl] amino] -2-oxo-ethoxyl ethoxy] ethoxy] ethoxy] ethoxyl-3-methyl-butyll pyridine-3-carboxamide, _ 1-118



[004940] Step 1 - Ethyl 2-[2-[2-[2-[2-[3-[[6-(5-cyanopyrazolo[3,4-b]pyridin-1-yl)-4-(cyclopropylamino)_ _pyridine-3-carbonyllaminol-2-fluoro- 1.1-dimethylpropoxyl ethoxy]ethoxy]ethoxy]ethoxy]acetate

[004941] To a mixture of ethyl 2-[2-[2-[2-[2-(3-amino-2-fluoro-l,l-dimethyl-propoxy)ethoxy]ethoxy]ethoxy] ethoxy]acetate (200 mg, 521 umol, Intermediate BJ) and DIPEA (337 mg, 2.61 mmol) in DMF (3 mL) was added 6-(5-cyanopyrazolo[3,4-b]pyridin-l-yl)-4-(cyclopropylamino)pyridine-3-carboxylic acid (271 mg, 625 umol, Intermediate L as the TFA salt) and HATU (257 mg, 678 umol). The reaction mixture was stirred at rt for 1 hour. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (0.1 %

FA) to give the title compound (80.0 mg, 22% yield) as a red oil. LC-MS (ESI^+) *m/z* 686.6 $(M+H)^+$.

[004942] Step 2 - 2-r2-r2-r2-r2-r3-IT6-(5-Cvanopyrazolor3.4-b1pyridin-l-vD-4-(cvclopropylamino)pyridine-3- carbonyllaminol-2-fluoro- 1.1-dimethyl - propoxylethoxylethoxylethoxylethoxylacetic acid

[004943] To a mixture of ethyl 2-[2-[2-[2-[2-[3-[[6-(5-cyanopyrazolo[3,4-b]pyridin-l-yl)-4-(cyclopropylamino) pyridine-3-carbonyl]amino]-2-fluoro-l,l-dimethyl-propoxy]ethoxy]ethoxy]ethoxy]ethoxy]acetate (70.0 mg, 102 umol) in THF (4 mL) and MeOH (1 mL) was added a solution of LiOH (4.89 mg, 204 umol) in H_20 (1 mL). The reaction mixture was stirred at rt for 0.5 hour. On completion, the reaction mixture was acidified with HC1 (1 N) until the pH = 5-6, then concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*30 mm*4 um; mobile phase: [water (0.05% HCl)-ACN]) to give the title compound (20.0 mg, 29% yield) as a light yellow oil. LC-MS (ESI^+) *m/z* 658.1 $(M+H)^+$.

[004944] Step 3 - 6-(5-Cvanopyrazolor3.4-b1pyridin- l-yl)-4-(cvclopropylamino)-N-r2-fluoro-3-r2-r2-r2-r2-r2-rrnS)-l-r(4R)-4-hvdroxy-2-rr4-(4-methylthiazol-5-yl)phenylImethylcarbamoyl lpyrrolidine-1 -carbonyl1-2.2-dimethyl -propyl laminol-2-oxo-ethoxy] ethoxy] ethoxy] ethoxy] ethoxy] -3-methyl -butyl]pyridine-3 -carboxamide

[004945] To a mixture of (2S,4R)-l-[(2S)-2-amino-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol- 5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (21.3 mg, 45.6 umol, Intermediate Cl, as the HC1 salt) and DIPEA (29.4 mg, 228 umol) in DMF (3 mL) was added 2-[2-[2-[2-[2-[3-[[6-(5-cyanopyrazolo[3,4-b] pyridin- l-yl)-4-(cy clopropylamino)pyri dine-3 - carbonyl] amino] -2-fluoro- 1,1-dimethyl -propoxy] ethoxy] ethoxy] ethoxy] acetic acid (30.0 mg, 45.6 umol) and HATU (20.8 mg, 54.7 umol). The reaction mixture was stirred at rt for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (column: Phenomenex Synergi Cl 8 150*25 *l0um; mobile phase: [water (0.225% FA)-ACN]) to give the title compound **1-118** (10.9 mg, 21% yield) as a yellow solid. ^1H NMR (400MHz, DMSO-de) δ 9.07 (s, 1H), 9.03 (d, *J* = 2.0 Hz, 1H), 8.98 (s, 1H), 8.87 (t, *J* = 5.2 Hz, 1H), 8.72 - 8.58 (m, 4H), 7.76 (s, 1H), 7.49 - 7.34 (m, 5H), 4.57 (d, *J* = 9.6 Hz, 1H), 4.48 - 4.43 (m, 1H), 4.43 - 4.37 (m, 1H), 4.35 (s, 1H), 4.30 - 4.21 (m, 1H), 3.97 (s, 2H), 3.66 - 3.50 (m, 20H), 2.59 (s, 1H), 2.54 - 2.53 (m, 1H), 2.44 (s, 3H), 2.10 - 2.01 (m, 1H), 1.93 - 1.87 (m, 1H), 1.21 (s, 6H), 0.94 (s, 9H), 0.89 - 0.84 (m, 2H), 0.58 (d, *J* = 2.0 Hz, 2H). LC-MS (ESI^+) *m/z* 1070. 1 $(M+H)^+$.

[004946] **Table 8: Compounds synthesized via Method 10 with the coupling of various acids and amines in Step 1, followed by coupling with an amine in Step 3.**

Ex-#	I-#	Step 1 Intermediate Amine	Step 1 Intermediate Acid	Step 3 Intermediate Amine	LCMS (ES+) m/z $(M+H)^+$	HNMR (400MHz, DMSO-d_6) δ
119	**I-119**	BW	N	CI	1087.6	10.38 (s, 1H), 9.06 (s, 1H), 8.99 (s, 1H), 8.63 - 8.52 (m, 5H), 8.47 (s, 1H), 8.31 (s, 1H), 8.28 (d, J = 9.2 Hz, 1H), 7.57 (d, J = 5.6 Hz, 1H), 7.51 (d, J = 8.8 Hz, 1H), 7.46 - 7.37 (m, 5H), 4.84 - 4.68 (m, 1H), 4.57 (d, J = 9.6 Hz, 1H), 4.48 - 4.43 (m, 1H), 4.42 - 4.37 (m, 1H), 4.36 (s, 1H), 4.29 - 4.22 (m, 1H), 3.97 (s, 2H), 3.56 - 3.48 (m, 24H), 2.62 (s, 2H), 2.46 - 2.45 (m, 1H), 2.44 (s, 3H), 2.09 - 2.02 (m, 1H), 1.96 - 1.85 (m, 1H), 0.95 (s, 9H), 0.93 (s, 2H), 0.59 (s, 2H)
120	**I-120**	BX	N	CI	955.5	10.4 (s, 1H), 9.06 (s, 1H), 8.97 (s, 1H), 8.63 - 8.52 (m, 3H), 8.47 (s, 1H), 8.27 (d, J = 8.8 Hz, 1H), 7.57 (d, J = 6.0 Hz, 1H), 7.51 (d, J = 8.8 Hz, 1H), 7.45 (d, J = 9.6 Hz, 1H), 7.40 (s, 4H), 4.85 - 4.65 (m, 1H), 4.57 (d, J = 9.6 Hz, 1H), 4.48 - 4.37 (m, 2H), 4.36 (s, 1H), 4.30 - 4.23 (m, 1H), 3.98 (s, 2H), 3.73 - 3.52 (m, 15H), 3.32 - 3.25 (m, 1H), 2.69 - 2.65 (m, 1H), 2.71 - 2.60 (m, 1H), 2.43(s, 3H), 2.05 (m,


						1H), 1.90 (m, 1H), 0.98 - 0.92 (m, 11H), 0.59 (s, 2H)
121	**I-121**	BL	L	CI	1056.6	9.06 (d, *J* = 2.0 Hz, 1H), 9.02 (d, *J* = 2.0 Hz, 1H), 8.98 (s, 1H), 8.86 - 8.80 (m, 1H), 8.66 (s, 1H), 8.63 (s, 1H), 8.62 - 8.55 (m, 2H), 7.72 (s, 1H), 7.45 - 7.38 (m, 5H), 5.20 - 5.15 (m, 1H), 4.70 - 4.61 (m, 1H), 4.56 - 4.5 (m, 1H), 4.47 - 4.33 (m, 3H), 4.29 - 4.21 (m, 1H), 3.96 (s, 2H), 3.72 - 3.48 (m, 16H), 2.62 - 2.57 (m, 1H), 2.55 - 2.52 (m, 4H), 2.43 (s, 3H), 2.07 - 2.00 (m, 1H), 1.94 - 1.86 (m, 1H), 1.27 - 1.22 (m, 1H), 1.19 - 1.14 (m, 3H), 0.94 (s, 9H), 0.88 - 0.84 (m, 2H), 0.59 - 0.54 (m, 2H)
122[a]	**I-122**	BM	L	CI	968.1	9.05 (s, 1H), 9.01 (d, *J* = 2.0 Hz, 1H), 8.96 (s, 1H), 8.83 (d, *J* = 5.6 Hz, 1H), 8.66 (s, 1H), 8.65 - 8.53 (m, 3H), 7.72 (s, 1H), 7.46 - 7.36 (m, 5H), 5.19 (s, 1H), 4.69 - 4.61 (m, 1H), 4.69 - 4.61 (m, 1H), 4.59 - 4.50 (m, 2H), 4.49 - 4.40 (m, 2H), 4.39 - 4.33 (m, 2H), 4.29- 4.22 (m, 1H), 3.98 (s, 2H), 3.63 -3.60 (m, 10H), 2.59 - 2.56 (m, 2H), 2.43 (s, 3H), 2.10 - 2.02 (m, 1H), 1.92 - 1.90 (m, 1H), 1.17 - 1.11 (m, 3H), 0.94 (s, 9H), 0.89 - 0.83 (m, 2H), 0.56 (s, 2H)

123	**I-123**	CI	DT	DR	1150.6	8.98 (s, 1H), 8.60 (br t, *J* = 6.0 Hz, 1H), 8.52 (s, 1H), 7.45 - 7.39 (m, 5H), 7.19 - 7.16 (m, 1H), 7.13 - 7.10 (m, 1H), 5.48 - 5.42 (m, 1H), 5.21 - 5.11 (m, 2H), 4.60 - 4.54 (m, 1H), 4.48 - 4.38 (m, 2H), 4.37 - 4.34 (m, 1H), 4.28 - 4.23 (m, 1H), 4.16 - 4.10 (m, 2H), 3.97 (s, 2H), 3.94 - 3.90 (m, 1H), 3.69 - 3.66 (m, 1H), 3.63 - 3.53 (m, 16H), 3.49 (s, 7H), 3.06 - 3.00 (m, 1H), 2.95 - 2.88 (m, 1H), 2.61 - 2.54 (m, 2H), 2.44 (s, 3H), 2.42 - 2.38 (m, 3H), 2.37 - 2.02 (m, 4H), 1.95 - 1.89 (m, 1H), 1.88 - 1.81 (m, 2H), 1.71 - 1.35 (m, 6H), 0.94 (s, 9H)

Variations in reaction time for Method 10 were as follows: Step 1 was run anywhere from 0.5-12 h, Step 2 anywhere from 0.5-3.5 h, and Step 3 anywhere from 0.5-3 hr. [a]Product isolated as the FA salt.

[004947] **Further Examples using synthetic methods similar to Method 10:**


[004948] **Example 124: (2S,4R)-1-[(2S)-2-[[2-[2-[2-[2-[2-[2-[4-[4-[[(8R)-8-[(2S)-3-amino-2-hydroxy-3-oxo-propyl]-7,8-dihydro-6H-cyclopenta[4,5]thieno[1,2-c]pyrimidin-1-yl]oxy]cyclohexyl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]acetyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide, 1-124**



[004949] Ethyl 2-[2-[2-[2-[2-[2-[4-[4-[[(8R)-8-[(2S)-3-amino-2-hydroxy-3-oxo-propyl]-7,8-dihydro-6 H-cyclopenta[4,5]thieno[l,2-c]pyrimidin-l-yl]oxy]cyclohexyl]piperazin-l-yl] ethoxy] ethoxy] ethoxy] ethoxy] ethoxy] acetate was synthesized as follows: to a solution of (2S)-2-hydroxy-3-[(8A')-l -(4-piperazin- l-ylcyclohexoxy)-7,8-dihydro-6//-cyclopenta [4,5]thieno[l,2-c]pyrimidin-8-yl]propanamide (90.0 mg, 187 umol, Intermediate DR) in DMF (5 mL) was added K2CO3 (129 mg, 933 umol) and ethyl 2-[2-[2-[2-[2-(2-methylsulfonyloxyethoxy)ethoxy]ethoxy]ethoxy] ethoxy] acetate (113 mg, 280 umol, synthesized via Steps 1-2 of Intermediate BW). The reaction mixture was stirred at 60 °C for 25 h. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (130 mg,

92% yield) as a yellow solid (LC-MS (ESI^+) *m/z* 752.4 $(M+H)^+$). The final product was then synthesized via Steps 2-3 of Method 10, where Step 2 was run for 15 h at rt and Step 3 was run for 3 h at rt using acid Intermediate Cl. Characterization of the final product **1-124:** ^{1}**H** NMR (400MHz, DMSO-di) δ 8.98 (s, 1H), 8.60 (t, *J* = 6.0 Hz, 1H), 8.52 (s, 1H), 8.22 (s, 1H), 7.42 (d, *J* = 9.6 Hz, 2H), 7.39 (s, 2H), 7.15 (s, 1H), 7.11 (s, 1H), 5.18 - 5.12 (m, 1H), 4.57 (d, *j* = 9.6 Hz, 1H), 4.47 - 4.40 (m, 2H), 4.40 - 4.33 (m, 2H), 4.25 (dd, *J* = 5.6, 15.8 Hz, 2H), 3.97 (s, 2H), 3.95 - 3.90 (m, 2H), 3.68 - 3.48 (m, 20H), 3.05 - 2.98 (m, 1H), 2.94 - 2.87 (m, 1H), 2.61 - 2.53 (m, 2H), 2.44 (s, 12H), 2.16 - 2.04 (m, 3H), 1.92 - 1.83 (m, 3H), 1.69 - 1.58 (m, 2H), 1.57 - 1.41 (m, 2H), 1.41 - 1.32 (m, 2H), 0.94 (s, 9H); LC-MS (ESI^+) *m/z* 1136.1 $(M+H)^+$.


[004950] Example 125: N-[3-carbamoyl-1-[4-[8-[2-[[(1S)-1-[(2S,4R)-4-hydroxy-2-[[4-(4-methylthiazol-5-yl)phenyl]methylcarbamoyl]pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]amino]-2-oxo-ethoxy]octylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(2,2,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide, 1-125



[004951] Tert-butyl 2-[8-[[4-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-

pyridyl] oxazole-4-carbonyl]amino]-3-carbamoyl-pyrazol-l-yl]benzoyl]amino]octoxy]acetate was synthesized via Method 10, Stepl, where amine Intermediate DX and acid Intermediate CN were coupled at rt for 2 hours. In Step 2, the Boc groups were removed as follows: to a solution of tert-butyl 2-[8-[[4-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carbonyl]amino]-3-carbamoyl-pyrazol-l-yl]benzoyl]amino]octoxy]acetate (120 mg, 134 umol) in DCM (3 mL) was added TFA(760 mg, 6.75 mmol). The mixture was stirred at rt for 3 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (110 mg, 100% yield, TFA salt) as light yellow oil (LC-MS (ESI^+) *m/z* 701.4 $(M+H)^+$). The third step followed Method 10, where amine Intermediate Cl was coupled with the acid at rt for 3 hours. Characterization of the final product 1-125: ^1H NMR (400MHz, DMSO-d_6) δ 11.02 (s, 1H), 9.04 (d, *J* = 2.0 Hz, 2H), 8.97 (s, 1H), 8.61 (t, *J* = 6.0 Hz, 1H), 8.54 (t, *J* = 6.0 Hz, 1H), 8.25 (d, *J* = 5.6 Hz, 1H), 8.13 (s, 1H), 8.08 (d, *J* = 8.8 Hz, 2H), 8.02 (d, *J* = 8.8 Hz, 2H), 7.77 (s, 1H), 7.70 (t, *J* = 6.4 Hz, 1H), 7.47 - 7.31 (m, 5H), 7.27 (s, 1H), 7.20 - 7.16 (m, 1H), 5.16 (d, *J* = 3.6 Hz, 1H), 4.56 (d, *J* = 9.6 Hz, 1H), 4.48 - 4.32 (m, 3H), 4.29 - 4.19 (m, 3H), 3.91 (s, 2H), 3.71 - 3.57 (m, 2H), 3.49 - 3.44 (m, 2H), 3.29 - 3.21 (m, 2H), 2.43 (s, 3H), 2.11 - 2.01 (m, 1H), 1.95 - 1.84 (m, 1H), 1.59 - 1.47 (m, 4H), 1.36 - 1.23 (m, 8H), 0.93 (s, 9H); LC-MS (ESI^+) *m/z* 1113.5 $(M+H)^+$.

[004952] Example 126: 4-[2-[4-[2-[2-[2-[2-[[2-(2,6-Dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethoxy] ethoxy|ethoxy|ethylcarbamoyl]phenyl]ethynyl]-l-[[[2S.,3S,4SV3-ethyl-4-fluoro-5-oxo-pyrrolidin-2-yl]methoxy]-7-methoxy-isoquinoline-6-carboxamide, 1-126



[004953] Step 1 - 4-bromo-1-[[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxo-pyrrolidin-2-yl]methoxyl-7-methoxy-iso quinoline-6-carbonitrile

[004954] To a solution of l-[[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxo-pyrrolidin-2-yl]methoxy]-7- methoxy-isoquinoline-6-carbonitrile (200 mg, 582 umol, Intermediate CD) in ACN (7.00 mL) was added NBS (228 mg, 1.28 mmol), and the mixture was stirred at 60 °C for 2 hours. On completion, the mixture was concentrated *in vacuo*. The mixture was purified by prep-TLC (EA) to give the title compound (130 mg, 52% yield) as a yellow solid. ¾ NMR (400MHz, CDCb) δ 8.31 (s, 1H), 8.06 (s, 1H), 7.68 (s, 1H), 7.57 (s, 1H), 4.99 - 4.79 (m, 1H), 4.71 (d, *J* = 11.6 Hz, 1H), 4.41 - 4.32 (m, 1H), 4.21 - 4.14 (m, 1H), 4.07 (s, 3H), 2.70 - 2.47 (m, 1H), 1.86 - 1.66 (m, 2H), 1.13 (t, 7 = 7.2 Hz, 3H).

[004955] Step 2 - 4-Bromo-l-[[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxo-pyrrolidin-2-

vHmethoxyl-7-methoxy- isoquinoline-6-carboxamide

[004956] To a solution of 4-bromo-l-[[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxo-pyrrolidin-2-yl]methoxy]-7-methoxy- isoquinoline-6-carbonitrile (300 mg, 710 umol) in DMSO (3.00 mL) was added K2CO3 (39.2 mg, 284 umol) and H2O2 (241 mg, 2.13 mmol, 30% solution). The mixture was stirred at rt for 16 hours. On completion, the mixture was diluted with H2O (30 mL) and extracted with EA (3 X 30 mL). The organic layers were dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (300 mg, 80% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-de) δ 8.88 (s, 1H), 8.24 (s, 1H), 8.16 (s, 1H), 7.95 (s, 1H), 7.85 (s, 1H), 7.80 (s, 1H), 5.00 - 4.82 (m, 1H), 4.56 - 4.50 (m, 1H), 4.30 - 4.23 (m, 1H), 4.10 (s, 1H), 4.00 (s, 3H), 1.64 - 1.53 (m, 2H), 1.02 (t, J = 7.2 Hz, 3H).

[004957] Step 3 - Methyl 4-[2-[6-carbamoyl-1-[[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxo-pyrrolidin-2-vnmethoxy1-7 -methoxy-4-isoquinolyl1ethvnyl1benzoate

[004958] 4-bromo-l-[[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxo-pyrrolidin-2-yl]methoxy]-7-methoxy-isoquinoline-6-carboxamide (100 mg, 227 umol), Pd(PPh $_3$)2Cl2 (15.9 mg, 22.7 umol) and Cul (8.65 mg, 45.4 umol) were placed in a microwave tube. Then methyl 4-ethynylbenzoate (72.7 mg, 454 umol, CAS# 10602-03-6), TEA (229 mg, 2.27 mmol) and DMF (2.00 mL) were added into the above tube. The mixture was degassed with nitrogen for 5 minutes. The sealed tube was heated at 120 °C for 3 hours under microwave. On completion, the mixture was concentrated *in vacuo*. The mixture was purified by reverse phase chromatography (0.1% FA) to give the title compound (40.0 mg, 33% yield) as a black solid. LC-MS (ESI$^+$) *m/z* 520.3 (M+H)$^+$.


[004959] Step 4 - 4-[2-[6-Carbamoyl-1-[[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxo-pyrrolidin-2-yllmethoxyl-7- methoxy-4-isoquinolyllethvnyllbenzoicacid

[004960] To a solution of methyl 4-[2-[6-carbamoyl-l-[[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxo-pyrrolidin-2-yl] methoxy]-7-methoxy-4-isoquinolyl]ethynyl]benzoate (40.0 mg, 76.9 umol) in a mixed solvent of THF (3.00 mL), MeOH (1.00 mL) and H2O (1.00 mL) was added LiOH (9.22 mg, 384 umol). The mixture was stirred at rt for 16 hours. On completion, the mixture was acidified with 1N HC1 solution until the pH = 5. The mixture was concentrated *in vacuo* to give the title compound (38.0 mg, 85% yield) as a black solid. LC-MS (ESI$^+$) *m/z* 506.2 (M+H)$^+$.

[004961] Step 5 - 4-[2-[4-[2-[2-[2-[2-[[2-(2,6-Dioχo-3-ρiρeriάvl)-1.3-άioχo-isθiήάo1ίη-4-yl]amino] ethoxy]_ ethoxylethoxylethyl carbamoyl Iphenyllethynyl 1-1-ri(2S.3S.4S)-3-ethyl-4-fluoro-5-oxo-pyrrolidin-2-yl1methoxy1-7-methoxy-isoquinoline-6-carboxamide

[004962] To a solution of 4-[2-[6-carbamoyl-l-[[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxo-pyrrolidin-2-yl]methoxy]-7- methoxy-4-isoquinolyl]ethynyl]benzoic acid (28.0 mg, 55.3 umol) and 4-[2-[2-[2-(2-aminoethoxy)ethoxy] ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (26.8 mg, 55.3 umol, HC1, synthesized via Steps 1-2 of Example 128) in DMF (2.00 mL) was added HATU (25.2 mg, 66.4 umol) and DIPEA (28.6 mg, 221 umol). The mixture was stirred at rt for 30 minutes. On completion, the mixture was quenched with H_20 (2 mL), and the mixture was concentrated *in vacuo.* The mixture was purified by prep-HPLC (column: Boston Green ODS 150*30 5 u; mobile phase: [water (0.225% FA) - ACN]; B%: 37%-67%, 10 min) to give the title compound **1-126** (13.3 mg, 25% yield) as yellow solid. ^{1}H NMR (400MHz, DMSO-d_6) δ 11.10 (s, 1H), 8.91 (s, 1H), 8.65 (t, 7 = 5.2 Hz, 1H), 8.39 (s, 1H), 8.27 (s, 1H), 7.95 (s, 2H), 7.93 (s, 1H), 7.82 (s, 1H), 7.80 (s, 1H), 7.74 (s, 1H), 7.71 (s, 1H), 7.60 - 7.54 (m, 1H), 7.13 (d, *J* = 8.4 Hz, 1H), 7.03 (d, *J* = 8.0 Hz, 1H), 6.60 (t, 7 = 5.6 Hz, 1H), 5.09 - 5.02 (m, 1H), 5.01 - 4.84 (m, 1H), 4.63 - 4.57 (m, 1H), 4.35 - 4.28 (m, 1H), 4.16 - 4.09 (m, 1H), 4.00 (s, 3H), 3.63 - 3.59 (m, 2H), 3.56 - 3.44 (m, 14H), 2.89 - 2.85 (m, 1H), 2.63 - 2.61 (m, 1H), 2.58 - 2.58 (m, 1H), 2.57 - 2.56 (m, 1H), 2.05 - 2.00 (m, 1H), 1.65 - 1.58 (m, 2H), 1.03 (t, *J* = 7.2 Hz, 3H); LC-MS (ESI$^+$) *m/z* 936.2 (M+H)$^+$.

[004963] Example 127 [Method 111: N-[3-carbamoyl-1-[4-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyll- 1,3-dioxo-isoindolin-4-yl] amino] ethoxy] ethoxy] ethylcarbamoyl] phenyl] pyrazol-4-yl]-2-[2-[2.,2.,2-trifluoroethylamino)-4-pyridyl1oxazole-4-carboxamide, 1-127



[004964] Step 1 - Tert-butyl n-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethyllcarbamate

[004965] A solution of tert-butyl N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]carbamate (2.50 g, 10.1 mmol, CAS# 153086-78-3), 2-(2,6- dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (3.34 g, 12.1 mmol, Intermediate R) and diisopropyl ethylamine (2.60 g, 20.1 mmol) in dioxane (120 mL) was stirred at 115 °C for 16 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by column chromatography (petroleum ether : ethyl acetate = 1:1) to give the title compound (2.10 g, 40% yield) as a yellow gum. ^{1}H NMR (400MHz, CDCh) δ 8.50 (s, 1H), 7.54 - 7.48 (m, 1H), 7.12 (d, *J* = 7.2 Hz, 1H), 6.92 (d, *J* = 8.4 Hz, 1H), 6.59 - 6.48

(m, 1H), 5.15 - 5.00(m, 1H), 4.95 - 4.85 (m, 1H), 3.79 - 3.71 (m, 2H), 3.70 - 3.62(m, 4H), 3.60 - 3.54 (m, 2H), 3.52 - 3.45 (m, 2H), 3.35 - 3.25 (m, 2H), 2.92 - 2.71 (m, 3H), 2.19 - 2.09 (m, 1H), 1.44 (s, 9H); LC-MS (ESI^+) m/z 527.1 $(M+Na)^+$.

[004966] Step 2 - 4-[2-[2-(2-Aminoethoxy)ethoxy1 ethylamino]-2-(2.6-dioxo-3-piperidvOisoindoline-L3-dione

[004967] To a solution of tert-butyl N-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino] ethoxy]ethoxy]ethyl]carbamate (200 mg, 396 umol) in DCM (5 mL) was added HC1 in dioxane (4 M, 5 mL). The reaction mixture was stirred at rt for 10 minutes. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (200 mg, 90% yield) as a yellow solid. LC-MS (ESI^+) m/z 405.2 $(M+H)^+$.

[004968] Step 3 - Tert-butyl N-[4-[4-[[3-carbamoyl-1-[4-[2-[2-[2-[[2-(2.6-dioxo-3-piperidvD-L3-dioxo- isoindolin-4-yl1amino1ethoxy1ethoxy1ethylcarbamoyl1phenyl1pyrazol-4-yl1carbamoyl1oxazol-2-yl1-2-pyridyl1-N-(2.2.2-trif1uoroethyl icarbamate

[004969] To a solution of 4-[2-[2-(2-aminoethoxy)ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3 -dione (200 mg, 418 umol) and 4-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl] oxazole-4-carbonyl]amino]-3-carbamoyl-pyrazol-l-yl]benzoic acid (257 mg, 418 umol, Intermediate CN) inDMF (5 mL) was added DIPEA (270 mg, 2.09 mmol, 364 uL). The mixture was stirred at rt for 12 minutes, and then HATU (191 mg, 502 umol) was added to the mixture. The reaction mixture was stirred at rt for 12 hours. On completion, the mixture was quenched with H_2O (10 mL) and filtered. The filter cake was dried *in vacuo* to give the title compound (400 mg, 95% yield) as a yellow solid. LC-MS (ESI^+) m/z 902.2 $(M+H-l00)^+$.

[004970] Step 4 - N-[3-carbamovl-l-[4-[2-[2-[[2-(2.6-dioxo-3-piperidvl)-1.3-dioxo-isoindolin-4- vl]amino]_ ethoxylethoxylethyl carbamoyl 1phenyl1pyrazol-4-yl1-2-r2-(2.2.2-trifluoroethylamino)-4-pyridyl1oxazole-4-carboxamide

[004971] To a solution of tert-butyl N-[4-[4-[[3-carbamoyl-l-[4-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo -isoindolin-4-yl]amino]ethoxy]ethoxy]ethylcarbamoyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (400 mg, 399 umol) in DCM (3 mL) was added HC1 in dioxane (4 M, 3 mL). The reaction mixture was stirred at rt for 20 minutes. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (column: Phenomenex Synergi Max-RP 250*50mm*l0 um; mobile phase: [water

(0.225% FA)-ACN]; **B%:** 35 ACN%-63 ACN%) to give the title compound **1-127** (121 mg, 31% yield) as a yellow solid. ¾ NMR (400MHz, DMSO-de) δ 11.10 (s, 1H), 11.02 (s, 1H), 9.05 (s, 1H), 9.04 (s, 1H), 8.63 (t, 7 = 5.2 Hz, 1H), 8.26 (d, 7 = 5.2 Hz, 1H), 8.14 (m, 1H), 8.11 - 8.06 (m, 2H), 8.05 - 7.99 (m, 2H), 7.79 (m, 2H), 7.56 (dd, *J* = 7.2, 8.4 Hz, 1H), 7.29 (s, 1H), 7.19 (dd, *J* = 1.2, 5.2 Hz, 1H), 7.12 (d, *J* = 8.4 Hz, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.60 (s, 1H), 5.06 (dd, 7 = 5.6, 13.2 Hz, 1H), 4.34 - 4.20 (m, 2H), 3.67 - 3.52 (m, 12H), 2.96 - 2.82 (m, 1H), 2.64 - 2.58 (m, 1H), 2.57 - 2.55 (m, 1H), 2.13 - 1.96 (m, 1H); LC-MS (ESI^+) m/z 902.3 $(M+H)^+$.

[004972] **Table 9: Compounds synthesized via Method 11 with the addition of various amines to fluoride Intermediate R in Step 1, followed by coupling with various acids in Step 3.**

Ex-#	I-#	Step 1 Intermediate Amine	Step 3 Intermediate Acid	LCMS (ES+) m/z $(M+H)^+$	^{1}HNMR (400MHz, DMSO-d6) δ
128[a]	**I-128**	tert-butyl N-[2-[2-[2-(2-aminoethoxy) ethoxy]-ethoxy]ethyl]-carbamate (CAS# 101187-40-0)	CN	946.5	11.15 - 11.04 (s, 1H), 11.02 (s, 1H), 9.04 (s, 2H), 8.64 (t, *J* = 5.2 Hz, 1H), 8.27 (d, *J* = 5.2 Hz, 1H), 8.14 (s, 1H), 8.12 (s, 1H), 8.10 (s, 1H), 8.04 (s, 1H), 8.02 (s, 1H), 7.78 (s, 1H), 7.71 (t, *J* = 6.4 Hz, 1H), 7.60 - 7.55 (m, 1H), 7.28 (s, 1H), 7.19 (dd, *J* = 5.2 Hz, 1H), 7.12 (d, *J* = 8.4 Hz, 1H), 7.03 (d, *J* = 7.2 Hz, 1H), 6.59 (t, *J* = 5.6 Hz, 1H), 5.09 - 5.03 (m, 1H), 4.30 - 4.21 (m, 2H), 3.63 - 3.41 (m, 16H), 2.94 - 2.83 (m, 1H), 2.64 - 2.55 (m, 2H), 2.07 - 1.98 (m, 1H)
129[g]	**I-129**	BF	L	810.4	11.12 (s, 1H), 9.09 (d, *J* = 2.0 Hz, 1H), 9.05 (d, *J* = 2.0 Hz, 1H), 8.97 (br s, 1H), 8.70 (s, 1H), 8.65 - 8.63 (m, 2H), 7.79 (s, 1H), 7.59 (dd, *J* = 7.2, 8.4 Hz, 1H), 7.16 (d, *J* = 8.4 Hz, 1H), 7.05 (d, *J* = 7.2 Hz, 1H), 6.63 (br s, 1H), 5.06 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.64 - 4.47 (m, 1H), 3.76 - 3.70 (m, 10H), 3.44 - 3.33 (m, 1H), 3.24 - 3.13 (m, 4H), 2.94 - 2.83 (m, 1H), 2.60 - 2.57 (m, 3H), 2.08 - 1.99 (m, 1H), 1.24 (d, *J* = 3.6 Hz, 6H), 0.92 - 0.85 (m,

					2H), 0.58 - 0.55 (m, 2H)
130[b]	**I-130**	tert-butyl N-[2-(2-aminoethoxy) - ethyl]carbamate (CAS# 127828-22-2)	CN	858.0	11.09 (s, 1H), 11.02 (s, 1H), 9.04 (d, *J* = 1.6 Hz, 2H), 8.63 (t, *J* = 5.2 Hz, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.15 (s, 1H), 8.11 - 8.06 (m, 2H), 8.03 - 7.97 (m, 2H), 7.79 (s, 1H), 7.71 (t, *J* = 6.4 Hz, 1H), 7.60 - 7.54 (m, 1H), 7.28 (s, 1H), 7.21 - 7.14 (m, 2H), 7.02 (d, *J* = 6.8 Hz, 1H), 6.64 (t, *J* = 5.6 Hz, 1H), 5.04 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.31 - 4.19 (m, 2H), 4.12 (s, 2H), 3.70 - 3.59 (m, 4H), 3.52 - 3.49 (m, 2H), 2.90 - 2.83 (m, 1H), 2.63 -2.52 (m, 2H), 2.06 - 1.97 (m, 1H)
131[f]	**I-131**	BD	L	854.1	11.10 (s, 1H), 9.14 - 8.98 (m, 2H), 8.86 (s, 1H), 8.65 (d, *J* = 8.8 Hz, 2H), 8.62 - 8.58 (m, 1H), 7.72 (s, 1H), 7.56 (t, *J* = 8.0 Hz, 1H), 7.12 (d, *J* = 8.8 Hz, 1H), 7.07 - 6.99 (m, 1H), 6.60 (t, *J* = 5.6 Hz, 1H), 5.05 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.61 - 4.42 (m, 1H), 3.75 - 3.59 (m, 14H), 2.95 - 2.84 (m, 1H),2.82 - 2.74 (m, 4H), 2.62 -2.57 (m, 2H), 2.56 - 2.53 (m, 1H), 2.49 - 2.39 (m, 1H), 2.06 - 1.97 (m, 1H), 1.21 (s, 6H), 0.90 – 0.82 (m, 2H),0.60 - 0.53 (m, 2H)
132[c]	**I-132**	tert-butyl N-(8-aminooctyl)-carbamate (CAS# 88829-82-7)	CN	898.3	11.08 (s, 1H), 11.02 (s, 1H), 9.04 (d, *J* = 3.2 Hz, 2H), 8.56 (t, *J* = 5.6 Hz, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.13 (s, 1H), 8.11 - 8.07 (m, 2H), 8.06 - 7.99 (m, 2H), 7.77 (s, 1H), 7.70 (t, *J* = 6.4 Hz, 1H), 7.62 - 7.54 (m, 1H), 7.27 (s, 1H), 7.18 (dd, *J* = 1.2, 5.2 Hz, 1H), 7.09 (d, *J* = 8.4 Hz, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.52 (t, *J* = 5.6 Hz, 1H), 5.05 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.31 - 4.20 (m, 2H), 3.31 - 3.25 (m, 4H), 2.94 - 2.83 (m, 1H), 2.63 - 2.58 (m, 1H), 2.56 - 2.53 (m, 1H), 2.08 - 1.98 (m, 1H), 1.61 - 1.52 (m, 4H), 1.33 (s, 8H)

133[d]	**I-133**	undecane-1,11-diamine (CAS# 822-08-2)	CN	940.0	11.09 (br s, 1H), 11.01 (s, 1H), 9.06 - 8.99 (m, 2H), 8.56 (t, *J* = 5.6 Hz, 1H), 8.26 (d, *J* = 5.6 Hz, 1H), 8.13 (s, 1H), 8.11 - 8.06 (m, 2H), 8.01 (d, *J* = 8.8 Hz, 2H), 7.77 (s, 1H), 7.69 (t, *J* = 6.4 Hz, 1H), 7.61 - 7.53 (m, 1H), 7.27 (s, 1H), 7.21 - 7.16 (m, 1H), 7.08 (d, *J* = 8.4 Hz, 1H), 7.01 (d, *J* = 7.2 Hz, 1H), 6.50 (t, *J* = 5.6 Hz, 1H), 5.04 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.30 - 4.20 (m, 2H), 3.30 - 3.14 (m, 2H), 2.94 - 2.80 (m, 1H), 2.63 - 2.54 (m, 2H), 2.09 - 1.97 (m, 1H), 1.55 - 1.50 (m, 4H), 1.35 - 1.19 (m, 16H)
134	**I-134**	tert-butyl N-[2-[2-(2-aminoethoxy)-ethoxy]-ethyl]-carbamate (CAS# 153086-78-3)	DE	926.9	^{1}H NMR (400MHz, DMSO-d_6) δ 11.09 (s, 1H), 9.98 (s, 1H), 8.99 (d, *J* = 4.8 Hz, 2H), 8.63 (s, 1H), 8.24 (d, *J* = 4.8 Hz, 1H), 8.10 - 7.92 (m, 4H), 7.68 - 7.49 (m, 2H), 7.25 (s, 1H), 7.21 (d, *J* = 4.0 Hz, 1H), 7.10 (d, *J* = 8.8 Hz, 1H), 7.01 (d, *J* = 6.4 Hz, 1H), 6.58 (s, 1H), 5.05 (d, *J* = 7.2 Hz, 1H), 4.34 - 4.15 (m, 2H), 3.65 - 3.44 (m, 12H), 2.92 - 2.82 (m, 1H), 2.61 - 2.59 (m, 1H), 2.57 - 2.54 (m, 1H), 2.10 – 1.95 (m, 1H)
135	**I-135**	tert-butyl N-[2-[2-(2-aminoethoxy)-ethoxy]ethyl]-carbamate (CAS# 153086-78-3)	DD	902.7	11.07 (s, 1H), 11.02 (s, 1H), 9.03 (s, 1H), 9.00 (s, 1H), 8.74 (s, 1H), 8.35 (s, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.12 (d, *J* = 8.0 Hz, 1H), 8.07 (s, 1H), 7.85 (d, *J* = 8.0 Hz, 1H), 7.74 (s, 1H), 7.70 - 7.60 (m, 2H), 7.55 - 7.50 (m, 1H), 7.27 (s, 1H), 7.18 (d, *J* = 4.4 Hz, 1H), 7.06 (d, *J* = 8.8 Hz, 1H), 7.00 (d, *J* = 6.8 Hz, 1H), 6.56 (s, 1H), 5.07 - 4.98 (m, 1H), 4.31 - 4.19 (m, 2H), 3.66 - 3.52 (m, 12H), 2.88 - 2.80 (m, 1H), 2.63 - 2.57 (m, 1H), 2.57 - 2.55 (m, 1H), 2.03 - 1.99 (m, 1H)
136	**I-136**	*tert*-butyl (14-amino-3,6,9,12-tetraoxa-tetradecyl)-	DD	990.3	11.08 (s, 1H), 11.03 (s, 1H), 9.05 (s, 1H), 9.02 (s, 1H), 8.76 (s, 1H), 8.37 (s, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.14 (d, *J* = 7.2 Hz, 1H), 8.08 (s, 1H), 7.87 (d, *J* = 7.2 Hz, 1H),

		carbamate (CAS# 811442-84-9)			7.75 (s, 1H), 7.70 - 7.61 (m, 2H), 7.58 - 7.52 (m, 1H), 7.27 (s, 1H), 7.18 (d, *J* = 4.4 Hz, 1H), 7.11 (d, *J* = 8.4 Hz, 1H), 7.02 (d, *J* = 6.8 Hz, 1H), 6.57 (s, 1H), 5.07 - 5.01 (m, 1H), 4.28 - 4.21 (m, 2H), 3.55 - 3.43 (m, 20H), 2.94 - 2.80 (m, 1H), 2.62 - 2.59 (m, 1H), 2.59 - 2.57 (m, 1H), 2.02 - 1.97 (m, 1H)
137	**I-137**	tert-butyl N-[2-[2-(2-aminoethoxy) - ethoxy]ethyl]-carbamate (CAS# 153086-78-3)	CU	912.4	12.09 (s, 1H), 11.08 (s, 1H), 9.12 (s, 1H), 8.63 - 8.60 (m, 1H), 8.28 - 8.21 (m, 4H), 8.14 (s, 1H), 8.13 - 8.09 (m, 2H), 8.03 (d, *J* = 8.8 Hz, 2H), 7.88 (s, 1H), 7.65 (d, *J* = 5.6 Hz, 1H), 7.60 - 7.53 (m, 1H), 7.50 (s, 1H), 7.19 (t, *J* = 6.8 Hz, 1H), 7.12 (d, *J* = 8.4 Hz, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.60 (t, *J* = 5.6 Hz, 1H), 5.06 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.41 - 4.22 (m, 2H), 3.65 - 3.60(m, 2H), 3.61 - 3.56 (m, 6H), 3.45 (d, *J* = 5.6 Hz, 4H), 2.93 - 2.82 (m, 1H), 2.63 - 2.55 (m, 1H), 2.55 - 2.53 (m, 1H), 2.08 - 1.99 (m, 1H)
138[e]	**I-138**	tert-butyl N-[2-[2-(2-aminoethoxy) - ethoxy]ethyl]-carbamate (CAS# 153086-78-3)	DF	874.4	10.84 (s, 1H), 10.77 (s, 1H), 8.79 (s, 1H), 8.77 (s, 1H), 8.40 – 8.36 (m, 1H), 7.93 (d, *J* = 5.6 Hz, 1H), 7.90 - 7.82 (m, 3H), 7.80 - 7.76 (m, 2H), 7.53 (s, 1H), 7.35 - 7.30 (m, 1H), 6.94 - 6.86 (m, 3H), 6.80 - 6.75 (m, 2H), 6.35 (t, *J* = 6.0 Hz, 1H), 4.81 (dd, *J* = 5.6, 13.2 Hz, 1H), 3.42 - 3.30 (m, 8H), 3.23 - 3.19 (m, 2H), 2.99 - 2.92 (m, 2H), 2.69 - 2.58 (m, 1H), 2.37 - 2.28 (m, 4H), 1.83 - 1.75 (m, 1H), 0.87 - 0.77 (m, 1H), 0.26 - 0.18 (m, 2H), 0.02 - 0.04 (m, 2H)

139	**I-139**	tert-butyl N-[2-[2-(2-aminoethoxy)-ethoxy]ethyl]-carbamate (CAS# 153086-78-3)	CW	908.4	11.09 (s, 1H), 10.94 (d, *J* = 3.6 Hz, 1H), 8.96 (d, *J* = 6.4 Hz, 1H), 8.34 (d, *J* = 16.8 Hz, 1H), 8.25 (d, *J* = 5.2 Hz, 1H), 7.87 - 7.74 (m, 1H), 7.72 - 7.61 (m, 2H), 7.61 - 7.55 (m, 1H), 7.51 (s, 1H), 7.26 (s, 1H), 7.19 - 7.10 (m, 2H), 7.04 (t, *J* = 7.2 Hz, 1H), 6.65 - 6.56 (m, 1H), 5.06 - 5.04 (m, 1H), 4.35 - 4.27 (m, 1H), 4.26 - 4.19 (m, 2H), 3.66 - 3.53 (m, 6H), 3.51 - 3.44 (m, 4H), 3.30 - 3.14 (m, 2H), 2.94 - 2.83 (m, 1H), 2.64 - 2.57 (m, 1H), 2.56 - 2.53 (m, 1H), 2.46 - 2.37 (s, 1H), 2.24 - 2.17 (m, 1H), 2.13 - 2.02 (m, 2H), 1.94 - 1.76 (m, 4H), 1.66 - 1.53 (m, 2H)
140[h]	**I-140**	tert-butyl N-[2-[2-(2-aminoethoxy)-ethoxy]ethyl]-carbamate (CAS# 153086-78-3)	EE	805.4	11.18 - 11.06 (m, 2H), 9.10 (s, 1H), 9.03 (s, 1H), 8.85 (d, *J* = 6.0 Hz, 2H), 8.62 (t, *J* = 5.4 Hz, 1H), 8.15 (s, 1H), 8.11 - 8.06 (m, 2H), 8.05 - 8.00 (m, 2H), 7.97 (d, *J* = 6.0 Hz, 2H), 7.82 (s, 1H), 7.60 - 7.52 (m, 1H), 7.12 (d, *J* = 8.4 Hz, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.59 (t, *J* = 6.0 Hz, 1H), 5.05 (dd, *J* = 5.4, 12.8 Hz, 1H), 3.65 - 3.53 (m, 8H), 3.43 - 3.41 (m, 4H), 2.94 - 2.82 (m, 1H), 2.63 - 2.57 (m, 1H), 2.58 - 2.56 (m, 1H), 2.03 - 1.99 (m, 1H)
141	**I-141**	EF	CN	886.3	11.08 (s, 1H), 11.02 (s, 1H), 9.03 (s, 2H), 8.57 (t, *J* = 4.8 Hz, 1H), 8.25 (d, *J* = 5.6 Hz, 1H), 8.13 (s, 1H), 8.09 (d, *J* = 8.8 Hz, 2H), 8.02 (d, *J* = 8.8 Hz, 2H), 7.77 (s, 1H), 7.70 (t, *J* = 6.4 Hz, 1H), 7.57 (t, *J* = 7.6 Hz, 1H), 7.27 (s, 1H), 7.18 (d, *J* = 5.2 Hz, 1H), 7.10 (d, *J* = 8.4 Hz, 1H), 7.01 (d, *J* = 6.8 Hz, 1H), 6.67 (t, *J* = 5.6 Hz, 1H), 5.04 (dd, *J* = 5.6, 13.2 Hz, 1H), 4.32 - 4.18 (m, 2H), 3.50 - 3.44 (m, 4H), 3.41 - 3.37 (m, 4H), 2.94 - 2.80 (m, 1H), 2.59 - 2.53 (m, 2H), 2.06 - 1.97 (m, 1H), 1.87 -1.78 (m, 4H)


142	**I-142**	tert-butyl N-[2-[2-(2-aminoethoxy)-ethoxy]ethyl]-carbamate (CAS# 153086-78-3)	EC	854.1	9.12 (s, 1H), 8.62 (t, *J* = 5.6 Hz, 1H), 8.48 (d, *J* = 7.2 Hz, 1H), 8.37 (s, 1H), 8.05 - 7.98 (m, 4H), 7.83 (d, *J* = 5.6 Hz, 1H), 7.67 - 7.35 (m, 2H), 7.11 (d, *J* = 8.4 Hz, 1H), 7.01 (d, *J* = 7.2 Hz, 1H), 6.59 (t, *J* = 5.6 Hz, 1H), 6.45 (d, *J* = 7.2 Hz, 1H), 6.31 (s, 1H), 5.08 - 5.01 (m, 1H), 4.33 - 4.24 (m, 1H), 3.65 - 3.62 (m, 2H), 3.57 - 3.54 (m, 11H), 2.92 - 2.81 (m, 1H), 2.62 - 2.55 (m, 1H), 2.54 - 2.52 (m, 1H), 2.07 - 1.97 (m, 1H), 1.83 - 1.73 (m, 2H), 1.70 - 1.53 (m, 4H), 1.46 - 1.30 (m, 2H)
143	**I-143**	tert-butyl N-[2-[2-(2-aminoethoxy)-ethoxy]ethyl]-carbamate (CAS# 153086-78-3)	DZ	903.0	11.09 (s, 1H), 11.03 (s, 1H), 9.24 (d, *J* = 2.4 Hz, 1H), 9.14 (s, 1H), 9.05 (s, 1H), 8.71 (t, *J* = 5.6 Hz, 1H), 8.56 (dd, *J* = 2.8, 8.4 Hz, 1H), 8.26 (d, *J* = 5.6 Hz, 1H), 8.20 (s, 1H), 8.16 (d, *J* = 8.4 Hz, 1H), 7.84 (s, 1H), 7.71 (t, *J* = 6.4 Hz, 1H), 7.54 (t, *J* = 7.6Hz, 1H), 7.27 (s, 1H), 7.18 (d, *J* = 5.2 Hz, 1H), 7.11 (d, *J* = 8.8 Hz, 1H), 6.99 (d, *J* = 7.2 Hz, 1H), 6.58 (t, *J* = 5.6 Hz, 1H), 5.04 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.28 - 4.22 (m, 2H), 3.64 (d, *J* = 5.6 Hz, 2H), 3.61 - 3.58 (m, 6H), 3.51 - 3.46 (m, 4H), 2.92 - 2.82 (m, 1H), 2.61 - 2.59 (m, 1H), 2.57 - 2.55 (m, 1H), 2.03 - 2.01 (m, 1H)

Variations in reaction time for Method 11 were as follows: Step 1 was run anywhere from 12-16 h, Step 2 anywhere from 10 min- 12 h, Step 3 anywhere from 0.5-12 h, and Step 4 was run anywhere from 20 min-lO h. The product of Step 3 was also extracted with EtOAc when it did not precipitate out of solution. [a]The product of Step 1 was purified by prep-TLC (SiO_2, PE:EA = 1:2). [b]The product of Step 3 was purified by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 55%-85%). [c]The final product was purified by prep-HPLC under basic conditions (column: Phenomenex Luna Phenyl-Hexyl l50_30_ 5 um; mobile phase: [water (l0mMNH_4HCO_3)-ACN]; B%: 45%-90%). [d]Step 2, the first deprotection step with HC1 was skipped as there was no BOC group to deprotect from the amine intermediate. [e]Step 4 was run in a mixed solvent of DCM (1 mL) and DMF (2 mL). [f]The deprotection of the CBZ group

in Step 2 was achieved with a hydrogenation using $Pd(OH)_2/C$ and hydrogen gas (15 psi pressure) in THF at rt for 16 h. [g]The deprotection of the benzyl groups in Step 2 was achieved with a hydrogenation using $Pd(OH)_2/C$, Pd/C and hydrogen gas (15 psi pressure) in THF and a catalytic amount of HC1 at rt for 20 h. After filtration and concentration, the intermediate was purified by reversed phase chromatography (0. 1% $NH_3 \cdot H_20$). The final product was also purified by reversed phase chromatography using TFA not FA as the acidic modifier. [h]Step 4 was skipped as no deprotection was required.

[004973] Further Examples using synthetic methods similar to Method 11:

[004974] Example 144: N-[3-carbamoyl-l-[4-[2-[5-[[2-(2.,6-dioxo-3-piperidv0-l.,3-dioxo-isoindolin-4-yl1amino1 pentylamino1ethylcarbamoyl1phenyl]pyrazol-4-yl1-2-[2-t2,2,2-trifluoroethylamino)-4-pyridyl1oxazole-4-carboxamide, 1-144




[004975] 4-(5-aminopentylamino)-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione was synthesized via Steps 1-2 of Method 11, where fluoride Intermediate R was coupled with amine tert-butyl N-(5-aminopentyl)carbamate (CAS#5 1644-96-3) in the first step, and Step 2 was run at rt for 1 hr. Step 3 involved a reductive amination performed as follows: to a solution of 4-(5-aminopentylamino)-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (300 mg, 759 umol, HC1) and tert-butyl N-(2-oxoethyl)carbamate (193 mg, 1.22 mmol, CAS# 89711-08-0) in THF (60 mL) was added KOAc (149 mg, 1.52 mmol) and $NaBH(OAc)_3$ (402 mg, 1.90 mmol). The mixture was


stirred at rt for 20 hours. On completion, the reaction mixture was added to ice water (100 mL) and extracted with DCM (3 X 60 mL). The organic phase was collected, dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by prep-HPLC (0.1% FA) to give tert-butyl N-[2-[5-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]pentylamino] ethyljcarbamate (180 mg, 42% yield) as a yellow solid gum (LC-MS (ESI^+) *m/z* 502.2 $(M+H)^+$).

[004976] Step 4 followed Method 11 with deprotection of the Boc group with HC1 in dioxane. This intermediate was carried on without purification to the final step which was performed as follows: to a mixture of 4-[5-(2-aminoethylamino)pentylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3- dione (110 mg, 251 umol, HC1 salt) and DIPEA (162 mg, 1.26 mmol) in DMF (3 mL) was added 4-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carbonyl]amino]-3-carbamoyl-pyrazol-l-yl]benzoic acid (123 mg, 200 umol, Intermediate CN) and HATU (114 mg, 301 umol). The reaction mixture was stirred at rt for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by reverse phase (0. 1% HC1), then it was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]) to give the title compound **1-144** (11.4 mg, 4% yield, FA) as yellow solid. ^1H NMR (400MHz, DMSO-^e) δ 11.02 (s, 1H), 9.05 (d, *J* = 2.4 Hz, 2H), 8.70 (s, 1H), 8.33 (s, 1H), 8.27 (d, *J* = 5.6 Hz, 1H), 8.14 (s, 1H), 8.13 - 8.00 (m, 4H), 7.78 (s, 1H), 7.71 (t, *J* = 6.4 Hz, 1H), 7.61 - 7.55 (m, 1H), 7.28 (s, 1H), 7.20 - 7.16 (m, 1H), 7.10 (d, *J* = 8.4 Hz, 1H), 7.04 - 6.99 (m, 1H), 6.54 (t, *J* = 5.8 Hz, 1H), 5.06 (dd, *J* = 5.5, 13.2 Hz, 1H), 4.32 - 4.21 (m, 2H), 3.40 - 3.27 (m, 4H), 2.95 - 2.84 (m, 3H), 2.81 (t, *J* = 6.0 Hz, 2H), 2.66 - 2.61 (m, 3H), 2.06 - 2.00 (m, 1H), 1.64 - 1.47 (m, 4H), 1.44 - 1.35 (m, 2H); LC-MS (ESI^+) *m/z* 899.4 $(M+H)^+$.

[004977] Example 145: N-[3-carbamoyl-l-[i-[2-[2-[2-[[2-(2,6-dioxo-3-piperidvl)-1,3-dioxo-isoindolin-4-yl1amino1 ethoxylethoxylethylcarbamoyll-4-piperidyllpyrazol-4-yll-2-[2-[2.,2.,2-trifluoroethylamino)-4-pyridyl1oxazole-4-carboxamide, 1-145




CX



[004978] **To** a solution of triphosgene (14.4 mg, 48.5 umol) in DCM (2 mL) was added a solution of 4-[2-[2-(2-aminoethoxy)ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione (42.8 mg, 97.1 umol, HC1 salt, synthesized via Steps 1-2 of Example 127) in DCM (3 mL) at 0 °C. Then TEA (49. 1 mg, 485 umol) was added to the solution dropwise at 0°C, followed by N-[3-carbamoyl-l-(4-piperidyl)pyrazol-4-yl]-2-[2-(2,2,2-tri fluoroethylamino)-4-pyridyl]oxazole-4-carboxamide (50.0 mg, 97.1 umol, HCl salt, Intermediate CX). The reaction mixture was then stirred at 0°C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo*. The residue was purified by prep-HPLC (column: Boston Green ODS 150*30 5u; mobile phase: [water (0.225% FA)-ACM]) to give the title compound 1-145 (20.4 mg, 22% yield, FA) as a yellow solid. ¾ NMR (400M1-Hz, DMSO-de) δ 11.10 (s, H-i), 10.95 (s, H-i), 8.98 (s, 1H), 8.39 (s, 1H), 8.25 (d, *J* = 5.2 Hz, 1H), 7.75 - 7.67 (m, 2H), 7.62 - 7.55 (m, 1H), 7.52 (s, 1H), 7.26 (s, 1H), 7.17 (d, *J* = 1.2 Hz, 1H), 7.16 - 7.13 (m, 1H), 7.12 - 7.12 (m, H-i), 7.04 (d, *J* = 7.2 Hz, 1H), 6.62 - 6.60 (m, 2H), 5.07 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.50 - 4.41 (m, 1H), 4.30 - 4.19 (m, 2H), 4.09 (d, *J* = 12.8 Hz, 2H), 3.65 - 3.61 (m, 2H), 3.59 - 3.52 (m, 4H), 3.48 - 3.45 (m, 2H), 3.44 - 3.41 (m, 2H), 3.24 - 3.13 (m, 2H), 2.95 - 2.86 (m, 1H), 2.86 - 2.78 (m, 2H), 2.62 - 2.57 (m, 1H), 2.56 m 2.53 (m, 1H), 2.05 - 1.96 (m, 3H), 1.89 - 1.78 (m, 2H); LC-MS (ESI^+) *m/z* 909.1 $(M+H)^+$.

[004979] **Example 146 [Method 121: N-(3-carbamoyl-l-(4-((2-(3-(2-(2,6-**

dioxopiperidin-3-yP-l,3-dioxoisoindolin-5-yPpr()poxy)ethyPcarbamoyPphenvP-lH-Pyrazol-4-vP-2-f2-P2,2,2-trifluoroethvPamino)pyridin-4-vPoxazole-4-carboxamide, 1-146



[004980] Step 1 - Tert-butyl (4-(4-((3-carbamoyl-1-(4-((2-(3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)propoxy)ethyl)carbamoyl)phenyl)-1H-pyrazol-4-yl)carbamoyl)oxazol-2-yl)Dyridin-2-yl)(2,2,2-trifluoroethyl)carbamate

[004981] To a solution of 4-[3-(2-aminoethoxy)propyl]-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (90 mg, 250 umol, Intermediate CP) and (154 mg, 250 umol, Intermediate CN) in DMF (2 mL) was added DIPEA (162 mg, 1.25 mmol). Ten minutes later, HATU (114 mg, 300 umol) was added into the above mixture. The reaction mixture was stirred at rt for 0.5 h. On completion, the mixture was diluted was water (30 mL), stirred and filtered. The filter cake was dried *in vacuo* to give the title compound (110 mg, 43% yield) as a white solid. LC-

MS (ESI+) *m/z* 957.3 (M+H)+.

[004982] Step 2 - N-(3-carbamoyl-1-(4-((2-(3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)propoxy)ethyl)carbamoyl)phenyl)-1H-pyrazol-4-yl)-2-(2-((2,2,2-trifluoroethyl)amino)pyridin-4-yl)oxazole-4-carboxamide

[004983] To a solution of tert-butyl N-[4-[4-[[3-carbamoyl-1-[4-[2-[3-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]propoxy]ethylcarbamoyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (110 mg, 115 umol) in DCM (2 mL) was added HCl in dioxane (4 M, 2 mL). The reaction mixture was stirred at rt for 17 h. On completion, the mixture was concentrated *in vacuo*. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10um; mobilephase: [water (0.225%FA)-ACN]; B%: 32%-62%) to give the title compound **1-146** (13.3 mg, 13% yield, FA) as a white solid. ^{1}H NMR (400MHz, DMSO-d6) δ 11.11 (s, 1H), 11.02 (s, 1H), 9.04 (d, *J* = 5.2 Hz, 2H), 8.71 - 8.62 (m, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.15 - 8.07 (m, 3H), 8.07 - 8.02 (m, 2H), 7.84 - 7.75 (m, 3H), 7.73 - 7.67 (m, 2H), 7.28 (s, 1H), 7.19 (d, *J* = 5.2 Hz, 1H), 5.14 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.32 - 4.19 (m, 2H), 3.54 (t, *J* = 5.2 Hz, 2H), 3.48 - 3.43 (m, 4H), 2.96 - 2.87 (m, 1H), 2.86 - 2.83 (m, 2H), 2.63 - 2.59 (m, 2H), 2.11 - 2.02 (m, 1H), 1.93 - 1.84 (m, 2H); LC-MS (ESI+) *m/z* 857.3 (M+H)+

[004984] **Table 10: Compounds synthesized via Method 12 with the coupling of various amines and acids in Step 1.**


Ex-#	I-#	Step 1 Intermediate Amine	Step 1 Intermediate Acid	LCMS (ES+) m/z (M+H)+	^{1}HNMR (400MHz, DMSO-d6) δ
147	I-147	CQ	CN	901.3	11.10 (s, 1H), 11.01 (s, 1H), 9.02 (d, *J* = 5.6 Hz, 2H), 8.64 (t, *J* = 5.6 Hz, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.14 - 8.06 (m, 3H), 8.05 - 7.99 (m, 2H), 7.82 - 7.73 (m, 3H), 7.72 - 7.66 (m, 2H), 7.28 (s, 1H), 7.19 (d, *J* = 5.2 Hz, 1H), 5.12 (dd, *J*=5.2, 12.8 Hz, 1H), 4.30 - 4.21 (m, 2H), 3.60 - 3.45 (m, 10H), 2.81 - 2.76 (m, 1H), 2.79 (t, *J* = 7.2 Hz, 2H), 2.63 - 2.60 (m, 1H), 2.63 - 2.60 (m, 1H), 2.58 - 2.56 (m, 1H), 2.09 - 2.03 (m, 1H), 1.87 - 1.80 (m, 1H)

148	**I-148**	**CT**	**CN**	989.9	11.12 (s, 1H), 11.01 (s, 1H), 9.04 (d, *J* = 2.4 Hz, 2H), 8.64 (t, *J* = 5.2 Hz, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.18 - 8.07 (m, 3H), 8.07 - 8.00 (m, 2H), 7.84 - 7.74 (m, 3H), 7.74 - 7.67 (m, 2H), 7.27 (s, 1H), 7.18 (d, *J* = 5.2 Hz, 1H), 5.13 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.33 - 4.20 (m, 2H), 3.59 - 3.37 (m, 18H), 2.95 - 2.76 (m, 3H), 2.65 - 2.57 (m, 2H), 2.11 - 1.99 (m, 1H), 1.90 - 1.82 (m, 2H)
149	**I-149**	**CS**	**CN**	985.9	11.12 (s, 1H), 11.01 (s, 1H), 9.04 (s, 2H), 8.65 (t, *J* = 5.2 Hz, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.16 - 8.08 (m, 3H), 8.07 - 8.00 (m, 2H), 7.95 - 7.89 (m, 3H), 7.77 (s, 1H), 7.71 (t, *J* = 6.4 Hz, 1H), 7.27 (s, 1H), 7.18 (dd, *J* = 1.6, 5.2 Hz, 1H), 5.16 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.46 (s, 2H), 4.31 - 4.19 (m, 2H), 3.68 - 3.62 (m, 2H), 3.61 - 3.50 (m, 12H), 3.49 - 3.41 (m, 2H), 2.95 - 2.82 (m, 1H), 2.64 - 2.54 (m, 2H), 2.11 - 2.02 (m, 1H)
150	**I-150**	**EL**	**EG**	896.0	10.87 (s, 1H), 9.74 (s, 1H), 8.77 (s, 1H), 8.75 (s, 1H), 8.34 (t, *J* = 5.2 Hz, 1H), 8.07 (s, 1H), 7.93 (d, *J* = 5.2 Hz, 1H), 7.83 - 7.72 (m, 4H), 7.38 - 7.32 (m, 1H), 6.91 - 6.77 (m, 5H), 6.56 (t, *J* = 4.8 Hz, 1H), 4.82 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.06 - 3.03 (m, 2H), 2.97 - 2.94 (m, 1H), 2.72 - 2.53 (m, 4H), 2.40 - 2.30 (m, 4H), 2.29 - 2.28 (m, 2H), 1.83 - 1.75 (m, 1H), 1.36 - 1.22 (m, 4H), 1.18 - 1.11 (m, 2H), 0.88 - 0.80 (m, 1H), 0.26 - 0.20 (m, 2H), 0.02 - -0.03 (m, 2H)

151	**I-151**	**EJ**	**CN**	957.3	11.10 (s, 1H), 11.02 (s, 1H), 9.04 (s, 2H), 8.66 - 8.64 (m, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.15 (s, 1H), 8.12 - 8.06 (m, 3H), 7.78 (s, 1H), 7.71 (t, *J* = 6.8 Hz, 1H), 7.61 - 7.54 (m, 1H), 7.27 (s, 1H), 7.19 (d, *J* = 5.2 Hz, 1H), 7.14 (d, *J* = 8.4 Hz, 1H), 7.03 (d, *J* = 7.2 Hz, 1H), 6.60 (s, 1H), 5.06 (dd, *J* = 12.0, 5.2 Hz, 1H), 4.33 - 4.17 (m, 4H), 3.76 - 3.70 (m, 12H), 2.97 - 2.90 (m, 1H), 2.34 - 2.30 (m, 2H), 2.12 - 1.95 (m, 4H)

Variations in reaction time for Method 12 were as follows: Step 1 was run anywhere from 0.5-12 h, and Step 2 anywhere from 10 min- 17 h. If the product of Step 1 was not a precipitate, a standard work up with water and extraction with ethyl acetate was used to isolate the product.

[004985] Example 152 [Method 13): N-[3-carbamoyl-l-[i-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidvP-l.,3-dioxo-isoindolin-4-yl] amino] ethoxy] ethoxy] ethoxy] acetyl]-4-piperidyllpyrazol-4-yll-2-[2-(2.,2.,2-trifluoroethylamino)-4-pyridylloxazole-4-carboxamide, 1-152



[004986] Step 1 - Tert-butyl 2-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy) ethoxy)ethoxy)acetate

[004987] To a solution of tert-butyl 2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]acetate (6.40 g, 24.3 mmol, Intermediate CY) and 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-1,3-dione (6.71 g, 24.3 mmol, Intermediate R) in dioxane (100 mL) was added DIPEA (9.42 g, 72.9 mmol). The reaction mixture was stirred at 115 °C for 24 hours. On completion, the reaction mixture was concentrated *in vacuo* to give yellow oil. The yellow oil was purified by prep-HPLC (water (0.1% FA)-ACN) to give the title compound (6.00 g, 48% yield) as a yellow oil. ^{1}H NMR (400MHz, CDCh) δ 8.19 (s, 1H), 7.54 - 7.45 (m, 1H), 7.11 (d, J = 8.4 Hz, 1H), 6.93 (d, J = 8.4 Hz, 1H), 6.52 - 6.48 (m, 1H), 4.99 - 4.87 (m, 1H), 4.02 (s, 2H), 3.75 - 3.68 (m, 10H), 3.50 - 3.46 (m, 2H), 2.93 - 2.69 (m, 3H), 2.17 - 2.10 (m, 1H), 1.49 (s, 9H).

[004988] Step 2 - 2-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy) ethoxy)acetic acid

[004989] To a solution of tert-butyl 2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino] ethoxy] ethoxy] ethoxy] acetate (6.00 g, 11.6 mmol) in DCM (30 mL) was

added TFA(30.8 g, 270 mmol). The reaction mixture was stirred at rt for 12 hours. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (5.60 g, 99%yield) as a yellow oil. LC-MS (ESI^+) *m/z* 464.0 $(M+H)^+$.

[004990] Step 3 - N-[3-carbamoyl-l-[l-[2-[2-[2-[2-[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4- yl]_ amino1ethoxy1ethoxy1ethoxy1acetyl1-4-piperidyl1pyrazol-4-yl1-2-r2-(2.2.2-trifluoroethylamino)-4-pyridyl1oxazole-4-carboxamide

[004991] To a mixture of N-[3-carbamoyl-l-(4-piperidyl)pyrazol-4-yl]-2-[2-(2,2,2-trifluoroethylamino)-4- pyridyl]oxazole-4-carboxamide (50.0 mg, 97.1 umol, Intermediate CX) and DIPEA(l25 mg, 971 umol) in DMF (5 mL) was added 2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy] ethoxy]acetic acid (54.0 mg, 116 umol) and F[A'FU (44.3 mg, 116 umol). The reaction mixture was stirred at rt for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo*. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]) to give the title compound **1-152** (55.7 mg, 59% yield, FA) as a yellow solid. ^{1}HNMR (400MHz, DMSO-i¾) δ 11.10 (s, 1H), 10.94 (s, 1H), 8.96 (s, 1H), 8.39 (s, 1H), 8.25 (d, *J* = 5.6 Hz, 1H), 7.74 - 7.66 (m, 2H), 7.62 - 7.54 (m, 1H), 7.51 (s, 1H), 7.26 (s, 1H), 7.16 (d, *J* = 5.2 Hz, 1H), 7.13 (d, *J* = 8.4 Hz, 1H), 7.03 (d, *J* = 7.2 Hz, 1H), 6.59 (s, 1H), 5.05 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.61 - 4.39 (m, 2H), 4.32 - 4.21 (m, 2H), 4.20 - 4.12 (m, 2H), 3.94 (d, *J* = 13.6 Hz, 1H), 3.63 - 3.59 (m, 2H), 3.58 - 3.53 (s, 8H), 3.46 (d, *J* = 5.2 Hz, 2H), 3.18 - 3.10 (m, 1H), 2.94 - 2.83 (m, 1H), 2.83 - 2.71 (m, 1H), 2.63 - 2.56 (m, 1H), 2.56 - 2.53 (m, 1H), 2.07 - 1.92 (m, 4H), 1.85 (d, *J* = 9.6 Hz, 1H); LC-MS (ESI^+) *m/z* 924.3 $(M+H)^+$.

[004992] **Table 11: Compounds synthesized via Method 13 with the addition of various amines to fluoride Intermediate R in Step 1, followed by coupling with various amines in Step 3.**

Ex-#	I-#	Step 1 Intermediate Amine	Step 3 Intermediate Amine	LCMS (ES+) m/z $(M+H)^+$	1HNMR (400MHz, DMSO-d6) δ

153	**I-153**	**DS**	**DR**	803.3	11.11 (br s, 1H), 8.53 (s, 1H), 7.65 - 7.55 (m, 1H), 7.21 - 7.13 (m, 2H), 7.11 (s, 1H), 7.06 (d, *J* = 6.8 Hz, 1H), 6.68 (t, *J* = 5.6 Hz, 1H), 5.20 - 5.11 (m, 1H), 5.07 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.20 (s, 2H), 3.93 (t, *J* = 6.4 Hz, 1H), 3.71 - 3.60 (m, 2H), 3.53 - 3.49 (m, 3H), 3.47 - 3.44 (m, 3H), 3.14 - 2.99 (m, 2H), 2.96 - 2.88 (m, 2H), 2.66 - 2.54 (m, 4H), 2.44 - 2.40 (m, 5H), 2.32 - 2.25 (m, 1H), 2.18 - 2.02 (m, 3H), 1.81 - 1.79 (m, 2H), 1.69 - 1.48 (m, 3H), 1.42 - 1.27 (m, 2H)
154[a]	**I-154**	**CZ**	**CX**	880.4	11.11 (s, 1H), 10.93 (s, 1H), 8.97 (s, 1H), 8.39 (s, 1H), 8.25 (d, *J* = 5.6 Hz, 1H), 7.71 (s, 1H), 7.69 (s, 1H), 7.57 (t, *J* = 7.6 Hz, 1H), 7.52 (s, 1H), 7.25 (s, 1H), 7.19 - 7.11 (m, 2H), 7.03 (d, *J* = 7.2 Hz, 1H), 6.60 (s, 1H), 5.06 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.58 - 4.41 (m, 2H), 4.30 - 4.22 (m, 2H), 4.20 (s, 2H), 3.92 (d, *J* = 12.8 Hz, 1H), 3.70 - 3.53 (m, 8H), 3.47 (d, *J* = 4.8 Hz, 4H), 3.25 - 3.04 (m, 1H), 2.91 - 2.80 (m, 1H), 2.77 - 2.71 (m, 1H), 2.61 (s, 1H), 2.58 - 2.56 (m, 1H), 2.04 (s, 4H), 1.85 (d, *J* = 9.2 Hz, 1H)
155	**I-155**	**DA**	**CX**	968.5	11.10 (s, 1H), 10.94 (s, 1H), 8.97 (s, 1H), 8.40 (s, 1H), 8.24 (d, *J* = 5.2 Hz, 1H), 7.72 (s, 1H), 7.69 (s, 1H), 7.60 - 7.55 (m, 1H), 7.52 (s, 1H), 7.25 (s, 1H), 7.17 - 7.14 (m, 1H), 7.13 (d, *J* = 8.4 Hz, 1H), 7.03 (d, *J* = 6.8 Hz, 1H), 6.62 - 6.55 (m, 1H), 5.05 (dd, *J* = 5.6, 13.2 Hz, 1H), 4.63 - 4.39 (m, 2H), 4.24 (dd, *J* = 6.4, 9.6 Hz, 2H), 4.18 (d, *J* = 6.8 Hz, 2H), 3.94 (d, *J* = 13.2 Hz, 1H), 3.60 (d, *J* = 5.2 Hz, 2H), 3.57 - 3.49 (m, 12H), 3.48 - 3.44 (m, 2H), 3.21 - 3.07 (m, 1H), 2.93 - 2.85 (m, 1H), 2.80 - 2.73 (m, 1H), 2.64 - 2.59 (m, 1H), 2.58 - 2.56 (m, 1H), 2.08 - 1.91 (m, 4H), 1.86 (d,


					J = 14.4 Hz, 1H)
156[a]	**I-156**	**CZ**	**DB**	852.4	11.10 (s, 1H), 10.91 (s, 1H), 8.97 (s, 1H), 8.48 (s, 1H), 8.25 (d, *J* = 5.2 Hz, 1H), 7.84 (s, 1H), 7.69 (t, *J* = 6.4 Hz, 1H), 7.58 (s, 1H), 7.57 - 7.51 (m, 1H), 7.25 (s, 1H), 7.17 (d, *J* = 5.2 Hz, 1H), 7.10 (d, *J* = 8.8 Hz, 1H), 6.99 (d, *J* = 6.8 Hz, 1H), 6.55 (s, 1H), 5.45 - 5.34 (m, 1H), 5.08 - 5.01 (m, 1H), 4.70 - 4.63 (m, 1H), 4.60 - 4.53 (m, 1H), 4.41 - 4.33 (m, 1H), 4.29 - 4.20 (m, 3H), 4.11 - 4.03 (m, 2H), 3.63 - 3.46 (m, 8H), 2.91 - 2.82 (m, 1H), 2.64 - 2.57 (m, 1H), 2.57 - 2.55 (m, 1H), 2.06 - 2.00 (m, 1H)
157	**I-157**	**DA**	**DB**	940.5	11.10 (s, 1H), 10.95 (s, 1H), 8.97 (s, 1H), 8.52 (s, 1H), 8.24 (d, *J* = 5.2 Hz, 1H), 7.88 (s, 1H), 7.68 (t, *J* = 6.8 Hz, 1H), 7.59 (s, 1H), 7.55 (d, *J* = 8.4 Hz, 1H), 7.24 (s, 1H), 7.15 (d, *J* = 4.4 Hz, 1H), 7.11 (d, *J* = 8.8 Hz, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.60 - 6.55 (m, 1H), 5.47 - 5.37 (m, 1H), 5.08 - 5.01 (m, 1H), 4.72 - 4.62 (m, 1H), 4.58 - 4.50 (m, 1H), 4.41 - 4.32 (m, 1H), 4.30 - 4.19 (m, 3H), 4.04 (s, 2H), 3.61 - 3.49 (m, 16H), 2.93 - 2.87 (m, 1H), 2.63 - 2.60 (m, 1H), 2.58 - 2.57 (m, 1H), 2.06 - 2.00 (m, 1H)
158	**I-158**	**CY**	**DB**	896.4	11.11 (s, 1H), 10.94 (s, 1H), 8.97 (s, 1H), 8.51 (s, 1H), 8.24 (d, *J* = 5.2 Hz, 1H), 7.89 (s, 1H), 7.74 - 7.65 (m, 1H), 7.60 (s, 1H), 7.57 - 7.50 (m, 1H), 7.24 (s, 1H), 7.16 (d, *J* = 4.8 Hz, 1H), 7.09 (d, *J* = 8.4 Hz, 1H), 7.01 (d, *J* = 6.8 Hz, 1H), 6.61 - 6.52 (m, 1H), 5.48 - 5.35 (m, 1H), 5.08 - 5.02 (m, 1H), 4.73 - 4.62 (m, 1H), 4.59 - 4.49 (m, 1H), 4.40 - 4.33 (m, 1H), 4.30 - 4.21 (m, 3H), 4.03 (s, 2H), 3.61 - 3.58 (m, 2H), 3.57 - 3.53 (m, 10H), 2.91 - 2.85 (m, 1H), 2.63 - 2.59 (m, 1H), 2.57 - 2.55 (m, 1H), 2.05 - 1.97 (m,

					1H)

Variations in reaction time for Method 13 were as follows: Step 1 was run anywhere from 16-24 h and Step 2 was run anywhere from 0.5-16 h. [a]Since the product of Step 1 was the ethyl ester, not BOC ester, the deprotection for Step 2 used $(Bu_3Sn)_20$ in toluene and the reaction mixture was stirred at 115 °C for 4 hours. This intermediate was then purified by prep-HPLC (0.1% FA.)

[004993] Further Examples using synthetic methods similar to Method 13:

[004994] Example 159: N-[3-carbamoyl-l-[4-[2-[2-[2-[[2-t2,6-dioxo-3-piperidvB-l,3-dioxo-isoindolin-4-yl1amino1 ethoxylethoxylethyl-methyl-carbamoyllphenyllpyrazol-4-yll-2-[2-(2,2.,2-trifluoroethylaminoV4-pyridylloxazole-4-carboxamide, 1-159



[004995] Step 1 - 2-(2.6-Dioxo-3-DiDeridyl)-4-r2-r2-r2-r(4-methoxyphenyl)methyl-methyl-amino] ethoxy] ethoxy] ethyl aminoli soindoline- 1,3-dione

[004996] To a solution of 2-[2-[2-[(4-methoxyphenyl)methyl-methyl-amino] ethoxy] ethoxy] ethanamine (350 mg, 1.24 mmol, Intermediate CR) and 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (342 mg, 1.24 mmol, Intermediate R) in dioxane (5 mL) was added DIPEA (1.60 g, 12.3 mmol, 2.16 mL). The reaction mixture was stirred at 115 °C for

16 hours. On completion, the mixture was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% $NH_3 \cdot H_2O$) to give the title compound (600 mg, 89% yield) as a yellow oil. LC-MS (ESI^+) m/z 539.4 $(M+H)^+$.

[004997] Step 2 - 2-(2.6-Dioxo-3-piperidylV4-r2-r2-r2-(methylamino)ethoxylethoxylethylaminolisoindoline -1,3-dione

[004998] To a mixture of 2-(2,6-dioxo-3-piperidyl)-4-[2-[2-[2-[(4-methoxyphenyl)methyl-methyl-amino]ethoxy] ethoxy]ethylamino]isoindoline-l,3-dione (0.10 g, 185 umol) in MeOH (3 mL) and 1N HC1 (0.05 mL) was added Pd/C (0.05 g, 10 wt %) and $Pd(OH)_2/C$ (0.05 g, 10 wt %). Then the reaction mixture was stirred at rt for 2 hours under hydrogen atmosphere (15 psi pressure). On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (60.0 mg, 77% yield) as a yellowish oil. LC-MS (ESI^+) m/z 419.1 $(M+H)^+$.

[004999] Step 3 - Tert-butyl N-[4-[4-[[3-carbamoyl-1-[4-[2-[2-[2-[[2-(2,6-dioxo-3-piperidvD-U-dioxo- isoindolin-4-vl]amino] ethoxy] ethoxy] ethyl-methyl-carbamoyl1phenyl1pyrazol-4-yl1carbamoyl1oxazol-2-yl1-2-pyridyl1-N-(2.2.2-trifluoroethvDcarbamate


[005000] To a mixture of 2-(2,6-dioxo-3-piperidyl)-4-[2-[2-[2-(methylamino)ethoxy]ethoxy]ethylamino]isoindoline -l,3-dione (77.0 mg, 169 umol, HC1) and 4-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4- pyridyl]oxazole-4-carbonyl]amino]-3-carbamoyl-pyrazol-l-yl]benzoic acid (88.5 mg, 143 umol, Intermediate CN) in DMF (3 mL) was added DIPEA(l09 mg, 846 umol, 147 uL). Then HATLi (83.6 mg, 220 umol) was added to the mixture. The reaction mixture was stirred at rt for 12 hours. On completion, the mixture was concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]; B%: 50%-80%) to give the title compound (0.05 g, 23% yield) as white solid. LC-MS (ESI^+) m/z 1016.0 $(M+H)^+$.

[005001] Step 4 - N-[3-carbamoyl-l-[4-[2-[2-[2-[[2-(2,6-dioxo-3-piperidvl)-1,3-dioxo-isoindolin-4-vl]amino] ethoxylethoxylethyl-methyl-carbamoyl 1phenyl1pyrazol-4-yl1-2-[2-(2,2,2-trifluoroethylamino)-4-pyridyl1oxazole-4-carboxamide

[005002] To a mixture of tert-butyl N-[4-[4-[[3-carbamoyl-l-[4-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo- isoindolin-4-yl]amino]ethoxy]ethoxy]ethyl-methyl-


carbamoyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (42.0 mg, 41.3 umol) in DCM (3 mL) was added HC1 in dioxane (4 M, 0.3 mL). Then the reaction mixture was stirred at rt for 0.5 hour. On completion, the mixture was concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (columnPhenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]; **B%:** 31% -61%) to give the title compound **1-159** (20.0 mg, 50% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-de) 511.15 - 10.96 (m, 2H), 9.18 - 8.78 (m, 2H), 8.27 (s, 1H), 8.12 - 7.96 (m, 3H), 7.78 - 7.50 (m, 5H), 7.31 - 7.00 (m, 4H), 6.58 (s, 1H), 5.05 (s, 1H), 4.25 (s, 2H), 3.70 - 3.62 (s, 8H), 3.55 - 3.49 (m, 4H), 2.98 (s, 3H), 2.87 (s, 1H), 2.65 - 2.58 (m, 2H), 2.02 - 2.00 (m, 1H); LC-MS (ESI^{+}) m/z 916.3 (M +H)$^{+}$.

[005003] Example 160: (2S)-3-[(8R)-1-[4-[4-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino] ethoxy]ethoxy]acetyl]piperazin-l-yl]cyclohexoxy]-7,8-dihydro-6H-cyclopenta[4.,5]thieno[l.,2-c]pyrimidin-8-yl]-2-hydroxy-propanamide, 1-160



[005004] The title compound was synthesized via Method 13, using fluoride Intermediate R and amine intermediate CZ in the first step which was run at 115 °C for 18 hours. In Step 2, the ester was deprotected as follows: to a mixture of $(Bu_3Sn)_20$ (1.17 g, 1.97 mmol) in toluene (5 mL) was added ethyl 2-[2-[2-[[2-(2,6- dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]acetate (440 mg, 983 umol). The reaction mixture was stirred at 115 °C for 4 hours. On completion, the reaction mixture was concentrated *in vacuo*. The residue was purified by prep-HPLC (0.1 % FA) to give 2-[2-[2-[[2-(2,6-Dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]acetic acid (230 mg, 55% yield) as a yellow solid (LC-MS (ESI^+) *m/z* 420.1 $(M+H)^+$; ^1H NMR (400MHz, DMSO-7 ,) δ = 13.39 - 11.73 (m, 1H), 11.10 (s, 1H), 7.65 - 7.52 (m, 1H), 7.16 (d, *J* = 8.4 Hz, 1H), 7.05 (d, *J* = 7.2 Hz, 1H), 7.08 - 7.02 (m, 1H), 6.62 (t, *j* = 5.6 Hz, 1H), 5.06 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.02 (s, 2H), 3.67 - 3.56 (m, 6H), 3.52 - 3.46 (m, 2H), 2.95 - 2.81 (m, 1H), 2.69 - 2.54 (m, 2H), 2.07 - 1.99 (m, 1H)). Intermediate DR was used as the amine in Step 3 to give the final compound **1-160.** Characterization data: ^1H NMR (400MHz, DMSO-i¾) δ = 11.12 (s, 1H), 8.52 (s, 1H), 7.59 (t, *j* = 7.6 Hz, 1H), 7.15 (dd, *j* = 9.6, 18.4 Hz, 3H), 7.05 (d, *j* = 6.8 Hz, 1H), 6.60 (s, 1H), 5.11 (d, 7 = 11.2 Hz, 1H), 5.06 (dd, 7 = 5.2, 12.8 Hz, 1H), 4.14 (s, 2H), 3.95 - 3.90 (m, 5H), 3.64 (d, *J* = 4.8 Hz, 2H), 3.59 - 3.55 (m, 4H), 3.52 - 3.34 (m, 8H), 3.02 (dd, *J* = 8.4, 16.0 Hz, 1H), 2.94 - 2.86 (m, 2H), 2.65 - 2.54 (m, 3H), 2.41 (d, *J* = 9.6 Hz, 2H), 2.33 - 2.26 (m, 1H), 2.16 - 2.04 (m, 3H), 1.82 (d, *J* = 10.0 Hz, 2H), 1.64 - 1.47 (m, 3H), 1.43 - 1.31 (m, 2H). LC-MS (ESI^+) *m/z* 847.1 $(M+H)^+$.


[005005] Example 161: (2S)-3-[(8R)-1-[4-[4-[2-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl] amino]ethoxy]ethoxy]ethoxy]ethoxy]acetyl]piperazin-1-yl]cyclohexoxy]-7,8-dihydro-6H-cyclopenta[4,5]thieno[1,2-c]pyrimidin-8-yl]-2-hydroxy-propanamide, 1-161




[005006] The title compound was synthesized via Method 13, using fluoride Intermediate R and amine Intermediate DW in the first step which was run at 115 °C for 16 hours. In Step 2, the ester was deprotected as follows: to a solution of $(Bu_3Sn)_20$ (779 mg, 1.31 mmol) in toluene (20 mL) was added ethyl 2-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]acetate (0.35 g, 654 umol). The reaction mixture was stirred at 115 °C for 12 hours. On completion, the reaction mixture was quenched with 1 N sodium fluoride solution. The mixture was extracted with DCM (100 mL), then dried and concentrated *in vacuo*. The crude was purified by reverse phase flash chromatography (0.1% FA) to give 2-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy] ethoxy] ethoxy] acetic acid_(0. 175 g, 53% yield) as yellow oil (LCMS (M+l) $^+$: 508.2). Intermediate DR was used as the amine in Step 3 to give the final compound **1-161.** Characterization data: ^{1}H NMR (400MHz, DMS0-d_6) δ 11.10 (s, 1H), 8.52 (s, 1H), 7.58 (t, *J* = 7.6 Hz, 1H), 7.21 - 7.07 (m, 3H), 7.04 (d, *J* = 7.2 Hz, 1H), 6.61 (t, *J* = 5.6 Hz, 1H), 5.21 - 5.11 (m, 1H), 5.10 - 5.01 (m, 1H), 4.12 (s, 2H), 3.93 (t, *J* = 6.4 Hz, 1H), 3.66 - 3.62 (m, 2H), 3.60 - 3.49 (m, 20H), 3.07 - 3.00 (m, 1H), 2.94 - 2.84 (m, 2H), 2.63 - 2.56 (m, 2H), 2.55 - 2.53 (m, 2H), 2.47 - 2.36 (m, 5H), 2.32 - 2.26 (m, 1H), 2.20 - 2.08 (m, 2H), 2.06 - 1.99 (m, 1H), 1.90 - 1.79 (m, 2H), 1.70 - 1.57 (m, 2H), 1.56 -

1.47 (m, 1H), 1.45 - 1.33 (m, 2H); LC-MS (ESI$^+$) *m/z* 957.4 (M+Na)$^+$.

[005007] Example 162 [Method 14): 5-rraS.2RV2-aminocvclohexyllaminol-7-r3-r2-r2-[2-[2-[[q S)-1-[(2S,4R)-4-hvdroxy-2-_ rr4-(4-methylthiazol-5-vnphenyl]methylcarbamoyllpyrrolidine-l-carbonyl]-2.,2-dimethyl-propyllaminol-2-oxo-ethoxylethoxylethoxylethoxyl-5-methoxy-anilino]imidazo[l,2-c]pyrimidine-8-carboxamide. 1-162


MsO
OEt
BI
EZ
MeO
OH
SMe
K_2CO_3, DMF
DMF
$(Boc)_2O$, I_2
MeOH
LiOH
THF, H_2O
NHBoc
t-Bu
CI
HATU, DIPEA, DMF
HCl in dioxane
MeOH



[005008] Step 1 - Ethyl 2-[2-[2-[2-[3-[(8-carbamoyl-5-methylsulfanyl-imidazo[1,2-c]pyrimidin-7-yl)amino]-5-methoxy-phenoxy]ethoxy]ethoxy]ethoxy]acetate

[005009] To a solution of ethyl 2-[2-[2-(2-methylsulfonyloxyethoxy)ethoxy]ethoxy]acetate (819 mg, 2.61 mmol, Intermediate BI) and 7-(3-hydroxy-5-methoxy-anilino)-5-methylsulfanyl-imidazo[1,2-c]pyrimidine-8-carboxamide (300 mg, 868 umol, Intermediate EZ) in DMF (10 mL) was added K_2CO_3 (360 mg, 2.61 mmol). The mixture was stirred at 50 °C for 12 hours. On completion, the reaction mixture was concentrated *in vacuo* to remove solvent. The residue was diluted with water (5 mL) and extracted with DCM (3 X 10 mL). The combined organic layer was dried over sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (320 mg, 65% yield) as a yellowish oil. LC-MS (ESI^+) *m/z* 564.0 $(M+H)^+$.

[005010] Step 2 - Ethyl 2-[2-[2-[2-[3-[[5-[[(1S,2R)-2-aminocyclohexyl]amino]-8-carbamoyl-imidazo[1,2-c]pyrimidin-7-yl]amino]-5-methoxy-phenoxy]ethoxy]ethoxy]ethoxy]acetate

[005011] A solution of ethyl 2-[2-[2-[2-[3-[(8-carbamoyl-5-methylsulfanyl-imidazo[1,2-c]pyrimidin-7-yl)amino]-5-methoxy-phenoxy]ethoxy]ethoxy]ethoxy]acetate (220 mg, 390 umol) and (1R,2S)-cyclohexane-1,2-diamine (89.1 mg, 781 umol, CAS# 1436-59-5) in DMF (2 mL) was stirred at 90 °C for 3 hours. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was diluted with water (5 mL) and extracted with DCM (3 X 10 mL). The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (220 mg, 65% yield) as a yellowish oil. LC-MS (ESI^+) *m/z* 630.1 $(M+H)^+$.

[005012] Step 3 - Ethyl 2-[2-[2-[2-[3-[[5-[[(1S,2R)-2-(tert-butoxycarbonylamino)cyclohexyl]amino]-8-carbamoyl-imidazo[1,2-c]pyrimidin-7-yl]amino]-5-methoxy-phenoxy]ethoxy]ethoxy]ethoxy]acetate

[005013] To a solution of ethyl 2-[2-[2-[2-[3-[[5-[[(lS,2R)-2-aminocyclohexyl]amino]-8-carbamoyl-imidazo[l,2-c]pyrimidin-7-yl]amino]-5-methoxy-phenoxy]ethoxy]ethoxy]ethoxy]acetate (220 mg, 349 umol) and $(Boc)_20$ (152 mg, 699 umol) in MeOH (3 mL) was added I_2 (17.7 mg, 69.9 umol). The reaction mixture was stirred rt for 12 hours. On completion, the reaction mixture was concentrated *in vacuo* to remove solvent. The residue was diluted with water (5 mL) and extracted with DCM (3 X 5 mL). The combined organic layer was dried over sodium sulfate, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica gel column chromatography (DCM:MeOH = 20:1) to give the title compound (150 mg, 58% yield) as a yellowish solid. LC-MS (ESI^+) *m/z* 730.1 $(M+H)^+$.

[005014] Step 4 - 2-[2-[2-[2-[3-[[5-[[(1S,2R)-2-(tert-butoxycarbonylamino)cyclohexyl]amino]-8-carbamoyl-imidazo[1,2-c]pyrimidin-7-yl]amino]-5-methoxy-phenoxy]ethoxy]ethoxy]ethoxy]acetic acid

[005015] To a solution of ethyl 2-[2-[2-[2-[3-[[5-[[(lS,2R)-2-(tert-butoxycarbonylamino)cyclohexyl]amino]-8-carbamoyl-imidazo[l,2-c]pyrimidin-7-yl]amino]-5-methoxy-phenoxy]ethoxy]ethoxy]ethoxy]acetate (150 mg, 205 umol) in a mixed solvent of THF (2 mL) and H_20 (2 mL) was added LiOH (19.7 mg, 822 umol). Then the mixture was stirred at rt for 0.5 hour. On completion, saturated citric acid aqueous solution was added to the mixture to adjust the pH = 5.0. The residue was diluted with water (3 mL) and extracted with DCM (3 X 5 mL). The combined organic layer was dried over sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (135 mg, 94% yield) as white solid. LC-MS (ESI^+) *m/z* 702.3 $(M+H)^+$.

[005016] Step 5 - Tert-butyl N-[(lR,2S)-2-[8-carbamoyl-7-[3-[2-[2-[2-[2-[(lS)-1-[(2S,4R)-4-hydroxy-2-[4-[(4-methylthiazol-5-yl)phenyl]methylcarbamoyl]pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]amino]-2-oxo-ethoxy]ethoxy]ethoxy]ethoxy]-5-methoxy-anilino]imidazo[1,2-c]pyrimidin-5-yl]amino]cyclohexyl]carbamate

[005017] A solution of 2-[2-[2-[2-[3-[[5-[[(lS,2R)-2-(tert-butoxycarbonylamino)cyclohexyl]amino]-8-carbamoyl-imidazo[l,2-c]pyrimidin-7-yl]amino]-5-methoxy-phenoxy]ethoxy]ethoxy]ethoxy]acetic acid (135 mg, 192 umol) in DMF (2 mL) was cooled to 0 °C. Then, DIPEA (67.8mg, 525 umol), (2S,4R)-l-[(2S)-2-amino-3,3-dimethyl-

butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl] methyl]pyrrolidine-2-carboxamide (75.3 mg, 175 umol, Intermediate Cl) and HATU (79.8 mg, 210 umol) were added. Then the mixture allowed to warm to rt and stirred for 6 hours. On completion, the mixture was diluted with water (5 mL) and extracted with EA (3 X 5 mL). The combined organic layer was dried over sodium sulfate, filtered and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase chromatography (0. 1% FAin water) to give the title compound (90.0 mg, 46% yield) as a yellowish solid. LC-MS (ESI^+) *m/z* 1114.2 $(M+H)^+$.

[005018] Step 6 - 5-ŕ (1S,2R)-2-aminocyclohexyl]amino]-7-[3-[2-[2-[2-[2-[[(1S)-1-r(2S.4R)-4-hydroxy-2- [[4-(4-methylthiazol-5-yl)phenyl1methylcarbamoyl1pyrrolidine-1-carbonyl1-2.2-dimethyl-propyl1amino1-2-oxo-ethoxy1ethoxy1ethoxy1ethoxy1-5-methoxy-anilino1imidazorE2-c1pyrimidine-8-carboxamide

[005019] To a solution of tert-butyl N-[(lR,2S)-2-[[8-carbamoyl-7-[3-[2-[2-[2-[2-[[(lS)-l-[(2S,4R)-4-hydroxy -2-[[4-(4-methylthiazol-5-yl)phenyl]methylcarbamoyl]pyrrolidine-l-carbonyl]-2, 2-dimethyl -propyl] amino]-2-oxo-ethoxy]ethoxy]ethoxy]ethoxy]-5-methoxy-anilino]imidazo[l,2-c]pyrimidin-5-yl]amino]cyclohexyl]carbamate (90.0 mg, 80.8 umol) in MeOH (2 mL) was added HC1 in dioxane (4 M, 2 mL). Then the mixture was stirred at rt for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (column: Boston Green ODS 150*30 5u; mobile phase: [water (0.225% FA)-ACN]) to give the title compound **1-162** (20.0 mg, 24% yield, FA salt) as white solid. ^{1}H NMR (400MHz, DMSO-d) δ 12.39 (s, 1H), 9.56 (d, *J* = 3.2 Hz, 1H), 8.96 (s, 1H), 8.59 (t, *J* = 5.6 Hz, 1H), 8.l4(s, 1H), 7.48 - 7.36 (m, 6H), 7.32 (s, 1H), 6.92 (s, 1H), 6.67 (s, 1H), 6.21 (s, 1H), 4.59 - 4.52 (d, *J* = 9.6 Hζ,IH), 4.45 - 4.31 (m, 4H), 4.29 - 4.18 (m, 2H), 4.12 - 4.00 (m, 3H), 3.96 (s, 2H), 3.74 (s, 4H), 3.72 - 3.64 (m, 7H), 3.61 - 3.57 (m, 10H), 2.53 - 2.51 (m, 2H), 2.43 (s, 3H), 2.10 - 1.98 (m, 2H), 1.92 - 1.80 (m, 2H), 1.76 - 1.70 (m, 2H), 1.47 - 1.34 (m, 2H), 0.94 (s, 9H); LC-MS (ESI^+) *m/z* 1014.2 $(M+H)^+$.

[005020] Table 12: Compounds synthesized via Method 14 with the displacement of various mesylates with alcohols in Step 1, followed by coupling of various amines in Step 5.


Ex-#	I-#	Step 1 Mesylate	Step 1 Alcohol	Step 5 Amine	LCMS (ES+) m/z $(M+H)^+$	^{1}HNMR (400MHz, DMSO-d6) δ


163	**I-163**	ethyl 2-[2-[2-[2-[2-(2-methylsulfonyl-oxyethoxy)ethoxy]-ethoxy]ethoxy]-ethoxy]acetate (synthesized via Steps 1-2 of Intermediate BW)	**EZ**	**CI**	1124.6[a]	12.39 (s, 1H), 9.56 (s, 1H), 8.96 (s, 1H), 8.59 (t, *J* = 5.6 Hz, 1H), 8.14 (s, 1H), 7.48 - 7.34 (m, 6H), 7.31 (s, 1H), 6.93 (s, 1H), 6.66 (s, 1H), 6.21 (s, 1H), 4.57 - 4.55 (d, *J* = 9.6 Hz, 1H), 4.48 - 4.31 (m, 3H), 4.29 - 4.19 (m, 2H), 4.06 (s, 3H), 3.95 (s, 2H), 3.80 - 3.74 (m, 4H), 3.73 - 3.65 (m, 8H), 3.58 (m, 18H), 2.43 (s, 3H), 2.10 - 1.98 (m, 2H), 1.94 - 1.83 (m, 2H), 1.73 - 1.65 (m, 3H), 1.59 - 1.35 (m, 3H), 0.93 (s, 9H)
164	**I-164**	**BK**	**FA**	**CI**	1110.4[a]	12.19 (s, 1H), 9.54 (s, 1H), 8.97 (s, 1H), 8.60 (t, *J* = 5.6 Hz, 1H), 8.37 (s, 1H), 8.16 (s, 1H), 7.47 - 7.34 (m, 6H), 7.33 - 7.28 (m, 1H), 6.83 (s, 2H), 4.57 (d, *J* = 9.6 Hz, 1H), 4.55 - 4.51 (m, 4H), 4.50 - 4.33 (m, 3H), 4.31 - 4.19 (m, 3H), 3.80 (s, 6H), 3.69 - 3.61 (m, 14H), 2.44 (s, 3H), 2.08 - 1.80 (m, 4H), 1.67 (s, 2H), 1.58 - 1.36 (m, 3H), 1.35 - 1.20 (m, 1H), 0.95 (s, 9H)
165	**I-165**	**BI**	**FA**	**CI**	1044.5	12.18 (s, 1H), 9.53 (br s, 1H), 9.00 - 8.90 (m, 1H), 8.59 - 8.56 (m, 1H), 8.15 (s, 1H), 7.49 - 7.27 (m, 7H), 6.82 (s, 2H), 4.74 - 4.14 (m, 7H), 4.02 - 3.85 (m, 4H), 3.78 (s, 6H), 3.62 - 3.58 (m, 10H), 2.45 - 2.41 (m, 3H), 2.10 - 1.19 (m, 12H), 0.98 (d, *J* = 8.4 Hz, 9H)

Variations in temperature and time for Method 14 were as follows: Step 1 was run at 50-90 C for anywhere from 4-24 h, Step 3 was run at rt anywhere from 2-12 hours, Step 4 was run at rt anywhere from 0.5-2.5 h, Step 5 was run at rt anywhere from 6-16 h, and Step 6 was run at rt for anywhere from 0.5-1 h. [a]LCMS measure as $(M+Na)^+$.

[005021] Example 166 [Method 15) 4-[2-[2-[2-[2-[4-[[7-[[(1R,2S)-2-

aminocvclohexyll aminol-4-oxo-3H-pyrido [4,3-d]pyrimidin _ -5-yll amino Iindol-1- yllethoxy|ethoxy|ethoxy|ethylaminol-2-(2.,6-dioxo-3-piperidy0isoindoline-l.,3-dione,	1-166


EY
FB
R
K2CO3,DMF
Fe, NH4Cl
EtOH, H2O
TEA, NMP
NMP, mw
(Boc)2O
DCM
Pd(OH)2/C, H2
EtOAc
DIPEA, DMF



[005022] Step 1 - Benzyl N-[2-[2-[2-[2-(4-nitroindol-1-yl)ethoxy]ethoxy]ethoxy]ethyl]carbamate

[005023] To a mixture of 2-[2-[2-[2-(benzyloxycarbonylamino)ethoxy]ethoxy]ethoxy]ethyl methanesulfonate (100 mg, 246 umol, Intermediate EY) in DMF (2 mL) was added K_2CO_3 (68.1 mg, 493 umol) and 4-nitro-lH-indole (39.9mg, 246 umol). The reaction mixture was stirred at 100 °C for 3 hours. On completion, the reaction mixture was concentrated *in vacuo* to remove DMF. The residue was diluted with water (4 mL) and extracted with dichloromethane (2 X 6 mL). The combined organic layer was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by prep-TLC (PE:EA = 1:1) to give the title compound (67.0 mg, 57% yield) as a light yellow oil. LC-MS (ESI^+) *m/z* 494.1 $(M+Na)^+$.

[005024] Step 2 - Benzyl N-[2-[2-[2-[2-(4-aminoindol-1-yl)ethoxy]ethoxy]ethoxy]ethyl]carbamate

[005025] To a mixture of benzyl N-[2-[2-[2-[2-(4-nitroindol-l-yl)ethoxy]ethoxy]ethoxy]ethyl]carbamate (1.30 g, 2.76 mmol) in EtOH (10 mL) and H_20 (4 mL) was added NH_4CI (1.48 g, 27.6 mmol) andFe (1.54 g, 27.6 mmol) under nitrogen atmosphere. The reaction mixture was stirred at 80 °C for 3 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to remove EtOH. The residue was diluted with water (10 mL) and neutralized with sat. $NaHC0_3$ until the pH = 8-9. The residue was diluted with water (10 mL) and extracted with ethyl acetate (2 X 20 mL). The combined organic layer was dried over Na_2S0_4,

filtered and concentrated *in vacuo* to give the title compound (1.14 g, 93% yield) as a light yellow oil. LC-MS (ESI^+) *m/z* 442.1 $(M+H)^+$.

[005026] Step 3 - Benzyl N-[2-[2-[2-[2-[4-[(7-chlθΓθ-4-oχo-3H-ρvιiάo[4.3-ά]ρvιimιdiη-5-vDaminolindol-l- vl] ethoxylethoxylethoxylethyllcarbamate

[005027] To a mixture of benzyl N-[2-[2-[2-[2-(4-aminoindol-l-yl)ethoxy]ethoxy]ethoxy]ethyl]carbamate (1.14 g, 2.58 mmol) and 5,7-dichloro-3H-pyrido[4,3-d]pyrimidin-4-one (550 mg, 2.55 mmol, Intermediate FB) in NMP (10 mL) was added TEA (774 mg, 7.65 mmol) under a nitrogen atmosphere. The reaction mixture was stirred at 140 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to remove the NMP. The residue was diluted with water (8 mL) and extracted with ethyl acetate (2 X 10 mL). The combined organic layer was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase chromatography (0.1% FA in water) to give the title compound (800 mg, 50% yield) as a yellow solid. ^1H NMR (400MHz, MeOD) δ 8.26 (dd, *J* = 2.4, 6.0 Hz, 1H), 8.15 (s, 1H), 7.34 - 7.25 (m, 6H), 7.20 - 7.17 (m, 2H), 6.78 (s, 1H), 6.68 *(d, J* = 3.2 Hz, 1H), 5.03 (s, 2H), 4.63 (s, 1H), 4.34 (t, *j* = 5.2 Hz, 2H), 3.83 (t, *J=5.2* Hz, 2H), 3.53 (s, 4H), 3.49 - 3.44 (m, 5H), 3.25 (t, *J* = 5.6 Hz, 2H); LC-MS (ESI^+) *m/z* 621.1 $(M+H)^+$.

[005028] Step 4 - Benzyl N-[2-[2-[2-[2-[4-[[7-[[(TR,2S)-2-aminocvclohexyl]amino]-4-oxo-3H-pyridor4.3-d1 pyrimidin-5-yl1amino1indol-l-yl1ethoxy1ethoxy1ethoxy1ethyl1carbamate

[005029] A mixture of benzyl N-[2-[2-[2-[2-[4-[(7-chloro-4-oxo-3H-pyrido[4,3-d]pyrimidin-5-yl)amino]indol- l-yl]ethoxy]ethoxy]ethoxy]ethyl]carbamate (550 mg, 886 umol) and (lR,2S)-cyclohexane-l,2 -diamine (1.01 g, 8.86 mmol) in NMP (3 mL) was heated in a microwave at 150 °C for 1.5 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to remove the NMP. The residue was purified by prep-HPLC (column: Phenomenex Synergi Max-RP 250 * 50 mm * 10 um; mobile phase: [water (0.225% FA)-ACN]) to give the title compound (200 mg, 32% yield) as a yellowish solid. LC-MS (ESI^+) *m/z 699.6* $(M+H)^+$.

[005030] Step 5 - Tert-butyl N-[(1S,2R)-2-[[5-[[1-[2-[2-[2-[2-(benzyloxycarbonylamino)ethoxylethoxylethoxyl ethyl1indol-4-yl1amino1-4-oxo-3H-pyridor4.3-d1pyrimidin-7-vnamino1cvclohexyl1carbamate

[005031] To a mixture of benzyl N-[2-[2-[2-[2-[4-[[7-[[(lR,2S)-2-aminocyclohexyl]amino]-4-oxo-3H-pyrido [4,3-d]pyrimidin-5-yl]amino]indol-l-yl]ethoxy]ethoxy]ethoxy]ethyl]carbamate

(200 mg, 286 umol) in dichloromethane (1 mL) was added $(Boc)_20$ (62.4 mg, 286 umol) under a nitrogen atmosphere. The reaction mixture was stirred at rt for 12 hours. On completion, the reaction mixture was diluted with water (5 mL) and extracted with dichloromethane (2 X 10 mL). The combined organic layer was dried over Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by prep-TLC (dichloromethane: methanol = 20:1) to give the title compound (150 mg, 65% yield) as a yellowish solid. LC-MS (ESI^+) *m/z* 799.5 $(M+H)^+$.

[005032] Step 6 - Tert-butyl N-[(1S,2R)-2-[[5-[[1-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethyl]indol-4-yl]amino]-4-oxo-3H-pyrido[4,3-d]pyrimidin-7-yl]amino]cyclohexyl]carbamate

[005033] To a mixture of tert-butyl N-[(1S,2R)-2-[[5-[[1-[2-[2-[2-[2-(benzyloxycarbonylamino)ethoxy]ethoxy] ethoxy]ethyl]indol-4-yl]amino]-4-oxo-3H-pyrido[4,3-d]pyrimidin-7-yl]amino]cyclohexyl]carbamate (10.0 mg, 12.5 umol) in EtOAc (5 mL) was added $Pd(OH)_2/C$ (17.5 mg, 12.5 umol, 10 wt) under a hydrogen atmosphere (50 psi pressure). The reaction mixture was stirred at rt for 2 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (3.00 mg, 36% yield) as a yellowish solid. LC-MS (ESI^+) *m/z* 665.3 $(M+H)^+$.


[005034] Step 7 - Tert-butyl N-[(1S,2R)-2-[[5-[[1-[2-[2-[2-[2-(2,6-(1ioχo-3-ριρεΙϊάνη-L3-dioxo-isoindolin-4 -yl1amino1ethoxy1ethoxy1ethoxy1ethyl1indol-4-yl1amino1-4-oxo-3H-pyridor4.3-d1pyrimidin-7-yl1amino1cvclohexyl1carbamate

[005035] To a mixture of tert-butyl N-[(1S,2R)-2-[[5-[[1-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethyl]indol -4-yl]amino]-4-oxo-3H-pyrido[4,3-d]pyrimidin-7-yl]amino]cyclohexyl]carbamate (50.0 mg, 75.2 umol) and 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (24.9 mg, 90.2 umol, Intermediate R) in DMF (2 mL) was added DIPEA (19.4 mg, 150 umol) under a nitrogen atmosphere. The reaction mixture was stirred at 90 °C for 12 hours. On completion, the reaction mixture was purified by prep-HPLC (Boston Green ODS 150*30 5u; mobile phase: [water (0.225% FA)-ACN]) to give the title compound (18.0 mg, 25% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 921.2 $(M+H)^+$.

[005036] Step 8 - 4-[2-[2-[2-[2-[4-[[7-[[(1R,2S)-2-aminocvclohexyl1amino1-4-oxo-3H-pyridor4.3-d1pyrimidin -5-yllaminolindol-l -yl1ethoxy1ethoxy1ethoxy1ethylamino1-2-(2.6-dioxo-3-piperidvPisoindoline-L3-dione

[005037] To a mixture of tert-butyl N-[(lS,2R)-2-[[5-[[l-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo- isoindolin-4-yl]amino]ethoxy]ethoxy]ethoxy]ethyl]indol-4-yl]amino]-4-oxo-3H-pyrido[4,3-d]pyrimidin-7-yl]amino]cyclohexyl]carbamate (33.0 mg, 35.8 umol) in dichloromethane (8 mL) was added TFA (3.08 g, 27.0 mmol). The reaction mixture was stirred at rt for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo* to remove the dichloromethane. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.1% TFA)-ACN]) to give the title compound **1-166** (24.8 mg, 84% yield) as a yellow solid. ¾ NMR (400MHz, DMSO-^e) δ 11.69 (s, 1H), 11.11 (s, 1H), 8.16 (s, 1H), 8.03 (s, 1H), 7.79 (s, 3H), 7.54 (t, *J* = 7.2 Hz, 1H), 7.39 (s, 1H), 7.20 - 7.16 (m, 1H), 7.15 - 7.06 (m, 3H), 7.02 *(d, J* = 6.0 Hz, 1H), 6.56 (s, 2H), 6.06 (s, 1H), 5.05 (d, *J* = 8.0 Hz, 1H), 4.32 (s, 4H), 3.74 (s, 2H), 3.64 - 3.53 (m, 13H), 2.85 *(d, J* = 12.8 Hz, 1H), 2.62 - 2.59 (m, 1H), 2.01 (s, 1H), 1.88 - 1.57 (m, 6H), 1.47 (s, 2H); LC-MS (ESI^+) *m/z* 821.2 $(M+H)^+$.


[005038] **Example 167: 4-[2-[2-[2-[2-[2-[4-[[7-[[(1R,2SV2-Aminocvclohexyllaminol-4-oxo-3H-pyrido [4,3-dl pyrimidin-5-yllaminolindol-l-yll ethoxy] ethoxy] ethoxy] ethoxy] ethylamino] -2-(2.,6-dioxo-3-piperidy0isoindoline- 1,3-dione, 1-167**



[005039] 4-[2-[2-[2-[2-[2-[4-[[7-[[(lR,2S)-2-Aminocyclohexyl]amino]-4-oxo-3H-

pyrido[4,3-d] pyrimidin-5-yl]amino]indol-l-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione **1-167** was synthesized via Method 15, using Intermediate FC as the mesylate in Step 1. Variations in time and temperature were as follows: Step 3 was run at 140 °C for 4 h, Step 5 was run at rt for 7 h, Step 6 was run at rt for 4 h with 15 psi pressure of hydrogen, Step 7 was run at 100 °C for 8 h, and Step 8 was run at rt for 1 h. The intermediate formed from Step 5 was purified by prep-HPLC (column: Phenomenex luna C18 250*50mm*l0 um; mobile phase: [water (0.225% FA)-ACN]; B%: 35ACN%-65ACN%, 33 min). Characterization of the final product: ^{1}HNMR (400MHz, DMSO-d $_6$) δ 11.7 (s, 1H), 11.1 (s, 1H), 8.18 (br s, 1H), 7.99 (s, 1H), 7.78 - 7.76 (m, 3H), 7.56 (dd, *J* = 7.2, 8.4 Hz, 1H), 7.39 (d, *J* = 3.2 Hz, 1H), 7.22 - 7.16 (m, 1H), 7.16 - 7.06 (m, 3H), 7.03 (d, *J* = 7.0 Hz, 1H), 6.64 - 6.50 (m, 2H), 6.06 (s, 1H), 5.05 (dd, 7 = 5.6, 12.8 Hz, 1H), 4.47 - 4.17 (m, 4H), 3.67 - 3.65 (m, 2H), 3.63 - 3.56 (m, 4H), 3.55 - 3.53 (m, 4H), 3.52 - 3.47 (m, 10H), 2.96 - 2.80 (m, 1H), 2.06 - 1.95 (m, 1H), 1.94 - 1.55 (m, 6H), 1.47 - 1.45 (m, 2H); LC-MS (ESI$^+$) *m/z* 865.2 (M+H)$^+$.

[005040] Example 168: 4-[2-[2-[2-[4-[[7-[[(1R,2S)-2-Aminocyclohexyl]amino]-4-oxo-3H-pyrido [4,3-d]pyrimidin- 5-yl] amino] indol- l-yl] ethoxy] ethoxy] ethylamino] -2-12,6-dioxo-3-piperidvDisoindoline-l.,3-dione, 1-168




[005041] 4-[2-[2-[2-[4-[[7-[[(lR,2S)-2-Aminocyclohexyl]amino]-4-oxo-3H-pyrido[4,3-d]pyrimidin- 5-yl]amino]indol-l-yl]ethoxy]ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione **1-168** was synthesized via Method 15, using Intermediate FD as the mesylate in Step 1. Variations in time and temperature were as follows: Step 1 & 2 were run at 70 °C for 2 h, and Step 6 was run at rt for 6 h with 15 psi pressure of hydrogen. Characterization

of the final product: ¾NMR (400MHz, DMSO-i&) δ 11.72 (s, 1H), 8.38 (s, 1H), 8.24 (d, *J* = 5.2 Hz, 1H), 7.93 (s, 1H), 7.53 (dd, *J* = 7.2, 8.4 Hz, 1H), 7.36 (d, *J* = 3.2 Hz, 1H), 7.18 - 7.12 (m, 1H), 7.11 - 7.05 (m, 2H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.60 - 6.53 (m, 2H), 6.02 (s, 1H), 5.05 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.31 (t, *j* = 5.2 Hz, 2H), 3.75 (t, *j* = 5.2 Hz, 2H), 3.64 - 3.58 (m, 10H), 3.40 - 3.11 (m, 2H), 2.91 - 2.81 (m, 2H), 2.59 - 2.58 (m, 1H), 2.53 - 2.52 (m, 1H), 2.46 - 2.43 (m, 1H), 2.05 - 1.96 (m, 1H), 1.89 - 1.82 (m, 2H), 1.75 - 1.57 (m, 4H), 1.45 - 1.33 (m, 2H); LC-MS (ESI$^+$) *m/z* 777.3 (M+H)$^+$.

[005042] Further Examples:

[005043] Example 169: N-[3-carbamoyl-l-[i-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yllaminol ethoxy|ethoxy|ethoxy|ethyllazetidin-3-yllpyrazol-4-yll-2-[2-(2,2.,2-trifluoroethylaminoV4-pyridylloxazole-4-carboxamide, 1-169



[005044] Step_ _____1_ _____-_ _____2-(2.6- Dïoχo-3-ρïρeïï άvl)-4- I2- I2- I2-(2-hvdroxyethoxy)ethoxy1 ethoxy] ethyl amino]

[005045] isoindoline-l.3-dione

[005046] To a mixture of 2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethanol (0.60 g, 2.61 mmol, HC1 salt, Intermediate DC) and DIPEA (2.70 g, 20.9 mmol) in dioxane (15 mL) was added 2-(2,6-dioxo-3-piperidyl)-4-fluoro- isoindoline-l,3-dione (721 mg, 2.61 mmol, Intermediate R). The reaction mixture was stirred at 115 °C for 24 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by silica gel chromatography (petroleum ethenethyl acetate = 0:1) to give the title compound (0.80 g, 68% yield) as a brown solid. 'H NMR (400MHz, DMSO-i¾) δ 11.11 (s, 1H), 7.59 (dd, *J* = 3.2, 4.4 Hz, 1H), 7.16 (d, *J* = 8.4 Hz, 1H), 7.05 *(d, J* = 7.2 Hz, 1H), 6.61 (t, 7=5.6 Hz, 1H), 5.06 (dd, 7 = 5.2, 12.8 Hz, 1H), 4.58 - 4.56 (m, 1H), 3.62 (t, *J* = 5.6 Hz, 2H), 3.59 - 3.56 (m, 2H), 3.55 - 3.53 (m, 2H), 3.51 - 3.44 (m, 8H), 3.42 - 3.38 (m, 2H), 2.95 - 2.81 (m, 1H), 2.64 - 2.53 (m, 2H), 2.09 - 2.00 (m, 1H).

[005047] Step 2 - 2-[2-[2-[2-[[2-(2,6-Dioxo-3-piperidyl)-L3-dioxo-isoindolin-4-yllaminolethoxylethoxyl ethoxy] acetaldehyde


[005048] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-[2-[2-[2-(2-hydroxyethoxy)ethoxy] ethoxy] ethylamino] isoindoline-l,3-dione (250 mg, 556 umol) in DCM (10 mL) was added DMP (471 mg, 1.11 mmol) at 0 °C. Then the mixture was allowed to warm to rt and stirred for 2 hours. On completion, the reaction mixture was quenched with saturated $NaHC0_3$ (10 mL) and saturated $Na_2S_20_3$ (10 mL) at rt, and then stirred for an additional 30 minutes. The mixture was then extracted with DCM (3 X 20 mL). The combined organic layer was dried with Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (226 mg, 91% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 448.0 $(M+H)^+$.

[005049] Step 3 - N-[3-carbamoyl-l-[l-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-L3-dioxo-isoindolin-4- yl]amino]_ ethoxy1ethoxy1ethoxy1ethyl1azetidin-3-yl1pyrazol-4-yl1-2-r2-(2.2.2-trifluoroethylamino)-4-pyridyl1oxazole-4-carboxamide

[005050] To a mixture of N-[l-(azetidin-3-yl)-3-carbamoyl-pyrazol-4-yl]-2-[2-(2,2,2-trifluoroethylamino)-4-pyridyl] oxazole-4-carboxamide (44.1 mg, 78.2 umol , TFA salt, Intermediate DB) in DCM (2 mL) was added TEA (11.8 mg, 117 umol), HOAc (9.39 mg, 156 umol) and 2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo- isoindolin-4-yl]amino]ethoxy]ethoxy]ethoxy]acetaldehyde (35.0 mg, 78.2 umol), and the mixture was stirred for 30 minutes at rt. Then $NaBH(OAc)_3$ (24.8mg, 117 umol) was added and the mixture was stirred rt for 16 hours. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (column: Kromasil l50*25mm *10 um; mobile phase:

[water (0.225%FA)-ACN]) to give the title compound **1-169** (16.4 mg, 21% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-d_6) δ 11.10 (s, 1H), 10.93 (s, 1H), 8.96 (s, 1H), 8.28 - 8.20 (m, 2H), 7.76 (s, 1H), 7.68 (t, J = 6.4 Hz, 1H), 7.61 - 7.49 (m, 2H), 7.25 (s, 1H), 7.18 - 7.08 (m, 2H), 7.02 (*d*, J = 6.8 Hz, 1H), 6.58 (t, J = 5.6 Hz, 1H), 5.07 (dd, J = 6.4, 12.8 Hz, 2H), 4.25 - 4.21 (m, 2H), 3.70 (t, j = 7.6 Hz, 2H), 3.61 (t, j = 5.2 Hz, 2H), 3.57 - 3.47 (m, 14H), 2.92 - 2.84 (m, 1H), 2.68 - 2.64 (m, 2H), 2.62 - 2.54 (m, 2H), 2.06 - 1.99 (m, 1H). LC-MS (ESI$^+$) *m/z* 904.3 (M+Na)$^+$.


[005051] **Example 170: N-[3-carbamoyl-l-[i-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoiiKloliii-4-yl lanii no I ethoxy] ethoxy] ethoxy] ethyl1-4-piperidyl1 pyrazol-4-yl1-2- [2-[2.,2.,2-trifluoroethylamino)-4-pyridyl1oxazole-4-carboxamide, 1-170**



[005052] To a mixture of N-[3-carbamoyl-l-(4-piperidyl)pyrazol-4-yl]-2-[2-(2,2,2-trifluoroethylamino)-4- pyridyl]oxazole-4-carboxamide (100 mg, 194 umol, HC1 salt, Intermediate CX) in DCM (4 mL) was added TEA (29.4 mg, 291 umol), HOAc (23.3 mg, 388 umol) and 2-[2-[2-[2-[[2-(2,6-dioxo-3-n piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethoxy]acetaldehyde (86.9 mg, 194 umol, synthesized via Steps 1-2 of Example 169) and the reaction was stirred at rt for 30 minutes. Then, $NaBH(OAc)_3$ (61.7 mg, 291 umol) was added to the reaction mixture and the mixture was stirred at rt for an additional 16 hours. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*l0um; mobile phase: [water (0.1% TFA)-ACN]) to give the title compound **1-170** (31.4 mg, 15% yield) as a

yellow solid. ^{1}H NMR (400MHz, DMSO-i&) δ = 11.1 1 (s, 1H), 10.92 (m, 1H), 9.64 (s, 1H), 8.97 (s, 1H), 8.39 (m, 1H), 8.24 (d, *J* = 5.2 Hz, 1H), 7.76 (t, *J* = 5.2 Hz, 1H), 7.61 - 7.54 (m, 2H), 7.26 (s, 1H), 7.20 - 7.14 (m, 1H), 7.14 - 7.08 (m, 1H), 7.07 - 6.99 (m, 1H), 6.57 (s, 1H), 5.05 (dd, *J* = 6.4, 12.8 Hz, 1H), 4.80 - 4.48 (m, 1H), 4.37 - 4.15 (m, 2H), 3.76 - 3.53 (m, 14H), 3.49 - 3.37 (m, 4H), 3.35 - 3.29 (m, 1H), 3.22 - 3.11 (s, 1H), 2.99 - 2.78 (m, 1H), 2.62 - 2.51 (m, 2H), 2.41 - 2.17 (m, 4H), 2.09 - 1.97 (m, 1H). LC-MS (ESI$^+$) *m/z* 910.0 (M+H)$^+$.

[005053] **Example 171: N-[3-carbamoyl-l-[4-[[2-[2-[2-[[2-(2,6-dioxo-3-piperidvi)-i,3-dioxo-isoindolin-4-yllaminol ethoxylethoxylethylamino]methyl]phenyl]pyrazol-4-yl]-2-[2-[2.,2.,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide, 1-171**



[005054] Step 1 - Tert-butyl N-[4-[4-[[3-carbamoyl-l-(4-6 rmylphenvl)pyrazol-4-yl1carbamoyl1oxazol-2-vn-2- pyridyl1-N-(2.2.2-trif1uoroethyl icarbamate

[005055] To a solution of *tert*-butyl N-[4-[4-[[3-carbamoyl-l-[4-(hydroxymethyl)phenyl]pyrazol-4-yl] carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (200 mg, 332 umol, synthesized via Step 1 of Intermediate CV) in THF

(5 mL) and DCM (5 mL) was added DMP (282 mg, 665 umol) at 0 °C and the mixture was stirred at 0 °C for 2 hours. On completion, the mixture was quenched with saturated $NaHC0_3/Na_2S_20_3$ (1: 1, 30 mL) and stirred for an additional 30 min. The aqueous layer was then separated from the organic and extracted with DCM (3 X 20 mL). The combined organic solutions were washed with H_20 (3 X 20 mL) and brine (20 mL), dried over $MgS0_4$, filtered and concentrated *in vacuo.* The residue was purified by reverse phase flash chromatography (0.1% FA in water) to give the title compound (100 mg, 48% yield) as a white solid. LC-MS (ESI^+) *m/z* 600.4 $(M+H)^+$.

[005056] Step 2 - Tert-butyl N-[4-[4-[[3-carbamoyl-1-[4-[[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethylamino]methyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate


[005057] A mixture of *tert*-butyl N-[4-[4-[[3-carbamoyl-l-(4-formylphenyl)pyrazol-4-yl]carbamoyl] oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (40.5 mg, 66.7 umol), 4-[2-[2-(2-amino ethoxy)ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (40.0 mg, 100 umol, synthesized via Steps 1-2 of Example 127) in a mixed solvent of DCM (5 mL) and THF (5 mL) was added HOAc (6.01 mg, 100 umol) and NaBH(OAc)3 (42.4 mg, 200 umol). The mixture was stirred at rt for 72 hours under nitrogen atmosphere. On completion, the mixture was concentrated *in vacuo* and the residue was purified by reverse phase flash chromatography (0.1% FA in water) to give the title compound (50.0 mg, 76% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 988.5 $(M+H)^+$.

[005058] Step 3 - N-[3-carbamoyl-1-[4-[[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino] ethoxy]ethoxy]ethylamino]methyl]phenyl]pyrazol-4-yl]-2-[2-(2,2,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide

[005059] To a solution of *tert*-butyl N-[4-[4-[[3-carbamoyl-l-[4-[[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo- isoindolin-4-yl]amino]ethoxy]ethoxy]ethylamino]methyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (50.0 mg, 50.6 umol) in THF (5 mL) was added HC1 in dioxane (4 N, 2 mL). The mixture was stirred at rt for 2 hours. On completion, the mixture was concentrated *in vacuo*, and the residue was purified Pre-HPLC (column: Boston Green ODS 150*30 5u; mobile phase: [water (0.225% FA)-ACN]; B%: 25%-52%, 10 min) to give the title compound **1-171** (23.0 mg, 51% yield) as a yellow solid. ^1H NMR (400MHz, DMSO-de) δ 11.00 (s, 1H), 9.01 (s, 1H), 8.91 (s, 1H), 8.29 - 8.21 (m, 2H), 8.03 (s, 1H), 7.89 (d, *J* = 8.4 Hz, 2H), 7.76 - 7.66 (m, 2H), 7.61 - 7.54 (m, 1H), 7.49 *(d, J* = 8.4 Hz, 2H), 7.27

(s, 1H), 7.18 (d, *J* = 5.2 Hz, 1H), 7.13 (d, *j* = 8.8 Hz, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.59 (t, *j* = 5.6 Hz, 1H), 5.05 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.32 - 4.19 (m, 2H), 3.81 (s, 2H), 3.72 - 3.53 (m, 10H), 2.93 - 2.80 (m, 1H), 2.75 - 2.67 (m, 2H), 2.56 - 2.53 (m, 3H), 2.09 - 1.97 (m, 1H); LC-MS (ESI^+) *m/z* 888.4 $(M+H)^+$.

[005060] Example 172: N-[3-carbamoyl-l-[4-[5-[2-[[2-(2.,6-dioxo-3-piperidyD-l.,3-dioxo-isoindolin-4-yllaminol ethylaminolpentylcarbamoyllphenyl]pyrazol-4-yll-2-[2-[2,2,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide, 1-172



[005061] Step 1 - Tert-butyl N-[4-[4-[[3-carbamoyl-1-[4-(5-hydroxypentylcarbamoyOphenyl]pyrazol-4-yl] carbamoyl]oxazol-2-yl1-2-pyridyl1-N-(2,2,2-trifluoroethyncarbamate

[005062] To a mixture of 4-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4- carbonyl]amino]-3-carbamoyl-pyrazol-l-yl]benzoic acid (100 mg, 162 umol, Intermediate CN) and 5-aminopentan-l-ol (22.0 mg, 211 umol) in DMF (5 mL) was added DIPEA (63.0 mg, 487 umol, 85 uL) and HATU (74.0 mg, 195 umol). The mixture was stirred at rt for 2 hours. On completion, the mixture was quenched by water (15 mL), and then filtered. The filter cake was dried *in vacuo.* The residue was purified by reverse phase flash chromatography (0.1% FA in water) to give the title compound (80.0 mg, 67% yield) as a white solid. LC-MS (ESI^+) *m/z* 701.3 $(M+H)^+$.

[005063] Step 2 - Tert-butyl N-[4-[4-[[3-carbamoyl-l-[4-(5-oxopentylcarbamovDphenvnpyrazol-4- vl]carbamoyl1oxazol-2-yl1-2-pyridyl1-N-(2,2,2-trifluoroethvDcarbamate

[005064] To a solution of ter/-butyl N-[4-[4-[[3-carbamoyl-l-[4-(5-hydroxypentylcarbamoyl)phenyl]pyrazol-4- yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (80.0 mg, 114 umol) in THF (5.0 mL) and DCM (5.0 mL) was added DMP (54.0 mg, 125. umol) at 0 °C. The mixture was stirred at 0 °C for 2 hours. On completion, the reaction mixture was quenched with saturated $NaHC0_3$/$Na_2S_20_3$ solution (1: 1, 10 mL) and stirred for 30 minutes. The aqueous layer was separated from the organic and extracted with DCM (3 X 20 mL). The combined organic layers were washed with H_2O (3 X 10 mL) and brine (20 mL), dried over $MgS0_4$, then filtered and concentrated *in vacuo* to give the title compound (80.0 mg, crude) as a yellowish solid. LC-MS (ESI^+) *m/z 599.2* $(M+H-l00)^+$.

[005065] Step 3 - Tert-butyl N-r4-r4-rr3-carbamoyl-l-r4-r5-r2-rr2-(2.6-dioxo-3-piperidvD-L3-dioxo-isoindolin -4-yl1amino1ethylamino1pentylcarbamoyl1phenyl1pyrazol-4-yl1carbamoyl1oxazol-2-yl1-2-pyridyl1-N-(2.2.2-trif1uoroethyl icarbamate


[005066] To a mixture of *tert*-butyl N-[4-[4-[[3-carbamoyl-l-[4-(5-oxopentylcarbamoyl)phenyl]pyrazol-4-yl] carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (60.0 mg, 86.0 umol) and 4-(2- aminoethylamino)-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (34.0 mg, 95.0 umol, HC1 salt, Intermediate DJ) in THF (5 mL) was added AcOH (7.00 mg, 112 umol) and $NaBH(OAc)_3$ (27.0 mg, 128 umol). The mixture was stirred at rt for 24 hours under nitrogen atmosphere. On completion, the mixture was concentrated *in vacuo.* The residue was purified by reverse phase flash chromatography (0. 1% FA in water) to

give the title compound (30.0 mg, 35% yield) as a yellow solid. LC-MS (ESI$^+$) *m/z* 999.0 (M+H)$^+$.

[005067] Step 4 - N-[3-carbamoyl-1-[4-[5-[2-I[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino] ethylaminolpentyl carbamoyllphenyll pyrazol-4-yl 1-2-[2-(2,2,2-trifluoroethylamino)-4-pyridyl1oxazole-4-carboxamide

[005068] To a solution of *tert*-butyl N-[4-[4-[[3-carbamoyl-l-[4-[5-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo- isoindolin-4-yl]amino]ethylamino]pentylcarbamoyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (40.0 mg, 40.0 umol) in THF (5 mL) was added HC1 in dioxane (4 N, 2 mL). The mixture was stirred at rt for 1 hour. On completion, the mixture was concentrated *in vacuo*, and the residue was purified by Pre-HPLC (column: Boston Green ODS 150*30 5u; mobile phase: [water (0.225% FA)-ACN]; B%: 27%-57%, 10 min).to give the title compound **1-172** (20.0 mg, 56% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-i¾) δ 11.01 (s, 1H), 9.03 (d, *J* = 5.6 Hz, 2H), 8.65 - 8.54 (m, 1H), 8.38 - 8.23 (m, 2H), 8.16 - 7.98 (m, 5H), 7.82 - 7.73 (m, 1H), 7.69 (t, *J* = 6.4 Hz, 1H), 7.59 (t, *J* = 7.6 Hz, 1H), 7.27 (s, 1H), 7.21 - 7.12 (m, 2H), 7.05 (d, *J* = 7.2 Hz, 1H), 6.82 (m, 1H), 5.06 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.32 - 4.16 (m, 2H), 3.48 - 3.47 (m, 2H), 3.29 (m, 2H), 2.97 - 2.85 (m, 3H), 2.77 - 2.66 (m, 2H), 2.64 - 2.53 (m, 3H) , 2.09 - 1.98 (m, 1H), 1.56 (m, 4H), 1.38 (m, 2H); LC-MS (ESI$^+$) *m/z* 899.4 (M+H)$^+$.

[005069] Example 173: 6-[5-Cvanopyrazolo[3,4-b1pyridin-l-vB-4-[cvclopropylamino)-N-[3-[2-(2.,6-dioxo-3- piperidyl)-l,3-dioxo-isoindolin-4-yl]oxy-2-f uoro-propyl]pyridine-3-carboxamide, 1-173



[005070] Step 1 - 4-[3-(Dibenzylamino)-2-fluoro-propoxy]-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione

[005071] **To** a mixture of 2-(2,6-dioxo-3-piperidyl)-4-hydroxy-isoindoline-1,3-dione (2.00 g, 7.29 mmol, synthesized via Step 1 of Intermediate CA) in THF (200 mL) was added 3-(dibenzylamino)-2-fluoro-propan-1-ol (1.99 g, 7.29 mmol, Intermediate AH) and PPh_3 (3.83 g, 14.5 mmol). Then DIAD (2.21 g, 10.9 mmol) was added to the mixture dropwise at 0°C. The reaction mixture was allowed to warm to rt and stirred for 12 hours. On completion, the reaction mixture was concentrated *in vacuo*. The crude product was purified by prep-HPLC (column: Phenomenex Synergi Max-RP 250*50 mm*10 um; mobile phase: [water (0.225% FA)-ACN]; B%: 25ACN%-50ACN%, 30 min, 50% min) to give the title compound (2.70 g, 60% yield) as a white solid. ^1H NMR (400MHz, DMSO-de) δ 11.13 (s, 1H), 7.97 - 7.73 (m, 1H), 7.47 (d, *J* = 7.2 Hz, 1H), 7.41 (d, *J* = 8.4 Hz, 1H), 7.37 - 7.21 (m, 8H), 7.21 - 7.08 (m, 2H), 5.21 - 4.88 (m, 2H), 4.47 - 4.17 (m, 2H), 3.73 - 3.53 (m, 4H), 3.06 - 2.75 (m, 3H), 2.70 - 2.54 (m, 2H), 2.14 - 1.92 (m, 1H); LC-MS (ESI^+) *m/z* 530.0 $(M+H)^+$.

[005072] Step 2 - 4-(3-Amino-2-fluoro-propoxy)-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione


[005073] To a mixture of 4-[3-(dibenzylamino)-2-fluoro-propoxy]-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione (100 mg, 188 umol), $Pd(OH)_2/C$ (60.0 mg, 10 wt %) and Pd/C

(60.0 mg, 10 wt %) in MeOH (6 mL) was added HC1 (1 M, 100 uL) under hydrogen atmosphere (15 psi pressure). The reaction mixture was stirred at rt for 18 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the compound (68.0 mg, HC1 salt, 95% yield) as a colorless solid. LC-MS (ESI$^+$) *m/z* 350.0 (M+H)$^+$.

[005074] Step 3 - 6-(5-Cvanopyrazolor3.4-b1pyridin-l-vO-4-(cvclopropylamino)-N-r3-r2-(2.6-dioxo-3- piperidvn-l.3-dioxo-isoindolin-4-yl1oxy-2-fluoro-propyl1pyridine-3-carboxamide

[005075] To a mixture of 4-(3-amino-2-fluoro-propoxy)-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (48.0 mg, 124 umol, HC1 salt) in DMF (2 mL) was added 6-(5-cyanopyrazolo[3,4-b]pyridin-l-yl)-4- (cyclopropylamino)pyridine-3-carboxylic acid (64.8 mg, 149 umol, TFA salt, Intermediate L) and DIPEA (96.4 mg, 746 umol). Then HATU (70.9 mg, 186 umol) was added to the mixture and the mixture was stirred at rt for 2 hours. On completion, the reaction mixture was concentrated *in vacuo.* The crude product was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]) to give the title compound **1-173** (24.0 mg, 28% yield) as a white solid. ^{1}HNMR (400MHz, DMSO-d_6) δ 11.13 (s, 1H), 9.08 (d, *J* = 2.0 Hz, 1H), 9.04 (d, *J* = 2.0 Hz, 1H), 8.95 (t, *J* = 5.6 Hz, 1H), 8.72 - 8.62 (m, 2H), 8.55 (s, 1H), 7.88 - 7.84 (m, 1H), 7.72 (s, 1H), 7.57 - 7.50 (m, 2H), 5.18 - 5.01 (m, 2H), 4.69 - 4.44 (m, 2H), 3.80 - 3.66 (m, 2H), 2.93 - 2.82 (m, 1H), 2.71 - 2.56 (m, 3H), 2.09 - 1.99 (m, 1H), 0.99 - 0.81 (m, 2H), 0.58 - 0.56 (m, 2H); LC-MS (ESI$^+$) *m/z* 652.2 (M+H)$^+$.


[005076] Example 174: 4-(CvclopropylaminoVN-[3-[2-(2.,6-dioxo-3-piperidvD-l.,3-dioxo-isoindolin-4-yl]oxy-2- fluoro-propyl1-6-H,6-naphthyridin-2-ylamino)pyridine-3-carboxamide, 1-174



[005077] To a mixture of 4-(3-amino-2-fluoiO-propoxy)-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (100 mg, 259 umol, HC1 salt, synthesized via Steps 1-2 of Example 173) andDIPEA(167 mg, 1.30 mmol) in DMF (2 mL) was added 4-(cyclopropylamino)-

6-(l,6-naphthyridin-2-yiamino)pyridine-3-carboxylic acid (83.3 mg, 259 umol, Intermediate N) and HATU (l l8 mg, 3 11 umol). The reaction mixture was stirred at t for 1 hour. On completion, the reaction mixture was concentrated *in vacuo.* Then the residue was purified by prep-HPLC (column: Phenomenex Synergi CIS 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]) to give the title compound I-174 (44.7 mg, 26% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-d_6) δ 11.13 (s, 1H), 10.37 (s, 1H), 9.06 (s, 1H), 8.67 (t, *J* = 5.2 Hz, 1H), 8.62 - 8.56 (m, 2H), 8.49 (s, 1H), 8.28 (d, *J* = 8.8 Hz, 1H), 8.18 (s, 1H), 7.86 (t, *J* = 7.6 Hz, 1H), 7.65 - 7.44 (m, 4H), 5.15 - 4.98 (m, 2H), 4.60 - 4.43 (m, 2H), 3.76 - 3.70 (m, 2H), 2.97 - 2.86 (m, 1H), 2.71 - 2.56 (m, 3H), 2.08 - 2.00 (m, 1H), 1.01 - 0.87 (m, 2H), 0.60 - 0.58 (m, 2H). LC-MS (ESI$^+$) *m/z* 653.2 (M+H)$^+$.

[005078] Example 175: l-[4-(cvclopropylaminoV5-[i-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyQ-l.,3-dioxo-isoindolin_ -4-yll aminol ethoxyl ethoxyl ethoxyl ethyll triazol-4-yll -2-pyridyl] pyrazolo [3,4-bl pyridine-5-carbonitrile, _ 1-175



[005079] Step 1 - Tert-butyl N-r2-r2-r2-r2-r4-r6-chloro-4-(cvclopropylamino)-3-

pyridylltriazol- 1-yll ethoxyl ethoxyl ethoxyl ethyllcarbamate

[005080] To a solution of tert-butyl N-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethyl]carbamate (1.65 g, 5.19 mmol, Intermediate BN), $CuS0_4$ (4.14 mg, 26.0 umol) and sodium (2R)-2-[(lS)-l,2-dihydroxyethyl]-4-hydroxy -5-oxo-2H-furan-3-olate (10.3 mg, 51.9 umol) in a mixed solvent of H_20 (5 mL) and t-BuOH (5 mL) was added 2-chloro-N-cyclopropyl-5-ethynyl-pyridin-4-amine (500 mg, 2.60 mmol, Intermediate DL). The reaction mixture was stirred at 60 °C for 2 h. On completion, the mixture was diluted with H_20 (20 mL) and extracted with EA (2 X 30 mL). The organic layer was washed with brine (50 mL), dried with Na_2S0_4, filtered and concentrated *in vacuo*. The residue was purified by reverse phase chromatography (0.1% $NH_3•H_20$) to give the title compound (1.02 g, 77% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 511.4 $(M+H)^+$.

[005081] Step 2 - Tert-butyl N-r2-r2-r2-r2-r4-r6-(5-cvanopyrazolor3.4-b1pyridin-l-v0-4-(cvclopropylamino) -3-pyridylltriazol- 1-yl]ethoxyl ethoxyl ethoxyl ethyl] carbamate

[005082] Tert-butyl N-[2-[2-[2-[2-[4-[6-chloro-4-(cyclopropylamino)-3-pyridyl]triazol-l-yl]ethoxy]ethoxy] ethoxy]ethyl]carbamate (250 mg, 489 umol), lH-pyrazolo[3,4-b]pyridine-5-carbonitrile (177 mg, 1.22 mmol, CAS# 1234616-67-1), $Pd_2(dba)_3$ (179 mg, 196 umol), K_3P0_4 (312 mg, 1.47 mmol) and t-Bu Xphos (83.1 mg, 196 umol) were taken up into a microwave tube. Then dioxane (5 mL) and H_20 (0.5 mL) were added into the microwave tube. The mixture was degassed and purged with nitrogen gas three times, and then the sealed tube was heated to 100 °C and stirred for 8 hrs under microwave. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo*. The residue was purified by pre-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 36%-66%) to give the title compound (30 mg, 9.4% yield) as a white solid. LC-MS (ESI^+) *m/z* 619.0 $(M+H)^+$.

[005083] Step _3_-_l-r5-rl-r2-r2-r2-(2-aminoethoxy)ethoxy1ethoxy1ethyl1triazol-4-yl1-4-(cvclopropylamino)-2- pyridyl1pyrazolor3.4-b1pyridine-5-carbonitrile


[005084] To a solution of tert-butyl N-[2-[2-[2-[2-[4-[6-(5-cyanopyrazolo[3,4-b]pyridin-l-yl)-4- (cyclopropylamino)-3-pyridyl]triazol-l-yl]ethoxy]ethoxy]ethoxy]ethyl]carbamate (30 mg, 48.5 umol) in DCM (1.5 mL) was added HC1 in dioxane (4 M, 1.5 mL). The reaction mixture was stirred at rt for 0.5 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (26.9 mg, 100% yield, HC1 salt). LC-MS (ESI^+) *m/z* 519.3 $(M+H)^+$

[005085] Step 4 - l-[4-(cvclopropylamino)-5-[l-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidvl)-L3-

dioxo-isoindolin -4-yl1amino1ethoxy1ethoxy1ethoxy1ethyl1triazol-4-yl1-2-pyridyl1pyrazolor3.4-blpyridine-5-carbonitrile

[005086] To a solution of l-[5-[l-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethyl]triazol-4-yl]-4- (cyclopropylamino)-2-pyridyl]pyrazolo[3,4-b]pyridine-5-carbonitrile (26.9 mg, 48.5 umol, HC1 salt) and 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (14.7 mg, 53.3 umol, Intermediate R) in dioxane (3 mL) was added DIPEA (62.6 mg, 485 umol). The reaction mixture was stirred at 115 °C for 60 hrs. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 l50*25*l0um; mobile phase: [water (0.225%FA) -ACN]; B%: 20%-50%) to give the title compound **1-175** (13 mg, 35% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-d«) δ 11.16 - 11.03 (m, 1H), 9.06 - 9.03 (m, 1H), 9.03 - 9.00 (m, 1H), 8.75 (s, 1H), 8.64 (s, 1H), 8.60 (s, 1H), 8.44 - 8.41 (m, 1H), 7.69 (s, 1H), 7.57 - 7.43 (m, 1H), 7.07 - 7.02 (m, 1H), 7.01 - 6.97 (m, 1H), 6.57 - 6.48 (m, 1H), 5.07 - 5.00 (m, 1H), 4.66 - 4.59 (m, 2H), 3.92 - 3.86 (m, 2H), 3.58 - 3.54 (m, 4H), 3.53 - 3.49 (m, 6H), 3.42 - 3.40 (m, 2H), 2.96 - 2.81 (m, 1H), 2.62 - 2.59 (m, 1H), 2.57 - 2.55 (m, 2H), 2.06 - 1.99 (m, 1H), 0.94 - 0.87 (m, 2H), 0.65 - 0.57 (m, 2H); LC-MS (ESI$^+$) *m/z* 775.4 (M+H)$^+$.


[005087] **Example 176: 1-[4-(Cyclopropylamino)-5-[1-[2-[2-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]triazol-4-yl]-2-pyridyl]pyrazolo[3,4-b]pyridine-5-carbonitrile, 1-176**




[005088] l-[4-(Cyclopropylamino)-5-[l-[2-[2-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo- isoindolin-4-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]triazol-4-yl]-2-pyridyl]pyrazolo[3,4-b]pyridine-5-carbonitrile **1-176** was synthesized as described above for Example 175 except that Intermediate BQ was used as the azide in Step 1. ^{1}H NMR (400MHz, CDsCN) δ 9.07 (s, 1H), 8.92 (d, *J* = 2.0 Hz, 1H), 8.70 (d, *J* = 2.0 Hz, 1H), 8.56 (s, 1H), 8.49 (s, 1H), 8.45 (s, 1H), 8.39 (s, 1H), 7.82 (s, 1H), 7.55 - 7.50 (m, 1H), 7.02 (dd, *J* = 4.0, 5.2 Hz, 2H),


6.49 - 6.40 (m, 1H), 5.00 - 4.90 (m, 1H), 4.63 (t, J = 4.8 Hz, 2H), 3.95 - 3.92 (m, 2H), 3.66 - 3.55 (m, 8H), 3.54 - 3.50 (m, 10H), 3.45 - 3.38 (m, 2H), 2.75 - 2.67 (m, 3H), 2.14 - 2.13 (m, 1H), 1.82 - 1.77 (m, 1H), 0.95 - 0.90 (m, 2H), 0.72 - 0.63 (m, 2H); LC-MS (ESI^+) *m/z* 863.4 $(M+H)^+$.

[005089] **Example 177: N-[3-carbamoyl-l-[4-[6-[[2-(2.,6-dioxo-3-piperidyO-l.,3-dioxo-isoindolin-4-yll aminolhexa-2,4-divnylcarbamoyll phenyl] pyrazol-4-yll-2- [2-12,2,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide, 1-177**



CN





[005090] Step 1 - Tert-butyl N-[4-[4-[[3-carbamoyl-1-[4-(prop-2-ynylcarbamovnphenyllpyrazol -4-yl1carbamoyl1oxazol-2-yl1-2-pyridvH-N-(2.2.2-trifluoroethvncarbamate

[005091] To a solution of 4-[4-[[2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4 -carbonyl]amino]-3-carbamoyl-pyrazol-l-yl]benzoic acid (200 mg, 324 umol, Intermediate CN) and prop-2-yn-l -amine (21.4 mg, 389 umol, 24.9 uL) in DMF (5.00 mL) was added HATU (148 mg, 389 umol) and DIPEA (125 mg, 974 umol, 169 uL), and the mixture was stirred at rt for lhr. On completion, the mixture was diluted with H_20 (30 mL) and extracted with

EA (3 X 15 mL). The organic layers were dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (210 mg, 99% yield) as a white solid. ^{1}H NMR (400MHz, MeOD-d_4) δ 11.04 (s, 1H), 9.07 (s, 1H), 9.04 - 8.99 (m, 2H), 8.63 (d, *J* = 5.2 Hz, 1H), 8.22 (s, 1H), 8.12 - 8.06 (m, 3H), 8.03 - 7.98 (m, 2H), 7.77 - 7.73 (m, 2H), 4.92 - 4.82 (m, 2H), 4.08 - 4.03 (m, 2H), 3.11 (t, 7 = 2.4 Hz, 1H), 1.50 (s, 9H).

[005092] Step 2 - Tert-butyl N-r4-r4-rr3-carbamoyl-l-r4-r6-IT2-(2.6-dioxo-3-piperidvD-E3-dioxo-isoindolin -4-yl] ami no]hexa-2.4-divnyl carbarn oyl]phenvl]pyrazol-4-yllcarb amoylloxazol-2-yl1-2-pyridyl1-N-(2.2.2-trif1uoroethyl)carbamate


[005093] A solution of Cul (5.84 mg, 30.6 umol), $MCI_2{\cdot}6H_2O$ (1.82 mg, 7.66 umol) and N,N,N',N'-tetram ethyl ethane- 1,2-diamine (356 ug, 3.06 umol) were dissolved in THF (4.00 mL) and stirred at rt for 5 min. Tert-butyl N-[4-[4-[[3-carbamoyl-l-[4-(prop-2-ynylcarbamoyl)phenyl] pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (100 mg, 153 umol) and 2-(2,6-dioxo-3-piperidyl)-4-(prop-2-ynylamino)isoindoline-l,3-dione (238 mg, 766 umol, Intermediate DN) in THF (4.00 mL) was then added and the reaction mixture was stirred at rt for 16 h. On completion, the reaction mixture was filtered through a pad of celite, and the celite layer was washed with AcOEt (30 mL). The combined filtrate was concentrated *in vacuo.* The mixture was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25 *l0um; mobile phase: [water (0.225%FA)-ACN]; B%: 50%-80%) to give the title compound (25.0 mg, 16% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 962.0 $(M+H)^+$.

[005094] Step 3 - N-r3-carbamoyl-l-r4-r6-rr2-(2.6-dioxo-3-piperidyl)-l.3-dioxo-isoindolin-4-yll_amino1hexa-2.4-divnylcarbamoyl1phenyl1pyrazol-4-yl1-2-r2-(2.2.2-trifluoroethylamino)-4-pyridyl1oxazole-4-carboxamide

[005095] To a solution of tert-butyl N-[4-[4-[[3-carbamoyl-l-[4-[6-[[2-(2,6-dioxo-3-piperidyl)-l,3- dioxo-isoindolin-4-yl]amino]hexa-2,4-diynylcarbamoyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (20.0 mg, l9.75umol) in DCM (2.00 mL) was added HC1 in dioxane (4 M, 2.00 mL), and the mixture was stirred at rt for 30 min. On completion, the mixture was concentrated *in vacuo.* The mixture was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25 *l0um; mobile phase: [water (0.225%FA)-ACN]; B%: 40%-70%, l3min) to give the title compound 1-177 (2.94 mg, 16% yield, FA) as a yellow solid. ^{1}H NMR (400MHz, DMSO-de) δ 11.11 (s, 1H), 11.01 (s, 1H), 9.14 - 9.08 (m, 1H), 9.05 (s, 1H), 9.03 (s, 1H), 8.26 (d, 7 = 5.2 Hz, 1H), 8.16 (s, 1H), 8.11 (d, 7 = 8.8 Hz, 2H), 8.01 (d,


J = 8.8 Hz, 2H), 7.78 (s, 1H), 7.72 - 7.65 (m, 2H), 7.27 (s, 1H), 7.20 - 7.12 (m, 3H), 7.02 (t, *J* = 6.2 Hz, 1H), 5.12 - 5.02 (m, 1H), 4.36 - 4.30 (m, 2H), 4.28 - 4.22 (m, 2H), 4.21 - 4.17 (m, 2H), 2.99 - 2.81 (m, 1H), 2.64 - 2.56 (m, 2H), 2.09 - 1.99 (m, 1H), LC-MS (ESI^+) *m/z* 862.1 $(M+H)^+$.

[005096] Example 178: N-[3-carbamoyl-l-[4-[7-[[2-(2.,6-dioxo-3-piperidyO-l.,3-dioxo-isoindolin-4-yllaminolhepta- 2,4-divnylcarbamoyllphenyl]pyrazol-4-yll-2-[2-[2,2,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide, 1-178




[005097] N-[3-carbamoyl-l-[4-[7-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]hepta- 2,4-diynylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(2,2,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide **1-178** was synthesized as described for Example 177, using Intermediate CN as the acid and prop-2-yn-l -amine as the alkyne in Step 1 and Intermediate DO as the alkyne in Step 2, which was run for 80 h at rt. Characterization of the final product: 'H NMR (400MHz, DMSO-de) δ 11.10 (s, 1H), 11.02 (s, 1H), 9.12 (t, J = 5.2 Hz, 1H), 9.06 (d, J = 7.6 Hz, 2H), 8.26 (d, J = 5.2 Hz, 1H), 8.16 (s, 1H), 8.14 (d, J = 8.8 Hz, 2H), 8.04 (d, J = 8.8 Hz, 2H), 7.79 (s, 1H), 7.70 (t, J = 6.4 Hz, 1H), 7.62 - 7.56 (m, 1H), 7.28 (s, 1H), 7.19 (s, 1H), 7.19 - 7.17 (m, 1H), 7.06 (d, J = 7.2 Hz, 1H), 6.76 (t, J = 6.0 Hz, 1H), 5.10 - 5.04 (m, 1H), 4.28 - 4.22 (m, 2H), 4.20 (d, J = 5.2 Hz, 2H), 3.73 - 3.45 (m, 2H), 2.95 - 2.81 (m, 1H), 2.65 (s, 1H), 2.61 - 2.58 (m, 1H), 2.57 - 2.50 (m, 2H), 2.07 - 1.97 (m, 1H); LC-MS (ESI^+) m/z 876.2 $(M+H)^+$.

[005098] Example 179: N-[3-carbamoyl-l-[4-[8-[[2-(2.,6-dioxo-3-piperidy0-l.,3-dioxo-isoindolin-4-yllaminolocta- 3,5-diynylcarbamoyllphenyllpyrazol-4-yll-2-[2-[2,2,2-trifluoroethylamino)-4-pyridylloxazole-4-carboxamide, 1-179





[005099] N-[3-carbamoyl-l-[4-[8-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]octa- 3,5-diynylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(2,2,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide **1-179** was synthesized as described for Example 177, using Intermediate CN as the acid and but-3-yn-l-amine(hydrochloride salt) as the alkyne in Step 1 and Intermediate DO as the alkyne in Step 2, which was run for 80 h at rt. Characterization of the final product: ¾ NMR (400MHz, DMSO-de) δ 11.10 (s, 1H), 11.02 (s, 1H), 9.05 (d, *J* = 6.8 Hz, 2H), 8.83 (t, *J* = 5.6 Hz, 1H), 8.26 (d, *J* = 5.6 Hz, 1H), 8.13 *(d, J* = 8.8 Hz, 3H), 8.03 (d, *J* = 8.8 Hz, 2H), 7.78 (s, 1H), 7.70 (t, *j* = 6.4 Hz, 1H), 7.62 - 7.55 (m, 1H), 7.28 (s, 1H), 7.18 (d, *J* = 8.8 Hz, 2H), 7.05 (d, *J* = 7.2 Hz, 1H), 6.74 (t, *J* = 6.0 Hz, 1H), 5.07 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.30 - 4.21 (m, 2H), 3.53 - 3.48 (m, 4H), 2.93 - 2.86 (m, 1H), 2.65 - 2.60 (m, 6H), 2.03 (d, *J* = 7.6 Hz, 1H); LC-MS (ESI$^+$) *m/z* 890.2 $(M+H)^+$.

[005100] Example 180: N-[3-carbamoyl-l-[4-[[l-[3-[[2-(2.,6-dioxo-3-piperidvD-l.,3-dioxo-isoindolin-4-yl1amino1 propyl1triazol-4-yl1methylcarbamoyl]phenyl1pyrazol-4-yl1-2-[2-[2,2,2-trifluoroethylamino)-4-pyridyl1oxazole-4-carboxamide, 1-180



DP





[005101] Step 1 - Tert-butyl N-r4-r4-rr3-carbamoyl-l-r4-nT-r3-rr2-(2.6-dioxo-3-piperidvO-E3-dioxo-isoindolin _ _-4-yl1amino1propyl1triazol-4-yl1methylcarbamoyl1phenyl1pyrazol-4-yl]carbamoyl1oxazol-2-yl1-2-pyridyl1-N-(2.2.2-trifluoroethyl)carbamate


[005102] To a solution of 4-(3-azidopropylamino)-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (131 mg, 368 umol, Intermediate DP) and tert-butyl N-[4-[4-[[3-carbamoyl-l-[4-(prop-2-ynylcarbamoyl)phenyl]pyrazol-4-yl] carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (120 mg, 184 umol, synthesized via Step 1 of Example 177) in tert-butanol (4 mL) and H_20 (4 mL) was added sodium (2R)-2-[(lS)-l,2-dihydroxyethyl] -4-hydroxyl-5-oxo-2H-furan-3-olate (728 ug, 3.68 umol) and $CuS0_4$ (293 ug, 1.84 umol). The reaction mixture was heated to 60 °C and stirred for 12 hours. On completion, the mixture was concentrated *in*

vacuo to give a residue, and the residue was triturated with H_2O (50 mL). Then the solid the filtered and dried *in vacuo.* The crude product was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]; B%: 48%-78%, 10 min) to give the title compound (60.0 mg, 32% yield) as a yellow solid. LC-MS (ESI^+) m/z 1009.5 $(M+H)^+$.

[005103] Step 2 - N-[3-carbamoyl-1-[4-[[1-[3-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]propyl]triazol-4-yl]methylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(2,2,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide


[005104] To a solution of tert-butyl N-[4-[4-[[3-carbamoyl-1-[4-[[1-[3-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]propyl]triazol-4-yl]methylcarbamoyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (60.0 mg, 59.5 umol) in DCM (2 mL) was added HC1 in dioxane (4 M, 2 mL). The reaction mixture was stirred at rt for 30 minutes. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (column: Boston Green ODS 150*30 5u; mobile phase: [water (0.225% FA)-ACN]; B%: 35%-65%, 10 min) to give the title compound **1-180** (14.2 mg, 24% yield) as yellow solid. ^1H NMR (400MHz, DMSO-d_6) δ 11.02 (s, 1H), 9.20 - 9.20 (m, 1H), 9.05 (d, J = 4.4 Hz, 2H), 8.26 (d, J = 5.2 Hz, 1H), 8.23 - 7.98 (m, 7H), 7.79 (s, 1H), 7.75 - 7.68 (m, 1H), 7.57 (t, j = 8.0 Hz, 1H), 7.27 (s, 1H), 7.18 (d, j = 4.8 Hz, 1H), 7.04 (t, j = 8.0 Hz, 2H), 6.72 (m, 1H), 5.05 (dd, J = 4.8, 12.8 Hz, 1H), 4.54 *(d, J* = 4.8 Hz, 2H), 4.44 (t, J = 6.8 Hz, 2H), 4.30 - 4.20 (m, 2H), 3.49 - 3.43 (m, 2H), 2.95 - 2.83 (m, 1H), 2.61 (m, 1H), 2.58 - 2.56 (m, 1H), 2.15 - 2.09 (m, , 2H), 2.05 - 2.00 (m, 1H); LC-MS (ESI^+) m/z 909.4 $(M+H)^+$.

[005105] Example 181: N-[3-carbamoyl-1-[4-[2-[1-[3-[[2-12,6-dioxo-3-piperidvB-l,3-dioxo-isoindolin-4-yl] amino] propyl] triazol-4-yl] ethylcarbamoyl] phenyl] pyrazol-4-yl] -2-[2-12,2.,2-trifluoroethylamino]-4-pyridyl1oxazole-4-carboxamide, 1-181



[005106] N-[3-carbamoyl-l-[4-[2-[l-[3-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl] amino]propyl]triazol-4-yl]ethylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(2,2,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide **1-181** was synthesized as described for Example 180, using azide Intermediate DP and alkyne tert-butyl N-[4-[4-[[l-[4-(but-3-ynylcarbamoyl)phenyl]-3-carbamoyl-pyrazol-4-yl] carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (synthesized via Step 1 of Example 179) in the first step. Characterization of the final product: ¾ NMR (400MHz, DMSO-d_6) δ 11.11 (s, 1H), 11.03 (s, 1H), 9.05 (s, 1H), 9.04 (s, 1H), 8.74 (t, *J* = 5.6 Hz, 1H), 8.27 (d, *J* = 5.2 Hz, 1H), 8.15 (s, 1H), 8.12 - 8.08 (m, 2H), 8.02 (s, 2H), 8.00 (s, 1H), 7.79 (s, 1H), 7.74 - 7.68 (m, 1H), 7.60 - 7.54 (m, 1H), 7.28 (s, 1H), 7.21 - 7.17 (m, 1H), 7.06 - 7.01 (m, 2H), 6.69 (t, *J* = 6.0 Hz, 1H), 5.10 - 5.02 (m, 1H), 4.46 - 4.41 (m, 4H), 4.34 - 4.28 (m, 2H), 3.57 - 3.53 (m, 2H), 2.95 - 2.91 (m, 2H), 2.89 - 2.84 (m, 1H), 2.64 - 2.59 (m, 2H), 2.13 - 2.08 (m, 2H), 2.07 - 2.05 (m, 1H); LC-MS (ESI^+) *m/z* 923.4 $(M+H)^+$.

[005107] Example 182: N-[3-carbamoyl-l-[4-[3-[4-[2-[[2-(2,6-dioxo-3-piperidyl).3-dioxo-isoindolin-4-yl1amino1 ethyl1triazol-l-11propylcarbamoyl1phenyl]pyrazol-4-yl1-2-[2-[2,2,2-trifluoroethylamino)-4-pyridylloxazole-4-carboxamide, 1-182



[005108] Step 1 - Tert-butyl N-[4-[4-[[1-[4-(3-azidopiOpylcarbamovl)phenyl]-3-carbamoyl-pyrazol-4-yll carbamoyl1oxazol-2-yl1-2-pyridyl1-N-(2,2,2-trifluoroethyl‘icarbamate

[005109] To a solution of 3-azidopropan-l-amine (44.3 mg, 324 umol, HC1 salt) and 4-[4-[[2-[2-[tert -butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carbonyl]amino]-3-carbamoyl-pyrazol-l-yl]benzoic acid (0.20 g, 324 umol, Intermediate CN) in DMF (4 mL) was added DIPEA (209 mg, 1.62 mmol, 282 uL). The mixture was stirred at rt for 12 minutes, and then HATU (148 mg, 389 umol) was added to the mixture. The reaction mixture was stirred at rt for 2 hours. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase chromatography ($NH_3 \cdot H_2O$) to give the title compound (180 mg, 77% yield) as a white solid. LC-MS (ESI^+) m/z 698.2 $(M+H)^+$.

[005110] Step 2 - Tert-butyl N-[4-[4-[[3-carbamoyl-1-[4-[3-[4-[2-[[2-(2,6-άioχo-3-

piperidyl)-1J-dioxo _-isoindolin-4-yllaminolethylltriazol-l-yllpropylcarbamoyllphenyllpyrazol-4-yl]carbamoyl]oxazol-2-yl1-2-pyridyl1-N-(2,2,2-trifluoroethyl)carbamate


[005111] To a solution of 4-(but-3-ynylamino)-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (35.0 mg, 107 umol, Intermediate DO) and tert-butyl N-[4-[4-[[l-[4-(3-azidopropylcarbamoyl) phenyl]-3-carbamoyl- pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (112 mg, 161 umol) in H_20 (1.00 mL) and tert-butanol (3.00 mL) was added $CuS0_4$ (171 ug, 1.08 umol) and sodium (2R)-2-[(lS)-l,2-dihydroxyethyl]-4-hydroxy-5-oxo-2H -furan-3-olate (426 ug, 2.15 umol), and the mixture was heated to 60 °C and stirred for 16 hr. On completion, the mixture was concentrated *in vacuo.* The mixture was purified by prep-HPLC (column: Boston Green ODS 150*30 5u; mobile phase: [water (0.225%FA)-ACN]; B%: 50%-80%, lOmin) to give the title compound (30.0 mg, 27% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 1045.2 $(M+Na)^+$.

[005112] Step _3_-_N-[3-carbamoyl-l-[4-[3-[4-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]_ ethyl]triazol-14Ipropyl carbamoyl Iphenyl lpyrazol-4-yl 1-2-[2-(2,2,2-trifluoroethylamino)-4-pyridyl1oxazole-4-carboxamide

[005113] To a solution of tert-butyl N-[4-[4-[[3-carbamoyl-l-[4-[3-[4-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3 -dioxo-isoindolin-4-yl]amino]ethyl]triazol-l-yl]propylcarbamoyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (30.0 mg, 29.3 umol) in DCM (2.00 mL) was added HC1 in dioxane (4 M, 5.00 mL), and the mixture was stirred at rt for 30 min. On completion, the mixture was concentrated *in vacuo.* The mixture was purified by prep-HPLC (column: Boston Green ODS 150*30 5u; mobile phase: [water (0.225%FA)-ACN]; B%: 35%-65%) to give the title compound **1-182** (11.8 mg, 43% yield) as a yellow solid. ^1H NMR (400MHz, DMSO-i¾) δ 11.10 (s, 1H), 11.02 (s, 1H), 9.08 - 9.05 (m, 1H), 9.04 (s, 1H), 8.68 (s, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.13 (d, *J* = 3.2 Hz, 2H), 8.10 (s, 1H), 8.03 (s, 1H), 8.02 - 8.01 (m, 2H), 7.79 (s, 1H), 7.74 - 7.68 (m, 1H), 7.61 - 7.57 (m, 1H), 7.27 (s, 1H), 7.20 - 7.17 (m, 1H), 7.12 (d, *J* = 8.8 Hz, 1H), 7.03 (d, *J* = 7.2 Hz, 1H), 6.75 - 6.71 (m, 1H), 5.06 - 5.02 (m, 1H), 4.43 - 4.39 (m, 2H), 4.32 - 4.21 (m, 2H), 3.64 - 3.57 (m, 2H), 3.30 - 3.28 (m, 2H), 2.97 - 2.93 (m, 2H), 2.88 - 2.84 (m, 1H), 2.62 - 2.59 (m, 1H), 2.57 - 2.56 (m, 1H), 2.12 - 2.07 (m, 2H), 2.04 - 1.98 (m, 1H), LC-MS (ESI^+) *m/z* 944.9 $(M+Na)^+$.


[005114] Example _183: ___N-[3-carbamoyl-l-[4-[3-[4-[[[2-[2,6-dioxo-3-piperidvB-l,3-dioxo-isoindolin-4-yl1amino1 __methyl1triazol-l-yl1propylcarbamoyl]phenyl1pyrazol-4-yl1-2-

[2-(2,2,2-trifluoroethylaminoV4-pyridylloxazole-4-carboxamide, 1-183



[005115] N-[3-carbamoyl-l-[4-[3-[4-[[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yljamino] methyl]triazol-l-yl]propylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(2,2,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide **1-183** was synthesized as described above for Example 182, using alkyne Intermediate DN in the second step. Characterization of the final product: ^{1}H NMR (400 MHz, DMSO-de) δ 11.09 (s, 1H), 11.02 (s, 1H), 9.04 (d, *J* = 5.2 Hz, 2H), 8.64 (t, *J* = 5.2 Hz, 1H), 8.26 *(d, J* = 5.2 Hz, 1H), 8.15 - 8.07 (m, 4H), 8.02 *(d, J* = 8.8 Hz, 2H), 7.77 (s, 1H), 7.70 (t, *J* = 6.4 Hz, 1H), 7.63 - 7.55 (m, 1H), 7.28 (s, 1H), 7.21 - 7.14 (m, 2H), 7.12 - 7.02 (m, 2H), 5.07 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.61 *(d, J* = 6.0 Hz, 2H), 4.43 (t, *J* = 7.2 Hz, 2H), 4.25 (dd, *J* = 6.4, 9.8 Hz, 2H), 3.29 - 3.24 (m, 2H), 2.95 - 2.82 (m, 1H), 2.64 - 2.55 (m, 2H), 2.13 - 2.00 (m, 3H); LC-MS (ESI^{+}) m/z 909.2 (M+H)$^{+}$.

[005116] Example 184: Tt2RV3-ri8RVl-r4-r4-r2-r2-rr2-t2.6-dioxo-3-piperidylVl.3-dioxo-isoindolin-4-yllaminolV ethoxy]ethyl]piperazin-l-yl]cyclohexoxy]-7,8-dihydro-6H-cyclopenta [4,51thieno[l.,2-clpyrimidin-8-yll -2-hydroxy-propanamide, 1-184



[005117] Step 1 -2-(2,6-Dioxo-3-piperidyl)-4-r2-(2-hydroxyethoxy)ethyl amino]isoindoline-L3-dione

[005118] To a solution of 2-(2-aminoethoxy)ethanol (500 mg, 3.53 mmol, HC1 salt) in dioxane (15 mL) was added DIPEA (3.65 g, 28.2 mmol) and 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (1.07 g, 3.88 mmol, Intermediate R), and the mixture was stirred at 115 °C for 16 h. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE: EA = 1:1) to give the title compound (500 mg, 37% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-^e) δ 11.10 (s, 1H), 7.59 (dd, *J* = 7.6, 8.4 Hz, 1H), 7.15 *(d, J* = 8.8 Hz, 1H), 7.04 *(d, J* = 6.8 Hz, 1H), 6.61 (t, *J* = 5.6 Hz, 1H), 5.06 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.63 (t, *J* = 5.6 Hz, 1H), 3.61 (t, *j* = 5.6 Hz, 2H), 3.55 - 3.44 (m, 6H), 2.94 - 2.80 (m, 1H), 2.64 - 2.52 (m, 2H), 2.08 - 1.97 (m, 1H); LC-MS (ESI$^+$) *m/z* 362.0 (M+H)$^+$.

[005119] Step 2 - 2-[2-[[2-(2,6-Dioxo-3-piperidyl)-E3-dioxo-isoindolin-4-yllaminolethoxylethyl methane- sulfonate


[005120] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-[2-(2-hydroxyethoxy)ethylamino]isoindoline-l,3-dione (200 mg, 525 umol) and TEA (159 mg, 1.58 mmol) in DCM (20 mL) was added MsCl (120 mg, 1.05 mmol) at 0°C. Then the mixture was allowed to warm to rt and stirred for 3 h. On completion, the reaction mixture was quenched by adding water (30 mL) at 0 °C, and then the mixture was extracted with DCM (3 X 40 mL). The combined organic layers were washed with saturated citric acid (2 X 20 mL), dried over Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (200 mg, 86% yield) as a yellow

solid. LC-MS (ESI^+) *m/z* 440.0 $(M+H)^+$.

[005121] Step 3: (2R)-3-[(8R)-1-[4-[4-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethyl]piperazin-1-yl]cyclohexoxy]-7,8-dihydro-6H-cyclopenta[4,5]thieno[2,3-c]pyrimidin-8-yl]-2-hydroxy-propanamide

[005122] To a solution of (2i?)-2-hydroxy-3-[(8i?)-1-(4-piperazin-1-ylcyclohexoxy)-7,8-dihydro-6//- cyclopenta[4,5]thieno[l,2-c]pyrimidin-8-yl]propanamide (40 mg, 82.9 umol HC1 salt, Intermediate DR) in DMF (3 mL) was added K2CO3 (45.8 mg, 331 umol) and 2-[2-[[2-(2,6-dioxo-3- piperidyl)-l,3- dioxo-isoindolin-4-yl] amino] ethoxy] ethyl methanesulfonate (48.6 mg, 99.5 umol), and the mixture was stirred at 60 °C for 24 h. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Gemini l50*25mm*l0um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]) to give the title compound **1-184** (23.5 mg, 35% yield, FA salt) as a yellow solid. ^1H NMR (400MHz, DMSO-i/e) δ 11.11 (s, 1H), 8.53 (s, 1H), 7.64 - 7.53 (m, 1H), 7.20 - 7.13 (m, 2H), 7.11 (s, 1H), 7.05 (d, J = 6.8 Hz, 1H), 6.60 (t, J = 5.6 Hz, 1H), 5.20 - 5.11 (m, 1H), 5.07 (dd, J = 5.6, 12.8 Hz, 1H), 3.93 (t, J = 6.4 Hz, 1H), 3.60 - 3.55 (m, 6H), 3.10 - 2.99 (m, 2H), 2.95 - 2.87 (m, 2H), 2.72 - 2.56 (m, 3H), 2.48 - 2.39 (m, 10H), 2.38 - 2.26 (m, 4H), 2.20 - 2.01 (m, 3H), 1.85 - 1.82 (m, 2H), 1.63 - 1.49 (m, 3H), 1.41 - 1.30 (m, 2H); LC-MS (ESI^+) *m/z* 789.3 $(M+H)^+$.

[005123] Example 185: 3-2-(2-((Cyclopropylmethyl)amino)pyridin-4-yl)-N-(1-(4-(((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl]-l.,3-dioxoisoindolin-4-yDamino)ethoxy)ethoxy)ethyDamino)methyDphenyD-3-(trifluoromethyD-lH-pyrazol-4-yDoxazole-4-carboxamide, 1-185



[005124] Step **1** - 4-(4-(2-(2-(YTert-butoxycarbonvO(cvclopropylmethvOamino)pyridin-4-vOoxazole-4-carboxamido)- 3-(trifluorom ethyl)- !H-pyrazol- 1-yl)benzoiciisopropylcarbonic)anhydride

[005125] To a solution of 4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4- carbonyl]amino]-3-(trifluoromethyl)pyrazol-l-yl]benzoic acid (700 mg, 960 umol, Intermediate EG) in THF (10 mL) was added TEA (194 mg, 1.92 mmol). Then, the reaction mixture was cooled to -10 °C. Next, isopropyl carbonochloridate (235 mg, 1.92 mmol) was added and the reaction mixture was stirred at -10 °C for 2 hours. On completion, the reaction mixture was filtered. The filtrate was concentrated *in vacuo* to give the title compound (720 mg, 91% yield) as white solid. LC-MS (ESI^+) *m/z* 699.0 $(M+H)^+$.

[005126] Step 2 - Tert-butyl (cvclopropylmethvD(4-(4-(n-(4-(hvdiOxymethvDphenvD-3-(trifluoromethyP-lH- pyrazol-4-vDcarbamovDoxazol-2-vDpyridin-2-vDcarbamate

[005127] To a solution of isopropoxycarbonyl 4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4- pyridyl]oxazole-4-carbonyl]amino]-3-(trifluoromethyl)pyrazol-l-yl]benzoate (720 mg, 876 umol) in THF (20 mL) was added $NaBH_4$ (66.3 mg, 1.75 mmol) and water (63.1 mg, 3.50 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 1 hour. On completion, the reaction mixture was quenched with water (5 mL) and the mixture was extracted with DCM (3 X 50 mL). The combined organic layer was washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (520 mg, 99 % yield) as a white solid. ¾ NMR (400MHz, CDCh) δ 9.06 (s, 1H), 8.88 (s, 1H), 8.54 (d, *J* = 5.2 Hz, 1H), 8.42 (s, 1H), 8.36 (s, 1H), 7.76 (d, *J* = 8.4 Hz, 2H), 7.64 (d, *J* = 4.8 Hz, 1H), 7.51 (d, *J* = 8.4 Hz, 2H), 4.78 (s, 2H), 3.96 (d, *J* = 7.2 Hz, 2H), 1.59 (s, 9H), 0.93 - 0.81 (m, 1H), 0.47 - 0.42 (m, 2H), 0.30 - 0.26 (m, 2H); LC-MS (ESI^+) *m/z* 599.2 $(M+H)^+$.

[005128] Step 3 - Tert-butyl (cvclopropylmethvD(4-(4-((l-(4-formylphenvD-3-(trifluoromethvP-lH-pyrazol- 4-v0carbamov0oxazol-2-v0pyridin-2-v0carbamate

[005129] To a solution of tert-butyl /V-(cyclopropylmethyl)-/V-[4-[4-[[l-[4-(hydroxymethyl)phenyl]-3- (trifluoromethyl)pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (320 mg, 535 umol) in DCM (10 mL) was added DMP (454 mg, 1.07 mmol). The reaction mixture was stirred at rt for 5 hours. On completion, the reaction mixture was quenched with saturated $Na_2S_20_3$ (20 mL) and extracted with DCM (3 X 30 mL). The combined organic layers were washed with saturated $NaHC0_3$ (2 X 20 mL), then washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo*. The residue was purified by prep-HPLC (0.1% HC1) to give the title compound (123 mg, 39% yield) as a white solid. ^1H NMR (400MHz, CDCh) δ 10.08 (s, 1H), 9.08 (s, 1H), 9.01 (d, *J* = 5.2 Hz, 1H), 8.98 (s, 1H), 8.57 (s, 1H), 8.06 (d, *j* = 8.4 Hz, 2H), 7.95 (d, *j* = 8.8 Hz, 2H), 7.45 (s, 1H), 7.39 (s, 1H), 3.35 (s, 2H), 1.67 (s, 9H), 1.15 - 1.05 (m, 1H), 0.78 - 0.76 (m, 2H), 0.45 - 0.44 (m, 2H).

[005130] Step 4 - Tert-butyl (cvclopropylmethyl)*(4-(4-((\ -(4-(((2-(2-(2-((2-(2,6-*dioxopiperidin-3-vD-L3- _ dioxoi soindolin-4-vDamino)ethoxy)ethoxy)ethvDamino)methvDphenvD-3 -(trifluorom ethyl)- lH-pyrazol-4-vDcarbamovDoxazol-2-vDpyridin-2-vPcarbamate


[005131] To a solution of 4-[2-[2-(2-aminoethoxy)ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline- l,3-dione (67.8 mg, 154 umol, HC1) in a mixed solvent of DCM (30 mL) and THF (30 mL) was added TEA (17.0 mg, 168 umol). The reaction mixture was stirred at rt for 0.5 hour. Then, tert-butyl N-(cyclopropylmethyl)-N-[4-[4-[[l-(4-formylphenyl)-3-(trifluoromethyl)pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (100 mg, 168 umol, synthesized via Steps 1-2 of Example 127), HOAc (20.1 mg, 335 umol, 19.2 uL) and $NaBH(OAc)_3$ (71.1 mg, 335 umol) were added to the mixture. The resulting reaction mixture was stirred at rt for 12 hours. On completion, the reaction mixture was quenched with water (2 mL) and extracted with ethyl acetate (3 X 50 mL). The combined organic layers were washed with brine, dried over with anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (150 mg, 91% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 885.1 $(M+H-l00)^+$.

[005132] Step 5 - 3- 2-(2-(YCvclopropylmethv0amino)pyridin-4-vQ-N-(T-(4-(´((2-(2-(2-((2-(2.6-dioxopiperidin- _ 3-vD-L3-dioxoisoindolin-4-vDamino)ethoxy)ethoxy)ethvDamino)methvDphenvD-3 -(trifluorom ethyl)- lH-pyrazol-4-vDoxazole-4-carboxamide

[005133] To a solution of tert-butyl N-(cyclopropylmethyl)-N-[4-[4-[[l-[4-[[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)- l,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethylamino]methyl]phenyl]-3-(trifluoromethyl)pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (150 mg, 152 umol) in DCM (4 mL) was added HC1 in dioxane (4 M, 4 mL). The reaction mixture was stirred at rt for 0.5 hour. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA)- ACN]; B%: l0%-40%) to give the title compound **1-185** (61.0 mg, 45% yield) as a yellow solid. ^1H NMR (400MHz, DMSO-^e) δ 10.88 (s, 1H), 9.70 (s, 1H), 8.75 (s, 1H), 8.63 (s, 1H), 8.03 (s, 1H), 7.94 (d, *J* = 5.2 Hz, 1H), 7.58 (d, *J* = 8.4 Hz, 2H), 7.37 - 7.30 (m, 1H), 7.27 (d, *J* = 8.4 Hz, 2H), 6.92 - 6.89 (m, 2H), 6.87 (t, *J* = 5.6 Hz, 1H), 6.83 - 6.77 (m, 2H), 6.38 (t, *J* = 5.6 Hz, 1H), 4.83 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.55 (s, 2H), 3.43 - 3.39 (m, 2H), 3.38 - 3.35 (m, 2H), 3.33 - 3.30 (m, 2H), 3.29 - 3.27 (m, 2H), 3.24 (d, *J* = 5.6 Hz, 2H), 2.96 (t, *J* = 5.6 Hz, 2H), 2.72 - 2.59 (m, 1H), 2.48 - 2.42 (m, 2H), 2.38 - 2.31 (m, 1H), 2.30 - 2.85 (m, 1H), 1.83 - 1.76 (m, 1H), 0.89 - 0.81 (m, 1H), 0.27 - 0.21 (m, 2H), 0.01 (m, 2H); LC-MS (ESI^+) *m/z* 885.1 $(M+H)^+$.

[005134] **Example 186: 2-[2-(Cvclopropylmethylamino)-4-pyridyll-N-[l-[3-[[2-[2-[2-**

[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yllaminolethoxylethoxylethylaminolmethyllphenyll-3-(trifluoromethvPpyrazol-4-ylloxazole-4-carboxamide, 1-186



[005135] Step 1 - Tert-butyl N-(cvclopropylmethvl)-N-[4-[4-[[1-(3-6 rmvlphenvl)-3-(trifluoromethvOpyrazol-4-yl1carbamoyl1oxazol-2-vH-2-pyridyl1carbamate

[005136] To a solution of tert-butyl N-(cyclopropylmethyl)-N-[4-[4-[[l-[3-(hydroxymethyl)phenyl]-3-(trifluoro methyl)pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (320 mg, 534 umol. Intermediate El) in DCM (8.00 mL) was added DMP (105 mg, 249 umol), and the mixture was stirred at 25°C for 20 hours. On completion, the mixture was quenched with saturated $Na_2S_20_3$ (2 X 30 mL) and extracted with DCM (30 mL). The organic layer was washed with saturated $NaHC0_3$ (2 X 30mL), dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (280 mg, 87% yield) as a red solid. ^{1}H NMR (400MHz, CDCh) δ 10.04 (s, 1H), 9.01 (s, 1H), 8.92 (s, 1H), 8.46 (d, *J* = 5.2 Hz, 1H), 8.36 (s, 1H), 8.30 (s, 1H), 8.22 (s, 1H), 8.03 - 7.98 (m, 1H), 7.83 (d, *J* = 7.6 Hz, 1H), 7.66 - 7.60 (m, 1H), 7.56 (dd, *J* = 1.2, 5.2 Hz, 1H), 3.88 (d, *J* = 7.2 Hz, 2H), 1.51 (s, 9H), 1.18 - 1.11 (m, 1H), 0.39 - 0.34 (m, 2H), 0.24 - 0.20 (m, 2H).

[005137] Step 2 - Tert-butyl N-tcvclopropyl methyl)-N-[4-[4-[[1-[3-[[2-[2-[2-[[2-(2,6-dioχo-3-piperidvO -1,3-dioxo-isoindolin-4-yl]aminolethoxylethoxylethylaminolmethyllphenyl]-3-(trifluoromethvnpyrazol-4-yl1carbamoyl1oxazol-2-vH-2-pyridyl1carbamate


[005138] To a solution of tert-butyl N-(cyclopropylmethyl)-N-[4-[4-[[l-(3-formylphenyl)-3-(trifluoromethyl) pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (100 mg, 167 umol) and 4-[2-[2-(2-amino ethoxy)ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (88.6 mg, 201 umol, HC1, synthesized via Steps 1-2 of Example 127) in THF (30.0 mL) was added KOAc (32.9 mg, 335 umol) and $NaBH(OAc)_3$ (71.0 mg, 335 umol). The mixture was stirred at rt for 16 hours. On completion, the mixture was quenched with water (2 mL) and extracted with ethyl acetate (3 X 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo.* The mixture was purified by reverse phase prep-HPLC (0.1% FA) to give the title compound (80.0 mg, 48% yield) as a yellow solid. LC-MS (ESL) *m/z* 985.4 $(M+H)^+$.

[005139] Step 3 - 2-[2-(Cyclopropylmethylamino)-4-pyridyl]-N-[1-[3-[[2-[2-[2-[[2-(2,6-dioxo-3-piperidvD-L3 -dioxo-isoindolin-4-yllaminolethoxylethoxylethylaminolmethyllphenyll-3-(trifluoromethvnpyrazol-4-yl1oxazole-4-carboxamide

[005140] To a solution of tert-butyl N-(cyclopropylmethyl)-N-[4-[4-[[l-[3-[[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)- l,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethylamino]methyl]phenyl]-3-(trifluoromethyl)pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (80.0 mg, 81.2 umol) in DCM (2.00 mL) was added HC1 in dioxane (4 M, 2.00 mL). The mixture was stirred at rt for 15 minutes. On completion, the mixture was concentrated *in vacuo.* The mixture was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]; B%: 10%-40%, 10 min) to give the title compound **1-186** (41.2 mg, 57% yield) as a yellow solid. ^1H NMR (400MHz, DMSO-de) δ 11.11 (s, 1H), 9.92 (s, 1H), 8.98 (s, 1H), 8.88 (s, 1H), 8.23 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.86 (s, 1H), 7.73 (d, *J* = 8.4 Hz, 1H), 7.55 (dd, *J* = 7.2, 8.4 Hz, 1H), 7.48 (t, *J* = 8.0 Hz, 1H), 7.37 (d, *J* = 7.6 Hz, 1H), 7.13 - 7.08 (m, 3H), 7.06 - 7.01 (m, 2H), 6.64 - 6.54 (m, 1H), 5.08 - 5.01 (m, 1H), 3.82 (s, 2H), 3.59 - 3.53 (m, 10H), 3.23 - 3.16 (m, 2H), 2.92 - 2.84 (m, 1H), 2.69 - 2.66 (m, 2H), 2.62 - 2.58 (m, 1H), 2.57 - 2.55 (m, 1H), 2.06 - 1.94 (m, 1H), 1.12 - 1.01 (m, 1H), 0.50 - 0.43 (m, 2H), 0.27 - 0.20 (m, 2H); LC-MS (ESI^+) *m/z* 885.1 $(M+H)^+$.

[005141] **Example 187: 2-[2-(Cvclopropylmethylamino)-4-pyridyl1-N-[l-[4-[[2-[2-[3-**


[2-[2,6-dioxo-3-piperidvB-l,3- _ dioxo-isoindolin-5-yl] propoxy] ethoxy] ethylamino] methyl] phenyl] -3-(trifluoromethvDpyrazol-4-yll oxazole-4-carboxamide, _ 1-187



[005142] To a solution of 5-[3-[2-(2-aminoethoxy)ethoxy]propyl]-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3- dione (45.0 mg, 102 umol, HC1 salt, Intermediate CQ) and 2-[2-(cyclopropylmethylamino)-4-pyridyl]-N-[l-(4-formylphenyl) -3-(trifluoromethyl)pyrazol-4-yl]oxazole-4-carboxamide (54.5 mg, 102 umol, synthesized via Steps 1-3 of Example 185) in THF (10 mL) was added KOAc (20. 1 mg, 205 umol) and the reaction mixture was stirred for 30 minutes at rt. Then $NaBH(OAc)_3$ (54.2 mg, 256 umol) was added in portions and the mixture was stirred at rt for 2 hours. Then HOAc (1.23 g, 20.5 mmol, 1.17 mL) was added and the mixture was stirred for 30 minutes. Finally, more $NaBH(OAc)_3$ (54.2 mg, 256 umol) was added and the reaction was stirred for 2 hours. On completion, the reaction mixture was quenched by addition water (2 mL), and then concentrated *in vacuo.* The residue was purified by prep-HPLC (reserve phase (ACN-water/0. l%FA)) and lyophilized to give the title compound **1-187** (21.5 mg, 22% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-de) δ 11.12 (s, 1H), 9.92 (s, 1H), 8.98 (s, 1H), 8.86 (s, 1H), 8.26 (s, 1H), 8.16 (d, J = 5.2 Hz, 1H), 7.84 - 7.79 (m, 3H), 7.77 (s, 1H), 7.70 (d, J = 7.6 Hz, 1H), 7.51

(d, J = 8.4 Hz, 2H), 7.14 - 7.07 (m, 2H), 7.06 - 7.02 (m, 1H), 5.14 (dd, *J* = 5.6, 13.2 Hz, 1H), 3.79 (s, 2H), 3.53 - 3.50 (m, 4H), 3.41 - 3.75 (m, 2H), 3.19 (t, *J* = 6.4 Hz, 2H), 2.95 - 2.76 (m, 4H), 2.71 - 2.60 (m, 4H), 2.59 - 2.53 (m, 2H), 2.08 - 2.01 (m, 1H), 1.90 - 1.81 (m, 2H), 1.11 - 1.04 (m, 1H), 0.49 - 0.43 (m, 2H), 0.26 - 0.20 (m, 2H); LC-MS (ESI^+) *m/z* 884.0 $(M+H)^+$.

[005143] Example 188: N-{3-carbamoyl-1-{4-((5-{2-((5-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)pentyl)oxy)ethoxy)pentyl)carbamoyl)phenyl)-1H-pyrazol-4-yl}-2-(2-((2,2,2-trifluoroethyl)amino]pyridin-4-yl)oxazole-4-carboxamide, 1-188



[005144] Step 1 - N-(3-carbamoyl-1-(4-((5-(2-(4-((tetrahydro-2H-pyran-2-yl)oxy)butoxy)ethoxy)pentyl)carbamoyl)phenyl)-1H-pyrazol-4-yl)-2-(2-((2,2,2-trifluoiOethv0amino)pyridin-4-v0oxazole-4-carboxamide

[005145] 5-(2-(4-((tetrahydro-2H-pyran-2-yl)oxy)butoxy)ethoxy)pentan-l-amine (122 mg,

0.38 mmol, Intermediate EV) was dissolved in DMF (2 mL). 4-(3-carbamoyl-4-(2-(2-((2, 2,2-trifluoroethyl)amino)pyridin-4-yl)oxazole-4-carboxamido)-1//-pyrazol-1-yl)benzoic acid (198 mg, 0.38 mmol, Intermediate ET), E1ATE[(159 mg, 0.42 mmol) and N,N-diisopropylethylamine (0.13 mL, 0.76 mmol) were then added and the reaction mixture was stirred at rt for 16 h. The reaction mixture was then diluted with a saturated aqueous solution of NaHCCh and extracted with Ethyl Acetate (3 times). The combined organic was washed with water, dried over magnesium sulfate and filtered. The mixture was then concentrated *in vacuo* and the residue was purified by silica gel chromatography (gradient of 0-10% methanol in dichloromethane) to give the title compound (161 mg, 50%) as a yellow powder.

[005146] Step 2: N-(3-caibamoyl-l-(4-((5-(2-(4-hvdroxybutoxy)ethoxy)pentvDcarbamovDphenvD-lH-pyrazol-4-vD-2-(2-((2.2.2-trifluoroethvDamino)pyridin-4-vDoxazole-4-carboxamide

[005147] N-(3-carbamoyl-l-(4-((5-(2-(4-((tetrahydro-2H-pyran-2-yl)oxy)butoxy)ethoxy)pentyl)carbamoyl)phenyl)-lH-pyrazol-4-yl)-2-(2-((2,2,2-trifluoroethyl)amino)pyridin-4-yl)oxazole-4-carboxamide (161 mg, 0.19 mmol) was dissolved in a 1.25 M solution of HC1 in methanol (1.6 mL) and the reaction mixture was stirred at rt for 2 hours. The reaction mixture was then concentrated *in vacuo* to give the title compound as an orange solid (142 mg, quantitative yield). LC-MS (ESI^+) *m/z* 731.4 $(M+H)^+$.

[005148] Step 3: N-(3-caibamoyl-l-(4-((5-(2-(4-oxobutoxy)ethoxy)pentvDcarbamoyl)phenvD-lH-pyrazol-4-yl)-2-(2-((2.2.2-trifluoroethvDamino)pyridin-4-vDoxazole-4-carboxamide


[005149] To a suspension of N-(3-carbamoyl-l-(4-((5-(2-(4-hydroxybutoxy)ethoxy)pentyl)carbamoyl)phenyl)-lH-pyrazol-4-yl)-2-(2-((2,2,2-trifluoroethyl)amino)pyridin-4-yl)oxazole-4-carboxamide (142 mg, 0.19 mmol) in acetone (10 mL) was added 2-iodoxybenzoic acid (156 mg, 0.57 mmol) and the reaction mixture was heated at 55 °C in a sealed tube for 16 h. The reaction mixture was then quenched with a saturated aqueous solution of NaHCCh and extracted with Ethyl Acetate. The organic layer was dried over magnesium sulfate, filtered and concentrated *in vacuo* to give the title compound which was used directly in the subsequent step. LC-MS (ESI^+) *m/z* 729.4 $(M+H)^+$.

[005150] Step 4: N-(3-carbamoyl-l-(4-((5-(2-(((5-(((SVl-((2S.4RV4-hvdroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-

yl)amino)pentyl)oxy)ethoxy)pentyl)carbamoyl)phenyl)-1H-pyrazol-4-yl)-2-(2-((2,2,2-trifluoroethyl)amino)pyridin-4-yl)oxazole-4-carboxamide

[005151] N-(3-carbamoyl-1-(4-((5-(2-(4-oxobutoxy)ethoxy)pentyl)carbamoyl)phenyl)-1H-pyrazol-4-yl)-2-(2-((2,2,2-trifluoroethyl)amino)pyridin-4-yl)oxazole-4-carboxamide (177 mg, 0.24 mmol) and (2S,4R)-1-[(2S)-2-amino-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)-phenyl]methyl]pyrrolidine-2-carboxamide (125 mg, 0.29 mmol, Intermediate C1) was dissolved in a mixture of methanol (1.4 mL) and dichloromethane (0.8 mL) and stirred for 5 minutes before the addition of borane pyridine complex (49 μL, 0.48 mmol). The reaction mixture was stirred at rt until completion. The reaction mixture was then concentrated *in vacuo*, diluted in Ethyl Acetate and partitioned with a saturated aqueous solution of NaHCO3. The precipitate was filtered off and the mixture was extracted with Ethyl Acetate (3 times). The combined organic layer was concentrated *in vacuo*. Purification with silica gel chromatography (gradient mixture of 0-60% methanol in dichloromethane) gave 74 mg of the impure product. A second purification was performed using silica gel chromatography (gradient of 10-40% methanol in dichloromethane) to give the title compound **1-188** (20 mg, 7%) as a yellow powder. ^{1}H NMR (400 MHz, DMSO): δ 11.00 (s; 1 H); 9.02 (d; J = 2.46 Hz; 2 H); 8.95-8.96 (m; 1 H); 8.52-8.56 (m; 2 H); 8.24 (d; J = 5.29 Hz; 1 H); 8.12 (s; 1 H); 8.08 (d; J = 8.51 Hz; 2 H); 7.99 (d; J = 8.39 Hz; 2 H); 7.76 (s; 1 H); 7.68 (t; J = 6.53 Hz; 1 H); 7.34-7.42 (m; 4 H); 7.25 (s; 1 H); 7.16 (d; J = 5.39 Hz; 1 H); 5.02 (d; J = 3.19 Hz; 1 H); 4.50 (t; J = 8.16 Hz; 1 H); 4.30-4.39 (m; 3 H); 4.17-4.28 (m; 4 H); 3.48-3.57 (m; 2 H); 3.44 (s; 4 H); 3.20-3.40 (m; 6 H); 2.99 (s; 1 H); 2.41-2.43 (m; 4 H); 2.22-2.32 (m; 2 H); 1.41-1.57 (m; 6 H); 1.28-1.37 (m; 6 H); 0.88 (s; 9 H). LC-MS (ESI$^+$) *m/z* $[M+2H]^{2+}$: 572.3.

[005152] Example 189: (2S,4R)-1-[(2S)-2-[[2-[2-[2-[4-[[7-[[(1R,2S)-2-aminocyclohexyl]amino]-4-oxo-3H-pyrido[4,3-d]pyrimidin-5-yl]amino]indol-1-yl]ethoxy]ethoxy]acetyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-[4-methylthiazol-5-yl)phenyl]methyl] pyrrolidine-2-carboxamide, 1-189



[005153] Step 1 - Ethyl 2-r2-r2-(4-nitiOindol-l-v0ethoxy1ethoxy1acetate and 2-[2-[2-(4-nitroindol-l-yl) ethoxylethoxyl acetic acid

[005154] To a solution of 4-nitro-lH-indole (649 mg, 4.01 mmol) and CS2CO3 (3.26 g, 10.0 mmol) in DMF (15.0 mL) was added ethyl 2-[2-(2-methylsulfonyloxyethoxy)ethoxy]acetate (1.30 g, 4.81 mmol, synthesized via Steps 1-2 of Intermediate BM), then the reaction mixture was stirred at 80°C for 12 hours. On completion, the reaction mixture was concentrated *in vacuo* to give a residue, the residue was diluted with water (40 mL) and acidified with the saturated citric acid aqueous solution (10 mL) until the pH = 2. Then the mixture was extracted with EA (30 mL X 5). The combined organic layers were dried over sodium sulfate, filtered and concentrated *in vacuo* to give a mixture of ethyl 2-[2-[2-(4-nitroindol-l-yl) ethoxy] ethoxy] acetate (800 mg, 59% yield) and 2-[2-[2-(4-nitroindol-l-yl)ethoxy]ethoxy]acetic acid (500 mg, 40% yield). LC-MS (ESI^+) *m/z* 359.0 $(M+Na)^+$ and LC-MS (ESI^+) *m/z* 309.0 $(M+H)^+$.

[005155] Step 2 - Ethyl 2-r2-r2-(4-nitroindol-l-v0ethoxy1ethoxy1acetate

[005156] To a mixture of ethyl 2-[2-[2-(4-nitroindol-l-yl) ethoxy] ethoxy] acetate (800 mg, 2.38 mmol) and 2-[2-[2-(4-nitroindol-l-yl)ethoxy]ethoxy]acetic acid (500 mg, 1.62 mmol) in EtOH (10.0 mL) was added SOCL (LOO g, 8.44 mmol), and the reaction mixture was stirred at 80°C for 2 hours. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was diluted water (15 mL) and extracted with EA (20 mL X 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated *in vacuo* to give the title compound (950 mg, 66% yield). ^{1}HNMR (400MHz, CDCb) δ 8.12 (d, J = 8.0 Hz, 1H), 7.71 (d, J = 8.0 Hz, 1H), 7.44 (d, j = 3.2 Hz, 1H), 7.25 (d, j = 1.6 Hz, 1H), 7.22 (d, j = 3.2 Hz, 1H), 4.38 (t, j = 5.6 Hz, 2H), 4.19 (q, J = 7.2 Hz, 2H), 4.01 (s, 2H), 3.82 (t, J = 5.2 Hz, 2H), 3.64 - 3.60 (m, 2H), 3.59 - 3.54 (m, 2H), 1.26 (t, j = 7.2 Hz, 3H); LC-MS (ESI^+) *m/z* 337.1 $(M+H)^+$.

[005157] Step 3 - Ethyl 2-r2-r2-(4-aminoindol-l-v0ethoxy1ethoxy1acetate

[005158] To a solution of ethyl 2-[2-[2-(4-nitroindol-l-yl)ethoxy]ethoxy]acetate (950 mg, 2.82 mmol) in EA (12.0 mL) was added Pd/C (600 mg, 2.82 mmol) under nitrogen atmosphere. The suspension was degassed and purged with hydrogen gas 3 times. The mixture was stirred under hydrogen atmosphere (15 psi pressure) at rt for 2 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (850 mg, 98% yield). ^{1}H NMR (400MHz, CDCb) δ 7.09 (d, J = 3.6 Hz, 1H), 7.03 (t, J = 8 Hz, 1H), 6.83 (d, J = 8.0 Hz, 1H), 6.41 - 6.39 (m, 2H), 4.27 (t, j = 6.0 Hz, 2H), 4.23 (q, j = 7.2 Hz, 2H), 4.09 (s, 2H), 3.91 (s, 2H), 3.81 (t, J = 6.0 Hz, 2H), 3.69 - 3.64 (m, 2H), 3.60 - 3.56 (m, 2H), 1.30 (t, j = 7.2 Hz, 3H); LC-MS (ESI^+) *m/z* 307.1 $(M+H)^+$.

[005159] Step 4- Ethyl 2-r2-r2-r4-r(7-chloro-4-oxo-3H-pyridor4.3-d1pyrimidin-5-vDaminolindol- 1-yllethoxyl ethoxy] acetate

[005160] To a solution of ethyl 2-[2-[2-(4-aminoindol-l-yl)ethoxy]ethoxy]acetate (500 mg, I.63 mmol) and 5,7-dichloro-3H-pyrido[4,3-d]pyrimidin-4-one (352 mg, 1.63 mmol, Intermediate FB) in NMP (4 mL) was added TEA (329 mg, 3.26 mmol), and the reaction mixture was stirred at 140 °C for 2 hours. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (PE/EA = 1/2) to give the title compound (500 mg, 63% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-i/e) δ 12.95 (s, 1H), II.75 (s, 1H), 8.31 (s, 1H), 8.17 (d, *J* = 7.6 Hz, 1H), 7.44 (d, *J* = 3.2 Hz, 1H), 7.28 (d, *J* = 8.0 Hz, 1H), 7.17 (t, *J* = 8.0 Hz, 2H), 6.91 (s, 1H), 6.56 (d, *J* = 3.2 Hz, 1H), 4.36 (t, *J* = 5.6 Hz, 2H), 4.10 (q, *j* = 7.2 Hz, 2H), 4.05 (s, 2H), 3.76 (t, *j* = 5.2 Hz, 2H), 3.53 (d, *j* = 3.6 Hz, 4H), 1.18 (t, *j* = 7.2 Hz, 3H); LC-MS (ESI$^+$) *m/z* 486.0 (M+H)$^+$.

[005161] Step 5 - 2-r2-r2-r4-r(7-Chloro-4-oxo-3H-pyridor4.3-d1pyrimidin-5-vDaminolindol-l -yllethoxyl ethoxylacetic acid

[005162] To a solution of ethyl 2-[2-[2-[4-[(7-chloro-4-oxo-3H-pyrido[4,3-d]pyrimidin-5-yl)amino]indol-l-yl] ethoxy] ethoxy] acetate (260 mg, 535 umol) in THF (3.00 mL) and H_20 (3.00 mL) was added LiOH (51.2 mg, 2.14 mmol), and the mixture was stirred at rt for 2 hours. On completion, the mixture was acidified with 1N HC1 solution (1 mL) until the pH = 3, then diluted with water (5 mL) and extracted with DCM (50 mL X 3). The combined organic layers were dried over sodium sulfate, filtrated and concentrated *in vacuo* to give the product (230 mg, 93% yield) as a light yellow solid. LC-MS (ESI$^+$) *m/z* 458.1 (M+H)$^+$.

[005163] Step 6 - (2S.4R)-l-I(2S)-2-[[2-[2-[2-[4-I(7-chloro-4-oxo-3H-pyr do[4.3-dlpyrimidin-5-vDaminolindo l-l-yl1ethoxy1ethoxy1acetyl1amino1-3.3-dimethyl-butanoyl1-4-hvdroxy-N-rr4-(4-methylthiazol-5-vnphenyl1methvnpyrrolidine-2-carboxamide


[005164] A solution of 2-[2-[2-[4-[(7-chloro-4-oxo-3H-pyrido[4,3-d]pyrimidin-5-yl)amino]indol-l-yl]ethoxy] ethoxy]acetic acid (180 mg, 393 umol) in DMF (3.00 mL) was cooled to 0 °C. Then, (2S,4R)-l-[(2S)- 2-amino-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (166 mg, 357 umol, HC1 salt, Intermediate Cl), DIPEA (277 mg, 2.14 mmol) and HATU (163 mg, 428 umol) were added. Then the mixture was stirred at rt for 6 hours. On completion, the reaction mixture was concentrated *in vacuo* to remove the DMF. The residue was diluted with water (40 mL) and extracted with EA (40

mL X 3). The combined organic layers were dried over sodium sulfate and concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (reverse phase (0.1% FA)) to give the title compound to (255 mg, 81% yield) as light yellow solid. LC-MS (ESI^+) *m/z* 870.4 $(M+H)^+$.

[005165] Step 7 - (2S,4R)-1-[(2S)-2-[[2-[2-[2-[4-[[7-[[(1R,2S)-2-aminocyclohexyl]amino]-4-oxo-3H-pyrido [4,3-d]pyrimidin-5-yl]amino]indol-1-yl]ethoxy]ethoxy]acetyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide


[005166] A mixture of (2S,4R)-1-[(2S)-2-[[2-[2-[2-[4-[(7-chloro-4-oxo-3H-pyrido[4,3-d]pyrimidin-5-yl) amino]indol-1-yl]ethoxy]ethoxy]acetyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthi-azol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (100 mg, 114 umol) and (1R,2S)-cyclohexane-1,2-diamine (52.4 mg, 459 umol) in NMP (2 mL) were placed in a sealed tube and stirred at 140°C for 1.5 hours under microwave. On completion, the mixture was purified by prep-HPLC (column: Boston Green ODS 150*30 5u; mobile phase: [water (0.225% FA)-ACN]) to give the title compound **1-189** (21.0 mg, 18% yield) as a white solid. ^{1}**H** NMR (400MHz, DMSO-d_6) δ 11.71 (s, 1H), 8.94 (s, 1H), 8.61 (t, *J* = 5.6 Hz, 1H), 8.35 (s, 2H), 8.30-8.24 (m, 1H), 7.91 (s, 1H), 7.47 - 7.30 (m, 6H), 7.17 (d, *J* = 8.0 Hz, 1H), 7.08 (t, *J* = 5.6 Hz, 1H), 6.57 (d, *J* = *3.2* Hz, 1H), 6.00 (s, 1H), 4.60 (d, *J* = 9.6 Hz, 1H), 4.46 (t, *J* = 8.0 Hz, 1H), 4.39 - 4.31(m, 4H), 4.27 - 4.22 (m, 1H), 3.99 - 3.94 (m, 2H), 3.77 (t, *j* = 5.4 Hz, 2H), 3.71 - 3.65 (m, 2H), 3.63 - 3.60(m, 2H), 3.58 - 3.56 (m, 2H), 3.54 - 3.53 (m, 2H), 2.53 - 2.52 (m, 2H), 2.41 (s, 3H), 2.07 (s, 1H), 1.97 - 1.87 (m, 2H), 1.80 - 1.74 (m, 2H), 1.68 - 1.60 (m, 4H), 1.44 - 1.36 (m, 2H), 1.00 - 0.92 (s, 9H). LC-MS (ESI^+) *m/z* 948.3 $(M+H)^+$.

[005167] Example 190: (2S,4R)-1-[(2S)-2-[[2-[2-[2-[2-[2-[4-[[7-[[(1R,2S)-2-aminocyclohexyl] amino]-4-oxo-3H-pyrido [4,3-d]pyrimidin-5-yl] amino]indol-1-yl] ethoxy] ethoxy] ethoxy] ethoxy] acetyl] amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide, 1-190



[005168] The title compound **1-190** was synthesized as described in the method above for Example 189, using Intermediate BK as the mesylate in the first step which was run at 80 °C for 8 h. Time and temperature variations were as follows: Step 2 was run at 80 °C for 6 h, Step 3 was run at rt for 6 h and Step 7 was run at 150 °C for 1.5 h. Characterization data of the final compound: ^{1}H NMR (400MHz, DMSO-d_6) δ 11.25 (s, 1H), 9.18 (s, 1H), 9.09 (s, 1H), 8.68 (t, J = 5.6 Hz, 1H), 8.30 - 8.28 (m, 3H), 8.20 (s, 1H), 8.10 (d, J = 7.2 Hz, 1H), 7.46 - 7.35 (m, 6H), 7.24 (d, J = 7.6 Hz, 1H), 7.12 (t, J = 7.6 Hz, 1H), 6.51 (d, J = 2.8 Hz, 1H), 6.33 (s, 1H), 4.44 - 4.17 (m, 1OH), 3.90 (s, 2H), 3.79 - 3.37 (m, 18H), 2.44 (s, 3H), 2.13 - 1.83 (m, 4H), 1.79 - 1.56 (m, 4H), 1.48 - 1.34 (m, 2H), 0.92 (s, 9H); LC-MS (ESI$^+$) *m/z* 1036.3 (M+H)$^+$.

[005169] **Example 191: N-[2-[[5-chloro)-2-[5-[2-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yll aminolethoxy|ethoxy|ethoxy|ethoxy|ethoxy|-4-methoxy-2-methyl-anilino]pyrimidin-4-yl1amino1-5-methoxy-phenyl1methanesulfonamide, 1-191**



[005170] Step 1 - N-r2-IT2-(5-benzyloxy-4-methoxy-2-methyl-anilino)-5-chloiO-pyrimidin-4-yl1amino1-5- methoxy-phenyllmethanesulfonamide

[005171] A mixture of N-[2-[(2,5-dichloropyrimidin-4-yl)amino]-5-methoxy-phenyl]methanesulfonamide (1.00 g, 2.75 mmol, Intermediate FE), 5-benzyloxy-4-methoxy-2-methyl-aniline (735 mg, 3.03 mmol, synthesized via Steps 1-3 of Intermediate FE), HC1 in dioxane

(4 M, 996 uL) and IPA(lOmL) was heated in a microwave at l20°C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-column chromatography to give the title compound (1.50 g, 95% yield) as a yellowish solid. LC-MS (ESI^+) *m/z* 570.0 $(M+H)^+$.

[005172] Step 2 - N-r2-IT5-chloro-2-(5-hvdroxy-4-methoxy-2-methyl-anilino)pyrimidin-4-yl1amino1-5- methoxy-phenyllmethanesulfonamide

[005173] To a mixture of N-[2-[[2-(5-benzyloxy-4-methoxy-2-methyl-anilino)-5-chloro-pyrimidin-4-yl]amino] -5-methoxyphenyl]methanesulfonamide (2.50 g, 4.39 mmol) in DCM (20 mL) was added BCl_3·DCM (1 M, 26.34 mL) dropwise at rt. Then the reaction mixture was stirred at rt for 2 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was washed with sat.$NaHC0_3$ (100 mL) and extracted with DCM (3 X 200 mL). Then the combined organic layer was dried with Na_2S0_4, filtered and concentrated *in vacuo.* The residue was purified by prep-column chromatography to give the title compound (l.70g, 80% yield) as a pale solid. LC-MS (ESL) *m/z* 480.1 $(M+H)^+$.

[005174] Step 3 - Benzyl N-[2-[2-[2-[2-[2-[5-[[5-chloro-4-[2-(methanesulfonamido)-4-methoxy-anilinol pyrimidin-2-yl1amino1-2-methoxy-4-methyl-phenoxyl ethoxy] ethoxy] ethoxy] ethoxy] ethyl]carbamate

[005175] To a mixture of N-[2-[[5-chloro-2-(5-hydroxy-4-methoxy-2-methyl-anilino)pyrimidin-4-yl]amino]-5- methoxy-phenyl]methanesulfonamide (150 mg, 312 umol) and 2-[2-[2-[2-[2-(benzyloxycarbonyl amino)ethoxy] ethoxy] ethoxy] ethoxy] ethyl methanesulfonate (168 mg, 375 umol, Intermediate FC) in DMF (10 mL) was added K2CO3 (64.7 mg, 468 umol). Then the reaction mixture was stirred at 100 °C for 12 hours. On completion, the reaction mixture was concentrated *in vacuo.* Then the reaction mixture was purified by reverse phase chromatography to give the title compound (120 mg, 46% yield) as a yellowish oil. LC-MS (ESI^+) *m/z* 833.4 $(M+H)^+$.

[005176] Step 4 - N-[2-[[2-[5-[2-[2-[2-[2-(2-aminoethoxy)ethoxy1ethoxy1ethoxy1ethoxy1-4-methoxy-2-methyl -anilinol -5-chloro-pyrimidin-4- v1]amino] -5-methoxy-phenyllmethanesulfonamide


[005177] To a mixture of benzyl N-[2-[2-[2-[2-[2-[5-[[5-chloro-4-[2-(methanesulfonamido)-4-methoxy-anilino] pyrimidin-2-yl]amino]-2-methoxy-4-methyl-

phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]-ethyl]carbamate (90.0mg, 108 umol) in ACN (500 uL) was added 40% HBr solution (4.47 g, 55.2 mmol, 3.00 mL). Then the reaction mixture was stirred at 60 °C for 6 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was washed with sat.$NaHC0_3$ (30 mL) and extracted with DCM (3 X 50 mL). The organic layer was dried with Na_2S0_4, filtered and concentrated *in vacuo to* give the title compound (55.0 mg, 62% yield) as a yellowish oil. LC-MS (ESI^+) *m/z* 699.1 $(M+H)^+$.

[005178] **Step** 5 - N -[2-[[5-chlθrθ-2-[5-[2-[2-[2-[2-[[2-(2.6-άïoχo -3-ρïρeriάvl)-1.3-άïoχo - isoindolin-4-vl]_ amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-4-methoxy-2-methyl-anilino1pyrimidin-4-yl1amino1-5-methoxy-phenyl]methanesulfonamide

[005179] To a mixture of N-[2-[[2-[5-[2-[2-[2-[2-(2-aminoethoxy)ethoxy] ethoxy] ethoxy] ethoxy] -4-m ethoxy-2- methyl-anilino]-5-chloro-pyrimidin-4-yl]amino]-5-methoxy-phenyl]methanesulfonamide (50.0 mg, 71.5 umol) and 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (23.7 mg, 85.8 umol, Intermediate R) in DMF (2 mL) was added DIPEA (27.7 mg, 214 umol, 37.4 uL). Then the reaction mixture was stirred at 90 °C for 12 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (column: Boston Green ODS 150*30 5u; mobile phase: [water (0.225% FA)-ACN]) to give the title compound **1-191** (14.0 mg, 19% yield) as a white solid. ^1H NMR (400MHz, DMSO-t/$_f$) δ 11.11 (s, 1H), 8.66 (s, 1H), 8.40 (s, 1H), 8.23 (s, 1H), 7.96 (s, 1H), 7.81 (d, *J* = 8.8 Hz, 1H), 7.62 - 7.54 (m, 1H), 7.13 (d, *J* = 8.8 Hz, 1H), 7.04 (d, *J* = 7.2 Hz, 1H), 6.90 (s, 1H), 6.83 *(d, J* = 2.8 Hz, 1H), 6.80 (s, 1H), 6.60 (t, *J* = 5.6 Hz, 1H), 6.31 (s, 1H), 5.08 - 4.99 (m, 1H), 3.93 - 3.86 (m, 2H), 3.76 (s, 3H), 3.68 (s, 3H), 3.67 - 3.63 (m, 3H), 3.62 - 3.58 (m, 4H), 3.56 - 3.52 (m, 8H), 3.50 (s, 3H), 3.05 (s, 1H), 2.95 - 2.84 (m, 2H), 2.79 (s, 3H), 2.09 (s, 3H), 2.04 - 2.00 (m, 1H); LC-MS (ESI^+) *m/z* 955.4 $(M+H)^+$.

[005180] **Example 192: 12S.4RV1-[(2S)-2-[[2-[2-[2-[2-[2-[5-[[5-chloro-4-[2-[methanesulfonamidol-4-methoxy- anilinolpyrimidin-2-yllaminol-2-methoxy-4-methyl-phenoxy] ethoxy] ethoxy] ethoxy] ethoxy] acetyll amino] -3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-14-methylthiazol-5-yl]phenyl1 methyl] pyrrolidine-2-carboxamide, 1-192**



[005181] **Step_ __1_ __-_** Ethyl2-r2-r2-r2-r2-(2-methoxy-4-methyl-5-nitro-phenoxy)ethoxy1 ethoxy] ethoxy] ethoxy] acetate

[005182] To a mixture of 2-methoxy-4-methyl-5-nitro-phenol (500 mg, 2.73 mmol, Intermediate FF) and K2CO3 (1.13 g, 8.19 mmol) in DMF (15 mL) was added ethyl 2-[2-[2-[2-(2-methylsulfonyloxyethoxy)ethoxy] ethoxy] ethoxy] acetate (978 mg, 2.73 mmol, Intermediate BK) at rt. The reaction mixture was then heated to 100 °C and stirred for 1 hour. On completion, the reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (3 X 50 mL). The

combined layer was washed with brine (50 mL), dried over Na_2SO_4, filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by silica gel chromatography (petroleum ether: ethyl acetate = 5:1) to give the title compound (900 mg, 74% yield) as a yellow oil. ¾NMR (400MHz, CDCh) δ 7.73 (s, 1H), 6.71 (s, 1H), 4.27 - 4.18 (m, 4H), 4.15 (s, 2H), 3.94 (s, 3H), 3.93 - 3.88 (m, 2H), 3.76 - 3.66 (m, 12H), 2.62 (s, 3H), 1.29 (t, J = 7.2 Hz, 3H).

[005183] Step 2 - Ethyl 2-[2-[2-[2-/5-amino-2-methoxy-4-methyl-phenoxyiethoxyl ethoxy] ethoxy] ethoxy] acetate

[005184] To a mixture of ethyl 2-[2-[2-[2-[2-(2-methoxy-4-methyl-5-nitro-phenoxy)ethoxy] ethoxy] ethoxy] ethoxy] acetate (550 mg, 1.23 mmol) in EtOAc (10 mL) was added Pd/C (450 mg, 10 wt %) under hydrogen atmosphere (15 psi pressure). The reaction mixture was stirred at rt for 12 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (470 mg, 91% yield) as a light yellow oil. LC-MS (ESI^+) *m/z* 416.2 $(M+H)^+$.

[005185] Step 3 - Isopropyl 2-[2-[2-[2-[2-[5-[[5-chloro-4-[2-(methanesulfonamido)-4-methoxy-anilinol pyrimidin-2-yl1amino1-2-methoxy-4-methyl-phenoxyl ethoxy] ethoxy] ethoxy] ethoxy] acetate

[005186] To a mixture of ethyl 2-[2-[2-[2-[2-(5-amino-2-methoxy-4-methyl-phenoxy)ethoxy] ethoxy] ethoxy] ethoxy] acetate (470 mg, 1.13 mmol) and N-[2-[(2,5-dichloropyrimidin-4-yl)amino]-5-methoxy-phenyl] methanesulfonamide (410 mg, 1.13 mmol, Intermediate FE) in IPA (10 mL) was added HC1 in dioxane (4 M, 409 uL). The reaction mixture was stirred at 120 °C for 1 hour in a microwave. On completion, the reaction mixture was concentrated *in vacuo* to remove the IPA. The residue was poured into 5 mL of water and basified with sat. Na_2CO_3 until the pH = 7-8, then the mixture was extracted with dichloromethane (2 X 10 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (dichloromethane:methanol = 100:1) to give the title compound (226 mg, 26% yield) as a light yellow oil. LC-MS (ESI^+) *m/z* 742.1 $(M+H)^+$.

[005187] Step 4 - 2-[2-[2-[2-[2-[5-[[5-Chloro-4-[2-(methanesulfonamido)-4-methoxy-anilinolpyrimidin-2- vl]L amino1-2-methoxy-4-methyl-phenoxyl ethoxy] ethoxy] ethoxy] ethoxy] acetic acid


[005188] To a mixture of ethyl 2-[2-[2-[2-[2-[5-[[5-chloro-4-[2-(methanesulfonamido)-4-

methoxy-anilino] pyrimidin-2-yl]amino]-2-methoxy-4-methyl-phenoxy] ethoxy] ethoxy] ethoxy] ethoxy] acetate (226 mg, 304 umol) in THF (4 mL) and H_20 (2 mL) was added LiOHH $_20$ (51.1 mg, 1.22 mmol). The reaction mixture was stirred at rt for 12 hours. On completion, the reaction mixture was concentrated *in vacuo* to remove THF. The residue was poured into 5 mL of water and acidified with HC1 until the pH = 6-7, then the mixture was extracted with dichloromethane (3 X 10 mL). The combined organic layers were dried over Na_2S04, filtered and concentrated *in vacuo* to give the title compound (162 mg, 74% yield) as a yellowish solid. ^1H NMR (400MHz, CDCh) δ 8.23 (s, 1H), 7.92 (s, 1H), 7.70 (s, 1H), 7.38 (d, *J* = 8.8 Hz, 1H), 6.99 (s, 1H), 6.94 (d, *J* = 2.4 Hz, 1H), 6.70 (dd, *J* = 2.8, 8.8 Hz, 1H), 6.64 (s, 1H), 4.12 (s, 2H), 3.82 - 3.80 (m, 8H), 3.75 - 3.71 (m, 4H), 3.69 - 3.61 (m, 10H), 2.87 (s, 3H), 2.10 (s, 3H); LC-MS (ESI^+) *m/z* 714.1 $(M+H)^+$.

[005189] Step 5 - (2S,4R)-1-[(2S)-2-гг2-г2-г2-г2-г2-г5-гг5-chloro-4- г2-(methanesulfonamido)-4-methoxy- anilino1pyrimidin-2-yl1amino1-2-methoxy-4-methyl-phenoxy] ethoxy] ethoxy] ethoxy] ethoxy] acetyl]amino] -3,3-dimethyl -butanoyl 1-4-hydroxy-N -[[4-(4-methylthiazol-5-vnphenyl1methyl]pyrrolidine-2-carboxamide

[005190] To a mixture of 2-[2-[2-[2-[2-[5-[[5-chloro-4-[2-(methanesulfonamido)-4-methoxy-anilino]pyrimidin -2-yl]amino]-2- methoxy-4-methyl-phenoxy] ethoxy] ethoxy] ethoxy] ethoxy] acetic acid (80.0 mg, 112 umol) and (2S,4R)-l-[(2S)-2-amino-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl) phenyl]methyl]pyrrolidine-2-carboxamide (48.2 mg, 103 umol HC1, Intermediate Cl) in DMF (3 mL) was added HATU (51.1 mg, 134 umol) and DIPEA (72.3 mg, 560 umol) under nitrogen atmosphere. The reaction mixture was stirred at rt for 3.5 hours. On completion, the reaction mixture was purified prep-HPLC (Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]) to give the title compound **1-192** (24.5 mg, 19% yield) as a white solid. '**H** NMR (400MHz, DMSO-^e) δ 9.00 (s, 1H), 8.62 (t, *J* = 5.6 Hz, 1H), 8.55 (s, 1H), 8.40 (s, 1H), 7.97 (s, 1H), 7.77 (d, *J* = 8.8 Hz, 1H), 7.47 - 7.35 (m, 6H), 6.88 (s, 1H), 6.84 (d, *J* = 2.4 Hz, 1H), 6.79 (s, 1H), 6.40 (s, 1H), 5.18 (d, *J* = 2.4 Hz, 1H), 4.56 (d, *J* = 9.6 Hz, 1H), 4.46 - 4.42 (m, 1H), 4.41 - 4.33 (m, 2H), 4.28 - 4.22 (m, 1H), 3.96 (s, 2H), 3.87 (s, 2H), 3.75 (s, 3H), 3.69 (s, 3H), 3.65 (d, *J* = 3.2 Hz, 2H), 3.59 (s, 2H), 3.55 - 3.49 (m, 11H), 3.03 - 2.96 (m, 1H), 2.82 (s, 3H), 2.44 (s, 3H), 2.08 (s, 3H), 1.92 - 1.90 (m, 1H), 1.66 - 1.54 (m, 1H), 0.94 (s, 9H); LC-MS (ESI^+) *m/z* 1148.2 $(M+H)^+$.

[005191] **Example 193: 3-rraR.2SV2-aminocvclohexyllaminol-5-rri-r2-r2-r2-r2-rr2-(2.,6-dioxo-3-piperidv0-l.,3-dioxo-isoindolin-4-yllaminolethoxylethoxylethoxylethyllindol-4-yl1amino1-l,2,4-triazine-6-carboxamide. 1-193**



[005192] Step 1 - Ethyl 5-rr1-I2-I2-I2-I2-(benzyloxycarbonylamino)ethoxy1ethoxy1ethoxy1ethyl1indol-4-yl1amino1-3-methylsulfanyl-1.2.4-triazine-6-carboxylate

[005193] A mixture of benzyl N-[2-[2-[2-[2-(4-aminoindol- 1-

yl)ethoxy]ethoxy]ethoxy]ethyl]carbamate (250 mg, 566 umol, synthesized via Steps 1-2 of Example 166) and ethyl 5-chloro-3-methylsulfanyl-l,2,4-triazine-6-carboxylate (140 mg, 599 umol, CAS# 75824-03-2) in NMP (3 mL) was stirred at rt for 1 hour. On completion, the residue was purified by reverse phase chromatography (0.1% FA) to afford the title compound (220 mg, 56 % yield) as a yellow oil. LC-MS (ESI^+) *m/z* 639. 1 $(M+H)^+$.

[005194] Step 2 - Benzyl N-r2-r2-r2-r2-r4-r(6-carbamoyl-3-methylsulfanyl- 1.2.4-tri azin-5-vDaminolindol-l- yllethoxylethoxylethoxylethyllcarbamate

[005195] A mixture of ethyl 5-[[l-[2-[2-[2-[2-(benzyloxycarbonylamino)ethoxy]ethoxy]ethoxy]ethyl]indol-4-yl

[005196]]amino]-3-methylsulfanyl-l,2,4-triazine-6-carboxylate (220 mg, 344 umol) in MeOH (15 mL) and 70 N NEE in MeOH (15 mL) was stirred at -40 °C for 1 hour. On completion, the mixture was concentrated *in vacuo* at 45 °C to afford the title compound (180 mg, 81 % yield) as a yellow solid. LC-MS (ESI^+) *m/z* 610.2 $(M+H)^+$.

[005197] Step 3 - Tert-butyl N-I(18.2IO-2-rr5-rr1-I2-I2-I2-I2-(benzyloxycarbonylamino)ethoxy1ethoxy1ethoxy1ethyl1indol-4-yl1amino1-6-carbamoyl-L2.4-triazin-3-yllaminolcvclohexyllcarbamate

[005198] To a mixture of benzyl N-[2-[2-[2-[2-[4-[(6-carbamoyl-3-methylsulfanyl- 1,2,4-triazin-5-yl)amino]indol-l-yl]ethoxy]ethoxy]ethoxy]ethyl]carbamate (180 mg, 295 umol) in DMF (3 mL) was added m-CPBA (150 mg, 869 umol) in one portion at 0 °C under nitrogen. The mixture was stirred at rt for 1 hour. On completion, TEA (255 mg, 2.52 mmol) and tert-butyl N-[(lS,2R)-2-aminocyclohexyl]carbamate (100 mg, 466 umol) was added to above solution. Then the reaction mixture was heated to 65 °C and stirred for 0.5 hour. On completion, the mixture was poured into water (50 mL) and stirred for 2 minutes. The aqueous phase was extracted with ethyl acetate (3 X 50 mL). The combined organic phase was washed with brine (1 X 50 mL), dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo*. The residue was purified by reverse phase chromatography (0.1% FA) to afford the title compound (120 mg, 49% yield) as yellow solid. LC-MS (ESL) *m/z* 776.5 $(M+H)^+$.

[005199] Step 4 - Tert-butyl N-I(18.2IO-2-rr5-rr1-I2-I2-I2-(2-aminoethoxy)ethoxy1ethoxy1ethyl1indol-4-yl1amino1-6-carbamoyl-l .2.4-triazin-3-yllaminolcvclohexyll

[005200] To a mixture of tert-butyl N-[(lS,2R)-2-[[5-[[l-[2-[2-[2-[2-(benzyloxycarbonylamino)ethoxy]ethoxy]ethoxy]ethyl]indol-4-yl]amino]-6-carbamoyl-l,2,4-triazin-3-yl]amino]cyclohexyl]carbamate (120 mg, 154 umol) in EA (10 mL) was added $Pd(OH)_2/C$ (270 mg, 10 wt %) and $NH_3{\cdot}H_2O$ (100 uL) in one portion at rt under a hydrogen atmosphere (15 psi pressure). The mixture was stirred at rt for 16 hours. LCMS showed 30% starting material was not consumed. More $Pd(OH)_2/C$ (150 mg, 10 wt %) was added to above solution, and the mixture was stirred at rt under a hydrogen atmosphere (15 psi pressure)for another 16 hours. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to afford the title compound (100 mg, 70% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 642.3 $(M+H)^+$.

[005201] Step 5 - Tert-butyl N-r(lS.2R)-2-rr6-caibamoyl-5-rrl-r2-r2-r2-r2-rr2-(2.6-dioxo-3-piperidvD-l.3- _ dioxo-isoindolin-4-yl1amino1ethoxy1ethoxy1ethoxy1ethyl1indol-4-yl1amino1-1.2.4-triazin-3-yl1amino1cvclohexyl1carbamate


[005202] To a solution of tert-butyl N-[(lS,2R)-2-[[5-[[l-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethyl]indol-4-yl]amino]-6-carbamoyl-l,2,4-triazin-3-yl]amino]cyclohexyl]carbamate (82.0 mg, 128 umol) and 2-(2,6- dioxo-3-piperidyl)-4-fluoroisoindoline-l,3-dione (38.8 mg, 141 umol, Intermediate R) in DMF (3 mL) was added DIPEA (33.0 mg, 256 umol) under nitrogen atmosphere. The reaction mixture was stirred at 90 °C for 7 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-TLC (DCM:MeOH = 10:1) to afford the title compound (100 mg, 57% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 898.3 $(M+H)^+$.

[005203] Step 6 - 3-[[(1R,2S)-2-aminocyclohexyl]amino]-5-[[1-[2-[2-[2-[2-[[2-(2.6-dioxo-3-piperidvO-E3-dioxo-isoindolin-4-yl1amino1ethoxy1ethoxy1ethoxy1ethyl1indol-4-yl1amino1-1.2.4-triazine-6-carboxamide

[005204] To a solution of tert-butyl N-[(lS,2R)-2-[[6-carbamoyl-5-[[l-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l, 3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethoxy]ethyl]indol-4-yl]amino]-l,2,4-triazin-3-yl]amino]cyclohexyl]carbamate (100 mg, 111 umol) in DCM (3 mL) was added HC1 in dioxane (4N, 2 mL) under a nitrogen atmosphere. The reaction mixture was stirred at rt for 2 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (column: Boston Green ODS 150*30 5u; mobile phase [water (0.225% FA)-ACN]; B%:24%-48%, 10 min) to afford the title compound **1-193** (10.0 mg, 11%

yield). ^{1}H NMR (400MHz, DMSO-^e) δ 12.92 (s, 1H), 8.39 (d, *J* = 12.8 Hz, 3H), 7.95 - 7.85 (m, 1H), 7.79 - 7.71 (m, 1H), 7.69 - 7.52 (m, 1H), 7.45 - 7.32 (m, 1H), 7.31 - 7.21 (m, 1H), 7.20 - 7.09 (m, 2H), 7.09 - 7.01 (m, 1H), 6.62 - 6.50 (m, 1H), 6.49 - 6.40 (m, 1H), 5.10 - 5.01 (m, 1H), 4.45 - 4.32 (m, 2H), 3.95 - 3.82 (m, 1H), 3.80 - 3.60 (m, 2H), 3.55 - 3.45 (m, 14H), 2.93 - 2.81 (m, 1H), 2.59 - 2.63 (m, 2H), 2.06 - 1.95 (m, 1H), 1.89 - 1.72 (m, 2H), 1.68 - 1.49 (m, 4H), 1.45 - 1.25 (m, 3H); LC-MS (ESI$^+$) *m/z* 798.6 (M+H)$^+$.

[005205] **Example 194: 3-[[(1R,2S)-2-aminocyclohexyl]amino]-5-[[1-[2-[2-[2-[2-[2-[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]indol-4-yl]amino]-1,2,4-triazine-6-carboxamide, 1-194**





[005206] 3-[[(1R,2S)-2-aminocyclohexyl]amino]-5-[[1-[2-[2-[2-[2-[2-[2-(2,6-dioxo-3-

piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]indol-4-yl]amino]-l,2,4-triazine-6-carboxamide was synthesized as described for Example 193, using benzyl N-[2-[2-[2-[2-[2-(4-aminoindol-l-yl)ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate (synthesized via Steps 1-2 of Example 167) as the starting material in the first step. In Step 4, the hydrogenation was run at rt with 50 psi pressure of hydrogen. In Step 6, TFA not HC1 was used for the Boc deprotection. The procedure was as follows:

[005207] A mixture of tert-butyl N-[(lS,2R)-2-[[6-carbamoyl-5-[[l-[2-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]indol-4-yl]amino]-l,2,4-triazin-3-yl]amino]cyclohexyl]carbamate (72 mg, 76.4 umol) in TFA (300 uL) and DCM (500 uL) was stirred at rt for 0.5 hour. On completion, the mixture was concentrated *in vacuo*. The residue was purified by column (Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.05% HCCOH)-ACN]; B%: l0%-40%, 12 min) to afford the title compound **I-194** (20 mg, 30% yield) as a yellow solid. ^{1}H NMR (400 MHz, CD_3OD) δ 8.53 (br s, 1H), 7.45 (dd, J = 7.2, 8.8 Hz, 1H), 7.33 (d, J = 3.2 Hz, 1H), 7.27 (d, J = 8.0 Hz, 1H), 7.21 - 7.12 (m, 1H), 7.00 - 6.95 (m, 2H), 6.55 (d, J = 3.2 Hz, 1H), 4.34 (t, J = 4.8 Hz, 2H), 3.81 (t, J = 5.2 Hz, 2H), 3.63 (t, J = 5.6 Hz, 2H), 3.60 - 3.55 (m, 4H), 3.55 - 3.49 (m, 6H), 3.50 - 3.47 (m, 2H), 3.39 (t, J = 5.2 Hz, 2H), 2.85 - 2.64 (m, 2H), 2.16 - 1.93 (m, 2H), 1.90 -1.75 (m, 5H), 1.73 - 1.47 (m, 3H), 1.41 - 1.25 (m, 2H). LC-MS (ESI^+) *m/z* 842.5$(M+H)^+$.

[005208] **Example 195: (2S,4R)-1-[(2S)-2-[[2-[2-[2-[2-[2-[2-[[2-[4-[[7-[[(1R,2S)-2-Aminocyclohexyl]amino]-4-oxo-3H-pyrido[4,3-d]pyrimidin-5-yl]amino]indol-l-yl]acetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]acetyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-[4-methylthiazol-5-yl]phenyl]methyl]pyrrolidine-2-carboxamide, 1-195**


Br
OEt
K_2CO_3, NaI DMF
Pd/C, H_2, THF
FB
NMP
$LiOH·H_2O$
THF, H_2O
H_2N
DW
HATU, DIEA, DMF
LiOH, THF, H_2O



[005209] Step 1 - Ethyl 2-(4-nitroindol-l-vOacetate

[005210] To a solution of 4-nitro-lH-indole (5.00 g, 30.8 mmol, CAS# 4769-97-5) in DMF (100 mL) was added ethyl 2-bromoacetate (7.73 g, 46.3 mmol, 5.12 mL), K2CO3 (12.8 g, 92.5 mmol) and Nal (462 mg, 3.08 mmol). The reaction mixture was stirred at 40 °C for 12 hrs. On completion, the reaction mixture was diluted with water (100 mL) and extracted with dichloromethane (3 X 200 mL). The combined organic layer was washed with brine (200 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo*. The residue was triturated

with ethyl acetate (30 mL) to give the title compound (6.50 g, 85% yield) as a yellow solid. ^{1}H NMR (400MHz, CDCh) δ 8.17 (dd, *J* = 0.8, 8.2 Hz, 1H), 7.59 (d, *J* = 8.2 Hz, 1H), 7.38 - 7.36 (m, 1H), 7.35 - 7.29 (m, 2H), 4.94 (s, 2H), 4.24 (q, *J* = 7.2 Hz, 2H), 1.28 (t, *J* = 7.2 Hz, 3H).

[005211] Step 2 - Ethyl 2-(4-aminoindol-l-vDacetate

[005212] To a solution of ethyl 2-(4-nitroindol-l-yl)acetate (2.60 g, 10.5 mmol) in THF (20 mL) was added Pd/C (260 mg, 10 wt %), and the suspension was degassed and purged with hydrogen gas three times. The mixture was stirred under hydrogen (15 psi pressure) at rt for 12 hrs. On completion, the reaction was filtered and concentrated *in vacuo* to give the title compound (2.20 g, 96% yield) as a colorless oil. ^{1}H NMR (400MHz, CDCh) δ 7.06 (t, *J* = 8.0 Hz, 1H), 7.02 (d, *j* = 3.2 Hz, 1H), 6.72 (d, *j* = 8.0 Hz, 1H), 6.49 (dd, *j* = 0.8, 3.2 Hz, 1H), 6.43 (dd, J = 0.8, 8.0 Hz, 1H), 4.81 (s, 2H), 4.22 (q, *J* = 7.2 Hz, 2H), 1.27 (t, *J* = 7.2 Hz, 3H).

[005213] Step 3 - Ethyl 2-r4-r(7-chloro-4-oxo-3H-pyridor4.3-d1pyrimidin-5-yl)amino1indol-l-yll acetate

[005214] To a solution of ethyl 2-(4-aminoindol-l-yl)acetate (2.20 g, 10.1 mmol) in NMP (40 mL) was added 5,7-dichloro-3H-pyrido[4,3-d]pyrimidin-4-one (2.18 g, 10.1 mmol, Intermediate FB) under nitrogen. The reaction mixture was stirred at 140 °C for 1 hr. On completion, the reaction mixture was concentrated *in vacuo.* The residue was triturated with DMF/MeOH = (5 mL/l0 mL) to give the title compound (3.20 g, 80% yield) as a yellow oil. ^{1}H NMR (400MHz, DMSO-de) δ 12.95 (s, 1H), 11.76 (s, 1H), 8.32 (s, 1H), 8.22 - 8.15 (m, 1H), 7.41 (d, *J* = 3.2 Hz, 1H), 7.21 - 7.l5 (m, 2H), 6.92 (s, 1H), 6.60 (d, *J* = 3.2 Hz, 1H), 5.16 (s, 2H), 4.16 (q, *j* = 7.2 Hz, 2H), 1.22 (t, *j* = 7.2 Hz, 3H).

[005215] Step 4 - 2-r4-r(7-Chloro-4-oxo-3H-pyridor4.3-d1pyrimidin-5-vDamino1indol-l-yllacetic acid

[005216] To a solution of ethyl 2-[4-[(7-chloro-4-oxo-3H-pyrido [4,3-d]pyrimidin-5-yl)amino]indol-l-yl]acetate (2.00 g, 5.03 mmol) in THF (30 mL) and H_20 (10 mL) was added LiOHH $_2$0 (633 mg, 15.0 mmol). The reaction mixture was stirred at rt for 12 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was acidified with HC1 (2 N, 20 mL) to pH = 3. The precipitate was collected by filtration and the solid was dried *in vacuo* to give the title compound (1.80 g, 87% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-i/e) δ 12.98 (s, 2H), 11.78 (s, 1H), 8.31 (s, 1H), 8.22 - 8.13 (m, 1H), 7.41 (d, *J* = 3.2 Hz, 1H), 7.22 - 7.13 (m, 2H), 6.91 (s, 1H), 6.59 (d, *J* = *3.2* Hz, 1H), 5.04 (s, 2H); LC-MS (ESI$^+$) *m/z* 370.0 (M+H)$^+$.

[005217] Step 5 - Ethyl 2-[2-[2-[2-[2-[[2-[4-[(7-chloro-4-oxo-3H-pyrido[4,3-d]pyrimidin-5-yl)amino]indol-1-yl]acetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]acetate

[005218] To a solution of ethyl 2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]acetate (287 mg, 1.03 mmol, Intermediate DW) and 2-[4-[(7-chloro-4-oxo-3H-pyrido[4,3-d]pyrimidin-5-yl)amino]indol-1-yl]acetic acid (380 mg, 1.03 mmol) in DMF (10 mL) was added DIPEA (398 mg, 3.08 mmol). After stirring for 30 minutes, HATU (430 mg, 1.13 mmol) was added. The mixture was stirred at rt for 2 hours. On completion, 50 mL water was added to the mixture. A large quantity of yellow precipitate formed, which was collected by filtration to give the title compound (575 mg, 88% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 631.2 $(M+H)^+$.

[005219] Step 6 - 2-[2-[2-[2-[2-[[2-[4-[(7-Chloro-4-oxo-3H-pyrido[4.3-d]pyrimidin-5-yl)amino]indol-1-

[005220] yl]acetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]acetic acid

[005221] To a mixture of ethyl 2-[2-[2-[2-[2-[[2-[4-[(7-chloro-4-oxo-3H-pyrido[4,3-d]pyrimidin-5-yl)amino] indol-1-yl]acetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]acetate (600 mg, 950 umol) in THF (10 mL) and H2O (10 mL), was added LiOH (228 mg, 9.51 mmol). Then, the mixture was stirred at rt for 5 hours. On completion, the mixture was adjusted to pH = 5 with HC1 (1N), then the mixture was extracted with DCM (2 X 20 mL). The combined organic layer was dried over anhydrous Na_2SO_4, filtered and concentrated *in vacuo* to give the title compound (400 mg, 69% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 603.1 $(M+H)^+$.

[005222] Step 7 - (2S,4R)-1-[(2S)-2-[[2-[2-[2-[2-[2-[[2-[4-[(7-Chloro-4-oxo-3H-pyrido[4.3-d]pyrimidin-5-yl)amino]indol-1-yl]acetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]acetyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide


[005223] A mixture of 2-[2-[2-[2-[2-[[2-[4-[(7-chloro-4-oxo-3H-pyrido[4,3-d]pyrimidin-5-yl)amino]indol-1-yl] acetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]acetic acid (400 mg, 597 umol), (2S,4R)-1-[(2S)-2-amino -3,3-dimethyl -butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (279 mg, 597 umol, HC1 salt, Intermediate Cl), and DIPEA (308 mg, 2.39 mmol) in DMF (20 mL) was degassed and purged with nitrogen gas three times. Then HATU (249 mg, 657 umol) was added, and the mixture was stirred at rt for 2 hours under a nitrogen atmosphere. On completion, the mixture was poured into water (50 mL) and

extracted with DCM (2 X 40 mL). The organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by silica column chromatography to give the title compound (110 mg, 18% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 1037.6 $(M+Na)^+$.

[005224] Step 8 - (2S,4R)-1-[(2S)-2-[[2-[2-[2-[2-[2-[[2-[4-[[7-[[(1R,2S)-2-Aminocyclohexyl]amino]-4-oxo-3H-pyrido[4,3-d]pyrimidin-5-yl]amino]indol-1-yl]acetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]acetyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide

[005225] A mixture of (2S,4R)-1-[(2S)-2-[[2-[2-[2-[2-[2-[[2-[4-[(7-chloro-4-oxo-3H-pyrido[4,3-d]pyrimidin-5-yl)amino]indol-1-yl]acetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]acetyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (60.0 mg, 59.0 umol) and (lR,2S)-cyclohexane-l, 2-diamine (67.4 mg, 590 umol) in NMP (0.5 mL) was heated under microwave irradiation at 150 °C for 1.5 hours. On completion, the mixture was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]) to give the title compound **1-195** (26.0 mg, 40% yield) as a yellow solid. ^1H NMR (400MHz, DMSO-i¾) δ 11.75 (s, 1H), 9.06 - 8.91 (m, 1H), 8.62 (t, J = 6.0 Hz, 1H), 8.39 - 8.32 (m, 2H), 7.93 (s, 1H), 7.49 - 7.29 (m, 6H), 7.14 - 6.99 (m, 2H), 6.58 (d, J = 3.2 Hz, 1H), 6.03 (s, 1H), 4.83 (s, 2H), 4.57 *(d, J* = 9.6 Hz, 1H), 4.49 - 4.33 (m, 3H), 4.25 (m, 2H), 3.97 (s, 2H), 3.71 -3.40 (m, 17H), 3.25 (m, 2H), 2.57 - 2.52 (m, 4H), 2.45 (s, 3H), 2.12 - 2.01 (m, 1H), 1.96 - 1.78 (m, 3H), 1.65 (d, 7 = 11.2 Hz, 4H), 1.41 (s, 2H), 1.00 - 0.88 (m, 9H); LC-MS (ESI^+) *m/z* 1093.2 $(M+H)^+$.

[005226] **Example 196: 3-[[(1R,2S)-2-aminocyclohexyl]amino]-5-[[1-[2-[2-[2-[2-[[(1S)-1-[(2S,4R)-4-hydroxy-2-[[4-(4-methylthiazol-5-yl)phenyl]methylcarbamoyl]pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]amino]-2-oxo-ethoxy]ethoxy]ethoxy]ethyl]indol-4-yl]amino]-1,2,4-triazine-6-carboxamide, 1-196**



[005227] Step 1 - 2-r2-r2-r2-(4-Nitroindol-l-v0ethoxy1ethoxy1ethoxy1acetic acid

[005228] To a mixture of ethyl 2-[2-[2-(2-methylsulfonyloxyethoxy)ethoxy]ethoxy]acetate (1.10 g, 3.51 mmol, Intermediate BI) and 4-nitro-lH-indole (500 mg, 3.08 mmol) in DMF (10 mL) was added CS2CO3 (2.51 g, 7.70 mmol) in one portion at rt under nitrogen. The mixture was stirred at 100 °C for 16 hours. Next, LiOHH $_2$0 (129 mg, 3.08 mmol) in MeOH (3 mL) was then added to above solution, and the solution was stirred at rt for 4 hours. On completion, the mixture was poured into water (50 mL) and stirred for 2 minutes. The aqueous phase was extracted with ethyl

acetate (4 X 50 mL). The combined organic phase was washed with H_20 (2 X 20 mL), the combined aqueous phase was adjusted to pH = 5 with citric acid. The aqueous phase was then extracted with ethyl acetate (4 X 50 mL). The combined organic phase was washed with brine (2 X 50 mL), dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to afford the title compound (1.00 g, 92% yield) as a brown oil. ^1H NMR (400 MHz, CDCh) δ 8.15 (d, *J* = 8.0 Hz, 1H), 7.75 (d, *j* = 8.0 Hz, 1H), 7.47 *(d, J* = 3.2 Hz, 1H), 7.31 - 7.28 (m, 1H), 7.27 - 7.23 (m, 1H), 4.41 (t, *j* = 5.6 Hz, 2H), 4.15 (s, 2H), 3.84 (t, *J* = 5.6 Hz, 2H), 3.72 - 3.64 (m, 2H), 3.63 - 3.47 (m, 6H).

[005229] Step 2 - (2S.4RVl-IY2SV3.3-dimethyl-2-IT2-r2-r2-r2-(4-nitroindol-l-vDethoxy1ethoxy1ethoxy1acetvHamino1butanovH-4-hvdroxy-N-IT4-(4-methylthiazol-5-vnphenyllmethyllpyrrolidine-2-carboxamide

[005230] To a mixture of 2-[2-[2-[2-(4-nitroindol-l-yl)ethoxy]ethoxy]ethoxy]acetic acid (171 mg, 484 umol) and (2S,4R)-l-[(2S)-2-amino-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl] methyl]pyrrolidine-2-carboxamide (200 mg, 428 umol, HC1, Intermediate Cl) in DMF (2 mL) was added TEA (183 mg, 1.80 mmol) and HATU (299 mg, 787 umol) in one portion at rt. The mixture was stirred at rt for 3 hours. On completion, the mixture was poured into water (30 mL) and stirred for 2 minutes. The aqueous phase was extracted with ethyl acetate (3 X 30 mL). The combined organic phase was washed with brine (1 X 20 mL), dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to afford the title compound (270 mg, 82% yield) as a yellow solid. ^1H NMR (400 MHz, CDCh) δ 8.68 (s, 1H), 8.14 (d, *j* = 7.2 Hz, 1H), 7.69 (d, *j* = 8.0 Hz, 1H), 7.45 (d, *j* = 3.2 Hz, 1H), 7.34 (q, *j* = 8.4 Hz, 5H), 7.24 (d, *j* = 4.0 Hz, 2H), 4.73 (t, *J* = 8.0 Hz, 1H), 4.59 - 4.51 (m, 2H), 4.48 (d, *J* = 8.4 Hz, 1H), 4.41 - 4.29 (m, 3H), 4.18 - 4.11 (m, 1H), 4.05 - 3.94 (m, 2H), 3.81 (t, *J* = 5.2 Hz, 2H), 3.77 - 3.68 (m, 1H), 3.63 - 3.53 (m, 8H), 2.82 (br s, 1H), 2.63 - 2.55 (m, 1H), 2.52 (s, 3H), 2.12 (dd, *J* = 8.0, 13.6 Hz, 1H), 0.94 (s, 9H).

[005231] Step 3 - (2S.4RVl-IY2SV2-IT2-r2-r2-r2-(4-aininoindol-l-v0ethoxy1ethoxy1ethoxy1acetyl1amino1-3.3-dimethyl-butanoyl1-4-hvdroxy-N-rr4-(4-methylthiazol-5-vnphenyl1methyl1pyrrolidine-2-carboxamide

[005232] To a mixture of (2S,4R)-l-[(2S)-3,3-dimethyl-2-[[2-[2-[2-[2-(4-nitroindol-l-yl)ethoxy] ethoxy] ethoxy] acetyl]amino]butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (270 mg, 353 umol) in EA(l0 mL) was added Pd/C

(100 mg, 10 wt %) in one portion at it under hydrogen (15 psi pressure). The mixture was stirred at rt for 16 hours. On completion, the mixture was filtered and concentrated *in vacuo* to afford the title compound (200 mg, 77.1% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 757.1 $(M+Na)^+$.

[005233] Step 4 - Ethyl 5-[[1-[2-[2-[2-[2-[[(1S)-1-[(2S,4R)-4-hydroxy-2-[[4-(4-methylthiazol-5-yl)phenyl]methylcarbamoyl]pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]amino]-2-oxo-ethoxy]ethoxy]ethoxy]ethyl]indol-4-yl]amino]-3-methylsulfanyl-1,2,4-triazine-6-carboxylate

[005234] A mixture of (2S,4R)-1-[(2S)-2-[[2-[2-[2-[2-(4-aminoindol-1-yl)ethoxy]ethoxy]ethoxy]acetyl]amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (200 mg, 272 umol) and ethyl 5-chloro-3-methylsulfanyl-1,2,4-triazine-6-carboxylate (64.8 mg, 278 umol) in NMP (2 mL) was stirred at rt for 1 hour. On completion, the mixture was purified by reverse phase flash column (0.1% FA) to afford the title compound (200 mg, 79% yield) as a blue oil. LC-MS (ESI^+) *m/z* 932.7 $(M+H)^+$.

[005235] Step 5 - 5-[[1-[2-[2-[2-[2-[[(1S)-1-[(2S,4R)-4-hydroxy-2-[[4-(4-methylthiazol-5-yl)phenyl]methylcarbamoyl]pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]amino]-2-oxo-ethoxy]ethoxy]ethoxy]ethyl]indol-4-yl]amino]-3-methylsulfanyl-1,2,4-triazine-6-carboxamide


[005236] To a mixture of ethyl 5-[[1-[2-[2-[2-[2-[[(1S)-1-[(2S,4R)-4-hydroxy-2-[[4-(4-methylthiazol-5-yl)phenyl]methylcarbamoyl]pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]amino]-2-oxo-ethoxy]ethoxy]ethoxy]ethyl]indol-4-yl]amino]-3-methylsulfanyl-1,2,4-triazine-6-carboxylate (200 mg, 215 umol) in MeOH (300 uL) was added 17 N NEE in MeOH (300 uL) in one portion at -40 °C under nitrogen. The mixture was stirred at -40 °C for 1 hour. On completion, the mixture was concentrated at reduced pressure at 45°C. The residue was purified by reverse phase flash column (0.1% FA) to afford the title compound (160 mg, 78% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 903.4 $(M+H)^+$.

[005237] Step 6 - 3-[[(1R,2S)-2-aminocyclohexyl]amino]-5-[[1-[2-[2-[2-[2-[[(1S)-1-[(2S,4R)-4-hydroxy-2-[[4-(4-methylthiazol-5-yl)phenyl]methylcarbamoyl]pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]amino]-2-oxo-ethoxy]ethoxy]ethoxy]ethyl]indol-4-yl]amino]-1,2,4-triazine-6-carboxamide

[005238] 5-[[1-[2-[2-[2-[2-[[(1S)-1-[(2S,4R)-4-hydroxy-2-[[4-(4-methylthiazol-5-

yl)phenyl]methylcarbamoyl]pyrrolidine-l-carbonyl]-2, 2-dimethyl -propyl]amino]-2-oxo-ethoxy]ethoxy]ethoxy]ethyl]indol-4-yl]amino]-3-methylsulfanyl-l,2,4-triazine-6-carboxamide (150 mg, 166 umol) and (lR,2S)-cyclohexane-l, 2-diamine (200 mg, 1.75 mmol) dissolved in a microwave tube in NMP (3 mL). The sealed tube was heated at 150 °C for 1.5 hours under microwave. On completion, the residue was purified by column (Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.05% HCl)-ACN]; B%: l0%-40%, 12 min) to afford the title compound **1-196** (107 mg, 60% yield) as a red solid. ¾ NMR (400 MHz, DMSO-d«) δ 12.91 (s, 1H), 9.24 (d, *J* = 7.2 Hz, 1H), 9.15 - 9.08 (m, 1H), 8.90 - 8.70 (m, 1H), 8.70 - 8.60 (m, 1H), 8.49 - 8.39 (m, 1H), 8.44 - 8.34 (m, 2H), 7.94 (d, *J* = 7.6 Hz, 1H), 7.51 - 7.37 (m, 7H), 7.27 - 7.18 (m, 1H), 6.52 (d, *J* = 2.4 Hz, 1H), 4.55 (d, *J* = 10.8 Hz, 1H), 4.44 (t, *j* = 8.2 Hz, 2H), 4.40 - 4.34 (m, 5H), 4.30 - 4.24 (m, 1H), 4.20 - 1.12 (m, 1H), 3.73 (d, *J* = 4.8 Hz, 2H), 3.66 - 3.60 (m, 2H), 3.59 - 3.47 (m, 12H), 2.43 (s, 3H), 2.11 - 2.03 (m, 1H), 1.93 - 1.80 (m, 4H), 1.70 -1.60 (m, 3H), 1.45 - 1.30 (m, 2H), 0.93 (s, 9H); LC-MS (ESI$^+$) *m/z* 969.5 $(M+H)^+$.


[005239] Example 197: 3-[[(1R,2S)-2-aminocyclohexyl]amino]-5-[[1-[2-[2-[2-[2-[2-[[HSVl-[12S.,4RV4-hydroxy-2-[[4-(4-methylthiazol-5-vBphenyl]methylcarbamoyl]pyrrolidine-l-carbonyl]-2.,2-dimethyl-propyl]amino]-2-oxo-ethoxy]ethoxy]ethoxy]ethoxy]ethyl]indol-4-yl]amino]-1,2,4-triazine-6-carboxamide, 1-197



[005240] 3-[[(lR,2S)-2-aminocyclohexyl]amino]-5-[[l-[2-[2-[2-[2-[2-[[(lS)-l-[(2S,4R)-4-hydroxy-2-[[4-(4-methylthiazol-5-yl)phenyl]methylcarbamoyl]pyrrolidine-l-carbonyl]-2,2-dimethyl-propyl]amino]-2-oxo-ethoxy]ethoxy]ethoxy]ethoxy]ethyl]indol-4-yl]amino]-l,2,4-triazine-6-carboxamide **1-197** was synthesized as described for Example 196, using Intermediate BK as the mesylate in the first step. Characterization of the final compound: ^{1}H NMR (400 MHz, DMSO-di) δ 12.93 (s, 1H), 9.26 (d, *J* = 8.0 Hz, 1H), 9.21 - 9.17 (m, 1H), 8.77 - 8.65 (m, 1H), 8.67 (t, *j* = 5.6 Hz, 1H), 8.45 (br s, 1H), 8.36 (br s, 2H), 7.94 (d, *j* = 7.6 Hz, 1H), 7.52 - 7.42 (m, 4H), 7.40 (s, 5H), 7.37 - 7.27 (m, 1H), 6.52 (d, *j* = 2.8 Hz, 1H), 4.55 (d, *J* = 9.6 Hz, 1H), 4.46 - 4.38

(m, 2H), 3.95 (s, 2H), 3.73 (*d*, *J* = 5.2 Hz, 2H), 3.71 - 3.65 (m, 1H), 3.68 - 3.26 (m, 20H), 2.46 - 2.40 (m, 3H), 2.10 - 2.03 (m, 1H), 1.95 - 1.75 (m, 5H), 1.68 - 1.58 (m, 4H), 1.45 - 1.25 (m, 2H), 0.92 (s, 9H); LC-MS (ESI$^+$) *m/z* 1013.3 $(M+H)^+$.

[005241] **Example 198: 5-rraS.2Ry2-aminocvclohexyllaminol-7-r3-r2-r2-r2-r2-rr2-12.6-dioxo-3-piperidvP- 1,3-_ _dioxo-isoindolin-4-yll aminol ethoxy]ethoxy]ethoxy]ethoxy]-5-methoxy-anilinolimidazo[l,2-c|pyrimidine-8-carboxamide, 1-198**



[005242] Step 1 - Benzyl 12-12-12-12-13-118-carbamoyl-5-lm ethylthio)imidazoFl*2*-clpyrimidin-7-vOaminoy 5-methoxyphenoxy)ethoxy)ethoxy)ethoxy)ethv0carbamate

[005243] To a solution of 7-(3-hydroxy-5-methoxy-anilino)-5-methylsulfanyl-imidazo[l,2-c]pyrimidine-8- carboxamide (300 mg, 869 umol, Intermediate EZ) in DMF (10 mL) was added K2CO3 (480 mg, 3.47 mmol) and 2-[2-[2-[2-

(benzyloxycarbonylamino)ethoxy]ethoxy]ethoxy]ethyl methanesulfonate (1.76 g, 4.34 mmol, Intermediate EY) under nitrogen atmosphere. The reaction mixture was stirred at 100 °C for 12 hrs. On completion, the reaction mixture was concentrated *in vacuo*. The residue was extracted with ethyl acetate (100 mL) and filtered. The filtrate was concentrated *in vacuo*. The residue was purified by reverse phase chromatography (0.1% $NH_3 \cdot H_2O$) to give the title compound (380 mg, 67% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 655.1 $(M+H)^+$.

[005244] Step 2 - Benzyl *(2-(2-(2-(2-(3-((5-(((\ S.2R)-2-aminocvclohexyl)amino)-8-carbamoylimidazo [1,2-c]pyrimidin-7-vl)amino)-5-methoxyphenoxy)ethoxy)ethoxy)ethoxy)ethvPcarbamate

[005245] A solution of benzyl *N*-[2-[2-[2-[2-[3-[(8-carbamoyl-5-methylsulfanyl-imidazo[l,2-c]pyrimidin-7-yl)-amino]-5-methoxy-phenoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate (200 mg, 305 umol) and (lR,2S)-cyclohexane-1,2-diamine (38.4 mg, 336 umol) in DMF (5 mL) was heated to 90 °C for 12 hrs. On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (220 mg, 100% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 721.1 $(M+H)^+$.

[005246] Step 3 - Tert-butyl N-I(1R,2S)-2-rr7-I3-I2-I2-I2-I2-(benzyloxycarbonylamino)ethoxylethoxylethoxyl ethoxy1-5-methoxy-anilino1-8-carbamoyl-imidazorl.2-c1pyrimidin-5-yl1amino1cvclohexyl1carbmate

[005247] To a solution of benzyl /V-[2-[2-[2-[2-[3-[[5-[[(l S,2R)-2-aminocyclohexyl]amino]-8-carbamoyl-imidazo[l,2-c]pyrimidin-7-yl]amino]-5-methoxy-phenoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate (220 mg, 305 umol) in methanol (3 mL) was added I_2 (7.75 mg, 30.5 umol) and $(Boc)_20$ (133 mg, 610 umol) at rt. The reaction mixture was stirred at rt for 6 hrs. On completion, the reaction mixture was concentrated *in vacuo*. The residue was purified by silica gel chromatography (dichloromethane: methanol = 20:1) to give the title compound (230 mg, 91% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 821.1 $(M+H)^+$.

[005248] Step 4 - Tert-butyl N-I(1R,2S)-2-rr7-I3-I2-I2-I2-(2-aminoethoxy)ethoxy1ethoxy1ethoxy1-5-methoxy- anilino1-8-carbamoyl-imidazorL2-c1pyrimidin-5-vnaminolcvclohexyllcarbamate

[005249] To a solution of tert-butyl /V-[(lR,2S)-2-[[7-[3-[2-[2-[2-[2-(benzyloxycarbonylamino)ethoxy]ethoxy] ethoxy]ethoxy]-5-methoxy-anilino]-8-carbamoyl-

imidazo[l,2-c]pyrimidin-5-yl]amino]cyclohexyl]carbamate (230 mg, 280 umol) in ethyl acetate (3 mL) was added $Pd(OH)_2/C$ (120 mg, 280 umol, 10 wt %) under nitrogen atmosphere. The suspension was degassed and purged with hydrogen three times. The mixture was stirred under hydrogen gas (15 psi pressure) at rt for 12 h. On completion, the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give the title compound (130 mg, 65% yield) as yellow oil. LC-MS (ESI^+) *m/z* 687.2 $(M+H)^+$.

[005250] Step 5 - Tert-butyl N-[(1R,2S)-2-[[8-carbamoyl-7-[3-[2-[2-[2-[2-[2-(2.6-dioxo-3-piperidvO-l.3- _ ___dioxo-isoindolin-4-yl1amino1ethoxy1ethoxy1ethoxy1ethoxy1-5-methoxy-anilino1imidazorl.2-c1pyrimidin-5-vnamino1cvclohexyl1carbamate


[005251] To a solution of tert-butyl /V-[(lR,2S)-2-[[7-[3-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]-5- methoxy-anilino]-8-carbamoyl-imidazo[l,2-c]pyrimidin-5-yl]amino]cyclohexyl]carbamate (130 mg, 189 umol) and 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (57.5 mg, 208 umol, Intermediate R) in DMF (4 mL) was added DIPEA (73.4 mg, 568 umol) under nitrogen. The reaction mixture was stirred at 90 °C for 12 h. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by reverse phase chromatography to give the title compound (70.0 mg, 39% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 943.1 $(M+H)^+$.

[005252] Step 6 - 5-[[(1S,2R)-2-aminocyclohexyl]amino]-7-[3-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidvl)-1,3-_ ___dioxo-isoindolin-4-yl1amino1ethoxy1ethoxy1ethoxy1ethoxy1-5-methoxy-anilino1imidazorL2-c1pyrimidine-8-carboxamide

[005253] To a solution of tert-butyl /V-[(lR,2S)-2-[[8-carbamoyl-7-[3-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3- dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]-5-methoxy-anilino]imidazo[l,2-c]pyrimidin-5-yl]amino]cyclohexyl]carbamate (70.0 mg, 74.2 umol) in DCM (4 mL) was added HC1 in dioxane (4 M, 4.00 mL) at rt. The reaction mixture was stirred at rt for 1 hour. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (column: Boston pH-lex 150*25 lOum; mobile phase: [water (0.225%FA)-ACN]; B%: 20%-50%) to give the title compound **1-198** (13.5 mg, 21% yield) as a white solid. ^{1}HNMR (400MHz, DMSO-7,) δ 12.39 (s, 1H), 9.55 (d, *J* = 3.2 Hz, 1H), 8.36 (s, 1H), 8.12 (s, 1H), 7.57 - 7.53 (m, 1H), 7.40 (d, 7 = 3.6 Hz, 1H), 7.32 (d, *j* = 1.6 Hz, 1H), 7.10 (d, *j* = 8.4 Hz, 1H), 7.01 (d, *J* = 6.8 Hz, 1H), 6.93 (s, 1H), 6.67 (s, 1H), 6.58 (t, *J* = 5.6 Hz, 1H), 6.20 (s, 1H), 5.06 - 5.02 (m, 1H), 4.20 (d, 7 = 11.2 Hz, 1H), 4.08 - 4.04 (m, 2H), 3.74 (s, 3H), 3.71 (s, 2H), 3.62 (s, 2H), 3.59 -


3.50 (m, 12H), 2.92 - 2.81 (m, 1H), 2.62 - 2.58 (m, 2H), 2.28 - 2.26 (m, 1H), 2.04 - 1.94 (m, 2H), 1.82 - 1.64 (m, 4H), 1.56 - 1.53 (m, 2H), 1.46 - 1.33 (m, 2H); LC-MS (ESI^+) *m/z* 843.4 $(M+H)^+$.

[005254] Example 199: Tert-butyl ((1R,2S)-2-((8-carbamoyl-7-((3-((14-((2-(2,6-dioxopiperidin-3-yP-l.,3-dioxoiso indolin-4-vPamino)-3.,6.,9.,12-tetraoxatetradecvPoxyV5-methoxyphenvPamino)imidazo[l.,2-c]pyrimidin-5-vPamino)cvclohexyPcarbamate, 1-199



[005255] Tert-butyl ((lR,2S)-2-((8-carbamoyl-7-((3-((l4-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoiso indolin-4-yl)amino)-3,6,9,l2-tetraoxatetradecyl)oxy)-5-methoxyphenyl)amino)imidazo[l,2-c]pyrimidin-5-yl)amino)cyclohexyl)carbamate **1-199** was synthesized as described above for Example 198 using Intermediate FC as the mesylate. Step 1 was run at 60 C for 12 h. Characterization of the final product: ^1H NMR (400MHz, DMSO-r/$_3$) δ 12.39 (s, 1H), 9.55 (s, 1H), 8.36 (s, 2H), 8.13 (s, 1H), 7.58 - 7.53 (m, 1H), 7.39 (s, 1H), 7.32 (s, 1H), 7.11 (d, *J* = 8.4 Hz, 1H), 7.02 (d, *J* = 6.8 Hz, 1H), 6.93 (s, 1H), 6.67 (s, 1H), 6.58 (s, 1H), 6.21 (s, 1H), 5.04 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.22 (d, *J* = 10.4 Hz, 1H), 4.07 (s, 2H), 3.74 (s, 3H), 3.71 (s, 2H), 3.64 - 3.56 (m, 18H), 2.89 - 2.85 (m, 2H), 2.63 - 2.60 (m, 2H), 2.27- 2.65 (m, 1H), 1.80 - 1.72 (m, 1H), 1.71 -1.65 (m, 4H), 1.56 - 1.52 (m, 2H), 1.45 - 1.51 (m, 2H); LC-MS (ESI^+) *m/z* 887.4 $(M+H)^+$.

[005256] Example 200: 5-((YlS.,2RV2-aminocyclohexyPamin(p-7-(Y4-(2-(2-(2-(2-(Y2-(2,6-dioxopiperidin-3-vP-l ,3- dioxoisoindolin-4-vPamino)ethoxy)ethoxy)ethoxy)ethoxy)-3,5-dimethoxyphenyPamino)imidazo[l.,2-clpyrimidine-8-carboxamide, 1-200



[005257] Step 1 - Benzyl (2-(2-(2-(2-(4-((8-carbamoyl-5-(methylthio)imidazo[1,2-c]pyrimidin-7-yl)amino)-2,6-dimethoxyphenoxy)ethoxy)ethoxy)ethoxy)ethyl)carbamate

[005258] To a mixture of 7-(4-hydroxy-3,5-dimethoxy-anilino)-5-methylsulfanyl-imidazo[1,2-c]pyrimidine-8- carboxamide (200 mg, 532 umol, Intermediate FA) in DMF (3 mL) was added 2-[2-[2-[2-(benzyloxycarbonylamino) ethoxy]ethoxy]ethoxy]ethylmethanesulfonate (237 mg, 586 umol, Intermediate EY) and K2CO3 (220 mg, 1.60 mmol). Then the reaction mixture was stirred at 70 °C for 12 hours. On completion, the reaction mixture was washed with water (50

mL) and extracted with ethyl acetate (2 X 50 mL). The combined organic layer was dried with Na_2SO_4, filtrated and concentrated *in vacuo*. The residue was purified by prep-column chromatography (PE:EA = 3:1 to DCM:MeOH = 20:1) to give the title compound (172 mg, 47% yield) as a yellow oil. LC-MS (ESI^+) *m/z* 685.0 $(M+H)^+$.

[005259] Step 2 - 7-((4-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)ethoxy)-3.5-dimethoxyphenyl)amino)-5- (methylthio)imidazo[1,2-c]pyrimidine-8-carboxamide

[005260] To a mixture of benzyl N-[2-[2-[2-[2-[4-[(8-carbamoyl-5-methylsulfanyl-imidazo[1,2-c]pyrimidin-7-yl)amino]-2,6-dimethoxyphenoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate (200 mg, 292 umol) in CH_3CN (2 mL) was added HBr in HOAc (32.9 mg, 292 umol, 1 mL). Then the reaction mixture was stirred at 50 °C for 1 hour. On completion, the reaction mixture was quenched with sat. $NaHCO_3$ (3 X 30 mL) and extracted with DCM (3 X 30 mL). The organic layer was dried with Na_2SO_4, filtrated and concentrated *in vacuo*. The residue was purified by reverse phase chromatography (0.1% FA in water) to give the title compound (70.0 mg, 43% yield) as a yellowish oil.

[005261] Step 3 - 7-((4-(2-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)aminoethoxy) ethoxy)ethoxy)ethoxy)-3.5-dimethoxyphenyl)amino)-5-(methylthio)imidazo[1.2-c]pyrimidine-8-carboxamide


[005262] To a mixture of 7-[4-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]-3,5-dimethoxy-anilino]-5- methylsulfanyl-imidazo[1,2-c]pyrimidine-8-carboxamide (70.0 mg, 127 umol) and 2-(2,6-dioxo-3- piperidyl)-4-fluoro-isoindoline-1,3-dione (38.6 mg, 139 umol, Intermediate R) in DMF (1.5 mL) was added DIPEA (32.8 mg, 254 umol). Then the reaction mixture was stirred at 90 °C for 8 hours. On completion, the reaction mixture was concentrated *in vacuo*. The residue was purified by prep-TLC (PE:EA = 0:1) to give the title compound (30.0 mg, 23% yield) as a yellowish solid. LC-MS (ESI^+) *m/z* 829.1 $(M+Na)^+$.


[005263] Step 4 - 5-(((1S,2R)-2-aminocyclohexyl)amino)-7-((4-(2-(2-(2-(2-((2-(2.6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)ethoxy)-3.5-dimethoxyphenyl)aminoimidazo[1.2-c]pyrimidine-8-carboxamide

[005264] To a mixture of 7-[4-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethoxy] ethoxy]ethoxy]ethoxy]-3,5-dimethoxy-anilino]-5-methylsulfanyl-imidazo[1,2-c]pyrimidine-8-carboxamide (30.0 mg, 37.1 umol) in DMF (1 mL) was added (1R,2S)-cyclohexane-1, 2-diamine (8.49 mg, 74.3 umol). Then the reaction mixture was stirred at

90 °C for 8 hours. On completion, the reaction mixture was concentrated *in vacuo*. The residue was purified by prep-HPLC (column: Boston Green ODS 150*30 5u; mobile phase: [water (0.225% FA)-ACN]; B%: 20%-44%, 10 min) to give the title compound **1-200** (6.00 mg, 18% yield) as a yellowish oil. ^{1}H NMR (400MHz, DMSO-de) δ 12.19 (s, 1H), 9.53 (d, *J* = 2.8 Hz, 1H), 8.36 (s, 1H), 8.12 (s, 1H), 7.57 (t, *J* = 7.6 Hz, 1H), 7.37 (d, *J* = 3.2 Hz, 1H), 7.32 (s, 1H), 7.14 (d, *J* = 8.4 Hz, 1H), 7.03 (d, *J* = 7.2 Hz, 1H), 6.91 - 6.76 (m, 2H), 6.61 (t, *j* = 5.6 Hz, 1H), 5.05 (dd, *J* = 5.6, 12.0 Hz, 1H), 4.19 (d, 7 = 10.4 Hz, 1H), 4.12 - 4.06 (m, 1H), 4.05 - 3.99 (m, 1H), 3.93 (d, *J* = 4.8 Hz, 1H), 3.79 (s, 6H), 3.64 - 3.63 (m, 4H), 3.56 - 3.50 (m, 8H), 2.94 - 2.88 (m, 2H), 2.08 - 1.85 (m, 3H), 1.76 - 1.19 (m, 9H); LC-MS (ESI$^+$) *m/z* 873.1 (M+H)$^+$.

[005265] Example 201: (±)-2-(2,6-Dioχo-3-ρiρeridνl)-4-[2-[2-[2-[2-[2-[5-[[4-[6-(3-ethylpiperazin-l-yB-3-pyridyll pyrimidin-2-yl] amino]-2,3-dimethoxyphenoxy] ethoxy] ethoxy] ethoxy] ethoxy] ethylamino] isoindol ine-1,3-dione, 1-201


NO2
MeO
OMe
OH
FG
MsO
NHCbz
FC
K2CO3, DMF
Fe, NH4Cl
ethanol, H2O
NH2
FH
Boc
Pd(OAc)2, BINAP, Cs2CO3
toluene, 4A MS
Pd/C, H2
MeOH
HN
F
R
DIPEA, DMF
NH



[005266] Step 1 - Benzyl N-[2-[2-[2-[2-[2-(2,3-dimethoxy-5-nitro-phenoxy)ethoxy] ethoxy] ethoxy] ethoxy] ethyl] carbamate

[005267] To a mixture of 2-[2-[2-[2-[2-(benzyloxycarbonylamino)ethoxy]ethoxy]ethoxy]ethoxy]ethyl methane sulfonate (606 mg, 1.35 mmol, Intermediate FC) in DMF (10 mL) was added 2,3-dimethoxy-5-nitro-phenol (268 mg, 1.35 mmol, Intermediate FG) and potassium carbonate (559 mg, 4.05 mmol). Then the reaction mixture was stirred at 70 °C for 12 hours. On completion, the reaction mixture was washed with water (20 mL) and extracted with ethyl acetate (3 X 30 mL). The combined organic layer was dried with anhydrous sodium sulfate, filtered and concentrated *in vacuo*. The residue was purified by column (petroleum ethenethyl acetate = 1:1 to dichloromethane:methanol = 20:1) to give the title compound (610 mg, 74% yield) as a yellowish oil. LC-MS (ESI^+) *m/z* 553.1 $(M+H)^+$.

[005268] Step 2 - Benzyl N-r2-r2-r2-r2-r2-(5-amino-2.3-dimethoxy-phenoxy)ethoxy1 ethoxy] ethoxy] ethoxy] ethyllcarbamate

[005269] To a solution of benzyl N-[2-[2-[2-[2-[2-(2,3-dimethoxy-5-nitro-phenoxy)ethoxy] ethoxy] ethoxy] ethoxy]ethyl]carbamate (460 mg, 832 umol) in water (2 mL) and ethanol (8 mL) was added ammonium chloride (445 mg, 8.32 mmol) and Fe (464 mg, 8.32 mmol). The reaction mixture was stirred at 78 °C for 1 hour. On completion, the reaction mixture was filtered and concentrated *in vacuo*. The residue was purified by silica gel chromatography (dichloromethane:methanaol = 50:1) to give the title compound (430 mg, 98% yield) as a yellow

oil. ¾NMR (400MHz, CDCh) δ 7.37 - 7.35 (m, 5H), 6.03 - 5.82 (m, 2H), 5.52 (br s, 1H), 5.16 - 5.07 (m, 2H), 4.19 - 4.08 (m, 2H), 3.84 (d, *J* = 5.6 Hz, 2H), 3.81 (s, 3H), 3.77 (s, 3H), 3.74 - 3.70 (m, 2H), 3.68 - 3.63 (m, 10H), 3.59 - 3.55 (m, 3H), 3.44 - 3.39 (m, 2H); LC-MS (ESI^+) *m/z* 523.1 $(M+H)^+$.

[005270] Step 3 -(±>Tert-butyl 4-[5-[2-[3-[2-[2-[2-[2-(benzyloxycarbonylaminolethoxy] ethoxy]ethoxy] ethoxy]ethoxy]-4.5-dimethoxyanilino1pyrimidin-4-yl1-2-pyridyl1-2-ethyl-piperazine-l-carboxylate

[005271] To a solution of (±)-tert-butyl 2-ethyl-4-[5-(2-methylsulfonylpyrimidin-4-yl)-2-pyridyl]piperazine-l- carboxylate (200 mg, 446 umol, Intermediate FH) and benzyl N-[2-[2-[2-[2-[2-(5-amino-2,3-dimethoxyphenoxy)ethoxy] ethoxy]ethoxy]ethoxy]ethyl]carbamate (233 mg, 446 umol) in toluene (3 mL) was added $Pd(OAc)_2$ (10.0 mg, 44.6 umol), BINAP (41.7 mg, 67.0 umol), cesium carbonate (436 mg, 1.34 mmol) and 4AMS (1.00 g, 446 umol) under nitrogen. The reaction mixture was stirred at 100 °C for 12 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo.* The residue was purified by reverse phase chromatography (0.1% FA in water) to give the title compound (160 mg, 32% yield) as a yellow oil. ^1H NMR (400MHz, CDCh) δ 8.87 (d, *J* = 2.4 Hz, 1H), 8.34 *(d, J* = 5.2 Hz, 1H), 8.20 (dd, *J* = 2.4, 9.2 Hz, 1H), 7.37 - 7.29 (m, 5H), 7.19 (d, *j* = 2.0 Hz, 1H), 7.03 (d, *j* = 5.2 Hz, 1H), 6.92 (s, 1H), 6.65 (d, *J* = 9.2 Hz, 1H), 5.59 (br s, 1H), 5.09 (s, 2H), 4.36 - 4.24 (m, 2H), 4.20 (t, *J* = 4.8 Hz, 2H), 4.16 - 3.97 (m, 2H), 3.91 (s, 3H), 3.87 (t, *J* = 4.8 Hz, 2H), 3.84 (s, 3H), 3.72 (d, *J* = 4.8 Hz, 2H), 3.63 - 3.61 (m, 10H), 3.57 - 3.53 (m, 2H), 3.42 - 3.36 (m, 2H), 3.24 (dd, *J* = 4.0, 13.2 Hz, 1H), 3.18 - 3.01 (m, 2H), 1.66 - 1.56 (m, 2H), 1.50 (s, 9H), 0.92 (t, *J* = 7.2 Hz, 3H).

[005272] Step 4 -(±VTert-butyl 4-[5-[2-[3-[2-[2-[2-[2-(2-aminoethoxylethoxy] ethoxy]ethoxy]ethoxy]-4,5-di methoxy-anilino1pyrimidin-4-yl1-2-pyridyl1-2-ethyl-piperazine-l -carboxylate

[005273] To a mixture of (±)-tert-butyl 4-[5-[2-[3-[2-[2-[2-[2-[2-(benzyloxycarbonylamino)ethoxy]ethoxy] ethoxy]ethoxy]ethoxy]-4,5-dimethoxy-anilino]pyrimidin-4-yl]-2-pyridyl]-2-ethyl-piperazine-l-carboxylate (160 mg, 179 umol) in NH3·H2O (50 uL) and methanol (6 mL) was added $Pd(OH)_2/C$ (60.0 mg, 10 wt %). Then the reaction mixture was stirred at rt for 10 hours under hydrogen (50 psi pressure). On completion, the reaction mixture was concentrated *in vacuo* to give the title compound (130 mg, 95% yield) as a yellowish oil. LC-MS (ESI^+) *m/z* 756.4 $(M+H)^+$.

[005274] Step 5 - (±>Tert-butyl 4-I5-I2-I3-I2-I2-I2-I2-I2-rr2-(2.6-(1ïoχo-3-piperidyl)-1·3-dioxo-isoindolin-4-yll _ _____amino] ethoxy] ethoxy] ethoxy] ethoxy] -4¸5-dimethoxy-anilino1pyrimidin-4-yl1-2-pyridyl1-2-ethyl-piperazine-l-carboxylate


[005275] To a mixture of (±)-tert-butyl 4-[5-[2-[3-[2-[2-[2-[2-(2-aminoethoxy)ethoxy] ethoxy] ethoxy] ethoxy] -4, 5-dimethoxyanilino]pyrimidin-4-yl]-2-pyridyl]-2-ethyl-piperazine-l-carboxylate (70.0 mg, 92.6 umol) in DMF (2 mL) was added (±)-2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (28.1 mg, 101 umol, Intermediate R) and DIPEA (29.9 mg, 231 umol, 40.4 uL). Then the reaction mixture was stirred at 90 °C for 12 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-TLC (dichloromethane :methanaol = 20:1) to give the title compound (40.0 mg, 40% yield) as a yellowish solid. LC-MS (ESI^+) *m/z* 1012.2 $(M+H)^+$.


[005276] Stеp 6 - (±>2-(2.6- Diοχ ο-3-ριρеriάνη-4-I2-I2-I2-I2-I2-I5-rr4-I6-(3-ethylpiperazin-l-vO-3-pyridvn _ _____pyrimidin-2-yl1amino1-2.3-dimethoxyphenoxy] ethoxy] ethoxy] ethoxy] ethoxy] ethyl aminoli soindoline- 1¸3-dione

[005277] To a mixture of (±)-tert-butyl 4-[5-[2-[3-[2-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-iso indolin-4-yl] amino] ethoxy] ethoxy] ethoxy] ethoxy] ethoxy] -4, 5-dimethoxy-anilino]pyrimidin-4-yl]-2-pyridyl]-2-ethyl-piperazine-l-carboxylate (73.0 mg, 72.1 umol) in a mixture of methanol (1 mL) and dichloromethane (1 mL) was added 4M HC1 in dioxane (72.1 umol, 1.00 mL) at 0 °C. Then the reaction mixture was allowed to warm to rt and stirred for 2 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (column: Boston Green ODS 150*30 5u; mobile phase: [water (0.225% FA)-ACN]; B%: 27%-48%, 10 min) to give the title compound **1-201** (35.0 mg, 53% yield) as a yellowish solid. ^1H NMR (400MHz, DMSO-7 ₅) δ 11.12 (s, 1H), 9.39 (s, 1H), 8.93 (s, 1H), 8.42 (d, *J* = 5.6 Hz, 1H), 8.26 (d, *J* = 9.2 Hz, 1H), 7.56 (t, *J* = 7.6 Hz, 1H), 7.34 - 7.22 (m, 3H), 7.16 - 7.09 (m, 1H), 7.06 - 6.99 (m, 1H), 6.98 - 6.88 (m, 1H), 6.67 - 6.54 (m, 1H), 6.58 (t, *j* = 5.6 Hz, 1H), 5.05 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.39 - 4.19 (m, 2H), 4.11 (d, *J* = 3.6 Hz, 2H), 3.79 (s, 3H), 3.65 (s, 3H), 3.63 - 3.57 (m, 6H), 3.56 - 3.52 (m, 2H), 3.54 - 3.50 (m, 6H), 3.47 - 3.41 (m, 4H), 3.00 (d, 7 = 11.6 Hz, 2H), 2.86 (d, *J* = 12.0 Hz, 3H), 2.75 - 2.64 (m, 3H), 2.10 - 1.95 (m, 1H), 1.50 - 1.34 (m, 2H), 0.95 (t, *J* = 7.6 Hz, 3H); LC-MS (ESI^+) *m/z* 912.2 $(M+H)^+$.

[005278] **Example 202: _(2S,4R)-1-[(2S)-2-[[2-[2-[2-[2-[2-[5-[[4-[6-(3-ethylpiperazin-l-yl)-3-pyridyl]pyrimidin-2-yl] _ _____amino] -2,3-dimethoxy-**

phenoxyl ethoxyl ethoxyl ethoxyl ethoxyl acetyll aminol -3,3-dimethyl-butanoyll-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide, I-202





[005279] Step 1 - Ethyl2-r2-r2-r2-r2-r2-r3-r(8-carbamoyl-5-methylsulfanyl-imidazorl.2-clpyrimidin-7- yl)

[005280] amino] -5-methoxy-phenoxyl ethoxy] ethoxy] ethoxy] ethoxy] ethoxy] acetate

[005281] To a solution of 2,3-dimethoxy-5-nitro-phenol (510 mg, 2.56 mmol, Intermediate FG) and ethyl 2-[2-[2-[2-(2-methyl sulfonyloxyethoxy)ethoxy]ethoxy]ethoxy]acetate (1.10 g, 3.07 mmol, Intermediate BK) in DMF (15 mL) was added K2CO3 (1.06 g, 7.68 mmol). The mixture was stirred at 50 °C for 12 hours. On completion, the reaction mixture was diluted with water (20 mL) and extracted with DCM (3 X 30 mL). The combined organic layer was dried over sodium sulfate, filtered and concentrated *in vacuo* to give a residue. The residue was purified by column chromatography (PE:EA = 1:1) to give the title compound (1.10 g, 93% yield) as a light yellow oil. ^{1}H NMR (400MHz, CDCb) δ 7.55 (d, *J* = 2.4 Hz, 1H), 7.50 (d, *J* = 2.4 Hz, 1H), 4.26 - 4.16

(m, 4H), 4.13 (s, 2H), 3.95 (s, 3H), 3.92 (s, 3H), 3.90 (m, 2H), 3.74 - 3.63 (m, 12H), 1.27 (t, *J* = 14.4 Hz, 3H); LC-MS (ESI^+) *m/z* 431.1 $(M+l8)^+$.

[005282] Step 2 - ethyl 2-r2-r2-r2-r2-(5-amino-2.3-dimethoxy-phenoxy)ethoxy1 ethoxy] ethoxy] ethoxy] acetate

[005283] To a solution of ethyl 2-[2-[2-[2-[2-(2,3-dimethoxy-5-nitro-phenoxy)ethoxy] ethoxy] ethoxy] ethoxy] acetate (600 mg, 1.30 mmol) in MeOH (8 mL) was added Pd/C (300 mg, 10 wt %) under nitrogen atmosphere. The suspension was degassed and purged with hydrogen gas three times. The mixture was stirred under hydrogen (15 psi pressure) at rt for 12 hours. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (400 mg, 71% yield) as a red oil. ^1H NMR (400MHz, CDCh) δ 5.97 (s, 1H), 5.94 (s, 1H), 4.26 - 4.18 (m, 1H), 4.22 (q, *J* = 7.2 Hz, 1H), 4.16 - 4.09 (m, 4H), 3.87 - 3.83 (m, 2H), 3.80 (s, 3H), 3.76 (s, 3H), 3.74 - 3.65 (m, 12H), 1.31 - 1.27 (t, *J* = 7.2 Hz, 3H); LC-MS (ESI^+) *m/z* 432.1 $(M+H)^+$.

[005284] Step 3 - Ethv1-2-I2-I2-I2-I2-I2-I3-rr5-rr(18.2Rv2-(tert-butoxycarbonylamino)cvclohexyl1amino1-8-carbamoyl-imidazorE2-c1pyrimidin-7-yl1amino1-5-methoxy-phenoxyl ethoxy] ethoxy] ethoxy] ethoxy] ethoxy] acetate

[005285] To a solution of ethyl 2-[2-[2-[2-[2-(5-amino-2,3-dimethoxy-phenoxy)ethoxy] ethoxy] ethoxy] ethoxy] acetate (300 mg, 695 umol) and tert-butyl 2-ethyl-4-[5-(2-methylsulfonylpyrimidin-4-yl)-2- pyridyl]piperazine-l-carboxylate (311 mg, 695 umol, Intermediate FH) in toluene (10 mL) was added 4A MS (600 mg), CS_2CO_3 (679 mg, 2.09 mmol), BINAP (64.9 mg, 104 umol) and $Pd(OAc)_2$ (15.6 mg, 69.5 umol) under nitrogen atmosphere. The suspension was degassed and purged with nitrogen three times. The mixture was stirred at rt for 1 h, and then heated to 100 °C for 12 hours. On completion, the reaction mixture was concentrated under reduced pressure to remove the toluene. The residue was diluted with water (5 mL) and extracted with DCM (3 X 6 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase chromatography (0.1% FAin water) to give the title compound (400 mg, 72% yield) as a yellowish solid. LC-MS (ESI^+) *m/z* 799.2 $(M+H)^+$.

[005286] Step 4 - 2-[2-[2-[2-[2-[5-[[4-[6-(4-tert-butoxycarbonyl-3-ethyl-piperazin-l-vl)-3-pyridyllpyrimidin- 2-yl1amino1-2.3-dimethoxy-phenoxy1ethoxy1ethoxy1ethoxy1ethoxy1acetic

acid

[005287] To a solution of tert-butyl 4-[5-[2-[3-[2-[2-[2-[2-(2-ethoxy-2-oxo-ethoxy)ethoxy] ethoxy] ethoxy] ethoxy]-4,5-dimethoxy-anilino]pyrimidin-4-yl]-2-pyridyl]-2-ethyl-piperazine-l-carboxylate (200 mg, 250 umol) in THF (6 mL) was added a solution of LiOH (52.5 mg, 1.25 mmol) in H_20 (1 mL). The reaction mixture was stirred at rt for 3 hours. On completion, the mixture saturated citric acid aqueous solution (0.3 mL) was added to the mixture to adjust the pH to 5. The residue was diluted with 3 mL water and extracted with DCM (3 X 5 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to give title compound (193 mg, 100% yield) as a yellowish oil.

[005288] Step 5 - Tert-butyl 2-ethyl-4-[5-[2-[3-[2-[2-[2-[2-[2-[(1S)-1-[(2S,4R)-4-hydroxy-2-[[4-(4-methyl thiazol-5-yl)phenyl]methylcarbamoyl]pyrrolidine- 1-carbonyl 1-2.2-dim ethyl-propyl 1amino1-2-oxo-ethoxy1ethoxy1ethoxy1ethoxy1ethoxy1-4.5-dimethoxy-anilino1pyri midin-4-vH-2-pyridyllpiperazine- 1-carboxylate

[005289] To a solution of 2-[2-[2-[2-[2-[5-[[4-[6-(4-tert-butoxycarbonyl-3-ethyl-piperazin-l-yl)-3-pyridyl] pyrimidin-2-yl]amino]-2,3-dimethoxy-phenoxy] ethoxy] ethoxy] ethoxy] ethoxy] acetic acid (192 mg, 250 umol), (2S,4R)-l-[(2S)-2-amino-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl) phenyl]methyl]pyrrolidine-2-carboxamide (129 mg, 300 umol, Intermediate Cl), and DIPEA (96.9 mg, 750 umol) in DMF (5 mL) was added HATU (114 mg, 300 umol) at 0 °C. The reaction mixture was then allowed to warm to rt and stirred for 16 hours. On completion, the reaction mixture was concentrated under reduced pressure to remove DMF, then diluted with water (15 mL) and extracted with DCM (3 X 10 mL). The combined organic layers were dried over sodium sulfate, and concentrated *in vacuo* to give a residue. The residue was purified by reverse phase chromatography (0.1% FA in water) to give the title compound (210 mg, 71% yield). LC-MS (ESI^+) *m/z* 1183.2 $(M+H)^+$.

[005290] Step 6 - (2S,4R)-l-[(2S)-2-[[2-[2-[2-[2-[2-[5-[4-[6-(3-ethylpiperazin-l-yl)-3-Pyridyllpyrimidin-2- yl]_ amino]-2.3-dimethoxy-phenoxy] ethoxy] ethoxy] ethoxy] ethoxy] acetyl]amino]-3,3-dimethyl -butanoyl 1-4-hydroxy-N -[[4-(4-methylthiazol-5-vnphenyl]methyl1pyrrolidine-2-carboxamide

[005291] To a solution of tert-butyl 2-ethyl-4-[5-[2-[3-[2-[2-[2-[2-[2-[[(lS)-l-[(2S,4R)-4-hydroxy-2- [[4-(4-methylthiazol-5-yl)phenyl]methylcarbamoyl]pyrrolidine-l-carbonyl]-2,2-dimethyl-propyl]amino]-2-oxo-ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-4,5-dimethoxy-

anilino]pyrimidin-4-yl]-2-pyridyl]piperazine-l-carboxylate (210 mg, *111* umol) in MeOH (3 mL) was added HC1 in dioxane (4 M, 5 mL). Then the mixture was stirred at rt for 15 mins. On completion, the reaction mixture was concentrated under reduced pressure to remove solvent to give a residue. The residue was purified by prep-HPLC (column: Luna C18 150*25 5u; mobile phase: [water (0.225%FA)-ACN]) to give the title compound **1-202** (118 mg, 61% yield). ¾NMR (400MHz, DMSO-i/e) δ 9.40 (s, 1H), 8.95 (s, 1H), 8.93 (d, *J* = 1.6 Hz, 1H), 8.61 (*J* = 4.0 Hz, 1H), 8.42 (d, *J* = 5.6 Hz, 1H), 8.32 - 8.22 (m, 2H), 7.47 - 7.34 (m, 5H), 7.29 *(d, J* = 5.6 Hz, 1H), 7.25 (d, *J* = 6.4 Hz, 2H), 6.97 (d, *J* = 9.6 Hz, 1H), 4.55 (d, *J* = 9.6 Hz, 1H), 4.47 - 4.32 (m, 4H), 4.29 - 4.19 (m, 2H), 4.13 - 4.04 (m, 2H), 3.94 (s, 2H), 3.81 - 3.72 (m, 6H), 3.68 - 3.58 (m, 14H), 3.13 - 3.04 (m, 1H), 2.98 (m, 1H), 2.83 - 2.73 (m, 1H), 2.67 (d, *J* = 6.4 Hz, 2H), 2.42 (3H), 2.10 - 2.01 (m, 1H), 1.94 - 1.84 (m, 1H), 1.49 - 1.43 (m, 2H), 1.01 - 0.85 (m, 12H); LC-MS (ESI$^+$) *m/z* 1083.2 $(M+H)^+$.

[005292] **Example 203: PBMC degradation assay**

[005293] Protocol summary of PBMC degradation studies from compound treatment through quantitation.

[005294] **Table 13. Cell Culture Materials**

Reagent	Vendor	Catalogue no.
6 well plate	Falcon	353046
Frozen PBMCs	AllCells	PB006F, PB005F or PB004F
RPMI	Gibco	11875-093
FBS, certified one-shot	Gibco	A31604-02
Pen/Strep 1000 units/mL	Gibco	10378016
DMSO	Sigma	D8418-50mL
2.0mL centrifuge tubes	Corning	311-10-051
PBS	Gibco	10010-023

[005295] PBMC culture medium: Human peripheral blood mononuclear cells (PBMCs): RPMI+l0%FBS (Heat-inactivated) +l%P/S.

[005296] **Table 14. Lysate preparation and Western Reagents.**

Reagent	Vendor	Catalogue no.
LDS Sample Buffer (4x)	Life Technologies	NP0008
Reducing Agent (10x)	Invitrogen	NP0009
Molecular Grade diH2O	Corning	46-000-CV
96 well PCR plate	Eppendorf	951020346_EA

SDS-Page protein gel (4-12% Bis-Tris) 20 well	Invitrogen	WG1402BOX
20x MES running buffer (20x)	Invitrogen	NP0002
TransBlot Turbo RTA Midi LF PVDF transfer kit, for 40 blots	BioRad	1704275
10x RIPA buffer	Cell Signaling Technologies	9806
HALT Protease and Phosphatase Inhibitor Cocktail (100x)	Thermo Scientific	1861281
Odyssey Blocking buffer (TBS)	Licor	927-50000
TBST 10x	Cell Signaling Technologies	9997
Molecular Weight Markers	Licor	928-40000

[005297] **Table 15. Antibodies.**

Antibody	Vendor	Catalogue no.
IRAK1	Cell Signaling Technologies	4504S
IRAK4	Cell Signaling Technologies	4363S
IRAK3	Cell Signaling Technologies	4369S
MYD88	Abcam	133739
Actin	Licor	926-42212
Goat anti-rabbit IRDye 800CW	Licor	926-32211
Goat anti-mouse IRDye 680CW	Licor	926-68070

[005298] **Table 16. Equipment.**

Equipment	Vendor	Catalogue no.
XCell Surelock Midi Cell	Invitrogen	WR0100
TransBlot Turbo transfer system	BioRad	1704150
Odyssey CLx	Licor	

[005299] **Protocol Summary**

- Frozen human PBMCs were thawed into culture medium.

- A cell count/viability assessment by trypan blue exclusion was performed. Cells were cultured at a minimum of 2.5xl0 ^{6} c/mL.
- PBMCs were incubated @ 37 °C/5% C0 $_{2}$ and allowed to rest overnight.
- Following overnight recovery, a cell count/viability assessment by trypan blue exclusion was performed. Cells densities were adjusted back to 2.5xl0 ^{6} c/mL (proceed with plating only if viability >80%).
- In a 6 well plate, 2.0 mL of cells were added to each well for a minimum of 5xl0 ^{6} CT per treatment condition. Compounds dilltutions were prepared from 20 mM stock and were added at a final lOOOx dilution (0.1% DMSO concentration).
- At the end of treatment, cells were harvested and spun @ 1800 rpm for 5 min. lxPBS wash and spun again @ 1800 rpm for 5min. Cell pellets were frozen and stored at -80 °C until further processing.
- Lysates were generated by resuspending in lysis buffer. Protein quantification was performed with a BCA kit.
- 20 μg of protein were loaded per lane and run on a 26-well 4-12% Bis-Tris SDS-page gel.
- Transfers were performed on PVDF membranes using the BioRad Mixed MW turbo program for 7 min.
- Membranes were blocked for one hour on a rocker at room temperature.
- Primary antibodies were incubated overnight at 4 °C on a rocker.
- Membranes were washed 3x TBST, 5 min each.
- Secondaries were added and incubated for one hour on a rocker at room temperature.
- Membranes were washed 3x TBST, 5 min each and rinsed well with deionized FLO. Membranes were scanned using the Licor Odessey CLx and bands were quantified using Image Studio Lite Version 5.2 software.

[005300] PBMC results at 4 hours. The letter codes indicate the percentage of IRAK4 degraded after 4 hours: A (>50% degradation), B (>20-50% degredation) and C (<20% degredation)

[005301] Table 17. PBMC % IRAK4 Degradation Results.

Compound Number	PBMC % IRAK4 Degradation
I-53	A

I-104	C
I-106	A
I-108	C
I-109	B
I-109	B
I-110	A
I-111	B
I-112	A
I-116	A
I-117	A
I-127	A
I-128	A
I-130	A
I-132	B
I-132	C
I-133	B
I-134	C
I-141	A
I-144	A
I-145	C
I-146	A
I-150	A
I-152	C
I-154	B
I-155	C
I-156	C
I-157	C
I-158	C
I-159	A
I-171	A

I-172	A
I-179	C
I-180	A
I-181	B
I-182	B
I-183	B
I-185	A
I-186	C

[005302] **Example 204: THP-1 and OCI-LY-10 degradation assay**

[005303] **Methods**

[005304] **Compound treatment:**

[005305] Compounds were reconstituted in DMSO to make stock solutions at concentration of 60 mM. THEM and OCI-LY10 cells were maintained in RPMI-1640 medium containing 10% FBS, 0.5 μM 2-ME or 20% FBS, 55 μM 2-ME, and 1% L-Glutamine respectively.

[005306] Cells were seeded into 6-well plates with 5e6 cells per well. 200 pL of diluted compounds were added to cells to the final concentration of 0.003 - 10 pM. After 4 or 24 hour-incubation at 37 °C, cells were collected into 2 mL Eppendorf tubes and centrifuged at 1,000 rpm for 5 min. The cell pellets were washed with 1xDPBS once and resuspended in 60 pL lysis buffer. The cells were lysed on ice for 10 min, then centrifuged at 14,000 rpm for 10 min at 4 °C and the supernatants were collected for western blots. For THP-l cells, the lysis buffer contained 40 mM pH 7.4 HEPES, 140 mM NaCl, 2.5 mM EDTA, 1% NP-40, 0.1% SDS, and protease inhibitor cocktail (Roche, Cat. No.0589279l00l). For OCI-LY10 cells, RIPA buffer (Thermo Fisher, 89900) with Halt Protease and Phophatase Inhibitor Cocktail (Thermo Fisher, 78446) was applied.

[005307] **Protein concentration determination:**

[005308] The protein concentration of cell lysates was quantified with Pierce™ BCA Protein Assay Kit (Pierce, 23227). Albumin standards at different concentrations were prepared, involving 2,000 ug/mL, 1,500 ug/mL, 1,000 ug/mL, 750 ug/mL, 500 ug/mL, 250 ug/mL, 125 ug/mL, and 25 ug/mL. BCA working reagents were prepared by mixing BCA reagent A with reagent B in 50 : 1 ratio. 200 pL of the BCA working reagents were added to 25 pL of BCA standard or cell lysates in microplate, and mixed thoroughly on a plate shaker for 30 seconds. After incubation at 37 °C

for 30 min, the absorbance of samples at 562 nm were measured with EnVision Plate Reader.

[005309] Western blot assay:

[005310] Protein lysates were prepared in NuPAGE™ LDS sample buffer and NuPAGE™ sample reducing agent, and incubated at 95 °C for 5 min. For western blots, 20 - 25 μg of total proteins were resolved in 4 - 12% Bis-Tris gels (Introgen, WG1403A) or 10% Bis-Tris Midi gels (Invitrogen, WG1202BOX) running with l xMOPS SDS running buffer (Invitrogen, NP0001) or lxMES SDS running buffer (Invitrogen, NP0002). The proteins were transferred to low fluorescence PVDF membranes using the Trans-Blot Turbo Transfer System. Membranes were then blocked in Odyssey blocking buffer at RT for 1 h followed by primary incubation at 4 °C overnight. The primary antibodies were IRAK1 rabbit monoclonal antibody (CST, #4504S, 1:500), IRAK3 rabbit polyclonal antibody (CST, #4369, 1:500), IRAK4 rabbit polyclonal antibody (CST, #4363S, 1:1,000), MyD88 rabbit monoclonal antibody (Abeam, AM33739, 1:2,000), β-actin mouse monoclonal antibody (Sigma, A5441, 10,000), and Gapdh mouse monoclonal antibody (Millipore, MAB374, 1:5,000). Membranes were washed three times with lxTBST, and then incubated with IR Dye 800 CW Goat anti-rabbit (Licor, #926-32211) and IR Dye 700 CW Goat anti-mouse (Licor, #926-68070) secondary antibodies in 1:10,000 dilution at RT for 1 h. The western blot images were obtained using Odyssey Imaging System.

[005311] THP-l results at 24 hours. The letter codes indicate the percentage of IRAK4 degraded after 24 hours: A (>50% degradation), B (>20-50% degredation) and C (<20% degredation)

[005312] Table 18. THP-l % IRAK4 Degradation Results.

Compound Name	THP-1 24 h % IRAK4 Degradation
I-1	B
I-2	C
I-3	C
I-4	A
I-5	B
I-6	B
I-7	B
I-8	C

I-10	C
I-11	C
I-12	C
I-13	C
I-14	C
I-15	A
I-16	C
I-19	C
I-25	B
I-30	C
I-40	C
I-43	C
I-47	B
I-48	B
I-49	B
I-50	B
I-51	C
I-52	C
I-55	C
I-58	C
I-96	C
I-97	B
I-98	B
I-99	C
I-100	B
I-119	B
I-120	C
I-122	C
I-162	A
I-163	C

I-164	C
I-165	C
I-189	C
I-194	C
I-195	C
I-198	C
I-199	C
I-200	C
I-203	B

[005313] OCI-LY-10 results at 4 hours. The letter codes indicate the percentage of IRAK4 degraded after 4 hours: A (>50% degradation), B (>20-50% degredation) and C (<20% degredation)

[005314] **Table 19. OCI-LY-10 % IRAK4 Degradation Results.**

Compound Name	**OCI-LY10 % IRAK4 Degradation**
I-9	C
I-17	C
I-18	B
I-21	C
I-22	C
I-26	C
I-27	C
I-29	C
I-31	C
I-32	C
I-33	C
I-34	C
I-35	C
I-36	C

I-37	C
I-38	C
I-39	C
I-41	C
I-42	C
I-44	B
I-45	C
I-46	C
I-54	C
I-56	C
I-57	C
I-59	C
I-60	C
I-61	C
I-62	C
I-63	C
I-64	C
I-65	C
I-66	C
I-67	C
I-68	C
I-69	C
I-70	C
I-71	C
I-72	C
I-73	C
I-74	C
I-75	C
I-76	C
I-77	C

I-78	C
I-79	C
I-80	C
I-81	C
I-82	C
I-83	C
I-84	C
I-85	C
I-86	C
I-87	C
I-88	C
I-89	C
I-90	B
I-91	C
I-92	A
I-93	C
I-94	B
I-95	C
I-101	C
I-102	C
I-103	C
I-105	A
I-107	C
I-113	C
I-114	C
I-115	B
I-118	C
I-121	C
I-123	C
I-124	C

I-125	C
I-126	B
I-129	C
I-131	C
I-135	B
I-136	B
I-137	B
I-138	A
I-139	B
I-140	B
I-142	B
I-143	B
I-147	A
I-148	B
I-149	A
I-151	A
I-153	C
I-160	C
I-161	C
I-169	C
I-170	B
I-173	C
I-174	C
I-175	C
I-176	C
I-177	C
I-178	C
I-184	C
I-187	B
I-188	C

I-204	C
I-205	C
I-207	C
I-208	C
I-209	C

[005315] OCI-LY-10 results at 4 hours. The letter codes for % IRAK4 degradation indicate the percentage of IRAK4 degraded after 4 hours across three different concentrations: A (>50% degradation), B (>20-50% degredation) and C (<20% degredation).

[005316] **Table 19a. OCI-LY-10 % IRAK4 Degradation**

Compound Name	OCI-LY10 % IRAK4 Degradation (0.01 uM)	OCI-LY10 % IRAK4 Degradation (0.1 uM)	OCI-LY10 % IRAK4 Degradation (1 uM)
I-210	C	B	A
I-211	B	B	B
I-212	B	A	A
I-215	A	A	A
I-219	A	A	A
I-220	B	B	B
I-221	B	B	A
I-222	A	A	A
I-224	B	A	A
I-225	C	A	A
I-226	B	A	A
I-227	B	A	A
I-228	A	A	A
I-229	C	C	C
I-230	C	C	C

I-231	A	A	A
I-233	C	A	A
I-234	C	B	B
I-235	C	A	A
I-236	C	B	A
I-238	C	B	A
I-239	C	C	C
I-240	B	B	B
I-241	B	A	A
I-242	B	A	A
I-243	C	C	C
I-244	C	B	B
I-245	C	B	A
I-246	C	A	A
I-247	B	A	A
I-248	B	A	A
I-249	C	A	A
I-250	C	A	A
I-252	B	A	A
I-254	C	C	B
I-255	C	C	C
I-256	B	A	A
I-257	C	C	C
I-258	C	B	C
I-259	C	C	C
I-260	C	C	C

I-262	C	B	B
I-263	C	C	C
I-264	C	C	C
I-265	B	A	A
I-266	C	A	A
I-267	C	A	B
I-269	C	B	A
I-270	C	B	A
I-272	C	B	A
I-275	C	B	A
I-276	C	B	A
I-277	C	A	A
I-278	C	B	A
I-279	C	A	A
I-281	C	A	A
I-282	C	C	C
I-283	A	A	A
I-284	C	C	C
I-285	C	C	B
I-287	C	C	B
I-288	C	C	A
I-290	B	B	B
I-297	C	C	C
I-302	B	A	A
I-303	B	A	A
I-304	C	C	C

I-305	A	A	A
I-306	C	B	B
I-307	C	C	C
I-308	B	A	A
I-309	B	A	A
I-310	C	A	A
I-311	C	A	A
I-312	C	A	A
I-313	C	B	C
I-313	B	A	A
I-314	C	B	B
I-315	C	C	B
I-316	B	B	B
I-317	C	C	B
I-318	C	A	B
I-319	B	A	A
I-320	C	B	B
I-321	B	A	A
I-322	C	C	A
I-323	B	A	A
I-324	B	A	B
I-325	B	A	A
I-326	B	C	C
I-327	C	B	A
I-328	A	A	A
I-329	B	A	A

I-330	C	A	A
I-331	C	B	C
I-332	A	A	A
I-333	C	C	C
I-335	C	C	A
I-336	C	C	B
I-337	C	A	A
I-338	C	B	B
I-339	C	B	A
I-340	C	A	A
I-341	C	A	A
I-342	C	B	A
I-343	C	B	A
I-344	C	A	A
I-345	C	A	A
I-346	B	A	A
I-347	C	A	A
I-348	C	C	A
I-349	C	B	A
I-350	C	C	B
I-351	C	C	A
I-352	C	C	C
I-353	C	C	C
I-354	C	A	A
I-355	B	B	C
I-356	C	C	C

I-357	C	C	C
I-358	C	C	C
I-359	C	C	C
I-360	B	C	C
I-361	C	C	C
I-362	C	B	A
I-363	C	C	C
I-364	C	C	C
I-365	C	C	C
I-366	C	C	C
I-367	B	B	A
I-369	B	B	B
I-370	C	B	B
I-371	C	C	B
I-372	C	C	C
I-372	C	C	C
I-374	C	B	B
I-375	B	B	B
I-376	B	A	A
I-377	C	C	B
I-378	C	C	A
I-380	C	C	C
I-381	B	A	A
I-382	C	C	B
I-383	C	C	A
I-385	C	B	B

I-386	C	B	A
I-387	C	C	B
I-389	C	C	A
I-392	B	A	A
I-393	C	A	A
I-394	C	A	A
I-395	C	B	B
I-397	B	A	A
I-424	B	B	B
I-425	B	A	A
I-426	C	C	C
I-427	B	A	A
I-434	C	C	C
I-435	C	C	C

[005317] **Example 204a: OCI-LY-10 DCso**

[005318] A MSD assay was **ran** to determine the concentration of compound required to degrade 50% of protein (DCso).

[005319] **MSD Assay DCso Protocol**

[005320] **Day 1**

- Compounds were reconstituted to 10 mM in stock solutions. The stock solutions were diluted to 5mM and 45 μL of each dilution was transferred to a 384 pp-plate. A 3 fold, 8-point serial dilution was performed by transferring 15 pL of compound into 30 pL DMSO using Janus.
- 20 nL of each compounds were added into each well of a 96-well plate (Corning3799).
- OCI-LylO cells were seeded into the 96-well plate at 3.0*l0e ^{5} cells/lOO pL/well.
- The cell plate was shaken at 720 rpm for 5 min and incubated for 4 hr.
- The 100 pL of cells were transferred into the 96-PCR plate and spun down at high speed for 5 mins.
- The supernatant was discarded and 100 pL of RIPA lysis buffer with proteinase inhibitors

was added per well. The plate was then sealed and shaken at 600 rpm and 4 °C for about 20 min.

- The plate was then spun down at high speed (about 3200g) for 30 min and then frozen in a -80°C fridge.
- A bare MSD plate (Ll 5XA-3) was coated with 2 pg/mL of capture antibody (mouse Anti-IRAK4 antibody [2H9], abl 19942) in PBS to 40 pL/well and incubated overnight at 4 °C.

[005321] Day 2

- The MSD coated plate was washed 3x (150 pL/well) with lx TBST (CST#9997S).
- The MSD plate was then blocked with 150 pL of blocking buffer [3% Blocker A (MSD, R93BA-4) in TBST]/well and shaken for 1 hr at RT and 600 rpm.
- The MSD plate was washed 3x (150 pL/well) with lx TBST. The sample RIPA lysates were then added to the MSD plate (50 pL/well) and shaken for 1 hr at RT and 600 rpm.
- The MSD plate was washed 3x (150 pL/well) with lx TBST and the primary detection antibody (Rabbit Anti-IRAK4 antibody [Y279], ab325ll) was added to a final concentration of 1 pg/ml with 25 pL/well. The plate was then shaken for 1 hr at RT and 600 rpm.
- The MSD plate was washed 3x (150 pL/well) with lx TBST and the secondary detection antibody, SULFO-TAG anti-species antibody (Anti Rabbit Antibody (R32AB-5) MSD,R32AB-l) was added to a volume of 25 pL/well at a final concentration of 1 pg/ml. The plate was then shaken for 1 hr at RT and 600 rpm.
- The MSD plate was then washed 3x (150 pL/well) with lx TBST.
- lx MSD reading buffer was then added (150 pL/well) and the plate was diluted with 4x water. (MSD, R92TC-2)
- The MSD instrument was then read.

[005322] Data analysis

- The remaining activity was calculated following the formula below:

$$\text{Relative Level of IRAK4 (\%)} = 100\% \times \frac{\text{MSD Signal}_{\text{sample}} - \text{MSD Signal}_{\text{NC}}}{\text{MSD Signal}_{\text{PC}} - \text{MSD Signal}_{\text{NC}}}$$

[005323] Calculate

- The DC50 was calculated by fitting the Curve using Xlfit (v5.3.l.3), equation 201:

Y = Bottom + (Top - Bottom)/(l + l0^((LogIC50 - X)*HillSlope))

[005324] OCI-LY-10 DC50 results. The letter codes for IRAK4 DC50 indicate the concentration of compound required to degrade 50% of protein: A (<0.05 μM), B (0.05 - 0.1 pM), C (0.1 - 0.5 pM), D (0.5 - 1.0 pM), and E (>1.0 pM).

[005325] Table 19b. OCI-LY-10 % IRAK4 DCso Results

Compound Name	OCI-LY10 IRAK4 DC_{50} (μM)
I-213	A
I-214	E
I-218	E
I-219	A
I-224	A
I-225	A
I-227	A
I-228	A
I-231	A
I-235	B
I-240	E
I-241	A
I-242	A
I-251	A
I-252	A
I-253	A
I-255	E
I-258	E
I-261	C
I-262	E
I-265	A
I-266	A
I-267	B
I-268	A

I-269	A
I-270	C
I-271	C
I-272	C
I-273	B
I-274	C
I-276	B
I-277	B
I-278	B
I-279	B
I-280	A
I-281	B
I-283	A
I-284	E
I-286	E
I-287	E
I-288	B
I-289	E
I-290	E
I-292	E
I-293	E
I-294	E
I-295	E
I-296	E
I-297	E
I-299	E

I-300	E
I-301	E
I-302	A
I-305	A
I-308	B
I-313	A
I-319	A
I-320	E
I-321	A
I-332	A
I-334	B
I-344	B
I-350	E
I-351	C
I-352	E
I-360	E
I-366	E
I-371	E
I-381	A
I-384	D
I-386	C
I-387	E
I-389	D
I-390	C
I-391	C
I-392	B

I-393	C
I-394	C
I-395	E
I-396	B
I-397	A
I-398	C
I-399	A
I-400	A
I-401	A
I-402	E
I-403	B
I-404	A
I-405	A
I-405	A
I-406	A
I-407	A
I-408	E
I-411	A
I-412	E
I-413	E
I-414	C
I-415	E
I-416	E
I-417	E
I-419	C
I-420	E

I-421	C
I-422	E
I-423	E
I-427	A
I-428	A
I-429	E
I-432	E
I-436	E
I-437	E
I-438	E
I-440	E
I-441	E
I-442	E
I-444	B
I-445	B
I-446	C
I-447	B
I-449	E
I-456	E
I-459	A
I-460	A
I-461	A
I-462	A
I-463	E
I-470	A
I-472	E

I-473	A
I-475	A
I-476	A
I-477	A
I-478	B
I-479	A
I-487	A
I-488	A
I-489	A
I-490	A
I-491	B
I-495	A
I-504	A
I-506	A
I-508	A
I-509	A
I-513	A
I-514	A
I-517	A
I-522	E
I-523	B
I-524	E
I-525	E
I-529	B
I-530	A
I-532	A

I-534	A
I-535	A
I-536	A
I-537	A
I-539	D
I-542	A
I-543	A
I-545	A
I-548	A
I-549	A
I-550	A
I-551	A
I-552	A
I-553	D
I-554	E
I-555	D
I-556	D
I-558	A
I-559	E
I-564	C
I-567	A
I-568	A
I-572	A
I-574	A
I-576	A
I-579	C

I-580	B
I-583	A
I-584	A
I-585	A
I-587	A
I-588	A
I-589	A
I-590	A
I-592	A
I-593	A
I-599	C
I-614	B
I-692	E
I-684	A
I-685	A
I-699	C
I-700	A
I-689	A
I-690	A
I-519	D
I-520	D
I-521	E
I-680	E
I-681	D
I-682	E

[005326] Example 204b: OCI-LY-10 ECso

[005327] A CTG cell viability assay using OCI-LY-lO cells was run to determine compound-mediated cell viability (ECso).

[005328] Cell Viability Protocol

[005329] Compound-mediated viability effect on OCI-LY10 was quantitatively determined using the CellTiter-Glo® Luminescent Cell Viability Assay kit from Promega (Catalog number G7570) following manufacturer's recommended procedures. Briefly, OCI-LY10 cells were seeded into 384 well plates (Grenier Bio-One, Catalog number 781080) with a density of 10,000 cells per well. Compounds were then added to the assay plate with final top concentration of 10μM and 1:3 dilution series with total of 9 doses. The final DMSO concentration was normalized to 0.2%. The assay plates were incubated at 37 °C for 4 days under 5% $C0_2$. Then the assay plate was equilibrated at room temperature for 10 minutes. To determine cell viability, 30 μL CellTiter Glo reagent was added to each well and the assay plate was centrifuged at 1000 rpm for 30 second, incubated at room temperature for 10 min, and analyzed by detecting the luminescence using a multimode plate reader (EnVision 2105, PerkinElmer). The data was then analyzed by software Prism 7.0 from GraphPad and the dose response curves were fit using a three-parameter logistic equation to calculate ECso.

[005330] OCI-LY-lO ECso results. The letter codes for IRAK4 ECso indicate the concentration of compound required to affect 50% of cells: A (<0.05 μM), B (0.05 - 0.1 pM), C (0.1 - 0.5 pM), D (0.5 - 1.0 pM), and E (>1.0 pM).

[005331] Table 19c. OCI-LY-10 IRAK4 ECso Results

Compound Name	OCI-LY10 IRAK4 EC_{50} (μM)
I-448	C
I-449	E
I-455	E
I-456	E
I-457	E
I-458	B
I-459	A

I-460	A
I-461	A
I-462	A
I-463	E
I-464	E
I-465	E
I-466	E
I-467	E
I-468	E
I-469	E
I-470	A
I-471	E
I-472	E
I-473	B
I-475	A
I-476	C
I-477	A
I-478	C
I-479	A
I-481	B
I-482	C
I-483	E
I-484	E
I-485	E
I-487	B
I-488	A

I-489	D
I-490	A
I-491	A
I-494	E
I-495	D
I-504	A
I-506	A
I-508	B
I-509	A
I-513	A
I-514	A
I-515	D
I-517	E
I-522	E
I-523	A
I-524	E
I-525	E
I-526	E
I-527	E
I-528	E
I-529	B
I-530	A
I-531	A
I-532	D
I-533	D
I-534	E

I-535	E
I-536	A
I-537	A
I-538	E
I-539	A
I-540	A
I-541	E
I-542	A
I-543	A
I-544	E
I-545	A
I-548	A
I-549	A
I-550	A
I-551	A
I-552	A
I-553	E
I-555	E
I-556	E
I-558	A
I-559	D
I-560	E
I-563	E
I-564	E
I-567	D
I-568	C

I-572	C
I-573	E
I-574	A
I-575	C
I-576	A
I-578	D
I-579	E
I-580	A
I-581	C
I-582	A
I-583	A
I-584	B
I-585	A
I-587	A
I-588	A
I-589	A
I-590	A
I-592	A
I-593	C
I-595	B
I-596	E
I-597	C
I-598	A
I-599	A
I-614	C
I-617	D

I-691	E
I-692	E
I-694	E
I-684	A
I-685	A
I-699	A
I-700	B
I-688	E
I-689	D
I-690	E
I-519	D
I-520	E
I-521	E
I-680	E
I-682	E

[005332] Table 20: Compounds synthesized via Method 11 with the addition of various amines to fluoride Intermediate R in Step 1, followed by coupling with various acids in Step 3.

Ex-#	**I-#**	**Step 1 Intermediate Amine**	**Step 3 Intermediate Acid**	**LCMS (ES+) m/z $(M+H)^+$**	**1HNMR (400MHz, DMSO-d_6) δ**

205[a]	**I-210**	FQ	EG	905.0	11.10 (s, 1H), 9.98 (s, 1H), 9.04 - 8.95 (m, 2H), 8.65 (t, *J* = 5.2 Hz, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.05 - 8.00 (m, 4H), 7.66 (s, 1H), 7.58 (t, *J* = 7.6 Hz, 1H), 7.20 - 7.15 (m, 2H), 7.13 - 7.07 (m, 2H), 7.04 (d, *J* = 6.8 Hz, 2H), 6.88 (t, *J* = 5.6 Hz, 1H), 5.05 (dd, *J*=5.4, 12.8 Hz, 1H), 4.37 (d, *J* = 5.6 Hz, 2H), 4.00 (t, *J* = 6.8 Hz, 2H), 3.26 - 3.25 (m, 2H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.94 - 2.83 (m, 1H), 2.60 - 2.54 (m, 2H), 2.05 - 1.94 (m, 3H), 1.10 - 1.02 (m, 1H), 0.48 - 0.43 (m, 2H), 0.24 - 0.21 (m, 2H)
206	**I-211**	tert-butyl N-[2-(2-aminoethoxy)-ethyl]carbamate CAS# 127828-22-2)	FX	837.5	11.08 (s, 1H), 10.03 (s, 1H), 8.98 (s, 1H), 8.91 (s, 1H), 8.62 (t, *J* = 5.6 Hz, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.04 - 7.92 (m, 4H), 7.59 - 7.53 (m, 1H), 7.47 - 7.18 (m, 1H), 7.17 - 7.00 (m, 5H), 6.63 (t, *J* = 5.6 Hz, 1H), 5.10 - 4.98 (m, 1H), 3.69 - 3.63 (m, 2H), 3.63 - 3.58 (m, 2H), 3.53 - 3.43 (m, 4H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.95 - 2.79 (m, 1H), 2.61 - 2.52 (m, 2H), 2.08 - 1.96 (m, 1H), 1.12 - 1.01 (m, 1H), 0.49 - 0.42 (m, 2H), 0.27 - 0.19 (m, 2H)
207	**I-212**	tert-butyl N-[2-[2-[2-[2-(2-aminoethoxy)-ethoxy]-ethoxy]ethoxy]-ethyl]carbamate (CAS# 811442-84-9)	FX	991.0 $(M+23)^+$	11.08 (s, 1H), 10.03 (s, 1H), 8.98 (s, 1H), 8.92 (s, 1H), 8.63 (t, *J* = 5.2 Hz, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.07 - 7.95 (m, 4H), 7.61 - 7.53 (m, 1H), 7.47 - 7.17 (m, 1H), 7.15 - 7.06 (m, 3H), 7.06 - 7.00 (m, 2H), 6.59 (t, *J* = 5.6 Hz, 1H), 5.05 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.63 - 3.58 (m, 2H), 3.56 - 3.48 (m, 14H), 3.47 - 3.42 (m, 4H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.94 - 2.82 (m, 1H), 2.63 - 2.52 (m, 2H), 2.06 - 1.97 (m, 1H), 1.12 - 1.02 (m, 1H), 0.50 - 0.41 (m, 2H), 0.27 - 0.20 (m, 2H)

208	**I-213**	KN	DF	888.5	11.10 (s, 1H), 11.01 (s, 1H), 9.04 (s, 1H), 9.02 (s, 1H), 8.63 (t, *J* = 5.2 Hz, 1H), 8.17 (d, *J* = 5.2 Hz, 1H), 8.14 (s, 1H), 8.08 (d, *J* = 8.8 Hz, 2H), 8.03 (d, *J* = 8.8 Hz, 2H), 7.79 (s, 1H), 7.57 (dd, *J* = 7.2, 8.4 Hz, 1H), 7.18 (t, *J* = 5.2 Hz, 1H), 7.15 - 7.09 (m, 2H), 7.06 - 6.99 (m, 2H), 6.60 (t, *J* = 5.2 Hz, 1H), 5.06 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.53 (t, *J* = 5.2 Hz, 2H), 3.53 - 3.47 (m, 8H), 3.20 (t, *J* = 6.0 Hz, 2H), 2.93 - 2.83 (m, 1H), 2.63 - 2.53 (m, 2H), 2.09 - 1.98 (m, 1H), 1.79 - 1.72 (m, 2H), 1.13 - 1.00 (m, 1H), 0.49 - 0.42 (m, 2H), 0.25 - 0.21 (m, 2H)
209	**I-214**	tert-butyl N-[2-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]-ethoxy]ethoxy]-ethoxy]ethyl]-carbamate (CAS# 189209-27-6)	KR	929.1	11.09 (s, 1H), 10.82 (s, 1H), 9.02 (s, 1H), 8.44-8.38 (m, 2H), 8.25-8.23 (m, 2H), 7.56(dd, *J* = 7.2 Hz, *J* = 8.4 Hz, 1H), 7.41 (s, 1H), 7.25 (d, *J* = 5.6 Hz, 1H), 7.11 (d, *J* = 8.4 Hz, 1H), 7.01 (d, *J* = 6.8 Hz, 1H), 6.58 (bs, 1H), 5.06-5.03 (m, 1H), 4.37-4.36 (m, 2H), 3.93-3.91 (m, 6H), 3.53-3.44 (m, 22H), 2.88 (m, 1H), 2.60-2.54 (m, 2H), 2.03-2.01 (m, 1H)

[a]For varations in Method 11, see Table 9 footnotes.

[005333] **Table 21: Compounds synthesized via Method 12 with the coupling of various amines and acids in Step 1.**

Ex-#	I-#	Step 1 Intermediate Amine	Step 1 Intermediate Acid	LCMS (ES+) m/z $(M+H)^+$	1HNMR (400MHz, DMSO-d6) δ

210[a]	**I-215**	OK	FI	888.4	11.1 (s, 1H), 10.3 (s, 1H), 9.00 (s, 1H), 8.84 (s, 1H), 8.61 (t, *J* = 5.2 Hz, 1H), 8.33 (s, 3H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.05 - 8.00 (m, 2H), 7.99 - 7.95 (m, 2H), 7.68 - 7.62 (m, 1H), 7.60 - 7.54 (m, 1H), 7.24 (s, 1H), 7.12 (d, *J* = 8.4 Hz, 1H), 7.03 (d, *J* = 7.2 Hz, 1H), 6.61 (s, 1H), 5.11 - 5.00 (m, 1H), 4.28 - 4.19 (m, 4H), 3.54 - 3.46 (m, 12H), 2.95 - 2.81 (m, 1H), 2.63 - 2.57 (m, 1H), 2.56 - 2.54 (m, 1H), 2.07 - 1.99 (m, 1H)
211	**I-216**	CT	CN	989.9	11.12 (s, 1H), 11.01 (s, 1H), 9.04 (d, *J* = 2.4 Hz, 2H), 8.64 (t, *J* = 5.2 Hz, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.18 - 8.07 (m, 3H), 8.07 - 8.00 (m, 2H), 7.84 - 7.74 (m, 3H), 7.74 - 7.67 (m, 2H), 7.27 (s, 1H), 7.18 (d, *J* = 5.2 Hz, 1H), 5.13 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.33 - 4.20 (m, 2H), 3.59 - 3.37 (m, 18H), 2.95 - 2.76 (m, 3H), 2.65 - 2.57 (m, 2H), 2.11 - 1.99 (m, 1H), 1.90 - 1.82 (m, 2H)
212	**I-217**	CS	CN	985.6	11.14 (s, 1H), 11.00 (s, 1H), 9.03 (m, 2H), 8.65 (t, *J* = 5.2 Hz, 1H), 8.26 (d, *J* = 5.6 Hz, 1H), 8.18 - 8.08 (m, 3H), 8.06 - 8.00 (m, 2H), 7.98 - 7.87 (m, 3H), 7.77 (s, 1H), 7.70 (t, *J* = 6.8 Hz, 1H), 7.27 (s, 1H), 7.22 - 7.10 (m, 1H), 5.16 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.45 (s, 2H), 4.31 - 4.19 (m, 2H), 3.69 - 3.50 (m, 16H), 2.93 - 2.84 (m, 1H), 2.62 (m, 1H), 2.57 (m, 1H), 2.10 - 2.02 (m, 1H)
213	**I-218**	FP	EG	896.1	11.11 (s, 1H), 9.99 (s, 1H), 9.01 (s, 1H), 8.98 (s, 1H), 8.75 - 8.74 (m, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.06 - 7.99 (m, 4H), 7.63 - 7.52 (m, 1H), 7.14 - 7.08 (m, 3H), 7.06 - 7.00 (m, 2H), 6.64 - 6.52 (m, 1H), 5.08 - 5.02 (m, 1H), 3.30 - 3.26 (m, 6H), 3.22 - 3.13 (m, 2H), 2.92 - 2.83 (m, 1H), 2.74 - 2.70 (m, 2H), 2.62 - 2.52 (m, 2H), 2.05 - 2.00 (m, 1H), 1.80 - 1.72 (m, 2H), 1.65 - 1.54 (m,

					4H), 1.10 - 1.04 (m, 1H), 0.48 - 0.43 (m, 2H), 0.25 - 0.20 (m, 2H)
214	**I-219**	FR	CN	955.6	11.11 (s, 1H), 11.03 (s, 1H), 9.05 (s, 1H), 9.02 (s, 1H), 8.37 (s, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.21 (s, 1H), 8.06 (d, *J* = 8.8 Hz, 2H), 7.97 (d, *J* = 8.8 Hz, 2H), 7.80 (s, 1H), 7.72 (t, *J* = 6.4 Hz, 1H), 7.57 - 7.50 (m, 1H), 7.28 (s, 1H), 7.18 (dd, *J* = 1.2, 5.2 Hz, 1H), 7.11 (dd, *J* = 2.8, 8.8 Hz, 1H), 7.00 (dd, *J* = 2.0, 7.2 Hz, 1H), 6.60 - 6.59 (m, 1H), 5.07 - 5.02 (m, 1H), 4.32 - 4.20 (m, 2H), 3.63 - 3.25 (m, 10H), 2.97 - 2.80 (m, 4H), 2.64 - 2.57 (m, 2H), 2.08 - 1.96 (m, 1H), 1.63 - 1.61 (m, 2H), 1.51 - 1.39 (m, 2H), 1.32 - 1.21 (m, 2H)
215	**I-220**	OK	EG	899.1	11.08 (s, 1H), 9.96 (s, 1H), 9.00 - 8.96 (m, 1H), 8.98 (d, *J* = 4.4 Hz, 2H), 8.63 (t, *J* = 5.2 Hz, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.05 - 7.97 (m, 4H), 7.55 (t, *J* = 7.6 Hz, 1H), 7.12 - 6.99 (m, 5H), 6.59 (t, *J* = 5.6 Hz, 1H), 5.05 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.65 - 3.54 (m, 8H), 3.46 - 3.43 (m, 4H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.92 - 2.83 (m, 1H), 2.60 - 2.54 (m, 2H), 2.07 - 1.99 (m, 1H), 1.11 - 1.03 (m, 1H), 0.48 - 0.43 (m, 2H), 0.25 - 0.20 (m, 2H)
216	**I-221**	FV	EG	895.5	11.19 (s, 1H), 10.00 (s, 1H), 9.03 - 8.97 (m, 2H), 8.61 (t, *J* = 5.2 Hz, 1H), 8.36 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.06 - 7.98 (m, 4H), 7.81 - 7.74 (m, 2H), 7.72 - 7.68 (m, 1H), 7.14 - 7.07 (m, 2H), 7.04 (d, *J* = 5.2 Hz, 1H), 5.13 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.31 - 3.32 (m, 4H), 3.18 (t, *J* = 6.0 Hz, 2H), 3.06 (t, *J* = 7.2 Hz, 2H), 2.93 - 2.85 (m, 1H), 2.64 - 2.61 (m, 2H), 2.59 - 2.56 (m, 1H), 2.55 - 2.53 (m, 1H), 2.10 - 2.02 (m, 1H), 1.86 - 1.76 (m, 2H), 1.59 - 1.46 (m, 4H), 1.36 - 1.35 (m, 2H),

					1.12 - 1.02 (m, 1H), 0.49 - 0.42 (m, 2H), 0.25 - 0.21 (m, 2H)
217	**I-222**	FS	EG	898.1	11.10 (s, 1H), 9.97 (s, 1H), 9.00 - 8.96 (m, 2H), 8.71 - 8.68 (m, 1H), 8.18 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.06 - 7.96 (m, 4H), 7.55 (t, *J* = 8.0 Hz, 1H), 7.13 - 6.97 (m, 5H), 6.77 - 6.71 (m, 1H), 5.09 - 5.99 (m, 1H), 3.57 - 3.52 (m, 4H), 3.49 - 3.44 (m, 4H), 3.21 - 3.16 (m, 2H), 2.93 - 2.86 (m, 1H), 2.85 - 2.74 (m, 4H), 2.62 - 2.55 (m, 2H), 2.05 - 1.96 (m, 1H), 1.11 - 1.03 (m, 1H), 0.48 - 0.42 (m, 2H), 0.25 - 0.20 (m, 2H)
218	**I-223**	EL	FX	878.2	11.11 (s, 1H), 10.08 (s, 1H), 9.00 (s, 1H), 8.93 (s, 1H), 8.57 (t, *J* = 5.2 Hz, 1H), 8.30 (s, 1H), 8.20 - 8.14 (m, 1H), 8.05 - 7.95 (m, 4H), 7.59 (t, *J* = 7.8 Hz, 1H), 7.46 - 7.19 (m, 1H), 7.16 - 7.11 (m, 2H), 7.07 - 7.01 (m, 2H), 6.82 (t, *J* = 5.2 Hz, 1H), 5.06 (dd, *J* = 5.4, 12.8 Hz, 1H), 3.37 - 3.19 (m, 8H), 2.95 - 2.80 (m, 4H), 2.67 - 2.62 (m, 2H), 2.08 - 2.00 (m, 1H), 1.61 - 1.47 (m, 4H), 1.38 (d, *J* =7.2 Hz, 2H), 1.14 - 1.02 (m, 1H), 0.51 - 0.43 (m, 2H), 0.23 (q, *J* = 4.8 Hz, 2H)
219	**I-224**	FZ	DF	887.5	11.12 (s, 1H), 10.98 (s, 1H), 9.00 (s, 1H), 8.98 – 8.93 (m, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.09 (s, 1H), 8.01 (d, *J* = 8.0 Hz, 2H), 7.80 - 7.69 (m, 3H), 7.63 (s, 1H), 7.60 - 7.52 (m, 2H), 7.17 (t, *J* = 5.2 Hz, 1H), 7.12 (s, 1H), 7.04 - 6.97 (m, 1H), 5.15 – 5.07 (m, 1H), 3.61 - 3.49 (m, 10H), 3.18 (t, *J* = 6.0 Hz, 2H), 3.09 - 3.02 (m, 2H), 2.99 (s, 3H), 2.93 - 2.81 (m, 1H), 2.64 - 2.55 (m, 2H), 2.09 - 2.00 (m, 1H), 1.90 - 1.76 (m, 2H), 1.12 - 1.01 (m, 1H), 0.48 - 0.42 (m, 2H), 0.26 - 0.20 (m, 2H)

220	**I-225**	FZ	FX	894.6	11.1 (s, 1H), 10.0 (s, 1H), 8.98 (s, 1H), 8.86 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.91 (d, *J* = 7.2 Hz, 2H), 7.73 (s, 2H), 7.66 (s, 1H), 7.57 (d, *J* = 6.4 Hz, 2H), 7.46 - 7.16 (m, 1H), 7.15 - 7.08 (m, 2H), 7.05 (d, *J* = 5.2 Hz, 1H), 5.17 - 5.06 (m, 1H), 3.67 - 3.49 (m, 10H), 3.22 - 3.16 (m, 2H), 3.10 - 3.02 (m, 2H), 3.00 (s, 3H), 2.94 - 2.82 (m, 1H), 2.64 - 2.57 (m, 1H), 2.57 - 2.53 (m, 1H), 2.12 - 1.99 (m, 1H), 1.92 - 1.80 (m, 2H), 1.15 - 1.01 (m, 1H), 0.52 - 0.43 (m, 2H), 0.28 - 0.19 (m, 2H)
221[b]	**I-226**	FZ	EE	818.4	11.12 (s, 2H), 9.11 (s, 1H), 8.97 (s, 1H), 8.87 (d, *J* = 5.6 Hz, 2H), 8.15 - 8.06 (m, 1H), 8.06 - 7.95 (m, 4H), 7.80 (s, 1H), 7.73 (s, 2H), 7.66 (s, 1H), 7.58 (d, *J* = 7.2 Hz, 2H), 5.12 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.66 - 3.49 (m, 10H), 3.06 (s, 2H), 3.01 (s, 3H), 2.95 - 2.82 (m, 1H), 2.65 - 2.54 (m, 2H), 2.11 - 2.00 (m, 1H), 1.85 (s, 2H)
222[b]	**I-227**	GD	EE	818.4	11.14 - 11.05 (m, 2H), 9.10 (d, *J* = 2.0 Hz, 1H), 8.97 (s, 1H), 8.86 (d, *J* = 5.2 Hz, 2H), 8.09 (s, 1H), 8.03 (s, 2H), 7.97 (d, *J* = 4.4 Hz, 2H), 7.82 - 7.63 (m, 4H), 7.58 (d, *J* = 7.6 Hz, 2H), 5.12 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.68 - 3.39 (m, 10H), 3.01 (s, 3H), 2.94 - 2.78 (m, 3H), 2.61 - 2.53 (m, 2H), 2.10 - 2.01 (m, 1H), 1.86 (s, 2H)
223	**I-228**	GD	DF	887.5	11.13 (s, 1H), 10.99 (s, 1H), 9.10 - 8.87 (m, 2H), 8.24 - 7.97 (m, 4H), 7.82 - 7.53 (m, 6H), 7.20 (t, *J* = 5.2 Hz, 1H), 7.13 (s, 1H), 7.01 (d, *J* = 5.6 Hz, 1H), 5.12 (d, *J* = 8.8 Hz, 1H), 3.68 - 3.39 (m, 12H), 3.01 (s, 3H), 2.90 - 2.72 (m, 3H), 2.64 - 2.54 (m, 2H), 2.10 - 2.01 (m, 1H), 1.85 (s, 2H), 1.07 (d, *J* = 6.4 Hz, 1H), 0.62 - 0.35 (m, 2H), 0.23 (d, *J* = 4.8 Hz, 2H)

224	**I-229**	GL	DF	843.6	10.88 (s, 1H), 10.77 (s, 1H), 8.76 (s, 2H), 7.93 (d, *J* = 5.2 Hz, 1H), 7.89 - 7.76 (m, 3H), 7.58 - 7.41 (m, 4H), 7.34 (d, *J* = 8.0 Hz, 2H), 6.96 - 6.85 (m, 2H), 6.77 (d, *J* = 4.8 Hz, 1H), 6.81 - 6.74 (m, 1H), 4.89 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.31 - 3.45 (m, 4H), 3.22 - 3.21 (m, 2H), 2.95 (t, *J* = 6.0 Hz, 2H), 2.89 - 2.81 (m, 1H), 2.77 (s, 3H), 2.70 - 2.58 (m, 1H), 2.40 - 2.30 (m, 2H), 1.87 - 1.76 (m, 1H), 1.71 - 1.55 (m, 2H), 0.89 - 0.77 (m, 1H), 0.22 (d, *J* = 8.0 Hz, 2H), 0.00 (d, *J* = 4.8 Hz, 2H)
225	**I-230**	GS	DF	883.6	10.89 (s, 1H), 10.82 - 10.65 (m, 1H), 8.86 - 8.66 (m, 2H), 7.93 (d, *J* = 5.2 Hz, 1H), 7.87 (s, 1H), 7.81 (d, *J* = 8.4 Hz, 2H), 7.54 - 7.28 (m, 6H), 6.94 (t, *J* = 5.2 Hz, 1H), 6.88 (s, 1H), 6.77 (d, *J* = 5.6 Hz, 1H), 4.94 - 4.81 (m, 1H), 3.25 - 3.18 (m, 2H), 2.95 (t, *J* = 6.0 Hz, 3H), 2.82 - 2.72 (m, 2H), 2.72 - 2.68 (m, 2H), 2.66 - 2.62 (m, 1H), 2.40 - 2.31 (m, 2H), 1.88 - 1. 76 (m, 1H), 1.42 - 1.19 (m, 4H), 1.14 - 0.83 (m, 10H), 0.81 - 0.76 (m, 1H), 0.25 - 0.18 (m, 2H), 0.03 – 0.00 (q, *J* = 4.8 Hz, 2H)
226	**I-231**	GV	CN	874.1	11.11 (s, 1H), 11.03 (s, 1H), 9.04 (d, *J* = 1.2 Hz, 2H), 8.64 (t, *J* = 5.6 Hz, 1H), 8.26 (d, *J* = 5.6 Hz, 1H), 8.15 (s, 1H), 8.12 - 8.07 (m, 2H), 8.05 - 8.00 (m, 2H), 7.79 (s, 1H), 7.71 (t, *J* = 6.4 Hz, 1H), 7.29 - 7.24 (m, 2H), 7.18 (dd, *J* = 1.2, 5.2 Hz, 1H), 7.11 (d, *J* = 8.0 Hz, 1H), 7.08 - 7.00 (m, 2H), 5.38 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.28 - 4.20 (m, 2H), 4.02 - 3.98 (m, 1H), 4.00 (t, *J* = 5.6 Hz, 1H), 3.69 (t, *J* = 5.6 Hz, 2H), 3.58 - 3.49 (m, 8H), 2.96 - 2.84 (m, 1H), 2.78 - 2.70 (m, 1H), 2.64 - 2.60 (m, 1H), 2.03 - 1.99 (m, 1H)

227	**I-232**	GU	CN	843.4	11.01 (s, 1H), 11.0 (s, 1H), 9.04 (s, 2H), 8.70 - 8.62 (m, 1H), 8.25 (d, *J* = 5.2 Hz, 1H), 8.15 (s, 1H), 8.10 (s, 1H), 8.08 (s, 1H), 8.03 (s, 1H), 8.01 (s, 1H), 7.78 (s, 1H), 7.76 - 7.70 (m, 1H), 7.47 - 7.73 (m, 1H), 7.46 - 7.40 (m, 2H), 7.27 (s, 1H), 7.19 - 7.15 (m, 1H), 5.16 - 5.08 (m, 1H), 4.49 - 4.40 (m, 1H), 4.34 - 4.23 (m, 3H), 3.57 - 3.50 (m, 2H), 3.49 - 3.40 (m, 4H), 2.98 - 2.85 (m, 1H), 2.72 - 2.67 (m, 2H), 2.63 - 2.55 (m, 1H), 2.45 - 2.38 (m, 1H), 2.05 - 1.93 (m, 1H), 1.89 - 1.79 (m, 2H)
228	**I-233**	GX	CN	923.4 $(M+Na)^+$	11.12 (s, 1H), 11.02 (s, 1H), 9.03 (d, *J* = 8.0 Hz, 2H), 8.69 - 8.61 (m, 1H), 8.26 (d, *J* = 4.8 Hz, 1H), 8.12 (s, 1H), 8.10 - 8.05 (m, 2H), 8.05 - 8.00 (m, 2H), 7.79 - 7.65 (m, 5H), 7.28 (s, 1H), 7.19 (d, *J* = 5.2 Hz, 1H), 5.12 (dd, *J* = 4.4, 12.0 Hz, 1H), 4.30 - 4.21 (m, 2H), 3.58 - 3.39 (m, 10H), 3.03 (t, *J* = 7.2 Hz, 2H), 2.95 - 2.83 (m, 1H), 2.64 - 2.57 (m, 1H), 2.56 - 2.54 (m, 1H), 2.10 - 2.01 (m, , 1H), 1.86 - 1.78 (m, 2H)
229	**I-234**	GW	CN	857.0	11.12 (s, 1H), 11.01 (s, 1H), 9.07 - 9.00 (m, 2H), 8.70 - 8.63 (m, 1H), 8.28 - 8.23 (m, 1H), 8.14 (s, 1H), 8.12 - 8.07 (m, 2H), 8.06 - 8.01 (m, 2H), 7.77 (s, 1H), 7.76 - 7.65 (m, 4H), 7.27 (s, 1H), 7.18 (d, *J* = 5.2 Hz, 1H), 5.16 - 5.08 (m, 1H), 4.31 - 4.19 (m, 2H), 3.56 - 3.50 (m, 2H), 3.49 - 3.43 (m, 4H), 3.08 (t, *J* = 7.2 Hz, 2H), 2.93 - 2.82 (m, 1H), 2.64 - 2.54 (m, 2H), 2.11 - 2.00 (m, 1H), 1.93 - 1.79 (m, 2H)

230	**I-235**	HA	CN	1011.5 $(M+Na)^+$	11.12 (s, 1H), 11.01 (s, 1H), 9.04 (d, J = 3.2 Hz, 2H), 8.64 (t, J = 5.2 Hz, 1H), 8.26 (d, J = 5.2 Hz, 1H), 8.14 (s, 1H), 8.12 - 8.08 (m, 2H), 8.06 - 8.00 (m, 2H), 7.79 - 7.66 (m, 5H), 7.28 (s, 1H), 7.18 (dd, J = 1.2, 5.2 Hz, 1H), 5.13 (dd, J = 5.2, 12.8 Hz, 1H), 4.33 - 4.19 (m, 2H), 3.58 - 3.44 (m, 16H), 3.40 (t, J = 6.4 Hz, 2H), 3.05 (t, J = 7.6 Hz, 2H), 2.94 - 2.84 (m, 1H), 2.63 - 2.55 (m, 2H), 2.10 - 2.02 (m, 1H), 1.88 - 1.78 (m, 2H)
231	**I-236**	MN	CN	985.5	11.14 (s, 1H), 11.00 (s, 1H), 9.03 (d, J = 2.4 Hz, 2H), 8.65 (s, 1H), 8.52 (s, 1H), 8.26 (d, J = 5.2 Hz, 1H), 8.15 - 8.07 (m, 3H), 8.06 - 8.01 (m, 2H), 7.92 - 7.83 (m, 3H), 7.77 (s, 1H), 7.71 (t, J = 6.8 Hz, 1H), 7.27 (s, 1H), 7.18 (dd, J = 1.2, 5.2 Hz, 1H), 5.15 (dd, J = 5.2, 12.8 Hz, 1H), 4.48 (s, 2H), 4.31 - 4.20 (m, 2H), 3.71 (dd, J = 3.6, 5.6 Hz, 2H), 3.56 - 3.53 (m, 8H), 3.50 - 3.40 (m, 5H), 2.95 - 2.88 (m, 1H), 2.70 - 2.55 (m, 5H), 2.36 - 2.31 (m, 1H), 2.11 - 2.04 (m, 1H)
232	**I-237**	HB	DF	859.5	11.04 - 10.97 (m, 2H), 9.03 (s, 1H), 9.01 (s, 1H), 8.65 (t, J = 5.2 Hz, 1H), 8.20 - 8.12 (m, 2H), 8.11 - 8.05 (d, J = 8.8 Hz, 2H), 8.04 - 7.98 (d, J = 8.8 Hz, 2H), 7.79 (s, 1H), 7.58 - 7.52 (m, 1H), 7.43 (d, J = 4.4 Hz, 2H), 7.17 (t, J = 5.2 Hz, 1H), 7.12 (s, 1H), 7.00 (dd, J = 1.2, 5.2 Hz, 1H), 5.13 (dd, J = 4.8, 13.2 Hz, 1H), 4.49 - 4.40 (d, J = 17.2 Hz, 1H), 4.34 - 4.24 (d, J = 17.2 Hz,, 1H), 3.58 - 3.54 (m, 4H), 3.51 - 3.48 (m, 2H), 3.47 - 3.44 (m, 2H), 3.39 (t, J = 6.4 Hz, 2H), 3.19 (t, J = 6.4 Hz, 2H), 2.97 - 2.87 (m, 1H), 2.66 - 2.52 (m, 4H), 2.06 - 1.95 (m, 1H), 1.84 -1.77 (m, 2H), 1.14 - 1.01 (m, 1H), 0.53 - 0.40 (m, 2H), 0.29 - 0.19 (m, 2H)

233	**I-238**	HC	DF	925.5 (M+Na)$^+$	11.01 (s, 1H), 10.99 (s, 1H), 9.04 (s, 1H), 9.01 (s, 1H), 8.64 (s, 1H), 8.21 - 8.13 (m, 2H), 8.12 - 8.07 (m, 2H), 8.05 - 7.99 (m, 2H), 7.78 (s, 1H), 7.58 - 7.52 (m, 1H), 7.44 (d, *J* = 4.0 Hz, 2H), 7.20 - 7.14 (m, 1H), 7.13 (s, 1H), 7.01 (d, *J* = 4.8 Hz, 1H), 5.17 - 5.08 (m, 1H), 4.47 - 4.40 (m, 1H), 4.32 - 4.27 (m, 1H), 3.57 - 3.52 (m, 8H), 3.48 - 3.44 (m, 6H), 3.25 - 3.09 (m, 2H), 3.04 - 2.90 (m, 1H), 2.66 - 2.55 (m, 1H), 2.55 - 2.54 (m, 1H), 2.42 - 2.41 (m, 2H), 2.04 - 1.99 (m, 1H), 1.85 - 1.80 (m, 2H), 1.11 - 1.04 (m, 1H), 0.49 - 0.43 (m, 2H), 0.26 - 0.20 (m, 2H)
234	**I-239**	HE	OM	799.4	10.87 (s, 1H), 10.71 (s, 1H), 8.69 (s, 1H), 8.16 (s, 1H), 7.91 (d, *J* = 5.2 Hz, 1H), 7.52 (s, 1H), 7.34 - 7.29 (m, 1H), 7.28 (s, 1H), 6.95 - 6.90 (m, 1H), 6.88 - 6.85 (m, 2H), 6.78 (d, *J* = 7.2 Hz, 1H), 6.75 - 6.73 (m, 1H), 6.36 - 6.30 (m, 1H), 4.84 - 4.78 (m, 1H), 4.13 - 4.08 (m, 2H), 3.60 - 3.55 (m, 2H), 3.37 - 3.34 (m, 2H), 3.29 - 3.26 (m, 6H), 3.24 - 3.17 (m, 4H), 2.97 - 2.93 (m, 2H), 2.66 - 2.59 (m, 1H), 2.40 - 2.35 (m, 1H), 2.33 - 2.31 (m, 1H), 1.82 - 1.74 (m, 1H), 0.86 - 0.80 (m, 1H), 0.24 - 0.21 (m, 2H), 0.02 - 0.01 (m, 2H)
235	**I-240**	HI	OM	843.5	11.09 (s, 1H), 10.94 (s, 1H), 8.93 (s, 1H), 8.39 (s, 1H), 8.14 (s, 1H), 7.74 (s, 1H), 7.59 - 7.53 (m, 1H), 7.51 (s, 1H), 7.14 (t, *J* = 5.2 Hz, 1H), 7.12 - 7.08 (m, 2H), 7.00 - 6.95 (m, 2H), 6.57 (t, *J* = 5.6 Hz, 1H), 5.10 - 5.00 (m, 1H), 4.35 (t, *J* = 5.2 Hz, 2H), 3.81 (t, *J* = 5.2 Hz, 2H), 3.62 - 3.56 (m, 2H), 3.54 - 3.41 (m, 14H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.93 - 2.82 (m, 1H), 2.62 - 2.53 (m, 2H), 2.07 - 1.97 (m, 1H),

					1.11 - 1.01 (m, 1H), 0.49 - 0.42 (m, 2H), 0.25 - 0.20 (m, 2H)
236[b]	**I-241**	OK	MP	819.1	11.18-11.00 (m, 2H), 9.09 (s, 1H), 9.02 (s, 1H), 8.70 (d, *J* = 5.6 Hz, 1H), 8.62 (t, *J* = 5.6 Hz, 1H), 8.19 - 8.11 (m, 1H), 8.11 - 7.98 (m, 4H), 7.86 - 7.79 (m, 2H), 7.76 (d, *J* = 4.8 Hz, 1H), 7.56 (t, *J* = 8.0 Hz, 1H), 7.11 (d, *J* = 8.8 Hz, 1H), 7.01 (d, *J* = 7.2 Hz, 1H), 6.59 (t, *J* = 6.0 Hz, 1H), 5.10 - 4.97 (m, 1H), 3.65 - 3.52 (m, 8H), 3.48 - 3.42 (m, 4H), 2.93 - 2.81 (m, 1H), 2.61 (s, 3H), 2.58 - 2.53 (m, 2H), 2.09 - 1.98 (m, 1H)
237	**I-242**	EL	FX	878.1	11.09 (s, 1H), 10.05 (s, 1H), 8.98 (s, 1H), 8.92 (s, 1H), 8.59 - 8.50 (m, 1H), 8.27 (s, 2H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.03 - 7.9 (m, 4H), 7.62 - 7.55 (m, 1H), 7.47 - 7.17 (t, *J* = 50.0 Hz, 1H), 7.15 - 7.01 (m, 5H), 6.85 - 6.78 (m, 1H), 5.0 - 5.1 (m, 1H), 3.40 (s, 2H), 3.30 - 3.24 (m, 1H), 3.21-3.15 (m, 2H), 2.97 - 2.87 (m, 1H), 2.86 - 2.79 (m, 2H), 2.71 - 2.56 (m, 4H), 2.07 - 1.96 (m, 1H), 1.64 - 1.44 (m, 4H), 1.40 - 1.30 (m, 2H), 1.14 - 1.01 (m, 1H), 0.48 - 0.42 (m, 2H), 0.27 - 0.18 (m, 2H)
238	**I-243**	GW	FX	836.4	11.12 (s, 1H), 10.06 (s, 1H), 8.99 (s, 1H), 8.92 (s, 1H), 8.66 (t, *J* = 5.2 Hz, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.01 (d, *J* = 8.8 Hz, 2H), 7.95 (d, *J* = 8.8 Hz, 2H), 7.78 - 7.71 (m, 2H), 7.70 - 7.64 (m, 1H), 7.32 (t, *J* = 54.0 Hz, 1H), 7.14 - 7.08 (m, 2H), 7.04 (dd, *J* = 1.2, 5.2 Hz, 1H), 5.12 (dd, J = 5.6, 12.8 Hz, 1H), 3.52 (t, *J* = 6.4 Hz, 2H), 3.45 (t, *J* = 6.0 Hz, 4H), 3.18 (t, *J* = 6.0 Hz, 2H), 3.08 (t, *J* = 6.8 Hz, 2H), 2.94 - 2.82 (m, 1H), 2.64 - 2.54 (m, 2H), 2.11 - 1.99 (m, 1H), 1.92 - 1.80 (m, 2H), 1.13 - 1.02 (m, 1H), 0.50 - 0.41 (m, 2H), 0.27 - 0.18 (m, 2H)

239	**I-244**	GX	FX	880.5	10.89 (s, 1H), 9.82 (s, 1H), 8.76 (s, 1H), 8.67 (s, 1H), 8.45 - 8.37 (m, 1H), 7.93 (d, *J* = 5.2 Hz, 1H), 7.81 - 7.75 (m, 2H), 7.74 - 7.69 (m, 2H), 7.53 - 7.47 (m, 2H), 7.45 - 7.41 (m, 1H), 7.24 - 6.94 (m, 1H), 6.91 - 6.85 (m, 2H), 6.83 - 6.77 (m, 1H), 4.89 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.37 - 3.20 (m, 10H), 2.95 (t, *J* = 6.8 Hz, 2H), 2.79 (t, *J* = 7.2 Hz, 2H), 2.71 - 2.62 (m, 1H), 2.41 - 2.38 (m, 1H), 2.36 - 2. 34 (m, 1H), 1.86 - 1.77 (m, 1H), 1.62 - 1.53 (m, 2H), 0.89 - 0.80 (m, 1H), 0.26 - 0.19 (m, 2H), 0.03 - 0.00
240	**I-245**	tert-butyl N-[2-[5-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]-pentylamino]-ethyl]carbamate (synthesized via Steps 1-4 of Example 144)	FX	878.2	11.24 - 11.01 (m, 1H), 10.09 (s, 1H), 9.00 (s, 1H), 8.93 (s, 1H), 8.69 (s, 1H), 8.34 (s, 1H), 8.17 (d, *J* = 5.2 Hz, 1H), 8.02 (d, *J* = 10.4 Hz, 3H), 7.58 (s, 1H), 7.33 (s, 1H), 7.21 - 7.03 (m, 4H), 6.55 (s, 1H), 5.05 (s, 1H), 3.19 (s, 6H), 2.95 - 2.91 (m, 1H), 2.87 (d, *J* = 14.8 Hz, 2H), 2.83 - 2.80 (m, 1H), 2.78 - 2.74 (m, 1H), 2.68 - 2.65 (m, 2H), 2.04 - 2.02 (m, 1H), 1.66 - 1.33 (m, 6H), 1.08 - 1.05 (m, 1H), 0.47 (d, *J* = 7.2 Hz, 2H), 0.24 (s, 2H)
241	**I-246**	OK	FX	881.5	11.10 (s, 1H), 10.05 (s, 1H), 8.99 (s, 1H), 8.92 (s, 1H), 8.61 (t, *J* = 5.6 Hz, 1H), 8.17 (d, *J* = 5.6 Hz, 1H), 8.08 - 7.92 (m, 4H), 7.61 - 7.50 (m, 1H), 7.49 - 7.16 (m, 1H), 7.15 - 6.99 (m, 5H), 6.60 (t, *J* = 5.6 Hz, 1H), 5.06 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.64 - 3.56 (m, 7H), 3.46 - 3.43 (m, 5H), 3.20 (t, *J* = 6.0 Hz, 2H), 2.94 - 2.83 (m, 1H), 2.69 - 2.56 (m, 2H), 2.09 - 1.99 (m, 1H), 1.17 - 1.02 (m, 1H), 0.52 - 0.43 (m, 2H), 0.29 - 0.18 (m, 2H)

242	**I-247**	HK	FX	936.1	11.10 (s, 1H), 10.04 (s, 1H), 8.98 (s, 1H), 8.92 (s, 1H), 8.67 - 8.60 (m, 1H), 8.16 (d, *J* = 5.4 Hz, 1H), 8.06 - 8.00 (m, 2H), 7.99 - 7.93 (m, 2H), 7.57 (t, *J* = 7.6 Hz, 1H), 7.47 - 7.17 (m, 1H), 7.16 - 6.98 (m, 5H), 6.63 - 6.55 (m, 1H), 5.11 - 5.01 (m, 1H), 3.75 (d, *J* = 10.8 Hz, 1H), 3.65 - 3.51 (m, 6H), 3.50 - 3.36 (m, 4H), 3.35 - 3.27 (m, 2H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.95 - 2.80 (m, 2H), 2.75 - 2.65 (m, 1H), 2.58 - 2.53 (m, 2H), 2.13 - 2.06 (m, 1H), 2.04 - 1.97 (m, 1H), 1.91 - 1.80 (m, 1H), 1.13 - 1.02 (m, 1H), 0.50 - 0.40 (m, 2H), 0.26 - 0.19 (m, 2H)
243	**I-248**	HO	CN	902.5	11.08 (s, 1H), 11.03 (s, 1H), 9.04 (s, 2H), 8.66 (t, *J* = 5.6 Hz, 1H), 8.27 (d, *J* = 4.8 Hz, 1H), 8.18 - 8.08 (m, 3H), 8.07 - 8.00 (m, 2H), 7.78 (s, 1H), 7.71 (t, *J* = 6.4 Hz, 1H), 7.28 (s, 1H), 7.19 (d, *J* = 5.2 Hz, 1H), 7.04 - 6.96 (m, 2H), 6.86 (d, *J* = 8.0 Hz, 1H), 5.33 (dd, *J* = 4.8, 12.4 Hz, 1H), 4.31 - 4.21 (m, 2H), 3.62 - 3.57 (m, 4H), 3.55 - 3.10 (m, 2H), 3.50 - 3.45 (m, 2H), 3.41 (t, *J* = 6.4 Hz, 2H), 3.32 (s, 3H), 2.96 - 2.84 (m, 1H), 2.70 - 2.58 (m, 4H), 2.04 - 1.97 (m, 1H), 1.85 - 1.76 (m, 2H)
244	**I-249**	HQ	CN	902.4	11.08 (s, 1H), 11.03 (s, 1H), 9.03 (d, *J* = 4.8 Hz, 2H), 8.66 (t, *J* = 5.2 Hz, 1H), 8.27 (d, *J* = 5.2 Hz, 1H), 8.14 (s, 1H), 8.09 - 8.01 (m, 4H), 7.78 (s, 1H), 7.71 (t, *J* = 6.4 Hz, 1H), 7.28 (s, 1H), 7.19 (d, *J* = 5.2 Hz, 1H), 6.96 - 6.91 (m, 2H), 6.87 - 6.82 (m, 1H), 5.36 (dd, *J* = 5.2, 12.5 Hz, 1H), 4.31 - 4.21 (m, 2H), 3.60 - 3.45 (m, 13H), 2.97 - 2.84 (m, 3H), 2.65 - 2.55 (m, 2H), 2.03 - 1.96 (m, 1H), 1.84 - 1.77 (m, 2H)

245	**I-250**	HR	FX	936.2	11.10 (s, 1H), 10.06 (s, 1H), 8.99 (s, 1H), 8.92 (s, 1H), 8.65 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.04 - 8.00 (m, 2H), 7.99 - 7.94 (m, 2H), 7.61 - 7.53 (m, 1H), 7.46 - 7.17 (m, 1H), 7.15 - 7.08 (m, 3H), 7.06 - 7.00 (m, 2H), 6.59 (s, 1H), 5.09 - 5.03 (m, 1H), 3.77 - 3.72 (m, 1H), 3.64 - 3.45 (m, 6H), 3.30 - 3.26 (m, 6H), 3.22 - 3.12 (m, 2H), 2.87 - 2.81 (m, 2H), 2.75 - 2.69 (m, 1H), 2.61 - 2.58 (m, 1H), 2.56 - 2.55 (m, 1H), 2.10 - 1.97 (m, 2H), 1.92 - 1.79 (m, 1H), 1.12 - 1.00 (m, 1H), 0.48 - 0.43 (m, 2H), 0.25 - 0.20 (m, 2H)
246	**I-251**	GV	FX	853.6	11.10 (s, 1H), 10.05 (s, 1H), 8.99 (s, 1H), 8.92 (s, 1H), 8.62 (t, *J* = 5.2 Hz, 1H), 8.17 (d, *J* = 5.2 Hz, 1H), 8.06 - 7.95 (m, 4H), 7.32 (s, 1H), 7.28 - 7.23 (m, 1H), 7.15 - 6.99 (m, 6H), 5.38 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.00 (t, *J* = 5.6 Hz, 2H), 3.69 (t, *J* = 5.6 Hz, 2H), 3.59 - 3.44 (m, 8H), 3.20 - 3.17 (m, 2H), 2.97 - 2.83 (m, 1H), 2.77 - 2.58 (m, 2H), 2.11 - 1.93 (m, 1H), 1.18 - 0.98 (m, 1H), 0.54 - 0.38 (m, 2H), 0.30 - 0.16 (m, 2H)
247	**I-252**	HO	FX	881.6	11.08 (s, 1H), 10.03 (s, 1H), 8.99 (s, 1H), 8.92 (s, 1H), 8.65 (t, *J* = 5.2 Hz, 1H), 8.17 (d, *J* = 5.6 Hz, 1H), 8.07 - 8.01 (m, 2H), 8.00 - 7.94 (m, 2H), 7.47 - 7.17 (m, 1H), 7.15 - 7.07 (m, 2H), 7.07 - 7.04 (m, 1H), 7.03 - 6.96 (m, 2H), 6.89 - 6.81 (m, 1H), 5.33 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.61 - 3.55 (m, 4H), 3.54 - 3.50 (m, 2H), 3.49 - 3.44 (m, 2H), 3.40 (t, *J* = 6.4 Hz, 2H), 3.31 (s, 3H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.94 - 2.85 (m, 1H), 2.65 - 2.61 (m, 4H), 2.03 - 1.97 (m, 1H), 1.83 - 1.76 (m, 2H), 1.12 - 1.04 (m, 1H), 0.50 - 0.41 (m, 2H), 0.28 - 0.19 (m, 2H)

248	**I-253**	HQ	FX	881.5	11.08 (s, 1H), 10.04 (s, 1H), 8.99 (s, 1H), 8.90 (s, 1H), 8.65 (t, *J* = 5.6 Hz, 1H), 8.48 (s, 1H), 8.17 (d, *J* = 5.2 Hz, 1H), 8.04 - 8.00 (m, 2H), 7.98 - 7.93 (m, 2H), 7.47 - 7.45 (m, 1H), 7.46 (s, 1H), 7.34 - 7.31 (m, 1H), 7.14 - 7.08 (m, 2H), 7.05 (d, *J* = 1.2, 5.3 Hz, 1H), 6.96 - 6.92 (m, 2H), 6.84 (dd, *J* = 2.8, 6.0 Hz, 1H), 5.36 (dd, *J* = 5.2, 12.4 Hz, 1H), 3.61 - 3.57 (m, 4H), 3.55 (s, 5H), 3.49 - 3.43 (m, 5H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.96 - 2.90 (m, 3H), 2.69 - 2.66 (m, 2H), 2.35 - 2.32 (m, 2H), 2.03 - 1.94 (m, 1H), 1.85 - 1.76 (m, 2H), 1.12 - 1.04 (m, 1H), 0.49 - 0.43 (m, 2H), 0.26 - 0.21 (m, 2H)
249	**I-254**	HU	OM	850.1	11.13 - 11.08 (m, 1H), 11.11 (s, 1H), 9.72 (s, 1H), 8.93 (s, 1H), 8.19 (s, 1H), 8.16 - 8.12 (m, 1H), 8.14 (d, *J* = 5.2 Hz, 1H), 7.57 (dd, *J* = 7.2, 8.4 Hz, 1H), 7.32 - 7.00 (m, 6H), 6.59 (t, *J* = 5.6 Hz, 1H), 5.05 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.32 (t, *J* = 5.2 Hz, 2H), 3.79 (t, *J* = 5.2 Hz, 2H), 3.59 (t, *J* = 5.2 Hz, 2H), 3.54 - 3.47 (m, 14H), 3.18 (t, *J* = 6.4 Hz, 2H), 2.93 - 2.84 (m, 1H), 2.64 - 2.53 (m, 2H), 2.07 - 1.98 (m, 1H), 2.07 - 1.98 (m, 1H), 1.11 - 1.00 (m, 1H), 0.48 - 0.43 (m, 2H), 0.25 - 0.20 (m, 2H)
250[b]	**I-255**	FU	JL	723.0	11.20 (s, 1H), 10.14 (s, 1H), 9.08 (s, 1H), 8.92 (s, 1H), 8.86 (d, *J* = 5.2 Hz, 2H), 8.62 (s, 1H), 8.09 - 7.93 (m, 7H), 7.78 (d, *J* = 2.0 Hz, 2H), 7.48 - 7.16 (m, 1H), 5.14 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.22 (s, 1H), 3.35 (d, *J* = 6.0 Hz, 2H), 3.16 - 3.12 (m, 1H), 2.98 - 2.83 (m, 1H), 2.65 - 2.53 (m, 4H), 2.17 - 2.01 (m, 1H), 1.97 - 1.89 (m, 1H)

251	**I-256**	JG	JE	896.6	11.19 (s, 1H), 10.02 (s, 1H), 9.00 (s, 1H), 8.91 (s, 1H), 8.63 (t, *J* = 5.6 Hz, 1H), 8.26 (d, *J* = 5.6 Hz, 1H), 8.06 - 8.00 (m, 2H), 7.99 - 7.93 (m, 2H), 7.61 (t, *J* = 6.4 Hz, 1H), 7.46 - 7.18 (m, 3H), 7.14 - 7.06 (m, 2H), 7.01 - 6.97 (m, 1H), 5.35 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.32 - 4.18 (m, 2H), 3.61 - 3.55 (m, 4H), 3.55 - 3.50 (m, 2H), 3.49 - 3.41 (m, 4H), 2.94 - 2.83 (m, 1H), 2.75 - 2.70 (m, 2H), 2.69 - 2.66 (m, 1H), 2.57 - 2.53 (m, 1H), 2.20 - 2.11 (m, 1H), 1.88 - 1.79 (m, 2H)
252	**I-257**	NK	OM	786.4	10.88 (s, 1H), 9.47 (s, 1H), 8.69 (s, 1H), 8.00 (s, 1H), 7.98 - 7.94 (m, 1H), 7.92 (d, *J* = 5.6 Hz, 1H), 7.57 - 7.54 (m, 2H), 7.06 - 6.82 (m, 3H), 6.80 - 7.80 (m, 1H), 4.91 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.96 - 3.90 (m, 1H), 3.54 - 3.31 (m, 10H), 2.97 - 2.94 (m, 2H), 2.72 - 2.63 (m, 3H), 2.42 - 2.32 (m, 2H), 1.93 - 1.81 (m, 2H), 1.71 - 1.63 (m, 3H), 0.87 - 0.80 (m, 1H), 0.26 - 0.19 (m, 2H), 0.02 -0.03 (m, 2H)
253	**I-258**	NL	OM	784.4	11.13 (s, 1H), 9.72 (s, 1H), 8.93 (s, 1H), 8.19 (s, 1H), 8.15 (d, *J* = 5.2 Hz, 1H), 7.80 - 7.70 (m, 3H), 7.31 - 7.04 (m, 3H), 7.03 - 7.00 (m, 1H), 5.13 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.26 - 4.17 (m, 1H), 3.17 (t, *J* = 6.0 Hz, 2H), 3.05 (t, *J* = 7.6 Hz, 2H), 2.96 - 2.91 (m, 2H), 2.91 - 2.83 (m, 1H), 2.64 - 2.54 (m, 1H), 2.53 - 2.51 (m, 1H), 2.33 - 2.27 (m, 2H), 2.10 - 1.89 (m, 7H), 1.69 - 1.58 (m, 2H), 1.53 - 1.44 (m, 2H), 1.39 - 1.31 (m, 2H), 1.10 - 1.02 (m, 1H), 0.47 - 0.42 (m, 2H), 0.24 - 0.20 (m, 2H)

254	**I-259**	NN	OM	756.4	11.08 (s, 1H), 9.68 (s, 1H), 8.89 (s, 1H), 8.35 (s, 1H), 8.16 (s, 1H), 8.12 (d, *J* = 5.2 Hz, 1H), 7.78 - 7.67 (m, 3H), 7.28 - 7.10 (m, 1H), 7.09 - 7.03 (m, 2H), 7.00 - 6.97 (m, 1H), 5.11 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.19 (t, *J* = 11.2 Hz, 1H), 3.17 - 3.12 (m, 3H), 3.05 (t, *J* = 7.6 Hz, 2H), 2.96 - 2.82 (m, 3H), 2.65 - 2.63 (m, 1H), 2.56 - 2.51 (m, 1H), 2.35 - 2.29 (m, 3H), 2.02 - 1.93 (m, 5H), 1.81 - 1.73 (m, 2H), 1.03 (t, *J* = 6.8 Hz, 1H), 0.45 - 0.39 (m, 2H), 0.21 - 0.16 (m, 2H)
255[b]	**I-260**	JI	JL	723.3	11.10 (s, 1H), 10.14 (s, 1H), 9.06 (s, 1H), 8.91 (s, 1H), 8.84 (d, *J* = 5.6 Hz, 2H), 8.58 (s, 1H), 7.98 (s, 6H), 7.87 - 7.81 (m, 2H), 7.79 - 7.73 (m, 1H), 7.47 - 7.16 (m, 1H), 5.13 (dd, *J* = 5.2, 12.8 Hz, 1H), 2.87 (t, *J* = 7.2 Hz, 3H), 2.65 - 2.52 (m, 4H), 2.09 - 2.00 (m, 1H), 1.99 - 1.88 (m, 2H)
256	**I-261**	OK	JE	909.3	10.26 (s, 1H), 9.22 (s, 1H), 8.20 (s, 1H), 8.10 (s, 1H), 7.78 (t, *J* = 5.6 Hz, 1H), 7.44 (d, *J* = 5.2 Hz, 1H), 7.23 - 7.12 (m, 4H), 6.83 - 6.71 (m, 2H), 6.65 - 6.36 (m, 3H), 6.30 (d, *J* = 8.8 Hz, 1H), 6.21 (d, *J* = 7.2 Hz, 1H), 5.78 (t, *J* = 5.6 Hz, 1H), 4.24 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.49 - 3.38 (m, 2H), 2.84 - 2.80 (m, 2H), 2.80 - 2.74 (m, 6H), 2.63 (q, *J* = 5.2 Hz, 4H), 2.15 - 2.00 (m, 1H), 1.81 - 1.72 (m, 2H), 1.25 - 1.18 (m, 1H)
257	**I-262**	JQ	OM	786.4	11.11 (s, 1H), 9.72 (s, 1H), 8.91 (s, 1H), 8.18 (s, 1H), 8.14 (d, *J* = 5.2 Hz, 1H), 7.87 - 7.83 (m, 2H), 7.79 - 7.75 (m, 1H), 7.30 - 7.11 (m, 1H), 7.11 - 7.06 (m, 2H), 7.03 - 6.99 (m, 1H), 5.19 5.11 (m, 1H), 4.20 - 4.13 (m, 1H), 3.83 - 3.60 (m, 2H), 3.20 - 3.14 (m, 2H), 3.06 - 3.00 (m, 2H), 2.96 - 2.90 (m, 2H), 2.89 - 2.82 (m, 1H), 2.63 - 2.57 (m, 1H), 2.57 - 2.54 (m, 1H), 2.54 - 2.51 (m, 4H),

					2.15 - 2.08 (m, 2H), 2.04 - 1.98 (m, 1H), 1.96 - 1.86 (m, 4H), 1.10 - 1.02 (m, 1H), 0.48 - 0.42 (m, 2H), 0.26 - 0.18 (m, 2H)
258	**I-263**	NP	OM	784.5	11.12 (s, 1H), 10.36 (s, 1H), 9.87 (s, 1H), 9.02 (s, 1H), 8.24 (s, 1H), 8.15 - 8.13 (m, 1H), 7.87 (d, *J* = 7.6 Hz, 1H), 7.82 (s, 1H), 7.76 (d, *J* = 7.6 Hz, 1H), 7.39 - 7. 08(m, 3H), 5.15 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.64 - 4.53 (m, 1H), 3.67- 3.59 (m, 2H), 3.27 - 3.25 (m, 2H), 3.12 - 3.02 (m, 4H), 2.96 - 2.79 (m, 3H), 2.70 - 2.58 (m, 2H), 2.40 - 2.24 (m, 4H), 2.10 - 2.02 (m, 1H), 1.82 - 1.65 (m, 4H), 1.39 - 1.30 (m, 2H), 1.14 - 1.05 (m, 1H), 0.53 - 0.47 (m, 2H), 0.30- 0.24 (m, 2H)
259	**I-264**	NR	OM	756.4	11.10 (s, 1H), 9.69 (s, 1H), 8.92 (s, 1H), 8.24 - 8.17 (m, 1H), 8.16 - 8.12 (m, 1H), 7.89 - 7.80 (m, 2H), 7.76 - 7.73 (m, 1H), 7.33 - 6.97 (m, 4H), 5.14 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.29 - 4.17 (m, 1H), 3.18 (t, *J* = 6.0 Hz, 2H), 3.00 - 2.91 (m, 2H), 2.91 - 2.79 (m, 3H), 2.65 - 2.55 (m, 2H), 2.37 - 2.29 (m, 2H), 2.14 - 1.90 (m, 7H), 1.87 - 1.73 (m, 2H), 1.10 - 1.01 (m, 1H), 0.53 - 0.40 (m, 2H), 0.30 - 0.16 (m, 2H)
260	**I-265**	JG	FX	868.4	11.18 (s, 1H), 10.02 (s, 1H), 8.97 (s, 1H), 8.90 (s, 1H), 8.63 (t, *J* = 5.6 Hz, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.05 - 7.99 (m, 2H), 7.98 - 7.92 (m, 2H), 7.46 - 7.17 (m, 1H), 7.15 - 7.02 (m, 5H), 7.01 - 6.96 (m, 1H), 5.34 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.61 - 3.55 (m, 4H), 3.54 - 3.51 (m, 2H), 3.47 - 3.42 (m, 4H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.92 - 2.82 (m, 1H), 2.74 - 2.69 (m, 2H), 2.53 - 2.52 (m, 2H), 2.19 - 2.10 (m, 1H), 1.88 - 1.79 (m, 2H), 1.12 - 1.01 (m, 1H), 0.49 - 0.41 (m, 2H), 0.25 - 0.19 (m, 2H)

261	**I-266**	JG	CN	889.4	11.18 (s, 1H), 11.02 (s, 1H), 9.03 (d, *J* = 2.8 Hz, 2H), 8.64 (t, *J* = 6.0 Hz, 1H), 8.27 (d, *J* = 5.2 Hz, 1H), 8.14 - 8.00 (m, 5H), 7.81 - 7.66 (m, 2H), 7.28 (s, 1H), 7.22 - 7.16 (m, 1H), 7.14 - 7.06 (m, 2H), 6.99 (d, *J* = 7.2 Hz, 1H), 5.35 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.35 - 4.14 (m, 2H), 3.60 - 3.57 (m, 4H), 3.56 - 3.51 (m, 2H), 3.50 - 3.41 (m, 4H), 2.91- 2.81 (m, 1H), 2.76 - 2.65 (m, 4H), 2.19 - 2.12 (m, 1H), 1.89 - 1.78 (m, 2H)
262	**I-267**	KK	FX	964.2	11.08 (s, 1H), 10.00 (s, 1H), 8.97 (s, 1H), 8.92 (s, 1H), 8.65 - 8.60 (m, 1H), 8.29 (s, 1H), 8.17 (d, *J* = 5.2 Hz, 1H), 8.06 - 8.02 (m, 2H), 8.00 - 7.96 (m, 2H), 7.59 - 7.54 (m, 1H), 7.46 - 7.17 (m, 1H), 7.15 - 7.11 (m, 2H), 7.10 - 7.01 (m, 4H), 6.22 (d, *J* = 8.0 Hz, 1H), 5.05 (*J* = 5.2, 12.8 Hz, 1H), 3.58 - 3.51 (m, 10H), 3.45 (d, *J* = 5.6 Hz, 3H), 3.22 - 3.18 (m, 2H), 2.77 (d, *J* = 11.6 Hz, 2H), 2.63 - 2.55 (m, 2H), 2.19 (t, *J* = 10.4 Hz, 2H), 2.07 - 1.99 (m, 1H), 1.90 (d, *J* = 10.4 Hz, 2H), 1.51 - 1.43 (m, 2H), 1.12 - 1.04 (m, 1H), 0.48 - 0.45 (m, 2H), 0.26 - 0.21 (m, 2H)
263	**I-268**	NU	FX	920.0	10.85 (s, 1H), 9.78 (s, 1H), 8.74 (s, 1H), 8.67 (s, 1H), 8.39 (t, *J* = 5.4 Hz, 1H), 7.98 (s, 1H), 7.93 (d, *J* = 5.2 Hz, 1H), 7.82 - 7.77 (m, 2H), 7.76 - 7.72 (m, 2H), 7.34 - 7.26 (m, 1H), 7.23 - 6.93 (m, 1H), 6.90 - 6.72 (m, 6H), 5.98 (d, *J* = 8.2 Hz, 1H), 4.81 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.35 - 3.28 (m, 5H), 3.25 - 3.18 (m, 2H), 2.95 (t, *J* = 6.0 Hz, 2H), 2.69 - 2.54 (m, 3H), 2.36 - 2.29 (m, 3H), 2.01 (t, *J* = 10.4 Hz, 3H), 1.84 - 1.74 (m, 1H), 1.64 (d, *J* = 10.4 Hz, 2H), 1.29 - 1.18 (m, 2H), 0.91 - 0.79 (m, 1H), 0.28 - 0.19 (m, 2H), 0.03 - 0.04 (m, 2H)

264	**I-269**	JY	FX	1008.7	11.07 (s, 1H), 10.00 (s, 1H), 8.96 (s, 1H), 8.92 (s, 1H), 8.64 - 8.58 (m, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.05 - 8.00 (m, 2H), 7.99 - 7.95 (m, 2H), 7.59 - 7.53 (m, 1H), 7.45 - 7.17 (m, 1H), 7.15 - 7.11 (m, 2H), 7.15 - 7.10 (m, 1H), 7.04 - 7.01 (m, 2H), 6.25 - 6.19 (m, 1H), 5.08 - 4.99 (m, 1H), 3.56 - 3.50 (m, 15H), 3.21 - 3.14 (m, 2H), 2.90 - 2.83 (m, 1H), 2.79 - 2.73 (m, 2H), 2.62 - 2.57 (m, 1H), 2.57 - 2.53 (m, 1H), 2.45 - 2.43 (m, 2H), 2.21 - 2.15 (m, 2H), 2.05 - 1.98 (m, 1H), 1.92 - 1.86 (m, 2H), 1.51 - 1.42 (m, 2H), 1.10 - 1.04 (m, 1H), 0.47 - 0.43 (m, 2H), 0.24 - 0.21 (m, 2H)
265	**I-270**	HZ	FX	964.5	11.04 (s, 1H), 10.00 (s, 1H), 8.97 (s, 1H), 8.92 (s, 1H), 8.63 (t, *J* = 5.6 Hz, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.05 - 7.96 (m, 4H), 7.53 (d, *J* = 8.4 Hz, 1H), 7.46 - 7.16 (m, 1H), 7.12 (s, 1H), 7.07 (t, *J* = 5.6 Hz, 1H), 7.04 (dd, *J* = 1.2, 5.2 Hz, 1H), 6.99 - 6.93 (m, 2H), 6.85 (dd, *J* = 1.6, 8.8 Hz, 1H), 5.01 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.62 - 3.36 (m, 13H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.92 - 2.80 (m, 3H), 2.61 - 2.53 (m, 2H), 2.14 (t, *J* = 10.8 Hz, 2H), 2.03 - 1.94 (m, 1H), 1.87 (d, *J* = 11.2 Hz, 2H), 1.45 - 1.35 (m, 2H), 1.11 - 1.03 (m, 1H), 0.50 - 0.41 (m, 2H), 0.26 - 0.19 (m, 2H)
266	**I-271**	JZ	FX	920.5	11.03 (s, 1H), 9.99 (s, 1H), 8.97 (s, 1H), 8.90 (s, 1H), 8.62 (t, *J*=5.6 Hz, 1H), 8.16 (d, *J*=5.2 Hz, 1H), 8.05 - 8.00 (m, 2H), 7.99 - 7.95 (m, 2H), 7.52 (d, *J*=8.4 Hz, 1H), 7.45 - 7.16 (m, 1H), 7.12 (s, 1H), 7.09 - 7.05 (m, 1H), 7.04 (d, *J*=6.4 Hz, 1H), 6.98 - 6.93 (m, 2H), 6.84 (d, *J*=8.4 Hz, 1H), 5.06 - 4.96 (m, 1H), 3.58 - 3.52 (m, 4H), 3.48 - 3.38 (m, 5H), 3.21 - 3.15 (m, 2H), 2.91 - 2.81 (m, 3H), 2.64 - 2.54 (m, 1H), 2.53 -

					2.52 (m, 1H), 2.20 - 2.12 (m, 2H), 2.03 - 1.95 (m, 1H), 1.90 - 1.82 (m, 2H), 1.44 - 1.34 (m, 2H), 1.11 - 1.00 (m, 1H), 0.48 - 0.43 (m, 2H), 0.25 - 0.20 (m, 2H)
267	**I-272**	KA	FX	1008.7	11.04 (s, 1H), 10.01 (s, 1H), 8.97 (s, 1H), 8.92 (s, 1H), 8.62 (t, *J* = 5.2 Hz, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.04 - 7.96 (m, 4H), 7.53 (d, *J* = 8.4 Hz, 1H), 7.45 - 7.17 (m, 1H), 7.11 (s, 1H), 7.07 (t, *J* = 5.6 Hz, 1H), 7.04 (d, *J* = 5.6 Hz, 1H), 6.99 - 6.93 (m, 2H), 6.88 - 6.83 (m, 1H), 5.01 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.52 - 3.43 (m, 14H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.92 - 2.81 (m, 3H), 2.58 - 2.61 (m, 1H), 2.57 - 2.54 (m, 2H), 2.46 - 2.44 (m, 2H), 2.13 (t, *J* = 10.8 Hz, 2H), 2.01 - 1.94 (m, 1H), 1.91 - 1.83 (m, 2H), 1.46 - 1.35 (m, 2H), 1.11 - 1.03 (m, 1H), 0.48 - 0.43 (m, 2H), 0.25 - 0.20 (m, 2H)
268	**I-273**	KL	FX	950.5	11.06 (s, 1H), 10.00 (s, 1H), 8.97 (s, 1H), 8.90 (s, 1H), 8.62 (t, *J* = 5.6 Hz, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.06 - 7.94 (m, 4H), 7.66 (dd, *J* = 7.2, 8.4 Hz, 1H), 7.46 - 7.16 (m, 3H), 7.12 (s, 1H), 7.07 (t, *J* = 5.2 Hz, 1H), 7.04 (dd, *J* = 1.2, 5.2 Hz, 1H), 5.08 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.59 - 3.53 (m, 8H), 3.48 - 3.41 (m, 2H), 3.27 - 3.22 (m, 4H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.90 - 2.81 (m, 1H), 2.62 - 2.57 (m, 4H), 2.57 - 2.54 (m, 2H), 2.54 - 2.52 (m, 2H), 2.08 - 1.97 (m, 1H), 1.12 - 1.01 (m, 1H), 0.49 - 0.41 (m, 2H), 0.25 - 0.20 (m, 2H)

269	**I-274**	NY	FX	906.4	11.07 (s, 1H), 10.02 (s, 1H), 8.99 (s, 1H), 8.91 (s, 1H), 8.62 (t, *J* = 5.6 Hz, 1H), 8.27 (s, 1H), 8.17 (d, *J* = 5.2 Hz, 1H), 8.09 - 8.02 (m, 2H), 8.01 - 7.94 (m, 2H), 7.69 - 7.61 (m, 1H), 7.33 (d, *J* = 5.2 Hz, 1H), 7.24 (d, *J* = 8.8 Hz, 1H), 7.20 - 7.11 (m, 1H), 7.10 - 7.02 (m, 2H), 5.08 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.62 - 3.55 (m, 8H), 3.21 (d, *J* = 6.0 Hz, 4H), 2.93 - 2.82 (m, 2H), 2.64 - 2.57 (m, 6H), 2.07 - 1.98 (m, 1H), 1.12 - 1.04 (m, 1H), 0.50 - 0.43 (m, 2H), 0.24 (q, *J* = 4.8 Hz, 2H)
270	**I-275**	KB	FX	994.6	10.84 (s, 1H), 9.77 (s, 1H), 8.74 (s, 1H), 8.68 (s, 1H), 8.38 (t, *J* = 5.6 Hz, 1H), 7.93 (d, *J* = 5.2 Hz, 1H), 7.85 - 7.68 (m, 4H), 7.53 - 7.32 (m, 1H), 7.24 - 6.92 (m, 3H), 6.91 - 6.74 (m, 3H), 4.85 (dd, *J* = 5.6, 12.8 Hz, 1H),3.37 - 3.17 (m, 15H), 3.03 (s, 4H), 2.95 (t, *J* = 6.0 Hz, 2H), 2.72 - 2.56 (m, 1H), 2.36 (d, *J* = 4.4 Hz, 5H), 2.24 - 2.20 (m, 2H),2.20 - 1.84 (m, 1H), 1.83 - 1.74 (m, 1H), 0.96 - 0.71 (m, 1H), 0.27 - 0.15 (m, 2H), 0.05 - 0.07 (m, 2H)
271	**I-276**	OA	FX	950.5	10.85 (s, 1H), 9.81 (s, 1H), 8.75 (s, 1H), 8.68 (s, 1H), 8.42 (t, *J* = 5.6 Hz, 1H), 8.06 (s, 1H), 7.93 (d, *J* = 5.6 Hz, 1H), 7.84 - 7.70 (m, 4H), 7.42 (d, *J* = 8.8 Hz, 1H), 7.25 - 6.93 (m, 3H), 6.91 - 6.83 (m, 2H), 6.81 (dd, *J* = 1.2, 5.2 Hz, 1H), 4.83 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.40 - 3.29 (m, 8H), 3.26 - 3.19 (m, 2H), 3.15 (s, 4H), 2.95 (t, *J* = 6.0 Hz, 2H), 2.71 - 2.58 (m, 1H), 2.36 (s, 2H), 2.31 - 2.29 (m, 6H), 1.84 - 1.70 (m, 1H), 0.85 - 0.81 (m, 1H), 0.28 - 0.14 (m, 2H), 0.03 - 0.15 (m, 2H)

272	**I-277**	KF	FX	906.4	11.06 (s, 1H), 10.00 (s, 1H), 8.97 (s, 1H), 8.92 (s, 1H), 8.63 (t, *J* = 5.6 Hz, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.02 (d, *J* = 8.8 Hz, 2H), 7.99 (d, *J* = 8.8 Hz, 2H), 7.63 (d, *J* = 8.4 Hz, 1H), 7.46 - 7.15 (m, 3H), 7.12 (s, 1H), 7.11 - 7.01 (m, 2H), 5.05 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.61 - 3.53 (m, 4H), 3.50 - 3.44 (m, 2H), 3.39 - 3.34 (m, 4H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.95 - 2.81 (m, 1H), 2.61 - 2.53 (m, 8H), 2.06 - 1.95 (m, 1H), 1.12 - 1.01 (m, 1H), 0.51 - 0.42 (m, 2H), 0.28 - 0.18 (m, 2H)
273	**I-278**	NZ	FX	994.5	11.07 (s, 2H), 10.21 (s, 1H), 9.17 (s, 1H), 8.92 (s, 1H), 8.68 (t, *J* = 5.2 Hz, 1H), 8.13 - 7.92 (m, 5H), 7.73 (d, *J* = 8.4 Hz, 1H), 7.65 (s, 1H), 7.50 - 7.18 (m, 4H), 5.08 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.19 (d, *J* = 13.6 Hz, 2H), 3.90 - 3.78 (m, 2H), 3.62 - 3.52 (m, 12H), 3.50 - 3.29 (m, 8H), 3.19 - 3.17 (m, 2H), 2.95 - 2.80 (m, 1H), 2.69 - 2.53 (m, 2H), 2.08 - 1.96 (m, 1H), 1.23 - 1.09 (m, 1H), 0.61 - 0.51 (m, 2H), 0.35 - 0.31 (m, 2H)
274	**I-279**	GD	JE	922.1	11.09 (s, 1H), 10.01 (s, 1H), 9.00 (s, 1H), 8.86 (s, 1H), 8.25 (d, *J* = 5.2 Hz, 1H), 7.90 (d, *J* = 6.4 Hz, 2H), 7.80 (d, *J* = 7.2 Hz, 1H), 7.74 (s, 1H), 7.68 (s, 1H), 7.63 - 7.53 (m, 3H), 7.45 - 7.14 (m, 3H), 5.12 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.31 - 4.18 (m, 2H), 3.66 - 3.38 (m, 10H), 3.00 (s, 3H), 2.93 - 2.76 (m, 3H), 2.64 - 2.52 (m, 2H), 2.09 - 1.99 (m, 1H), 1.85 (t, *J* = 7.2 Hz, 2H)

275	**I-280**	HQ	JE	909.5	11.07 (s, 1H), 10.03 (s, 1H), 9.00 (s, 1H), 8.93 - 8.89 (m, 1H), 8.66 - 8.61 (m, 1H), 8.25 (d, *J* = 5.2 Hz, 1H), 8.03 - 7.94 (m, 4H), 7.61 (t, *J* = 6.4 Hz, 1H), 7.46 - 7.18 (m, 3H), 7.08 - 6.75 (m, 3H), 5.41 - 5.30 (m, 1H), 4.30 - 4.20 (m, 2H), 3.62 - 3.43 (m, 13H), 2.98 - 2.81 (m, 3H), 2.66 - 2.53 (m, 2H), 2.03 - 1.95 (m, 1H), 1.86 - 1.75 (m, 2H)
276	**I-281**	HR	JE	964.4	11.11 (s, 1H), 10.07 (s, 1H), 9.02 (s, 1H), 8.93 (s, 1H), 8.65 (s, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.06 - 8.00 (m, 2H), 8.00 - 7.94 (m, 2H), 7.63 (t, *J* = 6.4 Hz, 1H), 7.57 (t, *J* = 8.0 Hz, 1H), 7.54 - 7.30 (m, 1H), 7.27 (s, 1H), 7.22 (d, *J* = 5.2 Hz, 1H), 7.14 (d, *J* = 8.8 Hz, 1H), 7.03 (d, *J* = 6.8 Hz, 1H), 6.60 (s, 1H), 5.11 - 5.01 (m, 1H), 4.32 - 4.21 (m, 2H), 3.80 - 3.70 (m, 1H), 3.59 - 3.45 (m, 10H), 2.95 - 2.87 (m, 1H), 2.87 - 2.72 (m, 2H), 2.71 - 2.63 (m, 1H), 2.63 - 2.57 (m, 1H), 2.56 - 2.53 (m, 2H), 2.13 - 1.99 (m, 2H), 1.92 - 1.80 (m, 1H)
277	**I-282**	HK	JE	964.1	11.08 (s, 1H), 10.03 (s, 1H), 9.01 (s, 1H), 8.92 (s, 1H), 8.62 (t, *J* = 5.6 Hz, 1H), 8.25 (d, *J* = 5.2 Hz, 1H), 8.06 - 8.00 (m, 2H), 8.00 - 7.94 (m, 2H), 7.64 - 7.55 (m, 2H), 7.47 - 7.17 (m, 3H), 7.13 (d, *J* = 8.8 Hz, 1H), 7.03 (d, *J* = 7.2 Hz, 1H), 6.59 (t, *J* = 6.0 Hz, 1H), 5.09 - 5.03 (m, 1H), 4.31 - 4.20 (m, 2H), 3.80 - 3.72 (m, 1H), 3.65 - 3.54 (m, 6H), 3.50 - 3.42 (m, 4H), 3.31 (t, *J* = 5.6 Hz, 2H), 2.94 - 2.86 (m, 1H), 2.85 - 2.81 (m, 1H), 2.75 - 2.68 (m, 1H), 2.62 - 2.54 (m, 2H), 2.12 - 1.99 (m, 2H), 1.87 (t, *J* = 10.4 Hz, 1H)

278	**I-283**	KK	JE	992.5	11.09 (s, 1H), 10.02 (s, 1H), 9.00 (s, 1H), 8.92 (s, 1H), 8.63 (t, *J* = 5.2 Hz, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.19 (s, 1H), 8.06 - 7.96 (m, 4H), 7.64 - 7.53 (m, 2H), 7.27 (s, 1H), 7.46 - 7.25 (m, 1H), 7.24 - 7.20 (m, 1H), 7.13 (d, *J* = 8.8 Hz, 1H), 7.03 (d, *J* = 7.2 Hz, 1H), 6.22 (d, *J* = 8.0 Hz, 1H), 5.05 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.30 - 4.20 (m, 2H), 3.48 - 3.43 (m, 1H), 3.60 - 3.42 (m, 1H), 2.95 - 2.74 (m, 3H), 2.63 - 2.52 (m, 5H), 2.21 (t, *J* = 10.4 Hz, 2H), 2.07 - 1.98 (m, 1H), 1.90 (d, *J* = 11.2 Hz, 2H), 1.47 (q, *J* = 10.0 Hz, 2H)
279[b]	**I-284**	KH	OL	1152.1	11.10 (s, 1H), 10.10 (s, 1H), 9.14 (s, 1H), 8.79 (s, 1H), 8.63 (t, *J* = 6.4 Hz, 1H), 8.10 (d, *J* = 6.4 Hz, 1H), 7.84 - 7.72 (m, 2H), 7.65 - 7.40 (m, 5H), 7.43 - 7.16 (m, 2H), 7.12 - 7.09 (m, 1H), 7.03 - 7.01 (m, 1H), 6.59 (s, 1H), 5.05 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.58 (d, *J* = 9.6 Hz, 1H), 4.48 - 4.21 (m, 4H), 4.01 - 3.92 (m, 2H), 3.77 - 3.60 (m, 15H), 3.35 - 3.30 (m, 2H), 2.96 - 2.82 (m, 1H), 2.60 - 2.58 (m, 2H), 2.12 - 1.97 (m, 2H), 1.96 - 1.85 (m, 1H), 1.19 - 1.10 (m, 1H), 1.00 - 0.88 (m, 9H), 0.59 - 0.56 (m, 2H), 0.34 - 0.32 (m, 2H)
280[b]	**I-285**	OC	OL	1193.8	10.86 - 10.84 (m, 1H), 10.85 (s, 1H), 9.76 (s, 1H), 8.80 - 8.74 (m, 1H), 8.77 (s, 1H), 8.55 (s, 1H), 8.39 (t, *J* = 6.4 Hz, 1H), 7.90 (d, *J* = 4.8 Hz, 1H), 7.53 (d, *J* = 8.4 Hz, 2H), 7.34 - 7.29 (m, 1H), 7.24 - 7.19 (m, 3H), 7.18 - 6.90 (m, 3H), 6.87 (d, *J* = 8.4 Hz, 2H), 6.78 (d, *J* = 6.8 Hz, 1H), 6.35 (t, *J* = 5.6 Hz, 1H), 5.03 (s, 1H), 4.81 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.27 - 4.14 (m, 3H), 4.08 - 4.00 (m, 1H), 4.08 - 4.00 (m, 1H), 3.71 (m, 2H), 3.68 (m, 1H), 3.63 - 3.56 (m, 1H), 3.38 - 3.33 (m, 10H), 3.21 (d, *J* = 5.2 Hz, 2H), 2.97 (m,

					2H), 2.70 - 2.58 (m, 1H), 2.38 - 2.34 (m, 1H), 2.34 - 2.30 (m, 1H), 2.05 - 1.99 (m, 1H), 1.90 - 1.86 (m, 1H), 1.79 (m, 1H), 1.76 (s, 3H), 1.77 - 1.74 (m, 1H), 0.90 - 0.84 (m, 1H), 0.72 (s, 9H), 0.26 (m, 2H), 0.04 - -0.01 (m, 2H)
282[b]	**I-287**	KG	OL	1160.5 $(M+23)^+$	11.09 (s, 1H), 10.09 (s, 1H), 9.12 (s, 1H), 8.80 (s, 1H), 8.51 (t, J = 6.4 Hz, 1H), 8.10 (d, J = 6.4 Hz, 1H), 7.86 - 7.76 (m, 2H), 7.64 - 7.50 (m, 2H), 7.43 (d, J = 8.4 Hz, 2H), 7.33 - 6.98 (m, 4H), 6.60 (s, 1H), 5.05 (dd, J = 5.2, 13.2 Hz, 1H), 4.41 - 4.29 (m, 4H), 4.09 (s, 2H), 3.70 - 3.23 (m, 18H), 2.94 - 2.82 (m, 1H), 2.60- 2.56 (m, 2H), 2.09 - 1.97 (m, 2H), 1.92 - 1.82 (m, 1H), 1.19 - 1.09 (m, 1H), 0.58- 0.54 (m, 2H), 0.34 - 0.30 (m, 2H)
283[b]	**I-288**	OB	OL	1080.7	11.09 (s, 1H), 9.98 (s, 1H), 8.95 (s, 1H), 8.78 (s, 1H), 8.58 (s, 1H), 8.15 (d, J = 4.8 Hz, 1H), 7.80 (d, J = 8.4 Hz, 2H), 7.86 - 7.76 (m, 1H), 7.62 - 7.52 (m, 1H), 7.48 - 7.12 (m, 4H), 7.12 - 6.98 (m, 4H), 6.59 (s, 1H), 5.25 (s, 1H), 5.04 (d, J = 8.4 Hz, 1H), 4.44 - 4.40 (m, 1H), 4.36 - 4.62 (m, 2H), 4.12 - 4.10 (m, 2H), 3.86 - 3.70 (m, 1H), 3.65 - 3.51 (m, 14H), 3.19 (d, J = 6.0 Hz, 2H), 2.88 - 2.82 (m, 1H), 2.62 - 2.60 (m, 1H), 2.58 - 2.57 (m, 1H), 2.28 - 2.22 (m, 1H), 2.10 - 2.04 (m, 1H), 2.01 (s, 3H) 1.10 - 1.02 (m, 1H), 0.50- 0.40 (m, 2H), 0.25 - 0.21 (m, 2H)

285	**I-290**	KK	DF	957.6	11.11 (s, 1H), 11.04 (s, 1H), 9.17 (s, 1H), 9.02 (s, 1H), 8.75 - 8.71 (m, 1H), 8.14 (s, 1H), 8.12 - 8.03 (m, 6H), 7.79 (s, 1H), 7.66 (s, 1H), 7.63 - 7.56 (m, 1H), 7.27 - 7.19 (m, 2H), 7.10 - 7.03 (m, 1H), 6.20 (d, *J* = 7.6 Hz, 1H), 5.06 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.83 (d, *J* = 4.0 Hz, 3H), 3.64 - 3.54 (m, 7H), 3.38 - 3.32 (m, 5H), 3.28 (s, 3H), 3.11 (d, *J* = 12.0 Hz, 1H), 2.93 - 2.85 (m, 1H), 2.70 - 2.55 (m, 3H), 2.14 (d, *J* = 12.8 Hz, 2H), 2.08 - 1.98 (m, 2H), 1.87 - 1.84 (m, 1H), 1.19 - 1.13 (m, 1H), 0.60 - 0.55 (m, 2H), 0.36 - 0.32 (m, 2H)
286	**I-291**	KP	2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]-ethoxy]ethoxy]acetic acid (synthesized via Steps 1-2 of Example 160)	860.4	11.1 (s, 1H), 10.3 (s, 1H), 9.88 (s, 1H), 8.98 (s, 1H), 8.37 (s, 1H), 8.22 (s, 1H), 8.17 (d, *J* = 5.6 Hz, 1H), 7.78 (d, *J* = 8.8 Hz, 2H), 7.58 (t, *J* = 7.6 Hz, 1H), 7.43 (d, *J* = 8.8 Hz, 2H), 7.16 (d, *J* = 8.8 Hz, 1H), 7.14 - 7.08 (m, 2H), 7.05 - 7.01 (m, 2H), 6.69 - 6.59 (m, 1H), 5.10 - 5.00 (m, 1H), 4.13 (s, 2H), 3.75 - 3.63 (m, 6H), 3.56 - 3.51 (m, 2H), 3.25 - 3.02 (m, 2H), 2.93 - 2.86 (m, 1H), 2.63 - 2.59 (m, 1H), 2.59 - 2.56 (m, 1H), 2.03 - 1.99 (m, 1H), 1.13 - 1.07 (m, 1H), 0.49 - 0.43 (m, 2H), 0.27 - 0.21 (m, 2H)
287	**I-292**	4-[2-[2-[2-(2-aminoethoxy)-ethoxy]ethoxy]-ethylamino]-2-(2,6-dioxo-3-piperidyl)-isoindoline-1,3-dione (synthesized via Steps 1-2 of Example 128)	KR	841.1	11.08 (s, 1H), 10.81 (s, 1H), 8.97 (s, 1H), 8.38 (s, 1H), 8.25 (d, *J* = 5.6 Hz, 1H), 8.21 (s, 1H), 7.71 - 7.65 (m, 1H), 7.56 (t, *J* = 8.0 Hz, 1H), 7.25 (s, 1H), 7.17 (d, *J* = 5.6 Hz, 1H), 7.11 (d, *J* = 8.4 Hz, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.58 (s, 1H), 5.04 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.33 - 4.17 (m, 2H), 3.93 (s, 3H), 3.61 (t, *J* = 5.2 Hz, 2H), 3.55 (d, *J* = 4.8 Hz, 10H), 3.46 (d, *J* = 4.8 Hz, 4H), 2.91 - 2.83 (m, 1H), 2.60 - 2.56 (m, 1H), 2.56 - 2.52 (m, 1H), 2.08 - 2.00-(m, 1H)

288	**I-293**	LP	CW	1109.6	10.95 (s, 1H), 9.01 - 8.93 (m, 2H), 8.60 - 8.54 (m, 1H), 8.37 - 8.32 (s, 1H), 8.25 - 8.23 (m, 1H), 8.18 (s, 1H), 7.89 - 7.77 (m, 1H), 7.74 - 7.61 (m, 2H), 7.51 (s, 1H), 7.46 - 7.33 (m, 4H), 7.25 (s, 1H), 7.16 (d, *J* = 5.2 Hz, 1H), 4.58 - 4.18 (m, 7H), 3.69 - 3.51 (m, 16H), 3.24 - 3.17 (m, 3H), 3.11 - 3.08 (m, 1H), 2.67 - 2.57 (m, 1H), 2.47 - 2.41 (m, 4H), 2.25 - 2.17 (m, 1H), 2.13 - 2.02 (m, 2H), 1.97 - 1.78 (m, 4H), 1.68 - 1.50 (m, 2H), 0.90 (s, 9H)
289	**I-294**	LR	KR	839.4	11.08 (s, 1H), 10.84 (s, 1H), 8.97 (s, 1H), 8.37 (s, 1H), 8.35 (t, *J* = 5.6 Hz, 1H), 8.25 (d, *J* = 5.6 Hz, 1H), 7.68 (t, *J* = 6.4 Hz, 1H), 7.59 - 7.53 (m, 1H), 7.25 (s, 1H), 7.17 (dd, *J* = 1.2, 5.2 Hz, 1H), 7.05 (d, *J* = 8.8 Hz, 1H), 7.00 (d, *J* = 7.2 Hz, 1H), 6.63 (t, *J* = 5.6 Hz, 1H), 5.04 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.30 - 4.19 (m, 2H), 3.93 (s, 3H), 3.54 - 3.39 (m, 12H), 2.93 - 2.83 (m, 1H), 2.60 (d, *J* = 2.4 Hz, 1H), 2.58 - 2.54 (m, 1H), 2.07 - 1.97 (m, 1H), 1.85 - 1.73 (m, 6H)
290	**I-295**	LP	KR	1020.1 $(M+Na)^+$	10.82 (s, 1H), 8.97 (d, *J* = 1.6 Hz, 2H), 8.57 (t, *J* = 6.0 Hz, 1H), 8.38 (s, 1H), 8.27 - 8.22 (m, 2H), 7.70 (t, *J* = 6.4 Hz, 1H), 7.46 - 7.30 (m, 4H), 7.25 (s, 1H), 7.17 (dd, *J* = 1.2, 5.2 Hz, 1H), 4.52 (t, *J* = 8.0 Hz, 1H), 4.44 - 4.31 (m, 2H), 4.29 - 4.19 (m, 3H), 3.94 (s, 3H), 3.74 - 3.52 (m, 14H), 3.20 (d, *J* = 6.0 Hz, 2H), 3.08 (s, 1H), 2.61 (td, *J* = 6.0, 12.0 Hz, 1H), 2.46 - 2.38 (m, 4H), 2.11 - 1.99 (m, 1H), 1.95 - 1.80 (m, 1H), 0.90 (s, 9H)

291	**I-296**	LX	FX	1204.2	10.04 (s, 1H), 8.98 (s, 1H), 8.92 (s, 1H), 8.64 (br t, *J* = 5.4 Hz, 1H), 8.20 - 8.14 (m, 2H), 8.06 - 7.95 (m, 5H), 7.47 - 7.42 (m, 1H), 7.33 - 7.29 (m, 1H), 7.14 - 7.02 (m, 9H), 6.93 (d, *J* = 2.0 Hz, 1H), 6.82 - 6.74 (m, 2H), 5.03 (d, *J* = 9.6 Hz, 1H), 4.93 - 4.85 (m, 2H), 4.71 - 4.61 (m, 2H), 4.36 (t, *J* = 5.2 Hz, 4H), 4.14 - 4.03 (m, 3H), 3.85 (d, *J* = 9.2 Hz, 2H), 3.73 (t, *J* = 4.4 Hz, 3H), 3.46 - 3.43 (m, 8H), 3.20 - 3.16 (m, 6H), 3.03 - 2.94 (m, 2H), 2.70 - 2.65 (m, 2H), 2.36 - 2.32 (m, 1H), 1.91 - 1.75 (m, 2H), 1.68 (d, *J* = 5.6 Hz, 1H), 1.62 - 1.50 (m, 2H), 1.04 (d, *J* = 3.6 Hz, 9H), 0.49 - 0.43 (m, 2H), 0.26 - 0.21 (m, 2H)
292	**I-297**	LZ	KR	853.4	11.09 (s, 1H), 10.85 (s, 1H), 8.96 (s, 1H), 8.36 (s, 1H), 8.34 - 8.20 (m, 2H), 7.71 - 7.66 (m, 1H), 7.25 (s, 1H), 7.17 (d, *J* = 4.4 Hz, 1H), 6.99 - 6.86 (m, 2H), 6.86 – 6.76 (m, 1H), 5.42 - 5.28 (m, 1H), 4.31 - 4.18 (m, 2H), 3.91 (s, 3H), 3.54 (s, 3H), 3.48 - 3.44 (m, 4H), 3.24 - 3.17 (m, 4H), 2.97 - 2.85 (m, 3H), 2.73 - 2.63 (m, 2H), 2.62 - 2.55 (m, 2H), 2.02 - 1.97 (m, 1H), 1.86 - 1.72 (m, 4H), 0.90 (s, 6H)
293[b]	**I-298**	MD	MC	1144.5	10.82 (s, 1H), 8.99 - 8.96 (m, 2H), 8.61 - 8.56 (m, 1H), 8.38 (s, 1H), 8.27 - 8.22 (m, 2H), 7.73 - 7.65 (m, 1H), 7.43 - 7.37 (m, 5H), 7.25 (s, 1H), 7.18 - 7.15 (m, Hz, 1H), 5.16 - 5.12 (m, 1H), 4.55 (d, *J* = 9.6 Hz, 1H), 4.46 - 4.41 (m, 1H), 4.36 - 4.32 (m, 1H), 4.27 - 4.23 (m, 2H), 3.95 (s, 2H), 3.93 (s, 3H), 3.70 - 3.40 (m, 26H), 2.53 - 2.52 (m, 1H), 2.45 - 2.41 (m, 4H), 2.06 - 2.00 (m, 1H), 1.93 - 1.85 (m, 1H), 0.95 - 0.90 (m, 9H)


294	**I-299**	ME	KR	1056.4	10.82 (s, 1H), 8.98 (s, 2H), 8.59 (t, *J* = 5.6 Hz, 1H), 8.39 (s, 1H), 8.28 - 8.20 (m, 2H), 7.69 (t, *J* = 6.4 Hz, 1H), 7.46 - 7.36 (m, 5H), 7.26 (s, 1H), 7.17 (d, *J* = 5.6 Hz, 1H), 5.16 (d, *J* = 3.2 Hz, 1H), 4.56 (d, *J* = 9.2 Hz, 1H), 4.48 - 4.42 (m, 1H), 4.42 - 4.31 (m, 2H), 4.30 - 4.27 (m, 1H), 4.26 - 4.19 (m, 2H), 3.96 (s, 2H), 3.94 (s, 3H), 3.70 - 3.43 (m, 16H), 2.56 - 2.52 (m, 2H), 2.44 (s, 3H), 2.09 - 2.03 (m, 1H), 1.96 - 1.84 (m, 1H), 0.94 (s, 9H)
295[b]	**I-300**	4-[2-[2-[2-(2-aminoethoxy)-ethoxy]ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)-isoindoline-1,3- dione (synthesized via Steps 1-2 of Example 128)	MF	667.3	11.10 (s, 1H), 10.82 (s, 1H), 8.82 (d, *J* = 0.8 Hz, 1H), 8.60 (d, *J* = 0.8 Hz, 1H), 8.33 (s, 1H), 8.21 (t, *J* = 5.6 Hz, 1H), 7.56 (dd, *J* = 7.2, 8.4 Hz, 1H), 7.11 (d, *J* = 8.4 Hz, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.59 (t, *J* = 5.6 Hz, 1H), 5.05 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.91 (s, 3H), 3.63 - 3.57 (m, 2H), 3.57 - 3.49 (m, 10H), 3.47 - 3.39 (m, 4H), 2.93 - 2.82 (m, 1H), 2.63 - 2.52 (m, 2H), 2.08 - 1.97 (m, 1H)
296[b]	**I-301**	4-[2-[2-[2-(2-aminoethoxy)-ethoxy] ethoxy]-ethylamino]-2-(2,6-dioxo-3-piperidyl)-isoindoline-1,3-dione (synthesized via Steps 1-2 of Example 128)	MI	744.1	11.08 (s, 1H), 10.89 (s, 1H), 9.07 (s, 1H), 8.83 (d, *J* = 6.4 Hz, 2H), 8.38 (s, 1H), 8.25 - 8.22 (m, 1H), 7.94 (d, *J* = 6.0 Hz, 2H), 7.57 - 7.53(m, 1H), 7.10 (d, *J* = 8.8 Hz, 1H), 7.01 (d, *J* = 6.4 Hz, 1H), 6.59 - 6.56 (m, 1H), 5.07 - 5.02 (m, 1H), 3.93 (s, 3H), 3.61 - 3.59 (m, 2H), 3.55 - 3.54 (m, 10H), 3.46 - 3.43 (m, 4H), 2.87 - 2.86 (m, 1H), 2.82 - 2.56 (m, 2H), 2.04 - 2.01 (m, 1H)

[a]For variations on Method 12, see Table 10. [b]No deprotection Step 2 was required.

[005334] **Further Examples using synthetic methods similar to Method 12:**

[005335] **Example 281: [(3R,5S)-5-[[4-[4-[[2-[2-(cvclopropylmethylamino)-4-**

pyridylloxazole-4-carbonyllaminol-3 _ _-(difluoromethvOpyrazol-l-yllphenyllmethylcarbamoyll-l -[(2S)-2-[[2-[2-[2-[2-[[2-(2,6-dioxo-3-piper dyP-l ,3-dioxo-isoindolin-4-yll aminol ethoxyl ethoxyl ethoxyl acetyl]aminol-3,3-dimethyl-butanoyl]pyrrolidin-3-yl] (2S)-pyrrolidine-2-carboxylate, I-286




KJ

[005336] To a solution of 0 1-benzyl 02-[(3R,5S)-5-[[4-[4-[[2-[2-(cyclopropylmethylamino)-4- pyridyl] oxazole -4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]phenyl]methylcarbamoyl]-l-[(2S)-2-[[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethoxy]acetyl]amino]-3,3-dimethyl-butanoyl]pyrrolidin-3-yl] (2S)-pyrrolidine-l,2-dicarboxylate (140 mg, 101 umol, synthesized via Method 12 with Intermediate KJ as the amine and 2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)acetic acid, syntheisized via Steps 1-2 of Example 152, as the acid in Step 1) in DCM (4 mL) was added HBr/HOAc (101 umol, 2 mL, 33% solution), and the reaction

mixture was stirred at rt for 1.5 hr. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10um;mobile phase: [water(0.225%FA)-ACN];B%: 21%-41%,8min) to give the title compound (42.9 mg, 32% yield) as a white solid. ¹H NMR (400MHz, DMSO-d_6) 11.07 (s, 1H), 9.95 (s, 1H), 8.96 (s, 1H), 8.78 (s, 1H), 8.64 (t, J = 6.0 Hz, 1H), 8.16 (d, J = 5.2 Hz, 1H), 7.85 - 7.71 (m, 2H), 7.55 (t, J = 8.0 Hz, 1H), 7.48 - 7.14 (m, 4H), 7.14 - 7.09 (m, 2H), 7.08 - 7.05 (m, 1H), 7.04 - 6.98 (m, 2H), 6.62 - 6.53 (m, 1H), 5.30 (s, 1H), 5.04 (dd, J = 5.2, 12.8 Hz, 1H), 4.54 - 4.35 (m, 3H), 4.32 - 4.24 (m, 1H), 3.98 - 3.89 (m, 3H), 3.87 - 3.82(m, 1H), 3.70 - 3.58 (m, 11H), 3.48 - 3.40 (m, 2H), 3.19 (t, J = 6.0 Hz, 2H), 2.93 - 2.83 (m, 2H), 2.80 - 2.72 (m, 1H), 2.63 - 2.54 (m, 2H), 2.29 - 2.22 (m, 1H), 2.18 - 1.87 (m, 4H), 1.77 - 1.69 (m, 1H), 1.68 - 1.53 (m, 1H), 1.09 - 1.02 (m, 1H), 1.00 - 0.90 (m, 9H), 0.49 - 0.41 (m, 2H), 0.26 - 0.19 (m, 2H); LC-MS (ESI$^+$) m/z 1248.3 $(M+H)^+$.

[005337] Example 284: [[3R,5S)-5-[[4-[4-[[2-[2-[cyclopropylmethylamino]-4-Pyridyl]oxazole-4-carbonyl]amino]-3-[(difluoromethyl)pyrazol-1-yl]phenyl]methylcarbamoyl]-1-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethoxy]acetyl]pyrrolidin-3-yl] (2S)-pyrrolidine-2-carboxylate, I-289




KI

[005338] To a solution of 0 1-benzyl 02-[(3R,5S)-5-[[4-[4-[[2-[2-(cyclopropylmethylamino)-4-pyridyl]oxazole -4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]phenyl]methylcarbamoyl]-l-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethoxy]acetyl]pyrrolidin-3-yl](2S)-pyrrolidine-l,2-dicarboxylate (70 mg, 55.1 umol, synthesized via Step 1 of Method 12, coupling amine intermediate KI with 2-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy) ethoxy)acetic acid (synthesized via Steps 1-2 of Example 152) as the acid) in DCM (2 mL) was added HBr/AcOH (4 M, 1 mL, 33 wt%), and the reaction mixture was stirred at rt for 4 hrs. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 l50*25*l0um;mobile phase: [water(0.225%FA)-ACN];B%: l0%-37%,2min) to give the title compound (40.7 mg, 61% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-^e) δ ^{1}H NMR (400MHz, DMSO-^e) δ 11.07 (s, 1H), 9.95 (s, 1H), 8.96 (s, 1H), 8.79 (s, 1H), 8.57 (t, *J* = 5.6 Hz, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.85


- 7.76 (m, 2H), 7.61 - 7.53 (m, 1H), 7.43 (d, *J* = 8.4 Hz, 2H), 7.41 - 7.09 (m, 3H), 7.09 - 6.97 (m, 3H), 6.64 - 6.52 (m, 1H), 5.29 (s, 1H), 5.04 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.42 (t, *j* = 7.6 Hz, 1H), 4.38 - 4.30 (m, 2H), 4.14 - 4.03 (m, 2H), 3.85 - 3.64 (m, 4H), 3.63 - 3.59 (m, 4H), 3.51 - 3.41 (m, 8H), 3.22 - 3.02 (m, 2H), 2.92 - 2.84 (m, 2H), 2.80 - 2.74 (m, 1H), 2.64 - 2.55 (m, 2H), 2.27 - 2.20 (m, 1H), 2.15 - 2.06 (m, 1H), 2.04 - 1.92 (m, 2H), 1.77 - 1.69 (m, 1H), 1.68 - 1.57 (m, 2H), 1.11 - 1.01 (m, 1H), 0.49 - 0.42 (m, 2H), 0.23 (q, *J* = 4.8 Hz, 2H); LC-MS (ESI+) m/z 1135.7 $(M+l)^+$.

[005339] Example 297: N-[3-carbamoyl-l-[4-[[4-[2-[2-[[2-(2,6-dioxo-3-piperidvi)-i,3-dioxo-isoindolin-4-yllaminol ethoxy]ethyl]morpholin-2-yl]methoxymethyl]phenyl]pyrazol-4-yll-2-[2-[2.,2.,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide, 1-302



[005340] To a mixture of N-[3-carbamoyl-l-[4-(morpholin-2-ylmethoxymethyl)phenyl]pyrazol-4-yl]-2-[2-(2,2,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide (70.0 mg, 109.89 umol, HC1, synthesized via Steps 1-2 of Method 12 coupling amine tert-butyl 2-[[4-(4-amino-3-carbamoyl-pyrazol-l-yl)phenyl]methoxymethyl] morpholine-4-carboxylate, Intermediate MK, and acid 2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid, Intermediate CM, in Step 1) in MeCN (10 mL) was added NaHCCb (36.93 mg, 439.55 umol). Then 2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo- isoindolin-4-yl]amino]ethoxy]ethyl methanesulfonate (48.29 mg, 109.89 umol, synthesized via Steps 1-2 of Example 184) was added into the mixture. The mixture was stirred at 80 °C for 12 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]; B%: 25%-42%, 6 min) to give the title compound (42.0 mg, 35% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-r¾) δ 11.09 (s, 1H), 11.00 (s, 1H), 9.02 (s, 1H), 8.92 (s, 1H), 8.24 (s, 1H), 8.06 - 8.02 (m, 1H), 8.04 (s, 1H), 7.94 (d, *J* = 8.4 Hz, 2H), 7.74 - 7.66 (m, 2H), 7.60 - 7.53 (m, 1H), 7.46 (d, *J* = 8.4 Hz, 2H), 7.26 (s, 1H), 7.19 - 7.10 (m, 2H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.59 (t, 7 = 5.6 Hz, 1H), 5.09 - 5.01 (m, 1H), 4.51 (s, 2H), 4.29 - 4.18 (m, 2H), 3.79 - 3.68 (m, 1H), 3.58 (d, *J* = 5.6, 15.2 Hz, 9H), 3.39 (d, *J* = 4.8 Hz, 4H), 2.92 - 2.75 (m, 2H), 2.72 - 2.53 (m, 3H), 2.33 (td, *J* = 1.8, 9.2 Hz, 1H), 2.08 - 1.97 (m, 1H), 2.10 - 1.97 (m, 1H); LC-MS (ESI^{+}) *m/z* 944.1 (M+H)$^{+}$.


[005341] Example 298: N-r3-carbamoyl-l-r4-rri-r2-r2-rr2-t2.6-dioxo-3-piperidviyi.3-dioxo-isoindolin-4-yllaminol ethoxy] ethyl]-2-piperidyl1 methoxymethyl] phenyl] pyrazol-4-yl1-2-[2-t2,2,2-trifluoroethylaminoy4-pyridyl]oxazole-4-carboxamide, 1-303



[005342] To a mixture of N-[3-carbamoyl-l-[4-(2-piperidylmethoxymethyl)phenyl]pyrazol-4-yl]-2-[2-(2,2,2- trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide (70.0 mg, 110.2 umol, HC1, synthesized via Method 12 coupling amine tert-butyl 2-[[4-(4-amino-3-carbamoyl-pyrazol-l-yl)phenyl]methoxymethyl]piperidine -l-carboxylate, Intermediate MM and acid 2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl] oxazole-4-carboxylic acid, Intermediate CM in Step 1) in CH3CN (10 mL) was added NaHCCb (37.0 mg, 441 umol). Then 2-[2-[[2-(2,6-

dioxo-3-piperidyl)-l,3-dioxo-isoindolin- 4-yl]amino]ethoxy]ethyl methanesulfonate (48.4 mg, 110 umol, synthesized via Steps 1-2 of Example 184) was added into the mixture. The mixture was stirred at 80 °C for 24 hrs. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225%FA)-ACN]; B%: 22%-42%, 7 min) to give the title compound (32.8 mg, 30% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-^e) δ 11.09 (s, 1H), 11.00 (s, 1H), 9.03 (s, 1H), 8.92 (s, 1H), 8.28 - 8.25 (m, 3H), 8.04 (s, 1H), 7.93 (d, *J* = 8.4 Hz, 2H), 7.74 - 7.66 (m, 2H), 7.59 - 7.53 (m, 1H), 7.46 (d, *J* = 8.4 Hz, 2H), 7.28 (s, 1H), 7.19 (d, *J* = 4.0 Hz, 1H), 7.12 (d, *j* = 8.4 Hz, 1H), 7.02 (d, *j* = 7.2 Hz, 1H), 6.58 (s, 1H), 5.05 (dd, *j* = 5.6, 12.8 Hz, 1H), 4.49 (s, 2H), 4.25 (dd, *J* = 6.0, 9.2 Hz, 2H), 3.60 - 3.55 (m, 6H), 3.51 (s, 7H), 2.87 - 2.85 (m, 4H), 2.70 - 2.64 (m, 3H), 2.34 - 2.14 (m, 2H), 1.60 (s, 3H), 1.36 - 1.24 (m, 1H). LC-MS (ESI^{+}) *m/z* 942.2 (M+H) $^{+}$.

[005343] Example 299: N-[3-carbamoyl-l-[[i-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino] ethoxy|ethoxy|ethyl]triazol-4-yl]methyl]pyrazol-4-yl]-2-r2-(cyclopropylmethylaminoV4-pyridyl]oxazole-4-carboxamide, 1-304



[005344] Step 2 - Tert-butyl N-[4-[4-[[3-carbamoyl-1-[[1-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethyl]triazol-4-yl]methyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(cyclopropylmethyl)carbamate


To a solution of tert-butyl N-[4-[4-[(3-carbamoyl-l-prop-2-ynyl-pyrazol-4-yl)carbamoyl]oxazol-2-yl]- 2-pyridyl]-N-(cyclopropylmethyl)carbamate (106 mg, 209 umol, synthesized via Step 1 of Method 12 coupling amine 4-amino- l-prop-2-ynyl-pyrazole-3 -carboxamide, Intermediate MT with acid 2-[2-[tert- butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid, synthesized via Steps 1-4 of Intermediate DF) and 4-[2-[2-(2-azidoethoxy)ethoxy]ethylamino]-2-(2,6-dioxo- 3-piperidyl)isoindoline-l,3-dione (60.0 mg, 139

umol, Intermediate MS) in t-BuOH (5 mL) was added $CuS0_4$ (4.6 mg, 28.8 umol, 4.42 uL) and sodium;(2R)-2-[(lS)-l,2-dihydroxyethyl]-4- hydroxy-5 -oxo-2H-furan-3-ol ate (11.1 mg, 55.8 umol) in H_20 (5 mL). The reaction mixture was stirred at 60 °C for 2 hours under nitrogen. On completion, the reaction mixture was poured into brine (30 mL) and extracted with EA (3 X 50 mL). The combined organic layers were washed with brine (50 mL), dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give the title compound (140 mg, 99% yield) as a light yellow solid. LC-MS (ESI^+) m/z 936.5 $(M+H)^+$.

[005345] Step _3_-_N-[3-carbamoyl-l-ɨ l-[2-[2-[2-IT2-(2,6-dioxo-3-piperɨ dvl)-L3-dioxo-isoindolin-4- vl]amino]_ _____ethoxy1ethoxy1ethyl1triazol-4-yl1methyl1pyrazol-4-yl1-2-r2-(cvclopropylmethylamino)-4-pyridyl1oxazole-4-carboxamide

To a solution of tert-butyl N-[4-[4-[[3-carbamoyl-l-[[l-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo -isoindolin-4-yl]amino]ethoxy]ethoxy]ethyl]triazol-4-yl]methyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(cyclopropylmethyl)carbamate (140 mg, 150 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 10 mL). The reaction mixture was stirred at rt for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* and purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225%FA)-ACN]; B%: 18%-35%, 6 min). The purity of product was only 85%. Then the impure product was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.05%HCl) - ACN]; B%: l6%-36%, 7.8 min) to give the title compound (6.40 mg, 5% yield) as a yellow solid. ¾ NMR (400 MHz, DMSO-^e) δ 11.09 (s, 1H), 10.99 (s, 1H), 9.47 (s, 1H), 9.09 (s, 1H), 8.44 (s, 1H), 8.13 (s, 1H), 8.06 (d, J = 6.0 Hz, 1H), 7.81 (s, 1H), 7.63 (s, 1H), 7.58 - 7.50 (m, 2H), 7.18 - 7.23 (m, 1H), 7.07 (d, J = 8.8 Hz, 1H), 6.99 (d, J = 6.4 Hz, 1H), 6.54 (s, 1H), 5.50 (s, 2H), 5.10 - 4.94 (m, 1H), 4.51 (t, j = 4.8 Hz, 2H), 3.93 - 3.66 (m, 2H), 3.55 - 3.52 (m, 6H), 3.45-3.28 (m, 4H), 2.90 - 2.78 (m, 1H), 2.61 - 2.56 (m, 1H), 2.05 - 1.96 (m, 1H), 1.19 - 1.09 (m, 1H), 0.60 - 0.53 (m, 2H), 0.36 - 0.29 (m, 2H). LC-MS (ESI^+) m/z 836.1 $(M+H)^+$.

[005346] Example 300: [Method 16) N-[3-carbamoyl-l-[4-[[[4-[2-[2-[[2-(2,6-dioxo-3-piperidvB-l.,3-dioxo-isoindolin-4-yl1amino1_ _____ethoxy]ethyl]morpholin-2-yl]methylamino] methyl]phenyl]pyrazol-4-yl]-2- [2-t2,2,2-trifluoroethylamino)-4-_ pyridyl]oxazole-4-car boxamide, 1-305



[005347] Step 1- Tert-butyl N-[4-[4-[[3-carbamoyl-1-[4-[[[4-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-3-dioxo- isoindolin-4-yl]amino]ethoxy]ethyl]morpholin-2-yl]methylamino]methyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate

[005348] To a mixture of 4-[2-[2-[2-(aminomethyl)morpholin-4-yl]ethoxy]ethylamino]-2-(2,6-dioxo-3- piperidyl)isoindoline-l,3-dione (60.0 mg, 120 umol, HC1 salt, Intermediate EJ) in DCM (5 mL) was added TEA (18.3 mg, 181 umol), HOAc (14.5 mg, 241 umol) and tert-butyl N-[4-[4-[[3-carbamoyl- l-(4-formylphenyl)pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (96.7 mg, 120 umol, Intermediate GY). The mixture was stirred for 30 minutes, and then $NaBH(OAc)_3$ (51.2 mg, 241 umol) was added. The mixture was then stirred rt for 16 hours. On completion, the reaction mixture was quenched by addition water (0.4 mL), and then concentrated *in vacuo* to give the title compound (120 mg, 95% yield) as yellow solid. LC-MS (ESI^+) *m/z* 1043.6 $(M+H)^+$.

[005349] Step 2 - N-[3-carbamoyl-1-[4-[[[4-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethyl]morpholin-2-yl]methylamino]methyl]phenyl]pyrazol-4-yl]-2-[2-(2,2,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide

To a solution of tert-butyl N-[4-[4-[[3-carbamoyl-1-[4-[[[4-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethyl]morpholin-2-yl]methylamino]methyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (120 mg, 115 umol) in DCM (4 mL) was added HCl/dioxane (4 M, 1.03 mL). The mixture was stirred at rt for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]) to give the title compound (72.2 mg, 63% yield) as yellow solid. ^{1}H NMR (400MHz, DMSO-d) δ 11.01 (s, 1H), 9.03 (s, 1H), 8.92 (s, 1H), 8.25 (d, *J* = 5.2 Hz, 1H), 8.20 (s, 1H), 8.06 (s, 1H), 7.91 (d, *J* = 8.4 Hz, 2H), 7.73 - 7.69 (m, 1H), 7.59 - 7.55 (m, 1H), 7.49 *(d, J* = 8.4 Hz, 2H), 7.26 (s, 1H), 7.20 - 7.11 (m, 2H), 7.03 (d, *J* = 6.8 Hz, 1H), 6.60 (t, *J* = 5.6 Hz, 1H), 5.05 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.33 - 4.19 (m, 2H), 3.78 (s, 2H), 3.72 (d, J = 12 Hz, 2H), 3.59 (t, *J* = 5.2 Hz, 2H), 3.55 (t, *J* = 6.0 Hz, 2H), 3.48 - 3.44 (m, 3H), 2.89 - 2.77 (m, 2H), 2.70 (d, *J* = 12.4 Hz, 1H), 2.62 - 2.55 (m, 2H), 2.49 - 2.43 (m, 4H), 2.07 - 1.97 (m, 2H), 1.80 (t, *J* = 10.8 Hz, 1H); LC-MS (ESI$^+$) *m/z* 943.1 $(M+H)^+$.

[005350] **Table 22: Compounds synthesized via Method 16 with the reductive amination of various amines with aldehydes in Step 1.**

Ex-#[a, e]	I-#	Step 1 Intermediate Amine	Step 1 Intermediate Aldehyde	LCMS (ES+) m/z $(M+H)^+$	1HNMR (400MHz, DMSO-d6) δ
301	**I-306**	FR	GY	941.6	11.09 (s, 1H), 11.00 (s, 1H), 9.03 (s, 1H), 8.89 (s, 1H), 8.29 - 8.21 (m, 2H), 8.02 (s, 1H), 7.87 (d, *J* = 8.0 Hz, 2H), 7.77 - 7.64 (m, 2H), 7.57 - 7.43 (m, 3H), 7.28 (s, 1H), 7.19 (d, *J* = 5.6 Hz, 1H), 7.08 (m, 1H), 7.04 - 6.97 (m, 1H), 6.60 - 6.51 (m, 1H), 5.06 (dd, *J* = 4.8, 13.2 Hz, 1H), 4.34 - 4.17 (m, 2H), 3.76 (s, 2H), 3.62 - 3.47 (m, 5H), 3.42 - 3.38 (m, 3H), 2.95 - 2.79 (m, 3H), 2.72 - 2.57 (m, 5H), 2.02 (m, 1H), 1.60 (m, 2H), 1.53 - 1.20 (m, 4H)

302	**I-307**	FS	HM	884.1	11.11 (s, 1H), 9.92 (s, 1H), 8.96 (s, 1H), 8.85 (s, 1H), 8.19 - 8.11 (m, 1H), 7.81 (d, *J* = 8.4 Hz, 2H), 7.59 - 7.47 (m, 3H), 7.14 - 6.97 (m, 5H), 6.75 (t, *J* = 5.2 Hz, 1H), 5.04 (dd, *J* = 5.2, 13.2 Hz, 1H), 3.87 (s, 2H), 3.38 - 3.26 (m, 6H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.93 - 2.85 (m, 1H), 2.84 - 2.79 (m, 2H), 2.73 (t, *J* = 5.6 Hz, 2H), 2.69 - 2.66 (m, 2H), 2.57 - 2.52 (m, 2H), 2.05 - 1.95 (m, 1H), 1.11 - 1.00 (m, 1H), 0.48 - 0.42 (m, 2H), 0.25 - 0.19 (m, 2H)
303	**I-308**	GD	GC	873.5	11.11 (s, 1H), 10.98 (s, 1H), 8.98 (s, 1H), 8.88 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.01 (s, 1H), 7.88 (d, *J* = 8.4 Hz, 2H), 7.79 (d, *J* = 7.6 Hz, 1H), 7.75 - 7.70 (m, 2H), 7.67 (d, *J* = 7.6 Hz, 1H), 7.45 (d, *J* = 8.4 Hz, 2H), 7.16 (t, *J* = 6.0 Hz, 1H), 7.12 (s, 1H), 7.00 (dd, *J* = 1.2, 5.2 Hz, 1H), 5.12 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.57 -5.55 (m, 4H), 3.51 -5.50 (m, 4H), 3.39 (t, *J* = 6.0 Hz, 2H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.93 - 2.83 (m, 1H), 2.79 (t, *J* = 7.6 Hz, 2H), 2.63 - 2.55 (m, 2H), 2.54 (s, 2H), 2.19 (s, 3H), 2.09 - 1.99 (m, 1H), 1.89 - 1.78 (m, 2H), 1.13 - 0.99 (m, 1H), 0.50 - 0.39 (m, 2H), 0.27 - 0.17 (m, 2H)
304	**I-309**	GD	GE	804.4	11.14 - 11.11 (m, 1H), 11.09 (s, 1H), 9.08 (s, 1H), 8.89 (s, 1H), 8.85 (d, J = 5.6 Hz, 2H), 8.29 (s, 1H), 8.03 (s, 1H), 7.97 (d, J = 6.0 Hz, 2H), 7.89 (d, J = 8.4 Hz, 2H), 7.79 (d, J = 7.6 Hz, 1H), 7.78 - 7.73 (m, 2H), 7.68 (d, J = 7.2 Hz, 1H), 7.46 (d, J = 8.4 Hz, 2H), 5.13 (dd, J = 5.4, 12.8 Hz, 1H), 3.62 - 3.58 (m, 2H), 2.93 - 2.86 (m, 1H), 2.80 (t, J = 7.2 Hz, 2H), 2.61 (s, 1H), 2.56 (d, J = 5.6 Hz, 4H), 2.20 (s, 3H), 2.06 (dd, J = 5.2, 10.3 Hz, 1H), 1.89 - 1.80 (m, 2H)

305	**I-310**	GD	GF	880.5	11.1 (s, 1H), 9.98 (s, 1H), 8.97 (s, 1H), 8.78 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.82 - 7.73 (m, 4H), 7.69 (d, *J* = 7.2 Hz, 1H), 7.45 (d, *J* = 8.4 Hz, 2H), 7.42 - 7.14 (m, 1H), 7.13 - 7.07 (m, 2H), 7.04 (d, *J* = 5.2 Hz, 1H), 5.17 - 5.09 (m, 1H), 3.57 - 3.55 (m, 4H), 3.52 - 3.48 (m, 8H), 3.24 - 3.04 (m, 2H), 2.84 - 2.80 (m, 1H), 2.63 - 2.58 (m, 1H), 2.57 - 2.55 (m, 1H), 2.44 - 2.41 (m, 2H), 2.19 (s, 3H), 2.08 - 2.02 (m, 1H), 1.87 - 1.81 (m, 2H), 1.11 - 1.03 (m, 1H), 0.50 - 0.43 (m, 2H), 0.25 - 0.20 (m, 2H)
306	**I-311**	GH	GC	857.5	10.99 (s, 1H), 8.99 (s, 1H), 8.93 (s, 1H), 8.25 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.03 (s, 1H), 7.94 (d, *J* = 8.8 Hz, 2H), 7.80 - 7.71 (m, 3H), 7.70 - 7.64 (m, 1H), 7.54 (d, *J* = 8.4 Hz, 2H), 7.16 (t, *J* = 5.2 Hz, 1H), 7.12 (s, 1H), 7.00 (dd, *J* = 1.2, 5.2 Hz, 1H), 5.12 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.87 (d, *J* = 6.4 Hz, 1H), 3.38 - 3.36 (m, 2H), 3.34 - 3.31 (m, 2H), 3.18 (t, *J* = 6.4 Hz, 2H), 3.06 (t, *J* = 7.2 Hz, 2H), 2.93 - 2.83 (m, 1H), 2.64 - 2.52 (m, 6H), 2.09 - 2.00 (m, 1H), 1.88 - 1.78 (m, 2H), 1.55 - 1.43 (m, 4H), 1.38 - 1.27 (m, 2H), 1.11 - 1.01 (m, 1H), 0.49 - 0.42 (m, 2H), 0.26 - 0.20 (m, 2H)
307	**I-312**	GJ	GC	871.2	11.13 (s, 1H), 10.98 (s, 1H), 8.98 (s, 1H), 8.89 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.03 (s, 1H), 7.90 (d, *J* = 8.4 Hz, 2H), 7.79 - 7.68 (m, 3H), 7.68 - 7.61 (m, 1H), 7.46 (d, *J* = 8.4 Hz, 2H), 7.16 (t, *J* = 5.2 Hz, 1H), 7.12 (s, 1H), 7.00 (dd, *J* = 1.2, 5.2 Hz, 1H), 5.12 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.55 (s, 2H), 3.36 (t, *J* = 6.4 Hz, 2H), 3.32 (t, *J* = 6.4 Hz, 2H), 3.19 (t, *J* = 6.4 Hz, 2H), 3.04 (t, *J* = 6.4 Hz, 2H), 3.08 - 3.00 (m, 1H), 2.95 - 2.81 (m, 1H), 2.64 - 2.53 (m, 2H), 2.37 (t, *J* = 7.2 Hz, 2H), 2.16

					(s, 3H), 2.10 - 2.00 (m, 1H), 1.88 - 1.76 (m, 2H), 1.52 - 1.43 (m, 4H), 1.34 - 1.24 (m, 2H), 1.12 - 1.03 (m, 1H), 0.49 - 0.43 (m, 2H), 0.24 - 2.2 (m, 2H)
308	**I-313**	GL	GC	829.5	δ11.14 (s, 1H), 11.01 (s, 1H), 9.01 (s, 1H), 8.92 (s, 1H), 8.17 (d, *J* = 5.2 Hz, 1H), 8.05 (s, 1H), 7.91 (d, *J* = 8.4 Hz, 2H), 7.79 - 7.68 (m, 4H), 7.47 (d, *J* = 8.4 Hz, 2H), 7.22 - 7.14 (m, 1H), 7.13 (s, 1H), 7.01 (d, *J* = 5.2 Hz, 1H), 5.14 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.58 (s, 2H), 3.54 - 3.50 (m, 2H), 3.45 - 3.41 (m, 2H), 3.20 (t, *J* = 5.6 Hz, 2H), 3.09 (t, *J* = 7.2 Hz, 2H), 2.93 - 2.86 (m, 1H), 2.65 - 2.61(m, 1H), 2.59 - 2.57 (m, 1H), 2.48 - 2.42 (m, 2H), 2.20 (s, 3H), 2.10 - 2.01 (m, 1H), 1.91 - 1.82 (m, 2H), 1.12 - 1.03 (m, 1H), 0.51 -0.42 (m, 2H), 0.28 - 0.20 (m, 2H)
309	**I-314**	GN	GC	827.5	11.12 (s, 1H), 10.99 (s, 1H), 8.98 (s, 1H), 8.91 (s, 1H), 8.17 - 8.14 (m, 1H), 8.03 (s, 1H), 7.94 - 7.88 (m, 2H), 7.78 - 7.70 (m, 3H), 7.67-7.64 (m, 1H), 7.48 - 7.43 (m, 2H), 7.18 - 7.13 (m, 1H), 7.11 (s, 1H), 7.02 - 6.98 (m, 1H), 5.15 - 5.08 (m, 1H), 3.56 (s, 2H), 3.18 (t, *J* = 6.0 Hz, 2H), 3.00 (t, *J* = 7.6 Hz, 2H), 2.93 - 2.83 (m, 1H), 2.64 - 2.52 (m, 2H), 2.38 (t, *J* = 7.2 Hz, 2H), 2.16 (s, 3H), 2.09 - 2.01 (m, 1H), 1.65 - 1.53 (m, 2H), 1.52 - 1.42 (m, 2H), 1.36 - 1.25 (m, 4H), 1.10 - 1.02 (m, 1H), 0.48 - 0.41 (m, 2H), 0.25 - 0.19 (m, 2H)

310	**I-315**	GO	GP	884.5	10.76 (s, 1H), 8.76 (s, 2H), 8.12 (s, 1H), 7.93 (d, *J* = 4.8 Hz, 1H), 7.87 (s, 1H), 7.81 (d, *J* = 8.0 Hz, 2H), 7.54 (m, 4H), 7.32 (m, 2H), 6.93 (m, 1H), 6.88 (s, 1H), 6.77 (d, *J* = 4.8 Hz, 1H), 4.91 - 4.87 (m, 1H), 3.26 - 3.16 (m, 2H), 2.95 (t, *J* = 5.6 Hz, 3H), 2.88 - 2.77 (m, 2H), 2.73 - 2.68 (m, 4H), 2.65 - 2.52 (m, 3H), 2.39 - 2.34 (m, 2H), 1.89 - 1.77 (m, 1H), 1.75 - 1.51 (m, 2H), 1.44 - 1.34 (m, 2H), 1.24 - 1.08 (m, 4H), 0.84 - 0.82 (m, 1H), 0.23 - 0.21 (m, 2H), 0.00-0.02 (m, 2H);
311	**I-316**	GS	GC	869.6	10.89 (s, 1H), 9.82 (s, 1H), 8.76 (s, 1H), 8.67 (s, 1H), 8.45 - 8.45 (m, 1H), 7.93 (d, *J* = 5.2 Hz, 1H), 7.81 - 7.75 (m, 2H), 7.74 - 7.69 (m, 2H), 7.53 - 7.47 (m, 2H), 7.45 - 7.40 (m, 1H), 7.24 - 6.94 (m, 1H), 6.91 - 6.85 (m, 2H), 6.83 - 6.78 (m, 1H), 4.89 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.37 - 3.20 (m, 10H), 2.95 (t, *J* = 6.8 Hz, 2H), 2.79 (t, *J* = 7.2 Hz, 2H), 2.71 - 2.62 (m, 1H), 2.41 - 2.38 (m, 1H), 2.36 - 2.34 (m, 1H), 1.86 - 1.76 (m, 1H), 1.62 - 1.53 (m, 2H), 0.89 - 0.80 (m, 1H), 0.26 - 0.19 (m, 2H), 0.03 – 0.00 (m, 2H)
312	**I-317**	GT	GC	855.2	11.00 (s, 1H), 9.00 (s, 1H), 8.93 (s, 1H), 8.28 (s, 1H), 8.17 (d, *J* = 5.2 Hz, 1H), 8.04 (s, 1H), 7.93 (d, *J* = 8.8 Hz, 2H), 7.79 - 7.71 (m, 3H), 7.71 - 7.67 (m, 1H), 7.52 (d, *J* = 8.8 Hz, 2H), 7.17 (t, *J* = 5.6 Hz, 1H), 7.13 (s, 1H), 7.01 (dd, *J* = 1.6, 5.2 Hz, 1H), 5.13 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.81 (s, 2H), 3.20 (t, *J* = 6.0 Hz, 2H), 3.06 - 2.98 (m, 2H), 2.96 - 2.81 (m, 1H), 2.65 - 2.52 (m, 4H), 2.09 - 2.03 (m, 1H), 1.65 - 1.55 (m, 2H), 1.51 - 1.40 (m, 2H), 1.33 - 1.23 (m, 10H), 1.13 - 1.02 (m, 1H), 0.51 - 0.44 (m, 2H), 0.28 - 0.20 (m, 2H)

313	**I-318**	GU	GY	829.5	11.02 (s, 2H), 9.04 (s, 1H), 8.93 (s, 1H), 8.25 (d, *J* = 5.2 Hz, 1H), 8.20 (s, 1H), 8.06 (s, 1H), 7.92 (d, *J* = 8.4 Hz, 2H), 7.77 - 7.68 (m, 2H), 7.58 - 7.56 (m, 1H), 7.53 - 7.44 (m, 4H), 7.26 (s, 1H), 7.17 (dd, *J* = 1.2, 5.2 Hz, 1H), 5.14 (dd, *J* = 5.2, 13.6 Hz, 1H), 4.53 - 4.41 (m, 1H), 4.30 (d, *J* = 17.2 Hz, 1H), 4.26 -4.22 (m, 2H), 3.81 (s, 2H), 3.47 (d, *J* = 6.0 Hz,, 2H), 3.39 (d, *J* = 6.0 Hz, 2H), 2.96 - 2.87 (m, 1H), 2.75 - 2.68 (m, 4H), 2.62 - 2.53 (m, 2H), 2.03 - 1.95 (m, 1H), 1.90 - 1.82 (m, 2H)
314	**I-319**	GV	GC	832.5	11.00 (s, 2H), 9.07 - 8.85 (m, 2H), 8.23 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.05 (s, 1H), 7.92 (d, *J* = 8.0 Hz, 2H), 7.74 (s, 1H), 7.50 (d, *J* = 8.0 Hz, 2H), 7.25 (d, *J* = 7.2 Hz, 1H), 7.17 (t, *J* = 5.2 Hz, 1H), 7.14 - 6.98 (m, 5H), 5.37 (m, 1H), 4.04 - 3.94 (m, 2H), 3.82 (s, 2H), 3.73 - 3.63 (m, 8H), 3.20 - 3.15 (m, 2H), 2.96 - 2.81 (m, 1H), 2.75 - 2.61 (m, 4H), 2.06 - 1.95 (m, 1H), 1.19 - 0.96 (m, 1H), 0.46 - 0.41 (m, 2H), 0.23 - 0.18 (m, 2H)
315	**I-320**	GW	GY	843.4	11.13 (s, 1H), 11.01 (s, 1H), 9.02 (s, 1H), 8.92 (s, 1H), 8.25 (d, *J* = 5.2 Hz, 1H), 8.22 (s, 1H), 8.04 (s, 1H), 7.92 (d, *J* = 8.4 Hz, 2H), 7.81 - 7.65 (m, 5H), 7.51 (d, *J* = 8.4 Hz, 2H), 7.26 (s, 1H), 7.17 (dd, *J* = 1.2, 5.6 Hz, 1H), 5.12 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.30 - 4.21 (m, 2H), 3.82 (s, 2H), 3.48 (t, *J* = 5.6 Hz, 2H), 3.42 (t, *J* = 6.4 Hz, 2H), 3.08 (t, *J* = 7.2 Hz, 2H), 2.92 - 2.83 (m, 1H), 2.75 - 2.67 (t, *J* = 5.6 Hz, 2H), 2.64 - 2.53 (m, 2H), 2.11 - 2.00 (m, 1H), 1.92 - 1.80 (m, 2H)

316	**I-321**	GX	GY	887.4	11.50 (s, 1H), 11.02 (s, 1H), 9.04 (s, 1H), 8.90 (s, 1H), 8.27 (d, *J* = 5.2 Hz, 1H), 8.21 (s, 1H), 8.04 (s, 1H), 7.89 (d, *J* = 8.8 Hz, 2H), 7.77 - 7.70 (m, 4H), 7.69 - 7.66 (m, 1H), 7.49 (d, *J* = 8.8 Hz, 2H), 7.28 (s, 1H), 7.19 (dd, *J* = 1.2, 5.2 Hz, 1H), 5.13 (dd, *J* = 5.2, 12.4 Hz, 1H), 4.31 - 4.21 (m, 2H), 3.79 (s, 2H), 3.57 - 3.41 (m, 8H), 3.05 (t, *J* = 6.8 Hz, 2H), 2.94 - 2.84 (m, 1H), 2.72 - 2.68 (m, 2H), 2.64 - 2.57 (m, 1H), 2.57 - 2.54 (m, 1H), 2.09 - 2.03 (m, 1H), 1.87 - 1.79 (m, 2H)
317	**I-322**	HA	GY	975.2	11.09 (s, 1H), 11.00 (s, 1H), 9.02 (s, 1H), 8.91 (s, 1H), 8.29 - 8.24 (m, 2H), 8.03 (s, 1H), 7.91 (d, *J* = 8.4 Hz, 2H), 7.77 - 7.67 (m, 5H), 7.49 (d, *J* = 8.8 Hz, 2H), 7.27 (s, 1H), 7.18 (dd, *J* = 1.6, 5.2 Hz, 1H), 5.13 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.30 - 4.21 (m, 2H), 3.79 (s, 2H), 3.52 - 3.46 (m, 14H), 3.40 (t, *J* = 6.4 Hz, 2H), 3.05 (t, *J* = 7.6 Hz, 2H), 2.95 - 2.83 (m, 1H), 2.68 (t, *J* = 5.6 Hz, 2H), 2.60 - 2.52 (m, 2H), 2.10 - 2.03 (m, 1H), 1.86 - 1.79 (m, 2H)
318	**I-323**	MN	GY	971.5	11.00 (s, 1H), 9.02 (s, 1H), 8.91 (s, 1H), 8.26 (d, *J* = 5.6 Hz, 2H), 8.04 (s, 1H), 7.93 - 7.83 (m, 5H), 7.74 - 7.68 (m, 2H), 7.49 (d, *J* = 8.4 Hz, 2H), 7.27 (s, 1H), 7.18 (d, *J* = 5.2 Hz, 1H), 5.15 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.49 (s, 2H), 4.31 - 4.21 (m, 2H), 3.78 (s, 2H), 3.75 - 3.68 (m, 3H), 3.61 - 3.57 (m, 3H), 3.53 - 3.48 (m, 9H), 2.96 - 2.84 (m, 1H), 2.71 - 2.57 (m, 5H), 2.34 (s, 1H), 2.12 - 2.02 (m, 1H)

319	**I-324**	HB	GC	845.5	10.99 (s, 1H), 8.99 (s, 1H), 8.90 (s, 1H), 8.25 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.03 (, 1H), 7.89 (d, *J* = 8.8 Hz, 2H), 7.72 (s, 1H), 7.58 - 7.53 (t, *J* = 4.4 Hz, 1H), 7.49 (d, *J* = 8.4 Hz, 2H), 7.46 - 7.39 (m, 2H), 7.16 (t, *J* = 5.6 Hz, 1H), 7.12 (s, 1H), 7.00 (dd, *J* = 1.2, 5.2 Hz, 1H), 5.13 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.43 (d, *J* = 17.2 Hz, 1H), 4.29 (d, *J* = 17.2 Hz, 1H), 3.81 (s, 2H), 3.54 - 3.47 (m, 6H), 3.39 (t, *J* = 6.4 Hz, 2H), 3.19 (t, *J* = 6.4 Hz, 2H), 2.98 - 2.86 (m, 1H), 2.75 - 2.63 (m, 4H), 2.63 - 2.52 (m, 2H), 2.05 - 1.96 (m, 1H), 1.87 - 1.77 (m, 2H), 1.13 - 1.02 (m, 1H), 0.49 - 0.41 (m, 2H), 0.26 - 0.20 (m, 2H)
320	**I-325**	HC	GC	889.5	10.99 (s, 1H), 8.99 (s, 1H), 8.91 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.04 (s, 1H), 7.92 (s, 1H), 7.89 (s, 1H), 7.73 (s, 1H), 7.58 - 7.53 (m, 1H), 7.50 (s, 1H), 7.48 (s, 1H), 7.44 (d, *J* = 4.4 Hz, 2H), 7.19 - 7.13 (m, 1H), 7.12 (s, 1H), 7.02 - 6.98 (m, 1H), 5.17 - 5.09 (m, 1H), 4.47 - 4.40 (m, 1H), 4.32 - 4.26 (m, 1H), 3.81 (s, 2H), 3.54 - 3.52 (m, 10H), 3.39 - 3.37 (m, 2H), 3.27 - 3.14 (m, 2H), 2.97 - 2.86 (m, 1H), 2.73 - 2.68 (m, 2H), 2.67 - 2.63 (m, 2H), 2.53 - 2.51 (m, 1H), 2.44 - 2.37 (m, 1H), 2.06 - 1.96 (m, 1H), 1.85 - 1.76 (m, 2H), 1.11 - 1.02 (m, 1H), 0.49 - 0.43 (m, 2H), 0.25 - 0.20 (m, 2H)
321	**I-326**	OK	HG	798.2	11.09 (s, 1H), 10.98 (s, 1H), 9.18 (s, 2H), 9.12 (s, 1H), 8.47 (s, 1H), 8.07 (d, *J* = 6.4 Hz, 1H), 7.99 (s, 1H), 7.64 (d, *J* = 15.6 Hz, 2H), 7.57 (t, *J* = 8.0 Hz, 1H), 7.23 (d, *J* = 6.8 Hz, 1H), 7.11 (d, *J* = 8.8 Hz, 1H), 7.02 (d, *J* = 6.8 Hz, 1H), 6.57 (s, 1H), 5.05 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.58 (t, *J* = 5.2 Hz, 2H), 3.74 (t, *J* = 5.2 Hz,, 2H), 3.63 - 3.59 (m, 10H), 3.36 (d, *J* = 6.8 Hz, 2H), 3.22

					- 3.14 (m, 2H), 2.94 - 2.82 (m, 1H), 2.64 - 2.53 (m, 2H), 2.07 - 1.99 (m, 1H), 1.21 - 1.10 (m, 1H), 0.61 - 0.52 (m, 2H), 0.36 – 0.30 (m, 2H)
322	**I-327**	HK	GF	922.2	11.09 (s, 1H), 9.99 (s, 1H), 8.98 (s, 1H), 8.79 (s, 1H), 8.21 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.80 (d, *J* = 8.4 Hz, 2H), 7.62 - 7.55 (m, 1H), 7.48 (d, *J* = 8.4 Hz, 2H), 7.44 - 7.17 (m, 1H), 7.17 - 7.08 (m, 3H), 7.07 - 7.01 (m, 2H), 6.60 (t, *J* = 5.6 Hz, 1H), 5.06 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.79 - 3.68 (m, 3H), 3.63 - 3.54 (m, 4H), 3.51 - 3.41 (m, 4H), 3.21 - 3.16 (m, 2H), 2.94 - 2.78 (m, 3H), 2.73 - 2.55 (m, 6H), 2.10 - 1.98 (m, 2H), 1.84 - 1.79 (m, 1H), 1.14 - 1.02 (m, 1H), 0.51 - 0.41 (m, 2H), 0.26 - 0.21 (m, 2H)
323	**I-328**	HO	GY	888.4	11.07 (s, 1H), 11.01 (s, 1H), 9.02 (s, 1H), 8.90 (s, 1H), 8.32 - 8.22 (m, 2H), 8.03 (s, 1H), 7.89 (d, *J* = 8.4 Hz, 2H), 7.75 - 7.66 (m, 2H), 7.49 (d, *J* = 8.4 Hz, 2H), 7.28 (s, 1H), 7.22 - 7.15 (m, 1H), 7.04 - 6.96 (m, 2H), 6.86 (d, *J* = 8.4 Hz, 1H), 5.33 (dd, *J* = 5.2, 12.4 Hz, 1H), 4.30 - 4.21 (m, 2H), 3.79 (s, 2H), 3.55 - 3.48 (m, 10H), 3.31 (s, 3H), 2.93 - 2.85 (m, 1H), 2.70 - 2.64 (m, 4H), 2.04 - 1.96 (m, 1H), 1.85 - 1.76 (m, 2H)
324	**I-329**	HQ	GY	888.5	11.07 (s, 1H), 11.00 (s, 1H), 9.01 (s, 1H), 8.89 (s, 1H), 8.29 (s, 1H), 8.25 (d, *J* = 5.2 Hz, 1H), 8.02 (s, 1H), 7.87 (d, *J* = 8.4 Hz, 2H), 7.73 - 7.66 (m, 2H), 7.47 (d, *J* = 8.8 Hz, 2H), 7.26 (s, 1H), 7.17 (dd, *J* = 1.2, 5.2 Hz, 1H), 6.97 - 6.90 (m, 2H), 6.86 - 6.82 (m, 1H), 5.35 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.29 - 4.19 (m, 2H), 3.77 (s, 2H), 3.55 - 3.50 (m, 11H), 2.95 - 2.84 (m, 3H), 2.71 - 2.61 (m, 4H), 2.03 - 1.91 (m, 1H), 1.85 - 1.75 (m, 2H)

325	**I-330**	HR	GF	922.1	11.09 (s, 1H), 10.00 (s, 1H), 8.97 (s, 1H), 8.79 (s, 1H), 8.23 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.80 (d, *J* = 8.4 Hz, 2H), 7.60 - 7.53 (m, 1H), 7.48 (d, *J* = 8.4 Hz, 2H), 7.43 - 7.16 (m, 1H), 7.15 - 7.07 (m, 3H), 7.06 - 7.00 (m, 2H), 6.59 (t, *J* = 5.2 Hz, 1H), 5.05 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.77 (s, 3H), 3.56 (dd, *J* = 6.0, 11.6 Hz, 4H), 3.51 - 3.43 (m, 4H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.94 - 2.83 (m, 1H), 2.80 (d, *J* = 10.8 Hz, 1H), 2.69 (d, *J* = 11.2 Hz, 1H), 2.60 (d, *J* = 2.4 Hz, 1H), 2.54 - 2.58 (m, 1H), 2.55 - 2.52 (m, 2H), 2.48 - 2.44 (m, 2H), 2.09 - 1.96 (m, 2H), 1.78 - 1.82 (m, 1H), 1.12 - 1.02 (m, 1H), 0.50 - 0.41 (m, 2H), 0.29 - 0.16 (m, 2H)
326	**I-331**	HO	GF	867.5	10.84 (s, 1H), 9.74 (s, 1H), 8.73 (s, 1H), 8.54 (s, 1H), 7.99 (s, 1H), 7.93 (d, *J* = 5.2 Hz, 1H), 7.55 (d, *J* = 8.8 Hz, 2H), 7.25 (d, *J* = 8.4 Hz, 2H), 7.20 - 6.91 (m, 1H), 6.89 - 6.83 (m, 2H), 6.82 - 6.78 (m, 2H), 6.76 (d, *J* = 8.0 Hz, 1H), 6.62 (d, *J* = 8.4 Hz, 1H), 5.09 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.55 (s, 2H), 3.31 - 3.23 (m, 10H), 3.07 (s, 3H), 3.01 - 2.89 (m, 2H), 2.69 - 2.62 (m, 1H), 2.46 - 2.41 (m, 4H), 1.78 - 1.74(m, 1H), 1.61 - 1.53 (m, 2H), 0.88 - 0.79 (m, 1H), 0.25 - 0.19 (m, 2H), -0.01 (q, *J* = 4.8 Hz, 2H)
327	**I-332**	HQ	GF	867.5	11.08 (s, 1H), 9.98 (s, 1H), 8.97 (s, 1H), 8.78 (s, 1H), 8.21 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.79 (d, *J* = 8.4 Hz, 2H), 7.49 (d, *J* = 8.8 Hz, 2H), 7.43 - 7.16 (m, 1H), 7.12 (s, 1H), 7.09 (t, *J* = 5.6 Hz, 1H), 7.06 - 7.02 (m, 1H), 6.98 - 6.91 (m, 2H), 6.88 - 6.82 (m, 1H), 5.36 (dd, *J* = 5.6, 12.4 Hz, 1H), 3.81 (s, 2H), 3.56 - 3.54 (m, 7H), 3.47 - 3.45 (m, 4H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.99 - 2.85 (m, 3H), 2.77 - 2.63 (m, 4H), 2.02 -

					1.95 (m, 1H), 1.87 - 1.77 (m, 2H), 1.13 - 1.01 (m, 1H), 0.50 - 0.40 (m, 2H), 0.26 - 0.19 (m, 2H)
328	**I-333**	HV	Tert-butyl N-[4-[4-[[3-carbamoyl-1-[4-(5-oxopentyl-carbamoyl)-phenyl]-pyrazol-4-yl] carbamoyl]-oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)-carbamate (synthesized via Steps 1-2 of Example 172)	885.1	11.02 (s, 1H), 9.03 (s, 2H), 8.56 (t, *J* = 5.6 Hz, 1H), 8.29 - 8.23 (m, 2H), 8.13 (s, 1H), 8.10 (d, *J* = 8.8 Hz, 2H), 8.02 (d, *J* = 8.8 Hz, 2H), 7.79 (d, *J* = 15.2 Hz, 2H), 7.70 (t, *J* = 6.0 Hz, 1H), 7.60 - 7.52 (m, 1H), 7.27 (s, 1H), 7.18 (dd, *J* = 1.2 Hz, 1H), 7.09 (d, *J* = 8.2 Hz, 1H), 6.99 (d, *J* = 7.2 Hz, 1H), 6.78 (t, *J* = 5.6 Hz, 1H), 4.51 (dd, *J* = 6.0, 12.0 Hz, 1H), 4.30 - 4.20 (m, 2H), 3.42 - 3.16 (m, 6H), 2.83 (t, *J* = 5.6 Hz, 2H), 2.69 - 2.59 (m, 2H), 2.27 - 2.17 (m, 1H), 2.03 - 1.82 (m, 3H), 1.61 - 1.45 (m, 4H), 1.42 - 1.34 (m, 2H)
329	**I-334**	KK	GF	950.3	10.87 (s, 1H), 9.76 - 9.70 (m, 1H), 8.79 - 8.67 (m, 1H), 8.56 (s, 1H), 7.97 - 7.91 (m, 3H), 7.58 (d, *J* = 8.4 Hz, 2H), 7.36 - 7.24 (m, 3H), 7.05 (s, 1H), 6.93 - 6.84 (m, 3H), 6.83 - 6.76 (m, 2H), 5.99 (d, *J* = 7.6 Hz, 1H), 4.81 (d, *J* = 4.8, 12.8 Hz, 1H), 3.58 (s, 3H), 3.20 - 3.08 (m, 12H), 2.98 - 2.92 (m, 2H), 2.53 (s, 2H), 2.51 - 2.42 (m, 4H), 2.10 (s, 2H), 1.96 (t, *J* = 10.0 Hz, 2H), 1.78 (d, *J* = 4.4 Hz, 1H), 1.66 (d, *J* = 10.0 Hz, 2H), 1.23 (d, *J* = 11.2 Hz, 2H), 0.84 (s, 1H), 0.26 - 0.19 (m, 2H), 0.02 - 0.04 (m, 2H)

330	**I-335**	HZ	GF	950.4	11.03 (s, 1H), 9.95 (s, 1H), 8.95 (s, 1H), 8.79 (s, 1H), 8.20 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.82 (d, *J* = 7.6 Hz, 2H), 7.56- 7.48 (m, 3H), 7.43 - 7.14 (m, 1H), 7.11 (s, 1H), 7.07 (t, *J* = 5.6 Hz, 1H), 7.03 (d, *J* = 5.6 Hz, 1H), 7.00 - 6.93 (m, 2H), 6.85 (d, *J* = 8.4 Hz, 1H), 5.01 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.86 - 3.83 (m, 2H), 3.60 - 3.45 (m, 10H), 3.44 - 3.34 (m, 2H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.92 - 2.81 (m, 3H), 2.85 (br d, *J*=12.5 Hz, 1H), 2.75 - 2.73 (m, 1H), 2.61 - 2.54 (m, 1H), 2.53 - 2.52 (m, 1H), 2.21 - 2.14 (m, 2H), 2.01 - 1.94 (m, 1H), 1.90 - 1.84 (m, 2H), 1.46 - 1.37 (m, 2H), 1.10 - 1.03 (m, 1H), 0.48 - 0.43 (m, 2H), 0.25 – 0.20 (m, 2H)
331	**I-336**	IA	GF	936.5	11.09 (s, 1H), 9.99 (s, 1H), 8.97 (s, 1H), 8.77 (s, 1H), 8.25 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.79 (d, *J* = 8.4 Hz, 2H), 7.69 - 7.64 (m, 1H), 7.49 (d, *J* = 8.8 Hz, 2H), 7.47 - 7.33 (m, 1H), 7.31 (d, *J* = 10.4 Hz, 1H), 7.28 (d, *J* = 5.2 Hz, 1H), 7.15 - 7.09 (m, 2H), 7.04 (d, *J* = 5.2 Hz, 1H), 5.12 - 5.05 (m, 1H), 3.80 (s, 2H), 3.55 - 3.51 (m, 8H), 3.27 - 3.22 (m, 4H), 3.20 - 3.16 (m, 2H), 2.91 - 2.81 (m, 1H), 2.75 - 2.65 (m, 4H), 2.61 - 2.57 (m, 4H), 2.57 - 2.55 (m, 1H), 2.54 - 2.53 (m, 1H), 2.05 - 1.98 (m, 1H), 1.60 - 1.50 (m, 1H), 0.48 - 0.43 (m, 2H), 0.25 - 0.20 (m, 2H)

332	**I-337**	IB	GF	936.2	11.06 (s, 1H), 9.95 (s, 1H), 8.96 (s, 1H), 8.78 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.80 (d, *J* = 8.4 Hz, 2H), 7.65 (d, *J* = 8.4 Hz, 1H), 7.50 (d, *J* = 8.4 Hz, 2H), 7.43 - 7.14 (m, 3H), 7.12 (s, 1H), 7.08 (t, *J* = 5.2 Hz, 1H), 7.06 - 7.02 (m, 1H), 5.06 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.81 (s, 2H), 3.60 - 3.53 (m, 4H), 3.53 - 3.50 (m, 4H), 3.43 - 3.35 (m, 4H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.93 - 2.82 (m, 1H), 2.71 (t, *J* = 5.6 Hz, 2H), 2.63 - 2.55 (m, 2H), 2.54 (m, 6H), 2.05 - 1.97 (m, 1H), 1.13 - 1.03 (m, 1H), 0.49 - 0.43 (m, 2H), 0.26 - 0.20 (m, 2H)
333	**I-338**	MX	GF	922.2	11.10 (s, 1H), 9.96 (s, 1H), 8.97 (s, 1H), 8.80 (s, 1H), 8.21 (s, 1H), 8.17 (d, *J* = 5.4 Hz, 1H), 7.83 (d, *J* = 8.4 Hz, 2H), 7.62 - 7.49 (m, 3H), 7.45 - 7.15 (m, 1H), 7.12 (s, 1H), 7.10 - 7.02 (m, 3H), 6.97 (d, *J* = 8.4 Hz, 1H), 6.61 (d, *J* = 7.2 Hz, 1H), 5.06 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.30 - 4.19 (m, 1H), 3.87 (s, 2H), 3.72 (t, *J* = 6.8 Hz, 2H), 3.55 (t, *J* = 5.4 Hz, 2H), 3.54 - 3.50 (m, 4H), 3.41 (t, *J* = 5.6 Hz, 2H), 3.20 (t, *J* = 6.4 Hz, 2H), 3.10 - 2.97 (m, 2H), 2.96 - 2.83 (m, 1H), 2.82 - 2.72 (m, 2H), 2.63 (t, *J* = 4.8 Hz, 2H), 2.60 - 2.52 (m, 1H), 2.48 - 2.44 (m, 1H), 2.07 - 1.99 (m, 1H), 1.13 - 1.02 (m, 1H), 0.50 - 0.43 (m, 2H), 0.27 - 0.20 (m, 2H)
334	**I-339**	IC	GF	922.5	11.05 (s, 1H), 9.97 (s, 1H), 8.97 (s, 1H), 8.79 (s, 1H), 8.28 - 8.26 (m, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.85 - 7.76 (m, 2H), 7.59 - 7.45 (m, 4H), 7.43 - 7.15 (m, 1H), 7.14 - 7.02 (m, 3H), 6.87 (s, 1H), 6.78 (d, *J* = 8.2 Hz, 1H), 5.03 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.84 (s, 3H), 3.70 -3.60 (m, 2H), 3.57 - 3.45 (m, 8H), 3.44 - 3.38 (m, 2H), 3.19 (t, *J* = 6.0 Hz, 2H), 3.00 - 2.83 (m, 3H), 2.62 - 2.56 (m, 4H), 2.04 - 1.93 (m, 1H),

					1.12 - 1.02 (m, 1H), 0.51 - 0.42 (m, 2H), 0.28 - 0.19 (m, 2H)
335	**I-340**	IE	GF	948.2	11.08 (s, 1H), 9.97 (s, 1H), 8.97 (s, 1H), 8.78 (s, 1H), 8.31 (s, 1H), 8.17 (d, *J* = 5.2 Hz, 1H), 7.99 (s, 1H), 7.79 (d, *J* = 8.4 Hz, 2H), 7.62 - 7.53 (m, 1H), 7.47 (d, *J* = 8.4 Hz, 2H), 7.29 (t, *J* = 14.0 Hz,1H), 7.15 (d, *J* = 14.0 Hz,, 2H), 7.10 - 7.01 (m, 4H), 5.06 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.58 (d, *J* = 6.0 Hz, 2H), 4.49 (t, *J* = 5.2 Hz, 2H), 3.80 (t, *J* = 5.2 Hz, 2H), 3.75 (s, 2H), 3.51 - 3.48 (m, 6H), 3.19 (d, *J* = 6.0 Hz, 2H), 2.94 - 2.83 (m, 1H), 2.66 - 2.55 (m, 4H), 2.06 - 1.98 (m, 1H), 1.16 - 1.00 (m, 1H), 0.49 - 0.43 (m, 2H), 0.26 - 0.19 (m, 2H)
336	**I-341**	IG	GF	948.1	11.04 (s, 1H), 9.97 (s, 1H), 8.97 (s, 1H), 8.80 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.99 (s, 1H), 7.82 (d, *J* = 8.4 Hz, 2H), 7.61 - 7.54 (m, 2H), 7.50 (d, *J* = 8.4 Hz, 2H), 7.45 - 7.15 (m, 1H), 7.12 (s, 1H), 7.10 - 7.01 (m, 3H), 6.95 (dd, *J* = 2.0, 8.4 Hz, 1H), 5.03 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.50 (t, *J* = 5.2 Hz, 2H), 4.46 (d, *J* = 5.6 Hz, 2H), 3.83 (s, 2H), 3.80 (t, *J* = 5.2 Hz, 2H), 3.53 - 3.44 (m, 6H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.92 - 2.80 (m, 1H), 2.72 (t, *J* = 5.6 Hz, 2H), 2.61 - 2.53 (m, 2H), 2.03 - 1.93 (m, 1H), 1.13 - 1.02 (m, 1H), 0.49 - 0.42 (m, 2H), 0.26 - 0.20 (m, 2H)
337	**I-342**	IH	GF	962.1	11.07 (s, 1H), 9.97 (s, 1H), 8.96 (s, 1H), 8.78 (s, 1H), 8.21 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.78 (d, *J* = 8.4 Hz, 2H), 7.63 - 7.53 (m, 2H), 7.45 (d, *J* = 8.4 Hz, 2H), 7.42 - 7.11 (m, 3H), 7.07 (d, *J* = 5.2 Hz, 1H), 7.04 (d, *J* = 6.0 Hz, 2H), 6.74 (t, *J* = 6.0 Hz, 1H), 5.05 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.52 - 4.44 (m, 2H), 3.79 (t, *J* = 4.8 Hz, 2H), 3.75 - 3.73 (m, 1H), 3.74 (s, 2H), 3.60 (d, *J* = 6.8 Hz,

					2H), 3.47 (d, *J* = 4.8 Hz, 2H), 3.41 (d, *J* = 6.4 Hz, 4H), 3.19 (t, *J* = 5.6 Hz, 2H), 3.01 (t, *J* = 6.8 Hz, 2H), 2.93 - 2.81 (m, 1H), 2.63 - 2.61 (m, 2H), 2.58 - 2.54 (m, 2H), 2.02 - 1.99 (m, 1H), 1.10 - 1.02 (m, 1H), 0.46 - 2.44 (m, 2H), 0.23 - 2.22 (m, 2H)
338	**I-343**	MY	GF	962.1	11.04 (s, 1H), 9.96 (s, 1H), 8.97 (s, 1H), 8.79 (s, 1H), 8.20 (s, 1H), 8.17 (d, *J* = 5.2 Hz, 1H), 7.80 (d, *J* = 8.4 Hz, 2H), 7.62 - 7.56 (m, 2H), 7.47 (d, *J* = 8.0 Hz, 2H), 7.44 - 7.28 (m, 1H), 7.23 (s, 1H), 7.13 (s, 1H), 7.09 - 7.01 (m, 3H), 6.91 (d, *J* = 8.3 Hz, 1H), 5.04 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.46 (t, *J* = 4.8 Hz, 2H), 3.82 - 3.74 (m, 4H), 3.55 - 3.40 (m, 6H), 3.23 - 3.17 (m, 2H), 3.00 (t, *J* = 6.8 Hz, 2H), 2.93 - 2.81 (m, 2H), 2.69 - 2.55 (m, 5H), 2.37 - 2.32 (m, 1H), 2.02 - 1.96 (m, 1H), 1.08 (s, 1H), 0.49 - 0.44 (m, 2H), 0.25 - 0.21 (m, 2H)
339	**I-344**	II	GF	949.1	11.11 (s, 1H), 10.00 (s, 1H), 8.98 (s, 1H), 8.79 (s, 1H), 8.30 - 8.20 (m, 2H), 8.17 (d, *J* = 5.2 Hz, 1H), 7.86 - 7.76 (m, 3H), 7.73 (d, *J* = 8.4 Hz, 1H), 7.51 - 7.44 (m, 3H), 7.44 - 7.15 (m, 1H), 7.14 - 7.08 (m, 2H), 7.05 (dd, *J* = 1.2, 5.2 Hz, 1H), 5.41 (s, 2H), 5.11 - 5.03 (m, 1H), 4.56 (t, *J* = 5.2 Hz, 2H), 3.83 (t, *J* = 5.2 Hz, 2H), 3.77 (s, 2H), 3.56 - 3.51 (m, 2H), 3.50 - 3.43 (m, 4H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.94 - 2.81 (m, 1H), 2.69 - 2.63 (m, 2H), 2.58 - 2.52 (m, 2H), 2.06 - 1.95 (m, 1H), 1.13 - 1.02 (m, 1H), 0.50 - 0.42 (m, 2H), 0.26 - 0.20 (m, 2H)

340	**I-345**	NB	GF	949.5	10.88 (s, 1H), 9.71 (s, 1H), 8.72 (s, 1H), 8.53 (s, 1H), 8.01 (s, 1H), 7.92 (d, *J* =5.4 Hz, 1H), 7.60 (d, *J* =8.2 Hz, 1H), 7.54 (d, *J* = 8.4 Hz, 2H), 7.35 (s, 1H), 7.25 - 7.16 (m, 2H), 7.05 (s, 1H), 6.91 - 6.87 (m, 1H), 6.86 - 6.78 (m, 2H), 5.12 (s, 2H), 4.88 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.32 (t, *J* = 5.2 Hz, 2H), 3.63 - 3.56 (m, 2H), 3.50 (s, 2H), 3.30 (s, 2H), 3.24 (d, *J* = 5.4 Hz, 4H), 2.96 (d, *J* = 6.0 Hz, 2H), 2.71 - 2.61 (m, 1H), 2.47 - 2.41 (m, 4H), 1.86 - 1.71 (m, 2H), 0.83 (d, *J* = 5.6 Hz, 1H), 0.27 - 0.19 (m, 2H), 0.01 (d, *J* = 4.4 Hz, 2H)
341	**I-346**	IJ	GF	963.1	11.08 (s, 1H), 9.96 (s, 1H), 8.97 (s, 1H), 8.78 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.83 - 7.76 (m, 3H), 7.75 (s, 1H), 7.53 - 7.44 (m, 4H), 7.43 - 7.15 (m, 1H), 7.12 (s, 1H), 7.08 (t, *J* = 5.6 Hz, 1H), 7.06 - 7.02 (m, 1H), 5.10 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.58 (t, *J* = 5.2 Hz, 2H), 4.41 (t, *J* = 6.0 Hz, 2H), 3.81 (t, *J* = 5.2 Hz, 2H), 3.77 (s, 2H), 3.52 - 3.49 (m, 2H), 3.46 - 3.42 (m, 4H), 3.25 (t, *J* = 6.0 Hz, 2H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.94 - 2.84 (m, 1H), 2.65 (t, *J* = 5.6 Hz, 2H), 2.59 - 2.54 (m, 2H), 2.09 - 1.98 (m, 1H), 1.13 - 1.01 (m, 1H), 0.49 - 0.43 (m, 2H), 0.26 - 0.21
342	**I-347**	ND	GF	963.1	11.09 (s, 1H), 9.95 (s, 1H), 8.97 (s, 1H), 8.78 (s, 1H), 8.22 (d, *J* = 6.8 Hz, 2H), 8.17 (d, *J* = 5.2 Hz, 1H), 7.81 - 7.76 (m, 3H), 7.63 (s, 1H), 7.50 - 7.44 (m, 3H), 7.36 (dd, *J* = 2.0, 8.4 Hz, 1H), 7.29 (s, 1H), 7.12 (s, 1H), 7.10 - 7.03 (m, 2H), 5.12 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.54 (t, *J* = 5.2 Hz, 2H), 4.43 t, *J* = 6.4 Hz, 2H), 3.82 (t, *J* = 5.2 Hz, 3H), 3.75 (s, 3H), 3.52 - 3.48 (m, 5H), 3.45 (s, 2H), 2.95 - 2.84 (m, 1H), 2.69 - 2.60 (m, 5H), 2.34 - 2.33 (m, 1H),

					2.08 - 2.00 (m, 1H), 1.12 - 1.03 (m, 1H), 0.48 - 0.44 (m, 2H), 0.26 - 0.21 (m, 2H)
343	**I-348**	IN	GF	979.5	11.07 (s, 1H), 9.95 (s, 1H), 8.96 (s, 1H), 8.79 (s, 1H), 8.24 - 8.21 (m, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.81 (d, *J* = 8.0 Hz, 2H), 7.56 (t, *J* = 8.4 Hz, 1H), 7.53 - 7.45 (m, 2H), 7.43 - 7.15 (m, 1H), 7.14 - 7.10 (m, 2H), 7.07 (t, *J* = 5.6 Hz, 1H), 7.05 - 7.00 (m, 2H), 6.57 (t, *J*= 5.6 Hz, 1H), 5.05 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.57 - 3.47 (m, 16H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.94 - 2.83 (m, 1H), 2.75 - 2.68 (m, 2H), 2.62 - 2.55 (m, 2H), 2.44 - 2.41 (m, 4H), 2.37 - 2.34 (m, 4H), 2.05 - 1.99 (m, 1H), 1.12 - 1.03 (m, 1H), 0.49 - 0.42 (m, 2H), 0.26 - 0.19 (m, 2H)
344	**I-349**	NE	GF	979.2	11.04 (s, 1H), 9.97 (s, 1H), 8.96 (s, 1H), 8.79 (s, 1H), 8.22 (s, 2H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.81 (d, *J* = 8.4 Hz, 2H), 7.55 (d, *J* = 8.4 Hz, 1H), 7.50 (d, *J* = 8.4 Hz, 2H), 7.45 - 7.15 (m, 1H), 7.14 - 7.03 (m, 4H), 7.00 (s, 1H), 6.88 (d, *J* = 8.4 Hz, 1H), 5.03 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.81 (s, 2H), 3.59 - 3.50 (m, 10H), 3.19 (t, *J* = 6.4 Hz, 2H), 2.93 - 2.84 (m, 1H), 2.71 - 2.68 (m, 2H), 2.60 - 2.56 (m, 2H), 2.44 (t, *J* = 5.6 Hz, 4H), 2.41 - 2.29 (m, 8H), 2.04 - 1.93 (m, 1H), 1.05 - 0.94 (m, 1H), 0.51 - 0.40 (m, 2H), 0.25 - 0.22 (m, 2H)
345[b]	**I-350**	IO	GF	991.6	11.13 (s, 2H), 10.32 (s, 1H), 10.11 (s, 1H), 9.11 (s, 1H), 9.04 (s, 1H), 8.90 (s, 1H), 8.16 (d, *J* = 6.0 Hz, 1H), 7.99 (d, *J* = 8.4 Hz, 2H), 7.69 (d, *J* = 8.4 Hz, 2H), 7.64 - 7.58 (m, 1H), 7.34 - 7.25 (m, 1H), 7.20 - 7.05 (m, 3H), 6.64 - 6.55 (m, 1H), 5.08 (dd, *J* = 5.4, 13.0 Hz, 1H), 4.48 - 4.14 (m, 10H), 3.71 (d, *J* = 5.2 Hz, 4H), 3.64 (d, *J* = 4.8 Hz, 9H), 3.37 (s, 2H), 3.23 (d, *J* = 6.8

					Hz, 2H), 3.16 (s, 2H), 2.97 - 2.85 (m, 1H), 2.64 (s, 1H), 2.59 (s, 1H), 2.11 - 1.99 (m, 1H), 1.11 (s, 1H), 0.51 (d, *J* = 8.4 Hz, 2H), 0.27 (d, *J* = 4.4 Hz, 2H)
346	**I-351**	NG	GF	991.3	11.07 (s, 1H), 10.33 (s, 2H), 10.12 (s, 1H), 9.17 (s, 1H), 9.05 (s, 1H), 8.89 (s, 1H), 8.15 (d, *J* = 6.0 Hz, 1H), 7.98 (d, *J* = 8.4 Hz, 2H), 7.68 (d, *J* = 8.4 Hz, 2H), 7.59 (d, *J* = 8.4 Hz, 1H), 7.47 - 7.07 (m, 4H), 7.02 (d, *J* = 1.6 Hz, 1H), 6.91 (dd, *J* = 1.6, 8.4 Hz, 1H), 5.04 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.46 - 4.19 (m, 10H), 3.70 (d, *J* = 5.2 Hz, 10H), 3.37 (s, 4H), 3.23 (d, *J* = 6.8 Hz, 2H), 3.16 (d, *J* = 5.6 Hz, 2H), 2.93 - 2.83 (m, 1H), 2.64 - 2.52 (m, 2H), 2.04 - 1.94 (m, 1H), 1.15 - 1.05 (m, 1H), 0.60 - 0.47 (m, 2H), 0.33 - 0.26 (m, 2H)
347[c]	**I-352**	OK	IW	801.1	11.09 (s, 1H), 9.97 (s, 1H), 9.40 - 9.38 (m, 2H), 8.82 (s, 1H), 8.80 (s, 1H), 8.43 (s, 1H), 8.00 (s, 1H), 7.90 (d, *J* = 8.8 Hz, 2H), 7.71 (d, *J* = 8.8 Hz, 2H), 7.59 - 7.52 (m, 1H), 7.31 (t, *J* = 56.0 Hz, 1 H), 7.12 (d, *J* = 8.4 Hz, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 5.08 - 5.02 (m, 1H), 4.12 - 4.30 (m, 2H), 3.95 (s, 3H), 3.75 (t, *J* = 5.2 Hz, 2H), 3.59 - 3.68 (m, 6H), 3.47 (t, *J* = 5.2 Hz, 2H), 3.20 - 3.00 (s, 2H), 2.96 - 2.78 (m, 1H), 2.64 - 2.56 (m, 2H), 2.08 - 1.97 (m, 1H)
348[c]	**I-353**	IX	IW	801.4	11.04 (s, 1H), 9.88 (s, 1H), 8.78 - 8.74 (m, 2H), 8.43 (s, 1H), 8.24 (s, 1H), 8.00 (s, 1H), 7.78 (d, *J* = 8.4 Hz, 2H), 7.57 - 7.53 (m, 1H), 7.47 (d, *J* = 8.8 Hz, 2H), 7.43 - 7.12 (m, 2H), 7.00 (d, *J* = 2.0 Hz, 1H), 6.89 (dd, *J* = 2.0, 8.4 Hz, 1H), 5.02 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.94 (s, 3H), 3.77 (s, 2H), 3.62 - 3.54 (m, 8H), 3.35 (d, *J* = 5.6 Hz, 2H), 2.92 - 2.81 (m, 1H), 2.67 (t, *J* = 5.6 Hz, 2H),

					2.60 - 2.52 (m, 2H), 2.03 - 1.93 (m, 1H)
349	**I-354**	IX	GF	867.5	11.05 (s, 1H), 9.98 (s, 1H), 8.96 (s, 1H), 8.77 (s, 1H), 8.28 (s, 1H), 8.15 (d, *J* = 5.3 Hz, 1H), 7.78 (d, *J* = 8.8 Hz, 2H), 7.54 (d, *J* = 8.4 Hz, 1H), 7.47 (d, *J* = 8.8 Hz, 2H), 7.42 - 7.17 (m, 1H), 7.15 (d, *J* = 3.6 Hz, 1H), 7.11 (s, 1H), 7.08 (t, *J* = 5.5 Hz, 1H), 7.03 (dd, *J* = 1.2, 5.2 Hz, 1H), 7.00 (d, *J* = 1.6 Hz, 1H), 6.88 (dd, *J* = 2.0, 8.4 Hz, 1H), 5.02 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.76 (s, 2H), 3.62 - 3.55 (m, 8H), 3.22 - 3.15 (m, 4H), 2.95 - 2.81 (m, 1H), 2.67 - 2.64 (m, 2H), 2.57 - 2.53 (m, 2H), 2.02 - 1.92 (m, 1H), 1.11 - 1.02 (m, 1H), 0.47 - 0.43 (m, 2H), 0.24 - 0.20 (m, 2H)
350	**I-355**	IZ	GF	792.1	11.12 (s, 1H), 9.99 (s, 1H), 8.97 (s, 1H), 8.78 (s, 1H), 8.16 (d, *J* = 5.6 Hz, 1H), 7.83 - 7.77 (d, *J* = 8.4 Hz, 2H), 7.76 - 7.72 (m, 2H), 7.72 - 7.67 (m, 1H), 7.45 (d, *J* = 8.4 Hz, 2H), 7.29 (t, *J* = 14.0 Hz, 1H), 7.14 - 7.07 (m, 2H), 7.04 (dd, *J* = 1.2, 5.6 Hz, 1H), 5.13 (dd, *J* = 5.2, 12.4 Hz, 1H), 3.52 (s, 2H), 3.18 (t, *J* = 6.0 Hz, 2H), 3.07 (t, *J* = 7.6 Hz, 2H), 2.94 - 2.83 (m, 1H), 2.64 - 2.53 (m, 2H), 2.41 (t, *J* = 6.8 Hz, 2H), 2.15 (s, 3H), 2.09 - 2.02 (m, 1H), 1.87 - 1.75 (m, 2H), 1.13 - 1.02 (m, 1H), 0.49 - 0.40 (m, 2H), 0.26 - 0.19 (m, 2H)
351[c]	**I-356**	IZ	JA	716.0	11.13 (d, *J* = 7.6 Hz, 2H), 11.05 (s, 1H), 9.17 (s, 1H), 9.01 (s, 1H), 8.94 (d, *J* = 6.0 Hz, 2H), 8.15 - 8.01 (m, 5H), 7.89 - 7.72 (m, 6H), 5.15 (dd, *J* = 3.6, 12.4 Hz, 1H), 4.48 - 4.26 (m, 2H), 3.12 (d, *J* = 6.8 Hz, 3H), 2.69 (d, *J* = 4.8 Hz, 3H), 2.62 - 2.54 (m, 3H), 2.22 - 1.98 (m, 4H)

352	**I-357**	FU	GF	778.1	11.11 (s, 1H), 9.98 (s, 1H), 8.97 (s, 1H), 8.78 (s, 1H), 8.29 (s, 2H), 8.16 (d, *J* = 4.8 Hz, 1H), 7.65 - 7.89 (m, 5H), 7.56 - 7.46 (m, 2H), 7.45-7.15 (m, 1H), 7.14 - 7.00 (m, 3H), 5.30 - 4.98 (m, 1H), 3.76 (s, 2H), 3.19 (t, *J* = 5.6 Hz, 2H), 3.05 - 3.13 (m, 2H), 2.83 - 2.95 (m, 1H), 2.65 - 2.56 (m, 4H), 2.00 - 2.12 (m, 1H), 1.72-1.86 (m, 2H), 0.98 - 1.15 (m, 1H), 0.38 - 0.51 (m, 2H), 0.15 - 0.27 (m, 2H)
353[c]	**I-358**	FU	JA	702.4	11.15 - 11.03 (m, 2H), 9.09 (s, 1H), 8.91 (s, 1H), 8.87 - 8.83 (m, 2H), 8.33 (s, 1H), 8.03 (s, 1H), 7.99 - 7.94 (m, 2H), 7.93 - 7.87 (m, 2H), 7.79 - 7.73 (m, 3H), 7.72 - 7.69 (m, 1H), 7.52 - 7.46 (m, 2H), 5.16 - 5.10 (m, 1H), 3.76 (s, 2H), 3.14 - 3.04 (m, 2H), 2.93 - 2.87 (m, 1H), 2.64 - 2.61 (m, 1H), 2.60 - 2.57 (m, 1H), 2.57 - 2.55 (m, 2H), 2.09 - 2.03 (m, 1H), 1.85 - 1.76 (m, 2H)
354[c]	**I-359**	NH	JD	681.1	11.13 (s, 1H), 10.35 - 10.17 (m, 1H), 10.16 - 9.81 (m, 2H), 9.27 - 9.05 (m, 1H), 8.94 - 8.84 (m, 3H), 8.23 - 8.07 (m, 3H), 8.00 - 7.90 (m, 4H), 7.84 - 7.66 (m, 2H), 7.49 - 7.15 (m, 1H), 5.23 - 5.08 (m, 1H), 4.72 - 4.56 (m, 2H), 4.33 (s, 2H), 3.10 - 2.80 (m, 1H), 2.68 - 2.52 (m, 2H), 2.09 - 1.97 (m, 1H)
355	**I-360**	IZ	JC	920.2	11.10 (s, 1H), 9.98 (s, 1H), 8.99 (s, 1H), 8.79 (s, 1H), 8.25 (d, *J* = 5.2 Hz, 1H), 7.79 (d, *J* = 8.4 Hz, 2H), 7.77 - 7.71 (m, 2H), 7.70 - 7.66 (m, 1H), 7.61 (t, *J* = 6.4 Hz, 1H), 7.45 (d, *J* = 8.4 Hz, 2H), 7.43 - 7.14 (m, 3H), 5.13 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.30 - 4.18 (m, 2H), 3.52 (s, 2H), 3.07 (t, *J* = 7.2 Hz, 2H), 2.96 - 2.82 (m, 1H), 2.65 - 2.51 (m, 2H), 2.42 (t, t, *J* = 7.2 Hz, 2H), 2.16 (s, 3H), 2.09 - 2.01 (m, 1H), 1.86 -1.79 (m, 2H)

356	**I-361**	FU	JC	806.3	11.11 (s, 1H), 9.99 (s, 1H), 9.00 (s, 1H), 8.79 (s, 1H), 8.28 - 8.24 (m, 2H), 7.82 - 7.75 (m, 4H), 7.73 - 7.69 (m, 1H), 7.61 (t, *J* = 6.4 Hz, 1H), 7.50 (d, *J* = 8.4 Hz, 2H), 7.27 (s, 1H), 7.22 (d, *J* = 5.2 Hz, 1H), 7.16 (s, 1H), 5.14 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.25 (dd, *J* = 6.8, 9.6 Hz, 2H), 3.77 (s, 2H), 3.10 (t, *J* = 7.6 Hz, 2H), 2.96 - 2.83 (m, 1H), 2.68 - 2.63 (m, 1H), 2.60 - 2.57 (m, 3H), 2.34 (s, 1H), 2.11 - 2.02 (m, 1H), 1.86 - 1.77 (m, 2H)
357	**I-362**	GL	GF	836.1	11.13 (s, 1H), 10.00 (s, 1H), 8.97 (s, 1H), 8.78 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.85 - 7.73 (m, 4H), 7.72 - 7.66 (m, 1H), 7.46 (d, *J* = 8.4 Hz, 2H), 7.43 - 7.15 (m, 1H), 7.14 - 7.07 (m, 2H), 7.05 (dd, *J* = 1.2, 5.2 Hz, 1H), 5.13 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.57 (s, 2H), 3.54 - 3.50 (m, 4H), 3.19 (t, *J* = 6.0 Hz, 2H), 3.08 (t, *J* = 7.6 Hz, 2H), 2.93 - 2.84 (m, 1H), 2.64 - 2.58 (m, 1H), 2.58 - 2.56 (m, 1H), 2.55 - 2.53 (m, 2H), 2.19 (s, 3H), 2.09 - 2.01 (m, 1H), 1.91 - 1.81 (m, 2H), 1.13 - 1.03 (m, 1H), 0.50 - 0.42 (m, 2H), 0.27 - 0.19 (m, 2H)
358	**I-363**	GL	JD	767.4	11.10 (s, 1H), 10.09 (s, 1H), 9.05 (s, 1H), 8.90 - 8.81 (m, 2H), 8.78 (s, 1H), 8.03 - 7.93 (m, 2H), 7.83 - 7.78 (m, 2H), 7.77 - 7.72 (m, 2H), 7.71 - 7.66 (m, 1H), 7.46 (d, *J* = 8.4 Hz, 2H), 7.43 - 7.13 (m, 1H), 5.12 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.56 (s, 2H), 3.51 (t, *J* = 6.0 Hz, 2H), 3.42 (t, *J* = 6.4 Hz, 2H), 3.08 (t, *J* = 7.6 Hz, 2H), 2.94 - 2.83 (m, 1H), 2.63 - 2.57 (m, 1H), 2.56 - 2.53 (m, 2H), 2.53 - 2.52 (m, 1H), 2.19 (s, 3H), 2.08 - 2.01 (m, 1H), 1.90 - 1.80 (m, 2H)

359[c]	**I-364**	FU	JM	780.1	11.11 (s, 1H), 10.29 - 10.23 (m, 1H), 9.20 - 9.16 (m, 1H), 9.09 (s, 1H), 9.01 - 8.92 (m, 3H), 8.89 (s, 1H), 8.24 - 8.14 (m, 2H), 8.01 - 7.90 (m, 2H), 7.84 - 7.77 (m, 2H), 7.74 - 7.66 (m, 1H), 7.62 - 7.54 (m, 1H), 7.42 - 7.29 (m, 1H), 5.30 - 5.08 (m, 1H), 3.77 (s, 2H), 3.36 - 3.09 (m, 3H), 3.04 - 2.97 (m, 3H), 2.92 - 2.83 (m, 1H), 2.64 - 2.56 (m, 2H), 2.14 - 1.96 (m, 2H)
360[c]	**I-365**	IZ	JD	723.3	11.10 (s, 1H), 10.09 (s, 1H), 9.05 (s, 1H), 8.84 (d, *J* = 6.0 Hz 2H), 8.78 (s, 1H), 7.99 (d, *J* = 6.0 Hz 2H), 7.79 (d, *J* = 8.4 Hz, 2H), 7.77 - 7.71 (m, 2H), 7.71 - 7.66 (m, 1H), 7.45 (d, *J* = 8.8 Hz, 2H), 7.29 (d, *J* = 54 Hz, 1H), 5.13 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.52 (s, 2H), 3.14 - 3.02 (m, 2H), 2.93 - 2.84 (m, 1H), 2.65 - 2.52 (m, 2H), 2.41 (t, *J* = 7.2 Hz, 2H), 2.15 (s, 3H), 2.10 - 2.02 (m, 1H), 1.86 -1.79 (m, 2H)
361[c]	**I-366**	FU	JD	709.1	11.12 (s, 1H), 10.23 (s, 1H), 9.41 (s, 2H), 8.90 (d, *J* = 6.0 Hz, 2H), 8.86 (s, 1H), 8.11 (d, *J* = 6.4 Hz, 2H), 7.94 (d, *J* = 8.8 Hz, 2H), 7.87 - 7.67 (m, 5H), 7.32 (t, *J* = 14.0 Hz,, 1H), 5.14 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.19 (t, *J* = 5.2 Hz, 2H), 3.12 (t, *J* = 7.2 Hz, 2H), 3.04 - 2.81 (m, 3H), 2.66 - 2.53 (m, 2H), 2.14 - 1.97 (m, 3H)
362	**I-367**	GW	GF	822.4	10.89 (s, 1H), 9.77 (s, 1H), 8.74 (s, 1H), 8.56 (s, 1H), 8.00 (s, 1H), 7.93 (d, *J* = 5.2 Hz, 1H), 7.57 (d, *J* = 8.4 Hz, 2H), 7.54 - 7.50 (m, 2H), 7.49 - 7.45 (m, 1H), 7.26 (d, *J* = 8.8 Hz, 2H), 7.20 - 6.91 (m, 1H), 6.91 - 6.85 (m, 2H), 6.78 - 6.82 (m, 1H), 4.90 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.56 (s, 2H), 3.23 (t, *J* = 5.6 Hz, 2H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.95 (t, *J* = 6.0 Hz, 2H), 2.85 (t, *J* = 7.2 Hz, 2H), 2.71 - 2.59 (m, 1H), 2.46 - 2.42 (m, 2H), 2.40 - 2.33(m, 1H),

					2.32 - 2.29 (m, 1H), 1.86 - 1.78 (m, 1H), 1.66 - 1.59 (m, 2H), 0.88 - 0.79 (m, 1H), 0.25 - 0.20 (m, 2H), 0.02 - -0.03 (m, 2H)
363[c]	**I-368**	GW	JD	753.3	11.12 (s, 1H), 10.12 (s, 1H), 9.06 (s, 1H), 8.84 (d, *J* = 6.0 Hz, 2H), 8.79 (s, 1H), 8.01 - 7.95 (m, 2H), 7.85 - 7.80 (m, 2H), 7.79 - 7.72 (m, 2H), 7.71 - 7.68 (m, 1H), 7.54 - 7.47 (m, 2H), 7.43 - 7.14 (m, 1H), 5.13 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.83 (s, 2H), 3.48 (t, *J* = 5.6 Hz, 2H), 3.42 (t, *J* = 6.4 Hz, 2H), 3.08 (t, *J* = 7.6 Hz, 2H), 2.94 - 2.83 (m, 1H), 2.71 (t, *J* = 5.6 Hz, 2H), 2.64 - 2.51 (m, 2H), 2.09 - 2.01 (m, 1H), 1.90 - 1.82 (m, 2H)
364	**I-369**	JH	GF	792.1	11.12 (s, 1H), 10.01 (s, 1H), 8.98 (s, 1H), 8.79 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.84 - 7.77 (m, 4H), 7.77 - 7.71 (m, 1H), 7.49 - 7.44 (m, 2H), 7.44 - 7.16 (m, 1H), 7.12 (s, 1H), 7.11 - 7.08 (m, 1H), 7.04 (dd, *J* = 1.2, 5.2 Hz, 1H), 5.14 (dd, *J* = 5.6, 13.0 Hz, 1H), 3.51 (s, 2H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.95 - 2.86 (m, 1H), 2.85 - 2.80 (m, 2H), 2.64 - 2.55 (m, 2H), 2.39 (d, *J* = 6.8 Hz, 2H), 2.14 (s, 3H), 2.09 - 2.00 (m, 1H), 1.90 - 1.80 (m, 2H), 1.12 - 1.03 (m, 1H), 0.49 - 0.43 (m, 2H), 0.26 - 0.21 (m, 2H)
365[c]	**I-370**	JH	GE	716.4	11.11 (s, 2H), 9.10 - 9.07 (m, 1H), 8.93 - 8.91 (m, 1H), 8.85 (d, *J* = 6.0 Hz, 2H), 8.04 (s, 1H), 7.96 (d, *J* = 6.0 Hz, 2H), 7.90 (d, *J* = 8.4 Hz, 2H), 7.83 - 7.76 (m, 3H), 7.71 (d, *J* = 7.6 Hz, 1H), 7.45 (d, *J* = 8.4 Hz, 2H), 5.14 (dd, *J* = 5.6, 13.2 Hz, 1H), 3.51 (s, 2H), 2.94 - 2.86 (m, 1H), 2.83 (d, *J* = 7.2 Hz, 2H), 2.64 - 2.54 (m, 2H), 2.39 - 2.35 (m, 2H), 2.15 (s, 3H), 2.08 - 2.00 (m, 1H), 1.89 - 1.81 (m, 2H)

366	**I-371**	JI	GF	778.4	11.14 (s, 1H), 10.03 (s, 1H), 8.98 (s, 1H), 8.79 (s, 1H), 8.30 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.87 - 7.77 (m, 4H), 7.72 (d, *J* = 7.2 Hz, 1H), 7.51 (d, *J* = 8.4 Hz, 2H), 7.46 - 7.15 (m, 1H), 7.15 - 7.08 (m, 2H), 7.05 (d, *J* = 5.2 Hz, 1H), 5.15 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.78 (s, 2H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.95 - 2.81 (m, 3H), 2.71 - 2.55 (m, 4H), 2.09 - 2.01 (m, 1H), 1.89 - 1.75 (m, 2H), 1.07 - 1.06 (m, 1H), 0.51 - 0.41 (m, 2H), 0.23 - 0.22 (m, 2H)
367[c]	**I-372**	JI	GE	702.3	11.10 (s, 2H), 9.08 (s, 1H), 8.92 (s, 1H), 8.85 (d, *J* = 5.6 Hz, 2H), 8.29 (s, 1H), 8.06 (s, 1H), 7.99 - 7.89 (m, 4H), 7.83 (d, *J* = 7.6 Hz, 1H), 7.81 - 7.75 (m, 2H), 7.72 (d, *J* = 7.6 Hz, 1H), 7.52 (d, *J* = 8.2 Hz, 2H), 5.14 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.86 - 3.75 (m, 2H), 2.95 - 2.83 (m, 3H), 2.65 - 2.54 (m, 4H), 2.10 - 2.01 (m, 1H), 1.89 - 1.81 (m, 1H)
368[c]	**I-373**	JJ	JD	681.3	11.11 (s, 1H), 10.09 (s, 1H), 9.06 (s, 1H), 8.85 (d, *J* = 6.0 Hz, 2H), 8.79 (s, 1H), 8.39 (s, 1H), 7.99 (d, *J* = 6.0 Hz, 2H), 7.95 (s, 1H), 7.90 - 7.86 (m, 2H), 7.82 (d, *J* = 8.4 Hz, 2H), 7.53 (d, *J* = 8.4 Hz, 2H), 7.43 - 7.15 (m, 1H), 5.20 - 5.08 (m, 1H), 3.91 (s, 2H), 3.76 (s, 2H), 2.94 - 2.87 (m, 1H), 2.65 - 2.61 (m, 1H), 2.60 - 2.57 (m, 1H), 2.09 - 2.00 (m, 1H)
369	**I-374**	JH	JC	820.4	11.09 (s, 1H), 9.98 (s, 1H), 8.99 (s, 1H), 8.79 (s, 1H), 8.25 (d, *J* = 5.2 Hz, 1H), 7.83 - 7.78 (m, 4H), 7.75 - 7.71 (m, 1H), 7.60 (t, *J* = 6.4 Hz, 1H), 7.47 - 7.43 (m, 2H), 7.30 - 7.16 (m, 3H), 5.13 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.30 - 4.20 (m, 2H), 3.51 (s, 2H), 2.95 - 2.85 (m, 1H), 2.83 (t, *J* = 7.2 Hz, 2H), 2.64 - 2.56 (m, 2H), 2.38 (t, *J* = 6.8 Hz, 2H), 2.14 (s, 3H), 2.09 - 2.01 (m, 1H), 1.89 - 1.82 (m, 2H)

370	**I-375**	JI	JC	806.3	11.11 (s, 1H), 10.01 (s, 1H), 9.00 (s, 1H), 8.82 (s, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.19 (s, 1H), 7.89 - 7.80 (m, 4H), 7.75 - 7.72 (m, 1H), 7.62 (t, *J* = 6.4 Hz, 1H), 7.56 (d, *J* = 8.4 Hz, 2H), 7.44 - 7.17 (m, 1H), 7.27 (s, 1H), 7.22 (dd, *J* = 1.2, 5.2 Hz, 1H), 5.15 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.32 - 4.20 (m, 2H), 3.90 (s, 2H), 2.95 - 2.82 (m, 3H), 2.70 - 2.53 (m, 4H), 2.11 - 2.01 (m, 1H), 1.94 - 1.83 (m, 2H)
371	**I-376**	JK	GF	836.4	11.12 (s, 1H), 9.99 (s, 1H), 8.97 (s, 1H), 8.78 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.84 - 7.81 (m, 2H), 7.78 (d, *J* = 6.0 Hz, 2H), 7.71 (d, *J* = 8.0 Hz, 1H), 7.46 (d, *J* = 8.4 Hz, 2H), 7.42 - 7.14 (m, 1H), 7.12 - 7.08 (m, 2H), 7.06 - 7.01 (m, 1H), 5.18 - 5.08 (m, 1H), 3.56 (s, 2H), 3.53 - 3.48 (m, 4H), 3.21 - 3.14 (m, 2H), 2.92 - 2.86 (m, 1H), 2.84 - 2.80 (m, 2H), 2.63 - 2.59 (m, 1H), 2.58 - 2.57 (m, 1H), 2.56 - 2.54 (m, 2H), 2.19 (s, 3H), 2.07 - 2.02 (m, 1H), 1.89 - 1.84 (m, 2H), 1.11 - 1.04 (m, 1H), 0.47 - 0.42 (m, 2H), 0.24 - 0.20 (m, 2H)
372[c]	**I-377**	JK	JD	767.4	11.11 (s, 1H), 10.09 (s, 1H), 9.06 (s, 1H), 8.87 - 8.82 (m, 2H), 8.79 (s, 1H), 8.01 - 7.97 (m, 2H), 7.86 - 7.77 (m, 4H), 7.72 (d, *J* = 7.2 Hz, 1H), 7.47 (d, *J* = 8.4 Hz, 2H), 7.44 - 7.12 (m, 1H), 5.18 - 5.11 (m, 1H), 3.58 (s, 2H), 3.54 - 3.51 (m, 2H), 3.41 - 3.40 (m, 2H), 2.95 - 2.88 (m, 1H), 2.87 - 2.82 (m, 2H), 2.64 - 2.58 (m, 1H), 2.57 - 2.54 (m, 2H), 2.54 - 2.52 (m, 1H), 2.21 (s, 3H), 2.08 - 2.01 (m, 1H), 1.92 - 1.84 (m, 2H)

373[c]	**I-378**	JI	JM	780.3	11.09 (s, 1H), 10.20 (s, 1H), 9.08 (s, 1H), 8.93 - 8.80 (m, 3H), 8.30 (s, 1H), 8.03 - 7.97 (m, 2H), 7.95 - 7.93 (m, 2H), 7.84 - 7.72 (m, 2H), 7.65 - 7.54 (m, 3H), 7.47 - 7.16 (m, 1H), 5.15 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.73 - 3.46 (m, 2H), 3.45 - 3.20 (m, 2H), 3.03 - 2.85 (m, 4H), 2.84 - 2.52 (m, 6H), 2.10 - 1.96 (m, 1H), 1.90 - 1.68 (m, 2H)
374[c]	**I-379**	JH	JD	723.3	11.10 (s, 1H), 10.11 (s, 1H), 9.03 (s, 1H), 8.83 (d, *J* = 5.6 Hz, 2H), 8.76 (s, 1H), 7.99 (d, *J* = 5.6 Hz, 2H), 7.84 - 7.76 (m, 4H), 7.75 - 7.67 (m, 1H), 7.49 - 7.42 (m, 2H), 7.42 - 7.14 (m, 1H), 5.13 (dd, *J* = 5.5, 13.0 Hz, 1H), 3.50 (s, 2H), 2.96 - 2.85 (m, 1H), 2.83 (d, *J* = 7.2 Hz, 2H), 2.63 - 2.53 (m, 2H), 2.37 (t, *J* = 6.8 Hz, 2H), 2.14 (s, 3H), 2.08 - 2.00 (m, 1H), 1.89 - 1.81 (m, 2H)
375[c]	**I-380**	JI	JD	709.3	11.11 (s, 1H), 10.10 (s, 1H), 9.06 (s, 1H), 8.89 - 8.82 (m, 2H), 8.79 (s, 1H), 8.25 (s, 1H), 8.02 - 7.97 (m, 2H), 7.87 - 7.77 (m, 4H), 7.73 - 7.71 (m, 1H), 7.51 (d, *J* = 8.4 Hz, 2H), 7.44 - 7.14 (m, 1H), 5.14 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.79 (s, 2H), 2.96 - 2.78 (m, 3H), 2.69 - 2.52 (m, 4H), 2.12 - 2.02 (m, 1H), 1.88 - 1.77 (m, 2H)
376	**I-381**	JR	GF	822.1	11.13 (s, 1H), 10.01 (s, 1H), 8.98 (s, 1H), 8.80 (s, 1H), 8.21 - 8.10 (m, 2H), 7.87 - 7.78 (m, 4H), 7.73 (d, *J* = 7.6 Hz, 1H), 7.52 (d, *J* = 7.6 Hz, 2H), 7.46 - 7.15 (m, 1H), 7.14 - 7.08 (m, 2H), 7.08 - 7.01 (m, 1H), 5.20 - 5.10 (m, 1H), 3.91 - 3.79 (m, 2H), 3.52 - 3.45 (m, 2H), 3.44 - 3.35 (m, 2H), 3.24 - 3.22 (m, 2H), 2.97 - 2.81 (m, 3H), 2.77 - 2.58 (m, 4H), 2.12 - 2.01 (m, 1H), 1.94 - 1.82 (m, 2H), 1.14 - 1.02 (m, 1H),

					0.53 - 0.41 (m, 2H), 0.29 - 0.19 (m, 2H)
377[c]	**I-382**	JR	JD	753.3	11.11 (s, 1H), 10.28 (s, 1H), 9.48 (s, 2H), 9.18 (s, 1H), 8.95 (d, *J* = 6.4 Hz, 2H), 8.87 (s, 1H), 8.20 (d, *J* = 6.0 Hz, 2H), 8.04 - 7.90 (m, 2H), 7.85 (d, *J* = 7.6 Hz, 1H), 7.81 - 7.73 (m, 3H), 7.49 - 7.19 (m, 1H), 5.16 - 5.11 (m, 1H), 4.23 (t, *J* = 5.2 Hz, 2H), 3.70 (t, *J* = 5.2 Hz, 2H), 3.45 (t, *J* = 6.4 Hz, 2H), 3.10 (s, 2H), 2.95 - 2.78 (m, 3H), 2.65 - 2.51 (m, 2H), 2.10 - 2.00 (m, 1H), 1.95 - 1.86 (m, 2H)
378	**I-383**	II	GF	949.2	9.96 (s, 1H), 8.96 (s, 1H), 8.78 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.87 - 7.81 (m, 2H), 7.79 (d, *J* = 8.4 Hz, 2H), 7.65 (d, *J* = 8.4 Hz, 1H), 7.52 - 7.44 (m, 3H), 7.43 - 7.15 (m, 1H), 7.12 (s, 1H), 7.07 (t, *J* = 5.6 Hz, 1H), 7.05 - 7.02 (m, 1H), 5.58 (s, 2H), 5.09 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.66 (t, *J* = 5.2 Hz, 2H), 3.84 (t, *J* = 5.2 Hz, 2H), 3.75 (s, 2H), 3.51 - 3.47 (m, 2H), 3.45 - 3.40 (m, 4H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.93 - 2.81 (m, 1H), 2.63 (t, *J* = 5.6 Hz, 2H), 2.60 - 2.54 (m, 2H), 2.06 - 1.97 (m, 1H), 1.15 - 1.00 (m, 1H), 0.49 - 0.42 (m, 2H), 0.26 - 0.19 (m, 2H)
379	**I-384**	NT	GF	936.4	11.01 (s, 1H), 9.99 (s, 1H), 8.96 (s, 1H), 8.82 (s, 1H), 8.17 (d, *J* = 5.2 Hz, 1H), 7.85 (d, *J* = 8.8 Hz, 2H), 7.56 (d, *J* = 8.8 Hz, 2H), 7.46 - 7.16 (m, 2H), 7.12 (s, 1H), 7.10 - 7.02 (m, 2H), 6.93 (d, *J* = 7.2 Hz, 1H), 6.79 (d, *J* = 8.0 Hz, 1H), 5.31 (s, 1H), 5.12 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.35 - 4.08 (m, 2H), 3.94 (s, 2H), 3.67 - 3.46 (m, 8H), 3.36 - 3.30 (m, 1H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.96 - 2.94 (m, 2H), 2.83 (t, *J* = 5.2 Hz, 2H), 2.62 - 2.55 (m, 2H), 2.69 - 2.54 (m, 1H), 2.36 - 2.19 (m, 3H), 2.11 - 2.00 (m, 1H), 1.93 -

					1.91 (m, 2H), 1.57 - 1.39 (m, 2H), 1.14 - 0.96 (m, 1H), 0.54 - 0.40 (m, 2H), 0.28 - 0.12 (m, 2H)
380	**I-385**	NU	GF	906.2	11.08 (s, 1H), 9.97 (s, 1H), 8.96 (s, 1H), 8.79 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.83 (d, *J* = 8.8 Hz, 2H), 7.60 - 7.50 (m, 3H), 7.43 - 7.12 (m, 2H), 7.11 (s, 1H), 7.07 (t, *J* = 5.2 Hz, 1H), 7.05 - 7.00 (m, 2H), 6.23 (d, *J* = 8.0 Hz, 1H), 5.04 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.88 (s, 2H), 3.66 - 3.56 (m, 1H), 3.55 - 3.49 (m, 4H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.93 - 2.85 (m, 1H), 2.85 - 2.79 (m, 2H), 2.79 - 2.73 (m, 2H), 2.63 - 2.55 (m, 2H), 2.55 - 2.53 (m, 2H), 2.25 (t, *J* = 10.4 Hz, 2H), 2.08 - 1.97 (m, 1H), 1.96 - 1.84 (m, 2H), 1.56 - 1.41 (m, 2H), 1.13 - 1.01 (m, 1H), 0.50 - 0.41 (m, 2H), 0.25 - 0.18 (m, 2H)
381	**I-386**	JY	GF	994.2	11.08 (s, 1H), 9.97 (s, 1H), 8.96 (s, 1H), 8.80 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.88 - 7.80 (m, 2H), 7.60 - 7.49 (m, 3H), 7.44 - 7.15 (m, 1H), 7.15 - 7.10 (m, 2H), 7.07 (t, *J* = 5.2 Hz, 1H), 7.05 - 7.01 (m, 2H), 6.22 (d, *J* = 8.0 Hz, 1H), 5.05 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.88 (s, 2H), 3.62 - 3.55 (m, 1H), 3.55 - 3.47 (m, 12H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.94 - 2.84 (m, 1H), 2.83 - 2.74 (m, 4H), 2.63 - 2.52 (m, 2H), 2.48 - 2.42 (m, 2H), 2.26 - 2.17 (m, 2H), 2.07 - 1.98 (m, 1H), 1.96 - 1.85 (m, 2H), 1.48 - 1.42 (m, 2H), 1.13 - 1.01 (m, 1H), 0.49 - 0.42 (m, 2H), 0.26 - 0.20 (m, 2H)

382	**I-387**	NX	GF	936.4	10.92 (s, 1H), 9.99 (s, 1H), 8.97 (s, 1H), 8.80 (s, 1H), 8.20 (s, 1H), 8.17 (d, *J* = 5.6 Hz, 1H), 7.82 (d, *J* = 8.4 Hz, 2H), 7.50 (d, *J* = 8.4 Hz, 2H), 7.43 - 7.16 (m, 2H), 7.13 - 7.08 (m, 2H), 7.05 (d, *J* = 5.2 Hz, 1H), 6.69 - 6.63 (m, 2H), 6.26 - 6.19 (m, 1H), 6.22 (d, *J* = 7.6 Hz, 1H), 5.00 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.26 - 4.10 (m, 2H), 3.81 (s, 2H), 3.64 - 3.48 (m, 8H), 3.26 - 3.24 (m, 2H), 3.22 - 3.15 (m, 2H), 2.94 - 2.90 (m, 1H), 2.88 - 2.82 (m, 3H), 2.74 - 2.86 (m, 2H), 2.61 - 2.58 (m, 1H), 2.57 - 2.55 (m, 1H), 2.15 - 2.11 (m, 2H), 1.91 - 1.89 (m, 3H), 1.41 - 1.38 (m, 2H), 1.10 - 1.06 (m, 1H), 0.49 - 0.44 (m, 2H), 0.26 - 0.21 (m, 2H)
383	**I-388**	JZ	GF	906.4	11.03 (s, 1H), 9.95 (s, 1H), 8.96 (s, 1H), 8.79 (s, 1H), 8.22 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.81 (d, *J* = 8.4 Hz, 2H), 7.54 (d, *J* = 8.4 Hz, 1H), 7.51 (d, *J* = 8.8 Hz, 2H), 7.44 - 7.14 (m, 1H), 7.12 (s, 1H), 7.09 - 7.05 (m, 1H), 7.04 (d, *J* = 6.4 Hz, 1H), 6.99 - 6.95 (m, 2H), 6.89 - 6.84 (m, 1H), 5.07 - 4.98 (m, 1H), 3.81 (s, 2H), 3.55 - 3.47 (m, 6H), 3.42 - 3.35 (m, 1H), 3.21 - 3.18 (m, 2H), 2.89 - 2.80 (m, 3H), 2.72 - 2.67 (m, 2H), 2.60 - 2.54 (m, 1H), 2.54 - 2.53 (m, 1H), 2.21 - 2.14 (m, 2H), 2.03 - 1.96 (m, 1H), 1.94 - 1.86 (m, 2H), 1.46 - 1.38 (m, 2H), 1.12 - 1.04 (m, 1H), 0.48 - 0.44 (m, 2H), 0.25 - 0.21 (m, 2H)

384	**I-389**	KA	GF	994.6	11.04 (s, 1H), 9.98 (s, 1H), 8.95 (s, 1H), 8.78 (s, 1H), 8.29 (s, 1H), 8.15 (d, *J* = 5.6 Hz, 1H), 7.80 (d, *J* = 8.4 Hz, 2H), 7.57 - 7.44 (m, 3H), 7.43 - 7.15 (m, 1H), 7.11 (s, 1H), 7.09 - 7.01 (m, 2H), 7.00 - 6.90 (m, 2H), 6.85 (d, *J* = 8.0 Hz, 1H), 5.01 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.56 - 3.45 (m, 16H), 3.21 - 3.15 (m, 2H), 2.90 - 2.78 (m, 3H), 2.71 (t, *J* = 5.6 Hz, 2H), 2.62 - 2.54 (m, 2H), 2.26 - 2.03 (m, 3H), 2.02 - 1.95 (m, 1H), 1.92 - 1.82 (m, 2H), 1.47 - 1.35 (m, 2H), 1.09 - 1.04 (m, 1H), 0.41 - 0.50 (m, 2H), 0.27 - 0.18 (m, 2H)
385	**I-390**	NY	GF	892.1	11.07 (s, 1H), 9.96 (s, 1H), 8.97 (s, 1H), 8.78 (s, 1H), 8.24 (s, 1H), 8.17 (d, *J* = 5.2 Hz, 1H), 7.80 (d, *J* = 8.4 Hz, 2H), 7.70 - 7.64 (m, 1H), 7.52 (s, 1H), 7.46 - 7.33 (m, 1H), 7.31 - 7.24 (m, 1H), 7.18 - 7.10 (m, 1H), 7.09 - 7.04 (m, 1H), 5.08 (dd, *J* = 5.2, 13.0 Hz, 1H), 3.81 (s, 2H), 3.59 (s, 1H), 3.27 - 3.19 (m, 3H), 2.73 - 2.71 (m, 1H), 2.69 - 2.67 (m, 1H), 2.61 (s, 4H), 2.58 - 2.54 (m, 4H), 2.06 - 1.99 (m, 1H), 1.12 - 1.04 (m, 1H), 0.50 - 0.44 (m, 2H), 0.27 - 0.18 (m, 2H)
386	**I-391**	KB	GF	980.5	11.06 (s, 1H), 9.95 (s, 1H), 8.96 (s, 1H), 8.78 (s, 1H), 8.29 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.79 (d, *J* = 8.8 Hz, 2H), 7.67 (dd, *J* = 7.2, 8.3 Hz, 1H), 7.48 (d, *J* = 8.8 Hz, 2H), 7.43 - 7.15 (m, 3H), 7.11 (s, 1H), 7.07 (t, *J* = 5.6 Hz, 1H), 7.03 (dd, *J* = 1.2, 5.2 Hz, 1H), 5.08 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.77 (s, 2H), 3.57 - 3.46 (m, 14H), 3.27 (s, 4H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.92 - 2.81 (m, 1H), 2.67 (t, *J* = 5.6 Hz, 2H), 2.62 - 2.58 (m, 4H), 2.54 - 2.52 (m, 2H), 2.06 - 1.99 (m, 1H), 1.12 - 1.03 (m, 1H), 0.48 - 0.43 (m, 2H), 0.25 - 0.21 (m, 2H)

387	**I-392**	KE	GF	922.7	10.93 (s, 1H), 9.98 (s, 1H), 8.97 (s, 1H), 8.78 (s, 1H), 8.20 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.80 (d, *J* = 8.4 Hz, 2H), 7.50 (d, *J* = 8.8 Hz, 3H), 7.43 - 7.14 (m, 1H), 7.13 - 7.07 (m, 2H), 7.04 - 7.00 (m, 3H), 5.09 - 4.96 (m, 1H), 4.33 - 4.17 (m, 2H), 3.79 (s, 2H), 3.55 - 3.51 (m, 6H), 3.25 - 3.23 (m, 8H), 3.20 - 2.18 (m, 2H), 2.94 - 2.84 (m, 1H), 2.72 - 2.68 (m, 2H), 2.61 - 2.56 (m, 1H), 2.56 - 2.54 (m, 4H), 2.41 - 2.34 (m, 1H), 2.00 - 1.86 (m, 1H), 1.13 - 1.00 (m, 1H), 0.48 - 0.42 (m, 2H), 0.26 - 0.20 (m, 2H)
388	**I-393**	KF	GF	892.5	11.06 (s, 1H), 9.95 (s, 1H), 8.96 (s, 1H), 8.78 (s, 1H), 8.22 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.81 (d, *J* = 8.4 Hz, 2H), 7.65 (d, *J* = 8.4 Hz, 1H), 7.52 (d, *J* = 8.4 Hz, 2H), 7.44 - 7.14 (m, 3H), 7.12 (s, 1H), 7.10 - 7.00 (m, 2H), 5.06 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.83 (s, 2H), 3.60 - 3.47 (m, 4H), 3.44 - 3.35 (m, 4H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.94 - 2.80 (m, 1H), 2.72 (t, *J* = 5.6 Hz, 2H), 2.60 - 2.52 (m, 8H), 2.04 - 1.97 (m, 1H), 1.12 - 1.01 (m, 1H), 0.50 - 0.38 (m, 2H), 0.29 - 0.17 (m, 2H)
389	**I-394**	NZ	GF	980.5	11.06 (s, 1H), 9.98 (s, 1H), 8.96 (s, 1H), 8.78 (s, 1H), 8.35 - 8.32 (m, 1H), 8.32 (s, 1H), 8.15 (d, *J* = 5.2 Hz, 1H), 7.79 (d, *J* = 8.4 Hz, 2H), 7.65 (d, *J* = 8.4 Hz, 1H), 7.52 - 7.45 (m, 1H), 7.48 (d, *J* = 8.4 Hz, 1H), 7.45 - 7.14 (m, 3H), 7.13 - 7.02 (m, 3H), 5.06 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.77 (s, 2H), 3.59 - 3.27 (m, 18H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.95 - 2.83 (m, 1H), 2.73 - 2.63 (m, 2H), 2.62 - 2.51 (m, 6H), 2.07 - 1.96 (m, 1H), 1.10 - 1.03 (m, 1H), 0.50 - 0.40 (m, 2H), 0.26 - 0.15 (m, 2H)

390	**I-395**	KK	GC	943.5	10.86 (s, 1H), 10.74 (s, 1H), 8.74 (s, 1H), 8.68 (s, 1H), 8.01 (s, 3H), 7.93 (d, *J* = 5.2 Hz, 1H), 7.80 (s, 1H), 7.70 (d, *J* = 8.4 Hz, 2H), 7.49 (s, 1H), 7.33 - 7.28 (m, 3H), 6.88 (s, 2H), 6.79 - 6.75 (m, 2H), 5.97 (d, *J* = 8.0 Hz, 1H), 4.81 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.90 (s, 9H), 3.64 (s, 2H), 3.34 - 3.30 (m, 3H), 2.95 (t, *J* = 6.0 Hz, 3H), 2.69 - 2.60 (m, 1H), 2.58 - 2.51 (m, 5H), 2.39 - 2.31 (m, 1H), 1.97 (t, *J* = 10.4 Hz, 2H), 1.82 - 1.76 (m, 1H), 1.65 (d, *J* = 10.4 Hz, 2H), 1.25 - 1.18 (m, 2H), 0.86 - 0.79 (m, 1H), 0.24 - 0.19 (m, 2H), 0.01- 0.03 (m, 2H)
391	**I-396**	KL	GC	929.5	11.10 (s, 1H), 10.98 (s, 1H), 8.98 (s, 1H), 8.92 (s, 1H), 8.17 (d, *J* = 5.2 Hz, 1H), 8.04 (s, 1H), 7.96 (d, *J* = 8.4 Hz, 2H), 7.74 (s, 1H), 7.70 - 7.63 (m, 1H), 7.56 (d, *J* = 8.4 Hz, 2H), 7.30 (dd, *J* = 7.6, 18.4 Hz, 2H), 7.16 (t, *J* = 5.2 Hz, 1H), 7.12 (s, 1H), 7.00 (dd, *J* = 1.2, 5.2 Hz, 1H), 5.08 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.94 (s, 2H), 3.62 - 3.53 (m, 8H), 3.30 - 3.21 (m, 4H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.93 - 2.86 (m, 1H), 2.84 (t, *J* = 5.2 Hz, 2H), 2.64 - 2.52 (m, 8H), 2.07 - 1.98 (m, 1H), 1.14 - 1.02 (m, 1H), 0.49 - 0.43 (m, 2H), 0.26 - 0.20 (m, 2H)
392	**I-397**	JI	KM	842.4	11.23 - 10.96 (m, 2H), 9.00 (s, 2H), 8.22 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.13 - 8.00 (m, 3H), 7.89 - 7.65 (m, 4H), 7.60 (s, 2H), 7.16 (t, *J* = 5.6 Hz, 1H), 7.12 (s, 1H), 7.00 (dd, *J*=1.2, 5.2 Hz, 1H), 5.14 (dd, *J* = 4.4, 12.8 Hz, 1H), 3.89 - 3.65 (m, 4H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.98 (s, 3H), 2.94 - 2.82 (m, 3H), 2.72 (s, 2H), 2.64 - 2.52 (m, 2H), 2.09 - 2.01 (m, 1H), 1.94 - 1.67 (m, 1H), 1.92 - 1.66 (m, 1H), 1.11 - 1.01 (m, 1H), 0.48 - 0.41 (m, 2H), 0.25 - 0.19 (m, 2H)

393	**I-398**	LR	GC	902.5	10.75 (s, 1H), 8.75 (s, 1H), 8.67 (s, 1H), 8.05 (s, 2H), 7.93 (d, *J* = 5.2 Hz, 1H), 7.79 (s, 1H), 7.67 (d, *J* = 8.8 Hz, 2H), 7.48 (s, 1H), 7.37 - 7.29 (m, 1H), 7.25 (d, *J* = 8.8 Hz, 2H), 6.92 (t, *J* = 5.2 Hz, 1H), 6.88 (s, 1H), 6.83 (d, *J* = 8.8 Hz, 1H), 6.77 (d, *J* = 6.8 Hz, 2H), 4.80 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.52 (s, 2H), 3.24 - 3.21 (m, 6H), 2.98 - 2.92 (m, 2H), 2.70 - 2.59 (m, 1H), 2.45 - 2.42 (m, 1H), 2.38 - 2.30 (m, 5H), 2.11 - 2.08 (m, 1H), 1.82 - 1.74 (m, 1H), 1.59 - 1.38 (m, 8H), 0.88 - 0.79 (m, 1H), 0.26 - 0.18 (m, 2H), 0.02 - 0.03 (m, 2H)
394	**I-399**	KS	GC	844.4	10.99 (s, 1H), 8.99 (s, 1H), 8.91 (s, 1H), 8.24 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.02 (s, 1H), 7.92 (d, *J* = 8.4 Hz, 2H), 7.73 (s, 1H), 7.59 - 7.49 (m, 3H), 7.17 (t, *J* = 5.6 Hz, 1H), 7.12 (s, 1H), 7.08 - 6.96 (m, 3H), 6.63 (t, *J* = 5.6 Hz, 1H), 5.04 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.85 (s, 2H), 3.49 - 3.40 (m, 4H), 3.33 (q, *J* = 6.4 Hz, 2H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.93 - 2.81 (m, 1H), 2.71 - 2.65 (m, 2H), 2.57 - 2.51 (m, 2H), 2.09 - 1.97 (m, 1H), 1.84 - 1.71 (m, 4H), 1.12 - 1.01 (m, 1H), 0.49 - 0.42 (m, 2H), 0.25 - 0.21 (m, 2H)
395	**I-400**	OK	KT	902.4	11.34 - 11.04 (m, 1H), 10.96 (s, 1H), 9.04 (s, 1H), 8.92 (s, 1H), 8.61 (d, *J* = 4.4 Hz, 1H), 8.28 (d, *J* = 4.8 Hz, 1H), 8.20 (d, *J* = 2.8 Hz, 1H), 7.89 (d, *J* = 8.8 Hz, 2H), 7.73 (t, *J* = 6.4 Hz, 1H), 7.60 - 7.53 (m, 1H), 7.48 (d, *J* = 8.4 Hz, 2H), 7.28 (s, 1H), 7.22 - 7.17 (m, 1H), 7.13 (d, *J* = 8.8 Hz, 1H), 7.03 (d, *J* = 6.8 Hz, 1H), 6.61 (s, 1H), 5.10 - 5.00 (m, 1H), 4.31 - 4.22 (m, 2H), 3.78 (s, 2H), 3.66 - 3.51 (m, 10H), 2.88 (d, *J* = 4.8 Hz, 3H), 2.71 - 2.68 (m, 1H), 2.66 - 2.57 (m, 1H), 2.57 -

					2.53 (m, 1H), 2.53 - 2.52 (m, 2H), 2.05 - 1.97 (m, 1H)
396	**I-401**	HQ	KV[d]	881.5	11.09 (s, 1H), 9.99 (s, 1H), 8.97 (s, 1H), 8.77 (s, 1H), 8.23 - 8.14 (m, 2H), 7.79 (d, *J* = 8.4 Hz, 2H), 7.51 (d, *J* = 8.4 Hz, 2H), 7.44 - 7.15 (m, 1H), 7.13 - 7.07 (m, 2H), 7.05 (d, *J* = 5.2 Hz, 1H), 6.95 (d, *J* = 6.0 Hz, 2H), 6.86 (dd, *J* = 2.8, 6.0 Hz, 1H), 5.36 (dd, *J* = 5.2, 12.6 Hz, 1H), 3.89 - 3.83 (m, 1H), 3.55 (s, 9H), 3.23 - 3.15 (m, 2H), 2.99 - 2.83 (m, 1H), 2.99 - 2.81 (m, 5H), 2.76 - 2.57 (m, 5H), 2.03 - 1.95 (m, 1H), 1.86 - 1.77 (m, 2H), 1.30 (d, *J* = 6.8 Hz, 3H), 1.12 - 1.04 (m, 1H), 0.49 - 0.42 (m, 2H), 0.25-0.23 (m, 2H)
397	**I-402**	OK	KY	903.4	11.13 (s, 1H), 9.97 (s, 1H), 8.93 (s, 1H), 8.58 (s, 1H), 8.28 - 8.20 (m, 2H), 7.72 (d, *J* = 8.4 Hz, 2H), 7.63 - 7.53 (m, 2H), 7.42 (d, *J* = 8.4 Hz, 2H), 7.28 - 7.22 (m, 2H), 7.13 (d, *J* = 8.8 Hz, 1H), 7.03 (d, *J* = 7.2 Hz, 1H), 6.60 (t, *J* = 5.2 Hz, 1H), 5.05 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.29 - 4.20 (m, 2H), 3.76 (s, 2H), 3.65 - 3.62 (m, 2H), 3.60 - 3.50 (m, 10H), 2.92 - 2.86 (m, 1H), 2.75 (t, *J* = 7.2 Hz, 2H), 2.71 - 2.68 (m, 2H), 2.64 - 2.56 (m, 1H), 2.56 - 2.54 (m, 1H), 2.04 - 1.98 (m, 1H), 1.87 - 1.80 (m, 2H)
398[c]	**I-403**	LB	LE	893.5	11.17 (s, 1H), 9.96 (s, 1H), 8.95 (s, 1H), 8.75 (s, 1H), 8.16 (d, *J* = 4.8 Hz, 1H), 7.75 (d, *J* = 8.4 Hz, 2H), 7.46 (d, *J* = 8.4 Hz, 2H), 7.42 - 7.13 (m, 1H), 7.12 - 6.84 (m, 6H), 5.40 - 5.30 (m, 1H), 3.54 (s, 3H), 3.50 - 3.44 (m, 8H), 3.23 - 3.15 (m, 2H), 2.98 - 2.94 (m, 2H), 2.89 - 2.82 (m, 1H), 2.65 -2.55 (m, 4H), 2.04 - 1.95 (m, 1H), 1.86 - 1.79 (m, 2H), 1.12 - 1.04 (m, 1H), 1.03 - 0.83 (m, 4H), 0.53 - 0.40 (m, 2H), 0.26 - 0.18 (m, 2H)

399	**I-404**	LF	GF	837.5	11.07 (s, 1H), 9.96 (s, 1H), 8.96 (s, 1H), 8.77 (s, 1H), 8.25 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.81 (d, *J* = 8.8 Hz, 2H), 7.52 (d, *J* = 8.8 Hz, 2H), 7.28 (t, *J* = 52 Hz, 1H), 7.12 (s, 1H), 7.09 - 7.02 (m, 2H), 6.97 - 6.91 (m, 2H), 6.84 (dd, *J* = 3.2, 5.6 Hz, 1H), 5.35 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.82 (s, 2H), 3.54 (s, 3H), 3.47 - 3.45 (m, 4H), 3.21 - 3.17 (m, 2H), 2.95 - 2.90 (m, 2H), 2.88 - 2.83 (m, 1H), 2.75 - 2.68 (m, 1H), 2.66 (d, *J* = 7.2 Hz, 2H), 2.63 - 2.56 (m, 1H), 2.03 - 1.95 (m, 1H), 1.86 - 1.77 (m, 2H), 1.74 - 1.69 (m, 2H), 1.13 - 1.02 (m, 1H), 0.49 - 0.43 (m, 2H), 0.25 - 0.20 (m, 2H)
400	**I-405**	LG	GF	836.4	10.84 (s, 1H), 9.75 (s, 1H), 8.73 (s, 1H), 8.54 (s, 1H), 8.06 (s, 1H), 7.93 (d, *J* = 5.2 Hz, 1H), 7.57 (d, *J* = 8.4 Hz, 2H), 7.26 (d, *J* = 8.8 Hz, 2H), 7.18 - 6.89 (m, 1H), 6.89 - 6.87 (m, 1H), 6.86 - 6.79 (m, 2H), 6.79 - 6.72 (m, 2H), 6.61 (dd, *J* = 1.2, 8.0 Hz, 1H), 5.09 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.54 (s, 2H), 3.24 - 3.18 (m, 8H), 2.98 - 2.91 (m, 2H), 2.72 - 2.60 (m, 1H), 2.52 - 2.45 (m, 1H), 2.42 - 2.33 (m, 5H), 1.80 - 1.73 (m, 1H), 1.61 - 1.53 (m, 2H), 1.48 - 1.44 (m, 2H), 0.88 - 0.80 (m, 1H), 0.26 - 0.19 (m, 2H), 0.03 - -0.04 (m, 2H)
401	**I-406**	LH	GF	895.5	11.10 (s, 1H), 10.01 (s, 1H), 8.98 (s, 1H), 8.80 (s, 1H), 8.21 (s, 1H), 8.17 (d, *J* = 4.8 Hz, 1H), 7.83 (d, *J* = 8.0 Hz, 2H), 7.52 (d, *J* = 8.0 Hz, 2H), 7.45 - 7.15 (m, 1H), 7.14 - 7.08 (m, 2H), 7.06 - 7.03 (m, 1H), 6.98 - 6.93 (m, 2H), 6.88 - 6.83 (m, 1H), 5.40 - 5.33 (m, 1H), 3.82 (s, 2H), 3.56 (s, 3H), 3.45 - 3.41 (m, 8H), 3.22 - 3.13 (m, 2H), 2.96 - 2.90 (m, 2H), 2.90 - 2.84 (m, 1H), 2.76 - 2.70 (m, 1H), 2.66 - 2.60 (m, 2H), 2.60 - 2.55 (m, 1H), 2.04 -

					1.92 (m, 1H), 1.86 - 1.77 (m, 2H), 1.76 - 1.68 (m, 4H), 1.13 - 1.00 (m, 1H), 0.49 - 0.44 (m, 2H), 0.25 - 0.21 (m, 2H)
402	**I-407**	LI	GF	895.5	11.06 (s, 1H), 10.02 (s, 1H), 8.96 (s, 1H), 8.80 (s, 1H), 8.29 (s, 1H), 8.15 (d, *J* = 5.2 Hz, 1H), 7.85 - 7.76 (m, 2H), 7.54 (d, *J* = 8.4 Hz, 2H), 7.43 - 7.15 (m, 1H), 7.11 (s, 1H), 7.08 (t, *J* = 5.2 Hz, 1H), 7.05 - 7.02 (m, 1H), 7.02 - 6.95 (m, 2H), 6.85 (d, *J* = 7.6 Hz, 1H), 5.32 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.89 (s, 2H), 3.42 - 3.32 (m, 8H), 3.31 (s, 3H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.95 - 2.83 (m, 1H), 2.74 - 2.58 (m, 6H), 2.04 - 1.94 (m, 1H), 1.84 - 1.65 (m, 6H), 1.11 - 1.01 (m, 1H), 0.49 - 0.41 (m, 2H), 0.22 (q, *J* = 4.8 Hz, 2H)
403	**I-408**	4-[2-[2-[2-(2-aminoethoxy)-ethoxy]ethoxy]-ethylamino]-2-(2,6-dioxo-3-piperidyl)-isoindoline-1,3-dione (synthesized via Steps 1-2 of Example 128)	LS	827.5	11.08 (s, 1 H), 10.09 (s, 1 H), 8.92 (s, 1 H), 8.88 (s, 2 H), 8.23 (d, *J* = 5.2 Hz, 1 H), 8.03 (s, 1 H), 7.63 - 7.55 (m, 2 H), 7.24 - 7.21 (m, 2 H), 7.11 (d, *J* = 8.8 Hz, 1 H), 7.03 (d, *J* = 6.8 Hz, 1 H), 6.56 (s, 1 H), 5.06 - 5.01 (m, 1 H), 4.30 - 4.13 (m, 5 H), 3.87 (s, 2 H), 3.70 - 3.67 (m, 3 H), 3.60 - 3.57 (m, 3 H), 3.54 - 3.52 (m, 4 H), 3.46 - 3.36 (m, 3 H), 3.18 (m, 2 H), 2.94 - 2.83 (m, 1 H), 2.63 - 2.53 (m, 2 H), 2.05 – 1.96 (m, 1 H)
404	**I-409**	4-[2-[3-(2-aminoethoxy)-propoxy]-ethylamino]-2-(2,6-dioxo-3-piperidyl)-isoindoline - 1,3-dione (synthesized via Steps 1-2 of Example 208, I-213)	GC	874.3	10.99 (s, 1 H), 8.99 (s, 1 H), 8.94 - 8.89 (m, 1H), 8.23 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.03 (s, 1H), 7.90 (d, *J* = 8.4 Hz, 2H), 7.72 (s, 1H), 7.59 - 7.54 (m, 1H), 7.48 (d, *J* = 8.4 Hz, 2H), 7.19 - 7.11 (m, 3H), 7.05 – 6.98 (m, 2H), 6.59 (m, 1H), 5.05 (m, 1H), 3.78 (s, 2H), 3.59 - 3.54 (m, 11H), 3.19 (m, 2H), 2.92 - 2.83 (m, 1H), 2.67 (m, 2 H), 2.61 - 2.55 (m, 2 H), 2.06 - 1.98 (m, 1 H), 1.74 (t, *J* = 6.36 Hz, 2 H), 1.11 - 1.03

					(m, 1 H), 0.46 - 0.43 (m, 2 H), 0.23 - 0.22 (m, 2 H)
405	**I-410**	LN	GF	865.5	11.09 (s, 1H), 10.03 (s, 1H), 8.96 (s, 1H), 8.80 (s, 1H), 8.28 (s, 1H), 8.15 (d, *J* = 5.2 Hz, 1H), 7.85 (d, *J* = 8.0 Hz, 2H), 7.56 (d, *J* = 7.6 Hz, 2H), 7.42 - 7.15 (m, 1H), 7.11 (s, 1H), 7.08 (t, *J* = 5.2 Hz, 1H), 7.05 - 7.03 (m, 1H), 7.00 - 6.91 (m, 2H), 6.88 - 6.83 (m, 1H), 5.35 (dd, *J* = 5.2, 12.4 Hz, 1H), 3.95 - 3.91 (m, 2H), 3.54 (s, 3H), 3.41 - 3.38 (m, 2H), 3.36 - 3.32 (m, 2H), 3.18 (t, *J* = 5.6 Hz, 2H), 2.92 - 2.87 (m, 2H), 2.87 - 2.83 (m, 1H), 2.71 - 2.68 (m, 2H), 2.65 - 2.58 (m, 2H), 2.03 - 1.94 (m, 1H), 1.64 - 1.50 (m, 8H), 1.11 - 1.02 (m, 1H), 0.48 - 0.41 (m, 2H), 0.22 (q, *J* = 4.4 Hz, 2H)
406	**I-411**	OD	GF	865.6	11.08 (s, 1H), 10.01 (s, 1H), 8.97 (s, 1H), 8.80 (s, 1H), 8.27 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.82 (d, *J* = 8.4 Hz, 2H), 7.52 (d, *J* = 8.0 Hz, 2H), 7.43 - 7.15 (m, 1H), 7.14 - 7.07 (m, 2H), 7.06 - 6.96 (m, 3H), 6.85 (d, *J* = 8.0 Hz, 1H), 5.41 - 5.25 (m, 1H), 3.76 (s, 2H), 3.78 - 3.69 (m, 1H), 3.83 (s, 2H), 3.35 - 3.33 (m, 2H), 3.31 (s, 3H), 3.21 - 3.15 (m, 2H), 2.91 - 2.82 (m, 1H), 2.75 - 2.68 (m, 1H), 2.64 - 2.58 (m, 5H), 2.02 - 1.95 (m, 1H), 1.66 - 1.55 (m, 2H), 1.54 - 1.47 (m, 6H), 1.13 - 0.97 (m, 1H), 0.48 - 0.41 (m, 2H), 0.25 - 0.19 (m, 2H)
407	**I-412**	LR	LS	825.2	11.10 (s, 1H), 10.87 (s, 1H), 8.89 (s, 1H), 8.24 (s, 1H), 8.21 (d, *J* = 5.2 Hz, 1H), 8.10 (s, 1H), 7.58 - 7.52 (m, 2H), 7.58 - 7.52 (m, 1H), 7.22 - 7.17 (m, 2H), 7.07 - 6.98 (m, 2H), 6.62 (t, *J* = 5.6 Hz, 1H), 5.04 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.23 (dd, *J* = 6.8, 9.2 Hz, 2H), 3.92 (s, 1H), 3.95 - 3.90 (m, 1H), 3.79 (s, 3H), 3.34 - 3.27 (m, 10H), 2.90 - 2.84 (m, 1H), 2.65 (t, *J* = 7 .2 Hz, 2H),

					2.62 - 2.58 (m, 1H), 2.58 - 2.54 (m, 1H), 2.06 - 1.97 (m, 1H), 1.82 (t, *J* = 6.8 Hz, 2H), 1.80 - 1.72(m, 2H), 1.68 - 1.60 (m, , 2H)
408	**I-413**	LP	LS	984.3	10.83 (s, 1H), 8.97 (s, 1H), 8.90 (s, 1H), 8.56 (s, 1H), 8.22 (s, 2H), 8.10 (s, 1H), 7.56 (s, 1H), 7.40 (s, 5H), 7.21 (s, 2H), 4.58 - 4.49 (m, 1H), 4.43 - 4.36 (m, 1H), 4.34 (s, 1H), 4.26 - 4.24 (m, 2H), 3.95 (s, 2H), 3.85 - 3.75 (m, 1H), 3.79 (s, 3H), 3.70 - 3.58 (m, 14H), 3.20 - 3.16 (m, 1H), 3.07 (s, 2H), 3.15 - 2.98 (m, 1H), 2.77 (s, 2H), 2.64 - 2.59 (m, 1H), 2.48 - 2.40 (m, 4H), 1.93 - 1.89 (m, 1H), 0.89 (s, 9H)
409	**I-414**	LO	GY	1103.2	11.01 (s, 1H), 9.02 (s, 1H), 8.97 (s, 1H), 8.92 (s, 1H), 8.61 (t, *J* = 6.0 Hz, 1H), 8.29 - 8.19 (m, 2H), 8.04 (s, 1H), 7.92 (d, *J* = 8.4 Hz, 2H), 7.78 - 7.63 (m, 2H), 7.50 (br d, *J* = 8.4 Hz, 2H), 7.46 - 7.35 (m, 5H), 7.26 (s, 1H), 7.17 (dd, *J* = 1.2, 5.2 Hz, 1H), 4.56 (d, *J* = 9.6 Hz, 1H), 4.49 - 4.34 (m, 3H), 4.32 - 4.16 (m, 4H), 3.96 (s, 2H), 3.82 (s, 2H), 3.56 - 3.44 (m, 11H), 2.70 (*J* = 6.0 Hz, 2H), 2.43 (s, 3H), 2.11 - 2.01 (m, 1H), 1.93 - 1.86 (m, 1H), 0.93 (s, 9H)
410	**I-415**	LP	GY	1089.2	11.00 (s, 1H), 9.01 (s, 1H), 8.98 - 8.95 (m, 1H), 8.93 (s, 1H), 8.56 (t, *J* = 6.0 Hz, 1H), 8.33 - 8.17 (m, 3H), 8.04 (s, 1H), 7.98 - 7.88 (m, 2H), 7.77 - 7.63 (m, 2H), 7.52 (d, *J* = 8.4 Hz, 2H), 7.43 - 7.34 (m, 4H), 7.26 (s, 1H), 7.17 (dd, *J* = 1.2, 5.2 Hz, 1H), 4.57 - 4.18 (m, 6H), 4.05 - 3.78 (m, 2H), 3.50 - 3.34 (m, 14H), 3.24 - 3.13 (m, 1H), 3.08 (s, 1H), 2.77 - 2.72 (m, 2H), 2.64 - 2.58 (m, 1H), 2.55 - 2.52 (m, 1H), 2.44 - 2.42 (m, 3H), 2.10 - 2.00 (m, 1H), 1.97 - 1.86 (m, 1H), 0.93 - 0.84 (m, 9H)

411	**I-416**	OE	GF	1233.7	9.96 (s, 1H), 8.96 (s, 1H), 8.79 (s, 1H), 8.22 - 8.13 (m, 2H), 7.81 (d, *J* = 8.8 Hz, 2H), 7.50 (d, *J* = 8.8 Hz, 2H), 7.44 - 7.42 (m, 1H), 7.32 - 6.90 (m, 10H), 6.83 - 6.74 (m, 2H), 5.12 - 4.63 (m, 5H), 4.07 - 4.01 (m, 2H), 3.87 - 3.81 (m, 4H), 3.74 - 3.71 (m, 2H), 3.58 - 3.49 (m, 20H), 3.29 (s, *3*H), 3.20 - 3.17 (m, 2H), 3.06 - 2.90 (m, 2H), 2.75 - 2.65 (m, 2H), 1.90 - 1.49 (m, 4H), 1.03 (s, 7H), 0.94 (s, 3H), 0.51 - 0.41 (m, 2H), 0.24 - 0.20 (m, 2H)
412	**I-417**	LY	GF	1145.2	9.99 (s, 1H), 8.97 (s, 1H), 8.78 (s, 1H), 8.22 - 8.17 (m, 1H), 8.17 - 8.13 (m, 1H), 7.80 - 7.76 (m, 2H), 7.52 - 6.72 (m, 15H), 5.08 - 4.96 (m, 1H), 4.92 - 4.58 (m, 4H), 4.12 (s, 2H), 3.90 - 3.81 (m, 2H), 3.77 - 3.71 (m, 4H), 3.56 - 3.50 (m, 9H), 3.31 - 3.27 (m, 5H), 3.20 - 3.16 (m, 2H), 3.09 - 2.91 (m, 3H), 2.69 - 2.64 (m, 3H), 1.89 - 1.51 (m, 4H), 1.12 (s, 9H), 0.49 - 0.42 (m, 2H), 0.25 - 0.20 (m, 2H)
413	**I-418**	LX	GF	1189.7	9.75 (s, 1H), 8.73 (s, 1H), 8.55 (s, 1H), 8.13 (s, 1H), 7.99 - 7.91 (m, 2H), 7.56 (d, *J*=8.4 Hz, 2H), 7.27 - 7.18 (m, 4H), 7.06 (s, 1H), 6.91 - 6.79 (m, 9H), 6.69 (d, *J* = 2.3 Hz, 1H), 6.59 - 6.52 (m, 2H), 4.79 (d, *J* = 9.4 Hz, 1H), 4.69 - 4.61 (m, 2H), 4.47 - 4.36 (m, 2H), 3.82 (s, 2H), 3.67 - 3.59 (m, 2H), 3.54 - 3.48 (m, 5H), 3.36 - 3.29 (m, 6H), 2.99 - 2.92 (m, 4H), 2.46 - 2.39 (m, 5H), 2.12 - 2.07 (m, 1H), 1.65 - 1.48 (m, 3H), 1.43 - 1.31 (m, 2H), 0.73 - 0.65 (m, 2H), 0.25 - 0.19 (m, 2H), 0.02 - -0.03 (m, 2H)


414	**I-419**	LZ	GF	923.5	11.07 (s, 1H), 9.96 (s, 1H), 8.96 (s, 1H), 8.77 (s, 1H), 8.29 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.78 (d, *J* = 8.8 Hz, 2H), 7.47 (d, *J* = 8.4 Hz, 2H), 7.42 - 7.15 (m, 1H), 7.12 (s, 1H), 7.08 (t, *J* = 5.6 Hz, 1H), 7.04 (d, *J* = 5.2 Hz, 1H), 6.99 - 6.90 (m, 2H), 6.87 - 6.81 (m, , 1H), 5.35 (dd, *J* = 5.2, 12.4 Hz, 1H), 3.75 (s, 2H), 3.56 (s, 3H), 3.44 - 3.42 (m, 2H), 3.19 (t, *J* = 6.4, 2H), 3.12 (d, *J* = 2.0 Hz, 4H), 2.98 - 2.90 (m, 2H), 2.89 - 2.84 (m, 1H), 2.67 - 2.56 (m, 6H), 2.03 -1.94 (m, 1H), 1.83 - 1.75 (m, 2H), 1.72 - 1.64 (m, 2H), 1.10 - 1.03 (m, 1H), 0.84 (s, 6H), 0.48 - 0.43 (m, 2H), 0.23 (q, *J* = 4.8 Hz, 2H)
415	**I-420**	LZ	LS	839.4	11.08 (s, 1H), 10.93 (s, 1H), 8.86 (s, 1H), 8.27 (s, 1H), 8.20 (d, *J* = 4.8 Hz, 1H), 8.10 (s, 1H), 7.53 (t, *J* = 6.4 Hz, 1H), 7.21 - 7.13 (m, 2H), 7.00 - 6.88 (m, 2H), 6.83 - 6.75 (m, 1H), 5.35 (dd, *J* = 5.6, 12.4 Hz, 1H), 4.26 - 4.19 (m, 2H), 3.90 (s, 2H), 3.76 (s, 3H), 3.51 (s, 3H), 3.46 - 3.42 (m, 4H), 2.98 (d, *J* = 7.2 Hz, 4H), 2.91 - 2.83 (m, 3H), 2.65 - 2.58 (m, 4H), 2.04 - 1.95 (m, 1H), 1.88 - 1.79 (m, 2H), 1.77 - 1.69 (m, 2H), 0.71 (s, 6H)
416	**I-421**	MA	GF	923.5	11.08 (s, 1H), 10.19 (s, 1H), 9.33 - 9.23 (m, 2H), 9.14 (s, 1H), 8.87 (s, 1H), 8.11 (d, *J* = 6.4 Hz, 1H), 7.95 (d, *J* = 7.6 Hz, 2H), 7.73 (d, *J* = 8.0 Hz, 2H), 7.57 (s, 1H), 7.48 - 7.19 (m, 1H), 7.27 - 7.17 (m, 1H), 7.02 (s, 2H), 6.85 (d, *J* = 8.0 Hz, 1H), 5.42 - 5.30 (m, 1H), 4.20 (s, 2H), 3.45 - 3.43 (m, 6H), 3.32 (s, 3H), 3.14 (s, 2H), 3.09 (s, 2H), 3.01 - 2.93 (m, 2H), 2.92 - 2.85 (m, 1H), 2.72 - 2.65 (m, 2H), 2.62 - 2.57 (m, 1H), 2.57 - 2.55 (m, 1H), 2.57 - 2.55 (m, 1H), 1.96 - 1.88 (m, 1H), 1.96 - 1.88 (m, 2H), 1.86 - 1.74 (m,

					2H), 1.20 - 1.10 (m, 1H), 0.85 (s, 6H), 0.60 - 0.53 (m, 2H), 0.36 - 0.30 (m, 2H)
417[c]	**I-422**	HQ	MB	714.3	11.08 (s, 1H), 10.88 (s, 1H), 8.98 (s, 2H), 8.88 (s, 1H), 8.66 (s, 1H), 8.06 (d, *J* = 8.8 Hz, 2H), 8.01 (s, 1H), 7.81 (s, 1H), 7.67 (d, *J* = 8.8 Hz, 2H), 6.99 - 6.92 (m, 2H), 6.86 - 6.83 (m, 1H), 5.41 - 5.30 (m, 1H), 4.26 (s, 2H), 3.74 - 3.70 (m, 2H), 3.66 - 3.60 (m, 2H), 3.60 - 3.57 (m, 2H), 3.55 (s, 3H), 3.50 - 3.46 (m, 2H), 3.16 (s, 2H), 2.99 - 2.91 (m, 2H), 2.90 - 2.81 (m, 1H), 2.76 - 2.68 (m, 1H), 2.68 - 2.62 (m, 1H), 2.05 - 1.94 (m, 1H), 1.89 - 1.77 (m, 2H)
418	**I-423**	MG	GF	779.1	11.10 (s, 1H), 10.00 (s, 1H), 8.97 (s, 1H), 8.80 (s, 1H), 8.28 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.82 (d, *J* = 8.8 Hz, 2H), 7.52 (d, *J* = 8.8 Hz, 2H), 7.45 - 7.15 (m, 1H), 7.12 (s, 1H), 7.09 (t, *J* = 5.6 Hz, 1H), 7.05 (dd, *J* = 1.2, 5.2 Hz, 1H), 6.99 - 6.92 (m, 2H), 6.87 (dd, *J* = 2.8, 6.0 Hz, 1H), 5.36 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.81 (s, 2H), 3.58 (s, 3H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.99 - 2.94 (m, 2H), 2.90 - 2.85 (m, 1H), 2.73 - 2.68 (m, 1H), 2.66 - 2.63 (m, 2H), 2.62 - 2.58 (m, 1H), 2.04 - 1.96 (m, 1H), 1.85 - 1.76 (m, 2H), 1.12 - 1.03 (m, 1H), 0.50 - 0.42 (m, 2H), 0.25 - 0.21 (m, 2H)

[a]For Method 16, when the amine is the HC1 salt, TEA was added to free base the salt, followed by HOAc to adjust the pH to 3-4. KOAc could also be used in place of the TEA/HOAc combination. [b]TFA not HC1 was used for the deprotection in Step 2. [c]No deprotection Step 2 required. [d]Coupling partner was a ketone not aldehyde. [e]Steps 1-2 was run anywhere from 0.5-48 hrs.

[005351] **Further Examples:**


[005352] **Example 419: N-[3-carbamoyl-1-[4-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl1amino1 ethoxy]ethoxy]ethylcarbamoyl] phenyl]pyrazol-4-yl]-2-(2-cyclopropyl-4-pyridyPoxazole-4-carboxamide, 1-424**



[005353] N-[3-carbamoyl-l-[4-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yljamino] ethoxy]ethoxy]ethylcarbamoyl]phenyl]pyrazol-4-yl]-2-(2-cyclopropyl-4-pyridyl)oxazole-4-carboxamide was synthesized via Method 10, coupling amine methyl 4-(4-amino-3 -carbarn oyl-pyrazol-l-yl)benzoate (Intermediate CL) and acid 2-(2-cyclopropyl-4-pyridyl)oxazole-4-carboxylic acid (Intermediate MQ) in Step 1, and coupling amine 4-[2-[2-(2-aminoethoxy)ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (synthesized via Steps 1-2 of Example 127) in Step 3. The final product was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225%FA)-ACN]; B%: 33%-53%, 7 min) to give the title compound (29.0 mg, 14% yield) as a yellow solid. ^{1}H NMR (400 MHz, DMSO-i¾) δ 11.14 - 11.04 (m, 2H), 9.10 (s, 1H), 9.03 (s, 1H), 8.66 - 8.61 (m, 2H), 8.15 (s, 1H), 8.11 - 8.06 (m, 2H), 8.04 - 7.98 (m, 2H), 7.88 - 7.81 (m, 2H), 7.69 (dd, *J* = 1.2, 5.6 Hz, 1H),

7.58 - 7.52 (m, 1H), 7.11 (d, *J* = 8.8 Hz, 1H), 7.01 (d, *J* = 6.8 Hz, 1H), 6.60 (t, *J* = 5.6 Hz, 1H), 5.11 - 4.90 (m, 1H), 3.64 - 3.53 (m, 8H), 3.49 - 3.40 (m, 5H), 2.92 - 2.83 (m, 1H), 2.68 - 2.53 (m, 1H), 2.34 -2.26 (m, 2H), 2.15 - 1.89 (m, 2H), 1.07-0.96 (m, 4H). LC-MS (ESI$^+$)m/z 845.2 (M+H)$^+$.

[005354] Example 420: 4-[2-[4-[2-[2-[2-[[2-(2,6-Dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yllaminolethoxyl ethoxylethoxylethoxylphenyl]ethynyll-l-[[[2S,3S,4S)-3-ethyl-4-fluoro-5-oxo-pyrrolidin-2-yllmethoxyl-7-methoxy-isoquinoline-6-carboxamide, 1-425


R
DIPEA, dioxane
FJ
TMS
Pd(PPh3)2Cl2, CuI,TEA
TBAF
THF
Pd(PPh3)2Cl2, CuI
Et3N, DMF

[005355] Step 1 - 2-(2·6-Pioχo-3-ριρεπάνη-4-Ι2-Ι2-Ι2-Ι2-(4-iodophenoxylethoxy] ethoxy] ethoxy] ethyl amino] isoindoline- 1,3-dione

[005356] To a solution of 2-[2-[2-[2-(4-iodophenoxy)ethoxy]ethoxy]ethoxy]ethanamine (800 mg, 1.85 mmol, HC1, Intermediate FJ) and 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (511 mg, 1.85 mmol, Intermediate R) in dioxane (10 mL) was added DIPEA (1.20 g, 9.27 mmol, 1.61 mL), and the reaction mixture was stirred at 115 °C for 16 hr. On completion, the mixture was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (900 mg, 75% yield) as yellow solid. LC-MS (ESI^+) m/z 652.3 $(M+H)^+$.

[005357] Step 2 - 2-(2·6-Pioχo-3-piperidyl)-4-Ι2-Ι2-Ι2-Ι2-Ι4-(2-trimethyl silylethynvOphenoxyl ethoxy] ethoxy] ethoxy] ethyl aminoli soindoline- 1,3-dione

[005358] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-[2-[2-[2-[2-(4-iodophenoxy)ethoxy]ethoxy]ethoxy] ethylamino]isoindoline-l,3-dione (800 mg, 1.23 mmol), $Pd(PPh_3)_2Cl_2$ (25.8 mg, 36.8 umol) and Cul (7.02 mg, 36.8 umol) in TEA (10 mL) was added ethynyl(trimethyl)silane (241 mg, 2.46 mmol, 340 Ul, CAS# 1066-54-2), and the reaction mixture was stirred at 80 °C for 12 hr. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (800 mg, 93% yield) as yellow oil. LC-MS (ESI^+) m/z 622.2 $(M+H)^+$.

[005359] Step 3 - 2-(2·6-Pioχo-3-ριρεπάνη-4-Ι2-Ι2-Ι2-Ι2-(4-ethynylphenoxylethoxy] ethoxy] ethoxy] ethyl aminoli soindoline- 1,3-dione


[005360] To a solution of 2-(2,6-dioxo-3-piperidyl)-4-[2-[2-[2-[2-[4-(2-trimethylsilylethynyl)phenoxy]ethoxy] ethoxy]ethoxy]ethylamino]isoindoline-l,3-dione (700 mg, 1.13 mmol) in THF (10 mL) was added TBAF (883 mg, 3.38 mmol), and the reaction mixture was stirred at 20 °C for 2 hours. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (500 mg, 81% yield) as a yellow solid. LC-MS (ESI^+) m/z 550.3 $(M+l)^+$.

[005361] Step 4 - 4-[2-[4-[2-[2-[2-[[2-(2.6-Pïoχo-3-ρïρεïριάνl)-1.3-άïoχo-isθίηdo1ïη-4-yllaminolethoxyl ethoxylethoxylethoxylphenyllethynyll-l -rii2S.3S.4S)-3-ethyl-4-fluoro-5-oxo-pyrrolidin-2-yl1methoxy1-7-methoxy-isoquinoline-6-carboxamide

[005362] To a solution of 4-bromo-l-[[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxo-pyrrolidin-2-yl]methoxy]-7-methoxy -isoquinoline-6-carboxamide (20.0 mg, 45.4 umol, synthesized via Steps

1-2 of Example 126), CuI (4.33 mg, 22.7 umol), $Pd(PPh_3)2Cl_2$ (15.9 mg, 22.7 umol) in DMF (2 mL) was added 2-(2,6-dioxo-3-piperidyl)-4-[2-[2-[2-[2-(4-ethynylphenoxy)ethoxy]ethoxy]ethoxy]ethylamino]-isoindoline-l,3-dione (50.0 mg, 90.9 umol) and TEA (82.8 mg, 818 umol, 113 uL). The reaction mixture was degassed with N_2 for 5 minutes, and then heated at 120 °C for 3 hours under microwave. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was dissolved in DCM (20 mL) and thiourea (resin) (50 mg) was added. The mixture was stirred at 20 °C for 2 hours. Then the reaction mixture was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]; B%: 35%-65%, 10 min) to give the title compound (4.19 mg, 9.85% yield) as yellow solid. ^{1}H NMR (400MHz, DMSO-7 $_5$) δ 11.10 (s, 1H), 8.89 (s, 1H), 8.18 (s, 1H), 7.95 (s, 1H), 7.79 (s, 2H), 7.61 - 7.40 (m, 4H), 7.12 (d, 7 = 8.4 Hz, 1H), 7.01 (d, *J* = 8.0 Hz, 3H), 6.61 - 6.54 (m, 1H), 5.04 (dd, *J* = 4.8, 12.4 Hz, 1H), 4.99 - 4.82 (m, 1H), 4.60 - 4.52 (m, 1H), 4.30 (dd, 7 = 5.6, 10.8 Hz, 1H), 4.16 - 4.06 (m, 3H), 3.98 (s, 3H), 3.75 - 3.68(m, 3H), 3.60 - 3.55 (m, 12H), 2.93 - 2.75(m, 1H), 2.63 - 2.60 (m, 1H), 2.59 - 2.57 (m, 1H), 2.08 - 1.94 (m, 1H), 1.67 - 1.50 (m, 2H), 1.01 (t, *J* = 7.2 Hz, 3H); LC-MS (ESI^+) m/z 909.5 $(M+H)^+$.


[005363] Example 421: 2-[2ACvclopropylmethylaminoV4-pyridyl]-N-[l-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidvl) -l,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethyl]isoindolin-5-yl]-3-(trifluoromethvBpyrazol-4-yl]oxazole-4-carboxamide, 1-426



[005364] To a solution of 2-[2-(cyclopropylmethylamino)-4-pyridyl]-N-[l-isoindolin-5-yl-3-(trifluoromethyl) pyrazol-4-yl]oxazole-4-carboxamide (190 mg, 348 umol, HC1, synthesized via Method 12 coupling 5-[4-amino-3-(trifluoromethyl)pyrazol-l-yl]isoindoline-2-carboxylate (Intermediate FM) and 2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (from Steps 1-4 of Intermediate DF) in Step 1), 2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)- l,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]acetaldehyde (116 mg, 290 umol, Intermediate FK) in THF (30.0 mL) was added KOAc (56.9 mg, 580 umol) and $NaBH(OAc)_3$ (122 mg, 580 umol). The reaction mixture was stirred at 25 °C for 16 hours. On completion, the mixture was diluted with H_20 (1 mL) and then concentrated *in vacuo*. The mixture was purified by prep-

HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225%FA)-ACN]; B%: l0%-40%, 10 min) to give the title compound (16.1 mg, 5.9% yield) as yellow solid. ^{1}H NMR (400MHz, DMSO-^e) δ 11.1 (s, 1H), 9.94 (s, 1H), 8.97 (s, 1H), 8.83 (s, 1H), 8.15 (d, *J* = 5.2 Hz, 1H), 7.72 (s, 1H), 7.68 (d, *J* = 8.4 Hz, 1H), 7.57 (t, *J* = 7.8 Hz, 1H), 7.37 (d, *J* = 8.4 Hz, 1H), 7.17 - 7.08 (m, 3H), 7.06 - 7.00 (m, 2H), 6.69 - 6.53 (m, 1H), 5.08 - 5.00 (m, 1H), 4.00 - 3.85 (m, 4H), 3.68 - 3.55 (m, 6H), 3.50 - 3.47 (m, 4H), 3.20 - 3.15 (m, 2H), 2.95 - 2.86 (m, 1H), 2.86 - 2.80 (m, 2H), 2.61 - 2.55 (m, 1H), 2.54 - 2.53 (m, 1H), 2.05 - 1.92 (m, 1H), 1.08 - 1.00 (m, 1H), 0.49 - 0.43 (m, 2H), 0.25 - 0.20 (m, 2H); LC-MS (ESI$^+$) *m/z* 897.4 (M+H)$^+$.


[005365] Example 422: 2-(2-Amino-4-pyridylVN-[3-carbamoyl-l-[4-[2-[2-[2-[[2-(2,6-dioxo-3-piperidvB-l.,3-dioxo- isoindolin-4-yl]amino]ethoxy]ethoxy]ethylcarbamoyl]phenyl]pyrazol-4-yl]oxazole-4-carboxamide, 1-427



[005366] To a solution of tert-butyl N-[4-[4-[[3-carbamoyl-l-[4-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo- isoindolin-4-yl]amino]ethoxy]ethoxy]ethylcarbamoyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (50.0 mg, 54.4 umol, synthesized via Method 10,

coupling acid Intermediate HI and amine Intermediate CL in Step 1, and coupling amine 4-[2-[2-(2-aminoethoxy)ethoxy]ethyl amino]-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione synthesized via Steps 1-2 of Example 127 in Step 3) in DCM (5 mL) was added HCl/dioxane (4 M, 13.6 uL). The mixture was stirred at 15 °C for 30 minutes. On completion, the mixture was concentrated in vacuo. The residue was purified by prep-HPLC (column: Luna C18 150*25 5u; mobile phase: [water (0.225% FA)-ACN]; B%: 29%-49%, 7.8 min) to give the title compound (22.0 mg, 44% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-^e) δ 11.11 (s, 1H), 11.01 (s, 1H), 9.04 (s, 1H), 9.02 (s, 1H), 8.63 (t, *J* = 5.2 Hz, 1H), 8.17 - 8.14 (m, 1H), 8.17 - 8.14 (m, 1H), 8.13 *(d, J* = 5.6 Hz, 1H), 8.11 - 8.06 (m, 2H), 8.05 - 8.00 (m, 2H), 7.80 (s, 1H), 7.59 - 7.54 (m, 1H), 7.59 - 7.54 (m, 1H), 7.12 *(d, J* = 8.8 Hz, 1H), 7.07 (s, 1H), 7.05 (s, 1H), 7.03 - 7.01 (m, 1H), 7.03 - 7.01 (m, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 6.60 (t, *J* = 5.6 Hz, 1H), 6.42 (s, 2H), 5.06 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.65 - 3.61 (m, 2H), 3.61 - 3.55 (m, 6H), 3.48 - 3.43 (m, 2H), 3.43 (s, 2H), 2.92 - 2.85 (m, 1H), 2.61 (s, 1H), 2.56 (s, 1H), 2.06 - 2.00 (m, 1H); LC-MS (ESI$^+$) m/z 820.5 (M+H)$^+$.


[005367] Example 423: N-[1-[4-[2-[2-[2-[[2-(2,6-dioχo-3-ριρeη̈dνï)-ï ,3-dïoχo-isoindolin-4-yl]amino]ethoxy]ethoxy] ethylcarbamoyl]phenyl]-3-[3-(2-hvdroxyethvB-2-oxo-imidazolidin-l-yl]pyrazol-4-yl]-2-[2-12.,2.,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide, 1-428



[005368] Tert-butylN-[4-[4-[[l-[4-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-

isoindolin-4-yl] amino]ethoxy]ethoxy]ethylcarbamoyl]phenyl]-3-[3-(2-hydroxyethyl)-2-oxo-imidazolidin-l-yl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate was synthesized via Method 10 with methyl 4-[4-amino-3-[3-(2-hydroxyethyl)-2-oxo-imidazolidin-l-yl]pyrazol-l-yl] benzoate (Intermediate JT) as the amine and 2-[2-[teit-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (Intermediate CM) as the acid in Step 1, and 4-[2-[2-(2-aminoethoxy)ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3- dione (50.3 mg, 114 umol, HC1, synthesized via Steps 1-2 of Example 127) as the amine in Step 3. In the final step, to a solution of tert-butylN-[4-[4-[[l-[4-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl] amino]ethoxy]ethoxy]ethylcarbamoyl]phenyl]-3-[3-(2-hydroxyethyl)-2-oxo-imidazolidin-l-yl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (100 mg, 91.9 umol) in DCM (10 mL) was added HCl/dioxane (4 M, 2 mL). The mixture was stirred at 20 °C for 3 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by Pre-HPLC (column: Phenomenex Synergi C18 l50*30mm*4um; mobile phase: [water (0.225%FA) -ACN]) to give the title compound (30 mg, 33% yield) as yellow solid. ^{1}H NMR (400MHz, DMSO-d) δ 11.65 (s, 1H), 11.09 (s, 1H), 8.97 - 8.93 (m, 2H), 8.54 (s, 1H), 8.25 - 8.24 (d, *J* = 5.6 Hz, 1H), 7.98 (d, *J* = 8.8 Hz, 2H), 7.88 (d, *J* = 8.8 Hz, 2H), 7.60- 7.50 (m, 2H), 7.23 (d, *J* = 8.4 Hz, 2H), 7.12 (d, *J* = 8.4 Hz, 1H), 7.01 (d, 7 = 7.2 Hz, 1H), 6.59 (s, 1H), 5.05 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.95 (s, lH),4.27- 4.24 (m, 2H), 4.06 - 3.96(m, 2H), 3.64 - 3.54 (m, 10H), 3.44 - 3.40 (m, 6H), 2.95 - 2.85 (m, 1H), 2.60 - 2.54 (m, 2H), 2.04 - 2.01 (m, 1H); LC-MS (ESI^{+}) *m/z* 987.8 $(M+H)^{+}$.


[005369] Example 424: N-[3-(3,3-dimethyl-2-oxo-pyrrolidin-l-yl)-l-[4-[2-[2-[2-[[2-(2,6-dioxo-3-piperidvP- 1,3-_ _dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(2,2,2-trifluoroethylamino)-4-pyridyl] oxazole-4-carboxamide, 1-429



[005370] Tert-butyl N-[4-[4-[[3-(3,3-dimethyl-2-oxo-pyrrolidin-l-yl)-l-[4-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)- 1,3-dioxo-isoindolin-4-


yl]amino]ethoxy]ethoxy]ethylcarbamoyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate was synthesized via Method 10, with methyl 4-[4-amino-3-(3,3-dimethyl-2-oxo-pyrrolidin-l-yl)pyrazol-l-yl]benzoate (Intermediate JV) as the amine and 2-[2-[tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino]-4-pyridyl]oxazole-4-carboxylic acid (Intermediate CM) as the acid in Step 1, and 4-[2-[2-(2-aminoethoxy)ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (synthesized via Steps 1-2 of Example 127) as the amine in Step 3. In the final step, to a solution of tert-butyl N-[4-[4-[[3-(3, 3-dimethyl-2-oxo-pyrrolidin-l-yl)-l-[4-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-l,3-dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethylcarbamoyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (42 mg, 39.2 umol) in DCM (2 mL) was added HCl/dioxane (4 M, 196 uL). The mixture was stirred at 20 °C for 3 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 l50*25*l0um; mobile phase: [water (0.05%HCl) -ACN]) to give the title compound (11.6 mg, 29% yield) as yellow solid. ^{1}H NMR (400MHz, DMSO-d_6) δ 11.14 (s, 1H), 11.08 (s, 1H), 8.99 (s, 1H), 8.96 (s, 1H), 8.55 (s, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 7.98 (d, *J* = 8.4 Hz, 2H), 7.88 (d, *J* = 8.4 Hz, 2H), 7.78 (s, 1H), 7.55 (t, *J* = 7.6 Hz, 1H), 7.26 (s, 1H), 7.22 (d, *J* = 5.2 Hz, 1H), 7.11 (d, 7 = 8.8 Hz, 1H), 7.01 (d, 7 = 7.2 Hz, 1H), 6.59 (s, 1H), 5.05 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.32- 4.23 (m, 2H), 3.98 (t, *J* = 6.8 Hz, 2H), 3.64 - 3.54 (m, 6H), 3.51 - 3.47 (m, 4H), 2.94 - 2.81 (m, 1H), 2.62 - 2.53 (m, 4H), 2.11 (t, *J* = 6.8 Hz, 2H), 2.02 (d, *J* = 11.2 Hz, 1H), 1.27 (s, 6H); LC-MS (ESI$^+$) *m/z* 970.5 (M+H)$^+$.

[005371] Example 427: N-[3-(difluoromethyl-l-methyl-pyrazol-4-yl]-2-[2-[2-[2-[2-[2-[[2-(2.,6-dioxo-3-piperidyl-l.,3- -dioxo-isoindolin-4-yl]amino]ethoxy]ethoxy]ethoxy]ethylamino]-3-pyridyl]oxazole-4-carboxamide, 1-432



[005372] To a solution of 2-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethylamino]-3-pyridyl]-N-[3- (difluoromethyl)-l-methyl-pyrazol-4-yl]oxazole-4-carboxamide (160 mg, 293 umol, HC1, Intermediate LW) in dioxane (20 mL) was added DIPEA (379 mg, 2.93 mmol) and 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline -l,3-dione (121 mg, 440 umol, Intermediate R). The mixture was stirred at 115 °C for 48 hours. On completion, the mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*25 lOu; mobile phase: [water (0.225%FA)-ACN]; B%: 22%-52%, lOmin) to give the title compound (60 mg, 26% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-^e) δ 11.10 (s, 1H), 9.98 (s, 1H), 8.86 (s, 1H), 8.40 - 8.32 (m, 1H), 8.26- 8.22 (m, 1H), 8.18 - 8.12 (m, 2H), 7.60- 7.49 (m, 1H), 7.25 - 6.98 (m, 3H), 6.75 - 6.68 (m, 1H), 6.60 - 6.52 (m, 1H), 5.08 - 4.92 (m, 1H), 3.90 (s, 3H), 3.82 - 3.69 (m, 2H), 3.68 - 3.58 (m, 2H), 3.57 - 3.35 (m, 12H), 2.94 - 2.78 (m, 1H), 2.60 - 2.52 (m, 2H), 2.08 - 1.94 (M, 1H); LC-MS (ESI^{+}) m/z 766.3 $(M+H)^{+}$.

[005373] Example 429: N-[3-carbamoyl-l-[6-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl1amino1 ethoxylethoxylhexa-2,4-diynyl]pyrazol-4-yl]-2-[2-(cyclopropylmethylaminoV4-pyridylloxazole-4-carboxamide, 1-434



[005374] Step 1 - Tert-butyl N-[4-[4-[[3-carbamoyl-1-[6-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-E3-dioxo-isoindolin _ -4-yl1amino1ethoxy1ethoxy1hexa-2.4-divnyl1pyrazol-4-yl1carbamoyl1oxazol-2-vn-2-pyridyl1-N-(cvclopropylmethv0carbamate


[005375] To a solution of CuI (6.33 mg, 33.2 umol), TMEDA (1.38 mg, 11.87 umol) in acetone (2 mL) was added 2-(2,6-dioxo-3-piperidyl)-4-[2-(2-prop-2-ynoxyethoxy)ethylamino]isoindoline-l,3-dione (118 mg, 297 umol, Intermediate MV) and tert-butyl N-[4-[4-[(3-carbamoyl-l-prop-2-ynyl-pyrazol-4-yl)carbamoyl]oxazol-2- yl]-2-pyridyl]-N-(cyclopropylmethyl)carbamate (15.0 mg, 29.7 umol, synthesized via Step 1 of of Example 299, 1-304). The reaction mixture was stirred at rt for 48 hrs under an oxygen atmosphere. On

completion, the mixture was concentrated *in vacuo*. The residue was purified by reverse phase (0.1% FA) to give title compound (20.0 mg, 74% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 903.1 $(M+H)^+$.

[005376] Step 2 - N-[3-carbamoyl-1-[6-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino] ethoxy1ethoxy1hexa-2.4-divnyl1pyrazol-4-yl1-2-r2-(cvclopropylmethylamino)-4-pyridyl1oxazole-4-carboxamide

[005377] To a mixture of tert-butyl N-[4-[4-[[3-carbamoyl-1-[6-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo- isoindolin-4-yl]amino]ethoxy]ethoxy]hexa-2,4-diynyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(cyclopropylmethyl)carbamate (20.0 mg, 22.1 umol) in DCM (2 mL) was added HCl/dioxane (4 M, 5.54 uL) and the reaction mixture was stirred at rt for 0.5 hr. On completion, the mixture was concentrated *in vacuo*. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]; B%: 15%-45%, 10 min) to give the title compound (2.00 mg, 14% yield, FA) as a yellow solid. ^1H NMR (400MHz, DMSO-^e) δ 11.09 (s, 1H), 10.97 (s, 1H), 8.95 (s, 1H), 8.49 - 8.44 (m, 2H), 8.15 (d, *J* = 5.6 Hz, 1H), 7.84 (s, 1H), 7.60 - 7.54 (m, 2H), 7.16 - 7.09 (m, 3H), 7.05 - 6.97 (m, 2H), 6.60 (t, *j* = 5.6 Hz, 1H), 5.35 (s, 2H), 5.05 (dd, *J* = 5.6, 13.2 Hz, 1H), 4.30 (s, 2H), 3.62 - 3.58 (m, 3H), 3.49 - 3.43 (m, 2H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.94 - 2.81 (m, 1H), 2.69 - 2.65 (m, 2H), 2.34 - 2.31 (m, 2H), 2.08 - 1.98 (m, 2H), 1.06 (s, 1H), 0.48 - 0.42 (m, 2H), 0.22 (d, *J* = 4.8 Hz, 2H); LC-MS (ESI^+) *m/z* 803.3 $(M+H)^+$.

[005378] Example 430: N-[3-carbamoyl-1-[6-[2-[2-[[2-[2,6-dioxo-3-piperidvB-l,3-dioxo-isoindolin-4-yl1amino1 ethoxy] ethoxy] hexyl] pyrazol-4-yl] -2-12-(cyclopropylmethylaminoV4-pyridylloxazole-4-carboxamide, 1-435



[005379] Step 1 - Tert-butyl N-[4-[4-[[1-[6-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]hexa-2,4-diynyl]-3 - carbamoyl-pyrazol-4-yl1carbamoyl1oxazol-2-yl1-2-pyridyl1-N-(cvclopropylmethvncarbamate

[005380] To a solution of CuI (84.4 mg, 443 umol), TMEDA (18.4 mg, 158 umol) in acetone (5 mL) was added tert-butyl N-[4-[4-[(3-carbamoyl-l-prop-2-ynyl-pyrazol-4-

yl)carbamoyl]oxazol-2-yl]-2-pyridyl]-N- (cyclopropylmethyl)carbamate (200 mg, 396 umol, synthesized via Step 1 of Example 299, 1-304) and tert-butyl N-[2-(2-prop-2-ynoxyethoxy)ethyl]carbamate (962 mg, 3.96 mmol, synthesized via Step 1 of Intermediate CQ). The reaction mixture was stirred for 12 hours under an oxygen atmosphere. On completion, the mixture was concentrated *in vacuo* to give the title compound (1.80 g, 97% yield, HC1) as a brown solid. LC-MS (ESI+) *m/z* 747.2 (M+H)+.

[005381] Step 2 - Tert-butylN-r4-r4-ITl-r6-r2-r2-(tert-butoxycarbonylamino)ethoxy1ethoxy1hexyl1-3- carbamoyl-pyrazol-4-yl1carbamoyl1oxazol-2-yl1-2-pyridvn-N-(cvclopropylmethvDcarbamate

[005382] To a mixture of tert-butyl N-[4-[4-[[l-[6-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]hexa-2,4- diynyl]-3-carbamoyl-pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(cyclopropylmethyl)carbamate (160 mg, 214 umol) in THF (10 mL) was added Pd/C (428.49 umol) and the suspension was degassed under vacuum and purged with Eh gas 3 times. The mixture was stirred at rt for 1 hr under Eh (15 Psi). On completion, the mixture was concentrated *in vacuo* to give the title compound (160 mg, 99% yield) as a brown solid. ¾NMR (400MHz, DMSO-i¾) δ 11.01 (s, 1H), 9.02 (s, 1H), 8.60 (d, *J* = 5.2 Hz, 1H), 8.38 (s, 1H), 8.25 (s, 1H), 7.73 - 7.64 (m, 2H), 7.49 (s, 1H), 6.87 (s, 1H), 5.31 (s, 1H), 4.57 (t, *J* = 5.6 Hz, 1H), 4.18 (t, *J* = 6.8 Hz, 2H), 3.86 (d, *J* = 6.4 Hz, 2H), 2.18 (s, 1H), 1.82 (d, *J* = 6.8 Hz, 3H), 1.46 (s, 19H), 0.91 - 0.82 (m, 2H), 0.41 (d, *J* = 7.6 Hz, 2H), 0.24 (d, *J* = 4.0 Hz, 2H), -0.06 (s, 4H).

[005383] Step 3 - N-rl-r6-r2-(2-aminoethoxy)ethoxy1hexyl1-3-carbamoyl-pyrazol-4-yl1-2-r2-(cvclopropyl methyl amino)-4-pyridyl1oxazole-4-carboxamide


[005384] To a mixture of tert-butyl N-[4-[4-[[l-[6-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]hexyl]-3-carbamoyl-pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(cyclopropylmethyl)carbamate (100 mg, 132 umol) in DCM (2 mL) was added HCl/dioxane (4 M, 6.7 mL). The reaction mixture was stirred at rt for 0.5 hr. On completion, the mixture was concentrated *in vacuo* to give the title compound (75.0 mg, 95% yield, HC1) as brown oil. LC-MS (ESI+) *m/z* 555.2 (M+H)+.

[005385] Step 4 - N-[3-carbamoyl-1-[6-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4- vl]amino] ethoxy1ethoxy1hexyl1pyrazol-4-yl1-2-r2-(cvclopropylmethylamino)-4-pyridylloxazole-4-carboxamide

[005386] To a mixture of N-[l-[6-[2-(2-aminoethoxy)ethoxy]hexyl]-3-carbamoyl-pyrazol-4-

yl]-2-[2-(cyclo propylmethylamino)-4-pyridyl]oxazole-4-carboxamide (45.0 mg, 76.lumol, HC1), 2-(2,6-dioxo-3- piperidyl)-4-fluoro-isoindoline-l,3-dione (21.0 mg, 76.1 umol, Intermediate R) in DMSO (2 mL) was added DIEA (98.4 mg, 761 umol). The mixture was stirred at 130 °C for 0.5 hr. On completion, the mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water(0.225% FA)-ACN]; B%: 23%-43%,7 min and column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.05%HCl)-ACN]; B%: 25%-45%, 9 min) to give the title compound (8.50 mg, 12% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-^e) δ 11.14 - 11.09 (m, 1H), 11.00 (s, 1H), 9.08 (s, 1H), 8.38 (s, 1H), 8.10 (d, *J* = 6.4 Hz, 1H), 7.76 (s, 1H), 7.61 - 7.48 (m, 3H), 7.24 - 7.1 1 (m, 2H), 7.03 (d, *J* = 7.2 Hz, 1H), 6.60 (s, 1H), 5.10 - 5.00 (m, 1H), 4.17 (t, *J* = 7.2 Hz, 2H), 3.65 - 3.44 (m, 12H), 3.28 (d, *J* = 6.8 Hz, 4H), 2.95 - 2.82 (m, 1H), 2.71 - 2.65 (m, 1H), 2.37 - 2.31 (m, 1H), 2.08 - 1.98 (m, 1H), 1.86 - 1.69 (m, 2H), 1.52 - 1.39 (m, 2H), 1.35 - 1.08 (m, 5H), 0.56 *(d, J* = 6.8 Hz, 2H), 0.39 - 0.25 (m, 2H); LC-MS (ESI^{+}) *m/z* 811.1 (M+H)$^{+}$.

[005387] Example 431: 3-[3-Methyl-2-oxo-5-[3-[3-[4-[4-IY5-tetrahvdropyran-4-ylpyrrolo[2,l-f|[1,2,4]triazin-4-vB_ aminolcvclohexyllpiperazin-1-yl1propoxy1propyl1benzimidazol-l-yl]piperidine-2.,6-dione (I -436)



[005388] Step 1 - 3-Prop-2-vnoxypropan-l-ol (3).

[005389] To a solution of propane- 1,3-diol (10.0 g, 13 1 mmol, 9.52 mL, CAS#l26-30-7) and 3-bromoprop-l-yne (15.6 g, 131 mmol, 11.3 mL, CAS#l06-96-7) in THF (250 mL) was added KOH (7.37 g, 131 mmol), Kl (3.27 g, 19.7 mmol) and TBAI (2.91 g, 7.88 mmol). The reaction mixture was stirred at 25 °C for 16 hrs. On completion, the mixture was filtered, and the filter was concentrated in *vacuo* to give a residue, the residue was diluted with H_20 (50 mL), and then extracted with EA (2 X 100 mL). The organic phase was concentrated in *vacuo* to give a residue. The residue was purified by flash silica gel chromatography to give the title compound (8.00 g, 53% yield) as yellow oil. ^{1}H NMR (400MHz, DMSO-^e) δ 4.14 (d, *J* = 2.4 Hz, 2H), 3.75 (t, *J* = 5.6 Hz, 2H), 3.68 (t, *J* = 5.6 Hz, 2H), 2.44 (t, *J* = 2.4 Hz, 1H), 2.23 (s, 1H), 1.88 - 1.81 (m, 2H).

[005390] Step 2 - 3-r5-r3-(3-Hvdroxypropoxy)prop-l-vnyl1-3-methyl-2-oxo-benzimidazol-l-yllpiperidine-2.6- dione (5).

[005391] To a solution of 3-prop-2-ynoxypropan-l-ol (506 mg, 4.44 mmol) and 3-(5-bromo-3-methyl -2-oxo- benzimidazol-l-yl)piperidine-2,6-dione (500 mg, 1.48 mmol, Intermediate HN) in DMSO (10 mL) was added DIEA (955 mg, 7.39 mmol, 1.29 mL), Cul (56.3 mg, 295 umol) and

$Pd(PPh_3)_2Cl_2$ (207 mg, 295 umol). The reaction mixture was stirred at 80 °C for 2 hr under N_2. On completion, the mixture was filtered; the filtrate was concentrated in *vacuo* to give a residue. The residue was purified by reverse phase column (0.1% FA condition) to give the title compound (370 mg, 67% yield) as a yellow solid. LC-MS (ESI^+) m/z 372.1$(M+H)^+$.

[005392] Step 3 - 3-r5-r3-(3-Hvdroxypropoxy)propyl1-3-methyl-2-oxo-benzimidazol-l-yl1piperidine-2.6-dione (6).

[005393] To a solution of 3-[5-[3-(3-hydroxypropoxy)prop-l-ynyl]-3-methyl-2-oxo-benzimidazol-l-yl] piperidine-2, 6-dione (370 mg, 996 umol) in THF (20 mL) was added Pd/C (100 mg, 10% purity) and $Pd(OH)_2/C$ (100 mg, 10% purity). The reaction mixture was stirred at 25 °C for 12 hrs under H_2 (15 psi). On completion, the residue was filtered and the filtrate was concentrated *in vacuo* to give the title compound (340 mg, 90% yield) as a white solid. ^1H NMR (400MHz, DMSO-i/e) δ 11.07 (s, 1H), 7.06 - 6.96 (m, 2H), 6.86 (d, J = 8.0 Hz, 1H), 5.33 (dd, J = 5.2, 12.8 Hz, 1H), 4.36 (s, 1H), 3.47 (t, J = 6.4 Hz, 2H), 3.43 - 3.40 (m, 2H), 3.37 - 3.34 (m, 2H), 3.34 (s, 3H), 2.95 - 2.85 (m, 1H), 2.76 - 2.57 (m, 4H), 2.04 - 1.96 (m, 1H), 1.85 - 1.76 (m, 2H), 1.69 - 1.62 (m, 2H); LC-MS (ESI^+) m/z 376.2 $(M+H)^+$.


[005394] Step 4 - 3-r3-rl-(2.6-Dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yllpropoxylpropyl methanesulfonate (7).

[005395] To a solution of 3-[5-[3-(3-hydroxypropoxy)propyl]-3-methyl-2-oxo-benzimidazol-l-yl]piperidine- 2,6-dione (100 mg, 266 umol) and TEA (80.8 mg, 799 umol, 111 uL) in DCM (5 mL) was added MsCl (36.6 mg, 319 umol, 24.7 uL) at 0 °C. The reaction mixture was stirred at 20 °C for 1 hr. On completion, the mixture was quenched by water (20 mL), and then extracted with DCM (2 X 50 mL). The organic phase was concentrated in vacuo to give the title compound (100 mg, 83% yield) as yellow oil. ^1H NMR (400MHz, DMSO-i/e) δ 11.09 (s, 1H), 7.03 (s, 1H), 7.00 (d, J = 8.0 Hz, 1H), 6.90 - 6.84 (m, 1H), 5.34 (dd, J = 5.2, 12.8 Hz, 1H), 4.27 (t, J = 6.4 Hz, 2H), 3.47 - 3.43 (m, 2H), 3.38 (t, J = 6.4 Hz, 2H), 3.34 (m, 3H), 3.17 (s, 3H), 2.95 - 2.84 (m, 1H), 2.73 - 2.57 (m, 4H), 2.04 - 1.96 (m, 1H), 1.94 - 1.88 (m, 2H), 1.86 - 1.78 (m, 2H); LC-MS (ESL) m/z 454.2 $(M+H)^+$.

[005396] Step 5 - 3-r3-Methyl-2-oxo-5-r3-r3-r4-r4-r(5-tetrahvdropyran-4-yl pyrrolo[2.1-f][1.2.4]tri azin-4-vl) amino1cvclohexyl1piperazin-l-yl1propoxy1propyl1benzimidazol-l-yl1piperidine-2.6-dione. **(1-436)**

[005397] To a solution of 3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]propoxy]propyl methanesulfonate (90.4 mg, 199 umol) and N-(4-piperazin-l-ylcyclohexyl)-5-tetrahydropyran-4-yl -pyrrolo[2,l-f][l,2,4]triazin-4-amine (70.0 mg, 166 umol, Intermediate OP) in CH_3CN (10 mL) was added KI (276 ug, 1.66 umol) and $NaHC0_3$ (41.9 mg, 498 umol). The reaction mixture was stirred at 130 °C for 12 hrs. On completion, the residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225%FA)-ACN]; B%: ll%-35%, 8 min) to give the title compound (20.8 mg, 16% yield) as a yellow solid. ¾NMR (400MHz, DMSO-i&) δ 11.10 (s, 1H), 7.79 (s, 1H), 7.54 (d, *J* = 2.4 Hz, 1H), 7.08 - 6.97 (m, 2H), 6.87 (d, *j* = 8.0 Hz, 1H), 6.53 (d, *j* = 2.8 Hz, 1H), 6.21 (d, *j* = 8.0 Hz, 1H), 5.34 (dd, *j* = 5.2, 12.8 Hz, 1H), 4.12 - 3.99 (m, 1H), 3.94 - 3.86 (m, 2H), 3.59 - 3.50 (m, 2H), 3.46 - 3.33 (m, 6H), 3.33 (s, 3H), 2.95 - 2.85 (m, 1H), 2.72 - 2.67 (m, 1H), 2.66 - 2.62 (m, 2H), 2.61 - 2.57 (m, 1H), 2.56 - 2.51 (m, 4H), 2.44 - 2.34 (m, 3H), 2.34 - 2.30 (m, 2H), 2.29 - 2.25 (m, 1H), 2.04 - 1.94 (m, 3H), 1.88 - 1.73 (m, 6H), 1.70 - 1.61 (m, 4H), 1.51 (q, *J* = 12.0 Hz, 2H), 1.33 (q, *J* = 11.6 Hz, 2H); LC-MS (ESI^+) m/z 742.5 $(M+H)^+$.

[005398] Example 432: 3-[3-Methyl-2-oxo-5-[3-[3-oxo-3-[4-[4-[(5-tetrahydropyran-4-ylpyrrolo[2,l-f][l,2,4]triazin-4-yBaminolcyclohexyllpiperazin-l-yl1propoxy]propyl1benzimidazol-l-yl1piperidine-2.,6-dione (1-437)



[005399] Step 1 - Tert-butyl 3-prop-2-ynoxypropanoate (3)

[005400] A mixture of tert-butyl prop-2-enoate (2 g, 15.6 mmol, 2.27 mL, CAS#l663-39-4), prop-2-yn-l-ol (2.62 g, 46.8 mmol, 2.77 mL, CAS#l07-l9-7) in THF (10 mL) was added NaOMe (84.3 mg, 1.56 mmol), and then the mixture was stirred at 25 °C for 16 hrs under N_2 atmosphere. On completion, the mixture was diluted with water (30 mL), and then extracted with EA (2 X 100 mL). The organic layer was dried with Na_2SO_4, filtrated and concentrated in *vacuo* to give the title compound (1.80 g, 63% yield) as light yellow oil. ^1H NMR (400MHz, CDCh) δ 4.18 (d, J = 2.4 Hz, 2H), 3.78 (t, j = 6.4 Hz, 2H), 2.54 (t, j = 6.4 Hz, 2H), 2.45 (s, 1H), 1.47 (s, 9H).

[005401] Step 2 - Tert-butyl 3-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-ynpropoxy]-2-nnoxy]propanoate (5)

[005402] A mixture of 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (400 mg, 1.18 mmol, Intermediate HN), tert-butyl 3-prop-2-ynoxypropanoate (654 mg, 3.55 mmol), $Pd(PPh_3)_2Cl_2$ (166 mg, 236 umol), CuI (45.0 mg, 236 umol) and TEA (2.15 g, 21.0 mmol,

2.96 mL) in DMF (15 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 85 °C for 4 hrs under N_2 atmosphere. On completion, the mixture was diluted with water (50 mL), and then extracted with EA (2 X 100 mL). The organic layer was washed with brine (20 mL), dried with Na_2S0_4, filtrated and concentrated in *vacuo.* The residue was purified by reverse phase flash to give the title compound (300 mg, 49% yield) as light yellow solid. LC-MS (ESI^+) *m/z* 386.1 $(M+l-56)^+$.

[005403] Step 3 - Tert-butyl 3-[3-[1-(2.6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]propoxy] propanoate (6)

[005404] To a solution of tert-butyl 3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]prop-2- ynoxy]propanoate (250 mg, 566 umol) in THF (50 mL) was added Pd/C (50 mg, 10% purity) and $Pd(OH)_2/C$ (50 mg, 10% purity). The mixture was stirred at 25 °C for 5 hrs under H_2 atmosphere (15 psi). On completion, the mixture was filtered and the filtrate was concentrated in *vacuo* to give the title compound (200 mg, 79% yield) as white solid. ^1H NMR (400MHz, DMSO-i/e) δ 11.09 (s, 1H), 7.07 - 6.98 (m, 2H), 6.90 - 6.83 (m, 1H), 5.34 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.63 - 3.53 (m, 2H), 3.39 - 3.37 (m, 2H), 3.33 (s, 3H), 3.02 - 2.83 (m, 1H), 2.78 - 2.58 (m, 4H), 2.43 (t, *j* = 6.0 Hz, 2H), 2.07 - 1.94 (m, 1H), 1.85 - 1.74 (m, 2H), 1.41 (s, 9H).

[005405] Step 4 - 3-[3-[1-(2.6-Dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yllpropoxylpropanoic acid (7)


[005406] To a solution of tert-butyl 3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]propoxy] propanoate (150 mg, 336 umol) in DCM (4 mL) was added TFA(4.62 g, 40.0 mmol, 3.00 mL). The mixture was stirred at 25 °C for 2 hrs. On completion, the mixture was concentrated in *vacuo* to give the title compound (120 mg, 91% yield) as brown solid. ^1H NMR (400MHz, DMSO^k) δ 11.08 (s, 1H), 7.11 - 6.95 (m, 2H), 6.87 (dd, 7 = 1.2, 8.0 Hz, 1H), 5.34 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.58 (t, *J* = 6.4 Hz, 2H), 3.38 (t, *J* = 6.4 Hz, 2H), 3.33 (s, 3H), 2.99 - 2.84 (m, 1H), 2.76 - 2.57 (m, 4H), 2.46 (t, *J* = 6.4 Hz, 2H), 2.03 - 1.98 (m, 1H), 1.86 - 1.74 (m, 2H).

[005407] Step 5 - 3-r3-Methyl-2-oxo-5-r3-r3-oxo-3-r4-r4-r(5-tetrahvdropyran-4-ylpyrrolor2.l-firL2.41triazin- 4-yl)amino1cvclohexyl1piperazin-l-yllpropoxylpropyllbenzimidazol- 1-yllpi peri dine-2.6-di one (1-437)

[005408] A mixture of 3-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]propoxy]propanoic acid (120 mg, 308 umol), N-(4-piperazin-l-ylcyclohexyl)-5-

tetrahydropyran-4-yl-pyrrolo[2,l-f][l,2,4] triazin-4-amine (129 mg, 308 umol, HC1, Intermediate OP), DIEA (119 mg, 924 umol), HATU (140 mg, 369 umol) in DMF (3 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 25 °C for 2 hrs under N_2 atmosphere. On completion, the mixture was concentrated in *vacuo.* The residue was purified by Pre-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225%FA)-ACN]; B%: ll%-39%, 9 min) to give the title compound (55.0 mg, 24% yield) as white solid. ¾ NMR (400MHz, DMSO-i¾) δ 11.09 (s, 1H), 7.79 (s, 1H), 7.55 (d, *J* = 2.8 Hz, 1H), 7.08 - 6.97 (m, 2H), 6.87 (d, *j* = 7.6 Hz, 1H), 6.54 (d, *j* = 2.4 Hz, 1H), 6.21 (d, *j* = 7.6 Hz, 1H), 5.34 (dd, *j* = 5.2, 12.8 Hz, 1H), 4.10 - 4.01 (m, 1H), 3.95 - 3.85 (m, 2H), 3.64 - 3.48 (m, 8H), 3.34 - 3.30 (m, 7H), 2.96 - 2.86 (m, 1H), 2.70 - 2.54 (m, 7H), 2.48 - 2.42 (m, 2H), 2.38 - 2.28 (m, 1H), 2.03 - 1.96 (m, 3H), 1.88 - 1.71 (m, 6H), 1.71 - 1.59 (m, 2H), 1.57 - 1.46 (m, 2H), 1.43 - 1.27 (m, 2H), LC-MS (ESI^+) *m/z* 756.5 $(M+l)^+$.

[005409] Example 433: 3-[3-Methyl-2-oxo-5-[7-oxo-7-[4-[4-IY5-tetrahvdropyran-4-ylpyrrolo[2.,l-f|[l.,2.,4]triazin-4- vBamino]cvclohexyl]piperazin-l-yl]heptyl]benzimidazol-l-yl]piperidine-2.,6-dione (l -438)



[005410] Step 1 - 7-[1-(2,6-Dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]hept-6-ynoic acid (3)

[005411] A mixture of hept-6-ynoic acid (224 mg, 1.77 mmol, CAS#30964-00-2), 3-(5-bromo-3-methyl-2-oxo- benzimidazol-l-yl)piperidine-2,6-dione (200 mg, 591 umol, Intermediate HN), Pd(PPh $_3$)2Cl2 (12.5 mg, 17.7 umol), CuI (1.13 mg, 5.91 umol) and DIEA (1.53 g, 11.8 mmol) in DMSO (5 mL) was degassed and purged with N2 for 3 times in glove box. The mixture was stirred at 80 °C for 2 hrs under N2 atmosphere. On completion, the crude product was purified by reverse phase column (0.1% FA condition) to give the title compound (180 mg, 60% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-r¾) δ = 11.12 (s, 1H), 7.97 - 7.67 (m, 1H), 7.29 - 7.18 (m, 1H), 7.17 - 7.03 (m, 2H), 5.37 (d, *J* = 13.2 Hz, 1H), 3.43 - 3.38 (m, 3H), 2.93 - 2.81

(m, 2H), 2.74 - 2.65 (m, 1H), 2.46 - 2.39 (m, 2H), 2.30 - 2.23 (m, 2H), 2.02 (d, *J* = 4.4 Hz, 1H), 1.72 - 1.43 (m, 4H).


[005412] Step 2 - Tert-butyl 6-[2-[2-I[2-(2,6-dioxo-3-piperidvP -L3-dioxo-isoindolin-4-yl]amino]ethoxy] ethyl1-2.6-diazaspiror3.31heptane-2-carboxylate (4)

[005413] To a solution of 7-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]hept-6-ynoic acid (160 mg, 417 umol) in THF (50 mL) was added Pd/C (200 mg, 417 umol, 50% purity) and $Pd(OH)_2/C$ (200 mg, 417 umol, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred at 15 °C for 2 hours under H_2 (15 psi). On completion, the mixture was filtered with Clite and the filtrate was concentrated in vacuo to give the title compound (100 mg, 40% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 388.2 $(M+H)^+$.

[005414] Step 3 - 3-r3-Methyl-2-oxo-5-r7-oxo-7-r4-r4-r(5-tetrahvdropyran-4-yl pyrrolo[2.1-firl.2.41triazin-4- vnaminolcvclohexyllpiperazin-l-yllheptyllbenzimidazol-l-yllpiperidine-2.6-dione **(1-438)**


[005415] To a solution of 7-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]heptanoic acid (100 mg, 258 umol) and N-(4-piperazin-l-ylcyclohexyl)-5-tetrahydropyran-4-yl-pyrrolo[2,l-f][l,2,4] triazin-4-amine (100 mg, 258 umol, Intermediate OP) in DMF (5 mL) was added HATU (118 mg, 310 umol) and DIEA (83.4 mg, 645 umol, H 2 uL). The mixture was stirred at 25 °C for 6 hrs. On completion, the residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.05%HCl)-ACN]; B%: l7%-35%, 9 min) to give the title compound (26.0 mg, 12.0% yield) as a light yellow solid. ^1H NMR (400MHz, DMSO-d_6) δ 11.16 (s, 1H), 11.10 (s, 1H), 7.97 (s, 1H), 7.80 (s, 1H), 7.05 - 7.00 (m, 2H), 6.87 (d, *J* = 8.0 Hz, 1H), 6.71 (d, *J* = 2.4 Hz, 1H), 5.35 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.49 (d, *J* = 14.4 Hz, 1H), 4.06 (d, *J* = 11.2 Hz, 2H), 3.92 *(d, J* = 8.0 Hz, 4H), 3.50 - 3.48 (m, 3H), 3.33 (s, 3H), 3.21 - 3.06 (m, 4H), 2.98 - 2.84 (m, 2H), 2.70 - 2.67 (m, 1H), 2.66 - 2.59 (m, 4H), 2.40 - 2.34 (m, 2H), 2.25 (s, 2H), 2.09 (s, 2H), 2.04 - 1.97 (m, 1H), 1.80 - 1.64 (m, 10H), 1.50 (s, 2H), 1.33 - 1.30 (m, 4H); LC-MS (ESI^+) m/z 754.5 $(M+H)^+$.

[005416] Example 434: 3-[3-Methyl-4-[3-[2-[2-[2-[2-[methyl-[4-[(5-tetrahvdropyran-4-yl-7H-pyrrolo[2.,3-d1 pyrimidin-4-vBaminolcvclohexyllaminolethoxylethoxylethoxylethoxylpropyH-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione 11-4391




[005417] To a mixture of Nl-methyl-N4-(5-tetrahydropyran-4-yl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)cyclohexane -1,4-diamine (80.0 mg, 242 umol, Intermediate OQ) in a mixed solvent of THF (6 mL) and DMF (1.5 mL) was added TEA (36.8 mg, 364 umol), HOAc (21.8 mg, 364 umol) and 2-[2-[2-[2-[3-[l-(2,6-dioxo -3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]propoxy]ethoxy]ethoxy]ethoxy]acetaldehyde (119 mg, 242 umol, from Example 437). The mixture was stirred for 30 minutes, and then $NaBH(OAc)_3$ (102 mg, 485 umol) was added. The mixture was stirred 25°C for 48 hours. On completion, the reaction mixture was quenched by water (15 mL), and then extracted with EA (3 X 30 mL). The combined organic layers were dried over Na_2S0_4, filtered and concentrated in vacuo to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.05%HCl)-ACN]) to give the title compound (6.12 mg, 2% yield) as yellow solid. ^1H NMR (400MHz, DMSO-d_6+D_20) δ 8.30 (s, 1H), 7.19 (s, 1H), 6.96 (d, J = 4.8 Hz, 2H), 6.91 - 6.83 (m, 1H), 5.30 (dd, J = 5.6, 12.4 Hz, 1H), 3.89 - 3.86 (m, 2H), 3.69 - 3.34 (m, 24H), 3.24 - 3.16 (m, 2H), 2.98 - 2.79 (m, 3H), 2.74 (s, 3H), 2.70 - 2.57 (m, 2H), 2.15 - 1.94 (m, 5H), 1.85 - 1.75 (m, 4H), 1.71 - 1.49 (m, 6H); LC-MS (ESI^+) *m/z* 805.6 $(M+H)^+$.

[005418] Example 435: 2-[2-[2-[2-[3-[l-[2,6-Dioxo-3-piperidyl]-3-methyl-2-oxo-benzimidazol-4-yl] propoxy] ethoxy] ethoxy] ethoxy] -N- [4- [(5-tetr ahy dropy ran-4-yl-7H-pyrrolo [2,3-dl pyrimidin-4-yDaminol cyclohexyl] acetamide 11-4401



[005419] To a solution of 2-[2-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]propoxy] ethoxy] ethoxy] ethoxy] acetic acid (70.7 mg, 113 umol, from Example 447) and N4-(5-tetrahydropyran-4- yl-7H-pyrrolo[2, 3-d]pyrimidin-4-yl)cyclohexane-l,4-diamine (40.0 mg, 113 umol, HC1, from **1-442)** in DMF (5 mL) was HATU (51.9 mg, 136 umol) and DIPEA (73.5 mg, 568 umol, 99.0 uL). The mixture was stirred at 25 °C for 1.5 hrs. On completion, the mixture was quenched with H_20 (5 mL), then concentrated in *vacuo* to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225%FA)-ACN]; B%: 7%-37%, 10 min) to give the title compound (33.2 mg, 36% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-^e) δ 11.31 (s, 1H), 11.10 (s, 1H), 8.06 (s, 1H), 7.47 (d, *J* = 8.4 Hz, 1H), 6.99 - 6.90 (m, 2H), 6.90 - 6.81 (m, 2H), 5.57 *(d, J* = 8.0 Hz, 1H), 5.35 (dd, 7 = 5.2, 12.4 Hz, 1H), 4.15 - 4.00 (m, 1H), 3.93 - 3.87 (m, 2H), 3.85 (s, 2H), 3.60 - 3.52 (m, 17H), 3.47 - 3.44 (m, 2H), 3.28 - 3.19 (m, 2H), 2.96 - 2.91 (m, 2H), 2.90 - 2.83 (m, 1H), 2.71 - 2.58 (m, 2H), 2.03 - 1.93 (m, 3H), 1.87 - 1.76 (m, 6H), 1.59 - 1.36 (m, 6H); LC-MS (ESI+) m/z 805.5 $(M+H)^+$.

[005420] **Example 436: N-[3-[difluoromethvB-l-[4-[[4-[4-[l-[2,6-dioxo-3-piperidvB-3-methyl-2-oxo-benzimidazol -5-yl] butoxyl butylamino] methyl] phenyl] pyrazol-4-yll-5-piperazin-l-yl-pyrazolo[l.,5-a1pyrimidine-3-carboxamide (1-441)**



[005421] Step 1 - Tert-butyl 4-[3-[[3-(difluoromethyl)-1-(4-methoxycarbonylphenvnpyrazol-4-yllcarbamoyll pyrazolopl .5-a1pyrimidin-5-yl1piperazine-1-carboxylate (3)

[005422] To a solution of methyl 4-[4-amino-3-(difluoromethyl)pyrazol-l-yl]benzoate (650 mg, 2.43 mmol, Intermediate FW), 5-(4-tertbutoxycarbonylpiperazin-l-yl)pyrazolo[l,5-a]pyrimidine-3 -carboxylic acid (650 mg, 1.87 mmol) in ACN (15.0 mL) was added DIEA (725 mg, 5.61 mmol), HATU (1.42 g, 3.74 mmol). The mixture was stirred at 60 °C for 16 hrs. On completion, the mixture was concentrated in *vacuo.* The mixture was purified by reverse phase: (0.1% FA) to give the title compound (700 mg, 62% yield) as yellow solid. ^{1}H NMR (400MHz, CDCh) δ 9.60 (s, 1H), 9.05 (s, 1H), 8.48 (s, 1H), 8.38 (d, *J* = 8.0 Hz, 1H), 8.17 (d, *J* = 8.8 Hz, 2H), 7.83 (d, *J* = 8.8 Hz, 2H), 6.92 (t, *J* = 54.0 Hz, 1H), 6.46 (d, *J* = 8.0 Hz, 1H), 3.96 (s, 3H), 3.91 - 3.80 (m, 4H), 3.70 - 3.60 (m, 4H), 1.54 (s, 9H).

[005423] Step 2 - 4-r4-IT5-('4-Tert-butoxycarbonylpiperazin- l-yl ipyrazolon .5-alpyrimidine-3-carbonyllaminol -3-(difluoromethv0pyrazol-l-vnbenzoic acid (4)

[005424] To a solution of tert-butyl 4-[3-[[3-(difluoromethyl)-l-(4-methoxycarbonylphenyl) pyrazol-4-yl] carbamoyl]pyrazolo[l,5-a]pyrimidin-5-yl]piperazine-l-carboxylate (1.00 g, 1.68 mmol) in THF (40.0 mL) and H_20 (8 mL) was added LiOH (200 mg, 8.38 mmol). The mixture was stirred at 20 °C for 16 hrs. On completion, the mixture was concentrated in *vacuo.* The mixture was diluted with H_20 (30 mL). The mixture was acidified with 1N HC1 solution till pH = 5, filtered and the filter cake was dried in *vauco* to give the title compound (900 mg, 92% yield) as yellow solid. ^{1}H NMR (400MHz, DMSO-^e) δ 12.01 (s, 1H), 9.48 (s, 1H), 9.08 (s, 1H), 8.82 (d, *j* = 8.0 Hz, 1H), 8.32 (s, 1H), 8.07 (d, *j* = 8.8 Hz, 2H), 7.97 (d, *J* = 8.8 Hz, 2H), 7.35 (t, *j* = 53.6 Hz, 1H), 6.89 (d, *J* = 8.0 Hz, 1H), 3.90 - 3.75 (m, 4H), 3.50 - 3.45 (m, 4H), 1.44 (s, 9H).

[005425] Step_ __3_ __-_ __Tert-butyl_ __4-[3-[[3-(difh1oromethvl)-l -(4-isopropoxycarbonyloxycarbonylphenvDpyrazol-4- ___yl1carbamoyl1pyrazolorL5-a1pyrimidin-5-yllpiperazine-l-carboxylate (6)

[005426] To a solution of 4-[4-[[5-(4-tert-butoxycarbonylpiperazin-l-yl)pyrazolo[l,5-a]pyrimidine-3 -carbonyl] amino]-3-(difluoromethyl)pyrazol-l-yl]benzoic acid (900 mg, 1.54 mmol), TEA (625 mg, 6.18 mmol) in THF (30.0 mL) was added isopropyl carbonochloridate (473 mg, 3.86 mmol) at -10 °C. The mixture was stirred at -10 °C for 1 hr. On completion, the mixture was filtered and the filtrate was concentrated in *vacuo* to give the title compound (1.00 g, 90% yield) as yellow solid. LC-MS (ESI^+) *m/z* 669.2 $(M+H)^+$.

[005427] Step 4 - Tert-butyl 4-r3-rr3-(difluoromethvO-l-r4-(hvdroxymethvOphenvnpyrazol-4-yllcarbamovn _pyrazolorL5-a1pyrimidin-5-yl1piperazine-l-carboxylate (7)

[005428] To a solution of tert-butyl 4-[3-[[3-(difluoromethyl)-l-(4-isopropoxycarbonyloxycarbonylphenyl) pyrazol-4-yl]carbamoyl]pyrazolo[l,5-a]pyrimidin-5-yl]piperazine-l-carboxylate (1.00 g, 1.50 mmol) in THF (50.0 mL) and H_20 (10.0 mL) was added $LiBH_4$ (195 mg, 8.97 mmol) at 0 °C. The mixture was stirred at 0 °C for 1 hr. On completion, the mixture was quenched with H_20 (10 mL), then extracted with DCM (2 X 30 mL). The organic layers were dried with anhydrous Na_2S0_4, filtered and concentrated in *vacuo.* The mixture was triturate with DCM (5 mL) to give the title compound (700 mg, 82% yield) as yellow solid. ^1H NMR (400MHz, DMSO-^e) δ 9.49 (s, 1H), 8.98 (s, 1H), 8.85 (d, *J* = 8.0 Hz, 1H), 8.33 (s, 1H), 7.80 (d, *J* = 8.4 Hz, 2H), 7.48 (d, *J* = 8.4 Hz, 2H), 7.20 (t, *J* = 53.2 Hz, 1H), 6.91 (d, *J* = 8.0 Hz, 1H), 5.35 - 5.24 (m, 1H), 4.56 (d, *J* = 4.4 Hz, 2H), 3.95 - 3.75 (m, 4H), 3.55 - 3.45 (m, 4H), 1.45 (s, 9H).

[005429] Step 5 - Tert-butyl 4-r3-rr3-(difluoromethvD-l-(4-formylphenvDpyrazol-4-yllcarbamoyllpyrazolo rL5-a1pyrimidin-5-yl1piperazine-l-carboxylate (8)

[005430] To a solution of tert-butyl 4-[3-[[3-(difluoromethyl)-l-[4-(hydroxymethyl)phenyl]pyrazol-4-yl] carbamoyl]pyrazolo[l,5-a]pyrimidin-5-yl]piperazine-l-carboxylate (700 mg, 1.23 mmol) in THF (30.0 mL) was added DMP (626 mg, 1.48 mmol). The mixture was stirred at 20 °C for 1 hour. On completion, the mixture was quenched with saturated $Na_2S_20_3$ (30 mL) and washed with saturated $NaHC0_3$ (2 X 30 mL). The organic layer was dried over anhydrous Na_2S0_4, filtered and concentrated in *vacuo* to give the title compound (680 mg, 90% yield) as yellow solid. ¾ NMR (400MHz, DMSO-^e) δ 10.04 (s, 1H), 9.52 (s, 1H), 9.17 (s, 1H), 8.86 (d, *J* = 8.0 Hz, 1H), 8.35 (s, 1H), 8.15 - 8.10 (m, 2H), 8.09 - 8.03 (m, 2H), 7.39 (t, *J* = 52.8 Hz, 1H), 6.96 - 6.86 (m, 1H), 3.90 - 3.80 (m, 4H), 3.50 - 3.40 (m, 4H), 1.45 (s, 9H).

[005431] Step 6 - Tert-butyl 4-[3-[[3-(difluoromethvl)-l-[4-[[4-[4-[l-(2,6-dioxo-3-piperidvn-3 -methyl -2-oxo- benzimidazol-5-yl1butoxy1butylamino1methyl1phenyl1pyrazol-4-yl1carbamovnpyrazolorL5-a1pyrimidin-5-vnpiperazine-l-carboxylate (10)


[005432] To a solution of tert-butyl 4-[3-[[3-(difluoromethyl)-l-(4-formylphenyl)pyrazol-4-yl]carbamoyl] pyrazolo[l,5-a]pyrimidin-5-yl]piperazine-l-carboxylate (129 mg, 227 umol), 3-[5-[4-(4-aminobutoxy) butyl]-3-methyl-2-oxo-benzimidazol-l-yl]piperidine-2,6-dione (100 mg, 227 umol, HC1, Intermediate OD) in THF (40.0 mL) was added TEA (46.1 mg, 455 umol) and HOAc (41.0 mg, 683 umol). The mixture was stirred at 20 °C for 0.5 hr, then $NaBH(OAc)_3$ (144 mg, 683 umol) was added. The mixture was stirred at 20 °C for 16 hrs. On completion, the mixture was


diluted with H_20 (2 mL) and concentrated in *vacuo.* The mixture was purified by reverse phase column (0. 1% FA) to give the title compound (60.0 mg, 27% yield) as yellow solid. LC-MS (ESI^+) *m/z* 953.4 $(M+H)^+$.

[005433] Step 7 - N-[3-(difluoromethyl)-l-[4-[[4-[4-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl1butoxy1butylamino1methyl1phenyl1pyrazol-4-yl1-5-piperazin-l-yl-pyrazolorl.5-a1pyrimidine-3-carboxamide **(1-441)**

[005434] To a solution of tert-butyl 4-[3-[[3-(difluoromethyl)-l-[4-[[4-[4-[l-(2,6-dioxo-3-piperidyl)-3- methyl-2-oxo-benzimidazol-5-yl]butoxy]butylamino]methyl]phenyl]pyrazol-4-yl]carbamoyl]pyrazolo[l,5-a]pyrimidin-5-yl]piperazine-l-carboxylate (60.0 mg, 62.9 umol) in DCM (3.00 mL) was added HCl/dioxane (4.00 M, 5.00 mL). The mixture was stirred at 20 °C for 0.5 hr. On completion, the mixture was concentrated in *vacuo.* The mixture was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]; B%: 8%-32%, 8 min) to give the title compound (31.2 mg, 54% yield) as white solid. ^1H NMR (400MHz, DMSO-^e) δ 11.00 (s, 1H), 9.51 (s, 1H), 9.01 (s, 1H), 8.80 (d, *J* = 8.0 Hz, 1H), 8.32 (s, 1H), 8.28 (s, 1H), 7.83 (d, *J* = 8.4 Hz, 2H), 7.54 (d, *J* = 8.4 Hz, 2H), 7.29 (t, *J* = 53.6 Hz, 1H), 7.04 - 6.96 (m, 2H), 6.92 (d, *J* = 8.0 Hz, 1H), 6.86 (d, *J* = 8.0 Hz, 1H), 5.42 - 5.26 (m, 1H), 3.90 - 3.86 (m, 4H), 3.67 - 3.54 (m, 4H), 3.40 - 3.33 (m, 4H), 3.31 (s, 3H), 2.88 (s, 4H), 2.75 - 2.70 (m, 1H), 2.70 - 2.65 (m, 2H), 2.65 - 2.61 (m, 1H), 2.61 - 2.59 (m, 1H), 2.05 - 1.95 (m, 1H), 1.66 - 1.48 (m, 8H); LC-MS (ESI^+) *m/z* 853.3 $(M+H)^+$.

[005435] Example 437: 3-[3-Methyl-2-oxo-4-[3-[2-[2-[2-[2-[[4-[(5-tetrahydropyran-4-yl-7H-pyrrolo[2.,3-dl pyrimidin-4-yBamino1cyclohexyl1amino1ethoxy1ethoxy1ethoxy1ethoxy]propyl1benzimidazol-l-yl]piperidine-2,6-dione (l -442)


SEMCl, NaH, DMF
Na2CO3, ACN
Berttphos-Pd-G3, K2CO3 THF
Pd/C, H2, MeOH
HCl/dioxane, DCM
LiOH•H2O
THF/H2O



[005436] **Step 1 - 2-r(5-Bromo-4-chloro-Dyrrolor2.3-dlDyrimidin-7-yl)methoxy1 ethyl-trimethyl-silane *(2)***

[005437] NaH (2.1 g, 52.5 mmol, 60% purity) was suspended in dimethylformamide (50 mL). The mixture was stirred for 10 min and then cooled at 0 °C with an ice bath. 5-bromo-4-chloro-7H-pyrrolo[2,3-d] pyrimidine (10 g, 43.0 mmol) dissolved in dimethylformamide (50 mL) was added drop-wise and the mixture was stirred for 30 min. At the same temperature 2-(chloromethoxy)ethyl-trimethyl-silane (9.00 g, 53.9 mmol, 9.55 mL) dissolved in dimethylformamide (50 mL) was added drop-wise and stirred for 30 min at 0 °C. On completed,

the mixture was quenched with water (30 mL), extracted with ethyl acetate (3 X 30 mL). The combined organic layers was washed with brine (2 X 10 mL), dried over anhydrous sodium sulfate, filtered and concentrated in *vacuo.* The reaction mixture was purified by silica gel chromatography (PE: EA= 30: 1) to give the title compound (13.2 g, 85% yield) as a white solid. ^{1}H NMR (400MHz, CD_3OD) δ 8.71 - 8.50 (m, 1H), 7.81 (s, 1H), 5.67 (s, 2H), 3.69 - 3.54 (m, 2H), 0.94 - 0.83 (m, 3H), -0.06 (s, 9H), LC-MS (ESI^+) *m/z* 361.9 $(M+H)^+$.

[005438] Step 2 - Tert-butyl N-[4-[[5-bromo-7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-d]pyrimidin-4-yl] aminolcyclohexyllcarbamate (4)

[005439] To a solution of 2-[(5-bromo-4-chloro-pyrrolo[2,3-d]pyrimidin-7-yl)methoxy]ethyl-trimethyl-silane (1 g, 2.76 mmol) and tert-butyl N-(4-aminocyclohexyl)carbamate (591 mg, 2.76 mmol, CAS# 177906-48-8) in ACN (20 mL) was added Na_2C0_3 (585 mg, 5.52 mmol). The reaction mixture was stirred at 80 °C for 12 hrs. On completion, the reaction mixture was filtered and concentrated in *vacuo.* The crude product was triturated with ethyl acetate (10 mL) to give the title compound (1.48 g, 95% yield) as a white solid. ^{1}H NMR (400MHz, CDCb) δ 8.33 (s, 1H), 7.06 (s, 1H), 5.91 (d, *J* = 7.2 Hz, 1H), 5.52 (s, 2H), 4.45 (s, 1H), 4.14 (d, *J* = 7.2 Hz, 1H), 3.60 - 3.46 (m, 3H), 2.25 (d, *J* = 9.8 Hz, 2H), 2.16 - 2.05 (m, 2H), 1.47 (s, 9H), 1.44 - 1.34 (m, 4H), 0.98 - 0.86 (m, 2H), -0.03 (s, 9H). LC-MS (ESI^+) *m/z* 540.1; 542.l(M+H, M+3)$^+$.

[005440] Step 3 - Tert-butyl N-[4-[[5-(3,6-dihydro-2H-pyran-4-yl)-7-(2-trimethylsilylethoxymethyl)pyrrolo [2,3-d]pyrimidin-4-yl]amino1cyclohexyl1carbamate (6)

[005441] A mixture of tert-butyl N-[4-[[5-bromo-7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-d]pyrimidin-4-yl] amino]cyclohexyl]carbamate (1.34 g, 2.48 mmol), 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl- l,3,2-dioxaborolane (1.56 g, 7.44 mmol, CAS# 287944-16-5), Berttphos-Pd-Gs (224 mg, 247 umol, CAS# 1470372-59-8) and K_2CO_3 (685 mg, 4.96 mmol) in a mixed solvent of THF (20 mL) and H_20 (4 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 55 °C for 3 hrs under N_2 atmosphere. On completion, the reaction mixture was concentrated in *vacuo.* The residue was washed with ethyl acetate (50 mL). After, the organic layer was concentrated in *vacuo.* The crude product was purified by reversed-phase HPLC (0.1% FA condition) to give the title compound (1.06 g, 78% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-r¾) δ 8.28 (s, 1H), 7.44 (s, 1H), 6.81 (d, *j* = 7.6 Hz, 1H), 5.89 (s, 1H), 5.68 (d, *j* = 7.6 Hz, 1H), 5.55 (s, 2H), 4.32 (d, *j* = 2.0 Hz,

2H), 4.04 (s, 1H), 3.92 (t, *J* = 5.2 Hz, 2H), 3.58 (t, *J* = 8.0 Hz, 2H), 3.37 - 3.30 (m, 1H), 2.52 (s, 2H), 2.10 *(d, J* = 8.0 Hz, 2H), 1.90 (s, 2H), 1.46 (s, 9H), 1.45 - 1.36 (m, 4H), 0.90 (t, *J* = 8.0 Hz, 2H), 0.00 (s, 9H); LC-MS (ESI^+) *m/z* 544.4 $(M+H)^+$.

[005442] Step 4 - Tert-butyl N-r4-IT5-tetrahvdiOPyran-4-yl-7-(2-trimethylsilylethoxymethvnpyrrolor2.3-d1 pyrimidin-4-yl1amino1cvclohexyl1carbamate (7)

[005443] To a solution of tert-butyl N-[4-[[5-(3,6-dihydro-2H-pyran-4-yl)-7-(2-trimethylsilylethoxymethyl) pyrrolo[2,3-d]pyrimidin-4-yl]amino]cyclohexyl]carbamate (1.06 g, 1.95 mmol) in methanol (5 mL) was added Pd/C (100 mg, 163 umol, 10%, *wf)* under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 20 °C for 36 hrs. On completion, the mixture was filtered and the filtrate was concentrated in *vacuo* to give the title compound (1.00 g, 94% yield) as a white solid. ^1H NMR (400MHz, DMSO-$i\ell_6$) δ 8.23 (s, 1H), 7.12 (s, 1H), 6.83 (d, *j* = 7.6 Hz, 1H), 5.81 (d, *J* = 7.6 Hz, 1H), 5.52 (s, 2H), 4.13 (d, *j* = 7.6 Hz, 1H), 4.00 (dd, *j* = 2.8, 11.2 Hz, 2H), 3.65 (t, *j* = 11.2 Hz, 2H), 3.56 (t, *J* = 8.0 Hz, 2H), 3.38 - 3.32 (m, 1H), 2.04 (d, *J* = 10.8 Hz, 2H), 1.98 - 1.92 (m, 3H), 1.70 - 1.54 (m, 4H), 1.48 (s, 9H), 1.46 - 1.27 (m, 4H), 0.91 - 0.83 (m, 2H), 0.00 (s, 9H); LC-MS (ESI^+) *m/z* 546.4 $(M+H)^+$.

[005444] Step 5 - r4-r(4-Aminocvclohexyl)aminol-5-tetrah vdropyran-4-yl -pyrrol o[2,3-dlpyrimidin-7- vl] methanol (8)

[005445] To a solution of tert-butyl N-[4-[[5-tetrahydropyran-4-yl-7-(2-trimethylsilylethoxymethyl)pyrrolo [2,3-d]pyrimidin-4-yl]amino]cyclohexyl]carbamate (1.00 g, 1.83 mmol) in DCM (20 mL) was added HCl/dioxane (4 M, 30 mL). The reaction mixture was stirred at 20 °C for 12 hrs. On completion, the reaction mixture was concentrated in vacuo to give the title compound (633 mg, 100% yield) as a white solid. LC-MS (ESI^+) *m/z* 346.2 $(M+H)^+$.

[005446] Step 6 - N4-(5-tetrahvdropyran-4-yl-7H-pyrrolor2.3-d1pyrimidin-4-vDcvclohexane-L4-diamine (9)

[005447] To a solution of [4-[(4-aminocyclohexyl)amino]-5-tetrahydropyran-4-yl-pyrrolo[2,3-d]pyrimidin- 7-yl]methanol (633 mg, 1.83 mmol) in a mixed solvent of THF (3 mL), H_20 (1 mL) and MeOH (1 mL) was added $LiOH.H_20$ (384 mg, 9.16 mmol). The reaction mixture was stirred at 20 °C for 12 hrs. On completion, the reaction mixture was acidified with HC1 (2 N) to pH = 2. The reaction mixture was concentrated in vacuo. The crude product was purified by

reversed-phase HPLC (0.1% $NH_3 \cdot H_2O$ condition) to give the title compound (250 mg, 43% yield) was added as a green solid. LC-MS (ESI^+) *m/z* 316.2 $(M+H)^+$.

[005448] Step 7 - 2-r2-r2-(2-Prop-2-vnoxyethoxy)ethoxy1ethoxy1ethanol (12)

[005449] To a mixture of 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethanol (20.0 g, 102 mmol, 17.7 mL) and 3-bromoprop-l-yne (14.7 g, 123 mmol) in THF (200 mL) was added TBAI (2.28 g, 6.18 mmol), KI (2.56 g, 15.45 mmol) and KOH (5.78 g, 102 mmol). The mixture was stirred at 25 °C for 12 hours. On completion, the reaction mixture was filtered and concentrated in *vacuo*. The residue was purified by column chromatography (PE: EA= 5/1 to 0/1) to give the title compound (16.0 g, 67% yield) as a light yellow oil. ^1H NMR (400MHz, CDCb) δ 4.18 (d, *J* = 2.4 Hz, 2H), 3.70 (d, *J* = 4.8 Hz, 2H), 3.67 (d, *J* = 3.2 Hz, 2H), 3.69 - 3.61 (m, 10H), 3.60 - 3.57 (m, 2H), 2.73 (s, 1H), 2.42 (t, *j* = 2.4 Hz, 1H).

[005450] Step 8 - 3-r4-r3-r2-r2-r2-(2-Hvdroxyethoxy)ethoxy1ethoxy1ethoxy1prop-l-ynyl1-3-methyl-2-oxo- benzimidazol-l-yl1piperidine-2.6-dione (14)

[005451] To a mixture of 2-[2-[2-(2-prop-2-ynoxyethoxy)ethoxy]ethoxy]ethanol (1.03 g, 4.44 mmol) and 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (0.50 g, 1.48 mmol, Intermediate HP) in DMSO (20 mL) was added Cul (56.3 mg, 295umol), P(t-Bu)3 (2.30 g, 1.48 mmol, 2.67 mL, 13% purity, a solution of toluene), DIEA (955 mg, 7.39 mmol) and $Pd(PPh_3)_2Cl_2$ (103 mg, 147 umol). The reaction mixture was stirred at 80 °C for 3 hours. On completion, the reaction mixture was diluted with water (60 mL) and extracted with EA (4 X 60 mL). The combined organic layers was dried over Na_2S0_4, filtered and concentrated in *vacuo* to give a residue. The crude product was purified by prep-HPLC (0.1 % FA condition) to give the title compound (0.50 g, 69% yield) as brown oil. ^1H NMR (400MHz, DMSO-T $_i$) 5 = 11.11 (s, 1H), 7.17 (d, *J* = 8.0 Hz, 1H), 7.15 - 7.11 (m, 1H), 7.06 - 7.00 (m, 1H), 5.40 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.55 (t, 7 = 5.2 Hz, 1H), 4.46 (s, 2H), 3.70 - 3.61 (m, 5H), 3.60 - 3.57 (m, 2H), 3.53 - 3.51 (m, 6H), 3.49 - 3.47 (m, 4H), 3.41 - 3.39 (m, 2H), 2.95 - 2.84 (m, 1H), 2.77 - 2.58 (m, 2H), 2.07 - 1.99 (m, 1H).

[005452] Step 9 - 3-r4-r3-r2-r2-r2-(2-Hvdroxyethoxy)ethoxy1ethoxy1ethoxy1propyl1-3-methyl-2-oxo- benzimidazol-l-yl1piperidine-2.6-dione (15)

[005453] To a mixture of 3-[4-[3-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]prop-l-ynyl]-3-methyl-2- oxo-benzimidazol-l-yl]piperidine-2,6-dione (200 mg, 408 umol) in THF (10 mL) was added Pd/C (100 mg, 10% *wi)* and Pd(OH)2/C (100 mg, 10% *wf).* The reaction mixture

was stirred at 25 °C for 12 hours under H_2 (15 Psi) atmosphere. On completion, the reaction mixture was concentrated in *vacuo* to give the title compound (180 mg, 89% yield) as white solid which was used for the next step without purification. 'H NMR (400MHz, DMSO-d«) δ 11.09 (s, 1H), 6.96 (d, *J* = 4.4 Hz, 2H), 6.90 - 6.86 (m, 1H), 5.36 (dd, *J* = 5.2, 12.4 Hz, 1H), 4.57 (t, *J* = 5.2 Hz, 1H), 4.03 (q, *J* = 7.2 Hz, 1H), 3.56 (s, 3H), 3.52 (d, *J* = 5.6 Hz, 10H), 3.48 - 3.45 (m, 4H), 3.40 (d, *J* = 5.2 Hz, 2H), 2.98 - 2.93 (m, 2H), 2.89 - 2.84 (m, 1H), 2.72 - 2.63 (m, 2H), 2.61 - 2.58 (m, 2H), 2.02 - 1.96 (m, 2H), 1.85 - 1.81 (m, 1H); LC-MS (ESI^+) *m/z* 494.3 $(M+H)^+$.

[005454] Step 10 - 2-r2-r2-r2-r3-rl-(2.6-Dioxo-3-piperidvD-3-methyl-2-oxo-benzimidazol-4-vHpropoxylethoxyl ethoxylethoxylacetaldehvde (16)


[005455] To a mixture of 3-[4-[3-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]propyl]-3-methyl-2-oxo- benzimidazol-l-yl]piperidine-2,6-dione (180 mg, 364 umol) in THF (20 mL) was added DMP (309 mg, 729 umol). The reaction mixture was stirred at 25 °C for 1.5 hours. On completion, the reaction mixture was quenched by saturated $Na_2S_2O_3$ (15 mL) and saturated $NaHCO_3$ (15 mL) at 25 °C, and then stirred for 30 minutes, then the organic layers were separated and concentrated in *vacuo* to give the title compound (179 mg, 100% yield) as a red oil. ^1H NMR (400MHz, DMSO-di) δ 11.07 (s, 1H), 9.56 (s, 1H), 6.96 *(d, J* = 8.8 Hz, 2H), 6.88 (d, *J* = 8.8 Hz, 1H), 5.41 - 5.31 (m, 1H), 4.16 (s, 2H), 3.60 - 3.43 (m, 15H), 3.01 - 2.92 (m, 2H), 2.90 - 2.84 (m, 1H), 2.74 - 2.54 (m, 4H), 2.04 - 1.96 (m, 1H), 1.85 - 1.81 (m, 2H). LC-MS (ESI^+) *m/z* 492.3 $(M+H)^+$.

[005456] Step 11 - 3-[3-Methyl-2-oxo-4-[3-[2-[2-[2-[2-[[4-[(5-tetrahvdropyran-4-yl-7H-pyrrolor2.3-d1 pyrimidin-4-vOaminolcvclohexyllaminolethoxylethoxylethoxylethoxylpropyllbenzimidazol-l-yllpiperidine-2.6-dione **(1-4423**

[005457] To a solution of N4-(5-tetrahydropyran-4-yl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)cyclohexane- 1,4-diamine (50.0 mg, 158 umol) and 2-[2-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo- benzimidazol-4-yl]propoxy]ethoxy]ethoxy]ethoxy]acetaldehyde (77.9 mg, 158 umol) in a mixed solvent of THF (5 mL) and DMF (1 mL) was added HOAc (9.52 mg, 158. umol) and $NaBH(OAc)_3$ (40.3 mg, 190 umol). The reaction mixture was stirred at 20 °C for 12 hrs. On completion, the reaction mixture was concentrated in *vacuo.* The crude product was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225%FA)-ACN]; B%: 13%-31%, 6 min) to give the title compound (11.0 mg, 8% yield) as

white solid. ^{1}H NMR (400MHz, DMSO-r¾) δ 11.35 (s, 2H), 8.35 (s, 1H), 8.08 (s, 1H), 7.05 - 6.80 (m, 4H), 5.60 (d, *J* = 7.6 Hz, 1H), 5.36 (dd, *J* = 4.8, 12.0 Hz, 1H), 4.05 (s, 1H), 3.90 (d, *J* = 8.4 Hz, 2H), 3.59 - 3.49 (m, 20H), 3.45 (t, *J* = 5.6 Hz, 2H), 3.26 - 3.21 (m, 1H), 3.01 - 2.91 (m, 4H), 2.90 - 2.84 (m, 1H), 2.76 - 2.67 (m, 1H), 2.62 (m, 1H), 2.13 - 1.78 (m, 9H), 1.60 - 1.34 (m, 6H). LC-MS (ESI$^+$) *m/z* 791.5 (M+H)$^+$.

[005458] **Example 438: 3-[3-Methyl-2-oxo-4-[3-[2-[2-[2-[2-oxo-2-[4-[4-[(5-tetrahydropyran-4-yl-7H-pyrrolo[2.,3-dl pyrimidin-4-vPaminol cvclohexyl] piperazin-1-yl] ethoxyl ethoxyl ethoxyl ethoxyl propyll benzimidazol- 1-yll piperidine-2,6-dione (I-444)**



[005459] Step 1 - Tert-butyl 2-r2-r2-r2-r3-rl-(2.6-dioxo-3-piperidv0-3-methyl-2-oxo-benzimidazol-4-yl1prop-2- ynoxy] ethoxy] ethoxy] ethoxy] acetate (3)

[005460] To a mixture of 3-(4-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (600 mg, 1.77 mmol, Intermediate HP), tert-butyl 2-[2-[2-(2-prop-2-ynoxyethoxy)ethoxy] ethoxy] acetate (1.07 g, 3.55 mmol, from Example 441) in DMF (10 mL) was added Cul (67.6 mg, 355 umol), CS2CO3 (2.89 g, 8.87 mmol) and Pd(PPh3)$_2$Cl2 (249 mg, 355 umol) under N_2. The reaction mixture was stirred at 80 °C for 3 hours. On completion, the mixture

was poured into water (30 mL). The aqueous phase was extracted with ethyl acetate (2 X 30 mL).The combined organic phase was washed with brine (2 X 30mL), dried with anhydrous Na_2SO_4, filtered and concentrated in *vacuo* to give a residue. The residue was purified by reversed-phase (0.1% FA condition) to give the title compound (598 mg, 60% yield) as brown oil. ^1H NMR (400MHz, CDCh) δ 8.29 (s, 1H), 7.16 (d, *J* = 7.6 Hz, 1H), 6.97 (t, *j* = 8.0 Hz, 1H), 6.75 *(d, J* = 8.0 Hz, 1H), 5.23 - 5.15 (m, 1H), 4.46 (s, 2H), 4.01 (s, 2H), 3.76 (s, 3H), 3.76 - 3.66 (m, 12H), 2.99 - 2.68 (m, 3H), 2.29 - 2.16 (m, 1H), 1.46 (s, 9H).

[005461] Step 2 - Tert-butyl 2-[2-[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl] propoxyl ethoxy] ethoxy] ethoxy] acetate (4)

[005462] To a solution of tert-butyl 2-[2-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol- 4-yl]prop-2-ynoxy]ethoxy]ethoxy]ethoxy]acetate (578 mg, 1.03 mmol) in THF (5 mL) was added Pd/C (100 mg, 20% purity) and $Pd(OH)_2/C$ (100 mg, 20% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 3 times. The mixture was stirred at 20 °C for 12 hours under H_2 (15 psi). On completion, the mixture was concentrated in *vacuo* to give a title compound (540 mg, 92% yield) as brown oil. LC-MS (ESI^+) *m/z* 586.3 $(M+Na)^+$.

[005463] Step 3 - 2-[2-[2-[2-[3-[1-(2,6-Dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yllpropoxylethoxyl ethoxy] ethoxy] acetic acid (5)


[005464] To a mixture of tert-butyl 2-[2-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4- yl]propoxy] ethoxy] ethoxy] ethoxy] acetate (520 mg, 922 umol) in DCM (2 mL) was added TFA (210 mg, 1.85 mmol). The reaction mixture was stirred at 20 °C for 1 hour. On completion, the mixture was concentrated in *vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (436 mg, 93% yield) as brown oil. LC-MS (ESI^+) *m/z* 508.3 $(M+H)^+$.

[005465] Step 4 - 3-r3-Methyl-2-oxo-4-r3-r2-r2-r2-r2-oxo-2-r4-r4-r(5-tetrahvdropyran-4-yl-7H-pyrrolor2.3-d1 pyrimidin-4-vOaminolcvclohexynpiperazin-l-yllethoxylethoxylethoxylethoxylpropyllbenzimidazol- 1-yllpi peri dine-2.6-di one **(1-444)**

[005466] To a mixture of 2-[2-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]propoxy] ethoxy] ethoxy] ethoxy] acetic acid (39.6 mg, 78.0 umol), N-(4-piperazin-l-ylcyclohexyl)-5-tetra hydropyran-4-yl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (30.0 mg, 78.0 umol, Intermediate OP) in DMF (1.5 mL) was added DIEA (30.2 mg, 234 umol) and

HATU (35.6 mg, 93.6 umol). The reaction mixture was stirred at 20 °C for 1 hr. On completion, water (1.5 mL) was added into the reaction mixture and the mixture was concentrated in *vacuo* to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.05% HCl)-ACN]; B%: 7%-27%) to give the title compound (2.00 mg, 2% yield) as a white solid. ¾ NMR (400MHz, DMSO-d_6) δ 11.08 (s, 1H), 9.07 (s, 1H), 8.10 (s, 1H), 7.07 - 6.80 (m, 4H), 5.36 (d, J = 5.2, 12.4 Hz, 1H), 4.18 (s, 2H), 3.90 (d, J = 10.4 Hz, 2H), 3.66 - 3.50 (m, 22H), 3.48 - 3.40 (m, 6H), 3.17 - 3.06 (m, 4H), 3.00 - 2.83 (m, 5H), 2.75 - 2.56 (m, 3H), 2.25 - 1.94 (m, 4H), 1.84 *(d, J* = 8.0 Hz, 4H), 1.60 - 1.46 (m, 4H); LC-MS (ESI$^+$) *m/z* 874.5 (M+H) $^+$.

[005467] Example 439: N-[3-fdifluoromethvB-l-[4-[4-[4-[l-f2,6-dioxo-3-piperidvB-3-methyl-2-oxo-benzimidazol-5-yl]butoxy]butylcarbamoyl]phenyl]pyrazol-4-yl]-5-piperazin-l-yl-pyrazolo[l,5-a]pyrimidine-3-carboxamide (1-445)




[005468] Step 1 - Tert-butyl 4-r3-rr3-(difluoromethvO-l-r4-r4-r4-rl-(2.6-dioxo-3-piperidvO-3-methyl -2-oxo-_ benzimidazol-5-yl1butoxy1butylcarbamoyl1phenyl1pyrazol-4-yllcarbamoyllDyrazolon .5-a1pyrimidin-5-yl1piperazine- l-carboxyl ate (3)

[005469] To a solution of 4-[4-[[5-(4-tert-butoxycarbonylpiperazin-l-yl)pyrazolo[l,5-a]pyrimidine-3 -carbonyl] amino]-3-(difluoromethyl)pyrazol-l-yl]benzoic acid (66.3 mg, 113 umol, from Example 436), 3-[5-[4- (4-aminobutoxy)butyl]-3-methyl-2-oxobenzimidazol-l-yl]piperidine-2,6-dione (50.0 mg, 113 umol, HC1, Intermediate OD) in DMF (3.00 mL) was added HATU (51.9 mg, 136 umol) and DIEA (73.6 mg, 569 umol). The mixture was stirred at 20 °C for 0.5 hr. On completion, the mixture was diluted with H_20 (15 mL), filtered and the filter cake was concentrated in *vacuo* to give the title compound (90.0 mg, 81% yield) as yellow solid. LC-MS (ESI^+) *m/z* 967.4 $(M+H)^+$.

[005470] Step 2 - N-[3-(difluoromethvl)-l-[4-[4-[4-[l-(2,6-dioxo-3-piperidvl)-3-methyl-2-oxo-benzimidazol-5-yl1butoxy1butylcarbamoyl1phenyl1pyrazol-4-yl1-5-piperazin-l-yl-pyrazolorE5-a1pyrimidine-3-carboxamide **(1-445)**

[005471] To a solution of tert-butyl 4-[3-[[3-(difluoromethyl)-l-[4-[4-[4-[l-(2,6-dioxo-3-piperidyl)-3 -methyl -2- oxo-benzimidazol-5-yl]butoxy]butylcarbamoyl]phenyl]pyrazol-4-yl]carbamoyl]pyrazolo[l,5-a]pyrimidin-5-yl]piperazine-l-carboxylate (150 mg, 155 umol) in DCM (5.00 mL) was added HCl/dioxane (4 M, 7.50 mL). The mixture was stirred at 20 °C for 0.5 hr. On completion, the mixture was concentrated in *vacuo*. The mixture was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]; B%: 17%-41%, 8 min) to give the title compound (67.5 mg, 49% yield) as off-white solid. ^1H NMR (400MHz, DMSO-^e) δ 11.07 (s, 1H), 9.53 (s, 1H), 9.10 (s, 1H), 8.79 (d, *J* = 8.0 Hz, 1H), 8.56 (t, *J* = 5.6 Hz, 1H), 8.32 (s, 1H), 8.26 (s, 1H), 8.04 - 7.98 (m, 2H), 7.97 - 7.92 (m, 2H), 7.31 (t, *J* = 5.6 Hz, 1H), 7.02 (s, 1H), 7.00 (d, *J* = 8.0 Hz, 1H), 6.91 (d, *J* = 8.0 Hz, 1H), 6.88 - 6.83 (m, 1H), 5.37 - 5.28 (m, 1H), 3.77 - 3.70 (m, 4H), 3.33 - 3.29 (m, 9H), 2.93 - 2.88 (m, 1H), 2.86 - 2.83 (m, 4H), 2.75 - 2.68 (m, 1H), 2.65 - 2.62 (m, 2H), 2.61 - 2.57 (m, 1H), 2.06 - 1.97 (m, 1H), 1.64 - 1.52 (m, 8H); LC-MS (ESI^+) *m/z* 867.3 $(M+H)^+$.

[005472] **Example 440: N-[3-[difluoromethvB-l-[4-[[2-[2-[3-[l-[2,6-dioxo-3-piperidvB-3-methyl-2-oxo- benzimidazol-4-yl] propoxy] ethoxy] ethylamino] methyl] phenyl] pyrazol-4-yl]-5-piperazin-l-yl-pyrazolo[l.,5-a1pyrimidine-3-carboxamide (1-446)**




[005473] Step 1 - Tert-butyl 4-[3-[[3-(difluoromethyl)-1-[4-[[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]propoxy]ethoxy]ethylamino]methyl]phenyl]pyrazol-4-yl]carbamoyl]pyrazolo[1,5-a]pyrimidin-5-yl]piperazine-1-carboxylate (3)

[005474] To a solution of tert-butyl 4-[3-[[3-(difluoromethyl)-1-(4-formylphenyl)pyrazol-4-yl]carbamoyl] pyrazolo[1,5-a]pyrimidin-5-yl]piperazine-1-carboxylate (128 mg, 226 umol, from Example 436), 3-[4-[3-[2-(2-aminoethoxy)ethoxy]propyl]-3-methyl-2-oxobenzimidazol-1-yl]piperidine-2,6-dione (100 mg, 226 umol, HC1, from Intermediate IQ) in THF (20.0 mL) was added TEA (45.9 mg, 453 umol) and HOAc (40.8 mg, 680 umol). The mixture was stirred at 20 °C for 0.5 hr, then $NaBH(OAc)_3$ (144 mg, 680 umol) was added. The mixture was stirred at 20 °C for 16 hrs. On completion, the mixture was diluted with H_20 (2.00 mL). The mixture was concentrated in *vacuo.* The mixture was purified by reverse phase column (0.1% FA) to give the title compound (180 mg, 83% yield) as yellow solid. LC-MS (ESI^+) *m/z* 955.3 $(M+H)^+$.

[005475] Step 2 - N-[3-(difluoiOmethvl)-l-[4-II2-[2-[3-[l-(2,6-dioxo-3-piperidvl)-3-methyl-2-oxo- benzimidazol-4-yl1propoxy1ethoxy1ethylamino1methyl1phenyl1pyrazol-4-yl1-5-piperazin-l-yl-pyrazolorl.5-a1pyrimidine-3-carboxamide **(1-446)**

[005476] To a solution of tert-butyl 4-[3-[[3-(difluoromethyl)-l-[4-[[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3- methyl -2-oxo-benzimidazol -4-yl]propoxy]ethoxy]ethylamino]methyl]phenyl]pyrazol-4-yl]carbamoyl]pyrazolo[l,5-a]pyrimidin-5-yl]piperazine-l-carboxylate(l80 mg, 188 umol) in DCM (2 mL) was added HCl/dioxane (4 M, 6 mL). The mixture was stirred at 20 °C for 0.5 hr. On completion, the mixture was concentrated in *vacuo*. The mixture was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]; B%: l2%-33%, 7 min) to give the title compound (89.5 mg, 53% yield) as white solid. ^{1}H NMR (400MHz, DMSO-rL) δ 11.10 (s, 1H), 9.50 (s, 1H), 9.50 (s, 1H), 8.98 (s, 1H), 8.82 (d, *J* = 8.0 Hz, 1H), 8.33 (s, 1H), 8.23 (s, 1H), 7.79 (d, *J* = 8.4 Hz, 2H), 7.5 1 (d, *J* = 8.4 Hz, 2H), 7.29 (t, *j* = 54 Hz, 1H), 6.95 (d, *J* = 6.4 Hz, 2H), 6.92 (s, 1H), 6.88 - 6.83 (m, 1H), 5.43 - 5.29 (m, 1H), 3.89 (s, 3H), 3.84 (s, 4H), 3.59 - 3.54 (m, 8H), 3.49 - 3.44 (m, 2H), 2.94 (s, 4H), 2.94 - 2.91 (m, 2H), 2.91 - 2.85 (m, 1H), 2.83 - 2.77 (m, 2H), 2.76 - 2.66 (m, 1H), 2.66 - 2.58 (m, 1H), 2.04 - 1.94 (m, 1H), 1.89 - 1.76 (m, 2H); LC-MS (ESI$^+$) *m/z* 855.5 $(M+H)^+$.

[005477] **Example 441 : 3-[3-Methyl-2-oxo-5-[3-[2-[2-[2-[2-oxo-2-14-[4-K5-tetrahvdropyran-4-yl-7H-pyr rolo[2,3-_ dlpyrimidin-4-vDaminol cvclohexyll piperazin-1-yll ethoxyl ethoxyl ethoxyl ethoxyl propyll benzimidazol- 1-yll piperidine-2.,6-dione (1-447)**



[005478] Step 1 - 2-r2-(2-Prop-2-vnoxyethoxy)ethoxy1ethanol (3)

[005479] To a solution of 2-[2-(2-hydroxyethoxy)ethoxy] ethanol (10.0 g, 66.5 mmol, 8.93 mL, CAS#l 12-27-6) and 3-bromoprop-l-yne (7.92 g, 66.5 mmol, 5.74 mL, CAS#l06-96-7) in THF (100 mL) was added KI (1.66 g, 9.99 mmol), TBAI (1.48 g, 4.00 mmol) and KOH (3.74 g, 66.5 mmol). The reaction mixture was stirred at 25 °C for 16 hrs. On completion, the mixture was filtered, and the filtrate was concentrated *in vacuo* to give a residue, the residue was diluted with H_20 (50 mL), and then extracted with EA (2 X 80 mL), the organic phase was concentrated *in vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (10.0 g, 79% yield) as yellow oil. ^{1}H NMR (400MHz, CDCh) δ 4.19 - 4.12 (m, 2H), 3.74 - 3.57 (m, 10H), 3.57 - 3.52 (m, 2H), 2.42 (s, 1H), 2.38 (t, J = 2.4 Hz, 1H).

[005480] Step 2 - Tert-butyl 2-r2-r2-(2-prop-2-vnoxyethoxy)ethoxy1ethoxy1acetate (5)

[005481] To a solution of 2-[2-(2-prop-2-ynoxyethoxy)ethoxy] ethanol (4.0 g, 21.25 mmol) in THF (50 mL) was added NaH (1.28 g, 31.8 mmol, 60% purity) at 0 °C, the mixture was stirred at 25 °C for 30 min, then tert-butyl 2-chloroacetate (6.40 g, 42.5 mmol, 6.10 mL, CAS#l07-59-5) was added to the mixture, the reaction mixture was stirred at 25 °C for 12 hrs. On completion, the mixture was quenched by H_20 (50 mL), and extracted with EA (2 X 100 mL). The organic phase was concentrated in *vacuo* to give a residue. The residue was purified by column chromatography to give the title compound (3.60 g, 56% yield) as yellow oil. ^{1}H NMR (400MHz, CDCh) δ 4.20 (d, *J* = 2.4 Hz, 2H), 4.01 (s, 2H), 3.72 - 3.65 (m, 12H), 2.42 (t, *J* = 2.4 Hz, 1H), 1.47 (s, 9H).

[005482] Step 3 - Tert-butyl 2-[2-[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl1prop-2- ynoxy]ethoxy] ethoxy] ethoxy] acetate (6)

[005483] To a solution of tert-butyl 2-[2-[2-(2-prop-2-ynoxyethoxy)ethoxy]ethoxy]acetate (1.16 g, 3.84 mmol) and 3-(5-bromo-3-methyl-2-oxo-benzimidazol-l-yl)piperidine-2,6-dione (650 mg, 1.92 mmol, Intermediate HN) in DMF (10 mL) was added CuI (73.2 mg, 384 umol), $Pd(PPh_3)_2Cl_2$ (269 mg, 384 umol) and Cs_2C0_3 (3.13 g, 9.61 mmol). The reaction mixture was stirred at 80 °C for 2 hrs under N_2. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (550 mg, 51% yield) as a yellow solid. ^{1}H NMR (400MHz, DMSO-i¾) δ 11.11 (s, 1H), 7.33 (s, 1H), 7.21 - 7.09 (m, 2H), 5.39 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.39 (s, 2H), 3.97 (s, 2H), 3.68 - 3.61 (m, 2H), 3.59 - 3.52 (m, 10H), 3.34 (s, 3H), 2.97 - 2.82 (m, 1H), 2.76 - 2.57 (m, 2H), 2.06 - 2.00 (m, 1H), 1.41 (s, 9H); LC-MS (ESI^+) m/z 582.3 $(M+Na)^+$.

[005484] Step 4 - Tert-butyl 2-[2-[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5- yl] propoxy] ethoxy] ethoxy] ethoxy] acetate (7)

[005485] To a solution of tert-butyl 2-[2-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]prop -2-ynoxy] ethoxy] ethoxy] ethoxy] acetate (550 mg, 982 umol) in THF (20 mL) was added $Pd(OH)_2$/C (250 mg, 915 umol, 10% purity) and Pd/C (250 mg, 915 umol, 10% purity), the reaction mixture was stirred at 25 °C for 12 hrs under H_2 (15 Psi). On completion, the residue was filtered and the filtrate was concentrated *in vacuo* to give the title compound (500 mg, 90% yield) as a white solid. LC-MS (ESI^+) m/z 508.2 $(M + H-56)^+$.

[005486] Step 5 - 2-[2-[2-[2-[3-[1-(2,6-Dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yllpropoxylethoxyl ethoxy] ethoxy] acetic acid

[005487] To a solution of tert-butyl 2-[2-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl] propoxy] ethoxy] ethoxy] acetate (100 mg, 177 umol)in DCM (3 mL) was added TFA (1.54 g, 13.5 mmol, 1 mL), the reaction mixture was stirred at 25 °C for 12 hrs. On completion, the mixture was concentrated *in vacuo* to give the title compound (110 mg, 95% yield) as colorless oil. LC-MS (ESI^+) m/z 508.3 $(M+H)^+$.

[005488] Step 6 - 3-r3-Methyl-2-oxo-5-r3-r2-r2-r2-r2-oxo-2-r4-r4-r(5-tetrahydropyran-4-yl-7H-pyrrolo[2,3-d1pyrimidin-4-yl)amino1cyclohexyl1piperazin-l-yllethoxylethoxylethoxylethoxylpropyllbenzimidazol-l-yl]piperidine-2.6-dione (1-447)

[005489] To a solution of 2-[2-[2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]propoxy] ethoxy] ethoxy] acetic acid (15.0 mg, 24.1 umol) and N-(4-piperazin-l-ylcyclohexyl)-5-tetrahydropyran-4-yl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9.28 mg, 24.1 umol, Intermediate OP) in DMF (5 mL) was DIPEA (15.5 mg, 120 umol, 21.0 uL) and HATU (11.0 mg, 28.9 umol). The mixture was stirred at 25 °C for 1.5 hrs. On completion, the mixture was quenched with $E[_2O$ (5 mL), then concentrated in *vacuo* to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 l50*25*l0um; mobile phase: [water (0.225%FA)-ACN]; B%: 8%-32%, 8 min) to give the title compound (6.09 mg, 28% yield) as a white solid. ¾ NMR (400MHz, DMSO-d_6) δ 11.29 (s, 1H), 11.07 (s, 1H), 8.06 (s, 1H), 7.05 - 6.96 (m, 2H), 6.92 - 6.78 (m, 2H), 5.51 (d, J = 8.0 Hz, 1H), 5.32 (dd, J = 5.2, 12.8 Hz, 1H), 4.12 (s, 2H), 4.08 - 3.98 (m, 1H), 3.94 - 3.85 (m, 2H), 3.61 - 3.45 (m, 18H), 3.31 (s, 3H), 3.29 - 3.18 (m, 3H), 2.92 - 2.84 (m, 1H), 2.71 - 2.57 (m, 4H), 2.49 - 2.39 (m, 4H), 2.36 - 2.28 (m, 1H), , 2.07 - 1.94 (m, 3H), 1.89 - 1.69 (m, 6H), 1.63 - 1.28 (m, 6H); LC-MS (ESI+) m/z 874.5 $(M+H)^+$.

[005490] **Table 23: Compounds synthesized via Method 12 with the coupling of various amines and acids in Step 1.**

Ex-#[a]	I-#	Step 1 Intermediate Amine	Step 1 Intermediate Acid	LCMS (ES+) m/z $(M+H)^+$	^{1}HNMR (400MHz, DMSO-d_6) δ

443	**I-448**	UD	OM	928.6	11.05 (s, 1H), 10.98 (s, 1H), 8.99 (s, 1H), 8.95 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.05 - 7.98 (m, 3H), 7.74 (s, 1H), 7.64 (d, *J* = 8.0 Hz, 2H), 7.18 - 7.10 (m, 2H), 7.02 - 6.95 (m, 3H), 6.83 (d, *J* = 8.0 Hz, 1H), 5.35 - 5.27 (m, 1H), 4.65 - 4.55 (m, 1H), 4.36 (s, 1H), 3.52 - 3.45 (m, 8H), 3.29 (s, 3H), 3.21 - 3.17 (m, 2H), 2.91 - 2.80 (m, 2H), 2.68 - 2.61 (m, 5H), 2.03 - 1.94 (m, 1H), 1.85 - 1.74 (m, 2H), 0.50 - 0.42 (m, 2H), 0.27 - 0.20 (m, 2H)
444	**I-449**	UE	KR	929.1	11.09 (s, 1H), 10.82 (s, 1H), 9.02 (s, 1H), 8.44-8.38 (m, 2H), 8.25-8.23 (m, 2H), 7.56(dd, *J* = 7.2 Hz, *J* = 8.4 Hz, 1H), 7.41 (s, 1H), 7.25 (d, *J* = 5.6 Hz, 1H), 7.11 (d, *J* = 8.4 Hz, 1H), 7.01 (d, *J* = 6.8 Hz, 1H), 6.58 (bs, 1H), 5.06-5.03 (m, 1H), 4.37-4.36 (m, 2H), 3.93-3.91 (m, 6H), 3.53-3.44 (m, 22H), 2.88 (m, 1H), 2.60-2.54 (m, 2H), 2.03-2.01 (m, 1H)
450	**I-455**	UX	KR	885.4	11.07 (s, 1H), 10.81 (s, 1H), 8.97 (s, 1H), 8.46 (s, 1H), 8.38 (s, 1H), 8.26 - 8.21 (m, 2H), 7.69 (t, *J* = 5.6 Hz, 1H), 7.25 (s, 1H), 7.16 (d, *J* = 5.2 Hz, 1H), 6.94 (d, *J* = 5.6 Hz, 1H), 6.84 (d, *J* = 8.8 Hz, 1H), 5.41 - 5.30 (m, 1H), 4.27 - 4.21 (m, 2H), 3.93 (s, 3H), 3.55 - 3.41 (m, 21H), 2.98 - 2.82 (m, 3H), 2.63 (s, 1H), 2.60 - 2.57 (m, 1H), 2.02 - 1.95 (m, 1H), 1.85 - 1.74 (m, 2H)

451	**I-456**	VA	KR	855.4	11.08 (s, 1H), 11.03 (s, 1H), 8.96 (s, 1H), 8.41 (s, 1H), 8.25 (d, *J* = 5.2 Hz, 1H), 7.70 - 7.62 (m, 1H), 7.58 - 7.53 (m, 1H), 7.24 (s, 1H), 7.16 (d, *J* = 4.8 Hz, 1H), 7.10 (d, *J* = 8.4 Hz, 1H), 7.02 (d, *J* = 6.8 Hz, 1H), 6.61 - 6.53 (m, 1H), 5.10 - 5.00 (m, 1H), 4.27 - 4.20 (m, 2H), 3.93 (s, 3H), 3.69 - 3.41 (m, 16H), 3.28 (s, 3H), 2.93 - 2.82 (m, 1H), 2.63 - 2.57 (m, 1H), 2.57 - 2.55 (m, 1H), 2.07 - 1.97 (m, 1H)
452	**I-457**	VK	KR	968.4	11.09 (s, 1H), 10.85 (s, 1H), 8.97 (s, 1H), 8.38 (s, 1H), 8.26 - 8.18 (m, 2H), 7.68 (t, *J* = 6.4 Hz, 1H), 7.25 (s, 1H), 7.17 (d, *J* = 5.2 Hz, 1H), 7.00 - 6.92 (m, 2H), 6.90 - 6.83 (m, 1H), 5.36 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.31 - 4.19 (m, 2H), 3.93 (s, 3H), 3.89 - 3.82 (m, 1H), 3.57 - 3.50 (m, 19H), 2.98 - 2.86 (m, 5H), 2.73 - 2.59 (m, 2H), 2.50 - 2.46 (m, 2H), 2.11 - 1.95 (m, 3H), 1.88 - 1.78 (m, 2H), 1.73 - 1.64 (m, 4H)
453	**I-458**	VO	FX	924.5	10.97 (s, 1H), 10.03 (s, 1H), 8.98 (s, 1H), 8.92 (s, 1H), 8.65 (s, 1H), 8.41 (s, 1H), 8.16 (d, *J* = 5.6 Hz, 1H), 8.03 - 7.97 (m, 4H), 7.66 (d, *J* = 7.6 Hz, 1H), 7.44 (s, 1H), 7.38 (d, *J* = 8.0 Hz, 1H), 7.33 - 7.10 (m, 2H), 7.07 - 7.04 (m, 1H), 6.57 (s, 1H), 6.04 (s, 1H), 5.15 - 5.06 (m, 1H), 4.42 - 4.29 (m, 4H), 3.57 - 3.55 (m, 4H), 3.47 - 3.40 (m, 8H), 3.21 - 3.18 (m, 2H), 2.96 - 2.85 (m, 1H), 2.64 - 2.55 (m, 1H), 2.42 - 2.38 (m, 1H), 2.01 - 1.97 (m, 1H), 1.12 - 1.05 (m, 1H), 0.49 - 0.44 (m, 2H), 0.25 - 0.22 (m, 2H)

454	**I-459**	LG	FX	851.1	11.07 (s, 1H), 10.02 (s, 1H), 8.98 (s, 1H), 8.92 (s, 1H), 8.57 (t, *J* = 5.2 Hz, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.03-7.96 (m, 4H), 7.32 (t, *J* = 53.6 Hz, 1H), 7.12 (s, 1H), 7.08 (t, *J* = 5.6 Hz, 1H), 7.06 - 7.02 (m, 2H), 7.01 - 6.97 (m, 1H), 6.90 - 6.85 (m, 1H), 5.33 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.45 (t, *J* = 6.0 Hz, 2H), 3.41 - 3.35 (m, 4H), 3.31 - 3.31 (m, 3H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.94 - 2.84 (m, 1H), 2.71 - 2.57 (m, 4H), 2.03 - 1.96 (m, 1H), 1.87 - 1.76 (m, 4H), 1.12 - 1.02 (m, 1H), 0.49 - 0.43 (m, 2H), 0.26 - 0.19 (m, 2H)
455	**I-460**	LF	FX	851.5	10.84 (s, 1H), 9.79 (s, 1H), 8.74 (s, 1H), 8.68 (s, 1H), 8.34 (d, *J* = 5.6 Hz, 1H), 7.93 (d, *J* = 5.2 Hz, 1H), 7.83 - 7.64 (m, 4H), 7.26 - 6.94 (m, 1H), 6.89 (s, 1H), 6.87 - 6.80 (m, 2H), 6.75 - 6.70 (m, 2H), 6.65 - 6.61 (m, 1H), 5.15-5.10 (m, 1H), 3.34 (s, 3H), 3.23 (d, *J* = 6.4 Hz, 6H), 2.95 (d, *J* = 6.4 Hz, 2H), 2.77 - 2.70 (m, 2H), 2.47 - 2.39 (m, 2H), 2.11 - 2.07 (m, 1H), 1.80 - 1.72 (m, 1H), 1.65 - 1.54 (m, 4H), 0.87 - 0.80 (m, 1H), 0.25 - 0.19 (m, 2H), 0.02 -0.04 (m, 2H)
456	**I-461**	VR	VQ	882.4	11.06 (s, 1H), 10.07 (s, 1H), 9.14 (d, *J* =2.4 Hz, 1H), 9.02 (s, 1H), 8.98 (s, 1H), 8.80 - 8.69 (m, 1H), 8.45 (dd, J = 8.8 Hz, 1H), 8.20 - 8.13 (m, 2H), 7.49 - 7.19 (m, 1H), 7.12 (s, 1H), 7.08 (t, *J* = 5.60 Hz, 1H), 7.04 (dd, *J* = 5.6, 1.6 Hz, 1H), 7.00 (s, 1H), 6.97 (d, *J* = 8.4 Hz, 1H), 6.83 (d, *J* = 7.8 Hz, 1H), 5.36 - 5.27 (m, 1H), 3.62 - 3.56 (m, 4H), 3.54 - 3.49 (m, 4H), 3.42 - 3.39 (m, 2H), 3.26 (s, 3H), 3.19 (d, *J* = 6.4 Hz, 2H), 2.91 - 2.84 (m, 1H), 2.64 - 2.61 (m, 2H), 2.03 - 1.96 (m, 1H), 1.85-1.74 (m, 2H), 1.24 (d, *J* = 0.8 Hz, 1H),

					1.11 - 1.04 (m, 1H), 0.50 - 0.41 (m, 2H), 0.27 - 0.17 (m, 2H)
457	**I-462**	PA	FX	868.4	11.20 (s, 1H), 10.05 (s, 1H), 8.98 (s, 1H), 8.91 (s, 1H), 8.66 (t, *J* = 5.6 Hz, 1H), 8.17 (d, *J* = 5.6 Hz, 1H), 8.04 - 8.01 (m, 2H), 7.99 - 7.96 (m, 2H), 7.45 - 7.18 (m, 2H), 7.16 - 7.12 (m, 2H), 7.11 - 7.07 (m, 1H), 7.05 (d, *J* = 6.4 Hz, 1H), 7.02 (d, *J* = 8.0 Hz, 1H), 5.34 (dd, *J* = 5.2, 13.2 Hz, 1H), 3.57 (d, *J* = 5.6 Hz, 8H), 3.53 - 3.51 (m, 2H), 3.19 (t, *J* = 5.6 Hz, 2H), 2.88 - 2.85 (m, 1H), 2.75 - 2.58 (m, 4H), 2.15 - 2.14 (m, 1H), 1.81 - 1.74 (m, 2H), 1.09 - 1.06 (m, 1H), 0.49 - 0.44 (m, 2H), 0.26 - 0.22 (m, 2H)
458	**I-463**	VT	KR	841.4	11.08 (s, 1H), 10.82 (s, 1H), 8.97 (s, 1H), 8.37 (s, 1H), 8.29 - 8.21 (m, 2H), 7.69 (t, *J* = 6.4 Hz, 1H), 7.25 (s, 1H), 7.16 (d, *J* = 5.6 Hz, 1H), 7.04 - 6.94 (m, 2H), 6.84 (d, *J* = 8.0 Hz, 1H), 5.32 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.31 - 4.17 (m, 2H), 3.92 (s, 3H), 3.57 - 3.50 (m, 8H), 3.48 - 3.40 (m, 4H), 3.30 (s, 3H), 3.25 (s, 2H), 2.95 - 2.83 (m, 1H), 2.75 - 2.60 (m, 4H), 2.02 - 1.97 (m, 1H), 1.85 - 1.72 (m, 2H)
459	**I-464**	VU	KR	841.3	11.08 (s, 1H), 10.82 (s, 1H), 8.97 (s, 1H), 8.37 (s, 1H), 8.28 - 8.23 (m, 2H), 7.70 (t, *J* = 6.4 Hz, 1H), 7.25 (s, 1H), 7.16 (d, *J* = 5.2 Hz, 1H), 6.97 - 6.89 (m, 2H), 6.83 (dd, *J* = 2.8, 5.9 Hz, 1H), 5.35 (dd, *J* = 5.2, 12.4 Hz, 1H), 4.30 - 4.19 (m, 2H), 3.91 (s, 3H), 3.57 - 3.40 (m, 17H), 2.91 (t, *J* = 7.6 Hz, 2H), 2.88 - 2.83 (m, 1H), 2.75 - 2.57 (m, 2H), 2.04 - 1.93 (m, 1H), 1.84 - 1.75 (m, 2H)

460[b]	**I-465**	RD	RX	866.4	11.07 (d, *J* = 4.4 Hz, 1H), 9.39 (s, 1H), 8.82 (d, *J* = 8.0 Hz, 1H), 8.36 (s, 1H), 8.30 (s, 1H), 7.29 - 6.98 (m, 1H), 6.97 - 6.84 (m, 4H), 5.36 (d, *J* = 5.6, 12.8 Hz, 1H), 4.22 (s, 2H), 3.88 (s, 3H), 3.85 (s, 3H), 3.66 - 3.45 (m, 22H), 2.96 - 2.84 (m, 3H), 2.73 - 2.58 (m, 2H), 2.04 - 1.95 (m, 1H), 1.85 - 1.74 (m, 2H)
461[b]	**I-466**	RD	2-[2-[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]propoxy]-ethoxy]ethoxy]-ethoxy]acetic acid (synthesized via Steps 1-5 of Example 441, I-447)	866.1	11.07 (s, 1H), 9.38 (s, 1H), 8.79 (d, *J* = 8.0 Hz, 1H), 8.35 (s, 1H), 8.29 (s, 1H), 7.26 - 6.95 (m, 3H), 6.88 (d, *J* = 8.0 Hz, 1H), 6.85 - 6.80 (m, 1H), 5.32 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.21 (s, 2H), 3.87 (s, 3H), 3.84 - 3.81 (m, 2H), 3.63 - 3.55 (m, 8H), 3.53 - 3.48 (m, 6H), 3.46 - 3.40 (m, 4H), 3.34 - 3.32 (m, 2H), 3.30 (s, 3H), 2.96 - 2.82 (m, 1H), 2.74 - 2.57 (m, 4H), 2.05 - 1.95 (m, 1H), 1.82 - 1.70 (m, 2H)
462[b]	**I-467**	RD	2-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]ethoxy]-ethoxy]ethoxy]-ethoxy]acetic acid (synthesized via Steps 1-2 of Example 161, I-161)	866.4	11.08 (s, 1H), 9.39 (s, 1H), 8.82 (d, *J* = 7.6 Hz, 1H), 8.42 - 8.26 (m, 2H), 7.65 - 7.50 (m, 1H), 7.21 - 6.85 (m, 4H), 6.58 (d, *J* = 5.2 Hz, 1H), 5.05 (d, *J* = 5.2, 12.8 Hz, 1H), 4.22 (s, 2H), 3.94 - 3.81 (m, 7H), 3.64 - 3.51 (m, 18H), 3.44 (d, *J* = 5.6 Hz, 2H), 2.99 - 2.77 (m, 1H), 2.61 (d, *J* = 2.4 Hz, 2H), 2.14 - 1.92 (m, 1H)

463[b]	**I-468**	RD	2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-yl]amino]-ethoxy]ethoxy]-ethoxy]acetic acid (synthesized via Steps 1-2 of Example 152, I-152)	822.2	11.08 (s, 1H), 9.37 (s, 1H), 8.80 (d, *J* = 8.0 Hz, 1H), 8.36 (s, 1H), 8.29 (s, 1H), 7.53 (d, *J* = 7.2, 8.4 Hz, 1H), 7.15 - 6.96 (m, 3H), 6.89 (d, *J* = 8.0 Hz, 1H), 6.57 (t, *J* = 5.6 Hz, 1H), 5.05 (d, *J* = 5.6, 12.8 Hz, 1H), 4.21 (s, 2H), 3.89 (s, 3H), 3.84 (s, 2H), 3.63 - 3.55 (m, 14H), 3.44 (d, *J* = 5.6 Hz, 2H), 3.29 (s, 2H), 2.93 - 2.82 (m, 1H), 2.62 - 2.53 (m, 2H), 2.06 - 1.98 (m, 1H)
464[b]	**I-469**	RD	VW	778.3	11.07 (s, 1H), 9.37 (s, 1H), 8.77 (d, *J* = 8.0 Hz, 1H), 8.35 (s, 1H), 8.28 (s, 1H), 7.27 - 6.90 (m, 3H), 6.87 - 6.81 (m, 2H), 5.33 - 5.29 (m, 1H), 4.24 (s, 2H), 3.96 - 3.75 (m, 7H), 3.61 (m, 6H), 3.54 - 3.53 (m, 2H), 3.44 - 3.39 (m, 2H), 3.29 (s, 3H), 2.95 - 2.84 (m, 1H), 2.74 - 2.57 (m, 4H), 2.04 - 1.96 (m, 1 H), 1.84 - 1.73 (m, 2H)
465	**I-470**	VR	VY	899.3	11.08 (s, 1H), 10.07 (s, 1H), 8.98 (s, 1H), 8.95 (s, 1H), 8.43 - 8.33 (m, 1H), 8.15 (d, *J* = 5.4 Hz, 1H), 7.91 - 7.74 (m, 3H), 7.50 - 7.12 (m, 1H), 7.12 - 7.07 (m, 2H), 7.05 - 6.96 (m, 3H), 6.90 - 6.82 (m, 1H), 5.32 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.59 - 3.40 (m, 10H), 3.30 (s, 3H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.97 - 2.81 (m, 1H), 2.76 - 2.68 (m, 1H), 2.66 - 2.61 (m, 2H), 2.58 - 2.52 (m, 1H), 2.05 - 1.94 (m, 1H), 1.85 - 1.74 (m, 2H), 1.15 - 0.98 (m, 1H), 0.49 - 0.41 (m, 2H), 0.26 - 0.18 (m, 2H)

466	**I-471**	4-[2-[2-[2-(2-aminoethoxy)-ethoxy]ethoxy]-ethylamino]-2-(2,6-dioxo-3-piperidyl) isoindoline-1,3-dione (synthesized via Steps 1-2)	WB	801.1	10.5 (s, 1H), 8.71 (d, *J* = 8.0 Hz, 1H), 8.38 (s, 1H), 8.28 - 8.20 (m, 2H), 8.05 (t, *J* = 5.6 Hz, 1H), 7.54 (dd, *J* = 7.2, 8.4 Hz, 1H), 7.08 (d, *J* = 8.8 Hz, 1H), 7.01 (d, *J* = 7.2 Hz, 1H), 6.83 (d, *J* = 8.0 Hz, 1H), 6.57 (t, *J* = 5.6 Hz, 1H), 5.04 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.05 - 3.85 (m, 7H), 3.61 - 3.57 (m, 2H), 3.55 - 3.50 (m, 10H), 3.45 - 3.38 (m, 4H), 2.93 - 2.88 (m, 4H), 2.87 - 2.80 (m, 1H), 2.62 - 2.52 (m, 2H), 2.06 - 1.98 (m, 1H)
467	**I-472**	HQ	WD	874.4	11.07 (s, 1H), 9.98 (s, 1H), 8.97 (d, *J* = 1.6 Hz, 1H), 8.92 (d, *J* = 1.6 Hz, 1H), 8.88 (s, 1H), 8.81 (t, *J* = 5.2 Hz, 1H), 8.49 (s, 1H), 8.22 (d, *J* = 5.2 Hz, 1H), 8.02 (s, 1H), 7.55 (t, *J* = 6.4 Hz, 1H), 7.29 - 7.16 (m, 2H), 6.98 - 6.88 (m, 2H), 6.84 - 6.82 (m, 1H), 5.36 - 5.32 (m, 1H), 4.29 - 4.17 (m, 2H), 3.93 (s, 3H), 3.57 - 3.44 (m, 13 H), 2.95 - 2.85 (m, 3H), 2.71 - 2.56 (m, 2 H), 2.03 - 1.92 (m, 1 H), 1.84 - 1.71 (m, 2H)
468	**I-473**	PP	FX	865.8	11.09 (s, 1H), 10.11 - 9.93 (m, 1H), 8.97 (s, 1H), 8.95 - 8.77 (m, 1H), 8.15 (d, *J* = 5.2 Hz, 1H), 7.92 (d, *J* = 8.4 Hz, 2H), 7.63 - 7.52 (m, 2H), 7.47 - 7.14 (m, 1H), 7.14 - 7.07 (m, 2H), 7.04 (dd, *J* = 1.2, 5.2 Hz, 1H), 6.98 - 6.84 (m, 2H), 5.40 - 5.25 (m, 1H), 3.62 - 3.50 (m, 4H), 3.45 (s, 3H), 3.27 (s, 3H), 3.18 (t, *J* = 6.4 Hz, 2H), 3.03 - 2.92 (m, 4H), 2.74 (s, 1H), 2.65 - 2.52 (m, 2H), 2.09 - 1.92 (m, 1H), 1.90 - 1.60 (m, 4H), 1.12 - 1.01 (m, 1H), 0.49 - 0.41 (m, 2H), 0.26 - 0.19 (m, 2H)

470	**I-475**	PY	FX	838.4	11.20 (s, 1H), 10.03 (s, 1H), 8.97 (s, 1H), 8.91 (s, 1H), 8.57 (t, *J* = 5.6 Hz, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.04 - 7.94 (m, 4H), 7.31 (t, *J* = 56 Hz, 1H), 7.15 - 7.06 (m, 4H), 7.06 - 7.00 (m, 2H), 5.39 - 5.31 (m, 1H), 3.49 - 3.40 (m, 6H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.93 - 2.82 (m, 1H), 2.76 (t, *J* = 7.6 Hz, 2H), 2.68 - 2.60 (m, 2H), 2.20 - 2.10 (m, 1H), 1.91 - 1.84 (m, 2H), 1.83 - 1.76 (m, 2H), 1.13 - 1.01 (m, 1H), 0.49 - 0.42 (m, 2H), 0.26 - 0.19 (m, 2H)
471	**I-476**	QA	FX	852.5	11.18 (s, 1H), 10.12 - 9.91 (m, 1H), 8.98 (s, 1H), 8.85 (d, *J* = 17.2 Hz, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.92 (d, *J* = 8.4 Hz, 2H), 7.62 - 7.51 (m, 2H), 7.44 - 6.82 (m, 7H), 5.41 - 5.26 (m, 1H), 3.55 - 3.40 (m, 4H), 3.39 - 3.36 (m, 3H), 3.28 - 3.23 (m, 2H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.99 - 2.92 (m, 3H), 2.89 - 2.75 (m, 2H), 2.20 - 2.08 (m, 1H), 1.93 - 1.65 (m, 4H), 1.11 - 1.02 (m, 1H), 0.49 - 0.41 (m, 2H), 0.26 - 0.19 (m, 2H)
472	**I-477**	QI	FX	865.4	11.07 (s, 1H), 10.12 - 9.87 (m, 1H), 8.97 (s, 1H), 8.92 - 8.72 (m, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.93 (d, *J* = 8.8 Hz, 2H), 7.65 - 7.48 (m, 2H), 7.44 - 6.70 (m, 7H), 5.40 - 5.23 (m, 1H), 3.61 - 3.42 (m, 6H), 3.32 - 3.23 (m, 6H), 3.21 - 3.18 (m, 2H), 2.98 - 2.94 (m, 2H), 2.91 - 2.81 (m, 1H), 2.69 - 2.60 (m, 2H), 2.04 - 1.93 (m, 1H), 1.92 - 1.61 (m, 4H), 1.12 - 1.02 (m, 1H), 0.49 - 0.42 (m, 2H), 0.27 - 0.19 (m, 2H)

473	**I-478**	QK	FX	866.3	($CDCl_3$) 9.36 (s, 1H), 9.17 (s, 1H), 8.86 (s, 1H), 8.51 (s, 1H), 8.24 (d, J = 5.2 Hz, 1H), 7.78 (d, J = 8.8 Hz, 2H), 7.65 (d, J = 8.8 Hz, 2H), 7.59 (s, 1H), 7.24 - 7.19 (m, 1H), 7.10 - 6.81 (m, 4H), 6.71 (d, J = 7.2 Hz, 1H), 5.20 - 5.12 (m, 1H), 3.74 (t, J = 5.3 Hz, 2H), 3.57 - 3.49 (m, 2H), 3.25 (d, J = 5.6 Hz, 2H), 3.06 - 2.93 (m, 1H), 2.92 - 2.69 (m, 4H), 2.41 - 2.27 (m, 1H), 2.03 - 1.92 (m, 4H), 1.61 (s, 6H), 1.23 - 1.08 (m, 1H), 0.69 - 0.57 (m, 2H), 0.39 - 0.29 (m, 2H)
474	**I-479**	PY	FX	839.5	11.18 (s, 1H), 10.08 (s, 1H), 9.11 (d, *J* = 2.4 Hz, 1H), 9.02 (s, 1H), 8.98 (s, 1H), 8.87 (t, *J* = 6.0 Hz, 1H), 8.46 (dd, *J* = 2.4, 8.8 Hz, 1H), 8.21 - 8.14 (m, 2H), 7.34 (d, *J* = 53.6 Hz, 1H), 7.14 - 7.00 (m, 6H), 5.34 (dd, *J* = 5.6, 13.2 Hz, 1H), 3.47 - 3.41 (m, 6H), 3.20 - 3.17 (m, 2H), 2.89 - 2.81 (m, 1H), 2.77 (t, *J* = 7.6 Hz, 2H), 2.70 - 2.64 (m, 2H), 2.17 - 2.09 (m, 1H), 1.93 - 1.86 (m, 2H), 1.86 - 1.77 (m, 2H), 1.11 - 1.02 (m, 1H), 0.48 - 0.43 (m, 2H), 0.25 - 0.20 (m, 2H)
476	**I-481**	OD	QW	983.3	11.07 (s, 1H), 10.98 (s, 1H), 9.08 (s, 1H), 9.02 (s, 1H), 8.56 (t, *J* = 5.6 Hz, 1H), 8.26 (d, *J* = 4.8 Hz, 1H), 8.00 (s, 4H), 7.67 (t, *J* = 6.4 Hz, 1H), 7.26 (s, 1H), .18 (dd, *J* = 1.2, 5.2 Hz, 1H), 7.01 (s, 1H), 6.99 (d, *J* = 7.6 Hz, 1H), 6.85 (d, *J* = 8.0 Hz, 1H), 5.38 - 5.21 (m, 1H), 4.41 - 4.31 (s, 2H), 4.30 - 4.19 (m, 2H), 3.81 - 3.80 (m, 2H), 3.32 - 3.26 (m, 11H), 2.96 -2.81 (m, 1H), 2.64 - 2.60 (m, 2H), 2.55 - 2.52 (m, 5H), 2.47 - 2.42 (m, 4H), 2.23 (s, 3H), 2.07 - 1.95 (m, 1H), 1.66 - 1.48 (m, 8H)

477	**I-482**	OD	QY	971.5	11.07 (s, 1H), 10.91 (s, 1H), 9.06 (s, 1H), 9.03 (s, 1H), 8.62 - 8.53 (m, 2H), 8.27 (d, *J* = 5.2 Hz, 1H), 8.12 - 8.05 (m, 2H), 8.04 - 7.99 (m, 2H), 7.69 (t, *J* = 6.4 Hz, 1H), 7.27 (s, 1H), 7.19 (d, *J* = 5.2 Hz, 1H), 7.03 - 6.97 (m, 2H), 6.86 (d, *J* = 8.4 Hz, 1H), 5.32 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.30 - 4.21 (m, 2H), 3.35 - 3.27 (m, 11H), 3.35 - 3.27 (m, 1H), 2.93 - 2.87 (m, 1H), 2.65 - 2.58 (m, 4H), 2.57 - 2.54 (m, 2H), 2.22 (s, 6H), 2.05 - 1.96 (m, 1H), 1.65 - 1.50 (m, 8H)
478	**I-483**	RD	QZ	1001.6	9.36 (s, 1H), 8.93 (s, 1H), 8.78 (d, *J* = 8.0 Hz, 1H), 8.52 (t, *J* = 6.0 Hz, 1H), 8.32 (s, 1H), 8.25 (s, 1H), 7.80 (d, *J* = 9.6 Hz, 1H), 7.35 (q, *J* = 8.4 Hz, 4H), 7.09 (t, *J* = 56 Hz, 1H), 6.86 (d, *J* = 8.0 Hz, 1H), 5.08 (s, 1H), 4.49 (d, *J* = 9.6 Hz, 1H), 4.44 - 4.33 (m, 2H), 4.30 (s, 1H), 4.16 (dd, *J* = 5.6, 16.0 Hz, 1H), 3.83 (s, 3H), 3.78 (s, 4H), 3.65 - 3.50 (m, 6H), 2.39 (s, 3H), 2.35 - 2.28 (m, 2H), 2.27 - 2.15 (m, 1H), 2.10 - 1.94 (m, 2H), 1.90 - 1.80 (m, 1H), 1.52 - 1.33 (m, 4H), 1.27 - 1.13 (m, 12H), 0.88 (s, 9H)
479[b]	**I-484**	RD	RA	1103.6 $(M+Na)^+$	9.39 (s, 1H), 8.97 (s, 1H) ,8.83 (d, *J* = 8.0 Hz, 1H), 8.59 (s, 1H), 8.36 (s, 1H), 8.30 (s, 1H), 7.43 - 7.36 (m, 5H), 7.27 - 6.97 (m, 1H), 6.91 (d, *J* = 7.6 Hz, 1H), 5.16 (d, *J* = 3.6 Hz, 1H), 4.55 (d, *J* = 9.2 Hz, 1H), 4.42 (m, 2H), 4.37 (m, 2H), 4.26 (m, 1H), 4.21 (s, 2H), 3.95 (s, 2H), 3.89 - 3.82 (m, 7H), 3.66 - 3.48 (m, 20H), 2.43 (s, 4H), 2.05 (m, 1 H), 1.89 (m, 1H), 1.23 (m, 1H), 0.93 (s, 9H)

480[b]	**I-485**	RD	RB	993.5	9.35 (s, 1H), 8.97 - 8.89 (m, 1H), 8.78 (d, *J* = 8.0 Hz, 1H), 8.56 (t, *J* = 6.0 Hz, 1H), 8.32 (s, 1H), 8.29 - 8.23 (m, 1H), 7.43 - 7.37 (m, 1H), 7.34 (s, 4H), 7.24 - 6.94 (m, 1H), 6.86 (d, *J* = 8.0 Hz, 1H), 5.13 (d, *J* = 3.2 Hz, 1H), 4.51 (d, *J* = 9.6 Hz, 1H), 4.43 - 4.28 (m, 3H), 4.26 - 4.14 (m, 3H), 3.91 (s, 2H), 3.83 (s, 3H), 3.79 (s, 4H), 3.61 - 3.50 (m, 15H), 2.40 - 2.38 (m, 3H), 2.07 - 1.95 (m, 1H), 1.88 - 1.85 (m, 1H), 0.86 (s, 9H)
482[b]	**I-487**	RR	RP	934.4	11.07 (s, 1H), 10.04 (s, 1H), 9.00 (s, 1H), 8.88 (s, 1H), 8.25 (d, *J* = 5.2 Hz, 1H), 7.93 (d, *J* = 7.6 Hz, 2H), 7.61 (t, *J* = 6.4 Hz, 1H), 7.56 (d, *J* = 8.4 Hz, 2H), 7.46 - 7.30 (m, 1H), 7.26 (s, 1H), 7.21 (dd, *J* = 1.2, 5.2 Hz, 1H), 7.08 - 6.96 (m, 2H), 6.92 - 6.83 (m, 1H), 5.37 - 5.28 (m, 1H), 4.30 - 4.19 (m, 2H), 3.88 - 3.69 (m, 2H), 3.70 - 3.58 (m, 1H), 3.57 - 3.46 (m, 3H), 3.31 (s, 3H), 3.00 (s, 3H), 2.95 - 2.84 (m, 1H), 2.82 - 2.70 (m, 1H), 2.69 - 2.56 (m, 4H), 2.36 - 2.31 (m, 1H), 2.27 - 2.20 (m, 1H), 2.09 - 1.91 (m, 2H), 1.83 - 1.47 (m, 3H)
483[b]	**I-488**	RW	RU	906.2	11.08 (s, 1H), 10.05 (s, 1H), 8.97 (s, 1H), 8.87 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.92 (s, 2H), 7.56 (d, *J* = 8.4 Hz, 2H), 7.30 (t, *J* = 54.8, 1H), 7.13 - 7.11 (m, 1H), 7.11 - 7.07 (m, 1H), 7.06 - 6.95 (m, 3H), 6.90 - 6.83 (m, 1H), 5.43 - 5.20 (m, 1H), 3.88 - 3.67 (m, 4H), 3.28 - 3.22 (m, 5H), 3.19 - 3.17 (m, 2H), 2.99 (s, 3H), 2.94 - 2.75 (m, 3H), 2.64 - 2.62 (m, 2H), 2.59 - 2.57 (m, 2H), 2.31 - 2.18 (m, 2H), 2.10 - 1.93 (m, 2H), 1.79 - 1.67 (m, 2H), 1.11 - 1.03 (m, 1H), 0.48 - 0.43 (m, 2H), 0.24 - 0.20 (m, 2H)

484	**I-489**	RT	CN	914.8	11.07 (s, 1H), 11.01 (s, 1H), 9.01 (d, *J* = 8.4 Hz, 2H), 8.26 (d, *J* = 4.8 Hz, 1H), 8.16 - 8.00 (m, 3H), 7.81 - 7.65 (m, 2H), 7.54 (s, 2H), 7.27 (s, 1H), 7.18 (d, *J* = 4.8 Hz, 1H), 7.07 - 6.93 (m, 2H), 6.86 - 6.80 (m, 1H), 5.37 - 5.27 (m, 1H), 4.40 - 4.15 (m, 2H), 3.45 -3.27 (m, 10H), 3.06 - 2.80 (m, 4H), 2.65 - 2.55 (m, 4H), 2.03 - 1.96 (m, 1H), 1.68 - 1.36 (m, 8H)
485[b]	**I-490**	RR	RU	906.5	11.07 (s, 1H), 10.03 (s, 1H), 8.98 (s, 1H), 8.88 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.93 (d, *J* = 7.6 Hz, 2H), 7.56 (d, *J* = 8.4 Hz, 2H), 7.30 (t, *J* = 8.4 Hz, 1H), 7.12 (s, 1H), 7.08 (t, *J* = 5.6 Hz, 1H), 7.06 - 6.95 (m, 3H), 6.92 - 6.82 (m, 1H), 5.37 - 5.28 (m, 1H), 3.88 - 3.76 (m, 2H), 3.72 - 3.63 (m, 2H), 3.62 - 3.58 (m, 1H), 3.31 (s, 3H), 3.19 (t, *J* = 6.0 Hz, 2H), 3.00 (s, 3H), 2.96 - 2.85 (m, 1H), 2.83 - 2.74 (m, 1H), 2.72 - 2.65 (m, 2H), 2.63 - 2.57 (m, 2H), 2.36 - 2.28 (m, 2H), 2.27 - 2.14 (m,, 1H), 2.12 - 1.94 (m, 2H), 1.86 - 1.53 (m, 3H), 1.17 - 0.95 (m, 1H), 0.49 - 0.43 (m, 2H), 0.25 - 0.18 (m, 2H)
486	**I-491**	RT	FX	893.5	11.08 (s, 1H), 10.04 (s, 1H), 8.98 (s, 1H), 8.88 (s, 1H), 8.17 (d, *J* = 5.2 Hz, 1H), 7.93 (d, *J* = 8.4 Hz, 2H), 7.59 - 7.49 (m, 2H), 7.31 (t, *J* = 54 Hz, 1H), 7.13 (s, 1H), 7.09 (t, *J* = 5.6 Hz, 1H), 7.06 - 7.04 (m, 1H), 6.99 (d, *J* = 7.6 Hz, 2H), 6.85 (s, 1H), 5.40 - 5.25 (m, 1H), 3.52 - 3.39 (m, 4H), 3.31 (s, 6H), 3.22 - 3.17 (m, 2H), 2.99 - 2.84 (m, 4H), 2.77 - 2.69 (m, 1H), 2.65 - 2.62 (m, 1H), 2.61 - 2.57 (m, 1H), 2.06 - 1.94 (m, 1H), 1.67 - 1.47 (m, 6H), 1.42 - 1.16 (m, 2H),

					1.10 - 1.01 (m, 1H), 0.49 - 0.44 (m, 2H), 0.26 - 0.21 (m, 2H)
489	**I-494**	QI	CN	886.6	11.14 - 10.87 (m, 2H), 9.09 - 8.83 (m, 2H), 8.27 (d, *J* = 5.2 Hz, 1H), 8.14 - 8.00 (m, 3H), 7.78 - 7.67 (m, 2H), 7.54 - 7.63 (m, 2H), 7.27 (s, 1H), 7.19 (d, *J* = 5.2 Hz, 1H), 7.12 - 6.94 (m, 1H), 6.93 - 6.66 (m, 2H), 5.40 - 5.17 (m, 1H), 4.31 - 4.21 (m, 2H), 3.57 - 3.37 (m, 6H), 3.32 - 3.23 (m, 6H), 3.05 - 2.92 (m, 3H), 2.68 - 2.91 (m, 2H), 2.08 - 1.98 (s, 1H), 1.89 - 1.59 (m, 4H)
490	**I-495**	QA	CN	873.6	11.19 (s, 1H), 10.99 (s, 1H), 9.04 (s, 1H), 9.02 - 8.91 (m, 1H), 8.27 (d, *J* = 5.2 Hz, 1H), 8.16 - 8.00 (m, 3H), 7.80 - 7.66 (m, 2H), 7.62 - 7.53 (m, 2H), 7.28 (s, 1H), 7.19 (d, *J* = 5.6 Hz, 1H), 7.16 - 6.75 (m, 3H), 5.42 - 5.24 (m, 1H), 4.31 - 4.20 (m, 2H), 3.59 - 3.38 (m, 6H), 3.28 - 3.21 (m, 3H), 3.01 - 2.92 (m, 3H), 2.90 - 2.73 (m, 2H), 2.20 - 2.12 (m, 1H), 1.91 - 1.64 (m, 4H)

499[b]	**I-504**	SI	RU	914.1	11.10 (s, 1H), 10.03 (s, 1H), 8.98 (s, 1H), 8.88 (s, 1H), 8.16 (s, 1H), 7.93 (d, *J* = 8.4 Hz, 2H), 7.62 - 7.48 (m, 2H), 7.46 - 7.17 (m, 2H), 7.14 - 7.00 (m, 5H), 5.37 (dd, *J* = 4.8, 12.0 Hz, 1H), 3.40 - 3.35 (m, 4H), 3.33 (s, 3H), 3.18 (t, *J* = 6.4 Hz, 2H), 2.95 (d, *J* = 13.2 Hz, 4H), 2.88 - 2.69 (m, 2H), 2.71 - 2.57 (m, 4H), 2.12 - 1.93 (m, 3H), 1.80 - 1.62 (m, 2H), 1.51 - 1.48 (m, 1H), 1.25 (d, *J* = 12.0 Hz, 1H), 1.11 - 1.02 (m, 1H), 0.95 - 0.80 (m, 1H), 0.49 - 0.42 (m, 2H), 0.26 - 0.19 (m, 2H)
501	**I-506**	SL	FX	947.5	11.14 - 11.04 (m, 1H), 10.05 (s, 1H), 8.98 (s, 1H), 8.93 (s, 1H), 8.76 (d, *J* = 6.8 Hz, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.06 - 7.95 (m, 4H), 7.47 - 7.17 (m, 1H), 7.12 (s, 1H), 7.10 - 7.09 (m, 2H), 7.06 - 7.04 (m, 1H), 7.03 (s, 1H), 6.96 (d, *J* = 8.4 Hz, 1H), 5.39 - 5.32 (m, 1H), 4.43 (d, *J* = 7.2 Hz, 1H), 4.14 - 4.10 (m, 1H), 3.47 (s, 2H), 3.42 - 3.41 (m, 2H), 3.33 (s, 3H), 3.16 - 3.18 (m, 2H), 2.92 - 2.85 (m, 1H), 2.77 - 2.70 (m, 1H), 2.70 - 2.66 (m, 1H), 2.64 - 2.62 (m, 1H), 2.61 - 2.57 (m, 2H), 2.56 - 2.53 (m, 3H), 2.47 - 2.44 (m, 4H), 2.30 – 2.24 (m, 4H), 2.06 - 1.97 (m, 1H), 2.05 - 1.97 (m, 1H), 1.12 -1.02 (m, 1H), 0.48 - 0.42 (m, 2H), 0.25 - 0.20 (m, 2H)


503[b]	**I-508**	SM	RU	903.4	10.98 (d, *J* = 8.0 Hz, 1H), 10.03 (s, 1H), 8.97 (s, 1H), 8.92 (s, 1H), 8.70 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.06 - 7.94 (m, 4H), 7.55 - 7.17 (m, 5H), 7.12 (s, 1H), 7.08 (t, *J* = 5.6 Hz, 1H), 7.04 (d, *J* = 5.2 Hz, 1H), 5.72 - 5.57 (m, 1H), 4.76 - 4.61 (m, 1H), 3.97 - 3.82 (m, 2H), 3.69 - 3.63 (m, 1H), 3.59 - 3.50 (m, 4H), 3.28 - 3.24 (m, 2H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.91 - 2.79 (m, 2H), 2.71 (s, 1H), 2.60 - 2.53 (m, 2H), 2.40 - 2.33 (m, 1H), 2.26 - 2.17 (m, 1H), 2.11 (t, *J* = 9.6 Hz, 1H), 2.04 - 1.92 (m, 1H), 1.11 - 1.03 (m, 1H), 0.48 - 0.42 (m, 2H), 0.25 - 0.20 (m, 2H)
504[b]	**I-509**	SO	RU	903.4	10.99 (d, *J* = 5.6 Hz, 1H), 10.04 (s, 1H), 8.98 (s, 1H), 8.93 (s, 1H), 8.71 (, *J* = 5.6 Hz, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.06 - 8.02 (m, 2H), 8.00 - 7.96 (m, 2H), 7.50 - 7.41 (m, 4H), 7.40 - 7.18 (m, 1H), 7.12 - 7.07 (m, 2H), 7.04 (dd, *J* = 1.2, 5.2 Hz, 1H), 5.72 - 5.58 (m, 1H), 4.75 - 4.61 (m, 1H), 3.94 - 3.84 (m, 2H), 3.68 - 3.63 (m, 1H), 3.57 (s, 2H), 3.55 - 3.51 (m, 1H), 3.26 - 3.21 (m, 2H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.88 - 2.81 (m, 2H), 2.79 - 2.69 (m, 1H), 2.58 - 2.55 (m, 2H), 2.43 - 2.35 (m, 1H), 2.26 - 2.17 (m, 1H), 2.14 - 2.07 (m, 1H), 2.02 - 1.92 (m, 1H), 1.10 - 1.03 (m, 1H), 0.48 - 0.43 (m, 2H), 0.24 - 0.21 (m, 2H)

508[b]	**I-513**	TT	RU	906.6	11.08 (s, 1H), 10.02 (s, 1H), 8.97 (s, 1H), 8.88 (s, 1H), 8.18 - 8.15 (m, 1H), 7.93 -7.91 (m, 2H), 7.56 – 7.55(m, 2H), 7.47 - 7.15 (m, 1H), 7.14 - 7.02 (m, 3H), 7.00 - 6.82 (m, 3H), 5.37- 5.33 (m, 1H), 3.88 - 3.68 (m, 3H), 3.57 (d, *J* = 2.8 Hz, 6H), 3.00 (s, 3H), 2.97 - 2.75 (m, 5H), 2.74 - 2.56 (m, 4H), 2.35 - 2.26 (m, 2H), 2.05 - 1.92 (m, 2H), 1.83 - 1.66 (m, 2H), 1.13 - 1.02 (m, 1H), 0.50 - 0.40 (m, 2H), 0.26 - 0.18 (m, 2H)
509	**I-514**	TU	FX	906.3	11.07 (s, 1H), 10.01 (s, 1H), 8.96 (s, 1H), 8.87 (s, 1H), 8.18 - 8.11 (m, 1H), 8.01 - 7.84 (m, 2H), 7.57 (s, 2H), 7.30 (t , *J* = 54.4 Hz, 1H), 7.11 (s, 1H), 7.07 (t, *J* = 4.8 Hz, 1H), 7.03 (dd, *J* = 1.6 Hz, 1H), 7.00 - 6.80 (m, 3H), 5.43 - 5.27 (m, 1H), 3.57 (s, 6H), 3.28 (s, 3H), 3.21 - 3.15 (t, *J* = 6.0 Hz, 3H), 3.00 (s, 3H), 2.96 - 2.83 (m, 4H), 2.51 (s, 6H), 2.04 - 1.92 (m, 2H), 1.11 - 1.01 (m, 1H), 0.50 - 0.39 (m, 2H), 0.26 - 0.17 (m, 2H)
510[b]	**I-515**	SV	RU	895.5	10.02 (s, 1H), 8.97 (s, 1H), 8.89 (s, 1H), 8.64 (t, *J* = 5.6 Hz, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.04 - 7.98 (m, 2H), 7.97 - 7.91 (m, 2H), 7.31 (t, *J* = 54.4 Hz,1H), 7.14 - 7.06 (m, 2H), 7.04 (d, *J* = 5.2 Hz, 1H), 6.96 - 6.89 (m, 2H), 6.83 (dd, *J* = 1.6, 6.9 Hz, 1H), 5.41 (dd, *J* = 5.2, 13.0 Hz, 1H), 3.60 - 3.56 (m, 4H), 3.55 - 3.53 (m, 4H), 3.48 - 3.44 (m, 4H), 3.18 (t, *J* = 6.0 Hz, 2H), 3.02 (s, 3H), 2.92 (dd, *J* = 7.2, 8.7 Hz, 3H), 2.80 - 2.73 (m, 1H), 2.03 - 1.95 (m, 1H), 1.84 - 1.76 (m, 2H), 1.11 - 1.02 (m, 1H), 0.49 - 0.42 (m, 2H), 0.23 (q, *J* = 4.8 Hz, 2H), -0.02 - -0.12 (m, 2H)

512	**I-517**	WN	FX	921.5	11.07 (s, 1H), 10.03 (s, 1H), 8.98 (s, 1H), 8.87 (s, 1H), 8.16 (d, *J* = 5.4 Hz, 1H), 7.93 (d, *J* = 8.8 Hz, 2H), 7.56 (d, *J* = 8.8 Hz, 2H), 7.31 (t, *J* = 54 Hz, 1H), 7.12 - 6.98 (m, 5H), 6.87 (d, *J* = 8.0 Hz, 1H), 5.35 - 5.31 (m, 1H), 4.06 - 3.85 (m, 1H), 3.62 - 3.55 (m, 3H), 3.53 - 3.49 (m, 2H), 3.44 - 3.39 (m, 2H), 3.35 (s, 3H), 3.27 (m, 2H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.93 - 2.84 (m, 1H), 2.77 - 2.69 (m, 1H), 2.64 (m, 2H), 2.54 (m, 2H), 2.03 - 1.95 (m, 1H), 1.91 - 1.77 (m, 4H), 1.55 - 1.40 (m, 2H), 1.11 - 1.01 (m, 1H), 0.50 - 0.40 (m, 2H), 0.24 - 0.21 (m, 2H)

[a]Variations in reaction time for Method 12 were as follows: Step 1 was run anywhere from 0.5-12 h, and Step 2 anywhere from 10 min- 17 h. If the product of Step 1 was not a precipitate, a standard work up with water and extraction with ethyl acetate was used to isolate the product. Step 2 deprotection could also be achieved under a variety of standard conditions if not with HCl/dioxane in DCM, including with TFAin DCM at rt. [b]No Step 2 deprotection required. cStep 2 deprotection was achieved using HBr/HOAc in DCM at rt for 12 h.

[005491] **Further Examples using synthetic methods similar to Method 12: Example 514: 2-[2-!Cvclopropylmethylamino)-4-pyridyl]-N-[3-!difluoromethvB-l-[4-[2-[2-[2-[2- [2-[[t3Sl-2-[t2Sl-3,3-dimethyl-2-[[t2Sl-2-tmethylaminolpropanoyl]amino]butanoyl]-3-[[(1R)-tetralin-l-yl]carbamoyl]-3,4-dihvdro-lH-isoquinolin-7-yl]oxy]ethoxy]ethoxy]ethoxy]ethylcarbamoyl] phenyl]pyrazol-4-yl] oxazole-4-carboxamide, 1-519**



[005492] Step 1 - Tert-butyl N-[4-[4-[1-[4-[2-[2-[2-[2-[(3S)-2-[(2S)-2-[(2S)-2-benzyloxycarbonyl(methyl)amino]propanoyl]amino]-3,3-dimethyl-butanoyl]-3-[(1R)-tetralin-1-yl]carbamoyl]-3,4-dihydro-1H-isoquinolin-7-

yl1oxy1ethoxy1ethoxy1ethoxy1ethoxy1ethylcarbamoyl1phenyl1-3-(difluoiOmethvDpyrazol-4-vHcarbamovHoxazol-2-vH-2-pyridvH-N-(cvclopiOpylmethvDcarbamate

[005493] To a mixture of benzyl N-[(lS)-2-[[(lS)-l-[(3S)-7-[2-[2-[2-[2-(2-aminoethoxy)ethoxy] ethoxy] ethoxy]ethoxy]-3-[[(lR)-tetralin-l-yl]carbamoyl]-3,4-dihydro-lH-isoquinoline-2-carbonyl]-2,2-dimethyl-propyl]amino]-l-methyl-2-oxo-ethyl]-N-methyl-carbamate (30.0 mg, 30.3 umol, TFA, Intermediate PJ) and DIPEA (19.6 mg, 151 umol, 26.4 uL) in DMF (2 mL) was added 4-[4-[[2-[2- [tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]benzoic acid (18.0 mg, 30.3 umol, Intermediate FX) and HATU (13.8 mg, 36.4 umol). The reaction mixture was stirred at 25 °C for 0.5 hour. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (0.1 % FA condition) to give the title compound (25.0 mg, 56% yield) as white solid. LC-MS (ESI^+) *m/z* 1451.8 $(M+H)^+$.


[005494] Step 2 - Tert-butyl N-(cvclopropylmethvO-N-r4-r4-rr3-(difluoromethvO-l-r4-r2-[2-[2-[2-[2-[[(3S) -2-r(2S)-3.3-dimethyl-2-rr(2S)-2-(methylamino)propanoyl1amino1butanoyl1-3-Ii(1RVtetralin- 1-yl]carbamoyl1-3.4-dihydro- 1H-isoquinolin-7 -yl1oxy1ethoxy1ethoxy1ethoxy1ethoxy1ethylcarbamoyl1phenyl1pyrazol-4-yl1carbamoyl1oxazol-2-vH-2-pyridyllcarbamate

[005495] To a mixture of tert-butyl N-[4-[4-[[l-[4-[2-[2-[2-[2-[2-[[(3S)-2-[(2S)-2-[[(2S)-2-[benzyloxycarbonyl (methyl)amino]propanoyl]amino]-3,3-dimethyl-butanoyl]-3-[[(lR)-tetralin-1-yl] carbamoyl] -3,4-dihydro- 1H-isoquinolin-7-yl]°xy]ethoxy]ethoxy]ethoxy]ethoxy]ethylcarbamoyl]phenyl]-3-(difluoromethyl)pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(cyclopropylmethyl)carbamate (30.0 mg, 20.6 umol) in THF (3 mL) was added Pd/C (30 mg, 10% *wt).* The reaction mixture was stirred at 25 °C for 2 hours under H_2 (15 psi) atmosphere. On completion, the reaction mixture was filtered and the filtrate concentrated *in vacuo* to give the title compound (27.0 mg, 99% yield) as light yellow oil. LC-MS (ESI^+) *m/z* 1316.6 $(M+H)^+$.

[005496] Step 3 - 2-r2-(Cvclopropylmethylamino)-4-pyridyl1-N-r3-(difluoromethyl)-l-r4-[2-[2-[2-[2-_ [2-[[(3S)-2-[(2S)-3.3-dimethyl-2-[[(2S)-2-(methylamino)propanoyl1amino1butanoyl1-3-rrn R)-tetralin- 1-yl lcarbam oyl1-3.4-di hydro-1 H-isoquinolin-7-yl1oxy1ethoxy1ethoxy1ethoxy1ethoxy1ethylcarbamoyl1phenyl1pyrazol-4-yl1oxazole-4-carboxamide

[005497] To a mixture of tert-butyl N-(cyclopropylmethyl)-N-[4-[4-[[3-(difluoromethyl)-l-[4-[2-[2-[2-[2-[2-[[(3S)-2-[(2S)-3,3-dimethyl-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]-3-[[(lR)-tetralin-l-yl]carbamoyl]-3,4-dihydro-lH-isoquinolin-7-yl]oxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylcarbamoyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (27.0 mg, 20.5 umol) in DCM (3 mL) was added HCl/dioxane (4 M, 5.13 uL). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo*. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 l50*25*l0um; mobile phase: [water (0.225%FA)-ACN]; B%: 13%-43%, lOmin) to give the title compound (10.7 mg, 42% yield) as white solid. ¾NMR (400MHz, DMSO-di) δ 10.06 (s, 1H), 8.98 (s, 1H), 8.92 (s, 1H), 8.65 (t, *J* = 5.2 Hz, 1H), 8.33 (s, 1H), 8.20 - 8.15 (m, 2H), 8.06 - 7.95 (m, 4H), 7.95 - 7.84 (m, 1H), 7.48 - 7.16 (m, 1H), 7.13 - 6.97 (m, 7H), 6.91 (d, *J* = 2.4 Hz, 1H), 6.81 - 6.75 (m, 1H), 4.99 - 4.81 (m, 2H), 4.79 - 4.61 (m, 2H), 4.08 - 4.01 (m, 2H), 3.73 (d, *J* = 3.6 Hz, 2H), 3.61 - 3.47 (m, 17H), 3.18 (t, 7 = 6.0 Hz, 2H), 3.02 - 2.90 (m, 3H), 2.74 - 2.62 (m, 2H), 2.16 (s, 1H), 2.12 (s, 2H), 1.89 - 1.73 (m, 2H), 1.72 - 1.62 (m, 1H), 1.60 - 1.50 (m, 1H), 1.12 - 0.99 (m, 10H), 0.98 - 0.88 (m, 3H), 0.48 - 0.43 (m, 2H), 0.26 - 0.20 (m, 2H). LC-MS (ESI^{+}) *m/z* 1216.6 (M+H)$^{+}$.

[005498] Example 515: 2-[2-(Cyclopropylmethylamino)-4-pyridyll-N-[3-(dif uoromethyl)-1-[4-[2-[2-[2-[2-[2-[2-[[(3S)-2-[(2S)-3,3-dimethyl-2-[[(2S)-2-[methylamino)propanoyl1amino1butanoyl1-3-[[[lR)-tetralin-l-yl1carbamoyl]-3.,4-dihvdro-lH-isoquinolin-7-yl1oxy1ethoxy1ethoxy1ethoxy1ethoxy1ethoxy1ethylcarbamoyl1phenyl1-pyrazol-4-yl1oxazole-4-carboxamide, 1-520



[005499] Step 1- Tert-butyl N-[4-[4-[1-[4-[2-[2-[2-[2-[2-[2-(3-[2-(2-[2-(3-[2-(1-benzyloxycarbonyl-(methyl)amino]propanoyl]amino]-3,3-dimethyl-butanoyl]-3-methyl-3,4-dihydro-1H-isoquinolin-7-yl]oxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylcarbamoyl]phenyl]-3-(difluoromethyl)pyrazol-

4-yl1carbamoyl1oxazol-2-yl1-2-pyridyl1-N-(cvclopiOpylmethvDcarbamate

[005500] To a mixture of benzyl N-[(lS)-2-[[(lS)-l-[(3S)-7-[2-[2-[2-[2-[2-(2-aminoethoxy)ethoxy] ethoxy] ethoxy]ethoxy]ethoxy]-3-[[(lR)-tetralin-l-yl]carbamoyl]-3,4-dihydro-lH-isoquinoline-2-carbonyl]-2-2-dimethyl-propyl]amino]-l -methyl-2-oxo-ethyl]-N-methyl-carbamate (70.0 mg, 76.2 umol, Intermediate WE), 4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carbonyl] amino]- 3-(difluoromethyl)pyrazol-l-yl]benzoic acid (45.3 mg, 76.2 umol, Intermediate FX) in DMF (2 mL) was added DIPEA (29.6 mg, 229 umol) and HATU (34.8 mg, 91.5 umol). The reaction mixture was stirred at 20 °C for 1 hour. On completion, the reaction mixture was poured into water (20 mL). The aqueous phase was extracted with ethyl acetate (2 X 20 mL). The combined organic phase was washed with brine (2 X 30 mL), dried with anhydrous Na_2S0_4, filtered and concentrated *in vacuo* to give residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (70 mg, 57% yield) as black solid. LC-MS (ESI^+) *m/z* 1494.9 $(M+H)^+$.

[005501] Step 2- Tert-butyl N-(cvclopropylmethvO-N-r4-r4-rr3-(difluoromethvO-l-r4-r2-r2-r2-r2-r2-r2-rr(3S)-2-r(2S)-3.3-dimethyl-2-rr(2S)-2-(methylamino)propanoyl1amino1butanoyl1-3-Ir(1RVtetralin- 1-yl]carbamoyl 1-3.4-di hydro- 1H-i soquinolin-7 -yl]oxyl ethoxy] ethoxy] ethoxy] ethoxy] ethoxy] ethyl carb amoyl]phenyl]pyrazol -4-yl1carbamoyl1oxazol-2-yl1-2-pyridyl1carbamate


[005502] To a mixture of tert-butyl N-[4-[4-[[l-[4-[2-[2-[2-[2-[2-[2-[[(3S)-2-[(2S)-2-[[(2S)-2-[benzyl oxycarbonyl(methyl)amino]propanoyl]amino]-3,3-dimethyl-butanoyl]-3-[[(lR)-tetralin-l-yl]carbamoyl]-3,4-dihydro-lH-isoquinolin-7-yl]oxy] ethoxy] ethoxy] ethoxy] ethoxy] ethoxy] -ethyl carb amoyl]phenyl]-3-(difluoromethyl)pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(cyclopropylmethyl)carbamate (35.0 mg, 23.4 umol) in THF (2 mL) was added Pd/C (20 mg, 20% *wt).* The suspension was degassed under vacuum and purged with Fh three times. The reaction mixture was stirred under Fh (15 psi) at 20 °C for 1 hour. On completion, the reaction mixture was filtered and concentrated *in vacuo* to give the title compound (32.0 mg, crude quant. yield) as brown solid. LC-MS (ESI^+) *m/z* 1360.6 $(M+H)^+$.

[005503] Step _3- _2-r2-(Cvclopropylmethylamino)-4-pyridyl1-N-r3-(difluoromethyl)-l-r4-[2-[2-[2-[2-[2-[2-_ rr(3SV2-r(2SV3.3-dimethyl-2-rr(2S>2-(methylamino)propanoyl1amino1butanoyl1-3-rrn R)-tetralin- l-yl lcarbam oyl1-3.4-di hydro-1 H-

isoquinolin-7-yl1oxy1ethoxy1ethoxy1ethoxy1ethoxy1-ethoxy1ethylcarbamoyl1phenyl1pyrazol-4-yl1oxazole-4-carboxamide

[005504] To a mixture of tert-butyl N-(cyclopropylmethyl)-N-[4-[4-[[3-(difluoromethyl)-l-[4-[2-[2-[2-[2-[2-[2-[[(3S)-2-[(2S)-3,3-dimethyl-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]-3-[[(lR)-tetralin-l-yl]carbamoyl]-3,4-dihydro-lH-isoquinolin-7-yl]oxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylcarbamoyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (32.0 mg, 23.5 umol) in DCM (5 mL) was added HCl/dioxane (4 M, 2 mL). The reaction mixture was stirred at 20 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo* to give the residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 l50*25*l0um;mobile phase: [water(0.225%FA)-ACN]; B%: l6%-46%,l0min) to give the title compound (8 mg, 6.17 umol, 26% yield) as a green solid. LC-MS (ESI^+) *m/z* 1260.9 $(M+H)^+$. ^1H NMR (400 MHz, DMSO-de) δ 10.07 (s, 1H), 9.03 - 8.90 (m, 2H), 8.66 (s, 1H), 8.25 - 8.13 (m, 2H), 8.07 - 7.85 (m, 5H), 7.48 - 7.17 (m, 1H), 7.16 - 6.99 (m, 8H), 6.92 (s, 1H), 6.82 - 6.77 (m, 1H), 5.01 - 4.82 (m, 2H), 4.80 - 4.61 (m, 2H), 4.05 (s, 2H), 3.73 (s, 2H), 3.58 - 3.51 (m, 18H), 3.19 - 3.17 (m, 4H), 3.00 - 2.97(m, 4H), 2.69 - 2.68(m, 3H), 2.22 - 2.04 (m, 3H), 1.92 - 1.74 (m, 2H), 1.73 - 1.51 (m, 3H), 1.14 - 1.00 (m, 10H), 0.94 (s, 2H), 0.47 - 0.45 (m, 2H), 0.23 - 0.22 (m, 2H).

[005505] Example 516: 2-[2-(Cvclopropylmethylamino)-4-pyridyll-N-[3-(dif uoromethyl)-1-[4-[2-[2-[2-[2-[[(3S)-2-l(2S)-3,3-dimethyl-2-ll(2S)-2-[methylamino)propanoyl1amino1butanoyl1-3-[[[lR)-tetralin-l-yl1carbamoyl]-3.,4-dihvdro-lH-isoquinolin-7-yl1oxy1ethoxy1ethoxy1ethoxy1ethylcarbamoyl1-phenyl1pyrazol-4-ylloxazole-4-carboxamide, 1-521



[005506] Step 1 - Tert-butyl N-[4-[4-[1-[4-[2-[2-[2-[(3S)-2-[(2S)-2-[(2S)-2-benzyloxycarbonyl(methyl)amino]propanoyl]amino]-3,3-dimethyl-butanoyl]-3-[(1R)-tetralin-1-yl]carbamoyl]-3,4-dihydro-1H-isoquinolin-7-yl]oxy]ethoxy]ethoxy]ethoxy]ethylcarbamoyl]phenyl]-3-(difluoromethyl)pyrazol-4-

yl1carbamoyl1oxazol-2-yl1-2-pyridyl1-N-(cvclopiO$_{Py}$lmethvDcarbamate

[005507] To a solution of benzyl N-[(lS)-2-[[(lS)-l-[(3S)-7-[2-[2-[2-(2-aminoethoxy)ethoxy] ethoxy] ethoxy] -3- [[(lR)-tetralin-l-yl]carbamoyl]-3,4-dihydro-lH-isoquinoline-2-carbonyl]-2,2-dimethyl-propyl]amino-l-methyl-2-oxo-ethyl]-N-methyl-carbamate (50 mg, 52.9 umol, TFA, Intermediate PF) and 4-[4-[[2-[2- [tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]benzoic acid (31.5 mg, 52.9 umol, Intermediate FX) in DMF (3 mL) was added DIPEA (34.2 mg, 264 umol, 46.1 uL) and HATU (24.1 mg, 63.5 umol). The mixture was stirred at 25 °C for 1.5 hr. On completion, the reaction mixture was quenched with FLO (1 mL) and then concentrated *in vacuo* to give a residue. The residue was purified by reverse phase (0.1% FA condition) to give the title compound (40 mg, 53% yield) as a white solid. LC-MS (ESI^+) m/z 1406.7 $(M+H)^+$.

[005508] Step 2 - Tert-butyl N-(cvclopropylmethvO-N-r4-r4-rr3-(difluoromethvO-l-r4-r2-[2-[2-[2-[[(3S)-2- r(2S)-3.3-dimethyl-2-rr(2S)-2-(methylamino)propanoyl1amino1butanoyl1-3-Π(1RVtetralin- 1-yl]carbamoyl 1-3.4-dihydro- 1H-isoquinolin-7 - yl1oxy1ethoxy1ethoxy1ethoxy1ethylcarbamoyl1-phenyl1pyrazol-4-yl1carbamoyl1oxazol-2-yl1-2-pyridyllcarbamate

[005509] To a solution of tert-butyl N-[4-[4-[[l-[4-[2-[2-[2-[2-[[(3S)-2-[(2S)-2-[[(2S)-2-[benzyloxycarbonyl (methyl)amino]propanoyl]amino]-3,3-dimethyl-butanoyl]-3-[[(lR)-tetralin-l-yl]carbamoyl]-3,4-dihydro-lH-isoquinolin-7-yl]oxy]ethoxy]ethoxy]ethoxy]ethyl carbamoyl]-phenyl]-3-(difluoromethyl)pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(cyclopropylmethyl)carbamate (40.0 mg, 28.4 umol) in THF (5 mL) was added Pd/C (20 mg, 10% *wi),* the reaction mixture was stirred at 25 °C for 40 mins under Ih. On completion, the mixture was filtered. The filtrate was concentrated *in vacuo* to give the title compound (35 mg, 96% yield) as a yellow solid. LC-MS (ESI^+) m/z 1272.8 $(M+H)^+$.

[005510] Step 3 - 2-r2-(CvclopropylmethylaminoV4-pyridyl1-N-r3-(difluoromethvD-l-r4-[2-[2-[2-[2-[[(3S)-2- r(2S)-3.3-dimethyl-2-rr(2S)-2-(methylamino)propanoyl1amino1butanoyl1-3-Π(1RVtetralin- 1-yl]carbamoyl1-3.4-dihydro- 1H-isoquinolin-7 - yl1oxy1ethoxy1ethoxy1ethoxy1ethylcarbamoyl1-phenyl1pyrazol-4-yl1oxazole-4-carboxamide

[005511] To a solution of tert-butyl N-(cyclopropylmethyl)-N-[4-[4-[[3-(difluoromethyl)-l-[4-[2-[2-[2-[2-[[(3 S) -2-[(2S)-3, 3-dimethyl -2-[[(2S)-2-

(methylamino)propanoyl]amino]butanoyl]-3-[[(lR)-tetralin-l-yl]carbamoyl]-3,4-dihydro-lH-isoquinolin-7-yl]oxy]ethoxy]ethoxy]ethoxy]ethylcarbamoyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (35.0 mg, 27.5 umol) in DCM (2 mL) was added HCl/dioxane (4 M, 2 mL), the reaction mixture was stirred at 20 °C for 1 hr. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 l50*25*l0um; mobile phase: [water(0.225%FA)-ACN]; B%: l5%-45%,l0min) to give the title compound (23.0 mg, 71% yield, FA) as a white solid. ^{1}H NMR (400MHz, DMSO-d_6) δ 10.05 (s, 1H), 8.97 (s, 1H), 8.91 (s, 1H), 9.71 - 8.60 (m, 1H), 8.21 - 8.13 (m, 2H), 8.04 - 8.00 (m, 2H), 7.99 - 7.95 (m, 2H), 7.94 - 7.85 (m, 1H), 7.45 - 7.17 (m, 1H), 7.14 - 7.00 (m, 8H), 6.91 - 6.76 (m, 2H), 5.09 - 4.47 (m, 6H), 4.06 - 4.01 (m, 2H), 3.74 - 3.68 (m, 2H), 3.55 (s, 9H), 3.48 - 3.45 (m, 2H), 3.18 (t, J = 6.0 Hz, 2H), 3.03 - 2.91 (m, 4H), 2.73 - 2.64 (m, 2H), 2.16 (s, 1H), 2.1 1 (s, 2H), 1.88 - 1.73 (m, 2H), 1.70 - 1.63 (m, 1H), 1.60 - 1.50 (m, 1H), 1.1 1 - 1.02 (m, 10H), 0.93 (s, 3H), 0.47 - 0.42 (m, 2H), 0.24 - 0.20 (m, 2H); LC-MS (ESI^{+}) m/z H72.8(M+H) $^{+}$.

[005512] Table 23: Compounds synthesized via Method 16 with the reductive amination of various amines with aldehydes in Step 1

Ex-#	I-#	Step 1 Intermediate Amine	Step 1 Intermediate Aldehyde	LCMS (ES+) m/z $(M+H)^+$	1HNMR (400MHz, DMSO-d6) δ
517	**I-522**	UE	LS	915.4	11.08 (s, 1H), 10.8 (s, 1H), 8.89 (s, 1H), 8.29 - 8.20 (m, 2H), 8.10 (s, 1H), 7.61 - 7.50 (m, 2H), 7.25 - 7.16 (m, 2H), 7.12 (d, J = 8.8 Hz, 1H), 7.03 (d, J = 7.2 Hz, 1H), 6.59 (t, J = 5.6 Hz, 1H), 5.07-5.04 (m, 1H), 4.32 - 4.16 (m, 2H), 3.95 (s, 2H), 3.79 (s, 3H), 3.53 - 3.41 (m, 22H), 2.94 - 2.82 (m, 1H), 2.77 (t, J = 5.6 Hz, 2H), 2.64 - 2.53 (m, 2H), 2.08 - 1.97 (m, 1H)

518	**I-523**	WI	GF	865.4	11.10 (s, 1H), 10.01 (s, 1H), 8.98 (s, 1H), 8.80 (s, 1H), 8.24 (s, 1H), 8.17 (d, *J* = 5.2 Hz, 1H), 7.82 (d, *J* = 8.4 Hz, 2H), 7.51 (d, *J* = 8.4 Hz, 2H), 7.45 - 7.15 (m, 1H), 7.14 - 7.08 (m, 2H), 7.07 - 7.02 (m, 1H), 6.99 - 6.92 (m, 2H), 6.88 - 6.85 (m, 1H), 5.37 (dd, *J* = 5.6, 12.8 Hz, 1H), 3.81 (s, 2H), 3.56 (s, 3H), 3.34 - 3.29 (m, 4H), 3.27 - 3.15 (m, 2H), 2.96 - 2.86 (m, 3H), 2.77 - 2.58 (m, 4H), 2.04 - 1.94 (m, 1H), 1.68 - 1.49 (m, 8H), 1.13 - 1.00 (m, 1H), 0.50 - 0.42 (m, 2H), 0.27 - 0.19 (m, 2H)
519	**I-524**	LP	LS	984.3	10.83 (s, 1H), 8.97 (s, 1H), 8.90 (s, 1H), 8.56 (s, 1H), 8.22 (s, 2H), 8.10 (s, 1H), 7.56 (s, 1H), 7.40 (s, 5H), 7.21 (s, 2H), 4.58 - 4.49 (m, 1H), 4.43 - 4.36 (m, 1H), 4.34 (s, 1H), 4.26 - 4.24 (m, 2H), 3.95 (s, 2H), 3.85 - 3.75 (m, 1H), 3.79 (s, 3H), 3.70 - 3.58 (m, 14H), 3.20 - 3.16 (m, 1H), 3.07 (s, 2H), 3.15 - 2.98 (m, 1H), 2.77 (s, 2H), 2.64 - 2.59 (m, 1H), 2.48 - 2.40 (m, 4H), 1.93 - 1.89 (m, 1H), 0.89 (s, 9H)
520	**I-525**	VE	LS	922.4	11.10 (s, 1H), 10.75 - 10.60 (m, 1H), 8.97 - 8.83 (m, 1H), 8.25 - 8.13 (m, 2H), 7.60 - 7.38 (m, 1H), 7.30 - 7.10 (m, 2H), 7.02 - 6.81 (m, 3H), 5.41 - 5.30 (m, 1H), 4.39 - 4.04 (m, 6H), 3.78 (s, 3H), 3.64 - 3.54 (m, 4H), 3.52 - 3.49 (m, 3H), 2.99 - 2.77 (m, 13H), 2.72 - 2.62 (m, 2H), 2.28 - 2.16 (m, 3H), 2.08 (s, 1H), 2.02 - 1.94 (m, 1H), 1.91 - 1.72 (m, 2H)

521	**I-526**	VH	GY	1027.5	11.06 - 10.07 (m, 1H), 10.16 - 9.95 (m, 1H), 9.01 (d, *J* = 2.4 Hz, 2H), 8.25 (d, *J* = 5.2 Hz, 1H), 8.16 - 7.97 (m, 3H), 7.83 - 7.67 (m, 3H), 7.50 - 7.37 (m, 1H), 7.35 - 7.24 (m, 2H), 7.22 - 7.15 (m, 1H), 7.13 - 6.95 (m, 2H), 6.92 - 6.81 (m, 1H), 5.38 - 5.27 (m, 1H), 4.50 - 3.99 (m, 6H), 3.27 - 3.20 (m, 4H), 3.02 - 2.65 (m, 15H), 2.37 - 1.69 (m, 3H), 1.58 - 1.39 (m, 1H), 1.23 (s, 4H), 1.20 - 1.14 (m, 1H), 0.85 (t, *J* = 6.4 Hz, 1H)
522[b]	**I-527**	HQ	VI	749.0	11.70 - 11.64 (m, 1H), 11.06 (s, 1H), 9.24 (s, 2H), 9.07 (s, 1H), 9.01 (d, *J* = 4.8 Hz, 1H), 8.50 (s, 1H), 8.18 (d, *J* = 4.8 Hz, 1H), 8.06-8.04 (m, 2H), 7.80 - 7.68 (m, 3H), 7.00 - 6.89 (m, 2H), 6.85-6.82 (m, 1H), 5.38-5.30 (m, 1H), 4.28-4.20 (m, 2H), 3.80 - 3.70 (m, 2H), 3.65 - 3.51 (m, 9H), 3.19 - 3.08 (m, 2H), 2.99 - 2.82 (m, 3H), 2.74 - 2.57 (m, 2H), 2.04 - 1.91 (m, 1H), 1.88 - 1.77 (m, 2H)
523	**I-528**	HQ	VM	885.4	11.07 (s, 1H), 8.84 (s, 1H), 8.77 (s, 1H), 8.22 (d, *J* = 1.6 Hz, 1H), 7.73 - 7.67 (m, 2H), 7.56 (t, *J* = 6.4 Hz, 1H), 7.41 (d, *J* = 8.6 Hz, 2H), 7.25 (s, 1H), 7.18 (dd, *J* = 1.2, 5.2 Hz, 1H), 6.98 - 6.91 (m, 2H), 6.92 - 6.82 (m, 1H), 5.39 - 5.32 (m, 1H), 4.28 - 4.17 (m, 4H), 3.77 (s, 2H), 3.55 (s, 3H), 3.54 - 3.51 (m, 6H), 3.47 - 3.44 (m, 2H), 2.97 - 2.92 (m, 2H), 2.92 - 2.85 (m, 1H), 2.82 (t, *J* = 6.4 Hz, 2H), 2.70 (t, *J* = 5.6 Hz, 2H), 2.68 - 2.56 (m, 2H), 2.08 - 2.01 (m, 2H), 2.01 - 1.95 (m, 1H), 1.86 - 1.77 (m, 2H)

524	**I-529**	VO	GF	910.5	10.99 (s, 1H), 10.01 (s, 1H), 8.97 (s, 1H), 8.79 (s, 1H), 8.32 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.80 (d, *J* = 8.4 Hz, 2H), 7.66 (d, *J* = 8.0 Hz, 1H), 7.49 (d, *J* = 8.8 Hz, 2H), 7.44 - 7.38 (m, 2H), 7.31 - 7.15 (m, 1H), 7.13 - 7.08 (m, 2H), 7.05 (d, *J* = 5.2 Hz, 1H), 6.59 (, *J* = 5.6 Hz, 1H), 6.09 - 6.04 (m, 1H), 5.15 - 5.05 (m, 1H), 4.42 - 4.30 (m, 4H), 3.77 (s, 2H), 3.56 - 3.52 (m, 12H), 3.22 - 3.17 (m, 2H), 2.95 - 2.90 (m, 1H), 2.69 - 2.66(m, 1H), 2.43 - 2.30 (m, 1H), 2.05 - 1.94 (m, 1H), 1.27 - 1.11 (m, 1H), 0.49 - 0.43 (m, 2H), 0.26 - 0.21 (m, 2H)
525	**I-530**	RI	GF	823.1	11.07 (s, 1H), 9.97 (s, 1H), 8.96 (s, 1H), 8.79 (s, 1H), 8.19 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.82 (d, *J* = 8.4 Hz, 2H), 7.51 (d, *J* = 8.4 Hz, 2H), 7.44 - 7.14 (m, 1H), 7.12 (s, 1H), 7.08 (t, *J* = 5.6 Hz, 1H), 7.04 (dd, *J* = 1.6, 5.2 Hz, 1H), 6.99 - 6.93 (m, 2H), 6.90 - 6.84 (m, 1H), 5.36 (dd, *J* = 5.2, 12.4 Hz, 1H), 3.84 (s, 2H), 3.56 (s, 3H), 3.52 -3.48 (m, 2H), 3.47 -3.44 (m, 2H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.99 - 2.94 (m, 2H), 2.90 - 2.82 (m, 1H), 2.74 (t, *J* = 5.2 Hz, 2H), 2.70 - 2.57 (m, 2H), 2.03 - 1.94 (m, 1H), 1.90 - 1.79 (m, 2H), 1.12 - 1.02 (m, 1H), 0.49 - 0.43 (m, 2H), 0.26 - 0.20 (m, 2H)
526	**I-531**	RH	GF	823.4	11.09 (s, 1H), 10.01 (s, 1H), 8.96 (s, 1H), 8.79 (s, 1H), 8.21 (s, 1H), 8.15 (d, *J* = 5.2 Hz, 1H), 7.83 (d, *J* = 8.4 Hz, 2H), 7.53 (d, *J* = 8.4 Hz, 2H), 7.44 - 7.14 (m, 1H), 7.13 - 7.07 (m, 2H), 7.06 - 7.02 (m, 2H), 7.00 (d, *J* = 8.0 Hz, 1H), 6.87 (d, *J* = 8.0 Hz, 1H), 5.37 - 5.28 (m, 1H), 3.86 (s, 2H), 3.40 - 3.38 (m, 4H), 3.31 (s, 3H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.94 - 2.84 (m, 1H), 2.76 (t, *J* = 5.6 Hz, 2H), 2.71 - 2.66 (m, 2H), 2.65 - 2.54 (m, 2H), 2.05 - 1.94 (m, 1H), 1.89 -

					1.77 (m, 2H), 1.13 - 1.00 (m, 1H), 0.50 - 0.41 (m, 2H), 0.25 - 0.20 (m, 2H)
527	**I-532**	RH	JC	951.4	11.07 (s, 1H), 9.98 (s, 1H), 8.99 (s, 1H), 8.79 (s, 1H), 8.25 (d, *J* = 5.6 Hz, 1H), 7.81 (d, *J* = 7.6 Hz, 2H), 7.61 (t, *J* = 6.4 Hz, 1H), 7.50 (d, *J* = 7.2 Hz, 2H), 7.43 - 7.15 (m, 3H), 7.06 - 6.97 (m, 2H), 6.87 (d, *J* = 7.6 Hz, 1H), 5.33 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.30 - 4.19 (m, 2H), 3.81 (s, 2H), 3.55 - 3.44 (m, 7H), 2.96 - 2.83 (m, 1H), 2.71 - 2.64 (m, 4H), 2.60 - 2.53 (m, 2H), 2.04 - 1.96 (m, 1H), 1.90 - 1.85 (m, 2H)
528	**I-533**	RI	JC	851.1	11.08 (s, 1H), 9.99 (s, 1H), 8.99 (s, 1H), 8.80 (s, 1H), 8.25 (d, *J* = 5.2 Hz, 1H), 8.16 (s, 1H), 7.83 (d, *J* = 8.4 Hz, 2H), 7.61 (t, *J* = 6.8 Hz, 1H), 7.53 (d, *J* = 8.4 Hz, 2H), 7.44 - 7.15 (m, 3H), 6.99 - 6.93 (m, 2H), 6.90 - 6.84 (m, 1H), 5.36 (dd, *J* = 5.2, 12.4 Hz, 1H), 4.32 - 4.19 (m, 2H), 3.87 (s, 2H), 3.56 (s, 3H), 3.52 (t, *J* = 5.2 Hz, 2H), 3.49 - 3.46 (t, *J* = 6.4 Hz, 2H), 3.01 - 2.94 (m, 2H), 2.91 - 2.82 (m, 1H), 2.77 (t, *J* = 5.6 Hz, 2H), 2.72 - 2.58 (m, 2H), 2.03 - 1.94 (m, 1H), 1.90 - 1.78 (m, 2H)
529	**I-534**	LG	JC	865.4	11.07 (s, 1H), 9.99 (s, 1H), 8.99 (s, 1H), 8.78 (s, 1H), 8.25 (d, *J* = 5.2 Hz, 1H), 7.81 (d, *J* = 8.4 Hz, 2H), 7.61 (t, *J* = 6.4 Hz, 1H), 7.51 (d, *J* = 8.4 Hz, 2H), 7.43 - 7.14 (m, 3H), 7.05 - 6.94 (m, 2H), 6.84 (d, J=8.2 Hz, 1H), 5.32 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.29 - 4.20 (m, 2H), 3.81 (s, 2H), 3.43 (t, *J* = 6.0 Hz, 2H), 3.36 (t, *J* = 6.0 Hz, 2H), 3.31 (s, 3H), 2.93 - 2.83 (m, 1H), 2.75 - 2.57 (m, 6H), 2.05 - 1.95 (m, 1H), 1.86 - 1.75 (m, 2H), 1.75 - 1.65 (m, 2H)

530	**I-535**	LF	JC	865.4	11.08 (s, 1H), 10.10 (d, *J* = 2.0 Hz, 1H), 9.06 (s, 1H), 8.87 (s, 1H), 8.26 (d, *J* = 5.6 Hz, 1H), 8.09 - 7.91 (m, 3H), 7.81-7.76 (m, 2H), 7.48 - 7.17 (m, 3H), 7.02 - 6.91 (m, 2H), 6.89 - 6.78 (m, 1H), 5.39-5.35 (m, 1H), 4.37 - 4.29 (m, 2H), 4.22 (m, 3H), 3.56 (d, *J* = 4.8 Hz, 3H), 3.50 - 3.44 (m, 4H), 3.13 - 2.79 (m, 5H), 2.70 (d, *J* = 4.8 Hz, 2H), 2.62 (d, *J* = 8.8 Hz, 1H), 2.07 - 1.93 (m, 3H), 1.88 - 1.75 (m, 2H)
531[c]	**I-536**	OS	GF	934.5	11.08 (s, 1H), 10.16 (s, 1H), 8.95 (s, 1H), 8.77 (s, 1H), 8.30 (s, 2H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.79 (d, *J* = 8.0 Hz, 2H), 7.49 (d, *J* = 8.0 Hz, 2H), 7.43 - 7.14 (m, 2H), 7.11 (s, 1H), 7.10 - 6.93 (m, 4H), 6.88 (d, *J* = 3.6 Hz, 1H), 5.35 - 5.33 (m, 1H), 4.31 (s, 2H), 3.81 - 3.79 (m, 11H), 3.22 - 3.12 (m, 2H), 2.93 - 2.91 (m, 4H), 2.72 - 2.59 (m, 2H), 2.59 - 2.58 (m, 2H), 2.59 - 2.57 (m, 1H), 2.39 - 2.36 (m, 1H), 2.29 - 2.26 (m, 2H), 2.01 - 1.98 (m, 1H), 1.79 1.76 (m, 2H), 1.9 - 1.06 (m, 1H), 0.48 - 0.44 (m, 2H), 0.50 - 0.40 (m, 1H), 0.24 - 0.21 (m, 2H)
532[c]	**I-537**	OV	GF	934.5	11.10 (s, 1H), 10.23 (s, 1H), 9.55 (s, 1H), 9.14 (s, 1H), 9.07 (s, 1H), 8.89 (s, 1H), 8.11 (d, *J* = 6.4 Hz, 1H), 7.96 (d, *J* = 8.8 Hz, 2H), 7.77 (d, *J* = 8.8 Hz, 2H), 7.56 (s, 1H), 7.49 - 7.18 (m, 3H), 7.13 - 7.02 (m, 2H), 6.91 (d, *J* = 8.0 Hz, 1H), 5.43 - 5.30 (m, 1H), 4.55 - 4.43 (m, 2H), 4.30 - 4.17 (m, 2H), 3.94 - 3.81 (m, 2H), 3.76 - 3.46 (m, 2H), 3.34 (s, 3H), 3.30 - 3.21 (m, 4H), 3.05 - 2.95 (m, 2H), 2.94 - 2.85 (m, 4H), 2.85 - 2.80 (m, 1H), 2.75 - 2.69 (m, 2H), 2.65 - 2.59 (m, 2H), 2.06 - 1.92 (m, 3H), 1.20 - 1.07 (m, 1H), 0.60 - 0.50 (m, 2H), 0.35 - 0.27 (m, 2H)

533	**I-538**	PA	OX	829.3	11.22 (s, 1H), 10.70 (s, 1H), 9.02 (s, 1H), 8.88 - 8.78 (m, 1H), 8.24 (s, 1H), 8.17 (d, *J* = 5.2 Hz, 1H), 7.83 (d, *J* = 8.4 Hz, 2H), 7.52 (d, *J* = 8.8 Hz, 2H), 7.25 (s, 1H), 7.18 - 7.01 (m, 5H), 5.34 (d, *J* = 5.6, 13.2 Hz, 1H), 3.79 (s, 2H), 3.57 - 3.47 (m, 5H), 3.24 - 3.15 (m, 2H), 2.70 - 2.61 (m, 7H), 2.37 - 2.31 (m, 2H), 2.21 - 2.08 (m, 1H), 2.21 - 2.07 (m, 2H), 1.78 (d, *J* = 7.2 Hz, 2H), 1.12 - 0.98 (m, 1H), 0.52 - 0.40 (m, 2H), 0.29 - 0.17 (m, 2H)
534	**I-539**	VR	VZ	885.5	11.09 (s, 1H), 9.99 (s, 1H), 8.97 (s, 1H), 8.84 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.75 - 7.67 (m, 2H), 7.64 - 7.55 (m, 1H), 7.29 (t, *J* = 54.0 Hz, 1H), 7.12 (s, 1H), 7.10 - 7.06 (m, 1H), 7.05 - 7.03 (m, 1H), 7.02 - 7.00 (m, 1H), 7.00 - 6.96 (m, 1H), 6.85 (d, *J* = 8.0 Hz, 1H), 5.32 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.80 (s, 2H), 3.56 - 3.47 (m, 6H), 3.42 - 3.37 (m, 2H), 3.30 (s, 3H), 3.19 (t, *J* = 6.0 Hz, 2H), 2.94 - 2.83 (m, 1H), 2.74 - 2.57 (m, 6H), 2.03 - 1.95 (m, 1H), 1.85 - 1.74 (m, 2H), 1.12 - 1.02 (m, 1H), 0.49 - 0.42 (m, 2H), 0.26 - 0.20 (m, 2H)
535[b]	**I-540**	PD	PB	865.3	10.85 (s, 1H), 9.78 (s, 1H), 8.73 (s, 1H), 8.57 (s, 1H), 8.07 (s, 1H), 7.93 (d, *J* = 5.2 Hz, 1H), 7.61 (d, *J* = 8.0 Hz, 2H), 7.32 (d, *J* = 8.0 Hz, 2H), 7.05 (t, *J* = 54 Hz, 1H), 6.88 (s, 1H), 6.85 - 6.80 (m, 2H), 6.80 - 6.74 (m, 2H), 6.63 (d, *J* = 7.2 Hz, 1H), 5.15 - 5.05 (m, 1H), 3.67 (s, 2H), 3.09 (s, 3H), 3.00 - 2.92 (m, 2H), 2.72 - 2.60 (m, 1H), 2.49 - 2.37 (m, 4H), 2.36 - 2.31 (m, 2H), 1.82 - 1.71 (m, 1H), 1.40 - 1.21 (m, 4H), 1.18 - 1.07 (m, 4H), 1.02 - 0.84 (m, 1H), 0.79 (s, 3H), 0.25 - 0.19 (m, 2H), 0.02 - 0.04 (m, 2H)

536	**I-541**	HQ	WJ	860.4	11.10 (s, 1H), 9.87 (s, 1H), 8.90 (s, 1H), 8.73 (d, *J* = 2.0 Hz, 1H), 8.43 (s, 1H), 8.32 (s, 1H), 8.22 (d, *J* = 5.2 Hz, 1H), 8.03 (s, 1H), 7.99 (s, 1H), 7.58 (t, *J* = 6.8 Hz, 1H), 7.22 (s, 1H), 7.19 (d, *J* = 5.26 Hz, 1H), 6.94 (d, *J* = 6.4 Hz, 2H), 6.86 - 6.81 (m, 1H), 5.37 - 5.34 (m, 1 H), 4.27 - 4.17 (m, 2H), 3.91 (s, 3H), 3.75 (s, 2H), 3.52 (s, 3H), 3.46 - 3.42 (m, 8H), 2.91 - 2.89 (m, 3H), 2.64 - 2.58 (m, 4H), 1.99 - 1.98 (m, 1H), 1.79 (m, 2H)
537	**I-542**	PH	PG	836.5	11.61 - 10.80 (m, 1H), 10.02 (s, 1H), 8.97 (s, 1H), 8.80 (s, 1H), 8.29 (s, 2H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.83 (d, *J* = 8.4 Hz, 2H), 7.53 (d, *J* = 8.4 Hz, 2H), 7.43 - 7.15 (m, 2H), 7.13 - 7.02 (m, 5H), 5.42 - 5.30 (dd, *J* = 5.4, 12.7 Hz, 1H), 3.91 (s, 2H), 3.85 - 3.83 (m, 2H), 3.39 - 3.28 (m, 3H), 3.18 (t, *J* = 6.4 Hz, 2H), 2.96 - 2.84 (m, 1H), 2.77 - 2.68 (m, 2H), 2.68 - 2.64 (m, 2H), 2.64 - 2.58 (d, *J* = 6.8 Hz, 2H), 2.04 - 1.94 (m, 1H), 1.58 - 1.42 (m, 4H), 1.38 - 1.26 (m, 2H), 1.17 - 0.97 (m, 1H), 0.50 - 0.41 (m, 2H), 0.28 - 0.19 (m, 2H)
538	**I-543**	WH	GF	852.3	11.09 (s, 1H), 10.00 (s, 1H), 8.97 (s, 1H), 8.79 (s, 1H), 8.55 (t, *J* = 6.0 Hz, 1H), 8.20 - 8.12 (m, 2H), 7.80 (d, *J* = 8.4 Hz, 2H), 7.49 (d, *J* = 8.4 Hz, 2H), 7.43 - 7.15 (m, 1H), 7.13 - 7.08 (m, 2H), 7.07 - 7.02 (m, 3H), 6.95 (d, *J* = 8.4 Hz, 1H), 5.34 (dd, *J* = 5.6, 12.8 Hz, 1H), 4.34 (d, *J* = 6.0 Hz, 2H), 3.95 (s, 2H), 3.82 (s, 2H), 3.59 - 3.57 (m, 2H), 3.30 (s, 3H), 3.21 - 3.14 (m, 2H), 2.93 - 2.84 (m, 1H), 2.77 (t, *J* = 5.2 Hz, 2H), 2.71 - 2.57 (m, 2H), 2.04 - 1.93 (m, 1H), 1.13 - 1.01 (m, 1H), 0.49 - 0.41 (m, 2H), 0.27 - 0.19 (m, 2H)

539	**I-544**	SV	GY	902.5	11.02 (s, 1H), 9.03 (s, 1H), 8.96 (s, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.06 (s, 1H), 8.00 (d, *J* = 8.4 Hz, 2H), 7.76 (s, 1H), 7.71 (t, *J* = 6.4 Hz, 1H), 7.60 (d, *J* = 8.4 Hz, 2H), 7.27 (s, 1H), 7.17 (dd, *J* = 1.2, 5.2 Hz, 1H), 6.98 - 6.89 (m, 2H), 6.84 (dd, *J* = 1.2, 7.2 Hz, 1H), 5.47 - 5.38 (m, 1H), 4.31 - 4.19 (m, 2H), 4.09 (s, 2H), 3.65 (t, *J* = 5.2 Hz, 2H), 3.61 - 3.58 (m, 2H), 3.58 - 3.56 (m, 2H), 3.55 (s, 3H), 3.47 (t, *J* = 6.0 Hz, 2H), 3.01 (s, 3H), 2.99 - 2.91 (m, 4H), 2.80 - 2.74 (m, 1H), 2.72 - 2.52 (m, 2H), 2.05 - 1.95 (m, 1H), 1.88 - 1.75 (m, 2H)
540	**I-545**	PL	GF	852.4	11.09 (s, 1H), 9.99 (s, 1H), 8.97 (s, 1H), 8.79 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.81 (d, *J* = 8.4 Hz, 2H), 7.63 (t, *J* = 5.6 Hz, 1H), 7.50 (d, *J* = 8.4 Hz, 2H), 7.27 (t, *J* = 7.6 Hz, 1H), 7.11 (s, 1H), 7.10 - 7.01 (m, 4H), 6.94 (d, *J* = 7.6 Hz, 1H), 5.34 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.19 (d, *J* = 5.6 Hz, 2H), 4.04 (t, *J* = 6.4 Hz, 2H), 3.80 (s, 2H), 3.31 (s, 3H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.94 - 2.86 (m, 1H), 2.73 - 2.60 (m, 2H), 2.55 - 2.52 (m, 2H), 2.04 - 1.94 (m, 1H), 1.81 - 1.70 (m, 2H), 1.11 - 1.02 (m, 1H), 0.48 - 0.42 (m, 2H), 0.25 - 0.19 (m, 2H)
544	**I-549**	PZ	GF	824.2	11.15 (s, 1H), 9.93 (s, 1H), 8.91 (s, 1H), 8.72 (s, 1H), 8.21 (s, 1H), 8.11 (d, *J* = 5.2 Hz, 1H), 7.75 (d, *J* = 8.8 Hz, 2H), 7.45 (d, *J* = 8.8 Hz, 2H), 7.38 - 7.17 (m, 2H), 7.12 - 7.03 (m, 3H), 7.01 - 6.94 (m, 2H), 5.28 (d, *J* = 5.2, 12.8 Hz, 1H), 3.72 (s, 2H), 3.19 - 3.09 (m, 8H), 2.89 - 2.76 (m, 2H), 2.62 (d, *J* = 2.0, 3.6 Hz, 4H), 2.58 - 2.52 (m, 5H), 2.32 - 2.25 (m, 2H), 2.09 (td, *J* = 5.2, 10.4 Hz, 1H), 1.78 - 1.68 (m, 2H), 1.64 (d, *J* = 6.5 Hz, 2H), 1.07 - 0.96 (m, 1H), 0.45 - 0.37 (m, 2H), 0.21 - 0.14 (m, 2H)

545	**I-550**	PA	GF	854.4	11.16 (s, 1H), 9.97 (s, 1H), 8.95 (s, 1H), 8.77 (s, 1H), 8.20 (s, 1H), 8.15 (d, *J* = 5.2 Hz, 1H), 7.80 (d, *J* = 8.4 Hz, 2H), 7.50 (d, *J* = 8.4 Hz, 2H), 7.42 - 7.10 (m, 4H), 7.08 - 6.99 (m, 3H), 5.32 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.83 (s, 2H), 3.55 - 3.52 (m, 2H), 3.50 - 3.48 (m, 6H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.95 - 2.81 (m, 1H), 2.75 - 2.70 (m, 2H), 2.68 - 2.60 (m, 4H), 2.19 - 2.08 (m, 1H), 1.82 - 1.73 (m, 2H), 1.08 - 1.06 (m, 1H), 0.51 - 0.40 (m, 2H), 0.24 - 0.20 (m, 2H)
546	**I-551**	JG	GF	854.3	11.21 (s, 1H), 10.00 (s, 1H), 8.97 (s, 1H), 8.77 (s, 1H), 8.25 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.78 (d, *J* = 8.4 Hz, 2H), 7.54 - 7.45 (m, 2H), 7.29 (t, *J* = 54 Hz 1H), 7.14 - 7.06 (m, 4H), 7.05 - 7.02 (m, 1H), 7.01 - 6.97 (m, 1H), 5.35 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.80 (s, 2H), 3.53 - 3.49 (m, 8H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.91 - 2.84 (m, 1H), 2.75 - 2.65 (m, 6H), 2.17 - 2.10 (m, 1H), 1.88 - 1.77 (m, 2H), 1.12 - 1.03 (m, 1H), 0.50 - 0.42 (m, 2H), 0.26 - 0.18(m, 2H)
547	**I-552**	QC	GF	839.4	11.08 (s, 1H), 9.97 (s, 1H), 8.95 (s, 1H), 8.78 (s, 1H), 8.15 (d, *J* = 5.2 Hz, 1H), 7.79 (d, *J* = 8.4 Hz, 2H), 7.48 (d, *J* = 8.8 Hz, 2H), 7.42 - 7.14 (m, 2H), 7.12 - 6.98 (m, 6H), 5.39 - 5.32 (m, 1H), 3.99 (t, *J* = 5.6 Hz, 2H), 3.78 (s, 2H), 3.69 (t, *J* = 5.6 Hz, 2H), 3.55 - 3.52 (m, 2H), 3.47 - 3.45 (m, 4H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.95 - 2.83 (m, 1H), 2.69 - 2.58 (m, 4H), 2.06 - 1.96 (m, 1H), 1.12 - 1.01 (m, 1H), 0.49 - 0.42 (m, 2H), 0.26 - 0.19 (m, 2H)

548[d]	**I-553**	QE	GF	1224.5	10.22 (s, 1H), 9.34 (s, 1H), 9.14 (s, 1H), 8.88 (s, 2H), 8.75 (d, *J* = 8.0 Hz, 1H), 8.49 (s, 1H), 8.10 (d, *J* = 6.4 Hz, 1H), 7.95 (d, *J* = 8.4 Hz, 2H), 7.73 (d, *J* = 8.4 Hz, 2H), 7.71 - 7.53 (m, 3H), 7.50 - 7.19 (m, 5H), 5.39 (dd, *J* = 3.2, 7.6 Hz, 1H), 4.47 (t, *J* = 7.6 Hz, 1H), 4.26 - 4.20 (m, 2H), 4.18 - 4.14 (m, 2H), 3.92 - 3.72 (m, 7H), 3.61 - 3.55 (m, 7H), 3.55 - 3.48 (m, 14H), 3.14 - 3.07 (m, 2H), 2.31 - 2.17 (m, 2H), 2.11 - 1.95 (m, 3H), 1.79 - 1.52 (m, 4H), 1.36 (d, *J* = 6.8 Hz, 2H), 1.26 - 1.23 (m, 3H), 1.19 - 1.00 (m, 5H), 0.58 - 0.52 (m, 2H), 0.35 - 0.29 (m, 2H)
549[d]	**I-554**	QF	GF	1136.5	10.00 (s, 1H), 8.95 (s, 1H), 8.78 (s, 1H), 8.47 (s, 1H), 8.26 (s, 1H), 8.15 (d, *J* = 4.8 Hz, 1H), 8.11 (s, 1H), 7.80 (d, *J* = 6.4 Hz, 2H), 7.71 - 7.60 (m, 2H), 7.55 - 7.14 (m, 6H), 7.13 - 6.99 (m, 3H), 5.38 (d, *J* = 5.2 Hz, 1H), 4.52 - 4.44 (m, 1H), 4.14 (s, 2H), 4.05 - 3.60 (m, 16H), 3.21 - 3.15 (m, 2H), 2.72 (s, 2H), 2.28 - 2.12 (m, 5H), 2.08 - 1.98 (m, 2H), 1.71 - 1.58 (m, 4H), 1.56 - 1.48 (m, 2H), 1.15 (s, 3H), 1.11 - 0.84 (m, 7H), 0.45 (d, *J* = 7.2 Hz, 2H), 0.22 (d, *J* = 3.2 Hz, 2H)
550[d]	**I-555**	QG	GF	1180.5	9.99 (s, 1H), 8.96 (s, 1H), 8.79 (s, 1H), 8.48 (s, 1H), 8.26 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.11 (d, *J* = 8.8 Hz, 1H), 7.81 (d, *J* = 8.4 Hz, 2H), 7.67 (d, *J* = 8.0 Hz, 1H), 7.64 (s, 1H), 7.51 (d, *J* = 8.4 Hz, 2H), 7.49 - 7.40 (m, 2H), 7.31 - 7.17 (m, 2H), 7.16 - 7.07 (m, 2H), 7.04 (d, *J* = 5.6 Hz, 1H), 5.41 - 5.35 (m, 1H), 4.55 - 4.45 (m, 1H), 4.17 - 4.12 (m, 2H), 3.81 - 3.73 (m, 14H), 3.59 - 3.57 (m, 2H), 3.55 - 3.53 (m, 2H), 3.49 (s, 3H), 3.22 - 3.16 (m, 2H), 2.76 - 2.70 (m, 2H), 2.25 (s, 3H), 2.23 - 2.14 (m, 2H), 2.11 - 2.01 (m, 2H), 1.68 - 1.62 (m, 2H), 1.58 - 1.52 (m, 2H),

					1.35 - 0.84 (m, 11H), 0.50 - 0.43 (m, 2H), 0.26 - 0.20 (m, 2H)
551[d]	**I-556**	QH	GF	1114.6 $(M+Na)^+$	9.95 (s, 1H), 8.96 (s, 1H), 8.76 (s, 1H), 8.47 (s, 1H), 8.16 (d, J = 5.2 Hz, 1H), 7.89 (d, J = 8.8 Hz, 1H), 7.77 (d, J = 8.4 Hz, 2H), 7.69 - 7.41 (m, 6H), 7.30 - 7.20 (m, 2H), 7.17 - 7.01 (m, 4H), 5.38 (dd, J = 2.4, 7.6 Hz, 1H), 4.54 - 4.43 (m, 1H), 4.18 - 4.15 (m, 2H), 3.81 - 3.73 (m, 6H), 3.63 - 3.59 (m, 2H), 3.56 - 3.48 (m, 4H), 3.18 (t, J = 6.4 Hz, 2H), 2.99 - 2.93 (m, 1H), 2.66 - 2.62 (m, 2H), 2.19 - 2.16 (m, 4H), 2.10 - 1.90 (m, 2H), 1.63 - 1.52 (m, 6H), 1.23 (s, 3H), 1.10 - 1.06 (m, 5H), 0.90 - 0.85 (m, 1H), 0.47 - 0.43 (m, 2H), 0.25 - 0.21 (m, 2H)
552	**I-557**	QN	GF	911.5	10.97 (s, 1H), 10.00 (s, 1H), 8.97 (s, 1H), 8.78 (s, 1H), 8.15 (d, J = 5.2 Hz, 1H), 7.90 (t, J = 6.4 Hz, 1H), 7.80 (d, J = 8.8 Hz, 2H), 7.66 (d, J = 7.6 Hz, 1H), 7.48 (d, J = 8.4 Hz, 2H), 7.45 (s, 1H), 7.40 (d, J = 12.4 Hz, 1H), 7.37 - 7.14 (m, 1H), 7.13 - 7.06 (m, 2H), 7.03 (dd, J = 1.2, 5.2 Hz, 1H), 5.15 - 5.02 (m, 1H), 4.45 - 4.38 (m, 1H), 4.31 - 4.29 (m, 1H), 4.27 (d, J = 6.4 Hz, 2H), 4.10 - 4.04 (m, 2H), 3.78 (s, 2H), 3.63 - 3.54 (m, 8H), 3.20 - 3.14 (m, 2H), 2.98 - 2.85 (m, 1H), 2.70 - 2.67 (m, 2H), 2.60 (s, 2H), 2.02 - 1.93 (m, 1H), 1.12 - 1.01 (m, 1H), 0.49 - 0.42 (m, 2H), 0.25 - 0.19 (m, 2H)

553	**I-558**	QP	GF	823.4	10.96 (s, 1H), 9.98 (s, 1H), 8.95 (s, 1H), 8.77 (s, 1H), 8.24 (s, 1H), 8.15 (d, *J* = 5.6 Hz, 1H), 7.79 (d, *J* = 8.0 Hz, 3H), 7.67 (d, *J* = 7.6 Hz, 1H), 7.52 - 7.46 (m, 3H), 7.42 - 7.39 (m, 1H), 7.39 - 7.15 (m, 1H), 7.11 (s, 1H), 7.08 - 7.02 (m, 2H), 5.12 - 5.05 (m, 1H), 4.50 - 4.35 (m, 2H), 4.31 - 4.27 (m, 2H), 4.09 - 4.03 (m, 2H), 3.78 (s, 2H), 3.20 - 3.16 (m, 2H), 2.95 - 2.83 (m, 1H), 2.79 - 2.68 (m, 2H), 2.64 - 2.58 (m, 1H), 2.42 - 2.38 (m, 1H), 2.03 - 1.92 (m, 1H), 1.10 - 1.02 (m, 1H), 0.49 - 0.43 (m, 2H), 0.25 - 0.18 (m, 2H)
554	**I-559**	OD	QV	969.4	10.99 (s, 1H), 9.00 (s, 1H), 8.97 (s, 1H), 8.26 (d, *J* = 5.6 Hz, 1H), 7.90 - 7.78 (m, 2H), 7.70 - 7.63 (m, 1H), 7.57 - 7.48 (m, 2H), 7.26 (s, 1H), 7.18 (d, *J* = 5.2 Hz, 1H), 7.03 - 6.96 (m, 2H), 6.88 - 6.81 (m, 1H), 5.37 - 5.26 (m, 1H), 4.44 - 4.32 (m, 2H), 4.31 - 4.11 (m, 4H), 3.84 - 3.80 (m, 2H), 3.78 - 3.69 (m, 4H), 3.31 - 3.30 (m, 3H), 2.94 - 2.82 (m, 1H), 2.65 - 2.56 (m, 6H), 2.46 - 2.40 (m, 4H), 2.22 (s, 3H), 2.09 - 1.93 (s, 1H), 1.64 - 1.55 (m, 2H), 1.54 - 1.44 (m, 6H)
555	**I-560**	OD	QX	957.4	11.07 (s, 1H), 10.88 (s, 1H), 9.02 (s, 1H), 8.95 (s, 1H), 8.47 (t, *J* = 5.6 Hz, 1H), 8.29 - 8.23 (m, 2H), 7.94 (d, *J* = 8.8 Hz, 2H), 7.69 (t, *J* = 6.4 Hz, 1H), 7.54 (d, *J* = 8.4 Hz, 2H), 7.27 (s, 1H), 7.22 - 7.15 (m, 1H), 7.05 - 6.94 (m, 2H), 6.85 (d, *J* = 8.4 Hz, 1H), 5.32 (dd, *J* = 5.2, 12.4 Hz, 1H), 4.30 - 4.20 (m, 2H), 3.89 (s, 2H), 3.42 - 3.32 (m, 8H), 3.31 (s, 3H), 2.95 - 2.84 (m, 1H), 2.68 - 2.55 (m, 6H), 2.23 (s, 6H), 2.03 - 1.94 (m, 1H), 1.66 - 1.44 (m, 8H)

558	**I-563**	PL	GY	873.5	11.10 (s, 1H), 11.00 (s, 1H), 9.01 (s, 1H), 8.91 (s, 1H), 8.24 (d, J = 2.0 Hz, 1H), 8.04 (s, 1H), 7.91 (d, J = 8.4 Hz, 2H), 7.74 - 7.66 (m, 2H), 7.74 - 7.66 (m, 1H), 7.62 (t, J = 6.4 Hz, 1H), 7.50 (d, J = 8.4 Hz, 2H), 7.26 (s, 1H), 7.18 (dd, J = 1.2, 5.6 Hz, 1H), 7.08 - 7.00 (m, 2H), 6.94 (d, J = 8.0 Hz, 1H), 5.37 - 5.30 (m, 1H), 4.30 - 4.16 (m, 4H), 4.04 (t, J = 6.4 Hz, 2H), 3.78 (s, 2H), 3.31 (s, 3H), 2.94 - 2.84 (m, 1H), 2.70 - 2.58 (m, 4H), 2.05 - 1.92 (m, 1H), 1.81 - 1.68 (m, 2H)
559	**I-564**	RG	GY	914.2	11.13 - 10.94 (m, 2H), 9.00 (s, 1H), 8.90 (s, 1H), 8.31 - 8.20 (m, 3H), 8.03 (s, 1H), 7.90 (d, *J* = 8.4 Hz, 2H), 7.75 - 7.65 (m, 2H), 7.50 (d, *J* = 8.4 Hz, 2H), 7.26 (s, 1H), 7.20 - 7.13 (m, 1H), 6.90 (d, *J* = 8.6 Hz, 1H), 6.80 (d, *J* = 1.6 Hz, 1H), 6.59 (dd, J = 2.4, 8.6 Hz, 1H), 5.25 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.24 (dd, *J* = 6.8, 9.6 Hz, 2H), 3.80 (s, 2H), 3.52 - 3.50 (m, 4H), 3.28 (s, 2H), 3.05 - 3.02 (m, 4H), 2.91 - 2.82 (m, 1H), 2.68 - 2.66 (m, 2H), 2.64 - 2.60 (m, 2H), 2.57 - 2.56 (m, 6H), 2.06 (s, 3H), 2.01 - 1.94 (m, 1H)
562	**I-567**	PZ	GY	845.3	11.01 (s, 1H), 9.03 (s, 1H), 8.92 (s, 1H), 8.33 - 8.22 (m, 2H), 8.04 (s, 1H), 7.92 (d, *J* = 8.4 Hz, 2H), 7.76 - 7.66 (m, 2H), 7.51 (d, *J* = 8.2 Hz, 2H), 7.27 (s, 1H), 7.24 (d, *J* = 1.2 Hz, 1H), 7.18 (d, *J* = 1.6, 5.2 Hz, 1H), 7.14 (d, *J* = 8.0 Hz, 1H), 7.02 (d, *J* = 1.2, 8.4 Hz, 1H), 5.33 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.31 - 4.20 (m, 2H), 3.79 (s, 2H), 2.94 - 2.82 (m, 1H), 2.70 - 2.65 (m, 4H), 2.62 (d, *J* = 4.8 Hz, 5H), 2.36 - 2.31 (m, 2H), 2.15 (dd, *J* = 5.2, 10.4 Hz, 1H), 1.82 - 1.74 (m, 2H), 1.73 - 1.66 (m, 2H)

563	**I-568**	PA	GY	875.4	11.18 (s, 1H), 11.00 (s, 1H), 9.01 (s, 1H), 8.89 (s, 1H), 8.25 (d, *J* = 5.2 Hz, 1H), 8.01 (s, 1H), 7.89 (d, *J* = 8.4 Hz, 2H), 7.75 - 7.64 (m, 2H), 7.48 (d, *J* = 8.4 Hz, 2H), 7.25 (d, *J* = 12.4 Hz, 2H), 7.20 - 7.12 (m, 2H), 7.02 (d, *J* = 8.0 Hz, 1H), 5.33 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.28 - 4.19 (m, 2H), 3.79 (s, 2H), 3.52- 3.50 (m, 6H), 3.38 (t, *J* = 6.4 Hz, 2H), 2.91 - 2.83 (m, 1H), 2.74 - 2.60 (m, 6H), 2.18 - 2.07 (m, 1H), 1.84 - 1.73 (m, 2H)
567	**I-572**	RJ	GY	899.4	11.09 (s, 1H), 11.01 (s, 1H), 9.03 (s, 1H), 8.92 (s, 1H), 8.25 (d, *J* = 4.8Hz, 1H), 8.18 (s, 1H), 8.06 (s, 1H), 7.97 - 7.86 (m, 2H), 7.80 - 7.65 (m, 2H), 7.53 -7.46 (m, 2H), 7.26 (s, 1H), 7.17 (d, *J* = 4.8 Hz, 1H), 7.04 (s, 1H), 6.99 (d, *J* = 8.0 Hz, 1H), 6.87 (d, *J* = 8.0 Hz, 1H), 5.33 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.29 - 4.20 (m, 2H), 3.85 - 3.73 (m, 3H), 3.59 - 3.55 (m, 2H), 3.31 (s, 3H), 2.95 - 2.77 (m, 2H), 2.69 - 2.56 (m, 7H), 2.27 (t, *J* = 6.4 Hz, 2H), 2.02 - 1.93 (m, 2H), 1.79 - 1.68 (m, 3H)
568	**I-573**	RJ	GF	878.5	11.07 (s, 1H), 9.98 (s, 1H), 8.95 (s, 1H), 8.78 (s, 1H), 8.16 (d, *J* = 1.6 Hz, 1H), 7.81 (d, *J* = 8.4 Hz, 2H), 7.50 (d, *J* = 8.4 Hz, 2H), 7.28 (t, *J* = 54.4 Hz, 1H), 7.11 (s, 1H), 7.09 - 7.03 (m, 3H), 6.99 (d, *J* = 8.0 Hz, 1H), 6.87 (d, *J* = 7.6 Hz, 1H), 5.35 - 5.29 (m, 1H), 3.82 (s, 2H), 3.78 (d, *J* = 11.6 Hz, 1H), 3.55 - 3.53 (m, 1H), 3.31 (s, 3H), 3.20 - 3.17 (m, 2H), 2.93 - 2.86 (m, 1H), 2.81 (d, *J* = 11.2 Hz, 1H), 2.72 - 2.57 (m, 9H), 2.28 (t, *J* = 7.2 Hz, 2H), 2.03 - 1.93 (m, 2H), 1.79 - 1.70 (m, 3H), 1.12 - 1.01 (m, 1H), 0.49 - 0.42 (m, 2H), 0.25 - 0.19 (m, 2H)

569	**I-574**	RK	GF	878.2	11.08 (s, 1H), 10.00 (s, 1H), 8.97 (s, 1H), 8.79 (s, 1H), 8.19 - 8.14 (m, 2H), 7.81 (d, *J* = 8.4 Hz, 2H), 7.49 (d, *J* = 8.4 Hz, 2H), 7.44 - 7.14 (m, 1H), 7.13 - 7.07 (m, 2H), 7.06 - 7.01 (m, 2H), 6.99 (d, *J* = 8.0 Hz, 1H), 6.90 - 6.83 (m, 1H), 5.37 - 5.28 (m, 1H), 3.79 (s, 2H), 3.76 (s, 1H), 3.31 (s, 3H), 3.17 (d, *J* = 6.2 Hz, 2H), 2.94 - 2.79 (m, 3H), 2.72 - 2.56 (m, 9H), 2.28 (t, *J* = 7.2 Hz, 2H), 2.03 - 1.92 (m, 2H), 1.79 - 1.67 (m, 3H), 1.12 - 0.98 (m, 1H), 0.49 - 0.38 (m, 2H), 0.26 - 0.17 (m, 2H)
570	**I-575**	RM	GY	913.5	11.22 - 10.08 (m, 2H), 9.02 (s, 1H), 8.92 (s, 1H), 8.31 - 8.23 (m, 3H), 7.91 (d, *J* = 8.8 Hz, 2H), 7.76 - 7.67 (m, 2H), 7.50 (d, *J* = 8.8 Hz, 2H), 7.27 (s, 1H), 7.20 - 7.15 (m, 1H), 7.08 - 6.96 (m, 2H), 6.89-6.84 (d, 1H), 5.42 - 5.27 (m, 1H), 4.29 - 4.17 (m, 2H), 3.96 - 3.67 (m, 3H), 3.35 - 3.33 (m, 2H), 3.31 (s, 3H), 3.25 - 3.18 (m, 2H), 2.91 - 2.84 (m, 1H), 2.90 - 2.84 (m, 2H), 2.63 - 2.59 (m, 4H), 2.26 (t, *J* = 6.8 Hz, 1H), 2.12 - 1.88 (m, 2H), 1.79 - 1.66 (m, 2H), 1.62 - 1.50 (m, 2H)
571	**I-576**	RO	GY	913.5	11.08 (s, 1H), 11.00 (s, 1H), 9.02 (s, 1H), 8.93 (s, 1H), 8.25 (d, *J* = 5.2 Hz, 1H), 8.18 (s, 1H), 8.04 (s, 1H), 7.94 (d, *J* = 8.4 Hz, 2H), 7.74 - 7.66 (m, 2H), 7.52 (d, *J* = 8.4 Hz, 2H), 7.26 (s, 1H), 7.19 - 7.16 (m, 1H), 7.04 (s, 1H), 6.99 (d, *J* = 8.0 Hz, 1H), 6.87 (d, *J* = 8.0 Hz, 1H), 5.35 - 5.30 (m, 1 H), 4.28 - 4.21 (m, 2H), 3.83 (s, 2H) , 3.75 - 3.73 (m, 1H), 3.45 - 3.44 (m, 3H), 3.31 (s, 3H), 2.91 - 2.87 (m, 1H), 2.72 (m, 2H), 2.65 - 2.59 (m, 5H), 2.27 - 2.25 (m, 2H), 2.06 - 1.88 (m, 3H), 1.77 - 1.65 (m, 3 H), 1.59 (m, 2H)

573	**I-578**	RT	GY	900.5	11.08 (s, 1H), 11.01 (s, 1H), 9.03 (s, 1H), 8.92 (s, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.05 (s, 1H), 7.91 (d, *J* = 8.8 Hz, 2H), 7.76 - 7.67 (m, 2H), 7.44 (d, *J* = 8.8 Hz, 2H), 7.27 (s, 1H), 7.18 (dd, *J* = 1.2, 5.2 Hz, 1H), 7.06 - 6.96 (m, 2H), 6.89 - 6.81 (m, 1H), 5.33 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.31 - 4.19 (m, 2H), 3.49 (s, 2H), 3.31 (s, 3H), 2.95 - 2.83 (m, 1H), 2.77 - 2.53 (m, 8H), 2.38 - 2.30 (m, 2H), 2.13 (s, 3H), 2.04 - 1.96 (m, 1H), 1.67 - 1.58 (m, 2H), 1.55 - 1.46 (m, 6H)
574	**I-579**	QN	GY	932.4	11.00 (s, 1H), 11.00 - 10.87 (m, 1H), 9.01 (s, 1H), 8.91 (s, 1H), 8.25 (d, *J* = 5.2 Hz, 1H), 8.02 (s, 1H), 7.95 - 7.84 (m, 3H), 7.68 (dd, *J* = 7.2, 11.2 Hz, 3H), 7.53 - 7.43 (m, 3H), 7.38 (d, *J* = 7.6 Hz, 1H), 7.27 (s, 1H), 7.18 (d, *J* = 5.2 Hz, 1H), 5.14 - 5.06 (m, 1H), 4.48 - 4.37 (m, 1H), 4.33 - 4.17 (m, 5H), 4.12 - 4.04 (m, 2H), 3.77 (s, 2H), 3.59 (s, 2H), 3.51 (dd, *J* = 5.6, 9.2 Hz, 6H), 2.98 - 2.84 (m, 1H), 2.67 (d, *J* = 5.2 Hz, 2H), 2.59 (d, *J* = 19.6 Hz, 2H), 2.43 - 2.35 (m, 1H), 2.03 - 1.93 (m, 1H)
575	**I-580**	TP	GF	862.4	10.99 (s, 1H), 10.03 (s, 1H), 8.93 (m, 1H), 8.81 (s, 1H), 8.33 - 8.08 (m, 2H), 7.88 (d, *J* = 7.6 Hz, 2H), 7.59 (d, *J* = 7.2 Hz, 2H), 7.46 - 7.02 (m, 8H), 5.70 - 5.57 (m, 1H), 4.69 - 4.60 (m, 1H), 4.05 (s, 2H), 3.94 - 3.86 (m, 4H), 3.23 (t, *J* = 8.0 Hz, 2H), 3.19 - 3.15 (m, 2H), 2.92 - 2.87 (m, 2H), 2.82 - 2.77 (m, 1H), 2.68 - 2.64 (m, 2H), 2.59 - 2.56 (m, 1H), 2.23 - 2.16 (m, 1H), 2.00 - 1.92 (m, 1H), 1.88 - 1.80 (m, 2H), 1.10 - 1.01 (m, 1H), 0.49 - 0.41 (m, 2H), 0.26 - 0.17 (m, 2H)

576	**I-581**	SF	GF	862.4	10.02 (s, 1H), 8.97 (s, 1H), 8.80 (s, 1H), 8.25 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.82 (d, *J* = 8.4 Hz, 2H), 7.58 - 7.46 (m, 3H), 7.46 - 7.39 (m, 4H), 7.32 - 7.13 (m, 1H), 7.13 - 7.08 (m, 2H), 7.05 (d, *J* = 5.2 Hz, 1H), 5.71 - 5.58 (m, 1H), 4.76 - 4.73 (m, 1H), 3.90 - 3.84 (m, 2H), 3.52 - 3.50 (m, 4H), 3.27 - 3.21 (m, 2H), 3.20 - 3.17 (m, 2H), 2.91 - 2.77 (m, 1H), 2.70 - 2.64 (m, 4H), 2.60 - 2.56 (m, 1H), 2.28 - 2.16 (m, 1H), 2.03 - 1.93 (m, 1H), 1.78 - 1.71 (m, 2H), 1.12 - 1.03 (m, 1H), 0.49 - 0.44 (m, 2H), 0.25 - 0.21 (m, 2H)
577[b]	**I-582**	YY	PB	886.6	11.11 (s, 1H), 9.98 (s, 1H), 8.96 (s, 1H), 8.78 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.79 (d, *J* = 8.4 Hz, 2H), 7.49 (d, *J* = 8.4 Hz, 2H), 7.31 - 7.00 (m, 7H), 5.41 - 5.31 (m, 1H), 3.74 (s, 3H), 3.30 - 3.25 (m, 2H), 3.20 - 3.16 (m, 2H), 2.95 - 2.82 (m, 3H), 2.65 - 2.54 (m, 7H), 2.39 - 2.35 (m, 2H), 2.00 - 1.91 (m, 2H), 1.76 -1.65 (m, 2H), 1.46 - 1.31 (m, 1H), 1.18 - 1.01 (m, 3H), 0.50 - 0.40 (m, 2H), 0.26 - 0.18(m, 2H)
578	**I-583**	SL	GF	933.6	11.09 (s, 1H), 9.99 (s, 1H), 8.96 (s, 1H), 8.78 (s, 1H), 8.15 (d, *J* = 5.2 Hz, 1H), 7.79 (d, *J* = 8.4 Hz, 2H), 7.47 (d, *J* = 8.4 Hz, 2H), 7.42 - 7.14 (m, 1H), 7.09 (d, *J* = 10 Hz, 3H), 7.05 - 7.01 (m, 2H), 6.98 - 6.92 (m, 1H), 5.34 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.11 - 4.01 (m, 2H), 3.65 (s, 3H), 3.45 - 3.45 (m, 2H), 3.29 - 3.28 (m, 2H), 3.19 - 3.16 (m, 4H), 2.96 - 2.83 (m, 3H), 2.75 - 2.69 (m, 1H), 2.64 - 2.57 (m, 4H), 2.44 - 2.41 (m, 6H), 2.29 - 2.25 (m, 1H), 2.01 - 1.99 (m, 4H), 1.09 - 1.02 (m, 1H), 0.49 - 0.42 (m, 2H), 0.26 - 0.19 (m, 2H)

579	**I-584**	SM	GF	889.4	11.00 (s, 1H), 9.97 (s, 1H), 8.97 (s, 1H), 8.78 (s, 1H), 8.23 (s, 1H), 8.16 (d, *J* = 5.6 Hz, 1H), 7.79 (d, *J* = 8.4 Hz, 2H), 7.55 - 7.43 (m, 6H), 7.28 (t, *J* = 54.4 Hz, 2H), 7.12 (s, 1H), 7.08 (t, *J* = 5.2 Hz, 1H), 7.04 (d, *J* = 5.2 Hz, 1H), 5.71 - 5.59 (m, 1H), 4.73 - 4.62 (m, 1H), 3.93 (t, *J* = 8.8 Hz, 1H), 3.86 (d, *J* = 8.8 Hz, 1H), 3.82 (d, *J* = 10.8 Hz, 1H), 3.76 (s, 2H), 3.61 - 3.52 (m, 2H), 3.28 - 3.23 (m, 2H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.90 - 2.77 (m, 2H), 2.69 - 2.66 (m, 1H), 2.65 - 2.55 (m, 2H), 2.35 - 2.32 (m, 1H), 2.31 - 2.12 (m, 2H), 2.07 (t, *J* = 10.4 Hz, 1H), 2.01 - 1.92 (m, 1H), 1.12 - 1.02 (m, 1H), 0.49 - 0.42 (m, 2H), 0.26 - 0.20 (m, 2H)
580	**I-585**	SO	GF	889.4	11.00 (s, 1H), 10.02 (s, 1H), 8.96 (s, 1H), 8.77 (s, 1H), 8.15 (d, *J* = 5.6 Hz, 1H), 7.79 (d, *J* = 8.4 Hz, 2H), 7.52 - 7.45 (m, 5H), 7.43 - 7.14 (m, 2H), 7.12 - 7.08 (m, 2H), 7.04 (d, *J* = 4.8 Hz, 1H), 5.72 - 5.59 (m, 1H), 4.73 - 4.61 (m, 1H), 3.96 - 3.78 (m, 3H), 3.76 (s, 2H), 3.58 - 3.52 (m, 2H), 3.26 - 3.14 (m, 5H), 2.92 - 2.73 (m, 3H), 2.64 - 2.57 (m, 2H), 2.31 - 2.25 (m, 1H), 2.23 - 2.14 (m, 1H), 2.09 - 2.02(m, 1H), 2.01 - 1.91 (m, 1H), 1.10 - 1.02 (m, 1H), 0.48 - 0.43 (m, 2H), 0.24 - 0.19 (m, 2H)
582	**I-587**	SQ	GF	878.4	11.08 (s, 1H), 9.99 (s, 1H), 8.96 (s, 1H), 8.79 (s, 1H), 8.18 - 8.15 (m, 2H), 7.86 - 7.77 (m, 2H), 7.50 (d, *J* = 8.4 Hz, 2H), 7.43 - 7.14 (m, 1H), 7.11 (s, 1H), 7.08 (t, *J* = 5.6 Hz, 1H), 7.05 - 7.02 (m, 1H), 6.99 - 6.85 (m, 3H), 5.36 (dd, *J* = 5.6, 12.0 Hz, 1H), 3.84 - 3.78 (m, 3H), 3.77 - 3.74, 3.57 (s, 3H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.95 - 2.83 (m, 4H), 2.71 - 2.54 (m, 6H), 2.36 - 2.32 (m, 2H), 2.04 - 1.93 (m, 2H), 1.82 - 1.67 (m, 3H), 1.14 - 1.00 (m, 1H), 0.51 - 0.37 (m, 2H), 0.25 - 0.19 (m, 2H)

583	**I-588**	SR	GF	878.2	11.09 (s, 1H), 9.99 (s, 1H), 8.97 (s, 1H), 8.80 (s, 1H), 8.16 (d, *J* = 5.6 Hz, 1H), 7.82 (d, *J* = 8.4 Hz, 2H), 7.51 (d, *J* = 8.4 Hz, 2H), 7.45 - 7.13 (m, 1H), 7.13 - 7.06 (m, 2H), 7.04 (dd, *J* = 1.2, 5.2 Hz, 1H), 6.98 - 6.92 (m, 2H), 6.91 - 6.85 (m, 1H), 5.37 (dd, *J* = 5.2, 12.4 Hz, 1H), 3.87 - 3.69 (m, 4H), 3.62 - 3.45 (m, 6H), 3.18 (t, *J* = 6.0 Hz, 2H), 3.04 - 2.79 (m, 4H), 2.76 - 2.58 (m, 4H), 2.42 - 2.23 (m, 2H), 2.04 - 1.93 (m, 2H), 1.81 - 1.71 (m, 3H), 1.13 - 1.01 (m, 1H), 0.51 - 0.40 (m, 2H), 0.26 - 0.18 (m, 2H)
584	**I-589**	SS	GF	865.0	11.20 (s, 1H), 9.98 (s, 1H), 8.96 (s, 1H), 8.78 (s, 1H), 8.16 (d, *J* = 5.4 Hz, 1H), 7.80 (d, *J* = 8.6 Hz, 2H), 7.48 (d, *J* = 8.7 Hz, 2H), 7.29 (s, 1H), 7.16 - 7.06 (m, 4H), 7.05 - 7.01 (m, 2H), 5.40 - 5.28 (m, 1H), 3.76 (s, 2H), 3.51 (d, *J* = 2.4 Hz, 2H), 3.20 - 3.15 (m, 3H), 2.90 - 2.78 (m, 2H), 2.75 - 2.61 (m, 6H), 2.56 (d, *J* = 6.5 Hz, 1H), 2.36 - 2.26 (m, 3H), 2.18 - 2.11 (m, 1H), 2.01 - 1.92 (m, 1H), 1.83 - 1.69 (m, 3H), 1.11 - 1.02 (m, 1H), 0.49 - 0.42 (m, 2H), 0.25 - 0.19 (m, 2H)
585	**I-590**	ST	GF	865.4	δ 11.20 (s, 1H), 9.99 (s, 1H), 8.96 (s, 1H), 8.78 (s, 1H), 8.19 - 8.15 (m, 2H), 7.86 - 7.75 (m, 2H), 7.50 (d, *J* = 8.0 Hz, 2H), 7.44 - 6.99 (m, 7H), 5.42 - 5.30 (m, 1H), 3.84 - 3.72 (m, 4H), 3.18 (t, *J* = 6.0, 2H), 2.90 - 2.79 (m, 2H), 2.75 - 2.54 (m, 8H), 2.34 - 2.31 (m, 2H), 2.18 - 2.12 (m, 1H), 2.01 - 1.94 (m, 1H), 1.85 - 1.69 (m, 3H), 1.12 - 1.02 (m, 1H), 0.49 - 0.41 (m, 2H), 0.26 - 0.18 (m, 2H)

586	**I-591**	TW	GF	906.5	11.08 (s, 1H), 9.99 (s, 1H), 8.98 (s, 1H), 8.80 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 8.13 (s, 1H), 7.82 (d, *J* = 8.8 Hz, 2H), 7.47 (d, *J* = 8.4 Hz, 2H), 7.29 (s, 1H), 7.13 - 7.07 (m, 2H), 7.05 - 7.02 (m, 2H), 6.99 (d, *J* = 8.0 Hz, 1H), 6.87 (d, *J* = 8.0 Hz, 1H), 5.36 - 5.30 (m, 1H), 3.77 - 3.71 (m, 1H), 3.63 - 3.53 (m, 2H), 3.51 - 3.43 (m, 3H), 3.31 (s, 3H), 3.20 - 3.16 (m, 2H), 2.94 - 2.83 (m, 1H), 2.80 - 2.68 (m, 2H), 2.65 - 2.58 (m, 3H), 2.55 - 2.53 (m, 2H), 2.32 - 2.25 (m, 2H), 2.24 - 2.13 (m, 3H), 2.04 - 1.92 (m, 2H), 1.82 - 1.69 (m, 3H), 1.68 - 1.55 (m, 2H), 1.12 - 1.00 (m, 1H), 0.50 - 0.42 (m, 2H), 0.26 - 0.19 (m, 2H)
587	**I-592**	TY	GF	906.2	11.09 (s, 1H), 10.01 (s, 1H), 8.97 (s, 1H), 8.78 (s, 1H), 8.15 (d, *J* = 5.2 Hz, 1H), 7.80 (d, *J* = 8.4 Hz, 2H), 7.47 - 7.14 (m, 3H), 7.14 - 7.07 (m, 2H), 7.07 - 7.01 (m, 2H),7.01 - 6.94 (m, 1H), 6.86 (d, *J* = 8.0 Hz, 1H), 5.32 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.77 - 3.68 (m, 2H), 3.49 (s, 2H), 3.31 (s, 3H), 3.18 (t, *J* = 6.0 Hz, 2H), 2.92 - 2.84 (m, 1H), 2.77 - 2.68 (m, 2H), 2.64 - 2.56 (m, 5H), 2.43 - 2.39 (m, 2H), 2.25 (t, *J* = 7.2 Hz, 2H), 2.12 (s, 3H), 2.01 - 1.89 (m, 2H), 1.78 - 1.64 (m, 3H), 1.61 - 1.51 (m, 2H), 1.09 - 1.03 (m, 1H), 0.51 - 0.38 (m, 2H), 0.27 - 0.17 (m, 2H)
588	**I-593**	SQ	GY	899.4	11.08 (s, 1H), 11.00 (s, 1H), 9.02 (s, 1H), 8.97 (s, 1H), 8.25 (d, *J* = 5.2 Hz, 1H), 8.13 (s, 1H), 8.09 - 7.96 (m, 3H), 7.75 (s, 1H), 7.69 (t, *J* = 6.4 Hz, 1H), 7.59 (d, *J* = 8.4 Hz, 2H), 7.26 (s, 1H), 7.17 (dd, *J* = 5.2 Hz, 1H), 6.95 (d, *J* = 4.8 Hz, 2H), 6.90 - 6.85 (m, 1H), 5.39 - 5.32 (m, 1H), 4.29 - 4.19 (m, 2H), 4.03 (s, 1H), 3.88 - 3.79 (m, 1H), 3.73 - 3.61 (m, 2H), 3.57 (s, 3H), 3.53 - 3.50 (m, 1H), 2.95 - 2.80 (m, 7H),2.76 -

					2.68 (m, 2H), 2.65 - 2.62 (m , 1H), 2.61 - 2.58 (m, 1H), 2.41 - 2.35 (m , 2H), 2.10 - 1.94 (m, 2H), 1.78 - 1.73 (m, 2H)
590	**I-595**	SU	GF	888.4	10.86 (s, 1H), 9.75 (s, 1H), 8.73 (s, 1H), 8.53 (s, 1H), 8.17 (dd, *J* = 1.6, 8.0 Hz, 1H), 8.09 (dd, *J* = 1.6, 4.8 Hz, 1H), 8.05 (s, 1H), 7.93 (d, *J* = 5.2 Hz, 1H), 7.55 (d, *J* = 8.8 Hz, 2H), 7.24 (d, *J* = 8.8 Hz, 2H), 7.20 - 7.04 (m, 3H), 6.94 - 6.88 (m, 3H), 6.85 (t, *J* = 5.6 Hz, 1H), 6.83 - 6.79 (m, 1H), 6.68 (dd, *J* = 2.0, 8.8 Hz, 1H), 5.73 - 5.59 (m, 1H), 3.54 (s, 2H), 3.44 - 3.40 (m, 2H), 3.38 - 3.32 (m, 8H), 3.06 - 3.02 (m, 2H), 2.96 - 29.4 (m, 2H), 2.77 - 2.73 (m, 1H), 2.48 - 2.46 (m, 1H), 2.43 - 2.40 (m, 1H), 1.84 - 1.82 (m, 1H), 0.26 - 0.20 (m, 2H), 0.10 - 0.02 (m, 2H)
591	**I-596**	SV	GF	881.5	9.97 (s, 1H), 8.95 (s, 1H), 8.75 (s, 1H), 8.15 (d, *J* = 5.6 Hz, 1H), 7.76 (d, *J* = 8.6 Hz, 2H), 7.45 - 7.51 (m, 2H), 7.13 - 7.42 (t, *J* =5.2 Hz, 1H), 7.06 - 7.12 (m, 2H), 7.03 (dd, *J* = 5.2 Hz, 1H), 6.89 - 6.97 (m, 2H), 6.83 (s, 1H), 5.41 - 5.38 (m, 1H), 3.78 (s, 2H), 3.54 (s, 3H), 3.51 - 3.53 (m, 6H), 3.45 - 3.40 (m, 4H), 3.17 (d, *J* = 6.4 Hz, 2H), 3.01 (s, 3H), 2.94 (d, *J* = 6.4 Hz, 2H), 2.73 - 2.80 (m, 2H), 2.69 - 2.71 (m, 2H), 2.66 - 2.68 (m, 2H), 1.95 - 2.02 (m, 1H), 1.77 - 1.84 (m, 2H), 1.03 - 1.10 (m, 1H), 0.42 - 0.47 (m, 2H), 0.19 - 0.23 (m, 2H)

592	**I-597**	2-(2-methoxy-ethoxy)-ethan-amine (CAS# 31576-51-9)	GF	603.3	11.01 (s, 1H), 9.03 (s, 1H), 8.99 (s, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.06 (d, *J* = 8.4 Hz, 3H), 7.77 (s, 1H), 7.70 (t, *J* = 6.4 Hz, 1H), 7.64 (d, *J* = 8.8 Hz, 2H), 7.26 (s, 1H), 7.18 (d, *J* = 5.2 Hz, 1H), 4.28 - 4.20 (m, 2H), 4.15 (s, 2H), 3.65 (t, *J* = 5.2 Hz, 2H), 3.59 - 3.56 (m, 2H), 3.49 - 3.47 (m, 2H), 3.26 (s, 3H), 3.05 (t, *J* = 5.2 Hz, 2H)
593	**I-598**	RR	GF	892.5	11.09 (s, 1H), 10.02 (s, 1H), 8.97 (s, 1H), 8.82 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.86 (d, *J* = 8.4 Hz, 2H), 7.51 (d, *J* = 8.4 Hz, 2H), 7.30 (t, *J* = 8.4 Hz, 1H), 7.14 - 7.08 (m, 2H), 7.07 - 7.00 (m, 3H), 6.92 - 6.86 (m, 1H), 5.34 (dd, *J* = 5.2, 12.4 Hz, 1H), 3.90 - 3.85 (m, 1H), 3.82 - 3.76 (m, 2H), 3.64 - 3.59 (m, 2H), 3.32 (s, 3H), 3.20 - 3.17 (m, 2H), 3.07 - 3.03 (m, 1H), 2.97 - 2.92 (m, 1H), 2.91 - 2.85 (m, 1H), 2.76 - 2.70 (m, 1H), 2.69 - 2.57 (m, 7H), 2.57 - 2.53 (m, 2H), 2.33 (s, 3H), 2.03 - 1.96 (m, 1H), 1.89 - 1.80 (m, 2H), 1.12 - 1.02 (m, 1H), 0.49 - 0.43 (m, 2H), 0.25 - 0.20 (m, 2H)
594	**I-599**	SZ	GF	892.2	11.08 (s, 1H), 10.00 (s, 1H), 8.96 (s, 1H), 8.78 (s, 1H), 8.22 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.80 (d, *J* = 8.4 Hz, 2H), 7.45 (d, *J* = 0.8 Hz, 2H), 7.12 (t , *J* = 14.8 Hz, 1H), 7.10 - 7.06 (m, 1H), 7.05 - 7.03 (m, 2H), 7.00 (d, *J* = 8.0 Hz, 1H), 6.87 (m, 1H), 5.35 - 5.30 (m, 1H), 3.75 (d, *J* = 11.6 Hz, 1H), 3.61 (s, 1H), 3.58 (s, 2H), 3.31 (s, 3H), 3.18 (t, *J* = 6.0 Hz, 3H), 2.95 - 2.84 (m, 2H), 2.81 (d, *J* = 10.8 Hz, 1H), 2.76 - 2.68 (m , 1H), 2.69 - 2.66 (m , 1H), 2.63 (d, *J* = 6.4 Hz, 3H), 2.40 - 2.38 (m, 1H), 2.35 - 2.31 (m, 1H), 2.31 - 2.24 (m, 2H), 2.18 (s, 3H), 2.02 - 1.96 (m, 1H), 1.95 - 1.89 (m, 1H), 1.78 - 1.72


					(m, 2H), 1.68 (t, *J* = 10.8 Hz, 1H), 1.12 - 1.01 (m, 1H), 0.48 - 0.42 (m, 2H), 0.25 - 0.19 (m, 2H)
609	**I-614**	RK	JC	906.5	11.09 (s, 1H), 10.08 (s, 1H), 9.00 (s, 1H), 8.87 (s, 1H), 8.25 (d, *J* = 5.6 Hz, 1H), 7.95 (d, *J* = 8.8 Hz, 2H), 7.69 - 7.61 (m, 3H), 7.44 - 7.17 (m, 3H), 7.07 - 6.98 (m, 2H), 6.87 (d, *J* = 8.8 Hz, 1H), 5.33 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.28 - 4.16 (m, 4H), 3.94 - 3.77 (m, 2H), 3.68 - 3.9 (m, 2H), 3.32 (s, 3H), 3.06 - 3.04 (m, 2H), 3.00 - 2.78 (m, 5H), 2.74 - 2.55 (m, 6H), 2.03 - 1.95 (m, 1H), 1.82 - 1.74 (m, 2H)
612	**I-617**	RK	TA	866.5	11.07 (s, 1H), 9.49 (s, 1H), 8.97 (s, 1H), 8.80 (d, *J* = 8.0 Hz, 1H), 8.31 (s, 1H), 8.20 (s, 1H), 7.79 (d, *J* = 8.4 Hz, 2H), 7.49 (d, *J* = 8.4 Hz, 2H), 7.43 - 7.10 (m, 1H), 7.03 (s, 1H), 6.99 (d, *J* = 8.0 Hz, 1H), 6.91 (d, *J* = 8.0 Hz, 1H), 6.87 (d, *J* = 8.0 Hz, 1H), 5.35 - 5.26 (m, 1H), 3.84 - 3.75 (m, 7H), 3.48 - 3.46 (m, 4H), 3.31 (s, 3H), 2.94 - 2.89 (m, 4H), 2.88 - 2.79 (m, 2H), 2.70 - 2.66 (m, 1H), 2.64 - 2.59 (m, 4H), 2.58 - 2.55 (m, 1H), 2.54 - 2.52 (m, 1H), 2.31 - 2.22 (m, 2H), 2.04 - 1.92 (m, 2H), 1.78 - 1.67 (m, 3H)

[a]For Method 16, when the amine is the HC1 salt, TEA was added to free base the salt, followed by HOAc to adjust the pH to 3-4. KOAc could also be used in place of the TEA/HOAc combination. Other standard deprotections conditions could be used for the deprotection in Step 2, including often with TFA. Steps 1-2 was run anywhere from 0.5-48 hrs. [b]No deprotection Step 2 required. [c]In Step 1, Intermediates OS and were heated at 80 °C for 1 hr with HOAc and 4A MS, then

NaBH3CN was added and the reaction mixture was stirred at rt for 1 h. [d]In Step 2, the deprotection was achieved using HBr/HOAc in THF at rt for 96-160 hrs. For Example 617, 1-622 the reaction was run in DCM with HBr/HOAc for 12 hr. [e]In Step 2, the deprotection was achieved using $ZnBr_2$ in DCM at rt.

[005513] Further Examples using synthetic methods similar to Method 16:

Example 675: 2-[2-!Cvclopropylmethylamino)-4-pyridvH-N-[3-!difluoromethvD-l-[4-[[2-[2-[2-[2-[2-[2-_ [|(3Sl-2-[(2Sl-3,3-dimethyl-2-[|(2S)-2-(methylamino)propanoyl]amino]butanoyl]-3-[[(lR)-tetralin-l-yl]carbamoyl]-3.,4-dihvdro-lH-isoquinolin-7-yl]oxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]methyl]-phenyl]pyrazol-4-ylloxazole-4-carboxamide, 1-680



[005514] Step 1 - Tert-butyl N-[4-[4-i[1-[4-i[2-[2-[2-[2-[2-[2-п(3Sv 2-i(2Sv 2-п(2S)-2-rbenzyloxycarbonyl (methyl)amino1propanoyl1amino1-3.3-dimethyl-butanoyl1-3-nTl R)-tetralin-l-yll carbamoyl!-3,4-dihvdiO-lH-isoquinolin-7-yl]oxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxyl-ethylamino1methyl1phenyl1-3-(difluoromethvnpyrazol-4-yl1carbamoyl1oxazol-2-yl1-2-pyridyl1-

N-icvclopropylmethyDcarbamate

[005515] To a solution of benzyl-N-[(lS)-2-[[(lS)-l-[(3S)-7-[2-[2-[2-[2-[2-(2-aminoethoxy)ethoxy] ethoxy] ethoxy]ethoxy]ethoxy]-3-[[(lR)-tetralin-l-yl]carbamoyl]-3,4-dihydro-lH-isoquinoline-2-carbonyl]-2,2-dimethyl-propyl]amino]-l-methyl-2-oxo-ethyl]-N-methyl-carbamate (100 mg, 96.9 umol, TFA, Intermediate WE) and tert-butyl-N-(cyclopropylmethyl)-N-[4-[4-[[3-(difluoromethyl)-l-(4-formylphenyl)pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (56.1 mg, 96.9 umol; Intermediate GF) in THF (4 mL) was added KOAc (19.0 mg, 194 umol) and $NaBH(OAc)_3$ (41.1 mg, 194 umol). The reaction mixture was stirred at 25 °C for 17 hrs. On completion, the mixture was concentrated *in vacuo.* The residue was purified by reverse phase (0.1% FA condition) to give the title compound (90.0 mg, 63% yield) as a white solid. LC-MS (ESI^+) *m/z* 1481.7 $(M+H)^+$.


[005516] Step 2 - Tert-butyl N-(cvclopropylmethvD-N-r4-r4-rr3-(difluoromethvD-l-r4-rr2-[2-[2-[2-[2-[2-rr(3S)-2-r(2SV3.3-dimethyl-2-rr(2SV2-(methylamino)propanovl]amino]butanovl]-3-[[(1R)-tetralin-1-yl1carbamoyl1-3.4-dihydro-l H-isoquinolin-7-ylloxylethoxylethoxylethoxylethoxyl-ethoxylethylaminolmethyllphenyllpyrazol-4-yl1carbamoyl1oxazol-2-vH-2-pyridyl1carbamate

[005517] To a solution of tert-butyl N-[4-[4-[[l-[4-[[2-[2-[2-[2-[2-[2-[2-[[(3S)-2-[(2S)-2-[[(2S)-2- [benzyloxycarbonyl(methyl)amino]propanoyl]amino]-3,3-dimethyl-butanoyl]-3-[[(lR)-tetralin-l-yl]carbamoyl]-3,4-dihydro-lH-isoquinolin-7-yl]oxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-ethylamino]methyl]phenyl]-3-(difluoromethyl)pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(cyclopropylmethylcarbamate (40 mg, 27.0 umol) in THF (5 mL) was added $Pd(OH)_2/C$ (0.1 g, 20% *wt).* The reaction mixture was stirred at 25 °C for 2 hrs under H_2 (15 psi) atmosphere. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was purified by reverse phase (0. 1% FA condition) to give the title compound (35.0 mg, 96% yield) as a white solid. LC-MS (ESI^+) *m/z* 1346.8 $(M+H)^+$.

[005518] Step 3 - 2-r2-(Cvclopropylmethylamino)-4-pyridyl1-N-r3-(difluoromethyl)-l-r4-[[2-[2-[2-[2-[2-[2-rr(3SV2-r(2SV3.3-dimethyl-2-rr(2S>2-(methylamino)propanoyl1amino1butanoyl1-3-rrn R)-tetralin-1-yl1carbamoyl1-3.4-dihydro-l H-isoquinolin-7-yl1oxy1ethoxy1ethoxy1ethoxy1ethoxy1-ethoxy1ethylamino1methyl1phenyl1pyrazol-4-yl1oxazole-4-carboxamide

[005519] To a solution of tert-butyl N-(cyclopropylmethyl)-N-[4-[4-[[3-(difluoromethyl)-l-[4-[[2-[2-[2-[2-[2 -[2-[[(3S)-2-[(2S)-3,3-dimethyl-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]-3-[[(lR)-tetralin-l-yl]carbamoyl]-3,4-dihydro-lH-isoquinolin-7-yl]oxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]methyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (30.0 mg, 22.3 umol) in DCM (2 mL) was added HCl/dioxane (2 mL). The reaction mixture was stirred at 25 °C for 2 hrs. On completion, the mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 l50*25*l0um; mobile phase: [water (0.225%FA)-ACN]; B%: 12%-39%, 9min) to give the title compound (4.00 mg, 14% yield, FA) as a brown solid. ^{1}H NMR (400MHz, DMSO-t/$_{f}$) δ 10.00 (s, 1H), 8.96 (s, 1H), 8.78 (s, 1H), 8.28 - 8.25 (m, 1H), 8.20 - 8.10 (m, 2H), 8.03 - 7.89 (m, 1H), 7.80 (d, *J* = 8.4 Hz, 2H), 7.49 *(d, J* = 8.4 Hz, 2H), 7.29 (t, *J* = 54.8 Hz 1H), 7.12 - 7.01 (m, 7H), 6.90 (s, 1H), 6.80 - 6.77 (m, 1H), 5.19 - 4.86 (m, 2H), 4.78 - 4.62 (m, 2H), 4.10 - 4.00 (m, 2H), 3.80 (s, 2H), 3.75 - 3.70 (m, 2H), 3.61 - 3.50 (m, 21H), 3.18 (t, *J* = 6.0 Hz, 2H), 3.09 - 3.02 (m, 1H), 3.01 - 2.92 (m, 2H), 2.76 - 2.63 (m, 4H), 2.21 - 2.12 (m, 3H), 1.92 - 1.72 (m, 2H), 1.70 - 1.49 (m, 2H), 1.10 (d, *J* =6.8Hz, 3H), 1.07 - 1.05 (m, 1H), 1.05 - 0.91 (m, 9H), 0.50 - 0.41 (m, 2H), 0.27 - 0.18 (m, 2H); LC-MS (ESI^{+}) *m/z* 1246.8 (M+H)$^{+}$.

[005520] Example 676: 2-[2-(Cvclopropylmethylamino)-4-pyridyll-N-[3-(dif uoromethyl)-1-[4-[[2-[2-[2-[2-[[(3S)-2- [(2S)-3,3-dimethyl-2-[[i2S)-2-[methylamino]propanoyl1amino1butanoyl1-3-[[[lR]-tetralin-l-yl1carbamoyl]-3.,4-dihvdro-lH-isoquinolin-7-yl1oxy1ethoxy1ethoxy1ethoxy1ethylamino1methyl1phenyl1pyrazol-4-ylloxazole-4-carboxamide, 1-681



[005521] **Step 1 - Tert-butyl** N-[4-[4-[[4-[[2-[2-[2-[2-[[(3S)-2-[(2S)-2-[[(2S)-2-

rbenzyl oxycarbonyl (methyl) _ amino1propanoyl1amino1-3.3-dimethyl-butanoyl1-3-ri(l Ri-tetralin-1-yl1carbamoyl1-3.4-dihvdro-l H-isoquinolin-7-yl1oxy1ethoxy1ethoxy1ethoxy1ethylamino1methyl1phenyl1-3-(difluoromethvnpyrazol-4-yl1carbamoyl1oxazol-2-yl1-2-pyridyl1-N-(cvclopropylmethvncarbamate

[005522] To a solution of benzyl N-[(lS)-2-[[(lS)-l-[(3S)-7-[2-[2-[2-(2-aminoethoxy)ethoxy] ethoxy] ethoxy]-3 -[[(lR)-tetralin-l-yl]carbamoyl]-3,4-dihydro-lH-isoquinoline-2-carbonyl]-2,2-dimethyl-propyl]amino]-l-methyl-2-oxo-ethyl]-N-methyl-carbamate (150 mg, 158 umol, TFA, Intermediate PF) and tert-butyl N-(cyclopropylmethyl)-N-[4-[4-[[3-(difluoromethyl)-l-(4-formylphenyl)pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (91.9 mg, 158 umol, Intermediate GF) in THF (30 mL) was added TEA (16.0 mg, 158 umol, 22.1 uL). The mixture was stirred at 20 °C for 30 mins, then HOAc (25.6 mg, 426 umol, 24.3 uL) and $NaBH(OAc)_3$ (67.3 mg, 317 umol) was added into the mixture, and the reaction mixture was stirred at 20 °C for 48 hrs. On completion, the reaction mixture was quenched with Fl_2O (0.5 mL) and then concentrated *in vacuo* to give a residue. The residue was purified by reverse phase chromatography (0.1% FA condition) to give the title compound (90 mg, 40% yield) as a white solid. LC-MS (ESI+) m/z 1392.3 $(M+H)^+$.

[005523] Step 2 - Tert-butyl N-(cvclopropylmethvO-N-r4-r4-rr3-(difluoromethvO-l-r4-rr2-[2-[2-[2-[[(3S)-2-___r(2S)-3.3-dimethyl-2-rr(2S)-2-(methylamino)propanoyl1amino1butanoyl1-3-[\(1RVtetralin- 1-yl]carb amoyl 1-3.4-di hydro- 1H-i soquinolin-7 -yl1oxy1ethoxy1ethoxy1ethoxy1ethylamino1methyl1phenyl1pyrazol-4-yl1carbamoyl1oxazol-2-yl1-2-pyridyll carbamate


[005524] To a solution of tert-butyl N-[4-[4-[[l-[4-[[2-[2-[2-[2-[[(3S)-2-[(2S)-2-[[(2S)-2-[benzyloxycarbonyl (methyl)amino]propanoyl]amino]-3,3-dimethyl-butanoyl]-3-[[(lR)-tetralin-1-yl] carb amoyl]-3,4-dihydro- 1H-i soquinolin-7-yl]oxy]ethoxy]ethoxy]ethoxy]ethylamino]methyl]phenyl]-3-(difluoromethyl)pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(cyclopropylmethyl)carbamate (70.0 mg, 50.2 umol) in THF (1 mL) was added $Pd(OH)_2/C$ (50 mg, 3.59 umol, 10% *wi),* and the reaction mixture was stirred at 25 °C for 40 min under H_2 gas (15 Psi). On completion, the mixture was filtered, the filtrate was concentrated *in vacuo* to give the residue, and the residue was purified by prep-HPLC(column: Phenomenex Synergi C18 150*25* l0um;mobile phase: [water(0.225%FA)-ACN];B%: 32%-50%, 6 min) to give the title compound (20 mg, 31% yield) as a yellow solid.

LC-MS (ESI+) m/z 1258.8 (M+H)+.

[005525] Step 3 - 2-r2-(CvclopropylmethylaminoV4-pyridvn-N-r3-(difluoromethvO-l-r4-[[2-[2-[2-[2-[[(3S)-2-_r(2S)-3.3-dimethyl-2-rr(2S)-2-(methylamino)propanoyl1amino1butanoyl1-3-[[(1R)-tetralin-l-yl1carbamoyl1-3,4-dihydro-lH-isoquinolin-7-yl1oxy1ethoxy1ethoxy1ethoxy1ethylamino1methyl1phenyl1pyrazol-4-yl1oxazole-4-carboxamide

[005526] To a solution of tert-butyl N-(cyclopropylmethyl)-N-[4-[4-[[3-(difluoromethyl)-l-[4-[[2-[2-[2-[2-[[(3S)-2-[(2S)-3,3-dimethyl-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]-3-[[(lR)-tetralin-l-yl]carbamoyl]-3,4-dihydro-lH-isoquinolin-7-yl]oxy]ethoxy]ethoxy]ethoxy]ethylamino]methyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]carbamate (20 mg, 15.8 umol) in DCM (2 mL) was added HCl/dioxane (4 M, 1 mL), and the reaction mixture was stirred at 25 °C for 1 hr. On completion, the reaction mixture was concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (column: Shim-pack C18 l50*25*l0um;mobile phase: [water(0.225%FA)-ACN];B%: l2%-42%, lOmin) to give the title compound (1.57 mg, 8.0% yield) as a white solid. ^{1}H NMR (400MHz, DMSO-i/e) δ 10.01 (s, 1H), 8.92 (s, 1H), 8.74 (s, 1H), 8.33 (s, 2H), 8.20 - 8.09 (m, 2H), 8.02 - 7.87 (m, 1H), 7.78 (d, *J* = 8.4 Hz, 2H), 7.52 - 7.42 (m, 2H), 7.25 (t, *j* = 54.8 Hz, 1H), 7.1 1 - 6.92 (m, 8H), 6.90 - 6.73 (m, 2H), 4.96 - 4.82 (m, 2H), 4.74 - 4.58 (m, 2H), 4.05 - 3.99 (m, 2H), 3.78 (s, 3H), 3.73 - 3.69 (m, 4H), 3.67 - 3.61 (m, 9H), 3.16 (t, *j* = 6.0 Hz, 2H), 3.05 - 2.91 (m, 3H), 2.70 - 2.65 (m, 4H), 2.20 - 2.15 (m, 1H), 2.13 (s, 2H), 1.89 - 1.71 (m, 2H), 1.70 - 1.61 (m, 1H), 1.59 - 1.52 (m, 1H), 1.1 1 - 1.05 (m, 3H), 1.04 - 0.89 (m, 9H), 0.47 - 0.41 (m, 2H), 0.24 - 0.18 (m, 2H); LC-MS (ESI+) m/z H58.7(M+H)+.

[005527] Example 677: N-[3-[[2-[2-[2-[2-[2-[[(3S)-2-[(2S)-3,3-dimethyl-2-[[t2S)-2-(methylamino)propanoyll amino] butanoyl]-3-[[(1R)-tetralin-l-yl]carbamoyl]-3,4-dihydro-lH-isoquinolin-7-ylloxylethoxylethoxylethoxylethoxylethylaminolmethyll-l-methyl-Pyrazol-4-yl1-2-[2-[2,2,2-trifluoroethylamino)-4-pyridyl1oxazole-4-carboxamide, 1-682


Cbz
NH2
TFA
PJ
LS
KOAc, NaBH(OAc)3, DMF/THF
Pd(OH)2/C, H2
THF
HCl/dioxane, DCM
Boc
CF3
F3C
HN

[005528] Step 1 - Tert-butyl N-[4-[4-[3-[2-[2-[2-[2-[(3S)-2-[(2S)-2-[(2S)-2-benzyloxycarbonyl (methyl)amino]propanoyl]amino]-3,3-dimethyl-butanoyl]-3-[[(lR)-tetralin-1-yl]carbamoyl]-3,4-dihydro-lH-isoquinolin-7-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethylaminomethyl]-l-methyl-pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate

[005529] To a solution of benzyl N-[(lri)-2-[[(lri)-l-[(3ri)-7-[2-[2-[2-[2-(2-aminoethoxy)ethoxy] ethoxy] ethoxy] ethoxy]-3-[[(lf?)-tetralin-l-yl]carbamoyl]-3,4-dihydro-lH-isoquinoline-2-carbonyl]-2,2-dimethyl-propyl]amino]-l-methyl-2-oxo-ethyl]-N-methyl-carbamate (55.0 mg, 55.7 umol, TFA, Intermediate PJ) and tert-butyl N-[4-[4-[(3-formyl-l-methyl-pyrazol-4-yl)carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (27.5 mg, 55.7 umol, Intermediate LS) in a mixed solvent of DMF (1 mL) and THF (5 mL) was added KOAc (10.9 mg, 111 umol). The mixture was stirred at 25 °C for 0.5 hour. $NaBH(OAc)_3$ (23.6 mg, 111 umol) was then added into the mixture and the reaction mixture was stirred at 25 °C for 24 hours. On completion, the mixture was concentrated *in vacuo.* The residue was purified by reverse phase chromatography (0.1% FA condition) to give the title compound (35.0 mg, 46% yield) as a brown solid. LC-MS (ESI^+) *m/z* 1352.7 $(M+H)^+$.

[005530] Step 2 - Tert-butyl N-[4-[4-[3-[2-[2-[2-[2-[(3S)-2-[(2S)-3,3-dimethyl-2-[methyl-[(2S)-2-(methylamino) propanoyl]amino]butanoyl]-3-[[(lR)-tetralin-1-yl]carbamoyl]-3,4-dihydro-lH-isoquinolin-7-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethylamino]methyl]-l-methyl-pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate

[005531] To a solution of tert-butyl N-[4-[4-[[3-[[2-[2-[2-[2-[2-[[(3S)-2-[(2S)-2-[[(2S)-2-[benzyloxycarbonyl (methyl)amino]propanoyl]amino]-3,3-dimethyl-butanoyl]-3-[[(lR)-tetralin-1-yl] carbamoyl] -3,4-dihydro- 1H-isoquinolin-7-yl]oxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]methyl]-l-methyl-pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (30.0 mg, 22.2 umol) in THF (3 mL) was added $Pd(OH)_2/C$ (0.05 g, 20% *wi).* The reaction mixture was stirred at 25 °C for 1 hour under H_2 (15 Psi) atmosphere. On completion, the mixture was filtered and the filtrate was concentrated *in vacuo.* The residue was purified by reverse phase chromatography (0.1% FA condition) to give the title compound (15.0 mg, 56% yield) as a yellow solid. LC-MS (ESI^+) *m/z* 1218.8 $(M+H)^+$.


[005532] Step 3 - N-[3-[[2-[2-[2-[2-[2-[[(3S)-2-[(2S)-3,3-dimethyl-2-[[(2S)-2-

(methylamino)propanoyllaminol butanoyll-3- [(1RFtetralin- 1-yl1carbamoyl1-3.4-dihvdro-l H-isoquinolin-7-yl1oxy1ethoxy1ethoxy1ethoxy1ethoxy1ethylamino1methyl1-l-methyl-pyrazol-4-yl1-2-[2-(2,2,2-trifluoroethylamino)-4-pyridyl1oxazole-4-carboxamide

[005533] To a solution of tert-butyl N-[4-[4-[[3-[[2-[2-[2-[2-[2-[[(3 ,S)-2-[(2,S)-3,3-dimethyl-*2-[[(2S)-2-* (methyl amino)propanoyl]amino]butanoyl]-3-[[(l/i)-tetral in- 1-yl]carbamoyl]-3,4-dihydro-lH-isoquinolin-7-yl]oxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]methyl]-l-methyl-pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (14.0 mg, 11.5 umol) in DCM (3 mL) was added HCl/dioxane (3 mL). The reaction mixture was stirred at 25 °C for 2 hours. On completion, the mixture was concentrated *in vacuo*. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10um; mobile phase: [water (0.225%FA)-ACN]; B%: 17%-41%, 8min) to give the title compound (2.00 mg, 15% yield, FA) as a yellow solid. ^{1}H NMR (400MHz, DMSO-^e) δ 10.92 (s, 1H), 8.88 (s, 1H), 8.25 - 8.18 (m, 2H), 8.13 - 8.10 (m, 1H), 7.98 - 7.88 (m, 1H), 7.61 - 7.54 (m, 1H), 7.20 (s, 1H), 7.18 - 7.16 (m, 1H), 7.12 - 7.07 (m, 2H), 7.07 - 7.01 (m, 2H), 6.89 (s, 1H), 6.82 - 6.72 (m, 2H), 5.23 - 4.92 (m, 2H), 4.90 - 4.80 (m, 2H), 4.71 - 4.60 (m, 2H), 4.29 - 4.18 (m, 3H), 4.05 - 3.97 (m, 2H), 3.92 (s, 2H), 3.79 - 3.56 (m, 16H), 3.00 - 2.93 (m, 3H), 2.75 - 2.71 (m, 2H), 2.20 - 2.04 (m, 6H), 1.90 - 1.73 (m, 2H), 1.71 - 1.60 (m, 2H), 1.57 -1.49 (m, 1H), 1.13 - 1.07 (m, 3H), 1.07 - 1.04 (m, 1H), 1.03 - 0.92 (m, 9H); LC-MS (ESI$^+$) *m/z* 1118.7 (M+H)$^+$.

[005534] Further Examples:

[005535] Example 679: 2-[2-(cvclopropylmethylaminoV4-pyridyl]-N-[3-(difluoromethvB-l-[4-[[2-[2-[[l-(2.,6-dioxo- 3-piperidvB-3-methyl-2-oxo-benzimidazol-5-yl]metliviaminolethoxy]ethylamino]methyl]phenyl]pyrazol-4-yl]oxazole-4-carboxamide, I-684



[005536] Step 1 - Tert-1butyl N-[[4-[4-[[2-[2-[tert-butoxycarbonyl(cvclopropylmethvnamino1-4-pyridyl1oxazole -4-carbonyl1amino1-3-(difluorom ethyl)pyrazol- 1-yl1phenyl1methyl1-N-[2-[2-[[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl1methylamino1ethoxy1ethyl1carbamate


[005537] To a solution of 2-[2-[tert-butoxycarbonyl-[[4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl) amino]-4-pyridyl]oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]phenyl]methyl]amino]ethoxy]ethyl methanesulfonate (200 mg, 236 umol, Intermediate PI) and 3-[5-(aminomethyl)-3-methyl-2-oxo- benzimidazol-l-yl]piperidine-2,6-dione (160 mg, 492 umol, HC1, Intermediate PH) in ACN (10 mL) was added KI (39.2 mg, 236 umol) and NaHCO, (59.5 mg, 709 umol). The reaction mixture was stirred at 25 °C for 48 hours. On completion, the reaction mixture was diluted with ACN (100 mL) and filtered. The filtrate was concentrated *in vacuo* and the residue was purified by reversed-phase flash chromatography (FA, 0.1%) to give the title compound (60.0 mg, 24% yield) as a white solid. LC-MS (ESI^+) m/z 1038.6 $(M+H)^+$.

[005538] Step 2 - 2-r2-(cvclopropylmethylamino)-4-pyridyl1-N-r3-(difluoromethyl)-l-r4-

rr2-I2-rr1-(2.6-ü oχo-_ 3-piperidvD-3-methyl-2-oxo-benzimidazol-5-vnmethylamino1ethoxy1ethylamino1methvnphenyl1pyrazol-4-vnoxazole-4-carboxamide

[005539] To a solution of tert-butyl N-[[4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl]oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]phenyl]methyl]-N-[2-[2-[[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]methylamino]ethoxy]ethyl]carbamate (50.0 mg, 48.1 umol) in DCM (2 mL) was added HCl/dioxane (4 M, 10 mL). The reaction mixture was stirred at 25 °C for 1 hour. On completion, the reaction mixture was concentrated *in vacuo*. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 l50*25*l0um; mobile phase: [water (0.05%HCl)-ACN]; B%: 9%-29%, 10 min) to give the title compound (6.50 mg, 14% yield, HC1) as a yellow solid. ¾ NMR (400MHz, DMSO-^e) δ 11.12 (s, 1H), 10.16 (s, 1H), 9.50 (s, 2H), 9.37 (s, 2H), 9.12 (s, 1H), 8.88 (s, 1H), 8.16 - 8.06 (m, 1H), 7.98 - 7.88 (m, 2H), 7.78 (d, *J* = 6.8 Hz, 2H), 7.54 (s, 1H), 7.36 - 7.12 (m, 4H), 5.47 - 5.32 (m, 1H), 4.27 - 4.22 (m, 2H), 3.73 (s, 3H), 3.30 - 3.23 (m, 6H), 3.16 - 3.06 (m, 4H), 2.97 - 2.83 (m, 1H), 2.62 - 2.58 (m, 2H), 2.04 - 1.90 (m, 1H), 1.18 - 1.07 (s, 1H), 0.62 - 0.48 (m, 2H), 0.36 - 0.25 (m, 2H); LC-MS (ESI^+) m/z 838.4 $(M+H)^+$.

[005540] Example 680: 2-[2-(Cyclopropylmethylamino)-4-pyridyl]-N-[3-(difluoromethvB-l-[4-[[2-[2-[4-[l-(2.,6-dioxo-3-piperidvB-3-methyl-2-oxo-benzimidazol-5-yl1piperazin-l-yl1ethoxy1ethylamino1methyl1phenylpyrazol-4-yl1oxazole-4-carboxamide, I-685



[005541] Step 1 - Tert-butyl N-[[4-[4-[[2-[2-[tert-butoxycarbonvKcvclopropylmethvOaminol -4-pyridyl1oxazole-4-carbonyl1amino1-3-(difluorom ethyl jpyrazol- 1-yl1phenyl1methyl1-N-r2-r2-r4-n -(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl1piperazin-l-yl1ethoxy1ethyl1carbamate


[005542] To a solution of 3-(3-methyl-2-oxo-5-piperazin-l-yl-benzimidazol-l-yl)piperidine-2,6-dione (50.0 mg, 146 umol, Intermediate PN), 2-[2-[tert-butoxycarbonyl-[[4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl) amino]-4-pyridyl]oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]phenyl]methyl]amino]ethoxy]ethyl methanesulfonate (148 mg, 175 umol, Intermediate PI) in CH_3CN (8 mL) was added $NaHCO_3$ (36.7 mg, 437 umol), and then the mixture was stirred at 80 °C for 6 hrs under N_2 atmosphere. On completion, the mixture was concentrated *in vacuo*, and the residue was purified by reversed-phase HPLC (0. 1% FA condition) to give the title compound (30.0 mg, 15% yield) as a yellow solid. LC-MS (ESI+) m/z 1093.6

$(M+H)^+$.

[005543] Step 2 - 2-r2-(˙CvclopropylmethylaminoV4-pyridvn-N-r3-(difluoromethvO-l-r4-[[2-[2-[4-[1-(2.6-_ _____dioxo-3-piperidvn-3-methyl-2-oxo-benzimidazol-5-yl1piperazin-l-yl1ethoxy1ethylamino1methyl1phenylpyrazol-4-yl1oxazole-4-carboxamide

[005544] To a solution of tert-butyl N-[[4-[4-[[2-[2-[tert-butoxycarbonyl(cyclopropylmethyl)amino]-4-pyridyl] oxazole-4-carbonyl]amino]-3-(difluoromethyl)pyrazol-l-yl]phenyl]methyl]-N-[2-[2-[4-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]piperazin-l-yl]ethoxy]ethyl]carbamate (20.0 mg, 18.3 umol) in DCM (2 mL) was added TFA (1.54 g, 13.5 mmol, 1.00 mL). The mixture was stirred at 15 °C for 0.5 hr. The mixture was then concentrated *in vacuo*, and the residue was purified by prep-HPLC (column: Phenomenex Synergi C18 l50*25*l0um;mobile phase: [water(0.225%FA)-ACN];B%: l%-3l%,l0min) to give the title compoud (13.6 mg, 83% yield) as a yellow solid. ¾**NMR** (400 MHz, **DMSO-di)** δ 10.96 - 11.11 (m, 2H), 9.01 (s, 1H), 8.91 (s, 1H), 8.23 - 8.34 (m, 3H), 8.04 (s, 1 H), 7.91 (d, *J* = 8.4 Hz, 2H), 7.65 - 7.77 (m, 2H), 7.51 (d, *J* = 8.4 Hz, 2H), 7.27 (s, 1H), 7.14 - 7.21 (m, 1H), 6.91 (d, *J* = 8.6 Hz, 1H), 6.80 (d, 7 = 1.6 Hz, 1 H), 6.60 (dd, *J* = 8.4, 2.20 Hz, 1H), 5.26 (dd, *J* = 13.2 Hz, 1H), 4.23 - 4.30 (m, 2H), 3.81 (s, 2H), 3.55 (s, 4H), 3.29 (s, 3H), 3.06 (m, 4H), 2.83 - 2.91 (m, 1H), 2.70 (m, 2H), 2.67 - 2.69 (m, 2H), 2.61 - 2.65 (m, 2H), 2.58 (m, 4H), 2.07 (s, 3H), 1.96 - 2.01 (m, 1H), LC-MS (ESI+) m/z 893.5 $(M+H)^+$.

[005545] Example 683: N-[2-[2-[2-[3-[l-[2,6-dioxo-3-piperidvB-3-methyl-2-oxo-benzimidazol-4-yl]prop-2-ynoxyl ethoxylethyll-6-(l-hvdroxy-l-methyl-ethvBindazol-5-yll-6-(trifluoromethvBpyridine-2-carboxamide, 1-688





TK

[005546] A mixture of N-[6-(l-hydroxy-l-methyl-ethyl)-2-[2-(2-prop-2-ynoxyethoxy)ethyl]indazol-5-yl]-6- (trifluoromethyl)pyridine-2-carboxamide (300 mg, 611 umol, Intermediate TK), 3-(4-bromo-3-methyl-2-oxo -benzimidazol-l-yl)piperidine-2,6-dione (130 mg, 384 umol, Intermediate HP), CuI (15.0 mg, 78.7 umol), $Pd(PPh_3)_2Cl_2$ (54.0 mg, 76.9 umol), Cs_2CO_3 (630 mg, 1.93 mmol) and 4Å molecular sieves (100 mg) in DMF (4 mL) was stirred at 80 °C for 2 hours under N_2. On completion, the reaction mixture was cooled to 20 °C and then filtered. The filter cake was washed with EA (10 mL) and the filtrate was concentrated *in vacuo.* The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]; B%: 35%-65%, 10 min) to give the title compound (74.2 mg, 25% yield) as yellow solid. ^1H NMR (400 MHz, DMSO-d_6) δ 12.36 (s, 1H), 11.12 (s, 1H), 8.72 (m, 1H), 8.44 (d, *J* = 8.0 Hz, 1H), 8.37 (d, *J* = 7.6 Hz, 1H), 8.34 (s, 1H), 8.16 (d, *J* = 8.0 Hz, 1H), 7.57 (s, 1H), 7.15 *(d, J* = 7.6 Hz, 1H), 7.11 (d, *J* = 7.6 Hz, 1H), 7.00 (t, *j* = 8.0 Hz, 1H), 5.95 (s, 1H), 5.41 - 5.36 (m, 1H), 4.57 (t, *J* = 5.2 Hz, 2H), 4.41 (s, 2H), 3.93 (t, *J* = 5.2 Hz, 2H), 3.65 - 3.55 (m, 7H), 2.93 - 2.82 (m, 1H), 2.74 - 2.68 (m, 1H), 2.65 - 2.57 (m, 1H), 2.06 - 1.96 (m, 1H), 1.61 (s, 6H); LC-MS (ESI^+) *m/z* 748.1 $(M+H)^+$.

[005547] Example 684 & 685: N-[3-carbamoyl-l-[4-[[2-[2-[3-[(1R)-1-(2,6-dioxo-3-piperidyl]-3-methyl-2-oxo- benzimidazol-4-yl]propoxy]ethoxy]ethylamino]methyl]phenyl]pyrazol-4-yl]-2-[2-(2,2,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide, 1-686 and N-[3-carbamoyl-l-[4-[[2-

[2-[3-IYlSM-(2.,6-dioxo-3-piperidvP-3-methyl-2-oxo- _ benzimidazol-4-yl]propoxyl ethoxyl ethylamino]methyll phenyll pyrazol-4-yll-2- [2-f2,2,2-trifluoroethylamino)- 4-pyridyll oxazole-4-carboxamide, 1-690





[005548] Step 1 - Tert-butyl N-[4-[4-[[3-carbamoyl-1-[4-[[2-[2-[3-[(1S)-1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]propoxy]ethoxy]ethylamino]methyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate & Tert-butyl N-[4-[4-[[3-carbamoyl-1-[4-[[2-[2-[3-[(1R)-1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]propoxy]ethoxy]ethylamino]methyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate

[005549] Tert-butyl N-[4-[4-[[3-carbamoyl-1-[4-[[2-[2-[3-[1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]propoxy]ethoxy]ethylamino]methyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (190 mg, 192 umol, Example 324, 1-329) was separated by SFC (column: DAICEL CHIRALPAK IC (250mm*30mm,10um);mobile phase: [0.1% DEA,IPA];B%: 70%-70%,5.7min;100minmin) to give the title compound tert-butyl N-[4-[4-[[3-carbamoyl-1-[4-[[2-[2-[3-[(1S)-1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]propoxy]ethoxy]ethylamino]methyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (95 mg, 50% yield) as a white solid and tert-butyl N-[4-[4-[[3-carbamoyl-1-[4-[[2-[2-[3-[(1R)-1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-

yl]propoxy]ethoxy]ethylamino]methyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (95 mg, 50% yield) as a white solid. LC-MS (ESI^+) *m/z* 988.5 $(M+H)^+$ for both isomers.

[005550] Step 2 - N-[3-carbamoyl-1-[4-[[2-[2-[3-[(1R)-1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]propoxy]ethoxy]ethylamino]methyl]phenyl]pyrazol-4-yl]-2-[2-(2,2,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide


[005551] To a solution of tert-butyl N-[4-[4-[[3-carbamoyl-1-[4-[[2-[2-[3-[(1R)-1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]propoxy]ethoxy]ethylamino]methyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifluoroethyl)carbamate (75.0 mg, 75.9 umol) in DCM (1 mL) was added TFA (1.15 g, 10.1 mmol). The reaction mixture was stirred at 25 °C for 0.5 hr. On completion, the reaction mixture was concentrated *in vacuo*. The crude product was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water (0.225%FA)-ACN]; B%: 16%-43%, 9 min) to give the title compound (36.6 mg, 52% yield, ee 81%, FA salt) as a white solid. ^1H NMR (400 MHz, DMSO-7 ,) δ 11.09 (s, 1H), 11.01 (s, 1H), 9.02 (s, 1H), 8.90 (s, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.04 (s, 1H), 7.89 (d, *J* = 8.8 Hz, 2H), 7.76 - 7.67 (m, 2H), 7.49 (d, *J* = 8.8 Hz, 2H), 7.27 (s, 1H), 7.18 (dd, 7 = 1.2, 5.2 Hz, 1H), 6.99 - 6.91 (m, 2H), 6.89 - 6.83 (m, 1H), 5.36 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.32 - 4.19 (m, 2H), 3.81 (s, 2H), 3.63 - 3.52 (m, 11H), 2.98 - 2.91 (m, 2H), 2.91 - 2.83 (m, 1H), 2.72 (t, *J* = 5.6 Hz, 2H), 2.69 - 2.65 (m, 1H), 2.64 - 2.58 (m, 1H), 2.04 - 1.95 (m, 1H), 1.87 - 1.77 (m, 2H); LC-MS (ESI^+) *m/z* 888.2 $(M+H)^+$.


[005552] Step 3 - N-[3-carbamoyl-1-[4-[[2-[2-[3-[(1S)-1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]propoxy]ethoxy]ethylamino]methyl]phenyl]pyrazol-4-yl]-2-[2-(2,2,2-trifluoroethylamino)-4-pyridyl]oxazole-4-carboxamide

[005553] To a solution of tert-butyl N-[4-[4-[[3-carbamoyl-1-[4-[[2-[2-[3-[(1S)-1-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-4-yl]propoxy]ethoxy]ethylamino]methyl]phenyl]pyrazol-4-yl]carbamoyl]oxazol-2-yl]-2-pyridyl]-N-(2,2,2-trifhioroethyl)carbamate (75.0 mg, 75.9 umol) in DCM (1 mL) was added TFA (1.15 g, 10.1 mmol). The reaction mixture was stirred at 25 °C for 0.5 hr. On completion, the reaction mixture was concentrated *in vacuo*. The crude product was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10 um; mobile phase: [water(0.225% FA)-ACN]; B%: 16%-46%, 10 min) to give the title compound (38.0 mg, 51% yield, ee value = 85%, FA salt) as a white

solid. ^{1}H NMR (400 MHz, DMSO-^e) δ 11.09 (s, 1H), 11.01 (s, 1H), 9.02 (s, 1H), 8.90 (s, 1H), 8.26 (d, *J* = 5.2 Hz, 1H), 8.04 (s, 1H), 7.89 *(d, J* = 8.8 Hz, 2H), 7.76 - 7.67 (m, 2H), 7.49 (d, *J* = 8.8 Hz, 2H), 7.27 (s, 1H), 7.18 (dd, *J* = 1.2, 5.2 Hz, 1H), 6.99 - 6.91 (m, 2H), 6.89 - 6.83 (m, 1H), 5.36 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.32 - 4.19 (m, 2H), 3.81 (s, 2H), 3.63 - 3.52 (m, 11H), 2.98 - 2.91 (m, 2H), 2.91 - 2.83 (m, 1H), 2.72 (t, *J* = 5.6 Hz, 2H), 2.69 - 2.65 (m, 1H), 2.64 - 2.58 (m, 1H), 2.04 - 1.95 (m, 1H), 1.87 - 1.77 (m, 2H); LC-MS (ESI$^+$) *m/z* 888.2 (M+H)$^+$.

[005554] **Example 686: 2-(2.6-Dioxo-3-piperidylU4-r2-r2-r2-r2-r4-rri-methyl-7-r(4-morpholinocvclohexyDaminol pyrazolo[4,3-d]pyrimidin-5-yllaminolpyrazol-l-yl]ethoxy]ethoxy]ethoxy]ethylaniino]isoindoline- 1,3-dione, 1-691**







[005555] To a solution of 5-chloro-l-methyl-N-(4-morpholinocyclohexyl)pyrazolo[4,3-d]pyrimidin-7-amine (100 mg, 285 umol, Intermediate LK), 4-[2-[2-[2-[2-(4-aminopyrazol-l-yl)ethoxy] ethoxy] ethoxy] ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-l,3-dione (220 mg, 427 umol, Intermediate UK) in dioxane (6 mL) was added TFA (650 mg, 5.70 mmol). The reaction mixture was stirred at 120 °C for 2 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 !50*25*l0um; mobile phase: [water (0.225%FA)-ACN]; B%: 7%-28%, 7min) to give the title

compound (26.0 mg, 11% yield) as yellow solid. ¾ NMR (400MHz, **DMSO-i¾)** δ 11.10 (s, 1H), 8.57 (s, 1H), 7.91 (s, 1H), 7.57 (s, 1H), 7.57 - 7.51 (m, 1H), 7.47 (s, 1H), 7.07 (d, *J* = 8.8 Hz, 1H), 7.02 (d, *J* = 6.8 Hz, 1H), 6.56 (t, *J* = 5.6 Hz, 1H), 6.45 (d, *J* = 6.8 Hz, 1H), 5.04 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.16 (t, *J* = 5.6 Hz, 2H), 4.13 (s, 3H), 4.07 *(d, J* = 8.0 Hz, 1H), 3.72 (t, *j* = 5.6 Hz, 2H), 3.63 - 3.59 (m, 4H), 3.57 - 3.49 (m, 12H), 2.92 - 2.81 (m, 1H), 2.62 - 2.58 (m, 4H), 2.57 -2.53 (m, 2H), 2.39 - 2.35 (m, 1H), 2.10 - 2.06 (m, 2H), 2.03 - 1.99 (m, 1H), 1.96 - 1.92 (m, 2H), 1.55 - 1.46 (m, 2H), 1.42 - 1.32 (m, 2H). LC-MS (ESI$^+$) *m/z* 829.5 (M+H)$^+$.

[005556] **Example 687: 2-(2,6-Dioχo-3-ρiρeridνl)-4-[2-[2-[2-[4-[[1-ηïet1ν1-7-[(4-morpholinocvclohexyDaminol _ pyrazolo[4,3-d]pyrimidin-5-yllaminolpyrazol-l-yl]ethoxy]ethoxy]ethylaminol isoindoline- 1,3-dione, 1-692**






[005557] To a solution of N5-[l-[2-[2-(2-aminoethoxy)ethoxy]ethyl]pyrazol-4-yl]-l-methyl-N7-(4- morpholinocyclohexyl)pyrazolo[4,3-d]pyrimidine-5, 7-diamine (60.0 mg, 106 umol, HC1, Intermediate UT) and 2-(2,6-dioxo-3-piperidyl)-4-fluoro-isoindoline-l,3-dione (29.3 mg, 106 umol, Intermediate R) in DMF (2 mL) was added DIPEA (68.6 mg, 530 umol, 92.4 uL). The mixture was stirred at 90 °C for 16 hours. On completion, the reaction mixture was concentrated *in vacuo.* The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 !50*25*l0um; mobile phase: [water (0.225%FA)-ACN]; B%: 9%-30%, 7min) to give the

title compound (13.2 mg, 15% yield, FA) as yellow solid. ^{1}H NMR (400MHz, DMSO-d«) δ 11.09 (s, 1H), 8.55 (s, 1H), 7.92 (s, 1H), 7.56 (s, 1H), 7.54 - 7.43 (m, 2H), 7.05 - 6.96 (m, 2H), 6.55 (t, *J* = 5.6 Hz, 1H), 6.43 (d, *j* = 7.6 Hz, 1H), 5.04 (dd, *J* = 5.2, 12.8 Hz, 1H), 4.17 (t, *j* = 5.2 Hz, 2H), 4.12 (s, 3H), 4.10 - 4.04 (m, 1H), 3.74 (t, *j* = 5.2 Hz, 2H), 3.57 - 3.51 (m, 14H), 2.94 - 2.78 (m, 2H), 2.63 - 2.58 (m, 1H), 2.57 - 2.54 (m, 1H), 2.28 - 2.21 (m, 1H), 2.13 - 1.82 (m, 6H), 1.56 - 1.45 (m, 2H), 1.39 - 1.29 (m, 2H); LC-MS (ESI$^+$) *m/z* 785.4 (M+H)$^+$.


[005558] Example 688: (2S,4R)-1-[(2S)-3,3-dimethyl-2-[[2-[2-[2-[2-[2-[[i-methyl-7-[(4-morpholinocvclohexyD _ amino]pyrazolo[4,3-d]pyrimidin-5-yl]amino] ethoxy] ethoxy] ethoxy] acetyl] amino] butanoyl] -4-hydroxy-N- [[4-14-methylthiazol-5-yPphenyl1methyl1pyrrolidine-2-carboxamide, 1-693




[005559] To a solution of (2S,4R)-l-[(2S)-2-[[2-[2-[2-[2-(2-aminoethoxy) ethoxy] ethoxy] ethoxy] acetyl] amino]-3,3-dimethyl-butanoyl]-4-hydroxy-N-[[4-(4-methylthiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide (30.0 mg, 45.1 umol, Intermediate ME), 5-chloro-l-methyl -N-(4-morpholinocyclohexyl) pyrazolo[4,3-d]pyrimidin-7-amine (14.4 mg, 41.0 umol, Intermediate LK) in NMP (2.00 mL) was added TsOH (707 ug, 4.11 umol). The mixture was stirred at 150 °C for 6 hours under microwave. On completion, the mixture was concentrated *in vacuo*. The mixture was purified by prep-HPLC (column: Phenomenex Gemini l50*25mm*l0um; mobile phase: [water (0.04% $NH_3.H_2O$+l0mM NH_4HC0_3)-ACN]; B%: 30%- 58%, min). The

residue was re-purified by prep-HPLC (column: Phenomenex Gemini l50*25mm*l0um; mobile phase: [water (0.04% NH3.H2O+ 10mM NH4HCO3) - ACN]; B%: 30%-54%, min) to give the title compound (2.39 mg, 5% yield) as brown solid. ^{1}H NMR (400MHz, DMSO-^) δ 8.97 (s, 1H), 8.59 (t, *J* = 5.6 Hz, 1H), 7.49 (s, 1H), 7.42 (s, 1H), 7.39 (m, 4H), 6.31 (d, *J* = 8.0 Hz, 1H), 5.96 (t, *J* = 5.6 Hz, 1H), 5.16 (d, *J* = 3.2 Hz, 1H), 4.56 (d, *J* = 9.6 Hz, 1H), 4.48 - 4.38 (m, 2H), 4.37 - 4.32 (m, 1H), 4.29 - 4.23 (m, 1H), 4.10 (s, 3H), 4.05 - 3.98 (m, 1H), 3.96 (s, 2H), 3.66 - 3.57 (m, 6H), 3.56 - 3.48 (m, 14H), 2.49 - 2.45 (m, 6H), 2.44 (s, 3H), 2.26 - 2.16 (m, 1H), 2.07 - 1.98 (m, 3H), 1.95 - 1.83 (m, 3H), 1.54 - 1.40 (m, 2H), 1.34 - 1.22 (m, 2H), 0.94 (s, 9H), LC-MS (ESI$^+$) *m/z* 978.7(M+H) $^+$.

[005560] Example 689: _N-[3-(difluoromethvB-l-methyl-pyrazol-4-yl]-5-[4-[2-[2-[3-[l-(2,6-dioxo-3-piperidvl)-3- methyl-2-oxo-benzimidazol-5-yl] propoxy] ethoxy] ethyl] piperazin-l-yl]pyrazolo[l.,5-a1pyrimidine-3-carboxamide, 1-694







[005561] To a mixture of 2-[2-[3-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]propoxy]ethoxy] ethyl methanesulfonate (70 mg, 144 umol, Intermediate UB) and N-[3-(difluoromethyl)-l-methyl-pyrazol-4-yl]-5-piperazin -l-yl-pyrazolo[l,5-a]pyrimidine-3-carboxamide (59.7 mg, 144 umol, HC1, Intermediate RD) in ACN (3 mL) was added NaHCCh (36.4 mg, 434 umol) and KI (2.40 mg, 14.4 umol), and the mixture was stirred at 80 °C for 16 hours. On completion, the reaction mixture was quenched with water (15 mL), and then extracted

with EA (4 X 20 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated *in vacuo* to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*25 lOu; mobile phase: [water (0.225%FA)-ACN]) to give the title compound (8.68 mg, 10.7 umol, 7% yield, FA) as yellow solid. ¾ NMR (400MHz, DMSO-$<7_6$) δ 11.07 (s, 1H), 9.39 (s, 1H), 8.74 (d, *J* = 7.6 Hz, 1H), 8.34 (s, 1H), 8.26 (s, 1H), 7.22 - 6.91 (m, 3H), 6.88 - 6.74 (m, 2H), 5.32 (dd, *J* = 5.2, 12.8 Hz, 1H), 3.87 (s, 3H), 3.84 - 3.70 (m, 4H), 3.58 (t, *J* = 5.6 Hz, 2H), 3.55 - 3.50 (m, 4H), 3.30 (s, 3H), 2.94 - 2.82 (m, 1H), 2.74 - 2.53 (m, 10H), 2.05 - 1.92 (m, 1H), 1.88 - 1.71 (m, 2H); LC-MS (ESE) *m/z* 764.1 $(M+H)^+$.

[005562] Examples 694 and 695: 2-[2-(Cyclopropylmethylamino)-4-pyridyll-N-[3-(dif uoromethvl)-l-[4-[[4-[4-[1-[(3S)-2,6-dioxo-3-piperidyll-3-methyl-2-oxo-benzimidazol-5-yl]butoxy]butylamino] methyl] phenyl] pyrazol-4-ylloxazole-4-carboxamide, 1-699 & 2-[2-(cyclopropylmethylaminoV4-pyridyll-N-[3- (dif uoromethyl)-l-[4-[[4-[4-[1-[(3R)-2,6-dioxo-3-piperidyl1-3-methyl-2-oxo-benzimidazol-5-yl1butoxy1butylamino1methyl]phenyl1pyrazol-4-yl1oxazole-4-carboxamide, 1-700



I-411



[005563] The 2-[2-(cyclopropylmethylamino)-4-pyridyl]-N-[3-(difluoromethyl)-l-[4-[[4-[4-[l-(2,6-dioxo-3-piperidyl)-3-methyl-2-oxo-benzimidazol-5-yl]butoxy]butylamino]methyl]phenyl]pyrazol-4-yl]oxazole-4-carboxamide (50.0 mg, 54.9 umol, FA salt, Example 406, 1-411) was separated by SFC (column: DAICEL CHIRALPAK IC (250 mm*30 mm, 10 um); mobile phase: [0.1% NH3H2O MeOH]; B%: 70%-70%, 13.7 min; 160 min) to give the two enantiomers. Then the two enantiomers were purified by prep-HPLC (column: Shim-pack C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]; B%: ll%-4l%) respectively to give 2-[2-(cyclopropylmethylamino)-4-pyridyl]-N-[3-(difluoromethyl)-l-[4-[[4-[4-[1-[(3 S)-2,6-dioxo-3-piperidyl]-3-methyl-2-oxo-benzimidazol-5-yl]butoxy]butylamino]methyl]phenyl]pyrazol-4-yl]oxazole-4-carboxamide (3.40 mg, 12% yield, ee value = 91 %) as a white solid and 2-[2-(cyclopropylmethylamino)-4-pyridyl]-N-[3-(difluoromethyl)-l-[4-[[4-[4-[l-[(3R)-2,6-dioxo-3-piperidyl]-3-methyl-2-oxo-benzimidazol-5-yl]butoxy]butylamino]methyl]phenyl]pyrazol-4-yl]oxazole-4-carboxamide (3.80 mg, 14% yield,


ee value = 77 %) as a white solid. The absolute configuration of the enantiomers was arbitratily assigned. Characterization of 2-[2-(cyclopropylmethylamino)-4-pyridyl]-N-[3-(difluoromethyl)-l-[4-[[4-[4-[l-[(3S)-2,6-dioxo-3-piperidyl]-3-methyl-2-oxo-benzimidazol-5-yl]butoxy]butylamino]methyl]phenyl]pyrazol-4-yl]oxazole-4-carboxamide: ^{1}H NMR (400 MHz, DMSO-di) δ 11.22 (s, 1H), 9.99 (s, 1H), 8.97 (s, 1H), 8.78 (s, 1H), 8.36 (s, 1H), 8.16 (d, *J* = 5.2 Hz, 1H), 7.79 *(d, J* = 8.8 Hz, 2H), 7.47 (d, *J* = 8.8 Hz, 2H), 7.42 - 7.15 (m, 1H), 7.13 - 7.07 (m, 2H), 7.06 - 6.96 (m, 3H), 6.88 - 6.82 (m, 1H), 5.33 (d, *J* = 5.2, 12.8 Hz, 1H), 3.73 (s, 2H), 3.31 (s, 6H), 3.21 - 3.16 (m, 3H), 2.97 - 2.82 (m, 1H), 2.75 - 2.55 (m, 6H), 2.03 - 1.94 (m, 1H), 1.66 - 1.57 (m, 2H), 1.55 - 1.43 (m, 6H), 1.11 - 1.03 (m, 1H), 0.49 - 0.41 (m, 2H), 0.26 - 0.19 (m, 2H); LC-MS (ESI^{+}) *m/z* 865.5(M+H)$^{+}$. Characterization of 2-[2-(cyclopropylmethylamino)-4-pyridyl]-N-[3-(difluoromethyl)-l-[4-[[4-[4-[l-[(3R)-2,6-dioxo-3-piperidyl]-3-methyl-2-oxo-benzimidazol-5-yl]butoxy]butylamino]methyl]phenyl]pyrazol-4-yl]oxazole-4-carboxamide: ^{1}H NMR (400 MHz, DMSO-i¾) δ 11.05 (s, 1H), 9.96 (s, 1H), 8.95 (s, 1H), 8.76 (s, 1H), 8.35 (s, 1H), 8.14 (d, *J* = 5.2 Hz, 1H), 7.76 (d, *j* = 8.8 Hz, 2H), 7.45 *(d, J* = 8.4 Hz, 2H), 7.40 - 7.12 (m, 1H), 7.11 - 7.05 (m, 2H), 7.04 - 6.94 (m, 3H), 6.83 (d, *J* = 8.0 Hz, 1H), 5.30 (d, *J* = 5.2, 12.8 Hz, 1H), 3.70 (s, 2H), 3.29 (s, 6H), 3.16 (d, *J* = 6.4 Hz, 3H), 2.93 - 2.81 (m, 1H), 2.73 - 2.55 (m, 6H), 2.02 - 1.92 (m, 1H), 1.65 - 1.55 (m, 2H), 1.53 - 1.40 (m, 6H), 1.11 - 0.99 (m, 1H), 0.47 - 0.39 (m, 2H), 0.23 - 0.17 (m, 2H); LC-MS (ESI^{+}) *m/z* 865.5(M+H)$^{+}$.

[005564] While we have described a number of embodiments of this invention, it is apparent that our basic examples may be altered to provide other embodiments that utilize the compounds and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims rather than by the specific embodiments that have been represented by way of example.

CLAIMS

We claim:

1. A compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:


IRAK is an IRAK binding moiety capable of binding to one or more of IRAK-l, -2, -3, or -4;

L is a bivalent moiety that connects IRAK to LBM; and

LBM is a ligase binding moiety.


2. The compound of claim 1, wherein LBM is a cereblon binding moiety, a VHL binding moiety, an IAP E3 ligase binding moiety, or an MDM2 E3 ligase binding moiety..

3. The compound of claim 2, wherein LBM is a cereblon binding moiety and said compound is of formula **1.1′**:



I-l′

or a pharmaceutically acceptable salt thereof, wherein:

X^1 is a bivalent moiety selected from a covalent bond, -CEE-, -C(O)-, -C(S)-, or 

;

































X^2 is a carbon atom or silicon atom;


X^3 is a bivalent moiety selected from -CEE- or -Si(R_2)-;

R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, -S(0)$_2$R, -N(R)$_2$, -Si(R)$_3$, or an optionally substituted C_{i-4} aliphatic;

each R^2 is independently hydrogen, -R^6, halogen, -CN, -N0$_2$, –OR, -SR, -NR_2, -S(0)$_2$R, -S(0)$_2$$NR_2$, -S(0)R, -C(0)R, -C(0)0R, -C(0)NR_2,

-C(0)N(R)0R, -0C(0)R, -0C(0)NR $_2$, -N(R)C(0)0R, -N(R)C(0)R, -N(R)C(0)NR$_2$, or -N(R)S(0) $_2$R;

Ring A is a bi- or tricyclic ring selected from  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  , , , , , ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  .



wherein

Ring B is a fused ring selected from 6-membered aryl containing 0-2 nitrogen atoms, 5 to 7-membered partially saturated carbocyclyl, 5 to 7-membered partially saturated heterocyclyl with 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;


R^3 is selected from hydrogen, halogen, -OR, $-N(R)_2$, or -SR;


each R^4 is independently hydrogen, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;


R^5 is hydrogen, Ci_{-4} aliphatic, or -CN;

each R^6 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;


L^1 is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-so hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -O-, -NR-, -S-, -OC(O)-, -C(0)0-, -C(O)-, -S(O)-, $-S(0)_2-$, $-NRS(0)_2-$, $-S(0)_2NR-$, -NRC(O)-, -C(0)NR-, -OC(O)NR-, –NRC(O)O-,




,


,


,



, or


, wherein:

each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroaryl enyl having 1-4 heteroatoms independently selected from nitrogen, oxygen,

and sulfur, or an 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;


m is 0, 1, 2, 3 or 4;

each of n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and

each R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:


two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

4. The compound of claim 2, wherein LBM is a cereblon binding moiety and said compound is of formula **I-m':**



I-m'



or a pharmaceutically acceptable salt thereof, wherein:


X^1 is a bivalent moiety selected from a covalent bond, $-CH_{2-}$, -C(O)-, -C(S)-, or  ;

X^2 is a carbon atom or silicon atom;

X^3 is a bivalent moiety selected from $-CH_{2-}$ or $-Si(R_2)-$;

R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, –S(0)R, $-S(0)_2R$, $-N(R)_2$, $-Si(R)_3$, or an optionally substituted C_{1-4} aliphatic;

Ring A is a mono- or bicyclic ring selected from  ,  ,



each R^2 is independently hydrogen, $-R^6$, halogen, $-CN$, $-NO_2$, $-OR$, -SR,






$-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

Ring B is selected from a 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;

each of R^3 and R^4 is independently hydrogen, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

R^5 is hydrogen, Ci_{-4} aliphatic, or -CN;

each R^6 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

L^1 is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-so hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -O-, -NR-, -S-, -OC(O)-, -C(0)0-, -C(O)-, -S(O)-, $-S(0)_2-$, $-NRS(0)_2-$, $-S(0)_2NR-$, -NRC(O)-, -C(0)NR-, -OC(O)NR-, –NRC(O)O-,  ,  ,  ,  , or  , wherein:


each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2

heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

m is 0, 1, or 2;

n is 0, 1, 2, 3, or 4;

p is 0 or 1, wherein when p is 0, the bond connecting Ring A and Ring B is connected to




;

each of q is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and

each R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:


two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

5. The compound of claim 2, wherein LBM is a cereblon binding moiety and said compound is selected formula **I-iT:**



I-n′










or a pharmaceutically acceptable salt thereof, wherein:













X^1 is a bivalent moiety selected from a covalent bond, $-CH_{2-}$, -C(O)-, -C(S)-, or  ;













X^2 is a carbon atom or silicon atom;


X^3 is a bivalent moiety selected from $-CH_{2-}$ or $-Si(R_2)-$;

R^1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, $-S(0)_2R$, $-N(R)_2$, $-Si(R)_3$, or an optionally substituted C_{i-4} aliphatic;

Ring A is a mono- or bicyclic ring selected from  ,  ,  ,  ,  ,  ,  ,  ,  .


,

,

,

,

,

,

,

,

,

,

,




, or ;

each R^2 is independently hydrogen, $-R^6$, halogen, -CN, -NO2, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;

Ring B is selected from a 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered


heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;


each of R^3 and R^4 is independently hydrogen, $-R^6$, halogen, -CN, $-N0_2$, -OR, -SR, $-NR_2$, $-S(0)_2R$, $-S(0)_2NR_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)NR_2$, -C(0)N(R)0R, -0C(0)R, $-0C(0)NR_2$, -N(R)C(0)0R, -N(R)C(0)R, $-N(R)C(0)NR_2$, or $-N(R)S(0)_2R$;


R^5 is hydrogen, Ci_{-4} aliphatic, or -CN;

each R^6 is independently an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;


L^1 is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-so hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -O-, -NR-, -S-, -OC(O)-, -C(0)0-, -C(0)-, -S(0)-, $-S(0)_2-$, $-NRS(0)_2-$, $-S(0)_2NR-$, -NRC(O)-, -C(0)NR-, -OC(O)NR-, –NRC(O)O-,




,


,


,



, or


, wherein:

each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroaryl enyl having 1-4 heteroatoms independently selected from nitrogen, oxygen,

and sulfur, or an 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

m is 0, 1, or 2;

n is 0, 1, 2, 3, or 4;

p is 0 or 1;


each of q is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and

each R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:


two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

6. The compound of claim 1, wherein LBM is a cereblon binding moiety and said compound is selected from any of the following formulae:


(0




I-a-1




I-a-2




I-a-3




I-a-4




I-a-5




I-a-6




I-a-7




I-a-8




I-a-9




I-a-10

or a pharmaceutically acceptable salt thereof, and wherein each of the variables  , X, Xi, X_2, Y, Ri, R_3, R_3', R_4, R_5, t, m and n is as defined and described in US 2018/0134684, the entirety of which is herein incorporated by reference;


iii)




I-h-l




I-h-2




I-h-3



I-h-4



I-h-5



I-h-6

or a pharmaceutically acceptable salt thereof, wherein

W is independently selected from the group CH_2, CHR, C=0, $S0_2$, NH, and N-alkyl;

X is independently selected from the group O, S and H_2,

Y is independently selected from the group NH, N-alkyl, N-aryl, N-hetaryl, N-cycloalkyl, N-heterocyclyl, O, and S;

Z is independently selected from the group O, and S or H_2except that both X and Z cannot be H_2;

G and G' are independently selected from the group H, alkyl, OH, CH_2-heterocyclyl optionally substituted with R', and benzyl optionally substituted with R';

Q1-Q4 represent a carbon C substituted with a group independently selected from R', N or N-oxide;

A is independently selected from the group H, alkyl, cycloalkyl, Cl and F;

R comprises, but is not limited to: —CONRR", —OR', —NR'R", —SR', —$S0_2$R', —$S0_2$NR'R", —CR'R"—, —CRTStR'R"—, -aryl, -hetaryl, -alkyl, -cycloalkyl, -heterocyclyl, —P(0)(0R')R", —P(0)R'R", —0P(0)(0R')R", —0P(0)R'R", —Cl, —F, —Br, —I, —CF_3, —CN, —NR'SO_2NR'R", —NR'CONR'R", —CONR'COR", —NR'C(=N—CN)NR'R", —C(=N—CN)NR'R", —NR'C(=N—CN)R", —NR'C(=C—$N0_2$)NR'R", —SOiNR'COR", —$N0_2$, —$C0_2$R', —C(C=N— OR')R", —CR'=CR'R", —CCR', —S(C=0)(C=N—R')R", —SF_5 and —OCF_3;


R' and R" are independently selected from a bond, H, alkyl, cycloalkyl, aryl, hetaryl, heterocyclyl;

n is an integer from 1-4;


$\sim^{W}$ represents a bond that may be stereospecific ((R) or (S)) or non-stereospecific; and

R_n comprises 1-4 independent functional groups or atoms; or


(Hi)




I-j-1



I-j-2



I-j-3



I-j-4

or a pharmaceutically acceptable salt thereof, wherein

A^1 is selected from the group consisting of -C(R^{16a})= and -N=;

A^2 is selected from the group consisting of -C(R^{16b})= and -N=;

A^3 is selected from the group consisting of -C(R^{16c})= and -N=;

G is selected from the group consisting of -C(R^{16d})= and -N=;

Z is selected from the group consisting of -CH_2 and -C(=0)-;

R^5 is selected from the group consisting of hydrogen, methyl, and fluoro;


R^{16a} is selected from the group consisting of hydrogen, halo, and Ci_{-4} alkyl;

R^{16b} is selected from the group consisting of hydrogen, halo, and C_{1-4} alkyl;


R^{16C} is selected from the group consisting of hydrogen, halo, and C_{1-4} alkyl; and

R^{16d} is selected from the group consisting of hydrogen, halo, and C_{1-4} alkyl; or


(iv)




I-o




I-p




I-q




I-r




I-s



I-t



I-u



I-v

or a pharmaceutically acceptable salt thereof, wherein:

Ar is aryl, heteroaryl, cycloalkyl, or heterocyclyl;

L^1 is absent or a linker selected from the group consisting of -S0 $_2$, -S0 $_2$R'; SO2R'R",- SO2NRR"; -SO2NR'R"C(=0); -NR'SO2R"; -R'SO2NR'R"'; -C(=0); -C(=0)R; -0C(=0)R; -

C(=O)NR'R"; -NR'C(=O)R"; -NR'C(=O)R"C(=O); -OR'; -NR'R"; -SR'; -N_3-C(=O)OR'; -O(CR'R")rC(=O)R'; -O(CR'R")rNR"C(=O)R'; -O(CR'R")rNR"SO_2R'; -OC(=O)NR'R"; -NRC(=0)0R '"; and substituted or unsubstituted Ci-C_6 aliphatic alkyl;

wherein R', R", and R'" are individually selected from hydrogen; substituted or unsubstituted alkyl; substituted or unsubstituted alkenyl; substituted or unsubstituted ether; substituted or unsubstituted cycloalkyl; substituted or unsubstituted heterocyclyl; substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkylheteroaryl, or substituted or unsubstituted amine; and r is an integer from 1 to 6;

A is C, S; substituted of unsubstituted Ci-Cx alkyl, or combinations thereof;

G comprises C, S, N, substituted of unsubstituted C1-C8 alkyl, or combinations thereof; R^3 is selected from the group consisting of hydrogen, halogen, hydroxyl, azide, alkoxyl, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, cyano, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, substituted or unsubstituted amine, substituted or unsubstituted amide, nitro, ester, morpholino, dioxolane, substituted or unsubstituted alkyl, substituted or unsubstituted alkylhalide, substituted or unsubstituted aralkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkyl; substituted or unsubstituted heterocyclyl; substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkylheteroaryl, and combinations thereof;

R^1, R^2, and R^3 are individually selected from the group consisting of hydrogen, halogen, hydroxyl, azide, alkoxyl, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, cyano, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, substituted or unsubstituted amine, substituted or unsubstituted amide, nitro, ester, morpholino, dioxolane, substituted or unsubstituted alkyl, substituted or unsubstituted alkylhalide, substituted or unsubstituted aralkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkyl; substituted or unsubstituted heterocyclyl; substituted or unsubstituted

cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkylheteroaryl, and combinations thereof; or

wherein R^1 and R^2 combine to form a 5-7 membered heterocyclic ring; and wherein when R^1 and R^2 combine to form a 5-7 membered heterocyclic ring, Ar is optionally not fused to the 5-7 membered heterocyclic ring but is a substituent of the 5-7 membered heterocyclic ring;


R^4 and R^5 are individually selected from the group consisting of hydrogen, halogen, hydroxyl, azide, ether, alkoxyl, sulfhydryl, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, substituted or unsubstituted alkyl, substituted or unsubstituted alkylhalide, substituted or unsubstituted aralkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, heterocyclyl, and combinations thereof;

R^6 and R^7 are individually =0, hydrogen, Ci-C_8 alkyl, or R^6 and R^7 combine to form =0;


R^8 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkylhalide, substituted or unsubstituted aralkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, and combinations thereof; and

x is 0, 1, or 2; or


(*v*)



I-z-1



I-z-2



I-z-3

or a pharmaceutically acceptable salt thereof, wherein

W^1 is CR^6R^7, C=0, C=S, $C=CH_2$, $S0_2$, S(0), P(0)0alkyl, P(0)NHalkyl, $P(0)N(alkyl)_2$, P(0)alkyl, P(0)0H, $P(0)NH_2$;

W^2 is CR^8R^9, C=0, C=S, $C=CH_2$, $S0_2$, S(0), P(0)0alkyl, P(0)NHalkyl, $P(0)N(alkyl)_2$, P(0)alkyl, P(0)0H, $P(0)NH_2$;

X is independently selected from NH, NR^3, CH_2, CHR^3, $C(R^3)_2$, O, and S;


n is 0, 1, 2, or 3;


--- is a single or double bond;

wherein when --- represents a single bond, n is 0, 1, 2, or 3;

wherein when --- represents a double bond, n is 0, 1, or 2;


R^1 is selected from:






and R1*;

or R1 is selected from:






R^2 is alkyl, hydrogen, aliphatic, heteroaliphatic, aryl, heteroaryl or heterocyclic;

or R^1 and R^2 are combined to form a 4, 5, 6, 7, 8, 9, or 10 membered heterocyclo or heteroaryl species, wherein the heterocyclo or heteroaryl species is substituted with R^{12} at any desired position, wherein the heterocyclo or heteroaryl species is optionally further substituted with one or more substituents selected from R^5;

R^{1*} is selected from:



R^3 is selected at each instance from: alkyl, -C(0)H, -C(0)0H, -C(0)alkyl, -C(0)0alkyl, alkene, and alkyne, aliphatic, heteroaliphatic, aryl, heteroaryl and heteroalkyl;

R^4 is selected at each instance from: alkyl, alkene, alkyne, halogen, hydroxyl, alkoxy, azide, amino, cyano, -NH(aliphatic), -N(aliphatic)2, -NHS0 $_2$(aliphatic), - N(aliphatic)S0 $_2$alkyl, -NHS0 $_2$(aryl, heteroaryl or heterocyclic), -N(alkyl)S0 $_2$(aryl, heteroaryl or heterocyclic) -NHSCkalkenyl, -N(alkyl)S0 $_2$alkenyl, -NHSChalkynyl, -N(alkyl)S0 $_2$alkynyl, and haloalkyl; aliphatic, heteroaliphatic, aryl, heteroaryl, heteroalkyl and carbocyclic;

or two R^4 substituents together with the carbon atom(s) to which they are bound can form a 3, 4, 5 or 6 membered ring; R^5 and R^{14} are selected at each instance from: hydrogen, alkyl, alkene, alkyne, halogen, hydroxyl, alkoxy, azide, amino, cyano, -NH(aliphatic), -N(aliphatic)2, -NHS0 $_2$(aliphatic), -N(aliphatic)S0 $_2$alkyl, -NHSCktaryl, heteroaryl or

heterocyclic), -N(alkyl)S0 $_{2(}$aryl, heteroaryl or heterocyclic) -NHSCkalkenyl, -N(alkyl)S0 $_{2}$alkenyl, -NHS02alkynyl, -N(alkyl)S0 $_{2}$alkynyl, and haloalkyl; aliphatic, heteroaliphatic, aryl, heteroaryl, heteroalkyl and carbocyclic;

or R^5 is independently selected from C(0)R^4, cyano, aryl, aryloxy, heterocyclo, heteroaryl, arylalkyl, alkoxy, hydroxyl, O-arylalkyl, or cycloalkyl;

R^6, R^7, R^8, R^9, R^{10}, and R^{11}, are independently selected from hydrogen, alkyl, aliphatic, heteroaliphatic, hydroxyl, alkoxy, amine, -NH(aliphatic), and -N(aliphatic)2;

or R^6 and R^7 together with the carbon to which they are bound form a 3-, 4-, 5-, or 6- membered spirocarbocycle, or a 4-, 5-, or 6-membered spiroheterocycle comprising 1 or 2 heteroatoms selected from N and O;

or R^8 and R^9 together with the carbon to which they are bound form a 3-, 4-, 5-, or 6- membered spirocarbocycle, or a 4-, 5-, or 6-membered spiroheterocycle comprising 1 or 2 heteroatoms selected from N and O;

or R^{10} and R^{11} together with the carbon to which they are bound form a 3-, 4-, 5-, or 6- membered spirocarbocycle, or a 4-, 5-, or 6-membered spiroheterocycle comprising 1 or 2 heteroatoms selected from N and O;

or R^6 and R^8 form a 1 or 2 carbon bridged ring;

or R^6 and R^{10} form a 1 or 2 carbon bridged ring;

or R^8 and R^{10} form a 1 or 2 carbon bridged ring;

or R^{14} and R^6 form a 3, 4, 5, or 6 carbon fused ring;


or R^{14} and R^{10} form a 3, 4, 5, or 6 carbon fused ring;

or R^{14} and R^8 form a 1 or 2 carbon bridged ring;

or R^{14} and R^4 form a 3, 4, 5, or 6 carbon fused ring wherein R^5 is on the carbon alpha to R^{14} or a 1, 2, 3, or 4 carbon bridged ring wherein R^5 is not on the carbon alpha to R^{14};

R^{12} is L;

R^{17} is selected from:


























Y is independently selected from N, CH, or CR^{101}, wherein 0, 1, 2, or 3 instances of Y are selected to be N;

R^{101} is independently selected at each occurrence from hydrogen, alkyl, alkene, alkyne, haloalkyl, alkoxy, hydroxyl, aryl, heteroaryl, heterocycle, arylalkyl, heteroarylalkyl, heterocycloalkyl, aryloxy, heteroaryloxy, CN, -COOalkyl, COOH, NO_2, F, Cl, Br, I, CF_3, NH_2, NHalkyl, $N(alkyl)_2$, aliphatic, and heteroaliphatic.

7. The compound according to claim 2, wherein cereblon ligase binding moiety is selected


from the group consisting of:



, 
, 
, and 
.

8. The compound of claim 2, wherein LBM is a VHL E3 ubiquitin ligase binding moiety and said compound is selected from any of the folling formulae:


(1)



I-b-3




I-b-4




I-b-5

or a pharmaceutically acceptable salt thereof, wherein each of the variables $R^{1'}$, $R^{2'}$, $R^{3'}$, X, and X' is as defined and described in US 2014/0356322, the entirety of which is herein incorporated by reference; or


(2)




I-f-1




I-f-2




I-f-3



I-f-4




I-f-5




I-f-6

or a pharmaceutically acceptable salt thereof, wherein each of the variables $R^{1'}$, $R^{2'}$, $R^{3'}$, R_5, R_6, R_7, R9, Rio, R11, R14, R15, Ri_6, R17, R23, R25, E, G, M, X, X', Y, Zi, Z2, Z_3, Z_4, and o is as defined and described in US 2016/0272639, the entirety of which is herein incorporated by reference; or


(3)



I-g-l



I-g-2




I-g-3

or a pharmaceutically acceptable salt thereof, wherein each of the variables R^p, R_9, Rio, R_{11}, Ri_{4a}, Ri_{4b}, R_{15}, Ri_6, W^3, W^4, W^5, X^1, X^2, and o is as defined and described in US 2016/0214972, the entirety of which is herein incorporated by reference.


9. The compound of claim 2, wherein IRAK is an IRAK binding moiety capable of binding to IRAK4.

10. The compound of claim 9, wherein said compound is selected from any one of the following formulae:

(a)



I-dd-1



I-dd-2

or a pharmaceutically acceptable salt thereof, wherein:

A is optionally substituted heteroaryl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted (heterocycloalkyl)alkyl, optionally substituted aralkyl, optionally substituted heteroaralkyl, optionally substituted cycloalkyl-$NR_{x—}$, optionally substituted heterocycloalkyl-$NR_{x—}$, optionally substituted aryl-$NR_{x—}$, optionally substituted heteroaryl-$NR_{X—}$, optionally substituted cycloalkyl-0 —, optionally substituted heterocycloalkyl-0 —, optionally substituted aryl-0 — or optionally substituted heteroaryl-0 —; e.g., wherein each optional substituent independently represents an occurrence of R_z;

B is hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxy, —$NR_aR_{b,}$ optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, optionally substituted (cycloalkyl)alkyl, optionally substituted (heterocycloalkyl)alkyl, optionally substituted aralkyl, optionally substituted heteroaralkyl, optionally substituted cycloalkyl-$NR_{x—}$, optionally substituted heterocycloalkyl-$NR_{x—}$, optionally substituted aryl-$NR_{x—}$, optionally substituted heteroaryl-$NR_{X—}$, optionally substituted cycloalkyl-

O—, optionally substituted heterocycloalkyl-0 —, optionally substituted aryl-0 —, optionally substituted heteroaryl-0 —; e.g., wherein each optional substituent independently represents an occurrence of R_y;

Q is absent or optionally substituted heterocycloalkyl, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted (heterocycloalkyl)alkyl, optionally substituted (heteroaryl)alkyl, optionally substituted aralkyl, optionally substituted (cycloalkyl)alkyl, —NR_3R_4, —O—R_3 or —S—R; e.g., wherein each optional substituent independently represents an occurrence of R_z;

W is N or CH;

Ri is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted (heterocycloalkyl)alkyl, optionally substituted heterocycloalkyl, optionally substituted aralkyl, optionally substituted (heteroaryl)alkyl-, optionally substituted alkoxyalkyl, optionally substituted aminoalkyl, or —$(CH_2)_m$—R_2; e.g., wherein each optional substituent independently represents halo, hydroxy, alkoxy, amino, nitro, cycloalkyl, aryl, heterocycloalkyl or heteroaryl;

R_2 is hydrogen, —NR_aR_b, alkoxy, hydroxy, optionally substituted heteroaryl or optionally substituted heterocycloalkyl; e.g., wherein each optional substituent independently represents an occurrence of R_y;

each R_3 and R_4 is independently selected from optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted aralkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted (heteroaryl)alkyl and optionally substituted (heterocycloalkyl)alkyl; e.g., wherein each optional substituent is independently selected from alkyl, halo, haloalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, amino, nitro, cycloalkyl, (cycloalkyl)alkyl, aryl, aralkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, heteroaryl and (heteroaryl)alkyl;

each R_a and R_b is independently selected from hydrogen, alkyl, aminoalkyl, acyl and heterocyclyl; or R_a and R_b are taken together with the nitrogen to which they are attached to form an optionally substituted ring;

R_x is hydrogen, alkyl, hydroxy, hydroxyalkyl, acyl or cycloalkyl;

each R_y and R_x is independently selected from hydroxy, hydroxyalkyl, halo, alkyl, oxo, haloalkyl, alkoxy, alkenyloxy, amino, nitro, cyano, —SH, —S(alkyl), glycinate, ester, thioester,


cycloalkyl, heterocycloalkyl, aryl, heteroaryl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, aralkyl, and (heteroaryl)alkyl; optionally wherein the hydroxy, hydroxyalkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are further substituted by one or more substituents selected from alkyl, halo, alkenyl, amino, nitro, cycloalkyl and (cycloalkyl)alkyl; or

R_y and R_z taken together with the atoms to which they are attached form an alkyl chain having 1-10 carbon atoms; optionally wherein 1-3 carbon atoms are replaced by O, NH or S;


m is 1, 2, or 3; and

n is 1 or 2; or


(b)




I-ee-1



I-ee-2



I-ee-3



I-ee-4

or a pharmaceutically acceptable salt thereof, wherein:

Ring A is selected from phenyl and 5- or 6-membered heteroaryl;

Ring B is selected from phenyl and 5- or 6-membered heteroaryl;

n is 0, 1, or 2;

p is 0, 1, or 2;

one of W and X is N, and the other of W and X is C;

Y is N or C—R^2;

R^1 is selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, 3- to 6-membered saturated heterocyclyl, halo, —CN, —$C(R^{1a})$═$NR(OR^{1a})$, —$C(R^{1a})$═$N(R^{1a})$, —$C(O)R^{1a}$, —$C(O)_2R^{1a}$, —$C(O)N(R^{1a})_2$, —NO_2, —$N(R^{1a})_2$, —$N(R^{1a})C(O)R^{1a}$, —$N(R^{1a})C(O)_2R^{1a}$, —$N(R^{1a})C(0)N(R^{1a})_2$, —$N(R^{1a})S(0)_2R^{1a}$, —OR^{1a}, —$0C(0)R^{1a}$, —$0C(0)N(R^{1a})_2$, —SR^{1a}, —$S(0)R^{1a}$, —$S(0)_2R^{1a}$, —$S(0)N(R^{1a})_2$, and —$S(0)_2N(R^{1a})_2$, wherein said Ci_{-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C3-6cycloalkyl, and 3- to 6-membered saturated heterocyclyl are optionally substituted with one or more R^{10}; or two R^1 substituents, together with their intervening atoms, form a Cs-vcydoalkyl or a saturated 5- to 7-membered heterocyclic ring, wherein said Cs-vcydoalkyl or a saturated 5- to 7-membered heterocyclic ring are optionally substituted with one or more R^{15};

R^{1a} in each occurrence is independently selected from H, Ci_{-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3- to 6-membered monocyclic carbocyclyl, and 3- to 6-membered monocyclic heterocyclyl wherein said Ci_{-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3- to 6-membered monocyclic carbocyclyl, and 3- to 6-membered monocyclic heterocyclyl in each occurrence are optionally and independently substituted with one or more R^{10};

R^{10} in each occurrence is independently selected from Ci_{-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3- to 6-membered carbocyclyl, 3- to 6-membered heterocyclyl, halo, —CN, —

$C(R^{10a})$=NR(OR^{10a}), —$C(R^{10a})$=N(R^{10a}), —$C(O)R^{10a}$, —$C(O)_2R^{10a}$, —$C(O)N(R^{10a})_2$, —NO_2, —$N(R^{10a})_2$, —$N(R^{10a})C(O)R^{10a}$, —$N(R^{10a})C(O)_2R_{10a}$, —$N(R^{10a})C(O)N(R^{10a})_2$, —$N(R^{10a})S(O)_2R^{10a}$, —$OR^{10a}$, —$OC(O)R^{10a}$, —$OC(O)N(R^{10a})_2$, —$SR^{10a}$, —$S(O)R^{10a}$, —$S(O)_2R^{10a}$, —$S(O)N(R^{10a})_2$, and —$S(O)_2N(R^{10a})_2$;

R^{10a} in each occurrence is independently selected from H and Ci_{-6}alkyl, wherein said Ci_{-6}alkyl is optionally substituted with one or more halo;

R^{15} in each occurrence is independently selected from Ci_{-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3- to 6-membered carbocyclyl, 3- to 6-membered heterocyclyl, halo, —CN, —$C(R^{15a})$=NR(OR^{15a}), —$C(R^{15a})$=N(R^{15a}), —$C(O)R^{15a}$, —$C(O)_2R^{15a}$, —$C(O)N(R^{15a})_2$, —NO_2, —$N(R^{15a})_2$, —$N(R^{15a})C(O)R^{15a}$, —$N(R^{15a})C(O)_2R^{15a}$, —$N(R^{15a})C(O)N(R^{15a})_2$, —$N(R^{15a})S(O)_2R^{15a}$, —$OR^{15a}$, —$OC(O)R^{15a}$, —$OC(O)N(R^{15a})_2$, —$SR^{15a}$, —$S(O)R^{15a}$, —$S(O)_2R^{15a}$, —$S(O)N(R^{15a})_2$, and —$S(O)_2N(R^{15a})_2$;

R^{15a} in each occurrence is independently selected from H and Ci_{-6}alkyl, wherein said Ci_{-6}alkyl is optionally substituted with one or more halo;

R^2 is selected from H, Ci_{-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, halo, —CN, —$C(R^{2a})$=NR(OR^{2a}), —$C(R^{2a})$=N(R^{2}), —$C(0)R^{2a}$, —$C(0)_2R^{2a}$, —$C(0)N(R^{2a})_2$, —$N0_2$, —$N(R^{2a})_2$, —$N(R^{2a})C(0)R^{2a}$, —$N(R^{2a})C(0)_2R^{2a}$, —$N(R^{2a})C(0)N(R^{2a})_2$, —$N(R^{2a})S(0)_2R^{2a}$, —OR^{2a}, —$0C(0)R^{2a}$, —$0C(0)N(R^{2a})_2$, —SR^{2a}, —$S(0)R^{2a}$, —$S(0)_2R^{2a}$, —$S(0)N(R^{2a})_2$, and —$S(0)_2N(R^{2a})_2$, wherein said Ci_{-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3- to 7-membered carbocyclyl, and 3-7 membered heterocyclyl are optionally substituted with one or more R^{20};

R^{2a} in each occurrence is independently selected from H and Ci_{-6}alkyl, wherein said Ci_{-6}alkyl in each occurrence is optionally and independently substituted with one or more R^{20};

R^{20} in each occurrence is independently selected from Ci_{-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, $C3-_7$cycloalkyl, 3- to 7-membered saturated heterocyclyl, halo, —CN, —$C(R^{20a})$=NR(OR^{20a}), —$C(R^{20a})$=N(R^{20a}), —$C(O)R^{20a}$, —$C(O)_2R^{20a}$, —$C(O)N(R^{20a})_2$, —$N0_2$, —$N(R^{20a})_2$, —$N(R^{20a})C(O)R^{20a}$, —$N(R^{20a})C(O)_2R^{20a}$, —$N(R^{20a})C(O)N(R^{20a})_2$, —$N(R^{20a})S(O)_2R^{20a}$, —$OR^{20a}$, —$OC(O)R^{20a}$, —$OC(O)N(R^{20a})_2$, —$SR^{20a}$, —$S(O)R^{20a}$, —$S(O)_2R^{20a}$, —$S(O)N(R^{20a})_2$, and —$S(O)_2N(R^{20a})_2$, wherein said Ci_{-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, $C3-_7$cycloalkyl, and 3-7 membered saturated heterocyclyl in each occurrence are optionally and independently substituted with one or more R^{25};

R^{20a} in each occurrence is independently selected from H and C_{1-6}alkyl, wherein said C_{1-6}alkyl is optionally substituted with R^{25};

R^{25} is selected from halo and —OR^{25a};

R^{25a} is selected from H and C_{1-6}alkyl;

R^{3} is selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, 3- to 6-membered saturated heterocyclyl, halo, —CN, —$C(R^{3a})$=$NR(OR^{3a})$, —$C(R^{3a})$=$N(R^{3a})$, —$C(O)R^{3a}$, —$C(O)_2R^{3a}$, —$C(O)N(R^{3a})_2$, —NO_2, —$N(R^{3a})_2$, —$N(R^{3a})C(O)R^{3a}$, —$N(R^{3a})C(O)_2R^{3a}$, —$N(R^{3a})C(O)N(R^{3a})_2$, —$N(R^{3a})S(O)_2R^{3a}$, —OR^{3a}, —$OC(O)R^{3a}$, —$OC(O)N(R^{3a})_2$, —SR^{3a}, —$S(0)R^{3a}$, —$S(0)_2R^{3a}$, —$S(0)N(R^{3a})_2$, and —$S(0)_2N(R^{3a})_2$, wherein said Ci-ealkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C3-6cycloalkyl, and 3- to 6-membered saturated heterocyclyl are optionally substituted with one or more R^{30};

R^{3a} in each occurrence is independently selected from H, C_{1-6}alkyl, 3- to 6-membered carbocyclyl, and 3- to 6-membered heterocyclyl, wherein said C_{1-6}alkyl, 3- to 6-membered carbocyclyl, and 3- to 6-membered heterocyclyl in each occurrence are optionally and independently substituted with one or more R^{30};

R^{30} in each occurrence is independently selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3- to 6-membered carbocyclyl, 3- to 6-membered heterocyclyl, halo, —CN, —$C(R^{30a})$=$NR(OR^{30a})$, —$C(R^{30a})$=$N(R^{30a})$, —$C(O)R^{30a}$, —$C(O)_2R^{30a}$, —$C(O)N(R^{30a})_2$, —$N0_2$, —$N(R^{30a})_2$, —$N(R^{30a})C(O)R^{30a}$, —$N(R^{30a})C(O)_2R^{30a}$, —$N(R^{30a})C(O)N(R^{30a})_2$, —$N(R^{30a})S(O)_2R^{30a}$, —$OR^{30a}$, —$OC(O)R^{30a}$, —$OC(O)N(R^{30a})_2$, —$SR^{30a}$, —$S(O)R^{30a}$ $S(O)_2R^{30a}$, —$S(O)N(R^{30a})_2$, and —$S(O)_2N(R^{30a})_2$, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3-6 membered carboyclyl, 3- to 6-membered heterocyclyl in each occurrence are optionally and independently substituted with one or more R^{35};

R^{30a} in each occurrence is independently selected from H and C_{1-4}alkyl, wherein C_{1-4}alkyl is optionally substituted with one or more R^{35};


R^{35} in each occurrence is independently selected from halo and —OR^{35a};

R^{35a} in each occurrence is independently selected from H and C_{1-6}alkyl;


R^{4} is selected from H, halo, C_{1-6}alkyl, $N(R^{4a})_2$, and —OR^{4a}; and

R^{4a} in each occurrence is independently selected from H and C_{1-6}alkyl; or


(c)




I-ff-1



I-ff-2



I-ff-3



I-ff-4

or a pharmaceutically acceptable salt thereof, wherein:

Ring A is selected from phenyl and 5- or 6-membered heteroaryl;

Ring B is selected from phenyl and 5- or 6-membered heteroaryl;

Ring C is a 3- to 6-membered carbocyclyl,

n is 1, 2 or 3;

p is 0, 1, or 2;

one of W and X is N, and the other of W and X is C;

Y is N or C-R^2;

R^1 is selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, halo, -CN, -C(R^{1a})=NR(OR^{1a}), -C(R^{1a})=N(R^{1a}), -C(0)R^{1a}, -C(0)$_2R^{1a}$, -C(0)N(R^{1a})$_2$, -N0$_2$, -N(R^{1a})$_2$, -N(R^{1a})C(0)R^{1a}, -N(R^{1a})C(0)$_2R^{1a}$, -N(R^{1a})C(0)N(R^{1a})$_2$, -N(R^{1a})S(0)$_2R^{1a}$, -OR^{1a}, -0C(0)R^{1a}, -0C(0)N(R^{1a})$_2$, -SR^{1a}, -S(0)R^{1a}, -S(0)$_2R^{1a}$, -S(0)N(R^{1a})$_2$, and -S(0)$_2$N(R^{1a})$_2$, wherein said Ci-ealkyl, C_{2-6}alkenyl, and C_{2-6}alkynyl are optionally substituted with one or more R^{10};

R^{1a} in each occurrence is independently selected from H or C_{1-6}alkyl wherein said C_{1-6}alkyl in each occurrence are optionally and independently substituted with one or more R^{10};

R^{10} in each occurrence is independently selected from halo, -CN, -C(R^{10a})=NR(OR^{10a}), -C(R^{10a})=N(R^{10a}), -C(O)R^{10a}, -C(O)$_2R^{10a}$, -C(O)N(R^{10a})$_2$, -N0$_2$, -N(R^{10a})$_2$, -N(R^{10a})C(O)R^{10a}, -N(R^{10a})C(O)$_2R^{10a}$, -N(R^{10a})C(O)N(R^{10a})$_2$, -N(R^{10a})S(O)$_2R^{10a}$, -OR^{10a}, -OC(O)R^{10a}, -OC(O)N(R^{10a})$_2$, -SR^{10a}, -S(O)R^{10a}, -S(O)$_2R^{10a}$, -S(O)N(R^{10a})$_2$, and -S(O)$_2$N(R^{10a})$_2$;

R^{10a} in each occurrence is independently selected from H and C_{1-6}alkyl, wherein said Ci-$_6$alkyl is optionally substituted with one or more halo;

R is selected from H, Ci-$_6$alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3- to 7-membered carbocyclyl, 3-to 7-membered heterocyclyl, halo, -CN, -C(R^{2a})=NR(OR^{2a}), -C(R^{2a})=N(R^{2a}), -C(0)R^{2a}, -C(0)$_2R^{2a}$, -C(0)N(R^{2a})$_2$, -N0$_2$, -N(R^{2a})$_2$, -N(R^{2a})C(0)R^{2a}, -N(R^{2a})C(0)$_2R^{2a}$, -N(R^{2a})C(0)N(R^{2a})$_2$, -N(R^{2a})S(0)$_2R^{2a}$, -OR^{2a}, -0C(0)R^{2a}, -0C(0)N(R^{2a})$_2$, -SR^{2a}, -S(0)R^{2a}, -S(0)$_2R^{2a}$, -S(0)N(R^{2a})$_2$, and -S(0)$_2$N(R^{2a})$_2$, wherein said Ci-ealkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3-to 7-membered carbocyclyl, and 3-7 membered heterocyclyl are optionally substituted with one or more R^{20};

R^{2a} in each occurrence is independently selected from H and C_{1-6}alkyl, wherein said C_{1-6}alkyl in each occurrence is optionally and independently substituted with one or more R 20 ;

R^{20} in each occurrence is independently selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-7}cycloalkyl, 3-to 7-membered saturated heterocyclyl, halo, -CN, -C(R^{20a})=NR(OR^{20a}), -C(R^{20a})=N(R^{20a}), -C(O)R^{20a}, -C(O)$_2R^{20a}$, -C(O)N(R^{20a})$_2$, -N0¾ -N(R^{20a})$_2$, -

$N(R^{20a})C(O)R^{20a}$, $-N(R^{20a})C(O)_2R^{20a}$, $-N(R^{20a})C(O)N(R^{20a})_2$, $-N(R^{20a})S(O)_2R^{20a}$, $-OR^{20a}$, $-OC(O)R^{20a}$, $-OC(O)N(R^{20a})_2$, $-SR^{20a}$, $-S(O)R^{20a}$, $-S(O)_2R^{20a}$, $-S(O)N(R^{20a})_2$, and $-S(O)_2N(R^{20a})_2$, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C3-7cycloalkyl, and 3-7 membered saturated heterocyclyl in each occurrence are optionally and independently substituted with one or more R^{25};

R^{20a} in each occurrence is independently selected from H and C_{1-6}alkyl, wherein said C_{1-6}alkyl is optionally substituted with R^{25};

R^{25} is selected from halo and $-OR^{25a}$;

R^{25a} is selected from H and C_{1-6}alkyl;

R is selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, 3-to 6-membered saturated heterocyclyl, halo, -CN, $-C(R^{3a})=NR(OR^{3a})$, $-C(R^{3a})=N(R^{3a})$, $-C(O)R^{3a}$, $-C(O)_2R^{3a}$, $-C(O)N(R^{3a})_2$, $-NO_2$, $-N(R^{3a})_2$, $-N(R^{3a})C(O)R^{3a}$, $-N(R^{3a})C(O)_2R^{3a}$, $-N(R^{3a})C(O)N(R^{3a})_2$, $-N(R^{3a})S(0)_2R^{3a}$, $-OR^{3a}$, $-0C(0)R^{3a}$, $-0C(0)N(R^{3a})_2$, $-SR^{3a}$, $-S(0)R^{3a}$, $-S(0)_2R^{3a}$, $-S(0)N(R^{3a})_2$, and $-S(0)_2N(R^{3a})_2$, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, and 3-to 6-membered saturated heterocyclyl are optionally substituted with one or more R^{30};

R^{3a} in each occurrence is independently selected from H, C_{1-6}alkyl, 3- to 6-membered carbocyclyl, and 3- to 6-membered heterocyclyl, wherein said C_{1-6}alkyl, 3- to 6- membered carbocyclyl, and 3- to 6-membered heterocyclyl in each occurrence are optionally and independently substituted with one or more R^{30};


R^{30} in each occurrence is independently selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3- to 6-membered carbocyclyl, 3-to 6-membered heterocyclyl, halo, -CN, $-C(R^{30a})=NR(OR^{30a})$, $-C(R^{30a})=N(R^{30a})$, $-C(O)R^{30a}$, $-C(O)_2R^{30a}$, $-C(O)N(R^{30a})_2$, $-N0_2$, $-N(R^{30a})_2$, $-N(R^{30a})C(O)R^{30a}$, $-N(R^{30a})C(O)_2R^{30a}$, $-N(R^{30a})C(O)N(R^{30a})_2$, $-N(R^{30a})S(O)_2R^{30a}$, $-OR^{30a}$, $-OC(O)R^{30a}$, $-OC(O)N(R^{30a})_2$, $-SR^{30a}$, $-S(O)R^{30a}$, $-S(O)_2R^{30a}$, $-S(O)N(R^{30a})_2$, and $-S(O)_2N(R^{30a})_2$, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, 3-6 membered carbocyclyl, 3- to 6-membered heterocyclyl in each occurrence are optionally and independently substituted with one or more R^{35};

R^{30a} in each occurrence is independently selected from H and C_{1-4}alkyl, wherein C_{1-4}alkyl is optionally substituted with one or more R^{35};

R^{35} in each occurrence is independently selected from halo and $-OR^{35a}$; and

R^{35a} in each occurrence is independently selected from H and C_{i-6}alkyl; or

(d)



I-gg-1

or a pharmaceutically acceptable salt thereof, wherein:

HET is a heteroaryl selected from pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, imidazolo[4,5-b]pyridinyl, and imidazolo[4,5-d]pyrimidinyl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a nitrogen ring atom in said heteroaryl and wherein said heteroaryl is substituted with zero to 2 R_b;

A is pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxadiazolyl or dihydroisoxazolyl, each substituted with R_a;

R_3 is C2-3 alkyl, C2-3 fluoroalkyl, C3-4 hydroxyalkyl, or a cyclic group selected from C3-6 cycloalkyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, and pyrazolyl, wherein said cyclic group is substituted with zero to 2 substituents independently selected from F, —OH, C1-2 alkyl, and — CH2CHF2;

R_a is:


(i) H, F, Ci, —OH, —CN, C_{i-6} alkyl, C_{i-6} fluoroalkyl, C1-4 cyanoalkyl, C_{i-6} hydroxyalkyl, Ci-5 hydroxy-fluoroalkyl, C2-4 alkenyl, C_{i-6}aminoalkyl, —(CH2)i-3NHR$_y$, —(CH2)i-3NR$_y$R$_y$, —CH_2CH(OH)(phenyl), —CH(CH_2OH)(phenyl), —CH_2CH(OH)CH_2(phenyl), —CH_2CH(0H)$CH_2$0(methoxyphenyl), —CH_2CH(NH2)CH_2(phenyl), —(CH_2CH_20)$_4$H, —(CH_2)$_{I-3}$0(C$_{I.3}$ alkyl), —CH_2CH(0H)$CH_2$0(C$_{1-3}$alkyl), —CH_2C(0)(C$_{1-3}$ alkyl), —CH_2C(0)NR$_y$R$_y$, —(CH2)i-3NR$_y$C(0)(Ci.3 alkyl), —CH_2C(0)0(Ci$_{-3}$ alkyl), —C(0)NH_2, —CH_2NR$_y$C(0)NH_2, —(CH2)i.2NR$_y$C(0)0(Ci.2 alkyl), —(CR$_y$R$_y$)i$_{-5}$0C(0)CH_2NR$_y$R$_y$, —CH_2CH_2S(0)$_2CH_3$, —CH_2S(0)$_2$(C$_{I.3}$ alkyl), —CH_2S(0)$_2$(phenyl), or —NH(aminocyclohexyl); or

(ii) —$(CH_2)_{0-3}R_z$ or —$(CH_2)_{0-1}C(0)R_z$, wherein R_z is C3-6 cycloalkyl, azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl, pyrrolyl, pyrrolidinonyl, morpholinyl, pyrrolidinyl, phenyl, pyrazolyl, imidazolyl, pyridinyl, pyrimidinyl, dioxopyrimidinyl, benzo[d]imidazolyl, benzo[d]thiazolyl, l,3-dioxolanyl, or 8-azabicyclo[3.2.l]octanyl, each substituted with zero to 4 substituents independently from F, —CN, —OH, —NR_yR_y, C1-3 alkyl, C1-3 fluoroalkyl, C1-3 hydroxyalkyl, —$CH(phenyl)_2$, —$0(C_{1-4}$ alkyl), —$C(0)(C_{1-4}$ alkyl), —$C(0)(C_{1-4}$ deuteroalkyl), —$C(0)(C_{1-5}$ hydroxyalkyl), —$C(0)(C_{1-3}$ fluoroalkyl), —$C(0)(C_{3-6}$cycloalkyl), —$C(0)0(C_{1-3}$ alkyl), —$C(0)NR_yR_y$, —C(0)(phenyl), —C(0)(pyridinyl), —$C(0)CH_2(C_{3-6}$ cycloalkyl), —$C(0)0(C_{1-4}$ alkyl), —$NH(C_{1-4}$ alkyl), —$NH(C_{1-3}$ fluoroalkyl), —$NHC(0)CH_3$, —$NHC(0)0(C_{1-3}$ alkyl), —$NHC(0)0C(CH_3)_3$, —$S(0)_2(C_{1-3}$ alkyl), —$0S(0)_2(C_{1-3}$ alkyl), methyl oxadiazolyl, and pyrimidinyl;


each R_b is independently selected from H, Cl, —CN, —NH_2, and —$C(0)NH_2$, wherein said heteroaryl is attached to the pyridinyl group by a nitrogen atom in said heteroaryl; and

each R_y is independently H or C_{1-2} alkyl; or


(e)




I-hh-1



I-hh-2



I-hh-3



I-hh-4

or a pharmaceutically acceptable salt thereof, wherein:

each Xi, X_2 and X_3 are independently CR^2 or N;

A is O, S, S(O) or $S(0)_2$;

Zi is optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted (heterocycloalkyl)alkyl-, optionally substituted aralkyl-, optionally substituted heteroaralkyl-, optionally substituted (cycloalkyl)alkyl-, optionally substituted aryloxy-, optionally substituted heteroaryloxy-, optionally substituted heterocycloalkyloxy-, optionally substituted cycloalkyloxy-, optionally substituted aryl-NR'—, optionally substituted heteroaryl-NR'—, optionally substituted heterocycloalkyl-NR'—, optionally substituted cycloalkyl-NR'—, optionally substituted aryl-S—, optionally substituted heteroaryl-S—, optionally substituted heterocycloalkyl-S—, optionally substituted cycloalkyl-S—, optionally substituted (cycloalkyl)alkyl-NR'—, optionally substituted aralkyl-NR'—, optionally substituted (heterocycloalkyl)alkyl-NR'—, optionally substituted heteroaralkyl-NR'—, optionally substituted (cycloalkyl)alkyl-S—, optionally substituted aralkyl-S—, optionally substituted (heterocycloalkyl)alkyl-S—, optionally substituted heteroaralkyl-S—, optionally substituted (cycloalkyl)alkyl-O—, optionally

substituted aralkyl-0—, optionally substituted (heterocycloalkyl)alkyl-O—, optionally substituted heteroaralkyl-O—; e.g., wherein each optional substituent independently represents an occurance of R_x;

Z_2 is absent or optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, optionally substituted aryloxy-, optionally substituted heteroaryloxy-, optionally substituted cycloalkyloxy-, optionally substituted heterocycloalkyloxy-, optionally substituted (cycloalkyl)alkyl-, optionally substituted aralkyl-, optionally substituted (heterocycloalkyl)alkyl-, optionally substituted heteroaralkyl-, optionally substituted (cycloalkyl)alkyl-NR"—, optionally substituted aralkyl-NR"—, optionally substituted (heterocycloalkyl)alkyl-NR"—, optionally substituted heteroaralkyl-NR"—, optionally substituted (cycloalkyl)alkyl-O—, optionally substituted aralkyl-0—, optionally substituted (heterocycloalkyl)alkyl-O—, optionally substituted heteroaralkyl-O—, optionally substituted (cycloalkyl)alkyl-S—, optionally substituted aralkyl-S—, optionally substituted (heterocycloalkyl)alkyl-S— or optionally substituted heteroaralkyl-S—; e.g., wherein each optional substituent independently represents an occurance of R_y;

Z_3 is optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, optionally substituted aryloxy-, optionally substituted heteroaryloxy-, optionally substituted cycloalkyloxy-, optionally substituted heterocycloalkyloxy-, optionally substituted (cycloalkyl)alkyl-, optionally substituted aralkyl-, optionally substituted (heterocycloalkyl)alkyl-, optionally substituted heteroaralkyl-, optionally substituted (cycloalkyl)-NR'"—, optionally substituted aryl-NR'"—, optionally substituted heteroaryl-NR'"—, optionally substituted heterocycloalkyl-NR'"—, optionally substituted aryl-S—, optionally substituted heteroaryl-S—, optionally substituted cycloalkyl-S—, optionally substituted heterocycloalkyl-S—, optionally substituted (cycloalkyl)alkyl-NR'"—, optionally substituted aralkyl-NR'"—, optionally substituted (heterocycloalkyl)alkyl-NR'"—, optionally substituted heteroaralkyl-NR'"—, optionally substituted (cycloalkyl)alkyl-O—, optionally substituted aralkyl-0—, optionally substituted (heterocycloalkyl)alkyl-O—, optionally substituted heteroaralkyl-O—, optionally substituted (cycloalkyl)alkyl-S—, optionally substituted aralkyl-S—,

optionally substituted (heterocycloalkyl)alkyl-S — or optionally substituted heteroaralkyl-S—; e.g., wherein each optional substituent independently represents an occurance of R_z;

each R^2 is independently selected from hydrogen, alkyl, haloalkyl, halo, cyano, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl-, optionally substituted cycloalkyloxy-, optionally substituted aryl, optionally substituted aralkyl-, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, optionally substituted (heterocycloalkyl)alkyl-, optionally substituted heteroaralkyl-, —NR_aR_b, —O—R_3 and —S—Ry e.g., wherein each optional substituent independently represents alkyl, alkoxy, halo, haloalkyl, hydroxy, hydroxyalkyl, —SH, —S(alkyl), cyano, amido, amino, carboxylate, glycinate, alaninate, oxo, aryl, cycloalkyl, heterocycloalkyl or heteroaryl;

each R', R" and R"' is independently selected from hydrogen, alkyl, hydroxy, hydroxyalkyl, acyl and cycloalkyl;


each R_x, R_y and R_z is independently selected from alkyl, alkenyl, alkynyl, halo, hydroxy, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, —SH, —S(alkyl), cyano, amido, carboxylic acid, carboxylate, ester, thioester, alkoxycarbonyl, —C(0)NH(alkyl), oxo, cycloalkyl, cycloalkyloxy, (cycloalkyl)alkyl-, aryl, aralkyl-, heterocycloalkyl, heteroaryl, (heterocycloalkyl)alkyl-, heteroaralkyl-, —NR_aR_b, —O—R_4 or —S—R_4; optionally wherein the cycloalkyl, aryl, heterocycloalkyl, and heteroaryl are further substituted by one or more substituents selected from halo, haloalkyl, amino, hydroxy, alkyl, cyano, nitro, alkenyl, aminoalkyl, hydroxyalkyl and haloalkoxy;

each R_a and R_b is independently selected from hydrogen, alkyl, aminoalkyl, acyl, aminoacyl, halo, haloalkyl, hydroxy, haloalkoxy, hydroxyalkyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, (cycloalkyl)alkyl-, (heterocycloalkyl)alkyl-, aralkyl-, and (heteroaryl)alkyl-; optionally wherein the cycloalkyl, heterocycloalkyl, aryl and heteroaryl are further substituted by one or more substituents selected from alkyl, halo, alkenyl, cyano, hydroxy, hydroxyalkyl, alkoxy, amino and nitro; or

R_a and R_b are taken together along with the atoms which they are attached to form a 3 to 8 membered optionally substituted ring; and

each R_3 and R_4 is independently selected from hydrogen, alkyl, aminoacyl, phosphate, phosphonate, alkylphosphate, alkoxycarbonyl, cycloalkyl, (cycloalkyl)alkyl-, aryl, heteroaryl, heterocycloalkyl, aralkyl-, heteroaralkyl and (heterocycloalkyl)alkyl-; or

(f)



I-ii-1

or a pharmaceutically acceptable salt thereof, wherein:

X is CR orN;

A is O, S, $S0_2$, SO, —NRC(O), —NRSO2, or N(R); or A is absent;

R^3 is —R, halogen, -haloalkyl, —OR, —SR, —CN, —$N0_2$, —$S0_2$R, —SOR, —C(0)R, —$C0_2$R, —C(0)N(R)$_2$, —NRC(0)R, —NRC(0)N(R)$_2$, —NRSO2R, or —N(R)$_2$; or

when A is —NRC(O), —NRSO2, or N(R); then R and R^3, together with the atoms to which each is attached, may form a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;

X' is CR orN;

Ring Z is a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;

R^1 is —R, halogen, -haloalkyl, —OR, —SR, —CN, —$N0_2$, —$S0_2$R, —SOR, —C(0)R, —$C0_2$R, —C(0)N(R)$_2$, —NRC(0)R, —NRC(0)N(R)$_2$, —NRSO2R, or —N(R)$_2$;

R^a is absent, —R, halogen, -haloalkyl, —OR, —SR, —CN, —$N0_2$, —$S0_2$R, —SOR, —C(0)R, —CO2R, —C(0)N(R)$_2$, —NRC(0)R, —NRC(0)N(R)$_2$, —NRSO2R, or —N(R)$_2$;

Ring Y is an optionally substituted 5-6 membered monocyclic heteroaryl ring having 2-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;


R^2 is —R, halogen, -haloalkyl, —OR, —SR, —CN, —NO_2, —SO_2R, —SOR, —C(O)R, —CO_2R, —C(O)N(R)$_2$, —NRC(O)R, —NRC(O)N(R)$_2$, —NRSO_2R, or —N(R)$_2$;

R^b is absent, —R, halogen, -haloalkyl, —OR, —SR, —CN, —NO_2, —SO_2R, —SOR, —C(O)R, —CO_2R, —C(O)N(R)$_2$, —NRC(O)R, —NRC(O)N(R)$_2$, —NRSO_2R, or —N(R)$_2$;


each R is independently hydrogen, C_{1-6} aliphatic, C3-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted; or

two R groups on the same atom are taken together with the atom to which they are attached to form a C3-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted; or

(g)



i-jj-i



I-jj-2

or a pharmaceutically acceptable salt thereof, wherein:

X is NH or O;

b is 0 or 1;

n is 0, 1, 2, 3 or 4;

Ri and R_2 are independently H, (Ci-C_4)alkyl and heterocyclyl, or Riand R_2 can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic (fused, bridged or spirocyclic) heterocycle containing 3-8 carbon atoms optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said alkyl and heterocycle are optionally substituted with one or more substituents selected from R_a;

R_3 is (Ci-C_4)alkyl wherein two adjacent alkyl groups can join together and form a bridged moiety of 3-6 carbon atoms;

R_4 is absent, halo or O_b(Ci-C_4)alkyl;


R_5 is selected from Ci-C_4 alkyl and C_2-C_4 alkenyl which are optionally substituted with one or more substituents selected from R_b;

Rsis absent, halo, or 0(Ci-C_4)alkyl;


R_a is halo, oxo, OH, O_b(Ci-C_4)alkyl, CF_3, $S0_2$(Ci-C_4)alkyl, or heterocyclyl, said heterocyclyl optionally substituted with one or more substituents independently selected from F, and (Ci-C_4)alkyl; and

R_b is independently selected from OH, halo, O_b(Ci-C_4)alkyl, and CN; or

(h)



I-kk-1



I-kk-2

or a pharmaceutically acceptable salt thereof, wherein:

B is CH, N or S; D is CH or N; E is CH or N; F is CH or N; G is CH or N; and J is C or N, wherein when B is S then D is CH, E is N, F is CH, G is N and J is C;

X is O, S, CH_2 or N;

m is 0 or 1; n is 0, 1 or 2;

Ring A is pyridinyl, pyrazolyl, thiophenyl, furanyl or phenyl;

Ri is independently selected from (Ci-C_4)alkyl, pyrimidine, piperidine and phenyl, each optionally substituted with (Ci-C_4)alkyl, OH, halo, 0(Ci-C_4)alkyl, methylpiperidine, $S(0)_2Rc$, C(0)N(R_b)$_2$, or C(0)0(Ci-C_4)alkyl;

R_2 is absent or H and R_3 is independently selected from: (Ci-C_4)alkyl, pyranyl, cyclopentyl, cyclohexyl, cycloheptyl, thiopyranyl, pyrazolyl, piperidinyl, morpholinyl, piperazinyl each


optionally substituted with one or more substituents independently selected from halo, OH, oxo, $N(R_b)2$, oxopyrrolidinyl, or morpholinyl, or R_2 and R_3 can be taken together with the nitrogen to which they are attached to form piperazine or morpholine, each optionally substituted with oxo;

R_4 is independently H or methyl;

R_b is independently selected from H and (Ci-C_4)alkyl; and

R_e is methyl; or

(i)



1-11-1

or a pharmaceutically acceptable salt thereof, wherein:

Ring A is aryl or heterocyclyl;

n is 0, 1, 2, 3 or 4;


Ri is independently selected from: (Ci-C_4)alkyl, (C3-C_6)cycloalkyl, heterocyclyl, CF_3, CHF_2, CN, halo, said alkyl, cycloalkyl and heterocyclyl optionally substituted with halo, OH, CH_3, and OCH_3;

R_2 is H and R_3 is independently selected from: (Ci-C_6)alkyl, (C_3-C_8)cycloalkyl, and heterocyclyl each optionally substituted with one or more halo, OH, $N(R_b)_2$, or morpholinyl, or R_2 and R_3 can be taken together with the nitrogen to which they are attached to form a heterocyclyl, said heterocyclyl optionally substituted with one or more substituents selected from R_a;

R_a is independently selected from (Ci-C_4)alkyl, (C_3-C_6)cycloalkyl, CF_3, CHF_2, OH, halo and NH_2, said alkyl optionally substituted with (C_3-C_6)cycloalkyl and CF_3; and

R_b is independently selected from H and (Ci-C_4)alkyl; or

ω



I-uuu-1

or a pharmaceutically acceptable salt thereof, wherein:

Ring A is aryl or heterocyclyl;

n is 0, 1, 2, 3 or 4;


Ri is independently selected from: (Ci-C_4)alkyl, (C3-C_6)cycloalkyl, heterocyclyl, CF_3, CHF_2, CN and halo, said alkyl, cycloalkyl and heterocyclyl optionally substituted with halo, OH, CH_3, and OCH_3;

R_2 is H and R_3 is independently selected from: (Ci-C_6)alkyl, (C_3-C_8)cycloalkyl, and heterocyclyl each optionally substituted with one or more halo, OH, $N(R_b)_2$, or morpholinyl, or R_2 and R_3 can be taken together with the nitrogen to which they are attached to form a heterocyclyl, said heterocyclyl optionally substituted with one or more substituents selected from R_a;

R_a is independently selected from (Ci-C_4)alkyl, (C_3-C_6)cycloalkyl, CF_3, CHF_2, OH, halo and NH_2, said alkyl optionally substituted with (C_3-C_6)cycloalkyl or CF_3; and

R_b is independently selected from H and (Ci-C_4)alkyl; or

(k)



I-nn-1

or a pharmaceutically acceptable salt thereof, wherein:

Ring A is aryl or heterocyclyl;

n is 0, 1, 2, 3 or 4;


Ri is independently selected from: (Ci-C_4)alkyl, (C3-C_6)cycloalkyl, heterocyclyl, CF_3, CHF_2, CN, halo, said alkyl, cycloalkyl and heterocyclyl optionally substituted with halo, OH, CH_3, and OCH_3;

R_2 is H and R_3 is independently selected from: (Ci-C_6)alkyl, (C_3-C_8)cycloalkyl, and heterocyclyl each optionally substituted with one or more halo, OH, $N(R_b)_2$, or morpholinyl, or R_2 and R_3 can be taken together with the nitrogen to which they are attached to form a heterocyclyl, said heterocyclyl optionally substituted with one or more substituents selected from R_a;

R_a is independently selected from (Ci-C_4)alkyl, (C_3-C_6)cycloalkyl, CF_3, CHF_2, OH, halo and NH_2, said alkyl optionally substituted with (C_3-C_6)cycloalkyl and CF_3; and

R_b is independently selected from H and (Ci-C_4)alkyl; or

(1)



I-oo-l

or a pharmaceutically acceptable salt thereof, wherein:

Ring A is aryl or heterocyclyl;

n is 0, 1, 2, 3 or 4;


R_i is independently selected from: (C_i-C_4)alkyl, (C_3-C_6)cycloalkyl, heterocyclyl, CF_3, CHF_2, CN, halo, said alkyl, cycloalkyl and heterocyclyl optionally substituted with halo, OH, CH_3, and OCH_3;

R_2 is H and R_3 is independently selected from: (C_i-C_6)alkyl, (C_3-C_8)cycloalkyl and heterocyclyl each optionally substituted with one or more halo, OH, $N(R_b)_2$, or morpholinyl, or R_2 and R_3 can be taken together with the nitrogen to which they are attached to form a heterocyclyl, said heterocyclyl optionally substituted with one or more substituents selected from R_a;

R_a is independently selected from (C_i-C_4)alkyl, (C_3-C_6)cycloalkyl, CF_3, CHF_2, OH, halo and NH_2, said alkyl optionally substituted with (C_3-C_6)cycloalkyl and CF_3; and

R_b is independently selected from H and (C_i-C_4)alkyl; or

(m)



I-pp-1


or a pharmaceutically acceptable salt thereof, wherein:

Ring A is a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

Ring B is 

wherein ~~ represents the portion of the ring fused to the pyrimidine ring and # is $-L^2(R^4)p-R^x$;

each R^1 and $R^{1'}$ is independently $-R^2$, halogen, -CN, -NO2, -OR, -SR, $-N(R)_2$, $-S(0)_2R$, $-S(0)_2N(R)_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)N(R)_2$, -C(0)N(R)0R, -N(R)C(0)0R, $-N(R)C(0)N(R)_2$, Cy, or $-N(R)S(0)_2R$; or R^1 is selected from one of the following formulae:



two R^1 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each Cy is independently an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-10 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each R is independently hydrogen, or an optionally substituted group selected from

C_{i-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or:

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, or sulfur;

each R^2 is independently an optionally substituted group selected from C_{i-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R^4 is independently halogen, -CN, $-N0_2$, -OR, -SR, $-N(R)_2$, $-S(0)_2R$, $-S(0)_2N(R)_2$, -S(0)R, -C(0)R, -C(0)0R, $-C(0)N(R)_2$, $-N(R)C(0)R$, $-N(R)C(0)N(R)_2$, -C(0)N(R)0R, $-N(R)C(0)0R$, $-N(R)S(0)_2N(R)_2$, $-N(R)S(0)_2R$, or an optionally substituted group selected from C_{i-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

R^x is hydrogen, $-R^2$, -CN, $-N0_2$, halogen, $-C(0)N(R)_2$, -C(0)0R, -C(0)R, $-N(R)_2$, -NH[Ar], -OR, or $-S(0)_2N(R)_2$;

R^z is hydrogen, $-R^2$, -CN, $-N0_2$, halogen, $-C(0)N(R)_2$, -C(0)0R, -C(0)R, $-N(R)_2$, -NH[Ar], -OR, or $-S(0)_2N(R)_2$;

[Ar] is phenyl or a 5-6 membered heteroaromatic ring having 1-4 heteroatoms indepently selected from nitrogen, oxygen, and sulfur, wherein [Ar] is substituted by m instances of R^1;

L^1 is a covalent bond or a C_{i-6} bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -N(R)-, -N(R)C(0)-, -C(0)N(R)-, $-N(R)S(0)_2-$, $-S(0)_2N(R)-$, -0-, -C(O)-, -OC(O)-, -C(0)0-, -S-, -S(O)- or $-S(0)_2-$;


L^2 is a covalent bond or a C_{i-6} bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -N(R)-, -N(R)C(0)-, -C(0)N(R)-, $-N(R)S(0)_2-$, $-S(0)_2N(R)-$, -0-, -C(O)-, -OC(O)-, -C(0)0-, -S-, -S(O)- or $-S(0)_2-$;

m is 0-4;

n is 0-4; and

p is 0-2; or

(n)




I-qq-1

or a pharmaceutically acceptable salt thereof, wherein:

Y is N or C-R^x;

Ring A is a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R^1 and R^v is independently -R^2, halogen, -CN, -$N0_2$, -OR, -SR, -$N(R)_2$, -$S(0)_2R$, -$S(0)_2N(R)_2$, -S(0)R, -C(0)R, -C(0)OR, -$C(0)N(R)_2$, -C(0)N(R)OR, -N(R)C(0)OR, -$N(R)C(0)N(R)_2$, Cy, or -$N(R)S(0)_2R$; or R^1 is selected from one of the following formulas:



; or

two R^1 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each Cy is independently an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-10 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R is independently hydrogen, or an optionally substituted group selected from Ci-6 aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, or sulfur;

each R^2 is independently an optionally substituted group selected from Ci-$_6$aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each of R^x and R^y is independently hydrogen, -R^2, -CN, -N0 $_2$, halogen, -C(0)N(R) $_2$, -C(0)0R, -C(0)R, -$N(R)_2$, - H[Ar], -OR, or -S(0) $_2$N$(R)_2$; or

R^x and R^y are taken together together with their intervening atoms to form a 4-7 membered partially unsaturated carbocyclic ring or a partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

R^z is hydrogen, -R^2, -CN, -N0 $_2$, halogen, -C(0)N(R) $_2$, -C(0)0R, -C(0)R, -$N(R)_2$, -NH[Ar], -OR, or -S(0) $_2$N$(R)_2$;


[Ar] is phenyl or a 5-6 membered heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said [Ar] is substituted by m instances of R^r;

L^1 is a covalent bond or a Ci-$_6$ bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -N(R)-, -N(R)C(0)-, - C(0)N(R)-, -N(R)S(0) $_2$-, -S(0) $_2$N(R)-, -0-, -C(O)-, -OC(O)-, -C(0)0-, -S-, -S(O)- or -S(0) $_2$-;


m is 0-4; and

n is 0-4; or


(o)



I-rr-1



I-rr-2



I-rr-3

or a pharmaceutically acceptable salt thereof, wherein:

R is aliphatic, heteroaliphatic, heteroaryl, aryl, halo, amide or CN;

R^1 is H, aliphatic or heteroaliphatic;


or R and R^1, together with the atoms to which they are attached, form a heterocyclyl ring;

R^2 is H, aliphatic, heteroaliphatic, heterocycloaliphatic, aryl, amide, heterocyclyl or araliphatic;

each R^3 independently is H, aliphatic, halogen, heteroaliphatic, —O-aliphatic, heterocyclyl, aryl, araliphatic, —O-heterocyclyl, hydroxyl, nitro, cyano, carboxyl, carboxyl ester, acyl, amide, amino, sulfonyl, sulfonamide, sulfanyl, sulfmyl, haloalkyl, alkylphosphate, or alkylphosphonate;


y is from 1 to 6; or


(P)



I-ss-1

or a pharmaceutically acceptable salt thereof, wherein:





A is

X is N or C—R^7;

R is hydrogen, R^1, halogen, cyano, nitro, —OR^1, —C(=O)—R^1, —C(=O)O—R^1, —C(=O)NR^{11}—R^1, —$S(=O)_2$—R^1, —NR^{11}C(=O)—R^1, —NR^{11}C(=O)$NR^{11}R^{11}$, —NR^{11}C(=O)O—R^1, —$NR^{11}S(=O)_2R^1$ or —$NR^{11}R^{11}$;

R^1 is C_{i-6} alkyl substituted with 0-4 R^{1a}, C_{i-6} haloalkyl, C2-6 alkenyl substituted with 0-3 R^{1a}, C2-6 alkynyl substituted with 0-3 R^{1a}, C3-10 cycloalkyl substituted with 0-3 R^{1a}, C_{6-io} aryl substituted with 0-3 R^{1a}, a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{1a}, or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{1a};

R^{1a} is hydrogen, =0, F, Cl, Br, OCF3, CN, $N0_2$, —$(CH_2)_rOR^b$, —$(CH_2)_rSR^b$, —$(CH_2)_rC(0)R^b$, —$(CH_2)_rC(0)OR^b$, —$(CH_2)_r0C(0)R^b$, —$(CH_2)_rNR^{11}R^{11}$, —$(CH_2)_rC(0)NR^{11}R^{11}$, —$(CH_2)_rNR^bC(0)R^c$, —$(CH_2)_rNR^bC(0)OR^c$, —$NR^bC(0)NR^{11}R^{11}$, —$S(0)_pNR^{11}R^{11}$, —$NR^bS(0)_pR^c$, —$S(0)R^c$, —$S(0)_2R^c$, C_{i-6} alkyl substituted with 0-2 R^a, C_{i-6} haloalkyl, —$(CFh)_r$-3-l4 membered carbocycle substituted with 0-3 R^a, or —$(CH_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-3 R^a;

R^2 is C_{6-io} aryl substituted with 0-4 R^{2a}, a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, substituted with 1-4 R^{2a}, or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-4 R^{2a};

R^{2a} at each occurrence is independently selected from hydrogen, =0, halo, OCF3, CN, NO2, —$(CH_2)_rOR^b$, —$(CFh)_rSR^b$, —$(CH_2)_rC(0)R^b$, —$(CH_2)_rC(0)OR^b$, —$(CH_2)_rOC(0)R^b$, —$(CH_2)_rNR^{11}R^{11}$, —$(CH_2)_rC(0)NR^{11}R^{11}$, —$(CH_2)_rNR^bC(0)R^c$, —$(CH_2)_rNR^bC(0)OR^c$, —$NR^bC(0)NR^{11}R^{11}$, —$S(0)_pNR^{11}R^{11}$, —$NR^bS(0)pR^c$, —$S(0)R^c$, —$S(0)_2R^c$, C_{i-6} alkyl substituted with 0-2 R^a, C_{i-6} haloalkyl, —$(CFh)_r$-3-l4 membered carbocycle substituted with 0-1 R^a, or —$(CH_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-2 R^a;

R^3 is C_{i-6} alkyl substituted with 0-3 R^{3a}, C_{i-6} haloalkyl, C2-6 alkenyl substituted with 0-3 R^{3a}, C2-6 alkynyl substituted with 0-3 R^{3a}, C3-10 cycloalkyl substituted with 0-3 R^{3a}, C_{6-io} aryl substituted with 0-3 R^{3a}, a 5-10 membered heterocyclyl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{3a} or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{3a};

R^{3a} is hydrogen, =O, F, Cl, Br, OCF_3, CN, NO_2, $—(CH_2)_rOR^b$, $—(CH_2)_rSR^b$, $—(CH_2)_rC(O)R^b$, $—(CH_2)_rC(O)OR^b$, $—(CH_2)_rOC(O)R^b$, $—(CH_2)_rNR^{11}R^{11}$, $—(CH_2)_rC(O)NR^{11}R^{11}$, $—(CH_2)_rNR^bC(O)R^c$, $—(CH_2)_rNR^bC(O)OR^c$, $—NR^bC(O)NR^{11}R^{11}$, $—S(O)_pNR^{11}R^{11}$, $—NR^bS(O)_pR^c$, —S(0)R^c, $—S(O)_2R^c$, C_{I-6} alkyl substituted with 0-2 R^a, Ci_{-6}haloalkyl, $—(CH_2)_r$-3-l4 membered carbocycle substituted with 0-1 R^a, or $—(CH_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-1 R^a;

R^4 and R^5 are independently selected from hydrogen, Ci_{-4} alkyl substituted with 0-1 R^f, (CH_2)-phenyl substituted with 0-3 R^d, and a $—(CH_2)$-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$;

R^6 and R^7 are independently at each occurrence is selected from hydrogen, =0, F, Cl, Br, OCF3, CN, $N0_2$, $—(CH_2)_rOR^b$, $—(CH_2)_rSR^b$, $—(CH_2)_rC(0)R^b$, $—(CH_2)_rC(0)OR^b$, $—(CH_2)_rOC(0)R^b$, $—(CH_2),NR"R"$, $—(CH_2)_rC(0)NR^{11}R^{11}$, $—(CH_2)_rNR^bC(0)R^c$, $—(CH_2)_rNR^bC(0)OR^c$, $—NR^bC(0)NR^{11}R^{11}$, $—S(0)_pNR^{11}R^{11}$, $—NR^bS(0)_pR^c$, $—S(0)_2R^c$, $—S(0)_2R^c$, C_{I-6} alkyl substituted with 0-2 R^a, Ci_{-6}haloalkyl, $—(CH_2)_r$-3-l4 membered carbocycle substituted with 0-3 R^a, or $—(CH_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-3 R^a, provided R^6 and R^7 are not both hydrogen;

R^{11} at each occurrence is independently hydrogen, R^c, Ci_{-4} alkyl substituted with 0-1 R^f, CH_2-phenyl substituted with 0-3 R^d, or $—(CH_2)$-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-3 R^d; or

R^{11} and along with another R^{11}, R^1, or R^2 on the same nitrogen atom may join to form an optionally substituted heterocycle;

R^a is hydrogen, F, Cl, Br, OCF3, CF_3, CHF_2, CN, $N0_2$, $—(CH_2)_rOR^b$, $—(CH_2)_rSR^b$, $—(CH_2)_rC(O)R^b$, $—(CH_2)_rC(O)OR^b$, $—(CH_2)_rOC(O)R^b$, $—(CH_2)_rNR^{11}R^{11}$, $—(CH_2)_rC(O)NR^{11}R^{11}$, $—(CH_2)_rNR^bC(O)R^c$, $—(CH_2)_rNR^bC(O)OR^c$, $—NR^bC(O)NR^{11}R^{11}$, $—(O)_pNR^{11}R^{11}$, $—NR^bS(O)_pR^c$, $—S(O)R^c$, $—S(O)_2R^c$, C_{1-6} alkyl substituted with 0-1 R^f, Ci_{-6} haloalkyl, $—(CH_2)_r$-3-l4 membered carbocycle, or $—(CH_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$; or two R^a on adjacent or the same carbon atom form a cyclic acetal

of the formula —O—$(CH_2)_n$— O—, or —O—CF_2— O—, wherein n is selected from 1 or 2;

R^b is hydrogen, R^z, Ci_{-6} alkyl substituted with 0-2 R^d, Ci_{-6}haloalkyl, C3-6 cycloalkyl substituted with 0-2 R^d, or $(CH_2)_r$-phenyl substituted with 0-3 R^d;

R^c is C_{1-6} alkyl substituted with 0-1 R^f, C_{3-6} cycloalkyl, or $(CH_2)_r$-phenyl substituted with 0-3 R^f;

R^d is hydrogen, F, Cl, Br, OCF_3, CF_3, CN, $N0_2$, —OR^z, —$(CH_2)_rC(0)R^c$, —NR^zR^z, —$NR^zC(0)OR^c$, Ci-$_6$ alkyl, or $(CH_2)_r$-phenyl substituted with 0-3 R^f;

R^z is selected from hydrogen, Ci_{-6} alkyl, C3-6 cycloalkyl, and $(CH_2)_r$-phenyl substituted with 0-3 R^f;


R^f is hydrogen, halo, NH_2, OH, or 0(Ci $_{-6}$alkyl);

p is 0, 1, or 2;

r is 0, 1, 2, 3, or 4; and

m is 0, 1, or 2; or

(q)



I-tt-1

or a pharmaceutically acceptable salt thereof, wherein:

A is a triazole optionally substituted by 0-2 R;

X is N or C—R^7;

R is hydrogen, R', halogen, cyano, nitro, —OR^1, —C(=0) —R^1, —C(=0)0 —R^1, —$C(=O)NR^{11}$—R^1, —$S(=O)_2$—R^1, —$NR^{11}C(=O)$—R′, —$NR^{11}C(=O)NR^{11}R^1$, —$NR^{11}C(=O)O$—R′, —$NR^{11}S(=O)_2R^1$ or —$NR^{11}R^1$;

R^1 is Ci-$_6$ alkyl substituted with 0-4 R^{1a}, Ci$_{-6}$ haloalkyl, C2-6 alkenyl substituted with 0-3 R^{1a}, C_2-$_6$ alkynyl substituted with 0-3 R^{1a}, C3-iocycloalkyl substituted with 0-3 R^{1a}, C_6-io aryl substituted with 0-3 R^{1a}, a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{1a}, or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{1a};

R^{1a} is hydrogen, =0, F, Cl, Br, OCF3, CN, N0 $_2$, —$(CH_2)_r$OR^b, —$(CH_2)_r$SR^b, —$(CH_2)_r$C(0)R ^{b}, —$(CH_2)_r$C(0)OR ^{b}, —$(CH_2)_r$OC(0)R ^{b}, —$(CH_2)_r$NR ^{11}R ^{11}, —$(CH_2)_r$C(0)NR ^{11}R^{11}, —$(CH_2)_r$NR^{b}C(0)R ^{c}, —$(CH_2)_r$NR^{b}C(0)OR ^{c}, —NR^{b}C(0)NR ^{11}R^{11}, —S(0) $_p$NR^{11}R^{11}, —NR^{b}S(0) $_p$R^c, —S(C)R ^{c}, —S(0) $_2$R^c, C $_{I-6}$ alkyl substituted with 0-2 R^a, Ci$_{-6}$ haloalkyl, —$(CH_2)_r$-3-l4 membered carbocycle substituted with 0-3 R^a, or —(CFh) $_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(0) $_p$ substituted with 0-3 R^a;

R^2 is C_6-io aryl substituted with 0-4 R^{2a}, a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, substituted with 1-4 R^{2a}, or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-4 R^{2a};

R^{2a} at each occurrence is independently selected from hydrogen, =0, halo, OCF3, CN, NO2, —$(CH_2)_r$OR^b, —(CFh) $_r$SR^b, —$(CH_2)_r$C(0)R ^{b}, —$(CH_2)_r$C(0)OR ^{b}, —$(CH_2)_r$OC(0)R ^{b}, —$(CH_2)_r$NR ^{11}R^{11}, —$(CH_2)_r$C(0)NR ^{11}R^{11}, —$(CH_2)_r$NR^{b}C(0)R ^{c}, —$(CH_2)_r$NR^{b}C(0)OR ^{c}, —NR^{b}C(0)NR ^{11}R^{11}, —S(0) $_p$NR^{11}R^{11}, —NR^{b}S(0)pR ^{c}, —S(0)R ^{c}, —S(0) $_2$R^c, Ci$_{-6}$ alkyl substituted with 0-2 R^a, Ci$_{-6}$ haloalkyl, —(CFh) $_r$-3-l4 membered carbocycle substituted with 0-1 R^a, or —$(CH_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, 0, and S(0) $_p$ substituted with 0-2 R^a;

R^3 is Ci-$_6$ alkyl substituted with 0-3 R^{3a}, Ci$_{-6}$ haloalkyl, C2-6 alkenyl substituted with 0-3 R^{3a}, C2-$_6$ alkynyl substituted with 0-3 R^{3a}, C3-iocycloalkyl substituted with 0-3 R^{3a}, C_6-io aryl substituted with 0-3 R^{3a}, a 5-10 membered heterocyclyl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 $R^{3'}$ or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{3a};

R^{3a} is hydrogen, =0, F, Cl, Br, OCF3, CN, N0 $_2$, —$(CH_2)_r$OR^b, —$(CH_2)_r$SR^b, —$(CH_2)_r$C(0)R ^{b}, —$(CH_2)_r$C(0)OR ^{b}, —$(CH_2)_r$0C(0)R ^{b}, —$(CH_2)_r$NR ^{11}R^{11}, —$(CH_2)_r$C(0)NR ^{11}R^{11}, —$(CH_2)_r$NR^{b}C(0)R ^{c}, —$(CH_2)_r$NR^{b}C(0)OR ^{c}, —NR^{b}C(0)NR ^{11}R^{11}, —S(0) $_p$NR^{11}R^{11}, —NR^{b}S(0) $_p$R^c, —S(0)R ^{c}, —S(0) $_2$R^c, C $_{I-6}$ alkyl substituted with 0-2 R^a, Ci$_{-6}$haloalkyl, —

$(CH_2)_r$-3-l4 membered carbocycle substituted with 0-1 R^a, or —$(CF[_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-1 R^a;

R^4 and R^5 are independently selected from hydrogen, Ci-$_4$ alkyl substituted with 0-1 R^f, (CH_2)-phenyl substituted with 0-3 R^d, and a —(CH_2)-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$;

R^6 and R^7 are independently at each occurrence is selected from hydrogen, =0, F, Cl, Br, OCF_3, CN, NO_2, —$(CH_2)_rOR^b$, —$(CH_2)_rSR^b$, —$(CH_2)_rC(O)R^b$, —$(CH_2)_rC(O)OR^b$, —$(CH_2)_rOC(O)R^b$, —$(CH_2)_rNR^{11}R^{11}$, —$(CH_2)_rC(O)NR^{11}R^{11}$, —$(CH_2)_rNR^bC(O)R^c$, —$(CH_2)_rNR^bC(O)OR^c$, —$NR^bC(O)NR^{11}R^{11}$, —$S(O)_pNR^{11}R^{11}$, —$NR^bS(O)_pR^c$, —$S(O)R^c$, —$S(0)_2R^c$, C1-6 alkyl substituted with 0-2 R^a, Ci-$_6$haloalkyl, —$(CH_2)_r$-3-l4 membered carbocycle substituted with 0-3 R^a, or —$(CH_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-3 R^a, provided R^6 and R^7 are not both hydrogen;

R^{11} at each occurrence is independently hydrogen, R^c, C1-4 alkyl substituted with 0-1 R^f, CH_2-phenyl substituted with 0-3 R^d, or —(CH_2)-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-3 R^d; or

R^{11} and along with another R^{11}, R^1, or R^2 on the same nitrogen atom may join to form an optionally substituted heterocycle;

R^a is hydrogen, F, Cl, Br, OCF_3, CF_3, CHF_2, CN, NO_2, —$(CH_2)_rOR^b$, —$(CH_2)_rSR^b$, —$(CH_2)_rC(O)R^b$, —$(CH_2)_rC(O)OR^b$, —$(CH_2)_rOC(O)R^b$, —$(CH_2)_rNR^{11}R^{11}$, —$(CH_2)_rC(O)NR^{11}R^{11}$, —$(CH_2)_rNR^bC(O)R^c$, —$(CH_2)_rNR^bC(O)OR^c$, —$NR^bC(O)NR^{11}R^{11}$, —$S(O)_pNR^{11}R^{11}$, —$NR^bS(O)_pR^c$, —$S(O)R^c$, —$S(0)_2R^c$, Ci-$_6$ alkyl substituted with 0-1 R^f, Ci-$_6$ haloalkyl, —$(CH_2)_r$-3-l4 membered carbocycle, or —$(CH_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$; or two R^a on adjacent or the same carbon atom form a cyclic acetal of the formula —O—$(CH_2)_n$— O—, or —O—CF_2— O—, wherein n is selected from 1 or 2;

R^b is hydrogen, R^c, Ci-$_6$ alkyl substituted with 0-2 R^d, Ci-$_6$ haloalkyl, C3-6 cycloalkyl substituted with 0-2 R^d, or $(CH_2)_r$-phenyl substituted with 0-3 R^d;

R^c is Ci-$_6$ alkyl substituted with 0-1 R^f, C3-6 cycloalkyl, or $(CH_2)_r$-phenyl substituted with 0-3 R^f;

R^d is hydrogen, F, Cl, Br, OCF3, CF_3, CN, NO_2, $—OR^c$, $—(CH_2)_rC(0)R^c$, $—NR^cR^c$, $—NR^cC(0)0R^c$, Ci_{-6} alkyl, or $(CH_2)_r$-phenyl substituted with 0-3 R^f;

R^c is selected from hydrogen, Ci_{-6} alkyl, C3-6 cycloalkyl, and $(CH_2)_r$-phenyl substituted with 0-3 R^f;


R^f is hydrogen, halo, NH_2, OH, or $0(Ci_{-6}$alkyl);

p is 0, 1, or 2;

r is 0, 1, 2, 3, or 4; and

m is 0, 1, or 2; or

(r)



I-uu-1

or a pharmaceutically acceptable salt thereof, wherein:

X is N or $C—R^7$;

R is R^1, halogen, cyano, nitro, $—O—R^1$, $—C(=0)—R^1$, $—C(=0)0—R^1$, $—C(=0)NR^{11}—R^1$, $—S(=0)_2—R^1$, $—NR^{11}C(=0)—R^1$, $—NR^{11}C(=0)NR^{11}—R^1$, $—NR^{11}C(=0)0—R^1$, $—NR^{11}S(=0)_2—R^1$, or $—NR^{11}—R^1$;

R^1 is Ci_{-6} alkyl substituted with 0-4 R^{1a}, Ci_{-6} haloalkyl, C_{2-6} alkenyl substituted with 0-3 R^{1a}, C_{2-6} alkynyl substituted with 0-3 R^{1a}, C3-iocycloalkyl substituted with 0-3 R^{1a}, C_{6-io} aryl substituted with 0-3 R^{1a}, a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{1a}, a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{1a};

R^{1a} is hydrogen, =O, F, Cl, Br, OCF_3, CN, NO_2, $—(CH_2)_rOR^b$, $—(CH_2)_rSR^b$, $—(CH_2)_rC(O)R^b$, $—(CH_2)_rC(O)OR^b$, $—(CH_2)_rOC(O)R^b$, $—(CH_2)_rNR^{11}R^{11}$, $—(CH_2)_rC(O)NR^{11}R^{11}$, —

$(CH_2)_rNR^bC(0)R^c$, $—(CH_2)_rNR^bC(0)0R^c$, $—NR^bC(0)NR^{11}R^{11}$, $—S(0)_pNR^{11}R^{11}$, $—NR^bS(0)_pR^c$, $—S(0)R^c$, $—S(0)_2R^c$, C_{1-6} alkyl substituted with 0-2 R^a, C_{1-6} haloalkyl, $—(CH_2)_r$-3-14 membered carbocycle substituted with 0-3 R^a, or $—(CH_2)_r$-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-3 R^a;

R^2 is C_{6-10} aryl substituted with 0-4 R^{2a}, a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-4 R^{2a}, a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-4 R^{2a};

R^{2a} at each occurrence is independently selected from hydrogen, =0, halo, OCF_3, CN, NO_2, $—(CH_2)_rOR^b$, $—(CH_2)_rSR^b$, $—(CH_2)_rC(O)R^b$, $—(CH_2)_rC(O)OR^b$, $—(CH_2)_rOC(O)R^b$, $—(CH_2)_rNR^{11}R^{11}$, $—(CH_2)_rC(O)NR^{11}R^{11}$, $—(CH_2)_rNR^bC(O)R^c$, $—(CH_2)_rNR^bC(O)OR^c$, $—NR^bC(O)NR^{11}R^{11}$, $—S(O)_pNR^{11}R^{11}$, $—NR^bS(O)_pR^c$, $—S(O)R^c$, $—S(O)_2R^c$, C_{1-6} alkyl substituted with 0-2 R^a, C_{1-6} haloalkyl, $—(CH_2)_r$-3-14 membered carbocycle substituted with 0-1 R^a, or $—(CH_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-2 R^a;

R^3 is C_{1-6} alkyl substituted with 0-3 R^{3a}, C_{1-6} haloalkyl, C_{2-6} alkenyl substituted with 0-3 R^{3a}, C_{2-6} alkynyl substituted with 0-3 R^{3a}, C3-10 cycloalkyl substituted with 0-3 R^{3a}, C_{6-10} aryl substituted with 0-3 R^{3a}, a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{3a}, or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R^{3a};

R^{3a} is hydrogen, =O, F, Cl, Br, OCF_3, CN, NO_2, $—(CH_2)_rOR^b$, $—(CH_2)_rSR^b$, $—(CH_2)_rC(O)R^b$, $—(CH_2)_rC(O)OR^b$, $—(CH_2)_rOC(O)R^b$, $—(CH_2)_rNR^{11}R^{11}$, $—(CH_2)_rC(O)NR^{11}R^{11}$, $—(CH_2)_rNR^bC(O)R^c$, $—(CH_2)_rNR^bC(O)OR^c$, $—NR^bC(O)NR^{11}R^{11}$, $—S(O)_pNR^{11}R^{11}$, $—NR^bS(O)_pR^c$, $—S(O)R^c$, $—S(O)_2R^c$, C_{1-6} alkyl substituted with 0-2 R^a, C_{1-6} haloalkyl, $—(CH_2)_r$-3-14 membered carbocycle substituted with 0-1 R^a, or $—(CH_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-1 R^a;

R^4 and R^5 are independently selected from hydrogen, C_{1-4} alkyl substituted with 0-1 R^f, (CH_2)-phenyl substituted with 0-3 R^d, and a $—(CH_2)$-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$;

R^6 and R^7 are independently at each occurrence is selected from hydrogen, =0, F, Cl, Br, OCF_3, CN, NO_2, $—(CH_2)_rOR^b$, $—(CH_2)_rSR^b$, $—(CH_2)_rC(O)R^b$, $—(CH_2)_rC(O)OR^b$, $—(CH_2)_rOC(O)R^b$, $—(CH_2)_rNR^{11}R^{11}$, $—(CH_2)_rC(O)NR^{11}R^{11}$, $—(CH_2)_rNR^bC(O)R^c$, $—(CH_2)_rNR^bC(O)OR^c$, $—NR^bC(O)NR^{11}R^{11}$, $—S(O)_pNR^{11}R^{11}$, $—NR^bS(O)_pR^c$, $—S(O)R^c$, $—S(0)_2R^c$, C1-6 alkyl substituted with 0-2 R^a, Ci_{-6} haloalkyl, $—(CH_2)_r$-3-l4 membered carbocycle substituted with 0-3 R^a, or $—(CH_2)_r$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-3 R^a, provided R^6 and R^7 are not both hydrogen;

R^{11} at each occurrence is independently R^c, C1-4 alkyl substituted with 0-1 R^f, CFh-phenyl substituted with 0-3 R^d, or $—(CH_2)$-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$ substituted with 0-3 R^d;

alternatively, R^{11} and along with another R^{11}, R^1, or R^2 on the same nitrogen atom may join to form an optionally substituted azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, or 4-(Ci-6alkyl jpiperazinyf

R^a is R^d, F, Cl, Br, OCF3, CF_3, CHF_2, CN, $N0_2$, $—(CH_2)_rOR^b$, $—(CH_2)_rSR^b$, $—(CH_2)_rC(0)R^b$, $—(CH_2)_rC(0)OR^b$, $—(CH_2)_rOC(0)R^b$, $—(CH_2)_rNR"R"$, $—(CH_2)_rC(0)NR"R"$, $—(CH_2)_rNR^bC(0)R^c$, $—(CH_2)_rNR^bC(0)OR^c$, $—NR^bC(0)NR^{11}R^{11}$, $—S(0)_pNR^{11}R^{11}$, $—NR^bS(0)_pR^c$, $—S(0)_2R^c$, $—S(0)_2R^c$, C_{I-6} alkyl substituted with 0-1 R^f, Ci_{-6} haloalkyl, $—(CH_2)_r$-3-l4 membered carbocycle, or $—(CH_2)_r$-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and $S(0)_p$; alternatively two R^a on adjacent or the same carbon atom form a cyclic acetal of the formula $—O—(CH_2)_n—O—$, or $—O—CF_2—O—$, wherein n is selected from 1 or 2;

R^b is R^c, Ci_{-6} alkyl substituted with 0-2 R^d, Ci_{-6} haloalkyl, C3-6cycloalkyl substituted with 0-2 R^d, or $(CFh)_r$-phenyl substituted with 0-3 R^d;

R^c is Ci_{-6} alkyl substituted with 0-1 R^f, C3-6 cycloalkyl, or $(CH_2)_r$-phenyl substituted with 0-3 R^f;

R^d is hydrogen, F, Cl, Br, OCF3, CF_3, CN, $N0_2$, $—OR^e$, $—(CH_2)_rC(0)R^e$, $—NR^eR^e$, $—NR^eC(0)OR^e$, Ci_{-6} alkyl, or $(CH_2)_r$-phenyl substituted with 0-3 R^f;

R^e is selected from hydrogen, Ci_{-6} alkyl, C3-6 cycloalkyl, and $(CH_2)_r$-phenyl substituted with 0-3 R^f;


R^f is hydrogen, halo, NH_2, OH, or $0(Ci_{-6}$alkyl);

p is 0, 1, or 2;


r is 0, 1, 2, 3, or 4; and

m is 0, 1, or 2; or

(s)



I-vv-1



I-vv-2

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is:

(a) C_{2-3} hydroxyalkyl substituted with zero to 4 R^{1a} wherein R^{1a} is independently selected from F, Cl, —OH, —CHF_2, —CN, —CF_3, —OCH_3, and cyclopropyl;

(b) C_{1-3} alkyl substituted with —0(Ci-$_3$ alkyl) and zero to 4 R^{1a} wherein R^{1a} is independently selected from F, Cl, —OH, —CHF_2, —CN, —CF_3, and cyclopropyl;

(c) C_{4-8} alkyl substituted with zero to 7 R^{1a} wherein R^{1a} is independently selected from F, Cl, —OH, —CHF_2, —CF_3, —CN— OCH3, cyclopropyl, and —0P(0)(0H)$_2$;

(d) —$(CH_2)_{2-4}$NHC(0)(C_{1-6} alkyl), —$(CH_2)_2$CH(CH_3)NHC(0)(Ci_{-6}alkyl), —$(CH_2)_2$CH(CH3)NHC(O)(CH_2)$_{0-1}$NH(C_{i-6} alkyl), or —$(CH_2)_2$CH(CH3)NHC(O)(CH_2)$_{0-i}$N(Ci_{-4} alkyl)$_2$;

(e) cyclohexyl substituted with zero to 2 substituents independently selected from —OH, —OCH3, C1-6 alkyl, Ci_{-6}hydroxyalkyl, —C(0)NH_2, —C(0)NH(C_{1-3} alkyl), —C(0)NH(Ci_{-6}hydroxyalkyl), —C(0)NH(C_{3-6} cycloalkyl), —C(0)NH(C_{3-6} fluoro cycloalkyl), —NHC(0)(Ci_{-3} alkyl), —NHC(0)0(Ci_{-3} alkyl), —NHS(0)$_2CH_3$, —S(0)$_2NH_2$, —S(0)$_2$(Ci-$_3$ alkyl), —S(Ci-$_3$ alkyl), thiazolyl, methyl pyrazolyl, and Ci-$_3$ alkyl substituted with —OH and cyclopropyl;

(f) —$(CH_2)_2$(phenyl) wherein said phenyl is substituted with —C(0)NH_2, —C(0)NH(C_{1-3} alkyl), or —S(0)$_2NH_2$; or

(g) piperidinyl substituted with —C(0)(Ci-$_3$ alkyl);

R^2 is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazolyl, thiazolyl, ortriazolyl, each substituted with zero to 2 substituents independently selected from F, Cl, —OH, —CN, Ci-$_3$ alkyl, —CH_2C(0)0CH_3, —0(Ci_{-3}alkyl), —NH_2, —NH(C_{1-3} alkyl), —NH(cyclopropyl), —C(0)NH_2, —NHC(0)(C_{1-3} alkyl), —NH(tetrahydropyranyl), hydroxypyrrolidinyl, =0, —O(piperidinyl), and pyridinyl; and


R^3 is:



(a) Ci-$_6$ alkyl substituted with zero to 4 substituents independently selected from F, —OH, —CH3, —CF3, and C3-6cycloalkyl;

(b) C3-6 cycloalkyl substituted with zero to 2 substituents independently selected from F, —OH, C1-3 hydroxyalkyl, —C¾, —CF_2H, —NH_2, and —C(0)0CH_2CH_3;


(c) oxetanyl, tetrahydropyranyl, or fluoro tetrahydropyranyl;

(d) phenyl substituted with zero to 2 substituents independently selected from —OH, —CN, —0(Ci-$_3$ alkyl), C_{1-3} hydroxyalkyl, —C(0)NH_2, —S(0)$_2NH_2$, —NHS(0)$_2$(C_{1-3} alkyl), pyrazolyl, imidazolyl, and methyl tetrazolyl; or



(e)  , or  ; or

(t)



I-xx-1

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is an optionally substituted aromatic heterocyclic group or an optionally substituted C_{6-14} aryl group;

R^2 is a hydrogen atom or a substituent;

R^3 and R^4 are independently a hydrogen atom or a substituent, or R^3 and R^4 in combination optionally form an optionally substituted ring;


R^5 and R^6 are independently a hydrogen atom or a substituent, or R^5 and R^6 in combination optionally form an optionally substituted ring;

X is CR^7R^8, NR^9, O or S;

R^7 and R^8 are independently a hydrogen atom or a substituent, or R^7 and R^8 in combination optionally form an optionally substituted ring; and

R^9 is a hydrogen atom or a substituent; or


(u)



I-zz-1

or a pharmaceutically acceptable salt thereof, wherein:

R^1 denotes absent, A or Q-Het,

Z is 

wherein

X denotes O, S or N,

Y denotes C or N,

T denotes C or N, or

Z denotes a pyridine or a pyridazine group,

R^a is absent, OR^3, CF_3, Hal, or NO_2,

R^b is absent, A, or COHet,

R^2 denotes H, Het, Q-Het, Cyc, A or OA,

each Het is independently a 4-9 membered monocyclic ring or a fused, spiro or bridged bicyclic ring, which is saturated, unsaturated, or aromatic, which contains 1 to 3 heteroatoms independently selected from N, O, and S, and a group CO, SO or SO_2, and wherein 1 or 2 H atoms may be replaced by A, OA, COA, CN, Hal, NO_2, OR^3, SOA and/or SO_2A,

Cyc denotes a 4-8 saturated carbocyclic ring optionally containing a group SO, SO_2, or CO, and optionally substituted once or twice by a group selected from $CO(NR^3)_2$, COHet, OR^3, Het^1, A, $CHzHet^1$, NH_2, NHCOA, $OCTHCyc^1$, SO_2A and —SA(=NH)(=0),

each Q is independently a linear or branched alkylene, having 1 to 6 carbon atoms wherein 1-5 H atoms may be replaced by a group independently selected from OR^3, Hal, and $N(R^3)_2$, and wherein 1 or 2 CH_2 groups may be replaced by a group independently selected from CO, SO, SO_2 and NR^3, or Q denotes a 4-8-membered bivalent heterocyclic ring, which is saturated, unsaturated or aromatic and which contains 1 to 3 heteroatoms independently selected from N, O and S,

each A is independently a linear or branched alkyl having 1 to 10 carbon atoms wherein 1 to 7 H atoms may be replaced by a group independently selected from —OR^3, Hal, $NHSO_2A$, SO_2A, SOA, and $N(R^3)_2$, and wherein 1, 2 or 3 non-adjacent —CH_2— groups may be replaced by a group independently selected from —CO—, NR^3 and —O—,


each Hal is independently F, Cl, Br or I,

each R^3 is independently H or Ci-C_6-alkyl wherein 1 H atom may be replaced by a group selected from OH, O—Ci-C_6-alkyl, and Hal,

each Het^1 is independently a five- or six membered saturated monocyclic heterocycle which contains 1-3 N- and/or O-atoms, which optionally is monosubstituted by A,

Cyc^1 denotes cycloalkyl with 3-7 atoms; or

(v)



I-aaa-1

or a pharmaceutically acceptable salt thereof, wherein:

Ring A is a monocyclic heteroaryl;

R^1 is one to three optionally substituted with R^{10} monocyclic or bicyclic heteroaryl;

R^2 is, -$C(0)NH_2$, -C(0)NH-R°, -C(O)NH-R^{00}-OH, -C(O)NH-R^{00}-OR°, -$C(0)N(R°)_2$, -C(0)NH-

cycloalkyl, -C(0)NH-heterocycloalkyl, -C(0)NH-(pyrazolyl optionally substituted with R°> -C(0)-R°, -C(0)-cycloalkyl, -S(0) $_2$NH$_2$, -S(0) $_2$NH-R°, -S(0) $_2$NH-cycloalkyl, -R^{00}-OH' -R^{00}-OR° , -R^{00}-(morpholin-4-yl) phenyl, oxadiazolyl, or tetrazolyl optionally substituted with R^{0,} wherein oxadiazolyl in R^2 is, R°, R^{00}-OH or may be substituted with R°-OR°;


R^3 is, H, R°, halogeno-lower alkyl, cycloalkyl, heterocycloalkyl, phenyl, pyridyl, pyrimidinyl, pyrazinyl, -C(0)N(R°) $_2$, -R^{00}-cycloalkyl, -R^{00}-heterocycloalkyl, -R^{00}-phenyl, -R^{00}-OH or a -R ^{00} -OR^{0}, wherein the cycloalkyl in R^3, heterocycloalkyl, phenyl and pyridyl, R°, halogen, -C(O)OR^{0}, -C(0)-R°, -OH, -OR^{0}, -S(0) $_2$-R°, -O-halogeno-lower alkyl, -OR^{00}-(morpholin-4-yl), -R^{00}-OH, -R^{00}-OR°, morpholin-4-yl or, -R^{00}-(morpholin-4-yl) may be substituted;

R^{10} may be the same or different from each other, R°, halogen, halogeno-lower alkyl, cycloalkyl, -OR^{0}, optionally substituted amino, -O-halogeno-lower alkyl, -R^{00}-OH, -R^{00}-OR° or, -R^{00}-is optionally amino substituted,

R° is the same or different from each other, lower alkyl,

R^{00} are identical or different from each other, it is a lower alkylene; or

(w)



I-bbb-1

or a pharmaceutically acceptable salt thereof, wherein:

X is selected from O, S, and NH;

A is selected from aryl or heteroaryl;

R at each occurrence is independently selected from hydrogen, cyano, halo, hydroxy, -$N0_2$, -NR^3R^4, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkyi, optionally substituted heterocycloalkyl or optionally substituted heteroaryl; wherein the optional substituent, in each occurrence, is independently selected from halo, alkyl, haloalkyl, cyano, -NR^5R^6or -$COOR^7$;

R^1 at each occurence is independently selected from hydrogen, halogen, alkyl, aryl, heterocycloalkyl, heterocycloalkylalkyi, heteroaryl, Y-arylalkyl or -Y-cycloalkyl; wherein cycloalkyi, aryl, heterocycloalkyl, heterocycloalkylalkyi, heteroaryl and arylalkyl can be optionally substituted with hydroxy, alkyl, haloalkyl, cyano or halo;

Y is selected from direct bond, O, -C(O)- or NR^7;

R^2 at each occurence is independently selected from hydrogen, carboxy, cyano, hydroxy, hydroxyalkyl, alkyl, aryl, heteroaryl, -$S0^2R^5$ or oxo;


R^3 and R^4 are independently selected from hydrogen, hydroxyalkyl, aminoalkyl, optionally substituted alkyl, optionally substituted heterocyclyl, optionally substituted aryl; wherein the optional substituent, in each occurrence, is independently selected from halo, haloalkyl or -$COOR^7$;

R^5 and $R^6$are independently selected from hydrogen, alkyl, COR^7 or -$COOR^7$;

R^7 at each occurrence is independently selected from hydrogen or alkyl; and

m, n and p are selected from 1, 2 or 3; or

(x)



I-ccc-1

or a pharmaceutically acceptable salt thereof, wherein:

Ring Zi is an optionally substituted heteroaryl;

Ring Z_2 is an optionally substituted heterocycloalkyl, optionally substituted heteroaryl or a direct bond;

Ri is alkyl, cyano, —NR_aR_b or optionally substituted groups selected from cycloalkyl, aryl or heterocyclyl; wherein the substituent, at each occurrence, independently is alkyl, alkoxy, halogen, hydroxyl, hydroxyalkyl, amino, aminoalkyl, nitro, cyano, haloalkyl, haloalkoxy, —OCO—CH_2— O-alkyl, —0P(0)(0-alkyl) $_2$ or —CH_2— 0P(0)(0-alkyl) $_2$;

R_2, at each occurrence, independently is an optionally substituted group selected from alkyl or cycloalkyl; wherein the substituent, at each occurrence, is independently halogen, alkoxy, hydroxyl, hydroxyalkyl, haloalkyl or haloalkoxy;


R_3, at each occurrence, independently is hydrogen, halogen, alkyl, haloalkyl, haloalkoxy, alkoxy, —NR_aR_b, hydroxyl or hydroxyalkyl;

R_a is hydrogen or alkyl;

R_b is hydrogen, alkyl, acyl, hydroxyalkyl, —$S0_2$-alkyl or optionally substituted cycloalkyl;

'm' and 'n' are independently 1 or 2; or

(y)



I-ddd-l

or a pharmaceutically acceptable salt thereof, wherein:

Xi and X_3 independently are CH or N; X_2 is CR_2 or N; provided one and not more than one of Xi, X_2 or X_3 is N;

A is O or S;

Y is —CH_2— or O;

Ring Z is aryl or heterocyclyl;

Ri, at each occurrence, is independently halo or optionally substituted heterocyclyl; wherein the substituent is alkyl, alkoxy, aminoalkyl, halo, hydroxyl, hydroxyalkyl or —NR_aR_b;

R_2 is hydrogen, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl or —NR_aR_b; wherein the substituent is alkyl, amino, halo or hydroxyl;


R_3, at each occurrence, is alkyl or hydroxyl;

R_a and R_b are independently hydrogen, alkyl, acyl or heterocyclyl;

m and n are independently 0, 1 or 2;

p is 0 or 1; or

(z)



I-eee-1

or a pharmaceutically acceptable salt thereof, wherein:

Zi is optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl or is absent;

Z_2 is optionally substituted cycloalkyl, aryl or heterocyclyl;

Ri is hydrogen, optionally substituted alkyl, amino, halogen, cyano, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl;

R_2 at each occurrence is hydrogen, halogen, amino, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl;


R_3 at each occurrence is hydroxy, halogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted cycloalkyl or $—NR_aR_b$;

R_a and R_b, independently for each occurrence, are hydrogen, optionally substituted alkyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl;

m at each occurrence, is 0, 1 or 2; and

n at each occurrence, is 0, 1, or 2; or

(aa)



I-fff-1

or a pharmaceutically acceptable salt thereof, wherein:

R° represents hydrogen or Ci-C_4-alkyl, where the Ci-C_4-alkyl radical may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy and halogen;

R^1 represents hydrogen, halogen, cyano, C(=0)0H, C(=0)0R ^{a}, $C(=0)NH_2$, C(=0)N(H)R ^{a}, C(=0)N(R ^{a})R^b, C(=0)R ^{d}, hydroxy or Ci-C_6-alkyl, where the Ci-C_6-alkyl radical is optionally mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, C(=0)0R ^{a}, S(=0) $_2$— Ci-C_6-alkyl, NH_2, NHR ^{a}, N(R ^{a})R^b, Ci-C_6-alkoxy which is optionally mono- or polysubstituted by identical or different radicals from the group consisting of halogen, C3-C_8-cycloalkoxy which is optionally mono- or polysubstituted by identical or different radicals from the

group consisting of halogen, heterocycloalkyl which is optionally mono- or polysubstituted by identical or different radicals from the group consisting of R^c,

or represents Ci-C_6-alkoxy, where the Ci-C_6-alkoxy radical may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, C(=0)0R^a, S(=0)$_2$— Ci-Ce-alkyl, NH_2, NHR^a, $N(R^a)R^b$, C_3-Cx-cycloalkyl which is optionally mono- or polysubstituted by identical or different radicals from the group consisting of halogen, Ci-C_6-alkoxy which is optionally mono- or polysubstituted by identical or different radicals from the group consisting of halogen, C_3-Cx-cycloalkoxy which is optionally mono- or polysubstituted by identical or different radicals from the group consisting of halogen, heterocycloalkyl which is optionally mono- or polysubstituted by identical or different radicals from the group consisting of R^c, aryl which is optionally mono- or polysubstituted by identical or different radicals from the group consisting of R^c, or 5- or 6-membered heteroaryl which is optionally mono- or polysubstituted by identical or different radicals from the group consisting of R^c,

or represents C_3-Cx-cycloalkoxy or heterocycloalkoxy which may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano and Ci-C_6-alkyl,

or represents aryloxy or 5- or 6-membered heteroaryloxy in which aryloxy and 5- or 6-membered heteroaryloxy may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, C(=0)0R^a, Ci-Ce-alkyl and Ci-C_6-alkoxy,

or represents C_3-Cx-cycloalkyl or heterocycloalkyl which may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano and Ci-C_6-alkyl,

or represents C2-C_6-alkenyl or C2-C_6-alkynyl,

or represents aryl, 5- to lO-membered heteroaryl, aryl-Ci-C_4-alkyl or 5- or 6-membered heteroaryl-Ci-C_4-alkyl, where aryl and heteroaryl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of halogen, hydroxy, cyano, C(=0)0H, C(=0)0R^a, Ci-C_6-alkyl, C_3-C_8-cycloalkyl and Ci-C_6-alkoxy;

R^a represents Ci-C_6-alkyl, C_3-Cio-cycloalkyl, heterocycloalkyl, aryl or heteroaryl, where alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl may optionally be mono- or

polysubstituted by identical or different radicals from the group consisting of halogen, hydroxy, cyano, Ci-C_3-alkyl, Ci-C_3-alkoxy, heterocycloalkyl, —C(=0)0 —Ci-C_6-alkyl and S(=0) $_2$— Ci-Ce-alkyl;

R^b represents Ci-C_6-alkyl or C_3-Cio-cycloalkyl;

or R^a and R^b together with the nitrogen atom form a 5- or 6-membered heterocycle which may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, and Ci-C_6-alkyl;

R^c represents hydroxy, halogen, cyano, Ci-C_3-alkyl or Ci-C_3-alkoxy;

R^d represents hydrogen, Ci-C_6-alkyl or C_3-Cio-cycloalkyl;

R^2 represents hydrogen, Ci-C_6-alkyl or C_3-C_6-cycloalkyl;

R^{13} represents hydrogen or Ci-C_6-alkyl;

W represents 5-membered heteroaryl which contains one to three heteroatoms selected from the group consisting of N, O and S and may optionally be monosubstituted by R^3 and optionally be mono- or polysubstituted by identical or different radicals R^4 or

W represents pyridyl, pyrazinyl, pyridazinyl, l,2,4-triazinyl or l,3,5-triazinyl which may optionally be monosubstituted by R^3 and optionally be mono- or polysubstituted by identical or different radicals R^4;

R^3 represents hydrogen, halogen, cyano, C(=0)R^a, NH_2, NHR^a, $N(R^a)R^b$, N(H)C(=0)R^a or Ci-C_6-alkyl,

where Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)R^a, C(=0)0H, C(=0)0R^a, S(=0) $_2$— Ci-Ce-alkyl, NH_2, NHR^a, $N(R^a)R^b$, Ci-C_6-alkoxy, C_3-C_8-cycloalkoxy,

where Ci-C_6-alkoxy and C_3-C_8-cycloalkoxy may optionally be mono- or polysubstituted by identical or different halogen radicals;

or Ci-C_6-alkyl is optionally mono- or polysubstituted by identical or radicals from the group consisting of C_3-C_6-cycloalkyl and heterocycloalkyl,

where C_3-C_6-cycloalkyl and heterocycloalkyl may optionally be mono-, di- or trisubstituted by identical or different radicals from the group consisting of halogen, cyano, Ci-C_3-alkyl and Ci-C_3-alkoxy,

or Ci-C_6-alkyl is optionally mono- or polysubstituted by identical or different radicals from the group consisting of aryl and 5- or 6-membered heteroaryl,

where aryl and 5- or 6-membered heteroaryl may optionally be mono-, di- or trisubstituted by identical or different radicals from the group consisting of halogen, cyano, C1-C3-alkyl and Ci-C3-alkoxy,

or R^3 represents Ci-C_6-alkoxy,

where Ci-C_6-alkoxy may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0R^a, S(=0)$_2$— Ci-C_6-alkyl, N(R^a)R^b, Cx-Cx-cycloalkyl, Ci-C_4-alkoxy, C_3-Cx-cycloalkoxy,

or represents C3-C_6-cycloalkyl, heterocycloalkyl or C_5-C_{11}-spirocycloalkyl, where cycloalkyl, heterocycloalkyl and spirocycloalkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)R^a, C(=0)0H, C(=0)0R^a, Ci-Ce-alkyl and Ci-C_4-alkoxy;

or represents aryl or 5- to lO-membered heteroaryl,

where aryl and heteroaryl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of halogen, hydroxy, cyano, C(=0)0R^a, S(=0)$_2$— Ci-Ce-alkyl, N0$_2$, NH_2, NHR^a, N(R^a)R^b, N(H)C(=0)R^a, Cs-Ce-cycloalkyl, Ci-C3-alkoxy and Ci-C3-alkyl, where

Ci-C3-alkyl may optionally be mono- or polysubstituted by identical or different halogen radicals;

R^4 represents halogen, hydroxy, cyano or Ci-C_6-alkyl, where Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of halogen, Ci-C_6-alkoxy, where Ci-C_6-alkoxy may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of halogen, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C3-Cio-cycloalkyl, 3- to lO-membered heterocycloalkyl and aryl, where aryl may optionally be mono- or polysubstituted by identical or different radicals R;

or R^4 represents aryl or heteroaryl which may optionally be mono- or polysubstituted by identical or different radicals R;

or R^4 represents C(=0)R^a, C(=0)NH_2, C(=0)N(H)R^a, C(=0)N(R^a)R^b, C(=0)0R^a, NH_2, NHR^a, N(R^a)R^b, N(H)C(=0)R^a, N(R^a)C(=0)R^a, N(H)C(=0)NH_2, N(H)C(=0)NHR^a, N(H)C(=0)N(R^a)R^b, N(R^a)C(=0)NH_2, N(R^a)C(=0)NHR^a, N(R^a)C(=0)N(R^a)R^b, N(H)C(=0)0R^a, N(R^a)C(=0)0R^a, N0$_2$, N(H)S(=0)R^a, N(R^a)S(=0)R^a, N(H)S(=0)$_2$R^a,


$N(R^a)S(=O)_2R^a$, $N=S(=O)(R^a)R^b$, $OC(=O)R^a$, $OC(=O)NH_2$, $OC(=O)NHR^a$, $OC(=O)N(R^a)R^b$, SH, SR^a, $S(=O)R^a$, $S(=O)_2R^a$, $S(=O)_2NH_2$, $S(=O)_2NHR^a$, $S(=O)_2N(R^a)R^b$ or $S(=O)(=N—R^a)R^b$;

R represents halogen, cyano, Ci-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C3-Cio-cycloalkyl, 3- to lO-membered heterocycloalkyl, aryl, heteroaryl, $C(=0)R^a$, $C(=0)NH_2$, $C(=0)N(H)R^a$, $C(=0)N(R^a)R^b$, $C(=0)0R^a$, NH_2, NHR^a, $N(R^a)R^b$, $N(H)C(=0)R^a$, $N(R^a)C(=0)R^a$, $N(H)C(=0)NH_2$, $N(H)C(=0)NHR^a$, $N(H)C(=0)N(R^a)R^b$, $N(R^a)C(=0)NH_2$, $N(R^a)C(=0)NHR^a$, $N(R^a)C(=0)N(R^a)R^b$, $N(H)C(=0)0R^a$, $N(R^a)C(=0)0R^a$, $N0_2$, $N(H)S(=0)R^a$, $N(R^a)S(=0)R^a$, $N(H)S(=0)_2R^a$, $N(R^a)S(=0)_2R^a$, $N=S(=0)(R^a)R^b$, OH, Ci-Ce-alkoxy, $0C(=0)R^a$, $0C(=0)NH_2$, $0C(=0)NHR^a$, $0C(=0)N(R^a)R^b$, SH, SR^a, $S(=0)R^a$, $S(=0)_2R^a$, $S(=0)_2NH_2$, $S(=0)_2NHR^a$, $S(=0)_2N(R^a)R^b$ or $S(=0)(=NR^a)R^b$;

n represents 0 or 1;

Y represents a group selected from:

(II)



where * represents the point of attachment of the group to the remainder of the molecule;

R^5 represents hydrogen, Ci-C_6-alkyl or C3-Cio-cycloalkyl, where

Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, $C(=0)0R^a$, $S(=0)_2$—Ci-C_6-alkyl, $N(R^a)R^b$, Ci-C_4-alkoxy and Cx-Cx-cycloalkyl;

R^6 represents hydrogen or Ci-C_6-alkyl, where

Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C3-Cio-cycloalkyl, $C(=0)R^a$, C(=0)0H, $C(=0)0R^a$, $S(=0)_2$— Ci-Ce-alkyl, $N(R^a)R^b$, Ci-C_4-alkoxy and C_3-C_8-cycloalkoxy, or represents C3-Cio-cycloalkyl, where

C3-Cio-cycloalkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano and Ci-C_6-alkyl, where

Ci-C_6-alkyl may optionally be substituted by hydroxy, or represents heterocycloalkyl, where

heterocycloalkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of halogen, cyano, Ci-C_3-alkyl and Ci-C_3-alkoxy, or represents aryl or 5- or 6-membered heteroaryl, where

aryl and 5- or 6-membered heteroaryl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of halogen, cyano, Ci-C_3-alkyl, Ci-C_3-alkoxy, $S(=0)_2NH_2$, $S(=0)_2NHR^a$ and $S(=0)_2N(R^a)R^b$;

R^{7a} represents hydrogen, halogen, $N(R^a)R^b$, Ci-C_6-alkyl or C_3-Cio-cycloalkyl, where Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, $C(=0)0R^a$, $S(=0)_2$— Ci-C_6-alkyl, $N(R^a)R^b$, Ci-C_4-alkoxy, C_3-C_8-cycloalkyl and heterocycloalkyl;

R^{7b} represents hydrogen, halogen or Ci-C_6-alkyl, where Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, $C(=0)0R^a$, $S(=0)_2$— Ci-Ce-alkyl, $N(R^a)R^b$, Ci-C_4-alkoxy, C_3-Cx-cycloalkyl and heterocycloalkyl;

or R^{7a} and R^{7b} together with the carbon atom form C_3-C_6-cycloalkyl which may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano and Ci-C_6-alkyl,

or R^{7a} and R^{7b} together represent an oxo group;

R^{7c} represents hydrogen, halogen, $N(R^a)R^b$, Ci-C_6-alkyl or C_3-Cio-cycloalkyl, where

Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, $C(=0)0R^a$, $S(=0)_2$— Ci-C_6-alkyl, $N(R^a)R^b$, Ci-C_4-alkoxy, C_3-C_8-cycloalkyl and heterocycloalkyl;

R^{7d} represents hydrogen, halogen or Ci-C_6-alkyl, where

Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, $C(=0)0R^a$, $S(=0)_2$— Ci-C_6-alkyl, $N(R^a)R^b$, Ci-C_4-alkoxy, C_3-C_8-cycloalkyl and heterocycloalkyl;

or R^{7c} and R^{7d} together with the carbon atom form C_3-C_6-cycloalkyl which may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano and Ci-C_6-alkyl,

or R^{7c} and R^{7d} together represent an oxo group;

R^{8a} represents hydrogen, halogen, $N(R^a)R^b$, Ci-C_6-alkyl or C3-Cio-cycloalkyl, where

Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, $C(=0)0R^a$, $S(=0)_2$—Ci-C_6-alkyl, $N(R^a)R^b$, Ci-C_4-alkoxy, Cx-Cx-cydoalkyl and heterocycloalkyl;

R^{8b} represents hydrogen, halogen or Ci-C_6-alkyl, where

Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, $C(=0)0R^a$, $S(=0)_2$—Ci-C_6-alkyl, $N(R^a)R^b$, Ci-C_4-alkoxy, Cx-Cx-cydoalkyl and heterocycloalkyl;

or R^{8a} and R^{8b} together with the carbon atom form C3-C_6-cycloalkyl which may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano and Ci-C_6-alkyl,

R^{8c} represents hydrogen, halogen, $N(R^a)R^b$, Ci-C_6-alkyl or C3-Cio-cycloalkyl, where

Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, $C(=0)0R^a$, $S(=0)_2$—Ci-C_6-alkyl, $N(R^a)R^b$, Ci-C_4-alkoxy, Cx-Cx-cydoalkyl and heterocycloalkyl;

R^{8d} represents hydrogen, halogen or Ci-C_6-alkyl, where

Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, $C(=0)0R^a$, $S(=0)_2$—Ci-C_6-alkyl, $N(R^a)R^b$, Ci-C_4-alkoxy, Cx-Cx-cydoalkyl and heterocycloalkyl;

or R^{8c} and R^{8d} together with the carbon atom form C3-C_6-cycloalkyl which may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano and Ci-C_6-alkyl,

or R^{8c} and R^{8d} together represent an oxo group;

o represents 0, 1 or 2,

p represents 0, 1 or 2,

q represents 0, 1 or 2,

r represents 0, 1 or 2,

s represents 0, 1 or 2,

where o, p, q, r and s do not simultaneously represent 0;

Z represents a group selected from C(=0), CR^9R^{10}, NR^{11}, O, S, S(=0) and $S(=0)_2$;

R^9 represents hydrogen or Ci-C_6-alkyl,

R^{10} represents hydrogen, halogen, cyano, C(=0)R^a, C(=0)0H, C(=0)0R^a, C(=0)NH_2, C(=0)N(H)R^a, C(=0)N(R^a)R^b, N(H)C(=0)R^a, N(R^b)C(=0)R^a, S(=0)$_2R^a$, hydroxy, N(R^a)R^b and Ci-C_6-alkyl, where

Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)R^a, C(=0)0H, C(=0)0R^a, S(=0)$_2$— Ci-C_6-alkyl, N(R^a)R^b, Ci-C_4-alkoxy and C_3-Cx-cycloalkoxy, or represents Ci-C_6-alkoxy, where

Ci-C_6-alkoxy may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, C(=0)0R^a, S(=0)$_2$— Ci-C_6-alkyl, N(R^a)R^b, C_3-Cx-cycloalkyl, Ci-C_4-alkoxy, C_3-Cx-cycloalkoxy, heterocycloalkyl, aryl and 5- or 6-membered heteroaryl, where

aryl and 5- or 6-membered heteroaryl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of halogen, cyano, Ci-Cx-alkyl and Ci-Cx-alkoxy, or represents aryloxy or 5- or 6-membered heteroaryloxy in which aryloxy and 5- or 6-membered heteroaryloxy may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)0H, C(=0)0R^a, Ci-Cs-alkyl and Ci-C_3-alkoxy,

or represents C_3-C_8-cycloalkyl, C_3-C_8-cycloalkyl-Ci-C_4-alkyl, heterocycloalkyl or heterocycloalkyl-Ci-C_4-alkyl, which may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)R^a, C(=0)0H, C(=0)0R^a, Ci-C_6-alkyl and Ci-C_6-alkoxy, where

Ci-C_6-alkoxy may optionally be mono- or polysubstituted by identical or different halogen radicals or an oxo group;

or represents C_2-C_6-alkenyl or C_2-C_6-alkynyl,

or represents aryl, 5- to lO-membered heteroaryl, aryl-Ci-C_4-alkyl or 5- or 6-membered heteroaryl-Ci-C_4-alkyl, where

aryl and heteroaryl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of halogen, hydroxy, cyano, C(=0)0H, C(=0)0R^a, NHR^a, N(R^a)R^b, Ci-C_3-alkyl, C_3-C_8-cycloalkyl and Ci-C_3-alkoxy;

or R^9 and R^{10} together with the carbon atom form Cx-Cx-cycloalkyl or a 4- to 6-membered heterocycle, where

the Cx-Cx-cycloalkyl radical or the 4- to 6-membered heterocycle may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, Ci-C_6-alkyl, C(=0)R^a and an oxo group;

R^{11} represents hydrogen, C(=0)R^a, C(=0)0R^a, C(=0)NH_2, C(=0)N(H)R^a, C(=0)N(R^a)R^b, S(=0)$_2R^a$, S(=0)$_2$N(R^a)R^b or Ci-Ce-alkyl, where

Ci-C_6-alkyl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, C(=0)R^a, C(=0)0R^a, C(=0)NH_2, C(=0)N(H)R^a, C(=0)N(R^a)R^b, S(=0)$_2$— Ci-Ce-alkyl, N(R^a)R^b, C_3-Cx-cycloalkyl, Ci-C_4-alkoxy and C_3-Cx-cycloalkoxy, where

C_3-C_8-cycloalkyl, Ci-C_4-alkoxy and C3-C_8-cycloalkoxy may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy and halogen;


or represents C_3-C_8-cycloalkyl, heterocycloalkyl or heterocycloalkyl-Ci-C4-alkyl which may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxy, halogen, cyano, Ci-C_6-alkyl, Ci-C_6-alkoxy, where alkyl and alkoxy may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of halogen and an oxo group,

or represents C_2-C_6-alkenyl or C_2-C_6-alkynyl,

or represents aryl, 5- to lO-membered heteroaryl, aryl-Ci-C_4-alkyl or 5- or 6-membered heteroaryl-Ci-C_4-alkyl, where

aryl and heteroaryl may optionally be mono- or polysubstituted by identical or different radicals from the group consisting of halogen, hydroxy, cyano, C(=0)0H, C(=0)0R^a, Ci-C_3-alkyl, C3-C_8-cycloalkyl and Ci-C3-alkoxy; or

(bb)



I-ggg-1

or a pharmaceutically acceptable salt thereof, wherein:

Ring A is phenylene or 5- to 6-membered heteroarylene containing 1-3 heteroatoms chosen from O, S, and N, wherein ring A is optionally substituted with lower alkyl that is further optionally substituted,

Ring B is phenylene, 5- to 6-membered heterocycloalkylene containing 1-3 heteroatoms chosen from O, S, and N, or 5- to 6-membered heteroarylene containing 1-3 heteroatoms chosen from O, S, and N, wherein ring B is optionally substituted with lower alkyl that is further optionally substituted,

R^3 is chosen from hydrogen, lower alkyl optionally substituted with alkoxy, amino, N-(alkyl)amino, N,N-(dialkyl)amino, or phenyl, heterocycloalkyl, and heteroaryl,

wherein phenyl, heterocycloalkyl, and heteroaryl are optionally substituted with one or two groups independently chosen from lower alkyl and wherein alkoxy is optionally substituted with tri(alkyl)silyl,

R^4 is chosen from heteroarylene and arylene, each of which is optionally substituted, or R^4 and R^3 taken together with the nitrogen to which they are bound, form an optionally substituted 3- to 7-membered heterocycloalkyl ring, or R^4 is an alkylene chain having 1-3 carbon atoms that is optionally substituted with one or two groups independently chosen from lower alkyl and cycloalkyl, each of which groups is optionally substituted with hydroxyl or alkoxy, or R^4 is absent,

R^5 is chosen from C(0)NR^{51}, NR^{52}, and O or R^5 is absent, provided that if R^4 is absent, then R^5 is absent,

R^6 is an alkylene or alkenylene chain having one or two double bonds,

wherein the alkylene or alkenylene chain has 2 to 10 carbon atoms,

wherein the alkylene or alkenylene chain is optionally substituted with one or two groups independently chosen from lower alkyl and cycloalkyl, each of which groups is optionally substituted with hydroxyl or alkoxy, and

further wherein one or two of the carbon atoms in the alkylene chain is optionally replaced by an O, S, SO, SO_2, or NR^{61}, and

wherein two of the carbon atoms in the alkylene chain, are optionally connected by a two or three carbon atom alkylene chain to form a 5- to 7-membered ring.

R^7 is chosen from NR^{71} and O or R^7 is absent,

R^{51} is chosen from hydrogen and lower alkyl,


R^{52} is chosen from hydrogen, lower alkyl, and —C(0)0R^{81},

R^{61} is chosen from hydrogen, lower alkyl, and —C(0)0R^{81},

R^{71} is chosen from hydrogen, lower alkyl, and —C(0)0R^{81}, and

R^{81} is lower alkyl; or

(cc)



I-hhh-1

or a pharmaceutically acceptable salt thereof, wherein:

HET is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-djpyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with R_a and $R_{t'}$;

R_a is H, F, Cl, Br, —CN, —OH, Ci-$_4$ alkyl, Ci-$_4$ fluoroalkyl, Ci$_{-4}$hydroxyalkyl, Ci-$_4$ alkoxy, —NH_2, —NH(Ci$_{-4}$ alkyl), —N(Ci-$_4$ alkyl)$_2$, —NH(Ci-$_4$ hydroxyalkyl), —NH(C$_{1-4}$ fluoroalkyl), —NH(Ci.$_6$ hydroxy-fluoroalkyl), —C(0)NH_2, —CH_2NHC(0)(C$_{1-6}$ alkyl), —CH_2NHC(0)(Ci$_{-6}$hydroxyalkyl), —CH_2NHC(0)NH(Ci$_{-6}$ alkyl), —CH_2NHC(0)NHCH_2(phenyl), —CH_2NHC(0)N(Ci$_{-4}$ alkyl)$_2$, —CH_2NHC(0)0(Ci$_{-4}$ alkyl), —CH_2NHC(0)(C$_{3-6}$ cycloalkyl), —CH_2NHC(0)(tetrahydrofuranyl), —CH_2NHC(0)CH_2(C$_{3-6}$ cycloalkyl), —CH_2NHC(0)CH_2(tetrahydropyranyl), —CH_2NHC(0)CH_2(phenyl), —NHC(0)(Ci$_{-4}$ alkyl), pyrrolidinyl, hydroxypyrrolidinyl, or pyridazinyl;

R_b is H or —NH_2;

Ri is:

(i) Ci-$_6$ alkyl, Ci$_{-6}$ fluoroalkyl, Ci$_{-6}$ hydroxyalkyl, Ci$_{-8}$ hydroxy-fluoroalkyl, —(Ci-$_6$ alkylenyl)0(Ci$_{-4}$ alkyl), —(Ci$_{-6}$ alkylenyl)0(Ci$_{-4}$fluoroalkyl), —(Ci-$_6$ fluoroalkylenyl)0(Ci$_{-4}$ alkyl), —(Ci.$_6$fluoroalkylenyl)0(Ci$_{-4}$ deuteroalkyl), —(Ci-$_6$ fluoroalkylenyl)0(Ci$_{-4}$fluoroalkyl), —(Ci$_{-4}$ fluoroalkylenyl)C(C$_{3-6}$ cycloalkyl)$_2$(OH), —(Ci$_{-4}$alkylenyl)NHC(0)(Ci$_{-4}$ alkylenyl)0C(0)(Ci-$_3$ alkyl), —(Ci-$_6$alkylenyl)NHS(0)$_2$(Ci$_{-4}$ alkyl), —(Ci$_{-6}$ alkylenyl)P(0)(Ci$_{-4}$ alkoxy)$_2$, —(Ci-$_6$ fluoroalkylenyl)NH(Ci$_{-4}$ alkyl), —(Ci$_{-6}$ alkylenyl)C(0)NH(Ci$_{-4}$ alkyl), —(Ci-$_6$ fluoroalkylenyl)C(0)NH(Ci$_{-4}$ alkyl), —(Ci-$_6$fluoroalkylenyl)C(0)NH(Ci.$_4$ hydroxyalkyl), or —(Ci$_{-6}$fluoroalkylenyl)0P(0)(0H)$_2$;

(ii) —(Ci-$_3$ alkylenyl)R_x, —(C$_{1-3}$ fluoroalkylenyl)R_x, —(Ci-$_3$alkylenyl)C(0)R_x, —(Ci-$_3$ alkylenyl)C(0)NHR_x, —(Ci-$_3$fluoroalkylenyl)C(0)R_x, or —CH_2CF=(tetrahydropyranyl), wherein R_x is a cyclic group selected from C$_3$-$_6$ cycloalkyl, tetrazolyl, l,l-dioxidotetrahydrothiophenyl, 1,1-dioxidothiomorpholinyl, oxadiazolyl, piperidinyl, piperazinyl, pyrrolidinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyridinyl, imidazolyl, morpholinyl, phenyl, and triazinyl, wherein each cyclic group is substituted with zero to 3 substituents independently selected from F, —OH, —C¾, —C(CH_2)$_2$OH, —0CH_3, —C(0)CH_2CN, —S(0)$_2$CH_3, —S(0)$_2$$NH_2$, —NHC(0)C$H_3$, —N(S(0)$_2CH_3$)$_2$, —$CH_2$$CH_2$(acetamidophenyl), —$CH_2$$CH_2$(methoxyphenyl), —$CH_2$$CH_2$(sulfamoylphenyl), oxetanyl, benzyl, and morpholinyl;

(iii) C3-6 cycloalkyl or C4-6 cycloalkenyl, each substituted with zero to 3 substituents independently selected from F, —OH, —CN, Ci-3alkyl, C1-3 alkoxy, —S(Ci-3 alkyl), —NO2, —S(0)2(Ci-3 alkyl), Ci-4hydroxyalkyl, —C(Ci-3 alkyl)(OH)(C3-6 cycloalkyl), —CH2C(0)NH(Ci-3 alkyl), —NHC(0)(Ci-3 alkyl), —NHC(0)(Ci-4hydroxyalkyl), —C(0)NH(CI-3 alkyl), —C(0)NH(CI-3 deuteroalkyl), —C(0)NH(C3-6 cycloalkyl), —NHC(0)0(Ci-3 alkyl), —NHS(0)2(Ci-3alkyl), pyridinyl, imidazolyl, pyrazolyl, methylimidazolyl, methylpyrazolyl, and thiazolyl;

(iv) tetrahydropyranyl, piperidinyl, pyrazolyl, phenyl, pyridinyl, or pyrimidinyl, each substituted with zero to 1 substituent selected from —OH, C1-3 alkyl, Ci-3 fluoroalkyl, Ci-4 hydroxyalkyl, Ci-3alkoxy, —C(0)(Ci-4 alkyl), —S(0)2(Ci-4 alkyl), —S(0)2NH(Ci-4 alkyl), —NH(C1-3 alkyl), —N(C1-3 alkyl)2, —0(Ci-3 alkylenyl)N(Ci-3 alkyl)2, —CH2(morpholinyl), azetidinyl, oxetanyl, tetrahydropyranyl, morpholinyl, piperazinyl, piperidinyl, methylpiperazinyl, methoxypiperidinyl, pyridinyl, pyrimidinyl, methyl sulfonyl azetidinyl, and —C(0)(m ethyl sulfonyl azetidinyl); or

(v) pyrrolo[2,3-c]pyridinyl, bicyclo[2.2.l]heptan-l-ol, tetrahydrobenzo[d]thiazol-2-amine, or l,3-diazaspiro[4.5]decane-2,4-dione; and

R_2 is:

(i) Ci-7 alkyl or C2-6 alkenyl, each substituted with zero to three substituents independently selected from F, —OH, and —CN; —(Ci-4 alkylenyl)0(Ci-4 alkyl), —(Ci-4 alkylenyl)0(Ci-4 fluoroalkyl), —(Ci-6 alkyl enyl)NH2, —(Ci-6 alkylenyl)S(0)2(Ci-3 alkyl), —(Ci-6fluoroalkylenyl)NH(C1-3 alkyl), or —(Ci-6 alkylenyl)NHC(0)(Ci-4fluoroalkyl);

(ii) —(Ci-4 alkyl enyl)Ry wherein Ry is C3-6 cycloalkyl, azetidinyl, oxetanyl, oxazolyl, pyridinyl, tetrahydropyranyl, or morpholinyl, each substituted with zero to 2 substituents independently selected from F, —OH, and C1-3 alkyl;


(iii) C3-6 cycloalkyl, azetidinyl, oxetanyl, furanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, or tetrahydropyranyl, each substituted with zero to 3 substituents independently selected from F, —OH, Ci^alkyl, C1-3 hydroxyalkyl, —C(0)(Ci-3 alkyl), —C(0)(C1-3 fluoroalkyl), —C(0)(Ci-3 cyanoalkyl), —C(0)0(C1-3 alkyl), —C(0)NH2, —C(0)NH(C1-3 alkyl), —C(0)(difluorophenyl), —NH2, —NH(Ci-

$_3$ alkyl), —NH(C $_{I-3}$ fluoroalkyl), —NH(oxetanyl), —NHC(0)(C $_{I-3}$ alkyl), —NHC(0)(C $_{I-3}$ fluoroalkyl), —NHC(0)(C $_{3-6}$ cycloalkyl), —NHC(0)(fluorophenyl), —S(0) $_2$(Ci-$_3$ alkyl), imidazolyl, phenyl, pyrimidinyl, fluoropyrimidinyl, chloropyrimidinyl, and methoxypyrimidinyl;

(iv) adamantanyl, hydroxyadamantanyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]triazolyl, benzothiazolyl, bicyclo[l.l.l]pentanyl, or hydroxy-bicyclo[2.2.l]heptanyl; or

(v) phenyl, pyrazolyl, thiazolyl, thiadiazolyl, or indazolyl, each substituted with 0 to 2 substituents independently selected from F, Cl, —OH, —CN, Ci-$_4$ alkyl, Ci-$_4$ hydroxyalkyl, C i$_{-4}$ fluoroalkyl, C i$_{-4}$ cyanoalkyl, C1-3 alkoxy, C3-6 cycloalkyl, —(C1-3 alkylenyl)0(Ci-$_3$alkyl), —(C1-3 alkyl enyl)0(C $_{1-3}$ fluoroalkyl), —C(0)NH $_2$, —C(0)NH(C $_{I-3}$ alkyl), —NHC(0)(Ci $_{-3}$ alkyl), —NHC(0)S(0) $_2$(Ci-$_3$alkyl), —S(0) $_2$NH $_2$, —S(0) $_2$(Ci-$_3$ alkyl), pyrazolyl, methyl pyrazolyl, imidazolyl, triazolyl, methyl tetrazolyl, ethyl tetrazolyl, phenyl, pyrimidinyl, fluoropyrimidinyl, and tetrahydropyranyl; or

(dd)



I-iii-1

or a pharmaceutically acceptable salt thereof, wherein:

=== is a single or double bond;

W is selected from CH, CH— CH, O, S, NR^6, and CO;

Y is N or CR^9;

Z is N or C, and Z is N if W is CH and Y is CR^9;

R^4 is selected from hydrogen, halogen, OR^6, CN, NR^7R^8, CH_2OR^6, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted non-aromatic ring, an optionally substituted carbocycle, an optionally substituted Ci-C_6 alkyl, an optionally substituted Ci-C_6 haloalkyl, an optionally substituted Ci-C_6 heteroalkyl, an optionally substituted Ci-C_6 alkenyl, an optionally substituted Ci-C_6 alkynyl, $CO2R^6$, SO_3R^6, $SO2R^6$ and $S0_2NR^7R^8$;

R_5 is selected from hydrogen, halogen, OR^6, an optionally substituted Ci-C_6 alkyl, an optionally substituted Ci-C_6 haloalkyl, an optionally substituted Ci-C_6 heteroalkyl, an optionally substituted Ci-C_6 haloheteroalkyl, an optionally substituted Ci-C_6 alkenyl, and an optionally substituted Ci-C_6 alkynyl;

or R_4 and R_5 are linked to form an optionally substituted non-aromatic ring;

each R_6 is independently selected from an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted non-aromatic ring, each optionally fused with a substituted aryl or a substituted heteroaryl, hydrogen, an optionally substituted Ci-Cioalkyl, an optionally substituted C_1-C_{10} haloalkyl, and an optionally substituted Ci-C_{10} heteroalkyl;

each R^7 and R^8 is independently selected from an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted non-aromatic ring, each optionally fused with a substituted aryl or a substituted heteroaryl, hydrogen, an optionally substituted Ci-C_{10} alkyl, an optionally substituted C_1-C_{10} haloalkyl, an optionally substituted Ci-C_{10} alkenyl, an optionally substituted C_1-C_{10} alkynyl, and an optionally substituted Ci-C_{10} heteroalkyl, or R^7 and R_8 are linked to form an optionally substituted non-aromatic ring;


R^9 is selected from hydrogen, halogen, OR^6, CN, NR^7R^8, CH_2OR^6, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted non-aromatic ring, an optionally substituted Ci-C_6 alkyl, an optionally substituted Ci-C_6 haloalkyl, an optionally substituted Ci-C_6 heteroalkyl, an optionally substituted Ci-C_6 alkenyl, an optionally substituted Ci-C_6 alkynyl, CO_2R^6, SO_3R^6, and $S0_2NR^7R^8$;

A is an optionally substituted aryl or an optionally substituted heteroaryl group;

each optionally substituted group is either unsubstituted or substituted with one or more groups independently selected from alkyl, heteroalkyl, alkenyl, alkynyl, haloalkyl, heterohaloalkyl, aryl, arylalkyl, heteroaryl, non-aromatic ring, hydroxy, alkoxy, aryloxy,

mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, =0, =S, amino, and protected derivatives of amino groups; or

(ee)



i-jjj-i

or a pharmaceutically acceptable salt thereof, wherein:

Q denotes Ar or Het;

E denotes —$(CH_2)_m$CO—, —$(CH_2)_m$S0 $_2$, —$(CH_2)_q$— , —$(CH_2)_m$NHCO—, or a single bond;

R^1 denotes H, OH, NH—Ci-C_6-alkyl, OCi-C_6-alkyl, Ci-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, Cyc, Hal, Het^1, O-Het^1, CO-Het^1, NH-Het^1, CO—Ar^1, O—Ar^1, Ar^1, NH—Ar^1, —$(CH_2)_q$$Het^1$, —CONH—$(CH_2)_q$$Het^1$, —CONH-$Het^1$, —$(CH_2)_q$O-$Het^1$, —$(CH_2)_q$O—$Ar^1$, —$(CH_2)_q$$Ar^1$, —CONH—$(CH_2)_q$$Ar^1$, —CONH—$Ar^1$, —CONH$C_3$-$C_6$-cycloalkyl, —$(CH_2)_q$Hal, —$(CH_2)_q$Cyc, CF_3, —$(CH_2)_s$NH—$(CH_2)_q$-Het^1, —$(CH_2)_s$NH—$(CH_2)_q$— Ar^1, wherein NH—Ci-C_6-alkyl, OCi-C_6-alkyl, Ci-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_3-C_6-cycloalkyl may be substituted by 1 to 3 groups independently selected from OCi-C_3-alkyl, OH, $CONH_2$, NH_2;

R^2 denotes H, Ci-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, Hal, CF_3, preferably H;

R^3 denotes Het^1, Ar^1, NR^aR^b, COOH, —$(CH_2)_q$$Het^1$, —$(CH_2)_q$Ar', —$(CH_2)_q$$NR^aR^b$, —$(CH_2)_q$COOH, or Ci-$C_6$-alkyl wherein 1 to 3 hydrogen atoms may be independently replaced by OH or CF_3;

R^4 denotes H, Ci-C_6-alkyl, C_2-C_6-alkenyl, Hal;

R^a denotes H, linear, branched or cyclic Ci-C_6-alkyl;

R^b denotes H, Het^b, Ar^b, —CO-Het^b, —CO—Ar^b, a C_3-Cx-cycloalkyl or a linear or branched alkyl having 1 to 6 carbon atoms, wherein 1 to 3 hydrogen atoms may be replaced by Het^b, Ar^b, NH_2, N(Ci-C_6-alkyl)$_2$, NH(Ci-C_6-alkyl), N(Ci-C_6-alkyl)(C3-C8-cydoalkyl), NH(C_3-C_8-cycloalkyl), 0(Ci-C_6-alkyl), CN, OH, CF_3, Hal;

n is 0, 1, 2, 3 or 4;

m is 0, 1, 2, 3 or 4;

q is 1, 2, or 3;

s is 0, 1, 2 or 3;

Hal denotes Cl, Br, I, F, preferably Cl or F;

Ar denotes a divalent monocyclic or fused bicyclic arylen group having 6 to 14 carbon atoms, which may be further substituted with 1 to 4 substitutents selected from Hal, Ci-C_6-alkyl, —$(CH_2)_m$OCi-C_6-alkyl, CN, OH, N0 $_2$, CF_3, —$(CH_2)_m$COOH, —$(CH_2)_m$COOCi-C_6-alkyl;

Het denotes a divalent monocyclic or fused bicyclic unsaturated, saturated or aromatic heterocyclic group having 1 to 5 heteroatom independently selected from N, O, S and/or a group —C=0, which may be further substituted with 1 to 4 substituent selected from Hal, Ci-C_6-alkyl, —$(CH_2)_m$OCi-C_6-alkyl, CN, OH, N0 $_2$, CF_3, —$(CH_2)_m$COOH, —$(CH_2)_m$COOCi-C_6-alkyl;

Ar^1 denotes a monocyclic or bicyclic, aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, —CF_3, —OCF_3, —N0 $_2$, —CN, perfluoroalkyl, Hal, —CF_3, —OCF_3, —N0 $_2$, —CN, perfluoroalkyl, linear or branched Ci-C_6-alkyl, cycloalkyl, —OH, —OCi-C_6-alkyl, —COCi-Ce-alkyl, —NH_2, —COH, —COOH, —$CONH_2$, a group R^b such as —$CH_2$0(Ci-Ce-alkyl), —S0 $_2$NR^aR^b or S0 $_2$(Ci-C_6alkyl);


Het^1 denotes a monocyclic or bicyclic (fused, bridged or spiro) saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 heteroatom independently selected from N, O, S and/or a CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, —CF_3, —OCF_3, —NO?, —CN, perfluoroalkyl, linear or branched Ci-C_6-alkyl, C_3-Cx-cycloalkyl, —OH, —OCi-C_6-alkyl, —NH_2, —N(Ci-C_6-alkyl)$_2$, —COH, —COOH, —$CONH_2$, —COCi-C_6-alkyl, —NHCO(C_3-C_6cycloalkyl), a group R^b—S0 $_2$NR^aR^b or S0 $_2$(Ci-C_6alkyl);

Het^b denotes a monocyclic or bicyclic (fused or spiro) saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 heteroatom independently selected from N, O, S and/or a CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, —CF_3, —OCF_3, —$N0_2$, —CN, perfluoroalkyl, —OH, —OCi-Ce-alkyl, —NH_2, —COH, —COOH, —$CONH_2$, or by a linear or branched Ci-C_6-alkyl wherein 1to 3 hydrogen atoms may be replaced by NH_2, N(Ci-C_6-alkyl)$_2$, NH(Ci-C_6-alkyl), N(Ci-C_6-alkyl)(C_3-C_8-cycloalkyl), NH(C_3-C_8-cycloalkyl), 0(Ci-C_6-alkyl), CN, OH, CF_3, Hal, C_3-C_8-cycloalkyl, or by a 4 to 8-membered heterocyclic ring containing an heteroatom selected from O, S and N;

Ar^b denotes a monocyclic or bicyclic, aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, —CF_3, —OCF_3, —$N0_2$, —CN, perfluoroalkyl, Hal, —CF_3, —OCF_3, —$N0_2$, —CN, perfluoroalkyl, —OH, —OCi-C_6-alkyl, —NH_2, —COH, —COOH, —$CONH_2$, or by a linear or branched Ci-C_6-alkyl wherein 1 to 3 hydrogen atoms may be replaced by NH_2, N(Ci-C_6-alkyl)$_2$, NH(Ci-C_6-alkyl), N(Ci-C_6-alkyl)(C_3-C_8-cydoalkyl), NH(C_3-C_8-cycloalkyl), 0(Ci-C_6-alkyl), CN, OH, CF_3, Hal, C_3-C_8-cycloalkyl, or by a 4 to 8-membered heterocyclic ring containing an heteroatom selected from O, S and N;

Cyc denotes a saturated or unsaturated carbocyclic ring having 3 to 8 carbon atoms, preferrably 5 or 6 carbon atoms, wherein 1 to 5 H atoms are replaced by Hal, —CF_3, —OCF_3, —NO?, —CN, perfluoroalkyl, Hal, —CF_3, —OCF_3, —NO?, —CN, perfluoroalkyl, linear or branched Ci-C_6-alkyl, cycloalkyl, —OH, —OCi-C_6-alkyl, —COCi-C_6-alkyl, —NH_2, —COH, —COOH, —CONHi, a group R^b such as —$CH_2$0(Ci-C_6-alkyl), —$S0_2NR^aR^b$ or $S0_2$(Ci-C_6alkyl); or

(if)



I-kkk-1

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is aryl, heteroaryl, heterocyclyl or (C_{1-6} alkyl)R^6, wherein said aryl, heteroaryl, and heterocyclyl groups are optionally substituted with one or two substituents selected from the group consisting of halo, cyano, R^4, C3-8 cycloalkyl, C_{1-3} aminoalkyl, Ci-3hydroxyalkyl, OR^4, NR^4R^5, NR^4COR^6, $NR^4SO_2R^6$, $SO_2NR^4R^5$, $CONR^4R^5$and $CONR^4R^5$;

R^2 is aryl, heteroaryl, C3-8 cycloalkyl, heterocyclyl or (C_{1-6} alkyl)R^6, wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl groups are optionally substituted with one or two substituents selected from the group consisting of halo, cyano, oxo, hydroxyl, imino, hydroxyimino, R^4, OR^4, $O(C_{3-8}$ cycloalkyl), $(C=O)OR^4$, SO_mR^6, SO_mR^4, NR^4R^5, $SO_2NR^4R^5$ and $NR^4SO_2R^6$;

R^3 is halo, cyano, oxo, hydroxyl, imino, hydroxyimino, R^4, OR^4, C3-8cycloalkyl, SO_mR^6, $SO_mR^4NR^4R^5$ or $(C=O)NR^4R^5$, $NR^4(CO)R^6$, $SO_mNR^4R^5$ and $NR^4SO_2R^6$;


R^4 is hydrogen or C_{1-6} alkyl, wherein said alkyl is optionally substituted with one to three halo or hydroxyl;

R^5 is hydrogen or C_{1-6} alkyl, wherein said alkyl is optionally substituted with halo or hydroxyl;

R^6 is aryl, heteroaryl, C3-8 cycloalkyl or heterocyclyl;

m is an integer from zero to two; or

(gg)



1-111-1

or a pharmaceutically acceptable salt thereof, wherein:

X is —N= or —CH=;

Y is selected from the group consisting of —NR^2—, —CH_2—, —CHR— and —O—, such that when Y is —CHR—, R and R^3 together with the carbon to which they are attached optionally form a 4- to 6-membered cycloalkyl, cycloalkenyl or heterocyclic ring, wherein the 4- to 6-membered cycloalkyl, cycloalkenyl, or heterocyclic ring is optionally substituted with one to three substituents independently selected from the group consisting of Ci-$_4$ alkyl, C_{3-6} cycloalkyl, phenyl, CF_3, heterocyclyl, halogen, —$COOR^8$, —NHR^8, —SR^8, —OR^8, —SO_2R^8, —COR^8, —$NHCOR^8$, and —$CONHR^8$; or when Y is —NR^2—, R^2 and R^3 together with the nitrogen to which they are attached optionally form a 4- to 6-membered heterocyclic ring, wherein the 4- to 6-membered heterocyclic ring is optionally substituted with one to three substituents independently selected from the group consisting of C_{1-4} alkyl, C_{3-6} cycloalkyl, phenyl, CF_3, heterocyclyl, halogen, —$COOR^8$, —NHR^8, —SR^8, —OR^8, —SO_2R^8, —COR^8, —$NHCOR^8$, and —$CONHR^8$;

R^1 is selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{3-8} cycloalkyl, aryl, heterocyclyl, halogen, —$COOR^7$, —NHR^7, —SR^7, —OR^7, —SO_2R^7, —COR^7, —$NHCOR^7$, and —$CONHR^7$; wherein said alkyl, cycloalkyl, aryl and heterocyclyl are optionally substituted with one to three substituents independently selected from the group consisting of Ci-$_4$ alkyl, C_{3-6} cycloalkyl, CN, phenyl, CF_3, heterocyclyl, halogen, —$COOR^8$, —NHR^8, —SR^8, —OR^8, —SO_2R^8, —COR^8, —$NHCOR^8$, and —$CONHR^s$, wherein said —NHR^8 is optionally substituted with —N(Ci-$_4$alkyl)NH_2 or —N(C3-$_6$ cycloalkyl)NH2;

R_2 is selected from the group consisting of hydrogen, Ci-io alkyl, and C_{3-8} cycloalkyl;


R_3 is selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{3-8}cycloalkyl, aryl, heterocyclyl, and —$COOR^7$; wherein said alkyl, cycloalkyl, aryl and heterocyclyl are optionally substituted with one to three substituents independently selected from the group consisting of C_{1-4} alkyl, C_{3-6} cycloalkyl, phenyl, CF_3, heterocyclyl, halogen, —$COOR^8$, —NHR^8, —SR^8, —OR^8, —SO_2R^8, —COR^8, —$NHCOR^8$, and —$CONHR^8$;

R_6 is selected from the group consisting of C_{1-10} alkyl, C_{3-8} cycloalkyl, aryl, heterocyclyl, —$COOR^7$, —SO_2R^7, and —COR^7; wherein said alkyl, cycloalkyl, aryl and heterocyclyl are optionally substituted with one to three substituents independently selected from the group consisting of C_{1-4} alkyl, C_{3-6} cycloalkyl, phenyl, CF_3, heterocyclyl, halogen, —$COOR^8$, —NHR^8, —SR^8, —OR^8, —SO_2R^8, —COR^8, —$NHCOR^8$, and —$CONHR^8$;

R_7 is selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{3-8}cycloalkyl, aryl, and heteroaryl; wherein said alkyl, cycloalkyl, aryl and heterocyclyl are optionally substituted with one to three substituents independently selected from the group consisting of C_{1-4} alkyl, C_{3-6}cycloalkyl, phenyl, CF_3, heterocyclyl, halogen, —$COOR^8$, —NHR^8, —SR^8, —OR^8, —SO_2R^8, —COR^8, —$NHCOR^8$, and —$CONHR^8$; and

R_8 is selected from the group consisting of hydrogen, C_{1-6} alkyl and C_{3-6} cycloalkyl; or

(hh)



I-mmm-1

or a pharmaceutically acceptable salt thereof, wherein:

X is independently CH or N;

Y is H or methyl;

a is 0 or 1; b is 0 or 1; m is 0, 1 or 2; n is 0, 1, 2, 3 or 4;

Ring A is (C3-C8)cycloalkenyl, aryl or heterocycle optionally substituted with one to three substituents independently selected from Ri;

Ri is selected from: H, oxo, (C=0) $_a$O$_b$(Ci-Cio)alkyl, (C=0) $_a$0 $_b$-aryl, (C=0) $_a$O$_b$(C$_2$-Cio)alkenyl, (C=0) $_a$O$_b$(C$_2$-Cio)alkynyl, C0 $_2$H, halo, OH, O$_b$(Ci-C$_6$)fluoroalkyl, (C=0) $_a$NR$_5$R$_6$, CN, (C=0) $_a$0 $_b$(C$_3$-C$_8$)cycloalkyl, S(0) $_m$NR$_5$R$_6$, SH, S(0) $_m$— (Ci-Cio)alkyl and (C=0) $_a$0 $_b$-heterocyclyl, said alkyl, aryl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are optionally substituted with one or more substituents selected from R$_a$;

R$_2$ and R$_3$ are independently selected from: H, (C=0) $_a$O$_b$Ci-Cio alkyl, (C=0) $_a$0 $_b$aryl, C$_2$-Cio alkenyl, C$_2$-Cio alkynyl, (C=0) $_a$0 $_b$ heterocyclyl, C0 $_2$H, CN, O$_b$Ci-C$_6$fluoroalkyl, 0 $_a$(C=0)bNR $_5$R$_6$, CHO, (N=0)R $_5$R$_6$, S(0) $_m$NR$_5$R$_6$, SH, S(0) $_m$— (Ci-Cio)alkyl, (C=0) $_a$0 $_b$C$_3$-Cx cycloalkyl, optionally substituted with one or more substituents selected from Ri; or R$_2$ and R$_3$ can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 3-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from Ri;


R$_4$ is independently selected from: (Ci-C$_6$)alkyl, OH, methoxy, CF$_3$ and F, said alkyl optionally substituted with OH;

R$_5$ and R$_6$ are independently selected from H, (C=0) $_a$O$_b$(Ci-Cio)alkyl, (C=0) $_a$0 $_b$-aryl, (C=0) $_a$O$_b$(C$_2$-Cio)alkenyl, (C=0) $_a$O$_b$(C$_2$-Cio)alkynyl, C0 $_2$H, O$_b$(Ci-C$_6$)fluoroalkyl, (0=0) $_a$N(R$_a$)$_2$, CN, (C=0) $_a$0 $_b$(C$_3$-C$_8$)cycloalkyl, S(0) $_m$N(R$_a$)$_2$, SH, S(0) $_m$— (Ci-Cio)alkyl and (C=0) $_a$O$_b$-heterocyclyl, said alkyl, aryl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are optionally substituted with one or more substituents selected from R$_a$;

R$_a$ is independently selected from R$_b$, OH, (Ci-C$_6$)alkoxy, halogen, cyclopropyl, C0 $_2$H, CN, O$_a$(C=0) $_b$(Ci-C$_6$)alkyl, oxo, and N(R$_b$)$_2$; and

R$_b$ is independently selected from H and (Ci-C$_6$)alkyl; or

(ii)



I-nnn-1

or a pharmaceutically acceptable salt thereof, wherein:

X is CH or N;

a is 0 or 1; b is 0 or 1; m is 0, 1 or 2;

Ring A is (C3-C8)cycloalkyl, (C_3-C_8)cycloalkenyl, aryl or heterocycle optionally substituted with one to three substituents independently selected from Ri;

Ri is selected from: H, oxo, (C=0) $_aO_b$(Ci-Cio)alkyl, (C=0) $_a0_b$-aryl, (C=0) $_aO_b$(C_2-Cio)alkenyl, (C=0) $_aO_b$(C_2-Cio)alkynyl, C0 $_2$H, halo, OH, O_b(Ci-C_6)fluoroalkyl, (C=0) $_aNR_5R_6$, CN, (C=0) $_a0_b$(C_3-C_8)cycloalkyl, S(0) $_mNR_5R_6$, SH, S(0) $_m$— (Ci-Cio)alkyl and (C=0) $_a0_b$-heterocyclyl, said alkyl, aryl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are optionally substituted with one or more substituents selected from R_a;

R_2 and R_3 are independently selected from: H, (C=0) $_aO_b$Ci-Cio alkyl, (C=0) $_a0_b$aryl, C_2-Cio alkenyl, C_2-Cio alkynyl, (C=0) $_a0_b$ heterocyclyl, C0 $_2$H, CN, O_bCi-C_6 fluoroalkyl, 0 $_a$(C=0)bNR $_5R_6$, CHO, (N=0)R $_5R_6$, S(0) $_mNR_5R_6$, SH, S(0) $_m$— (Ci-Cio)alkyl, (C=0) $_a0_bC_3$-Cx cycloalkyl, optionally substituted with one or more substituents selected from Ri; or R_2 and R_3 can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 3-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from Ri;


R_4 is selected from: (Ci-C_6)alkyl and (C_3-C_6)cycloalkyl, optionally substituted with R_a;

R_5 and R_6 are independently selected from: H, oxo, (C=0) $_aO_b$(Ci-Cio)alkyl, (C=0) $_a0_b$-aryl, (C=0) $_aO_b$(C_2-Cio)alkenyl, (C=0) $_aO_b$(C_2-Cio)alkynyl, C0 $_2$H, O_b(Ci-C_6)fluoroalkyl, (C=0) $_aN(R_a)_2$, CN, (C=0) $_a0_b$(C_3-C_8)cycloalkyl, S(0) $_mN(R_a)_2$, SH, S(0) $_m$— (Ci-Cio)alkyl and (C=0) $_aO_b$-heterocyclyl, said alkyl, aryl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are optionally substituted with one or more substituents selected from R_a;

R_a is independently selected from R_b, OH, (Ci-C_6)alkoxy, halogen, cyclopropyl, C0 $_2$H, CN, O_a(C=0) $_b$(Ci-C_6)alkyl, oxo, and $N(R_b)_2$; and


R_b is independently selected from H and (Ci-C_6)alkyl; or

Gj)



I-ooo-l

or a pharmaceutically acceptable salt thereof, wherein:

Z denotes a group  ; wherein

X is CH or N;

Y is CH or N;

Ra, Rc, R1 denote each independently H, Hal or Al;


Rb is H or alkyl;

Al is branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, such as 1 to 7, H atoms may be replaced by Hal, ORb, COORb, CN or $N(Rb)_2$ and wherein one or more,

preferably 1 to 5 CH_2-groups may be replaced by O, CO, NRb or S, SO, SO_2, 1,2-, 1,3- or 1,4-phenylen, —CH=CH— or —C≡C—; and

Hal denotes F, Cl, Br, I; or

(kk)



I-ppp-1

or a pharmaceutically acceptable salt thereof, wherein:

Rl, R3 denote each, independently of one another H, $(CH_2)_pCON(R5)_2$, OA, Hal, COOH, COOA, $(CH_2)_pNHCOA$, $(CH_2)_pHetl$, $(CH_2)_pNR2R5$, or OH;

R2 denotes H or linear or branched alkyl with 1, 2 or 3 C atoms, wherein one or two H atoms of the alkyl group are optionally replaced by OR6, NR5R6, NHCOR5, CONR5R6;

R4 denotes H or A;

R5 denotes H or linear or branched alkyl with 1, 2 or 3 C atoms;

R6 denotes H or linear or branched alkyl with 1, 2 or 3 C atoms;

Z is absent or denotes Ar-diyl or Het-diyl;

L denotes $(CH_2)_n$ wherein one or two CH_2 groups are optionally replaced by O and/or a CH=CH-group, and/or wherein one or two H atoms are optionally replaced by OR2, NR2R5 or Hetl;

Ar-diyl denotes 1,2-, 1,3- or l,4-phenylen optionally substituted with from 1 to 5 groups independently selected from the group consisting of Hal, CN, —CF_3, —OCF_3, OH, O-A, SO_2-A, COOH, COOA, —CO-A, O-phenyl, SO_2-phenyl, SO_2— CF3, Het2 and A;

Het-diyl denotes an unsaturated, saturated or aromatic 5- or 6-membered heterocycle comprising 1 to 2 N, O and/or S atoms, which are optionally unsubstituted or mono-, di- or trisubstituted by Hal, CN, —CF_3, —OCF_3, O-A, $S0_2$-A, COOH, COOA, —CO-A, O-phenyl, SCh-phenyl, $S0_2$— CF_3, Het2 and/or A;

A denotes an unbranched or branched alkyl comprising 1 to 10 C atoms, in which 1 to 5 H atoms are optionally replaced by F and/or in which one or two non-adjacent CH_2 groups are optionally replaced by O;

Hetl denotes morpholinyl, piperidinyl or pyrrolidinyl;


Het2 denotes morpholinyl, piperidinyl or pyrrolidinyl;

Hal denotes F, Cl, Br, I;

n denotes 1, 2, 3, 4, 5 or 6;

p denotes 0, 1 or 2; or

(H)



I-qqq-1


or a pharmaceutically acceptable salt thereof, wherein:

Ring A is a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

n is 0-4;

each R^1 is independently —R, halogen, —CN, —NO?, —OR, —CH_2OR, —SR, —$N(R)_2$, —$S0_2$R, —$S0_2N(R)_2$, —SOR, —C(0)R, —COiR, —$C(0)N(R)_2$, —C(0)N(R)— OR, —

NRC(0)R, —NRC(0)N(R) $_{2,}$ Cy, or —NRSO2R; or R^1 is selected from one of the following formulas:



or two R^1 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each Cy is an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R is independently hydrogen or an optionally substituted group selected from Ci_{-6} aliphatic, aryl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or:


two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, or sulfur;

R^z is —R, —CN, —NO2, halogen, —C(0)N(R) $_2$, —C(0)0R, —C(0)R, —N(R) $_2$, —OR, or —S0 ^{2}N(R) $_2$;

Ring B is an unsubstituted 4-8 membered partially unsaturated carbocyclic fused ring; and

L is a Ci_{-6} bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —NR—, —N(R)C(0) —, —C(0)N(R) —, —N(R)S0 $_{2}$— , —S0 $_2$N(R)—, —O—, —C(O)—, —OC(O)—, —C(0)0— , —s—, —so— or —S0 $_{2}$— ; or

(mm)




I-rrr-1

or a pharmaceutically acceptable salt thereof, wherein:

Ring A is a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

n is 0-4;

each R^1 is independently —R, halogen, —CN, —NO_2, —OR, —CH_2OR, —SR, —$N(R)_2$, —SO_2R, —$SO_2N(R)_2$, —SOR, —C(O)R, —CO_2R, —C(O)$N(R)_2$, —C(O)N(R)—OR, —NRC(O)OR, —NRC(O)$N(R)_2$, Cy, or —NRSO?R; or R^1 is selected from one of the following formulas:



or two R^1 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each Cy is an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2

heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or:

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, or sulfur;

Ring B is a cyclopento or cyclohexo fused ring;

m is 1-2;

p is 0-2;

W is N;

R^z is R, CN, NO_2, halogen, —C(O)N(R)$_2$, —C(O)OR, —C(O)R, —N(R)C(O)OR, —NRC(O)N(R)$_2$, —OR, or —SO_2N(R)$_2$;


L^1 is a covalent bond or a C_{1-6} bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —NR—, —N(R)C(O)—, —C(O)N(R)—, —N(R)SO_2—, —SO_2N(R)—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —SO— or —SO_2—;

each L^2 is independently a covalent bond or a C_{1-6} bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —NR—, —N(R)C(O)—, —C(O)N(R)—, —N(R)SO_2—, —SO_2N(R)—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —SO— or —SO_2—;

each R^4 is independently halogen, —CN, —NO?, —OR, —SR, —N(R)$_2$, —SO_2R, —SO_2N(R)$_2$, —SOR, —C(O)R, —CO_2R, —C(O)N(R)$_2$, —NRC(O)R, —NRC(O)N(R)$_2$, —C(O)N(R)OR, —N(R)C(O)OR, —N(R)S(O)$_2$N(R)$_2$, —NRSO_2R, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or:

two -L^2(R^4)$_p$—R^4 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or

(nn)




I-sss-1

or a pharmaceutically acceptable salt thereof, wherein:

Ring A is a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

n is 0-4;

each R^1 is independently —R, halogen, —CN, —NO$_2$, —OR, —CH$_2$OR, —SR, —N(R)$_2$, —S(O)$_2$R, —S(O)$_2$N(R)$_2$, —SOR, —C(O)R, —CO$_2$R, —C(O)N(R)$_2$, —C(O)N(R)—OR, —N(R)C(O)R, —N(R)C(O)OR, —N(R)C(O)N(R)$_2$, Cy, or —N(R)S(O)$_2$R, or R^1 is selected from one of the following formulas:



or two R^1 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each Cy is an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each R is independently hydrogen, or an optionally substituted group selected from C$_{1-6}$ aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2

heteroatoms independently selected from nitrogen, oxygen, and sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur;

Ring B is selected from a benzo fused ring and a 5-6 membered heteroaromatic fused ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said Ring B may be optionally substituted by one or more oxo, thiono, or imino groups;

m is 0-4;

p is 0-2;

W is N or —C(R^3)—;

R^z is R, CN, N0$_2$, halogen, —C(0)N(R)$_2$, —C(0)OR, —C(0)R, —N(R)$_2$, —N(R)C(0)OR, —N(R)C(0)N(R)$_2$, —OR, or —S(0)$_2$N(R)$_2$;

R^3 is hydrogen, halogen, —CN, Ci-$_4$ aliphatic, Ci-$_4$ haloaliphatic, —OR, —C(0)R, or —C(0)N(R)$_2$;


L^1 is a covalent bond or a Ci$_{-6}$ bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(0)—, —C(0)N(R)—, —N(R)S(0)$_2$—, —S(0)$_2$N(R)—, —O—, —C(O)—, —OC(O)—, —C(0)0—, —S—, —S(O)— or —S(0)$_2$—;

each L^2 is independently a covalent bond or a Ci$_{-6}$ bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(0)—, —C(0)N(R)—, —N(R)S(0)$_2$—, —S(0)$_2$N(R)—, —O—, —C(O)—, —OC(O)—, —C(0)0—, —S—, —S(O)— or —S(0)$_2$—; and

each R^4 is independently halogen, —CN, —NO?, —OR, —SR, —N(R)$_2$, —S(0)$_2$R, —S(0)$_2$N(R)$_2$, —S(0)R, —C(0)R, —C0$_2$R, —C(0)N(R)$_2$, —N(R)C(0)R, —N(R)C(0)N(R)$_2$, —C(0)N(R)OR, —N(R)C(0)OR, —N(R)S(0)$_2$N(R)$_2$, —N(R)S(0)$_2$R, or an optionally substituted group selected from Ci$_{-6}$ aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two -$L^2(R^4)_p$— R^4 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or

(oo)




I-ttt-1

or a pharmaceutically acceptable salt thereof, wherein:

Ring A is a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

n is 0-4;

each R^1 is independently —R, halogen, —CN, —NO_2, —OR, —CH_2OR, —SR, —$N(R)_2$, —$S(O)_2R$, —$S(O)_2N(R)_2$, —S(O)R, —C(O)R, —C(O)OR, —C(O)N(R)— C(O)N(R)—OR, —N(R)C(O)R, —N(R)C(O)OR, —N(R)C(O)$N(R)_2$, Cy, or —N(R)$S(O)_2R$; or R^1 is selected from one of the following formulas:



two R^1 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each Cy is an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated

heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each R is independently hydrogen, or an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur;

Ring B is selected from a 4-8 membered partially unsaturated carbocyclic fused ring and a 4-7 membered partially unsaturated heterocyclic fused ring having 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur; wherein said Ring B may be optionally substituted by one or more oxo, thiono, or imino groups;

m is 0-4;

p is 0-2;

R^z is —R, —CN, —$N0_2$, halogen, —$C(0)N(R)_2$, —C(0)OR, —C(0)R, —$N(R)_2$, —N(R)C(0)OR, —N(R)C(0)$N(R)_2$, —OR, or —$S(0)_2N(R)_2$;

R^3 is hydrogen, halogen, —CN, Ci_{-4} aliphatic, Ci_{-4} haloaliphatic, —OR, —C(0)R, or —$C(0)N(R)_2$;

L^1 is a covalent bond or a Ci_{-6} bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(0)—, —C(0)N(R)—, —N(R)$S(0)_{2}$—, —$S(0)_2N(R)$—, —O—, —C(O)—, —OC(O)—, —C(0)0—, —S—, —S(O)— or —$S(0)_{2}$—;


each L^2 is independently a covalent bond or a Ci_{-6} bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(0)—, —C(0)N(R)—, —N(R)$S(0)_{2}$—, —$S(0)_2N(R)$—, —O—, —C(O)—, —OC(O)—, —C(0)0—, —S—, —S(O)— or —$S(0)_{2}$—; and

each R^4 is independently halogen, —CN, —NO?, —OR, —SR, —$N(R)_2$, —$S(0)_2R$, —$S(0)_2N(R)_2$, —S(0)R, —C(0)R, —C(0)OR, —C(0)$N(R)_2$, —N(R)C(0)R, —N(R)C(0)$N(R)_2$, —C(0)N(R)OR, —N(R)C(0)OR, —N(R)$S(0)_2N(R)_2$, —N(R)$S(0)_2$R,

or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or

two $-L^2(R^4)_p-R^4$ groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or

(PP)




I-uuu-1

or a pharmaceutically acceptable salt thereof, wherein:

Ring A is a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

n is 0-4;

each R^1 is independently —R, halogen, —CN, —NO$_2$, —OR, —CH_2OR, —SR, —$N(R)_2$, —$S(O)_2R$, —$S(O)_2N(R)_2$, —S(O)R, —C(O)R, —C(O)OR, —C(O)N(R)—OR, —C(O)N(R)—C(O)N(R), —N(R)C(O)R, —N(R)C(O)OR, —N(R)C(O)$N(R)_2$, Cy, or —N(R)$S(O)_2R$; or R^1 is selected from one of the following formulas:




or two R^1 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each Cy is an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each R is independently hydrogen, or an optionally substituted group selected from Ci_{-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur;

each of R^x and R^y is independently —R, halogen, —CN, —$N0_2$, —OR, —SR, —$N(R)_2$, —$S(0)_2R$, —$S(0)_2N(R)_2$, —S(0)R, —C(0)R, —C(0)0R, —$C(0)N(R)_2$, —N(R)C(0)R, —N(R)C(0)$N(R)_2$, or —N(R)$S(0)_2R$, or:

R^x and R^y are taken together with their intervening atoms to form Ring B substituted with m occurrences of  ;

Ring B is selected from a benzo fused ring, a 4-8 membered partially unsaturated carbocyclic fused ring, a 4-8 membered partially unsaturated heterocyclic fused ring having one or two heteroatoms independently selected from nitrogen oxygen and sulfur, and a 5-6 membered heteroaromatic fused ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said Ring B may be optionally substituted by one or more oxo, thiono, or imino groups;

m is 0-4;

p is 0-2;

Q is —O— or —N(R)—

W is N or —C(R^3)—;

R^z is —R, —CN, —NO2, halogen, —C(0)N(R)$_2$, —C(0)0R, —C(0)R, —N(R)$_2$, —N(R)C(0)0R, —N(R)C(0)N(R)$_2$, —OR, or —S(0)$_2$N(R)$_2$;

R^3 is hydrogen, halogen, —CN, C_{i-4} aliphatic, C_{1-4} haloaliphatic, —OR, —C(0)R, or —C(0)N(R)$_2$;


L^1 is a covalent bond or a C_{i-6} bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(0) —, —C(0)N(R) —, —N(R)S(0)$_{2-}$, —S(0)$_2$N(R)—, —O—, —C(O)—, —OC(O)—, —C(0)0— , —S—, —S(O)— or —S(0)$_{2-}$;

each L^2 is independently a covalent bond or a C_{i-6} bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(0) —, —C(0)N(R)— , —N(R)S(0)$_{2-}$, —S(0)$_2$N(R)—, —O—, —C(O)—, —OC(O)—, —C(0)0— , —S—, —S(O)— or —S(0)$_{2-}$; and

each R^4 is independently halogen, —CN, —NO?, —OR, —SR, —N(R)$_2$, —S(0)$_2$R, —S(0)$_2$N(R)$_2$, —S(0)R, —C(0)R, —C(0)0R, —C(0)N(R)$_2$, —N(R)C(0)R, —N(R)C(0)N(R)$_2$, —C(0)N(R)0R, —N(R)C(0)0R, —N(R)S(0)$_2$N(R)$_2$, —N(R)S(0)$_2$R, or an optionally substituted group selected from C_{i-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or

two -L^2(R^4)$_{p-}$ R^4 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or

(qq)



I-vvv-1

or a pharmaceutically acceptable salt thereof, wherein:


Q is CH, C—CN, orN;

X is C-$L^2(R^4)_{p_}$ R^x and Y is N; or

X is N and Y is C—Rx;

Ring A is a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R^1 and $R^{1'}$ is independently —R^2, halogen, —CN, —$N0_2$, —OR, —SR, —$N(R)_2$, —$S(0)_2R$, —$S(0)_2N(R)_2$, —S(0)R, —C(0)R, —C(0)0R, —C(0)N(R)¾ _ C(0)N(R)0R, —N(R)C(0)0R, —N(R)C(0)$N(R)_2$, Cy, or —N(R)S(0)?R; or R^1 is selected from one of the following formulas:



or two R^1 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each Cy is an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-10 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or:

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, or sulfur;

each R^2 is independently an optionally substituted group selected from C_{1-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R^4 is independently halogen, —CN, —NO_2, —OR, —SR, —$N(R)_2$, —$S(O)_2R$, —$S(O)_2N(R)_2$, —S(O)R, —C(O)R, —C(O)OR, —$C(O)N(R)_2$, —N(R)C(O)R, —$N(R)C(O)N(R)_2$, —C(O)N(R)OR, —N(R)C(O)OR, —$N(R)S(O)_2N(R)_2$, —$N(R)S(O)_2R$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

R^x is hydrogen, —R^2, —CN, —NO_2, halogen, —$C(O)N(R)_2$, —C(O)OR, —C(O)R, —$N(R)_2$, —NH[Ar], —OR, or —$S(O)_2N(R)_2$;

R^z is hydrogen, —R^2, —CN, —NO_2, halogen, —$C(O)N(R)_2$, —C(O)OR, —C(O)R, —$N(R)_2$, —NH[Ar], —OR, or —$S(O)_2N(R)_2$;

[Ar] is a phenyl or heteroaromatic ring substituted by m instances of $R^{1'}$;

L^1 is a covalent bond or a C_{1-6} bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(O)—, —C(O)N(R)—, —N(R)$S(O)_2$—, —$S(O)_2$N(R)—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —S(O)— or —$S(O)_2$—;

L^2 is a covalent bond or a C_{1-6} bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(O)—, —


C(0)N(R)—, —N(R)S(0)$_2$—, —S(0)$_2$N(R)—, —O—, —C(O)—, —OC(O)—, —C(0)0— , —S—, —S(O)— or —S(0)$_2$—;

m is 0-4;

n is 0-4; and

p is 0-2; or

(rr)




I-www-1

or a pharmaceutically acceptable salt thereof, wherein:

Q is =N— or =CH—;

Ring A is a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R^1 is independently —R^2, halogen, —CN, —N0$_2$, —OR, —SR, —NR_2, —S(0)$_2$R, —S(0)$_2$NR_2, —S(0)R, —C(0)R, —C(0)0R, —C(0)NR_2, —C(0)N(R)0R, —N(R)C(0)0R, —N(R)C(0)NR_2, Cy, or —N(R)S(0)?R; or R^1 is selected from one of the following formulas:



or two R^1 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each Cy is independently an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-10 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or:

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, or sulfur;

each R^2 is independently an optionally substituted group selected from C_{1-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each of R^5 and R^6 is independently hydrogen or $-L^2(R^4)_p R^x$; or

R^5 and R^6 are taken together with their intervening atoms to form a 4-7 membered partially unsaturated, or aromatic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R^4 is independently halogen, —CN, $—NO_2$, —OR, —SR, $—NR_2$, $—S(O)_2R$, $—S(O)_2NR_2$, —S(O)R, —C(O)R, —C(O)OR, $—C(O)NR_2$, —N(R)C(O)R, $—N(R)C(O)NR_2$, —C(O)N(R)OR, —N(R)C(O)OR, $—N(R)S(O)_2NR_2$, $—N(R)S(O)_2R$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

R^x is hydrogen, $—R^2$, —CN, $—NO_2$, halogen, $—C(O)NR_2$, —C(O)OR, —C(O)R, $—NR_2$, —NH[Ar], —OR, or $—S(O)_2NR_2$;

R^z is hydrogen, $—R^2$, —CN, $—NO_2$, halogen, $—C(O)NR_2$, —C(O)OR, —C(O)R, $—NR_2$, —NH[Ar], —OR, or $—S(O)_2NR_2$;

[Ar] is an optionally substituted phenyl or an optionally substituted 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

L^1 is a covalent bond or a C_{i-6} bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(0) —, —C(0)N(R) —, —N(R)S(0) $_{2}$—, —S(0) $_{2}$N(R)—, —O—, —C(O)—, —OC(O)—, —C(0)0— , —S—, —S(O)— or —S(0) $_{2}$— ;


L^2 is a covalent bond or a C_{i-6} bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(0) —, —C(0)N(R) —, —N(R)S(0) $_{2}$—, —S(0) $_{2}$N(R)—, —O—, —C(O)—, —OC(O)—, —C(0)0— , —S—, —S(O)— or —S(0) $_{2}$— ;

m is 0-4;

n is 0-4; and

p is 0-2; or

(ss)



I-xxx-1

or a pharmaceutically acceptable salt thereof, wherein:

X and X' are each independently CR^8, N or —N^+—CT; Y is independently N, —N^+—O^- or $CR^{8'}$; provided that at least one of X, X' or Y is neither N nor —N^+—CT and that no more than one of X, X' or Y is —N^+—CT;

R^1 is Ci-C_6alkyl; C2-C_6alkenyl; C2-C_6alkynyl; —$(CR^{3a}R^{3b})_m$-(3- to 7-membered cycloalkyl); —$(CR^{3a}R^{3b})_m$-(3- to 7-membered heterocycloalkyl) having one to three heteroatoms; —$(CR^{3a}R^{3b})_m$-(5- to lO-membered heteroaryl), having one to three heteroatoms; or —$(CR^{3a}R^{3b})_m$— C_6-Ci2aryl; wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl or aryl is optionally substituted with one to five halogen,

deuterium, —OR^5, —SR^5, —$NR^{11a}R^{11b}$, cyano, Ci-C_6alkyl, C3-C_6cycloalkyl or —Ci-C_6alkoxy;

R^2 is —$(CR^{3a}R^{3b})_m$-(3- to lO-membered cycloalkyl); —$(CR^{3a}R^{3b})_m$-(3- to lO-membered heterocycloalkyl) having one to three heteroatoms; —$(CR^{3a}R^{3b})_m$-(5- to 10 membered heteroaryl) having one to three heteroatoms; or —$(CR^{3a}R^{3b})_m$—C_6-Ci2aryl; wherein said cycloalkyl, heterocycloalkyl, heteroaryl or aryl is optionally substituted with one to five R^4; and wherein, if the heteroatom on said heterocycloalkyl and heteroaryl is N, said N is optionally substituted with $R^{4'}$; or R^2 is Ci-C_6alkyl, wherein said alkyl is optionally substituted with NH_2, OH or cyano;

R^{3a} and R^{3b} for each occurrence are independently hydrogen or Ci-C_3alkyl;

R^4 for each occurrence is independently a bond, deuterium halogen, cyano, Ci-C_6alkyl, C_2-Cealkenyl, oxo, —OR^5, —SR^5, —$S(0)R^9$, —$S(0)_2R^9$, —$NR^{11a}R^{11b}$, —$C(0)R^{10}$, —$(CR^{3a}R^{3b})_n$-(3- to 7-membered cycloalkyl), —$(CR^{3a}R^{3b})_n$-(4- to lO-membered heterocycloalkyl), having one to three heteroatoms, —$(CR^{3a}R^{3b})_n$-(5- to 10 membered heteroaryl), having one to three heteroatoms, or —$(CR^{3a}R^{3b})_n$— C_6-Ci_2aryl wherein said alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or aryl is each optionally and independently substituted with one to five deuterium, halogen, OR^5, —SR^5, —$NR^{11a}R^{11b}$, cyano, Ci-C_6alkyl, C3-C_6cycloalkyl or —Ci-C_6alkoxy; or two R^4 taken together with the respective carbons to which each are bonded form a 3- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein said cycloalkyl or heterocycloalkyl is optionally substituted with one to three halogen, deuterium, —OR^5, —SR^5, —$NR^{11a}R^{11b}$, cyano or Ci-C_6alkyl or Ci-C_6alkoxy, wherein the alkyl or alkoxy is optionally substituted with halogen, deuterium, —OR^5, —SR^5, —$NR^{11a}R^{11b}$, or cyano; and wherein, if a heteroatom on said heterocycloalkyl is N, said N is optionally substituted with $R^{4'}$;

$R^{4'}$ is independently Ci-C_6alkyl, C_2-C_6alkenyl, —$C(0)R^{10}$, —$S(0)_2R^9$, —$(CR^{3a}R^{3b})_n$-(3- to 7-membered cycloalkyl), —$(CR^{3a}R^{3b})_n$-(4- to lO-membered heterocycloalkyl) or $C(0)(CH_2)_tCN$; wherein said alkyl, alkenyl, cycloalkyl, or heterocycloalkyl is each optionally and independently substituted with one to five deuterium, halogen, OH, cyano or Ci-C_6alkoxy; or R^4 and $R^{4'}$ taken together with the respective atoms to which each are bonded form a 3- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein said cycloalkyl or heterocycloalkyl is optionally substituted with one to three

halogen, deuterium, —OR^5, —SR^5, —$NR^{lla}R^{llb}$, cyano, Ci-C_6alkyl or Ci-C_6alkoxy, wherein the alkyl or alkoxy is optionally substituted with halogen, deuterium, —OR^5, —SR^5, —$NR^{lla}R^{llb}$, or cyano;

R^5 is independently hydrogen or Ci-C_6alkyl, wherein said alkyl is optionally substituted with halogen, deuterium, Ci-C_6alkoxy, Ci-C_6alkylthiolyl, —$NR^{lla}R^{llb}$, cyano, Ci-C_6alkyl or C3-C_6cycloalkyl; or two R^5 taken together with the oxygen atoms to which they are bonded form a 5- or 6-membered heterocycloalkyl;

R^6 is —C(0)NHR^7, $C0_2R^7$ or cyano;

R^7 is hydrogen or Ci-C_6alkyl;

each R^8 is independently hydrogen, halogen, cyano, —OR^5, —SR^5, —$NR^{lla}R^{llb}$, C_6alkyl, C_3-C_6cycloalkyl, 3- to lO-membered heterocycloalkyl or 5- to 6-membered heteroaryl or aryl, wherein said alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or aryl is optionally substituted with one to three halogen, —$NR^{lla}R^{llb}$, OR^5, —SR^5, cyano, C_1-C_3 alkyl, —$C(O)R^{10}$ or oxo;

$R^{8'}$ is hydrogen, deuterium, halogen, cyano, —OR^5, —SR^5 or $NR^{lla}R^{llb}$;

R^9 is —$(CR^{3a}R^{3b})_p$— (Ci-Csalkyl), —$(CR^{3a}R^{3b})_p$-(4- to 6-membered cycloalkyl), —$(CR^{3a}R^{3b})_p$-(4- to 6-membered heterocycloalkyl) or —$(CR^{3a}R^{3b})_p$— (C_5-C<;aryl), wherein said alkyl, cycloalkyl, heterocycloalkyl or aryl are each optionally substituted with fluoro or Ci-C_3alkyl;

R^{10} is Ci-C_6alkyl, wherein said alkyl is optionally substituted with deuterium, halogen, OH, Ci-C_6alkoxy or cyano;

R^{lla} and R^{llb} are each independently hydrogen or Ci-C_6alkyl, wherein said alkyl is optionally substituted with deuterium, Ci-C_6alkoxy or cyano; and if C2-C_6alkyl, said alkyl is optionally substituted with deuterium, Ci-C_6alkoxy, cyano, halogen or OH;


m is independently 0, 1, 2 or 3;

n is independently 0, 1, 2 or 3;


p is independently 0 or 1; and

t is 1, 2 or 3; or

(tt)



I-yyy-1



i-yyy-2

or a pharmaceutically acceptable salt thereof, wherein:

X is N or CH












m is 1 or 2;














Ar is optionally substituted aryl or optionally substituted heteroaryl;













R^1 is hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, hydroxyl, hydroxy-C_{1-6}alkyl, C_{1-6}alkyl-amino, amino-C_{1-6}alkyl, amino-Ci^alkyl-amino, hydroxy-Ci^alkylamino, C3-6cycloalkylamino, amino-C_{3-6}cycloalkylamino, amino-C3-6heterocycloalkylamino, aminocarbonyl, halo, hydroxy-C_{1-6}alkyl, or hydroxy-C_{1-6}alkoxy; and

R^2 is hydrogen or C_{1-6}alkyl.

11. The compound according to claim 9, wherein the IRAK4 binding moiety is selected from the group consisting of:














,

,

,

,

,

,

,

,

,

,

,
















,

,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,

,

,





,

,

,

,

,

,

,

,

,

,

,

,







,

,

,

,

,

,

,

,

,

,

,

,

,

,


,,


,

,

,

,

,

,

,

,

,

,

,

















,
















,

, and

.
















12. The compound according to claim 1, wherein L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-so hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -NR-, -S-, -OC(O)-, -C(0)0-, -C(O)-, -S(O)-, -S(0) $_2$-, -NRS(O)$_2$-, -S(O)$_2$NR-, -NRC(O)-, -C(O)NR-, -OC(O)NR-, –NRC(O)O-, 
,

,

,

, or

, wherein:




























each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroaryl enyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaryl enyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

13. The compound of claim 12, wherein L is selected from



,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



















,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



















,
















,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

.

,

,

,

,



















,



,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,













,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,









,



,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,




























,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,







,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,


,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




























,








,

























,




,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



























,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,





















,

,








,






,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

, and

.

14. The compound of claim 1, wherein said compound is selected from any one of the compounds depicted in **Table** 1, or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

16. The pharmaceutical composition according to claim 15, further comprising an additional therapeutic agent.

17. A method of degrading IRAK4 protein kinase in a patient or biological sample comprising administering to said patient, or contacting said biological sample with a compound according to claim 1, or a pharmaceutical composition thereof.

18. A method of treating an IRAK4-mediated disorder, disease, or condition in a patient comprising administering to said patient a compound according to claim 1, or a pharmaceutical composition thereof.

19. The method according to claim 18, further comprising administration of an additional therapeutic agent.

20. The method according to claim 18, wherein the IRAK4-mediated disorder, disease or condition is selected from a cancer, a neurodegenerative disease, a viral disease, an autoimmune disease, an inflammatory disorder, a hereditary disorder, a hormone-related disease, a metabolic disorder, a condition associated with organ transplantation, an immunodeficiency disorder, a destructive bone disorder, a proliferative disorder, an infectious disease, a condition associated with cell death, thrombin-induced platelet aggregation, liver disease, a pathologic immune condition involving T cell activation, a cardiovascular disorder, and a CNS disorder.

21. The method of claim 10, wherein the IRAK4-mediated disorder, disease or condition is selected from a MyD88 driven disorder.

22. The method of claim 21, wherein the MyD88 driven disorder is selected from ABC DLBCL, Waldenstrom's macroglobulinemia, Hodgkin's lymphoma, primary cutaneous T-cell lymphoma, and chronic lymphocytic leukemia.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2018/067304

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 39/395; A61K 47/64; A61K 47/68; C07K 16/00; C07K 16/18; C07K 16/28 (2019.01)
CPC - A61K 39/395; A61K 47/64; A61K 47/68; C07K 16/00; C07K 16/18; C07K 16/28 (2019.02)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2017/201449 A1 (GENENTECH, INC. et al) 23 November 2017 (23.11.2017) entire document	1-3, 7, 9-22
A	WO 2017/211924 A1 (GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED) 14 December 2017 (14.12.2017) entire document	1-3, 7, 9-22
A	US 2010/0279316 A1 (GORELIK et al) 04 November 2010 (04.11.2010) entire document	1-3, 7, 9-22

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
12 April 2019	30 APR 2019
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450 Facsimile No. 571-273-8300	Authorized officer Blaine R. Copenheaver PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2018/067304

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
See extra sheet(s).

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
1-3, 7, 9-22

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☒ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.

Continued from Box No. III Observations where unity of invention is lacking

Claims 1-3, 9, 10, 12, and 15-22 have been analyzed subject to the restriction that the claims read on a compound of formula I or a pharmaceutically acceptable salt thereof: wherein: IRAK is an IRAK binding moiety capable of binding one or more IRAK-1, -2, -3, or -4; L is a bivalent moiety that connects IRAK to LBM; and LBM is a ligase binding moiety, wherein LBM is a cereblon binding moiety, wherein the compound is of formula I-1', wherein X1 is a covalent bond, X2 is a carbon atom, X3 is –CH2-; R1 is hydrogen; Ring A is a bicyclic ring selected from the first structure shown in claim 3; wherein Ring B is a fused ring selected from 6-membered aryl containing 0 nitrogen atoms; R3 is hydrogen; L1 is a covalent bond; m is 0; L is a covalent bond; the IRAK binding moiety has the structure shown in formula I-dd-1; wherein A is unsubstituted heteroaryl, wherein the heteroaryl is pyrazolyl, wherein the pyrazolyl is attached to the amide carbon at the 4-position and attached to L at the 3-position; B is hydrogen; Q is absent; W is N; R1 is hydrogen; n is 1.

Claims 1-3, 7, and 9-22 have been analyzed subject to the restriction that the claims read on the formula I as described in the Response to the Invitation to Pay Additional Fees in the International Application dated 11 March 2019 as further restricted to the variable definitions listed below. The claims are restricted (as best interpreted) to a compound of formula I or a pharmaceutically acceptable salt thereof: wherein: IRAK is an IRAK binding moiety capable of binding one or more IRAK-1, -2, -3, -4; L is a bivalent moiety that connects IRAK to LBM; and LBM is a ligase binding moiety, wherein LBM is a cereblon binding moiety, wherein the compound is of I-1', wherein X1 is —C(O)-; X2 is a carbon atom; X3 is a —CH2-; R1 is hydrogen; Ring A is the structure shown; R2 is hydrogen; Ring B is a fused 6-membered aryl containing 0 nitrogen atoms; R4 is R6, wherein R6 is a C1 aliphatic group (methyl); m is 1; L is a bivalent, saturated, straight C11 hydrocarbon chain, wherein the C4 and C7 methylene units of L are replaced by —O- and the C10 methylene unit of L is replaced by —NR-, wherein R is hydrogen, wherein C1 of L is attached to the 4-position of Ring B; the IRAK binding moiety has the structure shown in formula I-aaa-1; wherein Ring A is a heteroaryl, wherein the heteroaryl is pyrazolyl, wherein the nitrogen of the amide group is attached to the pyrazolyl at the 4-position, wherein the carbonyl of the amide group is attached to the oxazole at the 4-position; R1 is a monocyclic heteroaryl substituted with one R10, wherein the heteroaryl is pyridine, wherein the oxazole is attached to the pyridine at the 4-position, wherein R10 is attached to the pyridine at the 2-position; R2 is —C(0)NH2; R3 is phenyl, wherein phenyl is attached at the 1-position of the pyrazolyl, wherein C11 of L is attached para to the pyrazolyl; R10 is a substituted amino, wherein the substituted amino is 2,2,2-trifluoroethylamino.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees need to be paid.

Group I+: claims 1-22 are drawn to compounds of formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, a method of degrading IRAK4 protein kinase in a patient, and methods of treating an IRAK4-mediated disorder, disease, or condition in a patient.

The first invention of Group I+ is restricted to a compound of formula I or a pharmaceutically acceptable salt thereof: wherein: IRAK is an IRAK binding moiety capable of binding one or more IRAK-1, -2, -3, or -4; L is a bivalent moiety that connects IRAK to LBM; and LBM is a ligase binding moiety, wherein LBM is a cereblon binding moiety, wherein the compound is of formula I-1', wherein X1 is a covalent bond, X2 is a carbon atom, X3 is –CH2-; R1 is hydrogen; Ring A is a bicyclic ring selected from the first structure shown in claim 3; wherein Ring B is a fused ring selected from 6-membered aryl containing 0 nitrogen atoms; R3 is hydrogen; L1 is a covalent bond; m is 0; L is a covalent bond; the IRAK binding moiety has the structure shown in formula I-dd-1; wherein A is unsubstituted heteroaryl, wherein the heteroaryl is pyrazolyl, wherein the pyrazolyl is attached to the amide carbon at the 4-position and attached to L at the 3-position; B is hydrogen; Q is absent; W is N; R1 is hydrogen; n is 1; pharmaceutical compositions thereof; and method of treating an IRAK4-mediated disorder, disease, or condition in a patient. It is believed that claims 1-3, 9, 10, 12, and 15-22 read on this first named invention and thus these claims will be searched without fee to the extent that they read on the above embodiment.

Applicant is invited to elect additional formula(e) for each additional compound to be searched in a specific combination by paying an additional fee for each set of election. Each additional elected formula(e) requires the selection of a single definition for each compound variable. An exemplary election would be a compound of formula I or a pharmaceutically acceptable salt thereof: wherein: IRAK is an IRAK binding moiety capable of binding one or more IRAK-1, -2, -3, or -4; L is a bivalent moiety that connects IRAK to LBM; and LBM is a ligase binding moiety, wherein LBM is a cereblon binding moiety, wherein the compound is of formula I-1', wherein X1 is a covalent bond, X2 is a carbon atom, X3 is –CH2-; R1 is hydrogen; Ring A is a bicyclic ring selected from the first structure shown in claim 3; wherein Ring B is a fused ring selected from 6-membered aryl containing 0 nitrogen atoms; R3 is hydrogen; L1 is a covalent bond; m is 0; L is a bivalent saturated C1 hydrocarbon chain; the IRAK binding moiety has the structure shown in formula I-dd-1; wherein A is unsubstituted heteroaryl, wherein the heteroaryl is pyrazolyl, wherein the pyrazolyl is attached to the amide carbon at the 4-position and attached to L at the 3-position; B is hydrogen; Q is absent; W is N; R1 is hydrogen; pharmaceutical compositions thereof; and method of treating an IRAK4-mediated disorder, disease, or condition in a patient. Additional formula(e) will be searched upon the payment of additional fees. Applicants must specify the claims that read on any additional elected inventions. Applicants must further indicate, if applicable, the claims which read on the first named invention if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the "+" group(s) will result in only the first claimed invention to be searched/examined.

The inventions listed in Groups I+ do not relate to a single general inventive concept under PCT Rule 13.1, because under PCT Rule 13.2 they lack the same or corresponding special technical features for the following reasons:

The Groups I+ formulae do not share a significant structural element requiring the selection of alternatives for the compound variables IRAK, LBM, L and accordingly these groups lack unity a priori.

Additionally, even if Groups I+ were considered to share the technical features of a compound having the core structure of formula I: or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising a compound, and a pharmaceutically acceptable carrier, adjuvant, or vehicle; and a method of treating or degrading an IRAK4-mediated disorder, disease, or condition in a patient comprising administering to said patient a compound, or a pharmaceutical composition thereof, these shared technical features do not represent a contribution over the prior art as disclosed by WO 2017/201449 A1 to Genentech Inc. et al.

WO 2017/201449 A1 to Genentech Inc. et al. teach a compound having the core structure of formula I, (Pg. 171, Lns. 10-16,...see reaction product...); a pharmaceutical composition (Pg. 2, Lns. 26-27, Another aspect of the subject matter described herein is a pharmaceutical composition comprising a PAC, and one or more pharmaceutically acceptable excipients.) comprising a compound (Pg. 2, Lns. 26-27), and a pharmaceutically acceptable carrier (Pg. 2, Lns. 26-27); and a method of treating an IRAK4-mediated disorder, disease, or condition in a patient (Claims 1, 7, 39; Pg. 2, Lns. 26-29) comprising administering to said patient a pharmaceutical composition thereof (Claims 1, 7, 39; Pg. 2, Lns. 26-29).

The inventions listed in Groups I+ therefore lack unity under Rule 13 because they do not share a same or corresponding special technical feature.